<SEC-DOCUMENT>0001104659-25-052381.txt : 20250523
<SEC-HEADER>0001104659-25-052381.hdr.sgml : 20250523
<ACCEPTANCE-DATETIME>20250523152747
ACCESSION NUMBER:		0001104659-25-052381
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		72
FILED AS OF DATE:		20250523
DATE AS OF CHANGE:		20250523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Caris Life Sciences, Inc.
		CENTRAL INDEX KEY:			0002019410
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				852077369
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-287551
		FILM NUMBER:		25981732

	BUSINESS ADDRESS:	
		STREET 1:		750 W JOHN CARPENTER FREEWAY
		STREET 2:		SUITE 800
		CITY:			IRVING
		STATE:			TX
		ZIP:			75039
		BUSINESS PHONE:		(866) 771-8946

	MAIL ADDRESS:	
		STREET 1:		750 W JOHN CARPENTER FREEWAY
		STREET 2:		SUITE 800
		CITY:			IRVING
		STATE:			TX
		ZIP:			75039
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>tm2415719-14_s1.htm
<DESCRIPTION>S-1
<TEXT>
<html>
  <head>
    <title>tm2415719-14_s1 - none - 45.5939491s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">As&#160;filed with the Securities and Exchange Commission on May&#160;23, 2025.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:3pt; text-align:right; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:4pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 4pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.5pt; text-align:center; width:541.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">UNITED STATES</font>
          <br >
          <font style="letter-spacing:-0.32pt;">SECURITIES AND EXCHANGE COMMISSION</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">FORM S-1</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">REGISTRATION STATEMENT</font>
          <br >
          <font style="letter-spacing:-0.16pt;">UNDER</font>
          <br >
          <font style="letter-spacing:-0.16pt;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:11pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.687%; margin-right: 41.687%; margin-top: 11pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.5pt; text-align:center; width:541.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">CARIS LIFE SCIENCES, INC.</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:7pt;">
          <font style="letter-spacing:0.14pt;">(Exact name of registrant as specified in its charter) </font>
        </div>
        <table style="width:541.31pt;height:23pt;margin-top:4.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Texas</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">8071</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">85-2077369</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.6pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center; line-height:7pt;">
                <font style="letter-spacing:0.14pt;">(State or other jurisdiction of </font>
                <br >
                <font style="letter-spacing:0.14pt;">incorporation or organization)</font><font style="font-size:8pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center; line-height:7pt;">
                <font style="letter-spacing:0.14pt;">(Primary Standard Industrial </font>
                <br >
                <font style="letter-spacing:0.14pt;">Classification Code Number)</font><font style="font-size:8pt;">&#8203;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center; line-height:7pt;">
                <font style="letter-spacing:0.14pt;">(I.R.S. Employer </font>
                <br >
                <font style="letter-spacing:0.14pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.9pt; text-align:center; width:541.31pt; line-height:8pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">750 W. John Carpenter Freeway</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Suite 800</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Irving, TX 75039</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Telephone: (866) 771-8946</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:7pt;">
          <font style="letter-spacing:0.14pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font><font style="font-size:8pt;">&#8203;<font style="letter-spacing:0.16pt;"> </font></font>
        </div>
        <div style="margin-top:10.9pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.687%; margin-right: 41.687%; margin-top: 10.9pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.4pt; text-align:center; width:541.31pt; line-height:8pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">David D. Halbert</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Founder, Chairman, and Chief Executive Officer</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Caris Life Sciences, Inc.</font>
          <br >
          <font style="letter-spacing:-0.16pt;">750 W. John Carpenter Freeway, Suite 800</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Irving, TX 75039</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Telephone: (866) 771-8946</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:541.31pt; line-height:8.5pt;font-size:7pt;">
          <font style="letter-spacing:0.14pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-size:8pt;">&#8203;<font style="letter-spacing:0.16pt;"> </font></font>
        </div>
        <div style="margin-top:10.9pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.687%; margin-right: 41.687%; margin-top: 10.9pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6.41pt; text-align:center; width:541.31pt; line-height:9.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:4.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:162.66pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">Nathan Ajiashvili</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Alison Haggerty </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Samer Zabaneh </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Latham &amp; Watkins LLP</font>
                <br >
                <font style="letter-spacing:-0.16pt;">1271 Avenue of the Americas</font>
                <br >
                <font style="letter-spacing:-0.16pt;">New York, NY 10020</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Telephone: (212) 906-1200</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:192pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">J. Russel Denton</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ginger Appleberry</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Michael R. Sullivan</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Caris Life Sciences, Inc.</font>
                <br >
                <font style="letter-spacing:-0.16pt;">750 W. John Carpenter Freeway, Suite 800</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Irving, TX 75039</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Telephone: (866) 771-8946</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:162.65pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">Eric Blanchard</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Divakar Gupta</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Charles S. Kim</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cooley LLP</font>
                <br >
                <font style="letter-spacing:-0.16pt;">500 Boylston Street</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Boston, MA 02116</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Telephone: (617) 937-2300</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.01pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.687%; margin-right: 41.687%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:36pt; margin-top:11.4pt; width:505.31pt; line-height:9.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.16pt;">Approximate date of commencement of proposed sale to the public:</font><font style="letter-spacing:0.16pt;"> As soon as practicable after the effective date of this registration statement. </font>
        </div>
        <div style="margin-top:10.9pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.687%; margin-right: 41.687%; margin-top: 10.9pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:36pt; margin-top:6.4pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:469.31pt;height:29.18pt;margin-left:36pt;margin-top:4.5pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:102pt;">
              <font style="letter-spacing:0.16pt;">Large accelerated filer </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:217.54pt;">
              <font style="letter-spacing:0.16pt;">&#9744; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:126pt;">
              <font style="letter-spacing:0.16pt;">Accelerated filer </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:7.77pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.16pt;">&#9744;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.003pt 0pt 0.607pt 0pt; width:102pt;">
              <font style="letter-spacing:0.16pt;">Non-accelerated filer </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.003pt 0pt 0.607pt 0pt; width:217.54pt;">
              <font style="letter-spacing:0.16pt;">&#9746; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.003pt 0pt 0.607pt 0pt; width:126pt;">
              <font style="letter-spacing:0.16pt;">Smaller reporting company </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.003pt 0.5pt 0.607pt 0pt; width:7.77pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.16pt;">&#9744;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:102pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:217.54pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.003pt 0pt 0.607pt 0pt; width:126pt;">
              <font style="letter-spacing:0.16pt;">Emerging growth company </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.003pt 0.5pt 0.607pt 0pt; width:7.77pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.16pt;">&#9746;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:10.9pt; width:541.31pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="margin-top:11pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.687%; margin-right: 41.687%; margin-top: 11pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:36pt; margin-top:6.5pt; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:736.83pt;left:48.66pt;height:32.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="margin-right:35pt; text-align:justify; width:671pt; line-height:9.5pt;color:#EA5B4E;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell, nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:0.2pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:51.9pt;margin-left:87.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:13pt;color:#EA5B4E;font-size:11pt;">
          <font style="letter-spacing:0.22pt;">Subject to Completion </font>
          <br >
          <font style="letter-spacing:0.22pt;">Preliminary Prospectus dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025</font><font style="color:#000000;letter-spacing:0.22pt;"> </font>
        </div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">P R O S P E C T U S</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;Shares</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="position:relative;margin-top:4pt; text-align:center; width:456pt;">
          <img src="lg_carislifesciences-pn.jpg" alt="[MISSING IMAGE: lg_carislifesciences-pn.jpg]" height="96" width="116" >
        </div>
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:26pt;font-weight:bold;font-size:24pt;">
          <font style="letter-spacing:-0.48pt;">Caris Life Sciences, Inc.</font><font style="font-weight:normal;letter-spacing:0.48pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Class A Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:5.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 40.132%; margin-right: 40.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:36pt; margin-top:7pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">This is Caris Life Sciences, Inc.&#8217;s initial public offering. We are selling&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class A common stock. </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">We expect the public offering price to be between $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. Currently, no public market exists for shares of our Class A common stock. After pricing of the offering, we expect that our Class A common stock will trade Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CAI.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">Upon the completion of this offering, we will have two classes of authorized common stock: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting, conversion, and transfer rights. Each share of Class A common stock is entitled to one vote. Each share of Class B common stock is entitled to 10 votes and is convertible at any time, at the option of the holder, and mandatorily upon the occurrence of certain events, into one share of Class A common stock. Immediately following the completion of this offering, the outstanding shares of our Class B common stock will collectively represent approximately &#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, with our executive officers, directors, and principal shareholders collectively holding approximately &#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, assuming no exercise by the underwriters of their option to purchase additional shares of Class A common stock. David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately &#8199;&#8199;&#8199;&#8199;% of our outstanding shares of capital stock and approximately &#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock. As a result, Mr. Halbert will have the ability to exercise significant influence over the outcome of matters submitted to our shareholders for approval, including the election of our directors and the approval of any change of control transaction, and, following this offering, we may become a &#8220;controlled company&#8221; as defined under the corporate governance rules of Nasdaq. See &#8220;Principal Shareholders&#8221; and &#8220;Description of Capital Stock&#8221; for additional information. </font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">At our request, the underwriters have reserved up to &#8199;&#8199;&#8199;&#8199;% of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management, including certain of our directors, officers, employees, and certain other parties related to us. See &#8220;Underwriting&#8212;Reserved Share Program.&#8221;</font>
        </div>
        <div style="text-indent:36pt; margin-top:3pt; width:456pt; line-height:9pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. See &#8220;Prospectus Summary&#8212;</font>&#8203;<font style="letter-spacing:-0.16pt;">Implications of Being an Emerging Growth Company.&#8221;</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font></div>
        <div style="text-indent:36pt; margin-top:3pt; width:456pt; line-height:13pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">Investing in our Class A common stock involves risks that are described in the &#8220;Risk Factors&#8221; section beginning on page <a href="#tRIFA">21</a> of this prospectus.</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:4.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 40.132%; margin-right: 40.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:384pt;height:38.34pt;margin-left:36pt;margin-top:0.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.65pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:309.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.285pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:309.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Underwriting discount</font><font style=" position:relative; bottom:3.5pt;font-size:5.5pt;letter-spacing:0.13pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.285pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:309.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Proceeds, before expenses, to us </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.285pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.285pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.95pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:10.5pt; text-align:left; margin-left:36pt;font-size:8.5pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.17pt;">We refer you to &#8220;Underwriting&#8221; for additional information regarding underwriting compensation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">The underwriters may also exercise their option to purchase up to an additional&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class A common stock from us, at the public offering price, less the underwriting discount, for 30&#160;days after the date of this prospectus. </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </font>
        </div>
        <div style="margin-left:36pt; margin-top:4pt; width:420pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">The shares will be ready for delivery on or about&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025. </font>
        </div>
        <div style="margin-top:4.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 40.132%; margin-right: 40.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:15pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">BofA Securities</font><font style="margin-left:25.35pt;"><font style="letter-spacing:-0.28pt;">J.P. Morgan</font>
          </font><font style="margin-left:25.35pt;"><font style="letter-spacing:-0.28pt;">Goldman Sachs &amp; Co. LLC</font>
          </font><font style="float:right;"><font style="letter-spacing:-0.28pt;">Citigroup</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
          </font>
        </div>
        <table style="width:456pt;height:32.39pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <tr style="line-height:11.99pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:12pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:53.73pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.24pt;">TD Cowen</font>
              </div>
            </td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:62.91pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.24pt;">Evercore ISI </font>
              </div>
            </td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:123.08pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:-0.24pt;">Guggenheim Securities</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11.99pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:12pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:7.507pt 0pt 0.5pt 0pt; width:53.73pt;">
              <font style="letter-spacing:-0.24pt;">BTIG</font>
            </td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:62.91pt;">&#8203;</td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:0pt; width:54.07pt;">&#8203;</td>
            <td style="padding:7.507pt 0.5pt 0.5pt 0pt; width:123.08pt;text-align:right;">
              <div style="white-space:nowrap; text-align:right;">
                <font style="letter-spacing:-0.24pt;">Wolfe | Nomura Alliance</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.9pt; text-align:center; width:456pt;">
          <div style="margin-left: 40.132%; margin-right: 40.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:23pt; text-align:center; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">The date of this prospectus is</font><font style="font-weight:bold;letter-spacing:-0.16pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;</font><font style="letter-spacing:0.16pt;">, 2025.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="min-height:759.71pt;page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="position:relative;padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-26pt;margin-left:-18pt;width:631.31pt;">
        <div style="width:631.31pt; line-height:12pt;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#8202;Where Molecular Science Meets Artificial Intelligence Arizona blood lab; the entrance lobby of Caris&#8217; Phoenix, Arizona tissue lab; tissue sample storage in Caris&#8217; Phoenix, Arizona tissue lab; a Caris laboratory technician preparing a centrifuge for Caris Assure&#8482; profiling of patient blood samples; a Caris laboratory technician preparing patient blood samples for Caris Assure&#8482; profiling; a Caris laboratory technician microdissecting a patient tissue sample in preparation for MI Profile&#8482; analysis; Caris laboratory technicians in our Phoenix, Arizona blood lab; sequencing machines in Caris&#8217; Phoenix, Arizona blood lab. </font><font style="color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;z-index:-1;z-index:-1;z-index:-1;margin-top:9.9pt; text-align:center; width:613.31pt; height:764pt; overflow:hidden;">
          <img src="pg_carislifesciences-4c.jpg" alt="[MISSING IMAGE: pg_carislifesciences-4c.jpg]" height="1056" width="816" >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-26pt;margin-left:-18pt;width:631.31pt;">
        <div style="margin-top:29.36pt; width:631.31pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#8202; </font><font style="color:#FFFFFF;letter-spacing:0.2pt;">By the Numbers Profiling, Data &amp; Technology Publications, Patents &amp; People Data points are as of March 31, 2025. </font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;z-index:-1;z-index:-1;margin-top:10pt; text-align:center; width:613.31pt; overflow:hidden;">
          <img src="pg_bynumbers-4c.jpg" alt="[MISSING IMAGE: pg_bynumbers-4c.jpg]" height="961" width="721" >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-26pt;margin-left:-18pt;width:631.31pt;">
        <div style="margin-top:73.05pt; width:631.31pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#8202; </font><font style="color:#FFFFFF;letter-spacing:0.2pt;">Case Volume Growth (Thousands*) Clinical Cases Biopharma &amp; External Research Cases 172.6 31% CAGR 136.9 2019-2024 103.4 162.9 77.5 30% Year-Over-Year Growth Rate 128.8 61.5 97.3 47.3 45.1 36.5 75.3 59.9 45.9 34.9 42.8 2019 2020 2021 2022 2023 2024 Q1 2024 Q1 2025 *Figures reflect case volume for the periods presented. Figures may not sum precisely due to rounding. </font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;z-index:-1;margin-top:10pt; text-align:center; width:613.31pt; overflow:hidden;">
          <img src="pg_casevaluegrowth-4c.jpg" alt="[MISSING IMAGE: pg_casevaluegrowth-4c.jpg]" height="845" width="634" >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.31pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:-26pt;margin-left:-18pt;width:631.31pt;">
        <div style="margin-top:33.45pt; width:631.31pt; line-height:12pt;color:#FFFFFF;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#8202; Revenue Growth ($ Millions*) Molecular Profiling Services Pharma Research &amp; Development Services 28% CAGR 2019-2024 $306.1 $258.5 $278.7 ($79.1) ($175.8) ($324.0) ($320.8) ($341.4) ($281.9) ($111.0) ($102.6) NET (LOSS) *Figures reflect revenue for the periods presented. Figures may not sum precisely due to rounding. </font><font style="color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;z-index:-1;z-index:-1;margin-top:10pt; text-align:center; width:613.31pt; overflow:hidden;">
          <img src="pg_revenuegrowth-4c.jpg" alt="[MISSING IMAGE: pg_revenuegrowth-4c.jpg]" height="950" width="714" >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:14.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:392.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:422.72pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">PAGE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLFDD"><font style="letter-spacing:0.2pt;">LETTER FROM DAVID DEAN HALBERT, FOUNDER, CHAIRMAN, AND CEO </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLFDD">iii</a></font> <a href="#tLFDD"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">21</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">100</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAID"><font style="letter-spacing:0.2pt;">MARKET AND INDUSTRY DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAID">102</a></font> <a href="#tMAID"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">103</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:0.2pt;">DIVIDEND POLICY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIPO">104</a></font> <a href="#tDIPO"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:0.2pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAP">105</a></font> <a href="#tCAP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">108</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:422.72pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMDAA"><font style="letter-spacing:0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMDAA">111</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:0.2pt;">BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBUS">138</a></font> <a href="#tBUS"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:0.2pt;">MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAN">213</a></font> <a href="#tMAN"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><font style="letter-spacing:0.2pt;">EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXCO">223</a></font> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCRAR"><font style="letter-spacing:0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCRAR">233</a></font> <a href="#tCRAR"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSH"><font style="letter-spacing:0.2pt;">PRINCIPAL SHAREHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSH">237</a></font> <a href="#tPRSH"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">241</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEFF"><font style="letter-spacing:0.2pt;">SHARES ELIGIBLE FOR FUTURE SALE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSEFF">252</a></font> <a href="#tSEFF"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:422.72pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">OUR CLASS A COMMON STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">257</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUND"><font style="letter-spacing:0.2pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUND">261</a></font> <a href="#tUND"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">272</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">272</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCIRPAF"><font style="letter-spacing:0.2pt;">CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCIRPAF">273</a></font> <a href="#tCIRPAF"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">274</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tITFS"><font style="letter-spacing:0.2pt;">INDEX TO FINANCIAL STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tITFS">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of Class A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class A common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">For investors outside the United States:</font><font style="letter-spacing:0.2pt;"> Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free writing prospectus outside of the United States.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TRADEMARKS, TRADE NAMES AND SERVICE MARKS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus includes our trademarks and trade names, including, without limitation, Caris&#160;Life&#160;Sciences</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caris</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caris Discovery</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caris Assure</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, MI Profile</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Molecular Intelligence</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caris&#160;Precision Oncology Alliance</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, MI Tumor Seek</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, MI Tumor Seek Hybrid</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, ABCDai</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, CODEai</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, ESPai</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, MI Cancer Seek</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, GPSai</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, FOLFIRSTai</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, Caris ChromoSeq</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, MGMTai</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;">, and our logo, which are protected under applicable intellectual property laws and are our property. This prospectus also contains trademarks, trade names, and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names, and service marks referred to in this prospectus, including logos, artwork, and other visual displays, may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#8482;</font><font style="letter-spacing:0.2pt;"> or </font><font style=" position:relative; bottom:6.25pt;font-weight:bold;text-transform:uppercase;font-size:4pt;letter-spacing:-0.08pt;">SM</font><font style="letter-spacing:0.2pt;"> symbols, but such references are not intended to indicate in any way that we or the applicable owner will not assert, to the fullest extent under applicable law, our or its rights or the rights of the applicable licensor to these trademarks, trade names, and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other parties. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ROUNDING ADJUSTMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain&#160;monetary amounts, percentages, and other figures included elsewhere in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed as&#160;percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the figures that precede them. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLFDD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LETTER FROM DAVID DEAN HALBERT, FOUNDER, CHAIRMAN, AND CEO</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Hello, my name is David Dean Halbert, and I am the Founder, Chairman, and CEO of Caris Life Sciences. Caris is the first and only company that I&#8217;ve founded without a business model. Our only purpose is to help patients live longer and have a better quality of life by applying personalized medicine to disease. We believe that precise, data-driven, and personalized molecular information is crucial to eradicating chronic health conditions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a science-focused company, Caris has been at the forefront of precision medicine from the beginning and has driven the industry forward through our focus on science and investments into technology, instrumentation, facilities, and people. When I started Caris, next-generation sequencing, and other technologies needed to realize the benefits of personalized medicine, did not exist. However, we have benefited from tremendous advances in sequencing technology, cloud computing, and AI technologies to power our expertise and insights in molecular biology. We believe that these advances provide an unmatched resource to develop the next generation of precision medicine solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our platform is built on the premise that more data enables us to answer questions about biology that could not be answered until now due to limited or narrow information. In the course of completing over 6.5&#160;million tests on over 849,000 cases, we have generated over 13 quadrillion molecular datapoints and measured over 38&#160;billion molecular markers. We measure billions of data points per clinical case using Caris Assure, our universal blood-based whole exome/whole transcriptome sequencing solution, that we have created based on our vast experience in tissue sequencing. We are utilizing this tremendous amount of molecular information to pioneer the transition from intuitive medicine, where decisions for cancer patients are made based on prior experience or intuition, to empirical medicine, where decisions are based on the genetic make-up of each person&#8217;s disease. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Driven by over 17&#160;years of innovation to help build a better world, we have gained vast expertise in sequencing and data interpretation. We believe we were the first to offer comprehensive molecular profiling as standard practice when we launched whole transcriptome sequencing in 2019, the first to offer whole exome sequencing as standard practice when we introduced our whole exome sequencing solution in 2020, and the first to offer whole exome and whole transcriptome sequencing in blood when we broadly launched Caris Assure in the first quarter of 2024. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have utilized AI and machine learning algorithms across our dataset to identify approximately 915,000 unique pathogenic mutations, of which only approximately 17,000 were previously identified, with approximately 130 novel pathogenic mutations found on average in each person. We can now identify a person&#8217;s circulating pathogenic mutations and design a customized individualized therapy to that specific set of mutations. So, it becomes an individualized, customized immunotherapy. We believe this is going to create the opportunity for physicians to use our solutions to effectively prevent various chronic diseases before they ever get started at the earliest of stages. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is a very exciting time because technology has finally advanced to the point where it enables this big idea. This is not something that could have been thought of in 2008 or even 2018 because the technologies were not available. Such as large sequencing capacity, AI, and the cloud, all of which have to be utilized to look at all of the different aberrations that are occurring at the molecular level with the outcomes. So over time, it&#8217;s just going to get better and better and better. We run the same assay in both blood and tissue on every eligible patient sample every day, so the only changes to the assay will be at the bioinformatic level utilizing specially-designed algorithms to provide new insights. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While we specialize in oncology today, we also believe that since we have designed the Caris Assure platform as a universal assay that runs on every coding gene in the blood, it can be utilized to identify alterations that drive other chronic disease states such as cardiovascular disease, neurological conditions, metabolic disorders, and many others. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We exist in a very exciting time of unprecedented technological disruption to benefit mankind and &#8220;go where no man has gone before&#8221;&#8212;something I have described as the molecular revolution&#8212;leading me to be bullish on humanity. Never before have we seen a convergence of molecular sequencing power, sophisticated AI technologies, and massive computer processing capabilities. We will continue to harness these and other advanced technologies, pushing the boundaries of what is possible and leading the precision medicine revolution in healthcare. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:542pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We feel honored to have served hundreds of thousands of patients in their battle against cancer. I would like to thank our Caris Life Sciences family for their tireless work to help our patients and to build a company that is actively changing the practice of medicine. We are excited about our future and welcome new shareholders that share our vision and passion to improve the human condition. </font>
        </div>
        <div style="margin-top:14pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">David Dean Halbert, D.Sc. (h.c.)</font> <br ><font style="letter-spacing:0.2pt;">Founder, Chairman, and CEO</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">iv</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. It does not contain all of the information that may be important to you and your investment decision. You should carefully read this entire prospectus, including the sections titled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; and our financial statements and related notes included elsewhere in this prospectus before making an investment decision. In this prospectus, unless context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Caris,&#8221; or &#8220;the Company&#8221; refer to Caris Life Sciences, Inc. and its wholly owned subsidiaries.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17&#160;years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our platform is purpose-built to leverage the convergence of next-generation sequencing (&#8220;NGS&#8221;), artificial intelligence (&#8220;AI&#8221;) and machine learning (&#8220;ML&#8221;) technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, minimal residual disease (&#8220;MRD&#8221;) tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Dysfunctionality at the molecular level underlies every chronic disease, and this dysfunction is now measurable using techniques such as NGS. Cells are embedded within highly complex biological networks that govern all aspects of life, including how these cells grow, divide, interact, and die. These biological networks and their inherent functions, as well as dysfunctions, are controlled and directed at the molecular level. The precise molecular origins or contributors to a given biological dysfunction, however, are often unknown, and a comprehensive molecular profile is necessary to determine these origins. The central dogma of molecular biology states that genetic information flows in one direction, from DNA, to RNA, to proteins. Our approach is designed to accurately capture the full breadth of the DNA and RNA coding information in cells as well as protein expression through immunohistochemical (&#8220;IHC&#8221;) tests, constructing a fulsome mosaic of disease, and ultimately unlocking the potential for precision medicine therapeutics to guide individualized patient diagnoses and treatment. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe we are well-positioned to realize the full potential of our vision and optimally leverage our vast datasets due to the recent convergence of several advancements in biology, medicine, and technology: (1)&#160;the medical community&#8217;s understanding and appreciation of the molecular nature of cancer has accelerated in recent&#160;years, resulting in a continued increase in molecular profiling of different cancer types and stages; (2)&#160;NGS costs have declined, making NGS more accessible to the healthcare ecosystem; (3)&#160;cloud-computing architecture has enabled massive scalability, distributed real-time collaboration, and greater cost efficiency for the analysis of previously unmanageable amounts of data; and (4) AI and ML computational capabilities have advanced to allow more effective interrogation of large biological datasets. We believe that our early foresight to generate comprehensive data at scale over the past many&#160;years and build a robust, foundational infrastructure have uniquely positioned Caris to leverage the benefits of these </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">biological and technological advances to deliver transformative and advanced innovations in precision medicine and patient care into the future. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. We provide whole exome sequencing (&#8220;WES&#8221;) (all 23,000 encoding DNA genes) and whole transcriptome sequencing (&#8220;WTS&#8221;) (all 61,000 RNA transcripts that encode proteins) on every eligible patient sample (a sample provided by ordering physicians that contains sufficient genetic material for profiling). Since launching our WTS solution in 2019 and WES solution in 2020, we have performed over 400,000 WES and WTS cases, which we believe is more than any other company. We sequence at a sector-leading depth of coverage, which directly correlates with increased accuracy and detection of low frequency molecular markers of relevance. MI Cancer Seek, our U.S. Food and Drug Administration (&#8216;&#8216;FDA&#8217;&#8217;)-approved companion diagnostic assay to identify cancer patients who may benefit from treatment with targeted therapies (a component of MI Profile), consistently reaches 1,500 times depth of coverage for clinically relevant DNA genes, which is a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage, and 300 times depth of coverage for the whole exome. Caris Assure features a raw average sequencing depth of 8,000 times for clinically relevant genes, similarly a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage. We generate tens of billions of datapoints per clinical case to reveal an individualized molecular blueprint of the patient&#8217;s disease. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. To our knowledge, we remain the only genomic profiling company to consistently utilize WES and WTS as standard practice on every eligible patient sample. We also evaluate protein molecular markers through an extensive menu of IHC tests performed in a tumor-type specific manner, which in combination with WES and WTS, provide a comprehensive view of a patient&#8217;s disease. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology, including genomic data, clinical data, digitized slide images, and remnant tissue. As of March 31, 2025, we have run more than 6.5&#160;million tests on over 849,000 cases, which have generated measurements of over 38&#160;billion molecular markers. Leveraging high-powered computing and AI/ML algorithms, we, and our biopharma and research partners who use our data and bioinformatics services, analyze our datasets to determine the key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our molecular profiling solutions and the data generated by our multi-omic technology platform provide value to our more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines. In addition to biopharma, we leverage our datasets to partner with outside academic centers and researchers to further advance precision oncology research. The Caris Precision Oncology Alliance (&#8220;Caris POA&#8221;), which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. As of March 31, 2025, the Caris POA was comprised of 96 members, including 45 National Cancer Institute (&#8220;NCI&#8221;)-designated comprehensive cancer centers. This academic-industry collaborative network has been exceptionally productive with over 145 peer-reviewed manuscripts published since the beginning of 2022. Close connectivity with this vast network of key opinion leaders (&#8220;KOLs&#8221;) in oncology clinical care, research, and drug development has enabled us to remain at the forefront of precision oncology and closely attuned to the key needs of the most sophisticated researchers. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">ultimate goal of contributing to improved patient results. This continuous feedback loop enabled us to develop Caris Assure, which utilized genomic data generated by MI Profile to inform our blood-based bioinformatics algorithms, allowing us to detect previously unknown features and signals in the blood that provide advanced insights into disease development. We believe we will be able to further leverage this process to continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our global annual clinical case volume has been growing rapidly, with year-over-year growth of 29% in 2022, 32% in 2023, 26% in 2024, and 31% in the first quarter of 2025, primarily driven by MI Profile. With our broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and the FDA approval of MI Cancer Seek as a companion diagnostic in the fourth quarter of 2024 followed by the broad commercial launch of MI Cancer Seek in the first quarter of 2025 as the NGS component of MI Profile, we believe that increased profiling volumes will meaningfully contribute to our growth in 2025 and beyond. For the&#160;years ended December&#160;31, 2024 and 2023, we generated total revenue of $412.3&#160;million and $306.1&#160;million, respectively. For the three months ended March 31, 2025 and 2024, we generated total revenue of $120.9 million and $80.7 million, respectively. We have incurred net losses and negative cash flows from operations since inception. For the years ended December&#160;31, 2024 and 2023, we incurred net losses of $257.1&#160;million and $341.4&#160;million, respectively. For the three months ended March 31, 2025 and 2024, we incurred net losses of $102.6 million and $111.0 million, respectively. Our Adjusted EBITDA was $(189.6)&#160;million and $(255.3) million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. Our Adjusted EBITDA was $(36.2) million and $(70.1) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding Adjusted EBITDA, a non-GAAP financial measure, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Non-GAAP Financial Measures.&#8221; We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million, $276.1 million, $31.3 million, and $73.9 million for the years ended December&#160;31, 2024 and 2023 and the three months ended March 31, 2025 and 2024, respectively. Our free cash flow was $(253.6)&#160;million and $(298.4) million for the years ended December 31, 2024 and 2023, respectively, and, $(34.0&#160;) million and $(75.7) million for the three months ended March&#160;31, 2025 and 2024, respectively. For additional information regarding free cash flow, a non-GAAP financial measure, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Non-GAAP Financial Measures.&#8221; Additionally, as of March&#160;31, 2025, we had cash, cash equivalents, and short-term marketable securities of $33.4 million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million. For additional information regarding our liquidity and capital resources, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources.&#8221; </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Industry Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Addressing the complexity of cancer remains a major challenge in healthcare and a critical area of unmet medical need, despite enormous investments in research and development (&#8220;R&amp;D&#8221;), and the introduction of new oncology therapeutics and treatments. The molecular revolution is upending the traditional paradigm of complex workflows of diagnosis, treatment, and monitoring of diseases, which largely uses a symptomatic, reactive approach to medicine. Over the last several decades, significant advances in genomics, proteomics, molecular technology, and computing power have enabled a comprehensive, multi-omic approach to the molecular profiling of diseases, both efficiently and at scale. The information provided by comprehensive molecular profiling is driving a revolution in medicine, where molecular information is used to guide individualized patient diagnoses and treatment. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Comprehensive molecular profiling entails evaluating thousands of potential biomarkers, including DNA, RNA, proteins, and other molecular and clinical information for characteristics unique to a particular patient&#8217;s disease. Given the complexity of a cancer&#8217;s origin and drivers, comprehensive molecular information incorporating DNA, RNA, and protein profiles can help provide the most robust picture of a patient&#8217;s disease and potential treatment pathways. WES/WTS streamlines the patient experience and clinical decision-making and offers increased value to patients, physicians, and payers. We believe WES/WTS </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">provides the most efficient and cost-effective way to obtain the maximum information on a patient&#8217;s cancer at the start of the patient journey. It enables accurate identification of a greater number of actionable genomic alterations that can be leveraged to match patients to the most effective treatments, yielding a higher probability of response and providing comprehensive predictive and prognostic information. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">While the molecular revolution has already changed the way cancer is being diagnosed and treated, we believe that molecular testing faces several major challenges in its current form, which have hindered broader adoption of precision oncology. These challenges include: (1)&#160;targeted panels are subject to missing information and significant variability; (2)&#160;lack of consistent RNA profiling; (3)&#160;lack of clonal hematopoiesis (&#8220;CH&#8221;) derived variant subtraction technology in current blood assays, contributing to the inability to identify false positive mutations that are not tumor-derived; (4)&#160;disparate data sets collected across testing modalities; (5)&#160;logistical drawbacks and sensitivity limitations of current MRD assays; and (6)&#160;false positives and a lack of early-stage sensitivity with current multi-cancer early detection (&#8220;MCED&#8221;) assays. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">As a result of these challenges, clinicians may make critical treatment decisions based on incomplete and/or inaccurate information and analytics, potentially resulting in suboptimal outcomes. We believe that our comprehensive molecular profiling solutions and the data generated by our multi-omic technology platform is well-suited to address the limitations and challenges of today&#8217;s molecular testing alternatives. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Caris Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">We are leading a molecular revolution and developing the latest generation of advanced precision medicine information solutions that we believe have applicability across the care continuum for a broad range of conditions. The fundamental differentiation of the Caris platform and our business model is the depth, breadth, and scale of data, including how that data is integrated vertically and horizontally across our business, as well as the resulting innovation which it fuels. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Our multi-omic technology platform is built on the following pillars: (1)&#160;Caris Assure; (2)&#160;MI Profile; (3)&#160;Caris Discovery; (4)&#160;Caris Strategic Data; and (5)&#160;Caris Infrastructure. These five pillars are designed to work together to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. We believe this continuing cycle will deepen our competitive advantage and allow us to achieve meaningful innovation and business success in precision oncology, while illuminating a path to precision medicine for other chronic disease states, including cardiology, neurology, and metabolic conditions. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:18pt;margin-left:12pt;width:456pt;">
          <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
            <img src="pc_platform-4c.jpg" alt="[MISSING IMAGE: pc_platform-4c.jpg]" height="451" width="602" >
          </div>
          <div style="text-indent:36pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We believe our growth and competitive differentiation are driven by the five pillars of our platform, each of which are both a product of the upstream data and a foundation to further innovation and data generation across the platform: </font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Assure.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our universal blood-based WES/WTS profiling solution is designed to deploy a single assay across the entire continuum of cancer care, including early detection, MRD tracking, therapy selection, and treatment monitoring, and generates over 42&#160;billion datapoints, spanning 168,000 molecular markers, per clinical case. We leveraged our experience and data from MI Profile to create Caris Assure, which enables us to understand how a patient&#8217;s disease started, what therapies the tumor may be sensitive to, how the tumor is transforming to resist therapies, and how best to control or cure the disease. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">MI Profile.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our tissue-based profiling solution for therapy selection includes MI Cancer Seek, our FDA-approved companion diagnostic WES/WTS profiling assay, and IHC protein expression testing. Our WES/WTS profiling solution generates over 28.8&#160;billion datapoints, spanning 84,000 molecular markers, per clinical case. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Discovery.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The combination of our data and our AI enables us to discover previously unknown drug targets for antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, and cell therapy. In addition, we believe Caris Discovery is well-positioned for neoantigen discovery for personalized therapy development given our ability to detect variants, insertions, and deletions by WES and to assess gene expression and detect fusions by WTS on every patient&#8217;s tumor. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Strategic Data.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As of March 31, 2025, we have run more than 6.5&#160;million tests that have measured over 38&#160;billion molecular markers from over 13 quadrillion datapoints. To assist us with analyzing the data we generate, we utilize over 220 AI and AI/ML tools across our </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:56pt; width:400pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">clinical testing, R&amp;D, and biopharma business. These tools include over 50 clinical sequencing automation and variant calling AIs, over 100 RNA expression AI signatures, approximately 20 multi-omic AI/ML therapy response predictors, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/ML classifiers, and 12 AI/ML support tools. The breadth and depth of our data assets, along with our ability to create algorithms and discover signatures, represent a deep competitive moat for us. </font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Infrastructure.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have a well-developed laboratory, R&amp;D, and sales infrastructure that we believe is foundational to our business. Our infrastructure includes substantial testing capacity and a dedicated workforce to support our R&amp;D efforts, sales activity, and expansion. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Market Opportunity and Vision for Leveraging Molecular Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We believe we are well-positioned to initially pursue a total addressable market in U.S. oncology of approximately $150&#160;billion through the provision of precision medicine solutions across the entire cancer care continuum, as well as offerings to support biopharma drug discovery and development. While our tissue-based molecular profiling solution for cancer therapy has generated the majority of our revenue to date, we believe the launch of our blood-based profiling offering for therapy selection, our expansion of our blood-based profiling offering beyond therapy selection in particular, and further leveraging our platform to provide solutions to biopharma companies will enable us to benefit significantly from this large market opportunity. Our estimated total addressable U.S. oncology market, which is based on a market study by Nephron Research LLC that we commissioned, is comprised of opportunities in the following areas: </font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Early detection:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;approximately $100&#160;billion. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Therapy selection:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;approximately $8&#160;billion. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">MRD tracking and treatment monitoring:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;approximately $28&#160;billion. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Core biopharma services:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;approximately $4&#160;billion. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Data services for biopharma:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;approximately $10&#160;billion. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We also believe there is a large market opportunity for our platform in other chronic disease states beyond oncology, including cardiology, neurology, and metabolic conditions, based on the fundamental premise that approaching blood-based disease detection with a comprehensive WES/WTS approach enables examination of biomarkers that go beyond oncology. For additional information, see &#8220;Business&#8212;Our Market Opportunity and Vision for Leveraging Molecular Information.&#8221; </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Caris Advantage</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We believe our approach is differentiated and we have a competitive advantage because: </font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">We purpose-built our Caris platform to put the patient first and make comprehensive precision medicine a reality.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.89pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.89pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">We are a leading provider of tissue-based molecular profiling, including through our FDA-approved companion diagnostic tissue-based profiling solution, MI Cancer Seek.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Our novel, universal blood-based profiling solution, Caris Assure, is unique in the market and poised for rapid adoption.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">We have built what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Our first mover advantage, specialized commercial channel, robust infrastructure, and deep research collaborations enable our leadership and provide us with the ability to scale for future growth.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">We are led by a founder with significant experience building and scaling businesses in the healthcare industry and a management team with scientific expertise.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Strategies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">To achieve our goal of leading a molecular revolution and developing the next generation of precision medicine information solutions for a broad range of conditions across the care continuum, we plan to: </font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Drive the continued adoption and use of our tissue-based profiling and expand blood-based profiling offering into early detection, MRD, and monitoring.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Utilize the data generated by our existing solutions to develop new solutions with additional revenue using our existing sales channel.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Leverage our platform to provide solutions to biopharma companies to drive advances in personalized medicine and accelerate the development of novel therapeutics.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Continue to expand and enrich our clinico-genomic datasets to drive breakthrough science and develop new solutions.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Maximize market reach through our regulatory approval and reimbursement strategy.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;font-weight:bold;">
            <font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;font-style:italic;font-weight:bold;">
            <!--blacklining:none;-->
            <font style="letter-spacing:-0.2pt;">Capitalize on the ultimate potential of our novel, universal blood-based profiling solution, Caris Assure, and broader innovation platform in other chronic disease states beyond oncology, including in cardiology, neurology, and metabolic conditions.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Caris Assure&#8212;Our Universal Blood-Based Profiling Solution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Caris Assure is our novel, universal blood-based solution that is purpose-built to extend across the entire continuum of cancer treatment, including early detection, monitoring of MRD and recurrent cancers, and precision selection of molecularly targeted therapies. Caris Assure also has applications in therapeutic discovery and development. We believe Caris Assure represents the most comprehensive blood-based solution on the market, featuring over 23,000 gene coverage at a raw average sequencing depth of coverage of 8,000 times for clinically relevant genes, as compared to other blood-based offerings in the market that only assess 500 to 1,000 genes from DNA. Caris Assure performs WES and WTS for every eligible patient blood sample. We integrate WES and WTS with sophisticated AI and ML technologies to offer diagnostic, prognostic, and predictive utility in a single test. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">For therapy selection, in addition to sequencing cell-free DNA and cell-free RNA isolated from the plasma to identify somatic tumor variants, Caris Assure also sequences genomic nucleic acid (gDNA and gRNA) isolated from the white blood cells, or buffy coat, from each sample. Sequencing the buffy coat in addition to the plasma allows Caris Assure to identify incidental germline mutations as well as CH mutations. CH mutations are age-related non-malignant mutations that occur in a substantial portion of the population, are not cancer-derived and are present in both the plasma and buffy coat and cannot be identified from sequencing plasma alone. Caris Assure &#8220;subtracts&#8221; CH mutations in the reporting of somatic tumor variants. This lessens the risk of incorrectly interpreting CH or germline mutations as tumor-derived and results in fewer false positive diagnoses and more accurate and effective treatment recommendations. We believe that CH subtraction is of critical importance to ensure optimal cancer care because of the prevalence of CH mutations. By identifying and distinguishing variants that are not from the tumor itself and, therefore not relevant to therapeutic decision-making, the CH subtraction feature of Caris Assure further separates our solution from other liquid biopsy tests currently on the market that do not sequence the white blood cells and therefore cannot definitively distinguish CH mutations from tumor-derived mutations. To our knowledge, Caris Assure is the only commercially available tissue-naive blood-based profiling assay that directly accounts for CH mutations instead of using algorithmic approximations, which we believe gives Caris Assure a differentiated ability to drive improved therapy selection. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Customers for Caris Assure include treating physicians as well as researchers and biopharma companies. The same benefits that blood-based WES, WTS, and CH subtraction bring to patients in the clinical setting also offer significant and previously unavailable advantages to biopharma companies. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We initiated a broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and currently offer the solution as a laboratory developed test (&#8220;LDT&#8221;), which is an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> diagnostic (&#8220;IVD&#8221;) test intended for clinical use and designed, manufactured, and used within a single laboratory. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The FDA has historically exercised enforcement discretion and not required marketing authorization for LDTs. Accordingly, we have not yet obtained FDA marketing authorization for Caris Assure. We anticipate seeking FDA marketing authorization&#160;for certain of our solutions in the future, including Caris Assure for therapy selection, in part as a result of the FDA&#8217;s planned phase out of its enforcement discretion policy with respect to LDTs. For additional information, see &#8220;Business&#8212;Government Regulation&#8212;U.S. Food and Drug Administration.&#8221; We have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States. The current pricing of Caris Assure for therapy selection under Medicare&#8217;s Molecular Diagnostic Services Program (&#8220;MolDX&#8221;) is $3,649. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Caris Assure for therapy selection is available in all U.S. states (other than New York, where we intend to apply in 2025 for approval from New York State&#8217;s Clinical Laboratory Evaluation Program (&#8220;NY CLEP&#8221;)) and in Puerto Rico. We also offer Caris Assure for therapy selection internationally through distributors and direct contracts with hospital systems, where permitted by applicable regulations. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Differentiated Approach to Address the Entire Cancer Care Continuum Through a Single Blood Test</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our universal approach to blood-based profiling is unique. Liquid biopsies can be used across the care continuum, including for: therapy selection in the advanced/metastatic setting; MRD and monitoring in the curative/adjuvant setting; and early detection in the diagnosis setting. Because many of our competitors&#8217; liquid biopsy assays are designed to address only a single portion of this care continuum, in order to develop products for other portions of the care continuum, our competitors must invest in the development of new wet lab assays and generate disparate datasets across the patient journey for patients, oncologists, and researchers. In contrast, Caris Assure is designed as a single test applicable across the entire patient journey. To our knowledge, there is no other assay on the market that can be applied as broadly as Caris Assure. We believe that our approach will enable us to scale our R&amp;D infrastructure to analyze increasingly larger testing volumes, process expanding datasets, and reach economies of scale in liquid biopsy across the entire cancer care continuum. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe that one of the most promising uses for Caris Assure is for detection of cancer at very early stages, such as stage 1 or stage 2. Our detection of cancer at very early stages would enable clinicians to treat disease sooner, which could significantly improve patient outcomes. We believe that Caris Assure for early detection of cancers will initially be available for early detection of certain types of cancers, such as breast cancer and colon cancer, and then we intend to expand Caris Assure for full MCED indications. In an internal validation study conducted by us, the performance of our Assure Blood-based Cancer Detection ai (&#8220;ABCDai&#8221;) for MCED (&#8220;ABCDai-MCED&#8221;) demonstrated a high level of sensitivity at a specificity that reduces the burden of false positives. For additional information on the validation study, see &#8220;Business&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">Our Solutions&#8212;Caris Assure&#8212;Our Universal Blood-Based Profiling Solution&#8212;Caris Assure for Early Detection.&#8221;</font></div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">For MRD, our detection methodology based on ABCDai takes a tumor na&#239;ve approach, and therefore does not require a bespoke panel to be created to track the recurrence of a patient&#8217;s tumor. This approach means that our MRD assay can be used without the need for a tissue sample and enables faster turn-around-time, enabling patients to be informed of additional therapy sooner to combat their disease.</font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">MI Profile&#8212;Our Tissue-Based Profiling Solution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">MI Profile is our tissue-based molecular profiling solution for cancer therapy selection, with over one&#160;million tests performed on approximately 146,500 clinical cases in 2024 and an additional approximately 40,000 clinical cases in the three months ended March 31, 2025. As of March 31, 2025, we have performed over 6.5 million tissue-based tests on over 790,000 clinical cases since inception. MI Profile includes MI Cancer Seek, our FDA-approved companion diagnostic WES/WTS NGS assay, and IHC protein expression testing. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Customers for MI Profile include treating physicians as well as researchers and biopharma companies. The information generated from profiling the patient&#8217;s tissue is used to create an interpretative report based on our bioinformatics pipeline and recommend individualized therapies for cancer patients. Our goal is to maximize the information generated and corresponding clinical utility for patients from the </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">limited available tumor tissue. Molecular profiling also has broad applications for our biopharma partners, including prospective screening, retrospective testing and deep translational analyses, stratification of patients for existing or future trials, and treatment monitoring. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have obtained Medicare and commercial reimbursement for MI Profile. We have also obtained a premarket approval (&#8220;PMA&#8221;) from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for tumor mutational burden (&#8220;TMB&#8221;) calling, and for which we have obtained a Proprietary Laboratory Analyses (&#8220;PLA&#8221;) code, Current Procedural Terminology (&#8216;&#8216;CPT&#8217;&#8217;) code 0211U, at a reimbursement rate of $8,455. In the first quarter of 2025, we began to market MI Cancer Seek as the WES/WTS NGS component of MI Profile. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS NCD. We currently offer MI Tumor Seek Hybrid, which is a WES/WTS NGS LDT assay, as an alternative assay if a specimen does not meet the eligibility requirements for MI Cancer Seek. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">MI Profile, including our MI Cancer Seek assay and proprietary clinical molecular signatures GPSai and FOLFIRSTai, is available in all U.S. states and in Puerto Rico. We also offer MI Profile internationally in over 40 countries through distributors and direct contracts with hospital systems, where permitted by applicable regulations. </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="fc_clinicalmole-4c.jpg" alt="[MISSING IMAGE: fc_clinicalmole-4c.jpg]" height="453" width="603" >
          </div>
          <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Caris Discovery</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Caris Discovery is our drug target and therapeutic discovery business. Caris Discovery leverages our profiling solutions, multi-modal clinico-genomic datasets, wet lab facilities, proprietary Adaptive Dynamic Artificial Polyligand Targeting (&#8220;ADAPT&#8221;) platform, and AI/ML-enabled </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> analyses to identify potential drug targets and develop therapeutics. We launched Caris Discovery in 2022 to partner with biopharma partners to address the lack of novel cancer-specific targets and the herding of biopharma pipelines around a discrete number of lower-risk targets. Caris Discovery is disease- and modality-agnostic </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">and can be applied to any therapeutic modality, including antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, and cell therapy. We have achieved external validation of our Caris Discovery approach through strategic partnerships with established biopharma companies, such as Merck KGaA and Xencor, to develop therapeutics against novel targets that emanate from our molecular insights and proprietary technology. In addition, we believe Caris Discovery is well-positioned for neoantigen discovery for personalized therapy development given our ability to detect variants, insertions, and deletions by WES and to assess gene expression and detect fusions by WTS on every patient&#8217;s tumor. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Our proprietary repositories of tissue and data, each of which we believe to be at an unmatched scale, are a resource that could not have been amassed without our underlying commercial profiling business, and as such are a significant differentiator and enabler of our discovery efforts. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Caris Strategic Data</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Data and molecular information are at the core of every aspect of our business. Our team of more than 60 data scientists deploy our proprietary advanced AI/ML algorithms to decipher unique features from our resulting clinico-genomic datasets, helping us decode and further unravel the molecular complexity of disease. Our 17-year history of utilizing AI and ML algorithms, together with the breadth and depth of our clinico-genomic datasets, provide us a significant advantage in sophisticated analysis of cancer, and a foundation that we believe will have applications in additional disease states. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The tremendous amount of data generated through our profiling solutions, which we have deidentified for research use, provides us a differentiated capability to advance precision oncology research through many business models. For example, we launched our data licensing business in late 2022, through which we license deidentified data that we have generated from our clinical profiling business to biopharma companies with the aim of generating insights directly responsible for superior clinical outcomes for patients. We have a rich pipeline of data opportunities that we believe will deliver new partnerships, as we continue to introduce biopharma companies to this unique data offering. Additionally, through the Caris POA, which is a growing network of leading cancer centers and research consortia across the globe, we support research partner engagement, collaboration opportunities, and the advancement of precision oncology research. Since its establishment in 2015, the Caris POA has grown to comprise 96 members as of March 31, 2025, including 45 NCI-designated comprehensive cancer centers that work collaboratively toward a common goal: to advance tumor profiling and establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. We estimate that the members of the Caris POA have over 3,000 oncologists in over 650 locations that treat more than 650,000 new cancer patients annually.</font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Future Assays</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Caris aims to develop the next generation of precision medicine tools that will allow us to transition from intuitive medicine to empirical medicine. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible. For example, we are developing Caris ChromoSeq, an assay to detect and analyze hematological (blood) cancers using whole genome sequencing (&#8220;WGS&#8221;) and WTS. We are internally validating this assay and developing it for commercial launch. We are also working to develop and validate the plasma portion of our Caris Assure assay for full germline testing. Additionally, we are using our molecular data to develop ESPai, an AI/ML algorithm to predict the risk of recurrence of early-stage breast cancer. We have obtained the samples and clinical data from the National Surgical Adjuvant Breast and Bowel Project and the ECOG-ACRIN Cancer Research Group. We are currently in the process of creating two AI/ML&#160;models for ESPai using these samples and are working to obtain additional samples for external validation studies. We are initially creating a model for late recurrence (five to 15 years following diagnosis), but we are also in the beginning stages of creating a model for early recurrence (zero to five years following diagnosis).</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Caris Infrastructure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe our well-developed laboratory, R&amp;D, and sales infrastructure is foundational to our business. We have substantial testing capacity, including over 275,000 square feet of space across four precision medicine laboratories with throughput capabilities of over one trillion reads per day generated by 50 NovaSeq sequencing systems. We believe this capacity provides us with ample capability to manage our current operations and future growth. We also have a dedicated R&amp;D infrastructure, including a specialized laboratory and over 200 employees dedicated to R&amp;D efforts. In addition to our internal research, we regularly partner with outside academic centers and researchers, including through the Caris POA. Additionally, to support our sales activity and expansion, as of March 31, 2025, we have assembled a targeted sales organization in the United States of over 270 sales team members and nearly 50 highly trained Ph.D. or M.D. molecular science liaisons (&#8220;MSLs&#8221;) who focus on physician and provider education. We believe that our robust, foundational infrastructure, together with our expansive multi-modal clinico-genomic datasets, has uniquely positioned Caris to deliver transformative and advanced innovations in precision medicine and patient care into the future. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Summary Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Participating in this offering involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading &#8220;Risk Factors&#8221; included elsewhere in this prospectus may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks we face include the following: </font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The precision medicine industry is highly competitive and subject to rapid change. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have incurred significant losses since inception, expect to incur losses in the future, and may not be able to generate sufficient revenue to achieve and maintain profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our current or future solutions may not achieve or maintain sufficient commercial market acceptance. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our solutions may not perform as expected, and the results of our validation studies or our clinical trials may not support the launch or use of our solutions and may not comply with the requirements, or be replicated in later trials required, for any necessary or desirable marketing authorizations. This could adversely affect our business, financial condition, results of operations, and growth prospects. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our current revenue is primarily generated from the continued adoption and use of our tissue-based profiling solution. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our future success and growth will depend in part on market acceptance and commercial success of our MI Cancer Seek and Caris Assure solutions. We may be unsuccessful in continuing the commercialization of MI Cancer Seek or Caris Assure, which would adversely affect our business, financial condition, results of operations, and growth prospects. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If we are unable to support demand for MI Profile, Caris Assure, and any other solutions we develop, including ensuring that we have adequate capacity to meet increased demand, or if we are unable to successfully manage our anticipated growth, our business could suffer. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations or any guidance we may provide. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If our solutions, or solutions we develop in the future, do not receive adequate coverage and reimbursement from third-party payers, including government and commercial payers, our ability to expand access to our solutions beyond our existing sales channels, and thus our overall commercial success, will be limited. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our billing, collections, and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements could have an adverse effect on our future revenue. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We rely on a limited number of third-party suppliers or, in many cases, sole suppliers, for some of our next-generation sequencers, lab materials, reagents, and supplies, and we may not be able to find replacements or immediately transition to alternative suppliers if necessary. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If we or our partners fail to comply with healthcare and other applicable laws and regulations, we could face substantial penalties and sanctions and our business, reputation, financial condition, and results of operations could be adversely affected. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to our solutions, and our ability to successfully commercialize our solutions may be impaired. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have incurred substantial indebtedness, and we may not generate sufficient cash flow from operations to meet our debt service requirements, continue our operations, and pursue our growth strategy, and we may be unable to raise capital when needed or on acceptable terms. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The dual class structure of our common stock will have the effect of concentrating voting control with our founder and the other shareholders who held our capital stock prior to the completion of this offering, including our executive officers, directors, principal shareholders, and their respective affiliates, which will limit the ability of our other shareholders to affect the outcome of key corporate decisions and transactions, including a change of control.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Following this offering, we may become a &#8220;controlled company&#8221; within the meaning of the rules of Nasdaq and, as a result, would qualify for, and could rely on, exemptions from certain corporate governance requirements. In such event, you would not have the same protections afforded to shareholders of companies that are subject to such requirements.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Before you invest in our Class A common stock, you should carefully consider all the information in this prospectus, including matters set forth in the section titled &#8220;Risk Factors.&#8221; </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were founded in 2008 when we entered the field of precision oncology through our acquisition of Molecular Profiling Institute, a Delaware-incorporated molecular life sciences company. We were incorporated under the laws of the Cayman Islands in October&#160;2011 as Caris Life Sciences, Ltd. and in July&#160;2020, we changed our name to Caris Life Sciences, Inc. and re-domiciled to be incorporated in Texas. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 750 West John Carpenter Freeway, Suite 800, Irving, Texas 75039, and our telephone number is (866) 771-8946. Our website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.carislifesciences.com</font><font style="letter-spacing:0.2pt;">. The information on, or that can be accessed through, our website is not incorporated into this prospectus. You should not consider information contained on our website to be part of this prospectus in deciding whether to purchase shares of our Class A common stock. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;). We will remain an emerging growth company until the earliest to occur of: (i)&#160;the last day of the fiscal year in which we have at least $1.235&#160;billion in total annual gross revenue; (ii)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which would occur if the market value of our Class A common stock held by non-affiliates exceeded $700&#160;million as of the last business day of the second fiscal quarter of such year; (iii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (iv)&#160;the last day of the fiscal year ending after the fifth anniversary of the date of the completion of this offering. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we will present in this prospectus only two&#160;years of audited financial statements, plus any required unaudited financial statements, and related management&#8217;s discussion and analysis of financial condition and results of operations; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX Section&#160;404&#8221;); </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we will provide less extensive disclosure about our executive compensation arrangements; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we will not be required to hold shareholder non-binding advisory votes on executive compensation or golden parachute arrangements. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Accordingly, the information contained herein may be different than the information you receive from our competitors that are public companies or other public companies in which you hold stock. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period for complying with new or revised accounting standards and, as a result, our results of operations and financial statements may not be comparable to those of companies that have adopted the new or revised accounting standards. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class A common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Option to purchase additional shares of Class A common stock </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have granted the underwriters an option for a period of 30&#160;days to purchase up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; additional shares of our Class A common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class A common stock to be outstanding immediately after this offering </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares (or &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares if the underwriters exercise their option to purchase additional shares of Class&#160;A common stock in full). </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class B common stock to be outstanding immediately after this offering</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares.</font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Total common stock to be outstanding immediately after this offering</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares (or &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares if the underwriters exercise their option to purchase additional shares of Class A common stock in full). </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Reserved share program </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">At our request, the underwriters have reserved up to &#8199;&#8199;&#8199;&#8199;% of the shares of Class&#160;A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management, including certain of our directors, officers, employees and certain other parties related to us. If these persons purchase reserved shares it will reduce the number of shares of Class A common stock available for sale to the general public. Any reserved shares of Class&#160;A common stock that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of Class A common stock offered by this prospectus. For more information, see &#8220;Underwriting&#8201;&#8212;&#8201; Reserved Share Program.&#8221; </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We estimate that the net proceeds from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million (or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriters exercise their option to purchase additional shares of Class A common stock in full), based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font>
          </div>
          <div style="margin-left:192pt; margin-top:8pt; width:264pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures. We also intend to use approximately $&#8199;&#8199;&#8199;&#8199; million of the net proceeds, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement (as defined below). We will have broad discretion in the way that we use the net proceeds from this offering. See the section titled &#8220;Use of Proceeds&#8221; for additional information. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Voting rights</font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Following the completion of this offering, we will have two classes of common stock: Class A common stock and Class B </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:192pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">common stock. Our Class A common stock will be entitled to one vote per share, and shares of our Class B common stock will be entitled to 10 votes per share. Holders of our Class A common stock and Class B common stock will generally vote together as a single class, unless otherwise required by law or our amended and restated certificate of formation. </font>
          </div>
          <div style="margin-left:192pt; margin-top:8pt; width:264pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The holders of our outstanding Class B common stock will collectively hold approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock immediately following the completion of this offering, with our executive officers, directors, principal shareholders, and their respective affiliates collectively holding approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock. These shareholders will have the ability to exercise significant influence over the outcome of matters submitted to our shareholders for approval, including the election of our directors and the approval of any change of control transaction. See the sections titled &#8220;Principal Shareholders&#8221; and &#8220;Description of Capital Stock&#8221; for additional information. </font>
          </div>
          <div style="margin-left:192pt; margin-top:8pt; width:264pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Following the completion of this offering, each share of our Class B common stock will be convertible into one share of our Class A common stock at any time and will convert automatically upon certain transfers and upon certain other circumstances as described in our amended and restated certificate of formation. See the section titled &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Common Stock&#8201;&#8212;&#8201;Conversion&#8221; for additional information. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Controlled company </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately &#8199;&#8199;&#8199;&#8199;% of our outstanding shares of capital stock and approximately &#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock. As a result, Mr. Halbert will have the ability to exercise significant influence over the outcome of matters submitted to our shareholders for approval, including the election of our directors and the approval of any change of control transaction, and, following this offering, we may become a &#8220;controlled company&#8221; as defined under the corporate governance rules of the Nasdaq.</font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">See the section titled &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">21</a> and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our Class A common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Proposed Nasdaq trading symbol </font>
            </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;CAI&#8221;</font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our common stock to be outstanding after this offering is based on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class B common stock outstanding as of March&#160;31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement (each as defined below), and excludes: </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:2pt; margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock issuable upon the exercise of options outstanding under our 2020 Incentive Plan, as amended and restated (the &#8220;2020 Plan&#8221;), as of March&#160;31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock issuable upon the exercise of options granted under our 2020 Plan subsequent to March 31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock issuable upon the vesting and settlement of restricted stock units (&#8216;&#8216;RSUs&#8221;) granted under our 2020 Plan that are held by current executive officers, employees, directors, and consultants and are subject to vesting conditions that are not satisfied in connection with this offering;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;B common stock issuable upon the exercise of options held by David D. Halbert that were outstanding under our 2020 Plan as of March&#160;31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199; per share;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;B common stock issuable upon the exercise of warrants issued in April 2025 at an exercise price of $0.01 per share (the &#8220;2025 Warrants&#8221;), based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock reserved for future issuance under our 2025 Incentive Award Plan (the &#8220;2025 Plan&#8221;), which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions of our 2025 Plan that automatically increase the share reserve under our 2025 Plan; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock reserved for future issuance under our 2025 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions in our ESPP that automatically increase the share reserve under our ESPP. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Unless otherwise indicated, all information in this prospectus assumes:</font>
          </div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">a one-for-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;reverse stock split of our common stock effected as of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the issuance of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Series&#160;C preferred stock upon the assumed exercise of warrants outstanding as of March&#160;31, 2025, which warrants are exercisable to purchase, at the holder&#8217;s election, shares of either our common stock or our Series&#160;C preferred stock and will expire upon the completion of this offering unless earlier exercised (the &#8220;Warrant Exercise&#8221;); </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the conversion of (i) all shares of our convertible preferred stock outstanding as of March&#160;31, 2025 (including the &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Series&#160;C preferred stock issued upon the Warrant Exercise) and (ii) all shares of our Series E and Series F convertible preferred stock issued and sold in April 2025 (such issuance and sale, the &#8220;Series E and F Issuance&#8221;), into an aggregate of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock, which will occur immediately prior to and in connection with the completion of this offering (the &#8220;Preferred Stock Conversion&#8221;); </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the issuance of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock upon the conversion of senior convertible notes issued by us in April 2025 (the &#8220;2025 Convertible Notes&#8221;), which conversion will occur immediately prior to and in connection with the completion of this offering (the &#8220;Notes Conversion&#8221;), based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the effectiveness of our amended and restated certificate of formation, which, among other things, will reclassify all outstanding shares of our common stock (including shares issued pursuant to the Warrant Exercise, the Preferred Stock Conversion, and the Notes Conversion) into an equivalent number of shares of our Class B common stock (the &#8220;Common Stock Reclassification&#8221;) and which will occur immediately prior to the completion of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the reclassification of all shares of common stock underlying equity awards outstanding under our 2020 Plan into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our Class A common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our Class B common stock (in the case of equity awards held by David D. Halbert), which will occur immediately prior to the completion of this offering;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the net issuance of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock underlying RSUs outstanding under our 2020 Plan that are held by current executive officers, employees, directors, and consultants and will vest in connection with this offering, after giving effect to the withholding of &#8199;&#8199;&#8199;&#8199; shares of our Class A common stock to satisfy the estimated tax withholding and remittance obligations (based on an assumed initial offering price of $&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and an assumed tax withholding rate of &#8199;&#8199;&#8199;&#8199;%) (the &#8220;RSU Class A Net Settlement&#8221;); </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the net issuance of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class B common stock underlying RSUs outstanding under our 2020 Plan that are held by David D. Halbert and will vest in connection with this offering, after giving effect to the withholding of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class B common stock to satisfy the estimated tax withholding and remittance obligations (based on an assumed initial offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and an assumed tax withholding rate of &#8199;&#8199;&#8199;&#8199;&#8199;%) (the &#8220;RSU Class B Net Settlement&#8221; and, together with the RSU Class A Net Settlement, the &#8220;RSU Net Settlement&#8221;);</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the adoption of our amended and restated bylaws, which will occur immediately prior to the completion of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">no exercise by the underwriters of their option to purchase additional shares of Class A common stock; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">no exercise of outstanding options or settlement of outstanding RSUs except as described above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The assumed tax withholding rates applicable to the RSU Net Settlement used in this prospectus are estimates. The estimates in this prospectus relating to the RSU Net Settlement and related share withholding may differ from actual results due to, among other things, the actual initial public offering price and other terms of this offering determined at pricing, actual forfeitures through the date of this prospectus, and actual tax withholding rates. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:10pt; margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">SUMMARY CONSOLIDATED FINANCIAL AND OTHER DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following tables set forth a summary of our historical consolidated financial and other data as of, and for the periods ended on, the dates indicated. The summary consolidated statements of operations data for the&#160;years ended December&#160;31, 2024 and 2023 and the summary consolidated balance sheet data as of December&#160;31, 2024 are derived from our audited consolidated financial statements and related notes included elsewhere in this prospectus. The summary consolidated statements of operations data for the three months ended March 31, 2025 and 2024 and the summary consolidated balance sheet data as of March&#160;31, 2025 are derived from our unaudited condensed consolidated financial statements and related notes included elsewhere in this prospectus. In our opinion, the unaudited interim financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such interim financial statements. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our historical results are not necessarily indicative of results that may be expected in the future. You should read these data together with our financial statements and related notes appearing elsewhere in this prospectus and the information in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </font>
          </div>
          <table style="width:456pt;height:436pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Three Months Ended March 31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2025</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2024 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2024</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:250.64pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:2.083pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in&#160;thousands, except </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">per share data) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <font style="letter-spacing:-0.2pt;">Consolidated Statements of Operations Data</font><font style="font-weight:normal;letter-spacing:0.2pt;">:</font>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Revenue:</font>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">114,081</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">73,233</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">349,115</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">278,748</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">6,834</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">7,444</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">63,145</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">27,380</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Total revenue </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">120,915</div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">80,677</div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">412,260</div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">306,128</div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Costs and operating expenses: </font>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">60,894</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,894</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">223,075</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">207,509</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:250.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development services </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,958</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,669</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,403</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">9,309</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,829</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,609</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">152,602</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">142,925</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">General and administrative expense </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,119</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">44,354</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">169,386</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">149,053</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Research and development expense </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">23,066</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">34,376</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">113,916</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">116,883</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:20pt;font-weight:normal;">
                  <font style="letter-spacing:0.2pt;">Total costs and operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">178,867</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">172,902</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">669,382</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">625,679</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Loss from operations </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(57,952<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(92,225<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(257,122<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(319,551<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Interest income </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">503</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,768</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,122</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">11,258</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Interest expense </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(12,782<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(9,290<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(50,025<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(31,610<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(32,333<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(11,064<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">18,484</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">11,094</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Other expense, net </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(219<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(349<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(12,606<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:250.64pt;text-align:left;">
                <div style="margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Total other expense, net </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(44,629<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(18,804<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(24,768<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(21,864<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.75pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Loss before income taxes and provision for income taxes </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(102,581<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(111,028<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(281,890<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(341,415<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:250.64pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Provision for income taxes </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">&#8212;</div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">&#8212;</div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">&#8212;</div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">&#8203;</div>
              </td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">&#8212;</div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:250.64pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Net loss </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(102,581<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(111,028<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(281,890<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(341,415<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:250.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Adjustments of redeemable convertible preferred stock to redemption value </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(24,262<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(23.113<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(96,367<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(121,112<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:250.64pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Net loss attributable to common shareholders </font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(127,043<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(134,141<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(378,257<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
                <div style="font-weight:bold;">$</div>
              </td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
                <div style="font-weight:bold;">(462,527<font style="position:absolute;">)</font></div>
              </td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0pt 0pt 2.083pt 0pt; width:250.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Net loss per share attributable to common shareholders, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(0.89<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(0.95<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(2.66<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(3.31<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <table style="width:456pt;height:148.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Three Months Ended March 31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:250.64pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2025</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2024 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2024</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:250.64pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:2.083pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in&#160;thousands, except </font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">per share data) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.417pt 0pt 2.083pt 0pt; width:250.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Weighted-average shares used to compute net loss per share attributable to common shareholders, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">142,492</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">141,252</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">141,987</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">139,771</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0.917pt 0pt 2.083pt 0pt; width:250.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Pro&#160;forma net loss per share attributable to common shareholders, basic and diluted (unaudited)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(1)(2)</font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:0.917pt 0pt 2.083pt 0pt; width:250.64pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Weighted-average shares used to compute pro&#160;forma net loss per share attributable to common shareholders, basic and diluted (unaudited)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(1)(2)</font>
                </div>
              </td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.795pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1.333pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt; width:2.5pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0.504999999999999pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4.5pt;line-height:4.5pt;">
              <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:9.9pt; width:456pt;">
            <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
            <font style="letter-spacing:0.18pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.18pt;">See Note 12 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate our historical basic and diluted net loss per share attributable to common shareholders and the weighted-average number of shares of common stock used in the computation of these per share amounts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:11pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
            <font style="letter-spacing:0.18pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.18pt;">Gives effect to (i)&#160;the Warrant Exercise, (ii)&#160;the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <table style="width:456pt;height:134.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.12pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2025 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.12pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Actual </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro Forma</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">As Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)(3)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:273.12pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in thousands) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:273.12pt;text-align:left;">
                <font style="letter-spacing:-0.2pt;">Consolidated Balance Sheet Data</font><font style="font-weight:normal;letter-spacing:0.2pt;">: </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.12pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">31,201</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.12pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Working capital</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">8,679</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.12pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total assets </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">291,583</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.12pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total liabilities </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">645,335</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:273.12pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total shareholders&#8217; (deficit) equity </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(2,599,865<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.57pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:12.41pt; width:456pt;">
            <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:11.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
            <font style="letter-spacing:0.18pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:11.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.18pt;">Gives effect to (i)&#160;the Warrant Exercise, (ii)&#160;the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v)&#160;the Common Stock Reclassification, and (vi) the RSU Net Settlement. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:11pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
            <font style="letter-spacing:0.18pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.18pt;">Gives effect to (i)&#160;the pro&#160;forma adjustments described in footnote (1)&#160;above, (ii)&#160;the sale by us of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and (iii)&#160;the use of approximately $&#8199;&#8199;&#8199;&#8199; million of the net proceeds from this offering, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:11pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
            <font style="letter-spacing:0.18pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.18pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, and total shareholders&#8217; (deficit) equity by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 in the number of shares of Class A common stock we are offering would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, and total shareholders&#8217; (deficit) equity by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the assumed initial public offering price per share remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Pro&#160;forma adjustments in this footnote and the footnotes above, as </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:36pt; width:420pt; line-height:11pt;font-size:9pt;">
            <font style="letter-spacing:0.18pt;">well as the related information in the balance sheet data, are illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </font>
          </div>
          <div style=" float:left; line-height:11pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
            <font style="letter-spacing:0.18pt;">(4)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.18pt;">We define working capital as current assets, less current liabilities. See our consolidated financial statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Non-GAAP Financial Measures</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <table style="width:384pt;height:65.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.68pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Three Months Ended March 31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.68pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2025</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2024 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2024</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2023 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:159.68pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in thousands) </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:159.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Adjusted EBITDA </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(36,216<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(70,062<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(189,566<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(255,309<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:159.68pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Free cash flow</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(34,027<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(75,663<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:5.545pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(253,643<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(298,419<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We use Adjusted EBITDA and free cash flow, financial measures not calculated in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) to supplement our consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, Adjusted EBITDA and free cash flow, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. </font>
          </div>
          <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. Adjusted EBITDA provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges. We define free cash flow as net cash used in operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash. For additional information regarding Adjusted EBITDA and free cash flow, including a reconciliation of these measures to the most directly comparable financial measure calculated in accordance with GAAP, see the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Non-GAAP Financial Measures.&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our Class A common stock involves risk. You should carefully consider the risks described below, as well as the other information in this prospectus, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this prospectus, before deciding whether to invest in our Class A common stock. This prospectus also contains forward-looking statements that involve risks and uncertainties. See the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our Class A common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Business and Industry</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The precision medicine industry is highly competitive and subject to rapid change.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our industry is highly competitive and characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements, and evolving industry standards. Our future success will depend on our ability to compete successfully and keep pace with the evolving needs of physicians, patients, and our biopharma partners on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of technological and scientific advances. In recent&#160;years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer and advances in methods used to analyze large amounts of genomic information. We must continuously enhance our proprietary profiling and signature offerings and develop new solutions in a cost-effective way to achieve meaningful innovation in precision oncology and other chronic disease states. If we do not update our suite of solutions to reflect new scientific knowledge or technological advancements, including as they relate to precision medicine, therapeutic developments, or relevant validation studies or clinical trials, adoption and use of our current solutions and any new solutions we may develop could decline, which would adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, as an AI TechBio company that has experienced significant recent growth in the rapidly evolving field of precision medicine, our current business, our future success, and the risks and challenges we may encounter can be difficult to evaluate or accurately predict. If we fail to address the risks and difficulties that we face, including those described elsewhere in this &#8220;Risk Factors&#8221; section, our business, financial condition, and results of operations could be adversely affected. We have encountered in the past, and expect to encounter in the future, risks and difficulties frequently experienced by companies operating in rapidly evolving fields. If our assumptions regarding these risks and difficulties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks and difficulties, our results of operations could differ materially from our or your expectations, and our business, financial condition, and results of operations could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred significant losses since inception, expect to incur losses in the future, and may not be able to generate sufficient revenue to achieve and maintain profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have incurred significant losses since our inception. For the&#160;years ended December&#160;31, 2024 and 2023, we incurred net losses of $281.9&#160;million and $341.4&#160;million, respectively. For the three months ended March&#160;31, 2025 and 2024, we incurred net losses of $102.6 million and $111.0 million, respectively. As of March&#160;31, 2025, we had an accumulated deficit of $2.6&#160;billion. To date, we have financed our operations principally from the sale of convertible preferred stock, the incurrence of indebtedness, and revenue from molecular profiling and pharma R&amp;D services. Over the last 17&#160;years, we have devoted significant resources towards developing our current portfolio that consists of tissue- and blood-based profiling solutions, building our multi-modal clinico-genomic datasets, expanding our operational capacity, and strengthening our AI/ML-driven data analysis capabilities. We also devote significant resources to clinical and regulatory initiatives to obtain marketing authorization, sales and marketing activities, and R&amp;D activities. We anticipate incurring significant costs to continue developing and commercializing our solutions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, because of the various risks and uncertainties associated with developing and commercializing our solutions, we are unable to predict the extent of future costs that may impact our prospects for profitability. Our future expenses will depend, in part, on the level of our expenditures and our ability to generate revenue at scale. We expect to continue to incur significant expenses and operating losses for the foreseeable future if and as we, among other things: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">attract, hire, and retain qualified personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">continue our R&amp;D activities and scale our R&amp;D infrastructure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">expand our laboratory capacity and operating capabilities, including completing the build-out of our laboratory facility in Irving, Texas; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">further build our sales, marketing, and distribution infrastructure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">continue to invest in the expansion and enrichment of our clinico-genomic datasets and related analysis capabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">seek marketing authorization that may be necessary or desired for our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property obtained through license agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">meet the requirements and demands of being a public company; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">defend against any claims or other lawsuits related to our solutions or otherwise. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to delay the launch of any new solutions, narrow or change our intended use or product claims, modify or expand our clinical trials or to perform additional clinical trials, either pre- or post-approval, in addition to those that we currently anticipate. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will also need to generate significant additional revenue to achieve and then sustain profitability, and even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. While we have commercially launched MI Cancer Seek, a new WES/WTS NGS assay, in the United States and seek to drive its increased adoption, and also plan to capitalize on the potential of Caris Assure applications for early detection, MRD tracking, and treatment monitoring and in chronic disease states beyond oncology, we cannot assure you that we will successfully be able to do so as planned, if at all, and our failure to do so may prevent us from generating increased revenue. Our failure to achieve or maintain profitability could negatively impact the value of our Class A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our current or future solutions may not achieve or maintain sufficient commercial market acceptance.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The commercial success of any of our solutions, including MI Profile and Caris Assure, or solutions that are marketed in the future, will depend upon the degree of commercial market acceptance, including by government payers, insurance companies, integrated health systems, healthcare providers, patients, biopharma companies and other third-party payers. The degree of market acceptance of our solutions will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the performance and clinical utility of such solutions as demonstrated in clinical trials and published in peer-reviewed journals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate of adoption and/or endorsement of our solutions by clinicians, KOLs, advocacy groups, and biopharma companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the ability of our newer solutions, such as Caris Assure, and solutions that may be marketed in the future, to demonstrate the same performance in real-world intended use populations as in clinical trials or analytical or clinical validation studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the willingness of medical providers to utilize our solutions as they are commercially released; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the willingness of commercial third-party payers and government payers to cover and reimburse for our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the development or introduction of competing products, including the expansion of the capabilities of existing products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the market acceptance of existing competitive products, including tests that are currently reimbursed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">publicity concerning our solutions or competing products; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the strength of our marketing and sales support. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that we will be successful in addressing each of these factors or other factors that might affect the market acceptance of our solutions. Failure to achieve broad market acceptance of our solutions, would harm our business, financial condition, and results of operations. For additional information, see &#8220;&#8212;Our current revenue is primarily generated from the continued adoption and use of our tissue-based profiling solution, and we are highly dependent on it for our success&#8221; and &#8220;&#8212;Our future&#160;success and growth will depend in part on market acceptance and commercial success of our MI Cancer&#160;Seek and Caris Assure solutions. We may be unsuccessful in continuing the commercialization of MI Cancer Seek or Caris Assure, which would adversely affect our business, financial condition, results of operations, and growth prospects.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our solutions may not perform as expected, and the results of our validation studies or our clinical trials may not support the launch or use of our solutions and may not comply with the requirements, or be replicated in later trials required, for any necessary or desirable marketing authorizations. This could adversely affect our business, financial condition, results of operations, and growth prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success depends on the market and the medical community&#8217;s confidence that we can provide reliable, high-quality solutions, as well as our ability to complete validation studies and clinical trials and comply with applicable regulatory requirements that would allow us to commercialize our solutions. Our solutions, including MI Cancer Seek, for which we have obtained PMA approval from the FDA, MI Tumor Seek Hybrid, and Caris Assure, may not perform as expected, and the results obtained from our ongoing or future studies and trials may be inconsistent with certain results obtained from our previous studies or trials. In addition, the application of Caris Assure in early detection, MRD tracking, and treatment monitoring, for which we are still collecting preliminary data to support, may not be as effective as we anticipate. If Caris Assure or our other solutions are ineffective or do not consistently perform as expected, either before or after launch, our business, financial condition, results of operations, and growth prospects would suffer. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our solutions require a number of complex and sophisticated biochemical and bioinformatics processes, many of which are highly sensitive to external factors. An operational or technological failure in one of these complex processes or fluctuations in external variables may result in sensitivity and specificity rates that are lower than we anticipate or that vary between test runs or in a higher than anticipated number of tests that fail to produce consistent results. In addition, we regularly evaluate and refine our AI/ML algorithms and other processes under development. These refinements may inadvertently result in unanticipated issues that may reduce our sensitivity and specificity rates or otherwise adversely affect the performance of our solutions and their results, such that supplemental submissions to the FDA may be required. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have obtained a PMA approval from the FDA for MI Cancer Seek and intend to seek FDA approval for Caris Assure and additional solutions, though the timing thereof is uncertain. The FDA and other regulators may request additional information or require that we generate additional clinical data to support such future approval applications, which could result in delays, increased costs, or other limitations on our ability to receive such approval. Additionally, the FDA included certain conditions of approval and limitations in the PMA approval letter for MI Cancer Seek, namely that we submit data evaluating the effects of interfering substances such as necrotic tissue, melanin, and fatty acids and also conduct a study and submit data regarding formalin-fixed paraffin-embedded block and slide stability duration claims. Our failure to comply with these limitations and conditions could result in the withdrawal of the PMA approval for MI Cancer Seek. Furthermore, in May&#160;2024, the FDA finalized an amendment to its regulations via issuance of a final rule pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four&#160;years. On March 31, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2025, the United States District Court for the Eastern District of Texas vacated the FDA&#39;s LDT final rule. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected. For additional information, see &#8220;&#8212;Risks Related to Regulation and Legal Compliance&#8212;The marketing authorization processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable marketing authorizations, or if such marketing authorizations are significantly delayed, our business will be substantially harmed&#8221; and &#8220;&#8212;We have current solutions marketed as LDTs and plan to launch future solutions as LDTs. The FDA recently finalized a rule, which has since been vacated by a federal court, pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its current policy of enforcement discretion over LDTs over a period of four&#160;years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected.&#8221; Further, we plan to enhance, iterate, and improve our solutions, scalability, and/or reduce our cost of goods. However, we may not be successful in transitioning our solutions to new or enhanced versions or iterations, or reducing our cost of goods. The improvement of our solutions involves a lengthy and complex process, may require regulatory approval, and we may be unable to commercialize, validate, or improve performance of any of our solutions on a timely basis, or at all. Our failure to successfully develop new and/or improved solutions (including new versions of existing solutions) on a timely basis could adversely affect our business, financial conditions, and results of operation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finally, generating the clinical data necessary to validate and support the launch of our solutions and new versions of solutions and subsequently obtain marketing authorization or third-party reimbursement, is time-consuming and carries with it the risk of not yielding the desired results. The performance achieved in our analytical validation studies, clinical trials, or published studies may not be replicated in later studies that may be required to obtain or maintain marketing authorization. For example, limited results from earlier-stage analytical validation studies, such as our analytical validation studies on the use of Caris Assure for early detection, MRD tracking, and treatment monitoring, may not predict results from studies in larger numbers of participants drawn from more diverse populations over a longer period of time. Unfavorable results from ongoing analytical validation studies or clinical trials, or delays in publication of such results, could lead to delays, modifications, or abandonment of ongoing or future studies and trials, or abandonment of a solution development program, or may delay, limit, or prevent marketing authorizations or commercialization of our solutions. In addition, results from such studies and trials may not be consistent with the results from real-world application of our solutions, if commercialized, for a particular care setting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our current revenue is primarily generated from the continued adoption and use of our tissue-based profiling solution.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to execute our growth strategy and become profitable is highly dependent on the continued adoption and use of MI Profile, our tissue-based profiling solution, which accounted for 78.2% and 91.0% of our revenue in the&#160;years ended December&#160;31, 2024 and 2023, respectively, and 83.9% and 87.9% of our revenue for the three months ended March 31, 2025 and 2024, respectively. Continued adoption and use of MI Profile will depend on several factors, including the prices we charge for our solution, the scope of coverage and amount of reimbursement available from government and third-party payers for our solution, the availability of clinical data that supports the value of MI Profile and the inclusion of MI Profile solutions in industry treatment guidelines. The commercial success of our tissue-based profiling solution depends significantly on its broad adoption and use by oncologists and other physicians. Many physicians and biopharma companies have existing relationships with companies that develop molecular diagnostic tests, including our competitors, and may continue to use their tests instead of MI Profile. Despite our business development efforts, it could be difficult, expensive, and/or time-consuming for physicians and/or biopharma companies to switch diagnostic tests for their products, and MI Profile may not be widely accepted, if at all, which could in turn hinder the rate of adoption and continued use of our solutions. We cannot assure you that MI Profile will continue to maintain or gain market acceptance, and any failure to do so would harm our business, financial condition, and results of operations. Moreover, as we have leveraged the data we </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">have generated to date with MI Profile to develop Caris Assure and other solutions, if the adoption and use of MI Profile wanes or if reliability or other issues with the data we generate with MI Profile are discovered, the further development and future success and growth of Caris Assure and other solutions would be adversely impacted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our future success and growth will depend in part on market acceptance and commercial success of our MI Cancer Seek and Caris Assure solutions. We may be unsuccessful in continuing the commercialization of MI Cancer Seek or Caris Assure, which would adversely affect our business, financial condition, results of operations, and growth prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MI Cancer Seek, for which we obtained a PMA approval from the FDA in November 2024 and commercially launched in January 2025, is the new WES/WTS NGS assay component of MI Profile, our tissue-based molecular profiling solution for cancer therapy that has generated the majority of our revenue to date. Driving increased adoption among physicians of, and obtaining reimbursement for, MI Cancer Seek are key expected drivers of our growth, particular in the near and medium term. The success of MI Cancer Seek will depend upon, among other things, the extent to which our recent FDA approval drives increased adoption and use of the solution by physicians as a companion diagnostic tool.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure, for which we initiated the broad commercial launch for therapy selection in the first quarter of 2024, ultimately aims to address the entire continuum of cancer treatment. Realizing the potential of Caris Assure across disease states is a key component of our long-term business strategy. The commercial success of Caris Assure for therapy selection and in other applications across the cancer treatment continuum will depend upon, among other things, additional analytical validation studies and clinical trials that demonstrate the effectiveness of Caris Assure, particularly for early detection, MRD tracking, and treatment monitoring, the continued adoption of Caris Assure by physicians, the medical community, patients, and third-party payers, and our ability to successfully run and market Caris Assure in substantial quantities or to manage and expand the required infrastructure to do so, including large-scale laboratory and information technology systems. Maintaining and expanding market acceptance of our solutions, marketing, and laboratory capabilities are expensive and time-consuming. If MI Cancer Seek or Caris Assure is not successfully commercialized, we will not be able to recover the significant investment we have made in developing these solutions, and our business, prospects, financial condition, and results of operations would be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to support demand for MI Profile, Caris Assure, and any other solutions we develop, including ensuring that we have adequate capacity to meet increased demand, or if we are unable to successfully manage our anticipated growth, our business could suffer.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As and to the extent the volumes of our current and new solutions continue to grow, we will need to simultaneously increase our capacity for sample intake, storage, and processing enhance our customer service, improve our billing and general processes, expand our internal quality assurance programs, incorporate new equipment, implement new technology systems and processes, expand laboratory capacity, and otherwise extend our operational capabilities to support comprehensive genomic analyses at a larger scale while retaining expected turnaround times. We will also need additional equipment and certified and licensed laboratory personnel to process higher volumes of solutions. We may face difficulties increasing the scale of our operations, including implementing changes in infrastructure or programs or acquiring additional equipment or personnel. As we refine our solutions and develop additional solutions, we may need to bring new equipment on-line, implement new systems, technology, controls and procedures, and hire personnel with different qualifications, licenses, or certifications. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also in the process of constructing additional facilities in order to increase capacity, including our laboratory facility in Irving, Texas. We may not be able to complete construction of such facilities and obtain necessary certifications, permits, licenses, and accreditations in a timely or cost-effective manner, or at all. Therefore, we may be unable to support our development and commercial activities in a timely manner, if at all. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities or process enhancements will be successfully implemented, or that we will have adequate resources and facilities to accommodate such required expansion. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The value of MI Profile, Caris Assure, and related solutions will depend, in part, on our ability to perform tests and return test results to providers on a timely basis and at an appropriate quality standard, and on our reputation for such timeliness and quality. If our business grows too quickly, our ability to meet demand for our solutions in a timely and efficient manner could be challenged, and our quality standards or turnaround time may be compromised. Failure to implement necessary procedures, to transition to new equipment or processes, or to hire the appropriate, qualified personnel could result in higher costs of processing, longer turnaround times, declining product quality, deteriorating customer service, an inability to meet market demand, or slower responses to competitive challenges, all of which could make it difficult for us to meet market expectations for our solutions and could damage our reputation and the prospects for our business. There can be no assurance that we will be able to perform tests on a timely basis at a level consistent with demand, that we will be able to maintain the quality of our test results as we scale our commercial operations, or that we will be successful in responding to the growing complexity of our laboratory operations, including the related data analysis requirements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to add new associates in our Phoenix and Tempe, Arizona and Irving, Texas facilities. We will need additional laboratory scientists, technicians, and other scientific and technical personnel with different qualifications, licenses, or certifications. As our development plans and strategies develop, and as we transition into operating as a public company, we must add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">identifying, recruiting, integrating, retaining, and motivating employees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">managing our internal development and commercialization efforts effectively, including creating and maintaining compliant programs and processes, such as a laboratory and manufacturing quality system, and managing the regulatory requirements for our solutions, while adhering with our contractual obligations to contractors and other third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">expanding our operational, human resources, financial and management controls, reporting systems, and procedures; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">managing the increasing complexity associated with a larger organization and expanded operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our growth may place a significant strain on our management, operating and financial systems, R&amp;D, and our sales, marketing, and administrative resources. As a result of our growth, our operating costs may escalate even faster than planned, and some of our internal systems may need to be enhanced or replaced. If we cannot effectively manage our expanding operations and our costs, we may not be able to successfully commercialize future solutions and grow successfully, and our business could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations or any guidance we may provide.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our quarterly and annual results of operations may fluctuate significantly, which makes it difficult for us to predict our future results of operations. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the level of demand for our solutions, which may vary significantly; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and cost of, and level of investment in, research, development, regulatory approval, or certification and commercialization activities relating to our solutions, which may change from time to time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the volume and customer mix of our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the introduction of new solutions or solution enhancements by us or others in our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">coverage and reimbursement policies with respect to our solutions and products that compete with our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">expenditures that we may incur to acquire, develop, or commercialize additional solutions and technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in governmental regulations or in the status of our regulatory approvals or certifications or applications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">future accounting pronouncements or changes in our accounting policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments or disruptions in the business and operations of physicians and our biopharma partners; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of natural disasters, political instability, including wars, terrorism, and political unrest, epidemics or pandemics, boycotts, and curtailment of trade and other business restrictions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effects of high inflation or other general market and economic conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, due to the inherent variability and unpredictability of the reimbursement landscape, including related to the amount that payers reimburse us for any of our solutions, when we recognize revenue we estimate the transaction price based on our historical collection experience and on the historical selling price of similar transactions, where applicable, and subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period where such changes occur. Both the estimate and any subsequent revision are uncertain and require the use of management&#8217;s judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Due to this variability and unpredictability, previously recorded revenue adjustments are not indicative of future revenue adjustments from actual cash collections, which may fluctuate significantly. Moreover, we receive a substantial portion of our revenue from a limited number of third-party commercial payers. If one or more of these payers were to significantly reduce or cease to pay the amount such payer reimburses us for our solutions, or if such payer does not reach or maintain favorable coverage and reimbursement decisions for our solutions, it could have an adverse effect on our business, financial condition, and results of operations. We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our solutions, and in other situations, payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. For additional information regarding risks associated with the reimbursement landscape, see &#8220;&#8212;If our solutions, or solutions we develop in the future, do not receive adequate coverage and reimbursement from third-party payers, including government and commercial payers, our ability to expand access to our solutions beyond our existing sales channels, and thus our overall commercial success, will be limited.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual results of operations. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our results of operations fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our Class A common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide, and which could harm our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we do not have the support of KOLs or if clinical data using our solutions is not published in peer-reviewed journals or is otherwise not well received, it may be difficult to drive adoption and use of our solutions and establish them as a component of the standard of care for patients with cancer.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March 31, 2025, the Caris POA was comprised of 96 members, including 45 NCI-designated comprehensive cancer centers. If these KOLs or others within the broader precision oncology industry </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">determine that our platform, our existing solutions, or other solutions that we develop are not clinically effective, that alternative technologies are more effective, or if they elect to use internally developed products or services, we may see lower demand for our solutions and face difficulty establishing our solutions as an integral component of the applicable standard of care, which would limit our revenue growth and our ability to achieve profitability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The publication of clinical data using our solutions in peer-reviewed journals is also crucial to our success. We are unable to control when, if ever, results are published, which may delay or limit broad adoption and use of our solutions. Our ability to publish clinical data relating to our solutions in peer-reviewed publications may be limited by many factors, including increased difficulty in obtaining acceptance for publication from journals, conflicts of interest, lack of qualified experts willing to participate in the peer review process, delays in the completion of, poor design of, or lack of compelling data from, validation studies or clinical trials, as well as delays in the review, acceptance, and publication process. If our solutions do not receive sufficient favorable exposure in peer-reviewed publications or are not well received by clinicians, the rate of clinician adoption and use of our solutions and positive reimbursement coverage determinations for our solutions, even if approved with guideline inclusion, could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our solutions, or solutions we develop in the future, do not receive adequate coverage and reimbursement from third-party payers, including government and commercial payers, our ability to expand access to our solutions beyond our existing sales channels, and thus our overall commercial success, will be limited.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our revenue and commercial success depend on achieving coverage and reimbursement for assays that comprise MI Profile, Caris Assure, and any solutions we may offer in the future, from third-party payers, including both government and commercial payers. Obtaining approvals from third-party payers to cover our solutions and establishing adequate coding recognition and reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may not always be successful. Coverage determinations from third-party payers may depend on a number of factors, including a payer&#8217;s determination that a solution is appropriate, medically necessary, and cost-effective. Each payer will make its own decision as to whether to establish a policy or enter into a contract to cover our solutions and the amount it will reimburse for such solutions. In addition, determinations by a payer whether to cover and the amount it will reimburse for our solutions are often made on an indication-by-indication basis. If we are unable to provide payers with sufficient evidence of the clinical utility and validity of our solutions, they may not provide coverage, may provide limited coverage, or may terminate coverage for our solutions, which will adversely affect our revenues and our financial condition. In addition, the fact that one of our solutions has been approved for reimbursement in the past does not guarantee that such solution will remain approved for reimbursement, that the approved reimbursement amount will not be reduced in the future, or that similar or additional solutions will be approved in the future. Moreover, there can be no assurance that any new solutions we launch will be reimbursed at rates that are comparable to the rates that we historically obtained for our existing portfolio or rates that other industry participants receive. Third-party payers may not cover or provide adequate payment for our current or future molecular and other solutions to enable us to maintain past levels of revenue or profitability with respect to such solutions. Further, third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in the development of our solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Healthcare providers may not order our solutions unless third-party payers cover and provide reimbursement rates for a substantial portion of the price of our solutions. If we are unable to obtain adequate coverage and an acceptable level of reimbursement for our solutions from third-party payers, patients could incur a greater co-insurance, co-payment, and/or deductible obligation. Uninsured patients or patients whose insurance does not cover our solutions may also be forced to pay for our solutions out-of-pocket. Such scenarios could dissuade physicians from ordering our solutions or, if ordered, could result in delay in or decreased likelihood of our collection of payment. We thus believe our revenue and revenue growth will depend on our success in achieving broad coverage and adequate reimbursement for our solutions from third-party payers. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the coding process used by third-party payers to identify various medical procedures during the billing process is complex, may not adapt well to the types of solutions we offer, and may not enable coverage and adequate reimbursement rates. Current Procedural Terminology (&#8220;CPT&#8221;) coding plays </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a significant role in how our solutions are reimbursed both from commercial and governmental payers. The CPT code set is maintained by the American Medical Association (&#8220;AMA&#8221;) and includes the Proprietary Laboratory Analyses (&#8220;PLA&#8221;) codes that are used to describe many molecular diagnostic tests. In cases where there is not a specific CPT code to describe a test, or when required by a commercial payer, we bill under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. In addition, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) maintains the Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;) and may assign unique Level&#160;II HCPCS code to tests that are not already described by a unique CPT code. New CPT codes are issued annually and new HCPCS codes are issued as frequently as quarterly. In addition to CPT and HCPCS codes, Z-Code Identifiers are used by certain payers, including under MolDX, to supplement CPT codes for our solutions. Our MI Tumor Seek Hybrid solution is reported to Medicare and to some commercial payers using unlisted molecular pathology CPT code 81479 and unique test-specific identifier (&#8220;a DEX&#160;Z-Code&#8221;). Our MI Cancer Seek solution is reported to Medicare and to commercial payers using the 0211U CPT code and a unique DEX Z-Code identifier. Our Caris Assure solution is reported to Medicare and to non-contracted, commercial payers using the 0485U CPT code and a unique DEX Z-Code identifier. Commercial payers sometimes require other codes to be reported for our solutions, and we will bill in accordance with the respective contract terms. Changes to the codes used to report our solutions to payers may result in significant changes in reimbursement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage of certain diagnostic tests and the amounts that they will pay for such tests. Payers may also create conditions for coverage or may contract with third-party vendors to manage laboratory benefits, in both cases creating administrative hurdles for ordering physicians and patients that may make our services more difficult to sell. U.S. and foreign governments continue to propose and pass legislation designed to reduce the cost of healthcare. In some foreign markets, the government controls the pricing of many healthcare products. In the United States, we expect that there will continue to be federal and state proposals to implement governmental controls or impose healthcare requirements, which may increase the pressure to reduce spending on genetic testing and comprehensive molecular profiling. In addition, the Medicare program and increasing emphasis on managed care in the United States will continue to put pressure on product pricing. Cost control initiatives could decrease the price that we would receive for any solutions in the future, which would limit our revenue and profitability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Obtaining approvals from third-party payers to cover our existing and new solutions and establishing adequate coding recognition and reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may not always be successful. If third-party payers do not provide adequate coverage and reimbursement for our solutions, our ability to succeed commercially will be limited.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Medicare</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Medicare is the single largest U.S. payer and a particularly important payer for many cancer-related laboratory services given the demographics of the Medicare population. Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. Medicare coverage criteria that define when items and services are reasonable and necessary are defined in National Coverage Determinations (&#8220;NCDs&#8221;) made by&#160;CMS through an evidence-based process, with opportunities for public participation, and Local Coverage&#160;Determinations (&#8220;LCDs&#8221;) made by Medicare Administrative Contractors (&#8220;MACs&#8221;) that apply&#160;within the specific jurisdictions. Medicare&#8217;s NCD for NGS (NCD&#160;90.2), first established in 2018 and subsequently&#160;updated in 2020, provides national Medicare coverage for certain molecular diagnostic tests (1)&#160;performed in a laboratory certified by the Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;), (2)&#160;ordered by a treating physician, (3)&#160;the patient meets certain clinical and treatment criteria, including having recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, (4)&#160;the test is approved or cleared by the FDA as a companion IVD for an FDA-approved or -cleared therapeutic for use in that patient&#8217;s cancer, and (5)&#160;results are provided to the treating physician for management of the patient using a report template to specify treatment options. The NGS NCD also provides discretion to the MACs to provide local coverage of other NGS tests for cancer patients only when the test is performed by a CLIA-certified laboratory, ordered by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered NGS tests under the NGS NCD. Palmetto GBA is the MAC </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">responsible for administering MolDX, which issues coverage determinations applicable to molecular diagnostic tests within the scope of the program, including for molecular assays that are LDTs. Our MAC for the Phoenix laboratory locations is Noridian, and Noridian relies on MolDX to make local coverage and pricing determinations relating to molecular testing. To achieve coverage under MolDX, laboratories must apply for and obtain a DEX Z-Code that is unique to the laboratory&#8217;s specific test and must also submit a technical assessment to demonstrate analytical and clinical validity, and clinical utility at a level that meets the Medicare reasonable and necessary requirement. Analytical validity relates to technical performance, such as that an assay accurately and reliably measures a specific feature. Clinical validity means whether a test can accurately identify, measure, or predict a clinical condition or characteristic in patients.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Diagnostic Tests: Tissue- and Blood-Based Solutions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have received DEX Z-Codes and MolDX technical assessments for our MI Cancer Seek, Caris Assure, and MI Tumor Seek Hybrid solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We received a PMA approval for MI Cancer Seek from the FDA in November 2024 and commercially launched the solution in January 2025. We have obtained Medicare coverage under the NGS NCD for MI Cancer Seek for CPT code 0211U at $8,455 under the CLFS. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our MI Tumor Seek Hybrid solution is covered for solid tumor testing as allowable under the NGS NCD and related LCD and are reported to Medicare with unlisted molecular pathology CPT code 81479 and the unique DEX Z-Code identifier issued by MolDX. MI Tumor Seek Hybrid is covered by Medicare as of August&#160;3, 2022, with current MolDX pricing of $3,500. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Caris Assure solution is currently reported to Medicare using a PLA code, CPT code 0485U, and a unique DEX Z-Code identifier issued by MolDX. Caris Assure is covered for therapy selection by Medicare as of December&#160;8, 2023 for Comprehensive Genomic Profiling from ctDNA of patients with recurrent, relapsed, refractory, metastatic, or advanced solid tumors who are seeking treatment, and for whom tissue-based, comprehensive genomic profiling (&#8220;CGP&#8221;) is infeasible (for example, quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), with current MolDX pricing of $3,649. In November 2024, CMS determined to price Caris Assure for therapy selection using the &#8220;Gapfill&#8221; method. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. For additional information, see &#8220;Business&#8212;Government Regulation&#8212;Coverage and Reimbursement&#8212;Coverage and Reimbursement in the United States.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Immunohistochemical Tests</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As part of our MI Profile solution, we perform certain third-party IHC tests. Medicare coverage and payment for these tests is under the Molecular Pathology Procedures Billing and Coding Article, with payment amounts assigned to specific HCPCS and CPT codes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Protecting Access to Medicare Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Medicare payment for clinical diagnostic laboratory tests (&#8220;CDLTs&#8221;) is generally made under the CLFS based on payment rates that are assigned to specific HCPCS or CPT codes. Under the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), laboratories that meet certain requirements related to volume and type of Medicare revenues are required to report to CMS, beginning in 2017 and every three&#160;years thereafter (or annually for &#8220;advanced diagnostic laboratory tests&#8221; &#8203;(&#8220;ADLTs&#8221;)), their private payer payment rates and volume for each test they perform that is reported with a specific HCPCS code (defined by PAMA to exclude miscellaneous or unlisted codes). ADLTs are subject to separate reporting and payment requirements under PAMA. New ADLTs are paid at a rate equal to their actual list charge during an initial period of three calendar quarters, after which CLFS payment is based on the weighted median of private payer rates, which must be reported annually for ADLTs. We are subject to these reporting requirements under PAMA for any solution we perform that is not reported with a miscellaneous HCPCS or CPT code, including the third-party IHC tests we perform, and for any profiling solutions that commercial payers currently require us to report using a HCPCS code that has been identified by CMS as subject to PAMA reporting requirements. In addition, MI Cancer Seek, which is reported with PLA code&#160;0211U, Caris Assure, which is reported using PLA Code 0485U, and any other solution for which we obtain a specific HCPCS </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">or CPT code, will be subject to these reporting requirements in future PAMA reporting cycles, and that the Medicare CLFS payment rates for such solutions will be calculated in the future based on our private payer rates. While we do not currently have ADLT status for any of our solutions, we may seek ADLT status for one or more of our solutions in the future. If we are successful in obtaining such ADLT status, any solution for which we obtain ADLT status will be subject to the PAMA reporting requirements and pricing methodology as an ADLT. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Congress passed legislation that delayed data reporting requirements for CDLTs that are not ADLTs and further delayed the phase-in of payment reductions under the CLFS from private payer rate implementation. Any reductions to reimbursement rates resulting from the new methodology are limited to 0% in 2025 and 15% per test per year in each of 2026 through 2028. The subsequent data reporting periods for CDLTs that are not ADLTs will occur in three-year cycles, with the next cycle beginning in 2026. CLFS rates for CDLTs will be updated every three&#160;years, and for ADLTs will be updated annually. For many tests and/or laboratories, the result of the PAMA pricing methodology has been lower pricing and reimbursement. As a result, our Medicare CLFS pricing for any solutions that may be subject to PAMA reporting requirements in the future could be negatively impacted by PAMA. In addition, private payer payment levels have more significance in setting Medicare reimbursement and, therefore, future Medicare payments may fluctuate more often and become subject to the willingness of private payers to recognize the value of diagnostic tests generally and any given test individually. Given the many uncertainties built into PAMA&#8217;s price-setting process, we cannot predict how payments we receive under the CLFS, and thus our revenue, may change from year to year. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to the reporting requirements and pricing methodology described above, PAMA codified Medicare coverage rules for laboratory tests by requiring any local coverage determination to be made following the local coverage determination process. PAMA also authorizes CMS to consolidate coverage policies for clinical laboratory tests among one to four laboratory specific MACs. These same contractors may also be designated to process claims if CMS determines that such a model is appropriate. It is unclear whether CMS will proceed with contractor consolidation under this authorization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Signature Tests, and Screening and Early Detection Intended Uses for Our Solutions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our proprietary molecular signature tests, GPSai and FOLFIRSTai, as well as early detection indications for our blood and tissue-based profiling solutions, are not currently covered by Medicare. Obtaining Medicare coverage for these molecular signatures would require significant investments and may ultimately be unsuccessful or may take several&#160;years to achieve. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we are developing screening capabilities for Caris Assure for MRD tracking and treatment monitoring in colorectal cancer (&#8220;CRC&#8221;), breast cancer, lung cancer, and other indications. On January&#160;19, 2021, CMS released an NCD that covers future tests for CRC screening if and when such screening tests have FDA approval and meet pre-specified CMS criteria. In addition, MolDX LCDs provide coverage for MRD for CRC, breast cancer, lung cancer, and other indications when applicable coverage criteria are satisfied. While this NCD and applicable LCDs may provide a pathway to coverage of Caris Assure in CRC and other indications under Medicare if applicable coverage criteria are satisfied, there is no assurance that we will be successful in completing the required studies, trials, or publications or obtaining FDA approval, or obtaining Medicare coverage even if we are successful in obtaining FDA approval, and if we are not successful, our business, financial condition, and results of operations would be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Commercial Payers and Other Payers</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our commercial success also depends on achieving acceptable coverage and reimbursement for our solutions from commercial payers. When we contract with a payer as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications, and in many cases require prior authorization. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our solutions and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s medical policies or the contract. Although we are a participating provider with many commercial payers, certain payers may not cover based on existing medical policy and may treat our solutions or solutions that we develop in the future as experimental and investigational or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">import restrictive coverage criteria. If we are not successful in obtaining coverage from such payers, or if other payers issue non-coverage policies, our business, financial condition, and results of operations could be adversely affected. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because current codes applicable to our solutions are not always test-specific, each insurance claim will have different submission criteria, including appending our DEX Z-Code, and typically must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require progress notes, medical records, or a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our solutions and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may never be successful in obtaining such approvals. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some payers have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it would have a negative impact on our revenue in the short term. Payers may resist reimbursement for our solutions in favor of less expensive tests, require pre-authorization for our solutions, or impose additional pricing pressure on and substantial administrative burden for reimbursement for our solutions. We expect to continue to focus substantial resources on increasing adoption of, and coverage and reimbursement for, our current solutions and any future solutions we may develop. We believe it may take several&#160;years to achieve broad coverage and adequate contracted reimbursement with a majority of payers for our solutions. However, we cannot predict whether, under what circumstances, or at what price levels payers will cover and reimburse our solutions. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for, our solutions, our ability to generate revenue could be harmed and our business, financial condition, and results of operations could be adversely affected. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if we establish relationships with commercial payers to provide our future solutions at negotiated rates, such agreements would not obligate any healthcare providers to order our solutions or guarantee that we would receive reimbursement for our solutions from these or any other payers at adequate levels. Thus, these payer relationships, or any similar relationships, may not result in acceptable levels of coverage and reimbursement for our solutions, or meaningful increases in the number of billable tests we perform. We believe it may take several&#160;years to achieve coverage and adequate reimbursement for our solutions with a majority of third-party payers, including with those payers offering negotiated rates. In addition, we cannot predict whether, under what circumstances, or at what payment levels payers will cover and reimburse for our solutions. In addition to the available Medicare coverage, we plan to market Caris Assure for early detection, MRD tracking, and treatment monitoring, as well as other solutions that we are developing or may develop in the future, to large self-insured employers, commercial insurance plans, certain physician directed channels, concierge medicine and executive health programs, and innovative health systems. Additionally, a third-party payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. If we fail to establish and maintain broad-based coverage and reimbursement for certain solutions, our ability to expand access to our solutions, generate increased revenue, and grow our clinical case volume and customer base for such solutions will be limited and our overall commercial success may be limited. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our billing, collections, and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements could have an adverse effect on our future revenue.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depending on the billing arrangement and applicable law, we bill and expect to bill various payers, such as governmental payers, insurance companies, hospitals, and patients, which may each have different billing requirements. We may face increased risk in our collection efforts, including long collection cycles and the risk that we never collect at all, either of which could adversely affect our business, financial condition, and results of operations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our failure to timely submit claims for our solutions to payers or failure to comply with applicable billing requirements could have an adverse effect on our revenue and our business, and could result in our inability to receive payment for our services or in attempts by private payers and state and federal healthcare programs, such as Medicare and Medicaid, to recover payments already made. Submission of claims in violation of billing requirements and applicable laws and regulations can result in recoupment of payments already received, substantial civil monetary penalties, and exclusion from state and federal health care programs, and can subject us to liability under the federal False Claims Act (the &#8220;FCA&#8221;) and similar laws. For example, in March 2025, we received a Civil Investigative Demand (&#8220;CID&#8221;) from the DOJ in connection with an investigation under the False Claims Act regarding our compliance with Medicare&#39;s date of service rule (also referred to as the 14-day rule). For additional information, see &#8220; &#8212;We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements&#8221; and &#8220;Business&#8212;Legal Proceedings.&#8221; The failure to report and return an overpayment to the Medicare or Medicaid program within 60&#160;days of identifying its existence can also give rise to liability under the FCA. Further, a government agency could attempt to hold us liable for causing the improper submission of claims by another entity for services that we performed if we were found to have knowingly participated in the arrangement at issue. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our claims for reimbursement may be denied and we may have to appeal such denials in order to get paid. Such appeals may not result in payment and can be time-consuming and costly. Moreover, payers often perform audits of historically paid claims and regularly attempt to recoup funds&#160;years after the funds were initially distributed if the payers believe the funds were paid in error or determine that our solutions were medically unnecessary. If a payer&#8217;s audit of our claims results in a negative finding, and we are unable to reverse the finding through appeal or subsequent litigation, any subsequent recoupment could have an adverse effect on our revenue. Additionally, in some cases commercial payers for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was excessive. In these situations, the payer typically notifies us of its decision and then offsets the amount it determines to be overpaid against amounts it owes us on current claims. We may not have a mechanism to dispute these retroactive adjustments, and we cannot predict when, or how often, a payer might engage in these reviews. We have been, are currently, and may in the future be, subject to overpayment demands, recoupment efforts, and related disputes from or with payers, managed care plans, and government healthcare programs relating to the billing and coding of our solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, we maintain financial assistance programs under which we assess patient financial need and offer to provide solutions at a discount, or at no cost, to certain eligible patients. These practices may result in scrutiny of our financial assistance programs by governmental and commercial payers and could result in recoupment actions or termination of coverage of our solutions, as well as scrutiny under health care fraud and abuse laws. For additional information, see &#8220;&#8212;We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements&#8221; and &#8220;Business&#8212;Legal Proceedings.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently handle our own billing and coding for our solutions but have initiated the process of transitioning certain of our billing and coding software and other operations to a vendor for revenue cycle management services. Our business, financial condition, and results of operations may be affected by our ability to successfully transition these functions and the ability of our vendor to timely, accurately, and appropriately code and bill claims and collect payments in compliance with the stringent billing, coding and documentation requirements imposed by government healthcare programs and other payers. Terminating or transitioning arrangements with revenue cycle management vendors could result in additional costs and a risk of operational problems, delays in collections from payers, potential errors and possible control issues during the termination and transition processes, any of which could adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on a limited number of third-party suppliers or, in many cases, sole suppliers, for some of our next-generation sequencers, lab materials, reagents, and supplies, and we may not be able to find replacements or immediately transition to alternative suppliers if necessary.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rely on Illumina, Inc. (&#8220;Illumina&#8221;) as the sole supplier of NGS instruments and the associated sequencing reagent kits for our solutions. Illumina is also the sole provider of maintenance and repair </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">services for these sequencing instruments. Without access to these sequencers, we may be unable to run our solutions and commercialize our solutions. Additionally, we rely on several sole suppliers, including, among others, Roche Diagnostics Corporation (&#8220;Roche&#8221;), Matsunami Glass USA (&#8220;Matsunami Glass&#8221;), and Agilent Technologies, Inc. (&#8220;Agilent&#8221;), for certain lab materials, reagents, and supplies. If we do not have timely access or access to sufficient quantities of these lab materials, reagents, and supplies, we may be unable to run our solutions and commercialize our solutions. We also rely on several sole suppliers, or manufacturers, for blood collection tubes, including the cfDNA PAXgene tubes for use with liquid biopsy profiling, for total nucleic acid extraction kits, and for the NGS panels and library preparation kits we use. Given the specialized function of certain instruments and reagents, suitable replacements may not be available if a product is discontinued or the product specification undergoes substantial changes due to their own external competition or otherwise. This may significantly delay our ability to continue to develop and commercialize any other future commercial products. All changes to instruments, associated software and reagents will undergo a risk evaluation to determine the level of validation required per the product regulatory status and may require supplementary submissions to, and approval of, regulatory agencies such as the FDA. Whether transitioning to a new supplier, instrument or reagent, the process is likely to be time-consuming, expensive and could affect test performance metrics. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have obtained a PMA approval from the FDA for MI Cancer Seek and intend to seek FDA approval for Caris Assure and additional solutions. We do not manufacture the instruments or reagents used with our solutions, nor do we control such process, and we rely on external suppliers to maintain development and commercialization activities. The molecular testing performed by us is highly complex and requires specialized instruments and reagents, some of which are considered critical and could not be substituted without significant impact to our operations. Any failures or delays in negotiating appropriate agreements with our suppliers on reasonable terms, or their inability to obtain any required marketing authorizations, may increase our costs or delay or prevent us from obtaining or maintaining FDA marketing authorization of the related solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our current suppliers may also discontinue or substantially change the specification of products that we use or intend to use in our solutions. We believe there are few other manufacturers that are currently capable of supplying and servicing the equipment and materials necessary for our laboratory operations, including certain instruments, components, consumables, and reagents. Transitioning to a new supplier for this equipment or these materials would be time-consuming and expensive, could result in interruptions in or otherwise affect the performance specifications of our laboratory operations and sample processing or could require that we revalidate our solutions and could require a new submission to the FDA and other regulatory bodies to authorize such changes for any of our solutions that have received FDA approval. We also cannot guarantee that we will appropriately prioritize or select alternative suppliers, where necessary. In addition, we do not have written supply agreements with certain of our suppliers, including Agilent, Matsunami Glass, and PAXgene, and instead purchase certain products on a purchase order basis, which exposes us to potential price increases and termination of supply without notice or recourse. We cannot guarantee a consistent source of supply and cannot assure you that any efforts to enter into written agreements with our suppliers will be successful. The use of equipment or materials provided by a replacement supplier could require us to alter our laboratory operations and sample collection and processing and related procedures. Moreover, replacement instruments and associated reagents, tubes, and panels that meet our quality control and performance requirements may not be available at all, or may not be available on reasonable terms or in a timely manner. If we encounter delays or difficulties in securing, reconfiguring, or revalidating the equipment, reagents, and other materials that we require for our solutions, laboratory operations and same collection and processing, in particular for those products that are sole sourced, we would likely face significant disruptions or delays in commercializing our solutions and our business, financial condition, results of operations, and growth prospects would be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to obtain additional financing, we may be unable to execute on our business strategies and our growth prospects could be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our operations have required substantial amounts of cash since our inception. The development of our solutions are expensive, and we expect to continue to spend substantial amounts as we continue to enhance our solutions, broaden the applications of our existing solutions, and develop new solutions. In </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">addition, obtaining any necessary or desirable marketing authorizations for our solutions will require substantial additional funding. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may consider raising additional capital in the future to expand our business, meet existing obligations, pursue acquisitions or strategic investments, take advantage of financing opportunities, or for other reasons, including to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">increase our sales and marketing efforts to drive market adoption of our current solutions and address competitive developments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fund development and marketing efforts of new solutions or any other future solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">expand our technologies into other types of cancer management and detection solutions for other chronic disease states; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">acquire, license, or invest in our existing and future technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">acquire or invest in complementary businesses or assets; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">finance capital expenditures and general and administrative expenses. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, we had $31.2&#160;million of cash and cash equivalents and $2.2&#160;million of short-term marketable securities. We could use our available capital resources sooner than we expect, including due to changing circumstances or those beyond our control that may cause us to increase our spending significantly faster than we anticipate, requiring us to raise additional funds sooner than we anticipate. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will require additional capital for the development and commercialization of MI Cancer Seek, Caris Assure, Caris ChromoSeq, and the development of additional solutions. Our future capital requirements depend on many additional factors, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the cost of development and commercialization activities, including marketing and sales, for our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to achieve revenue growth; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the cost related to scaling operating capabilities to support demand for our solutions, including the cost of completing the build-out of our laboratory in Irving, Texas; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of, and the costs involved in, obtaining any required or desired marketing authorizations for our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing, scope, progress, results and costs of developing additional solutions, and of conducting validation studies, clinical trials, and other studies that may be required in order to market our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the costs involved in obtaining, maintaining, protecting, and enforcing patent and other intellectual property rights and claims, including litigation costs and the outcome of such litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and amount of sales of our solutions, if any, and collection of related receivables; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the extent to which our solutions are eligible for coverage and reimbursement from third-party payers and government payers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the emergence of new technologies, scientific breakthroughs, or any competing tests, products, or services, and other adverse market developments; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other potential adverse developments. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital, having borrowed the remaining principal amount of $200.0&#160;million under the delayed draw loan of the 2023 Term Loan (as defined below) in March&#160;2024. Furthermore, any additional capital raised through the sale of equity or equity-linked securities will dilute shareholders&#8217; ownership interests in us, may require shareholder approval, may have an adverse effect on the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">price of our Class A common stock, and holders of these securities may have rights, preferences, or privileges senior to those of our then-existing shareholders. Debt financing, if available, may include restrictive covenants that could limit how we conduct our business. Our ability to incur additional indebtedness also is currently restricted by the terms of our 2023 Term Loan Agreement (as defined below). If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back, or discontinue the commercialization of our solutions or R&amp;D programs, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could adversely impact our business, financial condition, and results of operations and cause the price of our Class A common stock to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our facilities or those of our third-party collaborators are insufficient or become inoperable, our ability to provide our solutions will be significantly impaired and our business will be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently perform all R&amp;D and commercial profiling in our multiple laboratories in Phoenix and Tempe, Arizona and are building out our newest facility in Irving, Texas. Any disruption to the operations of these facilities could compromise the integrity of our samples and impede our ability to accurately perform our profiling and ultimately adversely impact our reputation, business, financial condition, and results of operations. In addition, we may maintain samples for several&#160;years. It is possible that some, if not all, of these samples may degrade over time, which could negatively impact our ability to use such samples to validate future solutions and which could adversely impact our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">One or more of our facilities may be harmed, rendered inoperable by physical damage or otherwise become partially or completely unusable due to fire, floods, earthquakes, power loss, telecommunications failures, break-ins, accidents, water shortages, floods, tornadoes, hurricanes, fires, extreme weather conditions, health epidemics, pandemics, and similar events, which may render it difficult or impossible for us to provide our solutions for some period of time. Our laboratories and the equipment we use to perform our R&amp;D or commercialization work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming, and expensive to rebuild one of our facilities, particularly in light of the licensure, permits, and accreditation requirements for clinical laboratories like ours. Although we carry insurance for damage to our properties and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have started the process of constructing a new laboratory facility in Irving, Texas to increase product development and operational capacity. Such construction requires significant resources, and we may encounter difficulties and delays in construction, procuring laboratory equipment, obtaining necessary validation, permits, licenses, and certifications (including CLIA certification and College of American Pathologists (&#8220;CAP&#8221;) accreditation, or completing the technology implementation) for this new facility. If we are unable to complete construction and go-live in a timely and satisfactory manner, obtain the necessary permits, licenses, certificates, and accreditations within our currently anticipated timelines, or meet demand for our solutions at our Arizona facilities, on a timely basis or at all, our reputation and commercial activities would be negatively impacted. We may be unable to regain customers or repair our reputation in the future, which would negatively impact our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also rely on our third-party collaborators, consultants, contractors, vendors, suppliers, and service providers. The facilities of these partners could be subject to fire, floods, earthquakes, power loss, telecommunications failures, break-ins, accidents, water shortages, floods, tornadoes, hurricanes, fires, extreme weather conditions, health epidemics, pandemics and other natural or man-made disasters or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations, and policies, or withdrawn funding. The occurrence of any of these business disruptions could seriously harm their ability to complete their contracted services to us, which may adversely impact our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our solutions result in direct or indirect patient harm or injury, we could be subject to significant reputational and liability risks, and our business, financial condition, and results of operations could suffer.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success depends on the market&#8217;s confidence that our solutions, including MI Profile, MI Cancer Seek, Caris Assure, MI Tumor Seek Hybrid, and GPSai and other solutions that we may develop in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">future, can provide reliable and high-quality results. We believe that patients, physicians, and regulators are likely to be particularly sensitive to errors in the use of our solutions or failure of our solutions to perform as described, and there can be no guarantee that our solutions will meet their expectations. Performance failures could establish a negative perception of our solutions among physicians, patients, and regulators, jeopardize our ability to successfully commercialize our solutions, impair our ability to obtain marketing authorizations or secure favorable coverage and reimbursement, or otherwise result in reputational harm. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating margins. Identifying the root cause of quality issues, particularly those affecting reagents and third-party components, may be difficult, which increases the time needed to address quality issues as they arise, and increases the risk that similar problems could recur. In addition, we may be subject to legal claims arising from any errors in the use, manufacture, design, labeling or performance of our solutions, including any false-positive or false-negative results. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our anticipated application of Caris Assure for early detection, MRD tracking, and treatment monitoring poses additional risks. Caris Assure is currently intended to be used to detect cancers in patients. A detection of cancer by Caris Assure would need to be followed up with a cancer diagnosis by a physician. Because Caris Assure is not currently able to detect all forms of cancer, a negative test would not rule out the presence of cancer. Additionally, an individual undergoing further diagnostic procedures on the basis of a false-positive result or an erroneous cancer lineage could expose us to significant liability and reputational risks, notwithstanding the emotional and mental health effects to which the patient may be exposed. Similarly, an individual who receives a cancer diagnosis shortly following an inaccurate result, such as a negative test or false negative result, may create adverse publicity about our solutions, which could damage our reputation and have a negative impact on our business, financial condition, and results of operations. Failure to accurately detect cancer and other performance failures could establish a negative perception of our solutions among physicians, patients, customers, and regulators, jeopardize our ability to successfully commercialize our solutions, impair our ability to obtain marketing authorizations or secure favorable coverage and reimbursement, or otherwise result in reputational harm or enforcement action or inquiry by a regulatory body. These risks may be more pronounced and could expose us to claims of injury or other adverse events under medical liability, product liability, or other liability laws if a provider uses our tests inaccurately or inappropriately for diagnosis purposes, as our solutions would be directly involved with the choice to use certain treatments. In addition, we may be subject to legal claims arising from any errors in the use, manufacture, design, labeling, marketing, or performance of our products, including from inaccurate results. If our solutions result in direct or indirect participant or patient harm or injury, we could be subject to significant reputational and liability risks, may be required to initiate corrective actions, recalls or suspend sales of our products, which may adversely impact our reputation, business, financial condition, and results of operations.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources, including any insurance coverage.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The marketing, adoption, and use of our solutions could lead to the filing of product liability claims if someone alleges that our solutions identified inaccurate or incomplete information regarding the genomic alterations of the tumor or malignancy analyzed, reported inaccurate or incomplete information concerning the available therapies for a certain type of cancer, or otherwise failed to perform as designed. We may also be subject to professional liability for errors in, a misunderstanding of, or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability or professional liability lawsuit could damage our reputation or cause current clinical customers to terminate existing agreements with us and potential clinical customers to seek other partners, any of which could adversely impact our business, financial condition, and results of operations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business and results of operations will suffer if we fail to compete effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The precision oncology industry, which is the focus of our current commercial portfolio, is intensely competitive. Our competitors include numerous companies offering or seeking to offer tissue-based molecular profiling, blood-based early detection, blood-based molecular profiling for therapy selection, MRD tracking, and/or treatment monitoring, core biopharma services, and genomic data and AI services to biopharma companies. For additional information, see &#8220;Business&#8212;Competition.&#8221; Our competitors have or may have substantially greater financial, technical, and other resources, such as larger R&amp;D staff and more well-established marketing and sales forces. Our competitors may succeed in developing, acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than our solutions. In addition, established medical technology, biotechnology, or biopharma companies, some of whom may be our customers, may invest heavily to accelerate discovery and development of tests that could make our solutions less competitive than we anticipate. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ability to compete successfully will depend largely on our ability to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">successfully commercialize and expand the features of our solutions and develop new solutions to achieve meaningful innovation in precision oncology and other chronic disease states; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">demonstrate compelling advantages in the performance and convenience of our solutions, including on a cost competitive basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">achieve market acceptance of our solutions by patients and healthcare providers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate of adoption and/or endorsement of our solutions by clinicians, KOLs, advocacy groups, and biopharma companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">achieve adequate coverage and reimbursement recognition from governmental payers, health insurance organizations, and other third-party payers for our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">address any technological, scientific, and market developments to differentiate our solutions from products and services offered by current and potential competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">attract qualified scientific, data science, clinical development, solution development, and commercial personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obtain, maintain, defend, and enforce patent and other proprietary protection as necessary for our solutions and platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">obtain and maintain any necessary or desirable marketing authorizations from regulators in the United States and other jurisdictions for any versions of our current solutions and any future solutions that we may develop; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">successfully collaborate with institutions in the discovery, development, and commercialization of our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">establish and maintain supply and manufacturing relationships with third parties that can timely and consistently provide adequate, in both amount and quality, products and services to support clinical development and the market demand for our solutions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">successfully expand our operations infrastructure and implement a successful sales and marketing strategy to support increased commercialization. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may not be able to compete effectively or keep pace with the rapid rate of change in our industry if we are unable to accomplish one or more of these or similar objectives. This could render our solutions obsolete or less attractive, result in significant price reductions, or substantially limit the volume of products that we offer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure of, or defects in, our AI/ML models and on-premise, co-located, and cloud-based computing infrastructure, including interruption of services through Amazon Web Services, or increased regulation in the AI/ML space, could impair our ability to process our data, develop solutions, or provide test results, and harm our business and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The design, development, maintenance, and operation of our technology over time is expensive and complex, and may involve unforeseen difficulties including material performance problems, undetected </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">defects, or errors. Overcoming technical obstacles and correcting defects or errors could prove to be impossible or impracticable, and the costs incurred may be substantial and adversely affect our business, financial condition, and results of operations. Additionally, regulation in the AI/ML space is constantly evolving. See &#8220;&#8212;Regulatory, social and ethical issues relating to our use of new and evolving technologies, such as AI and ML, may result in reputational harm and liability.&#8221; If our technology does not function reliably, fails to meet expectations in terms of performance, or cannot be fully utilized due to increasing regulation, including regulation by the FDA of AI or medical device software, we may be unable to provide, or our customers may stop using, our solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently host our data on, and conduct certain data analysis through, Amazon Web Services (&#8220;AWS&#8221;) cloud-based hosting facilities as well as on our own co-located or on-premise computing infrastructure. Any technical problems or outages that may arise in connection with AWS&#8217;s or our data center hosting facilities could result in operational disruption, loss of our data or delayed or ineffective data processing. A variety of factors, including infrastructure changes, human or software errors, viruses, malware, security attacks, fraud, denial of service or technical support issues could cause interruptions in our service. Such service interruptions may reduce or inhibit our ability to provide our solutions, delay our clinical trials, and damage our relationships with our customers. We could also be exposed to potential lawsuits, customer reputational impact, liability claims or regulatory actions, for example, if AWS or we experienced a privacy or data security breach. If we were required to transfer our data to an alternative hosting provider, the transfer and acclimation to the new provider could result in significant business delays and subject us to technological risks and require additional resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Regulatory, social, and ethical issues relating to our use of new and evolving technologies, such as AI and ML, may result in reputational harm, additional costs, and liability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We utilize AI/ML algorithms for data analysis of patient information and other data. As with many cutting-edge innovations, AI and ML present new risks and challenges, including social and ethical issues and a quickly evolving legal and regulatory environment, which may cause us to incur increased compliance or R&amp;D costs, or to divert resources from other development efforts. Regulation of AI/ML usage continues to evolve, and limitations placed on the use of data, including personal information, health data, or genetic/genomic data in such systems may make it difficult or more costly for us to continue using our ML algorithms. Existing laws and regulations may be interpreted to apply to us in new ways due to our use of AI and ML, the nature and extent of which are difficult to predict. The risks and challenges presented by AI and ML could undermine public confidence in AI and ML, which could slow its adoption, impact patients&#8217; and physicians&#8217; confidence in our solutions, and otherwise affect our business. Failure to adequately address ethical and social issues related to our use of AI/ML could adversely affect the adoption of our solutions and subject us to reputational harm, regulatory action, or legal liability, which may harm our financial condition and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Potential government regulation related to AI ethics or usage may also increase the burden and cost of R&amp;D in this area. Certain U.S. states have passed or are considering the passage of laws intended to regulate and/or require disclosures in connection with the usage of AI, including in interactions with customers or other market participants. For example, Colorado passed the Colorado Artificial Intelligence Act, which will require disclosures and compliance efforts associated with different uses of AI, and Utah passed the Utah Artificial Intelligence Policy Act, which requires certain disclosures to customers and confirms companies&#8217; responsibility for legal violations caused by their AI applications. It is possible that these or other states or the federal government could pass additional legislation or implement regulations impacting businesses&#8217; use of AI/ML, which could impact our operations and impose additional costs or liability on us. Additionally, employees or customers who are dissatisfied with our public statements, policies, practices, or solutions related to the development and use of AI and ML may express opinions that could introduce reputational or business harm, or legal liability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We use AI/ML to assist us in making certain diagnostic and benefit prediction decisions, which AI/ML is regulated by certain privacy laws. Due to inaccuracies or flaws in the training, development, inputs, outputs, and logic of an AI/ML model, the model could be biased. Any bias in a model could result in limits on the applicability or accuracy of the model across patient populations or could lead us to make decisions that could disadvantage certain individuals (or classes of individuals) and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are highly dependent on our key personnel, and if we lose key members of our senior management, scientific or technical teams or are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be successful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to compete in the competitive precision medicine industry depends upon our ability to attract, motivate, and retain highly qualified personnel. We are particularly dependent on key members of our senior management team, including David D. Halbert, our Founder, Chairman, and Chief Executive Officer. The loss or incapacity of existing members of our senior management team could adversely affect our operations if we experience difficulties in hiring qualified successors and could hamper or delay the development and commercialization of our solutions and harm our business, financial condition, and results of operations. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our R&amp;D programs and laboratory operations depend on our ability to attract and retain highly skilled scientists, technicians, and data scientists. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. In addition, we may have difficulties locating, recruiting, or retaining qualified sales representatives and business development managers. Recruiting and retention difficulties can limit our ability to support our R&amp;D and sales programs. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we provide stock option and RSU grants with vesting conditions. The value of these equity grants may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers made to our employees from other companies. Although we have employment agreements with certain key employees, consistent with all of our employment arrangements, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize highly qualified personnel on acceptable terms, or at all, our business, financial condition, and results of operations may suffer. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the ordinary course of our business, we and the third-parties with whom we work collect, store, receive, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, &#8220;Process&#8221;) personal information, including health-related information, individually identifiable health information and protected health information (&#8220;PHI&#8221;) as defined by the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations (collectively, &#8220;HIPAA&#8221;), personally identifiable information, credit card and other financial information, and intellectual property and proprietary business information (collectively &#8220;Sensitive Information&#8221;). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a result, we and the third parties with whom we work face numerous and evolving cybersecurity risks that threaten the confidentiality, integrity, and availability of our information technology and telecommunications systems and Sensitive Information. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and the third parties with whom we work are subject to threats from various threat actors, such as state-sponsored organizations, criminal threat actors, organized crime outfits, opportunistic hackers and &#8220;hacktivists,&#8221; as well as a variety of evolving threats, such as social engineering/phishing (including through deep fakes, which may be increasingly more difficult to identify as fake), malware (including ransomware and as a result of advanced persistent threat intrusions), network reconnaissance and intellectual property theft, use of illegitimate virtual private networks or anonymization tools, malfeasance by insiders (such as personnel misconduct or error), human or technological error, malicious code (such as viruses and worms), </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">denial-of-service attacks, database compromises, business email compromises, credential stuffing, credential harvesting, credential theft, software &#8220;bugs,&#8221; misconfigurations, or other vulnerabilities in software that is integrated into our (or the third parties with whom we work) IT systems, misuse of company resources and software, lack of adherence to company policy, products or services, adware, attacks enhanced or facilitated by AI, physical or electronic break-ins, earthquakes, fires, floods, and similar disruptive threats. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work are vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We depend on information technology and telecommunications systems, including those provided by third parties and their vendors (some of which are legacy systems developed internally and may carry additional information security vulnerabilities), for significant elements of our operations, such as our laboratory information management systems, including test validation, specimen tracking, and quality control; personal information collection, storage, maintenance, and transmission; our profiling report production systems; and our billing and reimbursement, R&amp;D, scientific and medical data analysis, and general administrative activities that collect, store and transmit large amounts of Sensitive Information, including intellectual property, proprietary business information, PHI, and other personal information of our customers, patients, business partners, employees, and contractors on such systems. In turn, the third parties and vendors with whom we work depend upon technology and telecommunications systems provided by outside vendors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If the third parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or that of the third parties with whom we work have not been compromised. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cyber-attacks, malicious internet-based activity, online and offline fraud, insider threats and other similar activities are increasing in their frequency, levels of persistence, sophistication, and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we and the third parties with whom we work may be unable to anticipate these techniques or implement adequate preventative measures. We and the third parties with whom we work may also experience security incidents that may remain undetected for an extended period. There can also be no assurance that our cybersecurity risk management program and processes, including our policies, controls, or procedures, will be fully implemented, complied with or effective in protecting our information technology and telecommunications systems and Sensitive Information. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of Sensitive Information and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">example, applicable laws or regulations prohibiting such payments. Some of these attacks have also been coupled with attackers directly threatening executives with physical harm. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Applicable privacy and data security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to implement other requirements such as providing credit monitoring. Such disclosures and compliance with such requirements are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. For example, a growing number of legislative and regulatory bodies around the world have adopted breach notification and other requirements in the event that information subject to such laws is accessed by unauthorized persons and additional regulations regarding the use, access, accuracy, and security of such data are possible. In particular, we are a &#8220;Covered Entity&#8221; as defined under HIPAA, and, in the event of a breach as defined by HIPAA, we have specific reporting requirements under HIPAA regulations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under HIPAA, in the event of a significant breach, the reporting requirements could include notification to the general public, in addition to affected individuals and certain governmental agencies. In addition, in the United States, we are subject to state and other laws that require notification. Complying with such numerous and complex regulations in the event of unauthorized access would be expensive and difficult, and failure to comply with these regulations could subject us to regulatory scrutiny and additional liability, could harm our reputation and our ability to compete, and could adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect or remediate all such vulnerabilities including on a timely basis. By way of example, in the spring of 2024, a security researcher informed us of a previously unknown vulnerability in one of our systems, which we have remediated. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. If attackers are able to exploit vulnerabilities before patches are installed or mitigating measures are implemented, compromises could impact our information technology systems and Sensitive Information. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our Sensitive Information or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services. If an attacker were to gain sufficient access to our systems, our data contained in those systems could be discovered by the attacker. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, and the third parties with whom we work have been the target of cybersecurity attacks in the past and expect that such cybersecurity incidents will continue to occur in the future. For example, the February 2024 cybersecurity attack on Change Healthcare, who we used to process certain insurance claims, resulted in a delay in our ability to submit claims for payment and could require us to issue notifications to impacted individuals and various regulators if Change Healthcare determines that any PHI of our patients was impacted. While we may be entitled to damages as a result of this incident, any award may be insufficient to cover all such damages, or we may be unable to recover such award. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain privacy and data security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and Sensitive Information. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Despite the precautionary measures we and the third parties with whom we work have taken to detect and prevent or solve problems that could affect our information technology and telecommunications systems and Sensitive Information, there is a risk that our security measures will not be fully effective in the future. Failures or significant downtime of these systems or those used by the third parties with whom we work could prevent us from conducting tests, preparing and providing reports to future customers, billing payers, conducting R&amp;D activities, maintaining our financial controls and other reporting functions, and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">managing the administrative aspects of our business. Any failure by us or the third parties with whom we work to prevent or mitigate security incidents, or other adverse impact to the availability, integrity, or confidentiality of our information technology systems or Sensitive Information, or improper access to, or use, acquisition, disclosure, alteration or destruction of, any such Sensitive Information, including loss of PHI or other data subject to privacy laws or proprietary business information, could result in operational or business delays, significant liability, regulatory action, a material loss of revenue resulting from the adverse impact on our reputation and brand, a diminished ability to retain or attract new customers, disruption to our business, and adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our existing cyber liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to experiencing a security incident, third parties may gather, collect, or infer Sensitive Information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, Sensitive Information of the Company or our customers could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of AI/ML technologies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be successful in developing and commercializing new solutions or new applications for our current solutions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We continue to expand our R&amp;D efforts to use our solutions and our multi-modal clinico-genomic datasets to develop enhanced versions of our solutions and create new solutions. These initiatives include expanding the application of Caris Assure to early detection, MRD tracking, and treatment monitoring, developing Caris ChromoSeq for hematological (blood) cancers, developing additional AI signatures using NGS or image data, and additional solutions, including for chronic disease states beyond cancer. The commercialization of any new solutions or new applications for our current solutions will require the completion of certain clinical development activities, validation studies and/or clinical trials, having guidelines or recommendations for healthcare providers, administrators, payers, and patient communities relating to such solutions, and receiving favorable exposure in peer-reviewed publications and from KOLs. We cannot assure you that we can successfully complete the clinical development or applicable subsequent requirements of any such solutions in order to commercialize such solutions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may fail to build a sustainable data licensing business, and our data licensing efforts may result in reputational harm that has an adverse effect on our business, financial condition, and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and our biopharma and academic partners leverage high-powered computing and AI/ML algorithms to analyze our data to find the key molecular characteristics of a particular disease or dysfunction that drives disease. As part of these efforts, we license data to our partners, and certain of our partners license data to us. We are in the early stages of these data licensing efforts and may not be able to grow these efforts into a sustainable business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The outbound licensing of data for research purposes is a novel business model without an established track record, which makes it difficult to evaluate our future prospects and the risks and challenges we may encounter in seeking to execute on this opportunity. Although we have negotiated data licensing agreements with several partners, these partners may have rights to terminate these agreements before the initial term has been completed, and these arrangements may not be renewed, or they may be renewed on less favorable terms. In addition, many of our data licensing agreements involve the use of third-party clinical data that is combined with our molecular data and then licensed to biopharma companies or other end users, and these third-party clinical data partners may not be willing to work with us in the future. We also depend on these third-party partners to provide access to data from their own data partners. We cannot guarantee that our third-party partners will enter into new data sharing arrangements with us, continue to provide their data, or that of their partners, to us, or include their data as part of combined data sets, and in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the event that any of these arrangements terminate, we may not be able to find a replacement, or a replacement may not be available on reasonable terms or in a timely manner. Any of the foregoing could result in us losing access to real-world evidence, longitudinal patient data, and clinical outcomes that are key to maintaining, expanding, and enriching our datasets, which could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The commercial market for licensing this type of data may not develop or may be limited by regulation or other factors, which could diminish the value of licensing this data over time and make it challenging to secure arrangements with these partners on similar terms, or at all, with any additional licensees. While our data licensing arrangements include protections against abuse and misuse of patient data, we may be unable to adequately control how our partners, or the commercial customers that they license our data to as part of a combined data set, use the data, and any abuse or misuse could adversely impact our reputation, which could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we cannot maintain our current relationships, or enter into new relationships, with biopharma companies, our development of solutions could be delayed or our business, financial condition, and results of operations could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We deploy our proprietary profiling and signature offerings to analyze tissue and blood samples provided by biopharma partners. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success in the future depends in part on our ability to maintain and expand relationships with our biopharma partners. This can be difficult due to several factors, including internal and external constraints placed on these organizations that can limit the number and type of relationships with companies like us they can consider and consummate; that certain of our agreements governing our relationships are terminable at will by our biopharma partners; and that our biopharma partners may be dissatisfied with our services. Continued usage of our services by particular biopharma partners may also depend on whether the partner obtains positive data in its clinical trials, is able to successfully obtain regulatory approval and subsequently commercializes a therapy for which we have partnered with them to develop a companion diagnostic, or other administrative factors that are outside our control. Additionally, some of our biopharma partners have contracted with us to provide profiling for large numbers of samples, which could strain our testing capacity and restrict our ability to perform tests for other customers. If we fail to maintain these relationships or enter into new ones, our business could suffer. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we expect to engage in discussions with biopharma companies regarding commercial opportunities. There is no assurance that any of these discussions will result in a commercial agreement, or if an agreement is reached, that the resulting engagement will be successful or that any clinical trials conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our existing or potential engagements with biopharma companies can be a catalyst for adverse speculation about us, our services, and our technology, which can result in harm to our reputation and our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third-party services to collect, process, transport, and store our samples in a secure and cost-efficient manner. If these services were disrupted, our business would be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rely on third-party providers to collect tissue and blood samples for our solutions. If third-party providers fail to adequately and properly obtain and collect viable blood and tissue samples from patients and to properly and timely package and ship the samples to us, our patients and their physicians may experience problems and delays in receiving test results, which could lead to dissatisfaction with our solutions, therefore harming our reputation and adversely affecting our business, financial condition, and results of operations. If our current third-party providers become unable to continue to collect samples for us or if our clients are unable to readily access a provider to collect a blood or tissue sample that we can analyze, we may be unable to compete effectively with other laboratories that have greater access to phlebotomy providers and our business, may be harmed. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may maintain samples and extracted material for several&#160;years. It is possible that the long-term stability of these samples may not be maintained with the passage of time, which could </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">negatively impact our ability to use such samples to validate our solutions. Further, interruptions in collection, processing, freezing, storing, or transportation of samples performed by third parties, whether due to labor disruptions, weather conditions, natural disaster, terrorist acts, threats, or for other reasons could adversely affect the samples and our ability to process the samples in a timely manner, which could negatively affect our ongoing research studies and harm our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The clinical trial process is lengthy and expensive with uncertain outcomes. We have encountered delays, and may encounter future substantial delays, in our clinical trials, and may therefore be unable to complete our clinical trials on the timelines we expect, if at all, which could adversely impact our ability to market our solutions or receive adequate reimbursement.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Clinical testing is expensive, time-consuming, and subject to uncertainty. Initiating and completing validation studies and clinical trials necessary to validate and market our solutions, and to support any submissions to CMS, MolDX, or other payers for reimbursement, or the FDA for marketing authorization for our solutions, will be time-consuming and expensive and the outcomes are inherently uncertain. Validation studies and clinical trials must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities&#8217; legal requirements and regulations, and are subject to oversight by these governmental agencies and institutional review boards (&#8220;IRBs&#8221;). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The results of preclinical studies and clinical trials of our solutions conducted to date and ongoing or future studies and trials of our current, planned, or future solutions may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our validation studies and clinical trials do not ensure that we will achieve similar results in future validation studies or clinical trials. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in validation studies, preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later validation studies or clinical trials. Products in later stages of validation studies or clinical trials may fail to show the desired analytical validity and clinical validity despite having progressed through validation studies, nonclinical studies, and earlier clinical trials. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we cannot guarantee that any validation studies or clinical trials will be conducted as planned or completed on schedule, if at all. The timely completion of validation studies in accordance with their protocols depends, among other things, on our ability to locate and test a sufficient number of samples to demonstrate satisfaction of the validation study criteria. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants who remain in the trial until its conclusion. Many of our validation studies and clinical trials require enrolling a large number of participants without cancer who may not see value in enrollment. Additionally, we may encounter delays as a result of the administrative complexities in managing and recruiting for validation studies and trials of this scope and size. If we are unable to recruit and enroll sufficient participants for our validation studies or clinical trials, or maintain sufficient participation of enrolled participants, our product development, commercialization activities and our ability to seek marketing authorization for our solutions could be delayed, modified, or prevented. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The initiation and completion of validation studies and clinical trials may be prevented, delayed, or halted for numerous reasons, including related to the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the inability to generate sufficient </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> or </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> data to support the initiation or continuation of clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the requirement to submit an IDE application to the FDA, which must become effective prior to commencing certain human clinical trials of significant risk medical devices, and which the FDA may disapprove; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delays caused by participants withdrawing from clinical trials or failing to return for follow-up or by institutions failing to timely submit data, including follow-up data, if at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delays or failure in reaching a consensus or agreement, if required, with regulatory agencies on trial design or feedback from regulatory agencies necessitating changes to ongoing or planned clinical trial design; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delays or failure in reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;), service providers, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delays or failure in obtaining any required IRB approvals or ethics committee (&#8220;EC&#8221;) approvals for our clinical trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delays in amending, or the inability to amend, our IRB-approved protocols at clinical trial sites when necessary or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">difficulty or delays in collaborating with sites, institutions, and investigators; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure by us, investigators, sites, or participants to comply with the applicable trial protocol or applicable regulatory requirements and standards for data collection, reporting, records maintenance, or data integrity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure by us, investigators, sites or any CROs or other third parties to adhere to clinical trial requirements, including the applicable protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure to perform in accordance with good clinical practice (&#8220;GCP&#8221;) and good laboratory practice requirements, and/or other applicable regulations and requirements of the FDA or other applicable governmental authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure to comply with applicable privacy and data security laws related to clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure of our solutions to achieve acceptable performance, and safety endpoints; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">unacceptable safety findings, including findings related to the risk of the false positive tests (which could lead to unnecessary biopsy or anxiety) or false negative tests (which could lead to a delay in diagnosis or disease progression); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">termination or suspension of a trial or site by us or the data safety monitoring board, suspension or termination of a trial or site by an IRB, EC, or institution, or clinical hold or termination of a trial or site by a regulatory authority, including the FDA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">disqualification, termination, or suspension of a clinical investigator; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">adverse inspections of our clinical trial sites or results by any applicable regulatory authority, including the FDA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in statutory or regulatory requirements or guidance, or clinical guidelines, that require amending existing or designing new clinical protocols, obtaining new IRB or EC approvals, modifying our clinical trials, modifying our consent process or obtaining additional consent from trial participants, or altering the pathway to marketing authorization of our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the cost of clinical trials of our solutions being greater than we anticipate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">destruction or compromise of, or other inability to access or receive, clinical trial samples processed, stored, or managed at a third-party site or otherwise in the control of a third party; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">clinical trials of our solutions producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">lack of adequate funding. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any such delays could adversely affect the costs, timing, or successful completion of any future clinical trials. Moreover, we may depend on our collaborators and on medical institutions and CROs to conduct any future clinical trials in compliance with applicable GCP requirements, and while we may have agreements governing their committed activities, we may have limited influence over their actual performance. To the extent any future collaborators, the CROs, or clinical sites fail to enroll participants for our clinical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">trials, fail to conduct the trial to GCP requirements or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays, and/or enforcement actions. In addition, any future clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any inability to initiate or complete clinical trials successfully could result in additional costs to us, slow down or prevent our product development and receipt of positive reimbursement and coverage decisions, or impair our ability to generate revenue. Delays in initiating or completing our planned clinical trials could also allow our competitors to bring competing products to market before we do or sooner than expected, which could impair our ability to successfully commercialize our solutions, if launched, and may harm our business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in initiation or completion of clinical trials may also ultimately lead to the delay or the narrowing or denial of any marketing authorization we may seek with respect to our solutions. Delays in the initiation or completion of any clinical trial of our solutions, such as Caris Assure for early detection, MRD tracking, or treatment monitoring, or seeking coverage and reimbursement, will increase our costs, slow down, or jeopardize our product development and marketing authorization process, and delay or potentially jeopardize broad adoption of our solutions and their ability to generate revenue. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Regulation and Legal Compliance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we or our partners fail to comply with healthcare and other applicable laws and regulations, we could face substantial penalties and sanctions and our business, reputation, financial condition, and results of operations could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our operations in the United States are subject to various U.S. federal and state laws and regulations that govern, among other things, the manner in which we provide and bill for tests and collect reimbursement from governmental programs, third-party payers and patients, our relationships with referral sources, and our marketing and advertising activities. In addition, the commercialization of our solutions outside the United States would also subject us to foreign equivalents of the healthcare laws described below, among other foreign laws. The laws that may impact our operations include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the federal Anti-Kickback Statute (the &#8220;AKS&#8221;), which prohibits, among other things, knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, rebate, a provision of free or discounted goods, services or items), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, recommendation, or arrangement of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation, and many courts have interpreted the AKS as being violated if merely one purpose of any arrangement is to induce referrals or purchases. The AKS includes statutory exceptions and regulatory safe harbors that protect certain arrangements. Failure to meet the requirements of an exception or safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate arrangements that do not fit into an exception or safe harbor on a case-by-case basis, taking into account all facts and circumstances, including the parties&#8217; intent and the arrangement&#8217;s potential for abuse, and such arrangements may be subject to greater scrutiny by enforcement agencies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), which establishes an all-payer anti-kickback prohibition for, among other things, knowingly and willfully paying or offering any remuneration directly or indirectly to induce a referral of an individual to or in exchange for an individual using the services of a clinical laboratory. EKRA applies to all payers including commercial payers and government payers. EKRA adopted safe harbors that are not directly analogous to the safe harbors under the AKS, and certain conduct that is permissible under the AKS may violate EKRA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the federal physician self-referral prohibition, commonly known as the Stark Law, which, in the absence of an applicable exception, prohibits a physician from making a referral for certain </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">designated health services covered by the Medicare or Medicaid program if the physician or an immediate family member of the physician has a financial relationship (including an ownership interest or a compensation arrangement) with the entity providing the designated health services. The Stark Law also prohibits the entity furnishing the designated health services from billing, presenting, or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral. The term &#8220;designated health services&#8221; includes, among other things, clinical laboratory services. Unlike the AKS, the Stark Law is violated if the financial arrangement does not meet an applicable exception, regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral; </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FCA, which imposes civil and criminal liability on individuals or entities that knowingly submit false or fraudulent claims for payment to the government or knowingly make, or cause to be made, a false statement in order to have a false claim paid. Actions under the FCA may be brought by the government or by a private person under a qui tam, or &#8220;whistleblower,&#8221; suit. There are many potential bases for liability under the FCA. For example, the government has used the FCA to prosecute Medicare and other government healthcare program fraud such as coding errors, coding and billing for tests not compliant with coverage and reimbursement requirements, including MolDX reimbursement and coverage standards and requirements, waiver of patient copayments and deductibles, and performing tests that are not medically necessary or that are substandard in quality. In addition, a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA, and courts have held that claims for services furnished pursuant to a referral prohibited by the Stark Law also are considered false for purposes of the FCA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the criminal healthcare fraud provisions of HIPAA and related rules that prohibit knowingly and willfully executing a scheme or artifice to defraud any healthcare benefit program or falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. These criminal healthcare fraud provisions are not limited to benefits, items, or services that may be paid for by federal or state healthcare programs, and similar to the AKS, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the federal Civil Monetary Penalties Law, which provides civil penalties for a wide variety of conduct relating to federal and state healthcare programs, including, subject to certain exceptions, prohibiting, among other things, the offer or transfer of remuneration, including free services, discounts, or waivers of copayments and deductible amounts (or any part thereof), to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the federal Physician Payment Sunshine Act, created under the Affordable Care Act (the &#8220;ACA&#8221;), and its implementing regulations, which require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) under the Open Payments Program, information related to payments or other transfers of value made to physicians (as defined by statute), teaching hospitals and other healthcare practitioners such as physician assistants and nurse practitioners, as well as ownership and investment interests held by such physicians and their immediate family members and similar state laws with various reporting requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">state self-referral, kickback, false claim, fraud, and abuse laws, some of which may apply to items or services reimbursed by any payer, including patients and commercial insurers, and include &#8220;whistleblower&#8221; provisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">federal and state &#8220;Anti-Markup&#8221; rules, which, among other things, typically prohibit a physician or supplier billing for clinical or diagnostic tests (with certain exceptions) from marking up the price of a purchased test performed by another physician or supplier that does not &#8220;share a practice&#8221; with the billing physician or supplier; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">federal and state laws applicable to test ordering, documentation of tests ordered, consent requirements, billing practices and claims payment and laws that prohibit other specified practices, such as providing tests at no or discounted cost to induce adoption, which may apply to laboratories; waiving co-insurance, deductibles or other amounts owed by patients; and billing a state healthcare program at a price that is higher than what is charged to other payers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the &#8220;No Surprises Act,&#8221; which prohibits balance billing for certain non-emergency care, including for out-of-network clinical laboratory tests, and analogous state laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">state corporate practice prohibitions and professional fee-splitting laws that prohibit employing, exercising control over, or splitting fees with licensed medical professionals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, self-referral, false claims, consumer protection, and unfair competition laws that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require healthcare companies to comply with the medical device industry&#8217;s voluntary compliance guidelines, the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers, and other potential referral sources or state-specific standards on financial interactions with healthcare providers; state laws that require healthcare companies to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensation, and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These laws and regulations, among other things, constrain our business and limit the types of financial arrangements we have with providers, customers, patients, vendors and third-party payers, and our billing, coding, and collection practices, including our patient financial assistance programs and our practices relating to collection of co-payments and deductibles. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available and lack of clear guidance, our business activities could be subject to challenge under one or more of such laws. To enforce compliance, the Office of the Inspector General (&#8220;OIG&#8221;) and the DOJ recently have increased their scrutiny of interactions between healthcare companies, on the one hand, and healthcare providers and patients on the other, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. These investigations often are focused on billing and coding practices as well as financial arrangements with referral sources and patients. We expect that the federal government will continue to devote substantial resources to investigating healthcare providers&#8217; compliance with the FCA and other applicable fraud and abuse laws. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also have been, are currently, and may be in the future, subject to actions or investigations relating to our arrangements and interactions with healthcare professionals and patients. For additional information, see &#8220;&#8212;We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Efforts to ensure that our business arrangements will comply with applicable laws, including healthcare laws and regulations, may involve substantial costs. In addition, the healthcare and other laws applicable to our business may change or be amended, and, it is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or then-existing statutes, regulations, or case law interpreting applicable fraud and abuse or other healthcare or applicable laws and regulations. We may not properly interpret certain requirements or fail to timely report activities, when required. If any such actions are instituted against us, and we are not successful in defending ourselves, those actions could have a material impact on our business, including the imposition of significant civil, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, imposition of forward-looking compliance obligations, and curtailment of our operations, any of which could adversely affect our business, financial condition, and our results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data security. Our actual or perceived failure to comply with privacy and data security obligations (or such failure by the third parties with whom we work) could result in significant liability, administrative or governmental penalties, reputational harm and/or, other adverse business consequences. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the ordinary course of business, we process Sensitive Information, including personal information, genetic information, and data about trial participants in connection with clinical trials. These data processing activities subject us to numerous federal, state, and foreign privacy and data security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations, including AI/ML usage, relating to privacy and data security. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, numerous state and federal laws and regulations govern the privacy and security of personal information, including health-related information, such as data breach notification laws, personal information privacy laws, consumer protection laws (for example, Section&#160;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, by health plans, healthcare clearinghouses and certain healthcare providers (&#8220;Covered Entities&#8221;), as well as for entities that perform certain services for or on behalf of such Covered Entities that involve creating, receiving, maintaining, or transmitting PHI (&#8220;Business Associates&#8221;), and their covered subcontractors. We are a Covered Entity when performing our healthcare services for customers, and also act as a Business Associate when performing certain services for or on behalf of Covered Entities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When we act as a Covered Entity, for example, through services provided by Caris MPI, Inc., we are subject to certain obligations such as notice of privacy practices and secure handling of protected health information. In addition, when we act as a Business Associate of Covered Entities, for example, through services provided by our other entities, we are subject to certain provisions of HIPAA and the terms of any business associate agreements we enter into with such other Covered Entities. In addition, we may obtain health information from third parties that are subject to privacy and security requirements under HIPAA. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under HIPAA, Covered Entities must report breaches of unsecured PHI to affected individuals without unreasonable delay, not to exceed 60&#160;days following discovery of the breach by a Covered Entity or its agents. Notification also must be made to the HHS Office for Civil Rights and, in certain circumstances involving large breaches, to the media. Business associates must report breaches of unsecured PHI to Covered Entities during the timeframe outlined in the operative Business Associate Agreement, but in no even longer than 60&#160;days of discovery of the breach by the Business Associate or its agents. A non-permitted use or disclosure of PHI is presumed to be a breach under HIPAA unless the Covered Entity or Business Associate establishes that there is a low probability the information has been compromised consistent with requirements enumerated in HIPAA. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by HHS may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. HIPAA also authorizes state Attorneys General to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain states have also implemented genetic testing and privacy laws imposing specific patient consent requirements and protecting test results by strictly limiting the disclosure of those results. In </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">addition, in the past few&#160;years, more than a dozen U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data; however, many of these laws have exceptions for entities subject to HIPAA or include exemptions for data subject to HIPAA, including clinical data protected under HIPAA and clinical trial data. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) (collectively, &#8220;CCPA&#8221;), applies to personal information of consumers, business representatives, and employees who are California residents, and gives California residents expanded rights regarding their personal information, including the right to opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500 per intentional violation, as well as a private right of action for certain data breaches. Although the CCPA exempts some data processed in the context of clinical trials and information subject to HIPAA, the CCPA increases compliance costs and potential liability with respect to other personal information we maintain about California residents. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may also be subject to new laws governing the privacy of consumer health data, including genetic information. For example, Washington&#8217;s My Health My Data Act broadly defines consumer health data, imposes obligations and restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. More than a dozen states have also adopted laws regarding the processing, privacy, and security of genetic information or expanded their comprehensive privacy laws to include additional restriction on companies with respect to processing of sensitive personal information, including genetic information; however, many of these laws have exceptions for entities subject to HIPAA or include exemptions for data subject to HIPAA, including clinical data protected under HIPAA and clinical trial data. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While several of these laws exempt some data processed in the context of clinical trials or deidentified information under HIPAA, such laws could have potentially conflicting requirements and may increase our compliance costs and potential liability. We could be adversely affected if such laws and other state or federal legislation or regulations applicable to us require changes in our business practices (including our ability to license deidentified information to biopharma companies) or privacy policies, or if governing jurisdictions interpret or implement their legislation or regulations in ways that adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, violation of consumers&#8217; privacy rights or failure to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair and/or deceptive acts or practices in or affecting commerce in violation of Section&#160;5(a) of the Federal Trade Commission Act, including entities subject to HIPAA. The Federal Trade Commission (&#8220;FTC&#8221;) expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits particularly strong safeguards. We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and data security. If these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we seek to utilize biological samples and data from participants in our clinical trials and validation studies in accordance with applicable law, IRB requirements, and participant permissions (through consent forms and HIPAA authorizations). If we are unable or significantly restricted in using participant samples and data for secondary research purposes, our ability to develop additional solutions and/or improve or refine existing solutions will be limited, which may impact our business and prospects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, we are subject to laws, regulations, and standards governing certain marketing, advertising, and other communications conducted by telephone, fax, or text. In particular, sending short message service text messages to participants and prospective participants in our clinical trials is governed by the Telephone Consumer Protection Act (&#8220;TCPA&#8221;) which imposes various consumer consent requirements </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and other restrictions on communications with consumers. Although we may be able to rely on certain exemptions for healthcare-related purposes, any actual or perceived violations of the TCPA can result in significant financial penalties, including penalties or criminal fines imposed by the Federal Communications Commission or fines of up to $1,500 per violation imposed through private litigation or by state authorities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, because we accept debit and credit cards payments, we are subject to the Payment Card Industry Security Standard (&#8220;PCI-DSS&#8221;), issued by the Payment Card Industry Security Standards Council; however, we rely on third-party payment processors to process such payments who are also separately subject to PCI-DSS. Noncompliance with PCI-DSS can result in penalties ranging from $5,000 to $100,000 per month by credit card companies, litigation, damage to our reputation, and revenue losses. If we or our third-party payment processors are unable to comply with the PCI-DSS, we may be subject to fines, restrictions, expulsion from card acceptance programs, or other consequences which could affect our business. Moreover, it is not guaranteed that PCI-DSS compliance will prevent illegal or improper use of our third-party payment processors&#8217; payment systems or the theft, loss or misuse of payment card data or transaction information. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business also increasingly relies on AI to improve our services. However, the development and use of AI presents various privacy and data security risks that may impact our business and is subject to various laws. For example, several countries, states, and localities have proposed or enacted measures related to the use of AI in products and services, including the EU&#8217;s AI Act, which may limit our ability to utilize AI or make utilization of such technology more expensive. The effects of these regulations are difficult to predict, and we expect other jurisdictions will adopt similar laws. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal information) and regulate automated decision making, which may be incompatible with our use of artificial intelligence. These obligations may make it harder for us to conduct our business using artificial intelligence, lead to regulatory fines or penalties, require us to change our business practices, retrain our artificial intelligence, or prevent or limit our use of artificial intelligence. For example, the FTC has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of AI where they allege the company has violated privacy and consumer protection laws. If we cannot use AI or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy and data security. For example, the European Union General Data Protection Regulation (the &#8220;EU GDPR&#8221;) and to the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (collectively, the &#8220;UK GDPR&#8221;) (the EU GDPR and UK GDPR together referred to as the &#8220;GDPR&#8221;) impose strict requirements for processing personal data. The GDPR imposes stringent and comprehensive data protection requirements, and provides for greater penalties for noncompliance. The GDPR expands the rights that individuals have to request access, correction, and deletion of their personal data, although certain exceptions exist for scientific research, and makes notification of data breaches to supervisory authorities and data subjects mandatory in certain circumstances. In addition, the GDPR imposes additional compliance obligations and local law derogations in relation to the processing of special category or sensitive personal data under the GDPR (e.g., health data); we may be subject to diverging requirements under EU member state laws and the United Kingdom (&#8220;UK&#8221;) laws, such as whether consent can be used as a legal basis for processing. Where we rely on consent as a legal basis for processing, the validity of informed consent from patients may be challenged, which could force us to stop offering our services, which could hinder our business and operations. In addition, as laws develop, we may need to make operational changes to adapt to diverging rules, which could increase our costs and adversely affect our business. The GDPR also regulates cross-border transfers of personal data outside of the EEA (in the case of the EU GDPR) and UK (in the case of the UK GDPR) and recent case law and regulatory guidance have increased legal complexity and uncertainty regarding international personal data transfers, which we expect to continue. In particular, we expect international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines; we may have to stop using certain tools and vendors and make other operational changes. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Penalties and fines for failure to comply with the GDPR include fines of up to 20&#160;million euros under the EU GDPR, 17.5&#160;million pounds sterling under the UK GDPR or, in each case, 4% of annual </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">global revenue, whichever is greater, and since we are subject to the supervision of relevant data protection authorities under both the EU GDPR and UK GDPR, we could be fined under each of those regimes independently in respect of the same breach. In addition to fines, a breach of the EU GDPR and/or UK GDPR may result in regulatory investigations, reputational damage, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, we expect the existing legal complexity and uncertainty regarding international data transfers from the European Economic Area (&#8220;EEA&#8221;) and the UK to continue. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement/Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges. As the regulatory guidance and enforcement landscape in relation to data transfers continues to develop, there is no assurance that we can continue to satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We furnish to biopharma partners and academic researchers genomic information that has been de-identified in accordance with applicable laws, regulations, and the requirements governing the clinical trial. Any data transferred pursuant to international health information privacy regulations is transferred under relevant data protection agreements at the direction of the Data Controller. We may also furnish our biopharma partners and academic researchers with identifiable genomic information for research purposes, so long as such disclosure has been consented to by the patient and/or approved by an IRB or other ethical or privacy review board. The laws of certain states and countries may require specific consent from the individual either to retain or utilize certain genetic information for research or other purposes even if such information has been de-identified, or may require that we obtain a waiver of such consent from an ethical or privacy review board. Even where we furnish to biopharma partners and academic researchers genomic information that has been de-identified in accordance with applicable laws and regulations, biopharma partners or academic researchers may use technology or other methods to link that de-identified genomic information to the patient from whom it was obtained in contravention of one or more applicable laws and regulations. A finding that we have failed to comply with any such laws and any remedial activities required to ensure compliance with such laws could cause us to incur substantial costs, to be subject to unfavorable publicity or public opinion, to change our business practices, or to limit the retention or use of genetic information in a manner that, individually or collectively, could be adverse to our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Obligations related to privacy and data security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. For example, HHS issued a notice of proposed rulemaking on January 6, 2025, clarifying existing requirements and imposing new security requirements for entities subject to HIPAA. The agency received thousands of proposed comments, and may adjust or clarify the rule as part of the rule making process. Under President Trump&#8217;s Regulatory Freeze Pending Review executive order, HHS cannot issue a final rule until a President-appointed department </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">head has reviewed and approved the rule. It is uncertain whether the proposed rule will move forward in its current state and what the timing of a final rule will be. If adopted in a form similar to the proposed rule, we anticipate our compliance costs could increase substantially. We would need to invest in additional cybersecurity technologies, hire specialized personnel, and potentially redesign certain aspects of our systems and processes. These investments were not contemplated in our current business plan and could impact our profitability. If we are unable to comply with new requirements by any prescribed deadlines, we could face penalties, enforcement actions, reputational damage, and potential loss of business from customers. While we have begun assessing our current security posture against the proposed requirements, the uncertainty regarding the final rule makes comprehensive preparation difficult. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. We also expect that there will continue to be new laws, regulations, and industry standards concerning privacy and data security proposed and enacted in various jurisdictions in which we do business. In addition to privacy and data security laws, we are also bound by other contractual obligations related to privacy and data security. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Compliance with privacy and data security obligations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. We strive, and contractually obligate our vendors, to comply with applicable laws, regulations, policies, and other legal obligations relating to privacy and data security. However, the various regulatory frameworks for privacy and data protection are, and are likely to remain, uncertain, and it is possible that these or other actual or alleged obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules and subject our business practices to uncertainty. In addition, it is not guaranteed that regulators or consumers will agree with our interpretation of our obligations or our steps to comply with them. Any actual or perceived failure by us to comply with privacy and data security laws, rules, regulations, industry standards and other obligations could result in proceedings or actions against us by individuals, consumer rights groups, government agencies, or others, or orders to cease/ change our data processing activities. We could incur significant costs in investigating and defending such claims and, if found liable, pay significant damages or fines or be required to make changes to our business practices. Further, these proceedings and requires to any subsequent adverse outcomes may subject us to significant negative publicity and an erosion of trust. If any of these events were to occur, our business, financial condition, and results of operations could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have current solutions marketed as LDTs and plan to launch future solutions as LDTs. The FDA recently finalized a rule, which has since been vacated by a federal court, pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four&#160;years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have obtained a PMA approval from the FDA for MI Cancer Seek as a companion diagnostic device. We currently anticipate eventually seeking FDA approval for Caris Assure and additional solutions. Except for MI Cancer Seek, we currently offer our NGS solutions, MI Tumor Seek Hybrid and Caris Assure, and our AI solutions, such as GPSai and FOLFIRSTai, as LDTs. LDTs are IVD tests that are intended for clinical use and are designed, manufactured, and used within a single laboratory. Until recently, the FDA has historically exercised enforcement discretion and has not enforced certain otherwise potentially applicable FDA requirements, including premarket review, with respect to LDTs, with certain exceptions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even under that enforcement discretion policy, the FDA has issued warning letters to, and published Medical Device Safety Communications about, manufacturers for commercializing laboratory tests that were purported to be LDTs but the FDA alleged failed to meet the definition of an LDT or that otherwise were not subject to the FDA&#8217;s enforcement discretion policy. If our current solutions fail to meet the definition of an LDT, our business, financial condition, and results of operations could be adversely affected. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has for a number of&#160;years stated its intention to modify its enforcement discretion policy with respect to LDTs and enforce applicable medical device requirements to LDTs more broadly. The FDA proposed an amendment to its regulations in October&#160;2023 to clarify the FDA&#8217;s historical view that LDTs are medical devices subject to the requirements applicable to IVDs, and to phase out its enforcement discretion policy over a period of four&#160;years from issuance of the final rule, which would involve a phase-in of medical device requirements to these products over this time period. The FDA issued this final rule on May&#160;6, 2024, which will subject our solutions currently marketed as LDTs and any solutions that we may market as LDTs in the future to the FDA&#8217;s regulatory requirements applicable to medical devices following this phase-in period, potentially including the requirement for an FDA premarket review and marketing authorization. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA&#39;s LDT final rule. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the final rule, the FDA established certain new and targeted enforcement discretion policies, including, among others, for LDTs marketed as of the date of publication of the final rule on May&#160;6, 2024, as well as for LDTs that have received approval from NY CLEP. Specifically, the FDA intends to exercise enforcement discretion and not enforce certain medical device requirements (including the requirements for marketing authorization and compliance with certain elements of the Quality System Regulation (&#8220;QSR&#8221;) with respect to LDTs that were marketed as of the date of the final rule&#8217;s publication, although such products must still comply with certain other FDA requirements, including registration and listing, portions of the QSR, medical device reporting, labeling, and corrections and removals reporting. However, where these tests are modified in certain ways from the version of the test marketed as of the final rule&#8217;s publication date, this enforcement discretion policy will no longer apply and the FDA intends to enforce all applicable FDA requirements (including premarket review and marketing authorization requirements) consistent with the phase-in policy. In addition, for LDTs that receive approval from NY CLEP, FDA intends to not enforce marketing authorization requirements when these requirements are phased in more generally at either three and a half or four&#160;years following the date of publication of the final rule. However, these tests will still be subject to the remaining medical device requirements, including registration and listing, medical device reporting, and quality system requirements, at the time that such requirements are phased in more generally. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding these new targeted enforcement discretion policies, depending on the kinds of future changes we make to our currently-marketed LDTs or any NY CLEP-approved LDT we offer, we may become subject to the application of the phase-in of all FDA medical device requirements, including the need to seek and obtain marketing authorization, at the time that those medical device requirements are phased in more generally. If we are unable to comply with the phase-in of medical device requirements applicable to LDTs over the phase-in period, we may be required to cease marketing any solutions that we market as LDTs. In addition, efforts by the FDA to actively regulate LDTs could create a negative public perception about the validity, safety, effectiveness, or performance of LDTs, including our solutions, which could adversely affect patient, provider, and customer perception about, and confidence in, our solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the FDA may assert that we are improperly marketing our LDTs and may take enforcement action against us and/or require premarket review and marketing authorization even before the deadline for phasing in medical device requirements for LDTs. If the FDA begins to phase out its policy of enforcement discretion for LDTs as recently described in its final rule affirmatively subjecting LDTs to medical device regulation, or if it asserts that our LDTs are not eligible for application of its new and targeted enforcement discretion policies, or we may be required to obtain marketing authorization for our LDT solutions from the FDA prior to initially launching our solutions or may be required to cease marketing any commercially marketed solutions that are marketed as LDTs until such marketing authorization is obtained or the applications are submitted. There can be no assurance that we will be able to obtain such marketing authorization or that any labeling claims will be consistent with the claims we have made or intend to make for such solutions when launched as LDTs, or that such claims will be adequate to support continued adoption of and reimbursement for our solutions. The FDA may request that we provide additional analyses and information beyond that which we intend to produce based on the designs of our current and planned validation studies or clinical trials, or that we modify or narrow our intended use or product claims. It is possible that the FDA, among other things, may disagree with our interpretation of data we have relied on to support our LDT launches for our intended uses. If we are required to provide additional analyses </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or additional data or perform additional clinical trials beyond those we currently contemplate to support the intended uses of our solutions, our planned commercial launches may be delayed and we may be required to cease commercialization of any solutions we currently market as LDTs. Even if our solutions are allowed to remain on the market prior to any required marketing authorization, demand or reimbursement for our solutions may decline if there is uncertainty about our solutions, if we are required by the FDA to label our solutions as investigational, or if the FDA limits the labeling claims we are permitted to make for our solutions. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our current or future solutions, which could reduce our revenues or increase our costs and adversely affect our business, financial condition, and results of operations. Additionally, an FDA enforcement action against us, a delay in the launch of our solutions, or significantly narrowing their intended uses, could negatively impact our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, Congress has, for over the past decade, considered a number of proposals, which if enacted, would subject LDTs to additional regulatory requirements. For example, in recent&#160;years Congress has worked on legislation to create a novel regulatory framework governing a new category of FDA-regulated products, referred to as </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> clinical tests (&#8220;IVCTs&#8221;), which would govern LDTs and would be separate and distinct from the existing medical device regulatory framework. For example, in March&#160;2023, the Verifying Accurate Leading-edge IVCT Development Act of 2023 (the &#8220;VALID Act&#8221;) was introduced. The bill would establish a risk-based approach to imposing requirements related to premarket review, quality systems, and labeling requirements on all IVCTs, including LDTs, but would grandfather certain LDTs marketed before the effective date of the bill and exempt them from certain requirements. It is unclear whether the VALID Act or any other legislative proposals (including any proposals to reduce FDA oversight of LDTs) will be passed by Congress or signed into law by the President and it is also unclear whether the FDA&#8217;s recent rulemaking around LDTs or related court decisions will impact Congress&#8217;s willingness to pass legislation relating to LDTs. Any such legislation could substantially alter our marketing of LDTs and negatively impact our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our early detection and MRD tracking assays are intended to introduce new approaches to cancer detection, which present a number of novel and complex issues for FDA review. Because the FDA has never provided marketing authorization for an early detection test and has only granted marketing authorization in limited instances for MRD tests, it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a proposed intended use of early detection or MRD tracking, or if we will be able to obtain such approval on a timely basis or at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has never granted marketing authorization for a early detection test and has only granted marketing authorization in limited instances for MRD tests. Therefore, obtaining FDA approval for Caris Assure for early detection and/or MRD tracking presents a number of novel issues. For example, in November&#160;2023, the Molecular and Clinical Genetics Panel (the &#8220;Panel&#8221;) of the FDA&#8217;s Medical Devices Advisory Committee held a public meeting in which the Panel discussed and made recommendations on the design of MCED IVD devices as well as potential study designs and study outcomes of interest that could inform the assessment of the probable benefits and risks of MCED screening tests. The FDA may continue to modify its thinking on how to evaluate the performance of these types of tests, as well as its views around MRD tests. As such, we believe the FDA requirements that will govern any early detection or MRD tracking test we develop, as well as the breadth and nature of data we must provide the FDA, to support the proposed intended use, will remain subject to change. </font>
        </div>
        <div style="text-indent:36pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Given the novel nature and complexity of our early detection and MRD tracking assays, we cannot be certain whether we will receive FDA marketing authorization for our screening tests and whether the trials we eventually conduct will be sufficient to provide the data that the FDA requires to support a proposed intended use. The FDA may require us to perform new analyses of future clinical data or perform additional clinical trials beyond any trials that we may conduct in the future. We may be required to undertake significant efforts to address the FDA requests, which could delay or prevent approval, lead to a more limited intended use statement than the broader intended use statement we plan to pursue, and/or lead to significant post-approval limitations or restrictions, if approval is obtained at all. </font>
        </div>
        <div style="margin-top:9.62pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business could be adversely affected by legal challenges to our business model or by actions restricting our ability to provide the full range of our solutions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many states prohibit, by statute, regulation, guidance from professional licensing boards or state attorneys general or under common law, the unlicensed practice of medicine. Corporate practice restrictions </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">are generally designed to prohibit a non-professional entity, such as us, from practicing medicine, employing physicians, or controlling or unduly influencing the professional practice and clinical decision making of physicians. The laws relating to corporate practice vary from state to state and are subject to change and to evolving interpretations by courts, state licensing boards and state attorneys general, among others. Further, changes to the membership or staff of state agencies, licensing boards or attorney general offices could lead to increased enforcement of these laws and regulations. In addition, many states also have laws that prohibit a non-professional entity or individual from sharing in or splitting profits or professional fees for patient care, often referred to as &#8220;fee-splitting.&#8221; Some states also prohibit entities from engaging in certain financial arrangements, such as fee-splitting, with physicians. The laws relating to fee-splitting also vary from state to state and are not fully developed or uniformly enforced. Generally, these laws restrict business arrangements that involve a physician sharing professional fees with a non-professional source, but in some states, these laws have been interpreted to extend to other agreements between physicians and business entities under some circumstances. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our test reports delivered to physicians provide information regarding solutions that oncologists and other physicians may use in making treatment decisions for their patients. We also employ pathologists and other medical professionals that interpret results of our solutions and sign our profiling results. These pathologists, physicians and other medical professionals are employed through our subsidiary non-profit corporation, Caris Molecular Pathology, which we believe complies with state corporate practice prohibitions and professional fee-splitting prohibitions. A governmental authority or other parties could allege that the business practices and services we provide constitute the practice of medicine or violate professional fee-splitting prohibitions and that our structure and arrangements are not compliant. A state may seek to have us discontinue the related services we provide, or subject us to fines, penalties, or other sanctions. Any determination that we are practicing medicine without a license may result in significant liability to us, and our business and reputation would be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining regulatory authorization of our solutions in one jurisdiction does not mean that we will be successful in obtaining regulatory authorization of our solutions in other jurisdictions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Obtaining and maintaining regulatory authorization of solutions in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory authorization in any other jurisdiction, but a failure or delay in obtaining regulatory authorization in one jurisdiction may have a negative effect on the regulatory authorization process in others. For example, even if the FDA or a comparable foreign regulatory authority grants marketing authorization for our solutions, comparable regulatory authorities in foreign jurisdictions may also need to authorize the solutions in those countries. Premarket authorization processes vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional clinical trials, because clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions or the data may not be considered applicable to the jurisdiction&#8217;s intended patient population. For example, while we have obtained a PMA approval from the FDA for MI Cancer Seek, we do not have any non-U.S. approvals for this solution, and there can be no assurance that we receive any such approvals in the future. In some cases, the price that we intend to charge for our solutions may also be subject to approval. In addition, NY CLEP approval is required in order to market LDTs in New York State. We have not received NY CLEP approval for Caris&#160;Assure. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Obtaining foreign regulatory authorization and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our solutions in certain countries. If we fail to comply with the regulatory requirements in other jurisdictions, or we fail to receive necessary or desirable marketing authorizations in other jurisdictions, our target market will be reduced and our ability to realize the full market potential of our solutions will be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our employees, independent contractors, consultants, commercial partners, customers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, customers, and vendors. Misconduct by these </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">parties could include intentional, reckless and negligent conduct that fails to: comply with the rules and regulations of the CMS, the FDA, and other comparable foreign regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing and clinical laboratory standards; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. Since we began commercializing MI Profile, Caris Assure and our earlier solutions in the United States, our potential exposure under such laws has increased significantly, and our costs associated with compliance with such laws have, and will likely continue to, increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices, as well as off-label product promotion. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of participant recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a Corporate Compliance Program, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Even if it is later determined after an action is instituted against us that we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions, and have to divert significant management resources from other matters. We expect our exposure to and costs associated with compliance with healthcare fraud and abuse laws to increase significantly if we commercialize additional solutions in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We use medical and hazardous materials that require considerable expertise and expense for handling, storage, or disposal and may result in claims against us.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and our facilities are subject on an ongoing basis to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of regulated medical waste, hazardous waste, and biohazardous waste, including chemicals, biological agents and compounds and blood and other tissue specimens. We cannot eliminate the risk of accidental contamination or injury to employees, consultants, or third parties from the use, storage, handling, or disposal of these materials. Typically, we use licensed or otherwise qualified outside vendors to dispose of this waste. However, many of these laws and regulations provide for strict liability, holding a party potentially liable without regard to fault or negligence. As a result, we could be held liable for damages and fines if our, or others&#8217;, business operations or other actions result in contamination of the environment or personal injury due to exposure to hazardous materials. Our costs for complying with these laws and regulations cannot be estimated or predicted with accuracy and depends on a number of factors, including the amount and nature of waste we produce, which depends in part on the number of tests we perform, and the terms we negotiate with our waste disposal vendors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Healthcare companies are subject to various criminal, civil, and administrative investigations and audits by governmental authorities. Both federal and state government agencies have heightened civil and criminal enforcement efforts in recent&#160;years and expanded collaborative program integrity initiatives. These efforts have led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry involving federal civil and criminal false claims laws, other healthcare fraud and abuse laws, and civil monetary penalties laws, including the FCA. Further, under the FCA, private parties may bring </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;">, or &#8220;whistleblower,&#8221; lawsuits on behalf of the government in connection with alleged false claims for payments submitted to the government or improper retention of overpayments, and these types of actions can be &#8220;under seal&#8221; for a long period of time while regulatory authorities investigate. The private parties who bring FCA lawsuits are entitled to share in any amounts recovered by the government. When an entity is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">determined to have violated the FCA and other criminal healthcare fraud laws, the government may impose substantial civil and criminal fines and penalties for each false claim, plus up to treble damages, and exclude the entity from participation in Medicare, Medicaid, and other federal healthcare programs. In addition, a number of states have adopted their own false claims and whistleblower provisions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have been, are currently, and may in the future be subject to lawsuits, qui tam actions, CIDs, subpoenas, investigations, audits, and other inquiries related to our operations. We have also been, are currently, and may be in the future, subject to subpoenas, CIDs, actions, or investigations relating to our arrangements and interactions with third parties such as healthcare professionals, healthcare institutions, market participants, or patients. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, in March 2025, we received a CID from the DOJ in connection with an investigation under the False Claims Act regarding our compliance with Medicare&#39;s date of service rule (also referred to as the 14-day rule), particularly focused on patients of certain health care providers, and our policies, procedures, and training related to compliance with the 14-day rule. The related investigation continues to evolve and is in too early a stage to assess potential outcomes. We are cooperating with the investigation. We have implemented compliance policies, procedures, and training designed to foster compliance with the 14-day rule, but there can be no certainties regarding the outcome of the CID. In June 2022, we entered into a settlement agreement with the United States in connection with a previous investigation into our compliance with the 14-day day rule. Pursuant to this settlement agreement, under which we admitted no fault or liability, we paid approximately $2.9 million in restitution and penalties and we obtained a nationwide release from all 14-day rule claims prior to January 1, 2018. For additional information see &#8220;Business&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">Legal Proceedings.&#8221; These interactions could result in the government or other parties pursuing legal claims against us that may result in liabilities, including damages penalties, the potential for exclusion from participation in federal healthcare programs, or the imposition of additional compliance and reporting requirements as part of a corporate integrity agreement, any of which could have an adverse effect on our business, financial condition, reputation, and results of operations. </font></div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to audits and investigations of the ordering, billing, and coding of our solutions, including whether these services were properly ordered, billed, and coded or otherwise compliant with requirements for coverage and payment. In particular, as a result of our participation in the Medicare and Medicaid programs, we face and are currently subject to various governmental reviews, audits, and investigations to verify our compliance with these program requirements and applicable laws and regulations. Government agencies and their agents, such as the MACs and Recovery Audit Contractors (&#8220;RACs&#8221;), as well as the OIG, CMS, and state Medicaid programs, conduct audits of post-payment reviews to detect and correct improper payments in the Medicare program. Private third-party payers conduct similar reviews, audits and pre-payment and post-payment audits. Government agencies and their contractors and other third-party payers regularly conduct audits and request documentation to support claims submitted for payment of services rendered and compliance with claim submission requirements. We are routinely subject to audits under various government programs and third-party payers, and any delays timely providing requested records, negative audit findings or allegations of fraud or abuse may subject us to liability, such as overpayment liability, refunds or recoupments of previously paid claims, payment suspension or the revocation of billing or payment privileges in governmental healthcare programs or other third-party payer programs. Such actions, if imposed on us or our subsidiaries, could adversely impact our business, financial condition, and results of operations. In addition, we perform internal audits and monitoring. Depending on the nature of the conduct uncovered in such audits, and whether the underlying conduct could be considered systemic, the resolution of these audits could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Responding to government investigations, qui tam lawsuits, payer audits, subpoenas, CIDs, or other legal and administrative proceedings can be time- and resource-consuming and can divert management&#8217;s attention from the business. Even an unsuccessful challenge or investigation into our practices could cause unfavorable publicity and require us to incur significant costs, resulting in an adverse effect to our reputation and business. If our operations are found to be in violation of applicable laws or regulations, we may be subject to civil and criminal penalties, including significant fines or damages or other sanctions, including exclusion from government healthcare programs. Settlements of lawsuits involving Medicare and Medicaid issues routinely require both monetary payments and corporate integrity agreements that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">require the imposition of substantial compliance and reporting requirements, any of which could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare reform measures or changes in policy or government spending could cause significant harm to our business, financial condition, and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Healthcare systems are subject to ongoing reform in the United States and abroad. Federal and state governments have made, and continue to make, significant modifications to the Medicare and Medicaid programs through statutory and regulatory changes, administrative rulings and other interpretations and determinations. For example, in the United States, the&#160;ACA made a number of substantial changes to the way healthcare is financed both by government and private insurers. The ACA, among other things, included provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse. We expect these and other provisions will influence our industry and our operations in ways that we cannot currently predict. Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. For example, on June&#160;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that efforts to reform, modify, or repeal parts of the ACA may continue under the new presidential administration. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In recent&#160;years, legislative and regulatory changes have resulted in limitations and reductions in reimbursement levels and payments to healthcare providers for certain services under the Medicare program. For example, In April&#160;2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. In addition, Congress established automatic spending reductions under the Budget Control Act of 2011 (the &#8220;BCA&#8221;), resulting in a 2% reduction in Medicare payments that began in 2013, and due to subsequent legislative amendments, will remain in effect until 2032, unless additional Congressional action is taken. In addition, as a result of the American Rescue Plan&#160;Act of 2021 (&#8220;ARPA&#8221;), an additional Medicare payment reduction of up to 4% was required to take effect in January&#160;2022; however, Congress has delayed implementation of this reduction until 2025. It is difficult to predict whether, when or what other deficit reduction initiatives may be proposed by Congress. We anticipate that the federal budget deficit will continue to place pressures on government healthcare programs and impose additional spending reductions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to changing federal policy and regulatory oversight, states and third-party payers may also introduce proposals and polices to reduce costs while expanding individual healthcare benefits. Certain of these proposals may limit the prices we will be able to charge for our solutions or limit coverage of or lower reimbursement for the procedures associated with the use of our solutions. Healthcare reform and pricing of prescription drugs and medical devices, including clinical laboratory tests, are and will remain a key bipartisan issue. Policies to be pursued in the future may be more aggressive, regardless of which party controls the White House or houses of Congress. Uncertainty surrounding future changes may adversely affect our operating environment and therefore our business, financial condition, results of operations, and growth prospects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or in foreign jurisdictions, or the full impact of current or future healthcare reform measures on our business. For example, the payment reductions imposed by the ACA and the changes to the reimbursement amounts paid by Medicare for tests based on the procedures set forth in PAMA, could limit the prices we are able to charge or the amount, if any, of available reimbursement or coverage for our solutions, which would reduce our revenue. Additionally, these healthcare policy changes could be amended or additional healthcare initiatives could be implemented in the future. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, the impact on our business of the expansion of the federal and state governments&#8217; role in the U.S. healthcare industry generally, including the social, governmental, and other pressures to reduce healthcare costs while expanding individual benefits is uncertain. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Statutory, regulatory, and policy changes, or government budget and funding levels, may also impact the ability of the FDA, the Department of Health and Human Services (including CMS) and other regulatory authorities to perform their regulatory functions. Inadequate funding or staffing for such organizations and/or potentially shifting priorities, including under the new administration, could prevent or delay regulatory reviews and approval processes on which certain of our initiatives may rely, adversely affect agencies&#8217; ability to hire and retain key personnel, or otherwise prevent those agencies from timely performing normal business functions on which the operation of our business may rely, any of which could negatively impact our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS, and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. Further, in June 2024, the U.S. Supreme Court reversed its longstanding approach under the Chevron doctrine, which provided for judicial deference to regulatory agencies&#39; interpretation of statutes that are silent or ambiguous, including the FDA and CMS. As a result of this decision, we cannot be sure whether there will be increased challenges to existing agency regulations or how lower courts will apply the decision in the context of other regulatory schemes without more specific guidance from the U.S. Supreme Court. For example, this decision may result in more companies bringing lawsuits against the regulatory agencies to challenge current regulations and longstanding decisions and policies of the FDA or CMS, which could lead to uncertainties in the industry. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, CMS, or other regulatory agencies, or the nature or extent of government regulation that may arise from future legislation or administrative action.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The marketing authorization processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable marketing authorizations, or if such marketing authorizations are significantly delayed, our business will be substantially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Except for MI Cancer Seek, for which we have obtained a PMA approval from the FDA, we currently offer our NGS solutions, MI Tumor Seek Hybrid and Caris Assure, and our AI solutions, such as GPSai and FOLFIRSTai, as LDTs. See &#8220;&#8212;We have current solutions marketed as LDTs and plan to launch future solutions as LDTs. The FDA recently finalized a rule, which has since been vacated by a federal court, pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected.&#8221; We currently anticipate eventually seeking FDA approval for Caris Assure and additional solutions. The time required and ability to obtain marketing authorization from the FDA and comparable foreign regulatory authorities is unpredictable and typically takes several&#160;years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of our solutions. In addition, policies, laws, regulations, or the type and amount of clinical data necessary to gain marketing authorization may change during the course of a test&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the marketing authorization of, or the decision not to approve, an application. Regulatory authorities have substantial discretion in the premarket review process and may refuse to accept any application, decide that our data are insufficient for marketing authorization, require additional clinical or other data, or determine that our manufacturing and quality systems are insufficient or in violation of applicable requirements. Even if we believe our data are sufficient to support marketing authorization, regulatory authorities may disagree, or may require the generation and submission of additional data or analyses, which could significantly delay or preclude marketing authorization. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before a new medical device can be marketed in the United States, a company must first submit a premarket notification to FDA and receive clearance by FDA under Section&#160;510(k) of the FDCA, a PMA application and receive approval by FDA under Section&#160;515 of the FDCA, or a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification request and receive a grant of the request from the FDA under section 513(f)(2) of the FDCA, unless an exemption </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May&#160;28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, a device that was classified under the </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification pathway, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device and performance data show that the proposed device is as safe and effective as the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective (which means analytically valid and clinically valid in the case of tests) for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. In the </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification process, a manufacturer whose novel device under the FDCA would otherwise be automatically classified as Class&#160;III and require the submission and approval of a PMA prior to marketing is able to request down-classification of the device to Class&#160;I or Class&#160;II on the basis that the device presents a low or moderate risk. If Class&#160;II, new special controls will be required to provide reasonable assurance of safety and effectiveness of the device. If the FDA grants the </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification request, the applicant will receive authorization to market the device. This device type may be used subsequently as a predicate device for future 510(k) submissions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The PMA approval, 510(k) clearance and </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification processes can be expensive, lengthy, and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to 12&#160;months, but can take longer. The process of obtaining a PMA approval or </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification is much more costly and uncertain than the 510(k) clearance process and the FDA has 180&#160;days from the day of filing under the FDC Act to complete its review of the PMA and FDA endeavors to review </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification requests within 150&#160;days, although, in practice, the FDA&#8217;s review often takes significantly longer. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not obtain marketing authorization by the FDA. Any delay or failure to obtain necessary marketing authorizations could harm our business. Furthermore, even if we are granted such marketing authorizations, they may include significant limitations on the indicated uses for the solution, which may limit the potential commercial market for the solution. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, any modification to a product for which we receive marketing authorization may require us to submit a new 510(k) notification and obtain clearance, to submit a supplemental PMA and obtain FDA approval, or to submit a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> request prior to implementing the change. For example, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, generally requires a new 510(k) clearance or other marketing authorization. The FDA requires every manufacturer to make such determinations in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with a manufacturer&#8217;s decisions regarding whether new marketing authorizations is necessary. If we obtain market authorizations from the FDA, we may make modifications or add additional features in the future that we believe do not require a new 510(k) clearance, </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> request or approval of a PMA or supplement. If the FDA disagrees with our determination and requires us to seek new marketing authorizations for the modifications for which we have concluded that new marketing authorizations are unnecessary, we may be required to cease marketing and/or to recall the modified product until we obtain such marketing authorization, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future solutions or modifications to existing solutions than we had expected, solution introductions or modifications could be delayed or canceled, which could adversely affect our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA or other regulators can delay, limit, or deny marketing authorization of a product for many reasons, including but not limited to the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation, or results of, or interpretation of the data from, our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may determine that our solution has not been shown to be safe and effective or substantially equivalent to a predicate device, or has other characteristics that preclude us from obtaining marketing authorization or prevent or limit its commercial use (for example, a narrowed indication for use claim); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the population studied in the clinical program may not be sufficiently broad, generalizable, or representative of the intended target population of our solution to assure effectiveness and safety in the population for which we seek approval or clearance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or may fail to accept data from clinical trials (or clinical sites), including if we fail to establish the integrity of our data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may determine that our clinical trials otherwise fail to comply with applicable regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">serious or unexpected adverse effects or other performance issues are identified with our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities may determine that our manufacturing or quality system fails to comply with applicable regulations or otherwise fails to meet the standards necessary to support approval; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">There can be no assurance that our solutions for which we may seek marketing authorization will receive such marketing authorization from by the FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of, and reimbursement for, our solutions. If our solutions receive marketing authorization but there is uncertainty about such solutions among providers or payers, or if the approved or cleared indication or other labeling claims the FDA or a comparable foreign regulatory authority has authorized us to make are more limited than we expect, reimbursement may be adversely affected and we may not be able to sell our solutions. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our solutions, if authorized. The lengthy and unpredictable marketing authorization processes, as well as the unpredictability of the results of our clinical trials, may result in our failing to obtain marketing authorization to market our solutions, which would significantly harm our business, results of operations, reputation, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Ethical, legal, and social concerns related to the use of genomic information could reduce demand for our solutions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Genomic testing, like that conducted using our solutions, has raised ethical, legal, and social issues regarding privacy and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genomic information or genomic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use genomic and somatic profiling tests even if permissible. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ethical and social concerns may also influence U.S. and foreign patent offices and courts with regard to patent protection for technology relevant to our business. These and other ethical, legal, and social concerns may limit market acceptance of our solutions or reduce the potential markets for services enabled by our platform, either of which could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If the validity of an informed consent from patients regarding our solution was challenged and proven invalid, unlawful, or otherwise inadequate for our purposes, we could be forced to stop offering our solutions or using our resources, our business, financial condition, and results of operations will be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We offer our solutions to physicians and to biopharma companies in connection with clinical trials. We generally rely on treating physicians to obtain required informed consent under applicable state laws, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">but we have also recently implemented measures to ensure that data and biological samples that we receive have been collected from subjects who have provided appropriate informed consent. We also conduct validation studies, or act as a sponsor of clinical trials in connection with the development and validation of our solutions, which are frequently conducted in collaboration with different parties. We submit for projects that meet the definition of &#8220;human subjects research,&#8221; to the IRB, or other reviewing body for review and approval of processes for subject informed consent and authorization for use of personal information or waivers thereof. We and our biopharma partners could conduct clinical trials in a number of different countries. When we are acting as a vendor in connection with a clinical trial sponsored by our biopharma partners, we rely upon them to comply with the requirements to obtain the subject&#8217;s informed consent and to comply with applicable laws and regulations. The collection of data and samples in many different countries results in complex legal questions regarding the adequacy of informed consent and the status of genetic material under a large number of different legal systems. Those informed consents could be challenged and proven invalid, unlawful, or otherwise inadequate for our purposes. Any such findings against us, or our biopharma partners, could force us to stop accessing or using data and samples or servicing or conducting clinical trials, which would hinder our product offerings or development. We could also become involved in legal actions, which could consume our management and financial resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with applicable data interoperability and information blocking rules, our business, financial condition, and results of operations could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 21</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">st</font><font style="letter-spacing:0.2pt;"> Century Cures Act (the &#8220;Cures Act&#8221;), which was passed and signed into law in December&#160;2016, includes provisions related to data interoperability, information blocking and patient access. In March&#160;2020, the HHS Office of the National Coordinator for Health Information Technology (&#8220;ONC&#8221;) finalized and issued complementary rules that are intended to clarify provisions of the Cures Act regarding interoperability and information blocking, and include, among other things, requirements surrounding information blocking and changes to ONC&#8217;s health IT certification program. The companion rules will transform the way in which healthcare providers, health IT developers, health information exchanges/</font>&#8203;<font style="letter-spacing:0.2pt;">health information networks and health plans share patient information, and create significant new requirements for healthcare industry participants. For example, the ONC rule, which went into effect on April&#160;5, 2021, prohibits healthcare providers from engaging in practices that are likely to interfere with, prevent, materially discourage, or otherwise inhibit the access, exchange, or use of electronic health information (&#8220;EHI&#8221;), also known as &#8220;information blocking.&#8221; To further support access and exchange of EHI, the ONC rule identifies eight &#8220;reasonable and necessary activities&#8221; as exceptions to information blocking activities, as long as specific conditions are met. On July&#160;3, 2023, the HHS Office of the Inspector General (&#8220;HHS-OIG&#8221;) published its final rule implementing information blocking penalties for &#8220;actors,&#8221; which is supplemented by ONC&#8217;s January&#160;9, 2024 final rule enhancing certain information blocking requirements, under which HHS-OIG may impose penalties for information blocking that has occurred after September&#160;1, 2023. In addition, ONC and HHS proposed a rule on November&#160;1, 2023, listing &#8220;appropriate disincentives&#8221; for noncompliance by healthcare providers. If we fail to comply with the requirements, it may negatively impact our business operations. The goals of increased use of electronic health data and interoperability are improved quality of care and lower healthcare costs generally. However, increased use of electronic health data and interoperability inherently magnifies the risk of security breaches involving that data and information systems used to share it. For additional information, see &#8220;&#8212;Risks Related to Our Business and Industry&#8212;If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.&#8221; Any failure to comply with these rules could adversely affect our business, financial condition, and results of operations. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we or our partners fail to comply with federal, state, and foreign laboratory and other applicable licensing and registration requirements, we could be prevented from performing our solutions or experience disruptions to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CLIA is a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention, or treatment of disease, or impairment of, or the assessment of the health of, human beings. CLIA regulations require, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">among other things, clinical laboratories to obtain a certificate and mandate specific standards in the areas of personnel qualifications, administration, participation in proficiency testing, test management, and quality assurance. CLIA certification is also required for us to be eligible to bill state and federal healthcare programs, if such reimbursement is otherwise available, as well as many private third-party payers, for our solutions. Certain product additions to our solution menu require notification to regulatory and accrediting bodies that regulate our laboratories. To renew these certifications, we are subject to routine surveys and inspections. Moreover, CLIA inspectors may make random or &#8220;for cause&#8221; inspections of our clinical laboratories. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently have two commercial clinical laboratory facilities in Phoenix, Arizona, and we are in the process of building out our newest clinical laboratory in Irving, Texas. Both of the Phoenix laboratory facilities hold independent CLIA Certificates of Accreditation. A CLIA Certificate of Accreditation is issued to a laboratory facility that performs moderate and/or high complexity testing after an accreditation organization conducts a survey and determines that the laboratory is in compliance with the CLIA regulations. Our laboratory facility in Irving, Texas will seek a CLIA Certificate of Registration from CMS, and upon required inspection, anticipate receiving a CLIA Certificate of Accreditation. The CLIA Certificate of Registration allows the laboratory facility to begin conducting moderate and/or high complexity testing, subject to a survey to determine compliance with the CLIA regulations. After a laboratory obtains a Certificate of Registration, CLIA begins scheduling regular, routine inspections. Once the inspection process for the laboratory facility is successfully completed, the facility qualifies for a CLIA Certificate of Accreditation and thereafter is inspected every two years.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Both of our Phoenix laboratories hold CAP accreditations upon which our CLIA Certificate of Accreditation are based. CAP typically conducts biannual surveys of each facility. Any failure to pass inspections, maintain our CAP accreditation, CLIA Certificate of Registration, CLIA Certificate of Accreditation, or state licenses, or add new validated solutions to our laboratory offerings could significantly harm our business, results of operations, and prospects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to obtaining federal certification for a laboratory under CLIA, we are also required to obtain and maintain state licenses to conduct profiling in our laboratories. Neither Arizona (where we currently operate two clinical laboratories) nor Texas (where we are completing the build-out of our newest clinical laboratory) requires us to obtain and maintain state licenses to conduct profiling in our laboratories. However, some states require out-of-state licensure if we test specimens originating from those states and return patient-specific results. Our tissue-based Arizona facility has obtained licenses from California, Rhode Island, Maryland, New York, and Pennsylvania, and our blood-based Arizona facility has obtained licenses from California, Maryland, Pennsylvania, and Rhode Island. If we have a blood-based profiling solution approved by New York state, we will also obtain a New York license for our blood-based facility. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, to be able to receive specimens originating from New York, we must obtain and maintain a New York State Department of Health clinical laboratory permit. We have a New York State Department of Health clinical laboratory permit for our tissue-based Arizona facility, and we intend to apply for such a permit for our other commercial facilities. Research testing (which we conduct at our R&amp;D laboratory in Tempe, Arizona), however, does not require licensure if patient-specific results are not generated and/or returned for diagnostic purposes. As our blood-based Arizona facility does not currently operate in New York, we have not sought a New York laboratory permit. We cannot guarantee that the New York State Department of Health will issue a clinical laboratory permit for our Texas facility or our blood-based Arizona facility, and if we do not receive this permit, our business may be adversely impacted. In addition, New York laws and regulations establish rigorous standards for day-to-day operation of a clinical laboratory, including training and skill levels required of laboratory personnel, physical requirements of a facility, equipment, and validation and quality control, and we are required to abide by these laws and regulations as a permit holder. Failure to comply with these laws and regulations could result in various significant penalties, including loss of our New York permit, fines and other penalties, or limitations on our potential profiling population, which could adversely impact our business. New York also requires specific reporting for companies in the oncology space. Failure to comply with any established reporting requires could negatively impact our license. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The states that require us to hold an out-of-state license may change, and we are uncertain whether states will continue to grant or may require us to hold these licenses in the future. Any failure or inability on </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our part to obtain required state licensure may result in substantial penalties, including prohibition form billing certain payers and thus adversely affect our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with CLIA certification and state laboratory licensing and permitting, we remain subject to a number of risks in the event of noncompliance. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure or permitting, or our failure to renew or maintain a CLIA certificate, a state license or permit, or accreditation (including CAP), could adversely affect our business and reputation. CMS also has the authority to impose a wide range of sanctions, including suspension, limitation, or revocation of the CLIA certification, termination of Medicare and Medicaid participation, civil money penalties, and a bar on the ownership or operation of a CLIA-certified laboratory by any owners or operators of the deficient laboratory. If we fail to obtain any required state licensure, or lose CLIA certification, CAP accreditation, or licensure once obtained, we would not be able to operate our clinical laboratories and offer our solutions in full or in particular states, which would adversely impact our business, financial condition, and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to state laboratory licensing laws, we may also be subject to foreign state registration and/or licensing requirements that apply to companies that manufacture medical devices. Certain states may require such registrations or licenses before the solutions are commercialized, including while manufacturers are evaluating the devices in clinical trials. Violations of these laws may result in a range of potential sanctions or penalties which could include the denial, suspension, limitation or revocation of the registration or license, as well as other fines and penalties, including imprisonment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our pathologists are subject to individual medical licensure requirements and our pathologists, physicians, and geneticists could also be subject to in the future additional licensure requirements under state law. If the physicians and geneticists are not able to timely maintain, obtain or otherwise satisfy any new licensure requirements, this could have a negative impact on our operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Data from our clinical trials that we announce or publish from time to time before our trials are complete may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may publicly disclose preliminary or topline data from our validation studies and clinical trials that we conduct ourselves or in partnership with other organizations, including on the application of Caris Assure in early detection, MRD tracking, and treatment monitoring, and Caris ChromoSeq, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may also disclose interim data from our validation studies that we conduct or from our clinical trials. Interim data from these studies or trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available. Adverse differences between interim data and top-line, preliminary, or final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our Class A common stock. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, and our ability to receive coverage, marketing authorization or commercialize a particular solution and our company in general. In addition, the information </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding our business. If the data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to commercialize or obtain marketing authorization for, our solutions may be harmed, which could harm our reputation, business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any LDT solution we market during the phase-in period of the FDA&#8217;s LDT final rule (if it comes into effect) and any solution for which we obtain marketing authorization will become subject to extensive ongoing regulatory requirements, and we may be subject to penalties if we or our partners fail to comply with regulatory requirements or if we experience unanticipated problems with our solutions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any solution for which we obtain marketing authorization from the FDA or other regulators, along with the manufacturing processes, post-market surveillance, labeling, packaging, advertising, and promotion, distribution, storage, import, export, reporting, and recordkeeping for such solutions, will become subject to continued regulatory review, oversight, requirements, and periodic inspections by the FDA and comparable foreign regulatory authorities. These requirements, certain of which may also apply to solutions we market during the phase-in period of the FDA&#8217;s LDT final rule, include submissions of safety and other post-marketing information and reports; registration and listing requirements; requirements relating to quality control, quality assurance, cyber security, and corresponding maintenance of records and documents; requirements relating to recalls, removals, and corrections; and requirements relating to product labeling, advertising and promotion, and recordkeeping. Under the FDA&#8217;s LDT final rule issued on May&#160;6, 2024, any LDT that receives marketing authorization would be subject to these medical device requirements, as applicable. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA&#39;s LDT final rule. The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA enforces these regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we will be found compliant in connection with any future regulatory inspections. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Marketing authorization of a test or device may be subject to limitations by the regulatory body as to the indicated uses for which the product may be marketed or to other conditions of marketing authorization. In addition, marketing authorization may contain requirements for costly post-marketing testing and surveillance to monitor the safety or effectiveness of the test or device. Discovery of problems with our solutions, suppliers, vendors, contract manufacturers, manufacturing processes (including software validation), and/or failure to comply with regulatory requirements, may result in actions such as: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">restrictions on operations of our laboratories; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">restrictions on manufacturing processes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">restrictions on marketing of a product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Untitled or Warning letters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">withdrawal or recall of the product from the market or seizure of the product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">refusal to approve applications or supplements to approved applications that we may submit; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fines, restitution or disgorgement of profits or revenue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">suspension, limitation, or withdrawal of marketing authorization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">safety communications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">refusal to permit the import or export of our solution; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">injunctions; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">imposition of civil or criminal penalties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and adversely affect our reputation, business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the FDA may change its marketing authorization policies, adopt additional regulations or revise existing regulations, or take other actions. For example, in addition to the FDA&#8217;s LDT final rule, a few&#160;months earlier in February&#160;2024, the FDA issued a final rule to amend and replace the Quality System Regulation (&#8220;QSR&#8221;), which sets forth the FDA&#8217;s current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically, this final rule, which the FDA expects to go into effect on February&#160;2, 2026, establishes the Quality Management System Regulation (&#8220;QMSR&#8221;), which among other things, incorporates by reference the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, it is unclear the extent to which this final rule, once effective, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise adversely affect our business. If we are unable to comply with the QMSR, once effective, or with any other changes in the laws or regulations enforced by the FDA or comparable regulatory authorities, we may be subject to enforcement action, which could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">For any LDT solution we market during the phase-in period of the FDA&#8217;s LDT final rule (if it occurs) and any solution for which we obtain marketing authorization from the FDA we will become subject to regulatory requirements, which require us to report to the FDA certain information about adverse medical events or malfunctions for any of our solutions, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, and results of operations. The discovery of serious safety issues with our solutions, or a recall of our solutions either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any LDT solution we market during the phase-in period of the FDA&#8217;s LDT final rule and any solution for which we obtain FDA marketing authorization, including MI Cancer Seek, or that are otherwise subject to affirmative FDA oversight, will become subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our solutions may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. Under the FDA&#8217;s LDT final rule issued on May&#160;6, 2024, and which was vacated by a federal court on March 31, 2025, any LDT that receives marketing authorization would be subject to these medical device reporting regulations, as applicable. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device marketing authorization, withdrawal of our solutions from the market, seizure of our solutions, or delay in marketing authorization of future solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies, or failures to comply with applicable regulations. Product defects or other errors may occur in the future. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new marketing authorizations for the device before we may market or distribute the corrected device. Seeking such marketing authorizations may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our solutions in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect the adoption and use of our solutions. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">To comply with the FDA&#8217;s LDT final rule and to obtain and maintain FDA marketing authorization, our solutions will need to be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we or our partners fail to comply with these regulations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The methods used in, and the facilities used for, the manufacture of our solutions must comply with the FDA&#8217;s QSR requirements (applicability subject to the phase-in periods of the FDA&#8217;s LDT final rule, which rule was vacated by a federal court on March 31, 2025), which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing, and shipping of medical devices. Furthermore, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR requirements through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our solutions are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our solutions. In addition, in February&#160;2024, the FDA issued a final rule to amend and replace the QSR, which sets forth the FDA&#8217;s current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically, this final rule, which the FDA expects to go into effect on February&#160;2, 2026, establishes the QMSR, which among other things, incorporates by reference the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2106 are substantially similar to those set forth in the QSR, it is unclear the extent to which this final rule, once effective, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise negatively affect our business. Failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our solutions or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our solutions; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; FDA&#8217;s refusal to grant pending or future marketing authorizations for our solutions; clinical holds; refusal to permit the import or export of our solutions; and criminal prosecution of us, our suppliers, or our employees. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these actions could significantly and negatively affect supply of our solutions. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers, experience reduced sales, and increased costs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The misuse or off-label use of our solutions may harm our reputation in the marketplace, lead to product liability suits or result in costly investigations, fines, or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any marketing authorization we may receive for our solutions will be limited to specified indications for use. We train our marketing personnel and direct sales force to not promote our solutions for uses </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">outside of FDA cleared or approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our solutions off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the FDA or any foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, physicians may misuse our solutions if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our solutions are misused, we may become subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Misleading, untruthful, or unsubstantiated labeling, advertising, marketing, or promotional practices could adversely impact our business, financial condition, and results of operations. The FTC has instituted enforcement actions against certain healthcare testing companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions may result in warning letters, consent decrees, and the payment of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or unsubstantiated, we could be subject to FTC enforcement action and may face significant penalties which may adversely impact our business, financial condition, and results of operations.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The labeling, advertising, marketing, and promotional practices related to our solutions is governed by numerous state and federal regulators, including the FDA and the FTC, as well as subject to third-party claims. Any statements related to our solutions that could be construed as misleading, untruthful, or unsubstantiated, could subject us to regulatory enforcement action, third-party lawsuits, or plaintiffs&#8217; complaints. Any of these actions could significantly and negatively affect our reputation, expose us to liability claims, and we could lose customers and experience reduced sales and increased costs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our &#8220;research use only&#8221; and any potential &#8220;investigational use only&#8221; products could become subject to more onerous regulation by the FDA or other regulatory authorities in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business, financial condition, and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, some of our products are currently available, or may become available, for research use only (&#8220;RUO&#8221;), or for investigational use only (&#8220;IUO&#8221;), depending on the proposed application. We make our RUO and IUO products available to a variety of parties, including pharmaceutical and biotechnology companies and research institutes. Because RUO and IUO products are not intended for use in clinical practice and cannot be advertised or promoted for clinical or diagnostic claims, they are exempt from many regulatory requirements otherwise applicable to medical devices. In particular, while the FDA regulations require that RUO products be labeled &#8220;For Research Use Only. Not for use in diagnostic procedures,&#8221; and IUO products be labeled &#8220;For Investigational Use Only. The performance characteristics of this product have not been established,&#8221; such products are not subject to the FDA&#8217;s pre- and post-market controls for medical devices. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A significant change in the laws governing RUO or IUO products or how they are enforced may require us to change our business model in order to maintain compliance. For instance, in November 2013, the FDA issued a guidance document entitled &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only&#8221; &#8203;(the &#8220;RUO/IUO Guidance&#8221;), which highlights the FDA&#8217;s interpretation that distribution of RUO or IUO products with any labeling, advertising or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">offer it for clinical diagnostic use as an LDT is in conflict with the RUO or IUO status. The RUO/IUO Guidance further articulates the FDA&#8217;s position that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to clinical laboratories, is in conflict with RUO or IUO status. If we engage in any activities that the FDA deems to be in conflict with the RUO or IUO status held by any of our products so labeled, we may be subject to immediate, severe, and broad FDA enforcement action that would adversely affect our ability to continue operations. Accordingly, if the FDA finds that we are distributing our RUO or IUO products in a manner that is inconsistent with its RUO/IUO Guidance, we may be forced to stop distribution of our RUO/IUO tests until we are in compliance, which would reduce our revenue, increase our costs, and adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could adversely impact our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA to review and provide marketing authorization new products or changes to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, federal government shutdowns, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund R&amp;D activities is subject to the political process, which is inherently fluid and unpredictable. Decreases in government funding of research and development, including any reductions in funding to the U.S. National Institutes of Health may impact our business, as could changes in government programs that provide funding to research institutions and companies, including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of time of the funding process. Disruptions at the FDA and such other agencies may also slow the time necessary for new medical devices or modifications to FDA cleared or approved medical devices to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, during the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates, and any resurgence of COVID-19 or emergence of new variants may lead to further inspectional delays. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could adversely affect our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Federal Policy for the Protection of Human Subjects or related state regulations may be revised or altered in a way that negatively impacts our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Federal Policy for the Protection of Human Subjects (typically referred to as the Common Rule) may be altered in a way that prevents or restricts us from using patient samples or clinical trial data to further develop or validate our solutions or future AI/ML algorithms which rely upon identifiable data. The revised Common Rule, effective as of July&#160;19, 2018, allows the use of prospective consent to unspecified future research (i.e., &#8220;broad consent&#8221;) from a human subject for the storage, maintenance, and secondary use of identifiable private information and identifiable biospecimens in research activities. We obtain both identifiable and de-identified data which we use to develop our solutions through biospecimen repositories and from our biopharma partners. If regulations allowing broad consent or the regulatory definition of &#8220;research&#8221; changes in a way that excludes our research activities, our business may be negatively impacted. State laws governing clinical research may complicate our compliance efforts and add costs and delay to our R&amp;D activities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business activities are subject to the FCPA and similar anti-bribery and anti-corruption laws, as well as export and import controls and economic sanctions laws and regulations of the United States and other jurisdictions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business activities are subject to the Foreign Corrupt Practices Act of 1977, as amended (the &#8220;FCPA&#8221;), and similar anti-bribery or anti-corruption laws, regulations, or rules of other countries, such as the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many countries, the healthcare providers who administer diagnostic tests are employed by their government, and the purchasers of diagnostics tests are government entities; therefore, our dealings with these providers and purchasers are subject to regulation under the FCPA. The Securities and Exchange Commission (&#8220;SEC&#8221;) and DOJ have increased their FCPA enforcement activities with respect to life sciences companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Filing of FCPA enforcement actions have been temporarily paused. Once enforcement resumes, companies may incur additional damage due to delayed prosecution. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business is also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. In particular, there is currently significant uncertainty about the future relationship between the United States and various other countries, including, without limitation, China, Mexico, and Canada, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our solutions in one or more countries and could harm our reputation, brand, international expansion efforts, and ability to attract and retain employees, which could have an adverse effect on our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to our solutions, and our ability to successfully commercialize our solutions may be impaired.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our success and ability to compete successfully will depend in part on our ability to obtain, maintain, and enforce issued patents, trademarks, and other intellectual property rights and proprietary technology protection for our solutions, preserve our trade secrets, and operate without infringing the intellectual property rights of third parties. Filing, prosecuting, enforcing, and defending patents on our solutions and other technologies in all countries throughout the world would be prohibitively expensive and time-consuming, and the laws of some foreign countries may not protect our rights to the same extent as the laws of the United States. We may not, and our exclusive licensors may not, be able to file, prosecute, maintain, enforce, or license all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner, or in all jurisdictions, or at all, or may choose not to do any of the foregoing. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our products and technologies and each of these provisional patent applications, or any future provisional patent application </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">on certain aspects of our products and technologies, is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12&#160;months of the filing date of the applicable provisional patent application. In cases where we have not obtained, or decided not to obtain, patent protection for certain of our inventions, we may not be able to prevent third parties from practicing our inventions or from selling or importing tests made using our inventions in and into the United States or other jurisdictions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent&#160;years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our solutions and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to prevent a competitor from developing, manufacturing, and commercializing a solution or technologies in a non-infringing manner that would be competitive with one or more of our solutions or technologies, or otherwise provide us with any competitive advantage. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, although we have applied for patents covering aspects of our technology in the United States and several other countries, we cannot be certain that our owned and exclusively licensed patents will not be challenged, or that all patents for which we have applied, or that are covered by our exclusive in-licenses, will be issued on a timely basis or at all, or that such patents will protect our technology, in whole or in part, or be issued in a form that will provide us with meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. As further described below, the enforceability of issued patents may be challenged on a number of fronts, including inventorship, scope, or validity, and certain of our owned or exclusively in-licensed patents have been, and others in the future may be, challenged in the courts or patent offices in the United States and abroad. As a result of such challenges, our issued patents may be held invalid or unenforceable and the scope of existing or future patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For additional information, see &#8220;&#8212;Issued patents covering our solutions and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States and abroad.&#8221; We may fail to identify patentable technologies in a timely fashion, which could impair our ability to obtain patent protection on such technology at all. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Our competitors may be able to circumvent our owned or exclusively in-licensed patents by developing similar or alternative technologies or tests in a non-infringing manner. In addition, to the extent we have granted, or may grant in the future, licenses, or sublicenses of our intellectual property rights to third parties, we cannot be certain that such intellectual property rights will not be used by those third parties in a manner that could compete with our business or otherwise negatively impact any competitive advantage provided by such intellectual property rights. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are uncertain. Given the amount of time required for the development, testing, and regulatory review of biological tests, patents protecting or covering such tests might expire shortly after such solutions are commercialized. As a result, our owned or exclusively in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a third party obtains an issued patent on a technology we use in our solutions, that party may be able to prevent us from using those inventions, and we may not be able to design around the third party&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">patents or obtain a license on commercially reasonable terms, if at all. Third-party patents or other intellectual property may exist that our current technology, manufacturing methods, solutions, platform, or future methods or tests will be alleged to infringe, which could result in litigation, the imposition of injunctions preventing our use of the foregoing, or require us to obtain licenses or pay royalties and/or other forms of compensation to third parties, which could be significant and could harm our results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services, and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any of our pending patent applications will issue as patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we will be able to successfully manufacture and commercialize our solutions on a substantial scale, if approved, before relevant patents we may have expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we were the first to make the inventions covered by each of our patents and pending patent applications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we were the first to file patent applications for these inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">others will not independently develop, manufacture and/or commercialize similar or alternative or duplicative solutions of any of our technologies or products that do not infringe our patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any of our challenged patents will be found to ultimately be valid and enforceable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any patents issued to us will provide a basis for an exclusive market for our commercially viable solutions or technologies, and will provide us with any competitive advantages or will not be challenged by third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we will develop additional proprietary technologies or solutions that are separately patentable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our pending patent applications or those that we may own in the future will lead to issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our competitors will not conduct R&amp;D activities in countries where we do not have patent rights and then use the information learned from such activities to develop, manufacture, and commercialize competitive products for sale in our major commercial markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the patents of others will not harm our business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a third party does not subsequently file a patent covering trade secrets or know-how that we chose not to seek patent protection; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercial activities or solutions will not infringe upon the patents of others. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Third parties may allege that we infringe, misappropriate, or violate their intellectual property rights, and if they prevail, could block sales of our solutions and force us to pay damages and/or royalties, which could adversely affect the success of our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our commercial success in part depends upon our ability, and the ability of our relevant commercial partners, to market, sell, and distribute our solutions and use our proprietary technologies and platform without infringing, misappropriating, or otherwise violating the intellectual property rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology, diagnostic, and pharmaceutical industries, and companies in these industries have used intellectual property litigation to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">gain a competitive advantage. In addition, there is ongoing intellectual property litigation involving the analysis of circulating nucleic acid, the outcome of which could also impact future litigation involving our intellectual property or our ability to commercialize our solutions. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights. Third parties may assert infringement claims against us based on existing patents or patents that issue in the future. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are found to infringe, misappropriate, or otherwise violate a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing, marketing, selling, and distributing our solutions or platform, or to cease using the infringing technology. However, we may not be able to obtain any required license on commercially reasonable terms, if at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages if we are found to have willfully infringed a patent and attorneys&#8217; fees if the court finds the case to be exceptional. A finding of infringement, misappropriation, or other violation could prevent us from commercializing our solutions or force us to cease some of our operations or develop alternate technologies, which could materially harm our business, financial condition, results of operations, and prospects. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our reputation and business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can if they have greater financial resources and/or more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Issued patents covering our solutions and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States and abroad.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to allegations of infringement of a third party&#8217;s intellectual property rights, a third party may also challenge the validity or enforceability of our owned or in-licensed patents in court or before administrative bodies in the United States or abroad. If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering a solution or a solution candidate, the defendant could counterclaim that the asserted patent is invalid and/or unenforceable. Though an issued patent is presumed valid and enforceable, defendant counterclaims alleging invalidity or unenforceability are commonplace in patent litigation in the United States. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, lack of subject matter eligibility, lack of written description, and non-enablement. Non-statutory grounds for unenforceability include inequitable conduct in obtaining the patent, such as an allegation that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark Office (the &#8220;USPTO&#8221;), or made a material misleading statement. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. In addition, the patent laws or interpretation thereof by the USPTO and courts could result in some of the claims of our patents to become invalidated. A court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop a third party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question and is therefore not infringed upon, violated, or misappropriated. For example, certain claims of five of our U.S. patents have previously been invalidated in </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review (&#8220;IPR&#8221;) proceedings, two of our European patents were challenged but ultimately upheld in their entirety in opposition proceedings, and one of our European patents was held unpatentable in an opposition that is currently under appeal. As a result of such challenges, our issued patents may be held invalid or unenforceable and the scope of existing or future patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a defendant were to prevail on its legal assertion of invalidity and/or unenforceability against our intellectual property related to a solution or a solution candidate, we could lose at least part, and perhaps all, of the patent protection on such solution or solution candidate. Such a loss of patent protection could adversely impact our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. Even if our patents or other intellectual property rights are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition, and results of operations. Moreover, even if we are successful in any litigation, we may incur significant cost and expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage from the infringement and proceedings. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to infringement claims against us, third parties have raised, and in the future may raise, claims challenging the validity or enforceability of our owned or in-licensed patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms before the USPTO include re-examination, post grant review, IPR, derivation proceedings, interference proceedings, and equivalent proceedings in foreign jurisdictions (such as opposition proceedings in Europe). Such administrative proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technologies or solutions. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our solutions or technologies. Such a loss of patent protection could adversely impact our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with our obligations in the agreements under which we license or may license intellectual property rights from third parties or we otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have entered into, and may further need to enter into, certain licenses or other collaboration agreements pertaining to the in-license of intellectual property rights from others to advance our research or allow commercialization of our solutions and technologies. Some of these licenses are for a limited term and may include the right for the licensor to terminate upon notice. If any such arrangement is terminated by the licensor, or if we need to enter into any additional licensing arrangements, then we may be unable to obtain such licenses at a reasonable cost or on reasonable terms, if at all, and as a result, we may be required to expend significant time and resources to redesign our technology or to develop or license replacement technology, any of which may not be feasible on a technical or commercial basis. If we are unable to obtain or maintain applicable licenses, we may be unable to commercialize certain solutions or continue to use certain technology, which could harm our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our intellectual property in-licenses may impose various reporting, development, diligence, milestone payment, royalty, insurance, commercialization, and other obligations on us, and we expect that our future license or development agreements will contain similar types of obligations. If we fail to comply with any of these obligations, our licensor or collaboration partners may have the right to terminate the relevant license or collaboration agreement, in which event we would not be able to develop or market the solutions or technologies covered by such licensed intellectual property, or to pursue other reasonable or alternative arrangements. Despite our efforts, our licensors or collaborators might conclude that we have materially breached our obligations under such license agreements. If our licensors or collaborators were to terminate the license agreements or otherwise modify our rights under those agreements, our ability to develop and commercialize solutions and technology covered by these license agreements could be limited if not halted. This could adversely affect our competitive position, business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Agreements under which we license or otherwise obtain rights to intellectual property or technology from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations, which could lead to disputes between us and our licensor, including: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the scope of rights granted under the license agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the extent to which our solution and technology are alleged to infringe the licensor&#8217;s intellectual property that is not subject to the license agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the right to sublicense patent and other rights under our collaborative development relationships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our diligence and other obligations under the license agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the priority of invention of patented technology; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the inventorship and ownership of inventions and know-how resulting from the collaboration with a licensor or joint invention of intellectual property by us and our licensors and our partners. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The resolution of any contract disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could adversely affect our business, financial condition, results of operations, and prospects. If we were required to engage in litigation to enforce or defend our rights under our license or development agreements, even if we were successful, such litigation could require significant financial resources, divert the attention of management, and harm our business. Moreover, if disputes over intellectual property rights that we have licensed or otherwise obtained rights to prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, or at all, we may be unable to successfully commercialize the affected solution or technology, which could adversely affect our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may have limited control over the maintenance and prosecution of in-licensed patents and patent applications, or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. If any of our current or future licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property, or these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business and our competitors could market competing products using the intellectual property. In the event we breach any of our obligations related to such maintenance or prosecution, we may incur significant liability to our licensing partners, including loss of our right to the licensed patent applications or early termination of the license by our licensor. We also may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensor&#8217;s infringement proceeding or defense activities may be less vigorous than had we conducted such activities ourselves. Our ability to enforce in-licensed patents may be in question if our licensors refuse to join in such activities initiated by us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our technology licensed from third parties may be subject to retained rights.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any license we may enter into could provide for the retention by the licensor of certain rights under their agreements with us, including for example, the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether any future licensors will limit their use of the technology to these uses, and we may incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the U.S. government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act (the &#8220;Bayh-Dole Act&#8221;). The U.S. government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. The Bayh-Dole Act also imposes </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">other obligations, including the requirement that products covered by the government funded patents be manufactured in the United States. We sometimes collaborate with academic institutions to accelerate our R&amp;D efforts. In the future, we may own or license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act. If the federal government exercises its rights under the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may become involved in lawsuits to protect or enforce or defend our patents or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate, or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful. We monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek enforce our rights against potential infringement, misappropriation, or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation, or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, for example, in certain countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights can depend on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, these lawsuits or other proceedings could be costly and could affect our operations and divert the attention of our managerial, legal, and scientific personnel. There is a risk that a court or administrative body would decide that our owned or in-licensed patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain claims is more limited than we believe. An adverse outcome in a litigation or other proceeding involving our owned or in-licensed patents could limit our ability to enforce our patents against competitors, affect our ability to receive royalties or other licensing consideration, and may curtail or preclude our ability to exclude third parties from making, using, and selling similar or competitive products. We may become more susceptible to these types of lawsuits and proceedings given the proliferation of organizations pursuing intellectual property protections in the biomarker testing space, particularly as relates to cell free nucleic acids. Any of these occurrences could adversely affect our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property litigation may lead to public disclosures and unfavorable publicity that harms our reputation and causes the market price of our Class A common stock to decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Further, during the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing solutions, programs or intellectual property could be diminished. Accordingly, the market price of shares of our Class A common stock may decline. Such announcements could also harm our reputation or the market for our future solutions, which could adversely affect our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent terms may be inadequate to protect our competitive position on our solutions for an adequate amount of time.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patents have a limited lifespan in all jurisdictions around the world. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">U.S. non-provisional filing date. Various extensions may be available, but the protection offered by a patent remains time limited. Once a patent covering our solutions expires, we may be subject to additional competition. Given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized or receive regulatory approval. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing solutions similar or identical to ours for a meaningful amount of time, or at all. Such an inability to exclude competitors from commercializing similar or identical products could have adversely impact our reputation, business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we do not obtain patent term extension and data or regulatory exclusivity for any solutions we may develop, our business may be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any therapeutic solutions we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable legal requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our solution will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, depending upon the timing, duration, and specifics of any FDA approval of biological products we may develop as part of Caris Discovery or otherwise, such products may be eligible for a period of regulatory exclusivity under the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), a subtitle of the Patient Protection and Affordable Care Act. The BPCIA created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full biologics license application for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Biological products we may develop, if any and if approved, could be considered reference products entitled to 12-year exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider a product candidate to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The FDA only approved the first interchangeable biosimilar in July 2021, and the law is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. If competitors are able to obtain marketing approval for biosimilars </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">referencing any biological products we may develop, our products may become subject to competition from such biosimilars, which could adversely impact our competitive position.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process to maintain patent applications and issued patents. In addition, periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications must be paid to the USPTO and similar patent agencies outside of the United States over the lifetime of our owned and in-licensed patents and applications. In some cases, we rely on our licensing partners to pay such fees and to take the necessary actions to comply with other requirements to maintain such in-licensed patents during their term. While an unintentional lapse of a patent or patent application can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, in some cases non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical tests or technology, which could adversely affect our competitive position. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Developments in patent law could have a negative impact on our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the U.S. Supreme Court or other federal courts, the U.S. Congress, the USPTO, or similar governmental authorities in other jurisdictions may change the standards of patentability and any such changes could have a negative impact on our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Several decisions from the U.S. Supreme Court regarding patentable subject matter are of particular relevance in the medical diagnostics and computer-implemented applications space. The 2012 decision in </font><font style="font-style:italic;letter-spacing:0.2pt;">Mayo Collaborative v. Prometheus Laboratories</font><font style="letter-spacing:0.2pt;"> (&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Mayo</font><font style="letter-spacing:0.2pt;">&#8221;) concerns patent claims directed to optimizing the amount of drug administered to a specific patient based on certain metabolite levels in blood. The Supreme Court held that the applicable patent&#8217;s claims were directed to a law of nature (i.e., a natural correlation between metabolite levels and efficacy or toxicity) and failed to incorporate a sufficiently inventive concept above and beyond routine and conventional method steps to allow the claimed methods of treatment to qualify as patent eligible. The 2014 decision in </font><font style="font-style:italic;letter-spacing:0.2pt;">Alice Corporation Pty. Ltd. v. CLS Bank International</font><font style="letter-spacing:0.2pt;"> (&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Alice</font><font style="letter-spacing:0.2pt;">&#8221;) concerns a computer-implemented, electronic escrow service for facilitating financial transactions. The Supreme Court held that an abstract idea could not be patented just because it is implemented on a computer. It is generally believed that </font><font style="font-style:italic;letter-spacing:0.2pt;">Mayo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Alice</font><font style="letter-spacing:0.2pt;">, and subsequent cases interpreting these decisions, have made it more difficult to patent medical diagnostic and computer-implemented inventions. Our efforts to seek patent protection for such technologies and solutions may be negatively impacted by this jurisprudence, or guidance or procedures issued by the USPTO or authorities in other jurisdictions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict the impact of the changing landscape of patent eligible subject matter on our ability, or that of our competitors, to obtain or enforce patents relating to products and services involving genomic or biomarker related discoveries, or computer-implemented technologies, such as molecular tests that implement ML. Indeed, many believe that the contours of whether claims are patent eligible, or recite laws of nature, natural phenomena, natural products, or abstract ideas remain unclear despite a decade of interpretation at the USPTO and in the courts. Third parties holding patents issued prior to </font><font style="font-style:italic;letter-spacing:0.2pt;">Mayo</font><font style="letter-spacing:0.2pt;">, </font><font style="font-style:italic;letter-spacing:0.2pt;">Myriad</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Alice</font><font style="letter-spacing:0.2pt;"> could allege that we infringe these patents, even if these patents are not likely enforceable under current U.S. laws. We could be forced to defend against claims of patent infringement or obtain license rights, if available on commercially reasonable terms or at all, under these patents. In jurisdictions other than the United States, gene- and computer-related patent claims may remain valid and may be enforceable against us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The U.S. Congress has periodically sought to pass laws concerning subject matter eligibility for patent protection, aimed in large part at abrogating the holdings of </font><font style="font-style:italic;letter-spacing:0.2pt;">Mayo</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Alice</font><font style="letter-spacing:0.2pt;">. To date, these efforts </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">have been unsuccessful, but are ongoing. We cannot fully predict the impact that such new laws may have on our ability to obtain patent protection on our solutions and technologies, and our ability to operate in view of the patents controlled by third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to enforce our intellectual property rights throughout the world.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The laws of foreign countries may not protect intellectual property rights to the same extent as the laws of the United States. In some cases, companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;1, 2023, the European Union implemented a unitary patent system with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (&#8220;UPC&#8221;) for litigation involving European patents. As a result, all European patents, including those issued prior to ratification of the unitary patent system, now by default automatically fall under the jurisdiction of the UPC, although patent applicants and patent holders may elect to opt-out of the new system for a transitional period of at least seven&#160;years. It is uncertain how the UPC will impact European patents, including those in the biotechnology and pharmaceutical industries. If we do not opt-out, our European patents could be challenged in the UPC. Thus far, like many others, we have elected to opt-out of the UPC as it matures. We may continue to opt-out our future European patents, but doing so may preclude us from realizing its benefits. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain a pan-European injunction. Such a loss of patent protection or injunction obtained by a competitor could adversely impact our business and our ability to commercialize our technology and solutions and, as a result, on our business, financial condition, prospects, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our solutions. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our solutions and technology. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to seeking patents for certain of our solutions and other technologies, we rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, data, and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. Our trade secrets and know-how may over time become known to others through various means such as independent development, personnel movement, collaborative efforts or other intentional or unintentional disclosure. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with relevant parties, such as our employees, directors, corporate and scientific collaborators, contract research organizations, contract manufacturers, suppliers, service providers, consultants, advisors, and other third parties. We generally enter into confidentiality and invention assignment agreements with our employees and consultants upon their commencement of a relationship with us, and remind departing employees of their continuing confidentiality obligations. However, we may not be successful in entering into such agreements with all employees and consultants. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, processes, or technology to enter into confidentiality agreements, we cannot </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provide any assurances that we have entered into confidentiality agreements with each person or party that had or may have had access to our proprietary know-how, information, processes, or technology. In addition, monitoring unauthorized use and disclosure of our proprietary know-how, information, processes or technology by employees, consultants and other third parties who have access can be difficult, and we cannot be certain whether the steps we have taken to protect our proprietary know-how, information, processes, or technology will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence of confidentiality restrictions. These agreements may also not provide meaningful protection against the unauthorized use or disclosure of our trade secrets, know-how or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Despite our efforts, any of these persons or parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a person or party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts outside the United States may be less willing or unwilling to protect trade secrets. Further, agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. We may enter into collaboration, license, contract research and/or manufacturing relationships with contract organizations that operate in certain countries that are at heightened risk of theft of technology, data, and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. If any of our trade secrets were to be misappropriated by, disclosed to, or independently developed by a competitor or other third party, our competitive position could be adversely harmed. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not be adequate for all scenarios, for example, in the case of misappropriation of a trade secret by an employee, consultant, or other third party with authorized access. An employee, consultant or other third party who misappropriates our trade secrets may provide such information to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our solutions, platform, or services that we consider proprietary. Although we use commonly accepted security measures, trade secret violations are a matter of both federal and state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our intellectual property rights or confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, it could adversely affect our competitive position, business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, our efforts to protect and enforce our trade secrets, know-how and intellectual property rights around the world may be inadequate to obtain a significant commercial advantage, and we may be at heightened risk of losing our trade secrets, proprietary know-how and intellectual property rights around the world, to the extent such theft or intrusion destroys their secrecy or other proprietary nature. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims by third parties asserting that we or our employees have infringed or misappropriated intellectual property rights, or to assertions by third parties or employees claiming ownership of what we regard as our own intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many of our former, current, and future employees, consultants and contractors have been previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors and strategic partners. Some of these employees, consultants and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">contractors may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or engagement. We train our employees, consultants, and contractors not to bring, or use in their work proprietary information or technology from former employers. Although we intend for such training and other measures to ensure that our employees do not use the proprietary information or know-how of others in their work for us, to the extent that our employees, consultants or contractors use intellectual property rights or proprietary information owned by others in their work for us, we may be subject to claims that an employee has used or disclosed intellectual property, including trade secrets or other proprietary information, of such employee&#8217;s former employer. Litigation, which would be expensive, time-consuming, a distraction to management, and uncertain of outcome, may be necessary to defend against these claims. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may be subject to claims from third parties challenging ownership interest in or inventorship of intellectual property rights we regard as our own, based on claims that our agreements with employees or consultants obligating them to assign their intellectual property rights to us are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. We are not aware of any threatened or pending claims related to these matters, but, in the future, litigation may be necessary to defend against such claims should they arise, and it may be necessary or we may desire to obtain a license to such third party&#8217;s intellectual property rights to settle any such claim. However, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If we fail in defending any such claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. A court could prohibit us from using technologies, features or other intellectual property rights that are essential to our solutions or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our solutions or technologies could adversely affect our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our solutions or technologies. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and our employees. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our solutions or services, which could adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor or co-inventor. We may be subject to ownership or inventorship disputes in the future arising, for example, from conflicting obligations of employees, consultants or others who were or are involved in developing our solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we fail to prevail on any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or be required to obtain a license, which may not be available to us on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management, which could harm our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently hold and/or have applied for a number of trademarks, covering Caris, MI Profile, MI Tumor Seek Hybrid, MI Cancer Seek, Caris Assure, and other solutions and services in certain jurisdictions. However, our pending or future trademark applications may not be approved or our registered or unregistered trademarks or trade names may be challenged, invalidated, infringed, or declared generic or determined to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our solutions or technologies, and we may not be able to protect our rights to these trademarks and trade </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">names, which we view as valuable to building name recognition among partners and customers in our markets of interest. At times, competitors or other third parties have adopted or may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion and/or litigation. In addition, there have been and could be trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. There can be no assurance that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may be unable to compete effectively and our business may be adversely affected. Our efforts to enforce, protect, or defend our trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our competitive position, business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our use of open-source software could subject our proprietary technology to unwanted open-source license conditions that could negatively impact our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We use open-source software in some of our technologies and solutions, and we may incorporate open-source software into future technologies and solutions. From time to time, companies that use third-party open source software have faced claims challenging the use of such open source software and requesting compliance with the open source software license terms. Accordingly, we may be subject to suits by parties claiming ownership of what we believe to be open source software or claiming non-compliance with the applicable open source licensing terms. Some open source software licenses require end users, who use, distribute, or make available across a network software and services that include open source software, to make publicly available or to license all or part of such software (which in some circumstances could include valuable proprietary code, such as derivative works of the open source software) under the terms of the particular open source license. If a third party were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to invest substantial time and resources to re-engineer some of our software or release certain portions of our proprietary source code, which could substantially help our competitors develop products that are similar to or improve upon ours and harm our business. We could also be required to incur significant legal expenses defending against such allegations. Further, the outcome of such litigation may be particularly uncertain because there are numerous open source software licenses which have not been tested in courts of law, and thus lack guidance regarding their proper legal interpretation. Any of the foregoing could disrupt and harm our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the use of third-party open source software typically exposes us to greater risks than the use of third-party commercial software because open source licensors generally do not provide warranties or controls on the functionality or origin of the software. Use of open source software may also present additional security risks because the public availability of such software may make it easier for hackers and other third parties to determine how to compromise platforms using such source code. Any of the foregoing could harm our business and could help our competitors develop products and services that are similar to or that improve upon ours. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The occurrence of any of these events could adversely affect our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Indebtedness</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred substantial indebtedness, and we may not generate sufficient cash flow from operations to meet our debt service requirements, continue our operations, and pursue our growth strategy, and we may be unable to raise capital when needed or on acceptable terms.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, we and our subsidiaries had approximately $400.0&#160;million aggregate principal amount of debt outstanding under the 2023 Term Loan. Subsequent to March&#160;31, 2025, we issued $30.0 million aggregate principal amount of our 2025 Convertible Notes in April 2025, which will convert into shares of our common stock in connection with this offering, in accordance with their terms (and thereafter be reclassified into shares of our Class B common stock). Our substantial level of indebtedness increases the risk that we may be unable to generate cash sufficient to pay amounts due in respect of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">indebtedness, pay dividends and to fund our general corporate and capital requirements. The substantial indebtedness of us and our subsidiaries could have important consequences to our shareholders, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a portion of our cash flow from operations must be dedicated to the payment of principal and interest on our debt, thereby reducing the funds available to us for other purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to satisfy our obligations under the 2023 Term Loan Agreement may be adversely affected; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to make loans and investments or engage in acquisitions without issuing additional equity or obtaining additional debt financing may be impaired in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain additional financing for working capital, capital expenditures, acquisitions, debt service requirements or general corporate purposes may be impaired in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to pay dividends or engage in share repurchases may continue to be restricted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our flexibility may be limited in planning for, or reacting to, changes or challenges relating to the business we conduct; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may be more vulnerable to general adverse economic and industry conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may be at a competitive disadvantage compared to our competitors who have less debt or comparable debt at more favorable interest rates or terms and who, as a result, may be better positioned to withstand economic downturns or to finance capital expenditures or acquisitions; our costs of borrowing may increase; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we may be unable to refinance our debt on terms as favorable as our existing debt or at all. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The occurrence of any one of these events could have an adverse effect on our business, financial condition, results of operations, and ability to satisfy our obligations under the 2023 Term Loan Agreement. We may not be able to access capital on acceptable terms, raise additional capital in the future, or make effective capital allocation decisions, which could result in our inability to achieve operational objectives. Any disruption in access to capital could require us to take measures to conserve cash until alternative credit arrangements or other funding for business needs can be arranged. Such measures could include deferring capital expenditures, acquisitions or other discretionary uses of cash, or revising capital allocation decisions. Any of these risks could adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The agreements and instruments governing our debt contain restrictions and limitations that could significantly impact our management&#8217;s flexibility and our financial and operational flexibility to operate our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Restrictive covenants in the 2023 Term Loan Agreement place limits on our ability to conduct our business. Covenants in the 2023 Term Loan Agreement include those that, subject to certain exceptions, restrict our ability to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">materially alter the business we conduct; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">incur certain additional indebtedness and guarantee indebtedness; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">create or incur liens; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchase, make, incur, assume, or permit to exist certain investments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">make any dividends, distributions, and certain other payments to our shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sell, transfer, or otherwise dispose of assets, including capital stock of our subsidiaries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">modify certain agreements that have an impact on our indebtedness; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">engage in certain transactions with our affiliates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">enter into any restrictive agreements prohibiting (i)&#160;the creation of liens to secure our obligations under the 2023 Term Loan Agreement, (ii)&#160;our or our subsidiaries&#8217; modification of the 2023 Term Loan Agreement, or (iii)&#160;our or our subsidiaries&#8217; ability to pay dividends or make any other distributions on any capital securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">enter into sale and leaseback transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">make changes to name, location, executive office, executive management, or fiscal&#160;years without prior notice; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">incur any actual or potential liability on benefit plans or allow any employee benefit plans to cease to be tax qualified. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2023 Term Loan Agreement also imposes maintenance requirements on our liquidity and revenue base and restricts our ability to engage in certain mergers or consolidations. For additional information, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Indebtedness&#8221; and &#8220;&#8212;Risks Related to Our Business and Industry&#8212;Our business and results of operations will suffer if we fail to compete effectively.&#8221; These restrictions may prevent us from taking actions that we believe would be in the best interest of our business and may make it difficult for us to execute our business strategy successfully or compete effectively with companies that are not similarly restricted. We may also incur future debt obligations that might subject us to additional restrictive covenants that could affect our financial and operational flexibility. Our ability to comply with the covenants and restrictions contained in the 2023 Term Loan Agreement may be affected by economic, financial and industry conditions beyond our control. The breach of any of these covenants or restrictions could result in a default under the 2023 Term Loan Agreement that would permit the applicable lenders or noteholders, as the case may be, to declare all amounts outstanding thereunder to be due and payable, together with accrued and unpaid interest. In addition, such a default or acceleration may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. Our obligations under the 2023 Term Loan Agreement are secured by our intellectual property. If we are unable to repay debt, lenders having secured obligations under the 2023 Term Loan Agreement could proceed against the collateral securing the debt. This could have serious consequences to our business, financial condition, and results of operations and could cause us to become bankrupt or insolvent. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rely on cash generated from our financing and operating activities as our primary source of liquidity. To support our operations, execute our growth strategy as planned and pay dividends, if declared, we will need to continue generating significant amounts of cash from operations, including funds required to pay our employees, related benefits and other operating expenses, finance future acquisitions, invest in the growth of our business and pay for the increased direct and indirect costs associated with operating as a public company. If our business does not generate sufficient cash flow from operations to fund these activities, we may need to seek additional capital, including by incurring additional debt or equity capital. Additional capital may not be available to us on acceptable terms or at all. In addition, incurring indebtedness requires that a portion of cash flow from operating activities be dedicated to interest and principal payments. Debt service requirements could reduce our ability to use our cash flow to fund operations and capital expenditures, to capitalize on future business opportunities, including additional acquisitions, or to pay dividends. Any of these risks could adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our variable rate debt subjects us to interest rate risk, which could cause our debt service obligations to increase significantly and affect our operating results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indebtedness under the 2023 Term Loan is at variable rates of interest, which exposes us to interest rate risk. In addition, our 2023 Term Loan references the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as the primary benchmark rate for our variable rate indebtedness. If benchmark interest rates, including SOFR, were to increase, our debt service obligations on our variable rate indebtedness would increase even if the amount borrowed remains the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly decrease. In addition, while our 2023 Term Loan will continue to be subject to SOFR, other factors may impact SOFR, including factors causing SOFR to cease to exist, new methods of calculating SOFR to be established, or the use of an alternative reference rate. Such circumstances are not entirely predictable, but could have an adverse impact on our financing costs and results of operations. As of March&#160;31, 2025, we had $400.0&#160;million outstanding principal amount of variable rate debt subject to interest rate exposure. While we currently hedge the interest rate risk on $200.0&#160;million principal amount of this outstanding variable rate debt with a purchased interest rate cap derivative with a strike rate of 6.0% and a February&#160;2026 maturity, the remainder of the outstanding amount is not similarly hedged. Accordingly, a 1% increase in interest rates would increase annual interest expense by $4&#160;million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Despite our indebtedness level, we and our subsidiaries may incur substantially more debt, including secured debt. This could further exacerbate the risks associated with our substantial indebtedness.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We and our subsidiaries may incur substantial additional indebtedness in the future. Although the terms of the 2023 Term Loan Agreement contain restrictions on the incurrence of additional indebtedness, such restrictions are subject to a number of significant exceptions and qualifications and any additional indebtedness incurred in compliance with such restrictions could be substantial. These restrictions also will not prevent us from incurring obligations that do not constitute indebtedness. If we and our subsidiaries incur significant additional indebtedness or other obligations, the related risks that we face could increase, and we may not be able to meet all our debt obligations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to This Offering and Ownership of Our Class A Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">An active, liquid, and orderly market for our Class A common stock may not develop or be sustained. As a result, it may be difficult to sell shares of our Class A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We currently expect our Class A common stock to be listed and traded on Nasdaq. Prior to listing on Nasdaq there has been no public trading market for our Class A common stock. If an active, liquid, and orderly trading market for our Class A common stock does not develop or is not sustained after this offering, it may be difficult to sell shares of our Class A common stock at an attractive price, if at all. We cannot predict the prices at which our Class A common stock will trade. It is possible that in one or more future periods our results of operations, regulatory approval process, and/or development of our platform and solutions may not meet the expectations of securities research analysts and investors. These and other factors could also significantly depress the market price of our Class A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The market price of our Class A common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The initial public offering price for our Class A common stock will be determined by agreement among us and the representatives of the underwriters. This initial public offering price may differ from the market price of our Class A common stock after this offering. As a result, if you purchase shares of our Class&#160;A common stock in this offering, it may not be possible for you to sell those shares at or above the initial public offering price. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as general economic, market, or political conditions, could reduce the market price of our Class A common stock regardless of our operating performance. Some of the factors that may cause the market price of our Class A common stock to fluctuate include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing or success of launch of our solutions, such as Caris Assure for early detection, MRD tracking, and treatment monitoring, as well as MI Cancer Seek or other solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the degree to which the launch and commercialization of our solutions meet the expectations of securities analysts and investors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in the structure of healthcare payment systems, including changes that would affect coverage and reimbursement by third-party or government payers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of, or perception of success of, our research and development efforts and our ability to develop new solutions and enhance our existing solutions, as well as our solutions&#8217; effectiveness or perceived effectiveness compared to those of our competitors;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing and results of validation studies and clinical trials for our solutions and solutions from our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">commencement or termination of collaborations for our solution development and research programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure or discontinuation of any of our solution development and research programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of existing or new competitive tests, services, or technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">results of validation studies, clinical trials, or regulatory approvals of diagnostic or other cancer-related screening tests of our competitors, or announcements about new research programs or diagnostic or other cancer-related tests of our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulatory or legal developments in the United States and other countries affecting our solutions or competing products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of public health crises on our business and on global economic conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the recruitment or departure of key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the level of expenses related to any of our research programs, clinical development programs or commercialization activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">actual or anticipated changes in our estimates as to our financial results or development timelines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether our quarterly and annual financial results, forecasts, and development timelines meet the expectations of securities analysts or investors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">announcement or expectation of additional financing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sales of our Class A common stock by us, our insiders, or other shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">expiration of lock-up agreements and market stand-off provisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">variations in our quarterly and annual financial results or those of companies that are perceived to be similar to us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in accounting standards, policies, guidelines, interpretations, or principles; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">market conditions in the healthcare sector; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">general economic, industry, and market conditions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the other factors described in this &#8220;Risk Factors&#8221; section. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stock markets in general, and the market for healthcare companies in particular (including companies in the precision oncology industry and broader precision medicine industry), experience significant price and volume fluctuations that are often unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may significantly affect the market price of our Class A common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading market for our Class A common stock will rely in part on the research and reports that industry or securities analysts publish about us or our business. We do not currently have, and may never obtain, research coverage by industry or securities analysts. If no or few analysts commence coverage of us, the trading price of our Class A common stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our Class A common stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our Class A common stock, which in turn could cause the price of our Class&#160;A common stock to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales of a substantial number of shares of our Class A common stock following the completion of this offering could cause the price of our Class A common stock to decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of a substantial number of shares of our Class A common stock in the public market following the completion of this offering, or the perception that these sales might occur, could depress the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">market price of our Class A common stock, and could impair our ability to raise capital through the sale of additional equity securities. Many of our existing equity holders have substantial unrecognized gains on the value of the equity they hold based upon the price of this offering, and therefore, may take steps to sell their shares or otherwise secure the unrecognized gains on those shares. We are unable to predict the timing of or the effect that such sales may have on the prevailing market price of our Class A common stock. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we, our directors and executive officers, and holders of substantially all of our common stock and securities exercisable for or convertible into our common stock, have entered or will enter into lock-up agreements with the underwriters that restrict our and their ability to sell or transfer shares of our common stock, and securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 180 days from the date of this prospectus, subject to certain customary exceptions and a potential earlier termination. See the sections titled &#8220;Shares Eligible for Future Sale&#8221; and &#8220;Underwriting&#8221; for a discussion of such exceptions that may allow for sales during the lock-up period. In addition, upon providing prior written notice to BofA Securities, Inc., J.P. Morgan Securities LLC, and Goldman Sachs &amp; Co. LLC, BofA Securities, Inc. and either J.P. Morgan Securities LLC or Goldman Sachs &amp; Co. LLC may, in their sole discretion, release certain shareholders from the lock-up agreements prior to the end of the lock-up period. Additionally, at our request, the underwriters have reserved up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of the shares of our Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management under the reserved share program, including certain of our directors, officers, employees, and certain other parties related to us. Except for any shares acquired by our directors and officers, shares purchased pursuant to the reserved share program will not be subject to lock-up restrictions with the underwriters. If not earlier released, all of our shares of common stock, other than those sold in this offering, which are freely tradable, will become eligible for sale upon expiration of the lock-up period, except for any shares held by our affiliates as defined in Rule&#160;144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, after this offering, up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of our Class B common stock (which is convertible into Class A common stock) may be issued upon exercise of outstanding stock options or vesting and settlement of outstanding RSUs, and up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class A common stock will be available for future issuance under our 2025 Plan and our ESPP, and will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, exercise limitations, the lock-up agreements, and Rule&#160;144 and Rule&#160;701 under the Securities Act. We intend to register all of the shares of common stock issuable upon exercise of outstanding options or other equity incentive awards we may grant in the future for public resale under the Securities Act. If any of these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our Class A common stock could decline. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, holders of approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares as of March&#160;31, 2025, or &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; approximately&#8199;&#8199;&#8199;&#8199;% of our capital stock after the completion of this offering, will have rights, subject to some conditions and the lock-up agreements described above, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The dual class structure of our common stock will have the effect of concentrating voting control with our founder and the other shareholders who held our capital stock prior to the completion of this offering, including our executive officers, directors, principal shareholders, and their respective affiliates, which will limit the ability of our other shareholders to affect the outcome of key corporate decisions and transactions, including a change of control.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the completion of this offering, our Class&#160;B common stock will have 10&#160;votes per share, and our Class&#160;A common stock, which is the stock we are offering in this offering, will have one vote per share. Upon the completion of this offering, all of our outstanding shares of Class&#160;B common stock will be held our existing shareholders. David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of our outstanding shares of capital stock and approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class&#160;A </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">common stock. As a result, Mr.&#160;Halbert will be able to significantly influence all matters submitted to our shareholders for approval, including the election of directors, amendments to our certificate of formation and bylaws, and the approval of significant corporate transactions, regardless of whether others believe that any such transaction is in our best interests. Additionally, immediately following the completion of this offering, our executive officers (including Mr.&#160;Halbert), directors, holders of more than 5% of our outstanding capital stock, and their respective affiliates will collectively beneficially own shares of Class&#160;B common&#160;stock representing approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of our outstanding shares of capital stock and approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class&#160;A common stock. If these shareholders act together, they will be able to influence our management and affairs and control all matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of our Class&#160;B common stock collectively will continue to be able to control all matters submitted to our shareholders for approval even if their stock holdings represent less than 50% of the outstanding shares of our capital stock. Because of the 10-to-one voting ratio between our Class&#160;B common stock and Class&#160;A common stock, the holders of our Class&#160;B common stock collectively will continue to control a majority of the combined voting power of our common stock even when the shares of Class&#160;B common stock represent as little as&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of the outstanding shares of our Class&#160;A common stock and Class&#160;B common stock. This concentrated control will limit your ability to influence corporate matters for the foreseeable future. It could also have the effect of delaying, deferring, or preventing a change in control, impeding a merger, consolidation, takeover, or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other shareholders. Moreover, it could deprive shareholders of an opportunity to receive a premium for their common stock as part of a sale of our company and may adversely affect the trading price for our Class&#160;A common stock because some investors perceive disadvantages in owning shares in companies with concentrated control. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Future transfers by holders of shares of Class&#160;B common stock, subject to limited exceptions set forth in our amended and restated certificate of formation, such as transfers to immediate family members, certain trusts for estate planning purposes, and entities under common control with or controlled by such holder of our Class B common stock, and transfers that are approved in advance by our board of directors as permitted transfers, will generally result in those shares converting to shares of Class&#160;A common stock. The conversion of Class&#160;B common stock to Class&#160;A common stock will have the effect, over time, of increasing the relative voting power of those holders of Class&#160;B common stock who retain their shares in the long term. See the section titled &#8220;Description of Capital Stock&#8221; for additional information. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The dual class structure of our common stock may adversely affect the trading market for our Class&#160;A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict whether our dual class structure will result in a lower or more volatile market price of our Class&#160;A common stock, adverse publicity, or other adverse consequences. Certain stock index providers exclude or limit the ability of companies with multi-class share structures from being added to certain of their indices. In addition, several shareholder advisory firms and large institutional investors oppose the use of multiple class structures. As a result, the dual class structure of our common stock may make us ineligible for inclusion in certain indices and may discourage other indices from selecting us for inclusion, notwithstanding our automatic termination provision. This dual class structure may also cause shareholder advisory firms to publish negative commentary about our corporate governance practices or otherwise seek to cause us to change our capital structure, and may result in large institutional investors not purchasing shares of our Class&#160;A common stock. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, any exclusion from certain stock indices could result in less demand for our Class&#160;A common stock. Any actions or publications by shareholder advisory firms or institutional investors critical of our corporate governance practices or capital structure could also adversely affect the value of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investors in our Class A common stock will incur immediate and substantial dilution as a result of this offering.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Class A common stock will incur immediate and substantial dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, representing the difference between the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and our pro&#160;forma as adjusted net tangible book value per share after giving effect to this offering, the Preferred Stock Conversion, the Warrant Exercises, the Series&#160;E and F Issuance, the issuance of the 2025 Convertible Notes and the related Notes Conversion, the Common Stock Reclassification, and the RSU Net Settlement. As of March&#160;31, 2025, there were&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of common stock issuable upon exercise of outstanding stock options with a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#160;shares of common stock issuable upon the vesting and settlement of outstanding RSUs. To the extent that these outstanding options or RSUs, or any other rights, are exercised, or we issue additional equity or convertible securities in the future, or the underwriters exercise their option to purchase additional shares of Class A common stock, investors will incur further dilution. See the section titled &#8220;Dilution&#8221; for a further description of the dilution that will occur immediately after this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to our technologies or our solutions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may need or determine to raise additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships, and alliances and licensing arrangements. We, and indirectly, our shareholders, will bear the cost of issuing and servicing securities issued in any such transactions. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. If we incur debt, debt holders would have rights senior to holders of our Class A common stock to make claims on our assets, and any debt financing we secure would result in increased fixed payment obligations and could involve restrictive and financial covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact our ability to conduct our business. If we issue additional equity securities, shareholders will experience dilution, and the new equity securities could have rights senior to those of our Class A common stock. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships, alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or our solutions, or grant licenses on terms unfavorable to us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have identified a material weakness in our internal control over financial reporting. If our remediation of such material weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to develop and maintain effective internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be impaired, investors may lose confidence in our financial reporting, and the trading price of our Class A common stock may decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the audit of our consolidated financial statements for the year ended December&#160;31, 2024, we identified a material weakness in our internal control over financial reporting. A material weakness, as defined by Rule&#160;12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The material weakness identified pertained to a lack of sufficient qualified accounting resources, including those with technical expertise necessary to account for and disclose accounting transactions which require complex calculations or thorough evaluation of the accounting literature. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have taken and will continue to take action to remediate the material weakness, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">implementation of controls to enhance our review of significant accounting transactions and other new technical accounting and financial reporting issues and the preparation and review of accounting memoranda addressing these issues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">implementation of controls to enable an effective and timely review of account analyses and account reconciliations; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">continued hiring of additional accounting and finance resources with public company experience and expanding the capabilities of the existing accounting and financial personnel through continuous training and education in the accounting and reporting requirements under GAAP and SEC rules and regulations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to SOX Section&#160;404, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the second annual report following the completion of this offering. When we lose our status as an &#8220;emerging growth company&#8221; and do not otherwise qualify as a &#8220;smaller reporting company&#8221; with less than $100.0&#160;million in annual revenue, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our Class A common stock may decline. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will not be able to fully remediate the material weakness until the steps detailed above have been completed and such controls have been operating effectively for a sufficient period of time. Additionally, as stated above, we have not performed an evaluation of our internal control over financial reporting as permitted under the JOBS Act; accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required under SOX Section&#160;404, beginning with our second annual report after the completion of this offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that additional material weaknesses in our internal control over financial reporting will not arise in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our Class&#160;A common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our Class A common stock less attractive to investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an emerging growth company and, for so long as we remain an emerging growth company, we are permitted by SEC rules and plan to rely on exemptions from certain disclosure requirements that are applicable to other SEC-registered public companies that are not emerging growth companies. Under these exemptions, we are not required to comply with the auditor attestation requirements of SOX Section&#160;404 or the auditor requirements to communicate critical audit matters in the auditor&#8217;s report on the financial statements, have reduced disclosure obligations regarding executive compensation, and have exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, the information we provide shareholders will be different than the information that is available with respect to other public companies. We have taken advantage of reduced reporting burdens in this prospectus. In particular, in this prospectus, we have provided only two&#160;years of audited financial statements and we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We could be an emerging growth company for up to five&#160;years following the completion of this offering. We will cease to be an emerging growth company upon the earliest of: (i)&#160;the end of the fiscal year </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">following the fifth anniversary of this offering, (ii)&#160;the first fiscal year after our annual gross revenues are $1.235&#160;billion or more, (iii)&#160;the date on which we have, during the previous three-year period, issued more than $1.0&#160;billion in nonconvertible debt securities or (iv)&#160;the end of any fiscal year in which the market value of our Class A common stock held by non-affiliates exceeded $700&#160;million as of the end of the second quarter of that fiscal year. We cannot predict whether investors will find our Class A common stock less attractive if we rely on these exemptions. If some investors find our Class A common stock less attractive as a result, there may be a less active trading market for our Class A common stock, and our stock price may be more volatile. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Following this offering, we may become a &#8220;controlled company&#8221; within the meaning of the rules of Nasdaq. In such event, we may take advantage of the &#8220;controlled company&#8221; exemptions to the corporate governance rules of Nasdaq.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately &#8199;&#8199;&#8199;% of our outstanding shares of capital stock and approximately &#8199;&#8199;&#8199;% of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As such, we may, following this offering, become eligible to elect the &#8220;controlled company&#8221; exemptions to the corporate governance rules of Nasdaq. Under these rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including the requirement that: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a majority of our board of directors consist of &#8220;independent directors&#8221; as defined under the rules of Nasdaq; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our director nominees be selected, or recommended for our board of directors&#8217; selection, by a nominating/governance committee comprised solely of independent directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the compensation of our executive officers be determined, or recommended to our board of directors for determination, by a compensation committee comprised solely of independent directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we choose to take advantage of controlled company status in the future, our status as a controlled company could cause our Class A common stock to be less attractive to certain investors or otherwise have an adverse effect on our trading price.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. SOX Section&#160;404, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable U.S. rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. Even if we are successful in remediating our material weaknesses, we believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our results of operations could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Class A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue, and expenses that are not readily apparent from other sources. For example, as we adopted and implemented the new revenue accounting standard, management made judgments and assumptions based on our interpretation of the new standard. The new revenue standard is principle-based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice and guidance may evolve as we continue to use these new accounting standards. If our assumptions change or if actual circumstances differ from our assumptions, our results of operations may be adversely affected and could fall below our publicly announced guidance or the expectations of analysts and investors, resulting in a decline in the market price of our Class A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section titled &#8220;Use of Proceeds&#8221; in this prospectus. Our management may spend a portion or all of the net proceeds from this offering in ways that our shareholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, and results of operations. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We do not intend to pay dividends for the foreseeable future. Investors in this offering may never obtain a return on their investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid any cash dividends on our capital stock, and we do not intend to pay any cash dividends in the foreseeable future. We expect to retain all available funds and future earnings, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">if any, to support our operations and to finance the growth and development of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our board of directors subject to applicable laws and dependent on factors our board of directors deems relevant. In addition, our ability to pay dividends on our capital stock is limited by the terms of the 2023 Term Loan Agreement and may be further restricted under the terms of any future debt or preferred securities or future credit facility. Accordingly, you must rely on the sale of your Class A common stock after price appreciation, which may never occur, as the only way to realize any future gain on your investment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Texas law and provisions in our amended and restated certificate of formation and bylaws that will be in effect prior to the completion of this offering might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Class A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Provisions in our amended and restated certificate of formation and bylaws that will be in effect prior to the completion of this offering may discourage, delay, or prevent a merger, acquisition, or other change in control that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our Class A common stock. These provisions may also prevent or frustrate attempts by our shareholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our Class A common stock. Among other things, our organizational documents will: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without shareholder approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">provide that (i)&#160;from and after the date on which no shares of Class B Common Stock are outstanding (such date, the &#8220;Trigger Date&#8221;), our directors may be removed only for cause and only upon the affirmative vote of holders of at least 50% of the voting power of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, (ii)&#160;vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum, or by a sole remaining director, or by the affirmative vote of at least 50% of the voting power of our then-outstanding capital stock entitled to vote generally in the election of directors, (iii)&#160;from and after the Trigger Date, any action required or permitted to be taken at an annual or special meeting of shareholders may be taken by written consent in lieu of a meeting of shareholders only with the unanimous written consent of our shareholders entitled to vote on such action, and (iv)&#160;from and after the Trigger Date, the affirmative vote of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of our then-outstanding capital stock entitled to vote thereon is required to amend our amended and restated bylaws and certain provisions of our amended and restated certificate of formation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">provide that, from and after the Trigger Date, the written request of the holders of at least 50% of the voting power of our outstanding capital stock (or the highest percentage of ownership that may be set under the Texas Business Organizations Code (the &#8220;TBOC&#8221;)) entitled to be voted at a special meeting is required for our shareholders to call a special meeting of shareholders; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">require that shareholders give advance notice to nominate directors or submit proposals for consideration at shareholder meetings. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Further, as a Texas corporation, we are also subject to provisions of Texas law that may impair a takeover attempt that our shareholders may find beneficial. For additional information, see &#8220;Description of Capital Stock&#8212;Anti-Takeover Effects of Certain Provisions of Our Amended and Restated Certificate of Formation.&#8221; Any provision of our amended and restated certificate of formation, bylaws, or Texas law that has the effect of delaying or preventing a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class A common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our amended and restated certificate of formation will provide that the Business Court in the First Business Court Division of the State of Texas will be the exclusive forum for substantially all disputes between us and our shareholders (excluding claims under the federal securities laws), which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation will provide that, unless we consent in writing to the selection of an alternative forum, the Business Court in the First Business Court Division of the State of Texas will be the exclusive forum for the following types of actions or proceedings under Texas statutory or common law: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any derivative action or proceeding brought on our behalf; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees, or shareholders to us or our shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any action asserting a claim arising pursuant to any provision of the TBOC or our amended and restated certificate of formation and bylaws; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any action asserting a claim governed by the internal affairs doctrine. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our amended and restated certificate of formation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents, or our other shareholders, may discourage such lawsuits against us and such other persons, and may result in increased costs for a shareholder to bring a claim. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The sizes of the markets for our current and future solutions have not been established with precision, and may be smaller than we estimate.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our estimates of the total addressable markets for our current or future solutions are based on a number of internal and third-party estimates, including, without limitation, the number of new cancer cases, the market size of oncology testing, and the number of patients with advanced stage cancer. While we believe the assumptions and the data underlying these estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting these assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, these estimates of the total addressable market for our current or future solutions may prove to be incorrect. If the actual number of patients who would benefit from our solutions, the price at which we can sell our solutions, or the annual total addressable market for our solutions is smaller than estimated, it may impair our sales growth and have an adverse impact on our business, financial condition, and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Adverse economic or market conditions may harm our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Worsening economic conditions, including heightened inflation, increasing interest rates, decreasing economic activity, volatility in equity and credit markets, or other changes in the economic environment, may adversely affect our business, financial condition, and results of operations. For example, we depend on third-party manufacturers and suppliers for some of our solutions, or components and materials used in our solutions, and the suppliers of these inputs may seek to raise prices in the current inflationary economic environment. If our costs increase and we are unable to successfully pass along those increased costs to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">our partners and patients, our revenue and or operating profitability may be adversely affected. In addition, we may in the future raise additional debt or refinance existing debt. Our cost of borrowing in the future may be higher than it has been to date because interest rates have risen and may continue to increase. An increased cost of borrowing may adversely affect our financial condition and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business is subject to economic, political, regulatory, and other risks associated with international operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some of our ordering physicians and biopharma partners are located outside of the United States. While we currently have limited international operations, international expansion could also become a key component of our future business strategy. Accordingly, our future results could be harmed by a variety of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign jurisdictions that do not respect and protect intellectual property rights to the same extent as the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">trade protection measures, import or export controls and licensing requirements (including possible restrictions on licensing intellectual property to certain non-U.S. persons) or other restrictive actions by U.S. or non-U.S. governments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in non-U.S. laws, regulations and customs, tariffs, and trade barriers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">exchange rate risk we may face from denominating a portion of our transactions in currencies other than the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">changes in a specific country&#8217;s or region&#8217;s political or economic environment, including inflation, including the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">negative consequences from changes in tax laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">negative consequences from changes in U.S. national security laws, including those governing non-U.S. investors&#8217; ownership of U.S. biotech and other technology companies and U.S. companies&#8217; ability to enter into joint ventures with non-U.S. entities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance challenges relating to the complexity of multiple, conflicting, and changing data protection laws and international data sharing and transfer restrictions globally. For additional information, see &#8220;&#8212;Risks Related to Regulation and Legal Compliance&#8212;We are subject to stringent and evolving U.S. and foreign privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data security. Our actual or perceived failure to comply with privacy and data security obligations could result in significant liability, administrative or governmental penalties, reputational harm and/or, other adverse business consequences&#8221;; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">adoption of new regulations, modification to existing regulations, or expiration of prior regulations that apply to the products we offer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">difficulties associated with staffing and managing international operations, including differing labor relations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulator and compliance risks that relate to maintaining and control over sales and distribution activities that may fall within the purview of the FCPA or comparable foreign laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">difficulties associated with the interpretation of laws and regulations in non-English speaking jurisdictions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">business interruptions resulting from geo-political actions, including war and terrorism, pandemics, or natural disasters, including earthquakes, typhoons, floods, and fires. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These and other risks associated with current and future international operations may adversely affect our business and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business is subject to risks arising from public health crises.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Widespread public health crises may pose the risk that our company, our personnel, courier delivery services, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. For example, the COVID-19 pandemic and mitigation measures have had an adverse impact on global economic conditions. Comparable future public health crises could have similar adverse effects on our business, financial condition, and results of operations, including impairing the ability to raise capital when needed. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Government-imposed quarantines and restrictions as a result of future public health crises may also require us to temporarily terminate our clinical sites. Furthermore, if we determine that our trial participants may suffer from exposure to such diseases as a result of their participation in our clinical trials, we may voluntarily terminate certain clinical sites as a safety measure until we reasonably believe that the likelihood of exposure has subsided. As a result, our expected regulatory submissions and development timelines for our solutions may be negatively impacted. Future public health crises may materially disrupt or delay our business operations, further divert the attention and efforts of the medical community to coping with such epidemics, reduce the number of patients getting physicals and physicians potentially ordering our solutions, disrupt the clinical sites on which we depend, and/or adversely affect our operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to utilize our net operating loss (&#8220;NOL&#8221;) and R&amp;D credit carryforwards is subject to certain conditions. For instance, we have experienced a history of losses and a lack of future taxable income that would adversely affect our ability to utilize our NOL and R&amp;D credit carryforwards. As of March&#160;31, 2025, we had NOL carryforwards of $1,150.7&#160;million for federal income tax purposes and $985.8&#160;million for state income tax purposes. In addition, our federal NOL carryforwards generated in taxable&#160;years beginning before January&#160;1, 2018, are permitted to be carried forward for only 20&#160;years. Although our federal NOL carryforwards generated in taxable&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, they are permitted to be used in any taxable year to offset only up to 80% of taxable income, if any, in such year. For state income tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. We also had R&amp;D credit carryforwards of $2.8&#160;million that will begin to expire in 2031. Our ability to use our NOL and R&amp;D credit carryforwards also may be subject to certain limitations due to prior or future ownership changes, if any, as defined in Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) (generally a greater than 50% change, by value, in a corporation&#8217;s equity ownership over a three-year period). Under Sections&#160;382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an ownership change, the corporation&#8217;s ability to use its pre-change NOL and R&amp;D credit carryforwards to offset the corporation&#8217;s post-change income or taxes may be limited. Although we have not experienced ownership changes in the past, we may experience ownership changes as a result of this offering or subsequent shifts in our stock ownership, some of which may be outside our control. As such, there can be no assurance that we will be able to utilize our NOL and R&amp;D credit carryforwards, and we have established valuation allowances against our NOL and R&amp;D credit carryforwards due to the uncertainty surrounding the realization of such assets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in tax laws or regulations may have an adverse effect on our business, financial condition, and results of operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For example, the Tax Cuts and Jobs Act, the Coronavirus Aid, Relief, and Economic Security Act, and the Inflation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Reduction Act made significant changes to U.S. tax laws. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may seek acquisitions or other strategic transactions from time to time that could increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary intellectual property rights, technologies, or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">increased operating expenses and cash requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the assumption of indebtedness or contingent liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the issuance of our equity securities that would result in dilution to our shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">assimilation of operations, personnel, intellectual property, and products of an acquired company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">failure to achieve any expected synergies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or candidates and regulatory approvals, and the validity and enforceability of their intellectual property. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, as our strategy evolves, we may opt to discontinue, deprioritize, or dispose of assets, technologies, or acquired businesses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The increasing focus on environmental, social, and governance (&#8220;ESG&#8221;) initiatives could increase our costs, harm our reputation, and adversely impact our financial results.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There has been increasing public focus by investors, patients, environmental activists, the media, and governmental and nongovernmental organizations on a variety of environmental, social, and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. While we may in the future engage in various initiatives (including but not limited to voluntary disclosures, policies, or goals) to improve our ESG profile or respond to stakeholder expectations, we cannot guarantee that these initiatives will have the desired effect. If we are not effective in addressing environmental, social, and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. In addition, even if we are effective at addressing such concerns, we may experience increased costs as a result of executing upon our sustainability goals that may not be offset by any benefit to our reputation, which could have an adverse impact on our business and financial condition. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, this emphasis on ESG matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements, including with respect to climate change. ESG and sustainability-related regulation and legislation, to the extent implemented, will require us to incur significant additional costs to comply, including the implementation of significant additional internal controls, processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors as well as impose additional disclosure obligations on us. Additionally, our suppliers, customers or other business partners may require us to provide additional climate-related information if they are also subject to additional climate-related disclosure laws or regulations in other jurisdictions. If we fail to comply with new laws, regulations or reporting requirements, or we fail to provide complete and accurate information to our suppliers, customers or other business partners, our reputation and business could be adversely impacted.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial condition, business strategy, information solutions, technology, R&amp;D costs, regulatory approvals, potential market opportunity, anticipated trends in our business, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms or other similar expressions, are intended to identify forward looking statements. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments in the precision oncology industry, including our biopharma partners&#8217; use of molecular information and the market size for molecular information services; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations as to our addressable U.S. market in oncology, future financial performance, results of operations, or other operational results or metrics; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the ability of the Caris platform to help our biopharma partners and physicians improve the efficiency and success of their therapeutic development, and clinical programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to scale the Caris platform and develop new solutions or enhancements to existing solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to capture, aggregate, analyze, or otherwise utilize molecular information in novel ways; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to compete with companies that are currently in, or may in the future enter, the industry in which we operate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">third-party payer reimbursement and coverage decisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish, maintain, protect, and enforce our intellectual property rights of our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">federal, state, and foreign regulatory requirements, including FDA regulation of our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing, likelihood, or conditions of regulatory filings and approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to hire and retain key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our anticipated cash needs and our estimates regarding our capital requirements and our needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding our expenses, future revenue, and capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations related to the use of proceeds from this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">remediating the material weakness in our internal control over financial reporting; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the volatility of the trading price of our Class A common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:416pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAID">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:288pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET AND INDUSTRY DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains estimates, projections, and other information concerning our industry, our business, and the markets for our precision medicine information solutions, including data regarding the estimated size of such markets. We obtained the industry, market, and similar data set forth in this prospectus from our internal estimates and research, including surveys and studies we have sponsored and/or conducted, and from academic and industry research, publications, surveys, and studies conducted by third parties, including governmental agencies. Information based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Forecasts and other forward-looking information with respect to industry, business, market, and other data are subject to the same qualifications and additional uncertainties regarding the other forward-looking statements in this prospectus. See the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The sources of certain industry, business, market, and other data contained in this prospectus include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Nephron Research LLC, Oncology Testing TAM Analysis, March&#160;2024, which we commissioned; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Evaluate Pharma, World Preview 2023, Outlook to 2028, August 2023; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Centers for Disease Control and Prevention; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The American Cancer Society; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The American Lung Association; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The International Agency for Research on Cancer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">National Center for Biotechnology Information; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The American Society of Clinical Oncology. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:104pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that the net proceeds from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million (or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriters exercise their option to purchase additional shares of Class A common stock in full), based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares of Class&#160;A common stock offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from this offering by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our Class A common stock, and enable access to the public equity markets for us and our shareholders. As of the date of this prospectus, we have no specific plan for any significant portion of the net proceeds from this offering. However, we intend to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures. We also intend to use approximately $&#8199;&#8199;&#8199;&#8199; of the net proceeds, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement. Based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and an assumed tax withholding rate of &#8199;&#8199;&#8199;&#8199;%, we would withhold an aggregate of &#8199;&#8199;&#8199;&#8199; shares of our common stock and use approximately $&#8199;&#8199;&#8199;&#8199; million to satisfy such tax withholding and remittance obligations. A 1% increase (decrease) in the tax withholding rate would increase (decrease) the amount of tax withholding and remittance obligations related to the RSU Net Settlement by $&#8199;&#8199;&#8199;&#8199; million. We may also use a portion of our net proceeds to co-develop, acquire, or invest in products, technologies, or businesses that are complementary to our business, although we do not have agreements or commitments for any material acquisitions or investments at this time. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will have broad discretion over the uses of the net proceeds from this offering. The expected use of net proceeds from this offering represents our intentions based upon our present plans and business conditions. We cannot predict with certainty all of the particular uses for the proceeds of this offering or the amounts that we will actually spend on the uses set forth above. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending the uses described above, we plan to invest the net proceeds in a variety of capital preservation investments, including short-term interest-bearing investment-grade securities, certificates of deposit, or government securities. Investors will be relying on the judgment of our management regarding the application of the net proceeds from this offering. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:488pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual, legal, tax, and regulatory restrictions, capital requirements, and such other factors as our board of directors may deem relevant. In addition, our ability to pay cash dividends is currently restricted by the terms of the 2023 Term Loan Agreement. Our future ability to pay cash dividends on our capital stock may also be limited by the terms of any future debt or preferred securities or future credit facility. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:11.28pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our cash and cash equivalents and capitalization as of March&#160;31, 2025, as follows: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on an actual basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on a pro&#160;forma basis to give effect to (i)&#160;the Warrant Exercise, (ii)&#160;the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v)&#160;the effectiveness of our amended and restated certificate of formation (which will effect the Common Stock Reclassification), and (vi)&#160;the RSU Net Settlement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on a pro&#160;forma as adjusted basis to give further effect to (i) our issuance and sale of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us and (ii) the use of approximately $&#8199;&#8199;&#8199;&#8199; million of the net proceeds from this offering, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The pro&#160;forma and pro&#160;forma as adjusted information below is illustrative only. Our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this table in conjunction with the information contained in &#8220;Use of Proceeds&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as the consolidated financial statements and the notes thereto included elsewhere in this prospectus. </font>
        </div>
        <table style="width:416pt;margin-bottom:5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:245.27pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:245.27pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                <br >
                <font style="letter-spacing:-0.16pt;">As Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:245.27pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except share and per share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:245.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">31,201 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:245.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Debt (including current portion of long-term debt)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">316,643</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Redeemable convertible preferred stock, par value $0.001 </font>
                <br >
                <font style="letter-spacing:0.2pt;">per share; 787,439,505 shares authorized, 734,142,041 </font>
                <br >
                <font style="letter-spacing:0.2pt;">shares issued and outstanding, actual; and no shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">authorized, issued, or outstanding, pro&#160;forma and </font>
                <br >
                <font style="letter-spacing:0.2pt;">pro&#160;forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,246,113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:245.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase capital stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">128,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:245.27pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Shareholders&#8217; (deficit) equity: </font>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Preferred stock, par value $0.001 per share; no shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">authorized, issued and outstanding, actual; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; </font>
                <br >
                <font style="letter-spacing:0.2pt;">shares authorized, no shares issued and outstanding, </font>
                <br >
                <font style="letter-spacing:0.2pt;">pro&#160;forma and pro forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock, par value $0.001 per share; </font>
                <br >
                <font style="letter-spacing:0.2pt;">1,173,000,000 shares authorized, 140,950,490 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">issued and outstanding, actual; no shares authorized, </font>
                <br >
                <font style="letter-spacing:0.2pt;">issued, or outstanding, pro forma and pro&#160;forma as </font>
                <br >
                <font style="letter-spacing:0.2pt;">adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:245.27pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:245.27pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma</font>
                <br >
                <font style="letter-spacing:-0.16pt;">As Adjusted</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:245.27pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except share and per share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class A common stock, par value $0.001 per share; no </font>
                <br >
                <font style="letter-spacing:0.2pt;">shares authorized, issued, or outstanding, actual; </font>
                <br >
                <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8199;&#8199; shares issued </font>
                <br >
                <font style="letter-spacing:0.2pt;">and outstanding, pro forma; and &#8199;&#8199;&#8199;&#8199;&#8199; shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and outstanding, </font>
                <br >
                <font style="letter-spacing:0.2pt;">pro forma as adjusted</font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:245.27pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class B common stock, par value $0.001 per share; no shares authorized, issued, or outstanding, actual; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares authorized, &#8199;&#8199;&#8199;&#8199; shares issued and outstanding, pro&#160;forma and pro&#160;forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:245.27pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Treasury stock&#8212;6,482,550 shares of common stock, par value $0.001 per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(16,917<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(2,583,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accumulated other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:245.27pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total shareholders&#8217; (deficit) equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(2,599,865<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:245.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">91,582 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.995000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="20">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Each&#160;$1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders&#8217; (deficit) equity, and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million shares in the number of shares of Class A common stock offered by us at the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders&#8217; (deficit) equity, and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the shares of our Class A common stock offered by this prospectus are sold at the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Represents long-term indebtedness, net of debt discounts. Total&#160;debt as of March&#160;31, 2025 consisted of approximately $400.0 million of borrowings outstanding under the 2023 Term Loan Agreement. In April&#160;2025, we also issued 2025 Convertible Notes to certain investors in aggregate principal amount of $30.0 million. The 2025 Convertible Notes mature on January 1, 2026, accrue interest at a rate of 8% per annum (payable quarterly in cash), and will, immediately prior to and in connection with the completion of this offering, convert at a conversion price equal to 70% of the initial public offering price per share, or into &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock, based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. The &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock to be issued upon conversion of the 2025 Convertible Notes based on such assumed initial public offering price will be reclassified into an equivalent number of shares of our Class&#160;B common stock in the Common Stock Reclassification. For a discussion of our long-term debt, see the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources.&#8221; Also, see our consolidated financial statements and related notes thereto included elsewhere in this prospectus, which include all recorded liabilities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of common stock in the table above excludes: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock issuable upon the exercise of options outstanding under our 2020 Plan as of March&#160;31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:346pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock issuable upon the exercise of options granted under our 2020 Plan subsequent to March&#160;31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock issuable upon the vesting and settlement of RSUs granted under our 2020 Plan that are held by current executive officers, employees, directors, and consultants and are subject to vesting conditions that are not satisfied in connection with this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class B common stock issuable upon the exercise of options held by David&#160;D. Halbert that were outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class B common stock issuable upon the exercise of 2025 Warrants at an exercise price of $0.01 per share, based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class A common stock reserved for future issuance under our 2025 Plan, which will become effective in connection with this offering, as well as shares of our Class&#160;A common stock that may be issued pursuant to provisions of our 2025 Plan that automatically increase the share reserve under our 2025 Plan; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class A common stock reserved for future issuance under our ESPP, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions in our ESPP that automatically increase the share reserve under the ESPP. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our Class A common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the pro&#160;forma as adjusted net tangible book value per share of our Class A common stock immediately after this offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Historical net tangible book value (deficit) per share represents our total tangible assets less our liabilities and preferred stock that is not included in equity divided by the total number of shares of common stock outstanding. As of March&#160;31, 2025, our historical net tangible book value (deficit) was approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. Our pro&#160;forma net tangible book value as of March&#160;31, 2025, was approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv)&#160;the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi)&#160;RSU Net Settlement as if such events had occurred on March&#160;31, 2025. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After giving further effect to receipt of the net proceeds of our sale of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses, our pro&#160;forma as adjusted net tangible book value as of March&#160;31, 2025 would have been approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. This represents an immediate increase in pro&#160;forma as adjusted net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to our existing shareholders and an immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to investors purchasing Class A common stock in this offering. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this dilution to new investors on a per share basis: </font>
        </div>
        <table style="width:456pt;height:113.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:384pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed initial public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Historical net tangible book value (deficit) per share as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:384pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Increase per share attributable to the pro&#160;forma adjustments described above </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:384pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma net tangible book value (deficit) per share as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:384pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Increase in pro&#160;forma net tangible book value per share attributable to new investors in this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:384pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma as adjusted net tangible book value per share immediately after this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:384pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors purchasing shares in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted net tangible book value, by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and the dilution per share to new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, assuming the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may also increase or decrease the number of shares of Class A common stock we are offering. An increase (decrease) of 1,000,000 shares in the number of shares of Class A common stock we are offering would increase (decrease) our pro&#160;forma as adjusted net tangible book value by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, and the pro&#160;forma dilution per share to investors in this offering by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters&#8217; option to purchase additional shares of Class A common stock in this offering is exercised in full, the pro&#160;forma as adjusted net tangible book value would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the increase in the pro&#160;forma net tangible book value per share for existing shareholders would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, and the dilution to new investors participating in this offering would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price, number of shares of Class A common stock offered and other terms of this offering determined at pricing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table below summarizes, as of March&#160;31, 2025, on the pro&#160;forma basis described above, the number of shares of our common stock, the total consideration, and the average price per share (i)&#160;paid to us by our existing shareholders and (ii)&#160;to be paid by new investors participating in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:22.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="8">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Purchased </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total Consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:33.96pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price Per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:30pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:251.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Existing shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:30pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:33.96pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">New investors </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:30pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:33.96pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:251.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 2.5pt 0pt; width:30pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0.92pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:33.96pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.9pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) total consideration paid by new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and increase (decrease) the&#160;percent of total consideration paid by new investors by&#8199;&#8199;&#8199;&#8199;%, assuming the number of shares of Class&#160;A common stock we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions. We may also increase or decrease the number of shares of Class&#160;A common stock we are offering. An increase (decrease) of 1,000,000 in the number of shares of Class&#160;A common stock offered by us would increase (decrease) total consideration paid by new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, assuming that the assumed initial price to the public remains the same, and after deducting estimated underwriting discounts and commissions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, if the underwriters&#8217; option to purchase additional shares of Class&#160;A common stock is exercised in full, the number of shares held by existing shareholders will be reduced to&#8199;&#8199;&#8199;&#8199;% of the total number of shares of common stock to be outstanding upon the completion of this offering, and the number of shares of Class&#160;A common stock held by new investors participating in this offering will be further increased to&#8199;&#8199;&#8199;&#8199;% of the total number of shares of common stock to be outstanding upon the completion of the offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of our common stock to be outstanding after this offering is based on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock and &#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class B common stock outstanding as of March&#160;31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v)&#160;the Common Stock Reclassification, and (vi)&#160;the RSU Net Settlement, and excludes: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock issuable upon the exercise of options outstanding under our 2020 Plan as of March&#160;31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock issuable upon the exercise of options granted under our 2020 Plan subsequent to March 31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock issuable upon the vesting and settlement of RSUs granted under our 2020 Plan subsequent to March 31, 2025 that are held by current executive officers, employees, directors, and consultants and are subject to vesting conditions that are not satisfied in connection with this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class B common stock issuable upon the exercise of options held by David&#160;D. Halbert that were outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class B common stock issuable upon the exercise of 2025 Warrants at an exercise price of $0.01 per share, based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:494pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class A common stock reserved for future issuance under our 2025 Plan, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions of our 2025 Plan that automatically increase the share reserve under our 2025 Plan; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class A common stock reserved for future issuance under our ESPP, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions in our ESPP that automatically increase the share reserve under our ESPP. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that any outstanding options are exercised, or new awards are granted and exercised or settled under our equity compensation plans, new investors will experience further dilution.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:72pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this prospectus. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. See the section titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; elsewhere in this prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and AI/ML algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17&#160;years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular&#160;markers. Our platform is purpose-built to leverage the convergence of NGS, AI and ML technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, MRD tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our current commercial product portfolio consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our early foresight to generate comprehensive data at scale over the past many&#160;years and build a robust, foundational infrastructure have uniquely positioned Caris to leverage the benefits of biological and technological advances to deliver transformative and advanced innovations in precision medicine and patient care into the future. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:36pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since our founding, we have achieved the following significant milestones: </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="fc_keydevelop-4c.jpg" alt="[MISSING IMAGE: fc_keydevelop-4c.jpg]" height="199" width="600" >
        </div>
        <div style="text-indent:36pt; margin-top:9.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To our knowledge, we remain the only genomic profiling company to consistently utilize WES and WTS as standard practice on every eligible patient sample. Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology. Our ever-expanding datasets include data generated from more than 6.5&#160;million tests that have generated measurements of over 38&#160;billion molecular markers from over 13 quadrillion datapoints as of March 31, 2025, as well as matched clinical outcomes for many of these patients. </font>
        </div>
        <div style="text-indent:36pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our global annual clinical case volume has been growing rapidly, with year-over-year growth of 29% in 2022, 32% in 2023, 26% in 2024, and 31% in the first quarter of 2025, primarily driven by MI Profile. With our broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and the FDA approval of MI Cancer Seek as a companion diagnostic in the fourth quarter of 2024 followed by the broad commercial launch of MI Cancer Seek in the first quarter of 2025 as the NGS component of MI Profile, we believe that increased profiling volumes will meaningfully contribute to our growth in 2025 and beyond. </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="bc_casevolume-4c.jpg" alt="[MISSING IMAGE: bc_casevolume-4c.jpg]" height="434" width="578" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. This continuous feedback loop enabled us to develop Caris Assure, which utilized genomic data generated by MI Profile to inform our blood-based bioinformatics algorithms, allowing us to detect previously unknown features and signals in the blood that provide advanced insights into disease development. We believe we will be able to further leverage this process to continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have funded our operations to date principally from the sale of our stock, convertible and&#160;senior secured notes, and revenue from our molecular profiling solutions and services with biopharma companies. For the&#160;years ended December&#160;31, 2024 and 2023, we generated total revenue of $412.3&#160;million and $306.1&#160;million, respectively, and incurred net losses of $281.9&#160;million and $341.4&#160;million, respectively. For the three months ended March 31, 2025 and 2024, we generated total revenue of $120.9 million and $80.7 million, respectively, and incurred net losses of $102.6 million and $111.0 million, respectively. Our Adjusted EBITDA was $(189.6) million and $(255.3) million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. Our Adjusted EBITDA was $(36.2) million and $(70.1) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding Adjusted EBITDA, a non-GAAP financial&#160;measure, see &#8220;&#8212;Non-GAAP Financial Measures.&#8221; We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million, $276.1 million, $31.3 million, and $73.9 million for the years ended December 31, 2024 and 2023 and the three months ended March 31, 2025 and 2024, respectively. Our free cash flow was $(253.6)&#160;million and $(298.4)&#160;million for the years ended December 31, 2024 and 2023, respectively, and $(34.0)&#160;million and $(75.7)&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. For additional information regarding free cash flow, a non-GAAP financial measure, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Non-GAAP Financial Measures.&#8221; Additionally, as of March&#160;31, 2025, we had cash, cash equivalents, and short-term marketable securities of $33.4&#160;million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million. For additional information regarding our liquidity and capital resources, see &#8220;&#8212;Liquidity and Capital Resources.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Business Model</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We generate revenue primarily from the provision of precision oncology solutions to ordering physicians utilizing MI Profile and Caris Assure. We have obtained Medicare and commercial reimbursement for MI Profile. We also have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States (other than New York State). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also generate revenue utilizing our Caris platform to provide R&amp;D services for biopharma partners, who we partner with to help improve the efficiency and success of their therapeutic development and clinical programs. For our biopharma partners, our profiling solutions provide prospective and retrospective testing, companion diagnostics development, data licensing, and commercial services that include identification of patients for approved therapies. In addition, our multi-modal data creates a differentiated capability to advance precision oncology research through novel target identification and discovery, translational sciences, clinical trial design solutions and patient enrollment facilitated by our right-in-time trials network, post-market label expansion, and commercialization insights. Under the strategic partnerships, targets discovered by us using our proprietary wet lab, </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;">, ADAPT, proximity labeling, and surfacesome analysis can be pursued by our biopharma partners to conduct their own preclinical and clinical research, as well as the eventual development and commercialization of drug candidates. Our biopharma partners select drug targets based, among other things, on their prevalence and expression across cancer types, the uniqueness of the targets and efficacy of current treatments, and their therapeutic modality. Our biopharma partners are also able to combine their relevant technology and/or drug </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">development capabilities, such as data analysis, </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> studies, molecule design, and therapeutic modality, to design and manufacture potential therapies for the treatment of cancer. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe the market for our solutions is large and expanding. We have made significant investments in our scaled and state-of-the-art infrastructure to support our growth and our ability to address the needs of the U.S. oncology market through the provision of molecular information services across the full patient care continuum and to support biopharma drug development. We operate two precision medicine laboratories in Phoenix, Arizona, and one R&amp;D laboratory in Tempe, Arizona. Our Arizona laboratories all utilize state-of-the-art genomic sequencing technology, including 50 NovaSeq sequencing systems, with capacity to perform more than one trillion &#8220;reads&#8221; daily. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet. To support our sales activity and expansion, as of March&#160;31, 2025, we have assembled a targeted sales organization in the United States of over 270 sales team members and nearly 50&#160;highly trained Ph.D. or M.D. MSLs who focus on physician and provider education and consultation. In addition, the Caris POA, which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that supports our academic partner engagement and research and collaboration opportunities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Factors Affecting Our Performance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that our operating performance and future success depend on a number of factors that present significant opportunities for us and may pose risks and challenges, including those discussed below and in the &#8220;Risk Factors&#8221; section of this prospectus. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Market acceptance and commercial success of our solutions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our success and future growth will depend on maintaining and expanding market acceptance of our molecular profiling solutions along with commercial success of these solutions across existing and new customers. Our MI Profile and Caris Assure case volumes have continued to increase over time. Such changes in our case volumes and the pricing of our solutions, however, are not impacted by the cancer type. For the&#160;years ended December&#160;31, 2024 and 2023, the number of clinical cases was 162,862 and 128,831, respectively. For the three months ended March 31, 2025 and 2024, the number of clinical cases was 45,858 and 34,902, respectively. We commercially launched our MI Cancer Seek solution in January&#160;2025 as the WES/WTS NGS component of MI Profile. We initiated the broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024, and realizing the potential of Caris Assure across the cancer treatment continuum is a key component of our business strategy. The commercial success of Caris Assure will depend upon, among other things, additional clinical trials that demonstrate the effectiveness of Caris Assure, particularly for early detection, MCED, MRD tracking, and treatment monitoring, and the continued adoption of Caris Assure by patients, the medical community, and third-party payers. In addition, we expect that our ability to maintain and expand our sales, marketing, and distribution capabilities to support the increased adoption of our molecular profiling solutions will play a key factor in our success. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Biopharma partners.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our revenue also depends on our ability to maintain and expand relationships with our biopharma partners and attract new biopharma partners. As we continue to develop these relationships, we expect to support a growing number of projects and&#160;continue to have opportunities to offer our platform to such customers for development and research services. For the&#160;years ended December&#160;31, 2024 and 2023, our year-over-year growth in pharma research and development services revenue has been 131% and 37%, respectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Development and introduction of new solutions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our business success will also depend on our ability to develop and commercialize new solutions. We plan to continue to invest in the enhancement of our molecular profiling solutions, the development of new solutions to achieve meaningful innovation in precision oncology and other disease states, and the expansion of our clinico-genomic datasets to drive breakthrough science. We intend to expand the application of Caris Assure to early detection, MCED, MRD tracking, and treatment monitoring. Our ability to develop and commercialize new solutions and services could face many challenges and thus impact our future performance and results of operations. Such challenges include, but </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">are not limited to, obtaining regulatory approvals; completing certain clinical development activities, validation studies, and/or clinical trials; having guidelines or recommendations for healthcare providers, administrators, payers, and patient communities relating to such solutions; and receiving favorable exposure in peer-reviewed publications and from KOLs. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Payer coverage and reimbursements.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our revenue and future revenue growth will depend on our success in achieving broad coverage and adequate reimbursement for our solutions from third-party payers. Coverage and reimbursement by third-party payers, including managed care organizations, private health insurers, and government healthcare programs for the types of solutions we offer can be limited and uncertain and may depend on a number of factors, including a payer&#8217;s determination that a product is appropriate, medically necessary, and cost-effective. Each payer will make its own decision as to whether to establish a policy or enter into a contract to cover our products and the amount it will reimburse for such products. In addition, Z-Code Identifiers are used by certain payers, including under MolDX, to supplement CPT codes for our molecular diagnostics solutions. Changes to the codes used to report to payers may result in significant changes in their reimbursement. We have obtained a PMA approval from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for tumor mutational burden (&#8220;TMB&#8221;) calling along with being designed to meet the stricter requirements applicable to companion diagnostic devices. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U, at a reimbursement rate of $8,455, under the NGS NCD. We currently market MI Cancer Seek as the WES/WTS NGS component of MI Profile. The current MolDX pricings of MI Tumor Seek Hybrid, and Caris Assure are $3,500 and $3,649, respectively. In&#160;July 2024, the AMA issued a PLA code, CPT code&#160;0485U, for Caris Assure, with an effective date of October&#160;1, 2024. In November&#160;2024, CMS determined to price Caris Assure for therapy selection using the &#8220;Gapfill&#8221; method, a method used when there are no comparable existing&#160;codes available. There is no certainty regarding the pricing that we will obtain for Caris Assure&#160;during the Gapfill process. For additional information, </font><font style="letter-spacing:0.196pt;">see &#8220;&#8212;Government Regulation&#8212;</font>&#8203;<font style="letter-spacing:0.196pt;">Coverage and </font><font style="letter-spacing:0.2pt;">Reimbursement&#8212;Coverage and Reimbursement in the United States.&#8221; While the average selling prices (&#8220;ASPs&#8221;) for Caris Assure and MI Cancer Seek reimbursed by a particular payer are determined by our arrangements with that payer and do not materially differ by cancer type, any fluctuation or differences in coverage and reimbursement among our third-party payers may impact our ASPs and gross margins. Moreover, if we are unable to obtain and/or maintain broad coverage and adequate reimbursement for our solutions from third-party payers, we may not be able to effectively increase our clinical case volume and our revenue would be impacted. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Scaling infrastructure to meet increasing demand.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our financial results are also dependent upon our ability to support current and future levels of demand for our solutions, including MI Profile and Caris Assure. As and to the extent the volumes of our current and new molecular profiling solutions continue to grow, we will need to simultaneously increase our capacity for sample intake and storage, enhance our customer service, improve our billing and general processes, expand our internal quality assurance programs, incorporate new equipment, implement new technology systems and processes, expand laboratory capacity, and otherwise extend our operational capabilities to support comprehensive genomic analyses at a larger scale while retaining expected turnaround times. This may result in us purchasing additional equipment, constructing additional facilities, hiring additional qualified labor, and implementing new systems, technology, controls, and procedures. As such, our capital expenditures and cost of services may increase as we continue our efforts to expand capacity. In addition, revenue may be impacted in the event that we are not able to meet the increase in demand. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Components of Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Revenue consists primarily of the following: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Molecular profiling services revenue is generated from the provision of precision oncology solutions to ordering physicians utilizing MI Profile, MI Cancer Seek (NGS component of MI Profile), and Caris Assure. Revenue is recorded when performance obligations are satisfied, which is deemed to be when the results of the profiling services are provided to the ordering physicians, including certain hospitals, cancer centers, and institutions. Revenue is recorded at the amount that reflects the consideration to which we expect to be entitled from customers and third-party payers in exchange for providing such services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pharma research and development services revenue is generated from the provision of research and development services for biopharma partners utilizing our Caris platform. Given the nature of these services, each contract may contain multiple performance obligations, such as molecular profiling solutions, developmental services, and strategic data services. Each performance obligation is analyzed, and revenue is recognized as or when such performance obligations are satisfied. The timing and extent of revenue recognized may vary from contract to contract. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Costs and Operating Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We allocate certain overhead expenses, such as rent, utilities, and depreciation to cost of services and operating expense categories based on headcount and facility usage. As a result, an overhead expense allocation is reflected in cost of services and operating expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Services&#8212;Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of molecular profiling services generally consists of cost of materials, direct labor (including bonus and stock-based compensation), equipment maintenance and depreciation expenses associated with processing cases (including accessioning, sequencing, quality control analyses, and shipping charges to transport samples), and freight. Costs associated with completing the molecular profiling services are recorded as the service is performed, regardless of whether revenue is recognized with respect to the service. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Services&#8212;Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services for pharma research and development services generally consists of costs incurred for the performance of the services requested by our biopharma partners related to research and development services. For the development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of services. Cost of services for pharma research and development services will vary depending on the nature, timing, and scope of customer projects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect cost of services to increase in absolute dollars as our revenue grows. In the short term, increases to cost of services may outpace revenue growth as we invest in expanding our laboratory capacity and implementing new processes. However, over time, the cost per clinical case is expected to decrease due to economies of scale. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Selling and Marketing Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our selling and marketing expense includes costs associated with our sales organization, including our direct sales force and sales management, marketing, and business development personnel. These expenses consist principally of salaries, incentive compensation, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities. We expense all selling and marketing expenses as incurred. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our marketing activities continue to drive awareness and differentiate our existing solutions and future solutions. We expect our selling and marketing expenses to continue to increase in absolute dollars as we expand our sales force and continue to grow our presence within and outside of the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our general and administrative expense includes costs for our executive, accounting and finance, legal, information technology, billing, and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees (such as audit and tax consulting), general corporate costs, and allocated overhead expenses. While we expect our general and administrative expenses will increase in absolute dollars as we continue to invest in our growth and operate as a public company, we expect them to decline as a&#160;percentage of revenue over time as we scale our business and leverage our investments already made. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to incur additional expenses after we complete this offering, primarily due to the costs of operating as a public company, which are expected to include additional legal, accounting, corporate governance, and investor relations expenses, as well as higher directors&#8217; and officers&#8217; insurance premiums. In addition, as a public company, we also expect to incur increased stock-based compensation expense related to our long-term equity incentive plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our research and development expense consists of costs incurred in performing research and development activities. These expenses include direct costs for salaries and benefits, supplies used in research and development, contract services and other outside costs, costs to acquire in-process research and development projects and technologies that have no alternative future use, and allocated overhead expenses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that our overall research and development expenses will vary from period to period as a&#160;percentage of revenue, as projects and prospective trials are initiated and completed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income (Expense), Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest income consists primarily of interest earned on our cash and cash equivalents and marketable securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense consists primarily of contractual interest expense on our term loan, amortization of the debt discount related to our term loans, and interest expense on our finance leases. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Changes in Fair Value of Financial Instruments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments consists of changes in the fair value of the warrant liability and changes in the fair value of the derivative liability. Our warrants are classified as a liability on our consolidated balance sheets and re-measured to fair value at each balance sheet date with the corresponding changes in fair value recorded within changes in fair value of financial instruments, as the holders have the option to convert their warrants into shares of either our common stock or our Series&#160;C preferred stock. The warrants will expire upon the completion of this offering unless earlier exercised. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Expense, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net consists of items related to foreign currency gains and losses, and other immaterial items. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:52.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Three Months Ended March&#160;31, 2025 and 2024</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of our results of operations for the periods presented: </font>
        </div>
        <table style="width:416pt;height:315.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:309.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">114,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">73,233</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">6,834</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">7,444</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">120,915</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">80,677</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and operating expenses</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font><font style="letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of Services&#8201;&#8211;&#8201;Molecular Profiling Services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">60,894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of Services&#8201;&#8211;&#8201;Pharma Research and Development Services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,958</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">39,609</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,119</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">44,354</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">23,066</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">34,376</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total costs and operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">178,867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">172,902</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(57,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(92,225<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">503</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,768</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(12,782<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(9,290<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(32,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(11,064<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(219<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total other expense, net</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(44,629<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(18,804<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss before income taxes and provision for income taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Provision for (benefit from) income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:309.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Costs and operating expenses contains the following stock-based compensation expense: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:416pt;height:135pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:331.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8201;&#8211;&#8201;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">427</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8201;&#8211;&#8201;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,243</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,118</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,636</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,346</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">966</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:331.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,458</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our results of operations as a&#160;percentage of revenue for the periods presented: </font>
        </div>
        <table style="width:416pt;height:348.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:334.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:334.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">94<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">91<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and operating expenses</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font><font style="letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8201;&#8211;&#8201;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">50<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">66<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of Services&#8201;&#8211;&#8201;Pharma Research and Development Services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">49<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">55<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">19<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total costs and operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">148<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">214<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(48<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(114<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(11<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(27<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(14<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total other expense, net</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(37<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(23<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss before income taxes and provision for income taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(85<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(138<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:334.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provision for (benefit from) income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:334.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(85<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(138<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:5.855pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.79pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:90pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:287.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:287.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:287.17pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:287.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">114,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">73,233</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">40,848</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">55.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:287.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">6,834</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,444</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(610<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(8.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:287.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">120,915</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">80,677</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">40,238</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">49.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Total revenue was $120.9 million for the three&#160;months ended March&#160;31, 2025, compared to $80.7 million for the three&#160;months ended March&#160;31, 2024, an increase of $40.2 million, or 49.9%. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Profiling Services Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Molecular profiling services revenue increased to $114.1 million for the three&#160;months ended March&#160;31, 2025, from $73.2 million for the three&#160;months ended March&#160;31, 2024, an increase of $40.8 million, or 55.8%. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This increase in revenue was primarily due to the increase in clinical cases associated with MI Profile and Caris Assure for therapy selection from 33,095 and 1,807 cases, respectively, for the three&#160;months ended March&#160;31, 2024, to 40,048 and 5,810 cases, respectively, for the three&#160;months ended March&#160;31, 2025, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a total increase of 10,956 cases, or 31.4%. We believe the growth in MI Profile clinical case volume is driven by increased market acceptance and adoption of MI Profile by ordering physicians year over year, and increased market acceptance and adoption of Caris Assure following its broad commercial launch in the first quarter of 2024. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue from clinical cases for patients covered by Medicare represented approximately 54.3% and 40.5% of our molecular profiling services revenue for the three&#160;months ended March&#160;31, 2025 and 2024, respectively due to mix. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the relative impacts of clinical volume and ASP on our increase in molecular profiling services revenue. </font>
        </div>
        <table style="width:416pt;height:84pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:356.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:356.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services revenue for the three&#160;months ended March&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">73,233</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MI Profile volume increase </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">14,894</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:356.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MI Profile ASP increase due to payer mix </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">15,704</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:356.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Caris Assure for therapy selection </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,250</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:356.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services revenue for the three&#160;months ended March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">114,081</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:15.41pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pharma Research and Development Services Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pharma research and development services revenue decreased to $6.8 million for the three&#160;months ended March&#160;31, 2025, from $7.4 million for the three&#160;months ended March&#160;31, 2024, a decrease of $0.6&#160;million, or 8.2%. The decrease is mainly driven by reduced research case volume. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Services</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:74.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:297.17pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8201;&#8211;&#8201;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">60,894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">15.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8201;&#8211;&#8201;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,958</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,289</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">77.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.3pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Services&#8212;Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services&#8722;Molecular profiling services was $60.9 million for the three&#160;months ended March&#160;31, 2025, compared to $52.9 million for the three&#160;months ended March&#160;31, 2024, an increase of $8.0&#160;million, or 15.1%. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Caris Assure laboratory contributed to the majority of the $8.0 million increase. The Caris Assure increase was primarily driven by an increase in materials and related testing costs of $5.0 million, a $1.3 million increase in utilities, rent, and allocated overhead, and an increase in labor costs of $1.1 million, due to the increased volume from broad launch in the first quarter of 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Services&#8212;Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services&#8722;Pharma research and development services was $3.0 million for the three&#160;months ended March&#160;31, 2025, compared to $1.7 million for the three&#160;months ended March&#160;31, 2024, an increase of $1.3 million, or 77.2%. The increase was driven primarily by an increase within costs associated with the delivery of data licensing and target discovery services of $2.5 million, offset by a reduction in delivering research services of $1.2 million, driven by lower research volume. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Gross Profit</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Gross profit, calculated as total revenue less cost of services, was $57.1 million for the three&#160;months ended March&#160;31, 2025, compared to $26.1 million for the three&#160;months ended March&#160;31, 2024, an increase of $30.9 million, or 118.5%, primarily due to the increase in clinical revenue. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Selling and Marketing Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:59.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:309.88pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:309.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">39,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">39,609</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">221</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">0.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Selling and marketing expenses were $39.8 million for the three&#160;months ended March&#160;31, 2025, compared to $39.6 million for the three&#160;months ended March&#160;31, 2024, an increase of $0.2 million, or 0.6%. This increase was primarily due to a $2.1 million increase in personnel costs to support existing solutions, offset by a $1.9 million decrease in travel and marketing expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:59.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:297.17pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:297.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52,119</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,354</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7,765</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.79pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $52.1 million for the three&#160;months ended March&#160;31, 2025, compared to $44.4 million for the three&#160;months ended March&#160;31, 2024, an increase of $7.8 million, or 17.5%. This increase was primarily due to an increase of $11.6 million in labor costs, benefits and stock-based compensation associated with an expansion of personnel, a $1.3 million increase in consulting, audit and legal professional fees, a $1.3 million increase related to utilities and cloud computing usages, offset by a $7.2 million decrease in depreciation expense.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:59.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:285.51pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:285.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,066</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,376</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,310<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(32.9<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $23.1 million for the three&#160;months ended March&#160;31, 2025, compared to $34.4 million for the three&#160;months ended March&#160;31, 2024, a decrease of $11.3 million, or 32.9%. The decrease was primarily driven by a reduction of $9.6 million in material and reference testing costs associated with the development of Caris Assure and FDA submission of MI Cancer Seek, a reduction of $0.8 million in labor costs, benefits and stock-based compensation, and a $0.8 million reduction in allocated overhead. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income (Expense), Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:120pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:277.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:277.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:277.18pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:277.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">503</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,768</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,265<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(71.6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:277.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,782<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,290<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,492<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">37.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:277.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(32,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,064<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(21,269<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">192.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(219<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(92.2<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:277.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,629<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(18,804<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,825<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">137.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:322.95pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Interest income was $0.5 million for the three&#160;months ended March&#160;31, 2025, compared to $1.8 million for the three&#160;months ended March&#160;31, 2024, a decrease of $1.3 million, or 71.6%. This decrease was primarily due to reduced investments in marketable securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Interest expense was $12.8 million for the three&#160;months ended March&#160;31, 2025, compared to $9.3 million for the three months ended March&#160;31, 2024, an increase of $3.5 million, or 37.6%. This increase was primarily due to increased interest expense associated with $200.0&#160;million of additional borrowing under the 2023 Term Loan Agreement, which was drawn on March&#160;5, 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Changes in Fair Value of Financial Instruments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments was $32.3 million for the three&#160;months ended March&#160;31, 2025, compared to $11.1 million for the three&#160;months ended March&#160;31, 2024, an increase of $21.3 million, or 192.2%. This increase is mainly driven by the increase in warrant and derivative fair values during the three&#160;months ended March&#160;31, 2025. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Expense, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net was $17 thousand for the three&#160;months ended March&#160;31, 2025, compared to $0.2 million for the three&#160;months ended March&#160;31, 2024, a decrease of $0.2 million, or 92.2%. This decrease was primarily due to the undrawn fee of the 2023 Term Loan, incurred during the three months ended March&#160;31, 2024. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:54.7199999999999pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Years Ended December&#160;31, 2024 and 2023</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth a summary of our results of operations for the periods presented: </font>
        </div>
        <table style="width:384pt;height:365.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:277.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:277.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:277.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">349,115</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">278,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">63,145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">27,380</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">412,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">306,128</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and operating expenses</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font><font style="letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">223,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">207,509</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development </font>
                <br >
                <font style="letter-spacing:0.2pt;">services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">152,602</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">142,925</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">169,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">149,053</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">113,916</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">116,883</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total costs and operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">669,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">625,679</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(257,122<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(319,551<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,258</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(50,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(31,610<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">18,484</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,094</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(12,606<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(24,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(21,864<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss before income taxes and provision for income taxes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provision for (benefit from) income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:277.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Costs and operating expenses contains the following stock-based compensation expense:</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:384pt;height:121.7pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:282.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years&#160;Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:282.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:282.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.27pt 0pt 1.79pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,504</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.52pt 0pt 1.79pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Cost of services&#8211;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.53pt 0pt 1.78pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">4,301</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,400</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.53pt 0pt 1.78pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">8,448</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">6,983</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.52pt 0pt 2.655pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.655pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.655pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">4,214</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.655pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.655pt 0pt;border-bottom:1px solid #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">3,344</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.27pt 0pt 3.405pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.655pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.655pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">18,643</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.655pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.655pt 0pt;border-bottom:3pt double #000000; min-width:20.25pt; text-align:right; white-space:nowrap;">15,241</td>
            <td style="padding:0pt;padding-left:4.555pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our results of operations as a&#160;percentage of revenue for the periods presented: </font>
        </div>
        <table style="width:384pt;height:339.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:282.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:282.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">85<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">91<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">15<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and operating expenses</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font><font style="letter-spacing:0.2pt;">: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">54<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">37<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">47<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">41<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">49<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">28<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">38<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total costs and operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">162<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">204<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(62<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(104<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(10<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="margin-left:20pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total other expense, net</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss before income taxes and provision for income taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(68<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(112<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provision for (benefit from) income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:282.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(68<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:11.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(112<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:10.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.42pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:262.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:262.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:262.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="26">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:262.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">349,115</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">278,748</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,367</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25.2</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:262.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">63,145</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">27,380</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">35,765</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">130.6</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:262.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">412,260</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">306,128</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">106,132</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">34.7</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:11.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Total revenue was $412.3 million for the year ended December&#160;31, 2024, compared to $306.1&#160;million for the year ended December&#160;31, 2023, an increase of $106.1&#160;million, or 34.7%. </font>
        </div>
        <div style="margin-top:11.42pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Profiling Services Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Molecular profiling services revenue increased to $349.1 million for the year ended December&#160;31, 2024, from $278.7&#160;million for the year ended December&#160;31, 2023, an increase of $70.4&#160;million, or 25.2%. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This increase in revenue was primarily due to the increase in clinical cases associated with MI Profile and Caris Assure for therapy selection from 128,168 and 663 cases, respectively, for the year ended December&#160;31, 2023, to 146,580 and 16,282 cases, respectively, for the year ended December&#160;31, 2024, a total increase of 34,031 cases, or 26.4%. We believe the growth in MI Profile clinical case volume is driven by increased market acceptance and adoption of MI Profile by ordering physicians year over year, and increased market acceptance and adoption of Caris Assure following its broad commercial launch in the first quarter of 2024. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For the year ended December 31, 2023, we recorded $4.4 million of revenue related to the transition of payers from &#8220;non-contract basis&#8221; to &#8216;&#8216;contract basis.&#8217;&#8217; Revenue from clinical cases for patients covered by Medicare represented approximately 39.0% and 39.3% of our molecular profiling services revenue for the&#160;years ended December&#160;31, 2024 and 2023, respectively. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the relative impacts of clinical volume and ASP on our increase in molecular profiling services revenue from 2023 to 2024. </font>
        </div>
        <table style="width:456pt;height:99pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:396.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:396.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services revenue for the year ended December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">278,748</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:396.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MI Profile volume increase </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">39,393</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:396.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MI Profile ASP increase due to payer mix </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,621</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:396.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transition adjustments for MI Profile payers in 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(4,390)</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:396.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Caris Assure for therapy selection </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">26,743</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:396.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services revenue for the year ended December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">349,115</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:4.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.2pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pharma Research and Development Services Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pharma research and development services revenue increased to $63.1 million for the year ended December&#160;31, 2024, from $27.4&#160;million for the year ended December&#160;31, 2023, an increase of $35.7 million, or 130.3%. This increase was primarily due to increased activity with our biopharma partners for our data licensing business of $35.6 million and an increase within pharma profiling services of $1.8 million. The increases were partially offset by a reduction in research revenue of $2.5 million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Services</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:65.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:272.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:272.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:272.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="26">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:272.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">223,075</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">207,509</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,566</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.5</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,403</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">9,309</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,094</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.8</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.19pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Services&#8212;Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services&#8212;Molecular profiling services was $223.1 million for the year ended December&#160;31, 2024, compared to $207.5&#160;million for the year ended December&#160;31, 2023, an increase of $15.6 million, or 7.5%.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Caris Assure laboratory contributed a $20.2 million increase, which was offset by a $4.6 million decrease within the MI Profile tissue laboratory. The Caris Assure increase was primarily driven by an increase in materials and related testing costs of $15.7 million and an increase in labor costs of $2.7 million, due to the increased volume from broad launch in the first quarter of 2024. The MI Profile decrease was driven primarily by a reduction in labor costs of $2.9 million and reduced depreciation of $5.7 million, mainly from lab equipment that has been fully depreciated, offset by an increase in materials and related testing costs of $2.0 million, driven by increased case volume.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Services&#8212;Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services&#8212;Pharma research and development services was $10.4 million for the year ended December&#160;31, 2024, compared to $9.3&#160;million for the year ended December&#160;31, 2023, an increase of $1.1 million, or 11.8%. The increase was driven primarily by an increase within costs associated with the delivery of data licensing and target discovery services, offset by a reduction in labor and materials used in pharma profiling services. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:81.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Gross Profit</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gross profit, calculated as total revenue less cost of services, was $178.8 million for the year ended December&#160;31, 2024, compared to $89.3&#160;million for the year ended December&#160;31, 2023, an increase of $89.5 million, or 100.2%, primarily due to the increase in the number of clinical cases and pharma research and development services revenue.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Selling and Marketing Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:50.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:282.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:282.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:282.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="26">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:282.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">152,602</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">142,925</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9,677</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">6.8</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Selling and marketing expenses were $152.6 million for the year ended December&#160;31, 2024, compared to $142.9&#160;million for the year ended December&#160;31, 2023, an increase of $9.7&#160;million, or 6.8%. This increase was primarily due to a $5.7 million increase in personnel costs to support existing solutions, a $1.4 million increase in professional service costs from expanded EMR integrations and consulting, and a $2.4 million increase in travel and marketing expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:50.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:272.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:272.25pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:272.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="26">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:272.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169,386</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">149,053</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20,333</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.6</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses were $169.4&#160;million for the year ended December&#160;31, 2024, compared to $149.1&#160;million for the year ended December&#160;31, 2023, an increase of $20.3&#160;million, or 13.6%. This increase was primarily due to an increase of $6.9 million in labor costs, benefits and stock-based compensation associated with an expansion of personnel, a $4.3 million increase in consulting, audit and legal professional fees, and a $6.9 million increase related to utilities and cloud computing usages.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:50.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:268.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="26">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:268.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113,916</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">116,883</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(2,967)</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">(2.5)</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses were $113.9 million for the year ended December&#160;31, 2024, compared to $116.9&#160;million for the year ended December&#160;31, 2023, a decrease of $3.0 million, or 2.5%. The decrease was primarily driven by a reduction of $8.2 million in material and reference testing costs associated with the development of Caris Assure and FDA submission of MI Cancer Seek and a reduction&#160;of $2.6 million in consulting fees, offset by an $8.0 million increase in labor costs, benefits and stock-based compensation.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income (Expense), Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:111pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:257.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="12">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:257.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="5">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:257.31pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="26">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(Dollars in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:257.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">7,122</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">11,258</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(4,136)</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">(36.7)</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:257.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(50,025)</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(31,610)</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(18,415)</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">58.3</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:257.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">18,484</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">11,094</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">7,390</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">66.6</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:257.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(349)</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(12,606)</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">12,257</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:18pt; text-align:right; white-space:nowrap;">(97.2)</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:257.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(24,768)</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(21,864)</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(2,904)</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:18pt; text-align:right; white-space:nowrap;">13.3</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0.01pt; text-align:left; ">%</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.2pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Income</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest income was $7.1 million for the year ended December 31, 2024, compared to $11.3&#160;million for the year ended December&#160;31, 2023, a decrease of $4.1&#160;million, or 36.7%. This decrease was primarily due to reduced investments in marketable securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense was $50.0 million for the year ended December 31, 2024, compared to $31.6&#160;million for the year ended December&#160;31, 2023, an increase of $18.4&#160;million, or 58.3%. This increase was primarily due to increased interest expense associated with $200.0 million of additional borrowing under the 2023 Term Loan Agreement, which was drawn on March 5, 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Changes in Fair Value of Financial Instruments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments was $18.5 million for the year ended December&#160;31, 2024, compared to $11.1&#160;million for the year ended December&#160;31, 2023, an increase of $7.4&#160;million, or 66.6%. This increase is mainly driven by the decrease in warrant and derivative fair values during the year ended December 31, 2024.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Expense, Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net was $0.3 million for the year ended December 31, 2024, compared to $12.6&#160;million for the year ended December&#160;31, 2023, a net decrease of $12.3&#160;million, or 97.2%. This decrease was primarily due to a loss on debt extinguishment of $10.9 million in connection with our prior term loan that was recorded in January 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-GAAP Financial Measures</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We use certain non-GAAP financial measures to supplement our consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, Adjusted EBITDA and free cash flow, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Adjusted EBITDA</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other&#160;expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe that Adjusted EBITDA provides useful information to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges. Some of the limitations related to the use of Adjusted EBITDA as an analytical tool include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it does not reflect interest income, interest expense or other non-operating gains and losses, which may represent an increase to or reduction in cash available to us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it does not reflect recurring, non-cash expenses of depreciation of property and equipment and amortization of right-of-use assets and intangible assets, and although these are non-cash expenses, the assets being depreciated and amortized may have to be replaced in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it does not reflect the impact of stock-based compensation expense, which has been, and will continue to be a part of our compensation strategy; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it may be calculated differently than similarly titled measures used by other companies, which reduces its usefulness as a comparative measure. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and our other GAAP results. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as, or similar to, some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides a reconciliation of net loss, the most directly comparable financial measure presented in accordance with GAAP, to Adjusted EBITDA for the periods presented: </font>
        </div>
        <table style="width:396pt;height:177pt;margin-left:30pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:183.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended March 31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:183.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:183.85pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(503<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(7,122<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(11,258<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,290</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">50,025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">31,610</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:183.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">32,333</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(18,484<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(11,094<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">219</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">349</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,606</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,045</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">17,705</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">48,913</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">49,001</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:183.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">4,458</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">18,643</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">15,241</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:183.85pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:normal;">
                <font style="letter-spacing:0.2pt;">Adjusted EBITDA </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(36,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(70,062<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(189,566<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(255,309<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.71pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Free Cash Flow</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We define free cash flow as net cash used in operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash. Some of the limitations related to the use of free cash flow as an analytical tool include:</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it does not reflect our future contractual commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it does not represent our total residual cash flow for a given period; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">it may be calculated differently than similarly titled measures used by other companies, which reduces its usefulness as a comparative measure. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of these limitations, you should consider free cash flow alongside other financial performance measures, including net cash used in operating activities, capital expenditures, and our other GAAP results. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides a reconciliation of net cash used in operating activities, the most directly comparable financial measure presented in accordance with GAAP, to free cash flow for the periods presented: </font>
        </div>
        <table style="width:384pt;height:102pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:181.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:181.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:181.85pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:181.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(31,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(73,925<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(245,199<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(276,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:181.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Less: purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,689<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,738<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(8,444<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(22,319<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:181.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Free cash flow </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(34,027<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(75,663<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(253,643<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">(298,419<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sources of Liquidity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have incurred net losses and negative cash flows from operations since inception. We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million and $276.1&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively, and an accumulated deficit of $2.6&#160;billion as of March&#160;31, 2025. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, we have funded our operations principally from the issuance of stock, term loan borrowings and convertible debt, and through revenue from molecular profiling and pharma research and development services. As of March&#160;31, 2025, we had cash and cash equivalents of $31.2&#160;million and short-term marketable securities of $2.2&#160;million. We believe our existing cash and cash equivalents and anticipated cash flows from operations, together with the net proceeds from our 2025 Private Placement and this offering, will provide sufficient capital and liquidity to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months after the completion of this offering. We will, however, continue to require additional capital to meet our operational needs. See &#8220;&#8212;Indebtedness&#8221; and &#8220;&#8212;Cash Requirements&#8221; below for additional information regarding our cash requirements and various factors that may impact our liquidity and capital resources, including the Non-conversion Amortization Payments (as defined below) in respect of our existing indebtedness. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our cash flows for the periods presented: </font>
        </div>
        <table style="width:384pt;height:89.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:180.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Ended March 31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:180.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180.18pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:180.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(31,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(73,925<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(245,199<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(276,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,689<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">59,638</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,932</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">214,774</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,285</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,107</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">200,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,132</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities during the year ended December 31, 2024 was $245.2 million, which was primarily due to a net loss of $281.9 million and a net change in our operating assets and liabilities of $29.1 million, and offset by non-cash charges of $65.8 million. The net change in our operating assets and liabilities was primarily the result of a $33.8 million increase in accounts receivable, a $1.4 million increase in prepaid expenses and other current assets, offset by a $5.5 million decrease in supplies and a $0.1 million decrease in other assets. Net non-cash charges, primarily consisted of $48.9 million of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">depreciation and amortization expense, $18.6 million of stock-based compensation expense and $7.1 million in amortization of debt discount costs, offset by a $18.5 million gain within changes in the fair value of financial instruments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities during the year ended December&#160;31, 2023 was $276.1&#160;million, which was primarily due to a net loss of $341.4&#160;million and a net change in our operating assets and liabilities of $7.1&#160;million, and offset by non-cash charges, net of $72.4&#160;million. The net change in our operating assets and liabilities was primarily the result of a $15.1&#160;million increase in accounts receivable, and offset by a $7.2&#160;million increase in accounts payable and a $1.3 million increase in accrued expenses and other current liabilities. Net non-cash charges primarily consisted of $49.0&#160;million of depreciation and amortization, $15.2&#160;million of stock-based compensation expense, $10.9&#160;million of debt extinguishment expense, offset by a $11.1&#160;million gain within changes in the fair value of financial instruments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities during the three&#160;months ended March&#160;31, 2025 was $31.3 million, which was primarily due to a net loss of $102.6 million and a net change in our operating assets and liabilities of $13.3 million, offset by non-cash charges of $57.9 million. The net change in our operating assets and liabilities was primarily the result of a $1.7 million decrease in accounts payable, offset by a $7.9 million decrease in accounts receivable, a $2.5 million decrease in prepaid expenses and other current assets, a $2.1 million decrease in supplies, and a $2.6 million increase in accrued expenses and other liabilities. Net non-cash charges primarily consisted of $7.0 million of depreciation and amortization expense, $14.7 million of stock-based compensation expense and $1.9 million in amortization of debt discount costs, offset by a $32.3 million loss within changes in the fair value of financial instruments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities during the three&#160;months ended March&#160;31, 2024 was $73.9 million, which was primarily due to a net loss of $111.0 million and a net change in our operating assets and liabilities of $1.2 million, and offset by non-cash charges of $38.3 million. The net change in our operating assets and liabilities was primarily the result of a $2.4 million increase in accounts receivable, a $0.1 million increase in prepaid expenses and other current assets, a $2.8 million decrease in accounts payable, a $0.8 million decrease in accrued expenses and other liabilities, offset by a $4.0 million decrease in supplies and a $0.3 million decrease in other assets. Net non-cash charges, primarily consisted of $17.7 million of depreciation and amortization expense, $4.5 million of stock-based compensation expense and $1.6 million in amortization of debt discount costs, offset by a $11.1 million loss within changes in the fair value of financial instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by investing activities during the year ended December&#160;31, 2024 was $52.9&#160;million, which was primarily due to maturities of marketable securities of $61.4 million, offset by purchases of purchases of property and equipment of $8.4 million.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by investing activities during the year ended December&#160;31, 2023 was $214.8&#160;million, which was primarily due to maturities of marketable securities of $300.5&#160;million, offset by purchases of marketable securities of $63.4&#160;million and purchases of property and equipment of $22.3&#160;million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities during the three&#160;months ended March&#160;31, 2025 was $2.7 million, which was primarily due to purchases of property and equipment of $2.7 million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by investing activities during the three&#160;months ended March&#160;31, 2024 was $59.6 million, which was primarily due to maturities of marketable securities of $61.4 million, offset by purchases of property and equipment of $1.7 million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the year ended December&#160;31, 2024 was $200.3&#160;million, which was primarily due to proceeds from issuance of additional borrowings under the 2023 Term Loan Agreement (as defined below) on March 5, 2024, net of issuance costs, of $200.0 million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the year ended December&#160;31, 2023 was $10.1&#160;million, which was primarily due to proceeds from issuance of the initial borrowing under the 2023 Term Loan Agreement, net of issuance costs, of $189.0&#160;million, offset by the repayment of the prior term loans of $180.0&#160;million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the three&#160;months ended March&#160;31, 2025 was $1.3 million, which was primarily due to proceeds from exercises of stock options of $1.4 million, offset by the payment of deferred offering costs of $0.1 million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities during the three&#160;months ended March&#160;31, 2024 was $200.1 million, which was primarily due to proceeds from issuance of additional borrowings under the 2023 Term Loan Agreement on March&#160;5, 2024, net of issuance costs, of $200.0 million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indebtedness</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2023, we entered into a term loan agreement, as amended (the &#8220;2023 Term Loan Agreement&#8221;) with OrbiMed Royalty &amp; Credit Opportunities III, LP, OrbiMed Royalty &amp; Credit Opportunities IV, LP, and Braidwell Transaction Holdings LLC (the &#8220;Lenders&#8221;), pursuant to which we issued senior, secured promissory notes and the Lenders agreed to lend us up to an aggregate principal amount of $400.0&#160;million (the &#8220;2023 Term Loan&#8221;), $200.0&#160;million of which was drawn down upon issuance of the notes. Net cash proceeds to us were $189.0&#160;million, after deducting customary debt discounts and debt issuance costs. The net proceeds were used to repay in full our then-outstanding term loans, including an aggregate principal amount of $175.0&#160;million, a prepayment premium of $5.0&#160;million, and accrued and unpaid interest of $1.0&#160;million. In March&#160;2024, we drew down the remaining $200.0&#160;million under the 2023 Term Loan Agreement. As of March 31, 2025, we had $400.0 million of borrowings outstanding under the 2023 Term Loan Agreement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The aggregate principal amount outstanding under the 2023 Term Loan Agreement is due and payable on January&#160;18, 2028. If an event of default occurs and is continuing, the lenders may declare all amounts outstanding under the 2023 Term Loan Agreement to be immediately due and payable. A final payment exit fee equal to 2.0% of the amount funded under the 2023 Term Loan Agreement is due upon prepayment or maturity. Amounts borrowed pursuant to the 2023 Term Loan Agreement may be prepaid at any time. Upon prepayment, we may be subject to a prepayment penalty based on the timing of repayment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, pursuant to the terms of the 2023 Term Loan Agreement, on the earlier to occur of (x)&#160;for dates prior to January&#160;1, 2026, any date that the redemption rights in respect of our Series&#160;C preferred stock, Series&#160;D preferred stock, or Series E preferred stock are or may become exercisable within 90&#160;days following such date, or (y)&#160;January&#160;1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of our Series&#160;C preferred stock, Series&#160;D preferred stock, or Series E preferred stock are or may become exercisable on or prior to the date that is six&#160;months after the maturity date, we will be required to make a one-time payment in an amount equal to 15% of the outstanding principal amount under the 2023 Term Loan Agreement together with any applicable repayment premium and exit fee as described in the 2023 Term Loan Agreement and, commencing with the first full fiscal quarter following such payment, we will be required to repay 2.5% of the outstanding principal amount in equal quarterly installments each quarter thereafter (such payments, the &#8220;Non-conversion Amortization Payments&#8221;). The Series&#160;C preferred stock redemption rights may be exercised on or after March&#160;31, 2026, and the Series&#160;D preferred stock and Series E preferred stock redemption rights may be exercised on or after May&#160;11, 2026. All outstanding shares of our Series&#160;C preferred stock, Series&#160;D preferred stock, and Series E preferred stock will convert into shares of Class B common stock as part of the Preferred Stock Conversion and any redemption rights&#160;thereunder will terminate in connection with the completion of this offering and consequently, the Non-conversion Amortization Payments discussed above would not be applicable following the completion of this offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The aggregate principal amount under the 2023 Term Loan Agreement bears interest at a rate per annum equal to a fixed margin of 6.5% plus the greater of (a)&#160;forward-looking three-month secured overnight financing rate (&#8220;SOFR&#8221;) and (b)&#160;2.5%. In the event of default, the fixed margin shall increase by 3.0% per annum. As of December&#160;31, 2024, the interest rate was 11.1%. Regular quarterly payments are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">interest-only for the 60-month term of the 2023 Term Loan Agreement, with the principal due at maturity. The effective interest rate for the term loan is 17.0%. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our obligations under the 2023 Term Loan Agreement are secured by a first lien security interest in substantially all of our assets and our subsidiaries&#8217; assets. The 2023 Term Loan Agreement contains certain customary representations and warranties, affirmative and negative covenants, financial covenants, and events of default applicable to us and our subsidiaries. Additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates, and subordinated debt. As of March&#160;31, 2025, we were in compliance with all covenants under the 2023 Term Loan Agreement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On April 1, 2025, we closed a private financing in which we issued a combination of senior convertible notes (the &#8220;2025 Convertible Notes&#8221;), Series E convertible preferred stock and Series F convertible preferred stock, for an aggregate of $167.7 million. The 2025 Convertible Notes have an aggregate principal amount of $30.0 million. The 2025 Convertible Notes accrue interest at a rate of 8% per annum, payable quarterly in cash, and mature on January 1, 2026. In connection with this financing, we also issued warrants to acquire shares of common stock to the holders of the 2025 Convertible Notes. These warrants are not initially exercisable for any shares of common stock, but such warrants become exercisable for a specified dollar value of shares on a monthly basis commencing on June 1, 2025 if we have not completed an initial public offering by such date. Any exercisable portion of the warrants will be automatically exercised prior to the closing of the initial public offering and such warrants will terminate upon the closing of the offering.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to and in connection with the completion of the initial public offering, the 2025 Convertible Notes, Series E convertible preferred stock and Series F convertible preferred stock (plus an 8% accretion in connection with the preferred stocks) will convert into Class B common stock at a price equal to 70% of the initial public offering price per share.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our primary use of cash is to fund operating expenses and capital expenditures (including leases of equipment and buildings), which consist of research and development expenditures, general and administrative expenditures, clinical and regulatory expenditures, purchases of testing equipment, and buildout of our laboratories. Cash used to fund such activities is impacted by the timing of when we pay or prepay these expenses. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our material cash requirements as of December&#160;31, 2024: </font>
        </div>
        <table style="width:456pt;height:96pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:217.46pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Due by </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:217.46pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:217.46pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(In thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:217.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">69,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,718</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">41,441</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:217.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">387</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">117</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">117</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:217.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Term loans and interest</font><font style=" position:relative; bottom:4.25pt;line-height:6.5pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">516,813</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">97,360</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">36,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">36,819</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">345,816</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:217.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total material cash requirements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">586,512</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">108,195</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">47,008</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">44,018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">387,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Excludes the Non-conversion Amortization Payments described above under &#8220;&#8212;Indebtedness,&#8221; as such payment will not be required if this offering is completed prior to December&#160;31, 2025 (the date that is 90&#160;days prior to March&#160;31, 2026, the first date the Series&#160;C preferred stock redemption rights may be exercised, if such rights are not earlier amended, waived, or terminated). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will continue to require additional capital to fund our operations and to continue to fund investments in the development and marketing of our solutions for the foreseeable future. We may need or determine to raise additional capital through private or public equity or debt financings, through collaborative or other arrangements with corporate sources, or through other sources of financing. Requirements for additional capital will depend on many factors, including: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the scope, timing, rate of progress and costs of our research efforts, preclinical development activities, laboratory testing, and clinical trials for our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number and scope of clinical programs we decide to pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the cost, timing, and outcome of preparing for and undergoing regulatory review of our solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the scope and costs of development and commercial manufacturing activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the cost and timing associated with commercializing our solutions if they receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the extent to which we acquire or in-license other complementary solutions or technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish and maintain collaborations on favorable terms, if at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our efforts to enhance operational systems and our ability to attract, hire, and retain qualified personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our success in achieving broad coverage and adequate reimbursement for our solutions from third-party payers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our implementation of operational, financial, and management systems; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the costs associated with being a public company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A change in the outcome of any of these or other variables with respect to the development and commercialization of any of our solutions could significantly change the costs and timing associated with such development and commercialization. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may experience increased costs and be required to raise additional capital much sooner than anticipated. In April 2025, we issued the 2025 Convertible Notes. Further, if the Series&#160;C preferred stock redemption rights described above have not been amended, waived, or otherwise terminated prior to December&#160;31, 2025 (the date that is 90&#160;days prior to March&#160;31, 2026, the first date on which such redemption rights would become exercisable), we will be required to make the Non-conversion Amortization Payments following such date. See &#8220;&#8212;Indebtedness&#8221; above. If this offering is not completed by such date and such early repayment and the repayment on maturity of the 2025 convertible notes are required, based on our existing assumptions and expenditures, our existing cash resources and projected operating cash flows would not be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months from the date of this prospectus. These conditions indicate the existence of a material uncertainty that raises substantial doubt as to our ability to continue as a going concern. See Note&#160;1 of our consolidated financial statements included elsewhere in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Accounting Policies and Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The preparation of the consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While our significant accounting policies are described in Note 2 to our consolidated financial statements included elsewhere in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We recognize revenue in accordance with ASC Topic 606, </font><font style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 606&#8221;). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ASC 606 provides a five-step framework through which revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract(s); (iii)&#160;determine the transaction price, including whether there are any constraints on variable consideration; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once a contract is determined to be within the scope of ASC 606, we assess whether individual goods or services promised within each contract are distinct and, therefore, represent separate performance obligations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We recognize revenue from our molecular profiling services at the time when the results of the profiling services are delivered to ordering physicians, including certain hospitals, cancer centers, and institutions. We identify each sale of our profiling case as a single performance obligation. We estimate the transaction price based on our historical collection experience using a portfolio approach for third-party payers and patients with similar reimbursement characteristics. This includes analysis of an average reimbursement per case per portfolio and a percentage of cases reimbursed by considering the historical reimbursement data (including any refunds and recoupments) from such third-party payers and patients, current contractual and statutory requirements, patient insurance eligibility and payer reimbursement contracts, and any known or current or anticipated reimbursement trends not reflected in the historical data. We monitor the estimated amount to be collected in the portfolio at each reporting period. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to molecular profiling services in the period of change. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Contracts with biopharma partners may include multiple distinct performance obligations, such as provision of molecular profiling services, pharma research and development services, and strategic data services. For each of our contracts with biopharma partners, we evaluate the terms and conditions to identify distinct performance obligations. For each performance obligation determined, based on when and how it is delivered, we recognize revenue either when or as such obligation is delivered. Under contracts that include a performance obligation to provide molecular profiling services, to facilitate the development and regulatory approval of drugs, or to provide target discovery services, we receive payments upon the achievement of milestones, as well as provision of on-going support. We recognize pharma research and development services revenue over the period in which pharma research and development services are provided. Depending on the nature of the service, we recognize revenue using either the output or input method to measure progress, whichever provides a more faithful depiction of the transfer of goods or services. Use of an output method or input method to depict the transfer of services generally does not result in a material difference with respect to the timing of revenue recognition because most services commence and end within the same reporting period. We determine the transaction price of each performance obligation by considering the historical selling price of similar transactions, where applicable, as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of our competitors, industry publications, and current pricing practices. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have granted stock-based awards consisting primarily of stock options and RSUs to employees, consultants, and members of our board of directors. We account for stock-based compensation in accordance with ASC Topic 718, </font><font style="font-style:italic;letter-spacing:0.2pt;">Compensation&#8212;Stock Compensation</font><font style="letter-spacing:0.2pt;">. Stock-based compensation expense is measured based on the fair value of the awards as of the grant date and is recognized as expense over the requisite service period, which is generally the vesting period. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The fair value of stock option awards as of the date of the grant is estimated by applying the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. These assumptions include the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair value per share of the underlying stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As our common stock is not publicly traded, the fair value of the common stock underlying our stock options is determined by our board of directors, with input from management and valuation reports prepared by third-party valuation specialists as described below under &#8220;&#8212;Common Stock Valuations.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected price volatility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As we are not a publicly traded company, the expected price volatility for our stock options is determined by using an average of historical volatilities of selected industry peers deemed to be comparable to our business and corresponding to the expected term of the awards. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-free interest rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for U.S. treasury notes with maturities corresponding to the expected term of the awards. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The expected term of stock options represents the period of time over which the options granted are expected to remain outstanding and is based on our estimate, taking into consideration vesting terms, contractual terms, and historical actual lives. Options granted have a maximum term of 10&#160;years. Due to the lack of historical option exercise data, we utilize the simplified method for determining the expected term. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected dividend rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividends, and we do not intend to pay any cash dividends in the foreseeable future. Therefore, we use an expected dividend yield of zero&#160;percent. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected forfeitures.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is based on historical forfeitures and is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may refine our estimation process, which could materially impact our future stock-based compensation expense. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we expect to incur approximately $28.9 million of stock-based compensation expense related to RSUs granted through March&#160;31, 2025, for which the performance-based vesting condition will be satisfied in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock Valuations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, given the absence of a public trading market for our common stock, and in accordance with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </font><font style="font-style:italic;letter-spacing:0.2pt;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font><font style="letter-spacing:0.2pt;">, our board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of our common stock at each grant date, including: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">independent third-party valuations of our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the prices of recent issuances of convertible preferred stock by us to investors in arm&#8217;s-length transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rights, preferences, and privileges of our convertible preferred stock relative to our common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our performance and market position relative to comparable publicly traded companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the likelihood and timing of achieving a liquidity event, such as an initial public offering or sale of our company, given prevailing market conditions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our developments and milestones; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our current business conditions and projections; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:3.82pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.82pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the lack of marketability inherent in our common stock; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the general economic outlook and global economic trends. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In valuing our common stock, the fair value of our business, or enterprise value, was determined using the market approach and/or income approach. The market approach estimates value based on a comparison of the subject company to comparable public companies in a similar line of business. From the comparable companies, a representative market value multiple is determined and then applied to the subject company&#8217;s financial results to estimate the value of the subject company. The precedent transaction method, a form of the market approach that derives the implied equity value from the recent issuance of stock by the subject company, was also utilized when appropriate. The income approach estimates value based on the expectation of future cash flows, which are then discounted to present value. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For each valuation, the equity value, which is calculated as the enterprise value, adjusted for cash and debt, was then allocated to the common stock using the option pricing method (&#8220;OPM&#8221;) and/or the probability-weighted expected return method (&#8220;PWERM&#8221;). The OPM allocates the equity value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy, and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including the likelihood and potential timing of various discrete future liquidity scenarios, such as an initial public offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Application of these approaches involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding our expected future revenues, expenses, cash flows, discount rates and market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions, or the relationships between those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of our common stock. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following this offering, it will not be necessary to estimate the fair value of our common stock, as our shares of Class A common stock will be traded in the public market, and the fair value of our common stock will be based on the closing price of our Class A common stock as reported by Nasdaq. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Emerging Growth Company Status</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The JOBS Act permits an &#8220;emerging growth company&#8221; such as us to delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period for complying with new or revised accounting standards and, as a result, our results of operations and financial statements may not be comparable to those of companies that have adopted the new or revised accounting standards. We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have at least $1.235&#160;billion in total annual gross revenue; (2)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2 under the Exchange Act, which would occur if the market value of our Class A common stock held by non-affiliates exceeded $700&#160;million as of the last business day of the second fiscal quarter of such year; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;the last day of the fiscal year ending after the fifth anniversary of the date of the completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">See Note 2 of our consolidated financial statements included elsewhere in this prospectus for more information regarding recently issued accounting pronouncements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Quantitative and Qualitative Disclosures about Market Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Rate Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March&#160;31, 2025, we had cash, cash </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:348pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">equivalents, and restricted cash of $35.3 million, and short-term marketable securities of $2.2 million, consisting of interest-bearing money market accounts, for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and investments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our borrowings under the 2023 Term Loan Agreement also subject us to market risk associated with movements in interest rates associated with forward-looking three-month SOFR. We had $400.0&#160;million in variable rate debt outstanding as of March&#160;31, 2025. A hypothetical 100 basis point adverse movement in the interest rate would increase our annual interest expense by $4.0&#160;million. We hedge interest rate risk on $200.0 million of this variable rate debt with a purchased interest rate cap derivative that has a strike rate of 6.0%. We did not receive any settlement payments from the counterparty to the interest rate cap for the year ended December&#160;31, 2024 or the three months ended March 31, 2025. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Substantially all of our revenue is generated in the United States, and we do not believe we are currently subject to significant foreign currency risk. To date, foreign currency transaction gains and losses have not had a material impact on our operations, and we have not engaged in any foreign currency hedging transactions. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. We will continue to reassess our approach to manage risk relating to fluctuations in currency rates as our international operations grow.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17&#160;years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our platform is purpose-built to leverage the convergence of next-generation sequencing (&#8220;NGS&#8221;), artificial intelligence (&#8220;AI&#8221;) and machine learning (&#8220;ML&#8221;) technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, minimal residual disease (&#8220;MRD&#8221;) tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dysfunctionality at the molecular level underlies every chronic disease, and this dysfunction is now measurable using techniques such as NGS. Cells are embedded within highly complex biological networks that govern all aspects of life, including how these cells grow, divide, interact, and die. These biological networks and their inherent functions, as well as dysfunctions, are controlled and directed at the molecular level. The precise molecular origins or contributors to a given biological dysfunction, however, are often unknown, and a comprehensive molecular profile is necessary to determine these origins. The central dogma of molecular biology states that genetic information flows in one direction, from DNA, to RNA, to proteins. Our approach is designed to accurately capture the full breadth of the DNA and RNA coding information in cells as well as protein expression through immunohistochemical (&#8220;IHC&#8221;) tests, constructing a fulsome mosaic of disease, and ultimately unlocking the potential for precision medicine therapeutics to guide individualized patient diagnoses and treatment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe we are well-positioned to realize the full potential of our vision and optimally leverage our vast datasets due to the recent convergence of several advancements in biology, medicine, and technology: (1)&#160;the medical community&#8217;s understanding and appreciation of the molecular nature of cancer has accelerated in recent&#160;years, resulting in a continued increase in molecular profiling of different cancer types and stages; (2)&#160;NGS costs have declined, making NGS more accessible to the healthcare ecosystem; (3)&#160;cloud-computing architecture has enabled massive scalability, distributed real-time collaboration, and greater cost efficiency for the analysis of previously unmanageable amounts of data; and (4) AI and ML computational capabilities have advanced to allow more effective interrogation of large biological datasets. We believe that our early foresight to generate comprehensive data at scale over the past many&#160;years and build a robust, foundational infrastructure have uniquely positioned Caris to leverage the benefits of these biological and technological advances to deliver transformative and advanced innovations in precision medicine and patient care into the future. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. We provide whole exome sequencing (&#8220;WES&#8221;) (all 23,000 encoding DNA genes) and whole transcriptome sequencing (&#8220;WTS&#8221;) (all 61,000 RNA transcripts that encode proteins) on every eligible patient sample (a sample provided by ordering physicians that contains sufficient genetic material for profiling). Since launching our WTS solution in 2019 and WES solution in 2020, we have performed over 475,000 WES and WTS cases, which we believe is more than </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">any other company. We sequence at a sector-leading depth of coverage, which directly correlates with increased accuracy and detection of low frequency molecular markers of relevance. MI Cancer Seek, our FDA-approved companion diagnostic assay to identify cancer patients who may benefit from treatment with targeted therapies (a component of MI Profile), consistently reaches 1,500 times depth of coverage for clinically relevant DNA genes, which is a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage, and 300 times depth of coverage for the whole exome. Caris Assure features a raw average sequencing depth of 8,000 times for clinically relevant genes, similarly a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage. We generate tens of billions of datapoints per clinical case to reveal an individualized molecular blueprint of the patient&#8217;s disease. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. To our knowledge, we remain the only genomic profiling company to consistently utilize WES and WTS as standard practice on every eligible patient sample. We also evaluate protein molecular markers through an extensive menu of IHC tests performed in a tumor-type specific manner, which in combination with WES and WTS, provide a comprehensive view of a patient&#8217;s disease. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology, including genomic data, clinical data, digitized slide images, and remnant tissue. As of March 31, 2025, we have run more than 6.5&#160;million tests on over 849,000 cases, which have generated measurements of over 38&#160;billion molecular markers. Leveraging high-powered computing and AI/ML algorithms, we, and our biopharma and research partners who use our data and bioinformatics services, analyze our datasets to determine the key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible. In 2018, our clinical case volume was approximately 29,000 cases, increasing to approximately 43,000 cases in 2019, approximately 60,000 cases in 2020, approximately 75,000 cases in 2021, approximately 97,000 cases in 2022, approximately 129,000 cases in 2023 and approximately 163,000 cases in 2024. Our clinical case volume for the first quarter of 2025 was approximately 45,900 cases, representing 31% year-over-year growth from approximately 34,900 clinical cases in the first quarter of 2024. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our molecular profiling solutions and the data generated by our multi-omic technology platform provide value to our more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines. In addition to biopharma, we leverage our datasets to partner with outside academic centers and researchers to further advance precision oncology research. The Caris Precision Oncology Alliance (&#8220;Caris POA&#8221;), which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. As of March 31, 2025, the Caris POA was comprised of 96&#160;members, including 45&#160;National Cancer Institute (&#8220;NCI&#8221;)-designated comprehensive cancer centers. This academic-industry collaborative network has been exceptionally productive with over 145 peer-reviewed manuscripts published since the beginning of 2022. Close connectivity with this vast network of key opinion leaders (&#8220;KOLs&#8221;) in oncology clinical care, research, and drug development has enabled us to remain at the forefront of precision oncology and closely attuned to the key needs of the most sophisticated researchers. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. This continuous feedback loop enabled us to develop Caris Assure, which utilized genomic data generated by MI Profile to inform our blood-based bioinformatics algorithms, allowing us to detect previously unknown features and signals in the blood that provide advanced insights into disease development. We believe we will be able to further leverage this process to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our global annual clinical case volume has been growing rapidly, with year-over-year growth of 29% in 2022, 32% in 2023, 26% in 2024, and 31% in the first quarter of 2025, primarily driven by MI Profile. With our broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and the FDA approval of MI Cancer Seek as a companion diagnostic in the fourth quarter of 2024 followed by the broad commercial launch of MI Cancer Seek in the first quarter of 2025 as the NGS component of MI Profile, we believe that increased profiling volumes will meaningfully contribute to our growth in 2025 and beyond. For the&#160;years ended December&#160;31, 2024 and 2023, we generated total revenue of $412.3&#160;million and $306.1&#160;million, respectively. For the three months ended March&#160;31, 2025 and 2024, we generated total revenue of $120.9 million and $80.7 million, respectively. We have incurred net losses and negative cash flows from operations since inception. For the years ended December&#160;31, 2024 and 2023, we incurred net losses of $257.1&#160;million and $341.4&#160;million, respectively. For the three months ended March&#160;31, 2025 and 2024, we incurred net losses of $102.6 million and $111.0 million, respectively. Our Adjusted EBITDA was $(189.6)&#160;million and $(255.3) million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. Our Adjusted EBITDA was $(36.2)&#160;million and $(70.1)&#160;million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding Adjusted EBITDA, a non-GAAP financial measure, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Non-GAAP Financial Measures.&#8221; We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million, $276.1 million, $31.3 million, and $73.9 million for the years ended December&#160;31, 2024 and 2023 and the three months ended March&#160;31, 2025 and 2024, respectively. Our free cash flow was $(253.6)&#160;million and $(298.4)&#160;million for the years ended December 31, 2024 and 2023, respectively, and $(34.0) million and $(75.7) million for the three months ended March&#160;31, 2025 and 2024, respectively. For additional information regarding free cash flow, a non-GAAP financial measure, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Non-GAAP Financial Measures.&#8221; Additionally, as of March&#160;31, 2025, we had cash, cash equivalents, and short-term marketable securities of $33.4 million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million. For additional information regarding our liquidity and capital resources, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Industry</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cancer is a Large and Growing Disease State with a Significant Human Cost and Economic Burden on Society</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Addressing the complexity of cancer remains a major challenge in healthcare and a critical area of unmet medical need, despite enormous investments in research and development (&#8220;R&amp;D&#8221;), and the introduction of new oncology therapeutics and treatments. According to the Centers for Disease Control and Prevention, cancer is the second leading cause of death in the United States, exceeded only by heart disease. The American Cancer Society (the &#8220;ACS&#8221;) reports that in January&#160;2022, there were more than 18&#160;million Americans with a history of cancer and that approximately two million new cancer cases will be diagnosed in 2024 in the United States. Furthermore, approximately 611,720 Americans are expected to die of cancer in 2024. The International Agency for Research on Cancer predicts that the annual global burden of cancer will reach 35&#160;million new cases and 18.5&#160;million cancer deaths by 2050. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The annual burden of cancer care in the United States was more than $200&#160;billion in 2020 and is expected to increase over the coming decades. According to an article published in JAMA Oncology, a peer-reviewed medical journal published by the American Medical Association (the &#8220;AMA&#8221;), it is estimated that the total cumulative global economic cost of cancer from 2020 to 2050 will be approximately $25&#160;trillion. Better information and solutions are needed to detect and treat cancer earlier and more effectively to improve lives and manage healthcare costs. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Central Dogma of Biology Drives the Fundamental Need for Comprehensive Molecular Information</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At its core, cancer represents the uncontrolled division and growth of the body&#8217;s cells. There are numerous biological processes in place for preventing the proliferation of cancerous cells. However, the failure of one or multiple genetic processes can lead to cancer. A cell is considered cancerous when it no longer responds to the body&#8217;s attempts to control its growth, function, and location due to abnormalities in its DNA. The central dogma of biology states that genetic information flows in one direction, from DNA, to RNA, to proteins. Thus, when present, DNA abnormalities in the exome, also referred to as genomic mutations, are transcribed into defective RNA in the transcriptome. This defective RNA, in turn, is translated into defective proteins, ultimately causing a cell to replicate uncontrollably or become cancerous. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The behavior of a specific cancer cell depends on which processes are not functioning properly. Oncogenes are genes that, when aberrantly active, cause a normal cell to become cancerous. Tumor suppressor genes must remain activated to prevent cancer; if deactivated, the cell proliferates uncontrollably. Many cancers begin with a few discreet genomic mutations, but additional mutations accumulate as the cells divide. In addition, chemical modifications to proteins post-production, known as post-translational modifications, can impact structure and function and may also result in uncontrollable cell growth. This dynamic range of potential mutations results in varying cancer types. For example, some cancer cells may simply divide and produce more cancer cells locally, while other cancer cells may invade normal tissue, enter the bloodstream, and metastasize to a remote site in the body. Given the complexity of a cancer&#8217;s origin and drivers, we believe comprehensive molecular information incorporating DNA, RNA, and protein profiles provides the most robust picture of a patient&#8217;s disease and potential treatment pathways. The below graphic depicts the central dogma of molecular biology and the profiling technology that can be used to capture the relevant molecular information at each step. </font>
        </div>
        <div style="position:relative;margin-top:7.71pt; text-align:center; width:456pt;">
          <img src="fc_centraldogma-4c.jpg" alt="[MISSING IMAGE: fc_centraldogma-4c.jpg]" height="198" width="580" >
        </div>
        <div style="margin-top:16.4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Technological Advancements have Ushered in a Molecular Revolution in Precision Oncology</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The molecular revolution is upending the traditional paradigm of complex workflows of diagnosis, treatment, and monitoring of diseases, which largely uses a symptomatic, reactive approach to medicine. For example, early detection of cancer has traditionally been performed using a myriad of different non-molecular tests, including mammograms for breast cancer, colonoscopy and fecal immunochemical test for colorectal cancer, pap test for cervical cancer, and low-dose computed tomography (&#8220;CT&#8221;) scan for lung cancer. Despite these techniques, cancers can still go undetected as many of these tests can be subject to interpretative bias or risk of inaccurate results. Further, prior to the use of genetic biomarkers for the treatment of cancers, all cancer patients were treated with generic chemotherapies with a broad applicability, often resulting in lower efficacy. Comprehensive molecular profiling is augmenting these different testing modalities by introducing streamlined workflows and replacing the patchwork of tests currently in use, using a small sample of the patient&#8217;s tissue or blood. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Molecular profiling in oncology began with single-gene testing focused on individual genes in an attempt to match patients with effective targeted therapies. With the declining cost of sequencing and growing number of targeted therapies, profiling evolved to include targeted testing focused on a small number of identified gene alterations correlated with effective targeted therapies and further expanded to include profiling using 500 to 1,000 gene panels. These targeted profiling methods are now acknowledged as being inefficient in the use of limited tumor tissue, as they generate a sub-optimal and incomplete amount of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:145pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">molecular information. For example, a study titled &#8220;Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients&#8221; published by authors associated with Memorial Sloan Kettering Cancer Center in New York in June 2017 in the scientific journal, </font><font style="font-style:italic;letter-spacing:0.2pt;">Nature Medicine</font><font style="letter-spacing:0.2pt;">, found that &#8220;hotspot&#8221; panels can miss 81% of actionable mutations in refractory cancers. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Over the last several decades, significant advances in genomics, proteomics, molecular technology, and computing power have enabled a comprehensive, multi-omic approach to the molecular profiling of diseases, both efficiently and at scale. Innovations in genomic sequencing and computing power have revealed deep insights into the cellular pathways and molecular nature of all types of cancer, heralding a new era of precision oncology. For example, a 2004 study published in Nature Reviews Cancer identified approximately 300 genes as being linked to cancer; a 2022 Genome Biology study identified approximately 3,350 genes were well-known or predictive drivers of cancer; and a 2022 Trends in Genetics analysis showed that of the approximately 17,300 human genes with at least one paper in PubMed, approximately 15,200 have at least one paper mentioning cancer. Precision oncology is defined as the use of molecular profiling&#8212;including analysis of DNA, RNA, and proteins&#8212;to identify a cancer&#8217;s alterations that can be targeted with specific therapies. NGS, the most advanced high-throughput sequencing method, has far surpassed other techniques used to analyze tumors and has become a cornerstone of precision oncology. This is due in large part to the genomically-driven nature of cancer, as well as the continued ongoing steep declines in the cost of sequencing over the last 30&#160;years and technology advances in speed and accuracy, which have made NGS far more available in the clinical setting. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The treatment paradigm for oncology continues to evolve with molecular medicine practiced across the entire continuum of the disease course: from using blood-based testing to detect cancers at its earliest stages; to the determination of whether a patient is at a high-risk of relapse after completing therapy; to the advanced/metastatic setting where molecular profiling is used to guide therapy interventions. Large scale studies interrogating cancers using NGS have led to the identification of thousands of biomarkers. Oncology therapeutics are now increasingly biomarker-driven targeted therapies. Over 100 biomarker-assisted therapeutics have been approved in the United States, and numerous clinical trials are currently in progress. In addition to being predictive markers for patients likely to benefit from certain treatments, biomarkers may also be used as diagnostic indicators of the presence or type of cancer, as prognostic indicators for patient outcomes, or as tools to monitor therapy response, residual disease, or recurrence. </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The information provided by comprehensive molecular profiling is driving a revolution in medicine, where molecular information is used to guide individualized patient diagnoses and treatment. Beyond oncology, this precision medicine approach has applications across a wide range of broad disease areas including cardiology, neurology, and metabolic conditions, among other chronic diseases. </font>
        </div>
        <div style="margin-top:3pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Importance of Comprehensive Molecular Profiling</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Comprehensive molecular profiling provides greater clinical and economic value than traditional targeted panel testing approaches. Comprehensive molecular profiling entails evaluating thousands of potential biomarkers, including DNA, RNA, proteins, and other molecular and clinical information for characteristics unique to a particular patient&#8217;s disease. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:13pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;min-height:322pt;margin-top:0pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="height:17.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:4.5pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">Case Study: Advancing Cancer Treatment with Caris Molecular Profiling </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:63pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Caris was presented with the case of a female patient in her early 50&#8217;s with a history of Stage I endometrial cancer. Her oncologist discovered a softball-sized tumor in her ovary. After undergoing a biopsy, it was determined to be late-stage ovarian cancer, which had metastasized into surrounding tissues and her bowels. She underwent immediate surgery to remove her ovaries and 18 inches of her sigmoid colon and began a standard chemotherapy regimen. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:75pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite the surgery and three rounds of chemotherapy, the cancer grew back within three&#160;months, now spreading into the patient&#8217;s lymph nodes. Her oncologist recognized the urgency of her situation and sent the patient&#8217;s tumor biopsy to Caris for molecular testing, noting additional rounds of chemotherapy would not be beneficial. The profiling using our MI Profile solution revealed the tumor was microsatellite instability-high, indicating responsiveness to immunotherapy and supporting her oncologists&#8217; prior suspicion of Lynch Syndrome, also known as hereditary nonpolyposis colorectal cancer (&#8220;HNPCC&#8221;). </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:63pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HNPCC is caused by mutations in genes responsible for DNA mismatch repair (&#8220;MMR&#8221;), leading to an accumulation of errors in DNA replication and an increased risk of cancer development. Individuals with HNPCC have a higher lifetime risk of developing various cancers, particularly colorectal and endometrial. Identifying it in patients can help guide screening and surveillance efforts to detect cancers at an early, more treatable stage, as well as inform preventive measures to reduce cancer risk for their families. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:75pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With the guidance of molecular profiling results, the patient commenced immunotherapy treatment, leading to remarkable results. Within three&#160;months, her tumor disappeared, and the cancer in her lymph nodes significantly regressed. The patient went from having no real treatment options to having multiple with the use of comprehensive profiling, and to our knowledge remains cancer-free. Additionally, the identification of Lynch Syndrome is invaluable in guiding screening and surveillance for her children and grandchildren. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:29.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;border-bottom:0.75pt solid #000000; ;padding:2pt 0pt 6pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This transformative outcome underscores the importance of comprehensive profiling in tailoring treatment strategies based on individual genetic profiles.</div>
            </td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.5pt; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">The Importance of WES/WTS</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">DNA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">Mutations and copy number alterations (variations) can be detected using the polymerase chain reaction (&#8220;PCR&#8221;) or NGS, while DNA methylation is analyzed using PCR or pyrosequencing, which is a method for sequencing short stretches of DNA on the basis of the detection of pyrophosphate. DNA sequencing can be performed for an entire genome, exome, or, as in the case of targeted panels, within specific regions containing common cancer-associated alterations. NGS-based targeted panels are currently FDA-approved for several tumor types. These targeted panels identify known alterations in key cancer genes but do not provide a comprehensive overview of a tumor&#8217;s molecular makeup. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">RNA</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">While mutations detected in DNA may be silent (not expressed) and therefore of little clinical relevance, those in RNA are one step closer to producing an abnormal protein. RNA is also needed to understand gene expression and splice variants through </font><font style="font-style:italic;letter-spacing:0.2pt;">in situ</font><font style="letter-spacing:0.2pt;"> hybridization and RNA sequencing. RNA sequencing provides information that DNA cannot and is superior for detecting expressed fusions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">As with DNA, RNA sequencing can be performed for one, multiple, or all transcribed genes, in either targeted areas or the full transcriptome. Transcriptome analysis using NGS generates information on splice variants and gene fusions, including fusions not previously described. This information can help define molecular signatures, stratify risk, and guide targeted therapy use. In combination with WES, WTS provides information on all expressed genes, thereby detecting alterations that can be targeted with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;min-height:247pt;margin-top:0pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="height:17.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:4.5pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">Case Study: The Importance of RNA Profiling </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:51pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Caris was presented with the case of a teenaged boy diagnosed with high-grade astrocytoma, a type of brain tumor. Two&#160;years prior, the patient&#8217;s oncologist had ordered DNA-only profiling from another provider who did not identify any actionable mutations in the patient&#8217;s DNA. As a result, the patient was placed on a standard chemotherapy regimen. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:63pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon recurrence of the tumor two&#160;years later, the oncologist ordered genomic testing from the same provider, who again did not identify any actionable mutations in the DNA. The patient began radiation therapy. Despite the initial profiling attempt and results, the tumor&#8217;s recurrence necessitated further investigation, leading the patient&#8217;s healthcare team to seek out more comprehensive testing with Caris. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:63pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Caris WES/WTS report revealed a significant finding: an FGFR fusion, which is a genetic alteration that can disrupt normal cell signaling and lead to cancerous cell growth, found in the patient&#8217;s RNA. Despite the challenges posed by the tumor&#8217;s recurrence, Caris&#8217; ability to detect this actionable variant offered hope for potential targeted therapies, including the National Cancer Institute-Children&#8217;s Oncology Group Pediatric MATCH trial* for pediatric patients with advanced, recurrent solid tumors. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:53.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;border-bottom:0.75pt solid #000000; ;padding:2pt 0pt 6pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This case demonstrated the critical role of comprehensive molecular profiling of both the DNA and RNA. By leveraging advanced testing methodologies such as WES and WTS, the provider was able to uncover potentially life-saving treatment options for this patient facing a challenging diagnosis,high-grade astrocytoma.</div>
            </td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:36pt; margin-top:11.2pt; width:420pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Signatures</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to individual gene alterations, profiling can provide information on specific patterns or combinations of molecular features that might otherwise be challenging to detect. These molecular signatures may be associated with particular cancer types, prognoses, or therapeutic responses. Examples of molecular signatures include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">TMB</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;TMB is a measurement of the number of somatic mutations per megabase of DNA sequenced. A high TMB is used as a biomarker for the selection of certain checkpoint inhibitors to treat solid tumors. WES is the gold standard for measuring TMB as it covers the entire coding region of the genome. Measurements derived from targeted panels or comprehensive genomic profiling, on the other hand, vary significantly from panel to panel due to variable and incomplete coverage. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Microsatellite instability (&#8220;MSI&#8221;)</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;MSI testing measures the ability of a cell to repair mistakes in DNA replication. Defective mismatch repair caused by alterations in mismatch repair genes is associated with elevated mutation rates in areas where short DNA sequences of base pairs are repeated. These areas are referred to as microsatellites. MSI analysis can identify candidates for immunotherapy or MSI-indicated clinical trials and diagnose Lynch Syndrome in colon and endometrial cancers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Genomic loss of heterozygosity (&#8220;gLOH&#8221;)</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Loss of one copy of a genomic region, known as gLOH, may cause tumor suppressor gene inactivation, thereby promoting cancer development. gLOH is indicative of a form of defective DNA repair called homologous recombination deficiency. When a tumor exhibits DNA repair mechanism impairment, drugs targeting a secondary repair pathway can kill tumor cells without harming normal cells, a phenomenon called synthetic lethality. Thus, gLOH is a biomarker for therapeutic response to poly adenosine diphosphate-ribose polymerase (&#8220;PARP&#8221;) inhibitors which target the single-strand break DNA repair pathway. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Homologous recombination deficiency (&#8220;HRD&#8221;)</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Related to gLOH, inefficient repair of damaged DNA via homologous recombination can contribute to the development of cancer. HRD often results from aberrations in key DNA repair genes, including BRCA1 and BRCA2 genes, ataxia telangiectasia mutated (&#8220;ATM&#8221;), PALB2, and CHEK2, and is associated with increased sensitivity to PARP inhibitors, as above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">https://www.cancer.gov/about-cancer/treatment/nci-supported/pediatric-match</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:1.97000000000003pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">WES/WTS Offers a Complete Molecular Blueprint from the Beginning and Provides Value across the Patient Journey</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">WES/WTS streamlines the patient experience and clinical decision-making and offers increased value to patients, physicians, and payers. We believe WES/WTS provides the most efficient and cost-effective way to obtain the maximum information on a patient&#8217;s cancer at the start of the patient journey, potentially identifying additional mutations and expanding treatment options compared to sequential targeted panels. Through the use of WES/WTS, we believe we have significantly reduced the need for a trade-off between time and information, two valuable resources in oncology that have historically come at the expense of one another, particularly when relying on sequential targeted panels, due to cancer&#8217;s rapidly progressive nature. In a single test, we believe WES/WTS provides substantially all the relevant information needed for physicians to make the best-informed clinical decisions for their patients and does so in less time than running multiple DNA or RNA single or targeted panels sequentially. While using comparable tissue, WES/</font>&#8203;<font style="letter-spacing:0.2pt;">WTS enables accurate identification of a greater number of actionable genomic alterations that can be leveraged to match patients to the most effective treatments, yielding a higher probability of response and providing comprehensive predictive and prognostic information. Furthermore, the benefits conferred by WES/</font>&#8203;<font style="letter-spacing:0.2pt;">WTS have the potential to extend across the healthcare ecosystem, beyond patients and their clinicians. By supporting WES/WTS, payers can reduce waste and harm from suboptimal treatment selection and resulting over-treatment and/or misdiagnosis. </font></div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">WES/WTS can also inform on acquired resistance to treatments and suggest potential synergistic therapy combinations, as well as providing substantial clinical benefit to patients with cancer of unknown origin or rare cancers. Additionally, by taking a tumor-agnostic approach compared to using tumor-specific panels, WES/WTS can detect biomarkers that have targeted therapies in other cancer types, indicating the potential to apply those drugs more broadly. Armed with these molecular insights, clinicians can identify the most suitable therapies and trials available to their patients today. Having a full molecular blueprint </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> also facilitates future use of newly approved biomarkers and therapies. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We also operate a Look Back Program that leverages our comprehensive WES/WTS to provide long-term clinical insights that help oncologists optimize patient care and identify patients that may be eligible for newly approved biomarker-driven therapies without the need for additional testing. When a novel therapy receives approval, our team reviews all of our recent clinical sequencing results to identify previously tested patients who sequencing results match the new therapy&#8217;s criteria. Through our molecular science liaisons (&#8220;MSLs&#8221;), we then contact treating physicians to ensure they are aware of these newly approved treatment options for their patients. Many clinicians may not be aware of evolving biomarker-driven therapies, and our Look Back Program bridges this gap by providing updated insights. By conducting comprehensive molecular testing upfront, the need for repeat testing is significantly reduced when new drug approvals or indications arise. This ensures timely treatment decisions, increasing the likelihood of patients receiving effective, biomarker-driven therapies. Through the Look Back Program, Caris empowers oncologists with continuous, data-driven insights that enhance patient outcomes and drive precision oncology forward. Since 2023, we have used this program to identify 556 patients that may benefit from Trastuzumab and Teucatinib for HER2+/KRAS wildtype colorectal cancer, 134 patients that may benefit from Talazoparib + Enzalutamide HRR deficient prostate cancer, 233 patients that may benefit from Reptrectinib for cancers with NTRK gene fusions, 1,737 patients that may benefit from Capivasertib for PIK3CA, AKT1 or PTEN-mutated HR+/HER2- breast cancer and 78 patients that may benefit from Zenocutuzumab for cancers with NRG1 fusions and 1,847 patients that may benefit from Trastuzumab Deruxtecan for Her2 Score 0 HR+ breast cancer. We have not broadly marketed our Look Back Program, but we use it in payer-facing materials to highlight the advantages of our WES/WTS platform. </font>
        </div>
        <div style="text-indent:36pt; margin-top:5pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Aside from its clinical benefits, WES/WTS is also a powerful research tool for identifying new predictive biomarkers. For example, pancreatic ductal carcinoma currently has the worst prognosis among common cancers&#8212;a situation compounded by a scarcity of predictive biomarkers and therapeutic targets. In a recent study, a comprehensive profiling approach involving WES and WTS sequencing was used to identify novel potential markers and targets for this cancer. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:36pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below compares targeted panels with WES/WTS. </font>
        </div>
        <div style="position:relative;margin-top:10.3pt; text-align:center; width:456pt;">
          <img src="tb_panels-4c.jpg" alt="[MISSING IMAGE: tb_panels-4c.jpg]" height="451" width="603" >
        </div>
        <div style="margin-top:17.59pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Convergence of NGS, AI/ML Technologies, and High-Performance Cloud Computing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">NGS can generate vast amounts of genomic data. The availability of large libraries of molecular data for each individual patient is creating exciting opportunities for research in the diagnosis, treatment, and early detection of cancer, especially when paired with a patient&#8217;s clinical data. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AI can be used to mine these large volumes of data to address complex biological questions and has the potential to deliver new insights and bring precision medicine into mainstream clinical care. ML is an AI approach that focuses on applications that learn from experience and large amounts of data to improve decision-making and predictive accuracy over time. While this is a promising field of research and clinical activity, there are significant challenges to achieving the promise of AI in cancer&#8212;specifically, generating accurate and broad molecular information to underpin algorithms. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accuracy of predictions made by AI/ML algorithms is highly dependent upon the accuracy and breadth of the underlying data used for training the AI/ML algorithms, analytically validating those algorithms, and applying the algorithms on real world data to make predictions. The accuracy of NGS-based genomic data is highly correlated to the depth of coverage of sequencing of the samples. Depth of coverage refers to the number of times a nucleotide is sequenced. A greater depth of coverage increases the confidence in the final results and allows for differentiation between sequencing errors and single nucleotide polymorphisms. A high depth of coverage is especially useful when a tumor is heterogeneous for specific mutations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ability to conduct research on genomic data using AI is also highly dependent on the number of genes being tested. Complex diseases are the result of multiple genomic alterations including point mutations, translocations, amplifications, and/or deletions. Cancers with more malignant properties and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">poorer prognosis are generally associated with larger numbers of genomic alterations. To accurately conduct research using AI, a large number of genes need to be tested and included in a given data set. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cloud-computing architecture has enabled massive scalability and distributed real-time collaboration across industries. In addition, it has created opportunities for greater cost efficiency for the storage, processing, and analysis of previously unmanageable amounts of data. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Caris platform was purpose-built to leverage the convergence of NGS, AI and ML technologies, and high-performance computing. </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="pc_unique-4c.jpg" alt="[MISSING IMAGE: pc_unique-4c.jpg]" height="434" width="578" >
        </div>
        <div style="margin-top:17.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations of Molecular Testing Today</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While the molecular revolution has already changed the way cancer is being diagnosed and treated, we believe that molecular testing faces several major challenges in its current form, which have hindered broader adoption of precision oncology. These challenges include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Targeted panels are subject to missing information and significant variability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Targeted panels test for only a small portion of all cancer-associated genomic alterations. As a result, they can miss critical clinically actionable information. This information deficit can lead to suboptimal treatment decisions and/or the need for further testing, requiring increased patient sample, time, and expense. Further, the treatment landscape in oncology continues to rapidly evolve, with new agents and their cognate predictive biomarkers entering clinical trials and achieving regulatory approval. This renders targeted panels insufficient to account for newly implicated cancer genes absent re-development and validation of such panels. Using broad sequencing approaches with WES and WTS enables comprehensive identification of information to effectively treat a patient. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Lack of consistent RNA profiling.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;RNA, which is transcribed from DNA, can better represent which genes are actively involved in cancer. By including both DNA and RNA </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">coverage, we believe Caris captures more tumor-informed information than others in the market, leading to more accurate and comprehensive molecular profiling results for the physician and patient. This approach includes enhanced sensitivity for gene fusions with the incorporation of RNA, as well as the deployment of multi-gene signatures that use RNA to support predictive and prognostic endpoints. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Lack of clonal hematopoiesis derived variant subtraction technology in current blood assays.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Blood is comprised of two major components that are pertinent to patient testing: plasma and the buffy coat (a concentration of white blood cells). Most liquid biopsy providers analyze only the plasma. This is suboptimal as a plasma-only approach is unable to identify false positive mutations derived from clonal hematopoesis (&#8220;CH&#8221;) variants and that are not tumor-derived. CH mutations are common aging-related non-malignant mutations that occur in a substantial portion of the population and are not drivers of solid tumors but contribute to the formation of a genetically distinct subpopulation of blood cells. If CH mutations are not distinguished from tumor-derived mutations, it can lead to therapy selection targeted at a mutation that is present in the white blood cells instead of in the tumor, which is not beneficial for the cancer patient. Because of the prevalence of CH mutations, we believe that CH subtraction is of critical importance to optimal cancer care. Other liquid biopsy tests currently on the market cannot definitively distinguish CH mutations from tumor-derived mutations because they do not sequence the white blood cells. Caris Assure incorporates CH subtraction, resulting in fewer false positives and representing a differentiated ability to drive improved and more effectively targeted therapy selection. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Disparate data sets collected across testing modalities.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Currently, liquid biopsy providers do not offer a single blood-based testing solution across the continuum of cancer care. Instead, the use of different assay technologies across different applications and settings results in the accumulation of non-uniform data sets, which are difficult to leverage and interpret across a patient&#8217;s comprehensive care journey. We utilize a novel approach consisting of a single wet-lab test across the cancer treatment continuum, with consistently-generated uniform datasets. The elegant simplicity of a single test paired with a comprehensive assessment of the patient&#8217;s DNA and RNA allows Caris Assure to be this integrated diagnostic solution. This approach allows many more datapoints to be assessed, enabling us to select those markers that we believe provide the greatest potential for sensitivity, specificity, and overall accuracy of our test and capture the dynamic nature of biological processes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Logistical drawbacks and sensitivity limitations of current MRD assays.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;There are several limitations with current MRD approaches. Traditional tumor-informed approaches struggle with logistical drawbacks, which include needing to sequence primary tumor tissue first and experiencing long turn-around times due to the creation of a bespoke panel. Further, current tumor-informed MRD tests also limit their sensitivity by the small number of tracker mutations utilized. Because sensitivity is proportional to the numbers of tumor-derived alterations that are tracked over time, limiting to a small number of mutations artificially limits sensitivity. Currently deployed tumor-na&#239;ve approaches, while logistically superior, also limit their sensitivity by using a targeted panel of genes and do not encompass the myriad of tumor-derived signals present in the circulation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">False positives and a lack of early-stage sensitivity with current multi-cancer early detection assays.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Multi-cancer early detection (&#8220;MCED&#8221;) testing holds significant promise to make improvements in overall survival by detecting cancers at their earliest stages when they are most treatable. However, significant limitations exist with current assays. Their high rate of false positives when used in an average-risk population is notable. This leads to unneeded and costly diagnostics, such as imaging and biopsies. Also, a lack of early-stage sensitivity for many tumor types inhibits current MCED testing assays&#8217; clinical utility. As seen in our data, the use of Caris Assure and our Assure Blood-based Cancer Detection ai (&#8220;ABCDai&#8221;) algorithm leverages detection of a wide swath of cancer-derived analytes, resulting in significantly higher Stage I/II sensitivity while mitigating false positives by maintaining high specificity. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a result of these challenges, clinicians may make critical treatment decisions based on incomplete and/or inaccurate information and analytics, potentially resulting in suboptimal outcomes. We believe that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">our comprehensive molecular profiling solutions and the data generated by our multi-omic technology platform is well-suited to address the limitations and challenges of today&#8217;s molecular testing alternatives. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Market Opportunity and Vision for Leveraging Molecular Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe we are well-positioned to pursue a very large market opportunity through the provision of precision medicine solutions across the entire cancer care continuum, as well as offerings to support biopharma drug discovery and development. Broad, deep, and consistent molecular information is expected to drive better clinical outcomes for patients and more efficient and effective drug discovery and development for biopharma companies. We believe our expansive multi-omic technology platform has application across multiple clinical and biopharma settings that collectively represent an estimated total addressable U.S. market of approximately $150&#160;billion in oncology, according to a market study by Nephron Research LLC (&#8220;Nephron Research&#8221;) that we commissioned. </font>
        </div>
        <div style="position:relative;margin-top:10.99pt; text-align:center; width:456pt;">
          <img src="pc_unlocking-4c.jpg" alt="[MISSING IMAGE: pc_unlocking-4c.jpg]" height="439" width="585" >
        </div>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Early Detection of Cancer in the Asymptomatic Population</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The availability of an MCED blood-based profiling solution offers the potential to augment and disrupt the standard of care in preventative cancer screening. Preventative cancer screening today is limited to a small group of high prevalence cancers, including cervical, breast, colon, lung, and prostate cancers. Low adherence rates are common among patients with several of these cancers due to challenges related to socioeconomic status, age, personal attitudes and beliefs, awareness gaps, and lack of access to healthcare facilities and social support, among other factors. For example, the American Lung Association estimates that in 2021, there were approximately 14&#160;million high-risk individuals in the United States who were eligible for lung cancer screening using low-dose CT scans yet only approximately 0.6&#160;million screenings were completed, representing a dismal screening recommendation adherence rate of 4.5%. An MCED blood-based profiling solution that entails a minimally invasive blood draw could expand the reach of testing to more cancers and drive higher adoption in this market. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe screening offers the greatest benefit for individuals aged 45 to 75&#160;years given the prevalence of cancer and potential for improved outcomes and reduction in cancer mortality within the U.S. population. Based on U.S. Census Bureau data, the 45 to 75&#160;years-old cohort who would benefit from screening for cervical, breast, colon, lung, and prostate cancers based on the recommendations of the U.S. Preventive Services Task Force (&#8220;USPSTF&#8221;), an independent body of experts that makes evidence-based recommendations for cancer screening, represents approximately 112&#160;million people in the United States. Clinical unmet needs in this population include low patient adherence, poor performance, and lack of screening options for a majority of cancer types. Access to liquid biopsies that are reliable and can detect multiple cancer types should drive greater access and penetration of the early detection market, with early detection liquid biopsy solutions supplementing or in certain instances replacing existing screening modalities. Based on the estimated size of the cohort of individuals aged 45 to 75&#160;years who would benefit from cancer screening per the above-referenced guidelines, and assuming pricing of at least $900 for a high-quality MCED liquid biopsy solution (based on cash pay pricing for existing available liquid biopsies), the estimated total addressable U.S. market for early detection of cancer using liquid biopsy is approximately $100&#160;billion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Therapy Selection for Cancer Patients</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patients with advanced and metastatic solid tumors are recommended to undergo molecular profiling to identify predictive markers for patients likely to benefit from certain approved biomarker-linked therapies. Molecular profiling of patients through either tissue biopsy or blood-based liquid biopsy allows physicians to identify a cancer&#8217;s targetable alterations. These molecular insights, particularly when generated through comprehensive molecular profiling, enable the tailoring of therapy to patients likely to benefit, while sparing exposure, toxicity, and cost for those who will not. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to the ACS, approximately 780,000 of the two&#160;million patients in the United States who are newly diagnosed with cancer each year are found to have advanced-stage solid tumor cancers at initial diagnosis. The ACS also estimates that there are 16.5&#160;million cancer survivors in the United States, approximately 4.3%, or 710,000, of whom are expected to relapse annually. Based on National Comprehensive Cancer Network (&#8220;NCCN&#8221;) guidelines suggesting that breast and lung cancer patients would benefit from at least two tests during therapy, and assuming that these benefits would apply to other types of solid tumors, Nephron Research estimates that approximately 520,000 newly-diagnosed advanced stage and recurrent cancer patients in the United States would benefit from repeat testing. Additionally, turnaround time for a blood test is typically shorter, but tissue tests are often more comprehensive so physicians will often order both a tissue test and a blood test. Accordingly, based on the newly-diagnosed patient, recurrent patient, and repeat testing patient cohorts described above, Nephron Research estimates that the total addressable U.S. market for therapy selection is comprised of approximately two&#160;million unique patient profiles annually and, assuming an average reimbursement of approximately $4,000 based on blended Medicare, commercial payer, and Medicaid coverage rates for various genomic profiling tests, amounts to approximately $8&#160;billion. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">According to the Nephron Research analysis, the number of annual unique patient profiles is expected to increase with clinical and payer adoption of broad molecular testing in earlier stages for newly-diagnosed cancer patients. The study also suggests that a majority of the market is currently being tested by either single gene tests or targeted testing for a low number of biomarkers recommended under NCCN guidelines and is currently approximately 30% penetrated by broad molecular testing (both tissue and blood) using broad panels (50 or more genes). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Minimal Residual Disease Tracking and Treatment Monitoring for Cancer Patients and Survivors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">According to the ACS, approximately 1.3&#160;million of the 2&#160;million patients in the United States who are newly diagnosed with cancer each year are found to have non-metastatic cancer. We believe MRD tracking and recurrence testing is most applicable to patients within this cohort. Patients in the non-metastatic cancer cohort are expected to be monitored during their treatment journey and beyond for up to five&#160;years for recurrence, including MRD testing for patients who underwent surgery for their cancer. In addition, patients with metastatic cancer are expected to receive treatment monitoring tests during their treatment journey. According to the Nephron Research analysis, these result in a cohort of approximately 5.6&#160;million patients being monitored at various points in their treatment journey. Assuming a range of two to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">three tests annually for each patient, consistent with MolDX coverage policy for MRD, pricing of $2,500 per reference test and $1,650 per follow-up blood test, in each case based on pricing for other tests available on the market, Nephron Research estimates that the total addressable U.S. market for MRD tracking tests represents approximately 16&#160;million tests annually and amounts to approximately $28&#160;billion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Core Biopharma: Profiling Services for Biopharma Drug Development and Commercial Testing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Key services relevant for biopharma companies include prospective and retrospective profiling services, companion diagnostics development, and commercial services that include identification of patients for approved therapies. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to the Nephron Research analysis, oncology testing associated with clinical trials includes approximately 250,000 cancer patients in targeted therapy clinical trials. Assuming five tests (one therapy selection test to establish cancer type and determine the therapeutic intervention(s) and four monitoring tests for follow-up consistent with typical trial designs) for each trial participant and pricing of $5,000 per therapy selection test and $1,950 per monitoring test, based on existing reimbursement rates for other tests available on the market, Nephron Research estimates that the addressable U.S. market for oncology testing in clinical trials is approximately $3.2&#160;billion. The development of companion diagnostics tests and the identification of patients for commercial targeted therapies are both attractive opportunities for molecular information-based services. Assuming approximately&#160;25 Phase 1b trials progress to Phase 2 each year based on recent historical data from ClinicalTrials.gov, with each trial having two partners per customary industry practice (a&#160;specialty lab and a distributable kit) and an average contract price of $10 million based on Nephron Research&#8217;s market analysis, the addressable U.S. market for the development of companion diagnostics tests is estimated to be approximately $500 million. For rare biomarkers, biopharma sponsors generally will reimburse laboratories that can help identify patients as candidates for their therapeutics. Assuming a rate of rare mutation of 4.0% within the population of newly-diagnosed cancer patients in the United States with advanced-stage solid tumor cancers, based on data from the National Institutes of Health, and an average reimbursement per patient of $10,000 based on Nephron Research&#8217;s market analysis, the addressable U.S. market for commercial services that include identification of patients for approved therapies is estimated to be approximately $300&#160;million. Accordingly, the estimated total addressable U.S. market for core biopharma services is approximately $4.0&#160;billion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Data Services for Biopharma Research and Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Matched genomic data has demonstrated use cases for biopharma applications across discovery, drug development, and clinical trial execution. Biopharma companies leverage multi-modal genomic data, including data they license, to identify key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. The valuable insights provided by multi-modal genomic datasets help biopharma companies identify optimal patient populations for therapeutic development and also help inform trial design, validate biomarker strategies, and assess execution feasibility of oncology clinical trials. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to Evaluate Pharma, global spending on pharmaceutical R&amp;D by biopharma companies grew from an estimated $145 billion in 2014 to an estimated $262&#160;billion in 2023. According to the Nephron Research analysis, it is estimated that approximately $70 billion of the $262 billion spent in 2023 represented R&amp;D investments in discovery, pre-trial costs, and real-world evidence, areas where matched genomic data has demonstrated use cases for biopharma applications. We expect biopharma companies to continue increasing the allocation of their total R&amp;D investment towards multi-modal genomic data and bioinformatics services to increase efficiency and development success rates. Based on Nephron Research&#8217;s market analysis, approximately 14% of the estimated $70 billion in R&amp;D investments in 2023 was allocated towards such data and services, resulting in an estimated total addressable U.S. market for this opportunity of approximately $10&#160;billion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Disease States Beyond Oncology</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe there is a large market opportunity for our platform in other chronic disease states beyond oncology, including cardiology, neurology, and metabolic conditions. This begins with a fundamental premise that approaching blood-based disease detection with a comprehensive WES/WTS approach </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:224.69pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">enables examination of biomarkers that go beyond oncology. It is already well known that other disease states have blood-based genomic markers that can be used for diagnostic assessment. The increasing role of CH in cardiovascular disease and neurology further buttress this approach. In cardiology, the first natural bridge exists in the field of cardio-oncology where, for example, biomarkers to predict cardiotoxicity to commonly used therapies could be implemented to help mitigate adverse events. In addition, the deployment of cardiovascular disease risk based on CH mutations could be used to augment early detection efforts. In neurology, disorders such as Alzheimer&#8217;s or Parkinson&#8217;s disease are difficult to diagnose, as the same symptoms manifest in different combinations across different disorders. Symptoms of one condition may often be similar to that of another, leading patients down the path of a &#8220;diagnostic odyssey.&#8221; The diagnosis involves tests such as CT scan, electroencephalogram, magnetic resonance imaging, electromyography, nerve conduction velocity, positron emission tomography, angiogram, spinal tap, myelogram, neurosonography, and ultrasound, among others. Personalized medicine and targeted therapies do not exist today for CNS disorders, however there is general consensus that detecting symptoms early and intervening can slow the development of disease. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Caris Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are leading a molecular revolution and developing the latest generation of advanced precision medicine information solutions that we believe have applicability across the care continuum for a broad range of conditions. The fundamental differentiation of the Caris platform and our business model is the depth, breadth, and scale of data, including how that data is integrated vertically and horizontally across our business, as well as the resulting innovation which it fuels. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our multi-omic technology platform is built on the following pillars: (1)&#160;Caris Assure; (2)&#160;MI Profile; (3)&#160;Caris Discovery; (4)&#160;Caris Strategic Data; and (5)&#160;Caris Infrastructure. These five pillars are designed to work together to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. We believe this continuing cycle will deepen our competitive advantage and allow us to achieve meaningful innovation and business success in precision oncology, while illuminating a path to precision medicine for other chronic disease states, including cardiology, neurology, and metabolic conditions. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="pc_platform-4c.jpg" alt="[MISSING IMAGE: pc_platform-4c.jpg]" height="438" width="584" >
        </div>
        <div style="text-indent:36pt; margin-top:12.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our growth and competitive differentiation are driven by the five pillars of our platform, each of which are both a product of the upstream data and a foundation to further innovation and data generation across the platform: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Assure</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Our universal blood-based WES/WTS profiling solution is designed to deploy a single assay across the entire continuum of cancer care, including early detection, MRD tracking, therapy selection, and treatment monitoring, and generates over 42&#160;billion datapoints, spanning 168,000 molecular markers, per clinical case. We leveraged our experience and data from MI Profile to create Caris Assure, which enables us to understand how a patient&#8217;s disease started, what therapies the tumor may be sensitive to, how the tumor is transforming to resist therapies, and how best to control or cure the disease. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">MI Profile</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;Our tissue-based profiling solution for therapy selection includes our comprehensive WES/WTS profiling assay and IHC protein expression testing. Our WES/WTS profiling solution generates over 28.8&#160;billion datapoints, spanning 84,000 molecular markers, per clinical case. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Discovery</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;The combination of our data and our AI enables us to discover previously unknown drug targets for antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, and cell therapy. In addition, we believe Caris Discovery is well-positioned for neoantigen discovery for personalized therapy development given our ability to detect variants, insertions, and deletions by WES and to assess gene expression and detect fusions by WTS on every patient&#8217;s tumor. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Strategic Data</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;As of March 31, 2025, we have run more than 6.5&#160;million tests that have measured over 38&#160;billion molecular markers from over 13 quadrillion datapoints. To assist us with analyzing the data we generate, we utilize over 220 AI and AI/ML tools across our clinical testing, R&amp;D, and biopharma business. These tools include over 50 clinical sequencing </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">automation and variant calling AIs, over 100 RNA expression AI signatures, approximately 20 multi-omic AI/ML therapy response predictors, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/ML classifiers, and 12 AI/ML support tools. We have used our datasets to create many of these algorithms and signatures. The breadth and depth of our data assets, together with our demonstrated ability to use them to create algorithms and discover signatures, represent a deep competitive moat for us. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Infrastructure</font><font style="letter-spacing:0.2pt;">:&nbsp;&nbsp;&nbsp;We have a well-developed laboratory, R&amp;D, and sales infrastructure that we believe is foundational to our business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:72pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:92pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Operational Capacity</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We have substantial testing capacity, including over 275,000 square feet of space across four precision medicine laboratories with throughput capabilities of over one trillion reads per day generated by 50 NovaSeq sequencing systems. We believe this capacity provides us with ample capability to manage our current operations and future growth. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:72pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:92pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Research and Development</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We have a dedicated R&amp;D infrastructure, including a specialized laboratory and over 200 employees dedicated to R&amp;D efforts. In addition to our internal research, we regularly partner with outside academic centers and researchers. The Caris POA, which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that supports research partner engagement, collaboration opportunities, and the advancement of precision oncology research. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:72pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:92pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Commercial Channel</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;To support our sales activity and expansion, as of March&#160;31, 2025, we have assembled a targeted sales organization in the United States of over 270&#160;sales team members and nearly 50 highly trained Ph.D. or M.D. MSLs who focus on physician and provider education. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Caris Advantage</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our approach is differentiated and we have a competitive advantage because: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">We purpose-built our Caris platform to put the patient first and make comprehensive precision medicine a reality</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our patient-centric ethos has guided us since inception. This guiding principle underpins our belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights would realize the potential of precision medicine, driving superior patient outcomes. Our approach, which includes deep sequencing all DNA encoding genes and RNA transcripts, maximizes the molecular information generated for each clinical case and enables us to analyze and provide patients and physicians with industry-leading breadth, depth, and accuracy of multi-omic information. By providing a high-quality, individualized molecular blueprint of a patient&#8217;s disease, our platform is designed to enable the discovery, development, and application of cutting-edge precision medicine that pushes the boundaries of current science. This differentiated approach has made Caris a destination for KOLs and clinicians seeking the most complete and accurate information available for treating their patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">We are a leading provider of tissue-based molecular profiling, including through our FDA-approved companion diagnostic tissue-based profiling solution, MI Cancer Seek</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;MI Profile is a leading tissue-based molecular profiling solution for therapy selection, with over one million tests performed on approximately 146,500 clinical cases in 2024, which represents a 31.2% compound annual growth rate in clinical tissue case volume since 2018. MI Profile consists of a WES and WTS NGS component, IHC analysis, and AI/ML analysis to identify the origin of a tumor for 90 unique cancer types with approximately 95% accuracy. This comprehensive solution assists clinicians in identifying patients who may benefit from treatment with specific targeted therapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Our novel, universal blood-based profiling solution, Caris Assure, is unique in the market and poised for rapid adoption</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We believe our leadership in tissue molecular profiling uniquely positions us to capitalize on the increased use of blood-based profiling and adoption into </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">clinical practice with Caris Assure, our novel, universal blood-based solution that is purpose-built to extend across the entire cancer care continuum and to therapeutic development by generating over 42&#160;billion datapoints per clinical case. We built upon the data we have generated to date with MI Profile and believe our data is a significant competitive advantage in the development and clinical utility of Caris Assure. Caris Assure naturally enriches our AI/ML algorithms and transfers learning across the care continuum, yielding greater sensitivity and specificity, while continuously expanding our longitudinal patient datasets. Moreover, we believe that our single-test approach will enable us to scale our R&amp;D infrastructure to analyze increasingly large testing volumes, process expanding datasets, and reach economies of scale in liquid biopsy. To our knowledge, we have developed and launched the most informationally rich blood-based solution in the market. We have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States (other than New York State). </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">We have built what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our proprietary oncology clinico-genomics datasets provide insights into the fundamental building blocks of disease, potentially enabling breakthroughs from targeted therapies to truly personalized medicine. Our ever-expanding datasets include data generated from more than 6.5&#160;million tests that have generated measurements of over 38&#160;billion molecular markers from over 13 quadrillion datapoints as of March 31, 2025, as well as matched clinical outcomes for many of these patients. Our platform generates over 111&#160;million reads per clinical case, and each new case further expands our datasets allowing us and our biopharma partners to generate even more clinically relevant insights. We also expand and enrich our datasets through partnerships that add real-world evidence, longitudinal patient data, and clinical outcomes. The breadth and depth of our large and growing data assets represents a deep competitive moat for us, overcoming which requires significant capital investment, scaled sequencing capacity, acquisition of patient samples, and generation of corresponding clinical outcomes data. These significant data assets enable us to effectively deploy our proprietary AI/ML algorithms to analyze patient information and empower our customers to make better informed diagnoses and treatment decisions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:55pt; margin-top:8pt; width:401pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. We believe this continuous feedback loop will allow us to achieve meaningful next-generation innovation in precision oncology as well as other chronic disease states. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Our first mover advantage, specialized commercial channel, robust infrastructure, and deep research collaborations enable our leadership and provide us with the ability to scale for future growth</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We believe we will be the first provider to achieve leadership in both solid tumor and liquid biopsy profiling solutions across the entire precision oncology care continuum. To support our sales activity and expansion, we have built a commercial organization specialized in precision oncology consisting of approximately 270 team members as of March 31, 2025, plus nearly 50 highly trained Ph.D. or M.D. MSLs, serving over 5,600 physicians in the United States across all major health systems, academic cancer institutions, and community settings. Due to the increased market acceptance of our solutions, we have achieved revenue growth and case volume growth without growing the aggregate sales headcount over the last three years.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:55pt; margin-top:8pt; width:401pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our robust infrastructure includes a team of over 60 Caris data scientists to decipher unique features from our datasets generated from millions of tests. We operate two precision medicine laboratories in Phoenix, Arizona, and one R&amp;D laboratory in Tempe, Arizona. Our Arizona laboratories all utilize state-of-the-art genomic sequencing technology, including 50 NovaSeq sequencing systems, with capacity to perform more than one trillion &#8220;reads&#8221; daily. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:55pt; width:401pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since its establishment in 2015, the Caris POA, whose members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients, has grown to comprise 96 members as of March 31, 2025, including 45 NCI-designated comprehensive cancer centers. This academic-industry collaborative network has been exceptionally productive with over 145 peer-reviewed manuscripts published since the beginning of 2022. Close connectivity with this vast network of KOLs in oncology clinical care, research, and drug development has enabled us to remain at the forefront of precision oncology and closely attuned to the key needs of the most sophisticated researchers. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">We are led by a founder with significant experience building and scaling businesses in the healthcare industry and a management team with scientific expertise</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our management team has deep domain expertise in molecular biology, oncology, artificial intelligence, data science, medicine, and genomics and have a track record of delivering innovative, high clinical utility solutions to the market. Our management team is highly entrepreneurial and has significant experience leading and operating large multi-national organizations and building innovative healthcare companies. In particular, our Founder, Chairman, and Chief Executive Officer, David D. Halbert, has successfully built and scaled profitable enterprises for approximately 40&#160;years, including AdvancePCS Inc. (acquired by CareMark in 2004 for $7.5&#160;billion), and Caris Diagnostics (acquired by Miraca Life Sciences in 2011 for $725&#160;million), among others. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strategies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As we execute on our vision, we will continue to put the patient first. Our solutions provide physicians and individual patients with actionable information throughout the disease journey, while contemporaneously generating data that can be aggregated and leveraged to unlock academic and biopharma scientific breakthroughs, which may lead to curative therapies for future generations. To achieve our goal of leading a molecular revolution and developing the next generation of precision medicine information solutions for a broad range of conditions across the care continuum, we plan to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Drive the continued adoption and use of our tissue-based profiling and expand our blood-based profiling offering into early detection, MRD, and monitoring</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;MI Profile continues to be one of the most comprehensive tissue-based molecular profiling solutions available. We plan to leverage our leadership with MI Profile and our proprietary clinico-genomics datasets, to drive the adoption of blood-based profiling with Caris Assure, our highly differentiated, comprehensive multi-omic liquid biopsy solution. We believe Caris Assure will address the significant unmet need across the entire cancer care continuum, with solutions for early detection, MRD tracking, therapy selection, and treatment monitoring. Broadly launched in the first quarter of 2024 for therapy selection, we have seen over 3,400 physicians from over 480&#160;institutions order Caris Assure for therapy selection through March 31, 2025. We intend to leverage our existing commercial infrastructure, including our substantial testing capacity across two precision medicine labs and our specialized commercial channel, to support the continued launch and commercialization of Caris Assure. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Utilize the data generated by our existing solutions to develop new solutions with additional revenue using our existing sales channel</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We will leverage our clinico-genomic datasets to identify novel AI-based molecular signatures that are predictive of a patient&#8217;s clinical journey. This will allow us to reach new patient populations at earlier stages of cancer, who may not be eligible for our current solutions. We are currently using an AI/ML approach driven by H&amp;E slide images and clinical results data from more than 10,000 breast cancer patients to develop ESPai, a new algorithm to predict the risk of disease recurrence for early-stage breast cancer patients. We have obtained the samples and clinical data from the National Surgical Adjuvant Breast and Bowel Project and the ECOG-ACRIN Cancer Research Group. We are currently in the process of creating two AI/ML models for ESPai using these samples and are working to obtain additional samples for external validation studies. We are initially creating a model for late recurrence (five to 15 years following diagnosis), but we are also in the beginning stages of creating a model for early recurrence (zero to five years following diagnosis). The ability to deliver results to patients who would otherwise require multiple tests, or for whom testing would </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">156</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">not be a possibility, further differentiates us and provides significant value to patients and their physicians. This business model, possible only through our testing platform and the comprehensiveness of our underlying data, has created a new category of operational efficiency centered around patient care as shown below: </font>
        </div>
        <div style="position:relative;margin-top:9.7pt; text-align:center; width:456pt;">
          <img src="pc_strategic-4c.jpg" alt="[MISSING IMAGE: pc_strategic-4c.jpg]" height="447" width="596" >
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Leverage our platform to provide solutions to biopharma companies to drive advances in personalized medicine and accelerate the development of novel therapeutics</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We partner with biopharma companies to improve the efficiency and success of their therapeutic development and clinical programs by leveraging our platform. We provide prospective and retrospective profiling services, companion diagnostics development, data licensing, and commercial services that include identification of patients for approved therapies. Our biopharma business continues to gain significant momentum, with $63.1&#160;million of revenue generated in 2024, representing a 130.3% increase compared to the prior year. A key strategy for future growth is continued pursuit of opportunities to partner with biopharma institutions to accelerate scientific breakthroughs through access to our datasets. These arrangements, such as our partnerships with Moderna, AbbVie, Xencor, and Merck KGaA include research into molecular markers and tumor-associated antigens, characterization of resistance mechanisms, and the development of personalized therapies. We believe the future of therapeutics will become more and more personalized, requiring the information that we produce to create individually tailored therapies that will have the greatest likelihood of controlling and/or curing patients of disease. Recent advances of personalized therapies that are specifically created for patients demonstrate the value of this approach. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Continue to expand and enrich our clinico-genomic datasets to drive breakthrough science and develop new solutions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our continued comprehensive sequencing for patients, together with our leadership in tissue-based profiling and expansion into blood-based profiling, will enable continued rapid expansion of our datasets, both with new profiling data as well as with longitudinal insights as we follow patients over time. We plan to accelerate the enrichment of </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">157</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">our datasets through continuous R&amp;D at our own laboratories, third party partnerships, and collaborative research with Caris POA members to remain at the cutting-edge of precision oncology and stay attuned to the key needs of our researchers. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Maximize market reach through our regulatory approval and reimbursement strategy</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A key aspect of our commercial strategy is to obtain regulatory approval and reimbursement for our solutions. In November&#160;2024, we obtained a premarket approval (&#8220;PMA&#8221;) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for TMB calling and has been designed to meet the stricter requirements applicable to companion diagnostic devices. We currently market MI Cancer Seek as the WES/WTS NGS component of MI Profile. We have secured a PLA code of 0211U from the AMA and pricing from CMS for this PLA code. We have obtained Medicare coverage for MI Cancer Seek for CPT code&#160;0211U under the NGS NCD. For MI&#160;Tumor Seek Hybrid, we have Medicare and commercial reimbursement. For Caris Assure, we received Medicare coverage in late 2023, have secured various levels of payer adoption and/or reimbursement coverage, and will continue working to expand coverage. In July&#160;2024, the AMA issued a PLA code, CPT code 0485U, for Caris Assure, with an effective date of October&#160;1, 2024. In November 2024, CMS determined to price Caris Assure for therapy selection using the &#8220;Gapfill&#8221; method, a method used when there are no comparable existing codes available. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. For additional information, see &#8220;&#8212;Government Regulation&#8212;Coverage and Reimbursement&#8212;Coverage and Reimbursement in the United States.&#8221; We plan to work closely with Medicare and private payers to continue to demonstrate the economic benefit of our platform and secure reimbursement coverage for our future offerings by leveraging our proprietary clinico-genomic datasets that contains a growing volume of corresponding clinical outcomes data. We believe this approach will lead to a differentiated reimbursement profile relative to our peers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Capitalize on the ultimate potential of our novel, universal blood-based profiling solution, Caris Assure, and broader innovation platform in other chronic disease states beyond oncology, including in cardiology, neurology, and metabolic conditions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We believe there is a large market opportunity to diagnose and treat chronic conditions beyond oncology through molecular information-based approaches. Beyond oncology, researchers are actively exploring the genetic and biological connections between patients and other disease states, including cardiology, neurology, and metabolic conditions. These diseases are frequently multifactorial in nature and are characterized by significant individual variability. Accordingly, a comprehensive understanding of the underlying biological pathway dysfunction is critical if we want to understand the molecular origins of disease and generate insights to bring new therapeutics to patients. As we continue to scale, we believe our solutions will drive superior clinical outcomes, leading to additional demand for our profiling solutions and further expansion of our clinico-genomic datasets, allowing us to achieve meaningful innovation in other disease states beyond oncology. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Solutions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Caris Assure&#8212;Our Universal Blood-Based Profiling Solution</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure is our novel, universal blood-based solution that is purpose-built to extend across the entire continuum of cancer treatment, including early detection, monitoring of MRD and recurrent cancers, and precision selection of molecularly targeted therapies. Caris Assure also has applications in therapeutic discovery and development. Customers for Caris Assure include treating physicians as well as researchers and biopharma companies. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our universal approach to blood-based profiling is unique. While Caris Assure is a single wet lab test, the backend bioinformatics pipeline and analyses are adapted to where the patient may be in their cancer journey. For example, the genes, molecular alterations, and features in late-stage metastatic cancer for therapy selection will be interpreted differently than in early detection. The elegant simplicity of a single test paired with a comprehensive assessment of the patient&#8217;s DNA and RNA allows Caris Assure to be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">158</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">this universal diagnostic. This approach also allows many more datapoints to be assessed, enabling us to select those markers that provide the greatest potential for sensitivity, specificity, and overall accuracy of our test. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Liquid biopsies can be used across the care continuum, including for: therapy selection in the advanced/metastatic setting; MRD and monitoring in the curative/adjuvant setting; and early detection in the diagnosis setting. Because many of our competitors&#8217; liquid biopsy assays are designed to address only a single portion of this care continuum, in order to develop products for other portions of the care continuum, our competitors must invest in the development of new wet lab assays and generate disparate datasets across the patient journey for patients, oncologists, and researchers. In contrast, Caris Assure is designed as a single test applicable across the entire patient journey. To our knowledge, there is no other assay on the market that can be applied as broadly as Caris Assure. We believe that our single-test approach will enable us to scale our R&amp;D infrastructure to analyze increasingly larger testing volumes, process expanding datasets, and reach economies of scale in liquid biopsy across the entire cancer care continuum. The figure below shows the opportunities for blood and tissue sampling and treatment therapies within stages of the cancer care continuum. As a blood-based profiling solution designed for the entire cancer care continuum, Caris Assure has many more opportunities for testing relative to tissue-based profiling, as can be seen on the chart below. </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="lc_oursolutions-4c.jpg" alt="[MISSING IMAGE: lc_oursolutions-4c.jpg]" height="239" width="517" >
        </div>
        <div style="text-indent:36pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure is currently being offered for therapy selection as a laboratory developed test (&#8216;&#8216;LDT&#8217;&#8217;), and we have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States (other than New York State), at current pricing under MolDX of $3,649. We are in the process of conducting studies and analysis to internally validate and refine the assay for application to early detection, MCED, MRD tracking, and treatment monitoring, with certain validation processes and results to date described below. The commercial application of Caris Assure as an LDT to the cancer care continuum beyond therapy selection is subject to further assay development, validation, and reimbursement coverage. Further, due to the FDA&#8217;s planned phase out of its enforcement discretion policy with respect to LDTs, the marketing of Caris Assure for these applications may require marketing authorization from the FDA depending on the timing of launch. Because many of these factors are outside of our control, we are not certain regarding the timing of the availability of Caris Assure for the early detection, MCED, MRD tracking, and treatment monitoring markets.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Drawing blood is a routine medical procedure that is much less invasive than a tissue biopsy. Processing of a blood specimen, from collection to isolation, analysis, and reporting, enables faster time to results and potentially earlier start of treatment. Clinical guidelines for molecular profiling in cancer have focused on tissue as the gold standard, but with recent advances in blood-based profiling demonstrating its clinical utility, we believe that evidence and clinical guidelines support complementary usage of both tissue- and blood-based profiling across many major cancer types. We believe that one example of the benefits of blood-based profiling is that cancers frequently become resistant to new targeted therapies by developing genetic mutations that can make drugs less effective and lead to cancer recurrence. When resistance develops, clinicians need an updated molecular profile of the cancer to guide subsequent treatment strategies. At this </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">159</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:102.52pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">stage in cancer progression, it is often not feasible to acquire additional tumor tissue to build the updated profile, or the amount or quality of accessible tissue is low. Small quantities or low quality of tissue from an inaccessible biopsy site can lead to a Quantity Not Sufficient (QNS) result when NGS fails for lack of input material. Without another way to generate an updated molecular profile of the patient&#8217;s tumor, the tools of precision oncology cannot be deployed. Conducting additional tissue biopsies also carries its own health risks, such as tumor seeding, which can occur when cancer cells are unintentionally deposited elsewhere in the body during the biopsy process, and infection. Liquid biopsy is a potential solution to the challenges and risks of tissue biopsies. A sample eligible for Caris Assure analysis consists of two 10 milliliter tubes of whole blood, gently inverted 10 times as is common practice in blood collection, shipped at room temperature.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Nonetheless, we believe that tissue-based profiling generally remains the gold standard for cancer therapy selection primarily because it is the most mature technology and is broadly supported by analytical validation studies. Microscopic examination of the tumor tissue is necessary for characterization of tumor type and stage and to confirm the presence of key proteins via IHCs. In blood, the variant allele frequencies of tumor biomarkers can be so low that negative results must be confirmed by tissue analysis. However, the tide is turning in clinical guidelines toward acceptance that tissue and liquid biopsy, used in combination, can improve clinical outcomes for patients. For example, the 2024 version of one of the prominent clinical guidelines for non-small cell lung cancer states that: (1) concurrent testing can improve time to test results and should be considered in the appropriate clinical situation, and (2) negative results (meaning absence of definitive driver mutation) by one method suggests the use of a complementary method.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We believe Caris Assure represents the most comprehensive blood-based solution on the market, featuring over 23,000 gene coverage at a raw average sequencing depth of coverage of 8,000 times for clinically relevant genes, as compared to other blood-based offerings in the market that only assess 500 to 1,000 genes from DNA. Caris Assure performs WES and WTS for every eligible patient blood sample. We couple this WES and WTS with advanced AI and ML technologies to offer diagnostic, prognostic, and predictive utility in a single test. Additionally, Caris Assure generates sequencing results from both the plasma and the white blood cells, or buffy coat, from each sample. This gives Caris Assure a differentiated ability to distinguish tumor variants, which are relevant for therapy selection, from both incidental germline variants and common age-related mutations that are not related to the tumor and which can confound analysis and therapy selection if not properly distinguished. For additional information regarding this capability, see &#8220;&#8212;Benefits of CH Subtraction with Caris Assure.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Molecular features we identify using Caris Assure&#8217;s WES and WTS data include single nucleotide variants (&#8220;SNVs&#8221;), insertions/deletions (&#8220;INDELs&#8221;), structural variants, gene expression, copy number alterations (&#8220;CNAs&#8221;), TMB, and MSI. In addition, we deploy our ABCDai algorithm on Caris Assure&#8217;s WES and WTS data to address important clinical needs in early detection and monitoring of MRD and recurrent cancers. We trained ABCDai using data for over 375,000 tissue profiles and over 7,000 paired blood and tissue profiles. In a first phase, separate AI models were trained on nine feature sets representative of cancer-related and cell-free nucleic acids. In a second phase, the 500 most important features determined by us from each feature set were used to train a final ABCDai model. We engineered three ABCDai models to work in concert with Caris Assure: (i) MCED; (ii) diagnostic pathway; and (iii) MRD and monitoring. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">160</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:173.45pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_abcdaiassure-4c.jpg" alt="[MISSING IMAGE: fc_abcdaiassure-4c.jpg]" height="332" width="506" >
        </div>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caris Assure for Early Detection</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that one of the most promising uses for Caris Assure is for early detection, including both cancer-type-specific early detection and MCED. Our detection of cancer at very early stages would enable clinicians to treat disease sooner, which could significantly improve patient outcomes. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We trained ABCDai for MCED (&#8220;ABCDai-MCED&#8221;) using the aforementioned features on samples from 1,013 patients (507 patients with cancer and 506 individuals with no reported cancer). Performance was assessed on an independent set of 2,675 patients (526 patients with cancer and 2,149 samples from individuals with no reported cancer). ABCDai-MCED&#8217;s performance on the stratification of blood samples from the independent cohort of patients with cancer versus those with no reported cancer resulted in sensitivities for stages I-IV (n= 284, 129, 90, and 23, respectively) of 83.1% (stage I), 86.0% (stage II), 84.4% (stage III), and 95.7% (stage IV) at 99.6% specificity (n=2,149).</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The chart below illustrates ABCDai-MCED&#8217;s sensitivity in detecting a range of cancer types at stages I and II, at a specificity of 99.5% </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">161</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="bc_caris-4c.jpg" alt="[MISSING IMAGE: bc_caris-4c.jpg]" height="413" width="547" >
        </div>
        <div style="text-indent:36pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ABCDai-MCED has been shown to be useful in detecting the presence of cancer in an asymptomatic individual. Additionally, the molecular information provided by Caris Assure can assist in predicting the diagnostic pathway that can confirm the presence and tissue of origin of cancer, which knowledge is needed for proper intervention. We focused diagnostic pathway prediction on those tumor types that are most common and thus provide the most clinical utility: colonoscopy, abdominal/chest CT, endoscopy, liver ultrasound, mammograph with MRI, neck ultrasound, pelvic ultrasound, and prostate-specific antigen (&#8220;PSA&#8221;). A model to predict diagnostic pathway, ABCDai-GPS, was trained by us using the feature sets described above obtained for treatment-na&#239;ve samples from 660 patients with stage I and II cancers and 506 individuals with no reported cancer. Using 5-fold cross validation, we observed that ABCDai-GPS predicted the diagnostic pathway for 100% of the ABCDai-MCED positive calls with a top-3 accuracy of 85% for stage I and II cancers. The relationship between the proposed diagnostic pathways and tissue of origin of the cancer is shown in the following table. </font>
        </div>
        <table style="width:456pt;height:128.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Diagnostic Pathway </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:300pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Cancer Types </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Colonoscopy </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Colorectal </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">CT Abdomen/Chest </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Pancreatic, Kidney, Bladder, Urinary tract, Lung </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Endoscopy </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Esophageal, GIST, Gastric, Small Intestine </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Liver ultrasound </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Cholangiocarcinoma, Liver </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Mammograph with MRI </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Breast </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Neck ultrasound </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Head and Neck, Thyroid </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Pelvic ultrasound </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Uterus, Cervical, Ovarian, Female Genital Tract Malignancy </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">PSA </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Prostate</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also in the early stages of developing a version of ABCDai to be used with Caris Assure for early detection of specific types of cancer. We are currently developing cancer-type-specific early detection for breast and colorectal cancers. We believe that cancer-specific early detection assays will benefit patients by providing them with clear treatment pathways. We currently intend to launch Caris Assure for early </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">162</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:145.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">detection of breast cancer and intend to do so in a capital efficient manner, with the expectation that we will leverage either a commercial partner or our existing sales channels, however, our plans and intentions may change. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caris Assure for Minimal Residual Disease Tracking and Treatment Monitoring</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">A third model was trained by us using the feature sets described above for deployment in the settings of MRD and recurrence monitoring. This model, ABCDai-M&amp;M, was trained using samples from 3,439 patients (1,290 patients with cancer and 2,149 individuals with no reported cancer) and performance was assessed on two independent validation cohorts: 86 patients in the MRD study and 101 patients in the recurrence monitoring study. The disease-free survival of patients whose cancers were predicted by ABCDai-M&amp;M to have an event was significantly shorter than those predicted not to have an event using a tumor na&#239;ve approach (HR=33.4, p&lt;0.005, HR=4.39, p=.008, respectively). The ABCDai-M&amp;M model captured 89% of MRD recurrence events with 98% NPV and 76% specificity, and 45% of recurrence monitoring events with 92.6% NPV and 83% specificity. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="lc_significant-4c.jpg" alt="[MISSING IMAGE: lc_significant-4c.jpg]" height="335" width="517" >
        </div>
        <div style="text-indent:36pt; margin-top:14.69pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following graphic illustrates the performance of Caris Assure for CRC in the MRD setting, in our clinical validation performed on 44 patient samples. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">163</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lc_colorectal-4c.jpg" alt="[MISSING IMAGE: lc_colorectal-4c.jpg]" height="288" width="519" >
        </div>
        <div style="text-indent:36pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our MRD detection methodology based on ABCDai takes a tumor naive approach, and therefore does not require a bespoke panel to be created to track the recurrence of a patient&#8217;s tumor. This bespoke-free approach enables faster turn-around-time, enabling patients to be informed of additional therapy sooner to combat their disease. Additionally, because Caris Assure analyzes the entire exome, any tumor-derived alterations including those that may derive from subclones not included in the original tissue biopsy, are also detectable, thus accounting for tumor heterogeneity to help contribute to sensitivity of detection. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Benefits of CH Subtraction with Caris Assure</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For therapy selection, in addition to sequencing cell-free DNA and cell-free RNA isolated from the plasma to identify somatic tumor variants, we also sequence genomic nucleic acid (gDNA and gRNA) isolated from the white blood cells, or buffy coat, from each sample. Plasma contains a mixture of cell-free variants derived from tumor, blood and other cells. These variants cannot be separated based on plasma sequencing alone. Sequencing the buffy coat separately from the plasma allows Caris Assure to identify incidental germline (inherited) mutations as well as CH mutations. CH mutations are somatic mutations that accumulate in the blood with age, occur in a substantial portion of the population, and are not cancer-derived. Caris Assure &#8220;subtracts&#8221; CH mutations in the reporting of somatic tumor variants. If CH mutations are not distinguished from tumor-derived mutations, it can confound liquid biopsy results and lead to selection of a therapy targeted at a mutation that is present in the white blood cells instead of in the tumor, which is not beneficial for the patient with cancer. Because of this, the College of American Pathologists (&#8220;CAP&#8221;) and Association for Molecular Pathology recommend that cfDNA assays should incorporate whole blood controls to differentiate CH from tumor-derived variants. Caris Assure sequencing follows this approach, thus lessening the risk of incorrectly interpreting CH or germline mutations as tumor-derived and thus result in fewer false positive diagnoses and more accurate and effective treatment recommendations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2025, we published in </font><font style="font-style:italic;letter-spacing:0.2pt;">Clinical Cancer Research</font><font style="letter-spacing:0.2pt;">, a peer-reviewed medical journal on oncology, our validation study conducted in collaboration with leading cancer centers such as Rocky Mountain Cancer Centers, OU Health University of Oklahoma Medical Center, Hope Cancer Center of Nevada, and Texas Oncology. The study analyzed over 16,800 patients with advanced cancer across 49 cancer types and found that nearly more than four of 10 patients had at least one CH variant among reportable clinical genes. The study also found a median rate of CH variant classification of 20% for patients ranged from 65 to 69, 33% for patients aged 70 to 74, 33% for patients aged 75 to 79, and 50% for patients 80&#160;years of age and older. High CH rates were notably detected in BRCA2, BRCA1, CHEK2, ATM and NRAS. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">164</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:54.47pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following graphic illustrates the study&#8217;s findings on variant classification by gDNA and plasma variant frequency, and illustrates the types of diagnostic errors that can occur when variants are not properly characterized as tumor, germline or CH mutations. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="lc_plasmabuffy-4c.jpg" alt="[MISSING IMAGE: lc_plasmabuffy-4c.jpg]" height="389" width="608" >
        </div>
        <div style="text-indent:36pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the prevalence of CH mutations, we believe that CH subtraction is critical to optimal cancer care. As noted above, the identification of CH mutations by an assay can lead to improper therapy selection if such mutations are not shown to be from the white blood cells. By identifying and distinguishing variants that are not from the tumor itself and, therefore not relevant to therapeutic decision-making, the CH subtraction feature of Caris Assure further separates our solution from other liquid biopsy tests currently on the market that do not sequence the white blood cells and therefore cannot definitively distinguish CH mutations from tumor-derived mutations. To our knowledge, Caris Assure is the only commercially available tissue-naive blood-based profiling assay that directly accounts for CH mutations instead of using algorithmic approximations, which we believe gives Caris Assure a differentiated ability to drive improved therapy selection. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">By leveraging CH subtraction, somatic mutation detection from blood collected within 30&#160;days of matched tumor tissue showed high concordance to our tissue-based assays, with a positive percent agreement (&#8220;PPA&#8221;) of 93.8% and a positive predictive value (&#8220;PPV&#8221;) of 96.8% PPA and PPV are terms commonly used in the context of diagnostic tests and medical studies and are helpful for evaluating assay performance. PPA stands for positive percent agreement and is a measure of the agreement between a test&#8217;s positive result and the true positive status as determined by a reference standard. PPV stands for positive predictive value, which is a measure of the probability of a positive result correctly identifying a disease or condition. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">165</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;min-height:298pt;margin-top:0pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="height:17.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:4.5pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">Case Study: The Benefits of CH Subtraction in Therapy Selection </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:87pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A male in his 80&#8217;s with a history of renal cell carcinoma presented with a large osseous (bone) metastasis involving the thoracic and lumbar spine, ribs, and pelvis. Pathology was consistent with an origin in the prostate. Immunohistochemical studies performed by the outside pathology team was consistent with this diagnosis, and a liquid biopsy performed outside of Caris revealed a mutation in the ATM gene, which helps repair damaged DNA that was potentially actionable as supported by a specific FDA-approval for PARP inhibitors for patients with this mutation. This outside liquid biopsy did not specify whether the detected ATM mutation was derived from the tumor or potentially from clonal hematopoiesis. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:39pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A tissue biopsy was sent to Caris for molecular profiling. Tissue molecular profiling done at Caris confirmed the diagnosis of metastatic prostate cancer with mutations in FOXA1 and MEK1, genes that play roles in regulating cell growth and behavior. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:51pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The patient received palliative radiation therapy and began androgen deprivation therapy (&#8220;ADT&#8221;). The ATM mutation detected by the outside liquid biopsy also indicated potential benefit from the PARP inhibitor olaparib. After an increase in the patient&#8217;s prostate-specific antigen levels led the clinician to consider new therapy options, a blood sample was sent for Caris Assure molecular profiling. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:63pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Caris Assure confirmed the previously-identified FOXA1 and MEK1 mutations, MSS, and low blood TMB consistent with low tissue TMB, but showed that the ATM mutation was CH-derived rather than tumor-derived. Therefore, ADT could continue while the patient is responsive and tolerant, but the clinician could avoid prescribing the PARP inhibitor olaparib, knowing that the ATM mutation targeted by that therapy is a false positive from CH and not a tumor biomarker. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:41.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;border-bottom:0.75pt solid #000000; ;padding:2pt 0pt 6pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The CH subtraction capability of Caris Assure in this case provided the patient and his clinicians more accurate information about potential future treatment options, and helped the patient avoid the potential harmful side effects, time and financial cost of therapies that would likely have been ineffective.</div>
            </td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.2pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caris Assure for Therapy Selection</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We initiated a broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and currently offer the solution as an LDT, which is an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> diagnostic (&#8220;IVD&#8221;) test intended for clinical use and designed, manufactured, and used within a single laboratory. The FDA has historically exercised enforcement discretion and not required marketing authorization for LDTs. Accordingly, we have not yet obtained FDA marketing authorization for Caris Assure. We anticipate seeking FDA marketing authorization for certain of our solutions in the future, including Caris Assure for therapy selection, in part as a result of the FDA&#8217;s planned phase out of its enforcement discretion policy with respect to LDTs. Additionally, while we currently market Caris Assure for therapy selection as an LDT, marketing authorization would be required in order for us to market Caris Assure as a companion diagnostic device for therapy selection. We do not yet have specific plans regarding the timing of a PMA or other submission, if any, for Caris Assure for therapy selection or any other indication. For additional information, see &#8220;Business&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">Government Regulation&#8212;U.S. Food and Drug Administration.&#8221; We have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States. The current pricing of Caris Assure for therapy selection under MolDX is $3,649. </font></div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure for therapy selection is available in all U.S. states (other than New York, where we intend to apply in 2025 for approval from New York State&#8217;s Clinical Laboratory Evaluation Program (&#8220;NY CLEP&#8221;)) and in Puerto Rico. We also offer Caris Assure for therapy selection internationally through distributors and direct contracts with hospital systems, where permitted by applicable regulations. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Caris Assure Profile Report</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure for therapy selection generates a personalized report that provides oncologists with the information to tailor each patient&#8217;s treatment plan. This report is built to maximize clinical utility in an easy-to interpret format. Our technology enables us to report our results for blood-based profiling even quicker than tissue-based profiling, as Caris Assure results are typically reported in approximately seven calendar days from &#8220;activation,&#8221; the time at which we receive the patient&#8217;s samples and required paperwork. A sample Caris Assure profile report is depicted below. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">166</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:134.37pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="fc_miprofile02-4c.jpg" alt="[MISSING IMAGE: fc_miprofile02-4c.jpg]" height="541" width="579" >
        </div>
        <div style="margin-left:36pt; margin-top:18.69pt; width:420pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Technical Specifications and Analytical Validation</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure analyzes all coding genes through WES (cell-free DNA) and WTS (cell-free RNA), and categorizes variants found in plasma as either tumor-derived or CH-derived and either somatic or germline. Caris Assure clinically reports SNVs, INDELs, and select fusions, as well as MSI, TMB, human leukocyte antigens, and select amplifications. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">167</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; width:456pt;">
          <img src="tb_technical-4c.jpg" alt="[MISSING IMAGE: tb_technical-4c.jpg]" height="534" width="606" >
        </div>
        <div style="position:relative;margin-top:14.69pt; width:456pt;">
          <img src="bc_novelcircul-4c.jpg" alt="[MISSING IMAGE: bc_novelcircul-4c.jpg]" height="287" width="608" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">168</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caris Assure for Biopharma</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The same benefits that blood-based WES, WTS, and CH subtraction bring to patients in the clinical setting also offer significant and previously unavailable advantages to biopharma companies across the drug development continuum. Caris Assure allows biopharma companies to conduct exploration into biology and address elusive questions around response and resistance with repeat and/or longitudinal biopsies, without the restriction of earlier generation liquid biopsies. This enables biopharma companies to understand the molecular alterations responsible for resistance. In a drug development setting, the only way to get this understanding is through the WES/WTS sequencing technology underlying Caris Assure. With a typical results turn-around-time of approximately seven calendar days from activation, Caris Assure can be used in early-stage trials to identify and enroll eligible patients that meet inclusion and exclusion criteria, or more broadly to leverage this comprehensive molecular profile of patients for exploratory analyses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caris Assure is designed to be particularly valuable when used serially for time point studies, real-time monitoring of disease progression and treatment response, and post-treatment monitoring for recurrence. Caris Assure offers the biopharma industry the opportunity, for the first time, to incorporate complete WES and WTS interrogation at multiple timepoints throughout clinical trials in a non-invasive and easy-to-implement modality. This would enable biopharma companies to not only track changes in the mutation profile of a tumor in response to treatment, but also to assess changes in gene expression over time. Until now, different assays and analysis methods were required at different time points. Caris Assure offers biopharma companies the ability to use the same, consistent, and uniform assay across their full development program, allowing for more consistent, complete, and inter-comparable datasets across drug studies and time points. With Caris Assure, we believe biopharma companies would be able to generate more NGS data on individual clinical trial patients than has ever been possible using a blood-based assay in the history of cancer research and clinical trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MI Profile&#8212;Our Tissue-Based Profiling Solution</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">MI Profile is our tissue-based molecular profiling solution for cancer therapy selection, with over one million tests performed on approximately 146,500 clinical cases in 2024 and an additional approximately 40,000 clinical cases in the three months ended March 31, 2025. As of March&#160;31, 2025, we have performed over 6.5 million tissue-based tests on over 790,000 clinical cases since inception. MI Profile includes our comprehensive WES/WTS NGS assay and IHC protein expression testing. Our tissue microdissection process has, to date, resulted in a high success rate in identifying actionable biomarkers in 95% of patients profiled. Eligibility of tissue samples for our MI Profile tissue profiling requires a presence of at least 20% tumor nuclei and at least 50 ng of DNA for MI Cancer Seek, and at least 25 ng for MI Tumor Seek Hybrid, and the sample must meet other requirements detailed in our requisition form used by ordering physicians. MI Cancer Seek requires formalin-fixed paraffin embedded tissue samples, but we can accept samples in different forms for MI Tumor Seek Hybrid as detailed in our requisition form.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The information generated from profiling the patient&#8217;s tissue is used to create an interpretative report based on our bioinformatics pipeline and recommend individualized therapies for cancer patients. Our goal is to maximize the information generated and corresponding clinical utility for patients from the limited available tumor tissue. The information generated, which further expands our multi-modal datasets, also provides valuable insights to aid drug discovery and development efforts. Customers for MI Profile include treating physicians as well as researchers and biopharma companies. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have obtained Medicare and commercial reimbursement for MI Profile. MI Profile, including our MI Cancer Seek assay and our proprietary clinical molecular signatures GPSai and FOLFIRSTai are available in all U.S. states and in Puerto Rico. We also offer MI Profile internationally in over 40 countries through distributors and direct contracts with hospital systems, where permitted by applicable regulations.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have obtained a PMA approval from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for TMB calling and for which we have obtained a Proprietary Laboratory Analyses (&#8220;PLA&#8221;) code, Current Procedural Terminology (&#8220;CPT&#8221;) code 0211U, at a reimbursement rate of $8,455. Our MI Cancer Seek solution was commercially launched in January 2025, and we currently market it as the WES/WTS NGS component of MI Profile. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">169</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">NCD. MI Tumor Seek Hybrid, which is a WES/WTS NGS LDT assay that we currently offer as an alternative assay in the event a specimen does not meet the requirements for MI Cancer Seek, is currently priced by MolDX at $3,500. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">MI Profile Report</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">MI Profile generates a personalized report that provides oncologists with the information to tailor each patient&#8217;s treatment plan. The MI Profile report was built by oncologists for oncologists and is designed to maximize clinical utility in an easy-to interpret format. We generally report our results for tissue-based profiling approximately 10 calendar days from activation. A sample MI Profile report is depicted below. </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="fc_miprofile-4c.jpg" alt="[MISSING IMAGE: fc_miprofile-4c.jpg]" height="678" width="510" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">170</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:140.25pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Technical Specifications and Validation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">MI Cancer Seek</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The current WES/WTS NGS component of MI Profile is MI Cancer Seek, for which we have received FDA approval for use as a companion diagnostic device to identify cancer patients who may benefit from treatment with targeted therapies. The assay includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. To our knowledge, MI Cancer Seek is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic indications for molecular profiling of solid tumors. MI Cancer Seek is available for adults and pediatric patients between the ages of one and 22. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">MI Cancer Seek is a NGS-based in vitro diagnostic device using total nucleic acid isolated from formalin-fixed paraffin embedded tumor tissue specimens for the detection of SNVs, InDels, MSI, TMB in patients with previously diagnosed solid tumors, and CNA in one gene in patients with breast cancer. MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table below, in accordance with the approved therapeutic product labeling. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="fc_companion-4c.jpg" alt="[MISSING IMAGE: fc_companion-4c.jpg]" height="345" width="578" >
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">171</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:252.73pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tb_micancer-4c.jpg" alt="[MISSING IMAGE: tb_micancer-4c.jpg]" height="370" width="578" >
        </div>
        <div style="text-indent:36pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">As of March 31, 2025, MI Cancer Seek had 20 FDA-approved therapies and therapy combinations associated with its companion diagnostic indications. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Beyond the MI Cancer Seek FDA-approved indications, MI Cancer Seek reports additional sequencing-based features from DNA such as gLOH, HRD, HLA genotype, chromosomal alterations, viruses, and additional sequencing-based features from RNA such as gene expression, fusions, and variant transcripts. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">172</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tb_micancerseek-4c.jpg" alt="[MISSING IMAGE: tb_micancerseek-4c.jpg]" height="461" width="603" >
        </div>
        <div style="margin-top:4.9pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:36pt; margin-top:11.7pt; width:456pt; line-height:9.5pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">PPA and NPA are terms commonly used in the context of diagnostic tests and medical studies and are helpful for evaluating the performance of diagnostic tests: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:10pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:56pt;font-size:8pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.16pt;">PPA</font><font style="letter-spacing:0.16pt;"> stands for Positive Percent Agreement. Similar to NPA, it is a measure of the agreement between a test&#8217;s positive results and the true positive status as determined by a reference standard. It reflects the test&#8217;s ability to correctly identify positive results.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:10pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:56pt;font-size:8pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.16pt;">NPA</font><font style="letter-spacing:0.16pt;"> stands for Negative Percent Agreement. It is a measure of the agreement between a test&#8217;s negative results and the true negative status as determined by a reference standard. It reflects the test&#8217;s ability to correctly identify negative results. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">MI Tumor Seek Hybrid</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our legacy MI Tumor Seek Hybrid profiling solution combines WES analysis of DNA for mutations, CNAs, INDELs, and genomic signatures (TMB, MSI, gLOH, and HRD) with WTS analysis for RNA fusions and variant transcripts. We have also analytically validated MI Tumor Seek Hybrid for viral detection and report HPV, MCV, and EBV presence from the WES data in the appropriate tumor context. MI Tumor Seek Hybrid achieves accurate results through high coverage depths for DNA and RNA sequencing. MI Tumor Seek Hybrid consistently reaches 1,500 times depth of coverage for clinically relevant DNA genes and 300 times depth of coverage for the whole exome. Our WTS technology allows for fusion detection, variant transcript analysis, and gene expression profiling. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">AI Signatures</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our WES/WTS profiling solutions generate over 28.8&#160;billion datapoints, spanning 84,000 molecular markers, per clinical case. To interpret this data, MI Profile utilizes an advanced, AI-powered bioinformatics pipeline. This bioinformatics pipeline includes a sophisticated rules engine, variant calling, fusion calling, copy number prediction, and expression analysis. We use over 220 AI algorithms in connection with the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">173</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">bioinformatic pipeline of our tissue-based sequencing. These AI algorithms assist in sample processing, quality control, biological processing, and biological interpretation. Collectively, these AI algorithms generate data on 84,000 molecular markers for each WES/WTS run.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">MI Profile can also include our proprietary clinical molecular signatures, GPSai and FOLFIRSTai, which were developed by training and clinically validating AI/ML algorithms with our extensive multi-modal clinico-genomic datasets. These molecular signatures, which we currently offer as LDTs, provide clinical utility for molecular diagnosis of cancer and prediction of patient response to treatment. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">GPSai</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our GPSai signature is a molecular disease classifier that utilizes multiple deep neural networks and hundreds of thousands of molecular features to predict a histologic diagnosis and tumor origin directly from the DNA and RNA sequencing data. The result is a probability of the most likely diagnosis, which is then reviewed by a Caris Board-Certified Pathologist in the context of all available clinicopathologic information before report release. The primary indication for GPSai is to determine if the initial diagnosis is correct and serves as a quality control for all patients. In addition, it can be used to help identify the tissue of origin for Cancers of Unknown Primary (&#8220;CUP&#8221;), cases where the starting point of the cancer is not yet clear, which is a major unmet need in clinical oncology. This tissue of origin prediction is provided along with the comprehensive biomarker data without the need for additional specimen utilization; this tool runs on the MI Profile exome and transcriptome sequencing results. GPSai is also utilized as a quality control metric where it is run on every clinical case and the results reviewed by a pathologist. If the GPSai results do not match the outside pathologic diagnosis of the specimen, our pathologists will do additional work-up, including IHC testing, to support a new diagnosis to provide the best overall service and patient care. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:55pt; margin-top:8pt; width:401pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">GPSai was trained and clinically validated by us through retrospective profiling data from over 250,000 clinical cases using the outside pathologist diagnosis as the baseline. In a prospectively run clinical validation study that we conducted, GPSai demonstrated overall accuracy of 94.8% and an overall call rate of 95.1%. This clinical validation of GPSai enabled us to offer the solution as an LDT in accordance with the Clinical Laboratory Improvement Amendments of 1988&#8217;s (&#8220;CLIA&#8221;) requirement of clinical validation of a variety of performance characteristics, including accuracy, precision, specificity, sensitivity, reportable range, and reference interval before an LDT is used in clinical testing. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-weight:bold;letter-spacing:-0.2pt;">FOLFIRSTai</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our FOLFIRSTai signature is our first clinically validated, AI-powered molecular predictor of efficacy of oxaliplatin-based chemotherapy combined with bevacizumab in patients with metastatic colorectal cancer (&#8220;mCRC&#8221;). According to estimates by the ACS, one in 23 men and one in 25 women in the United States will be diagnosed with colorectal cancer in their lifetime. FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients with mCRC. Some mCRC patients benefit from one combination chemotherapy regimen over the others, and identifying which patients would benefit from which regimen is a challenge for physicians. FOLFIRSTai is included for all clinical cases with completed WES results and a diagnosis of advanced stage colorectal adenocarcinoma. The FOLFIRSTai results appear in the MI Profile report as &#8220;Increased Benefit&#8221; or &#8220;Decreased Benefit&#8221; with additional detail provided about the results in the report. FOLFIRSTai is broadly accessible to patients and is covered by almost all insurance companies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:55pt; margin-top:8pt; width:401pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We clinically validated FOLFIRSTai using a real-world evidence dataset collected from the Caris POA registry, insurance claims data and samples from the TRIBE2 Phase&#160;3 clinical trial, which compared first-line use of FOLFOXIRI and FOLFOX. In a clinical validation study that we conducted, FOLFIRSTai demonstrated that the overall survival of patients treated in a manner consistent with the FOLFIRSTai prediction was 17.5&#160;months longer than the overall survival of patients treated counter to the prediction (representing a 71% difference). This clinical validation of FOLFIRSTai enabled us to offer the solution as an LDT in accordance with CLIA&#8217;s requirement of analytical validation of a variety of performance characteristics, including </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">174</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:55pt; width:401pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">accuracy, precision, specificity, sensitivity, reportable range, and reference interval before an LDT is used in clinical testing. </font>
        </div>
        <table style="width:456pt;min-height:416.7pt;margin-top:10pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="height:17.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:4.5pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">Case Study: The Power of Caris&#8217; AI Signatures to Inform Diagnosis and Treatment </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:87pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Caris was presented with the case of a female patient in her early 50&#8217;s with bilateral adnexal masses (growth occurring in or near the uterus, ovaries, fallopian tubes and connecting tissues), the largest of which measured 22 cm in greatest dimension. The patient&#8217;s pathological diagnosis was ovarian adenocarcinoma based on a morphological examination under a microscope. The patient underwent total abdominal hysterectomy (surgical removal of the uterus), bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) with pelvic debulking of tumor (removal of as much cancerous tissue in the abdomen as possible). </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:51pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A representative post-surgery tissue specimen of the patient&#8217;s right adnexal lesion was sent to Caris, to help her oncologist decide the best options for therapy. Based on the patient&#8217;s comprehensive sequencing results using WES and WTS, a GPSai&#8482; score was generated highly suggesting the colon as the malignant tissue of origin, as shown in the excerpt below: </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:106.7pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:3.5pt 0pt 4pt 0pt; width:444pt;">
              <div style="position:relative;text-align:center;">
                <img src="ph_cancercate-4c.jpg" alt="[MISSING IMAGE: ph_cancercate-4c.jpg]" height="132" width="505" >
              </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:39pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To help further validate the GPSai&#8482; finding, a panel of diagnostic IHCs (protein analysis) was performed that showed the tumor to be positive for colon-specific protein expression further pointing toward a diagnosis of colorectal cancer. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:75pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of these findings, the patient underwent colonoscopy that showed large nearly obstructive colonic lesion. This case was reviewed at the hospital tumor board and there was consensus that this patient would be best managed as metastatic colonic adenocarcinoma. As a result of the Caris GPSai&#8482; finding, the patient&#8217;s diagnosis and course of treatment was altered based on a detailed discussion of the results with the ordering physician. Caris also provided the FOLFIRSTai result for therapy sequencing and, through NGS, generated a targeted therapy recommendation for the treating physician. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:41.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;border-bottom:0.75pt solid #000000; ;padding:2pt 0pt 6pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This was an example of a use of Caris&#8217; collective sequencing and proprietary AI signatures to help a patient obtain a targeted therapy recommendation and avoid the potential cost, time and side effects of ineffective therapy.</div>
            </td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:36pt; margin-top:11.7pt; width:420pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">QuantumAI Report</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">We also use the in-depth sequencing data generated by MI Profile to produce the QuantumAI report, a research use only description of the patient&#8217;s molecular tumor biology and characterization of their phenotype using whole exome and whole transcriptome sequencing. The QuantumAI report, which we have analytically validated but not yet clinically validated, contains various biological signatures such as DNA variants counted towards TMB across the whole exome, the Catalogue of Somatic Mutations in Cancer (COSMIC) signatures resulting from a subset of TMB variants, genomic loss of heterozygosity, genomic scar score, and copy number alterations at the chromosome band level as well as exon-level copy number alterations on over 700 genes. An enhanced eKaryotype shows copy number alterations per chromosomal band along with associated confidence intervals to highlight areas of strong or likely amplifications and deletions. RNA gene expression signatures include consensus molecular subtypes (colorectal cancer), PAM50 (breast), and purIST (pancreatic). The report also includes measurements of tumor infiltrating lymphocytes and RNA heatmap expression for hundreds of genes relative to nearly 90 distinct cancer types. An additional RNA component is a circos diagram representing all RNA fusions observed across the whole transcriptome, to help oncologists and researchers understand relationships between genetic variations, mutations, and other molecular features and to help tailor precision medicine approaches. The report also </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:0.2pt;">175</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">features MGMTai, an AI signature that uses both DNA and RNA features to predict response to temozolomide in glioblastoma. Anticipated future additions to the report include pancreatic, lung, and breast cancer drug therapy response predictors using AI signatures, a brain metastasis predictor using AI signatures, an image of the H&amp;E stain used for sequencing, raw depth of coverage per genes/exons, gene expression interpretation and genetic predispositions. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">IHC Testing</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We leverage a broad menu of third-party IHC tests to create a customized set of tests for each patient to reveal a more complete molecular blueprint of the patient&#8217;s disease. We use IHC testing to complement our WES/WTS profiling both to inform decisions regarding therapy selection as well as to act as confirmatory testing in circumstances where our GPSai algorithm indicates a different diagnosis than that indicated in the patient record prior to our profiling or in CUP cases. We believe we have one of the broadest IHC testing menus available to patients and physicians to provide the most appropriate therapy results and diagnosis.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Testing patient specimens for protein-based biomarkers by IHC is the standard of care for both predictive and diagnostic purposes. For predictive IHCs, we run third-party companion diagnostic IHCs when available to provide therapy associations that cannot be identified through NGS testing. For example, checkpoint inhibitor therapies require IHC testing for PD-L1. We also utilize a number of third-party diagnostic IHCs to help with refining or changing a diagnosis. Most samples come to us for molecular profiling with a diagnosis in hand. However, WES and WTS provide a broad and deep data set that can help alter or refine a diagnosis. In some cases, we receive patient sample labeled as &#8216;Cancer of Unknown Primary,&#8217; where it is hoped that molecular profiling will allow a more specific diagnosis to be applied. Once we evaluate the molecular data, including the results of GPSai if applicable, our pathology team will often order diagnostic IHC testing to provide additional support for a specific diagnosis. </font>
        </div>
        <table style="width:456pt;min-height:223pt;margin-top:10pt;border-collapse: collapse;border:0.75pt solid #000000; font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="height:17.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:4.5pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">Case Study: Caris GPSai&#8482; Helps Diagnose Origin of Metastatic Malignancy </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:63pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A woman in her early 30&#8217;s presented to her primary care physician with symptoms of abdominal distension and gastrointestinal discomfort. Imaging revealed widespread metastatic disease, including pleural effusions (excess fluid in the space between the lungs and the chest wall), pulmonary nodules (small growths in the lung), and extensive lymphadenopathy (swelling of the lymph nodes). A biopsy of a soft tissue mass in the right abdominal wall was preliminarily thought to represent carcinoma. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:39pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IHC testing showed certain positive and negative markers that together led to a diagnosis by the patient&#8217;s physician of metastatic CUP. Seeking further clarity, the patient&#8217;s tissue sample was sent to Caris for molecular profiling and GPSai&#8482; analysis. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:39pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;padding:2pt 0pt 1pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The GPSai&#8482; result returned with a 99% probability of mesothelioma, suggesting the cancer originated from mesothelial cells, such as those lining the lungs and abdomen, rather than being a metastatic adenocarcinoma from another primary site. </div>
            </td>
            <td style="padding:0pt;background:#E1E9F2; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
          <tr style="height:65.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;">&#8203;</td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="background:#E1E9F2;border-bottom:0.75pt solid #000000; ;padding:2pt 0pt 6pt 0pt; width:444pt;">
              <div style="line-height:12pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The integration of Caris GPSai&#8482; into the patient&#8217;s care pathway facilitated a more precise understanding of her tumor&#8217;s origin and molecular characteristics, guiding personalized treatment decisions tailored specifically to mesothelioma. By pinpointing the precise nature of the cancer, Caris GPSai&#8482; enabled a more targeted and effective approach to treatment, with the goal of ultimately optimizing treatment and outcomes.</div>
            </td>
            <td style="padding:0pt;background:#E1E9F2;border-bottom:0.75pt solid #000000; ; width:6pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;background-color:#E1E9F2;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">MI Profile for Biopharma</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Maximizing knowledge and extracting the most information out of every patient sample on a clinical trial reduces the risk of researchers missing potential efficacy or safety signals. Sequencing the whole exome and the whole transcriptome not only yields far more biomarker data from limited specimens, but also allows for the power of such comprehensive information to be aggregated and deployed to improve patient outcomes in the future via real-world data analyses. The breadth and depth of data make our methodology fundamentally different from the currently available DNA panels, which are limited by only looking at known biomarkers. We believe that a non-comprehensive, subset panel of genes or DNA-only assay that ignores RNA is an inadequate solution for efficient and successful drug development, and represents </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">176</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the central underpinning for why we believe we are uniquely positioned in the marketplace to be the industry leading innovator and strategic partner of choice for biopharma companies, to jointly bring forward the next generation of novel therapies for patients with cancer. Oncology therapeutics are inevitably shifting from single driver alterations with single biomarkers to more sophisticated and complex biomarkers that can stratify patients such as novel signatures for DNA damage response repair targeting molecules and RNA-based expression for immunotherapies. Our comprehensive WES/WTS NGS assay is optimally positioned to seamlessly validate these novel biomarkers that are already included in our assay. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Molecular profiling has broad applications for our biopharma partners, including prospective screening, retrospective testing and deep translational analyses, stratification of patients for existing or future trials, and treatment monitoring. When our tissue WES/WTS assay is deployed as an integrated component of early development programs and clinical trials, that same assay can be leveraged for companion diagnostics development and commercial services that we deliver for our partners. Commitment to Caris as registration partner allows early regulatory interactions while minimizing pharma sponsor costs, maintaining flexibility to changing timelines and evolving biomarker strategies. We have obtained a PMA approval from the FDA for MI Cancer Seek as a companion diagnostic device, and we believe approval by the FDA will serve as another important inflection point for our biopharma business. Furthermore, the comprehensiveness of our WES/WTS approach creates a deep competitive moat for us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to testing of both DNA and RNA, we offer companion diagnostic partners opportunities to use samples sourced from our vast biobank of clinical specimens. This offers partners access to a large selection of fully characterized specimens of known positive and negative biomarker status. This can alleviate one of the most difficult hurdles of companion diagnostic development, namely access to enough biomarker-positive specimens across the minimum number of cancer types required to conduct FDA validation studies. For companion diagnostic projects involving a biomarker with low incidence, we offer partners a significant advantage. Beyond companion diagnostics, our biobank carries significant value for exploratory translational studies. When novel discoveries are made </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;">, or based on DNA or RNA, the path to validate these findings requires tissue for proteomic assessments or targets or biomarkers. Having any tissue is valuable however, our tissue biobank is unique because of the scale due to the number of cases and tests we have completed to date, the heterogeneity of tissue types which reflects cancer prevalence, and most importantly because of the amount of WES and WTS information we have generated. In aggregate, our biobank with accompanying data and digital images provides biopharma companies with a unique and highly valuable set of research tools to help validate and derisk the next wave of oncology therapeutics. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caris ChromoSeq</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through an exclusive license arrangement with Washington University in St. Louis (&#8220;WashU&#8221;) that we entered into in October 2024, we are developing Caris ChromoSeq, an assay that detects and analyzes hematological (blood) cancers using whole genome sequencing (&#8220;WGS&#8221;) and WTS for commercial launch. We are internally validating this assay, which is based upon the licensed assay and also includes our WTS technology, and developing it for commercial launch subject to successful validation and a successful application for reimbursement from MolDX. If successful, we believe this assay designed for genomic evaluation of patients with blood cancers would serve as a valuable complement to our existing tissue and liquid assay solutions, which are oriented towards identifying and profiling cancers of solid tumor origin, and enhance our position as a provider of choice for molecular profiling solutions. If we determine to commercialize this assay, we anticipate initially doing so as an LDT.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The licensed assay is a high coverage WGS assay currently designed and initially validated for the comprehensive genomic evaluation of patients diagnosed with acute myeloid leukemia (&#8220;AML&#8221;) or myelodysplastic syndromes (&#8220;MDS&#8221;). The licensed assay requires only 50 ng of tumor DNA (blood or bone marrow) for sequencing and is designed to identify over 600 clinically relevant chromosomal rearrangements known to be recurrent in myeloid malignancies. The licensed assay is an alternative to existing conventional diagnostic and risk assessment tools for AML and MDS, which are primarily cytogenic testing (karyotyping, or visual analysis of chromosomes), fluorescence </font><font style="font-style:italic;letter-spacing:0.2pt;">in situ</font><font style="letter-spacing:0.2pt;"> hybridization (&#8220;FISH&#8221;), or sequencing assays targeting specific genes or RNA transcripts, each of which conventional methods may provide incomplete information, have limited sensitivity, or present challenges in obtaining viable samples for testing. In a study published by WashU in 2021, the licensed assay was used to obtain genomic profiles for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">177</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">263 patients with myeloid cancers, including a 146 patient retrospective cohort and a 117 patient prospective cohort. Overall, the licensed assay identified 100% of the clinically significant abnormalities that had been identified by conventional cytogenic analysis and identified new clinically reportable genetic information not detected by conventional methods in 17% of the patients tested. Additionally, for 19 of the 117 patients in the prospective cohort (16%), analysis performed by the licensed assay changed their risk categorization on the basis of standard risk categories promulgated by the European Leukemia Network and the International Prognostic Scoring System&#8212;Revised. The licensed assay displayed similar performance as conventional cytogenetic analysis when predicting clinical outcomes using existing genetic risk groups (adjusted p=0.09 by log-rank test in groups identified by conventional testing; adjusted p=0.01 by log-rank test in groups identified by the licensed assay). The licensed assay was also found to stratify patients who had inconclusive results by cytogenetic analysis into risk groups in which clinical outcomes were measurably different&#160;(adjusted p=0.03 by log-rank test).</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">WashU has obtained Medicare coverage for patients diagnosed with AML and MDS. We believe the methods used by the licensed assay, to be modified by us, can be applied to, and we are working to expand and validate the assay&#8217;s capabilities for, hematological cancers beyond AML and MDS. In order to obtain MolDX coverage for Caris ChromoSeq, we will need to submit, and MolDX will need to approve, a technical assessment for Caris ChromoSeq. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Caris Discovery</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Caris Discovery is our drug target and therapeutic discovery business. Caris Discovery leverages our profiling solutions, multi-modal clinico-genomic datasets, wet lab facilities, proprietary Adaptive Dynamic Artificial Polyligand Targeting (&#8220;ADAPT&#8221;) platform, and AI/ML-enabled </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> analyses to identify potential drug targets and develop therapeutics. We launched Caris Discovery in 2022 to partner with biopharma partners to address the lack of novel cancer-specific targets and the herding of biopharma pipelines around a discrete number of lower-risk targets. Caris Discovery is disease- and modality-agnostic and can be applied to any therapeutic modality, including antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, cell therapy, and neoantigen discovery for personalized therapy development, among others. In addition to working with biopharma partners, Caris Discovery is developing a wholly-owned pipeline of biologics based on our platform.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An antibody-drug conjugate is a targeted cancer therapy that combines an antibody with a cytotoxic drug. The antibody specifically targets cancer cells, delivering the drug directly to them, which helps minimize the impact on healthy cells. This approach aims to increase the effectiveness of the drug while reducing side effects.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Degrader-antibody conjugates (&#8220;DACs&#8221;) are an emerging class of therapeutic agents that combine the targeting ability of antibodies with the protein degradation mechanism of degraders. DACs are designed to bind to specific proteins on the surface of cancer cells through the antibody component and then recruit the cell&#8217;s degradation machinery to eliminate the target protein inside the cell. This dual action allows for precise targeting and removal of disease-causing proteins, potentially leading to more effective treatments with fewer side effects.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">T-cell engagers are a class of artificial engagers that are designed to specifically direct the body&#8217;s immune system to target cancer cells. They function by simultaneously binding to CD3 on T cells and to a specific antigen on the tumor cell, thereby bringing the T cells into close proximity with the tumor cells, which can result in the T cells attacking and killing the tumor cells.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A small molecule refers to a low molecular weight organic compound that can regulate a biological process, with a size on the order of 1 nm. In the pharmaceutical industry, small molecules can include drugs that can be orally or intravenously administered and are often used to regulate biological processes. The term contrasts with larger molecules, such as biologics.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Targeted protein degradation is a therapeutic strategy that aims to eliminate disease-causing proteins from cells. It involves the use of small molecules, known as proteolysis-targeting chimeras, or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">178</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:252.49pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">molecular glues, that can bind to specific proteins and tag them for destruction by the cell. This approach is particularly useful for targeting proteins that are difficult to inhibit with traditional drugs or for which no inhibitors exist.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Synthetic lethal interactions in drug discovery refer to a relationship between two genes where the loss of function of either gene alone is survivable by the cell, but the simultaneous loss of both is lethal. This concept is utilized in drug discovery to target cancer cells with specific genetic mutations. By inhibiting the function of a gene that is synthetically lethal to a mutated gene already present in the cancer cell, the cell can be selectively killed without harming normal cells.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Cell therapy is a form of treatment where living cells are injected into a patient to help cure a disease. In the context of cancer treatment, cell therapy can involve the use of immune cells that are either taken from the patient or from a donor, modified in a lab to enhance their ability to fight cancer, and then injected back into the patient. This approach is part of a broader category known as immunotherapy, which aims to harness the body&#8217;s immune system to combat cancer.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we believe Caris Discovery can be leveraged to discover personalized therapies for cancer. A major paradigm-shift in cancer therapy in recent&#160;years has focused on harnessing the immune system&#8217;s ability to recognize and eliminate cancer cells. One promising approach involves using personalized therapies to stimulate the immune system against tumor-specific antigens also known as neoantigens. Those neoantigens are proteins that are produced by mutations in the DNA of cancer cells and are not present in normal cells. We believe Caris Discovery is well-positioned to be able to discover personalized neoantigens for cancer therapies given our ability to detect variants and INDELs by WES and to assess gene expression and detect fusions by WTS on every patient&#8217;s tumor. We also leverage our deep proteomics expertise utilizing mass spectrometry to validate neoantigens using our biorepository of contemporaneous molecular profiled remnant patient tissue that can be predicted by deep ML from our Caris Assure blood and MI Profile tissue sequencing. Furthermore, we can predict who may or may not respond to personalized therapies and who should be excluded from personalized therapy trials due to defects in antigen presentation machinery, such as loss of major histocompatibility complex genes due to mutations or downregulation. We are working with multiple partners that have a personalized therapy in clinical development or clinical trials. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">179</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our proprietary repositories of tissue and data, each of which we believe to be at an unmatched scale, are a resource that could not have been amassed without our underlying commercial profiling business, and as such are a significant differentiator and enabler of our discovery efforts. </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="fc_discovery-4c.jpg" alt="[MISSING IMAGE: fc_discovery-4c.jpg]" height="433" width="577" >
        </div>
        <div style="text-indent:36pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have achieved external validation of our Caris Discovery approach through strategic partnerships with established biopharma companies, such as Merck KGaA and Xencor, to develop therapeutics against novel targets that emanate from our molecular insights and proprietary technology. Our Caris Discovery partnerships are designed to emphasize both near term revenue and the potential upside of successful therapeutics developed against novel targets identified by us, thus aligning our partners&#8217; financial interests with our own. Our proprietary discovery proteomics and downstream target validation work is performed, by over 50 Caris scientists, in our R&amp;D laboratory in Tempe, Arizona, a 59,000 square foot facility that includes a cell culture laboratory and state-of the-art instrumentation dedicated to drug target discovery. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">In Silico Target Discovery Leveraging the Caris Clinico-genomic Dataset</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Caris Discovery leverages our multi-modal clinico-genomic datasets to define clinically relevant cohorts of unmet need for drug target discovery. Stratifying cases by molecular profile, histology, and/or clinical features </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> prior to performing our proprietary proteomic work on the profiled cases in our tissue repository is extremely powerful to identify drug targets in highly relevant therapeutic areas. Once potential targets are identified, the clinico-genomic data can be integrated with our proteomics data and can be utilized to filter the initial target pool down to the targets with the highest potential value for further downstream wet-lab validation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The proteomics work leveraging our </font><font style="font-style:italic;letter-spacing:0.2pt;">in silico</font><font style="letter-spacing:0.2pt;"> discovery work is driven by three complimentary components: (1)&#160;our ADAPT Biotargeting, (2)&#160;Proximity Labeling, and (3)&#160;the Caris Surfacesome. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">ADAPT Biotargeting&#8212;Aptamer-Based Proteomics Discovery System.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our ADAPT system uses a broad library of synthetically manufactured molecules called aptamers that bind to a wide range of biological targets and characterize complex biological systems, enabling the profiling </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">180</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:56pt; width:400pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of biological samples at a systems-wide scale coupled with affinity purification-mass spectrometry to identify the underlying target proteins. ADAPT is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural states and directly from patient tissue. ADAPT is powered by real world contemporaneous patient samples, including our combined clinico-genomic datasets, thus overcoming the limitations of traditional target discovery approaches, such as comparative genetics, molecular pharmacology of variants, analysis of molecular signaling pathways, cell-based and </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> disease models, limited panel based proteomics with a defined set of target proteins and traditional proteomics, which result in a high degree of off-target activity, false positives and bias, and lack enrichment of patient enriched cancer proteins. ADAPT allows us to make unbiased identification of unique features of disease state and allows for elucidation of novel biological mechanisms. Actionable drug targets (or molecular markers) include proteins that are present in diseased tissue but low to no detection in normal tissue. Traditional biomarker discovery tools suffer from a signal to noise challenge and require a hypothesis of where to look before being deployed. ADAPT can filter out features shared by both cancer and normal cells and enriches for features specific to cancer cells. </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proximity Labeling&#8212;Antibody-based Proteomics Discovery System.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We also apply proximity labeling on molecularly profiled remnant patient tissue to examine protein-protein interactions as well as to identify components that localize to discrete subcellular compartments. This approach enables us to identify actionable drug targets in patient tissue and permits the systemic analysis of spatially restricted proteomes. Applying proximity labeling on our proprietary tissue profiling data has resulted in the discovery of numerous novel drug targets potentially actionable for bispecific antibodies, dual targeting antibody modalities, and cell therapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Caris Surfacesome.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Cell-surface proteins are key to antibody-based therapeutics, and we have developed our own cell surfacesome comprising a database of cell surface proteins detected by mass spectrometry. This in-house database comprises genomic, transcriptomic, and proteomic data for multi-omic data analysis in addition to prepared cytosections and live cells instrumental for antibody quality control and wet-lab validation of drug targets discovered from our Aptamer and Antibody-based discovery systems. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Caris Strategic Data</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Data and molecular information are at the core of every aspect of our business. Our team of more than 60 data scientists deploy our proprietary advanced AI/ML algorithms to decipher unique features from our resulting clinico-genomic datasets, helping us decode and further unravel the molecular complexity of disease. Our 17-year history of utilizing AI and ML algorithms, together with the breadth and depth of our clinico-genomic datasets, provide us a significant advantage in sophisticated analysis of cancer, and a foundation that we believe will have applications in additional disease states. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March 31, 2025, we have run more than 6.5&#160;million tests that have measured over 38&#160;billion molecular markers from over 13 quadrillion datapoints. To assist us with analyzing the data we generate, we utilize over 220 AI and AI/ML tools across our clinical testing, R&amp;D, and biopharma business. These tools include over 50 clinical sequencing automation and variant calling AIs, over 100 RNA expression AI signatures, approximately 20 multi-omic AI/ML therapy response predictors, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/ML classifiers, and 12 AI/ML support tools. This tremendous amount of data, which we have deidentified for research use, provides us a differentiated capability to advance precision oncology research through many business models, including training new profiling solutions and signature development, therapy development, and research into new ways to treat and cure disease, including personalized treatments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our goal is to develop the next generation of precision medicine tools that will allow us to transition from intuitive medicine to empirical medicine. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">181</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Power of Big Data</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">With a dataset as large as ours, a key task is to reduce the dimensionality of data to those key features that are useful to understanding the systems biology while avoiding any preconceived bias in how we might expect the features to be related. We accomplish this through mathematical embedding, which we use to reduce the dimensionality of the datasets to provide powerful insights into the underlying relationships within the data. This massive amount of information, across the whole transcriptome and multiplied across hundreds of thousands of patients, then undergoes a process where features that tend to occur together more often (or clusters) are associated into a multidimensional vector space. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">One example of this methodology, and how additional data drives better predictions, can be seen in the pictures below, which show the clustering of a single gene set enrichment analysis (GSEA) across increasingly large datasets, from our research into a predictive algorithm for brain metastasis. This clustering, which reflects screening through AI to reduce dimensionality and identify underlying clusters, shows that meaningful clustering groups can only be seen with larger amounts of data. The clusters become increasingly visible as the datasets grow from 1,000 to 200,000 cases. </font>
        </div>
        <div style="position:relative;margin-top:9.6pt; text-align:center; width:456pt;">
          <img src="ph_powerofbigdata-4c.jpg" alt="[MISSING IMAGE: ph_powerofbigdata-4c.jpg]" height="170" width="578" >
        </div>
        <div style="text-indent:36pt; margin-top:12.2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In this study, once we identified the relevant clusters, we then used the coordinates of the clusters as inputs into a separate AI/ML model that would predict the likely outcome&#8212;in this case, whether a patient was more or less likely to develop a brain metastasis. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38&#160;billion molecular markers. Leveraging high-powered computing and AI/ML algorithms, we, and our biopharma and research partners who use our data and bioinformatics services, analyze our datasets to determine the key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. We believe this wealth of data and processing power, together with whole-slide imaging, our tissue and slide repository, can help our researchers and external partners gain previously unattainable insights about specific patient populations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A study that we recently published in </font><font style="font-style:italic;letter-spacing:0.2pt;">Nature Communications</font><font style="letter-spacing:0.2pt;">, a peer-reviewed scientific journal, demonstrated the power of our real-world clinical and genomic dataset, augmented through agreements with external providers of clinical outcomes data, to drive clinical insights. This study evaluated real-world outcomes for patients eligible for available tissue-agnostic&#160;therapies, which are powerful &#8220;pan-cancer&#8221; therapies that target specific molecular alterations across multiple cancer types and of which several have FDA approval. The study, using the largest real-world clinical and genomic dataset of tissue-agnostic indications reported to date across more than 295,000 de-identified patients and over 50 tumor types, demonstrated that over 20% of cancer patients are candidates for a tissue-agnostic therapies based on current FDA-approved indications. Additionally, the study found that over 5% of patients lacking any tumor-specific indication were found to carry a tissue-agnostic indication and thus to be candidates for a tissue-agnostic therapy. The study also generated insights into the different outcomes produced by tissue-agnostic therapies in different tissues. We believe the datasets built by our profiling solutions help enable further development of clinical insights with therapeutic and economic implications. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This study was conducted in 2024 by our researchers using data from all patients who had undergone comprehensive tissue sequencing at our Phoenix tissue laboratory between 2015 and 2023, who had successful </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">182</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">sequencing results, and for whom claims data was available. The study primarily measured time-on-treatment (&#8220;TOT&#8221;), determined as the interval from the initiation to the conclusion of treatment with an indicated therapy, and overall survival (&#8220;OS&#8221;), defined as the period from treatment initiation to the date of the patient&#8217;s last known clinical activity. Kaplan-Meier survival estimates were generated for patient cohorts defined by molecular characteristics. Significant p-values (generally p &lt; .05) were seen for the following major analyses of highly clinically relevant indications: (a) poor clinical uptake of therapies targeting NTRK gene fusions, which are rare but potent drivers of tumor growth that promote cancer cell survival and proliferations; (b) differences in tissue specific outcomes in TMB-high and MSI-high settings, as well as in BRAF V600E-mutant cancers; and (c) differences in TOT and OS outcomes for non-trial patients receiving pembrolizumab and similar TOT benefit of pembrolizumab and nivolumab, two widely-used PD-1 inhibitor therapies, for patients with TMB-high tumors across various cancer types. Collectively, these analyses test the assumption that FDA-approved tissue-agnostic therapies are truly tissue-agnostic in the sense of having similar benefits across all tumor types, and demonstrate the power of large real-world datasets combining clinical data with NGS data, such as the comprehensive data generated by our solutions, to further the medical community&#8217;s understanding of cancer.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Data for Biopharma</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We launched our data licensing business in late 2022. We license deidentified multi-modal datasets, components of which were generated from our clinical profiling business to external researchers, including those with biopharma companies, with the aim of generating insights directly responsible for superior clinical outcomes for patients. As the adoption of our tissue and blood-based profiling solutions continue to grow, this will result in further expansion of our multi-modal datasets, which can provide additional valuable insights to aid biopharma companies&#8217; drug discovery and development efforts to bring innovative therapies to market. We utilize a third-party tokenization process to match deidentified data from various sources to create the multi-modal product. The linked data is then provided to the external researcher. Prior to the tokenization process, we run a series of software solutions through standardized data fields designed to remove and replace any PHI with a randomly-generated string of letters and numbers. We then use a third-party expert to certify that the data is deidentified pursuant to 45&#160;CFR &#167;164.514(b)(1) under HIPAA. We contractually require recipients of the data to maintain compliance with laws and regulations. The end customer takes on the contractual responsibility to properly maintain the data, not to attempt to reidentify any patient from the deidentified data set, and to obtain its own expert certification before combining the Caris data with any other data. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery. These datasets generally consist of Caris molecular profiling data (and in some cases claims data), together with matched clinical data from our partners. We and our partners have entered into agreements with AbbVie, Moderna, and others to license our datasets for use in drug discovery. Together, our combined multi-modal data create a differentiated capability to advance precision oncology research through novel target identification and discovery, translational sciences, clinical trial design solutions and patient enrollment facilitated by our right-in-time trials network, post-market label expansion, and commercialization insights. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have a rich pipeline of data opportunities that we believe will deliver new partnerships, as we continue to introduce biopharma companies to this unique data offering. In addition, many of our biopharma-related data initiatives and data partnerships allow for the flow of multi-modal data to our internal research teams, providing further synergies and enabling AI/ML powered research across the broader Caris enterprise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Data for Clinical Research: The Caris Precision Oncology Alliance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We established the Caris POA in 2015. The Caris POA is a growing network of leading cancer centers and research consortia across the globe that supports research partner engagement, collaboration opportunities, and the advancement of precision oncology research. It consists of members that demonstrate a commitment to precision medicine and work collaboratively toward a common goal: to advance tumor </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">183</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">profiling and establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March 31, 2025, the Caris POA was comprised of 96 members. This represents a five-fold growth in total membership since 2017. Additionally, since 2020, we have more than doubled the number of NCI-designated comprehensive cancer centers in the Caris POA, from 20 in 2020 to 45 as of March&#160;31, 2025. </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="bc_carispoanet-4c.jpg" alt="[MISSING IMAGE: bc_carispoanet-4c.jpg]" height="447" width="596" >
        </div>
        <div style="text-indent:36pt; margin-top:13.4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that the members of the Caris POA have over 3,000 oncologists in over 650 locations that treat more than 650,000 new cancer patients annually. Members participate in the various activities of the Caris POA through the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">profiling cancer patients using our comprehensive profiling solutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">establishing guidelines to integrate molecular testing into cancer care and patient treatment management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">participating in research studies and clinical trials, both prospective and retrospective; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">collaborating in molecular tumor boards to advance the institution and industry&#8217;s understanding of cancer and the clinical utility of profiling in clinical care; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">tracking longitudinal outcomes and contribute data to the Caris POA; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">publishing novel research and clinical data. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As part of the Caris POA collaboration, we contribute de-identified molecular data obtained from tumor profiling of cancer patient samples, and our partners have an opportunity to contribute outcome or clinical data for use in joint research projects. Physicians and researchers across the Caris POA network are provided with information from our datasets as part of our mission to give greater access to and disseminate </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">184</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">this data in furtherance of creating solutions for oncology. Caris POA members access our datasets through CODEai, a custom interface for our multi-modal clinico-genomic datasets that we launched in 2020. CODEai allows users to explore a cohort of over 295,000 matched datasets and clinical outcomes. CODEai users can define patient cohorts of interest and direct the underlying AI to mine the data, extract cogent information such as molecular markers that correlate with defined patient cohorts, and perform various analyses. Working with leading oncologists at Caris POA member sites, we have established a number of tumor-specific working groups comprised of key academic thought leaders and subject matter expertise to assist us in ensuring our profiling components remain clinically up-to-date with the latest important molecular markers and testing threshold criteria. </font>
        </div>
        <div style="position:relative;margin-top:10.6pt; text-align:center; width:456pt;">
          <img src="lg_datacliniclogo-4c.jpg" alt="[MISSING IMAGE: lg_datacliniclogo-4c.jpg]" height="640" width="578" >
        </div>
        <div style="text-indent:36pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We also contribute to academic research to advance the understanding of molecular science and further enable the delivery of precision medicines through our collaborations with member institutions within the Caris POA. We routinely collaborate with leading cancer centers to publish and present new learnings with immediate implications on the clinical use and utility of comprehensive molecular profiling. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">185</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:37.04pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Together with collaborators, our medical and scientific experts have authored over 380 manuscripts in peer-reviewed medical and scientific journals, and more than 660 abstracts, posters and presentations at leading industry conferences and symposiums that expound on our innovative platforms and technologies. </font>
        </div>
        <div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img src="bc_publications-4c.jpg" alt="[MISSING IMAGE: bc_publications-4c.jpg]" height="447" width="597" >
        </div>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Data Driving Development of New Clinical Solutions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">A significant benefit of generating WES and WTS results for every eligible patient is that the resulting dataset becomes a unique and proprietary resource to fuel the development of new molecular-driven signatures, products, and profiling solution enhancements that are only possible due to the availability of large datasets. Our datasets have also been augmented through agreements with external data providers. We have leveraged our vast datasets to drive the development of AI-based signatures and other enhancements, including our ABCDai algorithm and hundreds of other AI algorithms that are used in our bioinformatics pipelines for our profiling solutions. These solutions are designed to allow us to better leverage our data to improve patient outcomes and significantly differentiate us from our competitors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to utilize our datasets and molecular profiling knowledge to continue to create proprietary molecular signatures that leverage NGS-based testing results and to utilize digital scans of tissue slides to predict the presence of certain molecular markers without the need for NGS profiling. In addition, we plan to establish patient-level prognosis and prediction of therapeutic benefit, with an initial focus on breast cancer, but that we believe will have therapeutic benefits across all cancer types. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">186</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tb_molecular-4c.jpg" alt="[MISSING IMAGE: tb_molecular-4c.jpg]" height="369" width="582" >
        </div>
        <div style="margin-top:16.4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Caris Proprietary Molecular AI/ML Driven Signatures</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to utilize our datasets to continue to create proprietary molecular signatures and potentially establish patient-level prognosis and prediction of therapeutic benefit, with an initial focus on breast cancer. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to our two clinically validated proprietary molecular signatures, GPSai and FOLFIRSTai, which can be ordered as part of MI Profile, we have a pipeline of proprietary molecular signatures that we are in the process of refining and validating. For example, we are developing MGMTai, a predictive signature that will help oncologists assess a patient&#8217;s risk of developing brain metastases, and other signatures in development include pancreatic cancer response predictors, a predictor of response to checkpoint inhibitor therapy for lung cancer patients, and a predictor of response to platinum-based therapies for ovarian cancer patients. Similar to our FOLFIRSTai signature, we believe these types of multi-omic, ML-driven signatures will add significant and differentiating clinical value to our solutions, positioning our profiling solutions as the most complete and comprehensive for late-stage cancer available. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that whole exome and whole transcriptome data is critical to develop robust AI signatures. For example, we are using whole exome and whole transcriptome data to train two AI signatures that predict therapeutic responses. The first AI signature that we are training predicts the response of lung cancer patients to immunotherapy and chemotherapy. This model demonstrated the capability to identify, at a p-value of less than 1%, patients that would benefit from immunotherapy along with chemotherapy, versus patients for whom chemotherapy would not be expected to have a benefit. Over 60% of several hundred genes and transcripts that this model identified as the most significant features are not included in a commercially available 700-gene panel. The second AI signature that we are training predicts response of pancreatic cancer patients to FOLFIRINOX and Gemcitabine + Abraxane&#174;. This model was shown to identify, at a p-value of less than 1%, Stage IV pancreatic patients who would have a survival benefit from FOLFIRINOX treatment but not Gemcitabine + Abraxane&#174;, and vice versa. Of the dozens of molecular features that feed into this model, nearly half are not analyzed in a commercially available 700-gene panel. Thus, we do not believe these types of models could be replicated without whole exome and whole transcriptome data like that produced by our sequencing solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our basic strategy for molecular signature development is to utilize our proprietary WES/WTS and claims data clinical databases for initial signature creation, with validation in external datasets (when advisable), including datasets that have been developed in other prospective clinical trials. These external </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">187</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">datasets will, in many cases, be derived from active and ongoing collaborations with cooperative oncology groups or single academic institutions, many of which are active members of the Caris POA. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Digital Pathology Innovation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also utilizing our datasets and AI/ML analysis to develop the ability to use digital scans of tissue slides to predict the presence of certain biomarkers without the need for NGS profiling. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have captured more than 4.4&#160;million images of patient tumor tissue as of March&#160;31, 2025, including approximately 3.1 million digitized IHC images and approximately 1.4&#160;million digitized hematoxylin and eosin (&#8220;H&amp;E&#8221;) images, and each image is associated with the patient&#8217;s full WES/WTS profile and clinical information. The workflow for WES and WTS sequencing of patient tumor tissue requires the sectioning of a Formalin Fixed Paraffin Embedded tissue specimen, leading to the creation of a set of unstained slides containing the patient&#8217;s tumor material. We stain two slides with traditional H&amp;E reagents, others with antibodies for downstream IHC testing, and others with Nuclear Fast Red stain to facilitate microdissection and DNA/RNA extraction for sequencing. We have implemented a fleet of seven Pramana SpectralHT next generation, robot-controlled digital slide systems (each with four scanners for 28 total scanners) to capture ultra high-definition images of all H&amp;E and IHC slides. The images are used to drive efficient and rapid analysis and processing during the testing workflow and also provide a unique and previously unavailable rich resource to fuel new assay development and innovation based on image-driven AI. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our data scientists are using this powerful combination of molecular and visual data together to fuel the development of new image-driven AI signatures. The goal is to use the molecular data to validate AI signatures that can predict molecular status based on the digital slide image alone. The applications of this new approach include rapid image-based diagnosis, biomarker status determination, and prognostic determinations rapidly and cost-effectively, using just the slide image. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are currently using an AI/ML approach driven by H&amp;E slide images and clinical results data from more than 10,000 breast cancer patients to develop ESPai, a new algorithm to predict the risk of disease recurrence for early-stage breast cancer patients. We have obtained the samples and clinical data from the National Surgical Adjuvant Breast and Bowel Project and the ECOG-ACRIN Cancer Research Group. We are currently in the process of creating two AI/ML models for ESPai using these samples and are working to obtain additional samples for external validation studies. We are initially creating a model for late recurrence (five to 15 years following diagnosis), but we are also in the beginning stages of creating a model for early recurrence (zero to five years following diagnosis).</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As an additional example, we have developed an AI tool that uses the digital image of a slide that has been stained with traditional H&amp;E reagents to predict whether a patient has an increased likelihood for being positive for a ROS1 fusion, which is a particular type of gene fusion that is associated with non-small cell lung cancer. Biopharma companies developing new ROS1-targeted therapies typically must use NGS or FISH testing to screen more than 100 patients to identify one or two positive patients, resulting in very high cost and long timelines for clinical trials. The Caris ROS1 AI signature can be used on the slide alone and identify patients who are 33 times more likely to be ROS1 positive, thereby reducing the number of patients who need to be screened by more expensive and precise methods by more than 97%. Imaged-based, low-cost AI signatures like this might also be useful in the future in countries with limited access to sequencing technology. We expect to develop more of such image-based AI signatures using the power of ML on the combined image and molecular datasets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Laboratory Infrastructure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have built substantial testing capacity with throughput capabilities of over one trillion &#8220;reads&#8221; per day. We operate two precision medicine laboratories in Phoenix, Arizona, and one R&amp;D laboratory in Tempe, Arizona. Our Arizona laboratories all utilize state-of-the-art genomic sequencing technology, including 50 NovaSeq sequencing systems. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet. We believe this operational capacity provides us with ample capability to manage future growth. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">188</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our solid tissue clinical laboratory in Phoenix, Arizona is an approximately 66,000 square foot, state-of-the-art laboratory. We provide high quality, reliable molecular testing services for all stages of the drug development cycle and routine clinical use. From pre-clinical research for compound development efforts to&#160;established, commercially available therapies, we provide robust genomic and proteomic testing capabilities across a variety of specimen types and high-throughput technologies. This laboratory has the following certifications: ISO 15189, ISO 13485, CLIA: CMI&#160;03D1019490, College of American Pathologists (&#8220;CAP&#8221;): 7195577, and New York State Department of Health. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our blood-based clinical laboratory in Phoenix, Arizona is approximately 35,500 square feet. This laboratory started testing operations in February&#160;2022 following the installation of liquid-handling robots and NovaSeq sequencing systems. This laboratory has the following certifications: ISO 15189, CLIA:&#160;CMI&#160;03D2210981 and CAP: 9536852. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also have an approximately 59,000 square foot R&amp;D laboratory in Tempe, Arizona that is utilized for R&amp;D and therapeutic discovery work. This laboratory has ISO 13485 certification. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have leased an approximately 114,500 square foot facility in Irving, Texas, close to our corporate headquarters, which includes office space and will house a clinical laboratory. We expect to build out the clinical laboratory in phases in the future to coincide with product launches and provide us with additional profiling capacity as we continue to grow our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We test patient samples on the most powerful sequencing systems available, which are built for high throughput sequencing, scalability, and speed and allow for high throughput more economically than prior platforms. Our use of high performance NGS sequencing systems improves our throughput efficiencies and lowers our cost of sequencing. We have an installation of 50 NovaSeq sequencing systems as of March&#160;31, 2025. In addition to NGS, we employ other technologies in our operations, including 33&#160;liquid handling robotic systems, ultra HD digital image scanning, dynamic light scattering, flow cytometry, fragment analysis, IHC, </font><font style="font-style:italic;letter-spacing:0.2pt;">in situ</font><font style="letter-spacing:0.2pt;"> hybridization, laser capture microdissection, mass spectrometry, Sanger sequencing, pyro sequencing, quantitative polymerase chain reaction, RT-PCR, and surface plasma resonance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Commercialization Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The precision medicine industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements, and evolving industry standards. Education of customers, both physicians and biopharma companies, remains one of the key barriers to higher adoption of molecular profiling. More than ever, oncologists need a trusted profiling partner to provide reliable, high-quality molecular profiling information to guide precise and individualized treatment decisions. Our relationships across key oncology stakeholders include more than 5,600 physicians and partnerships with more than 100 biopharma companies. Additionally, we have executed agreements with or recently engaged in commercial discussions with all of the top 30 pharmaceutical companies measured by market capitalization. We have optimized our systems to provide industry-leading reports, service, and turn-around-time, helping oncologists (1)&#160;navigate among therapies with potential benefit, (2)&#160;identify therapies that may not have been considered, (3)&#160;determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs), and (4)&#160;match patients to clinical trials. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, we market our solutions to clinical customers through our marketing and commercial sales organizations. Our commercial footprint consisted of nearly 300 sales team members at the end of 2021 compared to approximately 275 sales team members and approximately 25 marketing team members at the end of 2024. Since the end of 2021, the size of our sales organization has generally remained constant, though the team has grown slightly during certain periods and contracted slightly in others. Our sales team members cover the entire U.S. market, focusing on the community setting where the majority of cancer patients are treated. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, as of March 31, 2025, we had nearly 50 highly trained Ph.D. or M.D. MSLs who focus on physician and provider education and consultation, enabling us to provide a personalized consultation experience for oncologists. MSLs are responsible for communicating the value of Caris to external stakeholders, such as physicians, nurses, scientists, and other interested parties. This communication primarily involves face-to-face discussions with customers. The MSLs use a variety of opportunities such as molecular </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">189</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">tumor boards, educational seminars, and conference participation to act as a conduit of information and feedback between the medical community and us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Decisions about which profiling services to use have become increasingly &#8220;institutionalized,&#8221; where cancer center directors and other medical leaders are adopting the approach of designating a &#8220;preferred partner&#8221; that is a technology and service leader for molecular profiling services. We believe that the Caris POA and our deep, high-quality institutional relationships provide us with an advantage in being selected as a preferred partner, and we expect this trend to continue to accelerate to further drive growth in ordering of our profiling solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We market our solutions to biopharma companies through a separate Biopharma Business Development team. This team is differentiated from traditional sales organizations by recruiting professionals with a diversity of direct biopharma experience and strong scientific backgrounds and business acumen. We believe the credibility that our partnering team brings to discussions with biopharma companies has been well-received, and when combined with our profiling solutions and molecular datasets, has created a strong competitive edge.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We estimate that approximately two-thirds of our top 200 customers based on case volume were either academic medical centers or corporate physician practices. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">International Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Globally, we market our solutions through distributors and direct contracts with hospital systems, where permitted by the applicable regulations. Our distributors are generally obligated to obtain required in-country regulatory approvals and comply with in-country regulations. We have performed our clinical solutions to patients in over 50 countries since 2022 and are considering filing for regulatory approvals in Japan and the European Union. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EHR Integration and Electronic Ordering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have established bi-directional electronic healthcare record (&#8220;EHR&#8221;) interfaces with individual institutions and/or specific provider locations. Test ordering can be done within the local EHR, and discrete test results can be returned to the ordering site automatically. We have integrated connections with every major EHR vendor. In addition to EHR integrations, we have a physician portal in which physicians can order testing and receive clinical reports electronically. Together, our EHR and portal ordering constituted approximately 47% of our clinical volume during 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The precision oncology industry is highly competitive and subject to rapid change. An increasing awareness of the importance of genetic information to accurately understand cancer and deliver solutions for early detection, MRD tracking, therapy selection, and treatment monitoring is leading to more companies offering services in genomic profiling and sequencing. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our competitors in tissue-based molecular profiling include Foundation Medicine (Roche) and Tempus. In addition, some academic centers, such as Memorial Sloan Kettering Cancer Center and New York Presbyterian&#8201;&#8212;&#8201;Weil Cornell, offer profiling to patients in their networks. Our competitors in blood-based early detection include Grail, Freenome, Guardant Health, Exact Sciences, and Delfi Diagnostics, among numerous other companies pursuing the early detection market. Our competitors in blood-based molecular profiling for therapy selection include Guardant Health and Foundation Medicine (Roche). Our competitors in blood-based molecular profiling for MRD tracking and treatment monitoring include Natera, Guardant Health, and Adaptive Biotechnologies. Our competitors in core biopharma services include Foundation Medicine (Roche), Guardant Health, Tempus, Natera, and Personalis, among others. Our competitors in offering genomic data and AI services include Tempus and Foundation Medicine (Roche). Other companies offering testing in the precision oncology industry include Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, Quest Diagnostics, and BostonGene. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of these companies may have substantially greater financial and other resources than we have, such as larger R&amp;D staff and more established marketing and sales forces, or may operate in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">190</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">jurisdictions where lower standards of evidence are required to bring products to market. In addition, other established diagnostic, medical technology, biotechnology, or pharmaceutical companies may decide in the future to invest heavily to accelerate discovery and development of similar services that could make our solutions less competitive. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that we compete favorably based on the following competitive factors: our patient-first approach that includes deep sequencing all DNA encoding genes and RNA transcripts utilizing comprehensive WES and WTS, enabling us to provide patients and physicians with industry-leading breadth, depth, and accuracy of multi-omic information; our tissue-based molecular profiling solution; our novel, universal blood-based profiling solution; our large and comprehensive multi-modal clinco-genomic dataset; our specialized commercial channel, robust infrastructure, and deep research collaborations; and our highly experienced management team. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Protection of our intellectual property is fundamental to the long-term success of our business. We seek to ensure that investments made into the development of our solutions to transform healthcare through the use of comprehensive molecular information, AI/ML algorithms, and proprietary molecular technologies are protected by a combination of patents, trademarks, copyrights, trade secrets, license agreements, confidentiality agreements and procedures, employee agreements (such as proprietary information, intellectual property, restrictive covenant, and arbitration agreements), and other legal and contractual rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Patents</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We seek patent coverage for our foundational multi-cancer, multi-purpose molecular profiling solutions for tissue and blood and for our R&amp;D activities, including biomarker discovery using our expansive molecular profiling datasets and tumor tissue archive. Our policy is to enter into invention or patent assignment agreements with our employees and consultants that obligate these employees and consultants to assign to us any inventions they develop while working for us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our company-owned and in-licensed patents and applications generally fall into the following categories: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Patents and applications related to our molecular profiling services.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As of March 31, 2025, we owned 79 patents (including three allowances) and 75 pending applications, and had an exclusive license to one patent application, which collectively relate to our molecular profiling solutions, including claims directed to early detection of cancer, monitoring disease recurrence, identifying treatments of likely benefit or lack of benefit for cancer patients, and the use of AI and ML for prediction of response to various cancer therapies, prediction of tumor origin, and to assess other characteristics of cancers based on NGS data and/or digital pathology. The Caris-owned patents and applications are assigned to our subsidiary Caris MPI, Inc. and include 17 issued U.S. patents, 16 pending U.S. applications, 62 foreign patents (including three allowances), and 59 pending foreign applications. The in-licensed patent application is a U.S. application and is exclusively licensed to Caris MPI, Inc.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Patents and applications related to our pharma research and development services</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;As of March&#160;31, 2025, we owned 103 patents (including four allowances), and&#160;24 pending applications, and had exclusive licenses to 43 patents and applications, which collectively relate to aptamer library screening and uses thereof, including uses in biomarker discovery, as well as cell targeting constructs and therapeutic applications thereof. The Caris-owned patents and applications are assigned to our subsidiary Caris Science, Inc. and include 16 issued U.S. patents, six pending U.S. applications, 87 foreign patents (including four allowances), and 18 pending foreign applications. The in-licensed patents and applications are exclusively licensed to Caris Science, Inc. and include two issued U.S. patents, one pending U.S. application, 36 foreign patents, and four pending foreign applications. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patents and applications of particular importance within our portfolio that relate to our commercial molecular profiling services include:</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">191</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">63 patents and ten pending applications directed to systems and methods for comprehensive molecular profiling for cancer patients independent of cancer type. These include 14 issued U.S. patents and one pending U.S. application, and 49 foreign patents (including two allowances) and nine pending foreign applications between Australia, Austria, Belgium, Canada, China, Denmark, Europe, Finland, France, Germany, Iceland, India, Ireland, Israel, Italy, Japan, Mexico, Luxembourg, the Netherlands, Norway, Portugal, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, and the United Kingdom. These patents and applications are Caris-owned and assigned to our subsidiary Caris MPI, Inc., and are expected to expire between 2027 and 2033;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">One issued patent in Japan and 17 additional pending applications directed to AI/ML systems and methods for predicting cancer type. These include two pending U.S. applications, one PCT application, and 14 pending foreign applications between Australia, Canada, Europe, Israel, Japan, South Korea, and Mexico. These patents and applications are Caris-owned and assigned to our subsidiary Caris MPI, Inc., and are expected to expire between 2040 and 2044; and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">14 patents (including one allowance) and 16 pending applications directed to AI/ML systems and methods for predicting response to platinum compounds, including FOLFOX regimens. These include three issued U.S. patents and two pending U.S. applications, and 11 foreign patents (including one allowance) and 14 pending foreign applications between Australia, Canada, Europe, France, Germany, Ireland, Israel, Japan, South Korea, Mexico, Netherlands, Switzerland, and the United Kingdom. These patents and applications are Caris-owned and assigned to our subsidiary Caris MPI, Inc., and are expected to expire between 2039 and 2040. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additional patents and applications with varying levels of importance within our portfolio that relate to our commercial molecular profiling services include:</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">16 pending applications directed to AI/ML systems and methods for predicting response to various chemotherapies. These applications are Caris-owned and are expected to expire in 2041; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Six pending applications directed to AI/ML systems and methods for predicting likelihood of metastasis. These applications are Caris-owned and are expected to expire between 2041 and 2045; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">One pending application directed to profiling hematological malignancies using whole genome sequencing. This application is exclusively in-licensed and is expected to expire in 2042. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additional patents and applications with varying levels of importance within our portfolio that relate to our pharma research and development services include:</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">38 patents directed to methods for use of microvesicles and microRNA as cancer biomarkers. These patents are exclusively in-licensed and are expected to expire in 2028;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">47 patents and six pending applications directed to methods of sequencing aptamer libraries to detect targets of interest. These patents and applications are Caris-owned and expected to expire between 2028 and 2033; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">47 patents (including two allowances) and nine pending applications directed to methods for aptamer library enrichment. These patents and applications are Caris-owned and are expected to expire between 2028 and 2038; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Nine patents (including two allowances) and 14 pending applications directed to compositions and methods related to cell-targeting technologies. These patents and applications are either Caris-owned or exclusively in-licensed and are expected to expire between 2036 and 2044. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The expiration dates described above are subject to, in the case of pending applications, our continued prosecution to allowance at the applicable patent offices, and in the case of allowed, issued and granted patents, our payment of applicable issue fees, maintenance fees and annuities. Patent expiration dates are estimates and may be subject to terminal disclaimers and patent term adjustments.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">192</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In some instances, we have acquired or in-licensed patent rights developed by third parties to enhance our patent portfolio and competitive advantage. For example, we have acquired patent families related to aptamer technologies and in-licensed patent applications related to cell targeting and hematological cancer assay technologies that are currently under development. Under such license agreements, we would be obligated to pay royalties for future sales in which the patents are used in the product or service sold. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Trade Secrets</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to patent protection, we have determined that certain technologies are better kept as trade secrets, such as aspects of our NGS methodology, bioinformatic analysis techniques, and identity of cancer biomarkers under development. We have a policy to restrict access to our trade secrets to a need-to-know basis. To further mitigate the chance of trade secret misappropriation, we enter into confidentiality agreements with parties who have access to trade secrets, such as our employees, collaborators, outside scientific collaborators, consultants, advisors, and other third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Brand Protection</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our customers and partners recognize us as a leader in the molecular profiling field. Thus, just as patent and trade secret protection is essential to protecting our technology, we believe that it is equally as important for us to protect our brand and identity. We have obtained, and will continue to obtain, trademark protection for our name, logo, and solutions in countries where we operate, including our MI Profile and Caris Assure branding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Additional Information</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will continue to pursue intellectual property protection, whether developed in-house or via third parties, that we believe will advance our business objectives. Despite our efforts and vigorous defense, our intellectual property rights in the United States and abroad may be invalidated, circumvented, or challenged in the future. In addition, the laws of various countries where our solutions are distributed may not protect our intellectual property rights to the same extent as the laws in other countries. For additional information, see the section titled &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Regulatory Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our regulatory strategy aligns with our overall business objectives. We believe that receiving FDA approval of our diagnostic solutions would positively impact our ability to sell our solutions and enhance our reimbursement efforts with payers, including Medicare. The current marketing status and relevant regulatory approvals obtained, planned, and/or potentially required for each of our solutions is summarized in the table below. We currently market all of our existing solutions, including Caris Assure for therapy selection, MI Tumor Seek Hybrid, GPSai, and FOLFIRSTai, as LDTs and, as required under CLIA, continue to analytically validate such solutions across a variety of performance characteristics, including accuracy, precision, specificity, sensitivity, reportable range, and reference interval. We have obtained an FDA marketing authorization for MI Cancer Seek, and we anticipate seeking FDA marketing authorization for Caris Assure for therapy selection and additional solutions in the future, including as a result of the FDA&#8217;s planned phase out of its enforcement discretion policy with respect to LDTs. Additionally, while we currently market Caris Assure for therapy selection as an LDT, marketing authorization from the FDA would be required in order for us to market Caris Assure as a companion diagnostic device for therapy selection. We do not yet have specific plans regarding the timing of a PMA or other submission, if any, for Caris Assure for therapy selection or any other indication. For additional information, see &#8220;&#8212;Government Regulation&#8212; U.S. Food and Drug Administration&#8212;Laboratory Developed Tests.&#8221;</font>
        </div>
        <table style="width:456pt;height:74.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:72pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Solution Name</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:72pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Marketing Status</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">NY CLEP Approval</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">FDA Approval/Requirements</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:72pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">MI Cancer Seek</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:72pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Marketed since January 2025</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Not applicable</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">PMA approval obtained in November 2024</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">MI Tumor Seek Hybrid</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Marketed as an LDT since&#160;2022</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Approved in 2024</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">None planned, but if FDA marketing authorization is required, a PMA approval must be obtained</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">193</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:149.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:72pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Solution Name</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:72pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Marketing Status</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">NY CLEP Approval</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">FDA Approval/Requirements</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Caris Assure for Therapy Selection</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">Marketed as an LDT</font>
              <br >
              <font style="letter-spacing:0.2pt;">since 2024</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Plan to submit for NY CLEP in 2025</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:192pt;">
              <font style="letter-spacing:0.2pt;">Plan to submit PMA or a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> request or 510(k) notification </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">FOLFIRSTai</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Marketed as an LDT</font>
              <br >
              <font style="letter-spacing:0.2pt;">since 2020</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Approved in 2024</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:192pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">None planned, but if FDA marketing authorization is required, a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification or 510(k) clearance must be obtained</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
              <font style="letter-spacing:0.2pt;">GPSai</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Marketed as an LDT</font>
              <br >
              <font style="letter-spacing:0.2pt;">since 2019</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Approved in 2024</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:192pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">None planned, but if FDA marketing authorization is required, a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification or 510(k) clearance must be obtained</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:15.7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA premarket review process can be long and requires significant resources to complete all of the regulatory requirements necessary for market launch of an FDA-approved prescription medical device or diagnostic product. As we work with the FDA to seek marketing authorization for our diagnostic solutions, we must accurately describe the solution in terms of its intended use, indications for use, target population of patients, functional and/or performance characteristics, labeling, and anticipated marketing claims for the device, among other things. These factors, when combined with the result of the device classification, applicable product code for the device, and whether a predicate device exists, will allow us to plan the most appropriate submission type and regulatory pathway. Determining the appropriate pathway early is crucial to setting milestones, planning necessary preclinical and clinical trials, estimating cost requirements, and creating a timeline for when the product may reach the market. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA encourages participation in the FDA&#8217;s Pre-Submission Program, which allows manufacturers to seek the FDA&#8217;s feedback prior to an intended premarket submission. We have had formal pre-submission meetings with the FDA Center for Devices and Radiological Health (&#8220;CDRH&#8221;) and anticipate several more in the future to seek additional feedback from the agency on solutions that we intend to submit for premarket review. Feedback from these meetings are critical for our team to be able to put together the appropriate study designs to support a premarket submission. Though the FDA provides non-binding feedback within these discussions, obtaining this early input from CDRH can allow for necessary changes or modifications to the regulatory strategy and potentially provide long-term savings in cost and time. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have obtained a PMA approval from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that has been designed to meet the stricter requirements applicable to companion diagnostic devices. We currently market MI Cancer Seek as the WES/WTS NGS component of MI Profile. For additional information, see &#8220;Risk Factors&#8212;Risks Related to Regulation and Legal Compliance&#8212;The marketing authorization processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable marketing authorizations, or if such marketing authorizations are significantly delayed, our business will be substantially harmed.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to complex and frequently changing national, state, and local laws and regulations that govern various aspects of our business. In many jurisdictions, including the United States, the clinical laboratory and medical device industries must operate in accordance with extensive and complex legal standards, including laws and regulations related to certification, licensing, development, research, testing, manufacturing, laboratory operations, distribution, ordering and billing practices, advertising, promotion, marketing, sales and pricing practices, anti-markup practices, health information privacy and security, and consumer protection and unfair trade practices. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in some instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Clinical LDTs are regulated by the CLIA, described below, as well as by applicable state laws. In addition, the Federal Food, Drug and Cosmetic Act (&#8220;FDC Act&#8221;) defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, </font><font style="font-style:italic;letter-spacing:0.2pt;">in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">194</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">vitro</font><font style="letter-spacing:0.2pt;"> reagent, or other similar or related article, including a component part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Among other things, pursuant to the FDC Act and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. The FDA has statutory authority to assure that medical devices are safe and effective for their intended uses. While the FDA has historically exercised its enforcement discretion and not enforced certain applicable provisions of the FDC Act and implementing regulations with respect to LDTs, the FDA recently issued a final rule to phase out its enforcement discretion with respect to LDTs, which makes LDTs subject to the FDA&#8217;s medical device authority. Any solutions we develop and market would be considered by the FDA to be subject to regulation as a medical device. On March&#160;31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA&#8217;s LDT final rule. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For information on the risks we face related to the regulatory environment and other legal matters, see the section titled &#8220;Risk Factors&#8212;Risks Related to Regulation and Legal Compliance.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Clinical Laboratory Improvement Amendments of 1988</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Congress passed CLIA to establish rigorous quality standards for laboratories in the United States. Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from human beings for the purpose of providing information for the diagnosis, prevention, or treatment of disease or the impairment or assessment of health. Such testing may also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CLIA requires that such laboratories obtain certification from the federal government and maintain compliance with various operational, personnel qualification, facilities administration, quality control and assurance, and proficiency testing requirements intended to ensure the accuracy, reliability, and timeliness of patient test results. The CMS, part of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), administers the CLIA certification program. CLIA requires that we hold a certificate that specifies the categories of testing we perform and that we comply with certain standards applicable to such tests. For every LDT used in clinical testing, CLIA requires analytical validation of a variety of performance characteristics, including accuracy, precision, specificity, sensitivity, reportable range, and reference interval. In addition, CLIA specifies certain testing categories requiring periodic proficiency testing, and certified laboratories performing these tests must enroll in an approved proficiency testing program. To demonstrate proficiency, such laboratories must test specimens received from an outside proficiency testing organization, such as CAP, and then submit the results back to that organization for evaluation. Failing to achieve a passing score on a proficiency test may lead to loss of certification to perform testing in the corresponding category. Furthermore, failure to comply with other proficiency testing regulations can result in revocation of the laboratory&#8217;s CLIA certificate, among other penalties.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently have two clinical laboratory facilities in Phoenix, Arizona, and we are in the process of building a laboratory in Irving, Texas. Both of the Phoenix laboratory facilities hold CAP and CLIA Accreditations. A CLIA Certificate of Accreditation is issued to a laboratory facility that performs moderate and/or high complexity testing after an accreditation organization conducts a survey and determines that the laboratory is in compliance with the CLIA regulations. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will seek a CLIA Certificate of Registration from CMS, and upon required inspection, a CLIA Certificate of Accreditation. The CLIA Certificate of Registration allows the laboratory facility to begin conducting moderate and/or high complexity testing, subject to a survey to determine compliance with the CLIA regulations. After a laboratory obtains a Certificate of Registration, CLIA begins scheduling regular, routine inspections. Once the inspection process for the laboratory facility is successfully completed, the facility qualifies for a CLIA Certificate of Accreditation and thereafter is inspected every two years. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to offering a new solution at our laboratories, we must also satisfy certain notification requirements to change our solution menu, such as notifications to regulatory and accrediting bodies. At their discretion, these entities may inspect our clinical laboratories at any time. CLIA accredited laboratories </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">195</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">are subject to are required to be reviewed biannually by a CMS-approved accreditation organization (for example, CAP) and may be subject to additional random or &#8220;for cause&#8221; inspections. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our laboratories are determined to be out of compliance with CLIA requirements at any inspection or otherwise, we may be subject to a wide range of enforcement actions and sanctions, including suspension, limitation, or revocation of the laboratory&#8217;s CLIA certificate, as well as directed plan of correction, on-site monitoring, civil monetary penalties, civil injunctive suit, or criminal penalties, as well as significant adverse publicity, all of which could have a materially adverse impact on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">State Laboratory Licensure Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the federal certification requirements for laboratories, certain states, including Maryland, Pennsylvania, New York, California, and Rhode Island require state laboratory licenses. The state laboratory licensure requirements establish standards for the day-to-day operation of a clinical laboratory, including the training and qualifications required of personnel, quality control, and proficiency testing. CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law. A number of states have implemented their own more stringent laboratory regulatory requirements, and those states may conduct their own inspections. These states may also include reporting requirements that we must comply with in order to maintain licensure. Moreover, certain states, including New York, require approval of certain tests, including certain tests that have not been cleared or approved by the FDA (such as LDTs), through a premarket submission containing, among other information, documentation relating to device analytical and clinical performance data. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Several states require licensure of out-of-state laboratories that accept specimens from those states and/or receive specimens from laboratories in those states. Our Arizona solid tissue laboratory and our Arizona blood-based testing laboratory have obtained out-of-state licenses in states where we believe they are required, and we will file applications in additional states as applicable when we offer solutions in those states. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a laboratory is deemed to be out of compliance with state licensing laws or regulations governing laboratories, penalties may include suspension, limitation, or revocation of the license issued by that state, disapproval of a licensure application, assessment of substantial financial penalties or fines, onsite monitoring requirements, or imposition of corrective action plans. Certain statutory or regulatory noncompliance may also result in misdemeanor charges under state law. Loss of a laboratory&#8217;s state license may also result in the inability to compliantly perform laboratory testing and receive payments from third-party payers, all of which may have a materially adverse impact on our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to laboratory licensing, certain states, including New York and California, impose registration and/or licensing requirements on companies that manufacture medical devices. These laws can apply to a manufacturer before its products are commercialized, including when a company is evaluating its product candidates in clinical trials. Violations of these laws may result in the denial, suspension, or revocation of the registration or license, as well as other fines and penalties, including imprisonment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other states may adopt licensure requirements in the future, which could require us to modify, delay, or discontinue our operations in such jurisdictions. If we identify any state with such requirements or if we are contacted by a state advising us of such requirements, we intend to follow such instructions from the state regulators as to how to comply with such requirements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Food and Drug Administration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, laboratory tests are subject to regulation by the FDA under the FDC Act and its implementing regulations, and other federal and state statutes and regulations. The laws and regulations govern, among other things, medical device development, testing, manufacture, labeling, storage, premarket clearance or approval, advertising and promotion, export, import, and product sales and distribution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Laboratory Developed Tests</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the FDA&#8217;s regulatory framework, IVDs are a type of medical device that can be used in the diagnosis or detection of diseases, such as cancer, or other conditions. The FDA considers LDTs to be a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">196</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">subset of IVDs that are intended for clinical use and are designed, manufactured, and used within a single laboratory. Until recently, the FDA has historically exercised its enforcement discretion and not enforced certain otherwise potentially applicable provisions of the FDC Act and regulations with respect to LDTs, with certain exceptions. Even under that enforcement discretion policy, the FDA has issued warning letters to, and published Medical Device Safety Communications about, manufacturers for commercializing laboratory tests that were purported to be LDTs but that the FDA alleged failed to meet the definition of an LDT or that otherwise were not subject to the FDA&#8217;s enforcement discretion policy. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has for a number of&#160;years stated its intention to modify its enforcement discretion policy with respect to LDTs and impose applicable medical device requirements to LDTs more broadly. In May&#160;2024, the FDA finalized an amendment to its regulations via issuance of a final rule. This final rule clarifies the FDA&#8217;s historical view that LDTs are medical devices subject to the requirements applicable to other IVDs, and the FDA plans to phase in the enforcement of medical device requirements to LDTs over a period of four&#160;years. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA&#8217;s LDT final rule. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the final rule, the FDA established certain new, targeted enforcement discretion policies, including, among others, for LDTs marketed as of the date of publication of the final rule on May&#160;6, 2024, as well as for LDTs that have received approval from NY CLEP. Specifically, the FDA intends to exercise enforcement discretion and not enforce certain medical device requirements (including the requirements for marketing authorization and compliance with certain elements of the Quality System Regulation (&#8220;QSR&#8221;) with respect to LDTs that were marketed as of the date of the final rule&#8217;s publication, although such products must still comply with certain other FDA requirements, including registration and listing, portions of the QSR, medical device reporting, labeling, and corrections and removals reporting. However, where these tests are modified in certain ways from the version of the test marketed as of the final rule&#8217;s publication date, this enforcement discretion policy will no longer apply and the FDA intends to enforce all applicable FDA requirements (including premarket review and marketing authorization requirements) consistent with the phase-in policy. In addition, for LDTs that receive approval from NY CLEP, FDA intends to not enforce marketing authorization requirements when these requirements are phased in more generally at either three and a half or four&#160;years following the date of publication of the final rule. However, these tests will still be subject to the remaining medical device requirements, including registration and listing, medical device reporting, and quality system requirements, at the time that such requirements are phased in more generally. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, Congress has, for over the past decade, considered a number of proposals, which if enacted, would subject LDTs to additional regulatory requirements. For example, in recent&#160;years, Congress has worked on legislation to create a novel regulatory framework governing a new category of FDA-regulated products, referred to as </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> clinical tests (&#8220;IVCTs&#8221;), which would govern LDTs and would be separate and distinct from the existing medical device regulatory framework. For example, in March&#160;2023, the Verifying Accurate Leading-edge IVCT Development Act of 2023 (the &#8220;VALID Act&#8221;) was introduced. The bill would establish a risk-based approach to imposing requirements related to premarket review, quality systems, and labeling requirements on all IVCTs, including LDTs, but would grandfather certain LDTs marketed before the effective date of the bill and exempt them from certain requirements. Depending on the approach adopted under any potential legislation, certain LDTs (likely those of higher risk) may be required to undergo some form of premarket review of LDTs as IVCTs, potentially with a transition period for compliance and a grandfathering provision. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">FDA Classification and Premarket Review of Medical Devices</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">PMA Pathway.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The FDA categorizes medical devices into one of three classes&#8212;class I, II, or III&#8212;based on the risks presented by the device and the regulatory controls necessary to provide a reasonable assurance of the device&#8217;s safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class&#160;II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Special </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">197</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">controls are established by the FDA for a specific device type and often include specific labeling provisions, performance metrics, and other types of controls that mitigate risks of the device (usually incorrect results for an IVD). Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&#160;III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject to the FDA&#8217;s premarket notification and clearance process in order to be commercially distributed. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Class&#160;III devices require PMA approval before they can be marketed. Obtaining PMA approval requires the submission of &#8220;valid scientific evidence&#8221; to FDA to support a finding of a reasonable assurance of the safety and effectiveness of the device. A PMA must provide complete analytical and clinical performance data and also information about the device and its components regarding, among other things, device design, manufacturing, and labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180&#160;days from the day of filing under the FDC Act to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. As part of the FDA&#8217;s review of a PMA, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with QSR requirements, which impose requirements related to design controls, manufacturing controls, documentation, and other quality assurance procedures. The user fee costs and the length of the FDA review time for obtaining PMA approval are significantly higher than for a 510(k) notification or a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification. In addition, the FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments under the Medical Device User Fee Amendments to the FDC Act, which is subject to reauthorization by Congress every five&#160;years following extensive agency and industry negotiations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of&#160;years and to make periodic reports to FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">510(k) Notification Pathway.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating to the FDA&#8217;s satisfaction that the proposed device is &#8220;substantially equivalent&#8221; to another legally marketed device that itself does not require PMA approval (a predicate device). A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May&#160;28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class&#160;III to Class&#160;II or I, or a device that was found substantially equivalent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">198</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">through the 510(k) process. The FDA&#8217;s 510(k) clearance process usually takes from three to 12&#160;months, but often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device establishments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the FDA agrees that the device is substantially equivalent to a lawfully marketed predicate device, it will grant 510(k) clearance to authorize the device for commercialization. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class&#160;III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. Once a </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification request is reviewed and granted, it results in the device having a Class&#160;I or II classification and future devices from the company or a competitor may use the company </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;">-classified device as a 510(k) predicate. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After a device receives 510(k) clearance or </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or new </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Modifications that do not rise to the level of requiring a new 510(k) are accomplished through a &#8220;letter to file&#8221; in which the company documents the rationale for the change and why a new 510(k) is not required. However, if the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until new marketing authorization for the change is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Over the last several&#160;years, the FDA has proposed reforms to its 510(k) clearance process, and the implementation of such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in September&#160;2023, the FDA issued three draft guidances to strengthen and modernize the 510(k) program, and the FDA noted that in light of increasing technical complexity, clinical data are increasingly being required to support substantial equivalence determinations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">De Novo Classification Pathway.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If no legally marketed predicate can be identified for a new device to enable use of the 510(k) pathway, the device is automatically classified under the FDC Act into Class&#160;III, which generally requires PMA approval. However, the FDA can reclassify or use &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification&#8221; for a device that meets the FDC Act standards for a class I or class II device, which in turn permit the device to be marketed without PMA approval. To grant such a reclassification, the FDA must determine that the FDC Act&#8217;s general controls alone, or general controls and special controls together, are sufficient to provide a reasonable assurance of the device&#8217;s safety and effectiveness. If the manufacturer seeks reclassification into Class&#160;II, the classification request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the classification request if it identifies a legally marketed predicate device that would be appropriate for a 510(k) notification or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. The </font><font style="font-style:italic;letter-spacing:0.2pt;">de novo</font><font style="letter-spacing:0.2pt;"> classification route is generally less burdensome than the PMA approval process. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Investigational Device Exemption Process</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety, or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">199</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (&#8220;IRB&#8221;) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and the study protocol is approved by one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. IDE reporting to all reviewing IRBs regarding study progress is required at regular intervals and at least annually for ongoing IDE approved studies. For a significant risk device, the progress reports must also be submitted to FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety, or welfare of human subjects. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping, and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expedited Development and Review Programs.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The FDA has established programs to support and expedite the development of devices that meet criteria for Breakthrough Device designation, which can be voluntarily requested by sponsors. The program offers manufacturers of certain devices an opportunity to interact with the FDA more frequently and efficiently as they develop their products with the goal of expediting commercialization of such products to help patients have more timely access, as well as use of postmarket data collection, when scientifically appropriate, to facilitate expedited and efficient development and review of the device, opportunities for efficient and flexible clinical study design, and priority review of premarket submissions. The program is available to medical devices that meet certain eligibility criteria, including that the device provides more effective treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions, and constitutes a device (i)&#160;that represents a breakthrough technology, (ii)&#160;for which no approved or cleared alternatives exist, (iii)&#160;that offer significant advantages over existing approved or cleared alternatives, or (iv)&#160;the availability of which is in the best interest of patients. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Postmarket Regulation</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;After a device is cleared or approved by the FDA for marketing, numerous and pervasive regulatory requirements continue to apply. Additionally, LDTs marketed during the phase-in period of FDA&#8217;s LDT final rule, which rule was vacated by a federal court on March 31, 2025, will become subject to certain regulatory requirements over the course of four&#160;years. These include: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">establishment registration and device listing with the FDA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance with the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the design and manufacturing process; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">200</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">labeling regulations and FDA prohibitions against the promotion of &#8220;off-label&#8221; uses of cleared or approved products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">requirements related to promotional activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Medical Device Reporting, which requires that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">correction, removal, and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDC Act that may present a risk to health; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">post-market surveillance activities and regulations, which apply to certain Class&#160;II or III devices when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Device manufacturing processes subject to the FDA oversight are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation, and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. Manufacturers are subject to periodic scheduled or unscheduled inspections by the FDA. A failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, manufacturing operations and the recall or seizure of products. The discovery of previously unknown problems with products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">FDA Enforcement Powers</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, including the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issuance of warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">requesting or requiring recalls, withdrawals, or administrative detention or seizure of products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">imposing operating restrictions or partial suspension or total shutdown of production; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">refusing or delaying requests for 510(k) marketing clearance, or PMA approvals of new products or modified products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">withdrawing 510(k) clearances or PMA approvals that have already been granted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">refusal to grant export approvals for products; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">criminal prosecution. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.62pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare Fraud and Abuse Oversight</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A variety of federal and state laws prohibit fraud and abuse involving federal and state healthcare programs, as well as private insurers. These laws are interpreted broadly and actively enforced by various </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">201</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">state and federal agencies, including CMS, the Department of Justice (&#8220;DOJ&#8221;), and the Office of Inspector General for HHS (&#8220;OIG&#8221;). While we seek to conduct our business in compliance with all federal and state fraud and abuse laws, we are unable to predict how these laws will be applied in the future or whether our arrangements will be subject to scrutiny under them by federal or state enforcement agencies. Violations of such laws may result in a range of penalties, including but not limited to significant administrative and civil fines and penalties, criminal fines and penalties, loss of licensure, disgorgement, imprisonment, exclusion from federal healthcare programs, additional reporting obligations, and oversight or other agreement to resolve allegations of non-compliance with these laws. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Federal and State Physician Self-Referral Prohibitions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to a set of federal laws aimed at preventing physician self-referral, including the federal anti self-referral law commonly known as the Stark Law. The Stark Law generally prohibits entities from billing, presenting, or causing to be presented a claim for designated health services, including laboratory services, payable by the Medicare or Medicaid programs when the physician ordering the service, or any member of such physician&#8217;s immediate family, has an ownership interest in, or compensation arrangement with, that entity, unless the arrangement meets certain delineated exceptions to the prohibition. We rely on certain exceptions to the Stark Law, and if those exceptions were to change, we could face penalties for violations. Notably, the Stark Law is a strict liability statute, which means that no proof of scienter is required to demonstrate a violation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sanctions for a violation of the Stark Law, among other things, include denial of payment for the services provided in violation of the prohibition, refunds of amounts collected by the entity in violation of the Stark Law, monetary penalties, and exclusion from federal healthcare program participation. In addition, violations of the Stark Law may also serve as the basis for liability under the federal False Claims Act (the &#8220;FCA&#8221;), which prohibits knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many states also have their own self-referral bans, which may extend to all self-referrals regardless of payer, with which we may have to comply unless an exception applies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The Anti-Kickback Statute</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The federal Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits any person or entity, including a laboratory, from knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in order to induce either the referral of an individual, or the furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by any federal healthcare program, including the Medicare and Medicaid programs. &#8220;Remuneration&#8221; is broadly defined to include anything of value, which can include (but is not limited to) cash payments, gifts or gift cards, discounts, research opportunities, co-payment waivers or patient financial assistance, or the furnishing of services, supplies, or equipment. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The AKS can be interpreted broadly to prohibit many arrangements and practices that are lawful in businesses outside of the healthcare industry or which are innocuous or beneficial. The AKS contains statutory exceptions and regulatory safe harbors that protect certain interactions if specific requirements are met. If an arrangement meets all of the requirements of a safe harbor, it is deemed not to violate the AKS. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. The failure of a transaction or arrangement to fit within a specific safe harbor, however, does not necessarily mean that the transaction or arrangement violates the statute. A violation of the AKS may result in significant penalties, including imprisonment, fines, and possible exclusion from Medicare, Medicaid, and other federal healthcare programs. Actions that violate the AKS or any similar laws may also incur liability under the FCA. Some states also have their own AKS laws and they may apply to all payers, instead of just a state healthcare program. These statutes also typically have their own safe harbor provisions, or they may cross-reference the federal AKS safe harbors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Federal and state law enforcement authorities scrutinize arrangements between healthcare providers and potential referral sources to determine whether the arrangements were intended to induce referrals or the purchase, prescribing or ordering of products or services reimbursable by federal healthcare programs. Law enforcement authorities and the courts have also demonstrated a willingness to look behind the formalities </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">202</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of a transaction to determine the underlying purpose of any remuneration exchanged between healthcare providers and actual or potential referral sources. Generally, courts and federal agencies have taken the position that the AKS may be violated if even one purpose of an arrangement is to induce referrals. We rely on safe harbors to the AKS statutes in certain arrangements with potential referral sources, and those safe harbors could be revised or eliminated. In addition, the OIG periodically issues Special Fraud Alerts setting forth the agency&#8217;s view of how certain arrangements between laboratories and referring physicians implicate and potentially violate the AKS. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The penalties for violating the federal or state AKS provisions can be severe. Consequences include, among others, criminal and civil penalties, imprisonment, and possible exclusion from federal healthcare programs, among others. Moreover, claims submitted to federal healthcare programs for items or services that were the result of a violation of the AKS are deemed to be &#8220;false&#8221; for purposes of the FCA. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eliminating Kickbacks in Recovery Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2018, Congress enacted the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (&#8220;SUPPORT Act&#8221;). EKRA is an all-payer anti-kickback law that criminalizes paying or offering any remuneration directly or indirectly to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although it appears that EKRA was intended to reach patient brokering and similar arrangements in the context of substance use recovery and treatment, the language in EKRA is broad. Moreover, although there is some overlap between EKRA&#8217;s exceptions and the AKS safe harbors, certain arrangements that are expressly protected under the AKS do not expressly receive protection under EKRA. As such, compliance with a federal AKS safe harbor does not guarantee protection under EKRA. EKRA thus potentially expands the universe of arrangements that could be subject to enforcement under federal fraud and abuse laws, as well as substantial penalties. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">EKRA permits DOJ to issue regulations clarifying or expanding the statute&#8217;s exceptions, but such regulations have not yet been issued and thus there is little guidance to indicate how and to what extent it will be applied and enforced by government agencies. The relationships between laboratories and physicians, sales representatives, hospitals, and customers may be subject to scrutiny under this statute. Sanctions under the EKRA could have a negative effect on our business, if imposed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">False Claims Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FCA prohibits, among other things, a person from knowingly submitting (or causing to be submitted) a false claim, making a false record or statement in order to secure payment, or knowingly retaining an overpayment by the federal government. The government may assert that a claim including items and services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Moreover, overpayments from certain payers must be repaid within 60&#160;days of identification unless a favorable decision is obtained on appeal, or they may be subject to reverse false claims liability. Penalties for violating the FCA include payment, among other things, of up to three times the actual damages sustained by the government, plus substantial per-claim civil penalties, as well as possible exclusion from federal healthcare programs. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Another notable feature of the FCA is that its </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;"> provisions allow a private individual to bring an action on behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action. Because the </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;"> whistleblowers initially file their complaints under seal, the action may be pending for some time before the defendant is even aware of it. If the government is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government&#8217;s involvement, then the plaintiff will receive a&#160;percentage of the recovery. It is not uncommon for </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;"> lawsuits to be filed by current and former employees, as well as competitors or consultants of healthcare providers, including clinical laboratories. Several states have enacted similar laws modeled after the FCA that apply to items and services reimbursed under Medicaid and other state healthcare programs, and, in several states, such laws apply to claims submitted to any payer, including private insurers. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">203</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For a discussion of such a proceeding in which we are currently involved, please see &#8220;&#8212;Legal Proceedings.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Healthcare Fraud and False Statements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The federal healthcare fraud statute criminalizes knowingly and willfully defrauding any healthcare benefit program. A violation of this statute may result in fines, imprisonment, or exclusion from government healthcare programs. Exclusion from governmental healthcare programs also impacts the ability of the company to contract with private insurers. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making a materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute may result in fines or imprisonment. Conduct that could be considered a violation of the other healthcare related laws described herein could also form the basis of a claim under this statute. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Civil Monetary Penalties Law</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The federal Civil Monetary Penalties (&#8220;CMP&#8221;) law prohibits, among other things, (i)&#160;offering or transferring remuneration to a federal healthcare program beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by a federal healthcare program from a particular provider or supplier; (ii)&#160;employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal healthcare program; (iii)&#160;billing for services requested by an unlicensed physician or an excluded provider; and (iv)&#160;billing for medically unnecessary services. Conduct that could be considered a violation of the FCA or the AKS can also form the basis of a CMP complaint. Penalties for violating the CMP may include exclusion from federal healthcare programs and substantial fines. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Physician Payments Sunshine Act</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The federal Physician Payments Sunshine Act (&#8220;Sunshine Act&#8221;) was enacted by Congress in 2010 as part of the Affordable Care Act (&#8220;ACA&#8221;) and was amended in 2018 by the SUPPORT Act. The Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to collect and report annually to CMS certain data on payments and other transfers of value by those manufacturers (and in some cases their distributors) to U.S. licensed physicians, teaching hospitals, and certain advanced non-physician healthcare practitioners, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. The reporting program (known as the Open Payments program) is administered by CMS. Several states have enacted similar reporting requirements. The sale of covered medical devices triggers reporting obligations under the Sunshine Act as well as the similar state counterpart requirements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While we intend fully to comply with applicable federal and state fraud and abuse laws, and similar laws of other states and countries as we commercialize solutions, it is possible that some of our arrangements or arrangements we may enter into in the future could become subject to regulatory scrutiny, and we cannot be certain that we will be found to be in compliance with these laws following any such regulatory review.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Potentially Applicable State Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to the laws described above, states may have other fraud and abuse laws that apply to our business practices. Such laws include fee-splitting restrictions, insurance fraud laws, anti-markup laws, certain direct billing requirements, prohibitions on waiving coinsurance, copayments, deductibles, and other amounts owed by patients, and prohibitions on the provision of solutions at no or discounted cost to induce physician adoption. Other potentially applicable state laws prohibit the corporate practice of medicine, and are designed to prevent interference in the medical decision-making process by anyone who is not a licensed professional. Violation of these laws may result in a range of penalties, including civil or criminal penalties, as well as sanctions imposed against the business corporation and the professional through licensure proceedings and criminal penalties. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">204</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional International Regulation and Product Approval</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may have to obtain or submit approvals, markings, notifications, or satisfy other premarket requirements from regulatory authorities in non-U.S. jurisdictions prior to marketing our solutions in those countries and territories. The laws and regulations in other jurisdictions vary from those in the United States and may be more difficult to satisfy, and they are subject to change, in some cases frequently. Certain regulatory authorities regulate LDTs and IVDs differently than the United States, and our solutions may need to satisfy additional requirements to be offered commercially within the jurisdictions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">European Union</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In May&#160;2017, the European Union adopted a new </font><font style="font-style:italic;letter-spacing:0.2pt;">In Vitro</font><font style="letter-spacing:0.2pt;"> Diagnostic Medical Devices Regulation&#160;2017/746 (&#8220;IVDR&#8221;), which replaced the IVD Directive in May&#160;2022. Under the IVDR, many more IVDs will require the involvement of a notified body in their conformity assessment procedure. Under transitional provisions, IVDs with notified body certificates issued under the IVD Directive prior to May&#160;2022 may continue to be placed on the market for the remaining validity of the certificate, until May&#160;2024 at the latest. After the expiry of any applicable transitional period, only IVDs that have been CE marked under the IVDR may be placed on the market in the European Union. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Jurisdictions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event we expand our business into other countries or jurisdictions around the world, we will be required to comply with such countries&#8217; and jurisdictions&#8217; healthcare and other laws and regulations covering comparable subject matter to that discussed in the foregoing paragraphs and that do not currently apply to us. Such laws and regulations are complex, change frequently, and vary among jurisdictions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Coverage and Reimbursement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Reimbursement and billing for clinical laboratory services is highly complex. Laboratories must bill various payers, which may include federal healthcare programs (such as Medicare, Medicaid, and TRICARE), as well as Medicare Advantage plans, private insurers, and managed care organizations. Submitting claims to various payers is complicated because each payer may have different billing requirements. Additionally, the audit requirements laboratories must meet the ensure compliance with applicable laws and regulations, as well as internal compliance policies and procedures, add further complexity to the billing process. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are currently pursuing and will continue to pursue payment for our solutions through a diverse and broad range of channels, including coverage and reimbursement by government healthcare programs and commercial third-party payers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General Coverage and Reimbursement Considerations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Across jurisdictions, a decision by a payer (regardless of whether it is a governmental or private payer) to cover a solution does not guarantee that those payers will provide adequate reimbursement for that solution. Moreover, third-party payers are increasingly examining the medical necessity and cost- effectiveness of medical products and services, including clinical laboratory tests, in addition to their safety and efficacy. Furthermore, coverage and reimbursement for products, and services that utilize such products, can differ significantly from payer to payer. As a result, the coverage determination process is often time-consuming and costly and requires us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained at all. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In certain foreign markets, the government controls the coverage and pricing of many healthcare products, including clinical laboratory tests. In order to obtain coverage and reimbursement for any product that might be cleared or approved by regulators for sale, or for any procedure that utilizes such product, it may be necessary to conduct health economic studies in order to demonstrate the medical necessity and cost-effectiveness of the products. The cost of such studies would be in addition to the costs required to obtain regulatory approvals. If third-party payers do not consider a product to be cost-effective compared to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">205</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">other available products, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The marketability of our solutions may suffer if governmental and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased, and we expect will continue to increase the pressure on medical products and services pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for our solutions, less favorable coverage policies and reimbursement rates may be implemented in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Coverage and Reimbursement in the United States</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, there is no uniform coverage for clinical laboratory tests. The extent of coverage and rate of payment for covered services varies from payer to payer. Obtaining coverage for solutions like ours that involve genomic sequencing can be particularly challenging. Medicare is the single largest healthcare payer in the United States, and a particularly significant payer for many cancer-related laboratory services given the demographics of the Medicare population, a large portion of which includes elderly individuals. Many other U.S. payers look to the Medicare policies as a benchmark and model for their own coverage and reimbursement decisions. Medicare provides two main forms of insurance coverage: traditional Medicare fee-for-service, administered by the federal government and its contractors, and Medicare Advantage, administered by private insurers that must generally follow traditional Medicare rules and guidelines. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. National coverage determinations are made through an evidence-based process by the CMS, with opportunities for public participation. Medicare&#8217;s National Coverage Determination (&#8220;NCD&#8221;) for NGS, first established in 2018 and subsequently updated in 2020, provides national Medicare coverage for certain molecular diagnostic tests when: (1)&#160;performed in a CLIA-certified laboratory, (2)&#160;ordered by a treating physician, (3)&#160;the patient meets certain clinical and treatment criteria, including having recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, (4)&#160;the test is approved or cleared by the FDA as a companion IVD for an FDA approved or cleared indication for use in that patient&#8217;s cancer, and (5)&#160;results are provided to the treating physician for management of the patient using a report template to specify treatment options. The NGS NCD also states that each Medicare Administrative Contractor (&#8220;MAC&#8221;) may provide local coverage of other NGS tests for cancer patients only when the test is performed by a CLIA-certified laboratory, ordered by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered NGS tests under the NGS NCD. Palmetto GBA is the MAC responsible for administering Medicare&#8217;s MolDX, which issues local coverage determinations (&#8220;LCDs&#8221;) for molecular diagnostic tests that are not approved or cleared by the FDA. Our MAC for the Phoenix laboratory locations is Noridian, and Noridian relies on MolDX to make coverage and pricing determinations relating to molecular profiling. To achieve coverage under MolDX&#8217;s LCDs for molecular profiling, a test must demonstrate analytical and clinical validity, and clinical utility at a level that meets the Medicare reasonable and necessary requirement. Our MI Cancer Seek solution has Medicare coverage under the NGS NCD. Our MI Tumor Seek Hybrid solution and our Caris Assure solution for therapy selection are currently covered by Medicare under the MolDX Program. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January 19, 2021, CMS released an NCD that covers future tests for colorectal cancer (&#8220;CRC&#8221;) screening if and when such screening tests have FDA approval and meet pre-specified CMS criteria. In addition, MolDX LCDs provide coverage for MRD for CRC, breast cancer, lung cancer, and other indications when applicable coverage criteria are satisfied. Amongst other items, this coverage criteria includes published literature showing the clinical validity of an assay for the intended use of the assay in the intended population. While we have had preliminary discussions with MolDX regarding coverage for Caris Assure for MRD for CRC, it is possible that MolDX will require us to complete additional publications or validation studies and timing for MolDX coverage, if any, is uncertain. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">MolDX has also issued an LCD for coverage of NGS assays for myeloid malignancies where applicable coverage criteria are satisfied. Among other items, this coverage criteria includes that the assay has completed a technical assessment by MolDX for the assay&#8217;s stated indications. In order to obtain MolDX </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">206</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">coverage for Caris ChromoSeq, we will need to submit, and MolDX will need to approve, a technical assessment for Caris ChromoSeq. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Coding plays a significant role in how our solutions are reimbursed both from commercial and governmental payers. The CPT codes, which are maintained by the AMA, are a set of codes for medical services, including profiling services. In addition to CPT codes, there are PLA codes, also maintained by the AMA, that are a set of billing codes for laboratory services that are more specific than CPT codes. New In addition to CPT and PLA codes, Z-Code Identifiers are used by certain payers, including under Medicare&#8217;s MolDX, to supplement CPT codes for molecular diagnostics tests. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A laboratory launching a new advanced diagnostic laboratory test (&#8220;ADLT&#8221;) or clinical diagnostic laboratory test (&#8220;CDLT&#8221;) can apply for a PLA code with the AMA. This process requires the laboratory to submit an application to the AMA. The AMA then makes coding methodology recommendations to CMS that could include &#8220;Crosswalk&#8221; or &#8220;Gapfill.&#8221; A Crosswalk is used if it is determined that there is an existing similar code, set of codes, or portion of a code that could be used to describe the new test. In this case, pricing would be the equivalent of the existing comparable code, the sum of multiple comparable codes, or a fraction of the comparable code. Gapfill is used when there are no comparable existing codes available. In this case, pricing is based on historical payments from other payers and/or resources required to complete the test. CMS will review the recommendation made by the AMA but will ultimately decide upon the coding methodology independently. This initial decision will be posted for public comment, and pricing will be published at the end of the public comment period. After pricing and coding is published, a request is then submitted to CMS for coverage under an existing NCD, or a request is made to create a new NCD. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2020, the AMA issued a PLA code, CPT code 0211U, for our MI Cancer Seek solution with effective date October&#160;1, 2020. CMS subsequently established national pricing for CPT code 0211U under the CLFS at $8,455. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS NCD. Our MI Tumor Seek Hybrid solution is reported to Medicare and to some commercial payers using unlisted molecular pathology CPT code 81479 and unique Z-Code Identifiers. In July&#160;2024, the AMA issued a PLA code, CPT code 0485U, for Caris Assure for therapy selection, with an effective date of October&#160;1, 2024. In November 2024, CMS determined to price Caris Assure for therapy selection using the &#8220;Gapfill&#8221; method. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. Changes to these coverage polices or to the codes used to report to payers may result in significant changes in reimbursement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our early detection solution could be considered a screening test by Medicare and is not currently covered by Medicare. Medicare coverage for preventive services such as screening tests must be expressly authorized by statute or by CMS under an applicable NCD. Under CMS regulations, additional preventive services covered under an NCD must be (a)&#160;reasonable and necessary for the prevention or early detection of an illness or disability, (b)&#160;recommended with a grade of A or B by the USPSTF, which is an independent, volunteer panel of experts in the field of prevention, evidence-based medicine and primary care, and (c)&#160;appropriate for Medicare beneficiaries under Part&#160;A or Part&#160;B. None of our solutions have received such a grade or determination from USPSTF, which generally waits for FDA authorization before undertaking review of novel technology. In addition, the NCD process may take multiple&#160;years to complete, and currently, coverage decisions for preventive services are not made prior to FDA authorization. Even if we go through the lengthy NCD process, it is possible that the early detection solution will never become eligible for Medicare coverage and reimbursement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are evaluating opportunities for nearer-term coverage and reimbursement through Medicare Advantage plans as a supplemental benefit while generating evidence to meet the requirements of the traditional Medicare path. Medicare Advantage plans generally must cover all of the services that traditional Medicare covers (except hospice care), but they have the discretion to offer their enrollees additional, or supplemental, benefits not otherwise covered under traditional Medicare, including those benefits referred to as optional supplemental benefits, for which enrollees may elect to pay extra to receive coverage. Obtaining such coverage may, however, involve lengthy negotiations with individual Medicare Advantage plans, and there is no guarantee that we will receive such coverage. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also intend to pursue coverage and reimbursement from private payers for our solutions. Many of these private payers must cover certain services required by federal and state laws, such as preventive </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">207</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">health services that have received a rating of A or B by the USPSTF. Like Medicare Advantage plans, private payers have discretion to extend greater coverage than recognized under traditional Medicare but obtaining coverage from such payers may involve lengthy negotiations and there is no guarantee that we will receive such coverage. Even if we are successful in receiving coverage, the reimbursement amounts may not meet expected levels. State Medicaid programs make individual coverage decisions for diagnostic tests and have taken steps to control the cost, utilization and delivery of healthcare services meaning that, even if we receive coverage through private payers, there is no guarantee that our solutions will be covered by individual state Medicaid programs. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">With respect to private health plans, the ACA mandates that such plans cover evidence-based items or services recommended by USPSTF with a grade of A or B, with certain prohibitions on cost-sharing requirements. Accordingly, if the USPSTF does not recommend use of Caris Assure or other solutions we are developing or requires a substantial amount of time to review such solutions, our business, financial condition, and results of our operations would be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Protecting Access to Medicare Act of 2014</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2014, Congress passed the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), which included substantial changes to the way in which certain clinical laboratory services are paid under Medicare&#8217;s CLFS. Under PAMA (as amended by the Further Consolidated Appropriations Act in 2020 and Further Continuing Appropriations and Other Extensions Act of 2024), laboratories that receive the majority of their Medicare revenue from payments made under the CLFS and Physician Fee Schedule and receive at least $12,500 in Medicare revenues for CLFS services during a data collection period are subject to certain reporting requirements. CMS uses the data reported, including certain private payer payment rates, the volume of tests paid at each rate, and the HCPCS code associated with the test, to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for tests that are considered to be CDLTs. If the test falls into the category of new ADLT instead of CDLT, the test will be paid based on an actual list charge for an initial period of three quarters before being shifted to the weighted median private payer rate reported by the laboratory performing the ADLT. Laboratories offering ADLTs are subject to recoupment if the actual list charge exceeds the weighted median private payer rate by a certain amount. Accordingly, if newly developed tests receive Medicare coverage in the future, the reimbursement rate we receive for such tests may be affected by payment rates made by private payers for such tests. In addition, PAMA codified Medicare coverage rules for laboratory tests by requiring any local coverage determination to be made following the local coverage determination process. PAMA also authorizes CMS to consolidate coverage policies for clinical laboratory tests among one to four laboratory-specific MACs. These same contractors may also be designated to process claims if CMS determines that such a model is appropriate. It is unclear whether CMS will proceed with contractor consolidation under this authorization. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Congress passed legislation that delayed data reporting requirements for CDLTs that are not ADLTs, and delayed the phase-in of payment reductions under the CLFS from private payer rate implementation. The revised reimbursement methodology described above generally results in relatively lower reimbursement amounts under Medicare for clinical laboratory services than has been historically reimbursed. Any reductions to reimbursement rates resulting from the new methodology are limited to 0% in 2025 and 15% per test per year in each of 2026 through 2028. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The subsequent data reporting period for CDLTs that are not ADLTs will occur in three-year cycles, with the next cycle beginning in 2026. The pricing for our solutions may be negatively impacted by the PAMA reporting process. Given the many uncertainties built into PAMA&#8217;s price-setting process, we cannot predict how payments we receive under the CLFS, and thus our revenue, may change from year to year. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare Reform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system. Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our solutions, decrease our revenue and adversely impact sales of, and pricing of and reimbursement for, our solutions. For </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">208</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">example, in March&#160;2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The implementation of the ACA in the United States, for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA included, among other things, provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse. Since its enactment, there have been judicial, U.S. Congressional and executive branch challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how other healthcare reform measures, if any, will impact our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, resulted in reductions in payments to Medicare providers, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional Congressional action is taken. In addition, as a result of the American Rescue Plan&#160;Act of 2021 (&#8220;ARPA&#8221;), an additional Medicare payment reduction of up to 4% was required to take effect in January&#160;2022; however, Congress has delayed implementation of this reduction until 2025. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five&#160;years. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that there will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payers to reduce costs while expanding individual healthcare benefits. Certain of these proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our solutions. Changes in healthcare policy could increase our costs, decrease our revenue, and impact sales of and reimbursement for our solutions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Privacy Regulation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Data Privacy and Security Regulation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Numerous state, federal, and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA or HITECH, and federal and state consumer protection laws and regulations (for example, Section&#160;5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In particular, we are a &#8220;Covered Entity&#8221; as defined under HIPAA when performing our healthcare services for customers, and also act as a &#8220;Business Associate&#8221; when performing certain services for or on behalf of Covered Entities, which requires us to develop and maintain policies with respect to the protection of,&#160;use, and disclosure of PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and to provide notifications in the event of a breach of unsecured PHI. In addition, many states have also implemented healthcare privacy and genetic testing and privacy laws imposing specific patient consent requirements and protecting test results by limiting the disclosure of those results. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">209</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a healthcare provider, we are also subject to Section&#160;4004 of the 21</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">st</font><font style="letter-spacing:0.2pt;"> Century Cures Act, and regulations promulgated by HHS related to patient access to electronic PHI (&#8220;EHI&#8221;), to promote interoperability and to ensure the access, exchange, or use of EHI. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other International Privacy and Security Regulations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business is subject to a complex and evolving global web of laws and regulations governing data privacy, data security, cross-border data transfers, and data localization. Local, state, federal, and foreign governments are increasingly implementing or expanding their data protection regimes, resulting in additional compliance costs and risks. Many of these laws and regulations are subject to change and uncertain interpretation and could result in regulatory or litigation claims or actions, changes to our business practices, monetary penalties, increased cost of operations, declines in clinical study participation or engagement, or otherwise harm our business. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rely on information technology systems, including third-party hosted services, to support our business processes and activities and to store personal data (including employee and patient data). Consequently, we are at risk of a cybersecurity-related attack, intrusion, or disruption, including by criminal organizations, hackers, foreign governments, and terrorists. A cybersecurity incident could result in some or all of our systems being unavailable, the loss, misuse, or unauthorized disclosure of genetic information or other personal data, negative publicity and reputational damage, exposure to risk of loss, and litigation and regulatory investigations. In the event we are a victim of a cyberattack, data breach notification laws may require us to notify regulators, affected individuals, and potentially other third parties in multiple jurisdictions. Cyber threats are constantly evolving, increasing the difficulty of detecting and successfully defending against them. Despite our security measures, we cannot guarantee that these measures will prevent all possible security breaches or attacks. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employees and Human Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, we had 1,769 full-time employees. Of these employees, nearly 50 have Ph.D. or M.D. degrees and over 200 are engaged in R&amp;D activities. None of our employees are represented by a labor union or party to a collective bargaining agreement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors, and consultants. We believe our success depends on our ability to attract, retain, develop, and motivate diverse highly skilled personnel. In particular, we depend upon the personal efforts and abilities of the principal members of our senior management to partner effectively as a team and to provide strategic direction, develop our business, manage our operations, and maintain a cohesive and stable work environment. We also rely on qualified managers and skilled employees, such as scientists, engineers, and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering skills, and quality management experience in order to operate our business successfully. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our compensation program is designed to retain, motivate, and attract highly qualified personnel, including through the granting of stock-based and cash-based compensation awards, in order to increase shareholder value and the success of our Company by motivating such individuals to perform to the best of their abilities and achieve our business objectives. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Supply Agreement with Illumina</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2022, we entered into Illumina, Inc.&#8217;s (&#8220;Illumina&#8221;) &#8220;open offer&#8221; supply agreement wherein Illumina provides products and services that we use in our laboratory operations for certain research and clinical activities, including certain sequencers, equipment, and other materials (the &#8220;Illumina Agreement&#8221;). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">210</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Illumina Agreement, Illumina grants non-exclusive, non-transferable, personal, non-sublicensable rights to use certain Illumina know-how and technology with Illumina products purchased under the agreement, and we granted Illumina an irrevocable, perpetual, worldwide, fully paid-up, and royalty-free license covering improvements to certain Illumina know-how and technology. The Illumina Agreement does not contain any minimum purchase requirements but provides for volume discounts and other promotions. The Illumina Agreement also contains use limitations, representations and warranties, indemnification, limitations of liability, change notification, audit rights, and other provisions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Illumina Agreement is irrevocable by Illumina until its expiration in August&#160;2033. We have a unilateral right to terminate our supply relationship with Illumina at any time and for any reason without termination liability upon 90&#160;days&#8217; prior written notice to Illumina. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Master Supply Agreement with Roche</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In July 2024, we entered into a master supply agreement with Roche Diagnostics Corporation (&#8220;Roche&#8221;), for Roche to provide sequencing probes and other testing supplies and equipment for clinical and research uses in our laboratory operations (the &#8220;Roche Agreement&#8221;). Under the Roche Agreement, we receive certain pricing levels if we purchase a specified minimum annual quantity of supplies. Under the terms of the Roche Agreement, we also agreed to make rolling forecasts of our expected needs, which forecasts currently become three- and six-month binding purchase commitments for catalog and custom products, respectively. The pricing is fixed for the initial 12 months of the agreement term described below, and subject to increase thereafter. The Roche Agreement also contains negotiated use limitations, representations and warranties, indemnification, limitations of liability, and other provisions.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Roche Agreement has an initial term through April 2027 and will automatically renew with successive one-year terms unless either party provides 90-day advance notice of non-renewal. The agreement also provides for other customary termination rights, including in the case of material breach by, or insolvency of, either party.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Facilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our corporate headquarters are located in Irving, Texas, where we lease approximately 30,500 square feet pursuant to a lease expiring in 2028. We also lease office space in Arizona, Massachusetts, and New York, and in Switzerland and Japan for our international offices. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We lease an approximately 66,000 square foot solid tissue clinical laboratory facility and an approximately 35,500 square foot blood-based clinical laboratory facility in Phoenix, Arizona, with leases expiring in 2030 and 2026, respectively. We also lease an approximately 59,000 square foot R&amp;D laboratory facility in Tempe, Arizona and an approximately 114,500 square foot laboratory facility in Irving Texas, with leases expiring in 2026 and 2035, respectively. The laboratory facility in Irving, Texas is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We lease an approximately 54,500 square foot customer service office and an approximately 22,550 square foot warehouse facility in Phoenix, Arizona, with leases expiring in 2030 and 2031, respectively. We also lease an approximately 23,400 square foot warehouse facility in Irving, Texas, with a lease expiring in 2032. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not own any real property. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2025, we received a Civil Investigative Demand (&#8220;CID&#8221;) from the DOJ in connection with an investigation under the FCA regarding our compliance with Medicare&#8217;s date of service rule (also referred to as the 14-day rule), particularly focused on patients of certain health care providers, and our policies, procedures, and training related to compliance with the 14-day rule. The related investigation continues to evolve and is in too early a stage to assess potential outcomes. We are cooperating with the investigation. We have implemented compliance policies, procedures, and training designed to foster </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">211</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:416pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">compliance with the 14-day rule, but there can be no certainties regarding the outcome of the CID. In June 2022, we entered into a settlement agreement with the United States in connection with a previous&#160;investigation into our compliance with the 14-day day rule. Pursuant to this settlement agreement, under which we admitted no fault or liability, we paid approximately $2.9 million in restitution and penalties and we obtained a nationwide release from all 14-day rule claims prior to January 1, 2018.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to the matter described above, we are, from time to time, party to various claims and legal proceedings arising out of our ordinary course of business, including claims or proceedings relating to, among other things, regulatory matters, intellectual property, competition, tax, and employment matters, medical malpractice, product or professional liability or other tort claims. We cannot predict with certainty the results of any claims or proceedings. We may receive unfavorable preliminary or interim rulings in the course of litigation, and there can be no assurances that favorable final outcomes will be obtained. Moreover, the existence of any claim or legal proceeding, regardless of the outcome, may adversely impact us because of diversion of management time and attention as well as the financial costs related to resolving such disputes. For additional information, see &#8220;Risk Factors&#8212;Risks Related to Regulation and Legal Compliance&#8212;We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements.&#8221;</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">212</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers and Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Set forth below are the names, ages, and positions of our executive officers and directors as of the date of this prospectus. </font>
        </div>
        <table style="width:456pt;height:317.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:17pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:2pt;padding-right:2pt;letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:207pt;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:172pt;letter-spacing:-0.16pt;">Position(s) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:207pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">David D. Halbert, D.Sc. (h.c.) </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">69 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <div style="white-space:nowrap; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Founder, Chairman, and Chief Executive Officer </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brian J. Brille </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">64 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Vice Chairman and Executive Vice President </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">David Spetzler, M.S., Ph.D., M.B.A. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">49 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">President </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Luke Power </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">44</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Senior Vice President, Chief Financial Officer, </font>
              <br >
              <font style="letter-spacing:0.2pt;">and Chief Accounting Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">J. Russel Denton </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:207pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Senior Vice President, General Counsel, and Secretary </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:207pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">George H. Poste, D.V.M., Ph.D., D.Sc., F.R.S. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">81 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Vice Chairman </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jonathan Knowles, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">77 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Vice Chairman </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999997pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nathan Burns</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter M. Castleman</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">68 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">David Fredrickson </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">50 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joseph E. Gilliam</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">49 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jon S. Halbert </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laura I. Johansen</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">59 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lloyd B. Minor, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">67 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vijay Mohan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">45 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Danny Phillips</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jeffrey Vacirca, M.D., F.A.C.P.</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:17pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">56</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Member of the audit committee of our board of directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Member of the compensation committee of our board of directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Messrs.&#160;Burns and Mohan have notified us that they each intend to resign from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">David D. Halbert, D.Sc. (h.c.)</font><font style="letter-spacing:0.2pt;"> founded our Company in 2008 and has served as our Chief Executive Officer and the Chairman of our board of directors since our inception. Mr.&#160;Halbert and his family also created and solely support the Caris Foundation, a non-profit, private foundation formed in 2002 that aids impoverished people by helping to provide for their basic needs. From 2005 to 2011, Mr.&#160;Halbert served as Chairman and Chief Executive Officer of Caris Diagnostics, a Texas-based pathology company specializing in gastrointestinal pathology, which was sold to Miraca Life Sciences in 2011. Prior to Caris Diagnostics, Mr.&#160;Halbert served as Chairman and Chief Executive Officer of AdvancePCS Inc. (&#8220;AdvancePCS&#8221;), a prescription benefit plan administrator that he founded in 1987. Mr.&#160;Halbert holds a Bachelor of Business Administration from Abilene Christian University and an honorary Doctor of Science from Abilene Christian University for his contributions to precision medicine and his global philanthropic work. We believe Mr.&#160;Halbert&#8217;s extensive knowledge of the healthcare industry, business experience, and 20&#160;years of leadership as Caris&#8217; Founder, Chairman, and Chief Executive Officer make him well-qualified to serve as a member of our board of directors. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">213</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Brian J. Brille</font><font style="letter-spacing:0.2pt;"> has served as our Vice Chairman and Executive Vice President and as a member of our board of directors since January&#160;2018. Mr.&#160;Brille currently serves as a member of the board of trustees at the Cancer Research Institute, a non-profit organization funding cancer research. Since 2022, Mr.&#160;Brille has also served as member of the board of directors at the International Biomedical Research Alliance, a non-profit organization with a mission to support the NIH Oxford-Cambridge Scholars Program. Prior to joining Caris, Mr.&#160;Brille served in various finance-related roles for Bank of America Merrill Lynch (now BofA Securities, Inc.), a multinational investment bank and financial services company, from 1999 to 2013, including most recently as Chairman &amp; President of Asia Pacific from 2009 to 2013, as Head of Corporate and Investment Banking from 2005 to 2008, and as Head of Healthcare Investment Banking from 1999 to 2004. Mr.&#160;Brille began his career in 1987 at Morgan Stanley &amp; Co. LLC (&#8220;Morgan Stanley&#8221;), a multinational investment bank and financial services company, and founded Morgan Stanley&#8217;s Healthcare Services Investment Banking Group. Mr.&#160;Brille holds a Juris Doctor from Stanford Law School, a Master in Public Policy from the Harvard Kennedy School, and a Bachelor of Science in Accounting from the University of Illinois. We believe Mr.&#160;Brille&#8217;s extensive experience in the investment industry and knowledge of healthcare and technology companies make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">David Spetzler, M.S., Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as our President since November&#160;2016. Dr.&#160;Spetzler has also served as an adjunct faculty member of the molecular cellular biology program at Arizona State University since 2007. Dr.&#160;Spetzler joined Caris in August&#160;2009 as a Senior Scientist and has served in a variety of roles of increasing seniority during his tenure. Before Caris, Dr.&#160;Spetzler served in various research faculty roles at Arizona State University from January&#160;2003 to August&#160;2009. Dr.&#160;Spetzler holds a Master of Science, a Doctor of Philosophy in Molecular &amp; Cellular Biology, and a Master of Business Administration from Arizona State University. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Luke Power</font><font style="letter-spacing:0.2pt;"> has served as our Senior Vice President, Chief Financial Officer, and Chief Accounting Officer since February&#160;2023. Mr.&#160;Power joined Caris in December&#160;2011 as a Financial Reporting and Accounting Manager and has served in a variety of roles of increasing seniority during his tenure, including as Chief Accounting Officer from April&#160;2017 to February&#160;2023, Senior Director of Accounting from May&#160;2016 to September&#160;2016, and Director of Accounting from August&#160;2013 to May&#160;2016. Prior to joining Caris, Mr.&#160;Power worked as a Manager in the international assurance practice at PricewaterhouseCoopers LLP, a provider of business advisory services, from November&#160;2002 to October&#160;2011. Mr.&#160;Power is a certified public accountant and a fellow of Chartered Accountants Ireland. Mr.&#160;Power holds a degree in finance and accounting from Waterford Institute of Technology in Ireland. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">J. Russel Denton</font><font style="letter-spacing:0.2pt;"> has served as our Senior Vice President, General Counsel, and Secretary since September&#160;2022. Prior to joining Caris, Mr.&#160;Denton served as a partner at Shearman &amp; Sterling LLP, an international law firm, representing clients in mergers and acquisitions and equity financing transactions from March&#160;2018 to September&#160;2022. Prior to Shearman &amp; Sterling LLP, Mr.&#160;Denton served as a partner at Andrews Kurth Kenyon LLP from May&#160;2012 to February&#160;2018. Mr.&#160;Denton began his career in September&#160;2008 as an associate at Skadden, Arps, Slate, Meagher and Flom LLP. Mr.&#160;Denton holds a Juris Doctor from Stanford Law School and a Bachelor of Science from Duke University. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">George H. Poste, D.V.M., Ph.D., D.Sc., F.R.S.</font><font style="letter-spacing:0.2pt;"> has served as our Vice Chairman since our founding in 2008. Since February&#160;2009, Dr.&#160;Poste has served as the Chief Scientist of the Complex Adaptive Systems Initiative at Arizona State University, a program that links expertise across the university in research on synthetic biology, ubiquitous sensing, and healthcare informatics for personalized medicine, and as the Del&#160;E. Webb Professor of Health Innovation. From May&#160;2003 to February&#160;2009, Dr.&#160;Poste served as Director of The Biodesign Institute at Arizona State University. Since January&#160;2000, Dr.&#160;Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare. From July&#160;1992 to December&#160;1999, Dr.&#160;Poste was the Chief Science and Technology Officer and President, R&amp;D, of SmithKline Beecham Corporation, a pharmaceutical company. Dr.&#160;Poste served on the Defense Science Board of the U.S. Department of Defense from January&#160;2000 to December&#160;2009 and is a member of the Bipartisan Commission on Biodefense as well as other U.S. government organizations to advise on national security policy on advancing defenses against bioweapons and biowarfare. Dr.&#160;Poste has served as a member of the board of directors of Exelixis, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">214</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Inc., a genomics-based drug discovery company, since 2004. Previously, Dr.&#160;Poste served as a member of the board of directors of Monsanto Company, a provider of agricultural products and solutions, from 2003 to 2018, Orchid Cellmark, Inc., a DNA forensics company, from 2002 to 2009, AdvancePCS, from 2002 to 2005, Structural GenomiX, a biotechnology company, from 2000 to 2003, and Illumina, from 2000 to 2003. Dr.&#160;Poste also serves on several scientific advisory boards, including Synthetic Genomics Inc., VirBiotech, the University of Michigan Taubman Institute, and MIDAS Advanced Computing Initiative. Dr.&#160;Poste is a Fellow of the UK Royal Society, the UK Academy of Medical Sciences, American Institute for Medical and Biological Engineering. Dr.&#160;Poste is also a member of the Council for Foreign Relations and previously served as a member of the Hoover Institution, Stanford University, and has received several honorary doctorates from several universities. Dr.&#160;Poste holds a Doctor of Veterinary Medicine and a Doctor of Philosophy in Virology from the University of Bristol, England and Board Certification in Pathology from the Royal College of Pathologists. We believe Dr.&#160;Poste&#8217;s training as a scientist, knowledge of the life sciences, healthcare, and biopharma industries, and extensive service on multiple boards make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Jonathan Knowles, Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as our Vice Chairman since 2010. Dr.&#160;Knowles served as the President of Group Research at Roche Holding AG (&#8220;Roche&#8221;), a Swiss multinational healthcare company, from September&#160;1998 to January&#160;2010 and as a member of its Corporate Executive Committee from January&#160;1998 to January&#160;2010. From January&#160;1998 to January&#160;2010, Dr.&#160;Knowles served as a member of the board of directors and as Chairman of the Corporate Governance Committee of Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche. From January&#160;2007 to January&#160;2010, Dr.&#160;Knowles served as the Chairman of the Research Directors&#8217; Group of the European Federation of Pharmaceutical Industry Associations. He has also served on the boards of directors of various pharmaceutical companies. Dr.&#160;Knowles is a Professor Emeritus at the &#201;cole Polytechnique F&#233;d&#233;rale de Lausanne, a Distinguished Professor in Personalized Medicine at the University of Helsinki, Finland, and a visiting Professor at the University of Oxford. Dr.&#160;Knowles holds a Bachelor of Science in Molecular Genetics from the University of East Anglia and a Doctor of Philosophy in Genetics of Mitochondria from the University of Edinburgh. We believe Dr.&#160;Knowles&#8217; extensive experience in the pharmaceutical industry and&#160;years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Nathan Burns</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since August&#160;2022. Mr.&#160;Burns is currently a Managing Director &amp; Healthcare Portfolio Manager at Highland Capital Management, L.P., a global alternative investment manager based in Dallas, Texas. Mr.&#160;Burns joined Highland Capital Management, L.P. in July&#160;2014 as a Director of Healthcare Absolute Return Investments. Prior to joining Highland Capital Management, L.P., Mr.&#160;Burns was a Private Equity Associate at Ripplewood Holdings, a global private equity firm, from September&#160;2007 to December&#160;2013. Mr.&#160;Burns began his career as an Investment Banking Analyst in the Global Technology Mergers &amp; Acquisitions Group at Lehman Brothers, a global financial services firm, from June&#160;2004 to June&#160;2007. Mr.&#160;Burns holds a Bachelor of Science in Analytical Finance and Economics from Wake Forest University and Master of Business Administration from Columbia Business School. He also is a CFA charterholder. We believe Mr.&#160;Burns&#8217; extensive experience in the investment industry and knowledge of healthcare companies make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Peter M. Castleman</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since 2008. Mr.&#160;Castleman is a private company investor and entrepreneur. Mr.&#160;Castleman is actively involved with about a dozen private companies where he is a significant owner through his family office, which he established in December&#160;2006. Prior to establishing his family office, Mr.&#160;Castleman was the Chairman and Managing Partner of J.&#160;H.&#160;Whitney &amp; Co., LLC, a private equity firm, from December&#160;1992 to December&#160;2006, where he oversaw all the firm&#8217;s activities, including the private equity investing business. Prior to joining J. H. Whitney &amp; Co., LLC in May&#160;1987, Mr.&#160;Castleman was with Morgan Stanley &amp; Co. LLC in their leveraged buyout investment group. Mr.&#160;Castleman started his career at J.P. Morgan Securities LLC, where he was an international banking officer. Mr.&#160;Castleman holds a Master of Business Administration from Harvard Business School and a Bachelor of Arts from Duke University. We believe Mr.&#160;Castleman&#8217;s extensive experience in the investment industry and&#160;years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">215</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">David Fredrickson</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since August&#160;2024. Mr.&#160;Fredrickson currently serves as Executive Vice-President, Oncology Business Unit of AstraZeneca PLC, a position that he has held since October&#160;2017. Previously, Mr.&#160;Fredrickson served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care of AstraZeneca in the United States. While in Japan, Mr.&#160;Fredrickson also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Mr.&#160;Fredrickson worked at Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche, where he served in several functions and leadership positions, including as Oncology Business Unit Manager in Spain, and in strategy, marketing, and sales roles in the United States. Prior to this, Mr.&#160;Fredrickson worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy firm. Mr.&#160;Fredrickson holds a Bachelor of Arts in Government from Georgetown University. We believe Mr.&#160;Fredrickson&#8217;s extensive experience in the pharmaceutical and oncology industries and&#160;years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Joseph E. Gilliam</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since April&#160;2021. Mr.&#160;Gilliam is currently the President and Chief Operating Officer at Glaukos Corporation, an ophthalmic pharmaceutical and medical device company, a position he has held since April&#160;2022. From May&#160;2017 to April&#160;2022, Mr.&#160;Gilliam was Chief Financial Officer and Senior Vice President, Corporate Development at Glaukos Corporation. Prior to Glaukos Corporation, Mr.&#160;Gilliam served as a Managing Director in the Healthcare Investment Banking group at J.P. Morgan Securities LLC from 2013 to May&#160;2017, where he led the initial public offering for Glaukos Corporation. From 2000 to 2013, Mr.&#160;Gilliam held positions of increasing responsibility at J.P.&#160;Morgan Securities LLC and its predecessor organizations, The Beacon Group and Chase Manhattan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. Mr.&#160;Gilliam started his career at PricewaterhouseCoopers LLP as an Auditor. Mr.&#160;Gilliam holds a Bachelor of Science in accounting from the Kelly School of Business at Indiana University. We believe Mr.&#160;Gilliam&#8217;s extensive experience in the investment and healthcare industries and knowledge of healthcare companies make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Jon S. Halbert</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since May&#160;2014. Mr.&#160;Halbert currently serves as a member of the board of directors at Allegiance Group, a leading provider of fundraising services to nonprofit organizations in the United States, a position he has held since January&#160;2023. Since August&#160;2007, Mr.&#160;Halbert has also served as a member of the board of directors of the Pursuant Group, a nonprofit-focused marketing and fundraising organization that merged with the Allegiance Group in April&#160;2023. Mr.&#160;Halbert also currently serves on the boards of directors of CitiSquare and Forest Forward, Dallas-based nonprofit organizations that focus on poverty and the revitalization of South Dallas, respectively. Mr.&#160;Halbert served as the Chairman of Phytel, Inc., a technology driven provider-led population health improvement company, until its merger with the International Business Machines Corporation in 2015. Prior to Phytel, Inc., Mr.&#160;Halbert co-founded and served as Vice Chairman of AdvancePCS from 1987 until its merger with CVS Caremark Corporation in 2004. Mr.&#160;Halbert holds a Bachelor of Accounting from Abilene Christian University. We believe Mr.&#160;Halbert&#8217;s extensive experience in the healthcare and technology industries and&#160;years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Laura I. Johansen</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since our founding in 2008. Ms.&#160;Johansen served as our Vice Chairman until February&#160;2012. In 2015, Ms.&#160;Johansen founded and currently serves as the President of Pence Management, a family office focused on real estate and equity investments. Ms.&#160;Johansen previously served as the President of Halbert &amp; Associates, LLC (&#8220;Halbert &amp; Associates&#8221;), the family office of Mr.&#160;Halbert, from 2004 to 2010. Ms.&#160;Johansen began her career at AdvancePCS as General Counsel in 1996 and served as the Senior Vice President and Corporate Secretary from 2001 until its merger with CVS Caremark Corporation in 2004. Before joining AdvancePCS, Ms.&#160;Johansen served as an Associate in the Corporate and Securities Group of Akin, Gump, Strauss, Hauer and Feld, an international law firm. Ms.&#160;Johansen holds a Bachelor of Business Administration in Marketing and a Juris Doctor from the University of Texas. We believe Ms.&#160;Johansen&#8217;s extensive experience in the healthcare industry and&#160;years of leadership experience as our Vice Chairman make her well-qualified to serve as a member of our board of directors. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">216</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Lloyd B. Minor, M.D.</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since August&#160;2021. Dr.&#160;Minor is currently the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since 2012. In addition to being the Dean of the School of Medicine, he became the Vice President for Medical Affairs at Stanford University in August&#160;2023. Dr.&#160;Minor has also been a professor of Otolaryngology&#8212;Head and Neck Surgery and a professor of Neurobiology and Bioengineering, by courtesy, since 2012. Prior to 2012, Dr.&#160;Minor served as the Provost and Senior Vice President for Academic Affairs at Johns Hopkins University from 2009 to 2012. Dr.&#160;Minor began his career at Johns Hopkins School of Medicine in the Department of Otolaryngology&#8212;Head and Neck Surgery as a Professor from 1993 to 2003, before serving as department&#8217;s Andelot Professor and Director (Chair) from 2003 to 2009. Dr. Minor has served as a member of the board of directors of Biogen, a global pharmaceutical company, since 2024. Dr.&#160;Minor holds a Bachelor of Science in Biology and a Doctor of Medicine from Brown University. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine. We believe Dr.&#160;Minor&#8217;s experience as a professor and knowledge of the medical and healthcare industries make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Vijay Mohan</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since August&#160;2020. Mr.&#160;Mohan is currently a Co-Founder and Partner at Sixth Street Partners, a San Francisco-based investment firm, a position he has held since its founding in May&#160;2009. Prior to Sixth Street Partners, Mr.&#160;Mohan was a Managing Principal at Bardin Hill Investment Partners L.P., a New York investment firm. Mr.&#160;Mohan began his career in the Technology, Media, and Telecom Group of the Investment Banking Division of Goldman Sachs &amp; Co. LLC, a global investment banking, securities, and investment management firm. Mr.&#160;Mohan currently serves as a member of the Board of Visitors for Columbia College. He holds a Bachelor of Arts in Economics from Columbia University. We believe Mr.&#160;Mohan&#8217;s extensive experience in the investment industry and&#160;years of experience as the co-founder of Sixth Street Partners make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Danny Phillips</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since August&#160;2015. Mr.&#160;Phillips is currently the owner of the Diamond P Longhorn Ranch in Lindale, Texas, and manages his own financial investments. Mr.&#160;Phillips currently serves as a member of the board of directors of Fortress Youth Development Center, a non-profit organization that aids the homeless community and low-income families in Fort Worth, Texas, and served as its Chairperson from 2007 to 2015. In addition, Mr.&#160;Phillips currently serves as a member of the board of directors of Mission Increase Fort Worth, a non-profit organization that offers teaching, coaching, consulting, and fundraising tools to help other non-profits grow and be successful. He also currently serves as a member of the board of directors of Texas Mutual Insurance Company, a workers&#8217; compensation provider in Texas, a position he has held since 2012. Mr.&#160;Phillips has also previously served as a member of the board of directors of various academic organizations, such as on the board of regents at Pepperdine University and the investment board of Abilene Christian University. Mr.&#160;Phillips served in various finance-related roles at AdvancePCS for over 11&#160;years, including as its Chief Financial Officer and Senior Executive Vice President until its sale to CVS Caremark Corporation in 2004. Prior to AdvancePCS, Mr.&#160;Phillips served various senior financial roles at Harken Energy Corporation (now HKN Inc.), a company engaged in hydrocarbon exploration in Texas, and Aloha Petroleum, Ltd., a gasoline marketer and convenience store operator in Hawaii. Mr.&#160;Phillips holds a Bachelor of Arts in Accounting from Abilene Christian University. We believe Mr.&#160;Phillips&#8217; extensive experience in the pharmaceutical and investment industries and&#160;years of experience as a director and executive officer make him well-qualified to serve as a member of our board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Jeffrey Vacirca, M.D., F.A.C.P.</font><font style="letter-spacing:0.2pt;"> has served as a member of our board of directors since November&#160;2024. Since 2008, Dr. Vacirca has served as Chief Executive Officer and Chairman of the Board of New York Cancer &amp; Blood Specialists, a cancer care center specializing in hematology/oncology and medical oncology. Since 2011, he has served as President and Co-Founder of National Translational Research Group, a group focusing on non-clinical research, and, from 2012 to 2023, he served as a Medical Director and Strategic Advisor for the International Oncology Network specialty group at Amerisource Bergen, a pharmaceutical products company. Since 2018, Dr. Vacirca has served as the Medical Director of the Oncology Network Development at Mount Sinai Health Network and as an associate clinical professor at Icahn School of Medicine at Mount Sinai, New York. He served as Medical Director for the Long Island Association for AIDS Care from 2008 to 2024. Dr. Vacirca also serves on the boards of directors of privately held companies Annexus Health, OneOncology (where he was a co-founder) and PatientPoint. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">217</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Vacirca served as a director of Assertio Holdings, a publicly-traded pharmaceutical company, from July&#160;2023 to November 2024, Spectrum Pharmaceuticals, a publicly-traded pharmaceutical company, from November 2018 to its July 2023 acquisition by Assertio, and BeyondSpring Inc., a publicly-traded biopharmaceutical company, from December 2020 to April 2022. Dr. Vacirca is the past president of the Community Oncology Alliance and continues to be a member of its executive committee. Dr. Vacirca also served on our Scientific Advisory Board from 2014 to 2020 and was a consultant for us from February 2022 through his election as a director. He has also been part of early funding for various companies including Cedar, Thyme Care, and Sherpa Health. Dr. Vacirca co-founded Odonate Therapeutics, a publicly held pharmaceutical company, in 2016 and served as a director until September 2019. Dr. Vacirca is the founder and Chairman of the Board of Directors of the New York Cancer Foundation, which provides financial assistance to patients undergoing treatment for cancer. Dr. Vacirca holds a Bachelor of Arts in Human Biology from the University at Albany and a Doctor of Medicine from St. George&#8217;s University. We believe that Dr. Vacirca&#8217;s extensive clinical expertise in oncology, experience in the healthcare and pharmaceutical industries, and leadership roles in cancer-focused organizations make him well-qualified to serve as a member of our board of directors.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Family Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">David D. Halbert, our Founder, Chairman, and Chief Executive Officer, is the brother of Jon S. Halbert, a member of our board of directors. Aside from the foregoing relationship, there are no family relationships among any of our executive officers or directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Composition of Our Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business and affairs are managed under the direction of our board of directors. Messrs.&#160;Burns and Mohan have notified us that they each intend to resign from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. There have been no disagreements between us and the resigning directors on any matter relating to our operations, policies, or practices. Our board of directors upon the completion of this offering will consist of&#160;12 members, eight of whom qualify as &#8220;independent&#8221; under the listing standards of Nasdaq. Our amended and restated certificate of formation and amended and restated bylaws, each of which will become effective immediately prior to the completion of this offering, will provide that the number of directors on our board of directors will be fixed from time to time by resolution of the board of directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When considering whether directors have the experience, qualifications, attributes, or skills, taken as a whole, to enable our board of directors to satisfy its oversight responsibilities effectively in light of our business and structure, the board of directors focuses primarily on each person&#8217;s background and experience as reflected in the information discussed in each of the directors&#8217; individual biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Independence</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the completion of this offering, our board of directors undertook a review of the independence of each director who is not an employee of Caris. Based on information provided by each such director concerning his or her background, employment, and affiliations, our board of directors has affirmatively determined that each of our directors, other than David D. Halbert, Brian J. Brille, George&#160;H.&#160;Poste, and Jon S. Halbert, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the listing standards of Nasdaq. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our Company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them, if any, described in the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following this offering, we may become a &#8220;controlled company&#8221; as defined under the corporate governance rules of Nasdaq. The Nasdaq rules define a &#8220;controlled company&#8221; as a company of which more </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">218</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">than 50% of the voting power for the election of directors is held by an individual, a group, or another company. In the event we become a controlled company, we may elect not to comply with certain corporate governance rules of Nasdaq. See &#8220;Risk Factors&#8212;Risks Related to This Offering and Ownership of Our Class A Common Stock&#8212;Following this offering, we may become a &#8220;controlled company&#8221; within the meaning of the rules of Nasdaq. In such event, we may take advantage of the &#8220;controlled company&#8221; exemptions to the corporate governance rules of Nasdaq.&#8221;</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lead Independent Director</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">David D. Halbert serves as both our Chief Executive Officer and as Chairman of our board of directors. Our board of directors has appointed Peter M. Castleman to serve as our lead independent director. As lead independent director, Mr. Castleman will preside over all meetings of the board of directors at which the Chairman of the board or directors is not present, including any executive sessions of the independent directors; call meetings or separate sessions of the independent directors; approve meeting schedules and agendas for the board of directors; approving information sent to the board of directors; acting as the liaison between the independent directors and the Chief Executive Officer and Chairman of the board of directors; and when appropriate, meeting or otherwise communicating with major shareholders or other constituencies.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Committees of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has established an audit committee and a compensation committee, each of which will have the composition and responsibilities described below upon the completion of this offering. Members will serve on these committees until their resignation or until as otherwise determined by our board of directors. Each committee will operate under a written charter approved by our board of directors that satisfies the applicable rules of the SEC and the listing standards of Nasdaq. Upon the completion of this offering, copies of each committee&#8217;s charter will made available on our website. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not intend to have a standing nominating committee. In accordance with Rule&#160;5605 of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by the board of directors. The board of directors believes that the independent directors can satisfactorily carry out the responsibility of properly selecting or approving director nominees without the formation of a standing nominating committee. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we expect our audit committee will consist of Danny&#160;Phillips, Peter M. Castleman, and Joseph E. Gilliam, with Mr. Phillips serving as Chair, and each of whom meet the requirements for independence under the listing standards of Nasdaq and SEC rules and regulations. Each member of our audit committee also meets the financial literacy and sophistication requirements of the listing standards of Nasdaq. In addition, our board of directors has determined that each member of our audit committee is an audit committee financial expert within the meaning of Item&#160;407(d) of Regulation&#160;S-K under the Securities Act. We intend to comply with the listing requirements of Nasdaq regarding the composition of our audit committee within the transitions period for newly public companies. Following the completion of this offering, our audit committee will be responsible for, among other things: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the appointment, compensation, retention, and oversight of our independent registered public accounting firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and discussing with management and the independent registered public accounting firm the adequacy of our internal control over financial reporting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">establishing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">discussing our policies on risk assessment and risk management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">219</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and, if appropriate, approving related party transactions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">pre-approving, all audit and all permissible non-audit services to be performed by the independent registered public accounting firm. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we expect our compensation committee will consist of Peter&#160;M. Castleman, Joseph E. Gilliam, and Laura I. Johansen, with Mr. Castleman serving as Chair. Following the completion of this offering, our compensation committee will be responsible for, among other things: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing, approving and determining, or making recommendations to our board of directors regarding, the compensation of our executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">recommending compensation for non-employee directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">administering our equity compensation plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reviewing and approving, or making recommendations to our board of directors, regarding incentive compensation and equity compensation plans; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">establishing and reviewing general policies relating to compensation and benefits of our employees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of our compensation plans, our compensation committee will have discretion to determine the amount, form, structure and implementation of compensation payable to our employees and executive officers, including, where appropriate, discretion to increase or decrease awards or to award compensation absent the attainment of performance goals and to award discretionary cash compensation outside of the parameters of our compensation plans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Role of the Board in Risk Oversight</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is responsible for overseeing our risk management process. Our board of directors focuses on our general risk management policies and strategy, the most significant risks facing us, and oversees the implementation of risk mitigation strategies by management. Our board of directors is also apprised of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors does not have a standing risk management committee but intends to administer its oversight function through our audit committee, which will be responsible for overseeing enterprise risk management, including the management of financial risks and cybersecurity risks, reviewing and discussing our guidelines and policies with respect to risk assessment and risk management, and discussing with management the steps management has taken to monitor and control these exposures. In addition, the standing committees of our board of directors will address risks inherent in their respective areas of oversight. Our compensation committee will oversee risks related to our executive compensation, equity incentive plans, and other compensatory arrangements, and our will oversee risks associated with our corporate governance framework. Our board of directors intends to implement its risk oversight function both as a whole and through delegation to its committees, which will meet regularly and report back to the board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our board of directors or compensation committee. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Code of Business Conduct and Ethics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to the completion of this offering, our board of directors will adopt a written code of business conduct and ethics that will apply to all of our employees, officers, and directors, including our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">220</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. Upon the completion of this offering, the full text of our code of business conduct and ethics will be posted on our website, </font><font style="font-style:italic;letter-spacing:0.2pt;">www.carislifesciences.com</font><font style="letter-spacing:0.2pt;">. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision of the code of business conduct and ethics. The information on our website is deemed not to be incorporated in this prospectus or to be part of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For 2024, we provided a $50,000 cash retainer, paid in quarterly installments, to certain non-employee directors for their service on our board of directors. We also provided additional cash retainers to committee chairs and members as follows: audit committee chair ($24,000); audit committee members ($10,000); compensation committee chair ($17,750); compensation committee members ($8,000); governance and nominating committee chair ($10,000) and governance and nominating committee members ($5,000). Dr.&#160;Minor did not receive an annual retainer but instead received a fee of $40,000 for every meeting he attended. We also reimbursed all of our directors for their out-of-pocket expenses in connection with attending board of directors and committee meetings, and our directors are eligible to obtain our solutions on the same terms and conditions available to our employees. We did not provide compensation for 2024 to our investor designee directors, Messrs. Burns and Mohan, for their services on our board of directors. David D.&#160;Halbert and Brian J. Brille, who are employees of the Company, did not receive any additional compensation for their services on our board of directors. See the section titled &#8220;Executive Compensation&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">Summary Compensation Table&#8221; for the compensation received by Mr.&#160;Halbert and Mr. Brille for 2024. </font></div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information regarding compensation paid to our non-employee directors for the fiscal year ended December&#160;31, 2024. </font>
        </div>
        <table style="width:456pt;height:173.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 1.167pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1.16666666666667pt;padding-right:1pt;letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fees Earned or </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid in Cash ($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stock Awards ($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option Awards ($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation ($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total ($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">George H. Poste </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">55,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;"><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(3)</font></font></td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107,500<font style="position:absolute;"><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(4)</font></font></td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">162,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jonathan Knowles </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nathan Burns</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter M. Castleman </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">77,750</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">77,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">David Fredrickson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">963,000</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">988,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joseph E. Gilliam </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jon S. Halbert </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laura I. Johansen </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">63,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">63,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lloyd B. Minor </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">160,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">160,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vijay Mohan</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Danny Phillips </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,000</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">74,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:111.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jeffrey Vacirca </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:10.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:27.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">972,000</td>
            <td style="padding:0pt;padding-left:21.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">984,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">As of December&#160;31, 2024, certain of our non-employee directors held outstanding options to purchase a number of shares of our common stock, as follows: Dr.&#160;Poste&#8212;700,000 shares; Dr.&#160;Knowles&#8212;10,000 shares; Mr.&#160;Fredrickson&#8212;300,000 shares; Mr.&#160;Gilliam&#8212;300,000 shares; Mr.&#160;Phillips&#8212;400,000 shares; and </font>
          <br >
          <font style="letter-spacing:0.18pt;">Dr. Vacirca&#8212;400,000 shares. Additionally, as of December&#160;31, 2024, Dr. Poste held a total of 874,500 restricted stock units (&#8220;RSUs&#8221;), which RSUs fully vest only upon the occurrence of an initial public offering or a change in control of the Company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">The amounts in this column reflect the aggregate grant date fair value of stock options granted under our 2020 Plan in 2024, as calculated in accordance with FASB ASC Topic 718 (without any reduction for risk of forfeiture) as determined based on applying the assumptions used in Note&#160;7 to our consolidated financial statements for 2024 included elsewhere in this prospectus. Options were granted to each of Mr. Fredrickson and Dr. Vacirca in connection with their election to our board of directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Reflects the aggregate grant date fair value of RSUs granted under the 2020 Plan in 2024, as calculated in accordance with FASB ASC 718 (without any reduction for risk of forfeiture) as determined based on applying the assumptions used in Note&#160;7 to our consolidated financial statements for 2024 included elsewhere in this prospectus. The RSUs will fully vest only upon the occurrence of a specific performance milestone (either an </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">221</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:252pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:36pt; width:420pt; line-height:11pt;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">initial public offering or a change in control of the Company). Assuming the maximum performance levels are achieved, the maximum value of the RSUs would be $4,250,070. This amount may not reflect the actual value realized upon vesting or settlement, if any. </font>
        </div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">The amounts reported reflect fees received for consulting services provided to the Company and for service on the Company&#8217;s Scientific Advisory Board. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Messrs.&#160;Burns and Mohan have notified us that they each intend to resign from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Paid to Employee Directors for 2024</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">David D. Halbert is the Chairman of our board of directors, our Founder and also serves as our Chief Executive Officer. Brian J. Brille is the Vice Chairman of our board of directors and also serves as Executive Vice President. Mr. Halbert and Mr. Brille do not receive any additional compensation for their services on our board of directors. For the compensation received by Mr.&#160;Halbert and Mr. Brille for the fiscal year ended December 31, 2024 and a description of the elements of their compensation, see the section titled &#8220;Executive Compensation.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Director Compensation Policy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective January 1, 2025, our compensation committee adopted a Non-Employee Director Compensation Policy, pursuant to which our non-employee directors are compensated effective January 2025. Under the policy, each non-employee director will receive an annual cash retainer equal to $50,000 and an annual equity retainer consisting of time-vested RSUs with a grant date fair value equal to $300,000. The non-employee director, if any, who serves as a lead independent director will additionally receive an annual cash retainer equal to $30,000. The committee chairs of the audit committee and compensation committee, will receive annual cash retainers equal to $25,000 and $18,000, respectively. The committee members will receive the following annual cash retainers: $12,500 for service on the audit committee and $9,000 for service on the compensation committee. A non-employee director may elect to receive any cash retainer or specified portion thereof in shares of our common stock. Upon election to our board of directors, a non-employee director will receive an initial grant of RSUs with an aggregate grant date fair value of $500,000, which will vest ratably in three equal installments on the first three anniversaries of the grant date. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">222</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This section sets forth the compensation of our named executive officers (&#8220;NEOs&#8221;) for the fiscal year ended December&#160;31, 2024. Our NEOs are our Chief Executive Officer and our two most highly compensated executive officers (as determined in accordance with SEC rules) for the fiscal year ended December&#160;31, 2024: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">David D. Halbert, Founder, Chairman, and Chief Executive Officer </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Brian J. Brille, Vice Chairman and Executive Vice President</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">David Spetzler, President </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As an emerging growth company, we have elected to take advantage of exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including reduced disclosure obligations regarding executive compensation in this prospectus and, while an emerging growth company, our future periodic reports and proxy statements, as well as exemptions from the requirements of holding nonbinding advisory votes on executive compensation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the total compensation paid to or earned by each of our NEOs for the fiscal year ended December&#160;31, 2024. </font>
        </div>
        <table style="width:456pt;height:119.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:142.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:2.16666666666667pt;padding-right:1pt;letter-spacing:-0.16pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Salary </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Bonus</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:142.46pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">David D. Halbert</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Chief Executive Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">750,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,250,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:142.46pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Brian J. Brille</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Vice Chairman and Executive </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Vice President</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:142.46pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">David Spetzler</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">President</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;<font style="position:absolute;"><font style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,800</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,213,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">The&#160;amounts shown in this column are the annual bonus amounts payable in respect of fiscal year 2024 to each of our NEOs. See &#8220;&#8212;Narrative to Summary Compensation Table&#8212;Annual Bonus&#8221; for a description of the terms of these bonuses. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Reflects&#160;the aggregate grant date fair value of RSUs granted under the 2020 Plan in 2024, as calculated in accordance with FASB ASC 718 (without any reduction for risk of forfeiture) as determined based on applying the assumptions used in Note&#160;7 to our consolidated financial statements for 2024 included elsewhere in this prospectus. These RSUs will fully vest only upon the occurrence of a specific performance milestone (either an initial public offering or a change in control of the Company). Assuming the maximum performance levels are achieved, the value for the RSUs granted in 2024 would be $2,123,820. This amount may not reflect the actual value realized upon vesting or settlement, if any. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-size:9pt;">
          <font style="letter-spacing:0.18pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;font-size:9pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">The&#160;amounts in this column represent matching contributions to the Company&#8217;s 401(k) plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.91pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Narrative Disclosure to Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Base Salary</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our NEOs each receive a base salary to compensate them for services rendered to our Company. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, and responsibilities. For 2024, the NEOs&#8217; annual base salaries were as follows: Mr.&#160;Halbert&#8212;$750,000, Mr. Brille&#8212;$600,000, and Dr.&#160;Spetzler&#8212;$600,000. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Annual Bonus</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We maintain an annual cash bonus program in which each of our NEOs participated for 2024. Each NEO&#8217;s target bonus is expressed as a&#160;percentage of his annual base salary. Bonuses for our NEOs are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">223</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">determined by the compensation committee based on a rigorous assessment of Company performance. The 2024 annual bonus targets are 200% of base salary for Mr. Halbert and 100% of base salary for each of Mr.&#160;Brille and Dr.&#160;Spetzler. In February 2025, the compensation committee determined to award two separate bonuses to Mr. Halbert: one bonus of $750,000, with respect to the first half of 2024, and another bonus of $750,000, with respect to the second half of 2024.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity and Long-Term Incentives</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that equity awards provide our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executive officers and our shareholders. To date, we have used stock option and RSU grants for this purpose because we believe they are effective means by which to align the long-term interests of our executive officers with those of our shareholders. The use of stock options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention tool for our executive officers, as well as for our other employees. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We award stock options broadly to our employees. Grants to our executive officers and other employees are made at the discretion of our compensation committee and are not made at any specific time period during a year. In 2024, all of our equity incentive awards grants were made under the terms of the Caris Life Sciences, Inc. 2020 Incentive Plan, as amended and restated (the &#8220;2020 Plan&#8221;). See &#8220;&#8212;Equity Incentive Plans&#8221; for additional information on our equity plans. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August 2024, the compensation committee approved a grant of 1,443,000 RSUs to Mr. Halbert, subject to shareholder approval that was obtained in March 2025. Such RSUs were granted in March 2025 following such approval and will fully vest upon the completion of this offering. In March 2025, the compensation committee approved a stock option grant to Dr.&#160;Spetzler with respect to 3.0&#160;million shares at a strike price of $4.65 in order to further align his interests with those of our shareholders.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Benefits</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain of our NEOs (and their guests) may use aircraft or private travel service arrangements or programs (such as car services) that we have access to for reasonable personal use and for which they bear the cost. In addition, Mr. Brille and Dr.&#160;Spetzler have certain severance rights. For further information, on Mr.&#160;Brille and Dr. Spetzler&#8217;s severance rights, see &#8220;Narrative Disclosure to Summary Compensation Table&#8212;</font>&#8203;<font style="letter-spacing:0.2pt;">Employment Agreements&#8221;. </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Agreement with Brian Brille</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We entered into an employment agreement with Mr. Brille, dated as of May 31, 2018 (the &#8220;Brille Agreement&#8221;) in connection with Mr. Brille&#8217;s &#8220;at-will&#8221; employment with us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Brille Agreement, Mr. Brille is entitled to an annual base salary of $500,000 and eligible to receive an annual target bonus equal to 100% of his salary. For the fiscal year ended December&#160;31, 2024, Mr. Brille&#8217;s base salary was $600,000 and his annual bonus target was equal to 100% of his salary. The Brille Agreement provides that Mr. Brille is eligible to participate in the Company&#8217;s employee benefit plans and includes certain vesting rights applicable to his equity awards. Upon the termination of Mr.&#160;Brille&#8217;s employment by the Company without cause or by Mr. Brille for good reason, Mr. Brille would be entitled to the following payments and benefits, in addition to any accrued obligations: (1) a lump sum payment equal to six months of his then-current annual base salary; (2) six months of company-paid COBRA benefits; and (3) continued eligibility for consideration for any annual bonus that would otherwise be due to him with respect to the fiscal year of termination, prorated based on the number of days during the fiscal year that he was employed and payable at the same time as the bonus would have otherwise been paid had his employment not been terminated (a &#8220;Prorata Bonus&#8221;). Upon Mr. Brille&#8217;s termination of employment due to death or disability, Mr. Brille or his estate, as applicable, will be eligible to receive a Prorata Bonus, as well as any accrued obligations, and in the case of his disability, any disability benefits he is entitled to under any applicable Company plans. The Brille Agreement also includes an indefinite confidentiality covenant, as well as non-competition, customer non-solicitation and employee non-solicitation covenants that each </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">224</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:224pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">apply for one year following Mr. Brille&#8217;s termination date and a non-interference with vendors and suppliers covenant that applies for two years following his termination date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Invention Assignment Agreement</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Mr. Brille is also party to an Inventions Assignment Agreement with us, under which he agreed to assign his right, title and interest to any inventions and related intellectual property that he may develop in the course of his employment, and is subject to confidentiality restrictions related thereto. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Agreement with Dr. David Spetzler</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We entered into an employment agreement with Dr. Spetzler, dated as of February 1, 2010, and an amendment to this employment agreement on July 27, 2015 (as amended, the &#8220;Spetzler Agreement&#8221;) in connection with Dr. Spetzler&#8217;s &#8220;at-will&#8221; employment with us. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Spetzler Agreement, Dr. Spetzler is entitled to an annual base salary of $320,000 and eligible to receive an annual target bonus equal to 50% of his salary. For the fiscal year ended December&#160;31, 2024, Dr. Spetzler&#8217;s base salary was $600,000 and his annual bonus target was equal to 100% of his salary. The Spetzler Agreement provides that Dr. Spetzler is eligible to participate in the Company&#8217;s employee benefit plans and, upon Dr. Spetzler&#8217;s termination of employment by the Company without cause or by Dr. Spetzler for good reason, Dr. Spetzler would be entitled to the following payments and benefits, in addition to any accrued obligations: (1) a lump sum payment equal to six months of his then-current annual base salary; (2) six months of company-paid COBRA benefits; and (3) continued eligibility for consideration for a Prorata Bonus. Upon Dr. Spetzler&#8217;s termination of employment due to death or disability, Dr. Spetzler or his estate, as applicable, will be eligible to receive a Prorata Bonus, as well as any accrued obligations, and in the case of his disability, any disability benefits he is entitled to under any applicable Company plans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Spetzler is also party to the Company&#8217;s Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement (the &#8220;PIIA&#8221;). Under the PIIA, Dr. Spetzler is subject to an indefinite confidentiality covenant, as well as non-competition, customer non-solicitation, employee non-solicitation, non-interference with vendors and suppliers, and non-disparagement covenants that each apply for one year following Dr. Spetzler&#8217;s termination date. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">225</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards at Fiscal Year 2024</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information regarding outstanding equity awards held by our NEOs as of December&#160;31, 2024. All awards shown in this table were granted pursuant to either the Caris Life Sciences, Inc. 2012 Incentive Plan (the &#8220;2012 Plan&#8221;) or the 2020 Plan. All references to &#8220;common stock&#8221; in the table below are references to shares that will be Class A common stock (or, in the case of David D. Halbert, Class B common stock) following the completion of this offering. </font>
        </div>
        <table style="width:456pt;height:263.39pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
          <tr style="line-height:7.8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.156pt;">Option Awards</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.156pt;">Stock Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.76pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0.6pt 0pt 0.68pt 0pt; width:54.58pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-right:1pt;letter-spacing:-0.156pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.156pt;">Grant Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Securities </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Unexercised </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Options </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Exercisable </font>
                <br >
                <font style="letter-spacing:-0.156pt;">(#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Securities </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Unexercised </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Options </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Unexercisable </font>
                <br >
                <font style="letter-spacing:-0.156pt;">(#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Price ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Expiration </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Shares or </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Units of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Stock That </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Have Not </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Vested (#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt; width:36.46pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Market </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Value of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Shares of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Units of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Stock That </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Have Not </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Vested </font>
                <br >
                <font style="letter-spacing:-0.156pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Equity </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Incentive </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Plan </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Awards: </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Unearned </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Shares, </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Units or </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Rights </font>
                <br >
                <font style="letter-spacing:-0.156pt;">That Have </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Not Vested </font>
                <br >
                <font style="letter-spacing:-0.156pt;">(#) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.6pt 0pt 0.68pt 0pt; width:35.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.156pt;">Equity </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Incentive </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Plan </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Awards: </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Market or </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Payout </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Value of </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Unearned </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Shares, </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Units or </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Rights </font>
                <br >
                <font style="letter-spacing:-0.156pt;">That Have </font>
                <br >
                <font style="letter-spacing:-0.156pt;">Not Vested </font>
                <br >
                <font style="letter-spacing:-0.156pt;">($)</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.35pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0.207pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">
              <div style="margin-left:7.8pt; text-indent:-7.8pt;">
                <font style="letter-spacing:0.156pt;">David D. </font>
                <br >
                <font style="letter-spacing:0.156pt;">Halbert </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11/15/2018</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">8,000,000</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.207pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11/14/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.35pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0.457pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">
              <div style="margin-left:7.8pt; text-indent:-7.8pt;">
                <font style="letter-spacing:0.156pt;">Brian J. </font>
                <br >
                <font style="letter-spacing:0.156pt;">Brille</font><font style=" position:relative; bottom:3.25pt;font-size:5pt;letter-spacing:0.12pt;">&#65279;(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1/15/2018</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">8,000,000</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1/14/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2/27/2020</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,200,000</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">800,000</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">2.00</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2/26/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8/11/2022</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,750,000<font style="position:absolute;"><font style=" position:relative; bottom:2.29166666666667pt;font-size:5pt;">(4)</font> </font></td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">4.05</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8/11/2032</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.35pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0.457pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">
              <div style="margin-left:7.8pt; text-indent:-7.8pt;">
                <font style="letter-spacing:0.156pt;">David </font>
                <br >
                <font style="letter-spacing:0.156pt;">Spetzler</font><font style=" position:relative; bottom:3.25pt;font-size:5pt;letter-spacing:0.12pt;">&#65279;(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">6/24/2015</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.457pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">6/23/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9/12/2016</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9/12/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4/1/2020</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,200,000</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">800,000</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">2.00</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.507pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4/1/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8/11/2022</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,200,000<font style="position:absolute;"><font style=" position:relative; bottom:2.29166666666667pt;font-size:5pt;">(5)</font> </font></td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5/17/2023</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">170,000<font style="position:absolute;"><font style=" position:relative; bottom:2.29166666666667pt;font-size:5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.78999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:54.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8/14/2024</td>
            <td style="padding:0pt;padding-left:0.774999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.24pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.46pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.497pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">437,000<font style="position:absolute;"><font style=" position:relative; bottom:2.29166666666667pt;font-size:5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.36pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Except&#160;where otherwise described in these footnotes, stock option awards vest over five&#160;years, with one-fifth of the shares subject to the stock option vesting annually on each of the first five anniversaries of the grant date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The&#160;market value of the restricted stock and RSUs as of December&#160;31, 2024 is calculated by multiplying the number of unvested shares or&#160;units outstanding under the award by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share, which our board of directors determined equaled the fair market value of a share of our common stock as of December&#160;31, 2024. Amounts disclosed in this column are not yet available, as our board of directors has not yet determined the market value of our common stock as of December 31, 2024. The reportable amounts will be included in an amendment to this prospectus once such determination has been made. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The shares of common stock subject to this option are immediately issuable pursuant to Mr.&#160;Brille&#8217;s right to early exercise this option. As of December 31, 2024, Mr. Brille had not early exercised this option. The shares underlying this option vested 20% on the date of the option grant with the remainder vesting in equal 20% installments over four&#160;years on the anniversaries of the grant date, subject to Mr.&#160;Brille&#8217;s continued services to us on each vesting date. As of December&#160;31, 2024, 1,050,000 shares of common stock underlying this option had vested, with an unvested balance of 700,000 shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents shares of restricted stock acquired pursuant to Dr. Spetzler&#8217;s early exercise of an option to purchase 3,000,000 shares of common stock. The shares vested 20% on the date of the option grant with the remainder vesting in equal 20% installments over four&#160;years on the anniversaries of the grant date, subject to Dr.&#160;Spetzler&#8217;s continued services to us on each vesting date. As of December&#160;31, 2024, 1,800,000&#160;shares of common stock underlying this option had vested, and the remaining 1,200,000 shares were unvested. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">226</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents RSUs that will vest in full in connection with this offering, subject to the RSU holders&#8217; continuous service through the completion of the initial public offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policies and Practices for Granting Option Awards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has not granted any option awards as a reporting company. The Company does not plan to time the disclosure of material non-public information for purposes of affecting the exercise price of the options or the value of executive compensation or grant options during the four business days prior to or the one business day following the filing of a periodic report on Form 10-Q or Form 10-K, or the filing or furnishing of a Form 8-K that discloses material non-public information. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Long-Term Incentive Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The purpose of our equity compensation plans is to attract, retain, and motivate our employees, officers, and directors, by providing them with the opportunity to acquire a proprietary interest in the Company and to align their interests and efforts with the long-term interests of our shareholders. In connection with this offering, we expect our board of directors to adopt, and our shareholders to approve, the 2025 Plan. Under the 2025 Plan, we will have &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock reserved for issuance (plus any shares available for future grants under our 2020 Plan and any shares underlying outstanding stock awards granted under our 2020 Plan that expire or are repurchased, forfeited, canceled, or withheld). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2012 Plan was initially adopted by our board of directors in May 2012 and, in August 2020, was amended and restated to become the 2020 Plan. The 2020 Plan was further amended and restated in connection with this offering in order to reflect the authorization of shares of Class A common stock and Class B common stock under the 2020 Plan. Following completion of this offering, and subject to approval of the 2025 Plan by our shareholders, we will not make any additional grants under the 2020 Plan. Grants, including to our NEOs, have been and may continue to be made under the 2020 Plan prior to this offering. The material terms of the 2012 Plan and the 2020 Plan are substantially similar to the 2025 Plan, as described below. For additional information on the equity awards held by our NEOs and outstanding as of December&#160;31, 2024 under the 2012 Plan and the 2020 Plan, see &#8220;&#8212;Outstanding Equity Awards at Fiscal Year End&#160;2024.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2025 Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Types of Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our 2025 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, RSU awards, performance-based awards, and other awards. ISOs may be granted only to our employees, including our officers, and the employees of our affiliates. All other awards may be granted to our employees, including our officers, our non-employee directors and consultants, and the employees and consultants of our affiliates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Authorized Shares</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The maximum number of shares of Class A common stock that may be issued under our 2025 Plan is equal to (a) 5% of all classes of our common stock on a fully diluted basis after giving effect to this offering (including, but not limited to, all shares in respect of the Warrant Exercise, the Preferred Stock Conversion, and the Notes Conversion, shares subject to outstanding awards under the 2020 Plan, and the issuance of the Class&#160;A common stock to be sold in this offering), plus (b) the number of shares that would have returned to the share reserve of the 2020 Plan following the effectiveness of the registration statement of which this prospectus forms a part, all of which may be issued as ISOs. The 2025 Plan&#8217;s share reserve will increase on January 1 of each calendar year during the term of the 2025 Plan, beginning in 2026, by a number of shares as determined by the administrator of the 2025 Plan and in consultation with the Company, provided, that such increase (if any) will be no greater than the amount by which (y) 4% of the aggregate number of outstanding shares of all classes of our common stock as of the last day of the immediately preceding fiscal year exceeds (z) the aggregate number of shares remaining available for grant under the 2025 Plan on the last day of the immediately preceding fiscal year. Shares issued under our 2025 Plan will be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">227</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">authorized but unissued or reacquired shares of Class A common stock. Shares issued pursuant to awards under our 2025 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become available for future grant under our 2025 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors, or a duly authorized committee of our board of directors, may administer our 2025 Plan. Our board of directors has delegated concurrent authority to administer our 2025 Plan to the compensation committee under the terms of the compensation committee&#8217;s charter. We sometimes refer to the board of directors, or the applicable committee with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more of our officers the authority to (1)&#160;designate employees (other than officers) to receive specified awards and (2)&#160;determine the number of shares subject to such awards. The administrator has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of awards, if any, the number of shares subject to each award, the fair market value of a share of Class A common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2025 Plan. In addition, subject to the terms of the 2025 Plan, the administrator also has the power to modify outstanding awards under our 2025 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel and re-grant any outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any materially adversely affected participant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stock Options</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ISOs and NSOs are granted pursuant to stock option agreements adopted by the administrator. The administrator determines the exercise price for a stock option, within the terms and conditions of the 2025 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Class A common stock on the date of grant. Options granted under the 2025 Plan vest at the rate specified in the stock option agreement as specified in the stock option agreement by the administrator. The administrator determines the term of stock options granted under the 2025 Plan, up to a maximum of 10&#160;years. Acceptable consideration for the purchase of Class A common stock issued upon the exercise of a stock option will be determined by the administrator and may include (1)&#160;cash, check, bank draft, or money order, (2)&#160;a broker-assisted cashless exercise, (3)&#160;the tender of shares of Class A common stock previously owned by the optionholder, (4)&#160;a net exercise of the option, and (5)&#160;other legal consideration approved by the administrator. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the optionholder may generally exercise any vested options until the earlier of (i)&#160;the date 90&#160;days following the termination of the optionholder&#8217;s service and (ii)&#160;the expiration of the term of the option. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options until the earlier of (x)&#160;12&#160;months following the termination and (y)&#160;the expiration of the term of the options. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Tax Limitations on ISOs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The aggregate fair market value, determined at the time of grant, of Class A common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will be treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">228</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">subsidiary corporations, unless (1)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&#160;the term of the ISO does not exceed five&#160;years from the date of grant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Restricted Shares</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Restricted shares may be granted to any eligible individual and made subject to such restrictions as may be determined by the administrator. Restricted shares may generally not be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Except as otherwise provided in the applicable award agreement, restricted shares that remain subject to vesting conditions that have not been satisfied will not vest. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Restricted Stock Units</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">RSUs may be awarded to any eligible individual, typically without payment of consideration, but subject to vesting conditions based on continued employment or service or on performance criteria established by the administrator. RSUs may not typically be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Stock underlying RSUs will not be issued until the RSUs have vested, and recipients of RSUs generally will have no voting or dividend rights prior to the time when vesting conditions are satisfied. Except as otherwise provided in the applicable award agreement, RSUs that remain subject to vesting conditions that have not been satisfied will not vest and will be canceled without payment to the participant therefor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Stock Appreciation Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stock appreciation rights are granted pursuant to stock appreciation right grant agreements adopted by the administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of Class A common stock on the date of grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (1)&#160;the excess of the per share fair market value of Class A common stock on the date of exercise over the strike price, multiplied by (2)&#160;the number of shares of Class A common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2025 Plan vests at the rate specified in the stock appreciation right agreement as determined by the administrator. The administrator determines the term of stock appreciation rights granted under the 2025 Plan, up to a maximum of 10&#160;years. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless the terms of a participant&#8217;s stock appreciation right agreement provide otherwise, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability or death, the participant may generally exercise any vested stock appreciation right until the earlier of (i)&#160;the date 90&#160;days following the termination of service and (ii)&#160;the expiration of the term of the stock appreciation right. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right until the earlier of (x)&#160;12&#160;months following the termination and (y)&#160;the expiration of the term of the stock appreciation right. In no event may a stock appreciation right be exercised beyond the expiration of its term. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Performance Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our 2025 Plan permits the grant of performance-based stock and cash awards. The compensation committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of certain pre-established performance goals during a designated performance period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Changes to Capital Structure</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1)&#160;the class and maximum number of shares reserved for issuance under the 2025 Plan, (2)&#160;the class and maximum number of shares by which the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">229</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">share reserve may increase automatically each year, (3)&#160;the class and maximum number of shares that may be issued upon the exercise of ISOs, and (4)&#160;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Corporate Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the 2025 Plan, a corporate transaction is generally the consummation of (1)&#160;a sale or other disposition of all or substantially all of our assets, (2)&#160;a sale or other disposition of at least 50% of our outstanding securities, (3)&#160;a merger, consolidation, or similar transaction following which we are not the surviving corporation, or (4)&#160;a merger, consolidation, or similar transaction following which we are the surviving corporation but the shares of common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. In the event of a corporate transaction, unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or otherwise expressly provided by the administrator at the time of grant, any stock awards outstanding under the 2025 Plan may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company), accelerated in full or in part or canceled for or without consideration, as determined by the administrator. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Transferability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A participant may not transfer awards under our 2025 Plan other than by will, the laws of descent and distribution, or as otherwise provided under our 2025 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Amendment or Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has the authority to amend, suspend, or terminate our 2025 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our shareholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2025 Plan. No awards may be granted under our 2025 Plan while it is suspended or after it is terminated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2025 Employee Stock Purchase Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we expect our board of directors to adopt, and our shareholders to approve, the ESPP, that will be effective following the offering. The ESPP is designed to allow our eligible employees to purchase shares of our common stock, at periodic intervals, with their accumulated payroll deductions. The ESPP is intended to qualify under Section&#160;423 of the Code. The material terms of the ESPP, as it is currently contemplated, are summarized below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms and conditions of the ESPP, our board of directors, or a duly authorized committee of our board of directors, may administer the ESPP. The administrator will have the authority to administer and interpret the ESPP. All decisions made by the administrator pursuant to the ESPP will be final, binding, and conclusive on us and all participants. We will bear all expenses of administering the ESPP. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Share Reserve</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The maximum number of our shares of our Class&#160;A common stock which will be authorized for sale under the ESPP is equal to 0.85% of the fully diluted shares of all classes of our common stock after giving effect to the offering (including, but not limited to, all shares in respect of the Warrant Exercise, the Preferred Stock Conversion, and the Notes Conversion, shares subject to outstanding awards under the 2020 Plan, and the issuance of the Class A common stock to be sold in this offering). The ESPP&#8217;s share reserve will automatically increase on January&#160;1 of each calendar year during the term of the ESPP, beginning in 2026, by a number of shares equal to 1% of all classes of our common stock outstanding on the last day of the immediately preceding fiscal year, unless the administrator should decide to increase the number of shares </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">230</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">available under the ESPP by a lesser amount. The shares reserved for issuance under the ESPP may be authorized but unissued shares or reacquired shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eligibility</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Employees eligible to participate in the ESPP for a given offering period generally include employees who are employed by us or one of our subsidiaries on the enrollment date of an offering period. Our employees (and, if applicable, any employees of our subsidiaries) who customarily work less than five&#160;months in a calendar year or are customarily scheduled to work less than 20 hours per week will not be eligible to participate in the ESPP. Finally, an employee who owns (directly or through attribution) 5% or more of the combined voting power or value of all our classes of stock or of one of our subsidiaries will not be allowed to participate in the ESPP. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Participation</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Employees will enroll under the ESPP by completing a subscription agreement designating the&#160;percentage of their compensation to be withheld as payroll deductions during the offering period (of at least 1% of their compensation but not more than 15% of their base compensation). Such payroll deductions may be expressed as either a whole number&#160;percentage or a fixed dollar amount, and the accumulated deductions will be applied to the purchase of shares on each purchase date. However, a participant may not accrue the right to purchase shares of common stock at a rate that exceeds $25,000 in fair market value of shares of our common stock (determined at the time the option is granted) for each calendar year the option is outstanding (as determined in accordance with Section&#160;423 of the Code). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Offering</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the ESPP, participants are offered the option to purchase shares of our common stock at a discount during a series of successive offering periods, the duration and timing of which will be determined by the ESPP administrator. However, in no event may an offering period be longer than 27&#160;months in length. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The option purchase price designated by the ESPP administrator will be no less than the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each purchase period within an offering period. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A participant may withdraw all (but not less than all) of the payroll deductions credited to the participant&#8217;s account and not yet used to exercise the participant&#8217;s rights under the ESPP at any time by giving us written notice no later than 30&#160;days prior to the end of the offering period. All of the participant&#8217;s payroll deductions credited to the participant&#8217;s account during an offering period will be paid to the participant as soon as reasonably practicable after receipt of notice of withdrawal. As a result, the participant&#8217;s rights for the offering period will be automatically terminated, and no further payroll deductions for the purchase of shares will be made for such offering period. If a participant withdraws from an offering period, payroll deductions will not resume at the beginning of the next offering period unless the participant timely delivers to us a new subscription agreement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A right granted under the ESPP to a participant will not be transferable other than by will or the applicable laws of descent and distribution and is exercisable during the participant&#8217;s lifetime only by the participant. Except in the case of a participant&#8217;s death, a right under the ESPP may not be exercised to any extent except by the participant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Adjustments upon Changes in Common Stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon any reclassification, recapitalization, share split, or reverse share split; any merger, combination, consolidation, or other reorganization; any split-up, spin-off, or similar extraordinary dividend distribution in respect of the common stock; or any exchange of our common stock or other securities, or any similar, unusual or extraordinary corporate transaction in respect of the common stock; then, subject to any required action by the shareholders under applicable law, the ESPP administrator will </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">231</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">equitably and proportionately adjust (i)&#160;the ESPP share reserve, (ii)&#160;the classes and number of shares and price per share subject to outstanding rights; and (iii)&#160;the purchase price with respect to any outstanding rights. In the event of any of the above described transactions or any unusual or nonrecurring transactions or events affecting us or our subsidiaries or our financial statements, the ESPP administrator, in its discretion, will be authorized to provide either: (i)&#160;the termination of any outstanding right in exchange for an amount of cash equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or the replacement of such outstanding right with other rights or property selected by the ESPP administrator in its sole discretion; (ii)&#160;to provide that outstanding rights under the ESPP will be assumed by the successor or survivor corporation or a parent or subsidiary thereof, with appropriate adjustments to the number and kind of stock and prices; (iii)&#160;to make adjustments in the number and type of shares (or other securities or property) subject to outstanding rights under the ESPP; (iv)&#160;to provide that participants&#8217; accumulated payroll deductions may be used to purchase shares prior to the next occurring purchase date, following which the participants&#8217; rights under the ongoing offering period will be terminated; or (v)&#160;to provide that all outstanding rights will terminate without being exercised. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Amendment and Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ESPP administrator may amend, suspend, or terminate the ESPP at any time. However, no amendment will be effective unless approved by the shareholders to the extent required by applicable laws. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Narrative Disclosure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Retirement and Employee Benefits Plans</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of our current NEOs are eligible to participate in our employee benefit plans, including our medical, dental, vision, life, and disability insurance plans, and may obtain our solutions, in each case on the same basis as all of our other employees. We maintain a 401(k) plan for employees. The 401(k) plan is intended to qualify under Section&#160;401(k) of the Code so that contributions to the 401(k) plan by employees or by us, and the investment earnings thereon, are not taxable to the employees until withdrawn from the 401(k) plan, and so that contributions by us, if any, will be deductible by us when made. Under the 401(k) plan, we make a matching contribution of 100% of the first 3% of salary contributed and 50% on the next 2% of salary. The maximum match is 4% up to the IRS limit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Change-in-Control Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain of our senior executives (including Mr. Brille and Dr.&#160;Spetzler but excluding Mr.&#160;Halbert) and non-employee directors participate in the Caris Life Sciences, Inc. Executive and Director Change in Control Plan (the &#8220;Change in Control Plan&#8221;), which is administered by our compensation committee. Under the Change in Control Plan, upon a &#8220;Change in Control&#8221; &#8203;(as defined in the 2020 Plan) and subject to the execution of a general release of claims in our favor, all outstanding and unvested equity awards granted to a participant will automatically vest in full immediately prior to the consummation of the Change in Control. The Change in Control Plan does not contain excise tax gross-up provisions and, instead, employs a &#8220;best-net&#8221; approach under which payments and benefits are either reduced to avoid the excise tax on excess parachute payments within the meaning of Section&#160;280G of the Code or not reduced, depending on which approach would result in the greatest after-tax amount being retained. At any time prior to a Change in Control, the Change in Control Plan may be modified, amended, or terminated by the compensation committee without notice to participants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Clawback Policy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we will adopt a compensation recovery policy that is compliant with the listing rules of Nasdaq, as required by the Dodd-Frank Act, to be effective upon the completion of this offering.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">232</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a description of transactions since January&#160;1, 2022 and each currently proposed transaction in which we have been or are to be a participant and: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the amounts involved exceeded or will exceed $120,000; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any of our directors, executive officers, or holders of more than 5% of our outstanding capital stock, or any immediate family member of or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transactions with Our Founder</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Guarantee of Office Lease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We lease approximately 30,500 square feet of office space in Irving, Texas for our principal executive offices pursuant to a lease expiring in April&#160;2028. Our complete and timely performance of each obligation under the lease agreement is unconditionally and irrevocably guaranteed by David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, and his spouse, in their personal capacities. During each of the&#160;years ended December&#160;31, 2024, 2023, and 2022, we recorded rental expense of $0.9&#160;million in connection with this guaranteed lease. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Aircraft Charter Arrangements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2017, we entered into an intercompany consulting agreement (the &#8220;Caris Air Consulting Agreement&#8221;) with Halbert &amp; Associates and Caris Air Services, LLC (&#8220;Caris Air&#8221;), each of which is affiliated with Mr.&#160;Halbert. Pursuant to the Caris Air Consulting Agreement, we have the right to use, from time to time, an aircraft owned by Halbert &amp; Associates and operated by Caris Air. The Caris Air Consulting Agreement has an initial term of one year and automatically renews for subsequent one-year terms on an annual basis. We only use the aircraft for business purposes and reimburse Caris Air for our usage of the aircraft based on hours of use, operating costs, and related expenses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2021, we also entered into an aircraft charter lease and services agreement (the &#8220;Aircraft Agreement&#8221;) with Caris Air, pursuant to which Caris Air dry leases from us an aircraft we own and provides chartered aircraft services, as operator of the aircraft. The Aircraft Agreement has an initial term of one year and automatically renews for subsequent one-year terms on an annual basis. Under the Aircraft Agreement, we are entitled to receive payment from Caris Air for rental of our aircraft, and we reimburse Caris Air for the chartered aircraft services it provides to us. Mr.&#160;Halbert and his family members also use our aircraft from time to time for personal use and reimburse us based on hours of use, operating costs, and related expenses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the foregoing aircraft charter arrangements, we generally credit amounts owed to us by Caris Air and Mr.&#160;Halbert and his family members for rental and use of our aircraft against any amounts owed by us to Caris Air for the chartered aircraft services it provides under either the Caris Air Consulting Agreement or the Aircraft Agreement. During the&#160;years ended December&#160;31, 2024, 2023, and 2022, we paid Caris Air aggregate net amounts of $1.6&#160;million, $1.8&#160;million, and $1.6&#160;million, respectively, pursuant to these arrangements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Loan Agreement with Sixth Street</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2023, pursuant to a convertible loan agreement, dated as of September&#160;21, 2018, between us, as borrower, certain of our subsidiaries, as guarantors, and entities affiliated with Sixth Street, as lenders (as amended, the &#8220;Convertible Loan Agreement&#8221;), we issued an aggregate of 31,055,901 shares of our Series&#160;C preferred stock to the Sixth Street-affiliated lenders, TOP III Barnett Investments, LLC, TAO Barnett Investments, LLC, and Sixth Street Specialty Lending, Inc., at a conversion price of $1.61 per share, in connection with the conversion of the original aggregate principal amount of $50.0&#160;million outstanding under the Convertible Loan Agreement. Entities affiliated with Sixth Street collectively hold more than 5% of our outstanding capital stock, and Vijay Mohan, a member of our board of directors, is a Co-Founding Partner of Sixth Street. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">233</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The loans under the Convertible Loan Agreement had an interest rate of 8.0% per annum, payable in kind (&#8220;PIK&#8221;) and accretive as additional principal. Upon the issuance of shares of our Series&#160;C preferred stock and following our September&#160;2023 cash payment of $3.0&#160;million in respect of accrued and unpaid PIK interest under the Convertible Loan Agreement, all of our obligations under the Convertible Loan Agreement were deemed satisfied in full, and the Convertible Loan Agreement was irrevocably terminated. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Term Loan Refinancing with Sixth Street</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September 2018, we entered into a secured term loan agreement (the &#8220;Original Term Loan Agreement&#8221;) with Sixth Street Specialty Lending, Inc. and Barnett Debt Holdings, LLC, which provided us with an initial term loan of $50.0 million (the &#8220;2018 Term Loan&#8221;) and a delayed term loan draw option of $50.0 million, which we drew down in full on October 4, 2019 (the &#8220;2019 Term Loan&#8221;). In April 2020, we amended the Original Term Loan Agreement (the &#8220;Amended Term Loan Agreement&#8221;) to obtain additional term loan proceeds of $75.0 million (the &#8220;2020 Term Loan&#8221; and collectively with the 2018 Term Loan and the 2019 Term Loan, the &#8220;Original Term Loans&#8221;).</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January 2023, we entered into the 2023 Term Loan Agreement. The net cash proceeds from the 2023 Term Loan were used to repay in full the Original Term Loans (with an aggregate principal amount of $175.0 million), including a prepayment premium of $5.0 million and accrued and unpaid interest of $1.0&#160;million. As of December 31, 2023, we have no continuing obligations associated with the Original Term Loans. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officer Promissory Notes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;30, 2022, David Spetzler, our President, and J. Russel Denton, our Senior Vice President, General Counsel, and Secretary, exercised their options to purchase 3,000,000 shares and 1,020,000 shares, respectively, of our common stock at an exercise price of $4.05 per share through the tender of promissory notes, each with an interest rate of 2.93% per annum. As of December&#160;31, 2024, no principal or interest payments had been made with respect to these promissory notes. In March 2025, the full outstanding principal amount of, and accrued and unpaid interest on, each of the promissory notes was repaid by each of the executive officers in the form of stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investors&#8217; Rights Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are party to an amended and restated investors&#8217; rights agreement (the &#8220;Investors&#8217; Rights Agreement&#8221;), dated as of April 1, 2025, with certain holders of our capital stock, including David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, entities affiliated with Mr.&#160;Halbert, and entities affiliated with Sixth Street, J.H. Whitney VI, L.P., and Highland Capital Management, L.P., each of which are holders of more than 5% of our outstanding capital stock and/or entities with which certain of our directors are affiliated. Under the Investors&#8217; Rights Agreement, certain holders of our capital stock have registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. The Investors&#8217; Rights Agreement also provides certain of these shareholders with information and observer rights, which will terminate immediately prior to the completion of this offering, and a right of first offer with regard to certain issuances of our capital stock, which right will terminate immediately following the completion of this offering. For a description of the registration rights that will continue to apply following this offering, see the section titled &#8220;Description of Capital Stock&#8212;Registration Rights.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are party to an amended and restated voting agreement (the &#8220;Voting Agreement&#8221;), dated as of April 1, 2025, under which certain holders of our capital stock, including David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, entities affiliated with Mr.&#160;Halbert, and entities affiliated with Sixth Street, J.H. Whitney VI, L.P., and Highland Capital Management, L.P., each of which are holders of more than 5% of our outstanding capital stock and/or entities with which certain of our&#160;directors are affiliated, have agreed as to the manner in which they will vote their shares of our capital stock on certain matters, including with respect to the election of directors. The Voting Agreement will terminate in its entirety upon the completion of this offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">234</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Right of First Refusal and Co</font><font style="font-weight:normal;letter-spacing:0.2pt;">-</font><font style="letter-spacing:-0.2pt;">Sale Agreement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are party to an amended and restated right of first refusal and co-sale agreement (the &#8220;ROFR and Co-Sale Agreement&#8221;), dated as of April 1, 2025, with certain holders of our capital stock, including David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, entities affiliated with Mr.&#160;Halbert, and entities affiliated with Sixth Street, J.H. Whitney VI, L.P., and Highland Capital Management, L.P., each of which are holders of more than 5% of our outstanding capital stock and/or entities with which certain of our directors are affiliated. Under the ROFR and Co-Sale Agreement, we and certain holders of our capital stock have a right to purchase shares of our capital stock that shareholders propose to sell in certain circumstances to other parties. The ROFR and Co-Sale Agreement will terminate in its entirety immediately prior to the completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consulting and Expert Advisory Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into consulting and expert advisory agreements with George H. Poste and Jonathan Knowles, members of our board of directors, pursuant to which Dr.&#160;Poste and Dr.&#160;Knowles provide certain consulting services to us as independent contractors and serve on our Scientific Advisory Board, a team comprised of leading scientists and clinical experts who advise us on research, development, and strategy matters pertaining to precision medicine. We also entered into a consulting agreement with Jeffrey Vacirca in February 2022 pursuant to which he provided consulting services to us, which agreement was terminated upon Dr. Vacirca&#8217;s election to our board of directors in November 2024. During the years ended December&#160;31, 2024, 2023, and 2022, we paid Dr. Poste $107,500, $137,917, and $147,083, respectively, for consulting services provided to us and for his service on our Scientific Advisory Board. During each of the years ended December 31, 2024, 2023, and 2022, we paid Dr. Knowles amounts not exceeding $120,000 for consulting services provided to us and for his service on our Scientific Advisory Board. In February 2022, we granted Dr.&#160;Vacirca an option to purchase 100,000 shares of common stock at an exercise price of $4.29 per share pursuant to his consulting agreement, and we have not paid any additional amounts under such consulting agreement. For additional information, see the section titled &#8220;Management&#8212;Director Compensation.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Agreements and Family Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are party to employment agreements with certain of our executive officers. For additional information regarding agreements with our named executive officers, see the section titled &#8220;Executive Compensation.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, Michael Halbert, our Senior Vice President, Human Resources, is the son of David D. Halbert, our Founder, Chairman, and Chief Executive Officer, and has been employed by us in various capacities since June&#160;2011. Michael Halbert does not reside with David D. Halbert and is not one of our executive officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Awards to Directors and Executive Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have granted stock options and other equity awards to our directors and executive officers as more fully described in the sections titled &#8220;Management&#8212;Director Compensation&#8221; and &#8220;Executive Compensation.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director and Officer Indemnification Agreements and Insurance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation and amended and restated bylaws will provide indemnification and advancement of expenses for our directors and executive officers to the fullest extent permitted by the Texas law, subject to limited exceptions. We also have entered into separate indemnification agreements with each of our directors and executive officers, which require us to indemnify them in certain circumstances, and have purchased directors&#8217; and officers&#8217; liability insurance for each of our directors and executive officers. For further information, see the section titled &#8220;Description of Capital Stock&#8212;Limitations on Liability and Indemnification of Officers and Directors.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">235</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:348pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reserved Share Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At our request, the underwriters have reserved up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management, including certain of our directors, officers, employees, and certain other parties related to us. See the section titled &#8220;Underwriting&#8212;Reserved Share Program.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policies and Procedures for Related Person Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests or the perception thereof. Prior to the completion of this offering, our board of directors will adopt a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item&#160;404 of Regulation&#160;S-K under the Securities Act, any transaction, arrangement, or relationship, or any series of similar transactions, arrangements, or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year, and a related person had, has, or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness, and employment by us of a related person. In reviewing and approving any such transactions, our audit committee will be tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">236</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:113.33pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRINCIPAL SHAREHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table contains information about the beneficial ownership of our common stock as of March&#160;31, 2025 (i)&#160;immediately prior to the completion of this offering and (ii)&#160;as adjusted to reflect the sale of shares of our Class A common stock offered by this prospectus by: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each individual or entity known by us to beneficially own more than 5% of our outstanding shares of Class A common stock or Class B common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each of our named executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">each of our directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">all of our directors and executive officers as a group. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our calculation of the&#160;percentage of beneficial ownership prior to and after this offering is based on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class B common stock outstanding as of March&#160;31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F&#160;Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the Notes Conversion, (v) the Common Stock Reclassification, and (vi)&#160;the RSU Net Settlement. The exact number of shares of our common stock that will be withheld from a shareholder in connection with the RSU Net Settlement may differ based on the shareholder&#8217;s personal tax rates. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Beneficial ownership and&#160;percentage ownership are determined in accordance with the rules and regulations of the SEC. Under SEC rules, a person is deemed to be a &#8220;beneficial owner&#8221; of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to&#160;direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60&#160;days. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person&#8217;s ownership&#160;percentage, but not for purposes of computing any other person&#8217;s&#160;percentage. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. Except as indicated in the footnotes to the following table or pursuant to applicable community property laws, we believe, based on information furnished to us, that each shareholder named in the table has sole voting and investment power with respect to the shares set forth opposite such shareholder&#8217;s name. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The table below does not reflect any shares of our Class A common stock that our directors and executive officers may purchase in this offering, including through the reserved share program described under &#8220;Underwriting&#8201;&#8212;&#8201;Reserved Share Program.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">For further information regarding material transactions between us and certain of our shareholders, see the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in the footnotes, the address of each of the individuals named below is: c/o&#160;750 W. John Carpenter Freeway, Suite 800, Irving, Texas 75039. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">237</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:419.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:138.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Before this Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="3">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:6.8pt 0pt 2.167pt 0pt; width:44.3pt;vertical-align:top;" rowspan="3">
              <div style="text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">% of Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Voting Power</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Before this</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering</font><font style=" position:relative; bottom:3.25pt;line-height:6pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Shares Beneficially Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After this Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="3">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35.76pt;" rowspan="3">
              <div style="text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">% of Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Voting</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Power</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After this</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering</font><font style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="3">&#8203;</td>
          </tr>
          <tr style="height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:138.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.05pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Class&#160;A </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.05pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Class&#160;B </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.05pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Class&#160;A </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.05pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Class&#160;B </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:22.32pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:7pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:22.32pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:7pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:22.32pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:7pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:22.32pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.05pt 0pt 2.5pt 0pt; width:7pt;">
              <div style="white-space:nowrap; text-align:center; line-height:9pt;font-size:8pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.75pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="font-size:10pt;">
                <font style="letter-spacing:-0.2pt;">5% Shareholders:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 0.833pt 0pt; width:138.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with David D. Halbert</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(2)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 0.833pt 0pt; width:138.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Sixth Street</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">&#65279;(3)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">J.H. Whitney VI L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(4)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 0.833pt 0pt; width:138.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-size:10pt;">
                <font style="letter-spacing:-0.2pt;">Named Executive Officers and Directors:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">David D. Halbert</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">David Spetzler</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(5)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Brian J. Brille</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(6)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">George H. Poste</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(7)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Jonathan Knowles</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(8)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Nathan Burns </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">David Fredrickson</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(9)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Peter M. Castleman</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(10)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Joseph E. Gilliam</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(11)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Jon S. Halbert</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(12)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Laura I. Johansen</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(13)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Lloyd B. Minor </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">Vijay Mohan </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt;font-size:7.5pt;">
                <font style="font-size:10pt;letter-spacing:0.2pt;">Danny Phillips</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">14)</font><font style="font-size:10pt;">&#8203;</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt;font-size:7.5pt;">
                <font style="font-size:10pt;letter-spacing:0.2pt;">Jeffrey Vacirca</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">15)</font><font style="font-size:10pt;">&#8203;</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:0pt;">
            <td style="padding:0.5pt 0pt 1.5pt 0pt; width:138.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-size:10pt;">
                <font style="letter-spacing:0.2pt;">All executive officers and directors as a group </font>
                <br >
                <font style="letter-spacing:0.2pt;">( &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;individuals)</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">16&#65279;)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:44.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:22.32pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:7pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35.76pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.61pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:6.61pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Represents beneficial ownership of less than 1%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:2.61pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:2.61pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Percentage of total voting power represents voting power with respect to all shares of our Class&#160;A common stock and Class&#160;B common stock, as a single class. The holders of our Class&#160;B common stock are entitled to 10&#160;votes per share, and holders of our Class&#160;A common stock are entitled to one vote per share. See the section titled &#8220;Description of Capital Stock&#8212;Common Stock&#8221; for additional information about the voting rights of our Class&#160;A common stock and Class&#160;B common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:2.61pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:2.61pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by David D. Halbert, of which &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;B common stock are pledged as collateral to secure certain personal indebtedness of Mr.&#160;Halbert, (ii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock underlying options to purchase Class&#160;B common stock held by Mr.&#160;Halbert that are currently exercisable or would be exercisable within 60&#160;days of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025, (iii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Caris Halbert, L.P., (iv)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by ADAPT I Ltd., (v)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; shares of Class&#160;B common stock held by Carisome I, L.P., (vi)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; shares of Class&#160;B common stock held by Caris Investment II Ltd., and (vii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; shares of Class&#160;B common stock held by Caris Investment III Ltd. (collectively with Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., and Caris Investment III Ltd., the &#8220;DDH Entities&#8221;). Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert, our Founder, Chairman, and Chief Executive Officer, is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held by each of the DDH Entities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">238</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:11pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(3)</font>
          <br >
        </div>
        <div style=" line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Barnett Equity Holdings, LLC (&#8220;Barnett Equity Holdings&#8221;), (ii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Barnett Equity Holdings II, LLC (&#8220;Barnett Equity Holdings II&#8221;), (iii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by TOP III Barnett Investments, LLC (&#8220;TOP III Barnett&#8221;), (iv)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by TAO Barnett Investments, LLC (&#8220;TAO Barnett&#8221; and, together with Barnett Equity Holdings, Barnett Equity Holdings II, and TOP III Barnett, the &#8220;Barnett Holders&#8221;), and (v)&#160;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;B common stock held by Sixth Street Specialty Lending, Inc. (&#8220;SLX&#8221;). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:36pt; margin-top:2.2pt; width:420pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">TSSP Sub-Fund&#160;Holdco, LLC, a Delaware limited liability company (&#8220;Sub-Fund&#160;HoldCo&#8221;), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (&#8220;TAO SPV&#8221;), and Empire SPV GP, LLC, a Delaware limited liability company (&#8220;Empire SPV&#8221;). TAO SPV is the managing member of each of (i) Barnett Equity Holdings; (ii)&#160;Barnett Equity Holdings II; and (iii)&#160;TAO Barnett. Empire SPV is the managing member of TOP III Barnett. </font>
        </div>
        <div style="margin-left:36pt; margin-top:2.19pt; width:420pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">TSSP Holdco Management, LLC, a Delaware limited liability company (&#8220;Holdco Management&#8221;), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (&#8220;Adviser Holdings&#8221;). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (&#8220;Adviser&#8221;), are managed by Adviser Holdings, the sole member of Adviser. SLX is managed by Adviser. </font>
        </div>
        <div style="margin-left:36pt; margin-top:2.2pt; width:420pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">Sub-Fund&#160;HoldCo is managed by its sole member, whose managing member is Alan Waxman (&#8220;Mr.&#160;Waxman&#8221;). Holdco Management is managed by a board of directors, which is currently comprised of Mr.&#160;Waxman. Mr.&#160;Waxman is the CEO and Managing Partner of Holdco Management. </font>
        </div>
        <div style="margin-left:36pt; margin-top:2.19pt; width:420pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">Because (i)&#160;of Sub-Fund&#160;HoldCo&#8217;s relationship with the Barnett Holders, Sub-Fund&#160;HoldCo may be deemed to beneficially own the shares of Class&#160;B common stock owned by the Barnett Holders; (ii)&#160;of the relationship between Mr.&#160;Waxman and the Barnett Holders, Mr.&#160;Waxman may be deemed to beneficially own the shares of Class&#160;B common stock owned by the Barnett Holders; and (iii)&#160;Mr.&#160;Waxman is a member of the board of directors of Holdco Management, he may be deemed to beneficially own the shares of Class&#160;B common stock owned by SLX. Each of Sub-Fund&#160;HoldCo and Mr.&#160;Waxman disclaims beneficial ownership of the shares of Class&#160;B common stock except to the extent of their pecuniary interest therein. </font>
        </div>
        <div style="margin-left:36pt; margin-top:2.2pt; width:420pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;">The address for each of the foregoing entities is 2100 McKinney Avenue, Suite 1500, Dallas, Texas 72501. The principal business address for Mr.&#160;Waxman is c/o&#160;Sixth Street Partners, LLC, 1 Letterman Drive, Building&#160;B, Suite B6-100, San Francisco, California 94129. </font>
        </div>
        <div style=" float:left; line-height:11pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by J.H. Whitney VI L.P. J.H. Whitney Equity Partners VI, L.P. is the sole general partner of J.H. Whitney VI L.P. Paul R. Vigano and Robert M. Williams, Jr., as the managing members of J.H. Whitney Equity Partners VI, L.P., share voting and investment power with respect to the shares held by J.H. Whitney VI L.P. The address for each of the foregoing entities is 212 Elm Street, Suite 1, New Canaan, Connecticut 06840. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#160;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock held by David Spetzler, (ii)&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by Dr.&#160;Spetzler that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025, and (iii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Dr.&#160;Spetzler, of which&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock are pledged as collateral to secure certain personal indebtedness of Dr.&#160;Spetzler. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by Brian J. Brille that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025, and (ii)&#160;an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by five family trusts, each of which Mr.&#160;Brille serves as trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock held by George H. Poste, (ii)&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock underlying options to purchase Class&#160;A common stock held by Dr.&#160;Poste that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025, (iii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class B common stock held by Dr. Poste, and (iv)&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199; shares of Class&#160;B common stock held by a family trust, of which Dr.&#160;Poste serves as trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#160;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by Jonathan Knowles that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025 and (ii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Dr.&#160;Knowles. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by David Fredrickson that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by a family trust of which Peter M. Castleman serves as a trustee, (ii)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock underlying options to purchase Class A </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">239</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:351pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:36pt; width:420pt; line-height:11pt;">
          <font style="letter-spacing:0.18pt;">common stock held by Mr. Castleman that are currently exercisable or would be exercisable within 60 days of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025, and (iii) &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;B common stock held by CLS-PF-SPE, LLC (&#8220;CLS-PF-SPE&#8221;). CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE. Mr.&#160;Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE.</font>
        </div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by Joseph E. Gilliam that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Jon S. Halbert, and (ii)&#160;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;B common stock held by Ke&#8217;Ohana Ventures, LLC, of which Mr.&#160;Halbert serves as the manager. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;B common stock held by Laura I. Johansen. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by Danny Phillips that are currently exercisable or would be exercisable within 60&#160;days </font>
          <br >
          <font style="letter-spacing:0.18pt;">of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(15)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock underlying options to purchase Class&#160;A common stock held by Jeffrey Vacirca that are currently exercisable or would be exercisable within 60&#160;days of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.18pt;">(16)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.18pt;">Consists of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock held by our executive officers and directors, (ii)&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock underlying options to purchase Class&#160;A common stock held by our executive officers and directors that are currently exercisable or would be exercisable within 60&#160;days of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025, (iii)&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class B common stock, held by our executive officers and directors, and (iv)&#160;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class B common stock underlying options to purchase Class B common stock held by David D. Halbert that are currently exercisable or would be exercisable within 60 days of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">240</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following summary describes the material provisions of our capital stock and certain provisions of our amended and restated certificate of formation and our amended and restated bylaws, each of which will become effective immediately prior to the completion of this offering, and the Texas Business Organizations Code (the &#8220;TBOC&#8221;), and is qualified by reference to the amended and restated certificate of formation, the amended and restated bylaws, and the TBOC. We urge you to read our amended and restated certificate of formation and our amended and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, our authorized capital stock will consist of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class A common stock and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class B common stock, in each case, par value $0.001 per share, and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of undesignated preferred stock, par value $0.001 per share. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, after giving effect to (i)&#160;the Warrant Exercise, (ii)&#160;the Series E and F&#160;Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi)&#160;the RSU Net Settlement, there were &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class A common stock outstanding, held of record by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shareholders, and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class B common stock outstanding, held of record by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shareholders. No shares of preferred stock will be issued and outstanding immediately after completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we will have two classes of authorized common stock: Class&#160;A common stock and Class&#160;B common stock. The rights of the holders of Class&#160;A common stock and Class&#160;B common stock will be identical, except with respect to voting, conversion, and transfer rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of our Class&#160;A common stock will be entitled to one vote per share of Class&#160;A common stock held, and holders of our Class&#160;B common stock will be entitled to 10 votes per share of Class&#160;B common stock held. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of our Class&#160;A common stock and Class&#160;B common stock will generally vote together as a single class on all matters (or, if any holders of preferred stock are entitled to vote together with the holders of common stock, as a single class with the holders of preferred stock), submitted to a vote of our shareholders, including the election of our directors, unless otherwise provided in our amended and restated certificate of formation or required by a non-waivable provision of the TBOC. Texas law could require either holders of our Class&#160;A common stock or Class&#160;B common stock to vote separately as a single class in the following circumstances, among others: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we were to seek to amend our amended and restated certificate of formation to increase or decrease the par value or the aggregate number of authorized shares of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we were to seek to amend our amended and restated certificate of formation to create a new class or increase the rights and preferences of an existing class, where in either case, the rights and preferences of such class are equal, prior, or superior to an existing class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we were to seek to amend our amended and restated certificate of formation to effect an exchange, reclassification, or cancellation of all or part of the shares of a class of our capital stock, then that class would be required to vote separately to approve such exchange, exchange, reclassification, or cancellation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">241</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we were to enter into a plan of merger or conversion under which a class of our capital stock is to be converted into or exchanged for other securities, interests, obligations, rights to acquire shares, interests, or other securities, cash, property, or any combination of the aforementioned, then that class would be required to vote separately to approve the plan of merger or conversion. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividend Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Class&#160;A common stock and Class&#160;B common stock will be entitled to share equally, identically, and ratably, on a per share basis, with respect to any dividend or distribution of cash or property paid or distributed by us, unless different treatment of the shares of the affected class is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting separately as a class. See the section titled &#8220;Dividend Policy&#8221; for additional information. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On our liquidation, dissolution, or winding-up, the holders of Class&#160;A common stock and Class&#160;B common stock will be entitled to share equally, identically, and ratably in all assets remaining after the payment of any liabilities, liquidation preferences, and accrued or declared but unpaid dividends, if any, with respect to any outstanding preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting separately as a class. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Preemptive or Similar Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Class&#160;A common stock and Class&#160;B common stock will not be entitled to preemptive rights, and will not be subject to conversion, redemption, or sinking fund provisions, except for the conversion provisions with respect to the Class&#160;B common stock described further below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Change of Control Transactions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the case of any distribution or payment in respect of the shares of our Class A common stock or Class B common stock upon a merger or consolidation with or into any other entity, or other substantially similar transaction, the holders of our Class A common stock and Class B common stock will be treated equally and identically with respect to shares of Class A common stock or Class B common stock owned by them, unless the only difference in the per share distribution to the holders of the Class A common stock and Class B common stock is that any securities distributed to the holder of a share of Class B common stock have 10 times the voting power of any securities distributed to the holder of a share of Class A common stock, or such merger, consolidation, or other transaction is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting as a separate class.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Subdivisions and Combinations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we subdivide or combine in any manner outstanding shares of Class&#160;A common stock or Class&#160;B common stock, the outstanding shares of the other class will be subdivided or combined in the same proportion and manner, unless different treatment of the shares of each class is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class&#160;A common stock and Class&#160;B common stock, each voting separately as a class. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each outstanding share of Class&#160;B common stock is convertible at any time at the option of its holder into one share of Class&#160;A common stock. In addition, each share of Class&#160;B common stock will convert automatically into one share of Class&#160;A common stock upon any transfer, whether or not for value, that occurs after the completion of this offering, except for certain permitted transfers set forth in our amended and restated certificate of formation, including, transfers to immediate family members, certain </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">242</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">trusts for estate planning purposes, and entities under common control with or controlled by such holder of our Class&#160;B common stock, and transfers that are approved in advance by our board of directors as permitted transfers. Once converted into Class&#160;A common stock, the Class&#160;B common stock will be retired and cancelled and will not be reissued or available for reissuance. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All of the outstanding shares of Class&#160;B common stock will convert automatically into shares of Class&#160;A common stock upon the earliest to occur of: (i)&#160;the date fixed by our board of directors that is no less than 60&#160;days and no more than 80&#160;days following the date on which David D. Halbert, our Founder, Chairman, and Chief Executive Officer, dies or becomes disabled, (ii)&#160;the date fixed by our board of directors that is no less than 60&#160;days and no more than 80&#160;days following the date on which Mr.&#160;Halbert is no longer providing services to Caris as an executive officer or director, (iii)&#160;the date fixed by our board of directors that is no less than 60&#160;days and no more than 80&#160;days following the date on which Mr.&#160;Halbert, together with his affiliates and their permitted transferees, hold less than 20% of the number of shares of our capital stock that they collectively held as of the completion of this offering, or (iv)&#160;the date specified in writing by the holders of a majority of the then-oustanding shares of Class&#160;B common stock, provided that such date is no less than 10&#160;days after such writing is delivered to us unless otherwise approved by our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation will authorize our board of directors to establish one or more series of preferred stock (including convertible preferred stock). Unless required by law or by the TBOC, the authorized shares of preferred stock will be available for issuance without further action by our shareholders. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors will be able to determine, with respect to any series of preferred stock, the voting powers (full or limited, or no voting powers), designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations, or restrictions thereof, of that series, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares of the series, which our board of directors may, except where otherwise provided in the preferred stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether dividends, if any, will be cumulative or non-cumulative and the dividend rate of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates at which dividends, if any, will be payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the redemption rights and price or prices, if any, for shares of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the affairs of the Company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the shares of the series will be convertible into shares of any other class or series, or any other security, of the Company or any other corporation and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be convertible, and all other terms and conditions upon which the conversion may be made; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">restrictions on the issuance of shares of the same series or of any other class or series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the voting rights, if any, of the holders of the series. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will be able to issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt or other transaction that some, or a majority, of the holders of our common stock might believe to be in their best interests or in which the holders of our common stock </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">243</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">might receive a premium for their common stock over the market price of the common stock. In addition, the issuance of preferred stock may adversely affect the rights of holders of our common stock by restricting dividends on the common stock, diluting the voting power of the common stock, or subordinating the liquidation rights of the common stock. As a result of these or other factors, the issuance of preferred stock may have an adverse impact on the market price of our Class A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a Texas corporation, we are subject to certain restrictions on dividends under the TBOC. Generally, a Texas corporation may pay dividends to its shareholders out of its surplus (the excess of its assets over its liabilities and stated capital) unless the dividend would render the corporation insolvent. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The declaration, amount, and payment of any future dividends will be at the sole discretion of our board of directors, subject to restrictions under the 2023 Term Loan Agreement, and the holders of our preferred stock we may at the time have outstanding. Our board of directors may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax, and regulatory restrictions and implications on the payment of dividends by us to our shareholders or by our subsidiaries to us, including restrictions under the 2023 Term Loan Agreement and other indebtedness we may incur, and such other factors as our board of directors may deem relevant. See the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently expect to retain all future earnings for use in the operation and expansion of our business and have no current plans to pay dividends. See the section titled &#8220;Risk Factors&#8212;Risks Related to This Offering and Ownership of Our Class A Common Stock&#8212;We do not intend to pay dividends for the foreseeable future. Investors in this offering may never obtain a return on their investment.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Options and RSUs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, we had outstanding under our 2020 Plan options to purchase an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock, with a weighted-average exercise price of approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. In connection with this offering, all options outstanding under our 2020 Plan will become exercisable for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our Class A common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our Class B common stock (in the case of equity awards held by David D. Halbert). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, we had outstanding under our 2020 Plan&#160;RSUs that may be settled once vested for an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock.&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; of these RSUs will vest in full in connection with this offering, subject to the RSU holders&#8217; continuous service through the date of this prospectus, and will be settled in the RSU Net Settlement, where we will issue &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class B common stock, after withholding an aggregate of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class B common stock, respectively, to satisfy associated estimated tax withholding and remittance obligations (based on an assumed initial offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assumed tax withholding rates of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;% and &#8199;&#8199;&#8199;&#8199;&#8199;%, respectively). The Class&#160;B common stock issued in the RSU Net Settlement will be held by David D. Halbert. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, we had outstanding warrants to purchase an aggregate of up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock or, at the holder&#8217;s election, Series&#160;C preferred stock, at an exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. Prior to the completion of this offering, we expect that all of these warrants, which, in each case, will expire upon the completion of this offering unless earlier exercised, will be exercised in full for shares of our Series&#160;C preferred stock. The&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Series&#160;C preferred stock issued upon the expected exercise of the warrants would convert into an equivalent number of shares of our common stock in the Preferred Stock Conversion and then would be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April 2025, we issued warrants to, if exercised on or after June 1, 2025, purchase at least an aggregate of &#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock, based on an assumed initial public offering price of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">244</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">$&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, at an exercise price of $0.01 per share. All of these warrants will terminate in connection with this offering, assuming the offering will occur before June 1, 2025, the date such warrants would otherwise have initially become exercisable for shares of our common stock. If these warrants become exercisable, the shares of our common stock to be issued upon conversion of the warrants will be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Notes</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April 2025, we issued the 2025 Convertible Notes to certain investors in aggregate principal amount of $30.0 million. The 2025 Convertible Notes mature on January 1, 2026 and accrue interest at a rate of 8% per annum, payable quarterly in cash. Immediately prior to and in connection with the completion of this offering, the 2025 Convertible Notes will convert at a conversion price equal to 70% of the initial public offering price per share, or into &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock, based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. The &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock to be issued upon conversion of the 2025 Convertible Notes (based on such assumed initial public offering price) will be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Investors&#8217; Rights Agreement, following the completion of this offering, certain holders of our common stock, including, but not limited to, certain holders of more than 5% of our outstanding capital stock and entities affiliated with certain of our officers and directors, will have certain registration rights, as set forth below. Such registration rights will terminate upon the earliest of (i)&#160;the fourth anniversary of the completion of this offering and (ii)&#160;the completion of certain liquidation events. Under the Investors&#8217; Rights Agreement, we will generally be required to pay all expenses (other than underwriting discounts and commissions and certain other expenses) related to any registration effected pursuant to the exercise of such registration rights. The Form S-1 and Form S-3 demand registration rights described below are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares of common stock included in any such registration under specified circumstances. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form S-1 Demand Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the completion of this offering, the holders of up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock will be entitled to certain Form S-1 demand registration rights. At any time beginning 180&#160;days after the effective date of this registration statement, the holders of at least 20% of the shares having these rights then outstanding may request that we file a registration statement on Form S-1 to register the offer and sale of their shares. We will generally only be obligated to effect up to two such registrations. Each such request for registration must cover securities the anticipated aggregate offering price of which, net of underwriting discounts and commissions, is at least $10.0&#160;million. If our board of directors determines that it would be materially detrimental to us and our shareholders to effect such a demand registration, we will have the right to defer such registration, not more than once in any 12-month period, for a period of up to 30&#160;days. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form S-3 Demand Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the completion of this offering, holders of up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock will be entitled to certain Form S-3 demand registration rights. At any time when we are eligible to file a registration statement on Form S-3, the holders of at least 20% of the shares having these rights then outstanding will be able to request that we register the offer and sale of their shares on a registration statement on Form S-3 so long as the request covers securities the anticipated aggregate public offering price of which, net of any underwriting discounts or commissions, is at least $3.0&#160;million. These holders may make an unlimited number of requests for registration on a registration statement on Form S-3. However, we will not be required to effect a registration on Form S-3 if we have effected three such registrations within the 12-month period preceding the date of the request. If our board of directors determines that it would be materially detrimental to us and our shareholders to effect such a demand registration, we will have the right to defer such registration, not more than once in any 12-month period, for a period of up to 30&#160;days. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">245</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Piggyback Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the completion of this offering, the holders of up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock will be entitled to certain &#8220;piggyback&#8221; registration rights. If we propose to register shares of our common stock or other securities under the Securities Act, either for our own account or for the account of our shareholders, in connection with such offering, all holders of these shares then outstanding will be able to request that we include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to (i)&#160;a registration relating solely to our stock plans, (ii)&#160;a registration relating to a corporate reorganization or other transaction covered by Rule&#160;145 promulgated under the Securities Act, (iii)&#160;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the shares having registration rights, or (iv)&#160;a registration relating to the offer and sale of debt securities, the holders of these shares will be entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Effects of Certain Provisions of Our Amended and Restated Certificate of Formation, Amended and Restated Bylaws, and Texas Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation and amended and restated bylaws will contain and the TBOC contains provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile change of control, and enhance the ability of our board of directors to maximize shareholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect and may delay, deter, or prevent a merger or acquisition of us by means of a tender offer, a proxy contest, or other takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of Class A common stock held by shareholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dual Class Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described above in the section titled &#8220;&#8212;Common Stock&#8212;Voting Rights,&#8221; our amended and restated certificate of formation will provide for a dual class common stock structure pursuant to which holders of our Class B common stock will have the ability to exercise significant influence over the outcome of matters requiring shareholder approval, even if they own significantly less than a majority of all outstanding shares of our common stock, including the election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets for the foreseeable future. Our existing shareholders will have the ability to exercise significant influence over those matters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorized but Unissued Capital Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Texas law does not require shareholder approval for any issuance of authorized shares. Accordingly, the authorized but unissued shares of our common stock and our preferred stock are available for future issuance without shareholder approval, subject to any limitations imposed by the listing standards of Nasdaq and restrictions under the 2023 Term Loan Agreement and other indebtedness we may incur. The listing standards of Nasdaq, which would apply if and so long as our common stock remains listed on Nasdaq, require shareholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock. These additional shares may be issued in the future for a variety of corporate finance transactions, acquisitions, and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Business Combinations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the affiliated business combinations provisions of Title 2, Chapter 21, Subchapter M of the TBOC (Sections&#160;21.601 through 21.610), which provides that a Texas corporation may not engage in specified types of business combinations, including mergers, consolidations, and asset sales, with a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">246</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">person, or an affiliate or associate of that person, who is an &#8220;affiliated shareholder.&#8221; For purposes of this law, an &#8220;affiliated shareholder&#8221; is generally defined as the holder of 20% or more of the corporation&#8217;s voting shares, for a period of three&#160;years from the date that person became an affiliated shareholder. The law&#8217;s prohibitions do not apply if: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the business combination or the acquisition of shares by the affiliated shareholder was approved by the board of directors of the corporation before the affiliated shareholder became an affiliated shareholder; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the business combination was approved by the affirmative vote of the holders of at least two-thirds of the outstanding voting shares of the corporation not beneficially owned by the affiliated shareholder, at a meeting of shareholders called for that purpose, not less than six&#160;months after the affiliated shareholder became an affiliated shareholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have more than 100 shareholders and are considered to be an &#8220;issuing public corporation&#8221; for purposes of this law. The affiliated business combinations provisions of the TBOC do not apply to the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the business combination of an issuing public corporation where: (a)&#160;the corporation&#8217;s original certificate of formation or bylaws contain a provision expressly electing not to be governed by the affiliated business combinations provisions of the TBOC; or (b)&#160;the corporation adopts an amendment to its certificate of formation or bylaws, by the affirmative vote of the holders, other than affiliated shareholders, of at least two-thirds of the outstanding voting shares of the corporation, expressly electing not to be governed by the affiliated business combinations provisions of the TBOC, so long as the amendment does not take effect for 18&#160;months following the date of the vote and does not apply to a business combination with an affiliated shareholder who became affiliated on or before the effective date of the amendment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a business combination of an issuing public corporation with an affiliated shareholder that became an affiliated shareholder inadvertently, if the affiliated shareholder: (a)&#160;divests itself, as soon as possible, of enough shares to no longer be an affiliated shareholder; and (b)&#160;would not at any time within the three-year period preceding the announcement of the business combination have been an affiliated shareholder but for the inadvertent acquisition; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a business combination with an affiliated shareholder who became an affiliated shareholder through a transfer of shares by will or intestacy and continuously was an affiliated shareholder until the announcement date of the business combination; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a business combination of a corporation with its wholly owned Texas subsidiary if the subsidiary is not an affiliate or associate of the affiliated shareholder other than by reason of the affiliated shareholder&#8217;s beneficial ownership of voting shares of the corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither our amended and restated certificate of formation nor our amended and restated bylaws contain any provision expressly providing that we will not be subject to the affiliated business combinations provisions of the TBOC. The affiliated business combinations provisions of the TBOC may have the effect of inhibiting a non-negotiated merger or other business combination involving us, even if that event would be beneficial to our shareholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vacancies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation will provide that, subject to the rights granted to one or more series of preferred stock then outstanding, and except as otherwise provided in the TBOC, any vacancies on our board of directors may only be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, or by the affirmative vote of a majority of the voting power of our then-outstanding capital stock entitled to vote generally in the election of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Cumulative Voting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Texas law, the right to vote cumulatively does not exist unless the certificate of formation specifically authorizes cumulative voting. Our amended and restated certificate of formation will not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">247</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">authorize cumulative voting. Therefore, shareholders holding a majority in voting power of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Shareholder Meetings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation will provide that special meetings of our shareholders may be called at any time only by or at the direction of the board of directors, the Chairman of the board of directors, our President, our Chief Executive Officer, or from and after the date on which no shares of Class B common stock are outstanding (such date, the &#8220;Trigger Date&#8221;), by our Secretary at the written request of the holders of the greater of (a)&#160;at least 50% and (b)&#160;the highest&#160;percentage of ownership that may be set under the TBOC, of all the voting power of all of the shares of our capital stock entitled to be voted at the special meeting. Our amended and restated bylaws will prohibit the conduct of any business at a special meeting other than procedural matters or as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, or changes in control or management of the Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Requirements for Advance Notification of Director Nominations and Shareholder Proposals</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated bylaws will establish advance notice procedures with respect to shareholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a shareholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a shareholder&#8217;s notice must be received at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary date of the immediately preceding annual meeting of shareholders. Our amended and restated bylaws will also specify requirements as to the form and content of a shareholder&#8217;s notice. Our amended and restated bylaws will allow the chair of the meeting at a meeting of the shareholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to influence or obtain control of us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder Action by Written Consent</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation will provide that from and after the Trigger Date, any action required or permitted to be taken at an annual or special meeting of shareholders may be taken by written consent in lieu of a meeting of shareholders only with the unanimous written consent of all holders of shares entitled to vote on such action. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment of Bylaws and Certificate of Formation Provisions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of formation and amended and restated bylaws will provide that our board of directors is expressly authorized to adopt, amend, alter, or repeal, in whole or in part, our amended and restated bylaws without a shareholder vote in any manner not inconsistent with the laws of the State of Texas and our amended and restated certificate of formation. The shareholders may not adopt, amend, alter, or repeal our amended and restated bylaws unless such action is approved, in addition to any other vote required by our amended and restated certificate of formation, by the affirmative vote of, from and after the Trigger Date, the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The TBOC provides generally that the affirmative vote of the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the outstanding shares entitled to vote thereon, voting together as a single class, is required to amend a corporation&#8217;s certificate of formation, unless the certificate of formation requires a greater or lesser&#160;percentage, but not less than a majority. Our amended and restated certificate of formation will provide that the affirmative vote of, from and after the Trigger Date, the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all the then-outstanding shares entitled to vote thereon, voting together as a single class, will continue to be required to amend or repeal, or adopt any provision of our amended and restated certificate of formation inconsistent with: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">248</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions providing for the election and term of our directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions regarding resignation and removal of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions regarding filling vacancies on our board of directors and newly created directorships; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions eliminating monetary damages for breaches of fiduciary duty by a director; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions regarding shareholder action by written consent; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions regarding calling special meetings of shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions regarding jurisdiction and forums for proceedings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions denying preemptive rights; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the amendment provision requiring that the above provisions be amended only with the affirmative vote of, from and after the Trigger Date, the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all the then-outstanding shares entitled to vote thereon, voting together as a single class; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provided, however, that for so long as any shares of Class&#160;B common stock remain outstanding, the affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of Class&#160;B common stock, voting as a separate class, in addition to any other vote required by law or our amended and restated certificate of formation, shall be required to amend, alter, change, repeal, or adopt any provision inconsistent with the provisions regarding the designations and the powers, preferences, privileges, and rights, and the qualifications, limitations, or restrictions with respect to our Class&#160;A common stock and Class&#160;B common stock or the amendment provision requiring that the above bulleted provisions be amended only with the affirmative vote of, from and after the Trigger Date, the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all the then-outstanding shares entitled to vote thereon, voting together as a single class. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The combination of the lack of cumulative voting and the supermajority voting requirements will make it more difficult for shareholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing shareholders or another party to effect a change in management. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management or of us, such as a merger, reorganization, or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of our Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exclusive Forum</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated organizational documents will provide that the Business Court in the First Business Court Division of the State of Texas shall be the sole and exclusive forum for certain shareholder litigation matters, unless we consent in writing to the selection of an alternative forum or if the Business Court in the First Business Court Division of the State of Texas is not accepting filings or determines that it lacks jurisdiction, the exclusive forum will be the federal district courts in the Northern District of Texas or, if such federal district courts do not have jurisdiction, the State District Court in Dallas County, Texas; provided, however, that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act and provided, further, that the foregoing choice of forum provision shall not apply to claims seeking to enforce </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">249</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any liability or duty created by the Securities Act, the Exchange Act, or any other claim for which the U.S. federal courts have exclusive jurisdiction. Although we believe this provision benefits us by providing increased consistency in the application of Texas law in the types of lawsuits to which it applies and in limiting our litigation costs, the provision may have the effect of discouraging lawsuits against our directors and officers, may result in increased costs for our shareholders to bring claims, and may limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us. However, it is possible that a court could rule that this provision is unenforceable or inapplicable to a particular dispute. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conflicts of Interest</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Texas law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors, or shareholders. Our amended and restated certificate of formation will, to the maximum extent permitted from time to time by Texas law, renounce any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to our officers, directors, or shareholders or their respective affiliates, other than those officers, directors, shareholders, or affiliates who are our or our subsidiaries&#8217; employees. Our amended and restated certificate of formation will provide that, to the fullest extent permitted by law, no director (or his or her affiliates) who is not employed by us will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar lines of business in which we or our subsidiaries from time to time are engaged or propose to engage or (ii)&#160;otherwise competing, directly or indirectly, with us or any of our subsidiaries. In addition, to the fullest extent permitted by law, in the event that any non-employee director acquires knowledge of a potential transaction or other business opportunity that may be a corporate opportunity for himself or herself or his or her affiliates or for us or our affiliates, such person will have no duty to communicate or offer such transaction or business opportunity to us or any of our subsidiaries, and they may take any such opportunity for themselves or offer it to another person or entity. Our amended and restated certificate of formation will not renounce our interest in any business opportunity that is expressly offered to a non-employee director solely in his or her capacity as a director or officer of our Company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted to undertake the opportunity under our amended and restated certificate of formation, we have sufficient financial resources to undertake the opportunity, and the opportunity would be in line with our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations on Liability and Indemnification of Officers and Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The TBOC authorizes corporations to limit or eliminate the personal liability of directors to corporations and their shareholders for monetary damages for breaches of directors&#8217; fiduciary duties (other than breaches of the directors&#8217; duty of loyalty to corporations or their shareholders), subject to certain exceptions. Our amended and restated certificate of formation will include a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the TBOC. The effect of these provisions will be to eliminate the rights of us and our shareholders, through shareholders&#8217; derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any director if the director has acted in bad faith, engaged in intentional misconduct, knowingly violated the law, authorized illegal dividends or redemptions, derived an improper benefit from his or her actions as a director, or engaged in an act or omission for which the liability of the director is expressly provided by an applicable statute. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated bylaws will provide generally that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the TBOC. We also have entered into separate indemnification agreements with each of our directors and executive officers and will be expressly authorized to carry directors&#8217; and officers&#8217; liability insurance providing indemnification for our directors, officers, and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance will be useful to attract and retain qualified directors and officers. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These limitation of liability, indemnification, and advancement provisions may discourage shareholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">250</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:228pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our shareholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is currently no pending material litigation or proceeding involving any of our directors, officers, or employees for which indemnification is sought. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dissenters&#8217; Rights of Appraisal and Payment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the TBOC, with certain exceptions, our shareholders will have appraisal rights in connection with a merger, a sale of all or substantially all of our assets, an interest exchange, or a conversion. Pursuant to the TBOC, shareholders who properly request and perfect appraisal rights in connection with such merger, sale of all or substantially all of our assets, interest exchange, or conversion will have the right to receive payment of the fair value of their shares as agreed to between the shareholder and us or, if unable to reach agreement, as determined by the State District Court in Dallas County, Texas. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholders&#8217; Derivative Actions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the TBOC, any of our shareholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that the shareholder bringing the action (i)&#160;is a holder of our shares at the time of the transaction to which the action relates or such shareholder became a shareholder by operation of law from a person that was a shareholder at the time of the transaction to which the action relates and (ii)&#160;fairly and adequately represents the interests of the Company in enforcing the right of the Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have applied to list our Class A common stock on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CAI.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our Class A common stock will be Equiniti Trust Company, LLC. The transfer agent and registrar&#8217;s address is 48 Wall Street, 22nd Floor, New York, New York 10005.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">251</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEFF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SHARES ELIGIBLE FOR FUTURE SALE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before this offering, there has not been a public market for shares of our Class A common stock. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, future sales of substantial amounts of shares of our Class A common stock, including shares issued upon the exercise of outstanding options or upon conversion of our Class B common stock, in the public market following this offering or the possibility of these sales occurring, could cause the prevailing market price for our Class A common stock to fall or impair our ability to raise equity capital in the future. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following this offering, we will have outstanding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Class A common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our Class B common stock, based on the number of shares of common stock outstanding as of March&#160;31, 2025, after giving effect to (i)&#160;the Warrant Exercise, (ii)&#160;the Series E and F Issuance, (iii)&#160;the Preferred Stock Conversion, (iv)&#160;the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v)&#160;the Common Stock Reclassification, and (vi)&#160;the RSU Net Settlement. This includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Class A common stock that we are selling in this offering, which shares may be resold in the public market immediately unless purchased by our affiliates and assumes no additional exercise of outstanding options other than as described elsewhere in this prospectus. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that are not sold in this offering will be &#8220;restricted securities,&#8221; as that term is defined in Rule&#160;144 under the Securities Act (&#8220;Rule&#160;144&#8221;). These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule&#160;144 or Rule&#160;701 under the Securities Act (&#8220;Rule&#160;701&#8221;), which are summarized below. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a result of the lock-up agreements and market stand-off provisions described below, and subject to the provisions of Rule&#160;144 or Rule&#160;701, the earliest these restricted securities may generally be available for sale in the public market is as follows: </font>
        </div>
        <table style="width:456pt;height:59.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:222pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Earliest Date Available for Sale in the Public Market </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:222pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares of Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025, which is &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.5pt 0pt; width:222pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">All remaining shares held by our shareholders not previously eligible for sale, subject to volume limitations applicable to &#8220;affiliates&#8221; under Rule&#160;144 as described below.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:7.9pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, pursuant to certain exceptions to the lock-up agreements, shares of our Class&#160;A common stock will be eligible for sale in the open market during the Lock-Up Period (as defined below) in sell-to-cover transactions in order to satisfy tax withholding obligations. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect each sell-to-cover transaction to extend over a multi-day period based on trading volumes. Because the purpose of sell-to-cover transactions is to generate proceeds sufficient to satisfy tax withholding obligations or remittance payments due as a result of the vesting or settlement of RSUs or the exercise of options that are expiring during the Lock-Up Period, the exact number of shares sold will depend on the sale prices of the Class&#160;A common stock in such transactions and our shareholders&#8217; personal tax rates. In addition, if net settlement transactions occur on or prior to the dates set forth above, the number of shares of Class&#160;A common stock to be sold in each sell-to-cover transaction will be reduced proportionally. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;144</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, under Rule&#160;144 as currently in effect, a person who has beneficially owned shares of our restricted common stock for at least six&#160;months would be entitled to sell their securities provided that such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90&#160;days preceding, a sale, and we are subject to the periodic reporting requirements of the Exchange Act, for at least 90&#160;days before the sale. In addition, under Rule&#160;144, any person who is not an affiliate of ours and has held their shares of common stock for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares of common stock immediately upon the completion of this offering without regard to whether current public information about </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">252</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">us is available. Persons who have beneficially owned shares of our restricted common stock for at least six&#160;months but who are our affiliates at the time of, or any time during the 90&#160;days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">1% of the number of shares of our capital stock then outstanding, which will equal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#160;shares immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares of Class A common stock; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the average weekly trading volume of our Class A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90&#160;days before the sale. Such sales both by affiliates and by non-affiliates must also comply with the manner of sale, current public information and notice provisions of Rule&#160;144. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;701</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of our service providers who purchased shares under a written compensatory plan or contract prior to this offering may be entitled to rely on the resale provisions of Rule&#160;701. Rule&#160;701, as currently in effect, permits resales of shares, including by affiliates, in reliance upon Rule&#160;144 but without compliance with certain restrictions, including the holding period requirement, of Rule&#160;144. Rule&#160;701 further provides that non-affiliates may sell such shares in reliance on Rule&#160;144 without having to comply with the public information, volume limitation or notice provisions of Rule&#160;144. All holders of Rule&#160;701 shares are required to wait until 90&#160;days after the date of this prospectus before selling such shares if such resale is pursuant to Rule&#160;701. All Rule&#160;701 shares are, however, subject to lock-up agreements and will only become eligible for sale upon the expiration of these lock-up agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-Up Agreements and Market Stand-off Provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, our executive officers, directors, and other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180&#160;days after the date of this prospectus (the &#8220;Lock-Up Period&#8221;) without first (a)&#160;providing prior written notice to BofA Securities, Inc., J.P. Morgan Securities LLC, and Goldman Sachs &amp; Co. LLC and (b)&#160;obtaining the written consent of BofA Securities, Inc. and either J.P. Morgan Securities LLC or Goldman Sachs &amp; Co. LLC, who may release the securities subject to any of the lock-up agreements in whole or in part at any time. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">offer, pledge, sell, or contract to sell any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sell any option or contract to purchase any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchase any option or contract to sell any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">grant any option, right, or warrant for the sale of any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">lend or otherwise dispose of or transfer any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">request or demand that we file or make a confidential submission of a registration statement related to the common stock, or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">enter into any hedging, swap, loan, or any other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such hedging, swap, loan, or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any director, officer or shareholder is granted an early release from its obligations under any lock-up restrictions with respect to our securities in an aggregate amount in excess of one&#160;percent of our outstanding Class&#160;A common stock, then every other lock-up party automatically will be granted an equivalent early release from its obligations under their respective lock-up agreement on a pro&#160;rata basis, provided that such release shall not apply (i)&#160;if it is effected solely to permit a transfer not for consideration and the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">253</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transferee has agreed in writing to be bound by the same terms described in the lock-up agreement to the extent and for the duration that such terms remain in effect at the time of the transfer and (ii)&#160;in the event of an underwritten public offering, except with respect to the lock-up party&#8217;s participation in such underwritten public offering, provided that the lock-up party shall be offered the opportunity to participate in such underwritten public offering in accordance with, and subject to, the terms of any rights agreement (including the Investors&#8217; Rights Agreement). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The agreements of our executive officers, directors, and other existing security holders do not apply to transfers, sales or dispositions: (i)&#160;as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona fide estate planning purposes; (ii)&#160;by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the lock-up party; (iii)&#160;(A)&#160;if the lock-up party is an individual, by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement or (B)&#160;if the lock-up party is a corporation, partnership, limited liability company or other business entity, pursuant to a merger or reorganization with or into another entity; (iv)&#160;pursuant to an order of a court or regulatory agency having jurisdiction over the lock-up party; (v)&#160;to any corporation, partnership, limited liability company or other entity controlled or managed, or under common control or management by, the lock-up party or the immediate family of the lock-up party; (vi)&#160;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i)&#160;through (v)&#160;above; (vii)&#160;to any immediate family member or any trust, partnership, limited liability company or other entity for the direct or indirect benefit of the lock-up party or one or more immediate family members of the lock-up party, or if the lock-up party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; (viii)&#160;if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity, (A)&#160;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule&#160;405 promulgated under the Securities Act) of the lock-up party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or common investment management with the lock-up party or affiliates of the lock-up party (including, for the avoidance of doubt, pursuant to a merger, acquisition or reorganization of the lock-up party and, further, where the lock-up party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&#160;as part of a distribution to partners (general or limited partners), limited liability company members, shareholders or other equityholders of the lock-up party or holders of similar equity interests in the lock-up party; (ix)&#160;to us upon the lock-up party&#8217;s death, disability or termination of employment or other service relationship with us; provided that such common stock were issued to the lock-up party pursuant to an agreement or equity award granted pursuant to an employee benefit plan, option, warrant or other right disclosed in this prospectus; (x)&#160;pursuant to a bona fide third-party tender offer, or in connection with a merger, consolidation or other similar transaction, that is approved by the our board of directors, made to all holders of our capital stock involving a change of control of us (including, without limitation, entering into any lock-up, voting or similar agreement pursuant to which the lock-up party may agree to transfer, sell, tender or otherwise dispose of lock-up securities in connection with such transaction, or vote any common stock or other securities in favor of any such transaction); provided that, in the event that such tender offer, merger, consolidation or other transaction is not completed, the lock-up party&#8217;s lock-up securities shall remain subject to the restrictions set forth in this lock-up agreement; provided further that any shares of common stock not transferred, sold or otherwise disposed of in such third-party tender offer, merger, consolidation, or other similar transaction shall remain subject to the restrictions set forth in this lock-up agreement (for purposes hereof, &#8220;change of control&#8221; shall mean the transfer, sale or other disposition (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of our capital stock if, after such transaction or transactions, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or the surviving entity)); to us in connection with the conversion or exercise of any of our outstanding equity securities into shares of common stock or in connection with the reclassification or exchange of shares of common stock, in each case as described and as contemplated in this prospectus; provided that any shares of common stock received by the lock-up party upon such conversion, exercise, reclassification, reclassification or exchange shall be subject to the restrictions set forth in this lock-up agreement; (xii)&#160;in connection with the vesting or settlement of restricted stock&#160;units or the exercise of options or other rights to purchase the shares of common stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including (A)&#160;any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">254</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transfer, sale or other disposition to us for the payment of exercise price, tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock&#160;units, options or rights, and (B)&#160;any transfer, sale or other disposition of shares of common stock necessary to generate such amount of cash needed to satisfy tax withholdings or remittance payments due as a result of the vesting or settlement of restricted stock&#160;units or the exercise of options, which are expiring during the lock-up period, to purchase the shares of common stock; provided that, in each case, any such restricted stock&#160;units and options to purchase shares of common stock were granted under an equity incentive plan or other equity award plan that is described in this prospectus and provided, further, that, in each case, any such shares of common stock received by the lock-up party upon such vesting, settlement or exercise that are not so transferred, sold or otherwise disposed shall be subject to the restrictions set forth in this lock-up agreement; (xiii)&#160;up to 15% of the lock-up party&#8217;s lock-up securities, to any third-party pledgee in a bona fide transaction as collateral to secure obligations pursuant to lending or other arrangements between such third parties (or their affiliates or designees) and the lock-up party and/or its affiliates or any similar arrangement relating to a financing arrangement for the benefit of the lock-up party and/or its affiliates; and upon foreclosure of any such lending or other arrangements; (xiv)&#160;if the lock-up party is not our officer or director, in connection with a sale of the lock-up party&#8217;s shares of Class&#160;A common stock acquired (A)&#160;from the underwriters in this offering or (B)&#160;on the open market or in other transactions following this offering; or (xv)&#160;to the underwriters pursuant to the underwriting agreement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, notwithstanding the restrictions in the lock-up agreement, the lock-up party may make any demand or requests for, exercise any right with respect to, or take any action in preparation of, the registration by us under the Securities Act of the lock-up party&#8217;s lock-up securities or other securities; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that (i)&#160;no public filing with the Securities and Exchange Commission or any other public announcement may be made during the lock-up period in relation to such registration, (ii)&#160;the representatives must have received prior written notice from us and/or the lock-up party of a confidential submission of a registration statement with the Securities and Exchange Commission during the lock-up period at least five (5)&#160;business days prior to such submission and (iii)&#160;no lock-up securities or other securities of us may be sold, distributed or exchanged during the lock-up period. Notwithstanding the foregoing, the lock-up party also may establish trading plans pursuant to Rule&#160;10b5-1 under the Exchange Act for the transfer, sale or other disposition of lock-up securities, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that (1)&#160;none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the lock-up period and (2)&#160;no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the lock-up period, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate therein that none of the securities subject to such plan may be transferred, sold, or otherwise disposed pursuant to such plan until after the expiration of the lock-up period.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event that (i)&#160;at least 150&#160;days have elapsed since the date of this prospectus and (ii)&#160;the end of the restricted period would fall during one of our quarterly blackout periods during which trading by certain of our employees in our securities would not be permitted under our insider trading policy then in effect (a &#8220;Blackout Period&#8221;), or within 10 trading days prior to such Blackout Period the restricted period shall end on the date that is the later of (a)&#160;10 trading days prior to the commencement of a Blackout Period and (b)&#160;the 150th day after the date of this prospectus. For a further description of these lock-up agreements, please see &#8220;Underwriting.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to the restrictions contained in the lock-up agreements described above, the holders of outstanding equity awards and holders of outstanding common stock issued pursuant to the vesting, settlement, or exercise of equity awards, are subject to market stand-off provisions in agreements with us that impose similar restrictions on the ability of such security holders to offer, sell, or transfer our equity securities during the Lock-Up Period.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the completion of this offering, the holders of up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will, subject to the lock-up agreements referred to above, be entitled to certain rights with respect to the registration of such shares under the Securities Act. The registration of these shares of our common stock under the Securities Act would result in these shares becoming eligible for sale in the public market without </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">255</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule&#160;144 limitations applicable to affiliates. See the section titled &#8220;Description of Capital Stock&#8212;Registration Rights&#8221; for a description of these registration rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to file a registration statement on Form S-8 under the Securities Act covering all of the shares of our common stock subject to options outstanding or reserved for issuance under our equity plans. We expect to file this registration statement as soon as practicable after the completion of this offering. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will thereupon be eligible for sale in the public markets, subject to vesting restrictions, the lock-up agreements described above and Rule&#160;144 limitations applicable to affiliates. For a more&#160;complete discussion of our stock plans, see the section titled &#8220;Executive Compensation&#8212;Long-Term Incentive Plans.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">256</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR CLASS A COMMON STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership, and disposition of our Class A common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely&#160;affect a Non-U.S. Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership, and disposition of our Class A common stock. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to Non-U.S. Holders that hold our Class A common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#8217;s particular circumstances, including the impact of the Medicare contribution tax on net investment income, the special tax accounting rules under Section&#160;451(b) of the Code, and the alternative minimum tax. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">U.S. expatriates and former citizens or long-term residents of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons holding our Class A common stock as part of a hedge, straddle, or other risk reduction&#160;strategy or as part of a conversion transaction or other integrated investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">banks, insurance companies, and other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">brokers, dealers, or traders in securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">tax-exempt organizations or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons deemed to sell our Class A common stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons who hold or receive our Class A common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If an entity treated as a partnership for U.S. federal income tax purposes holds our Class&#160;A common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships holding our Class A common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">257</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AND DISPOSITION OF OUR CLASS A COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Definition of a Non-U.S. Holder</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is any beneficial owner of our Class A common stock that is neither a &#8220;U.S. person&#8221; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; &#8203;(within the meaning of Section&#160;7701(a)(30) of the Code), or (2)&#160;has a valid election in effect to be treated as a United States person for U.S. federal&#160;income tax purposes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distributions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As described in the section titled &#8220;Dividend Policy,&#8221; we do not anticipate declaring or paying dividends to holders of our Class A common stock in the foreseeable future. However, if we do make distributions of cash or property on our Class A common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder&#8217;s adjusted tax&#160;basis in its Class A common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#8220;&#8212;Sale or Other Taxable Disposition.&#8221; </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussions below on effectively connected income, backup withholding, and&#160;FATCA (as defined below) dividends paid to a Non-U.S. Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other&#160;applicable documentation) certifying qualification for the lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&#8217;s&#160;conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates in the same manner as if the Non-U.S. Holder were a resident of the United States. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">258</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sale or Other Taxable Disposition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussions below on backup withholding and FATCA (as defined below), a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our Class A common stock unless: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the Non-U.S. Holder is a nonresident alien individual present in the United States for 183&#160;days or more during the taxable year of the disposition and certain other requirements are met; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Class A common stock constitutes a U.S. real property interest (&#8220;USRPI&#8221;) by reason of our status as a U.S. real property holding corporation (&#8220;USRPHC&#8221;) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the Non-U.S. Holder&#8217;s holding period for our Class A common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular rates in the same manner as if the Non-U.S. Holder were a resident of the United States. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A Non-U.S. Holder described in the second bullet point above will be subject to U.S. federal&#160;income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our Class A common stock, which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our Class A common stock by a Non-U.S. Holder will not be subject to U.S. federal income tax if our Class A common stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on an established securities market and such Non-U.S. Holder owned, actually and constructively, 5% or less of our Class A common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder&#8217;s holding period. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Reporting and Backup Withholding</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payments of dividends on our Class A common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form&#160;W-8BEN, W-8BEN-E, or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on our Class A common stock paid to the Non-U.S. Holder, regardless of whether such distributions constitute dividends or whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our Class A common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to&#160;backup withholding or information reporting if the applicable withholding agent receives the certification&#160;described above and does not have actual knowledge or reason to know that such holder is a United States person or the holder otherwise establishes an exemption. Proceeds of a disposition of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">259</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:168pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Class A common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup&#160;withholding or information reporting. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Withholding Tax on Payments Made to Foreign Accounts</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Withholding taxes may be imposed under Sections&#160;1471 to 1474 of the Code (such Sections&#160;commonly referred to as the Foreign Account Tax Compliance Act, or &#8220;FATCA&#8221;) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our Class A common stock paid to a &#8220;foreign financial institution&#8221; or a &#8220;non-financial foreign entity&#8221; &#8203;(each as defined in the Code), unless (1)&#160;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&#160;the non-financial foreign entity either certifies it does not have any &#8220;substantial United States owners&#8221; &#8203;(as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3)&#160;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1)&#160;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#8220;specified United States persons&#8221; or &#8220;United States owned foreign entities&#8221; &#8203;(each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account&#160;holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the applicable Treasury Regulations and administrative guidance, withholding under&#160;FATCA generally applies to payments of dividends on our Class A common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&#160;1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our Class A common stock. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">260</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNDERWRITING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">BofA Securities, Inc., J.P. Morgan Securities LLC, Goldman Sachs &amp; Co. LLC, and Citigroup Global Markets Inc. are acting as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of Class A common stock set forth opposite its name below. </font>
        </div>
        <table style="width:456pt;height:183pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Underwriter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:35pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">BofA Securities, Inc. </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:35pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">J.P. Morgan Securities LLC </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Goldman Sachs &amp; Co. LLC </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Citigroup Global Markets Inc. </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">TD Securities (USA) LLC </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Evercore Group L.L.C. </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Guggenheim Securities, LLC </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">BTIG, LLC </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nomura Securities International, Inc. </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:409pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">WR Securities, LLC </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.25pt 0pt; width:409pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Total</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 1.5pt 0pt; width:35pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.81pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the shares of Class A common stock sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and&#160;accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#8217;s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. Sales of shares made outside of the United States may be made by affiliates of the underwriters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Commissions and Discounts</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. After the initial offering, the public offering price, concession, or any other term of the offering may be changed. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the public offering price, underwriting discount, and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of Class A common stock. </font>
        </div>
        <table style="width:381pt;height:56.5pt;margin-left:37.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:261.36pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Without </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">With </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:261.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.91pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:261.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Underwriting discount </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.91pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:261.36pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds, before expenses, to us </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.91pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">261</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The expenses of the offering, not including the underwriting discount, are estimated at $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and are payable by us. We have also agreed to reimburse the underwriters for their expenses relating to clearance of this offering with the Financial Industry Regulatory Authority in an amount up to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have engaged NCMG LLC to provide certain financial advisory services in connection with this offering. The underwriters have agreed to reimburse us for such financial advisory services provided by NCMG LLC in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Option to Purchase Additional Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have granted an option to the underwriters, exercisable for 30&#160;days after the date of this&#160;prospectus, to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of Class A common stock at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares of Class A common stock proportionate to that underwriter&#8217;s initial amount reflected in the above table. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Sales of Similar Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days (the &#8220;Lock-Up Period&#8221;) after the date of this prospectus without (a) providing prior written notice to BofA Securities, Inc., J.P. Morgan Securities LLC, and Goldman Sachs &amp; Co. LLC and (b) first obtaining the written consent of BofA Securities, Inc. and either J.P. Morgan Securities LLC or Goldman Sachs &amp; Co. LLC, who may release the securities subject to any of the lock-up agreements in whole or in part at any time. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">offer, pledge, sell, or contract to sell any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">sell any option or contract to purchase any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">purchase any option or contract to sell any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">grant any option, right, or warrant for the sale of any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">lend or otherwise dispose of or transfer any common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">request or demand that we file or make a confidential submission of a registration statement related to the common stock, or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">enter into any hedging, swap, loan, or any other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such hedging, swap, loan or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock (collectively, the &#8220;lock-up securities&#8221;). It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The agreements of our executive officers, directors, and other existing security holders do not apply to transfers, sales or dispositions: (i)&#160;as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona fide estate planning purposes; (ii)&#160;by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the lock-up party; (iii)&#160;(A)&#160;if the lock-up party is an individual, by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement or (B)&#160;if the lock-up party is a corporation, partnership, limited liability company or other business entity, pursuant to a merger or reorganization with or into another entity; (iv)&#160;pursuant to an order of a court or regulatory agency having jurisdiction over the lock-up party; (v)&#160;to any corporation, partnership, limited liability company or other entity controlled or managed, or under common control or management by, the lock-up party or the immediate family of the lock-up party; (vi)&#160;to a nominee or custodian of a person or entity to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">262</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">whom a disposition or transfer would be permissible under clauses (i)&#160;through (v)&#160;above; (vii)&#160;to any immediate family member or any trust, partnership, limited liability company or other entity for the direct or indirect benefit of the lock-up party or one or more immediate family members of the lock-up party, or if the lock-up party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; (viii)&#160;if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity, (A)&#160;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule&#160;405 promulgated under the Securities Act) of the lock-up party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or common investment management with the lock-up party or affiliates of the lock-up party (including, for the avoidance of doubt, pursuant to a merger, acquisition or reorganization of the lock-up party and, further, where the lock-up party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&#160;as part of a distribution to partners (general or limited partners), limited liability company members, shareholders or other equityholders of the lock-up party or holders of similar equity interests in the lock-up party; (ix)&#160;to us upon the lock-up party&#8217;s death, disability or termination of employment or other service relationship with us; provided that such common stock were issued to the lock-up party pursuant to an agreement or equity award granted pursuant to an employee benefit plan, option, warrant or other right disclosed in this prospectus; (x)&#160;pursuant to a bona fide third-party tender offer, or in connection with a merger, consolidation or other similar transaction, that is approved by the our board of directors, made to all holders of our capital stock involving a change of control of us (including, without limitation, entering into any lock-up, voting or similar agreement pursuant to which the lock-up party may agree to transfer, sell, tender or otherwise dispose of lock-up securities in connection with such transaction, or vote any common stock or other securities in favor of any such transaction); provided that, in the event that such tender offer, merger, consolidation or other transaction is not completed, the lock-up party&#8217;s lock-up securities shall remain subject to the restrictions set forth in this lock-up agreement; provided further that any shares of common stock not transferred, sold or otherwise disposed of in such third-party tender offer, merger, consolidation, or other similar transaction shall remain subject to the restrictions set forth in this lock-up agreement (for purposes hereof, &#8220;change of control&#8221; shall mean the transfer, sale or other disposition (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of our capital stock if, after such transaction or transactions, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or the surviving entity)); to us in connection with the conversion or exercise of any of our outstanding equity securities into shares of common stock or in connection with the reclassification or exchange of shares of common stock, in each case as described and as contemplated in this prospectus; provided that any shares of common stock received by the lock-up party upon such conversion, exercise, reclassification, reclassification or exchange shall be subject to the restrictions set forth in this lock-up agreement; (xii)&#160;in connection with the vesting or settlement of restricted stock&#160;units or the exercise of options or other rights to purchase the shares of common stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including (A)&#160;any transfer, sale or other disposition to us for the payment of exercise price, tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock&#160;units, options or rights, and (B)&#160;any transfer, sale or other disposition of shares of common stock necessary to generate such amount of cash needed to satisfy tax withholdings or remittance payments due as a result of the vesting or settlement of restricted stock&#160;units or the exercise of options, which are expiring during the lock-up period, to purchase the shares of common stock; provided that, in each case, any such restricted stock&#160;units and options to purchase shares of common stock were granted under an equity incentive plan or other equity award plan that is described in this prospectus and provided, further, that, in each case, any such shares of common stock received by the lock-up party upon such vesting, settlement or exercise that are not so transferred, sold or otherwise disposed shall be subject to the restrictions set forth in this lock-up agreement; (xiii)&#160;up to 15% of the lock-up party&#8217;s lock-up securities, to any third-party pledgee in a bona fide transaction as collateral to secure obligations pursuant to lending or other arrangements between such third parties (or their affiliates or designees) and the lock-up party and/or its affiliates or any similar arrangement relating to a financing arrangement for the benefit of the lock-up party and/or its affiliates; and upon foreclosure of any such lending or other arrangements; (xiv)&#160;if the lock-up party is not our officer or director, in connection with a sale of the lock-up party&#8217;s shares of Class&#160;A common stock acquired (A)&#160;from the underwriters in this offering or (B)&#160;on the open market or in other transactions following this offering; or (xv)&#160;to the underwriters pursuant to the underwriting agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">263</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, notwithstanding the restrictions in the lock-up agreement, the lock-up party may make any demand or requests for, exercise any right with respect to, or take any action in preparation of, the registration by us under the Securities Act of the lock-up party&#8217;s lock-up securities or other securities; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that (i)&#160;no public filing with the Securities and Exchange Commission or any other public announcement may be made during the lock-up period in relation to such registration, (ii)&#160;the representatives must have received prior written notice from us and/or the lock-up party of a confidential submission of a registration statement with the Securities and Exchange Commission during the lock-up period at least five (5)&#160;business days prior to such submission and (iii)&#160;no lock-up securities or other securities of us may be sold, distributed or exchanged during the lock-up period. Notwithstanding the foregoing, the lock-up party also may establish trading plans pursuant to Rule&#160;10b5-1 under the Exchange Act for the transfer, sale or other disposition of lock-up securities, </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;"> that (1)&#160;none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the lock-up period and (2)&#160;no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the lock-up period, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate therein that none of the securities subject to such plan may be transferred, sold, or otherwise disposed pursuant to such plan until after the expiration of the lock-up period.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any director, officer, or shareholder of the Company is granted an early release from its obligations under any lock-up restrictions with respect to our securities in an aggregate amount in excess of one&#160;percent of our outstanding Class&#160;A common stock, then every other lock-up party automatically will be granted an equivalent early release from its obligations under their respective lock-up agreement on a pro&#160;rata basis, provided that such release shall not apply (i)&#160;if it is effected solely to permit a transfer not for consideration and the transferee has agreed in writing to be bound by the same terms described in the lock-up agreement to the extent and for the duration that such terms remain in effect at the time of the transfer and (ii)&#160;in the event of an underwritten public offering, except with respect to the lock-up party&#8217;s participation in such underwritten public offering, provided that the lock-up party shall be offered the opportunity to participate in such underwritten public offering in accordance with, and subject to, the terms of any rights agreement (including the Investors&#8217; Rights Agreement). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that (i)&#160;at least 150&#160;days have elapsed since the date of this prospectus and (ii)&#160;the end of the restricted period would fall during one of our quarterly blackout periods during which trading by certain of our employees in our securities would not be permitted under our insider trading policy then in effect (a &#8220;Blackout Period&#8221;), or within 10 trading days prior to such Blackout Period the restricted period shall end on the date that is the later of (a)&#160;10 trading days prior to the commencement of a Blackout Period and (b)&#160;the 150th day after the date of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect the shares of Class A common stock to be approved for listing on Nasdaq under the symbol &#8220;CAI.&#8221; In order to meet the requirements for listing on that exchange, the underwriters have undertaken to sell a minimum number of shares to a minimum number of beneficial owners as required by that exchange. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before this offering, there has been no public market for our Class A common stock. The initial public offering price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our financial information, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the history of, and the prospects for, our company and the industry in which we compete, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the present state of our development, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">264</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:36pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public market at or above the initial public offering price. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters do not expect to sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Price Stabilization, Short Positions and Penalty Bids</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling&#160;group members from bidding for and purchasing our Class A common stock. However, the representatives may engage in transactions that stabilize the price of the Class A common stock, such as bids or purchases to peg, fix, or maintain that price. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the offering, the underwriters may purchase and sell our Class A common stock in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering. &#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option to purchase additional shares of Class&#160;A common stock described above. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of Class A common stock or purchasing shares of Class&#160;A common stock in the open market. In determining the source of shares to close out the&#160;covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. &#8220;Naked&#8221; short sales are sales in excess of such option. The underwriters must close out any&#160;naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our Class A common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of Class A common stock made by the underwriters in the open market prior to the completion of the offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Similar to other purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our Class A common stock or preventing or retarding a decline in the market price of our Class A common stock. As a result, the price of our Class A common stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct&#160;these transactions on Nasdaq, in the over-the-counter market or otherwise. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our Class A common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Electronic Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as e-mail. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">265</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Wolfe | Nomura Alliance&#8221; is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura Securities International, Inc. and WR Securities, LLC are serving as underwriters in the offering described herein. In addition, WR Securities, LLC and certain of its affiliates may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reserved Share Program</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At our request, the underwriters have reserved up to &#8199;&#8199;&#8199;&#8199;% of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management. If these persons purchase reserved shares it will reduce the number of shares of Class A common stock available for sale to the general public. Any reserved shares of Class A common stock that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of Class A common stock offered by this prospectus. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Management will provide the list of potential participants to Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, which is an affiliate of BofA Securities, Inc., a participating underwriter, and which will administer the reserved shares program. At this time, no indications of interest will be taken. Once the preliminary prospectus has been filed, an invitation package will be made available or sent to each person identified by management, which will include the preliminary prospectus and other reserved share program documentation. An invitation to participate in the reserved share program does not guarantee that the participant will receive an allocation of Class A common stock. Accordingly, we cannot provide any assurance that any director, officer, employee, or participant will receive an invitation or an allocation in the reserved share program. If a potential participant is interested in participating, that participant will be required to complete the required documentation and will be required to return such documentation to the program administrator. The program administrator will not accept funds from any participant until after the registration statement for this offering is declared effective, this offering is priced, and the participants are notified of their final allocation and given an opportunity to confirm that they wish to purchase the shares of Class A common stock allocated to them. After the registration statement has been declared effective and this offering is priced, we and the program administrator will prepare a final approved list of allocations. The program administrator will notify each participant who has been allocated reserved shares of the number of shares of Class A common stock that have been allocated to them and the total purchase price due upon confirmation of their participation. Thereafter, participants will be required to wire or transfer their funds to the program administrator. The shares of Class A common stock under the reserved shares program will be allocated following pricing and settle in the same manner as the shares sold to the general public. If purchased by directors, officers or employees, these shares will be subject to a 180-day lock-up restriction described in this prospectus. If any potential participants purchase reserved shares, it will reduce the number of shares available for sale to the general public. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of Class A common stock offered hereby. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">European Economic Area</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In relation to each Member State of the European Economic Area (each a &#8220;Relevant State&#8221;), no shares have been offered or will be offered pursuant to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">266</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">a.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">b.</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent for any such offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">c.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within Article&#160;1(4) of the Prospectus Regulation, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the Prospectus Regulation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each person in a Relevant State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged, and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the case of any shares being offered to a financial intermediary as that term is used in Article&#160;5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements, and agreements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The above selling restriction is in addition to any other selling restrictions set out below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in the United Kingdom</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In relation to the United Kingdom (&#8220;UK&#8221;), no shares have been offered or will be offered pursuant to the public in the UK prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of shares may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">a.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">b.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent for any such offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">c.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at any time in other circumstances falling within section 86 of the FSMA, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Section&#160;85 of the FSMA or Article&#160;3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the UK Prospectus Regulation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each person in the UK who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged, and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">267</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the case of any shares being offered to a financial intermediary as that term is used in Article&#160;5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements, and agreements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, and the expression &#8220;FSMA&#8221; means the Financial Services and Markets Act 2000. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document is for distribution only to persons who (i)&#160;have professional experience in matters relating to investments and who qualify as investment professionals within the meaning of Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#8220;Financial Promotion Order&#8221;), (ii)&#160;are persons falling within Article&#160;49(2)(a) to (d)&#160;(&#8220;high net worth companies, unincorporated associations etc.&#8221;) of the Financial Promotion Order, (iii)&#160;are outside the United Kingdom, or (iv)&#160;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#8220;relevant persons&#8221;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Switzerland</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland. This&#160;document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or&#160;art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art.&#160;27&#160;ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#8220;CISA&#8221;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in the Dubai International Financial Centre</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (&#8220;DFSA&#8221;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">268</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Australia</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (&#8220;ASIC&#8221;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any offer in Australia of the shares may only be made to persons (the &#8220;Exempt Investors&#8221;) who are &#8220;sophisticated investors&#8221; &#8203;(within the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; &#8203;(within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12&#160;months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains general information only and does not take account of the investment objectives, financial situation, or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives, and circumstances, and, if necessary, seek expert advice on those matters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Hong Kong</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures&#160;Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap. 32) of Hong&#160;Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or&#160;may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Japan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#8220;Japanese Person&#8221; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Singapore</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or sold or caused to be made the subject of an invitation for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">269</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i)&#160;to an institutional investor (as defined in Section&#160;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&#160;274 of the SFA, (ii)&#160;to a relevant person (as defined in Section&#160;275(2) of the SFA) pursuant to Section&#160;275(1) of the SFA, or any person pursuant to Section&#160;275(1A) of the SFA, and in accordance with the conditions specified in Section&#160;275 of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Where the shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">securities or securities-based derivatives contracts (each term as defined in Section&#160;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&#160;275 of the SFA except: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">where no consideration is or will be given for the transfer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">where the transfer is by operation of law; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(d)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">as specified in Section&#160;276(7) of the SFA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Canada</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 </font><font style="font-style:italic;letter-spacing:0.2pt;">Prospectus Exemptions</font><font style="letter-spacing:0.2pt;"> or subsection&#160;73.3(1) of the </font><font style="font-style:italic;letter-spacing:0.2pt;">Securities Act</font><font style="letter-spacing:0.2pt;"> (Ontario), and are permitted clients, as defined in National Instrument 31-103 </font><font style="font-style:italic;letter-spacing:0.2pt;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font><font style="letter-spacing:0.2pt;">. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 </font><font style="font-style:italic;letter-spacing:0.2pt;">Underwriting Conflicts</font><font style="letter-spacing:0.2pt;"> (NI&#160;33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Brazil</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The offer and sale of the securities have not been and will not be registered with the Brazilian&#160;securities commission (Comiss&#227;o de Valores Mobili&#225;rios, or &#8220;CVM&#8221;) and, therefore, will not be carried out by any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">270</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:568pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">means that would constitute a public offering in Brazil under CVM resolution no 160, dated 13&#160;July&#160;2022, as amended (&#8220;CVM Resolution 160&#8221;) or unauthorized distribution under Brazilian laws and regulations. The securities may only be offered to Brazilian professional investors (as defined by applicable CVM regulation), who may only acquire the securities through a non-Brazilian account, with settlement outside Brazil in non-Brazilian currency. The trading of these securities on regulated securities markets in Brazil is prohibited. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">271</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:436pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the issuance of our Class A common stock offered in this prospectus will be passed upon for us by Latham &amp; Watkins LLP, New York, New York. Cooley LLP, New York, New York is representing the underwriters in this offering. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements as of and for the year ended December 31, 2024, included in this prospectus and elsewhere in the registration statement, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Ernst &amp; Young LLP, an independent registered public accounting firm, has audited our consolidated financial statements at December&#160;31, 2023 and for the&#160;year then ended as set forth in their&#160;report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst &amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">272</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCIRPAF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On July 17, 2024, we notified Ernst &amp; Young LLP (&#8220;EY&#8221;), which had served as our prior independent registered public accounting firm, of our intention to obtain proposals from other accounting firms to perform the audit of our consolidated financial statements as of and for the year ending December 31, 2024 (our &#8220;2024 Audit&#8221;). On July 24, 2024, EY notified the Company of its decision to decline to stand for re-election as our independent registered public accounting firm for our 2024 Audit. On September&#160;9, 2024, the audit committee of our board of directors approved the engagement of Deloitte &amp; Touche LLP (&#8220;Deloitte&#8221;) as our independent registered public accounting firm for our 2024 Audit, effective immediately.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The reports of EY on our consolidated financial statements as of December 31, 2023 and 2022, and for the years then ended, did not contain adverse opinions or disclaimers of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the years ended December 31, 2023 and 2022 and the subsequent interim period through July&#160;24, 2024, there were:</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">no &#8220;disagreements&#8221; &#8203;(as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of the disagreements in its report on our financial statements as of December 31, 2023 and 2022, and for the years then ended, and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">no &#8220;reportable events&#8221; &#8203;(as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto), other than the material weakness identified in our internal control over financial reporting, which pertained to the aggregation of several deficiencies reflecting ineffective control activities related to the incorrect application of generally accepted accounting principles. The audit committee of our board of directors discussed the above material weakness with EY. We have also authorized EY to respond fully to the inquiries of Deloitte concerning the subject matter of the material weakness.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We provided EY with a copy of the disclosure set forth in this section and requested that EY furnish us with a letter addressed to the SEC stating whether EY agrees with the statements made herein, each as required by applicable SEC rules. A copy of the letter, dated September&#160;12, 2024, furnished by EY in response to that request, is filed as Exhibit 16.1 to the registration statement of which this prospectus is a part.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the years ended December 31, 2023 and 2022 and the subsequent interim period through September&#160;9, 2024, when we engaged Deloitte, we did not consult with Deloitte with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, the type of audit opinion that might be rendered on our financial statements, and neither a written report nor oral advice was provided to us that Deloitte concluded was an important factor considered by us in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was the subject of a &#8220;disagreement&#8221; or a &#8220;reportable event&#8221; &#8203;(each as defined above). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">273</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:336pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of Class A common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules to the registration statement. Please refer to the registration statement and exhibits for further information with respect to the Class A common stock offered by this prospectus. Statements contained in this prospectus regarding the contents of any contract or other document are only summaries. With respect to any contract or document that is filed as an exhibit to the registration statement, you&#160;should refer to the exhibit for a copy of the contract or document, and each statement in this prospectus regarding that contract or document is qualified by reference to the exhibit. The SEC maintains an internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements and other information about us, are available at the SEC&#8217;s website, </font><font style="font-style:italic;letter-spacing:0.2pt;">www.sec.gov</font><font style="letter-spacing:0.2pt;">. The information on the SEC&#8217;s web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we will become subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, will be required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available on the website of the SEC referred to above. We also maintain a website at </font><font style="font-style:italic;letter-spacing:0.2pt;">carislifesciences.com</font><font style="letter-spacing:0.2pt;">, at which you may access these materials free of charge as soon as reasonably&#160;practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus. Investors should not rely on any such information in deciding whether to purchase our Class A common stock. We have included our website address in this prospectus solely as an inactive textual reference.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">274</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="tITFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:321.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Caris Life Sciences, Inc. and Subsidiaries</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:245.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:424pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Audited Consolidated Financial Statements </font>
                <br >
                <font style="letter-spacing:-0.2pt;">As of and for the Years Ended December&#160;31, 2024 and 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fROIR"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fROIR">F-2</a></font> <a href="#fROIR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCBS"><font style="letter-spacing:0.2pt;">Consolidated Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCBS">F-4</a></font> <a href="#fCBS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCSOO"><font style="letter-spacing:0.2pt;">Consolidated Statements of Operations and Comprehensive Loss </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCSOO">F-5</a></font> <a href="#fCSOO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCSOR"><font style="letter-spacing:0.2pt;">Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders&#8217; Deficit </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCSOR">F-6</a></font> <a href="#fCSOR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCSOC"><font style="letter-spacing:0.2pt;">Consolidated Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCSOC">F-7</a></font> <a href="#fCSOC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fNTCF2"><font style="letter-spacing:0.2pt;">Notes to the Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fNTCF2">F-8</a></font> <a href="#fNTCF2"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.2pt;">Unaudited Consolidated Financial Statements </font>
                <br >
                <font style="letter-spacing:-0.2pt;">As of and for the Three Months Ended March 31, 2025 and 2024</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCBS1"><font style="letter-spacing:0.2pt;">Condensed Consolidated Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCBS1">F-43</a></font> <a href="#fCBS1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCSOO1"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCSOO1">F-44</a></font> <a href="#fCSOO1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:424pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#fCSOR1"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders&#8217; Deficit </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCSOR1">F-45</a></font> <a href="#fCSOR1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fCSOC1"><font style="letter-spacing:0.2pt;">Condensed Consolidated Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fCSOC1">F-46</a></font> <a href="#fCSOC1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#fNTCF12"><font style="letter-spacing:0.2pt;">Notes to the Condensed Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#fNTCF12">F-47</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the shareholders and the Board of Directors of Caris Life Sciences, Inc. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying consolidated balance sheet of Caris Life Sciences, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2024, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and shareholders&#8217; deficit, and cash flows, for the year ended December&#160;31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024, and the results of its operations and its cash flows for the year ended December&#160;31, 2024, in conformity with accounting principles generally accepted in the United States of America. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Going Concern</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1 to the financial statements, the Company has redemptions in connection with the Series&#160;C preferred stock and debt payments in connection with the 2023 term loan and the 2025 convertible notes which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans in regard to these matters are also described in Note&#160;1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ Deloitte &amp; Touche LLP </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">San Jose, California </font> <br ><font style="letter-spacing:0.2pt;">April 4, 2025 </font></div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2024. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:138pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Shareholders and Board of Directors of Caris Life Sciences, Inc. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying consolidated balance sheet of Caris Life Sciences, Inc. (the&#160;Company) as of December&#160;31, 2023, the related consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and shareholders&#8217; deficit and cash flows for the&#160;year then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023, and the results of its operations and its cash flows for the&#160;year then ended in conformity with U.S. generally accepted accounting principles. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ Ernst &amp; Young LLP </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We served as the Company&#8217;s auditor from 2020 to 2024. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dallas, Texas</font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">March&#160;18, 2024</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">C</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">onsolidated Balance Sheets</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:7.30999999999995pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:7.05pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 1pt 0pt; width:344.26pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="border-bottom:1px solid #000000;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands, except share data) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:9.1pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">65,442</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">60,007</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,201</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">65,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">88,244</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">55,299</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">39,572</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">48,998</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">20,270</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">13,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">215,729</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">242,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">67,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">107,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Goodwill </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">19,344</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">19,344</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">40,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">43,856</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:-0.18pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">343,734</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">412,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Liabilities, Redeemable Convertible Preferred Stock, and Shareholders&#8217; Deficit</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">27,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">26,680</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accrued expenses and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">77,542</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">68,291</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Current portion of indebtedness </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">60,090</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">165,423</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">95,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Long-term indebtedness, net of debt discounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">319,438</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">166,421</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Warrant and derivative liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">91,642</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">116,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Other long-term liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">44,418</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">54,823</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">620,921</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">432,566</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Commitments and contingencies (see note 10) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Redeemable convertible preferred stock: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;A preferred stock. par value $0.001: 490,000,000 shares authorized as of December&#160;31, 2024 and December&#160;31, 2023; 485,795,293 shares issued and outstanding as of December&#160;31, 2024 and December&#160;31, 2023; and $296,335 aggregate liquidation preference as of December&#160;31, 2024 and December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;B preferred stock, par value $0.001: 30,000,000 shares authorized as of </font>
                <br >
                <font style="letter-spacing:0.18pt;">December&#160;31, 2024 and December&#160;31, 2023; 29,629,630 shares issued and </font>
                <br >
                <font style="letter-spacing:0.18pt;">outstanding as of December&#160;31, 2024 and December&#160;31, 2023; and $16,000 aggregate </font>
                <br >
                <font style="letter-spacing:0.18pt;">liquidation preference as of December&#160;31, 2024 and December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;C preferred stock, par value $0.001: 142,000,000 shares authorized as of </font>
                <br >
                <font style="letter-spacing:0.18pt;">December&#160;31, 2024 and December&#160;31, 2023; 116,200,835 shares issued and </font>
                <br >
                <font style="letter-spacing:0.18pt;">outstanding as of December&#160;31, 2024 and December&#160;31, 2023; and $408,715 and </font>
                <br >
                <font style="letter-spacing:0.18pt;">$381,908 aggregate liquidation preference as of December&#160;31, 2024 and December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.18pt;">2023, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">408,715</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">381,908</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt; margin-bottom:-0.503333333333343pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;D preferred stock, par value $0.001: 102,600,000 shares authorized as of </font>
                <br >
                <font style="letter-spacing:0.18pt;">December&#160;31, 2024 and December&#160;31, 2023; 102,516,283 shares issued and </font>
                <br >
                <font style="letter-spacing:0.18pt;">outstanding as of December&#160;31, 2024 and December&#160;31, 2023; and $1,060,712 and </font>
                <br >
                <font style="letter-spacing:0.18pt;">$996,458 aggregate liquidation preference as of December&#160;31, 2024 and December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.18pt;">2023, respectively </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">1,060,712</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">991,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,221,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,125,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Shareholders&#8217; deficit: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Common stock $0.001 par value; 1,150,000,000 shares authorized as of December&#160;31, </font>
                <br >
                <font style="letter-spacing:0.18pt;">2024 and December&#160;31, 2023; 146,747,083 and 145,790,960 shares issued as of </font>
                <br >
                <font style="letter-spacing:0.18pt;">December&#160;31, 2024 and December&#160;31, 2023, respectively; 146,017,083 and </font>
                <br >
                <font style="letter-spacing:0.18pt;">145,060,960 shares outstanding as of December&#160;31, 2024 and December&#160;31, 2023, </font>
                <br >
                <font style="letter-spacing:0.18pt;">respectively; shares issued and outstanding include 2,648,000 and 3,872,000 unvested </font>
                <br >
                <font style="letter-spacing:0.18pt;">shares subject to repurchase as of December&#160;31, 2024 and December&#160;31, 2023, </font>
                <br >
                <font style="letter-spacing:0.18pt;">respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">141</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Treasury stock at cost, 730,000 shares of common stock as of December&#160;31, 2024 and December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Related party promissory note receivable (see note 7) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(26,456<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(25,701<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,472,406<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,119,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">218</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total shareholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,498,838<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,144,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:344.26pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:-0.18pt;">Total liabilities, redeemable convertible preferred stock, and shareholders&#8217; deficit</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">343,734</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">412,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:9pt; margin-top:5.2pt; text-align:center; width:447pt; line-height:10.5pt;">
          <font style="letter-spacing:0.18pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCSOO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:66pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">C</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">onsolidated Statements of Operations and Comprehensive Loss</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:523pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:349.93pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands, except share and per share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">349,115</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">278,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">63,145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">27,380</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">412,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">306,128</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">223,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">207,509</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">10,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">9,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">152,602</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">142,925</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative expense (includes related party amounts of $1,869 and $2,061, for the&#160;years ended December&#160;31, 2024 and 2023, respectively) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">169,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">149,053</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">113,916</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">116,883</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total costs and operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">669,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">625,679</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(257,122<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(319,551<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">11,258</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(50,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(31,610<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">18,484</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">11,094</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(12,606<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total other expense, net</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(24,768<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(21,864<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss before income taxes and provision for income taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provision for income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other comprehensive (loss) income, net of tax: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Unrealized (loss) gain on available-for-sale securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(1,660<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign currency translation adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(15<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">180</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Comprehensive loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(281,898<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(342,895<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Net loss attributable to common shareholders: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments of redeemable convertible preferred stock to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(96,367<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(121,112<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss attributable to common shareholders</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(378,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(462,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(2.66<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(3.31<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">141,987</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">139,771</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCSOR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">C</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">onsolidated Statements of Redeemable Convertible Preferred Stock and Shareholders&#8217; Deficit</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:213.85pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:382.05pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
          <tr style="line-height:7.87pt;height:27.2pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:0pt 0pt 2.66pt 0pt; width:129.7pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:7.88pt; padding-bottom:0pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.14pt;">(amounts in thousands, except share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center; line-height:7.86pt;">
                <font style="letter-spacing:-0.14pt;">Redeemable Convertible </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Treasury Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.87pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.14pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Paid-In </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.87pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.14pt;">Related </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Party </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Promissory </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Note </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.87pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.14pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.87pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.14pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Comprehensive </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.66pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.87pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.14pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Shareholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;height:13.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.26pt 0pt 2.95pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.26pt 0pt 2.95pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.26pt 0pt 2.95pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.26pt 0pt 2.95pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.26pt 0pt 2.95pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.26pt 0pt 2.95pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:3.26pt 0pt 3.7pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.14pt;">Balances at December&#160;31, 2022</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">703,086,140</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,954,172</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">137,507,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">138</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">730,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">(24,969<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(1,678,650<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">1,698</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(1,702,113<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.98999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.767pt 0pt 2.383pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">15,241</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.767pt 0pt 2.383pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">15,241</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:129.7pt;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Issuance of common stock upon exercise of </font>
                <br >
                <font style="letter-spacing:0.14pt;">stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">2,457,143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">1,863</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">1,865</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:129.7pt;white-space:normal;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Interest income from related party promissory notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">(732<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(732<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:129.7pt;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Vesting of shares from early exercised stock </font>
                <br >
                <font style="letter-spacing:0.14pt;">options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">1,224,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">4,957</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">4,958</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:129.7pt;white-space:normal;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Adjustment of redeemable convertible preferred Series&#160;C and Series&#160;D to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">121,112</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">(21,899<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(99,213<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(121,112<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:129.7pt;white-space:normal;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Conversion of convertible note into Series&#160;C preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">31,055,901</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.98999999999998pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:3.517pt 0pt 2.383pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(1,480<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(1,480<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.98999999999998pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:3.517pt 0pt 2.383pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.517pt 0pt 2.383pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.52pt 0pt 2.95pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Foreign exchange gain </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">(162<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(162<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:3.27pt 0pt 3.7pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.14pt;">Balances at December&#160;31, 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,125,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">141,188,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">141</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">730,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">(25,701<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(2,119,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">218</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(2,144,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.98999999999998pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.777pt 0pt 2.373pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">18,643</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.777pt 0pt 2.373pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">18,643</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.593pt 0pt 0.5pt 0pt; width:129.7pt;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Issuance of common stock upon exercise of </font>
                <br >
                <font style="letter-spacing:0.14pt;">stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">956,123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">1,529</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">1,530</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.593pt 0pt 0.5pt 0pt; width:129.7pt;white-space:normal;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Interest income from related party promissory notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">(755<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(755<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.593pt 0pt 0.5pt 0pt; width:129.7pt;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt; line-height:8.38pt;">
                <font style="letter-spacing:0.14pt;">Vesting of shares from early exercised stock </font>
                <br >
                <font style="letter-spacing:0.14pt;">options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">1,224,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">4,958</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">4,960</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.39pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:2.593pt 0pt 0.5pt 0pt; width:129.7pt;white-space:normal;text-align:left;">
              <div style="margin-left:7pt; text-indent:-7pt;">
                <font style="letter-spacing:0.14pt;">Adjustment of redeemable convertible preferred Series&#160;C and Series&#160;D to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">96,367</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">(25,130<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(71,237<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.593pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(96,367<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:6.99000000000001pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:3.527pt 0pt 2.373pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.527pt 0pt 2.373pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.52pt 0pt 2.95pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.14pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.52pt 0pt 2.95pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="padding:3.28pt 0pt 3.7pt 0pt; width:129.7pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.14pt;">Balances at December&#160;31, 2024</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,221,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">143,369,083</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:4.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">730,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:10.5pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.465pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">(26,456<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(2,472,405<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:10.905pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.28pt 0pt 2.95pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">(2,498,837<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Consolidated Statements of Cash Flows</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:624.99pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:7.95pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 1.2pt 0pt; width:349.93pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:10.9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.95pt 0pt 1.2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.95pt 0pt 1.2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.95pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from operating activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.19pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.19pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.19pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">48,913</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">49,001</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.19pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">18,643</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.19pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15,241</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-cash operating lease expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,332</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of debt discounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,054</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,378</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(18,484<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(11,094<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loss on debt extinguishment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,915</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.18pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Others </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.18pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,329<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.17pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities:</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.17pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(33,816<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(15,081<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.17pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,459</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(4,435<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.17pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,408<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.17pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.16pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">121</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(588<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.16pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(226<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,171</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.16pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses and other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.16pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">803</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.16pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.16pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.91pt 0pt 0.75pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.91pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.91pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(245,199<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.91pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.91pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(276,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from investing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.15pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Maturities of marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">61,376</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">300,488</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.15pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Purchases of marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(63,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.15pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(8,444<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.15pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(22,319<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.9pt 0pt 0.75pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.9pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.9pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">52,932</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.9pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.9pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">214,774</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from financing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.14pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payments made on finance lease obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(157<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(743<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.14pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,530</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,865</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.14pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payment of deferred offering costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,059<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.13pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the 2023 term loan, net of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">199,978</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">191,310</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.13pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payment of third-party debt issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.13pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Repayment of the Original Term Loans </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.13pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(180,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.88pt 0pt 0.75pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.88pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.88pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">200,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.88pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.88pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">10,132</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">62</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.87pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net decrease in cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.87pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.87pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,021</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.87pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.87pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(51,132<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.12pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash at beginning of year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.12pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.12pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">60,007</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.12pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.12pt 0pt 1.2pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">111,139</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.87pt 0pt 0.75pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash at end of year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.87pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.87pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">68,028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.87pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.87pt 0pt 1.2pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">60,007</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of cash flow information</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.11pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">49,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15,776</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.11pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of non-cash activity</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.11pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash paid for amounts included in the measurement of lease liabilities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.11pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating cash flow used for operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,297</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.11pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,062</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating cash flow used for finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">78</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Financing cash flow used for finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">157</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">743</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment included in accounts payable and accrued liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,052</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred offering costs, accrued but not yet paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,266</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">254</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.1pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of convertible debt to Series&#160;C Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">50,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.09pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Lease liabilities arising from obtained right-of-use-assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.09pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">725</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.09pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.09pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fNTCF2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 1. Nature of the Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Caris Life Sciences, Inc. (the &#8220;Company&#8221; or &#8220;Caris&#8221;) is a patient-centric, next-generation artificial intelligence (&#8220;AI&#8221;) TechBio company and precision medicine pioneer. The Company commercializes and develops innovative solutions to transform healthcare through the use of comprehensive molecular information, and machine learning (&#8220;ML&#8221;) algorithms. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s current molecular profiling services portfolio is focused on oncology and consists of MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a novel, universal blood-based molecular profiling solution, with the aim to address the entire continuum of cancer treatment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company also collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company was incorporated under the laws of the Cayman Islands in November&#160;2011 (Caris Life Sciences, Ltd.) and re-domiciled to be incorporated in Texas in July&#160;2020 (Caris Life Sciences, Inc.) and is headquartered in Irving, Texas. The Company also has locations in Phoenix, Arizona; New York, New&#160;York; Cambridge, Massachusetts; Basel, Switzerland; and Tokyo, Japan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Going Concern</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December 31, 2024, the Company&#8217;s cash balance was approximately $64.0 million, and the short-term investments balance was $2.2 million, and the Company has a 2023 Term Loan (see Note 8) outstanding with a balance of $400.0 million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In 2025, the Company issued the 2025 Convertible Notes (see Note 15), in the amount of $30.0 million. In connection with the Company&#8217;s Series&#160;C redeemable convertible preferred stock, the 2023 Term Loan and the 2025 Convertible Notes, the following payments may become due within 12 months of the date of the issuance of the consolidated financial statements if, the Company has not completed an initial public offering raising at least $100.0 million in gross proceeds prior to such date: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Series&#160;C redemption rights will become exercisable on March&#160;31, 2026; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Company will be required to make a one-time acceleration payment on December 31, 2025 (see Note 15) in an amount equal to 15% of the outstanding principal amount under the 2023 Term Loan (or $60.0 million based on the principal amount currently outstanding) together with any applicable repayment premium and exit fee as described in the Term Loan agreement on such date; and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The 2025 Convertible Notes of $30.0 million will come due on January 1, 2026.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If these payments become due, the Company&#8217;s existing cash resources and projected operating cash flows may not be sufficient to repay these amounts and continue to fund operating activities for at least the next 12 months from the issuance of the consolidated financial statements. These conditions raise substantial doubt as to the Company&#8217;s ability to continue as a going concern. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Management intends to raise additional funding through an initial public offering raising at least $100.0 million in gross proceeds which would eliminate the requirement to make the one-time acceleration payment related to the 2023 Term Loan. Further, the initial public offering would cause the Series&#160;C redeemable convertible preferred stock and the 2025 Convertible Note to convert to common stock and thereby not be subject to redemption and repayment upon maturity on March&#160;31, 2026 and January&#160;1, 2026, respectively. Management may seek alternative private financing through additional debt or equity offerings that will fulfill its operating, capital and debt requirements for at least 12 months from the date of the issuance of the consolidated financial statements. However, the Company may not be able to complete such an initial public offering or otherwise secure such financing in a timely manner or on favorable terms, if at all.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2. Summary of Significant Accounting Policies and Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Financial Statement Presentation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements include the accounts of Caris and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preparation of the consolidated financial statements in conformity with GAAP in the United States requires the use of estimates and assumptions about future events that affect the amounts reported in the Company&#8217;s consolidated financial statements and related notes, including the amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods reported. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Significant estimates and assumptions are used for, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">revenue recognition </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fair value of stock-based awards and common stock </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fair value of financial assets and liabilities </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Future events and their effects cannot be predicted with certainty. Accordingly, the accounting estimates require the exercise of judgment. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. The accounting estimates used in the preparation of the Company&#8217;s consolidated financial statements may change as new events occur, additional information is obtained, and the operating environment changes. The Company will evaluate and update the assumptions and estimates on an ongoing basis and may employ outside experts to assist in its evaluation, as considered necessary. Actual results could materially differ from those estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reclassifications</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the preparation of the financial statements for the year ended December&#160;31, 2024, a reclassification was made to the prior period&#8217;s financial statements to conform to the current period&#8217;s presentation. This reclassification has no impact on previously reported net income attributable to common shareholders, total assets, or total liabilities. The details of the reclassifications is as follows: </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cost of services was previously included under the caption &#8220;Cost of services&#8221; in the Consolidated Statement of Operations and Comprehensive Loss. Cost of services is now presented separately as Cost of services&#8212;Molecular profiling services and Cost of services&#8212;Pharma research and development services. The reason for the reclassification is to provide a clearer presentation of the Company&#8217;s operating expenses and enhance comparability with industry peers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash, Cash Equivalents, and Restricted Cash</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less from date of acquisition to be cash equivalents. Refer to Note 4 for information on the Company&#8217;s restricted cash. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Marketable Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company classifies its marketable securities, which mainly consist of high-grade U.S. treasury bills, as available-for-sale. High-grade U.S. Treasury Bills with original maturities from date of acquisition between three and twelve&#160;months from the balance sheet dates are classified as short-term marketable securities, while those with maturities over twelve&#160;months from the balance sheet dates are classified as long-term marketable securities. The Company records all marketable securities at fair value, with changes reflected within unrealized gain or loss on available-for-sale securities on the consolidated statements of operations and comprehensive loss. The cost of short-term investments is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in interest income. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Transactions and Translation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s operating international subsidiaries, Caris Life Sciences Switzerland Holdings GmbH and Caris K.K., use their respective local currencies as their functional currencies. Assets and liabilities for operations in local currency environments are translated to U.S. dollars at exchange rates on the last day of the reporting period. Income and expense items are translated at average rates of exchange prevailing during the reporting period. Transactions denominated in currencies other than the functional currency are remeasured based on the exchange rates at the time of the transaction. Cumulative translation adjustments are recorded as a component of accumulated other comprehensive loss. Transaction and translation gains and losses arising from intercompany balances are reported as a component of net loss and presented within the consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Revenue is recognized when control of goods and services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ASC 606 provides for a five-step model that includes: </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Step 1: Identify the contract(s) with a customer. </font> <br ><font style="letter-spacing:0.2pt;">Step 2: Identify performance obligations in the contract. </font> <br ><font style="letter-spacing:0.2pt;">Step 3: Determine the transaction price. </font> <br ><font style="letter-spacing:0.2pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font><br ><font style="letter-spacing:0.2pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company derives revenue from two distinct channels: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Molecular profiling services involving the provision of precision oncology solutions utilizing MI Profile and Caris Assure. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Pharma research and development services involving delivery of laboratory, strategic data, and research services to biopharmaceutical customers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the majority of its molecular profiling services, the Company recognizes revenue from the sale of its precision oncology solutions, provided to customers, including certain hospitals, institutions and patients, at the point in time when the results of the profiling services are delivered to ordering physicians. Most cases requested on behalf of customers are provided without a written agreement; however, the Company determines that an implied contract exists with its customers for whom a physician orders the case. Results from molecular profiling services are delivered via fax, electronically, or in hard copy. Shipping and handling activities are considered fulfillment activities and as such, amounts incurred are recorded within Cost of services&#8212;Molecular profiling services on the consolidated statements of operations and comprehensive loss. The Company identifies each sale of the Company&#8217;s profiling service as a distinct performance obligation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(&#8220;contract basis&#8221;). Payment terms are a function of a patient&#8217;s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing. Occasionally, payers may recoup or we may refund consideration, mainly as a result of claim processing.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The total consideration to which the Company expects to be entitled in exchange for the Company&#8217;s services may be fixed or variable. Consideration includes reimbursement from patients, hospitals, and third-party commercial and governmental payers, such as insurance companies, adjusted for variable consideration related to implicit price concessions that the Company may grant. The Company estimates the variable consideration under a portfolio approach for third-party payers, hospitals and patients with similar reimbursement characteristics. This includes analysis of an average reimbursement per case per portfolio and a percentage of cases reimbursed by considering the historical reimbursement data (including any refunds and recoupments) from such third-party payers, hospitals and patients. Specifically, the Company calculates the historical average reimbursement rates for each portfolio and applies an estimated reimbursement rate, based on historical trends, to the number of cases delivered each period. The period for which historical data is drawn upon is determined on a by- portfolio basis for each payer group, taking into consideration the average collection period. Additionally, the estimate also considers current contractual and statutory requirements, patient insurance eligibility and payer reimbursement contracts, and any known current or anticipated reimbursement trends not reflected in the historical data and only recognizes revenue for variable consideration that the Company determines is probable will not result in a significant reversal in the future. The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Subsequent changes to the estimate of the transaction price are recorded as adjustments to molecular profiling services revenue in the period where such changes occur. Both the estimate and any subsequent revision are uncertain and require the use of management&#8217;s judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the remaining portion of its molecular profiling services, the Company has determined that collectability of the consideration to which it expects to be entitled is not probable, and thus does not recognize revenue for such services until it has provided the services to the customer and received nonrefundable consideration from the customer in exchange for the services (&#8220;non-contract basis&#8221;). The Company continually reassesses the likelihood of collection for these types of services. If collectability is deemed probable prior to receipt of consideration, then the Company recognizes revenue at the point in time that collection is deemed probable. For the&#160;year ended December&#160;31, 2023, the Company recorded $4.4&#160;million of revenue related to the transition of payers from non-contract basis to contract basis. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2024, all payers were on the contract basis. Molecular profiling services revenue recognized by contract type for the&#160;years ended December&#160;31, 2024 and 2023 was as follows: </font>
        </div>
        <table style="width:384pt;height:81pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:284.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:284.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:284.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services&#8212;contract basis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">349,115</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">240,119</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:284.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services&#8212;non-contract basis </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">38,629</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:284.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total molecular profiling services revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">349,115</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">278,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.81pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as molecular profiling services, pharma research and development services, and strategic data services. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">customers for proper revenue recognition, including whether services are capable of being distinct and considered distinct within the context of the contract. The performance obligations for biopharmaceutical customers vary by contract. Such contracts may include a performance obligation to provide molecular profiling services, to facilitate the development and regulatory approval of drugs, or to provide target discovery services. Under those contracts, the Company receives payments upon the achievement of milestones, as well as provision of on-going support. The transaction price of the development services contracts may include variable consideration, due to the uncertainty associated with the achievement of the milestones. In making the assessment of whether variable consideration should be included in the transaction price, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The Company recognizes pharma research and development services revenue over the period in which biopharmaceutical research and development services are provided. Depending on the nature of the service, the Company recognizes revenue using either the output or input method to measure progress, whichever provides a more faithful depiction of the transfer of goods or services. Use of an output method or input method to depict the transfer of services generally does not result in a material difference with respect to the timing of revenue recognition because most services commence and end within the same reporting period. A constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Standalone Selling Price</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company determines standalone selling prices by considering the historical selling prices of its performance obligations in similar transactions, where applicable, as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing from other vendors, industry publications, current pricing practices and management estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contract Balances</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period the Company delivers goods or provides services, or when the right to consideration is unconditional. In situations where revenue recognition occurs before invoicing, an unbilled receivable is created, which represents a contract asset. As of December&#160;31, 2024 and 2023, the unbilled receivable balance was $4.6 million and $6.6&#160;million, respectively, which is included in accounts receivable on the consolidated balance sheets. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes contract liabilities primarily related to payments received in advance of satisfaction of performance obligations from contracts with customers. Contract liabilities are relieved as the Company fulfills its obligations under the contract and revenue is recognized. As of December&#160;31, 2024 and 2023, the contract liability balance was $7.5 million and $6.2&#160;million, respectively, which is included in accrued expenses and other current liabilities on the consolidated balance sheets. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the changes in the contract liabilities during the period: </font>
        </div>
        <table style="width:416pt;height:108pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:327.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,190</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:327.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase in contract liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,816</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:327.78pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Revenue recognized during the period that was included in deferred revenues </font>
                <br >
                <font style="letter-spacing:0.2pt;">at the beginning of the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(5,406<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 0.5pt 0pt; width:327.78pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Revenue recognized from performance obligations satisfied within the same period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(6,130<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:327.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,470</td>
            <td style="padding:0pt;padding-left:21.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The amount of revenue recognized during the year ended December&#160;31, 2023 pertaining to amounts deferred as of December&#160;31, 2022 was $0.7&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Transaction Price Allocated to Remaining Performance Obligations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods and excludes performance obligations that are subject to cancellation terms. The Company has elected not to disclose information regarding the transaction price allocated to the remaining performance obligations for which the original expected duration of the contract is one year or less. The amount of transaction price allocated to the remaining performance obligations for contracts with original expected duration over one year as of December&#160;31, 2024 and 2023 was $5.8 million and $5.6&#160;million, respectively. The Company expects to recognize the amounts within twelve&#160;months from the respective balance sheet dates. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, for the&#160;years ended December&#160;31, 2024 and 2023, the Company recorded $3.9 million and $(1.9) million of adjustments to revenue related to services delivered in prior periods, which is based on variability that was subsequently resolved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Practical Expedients and Contract Costs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Payment terms and conditions vary by contract and customer. In instances where the timing of the Company&#8217;s revenue recognition differs from the timing of its invoicing, the Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised services to the customer will be one year or less. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a practical expedient, the Company recognizes the incremental costs of obtaining contracts, such as sales commissions, as expenses when incurred, if the amortization period of the asset that the Company otherwise would have recognized for the capitalized costs is one year or less. Sales commissions are recorded within selling and marketing expense on the consolidated statements of operations and comprehensive loss. The Company did not capitalize any sales commissions or contract fulfillment costs for the&#160;years ended December&#160;31, 2024 and 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Collaboration agreements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is party to various collaboration and licensing agreements under which the Company out-licenses certain know-how and molecular data. The collaboration arrangements are intended to solidify the Company&#8217;s third-party partnerships to align oncology capabilities and create industry-leading molecular oncology research platforms to accelerate drug development and novel research. Under these collaboration arrangements, the Company generally receives a split of fees from its collaborative partners that are earned pursuant to statements of work (&#8220;SOWs&#8221;) executed with end users of the Company&#8217;s licensed molecular data. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s collaboration and licensing agreements are within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) and ASC 606 because the counterparty to these agreements meets the definition of a customer. As such, the Company recognizes revenue earned from the licenses of molecular data granted to the Company&#8217;s collaborative partners in accordance with ASC 606. Each license of molecular data granted by the Company to a collaborative partner represents a distinct performance obligation in the contract. The transaction price for a given arrangement is entirely variable and depends on the SOWs executed by the counterparty with end users. The amount of revenue allocated to each license is equal to the amount of revenue to which the Company expects to be entitled. The Company recognizes revenue at the point in time that it delivers the molecular data to the third-party collaborative partner. For the&#160;years ended December&#160;31, 2024 and 2023, the Company recognized collaboration revenue of $16.2&#160;million and $5.8&#160;million, respectively, which is included in revenue from pharma research and development services on the consolidated statements of operations and comprehensive loss. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of services&#8212;Molecular profiling services</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services for molecular profiling services generally consists of cost of materials, direct labor including bonus and stock-based compensation, and equipment maintenance and depreciation&#160;expenses associated with processing cases (including accessioning, sequencing, quality control analyses and shipping charges to transport tissue samples), freight and profile results for ordering physicians. Costs associated with completing the molecular profiling services are recorded as the service is performed, regardless of when revenue is recognized with respect to the service. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of services&#8212;Pharma research and development services</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services for pharma research and development services generally consists of cost incurred for the performance of the services requested by the Company&#8217;s biopharmaceutical customers related to the delivery of laboratory, strategic data and research services, and will vary depending on the nature, timing, and scope of customer projects. Costs associated with delivery pharma research and development services are recorded as incurred. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of Credit Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash primarily with domestic financial institutions of high credit quality, with balances that exceed amounts insured by the Federal Deposit Insurance Corporation as of December&#160;31, 2024 and 2023, respectively. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company invests in treasury bills issued by the U.S. Government. U.S. treasury bills with original maturities of three&#160;months or less are classified within cash equivalents. Short-term marketable securities are comprised of U.S. treasury bills with original maturities between three and twelve&#160;months. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions. The goal of the Company&#8217;s investment policy is to ensure safety and preservation of the principal balance, and diversification of risk over cash balances held on deposit. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arise from the provision of molecular profiling services and pharma research and development services and other, primarily with biopharmaceutical companies, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any. Concentrations of credit risk are limited due to the number of payers and their dispersion across multiple geographic regions.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the years ended December 31, 2024 and 2023, the Company&#39;s revenues were primarily derived from the sale of the Caris molecular profiling services. As discussed above, payment terms of the services are a function of a patient&#8217;s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Revenue associated with each payer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue for the respective period, and accounts receivable balance attributable to each payer, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance at the respective consolidated balance sheet date, are as follows: </font>
        </div>
        <table style="width:456pt;height:76pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:278.72pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">% Revenue for the&#160;years </font>
                <br >
                <font style="letter-spacing:-0.16pt;">ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">% Accounts receivable </font>
                <br >
                <font style="letter-spacing:-0.16pt;">as of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:278.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Major Payer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:278.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payer 1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">33.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">35.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">16.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">18.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:278.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payer 2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">20.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:278.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payer 3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">14.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">14.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">19.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:6.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:20.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents major payers below 10.0%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, as of December&#160;31, 2024, one biopharmaceutical customer represented 22.3% of total accounts receivable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accounts Receivable</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Accounts receivable includes billed and unbilled receivables, net of an allowance for expected credit losses. Accounts receivable primarily represent receivables from biopharmaceutical customers and third-party payers. Accounts receivable for pharmaceutical services are established based on the amounts outstanding per the contractual arrangements with biopharmaceutical customers. The Company applies the current expected credit loss standard in ASC Subtopic 326-20, </font><font style="font-style:italic;letter-spacing:0.2pt;">Financial Instruments&#8212;Credit Losses</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 326-20&#8221;) and reserves a portion of the accounts receivable based on assessment of the collectability of customer accounts at the time of revenue recognition. The Company regularly reviews the reserve by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Receivables deemed to be uncollectible are written-off against the allowance for credit losses at the time such receivables are deemed to be uncollectible under a specific identification or estimated method. Recoveries of accounts receivable previously written off are recorded when received. As of December&#160;31, 2024 and 2023, the Company had an immaterial allowance for credit losses related to its accounts receivable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Supplies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Supplies consist primarily of laboratory items and reagents used by the Company in providing services. All supplies are raw materials and are stated at the lower of cost or net realizable value on a first-in, first-out basis. The Company periodically reviews its supplies for excess or obsolescence and writes down obsolete or otherwise unmarketable supplies to their estimated net realizable value. For the&#160;years ended December&#160;31, 2024 and 2023, the amount of write downs associated with the Company&#8217;s supplies was immaterial. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Deferred Offering Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company&#8217;s proposed initial public offering (&#8220;IPO&#8221;). These costs are recorded as prepaid expenses and other current assets on the consolidated balance sheets. The deferred offering costs will be recorded against IPO proceeds upon the consummation of the IPO. In the event the planned IPO is terminated, the deferred offering costs will be expensed. The Company had $4.5&#160;million of deferred offering costs as of December&#160;31, 2024. Deferred offering costs were not material as of December&#160;31, 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment, Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company reports property and equipment at cost, net of accumulated depreciation, amortization, and any asset impairments. The cost of properties held under finance leases is equal to the present value of lease payments not yet paid, adjusted for initial direct costs, prepaid lease payments and lease incentives received. Major improvements which add to productive capacity or extend the life of an asset are capitalized. Normal repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is reflected in the accompanying consolidated statements of operations and comprehensive loss for the period. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation and amortization expenses are calculated on a straight-line basis and applied to asset classes based upon the Company&#8217;s estimate of the asset class&#8217;s useful life, as summarized below: </font>
        </div>
        <table style="width:384pt;height:98.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186.87pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Estimated Useful Life </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment and software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aircraft </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">7&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements/leased buildings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Lesser of remaining lease term or useful life </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leased equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Lesser of initial lease term or 5&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Computer equipment and software includes the purchases of hardware, software and capitalized labor costs associated with internally developed software. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company capitalizes purchased software which is ready-for-service and capitalizes qualifying internal software development costs incurred on significant projects. Capitalization of costs begins when two criteria are met: (1)&#160;the preliminary project stage is completed, management with relevant authority authorizes and commits to funding the software project, and (2)&#160;it is probable that the software will be completed and used for its intended function. Capitalization ceases when the software is substantially complete and ready for its intended use, including the completion of all significant testing. Costs related to preliminary project activities and post-implementation operating activities are expensed as incurred. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Capitalized software costs are included in property and equipment, net. These costs are amortized using the straight-line method over the estimated useful life of the underlying software, which is three&#160;years. The Company capitalized $1.1 million and $3.3&#160;million in development costs for internal use software for the&#160;years ended December&#160;31, 2024 and 2023, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is a lessee for various types of property and equipment. The Company determines if an arrangement is or contains a lease at inception by evaluating whether the contract contains an identified asset that the Company has the right to control the use of throughout the contract term. Lease classification as either an operating or finance lease is determined at the lease commencement date when the leased assets are made available for use. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon lease commencement, the Company recognizes a lease liability and right-of-use (&#8220;ROU&#8221;) asset. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, regardless of whether the lease is an operating or finance lease. Lease payments consist primarily of fixed payments under the arrangement, less tenant incentives, if any. For each lease, the Company first assesses&#160;whether the rate implicit in the lease is readily determinable. When the rate implicit in the lease is not readily determinable, the Company uses an estimate of its incremental borrowing rate (&#8220;IBR&#8221;) based on the information available at the lease commencement date in determining the present value of lease payments. In determining the appropriate IBR, the Company considers information including, but not limited to, its credit rating, the lease term, collateral and the currency in which the arrangement is denominated. ROU assets are measured based on the corresponding lease liability adjusted for (i)&#160;prepayments made to the lessor at or before the commencement date, (ii)&#160;initial direct costs the Company incurs, and (iii)&#160;tenant incentives under the lease. Certain of the Company&#8217;s leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with recognizing and measuring the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. Amortization expense for finance leases is recognized on a straight-line basis over the lease term, and interest expense for finance leases is recognized using the effective interest method. The Company presents operating lease payments within cash flows from operating activities on the consolidated statements of cash flows. The Company presents finance lease payments related to principal amounts within cash flows from financing activities and finance lease payments related to the interest on the lease liability within cash flows from operating activities on the consolidated statements of cash flows. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The presentation of the Company&#8217;s leases on the consolidated balance sheets depends on whether the lease is classified as an operating or finance lease. Operating lease ROU assets are included within other assets, the current portion of operating lease liabilities are included within accrued expenses and other current liabilities, and the long-term operating lease liabilities are included within other long-term liabilities. Finance lease ROU assets are included in property and equipment, net, the current portion of finance lease liabilities are included within current portion of notes payable, and long-term finance lease liabilities are included within long-term indebtedness, net of discounts. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company elected the practical expedient to not separate lease and non-lease components for its leases. The Company does not record leases on the consolidated balance sheet that have a lease term of twelve&#160;months or less at the lease commencement date. Refer to Note 9 for additional disclosures related to the Company&#8217;s lease arrangements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant Liability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2020, the Company issued warrants and amended its outstanding warrants to include a provision to allow the purchase of either common stock or its Series&#160;C redeemable convertible preferred stock upon exercise. Because the warrants may be exercised for shares of the Company&#8217;s Series&#160;C redeemable convertible preferred stock, the warrants are classified as a liability pursuant to the guidance in ASC Topic 480, </font><font style="font-style:italic;letter-spacing:0.2pt;">Distinguishing Liabilities from Equity</font><font style="letter-spacing:0.2pt;">. The Company recognizes the liability associated with outstanding warrants within warrant and derivative liabilities on the consolidated balance sheets. The warrant liability is adjusted to fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company. Changes in fair value of the warrant liability are reported within changes in fair value of financial instruments on the consolidated statements of operations and comprehensive loss. Refer to Note 8 for additional information about the warrant liability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value Measurements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The basis for these assumptions establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Level&#160;1&#8212;</font><font style="letter-spacing:0.2pt;">Observable inputs such as quoted prices in active markets for identical assets and liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Level&#160;2</font><font style="letter-spacing:0.2pt;">&#8212;Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Level&#160;3</font><font style="letter-spacing:0.2pt;">&#8212;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Market approach</font><font style="letter-spacing:0.2pt;">&#8212;Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:10pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:10pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Cost approach</font><font style="letter-spacing:0.2pt;">&#8212;Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Income approach</font><font style="letter-spacing:0.2pt;">&#8212;Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments consist of cash, cash equivalents, restricted cash, short-term marketable securities, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities, debt (see Note 8), warrants, and derivative instruments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2024 and 2023, the carrying amounts of the Company&#8217;s cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair value based on the short-term nature of these items. There were no transfers between Levels 1, 2 or 3 for the years ended December 31, 2024 and 2023.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: </font>
        </div>
        <table style="width:456pt;height:110.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 1pt 0pt; width:289.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:289.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financial assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,201</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,201</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Financial liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">91,642</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">91,642</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,058</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,058</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:110.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:284.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:284.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.5pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financial assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">65,184</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">65,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.5pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financial liabilities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">98,733</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">98,733</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,451</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,451</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.19pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Short-term marketable securities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s short-term marketable securities, which have maturities of less than one year, are mainly comprised of U.S. treasury bills which have observable quoted prices. There were no outstanding U.S. Treasury Bills as of December 31, 2024. The following is a summary of the Company&#8217;s available-for-sale securities as of December 31, 2023: </font>
        </div>
        <table style="width:456pt;height:68.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:266.97pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:31.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amortized</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Cost </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Gross</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unrealized</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Gain </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Gross</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unrealized</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(Loss) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Estimated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:266.97pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:266.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">U.S. treasury bills </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.06pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">63,099</td>
            <td style="padding:0pt;padding-left:1.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:12.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">63,092</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrant liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company utilized a probability-weighted scenario approach factoring in various exit strategies and the related timing of such to estimate the fair value of its warrant liability. For each scenario, the Company utilized a Black-Scholes option pricing model with the following assumptions: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair value per share of the underlying stock&#8212;</font><font style="letter-spacing:0.2pt;">The fair value of the underlying stock represents the fair value of the Company&#8217;s Series&#160;C preferred stock that the warrants are convertible into. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Volatility&#8212;</font><font style="letter-spacing:0.2pt;">The volatility is derived from historical volatilities of several unrelated publicly-listed peer companies, since the Company has no trading history. When making the selections of industry peer companies to be used in the volatility calculation, the Company considers the size, operational and economic similarities to the Company&#8217;s principal business operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-free interest rate&#8212;</font><font style="letter-spacing:0.2pt;">The risk-free interest rate is based on U.S. treasury yield as of the measurement dates interpolated to match the maturity equal to the respective term to exit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividend yield&#8212;</font><font style="letter-spacing:0.2pt;">The expected dividend assumption is based on the Company&#8217;s current expectations about the Company&#8217;s anticipated dividend policy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected term (years)&#8212;</font><font style="letter-spacing:0.2pt;">Based on expected term under various exit strategies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The below table summarizes the significant unobservable inputs used in the fair value measurement of the warrant liability as of December&#160;31, 2024 and 2023: </font>
        </div>
        <table style="width:456pt;height:119.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.69pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.69pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.69pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2018 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:57.7pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2018 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:203.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value per share of the underlying stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$3.66&#8211;$5.65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$3.66&#8211;$5.65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:57.7pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$2.97&#8211;$8.14 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$2.97&#8211;$8.14 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">47.6%&#8211;63.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">61.2%&#8211;63.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.7pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">43.0% -55.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">50.0%&#8211;55.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.2%&#8211;4.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.7pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.4%&#8211;5.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.0%&#8211;5.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.7pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.29&#8211;0.75 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.29&#8211;2.25 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:57.7pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.5&#8211;1.72 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.5&#8211;3.25</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Derivative liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;18, 2023, the Company entered into a credit agreement (the &#8220;New Term Loan Agreement&#8221;) under which the Company issued senior, secured promissory notes (the &#8220;2023 Term Loan&#8221;) by which the New Term Loan lenders agreed to lend the Company up to an aggregate principal amount of $400.0&#160;million, $200.0&#160;million of which was received by the Company upon issuance. The Company identified certain embedded features in the 2023 Term Loan, including various contingent prepayment, compensatory payment, and default interest rate features, that are required to be bifurcated from the 2023 Term Loan and separately accounted for in the consolidated financial statements as a compound derivative liability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Fair value of the derivative liability was estimated using the discounted cash flow method under the income approach. This approach involves significant Level&#160;3 inputs and assumptions including an estimated probability and timing of certain contingent events, such as events of default, change of control, sale of assets, etc. The analysis also required the selection of a discount rate representative of the Company&#8217;s credit risk. The discount rate used for the initial fair value was calibrated to the transaction. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The initial fair value of the derivative liability was $28.3&#160;million at the inception date of January&#160;18, 2023. As of December&#160;31, 2023, the fair value of the embedded derivative liability was $17.5&#160;million, resulting in a remeasurement gain of $10.8&#160;million reported within changes in fair value of financial instruments in the consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Refer to Note 8 for additional information about the compound embedded derivative liability. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Debt</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December 31, 2024, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $380.9 million, compared to a carrying value of $373.1 million. As of December&#160;31, 2023, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $176.1&#160;million, compared to a carrying value of $166.1&#160;million. The Company estimated the fair value of the 2023 Term Loan as of December&#160;31, 2024 based on a discounted cash flow analysis, and an income approach, which represented the use of Level&#160;3 inputs in the fair value hierarchy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Goodwill</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities acquired through a business combination. The Company evaluates goodwill for impairment in accordance with ASC Topic 350, </font><font style="font-style:italic;letter-spacing:0.2pt;">Intangibles&#8212;Goodwill and Other</font><font style="letter-spacing:0.2pt;"> on an annual basis on October&#160;1, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, or the Company may determine to proceed directly to the quantitative impairment test. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Company assesses qualitative factors and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount or if the Company determines not to use the qualitative assessment, then a quantitative impairment test is performed. The factors utilized in the qualitative assessment include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and Company-specific events. The quantitative impairment test requires comparing the fair value of the reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is determined based on the present value of estimated cash flows using available information regarding expected cash flows of each reporting unit, discount rates, and the expected long-term cash flow growth rates. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has identified that its business operates as a single operating segment which is also a single reporting unit for purposes of testing goodwill for impairment. An impairment exists if the fair value of the reporting unit is lower than its carrying value. If the fair value of the reporting unit is lower than its carrying value, the Company would record an impairment loss equal to the excess of the reporting unit&#8217;s carrying value over its fair value. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no impairment losses for the&#160;years ended December&#160;31, 2024 and 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities. The costs include direct costs for salaries and benefits, materials, contract services and other outside costs, and costs to acquire in-process research and development projects and technologies that have no alternative future use. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advertising</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company expenses advertising costs as incurred. The Company incurred advertising costs of $1.2 million and $0.6&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Self-Insurance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company offers medical insurance coverage to eligible employees under a self-insured program managed by a third-party administrator, leveraging stop-loss insurance policies to mitigate risk. The Company records an estimate of its liability for medical claims, which includes the incurred claims amount plus an estimate of incurred, but not reported claims. Self-insurance liability of $1.9 million and $1.8&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively, is included within accrued expenses and other current liabilities on the consolidated balance sheets. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comprehensive Loss</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Comprehensive loss consists of net loss, unrealized gains on available-for-sale securities, foreign currency translation adjustments and gains affecting shareholders&#8217; deficit that under GAAP are excluded from net income or loss. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, </font><font style="font-style:italic;letter-spacing:0.2pt;">Compensation&#8212;Stock Compensation</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 718&#8221;). Stock-based compensation expense is measured based on the fair value of the stock-based awards at the grant date for all stock-based awards to employees and non-employees and is recognized as expense over the requisite service period on a straight-line basis, which is generally the vesting period. Forfeitures are estimated using historical trends. Refer to Note 7 for additional information on the Company&#8217;s stock-based compensation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensated Absences</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">When the Company&#8217;s obligation relating to employees&#8217; rights to receive compensation for future absences is attributable to employees&#8217; services rendered, the obligation relates to rights that vest or accumulate, payment is probable and amount can be reasonably estimated, a liability is recorded. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Loss Contingencies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. Refer to Note 10 for additional information on the Company&#8217;s loss contingencies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Redeemable Convertible Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s redeemable convertible preferred stock is recorded outside of permanent equity because, while it is not mandatorily redeemable, it is redeemable at the option of the holders for cash upon the passage of time or the occurrence of certain events considered not solely within the Company&#8217;s control, such as a merger, acquisition, and sale of all or substantially all of the Company&#8217;s assets (each, a &#8220;deemed liquidation event&#8221;). The redeemable convertible preferred stock classified in mezzanine equity is subject to subsequent measurement under the guidance provided in the SEC Staff Announcement: Classification and Measurement of Redeemable Securities. In accordance with that guidance, the Company has elected to recognize changes in redemption value immediately as they occur through adjustments to the carrying amounts of the instruments at the end of the reporting period with the corresponding amount recorded to additional paid-in capital or, in the absence of additional paid-in-capital, accumulated deficit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Treasury Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company records treasury stock purchases under the cost method by recording the entire cost of the acquired shares of common stock as treasury stock. In the case of re-issuance of treasury stock, amounts that exceed the acquisition cost will be recorded in additional paid-in capital. If the re-issuance price is below the treasury stock&#8217;s acquisition cost and additional paid-in capital is insufficient to cover the difference between the acquisition cost and the re-issuance price, the shortfall will be recorded in accumulated deficit. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Company decides to retire treasury stock, the Company will deduct the par value from common stock and reduce additional paid-in capital for any excess of cost over par value. If additional paid-in capital is insufficient, the Company reflects the shortfall in accumulated deficit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Shareholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company calculates its basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method required for companies with participating securities. Each series of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the Company&#8217;s redeemable convertible preferred stock is considered to be a participating security because the preferred shareholders have a right to receive dividends on a pari&#160;passu basis with the Company&#8217;s common shareholders. The two-class method determines net income (loss) per share for each class of common stock and participating security according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income (loss) available to common shareholders for the period to be allocated between common and participating securities based upon the respective rights of each to share in earnings as if all income (loss) for the period had been distributed. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method between common and participating securities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because the Company has reported a net loss for the&#160;years ended December&#160;31, 2024 and 2023, basic net loss per share attributable to common shareholders is calculated by dividing net loss attributable to common shareholders by the weighted-average common stock outstanding during the period, without consideration for potential common stock equivalents. Net loss attributable to common shareholders is equal to net loss, less accretion on preferred securities to their redemption value to the extent such securities are outstanding. Diluted net loss per share attributable to common shareholders is calculated by adjusting the weighted-average stock outstanding for the dilutive effect of potential common stock equivalents outstanding. For purposes of calculating the diluted net loss per share attributable to common shareholders, convertible preferred stock, convertible promissory notes, warrants, and stock options are considered to be potential common stock equivalents but are excluded from the calculation of diluted net loss per share attributable to common shareholders because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share attributable to common shareholders was the same for all periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for income taxes under the asset and liability method as set forth in ASC&#160;740 &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes</font><font style="letter-spacing:0.2pt;">&#8221; &#8203;(&#8220;ASC 740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across its global operations. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related taxing authority. For tax positions not meeting the more likely than not test, no tax benefit is recorded. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2024 and 2023, the Company has accumulated net operating loss carryforwards in both the U.S. and foreign jurisdictions, and no provision for income taxes is required. The Company&#8217;s deferred tax assets are subject to a full valuation allowance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Adopted Accounting Pronouncements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2023, the FASB issued ASU No. 2023-07, </font><font style="font-style:italic;letter-spacing:0.2pt;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</font><font style="letter-spacing:0.2pt;">. This ASU requires disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments require disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of the composition for other segment items to reconcile to segment profit or loss, and the title and position of the Company&#8217;s CODM. The ASU also extends certain annual disclosures to interim periods. The Company elected to early adopt this ASU for its annual reporting period ending December&#160;31, 2023. There was no impact on the Company&#8217;s reportable segments identified and additional required disclosures have been included in Note 13. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Pronouncements Not Yet Adopted</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2023, the FASB issued ASU No. 2023-09, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</font><font style="letter-spacing:0.2pt;"> which requires presentation of specific categories of reconciling items, as well as reconciling items that meet a quantitative threshold, in the reconciliation between the income tax provision and the income tax provision using statutory tax rates. The standard also requires disclosure of income taxes paid disaggregated by jurisdiction with separate disclosure of income taxes paid to individual jurisdictions that meet a quantitative threshold. For public business entities, the ASU is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than public business entities, the ASU is effective for annual periods beginning after December&#160;15, 2025. The amendments of the ASU should be applied on a prospective basis; however, entities have the option to apply retrospectively for each period presented. The Company does not expect the adoption of this new standard in 2026 to have an impact on its consolidated financial position, results of operations, or cash flow. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November 2024, the FASB issued ASU No. 2024-03, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Statement- Reporting Comprehensive Income-Expense disaggregation disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</font><font style="letter-spacing:0.2pt;">. This ASU requires disclosure of specified information about certain costs and expenses in the notes to financial statements. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on the disclosures within our financial statements, and expect to adopt this ASU for the year ending December 31, 2027.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 3. Consolidated Balance Sheet and Statement of Operations and Comprehensive Loss Components</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prepaid Expenses and Other Current Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets consist of the following: </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December 31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,562</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other current assets</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,708</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,358</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.25pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total prepaid expenses and other current assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">20,270</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">13,124</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.1pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment, Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net consist of the following: </font>
        </div>
        <table style="width:456pt;height:156.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment and software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">99,233</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">95,573</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">103,795</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">98,985</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,883</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements/Leased buildings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">63,039</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">66,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aircraft and leased equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">21,249</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">21,204</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">296,426</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">291,224</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(228,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(184,136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">67,817</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">107,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Total depreciation and amortization expense was $48.9 million and $49.0&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. Out of the total depreciation expense, amortization associated with finance leases was $0.1 million and $0.5&#160;million for the&#160;years ended December&#160;31, 2024 and 2023, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accrued Expenses and Other Current Liabilities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accrued expenses and other current liabilities consist of the following: </font>
        </div>
        <table style="width:456pt;height:171pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Trade accruals </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,131</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,680</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued payroll and employee medical </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,882</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">25,736</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,824</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current portion of early exercise stock option liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,957</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,957</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Contract liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,470</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,676</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current portion of operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,080</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,420</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued interest on current portion of notes payable and convertible loan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,332</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,286</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,839</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total accrued expenses and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">77,542</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">67,777</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Long-Term Liabilities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other long-term liabilities consist of the following: </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term operating lease liabilities, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term portion of early exercise stock option liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,724</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other long-term liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">44,418</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">54,823</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Expense, Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other expense, net consists of the following: </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:367.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:367.78pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:367.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:367.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss on debt extinguishment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,915<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:367.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,691<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:367.78pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12,606<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 4. Guaranty Agreement and Restricted Cash</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company entered into a Master Continuing Guaranty Agreement with Bank of America in 2011 to provide a guarantee for credit exposure related to the Company&#8217;s commercial bank accounts with Bank of America. The agreement was guaranteed through collateral accounts of $0.3&#160;million as of December&#160;31, 2024 and 2023. The agreement contains various customary affirmative and financial reporting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:133.26pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">obligations and is considered to be restricted cash, as the account is under a security deposit agreement. All obligations are in compliance with the terms of the agreement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company entered into a lease agreement with KCP NNN II Leasehold 4, LLC on July&#160;25, 2019 to lease 114,500 square feet of space in Irving, Texas. As part of the lease agreement, the Company delivered an unconditional, irrevocable letter of credit for $3.4&#160;million from a nationally recognized bank. The Company obtained this letter of credit and placed $3.4&#160;million in a security deposit account. As of December&#160;31, 2024 and 2023, amounts outstanding are $2.7 million and $3.1&#160;million, respectively, and are included within cash, cash equivalents, and restricted cash and other assets on the consolidated balance sheets. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The remaining restricted cash amounts are not material individually. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the amounts shown in the consolidated statements of cash flows. Restricted cash is presented within cash, cash equivalents, and restricted cash and other assets on the consolidated balance sheets.</font>
        </div>
        <table style="width:456pt;height:96pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:175.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:179.09pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:175.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:179.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Consolidated balance sheet line item </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:175.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:179.09pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:175.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:179.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">63,950</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">56,402</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:175.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restricted cash&#8201;&#8211;&#8201;short term </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:179.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,492</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,605</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:175.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restricted cash&#8201;&#8211;&#8201;long term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:179.09pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,586</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:175.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:179.09pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">68,028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">60,007</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 5. Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For financial reporting purposes, income before income taxes includes the following components: </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">United States </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(283,720<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(339,724<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Foreign </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,830</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(1,691<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:14.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company had no income tax expense or benefit for the&#160;years ended December&#160;31, 2024 or 2023. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The difference between income taxes expected at the U.S. federal statutory income tax rate of 21% and the reported income tax benefit are summarized as follows: </font>
        </div>
        <table style="width:456pt;height:188pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computed statutory benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(59,197<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(71,697<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">67,333</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">85,643</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State taxes, net of federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,173<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(15,342<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Permanent differences </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,946</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,231</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Permanent difference&#8212;warrant fair value adjustment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,489<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(55<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Foreign rate differential </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(267<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments to foreign NOL&#8217;s </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">117</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">174</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments to state NOL&#8217;s </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(114<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(522<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments to stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">137</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">671</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Rate change </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(68<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(40<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">775</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows: </font>
        </div>
        <table style="width:456pt;height:353pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Deferred tax assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net operating loss carryforward </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">290,514</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">249,229</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,854</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,993</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,346</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest limitation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">35,614</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">26,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,842</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,842</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Intangibles </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,557</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,286</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease obligation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13,038</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Contractual allowances </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">16,867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">17,543</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,140</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">40,911</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment basis difference </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,796</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,249</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Others </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,621</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total deferred tax assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">434,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">366,646</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Deferred tax liabilities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Right of use assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(9,033<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(10,401<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Excess tax goodwill amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(262<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(240<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Derivative liability fair value adjustment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(3,456<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,736<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Others </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(24<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total deferred tax liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(12,751<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(12,401<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(421,578<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(354,245<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net deferred tax asset (liability) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss over the three-year period ended December&#160;31, 2024. Such objective evidence limits the ability to consider other subjective evidence, such as the Company&#8217;s projections for future growth. On the basis of this evaluation, as of December&#160;31, 2024, a valuation allowance of $421.6&#160;million has been recorded to recognize only the portion of the deferred tax assets that is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted if additional objectively verifiable positive evidence materializes in future reporting periods, such as a demonstrated operating profitability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The valuation allowances increased $67.3&#160;million and $85.6&#160;million during the fiscal&#160;years ended December&#160;31, 2024 and 2023, respectively, primarily due to increased U.S. federal and state net operating loss carryforwards. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has gross federal, state, and foreign net operating loss carryforwards of approximately $2,152 million which expire as follows: </font>
        </div>
        <table style="width:456pt;height:93pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:246.76pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">(amounts in thousands)</font>
              <br >
              <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Expiration Year </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.16pt;">Federal </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.16pt;">State </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:4pt;padding-right:4pt;letter-spacing:-0.16pt;">Foreign </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:246.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2024&#8211;2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,736</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">31,704</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:246.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2031&#8211;2040 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">209,538</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">289,839</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,913</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">501,290</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:246.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2041&#8211;2045 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">516,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">516,068</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:246.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Indefinite </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">934,839</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">168,226</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,103,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:246.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,150,715</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">985,763</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,649</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,152,127</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2018 through 2024 net operating losses do not expire under the Tax Cuts and Jobs Act of 2017, and are subject to the 80% of taxable income limitation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Federal tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an ownership change, as defined in Section&#160;382 of the Internal Revenue Code of 1986. Accordingly, the Company&#8217;s ability to utilize these carryforwards may be limited in the event of any such ownership change. We have completed a Section&#160;382 analysis for changes in ownership through December&#160;31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of its federal net operating losses. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has U.S. federal and state tax research and development credit carryforwards of $2.8&#160;million as of December&#160;31, 2024 and 2023, with expiration dates through 2031 and 2026, respectively. The Company has recorded a full valuation allowance related to the credit carryforwards as of December 31, 2024.</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of December&#160;31, 2024, all loss&#160;years remain open to examination by the taxing authorities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The recognition and measurement of certain tax benefits includes estimates and judgment by management that inherently involve subjectivity. Changes in estimates may create volatility in the Company&#8217;s effective tax rate in future periods and may be due to the expiration of various statutes of limitations, settlements with tax authorities, or acquisition of new information about particular tax positions that may require management to change its estimates. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;22, 2017, the Tax Cuts and Jobs Act (TCJA) created new taxes on certain foreign earnings. Namely, U.S. shareholders are now subject to current tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by specified foreign subsidiaries. Available guidance related to GILTI provides for an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future&#160;years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. The Company has elected to recognize the current tax on GILTI as an expense in the period the tax is incurred. As of December&#160;31, 2024, the Company has a GILTI tax inclusion of $2.3&#160;million. As </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of December&#160;31, 2023, there is no GILTI tax inclusion. As of December&#160;31, 2024 and 2023, the Company had no undistributed earnings from its foreign subsidiaries due to losses generated since inception. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, TCJA includes a requirement to capitalize and amortize research and experimental expenditures beginning in 2022. Prior to 2022, the Company expensed these costs as incurred for tax purposes. The capitalization of the research and experimental expenditures resulted in a deferred tax asset of $52.1&#160;million and $41.9&#160;million as of December&#160;31, 2024 and 2023, respectively, which was offset by a valuation allowance, resulting in no significant impact to income tax expense for the&#160;years ended December&#160;31, 2024 and 2023. This deferred tax asset will be amortized over five&#160;years for the domestic costs and fifteen&#160;years for the foreign incurred costs. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for uncertainty in income taxes in accordance with ASC Topic 740, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 740&#8221;). Through December&#160;31, 2024, the Company has evaluated all tax positions for which the statute of limitations remained open, and the Company has not recognized any reserve for uncertain tax positions or any penalties or interest through the income statement or balance sheet as of December&#160;31, 2024. The Company has not recorded and does not expect any material changes to the liability for uncertain tax positions during the next 12&#160;months. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6. Redeemable Convertible Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Redeemable convertible preferred stock as of December&#160;31, 2024 and 2023, consisted of the following: </font>
        </div>
        <table style="width:456pt;height:127.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:157.43pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:157.43pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">(amounts in thousands, except share and per </font>
              <br >
              <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">share amounts)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:46.91pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original Issue </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price Per </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.16pt;">Share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Net Carrying </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">490,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">296,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">30,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.54</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">16,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">142,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">408,715</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">408,715</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">8.10</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,060,712</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,060,712</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:157.43pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">764,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,781,762</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,221,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:127.5pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:157.43pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:157.43pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">(amounts in thousands, except share and per </font>
              <br >
              <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">share amounts) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:46.91pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original Issue</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price Per</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.16pt;">Share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Net Carrying</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">490,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">296,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">30,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.54</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">16,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">142,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">381,908</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">381,908</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:157.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.10</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">996,458</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">991,152</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:157.43pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">764,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.1pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,690,701</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,125,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.7pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The rights, preferences, and privileges of the redeemable convertible preferred stock are as follows: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On any matter presented to the shareholders of the Company for their action or consideration at any meeting of shareholders of the Company (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of preferred stock will be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All classes of preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Company&#8217;s board of directors, prior to and in preference to any declaration or payment of any dividend on the common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidation Preference</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series&#160;C and Series&#160;D preferred stock then outstanding will be entitled to be paid out of the assets of the Company available for distribution to its shareholders at an amount per share equal to the greater of (i)&#160;the Series&#160;C and Series&#160;D original issue price, plus (A)&#160;any dividends declared but&#160;unpaid thereon and (B)&#160;a 7.0% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series&#160;C and Series&#160;D preferred stock, (ii)&#160;the amount that the holder of a share of Series&#160;C and Series&#160;D preferred stock would have received upon conversion to common stock, or (iii)&#160;solely with respect to the Series&#160;D preferred stock, 1.2 times the Series&#160;D original issue price. The Series&#160;A and Series&#160;B preferred stock are then paid on a pro&#160;rata, pari&#160;passu basis an amount equal to the greater of (i)&#160;the respective original issue price plus any dividends declared but unpaid thereon, and (ii)&#160;the amount that the holder of a share of Series&#160;A or Series&#160;B preferred stock, respectively, would receive upon conversion to common stock. The remaining proceeds will be distributed to the holders of common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conversion Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of the Company&#8217;s Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock have the right to convert their shares into a number of fully paid and nonassessable shares of common stock as determined by dividing the respective Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock original issue price by the conversion price in effect at the time. The initial conversion price of the Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock was $0.61, $0.54, $2.76 and $8.10, respectively, and is subject to adjustment in accordance with anti-dilution provisions provided for in the Company&#8217;s Certificate of Formation. As of December&#160;31, 2024, each share of Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock was convertible into one share of common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Redemption Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At any time on or after the fifth anniversary of the Series&#160;C and Series&#160;D original issue date, which will begin for Series&#160;C in August&#160;2025 and for Series&#160;D in May&#160;2026, upon written notice from the applicable shareholders, the Series&#160;C and Series&#160;D shares shall be redeemed by the Company at a price per share equal to the greater of (i)&#160;the original issue price plus (a)&#160;all declared by unpaid dividends thereon and (b)&#160;a 7.0% cumulative accruing dividend, compounding annually, or (ii)&#160;the fair market value as determined by an independent appraiser. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Anti-dilution</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain exceptions, the conversion price of the Series&#160;A and Series&#160;B preferred stock is subject to broad-based weighted average adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the then-applicable conversion price of the Series&#160;A and Series&#160;B preferred stock, respectively. Subject to certain exceptions, in the event the Company sells additional shares of stock at a price per share less that the Series&#160;C and Series&#160;D original issue price, the conversion price of the Series&#160;C preferred stock is adjusted to the lower price that the Company sells shares in such offering, and the conversion price of the Series&#160;D preferred stock is adjusted based on a broad-based weighted average anti-dilution formula. In the event the Company sells shares in an initial public offering, for less than 110.0% of the applicable Series&#160;C and Series&#160;D conversion price, then the Series&#160;C and Series&#160;D conversion price will be reduced (but never increased), concurrently with such issuance or deemed issuance, to 90.0% of the purchase price in such initial public offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 7. Shareholders&#8217; Equity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2024 and 2023, 1,150,000,000 shares of common stock with a $0.001 par value were authorized. There were 143,369,083 and 141,188,960 shares outstanding at December&#160;31, 2024 and 2023, respectively. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s shareholders. Common shareholders are entitled to receive dividends if and when declared by the Company&#8217;s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. No dividends have been declared or paid by the Company since its inception. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Treasury Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2024 and 2023, the Company did not repurchase any shares of common stock. Previously repurchased common stock is shown on the consolidated balance sheets and consolidated statements of redeemable convertible preferred stock and shareholders&#8217; deficit as treasury stock. The Company had 730,000 shares of treasury stock as of December&#160;31, 2024 and 2023. These shares have not been retired. The Company has not reissued any shares of treasury stock as of December&#160;31, 2024 and 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the 2020 Incentive Plan (the &#8220;Plan&#8221;), the Company may grant awards of options, restricted awards, performance awards or share appreciation rights to employees, consultants, and directors of the Company. A total of 99,297,441 shares of common stock are reserved for issuance upon the exercise of all awards granted or available to be granted under the Plan as of December&#160;31, 2024. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent permitted by applicable laws or any exchange rule, any shares of common stock issued under this Plan that are issued (a)&#160;in connection with the Company&#8217;s acquisition of an unaffiliated business entity, (b)&#160;to the employees of such entity, and (c)&#160;in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce the number of shares of common stock available for issuance under the Plan. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Plan provides for a repurchase feature for vested stock-based awards at the option of the Company if the employee&#8217;s continuous service terminates for any reason, with or without cause, including death or disability. The repurchase shall be exercisable at a price equal to the fair market value of vested shares or, in the case of exercisable options, the fair market value of the common stock underlying such unexercised options less the aggregate exercise price of such options. The Company&#8217;s repurchase lapses when the Company&#8217;s common stock becomes publicly traded.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Option Activity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, the Company has granted incentive stock options and non-qualified stock options to its employees and other service providers (non-employees). Most of the Company&#8217;s stock options vest incrementally over five&#160;years, subject to the grantee&#8217;s continuous employment with the Company (&#8220;time-vesting options&#8221;). The Company recognizes compensation cost on a straight-line basis over the requisite service period for its time-vesting options. In addition to its time-vesting options, the Company has also granted stock options to certain non-employees for which vesting is tied to the grantee&#8217;s performance (&#8220;performance-vesting options&#8221;). The Company evaluates whether it is probable that the performance metric will be achieved for its performance-vesting options and recognizes compensation cost on a straight-line basis over the implied service period if achievement of the performance metric is deemed probable. No option shall be exercisable after the expiration of 10&#160;years from the date it was granted. The exercise price of each option shall be not less than 100.0% of the fair market value of the common stock subject to the option on the date the option is granted. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the Company&#8217;s stock option activity during the year ended December&#160;31, 2024: </font>
        </div>
        <table style="width:456pt;height:171.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:256.04pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Options Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contract</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Term</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total outstanding as of December&#160;31, 2023: </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">87,050,440</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.00</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.78</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">167,491</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,928,221</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.75</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(956,123<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.60</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,808</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cancelled/forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,883,080<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.47</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,030</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expired </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(4,056,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">16,316</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total outstanding as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">87,082,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">2.27</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">5.40</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">226,117</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total exercisable as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">63,236,066</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.64</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.37</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">203,971</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:256.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total vested or expected to vest as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">85,354,436</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.22</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.31</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">225,506</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:150.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:261.8pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Unvested/Vested Activity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:261.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Grant Date</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:261.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested outstanding, as of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">30,216,142</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.44</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.87</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.54</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,928,221</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.75</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.09</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cancelled/forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(2,296,469<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.68</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.15</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:261.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested, outstanding shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(9,211,302<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">3.04</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">1.47</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:261.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested outstanding, as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">26,636,592</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.95</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.35</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.30</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:261.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Early exercised unvested, end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,648,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.05</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.60</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt; width:5.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The weighted average grant date fair value of options granted during the&#160;years ended December&#160;31, 2024 and 2023 was $3.09 and $2.38 per option, respectively. The total grant date fair value of options vested during the&#160;years ended December&#160;31, 2024 and 2023 was $13.5 million and $10.4&#160;million, respectively. The total intrinsic value of options exercised during the&#160;years ended December&#160;31, 2024 and 2023 was $2.8 million and $6.8&#160;million, respectively. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cash received for exercises of stock options during the&#160;years ended December&#160;31, 2024 and 2023 was $1.5 million and $1.9&#160;million, respectively. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2024, total unrecognized compensation cost related to unvested stock options was $49.0&#160;million. This amount is expected to be recognized as stock-based compensation expense in the consolidated statements of operations and comprehensive loss over a weighted average period of 3.3&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Modification to stock options</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;9, 2021 and February&#160;23, 2022, the Company granted stock options to certain executives that are exercisable upon vesting for 1,325,000 shares and 8,000,000 shares of the Company&#8217;s common stock, respectively (the &#8220;Prior Stock Options&#8221;). The Prior Stock Options vested over five&#160;years. On August&#160;11, 2022, the Company&#8217;s Compensation Committee approved a modification to the Prior Stock Options, which was communicated to holders of the Prior Stock Options on September&#160;1, 2022. The </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">modification reduced the exercise price to $4.05 and modified the vesting conditions such that 20.0% vest upon grant, while the remainder vest over the following four&#160;years. The total number of grantees affected by this modification was twelve. The modification was not mandatory, but rather could be elected by holders of the Prior Stock Options on an individual holder basis. If the holder elected to participate, the holder&#8217;s Prior Stock Options were immediately canceled, and the Company issued the holder an equivalent number of new stock options in exchange (the &#8220;New Stock Options&#8221;) which could be early exercised prior to vesting. All of the holders elected to participate in the modification and exchanged their Prior Stock Options for New Stock Options. In addition, as an alternative to paying cash, holders of the New Stock Options that&#160;elected to exercise their options were able to pay for the exercise price by executing a full recourse promissory&#160;note with the Company that is secured by the holder&#8217;s restricted shares that are issued upon early exercise. Five grantees elected to early exercise utilizing the promissory note. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The principal of each note is equal to the exercise price of the New Stock Options. Interest on the unpaid balance will compound annually and accrue at a fixed rate per annum equal to the mid-term applicable federal rate in effect on the issuance of the note. The maturity date of the notes is the earlier of (1)&#160;December&#160;31, 2030 or (2)&#160;the occurrence of a change in control event, unless an acceleration event occurs sooner. An acceleration event would generally occur if required to ensure compliance with Section&#160;402 of the Sarbanes-Oxley Act of 2022, the termination of the holder&#8217;s employment, the insolvency of the holder or the breach of any warranty of the holder. The holder may elect to prepay the outstanding principal and accrued interest balance of the promissory note at any time without penalty. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the outstanding balance of the note becoming due and payable immediately, upon the occurrence of an acceleration event, if the holder defaults on payment of the note, then interest will accrue at the maximum rate permitted by applicable law. The Company will have full recourse against the holder for failure to pay the note as and when due. Such promissory notes will be secured by the restricted shares issued to the holder that are underlying the note. If the note is not repaid upon an event of default or acceleration event, the Company has the right to repurchase the restricted shares issued upon the exercise of the note for fair market value, which proceeds will apply to repayment of the note (with any remaining balance remaining due). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company accounted for the modification as a Type I (Probable to Probable) modification under ASC 718 that does not change the classification of the award (i.e., the New Stock Options continue to be classified within equity). The Company calculated the fair value of the Prior Stock Options and New Stock Options immediately prior to and after the modification using the Black-Scholes option pricing model. The incremental fair value was added to the original unrecognized compensation cost to arrive at the new unrecognized compensation cost, to be recognized over the remaining requisite service period. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Unvested stock received from early exercises of the New Stock Options are subject to a right of repurchase at the lesser of (i)&#160;original issuance price or (ii)&#160;then-current fair market value in the event of the employee&#8217;s termination, either voluntary, or involuntary. The Company&#8217;s repurchase right with respect to these shares typically lapse over four&#160;years as the shares become vested. Early exercises of stock options are not deemed to be substantive exercises for accounting purposes and accordingly, consideration received for exercises of unvested stock options is initially recorded as a liability and subsequently reclassified into shareholders&#8217; deficit as the related shares vest. As of December&#160;31, 2024 and 2023, 2,648,000 and 3,872,000 shares from options exercised to date were subject to repurchase at a price of $4.05 per share. Of the amount subject to repurchase for the year ended December&#160;31, 2024 and 2023, $5.0&#160;million was recorded within other accrued expenses and current liabilities, respectively, and $5.8 million and $10.7&#160;million was recorded within other long-term liabilities on the consolidated balance sheets, respectively. In addition, as the early exercise was performed via issuance of a promissory note, a corresponding debt amount, plus related interest income was recorded as contra-equity. The total amount presented as contra-equity as of December&#160;31, 2024 and 2023 was $26.5 million and $25.7&#160;million, respectively, which includes interest income and the impact from exercises of both the vested portion of the New Stock Options and early exercises. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Restricted Awards Activity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2024, the Company granted to certain of its employees restricted stock&#160;units that will be settled in shares of the Company&#8217;s common stock upon vesting. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Vesting of the restricted stock&#160;units is contingent upon the Company completing either an initial public offering of its common stock or a change of control. The Company has determined that these performance conditions are not probable of being achieved, and thus has not recognized any compensation expense associated with its restricted stock&#160;units. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the Company&#8217;s restricted stock unit activity during the year ended December&#160;31, 2024: </font>
        </div>
        <table style="width:384pt;height:101.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:252.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Restricted Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Units </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average Grant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested as of December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">720,500</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.51</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,362,000</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.86</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cancelled/forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(32,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.78</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,050,000</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.55</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The total unrecognized compensation expense related to unvested restricted stock&#160;units as of December&#160;31, 2024 was $13.9&#160;million, which will be recognized upon the occurrence of an initial public offering or a change of control. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recorded stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows: </font>
        </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,504</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,301</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,400</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,448</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,983</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,214</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,344</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">18,643</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,240</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:36pt; margin-top:13pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There was no tax benefit associated with the above stock-based compensation expense. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Valuation of Stock-Based Awards to Employees</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company records stock-based compensation expense for stock-based awards based on the estimated fair value of the awards on the date of the grant. The fair value of the Company&#8217;s restricted stock&#160;units is based on the fair value of the Company&#8217;s common stock at the date of grant. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company estimates the fair value of stock options using a Black-Scholes option pricing model. The absence of a public market for the Company&#8217;s common stock requires the Company&#8217;s board of directors to estimate the fair value of its common stock for purposes of granting options and for determining stock-based compensation expense by considering several objective and subjective factors, including contemporaneous third-party valuations, actual and forecasted operating and financial results, market </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:108.09pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">conditions and performance of comparable publicly traded companies, developments and milestones in the Company, the rights and preferences of common and convertible preferred stock, transactions involving the Company&#8217;s common stock, and assumptions for a discount for lack of marketability. The fair value of the Company&#8217;s common stock was determined in accordance with the applicable elements of the American Institute of Certified Public Accountants Accounting and Valuations Guide, </font><font style="font-style:italic;letter-spacing:0.2pt;">Valuation of Privately Held Company Equity Securities Issued as Compensation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The key assumptions used in determining the fair value of options granted and a summary of the methodology applied to develop each assumption are as follows: </font>
        </div>
        <table style="width:384pt;height:97pt;margin-left:36pt;margin-top:9.99999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:246.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:246.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:56.87pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:56.87pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:246.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">62.5%&#8211;68.4% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">64.3%&#8211;77.2% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:246.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.7%&#8211;4.6% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.5%&#8211;4.4% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:246.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.97&#8211;6.60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.90&#8211;7.50 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:246.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:246.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected forfeiture rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8.3%&#8211;8.5% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8.4%&#8211;8.6%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:9.2pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected volatility.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This is a measure of the amount by which the share price has fluctuated or is expected to fluctuate. An increase in the expected price volatility will increase the fair value of the option granted and the related compensation expense. As the Company is not publicly traded, the expected price volatility for the Company&#8217;s options was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the business corresponding to the expected term of the awards. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-free interest rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for U.S. Treasury notes with maturities corresponding to the expected term of the awards. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This is the period of time over which the options granted are expected to remain outstanding and is based on the Company&#8217;s estimate, taking into consideration vesting term, contractual term and historical actual lives. Options granted have a maximum term of ten&#160;years. An increase in the expected life will increase the fair value of the option granted and the related compensation expense. Due to the lack of historical share option exercise data, the Company utilizes the simplified method for determining the expected term. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividend rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company has not made any dividend payments, nor does it have plans to pay dividends in the foreseeable future. Therefore, an expected dividend yield of zero is utilized. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Forfeitures.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 8. Long-Term Debt</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The carrying value of debt presented within current portion of notes payable and long-term indebtedness, net of debt discounts on the consolidated balance sheets as of December&#160;31, 2024 and 2023 includes the following components:</font>
        </div>
        <table style="width:456pt;height:143pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:332.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="13">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:332.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:332.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="13">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Term loan Initial Draw&#8211;January&#160;18, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exit fee on term loan&#8211;January&#160;18, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Term loan Subsequent Draw&#8211;March&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exit fee on term loan&#8211;March&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: Amortized debt discounts and financing costs</font><font style=" position:relative; bottom:4.25pt;line-height:6.5pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(30,863<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(35,893<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net debt </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">373,137</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">166,107</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:332.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Compound bifurcated derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">6,058</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">17,451</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes debt discounts of $28.3&#160;million associated with the initial carrying value of compound bifurcated derivative liability. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Maturities of the Company&#8217;s debt are expected to be as follows as of December&#160;31, 2024: </font>
        </div>
        <table style="width:384pt;height:98.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:334.29pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Years Ending December&#160;31, </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">2025</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">340,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents 15% of the outstanding principal amount under the 2023 Term Loan Agreement, which is due on the earlier of (x)&#160;for dates prior to January&#160;1, 2026, any date that the redemption rights in respect of our Series&#160;C preferred stock or Series&#160;D preferred stock are or may become exercisable within 90&#160;days following such date, or (y)&#160;January&#160;1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of our Series&#160;C preferred stock or Series&#160;D preferred stock are or may become exercisable on or prior to the date that is six&#160;months after the maturity date. The Series&#160;C preferred stock redemption rights may be exercised on or after August&#160;14, 2025. All outstanding shares of our Series&#160;C preferred stock and Series&#160;D preferred stock will convert into shares of common stock as part of the Preferred Stock Conversion and any redemption rights thereunder will terminate in connection with the completion of this offering and consequently, the payments disclosed herein would not be applicable. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Term Loan Refinancing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;21, 2018, the Company entered into a secured term loan agreement (the &#8220;Original Term Loan Agreement&#8221;) with Sixth Street Specialty Lending, Inc. and Barnett Debt Holdings, LLC (collectively, the &#8220;Original Term Loan Lenders&#8221;), which provided the Company with an initial term loan of $50.0&#160;million (the &#8220;2018 Term Loan&#8221;) and a delayed term loan draw option of $50.0&#160;million, which the Company drew down in full on October&#160;4, 2019 (the &#8220;2019 Term Loan&#8221;). On April&#160;2, 2020, the Company amended the Original Term Loan Agreement (the &#8220;Amended Term Loan Agreement&#8221;) to obtain additional </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">term loan proceeds of $75.0&#160;million (the &#8220;2020 Term Loan&#8221; and collectively with the 2018 Term Loan and the 2019 Term Loan, the &#8220;Original Term Loans&#8221;). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;18, 2023, the Company entered into the New Term Loan Agreement with OrbiMed Royalty &amp; Credit Opportunities III, LP, OrbiMed Royalty &amp; Credit Opportunities IV, LP (collectively, &#8220;OrbiMed&#8221;), and Braidwell Transaction Holdings LLC (&#8220;Braidwell&#8221;, and collectively with OrbiMed, the &#8220;New Term Loan Lenders&#8221;). Pursuant to the New Term Loan Agreement, the Company issued senior, secured promissory notes by which the New Term Loan Lenders agree to lend the Company up to an aggregate principal amount of $400.0&#160;million, $200.0&#160;million of which was received by the Company upon issuance (the &#8220;Initial Draw&#8221;), and the remaining $200.0&#160;million was received by the Company in March 2024 (the &#8220;Delayed Draw&#8221;). Net cash proceeds from the 2023 Term Loan were $200.0 million and $187.0&#160;million after deducting customary debt discounts and debt issuance costs for the years ended December 31, 2024 and 2023, respectively. The net cash proceeds in 2023 from the 2023 Term Loan were used to repay in full the Original Term Loans (with an aggregate principal amount of $175.0&#160;million), including a prepayment premium of $5.0&#160;million and accrued and unpaid interest of $1.0&#160;million. A loss on debt extinguishment of $10.9&#160;million, reflecting the difference between the cash paid to settle the Original Term Loans and the net carrying amounts of the Original Term Loans, was recognized in other expense, net on the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. As of December&#160;31, 2023 and onwards, the Company has no continuing obligations associated with the Original Term Loans. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until the earlier of December&#160;31, 2024 or the date on which the 2024 Term Loan amount was fully drawn, which occurred on March 5, 2024, the undrawn balance of the New Term Loan Commitment was subject to a fee of 0.5% per annum. The outstanding principal amount of the 2023 Term Loan is due and payable on January&#160;18, 2028. If an event of default occurs and is continuing, the New Term Loan Lenders may declare all amounts outstanding under the New Term Loan Agreement to be immediately due and payable. A final payment exit fee equal to 1.0% of the amount funded under the New Term Loan Agreement is due upon prepayment or maturity. Amounts borrowed pursuant to the New Term Loan Agreement may be prepaid at any time. Upon prepayment, the Company is subject to a prepayment penalty based on the timing of repayment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2023 Term Loan bears interest at a rate per annum equal to a fixed margin of 6.5% plus the greater of (a)&#160;forward-looking three-month secured overnight financing rate (&#8220;SOFR&#8221;) and (b)&#160;2.5%. In the event of default, the fixed margin shall increase by 3.0% per annum. As of December&#160;31, 2024, the interest rate was 11.1%. Regular quarterly payments are interest-only for the 60-month term of the New Term Loan Agreement, with the principal due at maturity. The effective interest rate for the Initial Draw of the 2023 Term Loan is 17.0%, and the effective interest rate for the Delayed Draw of the 2023 Term Loan is 12.0%. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s obligations under the New Term Loan Agreement are secured by a first lien security interest in substantially all of the assets of the Company and its subsidiaries. The New Term Loan Agreement contains certain customary representations and warranties, affirmative and negative covenants, financial covenants, and events of default applicable to the Company and its subsidiaries. Additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. At December&#160;31, 2024, the Company is in compliance with all covenants. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company identified multiple embedded derivatives that require bifurcation from the 2023 Term Loan. They are separately accounted for in the consolidated financial statements as one compound derivative liability. Those embedded features include various contingent prepayment and compensatory payment features as well as interest rate increases upon an event of default. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Loan Conversion</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Original Term Loan Agreement dated September&#160;21, 2018, the Company issued $50.0&#160;million of convertible notes to the Original Term Loan Lenders pursuant to a convertible loan agreement (the &#8220;Convertible Loan Agreement&#8221;) with interest accruing at a rate of 8.0% per annum (the &#8220;2018 Convertible Loan&#8221;). The Original Term Loan Lenders had the option on each interest payment date </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:13.48pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">to receive interest in cash or in kind in the form of additional term loan principal issued pursuant to the terms of the Convertible Loan Agreement. As of December&#160;31, 2022, the effective interest rate on the 2018 Convertible Loan was 9.4%. Following the amendment to the Convertible Loan Agreement in 2020, the Original Term Loan Lenders obtained the right to convert all or a portion of the principal amount of the 2018 Convertible Loan and any accrued but unpaid interest thereon (the &#8220;Convertible Amount&#8221;) into either Series&#160;C preferred stock or common stock at a conversion price of $1.61 per share (subject to certain anti-dilution adjustments). However, the maximum aggregate Convertible Amount that the Original Term Loan Lenders may convert without the Company&#8217;s consent is $50.0&#160;million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2023, the Original Term Loan Lenders exercised the conversion right and converted the maximum $50.0&#160;million Convertible Amount into 31,055,901 shares of Series&#160;C preferred stock. In connection with the conversion of the 2018 Convertible Loan, the Company also paid cash of $3.0&#160;million to the Original Term Loan Lenders in settlement of accrued but unpaid interest on the Convertible Loan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The components of interest expense associated with the Company&#8217;s long-term indebtedness, excluding finance leases, are as follows: </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:354.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Debt discount amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,052</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,378</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">42,938</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">26,157</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:354.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense on long-term indebtedness, excluding finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">49,990</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">31,535</td>
            <td style="padding:0pt;padding-left:2.92pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant Liability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As part of the Original Term Loan Agreement, the Company issued 13,694,623 warrants with an exercise price of $1.61 (the &#8220;2018 Warrants&#8221;). In connection with the amendment to the Original Term Loan Agreement in 2020, the Company issued an additional 11,399,814 warrants with an exercise price of $1.93 (the &#8220;2020 Warrants&#8221;) and amended the 2018 Warrants. Furthermore, these amendments also permit the exercise of both the 2018 Warrants and 2020 Warrants into Series&#160;C preferred stock or common stock at the option of the holder. As a result of the amendment to permit exercise of the warrants into redeemable preferred stock, the warrants are classified as a liability pursuant to the guidance in ASC 480. Therefore, the warrants are reported at fair value within warrant and derivative liabilities on the consolidated balance sheets, with changes in fair value reported within changes in fair value of financial instruments on the consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table reflects the changes in fair values associated with these warrants. </font>
        </div>
        <table style="width:456pt;height:80.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:259.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:86.41pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2018 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:86.41pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:259.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">13,694,623</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">11,399,814</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:259.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$1.61</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$1.93</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:259.18pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Earlier of 7&#160;years from the date of issuance, </font>
                <br >
                <font style="letter-spacing:0.2pt;">or immediately after closing IPO </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:259.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at date of issuance </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$0.8&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$7.9&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:93.4400000000001pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <table style="width:456pt;height:84.5pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at December&#160;31, 2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase / (decrease) in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(305<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:354.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54,540</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,193</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:354.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Decrease in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(2,911<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:354.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">51,629</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">40,013</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 9. Leases</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company enters into various building leases for office, lab and other uses. Additionally, certain of the Company&#8217;s arrangements to utilize data centers represent a lease. These leases are generally considered operating leases. The Company is obligated to make total fixed payments over the lease terms. Some of these arrangements include options to extend the leases. The Company determined that given the length of time between lease commencement and the renewal period, and the uncertainty of business and market conditions in the future, it is not reasonably certain that the renewal options will be exercised. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has also entered into various information technology equipment leases. Certain of these leases are classified as operating leases and others are classified as finance leases, based on the terms of each lease arrangement. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Lease assets and liabilities are reflected in the Company&#8217;s consolidated balance sheets as follows: </font>
        </div>
        <table style="width:456pt;height:236pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:157.73pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:196.86pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.75pt 0pt 2pt 0pt; width:157.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:196.86pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:39pt;padding-right:39pt;letter-spacing:-0.16pt;">Consolidated balance sheet line item </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:8pt;padding-right:8pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:8pt;padding-right:8pt;letter-spacing:-0.16pt;">2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:157.73pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:196.86pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:157.73pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:157.73pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:196.86pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other assets </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,950</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">40,426</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:157.73pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:196.86pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">40</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:157.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total lease assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">34,990</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">40,549</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 1pt 0pt; width:157.73pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:157.73pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:157.73pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:196.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued expenses and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,080</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,420</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:157.73pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:196.86pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current portion of notes payable </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">90</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:157.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total current lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,587</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 1pt 0pt; width:157.73pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Non-current </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:157.73pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:196.86pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other long-term liabilities </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">38,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">44,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:157.73pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:196.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term indebtedness, net of debt discounts </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">243</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">315</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:157.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total non-current lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">38,894</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">44,414</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:157.73pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:196.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">45,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">51,001</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Total lease cost reflected in the consolidated statements of operations and other comprehensive loss were as follows: </font>
        </div>
        <table style="width:456pt;height:168pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:152.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Consolidated statement of operations </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and comprehensive loss line item</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:152.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:6pt;padding-right:6pt;letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:152.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:192pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1px 0pt; width:152.59pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1px 0pt; width:192pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1px 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1px 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">1,607</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1px 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1px 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,935</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:152.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:192pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and </font>
                <br >
                <font style="letter-spacing:0.2pt;">development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">40</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">General and administrative expense </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">6,738</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8,037</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Research and development expense </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">2,416</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,116</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Finance lease cost: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:192pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:152.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of ROU assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">General and administrative expense </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">128</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:152.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest on lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:192pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Interest expense </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">37</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">78</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:152.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total finance lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:192pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">165.22463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">578</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:36pt; margin-top:14.19pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below presents additional information related to the Company&#8217;s leases. </font>
        </div>
        <table style="width:384pt;height:121pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:275.57pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:275.57pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:275.57pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Weighted average remaining lease terms</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8.04&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">8.43&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.28&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.49&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.57pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Weighted average discount rate</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.57pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">10.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">10.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.255pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company was not party to any short-term leases, and variable lease costs were immaterial for the&#160;years ended December&#160;31, 2024 and 2023. As of December&#160;31, 2024 and 2023, the Company does not have any additional operating and finance leases that have not yet commenced. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth by year, maturities of operating and finance lease liabilities as of December&#160;31, 2024: </font>
        </div>
        <table style="width:384pt;height:168.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Operating</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Finance</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:2pt;padding-right:2pt;letter-spacing:-0.16pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:9pt;padding-right:9pt;letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Years Ending December&#160;31, </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,718</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">117</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,189</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">7,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">117</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">7,199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,461</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,496</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,671</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">28,671</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total lease payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">69,312</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">388</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">69,699</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less imputed interest </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(55<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(24,635<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:249.92pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Present value of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">44,731</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">333</td>
            <td style="padding:0pt;padding-left:3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">45,064</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 10. Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchase Obligations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The Company enters into various supply agreements that contains purchase commitments. Most of the commitments are based on a binding forecast for an agreed-upon period, which is 12-month or less. Future minimum purchase commitments under such agreements amount to $7.7&#160;million, of which all are due in 2025. The total amount of supplies purchased during 2024 under such agreements was $32.3&#160;million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, in 2022, the Company entered into an arrangement for cloud computing services with non-cancellable purchase commitments for three&#160;years. The agreement was subsequently amended in 2024. For the&#160;years ended December&#160;31, 2024 and 2023, the Company purchased cloud computing services of $9.9&#160;million and $3.0&#160;million, respectively, related to non-cancelable arrangements. Under the agreement, the Company has purchase obligations of $11.3&#160;million, $12.4&#160;million and $13.7&#160;million for&#160;years ending December&#160;31, 2025, 2026 and 2027. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Liability and Insurance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains professional liability, general liability, and other customary insurance on a claims-made basis in amounts deemed appropriate by the Company&#8217;s management based upon historical claims and the nature and risks of the Company. The Company&#8217;s business may subject the Company to litigation and liability for damages. The Company believes that current insurance protection is adequate for present business operations, but there can be no assurance that the Company will be able to maintain professional and general liability insurance coverage in the future or that such insurance coverage will be available on acceptable terms or adequate to cover any or all potential product or professional liability claims. A successful liability claim in excess of insurance coverage could have a material adverse effect on the Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Litigation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the ordinary course of business, the Company has become and may in the future become subject to pending and threatened legal and regulatory actions and proceedings. While it is not feasible to predict or determine the ultimate outcome of these matters, the Company believes that none of its current legal proceedings will have a material adverse effect on its financial position, results of operations, or cash flows for&#160;years ended December&#160;31, 2024 and 2023. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 11. Related Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s officers and directors have ownership interests in certain vendors providing services to the Company. During the&#160;years ended December&#160;31, 2024 and 2023, the Company made payments to these entities for services and expenses for $1.8 million and $2.1&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 12. Net Loss Per Share Attributable to Common shareholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders: </font>
        </div>
        <table style="width:456pt;height:111.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands, except per share data)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments of redeemable convertible preferred stock to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(96,367<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(121,112<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss attributable to common shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(378,257<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(462,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2.66<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(3.31<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">141,987</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">139,771</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the periods presented as they had an anti-dilutive effect: </font>
        </div>
        <table style="width:416pt;height:142.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">25,094,437</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">25,094,437</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">87,082,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">87,050,440</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested shares subject to repurchase </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">2,648,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">3,872,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">848,967,136</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">850,158,918</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:15.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 13. Segment and Geographic Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company operates as a single operating segment. An operating segment is defined as a component of an entity for which discrete financial information is available and regularly reviewed by the entity&#8217;s chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing performance. The Company&#8217;s CODM, its Chairman and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Net loss as reported on the consolidated statements of operations and comprehensive loss is used by the CODM to assess segment performance against management budgets and prior period operating results for the purpose of making results-driven decisions about organizational resource allocation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Segment revenues are derived from molecular profiling, strategic data, and research services that are delivered to the Company&#8217;s biopharmaceutical and clinical customers, who are predominantly located in the United States. The Company provides these services primarily by leveraging the Company&#8217;s proprietary technologies and clinico-genomic database, which are core to the Company&#8217;s operations and are deployed similarly across the service offerings. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below is a summary of the segment profit or loss, including significant segment expenses: </font>
        </div>
        <table style="width:456pt;height:216pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">412,260</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">306,128</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Less: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8722;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">223,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">207,509</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8722;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,403</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">152,602</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">142,925</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">169,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">149,053</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">113,916</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">116,883</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,258</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(50,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(31,610<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">18,484</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,094</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(349<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(12,606<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Segment and consolidated net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(281,890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(341,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">N</font><font style="text-transform:uppercase;letter-spacing:-0.2pt;">otes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customer&#8217;s location: </font>
        </div>
        <table style="width:416pt;height:81pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Years Ended December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:314.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">United States </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">401,836</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">293,408</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">International </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,424</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">12,720</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:314.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">412,260</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">306,128</td>
            <td style="padding:0pt;padding-left:0.419999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No single country outside of the United States accounted for more than 10.0% of total revenue during each of the&#160;years ended December&#160;31, 2024 and 2023. As of December&#160;31, 2024 and 2023, approximately 99.0% of the Company&#8217;s total assets are located in the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 14. Employee Benefit Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100.0% of eligible compensation on a pre-tax basis. For the&#160;years ended December&#160;31, 2024 and 2023, the Company contributed $8.0 million and $6.8&#160;million, respectively, to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 15. Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March 3, 2025, five grantees of the New Stock Options (see Note 7), who had previously elected to early exercise utilizing the promissory note, signed agreements to repay their notes, plus accrued interest in the form of shares of our common stock. The number of shares of common stock used in the payoff was determined using the fair value of the Company&#39;s common stock at the time of the repayment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March 25, 2025, in connection with the financing described above, the Company amended the terms of its certificate of formation to provide that the Series C redemption rights would not be exercisable until March 31, 2026 (from August 2025) and increased the original issue price and conversion price of its Series C convertible preferred stock used to calculate the conversion ratio of Series C preferred stock into common stock in connection with the initial public offering from $2.76 to $4.58 per share. </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April 1, 2025, the Company closed a private financing in which it issued a combination of senior convertible notes (the &#8220;2025 Convertible Notes&#8221;), Series E convertible preferred stock and Series&#160;F convertible preferred stock, for an aggregate of $167.7&#160;million. The 2025 Convertible Notes have an aggregate principal amount of $30.0&#160;million. The 2025 Convertible Notes accrue interest at a rate of 8% per annum, payable quarterly in cash, and mature on January&#160;1, 2026. The Company issued 12,345,674 shares of Series&#160;E convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $100.0&#160;million. The Company also issued 4,657,401 shares of Series&#160;F convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $37.7&#160;million. In connection with this financing, the Company also issued warrants to acquire shares of common stock to the holders of the 2025 Convertible Notes. These warrants are not initially exercisable for any shares of common stock, but such warrants become exercisable for a specified dollar value of shares on a monthly basis commencing on June&#160;1, 2025 if we have not completed an initial public offering by such date. Any exercisable portion of the warrants will be automatically exercised prior to the closing of the initial public offering and such warrants will terminate upon the closing of the offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to and in connection with the completion of the initial public offering, the 2025 Convertible Notes, Series E convertible preferred stock and Series&#160;F convertible preferred stock (plus an 8% accretion in connection with the preferred stocks) will convert into common stock at a price equal to 70% of the initial public offering price per share. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There were no other significant subsequent events identified through the date that the consolidated financial statements were issued, that could impact the financial statements.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCBS1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:7.30999999999995pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 1pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands, except share data)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-left:19pt;padding-right:19pt;letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-left:25pt;padding-right:25pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">32,704</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">65,442</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,225</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,201</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">80,174</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">88,244</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">36,552</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">39,572</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">19,578</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">20,270</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">171,233</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">215,729</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">61,651</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">67,817</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Goodwill </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">19,344</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">19,344</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">39,355</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">40,844</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:-0.18pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">291,583</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">343,734</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:-0.18pt;">Liabilities, Redeemable Convertible Preferred Stock, and Shareholders&#8217; Deficit</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">24,226</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">27,791</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accrued expenses and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">78,235</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">77,542</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Current portion of indebtedness </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">60,093</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">60,090</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">162,554</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">165,423</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Long-term indebtedness, net of debt discounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">316,643</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">319,438</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Warrant liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">128,691</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">91,642</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Other long-term liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">37,447</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">44,418</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">645,335</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">620,921</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Commitments and contingencies (see note 9) </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Redeemable convertible preferred stock: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;A preferred stock, par value $0.001: 490,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 485,795,293 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024; and $296,335 aggregate liquidation preference as of March&#160;31, 2025 and December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;B preferred stock, par value $0.001: 30,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 29,629,630 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024; and $16,000 aggregate liquidation preference as of March&#160;31, 2025 and December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;C preferred stock, par value $0.001: 142,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 116,200,835 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024; and $415,616 and $408,715 aggregate liquidation preference as of March&#160;31, 2025 and December&#160;31, 2024, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">415,616</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">408,715</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt; margin-bottom:-0.503333333333343pt;">
                <font style="letter-spacing:0.18pt;">Series&#160;D preferred stock, par value $0.001: 102,600,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 102,516,283 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024; and $1,078,273 and $1,060,712 aggregate liquidation preference as of March&#160;31, 2025 and December&#160;31, 2024, respectively </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">1,078,273</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.41pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">1,060,712</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total redeemable convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,246,113</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">2,221,651</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <font style="letter-spacing:0.18pt;">Shareholders&#8217; deficit: </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Common stock $0.001 par value; 1,173,000,000 and 1,150,000,000 shares </font>
                <br >
                <font style="letter-spacing:0.18pt;">authorized as of March&#160;31, 2025 and December&#160;31, 2024, respectively; </font>
                <br >
                <font style="letter-spacing:0.18pt;">147,433,040 and 146,747,083 shares issued as of March&#160;31, 2025 and </font>
                <br >
                <font style="letter-spacing:0.18pt;">December&#160;31, 2024, respectively; 140,950,490 and 146,017,083 shares </font>
                <br >
                <font style="letter-spacing:0.18pt;">outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively; shares </font>
                <br >
                <font style="letter-spacing:0.18pt;">issued and outstanding include 174,412 and 2,648,000 unvested shares subject to </font>
                <br >
                <font style="letter-spacing:0.18pt;">repurchase as of March&#160;31, 2025 and December&#160;31, 2024, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt; line-height:10.78pt;">
                <font style="letter-spacing:0.18pt;">Treasury stock at cost, 6,482,550 and 730,000 shares of common stock as of March&#160;31, 2025 and December&#160;31, 2024, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(16,917<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.18pt;">Related party promissory note receivable (see note 7) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(26,456<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,583,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,472,406<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Accumulated other comprehensive income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:0.18pt;">Total shareholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,599,865<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">(2,498,838<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:323.79pt;text-align:left;">
              <div style="margin-left:18pt;">
                <font style="letter-spacing:-0.18pt;">Total liabilities, redeemable convertible preferred stock, and shareholders&#8217; deficit</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">291,583</td>
            <td style="padding:0pt;padding-left:5.345pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">343,734</td>
            <td style="padding:0pt;padding-left:10.89pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCSOO1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:42pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND </font>
          <br >
          <font style="letter-spacing:-0.2pt;">COMPREHENSIVE LOSS (UNAUDITED)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:535pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands, except share and per share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Revenue: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">114,081</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">73,233</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">6,834</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">7,444</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total revenue</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">120,915</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">80,677</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Costs and operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of Services&#8201;&#8211;&#8201;Molecular Profiling Services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">60,894</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,894</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of Services&#8201;&#8211;&#8201;Pharma Research and Development Services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,958</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,829</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">39,609</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:337.75pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative expense (includes related party amounts of $515 and $480, for the three&#160;months ended March&#160;31, 2025 and 2024, respectively) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">52,119</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">44,354</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">23,066</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">34,376</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total costs and operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">178,867</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">172,902</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(57,952<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(92,225<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense), net: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">503</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,768</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(12,782<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(9,290<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(32,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(11,064<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(219<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total other expense, net</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(44,629<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(18,804<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Loss before income taxes and provision for income taxes</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Provision for income taxes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other comprehensive (loss) income, net of tax: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Unrealized gain on available-for-sale securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Foreign currency translation adjustments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Comprehensive loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(102,546<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(111,013<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Net loss attributable to common shareholders: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments of redeemable convertible preferred stock to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(24,462<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(23,113<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.2pt;">Net loss attributable to common shareholders</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(127,043<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(134,141<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(0.89<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(0.95<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:337.75pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">142,492</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">141,252</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCSOR1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS&#8217; DEFICIT (UNAUDITED)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:214.06pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:381.69pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
          <tr style="line-height:7.28pt;height:24.91pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:112pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center; line-height:7.29pt;">
                <font style="letter-spacing:-0.13pt;">Redeemable Convertible </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.82pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.13pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.13pt;">Treasury Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.29pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.13pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Paid-In </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.29pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.13pt;">Related </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Party </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Promissory </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Note </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.29pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.13pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.29pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.13pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Other </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Comprehensive </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.07pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.77pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:7.29pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.13pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Shareholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.13pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:6.5pt;height:13.03pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:6.5pt;">
            <td style="padding:3.25pt 0pt 3.03pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.13pt;">(amounts in thousands, except share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.03pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.13pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.03pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:6pt;padding-right:6pt;letter-spacing:-0.13pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.03pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.13pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.03pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.13pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.03pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:6pt;padding-right:6pt;letter-spacing:-0.13pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.03pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:3pt;padding-right:3pt;letter-spacing:-0.13pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:3.25pt 0pt 3.625pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balances at December&#160;31, 2023</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,125,284</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">141,188,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">141</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">730,000</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(25,701<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,119,278<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">218</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,144,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.75pt 0pt 2.25pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">4,458</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">4,458</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Issuance of common stock upon exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">157,204</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">209</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Interest income from related party </font>
                <br >
                <font style="letter-spacing:0.15pt;">promissory notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(186<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(186<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Adjustment of redeemable convertible preferred Series&#160;C and Series&#160;D to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">23,113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(4,667<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(18,446<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(23,113<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:3.5pt 0pt 2.25pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.875pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:3.25pt 0pt 3.625pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balances at March&#160;31, 2024</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,148,397</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">141,346,164</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">142</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">730,000</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(25,887<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,248,752<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">233</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,274,594<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.75pt 0pt 3.625pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balances at December&#160;31, 2024</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,221,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">143,369,083</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">144</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">730,000</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(330<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(26,456<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,472,406<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,498,838<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.75pt 0pt 2.25pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">14,691</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">14,691</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Issuance of common stock upon exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">3,333,957</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,433</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,434</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Interest income from related party </font>
                <br >
                <font style="letter-spacing:0.15pt;">promissory notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(128<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(128<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Payoff of related party promissory </font>
                <br >
                <font style="letter-spacing:0.15pt;">notes </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">26,584</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">26,584</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:3.5pt 0pt 2.25pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Repurchases of common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">(5,752,550<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">5,752,550</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(16,587<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(16,587<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:112pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Adjustment of redeemable convertible preferred Series&#160;C and Series&#160;D to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">24,462</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(16,110<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(8,352<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(24,462<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:3.5pt 0pt 2.25pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Other comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(14<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.25pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.875pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.875pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:3.25pt 0pt 3.625pt 0pt; width:112pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balances at March&#160;31, 2025</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">2,246,113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:3pt solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.82pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">140,950,490</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:3.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">6,482,550</td>
            <td style="padding:0pt;padding-left:0.00500000000000078pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(16,917<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,583,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">245</td>
            <td style="padding:0pt;padding-left:12.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt; width:3.07pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.875pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,599,865<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fCSOC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:622pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:343.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:17pt;padding-right:17pt;letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:17pt;padding-right:17pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from operating activities</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,045</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">17,705</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">14,691</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,458</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-cash operating lease expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,452</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,551</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Amortization of debt discounts </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,590</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">32,333</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,064</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">456</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,919</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities:</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,913</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,378<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Supplies </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,061</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,024</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,470</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(81<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">326</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(1,739<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(2,778<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses and other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,580</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(31,338<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(73,925<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from investing activities</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Maturities of marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">61,376</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(2,689<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(1,738<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by (used in) investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(2,689<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">59,638</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from financing activities</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payments made on finance lease obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(22<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(80<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,434</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">210</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payment of deferred offering costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(105<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the 2023 term loan, net of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">199,978</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Purchase of treasury stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(22<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,285</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">200,108</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net increase (decrease) in cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(32,738<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">185,822</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash at beginning of year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">68,028</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">60,007</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 3pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash at end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">35,290</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">245,829</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of cash flow information</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,829</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">6,080</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of non-cash activity</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash paid for amounts included in the measurement of lease liabilities</font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating cash flow used for operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,847</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,853</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Operating cash flow used for finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Financing cash flow used for finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment included in accounts payable and accrued liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">242</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,413</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:343.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred offering costs, accrued but not paid </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,420</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,989</td>
            <td style="padding:0pt;padding-left:4.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these condensed consolidated financial statements </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fNTCF12">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 1. Nature of the Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Caris Life Sciences, Inc. (the &#8220;Company&#8221; or &#8220;Caris&#8221;) is a patient-centric, next-generation artificial intelligence (&#8220;AI&#8221;) TechBio company and precision medicine pioneer. The Company commercializes and develops innovative solutions to transform healthcare through the use of comprehensive molecular information, AI, and machine learning (&#8220;ML&#8221;) algorithms. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s current molecular profiling services portfolio is focused on oncology and consists of MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a novel, universal blood-based molecular profiling solution, with the aim to address the entire continuum of cancer treatment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company also collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company was incorporated under the laws of the Cayman Islands in November&#160;2011 (Caris Life Sciences, Ltd.) and re-domiciled to be incorporated in Texas in July&#160;2020 (Caris Life Sciences, Inc.) and is headquartered in Irving, Texas. The Company also has locations in Phoenix, Arizona; New York, New York; Cambridge, Massachusetts; Basel, Switzerland; and Tokyo, Japan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Going Concern</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, the Company&#8217;s cash and cash equivalents balance was approximately $31.2&#160;million, and the short-term investments balance was $2.2&#160;million, and the Company had a 2023 Term Loan (see Note 8) outstanding with a balance of $400.0&#160;million. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In 2025, the Company issued the 2025 Convertible Notes in the amount of $30.0&#160;million. In connection with the Company&#8217;s Series&#160;C redeemable convertible preferred stock, the 2023 Term Loan and the 2025 Convertible Notes, the following payments may become due within 12&#160;months of the date of the issuance of the condensed consolidated financial statements if the Company has not completed an initial public offering raising at least $100.0&#160;million in gross proceeds prior to such due dates: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Series&#160;C redemption rights will become exercisable on March&#160;31, 2026; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The Company will be required to make a one-time acceleration payment on December&#160;31, 2025 in an amount equal to 15% of the outstanding principal amount under the 2023 Term Loan (or $60.0&#160;million based on the principal amount currently outstanding) together with any applicable repayment premium and exit fee as described in the Term Loan agreement on such date; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:24pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The 2025 Convertible Notes of $30.0&#160;million will come due on January&#160;1, 2026. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If these payments become due, the Company&#8217;s existing cash resources and projected operating cash flows may not be sufficient to repay these amounts and continue to fund operating activities for at least the next 12&#160;months from the issuance of the condensed consolidated financial statements. These conditions raise substantial doubt as to the Company&#8217;s ability to continue as a going concern. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Management intends to raise additional funding through an initial public offering raising at least $100.0&#160;million in gross proceeds which would eliminate the requirement to make the one-time acceleration payment related to the 2023 Term Loan. Further, the initial public offering would cause the Series&#160;C redeemable convertible preferred stock and the 2025 Convertible Note to convert to common stock and thereby not be subject to redemption and repayment upon maturity on March&#160;31, 2026 and January&#160;1, 2026, respectively. Management may seek alternative private financing through additional debt or equity offerings that will fulfill its operating, capital and debt requirements for at least 12&#160;months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to complete such an initial public offering or otherwise secure such financing in a timely manner or on favorable terms, if at all. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2. Summary of Significant Accounting Policies and Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Financial Statement Presentation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The condensed consolidated financial statements include the accounts of Caris and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASUs&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Interim Consolidated Financial Information</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2025 and its results of operations and cash flows for the three&#160;months ended March&#160;31, 2025 and 2024. The results of operations for the three&#160;months ended March&#160;31, 2025 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2025, or for any other future annual or interim period. The condensed consolidated balance sheet as of December&#160;31, 2024 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted from these unaudited condensed consolidated financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP in the United States requires the use of estimates and assumptions about future events that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and related notes, including the amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the periods reported. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Significant estimates and assumptions are used for, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">revenue recognition </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fair value of stock-based awards and common stock </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">fair value of financial assets and liabilities </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Future events and their effects cannot be predicted with certainty. Accordingly, the accounting estimates require the exercise of judgment. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. The accounting estimates used in the preparation of the Company&#8217;s condensed consolidated financial statements may change as new events occur, additional information is obtained, and the operating environment changes. The Company will evaluate and update the assumptions and estimates on an ongoing basis and may employ outside experts to assist in its evaluation, as considered necessary. Actual results could materially differ from those estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash, Cash Equivalents, and Restricted Cash</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company considers all highly liquid investments with original maturities of three&#160;months or less from date of acquisition to be cash equivalents. Refer to Note 4 for information on the Company&#8217;s restricted cash. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes revenue under ASC Topic 606, </font><font style="font-style:italic;letter-spacing:0.2pt;">Revenue from Contracts with Customers</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 606&#8221;). Revenue is recognized when control of goods and services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ASC 606 provides for a five-step model that includes: </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Step 1: Identify the contract(s) with a customer. </font>
        </div>
        <div style="margin-left:36pt; margin-top:1.81pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Step 2: Identify performance obligations in the contract. </font>
        </div>
        <div style="margin-left:36pt; margin-top:1.9pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Step 3: Determine the transaction price. </font>
        </div>
        <div style="margin-left:36pt; margin-top:1.9pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font>
        </div>
        <div style="margin-left:36pt; margin-top:1.9pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company derives revenue from two distinct channels: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Molecular profiling services involving the provision of precision oncology solutions utilizing MI Profile and Caris Assure. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Pharma research and development services involving delivery of laboratory, strategic data, and research services to biopharmaceutical customers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Molecular Profiling Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the majority of its molecular profiling services, the Company recognizes revenue from the sale of its precision oncology solutions, provided to customers, including certain hospitals, institutions and patients, at the point in time when the results of the profiling services are delivered to ordering physicians. Most cases requested on behalf of customers are provided without a written agreement; however, the Company determines that an implied contract exists with its customers for whom a physician orders the case. Results from molecular profiling services are delivered via fax, electronically, or in hard copy. Shipping and handling activities are considered fulfillment activities and as such, amounts incurred are recorded within Cost of Services&#8212;Molecular Profiling Services on the condensed consolidated statements of operations and comprehensive loss. The Company identifies each sale of the Company&#8217;s profiling service as a distinct performance obligation. Payment terms are a function of a patient&#8217;s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Collection of consideration the Company expects to receive typically occurs within 90 to 120&#160;days of billing. Occasionally, payers may recoup or we may refund consideration, mainly as a result of claim processing. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The total consideration to which the Company expects to be entitled in exchange for the Company&#8217;s services may be fixed or variable. Consideration includes reimbursement from patients, hospitals, and third-party commercial and governmental payers, such as insurance companies, adjusted for variable consideration related to implicit price concessions that the Company may grant. The Company estimates the variable consideration under a portfolio approach for third-party payers, hospitals and patients with similar reimbursement characteristics. This includes analysis of an average reimbursement per case per portfolio and a&#160;percentage of cases reimbursed by considering the historical reimbursement data (including any refunds and recoupments) from such third-party payers, hospitals and patients. Specifically, the Company calculates the historical average reimbursement rates for each portfolio and applies an estimated reimbursement rate, based on historical trends, to the number of cases delivered each period. The period for which historical data is drawn upon is determined on a by- portfolio basis for each payer group, taking into consideration the average collection period. Additionally, the estimate also considers current contractual and statutory requirements, patient insurance eligibility and payer reimbursement contracts, and any known current or anticipated reimbursement trends not reflected in the historical data and only recognizes revenue for variable consideration that the Company determines is probable will not result in a significant reversal in the future. The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Subsequent changes to the estimate of the transaction price are recorded as adjustments to molecular profiling services revenue in the period where such changes occur. Both the estimate and any subsequent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">revision are uncertain and require the use of management&#8217;s judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Pharma Research and Development Services</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as molecular profiling services, pharma research and development services, and strategic data services. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers for proper revenue recognition, including whether services are capable of being distinct and considered distinct within the context of the contract. The performance obligations for biopharmaceutical customers vary by contract. Such contracts may include a performance obligation to provide molecular profiling services, to facilitate the development and regulatory approval of drugs, or to provide target discovery services. Under those contracts, the Company receives payments upon the achievement of milestones, as well as provision of on-going support. The transaction price of the development services contracts may include variable consideration, due to the uncertainty associated with the achievement of the milestones. In making the assessment of whether variable consideration should be included in the transaction price, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The Company recognizes pharma research and development services revenue over the period in which biopharmaceutical research and development services are provided. Depending on the nature of the service, the Company recognizes revenue using either the output or input method to measure progress, whichever provides a more faithful depiction of the transfer of goods or services. Use of an output method or input method to depict the transfer of services generally does not result in a material difference with respect to the timing of revenue recognition because most services commence and end within the same reporting period. A constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Standalone Selling Price</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company determines standalone selling prices by considering the historical selling prices of its performance obligations in similar transactions, where applicable, as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing from other vendors, industry publications, current pricing practices and management estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Contract Balances</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period the Company delivers goods or provides services, or when the right to consideration is unconditional. In situations where revenue recognition occurs before invoicing, an unbilled receivable is created, which represents a contract asset. As of March&#160;31, 2025 and December&#160;31, 2024, the unbilled receivable balance was $1.6&#160;million and $4.6&#160;million, respectively, which is included in accounts receivable on the condensed consolidated balance sheets. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes contract liabilities primarily related to payments received in advance of satisfaction of performance obligations from contracts with customers. Contract liabilities are relieved as the Company fulfills its obligations under the contract and revenue is recognized. As of March&#160;31, 2025 and December&#160;31, 2024, the contract liability balance was $7.7&#160;million and $7.5&#160;million, respectively, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the changes in the contract liabilities during the period: </font>
        </div>
        <table style="width:416pt;height:105pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:365.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in </font>
                <br >
                <font style="letter-spacing:-0.16pt;">thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:365.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,470</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:365.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase in contract liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,774</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:365.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Revenue recognized during the period that was included in deferred revenues at the beginning of the period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,797<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:365.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue recognized from performance obligations satisfied within the same period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,783<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:365.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">7,664</td>
            <td style="padding:0pt;padding-left:3.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:13.3pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The amount of revenue recognized during the three&#160;months ended March&#160;31, 2024 pertaining to amounts deferred as of December&#160;31, 2023 was $2.0&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Transaction Price Allocated to Remaining Performance Obligations</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods and excludes performance obligations that are subject to cancellation terms. The Company has elected not to disclose information regarding the transaction price allocated to the remaining performance obligations for which the original expected duration of the contract is one year or less. The amount of transaction price allocated to the remaining performance obligations for contracts with original expected duration over one year as of March&#160;31, 2025 was $7.1&#160;million. The Company expects to recognize the amounts within twelve&#160;months from the respective balance sheet dates. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, for the three&#160;months ended March&#160;31, 2025 and 2024, the Company recorded $3.9&#160;million and $(3.9) million of adjustments to revenue related to services delivered in prior periods, respectively, which is based on variability that was subsequently resolved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Practical Expedients and Contract Costs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payment terms and conditions vary by contract and customer. In instances where the timing of the Company&#8217;s revenue recognition differs from the timing of its invoicing, the Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised services to the customer will be one year or less. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a practical expedient, the Company recognizes the incremental costs of obtaining contracts, such as sales commissions, as expenses when incurred, if the amortization period of the asset that the Company otherwise would have recognized for the capitalized costs is one year or less. Sales commissions are recorded within selling and marketing expense on the condensed consolidated statements of operations and comprehensive loss. The Company did not capitalize any sales commissions or contract fulfillment costs for the periods ended March&#160;31, 2025 and December&#160;31, 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Collaboration agreements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is party to various collaboration and licensing agreements under which the Company out-licenses certain know-how and molecular data. The collaboration arrangements are intended to solidify the Company&#8217;s third-party partnerships to align oncology capabilities and create industry-leading molecular oncology research platforms to accelerate drug development and novel research. Under these collaboration arrangements, the Company generally receives a split of fees from its collaborative partners that are earned pursuant to statements of work (&#8220;SOWs&#8221;) executed with end users of the Company&#8217;s licensed molecular data. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s collaboration and licensing agreements are within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) and ASC 606 because the counterparty to these agreements meets the definition of a customer. As such, the Company recognizes revenue earned from the licenses of molecular data granted to the Company&#8217;s collaborative partners in accordance with ASC 606. Each license of molecular data granted by the Company to a collaborative partner represents a distinct performance obligation in the contract. The transaction price for a given arrangement is entirely variable and depends on the SOWs executed by the counterparty with end users. The amount of revenue allocated to each license is equal to the amount of revenue to which the Company expects to be entitled. The Company recognizes revenue at the point in time that it delivers the molecular data to the third-party collaborative partner. For the three&#160;months ended March&#160;31, 2025 and 2024, the Company recognized collaboration revenue of $1.3&#160;million and $1.4&#160;million, respectively, which is included in revenue from pharma research and development services on the condensed consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Services&#8212;Molecular Profiling Services</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services for molecular profiling services generally consists of cost of materials, direct labor including bonus and stock-based compensation, and equipment maintenance and depreciation expenses associated with processing cases (including accessioning, sequencing, quality control analyses and shipping charges to transport tissue samples), freight and profile results for ordering physicians. Costs associated with completing the molecular profiling services are recorded as the service is performed, regardless of when revenue is recognized with respect to the service. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Services&#8212;Pharma Research and Development Services</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of services for pharma research and development services generally consists of cost incurred for the performance of the services requested by the Company&#8217;s biopharmaceutical customers related to the delivery of laboratory, strategic data and research services, and will vary depending on the nature, timing, and scope of customer projects. Costs associated with delivering pharma research and development services are recorded as incurred. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of Credit Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash primarily with domestic financial institutions of high credit quality, with balances that exceed amounts insured by the Federal Deposit Insurance Corporation as of March&#160;31, 2025 and December&#160;31, 2024, respectively. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company invests in treasury bills issued by the U.S. Government. U.S. treasury bills with original maturities of three&#160;months or less are classified within cash equivalents. Short-term marketable securities are comprised of U.S. treasury bills with original maturities between three and twelve&#160;months. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions. The goal of the Company&#8217;s investment policy is to ensure safety and preservation of the principal balance, and diversification of risk over cash balances held on deposit. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arise from the provision of molecular profiling services and pharma research and development services and other, primarily with biopharmaceutical companies, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any. Concentrations of credit risk are limited due to the number of payers and their dispersion across multiple geographic regions. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the three&#160;months ended March&#160;31, 2025 and 2024, the Company&#8217;s revenues were primarily derived from the sale of the Caris molecular profiling services. As discussed above, payment terms of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">services are a function of a patient&#8217;s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Revenue associated with each payer, including its affiliated entities, as a&#160;percentage of the Company&#8217;s total revenue for the respective period, and accounts receivable balance attributable to each payer, including its affiliated entities, as a&#160;percentage of the Company&#8217;s total accounts receivable balance at the respective condensed consolidated balance sheet date, are as follows: </font>
        </div>
        <table style="width:456pt;height:85pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:239.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">% Revenue for the </font>
                <br >
                <font style="letter-spacing:-0.16pt;">three&#160;months ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">% Accounts </font>
                <br >
                <font style="letter-spacing:-0.16pt;">receivable as of </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:239.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Major Payer </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:14pt;padding-right:14pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:9pt;padding-right:9pt;letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:15pt;padding-right:15pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:239.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payer 1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">51.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">36.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">64.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">16.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payer 2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">10.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">19.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payer 3 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:8.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:13.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents major payers below 10.0%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accounts Receivable</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Accounts receivable includes billed and unbilled receivables, net of an allowance for expected credit losses. Accounts receivable primarily represent receivables from biopharmaceutical customers and third-party payers. Accounts receivable for pharmaceutical services are established based on the amounts outstanding per the contractual arrangements with biopharmaceutical customers. The Company applies the current expected credit loss standard in ASC Subtopic 326-20, </font><font style="font-style:italic;letter-spacing:0.2pt;">Financial Instruments&#8212;Credit Losses</font><font style="letter-spacing:0.2pt;"> (&#8220;ASC 326&#8209;20&#8221;) and reserves a portion of the accounts receivable based on assessment of the collectability of customer accounts at the time of revenue recognition. The Company regularly reviews the reserve by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Receivables deemed to be uncollectible are written-off against the allowance for credit losses at the time such receivables are deemed to be uncollectible under a specific identification or estimated method. Recoveries of accounts receivable previously written off are recorded when received. As of March&#160;31, 2025 and December&#160;31, 2024, the Company had an immaterial allowance for credit losses related to its accounts receivable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Supplies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Supplies consist primarily of laboratory items and reagents used by the Company in providing services. All supplies are raw materials and are stated at the lower of cost or net realizable value on a first-in, first-out basis. The Company periodically reviews its supplies for excess or obsolescence and writes down obsolete or otherwise unmarketable supplies to their estimated net realizable value. As of March&#160;31, 2025 and December&#160;31, 2024, the amount of write downs associated with the Company&#8217;s supplies was immaterial. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Deferred Offering Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company&#8217;s proposed initial public offering (&#8220;IPO&#8221;). These costs are recorded as prepaid expenses and other current assets on the condensed consolidated balance sheets. The deferred offering costs will be recorded against IPO proceeds upon the consummation of the IPO. In the event the planned IPO is terminated, the deferred offering costs will be expensed. The Company had $5.8&#160;million and $4.5&#160;million of deferred offering costs as of March&#160;31, 2025 and December&#160;31, 2024, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment, Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company reports property and equipment at cost, net of accumulated depreciation, amortization, and any asset impairments. The cost of properties held under finance leases is equal to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">present value of lease payments not yet paid, adjusted for initial direct costs, prepaid lease payments and lease incentives received. Major improvements which add to productive capacity or extend the life of an asset are capitalized. Normal repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is reflected in the accompanying condensed consolidated statements of operations and comprehensive loss for the period. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation and amortization expenses are calculated on a straight-line basis and applied to asset classes based upon the Company&#8217;s estimate of the asset class&#8217;s useful life, as summarized below: </font>
        </div>
        <table style="width:384pt;height:98.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186.87pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Estimated Useful Life </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment and software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aircraft </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">15&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements/leased buildings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Lesser of remaining lease term or useful life </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186.87pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leased equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:185.13pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Lesser of initial lease term or 5&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Computer equipment and software includes the purchases of hardware, software and capitalized labor costs associated with internally developed software. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company capitalizes purchased software which is ready-for-service and capitalizes qualifying internal software development costs incurred on significant projects. Capitalization of costs begins when two criteria are met: (1)&#160;the preliminary project stage is completed, management with relevant authority authorizes and commits to funding the software project, and (2)&#160;it is probable that the software will be completed and used for its intended function. Capitalization ceases when the software is substantially complete and ready for its intended use, including the completion of all significant testing. Costs related to preliminary project activities and post-implementation operating activities are expensed as incurred. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Capitalized software costs are included in property and equipment, net. These costs are amortized using the straight-line method over the estimated useful life of the underlying software, which is three&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fair Value Measurements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The basis for these assumptions establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Level&#160;1</font><font style="letter-spacing:0.2pt;">&#8212;Observable inputs such as quoted prices in active markets for identical assets and liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Level&#160;2</font><font style="letter-spacing:0.2pt;">&#8212;Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Level&#160;3</font><font style="letter-spacing:0.2pt;">&#8212;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:10pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:10pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Market approach</font><font style="letter-spacing:0.2pt;">&#8212;Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Cost approach</font><font style="letter-spacing:0.2pt;">&#8212;Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Income approach</font><font style="letter-spacing:0.2pt;">&#8212;Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments consist of cash, cash equivalents, restricted cash, short-term marketable securities, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities, debt, warrants, and derivative instruments. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025 and December&#160;31, 2024, the carrying amounts of the Company&#8217;s cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair value based on the short-term nature of these items. There were no transfers between Levels 1, 2 or 3 for the periods ended March&#160;31, 2025 and December&#160;31, 2024. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: </font>
        </div>
        <table style="width:456pt;height:110.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:281.15pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:281.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:281.15pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:281.15pt;">
              <font style="letter-spacing:-0.2pt;">Financial assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.15pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,225</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,225</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.15pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financial liabilities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.15pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">128,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">128,691</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.15pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,342</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,342</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:110.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:289.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.5pt;">
              <font style="letter-spacing:-0.2pt;">Financial assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Short-term marketable securities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,201</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,201</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Financial liabilities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">91,642</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">91,642</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,058</td>
            <td style="padding:0pt;padding-left:0.824999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.365pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,058</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.1pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrant liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company utilized a probability-weighted scenario approach factoring in various exit strategies and the related timing of such to estimate the fair value of its warrant liability. For each scenario, the Company utilized a Black-Scholes option pricing model with the following assumptions: </font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Fair value per share of the underlying stock&#8212;</font><font style="letter-spacing:0.2pt;">The fair value of the underlying stock represents the fair value of the Company&#8217;s Series&#160;C preferred stock that the warrants are convertible into. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Volatility&#8212;</font><font style="letter-spacing:0.2pt;">The volatility is derived from historical volatilities of several unrelated publicly-listed peer companies, since the Company has no trading history. When making the selections of industry peer companies to be used in the volatility calculation, the Company considers the size, operational and economic similarities to the Company&#8217;s principal business operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:10pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:10pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-free interest rate&#8212;</font><font style="letter-spacing:0.2pt;">The risk-free interest rate is based on U.S. treasury yield as of the measurement dates interpolated to match the maturity equal to the respective term to exit. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividend yield&#8212;</font><font style="letter-spacing:0.2pt;">The expected dividend assumption is based on the Company&#8217;s current expectations about the Company&#8217;s anticipated dividend policy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:36pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:56pt;">
          <!--blacklining:none;-->
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected term (years)&#8212;</font><font style="letter-spacing:0.2pt;">Based on expected term under various exit strategies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The below table summarizes the significant unobservable inputs used in the fair value measurement of the warrant liability as of March&#160;31, 2025 and December&#160;31, 2024: </font>
        </div>
        <table style="width:456pt;height:97pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:204.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:204.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:56.87pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2018 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:56.87pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:56.87pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2018 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:56.87pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:204.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value per share of the underlying stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$4.76&#8211;$7.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$4.76&#8211;$7.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$3.66&#8211;$5.65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">$3.66&#8211;$5.65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">46.0%&#8211;62.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">59.4%&#8211;62.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">47.6%&#8211;63.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">61.2%&#8211;63.0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.2%&#8211;4.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.9%&#8211;4.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.2%&#8211;4.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">4.3% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.19&#8211;0.50 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.19&#8211;2.75 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.29&#8211;0.75 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.87pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.29&#8211;2.25</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Derivative liability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;18, 2023, the Company entered into a credit agreement (the &#8220;New Term Loan Agreement&#8221;) under which the Company issued senior, secured promissory notes (the &#8220;2023 Term Loan&#8221;) by which the New Term Loan lenders agreed to lend the Company up to an aggregate principal amount of $400.0&#160;million, $200.0&#160;million of which was received by the Company upon issuance, and $200.0 was drawn down in March&#160;2024. The Company identified certain embedded features in the 2023 Term Loan, including various contingent prepayment, compensatory payment, and default interest rate features, that are required to be bifurcated from the 2023 Term Loan and separately accounted for in the condensed consolidated financial statements as a compound derivative liability. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fair value of the derivative liability was estimated using the discounted cash flow method under the income approach. This approach involves significant Level&#160;3 inputs and assumptions including an estimated probability and timing of certain contingent events, such as events of default, change of control, sale of assets, etc. The analysis also required the selection of a discount rate representative of the Company&#8217;s credit risk. The discount rate used for the initial fair value was calibrated to the transaction. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Refer to Note 8 for additional information about the compound embedded derivative liability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Debt</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $377.8&#160;million, compared to a carrying value of $375.1&#160;million. As of December&#160;31, 2024, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $380.9&#160;million, compared to a carrying value of $373.1&#160;million. The Company estimated the fair value of the 2023 Term Loan as of based on a discounted cash flow analysis, and an income approach, which represented the use of Level&#160;3 inputs in the fair value hierarchy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Goodwill</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities acquired through a business combination. The Company evaluates goodwill for impairment in accordance with ASC Topic 350, </font><font style="font-style:italic;letter-spacing:0.2pt;">Intangibles&#8212;Goodwill and Other</font><font style="letter-spacing:0.2pt;"> on an annual basis on October&#160;1, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, or the Company may determine to proceed directly to the quantitative impairment test. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the Company assesses qualitative factors and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount or if the Company determines not to use the qualitative assessment, then a quantitative impairment test is performed. The factors utilized in the qualitative assessment include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and Company-specific events. The quantitative impairment test requires comparing the fair value of the reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is determined based on the present value of estimated cash flows using available information regarding expected cash flows of each reporting unit, discount rates, and the expected long-term cash flow growth rates. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has identified that its business operates as a single operating segment which is also a single reporting unit for purposes of testing goodwill for impairment. An impairment exists if the fair value of the reporting unit is lower than its carrying value. If the fair value of the reporting unit is lower than its carrying value, the Company would record an impairment loss equal to the excess of the reporting unit&#8217;s carrying value over its fair value. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no impairment losses for the periods ended March&#160;31, 2025 and 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities. The costs include direct costs for salaries and benefits, materials, contract services and other outside costs, and costs to acquire in-process research and development projects and technologies that have no alternative future use. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advertising</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company expenses advertising costs as incurred. The Company incurred advertising costs of $0.1&#160;million and $0.2&#160;million for the three&#160;months ended March&#160;31, 2025 and 2024, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Self-Insurance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company offers medical insurance coverage to eligible employees under a self-insured program managed by a third-party administrator, leveraging stop-loss insurance policies to mitigate risk. The Company records an estimate of its liability for medical claims, which includes the incurred claims amount plus an estimate of incurred, but not reported claims. Self-insurance liability of $2.0&#160;million and $1.9&#160;million for the periods ended March&#160;31, 2025 and December&#160;31, 2024, respectively, is included within accrued expenses and other current liabilities on the condensed consolidated balance sheets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Shareholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company calculates its basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method required for companies with participating securities. Each series of the Company&#8217;s redeemable convertible preferred stock is considered to be a participating security because the preferred shareholders have a right to receive dividends on a pari&#160;passu basis with the Company&#8217;s common shareholders. The two-class method determines net income (loss) per share for each class of common stock and participating security according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income (loss) available to common shareholders for the period to be allocated between common and participating securities based upon the respective rights of each to share in earnings as if all income (loss) for the period had been distributed. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method between common and participating securities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because the Company has reported a net loss for the three&#160;months ended March&#160;31, 2025 and 2024, basic net loss per share attributable to common shareholders is calculated by dividing net loss attributable to common shareholders by the weighted-average common stock outstanding during the period, without </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">consideration for potential common stock equivalents. Net loss attributable to common shareholders is equal to net loss, less accretion on preferred securities to their redemption value to the extent such securities are outstanding. Diluted net loss per share attributable to common shareholders is calculated by adjusting the weighted-average stock outstanding for the dilutive effect of potential common stock equivalents outstanding. For purposes of calculating the diluted net loss per share attributable to common shareholders, convertible preferred stock, convertible promissory notes, warrants, and stock options are considered to be potential common stock equivalents but are excluded from the calculation of diluted net loss per share attributable to common shareholders because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share attributable to common shareholders was the same for all periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for income taxes under the asset and liability method as set forth in ASC&#160;740 &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes</font><font style="letter-spacing:0.2pt;">&#8221; &#8203;(&#8220;ASC 740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across its global operations. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1)&#160;we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related taxing authority. For tax positions not meeting the more likely than not test, no tax benefit is recorded. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At March&#160;31, 2025 and December&#160;31, 2024, the Company has accumulated net operating loss carryforwards in both the U.S. and foreign jurisdictions, and no provision for income taxes is required. The Company&#8217;s deferred tax assets are subject to a full valuation allowance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Pronouncements Not Yet Adopted</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2023, the FASB issued ASU No. 2023-09, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</font><font style="letter-spacing:0.2pt;"> which requires presentation of specific categories of reconciling items, as well as reconciling items that meet a quantitative threshold, in the reconciliation between the income tax provision and the income tax provision using statutory tax rates. The standard also requires disclosure of income taxes paid disaggregated by jurisdiction with separate disclosure of income taxes paid to individual jurisdictions that meet a quantitative threshold. For public business entities, the ASU is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than public business entities, the ASU is effective for annual periods beginning after December&#160;15, 2025. The amendments of the ASU should be applied on a prospective basis; however, entities have the option to apply retrospectively for each period presented. The Company does not expect the adoption of this new standard in 2026 to have an impact on its condensed consolidated financial position, results of operations, or cash flow. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2024, the FASB issued ASU No. 2024-03, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Statement- Reporting Comprehensive Income-Expense disaggregation disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</font><font style="letter-spacing:0.2pt;">. This ASU requires disclosure of specified information about certain costs and expenses in the notes to financial statements. This ASU is effective for annual periods beginning after December&#160;15, 2026, and interim periods within fiscal&#160;years beginning after December&#160;15, 2027. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on the disclosures within our financial statements, and expect to adopt this ASU for the year ending December&#160;31, 2027. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 3. Condensed Consolidated Balance Sheet and Statement of Operations and Comprehensive Loss Components</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prepaid Expenses and Other Current Assets</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets consist of the following: </font>
        </div>
        <table style="width:456pt;height:76.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.79pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,924</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,562</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7,654</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,708</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,578</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">20,270</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment, Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment, net consist of the following: </font>
        </div>
        <table style="width:456pt;height:167pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.79pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment and software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">77,118</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">73,312</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capitalized software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">22,622</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">25,921</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">103,900</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">103,795</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,110</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,110</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements/Leased buildings </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">63,290</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">63,039</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Aircraft and leased equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">21,249</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">21,249</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">297,289</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">296,426</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(235,638<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(228,609<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">61,651</td>
            <td style="padding:0pt;padding-left:6.76pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">67,817</td>
            <td style="padding:0pt;padding-left:12.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:14.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Total depreciation and amortization expense was $7.0&#160;million and $17.7&#160;million for the three&#160;months ended March&#160;31, 2025 and 2024, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Accrued Expenses and Other Current Liabilities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accrued expenses and other current liabilities consist of the following: </font>
        </div>
        <table style="width:456pt;height:151.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.79pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Trade accruals </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,470</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,131</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued payroll and employee medical </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">14,264</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">17,882</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued bonus </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">33,150</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">25,736</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current portion of early exercise stock option liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">327</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,957</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Contract liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,664</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,470</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current portion of operating lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,023</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,080</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other accrued expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,337</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,286</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total accrued expenses and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">78,235</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">77,542</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Long-Term Liabilities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other long-term liabilities consist of the following: </font>
        </div>
        <table style="width:456pt;height:76.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.79pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term operating lease liabilities, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">37,067</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">38,651</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Long-term portion of early exercise stock option liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">380</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,767</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total other long-term liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">37,447</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">44,418</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 4. Guaranty Agreement and Restricted Cash</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company entered into a lease agreement with KCP NNN II Leasehold 4, LLC on July&#160;25, 2019 to lease 114,500 square feet of space in Irving, Texas. As part of the lease agreement, the Company delivered an unconditional, irrevocable letter of credit for $3.4&#160;million from a nationally recognized bank. The Company obtained this letter of credit and placed $3.4&#160;million in a security deposit account. As of March&#160;31, 2025 and December&#160;31, 2024, amounts outstanding are $2.7&#160;million and are included within cash, cash equivalents, and restricted cash and other assets on the condensed consolidated balance sheets. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The remaining restricted cash amounts are not material individually. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the amounts shown in the condensed consolidated statements of cash flows. Restricted cash is presented within cash, cash equivalents, and restricted cash and other assets on the condensed consolidated balance sheets. </font>
        </div>
        <table style="width:456pt;height:91.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:138.7pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:179.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Condensed consolidated balance sheet line item </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:138.7pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:179.09pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:138.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:179.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">31,201</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">63,950</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restricted cash&#8722;short-term </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:179.09pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Cash, cash equivalents, and restricted cash </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,503</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,492</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:138.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Restricted cash&#8722;long-term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:179.09pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,586</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,586</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:138.7pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:179.09pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">35,290</td>
            <td style="padding:0pt;padding-left:10.925pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">68,028</td>
            <td style="padding:0pt;padding-left:16.47pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 5. Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to tax liabilities imposed by multiple jurisdictions. The Company determines our best estimate of the annual effective tax rate at each interim period using expected annual pre-tax earnings, statutory tax rates, and available tax planning opportunities. Certain significant or unusual items are separately recognized in the quarter in which they occur, which can cause variability in the effective tax rate from quarter to quarter. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The effective tax rate on income for the three&#160;months ended March&#160;31, 2025 and 2024 is 0%. For the three&#160;months ended March&#160;31, 2025 and 2024, the tax rates differed from the U.S. federal statutory rate of 21.0% primarily due to the impact of net operating losses and valuation allowances. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of March&#160;31, 2025, all loss&#160;years remain open to examination by the taxing authorities. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for temporary differences between the financial reporting bases and tax bases of assets and liabilities based on enacted tax rates expected to be in effect when such amounts are realized or settled. However, deferred tax assets are recognized only to the extent that it is more likely than not that they </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">will be realized based upon consideration of available evidence, including future reversals of existing taxable temporary differences, future projected taxable income, the length of the tax asset carryforward periods and tax planning strategies. The effects of remeasurement of deferred tax assets and liabilities resulting from changes in tax rates are recognized in income in the period of enactment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6. Redeemable Convertible Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Redeemable convertible preferred stock as of March&#160;31, 2025 and December&#160;31, 2024, consisted of the following: </font>
        </div>
        <table style="width:456pt;height:127.5pt;margin-top:9.99999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:168.01pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">(amounts in thousands, except share and per </font>
              <br >
              <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">share amounts) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:36.33pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issue Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:2pt;padding-right:2pt;letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Net</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">490,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">296,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">30,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.54</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">16,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">142,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">415,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">415,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.10</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,078,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,078,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:168.01pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total redeemable convertible preferred </font>
                <br >
                <font style="letter-spacing:0.2pt;">stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">764,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,806,224</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,246,113</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:127.5pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:168.01pt;text-align:left;">
              <font style="letter-spacing:-0.16pt;">(amounts in thousands, except share and per </font>
              <br >
              <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">share amounts) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued</font>
                <br >
                <font style="letter-spacing:-0.16pt;">and</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:36.33pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issue Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:2pt;padding-right:2pt;letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:5pt;padding-right:5pt;letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:45.41pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Net</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Carrying</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">490,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.61</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">296,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">709,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">30,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.54</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">16,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">42,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">142,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">408,715</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">408,715</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:168.01pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.10</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,060,712</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,060,712</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:168.01pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Total redeemable convertible preferred </font>
                <br >
                <font style="letter-spacing:0.2pt;">stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">764,600,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">734,142,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,781,762</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,221,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.41pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The rights, preferences, and privileges of the redeemable convertible preferred stock are as follows: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On any matter presented to the shareholders of the Company for their action or consideration at any meeting of shareholders of the Company (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of preferred stock will be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All classes of preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Company&#8217;s board of directors, prior to and in preference to any declaration or payment of any dividend on the common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidation Preference</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series&#160;C and Series&#160;D preferred stock then outstanding will be entitled to be paid out of the assets of the Company available for distribution to its shareholders at an amount per share equal to the greater of (i)&#160;the Series&#160;C and Series&#160;D original issue price, plus (A)&#160;any dividends declared but </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">unpaid thereon and (B)&#160;a 7.0% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series&#160;C and Series&#160;D preferred stock, (ii)&#160;the amount that the holder of a share of Series&#160;C and Series&#160;D preferred stock would have received upon conversion to common stock, or (iii)&#160;solely with respect to the Series&#160;D preferred stock, 1.2 times the Series&#160;D original issue price. The Series&#160;A and Series&#160;B preferred stock are then paid on a pro&#160;rata, pari&#160;passu basis an amount equal to the greater of (i)&#160;the respective original issue price plus any dividends declared but unpaid thereon, and (ii)&#160;the amount that the holder of a share of Series&#160;A or Series&#160;B preferred stock, respectively, would receive upon conversion to common stock. The remaining proceeds will be distributed to the holders of common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conversion Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of the Company&#8217;s Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock have the right to convert their shares into a number of fully paid and nonassessable shares of common stock as determined by dividing the respective Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock original issue price by the conversion price in effect at the time. The initial conversion price of the Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock was $0.61, $0.54, $2.76 and $8.10, respectively, and is subject to adjustment in accordance with anti-dilution provisions provided for in the Company&#8217;s Certificate of Formation. The Company&#8217;s Certificate of Formation also specifies that, solely with respect to the calculation of the conversion of the Series&#160;C preferred stock in connection with an initial public offering, the original issue price and the initial conversion price of the Series&#160;C preferred stock are both equal to $4.58. As of March&#160;31, 2025, each share of Series&#160;A, Series&#160;B, Series&#160;C and Series&#160;D preferred stock was convertible into one share of common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Redemption Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At any time on or after the fifth anniversary of the Series&#160;C and Series&#160;D original issue date, which will begin for Series&#160;C in March&#160;2026 and for Series&#160;D in May&#160;2026, upon written notice from the applicable shareholders, the Series&#160;C and Series&#160;D shares shall be redeemed by the Company at a price per share equal to the greater of (i)&#160;the original issue price plus (a)&#160;all declared by unpaid dividends thereon and (b)&#160;a 7.0% cumulative accruing dividend, compounding annually, or (ii)&#160;the fair market value as determined by an independent appraiser. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Anti-dilution</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain exceptions, the conversion price of the Series&#160;A and Series&#160;B preferred stock is subject to broad-based weighted average adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the then-applicable conversion price of the Series&#160;A and Series&#160;B preferred stock, respectively. Subject to certain exceptions, in the event the Company sells additional shares of stock at a price per share less than the Series&#160;C and Series&#160;D original issue price, the conversion price of the Series&#160;C preferred stock is adjusted to the lower price that the Company sells shares in such offering, and the conversion price of the Series&#160;D preferred stock is adjusted based on a broad-based weighted average anti-dilution formula. In the event the Company sells shares in an initial public offering for less than 1.11111 times the applicable Series&#160;C conversion price, then the Series&#160;C conversion price will be reduced (but never increased), concurrently with such issuance to 90.0% of the purchase price in such initial public offering. In the event the Company sells shares in an initial public offering for less than 110.0% of the applicable Series&#160;D conversion price, then the series D conversion price will be reduced (but never increased), concurrently with such issuance to 90.0% of the purchase price in such initial public offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 7. Shareholders&#8217; Equity</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2025 and December&#160;31, 2024, 1,173,000,000 and 1,150,000,000 shares of common stock with a $0.001 par value were authorized, respectively. There were 140,950,490 and 143,369,083 shares outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s shareholders. Common shareholders are entitled to receive dividends if and when declared by the Company&#8217;s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. No dividends have been declared or paid by the Company since its inception. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Treasury Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">During the three&#160;months ended March&#160;31, 2025, the Company repurchased 5,752,550 shares of common stock for an amount of $16.6&#160;million, mainly associated with previously early-exercised options. Refer to below for further details. No common shares were repurchased during the year ended December&#160;31, 2024. Repurchased common stock is shown on the condensed consolidated balance sheets and condensed consolidated statements of redeemable convertible preferred stock and shareholders&#8217; deficit as treasury stock. The Company had 6,482,550 and 730,000 shares of treasury stock as of March&#160;31, 2025 and December&#160;31, 2024, respectively. These shares have not been retired. The Company has not reissued any shares of treasury stock as of March&#160;31, 2025 and December&#160;31, 2024. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the 2020 Incentive Plan (the &#8220;Plan&#8221;), the Company may grant awards of options, restricted awards, performance awards or share appreciation rights to employees, consultants, and directors of the Company. A total of 104,364,034 shares of common stock are reserved for issuance upon the exercise of all awards granted or available to be granted under the Plan as of March&#160;31, 2025. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent permitted by applicable laws or any exchange rule, any shares of common stock issued under this Plan that are issued (a)&#160;in connection with the Company&#8217;s acquisition of an unaffiliated business entity, (b)&#160;to the employees of such entity, and (c)&#160;in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce the number of shares of common stock available for issuance under the Plan. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Plan provides for a repurchase feature for vested stock-based awards at the option of the Company if the employee&#8217;s continuous service terminates for any reason, with or without cause, including death or disability. The repurchase shall be exercisable at a price equal to the fair market value of vested shares or, in the case of exercisable options, the fair market value of the common stock underlying such unexercised options less the aggregate exercise price of such options. The Company&#8217;s repurchase lapses when the Company&#8217;s common stock becomes publicly traded. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Option Activity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Plan, the Company has granted incentive stock options and non-qualified stock options to its employees and other service providers (non-employees). Most of the Company&#8217;s stock options vest incrementally over five&#160;years, subject to the grantee&#8217;s continuous employment with the Company (&#8220;time-vesting options&#8221;). The Company recognizes compensation cost on a straight-line basis over the requisite service period for its time-vesting options. In addition to its time-vesting options, the Company has also granted stock options to certain non-employees for which vesting is tied to the grantee&#8217;s performance (&#8220;performance-vesting options&#8221;). The Company evaluates whether it is probable that the performance metric will be achieved for its performance-vesting options and recognizes compensation cost on a straight-line basis over the implied service period if achievement of the performance metric is deemed probable. No option shall be exercisable after the expiration of 10&#160;years from the date it was granted. The exercise price of each option shall be not less than 100.0% of the fair market value of the common stock subject to the option on the date the option is granted. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following tables summarize the Company&#8217;s stock option activity during the three&#160;months ended March&#160;31, 2025: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <table style="width:456pt;height:174.5pt;margin-top:12pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:248.04pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Options Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:248.04pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contract</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Term</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total outstanding as of December&#160;31, 2024: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">87,082,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.27</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.40</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">226,117</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,341,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.65</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(685,957<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.08</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,766</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cancelled/forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,282,283<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">2.45</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">2,839</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total outstanding as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">96,455,977</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">2.55</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">5.71</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">361,193</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total exercisable as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">67,399,410</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.80</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.44</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">302,635</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:248.04pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total vested or expected to vest as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">91,901,836</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.45</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.56</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">352,524</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:150.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:257.8pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Unvested/Vested Activity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:257.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Grant Date</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:257.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested outstanding, as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">26,636,592</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.95</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.35</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.30</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:257.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,341,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.65</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.89</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:257.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cancelled/forfeited </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(142,927<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.19</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.63</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:257.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested, outstanding shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(5,988,657<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">3.64</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">2.40</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:257.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested outstanding, as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">31,846,567</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.26</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.89</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.41</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:257.8pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Early exercised unvested, end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">174,412</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.05</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.60</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The weighted average grant date fair value of options granted during the three&#160;months ended March&#160;31, 2025 was $3.89 per option. The total grant date fair value of options vested during the three&#160;months ended March&#160;31, 2025 and 2024 was $14.4&#160;million and $5.9&#160;million, respectively. The total intrinsic value of options exercised during the three&#160;months ended March&#160;31, 2025 and 2024 was $1.8&#160;million and $0.4&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Modification to stock options</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On November&#160;9, 2021 and February&#160;23, 2022, the Company granted stock options to certain executives that are exercisable upon vesting for 1,325,000 shares and 8,000,000 shares of the Company&#8217;s common stock, respectively (the &#8220;Prior Stock Options&#8221;). The Prior Stock Options vested over five&#160;years. On August&#160;11, 2022, the Company&#8217;s Compensation Committee approved a modification to the Prior Stock Options, which was communicated to holders of the Prior Stock Options on September&#160;1, 2022. The modification reduced the exercise price to $4.05 and modified the vesting conditions such that 20.0% vest upon grant, while the remainder vest over the following four&#160;years. The total number of grantees affected by this modification was twelve. The modification was not mandatory, but rather could be elected by holders of the Prior Stock Options on an individual holder basis. If the holder elected to participate, the holder&#8217;s Prior Stock Options were immediately canceled, and the Company issued the holder an equivalent number of new stock options in exchange (the &#8220;New Stock Options&#8221;) which could be early exercised prior to vesting. All of the holders elected to participate in the modification and exchanged their Prior Stock Options for New Stock Options. In addition, as an alternative to paying cash, holders of the New Stock Options that elected to exercise their options were able to pay for the exercise price by executing a full recourse promissory </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">note with the Company that is secured by the holder&#8217;s restricted shares that are issued upon early exercise. Five grantees elected to early exercise 6,120,000 options utilizing the promissory note. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The principal of each note is equal to the exercise price of the New Stock Options. Interest on the unpaid balance will compound annually and accrue at a fixed rate per annum equal to the mid-term applicable federal rate in effect on the issuance of the note. The maturity date of the notes is the earlier of (1)&#160;December&#160;31, 2030 or (2)&#160;the occurrence of a change in control event, unless an acceleration event occurs sooner. An acceleration event would generally occur if required to ensure compliance with Section&#160;402 of the Sarbanes-Oxley Act of 2022, the termination of the holder&#8217;s employment, the insolvency of the holder or the breach of any warranty of the holder. The holder may elect to prepay the outstanding principal and accrued interest balance of the promissory note at any time without penalty. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the outstanding balance of the note becoming due and payable immediately, upon the occurrence of an acceleration event, if the holder defaults on payment of the note, then interest will accrue at the maximum rate permitted by applicable law. The Company will have full recourse against the holder for failure to pay the note as and when due. Such promissory notes will be secured by the restricted shares issued to the holder that are underlying the note. If the note is not repaid upon an event of default or acceleration event, the Company has the right to repurchase the restricted shares issued upon the exercise of the note for fair market value, which proceeds will apply to repayment of the note (with any remaining balance remaining due). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company accounted for the modification as a Type I (Probable to Probable) modification under ASC 718 that does not change the classification of the award (i.e., the New Stock Options continue to be classified within equity). The Company calculated the fair value of the Prior Stock Options and New Stock Options immediately prior to and after the modification using the Black-Scholes option pricing model. The incremental fair value was added to the original unrecognized compensation cost to arrive at the new unrecognized compensation cost, to be recognized over the remaining requisite service period. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unvested stock received from early exercises of the New Stock Options are subject to a right of repurchase at the lesser of (i)&#160;original issuance price or (ii)&#160;then-current fair market value in the event of the employee&#8217;s termination, either voluntary, or involuntary. The Company&#8217;s repurchase right with respect to these shares typically lapse over four&#160;years as the shares become vested. Early exercises of stock options are not deemed to be substantive exercises for accounting purposes and accordingly, consideration received for exercises of unvested stock options is initially recorded as a liability and subsequently reclassified into shareholders&#8217; deficit as the related shares vest. As of March&#160;31, 2025 and December&#160;31, 2024, 174,412 and 2,648,000 shares from options exercised to date were subject to repurchase at a price of $4.05 per share. Of the amount subject to repurchase as of March&#160;31, 2025 and December&#160;31, 2024, $0.3&#160;million and $5.0&#160;million was recorded within other accrued expenses and current liabilities, respectively, and $0.4&#160;million and $5.8&#160;million was recorded within other long-term liabilities on the condensed consolidated balance sheets, respectively. In addition, as the early exercise was performed via issuance of a promissory note, a corresponding debt amount, plus related interest income was recorded as contra-equity. The total amount presented as contra-equity as of December&#160;31, 2024 $26.5&#160;million, which includes interest income and the impact from exercises of both the vested portion of the New Stock Options and early exercises. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;3, 2025, the Company repurchased 5,716,850 common stock shares issued upon early exercise of stock options at $4.65 per share and proceeds were used to pay off the promissory notes and accrued interests. Repurchased common stock shares included 3,243,262 and 2,473,588 common stock shares, respectively, that were for options vested and unvested at the time of the repurchase, respectively. On the same day, the Company granted 6,120,000 new stock options to the same employees. New options were issued at an exercise price of $4.65 per share, have the same vesting status as cancelled options and are not early exercisable. The other terms of the new options are substantially the same as the original options. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company accounted for the repurchase of the shares and grant of the new options as a Type I (Probable to Probable) modification under ASC 718. The Company calculated the fair value of the original options and new options immediately prior to and after the modification using the Black-Scholes option pricing model based on the following assumptions: risk-free interest rate of 3.93%&#8201;&#8211;&#8201;3.99%; dividend yield </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of 0.00%; stock price volatility of 68.96%&#8201;&#8211;&#8201;69.48%; and an expected life of 5.0&#8201;&#8211;&#8201;5.3&#160;years. The total incremental fair value was $15.1&#160;million, of which $8.6&#160;million corresponding to the vested options was immediately recognized as compensation expense, with the remaining $6.5&#160;million and the original unrecognized compensation cost of $5.7&#160;million being recognized over the remaining requisite service period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Restricted Awards Activity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company grants restricted stock&#160;units that will be settled in shares of the Company&#8217;s common stock upon vesting to its employees and non-employee directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Vesting of the restricted stock&#160;units is contingent upon the Company completing either an initial public offering of its common stock or a change of control. The Company has determined that these performance conditions are not probable of being achieved, and thus has not recognized any compensation expense associated with its restricted stock&#160;units. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the Company&#8217;s restricted stock unit activity for the three&#160;months ended March&#160;31, 2025: </font>
        </div>
        <table style="width:384pt;height:72pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:252.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Restricted Stock </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Units </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average Grant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested as of December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,050,000</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.55</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,088,160</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">4.65</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:252.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested as of March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,138,160</td>
            <td style="padding:0pt;padding-left:7.28pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">4.59</td>
            <td style="padding:0pt;padding-left:14.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-Based Compensation Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recorded stock-based compensation expense in the condensed consolidated statements of operations and comprehensive loss as follows: </font>
        </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">466</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">427</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8211;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,243</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,118</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,636</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,346</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">966</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,691</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,458</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:36pt; margin-top:13pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There was no tax benefit associated with the above stock-based compensation expense. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Valuation of Stock-Based Awards to Employees</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company records stock-based compensation expense for stock-based awards based on the estimated fair value of the awards on the date of the grant. The fair value of the Company&#8217;s restricted stock&#160;units is based on the fair value of the Company&#8217;s common stock at the date of grant. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company estimates the fair value of stock options using a Black-Scholes option pricing model. The absence of a public market for the Company&#8217;s common stock requires the Company&#8217;s board of directors to estimate the fair value of its common stock for purposes of granting options and for determining stock-based compensation expense by considering several objective and subjective factors, including contemporaneous third-party valuations, actual and forecasted operating and financial results, market </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:82.4pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">conditions and performance of comparable publicly traded companies, developments and milestones in the Company, the rights and preferences of common and convertible preferred stock, transactions involving the Company&#8217;s common stock, and assumptions for a discount for lack of marketability. The fair value of the Company&#8217;s common stock was determined in accordance with the applicable elements of the American Institute of Certified Public Accountants Accounting and Valuations Guide, </font><font style="font-style:italic;letter-spacing:0.2pt;">Valuation of Privately Held Company Equity Securities Issued as Compensation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The key assumptions used in determining the fair value of options granted and a summary of the methodology applied to develop each assumption are as follows: </font>
        </div>
        <table style="width:384pt;height:101.5pt;margin-left:36pt;margin-top:9.99999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:69.75pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:302.25pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:69.75pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">69.0%&#8211;69.5% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.25pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:69.75pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">3.9%&#8211;4.1% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.25pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:69.75pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.00&#8211;6.55 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.25pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:69.75pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">&#8212;% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302.25pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected forfeiture rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:69.75pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.0%&#8211;8.3%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:36pt; margin-top:9.2pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No awards were granted during the three&#160;months ended March&#160;31, 2024. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected volatility.&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">This is a measure of the amount by which the share price has fluctuated or is expected to fluctuate. An increase in the expected price volatility will increase the fair value of the option granted and the related compensation expense. As the Company is not publicly traded, the expected price volatility for the Company&#8217;s options was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the business corresponding to the expected term of the awards. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Risk-free interest rate.&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for U.S. Treasury notes with maturities corresponding to the expected term of the awards. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Expected term.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;This is the period of time over which the options granted are expected to remain outstanding and is based on the Company&#8217;s estimate, taking into consideration vesting term, contractual term and historical actual lives. Options granted have a maximum term of ten&#160;years. An increase in the expected life will increase the fair value of the option granted and the related compensation expense. Due to the lack of historical share option exercise data, the Company utilizes the simplified method for determining the expected term. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividend rate.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company has not made any dividend payments, nor does it have plans to pay dividends in the foreseeable future. Therefore, an expected dividend yield of zero is utilized. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Forfeitures.&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;">Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 8. Long-Term Debt</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The carrying value of debt presented within current portion of notes payable and long-term indebtedness, net of debt discounts on the condensed consolidated balance sheets as of March&#160;31, 2025 and December&#160;31, 2024 includes the following components: </font>
        </div>
        <table style="width:456pt;height:138.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.79pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:311.79pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Term loan Initial Draw&#8211;January&#160;18, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exit fee on term loan&#8211;January&#160;18, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Term loan Subsequent Draw&#8211;March&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exit fee on term loan&#8211;March&#160;5, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: Amortized debt discounts and financing costs</font><font style=" position:relative; bottom:4.25pt;line-height:6.5pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(28,918<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(30,863<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net debt </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">375,082</div>
            </td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">$</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">373,137</div>
            </td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:311.79pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Compound bifurcated derivative liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,342</td>
            <td style="padding:0pt;padding-left:8.425pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">6,058</td>
            <td style="padding:0pt;padding-left:13.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Includes debt discounts of $28.3&#160;million associated with the initial carrying value of compound bifurcated derivative liability. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Maturities of the Company&#8217;s debt are expected to be as follows as of March&#160;31, 2025: </font>
        </div>
        <table style="width:384pt;height:98.5pt;margin-left:36pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:334.29pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Years Ending December&#160;31, </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Remainder of 2025</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">340,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:334.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Represents 15% of the outstanding principal amount under the 2023 Term Loan Agreement, which is due on the earlier of (x)&#160;for dates prior to January&#160;1, 2026, any date that the redemption rights in respect of our Series&#160;C preferred stock or Series&#160;D preferred stock are or may become exercisable within 90&#160;days following such date, or (y)&#160;January&#160;1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of our Series&#160;C preferred stock or Series&#160;D preferred stock are or may become exercisable on or prior to the date that is six&#160;months after the maturity date. The Series&#160;C preferred stock redemption rights may be exercised on or after March&#160;31, 2026. All outstanding shares of our Series&#160;C preferred stock and Series&#160;D preferred stock will convert into shares of common stock as part of the Preferred Stock Conversion and any redemption rights thereunder will terminate in connection with the completion of this offering and consequently, the payments disclosed herein would not be applicable. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.02pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Term Loan Refinancing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;21, 2018, the Company entered into a secured term loan agreement (the &#8220;Original Term Loan Agreement&#8221;) with Sixth Street Specialty Lending, Inc. and Barnett Debt Holdings, LLC (collectively, the &#8220;Original Term Loan Lenders&#8221;), which provided the Company with an initial term loan of $50.0&#160;million (the &#8220;2018 Term Loan&#8221;) and a delayed term loan draw option of $50.0&#160;million, which the Company drew down in full on October&#160;4, 2019 (the &#8220;2019 Term Loan&#8221;). On April&#160;2, 2020, the Company amended the Original Term Loan Agreement (the &#8220;Amended Term Loan Agreement&#8221;) to obtain additional term loan proceeds of $75.0&#160;million (the &#8220;2020 Term Loan&#8221; and collectively with the 2018 Term Loan and the 2019 Term Loan, the &#8220;Original Term Loans&#8221;). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;18, 2023, the Company entered into the New Term Loan Agreement with OrbiMed Royalty &amp; Credit Opportunities III, LP, OrbiMed Royalty &amp; Credit Opportunities IV, LP (collectively, &#8220;OrbiMed&#8221;), and Braidwell Transaction Holdings LLC (&#8220;Braidwell&#8221;, and collectively with OrbiMed, the &#8220;New Term Loan Lenders&#8221;). Pursuant to the New Term Loan Agreement, the Company issued senior, secured promissory notes by which the New Term Loan Lenders agree to lend the Company up to an aggregate principal amount of $400.0&#160;million, $200.0&#160;million of which was received by the Company upon issuance (the &#8220;Initial Draw&#8221;), and the remaining $200.0&#160;million was received by the Company in March&#160;2024 (the &#8220;Delayed Draw&#8221;). </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until the earlier of December&#160;31, 2024 or the date on which the 2024 Term Loan amount was fully drawn, which occurred on March&#160;5, 2024, the undrawn balance of the New Term Loan Commitment was subject to a fee of 0.5% per annum. The outstanding principal amount of the 2023 Term Loan is due and payable on January&#160;18, 2028. If an event of default occurs and is continuing, the New Term Loan Lenders may declare all amounts outstanding under the New Term Loan Agreement to be immediately due and payable. A final payment exit fee equal to 1.0% of the amount funded under the New Term Loan Agreement is due upon prepayment or maturity. Amounts borrowed pursuant to the New Term Loan Agreement may be prepaid at any time. Upon prepayment, the Company is subject to a prepayment penalty based on the timing of repayment. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2023 Term Loan bears interest at a rate per annum equal to a fixed margin of 6.5% plus the greater of (a)&#160;forward-looking three-month secured overnight financing rate (&#8220;SOFR&#8221;) and (b)&#160;2.5%. In the event of default, the fixed margin shall increase by 3.0% per annum. As of March&#160;31, 2025, the interest rate was 10.8%. Regular quarterly payments are interest-only for the 60-month term of the New Term Loan Agreement, with the principal due at maturity. The effective interest rate for the Initial Draw of the 2023 Term Loan is 17.0%, and the effective interest rate for the Delayed Draw of the 2023 Term Loan is 12.0%. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s obligations under the New Term Loan Agreement are secured by a first lien security interest in substantially all of the assets of the Company and its subsidiaries. The New Term Loan Agreement contains certain customary representations and warranties, affirmative and negative covenants, financial covenants, and events of default applicable to the Company and its subsidiaries. Additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. At March&#160;31, 2025, the Company is in compliance with all covenants. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company identified multiple embedded derivatives that require bifurcation from the 2023 Term Loan. They are separately accounted for in the condensed consolidated financial statements as one compound derivative liability. Those embedded features include various contingent prepayment and compensatory payment features as well as interest rate increases upon an event of default. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The components of interest expense associated with the Company&#8217;s long-term indebtedness, excluding finance leases, are as follows: </font>
        </div>
        <table style="width:456pt;height:81pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Debt discount amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,589</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,829</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,690</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense on long-term indebtedness, excluding finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">12,774</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,279</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant Liability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As part of the Original Term Loan Agreement, the Company issued 13,694,623 warrants with an exercise price of $1.61 (the &#8220;2018 Warrants&#8221;). In connection with the amendment to the Original Term </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Loan Agreement in 2020, the Company issued an additional 11,399,814 warrants with an exercise price of $1.93 (the &#8220;2020 Warrants&#8221;) and amended the 2018 Warrants. Furthermore, these amendments also permit the exercise of both the 2018 Warrants and 2020 Warrants into Series&#160;C preferred stock or common stock at the option of the holder. As a result of the amendment to permit exercise of the warrants into redeemable preferred stock, the warrants are classified as a liability pursuant to the guidance in ASC 480. Therefore, the warrants are reported at fair value within warrant liabilities on the condensed consolidated balance sheets, with changes in fair value reported within changes in fair value of financial instruments on the condensed consolidated statements of operations and comprehensive loss. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table reflects the changes in fair values associated with these warrants. </font>
        </div>
        <table style="width:456pt;height:80.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:259.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:86.41pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2018 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:86.41pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:259.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">13,694,623</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">11,399,814</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:259.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$1.61</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$1.93</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:259.18pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Earlier of 7&#160;years from the date of issuance, </font>
                <br >
                <font style="letter-spacing:0.2pt;">or immediately after closing IPO </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:259.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at date of issuance </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$0.8&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.833pt 0pt; width:86.41pt;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">$7.9&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:84.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at December&#160;31, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">54,540</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">44,193</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Decrease in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(2,911<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,180<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at December&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">51,629</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">40,013</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">20,405</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,644</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value at March&#160;31, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">72,034</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">56,657</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 9. Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchase Obligations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company enters into various supply agreements that contains purchase commitments. Most of the commitments are based on a binding forecast for an agreed-upon period, which is 12-month or less. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Liability and Insurance</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company maintains professional liability, general liability, and other customary insurance on a claims-made basis in amounts deemed appropriate by the Company&#8217;s management based upon historical claims and the nature and risks of the Company. The Company&#8217;s business may subject the Company to litigation and liability for damages. The Company believes that current insurance protection is adequate for present business operations, but there can be no assurance that the Company will be able to maintain professional and general liability insurance coverage in the future or that such insurance coverage will be available on acceptable terms or adequate to cover any or all potential product or professional liability claims. A successful liability claim in excess of insurance coverage could have a material adverse effect on the Company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Litigation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">During the ordinary course of business, the Company has become and may in the future become subject to pending and threatened legal and regulatory actions and proceedings. While it is not feasible to predict or determine the ultimate outcome of these matters, the Company believes that none of its current legal proceedings will have a material adverse effect on its financial position, results of operations, or cash flows for the periods ended March&#160;31, 2025 and December&#160;31, 2024. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 10. Related Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s officers and directors have ownership interests in certain vendors providing services to the Company. During the three&#160;months ended March&#160;31, 2025 and 2024, the Company made payments to these entities for services and expenses for $0.7&#160;million and $0.5&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 11. Net Loss Per Share Attributable to Common shareholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders: </font>
        </div>
        <table style="width:456pt;height:111.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">(amounts in thousands, except per share data) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Adjustments of redeemable convertible preferred stock to redemption value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(24,462<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(23,113<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss attributable to common shareholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(127,043<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(134,141<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(0.89<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(0.95<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:337.75pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">142,492</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">141,252</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:8.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the periods presented as they had an anti-dilutive effect: </font>
        </div>
        <table style="width:416pt;height:142.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:291.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">485,795,293</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">29,629,630</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">116,200,835</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">102,516,283</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">25,094,437</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">25,094,437</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">96,455,977</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:38.25pt; text-align:right; white-space:nowrap;">86,008,216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unvested shares subject to repurchase </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">174,412</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">3,872,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:291.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">855,866,867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:38.25pt; text-align:right; white-space:nowrap;">849,116,694</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.1pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 12. Segment and Geographic Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company operates as a single operating segment. An operating segment is defined as a component of an entity for which discrete financial information is available and regularly reviewed by the entity&#8217;s chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing performance. The Company&#8217;s CODM, its Chairman and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net loss as reported on the condensed consolidated statements of operations and comprehensive loss is used by the CODM to assess segment performance against management budgets and prior period operating results for the purpose of making results-driven decisions about organizational resource allocation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Segment revenues are derived from molecular profiling, strategic data, and research services that are delivered to the Company&#8217;s biopharmaceutical and clinical customers, who are predominantly located in the United States. The Company provides these services primarily by leveraging the Company&#8217;s proprietary technologies and clinico-genomic database, which are core to the Company&#8217;s operations and are deployed similarly across the service offerings. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="text-indent:36pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below is a summary of the segment profit or loss, including significant segment expenses: </font>
        </div>
        <table style="width:456pt;height:216pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">120,915</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">80,677</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Less: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8722;Molecular profiling services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">60,894</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,894</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of services&#8722;Pharma research and development services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,958</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,669</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Selling and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">39,829</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">39,609</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">52,119</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">44,354</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">23,066</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">34,376</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">503</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,768</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(12,782<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(9,290<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Changes in fair value of financial instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(32,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(11,064<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other expense, net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(219<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Segment and consolidated net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(102,581<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(111,028<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customer&#8217;s location: </font>
        </div>
        <table style="width:416pt;height:81pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.75pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2025 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:297.75pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(amounts in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">United States </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,432</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">78,430</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">International </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">2,483</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,247</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.75pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">120,915</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">80,677</td>
            <td style="padding:0pt;padding-left:5.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:36pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No single country outside of the United States accounted for more than 10.0% of total revenue during each of the three&#160;months ended March&#160;31, 2025 and 2024. As of March&#160;31, 2025 and December&#160;31, 2024, approximately 99.0% of the Company&#8217;s total assets are located in the United States. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 13. Employee Benefit Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100.0% of eligible compensation on a pre-tax basis. For the three&#160;months ended March&#160;31, 2025 and 2024, the Company contributed $1.9&#160;million and $2.2&#160;million, respectively, to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 14. Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On April&#160;1, 2025, the Company closed a private financing in which it issued a combination of senior convertible notes (the &#8220;2025 Convertible Notes&#8221;), Series&#160;E convertible preferred stock and Series&#160;F convertible preferred stock, for an aggregate of $167.7&#160;million. The 2025 Convertible Notes have an aggregate principal amount of $30.0&#160;million. The 2025 Convertible Notes accrue interest at a rate of 8% per annum, payable quarterly in cash, and mature on January&#160;1, 2026. The Company issued 12,345,674 shares of Series&#160;E convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $100.0&#160;million. The Company also issued 4,657,401 shares of Series&#160;F convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $37.7&#160;million. In connection with this financing, the Company also issued warrants to acquire shares of common stock to the holders of the 2025 Convertible Notes. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:458pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These warrants are not initially exercisable for any shares of common stock, but such warrants become exercisable for a specified dollar value of shares on a monthly basis commencing on June&#160;1, 2025 if we have not completed an initial public offering by such date. Any exercisable portion of the warrants will be automatically exercised prior to the closing of the initial public offering and such warrants will terminate upon the closing of the offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to and in connection with the completion of the initial public offering, the 2025 Convertible Notes, Series&#160;E convertible preferred stock and Series&#160;F convertible preferred stock (plus an 8% accretion in connection with the preferred stocks) will convert into common stock at a price equal to 70% of the initial public offering price per share. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no other significant subsequent events identified through the date that the condensed consolidated financial statements were issued, that could impact the financial statements.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:12pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:36pt; margin-top:14pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Through and including&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in the Class&#160;A common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</font>
        </div>
        <div style="margin-top:36pt; text-align:center; width:456pt; line-height:18pt;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;Shares</font>
        </div>
        <div style="position:relative;margin-top:14pt; text-align:center; width:456pt;">
          <img src="lg_carislifesciences-pn.jpg" alt="[MISSING IMAGE: lg_carislifesciences-pn.jpg]" height="96" width="116" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Class A Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:59.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 27.522%; margin-right: 27.522%; margin-top: 59.1666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:19pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">P R O S P E C T U S</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 27.522%; margin-right: 27.522%; margin-top: 18.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:52pt; text-align:center; width:456pt; line-height:20pt;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">BofA Securities</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:20pt;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">J.P. Morgan</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:20pt;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Goldman Sachs &amp; Co. LLC</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:20pt;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Citigroup</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.24pt;">TD Cowen</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.24pt;">Evercore ISI</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.24pt;">Guggenheim Securities</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.24pt;">BTIG</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.24pt;">Wolfe | Nomura Alliance</font>
        </div>
        <div style="margin-top:48pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:14.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 14.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;13.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the costs and expenses, other than underwriting discounts and commissions, payable in connection with this offering. All amounts are estimates except the SEC registration fee, the FINRA filing fee, and Nasdaq listing fee. Except as otherwise noted, all the expenses below will be paid by us. </font>
        </div>
        <table style="width:456pt;height:130.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">15,310 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">15,500 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nasdaq listing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing and engraving expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transfer agent and registrar fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:411.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:411.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:12.19pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:12.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To be completed by amendment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Caris Life Sciences, Inc. was incorporated under the laws of Texas. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Texas Business Organizations Code (the &#8220;TBOC&#8221;) permits a corporation to indemnify a director who was, is or is threatened to be a named defendant or respondent in a proceeding as a result of the performance of his or her duties if such person acted in good faith and, in the case of conduct in the person&#8217;s official capacity as a director, in a manner he or she reasonably believed to be in the best interests of the corporation and, in all other cases, that the person reasonably believed his or her conduct was not opposed to the best interests of the corporation and with respect to any criminal action or proceeding, that such person had no reasonable cause to believe his or her conduct was unlawful. Subject to certain exceptions, the TBOC further permits a corporation to eliminate in its charter all monetary liability of the corporation&#8217;s directors to the corporation or its shareholders for conduct in performance of such director&#8217;s duties, but not for a breach of the director&#8217;s duty of loyalty or receipt of an improper benefit. Our amended and restated certificate of formation will provide that a director of the corporation will not be liable to the corporation or its shareholders for monetary damages for any act or omission by the director in the performance of his or her duties, except that there will be no limitation of liability to the extent the director has been found liable under applicable law for: (i)&#160;breach of the director&#8217;s duty of loyalty owed to the corporation or its shareholders; (ii)&#160;an act or omission not in good faith that constitutes a breach of duty of the director to the corporation or that involves intentional misconduct or a knowing violation of the law; (iii)&#160;a transaction from which the director received an improper benefit, regardless of whether the benefit resulted from an action taken within the scope of the director&#8217;s duties; or (iv)&#160;an act or omission for which the liability of the director is expressly provided for by an applicable statute. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sections&#160;8.101 and 8.103 of the TBOC provide that a corporation may indemnify a person who was, is or is threatened to be a named defendant or respondent in a proceeding because the person is or was a director only if a determination is made that such indemnification is permissible under the TBOC: (i)&#160;by a majority vote of the directors who at the time of the vote are disinterested and independent, regardless of whether such directors constitute a quorum; (ii)&#160;by a majority vote of a board committee designated by a majority of disinterested and independent directors and consisting solely of disinterested and independent directors; (iii)&#160;by special legal counsel selected by the board of directors or a committee of the board of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">directors as set forth in (i)&#160;or (ii); (iv)&#160;by the shareholders in a vote that excludes the shares held by directors who are not disinterested and independent; or (v)&#160;by a unanimous vote of the shareholders. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;8.104 of the TBOC provides that the corporation may pay or reimburse, in advance of the final disposition of the proceeding, reasonable expenses incurred by a present director who was, is or is threatened to be made a named defendant or respondent in a proceeding after the corporation receives a written affirmation by the director of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification under Section&#160;8.101 and a written undertaking by or on behalf of the director to repay the amount paid or reimbursed if it is ultimately determined that he or she has not met that standard or if it is ultimately determined that indemnification of the director is not otherwise permitted under the TBOC. Section&#160;8.105 also provides that reasonable expenses incurred by a former director, or a present or former employee, agent, or officer of the corporation, who was, is or is threatened to be made a named defendant or respondent in a proceeding may be paid or reimbursed by the corporation, in advance of the final disposition of the action, as the corporation considers appropriate. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;8.105 of the TBOC provides that, subject to restrictions in its certificate of formation and to the extent consistent with other law, a corporation may indemnify and advance expenses to a person who is not a director, including an officer, employee, or agent of the corporation as provided by: (i)&#160;the corporation&#8217;s governing documents; (ii)&#160;an action by the corporation&#8217;s governing authority; (iii)&#160;resolution by the shareholders; (iv)&#160;contract; or (v)&#160;common law. As consistent with Section&#160;8.105, persons who are not directors may seek indemnification and advancement of expenses from a corporation to the same extent that directors may seek indemnification and advancement of expenses from a corporation. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, our amended and restated certificate of formation and amended and restated bylaws will provide that we must indemnify our directors and officers to the fullest extent authorized by law. We are also expressly required to advance certain expenses to our directors and officers, except for claims brought by us, and carry directors&#8217; and officers&#8217; insurance providing indemnification for our directors and officers for some liabilities. We believe that these indemnification provisions and the directors&#8217; and officers&#8217; insurance are useful to attract and retain qualified directors and executive officers. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have also entered into, or will enter into prior to the completion of this offering, indemnification agreements with each of our directors and executive officers. The indemnification agreements provide, or will provide, among other things, for indemnification to the fullest extent permitted by the TBOC and our amended and restated certificate of formation and amended and restated bylaws against (i)&#160;any and all direct and indirect liabilities and reasonable expenses, including judgments, fines, penalties, interest and amounts paid in settlement of any claim with our approval and reasonable counsel fees and disbursements and (ii)&#160;any liabilities incurred as a result of serving as a director, officer, employee, or agent (including as a trustee, fiduciary, partner, or manager or in a similar capacity) of another enterprise or an employee benefit plan at our request. The indemnification agreements also provide for, or will provide for, the advancement or payment of expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our amended and restated certificate of formation and amended and restated bylaws or the terms of the indemnification agreements. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to maintain standard policies of insurance that provide coverage (i)&#160;to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (ii)&#160;to us with respect to indemnification payments that we may make to such directors and officers. The underwriting agreement provides for indemnification by the underwriters of us and our officers and directors, and by us of the underwriters, for certain liabilities arising under the Securities Act or otherwise in connection with this offering. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons controlling us under any of the foregoing provisions, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following sets forth information regarding all unregistered securities sold by us since January&#160;1, 2022: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:36pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:36pt; width:420pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Notes Issuances</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April 2025, we issued&#160;convertible notes in the aggregate principal amount of $30.0 million to 12 accredited investors. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock Issuances</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2023, we issued an aggregate of 31,055,901 shares of our Series&#160;C preferred stock, par value $0.001 per share, to three lenders at a conversion price of $1.61 per share, in connection with the conversion of the original aggregate principal amount of $50,000,000 outstanding under a convertible loan agreement with such lenders. Upon such conversion and following our cash payment of $3,002,567.25 in respect of accrued and unpaid pay-in-kind interest under the convertible loan agreement, all of our obligations under the convertible loan agreement were deemed satisfied in full, and the agreement irrevocably terminated. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April 2025, we issued an aggregate of 12,345,674 shares of our Series E preferred stock, par value $0.001 per share, to 12 accredited investors at a purchase price of $8.10 per share, for an aggregate purchase price of $99,999,959.40. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April 2025, we issued an aggregate of 4,657,401 shares of our Series F preferred stock, par value $0.001 per share, to 11 accredited investors at a purchase price of $8.10 per share, for an aggregate purchase price of $37,724,948.10. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrant Issuances</font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April 2025, we issued warrants to, if exercised on or after June 1, 2025, purchase at least an aggregate of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock, based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, at an exercise price of $0.01 per share. All of these warrants will terminate in connection with this offering, assuming the offering will occur before June 1, 2025, the date such warrants would otherwise have initially become exercisable for shares of our common stock. </font>
        </div>
        <div style="margin-left:36pt; margin-top:12pt; width:420pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Plan-Related Issuances</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From January&#160;1, 2022 through the date of this registration statement, we granted to our employees, officers, and directors options to purchase an aggregate of 60,361,187 shares of our common stock at per share exercise prices ranging from $4.05 to $6.28, and restricted stock&#160;units representing an aggregate of 5,170,660 shares of our common stock, under our 2020 Incentive Plan. From January&#160;1, 2022 through the date of this registration statement, we issued an aggregate of 16,534,809 shares of common stock at per share purchase prices ranging from $0.61 to $5.60 pursuant to the exercise of options by our employees, officers, and directors. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The issuances of the securities in the transactions described above were deemed to be exempt from registration under the Securities Act in reliance upon Section&#160;4(a)(2) of the Securities Act and/or Rule&#160;506, Rule&#160;701, or Regulation&#160;S promulgated thereunder. The securities were issued directly by us and did not involve a public offering or general solicitation. The recipients of such securities represented their intentions to acquire the securities for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">None of the transactions set forth in Item&#160;15 involved any underwriters, underwriting discounts or commissions, or any public offering. All recipients had adequate access, through their relationships with us, to information about us. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Exhibits</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;"> The following exhibits are included herein or incorporated herein by reference: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:595.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:408pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; width:36pt;">
              <font style="margin-left:5pt;letter-spacing:0.2pt;">1.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; width:408pt;">
              <font style="letter-spacing:0.2pt;">Form of Underwriting Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex3-1.htm">Amended and Restated Certificate of Formation of Registrant, as currently in effect.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.2</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex3-2.htm">Form of Amended and Restated Certificate of Formation of Registrant, to be effective upon the completion of this offering. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.3</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex3-3.htm">Amended and Restated Bylaws of Registrant, as currently in effect.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.4</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex3-4.htm">Form of Amended and Restated Bylaws of Registrant, to be effective upon the completion of this offering.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;4.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <font style="letter-spacing:0.2pt;">Form of Registrant&#8217;s Class A common stock certificate. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;4.2+ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex4-2.htm">Amended and Restated Investors&#8217; Rights Agreement, dated as of April 1, 2025, among the Registrant and certain of its shareholders.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">&#8199;5.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <font style="letter-spacing:0.2pt;">Opinion of Latham &amp; Watkins LLP. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.1(a)+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-1a.htm">Credit Agreement, dated as of January&#160;18, 2023, among the Registrant, the lenders party thereto, and Wilmington Trust, National Association, as administrative agent and collateral agent.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;letter-spacing:0.2pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.1(b)+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-1b.htm">First Amendment to Credit Agreement, dated as of April 1, 2025, among the Registrant, the lenders party thereto, and Wilmington Trust, National Association, as administrative agent and collateral agent.</a>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.2(a)+&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-2a.htm">Supply Agreement, dated as of September&#160;21, 2022, by and between Caris MPI, Inc. and Illumina, Inc.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.2(b)+&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-2b.htm">Master Supply Agreement, effective as of July 8, 2024, by and between Roche Diagnostics Corporation and Caris MPI, Inc.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.3(a)+&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-3a.htm">Lease Agreement, dated as of March&#160;1, 2019, by and between WPT LAND 2 LP and 23andMe, Inc., as amended.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.3(b)+&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-3b.htm">Industrial Real Estate Lease (Single-Tenant Facility), dated as of August&#160;19, 2009, by and between Liberty Cotton Center, LLC and CDx Holdings, Inc., as amended.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.3(c)+&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-3c.htm">Lease, dated as of July&#160;25, 2019, by and between KCP NNN II Leasehold 4, LLC and Caris MPI, Inc.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(a)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4a.htm">Caris Life Sciences, Inc. Amended and Restated 2020 Incentive Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(b)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4b.htm">Form of Incentive Stock Option Award Agreement under the Amended and Restated 2020 Incentive Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(c)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4c.htm">Form of Nonqualified Stock Option Award Agreement under the Amended and Restated 2020 Incentive Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(d)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4d.htm">Form of Nonqualified Stock Option Award Agreement under the Amended and Restated 2020 Incentive Plan (Nonemployee Director)</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(e)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4e.htm">Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2020 Incentive Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(f)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4f.htm">Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2020 Incentive Plan (Chief Executive Officer).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.4(g)&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-4g.htm">Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2020 Incentive Plan (Non-Employee Director).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.5&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-5.htm">Caris Life Sciences, Inc. 2025 Incentive Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.6&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-6.htm">Caris Life Sciences, Inc. Employee Stock Purchase Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.7&#8224;&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-7.htm">Executive Employment Agreement, dated as of February 1, 2010, by and between the Registrant and David Spetzler.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:223.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:408pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.8&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-8.htm">First Amendment to Employment Agreement, dated as of July 27, 2015, by and between the Registrant and David Spetzler.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.9&#8224;&#167;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-9.htm">Employment Agreement, dated as of May 31, 2018, by and between Caris Science, Inc. and Brian Brille.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.10&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-10.htm">Caris Life Sciences, Inc. Executive and Director Change in Control Plan.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.11&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-11.htm">Non-Employee Director Compensation Program.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">10.12</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex10-12.htm">Form of Indemnification Agreement.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">16.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex16-1.htm">Letter from Ernst &amp; Young LLP to the Securities and Exchange Commission.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">21.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <font style="letter-spacing:0.2pt;">Subsidiaries of the Registrant. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">23.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex23-1.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">23.2</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex23-2.htm">Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">23.3*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <font style="letter-spacing:0.2pt;">Consent of Latham &amp; Watkins LLP (contained in Exhibit&#160;5.1). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">23.4</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex23-4.htm">Consent of Nephron Research LLC.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">24.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a href="#tSIGN">Power of Attorney (included on signature page).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:36pt;">
              <font style="letter-spacing:0.2pt;">107</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:408pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2415719d15_ex-filingfees.htm">Filing Fee Table.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 144pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.21pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">To be filed by amendment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8224;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Indicates a management contract or compensatory plan or arrangement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">+</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Certain of the schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5). The registrant hereby undertakes to provide further information regarding such omitted materials to the SEC upon request. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.1pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#167;</font>
          <br >
        </div>
        <div style=" margin-top:3.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been redacted pursuant to Regulation&#160;S-K, Item&#160;601(a)(6). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.11pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:3.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:36pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Financial Statement Schedules</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;"> All schedules have been omitted because the information required to be presented in them is not applicable or is shown in the consolidated financial statements or related notes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </font>
        </div>
        <div style="margin-left:36pt; margin-top:8pt; width:420pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes that: </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(1)&nbsp;&nbsp;&nbsp;For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:580pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:36pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">(2)&nbsp;&nbsp;&nbsp;For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSIGN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Irving, Texas, on this 23</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">rd</font><font style="letter-spacing:0.2pt;"> day of May, 2025. </font>
        </div>
        <div style="margin-left:252pt; margin-top:8pt; width:204pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CARIS LIFE SCIENCES, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:252pt; margin-top:17pt; width:204pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ David D. Halbert</font>
        </div>
        <div style="white-space:nowrap; margin-left:252pt; margin-top:3pt; width:204pt;">
          <div style="margin-left: 0pt; width: 204pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:252pt; margin-top:2.5pt; width:204pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">David D. Halbert </font>
          <br >
          <font style="font-style:italic;letter-spacing:0.2pt;">Founder, Chairman, and Chief Executive Officer</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">POWER OF ATTORNEY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David D. Halbert and Luke Power, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments) and any registration statement related thereto filed pursuant to Rule&#160;462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof. </font>
        </div>
        <div style="text-indent:36pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:305.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:120pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ David D. Halbert</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">David D. Halbert </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Founder, Chairman, and Chief Executive Officer</font>
              <br >
              <font style="font-style:italic;letter-spacing:0.2pt;">(Principal Executive Officer)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Luke Power</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Luke Power </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Senior Vice President, Chief Financial Officer, and Chief Accounting Officer</font>
              <br >
              <font style="font-style:italic;letter-spacing:0.2pt;">(Principal Financial and Accounting Officer)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;white-space:nowrap;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ George H. Poste</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">George H. Poste </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Vice Chairman </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Jonathan Knowles</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Jonathan Knowles </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Vice Chairman </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Brian J. Brille</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Brian J. Brille </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Vice Chairman and Executive Vice President </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Peter M. Castleman</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Peter M. Castleman </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ David Fredrickson</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">David Fredrickson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:356.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:254.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:120pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Joseph E. Gilliam</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Joseph E. Gilliam </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Jon S. Halbert</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Jon S. Halbert </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Laura I. Johansen</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Laura I. Johansen </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Lloyd B. Minor</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Lloyd B. Minor </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Danny Phillips</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Danny Phillips </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:120pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Jeffrey Vacirca</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Jeffrey Vacirca </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:216pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 0.5pt 0pt; width:96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">May 23, 2025</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2415719d15_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 3.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED<BR>
CERTIFICATE OF </B></FONT><B>FORMATION</B><BR>
<B>OF<BR>
CARIS LIFE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Caris Life Sciences, Inc.
(the &ldquo;<B><I>Corporation</I></B>&rdquo;), a for-profit corporation organized and existing under and by virtue of the provisions of
the Texas Business Organizations Code, as amended from time to time (the &ldquo;<B><I>TBOC</I></B>&rdquo;), does hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>First</B></FONT><B>:</B>
The name of the filing entity is Caris Life Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Second</B></FONT>:
The Corporation was formed as a Texas for-profit corporation pursuant to the TBOC on July 17, 2020, and issued file number 803691720 by
the Secretary of State of the State of Texas (&ldquo;<B><I>Secretary of State</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Third</B></FONT>:
Each new amendment has been made in accordance with the provisions of the TBOC. The amendments to the certificate of formation and the
Restated Certificate (as defined below) have been approved in the manner required by the TBOC and by the governing documents of the entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Fourth</B></FONT>:
The Amended and Restated Certificate of Formation in the form attached hereto as <B><U>Exhibit A</U></B> (the &ldquo;<B><I>Restated Certificate</I></B>&rdquo;),
accurately states the text of the certificate of formation being restated, and each amendment to the certificate of formation being restated
that is in effect, and as further amended by the Restated Certificate. The Restated Certificate does not contain any other change in the
certificate of formation being restated except for the information permitted to be omitted by the provisions of the TBOC applicable to
the filing entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned affirms that
the person designated as registered agent in the Restated Certificate has consented to the appointment. The undersigned signs this document
subject to the penalties imposed by law for the submission of a materially false or fraudulent instrument and certifies under penalty
of perjury that the undersigned is authorized under the provisions of law governing the entity to execute the filing instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CARIS
    LIFE SCIENCES, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    D. Halbert</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    24, 2025</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED<BR>
CERTIFICATE OF FORMATION</B></FONT><BR>
<B>OF<BR>
CARIS LIFE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>First</B></FONT><B>:</B>
The name of this corporation is Caris Life Sciences, Inc. (the &ldquo;<B><I>Corporation</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Second</B></FONT><B>:</B>
The address of the registered office of the Corporation in the State of Texas is 1999 Bryan Street, Suite 900, Dallas, Texas 75201 and
the name of the registered agent at that address is CT Corporation System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Third</B></FONT><B>:</B>
The purpose of the Corporation is to engage in any lawful business for which business corporations may be organized under the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Fourth</B></FONT><B>:</B>
The total number of shares of all classes of stock which the Corporation will have authority to issue is (i) 1,173,000,000 shares of Common
Stock, $0.001 par value per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;) and (ii) 830,600,000 shares of Preferred Stock, $0.001 par
value per share (&ldquo;<B><I>Preferred Stock</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a statement
of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each
class of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>COMMON STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by
the rights, powers and preferences of the holders of the Preferred Stock set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Voting</U>. The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of
shareholders (and written actions in lieu of meetings); <I>provided</I>, <I>however</I>, that, except as otherwise required by law, holders
of Common Stock, as such, will not be entitled to vote on any amendment to this Amended and Restated Certificate of Formation (&ldquo;<B><I>Restated
Certificate</I></B>&rdquo;) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such
affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant
to this Restated Certificate or pursuant to the TBOC. There will be no cumulative voting. The number of authorized shares of Common Stock
may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders
of one or more series of Preferred Stock that may be required by the terms of this Restated Certificate) the affirmative vote of the holders
of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock
of the Corporation entitled to vote, irrespective of the provisions of Section 21.364(d) of the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>PREFERRED STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
490,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B><I>Series A Preferred Stock</I></B>&rdquo;;
(ii) 30,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B><I>Series B Preferred Stock</I></B>&rdquo;;
(iii) 142,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B><I>Series C Preferred Stock</I></B>&rdquo;;
(iv) 102,600,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B><I>Series D Preferred Stock</I></B>&rdquo;;
(v) 12,345,678 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B><I>Series E Preferred Stock</I></B>&rdquo;;
and (vi) 10,493,827 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B><I>Series F Preferred
Stock</I></B>&rdquo;; each with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations.
Subject to compliance with <U>Section </U></FONT><U>3.3</U>, <U>Section 3.4</U> Section 3.5, and <U>Section 3.6</U>, the Board of Directors
(the &ldquo;<B><I>Board</I></B>&rdquo;) is hereby expressly authorized to provide, out of the authorized but unissued shares of Preferred
Stock, for one or more new series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such
series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative,
participating, optional, or other special rights, if any, and any qualifications, limitations, or restrictions thereof, of the shares
of such series without shareholder action in accordance with Section 21.155 of the TBOC. The powers, preferences and relative, participating,
optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any,
may differ from those of any and all other series at any time outstanding. Unless otherwise indicated, references to &ldquo;sections&rdquo;
or &ldquo;subsections&rdquo; in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Dividends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation will not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation
(other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents
required elsewhere in this Restated Certificate) the holders of the Preferred Stock then outstanding will first receive, or simultaneously
receive, on a <I>pari passu</I> basis, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the
case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred
Stock as would equal the product of (A) the dividend payable on each share of such class or series determined, if applicable, as if all
shares of such class or series had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion
of a share of Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend
or (ii) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock
determined by (A) dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance
price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization,
stock combination or similar transaction with respect to such class or series) and (B) multiplying such fraction by an amount equal to
the applicable Original Issue Price (as defined below); <I>provided</I> that, if the Corporation declares, pays or sets aside, on the
same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders
of Preferred Stock pursuant to this <U>Section </U></FONT><U>1</U> will be calculated based upon the dividend on the class or series of
capital stock that would result in the highest Preferred Stock dividend. The &ldquo;<B><I>Series A Original Issue Price</I></B>&rdquo;
will mean $0.61 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination
or similar transaction with respect to the Series A Preferred Stock; the &ldquo;<B><I>Series B Original Issue Price</I></B>&rdquo; will
mean $0.54 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination
or similar transaction with respect to the Series B Preferred Stock; the &ldquo;<B><I>Series C Original Issue Price</I></B>&rdquo; will
mean $2.76 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination
or similar transaction with respect to the Series C Preferred Stock; the &ldquo;<B><I>Series D Original Issue Price</I></B>&rdquo; will
mean $8.10 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination
or similar transaction with respect to the Series D Preferred Stock; the &ldquo;<B><I>Series E Original Issue Price</I></B>&rdquo; will
mean $8.10 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination
or similar transaction with respect to the Series E Preferred Stock; and the &ldquo;<B><I>Series F Original Issue Price</I></B>&rdquo;
will mean $8.10 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination
or similar transaction with respect to the Series F Preferred Stock. Notwithstanding anything to the contrary herein, solely with respect
to dividends declared on the Preferred Stock, such dividends shall not be paid in the form of stock; provided, that, the foregoing shall
not restrict the payment of dividends in the form of stock in connection with a dividend declared on the Common Stock or pursuant to <U>Sections
2</U> or <U>5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Preferential Payments to Holders of Series E Preferred Stock</U>. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation, the holders of shares of Series E Preferred Stock then outstanding will be entitled to be
paid out of the assets of the Corporation available for distribution to its shareholders, and in the event of a Deemed Liquidation Event
(as defined below), the holders of shares of Series E Preferred Stock then outstanding will be entitled to be paid out of the consideration
payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any
payment will be made to the holders of Series F Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series B Preferred
Stock, Series A Preferred Stock or Common Stock by reason of their ownership thereof, the following amounts per share: an amount per share
equal to the greater of (i) the Series E Original Issue Price, plus (A) any dividends declared but unpaid thereon and (B) a 7% cumulative
accruing dividend, compounding annually from the date of issuance of such share of Series E Preferred Stock, or (ii)&nbsp; such amount
per share as would have been payable had all shares of Series E Preferred Stock been converted into Common Stock pursuant to <U>Section&nbsp;4</U>
immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence
is hereinafter referred to as the &ldquo;<B><I>Series E Liquidation Amoun</I></B><I>t</I>&rdquo;). If upon any such liquidation, dissolution
or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its shareholders
will be insufficient to pay the holders of shares of Series E Preferred Stock the full amounts to which they will be entitled under this
<U>Section&nbsp;2.1</U>, the holders of shares of Series E Preferred Stock will share ratably, on a <I>pari passu</I> basis, in any distribution
of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares
held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Preferential Payments to Holders of Series D Preferred Stock and Series C Preferred Stock</U>. Subject to the prior right of
the holders of the Series E Preferred Stock provided in <U>Section 2.1</U>, in the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation, the holders of shares of Series D Preferred Stock and Series C Preferred Stock then outstanding
will be entitled to be paid, pro rata on a <I>pari passu</I> basis out of the assets of the Corporation available for distribution to
its shareholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series D Preferred Stock
and Series C Preferred Stock then outstanding will be entitled to be paid, pro rata on a <I>pari passu</I> basis, out of the consideration
payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any
payment will be made to the holders of Series F Preferred Stock, Series B Preferred Stock, Series A Preferred Stock or Common Stock by
reason of their ownership thereof, the following amounts per share: (a) in respect of the Series D Preferred Stock, an amount per share
equal to the greater of (i) the Series D Original Issue Price, plus (A) any dividends declared but unpaid thereon and (B) a 7% cumulative
accruing dividend, compounding annually from the date of issuance of such share of Series D Preferred Stock, (ii)&nbsp; such amount per
share as would have been payable had all shares of Series D Preferred Stock been converted into Common Stock pursuant to <U>Section&nbsp;4</U>
immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event, or (iii) 1.2 times the Series D Original Issue
Price for each share of Series D Preferred Stock (the amount payable pursuant to this sentence is hereinafter referred to as the &ldquo;<B><I>Series
D Liquidation Amoun</I></B><I>t</I>&rdquo;); <I>provided</I> that, without the prior written consent of the Requisite Series D Holders
(as defined below), the Series D Liquidation Amount shall consist, with respect to each share of Series D Preferred Stock, of an amount
of cash equal to at least 1.2 times (subject to reduction in accordance with the following sentence) the Series D Original Issue Price
for each such share; and (b) in respect of the Series C Preferred Stock, an amount per share equal to the greater of (i) the Series C
Original Issue Price, plus (A) any dividends declared but unpaid thereon and (B) a 7% cumulative accruing dividend, compounding annually
from the date of issuance of such share of Series C Preferred Stock, or (ii)&nbsp; such amount per share as would have been payable had
all shares of Series C Preferred Stock been converted into Common Stock pursuant to <U>Section&nbsp;4</U> immediately prior to such liquidation,
dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &ldquo;<B><I>Series
C Liquidation Amoun</I></B><I>t</I>&rdquo;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation
Event, the assets of the Corporation available for distribution to its shareholders will be insufficient to pay the holders of shares
of Series D Preferred Stock and Series C Preferred Stock the full amounts to which they will be entitled under this <U>Section&nbsp;2.2</U>,
the holders of shares of Series D Preferred Stock and Series C Preferred Stock will share ratably, on a <I>pari passu</I> basis, in any
distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect
of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Preferential Payments to Holders of Series F Preferred Stock</U>. Subject to the prior right of the holders of the Series E
Preferred Stock, Series D Preferred Stock and Series C Preferred Stock provided in <U>Sections 2.1</U> and <U>2.2</U>, in the event of
any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series F Preferred Stock
then outstanding will be entitled to be paid out of the assets of the Corporation available for distribution to its shareholders, and
in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series F Preferred Stock then outstanding will
be entitled to be paid out of the consideration payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds
(as defined below), as applicable, before any payment will be made to the holders of Series B Preferred Stock, Series A Preferred Stock
and Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Series F Original Issue Price,
plus (A) any dividends declared but unpaid thereon, and (B) 8% cumulative accruing dividend, compounding annually from the date of issuance
of such share of Series F Preferred Stock, (ii) 1.5 times the Series F Original Issue Price for each share of Series F Preferred Stock
or (iii) such amount per share as would have been payable had all shares of Series F Preferred Stock been converted into Common Stock
pursuant to <U>Section&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount
payable pursuant to this sentence is hereinafter referred to as the &ldquo;<B><I>Series F Liquidation Amoun</I></B><I>t</I>&rdquo;). If
upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available
for distribution to its shareholders will be insufficient to pay the holders of shares of the Series F Preferred Stock the full amount
to which they will be entitled under this <U>Section&nbsp;2.3</U>, the holders of shares of the Series F Preferred Stock will share ratably
in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable
in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Preferential Payments to Holders of Series B Preferred Stock and Series A Preferred Stock</U>. Subject to the prior right of
the holders of the Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock and Series F Preferred Stock provided
in <U>Sections 2.1</U>, <U>2.2</U> and <U>2.3</U>, in the event of any voluntary or involuntary liquidation, dissolution or winding up
of the Corporation, the holders of shares of Series B Preferred Stock and Series A Preferred Stock (together, the &ldquo;<B><I>Existing
Preferred Stock</I></B>&rdquo;) then outstanding will be entitled to be paid, pro rata on a <I>pari passu</I> basis out of the assets
of the Corporation available for distribution to its shareholders, and in the event of a Deemed Liquidation Event (as defined below),
the holders of shares of Existing Preferred Stock then outstanding will be entitled to be paid, pro rata on a <I>pari passu</I> basis,
out of the consideration payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below),
as applicable, before any payment will be made to the holders of Common Stock by reason of their ownership thereof, an amount per share
equal to the greater of (i) the applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount
per share as would have been payable had all shares of Existing Preferred Stock been converted into Common Stock pursuant to <U>Section&nbsp;4</U>
immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence
is hereinafter referred to as the &ldquo;<B><I>Existing Preferred Liquidation Amount</I></B>&rdquo; and, together with the Series E Liquidation
Amount, Series D Liquidation Amount, Series C Liquidation Amount, and Series F Liquidation Amount, the &ldquo;<B><I>Liquidation Amount</I></B>&rdquo;).
If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation
available for distribution to its shareholders will be insufficient to pay the holders of shares of the Existing Preferred Stock the full
amount to which they will be entitled under this <U>Section&nbsp;2.4</U>, the holders of shares of the Existing Preferred Stock will share
ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Payments to Holders of Common Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up
of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock,
the remaining assets of the Corporation available for distribution to its shareholders or, in the case of a Deemed Liquidation Event,
the consideration not payable to the holders of shares of Preferred Stock pursuant to <U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U> and
2.4 or the remaining Available Proceeds, as the case may be, will be distributed among the holders of shares of Common Stock, pro rata
based on the number of shares held by each such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Deemed Liquidation Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Definition</U>. Each of the following events will be considered a &ldquo;<B><I>Deemed Liquidation Event</I></B>&rdquo; unless
the holders of a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as-converted basis (the
 &ldquo;<B><I>Requisite Holders</I></B>&rdquo;), elect otherwise by written notice sent to the Corporation at least 10 days prior to the
effective date of any such event; <I>provided</I>, <I>however</I>, that if the price to be paid per share of Series C Preferred Stock
in connection with such Deemed Liquidation Event is less than the Series C Original Issue Price, the consent of the holders of a majority
of the outstanding shares of Series C Preferred Stock (including in such majority SH Caris Life US, LLC (&ldquo;<B><I>Stonebridge-Highland</I></B>&rdquo;)),
so long as Stonebridge-Highland and its Affiliates (as defined in that certain Amended and Restated Investors&rsquo; Rights Agreement
to be entered into in connection with the issuance of the Series E Preferred Stock (as amended, restated or modified from time to time
the &ldquo;<B><I>Investors&rsquo; Rights Agreement</I></B>&rdquo;) which are permitted assigns under the Investors&rsquo; Rights Agreement
hold at least 13,586,957 shares of Series C Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock
dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock)) voting as a separate
class (the &ldquo;<B><I>Requisite Series C Holders</I></B>&rdquo;), will be required for such waiver; <I>provided further</I>, that if
the price to be paid per share of Series D Preferred Stock in connection with such Deemed Liquidation Event is less than the Series D
Original Issue Price, the consent of the holders of a majority of the outstanding shares of Series D Preferred Stock (including in such
majority the holders of a majority of the shares of Series D Preferred Stock held by &ldquo;<B><I>Sixth Street</I></B>&rdquo; (which shall
mean Barnett Equity Holdings II, LLC, Sixth Street Specialty Lending, Inc. and their Affiliates which are permitted assigns under the
Investors&rsquo; Rights Agreement), so long as Sixth Street holds at least 18,518,518 shares of Series D Preferred Stock (subject to appropriate
adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the
Series D Preferred Stock)) voting as a separate class (the &ldquo;<B><I>Requisite Series D Holders</I></B>&rdquo;), will be required for
such waiver; <I>provided further</I>, that if the price to be paid per share of Series E Preferred Stock in connection with such Deemed
Liquidation Event is less than the Series E Original Issue Price, the consent of the holders of a majority of the outstanding shares of
Series E Preferred Stock (including in such majority (i) &ldquo;<B><I>Braidwell</I></B>&rdquo; (which shall mean Braidwell Transaction
Holdings LLC &ndash; Series 11, a Delaware limited liability company and its Affiliates which are permitted assigns under the Investors&rsquo;
Rights Agreement) for so long as Braidwell holds the lesser of (x) 8.75% of the shares of Series E Preferred Stock then outstanding (or
Common Stock issued upon conversion thereof) and (y) 25% of the Series E Preferred Stock sold to Braidwell pursuant to that certain Series
E/F Preferred Stock Purchase Agreement, dated on or about the date hereof and (ii) additional holders of Series E Preferred Stock that
(x) are not affiliated with Braidwell and (y) collectively hold at least 4% of the shares of Series E Preferred Stock then outstanding,
voting as a separate class (the &ldquo;<B><I>Requisite Series E Holders</I></B>&rdquo;), will be required for such waiver:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>a merger or consolidation in which</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">the Corporation is a constituent party or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital
stock pursuant to such merger or consolidation,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding
immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock
that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)
the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation
immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation. In the event the
Requisite Holders elect to not treat an event referred to in <U>Section </U></FONT><U>2.6.1(a)</U> as a Deemed Liquidation Event by sending
a written notice to the Corporation as set forth in <U>Section 2.6.1</U>, the Corporation will send written notice to each holder of Series
C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock, and each such holder will have its
shares of Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and/or Series F Preferred Stock, as applicable,
redeemed by the Corporation at a cash redemption price per share equal to the Series C Liquidation Amount, Series D Liquidation Amount,
Series E Liquidation Amount or Series F Liquidation Amount, as applicable, unless such holder opts out of such redemption within 15 days
following receipt of such written notice, subject to the Available Proceeds as defined in <U>Section 2.6.2(b)</U>. The Corporation will
use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series C Preferred Stock, Series D Preferred
Stock, Series E Preferred Stock and Series F Preferred Stock as required by this <U>Section 2.6.1(a)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions,
by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries
taken as a whole, or (2) the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or
a series of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation
and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive
license or other disposition is to a wholly owned subsidiary of the Corporation. In the event the Requisite Holders elect to not treat
an event referred to in <U>Section 2.6.1(b)</U> as a Deemed Liquidation Event by sending a written notice to the Corporation as set forth
in <U>Section 2.6.1</U>, the Corporation will send written notice to each holder of Series F Preferred Stock, Series E Preferred Stock,
Series D Preferred Stock, and Series C Preferred Stock, and each such holder will have its shares of Series F Preferred Stock, Series
E Preferred Stock, Series D Preferred Stock, and/or Series C Preferred Stock, as applicable, redeemed by the Corporation at a cash redemption
price per share equal to the Series F Liquidation Amount, Series E Liquidation Amount, Series D Liquidation Amount, or the Series C Liquidation
Amount, as applicable, unless such holder opts out of such redemption within 15 days following receipt of such written notice, subject
to the Available Proceeds as defined in <U>Section 2.6.2(b)</U>. The Corporation will use commercially reasonable efforts to obtain financing
to permit the Corporation to redeem the Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred
Stock as required by this <U>Section 2.6.1(b)</U>; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>a sale or transfer of the majority of the total outstanding voting power of the Corporation to a person or entity (other than a
person or entity that was (or whose affiliates or family members were) a shareholder of the Corporation or direct or indirect beneficial
owners of a shareholder of the Corporation prior to such transactions or series of related transactions) by means of any transaction or
series of related transactions to which the Corporation, or any subsidiary of the Corporation, is a party (including, without limitation,
a stock acquisition or other corporate reorganization), other than a public offering of the Corporation&rsquo;s capital stock or a sale
or transfer in which the holders (together with their affiliates, family members and direct and indirect beneficial owners) of a majority
of the outstanding shares of capital stock, by voting power, of the Corporation outstanding immediately prior to such sale or transfer
continue to hold (together with their affiliates, family members and direct and indirect beneficial owners) shares of capital stock that
represent, immediately following such sale or transfer, at least a majority, by voting power, of the capital stock of (1) the Corporation;
(2) the surviving or resulting corporation; or (3) if the Corporation or the surviving or resulting corporation is a wholly owned subsidiary
of another corporation immediately following such sale or transfer, the parent corporation of such surviving or resulting corporation.
In the event the Requisite Holders elect to not treat an event referred to in <U>Section 2.6.1(c)</U> as a Deemed Liquidation Event by
sending a written notice to the Corporation as set forth in <U>Section 2.6.1</U>, the Corporation will send written notice to each holder
of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock and each such holder will
have its shares of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and/or Series C Preferred Stock, as applicable,
redeemed by the Corporation at a cash redemption price per share equal to the Series F Liquidation Amount, Series E Liquidation Amount,
Series D Liquidation Amount or the Series C Liquidation Amount, as applicable, unless such holder opts out of such redemption within 15
days following receipt of such written notice, subject to the Available Proceeds as defined in <U>Section 2.6.2(b)</U>. The Corporation
will use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series F Preferred Stock, Series
E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock as required by this <U>Section 2.6.1(c)</U>. For the avoidance
of doubt, any transaction that qualifies as a Deemed Liquidation Event pursuant to <U>Section 2.6.1(a)</U> and <U>Section 2.6.1(c)</U>
shall be treated as a Deemed Liquidation Event under <U>Section 2.6.1(a)</U> only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding the other provisions of this <U>Section 2.6.1</U>, a merger, consolidation or other business combination transaction
between the Corporation and any of its subsidiaries on one hand and a SPAC (as defined below) on the other hand shall not constitute a
Deemed Liquidation Event so long as the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation
or other business combination transaction continue to represent, or are converted into or exchanged for shares of capital stock that represent,
immediately following such merger, consolidation or other business combination transaction, at least a majority, by voting power, of the
capital stock of the surviving or resulting corporation. &ldquo;<B><I>SPAC</I></B>&rdquo; means (1) a special purpose acquisition corporation,
(2) a blank check company, (3) any similar development stage company, and, in the case that any of the entities identified in clauses
(1)-(3) was newly-formed for the purpose of raising capital and completing a business combination transaction with another entity which
does not have material business operations or hold material assets other than cash, or (4) any subsidiary of any of the entities identified
in clauses (1)-(3), and (5) in the case of clauses (1)-(3), the equity securities of such entity that are publicly listed on the New York
Stock Exchange or Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Effecting a Deemed Liquidation Event</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation will not have the power to effect a Deemed Liquidation Event referred to in <U>Section 2.6.1(a)(i)</U> unless the
agreement or plan of merger or consolidation for such transaction (the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;) provides that the
consideration payable to the shareholders of the Corporation in such Deemed Liquidation Event will be paid to the holders of capital stock
of the Corporation in accordance with <U>Section 2.1</U> through <U>Section 2.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event of a Deemed Liquidation Event referred to in Section 2.6.1(a)(ii), Section 2.6.1(b) or Section 2.6.1(c), if the Corporation
does not effect a dissolution of the Corporation under the TBOC within ninety (90) days after such Deemed Liquidation Event, then (i)
the Corporation will send a written notice to each holder of Preferred Stock no later than the ninetieth (90<SUP>th</SUP>) day after the
Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms
of the following clause to require the redemption of such shares of Preferred Stock, and (ii) if (A) with respect to the Series A Preferred
Stock, the Requisite Series A Holders (as defined herein), (B) with respect to the Series B Preferred Stock, the Requisite Series B Holders,
(C) with respect to the Series C Preferred Stock, the Requisite Series C Holders, (D) with respect to the Series D Preferred Stock, the
Requisite Series D Holders, (E) with respect to the Series E Preferred Stock, the Requisite Series E Holders, or (F) with respect to the
Series F Preferred Stock, the Requisite Series F Holders (as defined below), as applicable, so request in a written instrument delivered
to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation will use the consideration
received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology
licensed, as determined in good faith by the Board), together with any other assets of the Corporation available for distribution to its
shareholders, all to the extent permitted by Texas law governing distributions to shareholders (the &ldquo;<B><I>Available Proceeds</I></B>&rdquo;),
on the one hundred fiftieth (150<SUP>th</SUP>) day after such Deemed Liquidation Event, to redeem all outstanding shares of such series
of Preferred Stock that have elected to be redeemed, excluding those of holders of any Preferred Stock who elect not to be redeemed, at
a price per share equal to the applicable Liquidation Amount. Notwithstanding the foregoing, in the event of a redemption pursuant to
the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation
will first redeem a pro rata portion of each holder&rsquo;s shares of (1) Series E Preferred Stock, then (2) Series D Preferred Stock
and Series C Preferred Stock on a <I>pari passu</I> basis, then (3) the Series F Preferred Stock, then (4) the Existing Preferred Stock,
and lastly (5) the Common Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise
be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and will redeem
the remaining shares as soon as it may lawfully do so under Texas law governing distributions to shareholders. The provisions of <U>Section
6</U> will apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred
Stock pursuant to this <U>Section 2.6.2(b)</U>. Prior to the distribution or redemption provided for in this <U>Section 2.6.2(b)</U>,
the Corporation will not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses
incurred in connection with such Deemed Liquidation Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation
upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption will be the cash or the value
of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to <U>Section 2.6.1(a)(i)</U>,
if any portion of the consideration payable to the shareholders of the Corporation is payable only upon satisfaction of contingencies
(the &ldquo;<B><I>Additional Consideration</I></B>&rdquo;), the Merger Agreement will provide that (a) the portion of such consideration
that is not Additional Consideration (such portion, the &ldquo;<B><I>Initial Consideration</I></B>&rdquo;) will be allocated among the
holders of capital stock of the Corporation in accordance with <U>Section 2.1</U> through <U>Section 2.5</U> as if the Initial Consideration
were the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional Consideration which becomes
payable to the shareholders of the Corporation upon satisfaction of such contingencies will be allocated among the holders of capital
stock of the Corporation in accordance with <U>Section 2.1</U> through <U>Section 2.5</U> after taking into account the previous payment
of the Initial Consideration as part of the same transaction. For the purposes of this <U>Section 2.6.4</U>, consideration placed into
escrow or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed
Liquidation Event will be deemed to be Initial Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Valuation of Non-Cash Consideration</U>. If any property, rights, securities or assets of the Corporation to be paid or distributed
to stockholders in connection with a Deemed Liquidation Event are other than cash, then the value of such property, rights, securities
or assets shall be their fair market value as determined in good faith by the Board, <I>except that</I> any publicly traded securities
to be distributed to stockholders in Deemed Liquidation Event shall be valued as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the securities are then traded on a national securities exchange, then the value of the securities shall be deemed to be the
volume-weighted average of the closing prices of the securities on such exchange over the ten (10) trading day period ending five (5)
trading days prior to the distribution, as such amounts are determined using the preceding methodology in good faith by the Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the securities are actively traded over the counter, then the value of the securities shall be deemed to be the volume-weighted
average of the closing bid prices of the securities over the ten (10) trading day period ending five (5) trading days prior to the distribution,
as such amounts are determined using the preceding methodology in good faith by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the purposes of this <U>Section </U></FONT><U> 2.6.5</U>, &ldquo;<B><I>trading day</I></B>&rdquo; shall mean any day which the exchange
or system on which the securities to be distributed are traded is open, <B>&ldquo;<I>volume-weighted average</I>&rdquo;</B> means the
average of the averages calculated by weighting the applicable closing prices by the volume of securities traded for each applicable trading
day, and &ldquo;<B><I>closing prices</I></B>&rdquo; or &ldquo;<B><I>closing bid prices</I></B>&rdquo; shall be deemed to be: (i)&nbsp;for
securities traded primarily on the New York Stock Exchange or a Nasdaq market, the last reported trade price or sale price, as the case
may be, at 4:00 p.m., New York time, on that day and (ii)&nbsp;for securities listed or traded on other exchanges, markets and systems,
the market price as of the end of the regular hours trading period that is generally accepted as such for such exchange, market or system.
If, after the date hereof, the benchmark times generally accepted in the securities industry for determining the market price of a stock
as of a given trading day shall change from those set forth above, the fair market value shall be determined as of such other generally
accepted benchmark times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Voting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>General</U>. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting
of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Preferred
Stock will be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred
Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as
provided by law or by the other provisions of this Restated Certificate, holders of Preferred Stock will vote together with the holders
of Common Stock as a single class and on an as-converted to Common Stock basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Election of Directors</U>. Subject to any rights granted to holders of indebtedness, the holders of record of the shares of
Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single
class on an as-converted basis, shall be entitled to elect the total number of directors of the Corporation. For so long as the holders
of Series C Preferred Stock hold at least 5,579,710 shares of Series C Preferred Stock (subject to appropriate adjustment in the event
of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock),
the holders of Series C Preferred Stock, together as a single class on an as-converted to Common Stock basis, will be entitled to elect
one (1) director of the Corporation (the &ldquo;<B><I>Series C Director</I></B>&rdquo;). At any meeting held for the purpose of electing
a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled
to elect such director will constitute a quorum for the purpose of electing such director. Except as otherwise provided in this <U>Section&nbsp;
3.2</U> or any shareholder agreement, a vacancy in any directorship filled by the holders of any class or series will be filled only by
vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected
by the holders of such class or series pursuant to this <U>Section&nbsp;3.2</U> or any shareholder agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Series C Preferred Stock Protective Provisions</U>. Only for so long as at least 5,579,710 shares of Series C Preferred Stock
(subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction
with respect to the Series C Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger,
consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law
or this Restated Certificate) the written consent or affirmative vote of the Requisite Series C Holders given in writing or by vote at
a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without
such consent or vote will be null and void <I>ab initio</I>, and of no force or effect:<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>liquidate, dissolve or wind-up the business and affairs of the Corporation, or effect any merger or consolidation that would not
qualify as a Deemed Liquidation Event or a Qualified SPAC Transaction, if such merger or consolidation would result in the cancellation
or conversion of the Series C Preferred Stock and the holders of the Series C Preferred Stock would receive an amount less than the Series
C Liquidation Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>amend, alter or repeal any provision of this Restated Certificate or Bylaws of the Corporation (the &ldquo;<B><I>Bylaws</I></B>&rdquo;)
in a manner that adversely affects the powers, preferences or rights of the Series C Preferred Stock, it being understood that amendments
or alterations to create Permitted Preferred Stock (as defined below) with rights and obligations that are (A) permitted by the definition
of Permitted Preferred Stock, (B) shared pro rata with the Preferred Stock, or (C) specific to the Permitted Preferred Stock, in each
instance of clauses (A), (B) or (C), do not adversely affect the powers, preferences or rights of the Series C Preferred Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>create, or authorize the creation of, or issue or obligate itself to issue shares of, any other securities convertible into or
exercisable for any equity securities, having rights, preferences or privileges <I>pari passu</I> or senior to the Series C Preferred
Stock (<I>provided</I> that the creation, authorization or issuance of Permitted Preferred Stock will not require the consent of the Requisite
Series C Holders);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>purchase or redeem any capital stock or pay any dividend on any capital stock prior to the Series C Preferred Stock other than
(A) dividends or distributions on the Preferred Stock, (B) dividends or other distributions payable on the Common Stock solely in the
form of additional shares of Common Stock, (C) redemptions of Preferred Stock pursuant to <U>Section 6</U>, or (D) repurchases of shares
from former employees, independent directors, officers or consultants or other persons who performed services for the Corporation (other
than the founder, the founder&rsquo;s family members and directors appointed by specific investors) in each instance in an aggregate amount
for each individual less than 1.5% of the Corporation&rsquo;s equity securities calculated on a fully-diluted basis in connection with
the cessation of such employment or service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>amend the rights, preferences or privileges of any existing security that is junior to the Series C Preferred Stock in a manner
that would render such existing security <I>pari passu</I> or senior to the Series C Preferred Stock in respect of the distribution of
assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>enter into any transaction after the Series D Original Issue Date (as defined below) with an affiliate, shareholder or director
of the Corporation unless such transaction (A) in the case of a director or employee of the Corporation, involves standard employee benefits
generally made available to all employees, (B) in the case of a director or officer of the Corporation, involves standard director and
officer indemnification agreements approved by the Board, (C) involves aggregate per transaction consideration of less than $1,000,000,
(D) is an issuance of equity to which the rights granted to the Series C Preferred Stock pursuant to Section 4 of the Investors&rsquo;
Rights Agreement are applicable and/or validly waived, (E) applies to all similarly situated shareholders in the same manner, or (F) involves
an affiliate, shareholder or director of the Corporation who holds less than 5% of the Corporation&rsquo;s equity securities on a fully
diluted basis and has been approved by a majority of the disinterested members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>enter into any merger, consolidation or other similar business combination transaction with a SPAC, other than a Qualified SPAC
Transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>except pursuant to a Deemed Liquidation Event, Qualified SPAC Transaction or a merger, consolidation or reorganization in which
the holders of Series C Preferred Stock receive securities with substantially similar rights as the Series C Preferred Stock, convert
any Series C Preferred Stock into any other security other than as expressly contemplated in <U>Sections 4</U> and <U>5</U> of this Restated
Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Permitted
Preferred Stock</I></B>&rdquo; means Preferred Stock that: (i) in the case of Preferred Stock having rights, preferences or privileges
senior to the Series D Preferred Stock or Series C Preferred Stock, has the following characteristics: (A) votes separately from each
of the Series D Preferred Stock and Series C Preferred Stock on any series-specific vote of the Series D Preferred Stock or Series C Preferred
Stock (as applicable), (B) does not have a redemption right exercisable prior to the Series D Preferred Stock&rsquo;s or the Series C
Preferred Stock&rsquo;s respective redemption rights pursuant to <U>Section </U></FONT><U> 6</U> hereof; <I>provided</I>, that if the
right to request a redemption of such Preferred Stock is permitted to be exercised on the same day as the right to request a redemption
of the Series D Preferred Stock or Series C Preferred Stock, such Preferred Stock may have a preference in seniority of payment on redemption
to the Series D Preferred Stock or Series C Preferred Stock (as applicable) to the extent the right to request redemption is exercised
within ninety (90) days of the date the Series D Preferred Stock or Series C Preferred Stock (as applicable) exercises their respective
right to request redemption, and (C) has a method for calculating aggregate senior liquidation preference on a liquidation, dissolution,
winding up or Deemed Liquidation Event (including any dividends) not more favorable to the holders thereof than the method for calculating
the Series D Liquidation Amount or Series C Liquidation Amount (as applicable); and (ii) in the case of Preferred Stock that does not
have rights, preferences or privileges senior to either the Series D Preferred Stock or the Series C Preferred Stock (as applicable);
has the following characteristics: (A) votes separately from each of the Series D Preferred Stock and Series C Preferred Stock on any
series-specific vote of the Series D Preferred Stock or Series C Preferred Stock, (B) does not have a redemption right exercisable prior
to the Series D Preferred Stock&rsquo;s or the Series C Preferred Stock&rsquo;s respective redemption right pursuant to <U>Section 6</U>
hereof and to the extent the right to request redemption is exercised within thirty (30) days of the date the Series D Preferred Stock
or Series C Preferred Stock (as applicable) exercises their respective right to request redemption, is redeemed pro rata, and (C) has
a method for calculating aggregate preference on a liquidation, dissolution, winding up or Deemed Liquidation Event (including any dividends)
not more favorable to the holders thereof than the method for calculating the Series D Liquidation Amount or Series C Liquidation Amount
(as applicable); and (iii) the aggregate original purchase price of such Preferred Stock described in the preceding clauses (i) and (ii)
shall not exceed $100,000,000.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series E Preferred Stock shall constitute
Permitted Preferred Stock and sales of Series E Preferred Stock shall decrease the aggregate original price of Permitted Preferred Stock
permitted to be issued by the Corporation in accordance with this Restated Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Series D Preferred Stock Protective Provisions</U>. Only for so long as at least 32,796,296 shares of Series D Preferred Stock
(subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction
with respect to the Series D Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger,
consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law
or this Restated Certificate) the written consent or affirmative vote of the Requisite Series D Holders given in writing or by vote at
a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without
such consent or vote will be null and void <I>ab initio</I>, and of no force or effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>liquidate, dissolve or wind-up the business and affairs of the Corporation, or effect any merger or consolidation that would not
qualify as a Deemed Liquidation Event or a Qualified SPAC Transaction, if such merger or consolidation would result in the cancellation
or conversion of the Series D Preferred Stock and the holders of the Series D Preferred Stock would receive an amount less than the Series
D Liquidation Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> amend, alter or repeal any provision of this Restated Certificate or the Bylaws in a manner that adversely affects the powers,
preferences or rights of the Series D Preferred Stock, it being understood that amendments or alterations to create Permitted Preferred
Stock (as defined above) with rights and obligations that are (A) permitted by the definition of Permitted Preferred Stock, (B) shared
pro rata with the Preferred Stock, or (C) specific to the Permitted Preferred Stock, in each instance of clauses (A), (B) or (C), do not
adversely affect the powers, preferences or rights of the Series D Preferred Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>create, or authorize the creation of, or issue or obligate itself to issue shares of, any other securities convertible into or
exercisable for any equity securities, having rights, preferences or privileges <I>pari passu</I> or senior to the Series D Preferred
Stock (<I>provided</I> that the creation, authorization or issuance of Permitted Preferred Stock will not require the consent of the Requisite
Series D Holders);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>purchase or redeem any capital stock or pay any dividend on any capital stock prior to the Series D Preferred Stock other than
(A) dividends or distributions on the Preferred Stock, (B) dividends or other distributions payable on the Common Stock solely in the
form of additional shares of Common Stock, (C) redemptions of Preferred Stock pursuant to <U>Section 6</U>, or (D) repurchases of shares
from former employees, independent directors, officers or consultants or other persons who performed services for the Corporation (other
than the founder, the founder&rsquo;s family members and directors appointed by specific investors) in each instance in an aggregate amount
for each individual less than 1.5% of the Corporation&rsquo;s equity securities calculated on a fully-diluted basis in connection with
the cessation of such employment or service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>amend the rights, preferences or privileges of any existing security that is junior to the Series D Preferred Stock in a manner
that would render such existing security <I>pari passu</I> or senior to the Series D Preferred Stock in respect of the distribution of
assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>enter into any transaction after the Series D Original Issue Date (as defined below) with an affiliate, shareholder or director
of the Corporation unless such transaction (A) in the case of a director or employee of the Corporation, involves standard employee benefits
generally made available to all employees, (B) in the case of a director or officer of the Corporation, involves standard director and
officer indemnification agreements approved by the Board, (C) involves aggregate per transaction consideration of less than $1,000,000,
(D) is an issuance of equity to which the rights granted to the Series D Preferred Stock pursuant to Section 4 of the Investors&rsquo;
Rights Agreement are applicable and/or validly waived, (E) applies to all similarly situated shareholders in the same manner, or (F) involves
an affiliate, shareholder or director of the Corporation who holds less than 5% of the Corporation&rsquo;s equity securities on a fully
diluted basis and has been approved by a majority of the disinterested members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>enter into any merger, consolidation or other similar business combination transaction with a SPAC, other than a Qualified SPAC
Transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>except pursuant to a Deemed Liquidation Event, Qualified SPAC Transaction or a merger, consolidation or reorganization in which
the holders of Series D Preferred Stock receive securities with substantially similar rights as the Series D Preferred Stock, convert
any Series D Preferred Stock into any other security other than as expressly contemplated in Sections 4 and 5 of this Restated Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Series E Preferred Stock Protective Provisions</U>. Only for so long as at least 3,703,703 shares of Series E Preferred Stock
(subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction
with respect to the Series E Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger,
consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law
or this Restated Certificate) the written consent or affirmative vote of the Requisite Series E Holders given in writing or by vote at
a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without
such consent or vote will be null and void <I>ab initio</I>, and of no force or effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>liquidate, dissolve or wind-up the business and affairs of the Corporation, or effect any merger or consolidation that would not
qualify as a Deemed Liquidation Event or a Qualified SPAC Transaction, if such merger or consolidation would result in the cancellation
or conversion of the Series E Preferred Stock and the holders of the Series E Preferred Stock would receive an amount less than the Series
E Liquidation Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> amend, alter or repeal any provision of this Restated Certificate or the Bylaws in a manner that adversely affects the powers,
preferences or rights of the Series E Preferred Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>create, or authorize the creation of, or issue or obligate itself to issue shares of, any other securities convertible into or
exercisable for any equity securities, having rights, preferences or privileges <I>pari passu</I> or senior to the Series E Preferred
Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>purchase or redeem any capital stock or pay any dividend on any capital stock prior to the Series E Preferred Stock other than
(A) dividends or distributions on the Preferred Stock, (B) dividends or other distributions payable on the Common Stock solely in the
form of additional shares of Common Stock, (C) redemptions of Preferred Stock pursuant to <U>Section 6</U> or (D) repurchases of shares
from former employees, independent directors, officers or consultants or other persons who performed services for the Corporation (other
than the founder, the founder&rsquo;s family members and directors appointed by specific investors) in each instance in an aggregate amount
for each individual less than 1.5% of the Corporation&rsquo;s equity securities calculated on a fully-diluted basis in connection with
the cessation of such employment or service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>amend the rights, preferences or privileges of any existing security that is junior to the Series E Preferred Stock in a manner
that would render such existing security <I>pari passu</I> or senior to the Series E Preferred Stock in respect of the distribution of
assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>enter into any transaction after the Series E Original Issue Date with an affiliate, shareholder or director of the Corporation
unless such transaction (A) in the case of a director or employee of the Corporation, involves standard employee benefits generally made
available to all employees, (B) in the case of a director or officer of the Corporation, involves standard director and officer indemnification
agreements approved by the Board, (C) involves aggregate per transaction consideration of less than $1,000,000, (D) is an issuance of
equity to which the rights granted to the Series E Preferred Stock pursuant to Section 4 of the Investors&rsquo; Rights Agreement are
applicable and/or validly waived, (E) applies to all similarly situated shareholders in the same manner, or (F) involves an affiliate,
shareholder or director of the Corporation who holds less than 5% of the Corporation&rsquo;s equity securities on a fully diluted basis
and has been approved by a majority of the disinterested members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>enter into any merger, consolidation or other similar business combination transaction with a SPAC, other than a Qualified SPAC
Transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>except pursuant to a Deemed Liquidation Event, Qualified SPAC Transaction or a merger, consolidation or reorganization in which
the holders of Series E Preferred Stock receive securities with substantially similar rights as the Series E Preferred Stock, convert
any Series E Preferred Stock into any other security other than as expressly contemplated in Sections 4 and 5 of this Restated Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Series F Preferred Stock Protective Provisions</U>. Only for so long as at least 3,148,148 shares of Series F Preferred Stock
(subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction
with respect to the Series F Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger,
consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law
or this Restated Certificate) the written consent or affirmative vote of the Requisite Series F Holders (as defined below) given in writing
or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered
into without such consent or vote will be null and void <I>ab initio</I>, and of no force or effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>amend, alter or repeal any provision of this Restated Certificate or the Bylaws in a manner that adversely affects the powers,
preferences or rights of the Series F Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Optional Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the Preferred
Stock will have conversion rights as follows (the &ldquo;<B><I>Conversion Rights</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Right to Convert</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Conversion Ratio</U>. Each share of Preferred Stock will be convertible, at the option of the holder thereof, at any time and
from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable
shares of Common Stock as is determined by dividing the applicable Original Issue Price, by the applicable Conversion Price (as defined
below) in effect at the time of conversion. The &ldquo;<B><I>Series A Conversion Price</I></B>&rdquo; will initially be equal to $0.61,
the &ldquo;<B><I>Series B Conversion Price</I></B>&rdquo; will initially be equal to $0.54, the &ldquo;<B><I>Series C Conversion Price</I></B>&rdquo;
will initially be equal to $2.76, the &ldquo;<B><I>Series D Conversion Price</I></B>&rdquo; will initially be equal to $8.10, the &ldquo;<B><I>Series
E Conversion Price</I></B>&rdquo; will initially be equal to $8.10, and the &ldquo;<B><I>Series F Conversion Price</I></B>&rdquo; will
initially be equal to $8.10. Each such initial Conversion Price, and the rate at which shares of Preferred Stock may be converted into
shares of Common Stock, will be subject to adjustment as provided below. Notwithstanding anything herein to the contrary, solely for the
purposes of <U>Sections 4.4.4(b)</U> and <U>4.4.4(c)</U> only, (i) the Series C Original Issue Price will be equal to $4.58 per share,
subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction
with respect to the Series C Preferred Stock and (ii) the Series C Conversion Price will initially be equal to $4.58 per share, subject
to adjustment as provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Series E Preferred Stock, Series
D Preferred Stock, or Series C Preferred Stock pursuant to <U>Section 6</U>, the Conversion Rights of the shares designated for redemption
will terminate at the close of business on the last full day preceding the date fixed for redemption, unless the applicable Redemption
Price is not fully paid on such Redemption Date, in which case the Conversion Rights for such shares will continue until such price is
paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event described in <U>Section
2.6.1(a)(i)</U>, the Conversion Rights will terminate at the close of business on the last full day preceding the date fixed for the payment
of any such amounts distributable on such event to the holders of Preferred Stock; provided that the foregoing termination of Conversion
Rights shall not affect the amount(s) otherwise paid or payable in accordance with <U>Section 2</U> to holders of Preferred Stock pursuant
to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event (including without limitation the Series
E Liquidation Amount, Series D Liquidation Amount, and the Series C Liquidation Amount).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Fractional Shares</U>. No fractional shares of Common Stock will be issued upon conversion of the Preferred Stock. In lieu of
any fractional shares to which the holder would otherwise be entitled, the Corporation will pay cash equal to such fraction multiplied
by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be
issuable upon such conversion will be determined on the basis of the total number of shares of Preferred Stock the holder is at the time
converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Mechanics of Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares
of Common Stock, such holder will (a) provide written notice to the Corporation&rsquo;s transfer agent at the office of the transfer agent
for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such
holder elects to convert all or any number of such holder&rsquo;s shares of Preferred Stock and, if applicable, any event on which such
conversion is contingent and (b), if such holder&rsquo;s shares are certificated, surrender the certificate or certificates for such shares
of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against
the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the
Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice will
state such holder&rsquo;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required
by the Corporation, any certificates surrendered for conversion will be endorsed or accompanied by a written instrument or instruments
of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized
in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its
own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) will be the time of
conversion (the &ldquo;<B><I>Conversion Time</I></B>&rdquo;), and the shares of Common Stock issuable upon conversion of the specified
shares will be deemed to be outstanding of record as of such date. The Corporation will, as soon as practicable after the Conversion Time
(i) issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number
of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number
(if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii) pay
in cash such amount as provided in <U>Section 4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such
conversion and (iii) pay all declared but unpaid dividends on the shares of Preferred Stock converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reservation of Shares</U>. The Corporation will at all times when the Preferred Stock is outstanding, reserve and keep available
out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its
duly authorized shares of Common Stock as will from time to time be sufficient to effect the conversion of all outstanding Preferred Stock;
and if at any time the number of authorized but unissued shares of Common Stock will not be sufficient to effect the conversion of all
then outstanding shares of the Preferred Stock, the Corporation will take such corporate action as may be necessary to increase its authorized
but unissued shares of Common Stock to such number of shares as will be sufficient for such purposes, including, without limitation, engaging
in best efforts to obtain the requisite shareholder approval of any necessary amendment to this Restated Certificate. Before taking any
action which would cause an adjustment reducing the Conversion Price below the then par value of the shares of Common Stock issuable upon
conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary
in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Conversion
Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Effect of Conversion</U>. All shares of Preferred Stock which will have been surrendered for conversion as herein provided will
no longer be deemed to be outstanding and all rights with respect to such shares will immediately cease and terminate at the Conversion
Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu
of any fraction of a share otherwise issuable upon such conversion as provided in <U>Section 4.2</U> and to receive payment of any dividends
declared but unpaid thereon. Any shares of Preferred Stock so converted will be retired and cancelled and may not be reissued as shares
of such series, and the Corporation may thereafter take such appropriate action (without the need for shareholder action) as may be necessary
to reduce the authorized number of shares of Preferred Stock accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the Conversion Price will be made for any declared but
unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Taxes</U>. The Corporation will pay any and all issue and other similar taxes (excluding, for the avoidance of doubt, any income
or withholding taxes of the holder) that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion
of shares of Preferred Stock pursuant to this <U>Section&nbsp;4</U>. The Corporation will not, however, be required to pay any tax which
may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in
which the shares of Preferred Stock so converted were registered, and no such issuance or delivery will be made unless and until the person
or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the
Corporation, that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustments to Conversion Price for Diluting Issues</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions will apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<B><I>Option</I></B>&rdquo; means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock
or Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<B><I>Series E Original Issue Date</I></B>&rdquo; means the date on which the first share of Series E Preferred Stock was
issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<B><I>Series D Original Issue Date</I></B>&rdquo; means May 11, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<B><I>Convertible Securities</I></B>&rdquo; means any evidences of indebtedness, shares or other securities directly or
indirectly convertible into or exchangeable for Common Stock, but excluding Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<B><I>Additional Shares of Common Stock</I></B>&rdquo; means all shares of Common Stock issued (or, pursuant to <U>Section&nbsp;
4.4.3</U> below, deemed to be issued) by the Corporation after the Series E Original Issue Date, other than (1) the following shares of
Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and
(2), collectively, &ldquo;<B><I>Exempted Securities</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock, Options or Convertible Securities issued or issuable upon conversion of any of
the Preferred Stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock or Options issued to officers, directors or employees of, or consultants or advisors
to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split,
split-up or other distribution on shares of Common Stock that is covered by <U>Section 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant
to the acquisition of another corporate entity by the Corporation by merger, purchase of substantially all of the assets or other reorganization
or to a joint venture agreement, <I>provided </I>that such issuances are approved by the Board and which is not for the principal purpose
of raising money;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock or Convertible Securities actually issued upon exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant
to the terms of such Option or Convertible Security approved by the Board;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock, Options or Convertible Securities issued to third-party banks, equipment lessors
or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing
transaction approved by the Board;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock issued or issuable in connection with a strategic alliance or licensing of technology
or intellectual property, research, development, collaboration or other OEM, marketing, or vendor/supplier arrangement approved by the
Board;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD><TD STYLE="text-align: justify">shares of Common Stock issued upon conversion of Series E Preferred Stock and Series F Preferred Stock
issued in connection with an IPO;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD><TD STYLE="text-align: justify">the Senior Convertible Notes issued pursuant to that certain Convertible Note Purchase Agreement, dated
on or about the date hereof (as may be amended or restated from time to time, the &ldquo;<B><I>Note Purchase Agreement</I></B>&rdquo;)
and shares of Common Stock issued upon conversion of any Senior Convertible Notes issued pursuant to the Note Purchase Agreement; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD><TD STYLE="text-align: justify">the Warrants to Purchase Common Stock issued pursuant to the Note Purchase Agreement and shares of Common
Stock issued upon exercise of any Warrant to Purchase Common Stock issued pursuant to the Note Purchase Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Adjustment of Conversion Price</U>. No adjustment in the Series E Conversion Price will be made as the result of the issuance
or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Series E Holders
agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.
No adjustment in the Series D Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common
Stock if the Corporation receives written notice from the Requisite Series D Holders agreeing that no such adjustment will be made as
the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series C Conversion Price
will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written
notice from the Requisite Series C Holders agreeing that no such adjustment will be made as the result of the issuance or deemed issuance
of such Additional Shares of Common Stock. No adjustment in the Series F Conversion Price will be made as the result of the issuance or
deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the
outstanding shares of Series F Preferred Stock, voting together as a single class on an as-converted basis (the &ldquo;<B><I>Requisite
Series F Holders</I></B>&rdquo;) agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such
Additional Shares of Common Stock. No adjustment in the Series B Conversion Price will be made as the result of the issuance or deemed
issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the outstanding
shares of Series B Preferred Stock, voting together as a single class on an as-converted basis (the &ldquo;<B><I>Requisite Series B Holders</I></B>&rdquo;)
agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.
No adjustment in the Series A Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common
Stock if the Corporation receives written notice from the holders of a majority of the outstanding shares of Series A Preferred Stock,
voting together as a single class on an as-converted basis (the &ldquo;<B><I>Requisite Series A Holders</I></B>&rdquo;) agreeing that
no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Deemed Issue of Additional Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the Corporation at any time or from time to time after the Series E Original Issue Date issues any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or fixes a record date for the determination of
holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of
Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility
or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the
exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible
Securities, will be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date
has been fixed, as of the close of business on such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Series C Conversion
Price pursuant to the terms of <U>Section&nbsp; 4.4.4</U> or the Series A Conversion Price, Series B Conversion Price, Series D Conversion
Price, Series E Conversion Price, or Series F Conversion Price pursuant to the terms of <U>Section 4.4.5</U>, are revised as a result
of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding
automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide
for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange
of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise,
conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the applicable Conversion Price computed
upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) will be
readjusted to such applicable Conversion Price as would have obtained had such revised terms been in effect upon the original date of
issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause&nbsp;(b) will
have the effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (i) applicable Conversion Price
in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)
the applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances
of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment
date and such readjustment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities),
the issuance of which did not result in an adjustment to the Series C Conversion Price pursuant to the terms of <U>Section&nbsp;4.4.4</U>
or the Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E Conversion Price, or Series F Conversion
Price pursuant to the terms of <U>Section 4.4.5</U> (either because the consideration per share (determined pursuant to <U>Section&nbsp;
4.4.6</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then
in effect, or because such Option or Convertible Security was issued before the Series E Original Issue Date), are revised after the Series
E Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible
Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible
Security) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange
of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion
or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto
(determined in the manner provided in <U>Section&nbsp;4.4.3(a))</U> will be deemed to have been issued effective upon such increase or
decrease becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof)
which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Series C Conversion Price pursuant
to the terms of <U>Section 4.4.4</U> or the Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E
Conversion Price, or Series F Conversion Price pursuant to the terms of <U>Section 4.4.5</U>, the applicable Conversion Price will be
readjusted to such applicable Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never
been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security,
or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option
or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the applicable
Conversion Price provided for in this <U>Section&nbsp;4.4.3</U> will be effected at the time of such issuance or amendment based on such
number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments
will be treated as provided in clauses (b) and (c) of this <U>Section&nbsp;4.4.3</U>). If the number of shares of Common Stock issuable
upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon
such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended,
any adjustment to the applicable Conversion Price that would result under the terms of this <U>Section&nbsp;4.4.3</U> at the time of such
issuance or amendment will instead be effected at the time such number of shares and/or amount of consideration is first calculable (even
if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the applicable Conversion Price that such
issuance or amendment took place at the time such calculation can first be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustment of Series C Conversion Price Upon Issuance of Additional Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event the Corporation at any time after the Series E Original Issue Date issues Additional Shares of Common Stock (including
Additional Shares of Common Stock deemed to be issued pursuant to <U>Section 4.4.3</U>, but excluding, for the avoidance of doubt, any
Additional Shares of Common Stock deemed to be issued pursuant to this <U>Section 4.4.4</U> or <U>Section 4.4.5</U>) other than in an
initial public offering, without consideration or for a consideration per share less than the applicable Series C Conversion Price in
effect immediately prior to such issuance or deemed issuance, then the Series C Conversion Price will be reduced, concurrently with such
issuance or deemed issuance, to the price at which the Additional Shares of Common Stock are issued; <I>provided </I>that if such issuance
or deemed issuance was without consideration, then the Corporation will be deemed to have received an aggregate of $0.001 of consideration
for all such Additional Shares of Common Stock issued or deemed to be issued. For the avoidance of doubt, there will be no adjustment
to the Series C Conversion Price pursuant to this <U>Section 4.4.4(a)</U> in the events described under <U>Section 4.4.4(b)</U> or <U>Section
4.4.4(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series C Preferred Stock, in the event of the issuance of Additional Shares of Common Stock in
an initial public offering by the Corporation in which the final offering price per share of Common Stock to the public (the &ldquo;<B><I>IPO
Price</I></B>&rdquo;) is less than 1.11111 times the Series C Original Issue Price, the Series C Conversion Price shall be automatically
reduced (concurrently with the closing of such initial public offering) to a price per share equal to ninety percent (90%) of the IPO
Price; provided that, the adjustments set forth in this Section 4.4.4(b) shall be applicable in the event of, and apply to, any direct
listing of the Corporation's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series C Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in <U>Section
5</U>) in which the SPAC Price (as defined below) is less than 1.2 times the Series C Original Issue Price, the Series C Conversion Price
shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such reduction is given effect in connection
with the mandatory conversion of the Series C Preferred Stock in connection with the Qualified SPAC Transaction) to a price per share
equal to eighty percent (80%) of the SPAC Price. The &ldquo;<B><I>SPAC Price</I></B>&rdquo; means the per share consideration payable
in respect of each issued and outstanding share of Common Stock in a Qualified SPAC Transaction (with such per share consideration determined
on the basis of the terms of the definitive agreement for the merger or combination of the Corporation or its subsidiary, as applicable,
with the SPAC and the volume-weighted average of the closing prices of the securities to be received in connection with the Qualified
SPAC Transaction on such exchange over the ten (10) trading day period ending five (5) trading days prior to the consummation of such
Qualified SPAC Transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustment of Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E Conversion Price, and
Series F Conversion Price Upon Issuance of Additional Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event the Corporation at any time after the Series E Original Issue Date issues Additional Shares of Common Stock (including
Additional Shares of Common Stock deemed to be issued pursuant to <U>Section 4.4.3</U>), without consideration or for a consideration
per share less than the Conversion Price for the Series A Preferred Stock, Series B Preferred Stock, Series D Preferred Stock, Series
E Preferred Stock, or Series F Preferred Stock in effect immediately prior to such issuance or deemed issuance, then the Conversion Price
for the Series A Preferred Stock, Series B Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, or Series F Preferred
Stock, as the case may be, will be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent)
determined in accordance with the following formula after the application of the adjustment set forth in this <U>Section 4.4.5(a)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CP<SUB>2</SUB> = CP<SUB>1</SUB>*(A + B) &divide;
(A + C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the foregoing formula, the following
definitions will apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">&ldquo;CP<SUB>2</SUB>&rdquo; means the applicable Conversion Price in effect immediately after such issuance
or deemed issuance of Additional Shares of Common Stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">&ldquo;CP<SUB>1</SUB>&rdquo; means the applicable Conversion Price in effect immediately prior to such
issuance or deemed issuance of Additional Shares of Common Stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify">&ldquo;A&rdquo; means the number of shares of Common Stock outstanding immediately prior to such issuance
or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable
upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible
Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such
issue);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify">&ldquo;B&rdquo; means the number of shares of Common Stock that would have been issued if such Additional
Shares of Common Stock had been issued or deemed issued at a price per share equal to CP<SUB>1</SUB> (determined by dividing the aggregate
consideration received by the Corporation in respect of such issue by CP<SUB>1</SUB>); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify">&ldquo;C&rdquo; means the number of such Additional Shares of Common Stock issued in such transaction,
including pursuant to <U>Section 4.4.4</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series D Preferred Stock, in the event of a Qualified IPO (as defined in <U>Section 5</U>) in
which the IPO Price is less than 1.1 times the Series D Original Issue Price, the Series D Conversion Price shall be automatically reduced
(concurrently with the closing of such Qualified IPO and such that such reduction is given effect in connection with the mandatory conversion
of the Series D Preferred Stock in connection with the Qualified IPO) to a price per share equal to ninety percent (90%) of the IPO Price;
provided that, the adjustments set forth in this Section 4.4.5(b) shall be applicable in the event of, and apply to, any direct listing
of the Corporation's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series D Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in <U>Section
5</U>) in which the SPAC Price is less than 1.2 times the Series D Original Issue Price, the Series D Conversion Price shall be automatically
reduced (concurrently with such Qualified SPAC Transaction and such that such reduction is given effect in connection with the mandatory
conversion of the Series D Preferred Stock in connection with the Qualified SPAC Transaction) to a price per share equal to eighty percent
(80%) of the SPAC Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series E Preferred Stock, in the event of a Qualified IPO, the Series E Conversion Price shall
be automatically reduced (concurrently with the closing of such Qualified IPO and such that such reduction is given effect in connection
with the mandatory conversion of the Series E Preferred Stock in connection with the Qualified IPO) to a price per share equal to seventy
percent (70%) of the IPO Price; provided, that, notwithstanding anything in this Restated Certificate to the contrary, solely for the
purposes of this <U>Section 4.4.5(d)</U>, each share of Series E Preferred Stock will convert into such number of fully paid and non-assessable
shares of Common Stock as is determined by dividing (i) the sum of (x) the Series E Original Issue Price plus (y) an additional amount
which shall accrue at the rate of 8% of the Series E Original Issue Price, compounded monthly from the issuance of such share of Series
E Preferred Stock, by (ii) the Series E Conversion Price; provided that, the adjustments set forth in this Section 4.4.5(d) shall be applicable
in the event of, and apply to, any direct listing of the Corporation's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series E Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in <U>Section
5</U>) the Series E Conversion Price shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such
reduction is given effect in connection with the mandatory conversion of the Series E Preferred Stock in connection with the Qualified
SPAC Transaction) to a price per share equal to seventy percent (70%) of the SPAC Price; provided, that, notwithstanding anything in <U>Section
4.1.1</U> to the contrary, solely for the purposes of this <U>Section 4.4.5(e)</U>, each share of Series E Preferred Stock will convert
into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the sum of (x) the Series E
Original Issue Price plus (y) an additional amount which shall accrue at the rate of 8% of the Series E Original Issue Price, compounded
monthly from the issuance of such share of Series E Preferred Stock, by (ii) the Series E Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series F Preferred Stock, in the event of a Qualified IPO the Series F Conversion Price shall
be automatically reduced (concurrently with the closing of such Qualified IPO and such that such reduction is given effect in connection
with the mandatory conversion of the Series F Preferred Stock in connection with the Qualified IPO) to a price per share equal to seventy
percent (70%) of the IPO Price; provided, that, notwithstanding anything in <U>Section 4.1.1</U> to the contrary, solely for the purposes
of this <U>Section 4.4.5(f)</U>, each share of Series F Preferred Stock will convert into such number of fully paid and non-assessable
shares of Common Stock as is determined by dividing (i) the sum of (x) the Series F Original Issue Price plus (y) an additional amount
which shall accrue at the rate of 8% of the Series F Original Issue Price, compounded monthly from the issuance of such share of Series
F Preferred Stock, by (ii) the Series F Conversion Price; provided that, the adjustments set forth in this Section 4.4.5(f) shall be applicable
in the event of, and apply to, any direct listing of the Corporation's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Solely with respect to shares of Series F Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in <U>Section
5</U>) the Series F Conversion Price shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such
reduction is given effect in connection with the mandatory conversion of the Series F Preferred Stock in connection with the Qualified
SPAC Transaction) to a price per share equal to seventy percent (70%) of the SPAC Price; provided, that, notwithstanding anything in <U>Section
4.1.1</U> to the contrary, solely for the purposes of this <U>Section 4.4.5(g)</U>, each share of Series F Preferred Stock will convert
into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the sum of (x) the Series F
Original Issue Price plus (y) an additional amount which shall accrue at the rate of 8% of the Series F Original Issue Price, compounded
monthly from the issuance of such share of Series F Preferred Stock, by (ii) the Series F Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Determination of Consideration</U>. For purposes of this <U>Section&nbsp; 4.4</U>, the consideration received by the Corporation
for the issuance or deemed issuance of any Additional Shares of Common Stock will be computed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Cash and Property</U>: Such consideration will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">insofar as it consists of property other than cash, be computed at the fair market value thereof at the
time of such issue, as determined in good faith by the Board; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify">in the event Additional Shares of Common Stock are issued together with other shares or securities or
other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as
provided in clauses (i) and (ii) above, as determined in good faith by the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional Shares of Common
Stock deemed to have been issued pursuant to <U>Section&nbsp;4.4.3</U>, relating to Options and Convertible Securities, will be determined
by dividing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">The total amount, if any, received or receivable by the Corporation as consideration for the issue of
such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments
relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options
for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible
Securities, by</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without
regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the
conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options
for Convertible Securities and the conversion or exchange of such Convertible Securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Multiple Closing Dates</U>. In the event the Corporation issues on more than one date Additional Shares of Common Stock that
are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a
series of Preferred Stock pursuant to the terms of <U>Section&nbsp;4.4.4</U> or <U>4.4.5</U>, then, upon the final such issuance, such
Conversion Price will be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and
without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustment for Stock Splits and Combinations</U>. If the Corporation at any time or from time to time after the Series E Original
Issue Date effects a subdivision of the outstanding Common Stock, the applicable Conversion Price in effect immediately before that subdivision
will be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series will
be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation at any time
or from time to time after the Series E Original Issue Date combines the outstanding shares of Common Stock, the applicable Conversion
Price in effect immediately before the combination will be proportionately increased so that the number of shares of Common Stock issuable
on conversion of each share of such series will be decreased in proportion to such decrease in the aggregate number of shares of Common
Stock outstanding. Any adjustment under this section will become effective at the close of business on the date the subdivision or combination
becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after
the Series E Original Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to
receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event
the applicable Conversion Price in effect immediately before such event will be decreased as of the time of such issuance or, in the event
such a record date will have been fixed, as of the close of business on such record date, by multiplying the applicable Conversion Price
then in effect by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the numerator of which will be the total number of shares of Common Stock issued and outstanding immediately prior to the time
of such issuance or the close of business on such record date, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the denominator of which will be the total number of shares of Common Stock issued and outstanding immediately prior to the time
of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend
or distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing (a) if such record
date has been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the applicable
Conversion Price will be recomputed accordingly as of the close of business on such record date and thereafter the applicable Conversion
Price will be adjusted pursuant to this section as of the time of actual payment of such dividends or distributions; and (b) that no such
adjustment will be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other distribution of shares
of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such
series of Preferred Stock had been converted into Common Stock on the date of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the
Series E Original Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive,
a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect
of outstanding shares of Common Stock) or in other property and the provisions of <U>Section&nbsp;1</U> do not apply to such dividend
or distribution, then and in each such event the holders of Preferred Stock will receive, simultaneously with the distribution to the
holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such
securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock
on the date of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Section&nbsp; 2.6</U> and <U>Section 5</U>,
if there occurs any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the
Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction
covered by <U>Section&nbsp;4.4</U>, <U>4.6, 4.7</U> or <U>Section 5</U>), then, following any such reorganization, recapitalization, reclassification,
consolidation or merger, each share of Preferred Stock will thereafter be convertible in lieu of the Common Stock into which it was convertible
prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock
of the Corporation issuable upon conversion of one share of Preferred Stock immediately prior to such reorganization, recapitalization,
reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate
adjustment (as determined in good faith by the Board) will be made in the application of the provisions in this <U>Section 4</U> with
respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this
<U>Section 4</U> (including provisions with respect to changes in and other adjustments of the applicable Conversion Price) will thereafter
be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion
of the Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of any Conversion Price pursuant to
this <U>Section 4</U>, the Corporation at its expense will, as promptly as reasonably practicable but in any event not later than ten
(10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Preferred
Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property
into which the Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The
Corporation will, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in
any event not later than ten (10) days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i) the
applicable Conversion Price then in effect, and (ii) the number of shares of Common Stock and the amount, if any, of other securities,
cash or property which then would be received upon the conversion of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notice of Record Date</U>. In the event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation will take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable
upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or
to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any
other security; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation
Event; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in each such case, the Corporation will
send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such dividend,
distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such
reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and
the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time
issuable upon the conversion of the Preferred Stock) will be entitled to exchange their shares of Common Stock (or such other capital
stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and
the Common Stock. Such notice will be sent at least ten (10) days prior to the record date or effective date for the event specified in
such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Mandatory Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Trigger Events</U>. Upon (a) the closing of the sale of shares of Common Stock to the public in a firm-commitment underwritten
initial public offering, pursuant to an effective registration statement under the Securities Act of 1933, as amended, (an &ldquo;<B><I>IPO</I></B>&rdquo;)
in which (i) the gross cash proceeds to the Corporation are equal to or greater than $100,000,000.00 (it being understood that stockholders
of the Corporation may also sell shares of Common Stock in such IPO in addition to the shares of Common Stock sold by the Corporation),
and (ii) the Common Stock is listed for trading on the New York Stock Exchange or the Nasdaq Stock Market (an IPO meeting the requirements
of both of the foregoing clauses, a &ldquo;<B><I>Qualified IPO</I></B>&rdquo;), (b) the consummation of a merger or combination of the
Corporation or its subsidiary, as applicable, with a SPAC and in which the SPAC consummates a concurrent private placement of its equity
securities resulting in gross cash proceeds to the SPAC of at least $450,000,000.00 (such transaction, a &ldquo;<B><I>Qualified SPAC Transaction</I></B>&rdquo;),
or (c) the date and time, or the occurrence of an event, specified by vote or written consent of: (i) with respect to the Series A Preferred
Stock, the Requisite Series A Holders; (ii) with respect to the Series B Preferred Stock, the Requisite Series B Holders; (iii) with respect
to the Series C Preferred Stock, the Requisite Series C Holders; (iv) with respect to the Series D Preferred Stock, the Requisite Series
D Holders; (v) with respect to the Series E Preferred Stock, the Requisite Series E Holders, and (vi) with respect to the Series F Preferred
Stock, the Requisite Series F Holders (the time of such closing or the date and time specified or the time of the event specified in such
vote or written consent is referred to herein as the &ldquo;<B><I>Mandatory Conversion Time</I></B>&rdquo;), then (i) all outstanding
shares of such series of Preferred Stock will automatically be converted into shares of Common Stock, at the then effective conversion
rate as calculated pursuant to <U>Section&nbsp;4.1.1,</U> and (ii) such shares may not be reissued by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock will be sent written notice of the Mandatory
Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section 5</U>.
Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of
shares of Preferred Stock in certificated form will surrender his, her or its certificate or certificates for all such shares (or, if
such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable
to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss,
theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation,
any certificates surrendered for conversion will be endorsed or accompanied by written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All
rights with respect to the Preferred Stock converted pursuant to <U>Section 5</U>, including the rights, if any, to receive notices and
vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder
or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender
of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided
for in the next sentence of this <U>Section&nbsp;5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable,
the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation will
(a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common
Stock issuable on such conversion in accordance with the provisions hereof and (b) pay cash as provided in <U>Section 4.2</U> in lieu
of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends
on the shares of Preferred Stock converted. Such converted Preferred Stock will be retired and cancelled and may not be reissued as shares
of such series, and the Corporation may thereafter take such appropriate action (without the need for shareholder action) as may be necessary
to reduce the authorized number of shares of Preferred Stock accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Redemption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>General</U>. Unless prohibited by Texas law governing distributions to shareholders or by an agreement entered into by the Corporation
in connection with bona fide third-party indebtedness existing as of the Series D Original Issue Date (including any refinancing of such
existing indebtedness so long as such refinancing does not extend the maturity date of such indebtedness), at any time on or after March
31, 2026 in respect of shares of Series C Preferred Stock or the fifth (5<SUP>th</SUP>) anniversary of the Series D Original Issue Date
in respect of shares of Series D Preferred Stock and Series E Preferred Stock, upon receipt of a written notice (the &ldquo;<B><I>Redemption
Request</I></B>&rdquo;) from the Requisite Series C Holders requesting redemption of the shares of Series C Preferred Stock, the Requisite
Series D Holders requesting redemption of the shares of Series D Preferred Stock, or the Requisite Series E Holders requesting redemption
of the shares of Series E Preferred Stock (as applicable) and designating the Redemption Majority Representative (as defined below), shares
of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable), in each case, other than Excluded
Shares (as defined below), will be redeemed by the Corporation (x) in respect of the Series C Preferred Stock, at a price per share equal
to the greater of (i) the Series C Original Issue Price, plus (A) all declared but unpaid dividends thereon and (B) a 7% cumulative accruing
dividend, compounding annually from the date of issuance of such share of Series C Preferred Stock, and (ii) the Fair Market Value (determined
in the manner set forth below) of a single share of Series C Preferred Stock as of the date of the Corporation&rsquo;s receipt of the
Redemption Request (the &ldquo;<B><I>Series C Redemption Price</I></B>&rdquo;); (y) in respect of the Series D Preferred Stock, at a price
per share equal to the greater of (i) the Series D Original Issue Price, plus (A) all declared but unpaid dividends thereon and (B) a
7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series D Preferred Stock, and (ii) the
Fair Market Value (determined in the manner set forth below) of a single share of Series D Preferred Stock as of the date of the Corporation&rsquo;s
receipt of the Redemption Request (the &ldquo;<B><I>Series D Redemption Price</I></B>&rdquo;); and (z) in respect of the Series E Preferred
Stock, at a price per share equal to the greater of (i) the Series E Original Issue Price, plus (A) all declared but unpaid dividends
thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series E Preferred
Stock and (ii) the Fair Market Value (determined in the manner set forth below) of a single share of Series E Preferred Stock as of the
date of the Corporation&rsquo;s receipt of the Redemption Request (the &ldquo;<B><I>Series E Redemption Price</I></B>&rdquo;). The Series
C Redemption Price, the Series D Redemption Price or the Series E Redemption Price (as applicable) will be paid or the Series C Preferred
Stock, the Series D Preferred Stock and the Series E Preferred Stock (as applicable) will be redeemed not more than the later of sixty
(60) days after the final determination of the applicable fair market value (as determined below, &ldquo;<B><I>Fair Market Value</I></B>&rdquo;).
For purposes of this <U>Section 6.1</U>, the Fair Market Value of a single share of Series C Preferred Stock, Series D Preferred Stock
or Series E Preferred Stock shall be determined by the Corporation within ten (10) business days upon receipt of a Redemption Notice (as
defined below) and communicated in writing to a representative (the &ldquo;<B><I>Redemption Majority Representative</I></B>&rdquo;) of
the holders of a majority of the outstanding shares of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock
(as applicable) that have elected to have their shares redeemed in a written notice sent by the Corporation stating in reasonable detail
the facts upon which such calculation was based (the &ldquo;<B><I>FMV Notice</I></B>&rdquo;). Upon request of the Redemption Majority
Representative, the Corporation shall, as promptly as possible, provide to such Redemption Majority Representative documentation supporting
the method of calculation of the determination of the Board, the facts upon which such calculation was based and all other information
or documents reasonably requested by the Redemption Majority Representative in a reasonably prompt manner. Upon the Redemption Majority
Representative&rsquo;s receipt of the FMV Notice and any documentation that may be reasonably requested by the Redemption Majority Representative,
the Redemption Majority Representative shall have ten (10) business days following the receipt of the FMV Notice to either accept the
Corporation&rsquo;s determination of the Fair Market Value or send to the Corporation a written notice (a &ldquo;<B><I>Dispute Notice</I></B>&rdquo;)
setting forth in reasonable detail the Redemption Majority Representative&rsquo;s proposed alternative calculation of the Fair Market
Value as of such date. The proposed Fair Market Value set forth in any FMV Notice shall become final, conclusive and binding on the parties
unless the Redemption Majority Representative provides a Dispute Notice pursuant to this Section. The Corporation and the Redemption Majority
Representative will attempt to promptly resolve the matters raised in any Dispute Notice. If the Corporation and the Redemption Majority
Representative cannot agree on the Fair Market Value within ten (10) business days of delivery of such Dispute Notice, either the Corporation
or the Redemption Majority Representative may elect to engage, at the Corporation&rsquo;s expense, a nationally recognized public accounting
firm to be mutually agreed upon by the parties (the &ldquo;<B><I>Independent Appraiser</I></B>&rdquo;) to determine the Fair Market Value.
If the Corporation and the Redemption Majority Representative cannot agree on an Independent Appraiser, each shall select a nationally
recognized public accounting firm within twenty-five (25) days of delivery of the Dispute Notice and those two firms at the Corporation&rsquo;s
expense will agree on a third nationally recognized public accounting firm to be the Independent Appraiser within fifteen (15) days of
their appointment to determine the Fair Market Value at the Corporation&rsquo;s expense. The Independent Appraiser&rsquo;s determination
of such Fair Market Value shall be rendered with a written decision as to its determination of the Fair Market Value which shall include
a statement in reasonable detail of the basis for its determination. The Independent Appraiser shall consult with the Corporation and
the Redemption Majority Representative concerning the proposed Fair Market Value. In no event shall the determination of the Independent
Appraiser provide for a calculation of Fair Market Value that is less than the lower value proposed, or greater than the higher value
proposed, in each case by the Corporation or the Redemption Majority Representative. The determination of the Independent Appraiser with
respect to the disputed Fair Market Value submitted to it will be final, conclusive and binding on the parties. The Corporation and the
Redemption Majority Representative shall use their commercially reasonable efforts to cooperate with the Independent Appraiser (including
by executing a customary engagement letter reasonably acceptable to it) and to cause any determination by the Independent Appraiser to
be made within three (3) business days after commencement of the Independent Appraiser&rsquo;s engagement. The date provided in the Redemption
Notice (as defined below) is referred to as a &ldquo;<B><I>Redemption Date</I>.</B>&rdquo; On the Redemption Date, the Corporation will
redeem, on a pro rata basis in accordance with the number of shares of Series C Preferred Stock, Series D Preferred Stock, or Series E
Preferred Stock (as applicable) owned by each holder, the number of outstanding shares of Series C Preferred Stock, Series D Preferred
Stock, or Series E Preferred Stock (as applicable); <I>provided</I>, <I>however</I>, that Excluded Shares (as such term is defined in
<U>Section&nbsp;6.2</U>) will not be redeemed and will be excluded from the calculations set forth in this sentence. If the Requisite
Series E Holders exercise a Redemption Request within thirty (30) days of the exercise of the redemption rights of the Requisite Series
D Holders or the Requisite Series D Holders exercise a Redemption Request within thirty (30) days of the exercise of the redemption rights
of the Requisite Series E Holders, the Corporation will (x) promptly (and in any event within five (5) business days) provide notice to
each holder of record of Series E Preferred and Series D Preferred that both classes of Preferred Stock will be redeemed (provided that
the failure to provide such notice shall not give rise to any claim or liability against the Corporation) and (y) redeem shares of Series
D Preferred Stock and Series E Preferred Stock on a <I>pro rata</I> basis. If, on the applicable Redemption Date, Texas law governing
distributions to shareholders prevents the Corporation from redeeming all shares of Series C Preferred Stock, Series D Preferred Stock,
or Series E Preferred Stock (as applicable) to be redeemed, the Corporation will ratably redeem the maximum number of shares that it may
redeem consistent with such law, and will redeem the remaining shares as soon as it may lawfully do so under such law. The Corporation
will use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series C Preferred Stock, Series&nbsp;D
Preferred Stock, and Series E Preferred Stock as required by this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Redemption Notice</U>. Without limiting any notice required by <U>Section 6.1</U>, the Corporation will send written notice
of the mandatory redemption (the &ldquo;<B><I>Redemption Notice</I></B>&rdquo;) to each holder of record of Series C Preferred Stock,
Series D Preferred Stock, or Series E Preferred Stock (as applicable) not less than thirty (30) days after the final determination of
the Fair Market Value as set forth in <U>Section 6.1</U>. The Redemption Notice will state:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the number of shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable) held by
the holder that the Corporation will redeem on the Redemption Date specified in the Redemption Notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Redemption Date (which will be no more than thirty (30) days following the determination of the applicable Redemption Price)
and the applicable Redemption Price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the date upon which the holder&rsquo;s right to convert such shares terminates (as determined in accordance with <U>Section&nbsp;
4.1.2</U>); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place
designated, his, her or its certificate or certificates representing the shares of Series C Preferred Stock, Series D Preferred Stock,
or Series E Preferred Stock (as applicable) to be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Corporation receives, on or prior to the fifteenth (15<SUP>th</SUP>) day after the date of delivery of the Redemption Notice to a
holder of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock, written notice from such holder that such holder
elects to be excluded from the redemption provided in this <U>Section </U></FONT><U>6</U>, then the shares of Series C Preferred Stock,
Series D Preferred Stock, or Series E Preferred Stock registered on the books of the Corporation in the name of such holder at the time
of the Corporation&rsquo;s receipt of such notice will thereafter be &ldquo;<B><I>Excluded Shares</I></B>.&rdquo; Excluded Shares will
not be redeemed or redeemable pursuant to this <U>Section 6</U>, whether on such Redemption Date or thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Surrender of Certificates; Payment</U>. On or before the applicable Redemption Date, each holder of shares of Series C Preferred
Stock, Series D Preferred Stock, or Series E Preferred Stock to be redeemed on such Redemption Date, unless such holder has exercised
his, her or its right to convert such shares as provided in <U>Section 4</U>, will, if a holder of shares in certificated form, surrender
the certificate or certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen
or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against
any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation,
in the manner and at the place designated in the Redemption Notice, and thereupon the applicable Redemption Price for such shares will
be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than
all of the shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock represented by a certificate are
redeemed, a new certificate, instrument, or book entry representing the unredeemed shares of Series C Preferred Stock, Series D Preferred
Stock, or Series E Preferred Stock will promptly be issued to such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Rights Subsequent to Redemption</U>. If the Redemption Notice has been duly given, and if on the applicable Redemption Date,
the applicable Redemption Price payable upon redemption of the shares of Series C Preferred Stock, Series D Preferred Stock, or Series
E Preferred Stock to be redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent
so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Series C
Preferred Stock or Series D Preferred Stock so called for redemption has not been surrendered, dividends with respect to such shares of
Series C Preferred Stock or Series D Preferred Stock will cease to accrue after such Redemption Date and all rights with respect to such
shares will forthwith after the Redemption Date terminate, except only the right of the holders to receive the applicable Redemption Price
without interest upon surrender of any such certificate or certificates therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation
or any of its subsidiaries will be automatically and immediately cancelled and retired and will not be reissued, sold or transferred.
Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock
following redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Waiver</U>. Any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on
behalf of all holders of Preferred Stock by the Requisite Holders; <I>provided</I>, <I>however</I>, that any waiver that adversely affects
the powers, rights and preferences of the Series F Preferred Stock will require the consent of the Requisite Series F Holders; <I>provided,
further,</I> that any waiver that adversely affects the powers, rights and preferences of the Series E Preferred Stock will require the
consent of the Requisite Series E Holders; <I>provided further</I>, that any waiver that adversely affects the powers, rights and preferences
of the Series D Preferred Stock will require the consent of the Requisite Series D Holders; <I>provided further</I>, that any waiver that
adversely affects the powers, rights and preferences of the Series C Preferred Stock will require the consent of the Requisite Series
C Holders; <I>provided further </I>that any waiver that adversely affects the powers, rights and preferences of the Series B Preferred
Stock will require the consent of the Requisite Series B Holders; <I>provided further </I>that any waiver that adversely affects the powers,
rights and preferences of the Series A Preferred Stock will require the consent of the Requisite Series A Holders. For the avoidance of
doubt, the right of a particular holder of (x) Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock, as applicable,
to be excluded from the redemption of the Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock pursuant to
<U>Sections 2.6.1(a)</U>, <U>2.6.1(b)</U> or <U>2.6.1(c)</U>, (y) the applicable series of Preferred Stock to be excluded from the redemption
of the applicable series of Preferred Stock following the request of the Requisite Series A Holders, Requisite Series B Holders, Requisite
Series C Holders, Requisite Series D Holders, Requisite Series E Holders, or Requisite Series F Holders, as applicable, to redeem the
applicable series of Preferred Stock pursuant to <U>Section 2.6.2(b)</U>, or <U>(z)</U> Series C Preferred Stock, Series D Preferred Stock,
or Series E Preferred Stock as applicable, to be to be excluded from redemption of the Series C Preferred Stock, Series D Preferred Stock,
or Series E Preferred Stock following receipt of a Redemption Request pursuant to <U>Section 6</U>, can be waived without the consent
of such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares of
Preferred Stock will be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by
electronic communication in compliance with the provisions of the TBOC, and will be deemed sent upon such mailing or electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Fifth</B></FONT><B>:</B>
The number constituting the Board is fourteen (14), and the name and address of the initial director(s) who are to serve as the director(s)
until the next annual meeting of shareholders, or until their respective successors are elected and qualified, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NAME</B></FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADDRESS</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">David D. Halbert</P></TD>
    <TD ROWSPAN="14" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">c/o Caris Life Sciences, Inc.<BR>
    750 W John Carpenter Fwy<BR>
    Suite 800<BR>
    Irving, TX 75039</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Laura I. Johansen</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Peter Castleman</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">George Poste</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Jonathan Knowles</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Jon S. Halbert</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Danny Phillips</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Brian Brille</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Vijay Mohan</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Joseph E. Gilliam</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Nathan Burns</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Dave Fredrickson</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Lloyd B. Minor</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 0.5pt solid">Jeffrey Vacirca</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Sixth</B></FONT><B>:</B>
Subject to any additional vote required by this Restated Certificate, the number of directors of the Corporation will be determined in
the manner set forth in the Bylaws. Each director will be entitled to one vote on each matter presented to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Seventh</B></FONT><B>:</B>
Elections of directors need not be by written ballot unless the Bylaws will so provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Eighth</B></FONT><B>:</B>
Meetings of shareholders may be held within or without the State of Texas, as the Bylaws may provide. The books of the Corporation may
be kept outside the State of Texas at such place or places as may be designated from time to time by the Board or in the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Ninth</B></FONT><B>:</B>
A director of the Corporation will not be personally liable to the Corporation or its shareholders for monetary damages for an act or
omission in the director&rsquo;s capacity as a director, except for liability (i) for any breach of the director&rsquo;s duty of loyalty
to the Corporation or its shareholders, (ii) for acts or omissions not in good faith which constitute a breach of duty to the Corporation
or involve intentional misconduct or a knowing violation of law, (iii) for any transaction from which the director derived any improper
personal benefit, regardless of whether the benefit resulted from an action taken within the scope of such person&rsquo;s duties or (iv)
for an act or omission for which the liability of the director is expressly provided for by statute. If the TBOC is amended hereafter
to authorize the further limitation of the liability of directors, then the limitation on personal liability provided in this Article
will, without the necessity of further action by the Corporation or the Board, be modified to provide such limitation to the fullest extent
permitted by the TBOC as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation will indemnify,
and provide advancement of expenses to, any person who was or is a party or is threatened to be made a party to any threatened, pending,
or completed action or other proceeding (whether civil, criminal, administrative, arbitrative, or investigative), including any appeal
thereof, or any inquiry or investigation that could lead to such an action or proceeding (any of the foregoing to be referred to hereafter
as a &ldquo;<B><I>proceeding</I></B>&rdquo;) by reason of the fact that the person (1) is or was a director or officer of the Corporation;
(2) is or was serving at the request of a director or officer of the Corporation as an agent of the Corporation; or (3) while a director,
officer or agent of the Corporation, is or was serving at the request of the Corporation as a partner, director, officer, venturer, proprietor,
trustee, employee, administrator, or agent of another entity, organization, or an employee benefit plan (each such person in (3) to be
referred to hereafter as a &ldquo;<B><I>delegate</I></B>&rdquo; and, together with each such person in (1) and (2), a &ldquo;<B><I>covered
person</I></B>&rdquo;) to the fullest extent permitted by the TBOC, as the same now exists or may hereafter be amended, substituted, or
replaced (but, in the case of any such amendment, substitution, or replacement, only to the extent that such amendment, substitution,
or replacement permits the Corporation to provide broader indemnification rights and advancement of expenses than the TBOC permitted the
Corporation to provide prior to such amendment, substitution, or replacement), against all judgments (including arbitration awards), court
costs, penalties, settlements, fines, excise, and other similar taxes and reasonable attorneys&rsquo; fees actually incurred by the covered
person in connection with such proceeding. The right to indemnification in this paragraph will continue as to a covered person who has
ceased to be a director, officer, agent or delegate and will inure to his or her heirs, executors, or administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, repeal or modification
of the foregoing provisions of this Article Ninth will not adversely affect any right or protection of a director, officer, agent, or
other person existing at the time of, or increase the liability of any director, office or agent of the Corporation with respect to any
acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Tenth</B></FONT><B>:</B>
Special meetings of the shareholders may be called by the holders of at least fifty percent (50%) of all the shares entitled to vote at
the proposed special meeting. Any action required by statute to be taken at any annual or special meeting of shareholders, or any action
which may be taken at any annual or special meeting of shareholders, may be taken without a meeting, without prior notice, and, as authorized
by Section 6.202 of the TBOC, without a vote, if a consent or consents in writing, setting forth the action so taken, will be signed by
the holder or holders of shares having not less than the minimum number of votes that would be necessary to take such action at a meeting
at which the holders of all shares entitled to vote on the action were present and voted. As authorized by Section 21.365 of the TBOC,
in lieu of the vote required by Section 21.364 of the TBOC, unless otherwise stated in this Restated Certificate, the shareholders by
Majority Vote (as defined below) will approve (a) any &ldquo;fundamental action&rdquo; as defined in Section 21.364 of the TBOC, (b) the
sale, transfer, or disposition of all or substantially all of the assets of the Corporation, or (c) any reorganization, merger, interest
exchange, or conversion. &ldquo;<B><I>Majority Vote</I></B>&rdquo; means the affirmative vote of the holders of a majority of the shares
entitled to vote on the matter at a shareholder&rsquo;s meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Eleventh</B></FONT>:
The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered
an opportunity to participate in, any Excluded Opportunity. An &ldquo;<B><I>Excluded Opportunity</I></B>&rdquo; is any matter, transaction
or interest that is presented to, or acquired by, or which otherwise comes into the possession of (i) any director of the Corporation
who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director,
shareholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries
(collectively, the persons referred to in clauses (i) and (ii) are &ldquo;<B><I>Covered Persons</I></B>&rdquo;), unless such matter, transaction
or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly
and solely in such Covered Person&rsquo;s capacity as a director of the Corporation while such Covered Person is performing services in
such capacity. Any repeal or modification of this Article Eleventh will only be prospective and will not affect the rights under this
Article Eleventh in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding
anything to the contrary contained elsewhere in this Restated Certificate, the affirmative vote of the Requisite Holders, the Requisite
Series D Holders and the Requisite Series C Holders, voting as a separate class, will be required to amend, repeal or adopt any provisions
inconsistent with this Article Eleventh.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Twelfth</B></FONT><B>:</B>
Unless the Corporation consents in writing to the selection of an alternative forum, the state courts in Dallas County, Texas (the &ldquo;<B><I>Court</I></B>&rdquo;)
shall be the sole and exclusive forum for any shareholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding
brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer
or other employee of the Corporation to the Corporation or the Corporation&rsquo;s shareholders, (iii)&nbsp;any action asserting a claim
against the Corporation, its directors, officers or employees arising pursuant to any provision of the TBOC or this Restated Certificate
or Bylaws, or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal
affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court determines that there is an indispensable
party not subject to the jurisdiction of the Court (and the indispensable party does not consent to the personal jurisdiction of the Court
within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court,
or for which the Court does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth is held to be
invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent
permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions
of this Article Twelfth (including, without limitation, each portion of any sentence of this Article Twelfth containing any such provision
held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such
provision to other persons or entities and circumstances will not in any way be affected or impaired thereby. Any person or entity purchasing
or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented
to the provisions of this Article Twelfth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act
of 1933, as amended. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the
Corporation shall be deemed to have notice of and consented to the provisions of this Article </FONT>Twelfth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Thirteenth</B></FONT><B>:</B>
The shareholders do not have statutory preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Fourteenth</B></FONT>:
Except as otherwise provided in this Restated Certificate, in furtherance and not in limitation of the powers conferred by statute, the
Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>tm2415719d15_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED<BR>
CERTIFICATE OF FORMATION</B></FONT><BR>
<B>OF<BR>
CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Caris Life Sciences,&nbsp;Inc.
(the &ldquo;<B><I>Corporation</I></B>&rdquo;), a for-profit corporation organized and existing under and by virtue of the provisions of
the Texas Business Organizations Code, as amended from time to time (the &ldquo;<B><I>TBOC</I></B>&rdquo;), does hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>First</B></FONT>:
The name of the filing entity is Caris Life Sciences,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Second</B></FONT>:
The Corporation was formed as a Texas for-profit corporation pursuant to the TBOC on July&nbsp;17, 2020, and issued file number 803691720
by the Secretary of State of the State of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Third</B></FONT>:
Each new amendment has been made in accordance with the provisions of the TBOC. The amendments to the certificate of formation and the
Restated Certificate (as defined below) have been approved in the manner required by the TBOC and by the governing documents of the entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Fourth</B></FONT>:
The Amended and Restated Certificate of Formation in the form attached hereto as <B><U>Exhibit&nbsp;A</U></B> (the &ldquo;<B><I>Restated
Certificate</I></B>&rdquo;), accurately states the text of the certificate of formation being restated, and each amendment to the certificate
of formation being restated that is in effect, as further amended by the Restated Certificate. The Restated Certificate does not contain
any other change in the certificate of formation being restated except for the information permitted to be omitted by the provisions of
the TBOC applicable to the filing entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Fifth</B></FONT>:
The Restated Certificate takes effect upon the occurrence of a future event or fact, other than the passage of time. The event or fact
that will cause the document to take effect is the closing of the initial public offering of the Corporation. The 90th day after the date
of signing is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned affirms that
the person designated as registered agent in the Restated Certificate has consented to the appointment. The undersigned signs this document
subject to the penalties imposed by law for the submission of a materially false or fraudulent instrument and certifies under penalty
of perjury that the undersigned is authorized to execute the filing instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">CARIS LIFE SCIENCES,&nbsp;INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">David D. Halbert&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chief Executive Officer&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of this corporation
is Caris Life Sciences,&nbsp;Inc. (the &ldquo;<B><I>Corporation</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The address of the registered
office of the Corporation in the State of Texas is 1999 Bryan Street, Suite&nbsp;900, Dallas, Texas 75201, and the name of the registered
agent at that address is CT Corporation System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the Corporation
is to engage in any lawful business for which business corporations may be organized under the Texas Business Organizations Code (the
 &ldquo;<B><I>TBOC</I></B>&rdquo;) as it now exists or may hereafter be amended and supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total number of shares
of all classes of capital stock which the Corporation will have authority to issue is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, consisting of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of Common Stock, $0.001 par value per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), of which (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares shall be a series designated as Class&nbsp;A Common Stock (&ldquo;<B><I>Class&nbsp;A Common Stock</I></B>&rdquo;) and (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares shall be a series designated as Class&nbsp;B Common Stock (&ldquo;<B><I>Class&nbsp;B Common Stock</I></B>&rdquo;), and (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of Preferred Stock, $0.001 par value per share (&ldquo;<B><I>Preferred Stock</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the rights of any
holders of Preferred Stock then outstanding, the number of authorized shares of Class&nbsp;A Common Stock, Class&nbsp;B Common Stock or
Preferred Stock may be increased or decreased (but not below (i)&nbsp;the number of shares thereof then outstanding and (ii)&nbsp;with
respect to the Class&nbsp;A Common Stock, the number of shares of Class&nbsp;A Common Stock reserved pursuant to Section&nbsp;8 of Part&nbsp;A
of this Article&nbsp;IV) by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of
the then outstanding shares of capital stock of the Corporation entitled to vote thereon, and no vote of the holders of the Class&nbsp;A
Common Stock, the Class&nbsp;B Common Stock or the Preferred Stock voting separately as a class shall be required therefor, to the extent
permitted by Section&nbsp;21.364(d)&nbsp;of the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the effectiveness of
this Amended and Restated Certificate of Formation (such certificate, the &ldquo;<B><I>Restated Certificate</I></B>&rdquo; and such time,
the &ldquo;<B><I>Effective Time</I></B>&rdquo;), (i)&nbsp;each share of Common Stock (as defined in the Corporation&rsquo;s certificate
of formation heretofore in effect (the &ldquo;<B><I>Prior Certificate</I></B>&rdquo;)) issued and outstanding or held in treasury immediately
prior to the Effective Time shall, automatically and without further action by any shareholder, be reclassified as, and shall become,
one (1)&nbsp;share of Class&nbsp;B Common Stock (the &ldquo;<B><I>Reclassification</I></B>&rdquo;) and (ii)&nbsp;any stock certificate
that, immediately prior to the Effective Time, represented one or more shares of Common Stock (as defined in the Prior Certificate), shall,
from and after the Effective Time, automatically and without the necessity of presenting the same for surrender or exchange, represent
the same number of shares of Class&nbsp;B Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The designations and the powers,
preferences, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock
of the Corporation are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Common
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Equal
Status; General</U>. Except as otherwise provided herein or required by law, shares of Class&nbsp;A Common Stock and Class&nbsp;B Common
Stock shall have the same rights, privileges, preferences and powers, rank equally (including as to dividends and distributions, and upon
any liquidation, dissolution, distribution of assets or winding up of the Corporation), share ratably and be identical in all respects
and as to all matters.&nbsp;The voting, dividend, liquidation and other rights, powers and preferences of the holders of Common Stock
are subject to, and qualified by, the rights, powers and preferences of any series of Preferred Stock as may be designated by the Board
of Directors of the Corporation (the &ldquo;<B><I>Board</I></B>&rdquo;) and outstanding from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Quorum;
Voting</U>. Except as otherwise provided by applicable law, this Certificate of Formation or the Bylaws, the presence, in person or by
proxy, at a shareholders meeting of the holders of shares of outstanding capital stock of the Corporation representing a majority of the
voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting and not less than one-third
of the outstanding shares of the Corporation entitled to vote at such meeting shall constitute a quorum for the transaction of business
at such meeting, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of
shares representing a majority of the voting power of the outstanding shares of such class or series entitled to vote at such meeting
and not less than one-third of the outstanding shares of such class or series entitled to vote at such meeting shall constitute a quorum
of such class or series for the transaction of such business. Except as otherwise provided herein or expressly required by a nonwaivable
provision of the TBOC, at all meetings of shareholders and on all matters submitted to a vote of shareholders of the Corporation generally,
(i)&nbsp;each holder of Class&nbsp;A Common Stock, as such, shall have one (1)&nbsp;vote per share of Class&nbsp;A Common Stock held of
record by such holder, and (ii)&nbsp;each holder of Class&nbsp;B Common Stock, as such, shall have ten (10)&nbsp;votes per share of Class&nbsp;B
Common Stock held of record by such holder; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Class&nbsp;A
Common Stock and Class&nbsp;B Common Stock, as such, shall not be entitled to vote on any amendment to this Restated Certificate that
relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled,
either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Restated Certificate
(including any Certificate of Designation (as defined below)) or pursuant to the TBOC. Except as otherwise provided herein or required
by a nonwaivable provision of the TBOC, the holders of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock shall at all
times vote together as a single class on all matters (or, if any holders of Preferred Stock are entitled to vote together with the holders
of Common Stock, as a single class with the holders of Preferred Stock), including the election of directors, submitted to a vote of the
shareholders of the Corporation generally. There shall be no cumulative voting. As authorized by Section&nbsp;21.365 of the TBOC, in lieu
of the vote required by Section&nbsp;21.457 or Section&nbsp;21.364 of the TBOC, unless otherwise stated in this Restated Certificate,
the shareholders by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then
outstanding shares of capital stock of the Corporation entitled to vote thereon will approve (i)&nbsp;any &ldquo;fundamental action&rdquo;
as defined in Section&nbsp;21.364 of the TBOC or (ii)&nbsp;any &ldquo;fundamental business transaction&rdquo; as defined in Section&nbsp;1.002
of the TBOC. To the extent permitted by Section&nbsp;21.365(b)&nbsp;of the TBOC, notwithstanding any other provision of the TBOC, except
as otherwise provided in this Restated Certificate, all classes or series of stock shall only be entitled to vote as a single class or
series, and separate voting by class or series is not required, for the purpose of approving any matter, including in connection with
any &ldquo;fundamental action&rdquo; as defined in Section&nbsp;21.364 of the TBOC or a &ldquo;fundamental business transaction&rdquo;
as defined in Section&nbsp;1.002 of the TBOC; <U>provided</U> that, if a class or series of shares is nevertheless entitled to vote as
a class or series on any &ldquo;fundamental action&rdquo; as defined in Section&nbsp;21.364 of the TBOC, then unless otherwise stated
in this Restated Certificate, the shareholders by the affirmative vote of the holders of capital stock representing a majority of the
voting power of all of the then outstanding shares of capital stock of the Corporation of such class or series shall approve such &ldquo;fundamental
action&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Dividends</U>.
Subject to the preferential or other rights of any holders of any then-outstanding shares of Preferred Stock, shares of Class&nbsp;A Common
Stock and Class&nbsp;B Common Stock shall be treated equally, identically and ratably, on a per share basis, with respect to any distributions
or share dividends as may be declared and paid from time to time by the Board out of any assets of the Corporation legally available therefor;
<U>provided</U><I>, </I><U>however</U>, that in the event a share dividend is paid in the form of shares of Class&nbsp;A Common Stock
or Class&nbsp;B Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares), then holders of
Class&nbsp;A Common Stock shall be entitled to receive shares of Class&nbsp;A Common Stock (or rights to acquire, or securities convertible
into or exchangeable for, such shares, as the case may be) and holders of Class&nbsp;B Common Stock shall be entitled to receive shares
of Class&nbsp;B Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares, as the case may be),
with holders of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock receiving, on a per share basis, an identical number
of shares of Class&nbsp;A Common Stock or Class&nbsp;B Common Stock (or rights to acquire, or securities convertible into or exchangeable
for, such shares, as the case may be), as applicable. Notwithstanding the foregoing, the Board may pay or make a disparate distribution
or share dividend per share of Class&nbsp;A Common Stock or Class&nbsp;B Common Stock (whether in the amount of such dividend payable
per share, the form in which such dividend is payable, the timing of the payment, or otherwise) if such disparate distribution or share
dividend is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class&nbsp;A Common Stock and Class&nbsp;B
Common Stock, each voting separately as a series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subdivisions,
Combinations or Reclassifications</U>. Shares of Class&nbsp;A Common Stock or Class&nbsp;B Common Stock may not be subdivided, combined
or reclassified unless the shares of the other class of Common Stock are concurrently therewith proportionately subdivided, combined or
reclassified in a manner that maintains the same proportionate equity ownership among the holders of the outstanding Class&nbsp;A Common
Stock and Class&nbsp;B Common Stock on the record date for such subdivision, combination or reclassification;&nbsp;<U>provided</U><I>,
</I><U>however</U>, that shares of one such series may be subdivided, combined or reclassified in a different or disproportionate manner
if such subdivision, combination or reclassification is approved by the affirmative vote of the holders of a majority of the outstanding
shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock, each voting separately as a series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Liquidation,
Dissolution or Winding Up</U>. Subject to the preferential or other rights of any holders of Preferred Stock then outstanding, upon the
dissolution, distribution of assets, liquidation or winding up of the Corporation, whether voluntary or involuntary, holders of Class&nbsp;A
Common Stock and Class&nbsp;B Common Stock will be entitled to receive ratably all assets of the Corporation available for distribution
to its shareholders in proportion to the number of shares held by each such shareholder, unless disparate or different treatment of the
shares of each such series with respect to distributions upon any such liquidation, dissolution, distribution of assets or winding up
is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class&nbsp;A Common Stock and Class&nbsp;B
Common Stock, each voting separately as a series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Merger,
Consolidation or Similar Transaction</U>. In the case of any distribution or payment in respect of the shares of Common Stock, or any
consideration into which such shares are converted, upon the merger or consolidation of the Corporation with or into any other entity,
or in the case of any other transaction having an effect on shareholders substantially similar to that resulting from a merger or consolidation
of the Corporation with or into any other entity, such distribution, payment or consideration that the holders of shares of Common Stock
have the right to receive, or the right to elect to receive, shall be made ratably on a per share basis among the holders of the Class&nbsp;A
Common Stock and Class&nbsp;B Common Stock as a single class; <U>provided</U><I>, </I><U>however</U>, that shares of each such series
may (but shall not be required to) receive, or have the right to elect to receive, different or disproportionate consideration in connection
with such merger, consolidation or other transaction if (i)&nbsp;the only difference in the per share consideration to the holders of
the Class&nbsp;A Common Stock and Class&nbsp;B Common Stock is that any securities distributed to the holder of, or issuable upon the
conversion of, a share of Class&nbsp;B Common Stock have ten (10)&nbsp;times the voting power of any securities distributed to the holder
of, or issuable upon the conversion of, a share of Class&nbsp;A Common Stock, or (ii)&nbsp;such merger, consolidation, or other transaction
is approved by the affirmative vote of the holders of a majority of the then outstanding shares of Class&nbsp;A Common Stock and Class&nbsp;B
Common Stock, each voting separately as a series. For the avoidance of doubt, any distribution, payment or consideration for purposes
of this Section&nbsp;6 of Part&nbsp;A of <U>Article&nbsp;IV</U> shall not be deemed to include (i)&nbsp;any amount or consideration to
be paid to or received by a holder of Common Stock pursuant to any indemnification, employment, consulting, severance or similar services
arrangement, whether or not entered into in connection with a transaction described in this Section&nbsp;or (ii)&nbsp;a negotiated agreement
between a holder of Common Stock with any counterparty (or Affiliate (as defined below) thereof) to a transaction described in this Section&nbsp;wherein
such holder is contributing, selling, transferring or otherwise disposing of shares of the Corporation&rsquo;s capital stock to such counterparty
(or Affiliate thereof) as part of a &ldquo;rollover&rdquo; or similar transaction that is in connection with such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conversion
of Class&nbsp;B Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Optional
Conversion</U>. Each share of Class&nbsp;B Common Stock shall be convertible into one (1)&nbsp;fully paid and nonassessable share of Class&nbsp;A
Common Stock at the option of the holder thereof at any time upon written notice to the Corporation, subject to the provisions of Subsection
7.4 of Part&nbsp;A of Article&nbsp;IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Automatic
Conversion Upon Certain Transfers</U>. With respect to each holder of Class&nbsp;B Common Stock, upon the occurrence of a Transfer (as
defined below), other than a Permitted Transfer (as defined below), of shares of Class&nbsp;B Common Stock held by such holder, each share
subject to such Transfer shall automatically, without further action by the Corporation or the holder thereof, convert into one (1)&nbsp;fully
paid and nonassessable share of Class&nbsp;A Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Final
Conversion of All Shares</U>. Each outstanding share of Class&nbsp;B Common Stock shall automatically, without further action by the Corporation
or any holder thereof, convert into one (1)&nbsp;fully paid and nonassessable share of Class&nbsp;A Common Stock at the Final Conversion
Time (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mechanics
of Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">7.4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Before
any holder of Class&nbsp;B Common Stock shall be entitled to convert any shares of Class&nbsp;B Common Stock into shares of Class&nbsp;A
Common Stock pursuant to Subsection 7.1 of Part&nbsp;A of Article&nbsp;IV, such holder shall surrender the certificate or certificates
therefor (if any), duly endorsed, at the principal corporate office of the Corporation or of any transfer agent for the Class&nbsp;B Common
Stock, and shall provide written notice to the Corporation, at its principal corporate office, of such conversion election and shall state
therein the name or names (i)&nbsp;in which the certificate or certificates representing the shares of Class&nbsp;A Common Stock into
which the shares of Class&nbsp;B Common Stock are so converted are to be issued (if such shares of Class&nbsp;A Common Stock will be certificated)
or (ii)&nbsp;in which such shares of Class&nbsp;A Common Stock are to be registered in book-entry form (if such shares of Class&nbsp;A
Common Stock will be uncertificated). If the shares of Class&nbsp;A Common Stock into which the shares of Class&nbsp;B Common Stock are
to be converted are to be issued in a name or names other than the name of the holder of the shares of Class&nbsp;B Common Stock being
converted, such notice shall be accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation,
duly executed by the holder. The Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder,
or to the nominee or nominees of such holder, a certificate or certificates representing the number of shares of Class&nbsp;A Common Stock
to which such holder shall be entitled upon such conversion (if such shares of Class&nbsp;A Common Stock are certificated) or shall register
such shares of Class&nbsp;A Common Stock in book-entry form (if such shares of Class&nbsp;A Common Stock are uncertificated). Such conversion
shall be deemed to be effective immediately prior to the close of business (i)&nbsp;with respect to certificated shares, on the date of
such surrender of the certificate or certificates representing the shares of Class&nbsp;B Common Stock to be converted or (ii)&nbsp;with
respect to shares that are uncertificated, immediately prior to the close of business on the date that the holder delivers notice of such
conversion election as required by this Subsection to the Corporation or its transfer agent, and, in each case, the shares of Class&nbsp;A
Common Stock issuable upon such conversion shall be deemed to be outstanding as of such time, and the person or persons entitled to receive
the shares of Class&nbsp;A Common Stock issuable upon such conversion shall be deemed to be the record holder or holders of such shares
of Class&nbsp;A Common Stock as of such time. Notwithstanding anything herein to the contrary, shares of Class&nbsp;B Common Stock represented
by a lost, stolen or destroyed stock certificate may be converted pursuant to Subsection 7.1 of Part&nbsp;A of Article&nbsp;IV if the
holder thereof notifies the Corporation or its transfer agent that such certificate has been lost, stolen or destroyed, provides an affidavit
of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation (and, if required by the Corporation,
posts a bond in such amount as the Corporation may determine is reasonably necessary) to indemnify the Corporation from any loss incurred
by it in connection with such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">7.4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
outstanding stock certificate (if shares are in certificated form) that, immediately prior to the occurrence of a conversion pursuant
to Subsections 7.2 and 7.3 of Part&nbsp;A of Article&nbsp;IV represented one or more shares of Class&nbsp;B Common Stock subject to such
conversion shall, upon such conversion, be deemed to represent an equal number of shares of Class&nbsp;A Common Stock, without the need
for surrender or exchange thereof. The Corporation shall, upon the request of any holder whose shares of Class&nbsp;B Common Stock have
been converted into shares of Class&nbsp;A Common Stock as a result of any conversion pursuant to Subsections 7.2 or 7.3 of Part&nbsp;A
of Article&nbsp;IV, and upon surrender by such holder to the Corporation of the outstanding certificate(s)&nbsp;formerly representing
such holder&rsquo;s shares of Class&nbsp;B Common Stock, if any (or, in the case of any lost, stolen or destroyed certificate, upon such
holder providing an affidavit of that fact acceptable to the Corporation and executing an agreement acceptable to the Corporation (and,
if required by the Corporation, posting a bond in such amount as the Corporation may determine is reasonably necessary) to indemnify the
Corporation from any loss incurred by it in connection with such certificate), issue and deliver to such holder&rsquo;s transferee(s)&nbsp;or
such holder, as applicable, certificate(s)&nbsp;representing the shares of Class&nbsp;A Common Stock into which such holder&rsquo;s shares
of Class&nbsp;B Common Stock were converted as a result of such conversion (if such shares are certificated) or, if such shares are uncertificated,
register such shares in book-entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">7.4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
share of Class&nbsp;B Common Stock that is converted pursuant to Subsections 7.1, 7.2 or 7.3 of Part&nbsp;A of Article&nbsp;IV shall thereupon
automatically be retired and cancelled in accordance with the applicable provisions of the TBOC, and shall not be available for reissuance.
Upon the retirement and cancellation of all shares of Class&nbsp;B Common Stock, all references to Class&nbsp;B Common Stock in this Restated
Certificate shall be eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">7.4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation may, from time to time, establish such policies and procedures, not in violation of applicable law or the other provisions
of this Restated Certificate or the Bylaws of the Corporation, relating to the conversion of the Class&nbsp;B Common Stock into Class&nbsp;A
Common Stock and the general administration of this dual series of Common Stock structure, as it may deem necessary or advisable in connection
therewith. If the Corporation has reason to believe that any circumstance giving rise to a conversion of shares of Class&nbsp;B Common
Stock into Class&nbsp;A Common Stock in accordance with the provisions of this Section&nbsp;7 of Part&nbsp;A of Article&nbsp;IV has occurred
but has not theretofore been reflected on the books and records of the Corporation (or in book-entry as maintained by the transfer agent
of the Corporation), the Corporation may request that the holder of such shares furnish affidavits or other evidence to the Corporation
as the Corporation deems necessary to determine whether a conversion of shares of Class&nbsp;B Common Stock to Class&nbsp;A Common Stock
has occurred, and if such holder does not within ten (10)&nbsp;days after the date of such request furnish sufficient evidence to the
Corporation (in the manner provided in the request) to enable the Corporation to determine that no such conversion has occurred, any such
shares of Class&nbsp;B Common Stock, to the extent not previously converted, shall be automatically converted into shares of Class&nbsp;A
Common Stock and the same shall thereupon be registered on the books and records of the Corporation (or in book-entry as maintained by
the transfer agent of the Corporation). In connection with any action of shareholders taken at a meeting, the stock ledger of the Corporation
(or in book-entry as maintained by the transfer agent of the Corporation) shall be presumptive evidence as to who are the shareholders
entitled to vote in person or by proxy at any meeting of shareholders and the class or classes or series of shares held by each such shareholder
and the number of shares of each class or classes or series held by such shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Reservation
of Stock</U>. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Class&nbsp;A
Common Stock, solely for the purpose of effecting the conversion of the shares of Class&nbsp;B Common Stock, such number of shares of
Class&nbsp;A Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Class&nbsp;B
Common Stock into shares of Class&nbsp;A Common Stock&#894; and if at any time the number of authorized but unissued shares of Class&nbsp;A
Common Stock will not be sufficient to effect the conversion of all the then outstanding shares of Class&nbsp;B Common Stock, the Corporation
will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of
Class&nbsp;A Common Stock to such number of shares as will be sufficient for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, with respect to any person, an &ldquo;affiliate&rdquo; of such person as defined in Rule&nbsp;405 of the Securities Act (as defined
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Code</I></B>&rdquo;
means Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>&ldquo;<I>Disability</I></B>&rdquo;
means, with respect to the Founder (as defined below), the permanent and total disability of the Founder such that the Founder is unable
to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected
to result in death within twelve (12) months or which has lasted or can be expected to last for a continuous period of not less than twelve
(12) months, in each case, as determined by a licensed medical practitioner jointly selected by a majority of the disinterested members
of the Board and the Founder&#894; <U>provided</U> that, if the Founder is incapable of selecting a licensed physician, then the Founder&rsquo;s
spouse shall make the selection on behalf of the Founder, or in the absence or incapacity of the Founder&rsquo;s spouse, the Founder&rsquo;s
adult children by majority vote shall make the selection on behalf of the Founder. In the event that (i)&nbsp;a dispute exists as to whether
the Founder has suffered a Disability or (ii)&nbsp;neither the Founder&rsquo;s spouse nor his adult children, as applicable, are able
to select a licensed physician on behalf of the Founder, no Disability of the Founder shall be deemed to have occurred unless and until
an affirmative ruling regarding such Disability has been made by a court of competent jurisdiction, and such ruling has become final and
nonappealable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Family
Member</I></B>&rdquo; means with respect to any natural person, the spouse, widow, widower, domestic partner, parents, grandparents, lineal
descendants, siblings and lineal descendants of siblings (in each case whether by blood relation, adoption, marriage or domestic partnership)
of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Final
Conversion Time</I></B>&rdquo; means 4:00 p.m.&nbsp;in Dallas, Texas on the earliest to occur of (i)&nbsp;the date fixed by the Board
that is no less than sixty (60) days and no more than one hundred eighty (180) days following the death or determination of Disability
of the Founder, (ii)&nbsp;the date fixed by the Board that is no less than sixty (60) days and no more than one hundred eighty (180) days
following the date that the Founder is no longer providing services to the Corporation as an executive officer or director, (iii)&nbsp;the
date fixed by the Board that is no less than sixty (60) days and no more than one hundred eighty (180) days following the date on which
the Founder, his Permitted Entities (as defined below) and any of their Permitted Transferees (as defined below) cease to hold or control
the vote of, in the aggregate, at least twenty percent (20%) of the shares of Class&nbsp;B Common Stock held by or subject to the Voting
Control (as defined below) of them as of the completion of the Corporation&rsquo;s IPO (as defined below) (as appropriately adjusted for
any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Class&nbsp;B Common Stock),
or (iv)&nbsp;the date specified in writing by the holders of a majority of the then-outstanding shares of Class&nbsp;B Common Stock, <U>provided</U>
that in the case of clause (iv), such specified date is at least ten (10)&nbsp;days after such writing is delivered to the Corporation
unless otherwise approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Founder</I></B>&rdquo;
means David D. Halbert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>IPO</I></B>&rdquo;
means the sale of shares of Class&nbsp;A Common Stock to the public in a firm-commitment underwritten initial public offering, pursuant
to an effective registration statement under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Permitted
Entity</I></B>&rdquo; means, with respect to any Qualified Shareholder (as defined below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(i)&nbsp;any Affiliate of, or corporation,
general partnership, limited partnership, limited liability company, private limited company or other entity that directly or indirectly
controls, is controlled by, or is under common control with, such Qualified Shareholder, one or more Family Members of such Qualified
Shareholder or any other Permitted Entity of such Qualified Shareholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(ii)&nbsp;any Permitted Trust (as defined
below) primarily for the benefit of (a)&nbsp;such Qualified Shareholder, (b)&nbsp;one or more Family Members of such Qualified Shareholder
and/or (c)&nbsp;any other Permitted Entity of such Qualified Shareholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(iii)&nbsp;any organization that is
tax-exempt under Section&nbsp;501(c)(3)&nbsp;of the Code, so long as such Qualified Shareholder and/or one or more Family Members of such
Qualified Shareholder have exclusive Voting Control with respect to the shares of Class&nbsp;B Common Stock held by such organization;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(iv)&nbsp;any organization that is tax-exempt
under Section&nbsp;501(c)(3)&nbsp;of the Code and is a Qualified Shareholder as of the Effective Time; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(v)&nbsp;any Individual Retirement Account,
as defined in Section&nbsp;408(a)&nbsp;of the Code, or a pension, profit sharing, stock bonus or other type of plan or trust of which
such Qualified Shareholder is a participant or beneficiary and which satisfies the requirements for qualification under Section&nbsp;401
of the Code; <U>provided</U> that in each case such Qualified Shareholder or such Qualified Shareholder&rsquo;s Permitted Transferees
have exclusive Voting Control with respect to the shares of Class&nbsp;B Common Stock held in such account, plan or trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Permitted
Transfer</I></B>&rdquo; shall mean, and be restricted to, any Transfer of a share of Class&nbsp;B Common Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
a Qualified Shareholder to (a)&nbsp;one or more Family Members of such Qualified Shareholder or (b)&nbsp;any Permitted Entity of such
Qualified Shareholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
a Permitted Entity of a Qualified Shareholder to (a)&nbsp;such Qualified Shareholder, (b)&nbsp;one or more Family Members of such Qualified
Shareholder, or (c)&nbsp;any other Permitted Entity of such Qualified Shareholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
a broker or other nominee so long as the transferor of such share of Class&nbsp;B Common Stock, immediately following such Transfer, retains
(a)&nbsp;Voting Control over such share and (b)&nbsp;control over the disposition of such share; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
is approved in advance by the Board as a &ldquo;Permitted Transfer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Permitted
Transferee</I></B>&rdquo; means a transferee of shares of Class&nbsp;B Common Stock received in a Permitted Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Permitted
Trust</I></B>&rdquo; means a bona fide trust where each trustee is (i)&nbsp;a Qualified Shareholder, (ii)&nbsp;a Family Member of such
Qualified Shareholder, (iii)&nbsp;a professional in the business of providing trustee services, including private professional fiduciaries,
trust companies and bank trust departments, or (iv)&nbsp;an individual who may be removed and replaced at the sole discretion of a Qualified
Shareholder or a Family Member of such Qualified Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Qualified
Shareholder</I></B>&rdquo; means (i)&nbsp;the record holder of a share of Class&nbsp;B Common Stock as of the Effective Time; (ii)&nbsp;the
initial record holder of any shares of Class&nbsp;B Common Stock that are originally issued by the Corporation after the Effective Time
pursuant to the exercise, settlement, conversion or exchange of any option, restricted stock unit, warrant or convertible security that,
in each case, was outstanding as of the Effective Time; (iii)&nbsp;each natural person who, prior to the Effective Time, transferred shares
of capital stock of the Corporation to a Permitted Entity that is a Qualified Shareholder as of the Effective Time pursuant to clause
(i); (iv)&nbsp;each natural person who, prior to the Effective Time, transferred equity awards granted to such person by the Corporation
to a Permitted Entity that is a Qualified Shareholder as of the Effective Time pursuant to clause (i)&nbsp;or becomes a Qualified Shareholder
pursuant to clause (ii); (v)&nbsp;a Permitted Transferee; and (vi)&nbsp;the Founder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Transfer</I></B>&rdquo;
means any direct or indirect sale, exchange, redemption, assignment, distribution, encumbrance, hypothecation, gift, pledge, retirement,
transfer, conveyance or other disposition or alienation in any way (whether or not for value and whether voluntarily, involuntarily or
by operation of law), including, without limitation: (i)&nbsp;any assignment or distribution resulting from death, incompetency, bankruptcy,
liquidation and dissolution; (ii)&nbsp;any transfer to a broker or other nominee (regardless of whether there is a corresponding change
in beneficial ownership); and (iii)&nbsp;any transfer of, or entering into a binding agreement with respect to the transfer of, Voting
Control; <U>provided</U>, <U>however</U>, that the following shall not be considered a &ldquo;Transfer&rdquo; within the meaning of this
Section&nbsp;9 of Part&nbsp;A of Article&nbsp;IV:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
granting of a revocable proxy to officers or directors of the Corporation at the request of the Board in connection with actions to be
taken at an annual or special meeting of shareholders or any other action of the shareholders permitted by this Restated Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
entering into a voting trust, agreement or arrangement (with or without granting a proxy) to which the Founder and/or the Founder&rsquo;s
Permitted Transferees are party that (a)&nbsp;the Corporation is aware as of the Effective Time or (b)&nbsp;is disclosed either in a Schedule
13D filed with the Securities and Exchange Commission or in writing to the Secretary of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
entering into a voting trust, agreement or arrangement (with or without granting a proxy) pursuant to a written agreement to which the
Corporation is a party or that has been approved by the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
entering into, or reaching an agreement, arrangement or understanding regarding, a support, voting, tender or similar agreement or arrangement
(with or without a proxy) in connection with a merger, asset transfer, asset acquisition or similar transaction approved by the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(a)&nbsp;the
pledge of shares of Class&nbsp;B Common Stock by a shareholder that creates a mere security interest in such shares pursuant to a bona
fide loan or other financing transaction, including, without limitation, any form of margin loan, or (b)&nbsp;a bona fide hedging or other
derivative transaction (including without limitation a swap, option or forward transaction (or combination thereof) and any related pledge),
in each case, for so long as such shareholder continues to exercise Voting Control over such shares; <U>provided</U>, <U>however</U>,
that each of (x)&nbsp;a foreclosure on such shares or other similar action by the pledgee and (y)&nbsp;the settlement of any hedging or
derivative transaction by delivery of shares of Class&nbsp;B Common Stock shall constitute a Transfer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
entering into a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act, with a broker or other nominee; <U>provided</U>, <U>however</U>,
that a sale of such shares of Class&nbsp;B Common Stock pursuant to such plan shall constitute a &ldquo;Transfer&rdquo; at the time of
such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Voting
Control</I></B>&rdquo; means, with respect to a share of Class&nbsp;B Common Stock, the power (whether exclusive or shared) to vote or
direct the voting of such share by proxy, voting agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Preferred
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares of Preferred Stock
may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the
resolution or resolutions providing for the creation and issuance of such series adopted by the Board as hereinafter provided. Any shares
of Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Section&nbsp;21.155
of the TBOC, authority is hereby expressly granted to the Board from time to time to issue the Preferred Stock in one or more series,
to establish the number of shares to be included in each such series and to determine and fix the voting powers, full or limited, or no
voting powers, and such designations, preferences and relative, participating, optional or other special rights of each such series and
such qualifications, limitations or restrictions thereof, as shall be stated and expressed in such resolution or resolutions adopted by
the Board providing for the establishment and issuance of such series of Preferred Stock, all to the fullest extent now or hereafter permitted
by the TBOC. The Board is also expressly authorized to increase or decrease (but not below the number of shares of such series issued
as of the time of such decrease) the number of shares of any series of Preferred Stock established by the Board pursuant to Section&nbsp;21.155
of the TBOC. Without limiting the generality of the foregoing, the resolution or resolutions providing for the designation and issuance
of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred
Stock to the extent permitted by law and this Restated Certificate (including any certificate of designation filed with respect to any
series of Preferred Stock (a &ldquo;<B><I>Certificate of Designation</I></B>&rdquo;)). Except as otherwise required by law, holders of
any series of Preferred Stock shall be entitled only to such voting rights, if any, as shall expressly be granted thereto by this Restated
Certificate (including any Certificate of Designation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;V</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the management of the
business and for the conduct of the affairs of the Corporation it is further provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General
Powers</U>. The business and affairs of the Corporation will be managed by or under the direction of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Number
of Directors; Initial Directors; Election of Directors</U>. As of the Effective Time, the number of directors of the Corporation constituting
the initial Board is twelve (12), and the names and addresses of the initial directors of the Corporation are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NAME</B></FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADDRESS</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">David D. Halbert</P></TD>
    <TD ROWSPAN="12" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">c/o Caris Life Sciences,&nbsp;Inc.<BR>
    750 W John Carpenter Fwy<BR>
    Suite&nbsp;800<BR>
    Irving, TX 75039</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Laura I. Johansen</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Peter M. Castleman</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">George H. Poste</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Jonathan Knowles</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Jon S. Halbert</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Danny Phillips</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Brian Brille</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Joseph E. Gilliam</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Lloyd B. Minor</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">David Fredrickson</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">Jeffrey Vacirca</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the rights of the
holders of any series of Preferred Stock to elect directors, the number of directors that constitutes the entire Board shall be fixed
solely in the manner set forth in the Bylaws of the Corporation. Each director will be entitled to one vote on each matter presented to
the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Term
and Removal</U>. Subject to the rights of the holders of any series of Preferred Stock to elect directors, each director shall hold office
until the annual meeting at which such director&rsquo;s term expires and until his or her successor is duly elected and qualified, or
until his or her earlier death, resignation, disqualification or removal. No decrease in the number of directors shall shorten the term
of any incumbent director. Subject to the rights of the holders of any series of Preferred Stock to elect directors, the Board or any
individual director may be removed from office at any time with or without cause by the affirmative vote of the holders of capital stock
representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote
thereon, voting together as a single class; <U>provided</U>, <U>however</U>, that from and after the date on which no shares of Class&nbsp;B
Common Stock shall be outstanding (such date, the &ldquo;<B><I>Trigger Date</I></B>&rdquo;), the Board or any individual director may
be removed from office at any time and only for cause by the affirmative vote of the holders of capital stock representing a majority
of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together
as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vacancies
and Newly Created Directorships</U>. Subject to the rights of the holders of any series of Preferred Stock to elect directors, and except
as otherwise provided in the TBOC, any newly created directorship that results from an increase in the number of directors or any vacancy
on the Board that results from the death, disability, resignation, disqualification or removal of any director or from any other cause
shall be filled solely by (i)&nbsp;the affirmative vote of a majority of the total number of directors then in office, even if less than
a quorum, or by a sole remaining director, or (ii)&nbsp;the affirmative vote of the holders of capital stock representing a majority of
the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election
of directors, voting together as a single class, at an annual or special meeting of shareholders called for that purpose. Any director
elected to fill a newly created directorship or vacancy in accordance with this Part&nbsp;D of Article&nbsp;V shall hold office until
the next annual meeting of shareholders and until his or her successor is duly elected and qualified or until his or her earlier death,
resignation, retirement, disqualification, or removal. Notwithstanding the foregoing, except as may be permitted under the TBOC, during
a period between two successive annual meetings of shareholders, the Board may not fill more than two vacancies created by an increase
in the number of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Preferred
Stock Directors</U>. Whenever the holders of any series of Preferred Stock issued by the Corporation shall have the right as provided
for herein (including any Certificate of Designation), voting separately as a series or separately as a class with one or more such other
series, to elect directors, the election, term of office, removal and other features of such directorships shall be governed by the terms
of this Restated Certificate (including any Certificate of Designation). Notwithstanding anything to the contrary in this Part&nbsp;E
of this Article&nbsp;V, during the period when the holders of any series of Preferred Stock issued by the Corporation shall have the right
to elect additional directors, the number of directors to be elected by the holders of any such series of Preferred Stock shall be in
addition to the number fixed pursuant to Part&nbsp;B of this Article&nbsp;V, and the total number of directors constituting the entire
Board shall be automatically increased by such number of directors to be elected by the holders of any such series of Preferred Stock
and each such additional director shall serve until such director&rsquo;s successor shall have been duly elected and qualified, or until
such director&rsquo;s right to hold such office terminates pursuant to said provisions, whichever occurs earlier, subject to his or her
earlier death, resignation, disqualification, or removal. Except as otherwise provided in the Certificate of Designation(s)&nbsp;in respect
of any series of Preferred Stock, whenever the holders of any series of Preferred Stock having such right to elect additional directors
are divested of such right pursuant to the provisions of this Restated Certificate (including any Certificate of Designation), the terms
of office of all such additional directors elected by the holders of such series of Preferred Stock, or elected to fill any vacancies
resulting from the death, resignation, disqualification or removal of such additional directors, shall forthwith terminate (in which case
each such director thereupon shall cease to be qualified as, and shall cease to be, a director) and the total authorized number of directors
of the Corporation shall automatically be reduced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Limitation
of Personal Liability</U>. To the fullest extent permitted by the TBOC, a director of the Corporation will not be personally liable to
the Corporation or its shareholders for monetary damages for an act or omission in the director&rsquo;s capacity as a director, except
for liability for (i)&nbsp;any breach of the director&rsquo;s duty of loyalty to the Corporation or its shareholders, (ii)&nbsp;acts or
omissions not in good faith that constitute a breach of duty to the Corporation or involve intentional misconduct or a knowing violation
of law, (iii)&nbsp;any transaction from which the director derived any improper benefit, regardless of whether the benefit resulted from
an action taken within the scope of such person&rsquo;s duties or (iv)&nbsp;an act or omission for which the liability of the director
is expressly provided for by an applicable statute. If the TBOC is amended hereafter to authorize the further limitation of the personal
liability of directors, then the limitation on personal liability provided in this Article&nbsp;VI will, without the necessity of further
action by the Corporation or the Board, be modified to provide such limitation to the fullest extent permitted by the TBOC as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification</U>.
To the fullest extent permitted by the TBOC, as the same now exists or may hereafter be amended, substituted, or replaced, the Corporation
is authorized to indemnify, and provide advancement of expenses to, its directors, officers, employees and agents (and any other persons
to which the TBOC permits the Corporation to provide indemnification) through provisions in the Bylaws of the Corporation, agreements
with such directors, officers, employees, agents or other persons, the vote of shareholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendments
to Article&nbsp;VI</U>. Any amendment, repeal or modification of the foregoing provisions of this Article&nbsp;VI will not adversely affect
any right or protection of a director, officer, employee, agent, or other person existing at the time of, or increase the liability of
any director, officer, employee, agent or other person of the Corporation with respect to, any acts or omissions of such director, officer,
employee, agent or other person occurring prior to, such amendment, repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meetings of shareholders may
be held within or without the State of Texas, as the Bylaws of the Corporation may provide. To the extent permitted by the TBOC, the books
of the Corporation may be kept outside the State of Texas at such place or places as may be designated from time to time by the Board
or in the Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VIII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Consent
of Shareholders in Lieu of Meeting</U>. Prior to the Trigger Date, any action required or permitted by the TBOC to be taken by the shareholders
may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action
so taken, shall be signed by the holders of the outstanding capital stock of the Corporation representing not less than the minimum number
of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present
and voted. From and after the Trigger Date, any action required or permitted by the TBOC to be taken at any annual or special meeting
of shareholders may be taken without a meeting, without prior notice and without a vote, only if a consent or consents in writing, setting
forth the action so taken, shall be signed by all holders of shares entitled to vote on such action. Any such action taken by written
consent pursuant to this Part&nbsp;A of Article&nbsp;VIII shall be delivered to the Corporation at its principal office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Special
Meetings</U>. Except as otherwise expressly provided by the terms of any series of Preferred Stock permitting the holders of such series
of Preferred Stock to call a special meeting of the holders of such series, special meetings of the shareholders of the Corporation may
be called, for any purpose or purposes, at any time only by or at the direction of (i)&nbsp;the Board, (ii)&nbsp;the Chair of the Board,
(iii)&nbsp;the President, (iv)&nbsp;the Chief Executive Officer, (v)&nbsp;from and after the Trigger Date, the Secretary of the Corporation
at the request of the holders of the greater of (a)&nbsp;at least fifty percent (50%) and (b)&nbsp;the highest percentage of ownership
that may be set under the TBOC without the necessity of further action by the Corporation or the Board, of the voting power of all the
shares of capital stock of the Corporation entitled to vote at the proposed special meeting or (v)&nbsp;prior to the Trigger Date, the
Secretary of the Corporation at the request of the holders of capital stock representing (a)&nbsp;at least fifty percent (50%) of the
voting power of all of the shares of capital stock of the Corporation entitled to vote at the proposed special meeting and (b)&nbsp;at
least ten percent (10%) of all of the shares of capital stock of the Corporation entitled to vote at the proposed special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Advance
Notice</U>. Advance notice of shareholder nominations for the election of directors and of other business proposed to be brought by shareholders
before any meeting of shareholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the Corporation consents
in writing to the selection of an alternative forum, (i)&nbsp;the Business Court in the First Business Court Division of the State of
Texas (the &ldquo;<B><I>Business Court</I></B>&rdquo;) located in Dallas, Texas (or, in the event that the Business Court is not then
accepting filings or determines that it lacks jurisdiction, the United States District Court for the Northern District of Texas (the &ldquo;<B><I>Federal
Court</I></B>&rdquo;) or, if the Federal Court lacks jurisdiction, the state district courts of Dallas County, Texas) shall be the sole
and exclusive forum for any shareholder (including a beneficial owner) to bring (a)&nbsp;any derivative action or proceeding brought on
behalf of the Corporation, (b)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee
of the Corporation to the Corporation or the Corporation&rsquo;s shareholders, including a claim alleging the aiding and abetting of such
a breach of fiduciary duty, (c)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees arising
pursuant to any provision of the TBOC, this Restated Certificate or the Bylaws of the Corporation (in each case, as they may be amended
from time to time), (d)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees governed by the
internal affairs doctrine or (e)&nbsp;any action asserting an &ldquo;internal entity claim&rdquo; as that term is defined in Section&nbsp;2.115
of the TBOC; and (ii)&nbsp;subject to the preceding provisions of this Article&nbsp;IX, the Federal Court shall be the exclusive forum
for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act or the Exchange Act, including
all causes of action asserted against any defendant to such complaint. If any action, the subject matter of which is within the scope
of this Article&nbsp;IX, is filed in a court other than, in the case of clause (i), the courts located in the State of Texas, and in the
case of clause (ii), the Federal Court (a &ldquo;<B><I>Foreign Action</I></B>&rdquo;) in the name of any shareholder, such shareholder
shall be deemed to have consented to (x)&nbsp;the personal jurisdiction of the state and federal courts in the State of Texas in connection
with any action brought in any such court to enforce the provisions of this Article&nbsp;IX and (y)&nbsp;having service of process made
upon such shareholder in any such action by service upon such shareholder&rsquo;s counsel in the Foreign Action as agent for such shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by law, any person purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed
to have notice of and consented to the provisions of this Article&nbsp;IX. This Article&nbsp;IX is intended to benefit and may be enforced
by the Corporation, its officers and directors, the underwriters of, or financial advisors in connection with, any offering giving rise
to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person and who has
prepared or certified any part of the documents underlying the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;X</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shareholders do not have
statutory preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;XI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment
of the Certificate of Formation</U>. The Corporation reserves the right to amend, alter, change, adopt or repeal any provision contained
in this Restated Certificate, in the manner now or hereafter prescribed by this Restated Certificate and the TBOC, and all rights conferred
upon shareholders herein are granted subject to this reservation; <U>provided</U><I>, </I><U>however</U>, that, notwithstanding any other
provision of this Restated Certificate or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to
any vote of the holders of shares of any class or series of capital stock of the Corporation required by law or by this Restated Certificate,
the affirmative vote of the holders of (a)&nbsp;prior to the Trigger Date, at least a majority of the voting power of all of the then
outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, and (b)&nbsp;from
and after the Trigger Date, at least 66 2/3% of the voting power of all of the then outstanding shares of capital stock of the Corporation
entitled to vote thereon, voting together as a single class, in each case with any shares of a class or series that does not otherwise
have a right to vote under this Certificate of Formation being treated as having no votes in the vote as a single class to the greatest
extent permitted by applicable law, shall be required to amend or repeal, or adopt any provision of this Restated Certificate inconsistent
with <U>Articles V</U>, <U>VI</U>, <U>VIII</U>,&nbsp;<U>IX</U>, <U>X</U>, this <U>Article&nbsp;XI</U> and <U>Article&nbsp;XII</U>; <U>provided</U><I>,
</I><U>however</U>, for so long as any shares of Class&nbsp;B Common Stock remain outstanding, the Corporation shall not, without the
prior affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of Class&nbsp;B Common Stock,
voting as a separate class, in addition to any other vote required by law or this Restated Certificate, directly or indirectly, amend,
alter, change, repeal or adopt any provision inconsistent with Part&nbsp;A of <U>Article&nbsp;IV</U> or this proviso of this Part&nbsp;A
of <U>Article&nbsp;XI</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment
of Bylaws</U>. Except as otherwise provided in this Restated Certificate, in furtherance and not in limitation of the powers conferred
upon it by the TBOC, the Board is expressly authorized to adopt, amend, alter or repeal any or all of the Bylaws of the Corporation. The
shareholders may not adopt, amend, alter or repeal the Bylaws of the Corporation unless such action is approved, in addition to any other
vote required by this Certificate of Incorporation, by the affirmative vote of the holders of (a)&nbsp;prior to the Trigger Date, at least
a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting
together as a single class, and (b)&nbsp;from and after the Trigger Date, at least 66 2/3% of the voting power of all of the then outstanding
shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any provision or provisions of this Restated Certificate, including, without limitation, Article&nbsp;IX, is held to be invalid, illegal
or unenforceable as applied to any person or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, (i)&nbsp;the
validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Restated Certificate
(including, without limitation, each portion of any paragraph of this Restated Certificate containing any such provision held to be invalid,
illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other
persons or entities and circumstances will not in any way be affected or impaired thereby and (ii)&nbsp;the provisions of this Restated
Certificate (including, without limitation, each portion of any paragraph of this Restated Certificate containing any such provision held
to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) will be construed so as to permit
the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service
to or for the benefit of the Corporation to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;XII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The right to a jury trial concerning any &ldquo;internal
entity claim&rdquo; as that term is defined in Section&nbsp;2.115 of the TBOC, to the fullest extent permitted by the TBOC and applicable
law, shall be waived. Without limiting the foregoing, to the fullest extent permitted by the TBOC and applicable law, any person purchasing
or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented
to the provisions of this Article&nbsp;XII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>tm2415719d15_ex3-3.htm
<DESCRIPTION>EXHIBIT 3.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 3.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AMENDED AND RESTATED
BYLAWS OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ADOPTED ON JULY 28, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;I</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>OFFICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;1.01 &#8239;&#8239;&nbsp;REGISTERED
OFFICE AND AGENT. </B>The registered office and registered agent of Caris Life Sciences,&nbsp;Inc. (the &ldquo;<B><I>Corporation</I></B>&rdquo;)
will be as set forth in the Corporation&rsquo;s Certificate of Formation (the &ldquo;<B><I>Certificate</I></B>&rdquo;). The registered
office or registered agent may be changed by resolution of the Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;), upon making
the appropriate filing with the Secretary of State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;1.02 &#8239;&#8239;&nbsp;PRINCIPAL
OFFICE. </B>The principal office of the Corporation will be located at such place within or without the State of Texas as will be fixed
from time to time by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;1.03 &#8239;&#8239;&nbsp;OTHER
OFFICES. </B>The Corporation may also have other offices at any places, within or without the State of Texas, as the Board may designate,
or as the business of the Corporation may require or as may be desirable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;1.04 BOOKS
AND RECORDS. </B>All records maintained by the Corporation in the regular course of its business, including its share transfer ledger,
books of account, and minute books, may be maintained in written paper form or another form capable of being converted to written paper
form within a reasonable time. The Corporation will convert any records so kept upon the request of any person entitled to inspect the
records pursuant to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.01 &#8239;&#8239;&nbsp;PLACE
OF MEETING. </B>All meetings of the shareholders will be held either at the principal office of the Corporation or at any other place,
either within or without the State of Texas, as will be designated in the notice of the meeting or duly executed waiver of notice. The
Board may, in its discretion, determine that the meeting may be held solely by means of remote communication as set out in Section&nbsp;2.02
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.02 &#8239;&#8239;&nbsp;MEETINGS
OF SHAREHOLDERS BY REMOTE COMMUNICATION</B>. If authorized by the Board, and subject to any guidelines and procedures adopted by the
Board, shareholders not physically present at a shareholders' meeting may participate in the meeting by means of remote communication
and may be considered present in person and may vote at the meeting, whether held at a designated place or solely by means of remote
communication, subject to the conditions imposed by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.03
 &#8239;&#8239;&nbsp;ANNUAL MEETING. </B>An annual meeting of shareholders will be held on the date and time set by the Board and
stated in the notice of the meeting for the purpose of electing directors and transacting any other business as may be brought
properly before the meeting. Failure to hold the annual meeting at the designated time does not result in the winding up or
termination of the Corporation. If the Board fails to call the annual meeting, any shareholder may make written demand to any
officer of the Corporation that an annual meeting be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.04 &#8239;&#8239;&nbsp;SPECIAL
SHAREHOLDERS' MEETINGS. </B>Special meetings of the shareholders may be called by the President, the Board, or by the holders of at least
fifty percent (50%) of all the shares entitled to vote at the proposed special meeting. The record date for determining shareholders
entitled to call a special meeting is the date the first shareholder signs the notice of that meeting. Only business within the purpose
or purposes described in the notice or executed waiver of notice may be conducted at a special meeting of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.05 &#8239;&#8239;&nbsp;FIXING
THE RECORD DATE. </B>For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders or any
adjournment thereof, the Board may fix a date, not more than sixty (60) days or less than ten (10)&nbsp;days before the meeting, as the
record date for such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever action by shareholders
is proposed to be taken by consent in writing without a meeting of shareholders, the Board may fix a record date for the purpose of determining
shareholders entitled to consent to that action, which record date will not precede, and will not be more than ten (10)&nbsp;days after,
the date upon which the resolution fixing the record date is adopted by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If no record date has been
fixed as provided in this Section&nbsp;2.05, then (a)&nbsp;the record date for determining shareholders entitled to notice of or to vote
at any meeting of shareholders or any adjournment thereof will be the date on which notice of the meeting is mailed, (b)&nbsp;the record
date for determining shareholders entitled to give written consent to action taken without a meeting, where no prior Board action is
required to be taken by the Texas Business Organizations Code (the &ldquo;<B><I>TBOC</I></B>&rdquo;), will be the date on which a signed
written consent is first delivered to the Corporation, and (c)&nbsp;the record date for determining shareholders entitled to give written
consent to action taken without a meeting, where prior Board action is required to be taken by the TBOC, will be the close of business
on the date on which the Board adopts a resolution taking such prior action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.06 &#8239;&#8239;&nbsp;NOTICE
OF SHAREHOLDERS&rsquo; MEETING. </B>Written notice stating the place, day, and hour of the meeting, the means of any remote communications
by which shareholders may be considered present and may vote at the meeting, and, in case of a special meeting, the purpose or purposes
for which the meeting is called, will be given not less than ten (10)&nbsp;days and not more than sixty (60) days before the date of
the meeting, personally, by electronic transmission, or by mail, by or at the direction of the President, the Secretary, or the officer
or person calling the meeting, to each shareholder entitled to vote at the meeting. If mailed, the notice will be deemed to be given
when deposited in the United States mail addressed to the shareholder at the shareholder's address as it appears on the share transfer
records of the Corporation, with postage prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the preceding
paragraph, notice of a shareholder meeting regarding a fundamental business transaction (as defined by Texas law) must be given to each
shareholder of the Corporation not later than twenty-one (21) days prior to the meeting, regardless of the shareholder&rsquo;s right
to vote on the matter. Notice of such action will comply with any other requirements set by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder entitled to
notice of a meeting may sign a written waiver of notice either before or after the time of the meeting. The participation or attendance
of a shareholder at a meeting constitutes waiver of notice, unless the shareholder participates in or attends the meeting solely to object
to the transaction of business on the ground that the meeting was not lawfully called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notice may be given to the
shareholder by electronic transmission. The shareholder may specify the form of electronic transmission to be used to communicate notice.
The shareholder may revoke this consent by written notice to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Notice by electronic transmission is deemed given when the
notice is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Transmitted to a fax number provided by
                                            the shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Transmitted to an email address provided
                                            by the shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">&nbsp;</TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Posted on an electronic network and
                                            a message is sent to the shareholder at the address provided by the shareholder.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Communicated to the shareholder by any other
                                            form of electronic transmission.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.07 &#8239;&#8239;&nbsp;VOTING
LISTS. </B>The officer or agent in charge of the share transfer records of the Corporation will prepare, at least eleven (11) days before
each meeting of shareholders, a complete list of the shareholders entitled to vote at the meeting or any adjournment thereof, arranged
in alphabetical order, with (a)&nbsp;the address of each shareholder, (b)&nbsp;the type of shares held by each shareholder, (c)&nbsp;the
number of shares held by each shareholder, and (d)&nbsp;the number of votes that each shareholder is entitled to if different than the
number of shares held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The list will be kept on
file at the registered office or principal place of business of the Corporation and will be subject to inspection by any shareholder
at any time during usual business hours for a period of ten (10)&nbsp;days prior to the meeting. The list will also be produced and kept
open at the meeting and will be subject to the inspection of any shareholder during the meeting. The original share transfer records
will be prima-facie evidence of the shareholders entitled to examine the list and to vote at any meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.08 &#8239;&#8239;&nbsp;QUORUM
OF SHAREHOLDERS. </B>The presence in person or by proxy of the holders of a majority of the shares entitled to vote constitutes a quorum
for a meeting of the shareholders. Unless otherwise required by the TBOC, the Certificate, or these Bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
affirmative vote of the holders of a majority of the shares represented at a meeting at which a quorum is present will be the act of
the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
shareholders represented in person or by proxy at a meeting at which a quorum is present may conduct any business properly brought before
the meeting until adjournment, and the subsequent withdrawal from the meeting of any shareholder or the refusal of any shareholder represented
in person or by proxy to vote will not affect the presence of a quorum at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a quorum is not present,
the shareholders represented in person or by proxy may adjourn the meeting until a time and place determined by a vote of the holders
of a majority of the shares represented in person or by proxy at that meeting. At such adjourned meeting at which the required number
of voting shares will be present or represented, any business may be transacted which might have been transacted at the meeting as originally
noticed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.09 &#8239;&#8239;&nbsp;CONDUCT
OF MEETINGS. </B>The Board may adopt by resolution rules<B>&nbsp;</B>and regulations for the conduct of meetings of the shareholders
as it will deem appropriate. At every meeting of the shareholders, a director or officer designated by the Board will act as chairman
of, and preside at, the meeting. The Secretary or, in his or her absence or inability to act, the person whom the chairman of the meeting
will appoint secretary of the meeting, will act as secretary of the meeting and keep the minutes thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.10 &#8239;&#8239;&nbsp;VOTING
OF SHARES. </B>Each outstanding share, regardless of class or series, will be entitled to one vote on each matter submitted to a vote
at a meeting of shareholders, except to the extent that the Certificate provides for more or less than one vote per share or limits or
denies voting rights to the holders of the shares of any class or series. Unless otherwise required by the TBOC, the Certificate, or
these Bylaws, any matter, other than the election of directors, brought before any meeting of shareholders at which a quorum is present
will be decided by the affirmative vote of the holders of the majority of shares present in person or represented by proxy at the meeting
and entitled to vote on the matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise required by the Certificate,
the election of directors will be decided by a plurality of the votes cast by the holders of shares entitled to vote in the election
at a meeting of the shareholders at which a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders are prohibited
from cumulating their votes in any election of directors of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any vote may be taken by voice or show of hands
unless a shareholder entitled to vote, either in person or by proxy, objects, in which case written ballots will be used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.11 &#8239;&#8239;&nbsp;VOTING
BY PROXY OR NOMINEE. </B>Shares of the Corporation owned by the Corporation itself or by another corporation or entity, the majority
of the voting shares or interest of which is owned or controlled by the Corporation, will not be voted, directly or indirectly, at any
meeting, and will not be counted in determining the total number of outstanding shares at any given time. Nothing in this section will
be construed as limiting the right of the Corporation or any domestic or foreign corporation or other entity to vote shares, held or
controlled by it in a fiduciary capacity, or with respect to which it otherwise exercises voting power in a fiduciary capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any shareholder may vote
either in person or by proxy executed in writing by the shareholder. No proxy will be valid after eleven (11) months from the date of
its execution unless otherwise provided in the proxy. A proxy will be revocable unless the proxy form conspicuously states that the proxy
is irrevocable and the proxy is coupled with an interest. Proxies coupled with an interest include the appointment as proxy of (a)&nbsp;a
pledgee; (b)&nbsp;a person who purchased or agreed to purchase, or who owns or holds an option to purchase, the shares subject to the
proxy; (c)&nbsp;a creditor of the Corporation who extended the Corporation credit under terms requiring the appointment; (d)&nbsp;an
employee of the Corporation whose employment contract requires the appointment; or (e)&nbsp;a party to a voting agreement or shareholders&rsquo;
agreement created under the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares owned by another corporation,
domestic or foreign, may be voted by any officer, agent, or proxy as the bylaws of that corporation may authorize or, in the absence
of authorization, as the board of directors of that corporation may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An administrator, executor,
guardian, or conservator may vote shares held in that fiduciary capacity if the shares forming a part of an estate are in the possession
and forming a part of the estate being served by the fiduciary, either in person or by proxy, without a transfer of the shares into the
fiduciary&rsquo;s name. A trustee may vote shares standing in the trustee&rsquo;s name, either in person or by proxy, but no trustee
will be entitled to vote shares held by him or her without a transfer of the shares into his or her name as trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A receiver may vote shares
standing in the name of a receiver and may vote shares held by or under the control of a receiver without the transfer thereof into the
receiver&rsquo;s name if authority to do so is contained in an appropriate order of the court by which the receiver was appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder whose shares
are pledged will be entitled to vote the shares until the shares have been transferred into the name of the pledgee, and thereafter the
pledgee will be entitled to vote the shares transferred, subject to any agreements containing restrictions on the hypothecation, assignment,
pledge, or voluntary or involuntary transfer of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may establish a
procedure by which a shareholder may file a statement with the Corporation that all or a portion of the shares registered in the name
of the shareholder are held for the account of a specified person to be recognized by the Corporation as the shareholder. The procedure
must determine the extent of the Corporation&rsquo;s recognition of the specified person as a shareholder and may include any provisions
that the Board deems necessary, including, but not limited to, any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The types of nominee shareholders who may
                                            file a statement.</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">&nbsp;</TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            rights or privileges of the beneficial owner to be recognized by the Corporation upon filing
                                            of a statement.</FONT></TD></TR>
                                                                                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The information to be included in the statement.</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">&nbsp;</TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The timeframe within which the statement
                                            must be received for the statement to be effective as to an upcoming meeting or vote.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">&nbsp;</TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The time period for which the statement
                                            filed will be recognized by the Corporation.</TD></TR>
                                                                                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.12 &#8239;&#8239;&nbsp;WRITTEN
CONSENT OF SHAREHOLDERS WITHOUT A MEETING. </B>Any action required by the TBOC to be taken at any annual or special meeting of shareholders,
or any action which may be taken at any annual or special meeting of shareholders, may be taken without a meeting, without prior notice,
and without a vote, if a consent or consents in writing, setting forth the action so taken, will have been signed by the holder or holders
of shares having not less than the minimum number of votes that would be necessary to take the action at a meeting at which holders of
all shares entitled to vote on the action were present and voted. Prompt notice of the taking of any action by shareholders without a
meeting by less than unanimous written consent will be given to those shareholders who did not consent in writing to the action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;III</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.01 &#8239;&#8239;&nbsp;BOARD.
</B>The business and affairs of the Corporation will be managed under the direction of the Board. Directors need not be residents of
the State of Texas or shareholders of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.02 &#8239;&#8239;&nbsp;NUMBER
OF DIRECTORS. </B>The number of directors will be one (1), provided that the number may be increased or decreased from time to time by
an amendment to these Bylaws or by resolution adopted by the Board. No decrease in the number of Directors will have the effect of shortening
the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.03 &#8239;&#8239;&nbsp;TERM
OF OFFICE. </B>At the first annual meeting of shareholders and at each annual meeting thereafter, the holders of shares entitled to vote
in the election of directors will elect directors, each of whom will hold office until a successor is duly elected and qualified or until
the director&rsquo;s earlier death, resignation, disqualification, or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.04 &#8239;&#8239;&nbsp;VACANCIES
AND NEWLY CREATED DIRECTORSHIPS. </B>Any vacancy occurring in the Board may be filled by election at an annual or special meeting of
shareholders called for that purpose, or may be filled by the affirmative vote of a majority of the remaining directors even when the
majority of the remaining directors is less than a quorum of the total number of directors specified in the Certificate or the Bylaws.
A director elected to fill a vacancy will be elected for the unexpired term of his or her predecessor in office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A directorship to be filled
by reason of an increase in the number of directors may be filled by election at an annual or special meeting of shareholders called
for that purpose, or may be filled by the Board for a term of office continuing only until the next election of one or more directors
by the shareholders; provided that the Board may not fill more than two (2)&nbsp;directorships during the period between any two (2)&nbsp;successive
annual meetings of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.05 &#8239;&#8239;&nbsp;REMOVAL.
</B>Any director or the entire Board may be removed, with or without cause, by a vote of the holders of a majority of the shares then
entitled to vote at an election of the director or directors, at any meeting of shareholders called expressly for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.06 &#8239;&#8239;&nbsp;RESIGNATION.
</B>A director may resign by providing written notice to the Corporation. The resignation will be effective upon the later of the date
of receipt of the notice of resignation or the effective date specified in the notice. Acceptance of the resignation will not be required
to make the resignation effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.07 &#8239;&#8239;&nbsp;REGULAR
MEETINGS OF DIRECTORS. </B>A regular meeting of the newly-elected Board will be held without other notice immediately following each
annual meeting of shareholders, at which the board will elect officers and transact any other business as will come before the meeting.
The board may designate a time and place for additional regular meetings, by resolution, without notice other than the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.08 &#8239;&#8239;&nbsp;SPECIAL
MEETINGS OF DIRECTORS. </B>The Chairman may call a special meeting of the Board at a time or place determined by the Chairman. The Chairman
will call a special meeting at the written request of two (2)&nbsp;or more directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.09 &#8239;&#8239;&nbsp;NOTICE
OF DIRECTORS&rsquo; MEETINGS. </B>All special meetings of the Board will be held upon not less than two (2)&nbsp;days&rsquo; written
notice stating the date, place, and time of the meeting delivered to each director either personally or by mail. Notice of a regular
or special meeting of the Board may be provided to a director by electronic transmission on consent of the director. The director may
specify the form of electronic transmission to be used to communicate notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A written waiver of the required
notice signed by a director entitled to the notice, before or after the meeting, is the equivalent of giving notice to the director who
signs the waiver. A director&rsquo;s attendance at any meeting will constitute a waiver of notice of the meeting, except where the directors
attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully
called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.10 &#8239;&#8239;&nbsp;QUORUM
AND ACTION BY DIRECTORS. </B>A majority of the number of directors will constitute a quorum for the transaction of business. The act
of the majority of the directors present at a meeting at which a quorum is present at the time of the act will be the act of the Board,
unless the act of a greater number is required by law, the Certificate, or these Bylaws. The directors at a meeting for which a quorum
is not present may adjourn the meeting until a time and place as may be determined by a vote of the directors present at that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.11 &#8239;&#8239;&nbsp;COMPENSATION.
</B>Directors, as such, will not receive any stated salary for their services, but by resolution of the Board a fixed sum and expenses
of attendance, if any, may be allowed for attendance at any meeting of the Board or committee thereof. A director will not be precluded
from serving the Corporation in any other capacity and receiving compensation for services in that capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.12 &#8239;&#8239;&nbsp;ACTION
BY DIRECTORS WITHOUT A MEETING. </B>Unless otherwise restricted by the Certificate or these Bylaws, any action required or permitted
to be taken at a meeting of the Board or any committee may be taken without a meeting if all members of the Board or committee consent
in writing or by electronic transmission and the writings or electronic transmissions are filed with the minutes of the proceedings of
the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.13 &#8239;&#8239;&nbsp;COMMITTEES
OF THE BOARD. </B>The Board, by resolution adopted by a majority of the Board, may designate one or more directors to constitute one
or more committees, to exercise the authority of the Board to the extent provided in the resolution of the Board and allowed under the
TBOC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">No committee of the Board will have the authority
to authorize a distribution or to authorize the issuance of shares of the Corporation unless the resolution designating a particular
committee expressly so provides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The designation of a committee of the Board and
the delegation thereto of authority will not operate to relieve the Board, or any member thereof, of any responsibility imposed by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;IV</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.01 &#8239;&#8239;&nbsp;POSITIONS
AND ELECTION. </B>The officers of the Corporation will be elected by the Board and will be a Chief Executive Officer, President and a
Secretary and any other officers, including assistant officers and agents, as may be deemed necessary by the Board. Any two (2)&nbsp;or
more offices may be held by the same person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each officer will serve until
a successor is elected and qualified or until the earlier death, resignation, or removal of that officer. Vacancies or new offices will
be filled at the next regular or special meeting of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.02 &#8239;&#8239;&nbsp;REMOVAL.
</B>Any officer elected or appointed by the Board may be removed with or without cause by the affirmative vote of the majority of the
Board. Removal will be without prejudice to the contract rights, if any, of the officer so removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.03 &#8239;&#8239;&nbsp;CHAIRMAN
AND VICE CHAIRMAN. </B>The Chairman of the Board (the &ldquo;<B><I>Chairman</I></B>&rdquo;), if any, will preside at all meetings of
the Board and of the shareholders at which the Chairman will be present. The Chairman will have and may exercise such powers as are,
from time to time, assigned to the Chairman by the Board and as may be provided by law. In the absence of the Chairman, the Vice Chairman
of the Board (the &ldquo;<B><I>Vice Chairman</I></B>&rdquo;), if any, will preside at all meetings of the Board and of the shareholders
at which the Vice Chairman will be present. The Vice Chairman will have and may exercise such powers as are, from time to time, assigned
to such person by the Board and as may be provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.04
 &#8239;&#8239;&nbsp;CHIEF EXECUTIVE OFFICER. </B>In the absence of a Chairman and/or Vice Chairman, the Chief Executive Officer will
preside as the chairman of meetings of the shareholders and the Board. The Chief Executive Officer will, subject to the control of
the Board, have general and active management of the business of the Corporation and will see that all orders and resolutions of the
Board are carried into effect. All other officers, officials, employees and agents will report directly or indirectly to the Chief
Executive Officer. The Chief Executive Officer, President or any executive Vice President will execute bonds, mortgages and other
contracts on behalf of the Corporation, except where required or permitted by law to be otherwise signed and executed and except
where the signing and execution thereof will be expressly delegated by the Board to some other officer or agent of the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.05 &#8239;&#8239;&nbsp;PRESIDENT.
</B>In the absence or disability of the Chief Executive Officer, the President will perform all the duties of the Chief Executive Officer.
When acting as the Chief Executive Officer, the President will have all the powers of, and be subject to all the restrictions upon, the
Chief Executive Officer. The President will have such other powers and perform such other duties as from time to time may be prescribed
by the Board, these Bylaws, the Chief Executive Officer or the Chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.06 &#8239;&#8239;&nbsp;VICE
PRESIDENTS. </B>Each Vice President may be designated by such title as the Board may determine, and each Vice President in order of their
rank as designated by the Board will, in the absence or disability of the President, or at his or her request, perform the duties and
exercise the powers of the President and will perform other duties as the Board will assign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.07 &#8239;&#8239;&nbsp;SECRETARY
AND ASSISTANT SECRETARIES. </B>The Secretary will attend all meetings of the Board and of the shareholders, and will record all votes
and the minutes of all proceedings and will perform like duties for the standing committees when required. The Secretary will give or
cause to be given notice of all meetings of the Board and of the shareholders, and will perform other duties as may be prescribed by
the Board. The Secretary will be the custodian of the records and of the seal of the Corporation, and will affix the seal to all documents
and attest to it when duly authorized by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Assistant Secretary
may, in the absence or disability of the Secretary, or at his or her request or the request of the President, perform the duties and
exercise the powers of the Secretary, and will perform other duties as the Board will assign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the absence of the Secretary
or an Assistant Secretary, the minutes of all meetings of the board and of the shareholders will be recorded by the person designated
by the President or by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.08 &#8239;&#8239;&nbsp;THE
TREASURER AND ASSISTANT TREASURERS. </B>The Treasurer will be the principal financial officer of the Corporation, will have the custody
of the corporate funds and securities, will keep full and accurate accounts of receipts and disbursements of the Corporation, will deposit
all moneys and other valuable effects in the name and to the credit of the Corporation in the depositories designated by the Board, and
in general will perform all the duties incident to the office of Treasurer and such other duties as the Board may assign from time to
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Treasurer will disburse
the funds of the Corporation as may be ordered by the Board, taking proper vouchers for the disbursements. The Treasurer will keep and
maintain the Corporation&rsquo;s books of account and will render to the President and directors an account of all of his or her transactions
as Treasurer and of the financial condition of the Corporation and exhibit the books, records, and accounts to the President or directors
at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If required by the Board,
the Treasurer will give the Corporation a bond in a sum and with a surety or sureties satisfactory to the Board for the faithful performance
of the duties of the office and for the restoration to the Corporation, in case of death, resignation, retirement, or removal from office,
of all books, papers, vouchers, money, and other property of whatever kind in the incumbent&rsquo;s possession or under the incumbent&rsquo;s
control belonging to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Assistant Treasurer
may, in the absence or disability of the Treasurer, or at his or her request or the request of the President, perform the duties and
exercise the powers of the Treasurer, and will perform other duties as the Board will assign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.09 &#8239;&#8239;&nbsp;AUTHORITY
TO EXECUTE AGREEMENTS. </B>All agreements of the Corporation will be executed on behalf of the Corporation by (a)&nbsp;the President
or any Vice President, (b)&nbsp;such other officer or employee of the Corporation authorized in writing by the President, with such limitations
or restrictions on such authority as the President deems appropriate or (c)&nbsp;such other person as may be authorized by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;V</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>UNCERTIFICATED SHARES
AND TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;5.01 &#8239;&#8239;&nbsp;UNCERTIFICATED SHARES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of the Corporation
will be uncertificated, provided, that any holder of uncertificated shares, upon request, will be entitled to have a certificate for
shares of the Corporation so held in which case the Corporation will issue a certificate for such shares to such holder. Any certificates
representing shares of the Corporation will be signed by the Chief Executive Officer, the President or a Vice President of the Corporation
and either the Secretary or an Assistant Secretary of the Corporation. The signature of any such officer on any such share certificate
may be a facsimile. In case any officer who has signed or whose facsimile signature has been placed on any such share certificate will
have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he or
she were such officer at the date of its issuance. Within a reasonable time after the issuance or transfer of uncertificated shares,
the Corporation will send to the registered owner of the uncertificated shares a written notice that sets forth all of the information
required by Section&nbsp;3.205 the Texas Business Organizations Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise expressly
provided by law, the rights and obligations of the holders of uncertificated shares and the rights and obligations of the holders of
certificates representing shares, if any, of the same class and series will be identical. No share will be issued until the consideration
therefor, fixed as provided by law, has been fully paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No requirement of the TBOC
with respect to matters to be set forth on certificates representing shares of the Corporation will apply to or affect certificates outstanding
when the requirement first becomes applicable to the certificates; but the requirements will apply to all certificates thereafter issued
whether in connection with an original issue of shares, a transfer of shares, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.02 &#8239;&#8239;&nbsp;TRANSFERS
OF SHARES. </B>Shares of the Corporation will be transferable in the manner prescribed by law and in these Bylaws. Transfers of shares
will be made on the books of the Corporation only by the holder of record thereof or by such other person as may under law be authorized
to endorse such shares for transfer or by such shareholder&rsquo;s attorney lawfully constituted in writing. Except as otherwise provided
by law, upon surrender to the Corporation or its transfer agent of a certificate for shares duly endorsed or accompanied by proper evidence
of succession, assignment, or authority to transfer, the Corporation will issue a new certificate to the person entitled thereto, cancel
the old certificate, and record the transaction upon its books. No transfer of shares will be valid as against the Corporation for any
purpose until it will have been entered in the share transfer records of the Corporation by an entry showing from and to what person
those shares were transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.03 &#8239;&#8239;&nbsp;REGISTERED
SHAREHOLDERS. </B>The Corporation will be entitled to treat the holder of record of any shares issued by the Corporation as the holder
in fact thereof for all purposes, including voting those shares, receiving dividends or distributions thereon or notices in respect thereof,
transferring those shares, exercising rights of dissent with respect to those shares, exercising or waiving any preemptive right with
respect to those shares, entering into agreements with respect to those shares in accordance with Texas law, or giving proxies with respect
to those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the Corporation nor
any of its officers, directors, employees, or agents will be liable for regarding that person as the owner of those shares at that time
for those purposes, regardless of whether that person possesses a certificate for those shares, and will not be bound to recognize any
equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it will have express
or other notice of such claim or interest, except as otherwise provided by Texas law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.04 &#8239;&#8239;&nbsp;LOST
CERTIFICATES. </B>The Board may direct a new certificate or certificates to be issued in place of any certificate or certificates previously
issued by the Corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person
claiming the certificate is lost, stolen, or destroyed. When authorizing the issue of a new certificate or certificates, the Board, in
its discretion and as a condition precedent to the issuance thereof, may require the owner of the lost, stolen, or destroyed certificate
or certificates or his or her legal representative to give the Corporation a bond with surety in a sum as it may direct, as indemnity
against any claim that may be made against the Corporation on account of the alleged loss, theft, or destruction of any such certificate
or the issuance of such new certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;VI</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>DISTRIBUTIONS AND DIVIDENDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.01 &#8239;&#8239;&nbsp;DECLARATION.
</B>The Board may authorize distributions on the outstanding shares in cash, property, or in the shares of the Corporation at any annual,
regular, or special meeting of the Board to the extent permitted by, and subject to the provisions of, the laws of the State of Texas.
The Board may by resolution create a reserve or reserves out of the Corporation&rsquo;s surplus or allocate any part or all of surplus
in any manner for any proper purpose or purposes, and may increase, decrease, or abolish any such reserve, designation, or allocation
in the same manner, after first obtaining the written approval of a majority of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.02 &#8239;&#8239;&nbsp;FIXING
RECORD DATES FOR DISTRIBUTIONS AND DIVIDENDS. </B>For the purpose of determining shareholders entitled to receive a distribution by the
Corporation (other than a distribution involving a purchase or redemption by the Corporation of any of its own shares) or a share dividend,
the Board may, at the time of declaring the distribution or dividend, set a date no more than sixty (60) days prior to the date of the
distribution or dividend. If no record date is fixed for the determination of shareholders entitled to receive a distribution (other
than a distribution involving a purchase or redemption by the Corporation of any of its own shares) or a share dividend, the date on
which the resolution of the Board declaring the distribution or share dividend is adopted will be the record date for the determination
of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;VII</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.01 &#8239;&#8239;&nbsp;INDEMNIFICATION
OF EXISTING AND FORMER DIRECTORS AND OFFICERS. </B>The Corporation will indemnify any person who was or is a party or is threatened to
be made a party to any threatened, pending, or completed action or other proceeding (whether civil, criminal, administrative, arbitrative,
or investigative), including any appeal thereof, or any inquiry or investigation that could lead to such an action or proceeding (any
of the foregoing to be referred to hereafter as a &ldquo;<B><I>proceeding</I></B>&rdquo;) by reason of the fact that the person (1)&nbsp;is
or was a director or officer of the Corporation; or (2)&nbsp;while a director or officer of the Corporation, is or was serving at the
request of the Corporation as a partner, director, officer, venturer, proprietor, trustee, employee, administrator, or agent of another
entity, organization, or an employee benefit plan (each such person in (2)&nbsp;to be referred to hereafter as a &ldquo;<B><I>delegate</I></B>&rdquo;
and, together with each such person in (1), a &ldquo;<B><I>covered person</I></B>&rdquo;) to the fullest extent permitted by the TBOC,
as the same now exists or may hereafter be amended, substituted, or replaced (but, in the case of any such amendment, substitution, or
replacement, only to the extent that such amendment, substitution, or replacement permits the Corporation to provide broader indemnification
rights than the TBOC permitted the Corporation to provide prior to such amendment, substitution, or replacement), against all judgments
(including arbitration awards), court costs, penalties, settlements, fines, excise, and other similar taxes and reasonable attorneys&rsquo;
fees (all of the foregoing to be referred to hereafter as &ldquo;<B><I>expenses</I></B>&rdquo;) actually incurred by the covered person
in connection with such proceeding. The right to indemnification in this Section&nbsp;7.01 will continue as to a covered person who has
ceased to be a director, officer, or delegate and will inure to his or her heirs, executors, or administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.02 &#8239;&#8239;&nbsp;ADVANCEMENT
OF EXPENSES. </B>The Corporation will pay or reimburse reasonable expenses incurred by a covered person currently serving as a director,
officer, or delegate of the Corporation who was or is a party or is threatened to be made a party to any proceeding in advance of the
final disposition of the proceeding, without any determination as to the covered person&rsquo;s entitlement to indemnification, if the
Corporation receives the following before any such advancement of expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
written affirmation by the covered person of the covered person&rsquo;s good faith belief that he or she has met the standard of conduct
necessary for indemnification under the TBOC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
written undertaking by or on behalf of the covered person to repay the amount so advanced if the final determination is that the covered
person has not met the required standard of conduct set forth in the TBOC or that indemnification is prohibited by the TBOC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.03 &#8239;&#8239;&nbsp;INDEMNIFICATION
OF AND ADVANCEMENT OF EXPENSES TO OTHER PERSONS. </B>Notwithstanding any other provision of this ARTICLE&nbsp;VII, the Corporation may
indemnify and advance expenses to persons other than covered persons, including advisory directors, non-executive officers, employees,
and agents of the Corporation, to the extent and in the manner provided by the TBOC and these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.04 &#8239;&#8239;&nbsp;INDEMNIFICATION
RIGHTS NOT EXCLUSIVE. </B>The rights provided pursuant to this ARTICLE&nbsp;VII will not be exclusive of any other rights to which a
person may be entitled by applicable law, the Corporation&rsquo;s Certificate, action or resolution of the Corporation&rsquo;s shareholders
or disinterested directors or contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.05 &#8239;&#8239;&nbsp;INSURANCE.
</B>The Corporation may purchase and maintain insurance or another arrangement to indemnify any covered person against any liability
asserted against and incurred by the covered person in that capacity or arising out of the covered person&rsquo;s status in that capacity,
regardless of whether the Corporation would have the power to indemnify the covered person against that liability under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.06 &#8239;&#8239;&nbsp;REPORTS
OF INDEMNIFICATION AND ADVANCES. </B>No later than one (1)&nbsp;year from the date that the Corporation indemnifies or advances expenses
to a director, it will give a written report of such indemnification or advancement to the shareholders, which report must be made with
or before the notice or waiver of notice of the next shareholders&rsquo; meeting or the next submission to the shareholders of a written
consent without a meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;VIII</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.01 &#8239;&#8239;&nbsp;SEAL.
</B>The Corporation may adopt a corporate seal in a form approved by the Board. The Corporation will not be required to use the corporate
seal and the lack of the corporate seal will not affect an otherwise valid contract or other instrument executed by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.02 &#8239;&#8239;&nbsp;CHECKS,
DRAFTS,&nbsp;ETC. </B>All checks, drafts or other instruments for payment of money or notes of the Corporation will be signed by an officer
or officers or any other person or persons as will be determined from time to time by resolution of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.03 &#8239;&#8239;&nbsp;FISCAL
YEAR. </B>The fiscal year of the Corporation will be as determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.04 &#8239;&#8239;&nbsp;INVALID
PROVISIONS. </B>If any one or more of the provisions of these Bylaws, or the applicability of any provision to a specific situation,
will be held invalid or unenforceable, the provision will be modified to the minimum extent necessary to make it or its application valid
and enforceable, and the validity and enforceability of all other provisions of these Bylaws and all other applications of any provision
will not be affected thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.05 &#8239;&#8239;&nbsp;CONFLICT
WITH APPLICABLE LAW OR CERTIFICATE. </B>These Bylaws are adopted subject to any applicable law and the Certificate. Whenever these Bylaws
may conflict with any applicable law or the Certificate, such conflict will be resolved in favor of such law or the Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE&nbsp;IX</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AMENDMENT OF BYLAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;9.01 &#8239;&#8239;&nbsp;AMENDMENT
OF BYLAWS. </B>The Board may amend, alter, change, and repeal these Bylaws or adopt new bylaws. The shareholders may make additional
bylaws and may alter and repeal any bylaws whether such bylaws were originally adopted by them or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>tm2415719d15_ex3-4.htm
<DESCRIPTION>EXHIBIT 3.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit&#8239;3.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED BYLAWS<BR>
OF<BR>
CARIS LIFE SCIENCES,&nbsp;INC.<BR>
(AS OF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;I</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
OFFICES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;1.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Registered
Office</B>. The address of the registered office of Caris Life Sciences,&nbsp;Inc. (the &ldquo;<B><I>Corporation</I></B>&rdquo;) in the
State of Texas, and the name of its registered agent at such address, shall be as set forth in the Corporation&rsquo;s certificate of
formation, as the same may be amended and/or restated from time to time (the &ldquo;<B><I>Certificate of Formation</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;1.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Additional
Offices</B>. The Corporation may, in addition to its registered office in the State of Texas, have such other offices and places of business,
both within and outside the State of Texas, as the Board of Directors of the Corporation (the &ldquo;<B><I>Board</I></B>&rdquo;) may from
time to time determine or as the business and affairs of the Corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;II</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>MEETINGS OF SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Place
of Meetings</B>. Meetings of shareholders shall be held at any place within or outside the State of Texas, designated by the Board. The
Board may, in its sole discretion, determine that a meeting of shareholders shall not be held at any place, but may instead be held solely
by means of remote communication pursuant to <U>Section&nbsp;9.5(a)</U>&nbsp;of these Bylaws. In the absence of any such designation or
determination, shareholders meetings shall be held at the Corporation&rsquo;s principal executive office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Annual
Meetings</B>. The Board shall designate the date and time of the annual meeting of shareholders. At the annual meeting of shareholders,
directors shall be elected and other business properly brought before the meeting in accordance with <U>Section&nbsp;2.8</U> of these
Bylaws may be transacted. The Board may postpone, adjourn, reschedule or cancel any previously scheduled annual meeting of shareholders
(for any reason or no reason).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Special
Meetings</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the rights of the holders of any outstanding series of the preferred stock of the Corporation (&ldquo;<B><I>Preferred Stock</I></B>&rdquo;),
and to the requirements of applicable law, special meetings of shareholders may be called only by such persons and only in such manner
as set forth in the Certificate of Formation. Other than procedural matters, no business may be transacted at any special meeting of shareholders
other than the business specified in the notice of such meeting. The Board may postpone, adjourn, reschedule or cancel (to the extent
permitted under the TBOC) any previously scheduled special meeting of shareholders (for any reason or no reason).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
special meeting requested by one or more shareholders holding the requisite percentage specified in the Certificate of Formation (the
 &ldquo;<B><I>Requisite Percentage</I></B>&rdquo;) pursuant to the Certificate of Formation (a &ldquo;<B><I>Shareholder Requested Meeting</I></B>&rdquo;)
shall be called by the Secretary only if the shareholders requesting such meeting provide the information set forth in <U>Section&nbsp;2.3(c)</U>&nbsp;of
these Bylaws below and otherwise comply with this <U>Section&nbsp;2.3</U>, as determined by the Board. For purposes of these Bylaws, any
determination to be made by the Board may be made by the Board, a committee of the Board or any officer of the Corporation designated
by the Board or a committee of the Board, and any such determination shall be final and binding on the Corporation, its shareholders and
any other person so long as made in good faith (without any further requirements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
order for a Shareholder Requested Meeting to be called by the Secretary pursuant to <U>Section&nbsp;2.3(b)&nbsp;</U>of these Bylaws, one
or more written requests for a special meeting (individually or collectively, a &ldquo;<B><I>Special Meeting Request</I></B>&rdquo;) signed
and dated by the shareholder(s)&nbsp;that Own(s)&nbsp;(as defined below) the Requisite Percentage (or its or their respective duly authorized
agent) must be delivered to the Secretary at the principal executive office of the Corporation and must be accompanied by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of any Shareholder Requested Meeting at which director nominations are proposed to be presented, the information and documentation
required by <U>Section&nbsp;3.4</U> of these Bylaws, including any updates or supplements thereto required pursuant to <U>Section&nbsp;3.4</U>
of these Bylaws, if applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of any Shareholder Requested Meeting at which any business other than director nominations is proposed to be presented, the information
and documentation required by <U>Section&nbsp;2.8(a)(ii)</U>&nbsp;of these Bylaws (as though such provision were applicable to special
meetings), as well as any updates or supplements thereto required pursuant to <U>Section&nbsp;2.8(a)(ii)</U>&nbsp;of these Bylaws, if
applicable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
to each shareholder of the Corporation signing such request, or if such shareholder is a nominee or custodian, the beneficial owner(s)&nbsp;on
whose behalf such request is signed, an affidavit by each such person (A)&nbsp;stating the class or series and number of shares of capital
stock of the Corporation that he, she, or it Owns as of the date such request was signed; and (B)&nbsp;agreeing to (1)&nbsp;update and
supplement such affidavit as of the record date for the Shareholder Requested Meeting (and such update and supplement shall be delivered
to the Secretary at the principal executive office of the Corporation not later than five (5)&nbsp;Business Days (as defined below) after
the record date for such Shareholder Requested Meeting) and as of the date that is ten (10)&nbsp;Business Days prior to the date of the
Shareholder Requested Meeting (and such update and supplement shall be delivered to the Secretary at the principal executive office of
the Corporation not later than seven (7)&nbsp;Business Days prior to the date of such Shareholder Requested Meeting) and (2)&nbsp;notify
the Corporation promptly (and in any event within forty-eight (48) hours) in writing to the Secretary at the principal executive office
of the Corporation of any disposition after the record date for such Shareholder Requested Meeting, but prior to the date of the Shareholder
Requested Meeting. For purposes of these Bylaws, &ldquo;<B><I>Business Day</I></B>&rdquo; shall mean any day other than a Saturday, a
Sunday or a day on which banking institutions in the State of Texas are authorized or obligated by law or executive order to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;One
or more written requests for a special meeting delivered to the Secretary shall constitute a valid Special Meeting Request only if each
such written request satisfies the requirements of this <U>Section&nbsp;2.3</U> and has been dated and delivered to the Secretary within
sixty (60) days of the earliest dated of such requests. Any requesting shareholder may revoke his, her, or its Special Meeting Request
at any time by written revocation delivered to the Secretary at the principal executive office of the Corporation; <U>provided</U>, however,
that if following such revocation, the unrevoked valid Special Meeting Requests represent in the aggregate less than the Requisite Percentage,
there shall be no requirement to hold a Shareholder Requested Meeting. Except as otherwise provided by applicable law or except to the
extent previously determined by the Board in connection with a Special Meeting Request, the chair of the Shareholder Requested Meeting
shall have the power and duty (i)&nbsp;to determine whether any business proposed to be brought before the meeting was made in accordance
with the procedures set forth in this <U>Section&nbsp;2.3</U> and applicable law and (ii)&nbsp;if any proposed business was not made or
proposed in compliance with this <U>Section&nbsp;2.3</U> and applicable law, to declare that such proposed business shall not be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
none of the shareholders who submitted the Special Meeting Request, or their qualified representatives, appears at the Shareholder Requested
Meeting and presents the matters to be presented for consideration that were specified in the Special Meeting Request, the Corporation
need not present such matters for a vote at such meeting (notwithstanding that ballots or proxies in respect of such matter may have been
received by the Corporation). For purposes of these Bylaws, to be considered a qualified representative of a shareholder, (i)&nbsp;a person
must be a duly authorized officer, manager, or partner of such shareholder or must be authorized by a writing executed by such shareholder
stating that such person is authorized to act for such shareholder as proxy at the meeting of shareholders; and (ii)&nbsp;prior to the
presentation of such matters at the meeting of shareholders, such person must produce a valid government-issued photo identification,
as well as either (A)&nbsp;proof that he, she, or it is a duly authorized officer, manager, or partner of such shareholder or (B)&nbsp;such
writing (or a reliable reproduction or electronic transmission of the writing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of these Bylaws, a shareholder or beneficial owner shall be deemed to &ldquo;<B><I>Own</I></B>&rdquo; only those outstanding
shares of the Corporation&rsquo;s capital stock as to which such person possesses both: (i)&nbsp;the full voting and investment rights
pertaining to such shares and (ii)&nbsp;the full economic interest in (including the opportunity for profit from and the risk of loss
on) such shares; provided that the number of shares calculated in accordance with clauses (i)&nbsp;and (ii)&nbsp;shall not include any
shares (A)&nbsp;purchased by such person or any of its Affiliates (as defined below) in any transaction that has not been settled or closed;
(B)&nbsp;sold short by such person or any of its Affiliates; (C)&nbsp;borrowed by such person or any of its Affiliates for any purpose
or purchased by such person or any of its Affiliates pursuant to an agreement to resell or subject to any other obligation to resell to
another person; or (D)&nbsp;subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar agreement
entered into by such person or any of its Affiliates, whether any such instrument or agreement is to be settled with shares or with cash
based on the notional amount or value of shares of outstanding capital stock of the Corporation, in any such case which instrument or
agreement has, or is intended to have, or if exercised would have the purpose or effect of (1)&nbsp;reducing in any manner, to any extent,
or at any time in the future, such person&rsquo;s or any of its Affiliates&rsquo; full right to vote or direct the voting of any such
shares, or (2)&nbsp;hedging, offsetting or altering to any degree any gain or loss arising from the full economic ownership of such shares
by such person or any of its Affiliates. For purposes of these Bylaws, a shareholder or beneficial owner shall Own shares held in the
name of a nominee or other intermediary so long as the person retains the right to instruct how the shares are voted with respect to the
election of directors and possesses the full economic interest in the shares. For purposes of these Bylaws, a person shall be deemed to
continue to Own shares during any period in which the person has delegated any voting power by means of a proxy, power of attorney, or
other instrument or arrangement that is revocable at any time by the person. For purposes of these Bylaws, a person shall also be deemed
to continue to Own shares during any period in which the person has loaned such shares provided that the person has the power to recall
such loaned shares on no more than five (5)&nbsp;Business Days&rsquo; notice, the person recalls the loaned shares no later than five
(5)&nbsp;Business Days after being notified that the Shareholder Requested Meeting will be held, and the person holds the recalled shares
through the date of the Shareholder Requested Meeting. The determination of the extent to which a shareholder or beneficial owner &ldquo;Owns&rdquo;
any shares of capital stock of the Corporation for these purposes shall be made by the Board. The terms &ldquo;Owned,&rdquo; &ldquo;Owning&rdquo;
and &ldquo;Ownership&rdquo; and other variations of the word &ldquo;Own&rdquo; shall have correlative meanings in these Bylaws. For purposes
of these Bylaws, the term &ldquo;<B><I>Affiliates</I></B>&rdquo; shall have the meaning given in Rule&nbsp;12b-2 under the Exchange Act
(as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Notices.</B>
Written notice of each shareholders meeting stating the place, if any, date, and time of the meeting, and the means of remote communication,
if any, by which shareholders and proxy holders may be deemed to be present in person and vote at such meeting and the record date for
determining the shareholders entitled to vote at the meeting, if such date is different from the record date for determining shareholders
entitled to notice of the meeting, shall be given in the manner permitted by <U>Section&nbsp;9.3</U> of these Bylaws to each shareholder
entitled to vote thereat as of the record date for determining the shareholders entitled to notice of the meeting, by the Corporation
not less than ten (10)&nbsp;nor more than sixty (60) days before the date of the meeting unless otherwise required by Section&nbsp;21.353
of the Texas Business Organizations Code (the &ldquo;<B><I>TBOC</I></B>&rdquo;). If said notice is for a special meeting of shareholders,
it shall in addition state the purpose or purposes for which the meeting is called, and the business transacted at such meeting shall
be limited to the matters so stated in the Corporation&rsquo;s notice of meeting (or any supplement thereto). Any meeting of shareholders
as to which notice has been given may be postponed, and any meeting of shareholders as to which notice has been given may be cancelled
(to the extent permitted by the TBOC), by the Board upon public announcement (as defined in <U>Section&nbsp;2.8(c)</U>&nbsp;of these Bylaws)
given before the date previously scheduled for such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Quorum</B>.
Except as otherwise provided by applicable law, the Certificate of Formation or these Bylaws, the presence, in person or by proxy, at
a shareholders meeting of the holders of shares of outstanding capital stock of the Corporation representing a majority of the voting
power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting and not less than one-third of the
outstanding shares of the Corporation entitled to vote at such meeting shall constitute a quorum for the transaction of business at such
meeting, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of shares
representing a majority of the voting power of the outstanding shares of such class or series entitled to vote at such meeting and not
less than one-third of the outstanding shares of such class or series entitled to vote at such meeting shall constitute a quorum of such
class or series for the transaction of such business. If a quorum shall not be present or represented by proxy at any meeting of the shareholders
of the Corporation, the chair of the meeting may adjourn the meeting from time to time in the manner provided in <U>Section&nbsp;2.7</U>
of these Bylaws until a quorum shall attend in person or be represented by proxy. The shareholders present at a duly convened meeting
may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.
Shares of its own stock belonging to the Corporation or to another corporation, if a majority of the voting power of the shares entitled
to vote in the election of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled
to vote nor be counted for quorum purposes; <U>provided</U>, <U>however</U>, that the foregoing shall not limit the right of the Corporation
or any such other corporation to vote shares held by it in a fiduciary capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Voting
of Shares</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Voting
Lists</U>. The Corporation shall prepare, no later than the eleventh (11th) day before each meeting of shareholders, a complete list of
the shareholders entitled to vote at the meeting (<U>provided</U>, <U>however</U>, that if the record date for determining the shareholders
entitled to vote is less than eleven (11) days before the date of the meeting, the list shall reflect the shareholders entitled to vote
as of the eleventh (11th) day before the meeting date), arranged in alphabetical order, and showing the address of each shareholder, the
number and class or series of shares registered in the name of each shareholder and the number of votes to which each shareholder is entitled.
The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Subject
to the last sentence of this <U>Section&nbsp;2.6(a)</U>, such list shall be open to the examination of any shareholder, for any purpose
germane to the meeting for a period of at least ten (10)&nbsp;days before the meeting date: (i)&nbsp;on a reasonably accessible electronic
network, <U>provided</U> that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;during
ordinary business hours, at the Corporation&rsquo;s principal executive office. In the event that the Corporation determines to make the
list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to
shareholders of the Corporation. Such list shall presumptively determine the identity of the shareholders entitled to vote at the meeting
and the number and class or series of shares held by each of them. Failure to comply with the foregoing requirements of this <U>Section&nbsp;2.6(a)</U>&nbsp;shall
not affect the validity of any action taken at a meeting of the shareholders of the Corporation. Except as otherwise provided by law,
the stock ledger shall be the only evidence as to who are the shareholders entitled to examine the list of shareholders required by this
<U>Section&nbsp;2.6(a)</U>&nbsp;or to vote in person or by proxy at any meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Manner
of Voting</U>. At any shareholders meeting, every shareholder entitled to vote may vote in person or by proxy. If authorized by the Board,
the voting by shareholders or proxy holders at any meeting conducted by remote communication may be effected by a ballot submitted by
electronic transmission (as defined in <U>Section&nbsp;9.3</U> of these Bylaws), <U>provided</U> that any such electronic transmission
must either set forth or be submitted with information from which the Corporation can determine that the electronic transmission was authorized
by the shareholder or proxy holder. The Board, in its discretion, or the chair of the meeting of shareholders, in such person&rsquo;s
discretion, may require that any votes cast at such meeting shall be cast by written ballot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Proxies</U>.
Each shareholder entitled to vote at a meeting of shareholders may authorize another person or persons to act for such shareholder by
proxy authorized by an instrument in writing or by a transmission permitted by law, including Rule&nbsp;14a-19 promulgated under the Securities
Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), filed in accordance with the procedure established for
the meeting, <U>provided</U> that no such proxy shall be valid after eleven (11) months after the date of its execution, unless the proxy
provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions
of Section&nbsp;21.369 of the TBOC. A proxy may be in the form of an electronic transmission that sets forth or is submitted with information
from which it can be determined that the transmission was authorized by the shareholder. Any shareholder directly or indirectly soliciting
proxies from other shareholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Required
Vote</U>. Subject to the rights of the holders of any series of Preferred Stock, voting separately by class or series, to elect directors
pursuant to the terms of any series of Preferred Stock, at all meetings of shareholders at which a quorum is present, the election of
directors shall be determined by a plurality of the votes cast by the shareholders present in person or represented by proxy at the meeting
and entitled to vote thereon. All other matters presented to the shareholders at a meeting at which a quorum is present shall be determined
by the vote of a majority of the votes cast for or against by the shareholders present in person or represented by proxy at the meeting
and entitled to vote thereon, unless the matter is one upon which, by a provision of applicable law, the Certificate of Formation, these
Bylaws or applicable stock exchange rules, a different vote is required, in which case such provision shall govern and control the decision
of such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Inspectors
of Election</U>. The Board may, and shall if required by law, in advance of any meeting of shareholders, appoint one or more persons as
inspectors of election, who may be employees of the Corporation or otherwise serve the Corporation in other capacities, to act at such
meeting of shareholders or any adjournment thereof and to make a written report thereof. The Board may appoint one or more persons as
alternate inspectors to replace any inspector who fails to act. If no inspectors of election or alternates are appointed by the Board,
the chair of the meeting may appoint one or more inspectors to act at the meeting. If applicable, each inspector, before discharging his
or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the
best of his or her ability. If applicable, the inspectors shall ascertain and report the number of outstanding shares and the voting power
of each; determine the number of shares present in person or represented by proxy at the meeting and the validity of proxies and ballots;
count all votes and ballots and report the results; determine and retain for a reasonable period a record of the disposition of any challenges
made to any determination by the inspectors; and certify their determination of the number of shares represented at the meeting and their
count of all votes and ballots. No person who is a candidate for an office at an election may serve as an inspector at such election.
Any report of an inspector shall be in writing and signed by the inspector or by a majority of them if there is more than one inspector
acting at such meeting. If there is more than one inspector, the report of a majority shall be the report of the inspectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Adjournments</B>.
Any meeting of shareholders, annual or special, may be adjourned by the chair of the meeting, from time to time, whether or not there
is a quorum, to reconvene at the same or some other place. Unless these Bylaws otherwise require, notice need not be given of any such
adjourned meeting if the date, time, and place, if any, thereof, and the means of remote communication, if any, by which shareholders
and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment
is taken. At the adjourned meeting the shareholders, or the holders of any class or series of stock entitled to vote separately as a class,
as the case may be, may transact any business that might have been transacted at the original meeting. If the adjournment is for more
than thirty (30) days, notice of the adjourned meeting shall be given to each shareholder of record entitled to vote at the meeting. If
after the adjournment a new record date for shareholders entitled to vote is fixed for the adjourned meeting, the Board shall fix a new
record date for notice of such adjourned meeting in accordance with <U>Section&nbsp;9.2</U> of these Bylaws, and shall give notice of
the adjourned meeting to each shareholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice
of such adjourned meeting. To the extent permitted by the TBOC, shareholders shall not be entitled to adjourn a meeting of shareholders,
whether or not a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Advance
Notice for Business</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Annual
Meetings of Shareholders</U>. No business may be transacted at an annual meeting of shareholders, other than business that is either (i)&nbsp;specified
in the Corporation&rsquo;s notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii)&nbsp;otherwise
properly brought before the annual meeting by or at the direction of the Board or (iii)&nbsp;otherwise properly brought before the annual
meeting by any shareholder of the Corporation (x)&nbsp;who is a shareholder of record entitled to vote at such annual meeting on the date
of the giving of the notice provided for in this <U>Section&nbsp;2.8(a),</U> on the record date for the determination of shareholders
entitled to vote at such annual meeting and on the date of the annual meeting and (y)&nbsp;who complies with the notice procedures set
forth in this <U>Section&nbsp;2.8(a)</U>. Notwithstanding anything in this <U>Section&nbsp;2.8(a)</U>&nbsp;to the contrary, only persons
nominated for election as a director to fill any term of a directorship that expires on the date of the annual meeting pursuant to <U>Section&nbsp;3.4</U>
of these Bylaws will be considered for election at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to any other applicable requirements, for business (other than director nominations) to be properly brought before an annual
meeting by a shareholder, such shareholder must have given timely notice thereof in proper written form to the Secretary and such business
must otherwise be a proper matter for shareholder action. Subject to <U>Section&nbsp;2.8(a)(iii)</U>&nbsp;of these Bylaws , a shareholder&rsquo;s
notice to the Secretary with respect to such business, to be timely, must be received by the Secretary at the principal executive office
of the Corporation not earlier than the close of business on the one hundred twentieth (120th) day nor later than the close of business
on the ninetieth (90th) day before the anniversary date of the immediately preceding annual meeting of shareholders; <U>provided</U>,
<U>however</U>, that in the event that the annual meeting is more than thirty (30) days before or more than sixty (60) days after such
anniversary date (or if there has been no prior annual meeting), notice by the shareholder to be timely must be so delivered not earlier
than the close of business on the one hundred twentieth (120th) day before the meeting and not later than the later of (x)&nbsp;the close
of business on the ninetieth (90th) day before the meeting and (y)&nbsp;the close of business on the tenth (10th) day following the day
on which public announcement of the date of the annual meeting is first made by the Corporation. The public announcement of an adjournment,
recess, rescheduling or postponement of an annual meeting shall not commence a new time period (or extend any time period) for the giving
of a shareholder&rsquo;s notice as described in this <U>Section&nbsp;2.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
be in proper written form, a shareholder&rsquo;s notice to the Secretary with respect to any business (other than director nominations)
to bring before any annual meeting of shareholders must set forth as to each such matter such shareholder proposes to bring before the
annual meeting (A)&nbsp;a brief description of the business desired to be brought before the annual meeting, the text of the proposal
or business (including the text of any resolutions proposed for consideration and in the event such business includes a proposal to amend
these Bylaws, the language of the proposed amendment) and the reasons for conducting such business at the annual meeting, (B)&nbsp;the
name and record address of such shareholder and the name and address of the beneficial owner, if any, on whose behalf the proposal is
made, (C)&nbsp;the class or series and number of shares of capital stock of the Corporation that are owned beneficially and of record
by such shareholder and by the beneficial owner, if any, on whose behalf the proposal is made, (D)&nbsp;a description of all agreements,
arrangements or understandings (whether written or oral) between or among such shareholder and the beneficial owner, if any, on whose
behalf the proposal is made and any other person or persons (including their names and addresses) in connection with the proposal of such
business by such shareholder, (E)&nbsp;any material interest, direct or indirect, of such shareholder and the beneficial owner, if any,
on whose behalf the proposal is made in such business, other than an interest arising from the ownership of Corporation securities where
such shareholder or such beneficial owner receives no extra or special benefit not shared on a <I>pro rata</I> basis by all other holders
of the same class or series, and (F)&nbsp;a representation that such shareholder (or a qualified representative of such shareholder) intends
to appear in person or by proxy at the annual meeting to bring such business before the meeting. As to the shareholder giving the notice
and each beneficial owner, if any, on whose behalf the proposal is made (including any Affiliate or Associate (as defined below)), such
shareholder&rsquo;s notice must set forth: (I)&nbsp;the name and address of the shareholder proposing such business as they appear on
the Corporation&rsquo;s books as of the date of the notice and the name and address of such beneficial owner, if any; (II)&nbsp;the class
or series and number of shares of the Corporation that are, directly or indirectly, owned beneficially or of record (within the meaning
of Rule&nbsp;13d-3 under the Exchange Act) by such shareholder and such beneficial owner, if any (except that any such person shall in
all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such person has a right to acquire
beneficial ownership at any time in the future); (III)&nbsp;a description of any agreement, arrangement, understanding, or relationship
with respect to the proposal between or among such shareholder or such beneficial owner and any of their respective Affiliates or Associates;
(IV)&nbsp;a description of any proxy, contract, agreement, arrangement, understanding, or relationship pursuant to which such shareholder
and such beneficial owner, if any, has a right to vote any shares of any security of the Corporation; (V)&nbsp;a description of any agreement,
arrangement, understanding, or relationship (including any hedging transactions and any derivative or short positions, profit interests,
options, warrants, convertible securities, stock appreciation or similar rights, and borrowed or loaned shares (a &ldquo;<B><I>Derivative
Instrument</I></B>&rdquo;)) directly or indirectly owned beneficially by such shareholder and such beneficial owner, if any, whether or
not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the effect or intent
of which is to mitigate loss to, manage risk, or benefit from share price changes for, or increase or decrease the voting power of, such
shareholder or such beneficial owner, with respect to securities of the Corporation; (VI)&nbsp;any proportionate interest in shares of
the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such shareholder
or beneficial owner, if any, is a general partner or, directly or indirectly, beneficially owns an interest in a general partner; (VII)&nbsp;any
performance-related fees (other than an asset-based fee) that such shareholder or beneficial owner, if any, is entitled to based on any
increase or decrease in the value of shares of the Corporation or Derivative Instruments, if any, as of the date of such notice, including,
without limitation, any such interests held by members of such shareholder&rsquo;s or beneficial owner&rsquo;s immediate family sharing
the same household; (VIII)&nbsp;any rights to distributions or dividends on the shares of the Corporation owned beneficially by such shareholder
or beneficial owner, if any, that are separated or separable from the underlying shares of the Corporation; (IX)&nbsp;a representation
as to whether such shareholder or such beneficial owner, if any, intends or is part of a group that intends to (1)&nbsp;deliver a proxy
statement and form of proxy to the Corporation&rsquo;s shareholders or (2)&nbsp;otherwise solicit proxies or votes from shareholders in
support of such proposal; and (X)&nbsp;any other information relating to such shareholder and such beneficial owner, if any, required
to be disclosed in a proxy statement required to be made in connection with a contested solicitation of proxies for the proposal pursuant
to and in accordance with Section&nbsp;14 of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes
of these Bylaws, the term &ldquo;<B><I>Associates</I></B>&rdquo; shall have the meaning given in Rule&nbsp;12b-2 under the Exchange Act.
A shareholder providing notice of any business proposed to be brought before a meeting shall further update and supplement such notice,
if necessary, so that the information provided or required to be provided in such notice pursuant to this <U>Section&nbsp;2.8</U> shall
be true and correct in all material respects as of the record date for the meeting and as of the date that is ten (10)&nbsp;Business Days
prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof. Such update and supplement shall be delivered
to, or mailed and received by, the Secretary at the principal executive office of the Corporation (i)&nbsp;not later than five (5)&nbsp;Business
Days after the record date for the meeting (in the case of the update and supplement required to be made as of the record date), and (ii)&nbsp;not
later than seven (7)&nbsp;Business Days prior to the date for the meeting or any adjournment, recess, rescheduling, or postponement thereof
(in the case of the update and supplement required to be made as of ten (10)&nbsp;Business Days prior to the meeting or any adjournment,
recess, rescheduling, or postponement thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
foregoing notice requirements of this <U>Section&nbsp;2.8(a)</U>&nbsp;shall be deemed satisfied by a shareholder as to any proposal (other
than nominations) if the shareholder has notified the Corporation of such shareholder&rsquo;s intention to present such proposal at an
annual meeting in compliance with Rule&nbsp;14a-8 (or any successor thereof) of the Exchange Act, and such shareholder has complied with
the requirements of such Rule&nbsp;for inclusion of such proposal in a proxy statement prepared by the Corporation to solicit proxies
for such annual meeting. If the Board or the chair of the annual meeting determines that any shareholder proposal was not made in accordance
with the provisions of this <U>Section&nbsp;2.8(a)</U>&nbsp;or that the information provided in a shareholder&rsquo;s notice does not
satisfy the information requirements of this <U>Section&nbsp;2.8(a)</U>, such proposal shall not be presented for action at the annual
meeting. Further, the Board may, in its discretion, exclude from any proxy materials sent to shareholders any matters that may properly
be excluded under the Exchange Act, Securities and Exchange Commission rules, or other applicable laws. Notwithstanding the foregoing
provisions of this <U>Section&nbsp;2.8(a)</U>, if the shareholder (or a qualified representative of the shareholder) does not appear at
the annual meeting of shareholders of the Corporation to present the proposed business, such proposed business shall not be transacted,
notwithstanding that proxies in respect of such matter may have been received by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to the provisions of this <U>Section&nbsp;2.8(a)</U>, a shareholder shall also comply with all applicable requirements of the
Exchange Act and the rules&nbsp;and regulations thereunder with respect to the matters set forth herein. Nothing in this <U>Section&nbsp;2.8(a)</U>&nbsp;shall
be deemed to affect any rights of shareholders to request inclusion of proposals in the Corporation&rsquo;s proxy statement pursuant to
Rule&nbsp;14a-8 under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Special
Meetings of Shareholders</U>. Other than procedural matters, only such business shall be conducted at a special meeting of shareholders
as shall have been brought before the meeting pursuant to the Corporation&rsquo;s notice of meeting. Nominations of persons for election
to the Board may be made at a special meeting of shareholders at which directors are to be elected pursuant to the Corporation&rsquo;s
notice of meeting only pursuant to <U>Section&nbsp;3.4</U> of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Public
Announcement</U>. For purposes of these Bylaws, &ldquo;<B><I>public announcement</I></B>&rdquo; shall mean disclosure in a press release
reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed or furnished
by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d)&nbsp;of the Exchange Act (or any successor
thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Conduct
of Meetings</B>. The chair of each annual and special meeting of shareholders shall be the Chair of the Board or, in the absence (or inability
or refusal to act) of the Chair of the Board, such other person as shall be appointed by the Board. The date and time of the opening and
the closing of the polls for each matter upon which the shareholders will vote at a meeting shall be determined and announced at the meeting
by the chair of the meeting, and after the polls close, no ballots, proxies or votes or any revocations or changes thereto may be accepted.
The Board may adopt by resolution such rules&nbsp;and regulations for the conduct of the meeting of shareholders as it shall deem appropriate.
Except to the extent inconsistent with these Bylaws or such rules&nbsp;and regulations as adopted by the Board, the chair of any meeting
of shareholders shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe
such rules, regulations and procedures and to do all such acts as, in the judgment of such chair, are appropriate for the proper conduct
of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the chair of the meeting, may include,
without limitation, the following: (a)&nbsp;the establishment of an agenda or order of business for the meeting; (b)&nbsp;rules&nbsp;and
procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules&nbsp;and procedures
regarding the manner of voting, conduct of discussion or removal of disruptive persons from the meeting); (c)&nbsp;limitations on attendance
at or participation in the meeting to shareholders of record of the Corporation, their duly authorized and constituted proxies or such
other persons as the chair of the meeting shall determine; (d)&nbsp;restrictions on entry to the meeting after the time fixed for the
commencement thereof; (e)&nbsp;limitations on the time allotted to questions or comments by participants or to the number of questions
or comments by an individual participant; and (f)&nbsp;restrictions on the use of cellphones, audio or video recording devices or other
electronic devices at the meeting. Unless and to the extent determined by the Board or the chair of the meeting, meetings of shareholders
shall not be required to be held in accordance with the rules&nbsp;of parliamentary procedure. The chair of the meeting may, if the facts
warrant, determine and declare to the meeting that a matter, nomination or other business was not properly brought before the meeting.
If the chair of the meeting should so determine, the chair of the meeting shall so declare to the meeting, and any such matter, nomination
or other business declared not to be properly brought before the meeting shall not be transacted or considered. The secretary of each
annual and special meeting of shareholders shall be the Secretary or, in the absence (or inability or refusal to act) of the Secretary,
an Assistant Secretary. In the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chair of the
meeting may appoint any person to act as secretary of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;III</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Powers.
</B></FONT>The business and affairs of the Corporation shall be managed by or under the direction of the Board, subject to any limitation
imposed by applicable law, the Certificate of Formation, or these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Number
of Directors</B>. Subject to the Certificate of Formation, the total number of directors constituting the Board shall be determined from
time to time by resolution of the Board. No reduction of the authorized number of directors shall have the effect of removing any director
before that director&rsquo;s term of office expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Chair
and Vice Chair of the Board</B>. The Chair of the Board, if any, will preside at all meetings of the Board and of the shareholders at
which the Chair will be present. The Chair of the Board will have and may exercise such powers as are, from time to time, assigned to
the Chair by the Board and as may be provided by law. . The Vice Chair of the Board, if any, will have and may exercise such powers as
are, from time to time, assigned to such person by the Board and as may be provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Advance
Notice for Nomination of Directors</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Only
persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation,
except as may be otherwise provided by the terms of one or more series of Preferred Stock with respect to the rights of holders of one
or more series of Preferred Stock to elect directors. Nominations of persons for election to the Board at any annual meeting of shareholders,
or at any special meeting of shareholders called for the purpose of electing directors as set forth in the Corporation&rsquo;s notice
of such special meeting, may be made (i)&nbsp;by or at the direction of the Board or (ii)&nbsp;by any shareholder of the Corporation (x)&nbsp;who
is a shareholder of record entitled to vote in the election of directors on the date of the giving of the notice provided for in this
<U>Section&nbsp;3.4</U>, on the record date for the determination of shareholders entitled to vote at such meeting and at the time of
such meeting and (y)&nbsp;who complies with the notice procedures and other requirements set forth in this <U>Section&nbsp;3.4</U> and
with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to any other applicable requirements, for a nomination to be made by a shareholder, such shareholder must have given timely notice
thereof in proper written form to the Secretary. To be timely, a shareholder&rsquo;s notice to the Secretary must be received by the Secretary
at the principal executive office of the Corporation (i)&nbsp;in the case of an annual meeting, not earlier than the close of business
on the one hundred twentieth (120th) day nor later than the close of business on the ninetieth (90th) day before the anniversary date
of the immediately preceding annual meeting of shareholders; <U>provided</U>, <U>however</U>, that in the event that the annual meeting
is more than thirty (30) days before or more than sixty (60) days after such anniversary date (or if there has been no prior annual meeting),
notice by the shareholder to be timely must be so received not earlier than the close of business on the one hundred twentieth (120th)
day before the meeting and not later than the later of (x)&nbsp;the close of business on the ninetieth (90th) day before the meeting and
(y)&nbsp;the close of business on the tenth (10th) day following the day on which public announcement of the date of the annual meeting
was first made by the Corporation; and (ii)&nbsp;in the case of a special meeting of shareholders called for the purpose of electing directors,
not later than the close of business on the tenth (10th) day following the day on which public announcement of the date of the special
meeting is first made by the Corporation. In no event shall the public announcement of an adjournment, recess, rescheduling or postponement
of an annual meeting or special meeting commence a new time period (or extend any time period) for the giving of a shareholder&rsquo;s
notice as described in this <U>Section&nbsp;3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything in paragraph (b)&nbsp;to the contrary, in the event that the number of directors to be elected to the Board at an annual meeting
is greater than the number of directors whose terms expire on the date of the annual meeting and there is no public announcement by the
Corporation naming all of the nominees for the additional directors to be elected or specifying the size of the increased Board before
the close of business on the ninetieth (90th) day prior to the anniversary date of the immediately preceding annual meeting of shareholders,
a shareholder&rsquo;s notice required by this <U>Section&nbsp;3.4</U> shall also be considered timely, but only with respect to nominees
for the additional directorships created by such increase that are to be filled by election at such annual meeting, if it shall be received
by the Secretary at the principal executive office of the Corporation not later than the close of business on the tenth (10th) day following
the date on which such public announcement was first made by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
be in proper written form, a shareholder&rsquo;s notice to the Secretary must (i)&nbsp;set forth as to each person whom the shareholder
proposes to nominate for election as a director (A)&nbsp;the name, age, business address and residence address of the person, (B)&nbsp;the
principal occupation or employment of the person, (C)&nbsp;the class or series and number of shares of capital stock of the Corporation
that are owned beneficially or of record by the person, (D)&nbsp;any other information relating to the person that would be required to
be disclosed in a proxy statement required to be made in connection with solicitations of proxies in an election contest pursuant to Section&nbsp;14
of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder and (E)&nbsp;a complete and accurate description of all
direct and indirect compensation and other material monetary agreements, arrangements, and understandings (whether written or oral) during
the past three (3)&nbsp;years, and any other material relationships between or among such shareholder and beneficial owner, if any, and
their respective Affiliates and Associates, on the one hand, and each proposed nominee, and his or her respective Affiliates and Associates,
on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Rule&nbsp;404 promulgated
under Regulation S-K of the Securities Act of 1933 if the shareholder making the nomination and any beneficial owner on whose behalf the
nomination is made, if any, or any Affiliate or Associate thereof, were the &ldquo;registrant&rdquo; for purposes of such rule&nbsp;and
the nominee were a director or executive officer of such registrant; and (ii)&nbsp;be accompanied by (A)&nbsp;a written consent of each
proposed nominee to being named as a nominee and to serve as a director if elected and (B)&nbsp;a completed signed questionnaire and written
representation and agreement, as required by <U>Section&nbsp;3.4(h)</U>&nbsp;of these Bylaws. The Corporation may require any proposed
nominee to furnish such other information as the Corporation may reasonably require to determine the eligibility of such proposed nominee
to serve as a director of the Corporation and that the Corporation believes could be material to a reasonable shareholder&rsquo;s understanding
of the independence (both from management and from the shareholder and beneficial owner, if any) and qualifications of such proposed nominee.
As to the shareholder giving the notice and each beneficial owner, if any, on whose behalf the nomination is made (including any Affiliate
or Associate), such shareholder&rsquo;s notice must set forth: (I)&nbsp;the information required by Section&nbsp;<U>2.8(a)(ii)(I)</U>&nbsp;through
<U>(II)</U>&nbsp;and <U>(IV</U>)&nbsp;through <U>(VIII)&nbsp;</U>of these Bylaws, (II)&nbsp;a description of all arrangements or understandings
relating to the nomination to be made by such shareholder among such shareholder, the beneficial owner, if any, on whose behalf the nomination
is made, and any of their respective Affiliates or Associates, each proposed nominee and any other person or persons (including their
names), (III)&nbsp;a representation that such shareholder (or a qualified representative of such shareholder) intends to appear in person
or by proxy at the meeting to nominate the persons named in its notice and a representation that such beneficial owner, if any, is the
beneficial owner of stock of the Corporation and (IV)&nbsp;any other information relating to such shareholder and the beneficial owner,
if any, on whose behalf the nomination is made that would be required to be disclosed in a proxy statement required to be made in connection
with solicitations of proxies in an election contest pursuant to Section&nbsp;14 of the Exchange Act and the rules&nbsp;and regulations
promulgated thereunder. A shareholder providing notice of any nomination proposed to be brought before a meeting shall further update
and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this
<U>Section&nbsp;3.4(d)</U>&nbsp;shall be true and correct in all material respects as of the record date for the meeting and as of the
date that is ten (10)&nbsp;Business Days prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof. Such
update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive office of the Corporation
(i)&nbsp;not later than five (5)&nbsp;Business Days after the record date for the meeting (in the case of the update and supplement required
to be made as of the record date) and (ii)&nbsp;not later than seven (7)&nbsp;Business Days prior to the date for the meeting or any adjournment,
recess, rescheduling, or postponement thereof (in the case of the update and supplement required to be made as of ten (10)&nbsp;Business
Days prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Board or the chair of the meeting of shareholders determines that any nomination was not made in accordance with the provisions of
this <U>Section&nbsp;3.4</U>, or that the information provided in a shareholder&rsquo;s notice does not satisfy the information requirements
of this <U>Section&nbsp;3.4</U>, then such nomination shall not be considered at the meeting in question. Notwithstanding the foregoing
provisions of this <U>Section&nbsp;3.4</U>, if the shareholder (or a qualified representative of the shareholder) does not appear at the
meeting of shareholders of the Corporation to present the nomination, such nomination shall be disregarded, notwithstanding that proxies
in respect of such nomination may have been received by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to the provisions of this <U>Section&nbsp;3.4</U>, a shareholder shall also comply with all of the applicable requirements of
state law and of the Exchange Act and the rules&nbsp;and regulations thereunder related to the submission of director nominations and
related solicitation of proxies. Nothing in this <U>Section&nbsp;3.4</U> shall be deemed to affect any rights of the holders of Preferred
Stock to elect directors pursuant to the Certificate of Formation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;These
Bylaws shall not be deemed to require inclusion in the Corporation&rsquo;s proxy statement of nominations or proposals of shareholders
which the Corporation is not otherwise required to include in its proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
be eligible to be a nominee for election or reelection as a director of the Corporation pursuant to this <U>Section&nbsp;3.4</U>, a proposed
nominee must deliver (in accordance with the time periods prescribed for delivery of notice under these Bylaws and applicable law) to
the Secretary at the principal executive office of the Corporation (i)&nbsp;a written questionnaire (in the form provided by the Secretary
upon written request by a stockholder of record) with respect to the background and qualification of such person and the background of
any other person or entity on whose behalf the nomination is being made and (ii)&nbsp;a written representation and agreement (in the form
provided by the Secretary upon written request by a stockholder of record) that such person (A)&nbsp;is not and will not become a party
to (I)&nbsp;any agreement, arrangement, or understanding (whether written or oral) with, and has not given any commitment or assurance
to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote in such capacity on any
issue or question (a &ldquo;<B><I>Voting Commitment</I></B>&rdquo;) that has not been disclosed to the Corporation or (II)&nbsp;any Voting
Commitment that could limit or interfere with such person&rsquo;s ability to comply, if elected as a director of the Corporation, with
such person&rsquo;s fiduciary duties under applicable law; (B)&nbsp;is not and will not become a party to any agreement, arrangement,
or understanding (whether written or oral) with any person or entity other than the Corporation with respect to any direct or indirect
compensation, reimbursement, or indemnification in connection with such person&rsquo;s nomination, candidacy, service, or action as a
director of the Corporation that has not been disclosed to the Corporation; and (C)&nbsp;would be in compliance, if elected as a director
of the Corporation, and will comply with all applicable law, applicable stock exchange rules, the Corporation&rsquo;s Code of Business
Conduct and Ethics, and any other policies and guidelines of the Corporation applicable to members of the Board and any applicable Board
committee(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything herein to the contrary, if (A)&nbsp;any shareholder providing notice pursuant to this <U>Section&nbsp;3.4</U> or each beneficial
owner, if any, on whose behalf the nomination is made (including any Affiliate or Associate) provides notice pursuant to Rule&nbsp;14a-19(b)&nbsp;under
the Exchange Act with respect to any proposed nominee and (B)&nbsp;(I)&nbsp;such person subsequently either (1)&nbsp;notifies the Corporation
that such person no longer intends to solicit proxies in support of the election or reelection of such proposed nominee in accordance
with Rule&nbsp;14a-19(b)&nbsp;under the Exchange Act or (2)&nbsp;fails to comply with the requirements of Rule&nbsp;14a-19(a)(2)&nbsp;or
Rule&nbsp;14a-19(a)(3)&nbsp;under the Exchange Act (or fails to timely provide reasonable evidence sufficient to satisfy the Corporation
that such person has met the requirements of Rule&nbsp;14a-19(a)(3)&nbsp;under the Exchange Act in accordance with the following sentence)
and (II)&nbsp;no other shareholder that has provided notice pursuant to this <U>Section&nbsp;3.4</U> or any beneficial owner, if any,
on whose behalf the nomination was made (including any Affiliate or Associate) has provided notice pursuant to Rule&nbsp;14a-19(b)&nbsp;under
the Exchange Act with respect to such proposed nominee (x)&nbsp;to the Corporation&rsquo;s knowledge based on information provided pursuant
to Rule&nbsp;14a-19 under the Exchange Act or these Bylaws, still intends to solicit proxies in support of the election or reelection
of such proposed nominee in accordance with Rule&nbsp;14a-19(b)&nbsp;under the Exchange Act and (y)&nbsp;has complied with the requirements
of Rule&nbsp;14a-19(a)(2)&nbsp;and Rule&nbsp;14a-19(a)(3)&nbsp;under the Exchange Act and the requirements set forth in the following
sentence, then the nomination of such proposed nominee shall be disregarded and no vote on the election of such proposed nominee shall
occur (notwithstanding that proxies in respect of such vote may have been received by the Corporation). Upon request by the Corporation,
if any shareholder providing notice pursuant to this <U>Section&nbsp;3.4</U> or each beneficial owner, if any, on whose behalf the nomination
is made (including any Affiliate or Associate) provides notice pursuant to Rule&nbsp;14a-19(b)&nbsp;under the Exchange Act, such person
shall deliver to the Secretary, no later than five (5)&nbsp;Business Days prior to the applicable meeting date, reasonable evidence that
the requirements of Rule&nbsp;14a-19(a)(3)&nbsp;under the Exchange Act have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Compensation</B>.
Unless otherwise restricted by the Certificate of Formation or these Bylaws, the Board shall have the authority to fix the compensation
of directors, including for service on a committee of the Board, and may be paid either a fixed sum for attendance at each meeting of
the Board or other compensation as director. The directors may be reimbursed their expenses, if any, for attendance at each meeting of
the Board. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor.
Members or chairs of committees of the Board may be allowed reimbursement of expenses and additional compensation for service on or chairing
the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;IV</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>BOARD MEETINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Regular
Meetings</B>. Regularly scheduled, periodic meetings of the Board may be held without notice at such times, dates and places (within or
without the State of Texas) as shall from time to time be determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Special
Meetings</B>. Special meetings of the Board (a)&nbsp;may be called by the Chair of the Board and (b)&nbsp;shall be called by the Chair
of the Board or Secretary on the written request of at least a majority of directors then in office, or the sole director, as the case
may be, and shall be held at such time, date and place (within or without the State of Texas) as may be determined by the person calling
the meeting or, if called upon the request of directors or the sole director, as specified in such written request. Notice of each special
meeting of the Board shall be given, as provided in <U>Section&nbsp;9.3</U> of these Bylaws, to each director (i)&nbsp;at least twenty
four (24) hours before the meeting if such notice is oral notice given personally or by telephone or written notice given by hand delivery
or by means of a form of electronic transmission and delivery; (ii)&nbsp;at least two (2)&nbsp;days before the meeting if such notice
is sent by a nationally recognized overnight delivery service; and (iii)&nbsp;at least five (5)&nbsp;days before the meeting if such notice
is sent through the United States mail. If the Secretary shall fail or refuse to give such notice, then the notice may be given by the
officer who called the meeting or the directors who requested the meeting. Any and all business that may be transacted at a regular meeting
of the Board may be transacted at a special meeting. Except as may be otherwise expressly provided by applicable law, the Certificate
of Formation, or these Bylaws, neither the business to be transacted at, nor the purpose of, any special meeting need be specified in
the notice or waiver of notice of such meeting. A special meeting may be held at any time without notice if all the directors are present
or if those not present waive notice of the meeting in accordance with <U>Section&nbsp;9.4</U> of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Quorum;
Required Vote</B>. A majority of the Board shall constitute a quorum for the transaction of business at any meeting of the Board, and
the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board, except as may
be otherwise specifically provided by applicable law, the Certificate of Formation or these Bylaws. If a quorum shall not be present at
any meeting, a majority of the directors present may adjourn the meeting from time to time, without notice other than announcement at
the meeting, until a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Consent
In Lieu of Meeting</B>. Unless otherwise restricted by the Certificate of Formation or these Bylaws, any action required or permitted
to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if all members of the Board or committee,
as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or
transmissions (or paper reproductions thereof) are filed with the minutes of proceedings of the Board or committee. Such filing shall
be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic
form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Organization</B>.
The chair of each meeting of the Board shall be the Chair of the Board or, in the absence (or inability or refusal to act) of the Chair
of the Board, a chair elected from the directors present. The Secretary shall act as secretary of all meetings of the Board. In the absence
(or inability or refusal to act) of the Secretary, an Assistant Secretary shall perform the duties of the Secretary at such meeting. In
the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chair of the meeting may appoint any
person to act as secretary of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;V</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>COMMITTEES OF DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Establishment</B>.
The Board may by resolution designate one or more committees, each committee to consist of one or more of the directors of the Corporation.
Each committee shall keep regular minutes of its meetings and report the same to the Board when required by the resolution designating
such committee. The Board shall have the power at any time to fill vacancies in, to change the membership of, or to dissolve any such
committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Available
Powers</B>. Any committee established pursuant to <U>Section&nbsp;5.1</U> of these Bylaws, to the extent permitted by applicable law and
by resolution of the Board, shall have and may exercise all of the powers and authority of the Board in the management of the business
and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Alternate
Members</B>. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified
member at any meeting of such committee. In the absence or disqualification of a member of the committee, the member or members thereof
present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another
member of the Board to act at the meeting in place of any such absent or disqualified member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Procedures</B>.
Unless the Board otherwise provides, the time, date, place, if any, and notice of meetings of a committee shall be determined by such
committee. At meetings of a committee, a majority of the number of members of the committee (but not including any alternate member, unless
such alternate member has replaced any absent or disqualified member at the time of, or in connection with, such meeting) shall constitute
a quorum for the transaction of business. The act of a majority of the members present at any meeting at which a quorum is present shall
be the act of the committee, except as otherwise specifically provided by applicable law, the Certificate of Formation, these Bylaws or
the Board. If a quorum is not present at a meeting of a committee, the members present may adjourn the meeting from time to time, without
notice other than an announcement at the meeting, until a quorum is present. Unless the Board otherwise provides and except as provided
in these Bylaws, each committee designated by the Board may make, alter, amend and repeal rules&nbsp;for the conduct of its business.
In the absence of such rules&nbsp;each committee shall conduct its business in the same manner as the Board is authorized to conduct its
business pursuant to <U>Article&nbsp;III</U> and <U>Article&nbsp;IV</U> of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Subcommittees</B>.
Unless otherwise provided in the Certificate of Formation, these Bylaws or the resolutions of the Board designating the committee, a committee
may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee
any or all of the powers and authority of the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VI</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;6.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Officers</B>.
The officers of the Corporation elected by the Board shall be a Chief Executive Officer, a President, a Secretary and such other officers
(including without limitation, a Chair of the Board, a Vice Chair of the Board, Vice Presidents, Assistant Secretaries, a Treasurer and
Assistant Treasurers) as the Board from time to time may determine. Officers elected by the Board shall each have such powers and duties
as generally pertain to their respective offices, subject to the specific provisions of this <U>Article&nbsp;VI</U>. Such officers shall
also have such powers and duties as from time to time may be conferred by the Board. The Chief Executive Officer may also appoint such
other officers (including without limitation one or more Vice Presidents) as may be necessary or desirable for the conduct of the business
of the Corporation. Such other officers shall have such powers and duties and shall hold their offices for such terms as may be provided
in these Bylaws or as may be prescribed by the Board or, if such officer has been appointed by the Chief Executive Officer, as may be
prescribed by the Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Chief
Executive Officer</U>. The Chief Executive Officer will, subject to the control of the Board, have general and active management of the
business of the Corporation and will see that all orders and resolutions of the Board are carried into effect. All other officers, officials,
employees and agents will report directly or indirectly to the Chief Executive Officer. The Chief Executive Officer, President or any
Vice President will execute bonds, mortgages and other contracts on behalf of the Corporation, except where required or permitted by law
to be otherwise signed and executed and except where the signing and execution thereof will be expressly delegated by the Board to some
other officer or agent of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>President</U>.
In the absence or disability of the Chief Executive Officer, the President will perform all the duties of the Chief Executive Officer.
When acting as the Chief Executive Officer, the President will have all the powers of, and be subject to all the restrictions upon, the
Chief Executive Officer. The President will have, subject to the supervision, direction and control of the Board and the Chief Executive
Officer, the general powers and duties of supervision, direction and management of the affairs and business of the Corporation customarily
and usually associated with the position of President. The President will have such other powers and perform such other duties as from
time to time may be prescribed by the Board, these Bylaws, the Chief Executive Officer or the Chair.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vice
Presidents</U>. Each Vice President will perform other duties as the Board, the Chief Executive Officer or the President may assign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Secretary</U>.
The Secretary will attend all meetings of the Board and of the shareholders, and will record all votes and the minutes of all proceedings
and will perform like duties for the standing committees when required. The Secretary will give or cause to be given notice of all meetings
of the Board and of the shareholders, will have all such further powers and duties as are customarily and usually associated with the
position of Secretary, and will perform other duties as may be prescribed by the Board, the Chief Executive Officer or the President.
.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assistant
Secretaries</U>. Each Assistant Secretary may, in the absence or disability of the Secretary, or at his or her request or the request
of the Chief Executive Officer or the President, perform the duties and exercise the powers of the Secretary, and will perform other duties
as the Board, the Chief Executive Officer, the President, or the Secretary may assign. In the absence of the Secretary or an Assistant
Secretary, the minutes of all meetings of the Board and of the shareholders will be recorded by the person designated by the Chief Executive
Officer, the President or by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Treasurer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Treasurer will have the custody of the corporate funds and securities, will keep full and accurate accounts of receipts and disbursements
of the Corporation, will deposit all moneys and other valuable effects in the name and to the credit of the Corporation in the depositories
designated by the Board, and in general will have all such further powers and duties as are customarily and usually associated with the
position of Treasurer and such other duties as the Board, the Chief Executive Officer, or the President may assign from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Assistant Treasurer may, in the absence or disability of the Treasurer, or at his or her request or the request of the Chief Executive
Officer or the President, perform the duties and exercise the powers of the Treasurer, and will perform other duties as the Board, the
Chief Executive Officer, the President, or the Treasurer may assign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;6.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Removal;
Vacancies</B>. Any officer may be removed, with or without cause, at any time by the Board. Any officer appointed by the Chief Executive
Officer may also be removed, with or without cause, by the Chief Executive Officer unless the Board otherwise provides. Any vacancy occurring
in any elected office of the Corporation may be filled by the Board. Any vacancy occurring in any office appointed by the Chief Executive
Officer may be filled by the Chief Executive Officer unless the Board then determines that such office shall thereupon be elected by the
Board, in which case the Board shall elect such officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;6.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Multiple
Officeholders</B>. Any number of offices may be held by the same person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;6.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Representation
of Shares of Other Corporations.</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Chair of the Board, the Chief Executive Officer, or the President
of the Corporation, or any other person authorized by the Board, the Chief Executive Officer or the President, is authorized to vote,
represent and exercise on behalf of the Corporation all rights incident to any and all shares or voting securities of any other corporation
or other person standing in the name of the Corporation. The authority granted herein may be exercised either by such person directly
or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VII</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Uncertificated
Shares</B>. The shares of the Corporation will be uncertificated, <U>provided</U>, that any holder of uncertificated shares, upon written
request to the transfer agent or registrar of the Corporation, will be entitled to a certificate for shares of the Corporation so held
in which case the Corporation will issue a certificate for such shares to such holder. Any certificates representing shares of the Corporation
shall be in such form as shall be approved by the Board of Directors and will be signed by the Chief Executive Officer, the President
or a Vice President of the Corporation and either the Secretary or an Assistant Secretary of the Corporation. The signature of any such
officer on any such share certificate may be a facsimile. In case any officer who has signed or whose facsimile signature has been placed
on any such share certificate will have ceased to be such officer before such certificate is issued, it may be issued by the Corporation
with the same effect as if he or she were such officer at the date of its issuance. Within a reasonable time after the issuance or transfer
of uncertificated shares, the Corporation will send to the registered owner of the uncertificated shares a written notice that sets forth
all of the information required by Section&nbsp;3.205 of the TBOC. Except as otherwise expressly provided by law, the rights and obligations
of the holders of uncertificated shares and the rights and obligations of the holders of certificates representing shares, if any, of
the same class and series will be identical. No requirement of the TBOC with respect to matters to be set forth on certificates representing
shares of the Corporation will apply to or affect certificates outstanding when the requirement first becomes applicable to the certificates;
but the requirements will apply to all certificates thereafter issued whether in connection with an original issue of shares, a transfer
of shares, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Multiple
Classes and/or Series&nbsp;of Stock</B>. If the Corporation shall be authorized to issue more than one class of stock or more than one
series of any class of stock, the Corporation shall (a)&nbsp;cause the powers, designations, preferences and relative, participating,
optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights to be set forth in full or summarized on the face or back of any certificate that the Corporation issues to
represent shares of such class or series of stock or (b)&nbsp;in the case of uncertificated shares, within a reasonable time after the
issuance or transfer of such shares, send to the registered owner thereof a written notice containing the information required to be set
forth on certificates as specified in clause (a)&nbsp;above; <U>provided</U>, <U>however</U>, that, except as otherwise provided by applicable
law, in lieu of the foregoing requirements, there may be set forth on the face or back of such certificate or, in the case of uncertificated
shares, on such written notice a statement that the Corporation will furnish without charge to each shareholder who so requests the powers,
designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the
qualifications, limitations or restrictions of such preferences or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Signatures</B>.
Each certificate representing capital stock of the Corporation shall be signed by or in the name of the Corporation by (a)&nbsp;the Chair
of the Board, the Chief Executive Officer, the President or a Vice President and (b)&nbsp;the Treasurer, an Assistant Treasurer, the Secretary
or an Assistant Secretary of the Corporation. Any or all the signatures on the certificate may be a facsimile. In case any officer, transfer
agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer,
transfer agent or registrar before such certificate is issued, such certificate may be issued by the Corporation with the same effect
as if such person were such officer, transfer agent or registrar on the date of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Consideration
and Payment for Shares</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to applicable law and the Certificate of Formation, shares of stock may be issued for such consideration, having in the case of shares
with par value a value not less than the par value thereof, and to such persons, as determined from time to time by the Board. The consideration
may consist of any tangible or intangible property or any benefit to the Corporation including cash, promissory notes, services performed,
contracts for services to be performed, securities of the Corporation or any other organization or any other property of any kind or nature,
or any combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to applicable law and the Certificate of Formation, shares may not be issued until the full amount of the consideration has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Lost,
Destroyed or Wrongfully Taken Certificates</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
an owner of a certificate representing shares claims that such certificate has been lost, stolen or destroyed, the Corporation shall issue
a new certificate representing such shares or such shares in uncertificated form if the owner notifies the Corporation or its transfer
agent that such certificate has been lost, stolen or destroyed, provides an affidavit of that fact acceptable to the Corporation and executes
an agreement acceptable to the Corporation (and, if required by the Corporation, posts a bond in such amount as the Corporation may determine
is reasonably necessary) to indemnify the Corporation from any loss incurred by it in connection with such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a certificate representing shares has been lost, apparently destroyed or stolen, and the owner fails to notify the Corporation of that
fact within a reasonable time after the owner has notice of such loss, apparent destruction or stealing and the Corporation registers
a transfer of such shares before receiving notification, the owner shall be precluded from asserting against the Corporation any claim
for registering such transfer or a claim to a new certificate representing such shares or such shares in uncertificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Transfer
of Shares</B>. Shares of the Corporation will be transferable in the manner prescribed by law, in the Certificate of Formation, these
Bylaws or an agreement between the Corporation and one or more shareholders. Transfers of shares will be made on the books of the Corporation
only by the holder of record thereof or by such other person as may under law be authorized to endorse such shares for transfer or by
such shareholder&rsquo;s attorney lawfully constituted in writing. Except as otherwise provided by law, upon surrender to the Corporation
or its transfer agent of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment, or authority
to transfer, the Corporation will issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction
upon its books. No transfer of shares will be valid as against the Corporation for any purpose until it will have been entered in the
share transfer records of the Corporation by an entry showing from and to what person those shares were transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Registered
Shareholders</B>. Before due presentment for registration of transfer of a certificate representing shares of the Corporation or of an
instruction requesting registration of transfer of uncertificated shares, the Corporation may treat the registered owner as the person
exclusively entitled to inspect for any proper purpose the stock ledger and the other books and records of the Corporation, vote such
shares, receive distributions or dividends or notifications with respect to such shares and otherwise exercise all the rights and powers
of the owner of such shares, except that a person who is the beneficial owner of such shares (if held in a voting trust or by a nominee
on behalf of such person) may, upon providing documentary evidence of beneficial ownership of such shares and satisfying such other conditions
as are provided under applicable law, may also so inspect the books and records of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Regulations</B>.
The Board shall have power and authority to make such additional rules&nbsp;and regulations, subject to any applicable requirement of
law, as the Board may deem necessary and appropriate with respect to the issue, transfer or registration of transfer of shares of stock
or certificates representing shares. The Board may appoint one or more transfer agents or registrars and may require for the validity
thereof that certificates representing shares bear the signature of any transfer agent or registrar so appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VIII</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Right
to Indemnification</B>. To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended, the Corporation
shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is otherwise involved
in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter
a &ldquo;<B><I>proceeding</I></B>&rdquo;), by reason of the fact that he or she is or was a director or officer of the Corporation or,
while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or
agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect
to an employee benefit plan (hereinafter an &ldquo;<B><I>Indemnitee</I></B>&rdquo;), whether the basis of such proceeding is alleged action
in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee
or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys&rsquo; fees, judgments, fines,
ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such Indemnitee in connection with such proceeding;
<U>provided</U>, <U>however</U>, that, except as provided in <U>Section&nbsp;8.3</U> of these Bylaws with respect to proceedings to enforce
rights to indemnification, the Corporation shall indemnify an Indemnitee in connection with a proceeding (or part thereof) initiated by
such Indemnitee only if such proceeding (or part thereof) was authorized by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Right
to Advancement of Expenses</B>. In addition to the right to indemnification conferred in <U>Section&nbsp;8.1</U> of these Bylaws, an Indemnitee
shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including,
without limitation, attorneys&rsquo; fees) incurred in defending or otherwise participating in any such proceeding in advance of its final
disposition (hereinafter an &ldquo;<B><I>advancement of expenses</I></B>&rdquo;); <U>provided</U>, <U>however</U>, that, if the TBOC requires,
an advancement of expenses incurred by an Indemnitee in his or her capacity as a director or officer of the Corporation (and not in any
other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit plan)
shall be made only upon the Corporation&rsquo;s receipt of an undertaking (hereinafter an &ldquo;<B><I>undertaking</I></B>&rdquo;), by
or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined that such Indemnitee is not entitled
to be indemnified under this <U>Article&nbsp;VIII</U> or otherwise and a written affirmation by such Indemnitee of the Indemnitee&rsquo;s
good faith belief that such Indemnitee has met the standard of conduct necessary for indemnification under Chapter 8 of the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Right
of Indemnitee to Bring Suit</B>. If a claim under <U>Section&nbsp;8.1</U> or <U>Section&nbsp;8.2</U> of these Bylaws is not paid in full
by the Corporation within sixty (60) days after a written claim therefor has been received by the Corporation, except in the case of a
claim for an advancement of expenses, in which case the applicable period shall be twenty (20) days, the Indemnitee may at any time thereafter
bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in
a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall
also be entitled to be paid the expense of prosecuting or defending such suit. In (a)&nbsp;any suit brought by the Indemnitee to enforce
a right to indemnification hereunder (but not in a suit brought by an Indemnitee to enforce a right to an advancement of expenses) it
shall be a defense that, and (b)&nbsp;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the Corporation shall be entitled to recover such expenses upon a final judicial decision from which there is no further
right to appeal (hereinafter a &ldquo;<B><I>final adjudication</I></B>&rdquo;) that, the Indemnitee has not met any applicable standard
for indemnification set forth in the TBOC. Neither the failure of the Corporation (including its directors who are not parties to such
action, a committee of such directors, independent legal counsel, or its shareholders) to have made a determination prior to the commencement
of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard
of conduct set forth in the TBOC, nor an actual determination by the Corporation (including a determination by its directors who are not
parties to such action, a committee of such directors, independent legal counsel, or its shareholders) that the Indemnitee has not met
such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or,
in the case of such a suit brought by the Indemnitee, shall be a defense to such suit. In any suit brought by the Indemnitee to enforce
a right to indemnification or to an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant
to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of
expenses, under this <U>Article&nbsp;VIII</U> or otherwise shall be on the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Non-Exclusivity
of Rights</B>. The rights provided to any Indemnitee pursuant to this <U>Article&nbsp;VIII</U> shall not be exclusive of any other right,
which such Indemnitee may have or hereafter acquire under applicable law, the Certificate of Formation, these Bylaws, an agreement, a
vote of shareholders or disinterested directors, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Insurance</B>.
The Corporation may maintain insurance, at its expense, to protect itself and/or any director, officer, employee or agent of the Corporation
or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the
Corporation would have the power to indemnify such person against such expense, liability or loss under the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Indemnification
of Other Persons</B>. This <U>Article&nbsp;VIII</U> shall not limit the right of the Corporation to the extent and in the manner authorized
or permitted by law to indemnify and to advance expenses to persons other than Indemnitees. Without limiting the foregoing, the Corporation
may, to the extent authorized from time to time by the Board and to the extent permitted by the TBOC, grant rights to indemnification
and to the advancement of expenses to any employee or agent of the Corporation and to any other person who is or was serving at the request
of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other
enterprise, including service with respect to an employee benefit plan, to the fullest extent of the provisions of this <U>Article&nbsp;VIII</U>
with respect to the indemnification and advancement of expenses of Indemnitees under this <U>Article&nbsp;VIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Amendments</B>.
Any repeal or amendment of this <U>Article&nbsp;VIII</U> by the Board or the shareholders of the Corporation or by changes in applicable
law, or the adoption of any other provision of these Bylaws inconsistent with this <U>Article&nbsp;VIII</U>, will, to the extent permitted
by applicable law, be prospective only (except to the extent such amendment or change in applicable law permits the Corporation to provide
broader indemnification rights to Indemnitees on a retroactive basis than permitted prior thereto), and will not in any way diminish or
adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such repeal or amendment
or adoption of such inconsistent provision; <U>provided</U>, <U>however</U>, that amendments or repeals of this <U>Article&nbsp;VIII</U>
shall require the affirmative vote of the shareholders holding at least 66 2/3% of the voting power of all outstanding shares of capital
stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Certain
Definitions</B>. For purposes of this <U>Article&nbsp;VIII</U>, (a)&nbsp;references to &ldquo;<B><I>other enterprise</I></B>&rdquo; shall
include any employee benefit plan; (b)&nbsp;references to &ldquo;<B><I>fines</I></B>&rdquo; shall include any excise taxes assessed on
a person with respect to an employee benefit plan; (c)&nbsp;references to &ldquo;<B><I>serving at the request of the Corporation</I></B>&rdquo;
shall include any service that imposes duties on, or involves services by, a person with respect to any employee benefit plan, its participants,
or beneficiaries; and (d)&nbsp;a person who acted in good faith and in a manner such person reasonably believed to be in the interest
of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner not opposed to the best interest
of the Corporation for purposes of Section&nbsp;21.401 of the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Contract
Rights</B>. The rights provided to Indemnitees pursuant to this <U>Article&nbsp;VIII</U> shall be contract rights and such rights shall
continue as to an Indemnitee who has ceased to be a director, officer, agent or employee and shall inure to the benefit of the Indemnitee&rsquo;s
heirs, executors and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Severability</B>.
If any provision or provisions of this <U>Article&nbsp;VIII</U> shall be held to be invalid, illegal or unenforceable for any reason whatsoever:
(a)&nbsp;the validity, legality and enforceability of the remaining provisions of this <U>Article&nbsp;VIII</U> shall not in any way be
affected or impaired thereby; and (b)&nbsp;to the fullest extent possible, the provisions of this <U>Article&nbsp;VIII</U> (including,
without limitation, each such portion of this <U>Article&nbsp;VIII</U> containing any such provision held to be invalid, illegal or unenforceable)
shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;IX</B></FONT><FONT STYLE="text-transform: uppercase"><BR>
<B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Place
of Meetings</B>. If the place of any meeting of shareholders, the Board or committee of the Board for which notice is required under these
Bylaws is not designated in the notice of such meeting, such meeting shall be held at the principal executive office of the Corporation;
<U>provided</U>, <U>however</U>, if the Board has, in its sole discretion, determined that a meeting shall not be held at any place, but
instead shall be held by means of remote communication pursuant to <U>Section&nbsp;9.5</U> of these Bylaws , then such meeting shall not
be held at any place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Fixing
Record Dates</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
order that the Corporation may determine the shareholders entitled to notice of any meeting of shareholders or any adjournment thereof,
the Board may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board,
and which record date shall not be more than sixty (60) nor less than ten (10)&nbsp;days before the date of such meeting. If the Board
so fixes a date, such date shall also be the record date for determining the shareholders entitled to vote at such meeting unless the
Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for
making such determination. If no record date is fixed by the Board, the record date for determining shareholders entitled to notice of
and to vote at a meeting of shareholders shall be at the close of business on the Business Day next preceding the day on which notice
is given, or, if notice is waived, at the close of business on the Business Day next preceding the day on which the meeting is held. A
determination of shareholders of record entitled to notice of or to vote at a meeting of shareholders shall apply to any adjournment of
the meeting; <U>provided</U>, <U>however</U>, that the Board may fix a new record date for the adjourned meeting, and in such case shall
also fix as the record date for shareholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for
determination of shareholders entitled to vote in accordance with the foregoing provisions of this <U>Section&nbsp;9.2(a)</U>&nbsp;of
these Bylaws at the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
order that the Corporation may determine the shareholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the shareholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the
purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution
fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date
is fixed, the record date for determining shareholders for any such purpose shall be at the close of business on the day on which the
Board adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Means
of Giving Notice</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Directors</U>. Whenever under applicable law, the Certificate of Formation or these Bylaws notice is required to be given to any director,
such notice shall be given either (i)&nbsp;in writing and sent by mail, or by a nationally recognized delivery service, (ii)&nbsp;by means
of facsimile telecommunication or other form of electronic transmission, or (iii)&nbsp;by oral notice given personally or by telephone.
A notice to a director will be deemed given as follows: (i)&nbsp;if given by hand delivery, orally, or by telephone, when actually received
by the director, (ii)&nbsp;if sent through the United States mail, when deposited in the United States mail, with postage and fees thereon
prepaid, addressed to the director at the director&rsquo;s address appearing on the records of the Corporation, (iii)&nbsp;if sent for
next day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid,
addressed to the director at the director&rsquo;s address appearing on the records of the Corporation, (iv)&nbsp;if sent by facsimile
telecommunication, when sent to the facsimile transmission number for such director appearing on the records of the Corporation, (v)&nbsp;if
sent by electronic mail, when sent to the electronic mail address for such director appearing on the records of the Corporation, or (vi)&nbsp;if
sent by any other form of electronic transmission, when sent to the address, location or number (as applicable) for such director appearing
on the records of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Shareholders</U>. Whenever under applicable law, the Certificate of Formation or these Bylaws notice is required to be given to any
shareholder, such notice may be given (i)&nbsp;in writing and sent either by hand delivery, through the United States mail, or by a nationally
recognized overnight delivery service for next day delivery, or (ii)&nbsp;by means of a form of electronic transmission consented to by
the shareholder, to the extent permitted by the TBOC. A notice to a shareholder shall be deemed given as follows: (i)&nbsp;if given by
hand delivery, when actually received by the shareholder, (ii)&nbsp;if sent through the United States mail, when deposited in the United
States mail, with postage and fees thereon prepaid, addressed to the shareholder at the shareholder&rsquo;s address appearing on the stock
ledger of the Corporation, (iii)&nbsp;if sent for next day delivery by a nationally recognized overnight delivery service, when deposited
with such service, with fees thereon prepaid, addressed to the shareholder at the shareholder&rsquo;s address appearing on the stock ledger
of the Corporation, and (iv)&nbsp;if given by a form of electronic transmission consented to by the shareholder to whom the notice is
given and otherwise meeting the requirements set forth above, (A)&nbsp;if by facsimile transmission, when directed to a number at which
the shareholder has consented to receive notice, (B)&nbsp;if by electronic mail, when directed to an electronic mail address at which
the shareholder has consented to receive notice, (C)&nbsp;if by a posting on an electronic network together with separate notice to the
shareholder of such specified posting, upon the later of (1)&nbsp;such posting and (2)&nbsp;the giving of such separate notice, and (D)&nbsp;if
by any other form of electronic transmission, when directed to the shareholder. A shareholder may revoke such shareholder&rsquo;s consent
to receiving notice by means of electronic communication by giving written notice of such revocation to the Corporation. Any such consent
shall be deemed revoked if (1)&nbsp;the Corporation is unable to deliver by electronic transmission two consecutive notices given by the
Corporation in accordance with such consent and (2)&nbsp;such inability becomes known to the Secretary or an Assistant Secretary or to
the Corporation&rsquo;s transfer agent, or other person responsible for the giving of notice; <U>provided</U>, <U>however</U>, the inadvertent
failure to treat such inability as a revocation shall not invalidate any meeting or other action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Electronic
Transmission</U>. &ldquo;<B><I>Electronic transmission</I></B>&rdquo; means any form of communication, not directly involving the physical
transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly
reproduced in paper form by such a recipient through an automated process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Shareholders Sharing Same Address</U>. To the extent permitted under the TBOC, without limiting the manner by which notice otherwise
may be given effectively by the Corporation to shareholders, any notice to shareholders given by the Corporation under any provision of
the TBOC, the Certificate of Formation or these Bylaws shall be effective if given by a single written notice to shareholders who share
an address if consented to by the shareholders at that address to whom such notice is given. A shareholder may revoke such shareholder&rsquo;s
consent by delivering written notice of such revocation to the Corporation. Any shareholder who fails to object in writing to the Corporation
within sixty (60) days of having been given written notice by the Corporation of its intention to send such a single written notice shall
be deemed to have consented to receiving such single written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exceptions
to Notice Requirements</U>. Whenever notice is required to be given by the Corporation, under any provision of the TBOC, the Certificate
of Formation or these Bylaws, to any shareholder to whom (1)&nbsp;notice of two consecutive annual meetings of shareholders and all notices
of shareholder meetings or of the taking of action by written consent of shareholders without a meeting to such shareholder during the
period between such two consecutive annual meetings, or (2)&nbsp;all, and at least two payments (if sent by first-class mail) of distributions
or interest on securities during a 12-month period, have been mailed by first class mail addressed to such shareholder at such shareholder&rsquo;s
address as shown on the ownership records of the Corporation and have been returned undeliverable, the giving of such notice to such shareholder
shall not be required. To the extent permitted by the TBOC, notice of a meeting is not required to be given to a shareholder entitled
to notice under the any provision of the TBOC, the Certificate of Formation or these Bylaws if the person entitled to notice of the meeting
is considered a lost securityholder under the Exchange Act and the regulations adopted under the Exchange Act. Any action or meeting that
shall be taken or held without notice to any such shareholder shall have the same force and effect as if such notice had been duly given
to any such shareholder. If any such shareholder shall deliver to the Corporation a written notice setting forth such shareholder&rsquo;s
then current address, the requirement that notice be given to such shareholder shall be reinstated. In the event that the action taken
by the Corporation is such as to require the filing of a certificate or other document with the Secretary of State of Texas or otherwise,
the certificate or other document need not state that notice was not given to persons to whom notice was not required to be given pursuant
to the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Waiver
of Notice</B>. Whenever any notice is required to be given under applicable law, the Certificate of Formation, or these Bylaws, a written
waiver of such notice, signed by the person or persons entitled to said notice, or a waiver by electronic transmission by the person entitled
to said notice, whether before or after the time stated therein, shall be deemed equivalent to such required notice. All such waivers
shall be kept with the books of the Corporation. Attendance at a meeting shall constitute a waiver of notice of such meeting, except where
a person attends for the express purpose of objecting to the transaction of any business on the ground that the meeting was not lawfully
called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Meeting
Attendance via Remote Communication Equipment</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Shareholder
Meetings</U>. If authorized by the Board in its sole discretion, and subject to such guidelines and procedures as the Board may adopt,
shareholders entitled to vote at such meeting and proxy holders not physically present at a meeting of shareholders may, by means of remote
communication:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;participate
in a meeting of shareholders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;be
deemed present in person and vote at a meeting of shareholders, whether such meeting is to be held at a designated place or solely by
means of remote communication, <U>provided</U> that (A)&nbsp;the Corporation shall implement reasonable measures to verify that each person
deemed present and permitted to vote at the meeting by means of remote communication is a shareholder or proxy holder, (B)&nbsp;the Corporation
shall implement reasonable measures to provide such shareholders and proxy holders a reasonable opportunity to participate in the meeting
and, if entitled to vote, to vote on matters submitted to the applicable shareholders, including an opportunity to read or hear the proceedings
of the meeting substantially concurrently with such proceedings, and (C)&nbsp;if any shareholder or proxy holder votes or takes other
action at the meeting by means of remote communication, a record of such votes or other action shall be maintained by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Board
Meetings</U>. Unless otherwise restricted by applicable law, the Certificate of Formation or these Bylaws, members of the Board or any
committee thereof may participate in a meeting of the Board or any committee thereof by means of conference telephone or other communications
equipment by means of which all persons participating in the meeting can hear each other. Such participation in a meeting shall constitute
presence in person at the meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction
of any business on the ground that the meeting was not lawfully called or convened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Distributions
and Dividends</B>. The Board may from time to time declare, and the Corporation may pay, distributions or dividends (payable in cash,
property or shares of the Corporation&rsquo;s capital stock) on the Corporation&rsquo;s outstanding shares of capital stock, subject to
applicable law and the Certificate of Formation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Reserves</B>.
The Board may set apart out of the funds of the Corporation available for distributions or dividends a reserve or reserves for any proper
purpose and may abolish any such reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Contracts
and Negotiable Instruments</B>. Except as otherwise provided by applicable law, the Certificate of Formation or these Bylaws, any contract,
bond, deed, lease, mortgage or other instrument may be executed and delivered in the name and on behalf of the Corporation by such officer
or officers or other employee or employees of the Corporation as the Board may from time to time authorize. Such authority may be general
or confined to specific instances as the Board may determine. Unless so authorized or ratified by the board of directors or within the
agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or
engagement or to pledge its credit or to render it liable for any purpose or for any amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Fiscal
Year</B>. The fiscal year of the Corporation shall be fixed by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Seal</B>.
The Board may adopt a corporate seal, which shall be in such form as the Board determines. The seal may be used by causing it or a facsimile
thereof to be impressed, affixed or otherwise reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Books
and Records</B>. The books and records of the Corporation may be kept within or outside the State of Texas at such place or places as
may from time to time be designated by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Resignation</B>.
Any director, committee member or officer may resign by giving notice thereof in writing or by electronic transmission to the Corporation.
The resignation shall take effect at the time it is delivered unless the resignation specifies a later effective date or an effective
date determined upon the happening of an event or events. Unless otherwise specified therein, the acceptance of such resignation shall
not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract
to which the officer is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Amendments</B>.
The Board shall have the power to adopt, amend, alter or repeal these Bylaws. The affirmative vote of a majority of the Board shall be
required to adopt, amend, alter or repeal these Bylaws. These Bylaws also may be adopted, amended, altered or repealed by the shareholders;
<U>provided</U>, <U>however</U>, that in addition to any vote required by applicable law or the Certificate of Formation, the affirmative
vote of the holders of (a)&nbsp;prior to the Trigger Date (as defined below), at least a majority of the voting power of all of the then
outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class (except as otherwise
provided in <U>Section&nbsp;8.7</U> of these Bylaws), and (b)&nbsp;from and after the Trigger Date, at least 66 2/3% of the voting power
of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class,
shall be required for the shareholders to adopt, amend, alter or repeal these Bylaws. For purposes of these Bylaws, the &ldquo;<B><I>Trigger
Date</I></B>&rdquo; means the date on which no shares of Class&nbsp;B Common Stock shall be outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>6
<FILENAME>tm2415719d15_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED<BR>
INVESTORS&rsquo; RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>TABLE OF CONTENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Page</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">1.</TD><TD STYLE="text-align: left; width: 85%">Definitions</TD>
                                <TD STYLE="text-align: right; width: 10%">1</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
                                <TD STYLE="text-align: right">&nbsp;</TD></TR>
                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">2.</TD><TD STYLE="text-align: left; width: 85%">Registration Rights&#9;</TD>
                                                          <TD STYLE="text-align: right; width: 10%">6</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.1</TD><TD STYLE="text-align: left; width: 80%">Demand Registration&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">6</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.2</TD><TD STYLE="text-align: left; width: 80%">Company Registration&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">8</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.3</TD><TD STYLE="text-align: left; width: 80%">Underwriting Requirements&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">8</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.4</TD><TD STYLE="text-align: left; width: 80%">Obligations of the Company&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">9</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.5</TD><TD STYLE="text-align: left; width: 80%">Furnish Information&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">11</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.6</TD><TD STYLE="text-align: left; width: 80%">Expenses of Registration&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">11</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.7</TD><TD STYLE="text-align: left; width: 80%">Delay of Registration&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">11</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.8</TD><TD STYLE="text-align: left; width: 80%">Indemnification&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">11</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.9</TD><TD STYLE="text-align: left; width: 80%">Reports Under Exchange Act&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">14</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.10</TD><TD STYLE="text-align: left; width: 80%">Limitations on Subsequent Registration Rights&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">14</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.11</TD><TD STYLE="text-align: left; width: 80%">&ldquo;Market Stand-off&rdquo; Agreement&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">15</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.12</TD><TD STYLE="text-align: left; width: 80%">Restrictions on Transfer&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">15</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.13</TD><TD STYLE="text-align: left; width: 80%">Termination of Registration Rights&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">16</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">2.14</TD><TD STYLE="text-align: left; width: 80%">Qualified SPAC Transaction&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">16</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
                                                                <TD STYLE="text-align: right">&nbsp;</TD></TR>
                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">3.</TD><TD STYLE="text-align: left; width: 85%">Information and Observer Rights</TD>
                                                          <TD STYLE="text-align: right; width: 10%">17</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">3.1</TD><TD STYLE="text-align: left; width: 80%">Delivery of Financial Statements&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">17</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">3.2</TD><TD STYLE="text-align: left; width: 80%">Inspection</TD>
                                                               <TD STYLE="text-align: right; width: 10%">18</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">3.3</TD><TD STYLE="text-align: left; width: 80%">Observer Rights&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">18</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">3.4</TD><TD STYLE="text-align: left; width: 80%">Termination of Information and Observer Rights&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">19</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">3.5</TD><TD STYLE="text-align: left; width: 80%">Confidentiality&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">19</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">3.6</TD><TD STYLE="text-align: left; width: 80%">Material Non-Public Information&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">20</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
                                                               <TD STYLE="text-align: right">&nbsp;</TD></TR>
                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">4.</TD><TD STYLE="text-align: left; width: 85%">Rights to Future Stock Issuances&#9;</TD>
                                                          <TD STYLE="text-align: right; width: 10%">20</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">4.1</TD><TD STYLE="text-align: left; width: 80%">Right of First Offer</TD>
                                                               <TD STYLE="text-align: right; width: 10%">20</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">4.2</TD><TD STYLE="text-align: left; width: 80%">Termination&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">23</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
                                                               <TD STYLE="text-align: right">&nbsp;</TD></TR>
                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">5.</TD><TD STYLE="text-align: left; width: 85%">Additional Covenants&#9;</TD>
                                                          <TD STYLE="text-align: right; width: 10%">23</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">5.1</TD><TD STYLE="text-align: left; width: 80%">Matters Requiring Series C Director Approval&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">23</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">5.2</TD><TD STYLE="text-align: left; width: 80%">Right to Conduct Activities&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">23</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">5.3</TD><TD STYLE="text-align: left; width: 80%">Permitted Issuances of Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">23</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">5.4</TD><TD STYLE="text-align: left; width: 80%">Termination of Covenants&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">24</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
                                                               <TD STYLE="text-align: right">&nbsp;</TD></TR>
                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">6.</TD><TD STYLE="text-align: left; width: 85%">Miscellaneous</TD>
                                                          <TD STYLE="text-align: right; width: 10%">24</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.1</TD><TD STYLE="text-align: left; width: 80%">Successors and Assigns&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">24</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.2</TD><TD STYLE="text-align: left; width: 80%">Governing Law&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">25</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>6.3</TD><TD STYLE="text-align: left">Counterparts</TD>
                                                               <TD STYLE="text-align: right">25</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.4</TD><TD STYLE="text-align: left; width: 80%">Titles and Subtitles&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">25</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.5</TD><TD STYLE="text-align: left; width: 80%">Notices&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">25</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.6</TD><TD STYLE="text-align: left; width: 80%">Amendments and Waivers&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">26</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.7</TD><TD STYLE="text-align: left; width: 80%">Severability&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">27</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.8</TD><TD STYLE="text-align: left; width: 80%">Aggregation of Stock&#9;</TD>
                                                               <TD STYLE="text-align: right; width: 10%">27</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.9</TD><TD STYLE="text-align: left; width: 80%">Additional Investors</TD>
                                                               <TD STYLE="text-align: right; width: 10%">27</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.10</TD><TD STYLE="text-align: left; width: 80%">Entire Agreement&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">27</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.11</TD><TD STYLE="text-align: left; width: 80%">Dispute Resolution&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">27</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.12</TD><TD STYLE="text-align: left; width: 80%">WAIVER OF JURY TRIAL&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">28</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.13</TD><TD STYLE="text-align: left; width: 80%">Delays or Omissions&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">28</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%">6.14</TD><TD STYLE="text-align: left; width: 80%">Massachusetts Business Trust&#9;</TD>
                                                                <TD STYLE="text-align: right; width: 10%">28</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%">Schedule A</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%">Schedule of Investors</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Schedule B</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Investment Management Entities</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Schedule C&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Material Non-Public Information Contacts</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED<BR>
INVESTORS&rsquo; RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">THIS
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT (this &ldquo;<B><I>Agreement</I></B>&rdquo;), is made as of the 1<SUP>st</SUP>
day of April, <FONT>2025</FONT>, by and <FONT>among</FONT> Caris Life Sciences,&nbsp;Inc.,
a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and each of the investors listed on </FONT><B><U>Schedule A</U></B> hereto,
each of which is referred to in this Agreement as an &ldquo;<B><I>Investor</I></B>&rdquo; and any <FONT>Additional</FONT>
Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with <U>Section&nbsp;6.9</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B></FONT>,
certain of the Investors hold shares of Common Stock, Preferred Stock and/or shares of Common Stock issued upon conversion thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B></FONT>,
the Company and certain of the Investors are parties to that certain Series&nbsp;E/F Preferred Stock Purchase Agreement of even date herewith
(the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;) providing for the sale of shares of the Series&nbsp;E Preferred Stock, par value
$0.001 per share (the &ldquo;<B><I>Series&nbsp;E Preferred Stock</I></B>&rdquo;) and Series&nbsp;F Preferred Stock, par value $0.001 per
share (the &ldquo;<B><I>Series&nbsp;F Preferred Stock</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B></FONT>,
the Company and certain of the Investors are parties to that certain Amended and Restated Investors&rsquo; Rights Agreement, dated as
of May&nbsp;11, 2021 (the &ldquo;<B><I>Existing Agreement</I></B>&rdquo;), and such Investors have the power and authority to amend and
restate the Existing Agreement pursuant to the provisions of Section&nbsp;6.6 thereof; and&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B></FONT>,
in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in the Company
pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement will amend and restate the Existing
Agreement in its entirety and that this Agreement will govern the rights of the Investors to cause the Company to register shares of
Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings
by the Company, and will govern certain other matters as set forth in this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>NOW,
THEREFORE</B></FONT>, the parties hereby agree as follows:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
For purposes of this Agreement:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, (a)&nbsp;with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is
under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee
of such Person, or any venture capital fund or registered investment company or other investment fund now or hereafter existing that is
controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment
adviser with, such Person; and (b)&nbsp;in the case of a Fidelity Investor, also an investment company registered under the Investment
Company Act of 1940 advised or sub-advised by Fidelity or any affiliated investment advisor of Fidelity, one or more mutual funds, pension
funds, pooled investment vehicles or institutional clients advised or sub-advised by Fidelity or any affiliated investment advisor of
Fidelity, in each case, registered under the Investment Advisors Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Board</I></B>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Braidwell</I></B>&rdquo;
means Braidwell Transaction Holdings LLC &ndash; Series&nbsp;11.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Certificate</I></B>&rdquo;
means the Company&rsquo;s Amended and Restated Certificate of Formation, as amended and/or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Common
Stock</I></B>&rdquo; means shares of the Company&rsquo;s common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Competitor</I></B>&rdquo;
means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture
or similar arrangement (whether now existing or formed hereafter)), in therapeutic development, drug delivery, diagnostics and disease
monitoring and that is materially competitive with any material portion of the business of the Company as determined in good faith by
the Board (including through ownership of any portfolio company), but does not include any financial investment firm or collective investment
vehicle that, together with its Affiliates, holds (i)&nbsp;less than a majority of the outstanding equity or securities exchangeable
for or convertible into equity of any Competitor or (ii)&nbsp;any indebtedness of any Competitor and does not, nor do any of its Affiliates,
have a right to directly or indirectly, control any Competitor, it being agreed that equity ownership of less than 20% of a publicly
traded company, in and of itself, does not constitute control over such company. The parties agree that the investment management entities
set forth on <B><U>Schedule B</U></B> (which schedule may be updated by the Company to add additional Investors from time to time) and
their affiliated investment management and/or sub-advisory clients are not Competitors as of the date of this Agreement and any existing
or future debt or equity holding (&ldquo;<B><I>Portfolio Company</I></B>&rdquo;) by affiliated investment management and/or sub-advisory
clients of such investment management entity will not be aggregated to determine whether such investment management entity becomes a
Competitor; <I>provided</I> that such Portfolio Company does not receive any confidential information and does not acquire any ownership
interest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Damages</I></B>&rdquo;
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the
Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any registration statement
of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements
therein not misleading; or (iii)&nbsp;any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates)
of the Securities Act, the Exchange Act, any state securities law, or any rule&nbsp;or regulation promulgated under the Securities Act,
the Exchange Act, or any state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Derivative
Securities</I></B>&rdquo; means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly
or indirectly)<B>,</B> Common Stock, including options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Excluded
Registration</I></B>&rdquo; means (i)&nbsp;a registration relating to the sale or grant of securities to employees of the Company or
a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii)&nbsp;a registration relating to an SEC
Rule&nbsp;145 transaction; (iii)&nbsp;a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration in which
the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Existing
Preferred Stock</I></B>&rdquo; means, collectively, shares of the Company&rsquo;s Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Fidelity</I></B>&rdquo;
means Fidelity Management&nbsp;&amp; Research Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Fidelity
Investor</I></B>&rdquo; means any Investor advised or sub-advised by Fidelity.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Form&nbsp;S-1</I></B>&rdquo;
means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act
subsequently adopted by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Form&nbsp;S-3</I></B>&rdquo;
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently
adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company
with the SEC.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>GAAP</I></B>&rdquo;
means generally accepted accounting principles in the United States as in effect from time to time.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Highland</I></B>&rdquo;
means Highland Capital Management, L.P.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Holder</I></B>&rdquo;
means any holder of Registrable Securities (including any Affiliate of an Investor) who is a party to this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>&ldquo;<B><I>Immediate
Family Member</I></B>&rdquo; means a child</FONT>, <FONT>stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,</FONT> or <FONT>sister-in-law,
including adoptive relationships, of a natural person referred to herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Initiating
Holders</I></B>&rdquo; means, collectively, Holders who properly initiate a registration request under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>&ldquo;<B><I>IPO</I></B>&rdquo;
means (i)&nbsp;the Company&rsquo;s first underwritten public offering of its Common Stock under the Securities Act or (ii)&nbsp;the Company&rsquo;s
direct listing on the New York Stock Exchange or Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>&ldquo;<B><I>Major
Investor</I></B>&rdquo; means any Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>New
Securities</I></B>&rdquo; means, collectively, equity securities of the Company and any of its wholly owned subsidiaries, whether or not
currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever
that are, or may become, convertible or exchangeable into or exercisable for such equity securities; <I>provided</I>, <I>however</I>,
that securities of the Company&rsquo;s subsidiaries that are to be issued to the Company or another direct or indirect subsidiary of the
Company shall not be &ldquo;New Securities&rdquo; for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>&ldquo;<B><I>Note
Purchase Agreement</I></B>&rdquo; means that certain Convertible Note Purchase Agreement, dated as of the date hereof, by and among the
Company and the other parties thereto, </FONT>, as may be amended and/or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>&ldquo;<B><I>OrbiMed</I></B>&rdquo;
means, collectively, OrbiMed Partners Master Fund Limited, Worldwide Healthcare Trust PLC and OrbiMed Genesis Master Fund, L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>&ldquo;<B><I>Person</I></B>&rdquo;
means any individual, corporation, partnership, trust, limited liability company, association </FONT>or other <FONT>entity<FONT>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Preferred
Stock</I></B>&rdquo; means, collectively, shares of the Company&rsquo;s Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock,
Series&nbsp;C Preferred Stock, Series&nbsp;D Preferred Stock, Series&nbsp;E Preferred Stock and Series&nbsp;F Preferred Stock<FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Qualified
SPAC Transaction</I></B>&rdquo; has the meaning assigned to such term in the Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Registrable
Securities</I></B>&rdquo; means (i)&nbsp;the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii)&nbsp;any Common
Stock<FONT>, or any Common Stock</FONT> issued or issuable <FONT>(directly
or indirectly)</FONT> upon conversion <FONT>and/or exercise </FONT>of any <FONT>other</FONT>
debt or equity <FONT>securities</FONT> of the Company, or other debt or equity instruments or other similar
agreements or arrangements, <FONT>held by the Investors or their Affiliates</FONT>; and (iii)&nbsp;any
Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in <U>clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;above;
excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the <FONT>applicable</FONT>
rights under <FONT>this Agreement</FONT> are not assigned <FONT>pursuant
to <U>Section&nbsp;6.1</U>, and excluding for purposes of <U>Section&nbsp;2</U></FONT> any shares for which registration rights have terminated
pursuant to <U>Section&nbsp;2.13</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Registrable
Securities then outstanding</I></B>&rdquo; means the number of shares determined by adding the <FONT>number
of shares of outstanding </FONT>Common Stock <FONT>that are Registrable Securities</FONT> and the <FONT>number
of shares of</FONT> Common Stock issuable <FONT>(directly or indirectly) </FONT>pursuant to then exercisable
<FONT>and/</FONT>or convertible securities that are Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Securities</I></B>&rdquo; means the securities of the Company required to be notated with the legend set forth in <U>Section&nbsp;2.12(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Right
of First Refusal&nbsp;&amp; Co-Sale Agreement</I></B>&rdquo; means that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement of even date herewith by and among the Company and the Shareholders (as defined therein), as may be amended and/or restated
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>SEC</I></B>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>SEC
Rule&nbsp;144</I></B>&rdquo; means Rule&nbsp;144 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>SEC
Rule&nbsp;145</I></B>&rdquo; means Rule&nbsp;145 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Selling
Expenses</I></B>&rdquo; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except <FONT>for the fees and disbursements
of the Selling Holder Counsel borne and paid by the Company </FONT>as provided in <U>Section&nbsp;2.6</U><FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.38&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Series&nbsp;A
Preferred Stock</I></B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;A Preferred Stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.39&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Series&nbsp;B
Preferred Stock</I></B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;B Preferred Stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.40&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Series&nbsp;C
Director</I></B>&rdquo; has the meaning assigned to such term in the Voting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.41&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Series&nbsp;C
Preferred Stock</I></B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;C Preferred Stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.42&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Series&nbsp;D
Preferred Stock</I></B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;D Preferred Stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.43&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Series&nbsp;D
Purchase Agreement</I></B>&rdquo; means that certain Series&nbsp;D Preferred Stock Purchase Agreement, dated May&nbsp;11, 2021 by and
among the Company and the investors party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.44&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Sixth
Street</I></B>&rdquo; means Sixth Street Specialty Lending,&nbsp;Inc., TAO Barnett Investments, LLC, TOP III Barnett Investments, LLC,
Barnett Equity Holdings, LLC and Barnett Equity Holdings II, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.45&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Stonebridge-Highland</I></B>&rdquo;
means SH Caris Life US, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.46&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Stonebridge</I></B>&rdquo;
means Stonebridge Capital,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.47&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Voting
Agreement</I></B>&rdquo; means that certain Amended and Restated Voting Agreement of even date herewith by and among the Company and the
Shareholders (as defined therein), as may be amended and/or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights</U>. The Company covenants and agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Demand
Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT><U>Form&nbsp;S-1
Demand</U>. </FONT>If at any time after one hundred eighty (180) days after the effective date of the registration statement for the IPO,
the Company receives a request from any of (i)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion
of the Series&nbsp;C Preferred Stock, (ii)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of
the Series&nbsp;D Preferred Stock, (iii)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of
the Series&nbsp;E Preferred Stock, or (iv)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of
the Existing Preferred Stock, that the Company <FONT>file</FONT> a <FONT>Form&nbsp;S-1
</FONT>registration <FONT>statement</FONT> with respect to outstanding Registrable Securities of such Holders
having an anticipated aggregate offering price, net of Selling Expenses, of at least $10 million, then the Company will (x)&nbsp;within
ten (10)&nbsp;days after the date such request is given, give notice thereof (the &ldquo;<B><I>Demand Notice</I></B>&rdquo;) to all Holders
other than the Initiating Holders; and (y)&nbsp;as soon as practicable, and in any event within sixty (60) days after the date such request
is given by the Initiating Holders, file a <FONT>Form&nbsp;S-1</FONT> registration statement under the
Securities Act covering all Registrable Securities that the I<FONT>nitiating </FONT>Holders <FONT>requested</FONT>
to be registered and <FONT>any additional Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice
is given, and, in each case, </FONT>subject to the limitations of <U>Sections 2.1(c)</U><FONT>&nbsp;and
<U>2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Form&nbsp;S-3
Demand</U>. If at any time when it is eligible to use a Form&nbsp;S-3 registration statement, the Company receives a request from any
of: (i)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series&nbsp;C Preferred Stock,
(ii)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series&nbsp;D Preferred Stock,
(iii)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series&nbsp;E Preferred Stock,
or (iv)&nbsp;Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Existing Preferred Stock that
the Company file a Form&nbsp;S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an
anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company will (i)&nbsp;within ten (10)&nbsp;days
after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii)&nbsp;as soon as
practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form&nbsp;S-3
registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by
any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice
is given, and in each case, subject to the limitations of <U>Sections 2.1(c)</U>&nbsp;and <U>2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this <U>Section&nbsp;2.1</U> a certificate
signed by the Company&rsquo;s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental
to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such
registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere with
a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature
disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render
the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company will have the right to defer
taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof will be tolled correspondingly,
for a period of not more than thirty (30) days after the request of the Initiating Holders is given; <I>provided</I>, <I>however</I>,
that the Company may not invoke this right more than once in any twelve (12) month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company will not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section&nbsp;2.1(a)</U>: (i)&nbsp;during
the period that is sixty (60) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on a date that
is one hundred eighty (180) days after the effective date of, a Company-initiated registration, <I>provided</I> that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;if the Initiating
Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form&nbsp;S-3 pursuant to a request
made pursuant to <U>Section&nbsp;2.1(b)</U>; (iii)&nbsp;with respect to <U>Section&nbsp;2.1(a)(i)</U>, after the Company has effected
two registrations <FONT>pursuant to <U>Section&nbsp;2.1(a)</U></FONT><U>(i)</U>; (iv)&nbsp;with respect
to <U>Section&nbsp;2.1(a)(ii)</U>, after the Company has effected two registrations <FONT>pursuant to <U>Section&nbsp;2.1(a)</U></FONT><U>(ii)</U>;
or <U>(v)&nbsp;</U>with respect to <U>Section&nbsp;2.1(a)(iii)</U>, after the Company has effected two registrations <FONT>pursuant
to <U>Section&nbsp;2.1(a)</U></FONT><U>(iii)</U><FONT>. The Company will not be obligated to effect, or
to take any action to effect, any registration pursuant to <U>Section&nbsp;2.1(b)</U></FONT>: <FONT>(i)&nbsp;during
the period that is thirty (30) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on a date that
is ninety (90) days after the effective date of, a Company-initiated registration, <I>provided</I> that the Company is actively employing
in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has
effected three registrations pursuant to <U>Section&nbsp;2.1(b)</U>&nbsp;within the twelve (12) month period immediately preceding the
date of such request.</FONT> A registration will not be counted as &ldquo;effected&rdquo; for purposes of this <U>Section&nbsp;2.1(d)</U>&nbsp;until
such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, <FONT>and forfeit their
right to one demand registration statement </FONT>pursuant to <U>Section&nbsp;2.6</U><FONT>, in which case
such withdrawn registration statement will be counted as &ldquo;effected&rdquo; for purposes of this <U>Section&nbsp;2.1(d)</U></FONT>;
<I>provided</I>, that if such withdrawal is during a period the Company has deferred taking action pursuant to <U>Section&nbsp;2.1(c)</U>&nbsp;or
follows an event or series of events that would reasonably be expected to have a material adverse effect on the business, assets, (including
intangible assets), financial condition, or results of operations of the Company and its subsidiaries, taken as a whole, then the Initiating
Holders may withdraw their request for registration and such registration will not be counted as &ldquo;effected&rdquo; for purposes of
this <U>Section&nbsp;2.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Company
Registration</U>. If the Company proposes to register (including, for this purpose, a registration effected by the Company for shareholders)
any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in
an Excluded Registration), the Company will, at such time, promptly give each Holder notice of such registration. Upon the request of
each Holder given within twenty (20) days after such notice is given by the Company, the Company will, subject to the provisions of <U>Section&nbsp;2.3</U>,
cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The
Company will have the right to terminate or withdraw any registration initiated by it under this <U>Section&nbsp;2.2</U> before the effective
date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses
(other than Selling Expenses) of such withdrawn registration will be borne by the Company in accordance with <U>Section&nbsp;2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Underwriting
Requirements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
pursuant to <U>Section&nbsp;2.1</U><FONT>,</FONT> the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they will so advise the Company as a part of their request made pursuant
to <U>Section&nbsp;2.1</U><FONT>,</FONT> and the Company will include such information in the Demand Notice.
The underwriter<FONT>(s)</FONT>&nbsp;will be selected by the Board and will be reasonably acceptable to
a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&rsquo;s Registrable Securities
in such registration will be conditioned upon such Holder&rsquo;s participation in such underwriting and the inclusion of such Holder&rsquo;s
Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting will (together with the Company as provided in <U>Section&nbsp;2.4(e)</U>) enter into an underwriting agreement in customary
form with the underwriter(s)&nbsp;selected for such underwriting. Notwithstanding any other provision of this <U>Section&nbsp;2.3</U><FONT>,</FONT>
if the underwriter(s)&nbsp;advise(s)&nbsp;the Initiating Holders in writing that marketing factors require a limitation on the number
of shares to be underwritten, then the Initiating Holders will so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting will be allocated among
<FONT>such</FONT> Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder <FONT>or in such other
proportion as will mutually be agreed to by all such selling Holders</FONT>; <I>provided</I>, <I>however</I>, that the number of Registrable
Securities held by the Holders to be included in such underwriting will not be reduced unless all other securities are first entirely
excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters
may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
connection with any offering involving an underwriting of shares of the Company&rsquo;s capital stock pursuant to <U>Section&nbsp;2.2</U>,
the Company will not be required to include any of the Holders&rsquo; Registrable Securities in such underwriting unless the Holders accept
the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters
in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by shareholders to be included in such offering exceeds the number of securities to be sold
(other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering,
then the Company will be required to include in the offering only that number of such securities, including Registrable Securities, which
the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters
determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable
Securities that are included in such offering will be <FONT>allocated</FONT> among the selling Holders
<FONT>in proportion (as nearly as practicable to)</FONT> the number of Registrable Securities <FONT>owned</FONT>
by <FONT>each selling Holder</FONT> or in such other proportions as will mutually be agreed to by all such
selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round
the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event will
<FONT>the number of Registrable Securities included in the offering be reduced unless all other securities
(other than securities to be sold by the Company) are first entirely excluded from the offering</FONT>. For purposes of the provision
in this <U>Section&nbsp;2.3(b)</U>&nbsp;concerning apportionment, for any selling <FONT>Holder</FONT> that
is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, shareholders, and
Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members
and any trusts for the benefit of any of the foregoing Persons, will be deemed to be a single &ldquo;selling Holder,&rdquo; and any pro
rata reduction with respect to such &ldquo;selling Holder&rdquo; will be based upon the aggregate number of Registrable Securities owned
by all Persons included in such &ldquo;selling Holder,&rdquo; as defined in this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
purposes of <U>Section&nbsp;2.1</U><FONT>,</FONT> a registration will not be counted as &ldquo;effected&rdquo;
if, as a result of an exercise of the underwriter&rsquo;s cutback provisions in <U>Section&nbsp;2.3(a)</U>, fewer than one hundred percent
(100%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually
included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Obligations
of the Company</U>. Whenever required under this <U>Section&nbsp;2</U> to effect the registration of any Registrable Securities, the Company
will, as expeditiously as reasonably possible:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts
to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier,
until the distribution contemplated in the registration statement has been completed; <I>provided</I>, <I>however</I>, that (i)&nbsp;such
one hundred twenty (120) day period will be extended for a period of time equal to the period the Holder refrains, at the request of an
underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii)&nbsp;in
the case of any registration of Registrable Securities on Form&nbsp;S-3 that are intended to be offered on a continuous or delayed basis,
subject to compliance with applicable SEC rules, such one hundred twenty (120) day period will be extended for up to thirty (30) days,
if necessary, to keep the registration statement effective until all such Registrable Securities are sold;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such
registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered
by such registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate the disposition of their Registrable Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as are reasonably requested by the selling Holders; <I>provided</I> that the Company will not be
required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions unless the Company
is already subject to service in such jurisdiction and except as may be required by the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter<FONT>(s)</FONT>&nbsp;of such offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>promptly
make available for inspection by the selling Holders, any underwriter<FONT>(s)</FONT>&nbsp;participating
in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter
or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and
cause the Company&rsquo;s officers, directors, employees, and independent accountants to supply all information reasonably requested by
any such seller, underwriter, attorney, accountant, or agent<FONT>, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence</FONT> in connection
<FONT>therewith</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition, the Company will
ensure that at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act will have become effective, its insider trading policy will provide that the Company&rsquo;s directors may implement a trading program
under Rule&nbsp;10b5-1 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Furnish
Information</U>. It will be a condition precedent to the obligations of the Company to take any action pursuant to this <U>Section&nbsp;2</U>
with respect to the Registrable Securities of any selling Holder that such Holder will furnish to the Company, upon reasonable notice,
such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as
is reasonably required to effect the registration of such Holder&rsquo;s Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses
of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to <U>Section&nbsp;2</U>, including all registration, filing, and qualification fees, printers&rsquo; and accounting fees, fees
and disbursements of counsel for the Company, and the reasonable fees and disbursements, not to exceed $75,000, of one counsel (and any
reasonably necessary local counsel) for the selling Holders <FONT>(&ldquo;<B><I>Selling Holder Counsel</I></B>&rdquo;)</FONT>,
will be borne and paid by the Company; <I>provided</I>, <I>however</I>, that the Company will not be required to pay for any expenses
of any registration proceeding begun pursuant to <U>Section&nbsp;2.1</U> if the registration request is subsequently withdrawn at the
request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders will bear such
expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the
Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to <U>Sections 2.1(a)</U>&nbsp;or
<U>2.1(b)</U><FONT>,</FONT> as the case may be; <I>provided further</I> that if, at the time of such withdrawal,
the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders
at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders
will not be required to pay any of such expenses and will not forfeit their right to one registration pursuant to <U>Sections 2.1(a)</U>&nbsp;or
<U>2.1(b)</U>. All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section&nbsp;2</U> will be borne
and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delay
of Registration</U>. No Holder will have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
<U>Section&nbsp;2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification</U>.
If any Registrable Securities are included in a registration statement under this <U>Section&nbsp;2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors,
investment advisors and shareholders of each such Holder, legal counsel and accountants for each such Holder, any underwriter (as defined
in the Securities Act) for each such Holder, and each Person, if any, who controls such Holder or underwriter within the meaning of the
Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person,
or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any
<FONT>claim or</FONT> proceeding from which Damages may result, as such expenses are incurred; <I>provided</I>,
<I>however</I>, that the indemnity agreement contained in this <U>Section&nbsp;2.8(a)</U>&nbsp;will not apply to amounts paid in settlement
of any such <FONT>claim</FONT> or proceeding if such settlement is effected without the consent of the
Company, which consent will not be unreasonably withheld, nor will the Company be liable for any Damages to the extent that they arise
out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf
of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within
the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act),
any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder,
against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with
such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such
expenses are incurred; <I>provided</I>, <I>however</I>, that the indemnity agreement contained in this <U>Section&nbsp;2.8(b)</U>&nbsp;will
not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,
which consent will not be unreasonably withheld; and <I>provided further</I> that in no event will the aggregate amounts payable by any
Holder by way of indemnity or contribution under <U>Sections 2.8(b)</U>&nbsp;and <U>2.8(d)</U>&nbsp;exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such
Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Promptly
after receipt by an indemnified party under this <U>Section&nbsp;2.8</U> of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is
to be made against any indemnifying party under this <U>Section&nbsp;2.8</U>, give the indemnifying party notice of the commencement
thereof. The indemnifying party will have the right to participate in such action and, to the extent the indemnifying party so desires,
participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel
mutually satisfactory to the parties; <I>provided</I>, <I>however</I>, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) will have the right to retain one (1)&nbsp;separate counsel, with the
fees and expenses to be paid by the indemnifying party, if the representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other
party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action will relieve such indemnifying party of any liability to the indemnified party under this <U>Section&nbsp;2.8</U>,
to the extent that such failure materially prejudices the indemnifying party&rsquo;s ability to defend such action. The failure to give
notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under
this <U>Section&nbsp;2.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i)&nbsp;any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section&nbsp;2.8</U> but it is
judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to
appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact
that this <U>Section&nbsp;2.8</U> provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be
required on the part of any party hereto for which indemnification is provided under this <U>Section&nbsp;2.8</U>, then, and in each
such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject
(after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party
and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability,
or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party will be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified
party and the parties&rsquo; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement
or omission; <I>provided</I>, <I>however</I>, that, in any such case (x)&nbsp;no Holder will be required to contribute any amount in
excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration
statement, and (y)&nbsp;no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <I>provided further</I>
that in no event will a Holder&rsquo;s liability pursuant to this <U>Section&nbsp;2.8(d)</U>, when combined with the amounts paid or
payable by such Holder pursuant to <U>Section&nbsp;2.8(b)</U>, exceed the proceeds from the offering received by such Holder (net of
any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered
into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of
the Company and Holders under this <U>Section&nbsp;2.8</U> will survive the completion of any offering of Registrable Securities in a
registration under this <U>Section&nbsp;2</U>, and otherwise will survive the termination of this Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reports
Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule&nbsp;144 and any other rule&nbsp;or regulation
of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form&nbsp;S-3, the Company will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>make
and keep <FONT>available adequate current </FONT>public information, as those terms are understood and
defined in SEC Rule&nbsp;144, at all times after the effective date of the registration statement filed by the Company for the IPO or
the closing of a Qualified SPAC Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a written
statement by the Company that it has complied with the reporting requirements of SEC Rule&nbsp;144 (at any time after ninety (90) days
after the effective date of the registration statement filed by the Company for the IPO or one (1)&nbsp;year after the closing of a Qualified
SPAC Transaction), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements),
or that it qualifies as a registrant whose securities may be resold pursuant to Form&nbsp;S-3 (at any time after the Company so qualifies);
and (ii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule&nbsp;or regulation of the SEC
that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form&nbsp;S-3 (at any time after the Company so qualifies to use such form); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>take
such further reasonable action as any Holder may reasonably request from time to time to enable such Holder (i)&nbsp;to remove any restrictive
legends from such Holder&rsquo;s Registrable Securities and transfer such Holder&rsquo;s Registrable Securities to a brokerage account
and (ii)&nbsp;to sell such Holder&rsquo;s Registrable Securities without registration under the Securities Act and within the limitations
of the exemptions provided by SEC Rule&nbsp;144 or any similar rule&nbsp;or regulation hereafter adopted by the SEC; <I>provided </I>that,
notwithstanding anything to the contrary, the Company shall not be required to provide a legal opinion or determination to any third
party with regards to the &ldquo;affiliate&rdquo; status of any Holder under SEC Rule&nbsp;144 as part of its obligations under this
<U>Section&nbsp;2.9(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company will not, without the prior written consent
of (x)&nbsp;the holders of a majority of the Series&nbsp;E Preferred Stock then outstanding (including in such majority (i)&nbsp;Braidwell
for so long as Braidwell and its Affiliates which are permitted assigns under this Agreement hold the lesser of (A)&nbsp;8.75% of the
shares of Series&nbsp;E Preferred Stock then outstanding (or Common Stock issued upon conversion thereof) and (B)&nbsp;25% of the Series&nbsp;E
Preferred Stock sold to Braidwell pursuant to the Purchase Agreement and (ii)&nbsp;additional holders of Series&nbsp;E Preferred Stock
that (A)&nbsp;are not Affiliated with Braidwell and (B)&nbsp;collectively hold at least 4% of the shares of Series&nbsp;E Preferred Stock
then outstanding (the &ldquo;<B><I>Requisite Series&nbsp;E Holders</I></B>&rdquo;); (y)&nbsp;the holders of a majority of the Series&nbsp;D
Preferred Stock then outstanding (including in such majority Sixth Street for so long as Sixth Street and its Affiliates which are permitted
assigns under this Agreement hold at least 18,518,518 shares of Series&nbsp;D Preferred Stock (or Common Stock issued upon conversion
thereof) (as adjusted for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the
date hereof)) (the &ldquo;<B><I>Requisite Series&nbsp;D Holders</I></B>&rdquo;); and (z)&nbsp;the holders of a majority of the Series&nbsp;C
Preferred Stock then outstanding (including in such majority Stonebridge-Highland for so long as Stonebridge-Highland and its Affiliates
which are permitted assigns under this Agreement hold at least 13,586,957 shares of Series&nbsp;C Preferred Stock (as adjusted for any
stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof)) (the &ldquo;<B><I>Requisite
Series&nbsp;C Holders</I></B>&rdquo;), enter into any agreement with any holder or prospective holder of any securities of the Company
that would (i)&nbsp;provide to such holder or prospective holder the right to include securities in any registration on other than either
a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include
in the registration and offering all shares of Registrable Securities that they wish to so include; or (ii)&nbsp;allow such holder or
prospective holder to vote with the holders of Series&nbsp;E Preferred Stock, Series&nbsp;D Preferred Stock, or Series&nbsp;C Preferred
Stock to initiate a demand for registration of any securities held by such holder or prospective holder; <I>provided</I> that this limitation
will not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with
<U>Section&nbsp;6.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>&ldquo;Market
Stand-off&rdquo; Agreement</U>. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter,
during the period commencing on the date of the final prospectus relating to the <FONT>IPO, and ending
on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case
of the IPO, or such other period as may be required by law to accommodate regulatory restrictions on (1)&nbsp;the publication or other
distribution of research reports, and (2)&nbsp;analyst recommendations and opinions, including, but not limited to, the restrictions contained
in applicable FINRA rules, or any successor provisions or amendments thereto), </FONT>(i)&nbsp;lend, offer, pledge, sell, contract to
sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase,
or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable <FONT>(directly or indirectly) </FONT>for Common Stock in each instance held immediately
before the effective date of the registration statement for the IPO (which for clarification excludes securities acquired in the related
offering); or (ii)&nbsp;enter into any swap, derivative security, or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of such securities held immediately before the effective date of the registration statement
for the IPO, whether any such transaction described in <U>clause (i)</U>&nbsp;or <U>(ii)</U>&nbsp;above is to be settled by delivery of
Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this <U>Section&nbsp;2.11</U> will not apply to the
sale of any shares to an underwriter pursuant to an underwriting agreement, <FONT>or the transfer of any
shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder; <I>provided</I> that the trustee
of the trust agrees to be bound in writing by the restrictions set forth herein; and <I>provided further</I> that any such transfer will
not involve a disposition for value,</FONT> and the foregoing provisions of this Section&nbsp;2.11 will be applicable to the Holders only
if all officers and directors are subject to the same restrictions and the Company obtains similar agreements from shareholders owning,
in the aggregate, more than ninety-two percent (92%) of the Company&rsquo;s outstanding Common Stock (after giving effect to conversion
into Common Stock of all outstanding Preferred Stock). For the avoidance of doubt, the restrictions described in this <U>Section&nbsp;2.11</U>
shall not apply to the sale of any shares acquired in the IPO or in the open market following the IPO. The underwriters in connection
with <FONT>such registration</FONT> are intended third-party beneficiaries of this <U>Section&nbsp;2.11</U>
and will have the right, power, and authority to enforce the provisions hereof as though they were a party hereto, subject to the terms
and conditions hereof. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in <FONT>connection
with such registration</FONT> that are consistent with this <U>Section&nbsp;2.11</U> or that are necessary to give further effect thereto.
If any of the obligations described in this <U>Section&nbsp;2.11</U> are waived or terminated with respect to any of the securities of
any Holder, officer, director, or other Company stockholder (in any such case, the &ldquo;<B><I>Released Securities</I></B>&rdquo;), (X)&nbsp;the
Company shall provide notice to each Holder within two (2)&nbsp;Business Days (provided that the failure to provide such notice shall
not give rise to any claim or liability against the Company) and (Y)&nbsp;the foregoing provisions shall be waived or terminated, as applicable,
to the same extent and with respect to the same percentage of securities held by each Holder as the percentage of the Released Securities
represents with respect to the securities held by the applicable Holder, officer, director, or other stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restrictions
on Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Preferred Stock and the Registrable Securities will not be sold, pledged, or otherwise transferred, and the Company will not recognize
and will issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions
specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder
to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding
the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the
IPO, SEC Rule&nbsp;144, in each case, to be bound by the terms of this <U>Section&nbsp;2.12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
certificate, instrument, or book-entry representing (i)&nbsp;the Preferred Stock, (ii)&nbsp;the Registrable Securities, and (iii)&nbsp;any
other securities issued in respect of the securities referenced in <U>clauses (i)</U>&nbsp;and <U>(ii)</U>, upon any stock split, stock
dividend, reorganization, stock combination, or similar transaction, will (unless otherwise permitted by the provisions of <U>Section&nbsp;2.12(c)</U>)
be notated with a legend substantially in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE
BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY&nbsp;NOT BE SOLD, PLEDGED,
OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF
SAID ACT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED HEREBY MAY&nbsp;BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH
THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities
in order to implement the restrictions on transfer set forth in this <U>Section&nbsp;2.12</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
<U>Section&nbsp;2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction or following the IPO, the transfer is made pursuant to SEC Rule&nbsp;144,
the, Holder thereof will give notice to the Company of such Holder&rsquo;s intention to effect such sale, pledge, or transfer. Each such
notice will describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested
by the Company, will be accompanied at such Holder&rsquo;s expense by either (i)&nbsp;a written opinion of legal counsel who will, and
whose legal opinion will, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction
may be effected without registration under the Securities Act; (ii)&nbsp;a &ldquo;no action&rdquo; letter from the SEC to the effect
that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by
the staff of the SEC that action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to
the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration
under the Securities Act, whereupon the Holder of such Restricted Securities will be entitled to sell, pledge, or transfer such Restricted
Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion
or &ldquo;no action&rdquo; letter (x)&nbsp;in any transaction in compliance with SEC Rule&nbsp;144, or (y)&nbsp;in any transaction in
which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; <I>provided</I> that each transferee
agrees in writing to be subject to the terms of this <U>Section&nbsp;2.12</U>. Each certificate, instrument, or book-entry representing
the Restricted Securities transferred as above provided will be notated with, except if such transfer is made pursuant to SEC Rule&nbsp;144,
the appropriate restrictive legend set forth in <U>Section&nbsp;2.12(b)</U>, except that such certificate instrument, or book-entry will
not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required
in order to establish compliance with any provisions of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to <U>Sections 2.1</U> or <U>2.2</U> will terminate upon the earlier of (a)&nbsp;closing of a Deemed Liquidation Event, as such
term is defined in the Certificate, other than a Deemed Liquidation Event under clause (c)&nbsp;of the definition of Deemed Liquidation
Event in circumstances where the Investors continue to own shares of the Company, or (b)&nbsp;the fourth anniversary of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Qualified
SPAC Transaction</U>. Upon the closing of any Qualified SPAC Transaction, the Company will use reasonable best efforts to cause the rights
of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to <U>Sections 2.1</U>, <U>Section&nbsp;2.2</U>,
<U>Section&nbsp;2.3</U>, <U>Section&nbsp;2.4</U>, <U>Section&nbsp;2.5</U>, <U>Section&nbsp;2.6</U>, <U>Section&nbsp;2.7</U>, <U>Section&nbsp;2.8</U>,
<U>Section&nbsp;2.9</U>, or <U>Section&nbsp;2.10</U> to apply <I>mutatis mutandis</I> to the stock of the publicly traded corporation
from such Qualified SPAC Transaction as if it was an IPO hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Information
and Observer Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Financial Statements</U>. The Company will deliver to each Major Investor, <I>provided</I> that the Board has not reasonably determined
that such recipient is a Competitor of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (i)&nbsp;a
balance sheet as of the end of such year, (ii)&nbsp;statements of income and of cash flows for such year, and a comparison between (x)&nbsp;the
actual amounts as of and for such fiscal year and (y)&nbsp;the comparable amounts for the prior year and as included in the Budget (as
defined in <U>Section&nbsp;3.1(e)</U>) for such year, and (iii)&nbsp;a statement of shareholders&rsquo; equity as of the end of such
year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected
by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable, but in any event within sixty (60) days after the end of each fiscal quarter of each fiscal year of the Company,
unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of shareholders&rsquo;
equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i)&nbsp;be
subject to normal year-end audit adjustments; and (ii)&nbsp;not contain all notes thereto that may be required in accordance with GAAP);&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable, but in any event within sixty (60) days after the end of each fiscal quarter of each fiscal year, a capitalization
table showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares
of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities
convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of
issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major
Investors to calculate their respective percentage equity ownership in the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>such
other information relating to the business of the Company as any Major Investor may from time to time reasonably request; <I>provided</I>,
<I>however</I>, that the Company shall not be obligated under this <U>Section&nbsp;3.1(d)</U>&nbsp;to provide any such requested information
more than once a fiscal quarter to any Major Investor or provide information (i)&nbsp;that the Company determines in its sole discretion
to be a trade secret, confidential information, or competitively sensitive; (ii)&nbsp;the disclosure of which would adversely affect
the attorney-client privilege between the Company and its counsel; or (iii)&nbsp;that is financial in nature; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable, but in any event within thirty (30) days following the end of each fiscal year, a budget and business plan for the
next fiscal year approved by the Board (collectively, the &ldquo;<B><I>Budget</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If, for any period, the Company
has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements
delivered pursuant to the foregoing sections will be the consolidated and consolidating financial statements of the Company and all such
consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Notwithstanding
anything else in this <U>Section&nbsp;3.1</U> to the contrary, the Company may cease providing the information set forth in this <U>Section&nbsp;3.1</U>
during the period starting with the date sixty (60) days before the Company&rsquo;s good-faith estimate of the date of filing</FONT>
of a registration statement if it reasonably concludes it must do so to comply with the SEC rules&nbsp;applicable to such registration
statement and related offering; <I>provided</I> that the Company&rsquo;s covenants under this <U>Section&nbsp;3.1</U> will be reinstated
at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement
to become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inspection</U>.
The Company shall permit the Major Investors (<I>provided</I> that the Board has not reasonably determined that any such Major Investor
is a Competitor), once a fiscal quarter upon at least seven (7)&nbsp;days&rsquo; advance notice, to visit the Company&rsquo;s properties,
discuss the Company&rsquo;s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be
reasonably requested by the Major Investors; <I>provided</I>, <I>however</I>, that the Company shall not be obligated pursuant to this
<U>Section&nbsp;3.2</U> to provide access to information that it, in its sole discretion, considers to be a trade secret, confidential
information, or competitively sensitive or the disclosure of which would adversely affect the attorney-client privilege between the Company
and its counsel. The Major Investors collectively may only exercise their inspection rights pursuant to this <U>Section&nbsp;3.2</U>
one (1)&nbsp;time per fiscal quarter, but the Company will give the Major Investors reasonably prompt notice of an exercise of these
rights and make reasonable arrangements to offer all Major Investors the opportunity to participate with one representative of such Major
Investor. Any information obtained during such inspection shall be treated as confidential information pursuant to <U>Section&nbsp;3.5</U>
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Observer
Rights</U>. (a)&nbsp;Unless the Series&nbsp;C Director is serving on the Board and is an employee, consultant or advisor of Stonebridge-Highland,
Stonebridge, or Highland or their respective Affiliates, for as long as Stonebridge-Highland owns at least 13,586,957 shares of Series&nbsp;C
Preferred Stock (or Common Stock issued upon conversion thereof) (as adjusted for any stock split, stock dividend, reorganization, stock
combination, or similar transaction effected after the date hereof), the Company will invite a representative of Stonebridge-Highland
reasonably acceptable to the Company (which will initially be Nate Burns) to attend all meetings of the Board in a nonvoting observer
capacity; (b)&nbsp;unless the Series&nbsp;C Director is serving on the Board and is an employee, consultant or advisor of Coatue US 21
LLC or its Affiliates (&ldquo;<B><I>Coatue</I></B>&rdquo;), for as long as Coatue owns at least 13,586,957 shares of Series&nbsp;C Preferred
Stock (or Common Stock issued upon conversion thereof) (as adjusted for any stock split, stock dividend, reorganization, stock combination
or similar transaction effected after the date hereof), the Company will invite a representative of Coatue reasonably acceptable to the
Company (the &ldquo;<B><I>Coatue Observer</I></B>&rdquo;) to attend all meetings of the Board in a nonvoting observer capacity; and (c)&nbsp;for
as long as OrbiMed owns at least 8,152,175 shares of Series&nbsp;C Preferred Stock (or Common Stock issued upon conversion thereof) (as
adjusted for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof),
the Company will invite a representative of OrbiMed reasonably acceptable to the Company (the &ldquo;<B><I>OrbiMed Observer</I></B>&rdquo;)
to attend all meetings of the Board in a nonvoting observer capacity, and in this respect, will give such representatives copies of all
notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided
to such directors (with respect to Stonebridge Highland&rsquo;s observer, without following the procedures in <U>Section&nbsp;3.6</U>);
<I>provided</I>, <I>however</I>, that such representatives will agree to hold in confidence and trust and to act in a fiduciary manner
with respect to all information so provided and will not disclose such information to any other persons; and <I>provided further</I>,
that the Company reserves the right to withhold any information and to exclude such representatives from any meeting or portion thereof
if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and
its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representatives is a Competitor
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Information and Observer Rights</U>. The covenants set forth in <U>Section&nbsp;3.1</U>, <U>Section&nbsp;3.2</U>, and <U>Section&nbsp;3.3</U>
will terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company
first becomes subject to the periodic reporting requirements of Section&nbsp;12(g)&nbsp;or 15(d)&nbsp;of the Exchange Act, (iii)&nbsp;upon
the closing of a Qualified SPAC Transaction, or (iv)&nbsp;upon the closing of a Deemed Liquidation Event, as such term is defined in the
Certificate, other than a Deemed Liquidation Event under clause (c)&nbsp;of the definition of Deemed Liquidation Event in circumstances
where the Investors continue to own shares of the Company, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Confidentiality</U>.
Each Investor, other than Sixth Street, agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company or its representatives
(including notice of the Company&rsquo;s intention to file a registration statement), unless such confidential information (a)&nbsp;is
known or becomes known to the public in general (other than as a result of a breach of this <U>Section&nbsp;3.5</U> by such Investor),
(b)&nbsp;is or has been independently developed or conceived by such Investor without use of the Company&rsquo;s confidential information,
or (c)&nbsp;is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality
such third party may have to the Company; <I>provided</I>, <I>however</I>, that an Investor may disclose (i)&nbsp;confidential information
to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; <I>provided </I>that such Person is subject to an obligation of confidentiality; (ii)&nbsp;high-level
summaries that only describe the Company&rsquo;s business and high-level general financial information without reference to business plans,
intellectual property, trade secrets, or other confidential information of the Company to prospective limited partners or members of such
Investor; (iii)&nbsp;general financial information and high-level summaries that only describe the Company&rsquo;s business without reference
to business plans, intellectual property, trade secrets, or other confidential information of the Company to limited partners or members
of such Investor (but not prospective limited partners or members); <I>provided</I> that such recipient is subject to an obligation of
confidentiality with respect to the information received<FONT>;</FONT> (iv)&nbsp;confidential information
to bona fide prospective purchasers of an Investor&rsquo;s capital stock of the Company; <I>provided</I> that (A)&nbsp;such prospective
purchaser is not a Competitor, (B)&nbsp;such prospective purchaser enters into a confidentiality agreement with the Investor that is consistent
with and on terms no less restrictive than this <U>Section&nbsp;3.5</U> that provides that the Company is a third-party beneficiary and
entitled to enforce such confidentiality agreement against such prospective purchaser, and (C)&nbsp;the Investor making such disclosure
to such prospective purchaser shall be liable under this Agreement for any disclosure or use of confidential information by such prospective
purchaser that would be a breach of this Agreement as if such prospective purchaser were an Investor under this Agreement; (iv)&nbsp;to
the extent required in connection with any routine or periodic examination, audit or similar process by any regulatory or self-regulatory
body or authority not specifically directed at the Company or the confidential information obtained from the Company pursuant to the terms
of the Agreement, including, without limitation, quarterly or annual reports; or (v)&nbsp;as may otherwise be required by law, regulation,
rule, court order, or subpoena; <I>provided</I> that such Investor promptly notifies the Company of such disclosure and takes reasonable
steps to minimize the extent of any such required disclosure. The Company acknowledges and agrees that in no event shall an Investor&rsquo;s
confidentiality and non-use obligations hereunder in any manner be deemed or construed as an outright restriction on such Investor&rsquo;s
or its representatives&rsquo; (or any of their respective Affiliates) ability to trade any securities of a company that is publicly traded;
provided, however, that each Investor acknowledges its obligations to comply with applicable securities laws, including those that prohibit
Persons from purchasing or selling securities while in possession of relevant material non-public information. For the avoidance of doubt,
Sixth Street shall not be subject to any of the restrictions set forth in this <U>Section&nbsp;3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Material
Non-Public Information</U>. The Company understands and acknowledges that in the regular course of the Investors&rsquo; businesses, certain
Investors may invest in companies that have issued securities that are publicly traded (each, a &ldquo;<B><I>Public Company</I></B>&rdquo;).
Accordingly, if the Company has identified material non-public information in its possession relating to a Public Company, the Company
will not share such material non-public information with the Investors. The Company will use commercially reasonable efforts to identify
the material non-public information about a Public Company (&ldquo;<B><I>Public Company Information</I></B>&rdquo;) and will contact the
Investors who have a contact set forth on <B><U>Schedule C</U></B> (the &ldquo;<B><I>Restricted Investors</I></B>&rdquo;). In the event
that the Company seeks an exception to the prohibition on providing material non-public information on a Public Company to the Restricted
Investors, the Company shall provide prior written notice (which may include e-mail) describing such information to and receive prior
written approval (which may include e-mail) from such contact set forth on <B><U>Schedule C</U></B>. The Company will be permitted to
disclose agreements entered into with Public Companies in the ordinary course of business, such as routine customer, supplier, advertising,
and publishing agreements without such written authorization. Each Investor acknowledges and agrees that this <U>Section&nbsp;3.6</U>
shall not apply to any Public Company Information that is disclosed during discussions at any meeting of the Board (or any committee thereof),
which, with respect to all Restricted Investors other than Braidwell, excludes disclosure in materials prepared for the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rights
to Future Stock Issuances</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of First Offer</U>. Subject to the terms and conditions of this <U>Section&nbsp;4.1</U> and applicable securities laws, if the Company
proposes to offer or sell any New Securities, the Company will first offer such New Securities to each Major Investor. A Major Investor
may apportion the right of first offer hereby granted to it in such proportions as such Major Investor deems appropriate, among (i)&nbsp;itself
and (ii)&nbsp;its Affiliates (other than portfolio companies or operating companies); <I>provided </I>that each such Affiliate (x)&nbsp;is
not a Competitor, (y)&nbsp;agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale
Agreement, as an &ldquo;<B><I>Investor</I></B>&rdquo; and &ldquo;<B><I>Shareholder</I></B>&rdquo; under the Voting Agreement and an Other
Holder under the Right of First Refusal and Co-Sale Agreement, and (z)&nbsp;the participation of such Affiliate in such offering would
not require the Company or such Affiliate to make any regulatory filing with any governmental authority (other than filings required in
accordance with the U.S. Corporate Transparency Act or any similar regulatory filings). It is understood and agreed that only funds jointly
managed by Highland and Stonebridge will be deemed Affiliates of Stonebridge-Highland for purposes of this <U>Section&nbsp;4.1</U> prior
to (x)&nbsp;<FONT>the Company&rsquo;s first IPO</FONT> or (y)&nbsp;a concurrent private placement in connection
with a Qualified SPAC Transaction (clauses (x)&nbsp;and (y)&nbsp;together, a &ldquo;<B><I>Public Offering</I></B>&rdquo;), and with respect
to a Public Offering, Affiliates of each of Highland and Stonebridge will be deemed Affiliates of Stonebridge-Highland for purposes of
this <U>Section&nbsp;4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company will give notice (the &ldquo;<B><I>Offer Notice</I></B>&rdquo;) to each Major Investor, stating (i)&nbsp;its bona fide intention
to offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any,
upon which it proposes to offer such New Securities; <I>provided</I>, that in the case of a Public Offering, the Company will only be
required to provide notice of the expected size of the offering (but will not be required to provide information regarding the expected
price of the offering).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>By
notification to the Company within twenty (20) days (or ten (10)&nbsp;days in connection with a Public Offering) after the Offer Notice
is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice,
up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including
all shares of Common Stock then issuable <FONT>(directly or indirectly) </FONT>upon conversion <FONT>and/or
exercise, as applicable, </FONT>of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to
the total Common Stock of the Company then outstanding (assuming full conversion and<FONT>/or</FONT> exercise<FONT>,
as applicable,</FONT> of all <FONT>Preferred Stock and any other </FONT>Derivative Securities then outstanding).
At the expiration of such twenty (20) day period (or ten (10)&nbsp;day period in connection with a Public Offering), the Company will
promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a &ldquo;<B><I>Fully Exercising
Investor</I></B>&rdquo;) of any other Major Investor&rsquo;s failure to do likewise. During the ten (10)&nbsp;day period (or three (3)&nbsp;day
period in connection with a Public Offering) commencing after the Company has given such notice, each Fully Exercising Investor may, by
giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of
the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which
is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion <FONT>and/or
exercise, as applicable, of </FONT>Preferred Stock <FONT>and any other Derivative Securities</FONT> then
held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable <FONT>(directly
or indirectly) </FONT>upon conversion <FONT>and/or exercise, as applicable, </FONT>of the Preferred Stock
<FONT>and any other Derivative Securities</FONT> then held, by all Fully Exercising Investors who wish
to purchase such unsubscribed shares. The closing of any sale pursuant to this <U>Section&nbsp;4.1(b)</U>&nbsp;will occur within the later
of one hundred twenty (120) days of the date that the Offer Notice is given and the date of the initial sale of <FONT>New
Securities pursuant to <U>Section&nbsp;4.1(c)</U>; <I>provided</I>, that in connection with a Public Offering, such closing will occur
pursuant to the terms of such Public Offering</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in <U>Section&nbsp;4.1(b)</U>,
the Company may, during the ninety (90) day period following the expiration of the periods provided in <U>Section&nbsp;4.1(b)</U>, offer
and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms
no more favorable to the offeree than, those specified in the Offer Notice; <I>provided</I>, that in connection with a Public Offering,
the Company will not be restricted regarding the aggregate size of the offering or the price per share. If the Company does not enter
into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within sixty (60) days
of the execution thereof, the right provided hereunder will be deemed to be revived and such New Securities may not be offered unless
first reoffered to the Major Investors in accordance with this <U>Section&nbsp;4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
right of first offer in this <U>Section&nbsp;4.1</U> will not be applicable to (i)&nbsp;Exempted Securities (as defined in the Certificate);
(ii)&nbsp;the issuance of shares of Series&nbsp;E Preferred Stock and/or shares of Series&nbsp;F Preferred Stock to Additional Purchasers
pursuant to <U>Section&nbsp;1.3</U> of the Purchase Agreement; provided, that, (x)&nbsp;with respect to the Series&nbsp;E Preferred Stock,
such shares shall have an aggregate original purchase price of no greater than $100,000,000.00, less the aggregate original purchase
price of the shares of Series&nbsp;E Preferred Stock sold at the Initial Closing (as defined in the Purchase Agreement) and (y)&nbsp;with
respect to the Series&nbsp;F Preferred Stock, such shares shall have an aggregate original purchase price of no greater than $85,000,000.00,
less the aggregate original purchase price of the shares of Series&nbsp;F Preferred Stock sold at the Initial Closing; (iii)&nbsp;the
issuance of Additional Notes (as defined in the Note Purchase Agreement) to Additional Purchasers (as defined in the Note Purchase Agreement)
pursuant to Section&nbsp;1.2.4 of the Note Purchase Agreement, so long as such Additional Notes are issued pursuant to the Note Purchase
Agreement in effect as of the Initial Closing (as defined in the Note Purchase Agreement) without giving effect to any material amendments
of the Note Purchase Agreement after the Initial Closing (as defined in the Note Purchase Agreement) or (iv)&nbsp;the issuance of the
Warrants (as defined in the Note Purchase Agreement) pursuant to Section&nbsp;6.1.3 of the Note Purchase Agreement, so long as such Warrants
are issued pursuant to the Note Purchase Agreement in effect as of the Initial Closing (as defined in the Note Purchase Agreement) on
the terms set forth in the form of Warrant attached thereto without giving effect to any material amendments of the Note Purchase Agreement,
the form of Warrant or any Warrants issued pursuant to the Note Purchase Agreement, in each case after the Initial Closing (as defined
in the Note Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
any provision hereof to the contrary, in lieu of complying with the provisions of this <U>Section&nbsp;4.1</U> except for New Securities
to be issued in connection with a Public Offering, the Company may elect to give notice to the Major Investors within thirty (30) days
after the issuance of New Securities. Such notice will describe the type, price, and terms of the New Securities. Each Major Investor
will have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased
by such Major Investor, maintain such Major Investor&rsquo;s percentage-ownership position, calculated as set forth in <U>Section&nbsp;4.1(b)</U>&nbsp;before
giving effect to the issuance of such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
The covenants set forth in <U>Section&nbsp;4.1</U> will terminate and be of no further force or effect (i)&nbsp;immediately following
the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g)&nbsp;or
15(d)&nbsp;of the Exchange Act, (iii)&nbsp;upon the closing of a Qualified SPAC Transaction, or (iv)&nbsp;upon the closing of a Deemed
Liquidation Event, as such term is defined in the Certificate, other than a Deemed Liquidation Event under clause (c)&nbsp;of the definition
of Deemed Liquidation Event in circumstances where the Investors continue to own shares of the Company, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Covenants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Matters
Requiring Series&nbsp;C Director Approval</U>. In the event the holders of Series&nbsp;C Preferred Stock are entitled to designate the
Series&nbsp;C Director as set forth in the Certificate, the Company hereby covenants and agrees with each of the Investors that it will
not, without the approval of the Board, which approval must include the affirmative vote of the Series&nbsp;C Director:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>incur
more than $30 million of additional indebtedness for borrowed money (beyond the principal amount of any indebtedness for borrowed money
that exists as of the appointment of the Series&nbsp;C Director to the Board) after the date of appointment of the Series&nbsp;C Director;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>change
the principal business of the Company or enter into a new line of business, in each case outside the life sciences sector, which for
clarification does not include the sale or licensing of data gathered from businesses within the life sciences sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
to Conduct Activities</U>. The Company hereby agrees and acknowledges that each Major Investor (together with their respective Affiliates)
is a professional investment organization and as such reviews the business plans and related proprietary information of many enterprises,
some of which may compete directly or indirectly with the Company&rsquo;s business (as currently conducted or as currently propose to
be conducted).&nbsp; The Company hereby agrees that, to the extent permitted under applicable law, no Major Investor (or its Affiliates)
will be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by such Major Investor (or its Affiliates)
in any entity competitive with the Company, or (ii)&nbsp;actions taken by any partner, officer, employee, or other representative of
such Major Investor (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the
board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company;
<I>provided</I>, <I>however</I>, that the foregoing will not relieve (x)&nbsp;any of the Investors from liability associated with the
unauthorized disclosure or use of the Company&rsquo;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any director
or officer of the Company from any liability associated with his or her fiduciary duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Permitted
Issuances of Series&nbsp;E Preferred Stock, Series&nbsp;D Preferred Stock, and Series&nbsp;C Preferred Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company hereby agrees and acknowledges that unless the Requisite Series&nbsp;E Holders give their prior written consent, the Company will
not issue shares of Series&nbsp;E Preferred Stock other than pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company hereby agrees and acknowledges that unless the Requisite Series&nbsp;D Holders give their prior written consent, the Company
will not issue shares of Series&nbsp;D Preferred Stock other than pursuant to the Series&nbsp;D Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company hereby agrees and acknowledges that unless the Requisite Series&nbsp;C Holders give their prior written consent, the Company
will not issue shares of Series&nbsp;C Preferred Stock other than pursuant to: (i)&nbsp;warrants issued to Sixth Street Specialty Lending,&nbsp;Inc.,
and Barnett Equity Holdings, LLC disclosed on the Disclosure Schedules to the Purchase Agreement; and (ii)&nbsp;that certain Convertible
Loan Agreement, dated as of September&nbsp;21, 2018, by and among Caris Life Sciences,&nbsp;Ltd., certain subsidiaries of Caris Life
Sciences,&nbsp;Ltd. from time to time and TPG Specialty Lending,&nbsp;Inc., as amended by that certain Amendment No.&nbsp;1 to Convertible
Loan Agreement, dated as of April&nbsp;2, 2020, by and among Caris Life Sciences,&nbsp;Ltd., Caris Molecular Diagnostics,&nbsp;Inc.,
Caris Science,&nbsp;Inc., Caris MPI,&nbsp;Inc., Caris Pharmatech,&nbsp;Inc., Caris Therapeutics,&nbsp;Inc., TAO Barnett Investments,
LLC, Top III Barnett Investments, LLC, and TPG Specialty Lending,&nbsp;Inc., as each such agreement may be further amended or restated
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Covenants</U>. The covenants set forth in <U>Section&nbsp;5.1</U> and <U>Section&nbsp;5.3</U> will terminate and be of no further
force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic
reporting requirements of Section&nbsp;12(g)&nbsp;or 15(d)&nbsp;of the Exchange Act, (iii)&nbsp;upon the closing of a Qualified SPAC
Transaction, or (iv)&nbsp;upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate, other than a Deemed
Liquidation Event under clause (c)&nbsp;of the definition of Deemed Liquidation Event in circumstances where the Investors continue to
own shares of the Company, whichever event occurs first.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. <FONT>The rights under this Agreement</FONT> may <FONT>be</FONT>
assigned (<FONT>but only with all related obligations</FONT>) <FONT>by a
Holder to a transferee of</FONT> Registrable Securities <FONT>that (i)&nbsp;is an Affiliate of a Holder,
(ii)&nbsp;is a Holder&rsquo;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&rsquo;s
Immediate Family Members, or (iii)&nbsp;after such transfer, holds at least 2,000,000 shares of Registrable Securities </FONT>(or such
lesser amount of Registrable Securities constituting all of such Investor&rsquo;s Registrable Securities) <FONT>(subject
to appropriate adjustments for </FONT>any stock split, stock dividend, reorganization, stock combination, or similar transaction effected
after the date hereof<FONT>); <I>provided</I>, <I>however</I>, that (x)&nbsp;the Company is, within a reasonable
time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities</FONT>
with respect to <FONT>which such</FONT> rights <FONT>are being transferred;
and (y)&nbsp;such transferee agrees in</FONT> a written instrument <FONT>delivered </FONT>to the Company
to be bound by <FONT>and subject to </FONT>the terms <FONT>and conditions
</FONT>of this <FONT>Agreement, including, without limitation, the provisions of <U>Section&nbsp;2.11</U>
and <U>Section&nbsp;3.5</U>; <I>provided</I>, <I>further</I> that such Affiliate or Immediate Family Member is not either (x)&nbsp;a Competitor
of the Company or (y)&nbsp;Person of the type described in Rule&nbsp;506(d)(1)&nbsp;of the Securities Act of 1933, as amended. For the
purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1)&nbsp;that
is an Affiliate or shareholder of a Holder; (2)&nbsp;who is a Holder&rsquo;s Immediate Family Member; or (3)&nbsp;that is a trust for
the benefit of an individual Holder or such Holder&rsquo;s Immediate Family Member will be aggregated together and with those of the transferring
Holder; <I>provided further</I> that all transferees who would not qualify individually for assignment of rights will, as a condition
to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking
any action under this Agreement.</FONT> The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective
successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided herein. No assignment shall relieve any party of its obligations under
<U>Section&nbsp;3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Agreement will be governed by the internal law of the State of Texas, without regard to conflict of law principles that
would result in the application of any law other than the law of the State of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which will be deemed an original, but all of which together
will constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g<I>.</I>, www.docusign.com) or other transmission method and any counterpart so
delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
All notices and other communications given or made pursuant to this Agreement will be in writing and will be deemed effectively given
upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by electronic
mail during the recipient&rsquo;s normal business hours, and if not sent during normal business hours, then on the recipient&rsquo;s
next business day; (iii)&nbsp;five (5)&nbsp;days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv)&nbsp;one (1)&nbsp;business day after the business day of deposit with a nationally recognized overnight courier, freight
prepaid, specifying next-day delivery, with written verification of receipt. All communications will be sent to the respective parties
at their addresses as set forth on <B><U>Schedule A</U></B> hereto, or to the principal office of the Company and to the attention of
the Chief Executive Officer, in the case of the Company, or to such email address or address as subsequently modified by written notice
given in accordance with this <U>Section&nbsp;6.5</U>. If notice is given to the Company, a copy will also be sent to <U>GC@carisls.com</U>
and to Latham&nbsp;&amp; Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Attn: Nathan Ajiashvili, Email: Nathan.Ajiashvili@lw.com,
if notice is given to Braidwell, a copy will also be given to Gibson, Dunn&nbsp;&amp; Crutcher LLP, One Embarcadero Center, # 2600, San
Francisco, CA 94111, Attn: Ryan Murr, Email: RMurr@gibsondunn.com, Stonebridge-Highland, a copy will also be given to Squire Patton Boggs
(US) LLP, 1801 California St., Suite&nbsp;4900, Denver, CO 80202, Attn: Thomas Reems, Email: thomas.reems@squirepb.com, and if notice
is given to Sixth Street, a copy will also be given to Ropes&nbsp;&amp; Gray LLP, 32nd Floor, 191 North Wacker Drive, Chicago,&nbsp;IL
60606, Attn: Matthew J. Richards; Email: Matthew.Richards@ropesgray.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
and Waivers</U>. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may
be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of
(i)&nbsp;the Company, (ii)&nbsp;the Principal Holders (as defined in the Right of First Refusal and Co-Sale Agreement), (iii)&nbsp;the
Requisite Series&nbsp;C Holders, (iv)&nbsp;the Requisite Series&nbsp;D Holders, and (v)&nbsp;the Requisite Series&nbsp;E Holders (unless
this Agreement is to be amended in connection with the authorization, creation, issuance, and/or sale of Permitted Preferred Stock (as
defined in the Certificate), to (A)&nbsp;add the purchaser(s)&nbsp;of Permitted Preferred Stock as Investor(s)&nbsp;or Major Investor(s)&nbsp;for
purposes of this Agreement, including <U>Sections 3</U> and <U>4</U>, (B)&nbsp;create a list of transactions which require the consent
of a director appointed solely by the purchasers of Permitted Preferred Stock, (C)&nbsp;grant such purchaser(s)&nbsp;registration rights
that may be granted in compliance with <U>Section&nbsp;2.10</U> and (D)&nbsp;grant such purchaser(s)&nbsp;rights that would not adversely
modify the rights of the holders of the Series&nbsp;C Preferred Stock, the holders of the Series&nbsp;D Preferred Stock or the holders
of the Series&nbsp;E Preferred Stock (beyond any modification associated with the addition of additional Investors, holders of Permitted
Preferred Stock or Major Investors) (for purposes of this clause (D)&nbsp;the Investors holding Series&nbsp;C Preferred Stock, Series&nbsp;D
Preferred Stock and Series&nbsp;E Preferred Stock agree that granting rights to the holder(s)&nbsp;of Permitted Preferred Stock on a
subject matter when the holders of Series&nbsp;C Preferred Stock, Series&nbsp;D Preferred Stock or Series&nbsp;E Preferred Stock, as
applicable, are not granted rights on that subject matter does not adversely modify the rights of the holders of Series&nbsp;C Preferred
Stock, Series&nbsp;D Preferred Stock or Series&nbsp;E Preferred Stock, as applicable), it being understood that any such amendment described
in this parenthetical shall not require the consent of the Requisite Series&nbsp;C Holders, the Requisite Series&nbsp;D Holders or the
Requisite Series&nbsp;E Holders); <I>provided</I> that the Company may in its sole discretion waive compliance with <U>Section&nbsp;2.12(c)</U>&nbsp;(and
the Company&rsquo;s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of <U>Section&nbsp;2.12(c)</U>&nbsp;will
be deemed to be a waiver); <I>provided furthe</I>r that this Agreement may not be amended, modified, terminated, or waived to adversely
modify the rights granted to J.H. Whitney VI, L.P. disproportionately to the effect on the rights of the other Investors without the
written consent of J.H. Whitney VI, L.P. Notwithstanding the foregoing, <U>Section&nbsp;1.1</U>, <U>Section&nbsp;1.5</U>, <U>Section&nbsp;1.21</U>,
<B><U>Schedule B</U></B>, <U>Section&nbsp;3.1</U>, <U>Section&nbsp;3.2</U>, S<U>ection&nbsp;3.5(iii)</U>, <U>Section&nbsp;6.8</U> and
this sentence of <U>Section&nbsp;6.6</U> shall not be amended, modified, terminated (other than as provided in <U>Section&nbsp;3.4</U>)
or waived in a manner that would adversely affect the rights of an Investor that is a mutual fund, pension fund, separately managed account
or other pooled investment vehicle, in each case managed by an investment advisor registered under the Investment Advisers Act of 1940,
as amended (an &ldquo;<B><I>Advisory Investor</I></B>&rdquo;), without either (i)&nbsp;the consent of such Advisory Investor, or (ii)&nbsp;providing
such Advisory Investor the rights in such sections in a separate letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, <U>Section&nbsp;3.1</U>, <U>Section&nbsp;4</U>, and any other section of this Agreement applicable to the Major Investors
(including this clause of this <U>Section&nbsp;6.6</U>) may not be amended, modified, terminated or waived without the written consent
of the Company and the holders of at least a majority of the Registrable Securities then outstanding and held by the Major Investors.
Notwithstanding the foregoing, </FONT><B><U>Schedule A</U></B>, <B><U>Schedule B</U></B>, and <B><U>Schedule C</U></B> hereto may be amended
by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without
the consent of the other parties; and <B><U>Schedule A</U></B>, <B><U>Schedule B</U></B>, and <B><U>Schedule C</U></B> hereto may also
be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional
Investor who becomes a party to this Agreement in accordance with <U>Section&nbsp;6.9</U>. The Company will give prompt notice of any
amendment, modification, or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment,
modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance with this <U>Section&nbsp;6.6</U>
will be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any
term, condition, or provision of this Agreement, in any one or more instances, will be deemed to be or construed as a further or continuing
waiver of any such term, condition, or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal, or unenforceable
in any respect, such invalidity, illegality, or unenforceability will not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision will be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Aggregation
of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates will be aggregated together for the purpose of determining
the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company&rsquo;s
Series&nbsp;E Preferred Stock and/or shares of Series&nbsp;F Preferred Stock after the date hereof pursuant to the Purchase Agreement,
any purchaser of such shares may become a party to this Agreement by executing and delivering an additional counterpart signature page&nbsp;to
this Agreement, and thereafter will be deemed an &ldquo;<B><I>Investor</I></B>&rdquo; for all purposes hereunder. No action or consent
by the Investors will be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor
has agreed in writing to be bound by all of the obligations as an &ldquo;<B><I>Investor</I></B>&rdquo; hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement</U>. This Agreement (including any Schedules and Exhibits hereto), the Side Letters (as defined in the Series&nbsp;D Purchase
Agreement) and any side letters entered into in connection with the Purchase Agreement constitute the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled (including the Existing Agreement, which this Agreement amends and restates
in its entirety).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dispute
Resolution</U>. The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Texas or
to the jurisdiction of the United States District Court for the Northern District of Texas, in each case located in Dallas County, Texas,
for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to commence any
suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Dallas County, Texas or the
United States District Court for the Northern District of Texas, and (c)&nbsp;hereby waive, and agree not to assert, by way of motion,
as a defense, or otherwise, in any such suit, action, or proceeding, any claim that it is not subject personally to the jurisdiction of
the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action, or proceeding is brought
in an inconvenient forum, that the venue of the suit, action, or proceeding is improper or that this Agreement or the subject matter hereof
may not be enforced in or by such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>WAIVER
OF JURY TRIAL</U>. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED
TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY&nbsp;BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION,&nbsp;INCLUDING,
WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY
CLAIMS. THIS SECTION&nbsp;HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS.
EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH
PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delays
or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, will impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor will it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor will any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, will be cumulative
and not alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Massachusetts
Business Trust</U>. A copy of the Declaration of Trust of each Fidelity Investor or any Affiliate thereof is on file with the Secretary
of State of the Commonwealth of Massachusetts and notice is hereby given that this Agreement has been executed on behalf of the trustees
of such Fidelity Investor or any Affiliate thereof as trustees and not individually and that the obligations of this Agreement are not
binding on any of the trustees, officers or stockholders of such Fidelity Investor or any Affiliate thereof individually but are binding
only upon such Fidelity Investor or any Affiliate thereof and its assets and property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of Page&nbsp;Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARIS
    LIFE SCIENCES,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARIS
     HALBERT, L.P.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: Caris Investment Management, LLC,
    its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David D.
    Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADAPT
    I LTD.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">By:
                                            DDH Adapt Trust, its General Partner</FONT></P>

</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David D.
    Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>CARISOME I, L.P.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: DDH Carisome Trust, its Managing
    General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Trustee</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>CARIS INVESTMENT III LTD.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: Caris Investment Management, LLC,
    its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Managing Member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<FONT STYLE="font-variant: small-caps">Signature Page&nbsp;to
Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"></FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>CARIS INVESTMENT II LTD.</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By: Caris Investment Management, LLC, its General Partner</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%">/s/ David D. Halbert</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">David D. Halbert</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Managing Member</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ David. D. Halbert</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">DAVID D. HALBERT</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">SH CARIS LIFE US, LLC</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Jun Park</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> Jun Park</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"> Authorizd Officer</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">SH CARIS LIFE US 2, LLC</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> /s/ Jun Park</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Jun Park</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Authorizd Officer</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">SH CARIS LIFE US 3, LLC</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Jun Park</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Jun Park</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Authorizd Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">SIXTH STREET
    SPECIALTY LENDING,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-size: 10pt">Vice President</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">TAO BARNETT
    INVESTMENTS, LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Vice President</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt"><B>TOP III
    BARNETT INVESTMENTS, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Vice President</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt"><B>BARNETT EQUITY
    HOLDINGS, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Vice President</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt"><B>BARNETT EQUITY
    HOLDINGS II, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Joshua Peck</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Vice President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE NEW HORIZONS FUND,
  INC.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE U.S. EQUITIES TRUST</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">MASSMUTUAL SELECT FUNDS -</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">MASSMUTUAL SELECT T. ROWE PRICE</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SMALL AND MID CAP BLEND FUND</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not
  jointly</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. <FONT STYLE="text-transform: uppercase"><B>ROWE
  PRICE HEALTH SCIENCES FUND,&nbsp;INC.</B></FONT></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">TD MUTUAL FUNDS - TD HEALTH SCIENCES
  FUND</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>T
  ROWE PRICE HEALTH SCIENCES PORTFOLIO</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not
  jointly</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. <FONT STYLE="text-transform: uppercase"><B>ROWE
  PRICE SMALL-CAP STOCK FUND,&nbsp;INC.</B></FONT></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>T.
                                            ROWE PRICE INSTITUTIONAL SMALL-CAP STOCK FUND</B></FONT></P>

</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>T.
                                            ROWE PRICE SPECTRUM CONSERVATIVE ALLOCATION FUND</B></FONT></P>

</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE SPECTRUM MODERATE
  ALLOCATION FUND</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE SPECTRUM MODERATE
  GROWTH ALLOCATION FUND</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>T.
  ROWE PRICE MODERATE ALLOCATION PORTFOLIO</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">U.S. SMALL-CAP STOCK TRUST</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">VALIC COMPANY I - SMALL CAP FUND</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">TD MUTUAL FUNDS - TD U.S. SMALL-CAP
  EQUITY FUND</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE U.S. SMALL-CAP CORE
  EQUITY TRUST</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>MINNESOTA
  LIFE INSURANCE COMPANY</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">COSTCO 401(K)&nbsp;RETIREMENT PLAN</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>MASSMUTUAL SELECT FUNDS - MASSMUTUAL</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>SELECT
                                            T. ROWE PRICE SMALL AND MID CAP BLEND FUND</B></FONT></P>

</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not
  jointly</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt">&nbsp;</TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt">&nbsp;</TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt">&nbsp;</TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-transform: uppercase"><FONT STYLE="font-size: 10pt">T.
    ROWE PRICE MID-CAP GROWTH FUND,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">T. ROWE PRICE
    INSTITUTIONAL MID-CAP EQUITY GROWTH FUND</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">T. ROWE PRICE
    MID-CAP GROWTH PORTFOLIO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">T. ROWE PRICE
    U.S. EQUITIES TRUST</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">TD MUTUAL FUNDS
    - TD U.S. MID-CAP GROWTH</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">FUND</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">MASSMUTUAL SELECT
    FUNDS - MASSMUTUAL</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">SELECT MID CAP
    GROWTH FUND</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">MML SERIES INVESTMENT
    FUND - MML MID CAP GROWTH FUND</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">BRIGHTHOUSE FUNDS
    TRUST I - T. ROWE PRICE MID CAP GROWTH PORTFOLIO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">T. ROWE PRICE
    U.S. MID-CAP GROWTH EQUITY</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">TRUST</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">COSTCO 401(K)&nbsp;RETIREMENT
    PLAN</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">MASSMUTUAL SELECT
    FUNDS - MASSMUTUAL</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">SELECT T. ROWE
    PRICE SMALL AND MID CAP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">BLEND FUND</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not
  jointly</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt">&nbsp;</TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt">&nbsp;</TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt">&nbsp;</TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-transform: uppercase">T. ROWE PRICE DIVERSIFIED MID-CAP GROWTH FUND,&nbsp;INC.&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">T. ROWE PRICE TAX-EFFICIENT EQUITY FUND</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">JEFFREY LLC</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">LINCOLN VARIABLE INSURANCE</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">PRODUCTS TRUST - LVIP T. ROWE PRICE STRUCTURED</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">MID-CAP GROWTH FUND&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">VOYA PARTNERS,&nbsp;INC. - VY T. ROWE PRICE</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">DIVERSIFIED MID CAP GROWTH PORTFOLIO</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">LINCOLN VARIABLE INSURANCE PRODUCTS</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">TRUST &ndash; LVIP BLENDED MID CAP MANAGED</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">VOLATILITY FUND</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not
  jointly</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-transform: uppercase">T. ROWE PRICE ALL-CAP OPPORTUNITIES FUND&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">T. ROWE PRICE ALL-CAP OPPORTUNITIES</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">PORTFOLIO</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">T. ROWE PRICE GLOBAL ALLOCATION FUND,&nbsp;INC.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not
  jointly</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>T.
  ROWE PRICE NEW HORIZONS TRUST</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">By:
  T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nicholas Garifo</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top; text-align: left">
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice President, Senior Legal Counsel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIDELITY
    SECURITIES FUND: FIDELITY SMALL CAP GROWTH FUND&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signatory&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIDELITY
    SECURITIES FUND: FIDELITY SMALL CAP GROWTH K6 FUND</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FMR
    CAPITAL,&nbsp;INC. &ndash; FLEX PILOT PORTFOLIO</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BY:
    FIDELITY MANAGEMENT&nbsp;&amp; RESEARCH COMPANY LLC, AS INVESTMENT ADVISOR</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIDELITY
    MT. VERNON STREET TRUST: FIDELITY SERIES GROWTH COMPANY FUND&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">FIDELITY MT. VERNON STREET TRUST:</P>
                                                                                <P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">FIDELITY GROWTH COMPANY FUND&nbsp;</P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">FIDELITY GROWTH COMPANY COMMINGLED POOL&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Fidelity Management Trust Company, as Trustee&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">FIDELITY MT. VERNON STREET TRUST: FIDELITY GROWTH COMPANY K6 FUND&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">FIDELITY SELECT PORTFOLIOS: HEALTH</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">CARE PORTFOLIO</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chris Maher</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">FIDELITY ADVISOR SERIES
    VII: FIDELITY</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ADVISOR HEALTH CARE FUND&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">FIDELITY CENTRAL INVESTMENT</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PORTFOLIOS LLC: FIDELITY U.S.
    EQUITY</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CENTRAL FUND - HEALTH CARE SUB&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">VARIABLE INSURANCE PRODUCTS FUND</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">IV: HEALTH CARE PORTFOLIO</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">FIDELITY SELECT PORTFOLIOS: SELECT</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">MEDICAL TECHNOLOGY AND DEVICES&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PORTFOLIO&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chris Maher</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">COATUE US 21 LLC</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Brent Duddie</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Brent Duddie</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">March&nbsp;24, 2025</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">COATUE US 44 LLC</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Brent Duddie</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Brent Duddie</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> March&nbsp;24, 2025</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SLP CHROME AGGREGATOR,
    L.P.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: SLP VI Aggregator GP, L.L.C., its general
    partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: Silver Lake Technology Associates VI, L.P.,
    its managing member</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: STLA VI (GP) L.L.C., its general partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: Silver Lake Group, L.L.C., its managing member</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Andrew Schader</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Andrew Schader</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ORBIMED PARTNERS MASTER FUND LIMITED</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Capital LLC, solely in its capacity as Investment Advisor&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ C. Scotland Stevens&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">C. Scotland Stevens</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">WORLDWIDE HEALTHCARE TRUST PLC&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Capital LLC, solely in its capacity as Portfolio Manager&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ C. Scotland Stevens&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">C. Scotland Stevens</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ORBIMED GENESIS MASTER FUND, L.P.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Genesis GP LLC,</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;its General Partner&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Advisors LLC,</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; its Managing Member</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> /s/ C. Scotland Stevens&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">C. Scotland Stevens</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORBIMED
    PARTNERS SPV, LTD&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    OrbiMed Capital LLC, solely in its capacity as Investment Advisor</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ C. Scotland Stevens</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. Scotland Stevens</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuberger
    berman principal strategies prima fund lp&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Neuberger Berman Investment Advisers LLC, its investment manager&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gabe Cahill</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabe Cahill</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuberger
    berman principal strategies Co-invest fund I lp</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Neuberger Berman Investment Advisers LLC, its investment manager</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gabe Cahill&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabe Cahill</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuberger
    berman principal strategies Co-invest fund I-B lp&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Neuberger Berman Investment Advisers LLC, its investment manager</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gabe Cahill&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabe Cahill</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.H.
    WHITNEY VI L.P.&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    J.H. Whitney Equity Partners VI, L.P.&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    General Partner&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul R. Vigano</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul R. Vigano</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Member</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CPP
    INVESTMENT BOARD PMI-3 INC.&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Thomas Kalvik</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Kalvik</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March&nbsp;26<SUP>th</SUP>, 2025</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bruce Hogg</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bruce Hogg</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March&nbsp;26<SUP>th</SUP>, 2025</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROCK
    SPRINGS CAPITAL MASTER FUND</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Rock Springs General Partner LLC, its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kris Jenner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kris
    Jenner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRAIDWELL
    TRANSACTION HOLDINGS LLC &ndash; SERIES 11</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Braidwell LP, its Investment Manager&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Colin Bettison&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colin Bettison&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GHISALLO
    FUND MASTER LTD</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Germino</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Germino</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PERCEPTIVE
    LIFE SCIENCES MASTER FUND,&nbsp;LTD.&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Perceptive Advisors, LLC</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James H. Mannix</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James H. Mannix&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SteelMill
    Master Fund LP</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    PointState Holdings LLC, its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alfred J. Barbagallo</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred J. Barbagallo</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WOODLINE
    MASTER FUND LP</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Erin Mullen</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erin Mullen</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST
    LIGHT FOCUS FUND, LP</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    First Light Asset Management LLC, its investment advisor</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mathew Arens</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mathew Arens</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EATON
    VANCE WORLDWIDE&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HEALTH
    SCIENCES FUND&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Eaton Vance Management, as its investment adviser&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jason Kritzer</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason Kritzer</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Longaeva
    Private Growth I L.P.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Longaeva Partners L.P., its investment manager&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dannia Altemimei</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dannia Altemimei</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Siclari</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Siclari</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEF
    Plus Privates Fund, LLC&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    Balyasny Asset Management L.P., its Manager&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dannia Altemimei</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dannia Altemimei</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Siclari</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Siclari</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RIVERVIEW
    GROUP LLC&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrated Holding Group LP,&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its Managing Member&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Millennium Management LLC,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Meskin&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Meskin</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategic Development Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PATRICK
    MCBRIEN</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Patrick McBrien</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick McBrien</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEREMY
    ABELSON</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeremy Abelson</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Abelson</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Amended and Restated Investors&rsquo; Rights Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Schedule
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 66; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE <!-- Field: Sequence; Type: UpperLetter; Name: PageNo -->A<!-- Field: /Sequence --> - 1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Schedule
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investment Management Entities</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE <!-- Field: Sequence; Type: UpperLetter; Name: PageNo -->B<!-- Field: /Sequence --> - 1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Schedule
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Material Non-Public Information Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE <!-- Field: Sequence; Type: UpperLetter; Name: PageNo -->C<!-- Field: /Sequence --> - 1</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1(A)
<SEQUENCE>7
<FILENAME>tm2415719d15_ex10-1a.htm
<DESCRIPTION>EXHIBIT 10.1(A)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit
10.1</B></FONT><B>(a)</B></P>

<P STYLE="border-top: Black 1pt double; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-size: 10pt; margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="border-top: Black 1pt double; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">CREDIT
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">dated as of January&nbsp;18,
2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">among</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC.,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">as the Borrower,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">THE LENDERS FROM
TIME TO TIME PARTY HERETO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">WILMINGTON TRUST,
NATIONAL ASSOCIATION,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">as the Administrative
Agent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-size: 10pt; margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>TABLE
OF CONTENTS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE I DEFINITIONS AND ACCOUNTING TERMS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 1.5in; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 1.1
    </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined Terms</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 1.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Defined Terms</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 1.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-References</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 1.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting and Financial Determinations</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 1.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Interpretive Provisions</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE II COMMITMENT AND BORROWING PROCEDURES</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 2.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 2.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowing Procedure</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 2.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 2.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction of the Commitment Amounts</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE III REPAYMENTS, PREPAYMENTS, INTEREST
    AND FEES</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayments and Prepayments</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization; Repayments and Prepayments</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Default Rate</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment Dates</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.7 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee Letters</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments Generally</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 3.9 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undrawn Fee</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE IV SOFR RATE AND OTHER PROVISIONS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased Costs, Etc</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased Capital Costs</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments, Computations; Proceeds of Collateral, Etc</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Setoff</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SOFR Rate Not Determinable</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 4.7 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaulting Lenders</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE V CONDITIONS TO MAKING THE LOANS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit Extensions</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary&rsquo;s Certificate, Etc</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Date Certificates</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Outstanding Indebtedness, Etc</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of Note</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.7</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Compliance Certificate</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.9 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guarantee</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.10
    </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Agreement</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.11 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property Security Agreements</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.12 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Counsel</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.13 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.14 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Fees, Expenses, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.15 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Terrorism Laws</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.16 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Documents</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.17 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory Legal Form</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.18 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Material Adverse Effect</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.19 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue Base</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 5.20 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Schedules</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE VI REPRESENTATIONS AND WARRANTIES</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due Authorization, Non-Contravention, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Approval, Regulation, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validity, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Material Adverse Effect</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.7 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation, Labor Matters and Environmental Matters</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.9 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership of Properties</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.10 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.11 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.12 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accuracy of Information</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.13 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations U and X</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.14 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.15 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.16 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Agreements</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.17 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permits</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.18 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Matters</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.19 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with Affiliates</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.20 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Company Act</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.21 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFAC</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.22 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit and Disbursement Accounts</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.23 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Privacy and Information Security</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.24 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 6.25 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Side Arrangements or Other Fees</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE VII AFFIRMATIVE COVENANTS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information, Reports, Notices, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Existence; Compliance with Contracts,
    Laws, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Properties</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Books and Records</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Law Covenant</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.7
    </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future Guarantors, Security, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.9 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining of Permits, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.10 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.11 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Regulatory Authorizations, Contracts,
    Intellectual Property, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.12 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.13 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Management</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.14 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Subsidiaries</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.15 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Closing Deliverables</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 7.16 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent HoldCo Reorganization</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE VIII NEGATIVE COVENANTS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Activities</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indebtedness</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liens</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Covenants</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Payments, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.7 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation, Merger; Permitted Acquisitions, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted Dispositions</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.9 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification of Certain Agreements</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.10 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with Affiliates</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.11 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictive Agreements, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.12 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale and Leaseback</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.13 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.14 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Name, Location, Executive Office or Executive
    Management; Change in Fiscal Year</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 8.15 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans and Agreements</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE IX EVENTS OF DEFAULT</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 9.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing of Events of Default</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 9.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Action if Bankruptcy</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 9.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Action if Other Event of Default</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 9.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right to Cure</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 9.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Funds</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE X MISCELLANEOUS PROVISIONS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waivers, Amendments, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices; Time; Inside Information</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Costs and Expenses</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification; Expenses; and Damage Waiver</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.7 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headings</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution in Counterparts, Effectiveness, Etc.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.9
    </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law; Entire Agreement</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.10 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors and Assigns</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.11 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Transactions</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.12</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forum Selection and Consent to Jurisdiction</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.13 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver of Jury Trial</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.14 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential Information</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.15 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exceptions to Confidentiality</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.16 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Waiver; Cumulative Remedies; Enforcement</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.17 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments Set Aside</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.18 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic Execution of Assignments and Certain Other
    Documents</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.19 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Nature of Lenders</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 10.20 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Fiduciary Relationship</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE XI ADMINISTRATIVE AGENT</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment and Authority</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.2 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights as a Lender</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.3 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exculpatory Provisions</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.4 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance by the Administrative Agent</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.5 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delegation of Duties</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.6 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation or Removal of the Administrative Agent</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.7 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Reliance on the Administrative Agent and Other
    Lenders</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.8 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative Agent May File Proofs of Claim</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.9 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral and Guarantee Matters</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION 11.10 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erroneous Payments</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</FONT></TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULES:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 17%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 83%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 2.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and Applicable Percentages</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.7(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.7(b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor Matters</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.8</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Subsidiaries</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.11</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans, Etc.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.15(a)(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property (Registrations and Applications)</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.15(a)(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property (In-Bound Licenses and Sub-Licenses)</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.15(f)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings Challenging Owned Intellectual Property</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.15(g)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validity of Owned and Licensed Intellectual Property</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.15(j)(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infringement Notices</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.15(j)(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infringement of Third Party Intellectual Property</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.16</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Agreements</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.18(i)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation of Fraud and Abuse Laws</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.18(l)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Program-Related Offenses</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.19</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with Permitted Holders</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.22</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit and Disbursement Accounts</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 6.24(d)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 8.2(b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indebtedness to be Paid</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 8.2(c)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Indebtedness</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 8.3(c)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Liens</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 8.5(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 8.10</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with Affiliates</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 8.11</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictive Agreements</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 10.2</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice Information</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS: </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.5in; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit A </FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Promissory Note </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit B</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Loan Request </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit C</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Compliance Certificate </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit D</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Guarantee </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit E</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Security Agreement </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit F</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Assignment and Assumption </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit G</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Solvency Certificate </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">CREDIT
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
CREDIT AGREEMENT dated as of January&nbsp;18, 2023 (as amended, supplemented or otherwise modified from time to time, this &ldquo;<U>Agreement</U>&rdquo;),
is among</FONT> <FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders (defined herein) and Wilmington Trust, National Association (together with its Affiliates, successors, transferees and assignees),
as Administrative Agent. The Borrower, the Administrative Agent and each Lender are sometimes referred to herein individually as a &ldquo;<U>Party</U>&rdquo;
and collectively as the &ldquo;<U>Parties</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>W
</U></FONT><U><FONT STYLE="font-size: 10pt">I T N E S S E T H</FONT></U><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the Borrower has requested that the Lenders provide a senior term loan facility to the Borrower in an aggregate principal amount of $400,000,000
(with $200,000,000 available on the Closing Date, an additional $200,000,000 available in minimum increments of $100,000,000 on or prior
to the Delayed Draw Unavailability Date), subject to the terms and conditions set forth herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the Lenders are willing, on the terms and subject to the conditions hereinafter set forth, to extend the Commitment and make the Loans
to the Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW, THEREFORE,
the parties hereto agree as follows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;I</FONT><FONT STYLE="font-size: 10pt"><BR>
DEFINITIONS AND ACCOUNTING TERMS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;1.1
</FONT><FONT STYLE="font-size: 10pt"><U>Defined Terms</U>. The following terms (whether or not underscored) when used in this Agreement,
including its preamble and recitals, shall, except where the context otherwise requires, have the following meanings (such meanings to
be equally applicable to the singular and plural forms thereof):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>2020
Incentive Plan</U>&rdquo; means the Caris Life Sciences,&nbsp;Inc. 2020 Incentive Plan, as amended, restated, supplemented or otherwise
modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>2023
Convertible Loan Agreement</U>&rdquo; means that certain Convertible Loan Agreement, dated as of September&nbsp;21, 2018, among the Borrower
(as successor to Caris Life Sciences,&nbsp;Ltd.), certain subsidiaries of the Borrower party thereto, the lenders from time to time party
thereto and Sixth Street Specialty Lending,&nbsp;Inc. (f/k/a TPG Specialty Lending,&nbsp;Inc.), as administrative agent for the lenders
(as supplemented or amended prior to the Closing Date and as further supplemented or amended from time to time in accordance with the
terms of this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>2023
Convertible Loan Documents</U>&rdquo; means the &ldquo;Loan Documents&rdquo; (as defined in the 2023 Convertible Loan Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>2023
Convertible Loan Repayment</U>&rdquo; means the conversion, repurchase, redemption, repayment or other retirement of all or a portion
of the 2023 Convertible Loans, including any accrued and unpaid interest and premium thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>2023
Convertible Loans</U>&rdquo; means those certain 8.00% unsecured convertible senior loans in an aggregate original principal amount of
$50,000,000 due on September&nbsp;21, 2023, issued by </FONT><FONT STYLE="font-size: 10pt">the Borrower and governed by the terms of
the 2023 Convertible Loan Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>ADAPT
Biotargeting System</U>&rdquo; means the Loan Parties&rsquo; technology platform for profiling the molecular composition of cells, tissues,
and circulating microvesicles/exosomes, including but not limited to the use of aptamer-based testing technology to develop assays for
diagnosis, prognosis, and theranostics of cancer and other diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Administration
Fee</U>&rdquo; has the meaning set forth in the Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Administrative
Agent</U>&rdquo; means Wilmington Trust, National Association, in its capacity as administrative agent under any of the Loan Documents,
or any successor administrative agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Administrative
Agent&rsquo;s Office</U>&rdquo; means the Administrative Agent&rsquo;s address and, as appropriate, account as set forth on <U>Schedule
10.2</U> or such other address or account as the Administrative Agent may from time to time notify the Borrower and the Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
of any Person means any other Person which, directly or indirectly, Controls, is Controlled by or is under common Control with such Person.
 &ldquo;<U>Control</U>&rdquo; (and its correlatives) by any Person means (a)&nbsp;the power of such Person, directly or indirectly, (i)&nbsp;to
vote 15% or more of the Voting Securities (determined on a fully diluted basis) of another Person or (ii)&nbsp;to direct or cause the
direction of the management and policies of such other Person (whether by contract or otherwise), or (b)&nbsp;the ownership by such Person
of 15% or more of the Capital Securities of another Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Agency
Fee Letter</U>&rdquo; means the fee letter, dated as of the Closing Date, between the Borrower and the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
is defined in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Amortization
Termination Date</U>&rdquo; is defined in <U>Section&nbsp;3.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Applicable
Margin</U>&rdquo; means 6.50%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Applicable
Percentage</U>&rdquo; means, with respect to any Lender at any time, (a)&nbsp;with respect to such Lender&rsquo;s portion of the outstanding
Loans at any time, the percentage of the outstanding principal amount of the Loans held by such Lender at such time and (b)&nbsp;with
respect to such Lender&rsquo;s portion of the outstanding Commitments at any time, the percentage of the Commitment Amount held by such
Lender at such time. The initial Applicable Percentage of each Lender is set forth opposite the name of such Lender on <U>Schedule 2.1
</U>or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Approved
Fund</U>&rdquo; means any Fund that is administered or managed by (a)&nbsp;a Lender, (b)&nbsp;an Affiliate of a Lender or (c)&nbsp;an
entity or an Affiliate of an entity that administers or manages a Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Assignment
and Assumption</U>&rdquo; means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any
party whose consent is required by <U>Section&nbsp;10.10(b)</U>), and accepted by the Administrative Agent, in substantially the form
of <U>Exhibit&nbsp;F</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Assignment
Effective Date</U>&rdquo; is defined in <U>Section&nbsp;10.10(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Attributable
Debt</U>&rdquo; means, with respect to any Sale/Leaseback Transaction that does not result in a Capitalized Lease Liability, the present
value (computed in accordance with GAAP) of the total obligations of the lessee for rental payments during the remaining term of the
lease included in such Sale/Leaseback Transaction (including any period for which such lease has been extended). In the case of any lease
which is terminable by the lessee upon payment of a penalty, the Attributable Debt shall be the lesser of (i)&nbsp;the Attributable Debt
determined assuming termination upon the first date such lease may be terminated (in which case the Attributable Debt shall also include
the amount of the penalty, but no rent shall be considered as required to be paid under such lease subsequent to the first date upon
which it may be so terminated) and (ii)&nbsp;the Attributable Debt determined assuming no such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Authorized
Officer</U>&rdquo; means, as applied to any Person, any individual holding the position of chairman of the board (if an officer), chief
executive officer, president or one of its vice presidents (or the equivalent thereof), such Person&rsquo;s chief financial officer or
treasurer or other similar officer or Person performing similar functions of such Loan Party and, solely for purposes of notices given
pursuant to <U>Article&nbsp;II</U> hereof, any other officer or employee of the applicable Loan Party so designated by any of the foregoing
officers in a notice to the Administrative Agent or the Required Lenders or any other officer or employee of the applicable Loan Party
designated in or pursuant to an agreement between the applicable Loan Party and the Administrative Agent or the Required Lenders and,
as to any document delivered on the Closing Date, any secretary or assistant secretary of a Loan Party, in each such case, whose signatures
and incumbency shall have been certified to the Administrative Agent and the Lenders. Unless otherwise specified, all references herein
to an &ldquo;Authorized Officer&rdquo; shall refer to an Authorized Officer of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Benefit
Plan</U>&rdquo; means any employee benefit plan, as defined in section 3(3)&nbsp;of ERISA, that is either (i)&nbsp;a Multiemployer Plan,
(ii)&nbsp;subject to section 412 of the Code, section 302 of ERISA or Title IV of ERISA or (iii)&nbsp;has assets that are invested in
Capital Securities of the Borrower or any Subsidiaries or any of their respective ERISA Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Bona
Fide Lending Affiliate</U>&rdquo; means any bona fide debt fund, investment vehicle, regulated banking entity, non-regulated lending
entity or other similar entity (in each case, other than a Person that is explicitly excluded pursuant to <U>clause (a)</U>&nbsp;of the
definition of &ldquo;Disqualified Institution&rdquo;) that is primarily engaged in commercial loans and similar extensions of credit
in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Borrower</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Borrower
Materials</U>&rdquo; means information, reports, financial statements and other materials delivered by the Borrower to the Administrative
Agent and the Lenders hereunder, as well as other reports and information provided by the Administrative Agent to the Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Borrower&rsquo;s
Charter</U>&rdquo; means that certain Amended and Restated Certificate of Formation of the Borrower, dated as of May&nbsp;3, 2021, and
as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time after the Closing Date to the
extent permitted by <U>Section&nbsp;8.9(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Braidwell</U>&rdquo;
means, collectively, </FONT><FONT STYLE="font-size: 10pt">Braidwell Transaction Holdings LLC &ndash; Series&nbsp;2 and its Affiliates
and Approved Funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Associate</U>&rdquo; has the same meaning as the term &ldquo;business associate&rdquo; in 45&nbsp;C.F.R. &sect;&nbsp;160.103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day which is neither a Saturday or Sunday nor a legal holiday on which banks are authorized or required to be
closed in New&nbsp;York, New&nbsp;York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Capital
Securities</U>&rdquo; means, with respect to any Person, all shares of, interests or participations in, or other equivalents in respect
of (in each case however designated, whether voting or non-voting), of such Person&rsquo;s capital stock, and any warrants, options or
other rights entitling the holder thereof to purchase or acquire any such capital stock, in each case, whether now outstanding or issued
on or after the Closing Date. Notwithstanding the foregoing, neither Post-IPO Convertible Indebtedness, any other convertible Indebtedness
permitted by this Agreement nor Permitted Call Spread Swap Agreements shall constitute Capital Securities unless and until so converted
into Capital Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Capitalized
Lease Liabilities</U>&rdquo; means, with respect to any Person, all monetary obligations of such Person and its Subsidiaries under any
leasing or similar arrangement which have been (or, in accordance with GAAP, should be) classified as finance leases, and for purposes
of each Loan Document the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP, and
the stated maturity thereof shall be the date of the last payment of rent or any other amount due under such lease prior to the first
date upon which such lease may be terminated by the lessee without payment of a premium or a penalty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Caris
Discovery</U>&rdquo; means the Loan Parties&rsquo; drug target or therapeutic target discovery platform, including the ADAPT Biotargeting
System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Caris
Molecular Intelligence</U>&rdquo; means the Loan Parties&rsquo; profiling business operated under the current names MI Tumor Seek (or
variations thereof), MI Profile and Caris Assure and any future name, which relates to: (i)&nbsp;the profiling of patient samples (whether
tissue or blood), including but not limited to immunohistochemistry, in situ hybridization, next-generation sequencing of DNA and/or
RNA, Sanger sequencing, pyrosequencing, and gene fusions, variant transcripts and fragment analysis, (ii)&nbsp;the analysis and performance
of bioinformatics, and any other analysis (including FOLFIRSTai, and GPSai) related to tumors and (iii)&nbsp;reporting, consultations,
treatment recommendations (including companion diagnostics) or other end product related tumor profiling and the analysis therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Caris
Strategic Data</U>&rdquo; means the Loan Parties&rsquo; data platform and business relating to molecular and clinical outcomes data and
molecular signatures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Cash Equivalent
Investment</U>&rdquo; means, at any time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
direct obligation of (or unconditionally guaranteed by) the United States (or any agency or political subdivision thereof, to the extent
such obligations are supported by the full faith and credit of the United States) maturing not more than one year after such time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;commercial
paper maturing not more than one year from the date of issue, which is issued by a corporation (other than an Affiliate of the Borrower
or any of its Subsidiaries) organized under the laws of any state of the United States or of the District of Columbia and rated A-1 or
higher by S&amp;P or P-1 or higher by Moody&rsquo;s; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
certificate of deposit, demand or time deposit or bankers&rsquo; acceptance, maturing not more than 180 days after its date of issuance,
which is issued by or placed with any bank or trust company organized under the laws of the United States (or any state thereof) and
which has (x)&nbsp;a credit rating of A2 or higher from Moody&rsquo;s or A or higher from S&amp;P and (y)&nbsp;a combined capital and
surplus greater than $500,000,000; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;investments
in money market mutual funds at least 95% of the assets of which are comprised of securities of the types described in <U>clauses (a)</U>&nbsp;through
<U>(c)</U>&nbsp;of this definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Casualty
Event</U>&rdquo; means the damage, destruction or condemnation, as the case may be, of property of any Person or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>CFC</U>&rdquo;
means a &ldquo;controlled foreign corporation&rdquo; within the meaning of Section&nbsp;957 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Change
in Control</U>&rdquo; means and shall be deemed to have occurred if</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.75in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">prior
                                            to the consummation of a Direct Listing, Qualified IPO or a Qualified SPAC Transaction, (A)&nbsp;the
                                            Permitted Holders shall at any time not own, in the aggregate, directly or indirectly, beneficially
                                            and of record, at least 40% of the Voting Securities of the Borrower (calculated without
                                            giving effect to the issuance or deemed issuance of any shares of Common Stock issued or
                                            deemed issued as a result of any adjustment to the Series&nbsp;C Conversion Price or Series&nbsp;D
                                            Conversion Price (each as defined in the Borrower&rsquo;s Charter) in accordance with the
                                            Borrower&rsquo;s Charter following the Closing Date) and the right to elect or designate
                                            for election at least a majority of the board of directors (or equivalent) of the Borrower
                                            or (B)&nbsp;any &ldquo;person&rdquo; or &ldquo;group&rdquo; (within the meaning of Rule&nbsp;13d-5
                                            of the Exchange Act), other than Permitted Holders, shall own, directly or indirectly, beneficially
                                            or of record, determined on a fully diluted basis, more than 35% of the Voting Securities
                                            of the Borrower (calculated without giving effect to the issuance or deemed issuance of any
                                            shares of Common Stock after the Closing Date to any Sixth Street Entity as a result of any
                                            adjustment to the Series&nbsp;C Conversion Price or Series&nbsp;D Conversion Price (each
                                            as defined in the Borrower&rsquo;s Charter) in accordance with the Borrower&rsquo;s Charter);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.75in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">upon
                                            and after the consummation of a Direct Listing, Qualified IPO or a Qualified SPAC Transaction,
                                            any &ldquo;person&rdquo; or &ldquo;group&rdquo; (within the meaning of Rule&nbsp;13d-5 of
                                            the Exchange Act), other than Permitted Holders, shall own, directly or indirectly, beneficially
                                            or of record, determined on a fully diluted basis, more than 35% of the Voting Securities
                                            of the Borrower (calculated without giving effect to the issuance or deemed issuance of any
                                            shares of Common Stock after the Closing Date to any Sixth Street Entity as a result of any
                                            adjustment to the Series&nbsp;C Conversion Price or Series&nbsp;D Conversion Price (each
                                            as defined in the Borrower&rsquo;s Charter) in accordance with the Borrower&rsquo;s Charter);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.75in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            majority of the seats (other than vacant seats) on the board of directors (or equivalent)
                                            of the Borrower shall at any time be occupied by persons (x)&nbsp;who were not</FONT> <FONT STYLE="font-size: 10pt">members
                                            of such board of directors (or equivalent) on the first day of such period, (y)&nbsp;whose
                                            election or nomination to such board was not approved by either the Permitted Holders or
                                            by individuals referred to in <U>clause (x)</U>&nbsp;above constituting at the time of such
                                            election or nomination at least a majority of such board or (z)&nbsp;whose election or nomination
                                            to such board was not approved by the Permitted Holders or by individuals referred to in
                                            <U>clauses (x)</U>&nbsp;and <U>(y)</U>&nbsp;above;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.75in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Borrower
                                            shall cease to own, directly or indirectly through other Wholly Owned Subsidiaries, beneficially
                                            and of record, 100% of the issued and outstanding Capital Securities of the Loan Parties,
                                            except as otherwise permitted by this Agreement or, after the occurrence of a Parent HoldCo
                                            Reorganization, any Parent HoldCo shall cease to own, directly or indirectly through another
                                            Parent HoldCo, beneficially and of record, 100% of the issued and outstanding Capital Securities
                                            of the Borrower;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided
</U></FONT><FONT STYLE="font-size: 10pt">that the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction (including
any change in board membership as a result thereof) shall not be deemed a Change in Control;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U></FONT><FONT STYLE="font-size: 10pt">,
<U>further</U>, that from and after a Parent HoldCo Reorganization, each reference to &ldquo;the Borrower&rdquo; in the foregoing <U>clauses
(i)</U>, <U>(ii)</U>&nbsp;or <U>(iii)</U>&nbsp;shall be deemed to be a reference to Parent HoldCo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Change
in Law</U>&rdquo; means the occurrence, after the date of this Agreement, of any of the following: (i)&nbsp;the adoption or taking effect
of any law, rule, regulation or treaty, (ii)&nbsp;any change in any law, rule, regulation or treaty or in the administration, interpretation,
implementation or application thereof by any Governmental Authority or (iii)&nbsp;the making or issuance of any request, rule, guideline
or directive (whether or not having the force of law) by any Governmental Authority; <U>provided</U> that, notwithstanding anything herein
to the contrary, (x)&nbsp;the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives
thereunder or issued in connection therewith and (y)&nbsp;all requests, rules, guidelines or directives promulgated by the Bank for International
Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory
authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &ldquo;Change in Law&rdquo;, regardless of the
date enacted, adopted or issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>CLIA</U>&rdquo;
means the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. </FONT><FONT STYLE="font-size: 10pt">&sect; 263a, et. seq.),
together with implementing regulations (42 C.F.R. &sect; 493) and interpretative guidelines issued by CMS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Date Certificate</U>&rdquo; means a closing date certificate executed and delivered by an Authorized Officer of the Borrower in form
and substance reasonably satisfactory to the Administrative Agent and the Required Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Date Transactions</U>&rdquo; means, collectively, (a)&nbsp;the execution and delivery of the Loan Documents on the Closing Date and the
funding of the Initial Loans hereunder on the Closing Date, (b)&nbsp;the consummation of the Existing Debt Refinancing and (c)&nbsp;the
payment of all fees, premiums, expenses and other transaction costs incurred in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>CMS</U>&rdquo;
means the U.S. Centers for Medicare and Medicaid Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Code</U>&rdquo;
means the Internal Revenue Code of 1986, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Collateral</U>&rdquo;
has the meaning set forth in the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Commitment</U>&rdquo;
means, as to each Lender, such Lender&rsquo;s obligation (if any) to make Loans hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Commitment
Amount</U>&rdquo; means the Initial Commitment Amount plus the Delayed Draw Commitment Amount. The aggregate principal amount of the
Commitment Amount of all of the Lenders as in effect on the Closing Date is $400,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Competitor</U>&rdquo; means any Person that competes with the business of the Borrower and its Subsidiaries from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Compliance
Certificate</U>&rdquo; means a certificate duly completed and executed by an Authorized Officer of the Borrower, substantially in the
form of <U>Exhibit&nbsp;C</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Confidential
Business Information</U>&rdquo; means, whether patentable or unpatentable and whether or not reduced to practice, confidential business
information, including trade secrets, proprietary information, technical data, laboratory notebooks, clinical data, know-how, inventions,
manufacturing processes and techniques, financial, marketing and business data, pricing and cost information, business, finance and marketing
plans, customer and prospective customer lists and information, and supplier and prospective supplier lists and information, research
and development information, data and other information included in or supporting Regulatory Authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Confidential
Information</U>&rdquo; means any and all non-public information or material (whether written or oral, or in electronic or other form)
that, at any time before, on or after the Closing Date, has been or is provided or communicated to the Receiving Party by or on behalf
of the Disclosing Party pursuant to this Agreement or in connection with the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Contingent
Liability</U>&rdquo; means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or
is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds
to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other
than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon
the Capital Securities of any other Person. The amount of any Person&rsquo;s obligation under any Contingent Liability shall (subject
to any limitation set forth therein) be deemed to be the outstanding amount of the debt, obligation or other liability guaranteed thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Control</U>&rdquo;
is defined within the definition of &ldquo;<U>Affiliate</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Controlled
Account</U>&rdquo; is defined in <U>Section&nbsp;7.13</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Controlled
Investment Affiliate</U>&rdquo; means, as to any Person, any other Person that (a)&nbsp; directly or indirectly, is in Control of, is
Controlled by, or is under common Control with, such Person and (b)&nbsp;is organized by such Person primarily for the purpose of making
equity or debt investments in one or more companies, in each case, including any trust or other holding, investment or estate planning
vehicles Controlled directly or indirectly by or organized by such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Copyright
Security Agreement</U>&rdquo; means any Copyright Security Agreement executed and delivered to the Administrative Agent by the Borrower
or any of the Guarantors in substantially the form of Exhibit&nbsp;C to the Security Agreement, as amended, supplemented, amended and
restated or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Copyrights</U>&rdquo;
means all registered and unregistered copyrights, whether statutory or common law, along with any and all (i)&nbsp;renewals, revisions,
extensions, derivative works, enhancements, modifications, updates and new releases thereof, (ii)&nbsp;rights in works of authorship,
including all rights of authorship of any type and in all forms of media, use, publication, reproduction, distribution, performance,
preparation of derivative works, transformation, moral and economic rights of authors, design rights and registered designs and (iii)&nbsp;foreign
copyrights and any other rights corresponding thereto throughout the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Core
Assets</U>&rdquo; means all rights, interest and title of the Borrower and its Subsidiaries in any Intellectual Property or other proprietary
products, services, data or processes that directly relate to Caris Molecular Intelligence or Caris Strategic Data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Covered
Entity</U>&rdquo; has the same meaning as the term &ldquo;covered entity&rdquo; in 45&nbsp;C.F.R. &sect;&nbsp;160.103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Cure
Right</U>&rdquo; is defined in <U>Section&nbsp;9.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Data
Processors</U>&rdquo; means any Third Party service providers, software developers, outsourcers, or others to which Borrower or its Subsidiaries
engage and allow access to Personal Data or IT Assets (solely with respect to all Personal Data stored or contained therein or transmitted
thereby).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Debtor
Relief Laws</U>&rdquo; means the Bankruptcy Code of the United States and all other liquidation, conservatorship, bankruptcy, assignment
for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the
United States or other applicable jurisdictions from time to time in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Default</U>&rdquo;
means any Event of Default or any condition, occurrence or event which, after notice or lapse of time or both, would constitute an Event
of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Defaulting
Lender</U>&rdquo; means, subject to <U>Section&nbsp;4.7(b)</U>, any Lender that (i)&nbsp;has refused or failed to (a)&nbsp;fund all or
any portion of its Loans, which refusal or failure is not cured within one Business Day of the date such Loans were required to be funded
hereunder unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender&rsquo;s
determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default,
shall be specifically identified in such writing) has not been satisfied or waived, or (b)&nbsp;pay to the Administrative Agent or any
other Lender any other amount required to be paid by it hereunder within one Business Day of the date when due, (ii)&nbsp;has notified
the Borrower or the Administrative Agent in writing that it does not intend to comply with its funding obligations hereunder, or has
made a public statement to that effect (unless such writing or public statement relates to such Lender&rsquo;s obligation to fund a Loan
hereunder and states that such position is based on such Lender&rsquo;s determination that a condition precedent to funding (which condition
precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied),
(iii)&nbsp;</FONT><FONT STYLE="font-size: 10pt">has failed to confirm in a manner reasonably satisfactory to the Administrative Agent
that it will comply with its funding obligations under this Agreement, or (iv)&nbsp;has, or has a direct or indirect parent company that
has, (a)&nbsp;become the subject of a proceeding under any Debtor Relief Law, or (b)&nbsp;had appointed for it a receiver, custodian,
conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation
of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting
in such a capacity; <U>provided</U>, a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any
equity interest in such Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership
interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the
enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority or instrumentality)
to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative
Agent that a Lender is a Defaulting Lender under <U>clauses (i)</U>&nbsp;through <U>(iv)</U>&nbsp;above shall be conclusive and binding
absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to <U>Section&nbsp;4.7(b)</U>) upon delivery
of written notice of such determination to the Borrower and each Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Delayed
Draw Closing Date</U>&rdquo; means each (or any) of the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Delayed
Draw Commitment Amount</U>&rdquo; as to each Lender, means its obligation to make Delayed Draw Loans to the Borrower pursuant to <U>Section&nbsp;2.1
</U>in the principal amount equal to such Lender&rsquo;s Applicable Percentage of Delayed Draw Loans requested by the Borrower in the
Loan Request delivered in accordance with <U>Section&nbsp;2.2</U>. The aggregate principal amount of the Delayed Draw Commitment Amount
of all of the Lenders as in effect on the Closing Date (after giving effect to the making of the Initial Loans) is $200,000,000; <U>provided
</U>that (i)&nbsp;upon the making of the Delayed Draw Loans on the First Delayed Draw Closing Date, the Delayed Draw Commitment Amount
shall be reduced by the aggregate principal amount of Delayed Draw Loans made on such date and (ii)&nbsp;on and subject to the occurrence
of the Second Delayed Draw Closing Date, the Delayed Draw Commitment Amount shall be reduced to $0; <U>provided</U>, <U>further</U>,
that the Delayed Draw Commitment Amount shall be reduced to $0 pursuant to and in accordance with <U>Section&nbsp;2.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Delayed
Draw Commitment Termination Date</U>&rdquo; means the earliest to occur of (i)&nbsp;the Second Delayed Draw Closing Date or, if the Delayed
Draw Commitment Amount is equal to $0 after the First Delayed Draw Closing Date, the First Delayed Draw Closing Date (in either case,
immediately after the making of the Delayed Draw Loans on such date), (ii)&nbsp;the Delayed Draw Unavailability Date and (iii)&nbsp;the
date upon which the Delayed Draw Commitment Amount is terminated or otherwise reduced to $0 pursuant to and in accordance with <U>Section&nbsp;2.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Delayed
Draw Loan</U>&rdquo; is defined in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Delayed
Draw Unavailability Date</U>&rdquo; means December&nbsp;31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Designated
Jurisdiction</U>&rdquo; means, at any time, a country or territory that is itself the target of comprehensive Sanctions (as of the Closing
Date, Cuba,&nbsp;Iran, North Korea, Syria, the Crimea region of Ukraine, the so-called Donetsk People&rsquo;s Republic, and the so-called
Luhansk People&rsquo;s Republic).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Determination
Date</U>&rdquo; is defined in <U>Section&nbsp;3.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Direct
Listing</U>&rdquo; means, with respect to any Person, the direct listing of such Person&rsquo;s Capital Securities on the New York Stock
Exchange or the NASDAQ Stock Market. Unless otherwise specified, a Direct Listing shall mean a Direct Listing of the Borrower&rsquo;s
Capital Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Disclosing
Party</U>&rdquo; means the Borrower or any of its Subsidiaries that is a Party disclosing Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Disposition</U>&rdquo;
(or similar words such as &ldquo;<U>Dispose</U>&rdquo;) means any sale, transfer, lease, license, contribution or other conveyance (including
by way of merger) of, or the granting of options, warrants or other rights to, any of the Borrower&rsquo;s or the Subsidiaries&rsquo;
assets (including accounts receivable and Capital Securities of Subsidiaries) to any other Person (other than to the Borrower or any
of its Subsidiaries) in a single transaction or series of transactions. For the avoidance of doubt, the issuance of any Capital Securities
by the Borrower (or by a Subsidiary to the Borrower or another Wholly Owned Subsidiary of the Borrower) shall not constitute a &ldquo;Disposition&rdquo;
for any purpose under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Disqualified
Capital Securities</U>&rdquo; means any Capital Securities that, by their terms (or by the terms of any security or other Capital Securities
into which they are convertible or for which they are exchangeable) or upon the happening of any event or condition, (a)&nbsp;mature
or are mandatorily redeemable (other than solely for Qualified Capital Securities), pursuant to a sinking fund obligation or otherwise
(except as a result of a Change in Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change
in Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued
and payable and the termination of the Commitment), (b)&nbsp;are redeemable at the option of the holder thereof (other than solely for
Qualified Capital Securities) (except as a result of a Change in Control or asset sale so long as any rights of the holders thereof upon
the occurrence of a Change in Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other
Obligations that are accrued and payable and the termination of the Commitment), in whole or in part, (c)&nbsp;provide for the scheduled
payment of dividends in cash or (d)&nbsp;are or become convertible into or exchangeable for Indebtedness or any other Capital Securities
that would constitute Disqualified Capital Securities, in each case, prior to the date that is ninety-one (91) days after the Maturity
Date; <U>provided</U> that if such Capital Securities are issued pursuant to a plan for the benefit of employees of the Borrower or any
of its Subsidiaries, or by any such plan to such employees, such Capital Securities shall not constitute Disqualified Capital Securities
solely because they may be required to be repurchased by the Borrower or its Subsidiaries in order to satisfy applicable statutory or
regulatory obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disqualified
Institution</U>&rdquo; means, on any date, (a)(i)&nbsp;any Company Competitor or (ii)&nbsp;other Person (including any financial institution),
in each case identified on the list delivered to the Administrative Agent by the Borrower prior to the Closing Date, (b)&nbsp;any Company
Competitor that is designated by the Borrower as a Disqualified Institution by prior notice to the Administrative Agent after the Closing
Date and approved by the Required Lenders (such approval not to be unreasonably withheld or delayed) in their sole discretion acting
reasonably (such designation will become effective three (3)&nbsp;Business Days after approval by the Required Lenders and will not apply
retroactively to disqualify the transfer of, or agreement to transfer, an interest in the Commitments or Loans, as applicable, that was
effective prior to the effective date of such supplement), and (c)&nbsp;any Disqualified Institution&rsquo;s known Affiliates or Affiliates
identified in writing to the Administrative Agent from time to time or otherwise readily identifiable as such by name. Notwithstanding
the foregoing, in no event will a Bona Fide Lending Affiliate be a Disqualified Institution, unless such Bona Fide Lending Affiliate
is explicitly identified under <U>clause (a)</U>&nbsp;of the definition of &ldquo;Disqualified Institution&rdquo; above. The Administrative
Agent shall not (x)&nbsp;be obligated to ascertain, monitor or inquire as to whether any Lender or participant or prospective Lender
or participant is a Disqualified Institution or (y)&nbsp;have any liability with respect to or arising out of any assignment or participation
of Loans, or disclosure of Confidential Information, to any Disqualified Institution,</FONT> <FONT STYLE="font-size: 10pt">except to the
extent resulting from the Administrative Agent&rsquo;s own gross negligence or willful misconduct as determined by a final non-appealable
judgment by a court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Division/Series&nbsp;Transaction</U>&rdquo;
means, with respect to any Person that is a limited liability company organized under the Laws of the State of Delaware, that any such
Person (a)&nbsp;divides into two or more Persons (whether or not the original Person survives such division) or (b)&nbsp;creates, or
reorganizes into, one or more series, in each case, as contemplated under the Laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Eligible
Assignee</U>&rdquo; means any Person that meets the requirements to be an assignee under <U>Section&nbsp;10.10(b)(iii)</U>&nbsp;and <U>(v)</U>&nbsp;(subject
to such consents, if any, as may be required under <U>Section&nbsp;10.10(b)(iii)</U>)</FONT><FONT STYLE="font-size: 10pt">; <U>provided
</U>that no Defaulting Lender or Disqualified Institution shall be an Eligible Assignee (in the case of (x)&nbsp;a Company Competitor
that has been designated as a Disqualified Institution under the definition thereof, only to the extent that no Event of Default arising
under <U>Section&nbsp;9.1(a)</U>&nbsp;or <U>Section&nbsp;9.1(h)</U>&nbsp;has occurred and is continuing at the time of such assignment
and (y)&nbsp;any other Disqualified Institution, only to the extent that no Event of Default has occurred and is continuing at the time
of such assignment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>EMA</U>&rdquo;
means the European Medicines Agency or any successor entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Environmental
Laws</U>&rdquo; means all federal, state, local or international laws, statutes, rules, regulations, codes, directives, treaties, requirements,
ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental
Authority, relating in any way to the environment, natural resources, Hazardous Material or health and safety matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Environmental
Liability</U>&rdquo; means any liability, loss, claim, suit, action, investigation, proceeding, damage, commitment or obligation, contingent
or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of or affecting
the Borrower or any Subsidiary directly or indirectly arising from, in connection with or based upon (i)&nbsp;any Environmental Law or
Environmental Permit, (ii)&nbsp;the generation, use, handling, transportation, storage, treatment, recycling, presence, disposal, Release
or threatened Release of, or exposure to, any Hazardous Materials, or (iii)&nbsp;any contract, agreement, penalty, order, decree, settlement,
injunction or other arrangement (including operation of law) pursuant to which liability is assumed, entered into, inherited or imposed
with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Environmental
Permit</U>&rdquo; is defined in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>ERISA
Affiliate</U>&rdquo; means, as applied to any Person, (i)&nbsp;any corporation that is a member of a controlled group of corporations
within the meaning of section 414(b)&nbsp;of the Code of which that Person is a member, (ii)&nbsp;any trade or business (whether or not
incorporated) that is a member of a group of trades or businesses under common control within the meaning of section 414(c)&nbsp;of the
Code of which that Person is a member, or (iii)&nbsp;any member of an affiliated service group within the meaning of section 414(m)&nbsp;or
414(o)&nbsp;of the Code of which that Person, any corporation described in clause (i)&nbsp;above or any trade or business described in
clause (ii)&nbsp;above is a member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>ERISA
Event</U>&rdquo; means: (a)&nbsp;a &ldquo;reportable event&rdquo; within the meaning of Section&nbsp;4043 of ERISA and the regulations
issued thereunder with respect to any Pension Plan (excluding those for which the provision for thirty day notice to the PBGC has been
waived by regulation); (b)&nbsp;the failure to meet the minimum funding standard Section&nbsp;412 or 430 of the Code with respect to
any Pension Plan or the failure to make any required contribution (including any installment) to a Multiemployer Plan; (c)&nbsp;the provision
by the administrator of any Pension Plan pursuant to Section&nbsp;4041(a)(2)&nbsp;of ERISA of a notice of intent to terminate such plan
in a distress termination described in Section&nbsp;4041(c)&nbsp;of ERISA; (d)&nbsp;the withdrawal by any Loan Party or any ERISA Affiliate
from any Pension Plan with two or more contributing sponsors or the termination of any such Pension Plan resulting in liability to the
Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates pursuant to Section&nbsp;4063 or 4064 of ERISA; (e)&nbsp;the
institution by the PBGC of proceedings to terminate any Pension Plan, or the appointment of a trustee to administer any Pension Plan;
(f)&nbsp;the imposition of liability on the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates pursuant to
Section&nbsp;4062(e)&nbsp;or 4069 of ERISA or by application of Section&nbsp;4212(c)&nbsp;of ERISA; (g)&nbsp;the withdrawal of any ERISA
Affiliate in a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan; or
(h)&nbsp;the imposition of a Lien pursuant to the Code or ERISA on any Loan Party of its Subsidiaries with respect to any Pension Plan
or Multiemployer Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Erroneous
Payment</U>&rdquo;</FONT> <FONT STYLE="font-size: 10pt">is defined in <U>Section&nbsp;11.10(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Event
of Default</U>&rdquo; is defined in <U>Section&nbsp;9.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Excluded
Accounts</U>&rdquo; is defined in <U>Section&nbsp;7.13</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Excluded
Assets</U>&rdquo; has the meaning set forth in the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Excluded
Subsidiary</U>&rdquo; means (A)&nbsp;any Foreign Subsidiary or Foreign Subsidiary Holding Company that: (i)&nbsp;does not </FONT><FONT STYLE="font-size: 10pt">hold
any exclusive right, title or interest in any material Core Asset or any other material Intellectual Property, (ii)&nbsp;does not hold
or maintain any material Regulatory Authorization, whether now in effect or hereafter issued by any Regulatory Agency, including any
Key Permits received from the FDA, (iii)&nbsp;is not party to any Material Agreement, other than ordinary course contracts or agreements
(including leases of or licenses to use real property) that are not material to the business of the Borrower and the Guarantors (taken
as a whole), (iv)&nbsp;does not, individually or together with all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant
to <U>clause (C)</U>&nbsp;of this definition, have cash or Cash Equivalent Investments exceeding $5,000,000 in the aggregate at any time,
(v)&nbsp;as of the last day of the most recent Fiscal Quarter for which financial statements have been delivered pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;or
<U>Section&nbsp;7.1(c)</U>&nbsp;(or, if prior to the date of the delivery of the first financial statements to be delivered pursuant
to <U>Section&nbsp;7.1(b)</U>&nbsp;or <U>Section&nbsp;7.1(c)</U>, the most recent financial statements referred to in <U>Section&nbsp;5.6</U>),
for the period of four consecutive Fiscal Quarters then ended, individually contributed less than 5.0% of Revenue for such period and,
together with all other Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to <U>clause (C)</U>&nbsp;of this definition,
contributed less than 10.0% of Revenue for such period, and (vi)&nbsp;as of the last day of the most recent Fiscal Quarter for which
financial statements have been delivered pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;or <U>Section&nbsp;7.1(c)</U>&nbsp;(or, if prior
to the date of the delivery of the first financial statements to be delivered pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;or <U>Section&nbsp;7.1(c)</U>,
the most recent financial statements referred to in <U>Section&nbsp;5.6</U>), for the period of four consecutive Fiscal Quarters then
ended, individually contributed less than 5.0% of the consolidated total assets of the Borrower and its Subsidiaries for such period,
and together with all other Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to <U>clause (C)</U>&nbsp;of this
definition, contributed less than 10.0% of the consolidated total assets of the Borrower and its Subsidiaries for such period, (B)&nbsp;any
other Foreign Subsidiary or Foreign Subsidiary Holding Company if the Borrower in good faith after consulting with its tax or other relevant
advisors and subject to the Required Lenders&rsquo; consent (not to be unreasonably withheld, conditioned or delayed) determines that
the burden or cost (including any adverse tax consequences to the Borrower or any of its Subsidiaries, which are not <I>de minimis</I>)
of providing a guarantee by such Foreign Subsidiary or Foreign Subsidiary Holding Company will outweigh the benefits to be obtained by
the Lenders therefrom, including by taking into account the overall collateral package under the Loan Documents and the amount of the
Loans, (C)&nbsp;any not-for-profit Subsidiary (which as of the Closing Date shall include, for the avoidance of doubt, Caris Molecular
Pathology, a Texas not-for-profit corporation), (D)&nbsp;any captive insurance Subsidiary, (E)(i)&nbsp;any newly acquired non-Wholly
Owned Subsidiary that is prohibited by its Organic Documents or contractual obligations in existence at the time of acquisition (but
not entered into in contemplation thereof) for so long as such prohibition or contractual obligation remains in effect or (ii)&nbsp;any
Foreign Subsidiary prohibited by the requirement of any Laws, in each case of the foregoing <U>clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;of
this <U>clause (E)</U>, from guaranteeing, or granting Liens to secure, the Obligations, or if guaranteeing or granting Liens to secure
the Obligations would require governmental (including regulatory) consent, approval, license or authorization unless and until such consent,
approval, license or authorization has been received, (F)&nbsp;any Subsidiary that is a special purpose vehicle (or similar entity) established
and used solely for the purposes of receivables factoring or any other permitted receivables securitization or (G)&nbsp;subject to compliance
with <U>Section&nbsp;7.14(c)</U>, Caris Research Institute,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Existing
Debt Refinancing</U>&rdquo; is defined in <U>Section&nbsp;5.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Exit Fee</U>&rdquo;
has the meaning set forth in the Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Family
Member</U>&rdquo; means, with respect to any individual, any other individual having a relationship by blood (to the second degree of
consanguinity), marriage, or adoption to such individual.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>FATCA</U>&rdquo;
means Sections 1471 through 1474 of the Code, as of the Closing Date (or any amended or successor version that is substantively comparable
and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements
entered into pursuant to Section&nbsp;1471(b)(1)&nbsp;of the Code and any fiscal or regulatory legislation, rules, or practices adopted
pursuant to any intergovernmental agreement, treaty, or convention among Governmental Authorities and implementing such sections of the
Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>FD&amp;C
Act</U>&rdquo; means the U.S. Federal Food, Drug, and Cosmetic Act (or any successor thereto), as amended from time to time, 21 U.S.C.
Section&nbsp;301 et. seq. and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
means the U.S. Food and Drug Administration and any successor entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Federal
Funds Rate</U>&rdquo; means, for any day, the rate per annum equal to the weighted average of the rates on overnight federal funds transactions
with members of the Federal Reserve System arranged by federal funds brokers on such day, as published by the Federal Reserve Bank of
New York on the Business Day next succeeding such day; <U>provided</U> that if such day is not a Business Day, the Federal Funds Rate
for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Fee
Letter</U>&rdquo; means the Fee Letter, dated as of the </FONT><FONT STYLE="font-size: 10pt">Closing Date, among the Borrower, the Lenders
and the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>First
Delayed Draw Closing Date</U>&rdquo; means the first date upon which any Delayed Draw Loans are made hereunder, which shall (i)&nbsp;consist
of Delayed Draw Loans in a minimum aggregate principal amount of $100,000,000 and (ii)&nbsp;occur no later than the Delayed Draw Unavailability
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Fiscal
Quarter</U>&rdquo; means a quarter ending on the last day of March, June, September&nbsp;or December.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Fiscal
Year</U>&rdquo; means any period of twelve consecutive calendar months ending on December&nbsp;31; references to a Fiscal Year with a
number corresponding to any calendar year (<U>e.g.</U>,&nbsp;the &ldquo;2022 Fiscal Year&rdquo;) refer to the Fiscal Year ending on December&nbsp;31
of such calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Fixture
Locations</U>&rdquo; means (i)&nbsp;the locations set forth in sub-clauses (iii)-(vi)&nbsp;of <U>Section&nbsp;7.15(b)</U>&nbsp;and (ii)&nbsp;each
other owned or leased location of any Loan Party after the Closing Date in which Collateral (other than any Collateral consisting of
aircraft) in excess of $10,000,000 is located.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Foreign
Lender</U>&rdquo; means a Lender that is organized under the laws of a jurisdiction outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Foreign
Subsidiary</U>&rdquo; means a Subsidiary of the Borrower that is not organized under the laws of the United States, any state thereof,
or the District of Columbia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Foreign
Subsidiary Holding Company</U>&rdquo; means any Subsidiary that is not a Foreign Subsidiary that owns (directly or through one or more
entities that are disregarded for U.S. federal income tax purposes) no material assets other than equity interests of one or more Foreign
Subsidiaries that are CFCs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Fund</U>&rdquo;
means any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in
commercial loans and similar extensions of credit in the ordinary course of its activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
means generally accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GCP</U>&rdquo;
</FONT><FONT STYLE="font-size: 10pt">means the Good Clinical Practices that establish the national and international ethical, regulatory
and scientific quality standards for designing, conducting, recording and reporting clinical trials that are enforced by the FDA (including
21 CFR Parts 50, 54, 56 and 312) and by comparable foreign Governmental Authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>GLP</U>&rdquo;
means the Good Clinical Laboratory Practices and regulatory requirements for or concerning the conduct of nonclinical research that are
enforced by the FDA (including 21 CFR Part&nbsp;58) and by comparable foreign Governmental Authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Governmental
Authority</U>&rdquo; means any national, supranational, federal, state, county, provincial, local, municipal or other government or political
subdivision thereof (including any Regulatory Agency), whether domestic or foreign, and any agency, authority, commission, ministry,
instrumentality, regulatory body, court, tribunal, arbitrator, central bank or other Person exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to any such government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Governmental
Payor</U>&rdquo; means Medicare, Medicaid, TRICARE, CHAMPVA, any state health plan adopted pursuant to Title XIX or Title XXI of the
Social Security Act any other state or federal health care program and any other Governmental Authority which presently or in the future
maintains a third party payor program, as well as any fiscal intermediary, contractor or similar claims processing and payment agent
acting on behalf of the foregoing programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Guarantee</U>&rdquo;
means the guarantee executed and delivered by an Authorized Officer of each Guarantor, substantially in the form of <U>Exhibit&nbsp;D
</U>hereto, as amended, supplemented, amended and restated or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Guarantors</U>&rdquo;
means </FONT><FONT STYLE="font-size: 10pt">each existing and each subsequently acquired or organized Subsidiary (other than any Excluded
Subsidiary) that shall have executed the Guarantee pursuant to <U>Section&nbsp;7.8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Hazardous
Material</U>&rdquo; means any material, substance, chemical, mixture or waste which is capable of damaging or causing harm to any living
organism, the environment or natural resources, including all explosive, special, hazardous, polluting, toxic, industrial, dangerous,
biohazardous, medical, infectious or radioactive substances, materials or wastes, noise, odor, electricity or heat, and including petroleum
or petroleum products, byproducts or distillates, asbestos or asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls,
radon gas, ozone-depleting substances, greenhouse gases, and all other substances or wastes of any nature regulated pursuant to any Environmental
Law or as to which any Governmental Authority requires investigation, reporting or remedial action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Hedging
Obligations</U>&rdquo; means, with respect to any Person, all liabilities of such Person under currency exchange agreements, interest
rate swap agreements, interest rate cap agreements and interest rate collar agreements, and all other agreements or arrangements designed
to protect such Person against fluctuations in interest rates or currency exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>herein</U>&rdquo;,
 &ldquo;<U>hereof</U>&rdquo;, &ldquo;<U>hereto</U>&rdquo;, &ldquo;<U>hereunder</U>&rdquo; and similar terms contained in any Loan Document
refer to such Loan Document as a whole and not to any particular Section, paragraph or provision of such Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>HIPAA</U>&rdquo;
means, collectively, the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191, as amended by the Health Information
Technology for Economic and Clinical Health Act, enacted as Title&nbsp;XIII of the American Recovery and Reinvestment Act of 2009, Public
Law&nbsp;111-5, and their implementing regulations, including but not limited to, the Standards for Privacy of Individually Identifiable
Health Information at 45&nbsp;C.F.R. Parts&nbsp;160 and&nbsp;164, Subparts&nbsp;A and&nbsp;E, the Security Standards for the Protection
of Electronic Protected Health Information at 45&nbsp;C.F.R. Parts&nbsp;160 and&nbsp;164, Subparts&nbsp;A and&nbsp;C, and the Notification
of Breach of Unsecured Protected Health Information requirements at 45&nbsp;C.F.R. Part&nbsp;160 and 164, Subparts A and&nbsp;D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Impermissible
Qualification</U>&rdquo; means any qualification or exception to the opinion or certification of any independent public accountant as
to any financial statement of the Borrower or any Subsidiary (i)&nbsp;which is of a &ldquo;going concern&rdquo; or similar nature other
than any such qualification that is related solely to (I)(A)&nbsp;the occurrence of the Maturity Date as a result of the Loans maturing
during such Fiscal Year or (B)&nbsp;the occurrence of any upcoming date where redemption rights in respect of the Series&nbsp;C Preferred
Stock and/or Series&nbsp;D Preferred Stock are or may become exercisable or (II)&nbsp;any prospective or actual inability to satisfy
any financial maintenance covenant included in the Loan Documents on a future date in a future period, (ii)&nbsp;which relates to the
limited scope of examination of matters relevant to such financial statement or (iii)&nbsp;which relates to the treatment or classification
of any item in such financial statement and which, as a condition to its removal, would require an adjustment to such item the effect
of which would be to cause the Borrower to be in Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>including</U>&rdquo;
and &ldquo;<U>include</U>&rdquo; means including without limiting the generality of any description preceding such term, and, for purposes
of each Loan Document, the parties hereto agree that the rule&nbsp;of ejusdem generis shall not be applicable to limit a general statement,
which is followed by or referable to an enumeration of specific matters, to matters similar to the matters specifically mentioned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
of any Person means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations of such Person for borrowed money or advances and all obligations of such Person evidenced by bonds, debentures, notes or
similar instruments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations relative to the face amount of all letters of credit, whether or not drawn, and banker&rsquo;s acceptances issued for the
account of such Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Capitalized Lease Liabilities of such Person, all obligations of such Person arising under Synthetic Leases and all Attributable Debt
of such Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;net
Hedging Obligations of such Person to the extent such obligations would appear as a net liability on a balance sheet of such Person (other
than in the footnotes) prepared in accordance with GAAP;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations of such Person in respect of Disqualified Capital Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;whether
or not so included as liabilities in accordance with GAAP, all obligations of such Person to pay the deferred purchase price of property
or services, including any earn-outs or other deferred payment obligations in connection with an acquisition (excluding (i)&nbsp;any
purchase price adjustment, royalty, earn-out, contingent payment or deferred payment of a similar nature incurred in connection with
an acquisition that are paid within 60 days after the conditions to such payment (other than any conditions that are simply the passage
of time) are met, and (ii)&nbsp;trade accounts payable in the ordinary course of business that are not overdue for a period of more than
90 days or, if overdue for more than 90 days, as to which a dispute exists and adequate reserves in conformity with GAAP have been established
on the books of such Person), and indebtedness secured by (or for which the holder of such indebtedness has an existing right, contingent
or otherwise, to be secured by) a Lien on property owned or being acquired by such Person (including indebtedness arising under conditional
sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in
recourse; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contingent Liabilities of such Person in respect of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Indebtedness
of any Person shall include the Indebtedness of any other Person (including any partnership in which such Person is a general partner)
to the extent such Person is liable therefor as a result of such Person&rsquo;s ownership interest in or other relationship with such
Person, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor. For the avoidance of doubt,&nbsp;Indebtedness
shall not include any bona fide royalty obligations payable by a Loan Party or any Subsidiary in respect of any in-license or acquisition
of Intellectual Property by any Loan Party or Subsidiary in connection with the Caris Discovery line of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Indemnified
Liabilities</U>&rdquo; is defined in <U>Section&nbsp;10.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Indemnified
Parties</U>&rdquo; is defined in <U>Section&nbsp;10.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Infringement</U>&rdquo;
and &ldquo;<U>Infringes</U>&rdquo; mean the infringement, misappropriation or other violation of know-how, trade secrets, confidential
information, or Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Initial
Commitment Amount</U>&rdquo; as to each Lender, means its obligation to make Initial Loans to the Borrower on the Closing Date pursuant
to <U>Section&nbsp;2.1</U> in the principal amount equal to such Lender&rsquo;s Applicable Percentage of Initial Loans. The aggregate
principal amount of the Initial Commitment Amount of all of the Lenders as in effect on the Closing Date is $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Initial
Commitment Termination Date</U>&rdquo; means the Closing Date (immediately after the making of the Initial Loans on such date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Initial
Loan</U>&rdquo; is defined in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Insolvency
Event</U>&rdquo; is defined in <U>Section&nbsp;9.1(h)(iv)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Intellectual
Property</U>&rdquo; means all intellectual property and other proprietary rights of any kind or nature, in any jurisdiction in the world,
whether registered or unregistered and whether registrable or not, protected, created or arising under any law, including any and all
rights in: (i)&nbsp;Patents; (ii)&nbsp;Trademarks; (iii)&nbsp;Copyrights; (iv)&nbsp;computer software, databases, data, compilations
of data, and documentation; (v)&nbsp;Confidential Business Information; and (vi)&nbsp;rights to sue for past, present and future Infringements
of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Interest
Period</U>&rdquo; means, (a)&nbsp;initially, the period beginning on (and including) the date on which the Initial Loans are made hereunder
pursuant to <U>Section&nbsp;2.3</U> and ending on (but not including) the last day of such Fiscal Quarter, and (b)&nbsp;thereafter, the
period beginning on (and including) the last day of the immediately preceding Fiscal Quarter and ending on the earlier of (x)&nbsp;(but
not including) the last day of such succeeding Fiscal Quarter thereafter and (y)&nbsp;(and including) the Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Investment</U>&rdquo;
means, relative to any Person, (i)&nbsp;any loan, advance or extension of credit made by such Person to any other Person, including the
purchase by such Person of any bonds, notes, debentures or other debt securities of any other Person, (ii)&nbsp;Contingent Liabilities
in favor of any other Person, and (iii)&nbsp;any Capital Securities held by such Person in any other Person. The amount of any Investment
shall be the original principal or capital amount thereof less all returns of principal or equity thereon and shall, if made by the transfer
or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair market
value of such property at the time of such Investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>IT
Assets</U>&rdquo; means the computers and other information technology infrastructure and assets used by the Borrower or any of the Subsidiaries
in the conduct of their business as currently operated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Key
Permits</U>&rdquo; means all Permits relating to the Products, including all Regulatory Authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>knowledge</U>&rdquo;
of the Borrower means the knowledge of any executive officer or senior vice president of the Borrower or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Laws</U>&rdquo;
means all applicable U.S. federal, state, local or foreign laws, statutes, ordinances, rules, regulations, judgments, orders, injunctions,
decrees, arbitration awards issued by any Governmental Authority, including Privacy Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>LDT</U>&rdquo;
means a laboratory developed test that is designed, developed, validated and performed by a single clinical laboratory authorized to
perform high complexity testing under CLIA. The parties acknowledge that, as of the Closing Date, the FDA&rsquo;s regulation of LDTs
has evolved considerably over time, and that the FDA has not historically required LDTs to be the subject of medical device clearances
or approvals, even when the FDA has asserted that the requirements for such premarket review apply as a matter of Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Lender</U>&rdquo;
means each Person identified as a &ldquo;Lender&rdquo; on the signature pages&nbsp;hereto and its successors and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Licensed
Intellectual Property</U>&rdquo; means all Intellectual Property that is licensed to, or otherwise authorized for use by, the Borrower
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Lien</U>&rdquo;
means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise),
charge against or interest in property, or other priority or preferential arrangement of any kind or nature whatsoever, to secure payment
of a debt or performance of an obligation. For the avoidance of doubt, Liens shall not include any bona fide royalty obligations payable
by a Loan Party or any Subsidiary in respect of any in-license or acquisition of Intellectual Property by any Loan Party or Subsidiary
in connection with the Caris Discovery line of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Liquidity</U>&rdquo;
means, at any time, an amount determined by the Borrower equal to the sum of unrestricted cash-on-hand and Cash Equivalent Investments
of the Borrower and the Guarantors, and, subject to <U>Section&nbsp;7.15</U>, to the extent held in a Controlled Account located in the
United States<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Loan
Documents</U>&rdquo; means, collectively, this Agreement, the Notes, the Security Agreement, the Fee Letter, the Agency Fee Letter, each
other agreement pursuant to which the Secured Parties are granted a Lien in the Collateral to secure the Obligations (including any mortgages
entered into pursuant to <U>Section&nbsp;7.8</U>), the Guarantee and each other agreement, certificate, document or instrument expressly
delivered in connection with any Loan Document, whether or not specifically mentioned herein or therein. For the avoidance of doubt,
neither the Organic Documents nor any shareholders or similar agreement of the Borrower or any Subsidiary shall constitute &ldquo;Loan
Documents&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Loan
Party</U>&rdquo; means, collectively, the Borrower and the Guarantors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Loan
Request</U>&rdquo; means a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form
of <U>Exhibit&nbsp;B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Loans</U>&rdquo;
means the Initial Loan and the Delayed Draw Loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means a material adverse effect on (i)&nbsp;the business, financial condition, operations, performance or properties
of the Borrower and the Subsidiaries taken as a whole, (ii)&nbsp;the rights and remedies of the Secured Parties under any Loan Document
or (iii)&nbsp;the ability of the Borrower and the Guarantors to perform their Obligations under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Material
Agreements</U>&rdquo; means (i)&nbsp;the 2023 Convertible Loan Documents, (ii)&nbsp;each contract or agreement to which the Borrower
or any Subsidiary is a party involving aggregate payments in the immediately preceding calendar year of more than $15,000,000, whether
such payments are being made by the Borrower or any Subsidiary to a non-Affiliated Person, or by a non-Affiliated Person to the Borrower
or any Subsidiary, and (iii)&nbsp;all other contracts or agreements the termination of which could reasonably be expected to result in
a Material Adverse Effect. Notwithstanding anything contained in this Agreement to the contrary, nothing contained herein shall limit
the Borrower or its Subsidiaries&rsquo; ability to terminate any Material Agreement (and, for the avoidance of doubt, upon such termination
such contract or agreement shall no longer constitute a &ldquo;Material Agreement&rdquo; for any purpose under this Agreement and the
other Loan Documents).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Real Property</U>&rdquo; </FONT><FONT STYLE="font-size: 10pt">means any individual real property in the United States that is owned in
fee by any Loan Party with a fair market value (as reasonably determined by the Borrower) in excess of $10,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Maturity
Date</U>&rdquo; means January&nbsp;18, 2028.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Moody&rsquo;s</U>&rdquo;
means Moody&rsquo;s Investors Service,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Multiemployer
Plan</U>&rdquo; means a Benefit Plan that is a &ldquo;multiemployer plan&rdquo; as defined in Section&nbsp;4001(a)(3)&nbsp;of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Net
Asset Sales Proceeds</U>&rdquo; means, with respect to a Disposition pursuant to <U>Section&nbsp;8.8(vii)</U>&nbsp;or <U>(xiii)</U>&nbsp;after
the Closing Date by the Borrower or any Subsidiary to any Person of any assets of the Borrower or any Subsidiary, the excess of gross
cash proceeds received by the Borrower or any Subsidiary from such Disposition in excess of $1,000,000, in each case individually or
in the aggregate in any Fiscal Year (in each case net of all reasonable and customary costs and expenses, and including Taxes payable
by the recipient of such proceeds, incurred in connection with such Disposition which have not been paid to Affiliates of the Borrower
in connection therewith); <U>provided</U>, that so long as (i)&nbsp;the Borrower has delivered Administrative Agent prior written notice
of its intention to apply such monies (the &ldquo;<U>Reinvestment Amounts</U>&rdquo;) to the costs of purchase of other assets useful
in the business of the Borrower and its Subsidiaries and (ii)&nbsp;the Borrower or any Subsidiary completes such purchase within 180
days (or, in the case of a binding commitment in respect of the application of such Reinvestment Amounts within such 180 days, 270 days)
after the initial receipt of such monies, the Borrower or any Subsidiary shall have the option to apply such monies to the costs of purchase
of other assets useful in the business of the Borrower or such Subsidiary, unless and to the extent that such applicable period shall
have expired without such purchase being made or completed, in which case, any amounts remaining shall be paid to Administrative Agent
and applied in accordance with <U>Section&nbsp;3.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Net
Casualty Proceeds</U>&rdquo; means, with respect to any Casualty Event, the amount of any insurance proceeds or condemnation awards received
by the Borrower or any of the Subsidiaries in connection with such Casualty Event, other than proceeds that are used to repair or replace
the assets subject to such Casualty Event within 180 days of receipt of such proceeds with respect to such Casualty Event with like or
similar assets (or, in the case of a binding commitment in respect of the application of such amounts within such 180 days, 270 days),
in excess of $1,000,000 individually or in the aggregate in any Fiscal Year (in each case net of all reasonable and customary collection
expenses thereof), but excluding any proceeds or awards required to be paid to a creditor (other than to the Lenders) which holds a first
priority Lien permitted by <U>Section&nbsp;8.3(e)</U>&nbsp;on the property which is the subject of such Casualty Event (it being understood
and agreed that the Borrower or such Subsidiary may retain such insurance proceeds or condemnation awards pending such reinvestment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Non-Defaulting
Lender</U>&rdquo; means, at any time, each Lender that is not a Defaulting Lender at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Non-Excluded
Taxes</U>&rdquo; means any Taxes other than (a)&nbsp;Taxes imposed on or measured by a Person&rsquo;s net income, and franchise Taxes,
in both cases with respect to any Lender and imposed by any Governmental Authority under the laws of which such Lender is organized or
in which it maintains its applicable lending office or that are Other Connection Taxes, (b)&nbsp;branch profits taxes imposed by the
United States or any similar tax imposed by any other jurisdiction described in clause (a)&nbsp;above, (c)&nbsp;any withholding tax that
is imposed by the United States on amounts payable to a Lender at the time such Lender first becomes a party to this Agreement (other
than pursuant to an assignment requested by the Borrower under <U>Section&nbsp;4.3(h)</U>) or designates a new lending office, except
to the extent that such Lender&rsquo;s assignor (or such Lender in case of the designation of a new lending office) was entitled, immediately
before the assignment (or designation of a new lending office), to receive additional amounts from the Borrower with respect to such
withholding tax pursuant to <U>Section&nbsp;4.3(a)</U>, (d)&nbsp;Taxes attributable to a recipient&rsquo;s failure to comply with <U>Section&nbsp;4.3(e)</U>,
and (e)&nbsp;any withholding Taxes or other amounts imposed or payable under FATCA</FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Note</U>&rdquo;
means a promissory note of the Borrower payable to a Lender, in the form of <U>Exhibit&nbsp;A</U> hereto (as such promissory note may
be amended, endorsed or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to such Lender resulting
from the outstanding amount of the Loans, and also means all other promissory notes accepted from time to time in substitution therefor
or renewal thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Obligations</U>&rdquo;
means all obligations (monetary or otherwise, whether absolute or contingent, matured or unmatured) of the Borrower and each Guarantor
arising under or in connection with a Loan Document and the principal of and premium, if any, and interest (including interest accruing
during the pendency of any proceeding of the type described in <U>Section&nbsp;9.1(h)</U>, whether or not allowed in such proceeding)
on the Loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>OFAC</U>&rdquo;
means the Office of Foreign Assets Control of the United States Department of the Treasury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>OrbiMed</U>&rdquo;
means, collectively, OrbiMed Royalty&nbsp;&amp; Credit Opportunities III, LP and OrbiMed Royalty&nbsp;&amp; Credit Opportunities IV,
LP and their respective Affiliates and Approved Funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Organic
Document</U>&rdquo; means, relative to the Borrower or any Subsidiary, its certificate of incorporation, by-laws, certificate of partnership,
partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting
trusts and similar arrangements applicable to the Borrower&rsquo;s or any Subsidiary&rsquo;s Capital Securities; <U>provided</U>, that
 &ldquo;Organic Documents&rdquo; shall not include any side letters executed by the Borrower and any of its shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Administrative Proceeding</U>&rdquo; means any administrative proceeding relating to a dispute involving a patent office, trademark office,
copyright office or other relevant intellectual property registry which relates to validity, opposition, revocation, ownership or enforceability
of the relevant Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Connection Taxes</U>&rdquo; means, with respect to any recipient, Taxes imposed as a result of a present or former connection between
such recipient and the jurisdiction imposing such Tax (other than connections arising solely from such recipient having executed, delivered,
become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged
in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Taxes</U>&rdquo; means any and all stamp, documentary or similar Taxes, or any other property Taxes or similar levies that arise on account
of any payment made or required to be made under any Loan Document or from the execution, delivery, registration, recording or enforcement
of, or otherwise with respect to, any Loan Document (excluding, for the avoidance of doubt, Taxes described in the definition of Non-Excluded
Taxes), except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant
to <U>Section&nbsp;4.3(h)</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Outside
Counsel</U>&rdquo; means, in respect of any Lender, such Lender&rsquo;s outside counsel as may be designated from time to time by such
Lender for purposes hereof and the other Loan Documents (including, to the extent applicable, receiving notices and communications hereunder
and under the other Loan Documents).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Owned
Intellectual Property</U>&rdquo; means all Intellectual Property that is owned (solely or jointly with others) by the Borrower or any
Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
HoldCo</U>&rdquo; means a company organized in the United States, any state thereof or in the District of Columbia, that directly or
indirectly owns 100% of the Capital Securities of the Borrower as a result of a Parent HoldCo Reorganization and that complies with the
requirements under <U>Section&nbsp;7.16</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
HoldCo Reorganization</U>&rdquo; means any transaction or series of transactions consummated in connection with or in anticipation of
a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction in which Borrower becomes a direct or indirect Wholly Owned Subsidiary
of Parent HoldCo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Party</U>&rdquo;
and &ldquo;<U>Parties</U>&rdquo; have the meanings set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Patent</U>&rdquo;
means any issued national, regional and international patent and any application or invention disclosure therefor (whether provisional
applications, non-provisional applications, divisionals, continuations, continuations in-part, and continued prosecution applications),
and which for purposes of this Agreement, shall be deemed to include any substitutions, reissues, reexaminations, renewals, extensions,
adjustments, restorations, supplemental protection certificates and patent rights in any form in connection therewith, whether in or
related to the United States or any foreign country or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Patent
Security Agreement</U>&rdquo; means any Patent Security Agreement executed and delivered to the Administrative Agent by the Borrower
or any of the Guarantors in substantially the form of Exhibit&nbsp;A to the Security Agreement, as amended, supplemented, amended and
restated or otherwise modified from time to time<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Payment
Recipient</U>&rdquo; is defined in <U>Section&nbsp;11.10(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>PBGC</U>&rdquo;
means the Pension Benefit Guaranty Corporation or any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Pension
Plan</U>&rdquo; means any Benefit Plan, other than a Multiemployer Plan, which is subject to Section&nbsp;412 of the Code or Section&nbsp;302
of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permits</U>&rdquo;
means all permits, licenses, registrations, certificates, orders, approvals, authorizations, consents, clearances, waivers, franchises,
variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation,
those relating to Environmental Laws and Regulatory Authorizations or to clinical laboratory certification or accreditation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Acquisition</U>&rdquo; means the purchase or other acquisition of all of the Capital Securities (other than qualifying directors&rsquo;
shares) in any, or all or substantially all of the property of, or all or substantially all of any business, business or product line,
unit or division of, any Person (other than any joint venture owned by another Person that is purchased or acquired) that, upon the consummation
thereof, will be owned by a direct or indirect Wholly Owned Subsidiary of the Borrower (including as a result of a merger or consolidation);
<U>provided</U> that, with respect to each Permitted Acquisition:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Borrower and its Subsidiaries (including any newly acquired or acquired Subsidiary in such Permitted Acquisition) shall comply with the
requirements of <U>Section&nbsp;7.8</U> to the extent required thereunder; <U>provided</U> that the aggregate amount of consideration
for all newly-created or acquired Subsidiaries that are Excluded Subsidiaries and all assets acquired in Permitted Acquisition that are
not directly owned by one or more Loan Parties and included in the Collateral shall not exceed $20,000,000 in the aggregate (and to be
measured without duplication);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
lines of business of the Person to be (or the property of which is to be) so purchased or otherwise acquired shall be permitted pursuant
to <U>Section&nbsp;8.1</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of a purchase or other acquisition of the Capital Securities of another Person, the board of directors (or other comparable
governing body) of such other Person shall have duly approved such purchase or other acquisition;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;immediately
before and after giving effect to any such purchase or other acquisition, no Event of Default, shall exist or result therefrom; <U>provided
</U>that, at the Borrower&rsquo;s election, this <U>clause (d)</U>&nbsp;shall be satisfied if there is no Default or Event of Default
in existence at the time of execution and effectiveness of the definitive documentation for such purchase or acquisition, so long as
the closing thereof occurs no more than 180 days after the execution and effectiveness of such definitive documentation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;immediately
before and after giving effect to any such purchase or other acquisition, the Borrower shall be in pro forma compliance with the financial
covenants set forth in <U>Section&nbsp;8.4</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Borrower shall have delivered to the Administrative Agent and the Lenders, at least five (5)&nbsp;Business Days prior to the date on
which any such purchase or other acquisition is to be consummated (or such shorter period of time as agreed by the Required Lenders in
their reasonable discretion), a written notice describing such transaction, and thereafter, if requested by the Required Lenders for
any such individual transaction involving consideration in excess of $15,000,000, to the extent available, (i)&nbsp;historical financial
statements of or related to the Person or assets to be acquired (for the avoidance of doubt, no financial statements shall be required
with respect to any Person, business or product line, unit or division for which no financial statements are available), (ii)&nbsp;twelve
month projections for such Person or assets to be acquired and for the Borrower after giving effect to such transaction, and (iii)&nbsp;material
documentation and other information relating to such transaction and reasonably requested by the Required Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Call Spread Swap Agreements</U>&rdquo; means (a)&nbsp;any Swap Agreement (including, but not limited to, any bond hedge transaction or
capped call transaction) pursuant to which the Borrower acquires an option requiring the counterparty thereto to deliver to the Borrower
shares of common stock of the Borrower, the cash value of such shares or a combination thereof from time to time upon exercise of such
option and (b)&nbsp;any Swap Agreement pursuant to which the Borrower issues to the counterparty thereto warrants to acquire common stock
of the Borrower (whether such warrant is settled in shares, cash or a combination thereof), in each case of c<U>lauses (a)</U>&nbsp;and
<U>(b)</U>&nbsp;entered into by the Borrower in connection with the issuance of Post-IPO Convertible Indebtedness; <U>provided</U> that
(i)&nbsp;the terms, conditions and covenants of each such Swap Agreement shall be such as are customary for Swap Agreements of such type
(as determined by the Borrower in good faith) and (ii)&nbsp;in the case of <U>clause (b)</U>&nbsp;above, such Swap Agreement would be
classified as an equity instrument in accordance with GAAP, and the settlement of such Swap Agreement does not require the Borrower to
make any payment in cash or cash equivalents that would disqualify such Swap Agreement from so being classified as an equity instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Cure Securities</U>&rdquo; means the Capital Securities of the Borrower or other equity securities thereof that do not constitute Disqualified
Capital Securities that are utilized to cure any breach by the Borrower or any of its Subsidiaries of their obligations under <U>Section&nbsp;8.4(b)</U>&nbsp;pursuant
to <U>Section&nbsp;9.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Holders</U>&rdquo; means David D. Halbert, his heirs and other Family Members and any trusts or other holding, investment or estate planning
vehicles for the benefit of any of the foregoing and any Controlled Investment Affiliate thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Receivables Indebtedness</U>&rdquo; means Indebtedness with respect to an accounts receivables facility; <U>provided</U> that (i)&nbsp;the
financing terms, covenants, termination events and other provisions thereof shall be market terms for similar facilities of reasonably
similar size, including the provision of a customary &ldquo;borrowing base&rdquo; concept, and (ii)&nbsp;such Indebtedness shall not
to exceed, in an aggregate amount at any time outstanding (in each case, measured solely at the time of incurrence thereof), the applicable
amounts set forth below based on the average Revenue of the Borrower and the Subsidiaries for the two most recently ended Fiscal Quarters
</FONT><FONT STYLE="font-size: 10pt">for which financial statements have been delivered pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;or
<U>Section&nbsp;7.1(c)</U>&nbsp;(or, if prior to the date of the delivery of the first financial statements to be delivered pursuant
to <U>Section&nbsp;7.1(b)</U>&nbsp;or <U>Section&nbsp;7.1(c)</U>, the most recent financial statements referred to in <U>Section&nbsp;5.6</U>):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
    (Average)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aggregate
    Amount of Permitted <BR>
    Receivables Indebtedness</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than $25,000,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $25,000,000 but less than $37,500,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $37,500,000 but less than $50,000,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $50,000,000 but less than $62,500,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $62,500,000 but less than $75,000,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $75,000,000 but less than $87,500,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$30,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $87,500,000 but less than $100,000,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$35,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $100,000,000 but less than $112,500,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$40,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $112,500,000 but less than $125,000,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$45,000,000</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equal
    to or greater than $125,000,000 per Fiscal Quarter</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$50,000,000</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Refinancing</U>&rdquo; means, with respect to any Indebtedness, any extensions, renewals, refinancings and replacements of such Indebtedness;
<U>provided</U> that such extension, renewal, refinancing or replacement (a)&nbsp;shall not increase the outstanding principal amount
of such Indebtedness, except by an amount equal to unpaid accrued interest and premium (including tender premiums) thereon plus other
reasonable amounts paid (including original issue discount and upfront fees), and fees and expenses reasonably incurred, in connection
with such renewals, refinancing or replacement and by an amount equal to any existing commitments unutilized thereunder, (b)&nbsp;contains
terms (i)&nbsp;relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any) taken
as a whole no less favorable in any material respect to the Borrower and its Subsidiaries or the Secured Parties than such terms of any
agreement or instrument governing such existing Indebtedness or (ii)&nbsp;otherwise on customary market terms (taken as a whole as determined
by the Borrower in its reasonable judgment), including with respect to high yield debt securities to the extent applicable, (c)&nbsp;[reserved],
(d)&nbsp;shall not contain any new requirement to grant any lien or security or to give any guarantee that was not an existing requirement
of such Indebtedness, except with respect to any new Subsidiary or assets acquired on or after the date such Indebtedness is incurred
that is also Collateral under the Loan Documents, (e)&nbsp;to the extent such modification, extension, renewal, refinancing and replacement
concerns Indebtedness that is subordinated in right of payment to the Obligations, shall require that such Indebtedness be subordinated
in right of payment to the Obligations on terms at least as favorable to the Lenders as those contained in the documentation governing
the Indebtedness being modified, extended, renewed, refinance or replaced, and (f)&nbsp;to the extent such modification, extension, renewal,
refinancing and replacement concerns Indebtedness that is subordinated to the Liens securing the Obligations, shall require that such
Indebtedness be unsecured or secured by Liens that are subordinated to the Liens securing the Obligations on terms at least as favorable
to the Lenders as those contained in the documentation (including any intercreditor or similar agreements) governing the Indebtedness
being modified, extended, renewed, refinance or replaced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Subordinated Indebtedness</U>&rdquo; means Indebtedness incurred after the Closing Date by the Borrower or the Subsidiaries that is (i)&nbsp;subordinated
to the Obligations and all other Indebtedness owing from the Borrower or the Subsidiaries to the Secured Parties pursuant to a written
subordination agreement satisfactory to the Administrative Agent and the Required Lenders in their sole discretion and (ii)&nbsp;in an
amount and on terms approved by the Administrative Agent and the Required Lenders in their sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means any natural person, corporation, limited liability company, partnership, joint venture, association, trust or unincorporated organization,
Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Personal
Data</U>&rdquo; means data that constitutes personal information that identifies a natural person or that is otherwise considered personally
identifiable information, personal data, nonpublic personal information or any term substantially equivalent to any of the foregoing
under applicable Law, including Protected Health Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Plan
Asset Regulation</U>&rdquo; means 29 C.F.R. &sect;2510.3-101, as modified by Section&nbsp;3(42) of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Plan
Assets</U>&rdquo; means &ldquo;plan assets&rdquo; as defined in the Plan Asset Regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<U>Platform</U>&rdquo;
is defined in <U>Section&nbsp;10.2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Post-IPO
Convertible Indebtedness</U>&rdquo; means Indebtedness that is convertible at the option of the holders thereof into common stock of
the Borrower incurred by the Borrower after the occurrence of a Qualified Direct Listing Event or the consummation of a Qualified IPO
or Qualified SPAC Transaction in an aggregate amount not to exceed the product of (x)&nbsp;the Revenue Base for the most recently ended
Test Period and (y)&nbsp;1.75; </FONT><FONT STYLE="font-size: 10pt"><U>provided</U>, <U>however</U>, that (a)&nbsp;such Indebtedness
shall be unsecured, (b)&nbsp;such Indebtedness shall not be guaranteed by any Subsidiary of the Borrower, (c)&nbsp;such Indebtedness
shall bear interest at a rate <I>per annum</I> as is customary in the market for public companies at such time, as determined by the
Borrower in its reasonable commercial judgment, (d)&nbsp;such Indebtedness shall not include covenants and defaults (other than covenants
and defaults customary for convertible indebtedness but not customary for loans for public company issuers, as determined by the Borrower
in its good faith judgment) that are, taken as a whole, more restrictive on the Loan Parties than the provisions of this Agreement (as
determined by the Borrower in its good faith judgment), (e)&nbsp;immediately prior to and after giving effect to the incurrence of such
Indebtedness, no Event of Default shall have occurred and be continuing or could reasonably be expected to occur as a result therefrom
and (f)&nbsp;such Indebtedness shall not (i)&nbsp;mature or be mandatorily redeemable, pursuant to a sinking fund obligation or otherwise,
(ii)&nbsp;be redeemable at the option of the holder thereof, in whole or in part or (iii)&nbsp;provide for the scheduled payment of dividends
or distributions (other than scheduled cash interest payments) in cash, in each case of the foregoing <U>sub-clauses (i)</U>, <U>(ii)</U>&nbsp;and
<U>(iii)</U>, prior to the date that is 6 months after the Maturity Date (it being understood, for the avoidance of doubt, that (w)&nbsp;a
redemption right of the Borrower in respect of such Indebtedness, (x)&nbsp;conversion rights of holders in respect of such Indebtedness,
(y)&nbsp;acceleration rights of holders of such Indebtedness upon the occurrence of an event of default specified in the agreement governing
such Indebtedness and (z)&nbsp;the obligation to pay customary amounts to holders of such Indebtedness in connection with an asset disposition,
casualty event, &ldquo;change of control&rdquo; or &ldquo;fundamental change&rdquo;, in each case, shall not be considered in connection
with the determination of scheduled maturity date for purposes of this <U>clause (f)</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Prime
Rate</U>&rdquo; means (a)&nbsp;the rate of interest last quoted by <I>The Wall Street Journal</I> as the &ldquo;Prime Rate&rdquo; in
the U.S. or, if <I>The Wall Street Journal</I> ceases to quote such rate, the per annum interest rate published by the Federal Reserve
Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &ldquo;bank prime loan&rdquo; rate or, if such
rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent) or any similar release
by the Federal Reserve Board (as determined by the Administrative Agent), minus (b)&nbsp;1.00%; <U>provided</U> that if the Prime Rate
shall be less than 2.50%, such rate shall be deemed to be 2.50% for the purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Privacy
Laws</U>&rdquo; mean each Law applicable to privacy and the protection and security of Personal Data, including HIPAA, Laws related to
localization of Personal Data, Laws related to online behavioral advertising, Laws related to consumer privacy with respect to direct
marketing such as the Telephone Consumer Protection Act (TCPA) and CAN-SPAM, and rules&nbsp;under the Payment Card Industry Data Security
Standards, in each case, solely to the extent applicable to the business of the Borrower or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Product</U>&rdquo;
means (i)&nbsp;</FONT><FONT STYLE="font-size: 10pt">Caris Molecular Intelligence, (ii)&nbsp;Caris Discovery (it being understood and
agreed that any targets developed by the Loan Parties within the Caris Discovery line of business and licensed to a third party (to the
extent not otherwise commercialized or developed by any Loan Party) as permitted by and in accordance with this Agreement will not be
considered to be Products), (iii)&nbsp;Caris Strategic Data and (iv)&nbsp;any current or future service or product (including LDTs and
software products and services and data products and services) researched, designed, developed, manufactured, licensed, marketed, offered,
sold, performed, distributed or otherwise commercialized by the Loan Parties and their Subsidiaries, including any such product in development
or which may be developed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Product
Authorizations</U>&rdquo; means any and all approvals, exemptions, licenses, notifications, registrations, listings, clearances or authorizations
or other Permits granted by, submitted to, obtained from or filed with any Governmental Authority necessary for the testing, manufacture,
performing, marketing, or sale of a Product in any country or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Product
Development and Commercialization Activities</U>&rdquo; means, with respect to any Product, any combination of research, development,
manufacture, import, use, sale, importation, storage, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing
or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which
is to commercially exploit such Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Protected
Health Information</U>&rdquo; has the same meaning as &ldquo;protected health information&rdquo; in 45&nbsp;C.F.R. &sect;&nbsp;160.103.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Public
Lender</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Money Indebtedness</U>&rdquo; means Indebtedness incurred to finance the </FONT><FONT STYLE="font-size: 10pt">acquisition, repair, replacement,
construction or improvement of fixed or capital assets, where the amount of such Indebtedness does not exceed the greater of (a)&nbsp;the
cost of the assets being financed and the cost of such repair, replacement, construction or improvement, as applicable, and (b)&nbsp;the
fair market value of such assets; <U>provided</U>, <U>however</U>, that such Indebtedness is incurred concurrently with or within one-hundred
and eighty days after or prior to such acquisition, repair, replacement, construction or improvement of the applicable assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Qualified
Capital Securities</U>&rdquo; means any Capital Securities that are not Disqualified Capital Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Qualified
Direct Listing Event</U>&rdquo; means the time after a Direct Listing at which the issuance of Capital Securities of the Borrower after
the Direct Listing has generated gross cash proceeds of at least $100,000,000 to the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Qualified
IPO&rdquo;</U> has the meaning assigned to such term in the Borrower&rsquo;s Charter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Qualified
SPAC Transaction</U>&rdquo; has the meaning assigned to such term in the Borrower&rsquo;s Charter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Receiving
Party</U>&rdquo; means any Lender that is a Party receiving Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Recipient</U>&rdquo;
is defined in <U>Section&nbsp;10.14</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Register</U>&rdquo;
is defined in <U>Section&nbsp;10.10(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Regulatory
Agencies</U>&rdquo; means any Governmental Authority that is concerned with the use, control, safety, efficacy, reliability, manufacturing,
testing, marketing, distribution, sale or other Product Development and Commercialization Activities relating to any Product of the Borrower
or any of the Subsidiaries, including CMS, FDA, and all similar agencies in other jurisdictions, including non-United States jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Regulatory
Authorizations</U>&rdquo; means all approvals, clearances, notifications, authorizations, orders, exemptions, registrations, listings,
certifications, licenses and Permits granted by, submitted to, obtained from, or filed with any Regulatory Agencies, including all Product
Authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Reinvestment
Amounts</U>&rdquo; has the meaning assigned to such term in the definition of &ldquo;Net Asset Sales Proceeds&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Related
Parties</U>&rdquo; means the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives
of the Borrower and the Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Release</U>&rdquo;
means any releasing, disposing, discharging, injecting, spilling, leaking, leaching, pumping, pouring, dumping, depositing, emitting,
escaping, emptying, seeping, dispersal, migrating or placing, including movement through, into or upon the environment or any natural
or man-made structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Repayment
Premium</U>&rdquo; has the meaning set forth in the Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Required
Lenders</U>&rdquo; means Non-Defaulting Lenders having Total Credit Exposures representing more than 50% of the Total Credit Exposures
of all Non-Defaulting Lenders; <U>provided</U>, to the extent there are any Significant Lenders, &ldquo;Required Lenders&rdquo; shall
also include each Significant Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Required
Revenue</U>&rdquo; is defined in <U>Section&nbsp;8.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Restricted
Payment</U>&rdquo; means (i)&nbsp;the declaration or payment of any dividend on, or the making of any payment or distribution on account
of, or setting apart assets for a sinking or other analogous fund for the purchase, redemption, defeasance, retirement or other acquisition
of, any class of Capital Securities of the Borrower or any Subsidiary or any warrants, options or other right or obligation to purchase
or acquire any such Capital Securities, whether now or hereafter outstanding, (ii)&nbsp;the making of any other distribution in respect
of such Capital Securities, in each case either directly or indirectly, whether in cash, property or obligations of the Borrower or any
Subsidiary or otherwise or (iii)&nbsp;the payment of any management fees, transaction fees, expense reimbursement or other indemnities
to any holder (or Affiliate thereof) of the Capital Securities of the Borrower or any Subsidiary or any warrants, options or other right
or obligation to purchase or acquire any such Capital Securities in respect of such Capital Securities or in respect of management, sponsoring,
structuring, arranging or other services. Notwithstanding the foregoing, and for the avoidance of doubt, (i)&nbsp;the conversion of (including
any cash payment or fractional shares upon conversion), or payment of any principal or premium on, or payment of any interest with respect
to, the 2023 Convertible Loans, any Post-IPO Convertible Indebtedness or other permitted convertible Indebtedness under this Agreement
shall not constitute a Restricted Payment and (ii)&nbsp;any payment with respect to, or early unwind or settlement of, any Permitted
Call Spread Swap Agreement shall not constitute a Restricted Payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Revenue</U>&rdquo;
means total consolidated revenue of the Borrower and its Subsidiaries, as determined in accordance with GAAP. Revenue shall be determined
in a manner consistent with the methodologies, practices and procedures used in developing the Borrower&rsquo;s audited financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Revenue
Base</U>&rdquo; means, with respect to any period, the Revenues for such period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Revenue
Deficiency</U>&rdquo; means, for any Test Period, the amount by which the Required Revenue for the trailing four quarter period ending
on the last day of the applicable Test Period exceeds the Revenue Base for such trailing four quarter period ending on the last day of
such Test Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>S&amp;P</U>&rdquo;
means S&amp;P Global Ratings, a S&amp;P Financial Services LLC business, and any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Sale/Leaseback
Transaction</U>&rdquo; is defined in <U>Section&nbsp;8.12</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Sanctions</U>&rdquo;
means any international economic sanction administered or enforced by the United States Government (including, without limitation, OFAC),
the United Nations Security Council, the European Union or His Majesty&rsquo;s Treasury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>SEC</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Second
Delayed Draw Closing Date</U>&rdquo; means the second date upon which Delayed Draw Loans are made hereunder, which shall (i)&nbsp;occur
after and subject the occurrence of the First Delayed Draw Closing Date (so long as the Delayed Draw Commitment Amount is greater than
$0 after the making of the Delayed Draw Loans on the First Delayed Draw Closing Date), (ii)&nbsp;consist of Delayed Draw Loans in a minimum
aggregate principal amount equal to the Delayed Draw Commitment Amount outstanding after the First Delayed Draw Closing Date and (iii)&nbsp;occur
no later than the Delayed Draw Unavailability Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Secured
Parties</U>&rdquo; means the Lenders and the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Security
Agreement</U>&rdquo; means the Pledge and Security Agreement executed and delivered by each of the parties thereto, substantially in
the form of <U>Exhibit&nbsp;E </U>hereto, as amended, supplemented, amended and restated or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Series&nbsp;C
Preferred Stock</U>&rdquo; means the Series&nbsp;C Preferred Stock of the Borrower issued pursuant to the Borrower&rsquo;s Charter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Series&nbsp;D
Preferred Stock</U>&rdquo; means the Series&nbsp;D Preferred Stock of the Borrower issued pursuant to the Borrower&rsquo;s Charter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Significant
Lender</U>&rdquo; means (x)&nbsp;OrbiMed (in its capacity as a Lender hereunder), so long as (i)&nbsp;OrbiMed is a Non-Defaulting Lender
and (ii)&nbsp;OrbiMed&rsquo;s Total Credit Exposure represents more than 33.33% of the Total Credit Exposures of all Non-Defaulting Lenders
and (y)&nbsp;Braidwell (in its capacity as a Lender hereunder), so long as (i)&nbsp;Braidwell is a Non-Defaulting Lender and (ii)&nbsp;Braidwell&rsquo;s
Total Credit Exposure represents more than 33.33% of the Total Credit Exposures of all Non-Defaulting Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Sixth
Street Entity</U>&rdquo; means each of Sixth Street Specialty Lending,&nbsp;Inc., TAO Barnett Investments, LLC, TOP III Barnett Investments,
LLC, Barnett Equity Holdings, LLC, Barnett Equity Holdings II, LLC, and any Affiliate of each of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>SOFR
Administrator</U>&rdquo; means the CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the secured overnight
financing rate).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>SOFR&#8239;Administrator&rsquo;s&#8239;Website</U>&rdquo;&#8239;means&#8239;the&#8239;website&#8239;of&#8239;the&#8239;SOFR&#8239;Administrator,&#8239;currently&#8239;at
https://www.cmegroup.com/market-data/cme-group-benchmark-administration.html, or any successor source for the secured overnight financing
rate identified as such by the SOFR Administrator from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>SOFR
Rate</U>&rdquo; means, for any Interest Period, the forward-looking three-month term rate based on the secured overnight financing rate
on the day (such day, the &ldquo;<U>SOFR Rate Determination Date</U>&rdquo;) that is two (2)&nbsp;Business Days prior to the first day
of any Interest Period, with the rate, or methodology for this rate, and conventions for this rate being established by the Administrative
Agent in accordance with the &ldquo;3 Month CME Term SOFR&rdquo; published on the SOFR Administrator&rsquo;s Website (as calculated by
the Administrative Agent and rounded upwards, if necessary, to the nearest 1/1,000 of 1%); <U>provided</U> that if as of 5:00 p.m.&nbsp;(New
York City time) on any SOFR Rate Determination Date, such 3 Month CME Term SOFR has not been published on the SOFR Administrator&rsquo;s
Website, then the SOFR Rate for the related Interest Period will be the 3 Month CME Term SOFR as published on the SOFR Administrator&rsquo;s
Website on the first preceding Business Day for which 3 Month CME Term SOFR was published on the SOFR Administrator&rsquo;s Website so
long as such first preceding Business Day is not more than three (3)&nbsp;Business Days prior to such SOFR Rate Determination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>SOFR Rate
Determination Date</U>&rdquo; is defined within the definition of &ldquo;SOFR Rate&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Solvent</U>&rdquo;
and &ldquo;<U>Solvency</U>&rdquo; mean, with respect to any Person on a particular date, that on such date (i)&nbsp;the fair value of
the property of such Person is greater than the total amount of liabilities, including Contingent Liabilities, of such Person, (ii)&nbsp;the
present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability
of such Person on its debts as they become absolute and matured, (iii)&nbsp;such Person does not intend to, and does not believe that
it will, incur debts or liabilities beyond its ability to pay as such debts and liabilities mature, (iv)&nbsp;such Person is not engaged
in a business or a transaction, and is not about to engage in a business or a transaction, for which the property of such Person would
constitute an unreasonably small capital and (v)&nbsp;such Person has not executed this Agreement or any other Loan Document, or made
any transfer or incurred any Obligations hereunder or thereunder, with actual intent to hinder, delay or defraud either present or future
creditors. The amount of Contingent Liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances
existing at such time, would reasonably be expected to become an actual or matured liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Specified
Events of Default</U>&rdquo; means an Event of Default arising under <U>Section&nbsp;9.1(a)</U>&nbsp;or <U>Section&nbsp;9.1(h)</U>&nbsp;or
an Event of Default arising under <U>Section&nbsp;9.1(c)</U>&nbsp;solely due to the Loan Parties&rsquo; default in the due performance
or observance of any of its obligations under <U>Section&nbsp;8.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Specified
Letter</U>&rdquo; means that certain letter agreement, dated as of the Closing Date, by and among the Borrower, Sixth Street Specialty
Lending,&nbsp;Inc., Barnett Equity Holdings, LLC, Barnett Equity Holdings II, LLC and SH Caris Life US, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means, with respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities of such other Person
(irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting
power upon the occurrence of any contingency) is at the time directly or indirectly owned or controlled by such Person, by such Person
and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person. Unless the context otherwise
specifically require</FONT><FONT STYLE="font-size: 10pt">s, the term &ldquo;Subsidiary&rdquo; shall be a reference to a Subsidiary of
the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Swap
Agreement</U>&rdquo; means any agreement with respect to any swap, forward, spot, future, credit default or derivative transaction or
option or similar agreement involving, or settled by reference to, one or more rates, currencies, commodities, equity or debt instruments
or securities, or economic, financial or pricing indices or measures of economic, financial or pricing risk or value or any similar transaction
or any combination of these transactions; <U>provided</U> that no phantom stock or similar plan providing for payments only on account
of services provided by current or former directors, officers, employees or consultants of the Borrower or the Subsidiaries shall be
a Swap Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Synthetic
Lease</U>&rdquo; means, as applied to any Person, any lease (including leases that may be terminated by the lessee at any time) of any
property (whether real, personal or mixed) (i)&nbsp;that is not a finance lease in accordance with GAAP and (ii)&nbsp;in respect of which
the lessee retains or obtains ownership of the property so leased for federal income tax purposes, other than any such lease under which
that Person is the lessor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Taxes</U>&rdquo;
means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees
or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Termination
Date</U>&rdquo; means the date on which all Obligations (other than contingent indemnification and expense reimbursement obligations
for which no claim has been made) have been paid in full in cash and all of the Commitments shall have terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Test
Period</U>&rdquo; in effect at any time means the most recent period of four consecutive Fiscal Quarters of the Borrower ended on or
prior to such time (taken as one accounting period) in respect of which financial statements for each Fiscal Quarter or Fiscal Year in
such period have been or are required to be delivered pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;or <U>(c)</U>, as applicable; <U>provided
</U>that, prior to the first date that financial statements have been or are required to be delivered pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;or
<U>(c)</U>, the Test Period in effect shall be the period of four consecutive fiscal quarters of the Borrower ended September&nbsp;30,
2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Third
Party</U>&rdquo; means any Person other than the Borrower or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Total
Credit Exposure</U>&rdquo; means, as to any Lender on any date, (i)&nbsp;the aggregate outstanding principal amount of the Loans of such
Lender after giving effect to any borrowings and prepayments or repayments of any Loans occurring on such date, <U>plus</U> (ii)&nbsp;the
unfunded amount of such Lender&rsquo;s Commitments that remains outstanding under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trademark</U>&rdquo;
means any trademark, service mark, trade name, logo, symbol, trade dress, domain name, corporate name or other indicator of source or
origin, and all applications, registrations and renewals therefor, together with all of the goodwill associated therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trademark
Security Agreement</U>&rdquo; means any Trademark Security Agreement executed and delivered to the Administrative Agent by the Borrower
or any of the Guarantors substantially in the form of Exhibit&nbsp;B to any Security Agreement, as amended, supplemented, amended and
restated or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>UCC</U>&rdquo;
means the Uniform Commercial Code as in effect from time to time in the State of New York; <U>provided</U> that, if, with respect to
any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the security
interests granted to any Secured Party pursuant to the applicable Loan Document is governed by the Uniform Commercial Code as in effect
in a jurisdiction of the United States other than New York, then &ldquo;UCC&rdquo; means the Uniform Commercial Code as in effect from
time to time in such other jurisdiction for purposes of the provisions of each Loan Document and any financing statement relating to
such perfection or effect of perfection or non-perfection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Undrawn
Fee</U>&rdquo; is defined in <U>Section&nbsp;3.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>United
States</U>&rdquo; or &ldquo;<U>U.S.</U>&rdquo; means the United States of America, its fifty states and the District of Columbia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Voting
Securities</U>&rdquo; means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote
for the election of directors, managers or other voting members of the governing body of such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, (a)&nbsp;Caris Life Sciences,&nbsp;Ltd. Warrant to Purchase Ordinary Shares, dated September&nbsp;21, 2018, by and
between the Borrower (f/k/a Caris Life Sciences,&nbsp;Ltd.) and Barnett Equity Holdings, LLC, as amended by (i)&nbsp;that certain Amendment
of Warrant, dated as of April&nbsp;2, 2020, by and between the Borrower (f/k/a Caris Life Sciences,&nbsp;Ltd.) and Barnett Equity Holdings,
LLC and (ii)&nbsp;that certain Omnibus Amendment of Warrants, by and among the Borrower (as successor to Caris Life Sciences, LLC), Barnett
Equity Holdings, LLC and Sixth Street Specialty Lending,&nbsp;Inc. (f/k/a TPG Specialty Lending,&nbsp;Inc.) (&ldquo;<U>SSSL</U>&rdquo;),
dated as of August&nbsp;4, 2020 (the &ldquo;<U>Omnibus Amendment</U>&rdquo;); (b)&nbsp;Caris Life Sciences,&nbsp;Ltd. Warrant to Purchase
Ordinary Shares, dated September&nbsp;21, 2018, by and between the Borrower (f/k/a Caris Life Sciences,&nbsp;Ltd.) and SSSL, as amended
by (i)&nbsp;that certain Amendment of Warrant, dated as of April&nbsp;2, 2020, by and between the Borrower (f/k/a Caris Life Sciences,&nbsp;Ltd.),
and SSSL and (ii)&nbsp;the Omnibus Amendment; (c)&nbsp;Caris Life Sciences,&nbsp;Ltd. Warrant to Purchase Shares, issued April&nbsp;2,
2020 by the Borrower (f/k/a Caris Life Sciences,&nbsp;Ltd.) to Barnett Equity Holdings, LLC, as amended by the Omnibus Amendment; and
(d)&nbsp;Caris Life Sciences,&nbsp;Ltd. Warrant to Purchase Shares, issued April&nbsp;2, 2020 by the Borrower (f/k/a Caris Life Sciences,&nbsp;Ltd.)
to SSSL, as amended by the Omnibus Amendment, in each case of the foregoing <U>clauses (a)</U>&nbsp;through <U>(d)</U>, as in effect
on the Closing Date and as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time after
the Closing Date to the extent permitted by <U>Section&nbsp;8.9(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Wholly
Owned Subsidiary</U>&rdquo; means any direct or indirect Subsidiaries of the Borrower, all of the outstanding Capital Securities of which
(other than any director&rsquo;s qualifying shares or investments by foreign nationals mandated by applicable laws) is owned directly
or indirectly by the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;1.2
</FONT><FONT STYLE="font-size: 10pt"><U>Use of Defined Terms</U>. Unless otherwise defined or the context otherwise requires, terms for
which meanings are provided in this Agreement shall have such meanings when used in each other Loan Document and the schedules attached
hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;1.3
</FONT><FONT STYLE="font-size: 10pt"><U>Cross-References</U>. Unless otherwise specified, references in a Loan Document to any Article&nbsp;or
Section&nbsp;are references to such Article&nbsp;or Section&nbsp;of such Loan Document, and references in any Article, Section&nbsp;or
definition to any clause are references to such clause of such Article, Section&nbsp;or definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;1.4
</FONT><FONT STYLE="font-size: 10pt"><U>Accounting and Financial Determinations</U>. Unless otherwise specified, all accounting terms
used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under Section&nbsp;8.4
and the definitions used in such calculations) shall be made, in accordance with GAAP, as in effect from time to time; provided that,
if either the Borrower or the Required Lenders request an amendment to any provision hereof to eliminate the effect of any change occurring
after the Closing Date in GAAP or the application thereof on the operation of such provision, regardless of whether any such notice is
given before or after such change in GAAP or the application thereof, then such provision shall be interpreted on the basis of GAAP in
effect and applied immediately before such change shall have become effective until such request shall have been withdrawn or such provision
amended in accordance herewith. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed
on a consolidated basis for the Borrower and the Subsidiaries, in each case without duplication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;1.5
</FONT><FONT STYLE="font-size: 10pt"><U>Other Interpretive Provisions</U>. Except as otherwise specified or limited herein, references
to any Person include the permitted successors and assigns of such Person. References &ldquo;from&rdquo; or &ldquo;through&rdquo; any
date mean, unless otherwise specified, &ldquo;from and including&rdquo; or &ldquo;through and including&rdquo;, respectively. References
to any statute or act shall include all related current regulations and all amendments and any successor statutes, acts and regulations.
References to any agreement, instrument or document shall include all schedules, exhibits, annexes and other attachments thereto. References
to capitalized terms that are not defined herein, but are defined in the UCC, shall have the meanings given them in the UCC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;II</FONT><FONT STYLE="font-size: 10pt"><BR>
COMMITMENT AND BORROWING PROCEDURES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;2.1
</FONT><FONT STYLE="font-size: 10pt"><U>Commitment</U>. On the terms and subject to the conditions of this Agreement, each Lender severally
agrees to make its portion of a term loan (the &ldquo;Initial Loan&rdquo;) to the Borrower on the Closing Date in an amount equal to
(but not less than) the Initial Commitment Amount. On the terms and subject to the conditions of this Agreement, each Lender agrees to
make its portion of term loans (the &ldquo;Delayed Draw Loans&rdquo;) to the Borrower (i)&nbsp;on the First Delayed Draw Closing Date
in the aggregate amount set forth on the Loan Request delivered pursuant to Section&nbsp;2.2 below (which aggregate amount must be in
an amount (A)&nbsp;equal to or greater than $100,000,000 (and an integral multiple of $50,000,000 in excess thereof) and (B)&nbsp;not
to exceed the Delayed Draw Commitment Amount) and (ii)&nbsp;on the Second Delayed Draw Closing Date in the aggregate amount set forth
on the Loan Request delivered pursuant to Section&nbsp;2.2 below (which aggregate amount must be in an amount equal to the remaining
Delayed Draw Commitment Amount); provided that (i)&nbsp;upon the funding of the Delayed Draw Loans on the First Delayed Draw Closing
Date, the Delayed Draw Commitment Amount shall be reduced by the aggregate principal amount of Delayed Draw Loans made on such date and
(ii)&nbsp;upon the funding of the Delayed Draw Loans on the Second Delayed Draw Closing Date, the Delayed Draw Commitment Amount shall
be reduced to $0. No amounts paid or prepaid with respect to the Loans may be reborrowed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;2.2
</FONT><FONT STYLE="font-size: 10pt"><U>Borrowing Procedure</U>. The Borrower may irrevocably request that the Initial Loans be made
by delivering to the Administrative Agent a Loan Request on or before 11:00 a.m.&nbsp;(New York City time) on a Business Day at least
three (3)&nbsp;Business Days prior to the proposed Closing Date (or such shorter period as the Administrative Agent and the Required
Lenders may agree in their discretion). The Borrower may irrevocably request that the Delayed Draw Loans be made by delivering to the
Administrative Agent a Loan Request on or before 11:00 a.m.&nbsp;(New York City time) on a Business Day at least twelve (12) Business
Days (or such shorter period as the Administrative Agent and each Lender may agree in their sole discretion) prior to the proposed Delayed
Draw Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;2.3
</FONT><FONT STYLE="font-size: 10pt"><U>Funding</U>. After receipt of the Loan Request in accordance with Section&nbsp;2.2 for the Initial
Loans, the Administrative Agent shall promptly notify each Lender of the amount of such Lender&rsquo;s portion of the Initial Loans.
Each Lender shall, on the Closing Date, and subject to the terms and conditions hereof, make the requested proceeds of such Lender&rsquo;s
portion of the Initial Loans available to or as instructed by the Administrative Agent. After receipt of the Loan Request in accordance
with Section&nbsp;2.2 for the Delayed Draw Loans, the Administrative Agent shall promptly notify each Lender of the amount of such Lender&rsquo;s
portion of the Delayed Draw Loans requested pursuant to such Loan Request and subject to the terms and conditions hereof. Each Lender
shall, on the applicable Delayed Draw Closing Date, and subject to the terms and conditions hereof, make the requested proceeds of such
Lender&rsquo;s portion of the Delayed Draw Loans requested pursuant to such Loan Request available to or as instructed by the Administrative
Agent. Upon satisfaction or waiver of the applicable conditions set forth in Article&nbsp;V, in each case, the Administrative Agent shall
make all funds so received available to the Borrower by wire transfer to the account the Borrower shall have specified in its applicable
Loan Request in an amount equal to (but not less than) the Lenders&rsquo; applicable Commitment Amount. It is understood that (i)&nbsp;no
Lender shall be responsible for any default by any other Lender in its obligation to make Loans hereunder and that each Lender severally
but not jointly shall be obligated to make the Loans provided to be made by it hereunder, regardless of the failure of any other Lender
to fulfill its commitments hereunder and (ii)&nbsp;other than as expressly provided herein with respect to a Defaulting Lender, failure
by a Lender to perform any of its obligations under any of the Loan Documents shall not release any Person from performance of its obligation
under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;2.4
</FONT><FONT STYLE="font-size: 10pt"><U>Reduction of the Commitment Amounts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mandatory</U>.
The Initial Commitment Amount shall automatically and permanently be reduced to zero on the Initial Commitment Termination Date (immediately
after the making of the Initial Loan on such date). The Delayed Draw Commitment Amount shall automatically and permanently be reduced
to zero on the Delayed Draw Commitment Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Optional</U>.
The Borrower may, upon written notice to the Administrative Agent at least five (5)&nbsp;Business Days (or such shorter period as the
Administrative Agent and the Required Lenders may agree in their sole discretion) prior to the date of termination, terminate the unused
Delayed Draw Commitment Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;III</FONT><FONT STYLE="font-size: 10pt"><BR>
REPAYMENTS, PREPAYMENTS,&nbsp;INTEREST AND FEES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.1
</FONT><FONT STYLE="font-size: 10pt"><U>Repayments and Prepayments</U>. The Borrower agrees that the Loans, and any fees or interest
accrued or accruing thereon, shall be repaid and prepaid solely in U.S. dollars pursuant to the terms of this Article&nbsp;III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.2
</FONT><FONT STYLE="font-size: 10pt"><U>Amortization; Repayments and Prepayments</U>. On the earlier to occur of (x)&nbsp;for dates prior
to January&nbsp;1, 2026, any date that the redemption rights in respect of the Series&nbsp;C Preferred Stock or the Series&nbsp;D Preferred
Stock are or may become exercisable within 90 days following such date, or (y)&nbsp;January&nbsp;1, 2026 or the first date thereafter
if, as of such date, the redemption rights in respect of the Series&nbsp;C Preferred Stock or the Series&nbsp;D Preferred Stock are or
may become exercisable on or prior to the date that is 6 months after the Maturity Date (such earlier applicable date (if any) or, if
such day is not a Business Day, the next succeeding Business Day, the &ldquo;<U>Determination Date</U>&rdquo;), the Borrower shall provide
written notice to the Administrative Agent at least five (5)&nbsp;Business Days prior to the likely occurrence of the Determination Date
and, on the Determination Date, make a one-time amortization payment in an amount equal to 15% of the outstanding principal amount of
the Loans outstanding on the Determination Date, together with the applicable Repayment Premium and Exit Fee. Following the occurrence
of a Determination Date, commencing with the first full Fiscal Quarter following such Determination Date and ending on the Amortization
Termination Date (as defined below), the Borrower shall repay the outstanding principal amount of the Loans on the last day of each Fiscal
Quarter (provided that if such day is not a Business Day, then such repayment shall be made on the next succeeding Business Day), in
equal quarterly installments equal to 2.5% of the outstanding principal balance of the Loan on the applicable Determination Date, together
with the applicable Repayment Premium and Exit Fee, unless sooner required to be repaid pursuant to the terms of this Agreement. &ldquo;Amortization
Termination Date&rdquo; shall mean the earliest to occur of (A)&nbsp;the Maturity Date, (B)&nbsp;the waiver or amendment of the terms
of the Series&nbsp;C Preferred Stock and the Series&nbsp;D Preferred Stock to cause the put rights thereunder to not be exercisable on
or prior to the date that is 6 months after the Maturity Date, (C)&nbsp;the redemption in full of all of the outstanding Series&nbsp;C
Preferred Stock and the Series&nbsp;D Preferred Stock and (D)&nbsp;the conversion of all of the outstanding Series&nbsp;C Preferred Stock
and Series&nbsp;D Preferred Stock into common stock of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
Borrower shall also repay in full the unpaid principal amount of the Loans on the Maturity Date; provided that, at any time prior to
the Maturity Date, payments and prepayments of the Loans shall also be made as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Borrower shall have the right, with at least three (3)&nbsp;Business Days&rsquo; (or such shorter period as the Administrative Agent
and the Required Lenders may agree in their sole discretion) notice to the Administrative Agent, at any time and from time to time to
prepay any unpaid principal amount of the Loans, in whole or in part, together with the applicable Repayment Premium and the Exit Fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
three Business Days of receipt by the Borrower or any Subsidiary of any (i)&nbsp;Net Casualty Proceeds or (ii)&nbsp;Net Asset Sales Proceeds,
the Borrower shall notify the Administrative Agent thereof. The Borrower shall within three (3)&nbsp;Business Days of such notice make
a mandatory prepayment of the Loans (<U>provided</U> that a Lender may elect to waive such prepayment with respect to its Loans upon
written notice to the Borrower and the Administrative Agent prior to the required prepayment date) in an amount equal to 100% of such
proceeds (or such lesser amount as the Required Lenders may specify on the date of such request), in each case, together with the applicable
Repayment Premium and the Exit Fee, to be applied as set forth in <U>Section&nbsp;3.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Borrower shall repay the Loans in full immediately upon any acceleration of the Maturity Date thereof pursuant to <U>Section&nbsp;9.2
</U>or <U>Section&nbsp;9.3</U>, unless, pursuant to <U>Section&nbsp;9.3</U>, only a portion of the Loans is so accelerated (in which
case the portion so accelerated shall be so repaid), in each case together with the applicable Repayment Premium and the Exit Fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.3
</FONT><FONT STYLE="font-size: 10pt"><U>Application</U>. Amounts repaid or prepaid in respect of the outstanding principal amount of
the Loans pursuant to clauses (a), (b)&nbsp;or (c)&nbsp;of Section&nbsp;3.2 shall be applied first (and subject to the occurrence of
a Determination Date), pro rata among the remaining principal payments due in respect of the Loans (if any), and thereafter, pro rata
to the Initial Loan and the Delayed Draw Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.4
</FONT><FONT STYLE="font-size: 10pt"><U>Interest Rate</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
each Interest Period, interest payable in cash by the Borrower shall accrue on the Loans during such Interest Period at a rate per annum
equal to the greater of (x)&nbsp;the SOFR Rate for such Interest Period and (y)&nbsp;2.50%, <U>plus</U>, in either case, the Applicable
Margin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each case pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.5
</FONT><FONT STYLE="font-size: 10pt"><U>Default Rate</U>. At all times commencing upon the date any Event of Default occurs, and continuing
until such Event of Default is no longer continuing, at the election of the Required Lenders (except to the extent provided below), the
Applicable Margin shall be increased by 3.00% per annum (with such increase applied from and after the date on which such Event of Default
initially occurred); <U>provided</U>, that no election or notice of the imposition of the default rate specified in this <U>Section&nbsp;3.5
</U>shall be required in the case of any Specified Event of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.6
</FONT><FONT STYLE="font-size: 10pt"><U>Payment Dates</U>. Interest accrued on the Loans shall be payable in cash, without duplication:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;on
the Maturity Date therefor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;on
the date of any payment or prepayment, in whole or in part, of principal outstanding on such Loan on the principal amount so paid or
prepaid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;on
the last day of each Interest Period; <U>provided</U> that if such day is not a Business Day, then such payment shall be made on the
next succeeding Business Day; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;on
that portion of the Loans that is accelerated pursuant to <U>Section&nbsp;9.2</U> or <U>Section&nbsp;9.3</U>, immediately upon such acceleration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Interest accrued
on the Loans or other monetary Obligations after the date such amount is due and payable (whether on the Maturity Date, upon acceleration
or otherwise) shall be payable upon demand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.7
</FONT><FONT STYLE="font-size: 10pt"><U>Fee Letters</U>. The Borrower shall pay to (i)&nbsp;the Administrative Agent such fees in the
amounts and at such times specified under the Agency Fee Letter, (ii)&nbsp;the Lenders (or to the Administrative Agent, for the account
of the applicable Lenders) such fees in the amounts and at such times specified under the Fee Letter and (iii)&nbsp;OrbiMed the Administration
Fee in the amounts and at such times specified under the Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.8
</FONT><FONT STYLE="font-size: 10pt"><U>Payments Generally</U>. Subject to Section&nbsp;9.3, all payments of principal, interest, fees
and any Repayment Premium on the Loans and all other Obligations payable by the Borrower or any Guarantor under the Loan Documents shall
be due, without any presentment thereof, to the Administrative Agent, at the Administrative Agent&rsquo;s Office. The Administrative
Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following
receipt. Except as otherwise set forth herein, all repayments and prepayments under the Loan Documents shall be made to the Lenders on
a pro rata basis in accordance with their respective Applicable Percentages. If any payment is scheduled to be made on a day that is
not a Business Day, then such payment shall be made on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;3.9
</FONT><FONT STYLE="font-size: 10pt"><U>Undrawn Fee</U>. Prior to the Delayed Draw Commitment Termination Date, on the last day of each
Fiscal Quarter (provided that if such day is not a Business Day, then such payment shall be made on the next succeeding Business Day)
until the Delayed Draw Commitment Termination Date (and if the Delayed Draw Commitment Termination Date occurs on a date that is not
the last day of a Fiscal Quarter, the amount of the fee for the corresponding Fiscal Quarter shall be a prorated amount for the portion
of such Fiscal Quarter ending on the Delayed Draw Commitment Termination Date and shall be paid on such date), the Borrower shall pay
to the Administrative Agent for the ratable account of each Lender, in cash, a fee (the &ldquo;Undrawn Fee&rdquo;) in an amount equal
to (x)&nbsp;0.50% per annum multiplied by (y)&nbsp;the undrawn Delayed Draw Commitment Amount. For purposes of this Section&nbsp;3.9,
the Undrawn Fee shall be calculated on a daily basis. The Undrawn Fee shall be fully earned and nonrefundable under any circumstances
and in addition to, and not creditable against, any other fee, cost or expense payable under the Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;IV</FONT><FONT STYLE="font-size: 10pt"><BR>
SOFR RATE AND OTHER PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.1
</FONT><FONT STYLE="font-size: 10pt"><U>Increased Costs, Etc</U>. The Borrower agrees to reimburse the Lenders for any increase in the
cost to the Lenders of, or any reduction in the amount of any sum receivable by the Lenders in respect of, the Lenders&rsquo; Commitments
and the making, continuation or maintaining of the Loans hereunder that may arise in connection with any Change in Law, except for such
changes with respect to increased capital costs and Taxes which are governed by Section&nbsp;4.2 and Section&nbsp;4.3, respectively.
The Administrative Agent shall notify the Borrower in writing of the occurrence of any such event, stating the reasons therefor and setting
forth in reasonable detail the additional amount required fully to compensate the Lenders for such increased cost. Such additional amounts
shall be payable by the Borrower directly to the Administrative Agent for the accounts of the Lenders within ten (10)&nbsp;Business Days
of its receipt of such notice, and such notice shall, in the absence of manifest error, be conclusive and binding on the Borrower. The
Borrower shall not be required to compensate any Lender for any amount claimed under this Section&nbsp;4.1 that was incurred more than
180 days prior to the date that such Lender (or the Administrative Agent on its behalf) notifies the Borrower of the event that gives
rise to such claim and that such Lender has determined to request such compensation; provided that if the circumstance giving rise to
such increased cost is retroactive, then such 180-day period referred to above shall be extended to include the period of retroactive
effect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.2
</FONT><FONT STYLE="font-size: 10pt"><U>Increased Capital Costs</U>. If any Change in Law affects or would affect the amount of capital
required or expected to be maintained by any Lender or any Person controlling such Lender, and such Lender determines (in good faith
but in its sole and absolute discretion) that the rate of return on its or such controlling Person&rsquo;s capital as a consequence of
the Commitments or the Loans made by it hereunder is reduced to a level below that which such Lender or such controlling Person could
have achieved but for the occurrence of any such circumstance, then such Lender shall notify the Borrower in writing of such Lender&rsquo;s
claim for compensation, stating the reasons therefor and setting forth in reasonable detail the additional amount required fully to compensate
such Lender for such reduction in rate of return. The Borrower shall within ten (10)&nbsp;Business Days following receipt of such notice
pay directly to the Administrative Agent for the account of such Lender additional amounts sufficient to compensate such Lender or such
controlling Person for such reduction in rate of return. A statement of such Lender as to any such additional amount or amounts shall,
in the absence of manifest error, be conclusive and binding on the Borrower. In determining such amount, such Lender may use any method
of averaging and attribution that it (in its sole and absolute discretion) shall deem applicable. The Borrower shall not be required
to compensate any Lender for any amount claimed under this Section&nbsp;4.2 that was incurred more than 180 days prior to the date that
such Lender (or the Administrative Agent on its behalf) notifies the Borrower of the event that gives rise to such claim and that such
Lender has determined to request such compensation; provided that if the circumstance giving rise to such reduction in rate of return
is retroactive, then such 180-day period referred to above shall be extended to include the period of retroactive effect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.3
</FONT><FONT STYLE="font-size: 10pt"><U>Taxes</U>. The Borrower covenants and agrees as follows with respect to Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as required by applicable Law, any and all payments by the Borrower or any Guarantor under each Loan Document shall be made without setoff,
counterclaim or other defense, and free and clear of, and without deduction or withholding for or on account of, any Taxes. In the event
that any Taxes are imposed and required to be deducted or withheld from any payment required to be made by the Borrower or any of the
Guarantors to or on behalf of the Lenders under any Loan Document (as determined in the good faith discretion of the applicable withholding
agent), then:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such Taxes are Non-Excluded Taxes or Other Taxes, the amount of such payment shall be increased as may be necessary so that such payment
is made, after the withholding or deduction for or on account of such Taxes (including such deductions and withholdings applicable to
additional sums payable under this <U>Section&nbsp;4.3</U>), in an amount that is not less than the amount provided for in such Loan
Document; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Borrower or such Guarantor shall withhold or deduct the full amount of such Taxes from such payment (as increased pursuant to <U>clause
(a)(i)</U>) and shall timely pay such amount to the Governmental Authority imposing such Taxes in accordance with applicable Law or at
the option of the Administrative Agent timely reimburse it for the payment of any Other Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition, without duplication of <U>Section&nbsp;4.3(a)</U>, the Borrower shall timely pay all Other Taxes imposed to the relevant Governmental
Authority imposing such Other Taxes in accordance with applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
promptly as practicable after the payment of any Taxes or Other Taxes required to be paid by the Borrower under <U>Section&nbsp;4.3(a)</U>&nbsp;or
<U>(b)</U>, and in any event within 45 days of any such payment being due, the Borrower shall furnish to the Administrative Agent a copy
of an official receipt (or a certified copy thereof) evidencing the payment of such Taxes or Other Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Loan Parties shall indemnify the Administrative Agent and each Lender, within 10 days after demand therefor, for any Non-Excluded Taxes
and Other Taxes levied, imposed or assessed on (and whether or not paid directly by) by the Administrative Agent or such Lender whether
or not such Non-Excluded Taxes or Other Taxes are correctly or legally asserted by the relevant Governmental Authority. Promptly upon
having knowledge that any such Non-Excluded Taxes or Other Taxes have been levied, imposed or assessed, and promptly upon notice thereof
by such Lender, the Borrower shall pay such Non-Excluded Taxes or Other Taxes directly to the relevant Governmental Authority (<U>provided
</U>that, such Lender shall not be under any obligation to provide any such notice to the Borrower). The Borrower acknowledges that any
payment made to any Lender or to any Governmental Authority in respect of the indemnification obligations of the Borrower provided in
this <U>clause (d)</U>&nbsp;shall constitute a payment in respect of which the provisions of <U>clause (a)</U>&nbsp;and this <U>clause
(d)</U>&nbsp;shall apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Status
of Lenders</U>. (i)&nbsp;Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made
under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the
Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the
Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any
Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable
Law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine
whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary
in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth
in <U>paragraphs (e)(ii)(1)</U>, <U>(e)(ii)(2)</U>&nbsp;and <U>(e)(iv)</U>&nbsp;of this Section) shall not be required if in the Lender&rsquo;s
reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or
would materially prejudice the legal or commercial position of such Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the generality of the foregoing, in the event that the Borrower is a U.S. Borrower,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or about the date on which such Lender becomes
a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent),
executed copies of IRS Form&nbsp;W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number
of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement
(and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following
is applicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x)&nbsp;with respect
to payments of interest under any Loan Document, executed copies of IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E establishing an exemption
from, or reduction of, U.S. federal withholding Tax pursuant to the &ldquo;interest&rdquo; article of such tax treaty and (y)&nbsp;with
respect to any other applicable payments under any Loan Document,&nbsp;IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E establishing an
exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &ldquo;business profits&rdquo; or &ldquo;other income&rdquo;
article of such tax treaty;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;executed
copies of IRS Form&nbsp;W-8ECI;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section&nbsp;881(c)&nbsp;of the Code,
(x)&nbsp;a certificate to the effect that such Foreign Lender is not a &ldquo;bank&rdquo; within the meaning of Section&nbsp;881(c)(3)(A)&nbsp;of
the Code, a &ldquo;10 percent shareholder&rdquo; of the Borrower within the meaning of Section&nbsp;871(h)(3)(B)&nbsp;of the Code, or
a &ldquo;controlled foreign corporation&rdquo; related to the Borrower as described in Section&nbsp;881(c)(3)(C)&nbsp;of the Code (a
 &ldquo;U.S. Tax Compliance Certificate&rdquo;) and (y)&nbsp;executed copies of IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form&nbsp;W-8IMY, accompanied by IRS Form&nbsp;W-8ECI,&nbsp;IRS
Form&nbsp;W-8BEN,&nbsp;IRS Form&nbsp;W 8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit&nbsp;B-2 or Exhibit&nbsp;B-3,&nbsp;IRS
Form&nbsp;W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is
a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such
Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit&nbsp;B-4 on behalf of each such direct
and indirect partner;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number
of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement
(and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other
form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed,
together with such supplementary documentation as may be prescribed by applicable Law to permit the Borrower or the Administrative Agent
to determine the withholding or deduction required to be made; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were
to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section&nbsp;1471(b)&nbsp;or 1472(b)&nbsp;of
the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law
and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable
Law (including as prescribed by Section&nbsp;1471(b)(3)(C)(i)&nbsp;of the Code) and such additional documentation reasonably requested
by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations
under FATCA and to determine that such Lender has complied with such Lender&rsquo;s obligations under FATCA or to determine the amount,
if any, to deduct and withhold from such payment. Solely for purposes of this <U>clause (iv)</U>, &ldquo;FATCA&rdquo; shall include any
amendments made to FATCA after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or before the Closing Date (and on or before the date any successor or replacement Administrative Agent becomes the Administrative Agent
hereunder), to the extent copies thereof have not previously been so delivered, the Administrative Agent shall deliver to the Borrower
duly completed and executed copies of either (i)&nbsp;IRS Form&nbsp;W-9 (or any subsequent versions thereof or successors thereto) or
(ii)&nbsp;(A)&nbsp;IRS Form&nbsp;W-8IMY (or any subsequent versions thereof or successors thereto) certifying that it is a &ldquo;U.S.
branch&rdquo; of a foreign bank and evidencing its agreement with the Borrower to be treated as a U.S. person with respect to payments
made to it by the Loan Parties such that the Administrative Agent assumes primary withholding and reporting responsibilities and (B)&nbsp;IRS
Form&nbsp;W-8ECI with respect to any amount payable to the Administrative Agent for its own account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Each Lender
agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update
such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been
indemnified pursuant to this Section&nbsp;(including by the payment of additional amounts pursuant to this Section), it shall pay to
the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section&nbsp;with
respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without
interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party,
upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (f)&nbsp;(plus
any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is
required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (f), in no event
will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (f)&nbsp;the payment of
which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the
Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification
payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified
party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying
party or any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
party&rsquo;s obligations under this <U>Section&nbsp;4.3</U> shall survive the resignation or replacement of the Administrative Agent
or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or
discharge of all other Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
any Lender requests compensation under <U>Sections 4.1</U>, <U>4.2</U> or <U>4.3</U>, or requires Borrower to pay any Non-Excluded Taxes,
Other Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to <U>Section&nbsp;4.3</U>,
then such Lender (at the request of the Borrower) will, to the extent not inconsistent with the internal policies of such Lender and
any applicable legal or regulatory restrictions, use reasonable efforts to (a)&nbsp;make, issue, fund or maintain its Loans through another
office of such Lender, or (b)&nbsp;take such other measures as such Lender may deem reasonable, if as a result thereof the additional
amounts which would otherwise be required to be paid to such Lender pursuant to <U>Sections 4.1</U>, <U>4.2</U> or <U>4.3</U> would be
materially reduced and if, as determined by such Lender in its sole discretion, the making, issuing, funding or maintaining of such Loans
through such other office or in accordance with such other measures, as the case may be, would not otherwise adversely affect such Loans
or the interests of such Lender; provided, such Lender will not be obligated to utilize such other office pursuant to this <U>Section&nbsp;4.3(h)</U>&nbsp;unless
Borrower agrees to pay all incremental expenses incurred by such Lender as a result of utilizing such other office as described above
and such designation or assignment would eliminate or reduce amounts payable pursuant to <U>Sections 4.1</U>, <U>4.2</U> or <U>4.3</U>,
as the case may be, in the future. A certificate as to the amount of any such expenses payable by Borrowers pursuant to this <U>Section&nbsp;4.3(h)</U>&nbsp;(setting
forth in reasonable detail the basis for requesting such amount) submitted by such Lender to Borrower (with a copy to Administrative
Agent) shall be conclusive absent manifest error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Loans are deemed to be made with original issue discount for U.S. federal income tax purposes. Requests for information regarding the
issue price, amount of original issue discount, issue date, and yield to maturity on the Loans shall be directed to the Borrower care
of Luke Power, Corporate Vice President,&nbsp;Interim Chief Financial Officer and Treasurer at ### or ###.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.4
</FONT><FONT STYLE="font-size: 10pt"><U>Payments, Computations; Proceeds of Collateral, Etc</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
otherwise expressly provided in a Loan Document, all payments by the Borrower pursuant to each Loan Document shall be made without setoff,
deduction or counterclaim not later than 12:00 p.m.&nbsp;(New York City time) on the date due in same day or immediately available funds,
marked for attention as indicated, or in such other manner or to such other account as the Administrative Agent may from time to time
direct in writing. Funds received after 12:00 p.m.&nbsp;(New York City time) on any day shall be deemed to have been received by the
Administrative Agent on the next succeeding Business Day and any applicable interest or fee shall continue to accrue. All interest and
fees shall be computed on the basis of the actual number of days occurring during the period for which such interest or fee is payable
over a year comprised of 360&nbsp;days. Payments due on other than a Business Day shall be made on the next succeeding Business Day and
such extension of time shall be included in computing interest and fees in connection with that payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
amounts received as a result of the exercise of remedies under the Loan Documents (including from the proceeds of collateral securing
the Obligations) or under applicable Law shall be applied upon receipt to the Obligations in accordance with <U>Section&nbsp;9.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
obligations of the Lenders hereunder to make Loans and to make payments pursuant to <U>Section&nbsp;10.4(c)</U>&nbsp;are several and
not joint. The failure of any Lender to make any Loan or to make any payment under <U>Section&nbsp;10.4(c)</U>&nbsp;on any date required
hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible
for the failure of any other Lender to so make its Loan or to make its payment under <U>Section&nbsp;10.4(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Nothing
herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation
by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
any Lender shall, by exercising any right of setoff or otherwise, obtain payment in respect of any principal of or interest on its portion
of any of the Loans, any Exit Fee or any Repayment Premium in connection therewith resulting in such Lender&rsquo;s receiving payment
of a proportion of the aggregate amount of the Loans and accrued interest thereon and any Exit Fee or Repayment Premium in connection
therewith greater than its Applicable Percentage thereof as provided herein, then such Lender shall (x)&nbsp;notify the Administrative
Agent of such fact and (y)&nbsp;purchase (for cash at face value) participations in the portions of the Loans of the other Lenders, or
make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in
accordance with the aggregate amount of principal of, accrued interest on and any Exit Fee or Repayment Premium in connection with their
respective portions of the Loans and other amounts owing them; <U>provided</U> that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall
be rescinded and the purchase price restored to the extent of such recovery, without interest; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
provisions of this <U>Section&nbsp;4.4(e)</U>&nbsp;shall not be construed to apply to (x)&nbsp;any payment made by or on behalf of the
Borrower pursuant to and in accordance with the express terms of this Agreement or (y)&nbsp;any payment obtained by a Lender as consideration
for the assignment of or sale of a participation in any of its portion of the Loans to any assignee or participant, other than an assignment
to a Borrower or any Guarantor (as to which the provisions of this Section&nbsp;shall apply).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The Borrower,
on behalf of itself and the Guarantors, hereby consents to the foregoing and agrees, to the extent it may effectively do so under applicable
Law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower or such Guarantor
rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower
or such Guarantor in the amount of such participation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.5
</FONT><FONT STYLE="font-size: 10pt"><U>Setoff</U>. Each Lender shall, upon the occurrence and during the continuance of any Event of
Default, have the right to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and (as security
for such Obligations) the Borrower hereby grants to each Lender a continuing security interest in, any and all balances, credits, deposits,
accounts or moneys of the Borrower then or thereafter maintained with or on behalf of such Lender. Each Lender agrees promptly to notify
the Borrower after any such appropriation and application made by such Lender; provided that, the failure to give such notice shall not
affect the validity of such setoff and application. The rights of each Lender under this Section&nbsp;4.5 are in addition to other rights
and remedies (including other rights of setoff under applicable law or otherwise) which such Lender may have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.6
</FONT><FONT STYLE="font-size: 10pt"><U>SOFR Rate Not Determinable</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
prior to the commencement of any Interest Period for a Loan, the Administrative Agent determines (which determination shall be conclusive
absent manifest error), or the Required Lenders notify the Administrative Agent that they have determined, that adequate and reasonable
means do not exist for ascertaining the SOFR Rate for such Interest Period, then the Administrative Agent shall give notice thereof to
the Borrower as promptly as practicable and, until the Administrative Agent notifies (if applicable, upon the instruction of the Required
Lenders) the Borrower that the circumstances giving rise to such notice no longer exist, (i)&nbsp;the Loans shall bear interest calculated
pursuant to <U>Section&nbsp;3.4</U> but using the Prime Rate instead of the SOFR Rate and (ii)&nbsp;the continuation of any outstanding
Loan or the extension of a new Loan hereunder shall be made with interest calculated pursuant to <U>Section&nbsp;3.4</U> but using the
Prime Rate instead of the SOFR Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
at any time the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Required Lenders
notify the Administrative Agent that they have determined, that (i)&nbsp;the circumstances set forth in <U>Section&nbsp;4.6(a)</U>&nbsp;have
arisen and such circumstances are unlikely to be temporary or (ii)&nbsp;the circumstances set forth in <U>Section&nbsp;4.6(a)</U>&nbsp;have
not arisen but the supervisor for the administrator of the SOFR Rate has made a public statement identifying a specific date after which
the SOFR Rate shall no longer be used for determining interest rates for loans, then the Administrative Agent (at the direction of the
Required Lenders) shall (in consultation with the Borrower) establish an alternate rate of interest to that based on the SOFR Rate that
gives due consideration to the then-prevailing market convention for determining a rate of interest for loans in the United States at
such time, and the Required Lenders and the Borrower shall enter into an amendment to this Agreement to reflect such alternate rate of
interest and such other related changes as the Borrower and the Required Lenders may determine to be appropriate. Until an alternate
rate of interest shall be determined in accordance with this <U>Section&nbsp;4.6(b)</U>&nbsp;(but, in the case of the circumstances described
in clause (ii)&nbsp;of the first sentence of this <U>Section&nbsp;4.6(b)</U>, only to the extent the SOFR Rate for such Interest Period
is not available or published at such time on a current basis), <U>Section&nbsp;4.6(a)</U>&nbsp;shall be applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;4.7
</FONT><FONT STYLE="font-size: 10pt"><U>Defaulting Lenders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Adjustments</U>.
Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time
as such Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Waivers
and Amendments</U>.&nbsp; Such Defaulting Lender&rsquo;s right to approve or disapprove any amendment, waiver or consent with respect
to this Agreement shall be restricted as set forth in the definition of Required Lenders and <U>Section&nbsp;10.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Defaulting
Lender Waterfall</U>.&nbsp; Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account
of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to <U>Article&nbsp;IX</U> or otherwise) or received
by the Administrative Agent from a Defaulting Lender pursuant to <U>Section&nbsp;10.17</U> shall be applied at such time or times as
may be determined by the Administrative Agent as follows: <I>first</I>, to the payment of any amounts owing by such Defaulting Lender
to the Administrative Agent hereunder; <I>second</I>, as the Borrower may request (so long as no Default or Event of Default shall have
occurred and be continuing), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof
as required by this Agreement, as determined by the Administrative Agent; <I>third</I>, if so determined by the Administrative Agent
and the Borrower, to be held in a deposit account and released pro rata in order to satisfy such Defaulting Lender&rsquo;s potential
future funding obligations with respect to Loans under this Agreement; <I>fourth</I>, to the payment of any amounts owing to the Lenders
as a result of any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of
such Defaulting Lender&rsquo;s breach of its obligations under this Agreement; <I>fifth</I>, so long as no Default or Event of Default
has occurred and is continuing, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent
jurisdiction obtained by such Borrower against such Defaulting Lender as a result of such Defaulting Lender's breach of its obligations
under this Agreement and <I>sixth</I>, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; <U>provided
</U>that if (x)&nbsp;such payment is a payment of the principal amount of any Loans in respect of which such Defaulting Lender has not
fully funded its appropriate share, and (y)&nbsp;such Loans were made at a time when the conditions set forth in <U>Article&nbsp;V</U>
were satisfied or waived, such payment shall be applied solely to pay the Loans of all Non-Defaulting Lenders on a pro rata basis prior
to being applied to the payment of any Loans of such Defaulting Lender until such time as all Loans are held by the Lenders pro rata
in accordance with the Commitments hereunder.&nbsp; Any payments, prepayments or other amounts paid or payable to a Defaulting Lender
that are applied (or held) to pay amounts owed by a Defaulting Lender shall be deemed paid to and redirected by such Defaulting Lender,
and each Lender irrevocably consents hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Fees</U>. No Defaulting Lender shall be entitled to receive any fees payable under <U>Section&nbsp;3.9</U> for any period during which
such Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required
to have been paid to that Defaulting Lender).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Defaulting
Lender Cure</U>. If the Borrower and the Administrative Agent agree in writing that a Lender is no longer a Defaulting Lender, the Administrative
Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set
forth therein, that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or
take such other actions as the Administrative Agent may determine to be necessary to cause the Loans to be held on a pro rata basis by
the Lenders in accordance with their Commitments, whereupon such Lender will cease to be a Defaulting Lender; <U>provided</U> that no
adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender
was a Defaulting Lender; and <U>provided</U>, <U>further</U>, that except to the extent otherwise expressly agreed by the affected parties,
no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising
from that Lender&rsquo;s having been a Defaulting Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 54; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;V</FONT><FONT STYLE="font-size: 10pt"><BR>
CONDITIONS TO MAKING THE LOANS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.1
</FONT><FONT STYLE="font-size: 10pt"><U>Credit Extensions</U>. The obligation of each Lender to make its portion of the Initial Loans
shall be subject to the execution and delivery of this Agreement by the parties hereto, the delivery of a Loan Request as requested pursuant
to Section&nbsp;2.2, and the satisfaction of each of the conditions precedent set forth below in this Article&nbsp;V (other than Sections
5.19 and 5.20). The obligation of each Lender to make its portion of the Delayed Draw Loans on the First Delayed Draw Closing Date shall
be subject to the prior making of the Initial Loan, the delivery of a Loan Request pursuant to Section&nbsp;2.2, and the satisfaction
of each of the conditions precedent set forth below in Sections 5.3, 5.8, 5.19 and 5.20. The obligation of each Lender to make its portion
of the Delayed Draw Loans on the Second Delayed Draw Closing Date shall be subject to the prior occurrence of the First Delayed Draw
Closing Date, the delivery of a Loan Request as requested pursuant to Section&nbsp;2.2, and the satisfaction of each of the conditions
precedent set forth below in Sections 5.3, 5.8, 5.19 and 5.20.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.2
</FONT><FONT STYLE="font-size: 10pt"><U>Secretary&rsquo;s Certificate, Etc</U>. The Administrative Agent and each Lender shall have received
from the Borrower and each Guarantor, (i)&nbsp;a copy of a good standing certificate, dated a date reasonably close to the Closing Date,
for each such Person and (ii)&nbsp;a certificate, dated as of the Closing Date, duly executed and delivered by such Person&rsquo;s Secretary
or Assistant Secretary, managing member or general partner, or other Authorized Officer, as applicable, as to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;resolutions
of each such Person&rsquo;s board of directors (or other managing body, in the case of a Person other than a corporation) and any other
corporate resolutions required by applicable Law or pursuant to such Person&rsquo;s Organic Documents, each of which shall be then in
full force and effect, authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the
transactions contemplated hereby and thereby;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
incumbency and signatures of those of its officers, managers, managing member or general partner, as applicable, authorized to act with
respect to each Loan Document to be executed by such Person; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
full force and validity of each Organic Document of such Person and copies thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">upon
which certificates the Administrative Agent and each Lender may conclusively rely until it shall have received a further certificate
of the Secretary, Assistant Secretary, managing member or general partner, as applicable, of any such Person canceling or amending the
prior certificate of such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.3
</FONT><FONT STYLE="font-size: 10pt"><U>Closing Date Certificates</U>. The Administrative Agent and each Lender shall have received a
Closing Date Certificate, dated as of the Closing Date, the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date,
as the case may be, and duly executed and delivered by an Authorized Officer of the Borrower, in which the Borrower shall certify that
(i)&nbsp;the representations and warranties set forth in each Loan Document shall, in each case, be true and correct in all material
respects (except with respect to any representation or warranty qualified by materiality or Material Adverse Effect, each of which representation
or warranty is true and correct in all respects) as of such date (except to the extent that they relate specifically to an earlier specified
date, in which case they are true and correct in all material respects (except with respect to any representation or warranty qualified
by materiality or Material Adverse Effect, each of which representation or warranty is true and correct in all respects) on and as of
such earlier date), (ii)&nbsp;no Default of Event of Default shall have then occurred and be continuing, or would result from the Loans
to be advanced on the Closing Date, the First Delayed Draw Closing Date or the Second Delayed Draw Closing Date, as the case may be,
and (iii)&nbsp;all of the conditions set forth in this Article&nbsp;V required to be satisfied by the Loan Parties on such date have
been satisfied, except for those conditions expressly and specifically waived by the Required Lenders in writing, and as of such date
as such certificate is delivered, such certifications by the Borrower shall in fact be true and correct. All documents and agreements
required to be appended to the Closing Date Certificate, if any, shall be in form and substance reasonably satisfactory to the Administrative
Agent and OrbiMed, shall have been executed and delivered by the requisite parties, and shall be in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.4
</FONT><FONT STYLE="font-size: 10pt"><U>Payment of Outstanding Indebtedness, Etc</U>. All Indebtedness identified in <U>Schedule 8.2(b)</U>,
together with all interest, all prepayment premiums and all other amounts due and payable with respect thereto, shall have been paid
in full from the proceeds of the Loans and the commitments in respect of such Indebtedness shall have been terminated, and all Liens
securing payment of any such Indebtedness shall have been released and the Administrative Agent and each Lender shall have received all
Uniform Commercial Code Form&nbsp;UCC-3 termination statements or other instruments (including customary payoff letters) as may be reasonably
required in connection therewith (collectively, the &ldquo;Existing Debt Refinancing&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.5
</FONT><FONT STYLE="font-size: 10pt"><U>Delivery of Note</U>. Each Lender shall have received a Note duly executed and delivered by an
Authorized Officer of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.6
</FONT><FONT STYLE="font-size: 10pt"><U>Financial Information, Etc.</U> The Administrative Agent and each Lender shall have received:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;audited
consolidated financial statements of the Borrower and the Subsidiaries for each of the Fiscal Years ended December&nbsp;31, 2020 and
December&nbsp;31, 2021; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;unaudited
consolidated balance sheets of the Borrower and the Subsidiaries for the Fiscal Quarters ended March&nbsp;31, 2022, June&nbsp;30, 2022
and September&nbsp;30, 2022, together with the related consolidated statements of income, stockholders&rsquo; equity and cash flows for
the twelve months then ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.7
</FONT><FONT STYLE="font-size: 10pt"><U>Compliance Certificate</U>. The Lenders and the Administrative Agent shall have received an initial
Compliance Certificate on a pro forma basis as if the Loans had been made as of September&nbsp;30, 2022 and as to such items therein
as the Administrative Agent and OrbiMed reasonably requests, dated the Closing Date, duly executed (and with all schedules thereto duly
completed) and delivered by the chief financial or accounting Authorized Officer of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.8
</FONT><FONT STYLE="font-size: 10pt"><U>Solvency, Etc.</U> The Lenders and the Administrative Agent shall have received a solvency certificate
as to the Solvency of the Borrower and its Subsidiaries on a consolidated basis, after giving effect to the incurrence of the applicable
Loans, and the use of proceeds of such Loans, duly executed and delivered by the chief financial or accounting Authorized Officer of
the Borrower, dated as of the Closing Date, First Delayed Draw Closing Date or the Second Delayed Draw Closing Date, as the case may
be, in the form attached as Exhibit&nbsp;G.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.9
</FONT><FONT STYLE="font-size: 10pt"><U>Guarantee</U>. The Lenders and the Administrative Agent shall have received executed counterparts
of the Guarantee, dated as of the Closing Date, duly executed and delivered by each Guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.10
</FONT><FONT STYLE="font-size: 10pt"><U>Security Agreement</U>. The Lenders and the Administrative Agent shall have received executed
counterparts of the Security Agreement, dated as of the Closing Date, duly executed and delivered by the Borrower and each Guarantor,
together with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;certificates
(in the case of Capital Securities that are securities (as defined in the UCC)) evidencing all of the issued and outstanding Capital
Securities directly owned by the Borrower or any Guarantor (including with respect to the Capital Securities of any Excluded Subsidiary
(other than Excluded Assets)), which certificates in each case shall be accompanied by undated instruments of transfer duly executed
in blank, or, in the case of Capital Securities that are uncertificated securities (as defined in the UCC), confirmation and evidence
satisfactory to the Administrative Agent and the Lenders that the security interest therein has been granted to and perfected by the
Administrative Agent for the benefit of the Secured Parties in accordance with Articles 8 and 9 of the UCC and all Laws otherwise applicable
to the perfection of the pledge of such Capital Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;subject
to <U>Section&nbsp;7.15</U>, UCC financing statements suitable in form for naming the Borrower and each Guarantor as a debtor and the
Administrative Agent as the secured party, or other similar instruments or documents to be filed under the UCC of all jurisdictions as
may be necessary or, in the opinion of the Required Lenders, desirable to perfect the security interests of the Administrative Agent,
on behalf of the Secured Parties, pursuant to the Security Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;subject
to <U>Section&nbsp;7.15</U>, evidence that all deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar
accounts of the Borrower and each Guarantor are Controlled Accounts (other than Excluded Accounts).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.11
</FONT><FONT STYLE="font-size: 10pt"><U>Intellectual Property Security Agreements</U>. The Administrative Agent and the Lenders shall
have received a Patent Security Agreement, a Copyright Security Agreement and a Trademark Security Agreement, as applicable, each dated
as of the Closing Date, duly executed and delivered by the Borrower or any Guarantor that, pursuant to the Security Agreement, is required
to provide such intellectual property security agreements to the Administrative Agent for the benefit of the Secured Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.12
</FONT><FONT STYLE="font-size: 10pt"><U>Opinion of Counsel</U>. The Administrative Agent and the Lenders shall have received customary
opinions, dated the Closing Date and addressed to the Secured Parties, from Shearman&nbsp;&amp; Sterling LLP, counsel to the Loan Parties,
in form and substance reasonably satisfactory to the Administrative Agent and the Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.13
</FONT><FONT STYLE="font-size: 10pt"><U>Insurance</U>. Subject to Section&nbsp;7.15, the Administrative Agent and the Lenders shall have
received insurance certificates and endorsements from one or more insurance companies satisfactory to the Administrative Agent and the
Lenders, evidencing coverage required to be maintained pursuant to each Loan Document, with the Administrative Agent named as loss payee
or additional insured, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.14
</FONT><FONT STYLE="font-size: 10pt"><U>Closing Fees, Expenses, Etc.</U> Each Lender and the Administrative Agent, as applicable, shall
have received for its own account (i)&nbsp;all fees, costs and expenses due and payable pursuant to Section&nbsp;10.3 and 10.4 and (ii)&nbsp;all
fees due and payable on the Closing Date pursuant to this Agreement, the Agency Fee Letter and the Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.15
</FONT><FONT STYLE="font-size: 10pt"><U>Anti-Terrorism Laws</U>. Each Lender and the Administrative Agent shall have received, as applicable,
all documentation and other information required by bank regulatory authorities under applicable &ldquo;know your customer&rdquo; and
anti-money laundering rules&nbsp;and regulations, including the U.S.A. Patriot Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.16
</FONT><FONT STYLE="font-size: 10pt"><U>Loan Documents</U>. The Administrative Agent shall have received executed counterparts of this
Agreement and the other Loan Documents, properly executed by an Authorized Officer of each of the Borrower and each other signing Guarantor
and by each Lender party to such Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.17
</FONT><FONT STYLE="font-size: 10pt"><U>Satisfactory Legal Form</U>. All documents executed or submitted pursuant hereto by or on behalf
of the Borrower or any Guarantor shall be reasonably satisfactory in form and substance to the Administrative Agent and the Lenders,
and the Administrative Agent and the Lenders shall have received all information, approvals, resolutions, opinions, documents or instruments
as the Administrative Agent or such Lender may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.18
</FONT><FONT STYLE="font-size: 10pt"><U>No Material Adverse Effect</U>. Since December&nbsp;31, 2021, there has not been a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.19
</FONT><FONT STYLE="font-size: 10pt"><U>Revenue Base</U>. Solely as a condition precedent to the First Delayed Draw Closing Date and
the Second Delayed Draw Closing Date, as the case may be, the Administrative Agent and the Lenders shall be satisfied that the Revenue
Base for the most recently ended Test Period prior to such Delayed Draw Closing Date was at least $300,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;5.20
</FONT><FONT STYLE="font-size: 10pt"><U>Disclosure Schedules</U>. Immediately prior to each Delayed Draw Closing Date, the Borrower shall
deliver to the Administrative Agent and the Lenders updates to <U>Schedules 6.15(a)(1)</U>, <U>6.15(j)(1)</U>&nbsp;and <U>6.22</U>, each
such updated Schedule to be complete and accurate in all material respects as of such Delayed Draw Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;VI</FONT><FONT STYLE="font-size: 10pt"><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In order to induce
the Lenders and the Administrative Agent to enter into this Agreement and to make the Loans hereunder, the Borrower represents and warrants
to the Lenders and the Administrative Agent that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.1
</FONT><FONT STYLE="font-size: 10pt"><U>Organization, Etc.</U> The Borrower and each Subsidiary (a)&nbsp;(i)&nbsp;is validly organized
and existing and in good standing (to the extent such concept exists in such jurisdiction) under the laws of the jurisdiction of its
incorporation or organization, and (ii)&nbsp;is duly qualified to do business and is in good standing as a foreign entity (to the extent
such concept exists in such jurisdiction) in each jurisdiction where the nature of its business requires such qualification (in the case
of this <U>clause (a)(ii)</U>, unless the failure to so qualify as a foreign entity would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect); and (b)&nbsp;except, as of the Closing Date, required approvals contemplated by the Specified
Letter and required board approvals in each case with respect to the borrowing of any Delayed Draw Term Loan on the applicable Delayed
Draw Closing Date, , has full power and authority and holds all requisite governmental licenses, permits, clearances and other approvals
required (i)&nbsp;in the case of the Loan Parties, to enter into and perform its obligations under each Loan Document to which it is
a party, and (ii)&nbsp;to own and hold under lease its property and to conduct its business substantially as currently conducted by it
(in the case of this <U>clause (b)(ii)</U>, except to the extent that failure to do so could not reasonably be expected to have a Material
Adverse Effect).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.2
</FONT><FONT STYLE="font-size: 10pt"><U>Due Authorization, Non-Contravention, Etc.</U> The execution, delivery and performance by the
Borrower and each Guarantor of each Loan Document executed or to be executed by it are in each case within such Person&rsquo;s corporate
or organizational powers, except, as of the Closing Date, required approvals contemplated by the Specified Letter and required board
approvals in each case with respect to the borrowing of any Delayed Draw Term Loan on the applicable Delayed Draw Closing Date, have
been duly authorized by all necessary corporate or organizational action, and do not:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;contravene
(i)&nbsp;the Borrower&rsquo;s or any Guarantor&rsquo;s Organic Documents, (ii)&nbsp;in any material respect, any court decree or order
binding on or affecting the Borrower or any Guarantor or (iii)&nbsp;in any material respect, any Law or governmental regulation binding
on or affecting the Borrower or any Guarantor; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;result
in (i)&nbsp;or require the creation or imposition of any Lien on the Borrower&rsquo;s or any Guarantor&rsquo;s properties (except as
permitted by this Agreement) or (ii)&nbsp;a material default under any material contract, agreement, or instrument binding on or affecting
the Borrower or any Guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.3
</FONT><FONT STYLE="font-size: 10pt"><U>Government Approval, Regulation, Etc.</U> No authorization, approval, clearance or other action
by, and no notice to or filing with, any Governmental Authority or other Person (other than (i)&nbsp;those that have been, or on the
Closing Date will be, duly obtained or made and which are, or on the Closing Date will be, in full force and effect, and (ii)&nbsp;recordings,
filings and other perfection actions in connection with the Liens granted to the Administrative Agent under this Agreement or any other
Loan Document) is required for the due execution, delivery or performance by the Borrower or any Guarantor of any Loan Document to which
it is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.4
</FONT><FONT STYLE="font-size: 10pt"><U>Validity, Etc.</U> Each Loan Document to which the Borrower or any Guarantor is a party constitutes
the legal, valid and binding obligations of such Person enforceable against such Person in accordance with its respective terms (except,
in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally and by principles of equity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.5
</FONT><FONT STYLE="font-size: 10pt"><U>Financial Information</U>. The consolidated financial statements of the Borrower and the Subsidiaries
furnished to the Administrative Agent and the Lenders pursuant to <U>Sections 5.6</U> and <U>7.1</U> have been prepared in accordance
with GAAP, consistently applied, and present fairly in all material respects the consolidated financial condition of the Persons covered
thereby as at the dates thereof and the results of their operations for the periods then ended, subject, in the case of unaudited financial
statements, to the absence of footnote disclosure and normal and recurring year-end adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.6
</FONT><FONT STYLE="font-size: 10pt"><U>No Material Adverse Effect</U>. Since December&nbsp;31, 2021 to the Closing Date, there has been
no Material Adverse Effect. As of any Delayed Draw Closing Date, no Material Adverse Effect has occurred and is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.7
</FONT><FONT STYLE="font-size: 10pt"><U>Litigation, Labor Matters and Environmental Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as described on <U>Schedule 6.7(a)</U>, there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority
(other than any actions, suits or proceedings commenced under seal that have not been disclosed to the Borrower) pending against, threatened
in writing against, or, to the knowledge of the Borrower, otherwise threatened against or affecting the Borrower or any Subsidiary (i)&nbsp;as
to which there is a reasonable likelihood of an adverse determination and that, if adversely determined, would reasonably be expected,
individually or in the aggregate, to (A)&nbsp;on the Closing Date, result in liabilities in excess of $5,000,000 or (B)&nbsp;on any Delayed
Draw Closing Date, have or result in a Material Adverse Effect that is continuing or (ii)&nbsp;that would reasonably be likely to adversely
affect this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as described on <U>Schedule 6.7(b)</U>, there are no labor controversies pending against, threatened in writing against, or, to the knowledge
of the Borrower, otherwise threatened against or affecting the Borrower or any Subsidiary (i)&nbsp;that would reasonably be expected,
individually or in the aggregate, to (A)&nbsp;on the Closing Date, result in liabilities in excess of $5,000,000 or (B)&nbsp;on any Delayed
Draw Closing Date, have or result in a Material Adverse Effect that is continuing or (ii)&nbsp;that would reasonably be likely to adversely
affect this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Borrower nor any Subsidiary (i)&nbsp;has failed to comply with any Environmental Law or to obtain, maintain or comply with any Permit
under or in connection with any Environmental Law (&ldquo;<U>Environmental Permit</U>&rdquo;), (ii)&nbsp;is or has been subject to any
Environmental Liability, (iii)&nbsp;has received notice of any Environmental Liability, or (iv)&nbsp;knows of any basis for any Environmental
Liability, in each case of <U>clauses (i)</U>&nbsp;through <U>(iv)</U>&nbsp;above, which would reasonably be expected to result in a
Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.8
</FONT><FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>. As of the Closing Date, the Borrower has no Subsidiaries except those Subsidiaries
which are identified in <U>Schedule 6.8</U> (which Schedule also identifies the direct and indirect owners of the Capital Securities
of such Subsidiaries).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.9
</FONT><FONT STYLE="font-size: 10pt"><U>Ownership of Properties</U>. Each of the Borrower and each Subsidiary owns (i)&nbsp;in the case
of owned real property, good and marketable fee title to, and (ii)&nbsp;in the case of owned personal property, good and valid title
to, or, in the case of leased real or personal property, valid and enforceable leasehold interests (as the case may be) in, all of its
properties and assets, tangible and intangible, of any nature whatsoever, that are reasonably necessary in the ordinary conduct of the
business of the Borrower and its Subsidiaries, free and clear in each case of all Liens or claims, except for Liens permitted pursuant
to Section&nbsp;8.3, unless the failure to own any such property, interests or assets would not, taken as a whole, be reasonably expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.10
</FONT><FONT STYLE="font-size: 10pt"><U>Taxes</U>. Each of the Borrower and each Subsidiary has filed all federal and material foreign,
state and local tax returns and reports required by Law to have been filed by it and has paid all material Taxes due and owing, except
any such Taxes which are being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance
with GAAP shall have been set aside on its books.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.11
</FONT><FONT STYLE="font-size: 10pt"><U>Benefit Plans, Etc.</U> Except as set forth on <U>Schedule 6.11</U>, as of the Closing Date,
none of the Borrower or any of the Subsidiaries or any of their respective ERISA Affiliates sponsors, maintains, contributes to, is required
to contribute to, or has any actual or potential liability with respect to, any Benefit Plan. As of the Closing Date, none of the Borrower
or any of the Subsidiaries is a party to any collective bargaining agreement and none of the employees of the Borrower or any of the
Subsidiaries are subject to any collective bargaining agreement with respect to their employment with Borrower or any of its Subsidiaries.
Except as would not, individually or in the aggregate, result in any Material Adverse Effect, (i)&nbsp;each &ldquo;employee benefit plan,&rdquo;
as defined in Section&nbsp;3(3)&nbsp;of ERISA, that provides retirement benefits, is sponsored by the Borrower or any of their ERISA
Affiliates and is intended to be tax qualified under section 401 of the Code is so qualified and no assets of any such plan are invested
in Capital Securities of the Borrower and (ii)&nbsp;each employee benefit plan, program or arrangement that is sponsored, maintained,
contributed to or required to be contributed to by the Borrower or any Subsidiary has complied, both in form and in operation, in all
respects with its terms and applicable Law. No ERISA Event has occurred or is reasonably expected to occur that could reasonably be expected
to result in a Material Adverse Effect. The underlying assets of the Borrower and its Subsidiaries do not constitute Plan Assets and,
to the knowledge of the Borrower and its Subsidiaries the execution, delivery and performance of this Agreement and the other Loan Documents
do not and will not constitute a non-exempt prohibited transaction under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.12
</FONT><FONT STYLE="font-size: 10pt"><U>Accuracy of Information</U>. None of the written information (other than any projections, estimates
and <I>pro forma </I>financial information and any general economic or specific industry information) heretofore or contemporaneously
furnished in writing to the Administrative Agent or any Lender by or on behalf of the Borrower or any Subsidiary in connection with any
Loan Document or any transaction contemplated hereby when furnished and when taken as a whole, contains any untrue statement of a material
fact, or omits to state any material fact necessary to make any such information not misleading in a material respect in light of the
circumstances under which such statements were made. All financial projections and <I>pro forma</I> financial information delivered to
the Administrative Agent and the Lenders by the Borrower (or its agents) have been prepared on the basis of good faith estimates and
assumptions believed by the Borrower to be fair and reasonable in light of current business conditions as of the date thereof; <U>provided</U>,
<U>however</U>, that such projections are subject to uncertainties and contingencies, that no assurances can be given that any particular
projections will be attained and that actual results during the period or periods covered by such financial information may differ significantly
from the projected results set forth therein and that such differences may be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.13
</FONT><FONT STYLE="font-size: 10pt"><U>Regulations U and X</U>. None of the Borrower or any Subsidiary is engaged principally, or as
one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying
or carrying margin stock, and no part of the proceeds of the Loans will be used to buy or carry any margin stock in violation of the
Federal Reserve Board&rsquo;s Regulation&nbsp;U or Regulation X. Terms for which meanings are provided in such Regulation&nbsp;U or Regulation
X, as from time to time in effect, are used in this Section&nbsp;with such meanings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.14
</FONT><FONT STYLE="font-size: 10pt"><U>Solvency</U>. On the Closing Date, the First Delayed Draw Closing Date and the Second Delayed
Draw Closing Date, as applicable, after giving effect to the incurrence of the Initial Loans and the applicable Delayed Draw Loans, respectively,
and the use of proceeds of such Loans, the Borrower and the Subsidiaries taken as a whole, on a consolidated basis, both before and after
giving effect to the Loans, are Solvent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.15
</FONT><FONT STYLE="font-size: 10pt"><U>Intellectual Property</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Schedule
6.15(a)(1)</U>&nbsp;sets forth a complete and accurate list as of the Closing Date or any relevant Delayed Draw Closing Date, as the
case may be, of all (x)&nbsp;Patents, including any Patent applications, (y)&nbsp;registered Trademarks (including domain names) and
any pending registrations or applications for Trademarks, and (z)&nbsp;registered Copyrights and any applications for Copyright registration,
in each case of <U>clauses (x)</U>&nbsp;through <U>(z)</U>, owned by the Borrower or any Subsidiary. <U>Schedule 6.15(a)(2)</U>&nbsp;sets
forth a complete and accurate list as of the Closing Date of all material in-bound license or sublicense agreements with respect to any
Intellectual Property owned by a Third Party that is used in and material to the conduct of the business of the Borrower and the Subsidiaries
as currently conducted (but excluding inbound licenses of over-the-counter or &ldquo;open source&rdquo; software that is commercially
available to the public or licenses to other Intellectual Property licensed or otherwise made available pursuant to a click-wrap, shrink
wrap or similar agreement or on a subscription basis). For each item of Intellectual Property listed on <U>Schedule 6.15(a)(1)</U>, the
Borrower has, where relevant, indicated (A)&nbsp;the countries in which such item is registered, (B)&nbsp;the application numbers, (C)&nbsp;the
registration or patent numbers, and (D)&nbsp;the owner of such item of Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the knowledge of the Borrower, the Owned Intellectual Property and Licensed Intellectual Property together constitute all Intellectual
Property reasonably necessary for the operation of the business of the Borrower and the Subsidiaries as currently conducted and as currently
proposed to be conducted, except in each case, on the relevant Delayed Draw Closing Date, as would not reasonably be expected to have
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Borrower and each Subsidiary owns, or has a valid license or rights in any other form, as applicable, to all rights associated
with the Owned Intellectual Property and the Licensed Intellectual Property (i)&nbsp;on the Closing Date, in all material respects, and
(ii)&nbsp;on the relevant Delayed Draw Closing Date, except as would not reasonably be expected to cause a Material Adverse Effect. The
Owned Intellectual Property and the agreements associated with the Licensed Intellectual Property are free and clear of any and all Liens
other than Liens permitted pursuant to <U>Section&nbsp;8.3</U>. This <U>Section&nbsp;6.15(c)</U>&nbsp;shall not be construed as a representation
that the Borrower or any Subsidiary is Infringing any Intellectual Property of any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Borrower or a Subsidiary, as applicable, is the sole and exclusive owner of all right, title and interest in and to all of its Owned
Intellectual Property and has possession of a proper chain of title from each inventor of any technology claimed in any Patent or Patent
application assigning full unconditional ownership to each of the Borrower or such Subsidiary, as applicable, in each case of the foregoing,
(i)&nbsp;on the Closing Date, in all material respects and (ii)&nbsp;on the relevant Delayed Draw Closing Date, except as would not reasonably
be expected to cause a Material Adverse Effect. All such Owned Intellectual Property is subsisting and has not expired, lapsed or been
forfeited, cancelled or abandoned unless permitted hereunder, except, on the relevant Delayed Draw Closing Date, where such event or
circumstance is not reasonably expected to cause a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Borrower and each Subsidiary, as applicable, has taken commercially reasonable actions to maintain and protect all Owned Intellectual
Property, including by timely paying all registration, maintenance, renewal and annuity fees, as applicable, except where the failure
to take such action would not reasonably be expected to cause a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule 6.15(f)</U>, (i)&nbsp;there is no proceeding challenging the ownership, inventorship validity or enforceability
of any Owned Intellectual Property, (ii)&nbsp;neither the Borrower nor any of the Subsidiaries is involved in any proceeding where it
is challenging the ownership, validity or enforceability of any Intellectual Property of any other Person, and (iii)&nbsp;none of the
Owned Intellectual Property is the subject of any material Other Administrative Proceeding, except in each case, on the relevant Delayed
Draw Closing Date, where such challenge is not reasonably expected to have a Material Adverse Effect, except for prosecution of pending
Intellectual Property applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule 6.15(g)</U>, to the knowledge of the Borrower, (A)&nbsp;all Owned Intellectual Property and the Licensed
Intellectual Property is valid, enforceable and subsisting, and (B)&nbsp;no event has occurred, and nothing has been done or omitted
to have been done, that would affect the validity or enforceability of any Owned Intellectual Property or Licensed Intellectual Property,
except where such event is not reasonably expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
are no claims pending or threatened in writing that have been brought by the Borrower or any of the Subsidiaries against any Person alleging
Infringement of any Owned Intellectual Property or Licensed Intellectual Property, except for, on any Delayed Draw Closing Date, any
claims that would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Borrower, no Third Party is committing
any act of Infringement of any Owned Intellectual Property or Licensed Intellectual Property, except where such Infringement is not reasonably
expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the Closing Date, with respect to each license agreement listed on <U>Schedule 6.15(a)(2)</U>, such license agreement (i)&nbsp;is
in full force and effect and is binding upon and enforceable against the Borrower and the Subsidiaries to the extent party thereto and,
to the knowledge of the Borrower, all other parties thereto in accordance with its terms, (ii)&nbsp;has not been amended or otherwise
modified, except as set forth on <U>Schedule 6.15(a)(2)</U>, and (iii)&nbsp;has not suffered a default or breach thereunder (with respect
to defaults or breaches of parties other than the Borrower and the Subsidiaries, to the knowledge of the Borrower) except, in each of
the foregoing <U>clauses (i)</U>&nbsp;through <U>(iii)</U>, to the extent as would not reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the Closing Date, the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date, as the case may be, except as set
forth on <U>Schedule 6.15(j)(1)</U>&nbsp;and as would not reasonably be expected to have a Material Adverse Effect, neither the Borrower
nor any of the Subsidiaries has received written notice or, to the knowledge of the Borrower, any other communications from any Third
Party: (i)&nbsp;alleging that the conduct of the business of the Borrower or any of the Subsidiaries (including the development, manufacture,
use, sale or other commercialization of any Product) Infringes any Intellectual Property of that or any other Third Party or (ii)&nbsp;challenging
the validity or enforceability of any of Patent owned by the Borrower or any Subsidiary. To the knowledge of the Borrower, except as
set forth on <U>Schedule 6.15(j)(2)</U>, the conduct of its respective business and the business of the Subsidiaries (including the development,
manufacture, use, sale or other commercialization of any Product) does not Infringe any Intellectual Property of any Third Party, except
as would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Borrower and the Subsidiaries have used commercially reasonable efforts and precautions to protect their (i)&nbsp;rights in, and with
respect to, Confidential Business Information, and maintain the confidentiality of, their respective Owned Intellectual Property and
(ii)&nbsp;respective commercially significant unregistered Intellectual Property, in each of the foregoing <U>clauses (i)</U>&nbsp;and
<U>(ii)</U>, (A)&nbsp;on the Closing Date, in all material respects and (B)&nbsp;on the relevant Delayed Draw Closing Date, except as
would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&#8239;All
current and former employees of the Borrower and each Subsidiary, and all other Persons with access to any Confidential Business Information,
are subject to written agreements that include customary confidentiality and restriction on use terms sufficient to maintain the confidential
status and limit the use of such Confidential Business Information, and (ii)&nbsp;no trade secret of the Borrower or any of its Subsidiaries
with respect to any Product has been published or disclosed by the Borrower or any of its Subsidiaries to any Person, except pursuant
to a written agreement requiring such Person to keep such trade secret confidential, in each case of the foregoing <U>clauses (i)</U>&nbsp;and
<U>(ii)</U>, (A)&nbsp;on the Closing Date, in all material respects, and (B)&nbsp;on the relevant Delayed Draw Closing Date, except as
would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
<U>Section&nbsp;6.15</U> sets forth the sole representations and warranties of the Borrower with respect to the Infringement of any Intellectual
Property of any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.16
</FONT><FONT STYLE="font-size: 10pt"><U>Material Agreements</U>. Set forth on <U>Schedule 6.16</U> is a complete and accurate list as
of the Closing Date, of all Material Agreements of the Borrower and the Subsidiaries, including any amendments and modifications thereto.
Except to the extent otherwise terminated as contemplated by the definition thereof, each Material Agreement is in full force and effect
and the legal, valid and binding obligation of (x)&nbsp;the Borrower or the Subsidiary party thereto and, (y)&nbsp;to the knowledge of
the Borrower, the other parties thereto, enforceable against the Borrower and the Subsidiaries party thereto and all other parties thereto
in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization
or similar laws affecting creditors&rsquo; rights generally and by principles of equity), except, in each of the foregoing clauses (x)&nbsp;and
(y), as would not reasonably be expected to have a Material Adverse Effect. (A)&nbsp;Neither the Borrower nor any of the Subsidiaries
is in breach or in default under any Material Agreement, nor has the Borrower or any of the Subsidiaries taken any action that would
permit any other Person party to any Material Agreement to have, and no such Person otherwise has, any defenses, counterclaims or rights
of setoff thereunder and (B)&nbsp;to the knowledge of the Borrower, no such other Person party to such Material Agreement is in breach
or in default thereunder, except, in each of the foregoing clauses (A)&nbsp;and (B), as would not reasonably be expected to have a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.17
</FONT><FONT STYLE="font-size: 10pt"><U>Permits</U>. The Borrower and the Subsidiaries have all Permits, including Key Permits and Environmental
Permits required for the ownership, operation and conduct of their business, including their testing and distribution of the Products,
except as would not reasonably be expected to have a Material Adverse Effect, it being understood and agreed that, as of the Closing
Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs. All such Permits
are validly held and there are no defaults thereunder, except as could not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.18
</FONT><FONT STYLE="font-size: 10pt"><U>Regulatory Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Permits held by the Borrower and the Subsidiaries are (i)&nbsp;legally and beneficially owned exclusively by the Borrower or such Subsidiary,
free and clear of all Liens other than Liens permitted pursuant to <U>Section&nbsp;8.3</U>, and (ii)&nbsp;validly registered and on file
with the applicable Governmental Authority, in compliance with all filing and maintenance requirements (including any fee requirements)
thereof, and are in good standing, valid and enforceable with the applicable Governmental Authority, it being understood and agreed that,
as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs.
All required notices, registrations and listings, supplemental applications or notifications, reports and other required filings with
respect to the Products have been filed with applicable Governmental Authorities, except where the failure to file the same would not,
whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
in each case as would not reasonably be expected to have a Material Adverse Effect, since January&nbsp;1, 2019, (i)&nbsp;the Products,
as well as the business of the Borrower and the Subsidiaries, comply with (A)&nbsp;all applicable Laws, including, without limitation,
applicable requirements of CLIA and the FD&amp;C Act (it being understood and agreed that, as of the Closing Date, the Borrower and its
Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs), and (B)&nbsp;the terms of all Product Authorizations
and other Permits; (ii)&nbsp;all laboratory testing services have been conducted in compliance with CLIA and all federal and state laws
regarding laboratory testing services; (iii)&nbsp;all LDTs have been designed, developed, validated, and performed in compliance with
CLIA, the FD&amp;C Act, and all federal and state laws regarding laboratory testing services; (iv)&nbsp;none of the Borrower and the
Subsidiaries, or, to the knowledge of the Borrower, their respective suppliers, have received any inspection reports, warning letters,
untitled letters or similar documents with respect to any Product and/or with respect to the business of the Borrower and/or the Subsidiaries,
from any Governmental Authority that assert lack of compliance with any applicable Laws (other than inspection reports that do not contain
material findings or that have been remedied); (v)&nbsp;none of the Borrower or any of the Subsidiaries has received any written notice
of, or otherwise have knowledge of, any pending regulatory enforcement action, investigation, or inquiry against the Borrower or any
of the Subsidiaries or, to the knowledge of the Borrower, any of their respective suppliers, with respect to the Products; (vi)&nbsp;to
the knowledge of the Borrower, there have been no Product recalls, safety alerts, withdrawals, clinical holds, marketing suspensions,
removals, seizures, injunctions or the like conducted, undertaken or issued by any Person, whether or not at the request, demand or order
of any Governmental Authority or otherwise, with respect to any Product nor, to the knowledge of the Borrower, has any such action been
requested, demanded, or ordered by any Governmental Authority; (vii)&nbsp;to the knowledge of the Borrower, none of the Borrower or any
of the Subsidiaries has received any written notice of (A)&nbsp;any criminal, injunctive, seizure, detention or civil penalty actions
that have at any time been commenced or threatened in writing by any Governmental Authority with respect to or in connection with any
Products, or (B)&nbsp;any consent decrees (including plea agreements) which relate to any Products; and (viii)&nbsp;to the knowledge
of the Borrower, there is no basis for commencement of any criminal, injunctive, seizure, detention, or civil penalty actions by any
Governmental Authority relating to the Products or for issuance of any consent decrees. To the knowledge of the Borrower, none of the
Borrower or any of the Subsidiaries is employing or utilizing the services of any individual who has been debarred or suspended under
any applicable Law since January&nbsp;1, 2019, other than, with respect to a Delayed Draw Closing Date, any employee or service provider
that has been terminated by the Borrower reasonably promptly following the Borrower or its Subsidiaries becoming aware of such suspension
or debarment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 66; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the Closing Date (and, except as would not reasonably be expected to result in a Material Adverse Effect, as of each Delayed Draw
Closing Date), none of the Borrower or the Subsidiaries has received any written notice from, any Governmental Authority or an institutional
review board or ethics committee alleging any material non-compliance with applicable laws or GCPs or otherwise requiring the termination
or suspension any clinical trial (in-whole or in-part) conducted, or being conducted, by or on behalf of the Borrower and the Subsidiaries
with respect to any Product. Except as would not reasonably be expected to have a Material Adverse Effect, no clinical trial conducted,
or being conducted, by or on behalf of the Borrower, and/or the Subsidiaries with respect to any Product has used, or is using, any clinical
investigator who has been disqualified from conducting clinical investigations by FDA or other Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
in each case as would not reasonably be expected to have a Material Adverse Effect, with respect to the Products, since January&nbsp;1,
2019: (i)&nbsp;all activities (including, without limitation, testing, validating, performing, marketing, sale, recordkeeping) by the
Borrower or any of the Subsidiaries and, to the knowledge of the Borrower, their respective suppliers relating to the Products have been
conducted, and are currently being conducted, in compliance with the applicable requirements of CLIA, the FD&amp;C Act, other applicable
requirements of Governmental Authorities, and (ii)&nbsp;none of the Borrower or any of the Subsidiaries, or, to the knowledge of the
Borrower, any of their respective suppliers, has received written notice or threat of commencement of action by any Governmental Authority
to withdraw its approval of any Product, to enjoin or prevent the performance of any LDT or otherwise prevent Borrower or any of its
Subsidiaries from performing laboratory services, or to otherwise disrupt the business of the Borrower and the Subsidiaries, in each
case, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances
or approvals from the FDA for its LDTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as would not have a Material Adverse Effect, all studies, tests and preclinical and clinical trials relating to the Products conducted
by or on behalf of the Borrower or any of the Subsidiaries have been conducted, and are currently being conducted, in compliance with
all applicable Laws, including, but not limited to, applicable provisions of the CLIA and the FD&amp;C Act, including applicable GCPs
and applicable GLPs, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical
device clearances or approvals from the FDA for its LDTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the Borrower&rsquo;s knowledge, there has been no untrue statement of fact and no fraudulent statement made by the Borrower or any of
the Subsidiaries at the time such statements were made, or to the knowledge of the Borrower, any of their respective agents or representatives
(when acting in such capacity) in any filing with the CMS, the FDA or any other Governmental Authority, and there has been no failure
to disclose any fact required to be disclosed to any Regulatory Agency, in each case, except where the failure to do so would not reasonably
be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule 6.18(i)</U>, as of the Closing Date (and, except as would not reasonably be expected to result in a Material
Adverse Effect, as of each Delayed Draw Closing Date), the Borrower and the Subsidiaries are in material compliance with federal and
state fraud and abuse laws, including the federal Anti-Kickback Statute, the False Claims Act, the Foreign Corrupt Practices Act, and
similar applicable state, federal or foreign laws. Except as set forth on <U>Schedule 6.18(i)</U>, from January&nbsp;1, 2019 to the Closing
Date (and, except as would not reasonably be expected to result in a Material Adverse Effect, from January&nbsp;1, 2019 to each Delayed
Draw Closing Date), none of the Borrower or any of the Subsidiaries has received any written notice from the United States Department
of Justice, any U.S. Attorney, any State Attorney General, or any other similar Governmental Authority alleging any violation of any
such laws in any material respect. The Borrower and its Subsidiaries have established and implemented a compliance program designed to
ensure material compliance with federal and state fraud and abuse laws, including the federal Anti-Kickback Statute, the False Claims
Act, the Foreign Corrupt Practices Act, and similar applicable state, federal or foreign laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
transactions contemplated by the Loan Documents (or contemplated by the conditions to effectiveness of any Loan Document) will not materially
impair the Borrower&rsquo;s or any of the Subsidiaries&rsquo; ownership of or rights under (or the license or other right to use, as
the case may be) any Key Permits relating to the Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Schedule 6.18(l)</U>, since January&nbsp;1, 2019, none of the Borrower or any of the Subsidiaries, nor, to the Borrower&rsquo;s
knowledge, any individual who is an officer, director, manager or employee of the Borrower or any of the Subsidiaries has been convicted
of or, to the Borrower&rsquo;s knowledge, charged with or investigated for any federal or state health program-related offense or any
other offense related to healthcare or been excluded or suspended from participation in any such program, except, as of any Delayed Draw
Closing Date, for any such individuals who have been promptly terminated by the Borrower or its Subsidiaries following such conviction
or charge or as would not reasonably be expected to result in a Material Adverse Effect. Except as set forth on <U>Schedule 6.18(l)</U>,
since January&nbsp;1, 2019, none of the Borrower or any of the Subsidiaries, nor, to the Borrower&rsquo;s knowledge, any individual who
is an officer or director of the Borrower or any of the Subsidiaries has been convicted of any crime that has resulted or would reasonably
be expected to result in a debarment or exclusion under (i)&nbsp;21 U.S.C. Section&nbsp;335a or (ii)&nbsp;any similar applicable Law,
except, as of any Delayed Draw Closing Date, for any such individuals who have been promptly terminated by the Borrower or its Subsidiaries
following such conviction or charge or as would not reasonably be expected to result in a Material Adverse Effect. Except as set forth
on <U>Schedule 6.18(l)</U>, from January&nbsp;1, 2019 through the Closing Date (and, except as would not reasonably be expected to result
in a Material Adverse Effect, from January&nbsp;1, 2019 through each Delayed Draw Closing Date), no debarment proceedings or investigations
in respect of the business of the Borrower or any of the Subsidiaries are pending or, to the Borrower&rsquo;s knowledge, threatened against
the Borrower, any of the Subsidiaries or any individual who is an officer, director, manager or employee of the Borrower or any of the
Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.19
</FONT><FONT STYLE="font-size: 10pt"><U>Transactions with Affiliates</U>. Except as set forth on <U>Schedule 6.19</U>, none of the Borrower
or any Subsidiary has entered into, renewed, extended or been a party to, any transaction (including the purchase, sale, lease, transfer
or exchange of property or assets of any kind or the rendering of services of any kind) with the Permitted Holders, in each case as in
effect on the Closing Date, except for (a)&nbsp;employment arrangements (including employee benefits, compensation, equity awards and
director/officer indemnification agreements) that have been approved by the Borrower&rsquo;s Board of Directors or a committee thereof
and (b)&nbsp;equity investments in the Borrower (including any related stockholders&rsquo; agreements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.20
</FONT><FONT STYLE="font-size: 10pt"><U>Investment Company Act</U>. None of the Borrower or any Subsidiary is required to register as
an &ldquo;investment company&rdquo; as such terms are defined in, or subject to regulation under, the Investment Company Act of 1940,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.21
</FONT><FONT STYLE="font-size: 10pt"><U>OFAC</U>. None of the Borrower, any Subsidiary or, to the knowledge of the Borrower, any Related
Party (a)&nbsp;is currently the subject of any Sanctions, (b)&nbsp;is located, organized or residing in any Designated Jurisdiction,
or (c)&nbsp;is or has been (within the previous five (5)&nbsp;years) engaged in any transaction with any Person who is now or was then
the subject of Sanctions or who is located, organized or residing in any Designated Jurisdiction. No Loan, nor the proceeds from any
Loan, has been or will be used, directly or indirectly, to lend, contribute or provide to, or has been or will be otherwise made available
to fund, any activity or business in any Designated Jurisdiction or to fund any activity or business of any Person located, organized
or residing in any Designated Jurisdiction or who is the subject of any Sanctions, or in any other manner that will result in any violation
by any Person (including the Administrative Agent, any Lender and any of their respective Affiliates) of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.22
</FONT><FONT STYLE="font-size: 10pt"><U>Deposit and Disbursement Accounts</U>. Set forth on <U>Schedule 6.22</U> is a complete and accurate
list as of the Closing Date or any Delayed Draw Closing Date of all banks and other financial institutions at which the Borrower or any
Guarantor maintains deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts, such Schedule
correctly identifies the name, address and telephone number of each bank or financial institution, the name in which each such account
is held, the type of each such account, and the complete account number for each such account, and each such account (other than Excluded
Accounts) is a Controlled Account to the extent required pursuant to Section&nbsp;7.13.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.23
</FONT><FONT STYLE="font-size: 10pt"><U>Data Privacy and Information Security</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Borrower and its Subsidiaries maintain data and privacy security policies, processes, and controls, all of which meet or exceed any requirements
of applicable Law, except as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Borrower, none
of the Borrower&rsquo;s or any Subsidiary&rsquo;s privacy statements or disclosures have been or are misleading or deceptive, and the
contemplated transactions to be consummated hereunder as of the Closing Date or any Delayed Draw Closing Date will not violate any privacy
statements, other consumer facing disclosures or Laws, in each case, except as would not reasonably be expected to have a Material Adverse
Effect. There is not currently pending and there has not been in the past five (5)&nbsp;years any action, proceeding, suit or claim against
the Borrower or its Subsidiaries with respect to privacy or data security, except as would not reasonably be expected to have a Material
Adverse Effect. To the knowledge of the Borrower, except as would not reasonably be expected to have a Material Adverse Effect, neither
the Borrower nor any Subsidiary, nor any Products, have experienced in the past five (5)&nbsp;years any security incident in which an
unauthorized party accessed or acquired Personal Data stored by the Borrower or any Subsidiary, Confidential Business Information stored
by the Borrower or any Subsidiary or IT Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as would not reasonably be expected to have a Material Adverse Effect, the Borrower and its Subsidiaries have used commercially reasonable
efforts to cause all Data Processors that process Personal Data on behalf of the Borrower or any of its Subsidiaries to protect the Personal
Data of the Borrower and its Subsidiaries, including without limitation (i)&nbsp;compliance with applicable Privacy Laws and (ii)&nbsp;implementation
of a commercially reasonable information security program to protect the applicable Personal Data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the Closing Date and any Delayed Draw Closing Date, except as would not reasonably be expected to have a Material Adverse Effect,
the IT Assets are sufficient to conduct the business of the Borrower and the Subsidiaries as currently conducted by the Borrower and
the Subsidiaries. To the knowledge of the Borrower, except as would not reasonably be expected to have a Material Adverse Effect, neither
the IT Assets nor any Products contain any &ldquo;virus,&rdquo; &ldquo;spyware,&rdquo; &ldquo;malware,&rdquo; &ldquo;worm,&rdquo; &ldquo;Trojan
horse&rdquo; (as such terms are commonly understood in the software industry), disabling codes or instructions, or other similar code
or software routines or components (collectively, &ldquo;<U>Malicious Code</U>&rdquo;) that are designed or intended to delete, destroy,
disable, interfere with, perform unauthorized modifications to, or provide unauthorized access to any data, files, software, system,
network, or other device. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower and its Subsidiaries
have established, implemented and tested commercially reasonable backup and disaster recovery policies, procedures and systems sufficient
to reasonably maintain the operation of the business of the Borrower and the Subsidiaries as currently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">The
Borrower, its Subsidiaries and, to the knowledge of the Borrower, any Data Processors have, in all material respects, implemented and
maintained reasonable technical measures consistent with generally accepted industry standards to protect the operation, confidentiality,
integrity, and security, as applicable, of all Confidential Business Information stored by the Borrower and its Subsidiaries, Personal
Data, and IT Assets (including, for clarity, all information and transactions stored or contained therein or transmitted thereby) against
unauthorized access, acquisition, interruption, alternation, modification, or use, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as would not reasonably be expected to have a Material Adverse Effect, the Borrower and its Subsidiaries have taken or caused to be taken
commercially reasonable actions designed to ensure that all IT Assets (i)&nbsp;are free from any defect, bug, Malicious Code or programming,
design or documentation error or corruption or other defect, and (ii)&nbsp;are fully functional and operate and run in a commercially
reasonable manner. Except as would not reasonably be expected to have a Material Adverse Effect, none of the IT Assets have malfunctioned
or failed or have experienced any breakdowns or continued substandard performance in the past 24 months that has caused disruption or
interruption in the Borrower&rsquo;s or any Subsidiary&rsquo;s use thereof or to the business of the Borrower and the Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.24
</FONT><FONT STYLE="font-size: 10pt"><U>HIPAA</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as would not reasonably be expected to have a Material Adverse Effect, in each instance where the Borrower or any Subsidiary acts as
a Covered Entity, such entity is in compliance with HIPAA. The Borrower, and each Subsidiary that acts as a Covered Entity, has implemented
reasonable and adequate policies, procedures and training designed to assure continued compliance and to detect non-compliance, except
where the failure to implement such policies, procedures, and training would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and
each Subsidiary that acts as a Covered Entity, has provided all requisite notices, obtained all required consents, and satisfied all
other requirements (i)&nbsp;for its use and disclosure of Protected Health Information and (ii)&nbsp;as necessary for the conduct of
business as currently conducted and in connection with this Agreement. Except as would not reasonably be expected to have a Material
Adverse Effect, the Borrower, and each Subsidiary that acts as a Covered Entity, has entered into business associate agreements with
Subsidiaries and Data Processors in all situations where required by 45 C.F.R. &sect;&sect; 164.502(e)&nbsp;and 164.504(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
each instance where Borrower or any Subsidiary acts as a Business Associate, such entity has entered into a Business Associate agreement
that is in material compliance with 45&nbsp;C.F.R. &sect;&nbsp;164.504(e)&nbsp;with each such Covered Entity, as required by 45&nbsp;C.F.R.
 &sect;&nbsp;164.502(e)(2), except where failure to have entered into a Business Associate agreement would not have a Material Adverse
Effect. Except as would not reasonably be expected to have a Material Adverse Effect, in those instances where the Borrower or any Subsidiary
acts as a Business Associate on behalf of Covered Entities, each of the Borrower and such Subsidiary is, and has been, in compliance
with all applicable Business Associate agreements and those portions of HIPAA applicable to Business Associates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and each Subsidiary that acts as a Covered Entity
or Business Associate, has implemented a comprehensive written information security program that complies with 45 C.F.R. Part&nbsp;164,
Subpart C. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and each Subsidiary that acts
as a Covered Entity or Business Associate, have addressed and fully remediated all identified threats and deficiencies to the security
of Protected Health Information maintained by such entity consistent with applicable Laws, including HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the Closing Date, except as set forth on <U>Schedule 6.24(d)</U>, to the knowledge of the Borrower, for the past three (3)&nbsp;years,
there has been no material security incident or material breach of any Protected Health Information held by the Borrower or any Subsidiary.
As of the Closing Date, except as set forth on <U>Schedule 6.24(d)</U>, the Borrower has not, nor has any Subsidiary or other third party
acting on Borrower&rsquo;s behalf, notified, or been required to notify, any person of any security incident, including any loss or unauthorized
access, use or disclosure, of Protected Health Information that would constitute a breach for which notification to individuals, the
media, or the U.S. Department of Health and Human Services is required under 45&nbsp;C.F.R. Part&nbsp;164, Subpart&nbsp;D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;6.25
</FONT><FONT STYLE="font-size: 10pt"><U>No Side Arrangements or Other Fees</U>. As of the Closing Date, (i)&nbsp;there are no agreements
or arrangements with any Lender or an Affiliate of a Lender relating to the Loans, Commitments, the Loan Documents or the facilities
contemplated by the Loan Documents that have not been disclosed to each Significant Lender on or prior to the Closing Date or (ii)&nbsp;there
are no fees payable to any Lender or an Affiliate of a Lender in connection with the Loans, Commitments, the Loan Documents or the facilities
contemplated by the Loan Documents other than as expressly set forth in this Agreement, the Fee Letter and Agency Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;VII</FONT><FONT STYLE="font-size: 10pt"><BR>
AFFIRMATIVE COVENANTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The Borrower covenants and agrees with
the Administrative Agent and the Lenders that until the Termination Date has occurred, the Borrower will, and will cause the Subsidiaries
to, perform or cause to be performed the obligations set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.1
</FONT><FONT STYLE="font-size: 10pt"><U>Financial Information, Reports, Notices, Etc.</U>. The Borrower will (or, solely in the case
of <U>clause (l)</U>&nbsp;below, will use commercially reasonable efforts to) furnish the Administrative Agent for further delivery to
the Lenders (or, solely in the case of <U>clause (i)</U>&nbsp;below, furnish the Significant Lenders upon request by any Significant
Lender) copies of the following financial statements, reports, notices and information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prior
to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction, concurrently with the delivery of the financial
information pursuant to <U>Section&nbsp;7.1(b)</U>&nbsp;(solely with respect to the Fiscal Quarter ending June&nbsp;30 and December&nbsp;31
of each Fiscal Year), the Borrower shall (x)&nbsp;identify to the Administrative Agent each Material Agreement then in effect and (y)&nbsp;provide
a copy of the &ldquo;Payer Revenue Per Case&rdquo; file previously provided to the Lenders containing updated information as of the last
day of such applicable Fiscal Quarter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 72; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;as
soon as available and in any event within 60&nbsp;days after the end of each Fiscal Quarter of each Fiscal Year beginning with the fiscal
quarter ended December&nbsp;31, 2022, an unaudited consolidated balance sheet of the Borrower and the Subsidiaries as of the end of such
Fiscal Quarter and related consolidated statements of income, stockholders&rsquo; equity and cash flows of the Borrower and the Subsidiaries
for such Fiscal Quarter and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Quarter,
and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal
Year, and (ii)&nbsp;as soon as available and in any event within 60&nbsp;days after the end of each Fiscal Quarter of each Fiscal Year,
the Revenue Base for such Fiscal Quarter and for the twelve-month period ending with the end of such Fiscal Quarter and including (in
each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year and the corresponding
twelve-month period immediately preceding such twelve-month period, certified as complete and correct by the chief financial or accounting
Authorized Officer of the Borrower (subject to normal year-end audit adjustments and the absence of footnotes);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available and in any event within 120&nbsp;days after the end of each Fiscal Year beginning with the Fiscal Year ended December&nbsp;31,
2022, (i)&nbsp;a copy of the consolidated balance sheet of the Borrower and the Subsidiaries, and the related consolidated statements
of income, stockholders&rsquo; equity and cash flows of the Borrower and the Subsidiaries for such Fiscal Year, setting forth in comparative
form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by independent public accountants
acceptable to the Required Lenders (it being understood that Ernst&nbsp;&amp; Young LLP or any other &ldquo;Big Four&rdquo; accounting
firm are reasonably acceptable to the Required Lenders); and (ii)&nbsp;a report of the Revenue Base for the Fiscal Quarter then ending
and such Fiscal Year and including in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding
Fiscal Year and the immediately preceding Fiscal Year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;concurrently
with the delivery of the financial information pursuant to <U>clauses (b)</U>&nbsp;(solely with respect to the first three Fiscal Quarters
of each Fiscal Year) and <U>(c)</U>, a Compliance Certificate, executed by the chief financial or accounting Authorized Officer of the
Borrower, (i)&nbsp;showing compliance with the financial covenants set forth in <U>Section&nbsp;8.4</U> and stating that no Default has
occurred and is continuing (or, if a Default has occurred, specifying the details of such Default and the action that the Borrower or
any of the Subsidiaries has taken or proposes to take with respect thereto), (ii)&nbsp;stating that no Subsidiary has been formed or
acquired since the delivery of the last Compliance Certificate (or, if such Subsidiary has been formed or acquired since the delivery
of the last Compliance Certificate, a statement that such Subsidiary has complied with <U>Section&nbsp;7.8</U> to the extent required
thereunder) and (iii)&nbsp;stating that no Material Real Property has been acquired by any Loan Party or any of the Subsidiaries since
the delivery of the last Compliance Certificate (or, if any Material Real Property has been acquired since the delivery of the last Compliance
Certificate, a statement that the Loan Parties have complied with <U>Section&nbsp;7.8</U> with respect to any such real property);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 73; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as possible and in any event within five (5)&nbsp;Business Days after the Borrower obtains knowledge of the occurrence of a Default,
a statement of an Authorized Officer of the Borrower setting forth details of such Default and the action which the Borrower or any of
the Subsidiaries has taken or proposes to take with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as possible and in any event within five (5)&nbsp; Business Days after the Borrower obtains knowledge of (i)&nbsp;the occurrence
of any material adverse development with respect to any litigation, action, proceeding or labor controversy described in <U>Schedule
6.7(a)</U>&nbsp;or (ii)&nbsp;the commencement of any litigation, action, proceeding or labor controversy of the type and materiality
described in <U>Section&nbsp;6.7</U>, notice thereof and, to the extent any Lender requests, copies of all documentation reasonably requested
by such Lender relating thereto (excluding any documentation subject to attorney-client privilege);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reasonably
promptly after the commencement thereof, notice of any adverse proceeding commenced by the Borrower or any Loan Party against any non-Affiliated
Person and involving an amount in controversy in excess of $10,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as possible and in any event within three days after the Borrower obtains knowledge of: (i)&nbsp;any claim that the Borrower, any
of the Subsidiaries or one of their ERISA Affiliates has actual or potential liability under a Benefit Plan (including the occurrence
of any ERISA Event) that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;any
effort to unionize the employees of the Borrower or any Subsidiary that, individually or in the aggregate, would reasonably be expected
to result in a Material Adverse Effect, or (iii)&nbsp;material, non-routine correspondence with the Internal Revenue Service regarding
the qualification of a retirement plan under section 401(a)&nbsp;of the Code that would reasonably be expected to result in liabilities
to the Borrower or any of the Subsidiaries in excess of $5,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prior
to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction, promptly upon request by a Significant Lender,
to such Significant Lender and to each other Significant Lender all notices and any materials delivered to the board of directors (or
equivalent) of the Borrower or any committees thereof in connection with a meeting of such board or committee, or with any action to
be taken by written consent, including drafts of any material resolutions or actions proposed to be adopted by written consent; <U>provided
</U>that the Borrower reserves the right to withhold any information if access to such information could adversely affect the attorney-client
privilege between the Borrower and its counsel or result in disclosure of trade secrets or a conflict of interest or to the extent that
the board of directors (or equivalent) of the Borrower in the exercise of its fiduciary obligations and with the advice of counsel determines
that (A)&nbsp;it is in the best interest of the Borrower to do so because any Lender or any of its respective Affiliates has an interest
in the subject matter under discussion or (B)&nbsp;doing so is necessary to discharge the directors&rsquo; fiduciary duties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;promptly
upon receipt thereof, copies of all &ldquo;management letters&rdquo; (or equivalent) submitted to the Borrower or any of the Subsidiaries
by the independent public accountants referred to in <U>clause (c)</U>&nbsp;in connection with each audit made by such accountants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;promptly
upon receipt thereof (or in the case of updates to previously disclosed matters under this <U>clause (k)</U>, promptly upon request by
the Required Lenders), copies of all subpoenas, requests for information and other notices regarding any active or potential investigation
of, or claim or litigation against, the Borrower or any of the Subsidiaries by any Governmental Authority, and the results of any inspections
of any manufacturing facilities of the Borrower or any of the Subsidiaries or, where the results are known by the Borrower, any Third
Party suppliers of the Borrower or any of the Subsidiaries by any Governmental Authority (including any Form&nbsp;FDA 483s), in each
case, to the extent that such investigation, claim or litigation, or the results of any such inspection, could reasonably be expected
to result in liability in excess of $7,500,000 or have or result in a Material Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prior
to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction, promptly, after the Administrative Agent or any
Significant Lender so requests, copies of any Material Agreement and information reasonably requested by the Administrative Agent or
such Significant Lender in connection with the listing of Material Agreements provided by the Borrower pursuant to Section&nbsp;7.1(a)(i);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;following
the consummation of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, after the sending or filing thereof, copies of
all reports, notices, prospectuses and registration statements which the Borrower or any of the Subsidiaries files with the SEC or any
national securities exchange;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but in any event not later than February&nbsp;28 of each calendar year, the Borrower&rsquo;s financial and business
projections and budget for such year, as approved by the Borrower&rsquo;s board of directors (or equivalent); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
other financial and other information as any Lender or the Administrative Agent may from time to time reasonably request (including information
and reports in such detail as such Lender or the Administrative Agent may reasonably request with respect to the terms of and information
provided pursuant to the Compliance Certificate).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 75; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Borrower hereby acknowledges that (a)&nbsp;the Administrative Agent will make available to the Lenders the Borrower Materials (for the
avoidance of doubt, other than any material required to be furnished pursuant to <U>Section&nbsp;7.1(i)</U>&nbsp;hereof) by posting the
Borrower Materials on the Platform and (b)&nbsp;certain of the Lenders may be &ldquo;public-side&rdquo; Lenders (i.e., any Lender that
has selected the &ldquo;Private-Side Information&rdquo; or similar designation on the content declaration screen of the Platform in order
to enable such Lender to make reference to information that is not made available through the &ldquo;Public-Side Information&rdquo; portion
of the Platform and that may contain material non-public information with respect to the Borrower or its securities) (each, a &ldquo;<U>Public
Lender</U>&rdquo;). The Borrower hereby agrees that (w)&nbsp;it will ensure that all Borrower Materials that are to be made available
to Public Lenders shall be clearly and conspicuously marked &ldquo;PUBLIC&rdquo; which, at a minimum, shall mean that the word &ldquo;PUBLIC&rdquo;
shall appear prominently on the first page&nbsp;thereof, (x)&nbsp;by marking Borrower Materials &ldquo;PUBLIC,&rdquo; the Borrower shall
be deemed to have authorized the Administrative Agent and the Lenders to treat the Borrower Materials as either information that would
be made publicly available if the Borrower was a public company or not material information (although it may be sensitive and proprietary)
with respect to the Borrower for purposes of United States Federal and state securities laws; <U>provided</U> that to the extent such
Borrower Materials constitute Confidential Information, the same shall be treated as set forth in <U>Section&nbsp;10.14</U>, (y)&nbsp;all
Borrower Materials marked &ldquo;PUBLIC&rdquo; are permitted to be made available through a portion of the Platform designated &ldquo;Public
Lender&rdquo; and (z)&nbsp;the Administrative Agent shall treat the Borrower Materials that are not marked &ldquo;PUBLIC&rdquo; as being
suitable only for posting on a portion of the Platform designated &ldquo;Private Lender.&rdquo; Notwithstanding the foregoing, subject
to Section&nbsp;10.2, the Borrower shall not be under any obligation to make any Borrower Materials public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">To
the extent applicable, documents required to be delivered pursuant to <U>clauses (b)</U>, <U>(c)</U>&nbsp;and <U>(m)</U>&nbsp;of this
<U>Section&nbsp;7.1 </U>shall be deemed to have been delivered on the date on which such documents are filed for public availability
on the SEC&rsquo;s Electronic Data Gathering and Retrieval System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.2
</FONT><FONT STYLE="font-size: 10pt"><U>Maintenance of Existence; Compliance with Contracts, Laws, Etc.</U>. The Borrower and each Subsidiary
will (a)&nbsp;preserve and maintain its legal existence (except as otherwise permitted by Section&nbsp;8.7) in its jurisdiction of organization
and each other jurisdiction in which they are it is qualified to do business other than any such jurisdiction (other than its jurisdiction
of organization) where the failure to be so qualified or in good standing would not reasonably be expected to have a Material Adverse
Effect; (b)&nbsp;perform in all material respects its obligations under Material Agreements, except where the failure to do so would
not reasonably be expected to have a Material Adverse Effect; (c)&nbsp;comply in all material respects with all applicable Laws, rules,
regulations and orders, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect; and (d)&nbsp;pay
(before the same become delinquent) all material Taxes, imposed upon the Borrower or any of the Subsidiaries or upon their property except
to the extent being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with
GAAP have been set aside on the books of the Borrower or any of the Subsidiaries, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.3
</FONT><FONT STYLE="font-size: 10pt"><U>Maintenance of Properties</U>. Except as would not reasonably be expected to result in a Material
Adverse Effect, the Borrower and the Subsidiaries will maintain, preserve, protect and keep its and their respective properties in good
repair, working order and condition (ordinary wear and tear excepted), and make reasonably necessary repairs, renewals and replacements
so that the business carried on by the Borrower or any of the Subsidiaries may be conducted at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 76; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.4
</FONT><FONT STYLE="font-size: 10pt"><U>Insurance</U>. The Borrower and each of the Subsidiaries will maintain:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;insurance
on its property with financially sound and reputable insurance companies against business interruption, loss and damage in at least the
amounts (and with only those deductibles) customarily maintained, and against such risks as are typically insured against in the same
general area, by Persons of comparable size engaged in the same or similar business as the Borrower and the Subsidiaries; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
worker&rsquo;s compensation, employer&rsquo;s liability insurance or similar insurance as may be required under the laws of any state
or jurisdiction in which it may be engaged in business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Without limiting
the foregoing, the Loan Parties shall deliver to the Administrative Agent endorsements to the property/casualty insurance and liability
insurance policies in form and substance reasonably acceptable to the Administrative Agent and the Required Lenders that: (i)&nbsp;(x)&nbsp;in
the case of property/casualty insurance, name the Administrative Agent as mortgagee (if applicable) and lender loss payee, and (y)&nbsp;in
the case of liability insurance, name the Administrative Agent as additional insured; and (ii)&nbsp;provide that no cancellation or modification
as to the amount or scope of coverage of such property/casualty and liability policies will be made without at least thirty (30) days&rsquo;
prior written notice thereof (or ten (10)&nbsp;days&rsquo; prior written notice thereof in the case of cancellation due to non-payment
of premiums) to the Administrative Agent; <U>provided</U> that the requirement in the foregoing <U>clause (ii)</U>&nbsp;shall not apply
to any policy renewals providing for the same or greater coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.5
</FONT><FONT STYLE="font-size: 10pt"><U>Books and Records</U>. The Borrower and each of the Subsidiaries will keep books and records
in accordance with GAAP which accurately reflect all of its business affairs and transactions and permit the Administrative Agent, any
Lender or any of their respective representatives, at reasonable times and intervals upon reasonable notice to the Borrower, to visit
the Borrower&rsquo;s or any of the Subsidiaries&rsquo; offices during normal business hours, to discuss the Borrower&rsquo;s or any of
the Subsidiaries&rsquo; financial or other matters with its officers and employees, and its independent public accountants (the Borrower
shall be given the opportunity to participate in any discussions with the Borrower&rsquo;s independent public accounts, but the Borrower
hereby authorizes such independent public accountant to discuss the Borrower&rsquo;s and any of the Subsidiaries&rsquo; financial and
other matters with the Administrative Agent, any Lender or their respective representatives whether or not any representative of the
Borrower or any of the Subsidiaries is present) and to examine any of its books and records; provided that excluding any such visits
and inspections during the continuation of any Event of Default, no more than one such visit during any calendar year shall be at the
Borrower&rsquo;s expense. The Borrower shall pay any fees of such independent public accountant incurred in connection with the Administrative
Agent&rsquo;s or any Lender&rsquo;s exercise of its rights pursuant to this Section. Notwithstanding anything to the contrary in this
Section&nbsp;7.5, none of the Borrower or any of the Subsidiaries will be required to disclose, permit the inspection, examination or
making copies or abstracts of, or discussion of, any document, information or other matter that (a)&nbsp;constitutes non-financial trade
secrets or non-financial proprietary information, (b)&nbsp;in respect of which disclosure to the Administrative Agent or any Lender (or
their respective representatives) is prohibited by law or any binding agreement or (c)&nbsp;is subject to attorney-client or similar
privilege or constitutes attorney work product. In any event, the inspections described in this Section&nbsp;7.5 shall be conducted in
a manner that will not unreasonably interfere with the business operations of the Borrower and the Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.6
</FONT><FONT STYLE="font-size: 10pt"><U>Environmental Law Covenant</U>. The Borrower and each of the Subsidiaries will (i)&nbsp;use and
operate all of its and their businesses, facilities and properties in material compliance with all Environmental Laws, and keep and maintain
all Environmental Permits and remain in compliance therewith, except as could not reasonably be expected to have a Material Adverse Effect,
and (ii)&nbsp;promptly notify the Administrative Agent of, and provide the Administrative Agent with copies of all material claims, complaints,
notices or inquiries relating to, any actual or alleged non-compliance with any Environmental Laws or Environmental Permits or any actual
or alleged Environmental Liabilities. The Borrower and each of the Subsidiaries will promptly resolve, remedy and mitigate any such non-compliance
or Environmental Liabilities, except as could not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.7
</FONT><FONT STYLE="font-size: 10pt"><U>Use of Proceeds</U>. The Borrower will use the proceeds of the Loans for general corporate purposes,
to consummate the Existing Debt Refinancing and to pay fees and expenses associated with the Closing Date Transactions and the other
transactions contemplated hereby and thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.8
</FONT><FONT STYLE="font-size: 10pt"><U>Future Guarantors, Security, Etc.</U> The Loan Parties will execute any documents, financing
statements, agreements and instruments, and take all further action that may be required under applicable Law, or that the Administrative
Agent or the Required Lenders may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and
in order to grant, preserve, protect and perfect the validity (subject to Liens permitted by Section&nbsp;8.3 and any exceptions and
limitations expressly permitted by the Loan Documents) of the Liens created or intended to be created by the Loan Documents. The Borrower
will cause (a)&nbsp;(i)&nbsp;any subsequently acquired Subsidiary (other than any Excluded Subsidiary), within twenty (20) Business Days
(or such later date as agreed by the Required Lenders in their reasonable discretion) of its acquisition, and (ii)&nbsp;any subsequently
organized Subsidiary (other than any Excluded Subsidiary), within ten (10)&nbsp;Business Days (or such later date as agreed by the Required
Lenders in their reasonable discretion) of its formation, to execute a supplement (in form and substance reasonably satisfactory to the
Administrative Agent and the Required Lenders) to the Guarantee and each other applicable Loan Document in favor of the Administrative
Agent for the benefit of the Secured Parties, to cause such Subsidiary to become compliant with the terms of the Security Agreement,
and take such other actions as may be required or reasonably requested by the Administrative Agent for the benefit of the Secured Parties
to have a valid Lien with the priority intended to be created on, and security interest in, substantially all of the assets of such Subsidiary
(other than any Excluded Assets), subject to no other Liens (other than Liens permitted by Section&nbsp;8.3) and the limitations set
forth below and (b)&nbsp;except to the extent constituting (or intended to constitute) Excluded Assets, all of the presently existing
or thereafter arising issued and outstanding shares of Capital Securities of any Subsidiary (other than any Excluded Subsidiary) to be
pledged to the Administrative Agent for the benefit of the Secured Parties pursuant to one or more pledge agreements or other documents
reasonably acceptable to the Administrative Agent. The Borrower will promptly notify the Administrative Agent of any subsequently acquired
ownership interest in Material Real Property and will provide the Administrative Agent with a description of such Material Real Property,
the acquisition date thereof and the purchase price therefor. In addition, from time to time, each of the Loan Parties will, at its cost
and expense, reasonably promptly take such actions as shall be necessary to secure the Obligations by pledging or creating, or causing
to be pledged or created, perfected Liens with respect to such assets and properties as the Administrative Agent or the Required Lenders
shall designate (other than any Excluded Assets and fee-owned real property that does not qualify as Material Real Property), it being
agreed that it is the intent of the parties that the Obligations shall be secured by, among other things, substantially all the assets
of the Loan Parties (including Material Real Property and personal property acquired subsequent to the Closing Date but excluding any
Excluded Assets and fee-owned real property that does not qualify as Material Real Property). Such Liens will be created under the Loan
Documents in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders, and the Loan Parties shall
deliver or cause to be delivered to the Administrative Agent all such instruments and documents (including mortgages, legal opinions,
title insurance policies and lien searches) as the Administrative Agent or the Required Lenders shall reasonably request to evidence
compliance with this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 78; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.9
</FONT><FONT STYLE="font-size: 10pt"><U>Obtaining of Permits, Etc.</U> With respect to Products, the Borrower and each of the Subsidiaries
will obtain, maintain and preserve, and take all necessary action to timely renew all Permits and accreditations which are necessary
in the proper conduct of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.10
</FONT><FONT STYLE="font-size: 10pt"><U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.11
</FONT><FONT STYLE="font-size: 10pt"><U>Maintenance of Regulatory Authorizations, Contracts,&nbsp;Intellectual Property, Etc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to the Products, each of the Borrower and each of the Subsidiaries will, in all material respects, (i)&nbsp;maintain in full
force and effect all Regulatory Authorizations, contract rights, or other rights necessary for the operations of its business; (ii)&nbsp;pursue
the prosecution of and pay all costs and expenses relating to, all Owned Intellectual Property and all Material Agreements, except in
the case of each of the foregoing in the event that the Borrower or any of the Subsidiaries determines in its reasonable commercial judgment
not to do so; (iii)&nbsp;notify the Administrative Agent (which shall furnish such notice to the Lenders), promptly after commencing
such legal action, of any legal action that is material to the Borrower and its Subsidiaries brought by the Borrower or any of its Subsidiaries
alleging Infringement by any Person of any Owned Intellectual Property and pursue any such legal action, except in any specific circumstances
where the Borrower reasonably determines it is not commercially reasonable to do so or where providing such notice could reasonably compromise
attorney-client privilege or otherwise adversely affect Borrower or its Subsidiaries ability to effectively enforce any Owned Intellectual
Property or otherwise pursue such legal action; (iv)&nbsp;use commercially reasonable efforts to pursue and maintain in full force and
effect legal protection for, and protect against Infringement with respect to, all Owned Intellectual Property and all Licensed Intellectual
Property for which Borrower or any Subsidiary has the right to enforce, except in the event that the Borrower or any of the Subsidiaries
determines in its reasonable commercial judgment not to do so; (v)&nbsp;notify the Administrative Agent (which shall furnish such notice
to the Lenders), where it is permissible to do so and promptly after learning thereof, of (1)&nbsp;any legal action filed by any Third
Party with a Governmental Authority, or any written notice, allegation, or other communication from any Third Party, alleging that the
conduct of the business of Borrower or any of the Subsidiaries (including the development, manufacture, use, sale or other commercialization
of any Product) Infringes any Intellectual Property of that or any other Third Party in any material respect or challenging the validity
or enforceability of any material Owned Intellectual Property or any material Licensed Intellectual Property, except where (1)&nbsp;it
is not commercially reasonable to provide such notice or (2)&nbsp;where providing such notice could reasonably compromise attorney-client
privilege or otherwise adversely affect Borrower or its Subsidiaries ability to effectively defend against any claims of Infringement,
invalidity, or unenforceability and Borrower will use commercially reasonable efforts to resolve any such claim(s), except where the
Borrower or any of its Subsidiaries determines in its reasonable commercial judgment not to do so; and (vi)&nbsp;maintain an appropriate
information security program with organizational, physical, administrative and technical measures to protect the operation, confidentiality,
integrity, and security, as applicable, of all Confidential Business Information of the Borrower or any Subsidiary, Personal Data stored
by the Borrower or any Subsidiary and material IT Assets against unauthorized access, acquisition, interruption, alteration, modification,
or use, as applicable, in each case of the foregoing <U>clauses (i)</U>, <U>(ii)</U>, <U>(iv)</U>&nbsp;and <U>(vi)</U>, except where
the failure to do so would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 79; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Borrower and its Subsidiaries will furnish to the Administrative Agent (which shall furnish such notice to the Lenders) prompt
written notice of the following, and, with respect to <U>clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;below, copies of any notices from,
or responses to, any Governmental Authority:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
written notice that any Governmental Authority is limiting, suspending or revoking any Regulatory Authorization, changing the market
classification or labeling of or otherwise materially restricting the marketing of the Products of the Borrower or any of its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Borrower or any of its Subsidiaries receiving written notice from CMS, FDA or another Governmental Authority of (A)&nbsp;such Person
becoming subject to any warning letter, untitled letter, notice of violation letter, or similar notification, (B)&nbsp;a material shut-down
or suspension of testing services at any laboratory operated by the Borrower or any of its Subsidiaries; or (C)&nbsp;any Product of the
Borrower or any of its Subsidiaries being seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing or import
alert, or the commencement of any proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, suspension,
import detention or refusal, or seizure of any Product are pending or threatened against the Borrower or any of its Subsidiaries; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;copies
of any written recommendation from any Governmental Authority or other regulatory body that the Borrower or any of its Subsidiaries,
or any obligor (to the extent received by the Borrower) to which the Borrower or any of its Subsidiaries provides services that are material
to the Borrower and its Subsidiaries, taken as a whole, should have any material licensure, clearance(s), provider or supplier number,
or accreditation suspended or revoked, or any material penalties or sanctions imposed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 80; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Borrower and the Subsidiaries will promptly notify the Administrative Agent (which shall furnish such notice to the Lenders) as
soon as possible and in any event within five (5)&nbsp;days of learning of a notification by the FDA, or any comparable foreign Governmental
Authority, that a Product that is an LDT must affirmatively be approved or cleared as a medical device to continue to be marketed, and
is not subject to an exercise of enforcement discretion, it being understood and agreed that, as of the Closing Date, the Borrower and
its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.12
</FONT><FONT STYLE="font-size: 10pt"><U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.13
</FONT><FONT STYLE="font-size: 10pt"><U>Cash Management</U>. The Loan Parties will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;maintain
a current and complete list of all accounts (of the type initially set forth on <U>Schedule 6.22</U>) of the Loan Parties (other than
(A)&nbsp;any accounts exclusively used for payroll, payroll taxes and other employee wage and benefit programs to or for the benefit
of the Borrower&rsquo;s or a Subsidiary&rsquo;s employees, which shall in no event hold in the aggregate more than the amount generally
maintained in such accounts in the ordinary course of business, (B)&nbsp;accounts of the Borrower and the Guarantors constituting trust,
fiduciary and escrow accounts, (C)&nbsp;accounts of the Borrower and the Guarantors that solely secure obligations in respect of letters
of credit, credit cards and other obligations which are permitted by <U>clauses (m)</U>, <U>(n)</U>&nbsp;and <U>(o)</U>&nbsp;of <U>Section&nbsp;8.2</U>,
(D)&nbsp;accounts of the Borrower and the Guarantors located outside the United States, in which, in the case of this <U>clause (D)</U>,
there is not maintained at any point in time funds on deposit, together with funds on deposit in accounts of Excluded Subsidiaries in
compliance with <U>clause (iv)</U>&nbsp;of the definition of &ldquo;Excluded Subsidiary&rdquo;, greater than $5,000,000 in the aggregate
for all such accounts under such clauses, (E)&nbsp;any accounts consisting solely of withheld income taxes and federal, state or local
employment taxes in such amounts as are required in the reasonable judgment of the Loan Party in the ordinary course of business to be
paid to the Internal Revenue Service or state or local government agencies with respect to current or former employees of any of the
Loan Parties, (F)&nbsp;any accounts consisting solely of amounts required to be paid over to an employee benefit plan pursuant to DOL
Reg. Sec. 2510.3-102 on behalf of or for the benefit of employees of one or more Loan Parties and (G)&nbsp;zero balance accounts so long
as the balance in such account is zero at the end of each Business Day (<U>provided</U> that any accounts pursuant to this <U>clause
(G)</U>&nbsp;shall remain zero balance accounts for such purpose during the term of this Agreement and shall be subject to a sweep agreement
reasonably satisfactory to the Administrative Agent and the Required Lenders, and the Borrower shall use commercially reasonable efforts
to require that the depositary bank thereunder provide ten (10)&nbsp;days&rsquo; prior notice to the Administrative Agent and the Lenders
prior to any change to the terms of the daily sweep of such account(s)) (<U>clauses (A)</U>&nbsp;through <U>(G)</U>, collectively, the
 &ldquo;<U>Excluded Accounts</U>&rdquo;)) and promptly deliver any updates to such list to the Administrative Agent; and (ii)&nbsp;in
addition to complying with <U>clause (c)</U>&nbsp;below and subject to <U>Section&nbsp;7.15</U> hereof, as applicable, execute and maintain
a &ldquo;springing&rdquo; account control agreement for each such account (other than Excluded Accounts) in form and substance reasonably
acceptable to the Administrative Agent and the Required Lenders (each such account, a &ldquo;<U>Controlled Account</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;deposit promptly after the date of receipt thereof in accordance with prudent business practices all cash, checks,
drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights
and interests into Controlled Accounts except to the extent permitted to be kept in Excluded Accounts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
order to perfect Administrative Agent&rsquo;s security interest in funds received from Governmental Payors making payments under Medicare,
Medicaid or any other federal or state healthcare program and other account debtors, the Loan Parties will create and maintain an account
into which all deposits from existing accounts which contain funds received from Governmental Payors and other account debtors shall
be swept on a daily basis, which account shall be a Controlled Account; <U>provided</U>, that, for the avoidance of doubt, no breach
of this <U>Section&nbsp;7.13(c)</U>&nbsp;shall be deemed to have occurred and the Loan Parties shall be deemed compliant with this <U>Section&nbsp;7.13(c)</U>&nbsp;if
any such funds shall not be swept on a daily basis in accordance with the foregoing provisions in this <U>Section&nbsp;7.13(c)</U>&nbsp;solely
due to the account bank&rsquo;s failure to perform its obligations under the applicable account documentation and not due to any action
by the Loan Parties or any failure of the Loan Parties to perform their respective obligations hereunder or under any account documentation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;at
any time after the occurrence and during the continuance of an Event of Default, at the request of the Administrative Agent (acting at
the direction of the Required Lenders), promptly cause all payments constituting proceeds of accounts to be directed into lockbox accounts
under agreements in form and substance reasonably satisfactory to the Required Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 82; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.14
</FONT><FONT STYLE="font-size: 10pt"><U>Excluded Subsidiaries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
at any time (x)&nbsp;the aggregate cash or Cash Equivalent Investments attributable to all Excluded Subsidiaries except for Excluded
Subsidiaries excluded pursuant to <U>clause (C)&nbsp;</U>of the definition of &ldquo;Excluded Subsidiary&rdquo; exceeds $5,000,000, the
Borrower shall (i)&nbsp;designate sufficient applicable Subsidiaries as &ldquo;Guarantors&rdquo; to eliminate such excess, and such designated
Subsidiaries shall for all purposes of this Agreement constitute Guarantors and be subject to the provisions of Section&nbsp;7.8, or
(ii)&nbsp;immediately repatriate cash and/or Cash Equivalent Investments in an aggregate amount sufficient to eliminate such excess,
(y)&nbsp;the aggregate portion of the Revenue attributable to (I)&nbsp;an Excluded Subsidiary exceeds 5.0% of the Revenue of the Borrower
and its Subsidiaries or (II)&nbsp;all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to <U>clause (C)</U>&nbsp;of
the definition of &ldquo;Excluded Subsidiary&rdquo; exceeds 10.0% of the Revenue of the Borrower and its Subsidiaries, as applicable,
in each case for any period of four consecutive Fiscal Quarters (determined as of the last day of the most recent Fiscal Quarter for
which financial statements have been delivered pursuant to Section&nbsp;7.1(b)&nbsp;or Section&nbsp;7.1(c)&nbsp;(or, if prior to the
date of the delivery of the first financial statements to be delivered pursuant to Section&nbsp;7.1(b)&nbsp;or Section&nbsp;7.1(c), the
most recent financial statements referred to in Section&nbsp;5.6)), the Borrower shall designate such applicable Excluded Subsidiary
or sufficient applicable Subsidiaries as &ldquo;Guarantors&rdquo; to eliminate such excess, and such designated Subsidiaries shall for
all purposes of this Agreement constitute Guarantors and be subject to the provisions of Section&nbsp;7.8 or (z)&nbsp;the aggregate portion
of total assets attributable to (I)&nbsp;an Excluded Subsidiary exceeds 5.0% of the consolidated total assets of the Borrower and its
Subsidiaries or (II)&nbsp;all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to <U>clause (C)&nbsp;</U>of the
definition of &ldquo;Excluded Subsidiary&rdquo; exceeds 10.0% of the consolidated total assets of the Borrower and its Subsidiaries,
as applicable, in each case for any period of four consecutive Fiscal Quarters (determined as of the last day of the most recent Fiscal
Quarter for which financial statements have been delivered pursuant to Section&nbsp;7.1(b)&nbsp;or Section&nbsp;7.1(c)&nbsp;(or, if prior
to the date of the delivery of the first financial statements to be delivered pursuant to Section&nbsp;7.1(b)&nbsp;or Section&nbsp;7.1(c),
the most recent financial statements referred to in Section&nbsp;5.6)), the Borrower shall designate such applicable Excluded Subsidiary
or sufficient applicable Subsidiaries as &ldquo;Guarantors&rdquo; to eliminate such excess, and such designated Subsidiaries shall for
all purposes of this Agreement constitute Guarantors and be subject to the provisions of Section&nbsp;7.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Should
(x)&nbsp;an Excluded Subsidiary cease to meet the criteria set forth in <U>clauses (i)</U>, <U>(ii)</U>&nbsp;or <U>(iii)</U>&nbsp;of
<U>clause (A)</U>&nbsp;of the definition thereof, (y)&nbsp;an Excluded Subsidiary hold any exclusive right, title or interest in any
material Core Asset or (z)&nbsp;should any not-for-profit Subsidiary (including Caris Molecular Pathology) no longer constitute or be
qualified as a &ldquo;non-for-profit&rdquo; Person in its jurisdiction of organization, in each case, the Borrower shall designate such
Subsidiary as a &ldquo;Guarantor&rdquo;, and such Subsidiary shall for all purposes of this Agreement constitute a Guarantor and be subject
to the provisions of <U>Section&nbsp;7.8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or prior to the date that is 90 days after the Closing Date or such longer period as the Administrative Agent and the Required Lenders
may agree in their sole discretion, the Borrower shall cause Caris Research Institute,&nbsp;Inc. to comply with the requirements of <U>Section&nbsp;7.8
</U>or to be dissolved. From the Closing Date until Caris Research Institute,&nbsp;Inc. either dissolves or complies with the requirements
of <U>Section&nbsp;7.8</U>, it shall be a dormant company with no operations, no assets and no liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 83; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.15
</FONT><FONT STYLE="font-size: 10pt"><U>Post-Closing Deliverables</U>. Notwithstanding anything to the contrary herein or in the other
Loan Documents (it being understood that to the extent that the existence of any of the following post-closing obligations that is not
overdue would otherwise cause any representation, warranty, covenant, default or event of default in this Agreement or any other Loan
Document to be in breach, the Lenders hereby waive such breach for the period from the Closing Date until the first date on which such
condition is required to be fulfilled (giving effect to any extensions thereof) pursuant to this Section&nbsp;7.15), the Borrower shall
deliver or cause to be delivered the following items to the Administrative Agent, or take or cause to be taken the following actions,
in each case, no later than the dates set forth below (or such later date agreed to by Required Lenders in their sole discretion), and
each deliverable shall be in form and substance reasonably satisfactory to the Required Lenders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
thirty (30) days after the Closing Date, all endorsements to insurance policies required to be maintained pursuant to the Loan Documents
in favor of the Administrative Agent required under the Loan Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
shall use commercially reasonable efforts (in consultation with the Significant Lenders and giving consideration to the interests of
the Lenders) to deliver landlord access agreements and bailee letters in form and substance reasonably satisfactory to the Required Lenders
from the landlords at the following locations within ninety (90) days after the Closing Date, or as promptly as reasonably practicable
thereafter:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;750
West John Carpenter Freeway, Suite&nbsp;800,&nbsp;Irving, Texas 75039;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;4415
Cotton Ctr Blvd., Suite&nbsp;100, Phoenix, Arizona;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;4610
S 44th Pl., Bldg 16 (BDO), Phoenix, Arizona;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;4025
E Cotton Ctr Blvd., Suite&nbsp;200, Phoenix, Arizona;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;350
W Washington St., 4th Floor, Tempe, Arizona;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;3600
West Royal Lane,&nbsp;Irving, Texas 75063;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;3680
West Royal Lane, Suite&nbsp;115,&nbsp;Irving, Texas 75063; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;2221
Alliance Boulevard, Suite&nbsp;100, Fort Worth, Texas 76177;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
ninety (90) days after the Closing Date, evidence that all deposit accounts, lockboxes, disbursement accounts, investment accounts or
other similar accounts of the Borrower and each Guarantor are Controlled Accounts (other than Excluded Accounts);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
sixty (60) days after the Closing Date, the Borrower shall have filed for recordation with the Federal Aviation Administration a security
agreement to perfect the Administrative Agent&rsquo;s security interest in the Gulfstream model G280 aircraft (bearing U.S. registration
mark N213GA and manufacturer&rsquo;s serial number 2213) registered to Caris Science,&nbsp;Inc., together with any other filings or registrations
related thereto; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 84; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Loan Parties shall use commercially reasonable efforts (in consultation with the Significant Lenders and giving consideration to the
interests of the Lenders) to deliver UCC &ldquo;fixture filing&rdquo; financing statements suitable in form for naming the applicable
Loan Party as a debtor and the Administrative Agent as the secured party, or other similar instruments or documents to be filed under
the UCC of all jurisdictions as may be necessary or, in the opinion of the Required Lenders, desirable to perfect the security interests
of the Administrative Agent, on behalf of the Secured Parties, in the Collateral located at each location described under clause (i)&nbsp;of
the definition of &ldquo;Fixture Location&rdquo;, in each case within ninety (90) days after the Closing Date, or as promptly as reasonably
practicable thereafter; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
ninety (90) days of the Closing Date, the Borrower shall have delivered (or caused its applicable Subsidiary to deliver) to the Administrative
Agent: (i)&nbsp;a joinder (which may be effectuated pursuant to counterpart signatures) to the intercompany note contemplated by Section&nbsp;8.2(k)(i),
duly executed by each applicable Subsidiary of the Borrower, (ii)&nbsp;to the extent constituting Collateral, the original stock certificate
for Caris Life Sciences (Gibraltar) Limited, together with the related executed stock power, and (iii)&nbsp;a duly executed &ldquo;authenticated
record&rdquo; as contemplated by Section&nbsp;4.1.2(b)&nbsp;of the Security Agreement, in relation to the Capital Securities of Caris
KK (solely to the extent constituting Collateral).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;7.16
</FONT><FONT STYLE="font-size: 10pt"><U>Parent HoldCo Reorganization</U>. Upon the consummation of a Parent HoldCo Reorganization, (i)&nbsp;each
Parent HoldCo shall become a Loan Party under this Agreement and the other Loan Documents and comply with the requirements under Section&nbsp;7.8,
(ii)&nbsp;each reference in this Agreement to &ldquo;the Borrower and its Subsidiaries&rdquo; shall be deemed to be a reference to &ldquo;each
Parent HoldCo, the Borrower and its Subsidiaries&rdquo; and each reference in this Agreement to &ldquo;the Borrower or its Subsidiaries&rdquo;
or to &ldquo;the Borrower or any of its Subsidiaries&rdquo; shall be deemed to be a reference to &ldquo;any of Parent HoldCo, the Borrower
or its Subsidiaries&rdquo;. At all times after the consummation of a Parent HoldCo Reorganization, each Parent HoldCo shall be a passive
holding company with no operations, no assets and no liabilities, other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;acting
as a holding company for, and owning the Capital Securities of the Borrower or any other Parent HoldCo and activities and assets incidental
thereto,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;maintenance
and administration of stock option and stock ownership plans and activities incidental thereto,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
receipt and making of Restricted Payments to the extent permitted by <U>Section&nbsp;8.6</U>,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;concurrently
with the issuance of Capital Securities (other than Disqualified Capital Securities), the redemption, purchase or retirement of any Capital
Securities of such Parent HoldCo using the proceeds of, or conversion or exchange of any Capital Securities of such Parent HoldCo for,
such Capital Securities,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
obtainment of, and the payment of any fees and expenses for, management, consulting, investment banking and advisory services to the
extent otherwise permitted by this Agreement,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
connection with, and following the completion of, a Direct Listing, Qualified IPO or Qualified SPAC Transaction, activities necessary
or reasonably advisable for or incidental to the initial registration and listing of such Parent HoldCo (or any of its parent company&rsquo;s)
common stock and the continued existence of such Parent HoldCo (or any of its parent company) as a public company,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;providing
indemnification to officers and directors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;participation
in tax, accounting and other administrative activities as a member of the consolidated group of companies, if applicable,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[reserved],</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;liabilities
and activities to comply with requirements of applicable Law,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;authorizing,
executing and performing its obligations under this Agreement and each other Loan Document to which it is a party,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;preserving
and keeping in full force and effect its existence, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;activities
incidental to the businesses of activities described in <U>clauses (a)</U>&nbsp;through <U>(k)</U>&nbsp;of this <U>Section&nbsp;7.16</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;VIII</FONT><FONT STYLE="font-size: 10pt"><BR>
NEGATIVE COVENANTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Borrower covenants and agrees with the Administrative Agent and the Lenders that until the Termination Date has occurred, the Borrower
and the Subsidiaries will perform or cause to be performed the obligations set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.1
</FONT><FONT STYLE="font-size: 10pt"><U>Business Activities</U>. None of the Borrower or any of the Subsidiaries will engage in any business
activity except those business activities engaged in on the date of this Agreement and activities reasonably incidental or ancillary
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.2
</FONT><FONT STYLE="font-size: 10pt"><U>Indebtedness</U>. None of the Borrower or any of the Subsidiaries will create, incur, assume
or permit to exist any Indebtedness, other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
in respect of the Obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
incurred in connection with Permitted Acquisitions or other Investment permitted by <U>Section&nbsp;8.5</U> (including existing Indebtedness
of a Person acquired in connection with a Permitted Acquisition or any such permitted Investment, <U>provided</U> such Indebtedness was
not incurred in anticipation of such acquisition); <U>provided</U>, <U>however</U>, that the aggregate amount of all such Indebtedness,
at any one time outstanding, shall not exceed $75,000,000; <U>provided</U>, <U>further</U>, that the obligors in respect of any such
Indebtedness assumed in connection with a Permitted Acquisition or other Investment permitted by <U>Section&nbsp;8.5 </U>shall be solely
the entities acquired in such Permitted Acquisition or such permitted Investment; <U>provided</U>, <U>further</U>, that any such Indebtedness
incurred (rather than assumed) in connection with Permitted Acquisitions or other Investment permitted by <U>Section&nbsp;8.5 </U>shall
be solely Indebtedness of the Loan Parties (including any entities that will become Loan Parties in connection with such Permitted Acquisition
or such permitted Investment) and shall be unsecured and subordinated to the Obligations in a manner satisfactory to Administrative Agent
and the Required Lenders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 86; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
existing as of the Closing Date which is identified in <U>Schedule 8.2(c)</U>&nbsp;and Permitted Refinancings thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
incurred by Borrower or any of its Subsidiaries arising from agreements providing for indemnification or from guaranties or letters of
credit, surety bonds or performance bonds securing the performance of Borrower or any such Subsidiary pursuant to such agreements and
Indebtedness which may be deemed to exist pursuant to any guaranties, performance, surety, statutory, appeal or similar obligations incurred
in the ordinary course of business and Indebtedness constituting guaranties in the ordinary course of business of the obligations of
suppliers, customers, franchisees and licensees of Borrower and its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Purchase
Money Indebtedness, Capitalized Lease Liabilities and Attributable Debt in a principal amount not to exceed $70,000,000 in the aggregate
outstanding at any time and Permitted Refinancings thereof; <U>provided</U> that Attributable Debt under this <U>clause (e)</U>&nbsp;shall
not exceed $10,000,000 in the aggregate outstanding at any time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Permitted
Subordinated Indebtedness and Permitted Refinancings thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
in respect of the 2023 Convertible Loans and Permitted Refinancings thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Hedging
Obligations (including the Permitted Call Spread Swap Agreements); <U>provided</U>, <U>however</U>, that such obligations are (or were)
entered into by a Loan Party or a Subsidiary for the purpose of directly mitigating risks associated with liabilities, commitments, investments,
assets, or property held or reasonably anticipated by such Person and not for purposes of speculation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
of any Guarantor or the Borrower owing to the Borrower or any Guarantor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
Indebtedness of the Borrower and the Subsidiaries in an aggregate amount at any time outstanding not to exceed $25,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
of (i)&nbsp;the Borrower or any Guarantor owing to an Excluded Subsidiary; <U>provided</U> that all of such Indebtedness shall be subordinated
to the Obligations pursuant to an intercompany debt subordination agreement in a form approved by the Administrative Agent and the Required
Lenders in their reasonable discretion, (ii)&nbsp;any Excluded Subsidiaries owing to the Borrower or any Guarantor in an aggregate principal
amount at any time outstanding not to exceed $20,000,000, and (iii)&nbsp;any Excluded Subsidiaries owing to any other Excluded Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 87; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, including to finance insurance premiums,
so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer
the cost of, such insurance for the policy year in which such Indebtedness is incurred and such Indebtedness is outstanding only during
such policy year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
incurred in the ordinary course of business in connection with credit cards (including commercial cards (including so-called &ldquo;purchase
cards&rdquo;, &ldquo;procurement cards&rdquo; or &ldquo;p-cards&rdquo;)), credit card processing services, debit cards, stored value
cards, and cash management or related services, including treasury, depository, return items, overdraft, controlled disbursement, merchant
store value cards, e-payables services, electronic funds transfer, interstate depository network, automatic clearing house transfer (including
the Automated Clearing House processing of electronic funds transfers through the direct Federal Reserve Fedline system) and other customary
cash management arrangements incurred in the ordinary course of business in an aggregate amount not to exceed $10,000,000 at any time
outstanding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
in respect of letters of credit incurred in the ordinary course of business in an aggregate amount not to exceed $10,000,000 issued at
any time and any Permitted Refinancing thereof; <U>provided</U> that any Indebtedness under this clause (n)&nbsp;may be cash collateralized;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
with respect to warehouse receipts, surety and appeal bonds, performance bonds, customs bonds or similar instruments issued to support
performance obligations incurred in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
in respect of netting services, overdraft protections and other like services, in each case incurred in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
Indebtedness of the Subsidiaries in an aggregate amount at any time not to exceed $10,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
unsecured Indebtedness (which, for the avoidance of doubt, may be <I>pari passu</I> with or subordinated to the Obligations in right
of payment) of the Borrower in an aggregate amount at any time outstanding equal to the product of (i)&nbsp;the Revenue Base for the
most recently ended Test Period and (ii)&nbsp;1.50; <U>provided</U> that (A)&nbsp;such Indebtedness does not require or incur cash interest
payments, (B)&nbsp;such Indebtedness shall not be guaranteed by any Subsidiary of the Borrower, (C)&nbsp;such Indebtedness shall not
include covenants and defaults that are, taken as a whole, more restrictive on the Loan Parties than the provisions of this Agreement
(as determined by the Borrower in its good faith judgment), and (D)&nbsp;such Indebtedness shall not (i)&nbsp;mature or be mandatorily
redeemable, pursuant to a sinking fund obligation or otherwise, (ii)&nbsp;be redeemable at the option of the holder thereof, in whole
or in part or (iii)&nbsp;provide for any payments of principal or other cash payments, in each case of the foregoing <U>sub-clauses (i)</U>,
<U>(ii)</U>&nbsp;and <U>(iii)</U>, prior to the date that is 6 months after the Maturity Date (it being understood, for the avoidance
of doubt, that (w)&nbsp;a redemption right of the Borrower in respect of such Indebtedness, (x)&nbsp;conversion rights of holders in
respect of such Indebtedness, (y)&nbsp;acceleration rights of holders of such Indebtedness upon the occurrence of an event of default
specified in the agreement governing such Indebtedness and (z)&nbsp;the obligation to pay customary amounts to holders of such Indebtedness
in connection with an asset disposition, casualty event, &ldquo;change of control&rdquo; or &ldquo;fundamental change&rdquo;, in each
case, shall not be considered in connection with the determination of scheduled maturity date for purposes of this <U>clause (D)</U>);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;unsecured
Indebtedness in respect of any judgment or order for the payment of money rendered against the Borrower or its Subsidiaries, individually
or in the aggregate, in an amount that would not result in an Event of Default under <U>Section&nbsp;9.1(f)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Permitted
Receivables Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Post-IPO
Convertible Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
arising from agreements of the Borrower or any Subsidiary providing for indemnification, adjustment of purchase or acquisition price
or similar obligations (including earn-outs or similar permitted Investments), in each case, incurred or assumed in connection with any
Permitted Acquisition or other Investment permitted by <U>Section&nbsp;8.5</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent constituting Indebtedness, the Series&nbsp;C Preferred Stock, the Series&nbsp;D Preferred Stock and the Warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided
</U></FONT><FONT STYLE="font-size: 10pt">that, no Indebtedness otherwise permitted by <U>clauses (f)</U>, <U>(j)</U>, <U>(q)</U>, <U>(r)</U>,
<U>(u)</U>&nbsp;and <U>(v)</U>&nbsp;shall be assumed, created or otherwise incurred if any Specified Event of Default has occurred and
is then continuing or would result therefrom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.3
</FONT><FONT STYLE="font-size: 10pt"><U>Liens</U>. None of the Borrower or any of the Subsidiaries will create, incur, assume or permit
to exist any Lien upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter
acquired, except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
securing payment of the Obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Lien existing on any property or asset prior to the acquisition thereof by a Loan Party or existing on any property or asset of any Person
that becomes a Subsidiary after the Closing Date prior to the time such Person becomes a Subsidiary, in each case, in connection with
a Permitted Acquisition or other Investment permitted by <U>Section&nbsp;8.5</U>; <U>provided</U> that (1)&nbsp;such Lien is not created
in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be, (2)&nbsp;such Lien
shall not apply to any other property or assets of the Loan Parties (other than the proceeds and products thereof, accessions thereto
and improvements thereon), and (3)&nbsp;such Liens existing pursuant to this clause (b)&nbsp;shall only secure Indebtedness in the aggregate
not to exceed $15,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 89; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
existing as of the Closing Date and disclosed in <U>Schedule 8.3(c)</U>&nbsp;securing Indebtedness described in <U>Section&nbsp;8.2(c)</U>,
and Permitted Refinancings thereof; <U>provided</U> that, no such Lien shall encumber any additional property and the amount of Indebtedness
secured by such Lien is not increased from that existing on the Closing Date or any Permitted Refinancings thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
securing payment of Permitted Subordinated Indebtedness that are (i)&nbsp;subordinate to the Liens securing payment of the Obligations
and all other Indebtedness owing from the Borrower or the Subsidiaries to the Secured Parties and (ii)&nbsp;subject to a written subordination
agreement satisfactory to the Required Lenders in their sole discretion;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
securing Indebtedness of the Borrower or the Subsidiaries permitted pursuant to <U>Section&nbsp;8.2(e)</U>&nbsp;(<U>provided</U> that
(i)&nbsp;such Liens shall be created substantially simultaneously with, or within one-hundred and eighty days of, the acquisition, repair,
replacement, construction or improvement of the assets financed with such Indebtedness and (ii)&nbsp;such Liens do not at any time encumber
any property other than the property so financed);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;carriers&rsquo;,
warehousemen&rsquo;s, mechanics&rsquo;, materialmen&rsquo;s, landlords&rsquo; and like Liens arising in the ordinary course of business
for amounts not overdue for more than 60 days or being diligently contested in good faith by appropriate proceedings and for which adequate
reserves in accordance with GAAP shall have been set aside on its books;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
incurred or deposits made in the ordinary course of business in connection with worker&rsquo;s compensation, unemployment insurance or
other forms of governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other
similar obligations (other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety
and appeal bonds or performance bonds;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;judgment
Liens in existence for less than 45&nbsp;days after the entry thereof or with respect to which execution has been stayed or the payment
of which is covered in full (subject to a customary deductible) by insurance maintained with responsible insurance companies and which
do not otherwise result in an Event of Default under <U>Section&nbsp;9.1(f)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;easements,
rights-of-way, zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material
respect with the value or use of the property to which such Lien is attached;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
for Taxes not at the time delinquent or thereafter payable without penalty or being diligently contested in good faith by appropriate
proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;licenses
and/or sublicenses of Intellectual Property otherwise permitted under this Agreement or the other Loan Documents, and restrictions under
licenses of Intellectual Property entered into in the ordinary course of business pursuant to which the Borrower or any Subsidiary is
a licensee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;banker&rsquo;s
liens, rights of setoff and similar non-consensual Liens in favor of financial institutions incurred in the ordinary course of business
arising in connection with the Borrower&rsquo;s or any Subsidiary&rsquo;s deposit accounts or securities accounts held at such institutions
to secure solely payment of fees and similar costs and expenses; <U>provided</U> such accounts are maintained in compliance with <U>Section&nbsp;7.13(a)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
in favor of customs and revenue authorities arising as a matter of Law to secure payment of customs duties in connection with the importation
of goods in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
granted in the ordinary course of business on the unearned portion of insurance premiums securing the financing of insurance premiums
to the extent the financing is permitted by <U>Section&nbsp;8.2(l)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
on cash and Cash Equivalent Investments (i)&nbsp;securing letters of credit to the extent permitted by <U>Section&nbsp;8.2(n)</U>&nbsp;or
(ii)&nbsp;securing Indebtedness permitted by <U>Section&nbsp;8.2(m)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(x)&nbsp;Liens
on cash and Cash Equivalent Investments securing Hedging Obligations permitted by <U>Section&nbsp;8.2(h)</U>&nbsp;in an aggregate amount
not to exceed $10,000,000 and (y)&nbsp;Liens on cash and Cash Equivalent Investments securing Permitted Call Spread Swap Agreements permitted
by <U>Section&nbsp;8.2(h)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
on accounts receivable and related assets securing Permitted Receivables Indebtedness; <U>provided</U> that the lender under the facility
governing such Permitted Receivables Indebtedness shall have entered into a customary intercreditor agreement with the Administrative
Agent in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
interest or title of a lessor or sublessor under any lease of real estate permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
solely on any cash earnest money deposits made by the Borrower or any of its Subsidiaries in connection with any letter of intent or
purchase agreement with respect to any acquisition or investment permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;purported
Liens evidenced by the filing of precautionary UCC financing statements relating solely to operating leases of personal property entered
into in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;leases
and subleases of assets (excluding Intellectual Property) granted to third parties in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
in the nature of the right of setoff in favor of counterparties to contractual agreements with the Borrower or its Subsidiaries in the
ordinary course of business; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
Liens that secure obligations permitted under this Agreement not exceeding $20,000,000 in the aggregate at any one time outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Each
Secured Party agrees to execute and deliver such collateral subordination agreements and related documents as reasonably requested of
it to confirm the priority of the Liens permitted pursuant to <U>Section&nbsp;8.3(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.4
</FONT><FONT STYLE="font-size: 10pt"><U>Financial Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Minimum
Liquidity</U>. The Liquidity of the Borrower shall not at any time be less than $20,000,000; <U>provided</U> that if the Borrower redeems
or repurchases for cash all or any portion of the Series&nbsp;C Preferred Stock or the Series&nbsp;D Preferred Stock (except for any
redemption or repurchase made using the proceeds of an issuance of Capital Securities, so long as such proceeds are escrowed solely for
the purpose of effectuating such repurchase or redemption of Series&nbsp;C Preferred Stock or Series&nbsp;D Preferred Stock or such issuance
is consummated substantially concurrently with such repurchase or redemption), from and after the date of such repurchase or redemption,
the Liquidity of the Borrower shall not at any time be less than the outstanding principal amount of the Loans at such time (as such
amount may be decreased from time to time); <U>provided</U>, <U>further</U>, that if all of the outstanding Series&nbsp;C Preferred Stock
and Series&nbsp;D Preferred Stock are converted into common stock of the Borrower following the occurrence of a Qualified Direct Listing
Event or consummation of a Qualified IPO or a Qualified SPAC Transaction, the Liquidity of the Borrower shall not at any time be less
than $20,000,000. The Borrower shall maintain an aggregate amount equal to the then applicable amount required under this <U>Section&nbsp;8.4(a)</U>,
along with its other cash and Cash Equivalent Investments, in a Controlled Account as required pursuant to <U>Section&nbsp;7.13(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 92; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Minimum
Revenue Base</U>. Subject to <U>Section&nbsp;9.4</U>, the Revenue Base for the last day of a Test Period shall not be less than (i)&nbsp;prior
to the First Delayed Draw Closing Date, the amount set forth in the second column below for the Test Period ending on such applicable
date and (ii)&nbsp;on and after the occurrence of the First Delayed Draw Closing Date, the amount set forth in the third column below
for the Test Period ending on such applicable date (each such amount for each applicable period, the &ldquo;<U>Required Revenue</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 97.5%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; width: 20%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Test
    Period Ending</B></FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; width: 38%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prior
                                            to the First Delayed Draw<BR>
                                            Closing Date &ndash;<BR>
                                            Minimum Revenue Base</B></FONT></P></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; width: 42%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>If
                                            the First Delayed Draw Closing Date has<BR>
                                            occurred&ndash;<BR>
                                            Minimum Revenue Base</B></FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,
    2022</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$270,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31,
    2023</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$202,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$272,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30,
    2023</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$205,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$275,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,
    2023</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$207,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$275,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,
    2023</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$210,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$275,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31,
    2024</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$212,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$275,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30,
    2024</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$215,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$280,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,
    2024</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$217,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$285,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,
    2024</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$220,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$290,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31,
    2025</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$222,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$295,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30,
    2025</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$225,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$300,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,
    2025</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$227,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$305,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,
    2025</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$230,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$312,500,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31,
    2026</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$232,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$320,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30,
    2026</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$235,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$327,500,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,
    2026</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$237,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$335,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,
    2026</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$240,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$342,500,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31,
    2027</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$242,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$350,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30,
    2027</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$245,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$357,500,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30,
    2027</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$247,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$365,000,000
    </FONT></TD></TR>
  <TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31,
    2027</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000,000
    </FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 1.5pt 5.4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$372,500,000
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.5
</FONT><FONT STYLE="font-size: 10pt"><U>Investments</U>. None of the Borrower or any of the Subsidiaries will purchase, make, incur,
assume or permit to exist any Investment in any other Person, except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;Investments
among the Loan Parties existing on the Closing Date and among the non-Loan Parties existing on the Closing Date, (ii)&nbsp;Investments
between a Loan Party and a Subsidiary of the Borrower that is not a Loan Party existing as of November&nbsp;30, 2022 and, other than
Investments consisting of a Loan Party&rsquo;s equity interests in a Wholly Owned Subsidiary, identified in <U>Schedule 8.5(a)</U>, and
(iii)&nbsp;other Investments existing on the Closing Date and identified in <U>Schedule 8.5(a)</U>, and any modification, replacement,
renewal or extension of the Investments identified in the foregoing <U>clause (i)</U>&nbsp;through <U>(iii)</U>&nbsp;otherwise permitted
by the terms of this Agreement; <U>provided</U> that, the amount of the original Investment is not increased except pursuant to a contractual
requirement to increase the amount of such Investment as in effect on the Closing Date, which requirement exists on the Closing Date
and is described on <U>Schedule 8.5(a)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cash
Equivalent Investments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and
suppliers, in each case in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of any deferred portion of the sales price received by the Borrower or any of the Subsidiaries in connection with any Disposition
permitted under <U>Section&nbsp;8.8</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
constituting (i)&nbsp;accounts receivable arising, (ii)&nbsp;trade debt granted, or (iii)&nbsp;deposits made, in each case of <U>clauses
(i)</U>&nbsp;through <U>(iii)</U>&nbsp;in connection with the purchase price of goods or services, in each case in the ordinary course
of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Permitted Acquisitions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
by (i)&nbsp;the Borrower or any Guarantor in the Borrower or any Guarantor, (ii)&nbsp;any Excluded Subsidiary in the Borrower or any
Guarantor and (iii)&nbsp;any Excluded Subsidiary in any other Excluded Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
by the Borrower or any Guarantor in any Excluded Subsidiary in an aggregate amount at any time outstanding not to exceed $20,000,000
and subject to the limitations set forth in <U>Section&nbsp;7.13(a)(i)(D)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;Investments in an amount not to exceed cash proceeds contributed as equity to the capital of the Borrower
from a Person that is not a Subsidiary of the Borrower, in each case contributed on or during the 6 months preceding the date on which
such Investment is made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of travel advances and employee relocation loans and other similar employee loans and advances in the ordinary course of business
not to exceed $1,000,000 at any time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;the granting of Liens permitted by <U>Section&nbsp;8.3</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent constituting Investments,&nbsp;Indebtedness permitted pursuant to <U>Section&nbsp;8.2(i)</U>&nbsp;or <U>Section&nbsp;8.2(k)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;transfers
of rights with respect to one or more targets identified in the Caris Discovery line of business to joint ventures with third parties
or to other entities where the Borrower or its applicable Subsidiary retains the right to acquire such joint ventures or other entities
or otherwise repurchase such targets at nominal consideration upon the termination of such joint venture or other entity; <U>provided
</U>that no transfer of exclusive rights with respect to any Core Asset for the Caris Molecular Intelligence line of business is permitted;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in joint ventures and acquisitions of Capital Securities that would constitute Permitted Acquisitions but for the fact that such joint
ventures and the Persons in which such Capital Securities are acquired do not become Wholly Owned Subsidiaries of a Loan Party; <U>provided
</U>that (i)&nbsp;the aggregate amount of such Investments shall not exceed $5,000,000 at any time outstanding and (ii)&nbsp;no Investment
in any joint venture pursuant to this <U>clause (o)</U>&nbsp;may be comprised of any transfer of exclusive rights with respect to any
Core Asset for the Caris Molecular Intelligence line of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
made to redeem or purchase the unvested portion of an award from a given service provider (or his/her successors, heirs, descendants
and/or estates);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;Permitted
Call Spread Swap Agreements and (ii)&nbsp;Hedging Obligations permitted by <U>Section&nbsp;8.2</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prepayments
and deposits to suppliers in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;guarantees
permitted by Section&nbsp;8.2 and (ii)&nbsp;guarantees by Borrower or any Subsidiary of operating leases or of other obligations that
do not constitute Indebtedness entered into in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
received as non-cash consideration in a Disposition permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
of any Person (or any Subsidiary of such Person) in existence at the time such Person (or any Subsidiary of such Person) becomes a Subsidiary
of Borrower; <U>provided</U> that, such Investments were not made in connection with or anticipation of such Person becoming a Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;loans
and advances to service providers, including officers, directors and employees, of the Borrower and its Subsidiaries solely to fund such
Person&rsquo;s purchase of Capital Securities of the Borrower in connection with the exercise or settlement by such Person of options
or other equity awards issued pursuant to the 2020 Incentive Plan, so long as no cash is advanced by the Borrower or its Subsidiaries
in connection with such loan or advance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
Investments, other than Investments by the Borrower or any Guarantor in any Excluded Subsidiary, in an aggregate amount not to exceed
$25,000,000 over the term of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.6
</FONT><FONT STYLE="font-size: 10pt"><U>Restricted Payments, Etc.</U> None of the Borrower or any of the Subsidiaries will declare or
make a Restricted Payment, make any deposit for any Restricted Payment, or make a payment or prepayment of principal of, premium, if
any, interest, fees, redemption, exchange, purchase, retirement, defeasance, sinking fund or similar payment with respect to any Permitted
Subordinated Indebtedness, Post-IPO Convertible Indebtedness,&nbsp;Indebtedness permitted pursuant to Sections 8.2(r)&nbsp;(with respect
to cash interest) or Indebtedness in respect of the 2023 Convertible Loans, except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Restricted
Payments made by the Borrower or any Subsidiaries to any Loan Party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;payments
on Permitted Subordinated Indebtedness expressly permitted to be paid under the subordination agreement relating to such Permitted Subordinated
Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
2023 Convertible Loan Repayment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;payments
of interest on any applicable Indebtedness as required by and in accordance with the definitive documentation governing such applicable
Indebtedness, (ii)&nbsp;required payments of principal, and any accrued interest, premium and fees thereon, at the scheduled maturity
date of such applicable Indebtedness and (iii)&nbsp;the issuance of Capital Securities in connection with or as part of the conversion,
redemption, retirement, payment, repurchase, exchange or cancellation of any such applicable Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;redemption,
repurchases, retirement or other acquisition or retirement for value of Capital Securities of the Borrower held by any future, present
or former service provider, including consultants, employees, directors or officers (or any Affiliates, spouses, former spouses, other
immediate family members, successors, executors, administrators, heirs, distributees, descendants or estates of any of the foregoing)
so long as any Specified Event of Default does not exist at the time of such redemption, repurchase, retirement or other acquisition
or retirement or value and would not exist after giving effect thereto; <U>provided</U>, that the amount of such redemption, repurchases,
retirement or other acquisition or retirement for value (not including the amount of Capital Securities withheld from equity awards to
satisfy tax withholding obligations) does not exceed $15,000,000 in the aggregate in any Fiscal Year (or, after the occurrence of a Qualified
Direct Listing Event or the consummation of a Qualified IPO or a Qualified SPAC Transaction, $30,000,000 in the aggregate in any Fiscal
Year) (<U>provided</U>, that any unused portion for any Fiscal Year may be carried forward to the immediately succeeding Fiscal Year);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;redemption
or repurchase on a cashless basis (by netting amounts owed under promissory notes owed to the Borrower) of the unvested portion of any
award from any former service provider, including consultants, employees, directors or officers (or any Affiliates, spouses, former spouses,
other immediate family members, successors, executors, administrators, heirs, distributees, descendants or estates of the foregoing);
<U>provided</U>, that the amount of any such redemptions or repurchases shall not exceed the lesser of (x)&nbsp;the amount previously
paid by such Person to the Borrower to purchase such award and (y)&nbsp;the fair market value of such award at the time such award becomes
eligible for redemption or repurchase by the Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payments
and distributions to fund the redemption or repurchase of the Series&nbsp;C Preferred Stock and/or Series&nbsp;D Preferred Stock, subject
to the Borrower&rsquo;s compliance with the terms and conditions set forth in <U>Sections 3.2</U> and <U>8.4(a)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Restricted
Payments payable solely in the Capital Securities (other than Disqualified Capital Securities) of such Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;cashless
repurchases of Capital Securities of the Borrower deemed to occur upon exercise of stock options or warrants if such Capital Securities
represent a portion of the exercise price of such options or warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;cash
payments in lieu of the issuance of fractional shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
payment of customary fees and reasonable out of pocket expenses to directors of the Borrower and its Subsidiaries not to exceed $3,000,000
in the aggregate per calendar year and indemnities provided on behalf of directors and officers of the Borrower and its Subsidiaries,
in each case, in the ordinary course of business to the extent attributable to the operation of the Borrower and its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
purchase, redemption, repurchase or defeasance of the 2023 Convertible Loans or any Permitted Subordinated Indebtedness (to the extent
permitted by the applicable subordination agreement) made by exchange for, or out of the proceeds of,&nbsp;Indebtedness incurred in compliance
with <U>Section&nbsp;8.2</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
repurchase of Capital Securities of the Borrower (or the payment of a dividend to a direct or indirect parent of the Borrower to fund
such repurchase) upon vesting of restricted stock, restricted stock units, performance shares units or similar equity incentives to satisfy
tax withholding or similar tax obligations with respect thereto; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
Restricted Payments in an amount not to exceed $5,000,000 over the term of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For the avoidance
of doubt, nothing contained in this <U>Section&nbsp;8.6</U> shall prohibit or otherwise limit (A)&nbsp;any payment or prepayment that
is (i)&nbsp;expressly permitted to be paid under the applicable subordination agreement related to any Indebtedness permitted under <U>Section&nbsp;8.2
</U>or (ii)&nbsp;scheduled interest payments and required payments of principal, and any accrued interest, premium and fees thereon,
at the scheduled maturity date of such Indebtedness or (B)&nbsp;the entry into, exercise of its rights under, and performance by the
Borrower or any applicable Subsidiary of its respective payment and other obligations under the Permitted Call Spread Swap Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N</FONT><FONT STYLE="font-size: 10pt">otwithstanding
the foregoing, the Borrower may repurchase, exchange or induce the conversion of Post-IPO Convertible Indebtedness or other convertible
Indebtedness permitted by this Agreement by delivery of shares of the Borrower&rsquo;s common stock and/or a different series of Post-IPO
Convertible Indebtedness or such other permitted convertible Indebtedness (which series matures after, and does not require any scheduled
amortization or other scheduled payments of principal prior to, the analogous date under the indenture or other definitive agreement
governing the Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness, as the case may be, that is so repurchased,
exchanged or converted) (any such series of Post-IPO Convertible Indebtedness, so long as it complies with the conditions of such definition,
 &ldquo;<U>Refinancing Convertible Debt</U>&rdquo;) and/or by payment of cash (x)&nbsp;in lieu of any fractional shares, (y)&nbsp;in respect
of accrued and unpaid interest of such Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness and (z)&nbsp;additional
cash in an amount that does not exceed the proceeds received by the Borrower from the substantially concurrent issuance of shares of
the Borrower&rsquo;s common stock and/or a Refinancing Convertible Debt plus the net cash proceeds, if any, received by the Borrower
pursuant to the related exercise or early unwinding or termination of the related Permitted Call Spread Swap Agreements pursuant to the
immediately following proviso; <U>provided</U> that, substantially concurrently with, or a commercially reasonable period of time before
or after, the related settlement date for the Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness, as
the case may be, that is so repurchased, exchanged or converted, the Borrower shall (and, for the avoidance of doubt, shall be permitted
under this <U>Section&nbsp;8.6</U> to) exercise or unwind or terminate early (whether in cash, shares or any combination thereof) the
portion of the Permitted Call Spread Swap Agreements, if any, corresponding to such Post-IPO Convertible Indebtedness or other permitted
convertible Indebtedness that is so repurchased, exchanged or converted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.7
</FONT><FONT STYLE="font-size: 10pt"><U>Consolidation, Merger; Permitted Acquisitions, Etc.</U> None of the Borrower or any of the Subsidiaries
will (a)&nbsp;liquidate or dissolve, consolidate with, or merge into or with, any other Person, or (b)&nbsp;purchase or otherwise acquire
all or substantially all of the assets of any Person (or any division, business unit, product or line of business thereof, including
any geographic subset thereof), other than, in the case of clause (b), to consummate a Permitted Acquisition or other Investment permitted
by Section&nbsp;8.5, except that, in the case of clauses (a)&nbsp;and (b), so long as no Event of Default has occurred and is continuing
(or would occur), any Subsidiary may liquidate or dissolve voluntarily into, and may merge with and into, the Borrower or any Subsidiary;
provided that, in connection with any Permitted Acquisition or other Investment permitted by Section&nbsp;8.5, the Borrower or any Subsidiary
may merge into or consolidate with any other Person or permit any other Person to merge into or consolidate with it, so long as (i)&nbsp;the
Person surviving such merger with any Subsidiary shall be a direct or indirect Wholly Owned Subsidiary of the Borrower and a Guarantor
(unless it is otherwise an Excluded Subsidiary) and (ii)&nbsp;in the case of any such merger to which the Borrower is a party, the Borrower
is the surviving Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.8
</FONT><FONT STYLE="font-size: 10pt"><U>Permitted Dispositions</U>. None of the Borrower or any of the Subsidiaries will Dispose of any
of its assets (including accounts receivable and Capital Securities of the Borrower or the Subsidiaries) to any Person in one transaction
or series of transactions unless such Disposition (i)&nbsp;is of inventory or obsolete, damaged, worn out or surplus property Disposed
of in the ordinary course of its business; (ii)&nbsp;is permitted by Section&nbsp;8.5, Section&nbsp;8.6 or Section&nbsp;8.7; (iii)&nbsp;constitutes
the lapse, abandonment, cancellation, non-renewal or discontinuance of use of non-material Owned Intellectual Property of the Borrower
or any Subsidiary, or non-exclusive licenses of Licensed Intellectual Property thereof that the Borrower reasonably determines in good
faith is no longer necessary or desirable in the conduct of the Borrower&rsquo;s or any Subsidiary&rsquo;s business, or the lapse, abandonment,
cancellation, non-renewal or other discontinuance of any of any Owned Intellectual Property that the Borrower or any Subsidiary reasonably
believes will not be allowed to issue or register by any Governmental Authority that needs to be issued or registered to be of value
to the Borrower and its Subsidiaries; (iv)&nbsp;(A)&nbsp;is a Disposition by a Loan Party to another Loan Party, (B)&nbsp;is a Disposition
by any Loan Party to an Excluded Subsidiary in an amount not to exceed $20,000,000 in the aggregate for all such Dispositions, or (C)&nbsp;is
a Disposition by any Excluded Subsidiary to another Excluded Subsidiary; (v)&nbsp;constitutes the sale, forgiveness or discounting, on
a non-recourse basis and in the ordinary course of business, of past due accounts in connection with the collection or compromise thereof
or the settlement of delinquent accounts or in connection with the bankruptcy or reorganization of suppliers or customers in accordance
with the applicable terms of this Agreement; (vi)&nbsp;to the extent constituting Dispositions, constitutes the granting of Liens permitted
by Section&nbsp;8.3 and any mergers, consolidations, dispositions, dissolutions and liquidations permitted pursuant to Section&nbsp;8.7;
(vii)&nbsp;constitutes Dispositions in which (I)&nbsp;the assets subject to such Disposition are sold for fair value, as determined by
the Borrower in good faith, (II)&nbsp;at least 75% of the consideration therefor is cash or Cash Equivalent Investments, (III)&nbsp;no
Specified Event of Default has occurred and is continuing or would result from the making of such Disposition and (IV)&nbsp;the amount
of assets Disposed of pursuant to this clause (vii)&nbsp;does not exceed $20,000,000 in the aggregate in any Fiscal Year (provided, that
any unused portion pursuant to this clause (vii)&nbsp;for any Fiscal Year may be carried forward to the immediately succeeding Fiscal
Year); (viii)&nbsp;constitutes the cancellation, termination or surrender by any Loan Party or any Subsidiary of any Loan Party of any
lease in the ordinary course of business; (ix)&nbsp;constitutes the unwinding of any Hedging Obligation in accordance with its terms;
(x)&nbsp;constitutes (i)&nbsp;a lease or sublease of property (other than of Intellectual Property) to other Persons or (ii)&nbsp;a non-exclusive
license or non-exclusive sublicense to suppliers, customers and distributors in connection with the commercialization of Products, in
each case of this clause (x), in the ordinary course of business not materially interfering with the business of Borrower and its Subsidiaries
taken as a whole; (xi)&nbsp;subject to compliance with Section&nbsp;3.2(b), constitutes a Disposition of property as a result of a casualty
event involving such property or any disposition of real property to a Governmental Authority as a result of a condemnation of such real
property; (xii)&nbsp;constitutes a Disposition of Investments in joint ventures, to the extent required by, or made pursuant to buy/sell
arrangements between the joint venture parties set forth in joint venture arrangements and similar binding arrangements; provided that,
the consideration received shall be in an amount at least equal to the fair market value thereof (as determined by the Borrower in good
faith); (xiii)&nbsp;constitutes a Disposition the proceeds of which do not exceed $1,000,000 in the aggregate in any Fiscal Year; (xiv)&nbsp;constitutes
the issuance of Capital Securities by a Subsidiary that represents all or a portion of the consideration paid by Borrower or a Subsidiary
in connection with any Investment permitted by this Agreement, including in connection with the formation of a joint venture with a Person
other than a Subsidiary; (xv)&nbsp;constitutes (A)&nbsp;a Disposition of Capital Securities (I)&nbsp;deemed to occur upon the exercise
of stock options, warrants or other equity derivatives or settlement of convertible securities if such Capital Securities represents
(1)&nbsp;a portion of the exercise price thereof or (2)&nbsp;withholding incurred in connection with such exercise, or (II)&nbsp;upon
the exercise of any warrant; or (B)&nbsp;a Disposition deemed to occur upon cancellation or forgiveness of loans and advances constituting
Investments permitted by this Agreement; (xvi)&nbsp;in connection with the enforcement and/or settlement of litigation, the non-exclusive
licensing of patents owned by Borrower and its Subsidiaries which do not impair Borrower&rsquo;s ability to carry out its business and
do not impact the projected revenues of the Borrower and its Subsidiaries, in any material respect; and (xvii)&nbsp;constitutes a non-exclusive
license or other grant of rights to use Intellectual Property in the ordinary course of business (or, (x)&nbsp;with respect to targets
identified in the Caris Discovery line of business, any exclusive or non-exclusive license or other grant of rights to use such Intellectual
Property (but not, for the avoidance of doubt, any Core Assets) and (y)&nbsp;with respect to prescribed data sets in the Caris Strategic
Data line of business, any exclusive or non-exclusive license or other grant of rights to use such Intellectual Property (but not, for
the avoidance of doubt, any Core Asset for the Caris Molecular Intelligence line of business)), in each case granted by the Borrower
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.9
</FONT><FONT STYLE="font-size: 10pt"><U>Modification of Certain Agreements</U>. None of the Borrower or any of the Subsidiaries will
consent to any amendment, supplement, waiver or other modification of, or enter into any forbearance from exercising any rights with
respect to, the terms or provisions contained in (a)&nbsp;any Organic Documents of the Borrower or any of the Subsidiaries, if the result
would have an adverse effect in any material respect on the Administrative Agent or the Lenders or their rights or remedies under this
Agreement or any Loan Document, (b)&nbsp;any agreement governing any Permitted Subordinated Indebtedness, if the result would shorten
the maturity date thereof or advance the date on which any cash payment is required to be made thereon or would otherwise change any
terms thereof in a manner adverse in any material respect to the Administrative Agent or the Lenders, (c)&nbsp;the 2023 Convertible Loan
Documents, if the result could reasonably be expected to have an adverse effect in any material respect on the Administrative Agent or
the Lenders, (d)&nbsp;the definitive documentation governing the Post-IPO Convertible Indebtedness, if the result could reasonably be
expected to have an adverse effect in any material respect on the Administrative Agent or the Lenders, or (e)&nbsp;the definitive documentation
governing any Permitted Receivables Indebtedness, if the result could reasonably be expected to have an adverse effect in any material
respect on the Administrative Agent or the Lenders; provided, that in each of the foregoing clauses (b), (c), (d)&nbsp;and (e), nothing
contained in this Section&nbsp;8.9 shall prohibit or otherwise limit the Borrower or any of its Subsidiary from consummating a Permitted
Refinancing with respect to the applicable Indebtedness or replacing such Indebtedness with other Permitted Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.10
</FONT><FONT STYLE="font-size: 10pt"><U>Transactions with Affiliates</U>. None of the Borrower nor any of the Subsidiaries will enter
into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property
or the rendering of services) involving aggregate payments (x)&nbsp;per transaction or series of related transactions in excess of $2,500,000
per Fiscal Year and (y)&nbsp;in the aggregate over the term of this Agreement, in excess of $10,000,000 for such transaction or series
of related transactions, in each case with any of its Affiliates, unless such arrangement, transaction or contract is on fair and reasonable
terms no less favorable to the Borrower or any Subsidiary than it could obtain in an arm&rsquo;s-length transaction with a Person that
is not one of its Affiliates, except for (a)&nbsp;compensation and other employment agreements or arrangements with David D. Halbert
(including employee benefits, compensation, equity awards and director/officer indemnification agreements), that are approved by the
Borrower&rsquo;s Board of Directors or a committee thereof, (b)&nbsp;equity investments in the Borrower (including any related stockholders&rsquo;
agreements), (c)&nbsp;transactions of the type set forth on <U>Schedule 8.10</U> and continuations thereof on substantially consistent
terms and other similar servicing arrangements entered into in the ordinary course of business from time to time, (d)&nbsp;any Restricted
Payments permitted pursuant to <U>Section&nbsp;8.6</U> or any Investments permitted pursuant to clauses (c), (k), (p)&nbsp;or (w)&nbsp;of
<U>Section&nbsp;8.5</U>, (e)&nbsp;any transaction between or among the Loan Parties and their Wholly Owned Subsidiaries to the extent
otherwise permitted under this Agreement, (f)&nbsp;compensation and other employment agreements and arrangements (including employee
benefits, compensation, equity awards and director/officer indemnification agreements and Dispositions permitted by <U>Section&nbsp;8.8(xv)</U>)
for service providers, including officers, directors and employees, of the Borrower and its Subsidiaries entered into in the ordinary
course of business or that are approved by the Borrower&rsquo;s Board of Directors or a committee thereof, (g)&nbsp;sales or issuances
of Capital Securities of the Borrower to Affiliates of the Borrower which are otherwise permitted or not restricted by the Loan Documents
(including any related stockholders&rsquo; agreements); and (h)&nbsp;any agreement between any Person and an Affiliate of such Person
existing at the time such Person is acquired by or merged into Borrower or its Subsidiaries pursuant to the terms of this Agreement;
provided that, such agreement was not entered into in contemplation of such acquisition or merger and such Affiliate of such Person was
not an Affiliate of the Borrower prior to such acquisition or merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.11
</FONT><FONT STYLE="font-size: 10pt"><U>Restrictive Agreements, Etc.</U> None of the Borrower or any of the Subsidiaries will enter into
any agreement prohibiting (i)&nbsp;the creation or assumption of any Lien to secure the Obligations upon its properties, revenues or
assets, whether now owned or hereafter acquired, (ii)&nbsp;the ability of the Borrower or any of the Guarantors to amend or otherwise
modify any Loan Document, or (iii)&nbsp;pay dividends or make any other distributions on any of the Borrower&rsquo;s or any Subsidiary&rsquo;s
Capital Securities owned by the Borrower or any Subsidiary. The foregoing prohibitions shall not apply to restrictions (A)&nbsp;contained
in any Loan Document (including any applicable intercreditor or subordination agreement) or in the 2023 Convertible Loan Documents,&nbsp;(B)&nbsp;in
the case of clause (i), contained in any agreement governing any Indebtedness permitted by Section&nbsp;8.2(e)&nbsp;as to the assets
financed with the proceeds of such Indebtedness, (C)&nbsp;in the case of clause (iii), contained in the definitive documentation governing
any Permitted Receivables Indebtedness, (D)&nbsp;in the case of clause (i), by reason of customary provisions restricting assignments,
subletting or other transfers contained in leases, licenses, joint venture agreements and similar agreements entered into in the ordinary
course of business, (E)&nbsp;in the case of clause (iii), that are or were created by virtue of any transfer or option or right with
respect to any property, assets or Capital Securities not otherwise prohibited under this Agreement, (F)&nbsp;existing on the Closing
Date identified on <U>Schedule 8.11</U>, (G)&nbsp;in the case of clause (i)&nbsp;or (iii), in agreements relating to Indebtedness of
any Subsidiary that does not become a Loan Party in existence at the time such Subsidiary became a Subsidiary of Borrower and any amendments
or modifications thereof that do not materially expand the scope of any such restriction; provided that, such restriction apply only
to such Subsidiary, (H)&nbsp;in the case of clause (i)&nbsp;or (iii), arising under or in connection with any agreement or instrument
of any joint venture that is not a Loan Party (including with respect to Capital Securities therein), (I)&nbsp;in the case of clause
(iii), in any agreement governing Indebtedness permitted by Section&nbsp;8.2; <U>provided</U> that such restrictions are no more restrictive,
taken as a whole, than the comparable restrictions set forth in this Agreement as determined in the good faith judgment of Borrower and
(K)&nbsp;imposed by any amendments, modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings
of the contracts, instruments or obligations referred to in <U>clauses (A)</U>&nbsp;through <U>(I)</U>&nbsp;of this <U>Section&nbsp;8.11</U>;
<U>provided </U>that they are permitted hereunder and do not expand the scope of any such restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.12
</FONT><FONT STYLE="font-size: 10pt"><U>Sale and Leaseback</U>. None of the Borrower or any of the Subsidiaries will directly or indirectly
enter into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to
a Person and the subsequent lease or rental of such property or other similar property from such Person (such agreement or arrangement,
a &ldquo;Sale/Leaseback Transaction&rdquo;), unless (a)&nbsp;the sale or transfer of property thereunder is permitted by Section&nbsp;8.7
and Section&nbsp;8.8, (b)&nbsp;any Capitalized Lease Liabilities or Attributable Debt arising in connection therewith are permitted by
Section&nbsp;8.2(e), and (c)&nbsp;any Liens arising in connection therewith (including Liens deemed to arise in connection with any such
Capitalized Lease Liabilities or Attributable Debt) are permitted by Section&nbsp;8.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 101; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.13
</FONT><FONT STYLE="font-size: 10pt"><U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.14
</FONT><FONT STYLE="font-size: 10pt"><U>Change in Name, Location, Executive Office or Executive Management; Change in Fiscal Year</U>.
None of the Borrower or any of the Subsidiaries will: (a)&nbsp;without 20 days&rsquo; prior written notice to the Administrative Agent,
(i)&nbsp;change in its legal name or any trade name used to identify it in the conduct of its business or ownership of its properties,
(ii)&nbsp;change its jurisdiction of incorporation, formation or organization or change its legal form in a manner that would result
in an adverse effect in any material respect on the Administrative Agent or the Lenders or their rights and remedies under this Agreement
or any Loan Document, (iii)&nbsp;relocate its chief executive office, principal place of business or any office in which it maintains
books or records relating to its business (including the establishment of any new office or facility) or (iv)&nbsp;change in its federal
taxpayer identification number or organizational number (or equivalent); (b)&nbsp;terminate the employment of or replace its chief executive
officer, chief scientific officer or chief financial officer without written notification (which may be by email) to the Administrative
Agent within 30 days thereafter; (c)&nbsp;change its Fiscal Year or any of its Fiscal Quarters; or (d)&nbsp;enter into any Division/Series&nbsp;Transaction,
or permit any of its Subsidiaries to enter into any Division/Series&nbsp;Transaction (it being understood that none of the provisions
in this Agreement nor any other Loan Document shall be deemed to permit any Division/Series&nbsp;Transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;8.15
</FONT><FONT STYLE="font-size: 10pt"><U>Benefit Plans and Agreements</U>. Except as would not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect, none of the Borrower or any Subsidiary will (i)&nbsp;become the sponsor of, incur
any responsibility to contribute to or otherwise incur actual or potential liability with respect to, any Benefit Plan, (ii)&nbsp;allow
any &ldquo;employee benefit plan,&rdquo; as defined in section 3(3)&nbsp;of ERISA, that provides retirement benefits, is sponsored by
the Borrower, any Subsidiary, or any of their ERISA Affiliates and is intended to be tax qualified under section 401 of the Code to cease
to be tax qualified or (iii)&nbsp;allow the assets of any tax qualified retirement plan sponsored by the Borrower, any Subsidiary, or
any of their ERISA Affiliates to become invested in Capital Securities of the Borrower or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;IX</FONT><FONT STYLE="font-size: 10pt"><BR>
EVENTS OF DEFAULT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;9.1
</FONT><FONT STYLE="font-size: 10pt"><U>Listing of Events of Default</U>. Each of the following events or occurrences described in this
Article&nbsp;IX shall constitute an &ldquo;<U>Event of Default</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Payment
of Obligations</U>. The Borrower shall default in the payment or prepayment when due of (i)&nbsp;any principal of or interest on any
Loan, or (ii)&nbsp;any fee described in <U>Article&nbsp;III</U> or any other monetary Obligation, and in the case of <U>clause (ii)</U>&nbsp;such
default shall continue unremedied for a period of three Business Days after such amount was due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Breach
of Warranty</U>. Any representation or warranty made or deemed to be made by any Loan Party in any Loan Document (including any certificates
delivered pursuant to <U>Article&nbsp;V</U>) is or shall be incorrect in any material respect when made or deemed to have been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Performance
of Certain Covenants and Obligations</U>. Any Loan Party shall default in the due performance or observance of any of its obligations
under <U>Section&nbsp;7.1</U>, <U>Section&nbsp;7.7</U>, <U>Section&nbsp;7.13(a)(ii)</U>, <U>Section&nbsp;7.13(c)</U>, <U>Section&nbsp;7.15
</U>or <U>Article&nbsp;VIII</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Performance
of Other Covenants and Obligations</U>. Any Loan Party shall default in the due performance and observance of any other covenant, obligation
or agreement contained in any Loan Document executed by it, and such default shall continue unremedied for a period of 30&nbsp;days after
the earlier to occur of (i)&nbsp;notice thereof given to the Borrower by the Lenders or (ii)&nbsp;the date on which the Borrower or any
Subsidiary has knowledge of such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Default
on Other Indebtedness</U>. (i)&nbsp;(x)&nbsp;Following the occurrence of an &ldquo;Event of Default&rdquo; (as defined in the 2023 Convertible
Loan Agreement), the exercise of any rights of acceleration under the 2023 Convertible Loan Agreement in accordance with the terms thereof
or (y)&nbsp;a default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration
or otherwise, of any principal or stated amount of, or interest or fees on, the 2023 Convertible Loan Agreement; <U>provided</U>, this
clause (i)&nbsp;shall be inoperative and the Indebtedness under the 2023 Convertible Loan Agreement shall instead be subject to the immediately
succeeding clause (ii)&nbsp;if the &ldquo;Maturity Date&rdquo; (as defined in the 2023 Convertible Loan Agreement) is extended to a date
beyond September&nbsp;21, 2023, and (ii)&nbsp;with respect to any Indebtedness (other than Indebtedness under the 2023 Convertible Loan
Agreement) of the Borrower or any of the Subsidiaries (and, to the extent clause (i)&nbsp;above becomes inoperative pursuant to the proviso
thereto,&nbsp;Indebtedness of the Borrower and Subsidiaries under the 2023 Convertible Loan Agreement), a default shall occur in the
payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated
amount of, or interest or fees on, any such Indebtedness having a principal or stated amount, individually or in the aggregate, in excess
of $25,000,000 or a default shall occur in the performance or observance of any obligation or condition with respect to such Indebtedness
if the effect of such default is to accelerate the maturity of any such Indebtedness or such default shall continue unremedied for any
applicable period of time sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders,
to cause or declare such Indebtedness to become due and payable or to require such Indebtedness to be prepaid, redeemed, purchased or
defeased, or require an offer to purchase or defease such Indebtedness to be made, prior to its expressed maturity. For the avoidance
of doubt and without limiting the generality of the foregoing <U>clauses (i)</U>&nbsp;and <U>(ii)</U>, the foregoing shall not apply
to any early payment requirement or unwinding or termination with respect to any Permitted Call Spread Swap Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Judgments</U>.
Any judgment or order for the payment of money individually or in the aggregate in excess of $25,000,000 (exclusive of any amounts fully
covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged its responsibility to cover such judgment
or order) shall be rendered against the Borrower or any of the Subsidiaries and such judgment shall not have been vacated or discharged
or stayed or bonded pending appeal within 30 days after the entry thereof or enforcement proceedings shall have been commenced by any
creditor upon such judgment or order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Change
in Control</U>. Any Change in Control shall occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Bankruptcy,&nbsp;Insolvency,
Etc.</U> The Borrower or (except as permitted pursuant to <U>Section&nbsp;8.7</U>) any of the Subsidiaries shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;become
insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;apply
for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of
the property of any thereof, or make a general assignment for the benefit of creditors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the absence of such application, consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator
or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian
shall not be discharged within 60&nbsp;days; <U>provided</U> that, the Borrower and each Subsidiary hereby expressly authorizes the Administrative
Agent and the Lenders to appear in any court conducting any relevant proceeding during such 60-day period to preserve, protect and defend
its rights under the Loan Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;permit
or suffer to exist the commencement of any bankruptcy, insolvency, reorganization, debt arrangement, arrangement (including any plan
of compromise or arrangement or other corporate proceeding involving or affecting its creditors) or other case or proceeding under any
bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof (each, an &ldquo;<U>Insolvency
Event</U>&rdquo;), and, if any such case or proceeding is not commenced by the Borrower or any Subsidiary, such case or proceeding shall
be consented to or acquiesced in by the Borrower or such Subsidiary, as the case may be, or shall result in the entry of an order for
relief or shall remain for 60 days undismissed; <U>provided</U> that the Borrower and each Subsidiary hereby expressly authorizes the
Administrative Agent and the Lenders to appear in any court conducting any such case or proceeding during such 60-day period to preserve,
protect and defend its rights under the Loan Documents; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;take
any action authorizing, or in furtherance of, any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Impairment
of Security, Etc</U>. Any Loan Document or any Lien granted thereunder in any portion of the Collateral of a value of $10,000,000 or
more shall (except in accordance with its terms), in whole or in part, terminate, cease to be effective or cease to be the legally valid,
binding and enforceable obligation of the Borrower or any Guarantor party thereto; the Borrower, any Guarantor or any other party shall,
directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability; or, except as permitted
under any Loan Document, any Lien on any portion of the Collateral of a value of $10,000,000 or more securing any Obligation shall cease
to be a perfected Lien.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Regulatory
Matters</U>. If any of the following occurs and has had or would reasonably be expected to have or result in a Material Adverse Effect:
(i)&nbsp;subject to the next sentence of this <U>Section&nbsp;9.1(k)</U>, the FDA, CMS, EMA or any other Governmental Authority (A)&nbsp;issues
a letter or other communication asserting that any Product lacks a required Regulatory Authorization or (B)&nbsp;initiates enforcement
action against, or issues a warning letter or takes any other action with respect to, the Borrower or any of the Subsidiaries, or any
of their Products or the manufacturing facilities therefor, that in either case of the foregoing clauses (A)&nbsp;or (B), causes the
Borrower or such Subsidiary to discontinue or suspend marketing or withdraw any of its Products, which discontinuance, suspension or
withdrawal would reasonably be expected to last for more than 90 days; (ii)&nbsp;the Borrower or any of the Subsidiaries enters into
a settlement agreement with the FDA, CMS, EMA or any other similar Governmental Authority; or (iii)&nbsp;a recall or similar event which
could reasonably be expected to result in liability to the Borrower and its Subsidiaries. For the avoidance of doubt, the failure to
obtain an FDA approval for the Borrower&rsquo;s LDTs shall not, in and of itself, constitute a Default or an Event of Default under this
<U>Section&nbsp;9.1(k)</U>&nbsp;unless such failure results in any event described in the preceding sentence of this <U>Section&nbsp;9.1(k)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sweep
of Governmental Payor Accounts</U>. The Loan Parties or any Subsidiary instructs the depository bank of any zero balance account referenced
in <U>Section&nbsp;7.13(a)(i)(G)</U>&nbsp;to discontinue the daily sweep of funds in such account into a Controlled Account, or otherwise
revokes instructions under the sweep agreement governing such account regarding the daily sweep of funds into a Controlled Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;9.2
</FONT><FONT STYLE="font-size: 10pt"><U>Action if Bankruptcy</U>. If any Event of Default described in clauses (i)&nbsp;through (iv)&nbsp;of
Section&nbsp;9.1(h)&nbsp;with respect to the Borrower shall occur, the Commitments (if not theretofore terminated) shall automatically
terminate and the outstanding principal amount of the Loans and all other Obligations shall automatically be and become immediately due
and payable, without notice or demand to any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;9.3
</FONT><FONT STYLE="font-size: 10pt"><U>Action if Other Event of Default</U>. If any Event of Default (other than any Event of Default
described in clauses (i)&nbsp;through (iv)&nbsp;of Section&nbsp;9.1(h)) shall occur for any reason, whether voluntary or involuntary,
and be continuing, the Administrative Agent may, and shall at the direction of the Required Lenders or OrbiMed (so long as OrbiMed holds
Total Credit Exposures representing more than 50% of the Total Credit Exposures of all Lenders), by notice to the Borrower declare all
or any portion of the outstanding principal amount of the Loans and other Obligations to be due and payable and/or the Commitments (if
not theretofore terminated) to be terminated, whereupon the full unpaid amount of the Loans and other Obligations which shall be so declared
due and payable shall be and become immediately due and payable, without further notice, demand or presentment, and the Commitments shall
terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 105; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;9.4
</FONT><FONT STYLE="font-size: 10pt"><U>Right to Cure</U>. Notwithstanding anything to the contrary otherwise contained in this Article&nbsp;IX,
in the event of any Event of Default arising under Section&nbsp;9.1(c)&nbsp;due to any Loan Party&rsquo;s default in the due performance
or observance of any of its obligations under Section&nbsp;8.4(b), the Borrower shall have the right (the &ldquo;Cure Right&rdquo;) within
45 days of the end of the respective Test Period to apply cash proceeds from the issuance of Permitted Cure Securities to prepay the
Loans (including any Repayment Premium and Exit Fee); provided that, the Cure Right shall not be exercised (x)&nbsp;more than once in
any period of two (2)&nbsp;consecutive Fiscal Quarters, (y)&nbsp;more than twice during any period of four (4)&nbsp;consecutive Fiscal
Quarters or (z)&nbsp;more than three times during the term of this Agreement. After giving effect to the foregoing prepayment, the Borrower&rsquo;s
Revenue Base shall be deemed (solely for purposes of measuring compliance with Section&nbsp;8.4(b)) to be increased with respect to such
Test Period (and for all future Test Periods that include all or any part of such Test Period) for all purposes under this Agreement
by an amount equal to the lesser of (x)&nbsp;100% of the proceeds so applied and (y)&nbsp;the Revenue Deficiency for such Test Period.
If, after giving effect to the foregoing pro forma adjustment, the Borrower and its Subsidiaries are in compliance with the financial
covenant set forth in Section&nbsp;8.4(b), the requirements of such Section&nbsp;8.4(b)&nbsp;shall be deemed to be satisfied as of the
relevant date of determination with the same effect as though there had been no failure to comply on such date, and the applicable breach
or default of such Section&nbsp;8.4(b)&nbsp;that had occurred shall be deemed cured for purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;9.5
</FONT><FONT STYLE="font-size: 10pt"><U>Application of Funds</U>. After the exercise of remedies provided for in Section&nbsp;9.3 (or
after the Loans have automatically become immediately due and payable as set forth in Section&nbsp;9.2), any amounts received by any
Lender or the Administrative Agent on account of the Obligations shall be applied in the following order:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>First</I></FONT><FONT STYLE="font-size: 10pt">,
to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and
disbursements of counsel to the Administrative Agent and amounts payable under Article&nbsp;III) payable to the Administrative Agent
in its capacity as such;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Second</I></FONT><FONT STYLE="font-size: 10pt">,
to payment of that portion of the Obligations constituting fees, indemnities and other amounts (other than principal, interest and any
amount payable under the Fee Letter) payable to the Lenders (including fees, charges and disbursements of counsel to the respective Lenders)
arising under the Loan Documents and amounts payable under <U>Section&nbsp;4.3</U>, ratably among them in proportion to the respective
amounts described in this clause Second payable to them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Third</I></FONT><FONT STYLE="font-size: 10pt">,
to payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans and amounts payable under the Fee
Letter, ratably among the Lenders in proportion to the respective amounts described in this clause <I>Third</I> held by them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Options: NewSection; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fourth</I></FONT><FONT STYLE="font-size: 10pt">,
to payment of that portion of the Obligations constituting accrued and unpaid principal of the Loans, ratably among the Lenders in proportion
to the respective amounts described in this clause Fourth held by them; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Last</I></FONT><FONT STYLE="font-size: 10pt">,
the balance, if any, after all of the Obligations have been paid in full, to the Borrower or as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;X</FONT><FONT STYLE="font-size: 10pt"><BR>
MISCELLANEOUS PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.1
</FONT><FONT STYLE="font-size: 10pt"><U>Waivers, Amendments, Etc</U>. No amendment or waiver of any provision of this Agreement or any
other Loan Document, and no consent to any departure by the Borrower or any Guarantor therefrom, shall be effective unless in writing
signed by the Required Lenders and by the Borrower or the applicable Guarantor, as the case may be, and acknowledged by the Administrative
Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given;
provided, further, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">no
such amendment, waiver or consent shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;extend
or increase the Commitment of a Lender (or reinstate any Commitment terminated pursuant to <U>Section&nbsp;9.2</U>) without the written
consent of such Lender whose Commitment is being extended or increased (it being understood and agreed that a waiver of any condition
precedent set forth in <U>Article&nbsp;V</U> or a waiver of any Default or a mandatory reduction in Commitments is not considered an
extension or increase in Commitments of any Lender);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;postpone
any date fixed by this Agreement or any other Loan Document for any payment of principal (excluding mandatory prepayments or scheduled
amortization and related amounts payable in connection therewith), interest, Repayment Premiums, fees or other amounts due to the Lenders
(or any of them) without the written consent of each Lender entitled to receive such payment (it being understood that a waiver of any
Default or Event of Default (or of any related default interest payable pursuant to Section&nbsp;3.5) shall not constitute such a postponement);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reduce
the principal of, the rate of interest specified herein on or any Repayment Premium specified herein on any Loan, or any fees or other
amounts payable hereunder or under any other Loan Document (including, for the avoidance of doubt, the Exit Fee) without the written
consent of each Lender entitled to receive such payment of principal, interest, fees or other amounts (other than any such reduction
in connection with a waiver of any Default, Event of Default (including, for the avoidance of doubt, any default interest payable pursuant
to Section&nbsp;3.5), mandatory prepayment, amortization payment or amendment to any financial covenant);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(x)&nbsp;amend
or waive any provision of <U>Section&nbsp;9.5</U>, or (y)&nbsp;amend or waive any provision providing for the pro rata treatment of the
Lenders, in each case, without the written consent of each Lender directly affected thereby;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;change
any provision of this <U>Section&nbsp;10.1(a)</U>&nbsp;or the definition of &ldquo;Required Lenders&rdquo; without the written consent
of all the Lenders; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;consent
to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents,
or release all or substantially all of the Collateral or release all or substantially all of the Guarantors from their obligations under
the Guarantee, in each case, without the written consent of all the Lenders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(x)&nbsp;amend,
waive or modify <U>Section&nbsp;11.6</U> hereof, without the consent of the Required Lenders; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;unless
also signed by the Administrative Agent, no amendment, waiver or consent shall affect the rights, duties, benefits, privileges, protections,
indemnities or immunities of the Administrative Agent under this Agreement or any other Loan Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U></FONT><FONT STYLE="font-size: 10pt">,
however, that notwithstanding anything to the contrary herein, (i)&nbsp;each Lender is entitled to vote as such Lender sees fit on any
bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section&nbsp;1126(c)&nbsp;of
the Bankruptcy Code of the United States supersedes the unanimous consent provisions set forth herein and (ii)&nbsp;the Required Lenders
shall determine whether or not to allow the Borrower or any Guarantor to use cash collateral in the context of a bankruptcy or insolvency
proceeding and such determination shall be binding on all of the Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent
hereunder, except (x)&nbsp;that the Commitments of such Lender may not be increased or extended without the consent of such Lender and
(y)&nbsp;for any such amendment, waiver or consent that treats such Defaulting Lender disproportionately and adversely from the other
Lenders (other than because of its status as a Defaulting Lender).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to <U>Section&nbsp;4.7</U>, a</FONT><FONT STYLE="font-size: 10pt">ny payments, fees or other consideration (other than reimbursements
for out-of-pocket expenses) received by or on behalf of the Administrative Agent or any of the Lenders in respect of any amendment, waiver
or consent under the Loan Documents shall be distributed to the Lenders on a pro rata basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.2
</FONT><FONT STYLE="font-size: 10pt"><U>Notices; Time; Inside Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
notices and other communications provided under any Loan Document shall be in writing (including by email) and addressed, delivered or
transmitted, if to the Administrative Agent, the Borrower or the Lenders, to the applicable Person at its physical address or email address
set forth on <U>Schedule 10.2</U> hereto, or at such other physical address or email address as may be designated by such party in a
notice to the other parties. Any notice, if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid
courier service, shall be deemed given when received; any notice, if transmitted by email, shall be deemed given upon the earlier of
(x)&nbsp;confirmation of receipt by the recipient and (y)&nbsp;the opening of business on the next Business Day for the recipient. Unless
otherwise indicated, all references to the time of a day in a Loan Document shall refer to New York City time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic or electronic loan notices)
purportedly given by or on behalf of the Borrower or any Guarantor even if (i)&nbsp;such notices were not made in a manner specified
herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii)&nbsp;the terms thereof,
as understood by the recipient, varied from any confirmation thereof. The Borrower and each Guarantor shall indemnify the Administrative
Agent, each Lender and their respective the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors
and representatives from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly
given by or on behalf of the Borrower and each Guarantor; <U>provided</U> that such indemnity shall not, as to any Person be available
to the extent that such losses, costs, expenses or liabilities are determined by a court of competent jurisdiction by final and non-appealable
judgment to have resulted from the gross negligence or willful misconduct of such Person. All telephonic notices to and other telephonic
communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents
to such recording.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
Materials may be delivered pursuant to procedures approved by the Administrative Agent, including electronic delivery (if possible) upon
request by the Administrative Agent to an electronic system maintained by the Administrative Agent (the &ldquo;<U>Platform</U>&rdquo;).
The Borrower shall notify the Administrative Agent of each posting of Borrower Materials on the Platform and the materials shall be deemed
received by the Administrative Agent only upon its receipt of such notice. Borrower Materials and other information relating to this
credit facility may be made available to Lenders on the Platform. The Platform is provided &ldquo;as is&rdquo; and &ldquo;as available.&rdquo;
The Administrative Agent does not warrant the accuracy or completeness of any information on the Platform nor the adequacy or functioning
of the Platform, and expressly disclaims liability for any errors or omissions in the Borrower Materials or any issues involving the
Platform, except to the extent resulting from the Administrative Agent&rsquo;s own gross negligence or willful misconduct as determined
by a final non-appealable judgment by a court of competent jurisdiction. NO WARRANTY OF ANY KIND, EXPRESS,&nbsp;IMPLIED OR STATUTORY,&nbsp;INCLUDING
ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THIRD PARTY RIGHTS, OR FREEDOM FROM VIRUSES OR
OTHER CODE DEFECTS,&nbsp;IS MADE BY ADMINISTRATIVE AGENT WITH RESPECT TO BORROWER MATERIALS OR THE PLATFORM. None of the Administrative
Agent nor any of its Affiliates, partners, directors, officers, employees, agents, trustees, administrators, managers or advisors, nor
any of the partners, directors, officers, employees, agents, trustees, administrators, managers or advisors of its Affiliates shall have
any liability to the Loan Parties, Lenders or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether
in tort, contract or otherwise) relating to use by any Person of the Platform or delivery of Borrower Materials and other information
through the Platform except to the extent any thereof result from the applicable Person&rsquo;s own gross negligence or willful misconduct
as determined by a final non appealable judgment by a court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction each Loan Party shall not, and shall cause
each of its Related Parties to not, provide any Lender, attorneys, agents or representatives with any material nonpublic information
regarding the Borrower or its Subsidiaries, the Borrower&rsquo;s securities, any of the Borrower&rsquo;s Affiliates or any other Person
(collectively, &ldquo;<U>Inside Information</U>&rdquo;) without the express prior written consent of such Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, notwithstanding the foregoing clause (d),
to the extent the Borrower reasonably and in good faith determines that it is necessary to disclose Inside Information to a Lender for
purposes relating to this Agreement or any other Loan Document (a &ldquo;<U>Necessary Disclosure</U>&rdquo;), the Borrower shall inform
Outside Counsel to such Lender of such determination without disclosing the applicable Inside Information, and the Borrower and such
Outside Counsel on behalf of the applicable Lender shall endeavor to agree upon a process for making such Necessary Disclosure to the
applicable Lender or its representatives that is mutually acceptable to such Lender and the Borrower (an &ldquo;<U>Agreed Disclosure
Process</U>&rdquo;). Thereafter, the Borrower shall be permitted to make such Necessary Disclosure (only) in accordance with the Agreed
Disclosure Process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, neither the Administrative Agent nor any
Affiliates thereof shall provide any Inside Information to any Lender without complying with the processes set forth in clauses (d)&nbsp;and
(e)&nbsp;of this Section&nbsp;10.2 as if the Administrative Agent were the Borrower for the purposes thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, at or prior to 9:00 a.m.&nbsp;(New York
City time) on the second (2nd) Business Day following each of the First Delayed Draw Closing Date and the Second Delayed Draw Closing
Date, the Borrower shall file a Form&nbsp;8-K with the SEC or furnish a Form&nbsp;8-K to the SEC describing the terms of the borrowing
occurring on such date and any other material transactions occurring in connection therewith. At or prior to 9:00 a.m.&nbsp;(New York
City time) on the fourth (4th) Business Day following Borrower&rsquo;s delivery of a notice of termination of any unfunded Commitments
or notice of any repayment, prepayment, redemption or payment in full of the outstanding principal amounts of the Loans, the Borrower
shall file a Form&nbsp;8-K with the SEC or furnish a Form&nbsp;8-K to the SEC describing such termination, repayment, prepayment, redemption
or payment (as applicable) and any other material transactions occurring in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.3
</FONT><FONT STYLE="font-size: 10pt"><U>Payment of Costs and Expenses</U>. The Borrower agrees to pay on demand all reasonable documented
expenses of the Administrative Agent and the Lenders (limited, in the case of attorneys&rsquo; fees and legal expenses, to the reasonable
and documented fees and out-of-pocket expenses of Covington&nbsp;&amp; Burling LLP, counsel to the Administrative Agent and the Lenders,
specialist counsel, if any, relating to any applicable legal subject matter who may be retained by or on behalf of the Administrative
Agent and the Lenders, and of local counsel, if any, in any applicable jurisdiction who may be retained by or on behalf of the Administrative
Agent and the Lenders) in connection with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
negotiation, preparation, execution and delivery of each Loan Document, including schedules and exhibits, and any amendments, waivers,
consents, supplements or other modifications to any Loan Document as may from time to time hereafter be required, whether or not the
transactions contemplated hereby are consummated;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
filing or recording of any Loan Document (including any financing statements) and all amendments, supplements, amendment and restatements
and other modifications to any thereof, searches made following the Closing Date in jurisdictions where financing statements (or other
documents evidencing Liens in favor of the Secured Parties) have been recorded and any and all other documents or instruments of further
assurance required to be filed or recorded by the terms of any Loan Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
preparation and review of the form of any document or instrument relevant to any Loan Document; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reasonable
legal diligence, consulting and other advice in connection with the Borrower, the Subsidiaries and any of their Related Parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U></FONT><FONT STYLE="font-size: 10pt">,
that, unless otherwise agreed by the Borrower in writing, the fees and expenses of OrbiMed (other than those fees and expenses incurred
by or on behalf of OrbiMed in connection with the syndication of the Loans) reimbursable by the Borrower on the Closing Date as contemplated
by this <U>Section&nbsp;10.3</U> shall not exceed $500,000 in the aggregate (with such amount to be inclusive of the Expense Deposit
(as defined below)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">OrbiMed
shall apply the $100,000 expense deposit (the &ldquo;<U>Expense Deposit</U>&rdquo;) that the Borrower furnished to OrbiMed prior to the
Closing Date to the documented fees and expenses that are payable or reimbursable in accordance with the foregoing sentence. The Borrower
also agrees to reimburse the Lenders upon demand for all reasonable out-of-pocket expenses (limited, in the case of attorneys&rsquo;
fees and legal expenses, to reasonable fees and expenses of counsel to the Administrative Agent and the Lenders) incurred by the Administrative
Agent and each Lender in connection with (x)&nbsp;the negotiation of any restructuring or &ldquo;work-out&rdquo; with the Borrower, whether
or not consummated, of any Obligations and (y)&nbsp;the enforcement of any Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.4
</FONT><FONT STYLE="font-size: 10pt"><U>Indemnification; Expenses; and Damage Waiver</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
consideration of the execution and delivery of this Agreement by the Lenders and the Administrative Agent, the Borrower hereby indemnifies,
agrees to defend, exonerates and holds each Lender and the Administrative Agent (and any sub-agent thereof) and each of the respective
partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of any of the foregoing
Persons (collectively, the &ldquo;<U>Indemnified Parties</U>&rdquo;) free and harmless from and against any and all actions, causes of
action, suits, losses, costs, liabilities, obligations and damages, claims and expenses incurred in connection therewith (irrespective
of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), reasonable attorneys&rsquo;
and professionals&rsquo; fees and disbursements (limited, in the case of attorneys&rsquo; fees and legal expenses, to one primary external
counsel to each of (x)&nbsp;(i)&nbsp;the Administrative Agent and (ii)&nbsp;the Required Lenders and local counsel to each of (y)&nbsp;(i)&nbsp;the
Administrative Agent and (ii)&nbsp;the Required Lenders in each relevant jurisdiction), whether incurred in connection with actions between
the parties hereto or the parties hereto and third parties (collectively, the &ldquo;<U>Indemnified Liabilities</U>&rdquo;), arising
out of or in connection with the Loan Documents, including, without limitation,&nbsp;Indemnified Liabilities arising out of or relating
to (i)&nbsp;the entering into, administration, performance and enforcement of any Loan Document by any of the Indemnified Parties (including
any action brought by or on behalf of the Borrower as the result of any determination by any Lender pursuant to <U>Article&nbsp;V</U>
not to fund any Loan), and (ii)&nbsp;any Environmental Liability; <U>provided</U> that the foregoing indemnity will not, as to any Indemnified
Party, apply to losses, claims, damages, liabilities or related expenses to the extent that they have resulted from (i)&nbsp;the willful
misconduct or gross negligence of such Indemnified Party (or any of its Related Parties) (as determined by a court of competent jurisdiction
in a final and non-appealable decision) or (ii)&nbsp;disputes solely among the Indemnified Parties that are not arising out of any act
or omission by the Borrower or any Affiliate of the Borrower, other than claims against the Administrative Agent in such capacity. If
and to the extent that the foregoing indemnification may be unenforceable for any reason, the Borrower agrees to make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable Law. This <U>Section&nbsp;10.4(a)</U>&nbsp;shall
not apply with respect to Taxes other than any Taxes that represent losses, claims and damages arising from any non-Tax claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Reimbursement
by Lenders</U>. To the extent that the Borrower and the Guarantors for any reason fail to pay any amount required under <U>subsection
(a)</U>&nbsp;of this <U>Section&nbsp;10.4</U> to be paid by them to the Administrative Agent (or any sub-agent thereof) or any of their
respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives, each Lender
severally agrees to pay to the Administrative Agent (or any such sub-agent) or such partners, directors, officers, employees, agents,
trustees, administrators, managers, advisors and representatives of such Person, as the case may be, such Lender&rsquo;s pro rata share
(determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender&rsquo;s share
of the Total Credit Exposure at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by
such Lender), such payment to be made severally among them based on such Lenders&rsquo; Applicable Percentages (determined as of the
time that the applicable unreimbursed expense or indemnity payment is sought); <U>provided</U>, <U>further</U>, that the unreimbursed
expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the
Administrative Agent (or any such sub-agent), or against any of their respective partners, directors, officers, employees, agents, trustees,
administrators, managers, advisors and representatives acting for the Administrative Agent (or any such sub-agent) in connection with
such capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Waiver
of Consequential Damages, Etc.</U> To the fullest extent permitted by applicable Law, no Party hereto shall assert, and each Party hereto
hereby waives, and acknowledges that no other Person shall have, any claim against any Indemnified Party, on any theory of liability,
for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with,
or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated
hereby or thereby, any Loan or the use of the proceeds thereof. No Indemnified Party referred to in <U>Section&nbsp;10.4(a)</U>&nbsp;above
shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it
through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan
Documents or the transactions contemplated hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payments</U>.
All amounts due under this <U>Section&nbsp;10.4</U> shall be payable not later than 10 Business Days after demand therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.5
</FONT><FONT STYLE="font-size: 10pt"><U>Survival</U>. The obligations of the Borrower under Section&nbsp;4.1, Section&nbsp;4.2, Section&nbsp;4.3,
Section&nbsp;10.3 and Section&nbsp;10.4, shall in each case survive any assignment by any Lender and the occurrence of the Termination
Date. The agreements in this Section&nbsp;10.5 and the indemnity provisions of Section&nbsp;10.4(c)&nbsp;shall survive the resignation
or replacement of the Administrative Agent, any assignment by any Lender, the termination of the Commitments and the repayment, satisfaction
or discharge of all the other Obligations. All representations and warranties made by the Borrower or any Guarantor hereunder and in
each other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive
the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Administrative
Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding
that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any borrowing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.6
</FONT><FONT STYLE="font-size: 10pt"><U>Severability</U>. Any provision of any Loan Document which is prohibited or unenforceable in
any jurisdiction shall, as to such provision and such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability
without invalidating the remaining provisions of such Loan Document affecting the validity or enforceability of such provision in any
other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.7
</FONT><FONT STYLE="font-size: 10pt"><U>Headings</U>. The various headings of each Loan Document are inserted for convenience only and
shall not affect the meaning or interpretation of such Loan Document or any provisions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.8
</FONT><FONT STYLE="font-size: 10pt"><U>Execution in Counterparts, Effectiveness, Etc.</U> This Agreement may be executed by the parties
hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement.
This Agreement shall become effective when counterparts hereof executed on behalf of the Borrower and the Lenders, shall have been received
by the Administrative Agent. Delivery of an executed counterpart of a signature page&nbsp;to this Agreement by email (e.g., &ldquo;pdf&rdquo;
or &ldquo;tiff&rdquo;) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.9
</FONT><FONT STYLE="font-size: 10pt"><U>Governing Law; Entire Agreement</U>. EACH LOAN DOCUMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE
OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN
DOCUMENT CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW
YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). The Loan Documents
constitute the entire understanding among the parties hereto with respect to the subject matter thereof and supersede any prior agreements,
written or oral, with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.10
</FONT><FONT STYLE="font-size: 10pt"><U>Successors and Assigns</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns Generally</U>. The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit
of the Parties hereto and thereto and their respective successors and assigns permitted hereby, except that the Borrower may not assign
or otherwise transfer any of its rights or obligations hereunder or thereunder without the prior written consent of the Administrative
Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i)&nbsp;to an
Eligible Assignee in accordance with the provisions of <U>Section&nbsp;10.10(b)</U>, or (ii)&nbsp;by way of pledge or assignment of a
security interest subject to the restrictions of <U>Section&nbsp;10.10(d)</U>&nbsp;(and any other attempted assignment or transfer by
any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person
(other than the parties hereto, their respective successors and assigns permitted hereby and, to the extent expressly contemplated hereby,
the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of each of the
Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. No assignment
or transfer of any Commitment or Loan shall be effective until receipt and acceptance into the Register by the Administrative Agent of
a fully executed Assignment and Assumption effecting the assignment or transfer thereof, together with the required forms and certificates
regarding tax matters and any fees payable in connection with such assignment, in each case, as provided in <U>Section&nbsp;10.10(b)</U>.
The date of such assignment shall be referred to herein as the &ldquo;<U>Assignment Effective Date</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assignments
by Lenders</U>. Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under
this Agreement and the other Loan Documents (including all or a portion of its Commitment and the Loans at the time owing to it); <U>provided
</U>that any such assignment shall be subject to the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Minimum
Amounts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of an assignment of the entire remaining amount of the assigning Lender&rsquo;s Commitment and/or the Loans at the time owing
to it or contemporaneous assignments to related Approved Funds that equal at least the amount specified in <U>Section&nbsp;10.10(b)(i)(B)&nbsp;</U>in
the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
any case not described in <U>Section&nbsp;10.10(b)(i)(A)</U>, the aggregate amount of the Commitment (which for this purpose includes
applicable Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of
the applicable Loans of the assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption
with respect to such assignment is delivered to the Administrative Agent or, if &ldquo;Trade Date&rdquo; is specified in the Assignment
and Assumption, as of the Trade Date, shall not be less than $1,000,000 (and in addition shall be subject to clause (b)(iii)&nbsp;below)
unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents
(each such consent not to be unreasonably withheld or delayed);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Proportionate
Amounts</U>. Each partial assignment shall be made as an assignment of a proportionate part of all of the assigning Lender&rsquo;s rights
and obligations under this Agreement with respect to the Loans or the Commitment assigned;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Required
Consents</U>. No consent shall be required for any assignment, except to the extent required by <U>Section&nbsp;10.10(b)(i)(B)</U>&nbsp;and,
in addition, (x)&nbsp;the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required
for assignments to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund and (y)&nbsp;the consent of the Borrower
(such consent not to be unreasonably withheld, conditioned or delayed, and which consent shall be deemed to have been provided if the
Borrower shall not have responded to a written request for such consent within ten (10)&nbsp;Business Days) shall be required for any
assignment of Loans and/or Commitments in an aggregate principal amount of less than $40,000,000 to a Person that is not a Lender, an
Affiliate of a Lender or an Approved Fund so long as no Event of Default has occurred and is continuing; <U>provided</U>, <U>however</U>,
in the event that, after giving effect to any assignment, OrbiMed would have Total Credit Exposures representing less than 50.1% of the
Total Credit Exposures of all Lenders, the consent of the Borrower (such consent not to be unreasonably withheld, conditioned or delayed,
and which consent shall be deemed to have been provided if the Borrower shall not have responded to a written request for such consent
within ten (10)&nbsp;Business Days) shall be required for any assignment (regardless of the amount assigned) so long as no Event of Default
has occurred and is continuing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assignment
and Assumption</U>. Assignments and assumptions of Loans and Commitments by Lenders shall be effected by manual execution and delivery
to the Administrative Agent of an Assignment and Assumption. Assignments made pursuant to the foregoing provision shall be effective
as of the Assignment Effective Date, subject to acceptance and recording thereof in the Register by the Administrative Agent pursuant
to <U>Section&nbsp;10.10(c)</U>. In connection with all assignments there shall be delivered to the Administrative Agent such forms,
certificates or other evidence, if any, with respect to United States federal income tax withholding matters as the assignee under such
Assignment and Assumption may be required to deliver pursuant to <U>Section&nbsp;4.3</U>, together with payment to the Administrative
Agent of a registration and processing fee of $3,500, (which shall not be required for assignments from a Lender to an Affiliate of such
Lender) and may otherwise be waived or reduced at the sole discretion of the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Assignment to Certain Persons</U>. No such assignment shall be made to the Borrower or any Guarantor or any Affiliate or Subsidiary of
the Borrower or any Guarantor, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons (other
than to the Lenders on the Closing Date and their respective Affiliates).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to acceptance and recording thereof by the Administrative Agent pursuant to <U>Section&nbsp;10.10(c)</U>, from and after the effective
date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the
interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning
Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under
this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender&rsquo;s rights and obligations
under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of <U>Sections
4.3</U>, <U>10.3</U> and <U>10.4</U> with respect to facts and circumstances occurring prior to the effective date of such assignment.
Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Register</U>.
The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at the Administrative Agent&rsquo;s
Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic form) and a register for the
recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans
owing to, each Lender pursuant to the terms hereof from time to time (the &ldquo;<U>Register</U>&rdquo;). The entries in the Register
shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name
is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall
be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.
The parties intend that any interest in or with respect to the Loans under this Agreement be treated as being issued and maintained in
 &ldquo;registered form&rdquo; within the meaning of Sections 163(f), 871(h)(2), and 881(c)(2)&nbsp;of the Code and any regulations thereunder
(and any successor provisions), including without limitation under United States Treasury Regulations Section&nbsp;5f.103-1(c)&nbsp;and
Proposed Regulations Section&nbsp;1.163-5 (and any successor provisions), and the provisions of this Agreement shall be construed in
a manner that gives effect to such intent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Pledges</U>. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement
(including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to
a Federal Reserve Bank; <U>provided</U> that no such pledge or assignment shall release such Lender from any of its obligations hereunder
or substitute any such pledgee or assignee for such Lender as a party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administrative
Agent</U>. Any corporation or association into which the Administrative Agent may be converted or merged, or with which it may be consolidated,
or to which it may sell or transfer all or substantially all of its corporate trust business and assets as a whole or substantially as
a whole, or any corporation or association resulting from any such conversion, sale, merger, consolidation or transfer to which the Administrative
Agent is a party, will be and become the successor to the Administrative Agent under this Agreement and will have and succeed to the
rights, powers, duties, immunities and privileges as its predecessor, without the execution or filing of any instrument or paper or the
performance of any further act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.11
</FONT><FONT STYLE="font-size: 10pt"><U>Other Transactions</U>. Nothing contained herein shall preclude any Lender or any of its Affiliates
from engaging in any transaction, in addition to those contemplated by the Loan Documents, with the Borrower or any of its Affiliates
in which the Borrower or such Affiliate is not restricted hereby from engaging with any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.12
</FONT><FONT STYLE="font-size: 10pt"><U>Forum Selection and Consent to Jurisdiction</U>. EACH OF THE PARTIES HERETO HEREBY AGREES THAT
ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, ANY LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF
DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE ADMINISTRATIVE AGENT, ANY LENDER OR THE BORROWER IN CONNECTION HEREWITH
OR THEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK
OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY
COLLATERAL OR OTHER PROPERTY MAY&nbsp;BE BROUGHT, AT THE ADMINISTRATIVE AGENT&rsquo;S OR THE LENDERS&rsquo; OPTION,&nbsp;IN THE COURTS
OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY&nbsp;BE FOUND. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY CONSENTS
TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT ITS
ADDRESS FOR NOTICES SPECIFIED IN SECTION&nbsp;10.2. EACH OF THE PARTIES HERETO HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY&nbsp;HAVE OR HEREAFTER MAY&nbsp;HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION
BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE
EXTENT THAT ANY PARTY HERETO HAS OR HEREAFTER MAY&nbsp;ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS
(WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF
OR ITS PROPERTY, EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, SUCH IMMUNITY IN RESPECT
OF ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.13
</FONT><FONT STYLE="font-size: 10pt"><U>Waiver of Jury Trial</U>. THE ADMINISTRATIVE AGENT, THE LENDERS AND THE BORROWER HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY&nbsp;HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, EACH LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE
OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE ADMINISTRATIVE AGENT, ANY LENDER OR THE BORROWER IN CONNECTION THEREWITH.
EACH OF THE PARTIES HERETO ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH
OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE PARTIES
ENTERING INTO THE LOAN DOCUMENTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.14
</FONT><FONT STYLE="font-size: 10pt"><U>Confidential Information</U>. Subject to the provisions of Section&nbsp;10.15, at all times prior
to the Termination Date, the Receiving Party shall keep confidential and shall not publish or otherwise disclose any Confidential Information
furnished to it by the Disclosing Party, except to those of the Receiving Party&rsquo;s employees, advisors or consultants who have a
need to know such information to assist such Receiving Party in the performance of such Receiving Party&rsquo;s obligations or in the
exercise of such Receiving Party&rsquo;s rights hereunder and who are subject to reasonable obligations of confidentiality consistent
with this Section&nbsp;10.14 (collectively, &ldquo;Recipients&rdquo;); provided that the Receiving Party shall remain liable for any
breach of this Section&nbsp;10.14 by any of its Recipients. Notwithstanding anything to the contrary set forth herein, any Lender may
disclose Confidential Information received from or on behalf of the Borrower and its Subsidiaries related hereto, to (i)&nbsp;its Affiliates,
(ii)&nbsp;other than with respect to any information provided pursuant to <U>Section&nbsp;7.1(i)</U>&nbsp;hereof, potential and actual
assignees of any of such Lender&rsquo;s rights hereunder and (iii)&nbsp;other than with respect to any information provided pursuant
to <U>Section&nbsp;7.1(i)</U>&nbsp;hereof, potential and actual investors in, or lenders to, such Lender (including, in each of the foregoing
cases, such Person&rsquo;s employees, advisors or consultants); provided that in each case, each such Person referred to in clauses (i)&nbsp;through
(iii)&nbsp;shall be subject to reasonable obligations of confidentiality and provided, further, that such Lender shall remain liable
for any breach of this Section&nbsp;10.14 by any such Person referred to in clause (i)&nbsp;through (iii)&nbsp;to whom such Lender disclosed
such Confidential Information. In addition to the foregoing, the Receiving Party may disclose Confidential Information belonging to the
Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in order to comply with applicable Laws
(including any securities law or regulation or the rules&nbsp;of a securities exchange) and with judicial process, if in the reasonable
opinion of the Receiving Party, such disclosure is necessary for such compliance, provided that the Receiving Party (x)&nbsp;will only
disclose those portions of the Confidential Information that are necessary or required to be so disclosed, and (y)&nbsp;to the extent
legally permissible, will notify the Disclosing Party of the Receiving Party&rsquo;s intent to make any disclosure pursuant thereto sufficiently
prior to making such disclosure so as to allow the Disclosing Party time to take whatever action it may deem appropriate to protect the
confidentiality of the information to be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 118; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.15
</FONT><FONT STYLE="font-size: 10pt"><U>Exceptions to Confidentiality</U>. The Receiving Party&rsquo;s obligations set forth in this
Agreement shall not extend to any Confidential Information of the Disclosing Party:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
is or hereafter becomes part of the public domain (other than as a result of a disclosure by the Receiving Party or its Recipients in
violation of this Agreement);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
is received from a Third Party without restriction on disclosure and without, to the knowledge of the Receiving Party, breach of any
agreement between such Third Party and the Disclosing Party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on disclosure prior to
its receipt from the Disclosing Party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party without use of or reference
to the Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.16
</FONT><FONT STYLE="font-size: 10pt"><U>No Waiver; Cumulative Remedies; Enforcement</U>. No failure by any Lender or the Administrative
Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder or under any other
Loan Document shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder
preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies,
powers and privileges herein provided, and provided under each other Loan Document, are cumulative and not exclusive of any rights, remedies,
powers and privileges provided by Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under
the other Loan Documents against the Borrower and the Guarantors or any of them shall be vested exclusively in, and all actions and proceedings
at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance
with Section&nbsp;11.1 for the benefit of all the Lenders; <U>provided</U>, <U>however</U>, that the foregoing shall not prohibit (a)&nbsp;the
Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative
Agent) hereunder and under the other Loan Documents, (b)&nbsp;any Lender from exercising setoff rights in accordance with <U>Section&nbsp;4.5
</U>(subject to the terms of <U>Section&nbsp;4.4(e)</U>), or (c)&nbsp;any Lender from filing proofs of claim or appearing and filing
pleadings on its own behalf during the pendency of a proceeding relative to the Borrower or any Guarantor under any Debtor Relief Law
or any proceedings arising out of or in connection with an Insolvency Event; and provided, further, that if at any time there is no Person
acting as Administrative Agent hereunder and under the other Loan Documents, then (i)&nbsp;the Required Lenders shall have the rights
otherwise ascribed to the Administrative Agent pursuant to <U>Section&nbsp;11.1 </U>and (ii)&nbsp;in addition to the matters set forth
in <U>clauses (b)</U>&nbsp;and <U>(c)</U>&nbsp;of the preceding proviso and subject to <U>Section&nbsp;4.4(e)</U>, any Lender may, with
the consent of the Required Lenders, enforce any rights and remedies available to it </FONT><FONT STYLE="font-size: 10pt">and as authorized
by the Required Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.17
</FONT><FONT STYLE="font-size: 10pt"><U>Payments Set Aside</U>. To the extent that any payment by or on behalf of the Borrower or any
Guarantor is made to the Administrative Agent or any Lender, or the Administrative Agent or any Lender exercises its right of setoff,
and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential,
set aside or required (including pursuant to any settlement entered into by the Administrative Agent or such Lender in its discretion)
to be repaid to a trustee, receiver, receiver, manager, monitor or any other party, in connection with any proceeding under any Debtor
Relief Law, any proceedings arising out of or in connection with an Insolvency Event or otherwise, then (a)&nbsp;to the extent of such
recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such setoff had not occurred, and (b)&nbsp;each Lender severally agrees to pay to the Administrative
Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus
interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from
time to time in effect. The obligations of the Lenders under <U>clause (b)</U>&nbsp;of the preceding sentence shall survive the payment
in full of the Obligations and the termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.18
</FONT><FONT STYLE="font-size: 10pt"><U>Electronic Execution of Assignments and Certain Other Documents</U>. The words &ldquo;execute,&rdquo;
 &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature&rdquo; and words of like import in this Agreement, any Assignment and
Assumption or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures,
the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or
the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually
executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable
Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records
Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.19
</FONT><FONT STYLE="font-size: 10pt"><U>Independent Nature of Lenders</U>. The obligations of each Lender under this Agreement and each
of the other Loan Documents are several and not joint with the obligations of any other Lender, and no Lender shall be responsible in
any way for the performance of the obligations of any other Lender under this Agreement or any other Loan Document. Each Lender shall
be responsible only for its own representations, warranties, agreements and covenants hereunder and under the other Loan Documents. Nothing
contained in this Agreement or any other Loan Document, and no action taken by any Lender pursuant hereto or thereto, shall be deemed
to constitute the Lenders as, and the Borrower and the Guarantors acknowledge and agree that the Lenders do not thereby constitute, a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Lenders are in any way acting
in concert or as a group with respect to the Obligations or the transactions contemplated by this Agreement or any other Loan Document,
and the Borrower and the Guarantors shall not assert any contrary position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;10.20
</FONT><FONT STYLE="font-size: 10pt"><U>No Fiduciary Relationship</U>. Each of the Borrower and the Guarantors acknowledge and agree
that (a)&nbsp;each Lender is acting at arm&rsquo;s length from the Borrower and the Guarantors with respect to this Agreement and the
Borrower and the Guarantors and the transactions contemplated hereby and thereby; (b)&nbsp;no Lender will, solely by virtue of this Agreement
or any of the Loan Documents or any transaction contemplated hereby or thereby, become an Affiliate of, or have any agency, tenancy or
joint venture relationship with, any of the Borrower and the Guarantors; (c)&nbsp;no Lender has acted, or is or will be acting, as a
financial advisor to, or fiduciary (or in any similar capacity) of, or has any fiduciary or similar duty to, any of the Borrower and
the Guarantors with respect to, or in connection with, this Agreement and the other Loan Documents and the transactions contemplated
hereby and thereby, and each of the Borrower and the Guarantors agree not to assert, and hereby waives, any claim that any Lender has
any fiduciary duty to any of the Borrower and the Guarantors; (d)&nbsp;any advice given by a Lender or any of its representatives or
agents in connection with this Agreement and the other Loan Documents and the transactions contemplated hereby and thereby is merely
incidental to such Lender&rsquo;s performance of its obligations hereunder and thereunder; and (e)&nbsp;each of the Borrower&rsquo;s
and the Guarantors&rsquo; decision to enter into this Agreement and the other Loan Documents has been based solely on the independent
evaluation by the Borrower, the Guarantors and their representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE&nbsp;XI</FONT><FONT STYLE="font-size: 10pt"><BR>
ADMINISTRATIVE AGENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.1
</FONT><FONT STYLE="font-size: 10pt"><U>Appointment and Authority</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Lenders hereby irrevocably appoints Wilmington Trust, National Association, to act on its behalf as the Administrative Agent hereunder
and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers
as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are incidental
thereto. The provisions of this Article&nbsp;are solely for the benefit of the Administrative Agent and the Lenders, and neither the
Borrower nor any Guarantor shall have rights as a third party beneficiary of any of such provisions. It is understood and agreed that
the use of the term &ldquo;agent&rdquo; herein or in any other Loan Documents (or any other similar term) with reference to the Administrative
Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable
law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship
between contracting parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrative Agent shall also act as the &ldquo;collateral agent&rdquo; under the Loan Documents, and each of the Lenders hereby irrevocably
appoints and authorizes the Administrative Agent to act as the agent of such Lender for purposes of acquiring, holding and enforcing
any and all Liens on Collateral granted by any of the Borrower and the Guarantors to secure any of the Obligations, together with such
powers and discretion as are incidental thereto. In this connection, the Administrative Agent, as &ldquo;collateral agent&rdquo; (and
any co-agents, sub-agents and attorneys-in-fact appointed by the Administrative Agent pursuant to <U>Section&nbsp;11.5</U> for purposes
of holding or enforcing any Lien on the Collateral (or any portion thereof) granted under the Security Agreement, or for exercising any
rights and remedies thereunder at the direction of the Administrative Agent), shall be entitled to the benefits of all provisions of
<U>Article&nbsp;X</U> (including <U>Section&nbsp;10.4(c))</U>, as though such co-agents, sub-agents and attorneys-in-fact were the &ldquo;collateral
agent&rdquo; under the Loan Documents and this <U>Article&nbsp;XI</U> as if set forth in full herein with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Lenders authorizes the Administrative Agent to perform the duties, obligations and responsibilities and to exercise the rights,
powers, authorities and discretions specifically given to the Administrative Agent under or in connection with the Loan Documents together
with any other incidental rights, powers, authorities and discretions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the direction of the Required Lenders, the Administrative Agent is hereby authorized to enter into any usual and customary intercreditor
agreement and/or subordination agreement to the extent contemplated by the terms hereof, and the Lenders acknowledge that each such intercreditor
agreement and/or subordination agreement is binding upon them. Each Lender (a)&nbsp;hereby agrees that it will be bound by and will take
no actions contrary to the provisions of any such intercreditor agreement or subordination agreement and (b)&nbsp;in connection therewith
agrees that, to the extent contemplated thereby, the Liens on the Collateral may be subject to the provisions thereof. In addition, but
in conformance with the terms hereof, at the direction of the Required Lenders the Administrative Agent shall enter into (i)&nbsp;any
amendments to any intercreditor agreements or subordination agreements, as the case may be, and (ii)&nbsp;any other intercreditor arrangements,
in the case of clauses (i)&nbsp;and (ii), to the extent required to give effect to the establishment of intercreditor rights and privileges
as contemplated and required by of this Agreement. Each Lender waives any conflict of interest, now contemplated or arising hereafter,
in connection therewith and agrees not to assert against the Administrative Agent or any of its affiliates any claims, causes of action,
damages or liabilities of whatever kind or nature relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.2
</FONT><FONT STYLE="font-size: 10pt"><U>Rights as a Lender</U>. The Person serving as the Administrative Agent hereunder shall have the
same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative
Agent and the term &ldquo;Lender&rdquo; or &ldquo;Lenders&rdquo; shall, unless otherwise expressly indicated or unless the context otherwise
requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates
may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally
engage in any kind of business with the Borrower, any Guarantor or any Affiliate thereof as if such Person were not the Administrative
Agent hereunder and without any duty to account therefor to the Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.3
</FONT><FONT STYLE="font-size: 10pt"><U>Exculpatory Provisions</U>. The Administrative Agent shall not have any duties or obligations
except those expressly set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature.
Without limiting the generality of the foregoing, the Administrative Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shall
not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shall
not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly
contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the
Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents),
<U>provided</U> that the Administrative Agent shall not be required to take any action or to exercise any of the rights or powers vested
in it by this Agreement at the request or direction of the Lenders, pursuant to the provisions of this Agreement, unless such Lenders
shall have offered to the Administrative Agent security or indemnity (satisfactory to the Administrative Agent in its sole and absolute
discretion) against the costs, expenses and liabilities which may be incurred by it in compliance with such request or direction, or
that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan
Document or applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any
Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any
Debtor Relief Law; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shall
not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the
failure to disclose, any information relating to any Borrower and any of the Subsidiaries that is communicated to or obtained by the
Person serving as the Administrative Agent or any of its Affiliates in any capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrative Agent shall not be liable for any action taken or not taken by it (i)&nbsp;with the consent or at the request of the Required
Lenders or (ii)&nbsp;in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction
by final and non-appealable judgment. </FONT><FONT STYLE="font-size: 10pt">Subject to the proviso in <U>Section&nbsp;11.3(b)</U>, with
respect to any discretion, consent, approval or similar such action to be made, taken, omitted to be taken or determined by the Administrative
Agent hereunder or under any other Loan Document (each an &ldquo;<U>Agent Determination</U>&rdquo;), such Agent Determination shall be
made by the Administrative Agent at the written direction of the Required Lenders (or such other number or percentage of the Lenders
as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary under the circumstances). The Administrative
Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event
of Default is given in writing to the Administrative Agent by the Borrower, or a Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrative Agent shall have the right to request instructions from the Required Lenders or, as required, each of the Lenders (or
such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall
be necessary under the circumstances). If the Administrative Agent shall request instructions from the Required Lenders or each of the
Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good
faith shall be necessary under the circumstances), as the case may be, with respect to any act or action (including the failure to act)
in connection with this Agreement or any other Loan Document, the Administrative Agent shall be entitled to refrain from such act or
taking such action unless and until the Administrative Agent shall have received instructions from the Required Lenders or such other
number or percentage of the Lenders, as the case may be, and the Administrative Agent shall not incur any liability to any Person by
reason of so refraining. The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i)&nbsp;any
statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii)&nbsp;the contents
of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii)&nbsp;the
performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence
of any Default or Event of Default, (iv)&nbsp;the validity, enforceability, effectiveness or genuineness of this Agreement, any other
Loan Document or any other agreement, instrument or document or (v)&nbsp;the satisfaction of any condition set forth in <U>Article&nbsp;V
</U>or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent</FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Administrative Agent shall have no liability for any action taken, or errors in judgment made, in good faith by it or any of its officers,
employees or agents, unless it shall have been negligent in ascertaining the pertinent facts. The permissive rights of the Administrative
Agent to do things enumerated in this Agreement shall not be construed as a duty and, with respect to such permissive rights, the Administrative
Agent shall not be answerable in respect thereof other than for its gross negligence or willful misconduct. Nothing in this Agreement
shall require the Administrative Agent to expend or risk its own funds or otherwise incur any financial liability in the performance
of any of its duties or in the exercise of any of its rights or powers hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Neither
the Administrative Agent nor any of its directors, officers, employees, agents or affiliates shall be responsible for nor have any duty
to monitor the performance or any action of the Borrower or any Guarantor, or any of their directors, members, officers, agents, affiliates
or employee, nor shall it have any liability in connection with the malfeasance or nonfeasance by such party. The Administrative Agent
may assume performance by all such Persons of their respective obligations. The Administrative Agent shall have no enforcement or notification
obligations relating to breaches of representations or warranties of any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Administrative Agent shall not be responsible or liable for any failure or delay in the performance of its obligations under this Agreement
arising out of or caused, directly or indirectly, by circumstances beyond its control, including without limitation, any act or provision
of any present or future law or regulation or governmental authority; acts of God; earthquakes; fires; floods; wars; terrorism; civil
or military disturbances; sabotage; epidemics; riots; interruptions, loss or malfunctions of utilities, computer (hardware or software)
or communications service; accidents; labor disputes; acts of civil or military authority or governmental actions; or the unavailability
of the Federal Reserve Bank wire or telex or other wire or communication facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.4
</FONT><FONT STYLE="font-size: 10pt"><U>Reliance by the Administrative Agent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate,
consent, statement, instrument, document or other writing (including any electronic message,&nbsp;Internet or intranet website posting
or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The
Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper
Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of
a Loan, that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition
is satisfactory to such Lender unless the Administrative Agent shall have received notice to the contrary from such Lender prior to the
making of such Loan. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower or the Subsidiaries),
independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance
with the advice of any such counsel, accountants or experts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Reliance
by the Administrative Agent and Lenders</U>. The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices
(including telephonic or electronic loan notices) purportedly given by or on behalf of the Borrower or any of the Guarantors even if
(i)&nbsp;such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form
of notice specified herein, or (ii)&nbsp;the terms thereof, as understood by the recipient, varied from any confirmation thereof. The
Borrower and the Guarantors shall indemnify the Administrative Agent, each Lender and their respective partners, directors, officers,
employees, agents, trustees, administrators, managers, advisors and representatives from all losses, costs, expenses and liabilities
resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower or any Guarantor; <U>provided
</U>that such indemnity shall not, as to any Person be available to the extent that such losses, costs, expenses or liabilities are determined
by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct
of such Person. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative
Agent, and each of the parties hereto hereby consents to such recording.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.5
</FONT><FONT STYLE="font-size: 10pt"><U>Delegation of Duties</U>. The Administrative Agent may perform any and all of its duties and
exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative
Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or
through their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives.
The rights, benefits and privileges (including the exculpatory and indemnification provisions) of Article&nbsp;X and this Article&nbsp;XI
shall apply to any such sub-agent and to the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors
and representatives of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection
with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. The Administrative Agent
shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction
determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in
the selection of such sub-agents. Notwithstanding anything herein to the contrary, with respect to each sub-agent appointed by the Administrative
Agent, (i)&nbsp;such sub-agent shall be a third party beneficiary under this Agreement with respect to all such rights, benefits and
privileges (including exculpatory rights and rights to indemnification) and shall have all of the rights and benefits of a third party
beneficiary, including an independent right of action to enforce such rights, benefits and privileges (including exculpatory rights and
rights to indemnification) directly, without the consent or joinder of any other Person, against any or all of the Borrower, the Guarantors
and the Lenders, (ii)&nbsp;any modification to such rights, benefits and privileges (including exculpatory rights and rights to indemnification)
shall not be effective as against such sub-agent without its written consent thereto, and (iii)&nbsp;such sub-agent shall only have obligations
to the Administrative Agent and not to the Borrower or any Guarantor, Lender or any other Person and none of the Borrower, the Guarantors,
the Lenders or any other Person shall have any rights, directly or indirectly, as a third party beneficiary or otherwise, against such
subagent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.6
</FONT><FONT STYLE="font-size: 10pt"><U>Resignation or Removal of the Administrative Agent</U>. The Administrative Agent may resign as
the Administrative Agent at any time by giving thirty (30) days advance notice thereof to the Lenders and the Borrower and, thereafter,
the retiring Administrative Agent shall be discharged from its duties and obligations hereunder. Upon any such resignation, the Required
Lenders shall have the right to appoint a successor Administrative Agent. No less than thirty (30) days following the delivery of such
written notice, the Required Lenders shall have the right with the consent of the Borrower (such consent not to be unreasonably withheld,
conditioned or delayed; provided, that no consent of the Borrower shall be required if an Event of Default has occurred and is continuing)
to appoint a successor Administrative Agent, which shall be a bank with an office in the United States, or an Affiliate of any such bank
with an office in the United States, with whom the Lenders shall be dealing on an arm&rsquo;s length basis. Upon the acceptance of any
appointment as the Administrative Agent hereunder by a successor Administrative Agent, such successor Administrative Agent shall thereupon
succeed to and become vested with all rights, powers, privileges and duties of the retiring Administrative Agent. After any retiring
Administrative Agent&rsquo;s resignation hereunder as the Administrative Agent or upon a removal of the Administrative Agent upon the
written request of the Required Lenders, the provisions of this Section&nbsp;11.6 shall continue in effect for its benefit in respect
of any actions taken or omitted to be taken by it while it was acting as the Administrative Agent. If no successor has accepted appointment
as the Administrative Agent by the date which is thirty (30) days following delivery of written notice of resignation or removal, the
retiring Administrative Agent&rsquo;s resignation or removal shall nevertheless thereupon become effective and the Required Lenders shall
perform all of the duties of the Administrative Agent hereunder until such time, if any, as the Required Lenders appoint a successor
agent as provided for above. For the avoidance of doubt, in no event shall any such successor Administrative Agent be a Defaulting Lender
or Disqualified Institution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.7
</FONT><FONT STYLE="font-size: 10pt"><U>Non-Reliance on the Administrative Agent and Other Lenders</U>. Each Lender acknowledges that
it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their respective partners, directors,
officers, employees, agents, trustees, administrators, managers, advisors and representatives and based on such documents and information
as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that
it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their respective partners, directors,
officers, employees, agents, trustees, administrators, managers, advisors and representatives and based on such documents and information
as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon
this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.8
</FONT><FONT STYLE="font-size: 10pt"><U>Administrative Agent May&nbsp;File Proofs of Claim</U>. In case of the pendency of any receivership,
insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the
Borrower or any Guarantor, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable
as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on
the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations
that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders
and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders
and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent
under <U>Section&nbsp;10.4</U>) allowed in such judicial proceeding; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">and any custodian,
receiver, receiver-manager, monitor, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding
is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent
shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable
compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due
the Administrative Agent under <U>Section&nbsp;10.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
</FONT><FONT STYLE="font-size: 10pt">addition, the Lenders hereby irrevocably authorize the Administrative Agent, based upon the written
instruction of the Required Lenders, to (a)&nbsp;credit bid and in such manner purchase (either directly or through one or more acquisition
vehicles) all or any portion of the Collateral at any sale thereof conducted under the provisions of the Debtor Relief Laws, including
under Section&nbsp;363 of the Bankruptcy Code of the United States or any similar laws in any other jurisdictions to which the Borrower
or any Guarantor is subject, or (b)&nbsp;credit bid and in such manner purchase (either directly or through one or more acquisition vehicles)
all or any portion of the Collateral at any other sale or foreclosure conducted by (or with the consent or at the direction of) the Administrative
Agent (whether by judicial action or otherwise) in accordance with applicable Law. In connection with any such credit bid and purchase,
the Obligations owed to the Lenders shall be entitled to be, and shall be, credit bid on a ratable basis (with Obligations with respect
to contingent or unliquidated claims being estimated for such purpose if the fixing or liquidation thereof would not unduly delay the
ability of the Administrative Agent to credit bid and purchase at such sale or other disposition of the Collateral and, if such claims
cannot be estimated without unduly delaying the ability of the Administrative Agent to credit bid, then such claims shall be disregarded,
not credit bid, and not entitled to any interest in the asset or assets purchased by means of such credit bid) and the Lenders whose
Obligations are credit bid shall be entitled to receive interests (ratably based upon the proportion of their Obligations credit bid
in relation to the aggregate amount of Obligations so credit bid) in the asset or assets so purchased (or in the Capital Securities of
the acquisition vehicle or vehicles that are used to consummate such purchase). Except as provided above and otherwise expressly provided
for herein or in the other Loan Documents, the Administrative Agent will not execute or deliver a release of any Lien on any Collateral.
Upon request by the Administrative Agent at any time, the Lenders will confirm in writing the Administrative Agent&rsquo;s authority
to release any such Liens on particular types or items of Collateral pursuant to, and in accordance with, this Section. Each Secured
Party whose Obligations are credit bid under this Section&nbsp;shall be entitled to receive interests in the Collateral or any other
asset acquired in connection with such credit bid (or in the Capital Securities of the acquisition vehicle or vehicles that are used
to consummate such acquisition) on a ratable basis in accordance with the percentage obtained by dividing (y)&nbsp;the amount of Obligations
of such Secured Party that were credit bid in such credit bid by (z)&nbsp;the aggregate amount of all Obligations that were credit bid
in such credit bid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Nothing
contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any
Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to
authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.9
</FONT><FONT STYLE="font-size: 10pt"><U>Collateral and Guarantee Matters</U>. The Lenders irrevocably authorize the Administrative Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
release any Lien on any Collateral granted to or held by the Administrative Agent under any Loan Document (i)&nbsp;upon the Termination
Date, (ii)&nbsp;that is sold or otherwise disposed of to a Person that is not the Borrower or any Guarantor as part of or in connection
with any sale or other Disposition permitted hereunder and under the other Loan Documents or any Casualty Event, (iii)&nbsp;owned by
a Guarantor upon release of such Guarantor from its obligations under its Guarantee pursuant to <U>Section&nbsp;11.9(b)</U>&nbsp;or <U>(iv)</U>&nbsp;as
approved in accordance with <U>Section&nbsp;10.1</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
release any Guarantor from its obligations under the Guarantee (i)&nbsp;upon the Termination Date or (ii)&nbsp;if such Person ceases
to be a Subsidiary as a result of a transaction permitted under the Loan Documents; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
subordinate any Lien on any Collateral relating to customary &ldquo;ABL Priority Collateral&rdquo; related to accounts receivable in
connection with the entering into of an intercreditor agreement in relation to Permitted Receivables Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Upon
request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent&rsquo;s authority
to release its interest in particular types or items of property, or to release any Guarantor from its obligations under the Guarantee,
pursuant to this <U>Section&nbsp;11.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
the event that any Collateral shall be attached, garnished or levied upon by any court order, or the delivery thereof shall be stayed
or enjoined by an order of a court, or any order, judgment or decree shall be made or entered by any court order affecting the Collateral,
the Administrative Agent is hereby expressly authorized, in its sole discretion, to respond as it deems appropriate or to comply with
all writs, orders or decrees so entered or issued, or which it is advised by legal counsel of its own choosing is binding upon it, whether
with or without jurisdiction. In the event that the Administrative Agent obeys or complies with any such writ, order or decree it shall
not be liable to any of the Parties or to any other person, firm or corporation, should, by reason of such compliance notwithstanding,
such writ, order or decree be subsequently reversed, modified, annulled, set aside or vacated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrative Agent shall have no obligation to give, execute, deliver, file, record, authorize or obtain any financing statements,
notices, instruments, documents, agreements, consents or other papers as shall be necessary to (i)&nbsp;create, preserve, perfect or
validate any security interest granted to the Administrative Agent pursuant to the Loan Documents or (ii)&nbsp;enable the Administrative
Agent to exercise and enforce its rights under the Loan Documents with respect to any such pledge and security interest. </FONT><FONT STYLE="font-size: 10pt">The
Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding
the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent&rsquo;s Lien
thereon, or any certificate prepared by the Borrower or any Guarantor in connection therewith, nor shall the Administrative Agent be
responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION&nbsp;11.10
</FONT><FONT STYLE="font-size: 10pt"><U>Erroneous Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Administrative Agent notifies a Lender, or any Person who has received funds on behalf of a Lender (any such Lender or other recipient,
a &ldquo;<U>Payment Recipient</U>&rdquo;), that the Administrative Agent has determined in its sole discretion (whether or not after
receipt of any notice under immediately succeeding <U>clause (b)</U>) that any funds (as set forth in such notice from the Administrative
Agent) received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously or mistakenly transmitted
to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender or other Payment
Recipient on its behalf) (any such funds, whether transmitted or received as a payment, prepayment or repayment of principal, interest,
fees, distribution or otherwise, individually and collectively, an &ldquo;<U>Erroneous Payment</U>&rdquo;) and demands in writing the
return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative
Agent pending its return or repayment as contemplated below in this Section&nbsp;11.10 and shall be segregated by the Payment Recipient
and held in trust for the benefit of the Administrative Agent, and such Lender shall (or, with respect to any Payment Recipient who received
such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two Business Days thereafter, return
to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same
day funds (in the currency so received), together with interest thereon in respect of each day from and including the date such Erroneous
Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in
same day funds at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking
industry rules&nbsp;on interbank compensation from time to time in effect. A notice of the Administrative Agent to any Payment Recipient
under this <U>clause (a)</U>&nbsp;shall be conclusive, absent manifest error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting immediately preceding <U>clause (a)</U>, each Lender, or any Person who has received funds on behalf of a Lender, hereby further
agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest,
fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x)&nbsp;that is in a different amount than,
or on a different date from, that specified in this Agreement or in a notice of payment, prepayment or repayment sent by the Administrative
Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y)&nbsp;that was not preceded or accompanied
by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z)&nbsp;that such Lender,
or other such recipient, otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part), then in
each such case:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">it
                                            acknowledges and agrees that (A)&nbsp;in the case of immediately preceding clauses (x)&nbsp;or
                                            (y), an error or mistake shall be presumed to have been made (absent written confirmation
                                            from the Administrative Agent to the contrary) or (B)&nbsp;an error and mistake has been
                                            made (in the case of immediately preceding clause (z)), in each case, with respect to such
                                            payment, prepayment or repayment; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">such
                                            Lender shall (and shall cause any other recipient that receives funds on its respective behalf
                                            to) promptly (and, in all events, within one Business Day of its knowledge of the occurrence
                                            of any of the circumstances described in immediately preceding clauses (x), (y)&nbsp;and
                                            (z)) notify the Administrative Agent of its receipt of such payment, prepayment or repayment,
                                            the details thereof (in reasonable detail) and that it is so notifying the Administrative
                                            Agent pursuant to this <U>Section&nbsp;11.10(b)(ii)</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Lender hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under
any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender under any Loan Document with respect
to any payment of principal, interest, fees or other amounts, against any amount that the Administrative Agent has demanded to be returned
under immediately preceding clause (a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
parties hereto agree that (x)&nbsp;irrespective of whether the Administrative Agent may be equitably subrogated, in the event that an
Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion
thereof) for any reason, the Administrative Agent shall be subrogated to all the rights and interests of such Payment Recipient (and,
in the case of any Payment Recipient who has received funds on behalf of a Lender or Secured Party, to the rights and interests of such
Lender or Secured Party, as the case may be) under the Loan Documents with respect to such amount and (y)&nbsp;an Erroneous Payment shall
not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower or any Guarantor; <U>provided</U> that this
Section&nbsp;11.10 shall not be interpreted to increase (or accelerate the due date for), or have the effect of increasing (or accelerating
the due date for), the Obligations of the Borrower relative to the amount (and/or timing for payment) of the Obligations that would have
been payable had such Erroneous Payment not been made by the Administrative Agent; <U>provided</U>, <U>further</U>, that for the avoidance
of doubt, immediately preceding clauses (x)&nbsp;and (y)&nbsp;shall not apply to the extent any Erroneous Payment is, and solely with
respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower or
any Guarantor for the purpose of making such Erroneous Payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives,
and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim
by the Administrative Agent for the return of any Erroneous Payment received, including, without limitation, any defense based on &ldquo;discharge
for value&rdquo; or any similar doctrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
party&rsquo;s obligations, agreements and waivers under this <U>Section&nbsp;11.10</U> shall survive the resignation or replacement of
the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Commitments
and/or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>Signature Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the day and
year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC.<BR>
                    as the Borrower</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David D. Halbert</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&nbsp;&amp; Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>Signature
Page&nbsp;to Credit Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WILMINGTON TRUST, NATIONAL ASSOCIATION,<BR>
    as the Administrative Agent </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jessica A. Jankiewicz</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jessica A. Jankiewicz</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>Signature
Page&nbsp;to Credit Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">ORBIMED ROYALTY &amp; CREDIT OPPORTUNITIES III, LP,<BR>
    as a Lender</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By OrbiMed ROF
    III LLC,<BR>
    its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;By OrbiMed
    Advisors LLC,<BR>
    its Managing Member</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Matthew Rizzo</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Rizzo</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">ORBIMED ROYALTY &amp; CREDIT OPPORTUNITIES IV, LP,<BR>
    as a Lender</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By OrbiMed ROF IV LLC,<BR>
    its General Partner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By OrbiMed Advisors LLC,<BR>
    its Managing Member</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Matthew Rizzo</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Rizzo</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Signature
Page&nbsp;to Credit Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRAIDWELL TRANSACTION HOLDINGS LLC &ndash;
    <BR>
    SERIES 2, as a Lender</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 42%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braidwell LP</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its Investment Manager</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Manish K. Mital</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manish K. Mital</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer &amp; General Counsel</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Colin Bettison</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colin Bettison</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Finance &amp; Operations</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>Signature
Page&nbsp;to Credit Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
2.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Commitments
and Applicable Percentages</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
1 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
2.1 (Commitments and Applicable Percentages)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.7(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Litigation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
2 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.7(a) (Litigation)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 137 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.7(b)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Labor
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
3 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.7(b) (Labor Matters)<B>&nbsp;</B></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Existing
Subsidiaries&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
4 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.8 (Existing Subsidiaries)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.11</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Benefit
Plans; Etc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
5 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.11 (Benefit Plans, Etc.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 140 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.15(a)(1)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Intellectual
Property (Registrations and Applications)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
6 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.15(a)(1) (Intellectual Property (Registrations and Applications))</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.15(a)(2)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Intellectual
Property (In-Bound Licenses and Sub-Licenses)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
                                            7 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.15(a)(2) (Intellectual Property (Registration and Applications))</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.15(f)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proceedings
Challenging Owned Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
8 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.15(f) (Proceedings Challenging Ownwed Intellectual Property)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.15(g)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Validity
of Owned and Licensed Intellectual Property&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
9 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.15(g) (Validity of Owned and Licensed Intellectual Property)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.15(j)(1)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Infringement
Notices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
10 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.15(j)(1) (Infringement Notices)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.15(j)(2)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Infringement
of Third Party Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
11 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.15(j)(2) (Infringement of Third Party Intellectual Property)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Material
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
12 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.16 (Material Agreements)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.18(i)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Violation
of Fraud and Abuse Laws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
13 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.18(i) (Violations of Fraud and Abuse Laws)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.18(l)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Health
Program-Related Offenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
14 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.18(l) (Health Program-Related Offenses)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Transactions
with Permitted Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
15 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.19 (Transactions with Permitted Holders)<B>&nbsp;</B></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
6.22</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Deposit
and Disbursement Accounts&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
16 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.22 (Deposit and Disbursement Accounts)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Section
6.24(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>HIPAA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
17 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
6.24(d) (HIPAA)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
8.2(b)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Indebtedness
to be Paid</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
18 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
8.2(b) (Indebtedness to be Paid)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
8.2(c)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Existing
Indebtedness</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
19 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
8.2(c) (Existing Indebtedness)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
8.3(c)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Existing
Liens</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
20 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
8.3(c) (Existing Liens)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
8.5(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Investments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
21 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
8.5(a) (Existing Investments)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
8.10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Affiliate
Transactions</B><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
22 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
8.10 (Affiliate Transactions)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
8.11</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Restrictive
Agreements</B><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
23 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
8.11 (Restrictive Agreements)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Schedule
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Notice
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">Page
24 | Schedules to Credit Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><I>Schedule
10.2 (Notice Information)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&nbsp;A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FORM&nbsp;OF
PROMISSORY NOTE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Up to $[__] </FONT></TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">January 18, 2023</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">FOR
VALUE RECEIVED, CARIS LIFE SCIENCES,&nbsp;INC., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;), hereby promises to pay to the
order of [<I>name of lender</I>], a [__] (the &ldquo; <U>Lender</U>&rdquo;) on the Maturity Date or as otherwise required from time to
time in accordance with the terms of the Credit Agreement (as defined below) at the Administrative Agent&rsquo;s Office, the principal
sum of [__] DOLLARS ($[__]), or, if less, the aggregate unpaid principal amount of the Loans (and any continuation thereof) made (or,
without duplication, continued) by the Lender pursuant to the Credit Agreement, dated as of January&nbsp;18, 2023 (as amended, restated,
amended and restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among
the Borrower, the Lenders party thereto and Wilmington Trust, National Association, as the Administrative Agent. Unless otherwise defined
herein or the context otherwise requires, capitalized terms used in this Note have the meanings provided in the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
Borrower also promises to pay interest on the unpaid principal amount hereof from time to time outstanding from the date hereof until
maturity (whether by acceleration or otherwise) and, after maturity upon demand, until paid in full, at the rates per annum and on the
dates specified in the Credit Agreement, as well as any other amounts due at maturity to the Lender in respect of the Loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Pursuant
to, and in accordance with, Section&nbsp;3.2, Section&nbsp;3.4 and Section&nbsp;3.6 of the Credit Agreement, payments of both principal
and interest are to be made in U.S. Dollars in same day or immediately available funds to the Administrative Agent for the account of
the Lender at the Administrative Agent&rsquo;s Office in accordance with the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">This
Note is referred to in, and evidences Indebtedness incurred under, the Credit Agreement, to which reference is made for a description
of the security and guarantee for this Note and for a statement of the terms and conditions on which the Borrower is permitted and required
to make prepayments and repayments of the unpaid principal amount of the Indebtedness evidenced by this Note and on which such Indebtedness
may be declared to be immediately due and payable. Any prepaid principal of this Note may not be reborrowed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">All
parties hereto, whether as makers, endorsers or otherwise, severally waive presentment for payment, demand, protest and notice of dishonor
to the fullest extent possible in accordance with applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">THIS
NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR U.S. FEDERAL INCOME TAX PURPOSES. REQUESTS FOR INFORMATION REGARDING THE ISSUE
PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT,&nbsp;ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY&nbsp;BE DIRECTED TO THE
BORROWER CARE OF LUKE POWER, CORPORATE VICE PRESIDENT,&nbsp;INTERIM CHIEF FINANCIAL OFFICER AND TREASURER AT ### OR ###.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>THIS
NOTE HAS BEEN DELIVERED IN NEW YORK, NEW YORK, AND SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY, AND CONSTRUED IN ACCORDANCE
WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW
OF THE STATE OF NEW YORK).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 161; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES, INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;to Promissory Note</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&nbsp;B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FORM&nbsp;OF
LOAN REQUEST</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 357pt; text-align: right"><FONT STYLE="font-size: 10pt">__________
___, 20__</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Wilmington Trust, National Association</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">50 South Sixth Street, Suite&nbsp;1290</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Minneapolis, MN 55402</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attn: Caris Life Sciences Loan Administrator</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Email: ###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Telephone: ###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is hereby made to that certain Credit Agreement, [to be dated on or about]</FONT><FONT STYLE="font-size: 10pt"><SUP>1</SUP> [dated as
of]<SUP>2</SUP> January&nbsp;18, 2023 (as amended, supplemented or otherwise modified from time to time and in effect on the date hereof,
the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among Caris Life Sciences,&nbsp;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders party thereto and Wilmington Trust, National Association, as administrative agent (together with its Affiliates, successors,
transferees and assignees, the &ldquo;<U>Administrative Agent</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Unless
otherwise defined herein or the context otherwise requires, terms used herein have the meanings provided in the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the provisions of Section&nbsp;2.2 of the Credit Agreement, the Borrower hereby requests [the Initial] [a Delayed Draw] Loan of $_________</FONT><FONT STYLE="font-size: 10pt"><SUP>3
</SUP>to be made on ___________</FONT>__, 20__ (the &ldquo;<U>Proposed Disbursement Date</U>&rdquo;) in accordance with the bank account
details and wire transfer instructions for disbursement of the proceeds of the proposed Loans as set forth on <U>Schedule A </U>hereto,
which Loans shall be evidenced by those certain Promissory Notes dated as of [__], 2023 issued to the Lenders in the aggregate original
principal amount of up to $400,000,000.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">[The
undersigned hereby represents and warrants to the Administrative Agent, for the benefit of the Secured Parties, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;no
Default or Event of Default has occurred and is continuing or would result from the proposed Loans; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0pt"></TD><TD STYLE="font-size: 10pt; width: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Note:
                                            Use for the request for the Initial Loan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0pt"></TD><TD STYLE="font-size: 10pt; width: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Note:
                                            Use for the request of any Delayed Draw Loan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT><SUP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></SUP><FONT STYLE="font-size: 10pt">Note:
For the Initial Loan, requested amount shall not be less than the Initial Commitment Amount. For Delayed Draw Loans requested on the
First Delayed Draw Closing Date, requested amount shall not be less than $100,000,000 (and integral multiples of $50,000,000 in excess
thereof). For Delayed Draw Loans requested on the Second Delayed Draw Closing Date, requested amount shall not be less than the remaining
Delayed Draw Commitment Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;the
representations and warranties contained in Article&nbsp;VI of the Credit Agreement and in the other Loan Documents are true and correct
in all material respects (except with respect to any representation or warranty qualified by materiality or Material Adverse Effect,
each of which representation or warranty is true and correct in all respects), before and after giving effect to the making of the proposed
Loan and to the application of the proceeds thereof, as though made on and as of the date hereof, except to the extent that they relate
specifically to an earlier specified date, in which case they are true and correct in all material respects (except to the extent that
they relate specifically to an earlier specified date, in which case they are true and correct in all material respects (except with
respect to any representation or warranty qualified by materiality or Material Adverse Effect, each of which representation or warranty
is true and correct in all respects) on and as of such earlier date).]</FONT><FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
officer signing below is an Authorized Officer of the Borrower and is authorized to request the Loans contemplated hereby and issue this
Loan Request on behalf of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4
</SUP></FONT><FONT STYLE="font-size: 10pt">Note: Include for the request for any Delayed Draw Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 164; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES, INC.,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">as the Borrower</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;to Loan Request</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Schedule
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Disbursement
/ Wire Instructions</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&nbsp;C</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FORM&nbsp;OF
COMPLIANCE CERTIFICATE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">CARIS
LIFE SCIENCES,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">COMPUTATION
DATE: _____________ __, 20__</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Compliance Certificate (this &ldquo;<U>Certificate</U>&rdquo;) is delivered pursuant to [Section&nbsp;5.7]</FONT><FONT STYLE="font-size: 10pt"><SUP>1
</SUP>[Section&nbsp;7.1(d)]<SUP>2</SUP> of the Credit Agreement, dated as of January&nbsp;18, 2023 (the &ldquo;<U>Credit Agreement</U>&rdquo;),
by and among Caris Life Sciences,&nbsp;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;), the Lenders party thereto and Wilmington
Trust, National Association, as administrative agent (together with its Affiliates, successors, transferees and assignees, the &ldquo;<U>Administrative
Agent</U>&rdquo;). Unless otherwise defined herein or the context otherwise requires, terms used in this Certificate have the meanings
provided in the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This Certificate relates to the [Fiscal
Quarter] [Fiscal Year] commencing on _____________, 20__ and ending on ____________ __, 20__ (such latter date being the &ldquo;<U>Computation
Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
undersigned, the chief financial or accounting Authorized Officer of the Borrower, is duly authorized to execute and deliver this Certificate
on behalf of the Borrower. By executing this Certificate, the undersigned hereby certifies to the Administrative Agent and each Lender
that as of the Computation Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;[Attached
hereto as <U>Annex I</U> are (i)&nbsp;an unaudited consolidated balance sheet of the Borrower and the Subsidiaries as of the end of such
Fiscal Quarter and related consolidated statements of income, stockholders&rsquo; equity and cash flows of the Borrower and the Subsidiaries
for such Fiscal Quarter and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Quarter,
including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year
and (ii)&nbsp;a report of the Revenue Base for such Fiscal Quarter and for the twelve-month period ending with the end of such Fiscal
Quarter and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding
Fiscal Year and the corresponding twelve-month period immediately preceding such twelve-month period (subject to normal year-end audit
adjustments and the absence of footnotes).]</FONT><FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt; width: 1%"><FONT STYLE="font-size: 9pt"><SUP>1</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 99%"><FONT STYLE="font-size: 10pt">Use for the delivery on the Closing Date.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt"><FONT STYLE="font-size: 9pt"><SUP>2</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Use for the delivery after the Closing Date.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt"><FONT STYLE="font-size: 9pt"><SUP>3</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Use for the delivery of quarterly financial statements.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Attached
hereto as <U>Annex I</U> are (i)&nbsp;the consolidated balance sheet of the Borrower and the Subsidiaries and the related consolidated
statements of income, stockholders&rsquo; equity and cash flows of the Borrower and the Subsidiaries for such Fiscal Year, setting forth
in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by independent
public accountants acceptable to the Required Lenders (it being understood that Ernst&nbsp;&amp; Young LLP or any other &ldquo;Big Four&rdquo;
accounting firm are reasonably acceptable to the Required Lenders)</FONT><FONT STYLE="font-size: 10pt">; and (ii)&nbsp;a report of the
Revenue Base for the Fiscal Quarter then ending and such Fiscal Year and including in comparative form the figures for the corresponding
Fiscal Quarter in the immediately preceding Fiscal Year and the immediately preceding Fiscal Year.]<SUP>4</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements or reports, as applicable, delivered with this Certificate in accordance with [Section&nbsp;7.1(b)]<SUP>5</SUP>
[Section&nbsp;7.1(c)]<SUP>6</SUP> of the Credit Agreement have been prepared in accordance with GAAP, consistently applied, and present
fairly in all material aspects the consolidated financial condition of the Borrower and the Subsidiaries and the results of operations
[(subject to normal year-end audit adjustments and the absence of footnotes in the case of unaudited financial statements)]<SUP>7</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
such [Fiscal Quarter] [Fiscal Year] and as of the Computation Date, the Borrower and the Subsidiaries have at all times been in compliance
in all respects with the financial covenant set forth in Section&nbsp;8.4(a)&nbsp;of the Credit Agreement. As of the Computation Date
(for the applicable Test Period ending on such Computation Date), the Borrower and the Subsidiaries are in compliance in all respects
with the financial covenant set forth in Section&nbsp;8.4(b)&nbsp;of the Credit Agreement. Set forth on <U>Attachment 1</U> hereto are
calculations showing compliance with the financial covenant set forth in Section&nbsp;8.4(a)&nbsp;of the Credit Agreement as of the Computation
Date. Set forth on <U>Attachment 2</U> hereto are calculations showing compliance with the financial covenant set forth in Section&nbsp;8.4(b)&nbsp;as
of the Computation Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Default has occurred and is continuing [except as set forth on <U>Attachment 3</U> hereto, which includes a description of the nature
and period of existence of such Default and what action the Borrower or any of the Subsidiaries has taken, is taking or proposes to take
with respect thereto].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
to the date of the most recent Compliance Certificate submitted by the undersigned pursuant to Section&nbsp;7.1(d)&nbsp;of the Credit
Agreement prior to the date hereof, neither the Borrower nor any Subsidiary has formed or acquired any new Subsidiary [except as set
forth on <U>Attachment 4</U> hereto, in which case such new Subsidiary has complied with the requirements of Section&nbsp;7.8 of the
Credit Agreement to the extent required thereunder].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
to the date of the most recent Compliance Certificate submitted by the undersigned pursuant to Section&nbsp;7.1(d)&nbsp;of the Credit
Agreement prior to the date hereof, neither the Borrower nor any Subsidiary has acquired any Material Real Property [except as set forth
on <U>Attachment 5</U> hereto, in which case the Loan Parties have complied with the requirements of Section&nbsp;7.8 of the Credit Agreement
with respect to such real property, to the extent required thereunder].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt; width: 6pt"><FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Use for the delivery of annual financial statements.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>5</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Use for the delivery of quarterly financial statements.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>6</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Use for the delivery of annual financial statements.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="vertical-align: super; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>7</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Include for the delivery of quarterly financial statements.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 168 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Attached
hereto as <U>Attachment 6</U> is a report listing all published applications for the registration of any Intellectual Property with the
United States Patent and Trademark Office filed during such Fiscal Quarter.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Attached
hereto as <U>Attachment 7</U> [is] [are (x)] a list of each Material Agreement in effect on the last day of such Fiscal Quarter [and
(y)] a copy of the &ldquo;Payer Revenue Per Case&rdquo; file [dated as of a date not later than the last day] of such Fiscal Quarter.<SUP>8</SUP>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>8
</SUP></FONT><FONT STYLE="font-size: 10pt">Include only, (x)&nbsp;as applicable, prior to the consummation of a Direct Listing, Qualified
IPO or Qualified SPAC Transaction and (y)&nbsp;with the delivery of any quarterly financial statements required pursuant to Section&nbsp;7.1(b)&nbsp;of
the Credit Agreement (solely with respect to the Fiscal Quarter ending June&nbsp;30 and December&nbsp;31 of each Fiscal Year).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 169 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the undersigned has caused this Certificate to be executed and delivered, and the certification and warranties contained
herein to be made, by its chief financial or accounting Authorized Officer as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES, INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;to Compliance Certificate</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 170 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Annex
I</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Quarterly
or Annual Deliverables]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 171 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; width: 83%; padding-left: 200pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Attachment
    1</U></B></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 15%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 200pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 113pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Covenant (Minimum Liquidity) Calculation</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.4(a)&nbsp;- Liquidity (as of the
    Computation Date)</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.1 Unrestricted cash-on-hand
    of the Borrower and the Guarantors in a</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled Account (subject
    to Section&nbsp;7.15) located in the United</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">States</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 4pt"></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.2 Cash Equivalent Investments
    of the Borrower and the Guarantors</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in a Controlled Account
    (subject to Section&nbsp;7.15) located in the United</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">States</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-left: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Liquidity Amount (A.1
    + A.2)</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-left: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable Liquidity Requirement</FONT><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-left: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compliance</I></B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[Yes/No]</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT><FONT STYLE="font-size: 10pt">The Liquidity of the Borrower shall not at any time be less than $20,000,000; <U>provided
</U>that if the Borrower redeems or repurchases for cash all or any portion of the Series&nbsp;C Preferred Stock or the Series&nbsp;D
Preferred Stock (except for any redemption or repurchase made using the proceeds of an issuance of Capital Securities, so long as such
proceeds are escrowed solely for the purpose of effectuating such repurchase or redemption of Series&nbsp;C Preferred Stock or Series&nbsp;D
Preferred Stock or such issuance is consummated substantially concurrently with such repurchase or redemption), from and after the date
of such repurchase or redemption, the Liquidity of the Borrower shall not at any time be less than the outstanding principal amount of
the Loans at such time (as such amount may be decreased from time to time); <U>provided</U>, <U>further</U>, that if all of the outstanding
Series&nbsp;C Preferred Stock and Series&nbsp;D Preferred Stock are converted into common stock of the Borrower following the occurrence
of a Qualified Direct Listing Event or the consummation of a Qualified IPO or a Qualified SPAC Transaction, the Liquidity of the Borrower
shall not at any time be less than $20,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 172 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Attachment
2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Financial
Covenant (Minimum Revenue Base) Calculation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;8.4(b)&nbsp;&ndash;
Revenue Base (as of the Computation Date)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 83%"><FONT STYLE="font-size: 10pt">Revenue Base is calculated as follows:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 17%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0.375in"><FONT STYLE="font-size: 10pt">total consolidated revenue of the Borrower and its Subsidiaries,
    as determined in accordance with GAAP, for the Test Period ending on the Computation Date;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Applicable Minimum Revenue Base requirement:<SUP>1</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B><I>Compliance</I></B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B><I>[Yes/No]</I></B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT><FONT STYLE="font-size: 10pt">Subject to Section&nbsp;9.4 of the Credit Agreement, the Revenue Base for the last day of
a Test Period shall not be less than (i)&nbsp;prior to the First Delayed Draw Closing Date, the amount set forth in the second column
below for the Test Period ending on such applicable date and (ii)&nbsp;on and after the occurrence of the First Delayed Draw Closing
Date, the amount set forth in the third column below for the Test Period ending on such applicable date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Prior to the First Delayed Draw</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">If the First Delayed Draw Closing Date</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Closing Date &ndash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">has occurred&ndash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt">Test Period Ending</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Minimum Revenue Base</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Minimum Revenue Base</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31, 2022</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">200,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">270,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31, 2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">202,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">272,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">205,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30, 2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">207,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31, 2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">210,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">212,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">215,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">280,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">217,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">285,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">220,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">290,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">222,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">295,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">225,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">300,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">227,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">305,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31, 2025</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">230,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">312,500,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31, 2026</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">232,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">320,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2026</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">235,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">327,500,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30, 2026</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">237,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">335,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31, 2026</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">240,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">342,500,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31, 2027</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">242,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">350,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;30, 2027</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">245,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">357,500,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30, 2027</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">247,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">365,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;31, 2027</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">372,500,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 173 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Attachment
3</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Description
of Default] [Intentionally omitted.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 174 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Attachment
4</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Formation
or Acquisition of New Subsidiaries] [Intentionally omitted.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 175 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Attachment
5</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Material
Real Property] [Intentionally omitted.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 176 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Attachment
6</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Intellectual
Property] [Intentionally omitted.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 177 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>Attachment
7</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Material
Agreements and &ldquo;Payer Revenue Per Case&rdquo; File] [Intentionally omitted.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 178 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&nbsp;D</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FORM&nbsp;OF
GUARANTEE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
GUARANTEE, dated as of January&nbsp;18, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time
to time, this &ldquo;<U>Guarantee</U>&rdquo;), is made by the entities listed on <U>Schedule I</U> hereto (together with any additional
Persons named pursuant to <U>Section&nbsp;5.5 </U>below, each, a &ldquo;<U>Guarantor</U>&rdquo;, and collectively, the &ldquo;<U>Guarantors</U>&rdquo;),
in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, as administrative agent (together with its successors, transferees and assignees,
in such capacity, the &ldquo;<U>Administrative Agent</U>&rdquo;), for the benefit of itself and the other Secured Parties (as defined
below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>W
I T N E S S E T H:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement, dated as of January&nbsp;18, 2023 (as amended, restated, amended and restated, supplemented or otherwise
modified from time to time, the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among CARIS LIFE SCIENCES,&nbsp;INC., a Texas corporation
(the &ldquo;<U>Borrower</U>&rdquo;), the Lenders party thereto and the Administrative Agent, the Lenders have extended Commitments to
make Loans to the Borrower from time to time; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
as a condition precedent to the making of the Loans and in order to induce the Lenders to make or continue to make, as the case may be,
the Loans under the Credit Agreement, the Guarantors are required to execute and deliver this Guarantee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in order to induce
the Lenders to make the Loans to the Borrower, each Guarantor hereby agrees, for the benefit of the Secured Parties, as follows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;1.1.
<U>Certain Terms</U>. The following terms (whether or not underscored) when used in this Guarantee, including its preamble and recitals,
shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Administrative Agent</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Borrower</U>&rdquo;
is defined in the <U>first recital</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Credit Agreement</U>&rdquo;
is defined in the <U>first recital</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Guarantee</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Guarantor</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Obligor</U>&rdquo;
means the Borrower and the Guarantors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 179 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;1.2.
<U>Credit Agreement Definitions</U>. Unless otherwise defined herein or the context otherwise requires, terms used in this Guarantee,
including its preamble and recitals, have the meanings provided in the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">GUARANTEE
PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.1.
<U>Guarantee</U>. Subject to the limitations expressly set forth herein, each Guarantor jointly and severally, absolutely, unconditionally
and irrevocably guarantees the full and punctual payment when due, whether at stated maturity, by required prepayment, declaration, acceleration,
demand or otherwise, and performance of all Obligations of the Borrower and each Guarantor now or hereafter existing, whether for principal,
interest (including interest accruing at the then applicable Default rate as provided in Section&nbsp;3.5 of the Credit Agreement, whether
or not a claim for post-filing or post-petition interest is allowed under applicable Law following the institution of a proceeding under
bankruptcy, insolvency or similar Laws), fees, expenses or otherwise (including all such amounts which would become due but for the operation
of the automatic stay under Section&nbsp;362(a)&nbsp;of the United States Bankruptcy Code, 11 U.S.C. &sect;362(a), and the operation
of Sections 502(b)&nbsp;and 506(b)&nbsp;of the United States Bankruptcy Code, 11 U.S.C. &sect;502(b)&nbsp;and &sect;506(b)) (the &ldquo;
<U>Guaranteed Obligations</U>&rdquo;); <U>provided</U> that each Guarantor shall only be liable under this Guarantee for the maximum
amount of such liability (after giving effect to any indemnification, contribution or similar rights) that can be hereby incurred without
rendering this Guarantee, as it relates to such Guarantor, voidable under applicable Law relating to fraudulent conveyance or fraudulent
transfer, and not for any greater amount. This Guarantee constitutes a guarantee of payment when due and not of collection, and each
Guarantor specifically agrees that it shall not be necessary or required that the Administrative Agent for the benefit of itself and
the other Secured Parties exercise any right, assert any claim or demand or enforce any remedy whatsoever against such Guarantor or any
other Person before or as a condition to the obligations of such Guarantor becoming due hereunder. Section&nbsp;10.4 of the Credit Agreement
is hereby incorporated by reference with respect to each Guarantor <I>mutatis mutandis</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.2.
<U>Reinstatement, Etc</U>. Each Guarantor agrees that this Guarantee shall continue to be effective or be reinstated (including on or
after the Termination Date), as the case may be, if at any time any payment (in whole or in part) of any of the Guaranteed Obligations
is invalidated, declared to be fraudulent or preferential, set aside, rescinded or must otherwise be restored by any Secured Party, including
upon the occurrence of any Event of Default set forth in Section&nbsp;9.1(h)&nbsp;of the Credit Agreement or otherwise, all as though
such payment had not been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.3.
<U>Guarantee Absolute, Etc</U>. Subject to the limitations expressly set forth herein, this Guarantee shall in all respects be a continuing,
absolute, unconditional and irrevocable guarantee of payment, and shall remain in full force and effect until (unless reinstated pursuant
to <U>Section&nbsp;2.2 </U>above) the payment in full in cash in immediately available funds of the Guaranteed Obligations or, with respect
to the Guarantee of any Guarantor, the release of such Guarantor in accordance with <U>Section&nbsp;5.14</U> hereof. Subject to the
limitations expressly set forth herein, the liability of each Guarantor under this Guarantee shall, to the fullest extent possible in
accordance with applicable Law, be absolute, unconditional and irrevocable irrespective of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 180; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> <FONT STYLE="font-size: 10pt">(a)</FONT> <FONT STYLE="font-size: 10pt">any lack of validity, legality or enforceability of any Loan Document;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
the failure of any Secured Party (i)&nbsp;to assert any claim or demand or to enforce</FONT> any right or remedy against such
Guarantor or any other Person (including any other guarantor) under the provisions of any Loan Document or otherwise, or
(ii)&nbsp;to exercise any right or remedy against any other guarantor (including such Guarantor and any other Guarantor) of, or
collateral securing, any Guaranteed Obligations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;any
change in the time, manner or place of payment of, or in any other term of, all or any part of the Guaranteed Obligations, or any other
extension, compromise or renewal of any Guaranteed Obligation, or any amendment to, rescission, waiver, or other modification of, or
any consent to or departure from, any of the terms of any Loan Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;any
reduction, limitation, impairment or termination of any Guaranteed Obligations for any reason, including any claim of waiver, release,
surrender, alteration or compromise, and shall not be subject to (and, to the fullest extent possible in accordance with applicable Law,
each Guarantor hereby waives any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason
of the invalidity, illegality, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Guaranteed
Obligations or otherwise (other than, in each case, a defense of payment in full in cash of the Guaranteed Obligations);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&nbsp;any
addition, exchange or release of any collateral or of any Person that is (or will become) a guarantor of the Guaranteed Obligations,
or any surrender or non-perfection of any collateral, or any amendment to, or waiver or release of, or addition to, or consent to or
departure from, any other guarantee held by the Secured Parties securing any of the Guaranteed Obligations; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&nbsp;any
other circumstance which might otherwise constitute a defense available to, or a legal or equitable discharge of, any Obligor, any surety
or any guarantor (including any Guarantor) (other than the defense of payment in full of cash).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.4.
<U>Setoff</U>. Each Guarantor hereby irrevocably authorizes the Administrative Agent on behalf of the Secured Parties, without the requirement
that any notice be given to such Guarantor (such notice being expressly waived by such Guarantor, to the extent permitted by applicable
Law), upon the occurrence and solely during the continuance of any Event of Default, to appropriate and apply to the payment of the Guaranteed
Obligations owing to it (whether or not then due), any and all balances, credits, deposits, accounts or moneys of such Guarantor then
or thereafter maintained with or on behalf of any Secured Party. By acceptance of this Guarantee, the Administrative Agent agrees to
notify such Guarantor after any such set-off and application made by the Administrative Agent on behalf of such Secured Party; <U>provided
</U>that the failure to give such notice shall not affect the validity of such setoff and application. The rights of the Secured Parties
under this <U>Section&nbsp;2.4</U> are in addition to other rights and remedies (including other rights of setoff under applicable Law
or otherwise) which the Secured Parties may have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.5.
<U>Waiver, Etc</U>. To the extent permitted by applicable Law, each Guarantor waives promptness, diligence, notice of acceptance and
any other notice with respect to any of the Guaranteed Obligations and this Guarantee and any requirement that the Secured Parties protect,
secure, perfect or insure any Lien, or any property subject thereto, or exhaust any right or take any action against any Obligor or any
other Person (including any Guarantor) or entity or any collateral securing the Guaranteed Obligations, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 181; Options: NewSection; Value: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.6.
<U>Postponement of Subrogation, Etc</U>. Each Guarantor agrees that it will not exercise any rights which it may acquire by way of rights
of subrogation under any Loan Document to which it is a party, nor shall such Guarantor seek or be entitled to seek any contribution
or reimbursement from the Borrower or any other Obligor, in respect of any payment made under any Loan Document or otherwise, until following
the payment in full in cash in immediately available funds of the Guaranteed Obligations. Any amount paid to such Guarantor on account
of any such subrogation rights prior to the payment in full in cash in immediately available funds of the Guaranteed Obligations shall
be held in trust for the benefit of the Secured Parties and shall immediately be paid and turned over to the Administrative Agent, for
the benefit of itself and the other Secured Parties, in the exact form received by such Guarantor (duly endorsed in favor of the Administrative
Agent, if required), to be credited and applied against the Guaranteed Obligations, whether matured or unmatured, in accordance with
<U>Section&nbsp;2.7</U>; <U>provided</U> that, if such Guarantor has made payment to the Administrative Agent of all or any part of the
Guaranteed Obligations and the Guaranteed Obligations have been paid in full in cash in immediately available funds, then, at such Guarantor&rsquo;s
request, the Administrative Agent will, at the expense of such Guarantor, execute and deliver to such Guarantor appropriate documents
(without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Guarantor of an interest
in the Guaranteed Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the payment in full
in cash in immediately available funds of the Guaranteed Obligations, such Guarantor shall refrain from taking any action or commencing
any proceeding against the Borrower or any other Obligor or Guarantor (or their successors or assigns, whether in connection with a bankruptcy
proceeding or otherwise) to recover any amounts in respect of payments made under this Guarantee to the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.7.
<U>Payments; Application</U>. Each Guarantor agrees that all obligations of such Guarantor hereunder shall be paid solely in U.S. Dollars
to the Administrative Agent for the benefit of itself and the other Secured Parties in immediately available funds, without set-off,
counterclaim or other defense and applied in accordance with the Credit Agreement, including Article&nbsp;III, Article&nbsp;IV and Article&nbsp;X
thereof, free and clear of and without deduction for any Taxes unless required by applicable Law and subject to the obligation to pay
additional amounts in accordance with Section&nbsp;4.3 of the Credit Agreement, such Guarantor hereby agreeing to comply with and be
bound by the provisions of the Credit Agreement, including Article&nbsp;III, Article&nbsp;IV and Article&nbsp;X thereof, in respect of
all payments and application of such payments made by it hereunder and the provisions of which Articles and Sections are hereby incorporated
into and made a part of this Guarantee by this reference as if set forth herein; <U>provided</U> that references to the &ldquo;Borrower&rdquo;
in such Articles and Sections shall be deemed to be references to such Guarantor, and references to &ldquo;this Agreement&rdquo; in such
Articles and Sections shall be deemed to be references to this Guarantee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 182; Options: NewSection; Value: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">REPRESENTATIONS
AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
order to induce the Secured Parties to enter into the Credit Agreement and make the Loans thereunder, each Guarantor represents and warrants
to the Administrative Agent, for the benefit of itself and the other Secured Parties, as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.1.
<U>Credit Agreement Representations and Warranties</U>. The representations and warranties contained in Article&nbsp;VI of the Credit
Agreement, insofar as the representations and warranties contained therein are applicable to such Guarantor and its properties, are true
and correct in all material respects, except for any representation and warranty that is qualified by materiality or reference to Material
Adverse Effect, which such representation and warranty shall be true and correct in all respects (except in the case of any representation
and warranty which expressly relates to a given date or period, which representation and warranty was true and correct in all material
respects (and in all respects if qualified by materiality or reference to Material Adverse Effect)) as of the Closing Date, with each
such representation and warranty set forth in Article&nbsp;VI of the Credit Agreement (insofar as applicable as aforesaid) and all other
terms of the Credit Agreement to which reference is made therein, together with all related definitions and ancillary provisions, being
hereby incorporated into this Guarantee by this reference as though specifically set forth in this <U>Article&nbsp;III</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.2.
<U>Financial Condition, Etc</U>. Each Guarantor has knowledge of the Borrower&rsquo;s and each other Guarantor&rsquo;s financial condition
and affairs and has adequate means to obtain from each such Person on an ongoing basis information relating thereto and to each such
Person&rsquo;s ability to pay and perform the Guaranteed Obligations. Each Guarantor acknowledges and agrees that the Secured Parties
shall have no obligation to investigate the financial condition or affairs of the Borrower or any other Guarantor for the benefit of
such Guarantor nor to advise such Guarantor of any fact respecting, or any change in, the financial condition or affairs of each such
Person that might become known to the Secured Parties at any time, whether or not the Secured Parties know or believe or have reason
to know or believe that any such fact or change is unknown to such Guarantor, or might (or does) materially increase the risk of such
Guarantor as guarantor, or might (or would) affect the willingness of such Guarantor to continue as a guarantor of the Guaranteed Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.3.
<U>Best Interests</U>. It is in the best interests of each Guarantor to execute this Guarantee inasmuch as each Guarantor will, as a
result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by
the Lenders pursuant to the Credit Agreement, and each Guarantor agrees that the Lenders are relying on this representation in agreeing
to make the Loans to the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 183; Options: NewSection; Value: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">COVENANTS,&nbsp;ETC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.
<U>Covenants</U>. Each Guarantor covenants and agrees that, at all times prior to the earlier of (x)&nbsp;the release of such Guarantor
in accordance with <U>Section&nbsp;5.14</U> hereof and (y)&nbsp;the payment in full in cash in immediately available funds of the Guaranteed
Obligations, it will perform, comply with and be bound by all of the agreements, covenants and obligations contained in the Credit Agreement
(including Articles VII and VIII of the Credit Agreement) which are applicable to such Guarantor or its properties, and each such agreement,
covenant and obligation contained in the Credit Agreement and all other terms of the Credit Agreement to which reference is made in this
<U>Article&nbsp;IV</U>, together with all related definitions and ancillary provisions, is hereby incorporated into this Guarantee by
this reference as though specifically set forth in this <U>Article&nbsp;IV</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.2.
<U>Contribution and Subrogation</U>. Each Guarantor (a &ldquo;Contributing Guarantor&rdquo;) agrees (subject to the <U>Section&nbsp;4.3</U>)
that, in the event a payment shall be made by any other Guarantor hereunder in respect of any Guaranteed Obligation, or assets of any
other Guarantor shall be sold pursuant to the Security Agreement or any other security document to satisfy any Guaranteed Obligation
owed to any Secured Party, and such other Guarantor (the &ldquo;Claiming Guarantor&rdquo;) shall not have been fully indemnified by the
Borrower, the Contributing Guarantor shall indemnify the Claiming Guarantor in an amount equal to (i)&nbsp;the amount of such payment
or (ii)&nbsp;the greater of the book value or the fair market value of such assets, as the case may be, in each case multiplied by a
fraction of which the numerator shall be the net worth of the Contributing Guarantor on the date hereof and the denominator shall be
the aggregate net worth of all the Guarantors now or hereafter existing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.3.
<U>Subordination</U>. (a)&nbsp;Notwithstanding any provision of this Agreement to the contrary, all rights of the Guarantors under <U>Sections
4.2</U> and all other rights of indemnity, contribution or subrogation under applicable law or otherwise shall be fully subordinated
to the indefeasible payment in full in cash of the Guaranteed Obligations. No failure on the part of the Borrower or any Guarantor to
make the payments required by <U>Section&nbsp;4.2</U> (or any other payments required under applicable law or otherwise) shall in any
respect limit the obligations and liabilities of any Guarantor with respect to its obligations hereunder, and each Guarantor shall remain
liable for the full amount of its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;V</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">MISCELLANEOUS
PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.1.
<U>Loan Document</U>. This Guarantee is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly
indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Section&nbsp;1.5
and Article&nbsp;X thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.2.
<U>Binding on Successors, Transferees and Assigns; Assignment</U>. This Guarantee shall (a)&nbsp;remain in full force and effect until
the payment in full in cash in immediately available funds of the Guaranteed Obligations or, with respect to a Guarantor, the release
of such Guarantor in accordance with <U>Section&nbsp;5.14</U> hereof, (b)&nbsp;be binding upon each Guarantor and its successors, transferees
and assigns and (c)&nbsp;inure to the benefit of and be enforceable by the Secured Parties; <U>provided</U> that such Guarantor may not
(unless otherwise permitted under the terms of the Credit Agreement) assign any of its obligations hereunder unless expressly permitted
by the Credit Agreement or with such consents required by Section&nbsp;10.1 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 184 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.3.
<U>Amendments, Etc</U>. No amendment to or waiver of any provision of this Guarantee, nor consent to any departure by any Guarantor from
its obligations under this Guarantee, shall in any event be effective except in accordance with Section&nbsp;10.1 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.4.
<U>Notices; Agency of Borrower for Guarantors</U>. All notices and other communications provided for hereunder shall be given or made
as set forth in Section&nbsp;10.2 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.5.
<U>Additional Guarantors</U>. Upon the execution and delivery by any other Person of a supplement in the form of <U>Annex I</U> hereto,
such Person shall become a &ldquo;Guarantor&rdquo; hereunder as of the date of such supplement with the same force and effect as if it
were originally a party to this Guarantee and named as a &ldquo;Guarantor&rdquo; hereunder. The execution and delivery of such supplement
shall not require the consent of any other Guarantor hereunder, and the rights and obligations of each Guarantor hereunder shall remain
in full force and effect notwithstanding the addition of any new Guarantor as a party to this Guarantee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.6.
<U>No Waiver; Remedies</U>. In addition to, and not in limitation of, <U>Section&nbsp;2.3</U> and <U>Section&nbsp;2.5</U>, no failure
on the part of any Secured Party to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other
right. The remedies herein provided are cumulative and not exclusive of any remedies provided by Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.7. <U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.8.
<U>Section&nbsp;Captions</U>. Section&nbsp;captions used in this Guarantee are for convenience of reference only and shall not affect
the construction of this Guarantee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.9.
<U>Severability</U>. Any provision of this Guarantee which is prohibited or unenforceable in any jurisdiction shall, as to such provision
and such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining provisions
of this Guarantee or affecting the validity or enforceability of such provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.10.
<U>Governing Law, Entire Agreement, Etc</U>. THIS GUARANTEE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT
OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS GUARANTEE OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401
AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Guarantee, along with the other Loan Documents, constitutes
the entire understanding among the parties hereto with respect to the subject matter hereof and supersedes any prior agreements, written
or oral, with respect hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 185 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.11.
<U>Forum Selection and Consent to Jurisdiction</U>. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS
GUARANTEE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE SECURED PARTIES OR ANY
GUARANTOR IN CONNECTION HEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN
THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; <U>PROVIDED</U> THAT ANY SUIT SEEKING
ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY&nbsp;BE BROUGHT, AT THE ADMINISTRATIVE AGENT&rsquo;S OR THE LENDERS&rsquo; OPTION,&nbsp;IN
THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY&nbsp;BE FOUND. THE SECURED PARTIES, BY ACCEPTANCE OF THIS
GUARANTEE, AND EACH GUARANTOR IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE
WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION&nbsp;10.2 OF THE CREDIT AGREEMENT. THE SECURED
PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, AND EACH GUARANTOR HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED
BY LAW, ANY OBJECTION WHICH IT MAY&nbsp;HAVE OR HEREAFTER MAY&nbsp;HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY
SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT THE
SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, OR ANY GUARANTOR HAS OR HEREAFTER MAY&nbsp;ACQUIRE ANY IMMUNITY FROM JURISDICTION OF
ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION
OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, THE SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, AND SUCH GUARANTOR, EACH
ON ITS OWN BEHALF, HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER
THIS GUARANTEE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.12.
<U>Counterparts</U>. This Guarantee may be executed by the parties hereto in several counterparts, each of which shall be an original
and all of which shall constitute together but one and the same agreement. This Guarantee shall become effective when counterparts hereof
executed on behalf of each Guarantor shall have been received by the Administrative Agent, on behalf of the Secured Parties. Delivery
of an executed counterpart of a signature page&nbsp;to this Guarantee by email (e.g., &ldquo;pdf&rdquo; or &ldquo;tiff&rdquo;) or telecopy
shall be effective as delivery of a manually executed counterpart of this Guarantee. The words &ldquo;execution,&rdquo; &ldquo;signed,&rdquo;
 &ldquo;signature,&rdquo; and words of like import this Guarantee or any amendment or other modification hereof (including waivers and
consents) shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the
same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the
case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National
Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic
Transactions Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 186; Options: NewSection; Value: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.13. <U>Waiver
of Jury Trial</U>. THE ADMINISTRATIVE AGENT FOR THE BENEFIT OF ITSELF AND THE OTHER SECURED PARTIES, BY ACCEPTANCE OF THIS
GUARANTEE, AND EACH GUARANTOR HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY </FONT>RIGHTS
THEY MAY&nbsp;HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH,
THIS GUARANTEE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF ANY SECURED PARTY OR
ANY GUARANTOR IN CONNECTION HEREWITH. EACH GUARANTOR ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION
FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A
MATERIAL INDUCEMENT FOR THE SECURED PARTIES TO ENTER INTO THE LOAN DOCUMENTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.14.
<U>Termination; Release</U>. This Guarantee shall terminate with respect to all Guaranteed Obligations upon the payment in full in cash
in immediately available funds of all such Guaranteed Obligations. A Guarantor shall be automatically released from its obligations hereunder
in accordance with Section&nbsp;11.9(b)&nbsp;of the Credit Agreement. In connection with the termination or release, upon the reasonable
request and at the sole expense of such Guarantor, the Administrative Agent shall execute and deliver, without any representations, warranties
or recourse of any kind whatsoever, all agreements and instruments to evidence the termination or such release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 187; Options: NewSection; Value: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, each Guarantor and Administrative Agent have caused this Guarantee to be duly executed and delivered by its Authorized
Officer as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CARIS SCIENCE, INC.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CARIS MPI, INC.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CARIS PHARMATECH, INC.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CARIS THERAPEUTICS, INC.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 48%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
Page&nbsp;to Guarantee]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 188 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>WILMINGTON TRUST, NATIONAL</B></FONT></P>
                           <P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>ASSOCIATION,</B></FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">as the Administrative Agent</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 48%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
Page&nbsp;to Guarantee]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 189 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Schedule
I</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS SCIENCE,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS MPI,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS PHARMATECH,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS THERAPEUTICS,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[Schedule
I to Guarantee]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 190 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 406pt; text-align: right; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">ANNEX
I<BR>
to Guarantee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">SUPPLEMENT
TO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>GUARANTEE</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
SUPPLEMENT, dated as of [__] (this &ldquo; <U>Supplement</U>&rdquo;), is to the Guarantee, dated as of January&nbsp;18, 2023 (as amended,
supplemented or otherwise modified from time to time, the &ldquo;<U>Guarantee</U>&rdquo;), by the Guarantors (such term, and other terms
used in this Supplement, to have the meanings set forth in Article&nbsp;I of the Guarantee, unless otherwise defined herein or if the
context otherwise requires) from time to time party thereto, in favor of the Secured Parties (as defined in the Guarantee).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>W
I T N E S S E T H:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to a Credit Agreement, dated as of January&nbsp;18, 2023 (as amended, restated, amended and restated, supplemented or otherwise
modified from time to time, the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among Caris Life Sciences,&nbsp;Inc., a Texas Corporation
(the &ldquo;<U>Borrower</U>&rdquo;), the Lenders party thereto and WILMINGTON TRUST, NATIONAL ASSOCIATION, as administrative agent (together
with its Affiliates, successors, transferees and assignees, the &ldquo;<U>Administrative Agent</U>&rdquo;), the Lenders have extended
Commitments to make the Loans to the Borrower; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the provisions of Section&nbsp;5.5 of the Guarantee, each of the undersigned is becoming a Guarantor under the Guarantee;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
each of the undersigned desires to become a &ldquo;Guarantor&rdquo; under the Guarantee in order to induce the Lenders to continue to
extend the Loans under the Credit Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned
agrees, for the benefit of the Secured Parties, as follows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;1.
<U>Party to Guarantee, Etc</U>. In accordance with the terms of the Guarantee, by its signature below, each of the undersigned hereby
irrevocably agrees to become a Guarantor under the Guarantee with the same force and effect as if it were an original signatory thereto
and each of the undersigned hereby (a)&nbsp;agrees to be bound by and comply with all of the terms and provisions of the Guarantee applicable
to it as a Guarantor and (b)&nbsp;represents and warrants that the representations and warranties made by it as a Guarantor thereunder
are true and correct in all material respects, except for any representation and warranty that is qualified by materiality or reference
to Material Adverse Effect, which such representation and warranty shall be true and correct in all respects (except in the case of any
representation and warranty which expressly relates to a given date or period, which representation and warranty was true and correct
in all material respects (and in all respects if qualified by materiality or reference to Material Adverse Effect) as of the respective
date or for the respective period, as the case may be). In furtherance of the foregoing, each reference to a &ldquo;Guarantor&rdquo;
and/or &ldquo;Guarantors&rdquo; in the Guarantee shall be deemed to include each of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Annex
I to Guarantee &ndash; Form&nbsp;of Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 191 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.
<U>Representations</U>. Each of the undersigned Guarantors hereby represents and warrants that this Supplement has been duly authorized,
executed and delivered by it and that this Supplement and the Guarantee constitute its legal, valid and binding obligation, enforceable
against it in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally and principles of equity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.
<U>Full Force of Guarantee</U>. Except as expressly supplemented hereby, the Guarantee shall remain in full force and effect in accordance
with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.
<U>Severability</U>. Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid
under applicable Law, but if any provision of this Supplement shall be prohibited by or invalid under such Law, such provision shall
be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining
provisions of this Supplement or the Guarantee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;5.
<U>Governing Law, Entire Agreement, Etc</U>. THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT
OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SUPPLEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402
OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire
understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral,
with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;6.
<U>Effectiveness</U>. This Supplement shall become effective when a counterpart hereof executed by each undersigned Guarantor shall have
been received by the Administrative Agent, on behalf of the Secured Parties. Delivery of an executed counterpart of a signature page&nbsp;to
this Supplement by email (e.g., &ldquo;pdf&rdquo; or &ldquo;tiff&rdquo;) or telecopy shall be effective as delivery of a manually executed
counterpart of this Supplement. The words &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature,&rdquo; and words of like import
this Supplement or any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic
signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability
as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided
for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic
Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&nbsp;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Annex
I to Guarantee &ndash; Form&nbsp;of Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 192; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first
above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">[NAME OF ADDITIONAL GUARANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">[NAME OF ADDITIONAL GUARANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
Page&nbsp;to Guarantee Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Annex
I to Guarantee &ndash; Form&nbsp;of Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 193 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&nbsp;E</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FORM&nbsp;OF
PLEDGE AND SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
PLEDGE AND SECURITY AGREEMENT, dated as of January&nbsp;18, 2023 (as amended, restated, amended or restated, supplemented or otherwise
modified from time to time, this &ldquo;<U>Security Agreement</U>&rdquo;), is made by CARIS LIFE SCIENCES,&nbsp;INC., a Texas corporation
(the &ldquo;<U>Borrower</U>&rdquo;), and the other entities listed on <U>Annex A</U> hereto (together with the Borrower and any other
entity that may become a party hereto as provided herein, each a &ldquo;<U>Grantor</U>&rdquo; and, collectively, the &ldquo;<U>Grantors</U>&rdquo;),
in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United
States of America, as administrative agent (together with its successors, transferees and assignees, in such capacity, the &ldquo;<U>Administrative
Agent</U>&rdquo;) for the Secured Parties (defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>W
I T N E S S E T H </U></FONT><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement, dated as of January&nbsp;18, 2023 (as amended, restated, amended or restated, supplemented or otherwise
modified from time to time, the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among the Borrower, the Lenders party thereto and the
Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
in order to induce the Lenders to make or continue to make, as the case may be, the Loans under the Credit Agreement, each Grantor is
required to execute and deliver this Security Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
it is required under the terms of the Credit Agreement that the Grantors shall have granted, pledged and assigned the security interests
and undertaken the obligations contemplated by this Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for
the benefit of the Secured Parties, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;1.1.
<U>Certain Terms</U>. The following terms (whether or not underscored) when used in this Security Agreement, including its preamble and
recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Administrative Agent</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Borrower</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Collateral</U>&rdquo;
is defined in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Collateral Accounts</U>&rdquo;
is defined in <U>Section&nbsp;4.3(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 194 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Control
Agreement</U>&rdquo; means a &ldquo;springing&rdquo; control agreement, in form and substance reasonably satisfactory to the Administrative
Agent and the Required Lenders, executed and delivered by a Loan Party, the Administrative Agent, and the applicable securities intermediary
(with respect to a Securities Account) or bank (with respect to a Deposit Account), which provides for &ldquo;control&rdquo; (as defined
in the UCC) by Administrative Agent with respect to the applicable account and certain Collateral related thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Copyright
Collateral</U>&rdquo; means (a)&nbsp;all Copyrights owned by a Grantor, including the Copyright registrations and applications referred
to in <U>Schedule V</U>, (b)&nbsp;the rights of a Grantor to sue for past, present and future infringements of any of the foregoing,
all rights corresponding thereto, all extensions and renewals of any thereof, (c)&nbsp;all Proceeds of a Grantor of any of the foregoing,
including royalties, income, payments, claims, damages and Proceeds of suit, and (d)&nbsp;all Copyright licenses to which a Grantor is
a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Credit Agreement</U>&rdquo;
is defined in the <U>first recital</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Distributions</U>&rdquo;
means all dividends paid on Capital Securities, liquidating dividends paid on Capital Securities, shares (or other designations) of Capital
Securities resulting from (or in connection with the exercise of) stock splits, reclassifications, warrants, options, non-cash dividends,
mergers, consolidations, and all other distributions (whether similar or dissimilar to the foregoing) on or with respect to any Capital
Securities constituting Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Excluded Assets</U>&rdquo;
is defined in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Excluded
Securities</U>&rdquo; means (a)&nbsp;Capital Securities in newly acquired or created non-wholly owned Subsidiaries or in newly acquired
or created entities where a Grantor holds 50% or less of the outstanding Capital Securities of such entity, to the extent (i)&nbsp;a
pledge of such Capital Securities is prohibited by the Organic Documents or agreements with the other equity holders of such entity in
existence at the time of such acquisition (but not entered into in contemplation thereof), (ii)&nbsp;where, despite the commercially
reasonable efforts of the Grantors to obtain a consent under such Organic Documents or agreements with other equity holders to permit
the pledge of such Capital Securities to Administrative Agent, such consent cannot be obtained and (iii)&nbsp;such Capital Securities
have not been pledged to any other Person and (b)&nbsp;Capital Securities in excess of 65% of the total combined voting power of all
classes of Capital Securities of any first- tier Foreign Subsidiaries; <U>provided</U> that if any such Foreign Subsidiary shall become
a Loan Party, the exclusion for Capital Securities of such Foreign Subsidiary in this clause (b)&nbsp;shall not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Financing Statements</U>&rdquo;
is defined in <U>Section&nbsp;3.7(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>General
Intangibles</U>&rdquo; means all &ldquo;general intangibles&rdquo; and all &ldquo;payment intangibles&rdquo;, each as defined in the
UCC and shall include all interest rate or currency protection or hedging arrangements, all tax refunds, all licenses, permits, concessions
and authorizations and all Intellectual Property Collateral (in each case, regardless of whether characterized as general intangibles
under the UCC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Grantor</U>&rdquo;
and &ldquo;<U>Grantors</U>&rdquo; are defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 195; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Intellectual
Property Collateral</U>&rdquo; means, collectively, the Copyright Collateral, the Patent Collateral, the Trademark Collateral and the
Trade Secrets Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Intercompany
Note</U>&rdquo; means any promissory note evidencing loans made by any Grantor to any other Grantor or Subsidiary of a Grantor, as the
case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Investment
Property</U>&rdquo; means, collectively, (a)&nbsp;all &ldquo;investment property&rdquo; as such term is defined in Section&nbsp;9-102(a)(49)
of the UCC and (b)&nbsp;whether or not constituting &ldquo;investment property&rdquo; as so defined, all Pledged Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Margin
Stock</U>&rdquo; means &ldquo;margin stock&rdquo; as such term is defined in Regulation T, U or X of the Board of Governors of the Federal
Reserve System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Patent Collateral</U>&rdquo;
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
of the Patents throughout the world owned by a Grantor, including each issued Patent and Patent application referred to in <U>Schedule
III</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Proceeds of the foregoing (including royalties income, payments, claims, damages and Proceeds of infringement suits) and the right to
sue third parties for past, present or future infringements of any Patent or Patent application and for breach or enforcement of any
Patent license; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Patent licenses providing any Grantor with the right to use any items of the type referred to in <U>clause (a)</U>&nbsp;above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted Liens</U>&rdquo;
means all Liens permitted by Section&nbsp;8.3 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Pledged
Notes</U>&rdquo; means all promissory notes listed on <U>Item J</U> of <U>Schedule II</U> (as such schedule may be amended or supplemented
from time to time), all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any
Grantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Secured
Parties</U>&rdquo; means, collectively, the Administrative Agent and the Lenders and &ldquo;Secured Party&rdquo; means any one of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities Act</U>&rdquo;
is defined in <U>Section&nbsp;6.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Security Agreement</U>&rdquo;
is defined in the <U>preamble</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Specified
Notes</U>&rdquo; means, collectively, (i)&nbsp;each of the five (5)&nbsp;Full Recourse Promissory Note, dated as of September&nbsp;30,
2022, by and between each maker thereof and the Borrower, in connection with each Nonqualified Stock Option Exercise Agreement, dated
as of September&nbsp;30, 2022, by and between such maker and the Borrower, and (ii)&nbsp;any promissory note evidencing Investments permitted
under Section&nbsp;8.5(w)&nbsp;of the Credit Agreement, in each case of the foregoing <U>clauses (i)&nbsp;</U>and <U>(ii)</U>, as amended,
restated, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"></P>

<!-- Field: Page; Sequence: 196; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trade Secrets</U>&rdquo;
of a Person means all of such Person&rsquo;s common law and statutory trade secrets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trade
Secrets Collateral</U>&rdquo; means all of the Trade Secrets owned by the Grantors, whether or not such Trade Secret has been reduced
to a writing or other tangible form and including the right to sue for and to enjoin and to collect damages for the actual or threatened
misappropriation of any Trade Secret and for the breach or enforcement of any such Trade Secret license and all Trade Secret licenses
to which a Grantor is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Trademark Collateral</U>&rdquo;
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;all
of the Trademarks owned by the Grantors and all goodwill of the business associated therewith, now existing or hereafter adopted or acquired
including those Trademark registrations and applications referred to in <U>Schedule IV</U>, whether currently in use or not, including
registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United
States of America, or any state thereof or any other country or political subdivision thereof or otherwise, and all common-law rights
relating to the foregoing, and (ii)&nbsp;the right to obtain all reissues, extensions or renewals of the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
right to sue third parties for past, present and future infringements of any Trademark Collateral described in <U>clause (a)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Proceeds of the foregoing, including any claim by any Grantor against third parties for past, present or future infringement or dilution
of any Trademark, or for any injury to the goodwill associated with the use of any such Trademark; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Trademark licenses for the grant by or to any Grantors of any right to use any Trademark.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;1.2.
<U>Credit Agreement Definitions</U>. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement,
including its preamble and recitals, have the meanings provided in the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;1.3.
<U>UCC Definitions</U>. When used herein the terms &ldquo;Account&rdquo;, &ldquo;Certificated Securities&rdquo;, &ldquo;Chattel Paper&rdquo;,
 &ldquo;Commercial Tort Claim&rdquo;, &ldquo;Commodity Account&rdquo;, &ldquo;Commodity Contract&rdquo;, &ldquo;Deposit Account&rdquo;,
 &ldquo;Document&rdquo;, &ldquo;Electronic Chattel Paper&rdquo;, &ldquo;Equipment&rdquo;, &ldquo;Goods&rdquo;, &ldquo;Instrument&rdquo;,
 &ldquo;Inventory&rdquo;, &ldquo;Letter-of-Credit Rights&rdquo;, &ldquo;Payment Intangibles&rdquo;, &ldquo;Proceeds&rdquo;, &ldquo;Promissory
Notes&rdquo;, &ldquo;Securities Account&rdquo;, &ldquo;Security Entitlement&rdquo;, &ldquo;Supporting Obligations&rdquo; and &ldquo;Uncertificated
Securities&rdquo; have the meaning provided in Article&nbsp;8 or Article&nbsp;9, as applicable, of the UCC. &ldquo;Letters of Credit&rdquo;
has the meaning provided in Section&nbsp;5-102 of the UCC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 197; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">SECURITY
INTEREST</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.1.
<U>Grant of Security Interest</U>. Each Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a
continuing security interest in all of such Grantor&rsquo;s right, title and interest in and to the following property, whether now or
hereafter existing, owned or acquired by such Grantor, and wherever located (collectively, the &ldquo;<U>Collateral</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Accounts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chattel Paper;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Commercial Tort Claims, including
those listed on <U>Item I</U> of <U>Schedule II</U> (as such schedule may be amended or supplemented from time to time);</FONT></TD>
</TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Deposit Accounts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Documents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">General Intangibles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Goods (including
                                            Goods held on consignment with third parties);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Instruments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Investment
                                            Property;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Letter-of-Credit
                                            Rights and Letters of Credit;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Supporting
                                            Obligations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all books, records, writings,
databases, information and other personal property relating to, used or useful in connection with, evidencing, embodying, incorporating
or referring to, any of the foregoing in this <U>Section&nbsp;2.1</U>;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all Proceeds of any of the foregoing
and, to the extent not otherwise included, all payments under insurance (whether or not the Administrative Agent is the loss payee thereof)
in respect of Collateral; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all other property and rights
of every kind and description and interests therein.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary contained herein or in any other Loan Document, the term &ldquo;Collateral&rdquo; shall not include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any General Intangibles or other
rights or interests, in each case arising under any contracts, instruments, leases, licenses, permits, letters of credit, purchase money
arrangements, instruments or other documents as to which the grant of a security interest would (A)&nbsp;constitute or result in the
unenforceability of any of the foregoing documents, (B)&nbsp;give any other party to such contract, instrument, lease, license, permit,
letter of credit, purchase money arrangement, instrument or other document the right to terminate its obligations thereunder or (C)&nbsp;otherwise
require consent thereunder (other than from any Grantor);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"></P>

<!-- Field: Page; Sequence: 198; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trademark
applications filed in the United States Patent and Trademark Office on the basis of such Grantor&rsquo;s &ldquo;intent to use&rdquo;
such trademark, unless and until acceptable evidence of use of the Trademark has been filed with the United States Patent and Trademark
Office pursuant to Section&nbsp;1(c)&nbsp;or Section&nbsp;1(d)&nbsp;of the Lanham Act (15 U.S.C. 1051, et seq.), to the extent that granting
a Lien in such Trademark application prior to such filing would adversely affect the enforceability or validity of such Trademark application;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(iii)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any asset or portion of any asset, the granting of a security interest in which <FONT STYLE="font-family: Times New Roman, Times, Serif">(A)</FONT>&nbsp;would
be void or illegal under any applicable Law, (B)&nbsp;would cause the destruction, invalidation or abandonment of such asset or portion
of asset under applicable Law, (C)&nbsp;would require any governmental or third party consent, approval, license or authorization (unless
such consent, approval license or authorization has been obtained), or (D)&nbsp;pursuant thereto would result in, or permit the termination
of, such asset or portion of asset;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(iv)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acquired property (including property acquired through acquisition or merger of another entity) if at the time of such acquisition the
granting of a security interest therein or the pledge thereof is prohibited by any contract or other agreement (in each case, not created
in contemplation thereof) to the extent and for so long as such contract or other agreement prohibits such security interest or pledge;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
asset subject to a Permitted Lien (other than Liens in favor of the Secured Parties) securing obligations permitted under the Credit
Agreement to the extent that the grant of other Liens on such asset (A)&nbsp;would result in a breach, violation or invalidation of,
or constitute a default under, the agreement or instrument governing such Permitted Lien, (B)&nbsp;would result in the loss of use of
such asset or (C)&nbsp;would require the consent of the holder of such Permitted Lien or permit the holder of such Permitted Lien to
terminate the Grantor&rsquo;s use of such asset;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Excluded
                                            Accounts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(vii)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any particular asset where the Borrower in good faith after consulting with its tax or other relevant advisors and subject to the Required
Lenders&rsquo; consent (not to be unreasonably withheld, conditioned or delayed) that the burden or cost (including any adverse tax consequences
to the Borrower or any of its Subsidiaries, which are not <I>de minimis</I>) of providing a pledge thereof or a security interest therein
will outweigh the benefits to be obtained by the Lenders therefrom, including by taking into account the overall collateral package and
the amount of the Loans;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Margin
                                            Stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(ix)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">[reserved];</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(x)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">[reserved];</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(xi)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any governmental licenses or state or local franchises, charters and authorizations, to the extent a security interest in any such license,
franchise, charter or authorization is prohibited or restricted thereby;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"></P>

<!-- Field: Page; Sequence: 199; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(xii)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any Excluded
                                            Securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(xiii)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any Specified
                                            Notes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(xiv)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Leasehold
                                            interests in real property;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(xv)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any fee-owned
                                            real property other than Material Real Property;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(xvi)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">[reserved];
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(xvii)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;motor vehicles and other assets subject to certificates of title (other than aircraft), except to the extent a security interest therein
can be perfected by the filing of a UCC financing statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided
</U></FONT><FONT STYLE="font-size: 10pt">that the property described in each of <U>clauses (i)</U>, <U>(iii)</U>, <U>(iv)</U>,
<U>(v)&nbsp;</U>and <U>(xi)&nbsp;</U>above shall only be excluded from the term &ldquo;Collateral&rdquo; to the extent the conditions
stated in such clauses are not rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC or any other applicable
Law; <U>provided further</U> that the property described in each of <U>clauses (i)</U>&nbsp;through <U>(xvii)</U>&nbsp;above shall not
include any Proceeds, products, substitutions or replacements thereof (unless such Proceeds, products, substitutions or replacements
would otherwise constitute property described in any of <U>clauses (i)</U>&nbsp;through <U>(xvii)</U>&nbsp;above) (all such assets excluded
from &ldquo;Collateral&rdquo; pursuant to the foregoing <U>clauses (i)</U>&nbsp;through <U>(xvii)</U>&nbsp;above and the provisos contained
in this paragraph, the &ldquo;<U>Excluded Assets</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.2.
<U>Security for Obligations</U>. This Security Agreement and the Collateral in which the Administrative Agent, for the benefit of the
Secured Parties, is granted a security interest hereunder by the Grantors secure the payment and performance of all of the Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.3. <U>Grantors
Remain Liable</U>. Anything herein to the contrary notwithstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Grantors will remain liable under the contracts and agreements included in the Collateral to the extent set forth therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
exercise by any Secured Party of any of its rights hereunder will not release any Grantor from any of its duties or obligations under
any such contracts or agreements included in the Collateral; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Secured Parties will not have any obligation or liability under any contracts or agreements included in the Collateral by reason of this
Security Agreement, nor will the Secured Parties be obligated to perform any of the obligations or duties of any Grantor thereunder or
to take any action to collect or enforce any claim for payment assigned hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.4.
<U>Distributions on Capital Securities; Payments on Pledged Notes</U>. In the event that any (a)&nbsp;Distribution with respect to any
Capital Securities or (b)&nbsp;payment with respect to any Pledged Notes, in each case pledged hereunder, is not prohibited under Section&nbsp;8.6
of the Credit Agreement, such Distribution or payment may be paid directly to the applicable Grantor. If any Distribution or payment
is made in contravention of Sections 8.5 or 8.6 of the Credit Agreement, such Grantor shall hold the same segregated and in trust for
the Administrative Agent, for the benefit of the Secured Parties, until paid to the Administrative Agent in accordance with <U>Section&nbsp;4.1.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 200; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.5.
<U>Security Interest Absolute, Etc</U>. Subject to <U>Section&nbsp;7.5</U> hereof and to the other limitations expressly set forth herein
and in the other Loan Documents, this Security Agreement shall in all respects be a continuing, absolute, unconditional and irrevocable
grant of security interest, and shall remain in full force and effect until the Termination Date. Subject to the limitations expressly
set forth herein and in the other Loan Documents, all rights of the Secured Parties and the security interests granted to the Administrative
Agent, for the benefit of the Secured Parties, hereunder, and all obligations of the Grantors hereunder, shall, to the fullest extent
permitted by applicable Law, in each case, be absolute, unconditional and irrevocable irrespective of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
lack of validity, legality or enforceability of any Loan Document (other than this Security Agreement);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
failure of any Secured Party (i)&nbsp;to assert any claim or demand or to enforce any right or remedy against the Borrower or any of
the Subsidiaries or any other Person (including any other Grantor) under the provisions of any Loan Document or otherwise, or (ii)&nbsp;to
exercise any right or remedy against any other guarantor (including any other Grantor) of, or Collateral securing, any Obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
change in the time, manner or place of payment of, or in any other term of, all or any part of the Obligations, or any other extension,
compromise or renewal of any Obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
reduction, limitation, impairment or termination of any Obligations for any reason, including any claim of waiver, release, surrender,
alteration or compromise and shall not be subject to (and each Grantor hereby waives, until payment of all Obligations, any right to
or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, nongenuineness,
irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Obligations or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
amendment to, rescission, waiver, or other modification of, or any consent to or departure from, any of the terms of any Loan Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
addition, exchange or release of any Collateral or of any Person that is (or will become) a Grantor (including the Grantors hereunder),
or any surrender or non-perfection of any Collateral, or any amendment to or waiver or release or addition to, or consent to or departure
from, any other guaranty held by the Administrative Agent, for the benefit of the Secured Parties, securing any of the Obligations; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other
than payment in full of the Obligations, any other circumstance which might otherwise constitute a defense available to, or a legal or
equitable discharge of the Borrower or any of the Subsidiaries, any surety or any guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 201; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;2.6.
<U>Postponement of Subrogation</U>. Each Grantor agrees that it will not exercise any rights against another Grantor which it may acquire
by way of rights of subrogation under any Loan Document to which it is a party until following the Termination Date. No Grantor shall
seek or be entitled to seek any contribution or reimbursement from the Borrower or any other Grantor, in respect of any payment made
by such Grantor under any Loan Document or otherwise, until following the Termination Date. Any amount paid to any Grantor on account
of any such subrogation rights prior to the Termination Date shall be held in trust for the benefit of the Secured Parties and shall
immediately be paid and turned over to the Administrative Agent, for the benefit of the Secured Parties, in the exact form received by
such Grantor (duly endorsed in favor of the Administrative Agent, if required), to be credited and applied against the Obligations then
due and payable in accordance with <U>Section&nbsp;6.1(b)</U>; <U>provided</U> that, if such Grantor has made payment to the Administrative
Agent of all or any part of the Obligations and the Termination Date has occurred, then at such Grantor&rsquo;s written request, the
Administrative Agent will, at the expense of such Grantor, execute and deliver to such Grantor appropriate documents (without recourse
and without representation or warranty) necessary to evidence the transfer by subrogation to such Grantor of an interest in the Obligations
resulting from such payment. In furtherance of the foregoing, at all times prior to the Termination Date, such Grantor shall refrain
from taking any action or commencing any proceeding against the Borrower or any other Grantor (or their successors or assigns, whether
in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Security Agreement
to the Administrative Agent or any other Secured Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">REPRESENTATIONS
AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
order to induce the Secured Parties to enter into the Credit Agreement and make the Loans thereunder, each Grantor represents and warrants
to the Administrative Agent, for the benefit of the Secured Parties, as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.1. <U>As to
Capital Securities of the Subsidiaries,&nbsp;Investment Property</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to any Subsidiary organized in the United States of such Grantor that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
corporation, business trust, joint stock company or similar Person, all Capital Securities issued by such Subsidiary, to the extent constituting
Collateral, are duly authorized and validly issued, fully paid and non-assessable, and represented by a certificate or certificates;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
partnership or limited liability company, no Capital Securities issued by such Subsidiary, to the extent constituting Collateral, (A)&nbsp;is
dealt in or traded on securities exchanges or in securities markets, (B)&nbsp;if constituting Uncertificated Securities, expressly provides
that such Capital Securities is a security governed by Article&nbsp;8 of the UCC or (C)&nbsp;is held in a Securities Account. Each Grantor
party hereto that is an issuer of any Uncertificated Securities constituting Collateral agrees that, at any time after the occurrence
and during the continuation of an Event of Default, it will comply with the instructions with respect to such Uncertificated Securities
originated by Administrative Agent without the consent of any other Grantor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"></P>

<!-- Field: Page; Sequence: 202; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 231pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Grantor has delivered to the Administrative Agent all Certificated Securities constituting Collateral held by such Grantor in a Subsidiary
on or substantially concurrent with the Closing Date (or such later date as may be applicable pursuant to the Credit Agreement), or,
solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes
a party to this Security Agreement or such other date agreed to by the Required Lenders) to the Administrative Agent, together with duly
executed undated blank stock powers, or other equivalent instruments of transfer acceptable to the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to Uncertificated Securities constituting Collateral owned by any Grantor in a Subsidiary that is not a Grantor party hereunder
on the Closing Date (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the
date such Grantor becomes a party to this Security Agreement or such other date agreed to by the Required Lenders), such Grantor has
caused the issuer thereof to agree in an authenticated record with such Grantor and the Administrative Agent that such issuer will comply
with instructions with respect to such security originated by the Administrative Agent given in accordance with this Security Agreement
at any time after the occurrence and during the continuation of an Event of Default without further consent of such Grantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage of the issued and outstanding Capital Securities of each Subsidiary of a Grantor pledged on the Closing Date (or, solely with
respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes a party to
this Security Agreement) by each Grantor hereunder is as set forth on <U>Schedule I</U>. All shares of such Capital Securities have been
duly and validly issued and are fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Intercompany Notes, to the extent constituting Collateral, constitutes the legal, valid and binding obligation of the obligor
with respect thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and other similar Laws relating to or affecting creditors&rsquo; rights generally, general equitable principles
(whether considered in a proceeding in equity or at Law) and an implied covenant of good faith and fair dealing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.2.
<U>Grantor Name, Location, Etc</U>. In each case as of the Closing Date (or, solely with respect to a Grantor that becomes a party to
this Security Agreement after the Closing Date, on the date such Grantor becomes a party to this Security Agreement):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The
jurisdiction in which each Grantor is located for purposes of Sections 9-301 and 9-307 of the UCC and (ii)&nbsp;the address of each Grantor&rsquo;s
executive office and principal place of business is set forth in <U>Item A</U> of <U>Schedule II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantors do not have any trade names other than those set forth in <U>Item C </U>of <U>Schedule II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the 12 months preceding the date hereof (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the
Closing Date, preceding the date such Grantor becomes a party to this Security Agreement), no Grantor has been known by any legal name
different from the one set forth on the signature page&nbsp;hereto, nor has such Grantor been the subject of any merger or other corporate
reorganization, except as set forth in <U>Item D</U> of <U>Schedule II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 203; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Grantor&rsquo;s federal taxpayer identification number (or foreign equivalent) is set forth in <U>Item E</U> of <U>Schedule II</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Reserved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Grantor maintains any Deposit Accounts, Securities Accounts or Commodity Accounts with any Person, in each case, other than any Excluded
Account and except as set forth on <U>Item G</U> of <U>Schedule II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Grantor is the beneficiary of any Letters of Credit with a face amount exceeding $5,000,000 individually, except as set forth on <U>Item
H</U> of <U>Schedule II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Grantor has Commercial Tort Claims in favor of such Grantor in excess of $5,000,000, except as set forth on <U>Item I</U> of <U>Schedule
II</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name set forth on the signature page&nbsp;attached hereto (or the signature page&nbsp;of the supplement hereto by which such Grantor
has become a party to this Security Agreement, as applicable) is the true and correct legal name (as defined in the UCC) of each Grantor
(but without giving effect to capitalization).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.3.
<U>No Liens, Etc</U>. No effective UCC financing statement or other filing similar in effect covering all or any part of the Collateral
is on file in any recording office, except those filed in favor of the Administrative Agent relating to this Security Agreement, Permitted
Liens or as to which a duly authorized termination statement relating to such UCC financing statement or other instrument has been delivered
to the Administrative Agent on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.4. <U>Possession
of Inventory, Control, Etc</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Grantor has, and agrees that it will maintain, exclusive possession of its Documents,&nbsp;Instruments, Promissory Notes, Goods, Equipment
and Inventory, in each case to the extent constituting Collateral, other than (i)&nbsp;Equipment, Goods or Inventory that is in transit
in the ordinary course of business, (ii)&nbsp;Equipment, Goods or Inventory that in the ordinary course of business is in the possession
or control of a warehouseman, bailee agent, employee, contractor or other Person, (iii)&nbsp;Inventory that is in the possession of a
consignee in the ordinary course of business and (iv)&nbsp;Instruments or Promissory Notes that have been delivered to the Administrative
Agent pursuant to <U>Section&nbsp;3.5</U>. With respect to any locations where Collateral in excess of $10,000,000 is located, each Grantor
shall use commercially reasonable efforts (in consultation with the Significant Lenders and giving consideration to the interests of
the Lenders) to furnish to the Administrative Agent landlord access agreements, bailee waivers or similar agreements, in form and substance
satisfactory to the Administrative Agent and the Required Lenders, from each landlord, lessor or warehouseman to such Grantor after the
date hereof, in each case subject to Section&nbsp;7.15 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 204; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Grantor is the sole entitlement holder of each of its Deposit Accounts to the extent constituting Collateral, and no other Person (other
than the Administrative Agent pursuant to this Security Agreement, the applicable depositary institution or any other Person with respect
to Permitted Liens) has control or possession of, or any other interest in, any of its Deposit Accounts or any other securities or property
credited thereto, in each case, except as otherwise expressly permitted under the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.5.
<U>Negotiable Documents,&nbsp;Instruments and Chattel Paper</U>. Each Grantor has delivered to the Administrative Agent possession of
all originals of all Documents,&nbsp;Instruments, Promissory Notes and tangible Chattel Paper (other than any Document,&nbsp;Instrument,
Promissory Note or tangible Chattel Paper (x)&nbsp;not constituting Collateral or (y)&nbsp;not exceeding $1,500,000 in principal amount
individually or $5,000,000 in principal amount in the aggregate) owned or held by such Grantor on the Closing Date (or, solely with respect
to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes a party to this Security
Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.6.
<U>Intellectual Property Collateral</U>. With respect to any Intellectual Property Collateral:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
settlement or consents, covenants not to sue, nonassertion assurances, or releases have been entered into by any Grantor or to which
such Grantor is bound that adversely affects its rights to own or use any Intellectual Property to the extent that it would materially
prevent such Grantor from carrying out its business operations as currently conducted;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Grantor has not granted a security interest or pledged as collateral any of its Intellectual Property that has not been terminated or
released except as permitted under the Credit Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Grantor has executed and delivered to the Administrative Agent Intellectual Property Collateral security agreements accordance with <U>Section&nbsp;4.5
</U>for all registrations and applications of Copyrights, Patents and Trademarks owned by such Grantor, including all registrations and
applications of Copyrights, Patents and Trademarks on <U>Schedules III </U>through <U>VI </U>(as such schedules may be amended or supplemented
from time to time by notice by such Grantor to the Administrative Agent); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Grantor uses commercially reasonable efforts designed to ensure the reasonable quality of the manufacture, distribution and sale of all
products sold by such Grantor and in the provision of all services rendered by such Grantor, in each case, under or in connection with
all Trademarks owned by such Grantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.7. <U>Validity,
Etc</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Security Agreement creates a valid security interest in the Collateral securing the payment of the Obligations to the extent such security
interest may be created pursuant to Article&nbsp;9 of the UCC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the Closing Date (or the date such Grantor becomes a party to this Security Agreement, as applicable), each Grantor has filed or caused
to be filed all UCC-1 financing statements in the filing office for each Grantor&rsquo;s jurisdiction of organization listed in <U>Item
A </U>of <U>Schedule II </U>(collectively, the &ldquo;<U>Financing Statements</U>&rdquo;) (or has delivered to the Administrative Agent
(or its designee) the Financing Statements suitable for timely and proper filing in such offices) and has taken all other actions necessary
for the Administrative Agent to obtain control of the Collateral as provided in Sections 9-104, 9-105, 9-106 and 9-107 of the UCC to
the extent required by the Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 205; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the filing of the Financing Statements with the appropriate agencies therefor, the security interests created under this Security Agreement
shall constitute a perfected security interest in the Collateral described on such Financing Statements in favor of the Administrative
Agent to the extent that a security interest therein may be perfected by filing a financing statement pursuant to the relevant UCC, prior
to all other Liens, except for Permitted Liens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.8.
<U>Authorization, Approval, Etc.</U> Except as have been obtained or made and are in full force and effect, no authorization, approval
or other action by, and no notice to or filing with, any Governmental Authority or any other third party is required either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
the perfection or maintenance of the security interests hereunder, including the first priority nature (subject to Permitted Liens) of
such security interest to the extent required hereunder or under any other Loan Document (to the extent same can be achieved by the filing
of Financing Statements or, with respect to Intellectual Property Collateral, the recordation of any agreements with the United States
Patent and Trademark Office or the United States Copyright Office or, with respect to foreign Intellectual Property Collateral of a Grantor
to the extent (i)&nbsp;such foreign Intellectual Property Collateral is registered in a foreign Law jurisdiction in which any Grantor
has entered into a security agreement or such other agreements governed by such foreign Law to create and perfect the security interests
granted by such Loan Party (any such jurisdiction, a &ldquo;<U>Foreign Grantor Jurisdiction</U>&rdquo;) and (ii)&nbsp;the Administrative
Agent (at the direction of the Required Lenders) has requested that the applicable Grantor take such action, the taking of appropriate
action under such Foreign Grantor Jurisdictions, and, with respect to after-acquired Intellectual Property Collateral, any subsequent
filings in such applicable intellectual property offices); <U>provided</U>, that the Grantors shall not have any obligation to perfect
any security interest or lien in any Intellectual Property Collateral in any jurisdiction other than the United States of America, and
will not be required hereunder to make any filings in any intellectual property offices or registrars other than the United States Patent
and Trademark Office or the United States Copyright Office, if such Grantor determines in good faith and subject to the Required Lenders&rsquo;
consent (not to be unreasonably withheld, conditioned or delayed) that the burden or cost of taking such action will outweigh the benefits
to be obtained by the Lenders therefrom, including by taking into account the overall collateral package and the amount of the Loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
the exercise by the Administrative Agent of the voting or other rights and remedies provided for in this Security Agreement, except (i)&nbsp;with
respect to any securities issued by a Subsidiary of the Grantors, as may be required in connection with a disposition of such securities
by Laws affecting the offering and sale of securities generally, the remedies in respect of the Collateral pursuant to this Security
Agreement and (ii)&nbsp;any &ldquo;change of control&rdquo; or similar filings required by state licensing agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 206; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;3.9.
<U>Best Interests</U>. It is in the best interests of each Grantor (other than the Borrower) to execute this Security Agreement inasmuch
as such Grantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans
made to the Borrower by the Lenders pursuant to the Credit Agreement, and each Grantor agrees that the Lenders are relying on this representation
in agreeing to make such Loans pursuant to the Credit Agreement to the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">COVENANTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Each
Grantor covenants and agrees that, until the Termination Date, such Grantor will perform, comply with and be bound by the obligations
set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1. <U>As to
Investment Property, Etc</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.1.
<U>Capital Securities of Subsidiaries</U>. No Grantor will allow any of its Subsidiaries that is organized in the United States, in each
case (to the extent applicable) solely with respect to the Collateral:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
is a corporation, business trust, joint stock company or similar Person, to issue Uncertificated Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
is a partnership or limited liability company, to (i)&nbsp;issue Capital Securities that are to be dealt in or traded on securities exchanges
or in securities markets, <FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT> expressly
provide in its Organic Documents that its Capital Securities are securities governed by Article&nbsp;8 of the UCC (unless its Capital
Securities are Certificated Securities and the Grantors have complied with Section&nbsp;4.1.3 to the extent applicable) and except to
the extent any Subsidiary acquired after the date hereof has provided for such in its Organic Documents (and such election to do so was
not implemented in contemplation of such acquisition, in which event the applicable Grantor will notify the Administrative Agent in writing
thereof and such Grantor shall comply with all perfection steps required hereunder with respect to such Capital Securities), or (iii)&nbsp;place
such Subsidiary&rsquo;s Capital Securities in a Securities Account; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to issue Capital Securities in addition to or in substitution for the Capital Securities pledged hereunder, except to such Grantor (so
long as such Capital Securities are promptly pledged and delivered to the Administrative Agent pursuant to the terms of this Security
Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.2. <U>Investment
Property (other than Certificated Securities)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to any Deposit Accounts, Securities Accounts, Commodity Accounts, Commodity Contracts or Security Entitlements constituting Investment
Property owned or held by any Grantor, such Grantor will cause (except for Excluded Accounts) the intermediary maintaining such Investment
Property or other assets to execute a Control Agreement relating to such Investment Property or other assets in compliance with Section
7.13 and Section&nbsp;7.15 of the Credit Agreement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 207; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to any Uncertificated Securities (other than Uncertificated Securities credited to a Securities Account) constituting Collateral
owned or held by any Grantor, such Grantor will cause the issuer of such securities that is not a party hereto to either (i)&nbsp;to
agree in an authenticated record with such Grantor and the Administrative Agent that such issuer will comply with instructions with respect
to such security originated by the Administrative Agent given in accordance with this Security Agreement at any time after the occurrence
and during the continuation of an Event of Default without further consent of such Grantor or (ii)&nbsp;execute a Control Agreement relating
to such Investment Property in compliance with Section&nbsp;7.13 and Section&nbsp;7.15 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise permitted under the Credit Agreement, no Grantor shall cause or permit any Person other than the Administrative Agent or
the Secured Parties or the financial institution maintaining such Investment Property to have &ldquo;control&rdquo; (as defined in Section&nbsp;9-104,
9-105, 9-106 and 9-107 of the UCC) any Investment Property constituting part of the Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.3.
<U>Certificated Securities (Stock Powers)</U>. Each Grantor agrees that all Certificated Securities constituting Collateral, including
the Capital Securities delivered by such Grantor pursuant to this Security Agreement, will be accompanied by duly executed undated blank
stock powers, or other equivalent instruments of transfer reasonably acceptable to the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.4.
<U>Continuous Pledge</U>. Each Grantor will (subject to the terms hereof and the terms of the Credit Agreement): (a)&nbsp;deliver to
the Administrative Agent all Investment Property and all Payment Intangibles, in each case constituting Collateral to the extent that
such Investment Property or Payment Intangibles are evidenced by a Document,&nbsp;Instrument, Promissory Note or Chattel Paper (other
than any Document,&nbsp;Instrument, Promissory Note or Chattel Paper not exceeding $1,500,000 in principal amount individually or $5,000,000
in principal amount in the aggregate), and (b)&nbsp;to the extent constituting Collateral, at all times keep pledged to the Administrative
Agent pursuant hereto, on a perfected basis, a security interest therein and in all interest and principal with respect to such Payment
Intangibles, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing
Collateral. Each Grantor agrees that it will, promptly following receipt thereof, deliver to the Administrative Agent possession of all
originals of negotiable Documents,&nbsp;Instruments, Promissory Notes and Chattel Paper constituting Collateral that it acquires following
the Closing Date (other than any Document,&nbsp;Instrument, Promissory Note or Chattel Paper not exceeding $1,500,000 in principal amount
individually or $5,000,000 in principal amount in the aggregate).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.5. <U>Voting
Rights, Dividends, Etc</U>. Each Grantor agrees:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;upon
receipt of notice of the occurrence and continuance of an Event of Default from the Administrative Agent and without any request therefor
by the Administrative Agent, so long as such Event of Default shall continue, to deliver (properly endorsed where required hereby or
requested by the Administrative Agent) to the Administrative Agent all dividends and Distributions with respect to Investment Property
constituting Collateral; all interest, principal, other cash payments on Payment Intangibles constituting Collateral; and all Proceeds
of the Collateral, in each case thereafter received by such Grantor, all of which shall be held by the Administrative Agent as additional
Collateral, except for payments made in accordance with Section&nbsp;8.6 of the Credit Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 208; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;immediately
upon the occurrence and during the continuance of an Event of Default and so long as the Administrative Agent has notified such Grantor
in writing of the Administrative Agent&rsquo;s intention to exercise its voting power under this <U>clause (b)</U>,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Administrative Agent may exercise (to the exclusion of such Grantor) the voting power and all other incidental rights of ownership with
respect to any Investment Property constituting Collateral, and such Grantor hereby grants the Administrative Agent an irrevocable proxy,
exercisable solely upon the occurrence and during the continuation of an Event of Default, to vote such Investment Property; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;upon
the request by the Administrative Agent, such Grantor shall promptly deliver to the Administrative Agent such additional proxies and
other documents as may be necessary to allow the Administrative Agent to exercise such voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">All dividends,
Distributions, interest, principal, cash payments, Payment Intangibles and Proceeds constituting Collateral and that may at any time
and from time to time be held by such Grantor, but which such Grantor is then obligated to deliver to the Administrative Agent pursuant
to the terms hereof, shall, until delivery to the Administrative Agent, be held by such Grantor separate and apart from its other property
in trust for the Administrative Agent. The Administrative Agent agrees that unless an Event of Default shall have occurred and be continuing
and the Administrative Agent shall have given the notice referred to in <U>clause (b)</U>&nbsp;above, such Grantor will have the exclusive
voting power with respect to any Investment Property and the Administrative Agent will, upon the written request of such Grantor, promptly
deliver such proxies and other documents, if any, as shall be reasonably requested by such Grantor which are necessary to allow such
Grantor to exercise that voting power; <U>provided</U> that no vote shall be cast, or consent, waiver or ratification given, or action
taken by such Grantor that would impair in any material respect any such Collateral or violate any provision of any Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.1.6.
<U>Margin Stock</U>. If at any time the Investment Property of a Grantor or any part thereof consists of Margin Stock, such Grantor shall
promptly so notify the Administrative Agent and deliver to the Administrative Agent a duly executed and completed Form&nbsp;U-1 and such
other instruments and documents reasonably requested by the Administrative Agent that are necessary to demonstrate conformity therewith
in form and substance satisfactory to the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&nbsp;4.2.
<U>Change of Name, Etc</U>. No Grantor will change its name or place of incorporation or organization or federal taxpayer identification
number except as otherwise permitted by the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 209; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.3. <U>As to
Accounts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Grantor shall have the right to collect all Accounts so long as no Event of Default shall have occurred and be continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
(i)&#8239;the occurrence and continuance of an Event of Default and (ii)&#8239;the delivery of notice by the Administrative Agent to each
Grantor, all Proceeds of Collateral received by such Grantor shall be delivered in kind to the Administrative Agent for deposit in a
Deposit Account of such Grantor maintained with the Administrative Agent or that otherwise is a Controlled Account (together with any
other Deposit Accounts or Controlled Accounts pursuant to which any portion of the Collateral is deposited with the Administrative Agent
after the occurrence and during the continuation of an Event of Default, the &ldquo;<U>Collateral Accounts</U>&rdquo;), and such Grantor
shall not commingle any such Proceeds, and shall hold separate and apart from all other property, all such Proceeds in express trust
for the benefit of the Administrative Agent until delivery thereof is made to the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Following
the delivery of notice pursuant to <U>clause (b)(ii)</U>&#8239;above and for so long as an Event of Default is continuing, the Administrative
Agent shall have the right to apply any amount in any Collateral Account to the payment of any Obligations which are then due and payable
in accordance with Section&#8239;4.4(b)&#8239;of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to each of the Collateral Accounts, it is hereby confirmed and agreed that (i)&#8239;deposits in such Collateral Account are subject
to a security interest as contemplated hereby, (ii)&#8239;such Collateral Account shall be under the control of the Administrative Agent
and (iii)&#8239;following the delivery of notice pursuant to <U>clause (b)(ii)</U>&#8239;above and for so long as an Event of Default is
continuing, the Administrative Agent shall have the sole right of withdrawal over such Collateral Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.4.&#8239;&#8239;&#8239; <U>As to
Grantors&rsquo; Use of Collateral</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to <U>clause (b)</U>&#8239;below, each Grantor: (i)&#8239;will, at its own expense, endeavor to collect in the ordinary course consistent
with its past practice all amounts due with respect to any of the Collateral, including the taking of such action with respect to such
collection as the Administrative Agent may reasonably request following the occurrence and during the continuance of an Event of Default
or, in the absence of such request, as such Grantor may deem advisable, (ii)&#8239;may grant, in the ordinary course of business, to any
party obligated on any of the Collateral, any rebate, refund or allowance to which such party may be lawfully entitled, and may accept,
in connection therewith, the return of Goods, the sale or lease of which shall have given rise to such Collateral, and (iii)&#8239;may
make Dispositions and take such other actions permitted under the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
any time following the occurrence and solely during the continuance of an Event of Default, whether before or after the maturity of any
of the Obligations, the Administrative Agent may (i)&#8239;revoke any or all of the rights of each Grantor set forth in <U>clause (a)</U>&#8239;above,
(ii)&#8239;notify any parties obligated on any of the Collateral to make payment to the Administrative Agent of any amounts due or to
become due thereunder and (iii)&#8239;enforce collection of any of the Collateral by suit or otherwise and surrender, release or exchange
all or any part thereof, or compromise or extend or renew for any period (whether or not longer than the original period) any indebtedness
thereunder or evidenced thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 210; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the request of the Administrative Agent following the occurrence and solely during the continuance of an Event of Default, each Grantor
will, at its own expense, notify any parties obligated on any of the Collateral to make payment to the Administrative Agent of any amounts
due or to become due thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
any time following the occurrence and solely during the continuance of an Event of Default, the Administrative Agent may endorse, in
the name of such Grantor, any item, howsoever received by the Administrative Agent, representing any payment on or other Proceeds of
any of the Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.5.&#8239;&#8239;
<U>As to Intellectual Property Collateral</U>. Without prejudice to the Credit Agreement, each Grantor covenants and agrees to comply
with the following provisions as such provisions relate to any Intellectual Property constituting Collateral that is material to the
operations or business of such Grantor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
Grantor will deliver, concurrently with the delivery of any Compliance Certificate in accordance with Section&#8239;7.1(d)&#8239;of the
Credit Agreement, a report listing all published applications for the registration of any Intellectual Property with the United States
Patent and Trademark Office filed during such quarter and, upon the request of the Administrative Agent (subject to the terms of the
Credit Agreement and this Security Agreement), such Grantor shall execute and deliver a customary Intellectual Property security agreement
as the Administrative Agent may reasonably request to evidence the Administrative Agent&rsquo;s security interest in such Intellectual
Property; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
Grantor will execute and deliver to the Administrative Agent, upon the Administrative Agent&rsquo;s written request, a Patent Security
Agreement, Trademark Security Agreement and/or Copyright Security Agreement, as the case may be, in the forms of <U>Exhibit&#8239;A</U>,
<U>Exhibit&#8239;B </U>and <U>Exhibit&#8239;C </U>hereto, respectively, following its obtaining an ownership interest in any such Patent,
Trademark or Copyright that is issued, registered, or applied for with the U.S. Patent and Trademark Office or the U.S. Copyright Office,
and shall execute and deliver to the Administrative Agent any other document reasonably requested by the Administrative Agent, in writing,
to evidence the Administrative Agent&rsquo;s interest in any part of such item of Intellectual Property that is Collateral unless such
Grantor determines, in each case, in good faith (with the consent of the Required Lenders) that any such Intellectual Property is either
(i)&#8239;of negligible economic value to such Grantor or (ii)&#8239;not material to such Grantor&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.6. <U>As to
Letter-of-Credit Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Grantor, by granting a security interest in its Letter of Credit Rights to the Administrative Agent, intends to (and hereby does) collaterally
assign to the Administrative Agent its rights (including its contingent rights thereunder) to the Proceeds of all Letter-of-Credit Rights
of which it is or hereafter becomes a beneficiary or assignee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence and solely during the continuation of an Event of Default, such Grantor will, promptly upon request by the Administrative
Agent, (i)&#8239;notify (and such Grantor hereby authorizes the Administrative Agent to notify) the issuer and each nominated Person with
respect to each of the Letters of Credit of such Grantor with value in excess of $5,000,000 that the Proceeds thereof have been assigned
to the Administrative Agent hereunder and any payments due or to become due in respect thereof are to be made directly to the Administrative
Agent and (ii)&#8239;arrange for the Administrative Agent to become the transferee beneficiary of each such Letter of Credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 211; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.7.
<U>As to Commercial Tort Claims</U>. Each Grantor covenants and agrees that, until the Termination Date, with respect to any Commercial
Tort Claim with value in excess of $5,000,000 hereafter arising, it shall reasonably promptly deliver to the Administrative Agent a supplement
in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders, together with all supplements to
schedules thereto, identifying such new Commercial Tort Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.8.
<U>Electronic Chattel Paper and Transferable Records</U>. If any Grantor at any time holds or acquires an interest in any Electronic
Chattel Paper or any &ldquo;transferable record,&rdquo; as that term is defined in Section&#8239;201 of the U.S. Federal Electronic Signatures
in Global and National Commerce Act or in Section&#8239;16 of the U.S. Uniform Electronic Transactions Act, as in effect in any relevant
jurisdiction, constituting Collateral and with a value in excess of $1,500,000 in principal amount individually or $5,000,000 in principal
amount in the aggregate, such Grantor shall promptly notify the Administrative Agent thereof and, at the request of the Administrative
Agent, shall take such action as the Administrative Agent may reasonably request to vest in the Administrative Agent control under Section&#8239;9-105
of the UCC of such Electronic Chattel Paper or control under Section&#8239;201 of the Federal Electronic Signatures in Global and National
Commerce Act or, as the case may be, Section&#8239;16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction,
of such transferable record. The Administrative Agent agrees with such Grantor that the Administrative Agent will arrange, pursuant to
procedures reasonably satisfactory to the Administrative Agent and so long as such procedures will not result in the Administrative Agent&rsquo;s
loss of control, for the Grantor to make alterations to the Electronic Chattel Paper or transferable record permitted under Section&#8239;9-105
of the UCC or, as the case may be, Section&#8239;201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act or
Section&#8239;16 of the U.S. Uniform Electronic Transactions Act for a party in control to allow without loss of control, unless an Event
of Default has occurred and is continuing or would occur after taking into account any action by such Grantor with respect to such Electronic
Chattel Paper or transferable record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.9.
<U>Certain Limitations</U>. Notwithstanding anything to the contrary set forth herein or in any other Loan Document:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Grantors shall not be required to provide any notice or obtain the consent of any governmental authorities under the Federal Assignment
of Claims Act (or any state equivalent thereof);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
than with respect to any fixture affixed to any real property located at any Fixture Location, the Grantors shall not be required to
file any fixture filing or take any action other than the filing of a UCC financing statement with respect to any security interest in
Fixtures affixed to or attached to any other real property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 212; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
than actions to be taken by the Grantors at the request of the Administrative Agent (at the direction of the Required Lenders)
pursuant to <U>Section&#8239;3.8(a)</U>, the Grantors that are not Foreign Subsidiaries shall not be required to take any action
(other than filings pursuant to the UCC in the office of the secretary of state (or similar central filing office) of the relevant
state(s)) (A)&#8239;with respect to any assets located outside of the United States, (B)&#8239;in any non-U.S. jurisdiction, or
(C)&#8239;required by the laws of any non-U.S. jurisdiction to create, perfect or maintain any security interest or otherwise (it
being understood that there shall be no security agreements or pledge agreements governed by the laws of any non-U.S. jurisdiction),
in each case of the foregoing <U>clauses (A)</U>&#8239;through <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>(C)</U></FONT>,
other than the delivery of any pledged Capital Securities of a Foreign Subsidiary of any Grantor and subject to the Required
Lenders&rsquo; consent (not to be unreasonably withheld, conditioned or delayed) that the burden or cost of taking such action will
outweigh the benefits to be obtained by the Lenders therefrom, including by taking into account the overall collateral package and
the amount of the Loans; <U>provided</U>, that no Grantor shall be required to take any action for the perfection or maintenance of
any security interest hereunder with respect to Intellectual Property Collateral in any non-U.S. jurisdiction other than pursuant to <U>Section&#8239;3.8(a)</U>;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
send notices to account debtors or other contractual third parties other than during the occurrence of an Event of Default; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
take any action with respect to a security interest in Letter-of-Credit Rights except the filing of a UCC financing statement and such
actions set forth in <U>Section&#8239;4.6</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.10.
<U>Further Assurances, Etc</U>. Each Grantor agrees that, from time to time at its own expense, it will, subject to the terms of this
Security Agreement and the other Loan Documents, promptly execute and deliver all further instruments and documents, and take all further
action, that may be necessary or that the Administrative Agent may reasonably request, in order to perfect, preserve and protect any
security interest granted or purported to be granted hereby or to enable the Administrative Agent to exercise and enforce its rights
and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, such Grantor will:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;from
time to time upon the request of the Administrative Agent, promptly deliver to the Administrative Agent such stock powers, instruments
and similar documents, reasonably satisfactory in form and substance to the Administrative Agent, with respect to such Collateral as
the Administrative Agent may request and will, from time to time upon the request of the Administrative Agent, after the occurrence and
solely during the continuance of any Event of Default, promptly transfer any securities constituting Collateral into the name of any
nominee designated by the Administrative Agent; if any Collateral shall be evidenced by an Instrument, negotiable Document, Promissory
Note or tangible Chattel Paper, deliver and pledge to the Administrative Agent hereunder such Instrument, negotiable Document, Promissory
Note or tangible Chattel Paper (other than Instruments, negotiable Documents, Promissory Notes or tangible Chattel Papers in principal
amount less than $1,500,000 individually or $ 5,000,000 in the aggregate) duly endorsed and accompanied by duly executed instruments
of transfer or assignment, all in form and substance reasonably satisfactory to the Administrative Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 213; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;file
(and such Grantor hereby authorizes the Administrative Agent to file) such Financing Statements or continuation statements, or amendments
thereto, and such other instruments or notices, as may be necessary and that the Administrative Agent may reasonably request in order
to perfect and preserve the security interests and other rights granted or purported to be granted to the Administrative Agent, for the
benefit of the Secured Parties, hereby;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;at
all times keep pledged to the Administrative Agent, for the benefit of the Secured Parties, pursuant hereto, on a first-priority (except
for Permitted Liens), perfected basis, all Investment Property constituting Collateral, all dividends and Distributions with respect
thereto, and all interest and principal with respect to Promissory Notes constituting Collateral, and all Proceeds and rights from time
to time received by or distributable to such Grantor in respect of any of the foregoing Collateral, in each case, to the extent required
hereunder or under any other Loan Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;not
take or omit to take any action the taking or the omission of which would result in the impairment or alteration of the obligations owing
under any Payment Intangible or other Instrument constituting Collateral in any material respect, except as provided in <U>Section&#8239;4.4</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;not
create any tangible Chattel Paper, with a value in excess of $1,500,000 individually or $5,000,000 in the aggregate, without, at the
request of the Administrative Agent, placing a legend on such tangible Chattel Paper reasonably acceptable to the Administrative Agent
indicating that the Administrative Agent has a security interest in such Chattel Paper;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;furnish
to the Administrative Agent, from time to time at the Administrative Agent&rsquo;s reasonable request, statements and schedules further
identifying and describing the Collateral and such other reports in connection with the Collateral, all in reasonable detail; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;do
all things reasonably requested by the Administrative Agent in accordance with and subject to the terms and conditions of this Security
Agreement and the other Loan Documents in order to enable the Administrative Agent to have and maintain control over the Collateral consisting
of Investment Property, Deposit Accounts (other than Excluded Accounts), Letter-of-Credit Rights and Electronic Chattel Paper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">With
respect to the foregoing and the grant of the security interest hereunder, each Grantor hereby authorizes the Administrative Agent to
file one or more financing or continuation statements, and amendments thereto, relative to all or any part of the Collateral. Each Grantor
agrees that a carbon, photographic or other reproduction of this Security Agreement or any UCC financing statement covering the Collateral
or any part thereof shall be sufficient as a UCC financing statement where permitted by Law. Each Grantor hereby authorizes the Administrative
Agent to file financing statements describing as the collateral covered thereby &ldquo;all of the debtor&rsquo;s personal property or
assets&rdquo; or words to that effect, notwithstanding that such wording may be broader in scope than the Collateral described in this
Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Notwithstanding
anything else herein, the Administrative Agent shall not be liable for the preparation, filing or maintenance of any UCC or other applicable
financing statements or instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 214; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&#8239;V</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">THE
ADMINISTRATIVE AGENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.1.
<U>Agent Appointed Attorney-in-Fact</U>. Each Grantor hereby irrevocably designates and appoints the Administrative Agent, on behalf
of the Secured Parties, as its attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor
or otherwise, from time to time in the Administrative Agent&rsquo;s discretion, solely following the occurrence and during the continuance
of an Event of Default, to take any action and to execute any instrument in accordance with applicable Law which the Administrative Agent
may deem reasonably necessary or advisable to accomplish the purposes of this Security Agreement, and, subject to and in furtherance
of the foregoing,:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
demand, collect, settle, compromise and adjust, and give discharges and releases concerning the Collateral, all as the Administrative
Agent may deem reasonably appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
commence and prosecute any actions at any court for the purposes of collecting any of the Collateral and enforcing any other right in
respect thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
defend, settle or compromise any action brought in respect of the Collateral and, in connection therewith, give such discharge or release
as the Administrative Agent may deem reasonably appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
pay or discharge taxes, liens, security interests or other encumbrances levied or placed on or threatened against the Collateral;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
direct any parties liable for any payment in connection with any of the Collateral to make payment of any and all monies due and to become
due thereunder directly to the Administrative Agent or as the Administrative Agent shall direct;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
receive payment of and receipt for any and all monies, claims, and other amounts due and to become due at any time in respect of or arising
out of any Collateral;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
sign and endorse any drafts, assignments, proxies, stock powers, verifications, notices and other documents relating to the Collateral;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
execute and deliver all assignments, conveyances, statements, financing statements, renewal financing statements, security and pledge
agreements, affidavits, notices and other agreements, instruments and documents that the Administrative Agent may deem reasonably appropriate
in order to perfect and maintain the security interests and liens granted in this Security Agreement and in order to fully consummate
all of the transactions contemplated herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
exchange any of the Collateral or other property upon any merger, consolidation, reorganization, recapitalization or other readjustment
of the issuer thereof and, in connection therewith, deposit any of the Collateral with any committee, depository, transfer agent, registrar
or other designated agency upon such terms as the Administrative Agent may deem reasonably appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 215; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;upon
delivery of notice in accordance with Section&#8239;4.1.5(b), to vote for a shareholder or member resolution, or to sign an instrument
in writing, sanctioning the transfer of any or all of the Collateral into the name of the Administrative Agent (or its designee) or one
or more of the Secured Parties or into the name of any transferee to whom the Collateral or any part thereof may be sold pursuant to
<U>Article&#8239;VI</U> hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
to perform the affirmative obligations of such Grantor hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Each Grantor hereby acknowledges, consents and agrees that the power
of attorney granted pursuant to this <U>Section&#8239;5.1 </U>is irrevocable until the Termination Date and coupled with an interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.2.
<U>Assignment by the Administrative Agent</U>. The Administrative Agent may from time to time assign its security interest in the Collateral
and any portion thereof to a successor agent in accordance with the Credit Agreement, and the assignee shall be entitled to all of the
rights and remedies of the Administrative Agent under this Security Agreement in relation thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.3.
<U>Administrative Agent May&#8239;Perform</U>. Upon the occurrence and solely during the continuation of any Event of Default, if any
Grantor fails to perform any agreement contained herein, the Administrative Agent, on behalf of the Secured Parties, may (but shall not
be obligated to), with written notice to such Grantor (which notice may be delivered to such Grantor after the Administrative Agent has
taken such actions as described in this <U>Section&#8239;5.3</U>), itself perform, or cause performance of, such agreement, that the Administrative
Agent deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein to
the extent provided for herein, and the expenses of the Administrative Agent incurred in connection therewith shall be payable by such
Grantor pursuant to Sections 10.3 and 10.4 of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.4.
<U>Administrative Agent Has No Duty</U>. The powers conferred on the Administrative Agent hereunder are solely to protect its interest
in the Collateral and shall not impose any duty on it to exercise any such powers. Except for reasonable care of any Collateral in its
possession and the accounting for moneys actually received by it hereunder, the Administrative Agent shall have no duty as to any Collateral
or responsibility for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ascertaining
or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relative to any Investment Property,
whether or not the Administrative Agent has or is deemed to have knowledge of such matters, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;taking
any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
provisions of Article&#8239;XI of the Credit Agreement, including the rights, privileges, protections, benefits, indemnities and immunities
of the Administrative Agent are incorporated herein, <I>mutatis mutandis</I>, as if a part hereof, and shall also apply to the Administrative
Agent acting under or in connection with this Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.5.
<U>Reasonable Care</U>. The Administrative Agent is required to exercise reasonable care in the custody and preservation of any of the
Collateral in its possession; <U>provided </U>that the Administrative Agent shall be deemed to have exercised reasonable care in the
custody and preservation of any of the Collateral, if such Collateral is accorded treatment substantially equal to that which the Administrative
Agent accords its own property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 216; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.6.
<U>Release of Collateral</U>. Without limiting the effects of Section&#8239;7.5, the Administrative Agent, upon the direction of the Required
Lenders or otherwise in accordance with the Credit Agreement, may release any of the Collateral from this Security Agreement or may substitute
any of the Collateral for other Collateral without altering, varying or diminishing in any way the force, effect, Lien, pledge or security
interest of this Security Agreement as to any Collateral not expressly released or substituted, and this Security Agreement shall continue
as a first priority Lien (subject to Permitted Liens) on all Collateral not expressly released or substituted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&#8239;VI</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">REMEDIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.1. <U>Certain
Remedies</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence and solely during the continuation of any Event of Default, the Administrative Agent may exercise in respect of the Collateral,
in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of the Administrative
Agent on default under the UCC and, subject to and in furtherance of the foregoing, in accordance with applicable Law the Administrative
Agent also may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;take
possession of any Collateral not already in its possession without demand and without legal process;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;require
each Grantor to, and each Grantor hereby agrees that it will, at its expense and upon request of the Administrative Agent forthwith,
assemble all or part of the Collateral as directed by the Administrative Agent and make it available to the Administrative Agent at a
place to be designated by the Administrative Agent that is reasonably convenient to both the Administrative Agent and such Grantor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;enter
onto the property where any Collateral is located and take possession thereof without demand and without legal process; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;without
notice except as specified below, lease, license, sell or otherwise dispose of the Collateral or any part thereof in one or more parcels
at any public or private sale, at any of the Administrative Agent&rsquo;s offices or elsewhere, for cash, on credit or for future delivery,
and upon such other terms as the Administrative Agent may deem commercially reasonable. Each Grantor agrees that, to the extent notice
of sale shall be required by Law, at least 10 days&rsquo; prior notice to such Grantor of the time and place of any public sale or the
time after which any private sale is to be made shall constitute reasonable notification. The Administrative Agent shall not be obligated
to make any sale of Collateral regardless of notice of sale having been given. The Administrative Agent may adjourn any public or private
sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the
time and place to which it was so adjourned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 217; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence and solely during the continuation of any Event of Default, all cash Proceeds received by the Administrative Agent in
respect of any sale of, collection from, or other realization upon, all or any part of the Collateral shall be applied by the Administrative
Agent against all or any part of the Obligations as set forth in Section&#8239;4.4(b)&#8239;of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence and solely during the continuation of any Event of Default, the Administrative Agent may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;transfer
all or any part of the Collateral into the name of the Administrative Agent or its nominee, with or without disclosing that such Collateral
is subject to the Lien hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;notify
the parties obligated on any of the Collateral to make payment to the Administrative Agent of any amount due or to become due thereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;withdraw,
or cause or direct the withdrawal, of all funds with respect to any Collateral Account;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;enforce
collection of any of the Collateral by suit or otherwise, and surrender, release or exchange all or any part thereof, or compromise or
extend or renew for any period (whether or not longer than the original period) any obligations of any nature of any party with respect
thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;endorse
any checks, drafts, or other writings in any Grantor&rsquo;s name to allow collection of the Collateral;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;take
control of any Proceeds of the Collateral; and</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;execute (in the name, place and stead of any Grantor) endorsements, assignments, stock powers and other instruments of conveyance or
transfer with respect to all or any of the Collateral.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.2. <U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.3.
<U>Compliance with Restrictions</U>. Each Grantor agrees that in any sale of any of the Collateral whenever an Event of Default shall
have occurred and be continuing, the Administrative Agent is hereby authorized to comply with any limitation or restriction in connection
with such sale as it may be advised by counsel is necessary in order to avoid any violation of applicable Law (including compliance with
such procedures as may restrict the number of prospective bidders and purchasers, require that such prospective bidders and purchasers
have certain qualifications, and restrict such prospective bidders and purchasers to Persons who will represent and agree that they are
purchasing for their own account for investment and not with a view to the distribution or resale of such Collateral), or in order to
obtain any required approval of the sale or of the purchaser by any Governmental Authority or official, and such Grantor further agrees
that such compliance shall not result in such sale being considered or deemed not to have been made in a commercially reasonable manner,
nor shall the Administrative Agent be liable nor accountable to such Grantor for any discount allowed by the reason of the fact that
such Collateral is sold in compliance with any such limitation or restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 218; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ARTICLE&#8239;VII</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">MISCELLANEOUS
PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.1.
<U>Loan Document</U>. This Security Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise
expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Section&#8239;1.5
and Article&#8239;X thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.2.
<U>Binding on Successors, Transferees and Assigns; Assignment</U>. This Security Agreement shall remain in full force and effect until
the Termination Date has occurred, shall be binding upon the Grantors and their successors, permitted transferees and permitted assigns
and shall inure to the benefit of and be enforceable by the Administrative Agent and the Secured Parties; <U>provided</U> that no Grantor
may assign or transfer any of its rights or obligations hereunder without the prior consent of the Required Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.3.
<U>Amendments, Etc</U>. No amendment or modification to or waiver of any provision of this Security Agreement, nor consent to any departure
by any Grantor from its obligations under this Security Agreement, shall in any event be effective unless the same shall be in writing
and signed by the Administrative Agent and the Grantors and then such waiver or consent shall be effective only in the specific instance
and for the specific purpose for which given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.4.
<U>Notices</U>. All notices and other communications provided for hereunder shall be delivered or made as provided in Section&#8239;10.2
of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.5. <U>Release
of Liens</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Security Agreement and all security interests granted hereunder shall terminate with respect to all Obligations upon the Termination
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
security interest granted hereunder in any Collateral shall be released in accordance with <U>Section&#8239;11.9(a)</U>&#8239;of the Credit
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
Grantor (other than the Borrower) shall be released from its obligations hereunder and the security interest granted hereunder in the
Collateral of such Grantor shall be released in accordance with <U>Section&#8239;11.9(b)</U>&#8239;of the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Upon
the occurrence of the Termination Date or any event specified in subclauses (i), (ii)&#8239;and (iii)&#8239;of Section&#8239;11.9(a)&#8239;of
the Credit Agreement, the security interest granted herein with respect to each applicable Grantor or any applicable property shall be
deemed to be automatically released and such property shall automatically revert to the applicable Grantor with no further action on
the part of any Person. In connection with any termination or release pursuant to <U>paragraph (a)</U>, <U>(b)&#8239;</U>or <U>(c)&#8239;</U>of
this <U>Section&#8239;7.5</U>, the Administrative Agent shall, at the Grantors&rsquo; sole expense, deliver to the Grantors, without any
representations, warranties or recourse of any kind whatsoever, all such Collateral held by the Administrative Agent hereunder, and execute
and deliver to, and authorize the filing by, the Grantors such documents as the Grantors shall reasonably request to evidence such termination
or release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 219; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.6.
<U>Additional Grantors</U>. Upon the execution and delivery by any other Person of a supplement in the form of <U>Annex I</U> hereto,
such Person shall become a &ldquo;Grantor&rdquo; hereunder with the same force and effect as if it were originally a party to this Security
Agreement and named as a &ldquo;Grantor&rdquo; hereunder. The execution and delivery of such supplement shall not require the consent
of any other Grantor hereunder, and the rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding
the addition of any new Grantor as a party to this Security Agreement. Any schedules delivered by any additional Grantor pursuant to
such supplement shall supplement the relevant schedules to this Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.7.
<U>No Waiver; Remedies</U>. In addition to, and not in limitation of <U>Section&#8239;2.5</U>, no failure on the part of the Administrative
Agent to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial
exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein
provided are cumulative and not exclusive of any remedies provided by Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.8.
<U>Severability</U>. Any provision of this Security Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such
provision and such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining
provisions of this Security Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.9.
<U>Governing Law, Entire Agreement, Etc</U>. THIS SECURITY AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER
IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY
SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS
5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Security Agreement, along with the other Loan Documents,
constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements,
written or oral, with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.10.
<U>Counterparts</U>. This Security Agreement may be executed by the parties hereto in several counterparts, each of which shall be an
original and all of which shall constitute together but one and the same agreement. This Security Agreement shall become effective when
counterparts hereof executed on behalf of all of the signatories hereto, shall have been received by the Administrative Agent. The words
 &ldquo;execute,&rdquo; &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature&rdquo; and words of like import in this Agreement
or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures, the
electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the
keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed
signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law,
including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records
Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 220; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.11.
<U>Rights of Required Lenders</U>. If the Administrative Agent has a right to take or omit to take any action hereunder, it shall exercise
such right if so instructed by the Required Lenders. With respect to any discretion, consent, approval or similar such action to be made,
taken, omitted to be taken or determined by the Administrative Agent under this Agreement (each, an &ldquo;<U>Agent Determination</U>&rdquo;),
such Agent Determination shall be made by the Administrative Agent at the direction of the Required Lenders. If the Administrative Agent
has resigned and no successor agent has been appointed pursuant to Section&#8239;10.10 of the Credit Agreement, all rights of the Administrative
Agent hereunder may be exercised by the Required Lenders (acting jointly and not severally).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 221; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
each of the parties hereto has caused this Security Agreement to be duly executed and delivered by its Authorized Officer as of the date
first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CARIS LIFE SCIENCES, INC. <BR>
    CARIS SCIENCE, INC. CARIS MPI, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CARIS PHARMATECH, INC. <BR>
    CARIS THERAPEUTICS, INC. <BR>
    </B>each, as a Grantor</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;to Security Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 222 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>WILMINGTN TRUST, NATIONAL ASSOCIATION</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">as the Administrative Agent</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;to Security Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 223 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">ANNEX A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS SCIENCE,&#8239;INC., a Texas corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS MPI,&#8239;INC., a Texas corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS PHARMATECH,&#8239;INC., a Texas
corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">CARIS THERAPEUTICS,&#8239;INC., a Texas
corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Annex
A to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 224 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE
I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">to
Security Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[Schedules
to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<!-- Field: Page; Sequence: 225; Options: NewSection; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE
II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">to
Security Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[Schedules
to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<!-- Field: Page; Sequence: 226; Options: NewSection; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE
III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">to
Security Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[Schedules
to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<!-- Field: Page; Sequence: 227; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE
IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">to
Security Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">[Schedules
to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<!-- Field: Page; Sequence: 228; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">EXHIBIT&#8239;A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>PATENT
SECURITY AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
PATENT SECURITY AGREEMENT, dated as of ________ __, 20__ (this &ldquo;<U>Agreement</U>&rdquo;), is made by [NAME OF GRANTOR], a ________
_______ (the &ldquo;<U>Grantor</U>&rdquo;), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized
and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the
 &ldquo;<U>Administrative Agent</U>&rdquo;), as Administrative Agent for the Secured Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>W
I T N E S S E T H </U></FONT><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement, dated as of January&#8239;18, 2023 (as amended, supplemented or otherwise modified from time to time,
the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among Caris Life Sciences,&#8239;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in
favor of the Administrative Agent, for the benefit of the Secured Parties, dated as of January&#8239;18, 2023 (as amended, supplemented
or otherwise modified from time to time, the &ldquo;<U>Security Agreement</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement and pursuant to clause (b)&#8239;of Section&#8239;4.5 of the Security Agreement, the Grantor is required
to execute and deliver this Security Agreement and to grant to the Administrative Agent, for the benefit of the Secured Parties, a continuing
security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the Grantor has duly authorized the execution, delivery and performance of this Security Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for
the benefit of the Secured Parties, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;1.
<U>Definitions</U>. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including
its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;2.
<U>Grant of Security Interest</U>. The Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing
security interest in all of the Grantor&rsquo;s right, title and interest in and to each issued Patent and Patent application referred
to in <U>Schedule I </U>attached hereto (the &ldquo;<U>Patent Collateral</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 229 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;3.
<U>Security Agreement</U>. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security
interest of the Administrative Agent in the Patent Collateral with the United States Patent and Trademark Office. The security interest
granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Administrative Agent
for the benefit of the Secured Parties under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured
Parties thereunder) shall remain in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.
<U>Release of Liens</U>. The security interests granted herein in such Patent Collateral shall terminate and be released in accordance
with Section&#8239;7.5 of the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.
<U>Acknowledgment</U>. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with
respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms
and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.
<U>Loan Document</U>. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly
indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article&#8239;X
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.
<U>Effectiveness</U>. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received
by the Administrative Agent. Delivery of an executed counterpart of a signature page&#8239;to this Security Agreement by email (e.g.,
 &ldquo;pdf&rdquo; or &ldquo;tiff&rdquo;) or telecopy shall be effective as delivery of a manually executed counterpart of this Security
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 230; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME OF GRANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;to Patent Security Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 231 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO PATENT SECURITY
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Issued
Patents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Country</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Patent No.</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issue Date</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Inventor(s)</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Title</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Pending
Patent Applications</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Country</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Serial No.</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Filing Date</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Inventor(s)</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
I to Patent Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 232; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">EXHIBIT&#8239;B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>TRADEMARK
SECURITY AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
TRADEMARK SECURITY AGREEMENT, dated as of ________ __, 20__ (this &ldquo;<U>Agreement</U>&rdquo;), is made by [NAME OF GRANTOR], a ________
_______ (the &ldquo;<U>Grantor</U>&rdquo;), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized
and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the
 &ldquo;<U>Administrative Agent</U>&rdquo;), as Administrative Agent for the Secured Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>W
I T N E S S E T H </U></FONT><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement, dated as of January&#8239;18, 2023 (as amended, supplemented or otherwise modified from time to time,
the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among Caris Life Sciences,&#8239;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in
favor of the Administrative Agent, for the benefit of the Secured Parties, dated as of January&#8239;18, 2023 (as amended, supplemented
or otherwise modified from time to time, the &ldquo;<U>Security Agreement</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement and pursuant to clause (b)&#8239;of Section&#8239;4.5 of the Security Agreement, the Grantor is required
to execute and deliver this Security Agreement and to grant to the Administrative Agent, for the benefit of the Secured Parties, a continuing
security interest in all of the Trademark Collateral (as defined below) to secure all of the Obligations; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the Grantor has duly authorized the execution, delivery and performance of this Security Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for
the benefit of the Secured Parties, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;1.
<U>Definitions</U>. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including
its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;2.
<U>Grant of Security Interest</U>. The Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing
security interest in all of Grantor&rsquo;s right, title and interest in and to the Trademark registrations and applications referred
to in <U>Schedule I</U> attached hereto, excluding Trademark applications filed in the United States Patent and Trademark Office on the
basis of such Grantor&rsquo;s &ldquo;intent to use&rdquo; such trademark, unless and until acceptable evidence of use of the Trademark
has been filed with the United States Patent and Trademark Office pursuant to Section&#8239;1(c)&#8239;or Section&#8239;1(d)&#8239;of the
Lanham Act (15 U.S.C. 1051, et seq.), (the &ldquo;<U>Trademark Collateral</U>&rdquo;).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Exhibit&#8239;B
to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 233; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;3.
<U>Security Agreement</U>. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security
interest of the Administrative Agent in the Trademark Collateral with the United States Patent and Trademark Office. The security interest
granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Administrative Agent
for the benefit of the Secured Parties under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured
Parties thereunder) shall remain in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.
<U>Release of Liens</U>. The security interests granted herein in such Trademark Collateral shall terminate and be released in accordance
with Section&#8239;7.5 of the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.
<U>Acknowledgment</U>. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with
respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms
and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.
<U>Loan Document</U>. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly
indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article&#8239;X
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.
<U>Effectiveness</U>. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received
by the Administrative Agent. Delivery of an executed counterpart of a signature page&#8239;to this Security Agreement by email (e.g.,
 &ldquo;pdf&rdquo; or &ldquo;tiff&rdquo;) or telecopy shall be effective as delivery of a manually executed counterpart of this Security
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Exhibit&#8239;B
to Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 234; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME OF GRANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;to Trademark Security Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 235 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO TRADEMARK SECURITY
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Registered
Trademarks</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top"><TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Country</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt"><U>Trademark</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt"><U>Registration No.</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt"><U>Registration Date</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Pending
Trademark Applications</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Country</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Trademark</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Serial No.</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Filing</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Date</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
I to Trademark Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<!-- Field: Page; Sequence: 236; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">EXHIBIT&#8239;C</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>COPYRIGHT
SECURITY AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
COPYRIGHT SECURITY AGREEMENT, dated as of ________ __, 20__ (this &ldquo;<U>Agreement</U>&rdquo;), is made by [NAME OF GRANTOR], a ________
_______ (the &ldquo;<U>Grantor</U>&rdquo;), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized
and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the
 &ldquo;<U>Administrative Agent</U>&rdquo;), as Administrative Agent for the Secured Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>W
I T N E S S E T H </U></FONT><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement, dated as of January&#8239;18, 2023 (as amended, supplemented or otherwise modified from time to time,
the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among Caris Life Sciences,&#8239;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in
favor of the Administrative Agent, for the benefit of the Secured Parties, dated as of January&#8239;18, 2023 (as amended, supplemented
or otherwise modified from time to time, the &ldquo;<U>Security Agreement</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement and pursuant to clause (b)&#8239;of Section&#8239;4.5 of the Security Agreement, the Grantor is required
to execute and deliver this Security Agreement and to grant to the Administrative Agent, for the benefit of the Secured Parties, a continuing
security interest in all of the Copyright Collateral (as defined below) to secure all of the Obligations; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the Grantor has duly authorized the execution, delivery and performance of this Security Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for
the benefit of the Secured Parties, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;1.
<U>Definitions</U>. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including
its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;2.
<U>Grant of Security Interest</U>. The Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing
security interest in all of the Grantor&rsquo;s right, title and interest in and to the Copyright registrations and applications referred
to in <U>Schedule I </U>attached hereto (the &ldquo;<U>Copyright Collateral</U>&rdquo;).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Exhibit&#8239;C
to Security Agreement &ndash; Copyright Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<!-- Field: Page; Sequence: 237; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;3.
<U>Security Agreement</U>. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security
interest of the Administrative Agent in the Copyright Collateral with the United States Copyright Office. The security interest granted
hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Administrative Agent for the
benefit of the Secured Parties under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Parties
thereunder) shall remain in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.
<U>Release of Liens</U>. The security interests granted herein in such Copyright Collateral shall terminate and be released in accordance
with Section&#8239;7.5 of the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.
<U>Acknowledgment</U>. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with
respect to the security interest in the Copyright Collateral granted hereby are more fully set forth in the Security Agreement, the terms
and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.
<U>Loan Document</U>. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly
indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article&#8239;X
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.
<U>Effectiveness</U>. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received
by the Administrative Agent. Delivery of an executed counterpart of a signature page&#8239;to this Security Agreement by email (e.g.,
 &ldquo;pdf&rdquo; or &ldquo;tiff&rdquo;) or telecopy shall be effective as delivery of a manually executed counterpart of this Security
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Exhibit&#8239;C
to Security Agreement &ndash; Copyright Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 238; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME OF GRANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;to Copyright Security Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 239 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO COPYRIGHT SECURITY
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Registered
Copyrights</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Country</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Registration No.</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Registration Date</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Author(s)</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Title</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>Copyright
Pending Registration Applications</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Country</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Serial No.</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Filing Date</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Author(s)</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt"><U>Title</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
I to Copyright Security Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 240; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">ANNEX I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">TO SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>SUPPLEMENT
TO</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>PLEDGE
AND SECURITY AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
SUPPLEMENT, dated as of __, 20__ (this &ldquo;<U>Supplement</U>&rdquo;), is to the Pledge and Security Agreement, dated as of January&#8239;18,
2023 (as amended, supplemented or otherwise modified from time to time, the &ldquo;<U>Security Agreement</U>&rdquo;), among the Grantors
(such term, and other terms used in this Supplement, to have the meanings set forth in Article&#8239;I of the Security Agreement, unless
otherwise defined herein or if the context otherwise requires) from time to time party thereto, in favor of WILMINGTON TRUST, NATIONAL
ASSOCIATION, a national banking association organized and existing under the laws of the United States of America (together with its
Affiliates, successors, transferees and assignees, the &ldquo;<U>Administrative Agent</U>&rdquo;), as Administrative Agent for the Secured
Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>W
I T N E S S E T H </U></FONT><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Credit Agreement, dated as of January&#8239;18, 2023 (as amended, supplemented or otherwise modified from time to time,
the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among Caris Life Sciences,&#8239;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the provisions of Section&#8239;7.6 of the Security Agreement, each of the undersigned is becoming a Grantor under the Security
Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
each of the undersigned desires to become a &ldquo;Grantor&rdquo; under the Security Agreement in order to induce the Lenders to continue
to extend Loans under the Credit Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned
agrees, for the benefit of the Secured Parties, as follows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;1.
<U>Party to Security Agreement, Etc</U>. In accordance with the terms of the Security Agreement, by its signature below, each of the
undersigned hereby irrevocably agrees to become a Grantor under the Security Agreement with the same force and effect as if it were an
original signatory thereto and each of the undersigned hereby (a)&#8239;agrees to be bound by and comply with all of the terms and provisions
of the Security Agreement applicable to it as a Grantor and (b)&#8239;represents and warrants that the representations and warranties
made by it as a Grantor thereunder are true and correct in all material respects as of the date hereof, except for any representation
and warranty that is qualified by materiality or reference to Material Adverse Effect, which such representation and warranty shall be
true and correct in all respects (except in the case of any representation and warranty which expressly relates to a given date or period,
which representation and warranty was true and correct in all material respects (and in all respects if qualified by materiality or reference
to Material Adverse Effect) as of the respective date or for the respective period, as the case may be). In furtherance of the foregoing,
each reference to a &ldquo;Grantor&rdquo; and/or &ldquo;Grantors&rdquo; in the Security Agreement shall be deemed to include each of
the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 241; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;2.
<U>Schedules</U>. Each of the undersigned Grantors hereby authorizes the Administrative Agent to add the information set forth on the
Schedules to this Supplement to the correlative Schedules attached to the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;3.
<U>Representations</U>. Each of the undersigned Grantors hereby represents and warrants that this Supplement has been duly authorized,
executed and delivered by it and that this Supplement and the Security Agreement constitute its legal, valid and binding obligation,
enforceable against it in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally and by principles of equity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;4.
<U>Full Force of Security Agreement</U>. Except as expressly supplemented hereby, the Security Agreement shall remain in full force and
effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;5.
<U>Severability</U>. Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid
under applicable Law, but if any provision of this Supplement shall be prohibited by or invalid under such Law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining
provisions of this Supplement or the Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;6.
<U>Governing Law, Entire Agreement, Etc</U>. THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT
OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SUPPLEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402
OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire
understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral,
with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SECTION&#8239;7.
<U>Effectiveness</U>. This Supplement shall become effective when a counterpart hereof executed by each undersigned Grantor shall have
been received by the Administrative Agent. The words &ldquo;execute,&rdquo; &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature&rdquo;
and words of like import in this Supplement or in any amendment or other modification hereof (including waivers and consents) shall be
deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms
approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect,
validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to
the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act,
the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
II to Security Agreement Supplement] </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 242; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first
above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME OF ADDITIONAL
    GRANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NAME OF ADDITIONAL
    GRANTOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;to Security Agreement Supplement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 243 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 379pt; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE
I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 214pt; text-align: right"><FONT STYLE="font-size: 10pt">TO SECURITY
AGREEMENT SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiary</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt"><U>Name of Grantor</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Interest</U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt"><U>Percentage</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
I to Security Agreement Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 244; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 394pt; text-align: right"><FONT STYLE="font-size: 10pt">SCHEDULE
II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right"><FONT STYLE="font-size: 10pt">TO SECURITY
AGREEMENT SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item A. <U>Location of each Grantor</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
  <TD STYLE="border: Black 1pt solid; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
  of Grantor:</FONT><FONT STYLE="font-size: 10pt"><BR> &#8239;&#8239;</FONT></TD>
  <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; border-right: Black 1pt solid; vertical-align: top; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Location&#8239;&#8239;&#8239;for&#8239;&#8239;&#8239;purposes&#8239;&#8239;&#8239;of&#8239;&#8239;&#8239;UCC
  (executive office / principal place of business):</FONT></TD>
</TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item B. <U>Filing locations (last five
years)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item C. <U>Trade names</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border: Black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of
    Grantor:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    Names:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 59pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item D. <U>Merger or other corporate
reorganization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item E. <U>Grantor's federal taxpayer
ID numbers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border: Black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of
    Grantor:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxpayer
    ID number:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 59pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item F. <U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item G. <U>Deposit Accounts, Securities
Accounts and Commodities Accounts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-size: 10pt; vertical-align: top">
  <TD STYLE="font-size: 10pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
  of Grantor:</FONT></TD>
  <TD STYLE="font-size: 10pt; border: Black 1pt solid; width: 50%"><FONT STYLE="font-size: 10pt">Description of Deposit Accounts, Securities Accounts
  and Commodities Accounts:</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
  <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
  <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item H. <U>Letter-of-Credit Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
II to Security Agreement Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 245; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item I. <U>Commercial Tort Claims</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Item J. <U>Pledged Notes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-size: 10pt; vertical-align: top">
  <TD STYLE="font-size: 10pt; border: Black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Grantor:</FONT></TD>
  <TD STYLE="font-size: 10pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%"><FONT STYLE="font-size: 10pt">Description
  of Pledged Notes:</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
  <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
  <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
II to Security Agreement Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 246; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right; text-indent: 157.25pt"><FONT STYLE="font-size: 10pt">SCHEDULE
III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right; text-indent: 157.25pt"><FONT STYLE="font-size: 10pt">TO
SECURITY AGREEMENT SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Patents</U></FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
III to Security Agreement Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 247; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right; text-indent: 156.65pt"><FONT STYLE="font-size: 10pt">SCHEDULE
IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right; text-indent: 156.65pt"><FONT STYLE="font-size: 10pt">TO
SECURITY AGREEMENT SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trademarks</U></FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
IV to Security Agreement Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 248; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right; text-indent: 160.6pt"><FONT STYLE="font-size: 10pt">SCHEDULE
V</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233pt; text-align: right; text-indent: 160.6pt"><FONT STYLE="font-size: 10pt">TO
SECURITY AGREEMENT SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Copyrights</U></FONT><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Schedule
V to Security Agreement Supplement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 249; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&#8239;F</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">FORM&#8239;OF
ASSIGNMENT AND ASSUMPTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Assignment and Assumption (the &ldquo;<U>Assignment and Assumption</U>&rdquo;) is dated as of the Effective Date set forth below and
is entered into by and between [the][each]</FONT><FONT STYLE="font-size: 10pt"><SUP>1</SUP> Assignor identified in item 1 below ([the][each,
an] &ldquo;<U>Assignor</U>&rdquo;) and [the][each]<SUP>2 </SUP>Assignee identified in item 2 below ([the][each, an] &ldquo;<U>Assignee</U>&rdquo;).
[It is understood and agreed that the rights and obligations of [the Assignors][the Assignees]<SUP>3</SUP> hereunder are several and
not joint.]<SUP>4</SUP> Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified
below (as amended, restated, amended and restated, supplemented or otherwise modified in writing from time to time, the &ldquo;<U>Credit
Agreement</U>&rdquo;), receipt of a copy of which is hereby acknowledged by [the][each] Assignee. The Standard Terms and Conditions set
forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption
as if set forth herein in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
an agreed consideration, [the][each] Assignor hereby irrevocably sells and assigns to [the Assignee][the respective Assignees], and [the][each]
Assignee hereby irrevocably purchases and assumes from [the Assignor][the respective Assignors], subject to and in accordance with the
Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated
below (i)&#8239;all of [the Assignor&rsquo;s][the respective Assignors&rsquo;] rights and obligations in [its capacity as a Lender][their
respective capacities as Lenders] under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the
extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of [the Assignor][the
respective Assignors] and (ii)&#8239;to the extent permitted to be assigned under applicable Law, all claims, suits, causes of action
and any other right of [the Assignor (in its capacity as a Lender)][the respective Assignors (in their respective capacities as Lenders)]
against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments
delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including,
but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related
to the rights and obligations sold and assigned pursuant to clause (i)&#8239;above (the rights and obligations sold and assigned by [the][any]
Assignor to [the][any] Assignee pursuant to clauses (i)&#8239;and (ii)&#8239;above being referred to herein collectively as [the][an] &ldquo;<U>Assigned
Interest</U>&rdquo;). Each such sale and assignment is without recourse to [the][any] Assignor and, except as expressly provided in this
Assignment and Assumption, without representation or warranty by [the][any] Assignor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT><FONT STYLE="font-size: 10pt">For bracketed language here and elsewhere in this form relating to the Assignor(s), if the
assignment is from a single Assignor, choose the first bracketed language. If the assignment is from multiple Assignors, choose the second
bracketed language.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT><FONT STYLE="font-size: 10pt">For bracketed language here and elsewhere in this form relating to the Assignee(s), if the
assignment is to a single Assignee, choose the first bracketed language. If the assignment is to multiple Assignees, choose the second
bracketed language.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP></FONT><FONT STYLE="font-size: 10pt">Select as appropriate.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4
</SUP></FONT><FONT STYLE="font-size: 10pt">Include bracketed language if there are either multiple Assignors or multiple Assignees.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 250 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; padding-bottom: 3pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify; width: 10%"><FONT STYLE="font-size: 10pt">Assignor[s]:</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify; width: 37%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify; width: 48%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
                                                                                                                      <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; padding-bottom: 3pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify">&nbsp;</TD>
                                                          <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">[Assignor [is][is not] a Defaulting
Lender]</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify">&nbsp;</TD></TR>
                                                                                                                      </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -3in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; padding-bottom: 3pt; width: 5%"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify; width: 10%"><FONT STYLE="font-size: 10pt"><U>Assignee[s]</U>:</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify; width: 37%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify; width: 48%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
                                                          <TD STYLE="font-size: 10pt; padding-bottom: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
                                                                                                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.44in"><FONT STYLE="font-size: 10pt">[for each Assignee, indicate [Affiliate][Approved
Fund] of [<I>identify Lender</I>]]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Borrower(s)</U>:
                                            Caris Life Sciences,&#8239;Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Administrative
                                            Agent</U>: Wilmington Trust, National Association, as the Administrative Agent under the
                                            Credit Agreement</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Credit
                                            Agreement</U>: Credit Agreement, dated as of January&#8239;18, 2023 by and among Caris Life
                                            Sciences,&#8239;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;), the Lenders
                                            party thereto and Wilmington Trust, National Association, as administrative agent (together
                                            with its Affiliates, successors, transferees and assignees, the &ldquo;<U>Administrative
                                            Agent</U>&rdquo;)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Assigned
                                            Interest[s]</U>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 16%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 1%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 16%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 1%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 1%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 20%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 1%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 1%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage Assigned</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD ROWSPAN="2" STYLE="text-align: center; font-size: 10pt; padding-left: 13pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignor[s]</FONT><FONT STYLE="font-size: 10pt"><SUP>5</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font-size: 10pt; padding-left: 14pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignee[s]</FONT><FONT STYLE="font-size: 10pt"><SUP>6</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Initial][Delayed</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Initial][Delayed</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of [Initial][Delayed</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Draw]</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Draw]</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Draw] Commitment/</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment/Loans</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment/Loans</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans</FONT><FONT STYLE="font-size: 10pt"><SUP>8</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for all Lenders</FONT><FONT STYLE="font-size: 10pt"><SUP>7</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assigned</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5
</SUP></FONT><FONT STYLE="font-size: 10pt">List each Assignor, as appropriate.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>6
</SUP></FONT><FONT STYLE="font-size: 10pt">List each Assignee, as appropriate.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>7
</SUP></FONT><FONT STYLE="font-size: 10pt">Amounts in this column and in the column immediately to the right to be adjusted by the counterparties
to take into account any payments or prepayments made between the Trade Date and the Effective Date. Set forth the type of Commitment/Loan
to be assigned.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>8
</SUP></FONT><FONT STYLE="font-size: 10pt">Set forth, to at least 9 decimals, as a percentage of the applicable Commitments/Loans of
all Lenders thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 251; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[7.</FONT><FONT STYLE="font-size: 10pt">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Trade
Date</U>:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]<SUP>9</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
Date:</FONT><FONT STYLE="font-size: 10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#8239;,
20&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;[TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE
EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[SIGNATURE
PAGES FOLLOW]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-size: 10pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>9
</SUP></FONT><FONT STYLE="font-size: 10pt">To be completed if the Assignor(s)&#8239;and the Assignee(s)&#8239;intend that the minimum assignment
amount is to be determined as of the Trade Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 252; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The terms set forth in this Assignment
and Assumption are hereby agreed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">ASSIGNOR [NAME OF ASSIGNOR]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">ASSIGNEE [NAME OF ASSIGNEE]</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
Page&#8239;to Assignment and Assumption]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 253 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consented
to:</FONT><FONT STYLE="font-size: 10pt"><SUP>10</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Wilmington Trust, National Association,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">as Administrative Agent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Consented
to:</FONT><FONT STYLE="font-size: 10pt"><SUP>11</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Caris Life Sciences,&#8239;Inc., as the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Borrower]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>10
</SUP></FONT><FONT STYLE="font-size: 10pt">To be added only if the consent of the Administrative Agent is required by the terms of the
Credit Agreement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>11
</SUP></FONT><FONT STYLE="font-size: 10pt">To be added only if the consent of the Borrower is required by the terms of the Credit Agreement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
Page&#8239;to Assignment and Assumption]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 254 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>ANNEX
1 TO ASSIGNMENT AND ASSUMPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">STANDARD
TERMS AND CONDITIONS FOR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ASSIGNMENT
AND ASSUMPTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assignor[s]</U>.
[The][Each] Assignor (a)&#8239;represents and warrants that (i)&#8239;it is the legal and beneficial owner of [the][the relevant] Assigned
Interest, (ii)&#8239;[the][such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim, (iii)&#8239;it has
full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate
the transactions contemplated hereby and (iv)&#8239;it is [not] a Defaulting Lender; and (b)&#8239;assumes no responsibility with respect
to (i)&#8239;any statements, warranties or representations made in or in connection with the Credit Agreement or any other Loan Document,
(ii)&#8239;the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral
thereunder, (iii)&#8239;the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in
respect of any Loan Document or (iv)&#8239;the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or any
other Person of any of their respective obligations under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assignee[s]</U>.
[The][Each] Assignee (a)&#8239;represents and warrants that (i)&#8239;it has full power and authority, and has taken all action necessary,
to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under
the Credit Agreement, (ii)&#8239;it meets all the requirements to be an assignee under Section&#8239;10.10(b)&#8239;of the Credit Agreement
(subject to such consents, if any, as may be required under Section&#8239;10.10(b)(i)(B)&#8239;and Section&#8239;10.10(b)(iii)&#8239;of the
Credit Agreement, or pursuant to any other applicable section of the Credit Agreement), (iii)&#8239;from and after the Effective Date,
it shall be bound by the provisions of the Credit Agreement and the other Loan Documents as a Lender thereunder and, to the extent of
[the][the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv)&#8239;it is sophisticated with respect
to decisions to acquire assets of the type represented by [the][such] Assigned Interest and either it, or the Person exercising discretion
in making its decision to acquire [the][such] Assigned Interest, is experienced in acquiring assets of such type, (v)&#8239;it has received
a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial
statements delivered pursuant to Section&#8239;7.1 thereof, as applicable, and such other documents and information as it deems appropriate
to make its own credit analysis and decision to enter into this Assignment and <FONT STYLE="font-family: Times New Roman, Times, Serif">Assumption
and to purchase [the][such] Assigned Interest and (vi)&#8239;it has, independently and without reliance upon the Administrative Agent
or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision
to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest; and (b)&#8239;agrees that (i)&#8239;it will,
independently and without reliance upon the Administrative Agent, [the][any] Assignor or any other Lender, and based on such documents
and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under
the Loan Documents, and (ii)&#8239;it will perform in accordance with their terms all of the obligations which by the terms of the Loan
Documents are required to be performed by it as a Lender.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 255 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payments</U>.
From and after the Effective Date, the Administrative Agent shall make all payments in respect of [the][each] Assigned Interest (including
payments of principal, interest, fees and other amounts) to [the][the relevant] Assignor for amounts which have accrued to but excluding
the Effective Date and to [the][the relevant] Assignee for amounts which have accrued from and after the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General
Provisions</U>. This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective
successors and permitted assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall
constitute one instrument. Delivery of an executed counterpart of a signature page&#8239;of this Assignment and Assumption by telecopy
shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption shall
be governed by, and construed in accordance with, the law of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 256 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>EXHIBIT&#8239;G</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>FORM&#8239;OF
SOLVENCY CERTIFICATE</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 386pt; text-align: right"><FONT STYLE="font-size: 10pt">Date: [_____],
20[_]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">To the Administrative Agent and each
of the Lenders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">party to the Credit Agreement referred
to below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant
to Section&#8239;5.8 of the Credit Agreement, dated as of January&#8239;18, 2023 (the &ldquo;<U>Credit Agreement</U>&rdquo;), by and among
Caris Life Sciences,&#8239;Inc., a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;), the Lenders party thereto and Wilmington Trust,
National Association, as administrative agent (together with its Affiliates, successors, transferees and assignees, the &ldquo;<U>Administrative
Agent</U>&rdquo;), the undersigned, solely in the undersigned&rsquo;s capacity as [chief financial officer][ <I>specify other chief financial
or accounting Authorized Officer</I>] of the Borrower, hereby certifies, on behalf of the Borrower and not in the undersigned&rsquo;s
individual or personal capacity and without personal liability, that, to his or her knowledge, as of the [[First][Second] Delayed Draw]
Closing Date, after giving effect to the incurrence of the applicable Loans under the Credit Agreement on such date and the use of proceeds
of such Loans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the
                                            fair value of the property of the Borrower and its Subsidiaries, on a consolidated basis,
                                            is greater than the total amount of liabilities, including Contingent Liabilities, of the
                                            Borrower and its Subsidiaries, on a consolidated basis;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the
                                            present fair saleable value of the assets of the Borrower and its Subsidiaries, on a consolidated
                                            basis, is not less than the amount that will be required to pay the probable liabilities
                                            of the Borrower and its Subsidiaries, on a consolidated basis, on their debts as they become
                                            absolute and matured;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the
                                            Borrower and its Subsidiaries, on a consolidated basis, do not intend to, and do not believe
                                            that they will, incur debts or liabilities beyond their ability to pay as such debts and
                                            liabilities mature;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the
                                            Borrower and its Subsidiaries, on a consolidated basis, are not engaged in a business or
                                            a transaction, and are not about to engage in a business or a transaction, for which the
                                            property of the Borrower and its Subsidiaries, on a consolidated basis, would constitute
                                            an unreasonably small capital; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the
                                            Borrower and its Subsidiaries, on a consolidated basis, have not executed the Credit Agreement
                                            or any other Loan Document, or made any transfer or incurred any Obligations thereunder,
                                            with actual intent to hinder, delay or defraud either present or future creditors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
purposes of this Solvency Certificate, the amount of any Contingent Liability at any time will be computed as the amount that, in light
of all the facts and circumstances existing at such time, would reasonably be expected to become an actual or matured liability. Capitalized
terms used but not otherwise defined herein have the meanings assigned to them in the Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
undersigned is familiar with the business and financial position of the Borrower and its Subsidiaries. In reaching the conclusions set
forth in this Solvency Certificate, the undersigned has made such investigations and inquiries as the undersigned has deemed appropriate,
having taken into account the nature of the business currently conducted or currently proposed to be conducted by the Borrower and its
Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature
Page&#8239;Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 257 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the undersigned has executed this Solvency Certificate, solely in the undersigned&rsquo;s capacity as <B>[</B>chief
financial officer<B>][</B><I>specify other chief financial or accounting Authorized Officer</I><B>]</B> of the Borrower, on behalf of
the Borrower and not in the undersigned&rsquo;s individual or personal capacity and without personal liability, as of the date first
stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&#8239;INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
Page&#8239;to Solvency Certificate]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 258; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1(B)
<SEQUENCE>8
<FILENAME>tm2415719d15_ex10-1b.htm
<DESCRIPTION>EXHIBIT 10.1(B)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-transform: none; text-align: right">Exhibit 10.1(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-transform: none; text-align: right"><I>Execution
Version</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B><U>FIRST AMENDMENT
TO CREDIT AGREEMENT</U></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>FIRST AMENDMENT TO CREDIT AGREEMENT </B>(this &ldquo;<U>Amendment</U>&rdquo;) is made and entered into as of April 1, 2025 by and among
</FONT><FONT STYLE="text-transform: uppercase"><B>CARIS LIFE SCIENCES, INC.</B></FONT>, a Texas corporation (the &ldquo;<U>Borrower</U>&rdquo;),
the Lenders party hereto (the &ldquo;<U>Lenders</U>&rdquo;), and <B>WILMINGTON TRUST, NATIONAL ASSOCIATION</B>, as administrative agent
for the Lenders (together with its Affiliates, successors, transferees and assignees, the &ldquo;<U>Administrative Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
the Borrower, the Lenders and the Administrative Agent entered into a Credit Agreement, dated as of January 18, 2023 (the &ldquo;<U>Credit
Agreement</U>&rdquo;), pursuant to which the Lenders have extended credit to the Borrower on the terms set forth therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
pursuant to Section 10.1 of the Credit Agreement, the Credit Agreement may be amended by an instrument in writing signed by the Borrower
and the Required Lenders and acknowledged by the Administrative Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
the Lenders constitute the Required Lenders under the Credit Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
the Borrower and the Lenders desire to amend certain provisions of the Credit Agreement as provided in this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B></FONT>, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Definitions; Loan Document</U></B>. Capitalized terms used herein without definition shall have the meanings assigned to
such terms in the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other
Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Amendments to Schedules</U></B>. The Schedules to the Credit Agreement are hereby supplemented by adding new Schedule 8.6(f)
thereto in the appropriate numeric order, in the form attached hereto as <U>Exhibit A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Amendments
to Section 1.1</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Section 1.1 of the Credit Agreement is hereby amended by inserting the following new defined terms therein in the proper alphabetical
order:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>2025 Convertible
Note Collateral Agent</U>&rdquo; means Wilmington Trust, National Association, in its capacity as collateral agent under the 2025 Convertible
Note Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>2025 Convertible
Note Purchase Agreement</U>&rdquo; means that certain Convertible Note Purchase Agreement, dated as of April 1, 2025, among the Borrower,
certain subsidiaries of the Borrower party thereto, the 2025 Convertible Note Collateral Agent, and the purchasers from time to time party
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>2025 Convertible
Note Documents</U>&rdquo; means the &ldquo;Transaction Agreements&rdquo; (as defined in the 2025 Convertible Note Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>2025 Convertible
Note Intercreditor Agreement</U>&rdquo; means that certain Intercreditor Agreement, dated as of April 1, 2025, among the Administrative
Agent, the 2025 Convertible Note Collateral Agent, the Borrower and the other Loan Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>2025 Convertible
Note Maturity Date</U>&rdquo; means January 1, 2026 (or such later date as the Borrower and the purchasers party to the 2025 Convertible
Note Purchase Agreement may agree so long as such extension of the 2025 Convertible Note Maturity Date by the purchasers is not made in
exchange for a fee or other compensation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&ldquo;<U>2025
Convertible Notes</U>&rdquo; means those certain 8.00% senior convertible notes in an aggregate original principal amount of up to $30,000,000
due on the 2025 Convertible Note Maturity Date, issued by </FONT>the Borrower and governed by the terms of the 2025 Convertible Note Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>First
Amendment</U>&rdquo; means the First Amendment to the Agreement, dated as of the First Amendment Effective Date, among the Borrower, the
Lenders party thereto and the Administrative Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>First
Amendment Effective Date</U>&rdquo; means April 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>Series
E Preferred Stock</U>&rdquo; means the Series E Preferred Stock of the Borrower issued pursuant to the Borrower&rsquo;s Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The definition of &ldquo;Borrower&rsquo;s Charter&rdquo; in Section 1.1 of the Credit Agreement is hereby amended and restated
in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;<U>Borrower&rsquo;s
Charter</U>&rdquo; means that certain Second Amended and Restated Certificate of Formation of the Borrower, dated as of March 24, 2025,
and as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time after the Closing Date to
the extent permitted by <U>Section 8.9(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The definition of &ldquo;Change of Control&rdquo; in Section 1.1 of the Credit Agreement is hereby amended by replacing each instance
of the phrase &ldquo;Series C Conversion Price or Series D Conversion Price (each as defined in the Borrower&rsquo;s Charter)&rdquo; therein
with the phrase &ldquo;Series C Conversion Price, Series D Conversion Price or Series E Conversion Price (each as defined in the Borrower&rsquo;s
Charter)&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The definition of &ldquo;Impermissible Qualification&rdquo; in Section 1.1 of the Credit Agreement is hereby amended and restated
in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Impermissible
Qualification</U>&rdquo; means any qualification or exception to the opinion or certification of any independent public accountant as
to any financial statement of the Borrower or any Subsidiary (i) which is of a &ldquo;going concern&rdquo; or similar nature other than
any such qualification that is related solely to any or a combination of (I)(A) the occurrence of the Maturity Date as a result of the
Loans maturing during such Fiscal Year or (B) in the case of sub-clauses (x), (y) and (z) of this clause (I)(B), for the Fiscal Year ending
December 31, 2024 only, the occurrence of (w) any upcoming date where redemption rights in respect of the Series C Preferred Stock, Series
D Preferred Stock and/or Series E Preferred Stock are or may become exercisable, (x) any upcoming date on which the Loans may become subject
to amortization as contemplated by <U>Section 3.2</U> as a result of the occurrence of any of the events specified in the foregoing clause
(I)(B)(x), (y) any upcoming date on which the principal obligations under the 2025 Convertible Note Documents would mature or otherwise
become mandatorily payable or redeemable in whole or in part or (z) any increase above $20,000,000 to the minimum amount of Liquidity
required to be maintained by the Borrower pursuant to <U>Section 8.4(a)</U>, or (II) any prospective or actual inability to satisfy any
financial maintenance covenant included in the Loan Documents on a future date in a future period, (ii) which relates to the limited scope
of examination of matters relevant to such financial statement or (iii) which relates to the treatment or classification of any item in
such financial statement and which, as a condition to its removal, would require an adjustment to such item the effect of which would
be to cause the Borrower to be in Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The definition of &ldquo;Loan Documents&rdquo; in Section 1.1 of the Credit Agreement is hereby amended by inserting &ldquo;the
First Amendment, the 2025 Convertible Note Intercreditor Agreement,&rdquo; immediately after the phrase &ldquo;the Agency Fee Letter,&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The definition of &ldquo;Material Agreements&rdquo; in Section 1.1 of the Credit Agreement is hereby amended by inserting &ldquo;(ii)
the 2025 Convertible Note Documents,&rdquo; immediately after clause (i) thereof and renumbering each successive clause therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The definition of &ldquo;Restricted Payment&rdquo; in Section 1.1 of the Credit Agreement is hereby amended by amending and restating
the last sentence thereof in its entirety to read as follows: &ldquo;Notwithstanding the foregoing, and for the avoidance of doubt, (i)
the conversion of (including any cash payment or fractional shares upon conversion), or payment of any principal or premium on, or payment
of any interest with respect to, or payment of any fees, expenses or other similar amounts in respect of or in relation to, the 2023 Convertible
Loans, the 2025 Convertible Notes, any Post-IPO Convertible Indebtedness or other permitted convertible Indebtedness under this Agreement
shall not constitute a Restricted Payment and (ii) any payment with respect to, or early unwind or settlement of, any Permitted Call Spread
Swap Agreement shall not constitute a Restricted Payment.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Amendments
to Section 3.2</U></B>. Section 3.2 of the Credit Agreement is hereby amended by (i) replacing each instance of the phrase &ldquo;the
Series C Preferred Stock or the Series D Preferred Stock&rdquo; therein with the phrase &ldquo;the Series C Preferred Stock, Series D
Preferred Stock or the Series E Preferred Stock&rdquo;, (ii) replacing each instance of the phrase &ldquo;the Series C Preferred Stock
and the Series D Preferred Stock&rdquo; therein with the phrase &ldquo;the Series C Preferred Stock, the Series D Preferred Stock and
the Series E Preferred Stock&rdquo; and (iii) adding a new sentence at the end of the first paragraph thereof to read as follows: &ldquo;For
the avoidance of doubt, there shall be only one &ldquo;Determination Date&rdquo; under this Section 3.2 and the amortization payment
in an amount equal to 15% of the outstanding principal amount of the Loans contemplated by this paragraph shall in all events be required
to be made (if at all) solely on a one-time basis.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Amendments
to Section 8.2</U>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify">Section 8.2 of the Credit Agreement is hereby amended by inserting a new clause (x) immediately after clause (w) thereof, as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&ldquo; and (x) Indebtedness
in respect of the 2025 Convertible Notes;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify">Section 8.2 of the Credit Agreement is hereby amended by inserting the phrase &ldquo;, the Series E Preferred Stock&rdquo; immediately
after the phrase &ldquo;the Series D Preferred Stock&rdquo; in clause (w) thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Amendments
to Section 8.3</U></B>. Section 8.3 of the Credit Agreement is hereby amended by inserting a new clause (x) immediately after clause
(w) thereof, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;and
(x) Liens securing Indebtedness of the Borrower or the Subsidiaries permitted pursuant to <U>Section 8.2(x)</U></FONT>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Amendments to Section 8.4</U></B>. Section 8.4(a) of the Credit Agreement is hereby amended and restated in its entirety
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Minimum Liquidity</U>. The Liquidity of the Borrower shall not at any time be less than $20,000,000; <U>provided</U> that (x)
if the Borrower redeems or repurchases for cash all or any portion of the Series C Preferred Stock or the Series D Preferred Stock (except
for any redemption or repurchase made using the proceeds of an issuance of Capital Securities, so long as such proceeds are escrowed solely
for the purpose of effectuating such repurchase or redemption of Series C Preferred Stock or Series D Preferred Stock or such issuance
is consummated substantially concurrently with such repurchase or redemption), from and after the date of such repurchase or redemption,
the Liquidity of the Borrower shall not at any time be less than the outstanding principal amount of the Loans at such time (as such amount
may be decreased from time to time) (<U>provided</U>, <U>further</U>, that if all of the outstanding Series C Preferred Stock and Series
D Preferred Stock are converted into common stock of the Borrower following the occurrence of a Qualified Direct Listing Event or consummation
of a Qualified IPO or a Qualified SPAC Transaction, the Liquidity of the Borrower shall not at any time be less than $20,000,000) and
(y) if the Borrower pays any principal under the 2025 Convertible Notes (excluding (i) any principal paid solely in common stock of the
Borrower and cash payments made in lieu of fractional shares of common stock of the Borrower and (ii) common stock of the Borrower issued
as a result of any conversion of the 2025 Convertible Notes in accordance with their terms), from and after the date of such repayment
(giving effect to such repayment), the Liquidity of the Borrower shall not at any time be less than $50,000,000. The Borrower shall maintain
an aggregate amount equal to the then applicable amount required under this <U>Section 8.4(a)</U>, along with its other cash and Cash
Equivalent Investments, in a Controlled Account as required pursuant to <U>Section 7.13(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Amendments
to Section 8.6</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify">Section 8.6 of the Credit Agreement is hereby amended by inserting the phrase &ldquo;, Indebtedness in
respect of the 2025 Convertible Notes&rdquo; immediately after the phrase &ldquo;(with respect to cash interest)&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify">Section 8.6 of the Credit Agreement is hereby amended by replacing the phrase &ldquo;the Series C Preferred
Stock and/or Series D Preferred Stock&rdquo; in clause (g) therein with the phrase &ldquo;the Series C Preferred Stock, the Series D Preferred
Stock and/or the Series E Preferred Stock&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify">Section 8.6(f) of the Credit Agreement is hereby amended and restated in its entirety as follows</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;
(f)&#8239;</FONT>transactions described on Schedule 8.6(f), completed prior to the First Amendment Effective Date;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">Section 8.6(m) of the Credit Agreement is hereby amended and restated in its entirety as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo; (m) the
repurchase of Capital Securities of the Borrower (or the payment of a dividend to a direct or indirect parent of the Borrower to fund
such repurchase) upon (x) vesting of restricted stock, restricted stock units, performance shares units or similar equity incentives or
(y) upon the vesting or exercise of any stock options or other equity awards, in each case under this clause (m) to satisfy tax withholding
or similar tax obligations with respect thereto; &rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify">Section 8.6 of the Credit Agreement is hereby amended by replacing the period and the end of clause (n)
with &ldquo;; and&rdquo; and inserting a new clause (o) immediately after clause (n) thereof, as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;
(o) </FONT>payments of scheduled interest on, or (so long as there is no Event of Default then existing or would result therefrom) principal
at the stated maturity of, Indebtedness under the 2025 Convertible Notes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Amendments to Section 8.9</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD>Section 8.9 of the Credit Agreement is hereby amended by inserting a new clause (f) immediately after clause (e) thereof, as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;or (f) the
2025 Convertible Note Documents, if the result could reasonably be expected to have an adverse effect in any material respect on the Administrative
Agent or the Lenders;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Amendments to Section 8.11</U></B>. Section 8.11 of the Credit Agreement is hereby amended by inserting the phrase &ldquo;,
in the 2025 Convertible Note Documents&rdquo; immediately before the phrase &ldquo;or in the 2023 Convertible Loan Documents&rdquo; in
clause (A) of the second sentence thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Amendments to Section 9.1</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD>Section 9.1 of the Credit Agreement is hereby amended by inserting the following sentence at the end of clause (e) of such section:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&ldquo;Notwithstanding
the foregoing, this Section 9.1(e) shall not apply to any &ldquo;Event of Default&rdquo; (as defined in the 2025 Convertible Note Documents)
or to any Indebtedness or other obligations under the 2025 Convertible Note Documents (which shall instead be subject to Section 9.1(m)
below).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD>Section 9.1 of the Credit Agreement is hereby amended by inserting the following new clause (m) at the end of such Section:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&ldquo;(m) <U>2025 Convertible
Notes</U>. (i) Any &ldquo;Event of Default&rdquo; (as defined in the 2025 Convertible Note Documents) shall occur and be continuing under
the 2025 Convertible Note Documents or (ii) a default shall occur in the payment of any amount when due (subject to any applicable grace
period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any Indebtedness under the
2025 Convertible Notes. If any &ldquo;Event of Default&rdquo; (as defined in the 2025 Convertible Note Documents) under clause (m)(i)
hereof shall exist solely as a consequence of the occurrence of a default or Event of Default under the Loan Documents (in such case,
a &ldquo;<U>Predicate Default</U>&rdquo;), and such Predicate Default shall cease to exist under the Loan Documents, it is understood
and agreed that the Event of Default under this Section 9.1(m) as a result of an &ldquo;Event of Default&rdquo; under the 2025 Convertible
Note Documents caused by such Predicate Default shall be deemed to no longer exist.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Conditions to Effectiveness of Amendment</U></B>. This Amendment shall become effective upon receipt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify">by the Lenders, the Administrative Agent and the Borrower of a counterpart signature of the other to this
Amendment duly executed and delivered by each of the Lenders, the Administrative Agent and the Borrower;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify">by the Lenders and the Administrative Agent of a certificate, dated as of the First Amendment Effective Date, duly executed and delivered
by an Authorized Officer of the Borrower, as to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; &#8239;</FONT>resolutions
of the Borrower&rsquo;s board of directors and any other corporate resolutions required by applicable Law or pursuant to the
Borrower&rsquo;s Organic Documents, each of which shall be then in full force and effect, authorizing the execution, delivery and
performance of this Amendment and the transactions contemplated hereby; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the full force and validity of each Organic Document of the Borrower and copies thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify">by the Lenders and the Administrative Agent of duly executed copies of the 2025 Convertible Note Documents and the 2025 Convertible
Note Intercreditor Agreement; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">by the Administrative Agent, for the ratable account of each Lender, a fee in an aggregate amount equal to one percent (1.00%) of
the aggregate Loans outstanding on the First Amendment Effective Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">The Borrower agrees
that the fee payable under clause (d) above shall be (i) paid in U.S. Dollars, (ii) fully earned upon the First Amendment Effective Date,
(iii) nonrefundable and (iv) in addition to, and not creditable against, any other fee, cost or expense payable under the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Expenses</U></B>. The Borrower agrees to pay on demand all expenses of the Administrative Agent and the Lenders (including,
without limitation, the fees and out-of-pocket expenses of Seward &amp; Kissel LLP, counsel to the Administrative Agent and Covington
 &amp; Burling LLP, counsel to OrbiMed and Gibson, Dunn &amp; Crutcher LLP, counsel to Braidwell) incurred in connection with the negotiation,
preparation, execution and delivery of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Representations and Warranties</U></B>. The Borrower represents and warrants to the Lenders, as of the effective date of
this Amendment, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The representations and warranties of the Borrower and the Subsidiaries contained in the Credit Agreement or any other Loan Document
are true and correct in all material respects as of the date hereof (except (i) with respect to representations and warranties expressly
made as of an earlier date, in which case such representations and warranties are true and correct in all material respects as of such
earlier date and (ii) if any such representation or warranty contains any materiality qualifier, such representation or warranty is true
and correct in all respects).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Default or Event of Default under the Credit Agreement has occurred and is continuing or would result from the effectiveness
of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>No Implied Amendment or Waiver</U></B>. Except as expressly set forth in this Amendment, this Amendment shall not, by implication
or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Administrative Agent and the Lenders
under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or
covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing
in this Amendment shall be construed to imply any willingness on the part of the Administrative Agent or any Lender to agree to or grant
any similar or future amendment, consent or waiver of any of the terms and conditions of the Credit Agreement or the other Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Waiver and Release</U></B>. TO INDUCE THE ADMINISTRATIVE AGENT AND THE LENDERS TO AGREE TO THE TERMS OF THIS AMENDMENT, THE
BORROWER AND ITS AFFILIATES (COLLECTIVELY, THE &ldquo;<B>RELEASING PARTIES</B>&rdquo;) REPRESENT AND WARRANT THAT, AS OF THE DATE HEREOF,
THERE ARE NO CLAIMS OR OFFSETS AGAINST, OR RIGHTS OF RECOUPMENT WITH RESPECT TO, OR DISPUTES OF, OR DEFENSES OR COUNTERCLAIMS TO, THEIR
OBLIGATIONS UNDER THE LOAN DOCUMENTS, AND IN ACCORDANCE THEREWITH THE RELEASING PARIES:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>WAIVE ANY AND ALL SUCH CLAIMS, OFFSETS, RIGHTS OF RECOUPMENT, DISPUTES, DEFENSES AND COUNTERCLAIMS, WHETHER KNOWN OR UNKNOWN, ARISING
PRIOR TO THE DATE HEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>FOREVER RELEASE, RELIEVE, AND DISCHARGE THE ADMINISTRATIVE AGENT, THE LENDERS, THEIR AFFILIATES AND THEIR RESPECTIVE OFFICERS,
DIRECTORS, SHAREHOLDERS, MEMBERS, PARTNERS, PREDECESSORS, SUCCESSORS, ASSIGNS, ATTORNEYS, ACCOUNTANTS, AGENTS, EMPLOYEES, AND REPRESENTATIVES
(COLLECTIVELY, THE &ldquo;<B>RELEASED PARTIES</B>&rdquo;), AND EACH OF THEM, FROM ANY AND ALL CLAIMS, LIABILITIES, DEMANDS, CAUSES OF
ACTION, DEBTS, OBLIGATIONS, PROMISES, ACTS, AGREEMENTS, AND DAMAGES, OF WHATEVER KIND OR NATURE, WHETHER KNOWN OR UNKNOWN, SUSPECTED OR
UNSUSPECTED, CONTINGENT OR FIXED, LIQUIDATED OR UNLIQUIDATED, MATURED OR UNMATURED, WHETHER AT LAW OR IN EQUITY, WHICH THE RELEASING PARTIES
EVER HAD, NOW HAVE, OR MAY, SHALL, OR CAN HEREAFTER HAVE, DIRECTLY OR INDIRECTLY ARISING OUT OF OR BASED UPON ANY OF THE LOAN DOCUMENTS
OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY (EXCLUDING, FOR CLARITY, TRANSACTIONS CONCERNING THE 2025 CONVERTIBLE NOTES OR THE BORROWER&rsquo;S
CAPITAL SECURITIES) AT ANY TIME FROM THE BEGINNING OF THE WORLD THROUGH AND INCLUDING THE DATE HEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>IN CONNECTION WITH THE RELEASE CONTAINED HEREIN, ACKNOWLEDGE THAT THEY ARE AWARE THAT THEY MAY HEREAFTER DISCOVER CLAIMS PRESENTLY
UNKNOWN OR UNSUSPECTED, OR FACTS IN ADDITION TO OR DIFFERENT FROM THOSE WHICH THEY KNOW OR BELIEVE TO BE TRUE, WITH RESPECT TO THE MATTERS
RELEASED HEREIN. NEVERTHELESS, IT IS THE INTENTION OF THE RELEASING PARTIES, THROUGH THIS AMENDMENT AND WITH ADVICE OF COUNSEL, FULLY,
FINALLY, AND FOREVER TO RELEASE ALL SUCH MATTERS, AND ALL CLAIMS RELATED THERETO, WHICH DO NOW EXIST, OR HERETOFORE HAVE EXISTED. IN FURTHERANCE
OF SUCH INTENTION, THE RELEASES HEREIN GIVEN SHALL BE AND REMAIN IN EFFECT AS A FULL AND COMPLETE RELEASE OR WITHDRAWAL OF SUCH MATTERS
NOTWITHSTANDING THE DISCOVERY OR EXISTENCE OF ANY SUCH ADDITIONAL OR DIFFERENT CLAIMS OR FACTS RELATED THERETO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>COVENANT
AND AGREE NOT TO BRING ANY CLAIM, ACTION, SUIT, OR PROCEEDING AGAINST THE RELEASED PARTIES, DIRECTLY OR INDIRECTLY, REGARDING OR RELATED
IN ANY MANNER TO THE MATTERS RELEASED HEREBY (FOR THE AVOIDANCE OF DOUBT, IN RELATION TO THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS
CONTEMPLATED THEREBY (EXCLUDING FOR CLARITY, TRANSACTIONS CONCERNING THE 2025 CONVERTIBLE NOTES OR THE BORROWER&rsquo;S CAPITAL SECURITIES)),
AND FURTHER COVENANT AND AGREE THAT THIS AMENDMENT IS A BAR TO ANY SUCH CLAIM, ACTION, SUIT, OR PROCEEDING.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>REPRESENT AND WARRANT TO THE RELEASED PARTIES THAT THEY HAVE NOT HERETOFORE ASSIGNED OR TRANSFERRED, OR PURPORTED TO ASSIGN OR
TRANSFER, TO ANY PERSON OR ENTITY ANY CLAIMS OR OTHER MATTERS HEREIN RELEASED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>ACKNOWLEDGE THAT THEY HAVE HAD THE BENEFIT OF INDEPENDENT LEGAL ADVICE WITH RESPECT TO THE ADVISABILITY OF ENTERING INTO THIS RELEASE
AND HEREBY KNOWINGLY, AND UPON SUCH ADVICE OF COUNSEL, WAIVE ANY AND ALL APPLICABLE RIGHTS AND BENEFITS UNDER, AND PROTECTIONS OF, CALIFORNIA
CIVIL CODE SECTION 1542, AND ANY AND ALL STATUTES AND DOCTRINES OF SIMILAR EFFECT. CALIFORNIA CIVIL CODE SECTION 1542 PROVIDES AS FOLLOWS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><I><U>A general release
does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing
the release, and that if known by him or her, would have materially affected his or her settlement with the debtor or released party.</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Counterparts; Governing Law</U></B>. This Amendment may be executed by the parties hereto in several counterparts, each of
which shall be an original and all of which shall constitute together but one and the same agreement. Delivery of an executed counterpart
of a signature page to this Amendment by email (e.g., &ldquo;pdf&rdquo; or &ldquo;tiff&rdquo;) or telecopy shall be effective as delivery
of a manually executed counterpart of this Amendment. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS
OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B><U>Agent Authorization</U></B>. Each of the Lenders party hereto, constituting the Required Lenders, hereby authorizes and directs
the Administrative Agent to execute and deliver the acknowledgment to this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">[Remainder of Page
Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have caused this </FONT>Amendment to be executed by their respective officers thereunto duly
authorized as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: justify"><B>CARIS LIFE SCIENCES, INC.</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">as the Borrower</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
               <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">/s/ Luke Power</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
               <TD STYLE="text-align: justify">Luke Power</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
               <TD STYLE="text-align: justify">Senior Vice President, Chief Financial Officer, and
Chief Accounting Officer</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to First Amendment to Credit Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORBIMED
    ROYALTY </B></FONT><B>&amp; CREDIT OPPORTUNITIES III, LP,</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">as a Lender</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OrbiMed ROF III LLC,</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD COLSPAN="2" STYLE="text-align: justify">its General Partner</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
               <TD STYLE="text-align: justify; width: 3%">By:</TD>
               <TD STYLE="text-align: justify; width: 42%">OrbiMed Advisors LLC,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">its Managing Member</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
               <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Rizzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Rizzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member </FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORBIMED
    ROYALTY </B></FONT><B>&amp; CREDIT OPPORTUNITIES IV, LP,</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">as a Lender</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify">OrbiMed ROF IV LLC,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD COLSPAN="2" STYLE="text-align: justify">its General Partner</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">By:</TD>
               <TD STYLE="text-align: justify"> OrbiMed Advisors LLC,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">its Managing Member</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
               <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Rizzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Rizzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD>
               <TD COLSPAN="2" STYLE="text-align: justify">Member</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORBIMED
    ROYALTY </B></FONT><B>&amp; CREDIT OPPORTUNITIES IV OFFSHORE, LP,</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">as a Lender</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify">OrbiMed ROF IV LLC,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD COLSPAN="2" STYLE="text-align: justify">its General Partner</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">By:</TD>
               <TD STYLE="text-align: justify">OrbiMed Advisors LLC,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">its Managing Member</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
               <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Rizzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
               <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Rizzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD>
               <TD COLSPAN="2" STYLE="text-align: justify">Member</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">[Signature Page to First Amendment to Credit Agreement]</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify"><B>BRAIDWELL
    TRANSACTION HOLDINGS LLC &ndash; SERIES 2,</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">as a Lender</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
               <TD STYLE="text-align: justify; width: 45%"> Braidwell LP,</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
               <TD STYLE="text-align: justify">its Investment Manager</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">By:</TD>
               <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> /s/ Colin Bettison</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">Name:</TD>
               <TD STYLE="text-align: justify">Colin Bettison</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD>
               <TD STYLE="text-align: justify">Authorized Signatory</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">ACKNOWLEDGED BY:</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2"><B>WILMINGTON
    TRUST, NATIONAL ASSOCIATION</B></TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">as the Administrative Agent</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jessica A. Jankiewicz</FONT></TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jessica A. Jankiewicz</FONT></TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President</FONT></TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to First Amendment to Credit Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule 8.6(f)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Certain Restricted Payments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2(A)
<SEQUENCE>9
<FILENAME>tm2415719d15_ex10-2a.htm
<DESCRIPTION>EXHIBIT 10.2(A)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.2(a)</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Certain confidential information contained in this document, marked by &ldquo;[***]&rdquo;, has been omitted because it is both (i) not
material and (ii) the type that the registrant treats as private or confidential.</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; width: 80%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2415719d15_ex10-2aimg001.jpg" ALT="" STYLE="height: 31px; width: 121px"></FONT></TD>
    <TD STYLE="text-align: left; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><B>Illumina,&nbsp;Inc.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">5200 Illumina Way <BR>
San Diego, CA 92122 <BR>
tel 858.202.4500<BR>

    fax 858.202.4545 <BR>
www.illumina.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 75%; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">David
    D. Halbert</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 23%"><FONT STYLE="font-style: normal; font-weight: normal">March&nbsp;29,
    2021</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">Chief Executive
Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">Caris MPI,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">750 West John
Carpenter Freeway</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">Suite&nbsp;800</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">Irving, Texas
75039</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">Dear Mr.&nbsp;Halbert:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">In connection
with Illumina Inc.&rsquo;s proposed acquisition of GRAIL,&nbsp;Inc. (the &ldquo;Transaction&rdquo;),&nbsp;Illumina is irrevocably offering
to Caris MPI Inc. (&ldquo;Caris&rdquo;) the terms enclosed in Exhibit&nbsp;A (the &ldquo;Supply Agreement&rdquo;) and Exhibit&nbsp;B
(the &ldquo;IVD Test Kit Agreement Terms&rdquo;) to allay any concerns relating to the Transaction, including that Illumina would disadvantage
GRAIL&rsquo;s potential competitors after the Transaction by increasing their sequencing prices or by withholding access to Illumina&rsquo;s
latest innovations in Next-Generation Sequencing (&ldquo;NGS&rdquo;). To address these concerns, these terms will be offered to any existing
or new customer of Illumina that purchases NGS products for developing and/or commercializing oncology tests and will remain open for
six (6)&nbsp;years from the closing of the Transaction (the &ldquo;Open Term&rdquo;). You may accept this offer and the attendant terms
in this letter and attached hereto any time from today until expiration of the Open Term by signing and returning this letter to the
undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">The Supply Agreement
shall not be effective unless and until the Transaction closes. The Supply Agreement shall be effective for twelve (12) years from the
closing of the Transaction, regardless of when this offer is accepted. This irrevocable offer is binding on Illumina. This offer to enter
into the Supply Agreement during the Open Term shall be governed by, and construed in accordance with, the laws of the State of New York,
without giving effect to the conflicts-of-law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">In addition,
Caris may enter into, at any time from today until expiration of the Open Term, an agreement with Illumina (</FONT><FONT STYLE="font-weight: normal"><I>i.e.,</I>
<FONT STYLE="font-style: normal">an &ldquo;IVD Test Kit Agreement&rdquo;) under which Caris may develop and commercialize in-vitro diagnostic
(&ldquo;IVD&rdquo;) distributable test kits that may be used by third-party laboratories for use on Illumina&rsquo;s diagnostic sequencing
platforms that have received FDA marketing authorization (</FONT><I>e.g.,</I> <FONT STYLE="font-style: normal">the NextSeq550Dx sequencing
platform). Specifically, under the terms specified in Exhibit&nbsp;B, Caris may enter into an IVD Test Kit Agreement to develop an IVD
distributable test kit on the NextSeq550Dx sequencing platform or any future Illumina diagnostic sequencing platform that receives FDA
authorization. An agreement under Exhibit&nbsp;B to develop an IVD distributable test kit on any Illumina diagnostic sequencing platform
would be effective for fifteen (15) years from the date the Transaction closes. The IVD Test Kit Agreement shall not be effective unless
and until the Transaction closes. Caris may also choose to enter into an IVD Test Kit Agreement for a single Illumina diagnostic sequencing
platform, either the NextSeq550Dx platform or any subsequent diagnostic platform, once it receives regulatory approval, under the terms
specified in Exhibit&nbsp;B. This irrevocable offer is binding on Illumina. This offer to enter into the IVD Test Kit Agreement during
the Open Term shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the
conflicts-of-law principles thereof.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">There will be
no change or disruption to Illumina&rsquo;s supply of NGS products to you irrespective of your execution of the Supply Agreement or the
IVD Test Kit Agreement. Illumina remains fully committed to enabling the innovation and exciting work that Caris is doing on Illumina&rsquo;s
next-generation sequencing platforms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2415719d15_ex10-2aimg001.jpg" ALT="" STYLE="height: 31px; width: 121px"></FONT></TD>
    <TD STYLE="text-align: left; width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><B>Illumina,&nbsp;Inc.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">5200 Illumina Way <BR>
San Diego, CA 92122 <BR>
tel 858.202.4500<BR>

    fax 858.202.4545 <BR>
www.illumina.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please contact me if you have any questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Sincerely,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Nicole Berry</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Nicole Berry</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">SVP and General Manager, Americas</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accepted and Agreed:</B></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: middle">Caris MPI,&nbsp;Inc.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">/s/ David D. Halbert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">David D. Halbert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">CEO</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">9/21/2022</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Exhibit&nbsp;A &ndash; Supply Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>DEFINITIONS</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Affiliate(s)</B>&rdquo; means with respect to
a party, any entity that, directly or indirectly, controls, is controlled by or is under common control with such Party for so long as
such control exists. For purposes of this definition, an entity has control of another entity if it has the direct or indirect ability
or power to direct or cause the direction of management policies of such other entity or otherwise direct the affairs of such other entity,
whether through ownership of the voting securities of such other entity, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Application Specific IP&rdquo; </B>means the Illumina
Intellectual Property Rights that pertain to the Supplied Product (and use thereof) only with regard to specific field(s)&nbsp;or specific
application(s). Application Specific IP excludes all Core IP. By way of non-limiting example,&nbsp;Illumina Intellectual Property Rights
for NIPT, for specific forensic methods, or for specific nucleic acid biomarkers, sequences, or combinations of biomarkers or sequences
are examples of Application Specific IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Core IP&rdquo; </B>means Illumina Intellectual
Property Rights that pertain to or cover aspects or features of any Supplied Product (or use thereof), or software embedded in or installed
on Illumina hardware (or use thereof), or software that Illumina hardware is designed to communicate or interact with (or use thereof),
that are common to such Supplied Product in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP
specifically excludes any and all Intellectual Property Rights relating to NIPT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Customer&rdquo; </B>means the For-Profit Entity
that enters into this Supply Agreement with Illumina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Customer Use&rdquo; </B>means use in all fields
of use, specifically excluding any use that (i)&nbsp;is not in accordance with the product&rsquo;s specifications or documentation (it
being understood that specifications and documentation shall not undermine or limit Customer&rsquo;s rights under this Supply Agreement),
(ii)&nbsp;is a re-use of a previously used consumable, (iii)&nbsp;is the disassembling, reverse-engineering, reverse-compiling, or reverse-assembling
of the Supplied Product, (iv)&nbsp;is the separation, extraction, or isolation of components of consumables or other unauthorized analysis
of the consumables, (v)&nbsp;gains access to or determines the methods of operation of the Supplied Product, or (vi)&nbsp;is the transfer
to a third party of, or sub-licensing of, software or third-party software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Equivalent&rdquo; </B>means, with respect to the comparison
of Customer to another customer, that (a)&nbsp;the aggregate volume of all Supplied Products purchased by such other customer from Illumina
in the immediately preceding year (measured in U.S. dollars) is not more than 10% greater than the volume purchased by Customer in prior
year, (b)&nbsp;such other customer is a For-Profit Entity, and (c)&nbsp;such other customer is not currently receiving Grandfathered
Pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;For-Profit Entity&rdquo; </B>means a for-profit
company in the United States that purchases Supplied Products for performing sequencing for liquid biopsy cancer screening or diagnostic
tests for clinical oncology purposes, on human samples received from, and delivered to, unaffiliated health care professionals, health
care organizations or other laboratories for clinical oncology purposes. A For-Profit Entity excludes governments, government agencies,
hospitals, research institutes, academic institutions, non-profits and Illumina Affiliates (including GRAIL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;GRAIL&rdquo; </B>means GRAIL,&nbsp;Inc.
for so long as it is an Affiliate of Illumina, or any successor to GRAIL,&nbsp;Inc. or any substantial part of the business of GRAIL,&nbsp;Inc.
that in either case is Illumina or an Affiliate of Illumina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Grandfathered Pricing&rdquo;
</B>means any pricing (either under a quote of duration longer than 30 days or a supply agreement) that is operative for the Customer
for use of the Supplied Products at the time that the Transaction closes, provided that this pricing is for ongoing, ordinary course purchases
of Supplied Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Illumina Intellectual Property Rights&rdquo; </B>means
all Intellectual Property Rights owned or controlled by Illumina or Affiliates of Illumina during the Term of this Agreement. Application
Specific IP and Core IP are separate, non-overlapping, subsets within the Illumina Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Intellectual Property Right(s)&rdquo; </B>means
all rights in patent, copyrights (including rights in computer software), trade secrets, know-how, trademark, service mark and trade dress
rights and other industrial or intellectual property rights under the laws of any jurisdiction, whether registered or not and including
all applications therefor and registrations thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Pre-Release Sequencing Product</B>&rdquo; means
Illumina sequencing hardware or Sequencing Consumables that are not available for purchase in Illumina&rsquo;s product catalogue. Such
sequencing hardware or Sequencing Consumables shall include any re-designed or modified products made available to any For-Profit Entity
or to GRAIL that optimize, in any material respect, a product&rsquo;s interoperability, capabilities, or performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Sequencing Consumables&rdquo; </B>means those
consumables intended by Illumina to be used to perform a sequencing process on Illumina&rsquo;s NextSeq, NextSeqDx and NovaSeq instruments
and any future sequencing hardware launched by Illumina or its Affiliates, and includes core consumables that are (i)&nbsp;commercialized
or otherwise made available by Illumina to customers or Affiliates of Illumina and (ii)&nbsp;intended by Illumina to be used to perform
a sequencing process on any such system. Sequencing Consumables do not include products that were at the &ldquo;end of life&rdquo; or
 &ldquo;end of sale&rdquo; or were announced (before January&nbsp;1, 2021) to customers as a planned &ldquo;end of life&rdquo; or &ldquo;end
of sale&rdquo;. Sequencing Consumables are limited to products that are shipped to and used in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Short Term Project&rdquo; </B>means a project
or circumstance giving rise to a discrete purchase of Sequencing Consumables outside of ongoing ordinary course of purchases made by a
For-Profit Entity. The duration of a Short Term Project is no more than two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;<B>Supplied Product(s)</B>&rdquo; means
Illumina&rsquo;s NextSeq, NextSeqDx and NovaSeq instruments, and any future sequencing instruments launched by Illumina or its Affiliates,
or Sequencing Consumables,<SUP>1</SUP> that are purchased by Customer for any Customer Use pursuant to the Supply
Agreement. Supplied Products do not include products that were at the &ldquo;end of life&rdquo; or &ldquo;end of sale&rdquo; or were
announced (before January&nbsp;1, 2021) to customers as a planned &ldquo;end of life&rdquo; or &ldquo;end of sale&rdquo;. Supplied Products
are limited to products that are shipped to and used in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP> The NextSeq
and NovaSeq instruments and associated Sequencing Consumables are labeled &ldquo;<B>For Research Use Only. Not for use in diagnostic
procedures.</B>&rdquo; They are subject to laws and regulations applicable to products with that label (<I>e.g.</I>, 21 C.F.R. &sect;
809.10(c)(2)(i)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NextSeqDx is an FDA-regulated device intended for targeted
sequencing of DNA libraries from human genomic DNA extracted from peripheral whole blood or formalin-fixed, paraffin-embedded (FFPE)
tissue, when used for <I>in vitro </I>diagnostic (IVD) assays performed on the instrument. The NextSeq 550Dx instrument is not intended
for whole genome or de novo sequencing. The NextSeq 550Dx</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Transaction&rdquo; </B>means Illumina Inc.&rsquo;s
proposed acquisition of GRAIL,&nbsp;Inc. pursuant to the Agreement and Plan of Merger, dated September&nbsp;20, 2020 (as amended on February&nbsp;4,
2021 by the Amendment to the Agreement and Plan of Merger, the &ldquo;Merger Agreement&rdquo;), among Illumina, Grail, SDG Ops,&nbsp;Inc.,
a Delaware corporation and direct, wholly owned subsidiary of Illumina, and SDG Ops, LLC, a Delaware limited liability company and direct,
wholly owned subsidiary of Illumina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Volume-Based Net Price&rdquo; </B>means the actual
list price of a Supplied Product less the applicable discount for a customer&rsquo;s volume under a volume-based discount schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>TERM</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Supply Agreement shall not be effective unless and
until the Transaction closes, regardless of the date of signing. Once the Supply Agreement is effective, it shall be effective for twelve
(12) years from the closing of the Transaction, regardless of the date either party signs this Supply Agreement (the <B>&ldquo;Term&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>TERMS&nbsp;&amp; CONDITIONS</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Supply Agreement is subject to compliance with the
terms and conditions herein and applicable law. Unless otherwise agreed with Customer,&nbsp;Illumina&rsquo;s standard Terms&nbsp;&amp;
Conditions, as available in the below links, apply to the extent they do not conflict with this Exhibit&nbsp;A, and in the event of a
conflict, the terms of Exhibit&nbsp;A supersede.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Terms and Conditions of Sale &ndash;
Research Use Products:</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><U>https://www.illumina.com/content/dam/illumina-marketing/documents/terms-<BR>
                                            conditions/united-states/usa-terms-and-conditions-of-sale-general.pdf</U></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD></TD><TD>b.</TD><TD>Terms and Conditions of Sale &ndash; Illumina Advantage Products:<BR>
                    <U>https://www.illumina.com/content/dam/illumina-marketing/documents/terms-<BR>
                    conditions/worldwide/terms-conditions-ai-products.pdf</U></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD></TD><TD>c.</TD><TD>Terms and Conditions of Sale &ndash; IVD Products:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD><U>https://www.illumina.com/content/dam/illumina-marketing/documents/terms-<BR>
                              conditions/united-states/usa-terms-and-conditions-of-sale-ivd.pdf</U></TD></TR>
                                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">instrument
is to be used with registered and listed, cleared or approved,&nbsp;IVD reagents and analytical software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>ACCESS TO SUPPLIED PRODUCTS</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Access
to Services. </FONT></B><FONT STYLE="font-size: 10pt">Customer shall have access to the same product services and support services for
purchase relating to the Supplied Products to which GRAIL or any For-Profit Entity has access, or which Customer had access before the
Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Access
to Supplied Products. </FONT></B><FONT STYLE="font-size: 10pt">Customer shall have access to the Supplied Products for purchase that
GRAIL or any For-Profit Entity has access within 45 days of when GRAIL or such For-Profit Entity, as applicable, is offered such access
(if not earlier) for purchase.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Access
to Pre-Release Sequencing Products. </FONT></B><FONT STYLE="font-size: 10pt">Customer shall have access for purchase to any Pre-Release
Sequencing Product to which GRAIL or any For-Profit Entity is offered access within 45 days of when GRAIL or such For-Profit Entity,
as applicable, is offered such access (if not earlier), and for the same categories of uses, specifically: (i)&nbsp;feedback to Illumina
for development of NGS products, including through alpha or beta testing; (ii)&nbsp;for clinical trials; (iii)&nbsp;for clinical validation;
(iv)&nbsp;for pre-commercial test development not relating to clinical trials; or (v)&nbsp;for a commercialized product developed by
Customer. Customer&rsquo;s purchase of any Pre-Release Sequencing Product is subject to the pricing terms in Section&nbsp;5 in this Supply
Agreement. This provision does not apply to Pre-Release Sequencing Products that are developed by Illumina for a specific For-Profit
Entity pursuant to a development agreement under 4.d. with such For-Profit Entity.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d.</FONT>&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Development
Agreement</FONT></B><FONT STYLE="font-size: 10pt">. Illumina shall enter into, upon Customer request, a separate development agreement
with Customer on commercially reasonable terms, relating to the design or modification of any Supplied Product, in a manner that optimizes
interoperability with Customer&rsquo;s tests, including, without limitation, capabilities, performance, speed, efficiency, cost, convenience,
accuracy, specificity, precision, ease of use and user experience.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e.</FONT>&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Obsolescence</FONT></B><FONT STYLE="font-size: 10pt">. Illumina shall not discontinue any Supplied Product so long as Customer continues
to purchase that Supplied Product. Illumina may discontinue a Supplied Product that Customer has not purchased in more than one year.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>PRICING</B></FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0">Under the pricing protections in this section,
Customer will be able to select one of two options for each Supplied Product that they purchase under this Supply Agreement. Customer
may elect to receive the Grandfathered Pricing that Customer received before the close of the Transaction under 5.a. Because all of the
Supplied Products that Customer currently purchases will remain available under 4.e, Customer may maintain its current pricing for the
Term. A Customer who has elected Grandfathered Pricing under 5.a will also receive the benefit of the No Price Increases term in 5.c,
the New Product Pricing under 5.d and Short Term Projects under 5.h.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Alternatively, Customer may elect to switch over to receiving
Universal Pricing under 5.b, under which Customer purchases each Supplied Product under the pricing in Appendix 1. Under Universal Pricing,
Customer will also receive the benefit of the No Price Increases provision for the Term of the Supply Agreement under 5.c. Customer will
also receive pricing protections for new versions of existing Supplied Products under 5.d. As described in 5.d.,&nbsp;Illumina also commits
to certain lower pricing for Suppled Products. Under the Universal Pricing option, pursuant to 5.e and 5.f, Customer will also receive
the benefit of any lower pricing offered to an Equivalent customer or to GRAIL, for any Supplied Product, and Customer will be notified
of such triggering lower pricing under 5.g.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Finally, under either Grandfathered Pricing or Universal
Pricing, Customer will also have access to pricing for Short Term Projects under 5.h.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Grandfathered
Pricing</FONT></B><FONT STYLE="font-size: 10pt">. Customer may continue to receive the benefit of any Grandfathered Pricing for the Term.
If Customer elects to receive Grandfathered Pricing for a Supplied Product Customer shall not receive the benefit of the terms in sections
5.b and 5.e&ndash;5.g for that Supplied Product, but will receive the benefit of the terms in sections 5.c, 5.d and 5.h for that Supplied
Product.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b.</FONT>&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Universal
Pricing</FONT></B><FONT STYLE="font-size: 10pt">. If Customer is not receiving Grandfathered Pricing for a Supplied Product, Customer
shall receive the Volume-Based Net Price for that Supplied Product in accordance with Appendix 1. The universal pricing grid in Appendix
1 contains all currently available universal pricing, including list prices and volume-based discount tiers, for currently available
Supplied Products, and such Appendix 1 will be updated as additional pricing tiers or new Supplied Products (including new versions of
existing Supplied Products) become available.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c.</FONT>&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Price Increases</FONT></B><FONT STYLE="font-size: 10pt">. The inflation-adjusted (based on the Bureau of Labor Statistics&rsquo; Analytical
Laboratory Instrument Manufacturing Index in the Producer Price Index (&ldquo;PPI&rdquo;)) Volume-Based Net Price (under Appendix 1)
that Customer has access to for each Supplied Product purchased under this Supply Agreement over the twelve (12) year term of this Supply
Agreement shall not increase. To the extent Illumina&rsquo;s costs of goods sold for a Supplied Product materially increase due to factors
beyond Illumina&rsquo;s control, then the Volume-Based Net Price (under Appendix 1) may increase solely to reflect that cost increase
and solely for the duration of that cost increase.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d.</FONT>&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">New
Product Pricing. </FONT></B><FONT STYLE="font-size: 10pt">To the extent that Illumina launches a new version of any Supplied Product
(e.g., a sequencing instrument of similar throughput, or a Sequencing Consumable of the same sequencing read length and similar number
of sequencing reads per flow cell), the inflation-adjusted (based on the PPI) Volume-Based Net Price per gigabase of sequencing shall
not be higher as compared to the Volume-Based Net Price of the prior version of the Supplied Product, provided that the new version of
the Supplied Product does not result in any material improvements in performance or capability. In addition, by 2025,&nbsp;Illumina commits
that, under this Supply Agreement, the Volume-Based Net Price (under Appendix 1) to Customer per gigabase of sequencing using the highest
throughput Illumina instrument then available, with the highest throughput, best-performance flow cell and kit then available, at full
capacity, will be at least 43% lower than the inflation-adjusted (based on the PPI) Volume-Based Net Price (under Appendix 1 as of March&nbsp;26,
2021), per gigabase of sequencing using the NovaSeq instrument, with an S4 300 flow cell, at full capacity. For the avoidance of doubt,
holding volume constant, every customer (regardless of their application, or whether they are in oncology screening) using the highest
throughput instrument and best-performance flow cell would observe by 2025 a reduction in price, under the Universal Pricing option,
per gigabase of sequencing, of 43%. By way of example, for a customer at the highest volume discount tier today, the per gigabase sequencing
price is $4, using a NovaSeq instrument with an S4 300 flow cell. Under this commitment, the per gigabase of sequencing price for that
customer at the same volume discount tier in 2025 would be no greater than $2.26 (inflation-adjusted based on the PPI) using the highest
throughput Illumina instrument then available, with the highest-throughput, best-performance flow cell and kit then available. To the
extent Illumina&rsquo;s costs of goods sold for a Supplied Product materially increase due to factors beyond Illumina&rsquo;s control,
then the Volume-Based Net Price (under Appendix 1) may increase solely to reflect that cost increase and solely for the duration of that
cost increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">e<FONT STYLE="font-size: 10pt">.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Equivalent
Customer. </FONT></B><FONT STYLE="font-size: 10pt">If Customer is not receiving Grandfathered Pricing for Supplied Product, without limiting
Section&nbsp;5.f, Customer shall have access to Volume-Based Net Prices (under Appendix 1) for that Supplied Product that are no less
favorable (i.e., the same or better) than the Volume-Based Net Prices provided by Illumina to an Equivalent customer after the date the
Transaction closes, for that Supplied Product.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">GRAIL</FONT></B><FONT STYLE="font-size: 10pt">.
If Customer is not currently receiving Grandfathered Pricing for Supplied Product, Customer shall have access to Volume-Based Net Prices
(under Appendix 1) for that Supplied Product that are no less favorable (i.e., the same or better) than the Volume-Based Net Prices provided
to GRAIL (including of transfer pricing, portability fees, and royalties), after the date the Transaction closes, for that Supplied Product.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notification
and Refund</FONT></B><FONT STYLE="font-size: 10pt">. In the event that Sections 5.e or 5.f are triggered,&nbsp;Illumina will notify Customer
promptly, and no later than 45 days after the end of the applicable Illumina fiscal quarter, and the pricing made available to Customer
for the applicable Supplied Products will be reduced, effective as of the date on which GRAIL or the Equivalent customer received the
triggering pricing, and Customer will receive such reduced pricing for the period of time that the triggering pricing is available to
GRAIL or the Equivalent customer. With respect to units of Supplied Product ordered and invoiced pursuant to a Purchase Order accepted
after the date the triggering purchase was made, and for which Customer has paid the applicable invoice,&nbsp;Illumina will refund to
Customer the difference between the pricing made available to Customer and the triggering pricing, multiplied by the number of affected
units of Supplied Product.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h<B>.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Short
Term Projects. </FONT></B><FONT STYLE="font-size: 10pt">Customer shall have access to Short Term Project pricing that is no less favorable
(<I>i.e.</I>, the same or better) than pricing extended to Equivalent customer or GRAIL for a Short Term Project of substantially similar
size (<I>i.e.</I>, using between 90% and 110% of the volume of Sequencing Consumables) and duration (<I>i.e.</I>, for a period of not
more than 3 months longer than the other Short Term Project), provided that Customer has requested such pricing. If Illumina offers GRAIL
pricing for a Short Term Project under this section,&nbsp;Illumina shall make Customer aware of such pricing promptly, but in no event
later than 45 days after the end of the applicable Illumina fiscal quarter. No customer, including GRAIL, may receive Short Term Project
pricing for more than two consecutive years. No customer, including GRAIL, may use Short Term Project pricing for ongoing ordinary course
purchases, including for its standard commercial testing. Pricing for Short Term Projects will not be considered as triggering with respect
to the obligations in Sections 5.e and 5.f.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>FDA</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Customer may enter into, at any time from today, effective as of the
closing of the Transaction, until the sixth anniversary of the closing of the Transaction, an agreement with Illumina under which Customer
may develop and commercialize in-vitro diagnostic (&ldquo;<B>IVD</B>&rdquo;) test kits for use on Illumina&rsquo;s diagnostic (&ldquo;<B>Dx</B>&rdquo;)
sequencing platforms. Illumina will provide standard terms for Customer to enter into a stand-alone agreement to enable Customer to develop
and commercialize IVD test kits on one or all of Illumina&rsquo;s Dx sequencing platforms. Illumina shall provide any documentation or
information reasonably required for Customer to seek FDA approval or FDA marketing authorization to sell a for-profit, clinical test
using the Supplied Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>PURCHASE ORDERS</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Supply Agreement is not contingent on any purchase
commitments by Customer, nor does it affect Customer&rsquo;s existing unilateral right to terminate its supply relationship with Illumina
at any time and for any reason. Written purchase orders (<B>&ldquo;Purchase Orders&rdquo;</B>) submitted in accordance with this Supply
Agreement,&nbsp;Illumina&rsquo;s Terms and Conditions, or an operative supply agreement may be rejected by Illumina only if Illumina does
not have sufficient supply of the applicable Supplied Product to fulfill the order or if the Purchase Order is not in accordance with
standard lead times for the applicable Supplied Product.</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>SHORT SUPPLY</B></FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event Illumina is experiencing a supply shortage
of the applicable Supplied Product (or components therein),&nbsp;Illumina will allocate the existing supply in an equitable manner among
its customers (including Affiliates) based on expiring lots, and which shall not favor Affiliates over other customers.</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>INTELLECTUAL PROPERTY</B></FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Core
IP Rights. </FONT></B><FONT STYLE="font-size: 10pt">Customer&rsquo;s purchase of Supplied Products under this Supply Agreement confers
upon Customer the non-exclusive, non-transferable, personal, non-sublicensable right solely under Illumina&rsquo;s Core IP to use the
Supplied Products, only with Illumina hardware and software, and only in Customer facilities. Except as expressly stated in this Section&nbsp;9
with respect to Core IP, no right or license under any Illumina Intellectual Property Rights is granted, expressly, by implication, or
by estoppel, to Customer under this Supply Agreement.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">IP
Infringement. </FONT></B><FONT STYLE="font-size: 10pt">In no event will Illumina have the right to cease shipping of the Supplied Product
solely on the basis of any alleged claim of infringement of any intellectual property rights of Illumina.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>CONFIDENTIAL INFORMATION</B></FONT></TD>
</TR></TABLE>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Confidentiality.
</FONT></B><FONT STYLE="font-size: 10pt">To the extent that Illumina may have access to confidential information (&ldquo;<B>Confidential
Information</B>&rdquo;) of Customer in connection with this Supply Agreement or the provision of Supplied Products by Illumina to Customer,&nbsp;Illumina
shall in no event share such Confidential Information of Customer with GRAIL or any subsidiary of GRAIL, or any employees who work within
GRAIL. Any Confidential Information received shall be used by Illumina only (i)&nbsp;to perform Illumina&rsquo;s product supply obligations,
service or obligations under any agreement to Customer, or (ii)&nbsp;for performance of general business practices by non-technical functions
(e.g., accounting, customer service) within Illumina, which functions shall have access to such information only on a need-to-know basis,
and Illumina shall not use such Confidential Information for any other purpose, expressly including without limitation, for any of its
own or Affiliates&rsquo; internal purposes. All employees who may receive Confidential Information will be advised of these confidentiality
obligations and use restrictions. Illumina shall continue its practice of maintaining all Confidential Information of Customer confidential
as to any other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">GRAIL
Firewall. </FONT></B><FONT STYLE="font-size: 10pt">Illumina shall establish a firewall designed to prevent any GRAIL personnel (and
any Illumina personnel carrying out activities with respect to the GRAIL business or products) from accessing any Confidential
Information obtained by or made available to Illumina </FONT>relating to Customer or its business or products, whether pursuant to
this Supply Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>TERMINATION</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">Customer has a unilateral right to terminate its supply
relationship with Illumina at any time and for any reason without termination liability upon ninety (90) days&rsquo; prior written notice
to Illumina, provided, however, that Customer shall honor all invoices, which invoices shall be issued upon shipment, for Supplied Products
ordered under a Purchase Order that was accepted by Illumina prior to the termination date. Illumina cannot terminate this Supply Agreement
for convenience during the Term. If either party materially breaches this Supply Agreement and fails to cure such breach within 60 days
after receiving written notice of the breach, the non-breaching party shall have the right to terminate this Supply Agreement by providing
written notice to the other party; provided, however, that if such breach is curable, but not reasonably curable within such 60-day period,
and the breaching Party is using commercially reasonable efforts to cure the breach, then such cure period will be extended to not longer
than 180 days. Notwithstanding anything to the contrary herein, this Supply Agreement may not be terminated based solely on a claim relating
to infringement of any Illumina Intellectual Property Rights pursuant to Section&nbsp;9.b.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>ENFORCEMENT</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a.</FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Audit.
</FONT></B><FONT STYLE="font-size: 10pt">Illumina agrees to conduct an annual audit by an independent third-party auditor selected by
Illumina from among the &ldquo;Big 4&rdquo; accounting firms to audit Illumina&rsquo;s compliance with the commitments set forth herein.
Illumina will provide Customers with a written report (with reasonable redactions) confirming compliance with the commitments set forth
herein. Illumina shall provide cooperation, including access to necessary books and records, in support of any audit conducted. To the
extent Customer has a good faith basis for alleging that Illumina is in breach of a commitment contained herein,&nbsp;Illumina shall
engage an auditor to assess Customer&rsquo;s allegation separate from and in addition to Illumina&rsquo;s annual audit.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Arbitration.
</FONT></B><FONT STYLE="font-size: 10pt">If any dispute arises from or relates to this Supply Agreement, including as a result of a dispute
over terms in a separate agreement that incorporates the terms herein (the &ldquo;Dispute&rdquo;), other than claims involving infringement,
validity, or enforceability of Intellectual Property Rights (whether Illumina&rsquo;s or Customer&rsquo;s), or about the scope of Intellectual
Property Rights in an agreement,&nbsp;Illumina and Customer (each a &ldquo;party&rdquo; and together the &ldquo;parties&rdquo;) shall
submit the matter to confidential binding arbitration to determine final terms and conditions of the supply agreement, or to settle the
dispute as to the terms of a supply agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Prior
to submitting any matter to arbitration,&nbsp;Illumina and Customer shall each designate a contact having the proper authorization to
resolve the Dispute in a final and binding fashion, who shall meet in person or by telephone for a period of thirty (30) days (or such
other period of time as Illumina and the Customer shall mutually agree) in an attempt to resolve the Dispute in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
arbitration proceeding shall be conducted in accordance with the Commercial Arbitration Rules&nbsp;of the AAA and as otherwise described
in this Section&nbsp;12.b.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
location of the arbitration proceeding will be mutually agreed by the parties. In the event there is no agreement as to location, the
arbitration proceeding will take place in New York City, NY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Within
five business days of the commencement of an arbitration, Customer and Illumina each shall furnish a legally binding writing to the other
committing to maintain the confidentiality of the arbitration and of any written statement and discovery materials exchanged during the
arbitration, and to limit the use of any such materials to the arbitration.</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Upon
written request by either party to the other party, the parties shall promptly negotiate in good faith to appoint an appropriate Arbitrator.
If the parties are not able to agree within ten (10)&nbsp;days after the receipt by a party of the written request in the immediately
preceding sentence, the AAA shall be responsible for selecting an Arbitrator with relevant experience related to the dispute of at least
ten (10)&nbsp;years and to do so within fifteen (15) days of being approached by a party. The fees and costs of the Arbitrator and the
AAA shall be shared equally (50%/50%) by the parties. Each party to the arbitration shall bear its own legal fees and expenses.</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Within
twenty (20) days after the designation of the Arbitrator, the parties shall each simultaneously submit to the Arbitrator and one another
a written statement of their respective positions on such Dispute. Each party shall have fifteen (15) days from receipt of the other party&rsquo;s
submission to submit a written response thereto. The Arbitrator shall have the right to meet with the parties, either alone or together,
as necessary to make a determination. Further, the Arbitrator shall have the right to request information and materials and to require
and facilitate discovery as it shall determine is appropriate in the circumstances, taking into account the needs of the parties and the
desirability of making discovery expeditious and cost-effective determinations. In reaching a decision, the Arbitrator may consider only
documents exchanged in discovery between the parties, testimony explaining the documents and the parties&rsquo; written statements and
other materials submitted and arguments made by counsel.</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
later than thirty (30) days after the parties each submit their written statements to the Arbitrator, or as otherwise agreed by the parties,
the Arbitrator shall make a determination by selecting the resolution proposed by one of the parties that as a whole is the most consistent
with this Agreement and the most fair and reasonable to the parties in light of the totality of the circumstances. The Arbitrator shall
provide the parties with a written statement setting forth the basis of the determination in connection therewith, provided that the Arbitrator
shall not have the authority to alter any explicit provision of the Supply Agreement. The decision of the Arbitrator shall be final, binding
and conclusive, absent manifest error; judgment on the award may be entered in any court having jurisdiction. Neither party may disclose
the existence, content, or results of any arbitration without the prior written consent of both parties, unless required by law.</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">viii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
parties may, by agreement, modify any time periods specified in this Section&nbsp;12.b. At any time after the commencement of arbitration,
the parties may agree to suspend the arbitration, for periods not to exceed fourteen (14) days in the aggregate, to attempt to resolve
their dispute through negotiation. The parties shall effectuate such suspension through a joint writing filed with the AAA. Either party
may terminate the suspension at any time by filing with the AAA a writing calling for the arbitration to resume.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-size: 10pt">c.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Choice
of Law. </B>This Supply Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without
giving effect to the conflicts-of-law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>Appendix 1 to Exhibit
A &ndash; Universal Consumables and Instruments Discount Schedules and List Price Catalogue</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT><U>Exhibit&nbsp;B
 &ndash; IVD Test Kit Agreement Terms</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT>In connection
with Illumina Inc.&rsquo;s proposed acquisition of GRAIL,&nbsp;Inc. (the &ldquo;<B>Transaction</B>&rdquo;),&nbsp;Illumina is offering
to Caris the following terms. Caris may select from the terms below for any of three types of IVD Test Kit Agreements: An &ldquo;All Platforms&rdquo;
Agreement described in the leftmost column, a &ldquo;NextSeq&rdquo; Agreement described in the middle column, or a &ldquo;NovaSeq&rdquo;
Agreement, described in the rightmost column. Caris is referred to as &ldquo;Customer&rdquo; in Exhibit&nbsp;B. Any IVD Test Kit Agreement
under the terms offered in this Exhibit&nbsp;B shall not be effective unless and until the Transaction closes, regardless of the date
of signing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border: black 1pt solid; padding: 2pt 5.4pt 2pt 6.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 2pt 6.2pt; border-left: black 1pt solid; width: 14%"><B>Objectives and Applicable Instruments</B> <B>&nbsp;</B></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; width: 32%"><P STYLE="text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;The
                                                                                        parties would enter into an IVD Test Kit Agreement (the &ldquo;<B>Agreement</B>&rdquo;) to enable Customer to develop and
                                                                                        commercialize distributable in-vitro diagnostic (IVD) test kits (&ldquo;<B>IVD Test Kits</B>&rdquo;) for use on Illumina&rsquo;s
                                                                                        NextSeq 550Dx and future Illumina regulatory approved Dx sequencing platforms, including the expected NovaSeqDx (&ldquo;<B>IVD
                                                                                        Hardware</B>&rdquo;).</FONT>&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<FONT STYLE="font-family: Symbol"></FONT></P>
                                                                                <P STYLE="text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina does not guarantee that NovaSeqDx or any future platforms will receive regulatory approval in any jurisdiction.2</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.375in; border-right: black 1pt solid; text-indent: -0.25in; width: 27%"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;The
parties would enter into an IVD Test Kit Agreement (the &ldquo;<B>Agreement</B>&rdquo;) to enable Customer to develop and commercialize
distributable in-vitro diagnostic (IVD) test kits (&ldquo;<B>IVD Test Kits</B>&rdquo;) for use on Illumina&rsquo;s NextSeq 550Dx sequencing
platform (the &ldquo;<B>NextSeqDx</B>&rdquo;).</FONT> &nbsp; &nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; width: 27%"><P STYLE="text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;The
parties would enter into an IVD Test Kit Agreement (the &ldquo;<B>Agreement</B>&rdquo;) to enable Customer to develop and commercialize
distributable in-vitro diagnostic (IVD) test kits (&ldquo;<B>IVD Test Kits</B>&rdquo;) for use on an Illumina platform for diagnostic
purposes that is currently under development that is similar to the NovaSeq (the &ldquo;<B>NovaSeqDx</B>&rdquo;).</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                                                                <P STYLE="text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
does not guarantee that NovaSeqDx will receive regulatory approval in any jurisdiction.3</FONT> &nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of IVD Test Kits</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Unlimited</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Up
to three (3)</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Up
to three (3)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 2pt 6.2pt; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory</B></FONT></TD>
    <TD COLSPAN="3" STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Worldwide, in jurisdictions where the applicable IVD Hardware has regulatory approval.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0; text-align: left"><FONT><SUP>2</SUP>
Illumina does not guarantee that the NovaSeqDx or any future platforms will be listed pursuant to applicable regulations in any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Term</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Term
    of Agreement (during which time Customer could sell IVD Test Kits) would be 15 years from the date the Transaction closes. Customer could
    enter into new IVD Plans for IVD Test Kit development during the first 10 years (the &ldquo;<B>Development Term</B>&rdquo;). </FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Continued
    Commercialization: After expiration of the Term, Customer may continue commercializing IVD Test Kits that were launched before expiration
    of the Term for so long as Illumina is still commercializing the applicable Sequencing Consumables and servicing and supporting the applicable
    IVD Hardware in the applicable Territory.</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;10
    years from the date the Transaction closes.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Continued
    Commercialization: After the expiration of the Term, Customer may continue commercializing IVD Test Kits that were launched before the
    expiration of the Term for so long as Illumina is still commercializing the applicable Sequencing Consumables and servicing and supporting
    the NextSeqDx in the applicable Territory.</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;10
    years from the later of (i)&nbsp;the date the Transaction closes or (ii) the date NovaSeqDx is listed with FDA in the U.S. pursuant to
    applicable law.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Continued
    Commercialization: After the expiration of the Term, Customer may continue commercializing IVD Test Kits that were launched before the
    expiration of the Term for so long as Illumina is still commercializing the applicable Sequencing Consumables and servicing and supporting
    the NovaSeqDx in the applicable Territory.</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Considerations</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Tech
    Access Fee: [***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Development
    Milestone Payments: [***]</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Tech
    Access Fee: [***]</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Development
    Milestone Payments: [***]</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Tech
    Access Fee: [***]</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Development
    Milestone Payments: [***]</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 14%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 32%; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Revenue Share: [***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Revenue Share: [***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Revenue Share: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governance for All Platforms Agreement</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-right: black 1pt solid; border-bottom: black 1pt solid; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;A Joint Steering Committee (&ldquo;<B>JSC</B>&rdquo;) composed of an equal number of representatives from each party would oversee the collaboration.</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;N/A</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;N/A</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional End- User Technical Support for All Platforms Agreement</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid"><P STYLE="margin-left: 0.25in; margin-top: 0; margin-bottom: 0; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;The parties would enter into one or more IVD Support Schedule(s)&nbsp;that would specify:</FONT></P>
                                                                                                   <P STYLE="margin-left: 0.25in; margin-top: 0; margin-bottom: 0; text-indent: -0.25in">&nbsp;</P>
                                                                                                                          <P STYLE="text-indent: -0.25in; margin-left: 0.75in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;cross-training activities to facilitate customer support</FONT></P>
                                                                                                                          <P STYLE="margin-left: 0.5in; margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="text-indent: -0.25in; margin-left: 0.75in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a customer triage mechanism, including turnaround time requirements and an Information Transfer Form&nbsp;to facilitate customer hand-offs</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;N/A</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;N/A</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; width: 14%; border: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; width: 32%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt 2pt 0.1in">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;timing
    and mechanism for review of customer support cases and quality/safety metrics</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;escalation
    procedures and adverse event reporting mechanisms</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;mechanism
    for discussing potential cross-product replacement processes</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-bottom: Black 1pt solid; text-indent: -0.25in; border-right: black 1pt solid"> &nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-bottom: Black 1pt solid; text-indent: -0.25in; border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-left: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional Commercial Support for All Platforms Agreement</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-right: black 1pt solid; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon Customer&rsquo;s request, the parties would establish a joint commercialization committee (JCC) to discuss potential opportunities to collaborate commercially, including co-marketing and co-promotion opportunities, commercialization cross-training opportunities, lead generation joint campaigns,&nbsp;etc.</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-right: black 1pt solid; text-align: left; text-indent: -0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;N/A</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;N/A</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-left: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-right: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
    would provide marketing materials concerning the IVD</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hardware and Sequencing Consumables for Customer&rsquo;s use in commercializing
    the IVD Test Kits.</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 5.4pt 0pt 0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 5.4pt 0pt 0.25in">&nbsp;</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 5.4pt 0pt 0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 5.4pt 0pt 0.25in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-bottom: Black 1pt solid; border-right: black 1pt solid; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Customer would have the right to reference the name and catalogue number of the IVD Hardware and Sequencing Consumables used in an IVD System in marketing materials for the IVD Test Kit and to reference the Illumina-provided information concerning the Illumina sales organization or channel partner responsible for selling the IVD Hardware and Sequencing Consumables for a given country.</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-bottom: Black 1pt solid; text-indent: -0.25in; border-right: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-bottom: Black 1pt solid; text-indent: -0.25in; border-right: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-top: 2pt; border: black 1pt solid; padding-left: 6pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0.1in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 6pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 6pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 14%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0.1in; width: 32%; padding-bottom: 2pt"><P STYLE="margin: 0 5.4pt 0 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;On a semi-annual basis Illumina would share the following information concerning Illumina&rsquo;s IVD Hardware install base to support Customer&rsquo;s commercialization of IVD Test Kits: &nbsp; </FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT></P>
                                                                                <P STYLE="margin: 0 5.4pt 0 0.25in; text-indent: -0.25in">&nbsp;</P>
                                                                                <P STYLE="margin: 0 5.4pt 0 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Total IVD Hardware instrument placements by Illumina in the Territory by region and by country &nbsp; </FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT></P>
                                                                                <P STYLE="margin: 0 5.4pt 0 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="margin: 0 5.4pt 0 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Total IVD Hardware instrument placements by Illumina, sorted by Illumina-designated customer segment (e.g., academic medical center labs,&nbsp;IDN/regional hospital labs, community hospital labs,&nbsp;etc.) &nbsp;</FONT></P>
                                                                                <P STYLE="margin: 0 5.4pt 0 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="margin: 0 5.4pt 0 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Total number of Customer sites who have purchased IVD Hardware from Illumina by customer segment</FONT></P></TD>
    <TD STYLE="padding-top: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%; padding-bottom: 2pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; width: 14%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; width: 32%; border-bottom: black 1pt solid; border-right: black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Agreement would contain a mechanism for agreeing upon
    Commercial Plans for support of IVD Test Kit commercialization, including:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;jurisdiction-specific
    commercialization planning, including connecting responsible Customer representatives and Illumina affiliates and channel partners who
    would operate in a particular jurisdiction</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;assistance
    with enabling third-party laboratories to perform pre-launch verification studies to ensure commercial readiness of the IVD Test Kit</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;mechanisms
    for providing assistance and documentation with respect to requests for public tender offers marketing materials Illumina would
    provide concerning the IVD Hardware and Sequencing Consumables for Customer&rsquo;s use in <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercializing
    the IVD</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Test Kits</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; width: 27%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; width: 27%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; vertical-align: top; width: 14%"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; vertical-align: top; width: 2%"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 43.45pt; width: 30%"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; vertical-align: top; width: 27%"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; padding-right: 5.4pt; vertical-align: top; width: 27%"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding: 2pt 5.4pt 7pt 6.45pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; padding-bottom: 7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Field: Oncology, including risk assessment, screening, diagnosis, staging, prognosis, monitoring, and treatment selection.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Exclusion: Whole genome sequencing (&ldquo;<B>WGS</B>&rdquo;), meaning an assay that sequences all or substantially all of the genome to a depth greater than 10x and reports information concerning nucleotide base calls or variants in nucleotide sequence, structure, or copy number; provided, however, that WGS does not include any such assay that reports only genome-wide signals such as (a)&nbsp;DNA fragmentation patterns or (b)&nbsp;nucleotide base modification such as methylations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2pt 5.4pt 4pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2pt 5.4pt 4pt 0.125in; text-indent: -0.125in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;For clarity, the field would not include forensic testing, non-invasive prenatal testing, pre-implantation genetic screening of embryos or pre-implantation genetic diagnosis of embryos, or human leukocyte antigen testing in connection with transplantation.</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2pt 5.4pt 2pt 6.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusivity</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2pt 5.4pt 2pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Non-exclusive</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding: 2pt 5.4pt 7pt 6.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IVD
    Systems <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and IVD Test Kits</B></FONT></B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Each IVD system (&ldquo;<B>IVD System</B>&rdquo;) would consist of, for the applicable agreement:</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 6.45pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the IVD Hardware/the NextSeqDx/the NovaSeqDx</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
    associated core sequencing consumables used in the sequencing process (&ldquo;<B>Sequencing Consumables</B>&rdquo;)</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
    LRM software module (or software having similar functionality for use with NovaSeqDx or other future</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IVD
    Hardware) developed by Illumina to run the IVD Test Kit on the applicable IVD Hardware/the</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NextSeqDx/the NovaSeqDx (the &ldquo;<B>LRM Software Module</B>&rdquo;)</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
IVD Test Kit</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;The
    IVD Test Kits would contain all reagents needed for the workflow (other than Sequencing Consumables) and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer&rsquo;s analysis software.</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Customer would supply the IVD Test Kits and LRM Software Modules to end-users.</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Illumina would supply the Sequencing Consumables and IVD Hardware/NextSeqDx/NovaSeqDx to end-users.</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-right: 5.4pt; vertical-align: top; padding-bottom: 7pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 7pt 6pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; padding: 2pt 5.4pt 7pt 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Each
    party would be responsible for development (other than Illumina developing the LRM Software Modules for</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer), regulatory approval, quality control, and commercialization of their products.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.45pt; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IVD Plans</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD COLSPAN="3" STYLE="padding: 2pt 5.4pt 2pt 0.125in; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;Each IVD Test Kit, and the parties&rsquo; specific development obligations and timelines with respect to each IVD Test Kit, would be described in a development plan to be negotiated in good faith (each, an &ldquo;<B>IVD Plan</B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.45pt; width: 14%; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; width: 32%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; width: 27%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.7pt; width: 27%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Customer
    would propose potential IVD Plans. Illumina may not unreasonably reject any proposed IVD Plan.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;It
    would be deemed reasonable for Illumina to reject any proposed IVD Plan that: (a)&nbsp;is reasonably likely to cause Illumina or its Affiliate
    not to comply with Law, or result in a breach of any agreement or other arrangement to which Illumina or its Affiliate is a party; (b)&nbsp;would
    result in an IVD Test Kit that is reasonably likely to be used in a manner that is contrary to ethical guidelines promulgated by established
    national and international ethical bodies; (c)&nbsp;is reasonably likely to require Illumina to engage in any development activities after
    expiration of the Development Term (in the case of the all-platforms Agreement) or the Term (in the case of the NextSeqDx or NovaSeqDx
    Agreement); (d)&nbsp;is not technologically feasible or would require IVD Hardware/NextSeqDx/NovaSeqDx or Sequencing Consumables to be
    used in a manner outside standard, published, specifications or Illumina&rsquo;s standard terms and conditions of sale; (e)&nbsp;is reasonably
    likely to result in an IVD Test Kit that violates or infringes upon the IP of a third party; or (f)&nbsp;requires Illumina to perform
    activities not specified in this Exhibit&nbsp;B or the Agreement.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="3" STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Customer Responsibilities</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border-right: black 1pt solid; font-size: 10pt; width: 86%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Development</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-right: black 1pt solid; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Develop and obtain regulatory approval for the IVD Test Kits (including all related testing, studies, and regulatory submissions). IVD
Hardware/NextSeqDx/NovaSeqDx instruments and Sequencing Consumables required for development would be purchased from Illumina under the
terms and conditions specified in the Supply Agreement. Customer may enter into the Supply Agreement provided in Exhibit A to the Open
Offer during the Open Offer Period.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Validate and obtain regulatory approval for the LRM Software Modules (including all related testing, studies, and regulatory submissions,
other than the LRM Software Module verification done by Illumina).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><B><U>Commercialization</U>&nbsp;</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Manufacture
and sell the IVD Test Kits and distribute the LRM Software Modules to end-users.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintain
    reasonable quality systems, consistent with industry standards and applicable legal requirements.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    reasonable product support and technical support, consistent with industry standards, for the IVD Test Kits and LRM Software
    Modules.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Refer
    to Illumina all support inquiries which Customer has reasonably determined to be caused by the IVD Hardware or Sequencing
    Consumables.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><B>Illumina</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><B>Responsibilities</B></P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 6pt; font-size: 10pt; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Development</U></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 6.2pt; font-size: 10pt; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Development</U></B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 6.7pt; font-size: 10pt; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Development</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-right: black 1pt solid; border-left: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Develop
    and verify the LRM Software Modules for the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Supply
    Customer the IVD Hardware and Sequencing Consumables needed for development and testing of the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    reasonable consultation in connection with Customer seeking, obtaining, and maintaining regulatory approvals for each IVD Test Kit and
    LRM Software Module.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    reasonable consultation with respect to performance optimization of IVD Test Kits with the IVD Hardware and Sequencing Consumables (which
    consultation would not involve technical development or testing).</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Once
    per calendar year during the Development Term, the Illumina JSC members would provide the Partner JSC members with a general, high-level,
    presentation concerning Illumina&rsquo;s in vitro diagnostic sequencing instrument pipeline, including a general description of instruments
    for which Illumina intends to seek Regulatory Approval during the following calendar year.</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Develop
    and verify the LRM Software Modules for the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Supply
    Customer the NextSeqDx and Sequencing Consumables needed for development and testing of the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide reasonable consultation in connection with Customer seeking, obtaining,
    and maintaining regulatory approvals for each IVD Test Kit and LRM Software Module.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    reasonable consultation with respect to performance optimization of IVD Test Kits with the NextSeqDx and Sequencing Consumables (which
    consultation would not involve technical development or testing).</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
    would not be required to obtain any regulatory approvals for the NextSeqDx or Sequencing Consumables or to otherwise expand or modify
    any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory
    approval in any jurisdiction(s)).</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Commercialization</U></B></FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Develop
    and verify the LRM Software Modules for the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Supply
    Customer the NovaSeqDx and Sequencing Consumables needed for development and testing of the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Provide reasonable consultation in connection with Customer
    seeking, obtaining, and maintaining regulatory approvals for each IVD Test Kit and LRM Software Module.</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Provide reasonable consultation with respect to performance
    optimization of IVD Test Kits with the NovaSeqDx and Sequencing Consumables (which consultation would not involve technical development
    or testing).</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
would not be required to obtain any regulatory approvals for the NovaSeqDx or Sequencing Consumables or to otherwise expand or modify
any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory
approval in any jurisdiction(s)).</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Commercialization</U></B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid; width: 14%; font-size: 10pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 32%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
    would not be required to obtain any regulatory approvals for the IVD Hardware or Sequencing Consumables or to otherwise expand or modify
    any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory
    approval in any jurisdiction(s)).</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
    would not be required to obtain any regulatory approvals for the IVD Hardware or Sequencing Consumables or to otherwise expand or modify
    any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory
    approval in any jurisdiction(s)).</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B><U>Commercialization</U></B></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Sell
    the IVD Hardware and Sequencing Consumables to end-users throughout the Change Period and use commercially reasonable efforts to sell Sequencing
    Consumables for an additional 5 years after the Change Period.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    product support and technical support to end-users for the IVD Hardware and Sequencing Consumables.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Refer
    to Customer all support inquiries which Illumina has reasonably determined to be caused by an IVD Test Kit or LRM Software Module.</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Sell
    the NextSeqDx and Sequencing Consumables to end-users throughout the Change Period and use commercially reasonable efforts to sell Sequencing
    Consumables for an additional 5 years after the Change Period.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    product support and technical support to end-users for the NextSeqDx and Sequencing Consumables.&nbsp;</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Refer
    to Customer all support inquiries which Illumina has reasonably determined to be caused by an IVD Test Kit or LRM Software Module.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    second-tier product and technical support for the LRM Software Modules to Customer.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    Customer with the right to engage in quality audits to the extent required by applicable law and regulatory requirements.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Use
    commercially reasonable efforts to maintain existing regulatory approvals for the NextSeqDx and related Sequencing Consumables throughout
    the Change Period and for five years thereafter.</FONT></P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Sell
    the NovaSeqDx and Sequencing Consumables to end-users throughout the Change Period and use commercially reasonable efforts to sell Sequencing
    Consumables for an additional 5 years after the Change Period.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    product support and technical support to end-users for the NovaSeqDx and Sequencing Consumables.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Refer
    to Customer all support inquiries which Illumina has reasonably determined to be caused by an IVD Test Kit or LRM Software Module.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    second-tier product and technical support for the LRM Software Modules to Customer.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    Customer with the right to engage in quality audits to the extent required by applicable law and regulatory requirements.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Use
    commercially reasonable efforts to maintain regulatory approvals (once obtained) for the NovaSeqDx and related Sequencing Consumables
    throughout the Change Period and for five years thereafter.</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid; width: 14%; font-size: 10pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 32%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    second-tier product and technical support for the LRM Software Modules to Customer.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Provide
    Customer with the right to engage in quality audits to the extent required by applicable law and regulatory requirements.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Use
    commercially reasonable efforts to maintain existing and new regulatory approvals (once obtained) for the IVD Hardware and related Sequencing
    Consumables throughout the Change Period and for five years thereafter.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp; &nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;During
    the Change Period for each IVD Hardware, Illumina would (a) provide at least 6 months&rsquo; notice for major, planned changes to the
    platform (IVD Hardware, Sequencing Consumables, or LRM Software Modules) and (b) notify Customer as soon as reasonably practicable of
    any major, unplanned changes to IVD Hardware, Sequencing Consumables, or LRM Software Modules. A major change is a change that Illumina
    reasonably expects to require Customer to make a filing or submission to any regulatory authority in connection with obtaining or maintaining
    regulatory approval for an IVD Test Kit.</FONT> </P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0">During the Change Period, Illumina would (a) provide at least
    6 months&rsquo; notice for major, planned changes to the platform (NextSeqDx, Sequencing Consumables, or LRM Software Modules) and (b)
    notify Customer as soon as reasonably practicable of any major, unplanned changes to the NextSeqDx, Sequencing Consumables, or LRM Software
    Modules. A major change is a change that Illumina reasonably expects to require Customer to make a filing or submission to any regulatory
    authority in connection with obtaining or maintaining regulatory approval for an IVD Test Kit.</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 27%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0">During the Change Period, Illumina would (a) provide at
least 6 months&rsquo; notice for major, planned changes to the platform (NovaSeqDx, Sequencing Consumables, or LRM Software Modules)
and (b) notify Customer as soon as reasonably practicable of any major, unplanned changes to the NovaSeqDx, Sequencing Consumables, or
LRM Software Modules. A major change is a change that Illumina reasonably expects to require Customer to make a filing or submission
to any regulatory authority in connection with obtaining or maintaining regulatory approval for an IVD Test Kit.</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6pt; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid; width: 14%; font-size: 10pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid; border-bottom: Black 1pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: center; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Following
a notice under (a)&nbsp;or (b)&nbsp;above, upon Customer&rsquo;s reasonable request,&nbsp;Illumina would discuss with Customer the steps
necessary to transition to modified or successor instruments, core consumables, or </FONT> LRM software modules, if any, and Illumina
would use commercially reasonable efforts to assist  Customer with such transition.</P></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-bottom: Black 1pt solid; border-right: black 1pt solid; width: 27%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-bottom: Black 1pt solid; border-right: black 1pt solid; width: 27%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.45pt; border-right: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Change Period</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-right: black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;The
    &ldquo;<B>Change Period</B>&rdquo; for the NextSeqDx and its related Sequencing Consumables and LRM Software Modules would end no earlier
    than ten years from the date the Transaction closes.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;For
    the NovaSeqDx and any other future IVD Hardware and their related Sequencing Consumables and LRM Software </FONT> Modules, the
    Change Period would end no earlier than ten years from the date the Transaction closes. Illumina would ensure that all customers
    with IVD development agreements have the same Change Period for the applicable  IVD Hardware, including any extensions to the
    Change Period Illumina may make from time to time.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.45pt; border-bottom: Black 1pt solid; border-left: black 1pt solid; border-top: Black 1pt solid; border-right: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rights Grants</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="padding: 2pt 5.4pt 2pt 0.1in; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid">
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
    would grant Customer, by exhaustion, the right under Illumina core sequencing IP (but not any application-specific IP) to use the IVD
    Hardware and Sequencing Consumables purchased from Illumina under the Agreement to develop the IVD Test Kits.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina would grant Customer a right to refer to the device listing for the
IVD Hardware and Sequencing </FONT> Consumables in support of seeking Regulatory Approval for the IVD Test Kits and to incorporate the
information contained in the device listings into the submissions for the IVD Test Kits and LRM Software Modules by reference.</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina
    would grant a non-exclusive license to enable Customer to distribute the LRM Software Modules in executable object code to end-users.
    Customer would not receive access to the source code.</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 572.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 572.6pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 572.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-top: 2pt; border: black 1pt solid; padding-left: 6pt; width: 14%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 6pt; width: 32%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Platforms</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 6pt; width: 27%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NextSeq</B></FONT></TD>
    <TD STYLE="padding-top: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 6pt; width: 27%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NovaSeq</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 572.6pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 14%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sublicensing and Assignment</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 86%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;All rights and licenses
    granted to Customer would be personal, non-sublicensable, and non-transferable. The IVD Test Kits could be commercialized only under
    a Customer-owned brand and not as a private label or &ldquo;white label&rdquo; for any person other than Customer or under any original
    equipment manufacturer (OEM) arrangement. Customer would not have the right to assign or transfer the Agreement or any rights or
    obligations under the Agreement without the prior written consent of Illumina (which restriction would not apply to acquisitions
    of Customer where the Customer entity that is party to the Agreement does not change).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: black 1pt solid; border-left: black 1pt solid; border-right: black 1pt solid"><B>Change of Control</B></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; border-bottom: black 1pt solid; text-indent: -0.25in; border-right: black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT>
                                            <FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;If
                                            Customer undergoes a Change of Control, Customer would notify Illumina within 5 business
                                            days.</FONT></P>
                                                                                                                          <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
                                            Under any Change of Control, Customer would pay Illumina a $2M change of control fee.</FONT></P></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Press Release</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Any press release announcing
    the Agreement would be reviewed and approved by both parties.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRAIL Firewall</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;Illumina shall establish
    a firewall designed to prevent any GRAIL personnel (and any Illumina personnel carrying out activities with respect to the GRAIL
    business or products) from accessing any Confidential Information obtained by or made available to Illumina relating to Customer
    or its business or products, whether pursuant to this Supply Agreement or otherwise.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arbitration</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;If any dispute arises
    from or relates to an Agreement as to the terms set forth above, other than claims involving infringement, validity, or enforceability
    of intellectual property rights (whether Illumina&rsquo;s or Customer&rsquo;s), or about the scope of intellectual property rights
    in an Agreement, the Parties shall submit the dispute to confidential binding arbitration.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional Provisions</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;This document contains
    a high-level summary of certain terms of the Agreement. Additional standard provisions, such as confidentiality, compliance requirements,
    representations and warranties, indemnification, termination rights, revenue share reporting and audit rights, limitations on liability,
    force majeure,&nbsp;etc. would be included in the Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt 2pt 6.2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Choice of Law</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.35in; text-indent: -0.25in; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;This IVD Test Kit Agreement
    shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the conflicts-of-law
    principles thereof.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 521.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a44 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 84%; vertical-align: middle"><IMG SRC="tm2415719d15_ex10-2asp4img01.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif">Illumina, Inc. <BR> 5200 Illumina Way<BR> San Diego, CA 92122<BR> tel 858.202.4500<BR> fax 858.202.4545 <BR> www.illumina.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 75%; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">David
    D. Halbert</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 23%"><FONT STYLE="font-style: normal; font-weight: normal">September
    8, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer<BR>
Caris MPI, Inc. <BR>
750 West John Carpenter Freeway <BR>
Suite 800 <BR>
Irving, Texas 70539</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: <U>Additional Terms &ndash; Addendum to Supply Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Halbert:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With reference to the standard contract terms Illumina, Inc. (&ldquo;Illumina&rdquo;) made available to any U.S. oncology customer on
March 30, 2021, specifically, Exhibit A to Illumina&rsquo;s letter dated March 29, 2021 (&ldquo;Exhibit A&rdquo;), Illumina is irrevocably
offering additional terms to further allay any concerns relating to Illumina&rsquo;s August 18, 2021 acquisition (the &ldquo;Tr hereafter
as &ldquo;GRAIL&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any terms used but not otherwise defined herein shall have the
meanings ascribed to them in the March 29, 2021 Letter, including Exhibit A. T he terms of this addendum may be accepted any time
from today until expiration of the Open Term for Exhibit A. The terms of this addendum shall become effective immediately upon
Customer&rsquo;s acceptance of these terms, and shall remain in effect during the Term for as long as GRAIL is an Affiliate of Illumina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under this addendum, each of the terms and conditions set forth
in the Exhibit A shall continue to apply, in addition to or as modified by the supplemental terms provided in Exhibit C to this
letter (together with Exhibit A, the &ldquo;Supply Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Sincerely,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Francis deSouza</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Francis deSouza</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accepted and Agreed:</B></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: middle">Caris </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ David D. Halbert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">David D. Halbert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">CEO</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">9/21/2022</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Exhibit C &ndash; Additional
Supply Agreement Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The following underlined text is hereby added to <U>Section
                                            4(a)</U> of Exhibit A:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;a. <B>Access to Services</B>. Customer shall have access
to the same product services and support services for purchase relating to the Supplied Products to which GRAIL or any For-Profit Entity
has access, or which Customer had access before the Transaction. <U>For such services, Customer shall have access to the same volume-based
pricing that GRAIL has access to for the equivalent level of service, or to which Customer had access before the transaction, at the
Customer&rsquo;s option.&rdquo;</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: left">In <U>Section 4(b)</U> of Exhibit A, the clause &ldquo;45 days
of when GRAIL or such For-Profit Entity&rdquo; is replaced with &ldquo;5 days of when GRAIL or such For-Profit Entity&rdquo;, such that
the section reads:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;b. <B>Access to Supplied Products</B>. Customer shall have
access to the Supplied Products for purchase that GRAIL or any For-Profit Entity has access, within 5 days of when GRAIL or such For-Profit
Entity, as applicable, is offered such access (if not earlier) for purchase.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: left">In <U>Section 4(c)</U> of
                                            Exhibit A, the clause &ldquo;45 days of when GRAIL or such For-Profit Entity&rdquo; is replaced
                                            with &ldquo;5 days of when GRAIL or such For-Profit Entity&rdquo;, such that the section
                                            reads:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;c.
                                            <B>Access to Pre-Release Sequencing Products</B>. Customer shall have access for purchase
                                            to any Pre-Release Sequencing Product to which GRAIL or any For-Profit Entity is offered
                                            access within 5 days of when GRAIL or such For-Profit Entity, as applicable, is offered such
                                            access (if not earlier), and for the same categories of uses, specifically: (i) feedback
                                            to Illumina for development of NGS products, including through alpha or beta testing; (ii)
                                            for clinical trials; (iii) for clinical validation; (iv) for pre-commercial test development
                                            not relating to clinical trials; or (v) for a commercialized product developed by Customer.
                                            Customer&rsquo;s purchase of any Pre- Release Sequencing Product is subject to the pricing
                                            terms in Section 5 in this Supply Agreement. This provision does not apply to Pre-Release
                                            Sequencing Products that are developed by Illumina for a specific For-Profit Entity pursuant
                                            to a development agreement under 4.d. with such For-Profit Entity.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify"><U>Section 4</U> of Exhibit
                                            A is hereby amended by adding the following <U>Section 4(f)</U> at the end thereof:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;f. <B>Access to Information</B>. Customer shall have access
to the same information about final product specifications of any new Supplied Product, any new version of a Supplied Product or any
Pre-Release Sequencing Product within 5 days of when GRAIL is provided such information.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify"><U>Section 4</U> of Exhibit A is hereby amended by adding the
following <U>Section 4(g)</U> at the end thereof:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;g.
                                            <B>GRAIL Purchases and Services</B>. Illumina shall publish, on the &ldquo;Oncology Contract
                                            Terms&rdquo; website, (i) the Supplied Products, by SKU, that GRAIL is purchasing; (ii) the
                                            service plans, by SKU, that GRAIL is purchasing; and (iii) the pricing grid for both products
                                            and services under which GRAIL is purchasing Supplied Products and services. To the extent
                                            necessary, Illumina shall update this website within 5 days of entry of any purchase order
                                            for Supplied Products or any service contract relating to the Supplied Products by GRAIL.
                                            &rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify"><U>Section 5(d)</U> of Exhibit A is hereby amended by adding the
following text at the end thereof:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;The price for a new Supplied Product or a new version of
a materially improved Supplied Product must be commercially reasonable. For any materially improved Supplied Product, the price of the
new version must take into account the value of the improvement. For avoidance of doubt, in any arbitration in which the price of a new
version of a Supplied Product or a new Supplied Product is disputed, the arbitrator is empowered to determine the reasonableness of the
price, including the value of the any improvement in performance or capability, and to require that Illumina charge a price that is commensurate
with the improvement, as well as require any associated refunds to Customer."</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">7.</TD><TD STYLE="text-align: justify"><U>Section 12(a)</U> of Exhibit A is hereby amended by:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Replacing both instances of the term &ldquo;annual&rdquo; with
the term &ldquo;bi-annual (every 6 months)&rdquo;; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Adding the following text at the end thereof: &ldquo;In addition
to providing the written report, in the event of any finding of potential noncompliance with Illumina&rsquo;s performance under the Supply
Agreement, Customer shall be notified within 10 days of identifying such a finding of potential noncompliance.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: justify"><U>Section 12(b)</U> of
                                            Exhibit A is hereby amended by adding the following <U>Section 12(b)(ix)</U> at the end thereof:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;ix. If the Arbitrator determines that Illumina has breached
any provision of the Supply Agreement, the Arbitrator may order any relief necessary to restore the status quo prior to Illumina&rsquo;s
breach, including monetary and/or injunctive relief. In resolving any dispute under the Supply Agreement, the Arbitrator shall take into
account, and the Arbitrator&rsquo;s decision shall reflect, that the purpose of the Supply Agreement is to allay any concerns relating
to the Transaction, including that Illumina would disadvantage GRAIL&rsquo;s potential competitors after the Transaction by increasing
their sequencing prices or by withholding access to Illumina&rsquo;s latest innovations in NGS.&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Appendix 1 to Exhibit A &ndash; Universal Consumables and Instruments
Discount Schedules and List Price Catalogue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2(B)
<SEQUENCE>10
<FILENAME>tm2415719d15_ex10-2b.htm
<DESCRIPTION>EXHIBIT 10.2(B)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.2(b)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain confidential information contained in this document, marked by &ldquo;[***]&rdquo;, has been omitted because it is both (i) not
material and (ii) the type that the registrant treats as private or confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MASTER SUPPLY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This Master Supply Agreement is entered
into and effective as of April&nbsp;1, 2024 (the &ldquo;<B>Effective Date</B>&rdquo;) by and between Roche Diagnostics Corporation, an
Indiana corporation with its principal offices at 9115 Hague Road,&nbsp;Indianapolis IN 46250 (&ldquo;<B>Roche</B>&rdquo;) and Caris MPI,&nbsp;Inc.,
a Texas corporation with its principal offices at 750 West John Carpenter Freeway, Suite&nbsp;800,&nbsp;Irving, Texas 75039 (&ldquo;<B>Customer</B>&rdquo;).
This Master Agreement sets forth the terms and conditions under which Customer agrees to purchase and/or use, equipment, products and/or
services from the Roche Sequencing division that may be identified on the attached schedules and exhibits (&ldquo;Schedules&rdquo;) that
are agreed upon by the Parties pursuant to this Master Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>A.</B></TD><TD><B><U>DEFINITIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For purposes of this Agreement, capitalized terms not otherwise
defined in this Agreement shall have the meanings set forth in this <B>Article&nbsp;A</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Affiliate</B>&rdquo;
means (a)&nbsp;an organization, which directly or indirectly controls a Party to this Agreement; (b)&nbsp;an organization, which is directly
or indirectly controlled by a Party to this Agreement; or (c)&nbsp;an organization, which is controlled, directly or indirectly, by the
ultimate parent company of a Party. Control as per (a)&nbsp;to (c)&nbsp;is defined as owning more than fifty percent of the voting stock
of a company or having otherwise the power to govern the financial and the operating policies or to appoint the management of an organization.
With respect to Roche, the term &ldquo;Affiliate&rdquo; shall not include Chugai Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Muromachi 2-chome,
Chuo-ku Tokyo, 103-8324, Japan (&ldquo;<B>Chugai</B>&rdquo;) and Foundation Medicine,&nbsp;Inc., 150 Second Street, Cambridge, MA 02141,
USA (&ldquo;<B>FMI</B>&rdquo;) and their respective subsidiaries, unless Roche opts for such inclusion of Chugai and/or FMI and their
respective subsidiaries by obtaining prior written consent from Customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD>&ldquo;<B>Agreement</B>&rdquo; or &ldquo;<B>Master Agreement&rdquo; </B>means this Master Supply Agreement, including all Schedules,
between Roche and Customer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Calendar
Year</B>&rdquo; means for any given year the period beginning on January&nbsp;1 and ending on December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>4.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Confidential
Information</B>&rdquo; means any and all of the following information of Roche (and/or its Affiliates) or Customer (and/or its Affiliates)
(each, a &ldquo;<B>Disclosing Party</B>&rdquo;) that may be hereafter disclosed by or on behalf of a Disclosing Party in any form, whether
in writing, orally, electronically or otherwise, or otherwise made available by observation, inspection or otherwise by such Disclosing
Party to the other Party (the &ldquo;<B>Receiving Party</B>&rdquo;): (a)&nbsp;all information that is a trade secret under applicable
trade secret law or other legal principles; (b)&nbsp;all information concerning product specifications, formulations, and other specific
and proprietary product information, including pricing; and (c)&nbsp;all information concerning the business and affairs of the Disclosing
Party that is marked as confidential, or a reasonable person would consider to be confidential. For purposes&#8239;of this Master Agreement, &ldquo;<B>Roche
Confidential Information</B>&rdquo; shall mean Confidential Information that is disclosed hereunder by or on behalf of Roche and/or its
Affiliates, and &ldquo;<B>Customer Confidential Information</B>&rdquo; shall mean Confidential Information that is disclosed hereunder
by or on behalf of Customer and/or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>5.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Party</B>&rdquo;
or &ldquo;<B>Parties</B>&rdquo; means Roche and Customer, which are collectively referred to as &ldquo;Parties&rdquo; and each individually
as a &ldquo;Party.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>6.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Product(s)</B>&rdquo;
means the products, raw materials, and reagents detailed in each Schedule to this Master Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>7.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Purchase
Order</B>&rdquo; means the firm, written orders (whether verbal, hard copy or electronic form) for the purchase, manufacturing and/or
delivery of the Product(s)&nbsp;submitted by Customer to Roche.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>8.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Quality
Claim</B>&rdquo; means a written notice delivered by Customer to Roche alleging that Products delivered to Customer (a)&nbsp;have suffered
damage in transit, (b)&nbsp;do not match the quantities ordered, (c)&nbsp;fail to meet Specifications upon completion of Quality Testing,
or (d)&nbsp;contain a Latent Defect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>9.&#8239;&#8239;&#8239;&#8239;</B></FONT>&ldquo;<B>Schedule</B>&rdquo;
means each Schedule attached to this Master Agreement, including any and all attachments and exhibits thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt"><B>10.</B></FONT> &ldquo;<B>Specifications</B>&rdquo; means the Roche description of the characteristics of a certain Product as set forth in the Certificate of Analysis (&ldquo;CoA&rdquo;) unless otherwise noted in the applicable Schedule or Exhibit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>B.</B></TD><TD><B><U>GENERAL TERMS AND CONDITIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><B>SCOPE OF MASTER AGREEMENT AND APPLICATION TO SCHEDULES. </B>The terms and conditions contained in this Master Agreement shall govern
each Schedule entered into by the Parties, unless a Schedule specifically provides otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><B>PURCHASE ORDERS AND SHIPMENTS. </B>Once a Purchase Order has been delivered to Roche, Roche will review each such Purchase Order,
and such Purchase Order is presumed approved, unless Roche rejects such Purchase Order within forty-five (45) days. Each Purchase Order,
once approved, shall constitute a binding obligation upon Customer and Roche. Roche will ship the Products specified to the facility specified
by Customer in the applicable Purchase Order, which shall be located in the continental United States (the &ldquo;<B>Designated Facility</B>&rdquo;).
Shipment dates shall be subject to standard lead times as set forth in the applicable Schedule. Customer is responsible for insurance
on and damage to the Products immediately upon delivery to Customer&rsquo;s Designated Facility. All freight, shipping, processing and
special delivery charges shall be included on Roche&rsquo;s invoices to Customer, and Customer agrees to pay same.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><B>PRICING. </B>The price for each Product is set forth in the applicable Schedule. Pricing is firm for the initial [***]
of the Term. Thereafter, Roche reserves the right to increase pricing up to [***] per year. Price decreases may be considered
with increased minimum order quantities as agreed upon by the Parties in this Agreement<B>.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD><B>MINIMUM ORDER QUANTITIES: </B>The Products can only be ordered in the minimum quantities specified in the applicable Schedule.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><B>FORECASTS. </B>[***].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>6.</B></TD><TD><B>PRODUCT QUALITY.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify">After delivery of a shipment of Products to Customer&rsquo;s Designated Facility, Customer shall have (i)&nbsp;five (5)&nbsp;business
days to determine whether the Products have been damaged in transit or fail to meet the quantities of Products ordered and submit a Quality
Claim based thereon, and (ii)&nbsp;thirty (30) days to determine whether the Products conform to Specifications by undertaking visual
inspections and commercially reasonable testing to determine conformity (&ldquo;<B>Quality Testing</B>&rdquo;) and submit a Quality Claim
based thereon. After thirty (30) days have passed following delivery of Products to Customer&rsquo;s Designated Facility without receipt
of a Quality Claim, the Products shall be deemed to meet the Specifications, unless a Latent Defect (as defined below) is discovered.
Thereafter, if a defect is discovered which causes Product(s)&nbsp;not to be in conformance with the Specifications which was not reasonably
discoverable upon Quality Testing by Customer and was in no way caused by Customer (&ldquo;<B>Latent Defect</B>&rdquo;), Customer shall
submit a Quality Claim to notify Roche of this Latent Defect. Any Quality Claims shall indicate in reasonable specificity the non-conforming
characteristics of the Products. As promptly as possible after a submission of a Quality Claim by Customer, the Parties will work together
cooperatively and in good faith to investigate and determine whether the Product meets the Roche Specifications, not any Customer specific
requirements. Customer shall have no obligation to pay for the Products that are
subject to the Quality Claims pending resolution of this investigation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN APPROVED
BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify">If this joint investigation confirms (i)&nbsp;the stated Quality Claim, and (ii)&nbsp;that the stated Quality Claim is Roche&rsquo;s
responsibility (a &ldquo;<B>Confirmed Claim</B>&rdquo;), then Roche shall, at Roche&rsquo;s option: (1)&nbsp;if payment has already been
made by Customer, provide Customer with a refund of the full amount paid by Customer for the non-conforming Products or issue Customer
a credit against future billings equal to the full amount paid by Customer for the non-conforming Products, or (2)&nbsp;replace such defective
or non- conforming Products with Products that conform to Specifications. The foregoing shall be Roche&rsquo;s sole and exclusive liability,
and Customer&rsquo;s sole and exclusive remedies with respect to Products determined to be Confirmed Claims. If the stated Quality Claim
either is determined not to be valid or is determined not to be Roche&rsquo;s responsibility, then Customer shall accept and pay for the
Products that were subject to the Quality Claim, and shall pay Roche&rsquo;s reasonable costs of such joint investigation. If the stated
Quality Claim is determined to be valid and Roche&rsquo;s responsibility, then Roche shall pay Customer&rsquo;s reasonable costs of such
joint investigation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify">Roche, at its option, may require that Customer return Products that are Confirmed Claims to Roche or dispose, in accordance with
all applicable laws, of Products that are Confirmed Claims. Roche shall pay for all shipping costs of returning Products that are Confirmed
Claims, or for all disposal costs incurred by Customer in connection with the disposal of Products that are Confirmed Claims. In the event
Roche requests that Products that are Confirmed Claims be returned to Roche, Roche shall bear the risk of loss for such Products from
the time such Products are picked up at Customer&rsquo;s premises for return delivery.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><B>FAILURE TO SUPPLY. </B>In the event either Party anticipates that a disruption, shortfall, or cessation in supply of Product by
Roche is likely to occur for any reason, such Party shall promptly notify the other Party, and the Parties shall discuss in good faith
appropriate steps to alleviate such a shortfall. If Roche fails, for any reason, to deliver at least one hundred percent (100%) of the
Product ordered by Customer on the agreed upon delivery date at Customer&rsquo;s designated facility, and fails to cure such failure within
forty-five (45) days (a &ldquo;<B>Failure to Supply</B>&rdquo;), Customer shall have the right to cancel all or any part of the corresponding
Purchase Order.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD><TD><B>PAYMENT TERMS. </B>All payments are due thirty (30) days from the Roche invoice date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><B>TAXES. </B>All sales taxes, value added taxes, duties, levies, surcharges or other similar charges and any penalties levied thereon
that relate to any amounts paid for the Products hereunder shall be the responsibility of, and paid by, Customer. If Roche is required
to pay any of these amounts, Customer shall reimburse Roche therefor or provide Roche at the time the order is submitted an exemption certificate
or other document acceptable to the authority that is imposing the payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN APPROVED
BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><B>WARRANTY. </B>Any and all warranties which may be provided with respect to any particular Product are detailed in the applicable
Schedule and/or on the Product packaging/labeling, except that all warranties shall be voided upon any reformulation or chemical or other
alteration or any other improper use or storage of a Product by Customer or its Affiliates or representatives. Any warranty provided with
respect to any Product will begin on the date of shipment for that Product. CUSTOMER EXPRESSLY ACKNOWLEDGES AND AGREES THAT ROCHE MAKES
NO OTHER REPRESENTATIONS GUARANTEES OR WARRANTIES, EXPRESS OR IMPLIED,&nbsp;INCLUDING, WITHOUT LIMITATION, REPRESENTATIONS, GUARANTEES
OR WARRANTIES AS TO THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF PRODUCTS. Each Party further warrants that it will comply with all applicable laws and regulations with respect to its duties and obligations
under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><B>FIELD OF USE AND LIMITATIONS ON RESALE [B2C] </B>Resale of Products are prohibited. All Products are intended for use solely by
Customer. Products may not in any circumstances be resold by Customer without the prior written consent of Roche.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><B>REGULATORY REQUIREMENTS. </B>Unless explicitly stated otherwise in the Product labeling, Customer acknowledges that the Products
under this Agreement are manufactured for &ldquo;Research Use Only,&rdquo; and are intended solely for use in basic or applied laboratory
research, including the evaluation of the design, limited-scale performance, or usability of the product. Customer acknowledges that the
Products are not intended to be used in clinical diagnostic, prognostic, or therapeutic indications. Customer's acknowledgment in the
previous sentences recognizes the regulatory requirements of Roche, but it is not intended to limit the rights and obligations of Customer
under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and its subsequent amendments, as well as any other state and local
requirements. Notwithstanding the foregoing, Customer is solely responsible for obtaining all requisite regulatory approvals and clearances
and any other approvals, consents or other authorizations necessary for using such Products for any diagnostics purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="text-align: justify"><B>LABELING. </B>Products (both kit and kit components) will be provided with standard label design and content unless otherwise noted
in <B>the applicable Schedule</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>14.</B></FONT></TD><TD STYLE="text-align: justify"><B>PACKAGING. </B>Roche will design Product packaging configuration of best fit unless otherwise noted in the applicable Schedule.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>15.</B></FONT></TD><TD STYLE="text-align: justify"><B>QUALITY TESTING AND CERTIFICATE OF ANALYSIS. </B>Products will be subject to standard functional and contamination testing and
accompanied by a standard Certificate of Analysis unless otherwise noted in the applicable Schedule.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>16.</B></TD><TD><B>INTELLECTUAL PROPERTY.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><B>Background IP</B>. Subject only to the rights expressly granted under this Agreement, each Party shall retain all rights, title
and interests in and to its Background IP, where &ldquo;<B>Background IP</B>&rdquo; means all intellectual property or intellectual property
rights: (i)&nbsp;developed, owned or controlled by a Party as of the Effective Date of this Agreement; and/ or (ii)&nbsp;any additional
feature or functionality, or any enhancement, refinement or advancement of any existing or additional feature or functionality of a Party&rsquo;s
Background IP to the extent such subsection (ii)&nbsp;intellectual property or intellectual property rights are solely developed by or
for such Party and do not arise from or include Confidential Information of the other Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><B>Improvements</B>. Each of the Parties acknowledges and agrees that (i)&nbsp;ownership of improvements in and to the Products shall
be determined in accordance with inventorship according to United States patent laws (each a &ldquo;<B>Product Improvement</B>&rdquo;);
and (ii)&nbsp;any such Product Improvements to Products, and any modifications or improvements to workflows using Products, whether made
by or on behalf of Customer, solely or jointly, shall remain exclusive to Customer, and shall constitute Customer Confidential Information
(each, a &ldquo;<B>Customer Improvement</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><B>No Other Rights &ndash; Roche</B>. Unless specifically granted otherwise, nothing contained in this Agreement shall be construed
to grant Customer a license or in any way give ownership to any Roche-owned intellectual property or intellectual property rights, or
any intellectual property or intellectual property rights owned by any Roche Affiliate or any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><B>No Other Rights &ndash; Customer</B>. Unless specifically granted otherwise, nothing contained in this Agreement shall be construed
to grant Roche a license or in any way give ownership to any Customer-owned intellectual property or intellectual property rights, or
any intellectual property or intellectual property rights owned by any Customer Affiliate or any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>17.</B></FONT></TD><TD STYLE="text-align: justify"><B>DEFAULT. </B>A Party is in default under this Master Agreement if: (a)&nbsp;such Party does not perform any of its material obligations
under the Master Agreement and this failure continues for forty-five (45) days after written notification of such failure; (b)&nbsp;such
Party notifies the other Party that it does not intend to perform its obligations under this Master Agreement; (c)&nbsp;Customer or any
Customer Affiliate offers Products for resale other than as allowed by this agreement; or (d)&nbsp;Roche&rsquo;s disclosure of any Customer
Improvement to a third party without Customer&rsquo;s prior written consent to such disclosure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>18.</B></TD><TD><B>REMEDIES.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><U>Default by Roche</U>. In the event of a default by Roche, Customer may (1)&nbsp;terminate this
                                                                                                     Master Agreement, with Roche remaining liable for all obligations which have not yet been met under the Master Agreement or any
                                                                                                     Schedule, and (2)&nbsp;exercise any and all other remedies available at law or
in equity. Customer agrees that it will remain obligated to pay all sums owed to Roche prior to the date of termination and for any deliveries/fulfillment
of obligations after the date of termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><U>Default by Customer</U>. In the event of a default by Customer, Roche may (1)&nbsp;terminate the Master Agreement and all Schedules,
and collect all amounts owing or that become due under the Master Agreement and Schedules, including a late payment charge of [***] per month or the highest rate permitted by law, whichever is less; (2)&nbsp;if Products purchased during the then-current
period are subject to tiered pricing based on Customer&rsquo;s purchase volumes, retroactively bill Customer for Products to reflect actual
Customer purchase volumes during such period; (3)&nbsp;require Customer to pay immediately the greater of (i)&nbsp;the difference between
the applicable Annual Commitment and the amount of Products actually purchased by Customer and invoiced by Roche during such period, or
(ii)&nbsp;the difference between the amount of Products subject to binding forecasts and the amount of Products actually purchased by
Customer and invoiced by Roche during such period, if any; and (4)&nbsp;exercise any and all other remedies available at law or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD><U>Cumulative Rights</U>. All of the remedies available are cumulative and may be exercised in any order.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><U>Other Expenses</U>. The defaulting Party agrees to reimburse the non-defaulting Party for all costs, expenses and damages, including
reasonable attorney&rsquo;s fees and all other expenses of collection incurred by the non-defaulting Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>19.</B></TD><TD><B>INDEMNITY / LIMITATION OF LIABILITY.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><U>Indemnification by Roche</U>. Roche agrees to indemnify and hold Customer, its directors, officers, employees, agents, successors
and assigns harmless from all liabilities, including reasonable attorneys&rsquo; fees, arising out of any claim by a third party to the
extent resulting from one or more of the following: (i)&nbsp;Roche&rsquo;s gross negligence or willful misconduct, (ii)&nbsp;Roche&rsquo;s
breach of its warranties set forth herein, or (iii)&nbsp;Roche&rsquo;s material failure to perform its duties or obligations as set forth
in this Master Agreement or any Schedule, except, in each case, to the extent related to Customer&rsquo;s negligence or willful misconduct.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><U>Indemnification by Customer</U>. Customer agrees to indemnify and hold Roche and its Affiliates, and their respective directors,
officers, employees, agents, successors and assigns harmless from all liabilities, including reasonable attorneys&rsquo; fees, arising
out of any claim by a third party to the extent resulting from one or more of the following: (1)&nbsp;Customer&rsquo;s gross negligence
or willful misconduct, (ii)&nbsp;Customer&rsquo;s material failure to perform its duties or obligations as set forth in this Master Agreement
or any Schedule, or (iii)&nbsp;the misuse, alteration or improper storage or handling of any Product(s)&nbsp;provided under this Master
Agreement or any Schedule by Customer, or any Affiliate or representative of
Customer, except, in each case, to the extent related to Roche&rsquo;s negligence or willful misconduct. Additionally Customer agrees
to indemnify and hold Roche harmless from all liabilities, including reasonable attorneys&rsquo; fees, to the extent arising as a result
of use of non-Roche products, provided that the foregoing indemnification obligation will not apply to the extent such use of non-Roche
products is authorized by Roche, is specified in Roche product manuals or literature, or is reasonably expected given the advertised or
expected uses of the Product/s.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><U>Third Party Claim of Infringement</U>. If a claim of patent infringement or misappropriation or wrongful use of a trade secret
or other proprietary right is brought against a Party hereto in any country by reason of any act conducted in the furtherance of this
Master Agreement or any of its Schedules, or if a Party becomes aware of any act potentially infringing a patent or other proprietary
right owned by a third party in any country related to the subject matter of this Master Agreement or any of its Schedules, such Party
shall promptly give notice thereof to the other Party. Each Party shall indemnify, defend and hold harmless the other Party and its Affiliates,
directors, officers, employees, agents, successors and assignees against any damages, costs, expenses and liabilities (including reasonable
attorneys&rsquo; fees and expenses) arising out of a third party claim of patent infringement or misappropriation or wrongful use of a
trade secret or other proprietary right to the extent that such damages, costs, expenses or liabilities are caused by the indemnifying
Party&rsquo;s products or actions in the furtherance of this Master Agreement or any of its Schedules. Notwithstanding the foregoing,
Roche shall not be required to indemnify, defend or hold harmless any person under this paragraph with respect to the Products to the
extent such claim is related to any combination, modification or other alteration made or action taken after delivery of the Products,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><U>Indemnity Procedures</U>. In any claim for indemnification (an &ldquo;<B>Indemnity Claim</B>&rdquo;), the indemnified Party agrees
to give the indemnifying Party prompt written notice of any matter upon which such indemnified Party intends to base such a claim under
this Agreement. Counsel shall be selected by the indemnifying Party. The indemnified Party may, at its sole option and expense, participate
in such defense with counsel of its own selection, and further agrees to fully cooperate in the conduct of any such defense. With respect
to any Indemnity Claim relating solely to the payment of money damages and which could not result in the indemnified Party&rsquo;s becoming
subject to injunctive or other equitable relief or otherwise adversely affect the business of the indemnified Party in any commercially
significant manner, and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the indemnified
Party hereunder, the indemnifying Party shall have the sole right to defend, settle or otherwise dispose of such Indemnity Claim, on such
terms as the indemnifying Party, in its sole discretion, shall deem appropriate; provided that the indemnifying Party shall provide reasonable
evidence of its ability to pay any damages claimed and with respect to any such settlement shall obtain the written release of the indemnified
Party from the Indemnity Claim. The indemnifying Party shall obtain the written consent of the indemnified Party, such consent not to
be unreasonably&#8239;withheld, prior to ceasing to defend,
settling or otherwise disposing of any Indemnity Claim if as a result thereof the indemnified Party would become subject to injunctive
or other equitable relief or the business of the indemnified Party would be adversely affected in any manner. In the event that any such
indemnity obligation shall be apportioned greater than 50% to any Party, that Party shall have the right to control the Indemnity Claim,
subject to the participation and involvement of the other Party. <B>EXCEPT FOR A BREACH OF ARTICLE&nbsp;B.23, CONFIDENTIALITY, AND WITHOUT
LIMITING EACH PARTY&rsquo;S INDEMNIFICATION OBLIGATIONS UNDER THIS SECTION,&nbsp;IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER
PARTY FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>20.</B></FONT></TD><TD STYLE="text-align: justify"><B>TERM AND TERMINATION. </B>The initial term (&ldquo;<B>Term</B>&rdquo;) of this Agreement shall begin on the Effective Date and
shall continue until the third anniversary of the Effective Date. Thereafter, this Agreement shall automatically renew for successive
one (1)&nbsp;year terms (each a &ldquo;<B>Renewal Term</B>&rdquo;), unless earlier terminated as provided below in this Section, or unless
one Party notifies the other in writing of its election not to renew no less than ninety (90) days prior to the end of the Term or the
then current Renewal Term, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD>This Agreement may be terminated at any time upon the mutual agreement of both Parties in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify">In the event of a Default under this Master Agreement or any Schedule, by either Party, as provided in <B>Article&nbsp;B.18, Default</B>,
then the other Party may terminate this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify">This Agreement shall terminate automatically if such Party becomes insolvent, dissolves or is dissolved, assigns its assets for the
benefit of creditors or enters voluntarily into any bankruptcy or reorganization proceeding (or has failed for a period of at least sixty
(60) days to dismiss any bankruptcy or reorganization proceeding that was filed against such Party involuntarily) or admits in writing
its inability to pay its debts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Termination of this Agreement, for any
reason, shall not release any Party from any liability or any obligation which, at the time of such termination, has already accrued to
the other Party or which is attributable to a period prior to such termination. In addition, termination of this Agreement shall not preclude
either Party from pursuing any rights and remedies it may have hereunder at law or in equity, subject to any limitations set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>21.</B></FONT></TD><TD STYLE="text-align: justify"><B>ASSIGNMENT. </B>Neither this Agreement nor any of the rights, interests nor obligations hereunder may be assigned by either Party
without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided that either Party may
assign or otherwise transfer this Agreement to any Affiliate or to any to a successor who purchases all or substantially all of such Party&rsquo;s
business, whether by merger, purchase of assets or stock or other transaction or series of transactions without consent, and agrees to
be bound by the terms and conditions of this Agreement
on a going-forward basis. Such assigning or transferring Party shall give the other Party prompt written notice of such assignment or
other transfer, and shall remain liable to the other Party for compliance with the terms and conditions of this Agreement prior to the
effective date of such assignment or other transfer. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit
of the Parties hereto and their respective successors and permitted assignees, and no other person shall have any right, benefit or obligation
under this Agreement as a third-party beneficiary or otherwise. Any assignment in violation of this Section&nbsp;is void.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>22.</B></FONT></TD><TD STYLE="text-align: justify"><B>CREDIT INFORMATION. </B>Customer agrees to provide Roche with complete and accurate financial statements and other financial information
that Roche reasonably requests from time to time, and Customer understands that Roche will obtain credit bureau reports and make credit
inquiries as necessary. All financial information provided to Roche will be treated as confidential.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>23.</B></FONT></TD><TD><B>CONFIDENTIALITY. </B>In the event that the Parties exchange Confidential Information, the following terms shall govern:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><U>Confidentiality and Restricted Use</U>. Each Receiving Party of Confidential Information hereunder acknowledges the confidential
and proprietary nature of the Confidential Information of the Disclosing Party and agrees that, for a period of five (5)&nbsp;years following
the expiration or termination of this Agreement, such Confidential Information (i)&nbsp;shall be kept confidential
by the Receiving Party; (ii)&nbsp;shall not be used for any reason or purpose other than in furtherance of such Party&rsquo;s performance
of its obligations hereunder; and (iii)&nbsp;without limiting the foregoing, shall not be disclosed by the Receiving Party to any person
or entity, except (1)&nbsp;in each case as otherwise expressly permitted by the terms of this Agreement, (2)&nbsp;with the prior written
consent of an authorized representative of the Disclosing Party, or (3)&nbsp;its employees, officers, directors, managers, and professional
advisors who have a need to know such information to perform such Party&rsquo;s obligations under this Agreement and who are bound by
a legal, ethical or contractual obligation at least as stringent as those contained herein to not use and keep confidential such Confidential
Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><U>Exceptions</U>. The restrictions set forth above do not apply to that part of the Confidential Information of a Disclosing Party
that the Receiving Party demonstrates (i)&nbsp;was, is or becomes generally available to the public other than as a result of a breach
of this paragraph by the Receiving Party or its Affiliates or other representatives; (ii)&nbsp;was or is developed by or for the Receiving
Party independently of and without reference to any Confidential Information of the Disclosing Party; or (iii)&nbsp;was, is or becomes
available to the Receiving Party on a non-confidential basis from a third party not bound by a confidentiality agreement or any legal,
fiduciary, or other obligation restricting disclosure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><U>Legal Proceedings</U>. If the Receiving Party becomes compelled in any legal proceeding or is requested by a governmental body
having the requisite legal or regulatory jurisdiction and authority, the Receiving Party shall provide the applicable Disclosing Party
with prompt notice of such compulsion or request (if permitted by law) so that it may seek an appropriate remedy or waive compliance with
the provisions of this paragraph. In the absence of a protective order or other remedy, the Receiving Party may disclose that portion
(and only that portion) of the Confidential Information of the Disclosing Party that, based upon advice of the Receiving Party&rsquo;s
counsel, the Receiving Party is legally compelled to disclose or that has been requested by such governmental body; <U>provided</U>, <U>however</U>,
that the Receiving Party shall use reasonable efforts to obtain reliable assurance that confidential treatment will be accorded by any
person, entity or governmental body to whom any Confidential Information is so disclosed. The provisions of this paragraph do not apply
to any legal proceedings between the Parties to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 30.8pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><U>Return or Destruction of Confidential Information</U>. Upon expiration or earlier termination of this Agreement, the Receiving
Party shall promptly deliver to the Disclosing Party all Confidential Information of the Disclosing Party, together with all copies thereof,
in the possession, custody or control of the Receiving Party or, alternatively, with the written consent of the Disclosing Party, destroy
all such Confidential Information and certify such destruction in writing to the Disclosing Party; <U>provided</U>, <U>however</U>, that
the Receiving Party may retain one copy of such Confidential Information in its legal department solely to facilitate the resolution of
any controversies after the Disclosing Party&rsquo;s Confidential Information is returned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>24.</B></FONT></TD><TD STYLE="text-align: justify"><B>GOVERNING LAW, VENUE, and RIGHT TO JURY TRIAL. </B>Customer agrees that the internal laws of the State of New York, without regard
to choice of law principles, will govern this Master Agreement and all Schedules hereto, and any disputes concerning the subject matter
addressed herein, and Customer consents to the exclusive jurisdiction of and venue in any state or federal court located within the State
of New York. Each Party expressly waives its rights to trial by jury.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>25.</B></FONT></TD><TD STYLE="text-align: justify"><B>FORCE MAJEURE. </B>Either Party&rsquo;s obligations under this Agreement shall be suspended in the event that Party is hindered
or prevented from complying with its obligations because of labor disturbances, wars, acts of domestic or international terrorism, fires,
storms, earthquakes, accidents, floods, droughts, global health emergencies or pandemics (including the COVID-19 global pandemic), interferences
or any other cause beyond its reasonable control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>26.</B></FONT></TD><TD STYLE="text-align: justify"><B>ENTIRE AGREEMENT. </B>Customer agrees that the terms and conditions in this Master Agreement and each Schedule (together with any
attachments or exhibits thereto), if any, make up the entire agreement between Customer and Roche with respect to the subject matter hereof.
In the event of a conflict between the terms of this Master Agreement and any Schedule (or any attachments or exhibits to a Schedule),
the terms of the applicable Schedule shall control. The terms and conditions contained in any
Purchase Order sent by Customer shall not apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>27.</B></FONT></TD><TD STYLE="text-align: justify"><B>NOTICES. </B>All notices, consents, waivers and other communications required or permitted by this Agreement shall be in writing
and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a)&nbsp;on
the date of delivery, when delivered in person or by nationally recognized overnight courier service (costs prepaid); (b)&nbsp;on the
date of receipt, if sent by a PDF image sent by email or other electronic transmission (with delivery confirmed); or (c)&nbsp;on the date
received or rejected by the addressee, if sent by first class certified mail, return receipt requested (or its equivalent). Notices shall
be sent to the other Party receiving the notice at its address shown on the face of this Master Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>28.</B></FONT></TD><TD STYLE="text-align: justify"><B>USE OF TRADEMARK AND NAME. </B>Customer may not use Roche&rsquo;s or its Affiliates&rsquo; names or trademarks, or refer to or
disclose the existence of this Agreement or the obligations performed hereunder, directly or indirectly, without the prior written consent
of Roche&rsquo;s Corporate Communications department, except as may be required by law or government regulation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>29.</B></FONT></TD><TD STYLE="text-align: justify"><B>NON-WAIVER. </B>No term or provision hereof shall be deemed waived and no breach excused unless such waiver or consent shall be
in writing and signed by a duly authorized representative of the Party claimed to have waived or consented.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>30.</B></FONT></TD><TD STYLE="text-align: justify"><B>MISCELLANEOUS. </B>The titles and headings used in this Agreement are for convenience only and shall not be used to interpret the
terms and conditions of this Agreement. This Master Agreement is not binding on Roche until signed by an authorized representative of
Roche. If either Party delays or fails to enforce any of its rights under this Master Agreement or any Schedule, such Party will be able
to enforce its rights at a later time. The terms of this Master Agreement and all Schedules are Confidential Information and shall not
be disclosed by either Party to any third party, except as may be required by law or government regulation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"><FONT STYLE="font-size: 10pt"><B>31.</B></FONT></TD><TD STYLE="text-align: justify"><B>BUSINESS REVIEWS</B>. During the Term, Customer and Roche will meet quarterly at a mutually agreeable time and place or by telephone
to review and discuss, in good faith, Customer&rsquo;s next pending Purchase Order, as well the Parties&rsquo; performance and any issues
or concerns arising under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGE TO FOLLOW]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE UNDERSIGNED, BEING DULY AUTHORIZED
SIGNATORIES, AGREE TO ALL TERMS AND CONDITIONS SET FORTH HEREIN AND THEY HEREBY EXECUTE THIS MASTER AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 49%"><FONT STYLE="font-size: 10pt"><B>Caris MPI,&nbsp;Inc.</B></FONT></TD><TD STYLE="width: 2%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify; width: 49%"><FONT STYLE="font-size: 10pt"><B>Roche
                                            Diagnostics Corporation</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ David D. Halbert</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/
                                            Lyndsi Matthews</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">Signature</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">Printed</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Printed</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">CEO</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Franchise
                                            Manager</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">Title</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">6/25/2024</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">07/08/2024</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-size: 10pt">Date</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THIS AGREEMENT HAS BEEN
APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT. <BR>
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <B><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B> of <B>13</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>SCHEDULE [Quote 5696054220]</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT A: PRODUCTS AND PRICING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>SCHEDULE [5696054220]</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT B: FORECAST FOR FIRST TWELVE MONTHS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(A)
<SEQUENCE>11
<FILENAME>tm2415719d15_ex10-3a.htm
<DESCRIPTION>EXHIBIT 10.3(A)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.3(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>LEASE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>WPT
LAND 2 LP,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>as
Landlord</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>23andMe,
Inc.,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>a
Delaware corporation as<BR>
Tenant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>AT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Workspace
Cotton Center &ndash; Building 5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>4415
Cotton Center Boulevard - Suite 100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Phoenix,
Arizona 85040</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>LEASE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>INDEX</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&sect;</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section</B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 3%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic Lease Terms and Definitions</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Premises</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term; Option to Renew; Option of Early Termination;
    Possession</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent; Taxes</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Expenses</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilities; Services</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance; Waivers; Indemnification</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance and Repairs</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signs</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alterations</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanics&rsquo; Liens</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Landlord&rsquo;s Rights</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damage by Fire or Other Casualty</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condemnation</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quiet Enjoyment</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment and Subletting</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subordination; Mortgagee&rsquo;s Rights</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant&rsquo;s Certificate; Financial Information;
    Confidentiality</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surrender</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults - Remedies</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant&rsquo;s Authority; OFAC</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability of Landlord</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Deposit</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mortgagee Approval</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant Improvements</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of First Refusal</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>THIS
LEASE AGREEMENT </B>dated March 1, 2019, is made by and between <B>WPT LAND 2 LP</B>, a Delaware limited partnership (&ldquo;<B>Landlord</B>&rdquo;),
and <B>23andMe, Inc., </B>a Delaware corporation (&ldquo;<B>Tenant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
good and valuable consideration of the rents and covenants hereinafter set forth, the receipt and sufficiency of which are acknowledged,
and the promises set forth herein, intending to be legally bound, Landlord hereby leases to Tenant, and Tenant hereby rents from Landlord,
the following described Premises (as defined below) upon the following terms and conditions. Accordingly, Landlord and Tenant agree as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Basic Lease Terms and Definitions</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Premises</B>:
                                            Suite 100, consisting of 21,001 rentable square feet of space on the first floor, as shown
                                            on <B>Exhibit &ldquo;A&rdquo;</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Building</B>:
                                            Workspace Cotton Center Building 5, 4415 Cotton Center Boulevard<B>, </B>Phoenix, Maricopa
                                            County, Arizona 85040, consisting of 35,463 rentable square feet of space, being Tax Parcel
                                            No. 123-06-058.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Term</B>:
                                            Eighty-eight (88) consecutive months commencing on the Commencement Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Commencement
                                            Date</B>: The date Landlord delivers possession of the Premises to Tenant. If the Commencement
                                            Date occurs on a date other than the first day of a calendar month, there shall be added
                                            to the first Lease Year, the number of days comprising the remainder of the calendar month
                                            following the Commencement Date, and all annual increases in Minimum Annual Rent shall occur
                                            as of the anniversary of the first day of the first full month following the Commencement
                                            Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Expiration
                                            Date</B>: The last day of the Term.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Minimum
                                            Annual Rent</B>: Payable in monthly installments as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 1in">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Dollar/Square</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Lease Month</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Foot
    per Year</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Annual</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Monthly</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">*1
    - 16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">13.50</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">283,514.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">23,626.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">17- 28</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">13.91</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">292,019.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">24,334.91</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">29 - 40</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">14.32</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">300,779.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">25,064.96</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">41 - 52</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">14.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">309,803.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">25,816.90</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">53 - 64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">15.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">319,097.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">26,591.41</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">65 - 76</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">15.65</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">328,670.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">27,389.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">77 - 88</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">16.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">338,530.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">28,210.83</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><I>* </I>Except
as set forth in the next succeeding sentence, Monthly Rent based on the Minimum Annual Rent but not Annual Operating Expense (as
defined below), payments (or the Management Fee which is a part of Operating Expenses and shall be calculated as if such monthly
Minimum Annual Rent is being paid in full) or Additional Taxes (as defined below) payments, shall be abated (the
 &ldquo;<B>Abatement</B>&rdquo;) for the first three (3) full calendar months following the Commencement Date. Should this Lease be
terminated during the initial Term by Landlord as a result of an uncured Event of Default (as defined below) by Tenant under this
Lease, Landlord shall be entitled to recover from Tenant (in addition to all other rights and remedies available to Landlord) such
Abatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Annual
                                            Operating Expenses</B>: Landlord&rsquo;s good faith estimate of Annual Operating Expenses
                                            for 2019 is $4.60 per rentable square foot of space per year which amount excludes utilities
                                            and janitorial and trash removal expenses to be paid directly be Tenant as set forth in Section
                                            7 below. Accordingly, from and after the Commencement Date, estimated Annual Operating Expenses
                                            shall be $92,004.60, payable in equal monthly installments of $7,667.05, subject to adjustment
                                            and reconciliation as provided in this Lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Tenant&rsquo;s
                                            Share</B>: 59.20%, obtained by dividing the rentable square feet of the Premises by the rentable
                                            square feet of the Building.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Use</B>:
                                            General office, research and development laboratory, CLIA laboratory and life science production,
                                            warehousing, shipping and receiving, and uses incidental thereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Security
                                            Deposit</B>: One Hundred Thousand Dollars ($100,000.00).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(k)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Addresses
                                            for Notices</B>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Landlord:</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt; vertical-align: bottom"></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Workspace Property Trust</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">700 Dresher Road</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">McCausland Keen + Buckman</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite 150</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80 W. Lancaster Avenue</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Horsham, PA 19044</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4<SUP>th </SUP>Floor</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Anthony A. Nichols, Jr.,</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devon, PA 19333</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice-President</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Stephan K. Pahides, Esq.</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail: [***]</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">If to Tenant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">23andMe, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">899 W. Evelyn Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Mountain
View, CA 94041</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Attn: Chief Legal and Regulatory
Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Phone: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(l)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Brokers</B>:
                                            Cushman + Wakefield, as Tenant&rsquo;s broker, and CBRE, as Landlord&rsquo;s broker.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Guarantor</B>:
                                            Not Applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Contents</B>:
                                            The following are attached to and made a part of this Lease:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 2in"></TD><TD STYLE="font-size: 10pt; width: 1.2361in"><FONT STYLE="font-size: 10pt">Exhibits:</FONT></TD><TD STYLE="font-size: 10pt; padding-right: 109pt"><FONT STYLE="font-size: 10pt">&ldquo;A&rdquo;
                                            - Plan Showing Premises &ldquo;B&rdquo; - Building Rules</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 2in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 1.2361in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;C&rdquo; &ndash; Payment Rider</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;D&rdquo; &ndash; Parking Area Plan</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;E&rdquo; - Tenant Estoppel Certificate
    Form</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;F&rdquo; &ndash;Tenant Improvement Plans
    and Specifications </FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;G&rdquo;- Hazardous Materials List</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;H&rdquo;- Sign Plans and Specifications</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;I&rdquo;- Intentionally omitted</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">2.
<B>&#8239;&#8239;&#8239;&#8239;<U>Premises</U></B>. Landlord leases to Tenant and Tenant leases from Landlord the Premises, together with the right in common with
others to use the Common Areas. Tenant accepts the Premises, Building and Common Areas in their &ldquo;<B>AS IS</B>&rdquo; &ldquo;<B>WHERE
IS</B>&rdquo; condition, without relying on any representation, covenant or warranty by Landlord other than as expressly set forth in
this Lease. Notwithstanding the above, Landlord agrees to perform Landlord&rsquo;s Work (as defined herein) and to deliver the Premises
to Tenant with all Building Systems (as defined herein) in good working order and repair. Landlord and Tenant stipulate and agree to
the rentable square footages set forth in <U>Sections 1(a) and (b)</U> above for all purposes with respect to this Lease. Following the
Commencement Date, Tenant shall have access to the Premises twenty-four (24) hours per day, seven (7) days per week, fifty-two (52) weeks
per year, subject to events beyond the reasonable control of Landlord and closures of the Premises permitted under this Lease. &ldquo;<B>Common
Areas</B>&rdquo; means all areas and facilities as provided by Landlord from time to time for the use or enjoyment of all tenants in
the Building or Property, including, if applicable and without limitation, lobbies, public hallways, public restrooms, fire stairs, elevators,
driveways, sidewalks, parking, loading areas, landscaped areas, mechanical and fan rooms, janitor closets, electrical and telephone closets,
pipe and elevator shafts, vertical ducts, structural components of the Building excluding the Building Structure (as defined below),
and all other general Building or Property components, facilities, and fixtures that serve or are available to more than one (1) tenant
at the Property. &ldquo;<B>Land</B>&rdquo; means the lot or plot of land on which the Building is situated or the portion thereof allocated
by Landlord to the Building. &ldquo;<B>Property</B>&rdquo; means the Land, the Building, adjoining parking areas, sidewalks, driveways,
landscaping and additional buildings situate thereon if applicable, and the Common Areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Use</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant shall occupy and use the Premises only for the Use specified in <U>Section l</U> above, and pursuant to the Building Rules (as
defined hereunder). Without limited the generality of the foregoing, Tenant shall not use the Premises for any on-site retail sales.
Tenant waives any implied warranty of Landlord that the Premises is suitable for Tenant&rsquo;s intended commercial purpose or Tenant&rsquo;s
permitted Use or for any other purpose under any and all applicable zoning ordinances or regulations. Tenant shall not permit any conduct
or condition which may endanger, disturb or otherwise interfere with any other Building occupant&rsquo;s normal operations or with the
management of the Building. Tenant may use all Common Areas only for their intended purposes. Subject to Tenant&rsquo;s use of the Common
Areas and the terms of this Lease, Landlord shall have exclusive control of all Common Areas at all times. &ldquo;<B>Building Rules</B>&rdquo;
means the rules and regulations attached to this Lease as <B>Exhibit &ldquo;B&rdquo;</B> as they may be amended from time to time. In
the event of any conflict between the Building Rules and this Lease, this Lease shall control. Tenant shall be responsible, at its sole
cost and expense, to obtain all required permits, approvals, zoning change or variance required by the City of Phoenix for Tenant&rsquo;s
Use including, without limitation, the operation of its business and the completion of Tenant&rsquo;s Improvements (as defined below)
and of any Alterations (as defined below) installed by or on behalf of Tenant to the Premises for the conduct of its business, but the
failure of Tenant to obtain any or all such permits and approvals shall not affect the validity of this Lease. Tenant understands, agrees
and acknowledges that neither Landlord nor its Agents have made any representation or warranty that Tenant&rsquo;s intended Use is permitted
under the City of Phoenix zoning ordinance applicable to the Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant shall have the right, at Tenant&rsquo;s sole risk and responsibility, and pursuant to the Building Rules, to use, on a non-exclusive
basis in common with other tenants and visitors of the Building, forty-eight (48) unreserved, uncovered parking spaces on the Property
and twelve (12) reserved canopy parking spaces (the &ldquo;<B>Covered Parking Spaces</B>&rdquo;) on the Property at the location, all
as shown on <B>Exhibit &ldquo;D&rdquo;</B>, attached hereto and made a part hereof (the &ldquo;<B>Parking Area</B>&rdquo;). Tenant will
have exclusive parking rights to the twelve (12) Covered Parking Space in the Parking Area identified as &ldquo;Tenant&rsquo;s Reserved
Parking Area&rdquo; as depicted on <B>Exhibit &ldquo;D&rdquo;</B>. Tenant will, upon request, promptly furnish to Landlord the license
numbers of the cars operated by Tenant and its subtenants, invitees, concessionaires, licensees and their respective officers, agents
and employees and which are expected to be parked at the Property from time to time. Notwithstanding the foregoing, Landlord is under
no obligation to enforce Tenant&rsquo;s parking rights granted hereunder and Landlord shall have no liability to Tenant for any unauthorized
parking of any vehicles within the Parking Area. The Parking Area provided for herein is provided as a license solely for the accommodation
of Tenant and other Building occupants or invitees, and Landlord assumes no responsibility or liability of any kind whatsoever from whatever
cause with respect to the automobile Parking Areas, including adjoining streets, sidewalks and passageways, or the use thereof by Tenant
or tenant&rsquo;s employees, customers, agents, contractors or invitees. Tenant may not assign, transfer, sublease or otherwise alienate
the use of the Parking Area without Landlord&rsquo;s prior written consent except in connection with an assignment, transfer or sublease
of this Lease approved by Landlord or permitted under <U>Section 18(b) </U>below. The Covered Parking Spaces shall be subject to a charge
of Thirty-Five Dollars ($35.00) per Covered Parking Space per month during the Term, payable in same manner and time as Minimum Annual
Rent. Landlord shall have the right to relocate all or any of the surface parking spaces of the Covered Parking Spaces to areas within
reasonably close proximity to the Leased Premises. Any such relocation of the Covered Parking Spaces shall be at Landlord&rsquo;s sole
cost, and the relocated covered parking spaces shall be covered. Such relocated covered parking spaces may, but are not required to,
be located within a structured parking facility. Landlord acknowledges that Tenant may be parking at the Property twenty-four hours a
days, seven days a week, and such parking may include Tenant&rsquo;s trucks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Without the prior written consent of Landlord, and except as required under applicable Laws (as defined below) or regulatory agency rules
(including those of the SEC), Tenant shall not Publicize (as defined hereunder) in any medium this Lease or the negotiations for, or
the terms, conditions or provisions included in it, provided, however, that Tenant may announce the fact that this Lease has been signed
and the size of the Premises. &ldquo;<B>Publicize</B>&rdquo; as used in the preceding sentence means public dissemination of information
for marketing or promotional purposes, whether by press release, in printed or digital marketing materials, on a website, or otherwise.
Landlord shall not have the right to use or Publicize any trademark, trade name, trade dress or any name, picture or logo which is commonly
identified with Tenant, and shall have no right to use any rights in or to any such trademark, trade name, trade dress or any name, picture
or logo of Tenant. Landlord may also: (i) include Tenant&rsquo;s name in any description of this Lease in any offering materials related to
the sale or other transfer of the Building; (ii) disclose the details of this Lease to prospective lenders, purchasers or other transferees
of Landlord&rsquo;s interest in the Property; (iii) photograph the Premises, which images may include Tenant&rsquo;s trademark, trade name,
trade dress or any name, picture or logo which is commonly identified with Tenant, for Landlord&rsquo;s use in its website or printed
promotional and marketing materials; and, (iv) publicize this Lease (without naming Tenant unless Tenant consents) after the Commencement
Date. Any press release issued by either party regarding this Lease shall be subject to the prior approval of both parties, which approval
shall not be unreasonably withheld, delayed or conditioned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord hereby discloses to Tenant that the Premises and Building are a portion of a larger development known as Cotton Center, and
that Cotton Center consists of certain improvements for the benefit of all owners and occupants in Cotton Center, in accordance with,
and under and subject to that certain Declaration of Covenants, Conditions, Easements and Restrictions dated December 24, 1998, recorded
in Instrument No. 98-1169019, as amended from time-to-time (collectively, the &ldquo;<B>Cotton Center CC&amp;Rs</B>&rdquo;). Pursuant
to the Cotton Center CC&amp;Rs, residents of Cotton Center are assessed association fees and other charges, which cover, among other
items, repair and maintenance of improvements within Cotton Center, such as sidewalks, curbs, landscape areas, fountains and lighting
and such charges are part of Tenant&rsquo;s Share of Operating Expenses. This Lease is subject to all terms and conditions of such Cotton
Center CC&amp;Rs. Landlord acknowledges that Tenant&rsquo;s proposed use of the Premises is for establishing a clinical testing laboratory.
Laboratory will be licensed in accordance with Clinical Laboratory Improvement Act (CLIA). The principle specimen type will be non-infectious
saliva and the testing performed will be genotyping DNA extracted from the specimen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord hereby discloses to Tenant that the Premises and Building are also part of a development known as Allred Cotton Center, within
Cotton Center, and that Allred Cotton Center consists of certain improvements for the benefit of all owners and occupants in Allred Cotton
Center, in accordance with, and under and subject to that certain Declaration of Covenants, Conditions and Restrictions and Grant of
Easements dated November 3, 2000, recorded in Instrument No. 2000-0862293, as amended from time-to-time (collectively, the &ldquo;<B>Allred
CC&amp;Rs</B>&rdquo;). Pursuant to the Allred CC&amp;Rs, residents of Allred Cotton Center are assessed association fees and other charges,
which cover, among other items, repair and maintenance of improvements within Allred Cotton Center, such as sidewalks, curbs, landscape
areas, fountains and lighting and such charges are part of Tenant&rsquo;s Share of Operating Expenses. This Lease is subject to all terms
and conditions of such Allred CC&amp;Rs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Term; Option to Renew; Option of
                                 Early Termination; Possession. </U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Term of this Lease shall commence on the Commencement Date and shall end on the Expiration Date, unless sooner terminated in accordance
with this Lease. If Landlord is delayed in delivering possession of all or any portion of the Premises to Tenant as of the Commencement
Date, this Lease will not be void or voidable, nor will Landlord be liable to Tenant for any loss or damage resulting therefrom, but
in that event, the Term will commence on the date Landlord delivers possession of the Premises to Tenant in the condition required herein,
which date will then become the Commencement Date (and the Expiration Date will be extended so that the length of the Term remains unaffected
by such delay) and the Monthly Rent due for any partial month shall be prorated on a per diem basis. Tenant acknowledges that neither
Landlord nor its Agents (as defined below) have agreed to undertake any alterations or construct any Tenant improvements to the Premises
except as expressly set forth in <U>Section 29</U> below. Within five (5) days after receipt of a request from Landlord, Tenant shall
execute and deliver a certificate in form and substance reasonably required by Landlord confirming the Commencement Date and the Expiration
Date, but the failure to do so shall not alter the terms of this Lease, and in such event, Landlord&rsquo;s determination of such dates
shall be deemed accepted. For purposes of this Lease, the term &ldquo;<B>Lease Year</B>&rdquo; means the period from the Commencement
Date through the succeeding twelve (12) full calendar months (including for the first Lease Year any partial month from the Commencement
Date until the first day of the first full calendar month) and each successive twelve (12) month period thereafter during the Term, and
any Renewal Term (as defined hereunder).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord shall not be liable for any loss or damage to Tenant resulting from any delay in delivering possession of the Premises to Tenant
due to the holdover of any existing tenant, other circumstances outside of Landlord&rsquo;s reasonable control, any event of Force Majeure
(as defined below), or any event or act by, or caused by Tenant or Tenant&rsquo;s Agents (as defined below) (collectively, an &ldquo;<B>Excused
Delay</B>&rdquo;), nor shall any delays affect the continuation or validity of this Lease. For purposes of this Lease, &ldquo;<B>Agents</B>&rdquo;
of a party means such party&rsquo;s employees, agents, servants, representatives, independent contractors, subcontractors, designees,
licensees or invitees and in the case of Landlord only, shall include without limitation, Workspace Property Management, L.P., Workspace
Property Trust, L.P., and any other associated or affiliated entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Provided that (i) there then exists no Event of Default by Tenant under this Lease, and (ii) Tenant, its Strategic Partners, and its
Permitted Transferees (as such terms are defined below) occupy at least 50% of the Premises, Tenant shall have the right and option to
extend the Term of this Lease for one (1) additional sixty (60) month period (the &ldquo;<B>Renewal Term</B>&rdquo;), commencing as of
the date immediately following the Expiration Date on the same terms and conditions as are in effect on the last day of the Term except
that no Abatement or Tenant Improvement Allowance shall be continued, and the Minimum Annual Rent shall be the FMV (as defined below),
as determined by Landlord and Tenant using the standard set forth in <U>Section 4(c)(ii) </U>of this Lease (the &ldquo;<B>Renewal Option</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>The Renewal Option is exercisable by Tenant giving Landlord prior written notice of Tenant&rsquo;s election to extend the Term (&ldquo;<B>Renewal
Notice</B>&rdquo;), on or prior to the date which is twelve (12) months prior to the Expiration Date; it being agreed that time is of
the essence with respect to the Renewal Notice. If and when the Renewal Term is in effect, all references to the Term of this Lease,
shall be deemed to mean the Renewal Term. This Renewal Option is personal to Tenant and is non-transferable to any assignee, subtenant
(regardless of whether any such assignment or sublease was made with or without Landlord&rsquo;s consent) or other party, other than
Permitted Transferee. Within thirty (30) days after Landlord receives notice of Tenant&rsquo;s Renewal Notice, but in no event prior
to the date that is more than twelve (12) months prior to the Expiration Date, Landlord will give notice to Tenant (the &ldquo;<B>Rent
Notice</B>&rdquo;) of Landlord&rsquo;s opinion of the FMV and comparing the FMV to the Minimum Annual Rent payable in the immediately
preceding Lease Year. If Tenant does not respond to the Rent Notice within thirty (30) days after receiving it, Landlord&rsquo;s opinion
of the FMV shall be deemed accepted as the Minimum Annual Rent due for each Lease Year of the Renewal Term. If, during such thirty (30)
day period, Tenant gives Landlord notice that Tenant contests Landlord&rsquo;s determination of the FMV (an &ldquo;<B>Objection Not</B>ice&rdquo;),
which notice must contain therein Tenant&rsquo;s opinion of the FMV, the parties may then negotiate to determine a FMV acceptable to
both parties to arrive at a mutually agreeable Minimum Annual Rent for each Lease Year of the Renewal Term. When the parties come to
an agreement, they will both execute an amendment to this Lease, establishing the Minimum Annual Rent for each Lease Year of such Renewal
Term. Following the exercise of this Renewal Option, Tenant shall not have any further renewal rights. If, within twenty (20) days after
Landlord&rsquo;s receipt of the Objection Notice the parties have not signed such an amendment to this Lease, the parties agree to submit
the determination of Minimum Annual Rent applicable to the Renewal Term to arbitration as set forth in <U>Section 4(c)(iii)</U> of this
Lease below (the &ldquo;<B>Arbitration Election</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>&ldquo;<B>FMV</B>&rdquo; shall mean, for the purposes of this <U>Section 4(c)(ii)</U>, as of the date in question, the fair market
value of the then current annual rental charge, including provisions for subsequent increases and other adjustments for leases or agreements
to lease then currently being negotiated, or executed in comparable space located in the Building, the office/laboratory park of which
the Building is a part, and leases or agreements to lease then currently being negotiated or executed for comparable class A office/laboratory
space located elsewhere in office/laboratory buildings located in the City of Phoenix, Arizona sub-market, for a term commencing on or
about the Expiration Date. In determining FMV, the following factors, among others, shall be taken into account and given effect: size,
location of premises, lease term, condition of the building, condition of the premises, economic strength of the tenant, pass-throughs
paid by tenants, commissions payable in connection with the leasing, economic concessions (including free rent, tenant improvements being
performed by landlords for tenants, or tenant improvement allowances being granted by landlords to tenants), then being granted by landlords
to tenants and services provided by landlords. The value of any Tenant Improvements or Alterations installed by Tenant at its own expense
and not using any of the Tenant Improvement Allowance shall not be taken into account in determining FMV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>If the parties submit to the Arbitration Election, FMV shall be determined by impartial arbitrators, one (1) to be chosen by the
Landlord, one (1) to be chosen by Tenant, and a third (3<SUP>rd</SUP>) to be selected, if necessary, as below provided. The unanimous
written decision of the two (2) first chosen, without selection and participation of a third (3<SUP>rd</SUP>) arbitrator, or otherwise,
the written decision of a majority of three (3) arbitrators chosen and selected as aforesaid, shall be conclusive and binding upon Landlord
and Tenant. Landlord and Tenant shall each notify the other of its chosen arbitrator within ten (10) business days following the Arbitration
Election and, unless such two (2) arbitrators shall have reached a unanimous decision within thirty (30) days after their designation,
they shall so notify the then President of the Maricopa County or City of Phoenix Board of Realtors (or such organization as may succeed
to said Maricopa or City of Phoenix County Board of Realtors) and request him/her to select an impartial third (3<SUP>rd</SUP>) arbitrator,
who shall be an office/laboratory building owner, a real estate counselor or a broker familiar with similar types of office /laboratory
space properties, to determine FMV as herein defined. Such third (3<SUP>rd</SUP>) arbitrator and the first two (2) chosen shall, subject
to commercial arbitration rules of the American Arbitration Association, hear the parties and their evidence and render their decision
within thirty (30) days following the conclusion of such hearing and notify Landlord and Tenant thereof. All arbitrators shall not have
been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least five (5) years prior to appointment
pursuant hereto. Landlord and Tenant shall bear the expense of the third (3<SUP>rd</SUP>) arbitrator (if any) equally. The arbitrators
shall be real estate brokers with at least ten (10) years full-time commercial brokerage experience who are familiar with the FMV of
first-class office/laboratory space in the Phoenix area. If the dispute between the parties as to a FMV has not been resolved before
the commencement of Tenant&rsquo;s obligation to pay Rent based upon such FMV, then Tenant shall pay Minimum Annual Rent and other charges
under the Lease for the Premises based upon the FMV designated by Landlord until either the agreement of the parties as to the FMV, or
the decision of the arbitrators, as the case may be, at which time Tenant shall pay any underpayment of Rent and other charges to Landlord,
or Landlord shall refund any overpayment of Rent and other charges to Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant shall have the one-time right and option (the &ldquo;<B>Termination Option</B>&rdquo;), exercisable by giving Landlord a minimum
of twelve (12) months prior written notice thereof, to terminate this Lease as of the end of the thirty-sixth (36<SUP>th</SUP>) month
after the Commencement Date, stating that Tenant is exercising its limited right of early termination (the &ldquo;<B>Early Termination
Notice</B>&rdquo;), provided that (i) this Lease is then in effect, and (ii) no Event of Default has occurred and is continuing prior
to such Early Termination Notice date. The date Tenant actually terminates this Lease shall be known as the &ldquo;<B>Early Termination
Date</B>&rdquo;. This limited early termination right is personal to Tenant and is non-transferable to any assignee, subtenant (regardless
of whether any such assignment or sublease was made with or without Landlord&rsquo;s consent), or other party, other than a Permitted
Transferee. Any assignment or sublease under this Lease then in effect shall likewise terminate on the Early Termination Date. At the
time of providing such Early Termination Notice, and as a condition to such early termination, Tenant must concurrently deliver to Landlord
payment in an amount equal to the aggregate of: (a) six (6) full month&rsquo;s Minimum Annual Rent at the then current or applicable
rental rate; and (b) the Unamortized Transaction Costs (as hereinafter defined) (the &ldquo;<B>Early Termination Payment</B>&rdquo;).
Tenant shall pay all Rent under the Lease and abide by all of the terms and conditions of the Lease through and including such Early
Termination Date. If the Early Termination Notice is not accompanied by such Early Termination Payment, the Early Termination Notice
shall be deemed null and void and this Lease shall continue in full force and effect. The term &ldquo;<B>Unamortized Transaction Costs</B>&rdquo;
shall mean: (1) the unamortized amount of the Tenant Improvement Allowance or any part thereof issued to Tenant; (2) the unamortized
amount of commissions, if any, that shall have been paid or shall become payable to the Broker in connection with this Lease; (3) the
unamortized amount of actual legal, engineering and other consultant fees that shall have been paid by Landlord in connection with this
Lease; and (4) if applicable the unamortized amount of the Additional Tenant Allowance or any part thereof issued to Tenant. The term
 &ldquo;unamortized amount&rdquo; means the balance of the amount remaining on the Early Termination Date after amortizing the amounts
in clauses (1), (2) and (3) of this Section 4(d), based upon an amortization term equal to the Term, using a hypothetical interest rate
of 9.0% per annum, and the amounts in clause (3) of this Section 4(d), based upon an amortization term equal to the Term, using a hypothetical
interest rate of eleven percent (11%) per annum, compounded monthly, with payments in arrears, on a level-payment, monthly payment, declining
balance basis. Promptly following receipt of request from Tenant at any time during the Term, Landlord shall provide a calculation of
the Early Termination Payment. Nothing herein contained shall afford Tenant the right to cure the failure to pay the Early Termination
Payment, or to cure the failure to give the Early Termination Notice when and as provided under this Lease, and any failure of Tenant
to make such payment or give such notice at the time set forth in this Section 4(d) shall render Tenant&rsquo;s right to exercise the
Termination Option void and of no further force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;
<B><U>Rent; Taxes</U></B>. This is a &ldquo;triple net&rdquo; lease, and the Minimum Annual Rent payments due from Tenant do not include
any Annual Operating Expenses, other additional Rent, or utilities and services, which amounts are Tenant&rsquo;s responsibility as set
forth herein. Notwithstanding the foregoing, Minimum Annual Rent does not include any applicable Arizona privilege, sales, excise, rental
and other taxes (except income taxes) imposed now or hereafter imposed by any governmental authority upon the Minimum Annual Rent provided
to be paid by Tenant to, or on behalf of, Landlord (collectively, &ldquo;<B>Additional Taxes</B>&rdquo;), which applicable Additional
Taxes shall be considered additional Rent under this Lease and shall be paid by Tenant in addition to the above noted Minimum Annual
Rent, together with each installment of Minimum Annual Rent payments, Operating Expenses (as defined hereunder) payments or other additional
Rent payments made by Tenant. Accordingly, Tenant agrees to pay to Landlord, without demand, deduction or offset, Minimum Annual Rent,
Annual Operating Expenses, Additional Taxes, and other additional Rent for the Term, in advance, on the first (1<SUP>st</SUP>) day of
each calendar month during the Term (collectively, the &ldquo;<B>Monthly Rent</B>&rdquo;), to Landlord&rsquo;s address set forth on the
 &ldquo;Payment Rider&rdquo; attached hereto as <B>Exhibit &ldquo;C&rdquo;</B> (unless Landlord designates otherwise) or if required by
Landlord to an account selected by Landlord by direct payment, in which event Tenant shall execute and deliver a direct payment authorization
within five (5) days after receipt of Landlord&rsquo;s notice; provided that Monthly Rent for the fourth (4<SUP>th</SUP>) full month
shall be paid at the signing of this Lease. If the Commencement Date is not the first (1<SUP>st</SUP>) day of the month, the monthly
installment of Minimum Annual Rent for that partial month shall be apportioned on a per diem basis and shall be paid on or before the
Commencement Date, and the Abatement shall commence as of the first day of the first full calendar month following the Commencement Date.
Tenant shall pay Landlord a service and handling charge equal to five percent (5%) of any Rent not paid within five (5) days after the
date due, which amount shall be considered part of Tenant&rsquo;s Rent obligation. In addition, any Rent, including such charge, not
paid within five (5) days after the due date will bear interest at the at the rate of One and One-Half Percent (1&frac12;%) per month
(the &ldquo;<B>Interest Rate</B>&rdquo;) from the date due to the date paid, which amount shall be considered part of Tenant&rsquo;s
Rent obligation. The payment of interest on such amounts will not extend the due date of any amount owed. Tenant shall pay before delinquent
all taxes or other charges levied or assessed upon, measured by, or arising from: (a) the conduct of Tenant&rsquo;s business; (b) Tenant&rsquo;s
leasehold estate; or (c) Tenant&rsquo;s property. Additionally, Tenant shall pay to Landlord all sales, use, transaction privilege, or
other excise tax that may at any time be levied or imposed upon, or measured by, any amount payable by Tenant under this Lease. For purposes
of this Lease, &ldquo;<B>Rent</B>&rdquo; means the Minimum Annual Rent, Annual Operating Expenses, Additional Taxes, and any other additional
amounts of money payable by Tenant to Landlord under this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">6.
 &#8239;&#8239;&#8239;&#8239;<B><U>Operating Expenses</U></B>. The amount and percentage of the Annual Operating Expenses set forth in <U>Section 1(g)</U> and <U>Section
1(h)</U> above represents Tenant&rsquo;s Share of the estimated Operating Expenses for the calendar year in which the Term commences,
and includes the cost of utilities and services for the Common Areas, and the cost of water, and other utilities and services supplied
to the Premises, except as set forth below but excludes the costs of electricity and other utilities and services that are separately
metered to the Premises or which are Tenant&rsquo;s responsibility, which shall be paid by Tenant directly to the utility or service
provider(s) as set forth in <U>Section 7</U> of this Lease, except as otherwise provided herein. As part of Landlord&rsquo;s Work, Landlord
shall cause a submeter to be installed for the electric service to the Premises, and Tenant shall timely pay all electric utility charges
directly to Landlord. Landlord shall provide annually prior to January 1 of each calendar year a reasonable estimate of the Annual Operating
Expenses due for such calendar year, and Tenant shall pay Tenant&rsquo;s Share of such estimate in equal installments on a monthly basis
as part of Rent. Landlord may adjust such amount from time to time if the estimated Annual Operating Expenses increase or decrease. Landlord
may also invoice Tenant separately from time to time for Tenant&rsquo;s Share of any extraordinary or unanticipated Operating Expenses.
By April 30<SUP>th</SUP> of each calendar year (and as soon as practical after the expiration or termination of this Lease or, at Landlord&rsquo;s
option, after a sale of the Property), Landlord shall provide Tenant with a statement of actual Operating Expenses representing Tenant&rsquo;s
Share for the preceding calendar year or part thereof. Within thirty (30) days after delivery of the statement to Tenant, Landlord or
Tenant shall pay to the other the amount of any overpayment or deficiency then due from one to the other or, at Landlord&rsquo;s option,
Landlord may credit Tenant&rsquo;s account for any overpayment. If Tenant does not give Landlord notice within ninety (90) days after
receiving Landlord&rsquo;s statement that Tenant disagrees with the statement and specifying the items and amounts in dispute, Tenant
shall be deemed to have waived the right to contest the statement. Landlord&rsquo;s and Tenant&rsquo;s obligation to pay any overpayment
or deficiency due the other pursuant to this <U>Section 6</U> shall survive the expiration or termination of this Lease. Notwithstanding
any other provision of this Lease to the contrary, Landlord may, in its reasonable discretion, determine from time to time the method
of computing and allocating Operating Expenses, including the method of allocating Operating Expenses to various types of space within
the Building to reflect any disparate levels of services provided to different types of space. If the Building is not fully occupied
during any period, Landlord may make a reasonable adjustment based on occupancy in computing the Operating Expenses for such period so
that Operating Expenses are computed as though the Building had been fully occupied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &ldquo;<B>Operating Expenses</B>&rdquo; means all costs, fees, charges and expenses incurred or charged by Landlord in connection with
the ownership, operation, maintenance and repair of, and services provided to, the Property, including, but not limited to, and to the
extent not otherwise payable by Tenant pursuant to this Lease, (i) the charges at standard retail rates for any services provided to
Tenant and other occupants of the Building by Landlord pursuant to <U>Section 7 </U>of this Lease, (ii) the cost of insurance carried
by Landlord pursuant to <U>Section 8 </U>of this Lease together with the cost of any deductible paid by Landlord in connection with an
insured loss (subject to the amortization of any permitted capital expenditures), (iii) Landlord&rsquo;s cost to Maintain (as defined
hereunder) the Property pursuant to <U>Section 9</U> of this Lease, including without limitation, fire protection, trash collection,
janitorial services pursuant to <U>Section 7(b) </U>below, water, sewer, heating, ventilation and air conditioning (&ldquo;<B>HVAC</B>&rdquo;)
systems, roof maintenance, elevator maintenance, interior and exterior landscaping, snow and ice removal, and Common Area cleaning and
exterminating, (iv) a non-reconcilable amount equal to the charges incurred by Landlord for personnel, vehicles, and supplies used or
attributable to the Premises a fixed amount of Eighteen Cents ($0.18) per rentable square foot of the Premises per year, (v) all levies,
taxes (including real estate taxes, sales taxes and gross receipt taxes), assessments, liens, license and permit fees, together with
the reasonable cost of contesting any of the foregoing, which are applicable to the Term, and which are imposed by any authority or under
any Law, or pursuant to any recorded covenants or agreements, upon or with respect to the Property pursuant to <U>Section 5</U> of this
Lease, or any improvements thereto, or directly upon this Lease or the Rent or upon amounts payable by any subtenants or other occupants
of the Premises, or against Landlord because of Landlord&rsquo;s estate or interest in the Property, (vi) the annual amortization (over
their estimated economic useful life or payback period, whichever is shorter) of the costs (including reasonable financing charges) of
capital improvements or replacements (a) required by any Laws coming into effect after the Commencement Date, (b) made for the purpose
of reducing Operating Expenses, or (c) made for the purpose of directly enhancing the safety of tenants in the Building, and (vii) a
management and administrative fee equal to five percent (5%) of gross rents (i.e. Minimum Annual Rent, Annual Operating Expenses, Additional
Taxes and any additional Rent other than the management fee) from the Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The foregoing notwithstanding, Operating Expenses will not include: (i) depreciation on the Building, (ii) financing and refinancing
costs (except as provided above), interest on debt or amortization payments on any Mortgage (as defined hereunder), or rental under any
ground or underlying lease, (iii) leasing commissions, advertising expenses, tenant improvements or allowances, or other costs directly
related to the leasing of the Property, (iv) income, excess profits or corporate capital stock tax imposed or assessed upon Landlord,
unless such tax or any similar tax is levied or assessed in lieu of all or any part of any taxes includable in Operating Expenses above,
(v) any bad debt loss, rent loss, or reserves for bad debt or rent loss or future expenses; (vi) costs associated with operation of the
business of the ownership of the Building or entity that constitutes Landlord or Landlord&rsquo;s property manager, as distinguished
from the cost of Building operations, including the costs of partnership or corporate accounting and legal matters; defending or prosecuting
any lawsuit with any mortgagee, lender, ground lessor, broker, tenant, occupant, or prospective tenant or occupant; selling or syndicating
any of Landlord&rsquo;s interest in the Building; and disputes between Landlord and Landlord&rsquo;s property manager; (vii) costs of
services or other benefits of a type that are not available to Tenant but that are available to other tenants or occupants of the Building,
and costs for which Landlord is reimbursed including reimbursements by other tenants or occupants of the Building other than through
payment of tenants&rsquo; shares of Operating Expenses; and (viii) fees paid to any affiliate or party related to Landlord to the extent
such fees exceed the charges for comparable services rendered by unaffiliated third parties of comparable skill, stature and reputation
in the same market;. If Landlord elects to prepay real estate taxes during any discount period, Tenant shall be entitled to the benefit
of any such prepayment. Landlord shall have the right to directly perform (by itself or through an affiliate) any services provided under
this Lease provided that the Landlord&rsquo;s charges included in Operating Expenses for any such services shall not exceed competitive
market rates for comparable services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If Tenant provides written notice to Landlord within the ninety (90) day period following delivery of the annual reconciliation statement
that Tenant disagrees with such statement for Operating Expenses, and specifies the items and amounts in dispute, Tenant shall, (i) pending
the resolution of such dispute, nonetheless pay all of Tenant&rsquo;s Share of Annual Operating Expenses in accordance with the statement furnished
by Landlord, and Tenant shall have the right, at its sole cost and expense, to examine Landlord&rsquo;s books and records relating to the determination
of Operating Expenses for such calendar year, and commence and diligently complete an audit of such charges (an &ldquo;<B>Audit</B>&rdquo;);
provided, however, that (1) Tenant shall give Landlord a minimum of five (5) business days&rsquo; prior written notice of its intent
to exercise such right, (2) the inspection may not take place outside of normal business hours at Landlord&rsquo;s corporate offices,
at Tenant&rsquo;s sole cost, (3) Tenant shall use reasonable efforts to not interfere with Landlord&rsquo;s normal business activities, taking
into account the workload of Landlord&rsquo;s employees involved in responding to the Audit request; and (4) an Event of Default under
this Lease has not occurred and is then continuing. The Audit of Landlord&rsquo;s records may be conducted by Tenant&rsquo;s accounting
staff or only a certified public accountant, subject to Landlord&rsquo;s approval, which approval shall not be unreasonably withheld.
Any accounting firm selected by Tenant in connection with the Audit (a) shall be a reputable independent nationally or regionally recognized
certified public accounting firm which has previous experience in auditing financial operating records of landlords of office /laboratory
buildings; (b) shall not already be providing accounting and/or lease administration service to Tenant and shall not have provided accounting
and/or lease administration service to Tenant in the past three (3) years; (c) shall not be retained by Tenant on a contingency fee basis
(i.e. Tenant must be billed based on the actual time and materials that are incurred by the accounting firm in the performance of the
Audit, and a statement signed by an officer of Tenant confirming such agreement between Tenant and auditor, shall be provided to Landlord
prior to the commencement of the Audit); and (d) at Landlord&rsquo;s option, both Tenant and its agent shall be required to execute a
commercially reasonable confidentially agreement prepared by Landlord. The foregoing Audit shall be completed, and the results delivered
to Landlord, within ninety (90) days after the date Tenant delivers its Audit notice (subject to delay due to any event caused by or
inaction of Landlord or Landlord&rsquo;s Agents), or Tenant shall be deemed to have waived the right to contest the statement. Landlord
and Tenant shall work together in good faith to resolve any issues raised in Tenant&rsquo;s Audit. In the event Tenant timely completes
its Audit and it reveals an overpayment by Tenant of Tenant&rsquo;s Share of Annual Operating Expenses (an &ldquo;<B>Overcharge</B>&rdquo;),
and Landlord in good faith agrees with such determination, the amount due Tenant (if any) shall be credited against no more than fifty
percent (50%) of Tenant&rsquo;s monthly Minimum Annual Rent next coming due for each month following the determination of such Overcharge
until such time as Tenant is reimbursed in full, and if the Audit reveals that Tenant was undercharged during any given year (an &ldquo;<B>Undercharge</B>&rdquo;),
Tenant shall promptly pay to Landlord the amount of such Undercharge. Landlord shall additionally reimburse Tenant in the event of an
Overcharge of greater than five percent (5%), and Tenant shall additionally reimburse Landlord, in the event of an Undercharge of greater
than five percent (5%), for the out of pocket costs incurred in connection with such Audit in an amount not to exceed Five Thousand Dollars
($5,000). If the parties are unable to resolve the dispute within thirty (30) days after completion of Tenant&rsquo;s Audit, then, at
Tenant&rsquo;s request, a certified public accounting firm selected by Landlord and subject to requirements (a), (b), and (c) above as
to Landlord, and reasonably approved by Tenant, shall, at Tenant&rsquo;s cost, conduct an audit of the relevant Operating Expenses (the
 &ldquo;<B>Neutral Audit</B>&rdquo;). The parties shall split all costs and expenses of the Neutral Audit unless the final determination
in such Neutral Audit is that Landlord Overcharged Tenant for Tenant&rsquo;s Share of Operating Expenses in the statement for the year
being audited by more than five percent (5%) in which case Landlord shall pay all costs and expenses of the Neutral Audit in an amount
not to exceed Five Thousand Dollars ($5,000). In any event, Landlord will reimburse or provide a credit for any Overcharge of Operating
Expenses and Tenant shall pay to Landlord any Undercharge of Operating Expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
The parties agree that Tenant&rsquo;s Share reflects and will be continually adjusted to reflect the ratio of the gross square feet of
the area rented to Tenant (including, if applicable, an allocable share of all Common Areas) as the numerator, as compared with the total
number of gross square feet of the entire Building (or additional buildings that are or may be constructed within the Property), as the
denominator, measured outside wall to outside wall, but excluding therefrom any storage areas. Notwithstanding anything to the contrary
set forth in this Section 8, with respect to water only, Tenant&rsquo;s share of charges for water shall be 100% until such time as another
tenant occupies any portion of the Building. Landlord shall have the right to make changes or revisions in the Common Areas of the Building
or the Land so as to provide additional leasing area. Landlord shall also have the right to construct additional buildings in the Property
for such purposes as Landlord may deem appropriate, and subdivide the lands for that purpose if necessary, and upon so doing, the Property
shall become the subdivided lot on which the Building in which the Premises is located. However, if any service provided for in <U>Section
6(b) </U>above is separately billed or separately metered within the Building, then the square footage so billed or metered shall be
subtracted from the denominator and the Tenant&rsquo;s Share for such service and/or utility shall be separately computed, and the Annual
Operating Expenses for such item shall not include any charges attributable to said square footage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Utilities; Services</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
With the exception of Tenant&rsquo;s Share of any utilities and services expressly included as part of the Operating Expenses in <U>Section
6(b) above</U>, Tenant shall directly pay for electricity, power, telephone, internet and other communication services and any other
utilities or services supplied to the Premises commencing on the Commencement Date. Except to the extent Landlord elects to provide any
such services and invoice Tenant for the cost or include the cost in Operating Expenses, Tenant shall obtain such service in its own
name and timely pay all charges directly to the provider(s). As part of Landlord&rsquo;s Work, Landlord shall either install a separate
dedicated electricity meter, or install a submeter allocated between various occupants of the Building to measure Tenant electricity
usage at the Premises. If such submeter is utilized, the cost of such actual measured amount shall be billed by Landlord directly to
Tenant as a charge separate and distinct from Tenant&rsquo;s Share of Operating Expenses. If such separate dedicated meter is installed,
Tenant shall pay all charges incurred directly to the applicable utility service provider. Landlord shall not be responsible or liable
for any interruption in such services, nor shall such interruption affect the continuation or validity of, or constitute a Landlord default
under, this Lease. Landlord shall have the exclusive right to select, and to change, the companies providing such services to the Building
or Premises. Any wiring, cabling or other equipment necessary to connect Tenant&rsquo;s telecommunications equipment shall be Tenant&rsquo;s
responsibility, and shall be installed by Tenant in a manner approved by Landlord. If because of Tenant&rsquo;s density, use, equipment
or other Tenant circumstances, Tenant&rsquo;s consumption of any utility or other service included as part of Landlord&rsquo;s Operating
Expenses or demands on the Building Systems (as defined hereunder) are excessive when compared with other occupants of the Property,
or cause extraordinary maintenance and repair issues beyond those customarily and routinely incurred by Landlord to operate the Building
Systems, Landlord may install supplemental equipment and meters at Tenant&rsquo;s expense, and may invoice Tenant separately for, and
Tenant shall pay on demand, the cost of Tenant&rsquo;s excessive consumption or use, or such additional equipment, as reasonably determined
by Landlord. Landlord shall have the option, at any time during the Term or extension thereof, to exclude any utility service from Operating
Expenses, in which case, Landlord may either: (i) provide any such services and invoice Tenant for the cost; or (ii) require Tenant to
obtain service in its own name and timely pay all charges directly to the provider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
Landlord will furnish the following services for the normal use and occupancy of the Premises for Tenant&rsquo;s Use, the costs of which
are included as part of Operating Expenses: (i) electricity, or normal lighting of Common Areas; (ii) HVAC; (iii) water, (iv) sanitary
sewer, (v) Common Area janitorial and litter removal, and (vi) such other services Landlord reasonably determines are appropriate or
necessary, all in a manner comparable to that of similar buildings in the area. If Tenant requests, and if Landlord is able to furnish
services in addition to those identified above, Tenant shall pay Landlord&rsquo;s reasonable charge for such supplemental services. Tenant
acknowledges that Landlord has no obligation to provide any additional services in or about the Premises or the Building, its parking
or access areas, or in or about the Land.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord shall have no obligation to provide surveillance or security systems in or about the Premises or the Building, the Parking Area,
or access areas, or in or about the Land, and Landlord shall have no liability and Tenant hereby waives all claims in connection with
the decision whether or not to provide such services, or the failure of any security personnel, mechanical surveillance or other security
or surveillance measures to prevent the occurrence of any theft, vandalism or any other criminal or like causes (or the failure to apprehend
the perpetrators of such acts), whether provided by Tenant or Landlord. Subject to the provisions of <U>Section 8(f) </U>below, Tenant
shall defend, indemnify, and hold Landlord harmless from any such claims made by any of Tenant&rsquo;s or Tenant&rsquo;s Agent&rsquo;s
employee, licensee, invitee, contractor, agent or other person whose presence in, on or about the Premises or the Building is attendant
to the business of Tenant. Tenant shall have the right, at its sole cost and expense and only after providing written notice to Landlord,
to install, maintain, operate, repair, update and replace its own security system on the Premises, including without limitation, card
access readers, and interior and exterior cameras (collectively, the &ldquo;<B>Security System</B>&rdquo;), subject to Landlord&rsquo;s
approval of the location and installation methods of such Security System, not to be unreasonably withheld. Any such installation of
Tenant&rsquo;s Security System shall be an Alteration (as defined hereunder) and shall be subject to all applicable provisions of Sections
12 and 13 of this Lease. Tenant shall provide to Landlord card access readers, keys or combinations, as the case may be, to permit Landlord
to access all part of the Premises, subject to the terms of this Lease and Tenant&rsquo;s security, safety, and clean-room procedures.
Upon the expiration or earlier termination of this Lease, Landlord, at its option, may either require Tenant to leave the Security System
in place, in good working order, and transfer ownership thereof to Landlord, or remove the Security System and repair any damage resulting
therefrom (which determination by Landlord shall be made and delivered to Tenant at the same time as the approval of Tenant&rsquo;s Security
System).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant,
at Tenant&rsquo;s sole cost and expense, shall have the right to install one 600 k.w. generator, together with one generator pad and
a sound attenuation house (not to exceed 480 contiguous useable square feet of ground area and 11&rsquo;4&rdquo; feet in height), reasonably
necessary for Tenant&rsquo;s business operations in the Premises for emergency, electrical back-up purposes, including one above-ground
diesel fuel tank with a capacity of up to 350 gallons, a conduit (no greater than six inches (6&rdquo;) in diameter) and wires running
within the said conduit to connect the generator to Tenant&rsquo;s equipment in the Building, a muffler with a sound/noise level not
to exceed sixty (60) decibels of a distance of not more than twenty (20) feet from the equipment (the sixty (60) decibels maximum sound
level applies to all equipment noise, including HVAC), and all related equipment and apparatus (the &ldquo;<B>Generator</B>&rdquo;),
strictly under and subject to the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Before
beginning the installation of the Generator, which Tenant shall perform in a good and workmanlike manner and in compliance with the following
standards, Tenant shall first obtain Landlord&rsquo;s written approval, not to be unreasonably withheld, and in connection therewith
Tenant shall provide to Landlord final plans and specifications prepared by an engineer approved by Landlord and setting forth in detail
the design, location, size, method of installation, screening and all related equipment and apparatus for Landlord&rsquo;s review and
written approval, together with evidence reasonably satisfactory to Landlord that all Laws and industry standards have been satisfied.
Landlord&rsquo;s approval shall not constitute a representation or warranty by Landlord that Tenant&rsquo;s plans and specifications
comply with any Laws or industry standards as such compliance shall be the sole responsibility of Tenant. Landlord, at Landlord&rsquo;s sole
and reasonable discretion, shall determine the type of screening required to be maintained around the generator and the places and method
of penetrating the exterior of the Building to connect the Generator to the Premises, at Tenant&rsquo;s sole cost and expense;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>At
least three (3) business days prior to the Generator installation, Tenant shall notify Landlord of the date and time of the installation
and such installation shall be fully coordinated with Landlord. Such installation shall not damage the Building or materially interfere
with the use of any portion of the Building during Normal Business Hours while such installation is taking place;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
shall have the obligation to perform and shall pay all costs and expenses in connection with, arising out of, or related to the Generator
including without limitation the installation, use, operation, insurance, maintenance, repair, tangible personal property taxes, and,
to the extent necessary and appropriate, replacement, as may be needed to keep the Generator in a safe, good, orderly condition and repair.
In connection with the Generator, Tenant shall reimburse Landlord for the reasonable costs and expenses of Landlord&rsquo;s consultants,
architects, engineers, contractors and attorneys upon invoice;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
shall properly fuel and immediately notify Landlord verbally and in writing and remove from the area and otherwise remediate any spills
or other leaks of fluid from the Generator or otherwise connected therewith and shall otherwise comply with all Environmental Laws (as
defined hereunder), industry standards and Building Rules, as reasonably imposed by Landlord. All testing of the Generator shall be performed
after Normal Business Hours and in accordance with a schedule to be submitted in advance to and approved in writing by Landlord. Landlord
shall have the right, during the Term, to relocate the Generator, at Landlord&rsquo;s sole cost and expense. Landlord shall have the
right, during the Term, to require Tenant to modify the Generator sound attenuation housing and exhaust system if, in Landlord&rsquo;s
reasonable discretion, noise or exhaust fumes are interfering with other tenants and occupants in the Building or the Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>During
the Term, the Generator shall remain the personal property of Tenant, but at the expiration or earlier termination of this Lease, the
Generator shall become the sole and exclusive property of Landlord without any payment to Tenant, subject to the provisions of <U>Section
21(a)</U> below; and,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>All
applicable terms and conditions of this Lease shall apply to the Generator, except that the Generator area shall not be included within
the rentable area calculation of the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord manages the roof access from the Building and Tenant shall abide by Landlord&rsquo;s roof access procedures, as set forth in
this <U>Section 7(e)</U>. Tenant shall have the right to install, maintain, and repair a satellite business terminal system and its components
for Tenant&rsquo;s business operations (hereinafter the &ldquo;<B>Satellite System</B>&rdquo;), consisting of an outdoor satellite antenna
and electronic unit on the roof of the Building, indoor electronics unit within the Premises and IFL or other signal cables under a non-exclusive
license from Landlord, under and subject to the following conditions: (i) Tenant shall comply with all Laws and industry standards with
respect to the Satellite System; (ii) Tenant shall obtain Landlord&rsquo;s prior approval of the Satellite System for aesthetics, sound consideration
and of the location of the Satellite System on the roof of the Building and all roof penetrations required for the installation of the
Satellite System, which approval shall not be unreasonably conditioned, withheld, or delayed; (iii) if Landlord approves installation
of the Satellite System on the roof of the Building, Tenant agrees to consult with Landlord&rsquo;s roofing contractor prior to installation
and strictly to comply with the roofing contractor&rsquo;s recommendations and requirements; and (iv) Tenant shall pay all costs incurred by
Landlord in connection with the Satellite System including, without limitation, all architectural, engineering, contractors&rsquo; and legal
fees, any charges incurred by Landlord&rsquo;s roofing contractor and other consultants, and any and all damage, repairs and restoration
resulting from the installation, operation, maintenance, repair, replacement, relocation and removal of the Satellite System. Access
to the roof of the Building shall be restricted by Landlord at all times. Accordingly, Tenant shall notify Landlord at least three (3)
business days prior to the installation of the Satellite System and Tenant, utilizing Landlord&rsquo;s roofing contractor, shall install
the Satellite System only if Landlord, its agent, or its roofing contractor is present. Tenant shall maintain the Satellite System in
a safe, good, and orderly condition. The installation, maintenance, repair, and removal of the Satellite System shall be performed by
Landlord&rsquo;s roofing contractor at Tenant&rsquo;s sole cost and expense in a manner which will not impair the integrity of, damage, or
adversely affect the warranty applicable to, the roof or any other portion of the Building. The Satellite System shall not cause interference
with any other existing telecommunications systems of Landlord or other tenants or occupants of the Building. The Satellite System shall
be used solely by Tenant in the ordinary course of its business for its Use, and Tenant shall not allow any parties other than Tenant,
its contractors, sublessees, licensees, and invitees within the Premises to use the Satellite System. If any work to the Building or
the Property by Landlord or its contractors necessitates removing or relocating the Satellite System or any Satellite System components,
Landlord shall, at Landlord&rsquo;s sole cost and expense, remove and reinstall or relocate same to a new location designated by Landlord,
as applicable. Tenant hereby waives all claims for recovery against Landlord for any and all loss or damage which may be inflicted upon
the Satellite System and its operation by Landlord or its Agents or other tenants in the Building or from any other cause. Landlord shall
not be responsible or liable for any interruption in connection with the Satellite System, nor shall such interruption affect the continuation
or validity of this Lease. Tenant shall retain ownership of the Satellite System. Accordingly, no later than the expiration or earlier
termination of this Lease, at Tenant&rsquo;s sole expense, Tenant, utilizing Landlord&rsquo;s roofing contractor, shall remove the Satellite
System and repair any resulting damage, ordinary wear and tear, damage by casualty, and repairs that are Landlord&rsquo;s responsibility
excepted, all in accordance with the terms of <U>Section 12</U> below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 18pt"><FONT STYLE="font-size: 10pt">8.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Insurance; Waivers; Indemnification.
                               </U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Landlord will at all times during the Term carry a policy of insurance which insures the Building, including the Premises, if any,
against loss or damage by fire or other casualty (namely, the perils against which insurance is afforded by a standard fire insurance
policy); provided, however, that Landlord will not be responsible for, and will not be obligated to insure against, any loss of or damage
to any personal property or trade fixtures of Tenant or any alterations which Tenant may make to the Premises or any loss suffered by
Tenant due to business interruption. All insurance maintained by Landlord pursuant to this Section 8 may be effected by blanket insurance
policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
</B>Prior to Tenant&rsquo;s entry onto the Premises, Tenant will obtain and have and thereafter keep in full force and effect at all
times until the expiration of the Term of this Lease, insurance coverage as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Commercial
general liability insurance policy on an ISO CG 00 01 form, on an occurrence basis, providing coverage for claims for bodily injury,
personal injury and property damage occurring on, in or about the Premises with a per occurrence/per offense limit of at least Three
Million and 00/100 Dollars ($3,000,000.00) with no deductible or self-insured retention unless specifically approved by Landlord. Defense
costs shall be in addition to the policy limits. Such insurance shall provide coverage for all of Tenant&rsquo;s operations and shall
include contractual liability coverage, including coverage applicable to the Tenant&rsquo;s indemnity requirements herein, and shall
include an endorsement naming Landlord, Workspace Property Management, L.P., Workspace Property Trust, L.P. and each of their respective
directors, officers, shareholders, members, employees, associated and affiliated entities, ground lessors, any Mortgagees(s) (as defined
hereunder), and any other party as designated by Landlord (hereinafter &ldquo;<B>Landlord Additional Insureds</B>&rdquo;) as additional
insureds on a primary and non-contributory basis for all liability, claims, costs, damages, and expenses arising out or resulting from
Tenant&rsquo;s acts, omissions, operations, occupancy, use, control, and/or tenancy of the Premises. This insurance may be effected by
a combination of a primary general liability policy and an excess liability policy provided the limit of the primary general liability
policy is not less than One Million and 00/100 Dollars ($1,000,000.00) per occurrence and the excess liability policy follows form. Any
aggregate under the policy(ies) shall apply separately to the Premises. Such policy(ies) shall include a severability of interest condition
or clause providing coverage to each insured as if such insured was the only insured under the policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Workers&rsquo;
compensation insurance in statutory amounts and in accordance with the laws of the state in which the Premises are located and employers&rsquo;
liability insurance with limits not less than Five Hundred Thousand and 00/100 Dollars ($500,000.00) bodily injury by accident and bodily
injury by disease. Such insurance shall cover all individuals employed at or retained on behalf of Tenant with respect to the Premises.
Such insurance shall include a waiver of subrogation against Landlord Additional Insureds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>All
risk property insurance upon property of every description and kind owned by Tenant and/or under Tenant&rsquo;s care, custody or control
and/or for which Tenant is responsible located at the Premises or for which Tenant is legally liable or installed by or on behalf of
Tenant. Such insurance shall be in an amount equal to the full replacement cost thereof. Such policy shall also include coverage for
business interruption and extra expense in an amount and with coverage adequate to indemnify Tenant for its loss of business and costs
of operations for a period of at least twelve (12) months. The deductible under such policy shall not exceed Five Thousand and 00/100
Dollars ($5,000.00) unless specifically approved by Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Environmental
liability insurance covering the Generator and all other operations in the Premises with limits of not less than $2,000,000.00 combined
single limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Insurance
for such other hazards and in such amounts as Landlord may reasonably require and as at the time are commonly insured against with respect
to property similar in character, general location and use and occupancy to the Premises or as required by any Mortgagee in amounts reasonably
determined by Landlord. If, by reason of changed economic conditions, the insurance amounts referred to in this <U>Section 8(b)</U> become
inadequate, Tenant agrees to increase the amounts of such insurance at its next renewal date upon Landlord&rsquo;s reasonable request.
If the forms of policies, endorsements, certificates, or evidence of insurance required by this <U>Section 8(b)</U> are superseded or
discontinued, Landlord may require other equivalent or better forms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">All
of Tenant&rsquo;s insurance policies shall be issued by insurers authorized to issue such insurance, licensed to do business and admitted
in the state in which the Property is located and rated at least A-VIII in the most current edition of <I>Best&rsquo;s Insurance Reports,
</I>shall be in a form and with terms and conditions acceptable to Landlord, all property insurance policies shall include a waiver of
subrogation against Landlord Additional Insureds, to the extent permitted by law, and, if commercially available, shall provide an undertaking
by the insurers to provide at least thirty (30) days prior written notice to Landlord and Landlord&rsquo;s Mortgagee prior to any material
change, reduction in coverage or cancellation of any of the insurance policies required herein (ten (10) days in the event of non-payment
of premium)<I>.</I> Tenant shall deliver to Landlord, within five (5) days after the date of this Lease or any earlier date on which
Tenant accesses the Premises, and at least five (5) days prior to the date of each policy renewal, a certificate of insurance, in a form
acceptable to Landlord, evidencing such coverage and including all policy forms and endorsements requested by Landlord. Tenant shall
provide complete copies of its insurance policies to Landlord within fifteen (15) days of Landlord&rsquo;s request. It is understood
and agreed that Tenant&rsquo;s insurance policies shall be primary to any separate coverage carried by any Landlord Additional Insured.
Any other insurance carried by Landlord Additional Insureds shall be excess of and non-contributory with Tenant&rsquo;s insurance. The
minimum limits of Tenant&rsquo;s liability insurance and other requirements designated in this <U>Section 8</U> shall in no way limit
or diminish Tenant&rsquo;s liability including Tenant&rsquo;s indemnification obligations under this Lease. Acceptance by Landlord of
delivery of any certificates of insurance does not constitute approval or agreement by Landlord that the insurance requirements in this
<U>Section 8(b)</U> have been met, and failure of Landlord to demand such evidence of full compliance with these insurance requirements
or failure of Landlord to identify a deficiency from certificates or evidence provided will not be construed as a waiver of Tenant&rsquo;s
obligation to maintain such insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Tenant&rsquo;s
insurance obligations set forth herein shall continue in effect throughout the Term and after the Term as long as Tenant, or anyone claiming
by, through or under Tenant, occupies all or any part of the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Tenant will not do or allow anything to be done on the Premises which will increase the rate of insurance on the Building from that
of a general office/laboratory building. If any use of the Premises by Tenant results in an increase in the insurance rate(s) for the
Building, Tenant will pay Landlord, as additional Rent, within thirty (30) days after being billed, any resulting increase in premiums
irrespective of whether Landlord shall have consented to Tenant&rsquo;s act. If Tenant installs, or causes the installation of, any electrical
equipment which overloads the electrical lines, Tenant shall, at its own expense, make all changes to its Premises and install any fire
extinguishing equipment and/or other safeguards that Landlord&rsquo;s insurance underwriters or applicable fire, safety and building
codes and regulations may require. Nothing herein contained shall be deemed to constitute Landlord&rsquo;s consent to such overloading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;
</B>Tenant&rsquo;s insurance may be maintained through blanket policies of insurance with Tenant and Tenant&rsquo;s affiliates provided such
policies provide coverage at least as broad and with limits for this location not less than a separate policy, for this location only,
would provide. In the event Tenant has a net worth of not less than $200,000,000 and Tenant provides financial records documenting same,
in a format acceptable to Landlord, and at all times as requested by Landlord, Tenant shall be permitted to self-insure for the general
liability and property insurance required herein, up to a limit agreed to by Landlord, provided all of the following terms are met: (a)
Tenant shall have the same obligations, duties, and responsibilities to all of the Landlord Additional Insureds as would an insurance
company to its insureds if the insurance required herein was maintained by Tenant on a first dollar (no deductible or self-insured retention)
basis, including, but not limited to, the obligation and duty to defend and indemnify all of the Landlord Additional Insureds and the
duty of fair claims handling practices; (b) Tenant agrees that such self-insurance shall be the primary insurance coverage for any occurrence
or event arising out of, occurring, or resulting from Tenant&rsquo;s operations or use or occupancy of the Premises and shall be deemed
insurance for purposes of any other insurance maintained directly by all of the Landlord Additional Insureds; (c) Tenant agrees that
any insurance maintained by all of the Landlord Additional Insureds shall be in excess of and non-contributory with Tenant&rsquo;s self-insurance;
(d) Tenant waives all claims and its rights of recovery against all of the Landlord Additional Insureds to the same extent as the waiver
of subrogation in the insurance policy, if maintained on a first dollar basis, would have applied; (e) Tenant maintains appropriate loss
reserves which are actuarially derived in accordance with accepted standards of the insurance industry and accrued (i.e. charged against
earnings) or otherwise funded; (f) Tenant shall pay any amounts due in lieu of insurance proceeds because of any self-insurance or retentions,
which amounts shall be treated as insurance proceeds for all purposes under this Lease; and (g) all amounts which Tenant pays or is required
to pay and all loss or damages resulting from risks for which Tenant has elected to self-insure or have self-insured retentions, shall
not limit Tenant&rsquo;s indemnification obligations under this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Notwithstanding anything to the contrary set forth in this Lease, Tenant shall waive and release Landlord Additional Insureds for
any loss or damage to the property, and any resulting loss of use of such property, arising out of fire or other casualty coverable by
a standard &ldquo;Causes of Loss-Special Form&rdquo; property insurance policy with such endorsements and additional coverages as are
considered good business practice in Tenant&rsquo;s business, even if such loss or damage shall be brought about by the fault or negligence
of any of the Landlord Additional Insured or their respective Agents. Notwithstanding anything to the contrary set forth in this Lease,
Landlord shall waive and release Tenant for any loss or damage to its property arising out of fire or other casualty coverable by a standard
 &ldquo;Causes of Loss-Special Form&rdquo; property insurance policy. This waiver and release is effective regardless of whether the releasing
party actually maintains the insurance described above in this subsection and is not limited to the amount of insurance actually carried,
or to the actual proceeds received after a loss. Each party shall have its insurance company that issues its property coverage waive any
rights of subrogation, and shall have the insurance company include an endorsement acknowledging this waiver, if necessary. Tenant assumes
all risk of damage of Tenant&rsquo;s property within or at the Property and any resulting loss of use or business interruption, including,
but not limited to, any loss or damage caused by water leakage, fire, windstorm, explosion, theft, act of any other tenant, or other cause.
Landlord and Tenant acknowledge that the insurance requirements of this Lease reflect their mutual recognition and agreement that each
party will look to its own insurance and that each can best insure against loss to its property and business no matter what the cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Subject
to <U>subsection 8(e)</U> above, and except to the extent caused by the active negligence or willful misconduct of any of the
Landlord Additional Insureds or their Agents, Tenant will indemnify, defend, and hold harmless such Landlord Additional Insureds and
their Agents from and against any and all claims, actions, damages, proceedings, costs, liability and expense (including reasonable
fees of attorneys, investigators and experts) which may be asserted against, imposed upon, or incurred by any of the Landlord
Additional Insureds or their Agents and arising out of or in connection with loss of life, personal injury or damage to property
(i)&nbsp;&nbsp; in or about the Premises during the Term or (ii) arising out of the occupancy or use of the Property by Tenant or
its Agents, whether in contract or tort, occasioned wholly or in part by any active negligence or willful misconduct of Tenant or
its Agents, whether prior to, during or after the Term. Tenant&rsquo;s obligations pursuant to this <U>subsection 8(f)</U> shall
survive the expiration or termination of this Lease with respect to occurrences during the Term. In case any action or proceeding be
brought against any of the Landlord Additional Insureds or their Agents by reason of any such claim, Tenant, upon notice from any of
the Landlord Additional Insureds or their Agents, will, at Tenant&rsquo;s expense, resist and defend such action or proceeding with
counsel acceptable to such Landlord Additional Insureds and their Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(g)</B>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject to <U>subsection 8(e)</U> above, and except to
the extent caused by the active negligence or willful misconduct of any of the Tenant or its Agents, Landlord will indemnify,
defend, and hold harmless such Tenant and its Agents from and against any and all claims, actions, damages, proceedings, costs,
liability and expense (including reasonable fees of attorneys, investigators and experts) which may be asserted against, imposed
upon, or incurred by Tenant or its Agents and arising out of or in connection with loss of life, personal injury or damage to
property, whether in contract or tort, occasioned wholly or in part by any active negligence or willful misconduct of any Landlord
Additional Insured or their Agents, whether prior to, during or after the Term. Landlord&rsquo;s obligations pursuant to this <U>subsection
8(g) </U>shall survive the expiration or termination of this Lease with respect to occurrences during the Term. In case any action
or proceeding be brought against Tenant or its Agents by reason of any such claim, Landlord , upon notice from Tenant or its Agents,
will, at Tenant&rsquo;s expense, resist and defend such action or proceeding with counsel acceptable to Tenant or its their
Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 9.&#8239;&#8239; <B><U>Maintenance and Repairs. </U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Landlord
shall Maintain the Building footings, foundation, structural steel columns and girders (the &ldquo;<B>Building Structure</B>&rdquo;)
at Landlord&rsquo;s sole expense. Subject to reimbursement as an Operating Expense, Landlord shall Maintain: (i) the exterior
utility lines and facilities to the point of connection to/distribution within the Building (unless maintained by the applicable
utility company); (ii) the Building (including the roof but excluding the Building Structure), including the Premises (except to the
extent of Tenant&rsquo;s obligations set forth in <U>Section 9(b) </U>hereof); (iii) the Building Systems; (iv) the Common Areas;
and, (v) any other improvements owned by Landlord located on the Property. If Tenant becomes aware of any condition that is
Landlord&rsquo;s responsibility to repair, replace or maintain, Tenant shall promptly notify Landlord of such condition. Moreover,
regardless of who bears responsibility for any repair, replacement or maintenance, Tenant shall immediately notify Landlord if
Tenant becomes aware of any areas of water intrusion or mold growth in or about the Premises. The cost of repairs to the Common
Areas will be included as an Operating Expenses, except where the repair has been made necessary by misuse or neglect by Tenant or
Tenant&rsquo;s Agents, in which event Landlord will nevertheless make the repair but Tenant will pay to Landlord, as additional
Rent, upon demand, the cost incurred by Landlord to complete such repairs. &ldquo;<B>Maintain</B>&rdquo; means to provide such
maintenance, repair and, to the extent necessary and appropriate, replacement, as may be needed to keep the subject property in good
working order or condition. Maintenance also includes utilizing such building-performance assessment tools and energy-optimizing
practices that Landlord in its discretion reasonably deems necessary and appropriate for planning, designing, installing, testing,
operating and maintaining the Building Systems and Common Areas in an energy efficient manner and providing a safe and comfortable
work environment, with a view toward achieving improved overall Building performance and minimizing the Building&rsquo;s impact on
the environment. &ldquo;<B>Building Systems</B>&rdquo; means any electrical, mechanical, structural, plumbing, HVAC, sprinkler, life
safety or security systems serving the Building. Notwithstanding anything to the contrary set forth in this <U>Section 9(a),</U> if
any part of the Building&rsquo;s roof or structure or any Building Systems requires repair or replacement during the eighteen (18)
months commencing on the Commencement Date, Landlord shall cause such repair or replacement to be made at its cost and expense and
not as an Operating Expense. Landlord may engage a HVAC service contractor at Landlord&rsquo;s sole discretion, to perform routine
maintenance of all Building HVAC units, including those serving the Premises, the cost of which is subject to reimbursement by
Tenant as an Operating Expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Except
as provided in <U>subsection 9(a)</U> above, Tenant, at its sole cost and expense, shall Maintain the Premises and all fixtures and equipment
in the Premises. Tenant, at its sole expense, shall keep the Premises in a neat and orderly condition. Alterations (as defined hereunder),
repairs and replacements to the Property, including the Premises, made necessary because of Tenant&rsquo;s Improvements, Alterations
or installations, any use or circumstances special or particular to Tenant, or any act or omission of Tenant or its Agents shall be made
at the sole expense of Tenant to the extent not covered by any applicable insurance proceeds paid to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 10.&#8239;&#8239;<B><U>Compliance. </U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
will, at its expense, promptly comply with all Laws now or subsequently pertaining to Tenant&rsquo;s use or occupancy of the Premises
including, without limitation, those relating to ADA. Tenant will pay any taxes or other charges by any authority on Tenant&rsquo;s property
or trade fixtures or relating to Tenant&rsquo;s use of the Premises. Neither Tenant nor its Agents shall use the Premises in any manner
that under any Law would require Landlord to make any alteration to or in the Building or Common Areas (without limiting the foregoing,
Tenant shall not use the Premises in any manner that would cause the Premises or the Property to be deemed a &ldquo;place of public accommodation&rdquo;
under the ADA if such use would require any such Alteration). Landlord shall be responsible for compliance with the ADA, and any other
Laws regarding accessibility, with respect to the Common Areas. Tenant shall be responsible for compliance with the ADA, and any other
Laws regarding accessibility, with respect to the Premises. &ldquo;<B>ADA</B>&rdquo; means the Americans with Disabilities Act of 1990
(42 U.S.C. &sect; 1201 et seq.), as amended and supplemented from time to time. As used herein, &ldquo;<B>Laws</B>&rdquo; means any and
all present or future federal, state, municipal, county and other local laws, statutes, ordinances, rules, orders, regulations, directives,
subdivisions, guidelines, common law, and any and all governmental, quasi-governmental, judicial or administrative orders, directives,
decrees, judgments, injunctions, and agreements, and any and all other requirements of federal, state or local governmental authorities,
bureaus, agencies, or offices having jurisdiction over the Property, or of any private association or contained in any restrictive covenants
or other declarations or agreements, now or subsequently pertaining to the Property or the use and occupation of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant will comply, and will cause its Agents to comply, with the Building Rules. Landlord may adopt, and Tenant shall comply with,
reasonable rules and regulations to promote energy efficiency, sustainability and environmental standards for the Property, as the same
may be changed from time to time upon reasonable notice to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 24; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>Landlord
represents to Tenant that to Landlord&rsquo;s actual knowledge, there are not Hazardous Materials (as defined hereunder) located in
the Premises or the Building that require any remediation. Tenant agrees that (i) no activity will be conducted on the Premises that
will use or produce any Hazardous Materials, except for activities which are part of the ordinary course of Tenant&rsquo;s business
and are conducted in accordance with all Environmental Laws (as defined hereunder) (&ldquo;<B>Permitted Activities</B>&rdquo;); (ii)
the Premises will not be used for storage of any Hazardous Materials, except for materials used in the Permitted Activities which
are properly stored in a manner and location complying with all Environmental Laws; (iii) no portion of the Premises or Property
will be used by Tenant or Tenant&rsquo;s Agents for disposal of Hazardous Materials; (iv) Tenant will deliver to Landlord copies of
all Material Safety Data Sheets and other written information prepared by manufacturers, importers or suppliers of any chemical; (v)
Tenant will immediately notify Landlord of any violation by Tenant or Tenant&rsquo;s Agents of any Environmental Laws or the release
or suspected release of Hazardous Materials in, under or about the Premises, and Tenant shall immediately deliver to Landlord a copy
of any notice, filing or permit sent or received by Tenant with respect to the foregoing; and (vi) Tenant will cooperate with
Landlord, any Mortgagee or any purchaser of the Property in their environmental assessments of the Property, including without
limitation, participation in interviews regarding the uses and environmental conditions at or affecting the Property, and providing
reasonable access to the Premises. &ldquo;<B>Environmental Laws</B>&rdquo; means all present or future federal, state or local laws,
ordinances, rules or regulations (including the rules and regulations of the federal Environmental Protection Agency and comparable
state agency) relating to the protection of human health or the environment. &ldquo;<B>Hazardous Materials</B>&rdquo; means
pollutants, contaminants, toxic or hazardous wastes or other materials the removal of which is required or the use of which is
regulated, restricted, or prohibited by any Environmental Law. If at any time during or after the Term, any portion of the Property
is found to be contaminated by Tenant or Tenant&rsquo;s Agents or subject to conditions prohibited in this Lease caused by Tenant or
Tenant&rsquo;s Agents, Tenant will indemnify, defend and hold Landlord harmless from all claims, demands, actions, liabilities,
costs, expenses, attorneys&rsquo; fees, damages and obligations of any nature arising from or as a result thereof, and Landlord
shall have the right to direct remediation activities, all of which shall be performed at Tenant&rsquo;s cost. Tenant&rsquo;s
obligations pursuant to this subsection shall survive the expiration or termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Landlord
acknowledges that it is not the intent of this <U>Section 10</U> to prohibit Tenant from using the Premises for the Permitted Use.
Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is
strictly and property monitored according to all then applicable Environmental Laws and the terms of this Lease. As a material
inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to
Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored,
handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals
or permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such
Hazardous Materials on or from the Premises (&ldquo;<B>Hazardous Materials List</B>&rdquo;). The initial Hazardous Materials List is
attached hereto as <B>Exhibit &ldquo;G&rdquo;</B>. Tenant shall deliver to Landlord an updated Hazardous Materials List at least
once a year and shall also deliver an updated list before any new Hazardous Material is brought onto, kept, used, stored, handled,
treated, generated on, or released or disposed of from, the Premises. Tenant shall deliver to Landlord true and correct copies of
the following documents (&ldquo;<B>Haz Mat Documents</B>&rdquo;) relating to the use, storage, handling, treatment, generation,
release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time, concurrent with the
receipt from or submission to a Governmental Authority: permits; approvals; reports and correspondence; storage and management
plans, notice of violations of any Laws; plans relating to the installation of any storage tanks to be installed in or under the
Project (provided, said installation of tanks shall only be permitted after Landlord has given Tenant its written consent to do so,
which consent may be withheld in Landlord&rsquo;s sole and absolute discretion); all closure plans or any other documents required
by any and all federal, state and local Governmental Authorities for any storage tanks installed in or on the Premises for the
closure of any such tanks; and a Surrender Plan. Tenant is not required, however, to provide Landlord with any portion(s) of the Haz
Mat Documents containing information of a proprietary nature which, in and of themselves, do not contain a reference to any
Hazardous Materials or hazardous activities. It is not the intent of this Section to provide Landlord with information which could
be detrimental to Tenant&rsquo;s business should such information become possessed by Tenant&rsquo;s competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(e) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In addition,
Tenant shall, at Tenant&rsquo;s sole expense, comply in all respects with all Laws applicable now or in the future to the handling, transportation,
generation, management, disposal, processing, treatment, storage and use of (i) &ldquo;chemotherapeutic waste&rdquo; and &ldquo;infectious
waste&rdquo; as each term in defined under all laws applicable now or in the future, (ii) &ldquo;radioactive waste&rdquo; as defined under
all Laws applicable now or in the future, (iii) human corpses, remains and anatomical parts that are donated and used for scientific or
medical education, research or treatment, (iv) body fluids or biologicals which are being stored at a laboratory prior to laboratory testing,
(v) similar laboratory wastes and materials, or (vi) discarded sharps used in patient care, medical research or laboratories, including
but not limited to hypodermic, intravenous, and other medical needles and syringes, scalpel blades, blood vials and glassware in contact
with infectious waste, including slides and cover slips at the Premises (&ldquo;<B>Regulated Waste</B>&rdquo;). Tenant solely is responsible
for obtaining, at Tenant&rsquo;s expense, any and all governmental permits or approval (&ldquo;<B>Permits</B>&rdquo;) required to handle,
transport, generate, manage, dispose, process, treat, store or use Regulated Waste at the Premises. Tenant shall comply in all respects
with all terms and conditions of such Permits. Under no circumstances shall Tenant be permitted under this Lease to accept at the Premises
for processing, treatment, storage, use, or disposal any radioactive, infectious or chemotherapeutic waste generated by any other entity
or facility. This Section should not be interpreted to abridge or to modify Tenant&rsquo;s obligation under this Lease to comply with
any other provision of any Law including, without limitation, Tenant&rsquo;s responsibility to comply with Environmental Laws governing
Hazardous Materials. Tenant, at its expense, shall defend, indemnify and hold harmless Landlord, Landlord&rsquo;s Affiliates and Landlord&rsquo;s
Affiliated Officers from and against any claims, damages, liabilities, losses, actions, and/or lawsuits, including, without limitation,
personal injury or property damage, arising from or related to (i) Tenant&rsquo;s breach of its covenants contained in this Section, (ii)
Tenant&rsquo;s handling, transportation, generation, management, disposal, processing, treatment, storage and/or use of Regulated Waste,
or (iii) the presence of any Regulated Waste at the Premises as a result of the activities of Tenant or any of its Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(f) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Without
limiting any of the foregoing, Tenant shall have the obligation and liability to treat, handle or dispose of its Regulated Waste at its
sole cost and expense and accordingly shall obtain its own Regulated Waste disposal vendor. Notwithstanding the foregoing, Tenant shall
be permitted to store its Regulated Waste in a location designated within the Premises by Tenant for such purpose and in an appropriate
container.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">11. <B><U>Signs</U></B>. <B>(a)</B>
Landlord will furnish Tenant Building standard identification signage on or beside the main entrance door to the Premises in
accordance with Landlord&rsquo;s standard graphics program for the Building and in accordance with all applicable State, Municipal
and County Laws and regulations, including without limitation, the requirements of the City of Phoenix and the Cotton Center
CCR&rsquo;s and the Allred CC&amp;Rs. Except as expressly permitted in this <U>Section 11</U>, Tenant shall not place any signs,
graphics, notice, picture, placard or poster, or any advertising matter whatsoever on the exterior of the Premises, Building, or the
Property, or make or permit any changes in or to Tenant&rsquo;s signage, without the prior consent of Landlord, in its sole
discretion, other than signs that are located wholly within the interior of the Premises and not visible from the exterior of the
Premises. Tenant shall maintain all signs installed by Tenant in good condition. Tenant shall remove its signs at the termination of
this Lease, shall repair any resulting damage, and shall restore the Premises and/or the Property to its condition existing prior to
the installation of Tenant&rsquo;s signs. Landlord shall have the right to install and maintain signs on the exterior and interior
of the Building, provided any such signs for other tenants are not above Tenant&rsquo;s window lines, and do not materially
interfere with Tenant&rsquo;s signage rights herein. In the event Tenant leases the Expansion Space, as defined in <U>Section 30</U>
below, then Tenant&rsquo;s signage rights shall be exclusive. Tenant will not have the right to have additional names placed on the
Building directory without Landlord&rsquo;s prior written consent. Tenant shall bear the cost of any additional names placed on the
Building directory approved by Landlord or any changes required to any existing sign due to a name change by Tenant. In the event
that Tenant desires to change its name on the Building directory or on any sign, Tenant shall provide an explanation to Landlord of
the circumstances prompting the need for such name change. If any sign for which this Lease requires Landlord&rsquo;s approval has
not been approved by Landlord is displayed, then Landlord shall, upon reasonable prior notice to Tenant, have the right to remove
such sign at Tenant&rsquo;s expense or to require Tenant to do the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the restriction in <U>Section 11(a)</U> and subject to compliance with all applicable state, municipal and county regulations, and any
other applicable covenants, so long as Tenant or a Permitted Transferee leases more rentable square feet of the Building than any other
tenant, then Tenant shall, subject to the terms of this <U>Section 11</U> and at Tenant&rsquo;s sole cost and expense, have the right
to install one (1) building mounted identification sign (&ldquo;<B>Building Mounted Sign</B>&rdquo;) in a location along the facade of
the Building that is the exterior to the Premises, as long as such location is approved by Landlord, and in compliance with all applicable
Laws, and in a size and design consistent with the location, size, terms, conditions, and restrictions set forth in <B>Exhibit &ldquo;H&rdquo;</B>,
attached hereto, identifying Tenant&rsquo;s name. The size of such Building Mounted Sign shall be equal to the maximum size of exterior
signage permitted by applicable Maricopa County / City of Phoenix regulation or any other applicable Law (which maximum size may also
be limited by monument and directional signage in the complex), provided such sign does not exceed the size of the sign ban, cover any
applicable window or otherwise exceed the parameters set forth in <B>Exhibit &ldquo;H&rdquo;</B>. Landlord shall have the right to allow
other tenants to install such signs on any portion of the of the Building on the exterior to the premises leased by such tenants and Landlord
shall have the right in Landlord&rsquo;s reasonable discretion to cause Tenant, at Tenant&rsquo;s expense, to change the size and location
of Tenant&rsquo;s Building Mounted Sign so that Tenant&rsquo;s exterior sign does not exceed fifty-seven percent (57%) of the maximum
sign of exterior signage permitted by applicable Maricopa County / City of Phoenix regulation or any other applicable Law (which maximum
size may also be limited by monument and directional signage in the complex) as Landlord determines reasonably necessary to allow for
additional exterior signs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The conditions
of Tenant&rsquo;s right to install such Building Mounted Sign are and shall be that (i) Tenant shall be responsible for obtaining all
necessary zoning and code approvals from Maricopa County / City of Phoenix, as well as any other governmental approvals at Tenant&rsquo;s
sole cost and expense, provided that Landlord shall use reasonable efforts to cooperate with Tenant in obtaining such approvals, (ii)
Tenant shall, at its sole cost and expense, be responsible for obtaining all approvals, if any, required under protective covenants applicable
to the Building, provided that Landlord shall use reasonable efforts to cooperate with Tenant in obtaining such approvals, (iii) the method
of mounting the sign on the Building shall be subject to the prior written approval of Landlord, which is hereby granted to the extent
such sign is depicted on <B>Exhibit &ldquo;H&rdquo;</B>, (iv) the final location of such sign shall be subject to Landlord&rsquo;s prior
written approval, (v) Tenant shall pay the cost of mounting and installing such sign, using a contractor approved in advance by Landlord,
(vi) Tenant shall be solely responsible for the electrical supply necessary to light the sign, if applicable, and for obtaining a separate
meter from the appropriate utility provider for such sign, (vii) if at any time after the Commencement Date has occurred, Tenant, its
Permitted Transferees and Strategic Partners occupy less than fifty percent (50%) of the rentable square feet in the Building and Tenant
is not leasing a premises larger than any other tenant of the Building, Landlord shall have the right to require Tenant to remove the
Building Mounted Sign at Tenant&rsquo;s expense upon thirty (30) days&rsquo; prior written notice to Tenant, (viii) if at any time an
Event of Default shall have occurred and be continuing, then in addition to any other remedies Landlord may have under this Lease, Landlord
shall have the right to remove Tenant&rsquo;s Building Mounted Sign and restore the exterior of the Building at Tenant&rsquo;s cost and
expense, and (ix) upon the expiration or earlier termination of this Lease, Tenant shall remove and bear the cost of removal of the Tenant&rsquo;s
Building Mounted Sign, and shall pay, within thirty (30) days after request therefor (together with reasonable evidence supporting such
cost) for the restoration of the exterior of the Building if exterior is damaged by such removal. Notwithstanding anything to the contrary
contained herein, Tenant shall have the right to transfer its signage rights to an approved Transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
any sign for which this Lease requires Landlord&rsquo;s approval has not been approved by Landlord is displayed, then Landlord shall,
upon reasonable prior notice to Tenant, have the right to remove such sign at Tenant&rsquo;s expense or to require Tenant to do the same.
Landlord reserves the right to install and display signs, advertisements and notices on any part of the exterior or interior of the Building;
provided, however, that Landlord shall only affix, install, or display signs on the interior of the Premises which pertain to the management
or operation of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 12. <B><U>Alterations</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
for non-structural Alterations that (i) do not exceed One Hundred Thousand and 00/100 Dollars ($100,000.00), (ii) are not visible
from the exterior of the Premises, (iii) do not affect any Building System, the roof, or the structural strength of the Building
(iv) do not require penetrations into the floor, ceiling or walls, and (v) do not require work within the walls, below the floor or
above the ceiling, Tenant shall not make or permit any Alterations in or to the Premises without first obtaining Landlord&rsquo;s
consent, and unless such alterations affect the structural elements of the Building, the Common Areas or Building Systems, or would
otherwise require a building permit. With respect to any Alterations made by or on behalf of Tenant (whether or not the Alteration
requires Landlord&rsquo;s consent): (i) not less than ten (10) days prior to commencing any Alteration, Tenant shall deliver to
Landlord for Landlord&rsquo;s review and approval the plans, specifications and necessary permits for the Alterations (the
 &ldquo;<B>Alteration Plans</B>&rdquo;), together with certificates evidencing that Tenant&rsquo;s contractors and subcontractors
have adequate insurance coverage naming the Landlord Additional Insureds, as their interests may appear, as additional insureds;
(ii) Tenant shall obtain Landlord&rsquo;s prior written approval of any contractor or subcontractor, which such approval shall not
be unreasonably withheld, conditioned or delayed; (iii) the Alteration shall be constructed with new materials, in a good and
workmanlike manner, and in compliance with all Laws and the plans and specifications delivered to, and, if required above, approved
by Landlord; (iv) the Alteration shall be performed in accordance with Landlord&rsquo;s reasonable requirements relating to
sustainability and energy efficiency; and (v) upon Landlord&rsquo;s request Tenant shall, prior to commencing any Alteration,
provide Landlord reasonable security against liens arising out of such construction. &ldquo;<B>Alteration(s)</B>&rdquo; means any
addition, alteration or improvement to the Premises or Property including Tenant&rsquo;s Improvements and FFE (as defined below).
Any Alteration by Tenant shall be the property of Tenant until the expiration or termination of this Lease; at that time without
payment by Landlord the Alteration shall remain on the Property and become the property of Landlord unless Landlord gives notice to
Tenant at the time Landlord approves such Alteration or if Landlord&rsquo;s approval is not required at least four (4) months prior
to the Expiration Date, provided that if this Lease is terminated earlier then no advance notice is required, to remove any of such
Alterations, in which event Tenant will remove them, will repair any resulting damage and will restore the Premises to the condition
existing prior to Tenant&rsquo;s installation of such Alteration(s), all in accordance with the terms of <U>Section 21(a)</U>
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord&rsquo;s
review or approval of any Alterations or plans or specifications therefor shall not be a representation or warranty of Landlord that such
Alterations, plans or specifications are fit for any use or comply with any Laws, and Tenant shall have no right to rely upon any review
or approval. Landlord shall have no liability to Tenant or any third party by reason of such review or approval, and any such review and
approval shall be for Landlord&rsquo;s own benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All workmen and
mechanics performing any Alterations must work in harmony and not interfere with labor employed by Landlord, Landlord&rsquo;s contractors
or labor employed by any other tenants or their contractors. If at any time during the course of the installation of any Alterations,
any workmen or mechanics performing the Alterations are unable to work in harmony, or interfere, with labor employed by Landlord, Landlord&rsquo;s
contractors or by any other tenants or their contractors, then the approval granted by Landlord to Tenant for the subject Alterations
may be withdrawn by Landlord upon forty eight (48) hours&rsquo; written notice to Tenant, and Tenant shall thereafter cause the Alterations
to cease, and shall at Landlord&rsquo;s sole option restore the Premises to the condition that existed prior to the commencement of such
Alteration. Tenant shall indemnify, defend and hold Landlord and its Agents harmless from and against any claim, liability or other losses
in any way arising from labor disharmony in connection with any Alterations or any other contractors or employees of Tenant, its subtenants,
successors or assigns. Landlord reserves the right to require Tenant to use contractors designated by Landlord, in its sole discretion,
for Alterations that are performed in secure areas of the Building or other portions of the Building outside of the Premises or which
impact any Building Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">13.&nbsp; <B><U>Mechanics&rsquo;
Liens</U></B>. Except to the extent contracted for by Landlord, the interest of Landlord in the Premises and the Property shall not be
subject in any way to any liens, including real estate commission liens and construction liens for improvements to or other work performed
by or on behalf of Tenant. Tenant promptly shall pay for any labor, services, materials, supplies or equipment furnished to Tenant in
or about the Premises. Tenant shall keep the Premises and the Property free from any liens arising out of any labor, services, materials,
supplies or equipment furnished or alleged to have been furnished to Tenant. Tenant shall take all steps permitted by law in order to
avoid the imposition of any such liens including a written provision in all construction contracts for suppliers of labor, services, materials
and equipment, approved in writing by Landlord prior to execution, that this Lease prohibits mechanics/construction liens against the
Premises and the Property. Should any such lien or notice of such lien be filed against the Premises or the Property, Tenant shall discharge
the same by satisfying or bonding over such lien within fifteen (15) days after Tenant has notice that the lien or claim is filed regardless
of the validity of such lien or claim. It is further understood and agreed that under no circumstance is the Tenant to be deemed the agent
of Landlord for any Alteration, repair, or construction within the Premises, the same being done at the sole expense and request of Tenant
and not as an express or implied agent of Landlord. All contractors, materialmen, suppliers, mechanics, and laborers are hereby charged
with notice that they must look only to Tenant for the payment of any charge for work done or materials furnished upon the Premises in
connection with any Tenant Improvements, Alterations, repair or construction by Tenant within the Premises during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 14. <B><U>Landlord&rsquo;s Rights</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall permit Landlord and its Agents to enter the Premises at all reasonable times following reasonable notice (but in no event
less than one business day except in an emergency) to inspect, perform any work to Maintain, or make alterations to the Premises or the
Property, to exhibit the Premises for the purpose of sale or financing, and, during the last twelve (12) months of the Term, to exhibit
the Premises to any prospective tenant for the Premises. Except in the event of an emergency, Landlord shall adhere to Tenant&rsquo;s
safety and cleanliness procedures and policies, including any of Tenant&rsquo;s &lsquo;advertised gown guidelines&rsquo; for entering
into any laboratory areas, and Tenant shall have the right to require Landlord to be escorted by an employee or representative of Tenant.
Landlord will make reasonable efforts not to inconvenience Tenant in exercising such rights. Tenant will provide Landlord or its designees
free and unfettered access to any mechanical or utility rooms, conduits, risers or the like located within the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to any other rights provided for herein and provided Landlord uses commercially reasonable efforts to limit any
interference with Tenant&rsquo;s use of or access to the Premises, Landlord reserves the following rights, exercisable without
liability to Tenant for damage or injury to property, person, or business and without effecting an eviction, constructive or actual,
or disturbance of Tenant&rsquo;s use or possession or giving rise to any claim: (i) to name the Building and to change the name or
street address of the Building or the roads leading to and from the Building or the Land; (ii) to relocate various facilities within
the Building and on the Land, including, without limitation, lobby areas, mechanical areas, entrances or passageways, doors or
doorways, corridors, elevators, stairs, toilets or other Common Areas; access to and from the Building; or the configuration of the
parking areas; (iii) to install vending machines of all kinds in the Building (but not the Premises) and to receive all of the
revenue derived therefrom; (iv) when reasonably necessary to temporarily close the Parking Area or any part thereof, walkways,
drives, entrances, doors, corridors, elevators or other facilities; (v) to subdivide the Property; (vi) to subject all or any part
of the Property to a condominium regime; (vii)&nbsp;&nbsp; to pursue, or allow any tenant or prospective Property purchaser to
pursue, any variance or other zoning relief which Landlord shall, in its good faith judgment, determine to be advisable;
(viii)&nbsp; to unilaterally alter Tenant&rsquo;s ingress and egress to the Building or make any change in operating conditions to
restrict pedestrian, vehicular or delivery ingress and egress to a particular location, or at any time close temporarily any Common
Areas to make repairs or changes therein or to effect construction, repairs or changes within the Building or on the Land on which
the Building is located, or to discourage non-tenant parking, and may do such other acts in and to the Common Areas as in
Landlord&rsquo;s sole judgment may be desirable to improve their convenience; (ix)&nbsp; to use and/or allow others to use the roof
of the Building or any portion of the Land on which the Building is located; (x) to limit the space on the directory of the Building
to be allotted to Tenant; and, (xi) to grant to anyone the right to conduct any particular business or undertaking in the
Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
No rights, easements or licenses are acquired in the Property or any land adjacent to the Property by Tenant by implication or otherwise
except as expressly set forth in this Lease. Any diminution or shutting off of light air or view by any structure which may be erected
on lands adjacent to the Building shall in no way effect this Lease or impose any liability on Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If Tenant breaches any covenant or condition of this Lease, in addition to all other remedies available to Landlord under this Lease,
Landlord may, on prior notice to Tenant (except that no notice need be given in case of emergency), cure such breach at the expense of
Tenant, and the reasonable amount of all expenses, including attorney&rsquo;s fees, incurred by Landlord in so doing (whether paid by
Landlord or not) will be deemed payable on demand as additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 15. <B><U>Damage by Fire or Other Casualty.</U></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>If the Premises or Common Areas shall be damaged or destroyed by fire or other casualty, Tenant shall promptly notify Landlord, and
Landlord, subject to the conditions set forth in this <U>Section 15</U>, shall repair such damage and restore the Premises or Common Areas
to substantially the same condition in which they were immediately prior to such damage or destruction, but not including the repair,
restoration or replacement of the Tenant Improvements, FFE or any Alterations installed by or on behalf of Tenant. Landlord shall notify
Tenant, within thirty (30) days after the date of the casualty, if Landlord anticipates that the restoration will take more than one hundred
eighty (180) days from the date of the casualty to complete; in such event, either Landlord or Tenant (unless the damage was caused by
Tenant) may terminate this Lease effective as of the date of casualty by giving notice to the other within ten (10) days after Landlord&rsquo;s
notice. If a casualty occurs during the last twelve (12) months of the Term that materially affects Tenant&rsquo;s use of or access to
the Premises, either Tenant Landlord may terminate this Lease; provided that if Landlord exercises such termination right and Tenant has
the right to extend the Term for at least three (3) more years and does so within thirty (30) days after the date of the casualty, such
termination shall not be effective. Moreover, Landlord may terminate this Lease if the loss is not substantially covered by the insurance
maintained or required to be maintained by Landlord under this Lease or if any holder of a Mortgage on the Land or Building does not permit
or release a substantial portion of the insurance proceeds for such repair or restoration. Tenant will receive an abatement of Minimum
Annual Rent and Annual Operating Expenses and Additional Taxes to the extent the Premises are rendered untenantable as a result of the
casualty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant hereby expressly waives the benefit of A.R.S. &sect;33-343 or any other or statute now or hereafter in effect which would otherwise
afford Tenant the right to terminate this Lease or its obligations hereunder due to damage to or destruction of the Premises and agrees
that the terms of this Lease shall govern the effect of any damage and destruction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">16.&nbsp; <B><U>Condemnation.</U>&#8239;</B>If
(a) all of the Premises are Taken (as defined hereunder), (b) any part of the Premises is Taken and the remainder is insufficient in
Landlord&rsquo;s opinion for the reasonable operation of Tenant&rsquo;s business, or (c) any of the Property is Taken, and, in
Tenant or Landlord&rsquo;s opinion, it would be impractical or the condemnation proceeds are insufficient to restore the remainder,
then this Lease shall terminate as of the date the condemning authority takes possession. If this Lease is not terminated, to the
extent that proceeds are paid to Landlord and made available by the holder of a Mortgage on the Land or the Building, Landlord shall
restore the Building to a condition as near as reasonably possible to the condition prior to the Taking, the Minimum Annual Rent
shall be abated for the period of time all or a part of the Premises is untenantable in proportion to the square foot area
untenantable, and this Lease shall be amended appropriately. The compensation awarded for a Taking shall belong to Landlord. Except
for any relocation benefits to which Tenant may be entitled, Tenant hereby assigns all claims against the condemning authority to
Landlord, including, but not limited to, any claim relating to Tenant&rsquo;s leasehold estate. &ldquo;<B>Taken</B>&rdquo; or
 &ldquo;<B>Taking</B>&rdquo; means acquisition by a public authority having the power of eminent domain by condemnation or conveyance
in lieu of condemnation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">17. <B><U>Quiet
Enjoyment.</U>&#8239;</B>Landlord covenants that Tenant, upon performing all of its covenants,agreements and conditions of this Lease,
shall have quiet and peaceful possession of the Premises as against anyone claiming by or through Landlord, subject, however, to the
terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 18. <B><U>Assignment and Subletting</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Except
as provided in <U>Section 18(b)</U> below, Tenant shall not enter into nor permit any Transfer (as defined hereunder) voluntarily or
by operation of law, without the prior consent of Landlord. Without limitation, Tenant agrees that Landlord&rsquo;s consent shall
not be considered unreasonably withheld if (i) the business, business reputation, or creditworthiness of the proposed transferee is
unacceptable to Landlord, in Landlord&rsquo;s sole discretion, (ii) Landlord or an affiliate of Landlord has comparable space
(including without limitation comparable size, finishes, function, parking and location) available for lease by the proposed
transferee, the intention being that Tenant shall not compete with Landlord in the leasing market, (iii) the proposed transferee is
a governmental agency or a quasi-governmental entity or any other person or entity entitled, directly or indirectly, to diplomatic
or sovereign immunity, regardless of whether the proposed transferee agrees to waive such diplomatic or sovereign immunity, or shall
not be subject to the service of process in, or the jurisdiction of the courts of, the State of Arizona; or (iv) an Event of Default
(as defined below) exists, or Tenant is in default under this Lease or any act or omission has occurred which would constitute a
default with the giving of notice and/or the passage of time. A consent to one Transfer shall not be deemed to be a consent to any
subsequent Transfer. In no event shall any Transfer relieve Tenant from any obligation under this Lease. Landlord&rsquo;s acceptance
of Rent from any person shall not be deemed to be a waiver by Landlord of any provision of this Lease or to be a consent to any
Transfer. Any Transfer not in conformity with this <U>Section 18</U> shall be void at the option of Landlord or its Mortgagee.
 &ldquo;<B>Transfer</B>&rdquo; means (i) any assignment, transfer, pledge or other encumbrance of all or a portion of Tenant&rsquo;s
interest in this Lease, (ii) any sublease, license or concession of all or a portion of Tenant&rsquo;s interest in the Premises, or
(iii) any transfer of a controlling interest in Tenant, other than as part of an initial public offering of stock in Tenant on a
national stock exchange. For the purpose of this definition, &ldquo;transfer of a controlling interest of Tenant&rdquo; means either
(i) ownership or voting control, directly or indirectly, or at least fifty (50%) percent of all equity or other beneficial interest
or (ii) the power to direct the management and policies of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>Notwithstanding
the provisions of <U>Section 18(a)</U> above, Landlord&rsquo;s consent shall not be required, and Sections 18 (c) and (d) shall not
apply, in the event of any Transfer by Tenant to an Affiliate (as defined hereunder) provided that (i) the Affiliate has a tangible
net worth at least equal to that of Tenant as of the Commencement Date of this Lease, (ii) Tenant provides Landlord notice of the
Transfer at least fifteen (15) days prior to the effective date of the Transfer, together with current financial statements of the
Affiliate certified by an executive officer of the Affiliate and a copy of the proposed Transfer documents, and (iii) in the case of
an assignment or sublease, Tenant delivers to Landlord an assumption agreement or a sublease (as applicable) reasonably acceptable
to Landlord executed by Tenant and the Affiliate, together with a certificate of insurance and appropriate endorsements evidencing
the Affiliate&rsquo;s compliance with the insurance requirements of Tenant under this Lease. &ldquo;<B>Affiliate</B>&rdquo; means
(x) any entity controlling, controlled by, or under common control of, Tenant, (y) any successor to Tenant by merger, consolidation
or reorganization, or (z) any purchaser of all or substantially all of the assets or equity of Tenant as a going concern. The term
 &ldquo;Permitted Transferee&rdquo; shall mean an Affiliate that meets the conditions set form in subsections 15(b)(i) through (iii)
above. Further, Landlord&rsquo;s consent, shall not be required but notice shall be provided to Landlord prior to the commencement
of occupancy, and Sections 18 (c) and (d) shall not apply to any occupancy of less than 2,000 rentable square feet by any
 &ldquo;Strategic Partners&rdquo; of Tenant on a short term or specific project basis. A Strategic Partner means a non-affiliated
company with whom Tenant or a Tenant Affiliate is participating in ongoing research and development, testing, marketing, or
consulting relating to the business of Tenant. Tenant shall be responsible for any and all actions or inactions of any Strategic
Partner (and its employees, agents and invitees) in, on or about the Premises or Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
provisions of <U>subsection 18(a)</U> above notwithstanding, if Tenant proposes to Transfer all of the Premises (other than to an Affiliate)
for all or substantially all the then remaining Term, Landlord may terminate this Lease, either conditioned on execution of a new lease
between Landlord and the proposed transferee or without that condition. If this Lease is not so terminated , Tenant shall pay to Landlord,
immediately upon receipt, fifty percent (50%) of the excess of (i) all compensation received by Tenant for the Transfer over (ii) the
Rent allocable to the Premises and Term transferred, after Tenant has recouped from such excess all brokers&rsquo; commissions, legal
fees, and tenant improvement costs and allowances incurred by Tenant in connection with such Transfer and the unamortized portion of
Tenant&rsquo;s investment in Tenant Improvements and Alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
Tenant requests Landlord&rsquo;s consent to a Transfer, Tenant shall provide Landlord, at least fifteen (15) days prior to the proposed
Transfer, current financial statements of the transferee certified by an executive officer of the transferee, a complete copy of the
proposed Transfer documents, and any other information Landlord reasonably requests. If Landlord fails to approve such Transfer within
fifteen (15) days after Landlord&rsquo;s receipt of all requested materials, Landlord&rsquo;s consent to such Transfer shall be deemed
rejected. Immediately following any approved assignment or sublease, Tenant shall deliver to Landlord an assumption agreement or a sublease
(as applicable) reasonably acceptable to Landlord executed by Tenant and the transferee, together with a certificate of insurance evidencing
the transferee&rsquo;s compliance with the insurance requirements of Tenant under this Lease. Each sublease will provide that such sublessee&rsquo;s
rights will be no greater than those of Tenant, and that the sublease is subject and subordinate to this Lease and to the matters to
which this Lease is or will be subordinate, and that upon an Event of Default, Landlord may, at its option, have such sublessee attorn
to Landlord or require that such sublessee pay its rent due to Tenant directly to Landlord, provided, however, in such case Landlord
will not (i) be liable for any previous act or omission of Tenant under such sublease or, (ii) be subject to any offset not expressly
provided for in this Lease or by any previous prepayment of more than one month&rsquo;s rent. Landlord shall apply any amounts received
from the Transferee as rent to Tenant&rsquo;s obligations under this Lease. The liability of Tenant and each assignee or sublessee will
be joint, several and primary for the observance of all the provisions, obligations and undertakings of this Lease, including the payment
of Rent through the entire Term, as the same may be renewed, extended or otherwise modified. The proposed assignee or subtenant may use
the Premises for the permitted Use only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>Tenant
acknowledges that Landlord will incur costs in connection with any Transfer under this Lease. Accordingly, Tenant shall promptly pay
to Landlord the amount (&ldquo;<B>Transfer Charge</B>&rdquo;) of all costs (including, without limitation, Landlord&rsquo;s
reasonable attorney&rsquo;s fees) actually incurred by Landlord in connection with any Transfer, not to exceed $2.500 without
Tenant&rsquo;s prior approval. Tenant shall pay the Transfer Charge even in the event that a proposed Transfer is not
effectuated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 19. <B><U>Subordination; Mortgagee&rsquo;s Rights</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
accepts this Lease subject and subordinate to any Mortgage of the entire Building and/or Land affecting the Premises, which may now or
in the future be secured upon the Building and/or Land, and to all renewals, modifications, consolidations, replacements and extensions
thereof, provided that Tenant&rsquo;s right of possession of the Premises shall not be disturbed by the Mortgagee so long as an Event
of Default does not exist. This clause shall be self-operative, and although no instrument or act on the part of Tenant will be necessary
to effectuate such subordination, Tenant will, nevertheless, in confirmation of such subordination, within ten (10) business days after
request, execute and deliver any further instruments confirming the subordination of this Lease and any further instruments of attornment
that the Mortgagee may reasonably request. However, any Mortgagee may at any time subordinate its Mortgage to this Lease, without Tenant&rsquo;s
consent, by giving notice to Tenant, and this Lease shall then be deemed prior to such Mortgage without regard to their respective dates
of execution and delivery; provided that such subordination shall not affect any Mortgagee&rsquo;s rights with respect to condemnation
awards, casualty insurance proceeds, intervening liens or any right which shall arise between the recording of such Mortgage and the
execution of this Lease. Notwithstanding the foregoing, the party holding the instrument to which this Lease is subordinate shall have
the right to recognize and preserve this Lease in the event of any foreclosure sale or possessory action, and in such case this Lease
shall continue in full force and effect at the option of the party holding the superior lien and Tenant shall attorn to such party and
shall execute, acknowledge and deliver any instrument that has for its purpose and effect the confirmation of such attornment within
ten (10) business days after request. Tenant waives the protection of any statute or rule of law that gives or purports to give Tenant
any right to terminate this Lease or surrender possession of the Premises upon the transfer of Landlord&rsquo;s interest. &ldquo;<B>Mortgage</B>&rdquo;
means any mortgage, deed of trust or other lien or encumbrance on Landlord&rsquo;s interest in the Property or any portion thereof, including
without limitation any ground or master lease if Landlord&rsquo;s interest is or becomes a leasehold estate. &ldquo;<B>Mortgagee</B>&rdquo;
means the holder of any Mortgage, including any ground or master lessor if Landlord&rsquo;s interest is or becomes a leasehold estate.
Notwithstanding the foregoing, Landlord will use commercially reasonable efforts to obtain a non-disturbance, subordination and attornment
agreement from Landlord&rsquo;s current Mortgagee on such Mortgagee&rsquo;s current standard form of agreement or such other commerically reasonable
form as is acceptable to such Mortgagee. Landlord shall not be required to incur any cost, expense or liability to obtain such agreement,
it being agreed that Tenant shall be responsible for any fee or review costs charged by the Mortgagee. Upon request of Landlord and provided
such form is commerically reasonable, Tenant will execute the Mortgagee&rsquo;s form of non-disturbance, subordination and attornment
agreement or such other agreed to form and return the same to Landlord for execution by the Mortgagee. Landlord&rsquo;s inability to obtain
a non-disturbance, subordination and attornment agreement for Tenant shall have no effect on the rights, obligations and liabilities
of Landlord and Tenant or be considered to be a default by Landlord hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Mortgagee shall be (i) liable for any previous act or omission of a prior landlord, (ii) subject to any rental offsets or defenses
hereunder because of any act or omission of any prior landlord, (iii) bound by any amendment of this Lease made without its written
consent, (iv) bound by payment of Monthly Rent more than one month in advance or liable for any other funds paid by Tenant to
Landlord unless such funds actually have been transferred to the Mortgagee by Landlord, or (v) liable for any security not actually
received by it. Subject to the foregoing, the provisions hereof shall be binding upon and inure to the benefit of the successors and
assigns of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>The
provisions of <U>Section 15</U> and <U>Section 16</U> above notwithstanding, Landlord&rsquo;s obligation to restore the Premises after
a casualty or condemnation shall be subject to the consent and prior rights of any Mortgagee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
shall send to each Mortgagee of any Mortgage covering the Property or any part thereof (after notification of the identity of such mortgagee
and the mailing address thereof) copies of all notices of default, termination, or renewal that Tenant sends to Landlord; such notices
to said Mortgagee shall be sent in the same manner and time as notices are required to be sent pursuant to <U>Section 25</U> hereof.
Tenant will accept performance of any provision of this Lease by such Mortgagee as performance by, and with the same force and effect
as though performed by, Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 20. <B><U>Tenant&rsquo;s Certificate; Financial Information; Confidentiality</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
ten (10) business days after Landlord&rsquo;s request from time to time, (i) Tenant shall execute, acknowledge and deliver to
Landlord, for the benefit of Landlord, Mortgagee, any prospective Mortgagee, and any prospective purchaser of Landlord&rsquo;s
interest in the Property, an estoppel certificate in the form of attached as <B>Exhibit &ldquo;E&rdquo;</B> (or other commercially
reasonable form requested by Landlord), modified as necessary to accurately state the facts represented, and (ii) Tenant shall
furnish to Landlord, Landlord&rsquo;s Mortgagee, prospective Mortgagee and/or prospective purchaser reasonably requested financial
information. Landlord agrees to keep any private financial information provided to it by Tenant confidential (except for disclosure
to the parties listed in this subsection (ii), and any Mortgagee, prospective Mortgagee and/or prospective purchaser with which
Landlord shares such information shall be informed by Landlord of the obligation to keep such information confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant agrees
not to disclose the terms, covenants, conditions or other facts with respect to this Lease, including the Minimum Annual Rent and additional
Rent, to any person, corporation, partnership, association, newspaper, periodical or other entity, except to Tenant&rsquo;s accountants
or attorneys (who shall also be required to keep the terms of this Lease confidential) or as required by law. This non-disclosure and
confidentiality agreement will be binding upon Tenant without limitation as to time, and a breach of this <U>Section 20(b)</U> will constitute
a material breach under this Lease. In addition, Tenant&rsquo;s employees, contractors, etc. shall keep any of the terms and conditions
of this Lease, including any billing statements and/or any backup supporting those statements, confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">21. <B><U>Surrender</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
the date on which this Lease expires or terminates, Tenant shall return possession of the Premises to Landlord in good condition,
except for ordinary wear and tear, and except for casualty damage or other conditions that Tenant is not required to remedy under
this Lease. Notwithstanding anything to the contrary contained in this Lease, and subject to the terms of this <U>Section 21(a)</U>,
prior to the expiration or earlier termination of this Lease, Tenant shall remove from the Premises all Tenant Improvements (subject
to <U>Section 29(c)</U> below), Alterations (subject to <U>Section 12(a)</U> above), the Satellite System (subject to <U>Section
7(e)</U> above), the Building Mounted Sign (subject to <U>Section 11(b)</U> above), and its FFE, partitions, and all other personal
property installed by Tenant or its assignees or subtenants. Tenant shall also cap or terminate all telephone, computer and data
connections at service entry panels in accordance with all applicable Laws. With respect to the Generator, or any Tenant
Improvements or Alterations Tenant is otherwise required to remove hereunder, Landlord agrees that Tenant shall be required to
remove the same only if Landlord provides notice to Tenant to remove such items at least three (3) months prior to the Expiration
Date, unless this Lease is terminated following an Event of Default in which case no notice shall be required. Tenant shall repair
any damage resulting from any and all such removal and shall restore the Premises to good order and the condition existing prior to
Tenant&rsquo;s installation of any Tenant Improvements or Alterations the Satellite System, or the Building Mounted Sign required to
be removed pursuant to the terms of this Lease. Any of the Tenant FFE or the Satellite System, or the Building Mounted Sign or
Tenant&rsquo;s personal property not removed or restored as required herein shall be deemed abandoned, and Landlord, at
Tenant&rsquo;s expense, may remove, store, sell or otherwise dispose of such property in such manner as Landlord may see fit and
retain such property as its property or sell such property and keep the proceeds. If Tenant does not return possession of the
Premises to Landlord in the condition required under this Lease, Tenant shall pay Landlord all resulting actual damages Landlord may
incur. Tenant&rsquo;s failure to comply with the terms and conditions of this <U>Section 21(a)</U> shall also be deemed an Event of
Default by the Tenant under this Lease, entitling Landlord to exercise all legal and equitable remedies available to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Upon the expiration of the Term or earlier
termination of Tenant&rsquo;s right of possession, Tenant shall surrender the Premises to Landlord free of Hazardous Materials
brought upon, kept, used, stored, handled, treated, generated in, or released or disposed of from, the Premises (collectively,
 &ldquo;<B>Tenant HazMat Operations</B>&rdquo;) and released of all Hazardous Materials Clearances, broom clean, ordinary wear and
tear and casualty loss and condemnation covered by <U>Sections 15 </U>and <U>16 </U>excepted. At least 3 months prior to the
surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions proposed (or required under any
Law) to be taken by Tenant in order to surrender the Premises (including any Alterations permitted by Landlord to remain in the
Premises) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant HazMat Operations and
otherwise released or unrestricted use and occupancy (&ldquo;<B>Surrender Plans</B>&rdquo;). Such Surrender Plan shall be
accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf of any Tenant Agent with
respect to the Premises, and (ii) all Hazardous Materials used, stored, handled, treated, generated, released or disposed of from
the Premises, and shall be subject to the review and approval of Landlord&rsquo;s environmental consultant. In connection with the
review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such
additional non-proprietary information concerning Tenant HazMat Operations as Landlord shall request. On or before such surrender,
Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been satisfactorily completed and Landlord
shall have the right, subject to reimbursement at Tenant&rsquo;s expense as set forth below, to cause Landlord&rsquo;s environmental
consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the
Premises are, as of the effective date of such surrender or early termination of this Lease, free from any residual impact from
Tenant HazMat Operations. Tenant shall reimburse Landlord, as Additional Rent, for the actual out-of-pocket expense incurred by
Landlord for Landlord&rsquo;s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify
satisfactory completion of the same, which cost shall not exceed $5,000. Landlord shall have the unrestricted right to deliver such
Surrender Plan and any report by Landlord&rsquo;s environmental consultant with respect to the surrender of the Premises to third
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If Tenant
remains in possession of the Premises or any part thereof after the expiration or termination of this Lease (&ldquo;<B>Holdover</B>&rdquo;),
without the written consent of Landlord, Tenant&rsquo;s occupancy of the Premises shall be that of a tenancy at sufferance. Tenant&rsquo;s
occupancy during any Holdover period shall otherwise be subject to the provisions of this Lease (unless clearly inapplicable), except
that the Monthly Rent shall be one hundred seventy-five percent (175%) of the Monthly Rent payable for the last full month immediately
preceding the Holdover, plus all other charges payable hereunder, and upon all the terms hereof applicable to such a tenancy at sufferance.
No Holdover or payment by Tenant after the expiration or termination of this Lease shall operate to extend the Term or prevent Landlord
from immediate recovery of possession of the Premises by summary proceedings or otherwise. Nothing contained herein shall be deemed to
authorize Tenant to remain in occupancy of the Premises after the Expiration Date or sooner termination of the Term. Any provision in
this Lease to the contrary notwithstanding, any Holdover by Tenant shall constitute an Event of Default entitling Landlord to exercise,
without obligation to provide Tenant any notice or cure period, all of the remedies available to Landlord upon an Event of Default, and
Tenant shall be liable for, and agrees to hold Landlord harmless from and against, all liabilities, obligations, damages, penalties, claims,
costs, charges and expenses, including attorneys&rsquo; fees and consequential damages, that Landlord suffers as a result of the Holdover,
including any claims made by any succeeding tenant based on such delay. Notwithstanding anything to the contrary set forth in this Section
21(c), Tenant shall have the one-time right to elect to extend the Term for a period of three (3) months upon providing to Landlord notice
of such election at least nine (9) months prior to the Expiration Date (the &ldquo;<B>Extended Term</B>&rdquo;). During the Extended Term
the Minimum Annual Rent shall be equal to 150% of the Minimum Annual Rent applicable at the last month of the Term, and all of the other
terms of provisions of this Lease shall apply, except that Tenant shall not have any right to make any Alterations or any Transfers, expand
the Premises, or extend the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>During the last ninety (90) days prior to the Expiration Date, if Tenant has vacated the Premises, Landlord may decorate, remodel,
repair, alter or otherwise prepare the Premises for occupancy, without affecting Tenant&rsquo;s obligation to pay Rent for the Premises,
however, Tenant&rsquo;s indemnification obligations shall not apply to any acts, omissions or events within the Premises that arise on
and after Landlord&rsquo;s entry for such purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 22. <B><U>Defaults - Remedies</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>It shall be an &ldquo;<B>Event of Default</B>&rdquo; following the expiration of all applicable notice and cure periods set forth
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>&#8239;(i) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If Tenant
does not pay in full when due any and all Rent, and such failure continues for more than five (5) business days following notice of delinquency
from Landlord; provided, however, that Landlord shall not be obligated to provide written notice of monetary default more than one (1)
time in any twelve-month period, and each subsequent monetary default during such twelve-month period shall be an Event of Default if
not received on the date due hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(ii)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Tenant enters into or permits any Transfer in violation of <U>Section 18 </U>above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>If Tenant
fails to observe and perform or otherwise breaches any other provision of this Lease, and, except as provided in <U>Section 22(d)</U>
below, Tenant fails to cure the default on or before the date that is ten (10) business days after Landlord gives Tenant notice of default;
provided, however, if the default cannot reasonably be cured within ten (10) business days following Landlord&rsquo;s giving of notice,
Tenant shall be afforded additional reasonable time (not to exceed thirty (30) days following Landlord&rsquo;s notice) to cure the default
if Tenant begins to cure the default within ten (10) business days following Landlord&rsquo;s notice and continues diligently in good
faith to completely cure the default; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(iv) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If Tenant
becomes insolvent or makes a general assignment for the benefit of creditors or offers a settlement to creditors, or if a petition in
bankruptcy or for reorganization or for an arrangement with creditors under any federal or state law is filed by or against Tenant, or
a bill in equity or other proceeding for the appointment of a receiver for any of Tenant&rsquo;s assets is commenced, or if any of the
real or personal property of Tenant shall be levied upon; provided that any proceeding brought by anyone other than Landlord or Tenant
under any bankruptcy, insolvency, receivership or similar law shall not constitute an Event of Default until such proceeding has continued
unstayed for more than sixty (60) consecutive days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Any notice periods provided for in this
Lease shall run concurrently with any statutory notice periods and any notice given hereunder may be given simultaneously with or incorporated
into any such statutory notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </B>If an
Event of Default occurs, Landlord shall, at any time thereafter, with or without notice or demand and without limiting Landlord in the
exercise of any other right or remedy which Landlord may have by reason of such default (with such remedies being cumulative and not exclusive),
have the following rights and remedies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(i) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord,
without any obligation to do so, may elect to cure the default on behalf of Tenant, in which event Tenant shall reimburse Landlord upon
demand for any sums paid or costs incurred by Landlord (together with an administrative fee of fifteen percent (15%) thereof) in curing
the default, plus interest at the Interest Rate from the respective dates of Landlord&rsquo;s incurring such costs, which sums and costs
together with interest at the Interest Rate shall be deemed additional Rent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(ii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>To exercise all rights and remedies under ARS&sect;&sect;33-361
and 362 including, without limitation, to enter, re-enter and repossess the Premises, by breaking open locked doors if necessary,
without terminating this Lease, and remove all persons and all or any property from the Premises, by action at law or otherwise,
without being liable for prosecution or damages, in which case Landlord shall be entitled to enforce all of Landlord&rsquo;s rights
and remedies under this Lease, including the right to recover the Rent and all other amounts due hereunder as they become due.
Landlord may, at Landlord&rsquo;s option, make Alterations and repairs in order to relet the Premises and relet all or any part(s)
of the Premises for Tenant&rsquo;s account. Tenant agrees to pay to Landlord within thirty (30) days any deficiency (taking into
account all reasonable costs incurred by Landlord) that may arise by reason of such reletting. In the event of reletting without
termination of this Lease, Landlord may at any time thereafter elect to terminate this Lease for such previous breach. No re-entry
or taking possession of the Premises by Landlord pursuant to this <U>Section 22(b)(ii)</U> or other action on Landlord&rsquo;s part
shall be construed as an election to terminate this Lease unless a written notice of such intention is given to Tenant or unless the
termination hereof is decreed by a court of competent jurisdiction. Landlord&rsquo;s election not to terminate this Lease pursuant
to this <U>Section 22(b)(ii)</U> or pursuant to any other provision of this Lease shall not preclude Landlord from subsequently
electing to terminate this Lease or pursuing any of its other remedies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(iii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>To accelerate
the whole or any part of the Rent for the balance of the Term as provided in <U>Section 22(b)(iv)</U> below, along with all sums past
due, and declare the same to be immediately due and payable, which sums shall be discounted to present value at the discount rate of the
Federal Reserve Bank of San Francisco at the time of award plus one percent (1%). In determining the amount of any future payments due
Landlord as a result of increases in Annual Operating Expenses and Additional Taxes, Landlord may make such determination based upon the
amount of Annual Operating Expenses and Additional Taxes paid by Tenant for the full year immediately prior to such Event of Default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(iv) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
terminate this Lease and the Term by any lawful means without any right on the part of Tenant to save the forfeiture by payment of
any sum due or by other performance of any condition, term or covenant broken, in which case Tenant shall promptly surrender
possession of the Premises to Landlord. In such event, Landlord shall be entitled to recover from Tenant all damages incurred by
Landlord by reason of Tenant&rsquo;s default including, but not limited to, the cost of recovering possession of the Premises;
expenses of re-letting, including necessary renovation and alteration of the Premises, reasonable attorneys&rsquo; fees, and any
real estate commission actually paid; the &ldquo;worth at the time of award&rdquo; established by the court having jurisdiction
thereof of the amount by which the unpaid rent and other charges due for the balance of the Term after the time of Tenant&rsquo;s
default exceeds the amount of such rental loss for the same period that Tenant proves by clear and convincing evidence could have
been reasonably avoided; and that portion of any leasing commission paid by Landlord applicable to the unexpired Term of this Lease
(which shall be calculated based on the assumption that any leasing commission applicable to the Term would have been evenly and
equally amortized in monthly payments over the number of months contained in the Term at an interest rate of seven percent (7%) per
annum). For purposes of this <U>Section 22(b)(iv)</U>, &ldquo;<B>worth at the time of award</B>&rdquo; of the amount referred to
above shall be computed by discounting each amount by a rate equal to the Prime Rate at the time of the award plus three percent
(3%), but in no event more than an annual rate of ten percent (10%). As used herein, the &ldquo;<B>Prime Rate</B>&rdquo; means the
then current prime rate published in the Western Edition of the Wall Street Journal provided, however, if the Western Edition of the
Wall Street Journal no publishes a prime rate then the Prime Rate shall be an equivalent rate established by a financial institution
or financial publication designated by Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(v) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintain
Tenant&rsquo;s right to possession, in which case this Lease shall continue in effect, whether or not Tenant shall have abandoned the
Premises. In such event Landlord shall be entitled to enforce all of Landlord&rsquo;s rights and remedies under this Lease, including
the right to recover the Rent and all other amounts due hereunder as they become due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(vi) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Landlord
may immediately proceed to collect or bring action for the whole Rent or such part thereof as aforesaid, as well as for liquidated damages
provided for hereinafter, as being rent in arrears, or may enter judgment therefor in an amicable action as herein elsewhere provided
for in case of rent in arrears, or may file a Proof of Claim in any bankruptcy or insolvency proceeding for such rent, or Landlord may
institute any other proceedings, whether similar to the foregoing or not, to enforce payment thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(vii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Landlord
shall have the right of injunction, in the event of a breach or threatened breach by Tenant of any of the agreements, conditions, covenants,
or terms hereof, to restrain the same and the right to invoke any remedy allowed by law or in equity, whether or not other remedies, indemnity
or reimbursements are herein provided. The rights and remedies given to Landlord in this Lease are distinct, separate, and cumulative
remedies, and no one of them, whether or not exercised by Landlord, shall be deemed to be in exclusion of any of the others; and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><B>(viii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Pursue
any other remedy now or hereafter available under the laws or judicial decisions of the state wherein the Premises are located. The expiration
or termination of this Lease and/or the termination of Tenant&rsquo;s right to possession shall not relieve Tenant from liability under
any indemnity provisions of this Lease as to matters occurring or accruing during the Term hereof or by reason of Tenant&rsquo;s occupancy
of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Any
provision to the contrary in this <U>Section 22</U> notwithstanding, (i) Landlord shall not be required to give Tenant the notice and
opportunity to cure provided in <U>Section 22(a)(iii) </U>above more than twice in any consecutive twelve (12) month period, and thereafter
Landlord may declare an Event of Default without affording Tenant any of the notice and cure rights provided under this Lease, and (ii)
Landlord shall not be required to give such notice prior to exercising its rights if Tenant fails to comply with the provisions of <U>Sections
8, 13, 18, 20, or </U>26 of this Lease or in an emergency.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>No
waiver by Landlord of any breach by Tenant shall be a waiver of any subsequent breach, nor shall any forbearance by Landlord to seek
a remedy for any breach by Tenant be a waiver by Landlord of any rights and remedies with respect to such or any subsequent breach.
Efforts by Landlord to mitigate the damages caused by Tenant&rsquo;s default shall not constitute a waiver of Landlord&rsquo;s right
to recover damages hereunder. No right or remedy herein conferred upon or reserved to Landlord is intended to be exclusive of any
other right or remedy provided herein or by law, but each shall be cumulative and in addition to every other right or remedy given
herein or now or hereafter existing at law or in equity. No payment by Tenant or receipt or acceptance by Landlord (or payment into
a lock-box account) of a lesser amount than the total amount due Landlord under this Lease shall be deemed to be other than on
account, nor shall any endorsement or statement on any check or payment be deemed an accord and satisfaction, and Landlord may
accept such check or payment without prejudice to Landlord&rsquo;s right to recover the balance of Rent due, or Landlord&rsquo;s
right to pursue any other available remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If either party commences an action or proceeding against the other party arising out of or in connection with this Lease, the prevailing
party shall be entitled to have and recover from the other party attorneys&rsquo; fees, costs of suit, investigation expenses and discovery
costs, including costs of appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;IN ANY CIVIL ACTION, COUNTERCLAIM, OR PROCEEDING, WHETHER AT LAW OR IN EQUITY, WHICH ARISES OUT OF, CONCERNS, OR RELATES TO THIS LEASE,
ANY AND ALL TRANSACTIONS CONTEMPLATED BY THIS LEASE, THE PERFORMANCE OF THIS LEASE, OR THE RELATIONSHIP CREATED BY THIS LEASE, WHETHER
SOUNDING IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE, TRIAL SHALL BE TO A COURT OF COMPETENT JURISDICTION AND NOT TO A JURY. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Landlord shall not be deemed to be in default under this Lease unless Tenant gives Landlord notice specifying the default and Landlord
fails to cure the default within a reasonable period following Tenant&rsquo;s notice. Further, and after the giving of two (2) written
notices to Landlord of the applicable Landlord default describing with specificity the nature of the default, and Landlord&rsquo;s failure
to commence to cure such default within a reasonable period following Landlord&rsquo;s receipt of such notice), Tenant may, unless Landlord
disputes the specifics of such default, perform such obligation of Landlord, in which instance Landlord shall be obligated to reimburse
Tenant for its actual costs expenses, and disbursements incurred in such performance which, if due and in Landlord&rsquo;s sole discretion,
may be paid as a credit against no more than fifty percent of (50%) of Tenant&rsquo;s monthly Minimum Annual Rent next coming due for
each month following the date such costs and expenses were incurred by Tenant, until such time as Tenant is reimbursed in full (provided
Tenant shall not be permitted to offset such costs or expenses against its payment of any Annual Minimum Rent, Operating Expenses or any
other Rent due hereunder). The provisions of this <U>Section 22(g)</U> shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">23. <B><U>Tenant&rsquo;s
Authority; OFAC</U></B>. Tenant represents and warrants to Landlord that: (a) Tenant is duly formed, validly existing and in good
standing under the laws of the state under which Tenant is organized, and qualified to do business in the state in which the
Property is located, and (b) the person(s) signing this Lease are duly authorized to execute and deliver this Lease on behalf of
Tenant, and if Tenant is a corporation, partnership, joint venture, limited liability company, or other type of organization (each,
an &ldquo;<B>Entity</B>&rdquo;), Tenant will, within fifteen (15) days after Landlord&rsquo;s request, provide Landlord with a
resolution confirming the authorization. Tenant represents and warrants to Landlord (i) that neither Tenant nor any person or Entity
that directly owns a ten percent (10%) or greater equity interest in Tenant nor any of its officers, directors or managing members
(collectively, &ldquo;<B>Tenant and Others in Interest</B>&rdquo;) is a person or Entity with whom U.S. persons or Entities are
restricted from doing business under regulations of the Office of Foreign Asset Control (&ldquo;<B>OFAC</B>&rdquo;) of the
Department of the Treasury (including those named on OFAC&rsquo;s Specially Designated and Blocked Persons List) or under any
statute, executive order (including Executive Order 13224 signed on September 24, 2001 (the &ldquo;<B>Executive Order</B>&rdquo;)
and entitled &ldquo;Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support
Terrorism&rdquo;), or other governmental action, (ii) that Tenant and Others in Interest&rsquo;s activities do not violate the
International Money Laundering Abatement and Financial Anti-Terrorism Act of 2001 or the regulations or orders promulgated
thereunder (as amended from time to time, the &ldquo;<B>Money Laundering Act</B>&rdquo;), and (iii) that throughout the Term Tenant
will comply with the Executive Order and the Money Laundering Act. Tenant certifies that it is not engaged in this transaction,
directly or indirectly on behalf of, or instigating or facilitating this transaction, directly or indirectly on behalf of, any such
person, group, entity, or nation. Tenant hereby agrees to defend, indemnify, and hold harmless Landlord from and against any and all
claims, damages, losses, risks, liabilities, and expenses (including attorney&rsquo;s fees and costs) arising from or related to any
breach of the foregoing certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">24.&nbsp; <B><U>Liability
of Landlord</U></B>. The word &ldquo;<B>Landlord</B>&rdquo; in this Lease includes the Landlord executing this Lease as well as its successors
and assigns, each of which shall have the same rights, remedies, powers, authorities and privileges as it would have had it originally
signed this Lease as Landlord. Any such person or entity, whether or not named in this Lease, shall have no liability under this Lease
after it ceases to hold title to the Premises except for obligations already accrued (and, as to any unapplied portion of Tenant&rsquo;s
Security Deposit, if applicable, Landlord shall be relieved of all liability upon transfer of such portion to its successor in interest).
Tenant shall look solely to Landlord&rsquo;s successor in interest for the performance of the covenants and obligations of the Landlord
hereunder which subsequently accrue. Landlord shall not be deemed to be in default under this Lease unless Tenant gives Landlord notice
specifying the default and Landlord fails to cure the default within a reasonable period following Tenant&rsquo;s notice. In no event
shall Landlord be liable to Tenant for any loss of business or profits of Tenant or for consequential, punitive or special damages of
any kind. Anything in this Lease to the contrary notwithstanding, covenants, undertakings and agreements herein made on the part of Landlord
are made and intended not as personal covenants, undertakings and agreements or for the purpose of binding Landlord personally or the
assets of Landlord, except Landlord&rsquo;s interest in the Property (including rental, sales, financing and insurance proceeds arising
from the Property), but are made and intended for the purpose of binding only Landlord&rsquo;s interest in the Property, as the same may
from time to time be encumbered. Neither Landlord nor any principal of Landlord nor any owner of the Property, nor any of their respective
partners, officers, employees, heirs, legal representatives, successors, and assigns, whether disclosed or undisclosed, shall have any
personal liability with respect to any of the provisions of this Lease or the Premises; Tenant shall look solely to the equity of Landlord
in the Property and any available insurance proceeds for the satisfaction of any claim by Tenant against Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">25.&nbsp; <B><U>Notices</U></B>.
Any notice, consent or other communication under this Lease shall be in writing and addressed to Landlord or Tenant at their
respective addresses specified in Section 1 above (or to such other address as either may designate by notice to the other) with a
copy to any Mortgagee or other party designated by Landlord. Each notice or other communication shall be deemed given if sent by
prepaid overnight delivery service or by certified mail, return receipt requested, postage prepaid or in any other manner, with
delivery in any case evidenced by a receipt, and shall be deemed to have been given on the day of actual delivery to the intended
recipient or on the business day delivery is refused. The giving of notice by Landlord&rsquo;s attorneys, representatives and Agents
under this <U>Section 25</U> shall be deemed to be the acts of Landlord. If a party refuses or fails to accept delivery of a notice,
such notice shall be deem to have been given upon attempted delivery thereof. Tenant consents to the receipt of electronic messages
from Landlord, its Affiliates or legal counsel sent to the email address set forth in <U>Section 1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 26. <B><U>Security Deposit</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>At
the time of signing this Lease, Tenant shall deposit with Landlord the Security Deposit to be retained by Landlord as cash security for
the faithful performance and observance by Tenant of the provisions of this Lease. Tenant shall not be entitled to any interest on the
Security Deposit. Landlord shall have the right to commingle the Security Deposit with its other funds. Landlord may use the whole or
any part of the Security Deposit for the payment of any amount as to which Tenant is in default or to compensate Landlord for any loss
or damage it may suffer by reason of Tenant&rsquo;s default under this Lease. If Landlord uses all or any portion of the Security Deposit
as herein provided, within ten (10) days after demand, Tenant shall pay Landlord cash in an amount equal to that portion of the Security
Deposit used by Landlord. If Tenant complies fully and faithfully with all of the provisions of this Lease, the Security Deposit shall
be returned to Tenant after the Expiration Date and surrender of the Premises to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At Tenant&rsquo;s
election, in place of the cash Security Deposit, Tenant may provide a letter of credit. If Tenant elects to provide a letter of credit,
then prior to the Effective Date, Tenant shall deliver a letter of credit (&ldquo;<B>Letter of Credit</B>&rdquo;) to Landlord, and maintain
the Letter of Credit in full force and effect through the Term, as set forth herein, from a commercial bank or trust company satisfactory
to Landlord maintaining branch banks in the metropolitan Philadelphia area or a letter of credit office at which the Letter of Credit
may be drawn upon (the &ldquo;<B>Issuing Bank</B>&rdquo;), in the amount of the $100,000, to be held by Landlord as additional security
for the faithful performance and observance by Tenant of all its obligations under the provisions of this Lease. Any such Letter of Credit
shall be in a form approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed so long as it meets
the requirements of this <U>Section 26(b)</U> and is otherwise generally consistent with the form of letter of credit used by any major
or regional financial institution in the metropolitan Philadelphia area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(i) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Letter of Credit
shall be unconditional, irrevocable, transferable, and payable to Landlord on sight (i) at a metropolitan Philadelphia area financial
institution, or (ii) by overnight mail or delivery service to the Issuing Bank&rsquo;s letter of credit office, in partial or full draws.
Any and all fees or costs charged by the Issuing Bank in connection with the Letter of Credit, including any assignment thereof by Landlord,
shall be paid by Tenant, subject to reimbursement by Landlord, as expressly provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(ii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Letter of Credit shall expire not earlier than twelve (12) months
after the date of delivery thereof to Landlord and shall provide that the same shall be automatically renewed for successive twelve
(12) month periods through a date which is not earlier than ninety (90) days after the Expiration Date, unless written notice of
nonrenewal has been given by the Issuing Bank to Landlord and Landlord&rsquo;s attorney by registered or certified mail, return
receipt requested, not less than ninety (90) days prior to the expiration of the then current period. If the Issuing Bank does not
renew the Letter of Credit, and if Tenant does not deliver a substitute Letter of Credit in the in the amount of the then current
balance, at least forty-five (45) days prior to the expiration of the then current period, then, in addition to its rights granted
under <U>Section 26 </U>of this Lease, Landlord shall have the right to draw on the existing Letter of Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(iii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord shall
have the right to draw upon the Letter of Credit in whole or in part and apply the proceeds thereof as may be necessary to compensate
Landlord for any damages incurred by Landlord on account of an Event of Default, whereupon Tenant, within twenty (20) days after receipt
of written demand, shall forthwith restore the Letter of Credit to the then current amount. Should Landlord elect to draw the full amount
of the Letter of Credit upon an Event of Default, Tenant expressly waives any right it might otherwise have to prevent Landlord from drawing
on the Letter of Credit and agrees that an action for damages, and not injunctive or other equitable relief, shall be Tenant&rsquo;s sole
remedy in the event Tenant disputes Landlord&rsquo;s claim to any such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(iv) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Letter of
Credit shall be subject to the Uniform Customs and Practice for Documentary Credits, International Chamber of Commerce Publication No.
600 (2007 Revision).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(v)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Issuing Bank shall have a Moody&rsquo;s rating of at least
 &ldquo;A-3&rdquo; (or other comparable rating). If at any time (a) the Issuing Bank is either (i) closed by the Federal Deposit
Insurance Corporation (&ldquo;<B>FDIC</B>&rdquo;) or any other governmental authority, or (ii) declared insolvent by the FDIC or
other governmental agency for any reason, or (b) Landlord reasonably believes that Issuing Bank will either be (y) closed by the
FDIC or any governmental authority, or (z) declared insolvent by the FDIC or other governmental authority for any reason, Tenant
shall, within five (5) days after either the occurrence of such closure or declaration of insolvency or notice from Landlord that
Landlord reasonably believes that Issuing Bank will close or be declared insolvent, either (1) provide Landlord a replacement Letter
of Credit satisfying all of the terms of this <U>Section 26</U>, or (2) post a cash security deposit in the amount of the then
current balance of the Letter of Credit with Landlord, and if Tenant fails to comply with this <U>subsection 26(e)(1) </U>or <U>(2)</U>,
an Event of Default shall be deemed to have occurred as of the end of such five (5) day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 1in">(vi)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord shall have the right to pledge or assign its interest in the Letter
of Credit and proceeds thereof to any Mortgagee of the Premises. In the event of a sale or transfer of Landlord&rsquo;s estate or
interest in the Premises, Landlord shall have the right to transfer, at Tenant&rsquo;s cost, the Letter of Credit, or the proceeds
thereof, to the extent not applied as set forth above, to the vendee or transferee as the new landlord under this Lease, and to the
extent the Letter of Credit, or proceeds thereof, to the extent not applied as set forth above, are so transferred, Landlord shall
be considered released by Tenant from all liability for the return of the Letter of Credit, or proceeds thereof, but only if the
transferee assumes all of Landlord&rsquo;s obligations under this Lease, respecting the Letter of Credit and otherwise. No Mortgagee
or purchaser of the Premises at any foreclosure proceeding brought under the provisions of any Mortgage shall (regardless of whether
the Lease is at the time in question subordinated to the lien of any Mortgage) be liable to Tenant or any other person for any or
all of such sums or the return of any Letter of Credit (or any other or additional security deposit or other payment made by Tenant
under the provisions of this Lease), unless Landlord has actually delivered the Letter of Credit, or proceeds thereof, to such
Mortgagee or purchaser. If requested by any such Mortgagee or purchaser, Tenant shall obtain an amendment to the Letter of Credit
which names such Mortgagee or purchaser as the beneficiary thereof in lieu of Landlord, and the costs incurred by Tenant in
obtaining any such amendment shall be reimbursed by Landlord as a credit against the next installment of Minimum Annual Rent due
following Tenant&rsquo;s delivery of the amendment in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">27.&nbsp; <B><U>Broker</U></B>.
Tenant represents and warrants to Landlord that Tenant has not consulted or negotiated with any broker or finder with regard to this Lease
except the Broker representing Tenant. Landlord and Tenant each will indemnify the other against, and hold the other harmless from, any
claims for fees or commissions from anyone with whom either of them has consulted or negotiated with regard to the Premises and this Lease,
including attorneys&rsquo; fees at all tribunal levels incurred in connection with the defense of any such claim, with the exception of
the Brokers. Landlord will pay the fees or commissions due to Brokers pursuant to a separate written agreement between Landlord and Broker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 28. <B><U>Mortgagee Approval</U></B>. Intentionally omitted.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 29. <B><U>Tenant Improvements</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Other
than as otherwise set forth in this Lease<B>,</B> Tenant accepts the Premises in its &ldquo;<B>AS IS</B>&rdquo; &ldquo;<B>WHERE IS</B>&rdquo;
condition, with all faults, and Landlord shall have no obligations whatsoever to improve or pay for any improvements to the Premises
for Tenant&rsquo;s use and occupancy thereof except only as provided in this <U>Section 29</U>. Tenant intends to make improvements to
the Premises (the &ldquo;<B>Tenant Improvements</B>&rdquo;), and pursuant to <U>Section 29</U>, shall be responsible for the cost thereof,
and will have plans for such Tenant Improvements designed and approved by Landlord in accordance with <U>Section 29(b)</U> below, and
constructed by Tenant in accordance with <U>Section 29(c)</U> below. Tenant confirms all Tenant Improvements are for the immediate use
and benefit of Tenant only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(b) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant&rsquo;s
improvement plans and specifications for such Tenant Improvements to the Premises shall be prepared by a licensed architect selected
by Tenant and subject to the approval by Landlord, such approval not to be unreasonably withheld, conditioned or delayed. The plans
and specifications for the Tenant Improvements will be prepared in sufficient detail to permit Tenant to construct the Tenant
Improvements, and shall include, as applicable, demising walls, a partition layout (dimensioned), door location and door schedule
including hardware, reflected ceiling plan, telephone and electrical outlets with locations (dimensioned), special electrical, HVAC
and/or plumbing work, mechanicals, special loading requirements, such as the location of file cabinets and special equipment,
openings in the walls or floors, all necessary sections and details for special equipment and fixtures, and finishes including,
without limitation, carpentry and millwork, floor coverings, wall coverings, color schedules, and any other special finishes. The
plans for the Tenant Improvements shall be prepared in accordance, and shall comply in all respects, with all Laws for the issuance
of a Building Permit from the City of Phoenix. Landlord shall not unreasonably withhold, condition or delay its approval of the
plans and specifications for the Tenant Improvements. Within ten (10) days after receipt, Landlord shall provide to Tenant in
writing either its approval of such plans and specifications of the Tenant Improvements submitted by Tenant, or any specific
comments or objections that Landlord may have. If Landlord fails to respond within such ten (10) day period, Tenant&rsquo;s plans
and specifications shall be deemed approved or Tenant may deemed such delay a Landlord Delay as defined below. If Landlord timely
provides to Tenant Landlord&rsquo;s comments or objections to the plans and specifications of the Tenant Improvements, Tenant will
revise such plans and specifications to address such comments or objections and re-submit the plans and specifications and Landlord
will continue to approve or object to the same in the process set forth above until such plans and specifications of the Tenant
Improvements are finally approved or deemed approved by Landlord. Upon approval or deemed approval by Landlord, the plans and
specifications for the Tenant Improvements shall become final and shall not be materially changed without Landlord&rsquo;s further
approval, which shall not be unreasonably withheld, conditioned or delayed (as finally approved, the &ldquo;<B>Final
Plans</B>&rdquo;, a copy of which shall be attached to and become a part of this Lease as <B>Exhibit &ldquo;F&rdquo;).</B>
Landlord&rsquo;s review or approval of the Tenant Improvement Plans does not constitute a code review and shall not be a
representation or warranty of Landlord that the Tenant Improvement Plans are fit for any use, comply with any Laws or satisfy all
requirements of the City of Phoenix and the Cotton Center CCR&rsquo;s and the Allred CC&amp;Rs, and Tenant shall have no right to
rely upon any such review or approval thereof by Landlord. Landlord shall have no liability to Tenant or any third party by reason
of such review or approval, and Landlord&rsquo;s review of the Tenant Improvement Plans and monitoring of construction shall be
solely for its own benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(c) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall
complete the Tenant Improvements to the Premises in accordance with the Final Plans, all applicable Laws, and all applicable provisions
of this Lease including, but not limited to, provisions relating to Alterations, the provision of insurance, the delivery of Lien Waivers
(as defined below) pursuant to <U>Section 29(f)</U> below, and the delivery of permits to Landlord pursuant to <U>Section 29(c)</U> below.
The contractors selected by Tenant for bidding on the Tenant Improvements shall be subject to the approval of Landlord, which shall not
be unreasonably withheld, conditioned or delayed. Landlord hereby approves the following contractor and subcontractors: DPR Construction,
Commonwealth Electric, and Harris Mechanical. Tenant shall require all contractors and subcontractors to be adequately insured as reasonably
required by Landlord, naming Landlord and the Landlord Additional Insureds, as additional insureds. The Tenant Improvements shall be the
property of Tenant until the expiration or termination of this Lease, as the same may be extended as set forth herein at that time without
payment by Landlord, the Tenant Improvements, including without limitation any laboratory fixtures and improvements, shall remain on the
Premises and become the property of Landlord unless Landlord gives notice to Tenant, at the time of Landlord&rsquo;s approval thereof,
to remove all or any part thereof at the expiration or termination of this Lease, in which event Tenant will remove all or such designated
parts, will repair any resulting damage and will restore the Premises to the condition existing prior to Tenant&rsquo;s installation of
the Tenant Improvements, all in accordance with <U>Section 21(a)</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>All
construction relating to the Tenant Improvements shall be done in a good and workmanlike manner and shall comply in all respects at
the time of completion with all Laws of the City of Phoenix and all other governmental authorities having jurisdiction over the
Premises. Tenant shall obtain all governmental approvals and permits related to the Tenant Improvements and promptly deliver copies
of the same to Landlord prior to the start of any work relating to the Tenant Improvements. Promptly after the substantial
completion of the Tenant Improvements, Tenant shall provide Landlord with the following documents with respect to the Premises and
the Tenant Improvements, if required by the City of Phoenix or other applicable Laws: (i) a Certificate of Occupancy; (ii) a full
set of final and un-appealable permits and approvals; (iii) &ldquo;as-built&rdquo; plans (hard copy and CAD); and, (iv) a statement
of completion by a licensed architect confirming that the Tenant Improvements were completed in accordance with the Final Plans.
Except to the extent caused by the active negligence or willful misconduct of Landlord or its Agents, Tenant will indemnify, defend,
and hold harmless the Landlord Additional Insureds and their respective Agents from and against any and all claims, actions,
damages, proceedings, costs, liability and expense (including reasonable fees of attorneys, investigators and experts) which may be
asserted against, imposed upon, or incurred by any of the Landlord Additional Insureds or their respective Agents and arising out of
or in connection with loss of life, personal injury or damage to property in or about the Premises or arising out of Tenant&rsquo;s
performance of the work to install the Tenant Improvements, whether in contract or tort, occasioned wholly or in part by any act or
omission of Tenant or its contractors and workers. Tenant&rsquo;s obligations pursuant to this <U>Section 29(d)</U> shall survive
the expiration or termination of this Lease. In case any action or proceeding is brought against any of the Landlord Additional
Insureds or their respective Agents by reason of any such claim, Tenant, upon notice from any of the Landlord Additional Insureds or
their respective Agents, will, at Tenant&rsquo;s sole cost and expense, resist and defend such action or proceeding with counsel
acceptable to such Landlord Additional Insureds and their respective Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(e) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall,
subject to <U>Section 29(f)</U> below, pay the costs, expenses and fees incurred for the construction of the Tenant Improvements, including
without limitation (i) architectural, engineering and design costs, (ii) the cost charged to Tenant by the general contractor and all
subcontractors for performing such construction, (iii) project management fees, (iv) construction permit fees, and (v) costs of built-in
furniture, (vi) mechanical and structural engineering fees, and, up to Fifty Thousand Dollars ($50,000) for the costs of the FEE incorporated
into the Premises (together, the &ldquo;<B>Tenant Improvement Costs</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(f) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
shall provide an allowance to Tenant not to exceed Four Hundred Seventy-Two Thousand Five Hundred Twenty-Two Dollars and Fifty Cents ($472,522.50)
(based on Twenty-Two Dollars and Fifty Cents ($22.50) per rentable square foot of the Premises) (the &ldquo;<B>Tenant Improvement Allowance</B>&rdquo;)
which shall be used by Tenant to pay for the Tenant Improvement Costs in accordance with <U>Section 29(e)</U> above. In no event shall
Landlord be responsible for any of the Tenant Improvement Costs in excess of the Tenant Improvement Allowance. Accordingly, Tenant shall
be responsible for all Tenant Improvement Costs in excess of the Tenant Improvement Allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(g)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall promptly pay all Tenant Improvement Costs as they become
due. Tenant may submit to Landlord no more than two (2) applications for payment reimbursement to be applied against the Tenant Improvement
Allowance (each, a &ldquo;<B>Reimbursement Application</B>&rdquo;). Each Reimbursement Application shall include: (i) executed statutory
unconditional waivers of liens and releases on final payment, in compliance with A.R.S. &sect; 33-1008 or any other or statute now or
hereafter in effect, reasonably satisfactory to Landlord, from all of Tenant&rsquo;s contractors, subcontractors, suppliers, and materialmen
performing work at the Premises in connection with the Tenant Improvements confirming the payment in full of all Tenant Improvement Costs
included in the then current Reimbursement Application (collectively, the &ldquo;<B>Lien Waivers</B>&rdquo;); (ii) sufficient evidence
of payment from Tenant to Tenant&rsquo;s contractor of all Tenant Improvement Costs included in the then current Reimbursement Application;
and (iii) a certification completed by Tenant&rsquo;s architect confirming the Tenant Improvements included in the then current Reimbursement
Application were performed in accordance with the Tenant Improvement Plans (collectively, the &ldquo;<B>Partial Reimbursement Requirements</B>&rdquo;).
When the Tenant Improvements are completed in their entirety, as a condition of the final Reimbursement Application, Tenant shall provide:
(i) executed final Lien Waivers, confirming the payment in full of all Tenant Improvement Costs up to the limit of the Tenant Improvement
Allowance and the release of liens against the Premises; (ii) sufficient evidence of payment from Tenant to Tenant&rsquo;s contractor(s)
of all Tenant Improvement Costs up to the limit of the Tenant Improvement Allowance; and (iii) a certification completed by Tenant&rsquo;s
architect confirming the Tenant Improvements are complete and were performed in accordance with the Tenant Improvement Plans (collectively,
the &ldquo;<B>Final Reimbursement Requirements</B>&rdquo;). Landlord shall have thirty (30) days after the receipt of each complete Reimbursement
Application to submit its reimbursement payment to Tenant. Landlord shall not be required to issue any reimbursement payment to Tenant
if the Reimbursement Application does not include the Partial Reimbursement Requirements or the Final Reimbursement Requirements, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(h) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
shall make a complete reimbursement submission for the Tenant Improvement Costs up to the amount of the Tenant Improvement Allowance
no later than one (1) year after the Commencement Date. Landlord shall not be required to make payments on account of the Tenant
Improvement Allowance for any Tenant Improvement Costs not submitted to Landlord by the foregoing date, and Tenant shall not have
any claim to any portion of the Tenant Improvement Allowance not properly used by such date. In no event shall any portion of the
Tenant Improvement Allowance be used to offset Tenant&rsquo;s Rent obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(i) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>In addition
to the Tenant Improvement Allowance, provided no Event of Default exists under the Lease, Tenant shall have the one (1) time right, upon
written notice to Landlord no later than April 1, 2019 to have Landlord provide an additional allowance (the &ldquo;<B>Additional Allowance</B>&rdquo;)
in an amount up to the product of (i) Thirty Dollars ($30.00), multiplied by (ii) the square feet of rentable area in the Premises. If
Tenant fails timely to elect for Landlord to provide the Additional Allowance then Tenant&rsquo;s right to the Additional Allowance will
automatically lapse and be of no further force and effect. If Tenant timely elects for Landlord to provide the Additional Allowance, then
(x) the Additional Allowance as determined by Tenant by notice to Landlord, shall only be applied toward Tenant Improvements, and (y)
except as provided in <U>Section 4(d)</U> the Additional Allowance will be deemed to be included in the term &ldquo;<B>Tenant Improvement
Allowance</B>&rdquo;. Commencing on the March 1, 2019, Tenant shall begin repaying, and thereafter repay each calendar month, the Additional
Allowance to Landlord as set forth herein. The Additional Allowance will be amortized at an annual interest rate of eleven percent (11%)
in 85 equal monthly installments. If the Additional Allowance is elected by Tenant, Landlord and Tenant shall promptly enter into an amendment
to the Lease specifying the amount of the Additional Allowance and the applicable installments or payments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(j) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything in this Lease to the contrary, the period to which the Abatement is applicable (three calendar months) shall be extended by
any delay in Tenant&rsquo;s completion of the Tenant Improvements arising from the acts or omissions of Landlord or its Agents,
including without limitation, (i) Landlord&rsquo;s failure to deliver the Premises to Tenant with all Building Systems in good
working order and repair, (ii) Landlord&rsquo;s failure to provide comments and approvals on a timely basis as required by this
Lease, or (iii) Landlord&rsquo;s failure to provide Tenant and its contractors access to the Premises or services reasonably
required to perform the Tenant Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 30. <B><U>Right of First Refusal</U></B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Subject
to the terms and provisions of this <U>Section 30</U>, provided that (a) there then exists no Event of Default by Tenant under this Lease,
nor any event that with the giving of notice and/or the passage of time would constitute a default, (b) Tenant, its Strategic Partners,
and Permitted Transferees occupy at least 80% of the Premises, during the initial 36 months of the Term, Tenant has the option to lease
all of space immediately adjacent to the Premises (being 14,462 rentable square feet) (the &ldquo;Expansion Space&rdquo;), pursuant to
the terms of this Section 30. Landlord shall notify Tenant when Landlord desires to lease such adjacent space and constructs a &ldquo;speculative
suite&rdquo; or when Landlord is prepared to respond to a proposal or request for proposals from a third party (&ldquo;Availability Notice&rdquo;).
Tenant must exercise its option within five (5) business days from receipt of the Availability Notice. If Landlord has constructed the
speculative suite in the Expansion Space, the terms and conditions for the Expansion Space shall be the terms and conditions set forth
in the Availability Notice. If Landlord has not constructed the speculative suite in the Expansion Space, if Tenant exercises its option,
the Expansion Space shall be added to this Lease on the date set forth in the Availability Notice (the &ldquo;Expansion Date&rdquo;)
and all Lease obligations of the parties remain the same, except: (i) if the Expansion Date is within the first 15 months of the Term,
the Minimum Annual Rent for the Expansion Space shall be calculated at the same per square foot basis then in effect for the initial
Premises, with annual increases occurring as set forth in <U>Section 1(f)</U> above, the Tenant Improvement Allowance for the Expansion
Premises shall be prorated to reflect the then remaining Term, and any other financial obligations based upon square footage shall be
proportionate to the terms specified in this Lease; and (ii) if the Expansion Date is after the first 15 months of the Term, the Minimum
Annual Rent and other financial terms based upon square footage shall be equal to the Fair Market Value determine in the same manner
as provided in Section 4(c). Unless otherwise agreed to in writing by the Parties, increases in Minimum Rent and Operating Expenses become
effective at the earlier of (i) the date when Tenant opens for business in the adjacent space, and (ii) 60 days after delivery of the
adjacent space to Tenant. If Tenant does not exercise its option within the five (5) business day period, subject to the immediately
following sentence, Landlord may proceed to lease the adjacent space to third parties; provided that if the rental rate terms to be agreed
to with third parties are more favorable than those that had been offered to Tenant by ten percent (10%) or more, Landlord shall submit
an offer to lease to Tenant on such terms (&ldquo;<B>Second Availability Notice</B>&rdquo;), and Tenant shall, for a period of five (5)
business days, have the right to accept such terms and lease the Expansion Space pursuant thereto. In addition, if Landlord does not
enter into a lease agreement with a third party tenant for the adjacent space within six (6) months of Landlord&rsquo;s delivery to Tenant
of the Availability Notice, then if Landlord thereafter desires to lease such adjacent space or respond to a proposal or request for
proposals from a third party, Landlord shall provide to Tenant another Availability Notice and the terms and conditions set forth above
shall apply; provided, that in no event shall Landlord be required to provide an Availability Notice more than two (2) times during the
Term. If Tenant fails to accept such terms within such period, then Tenant&rsquo;s &ldquo;right of first refusal&rdquo; is deemed void. Tenant
acknowledges that Landlord shall have no obligation to construct any improvements whatsoever to such adjacent space, except as may be
set forth in the Availability Notice or the Second Availability Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If Tenant exercises such right of first refusal, the parties enter into an amendment concerning the leasing of such Expansion Space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">31.&nbsp; <B><U>Miscellaneous</U></B>.
The captions in this Lease are for convenience only, are not a part of this Lease and do not in any way define, limit, describe or amplify
the terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.22in 0in; text-align: justify; text-indent: 0.5in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>This Lease represents the entire agreement between the parties hereto and there are no collateral or oral agreements or understandings
between Landlord and Tenant with respect to the Premises or the Property. No representations or promises will be binding on the parties
to this Lease except those representations and promises expressly contained in this Lease.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>This Lease shall not be modified in any manner except by an instrument in writing executed by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B>(c)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The masculine (or neuter)
pronoun and the singular number shall include the masculine, feminine and neuter genders and the singular and plural number. The
word &ldquo;<B>including</B>&rdquo; followed by any specific item(s) is deemed to refer to examples rather than to be words of
limitation. The word &ldquo;<B>person</B>&rdquo; includes a natural person, a partnership, a corporation, a limited liability
company, an association and any other form of business association or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(d) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Both parties
having participated fully and equally in the negotiation and preparation of this Lease, this Lease shall not be more strictly construed,
nor any ambiguities in this Lease resolved, against either Landlord or Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(e) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each covenant,
agreement, obligation, term, condition or other provision contained in this Lease shall be deemed and construed as a separate and independent
covenant of the party bound by, undertaking or making the same, not dependent on any other provision of this Lease unless otherwise expressly
provided. All of the terms and conditions set forth in this Lease shall apply throughout the Term unless otherwise expressly set forth
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>If any provisions of this Lease shall be declared unenforceable in any respect, such unenforceability shall not affect any other provision
of this Lease, and each such provision shall be deemed to be modified, if possible, in such a manner as to render it enforceable and to
preserve to the extent possible the intent of the parties as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>This Lease shall be construed and enforced in accordance with the Laws of the State of Arizona (without the application of any conflict
of laws principles).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>This Lease shall be binding upon and inure to the benefit of Landlord and Tenant and their respective permitted successors and assigns.
All persons liable for the obligations of Tenant or Landlord under this Lease shall be jointly and severally liable for such obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>(i)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall not record this Lease or any memorandum thereof, or otherwise file this Lease with any governmental authority, without Landlord&rsquo;s
prior consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(j) </B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Whenever
it is provided that Landlord&rsquo;s or Tenant&rsquo;s consent is required, unless another standard is provided in this Lease with respect
to such specific consent, neither Landlord nor Tenant, as applicable will unreasonably withhold, condition or delay such consent or approval
(such consent or approval and such exercise of judgment being collectively referred to as &ldquo;<B>consent</B>&rdquo;). If Landlord delays,
conditions or refuses such consent, Tenant waives any claim for money damages (including any claim for money damages by way of setoff,
counterclaim or defense) based upon any claim or assertion that Landlord unreasonably withheld, conditioned or delayed consent. Tenant&rsquo;s
sole remedy will be specific performance. Failure on the part of Tenant to seek relief within thirty (30) days after the date upon which
Landlord has withheld, conditioned or delayed its consent will be deemed a waiver of any right to dispute the reasonableness of such withholding,
conditioning or delaying of consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>This Lease may be executed in multiple counterparts, each of which, when assembled to include an original signature for each party
contemplated to sign this Lease, will constitute a complete and fully executed original. All such fully executed counterparts will collectively
constitute a single Lease agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Time periods for Landlord&rsquo;s or Tenant&rsquo;s performance under any provisions of this Lease shall be extended for periods
of time during which the non-performing party&rsquo;s&#8239;performance is prevented due to circumstances beyond the party&rsquo;s control,
including without limitation, including acts of God; fire or other casualty; unreasonable governmental delay; inability to procure labor,
materials, supplies, power or transportation despite reasonable efforts; strikes; unusual inclement weather; or, where applicable, the
passage of time while waiting for an adjustment of insurance proceeds (&ldquo;<B>Force Majeure</B>&rdquo;). Any time limits required
to be met by either party hereunder, whether specifically made subject to Force Majeure or not, except those related to the surrender
of the Premises by the end of the Term or payment of Fixed Basic Rent or Additional Rent, will, unless specifically stated to the contrary
elsewhere in this Lease, be automatically extended by the number of days by which any required performance is delayed due to Force Majeure.
The lack of capital shall not be an event of Force Majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Unless otherwise specified, in computing any period of time described herein, the day of the act or event after which the designated
period of time begins to run is not to be included and the last day of the period so computed is to be included, unless such last day
is a Saturday, Sunday or legal holiday for national banks in the State of Arizona (such day which is neither Saturday, Sunday or legal
holiday), in which event the period shall run until the end of the next day which is neither a Saturday, Sunday, or a legal holiday.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>(n)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Time is of the essence with respect to the parties&rsquo; obligations under this Lease.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this Lease, or make any claim
that this Lease is invalid or unenforceable, due to any failure of this document or this Lease to comply with ministerial requirements,
including requirements for corporate seals, attestations, witnesses, notarizations or other similar requirements, and each party hereby
waives the right to assert any such defense or make any claim of invalidity or unenforceability due to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Landlord and Tenant expressly agree that if the signature of Landlord and/or Tenant on this Lease is not an original, but is a digital,
mechanical or electronic reproduction (such as, but not limited to, an e-mail or PDF, then such digital, mechanical or electronic reproduction
shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional ink-on-paper original wet signature
penned manually by its signatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>This Lease is submitted to Tenant on the understanding that it will not be considered an offer by Landlord and will not bind Landlord
in any way until (a) Tenant has duly executed and delivered the required number of originals to Landlord and (b) Landlord has executed
and delivered one of such originals to Tenant. Tenant&rsquo;s offer of this Agreement shall be irrevocable and open for acceptance by
Landlord until 5:00 p.m. on the fifteenth (15th) day after execution and delivery hereof by Tenant, and if not accepted by then may be
withdrawn by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Any State statutory provisions dealing with termination rights due to casualty, condemnation, delivery of possession or any other
matter dealt with by this Lease are superseded by the terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SIGNATURES ON FOLLOWING PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">&#8239;THE PARTIES to this Lease, intending to
be legally bound, have executed and delivered this Lease as of the date on which this Lease has been fully executed by Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>LANDLORD:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 44%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 44%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>WPT LAND 2 LP</B></FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">WPT&nbsp;Land&nbsp;2&nbsp;GP&nbsp;LLC,</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">its sole general partner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Dated: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">3/4/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom">/s/ <FONT STYLE="font-size: 10pt">Anthony
A. Nichols, Jr.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Anthony A. Nichols, Jr.</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>TENANT:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>23andMe, Inc., </B>a Delaware corporation</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: left">/s/<FONT STYLE="font-size: 10pt">
    Anne Wojcicki</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Anne Wojcicki</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 10pt">CEO</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">March 1, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">/s/<FONT STYLE="font-size: 10pt">&#8239;Steve Schoch</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap"><FONT STYLE="font-size: 10pt">Steve Schoch</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">Approved as to Form 23andMe Legal Dept.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">March 1, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">By</TD>
    <TD STYLE="border-bottom: Black 1pt solid">AH/jmh</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;A&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>PLAN SHOWING PREMISES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;B&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>BUILDING RULES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;Any sidewalks, lobbies, passages, elevators and stairways shall not be obstructed or used by Tenant for any purpose other than ingress
and egress from and to the Premises. Landlord shall in all cases retain the right to control or prevent access by all persons whose presence,
in the judgment of Landlord, shall be prejudicial to the safety, peace or character of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;
The toilet rooms, toilets, urinals, sinks, faucets, plumbing or other service apparatus of any kind shall not be used for any purposes
other than those for which they were installed, and no sweepings, rubbish, rags, ashes, chemicals or other refuse or injurious substances
shall be placed therein or used in connection therewith or left in any lobbies, passages, elevators or stairways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;Tenant shall not impair in any way the fire safety system and shall comply with all safety, fire protection and evacuation procedures
and regulations established by Landlord, any governmental agency or any insurance company insuring the Building, including without limitation
the insurer&rsquo;s Red Tag Permit System, Hot Work Permit System and all other fire protection impairment procedures. No person shall
go on the roof without Landlord&rsquo;s prior written permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;Without Landlord&rsquo;s prior written consent, Tenant shall not hang, install, mount, suspend or attach anything from or to any sprinkler,
plumbing, utility or other lines. I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;Tenant shall not change any locks nor place additional locks upon any doors or any access codes or systems without first providing to
Landlord keys, access cards or fobs or codes to such locks or systems so that at all times Landlord has pass keys or access cards or fobs
or knowledge of the access codes. No additional locks or bolts of any kind will be placed on any of the doors or windows by Tenant. Tenant
will, on the expiration or earlier termination of Tenant&rsquo;s tenancy, deliver to Landlord all keys (or fobs or access cards, as the
case may be) to any space within the Building either furnished to or otherwise procured by Tenant, and in the event of the loss of any
keys, fobs or access cards furnished, Tenant will pay to Landlord the cost thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;Tenant shall not cause excessive noise or any disturbance, nor use nor keep in the Building any matter having an offensive odor, nor explosive
or highly flammable material, nor shall any animals other than handicap assistance dogs in the company of their masters be brought into
or kept in or about the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;If
Tenant desires to introduce electrical, signaling, telegraphic, telephonic, protective alarm or other wires, apparatus or devices, Landlord
shall direct where and how the same are to be placed, and except as so directed, no installation boring or cutting shall be permitted.
Landlord shall have the right to prevent and to cut off the transmission of excessive or dangerous current of electricity or annoyances
into or through the Building or the Premises and to require the changing of wiring connections or layout at Tenant&rsquo;s expense, to
the extent that Landlord may deem necessary, and further to require compliance with such reasonable rules as Landlord may establish relating
thereto, and in the event of non-compliance with the requirements or rules, Landlord shall have the right immediately to cut wiring or
to do what it considers necessary to remove the danger, annoyance or electrical interference with apparatus in any part of the Building.
All wires installed by Tenant must be clearly tagged at the distributing boards and junction boxes and elsewhere where required by Landlord,
with the number of the office/laboratory space to which said wires lead, and the purpose for which the wires respectively are&#8239;used, together
with the name of the concern, if any, operating same. Tenant shall not use any method of heating, air conditioning or air cooling other
than that provided by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;Tenant shall not place weights anywhere beyond the safe carrying capacity of the Building which is designed to normal office/laboratory
space building standards for floor loading capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;The use of rooms as sleeping quarters is strictly prohibited at all times. Tenant shall not use the Property for any type of residential
or childcare use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">10.&#8239; Tenant
shall comply with all parking regulations promulgated by Landlord from time to time for the orderly use of the vehicle parking areas.
Parked vehicles shall not be used for vending or any other business or other activity while parked in the parking areas. Vehicles shall
be parked only in striped parking spaces, except for loading and unloading, which shall occur solely in zones marked for such purpose,
and be so conducted as to not unreasonably interfere with traffic flow within the Property or with loading and unloading areas of other
tenants. Employee and tenant vehicles shall not be parked in spaces marked for visitor parking or other specific use. All vehicles entering
or parking in the parking areas shall do so at owner&rsquo;s sole risk and Landlord assumes no responsibility for any damage, destruction,
vandalism or theft. Tenant shall cooperate with Landlord in any measures implemented by Landlord to control abuse of the parking areas,
including without limitation access control programs, tenant and guest vehicle identification programs, and validated parking programs,
provided that no such validated parking program shall result in Tenant being charged for spaces to which it has a right to free use under
its Lease. Each vehicle owner shall promptly respond to any sounding vehicle alarm or horn, and failure to do so may result in temporary
or permanent exclusion of such vehicle from the parking areas. Any vehicle which violates the parking regulations may be cited, towed
at the expense of the owner, temporarily or permanently excluded from the parking areas, or subject to other lawful consequence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">11.&#8239;&#8239;Tenant
and its Agents shall not smoke in the Building or at the Building entrances and exits. If any individual owner, employee, invitee, or
representative of Tenant is found to be smoking other than in permitted smoking areas, then Tenant will pay Landlord One Hundred and 00/100
Dollars ($100.00) per such occurrence. Landlord may fully restrict smoking on the Land in Landlord&rsquo;s sole election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;Tenant
shall provide Landlord with a written identification of any vendors engaged by Tenant to perform services for Tenant at the Premises (examples:
janitorial service, trash haulers, security guards/monitors, telecommunications installers/maintenance), and all vendors shall be subject
to Landlord&rsquo;s reasonable approval. Landlord reserves the right to refuse entry into the Building of any person. No mechanics shall
be allowed to work on the Building or Building Systems other than those engaged by Landlord. Tenant shall permit Landlord&rsquo;s employees
and contractors and no one else to clean the Premises unless Landlord consents in writing. Tenant assumes all responsibility for protecting
its Premises from theft and vandalism and Tenant shall see each day before leaving the Premises that all lights are turned out and that
the windows and the doors are closed and securely locked. Tenant acknowledges that Landlord&rsquo;s election to provide surveillance or
security in or about the Premises or the Building, its Parking Areas, or in or about the Land is subject to Landlord&rsquo;s sole discretion.
Landlord shall have no liability in connection with the decision whether or not to provide, or any failure of, such services and Tenant
hereby waives all claims based thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">13.&#8239;&#8239;Tenant
shall comply with any move-in/move-out rules provided by Landlord and with any rules provided by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">14.&#8239;&#8239;&#8239;Tenant
shall not place oversized cartons, crates or boxes in any area for trash pickup without Landlord&rsquo;s prior approval. Tenant shall
be responsible for all trash pickup of normal office refuse placed in ordinary office trash receptacles only. Excessive amounts of trash
or other out-of-the-ordinary refuse loads will be removed by Tenant&rsquo;s at Tenant&rsquo;s expense. If at Tenant&rsquo;s request, Landlord
consents to Tenant having a dumpster on the Property, Tenant shall locate the dumpster in the area designated by Landlord and shall keep
and maintain the dumpster clean and painted with lids and doors in good working order and, at Landlord&rsquo;s request, locked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 15. &#8239;Tenant shall comply with the following sustainability requirements:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in">a. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall provide
within ten (10) days after Landlord&rsquo;s request from time to time, reasonably requested energy and water consumption data and related
information in connection with Tenant&rsquo;s use of the Premises and all construction, maintenance, repairs, cleaning, trash disposal
and recycling relating to the Premises performed by or on behalf of Tenant -- all to be used for purposes of monitoring and improving
building efficiencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in">b. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Low/No VOC Paint.
Tenant shall use only interior paints and coatings (including primers) meeting the environmental requirements of the current Green Seal&trade;
Environmental Standard For Paints And Coatings - GS-11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">c. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Green Cleaning Products. All cleaning products used in the Premises must be certified
under the current Green Seal&trade; Environmental
Standard for Industrial and Institutional Cleaners - GS-37.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recycling. The following
items must be recycled according to local capabilities, guidelines and regulations: (i) Paper; (ii) Cardboard; (iii) Plastics; (iv) Aluminum
Cans/Metals; and (v) Glass.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 16. &#8239;&#8239;Tenant shall cause all of Tenant&rsquo;s Agents to comply with these Building Rules.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&#8239;&#8239;Landlord reserves
the right to rescind, suspend or modify any rules or regulations and to make such other rules and regulations as, in Landlord&rsquo;s
reasonable judgment, may from time to time be needed for the safety, care, maintenance, operation and cleanliness of the Property. Notice
of any action by Landlord referred to in these Building Rules, given to Tenant, shall have the same force and effect as if originally
made a part of the foregoing Lease. New rules or regulations will not, however, be unreasonably inconsistent with the proper and rightful
enjoyment of the Premises by Tenant under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&#8239;&#8239;These Building Rules
are not intended to give Tenant any rights or claims in the event that Landlord does not enforce any of them against any other tenants
or if Landlord does not have the right to enforce them against any other tenants and such nonenforcement will not constitute a waiver
as to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;C&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>PAYMENT RIDER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">All Minimum Annual Rent, Annual Operating
Expenses, Additional Taxes, and other sums, fees and charges payable under the Lease shall be paid by good check or wire transfer of immediately
available federal funds, to WPT LAND 2 LP as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">If remitted by U.S. Mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B><U>Remitter address</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">WPT Land 2 LP et al</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">PO Box 714856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Cincinnati, OH 45271-4856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B><U>Overnight address</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">WPT Land 2 LP et al</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 332pt 0pt 0in">Attn: Wholesale Lockbox # 714856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 332pt 0pt 0in">895 Central Ave, Suite
600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 332pt 0pt 0in">Cincinnati, OH 45202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B><U>If remitted by wire transfer</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Bank Name: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Beneficiary: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Account number: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Routing number: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Landlord may elect to institute a direct
payment requirement upon notice given to Tenant in which event Tenant shall provide such information and complete such authorizations
as Landlord may reasonably require for ACH transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;D&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PARKING AREA PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SEE ATTACHED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;E&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>TENANT ESTOPPEL CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Please refer to the
documents described in Schedule 1 hereto, (the &ldquo;<B>Lease Documents</B>&rdquo;) including the &ldquo;<B>Lease</B>&rdquo; therein
described; all defined terms in this Certificate shall have the same meanings as set forth in the Lease unless otherwise expressly set
forth herein. The undersigned Tenant hereby certifies that it is the tenant under the Lease. Tenant hereby further acknowledges that it
has been advised that the Lease may be collaterally assigned in connection with a proposed financing secured by the Property and/or may
be assigned in connection with a sale of the Property and certifies both to Landlord and to any and all prospective mortgagees and purchasers
of the Property, including any trustee on behalf of any holders of notes or other similar instruments, any holders from time to time of
such notes or other instruments, and their respective successors and assigns (the &ldquo;<B>Beneficiaries</B>&rdquo;) that as of the date
hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 1. &#8239;&#8239;&#8239;The information set forth in attached Schedule 1 is true and correct.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;Tenant is in occupancy of the Premises and the Lease is in full force and effect, and, except by such writings as are identified on Schedule
l, has not been modified, assigned, supplemented or amended since its original execution, nor are there any other agreements between Landlord
and Tenant concerning the Premises, whether oral or written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;All conditions under the Lease to be satisfied or performed by Landlord have been satisfied and performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;Tenant is not in default under the Lease Documents, Tenant has not received any notice of default under the Lease Documents, and, to Tenant&rsquo;s
knowledge, there are no events which have occurred that, with the giving of notice and/or the passage of time, would result in a default
by Tenant under the Lease Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;Tenant has not paid any Rent due under the Lease more than thirty (30) days in advance of the date due under the Lease and Tenant has
no rights of setoff, counterclaim, concession or other rights of diminution of any Rent due and payable under the Lease except as set
forth in Schedule 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;To Tenant&rsquo;s knowledge, there are no uncured defaults on the part of Landlord under the Lease Documents, Tenant has not sent any
notice of default under the Lease Documents to Landlord, and there are no events which have occurred that, with the giving of notice and/or
the passage of time, would result in a default by Landlord thereunder, and that at the present time Tenant has no claim against Landlord
under the Lease Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;Except as expressly set forth in Part G of Schedule 1, there are no provisions for any, and Tenant has no, options with respect to the
Premises or all or any portion of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;No action, voluntary or involuntary, is pending against Tenant under federal or state bankruptcy or insolvency law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;The undersigned has the authority to execute and deliver this Certificate on behalf of Tenant and acknowledges that all Beneficiaries
will rely upon this Certificate in purchasing the Property or extending credit to Landlord or its successors in interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">10. &#8239;This Certificate shall be binding
upon the successors, assigns and representatives of Tenant and any party claiming through or under Tenant and shall inure to the benefit
of all Beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">IN WITNESS WHEREOF, Tenant has executed
this Certificate this ____ day of __________, 2____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE 1 TO TENANT ESTOPPEL CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Lease Documents, Lease Terms and Current Status</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">A.</TD><TD STYLE="text-align: justify">Date of Lease:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">B.</TD><TD STYLE="text-align: justify">Parties:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
<TD STYLE="width: 6%">1.</TD><TD STYLE="text-align: justify; width: 88%">Landlord:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
<TD STYLE="width: 6%">2.</TD><TD STYLE="text-align: justify; width: 88%">Tenant:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">C.</TD><TD STYLE="text-align: justify">Premises:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">D.</TD><TD STYLE="text-align: justify">Modifications, Assignments, Supplements or Amendments to Lease:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">E.</TD><TD STYLE="text-align: justify">Commencement Date:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">F.</TD><TD STYLE="text-align: justify">Expiration of Current Term:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">G.</TD><TD STYLE="text-align: justify">Option Rights:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">H.</TD><TD STYLE="text-align: justify">Security Deposit Paid to Landlord: $</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">I.</TD><TD STYLE="text-align: justify">Current Minimum Annual Rent: $</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">J.</TD><TD STYLE="text-align: justify">Current Annual Operating Expenses: $</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">K.</TD><TD STYLE="text-align: justify">Current Additional Taxes: $</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">L.</TD><TD STYLE="text-align: justify">Current Total Rent: $</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">M.</TD><TD STYLE="text-align: justify">Square Feet Demised:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;F&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>TENANT IMPROVEMENT PLANS AND SPECIFICATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;G&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>HARARDOUS MATERIALS LIST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WILL BE PROVIDED BY TENANT BEFORE OCCUPANCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &ldquo;H&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGN PLAN AND SPECIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">NONE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 272pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 272pt"></P>

<!-- Field: Page; Sequence: 68; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 272pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FIRST AMENDMENT TO LEASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.45in"><B>&#8239;THIS FIRST
AMENDMENT TO LEASE AGREEMENT </B>(this <U>&ldquo;Amendment&rdquo;)</U> is made on this 17th day of June, 2019, by and between <B>WPT LAND
2 LP, </B>a Delaware limited partnership <U>(&ldquo;Landlord&rdquo;),</U> and <B>23andMe, Inc., </B>a Delaware corporation (&ldquo;Tenant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.25in; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>BACKGROUND:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
and Tenant entered into a certain Lease Agreement dated March 1, 2019 (the <U>&ldquo;Original Lease&rdquo;)</U> covering that certain premises
containing approximately 21,001 rentable square feet (the <U>&ldquo;Original Premises&rdquo;),</U> being Suite 100 located in the building
(the <U>&ldquo;Building&rdquo;)</U> known as 4415 Cotton Center Boulevard, Building 5, Phoenix, Arizona 85040, as more fully described in
the Lease B. Tenant has exercised its right of first refusal set forth in Section 30 of the Original Lease with respect to the Expansion
Space (being 14,462 rentable square feet) and the parties desire to amend the Original Lease to include the Expansion Space as part of
the Premises, subject to the provisions of this Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE,
</B>the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally
bound, hereby agree that the Lease is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Lease. The Original
Lease as amended by this First Amendment is sometimes referred to herein as the &ldquo;Lease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord
and Tenant agree and confirm that the Commencement Date is March 8, 2019 and the Expiration Date is July 31, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From and after August 1, 2019 (the <U>&ldquo;Expansion Date&rdquo;),</U> the Expansion Space shall be added to the Premises. Accordingly,
from and after the Expansion Date the Premises shall consist of 35,463 rentable square feet and all references to the &ldquo;Premises&rdquo;
in the Lease shall be to and mean 35,463 rentable square feet. The entire Premises shall be referred to as &ldquo;Suite 100.&rdquo; Exhibit
A to the Original Lease is hereby replaced by the Exhibit A attached to this Amendment. Landlord and Tenant stipulate and agree to the
rentable square footages set forth in this First Amendment and the Lease. Landlord and Tenant agree that &ldquo;Common Area&rdquo; shall
not include any interior portions of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0in; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To reflect the increased size of the Premises, from and after the Expansion Date, Tenant&rsquo;s &ldquo;Minimum Annual Rent&rdquo; obligation
shall be as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-right: 0.1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Lease Period</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Per RSF</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Annual</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Monthly</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3/8/19 &ndash; 7/31/19*;**</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">$</TD><TD STYLE="width: 24%; font-size: 10pt; text-align: right">13.50</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">$</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">283,514.00</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">$</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">23,626.13</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/19 &ndash; 7/31/20***, ****</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">13.50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">478,751.50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">39,895.88</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/20 &ndash; 7/31/21</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">13.91</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="padding-right: 0.1; font-size: 10pt; text-align: right; padding-left: 1.25">493,290.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">41,107.53</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/21 &ndash; 7/31/22</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="padding-left: -0.25in; font-size: 10pt; text-align: right">14.32</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">507,830.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">42,319.18</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/22 &ndash; 7/31/23</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">14.75</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">523,079.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">43,589.94</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/23 &ndash; 7/31/24</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">15.19</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">538,683.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">44,890.25</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/24 &ndash; 7/31/25</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">15.65</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">554,996.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">46,249.66</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">8/1/25 &ndash; 7/31/26</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">16.12</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">571,664.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$</TD><TD STYLE="font-size: 10pt; text-align: right">47,638.63</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.7in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.7in; text-align: justify"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.7in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.25in; text-align: justify">*In accordance with the Original
Lease, except as set forth in the next succeeding sentence, with respect to the Original Premises, Monthly Rent based on the Minimum Annual
Rent but not Annual Operating Expense, payments (or the Management Fee which is a part of Operating Expenses and shall be calculated as
if such monthly Minimum Annual Rent is being paid in full) or Additional Taxes (as defined below) payments, shall be abated (the <U>&ldquo;Abatement&rdquo;)</U>
for the first three (3) full calendar months (being April, May and June, 2019) following the Commencement Date. Should this Lease be terminated
during the initial Term by Landlord as a result of an uncured Event of Default (as defined below) by Tenant under this Lease, Landlord
shall be entitled to recover from Tenant (in addition to all other rights and remedies available to Landlord) such Abatement. The first
Lease month was March, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.7in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">**Based only on the Original Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">***Includes the Original Premises and the Expansion Space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.7in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.25in; text-align: justify">**** With respect to the Expansion
Space only, Monthly Rent based on the Minimum Annual Rent but not Annual Operating Expense, payments (or the Management Fee which is a
part of Operating Expenses and shall be calculated as if such monthly Minimum Annual Rent is being paid in full) or Additional Taxes (as
defined below) payments, shall be abated (the <U>&ldquo;Expansion Abatement&rdquo;)</U> in the aggregate amount of $48,809.25 for the first
three (3) full calendar months (being August, September and October, 2019) following the Expansion Date. Should this Lease be terminated
during the initial Term by Landlord as a result of an uncured Event of Default (as defined below) by Tenant under this Lease, Landlord
shall be entitled to recover from Tenant (in addition to all other rights and remedies available to Landlord) such Expansion Abatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 1.7in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-indent: 0.45in">&#8239;&#8239;5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To reflect the increased size of the Premises, from and after the Expansion Date, estimated Annual Operating Expenses for 2019
shall increase to $163,129.80, payable in equal monthly installments of $13,594.15, subject to adjustment and reconciliation as provided
in the Lease. Likewise, from and after the Expansion Date, Tenant&rsquo;s Share shall be increased from 59.20% to 100%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.45in">&#8239;&#8239;6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Security Deposit shall be increased to One Hundred Sixty-Nine Thousand Dollars ($169,000.00). Tenant shall deposit with Landlord,
on or before the Expansion Date, the increased amount of Sixty-Nine Thousand Dollars ($69,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.45in">&#8239;&#8239;7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From and after the Expansion Date, Tenant shall have the right to use a total of ninety-six (96) unreserved, uncovered parking
spaces, and a total of twenty (20) reserved, canopy parking spaces (eight (8) in addition to the currently permitted twelve (12) reserved,
canopy parking spaces) which additional covered parking spaces shall be considered &ldquo;Covered Parking Spaces,&rdquo; and Tenant shall
pay the monthly charge provided in <U>Section 3(b)</U> of the&#8239;Original Lease for each Covered Parking Space. The location of all one hundred
sixteen (116) parking spaces are shown on the attached <U>Exhibit AA,</U> attached to an made a part of this First Amendment, which shall
replace <U>Exhibit D</U> to the Original Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -0.5in; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -0.5in; text-align: justify; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 70; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -0.5in; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-indent: 0.45in">&#8239;&#8239;8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
provided in <U>Section 11(a) and (b)</U> of the Original Lease, from and after the Expansion Date, Tenant shall have the exclusive right
to install or maintain any Building Mounted Sign. The last sentence of <U>Section 11(b)</U> is hereby deleted from the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.45in">&#8239;&#8239;9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Other
than as set forth in this First Amendment, Tenant accepts the Expansion Space in its &ldquo;as is&rdquo; &ldquo;where is&rdquo; condition
and Landlord shall have no obligations whatsoever to improve or pay for improvements to the Premises for Tenant&rsquo;s use and occupancy,
except only as provided in this <U>Section 9.</U> Tenant intends to make improvements to the Expansion Space (the <U>&ldquo;Tenant Expansion
Improvements&rdquo;),</U> and pursuant to <U>Section 9,</U> shall be responsible for the cost thereof, and will have plans for such Tenant
Expansion Improvements designed and approved by Landlord in accordance with <U>Section 9(a)</U> below, and constructed by Tenant in accordance
with <U>Section 9(b)</U> below. Tenant confirms all Tenant Expansion Improvements are for the immediate use and benefit of Tenant only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0.8in; text-align: justify; text-indent: 0.45in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&#8239;&#8239;&#8239;&#8239;(a)&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;Tenant&rsquo;s improvement plans and specifications for such Tenant Expansion Improvements to the Expansion Space shall
be prepared by a licensed architect selected by Tenant and subject to the approval by Landlord, such approval not to be unreasonably
withheld, conditioned or delayed. The plans and specifications for the Tenant Expansion Improvements will be prepared in sufficient detail
to permit Tenant to construct the Tenant Expansion Improvements, and shall include, as applicable, demising walls, a partition layout
(dimensioned), door location and door schedule including hardware, reflected ceiling plan, telephone and electrical outlets with locations
(dimensioned), special electrical, HVAC and/or plumbing work, mechanicals, special loading requirements, such as the location of file
cabinets and special equipment, openings in the walls or floors, all necessary sections and details for special equipment and fixtures,
and finishes including, without limitation, carpentry and millwork, floor coverings, wall coverings, color schedules, and any other special
finishes. The plans for the Tenant Expansion Improvements shall be prepared in accordance, and shall comply in all respects, with all
Laws for the issuance of a Building Permit from the City of Phoenix. Landlord shall not unreasonably withhold, condition or delay its
approval of the plans and specifications for the Tenant Expansion Improvements. Within ten (10) days after receipt, Landlord shall provide
to Tenant in writing either its approval of such plans and specifications of the Tenant Expansion Improvements submitted by Tenant, or
any specific comments or objections that Landlord may have. If Landlord fails to respond within such ten (10) day period, Tenant&rsquo;s plans
and specifications shall be deemed approved or Tenant may deemed such delay a Landlord Delay as defined below. If Landlord timely provides
to Tenant Landlord&rsquo;s comments or objections to the plans and specifications of the Tenant Expansion Improvements, Tenant will revise
such plans and specifications to address such comments or objections and re-submit the plans and specifications and Landlord will continue
to approve or object to the same in the process set forth above until such plans and specifications of the Tenant Expansion Improvements
are finally approved or deemed approved by Landlord. Upon approval or deemed approval by Landlord, the plans and specifications for the
Tenant Expansion Improvements shall become final and shall not be materially changed without Landlord&rsquo;s further approval, which shall
not be unreasonably withheld, conditioned or delayed (as finally approved, the <U>&ldquo;Final&#8239;Expansion Plans&rdquo;</U>, a copy
of which shall be attached to and become a part of this First Amendment as <U>Exhibit &ldquo;AB</U>&rdquo;). Landlord&rsquo;s review or approval
of the Tenant Expansion Improvements plans does not constitute a code review and shall not be a representation or warranty of Landlord
that the Tenant Expansion Improvements plans are fit for any use, comply with any Laws or satisfy all requirements of the City of Phoenix
and the Cotton Center CCR&rsquo;s and the Allred CC&amp;Rs, and Tenant shall have no right to rely upon any such review or approval thereof
by Landlord. Landlord shall have no liability to Tenant or any third party by reason of such review or approval, and Landlord&rsquo;s review
of the Tenant Expansion Improvements plans and monitoring of construction shall be solely for its own benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -1in; text-align: justify; text-indent: 0.95in"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -1in; text-align: justify; text-indent: 0.95in"><U></U></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -1in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&#8239;&#8239;&#8239;&#8239;(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Tenant
shall complete the Tenant Expansion Improvements to the Expansion Space and integrate the same with the Original Premises in accordance
with the Final Expansion Plans, all applicable Laws, and all applicable provisions of this First Amendment and the Original Lease including,
but not limited to, provisions relating to Alterations, the provision of insurance, the delivery of Lien Waivers pursuant to <U>Section
9(f)</U> below, and the delivery of permits to Landlord pursuant to <U>Section 9(c)</U> below. The contractors selected by Tenant for
bidding on the Tenant Expansion Improvements shall be subject to the approval of Landlord, which shall not be unreasonably withheld,
conditioned or delayed. Landlord hereby approves the following contractor and subcontractors: DPR Construction, Commonwealth Electric,
and Harris Mechanical. Tenant shall require all contractors and subcontractors to be adequately insured as reasonably required by Landlord,
naming Landlord and the Landlord Additional Insureds, as additional insureds. The Tenant Expansion Improvements shall be the property
of Tenant until the expiration or termination of this Lease, as the same may be extended as set forth herein at that time without payment
by Landlord, the Tenant Expansion Improvements, including without limitation any laboratory fixtures and improvements, shall remain on
the Premises and become the property of Landlord unless Landlord gives notice to Tenant, at the time of Landlord&rsquo;s approval thereof,
to remove all or any part thereof at the expiration or termination of this Lease, in which event Tenant will remove all or such designated
parts, will repair any resulting damage and will restore the Expansion Premises to the condition existing prior to Tenant&rsquo;s installation
of the Tenant Expansion Improvements, all in accordance with <U>Section 21(a)</U> of the Original Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
construction relating to the Tenant Expansion Improvements shall be done in a good and workmanlike manner and shall comply in all respects
at the time of completion with all Laws of the City of Phoenix and all other governmental authorities having jurisdiction over the Premises.
Tenant shall obtain all governmental approvals and permits related to the Tenant Expansion Improvements and promptly deliver copies of
the same to Landlord prior to the start of any work relating to the Tenant Expansion Improvements. Promptly after the substantial completion
of the Tenant Expansion Improvements, Tenant shall provide Landlord with the following documents with respect to the Premises and the
Tenant Improvements, if required by the City of Phoenix or other applicable Laws: (i) a Certificate of Occupancy; (ii) a full set of
final and un-appealable permits and approvals; (iii) &ldquo;as-built&rdquo; plans (hard copy and CAD); and, (iv) a statement of completion
by a licensed architect confirming that the Tenant Expansion Improvements were completed in accordance with the Final Expansion Plans.
Except to the extent caused by the active negligence or willful misconduct of Landlord or its Agents, Tenant will indemnify, defend,
and hold harmless the Landlord Additional Insureds and their respective Agents from and against any and all claims, actions, damages,
proceedings,&#8239;costs, liability and expense (including reasonable fees of attorneys, investigators and experts) which may be asserted against,
imposed upon, or incurred by any of the Landlord Additional Insureds or their respective Agents and arising out of or in connection with
loss of life, personal injury or damage to property in or about the Premises or arising out of Tenant&rsquo;s performance of the work to install
the Tenant Expansion Improvements, whether in contract or tort, occasioned wholly or in part by any act or omission of Tenant or its
contractors and workers. Tenant&rsquo;s obligations pursuant to this <U>Section 9(c)</U> shall survive the expiration or termination of this
Lease. In case any action or proceeding is brought against any of the Landlord Additional Insureds or their respective Agents by reason
of any such claim, Tenant, upon notice from any of the Landlord Additional Insureds or their respective Agents, will, at Tenant&rsquo;s sole
cost and expense, resist and defend such action or proceeding with counsel acceptable to such Landlord Additional Insureds and their
respective Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in"></P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 1in">&#8239;&#8239;(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall, subject to <U>Section 9(e)</U> below, pay the costs, expenses and fees incurred for the construction of the Tenant Expansion Improvements,
including without limitation (i) architectural, engineering and design costs, (ii) the cost charged to Tenant by the general contractor
and all subcontractors for performing such construction, (iii) project management fees, (iv) construction permit fees, and (v) costs
of built-in furniture, (vi) mechanical and structural engineering fees, and, up to Twenty Thousand Dollars ($20,000) for the costs of
the FEE incorporated into the Expansion Space (together, the <U>&ldquo;Tenant Expansion Improvement Costs&rdquo;).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord shall provide an allowance to Tenant not to exceed Two Hundred Eighty-Nine Thousand Two Hundred Forty Dollars and No Cents
($289,240.00) (based on Twenty Dollars ($20.00) per rentable square foot of the Expansion Space) (the <U>&ldquo;Tenant Expansion Improvement
Allowance&rdquo;)</U> which shall be used by Tenant to pay for the Tenant Expansion Improvement Costs in accordance with <U>Section 9(d)</U>
above. In no event shall Landlord be responsible for any of the Tenant Expansion Improvement Costs in excess of the Tenant Expansion Improvement
Allowance. Accordingly, Tenant shall be responsible for all Tenant Expansion Improvement Costs in excess of the Tenant Expansion Improvement
Allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 1in">&#8239;&#8239;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-indent: 1in; text-align: justify">&#8239;&#8239;&#8239;(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall promptly pay all Tenant Expansion Improvement Costs as&#8239;they become due. Tenant may submit to Landlord no more than two (2)
applications for payment reimbursement to be applied against the Tenant Expansion Improvement Allowance (each, a <U>&ldquo;Expansion Reimbursement
Application&rdquo;).</U>&#9;Each Expansion Reimbursement&#8239;Application shall include: (i) executed statutory unconditional Lien Waivers;
(ii) sufficient evidence of payment from Tenant to Tenant&rsquo;s contractor of all Tenant Expansion Improvement Costs included in the then
current Expansion Reimbursement Application; and (iii) a certification completed by Tenant&rsquo;s architect confirming the Tenant Expansion
Improvements included in the then current Expansion Reimbursement Application were performed in accordance with the Tenant Expansion
Improvement Plans (collectively, the <U>&ldquo;Partial Expansion Reimbursement Requirements&rdquo;).</U> When the Tenant Expansion Improvements
are completed in their entirety, as a condition of the final Expansion Reimbursement Application, Tenant shall provide: (i) executed
final Lien Waivers, confirming the payment in full of all Tenant Expansion Improvement Costs up to the limit of the Tenant Expansion
Improvement Allowance and the release of liens against the Premises; (ii) sufficient evidence of payment from Tenant to Tenant&rsquo;s contractor(s)
of all&#8239;Tenant Expansion Improvement Costs up to the limit of the Tenant Expansion Improvement Allowance; and (iii) a certification completed
by Tenant&rsquo;s architect confirming the Tenant Expansion Improvements are complete and were performed in accordance with the Tenant Expansion
Improvement Plans (collectively, the <U>&ldquo;Final Expansion Reimbursement Requirements&rdquo;).</U> Landlord shall have thirty (30)
days after the receipt of each complete Reimbursement Application to submit its reimbursement payment to Tenant. Landlord shall not be
required to issue any reimbursement payment to Tenant if the Reimbursement Application does not include the Partial Expansion Reimbursement
Requirements or the Final Expansion Reimbursement Requirements, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 1in; text-align: justify">&#8239;&#8239;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&#8239;&#8239;&#8239;&#8239;(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Tenant shall make a complete reimbursement submission for the Tenant Expansion Improvement Costs up to the amount of the Tenant
Expansion Improvement Allowance no later than one (1) year after the Expansion Date. Landlord shall not be required to make payments on
account of the Tenant Expansion Improvement Allowance for any Tenant Expansion Improvement Costs not submitted to Landlord by the foregoing
date, and Tenant shall not have any claim to any portion of the Tenant Expansion Improvement Allowance not properly used by such date.
In no event shall any portion of the Tenant Expansion Improvement Allowance be used to offset Tenant&rsquo;s Rent obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&#8239;&#8239;&#8239;&#8239;(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord and Tenant acknowledge that Tenant has not elected to avail itself of the Additional Allowance, and, accordingly, Tenant
no longer has any right to the Additional Allowance under <U>Section 29(i)</U> of the Original Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.95in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties agree that they have dealt with no brokers in connection with this First Amendment, except for the Brokers identified in Section
1(1) of the Original Lease, whose commission with respect to this First Amendment shall be paid by Landlord pursuant to separate agreement.
Each party agrees to indemnify and hold the other harmless from any and all claims for commissions or fees in connection with this First
Amendment from any other real estate brokers or agents with whom they may have dealt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt -0.25in; text-align: justify; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except as expressly modified herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Tenant acknowledges and agrees that the Lease is in full force and effect and Tenant has no claims or offsets against Rent due
or to become due hereunder. The Lease, as amended by this First Amendment, represents the entire agreement between the parties hereto
and there are no collateral or oral agreements or understandings between Landlord and Tenant with respect to the Premises or the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This First Amendment shall be binding upon and inure to the benefit of the parties and their respective successors and permitted
assigns. Both parties having participated fully and equally in the negotiation and preparation of this First Amendment, this First Amendment
shall not be more strictly construed, nor any ambiguities in this First Amendment resolved, against either Landlord or Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each covenant, agreement, obligation, term, condition or other provision contained in this First Amendment shall be deemed and
construed as a separate and independent&#8239;covenant of the party bound by, undertaking or making the same, not dependent on any other provision
of this First Amendment unless otherwise expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If any provisions of this First shall be declared unenforceable in any respect, such unenforceability shall not affect any other
provision of this First Amendment, and each such provision shall be deemed to be modified, if possible, in such a manner as to render
it enforceable and to preserve to the extent possible the intent of the parties as set forth herein.&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; &#8239;&#8239;&#8239;</FONT>This First Amendment shall be construed and enforced in accordance with the Laws of the State of Arizona (without the application
of any conflict of laws principles). Any Arizona statutory provisions dealing with termination rights due to casualty, condemnation, delivery
of possession or any other matter dealt with by this Lease are superseded by the terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this First Amendment,
or make any claim that this First Amendment or the Lease is invalid or unenforceable, due to any failure of this document or the Lease
to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations or other similar
requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforceability due
to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This First Amendment may be executed in multiple counterparts, each of which, when assembled to include an original signature for
each party contemplated to sign this First Amendment, will constitute a complete and fully executed original. All such fully executed
counterparts will collectively constitute a single First Amendment. Tenant expressly agrees that if the signature of Landlord and/or Tenant
on this First Amendment is not an original, but is a digital, mechanical or electronic reproduction (such as, but not limited to, a photocopy,
fax, email, PDF,), then such digital, mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal
equivalent to, an authentic and traditional ink-on-paper original wet signature penned manually by its signatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"><B>[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK; SIGNATURE PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"><B>FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>IN WITNESS WHEREOF,</B>
Landlord and Tenant, intending to be legally bound, have executed this Amendment as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Landlord:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WPT LAND 2 LP</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WPT Land 2 GP LLC, its general partner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#8239;Anthony A. Nichols, Jr.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony A. Nichols, Jr.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, <SUP></SUP>2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TENANT:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23andMe Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#8239;Anne Wojcicki</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anne Wojcicki</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#8239;Steve Schoch</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Schoch</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved as to form</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23andMe Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    H. Sedwick / jmh</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>



<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ASSIGNMENT AND ASSUMPTION OF LEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>THIS ASSIGNMENT
AND ASSUMPTION OF LEASE </B>(this <B>&ldquo;Agreement&rdquo;) </B>is entered into as of June 25, 2020 by and between <B>23ANDME, INC., a
Delaware corporation (&ldquo;Assignor&rdquo;) </B>and <B>CARIS MPI INC., a Texas corporation (&ldquo;Assignee&rdquo;) .</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>WPT LAND 2 LP, a Delaware limited partnership <B>(&ldquo;Landlord&rdquo;), </B>as landlord, and Assignor, as tenant, entered into
that certain Lease Agreement dated March 1, 2019 (the <B>&ldquo;Original Lease&rdquo;), </B>as amended by First Amendment to Lease Agreement
<B>(&ldquo;First Amendment&rdquo;) </B>dated June 17, 2019 (collectively, the <B>&ldquo;Lease&rdquo;), </B>for the lease of the premises commonly
known as Suite 100 of the located at 4415 Cotton Center Boulevard, Phoenix, Maricopa County, Arizona (as more particularly described in
the Lease, the <B>&ldquo;Premises&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to all of the terms and conditions of this Agreement, (i) Assignor desires to assign to Assignee all of Assignor&rsquo;s rights
and obligations under the Lease, as amended herein, and (ii) Assignee desires to assume from Assignor, all of Assignor&rsquo;s rights and remaining
obligations under the Lease as of the Effective Date (as defined below) and any obligations arising from and after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Assignment and Assumption</U>.</B> Subject to Section 7 below, effective as the date that the Consent (as defined in Section
7) is fully executed and delivered by Landlord, Assignor and Assignee (the <B>&ldquo;Effective Date&rdquo;) , </B>Assignor does hereby
transfer, assign, convey, set over, and deliver unto Assignee all of Assignor&rsquo;s right, title, and interest in, to, and under the Lease.
Assignee does hereby assume and agree to perform all of Assignor&rsquo;s duties, liabilities, and obligations in, to, and under the Lease as
of, from and after the Effective Date. Accordingly, Assignee shall pay and perform directly to Landlord, for Landlord&rsquo;s benefit, all
monetary and non-monetary obligations accruing under the Lease on and after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Premises &ldquo;As-Is&rdquo;; FF&amp;E</U>.</B> Assignee shall accept the Premises in its existing &ldquo;AS-IS&rdquo; condition
as of the Effective Date and expressly acknowledges that Assignor shall not be obligated to provide or pay for any improvements (other
than any improvements that were performed by Assignor prior to the Effective Date for which Assignor has no further obligation to pay
for or perform as of the Effective Date) . Notwithstanding anything to the contrary in the Lease, Assignee acknowledges that neither
Assignor nor Landlord have any responsibility for work which may be required to prepare or remodel the Premises for Assignee&rsquo;s use, and
that Assignor has not made any representations of any kind, either express or implied, in connection with improvements or physical conditions
on, or otherwise bearing on, the use or condition of the Premises and Assignee shall rely solely on Assignee&rsquo;s own inspection and examination
of such items and not on any representations of Assignor, of any kind, either express or implied. Subject to Section 7 below, Assignor
shall deliver possession of the Premises to Assignee with the construction items listed on <U>Exhibit A-1</U> attached hereto and the
lab items listed on <U>Exhibit A-2</U> attached hereto which shall become the property of Assignee as of the Effective Date (collectively,
the <B>&ldquo;FF&amp;E&rdquo;) . </B>As additional consideration for Assignee entering into this Agreement, on or prior to the Effective
Date, Assignor shall execute a Quitclaim Bill of Sale (the <B>&ldquo;Quitclaim&rdquo;) , </B>in the form attached hereto as <U>Exhibit
B,</U> to Assignee for consideration of $1.00 from Assignee for the FF&amp;E and shall deliver the Quitclaim to Assignee concurrent with
the mutual execution and delivery of the Consent. Assignor makes no representation or warranty as to the FF&amp;E, and hereby expressly
DISCLAIMS ANY WARRANTIES AS TO MERCHANTABILITY, CONDITION, USABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Assignee shall be solely responsible
for and shall pay any sales, use or transfer taxes or similar taxes payable with respect to any applicable governmental authority to
the transfer of the FF&amp;E to Assignee and Assignee hereby agrees to indemnify, defend, protect and hold Assignor harmless from and
against any and all claims, losses and damages, including without limitation, reasonable attorneys&rsquo; fees and disbursements, which may
at any time be asserted against or suffered by Assignor by reason of Assignee&rsquo;s failure to pay any applicable taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Security Deposit</U>.</B> As of the date hereof, Landlord holds a security deposit of $169,000 (the <B>&ldquo;Security Deposit&rdquo;)
</B>with respect to the Lease. The parties acknowledge that such Security Deposit will continue to be held by Landlord following the
Effective Date and all rights of Assignor to the Security Deposit shall be assigned to Assignee as of the Effective Date, subject to
Assignee&rsquo;s payment obligation set forth below. Concurrent with Assignee&rsquo;s execution and delivery of this Agreement to Assignor and as
a condition to the effectiveness of this Agreement, Assignee shall reimburse Assignor for the amount of such Security Deposit by paying
to Assignor an amount equal to $169,000 by wire transfer of immediately available funds to wire transfer coordinates to be provided by
Assignor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reconciliations</U>.</B> Within five (5) business days following Assignee&rsquo;s receipt of any reconciliation statements of Operating
Expenses provided by Landlord to Assignee in accordance with Section 6 of the Original Lease for calendar years 2019 (to the extent Assignor
has not received the same as of the Effective Date) and 2020 (collectively, the <B>&ldquo;Reconciliation Statements&rdquo;), </B>Assignee
shall tender a copy of the same to Assignor. If the amount of the Operating Expenses paid by Assignor prior to the Effective Date exceeds
Assignor&rsquo;s actual share of such items as indicated in the Reconciliation Statements, then Assignee shall reimburse Assignor for such
excess within thirty (30) days of Assignor&rsquo;s receipt of any refund or credit from Landlord with respect to such overpayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Tenant Improvement Work</U>.</B> Assignee hereby expressly acknowledges and agrees that as of the Effective Date, Assignee
shall assume all of Assignor&rsquo;s obligations and liabilities with respect to the performance of and payment for the Tenant Improvements
(with reasonable modifications to the existing plans approved by Landlord) and the Tenant Expansion Improvements and all other work performed
with respect to the Premises (collectively, the <B>&ldquo;Tenant Improvement Work&rdquo;), </B>including without limitation, the completion
of all such Tenant Improvement Work currently under construction at the Building in accordance with the terms of the Lease. Assignee
hereby acknowledges and agrees that (a) Assignor shall terminate the existing construction contract with Assignor&rsquo;s general contractor
for the Tenant Improvement Work, DPR Construction <B>(&ldquo;DPR&rdquo;), </B>(b) from and after the Effective Date, Assignee shall promptly
enter into a new construction contract with a contractor selected by Assignee and approved by Landlord for the performance of the Tenant
Improvement Work and (c) Assignee shall be solely responsible for the completion of the Tenant Improvement Work and shall comply with
all the terms and conditions of the Lease related to the performance of the Tenant Improvement Work. Assignee further acknowledges and
agrees that as of the Effective Date, Assignor has no obligations to perform any of the Tenant Improvement Work, including without limitation,
any work to be performed under the permits described on <U>Exhibit C </U>attached hereto issued with respect to the Tenant Improvement
Work (collectively, the <B>&ldquo;Existing Permits&rdquo;), </B>or to close out any of the Existing Permits. In addition, Assignee shall
be solely responsible for obtaining, at its sole cost and expense, any other permits and other governmental approvals required with respect
to the Tenant Improvement Work. Assignee hereby assumes and agrees to perform all of Assignor&rsquo;s obligations with respect to the Existing
Permits and to perform all requirements for the close-out of the Existing Permits and any such other permits obtaining in connection
with the Tenant Improvement Work. Assignor hereby represents and warrants that Assignor has paid all amounts payable by Assignor as of
the date hereof with respect to the Tenant Improvement Work. Assignee hereby acknowledges and agrees that as of the date hereof, Landlord
has paid to Assignor all of the Tenant Improvement Allowance payable pursuant to the Original Lease and that no portion of the Tenant
Improvement Allowance shall be paid to Assignor nor assigned or payable to Assignee hereunder or pursuant to the Lease. In addition,
Assignee hereby acknowledges and agrees that as of the date hereof, Landlord has paid to Assignor $11,590.00 of the Tenant Expansion
Improvement Allowance payable to Tenant pursuant to the First Amendment and accordingly, the balance of the Tenant Expansion Improvement
Allowance is $277,650.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Indemnity</U>.</B> Assignee shall indemnify, defend, and hold harmless Assignor from and against any and all liabilities, obligations,
damages, penalties, claims, costs, charges and expenses (including, without limitation, reasonable attorneys&rsquo; fees) which may be imposed
upon, incurred by, or asserted against Assignor, arising out of or relating to the Lease and/or the Consent from and after the Effective
Date, including without limitation, the construction and completion of the Tenant Improvement Work, any breach of Assignee&rsquo;s obligations
pursuant to Section 5 above and any liability of Assignor for the Surviving Rent Obligation (as defined in the Consent) or any breach
of this Agreement or the Consent by Assignee. Assignee&rsquo;s indemnity obligations hereunder shall survive the expiration or earlier termination
of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Landlord&rsquo;s Consent</U>.</B> Notwithstanding anything to the contrary set forth in this Agreement, this Agreement and the obligations
of the parties hereunder are expressly conditioned upon Assignor obtaining prior written consent to this Agreement by Landlord, in form
and content acceptable to Assignor and Assignee (the <B>&ldquo;Consent&rdquo;). </B>Assignee shall promptly deliver to Assignor any documents
and information as may be requested by Landlord regarding Assignee&rsquo;s business or financial condition with respect to providing such Consent.
In the event that, for any reason, the Consent of Landlord to this Agreement is not obtained within thirty (30) days after execution
of this Agreement by Assignor and Assignee, then either party may terminate this Agreement by giving the other party written notice thereof,
in which event this this Agreement shall terminate and neither party shall have any obligation hereunder. Upon such termination, Assignor
shall return to Assignee the Security Deposit paid by Assignee to Assignor pursuant to Section 3. Notwithstanding anything to the contrary
set forth in the Consent, solely as between Assignor and Assignee, in the event of a conflict between this Agreement and the Consent,
the terms of this Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notices.</U> </B>Any and all notices, approvals or demands required or permitted under this Agreement shall be in writing,
shall be served either personally, by United States certified mail, postage prepaid, return receipt requested or by reputable overnight
carrier and, shall be deemed to have been given or made on the day on which it was received and shall be addressed to the parties at
the addresses set forth below. If a party refuses or fails to accept delivery of a notice, such notice shall be given upon attempted
delivery thereof. Any party may, from time to time, by like notice, give notice of any change of address, and in such event, the address
of such party shall be deemed to have been changed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 30%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If to Assignor:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If to Assignee:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#8239;</P></TD>
    <TD STYLE="width: 70%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">23andme, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">223 N. Mathilda Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sunnyvale, CA 94086</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Attn: Chief Legal and Regulatory Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Email: ###</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Caris MPI, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">750 West John Carpenter Freeway, Suite 800</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Irving, TX 75039</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Attention: Caris Legal Department</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Email: ###</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Assignee Covenants</U>.</B> Assignee hereby covenants and agrees that until such time as Assignor is fully released from any
and all liability under the Lease pursuant to the terms of the Consent, Assignee shall (a) immediately provide Assignor with a copy of
any notices of default or breach under the Lease, or any notices relating to the Surviving Obligation (as defined in the Consent) received
from Landlord or any other party, (b) immediately reimburse Assignor upon demand for any amounts paid by Assignor for the Surviving Rent
Obligation, together with a five percent (5%) administrative charge and interest thereon (at the rate of interest payable under the Lease
for any unpaid rent) until such amount is paid in full to Assignor, (c) promptly notify Assignor in writing of any default or breach
under the Lease or any event which may, with notice or the passage of time or both, may constitute a default or breach under the Lease
of which Assignee has knowledge, (d) not amend or modify the Lease in any manner which may increase Assignor&rsquo;s liabilities or obligations
under the Lease or the Consent, (e) fully and timely perform all of Assignee&rsquo;s obligations under the Lease, as amended from time to time,
and (f) until the Tenant Release Date (as defined in the Consent), not assign or otherwise Transfer any of Assignee&rsquo;s rights or obligations
under the Lease, the Consent or this Agreement. Assignee&rsquo;s obligations hereunder shall survive the expiration or earlier termination
of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Successors and Assigns</U>.</B> This Agreement is binding on and inures to the benefit of the parties hereto and their respective
successors and assigns. Notwithstanding any assignment, subletting or other transfer by Assignee of the Lease or the Premises or any
portion thereof or consent thereto by Landlord, Assignee shall remain fully liable under this Agreement and shall not be released from
performing any of the terms, covenants and conditions of this Agreement for so long as Assignor remains liable under the Lease pursuant
to the terms of the Consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Counterparts</U>.</B> Assignor and Assignee may execute this Agreement in multiple counterparts, each of which constitutes
an original, and all of which, collectively, constitute only one agreement. The signatures of all of the parties need not appear on the
same counterpart, and delivery of an executed counterpart signature page by electronic means (e.g., scanned PDF by e-mail) is as effective
as executing and delivering this Agreement in the presence of the other parties to this Agreement. This Agreement is effective upon delivery
of one executed counterpart from each party to the other parties. THE PARTIES HERETO CONSENT AND AGREE THAT THIS AGREEMENT MAY BE SIGNED
AND/OR TRANSMITTED BY USING ELECTRONIC SIGNATURE TECHNOLOGY (E.G., VIA DOCUSIGN OR SIMILAR ELECTRONIC SIGNATURE TECHNOLOGY), AND THAT
SUCH SIGNED ELECTRONIC RECORD SHALL BE VALID AND AS EFFECTIVE TO BIND THE PARTY SO SIGNING AS A PAPER COPY BEARING SUCH PARTY&rsquo;S HAND-WRITTEN
SIGNATURE. THE PARTIES FURTHER CONSENT AND AGREE THAT (1) TO THE EXTENT A PARTY SIGNS THIS AGREEMENT USING ELECTRONIC SIGNATURE TECHNOLOGY,
BY CLICKING &ldquo;SIGN&rdquo;, SUCH PARTY IS SIGNING THIS AGREEMENT ELECTRONICALLY, AND (2) THE ELECTRONIC SIGNATURES APPEARING ON THIS
AGREEMENT SHALL BE TREATED, FOR PURPOSES OF VALIDITY, ENFORCEABILITY AND ADMISSIBILITY, THE SAME AS HAND-WRITTEN SIGNATURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Authority and Consent</U>.</B> Each of Assignor and Assignee represents to the other that this Agreement has been duly authorized,
executed, and delivered by and on behalf of such party and constitutes the valid, binding, and enforceable agreement of such party in
accordance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Construction Against Drafting Party</U>.</B> Each of Assignor and Assignee acknowledges that such party and their respective
counsel have had an opportunity to review this Agreement and that this Agreement will not be construed for or against either party merely
because such party prepared or drafted this Agreement or any particular provision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Choice of Law</U>.</B> The laws of the state, commonwealth, or jurisdiction where the Premises are located (without giving
effect to its conflict of laws principles) govern all matters arising out of or relating to this Agreement and the transactions it contemplates,
including its interpretation, construction, performance, and enforcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Attorneys&rsquo; Fees</U>.</B> In the event any proceeding to enforce any provision of this Agreement, the party prevailing in such
proceeding shall be entitled, in addition to such other relief as may be granted, to receive from the other party all reasonable attorneys&rsquo;
fees and costs incurred in connection with such proceeding and any appeal therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Entire Agreement</U>.</B> This Agreement and the attached exhibits, which are hereby incorporated into and made a part of this
Agreement, set forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional
oral or written representations or agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt">IN WITNESS WHEREOF,
the parties hereby execute this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>ASSIGNOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>23ANDME, INC.,</B> a Delaware corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-size: 10pt">/s/
    Steve Schoch</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Steve Schoch</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>ASSIGNEE:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>CARIS MPI, INC.,</B> a Texas corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ David D. Halbert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT
A-1 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>LIST
OF CONSTRUCTION ITEMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 84; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT A-2<BR></U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>LIST OF LAB ITEMS<BR></U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U></U>(see attached)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 85; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT B </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>FORM OF QUITCLAIM BILL OF SALE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>QUITCLAIM BILL OF SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>23ANDME,
INC., Delaware corporation </B>(&ldquo;<B>Seller</B>&rdquo;) having its principal place of business at 223 N. Mathilda Avenue, Sunnyvale,
California, in consideration of $1.00 and other valuable consideration, receipt and sufficiency whereof is hereby acknowledged, does
hereby quitclaim and convey to <B>CARIS MPI, INC., a Texas corporation </B>(&ldquo;<B>Buyer</B>&rdquo;), the personal property described
on <B>Schedule 1 </B>attached hereto (collectively, the &ldquo;<B>FF&amp;E</B>&rdquo;) located at the premises having the address of
4415 Cotton Center Boulevard, Phoenix, Arizona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All warranties
of quality, condition, fitness of use, and merchantability are hereby excluded and Buyer accepts the FF&amp;E in its &ldquo;as is&rdquo;
/ &ldquo;where is&rdquo; condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: -3in; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IN
WITNESS WHEREOF</B>, Seller has caused this quitclaim bill of sale as of June 25, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">SELLER:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>23ANDME, INC.,</B> a Delaware coporation</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Steve Schoch, CFO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Steve Schoch, CFO</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">06/26/20</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 88; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SCHEDULE 1 TO QUITCLAIM BILL OF
SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>List of FF&amp;E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>LIST OF EXISTING PERMITS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 90; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(B)
<SEQUENCE>12
<FILENAME>tm2415719d15_ex10-3b.htm
<DESCRIPTION>EXHIBIT 10.3(B)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.3(b)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>INDUSTRIAL REAL ESTATE
LEASE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(Single-Tenant Facility)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARTICLE ONE: BASIC TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.55pt">This Article One
contains the Basic Terms of this Lease between the Landlord and Tenant named below. Other Articles, Sections and Paragraphs of the Lease
referred to in this Article One explain and define the Basic Terms and are to be read in conjunction with the Basic Terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt"><B>Section 1.01. Date of Lease.
</B></FONT>August <FONT STYLE="font-size: 10pt">19,</FONT> 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt"><B>Section
1.02. Landlord (include legal entity). </B></FONT>Liberty Cotton Center, LLC, a Delaware limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt">LANDLORD:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt">Liberty Cotton Center, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt">2930 East Camelback Road, Suite 318</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Phoenix, AZ 85016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Attn: Senior Vice President/City Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt"><B>Section
1.03. Tenant (include legal entity). </B></FONT>CDx Holdings, Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">TENANT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">CDx Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Attn: Joe Ellison, Vice President, Human Resources</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">8400 Esters Boulevard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Suite 190</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Irving, TX 75063</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
1.04. Property. </B></FONT>The &quot;Property&quot; (also referred to as the &quot;Leased Premises&quot;) is located at 4610 South 44th
Place, Phoenix, Arizona 85040, and consists of 66,012 rentable square feet based on a standard perimeter drip line measurement (&quot;Building&quot;)
and the right to use the other improvements located on the land and the common areas described in Paragraph 4.03(a) relating to Building
as described or depicted in Exhibit &quot;A&quot;. Landlord has provided to Tenant the architects' certification of the rentable square
footage and the calculations of such square footage prior to execution of this Lease, and Tenant acknowledges receipt of such certification
as provided in the letter from Balmer Architectural Group, dated June 11, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>Section 1.05. Lease Term.
</B></FONT>Ten (10) years and six (6) months beginning on March 1, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
1.06. Permitted Uses (See Article Five). </B></FONT>Twenty-four hour, seven day a week access and use for general office use; medical
diagnostic; laboratory-based research; other medical review services; imaging center; clinical and anatomic pathology laboratory services;
molecular genetic laboratory services; cytogenetic laboratory services; Biosafety level 2 laboratory associated activities: processing
of any type of bodily fluids, tissues, or other products associated with or derived from human or animal tissues, cell lines, bacterial
cultures, viral cultures; recombinant DNA work; diagnostic medical laboratory and related services, testing and administration; use and
appropriate disposal of hazardous chemicals and biohazardous waste.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><B>Section 1.07. Tenant's Guarantor (if none, so state).
</B>NONE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 1.08. Brokers (See Article Fourteen) (See 13.15).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">LANDLORD'S BROKERS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Mark S. Krison</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">CB Richard Ellis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">Senior Vice President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">2415 East Camelback Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">Phoenix, AZ 85016-4290</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">TENANT'S BROKER:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">Scott T. Collier and Greg Bast</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">Jones Lang LaSalle Americas, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 107pt">8343 Douglas Avenue, Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106pt">Dallas, TX 75225</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 1.09. Commission Payable to Landlord's Broker
(See Article Fourteen). </B>Pursuant to separate agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 1.10. Security Deposit. </B>None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt; text-align: justify; text-indent: 34.5pt"><B>Section 1.11.
Vehicle Parking Spaces Allocated to Tenant. </B>Two Hundred Sixty Four (264) vehicle parking spaces at the locations set for in Exhibit
 &quot;A&quot; attached hereto for Tenant's exclusive use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt"><B>Section 1.12. Rent and Other Charges Payable by Tenant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Base
Rent. </B>Base Rent shall be made per month, plus all applicable rental taxes and privilege taxes, as provided in Section 3.05 and pursuant
the following (which amounts (other than for months 1-6) each include an amortized portion of the Tenant Allowance equal to $2.927):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.85in; width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 1-6</FONT></TD>
    <TD STYLE="width: 67%"><FONT STYLE="font-family: Times New Roman, Times, Serif">$0.00 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 7-18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$19.897 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 19-30</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$20.321 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 31-42</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$20.756 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 43-54</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$21.202 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 55-66</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$21.659 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 67-78</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$22.127 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 79-90</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$22.607 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 91-102</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$23.099 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Months 103-114</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$23.603 per rentable square feet per year</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Months 115-126</TD>
    <TD>$24.120 per rentable square feet per year</TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other Periodic Payments. </B></FONT>(i) Real Property Taxes (See Section 4.02); (ii)<FONT STYLE="font-size: 10pt">&nbsp;</FONT>Common
Area Costs (See Section 4.03); (iii) Insurance Premiums (See Section 4.04); (iv) Impounds for Insurance Premiums and Property Taxes
(See Section 4.07); and (v) Maintenance, Repairs and Alterations (See Article Six), including all applicable rental and privilege taxes
on said Periodic Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 1pt; text-indent: 35.05pt"><FONT STYLE="font-size: 10pt"><B>Section
1.13. Landlord's Share of Profit on Assignment or Sublease (See Section 9.05). </B></FONT>Fifty percent (50%) of the Profit (the &quot;Landlord's
Share&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 1pt; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
1.14. Riders/Exhibits. </B></FONT>The following Riders or Exhibits are attached to and made a part of this Lease (if none, so state):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Exhibit &quot;A&quot; Diagram of Property with Parking Designated.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(b)</B></FONT>&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;Exhibit &quot;B&quot; Work Letter Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(c)
</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Exhibit &quot;C&quot; Building Rules</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>ARTICLE TWO: LEASE TERM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-size: 10pt"><B>Section
2.01. Lease of Property For Lease Term. </B></FONT>Landlord leases the Property to Tenant and Tenant leases the Property from Landlord
for the Lease Term. The Lease Term is for the period stated in Section 1.05 above and shall begin and end on the dates specified in Section
1.05 above, unless the beginning or end of the Lease Term is changed under any provision of this Lease. The &quot;Commencement Date&quot;
shall be the date specified in Section 1.05 above for the beginning of the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-size: 10pt"><B>Section
2.02. Exempt Property. </B></FONT>The definition of Property in Section 1.04 shall exclude any advertising structure positioned on the
roof of any building, all antennae, satellite dishes and any other communication equipment and all banners or signs promoting the Property;
provided, however, such excluded area and structures on the roof shall not interfere with Tenant's installation or use of the rooftop
exhaust fans and satellite dishes (subject to the language at the end of this Section) installed for Tenant's use at the locations shown
on the Tenant's Space Plan that is approved by Landlord. Further excluded from the definition of Property is all internal space designed
to house mechanical equipment, conduit, wires, HVAC ducting and hookups with any such systems, including all mechanical run areas and
casements, which are currently in use or to be used in the future. Provided that Tenant is not in default under this lease, Tenant shall
have the right to install, maintain and repair a satellite dish antenna (the &quot;Antenna&quot;) on the Building under and subject to
the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall comply with all applicable rules, laws, regulations and restrictions applicable to the Property and shall obtain, and deliver to
Landlord written evidence of, any approval(s) required under any recorded covenants or restrictions applicable to the Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Tenant shall obtain Landlord's prior approval of the location of the Antenna on the Property and of the specifications for the
Antenna. <FONT STYLE="font-size: 10pt">If</FONT> Landlord approves installation of the Antenna on the roof of the Building, Tenant agrees
to consult with Landlord's roofing contractor prior to installation and strictly to comply with the roofing contractor's recommendations
and requirements. Tenant shall pay all costs incurred by Landlord in connection with the Antenna including without limitation all architectural,
engineering, contractors' and legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt">(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall comply with the provisions of Section 6 (Alterations) of this Lease.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>At least 3 business days prior to installation, Tenant shall notify Landlord of the date and time of the installation. Tenant
shall install the Antenna only if Landlord is present with Tenant at the installation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Tenant shall maintain the Antenna in a safe, good and orderly condition. The installation, maintenance, repair and removal of
the Antenna shall be performed at Tenant's sole expense in a manner which will not impair the integrity of, damage or adversely affect
the warranty applicable to, the roof or any other portion of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
later than the expiration or sooner termination of the Term, at Tenant's sole expense, Tenant shall remove the Antenna and repair any
resulting damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35.05pt">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Tenant's indemnification of Landlord pursuant to Section 5.05 of this Lease also applies to the Antenna and Tenant's use of
any portion of the Property therefor. Without limiting the foregoing, Tenant solely shall be responsible for any damages or injury caused
by or in any way relating to the Antenna, including, but not limited to, damage or injury caused by reason of the Antenna collapsing
or being blown from the roof or any other portion of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35pt"><B>Section 2.03. Early Occupancy.
</B><FONT STYLE="font-size: 10pt">If</FONT> Tenant occupies the Property and commences business operations prior to the scheduled Commencement
Date, the Commencement Date herein shall adjust to such earlier date, the Expiration Date shall be adjusted accordingly, and Tenant's
occupancy of the Property shall be subject to all of the provisions of this Lease, including the obligation to commence paying Additional
Rent; provided that Tenant may not commence business operations until the Tenant Improvements (as defined in the Work Letter Agreement
attached as Exhibit &quot;B&quot; hereto) have been completed. If Tenant so requests, Landlord will allow Tenant limited access
to the Property to begin installing equipment, fixtures, furniture and cabling and/or to properly coordinate such work with the construction
of the Tenant Improvements. Any such access will be subject to Landlord's prior consent in each instance, which consent will not be unreasonably
withheld but may be conditioned on Tenant's work not unreasonably interfering with the construction of the Tenant Improvements. Any such
use of the Property is also subject to, and Tenant must comply with and observe, all applicable laws, all safety rules and procedures,
and all other terms and conditions of this Lease. Except as provided in the first sentence of this Section 2.02, in no event may Tenant
conduct business in the Property during such early access period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.4pt"><B>Section 2.04. Holding
Over. </B>Tenant shall vacate the Property upon the expiration or earlier termination of this Lease. Tenant shall reimburse Landlord
for and indemnify Landlord against all reasonable damages which Landlord incurs from Tenant's delay in vacating the Property. <FONT STYLE="font-size: 10pt">If
</FONT>Tenant does not vacate the Property upon the expiration or earlier termination of the Lease and Landlord thereafter accepts rent
from Tenant, Tenant's occupancy of the Property shall be a &quot;month-to-month&quot; tenancy, subject to all of the terms of this Lease
and any governmental statutes which are applicable to a month-to-month tenancy, but do not conflict with any provision contained in this
Lease, except that the Base Rent then in effect shall be increased by one hundred fifty percent (150%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARTICLE THREE: BASE RENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt; text-align: justify; text-indent: 35.9pt"><B>Section 3.01.
Time and Manner of Payment. </B>Upon execution of this Lease, Tenant shall pay Landlord the Base Rent in the amount stated in Section
l.12(a) above for the first month of the Lease Term. On the first day of the first month of the Lease Term and each month thereafter,
Tenant shall pay Landlord the Base Rent, in advance, without offset, deduction or prior demand. The Base Rent shall be payable at Landlord's
address or at such other place as Landlord may designate in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 36.4pt"><B>Section 3.02.
Option To Renew. </B>At the expiration of the Lease Term, Tenant will have the option of extending the term of the Lease for two (2)
additional terms (the &quot;Renewal Options&quot;) of five (5) years each (collectively, the &quot;Renewal Terms&quot;); provided, however,
that Tenant is not in material default beyond any applicable cure period under the Lease on the date of giving such notice or on the
date of commencement of such Renewal Term; and provided, further that Tenant has not been in default (after the expiration of any notice
and cure periods) under the Lease more than three (3) times previously. Tenant shall notify Landlord in writing of its intention to exercise
any Renewal Option (&quot;Tenant's Notice&quot;) not later than nine (9) months prior to expiration of the Lease Term or first renewal
period, as the case may be. Any termination of the Lease shall result in automatic termination of the Renewal Options herein. The Renewal
Terms shall be upon all of the terms and conditions of this Lease, except that the following rights and obligations of Tenant during
the original Lease Term of this Lease shall not apply during any Renewal Term: (a) any right to rent-free or abated rent possession;
<FONT STYLE="font-size: 10pt">(b)</FONT> any right to further extension of the term of the Lease beyond the Renewal Terms set forth herein
above; (c) any right to an additional Tenant Improvement Allowance during the Renewal Terms, and (d) any right to continue to pay the
same Base Rent. The Base Rent for the Renewal Term shall be at Fair Market Value. Landlord shall provide Tenant with written notice of
its proposed determination of Fair Market Value for the Property within thirty (30) days after receipt of Tenant's Notice. The parties
shall have forty-five (45) days after Landlord has provided Tenant with Landlord's proposed determination of Fair Market Value for the
Property in order to agree on the Base Rent during such extended term. If the parties fail to agree on the Base Rent for such extended
term during that period, then <FONT STYLE="font-size: 10pt">(i)</FONT> either party may elect to terminate this Lease at the end of the
applicable term or (ii) the parties may agree to determine the Fair Market Rental through an appraisal. In the event the parties elect
to establish the Fair Market Rental through an appraisal process, Landlord and Tenant shall each appoint one appraiser within thirty
(30) days thereafter; provided, however, that if either party fails to designate an appraiser within the time period specified, then
the appraiser who is designated shall conclusively determine the Fair Market Rental. <FONT STYLE="font-size: 10pt">If</FONT> two (2)
appraisers are designated, then they shall submit within thirty (30) days after the second thereof has been designated their appraisals
of the Fair Market Rental. Landlord and Tenant intend that the &quot;Fair Market Rental&quot; shall be deemed to be the rentable square
feet of industrial space that is then being charged for industrial space located in industrial buildings in the vicinity of and involving
the use of the Property that are comparable in quality and offer similar amenities to the Property and involving arms length, new leases
with similar terms and conditions, taking into account the savings to the Landlord in putting a new tenant into possession of the Property
and all concessions offered in such other arms length new leases in the market (including without limitation free rent, tenant improvement
allowances, leasing commissions, and moving allowances). The spaces used for comparison shall be comparable in size, quality and design
to the Property, and such spaces used for comparison shall be comparable to the Property with respect to their location within such buildings,
the quality and quantity of tenant improvements installed at each landlord's expense, and the financial strength of Tenant. Should the
two appraisers be unable to agree within said thirty (30) days, the two appraisers shall each submit an independent written appraisal
and together they shall designate one (1) additional person as appraiser within five (5) days following the expiration of said thirty
(30) day period; provided however, that if the difference between the two appraisals is five percent (5%) or less of the lowest appraisal,
then an additional appraiser shall not be designated and the Fair Market Rental shall equal the average of the two (2) appraisals that
are submitted. The third appraiser shall submit an independent written appraisal within thirty (30) days following his or her appointment.
If the two appraisers cannot agree upon a third appraiser, then either party hereunder may request that the presiding Judge of the Maricopa
County Superior Court appoint such third appraiser. <FONT STYLE="font-size: 10pt">In</FONT> the event a third appraiser is appointed,
the Fair Market Rental shall be equal to the average of the two (2) written appraisals which are closest, and third (3rd) appraisal shall
be disregarded. Each party shall bear the costs of the appraiser appointed by it. If three (3) appraisers are appointed, each party shall
bear the cost of the appraiser appointed by it and the parties shall share equally in the cost of the third appraiser. No person shall
be appointed or designated an appraiser unless he or she is (i) an independent appraiser who is a currently certified member of the American
Institute of Real Estate Appraisers (with MM designation) and unless he or she has at least five (5) years experience as an appraiser
in Maricopa County, or (ii) a real estate broker with at least ten (10) years experience in leasing of commercial industrial space in
the vicinity of the Property. The third appraiser shall not have ever been employed (full-time or part-time or on a consulting basis)
by Landlord or Tenant. In the event that the Fair Market Rental is not established before the commencement of the extended term, Tenant
shall continue to pay the Base Rent in effect as of the end of the original term; when the Fair Market Rental has been established, the
new Base Rent shall be retroactively effective as of the beginning of the extended term, and Tenant shall pay Landlord any deficiency
with in thirty (30) days after the establishment of the new Base Rent. <FONT STYLE="font-size: 10pt">If</FONT> Tenant has overpaid the
Base Rent during such period, such overpayment shall be, at the election of Tenant, either offset against rent thereafter coming due
or refunded by Landlord to Tenant. Notwithstanding the foregoing, if either Landlord or Tenant is not satisfied with the Fair Market
Rental determined by the appraisal process, such party may elect to terminate this Lease at the end of the applicable term by providing
written notice to the other party within ten (10) days after the Fair Market Rent is determined by the appraiser(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 3.03. Intentionally Deleted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2pt; text-align: justify; text-indent: 35pt"><B>Section 3.04.
Termination; Advance Payments. </B>Upon termination of this Lease under Article Seven (Damage or Destruction), Article Eight (Condemnation)
or any other termination not resulting from Tenant's default, and after Tenant has vacated the Property <FONT STYLE="font-size: 10pt">in
</FONT>the manner required by this Lease, Landlord shall refund or credit to Tenant (or Tenant's successor) any advance rent or other
advance payments made by Tenant to Landlord, and any amounts paid for real property taxes and other reserves which apply to any time
periods after termination of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt; text-align: justify; text-indent: 35.8pt"><B>Section 3.05.
Rental/Privilege Taxes. </B>Tenant shall pay Landlord any and all privilege, commercial rental tax, transactional, excise or other taxes
(not including Landlord's income taxes) imposed or levied by any taxing authority against Landlord for, or on Landlord's right to receive
or the receipt by Landlord of, Base Rent, Additional Rent and any other charges or sums payable by Tenant under this Lease, said taxes
to be paid and due at the time provided for payment of said Base Rent, Additional Rent or other sums or charges by Tenant. Upon collection
of such amounts, Landlord shall timely pay such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"><B>ARTICLE FOUR: OTHER CHARGES PAYABLE BY TENANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 35.9pt"><B>Section
4.01. Additional Rent. </B>All charges payable by Tenant other than Base Rent are called &quot;Additional Rent.&quot; Unless this
Lease provides otherwise, Tenant shall pay all Additional Rent then due with the next monthly installment of Base Rent. The term
 &quot;rent&quot; shall mean Base Rent and Additional Rent. Additional Rent shall be payable upon the Commencement Date. During the
first six (6) months of this Lease (i.e., the period of time in which no Base Rent is due and payable), Additional Rent shall be due
and payable on the first day of each calendar month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 4.02. Property Taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Real
Property Taxes. </B>Tenant shall pay all real property taxes on the Property (including any fees, taxes or assessments against, or
as a result of, any tenant improvements installed on the Property by or for the benefit of Tenant) during the Lease Term. Subject to
Paragraph 4.02(c) and Section 4.07 below, such payment shall be made at least ten (10) days prior to the delinquency date of the
taxes. Within such ten (10) day period, Tenant shall furnish Landlord with satisfactory evidence that the real property taxes have
been paid. Landlord shall reimburse Tenant for any real property taxes paid by Tenant covering any period of time prior to or after
the Lease Term. If Tenant fails to pay the real property taxes when due, Landlord may pay the taxes and Tenant shall reimburse
Landlord for the amount of such tax payment as Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(b)
</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Definition <FONT STYLE="font-size: 10pt">of </FONT>&quot;Real Property
Tax.&quot;</B> &quot;Real property tax&quot; means: (i) any fee, license fee, license tax, business license fee, commercial rental tax,
levy, charge, assessment, penalty or tax imposed by any taxing authority against the Property; (ii) any tax against Landlord's business
of leasing the Property; (iii) any tax or charge for fire protection, streets, sidewalks, road maintenance, refuse or other services
provided to the Property by any governmental agency; (iv) any tax imposed upon this transaction or based upon a re-assessment of the
Property due to a change of ownership, as defined by applicable law, or other transfer of all or part of Landlord's interest in the Property;
and (v) any charge or fee replacing any tax previously included within the definition of real property tax. &quot;Real property tax&quot;
does not, however, include Landlord's federal or state income, franchise, inheritance or estate taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(c)
</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Joint Assessment.</B> If the Property is not separately assessed,
Landlord shall reasonably determine Tenant's share of the real property tax payable by Tenant under Section 4.02(a) from the assessor's
worksheets or other reasonably available information. Tenant shall pay such share to Landlord within fifteen (15) days after receipt
of Landlord's written statement. Tenant shall have the right to review the method of calculation for Tenant's share of real property
tax, and Landlord, upon request by Tenant, shall make available to Tenant the methods and calculations for such determination. If Tenant
disagrees with Landlord's above determination, such dispute will be resolved according to the arbitration provisions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(d)</B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Personal
Property Taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3in">(i) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall pay all taxes charged against trade fixtures, furnishings, equipment or any other personal property belonging to Tenant. Tenant
shall use Tenant's best efforts to have personal property taxed separately from the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If any of Tenant's personal property is taxed with the Property, Tenant shall pay Landlord the taxes for the personal property within
fifteen (15) days after Tenant receives a written statement from Landlord for such personal property taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(e)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant's Right to Contest Taxes. </B><FONT STYLE="font-size: 10pt">Tenant may attempt
to have the assessed valuation of the Property reduced or may initiate proceedings to contest the real property taxes. If required by
law, Landlord shall join in the proceedings brought by Tenant. However, Tenant shall pay all costs of the proceedings, including any
costs or fees incurred by Landlord. Upon the final determination of any proceeding or contest, Tenant shall immediately pay the real
property taxes due, together with all costs, charges, interest and penalties incidental to the proceedings. If Tenant does not pay the
real property taxes when due and contests such taxes, Tenant shall not be in default under this Lease for nonpayment of such taxes if
Tenant deposits funds with Landlord or opens an interest-bearing account reasonably acceptable to Landlord in the joint names of Landlord
and Tenant. The deposit shall be applied to the real property taxes due, as determined at such proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 4.03. Common Areas; Use, Maintenance and Costs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Common Areas. </B><FONT STYLE="font-size: 10pt">As used in this Lease, &quot;Common
Areas&quot; shall mean all areas which are available for the common use of tenants of the Cotton Center Park, including Tenant, and which
are not leased or held for the exclusive use of Tenant or other tenants, including, but not limited to, parking areas, driveways, sidewalks,
loading areas, access roads, corridors, landscaping and planted areas. Landlord, from time to time, may change the size, location, nature
and use of any of the Common Areas, convert Common Areas into leaseable areas, construct additional parking facilities (including parking
structures) in the Common Areas, and increase or decrease Common Area land and/or facilities. Tenant acknowledges that such activities
may result in inconvenience to Tenant. Except in an emergency, Landlord shall provide reasonable advance written notice to Tenant of
any such activities and shall in no event materially impair ingress and egress to the Property unless such impairment is required by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B>Liberty Cotton Center.</B> The Leased Premises is located within a business park known as the Liberty Cotton Center (&quot;Liberty
Cotton Center&quot;). Tenant, its agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, successors,
tenants, visitors, and others, shall have the nonexclusive right to use all drives, sidewalks and other common facilities and areas (collectively,
the &quot;Liberty Common Areas&quot;) located within Liberty Cotton Center, including the right of ingress and egress to 44th Street,
jointly with Landlord, other owners, tenants and occupants therein, and their respective agents, assigns, customers, designees, employees,
guests, invitees, licensees, representatives, servants, successors, tenants, visitors, and others. Landlord represents and warrants that
it has the legal right and authority to grant such rights to use the Liberty Common Areas to Tenant. Tenants, its agent, representatives,
licensees, or employees shall not use any of the Liberty Common Areas in a manner which obstructs or interferes with the reasonable use
thereof by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3in">(ii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cotton
Center Park. Liberty Cotton Center is a business park within a larger business park known as The Cotton Center (the &quot;Cotton Center
Park&quot;). Tenant, its agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, successors,
tenants, visitors, and others, shall also have the nonexclusive right to use all drives, sidewalks and other common areas and facilities
(collectively, the &quot;Cotton Center Common Areas&quot;) located within Cotton Center Park, jointly with Landlord, other owners, tenants
and occupants therein, and their respective agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives,
servants, successors, tenants, visitors, and others. Landlord represents and warrants that it has the legal right and authority to grant
such rights to use the Cotton Center Common Areas to Tenant. Tenant, its agents, assigns, customers, designees, employees, guests, invitees,
licensees, representatives, servants, successors, tenants, visitors, and others, shall not use any of the Cotton Center Common Areas
in a manner which obstructs or interferes with the reasonable use thereof by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Use of Common Areas. </B>Tenant shall have the nonexclusive right (in common
with other tenants and all others to whom Landlord has granted or may grant such rights) to use the Common Areas for the purposes intended,
subject to such reasonable rules and regulations as Landlord may establish from time to time. Tenant shall abide by such rules and regulations
and shall use its best effort to cause others who use the Common Areas with Tenant's express or implied permission to abide by Landlord's
rules and regulations. At any time, Landlord may temporarily close any Common Areas to perform any acts in the Common Areas as, in Landlord's
judgment, are desirable to improve Cotton Center Park or Liberty Cotton Center. Landlord shall provide Tenant with five (5) days prior
written notice of all anticipated closures of the Common Area, along with the estimated time period Landlord expects such closure to
continue. However, in emergency situations, Landlord shall provide the foregoing notice as soon as reasonably possible. Tenant shall
not interfere with the rights of Landlord, other tenants or any other person entitled to use the Common Areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Specific Provision re: Vehicle Parking. </B>Tenant shall be entitled to use the number of vehicle parking spaces in the Property allocated
to Tenant in Section 1.11 of the Lease, at the locations designated on the Diagram of the Property attached hereto as Exhibit &quot;A,&quot;
without paying any additional rent. Of the allocated parking spaces, Landlord agrees that one hundred (100) of such parking spaces shall
be covered and lit spaces, the location of such spaces of which will be mutually agreed upon by Tenant and Landlord and which improvements
shall occur prior to the Commencement Date. Tenant's parking shall be reserved and shall be limited to vehicles no larger than standard
size automobiles or pickup utility vehicles. Tenant shall not cause large trucks or other large vehicles to be parked within Cotton Center
Park or on the adjacent public streets. Temporary parking of large delivery vehicles in Cotton Center Park may be permitted by the rules
and regulations established by Landlord. Vehicles shall be parked only in striped parking spaces and not in driveways, loading areas
or other locations not specifically designated for parking. Handicapped spaces shall only be used by those legally permitted to use them.
<FONT STYLE="font-size: 10pt">If</FONT> Tenant parks more vehicles in the parking area than the number set forth in Section 1.11 of this
Lease, such conduct shall be a breach of this Lease, unless prior written consent for such parking is given by Landlord. In addition
to Landlord's other remedies under the Lease, Tenant shall pay a daily charge determined by Landlord for each such additional vehicle.
A breach shall not be deemed to occur under this Section unless written notice to Tenant of such violation is given. Notwithstanding
the foregoing, no more than two (2) written notices shall be required during any twelve (12) calendar months for such matter to be a
breach. Tenant shall be entitled to install covered parking at its sole cost and expense, provided Tenant complies with all applicable
rules, laws, regulations and restrictions applicable to the Property and such improvements, and subject to the requirements in Section
6.05 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(d)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintenance of Common Areas. </B></FONT>Landlord shall maintain the Common
Areas in good order, condition and repair and while in control of the Association applicable to the Property, shall operate Liberty Cotton
Center, in Landlord's sole discretion, as a first-class industrial/commercial real property development. Tenant shall pay Tenant's pro
rata share (as determined below) of all costs incurred by Landlord for the operation and maintenance of the Common Areas. Common Area
costs include, but are not limited to, costs and expenses for the following: gardening and landscaping; utilities, water and sewage charges;
maintenance of signs (other than tenant's signs); premiums for liability, property damage, fire and other types of casualty insurance
on the Common Areas and worker's compensation insurance; all property taxes and assessments levied on or attributable to the Common Areas;
any and all Association fees, assessments due and charges for any Owner's Association covering Cotton Center Park; all personal property
taxes levied on or attributable to personal property used in connection with the Common Areas; straight-line depreciation on personal
property owned by Landlord which is consumed in the operation or maintenance of the Common Areas; rental or lease payments paid by Landlord
for rented or leased personal property used in the operation or maintenance of the Common Areas; fees for required licenses and permits;
repairing, resurfacing, repaving, maintaining, painting, lighting, cleaning, refuse removal, security and similar items; a reasonable
allowance to Landlord for Landlord's supervision and management of the Common Areas and the real property of Landlord upon which the
Property is located, not to exceed three percent (3%) of the total of the gross Base Rent and the gross Additional Rent of the Property
for the calendar year; and all Common Area improvements. Notwithstanding the foregoing, the cost of any replacement (as opposed to repairs)
of the roof of the Building shall be amortized (with interest determined at the prevailing loan rate available to Landlord) on a straight-line
basis over the useful life the replacement in accordance with generally accepted accounting principles, consistently applied. Landlord
may cause any or all of such services to be provided by third parties and the cost of such services shall be included in Common Area
costs. Common Area costs shall not include depreciation of real property which forms part of the Common Areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><FONT STYLE="font-size: 10pt"><B>(e)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant's Share and Payment. </B></FONT>Tenant shall pay as Additional Rent, Tenant's
annual pro rata share of all Common Area costs (prorated for any fractional month) upon written notice from Landlord that such costs
are due and payable, and in any event prior to delinquency. Tenant's pro rata share shall be calculated by dividing the square foot area
of the Building, as set forth in Section 1.04 of the Lease, by the aggregate square foot area of all buildings which are leased or held
for lease by tenants, as of the date on which the computation is made. Any changes in the Common Area costs and/or the aggregate area
of the Property leased or held for lease during the Lease Term shall be effective on the first day of the month after such change occurs.
Landlord may, at Landlord's election, estimate in advance and charge to Tenant as Common Area costs, all real property taxes for which
Tenant is liable under Section 4.02 of the Lease, all insurance premiums for which Tenant is liable under Section 4.04 of the Lease,
all maintenance and repair costs for which Tenant is liable under Section 6.04 of the Lease, and all other Common Area costs payable
by Tenant hereunder. At Landlord's election, such statements of estimated Common Area costs shall be delivered, and at the request of
Landlord, payable in monthly intervals to Landlord. Landlord may adjust such estimates at any time based upon Landlord's experience and
reasonable anticipation of costs. Such adjustments shall be effective as of the next rent payment date after notice to Tenant. Within
sixty (60) days after the end of each calendar year of the Lease Term, Landlord shall deliver to Tenant a statement prepared in accordance
with generally accepted accounting principles setting forth, in reasonable detail, the Common Area costs paid or incurred by Landlord
during the preceding calendar year and Tenant's pro rata share. Upon receipt of such statement, there shall be an adjustment between
Landlord and Tenant, with payment to or credit given by Landlord (as the case may be) so that Landlord shall receive the entire amount
of Tenant's share of such costs and expenses for such period. Landlord shall use its best efforts to effect an equitable preparation
of bills of services rendered to the building and to any other property owned by Landlord. Landlord agrees to keep, books and records
showing the Operating Expenses in accordance with generally accepted accounting principles consistently maintained on a year-to-year
basis. Tenant, at its cost, may examine and audit the books and records of Landlord pertaining to the Common Area Operating Expenses
for the current or previous years of the Lease Term or Renewal Term for the purposes of verifying that such expenses were paid, the amounts
thereof and the accuracy of Landlord's annual accounting and Tenant's pro rata share required herein. Any overpayment or underpayment
of Tenant's allocable share of Common Area Operating Expenses correctly shown by such audit shall be promptly reconciled by a payment
equal to the amount thereof by Landlord to Tenant, or by Tenant to Landlord, as the case may be. If the results of such audit correctly
show that Tenant's allocable share has been overpaid by five percent (5%) or more, Landlord shall promptly reimburse Tenant for the reasonable
cost of such audit in addition to the amount overpaid. Not more than one such audit shall be conducted by Tenant for each calendar year
during the term hereof If at any time during the Lease Term or Renewal Term Landlord discovers Landlord has failed to include any item(s)
that are appropriate Common Area Operating Expenses under this Section during the current or previous years, Tenant shall be obligated
to promptly pay such deficient amount following notification of such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(f)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Utilities. </B>Tenant shall pay directly to the appropriate supplier,
the cost of all natural gas, heat, light, power, sewer service, telephone, water, refuse disposal and other utilities and services supplied
to the Property. However, if any services or utilities are jointly metered with other property, Landlord shall make a reasonable determination
of Tenant's proportionate share of the cost of such utilities and services and Tenant shall pay such share to Landlord within fifteen
(15) days after receipt of Landlord's written statement. Tenant shall have the right to review the method of calculation for Tenant's
pro-rata share of utilities, and Landlord, upon request by Tenant, shall make available to Tenant the methods, calculations, and billings
for such determination. If Tenant disagrees with Landlord's above determination, such dispute will be resolved according to the arbitration
provisions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 4.04. Insurance Policies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liability
Insurance. </B><FONT STYLE="font-size: 10pt">During the Lease Term, Tenant shall maintain a policy of commercial general liability insurance
(sometimes known as broad form comprehensive general liability insurance) insuring Tenant against liability for bodily injury, property
damage (including loss of use of property) and personal injury arising out of the operation, use or occupancy of the Property. Tenant
shall name Landlord as an additional insured under such policy. The amount of such insurance shall be Five Million Dollars ($5,000,000)
per occurrence. The liability insurance obtained by Tenant under this Section 4.04(a) shall (i) be primary and non-contributing; (ii)
contain cross-liability endorsements; and (iii) insure Landlord against Tenant's performance under Section 5.05, </FONT>if <FONT STYLE="font-size: 10pt">the
matters giving rise to the indemnity under Section 5.05 result from the negligence or other acts or failure to act where a duty to act
exists on the part of Tenant. The amount and coverage of such insurance shall not limit Tenant's liability nor relieve Tenant of any
other obligation under this Lease. Landlord may also obtain comprehensive public liability insurance in an amount and with coverage determined
by Landlord insuring Landlord against liability arising out of ownership, operation, use or occupancy of the Property. The policy obtained
by Landlord shall not be contributory and shall not provide primary insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Property and Rental Income Insurance. </B><FONT STYLE="font-size: 10pt">During
the Lease Term, Landlord shall maintain policies of insurance covering loss of or damage to the Property and Common Areas in the full
amount of its replacement value. Such policy shall contain an Inflation Guard Endorsement and shall provide protection against all perils
included within the classification of fire, extended coverage, vandalism, malicious mischief, special extended perils (all risk), sprinkler
leakage and any other perils which Landlord deems reasonably necessary. Landlord shall have the right to obtain flood insurance if required
by any lender holding a security interest in the Property. Landlord shall not obtain insurance for Tenant's fixtures or equipment or
Building improvements installed by Tenant on the Property. During the Lease Term, Landlord shall also maintain a rental income insurance
policy, with loss payable to Landlord, in an amount equal to one year's Base Rent, plus to the extent available and deemed appropriate
by Landlord, the Additional Rent, including without limitation, estimated real property taxes and insurance premiums. Tenant shall be
liable for the payment of any deductible amount under Landlord's insurance covering damage to the Property or Tenant's insurance policies
maintained pursuant to this Section 4.04, in an amount not to exceed Ten Thousand Dollars ($10,000) per occurrence. Tenant shall not
do or permit anything to be done which invalidates any such insurance policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(c)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment of Premiums. </B><FONT STYLE="font-size: 10pt">Subject to Section 4.07,
Tenant shall pay all premiums for the insurance policies described in Section 4.04(a) and (b) (whether obtained by Landlord or Tenant)
within fifteen (15) days after Tenant's receipt of a copy of the premium statement or other evidence of the amount due, except Landlord
shall pay all premiums for non-primary comprehensive public liability insurance which Landlord elects to obtain as provided in Section
4.04(a). If insurance policies maintained by Landlord cover improvements on real property other than the Property, Landlord shall deliver
to Tenant a statement of the premium </FONT>applicable to the Property showing in reasonable detail how Tenant's share of the premium
was computed. If the Lease Term expires before the expiration of an insurance policy maintained by Landlord, Tenant shall be liable
for Tenant's prorated share of the insurance premiums. Before the Commencement Date, Tenant shall deliver to Landlord a copy of any policy
of insurance which Tenant is required to maintain under this Section 4.04. At least thirty (30) days prior to the expiration of any such
policy, Tenant shall deliver to Landlord a renewal of such policy. As an alternative to providing a policy of insurance, Tenant shall
have the right to provide Landlord a certificate of insurance, executed by an authorized officer of the insurance company, showing that
the insurance which Tenant is required to maintain under this Section 4.04 is in full force and effect and containing such other information
which Landlord reasonably requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(d)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>General
Insurance Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.3in">(i)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any insurance which Tenant is required to maintain under this Lease shall
include a provision which requires the insurance carrier to give Landlord not less than fifteen (15) days' written notice prior to any
cancellation or modification of such coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.3in">(ii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If Tenant fails to deliver any policy, certificate or renewal to Landlord required
under this Lease within the prescribed time period or if any such policy is canceled or modified during the Lease Term without Landlord's
consent, Landlord may obtain such insurance, in which case Tenant shall reimburse Landlord for the cost of such insurance within thirty
(30) days after receipt of a statement that indicates the cost of such insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.3in">(iii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall maintain all insurance required under this Lease with companies holding
a &quot;General Policy Rating&quot; of A-8 or better, as set forth in the most current issue of &quot;Best Key Rating Guide&quot;. Landlord
and Tenant acknowledge the insurance markets are rapidly changing and that insurance in the form and amounts described in this Section
4.04 may not be available in the future. Tenant acknowledges that the insurance described in this Section 4.04 is for the primary benefit
of Landlord. If at any time during the Lease Term, Tenant is unable to maintain the insurance required under the Lease, Tenant shall
nevertheless maintain insurance coverage which is customary and commercially reasonable in the insurance industry for Tenant's type of
business, as that coverage may change from time to time. Landlord makes no representation as to the adequacy of such insurance to protect
Landlord or Tenant's interests. Therefore, Tenant shall obtain any such additional property or liability insurance which Tenant deems
necessary to protect Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.3in">(iv)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless prohibited under any applicable insurance policies maintained, Landlord and Tenant each
hereby waive any and all rights of recovery against the other, or against the officers, employees, or representatives of the other, for
loss of or damage to its property or the property of others under its control, if such loss or damage is covered by any insurance policy
in force (whether or not described in this Lease) at the time of such loss or damage. Upon obtaining the required policies of insurance,
Landlord and Tenant shall give notice to the insurance carriers of this mutual waiver of subrogation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34.9pt"><B>Section 4.05.
Late Charges. </B>Tenant's failure to pay rent promptly may cause Landlord to incur unanticipated costs. The exact amount of such costs
are impractical or extremely difficult to ascertain. Such costs may include, but are not limited to, processing and accounting charges
and late charges which may be imposed on Landlord by any ground lease, mortgage or trust deed encumbering the Property. Therefore, <FONT STYLE="font-size: 10pt">if
</FONT>Landlord does not receive any rent payment within ten (10) days after it becomes due following written demand by Landlord to Tenant,
Tenant shall immediately pay Landlord a late charge equal to five percent (5%) of the overdue amount. The parties agree that such late
charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of such late payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-size: 10pt"><B>Section
4.06. Interest on Past Due Obligations. </B>If </FONT>Landlord does not receive any rent payment within ten <FONT STYLE="font-size: 10pt">(1</FONT>0) days after it becomes due following written demand by Landlord to Tenant and a five (5) business day opportunity to cure, and
Landlord has provided such notice two (2) times during any twelve (12) calendar months, any such amount shall bear interest at the rate
of eight percent (8%) per annum from the due date of such amount and the Tenant shall immediately pay to Landlord such interest. However,
interest shall not be payable on late charges to be paid by Tenant under this Lease. The payment of interest on such amounts shall not
excuse or cure any default by Tenant under this Lease. If the interest rate specified in this Lease is higher than the rate permitted
by law, the interest rate is hereby decreased to the maximum legal interest rate permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt"><B>Section
4.07. Impounds for Insurance Premiums and Real Property Taxes. </B>If</FONT> requested by any ground lessor or lender to whom Landlord
has granted a security interest in the Property, or if Landlord does not receive any rent payment within ten (10) days after it becomes
due following written demand by Landlord to Tenant and a five (5) business day opportunity to cure, and Landlord has provided such notice
two (2) times in any twelve (12) calendar months Tenant shall pay Landlord a sum equal to one-twelfth (1/12) of the annual real property
taxes and insurance premiums payable by Tenant under this Lease, together with each payment of Base Rent. Landlord shall hold such payments
in a non-interest bearing impound account. If unknown, Landlord shall reasonably estimate the amount of real property taxes and insurance
premiums when due. Tenant shall pay any deficiency of funds in the impound account to Landlord upon written request. <FONT STYLE="font-size: 10pt">If
</FONT>Tenant monetarily defaults under this Lease, Landlord may apply any funds in the impound account to any monetary obligation then
due under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 34.85pt"><FONT STYLE="font-size: 10pt"><B>Section
4.08. Building Security. </B></FONT>Tenant, at Tenant's sole cost and expense, shall provide for the security of the Property. Tenant
acknowledges that Landlord shall not be liable for any damage, injury or loss suffered by Tenant or Tenant's employees, agents, contractors
or invitees arising from the inadequacy or failure of any Property security measures, unless caused by Landlord's actions, omissions,
intentional misconduct or gross negligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>ARTICLE FIVE: USE OF PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 34.55pt"><FONT STYLE="font-size: 10pt"><B>Section
5.01. Permitted Uses. </B></FONT>Tenant may use the Property only for the Permitted Uses set forth in Section 1.06 above. Except to the
extent such rules contradict any express term in this Lease, Tenant agrees to comply with the building rules attached to this Lease as
Exhibit &quot;C&quot; as they may be amended from time to time; provided, that any such amendments shall not be imposed in a discriminatory
manner to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 34pt"><FONT STYLE="font-size: 10pt"><B>Section
5.02. Manner of Use. </B></FONT>Tenant shall not cause or permit the Property to be used <FONT STYLE="font-size: 10pt">in any way which
constitutes a violation of any law, ordinance (including but not limited to </FONT>zoning ordinances) or governmental regulation or order,
which unreasonably annoys or interferes with the rights of other tenants of Landlord, or which constitutes a nuisance or waste. Tenant's
use of the Property shall be subject to and shall not violate any applicable CC&amp;R's or other restrictions of record. Tenant shall
obtain and pay for all permits, including a Certificate of Occupancy, required for Tenant's occupancy of the Property and shall promptly
take all actions necessary to comply with all applicable statutes, ordinances, rules, regulations, orders and requirements regulating
the use by Tenant of the Property, including the Occupational Safety and Health Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 35pt"><B>Section 5.03.
Hazardous Materials. </B><FONT STYLE="font-size: 10pt">As used in this Lease, the term &quot;Hazardous Material&quot; means any
flammable items, explosives, radioactive materials, hazardous or toxic substances, material or waste or related materials, including
any substances defined as or included in the definition of &quot;hazardous substances&quot;, &quot;hazardous wastes&quot;,
 &quot;hazardous materials&quot; or &quot;toxic substances&quot; now or subsequently regulated under any applicable federal, state or
local laws or regulations, including without limitation petroleum-based products, paints, solvents, lead, cyanide, DDT, printing
inks, acids, pesticides, ammonia compounds and other chemical products, asbestos, PCBs and similar compounds, and including any
different products and materials which are subsequently found to have adverse effects on the environment or the health and safety of
persons. Other than Hazardous Materials used in the ordinary course of Tenant's business, Tenant shall not cause or permit any
Hazardous Material to be generated, produced, brought upon, used, stored, treated or disposed of in or about the Property by Tenant,
its agents, employees, contractors, sublessees or invitees without the prior written consent of Landlord; provided however, Tenant
shall be allowed to store and use nominal amounts of commercially available cleaning products without the consent of Landlord.
Tenant shall provide Landlord with ten (10) days advance written notice, setting forth an itemization of all such Hazardous
Materials, with a detailed description thereof, and the intended volume, location and use of such Materials at the Property, prior
to the use or allowance of any cleaning products or any other products, materials or substances which are Hazardous Materials as
defined above or which have or may have adverse affects on the environment or the health and safety of persons. Landlord shall be
entitled to take into account such other factors or facts as Landlord deems to be relevant in determining whether to grant or
withhold consent to Tenant's proposed activity with respect to Hazardous Material not used in the ordinary course of Tenant's
business. In no event, however, shall Landlord be required to consent to the installation or use of any storage tanks in or on the
Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.9pt">To the extent Tenant
stores and uses any Hazardous Materials in or about the Property in accordance with the provisions of Section 5.03, Tenant shall be obligated
to provide Landlord with a Phase I Environmental Report prepared in accordance with current ASTM standards or such other appropriate
environmental review that relates to the actual Hazardous Materials stored, generated, or used by Tenant at the Property. The Phase I
Environmental Report, addressed and certified to Landlord and Landlord's lender, if any, shall be dated as of the date Tenant vacates
the Property. Tenant shall bear the cost of the Phase I Environmental Report and shall also be responsible for any and all costs, penalties
and fines incurred for any environmental contamination and subsequent remediation at the Property. Should Tenant fail to timely deliver
to Landlord the foregoing Report, Landlord may cause a Phase I Environmental Report to be prepared to like effect and Tenant shall be
liable to Landlord for the actual cost of said Report. Should the Report provided by either Landlord or Tenant state that a hazardous
condition exists in or on the Property or that the Property cannot be used or leased in a hazard-free condition (unless the hazardous
condition existed prior to the Commencement Date under the Lease), to the extent Tenant caused such condition, Tenant shall forthwith
cause the hazardous condition to be fully corrected at Tenant's expense. In addition, to the extent Tenant caused such condition Tenant
shall be required to pay to Landlord monthly, on or before the first day of each month, an amount equal to the Base Rent and Additional
Rent in the highest amount due under the Lease for the last year of the Lease Term, for any period following expiration of the Lease
Term until the Property is restored to a hazard free condition. This requirement shall not be construed as an extension of an expired
or terminated Lease, but solely as damages to Landlord due to such hazardous condition(s) existing at the Property which prevent Landlord
from re-leasing the Property. Tenant, following such expiration or termination of this Lease, shall be allowed access to the Property,
only to the extent necessary to remove or otherwise correct any hazardous condition, and shall conduct no gainful business activity whatsoever
at said Property. The provisions of this Section 5.03 shall survive the expiration or any termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt"><B>Section
5.04. Signs and Auctions. </B></FONT>Subject to Section 6.05, Tenant shall not place any exterior signs on the Property without Landlord's
prior written consent, which shall not be unreasonably withheld. All signage shall be in compliance with all applicable laws and ordinances
and all signage criteria of Landlord which will be provided to Tenant upon request thereof. To the extent or in the event Landlord erects
a monument sign at or near the entrances to the Property, Tenant shall be entitled to a pro rata share of such signage. Tenant shall
not conduct or permit any auctions or sheriffs sales at the Property. Notwithstanding the foregoing, Tenant shall have the exclusive
right to building signage permitted on the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
5.05. Indemnity. </B></FONT>Except for claims arising out of or caused by Landlord's gross negligence, or willful misconduct, Tenant
shall indemnify Landlord against and hold Landlord harmless from any and all reasonable costs, claims or liability arising from: (a)
Tenant's use of the Property; (b) the conduct of Tenant's business or anything else done or permitted by Tenant to be done in or about
the Property, including any contamination of the Property or any other property resulting from the presence or use of Hazardous Material
caused or permitted by Tenant; (c) any breach or default in the performance of Tenant's obligations under this Lease; (d) any material
misrepresentation or breach of warranty by Tenant under this Lease; or (e) other acts or omissions of Tenant. Tenant shall defend Landlord
against any such cost, claim or liability at Tenant's expense with counsel reasonably acceptable to Landlord or, at Landlord's election,
Tenant shall reimburse Landlord for all reasonable legal fees or costs incurred by Landlord in connection with any such claim. As a material
part of the consideration to Landlord, Tenant assumes all risk of damage to property or injury to persons in or about the Property arising
from any claims caused by Tenant or its employees and Tenant hereby waives all claims in respect thereof against Landlord, except for
any claim arising out of Landlord's gross negligence or willful misconduct. As used in this Section, the term &quot;Tenant&quot; shall
include Tenant's employees, officers and directors, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
5.06. Landlord's Access. </B></FONT>Landlord or its agents may enter the Property during business hours, except in an emergency (a)
during the last six (6) months of the Lease Term to show the Property to potential buyers, investors or tenants or other parties,
(b) to do any other act or to inspect and conduct tests in order to monitor Tenant's compliance with all applicable environmental
laws and all laws governing the presence and use of Hazardous Material, or (c) for any other purpose Landlord deems reasonably
necessary. Landlord shall give Tenant Forty-eight (48) hours prior written notice of such entry, except in the case of an emergency.
However, Landlord agrees that access to certain areas of the Property may be restricted in order to comply with applicable
governmental laws, rules and regulations concerning Tenant's operations therein and that in the case of every entry, Landlord shall
be accompanied by a representative designated by Tenant and Landlord agrees that it shall abide by all health and safety
requirements during such entry, including wearing protective gear, <FONT STYLE="font-size: 10pt">if</FONT> necessary. During the
last six (6) months of the Lease Term, Landlord may place customary &quot;For Sale&quot; or &quot;For Lease&quot; signs on the
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
5.07. Quiet Possession. </B></FONT>If Tenant pays the rent and complies with all other terms of this Lease, Tenant may occupy and enjoy
the Property for the full Lease Term, subject to the provisions of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify"><B>ARTICLE SIX: CONDITION OF PROPERTY;
MAINTENANCE, REPAIRS AND ALTERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.9pt"><FONT STYLE="font-size: 10pt"><B>Section
6.01. Existing Conditions. </B></FONT>Tenant accepts the Property in its condition as of the execution of the Lease, subject to all recorded
matters, laws, ordinances, and governmental regulations and orders. Except as provided herein, Tenant acknowledges that neither Landlord
nor any agent of Landlord has made any representation as to the condition of the Property or the suitability of the Property for Tenant's
intended use. Tenant represents and warrants that Tenant has made its own inspection of and inquiry regarding the condition of the Property
and is not relying on any representations of Landlord or any Broker with respect thereto. <FONT STYLE="font-size: 10pt">If</FONT> Landlord
or Landlord's Broker has provided a Property Information Sheet or other Disclosure Statement regarding the Property, a copy is attached
as an exhibit to the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 35.35pt"><FONT STYLE="font-size: 10pt"><B>Section
6.02. Exemption of Landlord from Liability. </B></FONT>Landlord shall not be liable for any damage or injury to the person, business
( or any loss of income therefrom), goods, wares, merchandise or other property of Tenant, Tenant's employees, invitees, customers or
any other person in or about the Property, whether such damage or injury is caused by or results from: (a) fire, steam, electricity,
water, gas or rain; (b) the breakage, leakage, obstruction or other defects of pipes, sprinklers, wires, appliances, plumbing, air conditioning
or lighting fixtures or any other cause; (c) conditions arising in or about the Property or upon other portions of Cotton Center Park,
or from other sources or places; or (d) any act or omission of any other tenant of Cotton Center Park. Landlord shall not be liable for
any such damage or injury even though the cause of or the means of repairing such damage or injury are not accessible to Tenant. The
provisions of this Section 6.02 shall not, however, exempt Landlord from liability for Landlord's gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-size: 10pt"><B>Section
6.03. Landlord's Obligations. </B></FONT>Except as provided in Article Seven (Damage or Destruction) and Article Eight (Condemnation),
Landlord shall keep the following in good order, condition and repair: the foundations, exterior walls and roof of the Property (including
painting the exterior surface of the exterior walls of the Property not more often than once every five (5) years, if necessary), sidewalks
and parking lots, and all Common Area components of electrical and plumbing, Landlord shall not be obligated to maintain or repair windows,
doors, plate glass, the interior surfaces of exterior walls, or any improvements installed by Tenant. Landlord shall maintain the Property
<FONT STYLE="font-size: 10pt">in</FONT> an attractive, first class and <FONT STYLE="font-size: 10pt">fully</FONT> operative condition
under this Section 6.03 and shall make or commence repairs within thirty (30) days after receipt of written notice from Tenant of the
need for such repairs. In the event Landlord does not timely make such repairs, Tenant may make such repairs and collect such amounts
from Landlord in accordance with the arbitration provisions set forth below. Prior to the Commencement Date, Landlord covenants to install,
at its sole expense, up to approximately 1,000 square feet of new windows on the first floor of the Building, the quality being at least
equivalent to the windows being replaced. <FONT STYLE="font-size: 10pt">As</FONT> to Tenant's office space in the Property, Landlord
shall use commercially reasonable efforts to not materially affect Tenant's use of the Property during repairs, maintenance and building
or construction activity. As to Tenant's laboratory areas and Landlord's work or activities which could reasonably be expected to impact
Tenant's laboratory business, Landlord shall not perform any proposed repairs, maintenance or building or construction activities, including
but not limited to cutting off electricity, utilities, water, drainage capacity, HVAC or plumbing, or disrupting ingress or egress through
the rear or the front entrances, or performing work which would reasonably be expected to result in ground vibrations at the Property
that would interfere with such laboratory business, without giving Tenant not less than seventy two (72) hours advanced written notice
(except in the case of an emergency) so that Tenant can take appropriate advance action where possible to avoid damage to equipment,
protect lab samples, and protect laboratory tests being performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 6.04. Tenant's Obligations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Except as provided in Article Seven (Damage or Destruction) and Article Eight
(Condemnation), Tenant shall keep all portions of the Property (including nonstructural, interior, exterior, and landscaped areas, portions,
systems and equipment) in good order, condition and repair (including interior repainting and refinishing, as needed). If any portion
of the Property or any system or equipment in the Property which Tenant is obligated to repair cannot be fully repaired or restored,
Tenant shall promptly replace such portion of the Property or system or equipment in the Property, regardless of whether the benefit
of such replacement extends beyond the Lease Term; but if the benefit or useful life of such replacement extends beyond the Lease Term
(as such term may be extended by exercise of any options), the useful life of such replacement shall be prorated over the remaining portion
of the Lease Term (as extended), and Tenant shall be liable only for that portion of the cost which is applicable to the Lease Term (as
extended). Tenant shall maintain a preventive maintenance contract providing for the regular inspection and maintenance of the heating
and air conditioning system by a licensed heating and air conditioning contractor. If any part of the Property is damaged by any act
or omission of Tenant, Tenant shall pay Landlord the cost of repairing or replacing such damaged property, whether or not Landlord would
otherwise be obligated to pay the cost of maintaining or repairing such property. It is the intention of Landlord and Tenant that at
all times Tenant shall maintain the portions of the Property which Tenant is obligated to maintain in an attractive, first-class and
fully operative condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Landlord shall provide electric capacity of not less than 1600 amps to Tenant,
such service to be made available at the exterior wall entry point of the Building wherein the Property is located, and shall provide
any necessary maintenance or replacement thereof when required. Tenant shall be responsible to obtain electrical service from the power
provider of its choice, and Landlord shall not be responsible for interruptions in such service. Tenant shall be responsible for and
provide distribution of the power and electrical service from the entry point of the Building to the areas required for use thereof by
Tenant, and Tenant shall be responsible for all repairs, maintenance and replacement of such electrical service and related equipment
from the point of entry at the Building during the Lease Term. The foregoing responsibilities of Tenant shall include payment for the
cost and expense of installation and any repairs, replacements, or upgrades, of such power and electrical service from said entry point
to the remainder of the Building used or occupied by Tenant and all costs related to installing and causing service to commence, including
payment of any security deposits required by any utility company serving the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(c)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If Tenant installs any rubberized, non-breathable or similar flooring at the Property,
Tenant shall provide and be responsible for sealcoating and installation of moisture barriers required for any such flooring, all in
accordance with all specifications of the provider of such flooring or sealcoating, sufficient as necessary to prevent moisture and liquids
from leaking or seeping underneath the flooring and sealcoating and sufficient to prevent any bubbling, blisters, separation or other
conditions resulting from water or liquid below the flooring installed by Tenant or within the concrete floor, and from any and all damages
occurring by reason thereof. It shall be Tenant's responsibility and obligation to install, maintain, repair or replace such flooring
and sealcoating in order to meet the foregoing requirements, and Tenant shall pay all costs and expenses for such installation, maintenance,
repair or replacement thereof. Tenant shall make its own inspection of and inquiry regarding the concrete floor at the Property, and
as to any flooring and any sealcoating which exists at the Property, whether provided by Landlord or a prior Tenant, and Tenant hereby
waives and relinquishes any claims against or liability of Landlord as to such flooring and sealcoating, or any damages or losses occurring
by reason of any defect in, or inadequacy of, such flooring and any sealcoating, including, without limitation, any right or claim against
Landlord for repair, maintenance or replacement thereof during the Lease Term. Nothing is this subsection shall be deemed to waive any
claims against the Landlord arising out of or caused by Landlord's gross negligence or willful misconduct. Tenant shall make such tests
and investigation as Tenant deems necessary prior to execution of this Lease, to determine and satisfy Tenant as to the condition of
said flooring and any sealcoating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B><FONT STYLE="font-size: 10pt">Tenant shall fulfill all of Tenant's obligations under this Section 6.04 at Tenant's sole expense.
</FONT>If <FONT STYLE="font-size: 10pt">Tenant fails to maintain, repair or replace the Property as required by this Section 6.04, Landlord
may, if Tenant has failed to cure such issue within ten (10) days after written notice from Landlord to Tenant (except that no prior
notice shall be required in the case of an emergency), perform such maintenance or repair (including replacement, as needed) on behalf
of Tenant. In the event of an emergency, Landlord shall notify Tenant as soon as reasonably possible. In such case, Tenant shall reimburse
Landlord for all reasonable costs incurred in performing such maintenance or repair immediately upon demand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 6.05. Alterations, Additions, and Improvements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
</B><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;After the Tenant Improvements are constructed, Tenant
shall not make any alterations, additions, or improvements to the Property without Landlord's prior written consent, which consent shall
not to be unreasonably withheld, conditioned, or delayed, except for non-structural alterations which do not cumulatively exceed a total
cost of Fifty Thousand Dollars ($50,000.00) over the Lease Term and which are not visible from the outside of any building of which the
Property is part. Landlord may require Tenant to provide demolition </FONT>and/or lien and completion bonds in form and amount satisfactory
to Landlord. Tenant shall promptly remove any alterations, additions, or improvements constructed in violation of this Section 6.05(a)
upon Landlord's written request. All alterations, additions, and improvements shall be done in a good and workmanlike manner, in conformity
with applicable laws and regulations, and by a licensed contractor approved by Landlord. Upon completion of any such work, Tenant shall
provide Landlord with &quot;as built&quot; plans, copies of all construction contracts, and proof of payment for all labor and materials
including appropriate lien releases. Landlord shall have no responsibility or liability for any death or injury to persons, including
but not limited to Tenant, Tenant's officers, directors, members, employees, personnel, contractors, invitees and/or any third persons
in or upon the real property of Landlord, or for damage to property caused by alterations, additions or improvements made to the Property
by Tenant, whether or not made pursuant to Landlord's prior written consent as required herein, and Tenant hereby indemnifies Landlord
against any such liability, obligation, cost or expense arising therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall pay when due all claims for labor and material furnished to
the Property. Tenant shall give Landlord at least ten (10) days prior written notice of the commencement of any work on the Property,
regardless of whether Landlord's consent to such work is required. Landlord may elect to record and post notices of non-responsibility
on the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(c)
</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall not make any alterations, additions, or improvements to the Property,
including but not limited to mezzanines, storage areas or any other structure, which increase or add to the usable square footage of
the Property. Tenant is hereby informed that the construction of any such structure or addition which increases the usable square footage
is strictly prohibited and shall be deemed a material breach of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><B>Section 6.06. Condition
upon Termination. </B>Upon the termination of the Lease, Tenant shall surrender the Property and all alterations, additions and improvements
to Landlord, broom clean and in the same condition as received except for ordinary wear and tear which Tenant was not otherwise obligated
to remedy under any provision of this Lease; provided, however, Tenant shall be responsible for and obligated to, at the cost of Tenant,
remedy any bubbling, blistering, leakage and separation occurring with respect to any flooring and any sealcoating so as to deliver and
surrender the Property upon termination of the Lease to Landlord in good repair and condition. At the termination of the Lease, Tenant
shall not be required to remove any flooring and sealcoating from the Property. However, Tenant shall not be obligated to repair any
damage which Landlord is required to repair under Article Seven (Damage or Destruction). In addition, Landlord may require Tenant to
remove any alterations, additions or improvements (whether or not made with Landlord's consent) prior to the expiration of the Lease
and to restore the Property to its prior condition; provided, however that the office space on the Property shall only be required to
be returned to its condition existing on the Commencement Date; and provided, further that the laboratory space on the Property shall
only be required to be returned to the equivalent of office space, including the removal of all alterations, additions, improvements
(whether or not made with Landlord's consent) and non-office related laboratory equipment and plumbing, all at Tenant's expense. All
alterations, additions and improvements which Landlord has not required Tenant to remove shall become Landlord's property and shall be
surrendered to Landlord upon the expiration or earlier termination of the Lease, except that Tenant may remove any of Tenant's machinery
or equipment which can be removed without material damage to the Property provided all obligations of Tenant have been fully met and
satisfied hereunder. Any trade fixture, machinery or equipment that has been bolted, wired or otherwise attached to the Building by ventilation
which was paid for with the Tenant Allowance pursuant to the Work Letter Agreement, shall be deemed fixtures to the Building and shall
remain at the Property following termination hereof, unless Tenant has fully performed all of its obligations hereunder. Tenant shall
repair, at Tenant's expense, any damage to the Property caused by the removal of any such machinery or equipment. In no event, however,
shall Tenant remove any of the following machinery or equipment (which shall be deemed Landlord's property) without Landlord's prior
written consent: any power wiring or power panels; lighting or lighting fixtures; wall coverings; drapes, blinds or other window coverings;
carpets or other floor coverings; heaters, air conditioners or any other heating or air conditioning equipment; fencing or security
gates; or other similar building operating equipment and decorations. Except as provided herein to the contrary, Tenant shall not be
obligated to remove any improvements installed as part of the original Tenant Improvements pursuant to the Work Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>ARTICLE SEVEN: DAMAGE OR DESTRUCTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 7.01. Partial Damage to Property.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall notify Landlord in writing immediately upon the occurrence of
any damage to the Property. If the Property is only partially damaged (meaning, less than fifty percent (50%) of the Property is untenantable
as a result of such damage or less than fifty percent (50%) of Tenant's operations are materially impaired) and if the proceeds received
by Landlord from the insurance policies described in Section 4.04(b) are sufficient to pay for the necessary repairs, this Lease shall
remain in effect and Landlord shall repair the damage as soon as reasonably possible. Landlord may elect (but is not required) to repair
any damage to Tenant's fixtures, equipment, or improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If the insurance proceeds received by Landlord are not sufficient to pay the entire
cost of repair, or if the cause of <FONT STYLE="font-size: 10pt"><B>the</B></FONT> damage is not covered by the insurance policies which
Landlord maintains under Section 4.04(b), Landlord may elect either to (i) repair the damage as soon as reasonably possible, in which
case this Lease shall remain in full force and effect, or (ii) terminate this Lease as of the date the damage occurred. Landlord shall
notify Tenant within thirty (30) days after receipt of notice of the occurrence of the damage whether Landlord elects to repair the damage
or terminate the Lease. <FONT STYLE="font-size: 10pt">If</FONT> Landlord elects to repair the damage and the damage was due to an act
or omission of Tenant, or Tenant's employees, agents, contractors or invitees, Tenant shall pay Landlord the &quot;deductible amount&quot;
(if any) under Landlord's insurance policies and the difference between the actual cost of repair and any insurance proceeds received
by Landlord. If Landlord elects to terminate the Lease, Tenant may elect to continue this Lease in full force and effect, in which case
Tenant shall repair any damage to the Property to the condition that existed prior to such damage. Tenant shall pay the cost of such
repairs, except that upon satisfactory completion of such repairs, Landlord shall deliver to Tenant any insurance proceeds received by
Landlord for the damage repaired by Tenant. Tenant shall give Landlord written notice of such election within ten (10) days after receiving
Landlord's termination notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(c)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If <FONT STYLE="font-size: 10pt">the damage to the Property occurs during
the last six (6) months of the Lease Term and such damage will require more than thirty (30) days to repair, either Landlord or Tenant
may elect to terminate this Lease as of the date the damage occurred, regardless of the sufficiency of any insurance proceeds. The party
electing to terminate this Lease shall give written notification to the other party of such election within thirty (30) days after Tenant's
notice to Landlord of the occurrence of the damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 35.4pt"><B>Section
7.02. Substantial or Total Destruction. </B><FONT STYLE="font-size: 10pt">If the Property is substantially or totally destroyed by any
cause whatsoever (meaning, the damage to the Property is greater than partial damage as described in Section 7.01), and regardless
of whether Landlord receives any insurance proceeds, this Lease shall terminate as of the date the destruction occurred. Notwithstanding
the preceding sentence, if the Property can be rebuilt within six (6) months after the date of destruction, Landlord may elect to rebuild
the Property at Landlord's own expense, in which case this Lease shall remain in full force and effect. Landlord shall notify Tenant
of such election within thirty (30) days after Tenant's notice of the occurrence of total or substantial destruction. If Landlord so
elects, Landlord shall rebuild the Property at Landlord's sole expense, except that if the destruction was caused by an act or omission
of Tenant, Tenant shall pay Landlord the difference between the actual cost of rebuilding and any insurance proceeds received by Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35pt"><B>Section
7.03. Temporary Reduction of Rent. </B>If <FONT STYLE="font-size: 10pt">the Property is destroyed or damaged and Landlord or Tenant repairs
or restores the Property pursuant to the provisions of this Article Seven, any rent payable during the period of such damage, repair
and or restoration shall be reduced according to the degree, if any, to which Tenant's use of the Property is impaired. However, the
reduction shall not exceed the sum of one year's payment of Base Rent, insurance premiums and real property taxes. Except for such possible
reduction in Base Rent, insurance premiums and real property taxes, Tenant shall not be entitled to any compensation, reduction, or reimbursement
from Landlord as a result of any damage, destruction, repair, or restoration of or to the Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.45pt"><B>Section
7.04. Waiver. </B><FONT STYLE="font-size: 10pt">Tenant waives the protection of any statute, code or judicial decision which grants a
tenant the right to terminate a lease in the event of the substantial or total destruction of the leased property. Tenant agrees that
the provisions of Section </FONT>7<FONT STYLE="font-size: 10pt">.02 above shall govern the rights and obligations of Landlord and Tenant
in the event of any substantial or total destruction to the Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt"><B>ARTICLE EIGHT: CONDEMNATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3pt; text-align: justify; text-indent: 35pt">If
all or any portion of the Property is taken under the power of eminent domain or sold under the threat of that power (all of which are
called &quot;Condemnation&quot;), this Lease shall terminate as to the part taken or sold on the date the condemning authority takes
title or possession, whichever occurs first. If more than twenty percent (20%) of the floor area of the Building is taken, either Landlord
or Tenant may terminate this Lease as of the date the condemning authority takes title or possession, by delivering written notice to
the other within ten <FONT STYLE="font-size: 10pt">(10)</FONT> days after receipt of written notice of such taking (or in the absence
of such notice, within ten (10) days after the condemning authority takes title or possession). If neither Landlord nor Tenant terminates
this Lease, this Lease shall remain in effect as to the portion of the Property not taken, except that the Base Rent and Additional Rent
shall be reduced in <FONT STYLE="font-size: 10pt">proportion to the reduction in the floor area of the Property. Any Condemnation award
or payment shall be distributed in the following order: (a) first, to any ground lessor, mortgagee or beneficiary under a deed of trust
encumbering the Property, the amount of its interest in the Property; (b) second, to Tenant, for any award available to Tenant under
Arizona law so long as such award does not reduce the amount available to Landlord; and (c) third, to Landlord, the remainder of such
award, whether as compensation for reduction in the value of the leasehold, the taking of the fee, or otherwise. </FONT>If <FONT STYLE="font-size: 10pt">this
Lease is not terminated, Landlord shall repair any damage to the Property caused by the Condemnation, except that Landlord shall not
be obligated to repair any damage for which Tenant has been reimbursed by the condemning authority. If the severance damages received
by Landlord are not sufficient to pay for such repair, Landlord shall have the right to either terminate this Lease or make such repair
at Landlord's expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>ARTICLE NINE: ASSIGNMENT AND SUBLETTING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.5pt"><B>Section 9.01.
Landlord's Consent Required. </B>No portion of the Property or of Tenant's interest in this Lease may be acquired by any other person
or entity, whether by sale, assignment, mortgage, sublease, transfer, operation of law, or act of Tenant, without Landlord's prior written
consent, except as provided in Section 9.02 below. Landlord has the right to grant or withhold its consent as provided in Section 9.05
below. Any attempted transfer without consent shall be void and shall constitute a non-curable breach of this Lease. If Tenant is a partnership
or limited liability company, any cumulative transfer of more than twenty percent (20%) of the partnership or membership interests shall
require Landlord's consent. If Tenant is a corporation, upon any change in the ownership of a controlling interest of the voting stock
of the corporation, Tenant shall immediately notify Landlord, in writing, of such change in ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 35pt"><B>Section 9.02. Tenant
Affiliate. </B>Tenant may assign this Lease or sublease the Property, without Landlord's consent, to any corporation which controls,
is controlled by or is under common control with Tenant, or to any corporation resulting from the merger of or consolidation with Tenant
(&quot;Tenant's Affiliate&quot;), including, without limitation, Caris MPI, Inc. and Caris Diagnostics, Inc. In such case, any Tenant's
Affiliate shall assume in writing all of Tenant's obligations under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.95pt"><FONT STYLE="font-size: 10pt"><B>Section
9.03. No Release of Tenant. </B>No transfer permitted by this Article Nine, whether with or without Landlord's consent, shall release
Tenant or change Tenant's primary liability to pay the rent and to perform all other obligations of Tenant under this Lease. Landlord's
acceptance of rent from any other person is not a waiver of any provision of this Article Nine. Consent to one transfer is not a consent
to any subsequent transfer. </FONT>If <FONT STYLE="font-size: 10pt">Tenant's transferee defaults under this Lease, Landlord may proceed
directly against Tenant without pursuing remedies against the transferee. Landlord may consent to subsequent assignments or modifications
of this Lease by Tenant's transferee, without notifying Tenant or obtaining its consent. Such action shall not relieve Tenant's liability
under this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 9.04. Intentionally Omitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 9.05. Landlord's Consent.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant's request for consent to any transfer described in Section 9.01 shall set
forth in writing the details of the proposed transfer, including the name, business and financial condition of the prospective transferee,
financial details of the proposed transfer (e.g., the term of and the rent and security deposit payable under any proposed assignment
or sublease), and any other information Landlord deems relevant. Landlord shall have the right to withhold consent, if reasonable, or
to grant consent, based on the following factors: (i) the business of the proposed assignee or subtenant and the proposed use of the
Property; (ii) the net worth and financial reputation of the proposed assignee or subtenant; (iii) Tenant's compliance with all of its
obligations under the Lease; and (iv) such other factors as Landlord may reasonably deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Tenant assigns or subleases to other than a Tenant Affiliate, the following shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3in">(i) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall pay to Landlord as Additional Rent under the Lease the Landlord's Share (stated in Section 1.13) of the Profit (defined below)
on such transaction as and when received by Tenant, unless Landlord gives written notice to Tenant and the assignee or subtenant that
Landlord's Share shall be paid by the assignee or subtenant to Landlord directly. The &quot;Profit&quot; means (A) all amounts paid to
Tenant for such assignment or sublease, including &quot;key&quot; money, monthly rent in excess of the monthly rent payable under the
Lease, and all fees and other consideration paid for the assignment or sublease, including fees under any collateral agreements, less
(B) costs and expenses directly incurred by Tenant in connection with the execution and performance of such assignment or sublease for
real estate broker's commissions and costs of renovation or construction of tenant improvements required under such assignment or sublease.
Tenant is entitled to recover such costs and expenses before Tenant is obligated to pay the Landlord's Share to Landlord. The Profit
in the case of a sublease of less than all the Property is the rent allocable to the subleased space as a percentage on a square footage
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3in">(ii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall provide Landlord a written statement certifying all amounts to
be paid from any assignment or sublease of the Property within thirty (30) days after the transaction documentation is signed, and
Landlord may inspect Tenant's books and records to verify the accuracy of such statement. On written request, Tenant shall promptly
furnish to Landlord copies of all the transaction documentation, all of which shall be certified by Tenant to be complete,
true and correct. Landlord's receipt of Landlord's Share shall not be a consent to any further assignment or subletting. The breach
of Tenant's obligation under this Section 9.05(b) shall be a material default of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 35.45pt"><B>Section
9.06. No Merger. </B>No merger shall result from Tenant's sublease of the Property under this Article Nine, Tenant's surrender of this
Lease or the termination of this Lease in any other manner. In any such event, Landlord may terminate any or all subtenancies or succeed
to the interest of Tenant as sublandlord under any or all subtenancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt"><B>ARTICLE TEN: DEFAULTS; REMEDIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 35.45pt"><B>Section
10.01. Covenants and Conditions. </B>Tenant's performance of each of Tenant's obligations under this Lease is a condition as well as
a covenant. Tenant's right to continue in possession of the Property is conditioned upon such performance. Time is of the essence in
the performance of all covenants and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><B>Section 10.02. Defaults. </B><FONT STYLE="font-size: 10pt">Tenant
shall be in material default under this Lease:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B><FONT STYLE="font-size: 10pt">If</FONT> Tenant fails to pay rent or any other
charge when due within ten (10) days after written notice provided that no more than two (2) written notices shall be required during
any 12 calendar month period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If Tenant fails to perform any of Tenant's non-monetary obligations under
this Lease for a period of thirty (30) days after written notice from Landlord; provided that if more than thirty (30) days are required
to complete such performance, Tenant shall not be in default if Tenant commences such performance within the thirty (30) day period and
thereafter diligently pursues its completion. However, Landlord shall not be required to give such cure period <FONT STYLE="font-size: 10pt">if
</FONT>Tenant's failure to perform constitutes a non-curable breach of this Lease (e.g., a transfer in violation of Article Nine above).
The notice required by this Section is intended to satisfy any and all notice requirements imposed by law on Landlord and is not in addition
to any such requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(c)</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
(i) <FONT STYLE="font-size: 10pt">If</FONT> Tenant makes a general assignment or general arrangement for the benefit of creditors; (ii)
if a petition for adjudication of bankruptcy or for reorganization or rearrangement is filed by or against Tenant and is not dismissed
within sixty (60) days; (iii) if a trustee or receiver is appointed to take possession of substantially all of Tenant's assets located
at the Property or of Tenant's interest in this Lease and possession is not restored to Tenant within sixty (60) days; or (iv) if substantially
all of Tenant's assets located at the Property or of Tenant's interest in this Lease is subjected to attachment, execution or other
judicial seizure which is not discharged within sixty (60) days. If a court of competent jurisdiction determines that any of the acts
described in this subparagraph (d) are not a default under this Lease, and a trustee is appointed to take possession (or if Tenant remains
a debtor in possession) and such trustee or Tenant transfers Tenant's interest hereunder, then Landlord shall receive, as Additional
Rent, the excess, if any, of the rent (or any other consideration) paid in connection with such assignment or sublease over the rent
payable by Tenant under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 35.4pt"><B>Section 10.03.
Remedies. </B><FONT STYLE="font-size: 10pt">On the occurrence of any material default by Tenant, Landlord may, at any time thereafter,
with or without notice or demand (unless notice is required as set forth in this Lease or as required under Arizona law) and without
limiting Landlord in the exercise of any right or remedy which Landlord may have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1pt; text-align: justify; text-indent: 0.85in"><B>(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B><FONT STYLE="font-size: 10pt">Terminate Tenant's right to possession of the
Property by any lawful means, in which case this Lease shall terminate and Tenant shall immediately surrender possession of the Property
to Landlord. In such event, Landlord shall be entitled to recover from Tenant all damages incurred by Landlord by reason of Tenant's
default, including (i) the worth at the time of the award of the unpaid Base Rent, Additional Rent and other charges which Landlord had
earned at the time of the termination; (ii) the worth at the time of the award of the amount by which the unpaid Base Rent, Additional
Rent and other charges which Landlord would have earned after termination until the time of the award exceeds the amount of such rental
loss that Tenant proves Landlord could have reasonably avoided; (iii) the worth at the time </FONT>of the award of the amount by which
the unpaid Base Rent, Additional Rent and other charges which Tenant would have paid for the balance of the Lease Term after the time
of award exceeds the amount of such rental loss that Tenant proves Landlord could have reasonably avoided; and (iv) any other amount
necessary to compensate Landlord for all the detriment proximately caused by Tenant's failure to perform its obligations under the Lease
or which in the ordinary course of things would be likely to result therefrom, including, but not limited to, any reasonable costs or
expenses Landlord incurs in maintaining or preserving the Property after such default, the cost of recovering possession of the Property,
expenses of reletting, including necessary renovation or alteration of the Property, Landlord's reasonable attorneys' fees incurred in
connection therewith, and any real estate commission paid or payable. As used in subparts (i) and (ii) above, the &quot;worth at the
time of the award&quot; is computed by allowing interest on unpaid amounts at the rate of eight percent (8%) per annum, or such lesser
amount as may then be the maximum lawful rate. As used in subpart (iii) above, the &quot;worth at the time of the award&quot; is computed
by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of the award, plus one percent
(1%). If Tenant has abandoned the Property, Landlord shall have the option of (i) retaking possession of the Property and recovering
from Tenant the amount specified in this Section 10.03(a), or (ii) proceeding under Section 10.03(b). Notwithstanding the above language
in this Section, nothing shall waive, impact, or ameliorate Landlord's duty to mitigate its damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2pt; text-align: justify; text-indent: 69.6pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Maintain
Tenant's right to possession, in which case this Lease shall continue in effect whether or not Tenant has abandoned the Property. In
such event, Landlord shall be entitled to enforce all of Landlord's rights and remedies under this Lease including the right to
recover the rent as it becomes due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 69.45pt"><B>(c)</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Pursue
recovery of any damages, including but not limited to rent or any other charges due and owing to Landlord under this Lease, against any
property, real or personal, subject to a security interest, mortgage, pledge, landlord's lien or other lien of Landlord provided by statute
or provided for under the terms of this Lease in favor of Landlord against the property of the Tenant; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2pt; text-align: justify; text-indent: 69.55pt"><B>(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Pursue
any other remedy now or hereafter available to Landlord under the laws or judicial decisions of the state in which the Property is located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 10.04.&#8239;&#8239;&#8239;&#8239;Intentionally
Deleted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34.95pt"><B>Section 10.05.&#8239;
Automatic Termination. </B>Notwithstanding any other term or provision hereof to the contrary, the Lease shall terminate on the occurrence
of any act which affirms the Landlord's intention to terminate the Lease as provided in Section 10.03 hereof, including the filing of
an unlawful detainer action against Tenant. On such termination, Landlord's damages for default shall include all costs and fees, including
reasonable attorneys' fees that Landlord incurs in connection with the filing, commencement, pursuing and/or defending of any action
in any bankruptcy court or other court with respect to the Lease; the obtaining of relief from any stay in bankruptcy restraining any
action to evict Tenant; or the pursuing of any action with respect to Landlord's right to possession of the Property. All such damages
suffered (apart from Base Rent, Additional Rent and other charges payable hereunder) shall constitute pecuniary&#8239;damages which must
be reimbursed to Landlord prior to assumption of the Lease by Tenant or any successor to Tenant in any bankruptcy or other proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 35.35pt"><FONT STYLE="font-size: 10pt"><B>Section
10.06. &#8239;&#8239;&#8239;Abandonment. </B></FONT>Any trade fixtures, Tenant alternations and personal property not removed by Tenant
or its secured lender with ten (10) days from the termination or expiration of this Lease shall be deemed abandoned, and such items may,
in any manner Landlord's deems appropriate, in its sole discretion, be removed, destroyed and disposed of by Landlord at Tenant's expense.
Tenant waives all claims against Landlord for any damages resulting from Landlord's retention, destruction and disposition of such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 34.4pt"><FONT STYLE="font-size: 10pt"><B>Section
10.07. &#8239;&#8239;&#8239;Cumulative Remedies. </B></FONT>Landlord's exercise of any right or remedy shall not prevent it from exercising
any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt"><B>Section
10.08.&#8239;&#8239;&#8239; Landlord Default and Tenant's Remedies. </B></FONT>In the event Landlord defaults in payments or performance
of its obligations hereunder, Tenant shall provide written notice to Landlord with opportunity to cure within thirty (30) days thereafter.
Landlord shall not be deemed to be in default hereunder if Landlord cures such default during the foregoing thirty (30) day period or
if such non-performance requires more than thirty (30) days to cure, Landlord shall commence curing the default within such thirty (30)
day period and thereafter diligently pursue said cure completion. To the extent Landlord fails to cure any default as set forth in this
Section 10.08, Tenant shall not be entitled to withhold Rent hereunder, but Tenant shall be entitled to undertake a claim relative to
such default against Landlord in accordance with the arbitration provisions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt"><B>ARTICLE ELEVEN: PROTECTION OF LENDERS/ASSOCIATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt"><B>Section
11.01. Subordination. </B></FONT>Landlord shall have the right to subordinate this Lease to any ground lease, deed of trust or mortgage
encumbering the Property, any advances made on the security thereof, any renewals, modifications, consolidations, replacements or extensions
thereof, whenever made or recorded, and any commercially reasonable covenants, conditions or restrictions to which the Property is subject
by Landlord. Tenant shall cooperate with Landlord and any lender which is acquiring a security interest in the Property or the Lease.
Tenant shall execute such further documents and assurances as Landlord or such lender may reasonably require, provided that Tenant's
obligations under this Lease shall not be increased in any material way (the performance of ministerial acts shall not be deemed material),
and Tenant shall not be deprived of its rights under this Lease. Tenant's right to quiet possession of the Property during the Lease
Term shall not be disturbed if Tenant pays the rent and performs all of Tenant's obligations under this Lease and is not otherwise in
default. <FONT STYLE="font-size: 10pt">If</FONT> any ground lessor, beneficiary or mortgagee elects to have this Lease superior to the
lien of its ground lease, deed of trust or mortgage and gives written notice thereof to Tenant, this Lease shall be deemed superior to
such ground lease, deed of trust or mortgage whether this Lease is dated prior or subsequent to the date of said ground lease, deed of
trust or mortgage or the date of recording thereof. In connection with any required subordination, Landlord shall cause any mortgagee
or beneficiary under a deed of trust to not disturb Tenant, and Landlord shall deliver to Tenant a commercially reasonable Non-Disturbance
agreement at the time of any such encumbrance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.45pt"><B>Section 11.02.&#8239;&#8239;
Attornment. </B>If Landlord's interest in the Property is acquired by any ground lessor, beneficiary under a deed of trust, mortgagee,
or purchaser at a foreclosure sale, Tenant shall attorn to the transferee of or successor to Landlord's interest in the Property and
recognize such transferee or successor as Landlord under this Lease. Tenant waives the protection of any statute or rule of law which
gives or purports to give Tenant any right to terminate this Lease or surrender possession of the Property upon the transfer of Landlord's
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 35pt"><B>Section 11.03.
 &#8239;&#8239;Signing of Documents. </B>Tenant shall sign and deliver any instrument or documents reasonably necessary or appropriate
to evidence any such attornment or subordination or agreement to do so. If Tenant fails to do so within ten (10) days after written
request, Tenant hereby makes, constitutes and irrevocably appoints Landlord, or any transferee or successor of Landlord, the attorney-in-fact
of Tenant to execute and deliver any such instrument or document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 11.04.&#8239;&#8239;&#8239; Estoppel Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 70.9pt"><B>(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</B>Upon either party's written request, the party to which the request is directed shall execute, acknowledge and deliver to the requesting
party a written statement certifying: (i) that none of the terms or provisions of this Lease have been changed (or if they have been
changed, stating how they have been changed); (ii) that this Lease has not been canceled or terminated; (iii) the last date of payment
of the Base Rent and other charges and the time period covered by such payment; (iv) that the requested party is not in default under
this Lease (or, if the requested party is claimed to be in default, stating why); and (v) such other representations or information with
respect to the requested party or the Lease as the requesting party may reasonably request or which any prospective purchaser or encumbrancer
of the Property may require. The requested party shall deliver such statement to the requesting party within ten ( 10) days after the
requesting party's request. Landlord may give any such statement by the requested party to any prospective purchaser or encumbrancer
of the Property and such purchaser or encumbrancer, as well as Landlord, may rely conclusively upon such statement as true and correct.
Tenant may give any such statement by the requested party to any third party that has reason to rely upon such statement, and such third
party, as well was Tenant, may rely conclusively upon such statement as true and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 69.65pt"><B>(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>If
the requested party does not deliver such statement to requesting party within such ten <FONT STYLE="font-size: 10pt">(1</FONT>0) day
period, the requesting party, and any prospective purchaser or encumbrancer, may conclusively presume and rely upon the following facts:
(i) that the terms and provisions of this Lease have not been changed except as otherwise represented by the requesting party; <FONT STYLE="font-size: 10pt">(ii)
</FONT>that this Lease has not been canceled or terminated except as otherwise represented by requesting party; (iii) that not more than
one month's Base Rent or other charges have been paid in advance; and (iv) that the requesting party is not in default under the Lease.
In such event, the requested party shall be estopped from denying the truth of such facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 35.05pt"><B>Section 11.05.
Tenant's Financial Condition. </B>Within ten (10) days after written request from Landlord, Tenant shall deliver to Landlord such financial
statements as Landlord reasonably requires to verify the net worth of Tenant or any assignee, subtenant, or guarantor of Tenant. In addition,
Tenant shall deliver to any lender designated by Landlord any financial <FONT STYLE="font-size: 10pt">statements required by such lender
to facilitate the financing or refinancing of the Property.&#8239;</FONT>Tenant represents and warrants to Landlord that each such financial
statement is a true and accurate statement as of the date of such statement. All financial statements shall be confidential and shall
be used only for the purposes set forth in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARTICLE TWELVE: LEGAL COSTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><B>Section 12.01.&#8239;&#8239;&#8239;
Arbitration. </B>The parties shall endeavor in good faith to promptly resolve disputes hereunder or need for interpretation of any portion
of this Lease (the &quot;Claim&quot;) by direct negotiations between executives who have authority to settle the matter. Such negotiations
shall be conducted in the spirit of collaboration and compromise to avoid more extreme dispute resolution procedures and at the same
time approximating satisfaction of the mutual interests of the parties. Any party may give the other notice of dispute not resolved
in the normal course of business. Within five (5) days after delivery of the notice of dispute, the executives of both parties shall
meet at a mutually acceptable time and place, telephonically or <FONT STYLE="font-size: 10pt">in</FONT> person, and thereafter as often
as they reasonably deem necessary to attempt to resolve the dispute. A party may elect, upon five (5) days notice, after the initial
meeting (or attempted meeting if the initial meeting has not occurred because the other party has failed to attend the initial meeting)
to proceed with binding arbitration of the dispute. The arbitration process shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.95pt"><B>(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Initiation of Arbitration. </B>In order to initiate an arbitration hereunder, the party wishing to make a claim (the &quot;Initiator&quot;)
shall give a written notice of demand for arbitration hereunder (the &quot;Initial Notice&quot;) to the other party (the &quot;Respondent&quot;)
and provide the name of the &quot;Initial Arbitrator&quot; (as hereinafter defined).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.95pt"><B>(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Initial
Notice. </B>To be valid the Initial Notice must include the following: (i)<FONT STYLE="font-size: 10pt">&nbsp; </FONT>a short statement
of the claim, including the elements of the claim, cause and effect; (ii) a proposed resolution (the &quot;Initial Resolution&quot;)
of the claim involved; (iii) the name of the arbitrator proposed by the Initiator (the &quot;Initial Arbitrator&quot;); (iv) the address,
phone number and facsimile information of both the Initiator and the Initial Arbitrator; (v) the date of the Initial Notice; and (vi)
the signature of the Initiator. The Initial Notice may include other matters as shall be deemed appropriate by the Initiator, but it
may not contain any conditions to the effectiveness of the Initial Notice nor any other matter which affects the validity of the Initial
Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 69.6pt"><B>(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Response.
</B>The Respondent is bound to respond to the Initial Notice in writing within ten (10) business days of the Initial Notice (the &quot;Response&quot;)
or suffer the consequences as hereinafter defined. If the Respondent fails to timely respond with a valid Response, the Initial Resolution
shall become effective as an arbitration award hereunder. A valid Response must be one of the following described below: (i) a Second
Arbitrator; (ii) Disputation of the Initial Resolution; or (iii) Acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 104.6pt">(i) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Second
Arbitrator. If the Respondent wishes to dispute the Initial Resolution and/or precipitate a panel of three arbitrators (Respondent may
elect to use the Initial Arbitrator), the Respondent must timely deliver a written notice (the &quot;Second Notice&quot;) to the Initiator
and the Initial Arbitrator, which to be valid, must include the following: (a) a short statement of the response, including the factual
disputes with the Initial Notice, other facts&#8239;supporting the Respondents position; (b) a proposed resolution (&quot;Second Resolution&quot;)
of the claim, such as alternative amounts of payment, disbursements or damages or alternative resolutions of the claim; (c) the name
of the arbitrator proposed by the Respondent (the &quot;Second Arbitrator&quot;) if desired; (d) the address, phone number and facsimile information of both the Respondent and the Second Arbitrator; (e) the date of the Response; and <FONT STYLE="font-size: 10pt">(f)
</FONT>the signature of the Respondent. The Response may include other matters as shall be deemed appropriate by the Respondent, but
it may not contain any conditions to the effectiveness of the Response nor any other matter which affects the validity of the Response.
If a valid Second Arbitrator notice is timely given, the Second Arbitrator and the Initial Arbitrator shall meet and agree on a third
arbitrator; if they do not or cannot within ten (10) days following the Response, then the Initiator, the Respondent and/or either Arbitrator
may request to have the Maricopa County Superior Court name the third arbitrator. Upon completing the panel of arbitrators, the panel
shall begin the arbitration process to ascertain information to make its award. The Arbitrators shall make an award of either the Initial
Resolution or the Second Resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 104.95pt">(ii) Disputation of Initial
Resolution. The Respondent may choose to only dispute the Initial Resolution. If the Respondent selects this alternative, the Respondent
must timely file a Response including the following: (a) a short statement of the response, including the factual disputes with the Initial
Notice and other facts supporting the Respondents position; (b) a proposed resolution (the &quot;Second Resolution&quot;) of the claims,
such as alternative amounts of damages, disbursements or alternative resolutions of the claims; (c) the address, phone number and facsimile
information of the Respondent; (d) the date of the Response; and (e) the signature of the Respondent. The Response may include other
matters as shall be deemed appropriate by the Respondent, including claims of the Respondent, but it may not contain any conditions to
the effectiveness of the Response nor any other matter which affects the validity of the Response. If the Response does not name the
Second Arbitrator, the Initial Arbitrator shall make the award as it deems appropriate in view of the facts as it determines them to
be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 104.65pt">(iii) Acceptance.
<FONT STYLE="font-size: 10pt">If</FONT> the Respondent fails to timely give a valid notice of Second Arbitrator or Disputation, or if
the Respondent gives notice of Acceptance of the Initial Resolution, then it may be implemented and acted upon by both parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><B>(d) Counterclaim.
</B>The Respondent may include a Counterclaim in the Response. <FONT STYLE="font-size: 10pt">If</FONT> the Respondent makes a Counterclaim,
the Initiator shall be obligated to respond in the same time and in the same fashion as the Respondent, except that the Initial Arbitrator
shall be the Initiator's arbitrator for both the initial claim and the counterclaim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.6pt"><B>(e) Arbitration
Costs. </B>In the absence of an award of arbitration costs hereunder, the costs of the arbitration shall be divided equally between the
parties hereto. The arbitrator shall award reasonable attorneys fees and costs to the successful party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.6pt"><B>(f) Scope of
Arbitration. </B>Arbitration may be invoked for all claims relating in any manner to this Lease except for Landlord's rights under Arizona
law to proceed with forcible detainer or eviction actions. The award of the arbitration shall be enforceable in courts of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.95pt"><B>Section 12.02.
 &#8239;&#8239;Legal Proceedings. </B><FONT STYLE="font-size: 10pt">Tenant shall indemnify Landlord against and hold Landlord harmless
from all reasonable costs, expenses, demands and liability Landlord may incur if Landlord becomes or is made a party to any claim or
action (a) instituted by Tenant against any third party, or by any third party against Tenant, or by or against any person holding any
interest under or using the Property by license of or agreement with Tenant; (b) for foreclosure of any lien for labor or material furnished
to or for Tenant or such other person; (c) otherwise arising out of or resulting from any act or transaction of Tenant or such other
person; or ( d) necessary to protect Landlord's interest under this Lease in a bankruptcy proceeding, or other proceeding under Title
11 of the United States Code, as amended. Tenant shall defend Landlord against any such claim or action at Tenant's expense with counsel
reasonably acceptable to Landlord or, at Landlord's election, Tenant shall reimburse Landlord for any reasonable legal fees or costs
Landlord incurs in any such claim or action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 35pt"><B>Section 12.03.&#8239;&#8239;&#8239;
Landlord's Consent. </B><FONT STYLE="font-size: 10pt">Tenant shall pay Landlord's reasonable attorneys' fees, not to exceed $2,500 per
request, incurred in connection with Tenant's request for Landlord's consent under Article Nine (Assignment and Subletting), or in connection
with any other act which Tenant proposes to do and which requires Landlord's consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>ARTICLE THIRTEEN: &#8239;&#8239;&#8239;&#8239;MISCELLANEOUS
PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.95pt"><B>Section 13.01.&#8239;
Periodic Rental Activity Updates. </B><FONT STYLE="font-size: 10pt">From the date of the execution of this Lease through and including
six (6) months thereafter, Landlord agrees to provide Joe Ellison and Scott T. Collier, managing director of Jones Lang LaSalle, periodic
rental activity updates, summarizing the general status of negotiations with prospective tenants for vacant space within Liberty Cotton
Center, subject to Jones Lang LaSalle entering into a confidentiality agreement satisfactory to Landlord in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 13.02. &#8239;&#8239;&#8239;Intentionally Deleted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 13.03.&#8239;&#8239;&#8239; Intentionally Deleted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt"><B>Section 13.04.&#8239;&#8239;&#8239; Landlord's Liability;
Certain Duties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 70pt"><B>(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B><FONT STYLE="font-size: 10pt">As
used in this Lease, the term &quot;Landlord&quot; means only the current owner or owners of the fee title to the Property or the leasehold
estate under a ground lease of the Property at the time in question. Each Landlord is obligated to perform the obligations of Landlord
under this Lease only during the time such Landlord owns such interest or title. Any Landlord who transfers its title or interest is
relieved of all liability with respect to the obligations of Landlord under this Lease to be performed on or after the date of transfer.
However, each Landlord shall deliver to its transferee all funds that Tenant previously paid if such funds have not yet been applied
under the terms of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2pt; text-align: justify; text-indent: 69.55pt"><B>(b) </B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall give written notice of any failure by Landlord to perform any of its obligations under this Lease to Landlord and to any ground
lessor, mortgagee or beneficiary under any deed of trust encumbering the Property whose name and address have been furnished to Tenant
in writing. Landlord shall not be in default under this Lease unless Landlord (or such ground lessor, mortgagee or beneficiary) fails
to cure such non-performance within thirty (30) days after receipt of Tenant's notice. However, if such non-performance&#8239;reasonably
requires more than thirty (30) days to cure, Landlord shall not be in default if such cure is commenced within such thirty (30) day period
and thereafter diligently pursued to completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 1pt; text-align: justify; text-indent: 69.6pt"><B>(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Notwithstanding
any term or provision herein to the contrary, the liability of Landlord for the performance of its duties and obligations under this
Lease is limited to Landlord's interest in the Property, and neither the Landlord nor its partners, shareholders, officers or other principals
shall have any personal liability under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 35pt"><B>Section 13.05.
 &#8239;&#8239;Severability. </B>A determination by a court of competent jurisdiction that any provision of this Lease or any part thereof
is illegal or unenforceable shall not cancel or invalidate the remainder of such provision or this Lease, which shall remain in full
force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 34.95pt"><B>Section 13.06. &#8239;&#8239;Interpretation.
</B>The captions of the Articles or Sections of this Lease are to assist the parties in reading this Lease and are not a part of the
terms or provisions of this Lease. Whenever required by the context of this Lease, the singular shall include the plural and the plural
shall include the singular. The masculine, feminine and neuter genders shall each include the other. <FONT STYLE="font-size: 10pt">In
</FONT>any provision relating to the conduct, acts or omissions of Tenant, unless otherwise stated the term &quot;Tenant&quot; shall
include Tenant's agents, employees, contractors, invitees, successors or others using the Property with Tenant's expressed or implied
permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 35.35pt"><B>Section 13.07.&#8239;&#8239;
Incorporation of Prior Agreements; Modifications. </B>This Lease is the only agreement between the parties pertaining to the lease of
the Property and no other agreements are effective. All of the agreements, conditions, covenants, terms, warranties and provisions of
the Lease relating to the Property are expressly contained <FONT STYLE="font-size: 10pt">in</FONT> this Lease, and none shall be implied.
Tenant acknowledges and agrees that no prior information provided or statement made by the Landlord or its agents have in any way induced
Tenant to enter into this Lease. All amendments to this Lease shall be in writing and signed by all parties. Any other attempted amendment
shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 34.5pt"><B>Section 13.08.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices. </B>All notices required or permitted under this Lease or otherwise
given between Landlord and Tenant shall be in writing and shall be personally delivered or sent by certified mail, return receipt requested,
postage prepaid or nationally recognized overnight delivery service. Notices to Tenant shall be delivered to the address specified in
Section 1.03 above, with a copy to Tenant's counsel at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109pt">TENANT'S COUNSEL:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Ballard Spahr Andrews &amp; Ingersoll</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109pt">3300 North Central Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109pt">Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109pt">Phoenix, Arizona 85012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109pt">Attn: Jeffrey Pitcher, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Notices to Landlord shall be delivered
to the address specified in Section 1.02 above, with a copy to Landlord's counsel at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">LANDLORD'S COUNSEL:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Quarles <FONT STYLE="font-size: 10pt">&amp;</FONT> Brady
LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Two North Central Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Phoenix, Arizona 85004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 105pt">Attn: Scott M. Berg, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: -0.45pt">All notices shall
be effective upon delivery. Except as provided above for notice to Tenant at the Property, either party may change its notice address
upon written notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt"><B>Section
13.09.&#8239;&#8239; Waivers. </B></FONT>All waivers must be in writing and signed by the waiving party. Landlord's failure to enforce
any provision of this Lease or its acceptance of rent shall not be a waiver and shall not prevent Landlord from enforcing that provision
or any other provision of this Lease in the future. No statement on a payment check from Tenant or in a letter accompanying a payment
check shall be binding on Landlord. Landlord may, with or without notice to Tenant, negotiate such check without being bound to the conditions
of such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt"><B>Section
13.10. &#8239;&#8239;No Recordation. </B></FONT>Tenant shall not record this Lease without prior written consent from Landlord. However,
either Landlord or Tenant may require that a &quot;Short Form&quot; memorandum of this Lease executed by both parties be recorded. The
party requiring such recording shall pay all transfer taxes and recording fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt"><B>Section
13.11. &#8239;&#8239;Binding Effect; Choice of Law. </B></FONT>This Lease binds any party who legally acquires any rights or interest
in this Lease from Landlord or Tenant. However, Landlord shall have no obligation to Tenant's successor unless the rights or interests
of Tenant's successor are acquired in accordance with the terms of this Lease. The laws of the state in which the Property is located
shall govern this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-size: 10pt"><B>Section
13.12. &#8239;&#8239;Corporate Authority; Partnership Authority; Limited Liability Company Authority. </B>If</FONT> Tenant is a corporation,
each person signing this Lease on behalf of Tenant represents and warrants that he has full authority to do so and that this Lease binds
the corporation. Within thirty (30) days after this Lease is signed, Tenant shall deliver to Landlord a certified copy of a resolution
of Tenant's Board of Directors authorizing the execution of this Lease or other evidence of such authority reasonably acceptable to Landlord.
<FONT STYLE="font-size: 10pt">If</FONT> Tenant is a partnership, each person or entity signing this Lease for Tenant represents and warrants
that he or it is a general partner of the partnership, that he or it has full authority to sign for the partnership and that this Lease
binds the partnership and all general partners of the partnership. Tenant shall give written notice to Landlord of any general partner's
withdrawal or addition. Within thirty (30) days after this Lease is signed, Tenant shall deliver to Landlord a copy of Tenant's recorded
statement of partnership or certificate of limited partnership. <FONT STYLE="font-size: 10pt">If</FONT> Tenant is a limited liability
company, each person or entity signing this Lease for Tenant represents and warrants that he or it is a member of the limited liability
company, that he or it has full authority to sign for the limited liability company and that this Lease binds the limited liability
company and all members of the limited liability company. Tenant shall give written notice to Landlord of any member's withdrawal or
addition. Within thirty (30) days after this Lease is signed, Tenant shall deliver to Landlord a certified copy of a resolution of Tenant's
members authorizing the execution of this Lease or other evidence of such authority reasonably acceptable to Landlord. Any such entity
acting as Tenant's Guarantor under this Lease shall deliver to Landlord a certified copy of a&#8239;resolution from either the Guarantor's
Board of Directors, general partners or members authorizing the execution of the Guaranty or other evidence of such authority reasonably
acceptable to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.05pt"><B>Section 13.13.&#8239;&#8239;
Joint and Several Liability. </B>All parties signing this Lease as Tenant shall be jointly and severally liable for all obligations of
Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 35pt"><B>Section 13.14.
 &#8239;&#8239;Force Majeure. </B>If Landlord cannot perform any of its obligations due to events beyond Landlord's control, the time
provided for performing such obligations shall be extended by a period of time equal to the duration of such events. Events beyond Landlord's
control include, but are not limited to, acts of God, war, civil commotion, labor disputes, strikes, fire, flood or other casualty, shortages
of labor or material, government regulation or restriction and weather conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 34.9pt"><B>Section 13.15. &#8239;&#8239;Execution
of Lease. </B>This Lease may be executed in counterparts and, when all counterpart documents are executed, the counterparts shall constitute
a single binding instrument. Landlord's delivery of this Lease to Tenant shall not be deemed to be an offer to lease and shall not be
binding upon either party until executed and delivered by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 34.55pt"><B>Section 13.16.&#8239;&#8239;
Survival. </B>All representations and warranties of Landlord and Tenant shall survive the termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 34.95pt"><B>Section 13.17.
 &#8239;&#8239;Broker's Fee. </B>When this Lease is signed by and delivered to both Landlord and Tenant, Landlord shall pay a real estate
commission to Landlord's and Tenants brokers named in Section 1.08 above (collectively, the &quot;Broker&quot;), in accordance with the
separate agreement between Landlord and such Broker for services rendered to Landlord by Broker in this transaction. Nothing contained
in this Lease shall impose any obligation on Landlord to pay a commission or fee to any party other than Broker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.4pt"><B>Section 13.18. &#8239;Protection
of Brokers. </B>If Landlord sells the Property, or assigns Landlord's interest in this Lease, the buyer or assignee shall, by accepting
such conveyance of the Property or assignment of the Lease, be conclusively deemed to have agreed to make any commission payments to
Broker if required of Landlord under this Article Thirteen, to the extent same has not been previously paid. If Broker shall bring a
legal action to enforce or declare rights under this provision, the prevailing party in such action shall be entitled to reasonable attorneys'
fees to be paid by the losing party. Such attorneys' fees shall be fixed by the court in such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 35.45pt"><B>Section 13.19.
 &#8239;&#8239;No Blocked Persons. </B>Landlord nor Tenant nor any of their affiliates, officers, directors, partners or members is an
entity or person (or to Landlord's and Tenant's knowledge, owned or controlled by an entity or person) that is listed in the Annex to,
or is otherwise subject to the provisions of, Executive Order 13224 issued on September 24, 2001 (&quot;EO13224&quot;), whose name appears
on the United States Treasury Department's Office of Foreign Assets Control most current list of &quot;Specifically Designated National
and Blocked Persons&quot; who commits, threatens to commit or supports &quot;terrorism,&quot; as that term is defined in EO13224 or who
is otherwise affiliated with any entity or person listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARTICLE FOURTEEN: SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><B>Section 14.01. &#8239;Counterparts/Facsimile
Signatures. </B><FONT STYLE="font-size: 10pt">This Agreement may be executed in any number of counterparts, each of which will for all
purposes be deemed to be an original, and when all counterpart documents are executed, the counterparts shall constitute a single binding
instrument. Facsimile signatures on this Agreement shall be deemed binding the same as original signatures, and upon and execution and
forwarding of this Agreement by facsimile, the parties so forwarding shall immediately mail the original signed document to said other
party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><B>Section 14.02. &#8239;&#8239;</B>IN
ANY REAL ESTATE TRANSACTION, IT IS RECOMMENDED THAT YOU CONSULT WITH A PROFESSIONAL, SUCH AS A CIVIL ENGINEER, INDUSTRIAL HYGIENIST OR
OTHER PERSON WITH EXPERIENCE IN EVALUATING THE CONDITION OF THE PROPERTY, INCLUDING THE POSSIBLE PRESENCE OF ASBESTOS, HAZARDOUS MATERIALS
AND UNDERGROUND STORAGE TANKS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">Signed on August 19, 2009, at 11 a.m.</TD><TD STYLE="text-align: justify; width: 50%">&quot;LANDLORD&quot;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="4"><B>LIBERTY COTTON CENTER, LLC</B></TD><TD COLSPAN="4" STYLE="text-align: justify"><B>LIBERTY COTTON CENTER, LLC</B></TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD COLSPAN="3">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                     <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD>
<TD COLSPAN="3">Liberty Cotton Center II, LLC,&#8239;its sole Member</TD><TD STYLE="text-align: justify">By:</TD>
                                                                                     <TD COLSPAN="3" STYLE="text-align: justify">Liberty
                                            Cotton Center II, LLC, its sole Member</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD>By:</TD>
<TD COLSPAN="2">Liberty Property Limited&#8239;Partnership, its sole Member</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                     <TD STYLE="text-align: justify">By:</TD>
                                                                                     <TD COLSPAN="2" STYLE="text-align: justify">Liberty
                                            Property Limited Partnership, its sole Member</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 3%">By:</TD>
<TD STYLE="width: 41%">Liberty Property Trust,&#8239;Sole General Partner</TD><TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
                                                                                     <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
                                                                                     <TD STYLE="text-align: justify; width: 3%">By:</TD>
                                                                                     <TD STYLE="text-align: justify; width: 41%">Liberty
                                            Property Trust, Sole General Partner</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">By:</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/&#8239;Michael T. Hagan</TD><TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
                            <TD STYLE="width: 5%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 43%">/s/&#8239;Robert
                                            Goldschmidt</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>Name:</TD>
<TD STYLE="border-bottom: Black 1pt solid">Michael T. Hagan</TD><TD STYLE="text-align: left">&nbsp;</TD>
                            <TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Robert
                                            Goldschmidt</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>Title:</TD>
<TD STYLE="border-bottom: Black 1pt solid">Chief Investment Officer</TD><TD STYLE="text-align: left">&nbsp;</TD>
                            <TD STYLE="text-align: left">Title:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Senior
                                            Vice President, &amp; Regional Director</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">Signed on August 12, 2009, at 5 p.m.</TD><TD STYLE="text-align: justify; width: 50%">"TENANT"</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">CDX HOLDINGS, INC., a Delaware corporation</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD>
                            <TD STYLE="width: 5%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">/s/&#8239;Laurie
                                            Johansen</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
                            <TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Laurie
                                            Johansen</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
                            <TD STYLE="text-align: left">Its:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Vice
                                            Chairman</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT "A"</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>DIAGRAM OF PROPERTY WITH
PARKING INDICATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT "B"</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>WORK LETTER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 35.05pt">The undersigned
Landlord and Tenant are executing concurrently with this Work Letter Agreement, a written Industrial Real Estate Lease (the &quot;Lease&quot;)
covering those certain premises more particularly described in Section 1.04 of the Lease, (hereinafter referred to as &quot;Premises&quot;),
commonly known as Liberty Cotton Center -Building 16.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Representatives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 35.05pt">Landlord appoints
Landlord's Representative to act for Landlord in all matters covered by this Work Letter. Tenant appoints Tenant's Representative to
act for Tenant in all matters covered by this Work Letter. All inquiries, requests, instructions, authorizations and other communications
with respect to the matters covered by this Work Letter will be made to Landlord's Representative or Tenant's Representative, as the
case may be. Tenant will not make any inquiries of or requests to, and will not give any instructions or authorizations to, any other
employee or agent of Landlord, including Landlord's architect, engineers and contractors or any of their agents or employees, with regard
to matters covered by this Work Letter. Either party may change its Representative under this Work Letter at anytime with three (3) days
prior written notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tenant's Representative:</FONT></TD>
    <TD STYLE="width: 54%; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Joe Ellison</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Senior Vice President -</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Human Resources &amp; Administration</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8400 Esters Boulevard</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Irving, Texas&nbsp;&nbsp;75063</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phone:&nbsp;&nbsp;[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Landlord's Representative:</FONT></TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jim Schow</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liberty Property Trust</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2390 East Camelback Road, Suite 318</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phoenix, AZ&nbsp;&nbsp;85016</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phone: &nbsp;[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Tenant's
Plans And Specifications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70.05pt">(a) Tenant agrees,
at its sole cost and expense, through its representative, at the firm, The Lauck Group and Lord Aeck &amp; Sargent. (&quot;Space Planner&quot;)
to furnish a space plan and specifications, including the space layout and improvement plan for the Premises (&quot;Tenant's Space Plan&quot;)
required for the performance of the work to construct the improvements to the building desired by Tenant (hereinafter referred to as
the &quot;Tenant Improvements&quot;). Tenant's Space Plan shall include but not be limited to partition layout, reflected ceiling plans
and electrical outlets, electrical switches and telephone outlets and locations. Tenant and Landlord agree to utilize a licensed and
bonded contractor (&quot;Contractor&quot;) as the Contractor for construction of the Tenant Improvements. Scott and Reid General Contractors,
Inc., DPR Construction and Hardison Downey Construction Inc. are acceptable to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-align: justify; text-indent: 69.6pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The Space Planner shall be responsible for providing to Tenant, with a copy to Landlord, a complete set of documents, including Tenant's
Space Plan, which are permit ready and have completed plan check by the government agency having jurisdiction, for construction of the
Tenant Improvements, the quantity and description of materials, equipment and other items required for bidding by the Contractor. The
Space Planner shall be responsible for completion and coordination of the architectural, mechanical, electrical and plumbing drawings.
Landlord, Tenant and Contractor shall cooperate to the best of their ability to provide all information required for such coordination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-align: justify; text-indent: 70.05pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant shall be responsible to pay the Space Planner's fees for the Tenant's Space Plan, which Landlord will reimburse Tenant by charging
said reimbursement against the Tenant Allowance provided under this Agreement; however, all interior design or decorating services, such
as selection of wall paint colors and/or wall coverings, fixtures, carpeting, and any or all other decorator or interior design services
and extraordinary work required by Tenant of the Space Planner shall be paid by the Tenant at the time and to the extent the Space Planner
has provided such services for the Tenant's Space Plans, and such services shall not be reimbursed by Landlord to Tenant and Landlord
shall have no liability therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 1pt; text-align: justify; text-indent: 70.05pt">(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
plans and specifications referred to hereinabove in Sections a, b and c are subject to the Landlord's approval, which the Landlord agrees
will not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord's
Approval</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 1pt; text-align: justify; text-indent: 34.55pt">Landlord may
withhold its approval of any Tenant Space Plan, Tenant Working Drawings, Tenant Extra Work or Change Orders which require work which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 1pt; text-align: justify; text-indent: 69.5pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
adversely affects the structural integrity of the Building, or any part of the heating, ventilating, air conditioning, plumbing, mechanical,
electrical, communication or other systems of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-indent: 69.6pt">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;is
not approved by the holder of any mortgage or deed of trust. encumbering the Building at the time the work is proposed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">would
not be approved by a prudent owner of property similar to the&#8239;</FONT>Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt">(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;violates
any agreement which affects the Building or binds Landlord;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord reasonably believes will increase the projected cost of operation or maintenance of any of the systems of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 2pt; text-indent: 70pt">(f) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
reasonably believes will reduce the rental value of the Premises or the sale value of the Building at the end of the Term;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 2pt; text-indent: 69.55pt">(g) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;does
not conform to applicable building codes or is not approved by any governmental authority with jurisdiction <FONT STYLE="font-size: 10pt"><B>over
</B></FONT>the Premises; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>is
not consistent <FONT STYLE="font-size: 10pt">with</FONT> or is inferior to the Building standard tenant improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Schedule
of Tenant Improvement Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.95pt">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or before five (5) days after the execution of the Lease (&quot;Submission Date&quot;), Tenant shall cooperate with and submit to Space
Planner the information (the &quot;Tenant Information&quot;) necessary for the Space Planner to prepare the Tenant's Space Plan for the
Premises. Tenant's Space Plan shall be completed in accordance with the requirements of Tenant within thirty (30) days after the execution
of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 69.6pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant, through the Contractor, will promptly prepare a preliminary estimate of the cost of Tenant's Improvements as set forth in the
Tenant Space Plan (the &quot;Tenant's Estimated Construction Cost&quot;). If the Tenant's Estimated Construction Cost is more than the
Tenant Allowance, Tenant will so notify Landlord in writing and Tenant will either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 104.6pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
agree in writing to pay the amount by which the Tenant's Estimated Construction Cost exceeds the Tenant Allowance and as though that
amount were Tenant Extra Work, subject to Paragraph 5, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 104.65pt">(ii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;revise
the Tenant Space Plan in order to assure that the Tenant's Estimated Construction Cost is either (A) no more than the Tenant Allowance
e, or (B) in excess of the Tenant Allowance by an amount which Tenant agrees to pay pursuant to clause <FONT STYLE="font-size: 10pt">(i)
</FONT>immediately above. Upon Tenant's fulfillment of its obligation in either clause (i) or clause (ii) immediately above, the Tenant's
Estimated Construction Cost will be deemed approved. If the Tenant's Estimated Construction Cost is less than the Tenant Allowance, the
Tenant's Estimated Construction Cost will be deemed approved without notice to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.05pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
After approval of the Tenant's Estimated Construction Cost, Space Planner will prepare and deliver to Tenant, Landlord and Contractor
working drawings for the Premises (&quot;Tenant Working Drawings&quot;). Tenant shall cause Contractor to prepare from the documents
a cost proposal (the &quot;Tenant Cost Proposal&quot;) for construction of Tenant's Improvements in accordance with the Tenant Working
Drawings, and a Construction Schedule which will set forth estimated time frames for completion of construction. If the Tenant Cost Proposal
is less than the sum of the Tenant Allowance and any amount in excess of the Tenant Allowance which Tenant has agreed to pay pursuant
to Paragraph 4b, Tenant will take steps necessary to complete construction of the improvements to the Premises. If the Tenant Cost Proposal
is more than the Tenant Allowance, plus any amount which Tenant has agreed to pay pursuant to clause (i) of Paragraph 4b immediately
above (the &quot;Maximum Approved Cost&quot;), Tenant will so notify Landlord in writing and Tenant shall either (i) agree in writing
to pay the amount by which the Tenant Cost Proposal exceeds the Maximum Approved Cost as if that additional amount were Tenant Extra
Work, subject to Paragraph 5, or (ii) revise the Tenant Working Drawings in order to assure that the Tenant Cost Proposal is no more
than the Maximum Approved Cost. Upon Tenant's fulfillment of its obligations in either clause <FONT STYLE="font-size: 10pt">(i)</FONT>
or clause (ii) above, Tenant will take steps necessary to complete construction of the improvements to the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 70.4pt">(d) &#8239;&#8239;&#8239;All
work shall be performed by the Contractor and/or contractors approved by Landlord. Landlord approves of Scott and Reid General Contractors,
Inc. as general contractor and The Lauck Group as space planner. Following approval of the Tenant Working Drawings and the Tenant Cost
Proposal, Tenant will cause Space Planner to make application to the appropriate governmental authorities for necessary approvals and
building permits. Upon receipt of the necessary approvals and permits and subject to receipt of the payment required under Paragraph
5, the Contractor will begin construction. The Contractor may substitute materials of comparable or better quality if the materials specified
in Tenant's Working Drawings are unavailable or not available within the time required for timely completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Payment
For Tenant Extra Work</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">Tenant shall pay Contractor for Tenant Extra Work as completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Change
Orders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.55pt">Tenant may authorize
changes in the work during construction only on written instructions to Landlord's Representative on a form approved by Landlord. All
such changes will be subject to Landlord prior written approval in accordance with Paragraph 3. Landlord may disapprove any change which
would materially delay the scheduled completion of work. Prior to commencing any change, the Tenant will prepare and deliver to Landlord,
for Landlord's approval, a change order (the &quot;Change Order&quot;) setting forth the total cost of such change, which will include
associated architectural, engineering and construction contractor's fees. If Landlord fails to approve such Change Order within five
(5) days after delivery by Tenant, Tenant will be deemed to have withdrawn the proposed change and Contractor will not proceed to perform
the change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.55pt">7.
 &#8239;&#8239;&#8239;&#8239;Mezzanine Improvements. Landlord acknowledges that the Tenant Improvements shall include the
construction of a mechanical riser approximately 12,000 square foot in size to house mechanical equipment at the Premises (the
 &quot;Mezzanine&quot;). The Mezzanine shall be subject to the same review and approval process as the rest of the Tenant
Improvements. The square footage added to the Premises as a result of the Mezzanine shall not be used  in calculating Base Rent or
Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.55pt">8. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Construction
Of The Premises</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 69.95pt">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall cause Contractor to construct the Tenant Improvements within the Premises under a contract with the Tenant following receipt of
the final Tenant Working Drawings and necessary approvals and permits. All subcontractors awarded shall be at market rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 70.5pt">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
shall have the right to approve Tenant's choice of the contractor to perform any of the nonstandard items listed in subparagraph (a)
immediately above in Landlord's discretion, not to be unreasonable withheld. Any contractor employed by Tenant shall be commercially
licensed, bonded and insured, with copies of all documentation evidencing such matters delivered to Landlord prior to the contractor
beginning any work at or upon the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">9.</TD><TD STYLE="text-align: justify">Tenant's Punch List</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 70.1pt">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;When
the Contractor believes the Tenant Improvements are substantially completed, and prior to Tenant's possession of the Premises, Tenant
shall give Landlord one (1) week prior written notification for Landlord to inspect the Tenant Improvements. Landlord's representative
shall completely examine the Premises and complete with Tenant's representative a list of all visible items to be completed by Contractor
to finish the work. Such list shall be formalized by Landlord and signed by both Landlord and Tenant. The Tenant Improvements shall be
deemed &quot;substantially completed&quot; when the Premises, as improved, can be legally occupied by Tenant without material interference
with Tenant's business, with only minor &quot;punch list&quot; items remaining to be completed. Landlord's good faith and reasonable
determination of substantial completion shall be conclusive. Further, issuance of a certificate of occupancy by the appropriate governmental
entity shall be deemed substantial completion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 69.6pt">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
shall diligently proceed to have all items noted on the list completed as soon as possible. Any work damaged during Tenant's move in
or occupancy shall be repaired or replaced at Tenant's sole cost and expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">10.</TD><TD STYLE="text-align: justify">Tenant Improvements
                                            At Landlord's Cost And Expense</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 35.5pt">Landlord agrees
to provide Tenant an allowance of Seventy-Five Dollars $75.00 per rentable square foot for the 66,012 rentable square feet of the Premises
to complete its Tenant Improvements in the Premises (&quot;Tenant Allowance&quot;) for a total of Four Million Nine Hundred Fifty Thousand
Nine Hundred ($4,950,900). The Tenant Allowance may be utilized by Tenant for any and all city permits, space planning (in the amount
limited by Section 2c), engineering, architectural and construction costs. The Tenant Allowance shall be used only to plan and construct
improvements which are real property fixtures that will remain with the Premises, and may not be used to purchase or construct trade
fixtures, furniture, or other personal property. Landlord shall pay directly to such persons <FONT STYLE="font-size: 10pt">or</FONT>
entities that portion of the Tenant Allowance for the amounts owed (or pay to Tenant and such person or entity by joint check if requested
by Tenant), subject to Tenant's delivery to Landlord of <FONT STYLE="font-size: 10pt">(1)</FONT> copies of the relevant invoices, and
(2) conditional lien releases, as applicable, in statutory form, with respect to the construction work or materials for which payment
is being made and for which a mechanics, materialmen's or professional lien may be asserted under applicable law. All aggregate costs
of Tenant Improvements in excess of the Tenant Allowance shall be the sole responsibility of the Tenant including any and all change
order expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left"><FONT STYLE="font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify">Building
                                            Standards</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 35.05pt">Tenant shall utilize
materials equivalent to or better in quality than the Landlord's Building standard tenant improvement items (the Building Standard) in
order to assure the consistent quality and appearance of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left"><FONT STYLE="font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify">Shell
                                            Construction</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.6pt">Landlord shall only
provide as part of the initial construction of the Building the following items: (i) outside walls, columns and unfinished concrete floors,
broom clean; (ii) Building Standard electric capacity of not less than 1,600 amps to the Building core, per building specifications;
and (iii) water lines to the Building (with Tenant to be responsible for all costs of hook-up of all and any utilities, water, sewer
and other similar services with the <FONT STYLE="font-size: 10pt">City </FONT>in which the Premises is located), including the costs
related to energizing Tenant's electrical service, and the cost of meter installation and meters, which shall be paid for by Tenant and/or
included in the Tenant Allowance. Landlord represents that the shell Building is currently in conformance with ADA requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">13.</TD><TD STYLE="text-align: justify">Responsibility For
                                            Design</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">Tenant will be responsible for the design, function and maintenance
of all improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">14.</TD><TD STYLE="text-align: justify">Indemnity</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 35.95pt">Except for claims
arising out of or caused by Landlord's gross negligence or willful misconduct, Tenant shall indemnify Landlord against and hold Landlord
harmless from any and all reasonable costs, claims or liability arising from: (a) any work performed on or about the Premises by or at
Tenant's request; (b) any breach or default in the performance of Tenant's obligations under this Work Letter; or (c) any other acts
or omissions of Tenant. Tenant shall defend Landlord against any such cost, claim or liability at Tenant's expense with counsel reasonably
acceptable to Landlord or, at Landlord's election, Tenant shall reimburse Landlord for any reasonable legal fees or costs incurred by
Landlord in connection with any such claim. As a material part of the consideration to Landlord, Tenant assumes all risk of damage to
property or injury to persons in or about the Premises arising from any claims caused by Tenant's or its employees. And except when resulting
from Landlord's gross negligence or willful misconduct, Tenant hereby waives all claims in respect thereof against Landlord. As used
in this Section, the term &quot;Tenant&quot; shall include Tenant or Tenant's employees, officers and directors, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">15.</TD><TD STYLE="text-align: justify">Lien Protection</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 35.9pt">Tenant shall pay
when due all claims for labor or materials furnished or alleged to have been furnished to or for Tenant for use in completing any work
at or upon the Premises, which claims are or may be secured by any mechanic's liens against the Premises or any interest therein. Tenant
shall give Landlord not less than ten (10) days prior written notice of any work done on or in the Premises and Landlord shall have the
right to post a notice of non-responsibility in or on the Premises as may be allowed by law. If Tenant or Landlord shall contest the
validity of any such lien, claim or demand, the Tenant, shall, at its sole cost and expense, defend and protect itself, the Premises
and Landlord against the same and shall pay and satisfy any such adverse judgment that may be rendered thereon before the enforcement
thereof against the Landlord or the Premises. If Landlord shall require, Tenant shall furnish to Landlord a surety bond satisfactory
to Landlord in an amount equal to one and one half times the amount of such contested lien claim or demand, indemnifying Landlord against
liability for the same, as required by law to hold the Premises free from the effect of such lien or claim. In addition, Landlord may
require Tenant to pay Landlord's reasonable attorney fees and costs in participating in such action if Landlord shall deem it is in its
best interest to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">16.</TD><TD STYLE="text-align: justify">Force Majeure</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 35.9pt; margin: 0pt 2pt 0pt 0; text-align: justify">If Landlord
cannot perform any of its obligations due to events beyond Landlord's control, the time provided for performing such obligations
shall be extended by a period of time equal to the duration of such events. Events beyond Landlord's control include, but are not
limited to, acts of God, war, civil commotion, labor disputes, strikes, fire, flood or other casualty, shortages of labor or
material, government regulation or restriction and weather conditions. Acts which are not beyond Landlord's control, include, but
are not limited to lack of sufficient funds for any liabilities or obligations, failure to pay for labor or materials, or any other
matter within the Landlord's reasonable control or ability to resolve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.65pt"></TD><TD STYLE="width: 34.35pt; text-align: left">17.</TD><TD STYLE="text-align: justify">Miscellaneous</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 35pt">In the event of any
conflict between the terms of this Work Letter Agreement and the remainder of the Lease, the terms of this Work Letter Agreement will
control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap; vertical-align: middle; width: 10%; text-align: left">Tenant Initiails</TD>
<TD STYLE="white-space: nowrap; vertical-align: middle; width: 10%; text-align: left">&nbsp;<IMG SRC="tm2415719d15_ex10-3bsp2img2.jpg" ALT=""></TD>
    <TD STYLE="white-space: nowrap; width: 10%">&nbsp;</TD>
<TD STYLE="white-space: nowrap; vertical-align: middle; text-align: left; width: 10%">Landlord Initials</TD>
<TD STYLE="white-space: nowrap; text-align: justify; width: 60%">&nbsp;<IMG SRC="tm2415719d15_ex10-3bsp2img3.jpg" ALT=""></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT &quot;C&quot;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>BUILDING RULES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26pt 0pt 0; text-indent: 0.6pt"><B>Any inconsistencies between the provisions
of the Lease and the rules contained herein shall be resolved in favor of the Lease provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 35.8pt">1.&#8239;<B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Any
sidewalks, lobbies, passages and stairways shall not be obstructed or used by Tenant for any purpose other than ingress and egress from
and to the Property. Landlord shall in all cases retain the right to control or prevent access by all persons whose presence, in the
judgment of Landlord, shall be prejudicial to the safety, peace or character of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
toilet rooms, toilets, urinals, sinks, faucets, plumbing or other service apparatus of any kind shall not be used for any purposes other
than those for which they were installed, and no sweepings, rubbish, rags, ashes, chemicals or other refuse or injurious substances shall
be placed therein or used in connection therewith or left in any lobbies, passages, elevators or stairways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.8pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall not impair in any way the fire safety system and shall comply with all safety, fire protection and evacuation procedures and regulations
established by Landlord or any governmental agency. No person shall go on the roof without Landlord's prior written permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.9pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Skylights,
windows, doors and transoms shall not be covered or obstructed by Tenant, and Tenant shall not install any window covering which would
affect the exterior appearance of the Building, except as approved in writing by Landlord. Tenant shall not remove, without Landlord's
prior written consent, any shades, blinds or curtains in the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.8pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
Landlord's prior written consent, Tenant shall not hang, install, mount, suspend or attach anything from or to any sprinkler, plumbing,
utility or other lines. If Tenant hangs, installs, mounts, suspends or attaches anything from or to any doors, windows, walls, floors
or ceilings, Tenant shall spackle and sand all holes and repair any damage caused thereby or by the removal thereof at or prior to the
expiration or termination of the Lease. Except as otherwise provided in the Lease, if Tenant elects to seal the floor, Tenant shall seal
the entire unfinished floor area within the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.8pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Except for secured areas of the Property required by Tenant's business to be secured or otherwise locked, for which Tenant will provide
Landlord a key or other immediate access mode, Tenant shall not change any locks nor place additional locks upon any doors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.35pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall not use nor keep in the Building any matter having an offensive odor, nor explosive or highly flammable material, nor shall any
animals other than handicap assistance dogs in the company of their masters be brought into or kept in or about the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 34.35pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Tenant desires to introduce electrical, signaling, telegraphic, telephonic, protective alarm or other wires, apparatus or devices,
Landlord shall direct where and how the same are to be placed, and except as so directed, no installation boring or cutting shall be
permitted. Landlord shall have the right to prevent and to cut off the transmission of excessive or dangerous current of electricity
or annoyances into or through the Building or the Property and to require the changing of wiring connections or layout at Tenant's
expense, to the extent that Landlord may deem necessary, and further to require compliance with such reasonable rules as Landlord
may establish relating thereto, and in the event of non-compliance with the requirements or rules, Landlord shall have the right
immediately to cut wiring or to do what it considers necessary to remove the danger, annoyance or electrical interference with
apparatus in any part of the Building. All wires installed by Tenant must be clearly tagged at the distributing boards and junction
boxes and elsewhere where required by Landlord, with the number of the office to which said wires lead, and the purpose for which
the wires respectively are used, together with the name of the concern, if any, operating same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall not place weights anywhere beyond the safe carrying capacity of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
use of rooms as sleeping quarters is strictly prohibited at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 35.7pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall have the right, at Tenant's sole risk and responsibility, to use only Tenant's share of the parking spaces at the Property as reasonably
determined by Landlord. Except as otherwise provided in the Lease, Tenant shall comply with all parking regulations promulgated by Landlord
from time to time for the orderly use of the vehicle parking areas, including without limitation the following: Parking shall be limited
to automobiles, passenger or equivalent vans, motorcycles, light four wheel pickup trucks and (in designated areas) bicycles. No vehicles
shall be left in the parking lot overnight without Landlord's prior written approval. Parked vehicles shall not be used for vending or
any other business or other activity while parked in the parking areas. Vehicles shall be parked only in striped parking spaces, except
for loading and unloading, which shall occur solely in zones marked for such purpose, and be so conducted as to not unreasonably interfere
with traffic flow within the Property or with loading and unloading areas of other tenants. Employee and tenant vehicles shall not be
parked in spaces marked for visitor parking or other specific use. All vehicles entering or parking in the parking areas shall do so
at owner's sole risk and Landlord assumes no responsibility for any damage, destruction, vandalism or theft. Tenant shall cooperate with
Landlord in any measures implemented by Landlord to control abuse of the parking areas, including without limitation access control programs,
tenant and guest vehicle identification programs, and validated parking programs, provided that no such validated parking program shall
result in Tenant being charged for spaces to which it has a right to free use under its Lease. Each vehicle owner shall promptly respond
to any sounding vehicle alarm or horn, and failure to do so may result in temporary or permanent exclusion of such vehicle from the parking
areas. Any vehicle which violates the parking regulations may be cited, towed at the expense of the owner, temporarily or permanently
excluded from the parking areas, or subject to other lawful consequence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.5pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If Landlord designates the Building as a non-smoking building, Tenant and its Agents shall not smoke in the Building nor at the Building
entrances and exits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2pt; text-align: justify; text-indent: 35.5pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
at Tenant's request, Landlord consents to Tenant having a dumpster at the Property, Tenant shall locate the dumpster in the area designated
by Landlord and shall keep and maintain the dumpster clean and painted with lids and doors in good working order and, at Landlord's request,
locked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.5pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall provide Landlord with a written identification of any vendors engaged by Tenant to perform services for Tenant at the Property
(examples: cleaners, security guards/monitors, trash haulers, telecommunications installers/maintenance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.5pt">15. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall comply with any reasonable move-in/move-out rules provided by Landlord.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.5pt">16. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall cause all of Tenant's Agents to comply with these Building Rules.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.5pt">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
reserves the right to rescind, suspend or modify any rules or regulations and to make such other rules and regulations as, in
Landlord's reasonable judgment, may from time to time be needed for the safety, care, maintenance, operation and cleanliness of the
Property. Notice of any action by Landlord referred to in this section, given to Tenant, shall have the same force and effect as if
originally made a part of the foregoing Lease. New rules or regulations will not, however, be unreasonably inconsistent with the
proper and rightful enjoyment of the Property by Tenant under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt; text-align: justify; text-indent: 35.5pt">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;These
Building Rules are not intended to give Tenant any rights or claims in the event that Landlord does not enforce any of them against any
other tenants or if Landlord does not have the right to enforce them against any other tenants and such nonenforcement will not constitute
a waiver as to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>LEASE ASSIGNMENT AND
ASSUMPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 22pt 0pt 1pt; text-align: justify; text-indent: 64.25pt">LEASE
ASSIGNMENT AND ASSUMPTION AGREEMENT (this <FONT STYLE="font-style: normal; font-weight: normal">&quot;</FONT><B><I>Agreement</I></B><FONT STYLE="font-style: normal; font-weight: normal">&quot;)
</FONT>dated as of November 22, 2011 between CARIS LIFE SCIENCES, INC. (formerly CDX HOLDINGS, INC.), a Delaware corporation <FONT STYLE="font-style: normal; font-weight: normal">(&quot;</FONT><B><I>Assignor</I></B><FONT STYLE="font-style: normal">'')
</FONT>and CARIS MPI, INC., a Delaware corporation <FONT STYLE="font-style: normal; font-weight: normal">(&quot;</FONT><B><I>Assignee</I></B><FONT STYLE="font-style: normal; font-weight: normal">&quot;)</FONT><FONT STYLE="font-style: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>W I T N E S S E T H:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 1pt; text-align: justify; text-indent: 64.55pt">WHEREAS, Assignor
is the tenant under that certain Industrial Real Estate Lease (Single-Tenant Facility) (the <FONT STYLE="font-style: normal; font-weight: normal">&quot;</FONT><B><I>Lease</I></B><FONT STYLE="font-style: normal; font-weight: normal">&quot;)
</FONT>dated August 19, 2009, between Assignor and Liberty Cotton Center, LLC <FONT STYLE="font-style: normal; font-weight: normal">(&quot;</FONT><B><I>Landlord</I></B><FONT STYLE="font-style: normal; font-weight: normal">'')
</FONT>relating to certain premises (the <FONT STYLE="font-style: normal; font-weight: normal">''</FONT><B><I>Premises</I></B><FONT STYLE="font-style: normal; font-weight: normal">'')
</FONT>consisting of approximately 66,012 rentable square feet located in the building known as Cotton Center Building 16, located at
4610 South 44<SUP>th</SUP> Place, Phoenix, AZ 85040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 64.65pt">WHEREAS, Assignor
and Assignee desire that Assignor transfer its right, title and interest in, to and under the Lease to Assignee upon the terms and conditions
set forth herein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19pt 0pt 1pt; text-align: justify; text-indent: 64.25pt">NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be bound hereby,
the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 64.25pt">SECTION 1. Effective
as of the date hereof, Assignor hereby assigns to Assignee all of Assignor's right, title and interest in, to and under the Lease, including
without limitation any security deposit thereunder, any prepaid rent or other prepaid amounts thereunder and any right to receive any
refund from or make any claim against Landlord thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 64.4pt">SECTION 2. Assignee
hereby assumes the performance and observance of all of the covenants, conditions and provisions in the Lease to be performed and observed
by Assignor from and after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14pt 0pt 0; text-align: justify; text-indent: 64.25pt">SECTION 3. Assignee
hereby represents and warrants that it has the sole and unencumbered right and power to enter into this Agreement and this Agreement
has been duly authorized, executed and delivered by and on behalf of Assignee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13pt 0pt 0; text-align: justify; text-indent: 64.4pt">SECTION 4. This
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. No provision
of this Agreement shall inure to the benefit of any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-align: justify; text-indent: 64.25pt">SECTION 5. No provision
of this Agreement shall be modified, waived or terminated, except by an instrument in writing signed by the party against whom enforcement
of such modification, waiver or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42pt 0pt 0; text-indent: 64.45pt">SECTION 6. This Agreement shall be
construed in accordance with and governed by the law of the State of Arizona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 64.35pt">SECTION 7. This Agreement
may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and
hereto were upon the same instrument. In making proof of this Agreement, it shall not be necessary to produce or account for more than
one such counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>[Remainder of the
page intentionally left blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 66.45pt">IN WITNESS WHEREOF, the parties have executed
and delivered this Agreement as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif"><U>Assignor</U>:</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">CARIS LIFE SCIENCES, INC.</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif">/s/ Laura I. Johansen&#8239;</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 50%">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 42%">Laura I. Johansen&#8239;</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">President</TD>
    </TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif"><U>Assignee</U>:</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">CARIS MPI, INC.</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif">/s/ Laura I. Johansen&#8239;</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 50%">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 3%">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left; width: 42%">Laura I. Johansen&#8239;</TD>
    </TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">President</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #1F1F1F"><B><U>FIRST
AMENDMENT TO LEASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 33pt"><FONT STYLE="font-size: 10pt; color: #1C1B1B"><B>THIS
FIRST AMENDMENT </B></FONT><B><FONT STYLE="font-size: 10pt; color: #303038">T</FONT></B><B><FONT STYLE="font-size: 10pt; color: #1C1B1B">O
LEASE AGREEMENT</FONT></B><FONT STYLE="color: #1C1B1B; font-size: 10pt"> (this &quot;<B>First Amendment</B>&quot;) </FONT><FONT STYLE="font-size: 10pt; color: #1E1E1F">dated
for reference purposes as May&#8239;9, 2019, is made by and between <B>WPT PROPERTIES </B></FONT><B>LP</B>, a Delaware limited partnership
(&quot;<B>Landlord</B>&quot;), and <B>CARIS MPI, INC.</B>, a Texas corporation (&quot;<B>Tenant</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #1C1C1C"><B><U>BACKGROUND:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 32.9pt; color: #1C1C1C">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liberty
Property Limited Partnership, mistakenly identified as Liberty Cotton Center, LLC (&quot;<B>Liberty</B>&quot;), and Caris Life Sciences,
Inc. (fonnerly CDx Holdings, Inc.) (''<B>Caris</B>&quot;) entered into that certain Industrial Real Estate Lease (Single-Tenant Facility)
dated August 19, 2009 (the &quot;<B>Lease</B>&quot;), covering certain Leased Premises containing approximately 66,012 rentable square
feet of space (the &quot;<B>Leased Premises</B>&quot;), being the entire building known as and located at 4610 South 44<SUP>th</SUP>
Place, Phoenix, Arizona (the &quot;<B>Building</B>&quot;), as more fully described in the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 32.8pt; color: #1C1C1C">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
that certain Lease Assignment and Assumption Agreement dated November 22, 2011, Caris assigned to Tenant, all of Caris' right, title
and interest in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2pt; text-align: justify; text-indent: 32.15pt; color: #1C1C1C">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
that certain Assignment and Assumption of Leases dated October 3, 2016, WPT Land 2 LP assumed all of Liberty's right, title and interest,
in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 32.65pt; color: #1C1C1C">D.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
connection with its acquisition of the Building, by that certain Assignment and Assumption of Leases dated June 8, 2018, Landlord assumed
all of WPT Land 2 LP's right, title and interest, in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 32.65pt; color: #1C1C1C">E.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
desires to extend the Term and modify other sections of the Lease, and Landlord has agreed to such extension and modifications, subject
to the provisions of this First Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 32.45pt; color: #1C1C1C"><B>NOW,
THEREFORE</B>, the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending
to be legally bound, hereby agree that the Lease is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 32.65pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: #1D1D1D">1.</FONT><FONT STYLE="color: #1C1C1C">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>&#8239;<U>Incorporation</U></B><U>.
</U>The above Background is incorporated herein by reference.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #1D1D1D">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 32.65pt; color: #1B1B1B; margin-top: 0pt; margin-bottom: 0pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Defined
Terms; Conflict</U></B><U>.</U> All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to
them in the Lease. In the event there is a conflict between the terms of the Lease and this First Amendment, this First Amendment shall
control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt; color: #1C1C1C">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Term</U></B><U>.
</U>The Lease is hereby amended to extend the Term for one (1) additional period of sixty-four (64) months (the &quot;Extended Term&quot;),
commencing on September 1, 2020, and expiring at 11:59 P .M. local time on December 31, 2025 (the &quot;Expiration Date&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Base
Rent</U>. </B>Effective as of September 1, 2020, and continuing through and including the Expiration Date, Tenant's Base Rent obligation
for the Leased Premises shall be as follows and all Rent shall be paid in accordance with the terms of the Lease:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 47pt; text-align: justify; text-indent: 0.35pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">PSF/annum</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Annual</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Monthly</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2020
    &ndash; 12/31/2020 *</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">18.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#8239;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 21%; text-align: right">--------</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: right">103,418.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/1/2021
 &ndash; 8/31/2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,241,025.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">103,418.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2021
    &ndash; 8/31/2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,274,031.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,169.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2022
    &ndash; 8/31/2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,307,037.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">108,919.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2023
    &ndash; 8/31/2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,043.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,670.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2024
    &ndash; 8/31/2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,373,049.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">114,420.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2025
    &ndash; 12/31/2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,406,055.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">117,171.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Notwithstanding the foregoing, Base Rent, but
not Additional Rent, shall be abated for the first four (4) months of the Extended Term. Should there occur an uncured Event of Default
by Tenant during said four (4) month period, then such abatement shall cease. Landlord's management fee shall not be reduced on account
of the abatement in Base Rent, and the Base Rent abatement shall be disregarded for purposes of calculating any management fee based
on a percentage of rental revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Tenant shall have
the </FONT>right <FONT STYLE="font-size: 10pt">to make all payments of Rent to Landlord via electronic funds transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 38pt; text-indent: -0.05pt">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt"><FONT STYLE="font-size: 10pt">5<I>.&#8239;&#8239;&#8239;&#8239;&#8239;</I></FONT><B><U>Annual
Operating Expenses</U></B>. All <FONT STYLE="font-size: 10pt">Additional</FONT> Rent applicable <FONT STYLE="font-size: 10pt">to </FONT>the
Leased <FONT STYLE="font-size: 10pt">Premises shall continue to </FONT>be <FONT STYLE="font-size: 10pt">paid by Tenant, in addition to
the Base Rent, subject to adjustment </FONT>and <FONT STYLE="font-size: 10pt">reconciliation and in accordance with</FONT> the terms
and <FONT STYLE="font-size: 10pt">conditions</FONT> of <FONT STYLE="font-size: 10pt">the</FONT> Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&#8239;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Options
</U></B></FONT><B><U>to Extend Term</U></B>. The parties acknowledge and <FONT STYLE="font-size: 10pt">agree </FONT>that the Extended
<FONT STYLE="font-size: 10pt">Term constitutes </FONT>for purposes of <FONT STYLE="font-size: 10pt">Section </FONT>3.02 of <FONT STYLE="font-size: 10pt">the
</FONT>Lease <FONT STYLE="font-size: 10pt">the </FONT>first <FONT STYLE="font-size: 10pt">Option Term, and, notwithstanding </FONT>anything
<FONT STYLE="font-size: 10pt">to </FONT>the <FONT STYLE="font-size: 10pt">contrary </FONT>set <FONT STYLE="font-size: 10pt">forth </FONT>is
such Section 3.02 <FONT STYLE="font-size: 10pt">of the </FONT>Lease, <FONT STYLE="font-size: 10pt">the terms and conditions of this First
Amendment shall control. Accordingly, Tenant shall have the right to extend the Term for only one (1) additional period of 5-years,
which right is subject to all of the terms </FONT>and <FONT STYLE="font-size: 10pt">conditions of Section 3.02 of the Lease.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: 33.1pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;<U>Parking</U>.
</B>The parties acknowledge and confirm that Tenant enjoys the right to use 264 parking spaces at the <FONT STYLE="font-size: 10pt">Leased
Premises</FONT> without additional charge <FONT STYLE="font-size: 10pt">(the</FONT> &quot;<B>Required <FONT STYLE="font-size: 10pt">Parking
Spaces</FONT></B><FONT STYLE="font-size: 10pt">''). Landlord</FONT> shall have the right <FONT STYLE="font-size: 10pt">to</FONT> relocate
all or any of the surface parking spaces of the Required <FONT STYLE="font-size: 10pt">Parking</FONT> Spaces to areas within reasonably
close proximity to the Leased Premises as shown on Exhibit &quot;A&quot; to this First Amendment. <FONT STYLE="font-size: 10pt">Any</FONT>
such relocation of the Required Parking shall be at Landlord's sole cost, the new parking spaces shall be paved and striped, and any
covered and lit parking space shall be replaced with a covered and lit parking space. Such relocated parking spaces <FONT STYLE="font-size: 10pt">may,
</FONT>but are not required to, be located within a structured parking facility. If, in the future, it becomes evident through an accurate
written accounting of Tenants parking which is delivered to Tenant and denotes actual usage and the average number of cars in <FONT STYLE="font-size: 10pt">Tenants
</FONT>parking <FONT STYLE="font-size: 10pt">lot</FONT> five days per week for a 30 day period illustrates that on a daily basis Tenant
is using less than 75% of the Required Parking Spaces due to changes in mobility use (such as shared automobiles and autonomous automobiles
and other technology driven changes) then upon notice to Tenant, Landlord may recapture an amount of parking spaces equal to the percentage
of Required Parking Spaces not being used by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Security
Deposit</U></B>. No additional Security Deposit is required from Tenant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.65pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Tenant
Improvements; Tenant Allowance</U></B>. Tenant is in possession of the Leased Premises. Landlord shall have no obligations whatsoever
to improve or pay for improvements to the Leased Premises for Tenant's continued use and occupancy thereof, except as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.7in; margin-top: 0pt; margin-right: 2pt; margin-bottom: 0pt; text-align: justify">(a)&#8239;&#8239;&#8239;&#8239;Any
improvements, alterations, or additions Tenant undertakes to remodel or reconstruct the Leased Premises are herein referred to as &quot;<B>Tenant
Improvements</B>&quot;. Pursuant to Section 9(e) of this First Amendment, Tenant shall be responsible for the cost of any Tenant Improvements,
and Tenant will have plans for such Tenant Improvements designed and approved in accordance with Section 9(b) of this First Amendment,
and constructed by Tenant in accordance with Section 9(c) of this First Amendment. Tenant confirms all Tenant Improvements are for the
immediate use and benefit of Tenant only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.7in">(b)&#8239;&#8239;&#8239;&#8239;Tenant's
improvement specifications and plans for such Tenant Improvements to the Leased Premises shall be prepared by an architect or engineer
selected by Tenant, subject <FONT STYLE="font-size: 10pt">to</FONT> the prior approval of Landlord, which such approval shall not <FONT STYLE="font-size: 10pt">be
</FONT>unreasonably withheld (&quot;<B>Tenant's Architect</B>&quot;<B>)</B>. SmithGroup, Inc. are architects acceptable to Landlord.
The <FONT STYLE="font-size: 10pt">plans for the Tenant Improvements </FONT>will be <FONT STYLE="font-size: 10pt">prepared in sufficient
detail to permit Tenant to construct the Tenant Improvements, and shall include, as applicable, a partition layout (dimensioned), door
location and door schedule including hardware, reflected ceiling plan, telephone and electrical outlets with locations (dimensioned),
special electrical, cabling, HVAC and/or plumbing work, mechanicals, special loading requirements, such as the location of file cabinets
and special equipment, openings in the walls or floors, all necessary sections and details for special equipment and fixtures, and finishes
including, without limitation, carpentry and millwork, floor coverings, wall coverings, color schedules, and any other special finishes.
The plans for the Tenant Improvements shall be prepared in accordance, and shall comply in all </FONT>material <FONT STYLE="font-size: 10pt">respects,
with all Laws. Landlord shall not</FONT> unreasonably <FONT STYLE="font-size: 10pt">withhold, condition or delay its approval of the
plans for the Tenant Improvements and Landlord may withhold its approval for any of the reasons enumerated in Section 3 of Exhibit &quot;B&quot;
of the Lease. Within ten (10) days after receipt, Landlord shall respond to any specifications and plans of the Tenant Improvements submitted
by Tenant, stating any specific comments or objections that Landlord may have. If Landlord fails to respond within such ten (10) day
period, Tenant's plans shall be deemed approved. Tenant will continue to submit plans and specifications and Landlord will continue to
approve or disapprove the same in the process set forth above until such are approved or deemed approved </FONT>by <FONT STYLE="font-size: 10pt">Landlord.
</FONT>Upon <FONT STYLE="font-size: 10pt">approval </FONT>by <FONT STYLE="font-size: 10pt">Landlord, the plans and specifications for
the Tenant Improvements shall become final and shall not be materially changed without Landlord's further approval, which shall not be
unreasonably withheld, conditioned or delayed (as finally approved, the </FONT>&quot;<B>Tenant Improvement <FONT STYLE="font-size: 10pt">Plans</FONT></B><FONT STYLE="font-size: 10pt">&quot;).
Landlord's review or approval of the Tenant Improvement Plans does not constitute a code review and shall not be a representation or
warranty of Landlord that the Tenant Improvement Plans are </FONT>fit <FONT STYLE="font-size: 10pt">for </FONT>any <FONT STYLE="font-size: 10pt">use
or comply with any Laws or other legal requirements, and Tenant shall have no right to</FONT> rely <FONT STYLE="font-size: 10pt">upon
</FONT>any <FONT STYLE="font-size: 10pt">review or approval for such purposes. Landlord shall have no liability </FONT>to <FONT STYLE="font-size: 10pt">Tenant
or any third party </FONT>by <FONT STYLE="font-size: 10pt">reason of such review</FONT> or approval, and Landlord's review of any plans
and specifications and monitoring of construction shall be solely for its own benefit. The Tenant Improvements be shall be <FONT STYLE="font-size: 10pt">the
property of Tenant until the expiration or termination of the Lease, as amended hereby, at which time and without payment by Landlord,
the Tenant Improvements shall remain on the Leased Premises and become the property of Landlord, subject to the terms and conditions
of Section 6.06 of the Lease.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 37pt; text-align: justify; text-indent: 65.15pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 37pt; text-align: justify; text-indent: 65.15pt"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 37pt; text-align: justify; text-indent: 65.15pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;Tenant
shall complete the Tenant Improvements to the Leased Premises substantially in accordance with the Tenant Improvement Plans and applicable
provisions of the Lease, including but not limited to Section 6.05 (Alterations, Additions and Improvements) and Section 6.06 (Condition
upon Termination) of the Lease, the provision of insurance, the delivery of Lien Waivers (as defined hereunder) pursuant to Section 9(g)
of this First Amendment, and the delivery of permits to Landlord pursuant lo Section 9(d) of this First Amendment. The contractors selected
by Tenant for bidding (and awarding of work) on the Tenant Improvements shall be licensed and qualified for the work they are to perform
and shall be subject to the approval of Landlord, which shall not be unreasonably withheld, conditioned or delayed. DPR Construction
and Oakland Construction are contractors acceptable to Landlord. Landlord reserves the right to require Tenant to use contractors designated
by Landlord for any part of the Tenant </FONT>Improvements <FONT STYLE="font-size: 10pt">Tenant shall require all contractors and </FONT>subcontractors
<FONT STYLE="font-size: 10pt">to </FONT>be <FONT STYLE="font-size: 10pt">adequately insured by maintaining commercial general liability
</FONT>insurance <FONT STYLE="font-size: 10pt">with </FONT>limits <FONT STYLE="font-size: 10pt">of coverage not less than $1,000,000
combined single limit with a $2,000,000 general aggregate limit, naming Landlord and the Landlord Additional Insureds, as additional
insureds, and at least ten (10) days prior lo the commencement of construction, Tenant shall deliver a certificate of insurance for each
of Tenant's contractors and their subcontractors to Landlord evidencing such insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.7in">(d)&#8239;&#8239;&#8239;&#8239;All
construction relating to the Tenant Improvements shall be done in a good and workmanlike manner and shall comply in all respects at the
time of completion with all Laws of the governmental authorities having jurisdiction. Tenant shall obtain all governmental approvals
and pennits related to the Tenant <FONT STYLE="font-size: 10pt">Improvements</FONT> and promptly deliver copies of same to Landlord prior
to the start of <FONT STYLE="font-size: 10pt">any</FONT> work. Within sixty days after the substantial completion of the Tenant Improvements,
Tenant shall provide Landlord with the following documents with respect to the Leased Premises and the Tenant Improvement, <FONT STYLE="font-size: 10pt">if
</FONT>required: <FONT STYLE="font-size: 10pt">(i)</FONT> a Certificate of Occupancy; <FONT STYLE="font-size: 10pt">(ii)</FONT> a full
set of final and un-appealable permits and approvals; <FONT STYLE="font-size: 10pt">(iii)</FONT> &quot;as-built'' plans (hard copy and
CAD); and, (iv) a statement of completion in accordance with the Tenant Improvement Plans <FONT STYLE="font-size: 10pt">by</FONT> Tenant
<FONT STYLE="font-size: 10pt">In</FONT> addition <FONT STYLE="font-size: 10pt">to</FONT> the right of Landlord and its Agents to inspect
the Leased Premises as set <FONT STYLE="font-size: 10pt">forth</FONT> in Section 5.06 of the Lease, Landlord and its Agents shall have
the right, at its sole <FONT STYLE="font-size: 10pt">cost</FONT> and <FONT STYLE="font-size: 10pt">expense,</FONT> to <FONT STYLE="font-size: 10pt">conduct
</FONT>a walk-through inspection of the <FONT STYLE="font-size: 10pt">Leased</FONT> Premises as completed by Tenant. The warranties from
Tenant's contractor(s) shall be for the benefit of Landlord, as well as Tenant, and Tenant shall deliver copies of such warranties to
Landlord promptly upon receipt. As used herein, &quot;substantial completion&quot; of the Tenant Improvements occurs when all aspects
of the Tenant Improvements are complete in accordance with <FONT STYLE="font-size: 10pt">the</FONT> Tenant Improvement Plans, save <FONT STYLE="font-size: 10pt">only
</FONT>minor punchlist items, the completion of which, by their <FONT STYLE="font-size: 10pt">nature,</FONT> do not materially interfere
with Tenant's instnllation of its trade fixtures and equipment and operation of its business therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 2pt; margin-bottom: 0pt; text-indent: 0.7in">(e)&#8239;&#8239;&#8239;&#8239;Tenant
shall, subject to Section 9(f) of this First Amendment below, pay the costs, expenses and fees incurred for the construction of the Tenant
Improvements, including without limitation <FONT STYLE="font-size: 10pt">(i)</FONT> architectural, engineering and design costs, <FONT STYLE="font-size: 10pt">(ii)
</FONT>the cost charged to Tenant by the general contractor and all subcontractors for performing such construction, <FONT STYLE="font-size: 10pt">(iii)
</FONT>construction pennit fees, (iv) costs of built-in furniture, and (v) mechanical and structural engineering fees, credited against
the Tenant Improvement Allowance (as defined hereunder) upon Landlord's receipt of each Reimbursement Application (as defined hereunder)
(together, the &quot;Tenant Improvement Costs&quot;). In no event shall Landlord charge to Tenant, or deduct from the Tenant Improvement
Allowance, any fee for any supervision, project management, or oversight Landlord elects to undertake during Tenant's construction
of the Tenant Improvement Work except that Landlord may charge Tenant for Landlord's actual out-of-pocket costs reasonably incurred with
respect to any third party engineers engaged by Landlord in connection with Landlord's review of the Tenant Improvement Plans. Landlord
<FONT STYLE="font-size: 10pt">has</FONT> no obligation to provide any construction administration or management services to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 38pt; text-align: justify; text-indent: 0.55pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 38pt; text-align: justify; text-indent: 0.55pt"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 38pt; text-align: justify; text-indent: 0.55pt">&#8239;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 38pt; text-align: justify; text-indent: 0.55pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.35in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
shall provide an allowance to Tenant of Four Hundred Ninety-Five Thousand Ninety Dollars ($495,090.00) (the &ldquo;<B>Tenant</B> <B>Improvement
Allowance</B>&rdquo;) (based on Seven Dollars and Fifty Cents ($7.50) per rentable square foot) which shall be used by Tenant to pay for the
Tenant Improvement Costs in accordance with Section 9(e) of this First Amendment. The Tenant Allowance shall be applied to the actual
out-of-pocket costs and expenses incurred by Tenant in connection with the Tenant Improvements for labor, materials, design, architectural
and engineering fees, and project management fees, but not for any &ldquo;soft costs&rdquo; (for example, excluded costs </FONT>will <FONT STYLE="font-size: 10pt">be
attorney fees, costs of permits, moving expenses, furniture purchase, moving, assembly and disassembly, telecommunication cabling costs
and similar &ldquo;soft costs&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: 66pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.35in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall promptly <FONT STYLE="font-size: 10pt">pay</FONT> all Tenant Improvement Costs as they become due. Tenant may submit to Landlord
(no more frequently than every three months) application(s) for payment reimbursement to be applied against the Tenant Improvement Allowance
(each, <FONT STYLE="font-size: 10pt">a &ldquo;<B>Reimbursement Application</B>&rdquo;).</FONT> Each Reimbursement Application shall include:
<FONT STYLE="font-size: 10pt">(i)</FONT> executed partial payment releases of liens (which shall be notarized and provide a specific
amount for which such lien is being waived), reasonably satisfactory to Landlord, from Tenant&rsquo;s general contractor and first tier
subcontractors, as certified by Tenant, confirming the payment in full of all Tenant Improvement Costs included in the then current Reimbursement
Application (collectively, the &ldquo;<B>Lien <FONT STYLE="font-size: 10pt">Waivers</FONT></B><FONT STYLE="font-size: 10pt">&rdquo;);
(ii)</FONT> sufficient evidence of payment from Tenant to Tenant&rsquo;s general contractor of all Tenant Improvement Costs included
in the then current Reimbursement Application; and, <FONT STYLE="font-size: 10pt">(iii)</FONT> a statement completed <FONT STYLE="font-size: 10pt">by
</FONT>Tenant or Tenant&rsquo;s project manager stating that the Tenant Improvements included in the then current Reimbursement Application
were substantially completed and performed in accordance with the Tenant Improvement Plans (collectively, the <FONT STYLE="font-size: 10pt">&ldquo;<B>Partial
Reimbursement Requirements</B>&rdquo;).</FONT> When the Tenant Improvements are substantially completed in their entirety, as a condition
of the final Reimbursement <FONT STYLE="font-size: 10pt">Application, Tenant shall</FONT> provide: <FONT STYLE="font-size: 10pt">(i)
executed final Lien Waivers, confirming</FONT> the <FONT STYLE="font-size: 10pt">payment in full of all Tenant</FONT> Improvement <FONT STYLE="font-size: 10pt">Costs
up to the limit of the Tenant Improvement Allowance and the release of liens against the Leased Premises from Tenant&rsquo;s general
contractor and first tier subcontractors; (ii) sufficient evidence of payment from Tenant to Tenant&rsquo;s general contractor of all
Tenant Improvement Costs up to the limit of the Tenant Improvement Allowance; and (iii) a statement completed by Tenant or Tenant&rsquo;s
project manager stating that the Tenant Improvements are substantially complete and were performed in accordance with the Tenant Improvement
Plans (collectively, the &ldquo;<B>Final Reimbursement Requirements</B>&rdquo;). Landlord shall have thirty (30) days after the receipt
of each complete Reimbursement Application to submit its reimbursement payment to Tenant. Landlord shall not be required to issue any
reimbursement payment to Tenant if the Reimbursement Application does not include the Partial Reimbursement Requirements or the Final
Reimbursement Requirements, as the case maybe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.35in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Tenant shall make a complete reimbursement submission for the Tenant Improvement Allowance no later than March 31, 2020. Landlord
shall not be required to make payments on <FONT STYLE="font-size: 10pt">account</FONT> of the <FONT STYLE="font-size: 10pt">Tenant</FONT>
Improvement Allowance for any <FONT STYLE="font-size: 10pt">Tenant Improvement</FONT> Costs not submitted to Landlord <FONT STYLE="font-size: 10pt">by</FONT>
the foregoing date, and Tenant shall not have any claim to any portion of the Tenant Improvement Allowance not properly used by such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Insurance</U></B>.
The liability insurance policy required to be maintained by Tenant pursuant to Section 4.4(a) of the Lease shall also name Landlord,
Workspace Property Management, L.P., Workspace Property Trust, L.P., and each of their respective directors, officers, partners, shareholders,
members, employees, and mortgagees (&ldquo;<B>Landlord Additional Insureds</B>&rdquo;) as additional insureds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 38pt; text-align: justify; text-indent: 33.6pt">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Indemnification</U></B>.
The indemnification of Landlord by Tenant pursuant to Section 5.05 of the Lease is hereby extended to the Landlord Additional Insureds
on the same terms and provisions of Section <I>5.05.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Notices</U></B>. The address for notices to Landlord&rsquo;s counsel in Section 13.08 of the Lease is changes to: McCausland Keen
+ Buckman, 80 W. Lancaster Avenue, 4<SUP>th</SUP> Floor, Devon, PA 19333, Attn.,: Stephan K. Pahides, Esq. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Brokers</U></B>.
Landlord and Tenant each covenants and represents to the other that <FONT STYLE="font-size: 10pt">it has dealt with no brokers in connection
with this First Amendment other than Newmark Knight Frank (&ldquo;<B>NKF</B>&rdquo;), representing Tenant, and CBRE Group, Inc., representing
Landlord (collectively, the &ldquo;<B>Brokers</B>&rdquo;). Landlord agrees to pay a one-time leasing commission in an amount equal to 5%
of the net new NNN base rent (commencing on September 1, 2020) to NKF pursuant to a separate agreement entered into by NKF. Landlord
and Tenant each agrees to indemnify and bold the other harmless from any and all claims for commissions or fees in connection with this
First Amendment from any real estate brokers or agents employed by or with whom they have dealt, other than the Brokers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Survival</U></B>.
All references to the &ldquo;Lease&rdquo; shall refer to the Lease as modified by this First Amendment. Except as expressly modified herein,
the terms and conditions of the Lease shall remain unchanged and in full force and effect in accordance with its terms. Specifically,
without limitation, in the event of any default by either party of any of its obligations under the Lease, as hereby amended, the non-defaulting
party shall be entitled to pursue nil remedies available under the Lease, as hereby amended, or otherwise available at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: 33.6pt">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Lease
Confirmation</U></B>. Except as amended hereby, the Lease remains in full force and effect and is hereby ratified and confirmed. The
Lease hereby constitutes the entire agreement between Landlord and Tenant with respect to the Leased Premises, may be amended or
altered only by written agreement executed by both parties, supersedes all prior agreements, whether written or oral, between the
parties, and is binding on the parties&rsquo; successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Options: NewSection; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">16.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Successors
and <FONT STYLE="font-size: 10pt">Assigns</FONT></U></B><FONT STYLE="font-size: 10pt">.</FONT> This First Amendment shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Ministerial
Actions</U></B>. Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this First
Amendment, or make any claim </FONT>that <FONT STYLE="font-size: 10pt">this First Amendment or the Lease is invalid or unenforceable,
due to any failure of this document or the Lease to comply with ministerial requirements, including requirements for corporate seals,
attestations, witnesses, notarizations or other similar requirements, </FONT>and <FONT STYLE="font-size: 10pt">each </FONT>party <FONT STYLE="font-size: 10pt">hereby
waives the right to assert any such defense or make </FONT>any <FONT STYLE="font-size: 10pt">claim of invalidity or unenforccabllity
due to any of the foregoing. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">18.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Signatures;
Multiple Counterparts</U></B>. This First Amendment may be executed in multiple counterparts, each of which, when assembled to include
an original signature for each party contemplated to sign this First Amendment, will constitute a complete and fully executed original.
</FONT>All <FONT STYLE="font-size: 10pt">such </FONT>fully <FONT STYLE="font-size: 10pt">executed counterparts </FONT>will <FONT STYLE="font-size: 10pt">collectively
constitute a single First Amendment. Landlord and Tenant each expressly agrees that if the signature of Landlord and/or </FONT>Tenant
on this First Amendment is not <FONT STYLE="font-size: 10pt">an original, but is</FONT> a <FONT STYLE="font-size: 10pt">digital, mechanical
</FONT>or <FONT STYLE="font-size: 10pt">electronic reproduction (such as, but not limited to, e-mail, PDF, or JPEG), then such digital,
mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, <FONT STYLE="font-family: Times New Roman, Times, Serif">an&#8239;authentic&#8239;&#8239;and&#8239;&#8239;traditional&#8239;&#8239;ink-on-paper&#8239;original&#8239;wet&#8239;signature&#8239;penned&#8239;manually&#8239;by&#8239;its
signatory.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85pt 0pt 38pt; text-align: justify; text-indent: 33.95pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Publication</U></B>. Neither Landlord nor Tenant shall publicize in a medium of general circulation available to the general public (e.g., trade journals, newspapers, radio, television, internet, etc.) the terms of or the transaction evidenced by this Amendment. The
foregoing prohibition is not applicable to disclosures required by applicable laws, non-public disclosures made in connection with efforts
to sell or finance the Building, or non-published statements made to parties on a need-to-know basis in the ordinary course of the business
of operating the Building.&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85pt 0pt 38pt; text-align: justify; text-indent: 33.95pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.<B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;NOTICE</B>.<B>&#8239;</B>In
any real estate transaction,&#8239;&#8239;it is recommended that the tenant consult with a professional, such as a civil engineer, industrial
hygienist or other person with experience in evaluation the condition of the property, including the possible presence of asbestos, hazardous
materials and underground storage tanks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[SIGNATURE PAGE FOLLOWS]</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, Landlord and Tenant, intending to be legally bound, have executed this First Amendment as of the day and year last
below written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>LANDLORD</B>:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">&#8239;</TD>
  <TD STYLE="width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>WPT PROPERTIES LP</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD>WPT PROPERTIES GP LLC,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">its general partner</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ Anthony A. Nichols, Jr.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Anthony A. Nichols, Jr.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Senior Vice President</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Date:</TD>
  <TD>May 9, 2019</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>TENANT</B>:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">&#8239;</TD>
  <TD STYLE="width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>CARIS MPI, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ David D. Halbert</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name:</TD>
  <TD>David D. Halbert</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Title:</TD>
  <TD>CEO</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Date:</TD>
  <TD>May 8, 2019</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;<IMG SRC="tm2415719d15_ex10-3bsp4img1.jpg" ALT="" STYLE="height: 172px; width: 200px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Page; Sequence: 55; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>SECOND AMENDMENT TO LEASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><B>THIS SECOND AMENDMENT
TO LEASE AGREEMENT </B>(this &ldquo;<B>Second Amendment</B>&rdquo;) dated for reference purposes as August __, 2019, is made by and between
<B>WPT PROPERTIES LP</B>, a Delaware limited partnership (&ldquo;<B>Landlord</B>&rdquo;), and <B>CARIS MPI</B>, <B>INC.</B>, a Texas corporation
(&ldquo;<B>Tenant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>BACKGROUND</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liberty
Property Limited Partnership, mistakenly identified as Liberty Cotton Center, LLC (&ldquo;<B>Liberty</B>&rdquo;), and Caris Life
Sciences, Inc. (formerly CDx Holdings, Inc.) (&ldquo;<B>Caris</B>&rdquo;) entered into that certain Industrial Real Estate Lease
(Single-Tenant Facility) dated August 19, 2009 (the &ldquo;<B>Original Lease</B>&rdquo;), covering certain Leased Premises
containing approximately 66,012 <FONT STYLE="font-size: 10pt">rentable square feet of space (the &ldquo;<B>Leased
Premises</B>&rdquo;), being the entire building known as and located at 4610 South 44<SUP>th </SUP>Place, Phoenix, Arizona (the
 &ldquo;<B>Building</B>&rdquo;), as more fully described in the Lease. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
By that certain Lease Assignment and Assumption Agreement dated November 22, 2011, Caris assigned to Tenant, all of Caris&rsquo; right,
title and interest in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">C.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>By that certain Assignment and Assumption of Leases dated October 3, 2016, WPT Land 2 LP assumed all of Liberty&rsquo;s right,
title and interest, in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">D.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
connection with its acquisition of the Building, by that certain Assignment and Assumption of Leases dated June 8, 2018, Landlord
assumed all of WPT Land 2 LP&rsquo;s right, title and interest, in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">E.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord and Tenant entered into that certain First Amendment to Lease Agreement dated May 9, 2019 (the &ldquo;<B>First Amendment</B>&rdquo;
amending the Original Lease to, among other things, extend the Term. (The Original Lease as amended by the First Amendment is sometimes
referred to herein as the &ldquo;<B>Lease.</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">F.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant desires to further extend the Term of the Lease, and Landlord has agreed to such further extension, subject to the provisions of
this Second Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><B>NOW, THEREFORE</B>,
the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally
bound, hereby agree that the Lease is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Incorporation</U></B>.
The above Background is incorporated herein by reference.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 3pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Defined Terms; Conflict</U></B>. All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed
to them in the Lease. In the event there is a conflict between the terms of the Lease and this Second Amendment, this Second Amendment
shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">&#8239;</P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Term</U></B>. The First Amendment extended the Term for one (1) additional period of sixty-four (64) months, commencing on September
1, 2020, and expiring at 11:59 P.M. local time on December 31, 2025. The Extended Term shall be further extended for an additional period
of sixty (60) months, commencing on January 1, 2025, so that the Term ends on December 31, 2029, which date shall now be the Expiration
Date. For the avoidance of doubt, the &ldquo;Extended Term&rdquo; shall be and mean the period commencing on September 1, 2020, and expiring
at 11:59 P.M. local time on December 31, 2029 and the &ldquo;Expiration Date&rdquo; shall be and mean December 31, 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Base Rent</U></B>. Effective as of September 1, 2020, and continuing through and including the Expiration Date, Tenant&rsquo;s Base
Rent obligation for the Leased Premises shall be as follows and all Rent shall be paid in accordance with the terms of the Lease:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">PSF/annum</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Annual</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Monthly</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: center">9/1/2020 &ndash; 12/31/2020 *</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">18.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#8239;</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--------</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#8239;</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">103,418.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1/1/2021 &ndash; 8/31/2021</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,241,025.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">103,418.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2021 &ndash; 8/31/2022</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,274,031.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,169.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2022 &ndash; 8/31/2023</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,307,037.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">108,919.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2023 &ndash; 8/31/2024</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,043.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,670.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2024 &ndash; 8/31/2025</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,373,049.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">114,420.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2025 &ndash; 8/31/2025</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,406,055.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">117,171.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2025 &ndash; 8/31/2026</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,439,061.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,921.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2026 &ndash; 8/31/2027</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,472,067.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">122,672.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2027 &ndash; 8/31/2028</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,505,073.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125,422.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2028 &ndash; 8/31/2029</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,538,079.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">128,173.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9/1/2029 &ndash; 12/31/2029</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,571,085.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">130,923.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 3pt; margin-bottom: 0pt; text-align: justify">* Notwithstanding the foregoing, Base
Rent, but not Additional Rent, shall be abated for the first four (4) months of the Extended Term. Should there occur an uncured Event
of Default by Tenant during said four (4) month period, then such abatement shall cease. Landlord&rsquo;s management fee shall not be
reduced on account of the abatement in Base Rent, and the Base Rent abatement shall be disregarded for purposes of calculating any management
fee based on a percentage of rental revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Tenant shall have the right to make all payments of Rent to
Landlord via electronic funds transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 3pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Annual Operating Expenses</U></B>. All Additional Rent applicable to the Leased Premises shall continue to be paid by Tenant, in
addition to the Base Rent, subject to adjustment and reconciliation and in accordance with the terms and conditions of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Options to Extend Term</U></B>. The parties acknowledge and agree that the Extended Term constitutes for purposes of Section 3.02
of the Lease the first Option Term (notwithstanding that the extension period is for a total of one hundred twenty-four (124) months),
and, notwithstanding anything to the contrary set forth is such Section 3.02 of the Lease, the terms and conditions of this Second Amendment
shall control. Accordingly, Tenant shall have the right to extend the Term for only one (1) additional period of 5-years, which right
is subject to all of the terms and conditions of Section 3.02 of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Security Deposit</U></B>. No additional Security Deposit is required from Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Tenant
Improvements; Tenant Allowance</U></B>. Tenant is in possession of the Leased Premises. Other than as specifically provided in the First
Amendment, Landlord shall have no obligations whatsoever to improve or pay for improvements to the Leased Premises for Tenant&rsquo;s
continued use and occupancy thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Brokers</U></B>.
Landlord and Tenant each covenant and represent to the other that it has dealt with no brokers in connection with this Second Amendment.
Landlord and Tenant each agree to indemnify and hold the other harmless from any and all claims for commissions or fees in connection
with this Second Amendment from any real estate brokers or agents employed by or with whom they have dealt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Survival</U></B>.
All references to the &ldquo;Lease&rdquo; shall refer to the Lease as modified by this Second Amendment. Except as expressly modified
herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect in accordance with its terms. Specifically,
without limitation, in the event of any default by either party of any of its obligations under the Lease, as hereby amended, the non-defaulting
party shall be entitled to pursue all remedies available under the Lease, as hereby amended, or otherwise available at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Lease
Confirmation</U></B>. Except as amended hereby, the Lease remains in full force and effect and is hereby ratified and confirmed. The
Lease hereby constitutes the entire agreement between Landlord and Tenant with respect to the Leased Premises, may be amended or altered
only by written agreement executed by both parties, supersedes all prior agreements, whether written or oral, between the parties, and
is binding on the parties&rsquo; successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">12.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Successors
and Assigns</U></B>. This Second Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Ministerial
Actions</U></B>. Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this Second
Amendment, or make any claim that this Second Amendment or the Lease is invalid or unenforceable, due to any failure of this document
or the Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations
or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforceability
due to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Signatures;
Multiple Counterparts</U></B>. This Second Amendment may be executed in multiple counterparts, each of which, when assembled to include
an original signature for each party contemplated to sign this Second Amendment, will constitute a complete and fully executed original.
All such fully executed counterparts will collectively constitute a single Second Amendment. Landlord and Tenant each expressly agrees
that if the signature of Landlord and/or Tenant on this Second Amendment is not an original, but is a digital, mechanical or electronic
reproduction (such as, but not limited to, e-mail, PDF, or JPEG), then such digital, mechanical or electronic reproduction shall be as
enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional ink-on-paper original wet signature penned
manually by its signatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>No Publication</U></B>. Neither Landlord nor Tenant shall publicize in a medium of general circulation available to the general
public (e.g., trade journals, newspapers, radio, television, internet, etc.) the terms of or the transaction evidenced by this Amendment.
The foregoing prohibition is not applicable to disclosures required by applicable laws, non-public disclosures made in connection with
efforts to sell or finance the Building, or non-published statements made to parties on a need-to-know basis in the ordinary course of
the business of operating the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Notice</U></B>. In any real estate transaction, it is recommended that the tenant consult with a professional, such as a civil engineer,
industrial hygienist or other person with experience in evaluation the condition of the property, including the possible presence of asbestos,
hazardous materials and underground storage tanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><B>IN WITNESS WHEREOF</B>, Landlord and
Tenant, intending to be legally bound, have executed this Second Amendment as of the day and year last below written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>LANDLORD</B>:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">&#8239;</TD>
  <TD STYLE="width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>WPT PROPERTIES LP</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD>WPT PROPERTIES GP LLC,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">its general partner</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ Anthony A. Nichols, Jr.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Anthony A. Nichols, Jr.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Senior Vice President</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>TENANT</B>:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">&#8239;</TD>
  <TD STYLE="width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>CARIS MPI, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ David D. Halbert</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name:</TD>
  <TD>David D. Halbert</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Title:</TD>
  <TD>CEO</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Date:</TD>
  <TD>9/19/2019</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>CORRECTED AND RESTATED
SECOND AMENDMENT TO LEASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><B>THIS CORRECTED AND RESTATED
SECOND AMENDMENT TO LEASE AGREEMENT </B>(this &ldquo;<B>Second Amendment</B>&rdquo;) dated for reference purposes as June 9, 2020, is <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
by and between <B>WPT PROPERTIES LP</B>, a Delaware limited partnership (&ldquo;<B>Landlord</B>&rdquo;), and <B>CARIS MPI</B>, <B>INC</B>.,
a Texas corporation (&ldquo;<B>Tenant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>BACKGROUND</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liberty
Property Limited Partnership, mistakenly identified as Liberty Cotton Center, LLC (&ldquo;<B>Liberty</B>&rdquo;), and Caris Life Sciences,
Inc. (formerly CDx Holdings, Inc.) (&ldquo;<B>Caris</B>&rdquo;) entered into that certain Industrial Real Estate Lease (Single-Tenant
Facility) dated August 19, 2009 (the &ldquo;<B>Original Lease</B>&rdquo;), covering certain Leased Premises containing approximately
66,012 <FONT STYLE="font-size: 10pt">rentable square feet of space (the &ldquo;<B>Leased Premises</B>&rdquo;), being the entire building
known as and located at 4610 South 44<SUP>th </SUP>Place, Phoenix, Arizona (the &ldquo;<B>Building</B>&rdquo;), as more fully described
in the Lease. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By that certain Lease Assignment and Assumption Agreement dated
November 22, 2011, Caris assigned to Tenant, all of Caris&rsquo; right, title and interest in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By that certain Assignment and Assumption of Leases dated October 3, 2016, WPT Land 2 LP assumed all of Liberty&rsquo;s right, title and interest,
in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">D.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In connection with its acquisition of the Building, by that certain Assignment and Assumption of Leases dated June 8, 2018, Landlord assumed
all of WPT Land 2 LP&rsquo;s right, title and interest, in, to and under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">E.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
and Tenant entered into that certain First Amendment to Lease Agreement dated May 9, 2019 (the &ldquo;<B>First Amendment</B>&rdquo; amending
the Original Lease to, among other things, extend the Term. (The Original Lease as amended by the First Amendment is sometimes referred
to herein as the &ldquo;<B>Lease</B>.&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">F.<B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Tenant
desires to further extend the Term of the Lease, and Landlord has agreed to such further extension, subject to the provisions of this
Second Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><B>NOW</B>, <B>THEREFORE</B>, the
parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally
bound, hereby agree that the Lease is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">l.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Incorporation</U>.
</B><FONT STYLE="font-size: 10pt">The above Background is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">2.<B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Defined
Terms: Conflict</U>. </B>All <FONT STYLE="font-size: 10pt">capitalized terms used herein and not otherwise defined herein shall have
the meanings ascribed to them in the Lease. In the event there is a conflict between the terms of the Lease and this Second Amendment,
this Second Amendment shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Term</U>.
</B>The First Amendment extended the Term for one (1) additional period of sixty-four (64) months, commencing on September 1, 2020, and
expiring at 11:59 P.M. local time on December 31, 2025. The Extended Term shall be further extended for an additional period of sixty
(60) months, commencing on January 1, 2026, so that the Term ends on December 31, 2030, which date shall now be the Expiration Date.
For the avoidance of doubt, the &ldquo;Extended Term&rdquo; shall be and mean the period commencing on September 1, 2020, and expiring
at 11:59 P.M. local time on December 31, 2030 and the &ldquo;Expiration Date&rdquo; shall be and mean December 31, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Base
Rent</U>.</B> <FONT STYLE="font-size: 10pt">Effective as of September 1,</FONT> 2020, <FONT STYLE="font-size: 10pt">and continuing through
and including the Expiration Date, Tenant&rsquo;s Base Rent obligation for the Leased Premises shall be as follows and all Rent shall be paid
in accordance with the terms of the Lease:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Period</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">PSF/annum</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Annual</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Monthly</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&#8239;</TD><TD STYLE="width: 30%; font-size: 10pt; text-align: center">&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2020
                                                                           &ndash; 12/31/2020*</FONT></TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">18.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#8239;</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--------</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#8239;</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">103,418.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/1/2021
                                                                                         &ndash; 8/31/2021</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,241,025.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">103,418.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2021
                                                                                         &ndash; 8/31/2022</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,274,031.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,169.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2022
                                                                                         &ndash; 8/31/2023</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,307,037.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">108,919.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2023
                                                                                         &ndash; 8/31/2024</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,043.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,670.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2024
                                                                                         &ndash; 8/31/2025</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,373,049.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">114,420.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2025
                                                                                         &ndash; 12/31/2025</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,406,055.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">117,171.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/1/2026
                                                                                         &ndash; 12/31/2026</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,406,055.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">117,171.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1/1/2027 &ndash; 12/31/2027</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,439,061.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,921.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1/1/2028 &ndash; 12/31/2028</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,472,067.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">122,672.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/1/2029
                                                                                         &ndash; 12/31/2029</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,505,073.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">125,422.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1/1/2030 &ndash; 12/31/2030</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,538,079.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">128,173.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#8239;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">*
Notwithstanding the foregoing, Base Rent, but not Additional Rent, shall be abated for the first four (4) months of the Extended Term.
Should there occur an uncured Event of Default by Tenant during said four (4) month period, then such abatement shall cease. Landlord&rsquo;s
management fee shall not be reduced on account of the abatement in Base Rent, and the Base Rent abatement shall be disregarded for purposes
of calculating any management fee based on a percentage of rental revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Tenant shall have the right to make all payments of Rent to
Landlord via electronic funds transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Annual
Operating Expenses</U>.</B> All Additional Rent applicable to the Leased Premises shall continue to be paid by Tenant, in addition to
the Base Rent, subject to adjustment and reconciliation and in accordance with the terms and conditions of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Options
to Extend Term</U>.</B></FONT> The parties acknowledge and agree that the Extended Term constitutes for purposes of Section <FONT STYLE="font-size: 10pt">3.02
</FONT>of the Lease the first Option Term (notwithstanding that the extension period is for a total of one hundred twenty-four <FONT STYLE="font-size: 10pt">(124)
</FONT>months), and, notwithstanding anything to the contrary set forth is such Section <FONT STYLE="font-size: 10pt">3.02</FONT> of
the Lease, the terms and conditions of this Second Amendment shall control. Accordingly, Tenant shall have the right to extend the Term
for only one (1) additional period of 5-years, which right is subject to <I>all</I> of the terms and conditions of Section 3.02 of the
Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Security Deposit</U>. </B>No additional Security Deposit is
required from Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Tenant
Improvements; Tenant Allowance</U>. </B>Tenant is in possession of the Leased Premises. Other than as specifically provided in the First
Amendment, Landlord shall have no obligations whatsoever to improve or pay for improvements to the Leased Premises for Tenant&rsquo;s continued
use and occupancy thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Brokers</U>.
</B>Landlord and Tenant each covenant and represent to the other that it has dealt with no brokers in connection with this Second Amendment.
Landlord and Tenant each agree to indemnify and hold the other harmless from any and all claims for commissions or fees in connection
with this Second Amendment from any real estate brokers or agents employed by or with whom they have dealt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Survival</U>.
</B><FONT STYLE="font-size: 10pt">All references to the &ldquo;Lease&rdquo; shall refer to the Lease as modified by this Second Amendment.
Except as expressly modified herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect in accordance
with its terms. Specifically, without limitation, in the event of any default by either party of any of its obligations under the Lease,
as hereby amended, the non-defaulting party shall be entitled to pursue all remedies available under the Lease, as hereby amended, or
otherwise available at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Lease
Confirmation</U>. </B>Except as amended hereby, the Lease remains in full force and effect and is hereby ratified and confirmed. The
Lease hereby constitutes the entire agreement between Landlord and Tenant with respect to the Leased Premises, may be amended or altered
only by written agreement executed by both parties; supersedes all prior agreements, whether written or oral, between the parties, and
is binding on the parties&rsquo; successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Successors
and Assigns</U>. </B>This Second Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Ministerial
Actions. </B>Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this Second
Amendment, or make any claim that this Second Amendment or the Lease is invalid or unenforceable, due to any failure of this
document or the Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses,
notarizations or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of
invalidity or unenforceability due to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Signatures;
Multiple Counterparts</U>.</B> This Second Amendment may be executed in multiple counterparts, each of which, when assembled to
include an original signature for each party contemplated to sign this Second Amendment, will constitute a complete and fully
executed original. All such fully executed counterparts will collectively constitute a single Second Amendment. Landlord and Tenant
each expressly agrees that if the signature of Landlord and/or Tenant on this Second Amendment is not an original, but is a digital,
mechanical or electronic reproduction (such as, but not limited to, e-mail, PDF, or JPEG), then such digital, mechanical or
electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional
ink-on-paper original wet signature penned manually by its signatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Publication</U>. </B>Neither Landlord nor Tenant shall publicize in a medium of general circulation available to the general public (e.g.,
trade journals, newspapers, radio, television, internet, etc.) the terms of or the transaction evidenced by this Amendment. The foregoing
prohibition is not applicable to disclosures required by applicable laws, non-public disclosures made in connection with efforts to sell
or finance the Building, or non-published statements made to parties on a need-to-know basis in the ordinary course of the business of
operating the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><FONT STYLE="font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B><U>Notice</U>.
</B><FONT STYLE="font-size: 10pt">In any real estate transaction, it is recommended that the tenant consult with a professional, such
as a civil engineer, industrial hygienist or other person with experience in evaluation the condition of the property, including the
possible presence of asbestos, hazardous materials and underground storage tanks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 64.45pt"><B>IN WITNESS WHEREOF, </B>Landlord
and Tenant, intending to be legally bound, have executed this Second Amendment as of the day and year last below written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>LANDLORD</B>:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">&#8239;</TD>
  <TD STYLE="width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>WPT PROPERTIES LP</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD>WPT PROPERTIES GP LLC,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">its general partner</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ Anthony A. Nichols, Jr.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Anthony A. Nichols, Jr.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Senior Vice President</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Date:</TD>
  <TD>June 9, 2020</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>TENANT</B>:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">&#8239;</TD>
  <TD STYLE="width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2"><B>CARIS MPI, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ David D. Halbert</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name:</TD>
  <TD>David D. Halbert</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Title:</TD>
  <TD>CEO</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Date:</TD>
  <TD>April 30, 2020</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(C)
<SEQUENCE>13
<FILENAME>tm2415719d15_ex10-3c.htm
<DESCRIPTION>EXHIBIT 10.3(C)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3(c)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>LEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>KCP NNN II LEASEHOLD
4, LLC,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>A DELAWARE LIMITED LIABILITY
COMPANY,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AS LANDLORD,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CARIS MPI, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>A TEXAS CORPORATION,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AS&#8239;TENANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>DATED AS OF JULY 25,
2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>LEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.45pt">THIS LEASE (this
<B>&ldquo;Lease&rdquo;</B>), dated as of July&#8239;25,&#8239;2019 (the <B>&ldquo;Effective Date&rdquo;</B>), is between KCP NNN II LEASEHOLD 4, LLC,
a Delaware limited liability company (herein, as further defined in Paragraph 33, called <B>&ldquo;Landlord&rdquo;</B>), and CARIS MPI,
INC., a Texas corporation (herein called <B>&ldquo;Tenant&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.45pt">NOW THEREFORE, in consideration
of the mutual covenants and promises hereinafter set forth, and intending to be legally bound, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Demise of Premises.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">In consideration of
the rents and covenants herein stipulated to be paid and performed, Landlord hereby demises and lets to Tenant, and Tenant hereby lets
from Landlord, for the term herein described, the premises (herein called the <B>&ldquo;Premises&rdquo;</B>) commonly known as 3600 W. Royal
Lane, Irving, Texas 75063, consisting of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
That parcel of land described on <B>Exhibit l(a)</B> attached hereto and made a part hereof, together with all of Landlord&rsquo;s right, title
and interest, if any, in and to all easements, rights of way, appurtenances, strips and gores of land, mineral rights, water rights and
other interests, rights and benefits thereunto belonging, and to all public or private streets, roads, avenues, alleys, or passways,
open or proposed, on or abutting the parcel of&#8239;land (collectively, the&#8239;<B>&ldquo;Land Parcel&rdquo;</B>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All buildings on and
other improvements on the Land Parcel, including an office building containing approximately 114,500 rentable square feet of space (the
<B>&ldquo;Building&rdquo;</B>); parking areas on the Land Parcel; and Landlord&rsquo;s right, title and interest in all systems, building fixtures,
amenities, facilities, machinery and equipment used in the operation of the facility and other improvements, conduits, ducts, hot water
heaters, oil burners, domestic water systems, and installations including those used to provide fire protection, heat, exhaust, ventilation,
air conditioning, electrical power, light, plumbing, refrigeration, gas, sewer and water thereto, all elevators, escalators, canopies,
and the physical structure of all signs, which are used for the operation of the Building (collectively, with the Building, the <B>&ldquo;Improvements&rdquo;</B>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord&rsquo;s right, title and interest in all intangible property used in connection with the Land Parcel and Improvements including, without
limitation, all contract rights, guarantees, licenses, permits, registrations and warranties relating to the ownership or the maintenance
of the Land Parcel or the Improvements, or both (the <B>&ldquo;Intangible Personal&nbsp;Property&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Title
and Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Premises are demised and let subject to (i) the existing state of the title as of the Commencement Date, including the Permitted Exceptions
(as set forth and defined in <B>Exhibit 2(a)</B>), (ii) any state of facts which an accurate survey or physical inspection thereof might
show, (iii) all zoning regulations, restrictions, rules and ordinances, building restrictions and other laws and regulations now in effect
or hereafter adopted by any governmental authority having jurisdiction, and (iv) the condition of any buildings, structures and other
improvements located&#8239;thereon, as of the Commencement Date, without representation or warranty by Landlord except as otherwise expressly
set forth herein. Tenant represents that it has examined the title to, zoning of and other restrictions applicable to, and the condition
of, the Premises as of the Effective Date and has found the same to be satisfactory to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;EXCEPT AS OTHERWISE
EXPRESSLY PROVIDED IN THIS LEASE AND THE WORK LETTER ATTACHED HERETO AS <B>EXHIBIT 2(b)</B> (THE <B>&ldquo;WORK LETTER&rdquo;</B>), LANDLORD
SHALL NOT BE OBLIGATED TO PROVIDE OR PAY FOR ANY IMPROVEMENT WORK OR SERVICES RELATED TO THE IMPROVEMENT OF THE PREMISES, AND TENANT ACKNOWLEDGES
AND AGREES THAT THE PREMISES ARE LEASED &ldquo;AS IS&rdquo;, WITH TENANT ACCEPTING ALL DEFECTS, IF ANY; AND LANDLORD MAKES NO WARRANTY OF
ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE PREMISES (WITHOUT LIMITATION, LANDLORD MAKES NO WARRANTY AS TO THE HABITABILITY, FITNESS
OR SUITABILITY OF THE PREMISES FOR A PARTICULAR PURPOSE, NOR AS TO COMPLIANCE WITH ANY LAWS, RULES OR REGULATIONS, NOR AS TO THE ABSENCE
OF ANY TOXIC OR OTHERWISE HAZARDOUS SUBSTANCES).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Use
of Premises.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Subject to applicable
Legal Requirements, Tenant may use the Premises for general office purposes and any other office-related uses typical or ancillary thereto,
provided all such uses shall comply with applicable Legal Requirements and any restrictive covenants applicable to the Premises (each,
a <B>&ldquo;Permitted Use&rdquo;</B> and collectively, the <B>&ldquo;Permitted Uses&rdquo;</B>). Without limiting the generality of the foregoing,
Tenant shall have twenty-four (24) hour, seven days per week access to and may use the Premises for (and the Permitted Uses shall include):
(i) medical diagnostics, (ii) laboratory-based research, (iii) other medical review services, (iv) imaging center, (v) clinical and anatomic
pathology laboratory services, (vi) molecular genetic laboratory services, (vii) cytogenetic laboratory services, (viii) Biosafety level
2 laboratory associated activities, (ix) processing of any type of bodily fluids, tissues, or other products associated with or derived
from human or animal tissues, cell lines, bacterial cultures, viral cultures, recombinant DNA, work, diagnostic medical laboratory and
related services, testing and administration, and (x) use and appropriate disposal of hazardous chemicals and biohazardous waste. Tenant
shall, at its own cost and expense, obtain and maintain any and all licenses, permits, and approvals necessary or appropriate for its
use, occupation and operation of the Premises for the Permitted Uses. Tenant shall not permit or cause any act to be done in or about
the Premises that will violate any applicable Legal Requirements or that could reasonably be expected to increase the existing rate of
insurance on the Premises. Tenant shall not commit or allow to be committed or exist any waste upon the Premises or any public or private
nuisance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Term;
Access; Tenant Improvements; Property Management.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
term of this Lease shall commence on the Effective Date (the <B>&ldquo;Commencement Date&rdquo;</B>) and continue in full force and effect
thereafter and expire on June 30, 2035 (the <B>&ldquo;Initial Term&rdquo;</B>), unless sooner terminated or extended as hereinafter provided
or otherwise agreed by Landlord and Tenant in writing. Upon expiration of&#8239;the Initial Term, provided Tenant is not then in default under
this Lease, Tenant may renew this Lease for two (2) additional&#8239;periods of sixty (60) months each, exercisable in accordance with the terms
of <FONT STYLE="font-size: 10pt"><B>Exhibit 4(a)</B></FONT> attached hereto (each, a <FONT STYLE="font-size: 10pt"><B>&ldquo;Renewal Term&rdquo;).
</B></FONT>The definition <FONT STYLE="font-size: 10pt"><B>&ldquo;Term&rdquo;</B></FONT> shall mean the Initial Term plus any Renewal Term,
unless sooner terminated as hereinafter provided in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant shall be permitted
to self-manage the Premises or to engage a property manager reasonably acceptable to Landlord to manage the Premises. Tenant may (but
shall not be obligated to) engage Landlord or an Affiliate of Landlord to provide such property management services pursuant to a separate
property management agreement between Tenant and Landlord or such Affiliate, which property management agreement shall provide for a management
fee not to exceed three percent (3.0%) of the annual Rent (without regard to any abatement period provided for in this Lease).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Rent.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant covenants to pay
to Landlord, as rent for the Premises during the Term of this Lease basic rent in the amounts set forth on <FONT STYLE="font-size: 10pt"><B>Exhibit
5</B></FONT> attached hereto (herein called the <FONT STYLE="font-size: 10pt"><B>&ldquo;Basic Rent&rdquo;</B>), in</FONT> advance on the
first Business Day of each calendar month during the Term by wire or other electronic transfer of immediately available funds to the Landlord
at the address set forth above or to such other person or such other place or account as Landlord from time to time may designate to Tenant
in writing; provided, Landlord may designate to Tenant in writing that all but not less than all of the monthly Basic Rent be paid directly
to a Mortgagee (as hereinafter defined) or an institutional payment agent. Basic Rent for any partial calendar month included in the Term
shall be prorated. Basic Rent for any partial calendar month at the beginning of the Term shall be paid by Tenant on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
covenants that all other amounts, liabilities and obligations which Tenant assumes or agrees to pay or discharge pursuant to this Lease
together with every fine, penalty, interest and cost which may be added for nonpayment or late payment thereof, shall constitute additional
rent hereunder (herein called <FONT STYLE="font-size: 10pt"><B>&ldquo;Additional Rent&rdquo;</B></FONT> and, together with Basic Rent,
<FONT STYLE="font-size: 10pt"><B>&ldquo;Rent&rdquo;</B>).</FONT> In the event of any failure by Tenant to pay or discharge any Additional
Rent due Landlord, Landlord shall have all rights, powers and remedies provided herein or by law in the case of nonpayment of Basic Rent.
Tenant also covenants to pay to Landlord on demand an amount (the <FONT STYLE="font-size: 10pt"><B>&ldquo;Late Charge&rdquo;</B>)</FONT>
equal to one percent (1 %) of the payment amount then due on all installments of Basic Rent or Additional Rent due to Landlord which
are more than fifteen (15) days overdue, to cover Landlord&rsquo;s administrative expenses; provided that Landlord shall not impose a Late
Charge for the first such late payment of Basic Rent in any calendar year if such Basic Rent payment is paid within three (3) Business
Days following Tenant&rsquo;s receipt of written notice from Landlord of such delinquency. The actual amount of Landlord&rsquo;s administrative expenses
arising by reason of a late payment will be difficult to ascertain, and the parties agree that the Late Charge as calculated above is
a reasonable estimate thereof. In addition, in the event any amount of Basic Rent or Additional Rent due to Landlord is not paid within
fifteen (15) days of the due date thereof, Tenant further covenants to pay to Landlord on demand interest on each such delinquent amount
of Basic Rent and Additional Rent due to Landlord from the due date until such amount is paid in full at the per annum rate of interest
(the <FONT STYLE="font-size: 10pt"><B>&ldquo;Default Rate&rdquo;</B>)</FONT> equal to an annual rate of three percent (3%) plus the annual
 &ldquo;prime rate&rdquo; as reported by the <I>Wall Street Journal</I> (the <FONT STYLE="font-size: 10pt"><B>&ldquo;Prime Rate&rdquo;</B>), </FONT>but
in no event shall the Default Rate exceed the maximum rate permitted by law; provided that Landlord shall not impose such interest for
the first late payment of Rent in any&#8239;calendar year if such Rent payment is paid within three (3) Business Days following Tenant&rsquo;s
receipt of written notice from Landlord of such delinquency. If the <I>Wall Street Journal</I> is no longer published or the <I>Wall
Street Journal</I> discontinues publication of the &ldquo;prime rate,&rdquo; then Landlord shall designate a reasonably comparable prime
rate as the Prime Rate. Notwithstanding anything in this Lease to the contrary, (i) Tenant&rsquo;s obligation to pay Additional Rent shall
be abated from the Commencement Date through and including December 31, 2019, <U>provided, however</U>, such abatement of Additional
Rent shall not relieve Tenant of its obligation to maintain the Required Insurance as required herein during the period of such abatement,
and if Tenant fails to maintain such Required Insurance and Landlord exercises its rights under Subparagraph 12(c), Tenant shall be fully
liable for the costs thereof notwithstanding the abatement of Additional Rent from the Effective Date through December 31, 2019; and
(ii) from the Commencement Date through and including December 31, 2019, Landlord shall, at its sole cost, manage (or cause to be managed)
the Premises and maintain such service agreements as reasonably required to keep the Premises in the same condition as exists on the
Commencement Date, excluding ordinary wear and tear, casualty, condemnation, and damage caused by Tenant, its Affiliates, agents, representatives,
employees, or contractors. For the avoidance of doubt, commencing January 1, 2020 and continuing through the Term, (i) Tenant shall be
fully responsible for all Additional Rent as set <FONT STYLE="font-size: 10pt">forth </FONT>in this Lease, (ii) Paragraph 10 of this
Lease shall govern the maintenance, repair and replacement of the Premises, and (iii) subject to Subparagraph 4(b), Tenant shall be responsible
for the management of the Premises. Landlord and Tenant shall cooperate and work in good faith to ensure the orderly transition of the
management of the Premises from Landlord to Tenant hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Net
Lease; Non-Terminability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Except as otherwise
expressly set forth in this Lease, this is an absolutely net lease to Landlord. It is the intent of the parties hereto that the Basic
Rent payable under this Lease shall be an absolutely net return to the Landlord and that the Tenant shall pay all costs and expenses relating
to the Premises and the business carried on therein, unless otherwise expressly provided to the contrary in this Lease. Any amount or
obligation relating to the Premises which is not expressly declared to be that of the Landlord shall be deemed to be an obligation of
the Tenant to be performed by the Tenant at the Tenant&rsquo;s expense. Except as expressly provided in this Lease, Basic Rent and Additional
Rent shall be paid by Tenant without notice or demand, setoff, counterclaim, suspension, deduction or defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Except as expressly
provided in this Lease, Tenant agrees that it will remain obligated under this Lease in accordance with its terms, and that it will not
take any action to terminate, rescind or avoid this Lease, notwithstanding (i) the bankruptcy, insolvency, reorganization, composition,
readjustment, liquidation, dissolution, or winding-up or other proceeding affecting Landlord or its successors in interest or (ii) any
action with respect to this Lease which may be taken by any trustee or receiver of Landlord or its successors in interest or by any court
in any such proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Except as expressly
provided in this Lease, Tenant waives, to the extent permitted by law, all rights which may now or hereafter be conferred by law (i) to
quit, terminate or surrender this Lease or the Premises or any part thereof or (ii) to any abatement, suspension, deferment or reduction
of the Basic Rent or Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> 7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <FONT STYLE="font-size: 10pt"><B>Taxes and Assessments; Tax and Insurance Escrow; Compliance with Law; Environmental Matters. </B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject to Paragraph
18 below, and to the abatement of Additional Rent as set forth in Paragraph 5(b) above, Tenant shall pay or discharge all Impositions,
as hereinafter defined, when due. Notwithstanding the foregoing provision of this Subparagraph 7(a), Tenant shall not be required to pay
any franchise, corporate, estate, inheritance, succession, transfer, net income or excess profits taxes of Landlord hereunder (other
than (i) any taxes on gross receipts or similar taxes imposed or levied upon, assessed against or measured by the Basic Rent or Additional
Rent or levied upon or assessed against the Premises, (ii) any Texas Franchise Taxes included in the definition of Impositions and (iii)
any such tax, assessment, charge or levy imposed or levied upon or assessed against Landlord in substitution for or in place of an Imposition).
Tenant agrees to furnish to Landlord, within thirty (30) days after written request therefor, evidence of the payment of all Impositions.
Subject to Paragraph 18 below, and to the abatement of Additional Rent as set forth in Paragraph 5(b) above, Tenant shall pay all&#8239;Taxes
and charges for utilities consumed on the Premises that are due and payable at any time or from time to time during the Term, and for
any Taxes and utility charges that are assessed, become a lien, or accrue during any year of the Term (regardless of when payable), which
obligation shall survive the termination or expiration of this Lease; provided, however, if this Lease expires or is terminated for any
reason other than the Tenant&rsquo;s default, all such Taxes and utility charges for the year of such expiration or termination shall be prorated
as of the date of termination. Taxes for the year in which the Term commences shall be prorated from the Commencement Date (subject to
the abatement of Additional Rent through December 31, 2019). For the avoidance of doubt, it is agreed that Landlord is responsible for
payment of the cost of Impositions for the period from the Commencement Date through December 31, 2019 and Landlord covenants to timely
pay the same as and when due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; In the event that any
special assessment levied or assessed against the Premises during the Term hereof may be legally paid in installments, Tenant shall have
the option to pay such special assessment in installments. In such event, Tenant shall be liable only for those installments of the special
assessment that become due and payable prior to the expiration of the Term, plus any accrued interest and penalties relating thereto.
For purposes of this Lease, the term</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>&ldquo;Imposition&rdquo; </B>means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; all real estate taxes
and assessments which become due during the Term and all other assessments, levies, fees, water and sewer rents and charges, and all other
governmental charges of every kind, general and special, ordinary and extraordinary, whether or not the same shall have been within the
express contemplation of the parties hereto, together with any interest and penalties thereon, which are, at any time, imposed or levied
upon or assessed against (A) the Premises or any part thereof, (B) any Basic Rent or any Additional Rent, (C) this Lease or the leasehold
estate hereby created or which arise in respect of the ownership, operation, possession, occupancy or use of the Premises and which either
become due during the Term or accrue during the Term;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(ii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any gross receipts
or similar taxes imposed or levied upon, assessed against or measured solely by the Basic Rent or Additional Rent hereunder or levied
upon or assessed against the Premises (but calculated assuming the Basic Rent and Additional Rent are the only receipts of Landlord);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; all sales and use
taxes which may be levied or assessed against, or payable by, Landlord or Tenant on account of the payment of Rent or leasing or use of
the Premises or any portion thereof and all franchise, margin and business taxes under Chapter 171 of the Texas Tax Code (<B>&ldquo;Texas
Franchise Taxes&rdquo;</B>) to the extent arising solely from Rent payable under this Lease (all taxes and other governmental charges referred
to in the foregoing clauses (i), (ii) and (iii) being referred to collectively as <B>&ldquo;Taxes&rdquo;</B>); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; all charges
for water, gas, light, heat, telephone, electricity, power and other utilities and communications services rendered or used on or about
the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Except as otherwise expressly provided in this Lease (including, without limitation, Subparagraph 10(b) hereof and the Work Letter),
Tenant shall, at its expense, make all payments required under and otherwise comply with, cause the Premises to comply with, and cause
the use of the Premises to comply with, all Legal Requirements, including those which require the making of any structural, unforeseen
or extraordinary changes, whether or not any of the same involve a change of policy on the part of the body enacting the same, including
but not limited to, the Americans With Disabilities Act of 1990 (42 U.S.C. Section 12101 </FONT><I>et seq.)</I> <FONT STYLE="font-size: 10pt">and
the Texas Architectural Barriers Act, Art. 9102, Tex. Civ. Stat. Ann. (1994), as the same may be may be amended and supplemented from
time to time. Tenant shall comply with the provisions of all agreements, instruments and restrictions existing at the Effective Date and
included in the Permitted Exceptions or thereafter created pursuant to the express provisions of this Lease. Tenant shall provide Landlord
(and any Mortgagee of whom Tenant has been provided written notice) with notice as soon as reasonably possible of any written complaints
pertaining to any alleged violation of any Legal Requirements and/or the commencement of any proceedings or investigation (of which Tenant
has knowledge) under any Legal Requirements affecting or pertaining to the Premises. For purposes of this Lease, the term <B>&ldquo;Legal
Requirements&rdquo;</B> means collectively (i) all laws, rules, regulations, ordinances or orders, in effect from time to time, of all
federal, state, local, county and other governmental authorities having authority over the Premises, any portion thereof, the use thereof,
or Tenant, including without limitation, all Environmental Laws and the Americans With Disabilities Act of 1990, 42 U.S.C. Section 12101
</FONT><I>et seq.,</I> <FONT STYLE="font-size: 10pt">(ii) any covenants, restrictions or agreements included in the Permitted Exceptions
and (iii) any covenants, restrictions or agreements included in the Easements (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall not cause or permit any Prohibited Hazardous Material to be discharged from or be released at the Premises in violation of Environmental
Laws and shall, in respect of Prohibited Hazardous Materials, promptly: (A) remove, remediate and dispose of all Prohibited Hazardous
Materials in compliance with applicable Environmental Law but in any event, prior to the end of the Term; (B) pay any Claim (as defined
below) against Tenant, any Indemnified Party (as defined below) or the Premises arising therefrom; (C) remove any charge or lien upon
any of the Premises relating thereto; (D) defend (with counsel selected by Tenant and reasonably acceptable to the Indemnified Parties),
indemnify and hold harmless Landlord, any Mortgagee and their respective officers, directors, trustees, members, partners, shareholders,&#8239;beneficiaries,
employees and agents (herein collectively called <B>&ldquo;Indemnified Parties&rdquo;</B> and individually an <B>&ldquo;Indemnified Party&rdquo;)
</B>from any and all Claims resulting from any Prohibited Hazardous Materials; and (E) without limitation of the foregoing, comply, at
its sole cost and expense, during the Term in all respects with all Environmental Laws applicable to the Premises in regard to all Prohibited
Hazardous Materials. Tenant shall notify Landlord (and any Mortgagee of whom Tenant has been provided written notice) in writing of any
Prohibited Hazardous Material that is discharged from or onto or released at the Premises (whether originating thereon, placed therein
by third parties or migrating to the Premises from other property) within five (5) Business Days after Tenant first has knowledge of
such existence or discharge. For purposes of this Lease, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(1)&#8239;&#8239;
</FONT><B>&ldquo;Hazardous Material&rdquo;</B> means any hazardous or toxic material, substance or waste which is defined by those or similar
terms or is regulated as such under any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(2) <B>&ldquo;Environmental
Laws&rdquo;</B> means any statute, law, ordinance, rule or regulation of any local, county, state or federal authority having jurisdiction
over the Premises or any portion thereof or its use, which pertains to environmental, health or safety matters and/or the regulation of
any hazardous or toxic materials, substance or waste, including but not limited to: (a) the Federal Water Pollution Control Act (33 U.S.C.
 &sect;1317 <I>et seq.)</I> as amended; <FONT STYLE="font-size: 10pt"><I>(b)</I></FONT> the Federal Resource Conservation and Recovery
Act (42 U.S.C. &sect;6901 <I>et seq.)</I> as amended; (c) the Comprehensive Environmental Response Compensation and Liability Act (42
U.S.C. &sect;9601 <I>et seq.) </I>as amended; <FONT STYLE="font-size: 10pt"><I>(d)</I></FONT> the Toxic Substance Control Act (15 U.S.C.
 &sect;2601 <I>et seq.), </I>as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-size: 10pt"><I>(e) </I></FONT>the Clean Air
Act (42, U.S. &sect;7401 <FONT STYLE="font-size: 10pt"><I>et seq.), </I></FONT>as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(3) <B>&ldquo;Legal
Hazardous Materials&rdquo;</B> means any Hazardous Materials used, in compliance with Legal Requirements and Environmental Laws, in the
ordinary course of operation of Tenant&rsquo;s and its subtenants&rsquo; business and use, repair and maintenance of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(4) <B>&ldquo;Prohibited
Hazardous Materials&rdquo;</B> means all Hazardous Materials, other than Legal Hazardous Materials, that existed in, on or under the surface
of the ground of the Premises on or prior to the Effective Date or (ii) are discharged from, released at or migrate onto the Premises
during the Term, unless caused by Landlord or any of Landlord&rsquo;s Affiliates, agents, contractors or invitees. Legal Hazardous Materials
used by Tenant or its subtenants in violation of Environmental Laws shall constitute Prohibited Hazardous Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(5) <B>&ldquo;Claims&rdquo;</B>
shall mean all claims, expenses, liability, loss and damage, including reasonable attorneys&rsquo; fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0.4pt">Tenant&rsquo;s obligations
and liabilities under this Paragraph 7 shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">8.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Indemnification.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Tenant agrees to
pay, and to protect, defend (with counsel selected by Tenant and reasonably acceptable to Landlord), indemnify and hold harmless Landlord
and the other Indemnified Parties from and against any and all liabilities, losses, damages, costs, expenses (including all reasonable
attorneys&rsquo; fees and expenses), causes of action, suits, claims, demands or&#8239;judgments of any nature (herein collectively called
<FONT STYLE="font-size: 10pt"><B>&ldquo;Damages&rdquo;</B>)</FONT> whatsoever arising from (i) any use, condition or event occurring on
the Premises during the Term and caused by Tenant, its Affiliates, agents, employees, or contractors (including without limitation, the
construction of any Alterations), (ii) any injury to, or the death of, any person or damage to property on the Premises during the Term
or arising by reason of any event or occurrence on or about the Premises during the Term and caused by Tenant, its Affiliates, agents,
employees, or contractors, (iii) any injury to, or the death of, any person or damage to property upon adjoining sidewalks, streets or
rights of way or in any manner growing out of or connected with the use, condition or occupation of the Premises during the Term and
caused by Tenant, its Affiliates, agents, employees, or contractors, (iv) any violation by Tenant of any agreement or condition of this
Lease and failure to cure such violation within any applicable notice and cure periods, or any contract or agreement to which Tenant
is a party or which pertains to the Premises or any part thereof or the ownership, occupancy or use thereof, and (v) any violation by
Tenant of any Legal Requirement; provided, however, the obligations of Tenant under this Paragraph 8 shall not apply as to an Indemnified
Party with respect to claims arising solely from the grossly negligent or affirmative negligent acts or willful misconduct of any Indemnified
Party. If an Indemnified Party shall be made a party to any litigation with respect to the matters covered by this Paragraph 8, Tenant
shall, at its option, either defend, at Tenant&rsquo;s sole cost and expense, such Indemnified Party with counsel selected by Tenant and reasonably
acceptable to such Indemnified Party or pay all costs and reasonable attorneys&rsquo; fees and expenses incurred or paid by such Indemnified
Party in connection with such litigation. In the event Tenant shall, pursuant to this Paragraph 8, discharge any claim against an Indemnified
Party, Tenant shall be subrogated to the rights of the Indemnified Party with respect thereto, except that in no event shall Tenant be
thereby subrogated to a claim against another Indemnified Party to the extent Tenant is obligated to indemnify the other Indemnified
Party with respect thereto. The Tenant&rsquo;s obligations and liabilities under this Paragraph 8 shall survive expiration or earlier termination
of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">9.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Liens.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Tenant will not,
directly or indirectly, create or permit to be created and to remain for more than sixty (60) days after the creation thereof, and will,
subject to Paragraph 18 below, promptly discharge, at Tenant&rsquo;s expense, within sixty (60) days after receipt of notice thereof any mechanics&rsquo;
and materialman&rsquo;s liens against the Premises for any labor, services or materials to be furnished to Tenant. Other than as set forth in
the Work Letter, nothing contained in this Lease shall be construed as constituting the consent or request, expressed or implied, by Landlord
to or for the performance of any labor or services or of the furnishing of any materials for any construction, alteration, addition, repair
or demolition of or to the Premises or any part thereof by any contractor, subcontractor, laborer, materialman or vendor. Notice is hereby
given that Landlord will not be liable for any labor, services or materials furnished or to be furnished to Tenant, or to anyone holding
the Premises or any part thereof, and that no mechanic&rsquo;s, construction or other liens for any such labor, services or materials shall
attach to or affect the interest of Landlord in and to the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">10.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Maintenance
and Repairs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tenant Maintenance and Repairs</U>. Subject to the terms set forth
in the Work Letter, Tenant has accepted the condition, state of repair and appearance of the Premises as of the&#8239;Effective
Date. Except as otherwise expressly provided in this Lease (including Subparagraph 10(b), Paragraph 13 and Paragraph 14 below) and
subject to Subparagraph 12(f), Tenant agrees that during the Term, at its expense, it shall put, keep and maintain the Premises,
including any altered, rebuilt, additional or substituted buildings, structures and other improvements thereto or thereon, in good
and safe condition, repair and appearance, reasonable wear and tear excepted, and shall make all repairs and replacements necessary
therefor. If Tenant fails to make such repairs or replacements beyond all applicable notice and cure periods, Landlord may, at its
option, make the repairs and non-capital replacements on Tenant&rsquo;s behalf and the costs of such repair or non-capital replacements
shall be charged to Tenant as Additional Rent. Tenant will keep the Premises orderly and free and clear of rubbish. Tenant covenants
to perform or observe all terms, covenants and conditions of any easement, restriction, covenant, declaration and maintenance
agreement to which the Premises are subject (collectively, as the same may be amended from time to time by instrument executed or
consented to by Landlord and Tenant, the <B>&ldquo;Easements&rdquo;</B>), including any obligation or performance required of Landlord
under such Easements, including without limitation, payment of all amounts due from Landlord or Tenant (whether as assessments,
service fees, dues or other charges) under such Easements. Following the Effective Date, Landlord shall not enter into any Easements
or modify any existing Easements without Tenant&rsquo;s prior written approval, which approval shall not be unreasonably withheld,
conditioned, or delayed so long as the same do not adversely restrict Tenant&rsquo;s use of the Premises for any Permitted Use, materially
and adversely impact Tenant&rsquo;s business operations, or materially increase Tenant&rsquo;s costs, provided, however, the foregoing
restriction shall not apply to Landlord&rsquo;s grant of a Mortgage and related financing instruments, subject to Paragraph 23.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Landlord
Maintenance and Repairs</U>. Except as expressly provided in this Lease, Landlord shall not be responsible for the cost or performance
of any maintenance, repairs, alterations or replacements of the Premises or any part thereof except for structural repairs and/or replacements
of the load bearing or structural walls and foundations of the Building and for the replacement of the Building&rsquo;s roof surface and roof
membrane (except to the extent any such repair or replacement is required due to the acts or omissions of Tenant or Tenant&rsquo;s Affiliates,
employees, agents, contractors or invitees). All such work performed on behalf of Landlord must be performed by contractors and workmen
who are qualified to do the work involved and where necessary, duly licensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Landlord Access to Premises</U>. Landlord, any Mortgagee and their respective agents and designees may, in the company of a representative
of Tenant if Tenant so requires, enter upon and inspect the Premises at reasonable times during normal business hours and on reasonable
prior notice and show the Premises to prospective Mortgagees and/or purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Alterations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
may make or suffer to be made any alterations, additions or improvements in, on or to the Premises or any part thereof (<B>&ldquo;Alterations&rdquo;),
</B>provided Tenant shall not make any Alterations which would (i) involve changes in the exterior of the Building or other improvements
on the Land Parcel that would be shown on an ALTA/ACSM survey, (ii) reasonably be expected to materially reduce the fair market value
of the Premises, (iii) be inconsistent with the Permitted Uses, (iv) create, or materially increase the likelihood of, a hazardous or
illegal condition, (v) materially affect the Building&rsquo;s elevator shafts, footings,&#8239;foundations, structural portions of load-bearing
walls, structural floors and subfloors, structural columns and beams, curtain walls, and the structural components of the Building&rsquo;s
roof (collectively, the <B>&ldquo;Building Structure&rdquo;</B>), (vi) materially affect the exterior walls and window systems, roof, foundation,
structural portions and the Building&rsquo;s mechanical (including elevators), electrical, plumbing, security, communication, life safety,
heating, ventilating and air-conditioning systems (collectively, the <B>&ldquo;Building Systems&rdquo;</B>) or the parking lot on the Land
Parcel, or (vii) result in the rescinding or modification of any waiver or standstill agreement as to environmental compliance matters,
zoning or any other Legal Requirements granted by any governmental agency without, in each such case, submitting a written request for
and obtaining the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed (except
Landlord reserves the right to withhold consent in its sole discretion with respect to Alterations affecting the Building Structure)
(Alterations described in any one or more of the foregoing clauses&#8239;(i) - (vii) being referred to as <B>&ldquo;Restricted Alterations&rdquo;).
</B>Redecoration of the interior of the Premises, such as painting, wallpapering and replacement of floor covering, shall not constitute
Alterations for purposes of this Lease. Without limitation of Landlord&rsquo;s right to withhold its consent to Restricted Alterations, Landlord
may withhold its consent if an Event of Default then exists. In the event Tenant makes any changes <FONT STYLE="font-size: 10pt"><B>in
</B></FONT>or to any mechanical component of the Premises (for example, a portion of the HVAC system), Tenant shall install mechanical
equipment of equal or greater value and utility. All Alterations shall be constructed in a good and workmanlike manner in compliance
with all Legal Requirements. Tenant&rsquo;s obligation to remove any Alterations which Tenant installs pursuant to this Paragraph 11 shall
be governed by Paragraph 26 herein. In no event shall Tenant be required to remove any element of the Premises which existed on the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;  Subject
to the terms of the Work Letter with respect to the Tenant Improvements (as defined in the Work Letter), Tenant shall satisfy the following
conditions in connection with all Alterations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"> (i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant shall pay or cause to be paid the entire cost of such Alterations;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant shall take all necessary steps to prevent the imposition of liens&#8239;against the Premises as a result of such Alterations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.95pt">(iii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall
obtain and pay for all building, occupancy and other required permits and shall comply with all applicable governmental requirements and
deliver copies of all such permits to Landlord as soon as reasonably possible following issuance thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iv) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall
cause the construction of Alterations, once commenced, to be diligently pursued to completion;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If the Alterations
include any changes or new matter which would be shown on an updated ALTA/ACSM survey of the Premises (including Table A and other items
customarily required by institutional lenders), then Tenant shall obtain and submit to Landlord (and, if requested, Mortgagee), promptly
following substantial completion of the Alterations, a revised ALTA/ACSM survey of the Premises certified to, and in a form reasonably
satisfactory to, Landlord and any Mortgagee of which Tenant has been provided written notice; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(vi) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant shall
provide Landlord copies of as-built plans for all Alterations as soon as reasonably possible following substantial completion of such
Alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except as Landlord and
Tenant otherwise agree in writing, all Alterations other than Severable Additions shall at once become a part of the realty and belong
to Landlord. Severable Additions and Tenant&rsquo;s Property may be removed from the Premises upon, or at any time prior to, the expiration
or earlier termination of this Lease, provided that Tenant shall repair any damage to the Premises resulting from such removal. For purposes
of this Lease, the term (A) <B>&ldquo;Severable Additions&rdquo; </B>shall mean all additions to the Premises during the Term which <FONT STYLE="font-size: 10pt">(i)</FONT>
are readily removable without causing material damage to the Premises, and (ii) are not required for lawful occupancy of the Premises,
and (B) <B>&ldquo;Tenant&rsquo;s Property&rdquo;</B> shall mean, collectively, all trade fixtures and personal property, including, without limitation,
furnishings, furniture, equipment, sign faces, computers, computer related equipment on property, cabling, safes, communications equipment
and other equipment for use in connection with the conduct of Tenant&rsquo;s business regardless of the manner in which they are installed.
The obligations of Tenant under this Paragraph 11 shall survive expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">12.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Insurance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant shall
maintain, or cause to be maintained, at its sole expense, the following insurance on the Premises during the Term (herein called the <B>&ldquo;Required
Insurance&rdquo;):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Property insurance
(<B>&ldquo;Property Insurance&rdquo;</B>) insuring the Tenant Improvements, any Alterations and Tenant&rsquo;s Property for all risks of direct
physical loss and for perils covered by the causes of loss-special form (all risk, extended coverage) and, in addition, ordinance or law
coverage (with highest sublimit as is reasonably available) and boiler and machinery coverage (if applicable). Property Insurance shall
include the following coverages: fire, windstorm, hail, explosion, vandalism, riot, civil commotion, smoke, sprinkler and water damage,
if applicable flood and earthquake, explosion, collapse and underground hazards. Such insurance shall be written on a replacement cost
basis with an agreed value equal to the full insurable replacement value of the property covered thereby. Except with respect to Tenant&rsquo;s
Property, the policy shall include Landlord and any Mortgagees as loss payees, as their respective interests may appear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(ii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;General liability insurance
naming the Landlord and any Mortgagee as additional insureds against any and all claims as are customarily covered under a standard policy
form routinely accepted, for bodily injury, death and property damage occurring in or about the Premises. Such insurance shall have a
combined single limit of not less than Three Million Dollars ($3,000,000) per occurrence with a minimum Five Million Dollars ($5,000,000)
aggregate limit and excess umbrella liability insurance in the amount of at least Ten Million Dollars ($10,000,000). Such liability insurance
shall be primary and not contributing to any insurance available to all additional insureds and any liability insurance carried by the
additional insureds shall be in excess thereto. In no event shall the limits of such insurance be considered as limiting the liability
of Tenant under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Business interruption
insurance with coverage for Rent for twelve (12) months following a Casualty, naming Landlord and any Mortgagee as loss payees, which
coverage may be included in Tenant&rsquo;s Property Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iv) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During any period
of construction on the Premises, builder&rsquo;s risk insurance insuring perils covered by the loss-special form (all risk, extended coverage)
shall be purchased for the value of the alteration and/or additions made to the Premises when the work is not insured under the Tenant&rsquo;s
property insurance policy. Each builder&rsquo;s risk policy shall name Landlord and any Mortgagee as additional insureds. Tenant shall also
cause all contractors to comply with the liability insurance requirements in this Paragraph 12, including primary and non-contributory
Additional Insured status for the Landlord and any Mortgagee and including waiver of subrogation for the benefit of the Landlord and any
Mortgagee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Workers&rsquo; compensation
insurance as required by Legal Requirements and employers&rsquo; liability insurance with minimum liability limits of One Million Dollars ($1,000,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(vi) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Pollution liability
insurance, naming Landlord and any Mortgagee as additional insureds, applicable to bodily injury; property damage, including loss of use
of damaged property or of property that has not been physically injured or destroyed; cleanup costs; and defense, including costs and
expenses incurred in the investigation, defense, or settlement of claims; all in connection with any loss arising from the Premises in
an amount not less than $3,000,000 each occurrence and aggregate. Such liability insurance shall be primary and not contributing to any
insurance available to all additional insureds and any liability insurance carried by the additional insureds shall be in excess thereto.
In no event shall the limits of such insurance be considered as limiting the liability of Tenant under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
policies required to be maintained by Tenant and Landlord hereunder shall be with companies having a general policy rating of A- or better
and a financial class of VII or better by A.M. Best Company, Inc. Insurers shall be authorized to do business in the state in which the
Premises are located. Except as may be otherwise specified in Subparagraph 12(a) or otherwise agreed to by Landlord and Tenant, any deductible
amounts under any Required Insurance hereunder shall not exceed Fifty Thousand Dollars ($50,000). Certificates of insurance (as to property
insurance, using ACORD Form No. 28 (or the equivalent or replacement thereof), and as to liability insurance, using Accord Form 25-S
(or the equivalent or replacement thereof)), together with reasonable evidence of payment of the premiums therefor, shall be delivered,
with respect to Tenant&rsquo;s Required Insurance, to Landlord (and each Mortgagee of which Tenant has been provided written notice), and with
respect to Landlord&rsquo;s Required Coverage, to Tenant. Thereafter, prior to the expiration date of each required policy, each of Landlord
and Tenant shall provide to the other (and with respect to Tenant&rsquo;s Required Insurance, to any Mortgagee of which Tenant has been provided
written notice), evidence reasonably satisfactory to such party of payment of the premiums for such policies, provided, however, in the
case of renewals, notwithstanding the foregoing, each party may provide the other with binders therefor prior to expiration to be followed
by certificates of insurance in the forms as required above. Landlord and Tenant shall each have the right to provide insurance coverage
which it is obligated to carry pursuant to the terms hereof in a blanket policy, provided such blanket policy affords coverage to the
Premises and to Landlord, any Mortgagee, or Tenant (as applicable) as required by this Lease. Each policy of insurance shall provide
notification to Tenant, Landlord and any Mortgagee (as&#8239;applicable) at least thirty (30) days prior to any non-renewal, cancellation or
modification to reduce the insurance coverage, provided, however, that only ten (10) days&rsquo; notice shall be required for cancellation
due to non-payment of premiums.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; In the event
Tenant does not purchase the Required Insurance or keep the same in full force and effect, Landlord may, but shall not be obligated to,
purchase such insurance and pay the premium therefor. Tenant shall repay to Landlord, as Additional Rent, the amount so paid promptly
upon demand together with interest at the Default Rate on such payment from the date expended until the date reimbursed. In addition,
Landlord may recover from Tenant and Tenant agrees to pay, as Additional Rent, any and all expenses (including reasonable attorneys&rsquo; fees)
and actual damages which Landlord may sustain by reason of the failure of Tenant to obtain and maintain the Required Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant shall
indemnify and hold harmless Landlord for any liability incurred by Landlord arising out of any deductibles for Required Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord shall, at all times during the Term, procure and maintain. or cause to be procured and maintained, a policy or policies of
insurance (subject to reimbursement pursuant to this Lease), causing the Premises (but specifically excluding the Tenant
Improvements, any Alterations, and Tenant&rsquo;s Property) to be insured under all-risk (special form or equivalent) property coverage
covering the full replacement cost of the Premises (other than the Tenant Improvements, Alterations, and Tenant&rsquo;s Property) and
including standard extended coverage endorsement perils, flood hazards (if applicable), leakage from fire protective devices and
other water damage (plus such additional endorsements or special coverages Landlord, in its sole and absolute discretion, may
consider appropriate), and such other insurance (if any) that Landlord reasonably deems appropriate for the Premises from time to
time (such policy or policies, collectively, <B>&ldquo;Landlord&rsquo;s Required Coverage&rdquo;</B>) provided that such coverage and
amounts are then typically carried by landlords of comparable properties in the Irving, Texas market. All insurance maintained by or
on behalf of Landlord shall be with such deductibles as Landlord reasonably determines would be carried by landlords of comparable
properties in the Irving, Texas market. Landlord&rsquo;s obligation to carry the Landlord&rsquo;s Required Coverage may be brought within the
coverage of a so-called blanket policy or policies of insurance carried and maintained by or on behalf of Landlord so long as the
coverages required herein are provided. Tenant shall pay to Landlord as Additional Rent all Insurance Expenses (as defined below)
within thirty (30) days after Tenant&rsquo;s receipt of an invoice therefor. Tenant&rsquo;s obligation to pay Insurance Expenses shall survive
the expiration or early termination of this Lease. Insurance Expenses for any partial calendar year during the Term shall be
prorated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(f) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limitation of any other waiver of Claims set forth in this Lease, each of Tenant and Landlord waives any Claim for property loss, damage
or injury it may have against the other to the extent any such Claim is covered by the property insurance actually maintained by a party
or which would have been covered by any property insurance required pursuant to the terms of this Lease to be in effect at the time of
such loss, damage or injury <B>regardless of whether the negligence of the other party caused such property loss, damage or injury. </B><FONT STYLE="font-size: 10pt">Each
party shall cause each policy of the insurance required to be carried by it under this Lease to contain the agreement of the insurer
to waive subrogation against Tenant, Landlord or any Indemnified Party (as applicable) in respect of any such Claim as well as acknowledgement&#8239;by
the insurer that the foregoing waiver of claim will not adversely affect the coverage afforded thereby. If both parties maintain (or
are required to maintain) insurance that covers the same property, then Tenant&rsquo;s insurance shall be deemed the applicable insurance for
purposes of this provision (as the primary insurance coverage as hereinabove provided). Any indemnity provided by Landlord and Tenant
in this Lease is subject to this Paragraph 12(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(g) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything to the contrary contained in this Lease, in the event of any termination of this Lease pursuant to the terms and conditions
of Paragraph 13 below:&nbsp;(i) if Landlord has not already received
the same directly from Tenant&rsquo;s insurer, Tenant shall assign and deliver to Landlord (or to any party designated by Landlord) insurance
proceeds received by Tenant under Tenant&rsquo;s Property Insurance covering the Tenant Improvements and Alterations in an amount equal to
the unamortized portion of the Allowance (as defined in the Work Letter), with such amortization to be calculated, as of the date of
termination of the Lease, on a straight-line basis over the Initial Term, (ii) the remainder of any insurance proceeds payable to or
received by Tenant with respect to such insurance shall belong solely to Tenant, and (iii) any insurance money received by Landlord and/or
Mortgagee (in connection with the casualty event that caused the termination of the Lease) under Tenant&rsquo;s Property Insurance in excess
of the amount owed to Landlord under subclause (i) hereinabove above shall be promptly reimbursed to or, if applicable, endorsed over
to Tenant. This subparagraph (g) shall survive any early termination of the Lease under Paragraph 13 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">13.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Casualty.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant shall give prompt written notice to the Landlord (and any Mortgagee of which Tenant has been provided written notice) of any fire
or other casualty to the Premises (<B>&ldquo;Casualty Loss&rdquo;</B>). In the event the Premises shall be partially or totally destroyed
by a Casualty Loss so as to become partially or totally untenantable, then unless Landlord shall elect to terminate this Lease as hereinafter
provided, the damage to the Premises shall be promptly repaired as set forth below in this <U>Paragraph 13</U>, and the Basic Rent payable
by Tenant to Landlord shall be equitably abated in proportion to the portion of the Premises rendered untenantable until the earlier
of such time that Tenant either reopens in the Premises or is required to recommence Basic Rent payments hereunder. There shall be no
abatement of Additional Rent in the event of a Casualty Loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If (i) more than fifty percent (50%) of the leasable area of the Building shall be damaged or destroyed by a Casualty Loss, or (ii)
Landlord&rsquo;s reconstruction or repair of the Premises is not capable of being completed with twelve (12) months, or (iii) the Casualty
Loss occurs during the last year of the Term, Tenant has not delivered a Renewal Notice, and Landlord&rsquo;s reconstruction or repair is not
capable of being completed within ninety (90) days, or (iv) all or any part of the Premises are damaged or destroyed at any time by the
occurrence of any risk not insured under the insurance that Landlord is required to procure and maintain (or caused to be procured and
maintained) hereunder, or (v) any Mortgagee shall require that the insurance proceeds payable as a result of such Casualty Loss be applied
to the payment of mortgage debt secured by the Premises, then in any of such cases, Landlord, at its sole option, may terminate this
Lease by giving written notice to Tenant of Landlord&rsquo;s election so to terminate, such notice to be given within sixty (60) days after
the occurrence of such Casualty Loss. <FONT STYLE="font-size: 10pt">If</FONT> this Lease is not terminated, the parties shall restore
the Premises as contemplated in <U>Subparagraph 13(c)</U>. For&#8239;purposes of this Paragraph 13, any determination of the portion
of the Building which is damaged by the Casualty Loss or tenantable shall be made by a reputable and qualified licensed engineer having
at least ten (10) years of experience with properties similar to the Premises, such engineer to be retained by Landlord and reasonably
acceptable to Tenant. The results of such determination shall be promptly provided to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
will not carry insurance of any kind on the Tenant Improvements, Alterations or Tenant&rsquo;s Property, and shall not be obligated to repair
any damage thereto or replace the same. Landlord shall be solely responsible to restore the Premises to the condition that existed immediately
prior to such casualty, exclusive of any of the Tenant Improvements, any Alterations and Tenant&rsquo;s Property or any other additions, improvements,
fixtures and equipment installed by Tenant, and subject to Legal Requirements then in effect. Tenant shall be solely responsible for
the restoration and repair of the Tenant Improvements, Alterations and Tenant&rsquo;s Property, which restoration and repair work shall be
performed after Landlord restores the Premises as required herein (or causes same to be so restored) and delivers the Premises (or the
portion thereof affected by the Casualty Loss) to Tenant, and to the extent Landlord or any Mortgagee received proceeds of Tenant&rsquo;s Property
Insurance covering the Tenant Improvements and Alterations, such proceeds shall be made available to Tenant for such repair and restoration
work. Tenant agrees that during any period of reconstruction or repair of the Premises, it will continue the operation of its business
within the Premises to the extent practicable. Tenant shall perform all such work with diligence and in accordance with the terms and
conditions of the provisions of this Lease governing Alterations. Notwithstanding anything herein to the contrary, any Basic Rent abatement
provided for in this <U>Paragraph 13</U> shall cease upon restoration of the Premises by Landlord in the condition required herein and
delivery of the Premises to Tenant, and Tenant shall commence paying full Basic Rent effective as of such date. As part of Tenant&rsquo;s restoration
work hereunder, Tenant, at Tenant&rsquo;s sole cost, shall repair and replace the Tenant Improvements, Alterations, and Tenant&rsquo;s Property
in a manner and to at least a condition equal to that prior to the Casualty Loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
In addition, if (i) more than fifty percent (50%) of the leasable area of the Building is rendered untenantable by a Casualty Loss and,
in the reasonable opinion of Landlord and Tenant, based on the recommendation of a licensed engineer as described in <U>Subparagraph
13(b)</U>, such damage cannot be repaired within twelve (12) months after the receipt of insurance proceeds and all applicable governmental
permits, or (ii) during the last year of the Term, more than fifty percent (50%) of the leasable area of the Building is rendered untenantable
by a Casualty Loss and, in the reasonable opinion of Landlord and Tenant (based on the recommendation of a licensed engineer as described
in <U>Subparagraph 13(b))</U>, such damage cannot be repaired within ninety (90) days after the receipt of insurance proceeds and all
applicable governmental permits, then Tenant shall have the right to terminate this Lease by written notice to Landlord delivered within
thirty (30) days after the date on which such engineer&rsquo;s opinion is delivered to Tenant (which Landlord shall provide to Tenant within
sixty (60) days after the date of the Casualty Loss). Upon termination of this Lease pursuant to this Paragraph 13, Basic Rent and Additional
Rent shall be apportioned as of the date of the Casualty Loss. If, following a Casualty Loss, Tenant has the right to terminate this
Lease under this provision but Tenant fails to deliver Tenant&rsquo;s termination notice to Landlord within the time period stated herein,
such right to terminate with respect to the Casualty Loss in question shall be deemed waived. Notwithstanding anything in this Paragraph
to the contrary, Tenant shall not have the right to terminate this Lease pursuant to&#8239;this <U>Paragraph 13</U> or be entitled to
any Basic Rent abatement to the extent such Casualty Loss was caused by the act or neglect of Tenant or its employees, agents, or contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">14.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Condemnation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If the whole of the Premises
shall be acquired or condemned by eminent domain for any public or quasi-public use or purpose (a sale in lieu of condemnation to be deemed
a taking for the purposes of this Paragraph 14), then the Term shall cease and terminate as of the date of possession being required by
the condemning authority and all Basic Rent and Additional Rent shall be paid through that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If any material part
of the Premises or Building shall be acquired or condemned by eminent domain for any public or quasi-public use or purpose, and the taking
would prevent or materially interfere with the use of the Premises or Building for the purpose for which they are then being used, then
the Term shall cease and terminate as of the date of possession being acquired by the condemning authority and all Basic Rent and Additional
Rent shall be paid through that date. In the event of a partial taking or condemnation. which is not extensive enough to render the Lease
terminable as provided above, then Landlord shall promptly restore the Premises (but not the Tenant Improvements, any Alterations or Tenant&rsquo;s
Property) or cause same to be restored to make the remaining portions of the Premises (outside the Building) reasonably functional, and
with respect to the remaining portions of the Building, to cause the same to be an architectural whole, and this Lease shall continue
in full force and effect, except that the Basic Rent shall be equitably adjusted to the extent of the taking that affected the Premises.
Notwithstanding the foregoing, Landlord&rsquo;s obligation to restore or cause restoration hereunder exists (i) only if and/or to the extent
that the condemnation or similar award received by Landlord is sufficient to compensate Landlord for its restoration costs, and/or (ii)
the area unaffected by the condemnation may, as determined by Landlord&rsquo;s reasonable judgment, be restored as a profitable and self-functioning
premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Landlord shall be entitled
to the entire award for any claim for a taking (or the proceeds of private sale in lieu thereof) of the Premises or for any portion of
the Building, without deduction or offset for Tenant&rsquo;s estate or interest; provided, however, Tenant may, in a separate proceeding, make
a separate claim for the unamortized portion of any Alterations paid for by Tenant with no reimbursement from Landlord, trade fixtures
and other Tenant&rsquo;s Property and Tenant&rsquo;s moving, relocation and other business expenses (including loss of lease value) to the extent
that Tenant&rsquo;s claim does not diminish the claims or awards of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt">15. <B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Building
Signage.</B>&nbsp;Tenant shall have the right to install Tenant&rsquo;s name or trade name on up to two (2) exterior walls of the Building
(each, a <B>&ldquo;Tenant Building Sign&rdquo;</B>). Prior to installing a Tenant Building Sign, Tenant shall submit the proposed signage
design, location and specifications to Landlord for Landlord&rsquo;s approval, not to be unreasonably withheld, conditioned or delayed. Each
Tenant Building Sign shall be installed at the expense of Tenant and shall be installed in compliance with the City of Irving, Texas
Building Codes and all other Legal Requirements. In addition, at the expiration or termination of this Lease, Tenant shall, at its sole
cost and expense, remove each Tenant Building Sign and restore the affected areas of the Building where such Tenant Building Sign was
installed to the condition as existed prior to such Tenant Building Sign installation, normal wear and tear and casualty excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Assignment
and Subletting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Subject to <U>Subparagraph 16(b)</U> below, Tenant shall not, without the prior written consent of Landlord, which consent shall not
be unreasonably withheld, conditioned or delayed: (a) assign or in any manner transfer this Lease or any estate or interest therein,
or (b) sublet any portion of the Premises (any of the events in clauses (a) and (b) being a </FONT><B>&ldquo;Transfer&rdquo;</B>). <FONT STYLE="font-size: 10pt">In
this regard, Tenant acknowledges and agrees that Landlord&rsquo;s acceptance of Rent from an assignee or subtenant shall not be deemed to constitute
Landlord&rsquo;s consent to such assignment or sublease. In addition, Landlord shall also be entitled to charge Tenant a $2,000.00 fee for
processing any Tenant request for such Transfer (inclusive of any attorneys&rsquo; fees and costs incurred by Landlord), regardless of whether
or not Landlord grants its consent. Consent by Landlord to one or more Transfers shall not operate as a waiver of Landlord&rsquo;s rights as
to any Transfers. Subject to Subpargraph 16(b) below, if Tenant is a corporation, partnership or other entity and if at any time during
the Term the person or persons who own, directly or indirectly, a majority of either the outstanding voting rights or the outstanding
ownership interests of Tenant at the time of the execution of this Lease cease to own a majority of such voting rights, ownership interests
or control (except as a result of transfers by devise or descent), the loss of a majority of such voting rights, ownership interests
or control shall be deemed to be a Transfer and, therefore, subject in all respects to the provisions of this Paragraph 16. Any Transfer
in violation of this Paragraph shall, at Landlord&rsquo;s option, be deemed an Event of Default, and shall be voidable by Landlord. Notwithstanding
the foregoing, nor anything in this Lease to the contrary, nothing contained in this Lease shall mean or imply that Landlord&rsquo;s consent
is required in the event that Tenant or its direct or indirect parent elects to go &ldquo;public&rdquo; and Tenant shall not be required
to obtain Landlord&rsquo;s consent to a change in the ownership of the voting stock of Tenant or its direct or indirect parent so long as such
stock of Tenant or its direct or indirect parent is listed on a public securities exchange at the time of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant may assign this
Lease to a successor to Tenant by merger, consolidation, recapitalization, reorganization, or the purchase of all or substantially all
of Tenant&rsquo;s assets <FONT STYLE="font-size: 10pt">(<B>&ldquo;Permitted Successor Event&rdquo;</B>),</FONT> or assign this Lease or sublet
all or a portion of the Premises to an Affiliate of Tenant, without the written consent of Landlord, provided that all of the following
conditions are satisfied (each a <FONT STYLE="font-size: 10pt"><B>&ldquo;Permitted Transfer&rdquo;,</B></FONT> and any transferee of a
Permitted Transfer being a <FONT STYLE="font-size: 10pt"><B>&ldquo;Permitted Transferee&rdquo;):</B></FONT> (a) no Event of Default shall
exist; (b) Tenant must give Landlord written notice at least 15 days prior to such Transfer; (c) the Transfer is not a subterfuge by Tenant
to avoid its obligations under this Lease or to avoid obtaining consent to a Transfer that would otherwise require Landlord&rsquo;s consent;
and (d) if the Transfer is a Permitted Successor Event, the Permitted Transferee shall have, immediately after giving effect to such Permitted
Transfer, a Tangible Net Worth (as defined below) at least equal to $50,000,000.00, as evidenced to Landlord&rsquo;s reasonable satisfaction,
which evidence shall include the Permitted Transferee&rsquo;s latest audited financial statements. Tenant&rsquo;s notice to Landlord hereunder shall
include information and documentation evidencing the Permitted Transfer and reasonable evidence showing that each of the above conditions
has been satisfied. Partial assignments of this Lease shall not be permitted under any circumstances. For purposes of this Subparagraph
16(b), the term <FONT STYLE="font-size: 10pt"><B>&ldquo;Tangible Net Worth&rdquo;</B></FONT> means the excess of total assets over total
liabilities, in each case as determined in accordance with GAAP (as hereafter defined) excluding, however, from the determination of total
assets all assets which would be classified as intangible assets under GAAP including goodwill, licenses, patents, trademarks, trade names,
copyrights and franchises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Any assignee
or sublessee of an interest in and to this Lease shall be deemed, by acceptance of such assignment or sublease or by taking actual or
constructive possession of all or any portion of the Premises, to have assumed all of the obligations set forth in or arising under this
Lease. Such assumption shall be effective as of the earlier of the date of such assignment or sublease or the date on which the assignee
or sublessee obtains possession of all or any portion of the Premises; however, with specific regard to any assignment, the assignee shall
be responsible for all unsatisfied obligations of Tenant under this Lease, regardless of when such obligations arose and when such assumption
became effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(d) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding any Transfer
and except as otherwise expressly set forth in the Guaranty (as defined in Paragraph 41), and/or as otherwise agreed to by Landlord in
writing, Tenant and any Guarantor of Tenant&rsquo;s obligations under this Lease shall at all times remain fully responsible and liable for
the payment of the Rent herein specified and for compliance with all of Tenant&rsquo;s other obligations under this Lease (even if Transfers
occur subsequent to the Transfer by Tenant, and regardless of whether or not Landlord&rsquo;s approval has been obtained for such future assignments
and sublettings). If Tenant consummates a Transfer (other than a Permitted Transfer), Tenant shall pay to Landlord, as Additional Rent,
fifty percent (50%) of all sums received by Tenant in excess of the Rent payable by Tenant hereunder which is attributable to any subletting
of all or any portion of the Premises so subleased, and fifty percent (50%) of all consideration received on account of or attributable
to any assignment of this Lease, in each case net of all reasonable and documented expenses and costs incurred by Tenant in connection
with such Transfer, including, without limitation, commissions, allowances, improvement costs and other concessions provided to the sublessee
or assignee. Finally, in the event of sublease of all or a portion of the Premises, it is understood and agreed that upon any Event of
Default by Tenant under this Lease, Landlord may collect any rent due under the terms of the sublease and apply the amount collected to
the next Rent payable hereunder; and all such rentals collected by Tenant shall be held in trust for Landlord and immediately forwarded
to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">17.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Financial
Statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Tenant will deliver
to Landlord (and, if requested, to any Mortgagee) the following with respect to Tenant and any guarantor of this Lease (each a <B>&ldquo;Principal&rdquo;):
</B>within one hundred fifty (150) days after the end of each fiscal year of each Principal and thereafter, within twenty (20) days after
receipt of written request by Landlord (such request to be limited to no more than one time in any twelve (12) month period unless such
request is in connection with a prospective sale or financing of the Premises by Landlord, in which case Landlord shall not be so limited)
in connection with any transfer of Landlord&rsquo;s interest in this Lease, copies of the financial statements and reports with respect to
each Principal and its consolidated subsidiaries, setting forth in each case, in comparative form, the figures for the previous fiscal
year, all in reasonable detail and accompanied by the report thereon, each containing an opinion unqualified as to limitations imposed
by the applicable Principal on the scope of the audit, prepared by a firm of independent certified public accountants of recognized national
standing selected by such Principal which opinion shall state that the consolidated financial statements of the Principal and its consolidated
subsidiaries fairly present the financial condition of the companies (including the results of their operations and changes in financial
position) being reported upon, have been prepared in accordance with accounting principles generally accepted in the U.S. consistently
applied <FONT STYLE="font-size: 10pt">(<B>&ldquo;GAAP&rdquo;</B>) and that the examination of such accounts in connection with such financial
statements&#8239;has been made in accordance with auditing standards generally accepted in the United States and, accordingly, included
such tests of the accounting records and such other auditing procedures as were considered necessary in the circumstances, <U>provided,
however</U>, if it is not the practice of a Principal to have financial reports prepared and certified by a firm of independent public
accountants then any such report may instead be prepared by the Principal and certified to by, and to the best knowledge of, its chief
financial officer; and <U>further provided</U> that any financial reports delivered to Landlord upon Landlord&rsquo;s written request (i.e.,
not in the ordinary course of a Principal&rsquo;s business auditing cycle) shall not be required to be certified by a firm of independent
public accountants and may instead be prepared by such Principal and certified to by, and to the best knowledge of, its chief financial
officer. Landlord shall hold and shall cause each Mortgagee to hold in confidence any non-public financial report and other information
delivered to Landlord or a Mortgagee pursuant to this Paragraph I 7, except that Landlord and any such Mortgagee may disclose such reports
and information (i) to the extent required by Legal Requirements and (ii) to prospective lenders, investors and purchasers and the financial
advisors, accountants and attorneys of Landlord, Mortgagee and such prospective lenders, investors and purchasers, all to the extent
so provided in the ordinary course of Landlord&rsquo;s and such Mortgagees&rsquo; business provided any such disclosure party agrees to maintain
the confidentiality required by this Paragraph 17. In the event that a Principal shall be required to file its financial statements with
the Securities and Exchange Commission and such statements are available for review on the Commission&rsquo;s EDGAR system, Tenant shall be
deemed to be in compliance with the requirements of this Paragraph 17 as to such Principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">18.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Permitted
Contests.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Tenant shall not
be required to (i) pay any Imposition; (ii) comply with any Legal Requirements; (iii) discharge or remove any lien, encumbrance or
charge; or (iv) obtain any waivers or settlements or make any 10(a), changes to the physical condition of the Premises or take any
other action with respect to any asserted defect in the Premises as required under Subparagraph so long as Tenant shall contest, in
good faith and at its expense, the existence, the amount or the validity thereof, the amount of the damages caused thereby, or the
extent of its liability therefor, by appropriate proceedings provided that (A) during the pendency of the contest there is prevented
(1) the collection of, or other realization upon, the tax, assessment, levy, fee, rent or charge or lien, encumbrance or charge so
contested (or in the alternative, Tenant pays the full amount in dispute under protest); (2) the sale, forfeiture or loss of the
Premises, or any part thereof, or the Basic Rent or any Additional Rent, or any portion thereof; (3) any interference with the
payment of the Basic Rent or any Additional Rent, or any portion thereof; and (4) any impairment of the fair market value of the
Premises; (B) Tenant provides to Landlord title insurance over, of if title insurance is not available, such other security against
any such lien, encumbrance or charge as Landlord shall reasonably request; and (C) such contest shall not subject Landlord or any
Mortgagee to the risk of any criminal liability. While any such proceedings are pending, so long as all of the foregoing conditions
continue to be met, Landlord shall not pay, remove or cause to be discharged the tax, assessment, levy, fee, rent or charge or lien,
encumbrance or charge thereby being contested. Tenant further agrees that each such contest shall be prosecuted to a final
conclusion as soon as reasonably possible. Tenant shall pay, indemnify, defend (with counsel selected by Tenant and reasonably
acceptable to Landlord) and hold harmless the Indemnified Parties against, any and all losses, judgments, decrees and costs
(including all reasonable attorneys&rsquo; fees and expenses) in connection with any such contest and&#8239;shall, promptly after
the final settlement, compromise or determination of such contest, fully pay and discharge the amounts which shall be levied,
assessed, charged or imposed or be determined to be payable therein or in connection therewith, together will all penalties, fines,
interests, costs and expenses thereof or in connection therewith, and perform all acts, the performance of which shall be ordered or
decreed as a result thereof. The obligations of Tenant under this Paragraph 18 shall survive expiration or earlier termination of
this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">19.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Tenant
Default Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Any of the following occurrences
or acts shall constitute an event of default (herein called an <FONT STYLE="font-size: 10pt"><B>&ldquo;Event of Default&rdquo;</B>)</FONT>
under this Lease:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If Tenant, at any time
during the continuance of this Lease (and regardless of the pendency of any bankruptcy, reorganization, receivership, insolvency or other
proceedings, at law, in equity, or before any administrative tribunal, which have or might have the effect of preventing Tenant from complying
with the terms of this Lease), shall (A) fail to make any payment when due of Basic Rent and such failure continues for five (5) days
following written notice from Landlord to Tenant specifying such failure, (B) fail to make any payment when due of Additional Rent and
such failure continues for thirty (30) days following written notice from Landlord or Mortgagee to Tenant specifying such failure, (C)
fail in any material respect to maintain any insurance required to be carried by Tenant under this Lease and such failure continues for
two (2) Business Days following Tenant&rsquo;s receipt of Landlord&rsquo;s notice of same, or (D) fail to observe or perform in any material respect
any other provision hereof for thirty (30) days following written notice from Landlord to Tenant specifying such failure, provided, that
in the case of any default referred to in this Lease which is reasonably susceptible of cure but cannot with diligence be cured within
such thirty (30) day period, then, upon receipt by Landlord of a certificate of Tenant signed by an officer of Tenant stating the reason
such default cannot be cured within thirty (30) days, describing the efforts being undertaken by Tenant to cure such default and reasonably
estimating the cure period, and provided that Tenant at all times proceeds with good faith due diligence to cure such default, the time
within which such failure may be cured shall be extended for such period, as may be necessary to complete the curing of the same with
continuous, good faith due diligence; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If Tenant or
Guarantor shall file a petition commencing a voluntary case under the Federal Bankruptcy Code or any other federal or state law (as now
or hereafter in effect) relating to bankruptcy, insolvency, reorganization, winding-up or adjustment of debts (hereinafter singly a <FONT STYLE="font-size: 10pt"><B>&ldquo;Bankruptcy
Law&rdquo;</B></FONT> and collectively <FONT STYLE="font-size: 10pt"><B>&ldquo;Bankruptcy Laws&rdquo;</B>)</FONT> and such proceeding is
not discharged within sixty (60) days after the date of filing or if Tenant or Guarantor shall (A) apply for or consent to the appointment
of, or the taking of possession by, any receiver, custodian, trustee, United States Trustee or liquidator (or other similar official)
of the Premises or any part thereof or of any substantial portion of Tenant&rsquo;s property and any such application or appointment is not
withdrawn or vacated within sixty (60) days after the filing or entry thereof, or (B) generally not pay its debts as they become due,
or admit in writing its inability to pay its debts generally as they become due, or (C) make a general assignment for the benefit of its
creditors, or (D) fail to controvert in timely and appropriate manner, or in writing acquiesce to, any petition commencing an involuntary
case against Tenant or Guarantor or otherwise filed against Tenant or Guarantor pursuant to any Bankruptcy Law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If an order for relief against Tenant or Guarantor shall be entered in any involuntary case under the Federal Bankruptcy Code or any
similar order against Tenant or Guarantor shall be entered pursuant to any other Bankruptcy Law, or if a petition commencing an involuntary
case against Tenant or Guarantor or proposing the reorganization of Tenant under any Bankruptcy Law shall be filed and not be discharged
or denied within ninety (90) days after such filing, or if a proceeding or case shall be commenced in any court of competent jurisdiction
seeking&#8239;(A) the liquidation, reorganization, dissolution, winding-up or adjustment of debts of Tenant or Guarantor, or (B) the
appointment of a receiver, custodian, trustee, United States Trustee or liquidator (or any similar official) of the Premises or any
part thereof or of Tenant or Guarantor or of any substantial portion of Tenant&rsquo;s or Guarantor&rsquo;s property, or (C) any similar relief as
to Tenant or Guarantor pursuant to any Bankruptcy Law, and any such proceeding or case shall continue undismissed, or an order, judgment
or decree approving or ordering any of the foregoing shall be entered and continue unstayed and in effect for ninety (90) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; If an Event of Default
shall have happened and be continuing, Landlord shall have, in its sole discretion, the following rights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; To terminate
the Term of this Lease by written notice to Tenant. Thereupon, the Term of this Lease and the estate hereby granted shall terminate on
the date on which Landlord sends such notice as completely and with the same effect as if such date were the date fixed herein for the
expiration of the term of this Lease, and all rights of Tenant hereunder shall terminate, but Tenant shall remain liable as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(ii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To (A) re-enter and repossess the Premises or any part thereof by
force, summary proceedings, ejections or otherwise and (B) remove all persons and property therefrom, whether or not the Lease has
been terminated pursuant to clause (i) above, Tenant hereby expressly waiving, to the extent permitted by law, any and all notices
to quit, cure or vacate provided by current or any future law. Landlord shall have no liability by reason of any such re-entry,
repossession or removal. No such re-entry or taking of possession of the Premises by Landlord shall be construed as an election on
Landlord&rsquo;s part to terminate the Term of this Lease unless a written notice of such intention be given to Tenant pursuant to
clause (i) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iii) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To use reasonable
efforts to relet the Premises or any part thereof for the account of Tenant, in the name of Tenant or Landlord or otherwise, without notice
to Tenant, for such term or terms (which may be greater or less than the period which would otherwise have constituted the balance of
the Term of this Lease) and on such conditions (which may include concessions or free rent) and for such uses as Landlord may reasonably
determine; provided the foregoing shall not be construed to reduce the obligation of Landlord to mitigate its damages to the extent required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(iv) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event of re-entry or repossession of the Premises or removal of persons or property therefrom by reason of the occurrence of an Event
of Default, Tenant shall pay to Landlord all Basic Rent and Additional Rent, in each case to and including the date of such re-entry,
repossession or removal; and, thereafter, until the Term has expired or has been terminated, Tenant shall, whether or not the Premises
shall have been relet, be liable to Landlord for, and shall pay to Landlord (A) all Basic Rent and all Additional Rent as and when such
amounts would be payable under this Lease by Tenant in the absence of any such re-entry, repossession or removal,&#8239;together with
all reasonable expenses of Landlord in connection with such reletting efforts, if any (including, without limitation, all reasonable
repossession costs, brokerage commissions, reasonable attorneys&rsquo; fees and expenses, employee&rsquo;s expenses, reasonable alteration costs
and expenses of preparation for such reletting), less (B) the net proceeds, if any, of any reletting effected for the account of Tenant
pursuant to Subparagraph 19(b)(iii) above. Notwithstanding the foregoing, in the event any such reletting is for a term longer than the
balance of the Term, Tenant shall be responsible for only a proportionate part of the expenses based on the balance of the Term as compared
to the fixed minimum term of the reletting. Tenant shall pay such amounts on the dates on which Rent would be payable under this Lease
in the absence of such re-entry, repossession or removal, and Landlord shall be entitled to recover the same from Tenant on each such
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <FONT STYLE="font-size: 10pt">In</FONT>
the event of the termination of the Term by reason of the occurrence of an Event of Default, whether or not Landlord shall have collected
any damages pursuant to Subparagraph 19(b)(iv) above with respect to the period prior to such termination, Landlord shall be entitled
to recover from Tenant, and Tenant shall pay to Landlord on demand, as and for liquidated and agreed final damages for Tenant&rsquo;s default
and in lieu of all liquidated and agreed current damages in respect of Basic Rent and Additional Rent due beyond the date of such termination
(it being agreed that it would be impracticable or extremely difficult to fix the actual damages), an amount equal to the sum of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(A)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
Basic Rent and Additional Rent, in each case from the date of such termination for what is or would have been, in the absence of such
termination, the then unexpired Term, discounted on a monthly basis at an annual rate equal to the then quoted semi-annual yields (which
shall be converted to monthly yields) on U.S. Treasury securities maturing nearest the end of the Term (as if no termination had occurred)
plus&#8239;one percent (1%) (such rate being the <FONT STYLE="font-size: 10pt"><B>&ldquo;Discount Rate&rdquo;</B>),</FONT> over (2) the
then fair rental value of the Premises for the same period, discounted on a monthly basis at the Discount Rate; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(B)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord&rsquo;s other reasonable expenses incurred as a result of such Event of Default. If any applicable Legal Requirement shall limit
the amount of liquidated final damages to less than the foregoing amount, Landlord shall be entitled to the maximum amount allowable under
such law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; No termination
of this Lease pursuant to Subparagraph 19(b)(i), by operation of law or otherwise, and no repossession of the Premises or any part thereof
pursuant to Subparagraph 19(b)(ii) or otherwise, and no re letting of the Premises or any part thereof pursuant to Subparagraph 19(b)(iii),
and no payment of any amounts by Tenant under Subparagraph 19(b) or the exercise by Landlord of any of its other rights under Subparagraph
19(b) shall, except to the extent of such payment, relieve Tenant of any liabilities under this Lease which by express provision of this
Lease survive such expiration, termination, repossession, reletting or purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
In the event Tenant retains possession beyond the expiration or earlier termination of the Term, then, without limitation of Landlord&rsquo;s other rights and remedies arising by reason of or in respect of such holdover, Tenant shall pay Basic Rent for such holdover period
at a rate, for the first three months of such holdover period, equal to one hundred twenty-five&#8239;percent (125%) of the Basic Rent
due for the last full calendar month immediately prior to such holdover period and thereafter at a rate equal to one hundred fifty percent
(150%) of the Basic Rent due for such calendar month, and Tenant shall also continue to perform all of its other obligations under this
Lease, including the payment of all Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(e) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In the event Tenant
fails to perform any of its obligations under this Lease with respect to the maintenance, repair and/or restoration of the Premises and
if (i) Tenant does not correct such failure within thirty (30) days following receipt of notice thereof from Landlord or, if the correction
cannot with diligence be corrected within such period, Tenant does not undertake such correction and thereafter diligently pursue such
correction or (ii) if an emergency condition exists which involves the threat of imminent personal injury or material property damage,
Tenant fails to correct or initiate correction of such condition promptly following notice from Landlord, then, in either such event,
Landlord may re-enter the Premises for the purpose of making such correction, provided Landlord complies with any Legal Requirements applicable
to such entry, gives Tenant reasonable advance notice of such re-entry considering the circumstances and takes reasonable measures to
minimize to the extent practicable any adverse impact on Tenant&rsquo;s business and its occupancy of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">20.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Additional
Rights of Landlord; Landlord Waiver of Lien.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The rights and
remedies set forth in Subparagraph 19(b) may be exercised in any order and in any combination whatsoever. No right or remedy herein conferred
upon or reserved to Landlord is intended to be exclusive of any other right or remedy, and each and every right and remedy shall be cumulative
and in addition to any other right or remedy given hereunder or now or hereafter existing at law or in equity. The failure of Landlord
to insist at any time upon the strict performance of any covenant or agreement or to exercise any option, right, power or remedy contained
in this Lease shall not be construed as a waiver or a relinquishment thereof for the future. A receipt by Landlord of any Basic Rent,
any Additional Rent or any other sum payable hereunder with knowledge of the breach of any covenant or agreement contained in this Lease
shall not be deemed a waiver of such breach, and no waiver by Landlord of any provision of this Lease shall be deemed to have been made
unless expressed in writing and signed by Landlord. In addition to other remedies provided in this Lease, Landlord shall be entitled,
to the extent permitted by Legal Requirements, to injunctive relief in case of the violation, or attempted or threatened violation, of
any of the covenants, agreements, conditions or provision of this Lease, or to a decree or judgment compelling performance of any of the
covenants, agreements, conditions or provisions of this Lease, or to any other remedy allowed to Landlord at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
To the extent permitted by law, Tenant hereby waives and surrenders for itself and all those claiming under it, including creditors
of all kinds, any right or privilege which it or any of them may have under any present or future constitution, statute or rule of
law to redeem the Premises or to have a continuance of this Lease for the Term hereby demised or for a lesser period after
termination of Tenant&rsquo;s right of occupancy by order or judgment of any court or by&#8239;any legal process or writ, or under
the terms of this Lease or after the termination of the Term of this Lease as herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Landlord waives
its statutory lien rights under Section 54.021 of the Texas Property Code as well as any constitutional and contractual liens with respect
to Tenant&rsquo;s personal property located at the Premises. Notwithstanding anything to the contrary herein, however, Landlord does not waive,
relinquish or subordinate any liens, rights or remedies that Landlord may now have, or shall ever enjoy, as a judgment creditor or under
any warehouseman&rsquo;s lien in the event that Landlord is required by applicable law to store Tenant&rsquo;s property if such property is abandoned
by Tenant following a default by Tenant under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">21.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Notices,
Demands and Other Instruments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.35pt">Any notice, demand,
request, consent, approval, or other instrument (<B>&ldquo;Notice&rdquo;</B>) which may be permitted, required or desired to be given in
connection herewith shall be given in writing and directed to Tenant or Landlord (as applicable) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">If to Tenant:</FONT></TD>
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Prior to July 1,
    2020</U></FONT>:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">750 W. John Carpenter Freeway, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, TX 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Michael Halbert, SVP Human Resources</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">750 W. John Carpenter Freeway, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, TX 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>From and After July 1, 2020</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3600 W. Royal Lane</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, TX 75063</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%"><FONT STYLE="font-size: 10pt">Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3600 W. Royal Lane</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, TX 75063</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If to Landlord:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">KCP NNN II Leasehold 4, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">c/o Kawa Capital Partners LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">21500 Biscayne Boulevard, Suite 700</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Aventura, Florida 33180</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: General Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">With a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Greenberg Traurig, P.A.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">333 S.E. 2nd Avenue, Suite 4400</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Miami, Florida 33131</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Gavin Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.05pt">Notices shall be either (i)
personally delivered (including delivery by reputable overnight courier service) to the offices set forth above, in which case they shall
be deemed delivered on the date of delivery to said offices or (ii) sent by facsimile or email (as applicable), provided that for any
notices sent by facsimile or email a copy shall also be sent by personal delivery or overnight delivery service. Any notice actually received
or deemed received pursuant to the foregoing provisions on a non-Business Day or after the close of business of the recipient on a Business
Day shall be deemed received on the next Business Day. Either party may by written notice to the other party given as provided hereunder
change its address for service of Notice to any other recognized business address in the continental United States. Any address so designated
shall include a street address for courier delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.5in">22. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Transfer
by Landlord.</B>&nbsp;Landlord shall be free to transfer its fee interest in the Premises or any part thereof or interest therein. Landlord
shall be released from the responsibility for the performance of any liabilities and obligations which shall arise under the terms, covenants
and conditions of this Lease subsequent to the date of any such transfer. Such instrument assigning Landlord&rsquo;s interest in this Lease
shall evidence the fact that such assignee or transferee has assumed full and complete liability for all future obligations and responsibilities
of Landlord (subject to the limitations set forth in Paragraph 36 of this Lease), which will arise under, out of and/or in connection
with this Lease from and after the effective date of such assignment or transfer. In the event that Landlord transfers its interest in
this Lease, Tenant agrees to attorn to such assignee or transferee with respect to Tenant&rsquo;s obligations under this Lease provided such
assignee or transferee recognizes Tenant&rsquo;s rights under this Lease. Tenant shall, upon Landlord&rsquo;s or such transferee&rsquo;s written request
and at no out-of-pocket expense to Tenant, enter into an attornment agreement providing for such attornment. The transferring Landlord
and its officers, directors, trustees, members, partners, shareholders, beneficiaries, employees and agents shall&#8239;remain Indemnified
Parties with respect to any event or occurrence that has happened prior to such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">23.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Mortgaging
<FONT STYLE="font-size: 10pt">by</FONT> Landlord.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">Landlord
shall be free to grant one or more mortgages, deeds of trust or like security interest in the Premises and this Lease and/or enter into
a ground lease with respect to the Premises (each such mortgage, deed of trust, like security interest or ground lease, and any renewals,
replacements, or extensions thereof, being a </FONT><B>&ldquo;Mortgage&rdquo;</B>) <FONT STYLE="font-size: 10pt">to one or more mortgagees,
deed of trust trustees, other grantees or ground lessors (individually, together with each holder of any note secured thereby, a </FONT><B>&ldquo;Mortgagee&rdquo;</B>)
<FONT STYLE="font-size: 10pt">on the condition that either (a) this Lease shall be superior to the Mortgage, or (b) if this Lease is to
be subordinate to the Mortgage, Tenant receives from the Mortgagee a subordination and nondisturbance agreement reasonably acceptable
to Tenant and the Mortgagee pursuant to which Tenant shall confirm the subordination of this Lease to such Mortgage and Mortgagee recognizes
this Lease and agrees not to disturb Tenant&rsquo;s interest in this Lease or possession of the Premises so long as an Event of Default has
not occurred and is continuing under this Lease (an <B>&ldquo;SNDA&rdquo;</B>), provided that in no event shall this Lease be subordinated
to a junior mortgage without the prior written consent of any then-existing Mortgagee. Tenant shall execute such SNDA within ten (10)
Business Days after receipt of such SNDA in form reasonably acceptable to Tenant. Any such recognition and non-disturbance agreement shall
provide that, in the event of a conflict between the Mortgage and this Lease, casualty insurance proceeds shall be received, used and
applied as provided in this Lease. Tenant agrees to attorn, at the request of any Mortgagee, to such Mortgagee or other transferee upon
a transfer of title by reason of foreclosure of such Mortgage or deed in lieu of foreclosure thereof or termination of any such ground
lease. </FONT>In <FONT STYLE="font-size: 10pt">connection with any proposed transfer, pledge or mortgage of Landlord&rsquo;s fee interest in
the Premises or any portion of the ownership interests in Landlord, Tenant shall, within ten (10) Business Days after receipt of Landlord&rsquo;s
written request therefor, provide Landlord and the proposed transferee and/or Mortgagee with confirmation in writing that Tenant shall
recognize such transferee and Mortgagee as such in the event of the consummation of the transaction described in such notice. Without
limitation of the foregoing, a SNDA substantially in the form attached hereto as </FONT><B>Exhibit 23</B> <FONT STYLE="font-size: 10pt">shall
be deemed reasonable for all relevant purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Without limiting
the generality of the foregoing, at the written direction of Landlord, Tenant shall agree in writing in respect of a first Mortgage
for the benefit of the Mortgagee thereunder that (i) the Mortgagee is a direct assignee of Landlord&rsquo;s interest under this Lease and
(ii) until said Mortgage has been released of record, all payments of Basic Rent are to be made as set forth in said direction and
no subsequent direction by Landlord shall be honored by Tenant until said Mortgage has been released of record unless the Mortgagee
consents in writing to such subsequent direction. Any Mortgagee which becomes an assignee of Landlord&rsquo;s interest in this Lease,
whether by foreclosure of a Mortgage or pursuant to a deed in lieu thereof, or any successor to such assignee, shall not be
obligated to perform any duty, covenant or condition required to be performed by Landlord under any of the terms hereof (except for
obligations that first arise on and after such time as the Mortgagee shall obtain title to the Premises following foreclosure or
deed in lieu of foreclosure), but on the contrary, Tenant and Landlord, by their respective executions hereof, each acknowledge and
agree that notwithstanding any such assignment each and all of such duties, covenants or conditions required to be performed
by&#8239;Landlord shall survive any such assignment and shall be and remain the sole liability of Landlord. Subject to the prior
sentence, any transferee of Landlord&rsquo;s interest which acquires such interest from a Mortgagee, and any purchaser of such interest at
a foreclosure sale in respect of a Mortgage (or transferee of a deed in lieu of such a foreclosure), shall not be obligated to any
duty, covenant or condition required to be performed by Landlord under any of the terms hereof, which obligation first arises prior
to said transferee&rsquo;s or purchaser&rsquo;s acquisition of Landlord&rsquo;s interest under this Lease, shall not otherwise be liable for the
defaults of any prior Landlord hereunder and shall not be obligated to account for or be subject to any offset in respect of (and
Tenant shall be given no credit for) any payment of rent made more than thirty (30) days in advance of the due date of such payment
unless and then only to the extent such rental payment is actually received by such transferee. Without limiting the foregoing,
Tenant acknowledges and agrees that the rights of all such assignees, purchasers and transferees in and to Basic Rent and Additional
Rent shall not be subject to any abatement whatsoever, or be subject to any defense, setoff, counterclaim or recoupment or reduction
of any kind by reason of any event or circumstance which occurred prior to the date upon which any such assignee, purchaser or
transferee obtained title to the Premises or the Landlord&rsquo;s interest in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">24.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Estoppel
Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant shall
at any time and from time to time (but in no event more than twice in any twelve (12) month period, unless such request is in connection
with a prospective sale or financing of the Premises by Landlord, in which case Landlord shall not be so limited), within ten (10) Business
Days following receipt by Tenant of a written request therefor from Landlord or any Mortgagee, execute, acknowledge and deliver to such
requesting party executed Tenant&rsquo;s Certificates substantially in the forms attached hereto as <B>Exhibit 24-1</B> and <B>Exhibit 24-2;</B>
together with such other factually correct information pertaining to this Lease as may be reasonably requested by Landlord or any Mortgagee.
Any such certificate may be relied upon by any Mortgagee, prospective purchaser or prospective Mortgagee of the Premises or any interest
in Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Landlord shall
at any time and from time to time, within ten (10) Business Days following receipt by Landlord of a written request therefor from Tenant,
execute, acknowledge and deliver to Tenant (or as Tenant may reasonably direct), a certificate reciting factually correct information
pertaining to this Lease as reasonably requested by Tenant, including, without limitation, whether to Landlord&rsquo;s actual knowledge Tenant
is then in default hereunder, the last dates and amounts of Rent paid hereunder and the dates of any modifications to this Lease. Such
certificates may be relied upon by the parties to whom Tenant requests that they be addressed and their respective successors and assigns,
including Tenant&rsquo;s actual and prospective lenders, subtenants and assignees and any potential purchaser of Tenant or a direct or indirect
interest in Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">25.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>No
Merger.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">There shall be no
merger of this Lease or the leasehold estate hereby created with the fee estate in the Premises or any part thereof by reason of the same
person acquiring or holding, directly or indirectly, this Lease or the leasehold estate hereby created or any interest in this Lease or
in such leasehold estate as well as the fee estate in the Premises or any portion thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">26.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Surrender.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Upon expiration or earlier
termination of this Lease, Tenant shall peaceably surrender the Premises to Landlord in the condition in which the Premises is to be kept
under the other provisions of this Lease, including without limitation, Paragraph 10, ordinary wear and tear and damage by casualty excepted.
Tenant shall, at Tenant&rsquo;s expense, remove from the Premises prior to such expiration or termination all of Tenant&rsquo;s Property, and immediately
repair any damage caused by such removal. Any of Tenant&rsquo;s Property not so removed within ninety (90) days following such expiration or
earlier termination shall, at Landlord&rsquo;s election, become the property of Landlord. Landlord may thereafter cause such Tenant&rsquo;s Property
to be removed and disposed of and the cost of repairing any damage caused by such removal shall be borne by Tenant. Tenant shall not be
required to remove any Alterations unless Landlord designated at the time of its approval of such Alteration that such Alteration shall
be removed by Tenant upon expiration or sooner termination of this Lease. Landlord expressly agrees that Tenant shall not be obligated
at the expiration or earlier termination of this Lease to remove any of the Tenant Improvements (as defined in the Work Letter) that are
of a type and nature included in general office space offered for lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">27.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Severability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Each and every covenant
and agreement contained in this Lease is separate and independent, and the breach of any thereof by Landlord shall not discharge or relieve
Tenant from any obligation hereunder. <FONT STYLE="font-size: 10pt">If</FONT> any term or provision of this Lease or the application thereof
to any person or circumstances shall at any time be invalid and unenforceable, the remainder of this Lease, or the application of such
term or provision to persons or circumstances or at any time other than those to which it is invalid or unenforceable, shall not be affected
thereby, and each such remaining term and provision of this Lease shall valid and shall be enforced to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">28.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Savings
Clause.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">No provision contained
in this Lease which purports to obligate the Tenant to pay any amount of interest or any fees, costs or expenses which are in excess of
the maximum permitted by applicable Legal Requirements shall be effective to the extent that it calls for payment of any interest or other
sums in excess of such maximum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">29.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Binding
Effect.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Subject to Paragraph
23, all of the covenants, conditions and obligations contained in this Lease shall be binding upon and inure to the benefit of the respective
successors and assigns of Landlord and Tenant. No amendment of this Lease shall be effective unless expressed in writing executed by Landlord
and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">30.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Memorandum
of Lease.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">Simultaneously
with the execution and delivery hereof, Landlord and Tenant shall enter into and record, at Tenant&rsquo;s expense, a memorandum of this Lease
in the form of <B>Exhibit 30&#8239;</B>attached hereto. Following expiration or earlier termination of the Term, Tenant shall, at the
request of Landlord, execute an appropriate termination of such memorandum in recordable form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">31.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Table
of Contents; Headings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">The table of contents
and headings used in this Lease are for convenient reference only and shall not to any extent have the effect of modifying, amending or
changing the provisions of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">32.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Governing
Law; Litigation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">This
Lease shall be governed by and interpreted under the laws of the state in which the Premises are located. </FONT>In <FONT STYLE="font-size: 10pt">the
event of litigation between the parties with respect to this Lease, the losing party shall reimburse the prevailing party for all reasonable
attorneys&rsquo; fees and expenses incurred by the prevailing party with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">33.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Certain
Definitions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The term </FONT><B>&ldquo;Business Day&rdquo;</B> <FONT STYLE="font-size: 10pt">shall mean a day other than Saturday, Sunday or any day
on which regular U.S. mail is not delivered or banks are generally closed in the State of Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The term </FONT><B>&ldquo;Lease&rdquo;</B> <FONT STYLE="font-size: 10pt">means this Lease, as amended and modified from time to time, together
with any memorandum or short form of lease entered into for the purpose of recording.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The term </FONT><B>&ldquo;Landlord&rdquo;</B> <FONT STYLE="font-size: 10pt">means the owner of the rights of the Landlord under this Lease
and upon any assignment or transfer of such rights, except an assignment or transfer made as security for an obligation, any heirs, successors
and assigns. The assignor or transferor shall be relieved of all future duties and obligations under this Lease provided the assignee
or the transferee shall expressly agree in writing to be bound by and to assume all the covenants of Landlord hereunder arising from and
after such assignment or transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; An </FONT><B>&ldquo;Affiliate&rdquo;</B> <FONT STYLE="font-size: 10pt">of a party shall mean a person or entity (i) which directly or
indirectly through one or more intermediaries controls, or is controlled by, or is under a common control with, the applicable party,
(ii) which beneficially owns or holds fifty percent (50%) or more (by number of votes) of any class of the voting stock of the applicable
party, or (iii) fifty percent (50%) or more (by number of votes) of the voting stock (or in the case of a person which is not a corporation,
fifty percent (50%) or more of the equity interest) of which is beneficially owned or held by the applicable party or its Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The term </FONT><B>&ldquo;control&rdquo;</B> <FONT STYLE="font-size: 10pt">means the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of a person or entity through the ownership of voting securities, by contract
of otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
The term </FONT><B>&ldquo;Subsidiary&rdquo;</B> <FONT STYLE="font-size: 10pt">shall mean any Business Entity of which more than fifty percent
(50%) of the equity interests at the time outstanding shall at the time be owned,&#8239;directly or indirectly, by any other Business
Entity or collectively by any Business Entity and its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The term <B>&ldquo;Business
Entity&rdquo;</B> shall mean an entity other than an individual or a government agency or political subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The term <B>&ldquo;Person&rdquo;</B>
shall mean an individual, partnership, corporation, limited liability company, limited liability partnership, trust, unincorporated organization
or other business entity or a government or agency or political subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The term <B>&ldquo;Insurance
Expenses&rdquo;</B> shall mean all premiums, deductibles and other expenses actually incurred by Landlord with respect to the Landlord&rsquo;s
Required Coverage under Subparagraph 12(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">34.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Assignment
of Intangibles.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Landlord hereby
assigns to Tenant, without recourse, all Intangible Personal Property for use by Tenant during the Term. Such assignment shall terminate
upon the expiration or earlier termination of the Term or, if earlier, upon termination of Tenant&rsquo;s right of possession of the Premises
following the occurrence of an Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; No later than ninety
(90) days following the expiration or earlier termination of this Lease, Landlord may require in a written notice to Tenant that Tenant
assign to Landlord, effective as of such expiration or earlier termination of the Term, all rights of Tenant in and to such Intangible
Personal Property used by Tenant in connection with the Premises as is designated by Landlord in such notice, including, without limitation,
any contract rights, guaranties, licenses, permits, registrations and warranties (including without limitation licenses, permits and registrations
pertaining to any clean-up or remediation of Hazardous Material on or about the Premises to the extent such licenses, permits and registrations
may be assigned to Landlord) but excluding any trade names, service marks, corporate names, or other business licenses, phone numbers,
and the like, used by Tenant or its Affiliates or its assignees or subtenants in the operation of their respective businesses. Subject
to and without release of any obligation of Tenant to Landlord under this Lease which by the terms of this Lease survives the termination
or expiration of this Lease, including without limitation Tenant&rsquo;s indemnity obligations under Paragraphs 7 and <FONT STYLE="font-size: 10pt"><B>8
</B>of this Lease, Landlord shall assume any future obligations of Tenant in respect of any such assigned Intangible Personal Property
in form reasonably acceptable to Landlord and Tenant. Tenant shall execute such assignments and/or bills of sale of the Intangible Personal
Property as Landlord may reasonably request, provided the same do not impose any additional liability on Tenant and are otherwise reasonably
acceptable to Tenant. The obligations of Tenant under this Paragraph 34 shall survive the expiration or earlier termination of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">35.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.8pt">The following Exhibits
attached hereto are hereby incorporated by reference into this Lease and made a part hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt">Exhibit l(a) (Legal Description)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt">Exhibit 2(a) (Permitted Exceptions)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 112pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 2(b) (Work Letter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 4(a) (Renewal Options)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 5 (Basic Rent Chart)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 23 (Form of
SNDA)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 24-1 (Estoppel Certificate)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 24-2 (Estoppel Certificate)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 30 (Memorandum of
Lease)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt"><FONT STYLE="font-size: 10pt">Exhibit 41 (Guaranty)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt">36.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Landlord
Defaults; Exculpatory Clause.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.7pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event of any default by Landlord, Tenant shall have the right to exercise any legal or equitable remedies (except as otherwise provided
herein), but, prior to exercising any such remedies, Tenant shall give Landlord and any Mortgagee of whom Tenant has been provided written
notice, written notice specifying such default with particularity, and Landlord shall have a period of thirty (30) days following Landlord&rsquo;s
receipt of such written notice in which to cure such default; provided, however, that if such default reasonably requires more than thirty
(30) days to cure, Landlord shall have a reasonable period of time to cure such default, provided Landlord commences the cure within
such thirty (30) day period and thereafter diligently prosecutes such cure to completion. In no event shall Tenant have the right to
offset Rent, to terminate or rescind this Lease or to exercise self-help (except as expressly provided in this Lease or by applicable
Legal Requirements) as a result of Landlord&rsquo;s default. Notwithstanding anything to the contrary contained in this Lease, Landlord and
Tenant each hereby waives its right to recover consequential damages (including, but not limited to, lost profits), special damages or
punitive damages arising out of any default by the other.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.7pt"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a default by Landlord is curable but is not cured by Landlord within the applicable notice and cure period (and Landlord has in fact
ceased efforts to cure same), and provided that the cure of such default will have no material adverse effect on the Building Structure,
Tenant may, upon five (5) Business Days&rsquo; prior written notice to Landlord (or sooner, if a bona fide emergency), cure the default and
bill Landlord for the actual out-of-pocket costs incurred by Tenant to cure the default, which shall be due within thirty (30) days following
invoice. Tenant shall not have the right to offset Rent for any sums due hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.55pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
any provision of this Lease to the contrary, the liability of Landlord under and with respect to this Lease shall be limited to the interest
of Landlord in the Premises, and, upon assignment by Landlord, any sales proceeds resulting from such sale as to any then existing default
by Landlord hereunder and any judgment in favor of Tenant or any party claiming by, through or under Tenant against Landlord shall be
collectible only out of Landlord&rsquo;s interest in the Premises and any proceeds, rents, awards, and income derived therefrom, and in no
event shall any judgment for damages be entered against Landlord which is in excess of the value of such interest plus such proceeds,
rents, awards, and income. IN FURTHERANCE OF THE FOREGOING, AND EXCEPT TO THE EXTENT TENANT IS A JUDGMENT CREDITOR AS HEREINABOVE DESCRIBED,
TENANT HEREBY WAIVES ITS STATUTORY LIEN UNDER SECTION 91.004 OF THE TEXAS PROPERTY CODE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt">37.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Jury
Waiver.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 68.65pt"><FONT STYLE="font-size: 10pt">LANDLORD
AND TENANT WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY OF ANY CONTRACT OR TORT CLAIM, COUNTERCLAIM, CROSS-COMPLAINT, OR CAUSE OF ACTION
IN ANY ACTION, PROCEEDINGS, OR HEARING BROUGHT BY EITHER PARTY AGAINST THE OTHER ON ANY MATTER ARISING OUT OF OR IN ANY WAY CONNECTED
WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, OR TENANT&rsquo;S USE OR OCCUPANCY OF THE PREMISES, INCLUDING WITHOUT LIMITATION
ANY CLAIM OF INJURY OR DAMAGE OR THE ENFORCEMENT OF ANY REMEDY UNDER ANY CURRENT OR FUTURE LAW, STATUTE, REGULATION, CODE, OR ORDINANCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt">38.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Quiet
Enjoyment.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.45pt"><FONT STYLE="font-size: 10pt">So
long as an Event of Default does not exist, Tenant shall be entitled to peaceful and quiet enjoyment of the Premises, subject, however,
to the express terms and conditions of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.7pt"><FONT STYLE="font-size: 10pt">39.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Landlord&rsquo;s Representations and Warranties.</B> Landlord represents
and warrants to Tenant that, as of the Effective Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.3pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Conflict;
Title</U>. This Lease does not conflict with, and its execution by Landlord shall not result in a default or event of default under,
any other agreement to which Landlord is bound. As of the Effective Date, there is no debt or mortgage lien granted by Landlord or any
Affiliate of Landlord and encumbering the Premises other than the Deed of Trust, Assignment of Leases and Rents, and Security Agreement
dated on or about the date hereof in favor of Citibank, N.A. Landlord will provide Tenant with a copy of Landlord&rsquo;s title insurance policy
for the Premises (together with copies of any exception documents referenced therein) within ten (10) Business Days following receipt
thereof by Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 68.85pt"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Claims
or Proceedings</U>. To Landlord&rsquo;s knowledge, there are no claims, causes of action or other proceedings pending or threatened in respect
to the ownership, operation or environmental condition of the Premises or any part thereof, except for claims which are fully insured
and as to which the insurer has accepted defense without reservation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Condemnation.
Etc</U>. To Landlord&rsquo;s knowledge, there is no existing, pending or contemplated, threatened or anticipated condemnation of any part of
the Premises, repaving, widening, change of grade or limitation on use of streets, roads, or highways abutting, change in the zoning
classification of the Premises, or special tax or assessment to be levied against the Premises due to capital improvements to be constructed
on, near or adjacent to the Premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.1pt"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Hazardous
Materials</U>. Other than any matters disclosed in that certain Phase I Environmental Site Assessment dated June 17, 2019 and prepared
by EBI Consulting under Project No. 1119003692, to Landlord&rsquo;s knowledge, there are no Hazardous Materials in the Building or the Premises,
other than those in compliance with Legal Requirements and Environmental Laws that are customarily used in connection with the operation
and maintenance of an office building.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.1pt"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Prohibited
Persons and Transactions</U>. Landlord represents and warrants to Tenant that Landlord is currently in compliance with and shall at times
during the Term (including any extension thereof) remain in compliance with the regulations of Office of Foreign Asset Control (the <B>&ldquo;OFAC&rdquo;)
</B>of the Department of the Treasury (including those named on OFAC&rsquo;s Specially Designated and Blocked Persons List) and any statute,
executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit,
Threaten to Commit, or Support Terrorism), or other governmental action relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt"><FONT STYLE="font-size: 10pt">As
used herein, <B>&ldquo;Landlord&rsquo;s knowledge&rdquo;</B> means the actual (not constructive or imputed) knowledge of Daniel Amer and Emily
Jones (<B>&ldquo;Landlord&rsquo;s Representatives&rdquo;</B>) as of the Effective Date after performing reasonable inspections of his or her
files regarding the Premises. Landlord represents and warrants to Tenant that Landlord&rsquo;s Representatives are the individuals within Landlord&rsquo;s
organization most familiar with the Building and Premises and most likely to know the information subject to Landlord&rsquo;s representations
and warranties hereunder. Tenant acknowledges and agrees that Landlord&rsquo;s Representatives are named solely for the purpose of defining
and narrowing the scope of knowledge of Landlord and not for the purpose of imposing any liability or creating any duties running from
such individuals to Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 35.1pt"><FONT STYLE="font-size: 10pt">40.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Tenant
Allowance and Tenant Improvements. </B>Landlord will provide to Tenant the Allowance (as defined in the Work Letter) to be applied to
the cost of the Tenant Improvement Costs as set forth in the Work Letter attached as <B>Exhibit 2(b)</B> hereto, which Work Letter is
hereby&nbsp;made a part of this Lease, and its provisions shall control in the event of a conflict with the provisions contained in this
Lease. If Landlord fails to pay to Tenant any installment of the Allowance within thirty (30) days following the date when due pursuant
to the Work Letter, then such late payment shall bear interest at the Default Rate from the date due until paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 35.15pt"></TD><TD STYLE="font-size: 10pt; width: 34.85pt"><FONT STYLE="font-size: 10pt">41.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Guaranty.
                                            </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.55pt"><FONT STYLE="font-size: 10pt">The
obligations of Tenant under this Lease are guaranteed by Caris Life Sciences, Ltd., a Cayman Islands exempted limited company (<B>&ldquo;Guarantor&rdquo;)
</B>pursuant to a Guaranty of substantially even date herewith in the form attached hereto as <B>Exhibit 41</B> and made a part hereof
for all purposes (the <B>&ldquo;Guaranty&rdquo;</B>). Landlord&rsquo;s receipt of the Guaranty, duly executed by the Guarantor, shall be a condition
to the effectiveness of this Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt">42.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Letter
of Credit.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.25pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall deliver to Landlord, within ten (10) Business Days after Tenant&rsquo;s execution of this Lease, an unconditional, clean, irrevocable
letter of credit (the <B>&ldquo;L-C&rdquo;</B>) in the amount set forth in Paragraph 42(c) below (the <B>&ldquo;L-C Amount&rdquo;</B>), which
L-C shall be issued by a money-center, solvent and nationally recognized bank (a bank which accepts deposits, maintains accounts, has
a local Dallas, Texas office which will negotiate a letter of credit, and whose deposits are insured by the FDIC) reasonably acceptable
to Landlord (such approved, issuing bank being referred to herein as the <B>&ldquo;Bank&rdquo;</B>), which Bank must have either (i) an
S&amp;P long term rating of A (or better) and an S&amp;P short term rating of A-1 (or better) or (ii) a Moody&rsquo;s long term rating of A2
(or better) and a Moody&rsquo;s short term rating of <B>P-1</B> (or better) (collectively, the <B>&ldquo;Bank&rsquo;s Credit Rating Threshold&rdquo;),
</B>and which L-C shall be in form and substance reasonably acceptable to Landlord. Tenant shall pay all expenses, points and/or fees
incurred by Tenant in obtaining the L-C. The L-C shall (i) be &ldquo;callable&rdquo; at sight, irrevocable and unconditional, (ii) subject
to <U>Subparagraph 42(c)</U>, be maintained in effect, whether through renewal or extension, for the period commencing on or about the
date of this Lease and continuing until the date (the <B>&ldquo;L-C Expiration Date&rdquo;</B>) that is no less than one hundred twenty
(120) days after the expiration of the Term, and Tenant shall deliver a new L-C or certificate of renewal or extension to Landlord at
least sixty (60) days prior to the expiration of the L-C then held by Landlord, without any action whatsoever on the part of Landlord,
(iii) be fully assignable by Landlord, its successors and assigns, (iv) permit partial draws and multiple presentations and drawings,
and (v) be otherwise subject to the Uniform Customs and Practices for Documentary Credits (1993-Rev), International Chamber of Commerce
Publication #500, or the International Standby Practices-ISP 98, International Chamber of Commerce Publication #590. Landlord, or its
then managing agent, shall have the right to draw down an amount up to the face amount of the L-C if any of the following shall have
occurred or be applicable: (A) such amount is due to Landlord under the terms and conditions of this Lease and Tenant has not paid such
amount as and when due hereunder after taking into account any applicable notice and cure period, or (B) Tenant has filed a voluntary
petition under the U.S. Bankruptcy Code or any state bankruptcy code (collectively, <B>&ldquo;Bankruptcy Code&rdquo;</B>), or (C) an involuntary
petition has been filed against Tenant under the Bankruptcy Code and remains undismissed for ninety (90) days, or (D) the Lease has been
rejected, or is deemed rejected, under Section 365 of the U.S. Bankruptcy Code, following the filing of a voluntary petition by Tenant
under the Bankruptcy Code, or the filing of an involuntary petition against Tenant under the Bankruptcy Code which remains undismissed
for ninety (90) days, or (E) the Bank has notified Landlord that the L-C will not be renewed or extended through the L-C Expiration Date,
or (F) Tenant is placed into receivership or conservatorship, or becomes subject to similar proceedings under Federal or State law, or
(G) Tenant executes an assignment for the benefit of creditors, or (H) if (1) any of the Bank&rsquo;s Fitch Ratings (or other comparable ratings
to the extent the Fitch Ratings are no longer available) have been reduced below the Bank&rsquo;s Credit Rating Threshold, or (2) there is
otherwise a material adverse change in the financial condition of the Bank, and Tenant has failed to provide Landlord with a replacement
letter of credit, conforming in all respects to the requirements of this Paragraph 42 (including, but not limited to, the requirements
placed on the issuing Bank more particularly set forth in this Paragraph 42(a)), in the amount of the applicable L-C Amount, within thirty
(30) days following Landlord&rsquo;s written demand therefor (with no other notice or cure or grace period being applicable thereto, notwithstanding
anything in this Lease to the contrary) (each of the foregoing being an <B>&ldquo;L-C Draw Event&rdquo;</B>). The L-C shall be honored
by the Bank regardless of whether Tenant disputes Landlord&rsquo;s right to draw upon the L-C. In the event of an assignment by Tenant of its
interest in this Lease (and irrespective of whether Landlord&rsquo;s consent is required for such assignment), the acceptance of any replacement
or substitute letter of credit by Landlord from the assignee shall be subject to Landlord&rsquo;s prior written approval, in Landlord&rsquo;s sole
and absolute discretion, and any reasonable attorney&rsquo;s fees incurred by Landlord in connection with such determination shall be payable
by Tenant to Landlord within thirty (30) days of billing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.85pt"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
hereby acknowledges and agrees that Landlord is entering into this Lease in material reliance upon the ability of Landlord to draw upon
the L-C upon the occurrence of any L-C Draw Event. In the event of any L-C Draw Event, Landlord may, but without obligation to do so,
and without notice to Tenant (except in connection with an L-C Draw Event under Paragraph 42(a)(H) above), draw upon the L-C, in part
or in whole, to cure any such L-C Draw Event and to compensate Landlord for any and all damages of any kind or nature sustained resulting
from Tenant&rsquo;s Event of Default under this Lease or other L-C Draw Event and to compensate Landlord for any and all damages arising out
of, or incurred in connection with, the termination of this Lease as a result of such Event of Default. The use, application or retention
of the L-C, or any portion thereof, by Landlord shall not prevent Landlord from exercising any other right or remedy provided by this
Lease or by any applicable Legal Requirement, it being intended that Landlord shall not first be required to proceed against the L-C,
and such L-C shall not operate as a limitation on any recovery to which Landlord may otherwise be entitled. Tenant agrees and acknowledges
that (i) the L-C constitutes a separate and independent contract between Landlord and the Bank, (ii) Tenant is not a third-party beneficiary
of such contract, (iii) Tenant has no property interest whatsoever in the L-C or the proceeds thereof, and (iv) in the event Tenant becomes
a debtor under any chapter of the Bankruptcy Code, Tenant is placed into receivership or conservatorship, or there is an event of a receivership,
conservatorship or a bankruptcy filing by, or on behalf of, Tenant, neither Tenant, any trustee, nor Tenant&rsquo;s bankruptcy estate shall
have any right to restrict or limit Landlord&rsquo;s claim and/or rights to the L-C or the proceeds thereof by application of Section 502(b)(6)
of the U.S. Bankruptcy Code or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.5pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;
The L-C Amount shall initially be equal to the amount of $3,435,000.00. Subject to the terms and conditions of Subparagraphs 42(c), and
provided that the Reduction Condition (as defined below) is satisfied on each applicable Reduction Date (as defined below), the L-C Amount
shall be reduced as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121"><B>Date
    of Reduction <BR></B></FONT><B>(each, a &ldquo;Reduction Date&rdquo;</B>)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; color: #212121"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; color: #212121; text-align: center"><FONT STYLE="font-size: 10pt">Amount
    of Reduction</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; color: #212121"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; color: #212121"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; color: #212121; text-align: center"><FONT STYLE="font-size: 10pt">Remaining
    L-C Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; color: #212121"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">3,091,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">2,748,000.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">2,404,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">2,061,000.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">1,717,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">1,374,000.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2029</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">1,030,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">687,000.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2031</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">June
    1, 2032</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">343,500.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #212121; text-align: right"><FONT STYLE="font-size: 10pt">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; color: #212121; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.35pt"><FONT STYLE="font-size: 10pt">(d)
 &#8239;&#8239;&#8239;&#8239;&#8239;The reduction of the L-C Amount is subject to each of the following conditions (collectively, the
<B>&ldquo;<U>Reduction Condition</U>&rdquo;):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 138pt"><FONT STYLE="font-size: 10pt">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
of the applicable Reduction Date, no Event of Default then exists; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 138.7pt"><FONT STYLE="font-size: 10pt">(2)
 &#8239;&#8239;&#8239;&#8239;The audited financial statements (as provided in Paragraph I 7) for the fiscal year immediately preceding
the applicable Reduction Date evidence that Tenant and Guarantor had an aggregate Tangible Net Worth in excess of $25,000,000.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.55pt"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;
In the event that Tenant is eligible for a reduction of the L-C Amount, Tenant shall have the right to reduce the L-C Amount as set forth
above via the delivery to Landlord of either (x) an amendment to the existing L-C (in form and content reasonably acceptable to Landlord)
modifying the L-C Amount to the amount then required under this Paragraph 42, or (y) an entirely new L-C (in the form and content otherwise
required in this Paragraph 42) in the total L-C Amount then required under this Paragraph 42 (in which instance Landlord shall promptly
return to Tenant the previously delivered L-C upon Landlord&rsquo;s receipt of the replacement L-C).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
If, as a result of any drawing by Landlord of all or any portion of the L-C, the amount of the L-C shall be less than the then-required
L-C Amount, Tenant shall, within five (5) Business Days thereafter, provide Landlord with additional letter(s) of credit in an amount
equal to the deficiency, and any such additional letter(s) of credit shall comply with all of the provisions of this Paragraph 42. Tenant
further covenants and warrants that it will neither assign nor encumber the L-C or any part thereof and that neither Landlord nor its
successors or assigns will be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance. Without limiting
the generality of the foregoing, if the L-C expires earlier than the L-C Expiration Date, Landlord will accept a renewal thereof (such
renewal letter of credit to be in effect and delivered to Landlord, as applicable, not later than sixty (60) days prior to the expiration
of the L-C then held by Landlord), which shall be irrevocable and automatically renewable as above provided through the L-C Expiration
Date upon the same terms as the expiring L-C or such other terms as may be acceptable to Landlord in its sole discretion. If the L-C
is not timely renewed, or if Tenant fails to maintain the L-C in the amount and in accordance with the terms set forth in this Paragraph
42, Landlord shall have the right to present the L-C to the Bank in accordance with the terms of this Paragraph 42, and the proceeds
of the L-C shall be applied by Landlord against any Rent payable by Tenant under this Lease that is not paid when due and/or to pay for
all losses and damages that Landlord has suffered as a result of any Event of Default by Tenant under this Lease. In such event (i) any
unused proceeds shall constitute the property of Landlord (and not Tenant&rsquo;s property or, in the event of a receivership, conservatorship,
or a bankruptcy filing by, or on behalf of, Tenant, property of such receivership, conservatorship or Tenant&rsquo;s bankruptcy estate) and
need not be segregated from Landlord&rsquo;s other assets, but shall be applied by Landlord to Tenant&rsquo;s obligations under this Lease as they
become due, and (ii) Landlord agrees to pay to Tenant within thirty (30) days after the L-C Expiration Date the amount of any proceeds
of the L-C received by Landlord and not applied against any Rent payable by Tenant under this Lease that was not paid when due or used
to pay for any losses and/or damages suffered by Landlord as a result of any Event of Default by Tenant under this Lease; <U>provided,
however</U>, that if prior to the L-C Expiration Date a voluntary petition is filed by Tenant, or an involuntary petition is filed against
Tenant by any of Tenant&rsquo;s creditors, under the Bankruptcy Code, then Landlord shall not be obligated to make such payment in the amount
of the unused L-C proceeds until either all preference issues relating to payments under this Lease have been resolved in such bankruptcy
or reorganization case or such bankruptcy or reorganization case has been dismissed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.95pt"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;
The L-C shall also provide that Landlord may, at any time and without notice to Tenant and without first obtaining Tenant&rsquo;s consent thereto,
transfer (one or more times) all or any portion of its interest in and to the L-C to another party, person or entity, in connection with
the assignment by Landlord of its rights and interests in and to this Lease. In the event of a transfer of Landlord&rsquo;s interest in under
this Lease, Landlord shall transfer the L-C, in whole or in part, to the transferee and thereupon Landlord shall, without any further
agreement between the parties, be released by Tenant from all liability therefor to the extent so transferred, and it is agreed that
the provisions hereof shall apply to every transfer or assignment of the whole of said L-C to a new landlord. Other than in connection
with an assignment of the Lease as security for a mortgage or deed of trust now or later encumbering the Premises or any portion thereof,
Landlord shall not transfer the Letter of Credit except to a transferee of Landlord&rsquo;s interest in the Lease. In connection with any such
transfer of the L-C by Landlord, Tenant shall, at Tenant&rsquo;s sole cost and expense, execute and submit to the Bank such applications, documents
and instruments as may be reasonably necessary to effectuate such transfer and Tenant shall be responsible for paying the Bank&rsquo;s transfer
and processing fees in connection therewith; provided that, Landlord shall have the right (in its sole discretion), but not the obligation,
to pay such fees on behalf of Tenant, <B>in</B> which case Tenant shall reimburse Landlord within ten (10) Business Days after Tenant&rsquo;s
receipt of an invoice from Landlord therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.75pt"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord and Tenant (i) acknowledge and agree that in no event or circumstance shall the L-C or any renewal thereof or substitute therefor
or any proceeds thereof be deemed to be or treated as a &ldquo;security deposit&rdquo; under any law applicable to security deposits in
the commercial context, as such section now exists or as it may be hereafter amended or succeeded (the <B>&ldquo;Security Deposit Laws&rdquo;),
</B>(ii) acknowledge and agree that the L-C (including any renewal thereof or substitute therefor or any proceeds thereof) is not intended
to serve as a security deposit, and the Security Deposit Laws shall have no applicability or relevancy thereto, and (iii) waive any and
all rights, duties and obligations that any such party may now, or in the future will, have relating to or arising from the Security
Deposit Laws. Tenant hereby irrevocably waives and relinquishes the provisions of any law, now or hereafter in effect, which (x) establish
the time frame by which a landlord must refund a security deposit under a lease, and/or (y) provide that a landlord or sublandlord may
claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of rent, to repair damage caused
by a tenant or to clean the premises, it being agreed that Landlord may, in addition, claim those sums specified in this Paragraph 42
and those sums reasonably necessary to (A) compensate Landlord for any loss or damage caused by an Event of Default by Tenant under this
Lease, including any damages Landlord suffers following termination of this Lease as a result of such Event of Default, and/or (B) compensate
Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease as a result of an Event
of Default by Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 69.5pt"><FONT STYLE="font-size: 10pt">(i)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant agrees not to interfere in any way with any payment to Landlord of the proceeds of the
L-C, either prior to or following a &ldquo;draw&rdquo; by Landlord of all or any portion of the L-C, regardless of whether any dispute
exists between Tenant and Landlord as to Landlord&rsquo;s right to draw down all or any portion of the L-C. No condition or term of this Lease
shall be deemed to render the L-C conditional and thereby afford the Bank a justification for failing to honor a drawing upon such L-C
in a timely manner. Tenant shall not request or instruct the Bank of any L-C to refrain from paying sight draft(s) drawn under such L-C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt">43.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;<B><U>DTPA</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 34.75pt"><FONT STYLE="font-size: 10pt">TENANT
HEREBY WAIVES ALL ITS RIGHTS UNDER THE DECEPTIVE TRADE PRACTICES - CONSUMER PROTECTION ACT, SECTION 17.41 ET SEQ. OF THE TEXAS BUSINESS
AND COMMERCE CODE, A LAW THAT GIVES CONSUMERS SPECIAL RIGHTS AND PROTECTIONS. AFTER CONSULTATION WITH AN ATTORNEY OF TENANT&rsquo;S OWN SELECTION,
TENANT VOLUNTARILY CONSENTS TO THIS WAIVER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.1pt"><FONT STYLE="font-size: 10pt">44.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Roof
Rights</U>. </B>Tenant shall have the right to use a portion of the roof area of the Building to install, repair and maintain a satellite
antenna dish with associated antennae and cables (the <B>&ldquo;Satellite System&rdquo;</B>), provided that the Satellite System is not
greater than three (3) feet in diameter, does not protrude above the parapet wall of the Building, the weight of the Satellite System
is less than one hundred fifty (150) pounds and does not impair the structural integrity of the roof. The installation and operation
of the Satellite System shall be at Tenant&rsquo;s sole cost and expense. Prior to the installation of the Satellite System, Tenant shall obtain
Landlord&rsquo;s prior approval, which will not be unreasonably withheld, delayed or conditioned, of the location, type and method of installation
of the Satellite System. Landlord may condition its approval on Tenant&rsquo;s ensuring that such installation or the maintenance of the Satellite
System does not invalidate any roof warranties in favor of Landlord. Tenant agrees to hire a roofing contractor approved by Landlord
for all penetrations, attachments or other work to the roof. Tenant shall, at its sole cost and expense, comply with all applicable Legal
Requirements, including but not limited to securing all necessary permits for the installation and operation of the Satellite System.
Tenant shall be solely responsible for the maintenance of the Satellite System. Tenant shall be responsible for liability and property
insurance for the Satellite System consistent with the requirements of this Lease. In the event the Satellite System causes interference
to equipment used by Landlord, Tenant shall use reasonable efforts, and shall cooperate with Landlord to promptly eliminate such interference.
Tenant shall, upon the expiration or termination of this Lease, at its sole cost and expense, remove the Satellite System and repair
any damage to the roof or other parts of the Building caused by such removal and return that portion of the roof of the Building that
has been affected by the Satellite System to the condition it was in prior to the installation of the Satellite System, normal wear and
tear and casualty excepted. Landlord shall not charge Tenant for the use of the roof space for the Satellite System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.1pt"><FONT STYLE="font-size: 10pt">45.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Broker</U>.
</B>Landlord and Tenant each represent and warrant that it has dealt with no broker, agent or other person in connection with this Lease
other than ESRP Advisory Dallas, LLC (<B>&ldquo;Broker&rdquo;</B>) and each party agrees to indemnify and hold the other party harmless
from and against any claims by any other broker, agent or other persons claiming a commission or other form of compensation by virtue
of having dealt with the party other than Broker with regard to this leasing transaction. Landlord covenants and agrees to pay the lease
commissions due to Broker for services performed in connection with this Lease pursuant to the written lease commission agreement between
Landlord and Broker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.1pt"><FONT STYLE="font-size: 10pt">46.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<B><U>Authoritv</U>. </B>Landlord and Tenant each represent and warrant to the other that such party is duly organized, validly existing,
and in good standing under the laws of the state of its organization, and is duly qualified to transact business in Texas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.4pt"><FONT STYLE="font-size: 10pt">4
7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Counterparts</U>. </B>This Lease may be executed in separate counterparts,
each such counterpart being deemed an original, and all of which taken together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.15pt"><FONT STYLE="font-size: 10pt">48.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<B><U>OFAC</U>. </B>Tenant represents and warrants to Landlord that Tenant is currently in compliance
with and shall at times during the Term (including any extension thereof) remain in compliance with the OFAC regulations of the
Department of the Treasury (including those named on OFAC&rsquo;s Specially Designated and Blocked Persons List) and any statute,
executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who
Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt"><FONT STYLE="font-size: 10pt">49.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<B><U>Force Majeure</U>. </B>Neither party shall be held responsible for delays in the performance of its obligations
hereunder when caused by acts of terrorists, war (whether declared or not) or national conflicts; strikes, lockouts, labor disputes,
boycotts or work stoppages not caused by or limited to such party, or its contractors or subcontractors; natural disasters, such as earthquake,
hurricane or flood; governmental restrictions, regulations or controls; or delay in obtaining or inability to obtain labor, materials
or reasonable substitutes therefor, any of which (a) could not reasonably have been anticipated by such party; (b) is beyond the reasonable
control of such party; and (c) could not be prevented or overcome, wholly or in part, by the exercise of due diligence by such party
(<B>&ldquo;Force Majeure&rdquo;</B>), <B>provided that this shall not apply (i) to excuse any failure of either party to comply with any
monetary obligations hereunder.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.75pt"><FONT STYLE="font-size: 10pt">50.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<B><U>Calculation of Charges</U>. </B>Landlord and Tenant are knowledgeable and experienced in
commercial transactions and agree that each provision of this Lease for determining charges, amounts and additional rental payments
by Tenant are commercially reasonable, and as to each such charge or amount, constitutes a &ldquo;method by which the charge is to be
computed&rdquo; for purposes of Section 93.012 (Assessment of Charges) of the Texas Property Code, as such section now exists or as
it may be hereafter amended or succeeded, even though such methods may not state a precise mathematical formula for determining such
charges. ACCORDINGLY, TENANT VOLUNTARILY AND KNOWINGLY WAIVES ALL RIGHTS AND BENEFITS OF TENANT UNDER SECTION 93.012 OF THE TEXAS
PROPERTY CODE; provided, however, that nothing contained in this waiver however is intended to limit or impair, except as otherwise
expressly set forth in this Lease to the contrary, any other remedy available to Tenant under this Lease or at law or in equity
(other than Section 93.012, Texas Property Code). In addition, nothing in this Paragraph 50 shall constitute a waiver of Tenant&rsquo;s
right to dispute and/or initiate a claim disputing Landlord&rsquo;s methods of calculating or determining amounts owed by Tenant hereunder
and/or Landlord&rsquo;s calculation or determination of Additional Rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Signature
page follows.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 69.85pt"><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF,
the parties hereto have executed this Lease as of the day and year first above set forth.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">LANDLORD:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">KCP NNN II LEASEHOLD 4, LLC,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">a Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/
    Daniel Ades&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Daniel Ades</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">TENANT:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARIS MPI, INC.,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">a Texas corporation</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/
    David D. Halbert</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CEO</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[<I>Signature Page to Lease</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
l(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>LEGAL
DESCRIPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
2(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>PERMITTED
EXCEPTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
2(b)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>WORK
LETTER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt">THIS
WORK LETTER (this <B>&ldquo;Work Letter&rdquo;</B>) is attached to and made a part of the Lease dated July___, 2019 (the <B>&ldquo;Lease&rdquo;</B>), by
and between <B>KCP NNN</B> II <B>LEASEHOLD 4, LLC,</B> a Delaware limited liability company (<B>&ldquo;Landlord&rdquo;</B>), and <B>CARIS
MPI, INC.,</B> a Texas corporation (<B>&ldquo;Tenant&rdquo;</B>), for the Premises described in the Lease. Capitalized terms used but
not otherwise defined in this Work Letter shall have the meanings set forth in the Lease. This Work Letter is attached to, and forms
a part of, the Lease. Should any inconsistency arise between this Work Letter and any other provision of the Lease as to the
specific matters which are the subject of this Work Letter, the terms and conditions of this Exhibit shall control. Time is of the
essence of this Work Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Acceptance
of Premises</U>. Except as set forth in the Lease or this Work Letter, Tenant accepts the Premises in their AS-IS condition on the Effective
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;2.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tenant Improvements</U>. This Work Letter sets forth the agreement
with respect to the construction of the Tenant Improvements (as defined below). All improvements to the Premises and/or the Building
constructed by Tenant pursuant to this Work Letter are referred to herein collectively as the <B>&ldquo;Tenant Improvements.&rdquo;</B>
The terms, definitions and other provisions of the Lease are hereby incorporated into this Work Letter by reference. In accordance with
the provisions of this Work Letter, Tenant will construct and install the Tenant Improvements in the Premises in accordance with the
Final Plans (defined below), at Tenant&rsquo;s sole cost and expense, subject to payment of the Allowance pursuant to the terms and conditions
herein. Tenant shall diligently pursue the completion of such Tenant Improvements pursuant to the terms and conditions of this Work Letter.
Tenant anticipates completing the Tenant Improvements and occupying the Premises in accordance with the following timeline:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border: Black 1pt solid; text-align: center; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Phase</U></B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Location</U></B></FONT></TD>
    <TD STYLE="font-size: 10pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Anticipated
    Occupancy Date</U></B></FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.05in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approx.&nbsp;&nbsp;57,250&nbsp;&nbsp;square&nbsp;&nbsp;feet&nbsp;&nbsp;of&nbsp;&nbsp;the
    Building</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 1pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    or about August 1, 2020</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II</FONT></TD>
    <TD STYLE="padding-left: 0.05in; border-bottom: Black 1pt solid; text-align: left; padding-right: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approx.&nbsp;&nbsp;28,625&nbsp;&nbsp;square&nbsp;&nbsp;feet&nbsp;&nbsp;of&nbsp;&nbsp;the
    Building</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    or about April 1, 2022</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center; border-left: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III</FONT></TD>
    <TD STYLE="padding-left: 0.05in; border-bottom: Black 1pt solid; text-align: left; padding-right: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approx.&nbsp;&nbsp;28,625&nbsp;&nbsp;square&nbsp;&nbsp;feet&nbsp;&nbsp;of&nbsp;&nbsp;the
    Building</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center; border-left: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    or about April 1, 2023</FONT></TD>
    </TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 68.95pt"><FONT STYLE="font-size: 10pt">Each
of Phase I, Phase II and Phase III described above may be referred to herein as a <B>&ldquo;Phase&rdquo;</B> and collectively as <B>&ldquo;Phases&rdquo;.
</B>Tenant shall have no liability in the event of a failure to meet all or any of the foregoing anticipated occupancy dates, each of
the same being an estimate only. Tenant may, in its sole discretion, accelerate the occupancy date of a Phase without Landlord&rsquo;s
prior written consent. Tenant shall not materially modify the size of the Phases without Landlord&rsquo;s prior written consent, which
consent shall not be unreasonably delayed, conditioned or withheld, <U>provided</U>, <U>however,</U> no such modification nor the failure
to meet all or any of the anticipated occupancy dates shall affect Tenant&rsquo;s obligation to pay Basic Rent or Additional Rent as
and when required by the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;3.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Plans and Specifications; Permits</U>. It is agreed that Tenant will
develop plans and necessary specifications for completion of the Tenant Improvements in accordance with this Work Letter and the following
provisions and procedures:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.75pt"><FONT STYLE="font-size: 10pt">(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;No later than one hundred (100) days after the Effective Date with respect to Phase I and, with respect
to the other Phases, no later than one hundred fifty (150) days prior to the anticipated construction start date for such Phase, Tenant
shall submit or cause Tenant&rsquo;s architect to submit to Landlord, for Landlord&rsquo;s review and approval, a space plan for the applicable Phase
(the <B>&ldquo;Space Plan&rdquo;</B>), showing the final layout for such Phase, including without limitation, all exterior improvements,
walls, corridors, entrances, exits, doors and interior partitions, and the locations of all kitchens, beverage and dining areas, reception
area(s), and other areas required for Tenant&rsquo;s occupancy, in sufficient form to serve as the basis for the Construction Drawings for
such Phase. Within ten (10) Business Days after Landlord receives the Space Plan, Landlord shall either approve or not approve the Space
Plan based on the following matters (individually, a <B>&ldquo;Design Issue&rdquo; </B>and, collectively, the <B>&ldquo;Design Issues&rdquo;):
</B>(i) adverse effect on or incompatibility with the Building Structure or Building Systems; (ii) effect on the exterior appearance
of the Building or other exterior portions of the Premises, (iii) conflict, inconsistency or incompatibility with the base building design,
(iv) non-compliance with applicable Legal Requirements, or (v) omissions or other missing or incomplete information. If Landlord does
not approve such Space Plan, Landlord shall provide Tenant with specific written comments detailing the reasons Landlord denied approval.
Tenant shall cause such Space Plan to be revised to address Landlord&rsquo;s comments, and shall resubmit same for Landlord&rsquo;s review and approval
in accordance with this Section (except that the time period for Landlord&rsquo;s response shall be three (3) Business Days for subsequent
submissions). This procedure shall be repeated until the Space Plan is finally approved by Landlord and written approval has been delivered
to and received by Tenant (such date, as applicable, the <B>&ldquo;Space Plan Approval Date&rdquo;</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.75pt"><FONT STYLE="font-size: 10pt">(b)
 &#8239;&#8239;&#8239;&#8239;No later than seventy-five (75) days after each Space Plan Approval Date, Tenant shall prepare or cause
Tenant&rsquo;s architect to prepare (based on the Space Plan for such Phase as finally approved by Tenant and Landlord) and deliver
to Landlord written drawings, plans and specifications for the construction of the Tenant Improvements in such Phase (collectively,
the <B>&ldquo;Construction Drawings&rdquo;</B>). The Construction Drawings for each Phase shall include, without limitation, (i)
fully dimensioned architectural plans; (ii) reflective ceiling plan with light switches; (iii) electric power circuitry diagram;
(iv) complete structural (if required), mechanical, electrical, plumbing, HVAC, telecommunication and cabling plans; (v) color and
finish selections; and (vi) all such other information or plans as may be required for the construction of the Tenant Improvements
in such Phase. Tenant&rsquo;s architect shall consult with Landlord&rsquo;s architect, Landlord&rsquo;s engineer(s) and other
Building design professionals designated by Landlord in the preparation of the Construction Drawings with respect to the Building
Structure and Building Systems. The Construction Drawings shall be in form and content sufficient for submission to the applicable
governmental authority, to obtain all necessary building permits for completion of the Tenant Improvements contemplated therein.
Within ten (10) Business Days after Landlord receives the Construction Drawings for a Phase, Landlord shall either approve or not
approve such Construction Drawings based on the Design Issues. If Landlord does not approve the Construction Drawings, Landlord
shall provide Tenant with specific written comments detailing the reasons Landlord denied approval. Tenant shall cause the
Construction Drawings to be revised to address Landlord&rsquo;s comments and shall resubmit same for Landlord&rsquo;s review and
approval in accordance with this Section within ten (10) Business Days of receiving Landlord&rsquo;s written comments, except that
the time period for Landlord&rsquo;s response shall be three (3) Business Days for subsequent submissions. This procedure shall be
repeated until the Construction Drawings for a Phase are finally approved by Landlord and written approval has been delivered to and
received by Tenant, whereupon such approved Construction Drawings shall become the <B>&ldquo;Final Construction Drawings&rdquo; </B>for
such Phase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 70.25pt"><FONT STYLE="font-size: 10pt">(c)
 &#8239;&#8239;&#8239;&#8239;&#8239;Tenant acknowledges and agrees that Tenant is solely responsible for obtaining, and shall work promptly
and diligently to obtain, the building permit from the applicable governmental authority and all other permits from any other governmental
authority as may be required in connection with the construction and performance of the Tenant Improvements. Promptly after Tenant receives
Landlord&rsquo;s approval of the Final Construction Drawings for a Phase, Tenant shall submit such approved Final Construction Drawings to
the applicable governmental authorities and, if required pursuant to any applicable Legal Requirements, to all other governmental authorities
having jurisdiction over the Premises for approval and the issuance of the Building Permit (as defined below). Tenant shall promptly
notify Landlord of any changes to the Final Construction Drawings required by such governmental authorities and Landlord shall have the
same approval rights (as set forth in Section 3(a) and Section 3(b)) with respect to any such changes to the extent they raise a Design
Issue. Each building permit for the construction and installation of the Tenant Improvements in a Phase shall be referred to herein as
a <B>&ldquo;Building Permit&rdquo; </B>and the date such Building Permit is issued by the applicable governmental authority shall be referred
to herein as a <B>&ldquo;Building Permit Date.&rdquo;</B> Copies of the Building Permit and any other governmental approvals or permits
obtained by Tenant in connection with the Tenant Improvements shall be delivered to Landlord promptly after Tenant&rsquo;s receipt of the same.
The Final Construction Drawings for a Phase as approved by Landlord and all applicable governmental authorities shall be referred to
herein as the <B>&ldquo;Final Plans&rdquo;</B> for such Phase. Tenant must submit to Landlord one (1) complete set of the Final Plans for
such Phase prior to commencing construction of the Tenant Improvements for such Phase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 69.75pt"><FONT STYLE="font-size: 10pt">(d)
 &#8239;&#8239;&#8239;&#8239;If Landlord and Tenant cannot agree on final Space Plans or Construction Drawings for a Phase within forty
(40) days after Tenant&rsquo;s initial submission thereof to Landlord, then any such dispute shall be resolved by the following process: Landlord
and Tenant shall have a period of ten (10) days from the request of either party to mutually agree on a reputable and qualified independent
architect that must have at least ten (10) years of experience with work similar to the Tenant Improvements, to resolve such dispute.
If the parties fail to agree, then each of Tenant and Landlord shall have an additional five (5) days to select an architect meeting
the same minimum qualifications set forth above, and the two (2) architects selected shall select a third architect who shall resolve
the dispute in question. If either of Landlord or Tenant fail to make its respective selection of an architect within the additional
5-day period provided for above, then the remaining party&rsquo;s selection shall be the expert who shall resolve the dispute in question.
Once the architect has been selected in accordance with this provision, the architect shall render a decision on the dispute as soon
as reasonably possible, but in any event within a period of fifteen (15) days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&#8239;&#8239;4.&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>General Contractor; Subcontractors and Budget</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;
Tenant shall select one or more qualified general contractors to perform the installation of each Phase of the Tenant Improvements, subject
to Landlord&rsquo;s prior written approval, which approval shall not be unreasonably withheld, conditioned, or delayed (each, a <B>&ldquo;General
Contractor&rdquo;</B>). Tenant represents that Tenant intends to conduct a competitive bid process to select the General Contractor for
the Tenant Improvements for each Phase in accordance with customary construction practices or Tenant shall select a General Contractor
for such Phase based on a negotiated fee, which General Contractor shall be required to competitively bid all major subcontracts. Tenant
shall enter into a construction contract for the construction and installation of the Tenant Improvements for a Phase with the applicable
General Contractor (each, a <B>&ldquo;GC Agreement&rdquo;</B>), which GC Agreement shall (i) require progress payments no more frequently
than monthly, (ii) include a detailed construction schedule for the performance and completion of such Tenant Improvements, (iii) include
retainage of ten percent (10%) until final completion of such Tenant Improvements for the applicable Phase, (iv) include the General
Contractor&rsquo;s agreement to attend any Landlord and Tenant construction meetings, and (v) provide from the General Contractor in favor
of Tenant and Landlord, a customary warranty of the Tenant Improvements in such Phase for a period of at least one (1) year from the
date of substantial completion of such Tenant Improvements. A true, correct and complete copy of the GC Agreement with each General Contractor,
and all amendments thereto, will be provided to Landlord. Tenant acknowledges and agrees that the Tenant Improvements shall be constructed
and installed only by parties holding all appropriate licenses as required by applicable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 70.2pt"><FONT STYLE="font-size: 10pt">(b)
 &#8239;&#8239;&#8239;&#8239;Tenant shall also furnish to Landlord a roster identifying all subcontractors performing any of the Tenant
Improvements, which, upon Landlord&rsquo;s request, shall be updated from time to time to add any new subcontractors performing the Tenant
Improvements. All subcontractors performing work that impacts the Building Systems, Building Structure, Building exteriors, or areas
outside the Building shall be subject to Landlord&rsquo;s prior written approval (prior to selection), which shall not be unreasonably withheld,
conditioned, or delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;
No later than thirty (30) days after completion of the Final Construction Drawings for a Phase, Tenant shall provide Landlord with a
detailed budget for the Tenant Improvements in such Phase, showing all Tenant Improvement Costs for such Phase (the <B>&ldquo;Construction
Budget&rdquo;</B>). The Construction Budget for each Phase shall be certified, to the best of Tenant&rsquo;s knowledge, as the final, accurate
and complete budget for the Tenant Improvement Costs for such Phase. Tenant acknowledges that Tenant is obligated to pay the Tenant Improvement
Costs (subject to the Allowance).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 69.75pt"><FONT STYLE="font-size: 10pt">(d)
 &#8239;&#8239;&#8239;&#8239;&#8239;Upon the issuance of all necessary building permits and governmental approvals for the Tenant Improvements
in each Phase, Tenant shall diligently pursue the completion of such Tenant Improvements pursuant to the terms and conditions of this
Work Letter. Tenant shall use commercially reasonable efforts to cause the Tenant Improvements for the entire Premises to be completed
in accordance with the Final Construction Drawings within six (6) years following the Effective Date, subject to extension for force
majeure as set forth in the GC Agreement and provided no Event of Default by Landlord exists under the Lease (including this Work Letter)
that affects the Tenant Improvements beyond applicable notice and cure periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;5.&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Allowance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;
Landlord will provide Tenant with an allowance of $6,940,000.00 (the <B>&ldquo;Allowance&rdquo;</B>) as a credit against the Tenant Improvement
Costs, which Allowance shall be allocated as follows: $3,575,000.00 to Phase I, $1,717,500.00 to Phase II, and $1,647,500.00 to Phase
III (each such amount, a <B>&ldquo;Phase Cap&rdquo;). &ldquo;Tenant Improvement Costs&rdquo;</B> means, collectively, all the actual costs
of designing, engineering, permitting (including impact fees), and constructing the Tenant Improvements in accordance with the Final
Plans (as amended by all Change Orders, as hereafter defined) and all other hard and soft costs associated with the preparation of the
Premises for Tenant&rsquo;s use and occupancy, including Tenant&rsquo;s costs for design, architectural, and engineering consultants; all costs associated
with the installation and completion of the Tenant Improvements; all conduit, cabling and wiring for Tenant&rsquo;s telecommunications, computer
and/or data systems; and all other furnishings, :fixtures and equipment permanently attached and made a part of the Premises required
for Tenant&rsquo;s use and occupancy of the Premises. Notwithstanding anything herein to the contrary, in no event shall the Allowance be used
for the purchase of Tenant&rsquo;s Property, other than conduit, cabling and wiring for Tenant&rsquo;s telecommunications, computer and data systems
in the Premises. If the Tenant Improvement Costs exceed the Allowance, Tenant will be solely responsible for and pay the full amount
of such excess costs as and when due. In addition, Tenant shall pay to Landlord, within thirty (30) days after receipt of Landlord&rsquo;s
written demand therefor, a construction management and oversight fee equal to One and 50/100 Percent (1.50%) of the hard costs component
of the total Tenant Improvement Costs for a Phase to compensate Landlord for reviewing the plans for the Tenant Improvements for such
Phase, reviewing and processing Allowance Requests, and for costs incurred by Landlord in facilitating Tenant&rsquo;s completion of the Tenant
Improvements for such Phase. Landlord reserves the right to deduct such fee from the Allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.05pt"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;
Provided no Event of Default by Tenant exists under the Lease (including this Work Letter) beyond applicable notice and cure periods,
then commencing after the Building Permit Date for a Phase, Landlord shall pay to Tenant the Allowance (or so much thereof as is necessary
to cover the Tenant Improvement Costs for such Phase, subject to the applicable Phase Cap), less a ten percent (10%) retainage (which
retainage shall be payable as part of the final draw for each Phase hereunder), in periodic disbursements pursuant to the terms and conditions
set forth in this Section. For each of the periodic disbursements (individually and collectively, as applicable, an <B>&ldquo;Allowance
Request&rdquo;</B>), Tenant shall deliver to Landlord the following documentation: (i) a request to disburse from Tenant containing an
approval by Tenant of the work done and a good faith estimate of the cost and time to complete the Tenant Improvements for such Phase;
(ii) a copy of the application and certificate for payment in the form of AIA documents G702 and G703 signed by the General Contractor
and Tenant&rsquo;s architect submitted for all work for which disbursement is to be made to a date specified therein (or other invoice in
the case of invoices for architecture or engineering fees or materials to be incorporated into the Tenant Improvements); (iii) from the
General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier that provided services
or materials in the completion of the Tenant Improvements for which the Allowance Request is being made, a statutorily compliant conditional
waiver and release on progress payment for the requested disbursement (conditioned only on the payment of the requested disbursement)
and from the General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier that
provided services or materials in the completion of the Tenant Improvements for which the immediately prior Allowance Request was made,
a statutorily compliant unconditional waiver and release on progress payment for the previously requested disbursement; (iv) copies of
paid invoices, paid receipts and other reasonably satisfactory evidence of payment from the General Contractor, major subcontractors/material
suppliers; and (v) such other supporting data, documents or information as Landlord or Mortgagee may reasonably require. Upon substantial
completion of the Tenant Improvements for a Phase, Tenant shall submit to Landlord a written request for the final disbursement of the
Allowance for such Phase (each, a <B>&ldquo;Final Request&rdquo;</B>), together with the following documentation: (1) reasonable evidence
of substantial completion of the Tenant Improvements for such Phase; (2) a Certificate of Occupancy or local equivalent for such Phase,
or if not available because of the Phase nature of the Tenant Improvements, then evidence of final approval for such Phase issued by
the City of Irving authorizing Tenant&rsquo;s use of such portion of the Building; (3) a certificate of completion in form and substance reasonably
satisfactory to Landlord from Tenant&rsquo;s architect certifying that completion of the Tenant Improvements has been achieved, and to Tenant&rsquo;s
architect&rsquo;s knowledge, the same were completed in accordance with all applicable Legal Requirements and substantially in accordance <I>with
</I>the Final Plans (including all Change Orders), (4) from the General Contractor, any contractor under a direct contract with Tenant,
and any subcontractor or material supplier that provided services or materials in the completion of the Tenant Improvements for which
the Final Request is being made, a statutorily compliant conditional final waiver and release on progress payment for the requested disbursement
(conditioned only on the payment of the requested disbursement) and, within ten (10) Business Days after the Final Request disbursement
was made, from the General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier
that provided services or materials in the completion of the Tenant Improvements for which such Final Request was made, a statutorily
compliant final and unconditional waiver and release for such Final Request, (5) two sets of copies of detailed as-built plans of the
Tenant Improvements for such Phase, and (6) copies of all such invoices, contracts, or other supporting data as Landlord or Mortgagee
may reasonably require. As used herein <B>&ldquo;substantial completion,&rdquo; &ldquo;substantially completed,&rdquo; </B>and any derivations
thereof mean the Tenant Improvements in the applicable Phase are substantially completed and a Certificate of Occupancy or local equivalent
for such Phase has been issued, or if not available because of the Phase nature of the Tenant Improvements, then evidence of final approval
for such Phase issued by the City of Irving authorizing Tenant&rsquo;s use of such Phase of the Building. Substantial completion shall have
occurred even though minor details of construction, decoration, and mechanical adjustments remain to be completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.8pt"><FONT STYLE="font-size: 10pt">(c)
 &#8239;&#8239;&#8239;&#8239;&#8239;Provided Tenant shall have complied with the provisions of this Section and there is no uncured Event
of Default under the Lease, then within forty (40) days after Landlord&rsquo;s receipt of an Allowance Request or the Final Request, as the
case may be, together with the accompanying documentation required herein, Landlord shall pay to Tenant the amount shown on such Allowance
Request or Final Request (less a ten (10%) retainage for each Allowance Request). In no event shall Landlord be required to disburse
the Allowance for a Phase (i) before the Building Permit Date for such Phase, (ii) more than one time per month, (iii) when an uncured
Event of Default exists under the Lease, or (iv) in excess of the Phase Cap for such Phase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 69.35pt"><FONT STYLE="font-size: 10pt">(d)
 &#8239;&#8239;&#8239;&#8239;In the event the Tenant Improvement Costs are less than the Allowance or Tenant does not otherwise use the
entire Allowance by seventy-two (72) months following the Effective Date, then any such unused portion of the Allowance shall be applied
to Basic Rent next coming due under the Lease until the entire unused portion has been disbursed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&#8239;&#8239;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<U>Construction of the Improvements; Change Orders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 69.35pt"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;
The Tenant Improvements shall be completed in a good and workmanlike manner, free of liens and in compliance with the Final Plans (including
any Change Orders) and all applicable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 69.1pt"><FONT STYLE="font-size: 10pt">(b)
 &#8239;&#8239;&#8239;&#8239;Tenant will abide by the provisions of the Lease with regard to mechanic&rsquo;s or construction liens relating
to the Tenant Improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 69.15pt"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;
Any damage to the Premises to the extent caused by Tenant, its contractors, subcontractors or agents must be promptly repaired by Tenant,
at its expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 69.75pt"><FONT STYLE="font-size: 10pt">(d)
 &#8239;&#8239;&#8239;&#8239;Tenant shall have the ability to request and authorize changes to the Tenant Improvements during construction.
If Tenant requires or desires any changes that deviate from the Final Construction Drawings, after same have been approved by each of
Landlord and Tenant, Tenant shall request such change in writing to Landlord and such request will be accompanied by (i) all plans and
specifications if necessary to show and explain the changes from the approved Final Construction Drawings, and (ii) a change order setting
forth any cost (including associated architectural and engineering fees) or savings and any potential incompatibility with or impact
on the exterior of the Premises, base building, Building Structure, or Building Systems, in each case associated with the proposed change.
Within five (5) Business Days after Landlord receives Tenant&rsquo;s proposed change(s) and all required supporting information, Landlord in
its reasonable judgment shall either approve or not approve such change(s) based on the Design Issues. If Landlord does not approve such
changes, Landlord shall provide Tenant with specific written comments detailing the reasons Landlord denied approval. If Landlord does
not approve Tenant&rsquo;s proposed change(s), Tenant shall either withdraw the proposed change(s) or cause the proposed change order (and
related plans and specifications) to be adjusted in order to address Landlord&rsquo;s comments, and shall resubmit same for Landlord&rsquo;s review
and approval in accordance with this Section (including the time period for Landlord&rsquo;s response, which shall be three (3) Business Days).
Unless Tenant withdraws the proposed change, this procedure shall be repeated until the proposed change is finally approved by Landlord
and written approval has been delivered to and received by Tenant, whereupon Tenant shall cause Tenant&rsquo;s architect and the General Contractor
to document the proposed change through a final change order (each a <B>&ldquo;Change Order&rdquo;</B> and, collectively, <B>&ldquo;Change
Orders&rdquo;</B>), which Change Order(s) shall include a revised Construction Budget and become part of the Final Plans. Notwithstanding
anything in this <U>Section 6(d)</U> to the contrary, Landlord&rsquo;s approval shall not be required for Change Orders that do not raise any
Design Issues, provided that (i) the net increase in the Construction Budget for the applicable Phase resulting from all such Change
Orders does not exceed (in the aggregate) two percent (2%) of the Tenant Improvement Costs for such Phase, and (ii) Tenant provides Landlord
with prior written notice of each such Change Order indicating that it is a Change Order permitted without Landlord&rsquo;s approval under
this Work Letter, which notice shall include a copy of such Change Order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;<U>Insurance</U>. The General Contractor and Tenant&rsquo;s other contractors must obtain and keep in force
throughout their performance of the applicable Tenant Improvements the following insurance in the following minimum amounts: (i)
Commercial General Liability Insurance on a primary basis and without any right of contribution from any insurance carried by
Landlord covering the Premises on an occurrence basis against all claims for personal injury, bodily injury, death and property
damage with a combined single limit of $5,000,000.00 for the General Contractor (which may be achieved through an umbrella or excess
coverage policy), and $1,000,000.00 for other contractors; (ii) Workers&rsquo; Compensation in statutory required amounts and Employers&rsquo;
Liability Insurance for an amount of not less than $1,000,000.00, both in accordance with the laws of the State of Texas; (iii)
 &ldquo;Builder&rsquo;s Risk&rdquo; insurance or an equivalent form per industry standards, covering the full replacement value of the Tenant
Improvements, and any such policy will contain a provision requiring the insurance carriers to waive their rights of subrogation
against Landlord; (iv) in the event a motor vehicle is to be used by such contractor in connection with its business operations from
the Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than $3,000,000.00 combined single limit
coverage against bodily injury liability and property damage liability arising out of the use by or on behalf of such contractor,
its agents and employees of any owned, non-owned or hired motor vehicles; and (v) such other insurance or coverages as Landlord or
its lender reasonably requires. Prior to their entry into the Premises for the accomplishment of any work, Tenant shall furnish to
Landlord all certificates of insurance for the insurance required herein, naming Landlord and Mortgagee as additional insureds or
loss payees, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;8.&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Representatives</U>. Tenant has designated Michael Halbert at tel. ### and email: ### as its
sole representative with respect to the matters set forth in this Work Letter, who shall have full authority and responsibility to
act on behalf of the Tenant as required in this Work Letter, until further written notice to Landlord. Landlord has designated (i)
David Israel of PKV Investment Management at tel.  ### and email:  ### and (ii) Steve Jarvis of JLL at tel.
 ### and email:  ###, as its sole representatives with respect to the matters set forth in this Work
Letter, who shall have full authority and responsibility to act on behalf of the Landlord as required in this Work Letter, until
further written notice to Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 34.5pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;<U>Landlord&rsquo;s Role and Rights</U>. Notwithstanding anything herein to the contrary, the parties acknowledge
that neither Landlord nor its property manager is an architect or engineer, and that the Tenant Improvements will be designed and performed
by independent architects, engineers and Tenant&rsquo;s contractors engaged by Tenant. Landlord and its property manager have no responsibility
for construction means, methods or techniques or safety precautions in connection with the Tenant Improvements and do not guarantee that
the Final Plans or Tenant Improvements will be free from errors, omissions or defects, and have no liability therefor. Landlord&rsquo;s review
and approval of the Space Plan, Final Construction Drawings, Change Orders, or Final Plans, and Landlord&rsquo;s designations, lists, recommendations
or approvals concerning Tenant&rsquo;s contractors are not a warranty, covenant or assurance as to the quality or adequacy thereof or of the
Final Plans or the Tenant Improvements, or the design thereof, or of their compliance with Legal Requirements, or that the Final Construction
Drawings are sufficient to enable Tenant&rsquo;s contractor to obtain a building permit for the Tenant Improvements. Tenant will permit access
to the Premises, and inspection of the Tenant Improvements by Landlord and Landlord&rsquo;s architects, engineers, contractors and other representatives,
with reasonable prior notice and at reasonable times during the period in which the Tenant Improvements are being planned, constructed
and installed and following substantial completion of the Tenant Improvements. In the event Tenant fails to comply with the provisions
of this Work Letter, in addition to all other rights and remedies of Landlord set forth in the Lease, Landlord shall have the right upon
twenty-four (24) hours&rsquo; advance notice to Tenant (which may be oral and delivered to Tenant&rsquo;s representative designated in <U>Section
8</U> above, provided that such notice is also sent by email or other written form) to require Tenant to cease the Tenant Improvements
until such time as Tenant is in full compliance with the provisions of this Work Letter. Landlord and Tenant agree to cooperate with
each other and use commercially reasonable and good faith efforts at all times to facilitate the timely planning, performance and completion
of the Tenant Improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
4(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>RENEWAL
OPTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6pt"><FONT STYLE="font-size: 10pt"><B><U>1<SUP>st
</SUP>RENEWAL</U>. </B>&#8239;&#8239;&#8239;&#8239;&#8239;Provided that Tenant is not in default of any of the terms, covenants and conditions
of the Lease beyond any applicable cure period as of the date of the Renewal Notice or as of the scheduled commencement date of the Renewal
Term, at the expiration of the Initial Term Tenant shall have the right and option to extend the Term of this Lease for one (1) further
term of sixty (60) months (the <B>&ldquo;Renewal Period&rdquo;</B>). Such extension of the Initial Term shall be on the same terms, covenants
and conditions as provided for in the Initial Term except that (i) the Basic Rent during such Renewal Period shall be at the fair market
rental in effect at the time of the commencement of the Renewal Period for equivalent properties, of equivalent size, in equivalent areas
and appropriate consideration shall be given to the length of the renewal term, market escalations, the credit of Tenant, and concessions
generally applicable to comparable renewal terms, including free rent, improvement allowances, and commissions (if any), amenities, common
area factors, availability of parking and the charges therefor, building signage rights, and the quality, size, and location of the Building
(the <B>&ldquo;Fair Market Rent&rdquo;</B>), <U>provided</U>, <U>however</U>, notwithstanding anything herein to the contrary, in no event
shall the monthly Basic Rent payable during the Renewal Term be less than the Basic Rent payable during the last month of the Initial
Term), and (ii) Landlord shall not be obligated to make any improvements or alterations in or to the Premises nor shall there be any
improvement allowance, rental abatement or other tenant concessions provided by Landlord in connection with the Renewal Term notwithstanding
the consideration of those items in determining the Fair Market Rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -0.2pt"><FONT STYLE="font-size: 10pt">Tenant
shall deliver written notice (the <B>&ldquo;Renewal Notice&rdquo;</B>) to Landlord of Tenant&rsquo;s election to exercise the renewal option
granted herein not more than eighteen (18) months nor less than fourteen (14) months prior to the expiration of the Initial Term. In
the event Tenant fails to deliver a Renewal Notice within the time period set forth above, Tenant&rsquo;s right to extend the term hereof shall
expire and be of no further force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.15pt"><FONT STYLE="font-size: 10pt">Landlord
and Tenant shall negotiate in good faith to determine the Basic Rent for the Renewal Term for a period of thirty (30) days after the
date on which Landlord receives the Renewal Notice. In the event Landlord and Tenant fail to agree in writing upon the Fair Market Rent
within said 30-day period, Tenant may (upon written notice to Landlord within five (5) Business Days following the expiration of said
30-day period) waive its right to renew and rescind the Renewal Notice, or if Tenant fails to deliver such written notice within such
five (5) Business Day Period, the Fair Market Rent shall be determined by the appraisal procedure set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.75pt"><FONT STYLE="font-size: 10pt">&#9632;
 &#8239;&#8239;&#8239;&#8239;Within ten (10) days of the expiration of the 30-day period, each party, by giving written notice to the
other party, shall appoint an appraiser to render a written opinion of the Fair Market Rent for the Renewal Period. Each appraiser must
be a member of the Appraisal Institute of America (MAI) for at least five years and with at least ten (10) years&rsquo; experience in the appraisal
of rental rates of office properties in the area in which the Premises are located and otherwise unaffiliated with either Landlord or
Tenant. The two appraisers shall render their written opinion of the Fair Market Rent for the Renewal Period to Landlord and Tenant within
ten (10) days after the appointment of the second appraiser. If the Fair Market Rent of each appraiser is within five percent (5%)
of each other, then the average of the two appraisals of Fair Market Rent shall be the Basic Rent for the Renewal Period (subject to
the minimum rate defined in this renewal option). If one party does not appoint its appraiser as provided above, then the one appointed
shall determine the Fair Market Rent. The Fair Market Rent so determined under this subparagraph shall be binding on Landlord and Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.8pt"><FONT STYLE="font-size: 10pt">&#9632;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Fair Market Rent determined by the appraisers is more than five percent (5%) apart, then the two appraisers shall pick a third appraiser
within ten (10) days after the two appraisers have rendered their opinions of Fair Market Rent as provided above. If the two appraisers
are unable to agree on the third appraiser within said ten (10) day period, Landlord and Tenant shall mutually agree on a third appraiser
within ten (10) days thereafter. The third appraiser shall be a person who has not previously acted in any capacity for either party
and must meet the qualifications stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 1.05pt"><FONT STYLE="font-size: 10pt">&#9632;&#8239;&#8239;&#8239;&#8239;&#8239;Within
ten (10) days after its appointment, the third appraiser shall render its written opinion of the Fair Market Rent for the Renewal Period
(<B>&ldquo;Third Opinion&rdquo;</B>), and the Fair Market Rent for the Renewal Period shall be the appraisal of Fair Market Rent made by
Landlord&rsquo;s or Tenant&rsquo;s appraiser that is closest to the Fair Market Rent specified in the Third Opinion (subject to the minimum rate
defined in this renewal option). If the Fair Market Rent set forth in the Third Opinion is equidistant from the Fair Market Rent made
by Landlord&rsquo;s or Tenant&rsquo;s appraiser, then the Fair Market Rent contained in the Third Opinion shall be the Basic Rent during the Renewal
Period. The Fair Market Rent so determined under this subparagraph shall be binding on Landlord and Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 10pt; text-align: justify; text-indent: 0.05pt"><FONT STYLE="font-size: 10pt">&#9632;&#8239;&#8239;&#8239;&#8239;Each
party shall bear the cost of its own appraiser and, if applicable, one-half (1/2) the cost of the third appraiser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 9pt; text-align: justify"><FONT STYLE="font-size: 10pt">After
the Fair Market Rent for the Renewal Period has been established in accordance with the terms hereof, Landlord and Tenant shall promptly
execute an amendment to this Lease to reflect the Basic Rent for the Renewal Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-size: 10pt"><B><U>2nd
RENEWAL</U>.&#8239;&#8239;&#8239;&#8239; </B>Provided that Tenant is not in default of any of the terms, covenants and conditions of
the Lease beyond any applicable cure period as of the date of the 2<SUP>nd</SUP> Renewal Notice or as of the scheduled commencement date
of the 2<SUP>nd</SUP> Renewal Term and Tenant renewed the Lease following the Initial Term as set forth above, Tenant shall have the
right and option to extend the Term for one (1) additional term of sixty (60) months beyond the expiration of the Renewal Period (the
<B>&ldquo;2<SUP>nd </SUP>Renewal Period&rdquo;</B>). Such extension shall be on the same terms, covenants and conditions as provided
for in the Renewal Period except that (i) the Basic Rent during the 2nd Renewal Period shall be at Fair Market Rent, <U>provided</U>,
<U>however</U>, notwithstanding anything herein to the contrary, in no event shall the monthly Basic Rent payable during the 2<SUP>nd
</SUP>Renewal Term be less than the Basic Rent payable during the last month of the Renewal Term) and (ii) Landlord shall not be obligated
to make any improvements or alterations in or to the Premises nor shall there be any improvement allowance, rental abatement or other
tenant concessions provided by Landlord in connection with the 2nd Renewal Term notwithstanding the consideration of those items in determining
the Fair Market Rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.4pt"><FONT STYLE="font-size: 10pt">Tenant
shall deliver written notice (the <B>&ldquo;2<SUP>nd</SUP> Renewal Notice&rdquo;</B>) to Landlord of Tenant&rsquo;s election to exercise the
renewal option granted herein not more than eighteen (18) months nor less than fourteen (14) months prior to the expiration of Renewal
Period. In the event Tenant fails to deliver the 2nd Renewal Notice within the time period set forth above, Tenant&rsquo;s right to extend
the Term for the 2nd Renewal Period shall expire and be of no further force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-size: 10pt">Landlord
and Tenant shall negotiate in good faith to determine the Basic Rent for the 2<SUP>nd</SUP> Renewal Term for a period of thirty (30)
days after the date on which Landlord receives the 2<SUP>nd</SUP> Renewal Notice. In the event Landlord and Tenant fail to agree in writing
upon the Fair Market Rent within said 30-day period, Tenant may (upon written notice to Landlord within five (5) Business Days following
the expiration of said 30-day period) waive its right to renew and rescind the Renewal Notice, or if Tenant fails to deliver such written
notice within such five (5) Business Day Period, the Fair Market Rent shall be determined by the appraisal procedure set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25pt"><FONT STYLE="font-size: 10pt">After
the Fair Market Rent for the 2<SUP>nd</SUP> Renewal Period has been established in accordance with the terms hereof, Landlord and Tenant
shall promptly execute an amendment to this Lease to reflect the Basic Rent for the 2<SUP>nd</SUP> Renewal Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45pt"><FONT STYLE="font-size: 10pt">Tenant
shall not have the right to renew the Lease for the Renewal Period or the 2<SUP>nd</SUP> Renewal Period for any amount of space less
than the entire Premises under the Lease. Additionally, Tenant&rsquo;s rights to renew the Lease for the Renewal Period or the 2<SUP>nd</SUP>
Renewal Period are personal to Tenant and its Permitted Transferees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>BASIC
RENT CHART</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font-size: 10pt; border-collapse: collapse; width: 40%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; text-align: left; border: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-left: 2pt; width: 50%; vertical-align: top"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><U>Phase</U></FONT></P></TD>
    <TD STYLE="padding-bottom: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B><U>Location</U></B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; text-align: left; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-left: 2pt; border-right: Black 1pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">Phase I</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Approx.
57,250 square feet of the Building</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; text-align: left; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-left: 2pt; border-right: Black 1pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">Phase II</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Approx.
28,625 square feet of the Building</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; text-align: left; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-left: 2pt; border-right: Black 1pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">Phase III</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Approx. 28,625 square feet of the Building</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Remainder
of Page Intentionally Blank - Basic Rent Schedule Appears on Following Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Period</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Phase
    I</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Phase
    II</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Phase
    III</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Annual
    Basic Rent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Monthly
    Basic<BR>
    Rent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: left"><FONT STYLE="font-size: 10pt">Commencement
    Date&nbsp;- 6/30/2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2020 - 6/30/2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1,116,375.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">93,031.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2021 - 6/30/2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">1,708,053.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">142,337.81</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2022 - 6/30/2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,322,953.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">193,579.43</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2023 - 6/30/2024</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right">2,369,412.16</TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right">197,451.01</TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2024 - 6/30/2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,416,800.41</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">201,400.03</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2025 - 6/30/2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,465,136.41</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">205,428.03</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2026 - 6/30/2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,514,439.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">209,536.60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2027 - 6/30/2028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,564,727.92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">213,727.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2028 - 6/30/2029</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,616,022.48</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">218,001.87</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2029 - 6/30/2030</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,668,342.93</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">222,361.91</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2030 - 6/30/2031</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,721,709.79</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">226,809.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2031 - 6/30/2032</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,776,143.99</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">231,345.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2032 - 6/30/2033</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,831,666.87</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">235,972.24</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2033 - 6/30/2034</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,888,300.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">240,691.68</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">7/1/2034 - 6/30/2035</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">2,946,066.21</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">245,505.52</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
23</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>FORM
OF SNDA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[see
following page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-size: 10pt"><U>RETURN TO</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-size: 10pt">Citibank, N.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-size: 10pt">388 Greenwich Street, 6<SUP>th
</SUP>Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">New York, NY 10013</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attn: Ana Rosu Marmann</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>SUBORDINATION,
NON-DISTURBANCE AND ATTORNMENT AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt">THIS
SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT (hereinafter referred to as <B>&ldquo;Agreement&rdquo;</B>) made as of the __ day
of July, 2019, among <B>CITIBANK, N.A.,</B> a national banking association, as administrative agent (in such capacity, together with
its successors, assigns, designees and/or nominees, collectively hereinafter referred to as <B>&ldquo;Administrative Agent&rdquo;</B>)
for the Lenders (defined below), <B>CARIS MPI, INC.,</B> a Texas corporation (hereinafter referred to as <B>&ldquo;Tenant&rdquo;</B>),
and <B>KCP NNN</B> II <B>LEASEHOLD 4, LLC, </B>a Delaware limited liability company (hereinafter referred to as <B>&ldquo;Landlord&rdquo;</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>RECITALS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.8pt"><FONT STYLE="font-size: 10pt">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Tenant is the tenant and lessee under a certain Lease dated July __, 2019 (as the same may now or hereafter be amended, restated, replaced
or otherwise modified, collectively, the <B>&ldquo;Lease&rdquo;</B>) relating to the premises described in the Lease (hereinafter referred
to as the <B>&ldquo;Premises&rdquo;</B>), located at the real property more particularly described on <U>Exhibit A</U> attached hereto
(hereinafter referred to as the <B>&ldquo;Property&rdquo;</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.4pt"><FONT STYLE="font-size: 10pt">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Certain
lenders (the <B>&ldquo;Lenders&rdquo;</B>) have made or are making one or more loans (collectively, the <B>&ldquo;Loan&rdquo;</B>), which
such Loan is (i) secured by a deed of trust, mortgage or security deed (as the same may be amended, restated, extended, or otherwise
modified from time to time, the <B>&ldquo;Mortgage&rdquo;</B>) and an assignment of leases and rents (as the same may be amended, restated,
extended, or otherwise modified from time to time, the <B>&ldquo;Assignment of Leases&rdquo;</B>), in each case, from Landlord to Lender
covering the Property including the Premises, and (ii) evidenced by certain other documents and instruments by and among Lender and Landlord,
among others (the same, together with the Mortgage and Assignment of Leases, collectively, the <B>&ldquo;Loan&nbsp;Documents&rdquo;</B>). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="font-size: 10pt">C.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
has agreed that the Lease shall be subject and subordinate to the Loan and Loan Documents, provided Tenant is assured of continued occupancy
of the Premises under the terms of the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, for and in consideration of the mutual covenants herein contained, the sum of Ten Dollars ($10.00) and other good and valuable
considerations, the receipt and sufficiency of which are hereby acknowledged, and notwithstanding anything in the Lease to the contrary,
it is hereby agreed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.75pt">1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subordination
and Consent</U>. Subject to Section 2 below, Administrative Agent, Tenant and Landlord do hereby covenant and agree that the Lease with
all rights, options, liens and charges created thereby (including, without limitation, any option or rights contained in the Lease, or
otherwise existing, to acquire any or all of the Premises, or any superior leasehold interest therein), is and shall continue to be subject
and subordinate in all respects to the lien and terms of the Loan Documents, and to any renewals, modifications, consolidations, replacements
and extensions thereof and to all advances made thereunder. Tenant acknowledges that Landlord will execute and deliver to Administrative
Agent an assignment of the Lease as security for the Loan, and Tenant hereby expressly consents to such assignment. Tenant agrees that
if there is a default by Landlord in the performance and observance of any of the terms of such Loan, Administrative Agent may, at its
option, demand all rents due under the Lease be paid by Tenant directly to Administrative Agent on behalf of the Lenders at the address
specified below, or as otherwise specified by Administrative Agent. Tenant agrees that upon Tenant&rsquo;s receipt of Administrative Agent&rsquo;s
written request for payment of rent directly to Administrative Agent on behalf of the Lenders, Tenant will thereafter timely remit any
and all payments due under the Lease directly to, and payable to the order of, Administrative Agent on behalf of the Lenders. Such payments
to Administrative Agent on behalf of the Lenders will constitute performance of Tenant&rsquo;s payment obligations under the Lease and Landlord
hereby agrees that Tenant shall receive credit against rent due under the Lease for any such payments made to Administrative Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Non-Disturbance</U>. Administrative Agent does hereby agree with Tenant that, in the event Administrative Agent succeeds to Landlord&rsquo;s
interest in the Premises by foreclosure, conveyance in lieu of foreclosure or otherwise, so long as Tenant complies with and performs
its obligations under the Lease, (a) the Lease shall continue in full force and effect as a direct Lease between Administrative Agent
and Tenant, upon and subject to all of the terms, covenants and conditions of the Lease, for the balance of the term of the Lease and
any renewals thereof, and Administrative Agent will not disturb the possession of Tenant, (b) Tenant&rsquo;s occupancy and possession of the
Premises and Tenant&rsquo;s other rights and privileges under the Lease, including, without limitation, the use and distribution of insurance
and condemnation proceeds as set forth in the Lease, shall not be disturbed or interfered with by Administrative Agent (1) in the exercise
of any of its foreclosure or other rights under the Mortgage, (2) by any conveyance in lieu of foreclosure, or (3) by any other action
taken by Administrative Agent during the term of the Lease and any renewals thereof, except in each case as may be permitted as by a
successor Landlord in accordance with the terms of the Lease, and ( c) the Premises shall be subject to the Lease and Administrative
Agent shall recognize Tenant as the tenant of the Premises for the remainder of the term of the Lease (including any renewals thereof)
in accordance with the provisions thereof; provided, however, that Administrative Agent shall not be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 35pt; text-align: justify; text-indent: 35.25pt">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject to any claims, offsets or defenses which Tenant might have against any prior landlord (including Landlord), except for
offset rights expressly provided for in the Lease and for which Administrative Agent received written notice of the matter giving rise
to such offset and was afforded the opportunity to cure as required by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 35pt; text-align: justify; text-indent: 35.25pt">&nbsp;</P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 35pt; text-align: justify; text-indent: 35.35pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
liable for any act or omission of any prior landlord (including Landlord), except acts or omissions that are continuing at the time of
attornment of which Administrative Agent received written notice and was afforded the opportunity to cure as required by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 35.1pt"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
bound by any rent or additional rent which Tenant might have paid more than one </FONT>(1) <FONT STYLE="font-size: 10pt">month in advance
or any security deposit (which has not, as such, been transferred to Administrative Agent) or other prepaid charge paid to any prior landlord
(including Landlord); </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: 35.1pt">(iv)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;bound by any amendment or modification of the Lease as
to (a) any reduction in the term of the Lease, (b) any reduction in the rent payable under the Lease, or (c) a material reduction of
the obligations of Tenant or a material increase of the obligations of Landlord under the Lease, unless Administrative Agent has
approved or consented to such amendment or modification in writing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 33.85pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
liable for any deposit that Tenant may have given to any previous landlord (including Landlord) which has not, as such, been transferred
to Administrative Agent; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 35pt; text-align: justify; text-indent: 34.85pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
obligated to reimburse Tenant for the cost of any Tenant Improvements constructed by or on behalf of Tenant in accordance with the Work
Letter; provided, however, following Administrative Agent&rsquo;s succession to Landlord&rsquo;s interest in the Premises by foreclosure, conveyance
in lieu of foreclosure or otherwise, if Administrative&#8239;Agent fails to pay to Tenant any installment of the Allowance when due pursuant
to the Work Letter, then, provided that Tenant has satisfied all of the requirements set forth in the Work Letter with respect to such
disbursement of the Allowance, Tenant shall be entitled to offset against Rent next becoming due under the Lease the amount of the installment
then due until such amount has been fully offset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.5pt">Except to the extent
required under applicable law or in order for Administrative Agent to avail itself and the Lenders of and complete the foreclosure or
other remedy, and provided that such complaint or action does not seek termination of Tenant&rsquo;s interest and estate under the Lease, Administrative
Agent shall not name Tenant in any foreclosure or other action or proceeding initiated by Administrative Agent pursuant to the Loan Documents.
Tenant acknowledges and agrees that it has no right or option of any nature whatsoever, whether pursuant to the Lease or otherwise, to
purchase the Premises or the Property, or any portion thereof or any interest therein, and to the extent that Tenant has had, or hereafter
acquires, any such right or option, the same is hereby acknowledged to be subject and subordinate to the lien and terms of the Loan Documents
and is hereby waived and released as against Administrative Agent and the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.2pt">3. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Attornment</U>.
Tenant does hereby agree with Administrative Agent that, in the event Administrative Agent becomes the owner of the Property by foreclosure,
conveyance in lieu of foreclosure or otherwise, then the Lease shall continue as a direct Lease between Tenant and Administrative Agent
upon all of the terms, covenants, conditions and agreements set forth in the Lease and this Agreement, and Tenant shall attorn to and
recognize Administrative Agent as the landlord under the Lease, and shall perform and observe Tenant&rsquo;s obligations thereunder, for the
remainder of the term thereof. Tenant further covenants and agrees to execute and deliver upon&#8239;request of Administrative Agent
an agreement of attornment reasonably acceptable to Administrative Agent or any subsequent titleholder of the Premises, which agreement
shall include non-disturbance provisions reasonably acceptable to Tenant. This Agreement, when fully executed, delivered and recorded,
satisfies the requirement in Section 23 of the Lease relating to the grant of a non-disturbance agreement with respect to the Mortgage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 34.55pt">4. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Lease
Defaults</U>. In the event Landlord shall fail to perform or observe any of the terms, conditions or agreements in the Lease, Tenant
shall give written notice thereof to Administrative Agent and Administrative Agent shall have the right (but not the obligation) to cure
such default. Other than as provided in Section 36(b) of the Lease, Tenant shall not take any action with respect to such default under
the Lease, including without limitation any action in order to terminate, rescind or avoid the Lease or to withhold any rent or other
monetary obligations thereunder, for a period equal to the greater of (a) the period of time afforded Landlord under the Lease to cure
or remedy such default or (b) thirty (30) days following receipt of such written notice by Administrative Agent; provided, however, that
in the case of any default which cannot with diligence be cured within said period, if Administrative Agent shall proceed promptly to
cure such default and thereafter prosecute the curing of such default with diligence and continuity, the time within which such default
may be cured shall be extended for such period as may be necessary to complete the curing of such default with diligence and continuity,
not to exceed one hundred eighty (180) days in the aggregate.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.5pt">5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Obligations and Liability of Administrative Agent</U>. Administrative Agent shall have no obligations nor incur any liability
with respect to any warranties of any nature whatsoever, whether pursuant to the Lease or otherwise, including, without limitation, any
warranties respecting use, compliance with zoning, hazardous wastes or environmental laws, Landlord&rsquo;s title, Landlord&rsquo;s authority, habitability,
fitness for purpose or possession. Furthermore, in the event that Administrative Agent shall acquire Landlord&rsquo;s interest in the Property,
Administrative Agent shall have no obligation, nor incur any liability, beyond Administrative Agent&rsquo;s then equity interest, if any, in
the Property, and Tenant shall look exclusively to such equity interest of Administrative Agent, if any, in the Property for the payment
and discharge of any obligations or liability imposed upon Administrative Agent hereunder, under the Lease (or under any new lease with
Tenant), and Administrative Agent is hereby released and relieved of any other obligations or liability hereunder, under the Lease or
under any such new lease. Administrative Agent shall not, either by virtue of the Loan Documents or this Agreement, be or become a mortgagee
in possession or be or become subject to any liability or obligation under the Lease or otherwise until Administrative Agent shall have
acquired the Landlord&rsquo;s interest in the Property and, except as specifically set forth in this Agreement, such liability or obligation
of Administrative Agent under the Lease (as modified by the terms of this Agreement) shall extend only to those liability or obligations
accruing subsequent to the date that Administrative Agent has acquired Landlord&rsquo;s interest in the Property. Neither the Loan Documents
nor this Agreement shall, prior to Administrative Agent&rsquo;s acquisition of Landlord&rsquo;s interest in the Property, operate to place responsibility
for the control, care, management or repair of the Property upon Administrative Agent or impose upon Administrative Agent responsibility
for the carrying out of any of the terms or conditions of the Lease, and Administrative Agent shall not be responsible or liable for
any waste committed on either the Premises or the Property by any party whatsoever, for any dangerous or defective condition of the Property
or for any negligence in the management, upkeep, repair or control of either the Premises or the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 34.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">6. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any portion or portions of this Agreement shall be held invalid or inoperative, then all of the remaining portions shall remain in
full force and effect, and, so far as is reasonable and possible, effect shall be given to the intent manifested by the portion or portions
held to be invalid or inoperative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.75pt">7.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.7pt">8.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Until the Mortgage has been released of record and a copy of such release delivered to Tenant, Tenant will mail or deliver to Administrative
Agent, at the address and in the manner herein below provided, a copy of all notices required to be given to the Landlord by Tenant under
and pursuant to the terms and provisions of the Lease, provided that Administrative Agent agrees to keep any information contained in
such notices confidential. All notices or other communications required or permitted to be given pursuant to the provisions hereof shall
be in writing and shall be considered as properly given if (i) mailed to the addressee by first class United States mail, postage prepaid,
registered or certified with return receipt requested, (ii) by delivering same in person to the addressee, or (iii) by delivery to a
third party commercial delivery service for same day or next day delivery to the office of the addressee with proof of delivery. Notice
so given shall be effective, as applicable, upon (i) the third (3rd) day following the day such notice is deposited with the U.S. Postal
Service, (ii) delivery to the addressee, or (iii) upon delivery to such third party delivery service. Notice given in any other manner
shall be effective only if and when received by the addressee. For purposes of notice, the addresses of the parties shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.5in; width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative Agent:</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Citibank, N .A.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">388 Greenwich Street, 6<SUP>th
    </SUP>Floor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10013</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: CMBS Real Estate Legal Notices</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Landlord:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KCP NNN II Leasehold 4, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Kawa Capital Partners LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21500 Biscayne Boulevard, Suite 700</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aventura, Florida 33180</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: General Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">750 W. John Carpenter Freeway, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irving, TX 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Michael Halbert, SVP Human Resources</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">750 W. John Carpenter Freeway, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irving, TX 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: justify; text-indent: 34pt">Notwithstanding the
foregoing, any party shall have the right to change its address for notice hereunder to any other location within the continental United
States by the giving of thirty (30) days&rsquo; notice to the other parties in the manner set forth herein. Any address so designated shall
include a street address for courier delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.5pt">9. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal
representatives, successors, successors-in-title and assigns, it being understood that the obligations and agreements herein of each
of the parties shall extend to any person who shall have succeeded to its interest under the Loan Documents and the Lease. Without limitation
of any provision contained herein, as used herein, the term (i) &ldquo;landlord&rdquo; refers to Landlord and to any successor to the interest
of Landlord under the Lease and (ii) &ldquo;Administrative Agent&rdquo; refers to Administrative Agent acting as authorized agent of the
Lenders and to any assignee of the note secured by the Mortgage and Administrative Agent&rsquo;s servicer of the Loan, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.5pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tenant&rsquo;s
Personal Propertv</U>. In no event shall the Mortgage cover or encumber (and shall not be construed as subjecting in any manner to the
lien thereof) any of Tenant&rsquo;s moveable trade fixtures, business equipment, furniture, signs or other personal property at any time placed
on or about the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.5pt">11.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in one or more counterparts, each of which when so executed shall be deemed to be an original, but all
of which when taken together shall constitute one and the same instrument. This Agreement, if executed by Tenant but not by all parties
necessary to fully execute the same, is valid for only thirty (30) days from the date Tenant executed this Agreement. This Agreement
is contingent upon Tenant receiving an original fully executed copy of the Agreement within such 30-day period, the failure of which
shall automatically cause this Agreement to become null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.5pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Headings</U>. The headings, captions, and arrangements used in this Agreement are for convenience only and shall not affect the interpretation
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.35pt"><B>IN WITNESS WHEREOF, </B><FONT STYLE="font-size: 10pt">the
parties hereto have executed this Agreement under seal as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>ADMINISTRATIVE AGENT:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>CITIBANK, N.A.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 0.125in">its Authorized Signatory</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>ACKNOWLEDGMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">STATE OF ____________</FONT></TD>
  <TD STYLE="width: 1%">)</TD>
  <TD STYLE="width: 74%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>)</TD>
  <TD>ss:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>COUNTY OF __________</TD>
  <TD>)</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 34.95pt">On the ___day of ____, in the year
2019, before me, the undersigned, a Notary Public in and for said State, personally appeared __________, personally known to me or
proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and
acknowledged to me that he executed the same in his capacity, and that by his signature on the instrument, the individual, or the
person upon behalf of which the individual acted, executed the instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="border-top: Black 1pt solid; width: 50%">Notary Public</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 0.5in">[SEAL]</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>TENANT:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>CARIS MPI, INC.,</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">a
Texas corporation </FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>ACKNOWLEDGMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">STATE OF TEXAS</FONT></TD>
  <TD>&sect;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">&nbsp;</TD>
  <TD>&sect;</TD>
  <TD></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 9%">COUNTY OF</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 8%">&nbsp;</TD>
  <TD STYLE="width: 8%">&nbsp;</TD>
  <TD STYLE="width: 2%">&sect;</TD>
  <TD STYLE="width: 73%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This instrument was acknowledged before me on July _____,<FONT STYLE="font-size: 10pt">
</FONT>2019, by ____________,   ___________ of Caris MPI, Inc., a Texas corporation, on behalf of said corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3" STYLE="border-top: Black 1pt solid">Notary Public in and for the State of Texas</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 16%">My commission expires:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 17%">&nbsp;</TD>
  <TD STYLE="width: 17%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>LANDLORD:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>KCP NNN </B><FONT STYLE="font-size: 10pt">II</FONT>
<B>LEASEHOLD 4, LLC,</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">a Delaware
limited liability company</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">&nbsp;</TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 42%">Daniel Ades</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>ACKNOWLEDGMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">STATE OF ____________</FONT></TD>
  <TD STYLE="width: 2%">)</TD>
  <TD STYLE="width: 73%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>)</TD>
  <TD>ss:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>COUNTY OF __________</TD>
  <TD>)</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 35.25pt">On the ____ day of ___,
in the year 2019, before me, the undersigned, a Notary Public in and for said State, personally appeared Daniel Ades, as Chief
Executive Officer of KCP NNN II Leasehold 4, LLC, personally known to me or proved to me on the basis of satisfactory evidence to be
the individual whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his capacity,
and that by his signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the
instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="border-top: Black 1pt solid; width: 50%">Notary Public</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 0.5in">[SEAL]</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT A TO SNDA</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>LEGAL DESCRIPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT 24-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ESTOPPEL CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-right: 2pt; margin-bottom: 0pt; text-align: justify">The
undersigned, CARIS MPI, INC., a Texas corporation (the <B>&ldquo;Tenant&rdquo;</B>), is the tenant under a lease (the <B>&ldquo;Lease&rdquo;</B>)
dated ____________, 2019, between Tenant and _______________________, a Delaware limited liability company, as the landlord (the <B>&ldquo;Landlord&rdquo;</B>), <FONT STYLE="font-size: 10pt">of
certain real property located at 3600 W. Royal Lane, Irving, Texas 75063, and legally described on attached </FONT><B>Exhibit A</B> <FONT STYLE="font-size: 10pt">(the </FONT><B>&ldquo;Premises&rdquo;</B>). <FONT STYLE="font-size: 10pt">With
the understanding that _______________ _________________, (together with its successors and assigns, <B>&ldquo;Lender&rdquo;</B>), a(n) ___________,
will rely upon the covenants, representations and statements made herein in <B>[select one]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">[---making a mortgage loan of $______________, more or less
(the <B>&ldquo;Loan&rdquo;</B>) to Landlord evidenced by <B>[a Promissory Note]</B> (the <B>&ldquo;Note&rdquo;</B>) in the aggregate principal
amount of the Loan, executed by Landlord in favor of Lender and secured by a <B>[Mortgage and Security Agreement] </B><FONT STYLE="font-size: 10pt">(the
</FONT><B>&ldquo;Deed of Trust&rdquo;</B>) <FONT STYLE="font-size: 10pt">creating a first lien on the Premises and Landlord&rsquo;s interest
in the Lease and by an </FONT><B>[Assignment of Leases and Rents]</B> <FONT STYLE="font-size: 10pt">(the </FONT><B>&ldquo;Assignment of
Leases and Rents&rdquo;</B>) <FONT STYLE="font-size: 10pt">creating a direct and absolute assignment to Lender of all of Landlord&rsquo;s rights,
title and interest as Landlord in and to the Lease and all rent due thereunder], </FONT><B>[OR]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">[---acquiring title
to the land forming part of the Premises and leasing the same back to Landlord pursuant to a Ground Lease.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: -0.2pt">Tenant understands that
Lender will rely upon the covenants, representations and warranties made herein <B>[in making the Loan or entering into said Ground Lease
transaction]</B> and Tenant hereby covenants and certifies as follows (terms used herein which are not otherwise defined herein shall
have the meaning ascribed to them in the Lease) as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Tenant is
the owner and holder of all rights, title and interest in the leasehold estate created by the Lease and has no actual knowledge of any
prior assignment of the Landlord&rsquo;s interest in the Lease, except as described above in favor of Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant and/or
its Affiliates and subtenants are in possession of the Premises and have accepted the condition thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">3. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attached hereto
is a true and correct copy of the Lease and the following amendments thereto: [If <B>none, state &ldquo;None.&rdquo;]</B> The Lease is in
full force and effect and has not been modified, supplemented, canceled or amended in any respect except as stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Term of the Lease commenced on _____________, _____________, and continues through ___________ [unless extended as provided in the Lease].
The Tenant is currently obligated to pay Basic Rent in monthly installments in the amount of $___________, which rent obligation is
continuing and is not past due or delinquent in any respect. No installment of rent has been prepaid more than thirty (30) days
before it comes due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">5. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To Tenant&rsquo;s actual
knowledge, no event has occurred or is continuing which would constitute a default by either the Tenant or the Landlord under the Lease
or would constitute such a default but for the requirement that notice be given or that a period of time elapse or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Beginning with the payment
of Basic Rent due ______ , Tenant hereby acknowledges and agrees to comply with Landlord&rsquo;s authorization and direction to Tenant to make
all payments of Basic Rent due under the Lease directly to Lender until otherwise advised in writing by Lender by wire transfer of immediately
available funds to Lender pursuant to instructions given by Lender from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">7. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
so long as the Loan is outstanding, Tenant agrees to deliver to Lender (at the address provided hereinbelow) a courtesy copy of any written
notice by Tenant to Landlord claiming default by Landlord under the Lease, and Tenant authorizes Landlord to provide to Lender copies
of any financial statements required to be provided by Tenant to Landlord under the Lease, provided that Lender shall keep such financial
statements confidential. Lender&rsquo;s notice address is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 70%; margin-left: 1.4in">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 7%">Attention:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 43%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 10%">&nbsp;</TD>
  <TD STYLE="width: 40%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without the prior written consent of the Lender, Tenant agrees not to enter into any agreement subordinating, terminating, amending or
modifying the Lease, so long as </FONT><B>[the Loan has not been repaid in full]. </B>Any such attempted subordination, modification,
amendment or termination shall be void. In the event that the Lease shall be amended, modified or supplemented with the Lender&rsquo;s prior
written consent, the Lease as so amended, modified or supplemented shall continue to be subject to the provisions of this Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">9.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Certificate may not be modified orally or in any manner other than by an agreement, in writing, signed by the parties hereto or their
respective successors in interest. This Certificate shall inure to the benefit of and be binding upon the parties hereto, and their respective
successors and assigns, and to no other person or entities. The representations, warranties and agreements made herein shall survive the
closing of </FONT><B>[the Loan or Ground Lease transaction] </B>between the Lender and Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant agrees that it shall, pursuant to Paragraph 23 of the Lease and any Subordination,
Non-Disturbance and Attornment Agreement between Tenant and Lender, attorn to and recognize Lender as the Landlord under the Lease,
should Lender become the Landlord under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; In the event
title to the Premises, or any part thereof, is acquired by or becomes vested in the Tenant, whether pursuant to the Lease or otherwise,
there shall be no merger of estates and the Lease shall not terminate or be affected thereby unless and until any Mortgage has been released.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
so long as the <FONT STYLE="font-size: 10pt"><B>[Loan is outstanding or the Ground Lease continues], </B>Lender or its designee may upon
reasonable prior notice (and, at the option of Tenant, accompanied by a representative of Tenant) enter upon the Premises during regular
business hours to visit or inspect the Premises at such reasonable times as Lender or its designee may request. Receipt by Tenant of
a recorded release of the Deed of Trust shall be prima facie evidence that the Loan is no longer outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">13. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Lease and this Certificate
have been duly authorized, executed and delivered by Tenant and constitute legal, valid and binding instruments enforceable against Tenant
in accordance with their respective terms, except to the extent limited by bankruptcy, insolvency or similar laws affecting creditor&rsquo;s
rights generally and general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
As between Landlord and Tenant, the execution and delivery of this Certificate shall in no way expand the rights or obligations of the
Landlord and Tenant arising under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The Guaranty
is in full force and effect and is binding upon, and enforceable against, Guarantor in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Certificate shall be governed by the laws of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">Tenant also makes the above certifications and representations
for the benefit of Landlord and its successors and assigns, with the understanding that they will be relied upon by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF,
this Certificate has been duly executed and delivered by the undersigned as of _____________, _____________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>TENANT:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">Its:</TD>
  <TD STYLE="width: 45%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT 24-2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ESTOPPEL CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0.5pt; text-indent: 69.8pt">&#8239;The undersigned, CARIS MPI,
INC., a Texas corporation (the <FONT STYLE="font-size: 10pt"><B>&ldquo;Tenant&rdquo;</B>),</FONT> is the tenant under a lease (the <FONT STYLE="font-size: 10pt"><B>&ldquo;Lease&rdquo;</B>) </FONT>dated
_______________, 2019, between Tenant and _____________________, a Delaware limited liability company, as the landlord (the <B>&ldquo;Landlord&rdquo;</B>) of
certain real property located in the County of Dallas, State of Texas commonly known as 3600 W. Royal Lane, Irving, Texas 75063, and
legally described on attached <FONT STYLE="font-size: 10pt"><B>Exhibit A</B></FONT> attached hereto (the <FONT STYLE="font-size: 10pt"><B>&ldquo;Premises&rdquo;</B>).</FONT>
With the understanding that ___________________ (together with its successors and assigns, <FONT STYLE="font-size: 10pt"><B>&ldquo;Purchaser&rdquo;</B>)</FONT>
will rely upon the representations and warranties made herein in purchasing the Premises and accepting an assignment of Landlord&rsquo;s
interest in the Lease [ <FONT STYLE="font-size: 10pt"><B>or purchasing the ownership interests in Landlord],</B></FONT> Tenant
hereby certifies as follows (terms used herein which are not otherwise defined herein shall have the meaning ascribed to them in the
Lease) as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Tenant
is the owner and holder of all rights, title and interest in the leasehold estate created by the Lease and has no actual knowledge of
any prior assignment of the Landlord&rsquo;s interest in the Lease except the assignment by Landlord pursuant to <FONT STYLE="font-size: 10pt"><B>[reference
mortgage and/or assignment of leases and rents].</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Tenant and/or
its Affiliates and subtenants are in possession of the Premises and have accepted the condition thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attached hereto
is a true and correct copy of the Lease and the following amendments thereto: [If <FONT STYLE="font-size: 10pt"><B>none, state &ldquo;None.&rdquo;]</B></FONT>
The Lease is in full force and effect and has not been modified, supplemented, canceled or amended in any respect except as stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Term of
the Lease commenced on ___________ and continues through ________ [unless extended as provided in the Lease]. The Tenant is currently
obligated to pay Basic Rent in monthly installments in the amount of <FONT STYLE="font-size: 10pt">$_______, </FONT>which rent obligation
is continuing and is not past due or delinquent in any respect. No installment of rent has been prepaid more than thirty (30) days before
it comes due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To Tenant&rsquo;s
actual knowledge, no event has occurred or is continuing which would constitute a default by either the Tenant or the Landlord under the
Lease or would constitute such a default but for the requirement that notice be given or that a period of time elapse or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; The Lease
and this Certificate have been duly authorized, executed and delivered by Tenant and constitute legal, valid and binding instruments enforceable
against Tenant in accordance with their respective terms, except to the extent limited by bankruptcy, insolvency or similar laws affecting
creditor&rsquo;s rights generally incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Guaranty
is in full force and effect and is binding upon, and enforceable against, Guarantor in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Certificate shall be governed by the laws of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Tenant also makes the above certifications for
the benefit of Landlord and its successors and assigns, with the understanding that they will be relied upon by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, this Certificate has
been duly executed and delivered by the undersigned as of ____________, ______.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>TENANT:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">Its:</TD>
  <TD STYLE="width: 45%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT 30</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepared by and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">when recorded send to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 356pt 0pt 0; text-indent: -0.3pt">Greenberg Traurig, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 356pt 0pt 0; text-indent: -0.3pt">Attn: Michael Larson&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 333pt 0pt 0; text-indent: 0.15pt">333 S.E. 2nd Ave., Suite 4400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 333pt 0pt 0; text-indent: 0.15pt">Miami,
FL 33131</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>MEMORANDUM OF LEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45pt"><FONT STYLE="font-size: 10pt">This
MEMORANDUM OF LEASE (this </FONT><B>&ldquo;Memorandum&rdquo;</B>) <FONT STYLE="font-size: 10pt">is made and entered into effective as
of _______, 2019 (the </FONT><B>&ldquo;Effective Date&rdquo;</B>), <FONT STYLE="font-size: 10pt">by and between
______________________, a Delaware limited liability company </FONT>(<B>&ldquo;Landlord&rdquo;</B>), <FONT STYLE="font-size: 10pt">and
CARIS MPI, INC., a Texas corporation (<B>&ldquo;Tenant&rdquo;</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">I.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Lease</U>. Concurrently herewith, Landlord and Tenant have entered
into that certain Lease (as amended from time to time, the </FONT><B>&ldquo;Lease&rdquo;</B>), <FONT STYLE="font-size: 10pt">pursuant to
which Landlord has leased to Tenant, and Tenant has leased from Landlord, those certain premises commonly known as 3600 W. Royal Lane,
Irving, Dallas County, Texas 75063, more particularly described on Exhibit A attached hereto and made a part hereof (the </FONT><B>&ldquo;Real
Property&rdquo;</B>), <FONT STYLE="font-size: 10pt">and all buildings located on the Real Property, together with all rights, privileges,
easements and appurtenances belonging to or in any way pertaining to said premises and together with the improvements and fixtures located
upon said premises (collectively, the </FONT><B>&ldquo;Premises&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Term</U>.
The effective date of the Lease is ______, 2019, and the initial Term thereunder expires June 30, 2035. Tenant has the right to renew
the term of the Lease for two (2) periods of sixty (60) months each, as more fully set forth in the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice</U>.
This Memorandum is executed for the purpose of recordation in the Real Property Records of Dallas County, Texas, in order to give notice
of the key terms, provisions and conditions of the Lease, and is not intended and shall not be construed, to define, limit or modify
the Lease. In the event of a conflict between the terms of the Lease and this Memorandum, the terms of the Lease shall control. Any party
acquiring any interest in the Real Property or the Premises on or after the date hereof shall do so subject to the terms and provisions
of the Lease and Tenant&rsquo;s rights thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Counterparts</U>.
This Memorandum may be executed in separate counterparts, each such counterpart being deemed an original, and all of which taken together
shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Pages Follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, this Memorandum
is executed as of the dates set forth in the acknowledgments below to be effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>LANDLORD:</B></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">___________________________ ,</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">a Delaware limited liability company</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">STATE OF ___________</FONT></TD>
  <TD>&sect;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">&nbsp;</TD>
  <TD>&sect;</TD>
  <TD></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 9%">COUNTY OF</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 8%">&nbsp;</TD>
  <TD STYLE="width: 8%">&nbsp;</TD>
  <TD STYLE="width: 2%">&sect;</TD>
  <TD STYLE="width: 73%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in; text-align: justify">This instrument was acknowledged before me on ____________, 2019,
by _________________, __________________&#8239;of ___________________,&#8239;a Delaware limited liability company, on behalf of said limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3" STYLE="border-top: Black 1pt solid">Notary Public in and for the State of _____________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 16%">My commission expires:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 17%">&nbsp;</TD>
  <TD STYLE="width: 17%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>TENANT:</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">CARIS MPI, INC.,</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">a Texas corporation</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">STATE OF TEXAS</FONT></TD>
  <TD>&sect;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">&nbsp;</TD>
  <TD>&sect;</TD>
  <TD></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 9%">COUNTY OF</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 8%">&nbsp;</TD>
  <TD STYLE="width: 8%">&nbsp;</TD>
  <TD STYLE="width: 2%">&sect;</TD>
  <TD STYLE="width: 73%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This instrument was acknowledged before me on ___________,
2019, by ________________,  ________________ of Caris MPI, Inc., a Texas corporation, on behalf of said corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3" STYLE="border-top: Black 1pt solid">Notary Public in and for the State of Texas</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 16%">My commission expires:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 17%">&nbsp;</TD>
  <TD STYLE="width: 17%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
A TO MEMORANDUM OF LEASE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>LEGAL
DESCRIPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EXHIBIT
41</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>GUARANTY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[see
following page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><U>GUARANTY
OF LEASE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt; text-align: justify; text-indent: 35.05pt"><FONT STYLE="font-size: 10pt">THIS
GUARANTY OF LEASE (this &ldquo;<U>Guarantv</U>&rdquo;) is made as of this __ day of July, 2019, by Caris Life Sciences, Ltd., a Cayman
Islands exempted limited company (&ldquo;<U>Guarantor</U>&rdquo;), in favor of KCP NNN II LEASEHOLD 4, LLC, a Delaware limited liability
company (&ldquo;<U>Landlord</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><U>RECITALS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Landlord
                                            and Caris MPI, Inc., a Texas corporation (&ldquo;<U>Tenant</U>&rdquo;), have entered into that
                                            certain Lease dated as of July , ____2019 (said Lease, as hereafter supplemented, amended, restated,
                                            renewed, extended, replaced or modified, hereinafter referred to as the &ldquo;<U>Lease</U>&rdquo;),
                                            pursuant to which Tenant leases from Landlord certain Premises (as defined in the Lease)
                                            commonly known as 3600 W. Royal Lane, Irving, Texas 75063, all as more particularly described
                                            in said Lease.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Landlord
                                            has required as a condition to its execution and performance of the Lease that Guarantor
                                            execute and deliver this Guaranty of all of the obligations of Tenant arising and all sums
                                            due by Tenant under the Lease. The execution and delivery of this Guaranty by Guarantor is
                                            a material inducement to Landlord for the execution and performance of the Lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">C.</FONT></TD><TD STYLE="text-align: justify; padding-right: 2pt"><FONT STYLE="font-size: 10pt">Guarantor
                                            owns directly or indirectly all of the ownership interest in Tenant and, having a financial
                                            interest in Tenant, will be benefited by the Lease. Accordingly, Guarantor has agreed to
                                            execute, deliver and perform this Guaranty.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, in consideration of the Recitals set forth above and for other good and valuable consideration, the receipt, adequacy and
sufficiency of which are hereby acknowledged, Guarantor covenants and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Recitals: Defined Terms</U>. The Recitals set
forth above are incorporated herein and shall be deemed terms and provisions hereof. All capitalized terms which are not expressly defined
in this Guaranty shall have the same meanings herein as are ascribed to such terms in the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Guaranty</U>. For the consideration described herein
and subject to the limitations hereof, Guarantor hereby absolutely and unconditionally guarantees to Landlord:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the full and prompt payment when due, whether upon acceleration
or otherwise, and at all times thereafter, of any and all rentals, charges, debts and obligations of Tenant pursuant to the Lease for
the payment of money, however created, arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing,
due or to become due, known or unknown to Guarantor at the time of the execution of this Guaranty including, without limitation, all
Basic Rent and Additional Rent, amounts required to discharge mechanics&rsquo; and materialmen&rsquo;s liens and claims therefor, and any other sums
which may now be or hereafter become due by Tenant under the Lease;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
payment of all Enforcement Costs (as hereinafter defined); and</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
the full, complete and punctual observance, performance and satisfaction of all covenants, terms, conditions, obligations, duties and
agreements of Tenant under the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; text-indent: -0.2pt"><FONT STYLE="font-size: 10pt">All
amounts due and debts, liabilities and payment obligations described in Paragraph 2(a) and 2(b) are referred to herein as the &ldquo;<U>Liabilities</U>.&rdquo;
All obligations described in Paragraph 2(c) are referred to herein as the &ldquo;<U>Obligations</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Landlord&rsquo;s Remedies</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
This Guaranty is an absolute, unconditional, irrevocable, present and continuing guaranty of payment and performance and not merely a
guaranty of collection. In the event of any default by Tenant under the Lease, after the expiration of any notice and cure period applicable
thereto, Guarantor agrees on demand by Landlord to pay all Liabilities then due hereunder, regardless of any defense, right of setoff
or claim which Tenant or Guarantor may have against Landlord. In the event that there shall be any default by Tenant in the due and timely
performance and observance of the Obligations after the expiration of any notice and cure period applicable thereto, then, in such event,
Guarantor agrees, on demand by Landlord: (i) to perform such Obligations, and (ii) to indemnify and hold Landlord and the other Indemnified
Parties (as defined in the Lease) harmless from and against any and all loss, damage, cost, expense, injury or liability Landlord or
the other Indemnified Parties may suffer or incur in connection with the exercise of their rights under the Lease or this Guaranty. If
Guarantor fails to commence and pursue diligently the performance of the Obligations within five (5) Business Days after its receipt
of written notice from Landlord demanding the performance of Guarantor, then, either before or after pursuing any other remedy of Landlord
against Guarantor or Tenant and regardless of whether Landlord shall ever pursue any such other remedy, Landlord shall have the right
(but not the obligation) to perform such Obligations or to call upon any other reputable parties to perform such Obligations, with such
changes or modifications as Landlord reasonably deems necessary or appropriate, and shall have the right to expend such sums as Landlord
in its reasonable discretion deems proper in order so to complete the performance of such Obligations. During the course of the performance
of any Obligations undertaken by Landlord or by any other party on behalf of Landlord, Guarantor shall pay on demand any amounts due
to third parties in connection therewith. All amounts required to be paid under this <U>Section 3</U> shall be included within the term
 &ldquo;<U>Liabilities</U>,&rdquo; and all obligations required to be performed under this <U>Section 3</U> shall be included within the
term &ldquo;<U>Obligations</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
Notwithstanding anything to the contrary herein contained, in any action to enforce any of the liabilities or obligations of Guarantor
under this Guaranty, Landlord, at its election, may proceed against Guarantor with or without: (i) joining Tenant in any such action;
(ii) commencing any action against or obtaining any judgment against Tenant; or (iii) commencing any proceeding to enforce or realize
upon any collateral or other security (including, without limitation, any security deposit or other guaranties) which may be given to
secure Tenant&rsquo;s obligations under the Lease, or to obtain any judgment, decree or foreclosure sale with respect thereto. Nevertheless,
the maintenance of any action or proceeding by Landlord to recover any sum or sums that may be or become due under the Lease or to secure
the performance of any of the other terms, covenants and conditions of the Lease shall not preclude Landlord from demanding and receiving
the payment of such sums and the performance of such other terms, covenants and conditions from Guarantor, or from thereafter instituting
and maintaining subsequent actions or proceedings for any subsequent default or defaults of Tenant under the Lease. Guarantor does hereby
consent that, without affecting the liability of Guarantor under this Guaranty and without notice to Guarantor, time may be given by
Landlord to Tenant for payment of Basic Rent and Additional Rent and such other sums and performance of said other terms, covenants and
conditions, or any of them, and such time extended and indulgence granted from time to time, or Tenant may be dispossessed or Landlord
may avail itself of or exercise any or all of the rights and remedies against Tenant provided by Legal Requirements or by the Lease,
and may proceed either against Tenant alone or jointly against Tenant and Guarantor or against Guarantor alone without first proceeding
or exhausting any remedy or claim against Tenant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Return
of Payments: Duty to Remain Informed.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Guarantor agrees that, if at any time all or any part of
any payment theretofore applied by Landlord to any Liabilities is rescinded or returned by Landlord for any reason whatsoever (including,
without limitation, the insolvency, bankruptcy, liquidation or reorganization of any party), such Liabilities shall, for the purposes
of this Guaranty, be deemed to have continued in existence to the extent of such payment, notwithstanding such application by Landlord,
and this Guaranty shall continue to be effective or be reinstated, as the case may be, as to such Liabilities, all as though such application
by Landlord had not been made. Guarantor does hereby further agree that with respect to any payments made by Guarantor hereunder, Guarantor
shall not have any rights based on suretyship, subrogation or otherwise to stand in the place of Landlord so as to compete with Landlord
as a creditor of Tenant, and Guarantor hereby waives all such rights to the fullest extent permitted by Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Guarantor assumes the responsibility to remain informed of the
financial condition of Tenant and of all other circumstances bearing risk of Tenant&rsquo;s default under the Lease which reasonable inquiry
would reveal, and agrees that Landlord shall have no duty to advise Guarantor of information known to it regarding any such condition
or circumstance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.8pt"><FONT STYLE="font-size: 10pt">5.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No Discharge.</U> Guarantor agrees that the
obligations, covenants and agreements of Guarantor under this Guaranty shall not be affected or impaired by any act of Landlord, or
any event or condition except the full, final and unavoidable performance of all Obligations and payment of all Liabilities and any
other sums due hereunder. Guarantor agrees that the liability of Guarantor under this Guaranty shall not be discharged, reduced or
otherwise affected by, and Guarantor hereby irrevocably consents to: (i) any subsequent change, modification or amendment of the
Lease in any of its terms, covenants and conditions, or in the Basic Rent and Additional Rent or any other sums payable thereunder,
or in the Premises demised thereby (whether said Premises be expanded, contracted, relocated, substituted or otherwise altered), and
to any assignments of the Lease and to any subletting of the Premises, and to any extensions or renewals of the Lease or its Term;
(ii) the renewal or extension of time for the payment of the Liabilities or performance of the Obligations under the Lease; (iii)
any transfer, waiver, compromise, settlement, modification, surrender or release of Tenant&rsquo;s obligations under the Lease; (iv)
the existence of any defenses to enforcement of the Lease; (v) any failure, omission, delay or inadequacy, whether entire or
partial, of Landlord to exercise any right, power or remedy regarding the Lease or to enforce or realize upon (or to make any
guarantor a party to the enforcement or realization upon) any of Landlord&rsquo;s security for the Lease, including, but not limited
to, any impairment or release of such security by Landlord; (vi) the existence of any setoff, claim or counterclaim or the reduction
or diminution of the Liabilities, or any defense of any kind or nature which Guarantor may have against Tenant or which Tenant or
Guarantor has against Landlord; (vii) the application of payments received from any source to the payment of any obligation other
than the Liabilities, even though Landlord might lawfully have elected to apply such payments to any part or all of the Liabilities;
(viii) the addition or release of any and all other guarantors, obligors and other persons liable for the payment of the Liabilities
and/or performance of the Obligations, and the acceptance or release of any and all other security for the payment of the
Liabilities and/or performance of the Obligations; (ix) any distress or reentry by Landlord or dispossession of Tenant or any action
or remedy taken by Landlord under the Lease following an Event of Default thereunder, including termination of the Lease (in which
event the Obligations and Liabilities of Guarantor shall not be reduced, released or otherwise affected and shall continue to accrue
as if the Lease had not been so terminated); or (x) any failure of Landlord to notify Guarantor of any default by Tenant under the
Lease; all whether or not Guarantor shall have had notice or knowledge of any act, omission or event referred to in the foregoing
clauses (i) through (x) inclusive of this Paragraph. In the event that the Lease is modified, renewed or extended in any respect by
agreement between Landlord and Tenant either pursuant to an option granted in the Lease or otherwise, or in the event that Tenant
holds over beyond the Term of the Lease, then the obligations of Guarantor under this Guaranty shall extend to the full and faithful
performance and observance of all of the covenants, terms and conditions of the Lease and of any such modification, renewal or
extension thereof. Guarantor intends that Guarantor shall remain liable hereunder as a principal until the full, final and
unavoidable performance of all of the Obligations and the full, final and unavoidable payment of all Liabilities, notwithstanding
any fact, act, event or occurrence which might otherwise operate as a legal or equitable discharge of a surety or
guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Application
of Amounts Received.</U> Any amounts received by Landlord from whatsoever source on account of any Liabilities may be applied by Landlord
toward the payment of such Liabilities and in such order of application, as Landlord may from time to time elect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-size: 10pt">7.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Waiver.</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Guarantor
expressly waives: (i) notice of the acceptance by Landlord of this Guaranty; (ii) notice of the existence, creation, payment or nonpayment
of the Liabilities; (iii) presentment, demand, notice of dishonor, protest and all other notices whatsoever; and (iv) any failure by
Landlord to inform Guarantor of any facts Landlord may now or hereafter know about Tenant, the Lease or the Premises, it being understood
and agreed that Guarantor has and will maintain knowledge of and is familiar with Tenant&rsquo;s financial condition and business affairs,
and that Landlord has no duty so to inform, and that Guarantor is fully responsible for being and remaining informed by, Tenant of all
circumstances bearing on the Lease and this Guaranty. No modification or waiver of any of the provisions of this Guaranty will be binding
upon the parties hereto except as expressly set forth in a writing duly signed and delivered on behalf of the parties hereto. No notice
to or demand on Guarantor, in any case shall, of itself, entitle Guarantor to any other or further notice or demand in similar or other
circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To the extent permitted by Legal Requirements, this Guaranty
shall be effective as a waiver of, and Guarantor waives, any and all rights, defenses or remedies to which Guarantor may have or may
otherwise have been entitled under any suretyship laws or similar laws in effect from time to time including, but not limited to, Section
17.001 of the Texas Civil Practice and Remedies Code, Texas Rule of Civil Procedure 31, and Chapter 43 of the Civil Practice and Remedies
Code, entitled Principal and Surety, including without limitation, notice, discharge, levy and subrogation. To the extent permitted by
Legal Requirements, Grantor additionally waives the benefit of any statute of limitations affecting Guarantor&rsquo;s liability under this
Guaranty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.95pt"><FONT STYLE="font-size: 10pt">8.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Enforcement Costs</U>. If: (i) the Lease or this
Guaranty is placed in the hands of an attorney for enforcement or collection or is enforced or collected through any legal proceeding,
or (ii) an attorney is retained to represent Landlord in any proceeding (including, without limitation, any bankruptcy, reorganization,
receivership or other proceeding affecting creditors&rsquo; rights) involving a claim under the Lease or this Guaranty, then Guarantor shall
pay to Landlord upon demand all reasonable attorneys&rsquo; fees, costs and expenses, including, without limitation, court costs and filing
fees, and all other reasonable out-of-pocket costs and expenses incurred in connection therewith (all of which are referred to herein
as &ldquo;<U>Enforcement Costs</U>&rdquo;), in addition to all other amounts due hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 34.75pt"><FONT STYLE="font-size: 10pt">9.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transfer of Lease</U>. Notwithstanding any assignment
or transfer of the Lease or any interest therein by Landlord, for collateral purposes or otherwise, each and every immediate and successive
assignee, transferee, or other successor in interest with respect to Landlord&rsquo;s interest under the Lease shall, to the extent of the
interests assigned or transferred, be entitled to the benefits of this Guaranty to the same extent as if such assignee or transferee
were Landlord. Any Mortgagee holding a collateral assignment of the Lease is expressly entitled to the benefits of this Guaranty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.2pt"><FONT STYLE="font-size: 10pt">10.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subordinated Debt</U>. Any indebtedness of Tenant
to Guarantor (the &ldquo;<U>Subordinated Debt</U>&rdquo;) now or hereafter existing is hereby subordinated to the Liabilities. Guarantor
agrees that, after receipt of written notice that an Event of Default exists under the Lease and during the continuance of such Event
of Default, Guarantor will not seek, accept or retain for Guarantor&rsquo;s own account, any payment from Tenant on account of the Subordinated
Debt until the full, final and unavoidable payment of the Liabilities. Any payments received by Guarantor on account of the Subordinated
Debt while an Event of Default exists under the Lease shall be collected and received by Guarantor in trust for Landlord and shall be
paid over to Landlord on account of the Liabilities without impairing or releasing the obligations of Guarantor under this Guaranty except
to the except of the payments so paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">11.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Binding Effect: Successors and Assigns</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Guaranty shall bind Guarantor and its successors and
assigns; provided that Guarantor shall not be entitled to transfer or delegate its obligations under this Guaranty without Landlord&rsquo;s
prior written consent, which consent may be withheld in Landlord&rsquo;s sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
It is agreed that Guarantor&rsquo;s liability hereunder is independent of any other guaranties or other obligations at any time in effect with
respect to the Liabilities, the Obligations or any part thereof and that Guarantor&rsquo;s liability hereunder may be enforced regardless of
the existence, validity, enforcement or non-enforcement of any such other guaranties or other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Guaranty shall inure to the benefit of, and may be
enforced by, Landlord and Landlord&rsquo;s successors and assigns under the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><FONT STYLE="font-size: 10pt">12.
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>One-Time Assignment of Guarantv</U>. Notwithstanding <U>Section
1 l(a)</U>, in connection with a Transfer that is a Permitted Successor Event, Guarantor shall have a one-time right, upon not less than
thirty (30) days&rsquo; prior written notice to Landlord, to assign its obligations under this Guaranty provided that the following requirements
are satisfied at the time of the Permitted Successor Event:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no material default has occurred under this Guaranty beyond
any applicable notice and cure period therefor and no Event of Default exists under the Lease which will not be cured in connection with
the Permitted Successor Event;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the proposed assignee is not an Affiliate of Guarantor and such
non-Affiliate proposed assignee shall have a Tangible Net Worth equal to or greater than $50,000,000, as evidenced by such assignee&rsquo;s
latest audited financial statements or other evidence reasonably satisfactory to Landlord;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Guarantor shall provide Landlord with such corporate organizational documents,
evidence of authority, good standing, and other similar materials as Landlord may reasonably require with respect to the proposed assignee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the proposed assignee shall be in compliance with OF AC regulations
of the US Department of Treasury (including those named on OFAC&rsquo;s Specially Designated and Blocked Persons List) and any
statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with
Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; the replacement guarantor shall enter into a replacement guaranty in
the same form as this Guaranty other than the deletion of this <U>Section 12</U> and any updates to the names of the parties, dates,
and references to the documents referred to herein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; any and all reasonable costs and expenses of Landlord incurred in connection with the
foregoing assignment (including, without limitation, Landlord&rsquo;s reasonable attorneys&rsquo; fees, costs and disbursements) up to $2,000.00
are paid to Landlord at or prior to the consummation of the assignment of the Guaranty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt"><FONT STYLE="font-size: 10pt">Upon
Landlord&rsquo;s reasonable determination that the foregoing requirements have been satisfied (such date referred to herein as the &ldquo;<U>Release
Date</U>&rdquo;), then Guarantor shall not have any liability for the Liabilities or Obligations to the extent arising from any circumstance,
condition, action, omission or event with respect to the Lease or Tenant first occurring after the Release Date; <U>provided, however</U>,
that Guarantor shall remain liable under this Guaranty for any Liabilities or Obligations to the extent arising from any circumstance,
condition, action, omission or event occurring on or prior to the Release Date. Landlord shall provide Guarantor with written confirmation
of the Release Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt"><FONT STYLE="font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Guaranty constitutes the entire agreement between Guarantor
and Landlord with respect to the subject matter hereof and supersedes any and all such prior agreements and understandings, both written
and oral. This Guaranty may not be modified or amended except by a written instrument signed by Landlord and Guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
This Guaranty shall be governed by the laws of the State of Texas without reference to the conflicts of law principles of that state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt; text-align: justify; text-indent: 69.7pt"><FONT STYLE="font-size: 10pt">(c)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The headings of Paragraphs in this Guaranty are for convenience
only and shall not be construed in any way to limit or define the content, scope or intent of the provisions hereof. As used in this
Guaranty, the singular shall include the plural, and masculine, feminine and neuter pronouns shall be fully interchangeable where the
context so requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If this Guaranty is executed by more than one person or
entity, then references to &ldquo;Guarantor&rdquo; herein shall be deemed to refer to each such person or entity and the liability of each
such person or entity shall be joint and several, and the release by Landlord of any of them shall not release or affect in any manner
the obligations of any other of them and this Guaranty shall not be revoked, discharged or impaired as to any such persons or entitles
by reason of the death or incapacity or insolvency of any other of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If any provision of this Guaranty, or any paragraph, sentence,
clause, phrase or word, or the application thereof, in any circumstances, is adjudicated by a court of competent jurisdiction to be invalid,
the validity of the remainder of this Guaranty shall be construed as if such invalid part were never included herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Time is of the essence of this Guaranty. </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; All payments to be made hereunder shall be made in in currency and coin
of the United States of America which is legal tender for public and private debts at the time of payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Guaranty may be executed at different times and in any number
of originals or counterparts, each of which shall be deemed an original, but all of which together shall constitute only one instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any notice, demand or request by Landlord to Guarantor or by Guarantor
to Landlord hereunder shall be in writing and shall be directed to Landlord or Guarantor (as applicable) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">If to Guarantor:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Prior to July 1. 2020:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris Life Sciences, Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">c/o Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">750 W. John Carpenter Freeway, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, Texas 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Michael Halbert, SVP Human Resources</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris Life Sciences, Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">c/o Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">750 W. John Carpenter Freeway, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, Texas 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>From and after July 1. 2020:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris Life Sciences, Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">c/o Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3600 W. Royal Lane</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, Texas 75063</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Michael Halbert, SVP Human Resources</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">with
    a copy to:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Caris
    Life Sciences, Ltd. </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">c/o Caris MPI, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3600 W. Royal Lane</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, Texas 75063</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">If to Landlord:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">KCP NNN II Leasehold 4, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">c/o Kawa Capital Partners LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">21500 Biscayne Boulevard, Suite 700</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Aventura, Florida 33180</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: General Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Greenberg Traurig, P.A.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">333 S.E. 2nd Avenue, Suite 4400</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Miami, Florida 33131</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Gavin Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile: [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.7pt"><FONT STYLE="font-size: 10pt">Notices
shall be either (i) personally delivered (including delivery by reputable overnight courier service) to the offices set forth above,
in which case they shall be deemed delivered on the date of delivery to said offices, or (ii) sent by facsimile or email (as applicable),
provided that for any notices sent by facsimile or email a copy shall also be sent by personal delivery or overnight delivery service.
Any notice actually received or deemed received pursuant to the foregoing provisions on a non-Business Day or after the close of business
of the recipient on a Business Day shall be deemed received on the next Business Day. Either party may by written notice to the other
party given as provided hereunder change its address for service of notice to any other recognized business address in the continental
United States. Any address so designated shall include a street address for courier delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;GUARANTOR KNOWINGLY, IRREVOCABLY, VOLUNTARILY, AND INTENTIONALLY
WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY OR AGAINST LANDLORD
OR ON ANY MATTER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS GUARANTY, THE LEASE, ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS
(WHETHER ORAL OR WRITTEN), ACTIONS OF GUARANTOR, THE TENANT OR THE LANDLORD, OR THE RELATIONSHIPS BETWEEN GUARANTOR, TENANT AND LANDLORD.
THIS PROVISION IS A MATERIAL INDUCEMENT FOR LANDLORD ACCEPTING THIS GUARANTY FROM GUARANTOR. Landlord and Guarantor agree to be subject
to the jurisdiction of state or federal courts sitting in or for Dallas County, Texas, to accept service of process in any action brought
in Texas and to accept service by certified mail or personal service and Landlord and Guarantor waive any objection to personal jurisdiction
in any such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within ten (10) Business Days after receipt of Landlord&rsquo;s written
request, Guarantor shall execute and deliver to Landlord a written statement certifying: (i) the continuing effect and enforceability
of this Guaranty; (ii) the absence of any modification of this Guaranty or, if there has been any such modification, stating the same;
and (iii) to the knowledge of the signatory, the absence of a default by Landlord under the Lease or the Guaranty, or, if there is such
a default, stating the same. Each such statement shall be addressed to, and may be relied upon (and the certificate shall so recite)
by Landlord, any Mortgagee, any purchaser of all or part of the Premises and such purchaser&rsquo;s lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[Remainder
of Page Intentionally Left Blank]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 14pt; text-indent: 34.6pt"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the undersigned has executed this Guaranty as of the day and year first above set forth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><FONT STYLE="font-size: 10pt"><B><U>GUARANTOR</U>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CARIS LIFE SCIENCES, LTD.,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">a Cayman Islands exempted limited company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 14pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 14pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-size: 10pt">STATE OF TEXAS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-size: 10pt">&sect;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&sect;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">COUNTY OF DALLAS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&sect;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">This
instrument was acknowledged before me on July___, 2019, by________, ______of Caris Life Sciences, Ltd., a Cayman Islands exempted limited
company, on behalf of said entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Notary Public in and for the State of Texas</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">My commission expires:_________</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 88; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(A)
<SEQUENCE>14
<FILENAME>tm2415719d15_ex10-4a.htm
<DESCRIPTION>EXHIBIT 10.4(A)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;10.4(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED 2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>PURPOSE; ELIGIBILITY.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General
Purpose</U>. The purpose of the Caris Life Sciences,&nbsp;Inc. Amended and Restated 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;),
is to enable Caris Life Sciences,&nbsp;Inc., a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and any Affiliate to align
and link the interests of the Company Group&rsquo;s Employees, Consultants and Directors with the interests of the Shareholders via the
issuance of Awards, the value of which are linked directly to sustained growth in the value of the Company. The Plan as amended and restated
shall be effective as of the date of approval by the Shareholders (the &ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Eligible
Award Recipients</U>. The persons eligible to receive Awards are the Employees, Consultants and Directors (each, a &ldquo;<B><I>Service
Provider</I></B>&rdquo;) of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Available
Awards</U>. The purpose of the Plan is to provide a means by which eligible recipients of Awards may be given an opportunity to benefit
from increases in value of the Common Stock through the granting of one or more of the following Awards: (a)&nbsp;Options, (b)&nbsp;Restricted
Awards, (c)&nbsp;Performance Awards and (d)&nbsp;Share Appreciation Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>DEFINITIONS.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Administrator</I></B>&rdquo;
means the Directors or the Committee appointed by the Directors in accordance with <U>Section&nbsp;3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Affiliate</I></B>&rdquo;
means any parent corporation or Subsidiary of the Company, whether now or hereafter existing, as those terms are defined in Sections 424(e)&nbsp;and
(f), respectively, of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Applicable
Laws</I></B>&rdquo; means any applicable legal requirements relating to the administration of and the issuance of ownership interests
and/or other securities under equity-based compensation plans, including, without limitation, U.S. state corporate laws, U.S. federal
and state securities laws, the Code and the requirements of any stock exchange or quotation system upon which the Common Stock may be
listed or quoted and the laws of any other country or jurisdiction where Awards are granted under the Plan. For all purposes of this Plan,
references to statutes and regulations shall be deemed to include any successor statutes or regulations, where necessary as determined
by the Administrator in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Articles</I></B>&rdquo;
means the Company&rsquo;s Articles of Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Award</I></B>&rdquo;
means any right granted under the Plan, including an Option, a Restricted Award, a Performance Award and a Share Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Award
Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of an Award evidencing the terms and conditions of
an individual Award grant. Each Award Agreement shall be subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Beneficial
Owner</I></B>&rdquo; has the meaning assigned to such term in Rule&nbsp;13d-3 and Rule&nbsp;13d-5 under the Exchange Act, except that
in calculating the beneficial ownership of any particular &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d)(3)&nbsp;of
the Exchange Act), such &ldquo;person&rdquo; shall be deemed to have beneficial ownership of all securities that such &ldquo;person&rdquo;
has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable
only after the passage of time. The terms &ldquo;Beneficially Owns&rdquo; and &ldquo;Beneficially Owned&rdquo; have a corresponding meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Board</I></B>&rdquo;
means the Board of Directors of the Company, as constituted from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Cashless
Exercise</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;6.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Change
of Control</I></B>&rdquo; shall mean</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
direct or indirect sale, transfer, conveyance, exclusive license or other disposition (other than by way of merger or consolidation),
in one or a series of related transactions, of all or substantially all of the properties or assets of the Company and its subsidiaries,
taken as a whole, to any &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d)(3)&nbsp;of the Exchange Act, which includes
any two or more persons acting as a group);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
adoption of a plan relating to the liquidation or dissolution of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>acquisition
by any &ldquo;person&rdquo; of Beneficial Ownership of 50% or more (on a fully-diluted basis) of either (i)&nbsp;the then outstanding
shares of Common Stock of the Company, taking into account as outstanding for this purpose such Common Stock issuable upon the exercise
of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock
(the &ldquo;<B><I>Outstanding Company Common Stock</I></B>&rdquo;) or (ii)&nbsp;the combined voting power of the then outstanding voting
securities of the Company entitled to vote generally in the election of directors (the &ldquo;<B><I>Outstanding Company Voting Securities</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the
Company that requires the approval of the Shareholders pursuant to the TBOC, whether for such transaction or the issuance of securities
in the transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
following individuals cease for any reason to constitute a majority of the number of Directors then serving: individuals who, on the Effective
Date, constitute the Board and any new Director (other than a Director whose initial assumption of office is in connection with an actual
or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of Directors of the Company)
whose appointment or election by the Board or nomination for election by the Shareholders was approved or recommended by either (x)&nbsp;a
vote of at least a majority of the Directors then still in office who either were Directors on the Effective Date or whose appointment,
election or nomination for election was previously so approved or recommended, or (y)&nbsp;a Permitted Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, a transaction of
any type shall not constitute a Change of Control if (A)&nbsp;it constitutes an initial public offering or a secondary public offering
that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved
for designation) as a national market security on an interdealer quotation system; (B)&nbsp;its sole purpose is to change the jurisdiction
of the Company&rsquo;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons
who held the Company&rsquo;s securities immediately before such transaction; (C)&nbsp;it is an acquisition by any employee benefit plan
sponsored or maintained by the Company or any subsidiary; or (D)&nbsp;immediately following the transaction, (i)&nbsp;more than 50% of
the total voting power of the entity resulting from such transaction, or if applicable, the ultimate parent entity that directly or indirectly
has beneficial ownership of sufficient voting securities eligible to elect a majority of the members of the board of directors (or the
analogous governing body) of the entity resulting from such transaction, is represented by the Outstanding Company Voting Securities that
were outstanding immediately prior to such transaction (or, if applicable, is represented by shares into which the Outstanding Company
Voting Securities were converted pursuant to such transaction), and such voting power among the holders thereof is in substantially the
same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the transaction
or (ii)&nbsp;a Permitted Holder continues to maintain voting control, directly or indirectly and whether by equity ownership, contract
or otherwise, of the Company. If a Change of Control constitutes a payment event with respect to any Award that provides for the deferral
of compensation and is subject to Section&nbsp;409A of the Code, the transaction or event must be both a Change of Control under this
definition and constitute a &ldquo;change in control event,&rdquo; as defined in Treasury Regulation &sect;1.409A-3(i)(5)&nbsp;to the
extent required by Section&nbsp;409A of the Code. The Administrator shall have full and final authority, which shall be exercised in good
faith, to determine conclusively whether a Change of Control of the Company has occurred pursuant to the above definition, and the date
of the occurrence of such Change of Control and any incidental matters relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Code</I></B>&rdquo;
means the Internal Revenue Code of 1986, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Committee</I></B>&rdquo;
means a committee of one or more Directors appointed by the Directors to administer the Plan in accordance with <U>Section&nbsp;3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Common
Stock</I></B>&rdquo; means a share of Class&nbsp;A common stock of the Company, par value US$0.001 per share, or Class&nbsp;B common stock
of the Company, par value US$0.001 per share, as applicable, issued subject to and in accordance with the provisions of the TBOC and the
Articles and having the rights provided for in the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Company</I></B>&rdquo;
means Caris Life Sciences,&nbsp;Inc., a Texas corporation, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Company
Group</I></B>&rdquo; means the Company and its Affiliates, or one of the members of the Company Group, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Competing
Business</I></B>&rdquo; means any business entity principally engaged in (i)&nbsp;the discovery, research, development and commercialization
of any clinical application involving or relating to microvesicles, exosomes, proteins or nucleic acids, irrespective of their form (including
messenger RNA, miRNA and any other molecular bio-markers, bio-signatures, particles, substances or entities); (ii)&nbsp;molecular profiling
and therapeutic decision support in the oncology field; (iii)&nbsp;artificial intelligence; or (iv)&nbsp;any other business that the Company
is then conducting or planning to conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Consultant</I></B>&rdquo;
means any person, including an advisor or contractor, (a)&nbsp;engaged by the Company Group to render consulting or advisory services
and who is compensated for such services or who provides bona fide services to the Company Group pursuant to a written agreement or (b)&nbsp;who
is a director of an Affiliate; <I>provided</I> that, except as otherwise permitted in <U>Section&nbsp;5.3(b)</U>&nbsp;hereof, such person
is a natural person and such services are not in connection with the offer or sale of securities in a capital raising transaction and
do not directly or indirectly promote or maintain a market for the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Continuous
Service</I></B>&rdquo; means that the Participant&rsquo;s service with the Company Group, whether as an Employee, Director or Consultant,
is not interrupted or terminated. The Participant&rsquo;s Continuous Service shall not be deemed to have terminated merely because of
a change in the capacity in which the Participant renders service to the Company Group as an Employee, Consultant or Director or a change
in the entity for which the Participant renders such service, <I>provided</I> that there is no interruption or termination of the Participant&rsquo;s
Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or a Director will
not constitute an interruption of Continuous Service. The Administrator, the chief executive officer of the Company or the president of
the Company, in that party&rsquo;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case
of any leave of absence approved by that party, including sick leave, military leave or any other personal leave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Date
of Grant</I></B>&rdquo; means the date on which the Administrator adopts a resolution, or takes other appropriate action, expressly granting
an Award to a Participant or, if a different date is set forth in such resolution, or determined by the Administrator, as the Date of
Grant, then such date as is set forth in such resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Detrimental
Activity</I></B>&rdquo; means: (i)&nbsp;violation of the terms of any agreement with or policy of the Company Group concerning non-competition,
non-disclosure, confidentiality, intellectual property, non-disparagement, privacy or exclusivity; (ii)&nbsp;disclosure of the Company
Group&rsquo;s confidential information to anyone outside the Company Group, without prior written authorization from the Company Group,
or in conflict with the interests of the Company Group, whether the confidential information was acquired or disclosed by the Participant
during or after employment by the Company Group; (iii)&nbsp;failure or refusal to disclose promptly or assign to the Company Group all
right, title and interest in any invention, work product or idea, patentable or not, made or conceived by the Participant during employment
by the Company Group, relating in any manner to the interests of the Company Group or, the failure or refusal to do anything reasonably
necessary to enable the Company Group to secure a patent where appropriate in the United States and in other countries; (iv)&nbsp;the
conviction of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude; (v)&nbsp;the commission of an act involving
willful malfeasance or material fiduciary breach with respect to the Company Group; (vi)&nbsp;gross negligence or willful misconduct with
respect to the Company Group; (vii)&nbsp;any breach of a restrictive covenant contained in any employment agreement, Award Agreement or
other agreement between the Participant and the Company Group, during any period for which a restrictive covenant prohibiting Detrimental
Activity, or other similar conduct or act, is applicable to the Participant during or after employment by the Company Group; (viii)&nbsp;any
attempt directly or indirectly to induce any Employee of the Company Group to be employed or perform services or acts in conflict with
the interests of the Company Group; (ix)&nbsp;any attempt, in conflict with the interests of the Company Group, directly or indirectly,
to solicit the trade or business of any current or prospective customer, client, supplier or partner of the Company Group; or (x)&nbsp;any
material breach or non-compliance with the terms of the Plan or an Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Director</I></B>&rdquo;
means a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Disability</I></B>&rdquo;
means a physical or mental disability or infirmity of the Participant that prevents the normal performance of substantially all of the
Participant&rsquo;s duties for a continuous period in excess of 90 days or for more than 180 days during any one year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Employee</I></B>&rdquo;
means any person employed by the Company Group. Mere service as a Director or payment of a director&rsquo;s fee by the Company Group shall
not be sufficient to constitute &ldquo;employment&rdquo; by the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Fair
Market Value</I></B>&rdquo; means, as of any date, the value, on a fully diluted basis, of a Common Stock as determined in good faith
by a nationally recognized valuation firm; <I>provided</I>, <I>however</I>, that, in the event that the Company conducts an initial public
offering, the Fair Market Value on the date of the Company&rsquo;s initial public offering of its Common Stock shall be the initial price
to the public of the Common Stock, and thereafter (i)&nbsp;if the Common Stock are admitted to quotation on a national securities exchange,
the Fair Market Value on any given date shall not be less than the average of the highest bid and lowest asked prices of the Common Stock
reported for such date or, if no bid and asked prices were reported for such date, for the last day preceding such date for which such
prices were reported or (ii)&nbsp;if the Common Stock are admitted to trading on an applicable securities exchange, the Fair Market Value
on any date shall not be less than the closing price reported for the Common Stock on such exchange or system for such date or, if no
sales were reported for such date, for the last date preceding the date for such a sale was reported. Any determination of Fair Market
Value made pursuant to this Plan shall be made without regard to any minority interest status or the limited liquidity of the Common Stock
and shall be final, binding and conclusive with respect to all Awards granted under this Plan. If the Common Stock are not listed on an
established securities exchange or regularly quoted by a recognized securities dealer, then Fair Market Value shall be established in
good faith, in compliance with the requirements of Section&nbsp;409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Form&nbsp;S-8</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>GAAP</I></B>&rdquo;
means the United States Generally Accepted Accounting Principles, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Incentive
Stock Option</I></B>&rdquo; means an Option that is intended to comply with the requirements of Section&nbsp;422 of the Code or any successor
provision thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Listing
Date</I></B>&rdquo; means the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance
on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer
quotation system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Market
Stand-Off</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;15</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Net
Exercise Period</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;11.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Nonqualified
Stock Option</I></B>&rdquo; means an Option that is not intended or fails to comply with the requirements of Section&nbsp;422 of the Code
or any successor provision thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Non-Employee
Director</I></B>&rdquo; means a Director who is a &ldquo;non-employee director&rdquo; within the meaning of Rule&nbsp;16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Option</I></B>&rdquo;
means an option to purchase Common Stock that is either an Incentive Stock Option or Nonqualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Option
Agreement</I></B>&rdquo; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an individual
Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan and need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Optionholder</I></B>&rdquo;
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Participant</I></B>&rdquo;
means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.38&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Performance
Award</I></B>&rdquo; means an Award entitling the recipient to receive Common Stock or a cash payment upon the attainment of Performance
Goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.39&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Performance
Goals</I></B>&rdquo; means, for a Performance Period, one or more goals established in writing by the Administrator for the Performance
Period based upon one or more performance criteria. Depending on the performance criteria used to establish such Performance Goals, the
Performance Goals may be expressed in terms of overall Company performance or the performance of a division, operating or business unit,
or an individual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Performance
Period</I></B>&rdquo; means the Company&rsquo;s fiscal year, or any other period of time as the Administrator may select, over which the
attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&rsquo;s right to, and the payment
of, a Performance Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Permitted
Holders</I></B>&rdquo; means (i)&nbsp;David D. Halbert, (ii)&nbsp;his spouse, widow, widower, domestic partner, parents, grandparents,
lineal descendants, siblings and lineal descendants of siblings (in each case whether by blood relation, adoption, marriage or domestic
partnership) of such person and heirs and any trusts or other holding, investment or estate planning vehicles for the benefit of any of
the foregoing (collectively, together with David D. Halbert, &ldquo;<B><I>Halbert Family Members</I></B>&rdquo;) and (iii)&nbsp;any Person,
any affiliate of, or corporation, general partnership, limited partnership, limited liability company, private limited company or other
entity that directly or indirectly controls, is controlled by, or is under common control with, the Halbert Family Members, or any Permitted
Trust primarily for the benefit of the Halbert Family Members. The phrase &ldquo;controlled by&rdquo; means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of
voting securities, by contract or otherwise, and &ldquo;Permitted Trust&rdquo; means a bona fide trust where each trustee is (i)&nbsp;a
Halbert Family Member, (ii)&nbsp;a professional in the business of providing trustee services, including private professional fiduciaries,
trust companies and bank trust departments, or (iii)&nbsp;an individual who may be removed and replaced at the sole discretion of a Halbert
Family Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.42&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Permitted
Transferee</I></B>&rdquo; means (i)&nbsp;any spouse, parents, siblings (by blood, marriage or adoption) or lineal descendants (by blood,
marriage or adoption) of a Participant; (ii)&nbsp;any trust or other similar entity for the benefit of a Participant or the Participant&rsquo;s
spouse, parents, siblings or lineal descendants; <I>provided</I>, <I>however</I>, that any transfer made by a Participant to a Permitted
Transferee may only be made if the Permitted Transferee, prior to the time of transfer of Common Stock, agrees in writing to be bound
by the terms of this Agreement and provides written notice to the Company of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.43&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Person</I></B>&rdquo;
means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association,
trust, joint venture, association or other similar entity, whether or not a legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Plan</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Related
Rights</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.46&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Award</I></B>&rdquo; means a Restricted Share or an RSU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.47&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Award Agreement</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Share</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.49&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Right
of First Refusal</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;11.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Right
of Repurchase</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;11.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.51&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>RSU</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Rule&nbsp;16b-3</I></B>&rdquo;
means Rule&nbsp;16b-3 promulgated under the Exchange Act or any successor to Rule&nbsp;16b-3, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.53&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Rule&nbsp;701</I></B>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.54&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>SAR
exercise price</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;7.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.55&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.56&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Service
Provider</I></B>&rdquo; has the meaning set forth in <U>Section&nbsp;1.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.57&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Share
Appreciation Right</I></B>&rdquo; means the right pursuant to an award granted under <U>Section&nbsp;7.3</U> to receive an amount equal
to the excess, if any, of (A)&nbsp;the Fair Market Value, as of the date such Share Appreciation Right or portion thereof is surrendered,
of the Common Stock covered by such right or such portion thereof, over (B)&nbsp;the aggregate SAR exercise price of such right or such
portion thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.58&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Shareholder</I></B>&rdquo;
means a shareholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.59&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means any foreign or domestic corporation, limited liability company, partnership or other entity of which 50% or more of the outstanding
voting equity securities or voting power is Beneficially Owned directly or indirectly by the Company. For purposes of determining eligibility
for the grant of Incentive Stock Options under the Plan, the term &ldquo;Subsidiary&rdquo; shall be defined in the manner required by
Section&nbsp;424(f)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.60&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>TBOC</I></B>&rdquo;
means the Texas Business Organizations Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>ADMINISTRATION.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Administration
by Directors</U>. The Plan shall be administered by the Directors unless and until the Directors delegate administration to a Committee,
as provided in <U>Section&nbsp;3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Powers
of Administrator</U>. The Administrator shall have the power and authority to select and grant Awards, pursuant to the terms of the Plan,
to Participants nominated for participation in the Plan by the Company&rsquo;s chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Specific
Powers</U>. In particular, the Administrator shall have the authority: (i)&nbsp;to construe and interpret the Plan and apply its provisions;
(ii)&nbsp;to promulgate, amend and rescind rules&nbsp;and regulations relating to the administration of the Plan; (iii)&nbsp;to authorize
any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; (iv)&nbsp;to determine
when Awards are to be granted under the Plan; (v)&nbsp;from time to time to select, subject to the limitations set forth in this Plan,
those Participants to whom Awards shall be granted; (vi)&nbsp;to determine the number of shares and class of Common Stock to be made subject
to each Award; (vii)&nbsp;to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium
of payment, vesting, net exercise and Right of Repurchase provisions, and to specify the provisions of the Award Agreement relating to
such grant or sale; (viii)&nbsp;to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting,
the purchase price or exercise price, or the term of any outstanding Award; <I>provided</I>, <I>however</I>, that if any such amendment
impairs a Participant&rsquo;s rights or increases a Participant&rsquo;s obligations under his or her Award or creates or increases a Participant&rsquo;s
federal income tax liability with respect to an Award, such amendment shall also be subject to the Participant&rsquo;s consent (<I>provided</I>,
<I>however</I>, a cancellation of an Award where the Participant receives a payment equal in value to the Fair Market Value of the vested
Award or, in the case of vested Options, the difference between the Fair Market Value of the Common Stock subject to an Option and the
exercise price, shall not constitute an impairment of the Participant&rsquo;s rights that requires consent); (ix)&nbsp;to determine the
duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment
for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company&rsquo;s
employment policies; (x)&nbsp;to make decisions with respect to outstanding Options that may become necessary upon a change in corporate
control or an event that triggers anti-dilution adjustments; and (xi)&nbsp;to exercise discretion to make any and all other determinations
which it determines to be necessary or advisable for administration of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Decisions
Final</U>. All decisions made by the Administrator pursuant to the provisions of the Plan shall be final, binding and conclusive on the
Company and the Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>The
Committee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General</U>.
The Directors may delegate administration of the Plan to a Committee or Committees consisting of one or more Directors, and the term &ldquo;<B><I>Committee</I></B>&rdquo;
shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee
shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Directors, including the power
to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to
the Directors or the Administrator shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent
with the provisions of the Plan, as may be adopted from time to time by the Directors. The Directors may abolish the Committee at any
time and reassume responsibility for the administration of the Plan. The members of the Committee shall be appointed by and serve at the
pleasure of the Directors. From time to time, the Directors may increase or decrease the size of the Committee, add additional members
to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in
the Committee. The Committee shall act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only
two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and
minutes shall be kept of all of its meetings and copies thereof shall be provided to the Directors. Subject to the limitations prescribed
by the Plan and the Directors, the Committee may establish and follow such rules&nbsp;and regulations for the conduct of its business
as it may determine to be advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Committee
Composition when Common Stock are Publicly Traded</U>. At such time as the Common Stock are publicly traded, in the discretion of the
Directors, the Committee may consist solely of two or more Non-Employee Directors who meet the independence requirements of any securities
market on which the Common Stock are traded. The Directors shall have discretion to determine whether or not they intend to comply with
the exemption requirements of Rule&nbsp;16b-3 of the Code. However, if the Directors intend to satisfy such exemption requirements with
respect to any insider subject to Section&nbsp;16 of the Exchange Act, the Committee shall be a compensation committee of the Directors
that at all times consists solely of two or more Non-Employee Directors. Within the scope of such authority, the Directors or the Committee
may delegate to a committee of one or more Directors who are not Non-Employee Directors the authority to grant Awards to eligible persons
who are not then subject to Section&nbsp;16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification</U>.
In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed
by Applicable Law, the Administrator shall be indemnified by the Company against the reasonable expenses, including attorney&rsquo;s fees,
actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Administrator
may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan,
and against all amounts paid by the Administrator in settlement thereof (<I>provided</I> that the settlement has been approved by the
Company, which approval shall not be unreasonably withheld) or paid by the Administrator in satisfaction of a judgment in any such action,
suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Administrator
did not act in good faith; <I>provided</I>, <I>however</I>, that within 60 days after institution of any such action, suit or proceeding,
such Administrator shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance
on Experts</U>. In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may
rely upon the advice of experts, including employees of and professional advisors to the Company. No director, officer or agent of the
Company Group shall be liable for any such action or determination taken or made or omitted in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>COMMON STOCK SUBJECT TO THE PLAN.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Reserve</U>. Subject to the provisions of <U>Section&nbsp;12.1</U> relating to adjustments upon changes in the Common Stock, the shares
that may be issued pursuant to Awards shall consist of the Company&rsquo;s authorized but unissued Common Stock or Common Stock held by
the Company in its treasury, or a combination thereof, and the maximum aggregate amount of the Common Stock which may be issued upon exercise
of all Awards under the Plan shall not exceed 133,500,000 shares, all of which may be issued as Incentive Stock Options. To the extent
permitted by Applicable Laws or any applicable exchange rule, any Common Stock issued under this Plan that are issued (a)&nbsp;in connection
with the Company&rsquo;s acquisition of an unaffiliated business entity, (b)&nbsp;to the employees of such entity, and (c)&nbsp;in substitution
of equity incentive awards previously issued to such employees by such entity shall not reduce the number of Common Stock available for
issuance under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;</FONT><U>Reversion of Shares to the Share Reserve</U>. If any Award shall for any reason expire or
otherwise terminate, in whole or in part, without having been exercised in full, the Common Stock not acquired under such Award
shall revert to and again become available for issuance under the Plan. If Common Stock issued under the Plan are reacquired by the
Company pursuant to the terms of any provision of this Plan, including a Net Exercise Offer under <U>Section&nbsp;11.8</U> or the
Right of Repurchase of unvested Common Stock under <U>Section&nbsp;11.9</U>, such shares shall again be available for purposes of
the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Source
of Shares</U>. The Common Stock subject to the Plan may be authorized but unissued Common Stock or reacquired Common Stock, however reacquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Availability
of Shares</U>. During the terms of the Awards, the Company shall keep available at all times the number of Common Stock required to satisfy
such Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>ELIGIBILITY.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Eligibility</U>.
Awards may be granted to Employees, Directors and Consultants nominated for participation in the Plan, subject to the approval of the
Company&rsquo;s compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consultants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Prior
to the Listing Date, a Consultant shall not be eligible for the grant of an Award if, at the time of grant, either the offer or the sale
of the Company&rsquo;s securities to such Consultant is not exempt under Rule&nbsp;701 of the Securities Act (&ldquo;<B><I>Rule&nbsp;701</I></B>&rdquo;)
because of the nature of the services that the Consultant is providing to the Company, or because the Consultant is not a natural person,
or as otherwise provided by Rule&nbsp;701, unless the Company determines that such grant need not comply with the requirements of Rule&nbsp;701
and will satisfy another exemption under the Securities Act as well as comply with all Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
and after the Listing Date, a Consultant shall not be eligible for the grant of an Award if, at the time of grant, a Form&nbsp;S-8 Registration
Statement under the Securities Act (&ldquo;<B><I>Form&nbsp;S-8</I></B>&rdquo;) is not available to register either the offer or the sale
of the Company&rsquo;s securities to such Consultant because of the nature of the services that the Consultant is providing to the Company,
or because the Consultant is not a natural person, or as otherwise provided by the rules&nbsp;governing the use of Form&nbsp;S-8, unless
the Company determines both (i)&nbsp;that such grant (1)&nbsp;shall be registered in another manner under the Securities Act (e.g., on
a Form&nbsp;S-3 Registration Statement) or (2)&nbsp;does not require registration under the Securities Act in order to comply with the
requirements of the Securities Act, if applicable, and (ii)&nbsp;that such grant complies with the securities laws of all other relevant
jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Directors</U>.
Each Director of the Company shall be eligible to receive discretionary grants of Awards under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>OPTION PROVISIONS.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator may from
time to time grant Options to Service Providers. Each Option shall be in such form and shall contain such terms and conditions as the
Administrator shall deem appropriate, including whether such Options granted shall be Incentive Stock Options or Nonqualified Stock Options
and the class of Common Stock that each underlying share is with respect to. Each Option shall be evidence by an Option Agreement that
shall expressly identify the Option as Incentive Stock Option or Nonqualified Stock Option. The provisions of separate Options need not
be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance
of each of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Term</U>.
No Option shall be exercisable after the expiration of 10 years from the date it was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
Price of an Option</U>. The exercise price of each Option shall be not less than the greater of (a)&nbsp;100% of the Fair Market Value
of the Common Stock subject to the Option on the date the Option is granted and (b)&nbsp;the par value of the Common Stock. Notwithstanding
the foregoing, an Option may be granted with an exercise price lower than 100% of Fair Market Value of the Common Stock subject to the
Option on the date it is granted (but not less than par value) if such Option is granted pursuant to an assumption or substitution for
another option in a manner satisfying the provisions of Section&nbsp;424(a)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consideration</U>.
The purchase price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by Applicable Laws and regulations,
either: (a)&nbsp;in cash, by certified or bank check or by electronic funds transfer at the time the Option is exercised; (b)&nbsp;by
tendering to the Company other Common Stock, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption
or repurchase equal to the exercise price (or portion thereof) due for the number of shares being acquired (with the proceeds of such
redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Common Stock); or (c)&nbsp;during
a Net Exercise Period, by means of the Participant making an election, under the terms of the applicable Award Agreement, to receive a
portion of the Common Stock underlying the Option being exercised as a cash payment and a portion as Common Stock, with instructions to
the Company to apply such cash payment towards paying the purchase price of the Common Stock for which the Option is being exercised;
(d)&nbsp;during any period for which the Common Stock are publicly traded (<I>i.e.</I>, the Common Stock are listed on any established
stock exchange or a national market system, or if the Common Stock are quoted on an applicable stock exchange or any similar system whereby
the Common Stock are regularly quoted by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions
to a broker directing such broker to sell the Common Stock for which such Option is exercised, and to remit to the Company the aggregate
Exercise Price of such Options (a &ldquo;<B><I>Cashless Exercise</I></B>&rdquo;) or (e)&nbsp;in any other form of legal consideration
that may be acceptable to the Administrator, including without limitation with a promissory note; <I>provided</I>, <I>however</I>, if
Applicable Laws require (or the Administrator otherwise considers appropriate), the par value (if any) of Common Stock, if newly issued,
shall be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the
minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator
(in its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note.
Unless otherwise specifically provided in the Option, the purchase price of Common Stock acquired pursuant to an Option that is paid by
tendering to the Company for redemption or repurchase other Common Stock acquired, directly or indirectly, from the Company, shall be
paid only by Common Stock of the Company that have been held for more than six months (or such longer or shorter period of time required
to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, during any period for which the Common
Stock are publicly traded (<I>i.e.</I>, the Common Stock are listed on any established stock exchange or a national market system or if
the Common Stock are quoted on an applicable stock exchange or any similar system whereby the Common Stock are regularly quoted by a recognized
securities dealer but closing sale prices are not reported), a Cashless Exercise, exercise with a promissory note or other transaction
by a Director or executive officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension
of credit by the Company, or an Affiliate in violation of Section&nbsp;402(a)&nbsp;of the Sarbanes-Oxley Act (codified as Section&nbsp;13(k)&nbsp;of
the Exchange Act shall be prohibited with respect to any Award under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting;
Exercisability</U>. The Administrator will determine the vesting and exercisability provisions of each Option (which may be based on performance
criteria, passage of time or other factors or any combination thereof), which provisions will be set forth in the applicable Award Agreement.
Unless the Administrator or the terms of the Plan or the Award Agreement expressly provides otherwise, once exercisable, an Option will
remain exercisable until the expiration or earlier termination of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Procedure
for Exercise</U>. An exercisable Option may be exercised in whole or in part and will be deemed exercised when the Company receives: (a)&nbsp;written
or electronic notice of exercise (in accordance with the Award Agreement) from the person entitled to exercise the Option, and (b)&nbsp;full
payment for the Common Stock with respect to which the Option is exercised (including provision for any applicable tax withholding); <I>provided</I>
that if any person other than the Participant exercises the Option, such person will be required to provide evidence sufficient to reasonably
establish that he or she is entitled to do so. Full payment may consist of any consideration and method of payment authorized by the Administrator
and permitted by the Award Agreement and the Plan. Common Stock issued upon exercise of an Option will be issued in the name of the Participant
or, if requested by the Participant, in the name of the Participant and his or her spouse. Exercising an Option in any manner will decrease
the number of Common Stock thereafter available for sale under the Option, by the number of Common Stock as to which the Option is exercised.
Unless otherwise determined by the Administrator, any fractional Common Stock acquired upon the exercise of an Option shall be rounded
up to the nearest whole Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Continuous Service</U>. Upon the termination of an Optionholder&rsquo;s Continuous Service:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
than as a result of the Optionholder&rsquo;s death or Disability, the Optionholder may exercise his or her Option (to the extent that
the Optionholder was entitled to exercise such Option as of the date of termination) until the earlier of (i)&nbsp;the date 90 days following
the termination of the Optionholder&rsquo;s Continuous Service and (ii)&nbsp;the expiration of the term of the Option as set forth in
the Option Agreement, after which time the Option shall terminate; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
a result of the Optionholder&rsquo;s death or Disability, the Optionholder (or the Optionholder&rsquo;s estate, by a person who acquired
the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Optionholder&rsquo;s
death) may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination),
but only until the earlier of (i)&nbsp;the date 12 months following such termination and (ii)&nbsp;the expiration of the term of the Option
as set forth in the Option Agreement, after which time the Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Optionholder does not exercise his or her
Option within the time specified in the Option Agreement, the Option shall terminate. Unless otherwise provided in an Option Agreement
or in an employment agreement the terms of which have been approved by the Administrator, outstanding Options that are not exercisable
at the time an Optionholder&rsquo;s Continuous Service terminates shall be forfeited and expire at the close of business on the date of
such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Substitution
of Share Appreciation Rights</U>. The Administrator may provide in an Award Agreement evidencing the grant of an Option that the Administrator,
in its sole discretion, shall have the right to substitute a Share Appreciation Right for such Option at any time prior to or upon exercise
of such Option; <I>provided</I> that such Share Appreciation Right shall be exercisable with respect to the same number of Common Stock
for which such substituted Option would have been exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Incentive
Stock Options</U>. The exercise price per Share of an Incentive Stock Option shall be fixed by the Administrator at the time of grant
or shall be determined by a method specified by the Administrator at the time of grant, but in no event shall the exercise price of an
Option be less than the minimum exercise price specified in <U>Section&nbsp;6.2</U>. No Incentive Stock Option may be issued to any individual
who, at the time the Incentive Stock Option is granted, owns stock possessing more than 10% of the total combined voting power of all
classes of stock of the Company or any of its Subsidiaries, unless (i)&nbsp;the exercise price determined as of the date of grant is at
least 110% of the Fair Market Value on the date of grant of the Shares subject to such Incentive Stock Option and (ii)&nbsp;the Incentive
Stock Option is not exercisable more than five (5)&nbsp;years from the date of grant thereof. No Participant shall be granted any Incentive
Stock Option which would result in such Participant receiving a grant of Incentive Stock Options that would have an aggregate Fair Market
Value in excess of $100,000, determined as of the time of grant, that would be exercisable for the first time by such Participant during
any fiscal year. Any grants in excess of this limit shall be treated as Nonqualified Stock Options. No Incentive Stock Option may be granted
under the Plan after the tenth (10th) anniversary of the Effective Date. The terms of any Incentive Stock Option granted under the Plan
shall comply in all respects with the provisions of Section&nbsp;422 of the Code, or any successor provision thereto, as amended from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Early
Exercise Options</U>. The Administrator may, in its discretion, provide that an Option may be exercised prior to the date such Option
has vested by express provision in the applicable Award Agreement (such Option, an &ldquo;<B><I>Early Exercise Option</I></B>&rdquo;).
If the Optionholder elects to exercise all or a portion of any Early Exercise Option before it is vested, the shares of Common Stock acquired
under the Option that are attributable to the unvested portion of the Option shall be Restricted Shares. The applicable Award Agreement
shall specify the extent (if any) to which and the time (if ever) at which the Optionholder will be entitled to dividends, voting and
other rights in respect of such Restricted Shares prior to any vesting, and the restrictions imposed on such Restricted Shares and the
conditions of release or lapse of such restrictions. Unless otherwise expressly provided in the applicable Award Agreement, Restricted
Shares received from an Early Exercise Option shall be subject to <U>Section&nbsp;7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>PROVISIONS OF AWARDS OTHER THAN OPTIONS.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restricted
Awards</U>. The Administrator may from time to time award (or sell at a purchase price determined by the Administrator) restricted shares
of Common Stock (&ldquo;<B><I>Restricted Shares</I></B>&rdquo;) or restricted stock units (&ldquo;<B><I>RSUs</I></B>&rdquo;) under the
Plan to eligible Participants. The Award Agreement evidencing a Restricted Award (a &ldquo;<B><I>Restricted Award Agreement</I></B>&rdquo;)
shall contain the terms established by the Administrator for that Award, as well as any other terms, provisions, or restrictions that
the Administrator may impose on the Award (including, but not limited to, the class of Common Stock that the shares that are subject to
a Restricted Award are with respect to); in each case subject to the applicable provisions and limitations of this <U>Section&nbsp;7</U>
and the other applicable provisions and limitations of this Plan. The terms and conditions of Restricted Award Agreements may change from
time to time, and the terms and conditions of separate Restricted Award Agreements need not be identical, but each Restricted Award Agreement
shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase
Price</U>. The purchase price of a Restricted Award shall be determined by the Administrator at the Date of Grant, and may be stated as
cash, property or a contract for prior or future services. In no event will such purchase price be less than the par value of the Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consideration</U>.
The consideration for Common Stock acquired pursuant to a Restricted Award Agreement shall be paid either in cash, by certified or bank
check or by electronic funds transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting</U>.
The restrictions imposed on the exercise and/or settling of a Restricted Award and the subsequent issue of Common Stock (which may be
based on performance criteria, passage of time or other factors or any combination thereof) will be set forth in the applicable Award
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Participant&rsquo;s Continuous Service</U>. Unless the Administrator otherwise expressly provides, Common Stock subject to a Restricted
Award that remain subject to vesting conditions that have not been satisfied by the time specified in the applicable Award Agreement (including
the termination of the Participant&rsquo;s Continuous Service), will not vest and in the case of RSUs, will be canceled without payment
to the Participant therefor, in each case to the extent not prohibited by law. The Award Agreement shall specify any other terms or conditions
of the repurchase or cancellation, as the case may be, if the Award fails to vest. Any other Restricted Award that has not been exercised
as of a termination of the Participant&rsquo;s Continuous Service shall terminate on that date unless otherwise expressly provided by
the Administrator in the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance
Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator may from time to time grant Performance Awards to any eligible Participant. Each Performance Award shall be in such form
and shall contain such terms and conditions as the Administrator shall deem appropriate. The terms and conditions of separate Performance
Awards need not be identical. The value of Performance Awards may be linked to any one or more specific criteria determined by the Administrator,
in each case on a specified date or dates or over any period or periods determined by the Administrator. In making such determinations,
the Administrator shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions,
responsibilities and other compensation of the particular Service Provider. Performance Awards may be paid in cash, Common Stock or both,
as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
limiting <U>Section&nbsp;7.2(a)</U>, the Administrator may grant Performance Awards in the form of a cash bonus payable upon the attainment
of objective Performance Goals, or such other criteria, whether or not objective, which are established by the Administrator, in each
case on a specified date or dates or over any period or periods determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Appreciation Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General</U>.
Share Appreciation Rights may be granted either alone or, provided the requirements of <U>Section&nbsp;7.3(b)</U>&nbsp;are satisfied,
in tandem with all or part of any Option granted under the Plan (&ldquo;<B><I>Related Rights</I></B>&rdquo;). Related Rights may be granted
either at or after the time of the grant of such Option. Share Appreciation Rights shall be in such form and shall contain such terms
and conditions as the Administrator shall deem appropriate and the provisions of separate Share Appreciation Rights need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Grant
Requirements</U>. A Share Appreciation Right may only be granted if the Share Appreciation Right: (i)&nbsp;does not provide for the deferral
of compensation within the meaning of Section&nbsp;409A of the Code; or (ii)&nbsp;satisfies the requirements of <U>Section&nbsp;8.3</U>
hereof. A Share Appreciation Right does not provide for a deferral of compensation if: (A)&nbsp;the value of the Common Stock the excess
over which the right provides for payment upon exercise (the &ldquo;<B><I>SAR exercise price</I></B>&rdquo;) may never be less than the
Fair Market Value of the underlying Common Stock on the date the right is granted; (B)&nbsp;the Common Stock subject to the right are
traded on an established securities market; (C)&nbsp;only such traded Common Stock may be delivered in settlement of the right upon exercise;
and (D)&nbsp;the right does not include any feature for the deferral of compensation other than the deferral of recognition of income
until the exercise of the right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting,
Exercise and Payment</U>. The Administrator will determine the vesting and exercisability provisions of each Share Appreciation Right
(which may be based on performance criteria, passage of time or other factors or any combination thereof), which provisions will be set
forth in the applicable Award Agreement. Unless the Administrator otherwise expressly provides, once exercisable a Share Appreciation
Right will remain exercisable until the expiration or earlier termination of the Share Appreciation Right. Upon exercise thereof, the
holder of a Share Appreciation Right shall be entitled to receive from the Company, an amount equal to the product of (i)&nbsp;the excess
of the Fair Market Value, on the date of such written request, of one Common Stock over the SAR exercise price per Common Stock specified
in such Share Appreciation Right or its related Option, multiplied by (ii)&nbsp;the number of shares for which such Share Appreciation
Right shall be exercised. Payment with respect to the exercise of a Share Appreciation Right that satisfies the requirements of <U>Section&nbsp;7.3(b)(i)</U>&nbsp;shall
be paid on the date of exercise and made in Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability,
as determined by the Administrator in its sole discretion), valued at Fair Market Value on the date of exercise. Payment with respect
to the exercise of a Share Appreciation Right that does not satisfy the requirements of <U>Section&nbsp;7.3(b)(i)</U>&nbsp;shall be paid
at the time specified in the Award in accordance with the provisions of <U>Section&nbsp;8.3</U>. Payment may be made in the form of Common
Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Administrator in its
sole discretion), cash or a combination thereof, as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
Price; Term</U>. The Administrator shall set the terms and conditions or restrictions on the exercise of a Share Appreciation Right, but
in no event shall a Share Appreciation Right have an exercise price less than 100% of the Fair Market Value of one Common Stock on the
Date of Grant of such Share Appreciation Right or a term of greater than 10 years. A Related Right granted simultaneously with or subsequent
to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related
Option, and shall be exercisable only to the same extent as the related Option; <I>provided</I>, <I>however</I>, that a Share Appreciation
Right, by its terms, shall be exercisable only when the Fair Market Value per Common Stock subject to the Share Appreciation Right and
related Option exceeds the exercise price per share thereof and no Share Appreciation Rights may be granted in tandem with an Option unless
the Administrator determines that the requirements of <U>Section&nbsp;7.3(b)(i)</U>&nbsp;are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reduction
in the Underlying Option Shares</U>. Upon any exercise of a Share Appreciation Right, the number of Common Stock for which any related
Option shall be exercisable shall be reduced by the number of shares for which the Share Appreciation Right shall have been exercised.
The number of Common Stock for which a Share Appreciation Right shall be exercisable shall be reduced upon any exercise of any related
Option by the number of Common Stock for which such Option shall have been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Written
Request</U>. Any election by a Participant to receive cash in full or partial settlement of a Share Appreciation Right, and any exercise
of such Share Appreciation Right for cash, may be made only by a written request filed with the Corporate Secretary of the Company during
the period beginning on the third business day following the date of release for publication by the Company of quarterly or annual summary
statements of earnings and ending on the twelfth business day following such date. Within 30 days of the receipt by the Company of a written
request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash,
the Administrator shall, in its sole discretion, either consent to or disapprove, in whole or in part, such written request. A written
request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise a Share Appreciation Right for cash
may provide that, in the event the Administrator shall disapprove such written request, such written request shall be deemed to be an
exercise of such Share Appreciation Right for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Disapproval
by Administrator</U>. If the Administrator disapproves in whole or in part any election by a Participant to receive cash in full or partial
settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash, such disapproval shall not affect such
Optionholder&rsquo;s right to exercise such Share Appreciation Right at a later date, to the extent that such Share Appreciation Right
shall be otherwise exercisable, or to elect the form of payment at a later date, <I>provided</I> that an election to receive cash upon
such later exercise shall be subject to the approval of the Administrator. Additionally, such disapproval shall not affect such Optionholder&rsquo;s
right to exercise any related Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Continuous Service</U>. Upon the termination of the Continuous Service of a Participant who holds a Share Appreciation Right:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">other than as a result of the Participant&rsquo;s death or Disability, the Participant may exercise his
or her Share Appreciation Right (to the extent that the Participant was entitled to exercise such Share Appreciation Right as of the date
of termination) until the earlier of (1)&nbsp;the date 90 days following the termination of the Participant&rsquo;s Continuous Service
and (2)&nbsp;the expiration of the term of the Share Appreciation Right as set forth in the Award Agreement, after which time the Share
Appreciation Right shall terminate; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">as a result of the Participant&rsquo;s death or Disability, the Participant (or the Participant&rsquo;s
estate, by a person who acquired the right to exercise the Share Appreciation Right by bequest or inheritance or by a person designated
to exercise the Share Appreciation Right upon the Participant&rsquo;s death) may exercise his or her Share Appreciation Right (to the
extent that the Participant was entitled to exercise such Share Appreciation Right as of the date of termination), but only until the
earlier of (i)&nbsp;the date 12 months following such termination and (ii)&nbsp;the expiration of the term of the Share Appreciation Right
as set forth in the Award Agreement, after which time the Share Appreciation Right shall terminate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Participant does not exercise his or her
Share Appreciation Right within the time specified in the Award Agreement, the Share Appreciation Right shall terminate. Unless otherwise
provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Administrator, outstanding Share
Appreciation Rights that are not exercisable at the time a Participant&rsquo;s Continuous Service terminates shall be forfeited and expire
at the close of business on the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>PROVISIONS APPLICABLE TO ALL AWARDS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Award
Agreements</U>. The Administrator shall have sole and exclusive authority to determine the terms and conditions pursuant to which an Award
may be made. By accepting an Award, a Participant shall be deemed to have accepted and agreed to the terms and conditions of the Plan
and the Award Agreement. The Administrator may require that a Participant promptly execute and return to the Company his or her Award
Agreement evidencing the Participant&rsquo;s acceptance of and agreement to the terms and conditions of the Plan and the Award as a condition
precedent to any Common Stock becoming issuable or deliverable by the Company pursuant to the Award. In addition, the Administrator may
require that the spouse of any married Participant also promptly execute and return to the Company the Award Agreement evidencing the
Award granted to the Participant or such other spousal consent form that the Administrator may require in connection with the grant of
the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Non-Transferability
of Awards</U>. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent or distribution; <I>provided</I>, <I>however</I>, that the Administrator
may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of an Award, other than an Incentive
Stock Option, for no consideration to a Permitted Transferee. Any Award transferred to a Permitted Transferee shall be further transferable
only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the
Participant. During the lifetime of a Participant, an Award shall be exercisable only by the Participant or by a Permitted Transferee
to whom such Award has been transferred in accordance with this <U>Section&nbsp;8.2</U>. In no event may an Award be transferred to any
person who has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;409A</U>.
Notwithstanding any contrary provision in the Plan or an Award Agreement, if any provision of the Plan or an Award Agreement contravenes
any regulations or guidance promulgated under Section&nbsp;409A of the Code or would cause an Award to be subject to additional taxes,
accelerated taxation, interest and/or penalties under Section&nbsp;409A of the Code, such provision of the Plan or Award Agreement may
be modified by the Administrator without the consent of the Participant in any manner the Administrator deems reasonable or necessary.
In making such modifications the Administrator shall attempt, but shall not be obligated, to maintain, to the maximum extent practicable,
the original intent of the applicable provision without contravening the provisions of Section&nbsp;409A of the Code. Moreover, any discretionary
authority that the Administrator may have pursuant to the Plan shall not be applicable to an Award that is subject to Section&nbsp;409A
of the Code to the extent such discretionary authority would contravene Section&nbsp;409A of the Code or the guidance promulgated thereunder.
In the event that it is reasonably determined by the Administrator that, as a result of Section&nbsp;409A of the Code, payments in respect
of any Award under the Plan may not be made at the time contemplated by the terms of the Plan or the relevant Award Agreement, as the
case may be, without causing the Participant holding such Award to be subject to taxation under Section&nbsp;409A of the Code, including
as a result of the fact that the Participant is a &ldquo;specified employee&rdquo; under Section&nbsp;409A of the Code, the Company will
make such payment on the first day that would not result in the Participant incurring any tax liability under Section&nbsp;409A of the
Code. The Company shall use commercially reasonable efforts to implement the provisions of this <U>Section&nbsp;8.3</U> in good faith;
<I>provided</I> that neither the Company, its Affiliates, the Administrator nor any of the officers, employees, managers, directors or
representatives of the Company Group shall have any liability to Participants with respect to this <U>Section&nbsp;8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>CONDITIONS UPON ISSUANCE OF COMMON STOCK.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legal
Compliance</U>. Notwithstanding any other provision of the Plan, any Award Agreement or any other agreement entered into by the Company
pursuant to the Plan, an Award may not be issued or exercised, and no Common Stock may be issued in connection with an Award unless the
exercise of such Award and the issuance and delivery of such Common Stock will comply with Applicable Laws, including, without limitation,
the Securities Act, the Exchange Act, U.S. state securities laws and regulations, and the regulations of any stock exchange or other securities
market on which the Company&rsquo;s securities may then be traded, and will be further subject to the approval of counsel for the Company
with respect to such compliance. All certificates for Common Stock delivered under the Plan shall be subject to such transfer orders and
other restrictions as the Administrator may deem advisable under the rules, regulations, and other requirements of the U.S. Securities
and Exchange Commission, any exchange upon which the Common Stock are then listed, and any applicable securities law, and the Administrator
may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. To the extent and
at such time or times as the Company is relying upon the exemption from registration under Section&nbsp;12(g)&nbsp;of the Exchange Act
pursuant to Rule&nbsp;12h-1 thereunder, the Company shall deliver semiannually the financial and risk information described under Rule&nbsp;701(e)(3),
(4)&nbsp;and (5)&nbsp;under the Securities Act; <I>provided</I> that the Company is subject to such delivery requirements thereunder.
Any financial or other information relating to the Company obtained by Participants in connection with or as a result of this Plan or
their Awards shall be treated as confidential by the Participants, their spouses and/or their beneficiaries, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Representations</U>. As a condition to the exercise and/or issuance of an Award, the Company may require the person acquiring such Award
to represent and warrant at the time of any such acquisition that the Common Stock are being acquired only for investment and without
any present intention to sell or distribute such Common Stock if, in the opinion of counsel for the Company, such a representation is
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Inability
to Obtain Authority</U>. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority
is deemed by the Company&rsquo;s counsel to be necessary to the lawful issuance and sale of any Common Stock hereunder, will relieve the
Company of any liability in respect of the failure to issue or sell such Common Stock as to which such requisite authority will not have
been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>USE OF PROCEEDS FROM COMMON STOCK.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proceeds from the sale of
Common Stock pursuant to Awards shall constitute general funds of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>MISCELLANEOUS.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acceleration
of Exercisability and Vesting</U>. The Administrator shall have the power to accelerate the time at which an Award may first be exercised
or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award
stating the time at which it may first be exercised or the time during which it will vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shareholder
Rights</U>. No Participant shall be deemed to be the holder of, or to have any of the rights of a Shareholder with respect to, any Common
Stock subject to such Award unless and until (a)&nbsp;the Participant has satisfied all requirements for exercise of the Award pursuant
to its terms, including the full satisfaction of any tax withholding liabilities and (b)&nbsp;his or her name has been entered on the
Company&rsquo;s Register of Shareholders, and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities
or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued,
except as provided in <U>Section&nbsp;12.1</U>, hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment or other Service Rights</U>. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer
upon any Participant any right to continue to serve the Company Group in the capacity in effect at the time the Award was granted or shall
affect the right of the Company Group to terminate (a)&nbsp;the employment of an Employee with or without notice and with or without cause,
(b)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&rsquo;s agreement with the Company Group or (c)&nbsp;the
service of a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in
which the Company or the Affiliate is incorporated, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer,
Approved Leave of Absence</U>. For purposes of the Plan, no termination of Continuous Service by an Employee shall be deemed to result
from either (a)&nbsp;a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate
to another; or (b)&nbsp;an approved leave of absence for military service or sickness, or for any other purpose approved by the Company,
if the Employee&rsquo;s right to re&not;employment is guaranteed either by a statute or by contract or under the policy pursuant to which
the leave of absence was granted or if the Administrator otherwise so provides in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Assurances</U>. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (a)&nbsp;to
give written assurances satisfactory to the Company as to the Participant&rsquo;s knowledge and experience in financial and business matters
and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and
business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks
of exercising the Award; and (b)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring
Common Stock subject to the Award for the Participant&rsquo;s own account and not with any present intention of selling or otherwise distributing
the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (i)&nbsp;the
issuance of the Common Stock upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently
effective registration statement under the Securities Act or (ii)&nbsp;as to any particular requirement, a determination is made by counsel
for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may,
upon advice of counsel to the Company, place legends on share certificates issued under the Plan as such counsel deems necessary or appropriate
in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withholding
Obligations</U>. Common Stock will be delivered to a Participant only after the Participant has satisfied any tax withholding requirements
relating to the exercise, vesting or acquisition of such Common Stock. To the extent provided by the terms of an Award Agreement and subject
to the discretion of the Administrator, the Participant may satisfy any federal, state or local tax withholding obligation relating to
the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company&rsquo;s right to
withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a)&nbsp;tendering a cash payment;
(b)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase at Fair Market Value Common Stock out of the Common
Stock issued to the Participant as a result of the exercise or acquisition of Common Stock under the Award; or (c)&nbsp;tendering to the
Company currently owned and unencumbered Common Stock of the Company for redemption or repurchase and, in each of (b)&nbsp;and (c), immediately
tendering the redemption or repurchase price paid by the Company in respect of such Common Stock back to the Company; <I>provided</I>,
<I>however</I>, that the Company shall redeem or repurchase only that number of Common Stock having a Fair Market Value equal to the minimum
amount of tax required to be withheld under Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Net
Exercise Offer</U>. The Company may, from time to time and in the Administrator&rsquo;s sole and exclusive discretion, allow the net exercise
of Options granted to a Participant pursuant to the Plan by issuing a notice to all Participants that sets forth: (a)&nbsp;the existence
of a net exercise window; and (b)&nbsp;the duration of the window (the &ldquo;<B><I>Net Exercise Period</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of First Refusal</U>. Each Award Agreement may provide that, if the Common Stock are not readily tradable on an established securities
market, the Company shall have a right of first refusal as described in this <U>Section&nbsp;11.8</U> (the &ldquo;<B><I>Right of First
Refusal</I></B>&rdquo;). The Right of First Refusal may be exercisable in connection with any proposed sale, hypothecation, gift or other
disposition of Common Stock, if purchased by the Participant pursuant to an Award Agreement, other than transfers to a Permitted Transferee.
If a Shareholder desires to accept a bona fide third-party offer to purchase any or all of his Common Stock, the Common Stock shall first
be tendered to the Company for its repurchase or redemption upon the same terms and conditions (as to timing and price) as are set forth
in the bona fide offer. In the case of a proposed gift or other non-compensatory transfer of Common Stock, the purchase price per Common
Stock under the Right of First Refusal shall be the Fair Market Value determined at the time of the proposed gift or other transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of Repurchase</U>. Each Award Agreement may provide that, following a termination of the Participant&rsquo;s Continuous Service, the Company
may repurchase the Participant&rsquo;s Common Stock acquired under the Plan as provided in this <U>Section&nbsp;11.9</U> (the &ldquo;<B><I>Right
of Repurchase</I></B>&rdquo;). The Right of Repurchase shall be exercisable at a price equal to (a)&nbsp;the Fair Market Value of vested
Common Stock or, in the case of exercisable options, the Fair Market Value of the Common Stock underlying such unexercised options less
the aggregate exercise price of such options or (b)&nbsp;in the case of unvested Common Stock, the lesser of the purchase price at which
such Common Stock were acquired under the Plan or the Fair Market Value of such Common Stock. The Award Agreement may specify the period
of time following a termination of the Participant&rsquo;s Continuous Service during which the Right of Repurchase may be exercised; <I>provided</I>
that such exercise may in any event be extended to a date that is within 60 days after the date that is six months after the date that
such Common Stock were issued to the Participant. Notwithstanding the above, nothing in this Plan is intended to interfere with the Company&rsquo;s
right to repurchase or redeem any Common Stock set forth in the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Repurchase and First Refusal Rights</U>. Each Award Agreement shall provide that the Right of Repurchase with respect to vested Common
Stock and the Right of First Refusal shall have no effect with respect to, or shall lapse and cease to have effect when the issuer&rsquo;s
securities become publicly traded or a determination is made by counsel for the Company that such Rights of First Refusal and Rights of
Repurchase are not permitted under applicable federal or state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Recoupment
Provisions</U>. Any Awards granted under the Plan shall be subject to any clawback or recoupment policies and procedures that are required
under Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>12.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>ADJUSTMENTS UPON CHANGES IN ORDINARY SHARES.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
(or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, share split (including
a share split in the form of a share dividend) or reverse share split; any merger, combination, consolidation, or other reorganization;
any split-up, spin-off, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock
or other securities of the Company, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then
the Administrator shall equitably and proportionately adjust (i)&nbsp;the number and type of Common Stock (or other securities) that thereafter
may be made the subject of Awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan),
(ii)&nbsp;the number, amount and type of Common Stock (or other securities or property) subject to any outstanding Awards, (iii)&nbsp;the
grant, purchase, or exercise price of any outstanding Awards, and/or (iv)&nbsp;the securities, cash or other property deliverable upon
exercise or vesting of any outstanding Awards, in each case to the extent necessary to preserve (but not increase) the level of incentives
intended by this Plan and the then-outstanding Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
otherwise expressly provided in the applicable Award Agreement, upon (or, as may be necessary to effect the adjustment, immediately prior
to) any event or transaction described in the preceding paragraph or a sale of all or substantially all of the business or assets of the
Company as an entirety, the Administrator shall equitably and proportionately adjust the performance standards applicable to any then-outstanding
performance-based Awards to the extent necessary to preserve (but not increase) the level of incentives by this Plan and the then-outstanding
performance-based Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
is intended that, if possible, any adjustments contemplated by the preceding two paragraphs shall be made in a manner that satisfies Applicable
Laws (including, without limitation and as applicable in the circumstances, Section&nbsp;424 of the Code and Section&nbsp;409A of the
Code) and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
good faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this <U>Section&nbsp;12.1</U>,
and the extent and nature of any such adjustment, shall be final, binding and conclusive on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
otherwise expressly provided by the Administrator, in no event shall a conversion of one or more outstanding shares of the Company&rsquo;s
Preference Stock or any new issuance of securities by the Company for consideration be deemed, in and of itself, to require an adjustment
pursuant to this <U>Section&nbsp;12.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dissolution
or Liquidation</U>. In the event of a dissolution or liquidation of the Company, then all outstanding Awards shall terminate immediately
prior to such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Change
of Control</U>. In the event of a Change of Control of the Company, or such other transaction in which all classes of the Common Stock
outstanding immediately prior to the transaction are converted by virtue of the transaction into other property, whether in the form of
securities, cash or otherwise, then, the Company, to the extent permitted by Applicable Law, but otherwise in the sole discretion of the
Administrator may provide for: (i)&nbsp;the continuation of outstanding Awards by the Company (if the Company is the surviving entity);
(ii)&nbsp;the assumption of the Plan and such outstanding Awards by the surviving entity or its parent; (iii)&nbsp;the substitution by
the surviving entity or its parent of Awards with substantially the same terms (including an award to acquire the same consideration paid
to the Shareholders in the transaction described in this <U>Section&nbsp;12.3</U>) for such outstanding Awards and, if appropriate, subject
to the equitable adjustment provisions of <U>Section&nbsp;12.1</U> hereof; (iv)&nbsp;the acceleration of the vesting, settlement and delivery
of all Awards outstanding under the Plan; (v)&nbsp;the cancellation of any outstanding Awards in consideration for a payment (in cash
or other property) equal in value to the Fair Market Value of vested Awards, or in the case of an Option or Share Appreciation Right,
the difference between the Fair Market Value and the exercise price for the Common Stock subject to exercise (<I>i.e.</I>, to the extent
vested) under any outstanding Option or Share Appreciation Right; or (vi)&nbsp;the cancellation of such outstanding Awards without payment
of any consideration. If Awards would be canceled without consideration for vested Awards, the Participant shall have the right, exercisable
during the later of the ten-day period ending on the fifth day prior to such merger or consolidation or ten days after the Administrator
provides the Award holder a notice of cancellation, to exercise such Awards in whole or in part without regard to any installment exercise
provisions in the Award Agreement; <I>provided</I> that the Administrator may, in its discretion, condition the exercise of any Award
on the consummation of the Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sale
of a Business</U>. In the event that a Service Provider&rsquo;s Continuous Service with the Company Group terminates because of the sale
or other divestiture of a Subsidiary or other business unit of the Company Group, then (i)&nbsp;any outstanding time-based Award made
to such Participant shall vest pro rata as of the date of termination and (ii)&nbsp;the treatment of any outstanding Performance Award
made to such Participant shall be determined by the Administrator in its sole and exclusive discretion at the time the Subsidiary or other
business unit of the Company Group is divested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Section&nbsp;409A</U>. No action shall be taken under this Article&nbsp;12 that will cause an Award to fail to comply with Section&nbsp;409A
of the Code, to the extent applicable to such Award. Any adjustments to outstanding Awards shall be effected in a manner which shall preclude
the enlargement or dilution of rights and benefits under such options and shall be conducted in compliance with Section&nbsp;409A of the
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>13.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>AMENDMENT OF THE PLAN AND AWARDS.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment
of Plan</U>. The Administrator at any time, and from time to time, may amend, suspend or terminate the Plan in accordance with Applicable
Law. However, except as provided in <U>Section&nbsp;12.1</U> relating to adjustments upon changes in the Common Stock, no amendment shall
be effective unless approved by the Shareholders to the extent Shareholder approval is necessary to satisfy any Applicable Law or any
applicable securities exchange listing requirements. At the time of such amendment, the Directors shall determine, upon advice from counsel,
whether such amendment will be contingent on Shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shareholder
Approval</U>. The Directors may, in their sole discretion, submit any other amendment to the Plan for Shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Impairment of Rights</U>. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan
(and shall continue to be subject to the terms of the Plan as in effect as of immediately prior to the applicable amendment) unless (a)&nbsp;the
Company requests the consent of the Participant and (b)&nbsp;the Participant consents in writing. However, a cancellation of an Award
where the Participant receives a payment equal in value to the Fair Market Value of the vested Award or, in the case of vested Options,
the difference between the Fair Market Value and the exercise price, shall not be an impairment of the Participant&rsquo;s rights that
requires consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment
of Awards</U>. The Administrator at any time, and from time to time, may amend the terms of any one or more Awards or, as approved by
the Directors and subject to Applicable Laws, provide for the substitution of a new Award for an existing Award; <I>provided</I>, <I>however</I>,
that the Administrator may not effect any amendment which would otherwise constitute an impairment of the rights under any Award unless
(a)&nbsp;the Company requests the consent of the Participant and (b)&nbsp;the Participant consents in writing. For the avoidance of doubt,
the cancellation of an Award where the Participant receives a payment equal in value to the Fair Market Value of the vested Award or,
in the case of vested Options, the difference between the Fair Market Value of the Common Stock underlying the Option and the aggregate
exercise price, shall not be an impairment of the Participant&rsquo;s rights that requires consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>14.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>GENERAL PROVISIONS.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Compensation Arrangements</U>. Nothing contained in this Plan shall prevent the Administrator from adopting other or additional compensation
arrangements, subject to Shareholder approval if such approval is required; and such arrangements may be either generally applicable or
applicable only in specific cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Recapitalizations</U>.
Each Award Agreement shall contain provisions required to reflect the provisions of <U>Section&nbsp;12.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery</U>.
Except in the event of an early exercise of an Option as provided in <U>Section&nbsp;6.9</U>, upon exercise of a right granted under this
Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory
or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation,
restrictions upon the exercise of the Awards, as the Administrator may deem advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
explicitly provided otherwise in an Award Agreement, if there is a conflict between the terms of the Plan and an Award Agreement, the
terms of the Plan shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation
and Rescission of Awards for Detrimental Activity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
exercise, payment or delivery pursuant to an Award, the Participant shall certify in a manner acceptable to the Company that the Participant
has not engaged in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
the Award Agreement specifies otherwise, the Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any unexpired,
unpaid, or deferred Awards at any time if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event a Participant engages in Detrimental Activity after any exercise, payment or delivery pursuant to an Award, during any period
for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may
be rescinded within one year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any
gain realized or payment received as a result of the exercise, payment or delivery, in such manner and on such terms and conditions as
may be required by the Company. The Company shall be entitled to set off against the amount of any such gain any amount owed to the Participant
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;14.5</U> via
the mandatory redemption or repurchase of the Participant&rsquo;s Common Stock at a price equal to the price paid by the Participant to
acquire the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Paperless
Administration</U>. In the event that the Company establishes, for itself or using the services of a third party, an automated system
for the documentation, granting or exercise of Awards, such as a system using an interne website or interactive voice response, then the
paperless documentation, granting or exercise of Awards by a Participant may be permitted through the use of such an automated system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Rights to Awards</U>. No Service Provider or other person shall have any claim to be granted any Award pursuant to the Plan, and neither
the Company nor the Administrator is obligated to treat Service Providers, Participants or any other persons uniformly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Unfunded
Status of Awards</U>. The Plan is intended to be an &ldquo;unfunded&rdquo; plan for incentive compensation. With respect to any payments
not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Agreement shall give the Participant any
rights that are greater than those of a general creditor of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses</U>.
The expenses of administering the Plan shall be borne by the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>15.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>MARKET STAND-OFF.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Award Agreement shall
provide that, in connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s initial public offering, the Participant shall agree not to sell,
make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership
or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any Common
Stock without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date
of such registration statement as may be requested by the Company or such underwriters (the &ldquo;<B><I>Market Stand-Off</I></B>&rdquo;).
In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Common Stock acquired
under this Plan until the end of the applicable stand-off period. If there is any change in the number of outstanding Common Stock by
reason of a share split, reverse share split, share dividend, recapitalization (excluding issuances of Common Stock in the ordinary course
of business), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including,
but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then any
new, substituted or additional securities which are by reason of such transaction distributed with respect to any Common Stock subject
to the Market Stand-Off, or into which such Common Stock thereby become convertible, shall immediately be subject to the Market Stand-Off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>16.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>EFFECTIVE DATE OF PLAN.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan shall become effective
as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>17.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>TERMINATION OR SUSPENSION OF THE PLAN.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless terminated by the Directors
at an earlier date pursuant to <U>Section&nbsp;13.1</U> hereof, the Plan will continue in effect for a term of ten (10)&nbsp;years commencing
on the Effective Date. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond
that date. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>18.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>CHOICE OF LAW; WAIVER OF JURY TRIAL.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The laws of the State of Texas
shall govern all questions concerning the construction, validity and interpretation of this Plan and any Award Agreement. The Participant
hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim arising out of or relating to this Plan
and/or any Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(B)
<SEQUENCE>15
<FILENAME>tm2415719d15_ex10-4b.htm
<DESCRIPTION>EXHIBIT 10.4(B)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit&nbsp;10.4(b)</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCENTIVE STOCK OPTION AWARD AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Incentive Stock Option
Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the date of grant set forth below (the &ldquo;<B><I>Date
of Grant</I></B>&rdquo;) by and between Caris Life Sciences,&nbsp;Inc., a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
and the participant named below (the &ldquo;<B><I>Participant</I></B>&rdquo;). Capitalized terms not defined herein shall have the meaning
ascribed to them in the Company&rsquo;s 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Participant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grant Number: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exercise Price Per Share: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of Grant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expiration Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting Commencement Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant options to purchase shares of common stock of the Company, par value US$0.001 per share (the &ldquo;<B><I>Shares</I></B>&rdquo;)
to certain employees of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has adopted
the Plan in order to effect such grants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Administrator
has determined that it is in the interest of the Company to grant these options to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Grant
of Option</B>. The Company hereby grants to Participant an option (this &ldquo;<B><I>Option</I></B>&rdquo;) to purchase the total number
of Shares set forth above as Total Shares of Common Stock at the Exercise Price Per Share set forth above (the &ldquo;<B><I>Exercise
Price</I></B>&rdquo;), subject to all of the terms and conditions of this Agreement and the Plan. The Option is intended to be an Incentive
Stock Option within the meaning of Section&nbsp;422 of the United States Internal Revenue Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;),
although the Company makes no representation or guarantee that this Option will qualify as an Incentive Stock Option. Participant shall
not be granted any Incentive Stock Option which would result in the Participant receiving a grant of Incentive Stock Options that would
have an aggregate Fair Market Value in excess of $100,000, determined as of the Date of Grant, that would be exercisable for the first
time by the Participant during any fiscal year. Any grant in excess of this limit shall be treated as Nonqualified Stock Options. Should
the Participant hold, in addition to this Option, one or more other options to purchase Shares which become exercisable for the first
time in the same calendar year as this option, then for purposes of the foregoing limitations on the exercisability of such options as
Incentive Stock Options, this Option and each of those other options shall be deemed to become first exercisable in that calendar year
on the basis of the chronological order in which they were granted, except to the extent otherwise provided under Applicable Law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exercise
Period; Vesting</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercisability</U>.
Unless expired as provided in <U>Section&nbsp;3</U> of this Agreement, this Option may be exercised in whole or in part from time to time
to the extent they have become vested, during the period of Participant&rsquo;s Continuous Service and pursuant to the terms of <U>Section&nbsp;4</U>.
Upon exercise of a portion of this Option that has vested in accordance with the vesting schedule set forth in <U>Section&nbsp;2.2</U>,
Participant shall receive Shares in accordance with <U>Section&nbsp;5.5</U>, in each case subject to the restrictions on transfer set
forth in <U>Sections 7</U> and <U>10</U> below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting</U>.
The Option shall become vested based on the table referenced on page&nbsp;1. This Option may not be exercised for less than a full share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Expiration</B>.
This Option shall expire on the Expiration Date set forth above or earlier as provided in <U>Section&nbsp;4</U> below or, if applicable,
pursuant to <U>Section&nbsp;6</U> of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Termination
of Continuous Service</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
than as a Result of Death or Disability</U>. Unless otherwise provided in an agreement the terms of which have been approved by the Administrator,
if Participant&rsquo;s Continuous Service is terminated for any reason, except death or Disability, the Participant may exercise this
Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (i)&nbsp;the
date ninety (90) days following the termination of the Participant&rsquo;s Continuous Service and (ii)&nbsp;the Expiration Date, after
which time this Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Because
of Death or Disability</U>. If Participant&rsquo;s Continuous Service is terminated because of the death or Disability of Participant,
the Participant (or the Participant&rsquo;s estate, by a person who acquired the right to exercise this Option by bequest or inheritance
or by a person designated to exercise this Option upon the Participant&rsquo;s death) may exercise the Participant&rsquo;s Option (to
the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (i)&nbsp;the
date twelve (12) months following such termination and (ii)&nbsp;the Expiration Date, after which time this Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group
in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
employment with or without notice and with or without cause or shall give the Participant any right to be reemployed by the Company Group
following a termination of employment for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation
and Rescission of Options for Detrimental Activity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any Options at any time if the Participant is not
in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
exercise, payment or delivery pursuant to exercise of this Option, the Participant shall certify in a manner acceptable to the Company
that he or she is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event
a Participant engages in Detrimental Activity after the exercise, payment or delivery of any Shares pursuant to this Agreement, during
any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery
may be rescinded within one (1)&nbsp;year thereafter. In the event of any such rescission, the Participant shall pay to the Company the
amount of any gain realized or payment received as a result of the exercise, payment or delivery of such Shares, in such manner and on
such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain
any amount owed to the Participant by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;4.4</U> via the
mandatory redemption or repurchase of the Participant&rsquo;s Shares at a price equal to the price paid by the Participant to acquire
the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Manner
of Exercise</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Option Exercise Agreement</U>. To exercise this Option, Participant (or the Participant&rsquo;s estate, by a person who acquired the
right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant&rsquo;s
death) must deliver to the Company an executed share option exercise agreement in the form attached hereto as <U>Exhibit&nbsp;A</U>,
or in such other form as may be approved by the Administrator from time to time (the &ldquo;<B><I>Exercise Agreement</I></B>&rdquo;),
which shall set forth, <I>inter alia</I>, (a)&nbsp;Participant&rsquo;s election to exercise this Option, (b)&nbsp;the number of Shares
being purchased, (c)&nbsp;any restrictions imposed on the Shares and (d)&nbsp;any representations, warranties and agreements regarding
Participant&rsquo;s investment intent and access to information as may be required by the Company to comply with Applicable Laws. If
someone other than Participant exercises this Option, then such person must submit evidence reasonably acceptable to the Company verifying
that such person is entitled to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
on Exercise and Issuance</U>. The Option may not be exercised unless such exercise is in compliance with all Applicable Laws as are in
effect on the date of exercise and the Shares underlying the exercised Option may not be issued until the Participant executes an Adoption
Agreement to become a Shareholder to that certain Voting Agreement of the Company by and among the Company and each of its Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment</U>.
The entire Exercise Price shall be payable in full by cash or check for an amount equal to the aggregate exercise price of the Shares
being purchased. Alternatively, in the sole discretion of the Administrator and upon such terms and at such times as the Administrator
shall approve, the Exercise Price may be paid by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>tendering
to the Company other Shares, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase
equal to the exercise price (or portion thereof) due for the number of Shares being acquired (with the proceeds of such redemption or
repurchase being automatically applied by the Company towards paying the purchase price of the Shares) (collectively a &ldquo;<B><I>Share
For Share Exercise</I></B>&rdquo;); <U>provided</U>, <U>however</U>, that the Shares used in such Share for Share Exercise (i)&nbsp;have
either (1)&nbsp;been held for more than six (6)&nbsp;months (or such longer or shorter period of time required to avoid a charge to earnings
for financial accounting purposes) and have been paid for within the meaning of SEC Rule&nbsp;144 (and if such shares were purchased from
the Company by use of a promissory note, such note has been fully paid with respect to such shares); or (2)&nbsp;were obtained by Participant
in the open public market; and (ii)&nbsp;are clear of all liens, claims, encumbrances or security interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>during
any period for which the Shares are publicly traded (<I>i.e.</I>, the Shares are listed on any established stock exchange or a national
market system, or if the Shares are quoted on an applicable stock exchange or any similar system whereby the Shares are regularly quoted
by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker
to sell the Shares for which this Option is exercised, and to remit to the Company the aggregate Exercise Price of this Option (a &ldquo;<B><I>Cashless
Exercise</I></B>&rdquo;); <U>provided</U>, <U>however</U>, a Cashless Exercise by a Participant officer that involves or may involve a
direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of
the Sarbanes-Oxley Act (codified as Section&nbsp;13(k)&nbsp;of the Securities Exchange Act of 1934, 15 U.S.C. &sect;&nbsp;78m(k)) shall
be prohibited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>during
a Net Exercise Period, by means of the Participant electing in the Exercise Agreement to receive a portion of the Shares underlying this
Option as a cash payment and a portion as Shares, with instructions to the Company to apply such cash payment towards paying the purchase
price of the Shares for which this Option is being exercised; <U>provided</U> that in no event shall the cash payment received by the
Participant pursuant to such election exceed the aggregate exercise price of the Shares for which this Option is being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a full-recourse promissory
note. However, if there is a stated par value of the Shares and Applicable Laws require, the par value of the Shares, if newly issued,
shall be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the
minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator
(in its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note.
Exercise with a promissory note or other transaction by a Participant officer that involves or may involve a direct or indirect extension
of credit or arrangement of an extension of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of the Sarbanes-Oxley
Act (codified as Section&nbsp;13(k)&nbsp;of the Securities Exchange Act of 1934, 15 U.S.C. &sect;&nbsp;78m(k)) shall be prohibited; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
any combination of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Tax
Withholding</U>. Prior to the issuance of the Shares upon exercise of this Option, Participant must satisfy any tax withholding obligations
relating to the exercise of this Option and the acquisition of the Shares. If the Administrator permits, in addition to the Exercise
Price payment alternatives in <U>Section&nbsp;5.3</U>, Participant may provide for payment of withholding taxes upon exercise of this
Option by (a)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the
Shares issued to the Participant as a result of the exercise of this Option or (b)&nbsp;tendering to the Company currently owned and
unencumbered Shares of the Company for redemption or repurchase and, in each of (a)&nbsp;and (b), immediately tendering the redemption
or repurchase price paid by the Company in respect of such Shares back to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of Shares</U>. <U>Provided</U> that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company,
the Company shall issue the Shares registered in the name of Participant or, if requested by the Participant, in the name of the Participant
and the Participant&rsquo;s spouse, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Compliance
with Laws and Regulations</B>. The exercise of this Option and the issuance and transfer of Shares shall be subject to compliance by
the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may
be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify
the Shares with any federal or state securities commission or any stock exchange to effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Nontransferability
of Option</B>. The Option may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than to a
designated beneficiary upon the Participant&rsquo;s death or by will or by the laws of descent and distribution. During the lifetime
of a Participant, this Option shall be exercisable only by the Participant. No assignment or transfer of this Option, or the rights represented
thereby, whether voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary upon death by will or
the laws of descent or distribution) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately
upon such assignment or transfer this Option will terminate and become of no further effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Privileges
of Share Ownership</B>. Participant shall not have any of the rights of a Shareholder with respect to any Shares until the Shares are
issued to Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Restrictive
Covenants</B>. As a condition to the grant of this Option, the Participant agrees to comply with the restrictive covenants (each a &ldquo;<B><I>Restrictive
Covenant</I></B>&rdquo;) set forth in any Proprietary Information,&nbsp;Intellectual Property, Restrictive Covenant and Arbitration Agreement
(the &ldquo;<B><I>PIIA</I></B>&rdquo;) or other agreement or policy that may be in effect between the Participant and the Company Group.
The Participant understands that the cancellation of any Option or rights under this Agreement may occur for any violation or lack of
enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained
by the Company. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall
not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by
the Participant of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of Shares pursuant
to this Agreement (including any breach occurring after termination of employment) shall cause the exercise of this Option and the delivery
of any Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement,
the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Administrator&rsquo;s discretion, the Company
may exercise the right of rescission set forth in this <U>Section&nbsp;9</U> via the mandatory redemption or repurchase of the Participant&rsquo;s
Shares at a price equal to the aggregate Exercise Price paid by the Participant for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Restrictions
on Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Securities
Law Restrictions</U>. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities
Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its
discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends
on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary
or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws
of any state or any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Market
Stand-Off</U>. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s initial public offering, the Participant shall not sell, make
any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership
or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the
Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Shares (whether such Shares or
any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or
its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the
Company or such underwriters (the &ldquo;<B><I>Market Stand-Off</I></B>&rdquo;). In order to enforce the Market Stand-Off, the Company
may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off
period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization,
combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited
to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted
or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off,
or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of Repurchase</U>. Following a termination of the Participant&rsquo;s Continuous Service, the Company may repurchase the Participant&rsquo;s
Shares acquired under the Plan as provided in this Section&nbsp;(the &ldquo;<B><I>Right of Repurchase</I></B>&rdquo;). With respect to
any vested portion of this Option and any Shares acquired upon exercise of this Option, the Right of Repurchase shall be exercisable
at a purchase price (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;) equal to (i)&nbsp;the Fair Market Value of vested Shares (the &ldquo;<B><I>Share
Repurchase Right</I></B>&rdquo;) or (ii)&nbsp;in the case of a vested Option (the &ldquo;<B><I>Option Repurchase Right</I></B>&rdquo;),
the Fair Market Value of the Shares underlying the vested portion of this Option less the aggregate exercise price of such portion of
this Option (in each case as of the date the written notice described in <U>Section&nbsp;10.3(b)</U>&nbsp;is delivered). For the avoidance
of doubt, any unvested portion of this Option will be forfeited for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Condition
Precedent to Exercise</U>. The Right of Repurchase shall be exercisable following the later of: (i)&nbsp;the date when the Participant&rsquo;s
Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii)&nbsp;the
date when this Option is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Right of Repurchase</U>. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice
shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s)&nbsp;representing
any Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company
(to the extent not already in the Company&rsquo;s custody) properly endorsed for transfer; <U>provided</U>, <U>however</U>, that the failure
to deliver such certificate(s)&nbsp;to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The
Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to
this <U>Section&nbsp;10.3</U>. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred
by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of First Refusal</U>. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell,
pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party (the &ldquo;<B><I>Transferee</I></B>&rdquo;),
the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the &ldquo;<B><I>Right of First
Refusal</I></B>&rdquo;). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase
or redemption, via a written transfer notice (&ldquo;<B><I>Transfer Notice</I></B>&rdquo;) describing in full the proposed transfer,
including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee
and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed
to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must
constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase
all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the
Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer
Notice is received by the Company; <U>provided</U>, <U>however</U>, that in the case of a proposed gift or other non-compensatory transfer
of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at
the time of the proposed transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Provisions Relating to Rights of Repurchase and First Refusal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Shares or Substituted Securities</U>. If there is any change in the number of outstanding Shares by reason of a share split, reverse share
split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification,
dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off
or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i)&nbsp;any new, substituted or additional securities
or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with
respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible
shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii)&nbsp;appropriate adjustments to reflect
the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to
the price per Share to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; <U>provided</U>, <U>however</U>,
that the aggregate Purchase Price payable for the Shares shall remain the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Rights of Repurchase and First Refusal</U>. Any other provision of <U>Section&nbsp;10.3</U> notwithstanding, the Right of Repurchase
with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement
under applicable federal securities laws and the issuer is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the
Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of
1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the
Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by
<U>Section&nbsp;10.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Rights as Participant and Shareholder</U>. If the Company makes available to a Participant, at the time and place and in the amount
and form provided in this Agreement, the consideration for this Option to be repurchased pursuant to the Company&rsquo;s Option Repurchase
Right in accordance with <U>Section&nbsp;10.3</U>, then after such time such Participant shall no longer have any rights as a Participant
in respect of such Option (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company
makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for
the Shares to be repurchased or redeemed pursuant to the Company&rsquo;s Share Repurchase Right in accordance with <U>Section&nbsp;10.3</U>
or Right of First Refusal in accordance with <U>Section&nbsp;10.4</U>, then after such time such Participant shall no longer have any
rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this
Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not
the certificate(s)&nbsp;therefore have been delivered as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Intent at Grant</U>. If the grant of this Option under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or any other representation, the Participant (a)&nbsp;shall,
and hereby does, represent and agree, at the time of grant of this Option, that the security being acquired upon the grant of this Option
is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b)&nbsp;shall make such other
representations as are deemed necessary or appropriate by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Intent at Exercise</U>. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or other representation, the Participant shall represent and
agree at the time of exercise that the Shares being acquired upon exercise of this Option are being acquired for investment purposes,
and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legends</U>.
All certificates evidencing the Shares purchased under this Agreement in an unregistered transaction shall bear the following legend
(and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THE SHARES OF COMMON STOCK EVIDENCED BY
THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES,&nbsp;INC. 2020 INCENTIVE PLAN,
THE INCENTIVE STOCK OPTION AWARD AGREEMENT AND THE EXERCISE AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE
ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY&nbsp;BE
MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND INCENTIVE STOCK OPTION AWARD AGREEMENT AND THE TERMS OF
THE EXERCISE AGREEMENT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal
of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold
under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate
representing the same number of Shares but without such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Administration</U>.
Any determination by the Company and its counsel in connection with any of the matters set forth in this <U>Section&nbsp;10</U> shall
be conclusive and binding on the Participant and all other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Qualification
as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock option as defined in
Section&nbsp;422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in order to
obtain the benefits of an incentive stock option, no sale or other disposition may be made of shares for which incentive stock option
treatment is desired within one (1)&nbsp;year following the date of exercise of this Option or within two (2)&nbsp;years from the Date
of Grant. The Participant understands and agrees that the Company shall not be liable or responsible for any additional tax liability
the Participant incurs in the event that the Internal Revenue Service for any reason determines that this Option does not qualify as
an incentive stock option within the meaning of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exchange
Act</B>. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under
the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section&nbsp;16(b)&nbsp;of
the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction
to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>General</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation</U>.
Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for
review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement</U>. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties
and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between
the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above,
nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the
Company and the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the
Corporate Secretary/General Counsel of the Company at its principal corporate offices. Any notice required to be given or delivered to
Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may
designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a)&nbsp;personal
delivery; (b)&nbsp;five (5)&nbsp;days after deposit in the United States mail by certified or registered mail (return receipt requested);
(c)&nbsp;two (2)&nbsp;business days after deposit with any return receipt express courier (prepaid); or (d)&nbsp;one (1)&nbsp;business
day after transmission by facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall
be binding upon Participant and Participant&rsquo;s heirs, executors, administrators, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Choice
of Law</U>. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by
and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision
of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision
will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to <U>Section&nbsp;13.6</U>,
the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction
with respect to any dispute or litigation arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Arbitration</U>.
The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect
between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions
shall govern: Subject to the Company&rsquo;s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy,
or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial
Arbitration Rules&nbsp;of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place
in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching
the arbitrator&rsquo;s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision
of this Agreement, but instead is limited to interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment or Other Service Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve
the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
(a)&nbsp;employment with or without notice and with or without cause, (b)&nbsp;service pursuant to the terms of a consulting agreement
with the Company Group or (c)&nbsp;service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate
law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right
to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Right to Future Awards</U>. This Option and all other equity-based awards under the Plan are discretionary. This Option does not confer
on the Participant any right or entitlement to receive another award of Option or any other equity-based award at any time in the future
or in respect of any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the
remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had
never been included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this
Agreement; <U>provided</U>, <U>however</U>, that no amendment or modification of this Agreement shall materially and adversely impair
the rights of the Participant with respect to any then outstanding Options without the consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Acceptance</B>.
Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and
provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing this Option and the terms and
conditions of the Plan governing this Option and any and all other outstanding options held by the Participant as of the date of execution.
Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the Shares and that
Participant should consult a tax advisor prior to such exercise or disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signatures on Following Page]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
witness whereof</B></FONT>, the Company has caused this Agreement to be executed by its duly authorized representative effective as of
[&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 5%">By:</TD><TD STYLE="width: 45%"></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Name:</TD><TD></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Title:</TD><TD>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 50%">Participant:</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%">Acceptance Date:</TD></TR>
                                                                                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(C)
<SEQUENCE>16
<FILENAME>tm2415719d15_ex10-4c.htm
<DESCRIPTION>EXHIBIT 10.4(C)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit&nbsp;10.4(c)</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NONQUALIFIED STOCK OPTION AWARD AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Nonqualified Stock Option
Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the date of grant set forth below (the &ldquo;<B><I>Date
of Grant</I></B>&rdquo;) by and between Caris Life Sciences,&nbsp;Inc., a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
and the participant named below (the &ldquo;<B><I>Participant</I></B>&rdquo;). Capitalized terms not defined herein shall have the meaning
ascribed to them in the Company&rsquo;s 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Participant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grant Number: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exercise Price Per Share: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of Grant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expiration Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting Commencement Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant options to purchase shares of common stock of the Company, par value US$0.001 per share (the &ldquo;<B><I>Shares</I></B>&rdquo;)
to certain employees, consultants and/or directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has adopted
the Plan in order to effect such grants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Administrator
has determined that it is in the interest of the Company to grant these options to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Grant
of Option</B>. The Company hereby grants to Participant an option (this &ldquo;<B><I>Option</I></B>&rdquo;) to purchase the total number
of Shares set forth above as Total Shares of Common Stock at the Exercise Price Per Share set forth above (the &ldquo;<B><I>Exercise
Price</I></B>&rdquo;), subject to all of the terms and conditions of this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exercise
Period; Vesting</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercisability</U>.
Unless expired as provided in <U>Section&nbsp;3</U> of this Agreement, this Option may be exercised in whole or in part from time, to
time to the extent they have become vested, during the period of Participant&rsquo;s Continuous Service and pursuant to the terms of
<U>Section&nbsp;4</U>. Upon exercise of a portion of this Option, Participant shall receive Shares in accordance with <U>Section&nbsp;5.5</U>,
in each case subject to the restrictions on transfer set forth in <U>Sections 7</U> and <U>10</U> below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting</U>.
The Option shall become vested based on the table referenced on page&nbsp;1. This Option may not be exercised for less than a full share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Expiration</B>.
This Option shall expire on the Expiration Date set forth above or earlier as provided in <U>Section&nbsp;4</U> below or, if applicable,
pursuant to <U>Section&nbsp;6</U> of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Termination
of Continuous Service</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
than as a Result of Death or Disability</U>. Unless otherwise provided in an agreement the terms of which have been approved by the Administrator,
if Participant&rsquo;s Continuous Service is terminated for any reason, except death or Disability, the Participant may exercise this
Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (i)&nbsp;the
date ninety (90) days following the termination of the Participant&rsquo;s Continuous Service and (ii)&nbsp;the Expiration Date, after
which time this Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Because
of Death or Disability</U>. If Participant&rsquo;s Continuous Service is terminated because of the death or Disability of Participant,
the Participant (or the Participant&rsquo;s estate, by a person who acquired the right to exercise this Option by bequest or inheritance
or by a person designated to exercise this Option upon the Participant&rsquo;s death) may exercise the Participant&rsquo;s Option (to
the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (i)&nbsp;the
date twelve (12) months following such termination and (ii)&nbsp;the Expiration Date, after which time this Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment or Other Service Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve
the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
(a)&nbsp;employment with or without notice and with or without cause, (b)&nbsp;service pursuant to the terms of a consulting agreement
with the Company Group or (c)&nbsp;service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate
law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any
right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation
and Rescission of Options for Detrimental Activity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any Options at any time if the Participant is not
in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
exercise, payment or delivery pursuant to exercise of this Option, the Participant shall certify in a manner acceptable to the Company
that he or she is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event
a Participant engages in Detrimental Activity after the exercise, payment or delivery of any Shares pursuant to this Agreement, during
any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery
may be rescinded within one (1)&nbsp;year thereafter. In the event of any such rescission, the Participant shall pay to the Company the
amount of any gain realized or payment received as a result of the exercise, payment or delivery of such Shares, in such manner and on
such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain
any amount owed to the Participant by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;4.4</U> via the
mandatory redemption or repurchase of the Participant&rsquo;s Shares at a price equal to the price paid by the Participant to acquire
the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Manner
of Exercise</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Option Exercise Agreement</U>. To exercise this Option, Participant (or the Participant&rsquo;s estate, by a person who acquired the
right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant&rsquo;s
death) must deliver to the Company an executed share option exercise agreement in the form attached hereto as <U>Exhibit&nbsp;A</U>,
or in such other form as may be approved by the Administrator from time to time (the &ldquo;<B><I>Exercise Agreement</I></B>&rdquo;),
which shall set forth, <I>inter alia</I>, (a)&nbsp;Participant&rsquo;s election to exercise this Option, (b)&nbsp;the number of Shares
being purchased, (c)&nbsp;any restrictions imposed on the Shares and (d)&nbsp;any representations, warranties and agreements regarding
Participant&rsquo;s investment intent and access to information as may be required by the Company to comply with Applicable Laws. If
someone other than Participant exercises this Option, then such person must submit evidence reasonably acceptable to the Company verifying
that such person is entitled to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
on Exercise and Issuance</U>. This Option may not be exercised unless such exercise is in compliance with all Applicable Laws as are
in effect on the date of exercise and the Shares underlying the exercised Option may not be issued until the Participant executes an
Adoption Agreement to become a Shareholder to that certain Voting Agreement of the Company by and among the Company and each of its Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment</U>.
The entire Exercise Price shall be payable in full by cash or check for an amount equal to the aggregate exercise price of the Shares
being purchased. Alternatively, in the sole discretion of the Administrator and upon such terms and at such times as the Administrator
shall approve, the Exercise Price may be paid by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>tendering
to the Company other Shares, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase
equal to the exercise price (or portion thereof) due for the number of Shares being acquired (with the proceeds of such redemption or
repurchase being automatically applied by the Company towards paying the purchase price of the Shares) (collectively a &ldquo;Share For
Share Exercise&rdquo;); provided, however, that the Shares used in such Share for Share Exercise (i)&nbsp;have either (1)&nbsp;been held
for more than six (6)&nbsp;months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting
purposes) and have been paid for within the meaning of SEC Rule&nbsp;144 (and if such shares were purchased from the Company by use of
a promissory note, such note has been fully paid with respect to such shares); or (2)&nbsp;were obtained by Participant in the open public
market; and (ii)&nbsp;are clear of all liens, claims, encumbrances or security interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>during
any period for which the Shares are publicly traded (<I>i.e.</I>, the Shares are listed on any established stock exchange or a national
market system, or if the Shares are quoted on an applicable stock exchange or any similar system whereby the Shares are regularly quoted
by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker
to sell the Shares for which this Option is exercised, and to remit to the Company the aggregate Exercise Price of this Option (a &ldquo;<B><I>Cashless
Exercise</I></B>&rdquo;); <U>provided</U>, <U>however</U>, a Cashless Exercise by a Director or Participant officer that involves or may
involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of
the Sarbanes-Oxley Act (codified as Section&nbsp;13(k)&nbsp;of the Securities Exchange Act of 1934, 15 U.S.C. &sect;&nbsp;78m(k)) shall
be prohibited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>during
a Net Exercise Period, by means of the Participant electing in the Exercise Agreement to receive a portion of the Shares underlying this
Option as a cash payment and a portion as Shares, with instructions to the Company to apply such cash payment towards paying the purchase
price of the Shares for which this Option is being exercised; <U>provided</U> that in no event shall the cash payment received by the
Participant pursuant to such election exceed the aggregate exercise price of the Shares for which this Option is being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a promissory note.
However, if there is a stated par value of the Shares and Applicable Laws require, the par value of the Shares, if newly issued, shall
be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the minimum
rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator (in
its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note. Exercise
with a promissory note or other transaction by a Director or Participant officer that involves or may involve a direct or indirect extension
of credit or arrangement of an extension of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of the Sarbanes-Oxley
Act (codified as Section&nbsp;13(k)&nbsp;of the Securities Exchange Act of 1934, 15 U.S.C. &sect;&nbsp;78m(k)) shall be prohibited; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
any combination of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Tax
Withholding</U>. Prior to the issuance of the Shares upon exercise of this Option, Participant must satisfy any tax withholding obligations
relating to the exercise of this Option and the acquisition of the Shares. If the Administrator permits, in addition to the Exercise
Price payment alternatives in <U>Section&nbsp;5.3</U>, Participant may provide for payment of withholding taxes upon exercise of this
Option by (a)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the
Shares issued to the Participant as a result of the exercise of this Option or (b)&nbsp;tendering to the Company currently owned and
unencumbered Shares of the Company for redemption or repurchase and, in each of (a)&nbsp;and (b), immediately tendering the redemption
or repurchase price paid by the Company in respect of such Shares back to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of Shares</U>. <U>Provided</U> that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company,
the Company shall issue the Shares registered in the name of Participant or, if requested by the Participant, in the name of the Participant
and the Participant&rsquo;s spouse, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Compliance
with Laws and Regulations</B>. The exercise of this Option and the issuance and transfer of Shares shall be subject to compliance by
the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may
be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify
the Shares with any federal or state securities commission or any stock exchange to effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Nontransferability
of Option</B>. Unless determined otherwise by the Administrator, this Option may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent and distribution; <U>provided</U>, <U>however</U>, that the
Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of this Option for
no consideration to a Permitted Transferee. An Option transferred to a Permitted Transferee shall be further transferable only by last
will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant.
During the lifetime of a Participant, this Option shall be exercisable only by the Participant or by a Permitted Transferee to whom this
Option has been transferred in accordance with this <U>Section&nbsp;7</U>. In no event may this Option be transferred to any person who
has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Privileges
of Share Ownership</B>. Participant shall not have any of the rights of a Shareholder with respect to any Shares until the Shares are
issued to Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Restrictive
Covenants.</B> As a condition to the grant of this Option, the Participant agrees to comply with the restrictive covenants (each a &ldquo;<B><I>Restrictive
Covenant</I></B>&rdquo;) set forth in any Proprietary Information,&nbsp;Intellectual Property, Restrictive Covenant and Arbitration Agreement
(the &ldquo;<B><I>PIIA</I></B>&rdquo;) or other agreement or policy that may be in effect between the Participant and the Company Group.
The Participant understands that the cancellation of any Option or rights under this Agreement may occur for any violation or lack of
enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained
by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and
shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach
by the Participant of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of the Shares
pursuant to this Agreement (including any breach occurring after termination of Continuous Service) shall cause the exercise of this
Option and the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued
pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the
sale of such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Administrator&rsquo;s discretion, the
Company may exercise the right of rescission set forth in this <U>Section&nbsp;9</U> via the mandatory redemption or repurchase of the
Participant&rsquo;s Shares at a price equal to the aggregate Exercise Price paid by the Participant for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Restrictions
on Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Securities
Law Restrictions</U>. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities
Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its
discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends
on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary
or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws
of any state or any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Market
Stand-Off</U>. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s initial public offering, the Participant shall not sell, make
any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership
or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the
Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares
or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company
or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by
the Company or such underwriters (the &ldquo;<B><I>Market Stand-Off</I></B>&rdquo;). In order to enforce the Market Stand-Off, the Company
may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off
period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization,
combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited
to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted
or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market
Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of Repurchase</U>. Following a termination of the Participant&rsquo;s Continuous Service, the Company may repurchase the Participant&rsquo;s
Shares acquired under the Plan as provided in this Section&nbsp;(the &ldquo;<B><I>Right of Repurchase</I></B>&rdquo;). With respect to
any vested portion of this Option and any Shares acquired upon exercise of this Option, the Right of Repurchase shall be exercisable
at a purchase price (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;) equal to (i)&nbsp;the Fair Market Value of vested Shares (the &ldquo;<B><I>Share
Repurchase Right</I></B>&rdquo;); or (ii)&nbsp;in the case of a vested Option (the &ldquo;<B><I>Option Repurchase Right</I></B>&rdquo;),
the Fair Market Value of the Shares underlying the vested portion of this Option less the aggregate exercise price of such portion of
this Option (in each case as of the date the written notice described in <U>Section&nbsp;10.3(b)</U>&nbsp;is delivered). For the avoidance
of doubt, any unvested portion of this Option will be forfeited for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Condition
Precedent to Exercise</U>. The Right of Repurchase shall be exercisable following the later of: (i)&nbsp;the date when the Participant&rsquo;s
Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii)&nbsp;the
date when this Option is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Right of Repurchase</U>. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice
shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s)&nbsp;representing
any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the
Company (to the extent not already in the Company&rsquo;s custody) properly endorsed for transfer; <U>provided</U>, <U>however</U>, that
the failure to deliver such certificate(s)&nbsp;to the Company shall not prevent the Company from repurchasing any Shares under this Agreement.
The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according
to this <U>Section&nbsp;10.3</U>. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred
by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of First Refusal</U>. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell,
pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the
 &ldquo;<B><I>Transferee</I></B>&rdquo;) the Company shall have a right of first refusal to purchase all (and not less than all) of such
Shares (the &ldquo;<B><I>Right of First Refusal</I></B>&rdquo;). If the Participant desires to transfer Shares, the Participant shall
first tender to the Company for its repurchase or redemption, via a written transfer notice (&ldquo;<B><I>Transfer Notice</I></B>&rdquo;)
describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the
name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate
any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the
Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company
shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing
and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within
thirty (30) days after the date the Transfer Notice is received by the Company; <U>provided</U>, <U>however</U>, that in the case of
a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be
the Fair Market Value of the Shares determined at the time of the proposed transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Provisions Relating to Rights of Repurchase and First Refusal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Shares or Substituted Securities</U>. If there is any change in the number of outstanding Shares by reason of a share split, reverse share
split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification,
dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off
or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i)&nbsp;any new, substituted or additional securities
or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with
respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible
shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii)&nbsp;appropriate adjustments to reflect
the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to
the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; <U>provided</U>,
<U>however</U>, that the aggregate Purchase Price payable for the Shares shall remain the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Rights of Repurchase and First Refusal</U>. Any other provision of <U>Section&nbsp;10.3</U> notwithstanding, the Right of Repurchase
with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement
under applicable federal securities laws and the issuer is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the
Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of
1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the
Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by
<U>Section&nbsp;10.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Rights as Participant and Shareholder</U>. If the Company makes available to a Participant, at the time and place and in the amount
and form provided in this Agreement, the consideration for this Option to be repurchased pursuant to the Company&rsquo;s Option Repurchase
Right in accordance with <U>Section&nbsp;10.3</U>, then after such time such Participant shall no longer have any rights as a Participant
in respect of such Option (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company
makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the
Shares to be repurchased or redeemed pursuant to the Company&rsquo;s Share Repurchase Right in accordance with <U>Section&nbsp;10.3</U>
or Right of First Refusal in accordance with <U>Section&nbsp;10.4</U>, then after such time such Participant shall no longer have any
rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this
Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the
certificate(s)&nbsp;therefore have been delivered as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Intent at Grant</U>. If the grant of this Option under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or any other representation, the Participant (a)&nbsp;shall,
and hereby does, represent and agree, at the time of grant of this Option, that the security being acquired upon the grant of this Option
is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b)&nbsp;shall make such other
representations as are deemed necessary or appropriate by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Intent at Exercise</U>. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or other representation, the Participant shall represent and
agree at the time of exercise that the Shares being acquired upon exercise of this Option are being acquired for investment purposes,
and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legends</U>.
All certificates evidencing the Shares purchased under this Agreement in an unregistered transaction shall bear the following legend
(and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THE SHARES OF COMMON STOCK EVIDENCED BY
THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES,&nbsp;INC. 2020 INCENTIVE PLAN,
THE NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE EXERCISE AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE
ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY&nbsp;BE
MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE TERMS
OF THE EXERCISE AGREEMENT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal
of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold
under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate
representing the same number of Shares but without such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Administration</U>.
Any determination by the Company and its counsel in connection with any of the matters set forth in this <U>Section&nbsp;10</U> shall
be conclusive and binding on the Participant and all other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exchange
Act</B>. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under
the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section&nbsp;16(b)&nbsp;of
the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction
to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>General</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation</U>.
Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for
review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement</U>. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties
and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between
the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above,
nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the
Company and the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the
Corporate Secretary/General Counsel of the Company at its principal corporate offices. Any notice required to be given or delivered to
Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may
designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a)&nbsp;personal
delivery; (b)&nbsp;five (5)&nbsp;days after deposit in the United States mail by certified or registered mail (return receipt requested);
(c)&nbsp;two (2)&nbsp;business days after deposit with any return receipt express courier (prepaid); or (d)&nbsp;one (1)&nbsp;business
day after transmission by facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall
be binding upon Participant and Participant&rsquo;s heirs, executors, administrators, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Choice
of Law</U>. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by
and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision
of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision
will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to <U>Section&nbsp;12.6</U>,
the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction
with respect to any dispute or litigation arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Arbitration</U>.
The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect
between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions
shall govern: Subject to the Company&rsquo;s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy,
or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial
Arbitration Rules&nbsp;of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place
in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching
the arbitrator&rsquo;s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision
of this Agreement, but instead is limited to interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Right to Future Awards</U>. This Option and all other equity-based awards under the Plan are discretionary. This Option does not confer
on the Participant any right or entitlement to receive another award of Option or any other equity-based award at any time in the future
or in respect of any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the
remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had
never been included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.95in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this
Agreement; <U>provided</U>, <U>however</U>, that no amendment or modification of this Agreement shall materially and adversely impair
the rights of the Participant with respect to any then outstanding Options without the consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Acceptance</B>.
Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and
provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing this Option and the terms and
conditions of the Plan governing this Option and any and all other outstanding options held by the Participant as of the date of execution.
Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the Shares and that
Participant should consult a tax advisor prior to such exercise or disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signatures on Following Page]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
witness whereof</B></FONT>, the Company has caused this Agreement to be executed by its duly authorized representative effective as of
[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 5%">By:</TD><TD STYLE="width: 45%"></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in">Name:</TD><TD>[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 3in"></TD><TD STYLE="width: 0.5in">Title:</TD><TD>[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD></TD><TD>Participant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%">&nbsp;</TD></TR>
                                                                                                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Acceptance Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</TD></TR>
                                                                                                                                                                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(D)
<SEQUENCE>17
<FILENAME>tm2415719d15_ex10-4d.htm
<DESCRIPTION>EXHIBIT 10.4(D)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;10.4(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NONQUALIFIED STOCK OPTION AWARD AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Nonqualified Stock Option
Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the date of grant set forth below (the &ldquo;<B><I>Date
of Grant</I></B>&rdquo;) by and between Caris Life Sciences,&nbsp;Inc., a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
and the participant named below (the &ldquo;<B><I>Participant</I></B>&rdquo;). Capitalized terms not defined herein shall have the meaning
ascribed to them in the Company&rsquo;s 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Participant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grant Number: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exercise Price Per Share: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of Grant: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expiration Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vesting Commencement Date: [<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant options to purchase shares of common stock of the Company, par value US$0.001 per share (the &ldquo;<B><I>Shares</I></B>&rdquo;)
to certain employees, consultants and/or directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has adopted
the Plan in order to effect such grants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Administrator
has determined that it is in the interest of the Company to grant these options to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Grant
of Option</B>. The Company hereby grants to Participant an option (this &ldquo;<B><I>Option</I></B>&rdquo;) to purchase the total number
of Shares set forth above as Total Shares of Common Stock at the Exercise Price Per Share set forth above (the &ldquo;<B><I>Exercise Price</I></B>&rdquo;),
subject to all of the terms and conditions of this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exercise
Period; Vesting</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercisability</U>.
Unless expired as provided in <U>Section&nbsp;3</U> of this Agreement, this Option may be exercised in whole or in part from time to time,
to the extent they have become vested, during the period of Participant&rsquo;s Continuous Service and pursuant to the terms of <U>Section&nbsp;4</U>.
Upon exercise of a portion of this Option, Participant shall receive Shares in accordance with <U>Section&nbsp;5.5</U>, in each case subject
to the restrictions on transfer set forth in <U>Sections 7</U> and <U>10</U> below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting</U>.
The Option shall become vested based on the table referenced on page&nbsp;1. This Option may not be exercised for less than a full share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Expiration</B>.
This Option shall expire on the Expiration Date set forth above or earlier as provided in <U>Section&nbsp;4</U> below or, if applicable,
pursuant to <U>Section&nbsp;6</U> of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Termination
of Continuous Service</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
than as a Result of Death or Disability</U>. Unless otherwise provided in an agreement the terms of which have been approved by the Administrator,
if Participant&rsquo;s Continuous Service is terminated for any reason, except death or Disability, the Participant may exercise this
Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (i)&nbsp;the
date ninety (90) days following the termination of the Participant&rsquo;s Continuous Service and (ii)&nbsp;the Expiration Date, after
which time this Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Because
of Death or Disability</U>. If Participant&rsquo;s Continuous Service is terminated because of the death or Disability of Participant,
the Participant (or the Participant&rsquo;s estate, by a person who acquired the right to exercise this Option by bequest or inheritance
or by a person designated to exercise this Option upon the Participant&rsquo;s death) may exercise the Participant&rsquo;s Option (to
the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (i)&nbsp;the
date twelve (12) months following such termination and (ii)&nbsp;the Expiration Date, after which time this Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment or Other Service Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve
the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
(a)&nbsp;employment with or without notice and with or without cause, (b)&nbsp;service pursuant to the terms of a consulting agreement
with the Company Group or (c)&nbsp;service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate
law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right
to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation
and Rescission of Options for Detrimental Activity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any Options at any time if the Participant is not
in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
exercise, payment or delivery pursuant to exercise of this Option, the Participant shall certify in a manner acceptable to the Company
that he or she is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event
a Participant engages in Detrimental Activity after the exercise, payment or delivery of any Shares pursuant to this Agreement, during
any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery
may be rescinded within one (1)&nbsp;year thereafter. In the event of any such rescission, the Participant shall pay to the Company the
amount of any gain realized or payment received as a result of the exercise, payment or delivery of such Shares, in such manner and on
such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain
any amount owed to the Participant by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;4.4</U> via
the mandatory redemption or repurchase of the Participant&rsquo;s Shares at a price equal to the price paid by the Participant to acquire
the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Manner
of Exercise</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Option Exercise Agreement</U>. To exercise this Option, Participant (or the Participant&rsquo;s estate, by a person who acquired the
right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant&rsquo;s
death) must deliver to the Company an executed share option exercise agreement in the form attached hereto as <U>Exhibit&nbsp;A</U>,
or in such other form as may be approved by the Administrator from time to time (the &ldquo;<B><I>Exercise Agreement</I></B>&rdquo;),
which shall set forth, <I>inter alia</I>, (a)&nbsp;Participant&rsquo;s election to exercise this Option, (b)&nbsp;the number of Shares
being purchased, (c)&nbsp;any restrictions imposed on the Shares and (d)&nbsp;any representations, warranties and agreements regarding
Participant&rsquo;s investment intent and access to information as may be required by the Company to comply with Applicable Laws. If
someone other than Participant exercises this Option, then such person must submit evidence reasonably acceptable to the Company verifying
that such person is entitled to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
on Exercise and Issuance</U>. This Option may not be exercised unless such exercise is in compliance with all Applicable Laws as are
in effect on the date of exercise and the Shares underlying the exercised Option may not be issued until the Participant executes an
Adoption Agreement to become a Shareholder to that certain Voting Agreement of the Company by and among the Company and each of its Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment</U>.
The entire Exercise Price shall be payable in full by cash or check for an amount equal to the aggregate exercise price of the Shares
being purchased. Alternatively, in the sole discretion of the Administrator and upon such terms and at such times as the Administrator
shall approve, the Exercise Price may be paid by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>tendering
to the Company other Shares, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase
equal to the exercise price (or portion thereof) due for the number of Shares being acquired (with the proceeds of such redemption or
repurchase being automatically applied by the Company towards paying the purchase price of the Shares) (collectively a &ldquo;Share For
Share Exercise&rdquo;); provided, however, that the Shares used in such Share for Share Exercise (i)&nbsp;have either (1)&nbsp;been held
for more than six (6)&nbsp;months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting
purposes) and have been paid for within the meaning of SEC Rule&nbsp;144 (and if such shares were purchased from the Company by use of
a promissory note, such note has been fully paid with respect to such shares); or (2)&nbsp;were obtained by Participant in the open public
market; and (ii)&nbsp;are clear of all liens, claims, encumbrances or security interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>during
any period for which the Shares are publicly traded (<I>i.e.</I>, the Shares are listed on any established stock exchange or a national
market system, or if the Shares are quoted on an applicable stock exchange or any similar system whereby the Shares are regularly quoted
by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker
to sell the Shares for which this Option is exercised, and to remit to the Company the aggregate Exercise Price of this Option (a &ldquo;<B><I>Cashless
Exercise</I></B>&rdquo;); <U>provided</U>, <U>however</U>, a Cashless Exercise by a Director or Participant officer that involves or may
involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of
the Sarbanes-Oxley Act (codified as Section&nbsp;13(k)&nbsp;of the Securities Exchange Act of 1934, 15 U.S.C. &sect;&nbsp;78m(k)) shall
be prohibited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>during
a Net Exercise Period, by means of the Participant electing in the Exercise Agreement to receive a portion of the Shares underlying this
Option as a cash payment and a portion as Shares, with instructions to the Company to apply such cash payment towards paying the purchase
price of the Shares for which this Option is being exercised; <U>provided</U> that in no event shall the cash payment received by the
Participant pursuant to such election exceed the aggregate exercise price of the Shares for which this Option is being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a promissory note.
However, if there is a stated par value of the Shares and Applicable Laws require, the par value of the Shares, if newly issued, shall
be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the minimum
rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator (in
its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note. Exercise
with a promissory note or other transaction by a Director or Participant officer that involves or may involve a direct or indirect extension
of credit or arrangement of an extension of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of the Sarbanes-Oxley
Act (codified as Section&nbsp;13(k)&nbsp;of the Securities Exchange Act of 1934, 15 U.S.C. &sect;&nbsp;78m(k)) shall be prohibited; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
any combination of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Tax
Withholding</U>. Prior to the issuance of the Shares upon exercise of this Option, Participant must satisfy any tax withholding obligations
relating to the exercise of this Option and the acquisition of the Shares. If the Administrator permits, in addition to the Exercise
Price payment alternatives in <U>Section&nbsp;5.3</U>, Participant may provide for payment of withholding taxes upon exercise of this
Option by (a)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the
Shares issued to the Participant as a result of the exercise of this Option or (b)&nbsp;tendering to the Company currently owned and
unencumbered Shares of the Company for redemption or repurchase and, in each of (a)&nbsp;and (b), immediately tendering the redemption
or repurchase price paid by the Company in respect of such Shares back to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of Shares</U>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company, the
Company shall issue the Shares registered in the name of Participant or, if requested by the Participant, in the name of the Participant
and the Participant&rsquo;s spouse, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Compliance
with Laws and Regulations</B>. The exercise of this Option and the issuance and transfer of Shares shall be subject to compliance by
the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may
be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify
the Shares with any federal or state securities commission or any stock exchange to effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Nontransferability
of Option</B>. Unless determined otherwise by the Administrator, this Option may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent and distribution; <U>provided</U>, <U>however</U>, that the
Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of this Option for
no consideration to a Permitted Transferee. An Option transferred to a Permitted Transferee shall be further transferable only by last
will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant.
During the lifetime of a Participant, this Option shall be exercisable only by the Participant or by a Permitted Transferee to whom this
Option has been transferred in accordance with this <U>Section&nbsp;7</U>. In no event may this Option be transferred to any person who
has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Privileges
of Share Ownership</B>. Participant shall not have any of the rights of a Shareholder with respect to any Shares until the Shares are
issued to Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Restrictive
Covenants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Generally</U>.
<U>As a condition to the grant of this Option, the Participant agrees to comply with the following restrictive covenants (each a &ldquo;<B><I>Restrictive
Covenant</I></B>&rdquo;):</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
assist Participant in the performance of the Participant&rsquo;s duties for the Company Group, the Company Group has provided and will
provide to Participant certain Confidential Information and Trade Secrets. Participant agrees that during the period of Participant&rsquo;s
service to the Company Group and at all times thereafter, Participant shall not, on Participant&rsquo;s own behalf or on behalf of any
third party, directly or indirectly divulge or make use of any Confidential Information or Trade Secrets without prior written consent
of the Company, which consent may be withheld in the Company&rsquo;s absolute discretion; <U>provided</U>, <U>however</U>, that Participant
may make disclosures required by a valid order or subpoena issued by a court or administrative agency of competent jurisdiction, in which
event Participant will promptly notify the Company of such order or subpoena, in a reasonable time prior to such disclosure so that the
Company has the opportunity to protect its interests. Participant further agrees that if Participant is questioned about information subject
to this Agreement by anyone not authorized to receive such information, Participant will promptly notify an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Participant
agrees to hold in confidence all Confidential Information, Trade Secrets and company records received from the Company or at the Company&rsquo;s
expense and shall not at any time directly or indirectly disclose, publish or use any Confidential Information, Trade Secrets and/or company
records for the benefit of anyone other than Company. This restriction shall apply to all information received prior to or after the effective
date of this Agreement and continue in effect after the Participant&rsquo;s service ends in perpetuity, or until such information becomes
a part of the public domain through means other than wrongful disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Confidential
Information</I></B>&rdquo; means information about the Company Group and its employees, customers, processes, technology and other information
that is not generally known outside of the Company Group, which Participant learns in connection with Participant&rsquo;s service with
the Company Group and which would be useful to competitors of the Company Group. Confidential Information includes, but is not limited
to: (1)&nbsp;business and employment policies, marketing methods and strategies and the targets of those methods and strategies, financial
data, business plans, promotional materials, pricing and pricing strategies, profit and loss statements, and sales and account records;
(2)&nbsp;present and prospective customer lists, customer preferences and buying patterns, distribution records and customer credit information;
(3)&nbsp;the Company Group&rsquo;s inventions, innovations, improvements, discoveries, methods, research data and results, databases,
research techniques and methodology, analytical approaches, software, and programs; and (4)&nbsp;the nature, origin, composition and development
of the Company Group&rsquo;s brands, products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B><I>Trade Secrets</I></B>&rdquo;
means Confidential Information which meets the additional requirements of the Uniform Trade Secrets Act or similar state law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation</U>.
The Participant understands that the cancellation of any Option or rights under this Agreement may occur for any violation or lack of
enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained
by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall
not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the
Participant of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of the Shares pursuant
to this Agreement (including any breach occurring after termination of Continuous Service) shall cause the exercise of this Option and
the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant
to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such
Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rescission</U>.
At the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this Section&nbsp;9 via the mandatory
redemption or repurchase of the Participant&rsquo;s Shares at a price equal to the aggregate Exercise Price paid by the Participant for
the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Restrictions
on Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Securities
Law Restrictions</U>. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities
Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its
discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends
on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary
or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws
of any state or any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Market
Stand-Off</U>. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s initial public offering, the Participant shall not sell, make
any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership
or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the
Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares
or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company
or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by
the Company or such underwriters (the &ldquo;<B><I>Market Stand-Off</I></B>&rdquo;). In order to enforce the Market Stand-Off, the Company
may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off
period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization,
combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited
to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted
or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market
Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of Repurchase</U>. Following a termination of the Participant&rsquo;s Continuous Service, the Company may repurchase the Participant&rsquo;s
Shares acquired under the Plan as provided in this Section&nbsp;(the &ldquo;<B><I>Right of Repurchase</I></B>&rdquo;). With respect to
any vested portion of this Option and any Shares acquired upon exercise of this Option, the Right of Repurchase shall be exercisable
at a purchase price (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;) equal to (i)&nbsp;the Fair Market Value of vested Shares (the &ldquo;<B><I>Share
Repurchase Right</I></B>&rdquo;); or (ii)&nbsp;in the case of a vested Option (the &ldquo;<B><I>Option Repurchase Right</I></B>&rdquo;),
the Fair Market Value of the Shares underlying the vested portion of this Option less the aggregate exercise price of such portion of
this Option (in each case as of the date the written notice described in <U>Section&nbsp;10.3(b)</U>&nbsp;is delivered). For the avoidance
of doubt, any unvested portion of this Option will be forfeited for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Condition
Precedent to Exercise</U>. The Right of Repurchase shall be exercisable following the later of: (i)&nbsp;the date when the Participant&rsquo;s
Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii)&nbsp;the
date when this Option is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Right of Repurchase</U>. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice
shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s)&nbsp;representing
any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the
Company (to the extent not already in the Company&rsquo;s custody) properly endorsed for transfer; <U>provided</U>, <U>however</U>, that
the failure to deliver such certificate(s)&nbsp;to the Company shall not prevent the Company from repurchasing any Shares under this Agreement.
The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according
to this <U>Section&nbsp;10.3</U>. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred
by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of First Refusal</U>. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell,
pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the
 &ldquo;<B><I>Transferee</I></B>&rdquo;) the Company shall have a right of first refusal to purchase all (and not less than all) of such
Shares (the &ldquo;<B><I>Right of First Refusal</I></B>&rdquo;). If the Participant desires to transfer Shares, the Participant shall
first tender to the Company for its repurchase or redemption, via a written transfer notice (&ldquo;<B><I>Transfer Notice</I></B>&rdquo;)
describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the
name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate
any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the
Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company
shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing
and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within
thirty (30) days after the date the Transfer Notice is received by the Company; <U>provided</U>, <U>however</U>, that in the case of
a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be
the Fair Market Value of the Shares determined at the time of the proposed transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Provisions Relating to Rights of Repurchase and First Refusal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Shares or Substituted Securities</U>. If there is any change in the number of outstanding Shares by reason of a share split, reverse
share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination,
reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up,
a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i)&nbsp;any new, substituted or
additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction
distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby
become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii)&nbsp;appropriate
adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject
to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First
Refusal; <U>provided</U>, <U>however</U>, that the aggregate Purchase Price payable for the Shares shall remain the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Rights of Repurchase and First Refusal</U>. Any other provision of <U>Section&nbsp;10.3</U> notwithstanding, the Right of Repurchase
with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement
under applicable federal securities laws and the issuer is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the
Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of
1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the
Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by
<U>Section&nbsp;10.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Rights as Participant and Shareholder</U>. If the Company makes available to a Participant, at the time and place and in the amount
and form provided in this Agreement, the consideration for this Option to be repurchased pursuant to the Company&rsquo;s Option Repurchase
Right in accordance with <U>Section&nbsp;10.3</U>, then after such time such Participant shall no longer have any rights as a Participant
in respect of such Option (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company
makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for
the Shares to be repurchased or redeemed pursuant to the Company&rsquo;s Share Repurchase Right in accordance with <U>Section&nbsp;10.3</U>
or Right of First Refusal in accordance with <U>Section&nbsp;10.4</U>, then after such time such Participant shall no longer have any
rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this
Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not
the certificate(s)&nbsp;therefore have been delivered as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Intent at Grant</U>. If the grant of this Option under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or any other representation, the Participant (a)&nbsp;shall,
and hereby does, represent and agree, at the time of grant of this Option, that the security being acquired upon the grant of this Option
is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b)&nbsp;shall make such other
representations as are deemed necessary or appropriate by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Intent at Exercise</U>. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or other representation, the Participant shall represent and
agree at the time of exercise that the Shares being acquired upon exercise of this Option are being acquired for investment purposes,
and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legends</U>.
All certificates evidencing the Shares purchased under this Agreement in an unregistered transaction shall bear the following legend
(and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THE SHARES OF COMMON STOCK EVIDENCED BY
THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES,&nbsp;INC. 2020 INCENTIVE PLAN,
THE NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE EXERCISE AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE
ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY&nbsp;BE
MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE TERMS
OF THE EXERCISE AGREEMENT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal
of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold
under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate
representing the same number of Shares but without such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Administration</U>.
Any determination by the Company and its counsel in connection with any of the matters set forth in this <U>Section&nbsp;10</U> shall
be conclusive and binding on the Participant and all other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Exchange
Act</B>. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under
the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section&nbsp;16(b)&nbsp;of
the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction
to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>General</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation</U>.
Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for
review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement</U>. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties
and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between
the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above,
nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the
Company and the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the
Corporate Secretary/General Counsel of the Company at its principal corporate offices. Any notice required to be given or delivered to
Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may
designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a)&nbsp;personal
delivery; (b)&nbsp;five (5)&nbsp;days after deposit in the United States mail by certified or registered mail (return receipt requested);
(c)&nbsp;two (2)&nbsp;business days after deposit with any return receipt express courier (prepaid); or (d)&nbsp;one (1)&nbsp;business
day after transmission by facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall
be binding upon Participant and Participant&rsquo;s heirs, executors, administrators, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Choice
of Law</U>. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by
and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision
of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision
will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to <U>Section&nbsp;12.6</U>,
the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction
with respect to any dispute or litigation arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Arbitration</U>.
Subject to the Company&rsquo;s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or
claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial
Arbitration Rules&nbsp;of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place
in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching
the arbitrator&rsquo;s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision
of this Agreement, but instead is limited to interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Right to Future Awards</U>. This Option and all other equity-based awards under the Plan are discretionary. This Option does not confer
on the Participant any right or entitlement to receive another award of Option or any other equity-based award at any time in the future
or in respect of any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the
remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had
never been included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this
Agreement; <U>provided</U>, <U>however</U>, that no amendment or modification of this Agreement shall materially and adversely impair
the rights of the Participant with respect to any then outstanding Options without the consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><B>Acceptance</B>.
Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and
provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing this Option and the terms and
conditions of the Plan governing this Option and any and all other outstanding options held by the Participant as of the date of execution.
Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the Shares and that
Participant should consult a tax advisor prior to such exercise or disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signatures on Following Page]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
witness whereof</B></FONT>, the Company has caused this Agreement to be executed by its duly authorized representative effective as of
 [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 5%">By:</TD><TD STYLE="width: 45%"></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Name:</TD><TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Title:</TD><TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 8%">Participant:</TD><TD STYLE="width: 42%">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"></TD><TD STYLE="text-align: justify; width: 50%">Acceptance Date:
                                                                            [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(E)
<SEQUENCE>18
<FILENAME>tm2415719d15_ex10-4e.htm
<DESCRIPTION>EXHIBIT 10.4(E)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;10.4(e)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
STOCK UNIT</B></FONT><B> AWARD AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Restricted Stock Unit Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the date of grant set
forth below (the &ldquo;<B><I>Date of Grant</I></B>&rdquo;) by and between Caris Life Sciences,&nbsp;Inc., </FONT>a Texas corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), and the participant named below (the &ldquo;<B><I>Participant</I></B>&rdquo;). Capitalized
terms not defined herein shall have the meaning ascribed to them in the Company&rsquo;s 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%">Participant:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Address:&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Grant Number:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Restricted Stock Units:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date of Grant:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Expiration Date:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant restricted stock units (&ldquo;<B><I>RSUs</I></B>&rdquo;) with respect to shares of common stock of the Company, par value US$0.001
per share (the &ldquo;<B><I>Shares</I></B>&rdquo;) to certain employees, consultants and/or directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has adopted
the Plan in order to effect such grants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Administrator
has determined that it is in the interest of the Company to grant these RSUs to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Grant
of RSUs</B>. The Company hereby grants to Participant the number of RSUs set forth above as Total Restricted Stock Units, each entitling
Participant to receive one Share upon settlement, subject to all of the terms and conditions of this Agreement and the Plan, including
vesting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Vesting;
Settlement of RSUs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vesting</U>.
RSUs shall vest only upon the occurrence, on or before the Expiration Date, of either (1)&nbsp;an IPO or (2)&nbsp;a Change of Control
(each a &ldquo;<B><I>Vesting Date</I></B>&rdquo;), subject to the Participant&rsquo;s Continuous Service with the Company through the
Vesting Date. For the purposes of this Agreement, an &ldquo;<B><I>IPO</I></B>&rdquo; means the occurrence of an initial public offering
that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved
for designation) as a national market security on an interdealer quotation system, on or before the date set forth above as Expiration
Date. Unless otherwise determined by the Administrator in its sole discretion, if Participant&rsquo;s Continuous Service is terminated
for any reason, all outstanding RSUs that are not vested at the date of such termination shall be cancelled and terminated without any
payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Settlement</U>.
Pursuant to such procedures established by the Administrator, and subject to any deferral of delivery pursuant to <U>Section&nbsp;8.2</U>,
the Company shall issue whole Shares to the Participant in settlement of the vested portion of the RSUs as soon as administratively practicable
after the applicable Vesting Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U>. Prior to the issuance of the Shares upon settlement of the RSUs, Participant must satisfy any tax withholding obligations
relating to the settlement of the RSUs and the acquisition of the Shares. The Company shall hold back a portion of the RSUs otherwise
deliverable to the Participant to cover any such required withholdings. If Shares are used to pay all or a portion of such withholding
tax obligation, the number of Shares that may be withheld, surrendered, or reduced shall be limited to the number of Shares equal in value
to the aggregate amount of such liabilities based on the greatest statutory withholding rates applicable to Participant for federal, state,
foreign, or local tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment with respect
to the RSUs, as determined by the Company. If the Administrator permits, Participant may provide for payment of withholding taxes upon
settlement of the RSUs by (a)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares
out of the Shares issued to the Participant as a result of the settlement of the RSUs or (b)&nbsp;tendering to the Company currently owned
and unencumbered Shares of the Company for redemption or repurchase and, in each of (a)&nbsp;and (b), immediately tendering the redemption
or repurchase price paid by the Company in respect of such Shares back to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Cancellation
and Rescission of RSUs for Detrimental Activity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any RSUs at any time if the Participant is not in
compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
settlement or delivery pursuant to settlement of the RSUs, the Participant shall certify in a manner acceptable to the Company that the
Participant is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a
Participant engages in Detrimental Activity after the settlement or delivery of any Shares pursuant to this Agreement, during any period
for which any restrictive covenant prohibiting such activity is applicable to the Participant, such settlement or delivery may be rescinded
within one (1)&nbsp;year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain
realized or payment received as a result of the settlement or delivery of such Shares, in such manner and on such terms and conditions
as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the
Participant by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;3</U> via the
mandatory redemption or repurchase of the Participant&rsquo;s Shares. It is expressly agreed by the Participant that, since the Participant
is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price
or other consideration shall be payable to the Participant by the Company for the Company&rsquo;s redemption or repurchase of the Participant&rsquo;s
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Compliance
with Laws and Regulations</B>. The settlement of the RSUs and the issuance and transfer of Shares shall be subject to compliance by the
Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be
listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify
the Shares with any federal or state securities commission or any stock exchange to effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Nontransferability
of the RSUs</B>. Unless determined otherwise by the Administrator, the RSUs may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator
may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of the RSUs for no consideration
to a Permitted Transferee. RSUs transferred to a Permitted Transferee shall be further transferable only by last will and testament or
the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. In no event may the
RSUs be transferred to any person who has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Privileges
of Share Ownership</B>. Participant shall not have any of the rights of a shareholder with respect to any Shares until the Shares are
issued and delivered to the Participant in such manner as the Company, in its sole discretion, shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Restrictive
Covenants</B>. As a condition to the grant and settlement of the RSUs, the Participant agrees to comply with the restrictive covenants
(each a &ldquo;<B><I>Restrictive Covenant</I></B>&rdquo;) set forth in any Proprietary Information,&nbsp;Intellectual Property, Restrictive
Covenant and Arbitration Agreement (the &ldquo;<B><I>PIIA</I></B>&rdquo;) or other agreement or policy that may be in effect between the
Participant and the Company Group. The Participant understands that the cancellation of any RSUs or rights under this Agreement may occur
for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages
potentially sustained by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group
has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future.
In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any delivery of the Shares pursuant
to this Agreement (including any breach occurring after termination of employment) shall cause the delivery of the Shares under this Agreement
to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required
to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;7</U> via the
mandatory redemption or repurchase of the Participant&rsquo;s Shares. It is expressly agreed by the Participant that, since the Participant
is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price
or other consideration shall be payable to the Participant by the Company for the Company&rsquo;s redemption or repurchase of the Participant&rsquo;s
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Restrictions
on Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities
Law Restrictions</U>. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities
Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its
discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends
on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary
or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws
of any state or any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Market
Stand-Off</U>. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s IPO, the Participant shall not sell, make any short sale of, loan,
hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer
for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible
into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned
by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of
time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the &ldquo;<B><I>Market
Stand-Off</I></B>&rdquo;). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to
the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding
Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or
liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off),
a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason
of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become
convertible, shall immediately be subject to the Market Stand-Off. To the extent the vesting of any RSUs occurs during the Market Stand-Off,
the Administrator retains the right, in its sole discretion, to defer the delivery of Shares underlying the RSUs until promptly following
the termination of the Market Stand-Off; provided, however, that in no event shall the delivery of such Shares be later than March&nbsp;15th
of the calendar year following the calendar year in which the RSUs vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Right
of Repurchase</U>. Following a termination of the Participant&rsquo;s Continuous Service, the Company may repurchase the Participant&rsquo;s
Shares acquired under the Plan as provided in this Section&nbsp;(the &ldquo;<B><I>Right of Repurchase</I></B>&rdquo;). With respect to
any vested RSUs and any Shares acquired upon settlement of the RSUs, the Right of Repurchase shall be exercisable at a purchase price
(the &ldquo;<B><I>Purchase Price</I></B>&rdquo;) equal to (i)&nbsp;the Fair Market Value of vested Shares (the &ldquo;<B><I>Share Repurchase
Right</I></B>&rdquo;); or (ii)&nbsp;in the case of a vested RSU (the &ldquo;<B><I>RSU Repurchase Right</I></B>&rdquo;), the Fair Market
Value of the Shares underlying the vested RSUs (in each case as of the date the written notice described in <U>Section&nbsp;8.3(b)</U>&nbsp;is
delivered). For the avoidance of doubt, any unvested RSUs will be forfeited for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Condition
Precedent to Settlement</U>. The Right of Repurchase shall be exercisable following the later of: (i)&nbsp;the date when the Participant&rsquo;s
Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii)&nbsp;the
date when the RSUs are settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
of Right of Repurchase</U>. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice
shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s)&nbsp;representing
any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the
Company (to the extent not already in the Company&rsquo;s custody) properly endorsed for transfer; provided, however, that the failure
to deliver such certificate(s)&nbsp;to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The
Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to
this <U>Section&nbsp;8.3</U>. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by
the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Right
of First Refusal</U>. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell,
pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the
 &ldquo;<B><I>Transferee</I></B>&rdquo;) the Company shall have a right of first refusal to purchase all (and not less than all) of such
Shares (the &ldquo;<B><I>Right of First Refusal</I></B>&rdquo;). If the Participant desires to transfer Shares, the Participant shall
first tender to the Company for its repurchase or redemption, via a written transfer notice (&ldquo;<B><I>Transfer Notice</I></B>&rdquo;)
describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the
name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate
any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant
and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall
have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price)
of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30)
days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory
transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined
at the time of the proposed transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Provisions Relating to Rights of Repurchase and First Refusal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Shares or Substituted Securities</U>. If there is any change in the number of outstanding Shares by reason of a share split, reverse share
split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification,
dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off
or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i)&nbsp;any new, substituted or additional securities
or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with
respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible
shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii)&nbsp;appropriate adjustments to reflect
the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to
the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however,
that the aggregate Purchase Price payable for the Shares shall remain the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Rights of Repurchase and First Refusal</U>. Any other provision of <U>Section&nbsp;8.3</U> notwithstanding, the Right of Repurchase
with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement
under applicable federal securities laws and the issuer is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the
Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of
1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the
Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by
<U>Section&nbsp;8.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Rights as Participant and Shareholder</U>. If the Company makes available to a Participant, at the time and place and in the amount
and form provided in this Agreement, the consideration for the RSUs to be repurchased pursuant to the Company&rsquo;s RSUs Repurchase
Right in accordance with <U>Section&nbsp;8.3</U>, then after such time such Participant shall no longer have any rights as a Participant
in respect of such RSUs (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company
makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the
Shares to be repurchased or redeemed pursuant to the Company&rsquo;s Share Repurchase Right in accordance with <U>Section&nbsp;8.3</U>
or Right of First Refusal in accordance with <U>Section&nbsp;8.4</U>, then after such time such Participant shall no longer have any rights
as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement).
Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s)&nbsp;therefore
have been delivered as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Intent at Grant</U>. If the grant of the RSUs under the Plan is not registered under applicable federal or state securities laws, but
an exemption is available which requires an investment representation or any other representation, the Participant (a)&nbsp;shall, and
hereby does, represent and agree, at the time of grant of the RSUs, that the security being acquired upon the grant of the RSUs is being
acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b)&nbsp;shall make such other representations
as are deemed necessary or appropriate by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Intent at Settlement</U>. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or other representation, the Participant shall represent and
agree at the time of settlement that the Shares being acquired upon settlement of the RSUs are being acquired for investment purposes,
and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Legends</U>.
All certificates evidencing the Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and
such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THE SHARES OF COMMON STOCK EVIDENCED BY
THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES,&nbsp;INC. 2020 INCENTIVE PLAN
AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH
ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY&nbsp;BE MADE EXCEPT IN ACCORDANCE
WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Removal
of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold
under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate
representing the same number of Shares but without such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
Any determination by the Company and its counsel in connection with any of the matters set forth in this <U>Section&nbsp;8</U> shall be
conclusive and binding on the Participant and all other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Exchange
Act</B>. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under
the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section&nbsp;16(b)&nbsp;of
the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction
to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Compliance
with Code Section&nbsp;409A</B>. Notwithstanding any contrary provision herein or in the Plan, if any RSU is deemed to be a &ldquo;deferral
of compensation&rdquo; under Code Section&nbsp;409A or any regulations or guidance promulgated thereunder or could cause any person to
recognize additional taxes, penalties or interest under Code Section&nbsp;409A, the Board may, in its sole discretion and without the
consent of any person, unilaterally modify such provision: (i)&nbsp;to comply with, or avoid being subject to, Code Section&nbsp;409A,
or to avoid the imposition of any additional taxes, penalties or interest under Code Section&nbsp;409A, and (ii)&nbsp;to maintain, to
the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Code Section&nbsp;409A.
This <U>Section&nbsp;10</U> does not create an obligation on the part of the Board to modify the Plan or this Agreement and does not guarantee
that any person shall not be subject to additional taxes, penalties or interest under Code Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Expiration</B>.
The RSUs shall expire on the Expiration Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>General</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Interpretation</U>.
Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review.
The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. </FONT>The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the
parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist
between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the
above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between
the Company and the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the
Corporate Secretary/Chief Legal Officer of the Company at its principal corporate offices. Any notice required to be given or delivered
to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party
may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a)&nbsp;personal
delivery; (b)&nbsp;five (5)&nbsp;days after deposit in the United States mail by certified or registered mail (return receipt requested);
(c)&nbsp;two (2)&nbsp;business days after deposit with any return receipt express courier (prepaid); or (d)&nbsp;one (1)&nbsp;business
day after transmission by facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be
binding upon Participant and Participant&rsquo;s heirs, executors, administrators, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Choice
of Law and Venue</U>. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed
by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision
of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will
be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. </FONT>Subject to <U>Section&nbsp;12.6</U>,
the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction
with respect to any dispute or litigation arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Arbitration</U>.
</FONT>The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect
between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions
shall govern: Subject to the Company&rsquo;s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy,
or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial
Arbitration Rules&nbsp;of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place
in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching
the arbitrator&rsquo;s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision
of this Agreement, but instead is limited to interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Employment or Other Service Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve
the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
(a)&nbsp;employment with or without notice and with or without cause, (b)&nbsp;service pursuant to the terms of a consulting agreement
with the Company Group or (c)&nbsp;service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate
law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right
to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Right to Future Awards</U>. This award of RSUs and all other equity-based awards under the Plan are discretionary. This award does not
confer on the Participant any right or entitlement to receive another award of RSUs or any other equity-based award at any time in the
future or in respect of any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the
remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had
never been included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
</FONT>Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify
this Agreement; <U>provided</U>, <U>however</U>, that no amendment or modification of this Agreement shall materially and adversely impair
the rights of the Participant with respect to any then outstanding RSUs without the consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Spousal
Consent</B>. I agree to cause any current or future spouse of mine to deliver to the Company a consent in the form of the consent attached
hereto validly executed by such spouse on the date hereof or promptly after any such person becomes my spouse, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Acceptance</B>.
Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions
thereof, and by executing below, accepts the terms and conditions of this Agreement governing the RSUs and the terms and conditions of
the Plan governing the RSUs and any and all other outstanding RSUs held by the Participant as of the date of execution. Participant acknowledges
that there may be adverse tax consequences upon settlement of the RSUs or disposition of the Shares and that Participant should consult
a tax advisor prior to such settlement or disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Release
of Claims</B>. In consideration of the grant of the RSUs provided to Participant under this Agreement and after having sufficient time
to consult with Participant&rsquo;s own counsel, Participant and each of Participant&rsquo;s respective heirs, executors, administrators,
representatives, agents, successors and assigns (collectively, the &ldquo;<B><I>Participant Parties</I></B>&rdquo;) hereby irrevocably
and unconditionally release and forever discharge the Company, the Company&rsquo;s former, current and future parents, subsidiaries and
affiliates, and each predecessor, successor and affiliate of each of the aforementioned entities, and each of their respective officers,
employees, directors, shareholders and agents from any and all claims, actions, causes of action, rights, judgments, obligations, damages,
demands, accountings or liabilities of whatever kind or character (collectively, &ldquo;<B><I>Claims</I></B>&rdquo;), including, without
limitation, any Claims under any federal, state, local or foreign law, that the Participant Parties may have, or in the future may possess,
arising from or relating to any RSU or other equity or equity-based award previously granted under the Plan; provided, however, that Participant
does not release, discharge or waive any rights to the RSUs and to the Shares provided under this Agreement that is contingent upon the
execution by Participant of this release of claims. This <U>Section&nbsp;15</U> does not apply to any Claims that the Participant Parties
may have as of the date Participant signs this Agreement arising under the Federal Age Discrimination in Employment Act of 1967, as amended,
and the applicable rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>SIGNATURE PAGE TO FOLLOW</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
witness whereof</B></FONT>, the Company has caused this Agreement to be executed by its duly authorized representative effective as of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 5%">By:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 45%"></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Name:</TD><TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Title:</TD><TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2">Participant</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signatures Page to RSU
Award Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SPOUSAL ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of
the Participant has read and hereby approves the foregoing Restricted Stock Unit Award Agreement. In consideration of the Company&rsquo;s
granting the Participant the right to acquire the Shares in accordance with the terms of such Agreement, the undersigned hereby agrees
to be irrevocably bound by all the terms of such Agreement and the Plan, including (without limitation) (i)&nbsp;the right of the Company
(or its assigns) to purchase any Shares in which the Participant is not vested at the time of the Participant&rsquo;s cessation of Continuous
Service, and (ii)&nbsp;any sale or by the Participant or any settlement of any Shares contemplated by such Agreement, and for purposes
of any community property laws and all other laws conveys all of the undersigned&rsquo;s right, title and interest in and to such Shares
to the purchaser of such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PARTICIPANT&rsquo;S SPOUSE&nbsp;</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(F)
<SEQUENCE>19
<FILENAME>tm2415719d15_ex10-4f.htm
<DESCRIPTION>EXHIBIT 10.4(F)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;10.4(f)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
STOCK UNIT</B></FONT><B> AWARD AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Restricted Stock Unit Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the date of grant set
forth below (the &ldquo;<B><I>Date of Grant</I></B>&rdquo;) by and between Caris Life Sciences,&nbsp;Inc., </FONT>a Texas corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), and the participant named below (the &ldquo;<B><I>Participant</I></B>&rdquo;). Capitalized
terms not defined herein shall have the meaning ascribed to them in the Company&rsquo;s 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%">Participant:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Address:&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Grant Number:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Restricted Stock Units:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date of Grant:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Expiration Date:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">[<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant restricted stock units (&ldquo;<B><I>RSUs</I></B>&rdquo;) with respect to shares of common stock of the Company, par value US$0.001
per share (the &ldquo;<B><I>Shares</I></B>&rdquo;) to certain employees, consultants and/or directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has adopted
the Plan in order to effect such grants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Administrator
has determined that it is in the interest of the Company to grant these RSUs to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Grant
of RSUs</B>. The Company hereby grants to Participant the number of RSUs set forth above as Total Restricted Stock Units, each entitling
Participant to receive one Share upon settlement, subject to all of the terms and conditions of this Agreement and the Plan, including
vesting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Vesting;
Settlement of RSUs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vesting</U>.
RSUs shall vest only upon the occurrence, on or before the Expiration Date, of either (1)&nbsp;an IPO or (2)&nbsp;a Change of Control
(each a &ldquo;<B><I>Vesting Date</I></B>&rdquo;), subject to the Participant&rsquo;s Continuous Service with the Company through the
Vesting Date. For the purposes of this Agreement, an &ldquo;<B><I>IPO</I></B>&rdquo; means the occurrence of an initial public offering
that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved
for designation) as a national market security on an interdealer quotation system, on or before the date set forth above as Expiration
Date. Unless otherwise determined by the Administrator in its sole discretion, if Participant&rsquo;s Continuous Service is terminated
for any reason, all outstanding RSUs that are not vested at the date of such termination shall be cancelled and terminated without any
payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Settlement</U>.
Pursuant to such procedures established by the Administrator, and subject to any deferral of delivery pursuant to <U>Section&nbsp;8.2</U>,
the Company shall issue whole Shares to the Participant in settlement of the vested portion of the RSUs as soon as administratively practicable
after the applicable Vesting Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U>. Prior to the issuance of the Shares upon settlement of the RSUs, Participant must satisfy any tax withholding obligations
relating to the settlement of the RSUs and the acquisition of the Shares. The Company shall hold back a portion of the RSUs otherwise
deliverable to the Participant to cover any such required withholdings. If Shares are used to pay all or a portion of such withholding
tax obligation, the number of Shares that may be withheld, surrendered, or reduced shall be limited to the number of Shares equal in value
to the aggregate amount of such liabilities based on the greatest statutory withholding rates applicable to Participant for federal, state,
foreign, or local tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment with respect
to the RSUs, as determined by the Company. If the Administrator permits, Participant may provide for payment of withholding taxes upon
settlement of the RSUs by (a)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares
out of the Shares issued to the Participant as a result of the settlement of the RSUs or (b)&nbsp;tendering to the Company currently owned
and unencumbered Shares of the Company for redemption or repurchase and, in each of (a)&nbsp;and (b), immediately tendering the redemption
or repurchase price paid by the Company in respect of such Shares back to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Cancellation
and Rescission of RSUs for Detrimental Activity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any RSUs at any time if the Participant is not in
compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
settlement or delivery pursuant to settlement of the RSUs, the Participant shall certify in a manner acceptable to the Company that the
Participant is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a
Participant engages in Detrimental Activity after the settlement or delivery of any Shares pursuant to this Agreement, during any period
for which any restrictive covenant prohibiting such activity is applicable to the Participant, such settlement or delivery may be rescinded
within one (1)&nbsp;year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain
realized or payment received as a result of the settlement or delivery of such Shares, in such manner and on such terms and conditions
as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the
Participant by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;3</U> via the
mandatory redemption or repurchase of the Participant&rsquo;s Shares. It is expressly agreed by the Participant that, since the Participant
is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price
or other consideration shall be payable to the Participant by the Company for the Company&rsquo;s redemption or repurchase of the Participant&rsquo;s
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Compliance
with Laws and Regulations</B>. The settlement of the RSUs and the issuance and transfer of Shares shall be subject to compliance by the
Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be
listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify
the Shares with any federal or state securities commission or any stock exchange to effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Nontransferability
of the RSUs</B>. Unless determined otherwise by the Administrator, the RSUs may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator
may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of the RSUs for no consideration
to a Permitted Transferee. RSUs transferred to a Permitted Transferee shall be further transferable only by last will and testament or
the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. In no event may the
RSUs be transferred to any person who has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Privileges
of Share Ownership</B>. Participant shall not have any of the rights of a shareholder with respect to any Shares until the Shares are
issued and delivered to the Participant in such manner as the Company, in its sole discretion, shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Restrictive
Covenants</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Generally</U>.
As a condition to the grant of the RSUs, the Participant agrees to comply with the following restrictive covenants (each a &ldquo;<B><I>Restrictive
Covenant</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
assist Participant in the performance of the Participant&rsquo;s duties for the Company Group, the Company Group has provided and will
provide to Participant certain Confidential Information and Trade Secrets. Participant agrees that during the period of Participant&rsquo;s
service to the Company Group and at all times thereafter, Participant shall not, on Participant&rsquo;s own behalf or on behalf of any
third party, directly or indirectly divulge or make use of any Confidential Information or Trade Secrets without prior written consent
of the Company, which consent may be withheld in the Company&rsquo;s absolute discretion; provided, however, that Participant may make
disclosures required by a valid order or subpoena issued by a court or administrative agency of competent jurisdiction, in which event
Participant will promptly notify the Company of such order or subpoena, in a reasonable time prior to such disclosure so that the Company
has the opportunity to protect its interests. Participant further agrees that if Participant is questioned about information subject to
this Agreement by anyone not authorized to receive such information, Participant will promptly notify an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Participant
agrees to hold in confidence all Confidential Information, Trade Secrets and company records received from the Company or at the Company&rsquo;s
expense and shall not at any time directly or indirectly disclose, publish or use any Confidential Information, Trade Secrets and/or company
records for the benefit of anyone other than Company. This restriction shall apply to all information received prior to or after the effective
date of this Agreement and continue in effect after the Participant&rsquo;s service ends in perpetuity, or until such information becomes
a part of the public domain through means other than wrongful disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Confidential
Information</I></B>&rdquo; means information about the Company Group and its employees, customers, processes, technology and other information
that is not generally known outside of the Company Group, which Participant learns in connection with Participant&rsquo;s service with
the Company Group and which would be useful to competitors of the Company Group. Confidential Information includes, but is not limited
to: (1)&nbsp;business and employment policies, marketing methods and strategies and the targets of those methods and strategies, financial
data, business plans, promotional materials, pricing and pricing strategies, profit and loss statements, and sales and account records;
(2)&nbsp;present and prospective customer lists, customer preferences and buying patterns, distribution records and customer credit information;
(3)&nbsp;the Company Group&rsquo;s inventions, innovations, improvements, discoveries, methods, research data and results, databases,
research techniques and methodology, analytical approaches, software, and programs; and (4)&nbsp;the nature, origin, composition and development
of the Company Group&rsquo;s brands, products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Trade
Secrets</I></B>&rdquo; means Confidential Information which meets the additional requirements of the Uniform Trade Secrets Act or similar
state law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cancellation</U>.
The Participant understands that the cancellation of any RSUs or rights under this Agreement may occur for any violation or lack of enforceability
of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company
Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute
a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant
of any provisions of any Restrictive Covenant that occurs after any delivery of the Shares pursuant to this Agreement (including any breach
occurring after termination of employment) shall cause the delivery of the Shares under this Agreement to be rescinded (and if the Participant
has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the
pre-tax proceeds received from the sale of such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rescission</U>.
At the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;7</U> via
the mandatory redemption or repurchase of the Participant&rsquo;s Shares. It is expressly agreed by the Participant that, since the Participant
is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price
or other consideration shall be payable to the Participant by the Company for the Company&rsquo;s redemption or repurchase of the Participant&rsquo;s
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Restrictions
on Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities
Law Restrictions</U>. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities
Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its
discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends
on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary
or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws
of any state or any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Market
Stand-Off</U>. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s IPO, the Participant shall not sell, make any short sale of, loan,
hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer
for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible
into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned
by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of
time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the &ldquo;<B><I>Market
Stand-Off</I></B>&rdquo;). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to
the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding
Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or
liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off),
a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason
of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become
convertible, shall immediately be subject to the Market Stand-Off. To the extent the vesting of any RSUs occurs during the Market Stand-Off,
the Administrator retains the right, in its sole discretion, to defer the delivery of Shares underlying the RSUs until promptly following
the termination of the Market Stand-Off; provided, however, that in no event shall the delivery of such Shares be later than March&nbsp;15th
of the calendar year following the calendar year in which the RSUs vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Right
of Repurchase</U>. Following a termination of the Participant&rsquo;s Continuous Service, the Company may repurchase the Participant&rsquo;s
Shares acquired under the Plan as provided in this Section&nbsp;(the &ldquo;<B><I>Right of Repurchase</I></B>&rdquo;). With respect to
any vested RSUs and any Shares acquired upon settlement of the RSUs, the Right of Repurchase shall be exercisable at a purchase price
(the &ldquo;<B><I>Purchase Price</I></B>&rdquo;) equal to (i)&nbsp;the Fair Market Value of vested Shares (the &ldquo;<B><I>Share Repurchase
Right</I></B>&rdquo;); or (ii)&nbsp;in the case of a vested RSU (the &ldquo;<B><I>RSU Repurchase Right</I></B>&rdquo;), the Fair Market
Value of the Shares underlying the vested RSUs (in each case as of the date the written notice described in <U>Section&nbsp;8.3(b)</U>&nbsp;is
delivered). For the avoidance of doubt, any unvested RSUs will be forfeited for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Condition
Precedent to Settlement</U>. The Right of Repurchase shall be exercisable following the later of: (i)&nbsp;the date when the Participant&rsquo;s
Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii)&nbsp;the
date when the RSUs are settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
of Right of Repurchase</U>. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice
shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s)&nbsp;representing
any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the
Company (to the extent not already in the Company&rsquo;s custody) properly endorsed for transfer; provided, however, that the failure
to deliver such certificate(s)&nbsp;to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The
Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to
this <U>Section&nbsp;8.3</U>. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by
the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Right
of First Refusal</U>. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell,
pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the
 &ldquo;<B><I>Transferee</I></B>&rdquo;) the Company shall have a right of first refusal to purchase all (and not less than all) of such
Shares (the &ldquo;<B><I>Right of First Refusal</I></B>&rdquo;). If the Participant desires to transfer Shares, the Participant shall
first tender to the Company for its repurchase or redemption, via a written transfer notice (&ldquo;<B><I>Transfer Notice</I></B>&rdquo;)
describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the
name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate
any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant
and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall
have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price)
of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30)
days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory
transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined
at the time of the proposed transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Provisions Relating to Rights of Repurchase and First Refusal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Shares or Substituted Securities</U>. If there is any change in the number of outstanding Shares by reason of a share split, reverse share
split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification,
dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off
or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i)&nbsp;any new, substituted or additional securities
or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with
respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible
shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii)&nbsp;appropriate adjustments to reflect
the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to
the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however,
that the aggregate Purchase Price payable for the Shares shall remain the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Rights of Repurchase and First Refusal</U>. Any other provision of <U>Section&nbsp;8.3</U> notwithstanding, the Right of Repurchase
with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement
under applicable federal securities laws and the issuer is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the
Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of
1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the
Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by
<U>Section&nbsp;8.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.57in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Rights as Participant and Shareholder</U>. If the Company makes available to a Participant, at the time and place and in the amount
and form provided in this Agreement, the consideration for the RSUs to be repurchased pursuant to the Company&rsquo;s RSUs Repurchase
Right in accordance with <U>Section&nbsp;8.3</U>, then after such time such Participant shall no longer have any rights as a Participant
in respect of such RSUs (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company
makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the
Shares to be repurchased or redeemed pursuant to the Company&rsquo;s Share Repurchase Right in accordance with <U>Section&nbsp;8.3</U>
or Right of First Refusal in accordance with <U>Section&nbsp;8.4</U>, then after such time such Participant shall no longer have any rights
as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement).
Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s)&nbsp;therefore
have been delivered as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Intent at Grant</U>. If the grant of the RSUs under the Plan is not registered under applicable federal or state securities laws, but
an exemption is available which requires an investment representation or any other representation, the Participant (a)&nbsp;shall, and
hereby does, represent and agree, at the time of grant of the RSUs, that the security being acquired upon the grant of the RSUs is being
acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b)&nbsp;shall make such other representations
as are deemed necessary or appropriate by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Intent at Settlement</U>. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or other representation, the Participant shall represent and
agree at the time of settlement that the Shares being acquired upon settlement of the RSUs are being acquired for investment purposes,
and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Legends</U>.
All certificates evidencing the Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and
such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THE SHARES OF COMMON STOCK EVIDENCED BY
THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES,&nbsp;INC. 2020 INCENTIVE PLAN
AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH
ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY&nbsp;BE MADE EXCEPT IN ACCORDANCE
WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Removal
of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold
under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate
representing the same number of Shares but without such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
Any determination by the Company and its counsel in connection with any of the matters set forth in this <U>Section&nbsp;8</U> shall be
conclusive and binding on the Participant and all other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Exchange
Act</B>. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under
the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section&nbsp;16(b)&nbsp;of
the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction
to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Compliance
with Code Section&nbsp;409A</B>. Notwithstanding any contrary provision herein or in the Plan, if any RSU is deemed to be a &ldquo;deferral
of compensation&rdquo; under Code Section&nbsp;409A or any regulations or guidance promulgated thereunder or could cause any person to
recognize additional taxes, penalties or interest under Code Section&nbsp;409A, the Board may, in its sole discretion and without the
consent of any person, unilaterally modify such provision: (i)&nbsp;to comply with, or avoid being subject to, Code Section&nbsp;409A,
or to avoid the imposition of any additional taxes, penalties or interest under Code Section&nbsp;409A, and (ii)&nbsp;to maintain, to
the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Code Section&nbsp;409A.
This <U>Section&nbsp;10</U> does not create an obligation on the part of the Board to modify the Plan or this Agreement and does not guarantee
that any person shall not be subject to additional taxes, penalties or interest under Code Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Expiration</B>.
The RSUs shall expire on the Expiration Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>General</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Interpretation</U>.
Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review.
The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. </FONT>The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the
parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist
between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the
above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between
the Company and the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the
Corporate Secretary/Chief Legal Officer of the Company at its principal corporate offices. Any notice required to be given or delivered
to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party
may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a)&nbsp;personal
delivery; (b)&nbsp;five (5)&nbsp;days after deposit in the United States mail by certified or registered mail (return receipt requested);
(c)&nbsp;two (2)&nbsp;business days after deposit with any return receipt express courier (prepaid); or (d)&nbsp;one (1)&nbsp;business
day after transmission by facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be
binding upon Participant and Participant&rsquo;s heirs, executors, administrators, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Choice
of Law and Venue</U>. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed
by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision
of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will
be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. </FONT>Subject to <U>Section&nbsp;12.6</U>,
the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction
with respect to any dispute or litigation arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Arbitration</U>.
</FONT>The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect
between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions
shall govern: Subject to the Company&rsquo;s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy,
or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial
Arbitration Rules&nbsp;of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place
in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching
the arbitrator&rsquo;s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision
of this Agreement, but instead is limited to interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Employment or Other Service Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve
the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
(a)&nbsp;employment with or without notice and with or without cause, (b)&nbsp;service pursuant to the terms of a consulting agreement
with the Company Group or (c)&nbsp;service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate
law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right
to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Right to Future Awards</U>. This award of RSUs and all other equity-based awards under the Plan are discretionary. This award does not
confer on the Participant any right or entitlement to receive another award of RSUs or any other equity-based award at any time in the
future or in respect of any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the
remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had
never been included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
</FONT>Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify
this Agreement; <U>provided</U>, <U>however</U>, that no amendment or modification of this Agreement shall materially and adversely impair
the rights of the Participant with respect to any then outstanding RSUs without the consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Spousal
Consent</B>. I agree to cause any current or future spouse of mine to deliver to the Company a consent in the form of the consent attached
hereto validly executed by such spouse on the date hereof or promptly after any such person becomes my spouse, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Acceptance</B>.
Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions
thereof, and by executing below, accepts the terms and conditions of this Agreement governing the RSUs and the terms and conditions of
the Plan governing the RSUs and any and all other outstanding RSUs held by the Participant as of the date of execution. Participant acknowledges
that there may be adverse tax consequences upon settlement of the RSUs or disposition of the Shares and that Participant should consult
a tax advisor prior to such settlement or disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Release
of Claims</B>. In consideration of the grant of the RSUs provided to Participant under this Agreement and after having sufficient time
to consult with Participant&rsquo;s own counsel, Participant and each of Participant&rsquo;s respective heirs, executors, administrators,
representatives, agents, successors and assigns (collectively, the &ldquo;<B><I>Participant Parties</I></B>&rdquo;) hereby irrevocably
and unconditionally release and forever discharge the Company, the Company&rsquo;s former, current and future parents, subsidiaries and
affiliates, and each predecessor, successor and affiliate of each of the aforementioned entities, and each of their respective officers,
employees, directors, shareholders and agents from any and all claims, actions, causes of action, rights, judgments, obligations, damages,
demands, accountings or liabilities of whatever kind or character (collectively, &ldquo;<B><I>Claims</I></B>&rdquo;), including, without
limitation, any Claims under any federal, state, local or foreign law, that the Participant Parties may have, or in the future may possess,
arising from or relating to any RSU or other equity or equity-based award previously granted under the Plan; provided, however, that Participant
does not release, discharge or waive any rights to the RSUs and to the Shares provided under this Agreement that is contingent upon the
execution by Participant of this release of claims. This <U>Section&nbsp;15</U> does not apply to any Claims that the Participant Parties
may have as of the date Participant signs this Agreement arising under the Federal Age Discrimination in Employment Act of 1967, as amended,
and the applicable rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>SIGNATURE PAGE TO FOLLOW</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
witness whereof</B></FONT>, the Company has caused this Agreement to be executed by its duly authorized representative effective as of
the Date of Grant set forth on the coverage page&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 5%">By:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 45%"></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Name:</TD><TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>Title:</TD><TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2">Participant</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signatures Page to RSU
Award Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SPOUSAL ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of
the Participant has read and hereby approves the foregoing Restricted Stock Unit Award Agreement. In consideration of the Company&rsquo;s
granting the Participant the right to acquire the Shares in accordance with the terms of such Agreement, the undersigned hereby agrees
to be irrevocably bound by all the terms of such Agreement and the Plan, including (without limitation) (i)&nbsp;the right of the Company
(or its assigns) to purchase any Shares in which the Participant is not vested at the time of the Participant&rsquo;s cessation of Continuous
Service, and (ii)&nbsp;any sale or by the Participant or any settlement of any Shares contemplated by such Agreement, and for purposes
of any community property laws and all other laws conveys all of the undersigned&rsquo;s right, title and interest in and to such Shares
to the purchaser of such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PARTICIPANT&rsquo;S SPOUSE&nbsp;</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4(G)
<SEQUENCE>20
<FILENAME>tm2415719d15_ex10-4g.htm
<DESCRIPTION>EXHIBIT 10.4(G)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;10.4(g)</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
STOCK UNIT</B></FONT><B> AWARD AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Restricted Stock Unit Award Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of the date of grant set
forth below (the &ldquo;<B><I>Date of Grant</I></B>&rdquo;) by and between Caris Life Sciences,&nbsp;Inc., </FONT>a Texas corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), and the participant named below (the &ldquo;<B><I>Participant</I></B>&rdquo;). Capitalized
terms not defined herein shall have the meaning ascribed to them in the Company&rsquo;s 2020 Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 1in; width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant:</FONT></TD>
    <TD STYLE="width: 70%; text-align: justify">[_______]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>[_______]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant Number:</FONT></TD>
    <TD>[_______]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Restricted Stock Units:</FONT></TD>
    <TD STYLE="text-align: justify">[_______]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Grant:</FONT></TD>
    <TD STYLE="text-align: justify">[_______]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration Date:</FONT></TD>
    <TD>[_______]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant restricted stock units (&ldquo;<B><I>RSUs</I></B>&rdquo;) with respect to shares of common stock of the Company, par value US$0.001
per share (the &ldquo;<B><I>Shares</I></B>&rdquo;) to certain employees, consultants and/or directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company has adopted
the Plan in order to effect such grants; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Administrator
has determined that it is in the interest of the Company to grant these RSUs to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan,
the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Grant
of RSUs</B>. The Company hereby grants to Participant the number of RSUs set forth above as Total Restricted Stock Units, each entitling
Participant to receive one Share upon settlement, subject to all of the terms and conditions of this Agreement and the Plan, including
vesting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Vesting;
Settlement of RSUs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Two
vesting requirements must be satisfied on or before the Expiration Date in order for an RSU to vest: (i)&nbsp;a &ldquo;<B><I>Service-Based
Requirement</I></B>&rdquo;, and (ii)&nbsp;a requirement that the Company complete either an IPO or a Change of Control (a &ldquo;<B><I>Liquidity
Event Requirement</I></B>&rdquo;). The RSUs will not vest (in whole or in part) if only one (or if neither) of such requirements is satisfied
on or before the Expiration Date. One hundred percent (100%) of the RSUs will vest on the first date on or before the Expiration Date
upon which <U>both</U> (i)&nbsp;the Service-Based Requirement and (ii)&nbsp;the Liquidity Event Requirement are satisfied with respect
to the RSUs (the &ldquo;<B><I>Vesting Date</I></B>&rdquo;). Unless otherwise determined by the Administrator in its sole discretion, if
Participant&rsquo;s Continuous Service is terminated for any reason prior to the Vesting Date, all outstanding RSUs that are not vested
at the date of such termination shall be cancelled and terminated without any payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Service-Based Requirement will be satisfied</FONT> on the date of the Company&rsquo;s first Annual Meeting of Shareholders held after
the completion of an IPO, subject to the Participant&rsquo;s Continuous Service with the Company through such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Liquidity Event Requirement will be satisfied (as to any then-outstanding RSUs that have not previously been terminated pursuant to the
Plan or this Agreement) on the earlier to occur of (i)&nbsp;an IPO or (ii)&nbsp;a Change of Control. For the purposes of this Agreement,
an &ldquo;IPO&rdquo; means the occurrence of an initial public offering that results in any security of the Company being listed (or approved
for listing) on any securities exchange or designated (or approved for designation) as a national market security on an interdealer quotation
system, on or before the date set forth above as Expiration Date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the above and anything to the contrary in the Plan, this Agreement or any other prior or future agreement that purportedly applies to
the RSUs: in no event shall the vesting or settlement of the RSUs be accelerated or deferred in connection with any event or otherwise
unless such acceleration or deferral is specifically approved by the Administrator after taking into account the impact of such acceleration
or deferral under the requirements of Code Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Settlement</U>.
Pursuant to such procedures established by the Administrator, and subject to any deferral of delivery pursuant to <U>Section&nbsp;8.2</U>,
the Company shall issue whole Shares to the Participant in settlement of the RSUs that meet both the Service-Based Requirement and the
Liquidity Event Requirement as soon as administratively practicable after the Vesting Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Withholding</U>. Participant shall have full responsibility, and the Company shall have no responsibility, for satisfying any liability
for any federal, state or local income or other taxes required by law to be paid with respect to the RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Cancellation
and Rescission of RSUs for Detrimental Activity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any RSUs at any time if the Participant is not in
compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity (as
applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
settlement or delivery pursuant to settlement of the RSUs, the Participant shall certify in a manner acceptable to the Company that the
Participant is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity (as applicable).
In the event a Participant engages in Detrimental Activity (as applicable) after the settlement or delivery of any Shares pursuant to
this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such
settlement or delivery may be rescinded within one (1)&nbsp;year thereafter. In the event of any such rescission, the Participant shall
pay to the Company the amount of any gain realized or payment received as a result of the settlement or delivery of such Shares, in such
manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount
of any such gain any amount owed to the Participant by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;3</U> via the
mandatory redemption or repurchase of the Participant&rsquo;s Shares. It is expressly agreed by the Participant that, since the Participant
is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price
or other consideration shall be payable to the Participant by the Company for the Company&rsquo;s redemption or repurchase of the Participant&rsquo;s
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Compliance
with Laws and Regulations</B>. The settlement of the RSUs and the issuance and transfer of Shares shall be subject to compliance by the
Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be
listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify
the Shares with any federal or state securities commission or any stock exchange to effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Nontransferability
of the RSUs</B>. Unless determined otherwise by the Administrator, the RSUs may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator
may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of the RSUs for no consideration
to a Permitted Transferee. RSUs transferred to a Permitted Transferee shall be further transferable only by last will and testament or
the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. In no event may the
RSUs be transferred to any person who has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Privileges
of Share Ownership</B>. Participant shall not have any of the rights of a shareholder with respect to any Shares until the Shares are
issued and delivered to the Participant in such manner as the Company, in its sole discretion, shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Restrictive
Covenants</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Generally</U>.
As a condition to the grant of the RSUs, the Participant agrees to comply with the following restrictive covenants (each a &ldquo;<B><I>Restrictive
Covenant</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
assist Participant in the performance of the Participant&rsquo;s duties for the Company Group, the Company Group has provided and will
provide to Participant certain Confidential Information and Trade Secrets. Participant agrees that during the period of Participant&rsquo;s
service to the Company Group and at all times thereafter, Participant shall not, on Participant&rsquo;s own behalf or on behalf of any
third party, directly or indirectly divulge or make use of any Confidential Information or Trade Secrets without prior written consent
of the Company, which consent may be withheld in the Company&rsquo;s absolute discretion; provided, however, that Participant may make
disclosures required by a valid order or subpoena issued by a court or administrative agency of competent jurisdiction, in which event
Participant will promptly notify the Company of such order or subpoena, in a reasonable time prior to such disclosure so that the Company
has the opportunity to protect its interests. Participant further agrees that if Participant is questioned about information subject
to this Agreement by anyone not authorized to receive such information, Participant will promptly notify an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Participant
agrees to hold in confidence all Confidential Information, Trade Secrets and company records received from the Company or at the Company&rsquo;s
expense and shall not at any time directly or indirectly disclose, publish or use any Confidential Information, Trade Secrets and/or company
records for the benefit of anyone other than Company. This restriction shall apply to all information received prior to or after the effective
date of this Agreement and continue in effect after the Participant&rsquo;s service ends in perpetuity, or until such information becomes
a part of the public domain through means other than wrongful disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Confidential
Information</I></B>&rdquo; means information about the Company Group and its employees, customers, processes, technology and other information
that is not generally known outside of the Company Group, which Participant learns in connection with Participant&rsquo;s service with
the Company Group and which would be useful to competitors of the Company Group. Confidential Information includes, but is not limited
to: (1)&nbsp;business and employment policies, marketing methods and strategies and the targets of those methods and strategies, financial
data, business plans, promotional materials, pricing and pricing strategies, profit and loss statements, and sales and account records;
(2)&nbsp;present and prospective customer lists, customer preferences and buying patterns, distribution records and customer credit information;
(3)&nbsp;the Company Group&rsquo;s inventions, innovations, improvements, discoveries, methods, research data and results, databases,
research techniques and methodology, analytical approaches, software, and programs; and (4)&nbsp;the nature, origin, composition and development
of the Company Group&rsquo;s brands, products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Trade
Secrets</I></B>&rdquo; means Confidential Information which meets the additional requirements of the Uniform Trade Secrets Act or similar
state law..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cancellation</U>.
The Participant understands that the cancellation of any RSUs or rights under this Agreement may occur for any violation or lack of enforceability
of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company
Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute
a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant
of any provisions of any Restrictive Covenant that occurs after any delivery of the Shares pursuant to this Agreement (including any
breach occurring after termination of employment) shall cause the delivery of the Shares under this Agreement to be rescinded (and if
the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the
Company Group the pre-tax proceeds received from the sale of such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rescission</U>.
At the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this <U>Section&nbsp;7</U> via
the mandatory redemption or repurchase of the Participant&rsquo;s Shares. It is expressly agreed by the Participant that, since the Participant
is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price
or other consideration shall be payable to the Participant by the Company for the Company&rsquo;s redemption or repurchase of the Participant&rsquo;s
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Restrictions
on Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities
Law Restrictions</U>. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities
Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its
discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends
on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary
or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws
of any state or any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Market
Stand-Off</U>. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration
statement filed under the Securities Act, including the Company&rsquo;s IPO, the Participant shall not sell, make any short sale of, loan,
hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer
for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible
into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned
by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of
time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the &ldquo;<B><I>Market
Stand-Off</I></B>&rdquo;). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to
the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding
Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or
liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off),
a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason
of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become
convertible, shall immediately be subject to the Market Stand-Off. To the extent the vesting of any RSUs occurs during the Market Stand-Off,
the Administrator retains the right, in its sole discretion, to defer the delivery of Shares underlying the RSUs until promptly following
the termination of the Market Stand-Off; provided, however, that in no event shall the delivery of such Shares be later than March&nbsp;15th
of the calendar year following the calendar year in which the RSUs vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Right
of Repurchase</U>. Following a termination of the Participant&rsquo;s Continuous Service, the Company may repurchase the Participant&rsquo;s
Shares acquired under the Plan as provided in this Section&nbsp;(the &ldquo;<B><I>Right of Repurchase</I></B>&rdquo;). With respect to
any vested RSUs and any Shares acquired upon settlement of the RSUs, the Right of Repurchase shall be exercisable at a purchase price
(the &ldquo;<B><I>Purchase Price</I></B>&rdquo;) equal to (i)&nbsp;the Fair Market Value of vested Shares (the &ldquo;<B><I>Share Repurchase
Right</I></B>&rdquo;); or (ii)&nbsp;in the case of a vested RSU (the &ldquo;<B><I>RSU Repurchase Right</I></B>&rdquo;), the Fair Market
Value of the Shares underlying the vested RSUs (in each case as of the date the written notice described in <U>Section&nbsp;8.3(b)</U>&nbsp;is
delivered). For the avoidance of doubt, any unvested RSUs will be forfeited for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Condition
Precedent to Settlement</U>. The Right of Repurchase shall be exercisable following the later of: (i)&nbsp;the date when the Participant&rsquo;s
Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii)&nbsp;the
date when the RSUs are settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
of Right of Repurchase</U>. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice
shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s)&nbsp;representing
any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the
Company (to the extent not already in the Company&rsquo;s custody) properly endorsed for transfer; provided, however, that the failure
to deliver such certificate(s)&nbsp;to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The
Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to
this <U>Section&nbsp;8.3</U>. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by
the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Right
of First Refusal</U>. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell,
pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the
 &ldquo;<B><I>Transferee</I></B>&rdquo;) the Company shall have a right of first refusal to purchase all (and not less than all) of such
Shares (the &ldquo;<B><I>Right of First Refusal</I></B>&rdquo;). If the Participant desires to transfer Shares, the Participant shall
first tender to the Company for its repurchase or redemption, via a written transfer notice (&ldquo;<B><I>Transfer Notice</I></B>&rdquo;)
describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the
name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate
any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant
and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall
have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price)
of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30)
days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory
transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined
at the time of the proposed transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Provisions Relating to Rights of Repurchase and First Refusal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Shares or Substituted Securities</U>. If there is any change in the number of outstanding Shares by reason of a share split, reverse
share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination,
reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up,
a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i)&nbsp;any new, substituted or
additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction
distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby
become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii)&nbsp;appropriate
adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject
to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First
Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Rights of Repurchase and First Refusal</U>. Any other provision of <U>Section&nbsp;8.3</U> notwithstanding, the Right of Repurchase
with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement
under applicable federal securities laws and the issuer is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the
Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of
1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the
Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by
<U>Section&nbsp;8.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
of Rights as Participant and Shareholder</U>. If the Company makes available to a Participant, at the time and place and in the amount
and form provided in this Agreement, the consideration for the RSUs to be repurchased pursuant to the Company&rsquo;s RSUs Repurchase
Right in accordance with <U>Section&nbsp;8.3</U>, then after such time such Participant shall no longer have any rights as a Participant
in respect of such RSUs (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company
makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the
Shares to be repurchased or redeemed pursuant to the Company&rsquo;s Share Repurchase Right in accordance with <U>Section&nbsp;8.3</U>
or Right of First Refusal in accordance with <U>Section&nbsp;8.4</U>, then after such time such Participant shall no longer have any rights
as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement).
Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s)&nbsp;therefore
have been delivered as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Intent at Grant</U>. If the grant of the RSUs under the Plan is not registered under applicable federal or state securities laws, but
an exemption is available which requires an investment representation or any other representation, the Participant (a)&nbsp;shall, and
hereby does, represent and agree, at the time of grant of the RSUs, that the security being acquired upon the grant of the RSUs is being
acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b)&nbsp;shall make such other representations
as are deemed necessary or appropriate by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Intent at Settlement</U>. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws,
but an exemption is available which requires an investment representation or other representation, the Participant shall represent and
agree at the time of settlement that the Shares being acquired upon settlement of the RSUs are being acquired for investment purposes,
and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate
by the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Legends</U>.
All certificates evidencing the Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and
such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THE SHARES OF COMMON STOCK EVIDENCED BY
THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES,&nbsp;INC. 2020 INCENTIVE PLAN
AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH
ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY&nbsp;BE MADE EXCEPT IN ACCORDANCE
WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Removal
of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold
under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate
representing the same number of Shares but without such legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Administration</U>.
Any determination by the Company and its counsel in connection with any of the matters set forth in this <U>Section&nbsp;8</U> shall be
conclusive and binding on the Participant and all other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Exchange
Act</B>. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under
the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section&nbsp;16(b)&nbsp;of
the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction
to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Compliance
with Code Section&nbsp;409A</B>. Notwithstanding any contrary provision herein or in the Plan, if any RSU is deemed to be a &ldquo;deferral
of compensation&rdquo; under Code Section&nbsp;409A or any regulations or guidance promulgated thereunder or could cause any person to
recognize additional taxes, penalties or interest under Code Section&nbsp;409A, the Board may, in its sole discretion and without the
consent of any person, unilaterally modify such provision: (i)&nbsp;to comply with, or avoid being subject to, Code Section&nbsp;409A,
or to avoid the imposition of any additional taxes, penalties or interest under Code Section&nbsp;409A, and (ii)&nbsp;to maintain, to
the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Code Section&nbsp;409A.
This <U>Section&nbsp;10</U> does not create an obligation on the part of the Board to modify the Plan or this Agreement and does not
guarantee that any person shall not be subject to additional taxes, penalties or interest under Code Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Expiration</B>.
The RSUs shall expire on the Expiration Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>General</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Interpretation</U>.
Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review.
The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. </FONT>The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the
parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist
between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the
above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between
the Company and the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the
Corporate Secretary/Chief Legal Officer of the Company at its principal corporate offices. Any notice required to be given or delivered
to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party
may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a)&nbsp;personal
delivery; (b)&nbsp;five (5)&nbsp;days after deposit in the United States mail by certified or registered mail (return receipt requested);
(c)&nbsp;two (2)&nbsp;business days after deposit with any return receipt express courier (prepaid); or (d)&nbsp;one (1)&nbsp;business
day after transmission by facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be
binding upon Participant and Participant&rsquo;s heirs, executors, administrators, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Choice
of Law and Venue</U>. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed
by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision
of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will
be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to <U>Section&nbsp;12.6</U>,
the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction
with respect to any dispute or litigation arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Arbitration</U>.&nbsp;&nbsp;
If no such other agreement or policy is in effect, then the following arbitration provisions shall govern:&nbsp; Subject to the Company&rsquo;s
remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating
to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules&nbsp;of the
American Arbitration Association.&nbsp; The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas.&nbsp;
Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction.&nbsp; In reaching the arbitrator&rsquo;s
decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but
instead is limited to interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Employment or Other Service Rights</U>. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve
the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant&rsquo;s
(a)&nbsp;employment with or without notice and with or without cause, (b)&nbsp;service pursuant to the terms of a consulting agreement
with the Company Group or (c)&nbsp;service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate
law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right
to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Right to Future Awards</U>. This award of RSUs and all other equity-based awards under the Plan are discretionary. This award does not
confer on the Participant any right or entitlement to receive another award of RSUs or any other equity-based award at any time in the
future or in respect of any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the
remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had
never been included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
</FONT>Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify
this Agreement; <U>provided</U>, <U>however</U>, that no amendment or modification of this Agreement shall materially and adversely impair
the rights of the Participant with respect to any then outstanding RSUs without the consent of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Spousal
Consent</B>. I agree to cause any current or future spouse of mine to deliver to the Company a consent in the form of the consent attached
hereto validly executed by such spouse on the date hereof or promptly after any such person becomes my spouse, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Acceptance</B>.
Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions
thereof, and by executing below, accepts the terms and conditions of this Agreement governing the RSUs and the terms and conditions of
the Plan governing the RSUs and any and all other outstanding RSUs held by the Participant as of the date of execution. Participant acknowledges
that there may be adverse tax consequences upon settlement of the RSUs or disposition of the Shares and that Participant should consult
a tax advisor prior to such settlement or disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Release
of Claims</B>. In consideration of the grant of the RSUs provided to Participant under this Agreement and after having sufficient time
to consult with Participant&rsquo;s own counsel, Participant and each of Participant&rsquo;s respective heirs, executors, administrators,
representatives, agents, successors and assigns (collectively, the &ldquo;<B><I>Participant Parties</I></B>&rdquo;) hereby irrevocably
and unconditionally release and forever discharge the Company, the Company&rsquo;s former, current and future parents, subsidiaries and
affiliates, and each predecessor, successor and affiliate of each of the aforementioned entities, and each of their respective officers,
employees, directors, shareholders and agents from any and all claims, actions, causes of action, rights, judgments, obligations, damages,
demands, accountings or liabilities of whatever kind or character (collectively, &ldquo;<B><I>Claims</I></B>&rdquo;), including, without
limitation, any Claims under any federal, state, local or foreign law, that the Participant Parties may have, or in the future may possess,
arising from or relating to any RSU or other equity or equity-based award previously granted under the Plan; provided, however, that
Participant does not release, discharge or waive any rights to the RSUs and to the Shares provided under this Agreement that is contingent
upon the execution by Participant of this release of claims. This <U>Section&nbsp;15</U> does not apply to any Claims that the Participant
Parties may have as of the date Participant signs this Agreement arising under the Federal Age Discrimination in Employment Act of 1967,
as amended, and the applicable rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>SIGNATURE PAGE TO FOLLOW</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
witness whereof</B></FONT>, the Company has caused this Agreement to be executed by its duly authorized representative effective as of
[_______].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARIS LIFE SCIENCES,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify">[_______]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify">[_______]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">Participant</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Director
2025 RSU Award Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SPOUSAL ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of
the Participant has read and hereby approves the foregoing Restricted Stock Unit Award Agreement. In consideration of the Company&rsquo;s
granting the Participant the right to acquire the Shares in accordance with the terms of such Agreement, the undersigned hereby agrees
to be irrevocably bound by all the terms of such Agreement and the Plan, including (without limitation) (i)&nbsp;the right of the Company
(or its assigns) to purchase any Shares in which the Participant is not vested at the time of the Participant&rsquo;s cessation of Continuous
Service, and (ii)&nbsp;any sale or by the Participant or any settlement of any Shares contemplated by such Agreement, and for purposes
of any community property laws and all other laws conveys all of the undersigned&rsquo;s right, title and interest in and to such Shares
to the purchaser of such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD COLSPAN="2"><B>PARTICIPANT&rsquo;S SPOUSE</B> <B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>21
<FILENAME>tm2415719d15_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;10.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARIS LIFE SCIENCES,&nbsp;INC.<BR>
2025 INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>PURPOSE</B>.
The purpose of the Caris Life Sciences,&nbsp;Inc. 2025&nbsp;Incentive Plan (this &ldquo;<B><I>Plan</I></B>&rdquo;) is to enable Caris
Life Sciences,&nbsp;Inc., a Texas corporation, and the other members of the Company Group to align and link the interests of the Company
Group&rsquo;s Employees, Consultants and Directors (each, a &ldquo;<B><I>Service Provider</I></B>&rdquo;) with the interests of the Shareholders
via the issuance of Awards, the value of which are linked directly to the value of the Company. This Plan shall be effective as of the
date of approval by the Shareholders (the &ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Administrator</I></B>&rdquo;
means the Board or the Committee appointed by the Board in accordance with Section&nbsp;3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Annual
Increase</I></B>&rdquo; has the meaning set forth in Section&nbsp;4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Applicable
Laws</I></B>&rdquo; means any applicable legal requirements relating to the administration of and the issuance of ownership interests
and other securities under equity-based compensation plans, including, without limitation, U.S. state corporate laws, U.S. federal and
state securities laws, the Code and the requirements of any stock exchange or quotation system upon which the Common Stock may be listed
or quoted and the laws of any other country or jurisdiction where Awards are granted under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Award</I></B>&rdquo;
means any right granted under this Plan, including an Option, a Restricted Award, a Performance Award and a Share Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Award
Agreement</I></B>&rdquo; means a written agreement or instrument between the Company and a holder of an Award evidencing the terms and
conditions of an individual Award grant. Each Award Agreement shall be subject to the terms and conditions of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Beneficial
Owner</I></B>&rdquo; has the meaning assigned to such term in Rule&nbsp;13d-3 and Rule&nbsp;13d-5 under the Exchange Act, except that
in calculating the beneficial ownership of any particular &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d)(3)&nbsp;of
the Exchange Act), such &ldquo;person&rdquo; shall be deemed to have beneficial ownership of all securities that such &ldquo;person&rdquo;
has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable
only after the passage of time. The terms &ldquo;Beneficially Owns&rdquo; and &ldquo;Beneficially Owned&rdquo; have corresponding meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Board</I></B>&rdquo;
means the Board of Directors of the Company, as constituted from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Certificate
of Formation</I></B>&rdquo; means the Company&rsquo;s Amended and Restated Certificate of Formation, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Change
of Control</I></B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
direct or indirect sale, transfer, conveyance[, exclusive license] or other disposition (other than by way of merger or consolidation),
in one or a series of related transactions, of all or substantially all of the properties or assets of the Company Group, taken as a whole,
to any &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d)(3)&nbsp;of the Exchange Act, which includes any two or more persons
acting as a group);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
adoption of a plan relating to the liquidation or dissolution of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>acquisition
by any &ldquo;person&rdquo; of Beneficial Ownership of 50% or more (on a fully-diluted basis) of either (i)&nbsp;the then-outstanding
Shares (the &ldquo;<B><I>Outstanding Company Common Stock</I></B>&rdquo;) or (ii)&nbsp;the combined voting power of the then-outstanding
voting securities of the Company entitled to vote generally in the election of directors (the &ldquo;<B><I>Outstanding Company Voting
Securities</I></B>&rdquo;), in each case taking into account as outstanding for this purpose such Common Stock issuable upon the exercise
of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock
to the extent exercisable or convertible;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the
Company that requires the approval of the Shareholders pursuant to the TBOC, whether for such transaction or the issuance of securities
in the transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
following individuals cease for any reason to constitute a majority of the number of Directors then serving: individuals who, on the Effective
Date, constitute the Board and any new Director (other than a Director whose initial assumption of office is in connection with an actual
or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of Directors) whose appointment
or election by the Board or nomination for election by the Shareholders was approved or recommended by either (x)&nbsp;a vote of at least
a majority of the Directors then still in office who either were Directors on the Effective Date or whose appointment, election or nomination
for election was previously so approved or recommended, or (y)&nbsp;a Permitted Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, a transaction of
any type shall not constitute a Change of Control if (A)&nbsp;its sole purpose is to change the jurisdiction of the Company&rsquo;s incorporation
or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&rsquo;s securities
immediately before such transaction; (B)&nbsp;it is an acquisition by any employee benefit plan sponsored or maintained by the Company
Group; or (C)&nbsp;immediately following the transaction, more than 50% of the total voting power of the entity resulting from such transaction,
or if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities eligible
to elect a majority of the members of the board of directors (or the analogous governing body) of the entity resulting from such transaction,
is (i)&nbsp;represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such transaction (or if
applicable, is represented by shares into which the Outstanding Company Voting Securities were converted pursuant to such transaction),
and such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company
Voting Securities among the holders thereof immediately prior to the transaction or (ii)&nbsp;controlled directly or indirectly and whether
by equity ownership, contract or otherwise, by one or more Permitted Holders. If a Change of Control constitutes a payment event with
respect to any Award that provides for the deferral of compensation and is subject to Section&nbsp;409A of the Code, the transaction or
event must be both a Change of Control under this definition and constitute a &ldquo;change in control event,&rdquo; as defined in Treasury
Regulation &sect;1.409A-3(i)(5)&nbsp;to the extent required by Section&nbsp;409A of the Code. The Administrator shall have full and final
authority, which shall be exercised in good faith, to determine conclusively whether a Change of Control has occurred pursuant to the
above definition, and the date of the occurrence of such Change of Control and any incidental matters relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Code</I></B>&rdquo;
means the Internal Revenue Code of 1986, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Committee</I></B>&rdquo;
means a committee of one or more Directors appointed by the Board to administer this Plan in accordance with Section&nbsp;3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the Class&nbsp;A common stock of the Company, par value US$0.001 per share, issued subject to and in accordance
with the provisions of the TBOC and the Certificate of Formation and having the rights provided for in the Certificate&nbsp;of&nbsp;Formation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Company</I></B>&rdquo;
means Caris Life Sciences,&nbsp;Inc., a Texas corporation, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Company
Group</I></B>&rdquo; means the Company and any subsidiary (which for this purpose means any foreign or domestic corporation, limited liability
company, partnership or other entity of which 50% or more of the outstanding voting equity securities or voting power is Beneficially
Owned directly or indirectly by the Company, and for purposes of determining eligibility for the grant of Incentive Stock Options under
the Plan, it shall be defined in the manner required by Section&nbsp;424(f)&nbsp;of the Code) and any person that directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under common control with, the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Competing
Business</I></B>&rdquo; means any person (including Employee), entity or business that: (a)&nbsp;engages or proposes to engage in any
conduct or action in furtherance of any discovery, research, development, provision, performance, marketing, sale or other commercialization
of any product, service or application that (i)&nbsp;directly or indirectly involves molecular profiling of any human-derived sample
or specimen and associated therapeutic decision support for any clinical or research purposes, including but not limited to applications
of artificial intelligence to the same or (ii)&nbsp;is directly or indirectly related to use of aptamers to identify, discover, detect
or otherwise bind aptamer targets; or (b)&nbsp;that is otherwise competitive with the business of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Consultant</I></B>&rdquo;
means any person, including an advisor or contractor, (a)&nbsp;engaged by the Company Group to render consulting or advisory services
and who is compensated for such services or who provides bona fide services to the Company Group pursuant to a written agreement or (b)&nbsp;who
is a director of the Company Group; <I>provided </I>that, except as otherwise permitted in Section&nbsp;5.2, such person is a natural
person and such services are not in connection with the offer or sale of securities in a capital raising transaction and do not directly
or indirectly promote or maintain a market for the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Continuous
Service</I></B>&rdquo; means that a Participant&rsquo;s service with the Company Group, whether as an Employee, Director or Consultant,
is not interrupted or terminated. A Participant&rsquo;s Continuous Service shall not be deemed to have terminated merely because of a
change in the capacity in which the Participant renders service to the Company Group as an Employee, Consultant or Director or a change
in the entity for which the Participant renders such service, <I>provided </I>that there is no interruption or termination of the Participant&rsquo;s
Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of another member of the Company Group
or a Director will not constitute an interruption of Continuous Service. The Administrator, or its designee, which shall include any person
delegated authority to grant Awards under this Plan pursuant to Section&nbsp;3.5, in that party&rsquo;s sole discretion, may determine
whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick
leave, military leave or any other personal leave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Date
of Grant</I></B>&rdquo; means the date on which the Administrator adopts a resolution, or takes other appropriate action, expressly granting
an Award to a Participant, or if a different date is set forth in such resolution, or determined by the Administrator, as the Date of
Grant, then such date as is set forth in such resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Detrimental
Activity</I></B>&rdquo; means: (i)&nbsp;violation of the terms of any agreement with or policy of the Company Group concerning non-competition,
non-disclosure, confidentiality, intellectual property, non-disparagement, privacy or exclusivity; (ii)&nbsp;disclosure of the Company
Group&rsquo;s confidential information to anyone outside the Company Group, without prior written authorization from the Company Group,
or in conflict with the interests of the Company Group, whether the confidential information was acquired or disclosed by the Participant
during or after employment by the Company Group; (iii)&nbsp;failure or refusal to disclose promptly or assign to the Company Group all
right, title and interest in any invention, work product or idea, patentable or not, made or conceived by the Participant during employment
by the Company Group, relating in any manner to the interests of the Company Group or, the failure or refusal to do anything reasonably
necessary to enable the Company Group to secure a patent where appropriate in the United States and in other countries; (iv)&nbsp;the
conviction of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude; (v)&nbsp;the commission of an act involving
willful malfeasance or material fiduciary breach with respect to the Company Group; (vi)&nbsp;gross negligence or willful misconduct with
respect to the Company Group; (vii)&nbsp;any breach of a restrictive covenant contained in any employment agreement, Award Agreement or
other agreement between the Participant and the Company Group, during any period for which a restrictive covenant prohibiting Detrimental
Activity, or other similar conduct or act, is applicable to the Participant during or after employment by the Company Group; (viii)&nbsp;any
attempt directly or indirectly to induce any Employee of the Company Group to be employed or perform services or acts in conflict with
the interests of the Company Group; (ix)&nbsp;any attempt, in conflict with the interests of the Company Group, directly or indirectly,
to solicit the trade or business of any current or prospective customer, client, supplier or partner of the Company Group; or (x)&nbsp;any
material breach or non-compliance with the terms of this Plan or an Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Director</I></B>&rdquo;
means a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Disability</I></B>&rdquo;
means a physical or mental disability or infirmity of the Participant that prevents the normal performance of substantially all of the
Participant&rsquo;s duties for a continuous period in excess of 90 days or for more than 180 days during any one-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Effective
Date</I></B>&rdquo; has the meaning set forth in Section&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Employee</I></B>&rdquo;
means any person employed by the Company Group and who is an employee within the meaning of Section&nbsp;3401(c)&nbsp;of the Code. Mere
service as a Director or payment of a director&rsquo;s fee by the Company Group shall not be sufficient to constitute &ldquo;employment&rdquo;
by the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Fair
Market Value</I></B><I>&rdquo; </I>means, with respect to a Share, the fair market value thereof as of the relevant date of determination,
as determined in accordance with the valuation methodology approved by the Administrator (based on objective criteria) from time to time.
In the absence of any alternative valuation methodology approved by the Administrator, Fair Market Value shall be deemed to be equal to
the closing selling price of a Share on the Nasdaq Stock Exchange (or such established national securities exchange as may be designated
by the Administrator) on the trading day immediately preceding the date as of which such valuation is made, or in the event that the Common
Stock is not listed for trading on the Nasdaq Stock Exchange or such other national securities exchange as may be designated by the Administrator
but is quoted on an automated system, in any such case, on the valuation date (or if there were no sales on the valuation date, the average
of the highest and lowest quoted selling prices as reported on said composite tape or automated system for the most recent day during
which a sale occurred). The definition of Fair Market Value may differ depending on whether Fair Market Value is in reference to the grant,
exercise, vesting, settlement or payout of an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Incentive
Stock Option</I></B>&rdquo; means an Option that is intended to comply with the requirements of Section&nbsp;422 of the Code or any successor
provision thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Nonqualified
Stock Option</I></B>&rdquo; means an Option that is not intended or fails to comply with the requirements of Section&nbsp;422 of the Code
or any successor provision thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Non-Employee
Director</I></B>&rdquo; means a Director who qualifies as a &ldquo;non-employee director&rdquo; under Rule&nbsp;16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Option</I></B>&rdquo;
means an option to purchase Common Stock that is either an Incentive Stock Option or Nonqualified Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Option
Agreement</I></B>&rdquo; means a written agreement or instrument between the Company and a Participant evidencing the terms and conditions
of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of this Plan and need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Participant</I></B>&rdquo;
means a person to whom an Award is granted pursuant to this Plan. or if applicable, such other person who holds an outstanding Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Performance
Award</I></B>&rdquo; means an Award entitling the recipient to receive Common Stock or a cash payment upon the attainment of Performance
Goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Performance
Goals</I></B>&rdquo; means, for a Performance Period, one or more goals established in writing by the Administrator for the Performance
Period based upon one or more performance criteria. Depending on the performance criteria used to establish such Performance Goals, the
Performance Goals may be expressed in terms of overall Company performance (including absolute or relative Share performance) or the performance
of a division, operating or business unit, or an individual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Performance
Period</I></B>&rdquo; means the Company&rsquo;s fiscal year, or any other period of time as the Administrator may select, over which the
attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&rsquo;s right to, and the payment
of, a Performance Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Permitted
Holders</I></B>&rdquo; means (i)&nbsp;David D. Halbert, (ii)&nbsp;his spouse, widow, widower, domestic partner, parents, grandparents,
lineal descendants, siblings and lineal descendants of siblings (in each case whether by blood relation, adoption, marriage or domestic
partnership) of such person and heirs and any trusts or other holding, investment or estate planning vehicles for the benefit of any of
the foregoing (collectively, together with David D. Halbert, &ldquo;<B><I>Halbert Family Members</I></B>&rdquo;) and (iii)&nbsp;any Person,
any affiliate of, or corporation, general partnership, limited partnership, limited liability company, private limited company or other
entity that directly or indirectly controls, is controlled by, or is under common control with, the Halbert Family Members, or any Permitted
Trust primarily for the benefit of the Halbert Family Members. The phrase &ldquo;controlled by&rdquo; means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of
voting securities, by contract or otherwise, and &ldquo;Permitted Trust&rdquo; means a bona fide trust where each trustee is (i)&nbsp;a
Halbert Family Member, (ii)&nbsp;a professional in the business of providing trustee services, including private professional fiduciaries,
trust companies and bank trust departments, or (iii)&nbsp;an individual who may be removed and replaced at the sole discretion of a Halbert
Family Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Permitted
Transferee</I></B>&rdquo; means (i)&nbsp;any spouse, parents, siblings (by blood, marriage or adoption) or lineal descendants (by blood,
marriage or adoption) of a Participant; (ii)&nbsp;any trust or other similar entity for the benefit of a Participant or the Participant&rsquo;s
spouse, parents, siblings or lineal descendants; <I>provided</I>, <I>however</I>, that any transfer made by a Participant to a Permitted
Transferee may only be made if the Permitted Transferee, prior to the time of transfer of Common Stock, agrees in writing to be bound
by the terms of this Agreement and provides written notice to the Company of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Person</I></B>&rdquo;
means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association,
trust, joint venture, association or other similar entity, whether or not a legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.38&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Plan</I></B>&rdquo;
has the meaning set forth in Section&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.39&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Related
Rights</I></B>&rdquo; has the meaning set forth in Section&nbsp;6.4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.40&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Award</I></B>&rdquo; means a Restricted Share or an RSU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.41&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Award Agreement</I></B>&rdquo; has the meaning set forth in Section&nbsp;6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.42&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Restricted
Share</I></B>&rdquo; has the meaning set forth in Section&nbsp;6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.43&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>RSU</I></B>&rdquo;
has the meaning set forth in Section&nbsp;6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.44&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Rule&nbsp;16b-3</I></B>&rdquo;
means Rule&nbsp;16b-3 promulgated under the Exchange Act or any successor to Rule&nbsp;16b-3, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.45&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>SAR
Exercise Price</I></B>&rdquo; has the meaning set forth in Section&nbsp;6.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.46&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the U.S. Securities Act of 1933, as amended, and the rules&nbsp;and regulations promogulated thereunder from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.47&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Service
Provider</I></B>&rdquo; has the meaning set forth in Section&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.48&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Share</I></B>&rdquo;
means a share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.49&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Share
Appreciation Right</I></B>&rdquo; means the right pursuant to an award granted under Section&nbsp;6.4 to receive an amount equal to the
excess, if any, of (A)&nbsp;the Fair Market Value, as of the date such Share Appreciation Right or portion thereof is surrendered, of
the Shares covered by such right or such portion thereof, over (B)&nbsp;the aggregate SAR Exercise Price of such right or such portion
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.50&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Share
Reserve</I></B>&rdquo; has the meaning set forth in Section&nbsp;4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.51&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Shareholder</I></B>&rdquo;
means a shareholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">2.52&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>TBOC</I></B>&rdquo;
means the Texas Business Organizations Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>ADMINISTRATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Administration
by Directors</U>. This Plan shall be administered by the Board unless and until the Board delegates administration to a Committee, as
provided in Section&nbsp;3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Powers
of Administrator</U>. The Administrator shall have the power and authority to select and grant Awards, pursuant to the terms of this Plan,
to Participants nominated for participation in this Plan by the Company&rsquo;s Chief Executive Officer or determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Specific
Powers</U>. In particular, the Administrator shall have the authority: (i)&nbsp;to construe and interpret this Plan and apply its provisions;
(ii)&nbsp;to promulgate, amend and rescind rules&nbsp;and regulations relating to the administration of this Plan and to interpret this
Plan and the Awards granted thereunder; (iii)&nbsp;to authorize any person to execute, on behalf of the Company, any instrument required
to carry out the purposes of this Plan; (iv)&nbsp;to determine when Awards are to be granted under this Plan; (v)&nbsp;from time to time
to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted; (vi)&nbsp;to determine
the number of Shares to be made subject to each Award; (vii)&nbsp;to prescribe the terms and conditions of each Award, including, without
limitation, the exercise price, Performance Goals and medium of payment, vesting, and net exercise provisions, and to specify the provisions
of the Award Agreement relating to such grant or sale; (viii)&nbsp;to amend any outstanding Awards, including for the purpose of modifying
the time or manner of vesting, the purchase price or exercise price, Performance Goals or the term of any outstanding Award in accordance
with this Plan; (ix)&nbsp;to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting
termination of their employment for purposes of this Plan, which periods shall be no shorter than the periods generally applicable to
Employees under the Company Group&rsquo;s employment policies; (x)&nbsp;establish or verify satisfaction of, or the level of performance
with respect to, Performance Goals or other conditions applicable to grant, exercisability, vesting or payment; (xi)&nbsp;to make decisions
with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution
adjustments; (xii)&nbsp;to correct any defect, omission or inconsistency in this Plan, in a manner and to the extent it is deemed necessary
or expedient to make this Plan fully effective; and (xiii)&nbsp;to exercise discretion to make any and all other determinations which
it determines to be necessary or advisable for administration of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Decisions
Final</U>. All decisions made by the Administrator pursuant to the provisions of this Plan shall be final, binding and conclusive on the
Company and the Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>The
Committee</U>. To the extent permitted under Applicable Laws, the Board may delegate administration of this Plan to a Committee or Committees
consisting of one or more Directors, and the term &ldquo;<B><I>Committee</I></B>&rdquo; shall apply to any person or persons to whom such
authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration
of this Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative
powers the Committee is authorized to exercise (and references in this Plan to the Board or the Administrator shall thereafter, to the
extent the delegation is applicable, be to the Committee or subcommittee), subject, however, to such resolutions not inconsistent with
the provisions of this Plan, as may be adopted from time to time by the Board. Within the scope of such authority, the Board or the Committee
may delegate to a committee of one or more Directors or officers of the Company Group the authority to grant Awards to eligible persons
who are not then subject to Section&nbsp;16 of the Exchange Act. Additionally, within the scope of such authority, the Board or the Committee
may delegate to (i)&nbsp;one or more of its members, (ii)&nbsp;one or more officers of the Company Group or (iii)&nbsp;one or more agents
or advisors such administrative duties with respect to this Plan as it may deem appropriate or advisable under such conditions and limitations
as it may set at the time of such delegation or thereafter. The Committee or any individuals to whom it has delegated duties or powers
as aforesaid may employ one or more individuals to render advice with respect to any responsibility the Committee or such individuals
may have under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification</U>.
In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed
by Applicable Laws, the Administrator shall be indemnified by the Company against the reasonable expenses, including attorney&rsquo;s
fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Administrator
may be party by reason of any action taken or failure to act under or in connection with this Plan or any Award granted under this Plan,
and against all amounts paid by the Administrator in settlement thereof (<I>provided </I>that the settlement has been approved by the
Company, which approval shall not be unreasonably withheld) or paid by the Administrator in satisfaction of a judgment in any such action,
suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Administrator
did not act in good faith; <I>provided</I>, <I>however</I>, that within 60&nbsp;days after institution of any such action, suit or proceeding,
such Administrator shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance
on Experts</U>. In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may
rely upon the advice of experts, including employees of and professional advisors to the Company. No director, officer or agent of the
Company Group shall be liable for any such action or determination taken or made or omitted in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>COMMON
STOCK SUBJECT TO THIS PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Reserve</U>. Subject to the provisions of Section&nbsp;9 relating to adjustments upon changes in the Common Stock, the maximum
aggregate number of Shares that may be issued upon exercise of all Awards under this Plan shall not exceed an amount equal to
(a)&nbsp;5% of all classes of the Company&rsquo;s common stock on a fully diluted basis after giving effect to the Company&rsquo;s
initial public offering (the &ldquo;<B><I>Offering</I></B>&rdquo;) (assuming the exercise of any outstanding warrants and conversion
of all preferred stock and senior convertible notes, and including, but not limited to, shares subject to outstanding awards under
the Amended and Restated 2020 Plan, and the issuance of the Company&rsquo;s common stock contemplated to be sold in the Offering), <I>plus</I>
(b)&nbsp;the number of shares that would return to the share reserve of the Amended and Restated 2020 Plan following the pricing of
the Offering (the &ldquo;<B><I>Share&nbsp;Reserve</I></B>&rdquo;). Notwithstanding the foregoing, the Share Reserve shall
 increase on January&nbsp;1 of each calendar year during the term of this Plan beginning in 2026, by a number of Shares
as approved by the Administrator following consultation with the Company; provided, that such increase (if any) shall be no greater than
the amount by which (y) 4% of the aggregate number of outstanding shares of all classes of the Company&rsquo;s common stock as of the last day of
the immediately preceding fiscal year exceeds (z) the aggregate number of Shares remaining available
for grant under the Plan on the last day of the immediately preceding fiscal year (the &ldquo;<B><I>Annual Increase</I></B>&rdquo;).
To the extent permitted by Applicable Laws or any applicable exchange rule, any Common Stock issued under this Plan that is issued
(i)&nbsp;in connection with the Company&rsquo;s acquisition of an unaffiliated business entity, (ii)&nbsp;to the employees of such
entity and (iii)&nbsp;in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce
the number of Shares available for issuance under this Plan. Any of the authorized Shares may be used for any type of Award under
this Plan, and any or all of the Shares may be allocated to Incentive Stock Options; <I>provided</I> that the maximum number of
Shares that may be issued pursuant to Incentive Stock Options under this Plan may not exceed the Share Reserve (as it may be
increased from time to time, including through the Annual&nbsp;Increase). &ldquo;<B><I>Amended and Restated 2020 Plan</I></B>&rdquo;
means the Caris Life Sciences,&nbsp;Inc. 2020 Incentive Plan, as amended and restated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reversion
of Shares to the Share Reserve</U>. If an Award or any portion thereof (i)&nbsp;expires or otherwise terminates without all of the Shares
covered by such Award having been issued, or (ii)&nbsp;is settled in cash (<I>i</I>.<I>e</I>., the Participant receives cash rather than
Shares), such expiration, termination or settlement will not reduce (or otherwise offset) the number of Shares that may be available for
issuance under this Plan. If any Shares issued pursuant to an Award are forfeited back to or repurchased by the Company because of the
failure to meet a contingency or condition required to vest such Shares in the Participant, then the Shares that are forfeited or repurchased
will revert to and again become available for issuance under this Plan. Any Shares reacquired by the Company in satisfaction of tax withholding
obligations on an Award or as consideration for the exercise or purchase price of an Award will again become available for issuance under
this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Source
of Shares</U>. The Shares subject to this Plan may be authorized but unissued Common Stock or reacquired Common Stock, however reacquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Availability
of Shares</U>. During the terms of the Awards, the Company shall keep available at all times the number of Shares required to satisfy
such Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Director
Award Limit</U>. Notwithstanding any provision to the contrary in this Plan or in any policy of the Company, the sum of cash compensation
and the Fair Market Value of all Awards that may be granted to a Director who is not an Employee under this Plan during any calendar year
shall not exceed $1,000,000 during a Director&rsquo;s first year of service as a Director and $750,000 for any year thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>ELIGIBILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Eligibility</U>.
Awards may be granted to Service Providers selected for participation in this Plan, subject to the approval of the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consultants</U>.
A Consultant shall not be eligible for the grant of an Award if, at the time of grant, a registration statement is not available to register
either the offer or the sale of the Company&rsquo;s securities to such Consultant because of the nature of the services that the Consultant
is providing to the Company Group, or because the Consultant is not a natural person, or as otherwise provided by the rules&nbsp;governing
the use of the registration statement, unless the Company determines both (a)&nbsp;that such grant (i)&nbsp;shall be registered in another
manner under the Securities Act or (ii)&nbsp;does not require registration under the Securities Act in order to comply with the requirements
of the Securities Act, if applicable, and (b)&nbsp;that such grant complies with the securities laws of all other relevant jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Directors</U>.
Each Director shall be eligible to receive discretionary grants of Awards under this Plan, subject to Section&nbsp;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>AWARD
PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Options</U>.
The Administrator may from time to time grant Options to Service&nbsp;Providers. Each Option shall be in such form and shall contain such
terms and conditions as the Administrator shall deem appropriate, including whether such Options granted shall be Incentive Stock Options
or Nonqualified Stock Options. Each Option shall be evidenced by an Option Agreement that shall expressly identify the Option as Incentive
Stock Option or Nonqualified Stock Option. The provisions of separate Options need not be identical, but each Option shall include (through
incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Term</U>.
No Option shall be exercisable after the expiration of 10&nbsp;years from the date it was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
Price of an Option</U>. The exercise price per Share of each Option shall be not less than the greater of (i)&nbsp;100% of the Fair Market
Value of a Share on the date the Option is granted and (ii)&nbsp;the par value of the Common Stock. Notwithstanding the foregoing, an
Option may be granted with a per Share exercise price lower than 100% of Fair Market Value of a Share on the date it is granted (but not
less than par value) if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the
provisions of Section&nbsp;424(a)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consideration</U>.
The purchase price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by Applicable Laws and regulations,
either: (i)&nbsp;in cash, by certified or bank check or by electronic funds transfer at the time the Option is exercised; (ii)&nbsp;by
tendering to the Company other Common Stock, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption
or repurchase equal to the exercise price (or portion thereof) due for the number of shares being acquired (with the proceeds of such
redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Common Stock); (iii)&nbsp;by
a copy of instructions to a broker directing such broker to sell the Common Stock for which such Option is exercised, and to remit to
the Company the aggregate exercise price of such Options; or (iv)&nbsp;in any other form of legal consideration that may be acceptable
to the Administrator. Unless otherwise specifically provided in the Option, the purchase price of Common Stock acquired pursuant to an
Option that is paid by tendering to the Company for redemption or repurchase other Common Stock acquired, directly or indirectly, from
the Company, shall be paid only by Common Stock of the Company that has been held for more than six months (or such longer or shorter
period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, any transaction
by a Director or executive officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension
of credit by the Company Group in violation of Section&nbsp;402(a)&nbsp;of the Sarbanes-Oxley Act (codified as Section&nbsp;13(k)&nbsp;of
the Exchange Act) shall be prohibited with respect to any Award under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting;
Exercisability</U>. The Administrator will determine the vesting and exercisability provisions of each Option (which may be based on performance
criteria, passage of time, or other factors, or any combination thereof), which provisions will be set forth in the applicable Award Agreement.
Unless the Administrator or the terms of this Plan or the Award Agreement expressly provides otherwise, once exercisable, an Option will
remain exercisable until the expiration or earlier termination of the Option. The Administrator may adjust the vesting or exercisability
provisions of an Option to reflect any approved leave of absence or less-than-full-time employment that is not a termination of Continuous
Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Procedure
for Exercise</U>. An exercisable Option may be exercised in whole or in part and will be deemed exercised when the Company receives: (i)&nbsp;written
or electronic notice of exercise (in accordance with the Award Agreement) from the person entitled to exercise the Option, and (ii)&nbsp;full
payment for the Common Stock with respect to which the Option is exercised (including provision for any applicable tax withholding); <I>provided
</I>that if any person other than the Participant exercises the Option, such person will be required to provide evidence sufficient to
reasonably establish that he or she is entitled to do so. Full payment may consist of any consideration and method of payment authorized
by the Administrator and permitted by the Award Agreement and this Plan. Common Stock issued upon exercise of an Option will be issued
in the name of the Participant, or if requested by the Participant, in the name of the Participant and the Participant&rsquo;s spouse.
Exercising an Option in any manner will decrease the number of Shares thereafter available for sale under the Option, by the number of
Shares as to which the Option is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Continuous Service</U>. Upon the termination of a Participant&rsquo;s Continuous Service, and unless otherwise provided by the Administrator
or in the applicable Award Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
than as a result of the Participant&rsquo;s death or Disability, the Participant may exercise the Participant&rsquo;s Option (to the extent
that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (x)&nbsp;the date 90 days
following the termination of the Participant&rsquo;s Continuous Service and (y)&nbsp;the expiration of the term of the Option as set forth
in the Option Agreement, after which time the Option shall terminate; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
a result of the Participant&rsquo;s death or Disability, the Participant (or the Participant&rsquo;s estate, by a person who acquired
the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Participant&rsquo;s
death) may exercise the Participant&rsquo;s Option (to the extent that the Participant was entitled to exercise such Option as of the
date of termination), but only until the earlier of (x)&nbsp;the date 12&nbsp;months following such termination and (y)&nbsp;the expiration
of the term of the Option as set forth in the Option Agreement, after which time the Option shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the Participant does not exercise the Participant&rsquo;s Option within the time specified in the Option Agreement, the Option shall terminate.
Unless otherwise provided in an Option Agreement or in an employment agreement the terms of which have been approved by the Administrator,
outstanding Options that are not exercisable at the time the Participant&rsquo;s Continuous Service terminates shall be forfeited and
expire at the close of business on the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Substitution
of Share Appreciation Rights</U>. The Administrator may provide in an Award Agreement evidencing the grant of an Option that the Administrator,
in its sole discretion, shall have the right to substitute a Share Appreciation Right for such Option at any time prior to or upon exercise
of such Option; <I>provided</I> that such Share Appreciation Right shall be exercisable with respect to the same number of Shares for
which such substituted Option would have been exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Incentive
Stock Options</U>. The exercise price per Share of an Incentive Stock Option shall be fixed by the Administrator at the time of grant
or shall be determined by a method specified by the Administrator at the time of grant, but in no event shall the exercise price of an
Option be less than the minimum exercise price specified in Section&nbsp;6.1(b). No Incentive Stock Option may be issued to any individual
who, at the time the Incentive Stock Option is granted, owns stock possessing more than 10% of the total combined voting power of all
classes of stock of the Company, unless (i)&nbsp;the exercise price determined as of the date of grant is at least 110% of the Fair Market
Value on the date of grant of the Common Stock subject to such Incentive Stock Option; and (ii)&nbsp;the Incentive Stock Option is not
exercisable more than five years from the date of grant thereof. No Participant shall be granted any Incentive Stock Option which would
result in such Participant receiving a grant of Incentive Stock Options that would have an aggregate Fair Market Value in excess of $100,000,
determined as of the time of grant, that would be exercisable for the first time by such Participant during any fiscal year. Any grants
in excess of this limit shall be treated as Nonqualified Stock Options. No Incentive Stock Option may be granted under this Plan after
the tenth anniversary of the Effective Date. The terms of any Incentive Stock Option granted under this Plan shall comply in all respects
with the provisions of Section&nbsp;422 of the Code, or any successor provision thereto, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restricted
Awards</U>. The Administrator may from time to time award (or sell at a purchase price determined by the Administrator) restricted Shares
(&ldquo;<B><I>Restricted Shares</I></B>&rdquo;) or restricted stock units with respect to Shares (&ldquo;<B><I>RSUs</I></B>&rdquo;) under
this Plan to eligible Participants. The Award Agreement evidencing a Restricted Award (a &ldquo;<B><I>Restricted Award Agreement</I></B>&rdquo;)
shall contain the terms established by the Administrator for that Award, as well as any other terms, provisions, or restrictions that
the Administrator may impose on the Award; in each case subject to the applicable provisions and limitations of this Section&nbsp;6.2
and the other applicable provisions and limitations of this Plan. The terms and conditions of Restricted Award Agreements may change from
time to time, and the terms and conditions of separate Restricted Award Agreements need not be identical, but each Restricted Award Agreement
shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase
Price</U>. The purchase price of a Restricted Award shall be determined by the Administrator at the Date of Grant, and may be stated as
cash, property or a contract for prior or future services. In no event will such purchase price be less than the par value of a Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consideration</U>.
The consideration for Common Stock acquired pursuant to a Restricted Award Agreement shall be paid either in cash, by certified or bank
check or by electronic funds transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting</U>.
The restrictions imposed on the exercise and settling of a Restricted Award and the subsequent issuance of Common Stock (which may be
based on performance criteria, passage of time or other factors or any combination thereof) will be set forth in the applicable Award
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Participant&rsquo;s Continuous Service</U>. Unless the Administrator otherwise expressly provides, Common Stock subject to a Restricted
Award that remain subject to vesting conditions that have not been satisfied by the time specified in the applicable Award Agreement (including
the termination of the Participant&rsquo;s Continuous Service), will not vest and in the case of RSUs, will be canceled without payment
to the Participant therefor, in each case to the extent not prohibited by law. The Award Agreement shall specify any other terms or conditions
of the repurchase or cancellation, as the case may be, if the Award fails to vest. Any other Restricted Award that has not been exercised
as of a termination of the Participant&rsquo;s Continuous Service shall terminate on that date unless otherwise expressly provided by
the Administrator in the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance
Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator may from time to time grant Performance Awards to any eligible Participant. Each Performance Award shall be in such form
and shall contain such terms and conditions as the Administrator shall deem appropriate. The terms and conditions of separate Performance
Awards need not be identical. The value of Performance Awards may be linked to any one or more specific criteria determined by the Administrator,
in each case on a specified date or dates or over any period or periods determined by the Administrator. In making such determinations,
the Administrator shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions,
responsibilities and other compensation of the particular Service Provider. Performance Awards may be paid in cash, Common Stock or both,
as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
limiting Section&nbsp;6.3(a), the Administrator may grant Performance Awards in the form of a cash bonus payable upon the attainment of
objective Performance Goals, or such other criteria, whether or not objective, which are established by the Administrator, in each case
on a specified date or dates or over any period or periods determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the satisfaction of any Performance Goals, the number of Shares granted, issued, retainable or vested under an Award, or the amount of
cash payable under an Award on account of either financial performance or personal performance evaluations, may, to the extent specified
in the Award Agreement, be adjusted by the Committee on the basis of such further considerations as the Committee shall determine, including
but not limited to those set forth in Section&nbsp;10.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Share
Appreciation Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General</U>.
Share Appreciation Rights may be granted either alone, or, <I>provided</I> that the requirements of Section&nbsp;6.4(b)&nbsp;are satisfied,
in tandem with all or part of any Option granted under this Plan (&ldquo;<B><I>Related Rights</I></B>&rdquo;). Related Rights may be granted
either at or after the time of the grant of such Option. Share Appreciation Rights shall be in such form and shall contain such terms
and conditions as the Administrator shall deem appropriate, and the provisions of separate Share Appreciation Rights need not be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Grant
Requirements</U>. A Share Appreciation Right may only be granted if the Share Appreciation Right: (i)&nbsp;does not provide for the deferral
of compensation within the meaning of Section&nbsp;409A of the Code; or (ii)&nbsp;satisfies the requirements of Section&nbsp;7.3. A Share
Appreciation Right does not provide for a deferral of compensation if: (A)&nbsp;the value of the Common Stock the excess over which the
right provides for payment upon exercise (the &ldquo;<B><I>SAR&nbsp;Exercise Price</I></B>&rdquo;) may never be less than the Fair Market
Value of the underlying Common Stock on the date the right is granted; (B)&nbsp;the Common Stock subject to the right are traded on an
established securities market; (C)&nbsp;only such traded Common Stock may be delivered in settlement of the right upon exercise; and (D)&nbsp;the
right does not include any feature for the deferral of compensation other than the deferral of recognition of income until the exercise
of the right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vesting,
Exercise and Payment</U>. The Administrator will determine the vesting and exercisability provisions of each Share Appreciation Right
(which may be based on performance criteria, passage of time or other factors or any combination thereof), which provisions will be set
forth in the applicable Award Agreement. Unless the Administrator otherwise expressly provides, once exercisable a Share Appreciation
Right will remain exercisable until the expiration or earlier termination of the Share Appreciation Right. Upon exercise thereof, the
holder of a Share Appreciation Right shall be entitled to receive from the Company, an amount equal to the product of (i)&nbsp;the excess
of the Fair Market Value, on the date of such written request, of one Common Stock over the SAR Exercise Price per Common Stock specified
in such Share Appreciation Right or its related Option, multiplied by (ii)&nbsp;the number of Shares for which such Share Appreciation
Right shall be exercised. Payment with respect to the exercise of a Share Appreciation Right that satisfies the requirements of Section&nbsp;6.4(b)&nbsp;shall
be paid on the date of exercise and made in Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability,
as determined by the Administrator in its sole discretion), valued at Fair Market Value on the date of exercise. Payment with respect
to the exercise of a Share Appreciation Right that does not satisfy the requirements of Section&nbsp;6.4(b)&nbsp;shall be paid at the
time specified in the Award in accordance with the provisions of Section&nbsp;7.3. Payment may be made in the form of Common Stock (with
or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Administrator in its sole discretion),
cash or a combination thereof, as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>SAR
Exercise Price; Term</U>. The Administrator shall set the terms and conditions or restrictions on the exercise of a Share Appreciation
Right, but in no event shall a Share Appreciation Right have an exercise price less than 100% of the Fair Market Value of one Common Stock
on the Date of Grant of such Share Appreciation Right or a term of greater than 10 years. A Related Right granted simultaneously with
or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price
as the related Option, and shall be exercisable only to the same extent as the related Option; <I>provided</I>, <I>however</I>, that a
Share Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per Common Stock subject to the Share Appreciation
Right and related Option exceeds the exercise price per Share thereof, and no Share Appreciation Rights may be granted in tandem with
an Option unless the Administrator determines that the requirements of Section&nbsp;6.4(b)&nbsp;are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reduction
in the Underlying Option Shares</U>. Upon any exercise of a Share Appreciation Right, the number of Common Stock for which any related
Option shall be exercisable shall be reduced by the number of Shares for which the Share&nbsp;Appreciation&nbsp;Right shall have been
exercised. The number of Common Stock for which a Share Appreciation Right shall be exercisable shall be reduced upon any exercise of
any related Option by the number of Common Stock for which such Option shall have been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Written
Request</U>. Any election by a Participant to receive cash in full or partial settlement of a Share Appreciation Right, and any exercise
of such Share Appreciation Right for cash, may be made only by a written request filed with the Corporate Secretary of the Company during
the period beginning on the third business day following the date of release for publication by the Company of quarterly or annual summary
statements of earnings and ending on the twelfth business day following such date. Within 30 days of the receipt by the Company of a written
request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash,
the Administrator shall, in its sole discretion, either consent to or disapprove, in whole or in part, such written request. A written
request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise a Share Appreciation Right for cash
may provide that, in the event the Administrator shall disapprove such written request, such written request shall be deemed to be an
exercise of such Share Appreciation Right for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Disapproval
by Administrator</U>. If the Administrator disapproves in whole or in part any election by a Participant to receive cash in full or partial
settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash, such disapproval shall not affect such
Participant&rsquo;s right to exercise such Share Appreciation Right at a later date, to the extent that such Share Appreciation Right
shall be otherwise exercisable, or to elect the form of payment at a later date, <I>provided </I>that an election to receive cash upon
such later exercise shall be subject to the approval of the Administrator. Additionally, such disapproval shall not affect such Participant&rsquo;s
right to exercise any related Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Continuous Service</U>. Upon the termination of the Continuous Service of a Participant who holds a Share Appreciation Right, and unless
otherwise provided by the Administrator or in the applicable Award Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
than as a result of the Participant&rsquo;s death or Disability, the Participant may exercise the Participant&rsquo;s Share Appreciation
Right (to the extent that the Participant was entitled to exercise such Share Appreciation Right as of the date of termination) until
the earlier of (x)&nbsp;the date 90 days following the termination of the Participant&rsquo;s Continuous Service and (y)&nbsp;the expiration
of the term of the Share Appreciation Right as set forth in the Award Agreement, after which time the Share Appreciation Right shall terminate;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
a result of the Participant&rsquo;s death or Disability, the Participant (or the Participant&rsquo;s estate, by a person who acquired
the right to exercise the Share Appreciation Right by bequest or inheritance or by a person designated to exercise the Share Appreciation
Right upon the Participant&rsquo;s death) may exercise the Participant&rsquo;s Share Appreciation Right (to the extent that the Participant
was entitled to exercise such Share Appreciation Right as of the date of termination), but only until the earlier of (x)&nbsp;the date
12&nbsp;months following such termination and (y)&nbsp;the expiration of the term of the Share Appreciation Right as set forth in the
Award Agreement, after which time the Share Appreciation Right shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the Participant does not exercise the Participant&rsquo;s Share Appreciation Right within the time specified in the Award Agreement, the
Share Appreciation Right shall terminate. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which
have been approved by the Administrator, outstanding Share Appreciation Rights that are not exercisable at the time a Participant&rsquo;s
Continuous Service terminates shall be forfeited and expire at the close of business on the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Share-Based Awards</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator may grant other Share-based awards not otherwise described by the terms of this Plan, including, but not limited to, the
grant or offer for sale of unrestricted Shares and the grant of deferred Shares or deferred Share units, in such amounts and subject to
such terms and conditions, including performance conditions, as the Administrator shall determine, in its sole discretion. Such Awards
may involve the transfer of actual Shares to Participants, or payment in cash or otherwise of amounts based on the value of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Administrator, at any time and from time to time, may grant cash-based awards that settle in Shares to a Participant in such amounts and
upon such terms as the Administrator shall determine, in its sole discretion, including performance conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Payment,
if any, with respect to Awards granted pursuant to this Section&nbsp;6.5 shall be made in accordance with the terms of the applicable
Award Agreement, in cash, Shares or a combination of both as determined by the Administrator in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>PROVISIONS
APPLICABLE TO ALL AWARDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Award
Agreements</U>. The Administrator shall have sole and exclusive authority to determine the terms and conditions pursuant to which an Award
may be made. By accepting an Award, a Participant shall be deemed to have accepted and agreed to the terms and conditions of this Plan
and the Award Agreement. The Administrator may require that a Participant promptly execute and return to the Company the Participant&rsquo;s
Award Agreement evidencing the Participant&rsquo;s acceptance of and agreement to the terms and conditions of this Plan and the Award
as a condition precedent to any Common Stock becoming issuable or deliverable by the Company pursuant to the Award. In addition, the Administrator
may require that the spouse of any married Participant also promptly execute and return to the Company the Award Agreement evidencing
the Award granted to the Participant or such other spousal consent form that the Administrator may require in connection with the grant
of the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Non-Transferability
of Awards</U>. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred,
or disposed of in any manner other than by will or by the laws of descent or distribution; <I>provided</I>, <I>however</I>, that the Administrator
may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of an Award, other than an Incentive
Stock Option, for no consideration to a Permitted Transferee. Any Award transferred to a Permitted Transferee shall be further transferable
only by last will and testament or the laws of descent and distribution, or for no consideration, to another Permitted Transferee of the
Participant. During the lifetime of a Participant, an Award shall be exercisable only by the Participant or by a Permitted Transferee
to whom such Award has been transferred in accordance with this Section&nbsp;7.2. In no event may an Award be transferred to any person
who has joined or is supporting a Competing Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;409A</U>.
Notwithstanding any contrary provision in this Plan or an Award Agreement, if any provision of this Plan or an Award Agreement contravenes
any regulations or guidance promulgated under Section&nbsp;409A of the Code or would cause an Award to be subject to additional taxes,
accelerated taxation, interest and penalties under Section&nbsp;409A of the Code, such provision of this Plan or Award Agreement may be
modified by the Administrator without the consent of the Participant in any manner the Administrator deems reasonable or necessary. In
making such modifications the Administrator shall attempt, but shall not be obligated, to maintain, to the maximum extent practicable,
the original intent of the applicable provision without contravening the provisions of Section&nbsp;409A of the Code. Moreover, any discretionary
authority that the Administrator may have pursuant to this Plan shall not be applicable to an Award that is subject to Section&nbsp;409A
of the Code to the extent such discretionary authority would contravene Section&nbsp;409A of the Code or the guidance promulgated thereunder.
In the event that it is reasonably determined by the Administrator that, as a result of Section&nbsp;409A of the Code, payments in respect
of any Award under this Plan may not be made at the time contemplated by the terms of this Plan or the relevant Award Agreement, as the
case may be, without causing the Participant holding such Award to be subject to taxation under Section&nbsp;409A of the Code, including
as a result of the fact that the Participant is a &ldquo;specified employee&rdquo; under Section&nbsp;409A of the Code, the Company will
make such payment on the first day that would not result in the Participant incurring any tax liability under Section&nbsp;409A of the
Code. The Company shall use commercially reasonable efforts to implement the provisions of this Section&nbsp;7.3 in good faith; <I>provided</I>
that none of the Company Group, the Administrator nor any of the officers, employees, managers, directors or representatives of the Company
Group shall have any liability to Participants with respect to this Section&nbsp;7.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Rule&nbsp;16b-3</U>. It is the Company&rsquo;s intent that this Plan and the Awards comply in all respects with Rule&nbsp;16b-3 of
the Exchange Act. If the consummation of any transaction under this Plan would result in the possible imposition of liability on a Participant
pursuant to Section&nbsp;16(b)&nbsp;of the Exchange Act, the Administrator shall have the right, but not the obligation, to defer such
transaction or the effectiveness of such action to the extent necessary to avoid such liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>CONDITIONS
UPON ISSUANCE OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legal
Compliance</U>. Notwithstanding any other provision of this Plan, any Award Agreement or any other agreement entered into by the Company
pursuant to this Plan, an Award may not be issued or exercised, and no Common Stock may be issued in connection with an Award unless the
exercise of such Award and the issuance and delivery of such Common Stock will comply with Applicable Laws, including, without limitation,
the Securities Act, the Exchange Act, U.S. state securities laws and regulations, and the regulations of any stock exchange or other securities
market on which the Company&rsquo;s securities may then be traded, and will be further subject to the approval of counsel for the Company
with respect to such compliance. All certificates for Common Stock delivered under this Plan shall be subject to such transfer orders
and other restrictions as the Administrator may deem advisable under the rules, regulations, and other requirements of the U.S. Securities
and Exchange Commission, any exchange upon which the Common Stock are then listed, and any applicable securities law, and the Administrator
may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Representations</U>. As a condition to the exercise and issuance of an Award, the Company may require the person acquiring such Award
to represent and warrant at the time of any such acquisition that the Common Stock are being acquired only for investment and without
any present intention to sell or distribute such Common Stock if, in the opinion of counsel for the Company, such a representation is
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inability
to Obtain Authority</U>. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority
is deemed by the Company&rsquo;s counsel to be necessary to the lawful issuance and sale of any Common Stock hereunder, will relieve the
Company of any liability in respect of the failure to issue or sell such Common Stock as to which such requisite authority will not have
been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>ADJUSTMENTS
UPON CHANGES IN COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
(or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, share split (including
a share split in the form of a share dividend) or reverse share split; any merger, combination, consolidation, or other reorganization;
any split-up, spin-off, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock
or other securities of the Company, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then
subject to any required action by the Shareholders under Applicable Laws, the Administrator shall equitably and proportionately adjust
(i)&nbsp;Share Reserve, (ii)&nbsp;the number and type of Common Stock (or other securities) that thereafter may be made the subject of
Awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan), (iii)&nbsp;the number,
amount and type of Common Stock (or other securities or property) subject to any outstanding Awards, (iv)&nbsp;the grant, purchase, or
exercise price of any outstanding Awards, or (v)&nbsp;the securities, cash or other property deliverable upon exercise or vesting of any
outstanding Awards, in each case to the extent necessary to preserve (but not increase) the level of incentives intended by this Plan
and the then-outstanding Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
otherwise expressly provided in the applicable Award Agreement, upon (or as may be necessary to effect the adjustment, immediately prior
to) any event or transaction described in the preceding paragraph or a sale of all or substantially all of the business or assets of the
Company as an entirety, the Administrator shall equitably and proportionately adjust the performance criteria applicable to any then-outstanding
performance-based Awards to the extent necessary to preserve (but not increase) the level of incentives by this Plan and the then-outstanding
performance-based Awards, which adjustments need not be uniform as between different Participants, Awards or types of Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
is intended that, if possible, any adjustments contemplated by the preceding two paragraphs shall be made in a manner that satisfies Applicable
Laws (including, without limitation and as applicable in the circumstances, Section&nbsp;424 of the Code and Section&nbsp;409A of the
Code) and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
good-faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section&nbsp;9.1,
and the extent and nature of any such adjustment, shall be final, binding and conclusive on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dissolution
or Liquidation</U>. In the event of a dissolution or liquidation of the Company, then all outstanding Awards shall terminate immediately
prior to such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Change
of Control</U>. In the event of a Change of Control, or such other transaction in which all of the Common Stock outstanding immediately
prior to the transaction are converted by virtue of the transaction into other property, whether in the form of securities, cash or otherwise,
then the Company, to the extent permitted by Applicable Laws, but otherwise in the sole discretion of the Administrator may provide for:
(a)&nbsp;the continuation of outstanding Awards by the Company (if the Company is the surviving entity); (b)&nbsp;the assumption of this
Plan and such outstanding Awards by the surviving entity or its parent; (c)&nbsp;the substitution by the surviving entity or its parent
of Awards with substantially the same terms (including an award to acquire the same consideration paid to the Shareholders in the transaction
described in this Section&nbsp;9.3) for such outstanding Awards and, if appropriate, subject to the equitable adjustment provisions of
Section&nbsp;9.1; (d)&nbsp;the acceleration of the vesting, settlement and delivery of all Awards outstanding under this Plan; (e)&nbsp;the
cancellation of any outstanding Awards in consideration for a payment (in cash or other property) equal in value to the Fair Market Value
of vested Awards, or in the case of an Option or Share Appreciation Right, the difference between the Fair Market Value and the exercise
price for the Common Stock subject to exercise (<I>i.e.</I>, to the extent vested) under any outstanding Option or Share Appreciation
Right; or (f)&nbsp;the cancellation of such outstanding Awards without payment of any consideration. If Awards would be canceled without
consideration for vested Awards, the Participant shall have the right, exercisable during the later of the ten-day period ending on the
fifth day prior to such merger or consolidation or ten days after the Administrator provides the Award holder a notice of cancellation,
to exercise such Awards in whole or in part without regard to any installment exercise provisions in the Award Agreement; <I>provided</I>
that the Administrator may, in its discretion, condition the exercise of any Award on the consummation of the Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Section&nbsp;409A</U>. No action shall be taken under this Section&nbsp;9 that will cause an Award to fail to comply with Section&nbsp;409A
of the Code, to the extent applicable to such Award. Any adjustments to outstanding Awards shall be effected in a manner that shall preclude
the enlargement or dilution of rights and benefits under such options and shall be conducted in compliance with Section&nbsp;409A of the
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>AMENDMENT
OF THIS PLAN AND AWARDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment
of Plan</U>. The Administrator at any time, and from time to time, may amend, suspend or terminate this Plan in accordance with Applicable
Laws. However, no amendment shall be effective unless approved by the Shareholders to the extent Shareholder approval is necessary to
satisfy any Applicable Law. Any amendment that under the requirements of Applicable Laws must be approved by the Shareholders shall not
be effective unless and until such Shareholder approval has been obtained in compliance with such law or rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment
of Awards</U>. The Administrator at any time, and from time to time, may amend the terms of any one or more Awards, or subject to Applicable
Laws, provide for the substitution of a new Award for an existing Award. For the avoidance of doubt, the Administrator shall have the
authority (without Shareholder approval) to (a)&nbsp;amend any outstanding Option or Share Appreciation Right to reduce its exercise price
per share or (b)&nbsp;cancel any Option or Share Appreciation Right in exchange for cash or another Award. Additionally, the Administrator
may appropriately adjust any evaluation of performance under a Performance Goal to (i)&nbsp;eliminate the effects of charges for restructurings,
discontinued operations, any other unusual or infrequent items and all items of gain, loss or expense determined to be unusual or infrequent
in nature; (ii)&nbsp;exclude any of the following events that occur during a Performance Period: (A)&nbsp;asset write-downs or impairments,
(B)&nbsp;litigation, claims, judgments or settlements, (C)&nbsp;the effect of changes in tax law, accounting standards or other such laws
or provisions affecting reported results and (D)&nbsp;accruals for reorganization and restructuring programs; or (iii)&nbsp;account for
any (x)&nbsp;material acquisition, disposition, merger, spin-off or other similar transaction, or new or existing joint venture or (y)&nbsp;gain,
loss or expense determined to be unusual or infrequent in nature, or otherwise materially outside the scope of those anticipated in the
Company&rsquo;s plans at the time such Performance Goals were originally set.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Impairment of Rights</U>. Rights under any Award granted before amendment of this Plan shall not be impaired by any amendment of this
Plan (and shall continue to be subject to the terms of this Plan as in effect as of immediately prior to the applicable amendment), and
rights under Awards shall not be materially impaired by any amendment of an Award, unless the Participant consents in writing; <I>provided</I>,
<I>however</I>, that no consent is required if the Administrator determines in its sole discretion and prior to a Change of Control that
such amendment is either required or advisable in order for the Company Group, this Plan or the Award to satisfy any Applicable Law, regulation
or stock exchange listing requirement or to avoid adverse tax or financial accounting consequences. A cancellation of an Award where the
Participant receives a payment equal in value to the Fair Market Value of the vested Award or, in the case of vested Options, the difference
between the Fair Market Value and the exercise price, shall not be an impairment of the Participant&rsquo;s rights that requires consent
of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>GENERAL
PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acceleration
of Exercisability and Vesting</U>. The Administrator shall have the power to accelerate the time at which an Award may first be exercised
or the time during which an Award or any part thereof will vest in accordance with this Plan, notwithstanding the provisions in the Award
stating the time at which it may first be exercised or the time during which it will vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shareholder
Rights</U>. With respect to Shares subject to an Award granted under this Plan, a Participant shall not be deemed to be a Shareholder,
and the Participant shall not have any of the rights or privileges of a Shareholder, until Shares have been issued to the Participant
or the Participant&rsquo;s nominee following exercise of the Participant&rsquo;s right under this Plan. No adjustments shall be made for
dividends (ordinary or extraordinary, whether in cash, securities or other property) or distribution or other rights for which the record
date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator. Shares
acquired under this Plan shall be subject to the Company&rsquo;s Insider Trading Policy to the extent applicable to a Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment or other Service Rights</U>. Nothing in this Plan or any instrument executed or Award granted pursuant thereto shall confer
upon any Participant any right to continue to serve the Company Group in the capacity in effect at the time the Award was granted or shall
affect the right of the Company Group to terminate (a)&nbsp;the employment of an Employee with or without notice and with or without cause,
(b)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&rsquo;s agreement with the Company Group or (c)&nbsp;the
service of a Director pursuant to the Certificate of Formation or the TBOC, and any applicable provisions of the corporate law of the
jurisdiction in which a Company Group member is incorporated, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Rights to Awards</U>. No Service Provider or other person shall have any claim to be granted any Award pursuant to this Plan, and neither
the Company nor the Administrator is obligated to treat Service Providers, Participants or any other persons uniformly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer,
Approved Leave of Absence</U>. For purposes of this Plan, no termination of Continuous Service by an Employee shall be deemed to result
from either (a)&nbsp;a transfer to the employment within the Company Group; or (b)&nbsp;an approved leave of absence for military service
or sickness, or for any other purpose approved by the Company, if the Employee&rsquo;s right to re-employment is guaranteed either by
a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides
in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withholding
Obligations</U>. Common Stock will be delivered to a Participant only after the Participant has satisfied any tax withholding requirements
relating to the exercise, vesting or acquisition of such Common Stock. To the extent provided by the terms of an Award Agreement and subject
to the discretion of the Administrator, the Participant may satisfy any federal, state or local tax withholding obligation relating to
the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company&rsquo;s right to
withhold from any compensation paid to the Participant by the Company Group) or by a combination of such means: (a)&nbsp;tendering a cash
payment; (b)&nbsp;authorizing the Company to issue and then immediately redeem or repurchase Common Stock at Fair Market Value; or (c)&nbsp;tendering
to the Company currently owned and unencumbered Common Stock of the Company for redemption or repurchase, and in each of clauses (b)&nbsp;and
(c), immediately tendering the redemption or repurchase price paid by the Company in respect of such Common Stock back to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Compensation Arrangements</U>. Nothing contained in this Plan shall prevent the Administrator from adopting other or additional compensation
arrangements, subject to Shareholder approval if such approval is required; and such arrangements may be either generally applicable or
applicable only in specific cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery</U>.
Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period
of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days
shall be considered a reasonable period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Provisions</U>. The Award Agreements authorized under this Plan may contain such other provisions not inconsistent with this Plan, including,
without limitation, restrictions upon the exercise of the Awards, as the Administrator may deem advisable. Unless explicitly provided
otherwise in an Award Agreement, if there is a conflict between the terms of this Plan and an Award Agreement, the terms of this Plan
shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Recoupment
Provisions</U>. Any Awards granted under this Plan shall be subject to any clawback or recoupment policies and procedures that are required
under Applicable Laws or any Company Group policy as enacted, adopted or modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cancellation
and Rescission of Awards for Detrimental Activity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
exercise, payment or delivery pursuant to an Award, the Participant shall, if requested, certify in a manner acceptable to the Company
that the Participant has not engaged in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
the Award Agreement specifies otherwise, the Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any unexpired,
unpaid or deferred Awards at any time if the Participant engages in any Detrimental Activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event a Participant engages in Detrimental Activity after any exercise, payment or delivery pursuant to an Award, during any period
for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may
be rescinded within one year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any
gain realized or payment received as a result of the exercise, payment or delivery, in such manner and on such terms and conditions as
may be required by the Company. The Company shall be entitled to set off against the amount of any such gain any amount owed to the Participant
by the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Administrator&rsquo;s discretion, the Company may exercise the right of rescission set forth in this Section&nbsp;11.11 via the mandatory
redemption or repurchase of the Participant&rsquo;s Common Stock at a price equal to the price paid by the Participant to acquire the
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Paperless
Administration</U>. In the event that the Company establishes, for itself or using the services of a third party, an automated system
for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then
the paperless documentation, granting or exercise of Awards by a Participant may be permitted through the use of such an automated system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Unfunded
Status of Awards</U>. This Plan is intended to be an &ldquo;unfunded&rdquo; plan for incentive compensation. With respect to any payments
not yet made to a Participant pursuant to an Award, nothing contained in this Plan or any Award Agreement shall give the Participant any
rights that are greater than those of a general creditor of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses</U>.
The expenses of administering this Plan shall be borne by the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been
duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any provision of this Plan is, or becomes, or is deemed to be invalid, illegal or unenforceable in any jurisdiction or as to any Participant,
or would disqualify this Plan under any law deemed applicable by the Administrator, such provision shall be construed or deemed amended
to conform to the Applicable Laws, or if it cannot be construed or deemed amended without, in the determination of the Administrator,
materially altering the intent of this Plan, such provision shall be stricken as to such jurisdiction or Participant and the remainder
of this Plan shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">11.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation</U>.
The definitions of terms in this Plan shall apply equally to the singular and plural forms of the terms defined. Whenever the context
may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The use of the words &ldquo;and&rdquo;
and &ldquo;or&rdquo; can mean both &ldquo;and&rdquo; and &ldquo;or&rdquo; where such construction would be applicable. The words &ldquo;include,&rdquo;
 &ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation.&rdquo; The
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall.&rdquo; Section&nbsp;headings
are included for convenience of reference only and shall not affect the interpretation of this Plan, and all references to Sections shall
be construed to refer to Sections of this Plan. Unless the context requires otherwise, (a)&nbsp;any definition of or reference to any
document shall be construed as referring to such document as from time to time amended, supplemented or otherwise modified, (b)&nbsp;any
reference to any Person shall be construed to include such Person&rsquo;s successors and assigns, and (c)&nbsp;any reference to any Applicable
Law shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>EFFECTIVE
DATE OF PLAN</B>. This Plan shall become effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>TERMINATION
OR SUSPENSION OF THIS PLAN</B>. Unless terminated by the Directors at an earlier date pursuant to Section&nbsp;10.1, this Plan will continue
in effect for a term of ten years commencing on the Effective Date. No Award shall be granted pursuant to this Plan after such date, but
Awards theretofore granted may extend beyond that date. No Awards may be granted under this Plan while this Plan is suspended or after
it is terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>CHOICE
OF LAW; WAIVER OF JURY TRIAL</B>. The laws of the State of Texas shall govern all questions concerning the construction, validity and
interpretation of this Plan and any Award Agreement. <B>BY ACCEPTING AN AWARD, EACH PARTICIPANT IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL
BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS PLAN OR ANY AWARD AGREEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>22
<FILENAME>tm2415719d15_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;10.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARIS
LIFE SCIENCES,&nbsp;INC.<BR>
</B></FONT><B>EMPLOYEE STOCK PURCHASE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>PURPOSE</B>.
The purpose of the Caris Life Sciences,&nbsp;Inc. Employee Stock Purchase Plan (this &ldquo;<B><I>Plan</I></B>&rdquo;) is to provide Eligible
Employees of the Company Group with an opportunity to acquire a stock ownership interest in the Company. This Plan is intended to qualify
as an &ldquo;employee stock purchase plan&rdquo; under Section&nbsp;423 of the Code and shall be administered, interpreted and construed
in a manner consistent with the requirements of Section&nbsp;423 of the Code. This Plan shall be effective as of the date of approval
by the Shareholders (the &ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Administrator</I></B>&rdquo;
</FONT>means the Board or the Committee appointed by the Board in accordance with Section&nbsp;3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Agent</I></B>&rdquo;
means the brokerage firm, bank or other financial institution, entity or person(s), if any, engaged, retained, </FONT>appointed or authorized
to act as the agent of the Company or an Eligible Employee with regard to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Annual
Increase</I></B>&rdquo; has the meaning set forth in Section&nbsp;4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Applicable
Laws</I></B>&rdquo; means any applicable legal requirements relating to the administration of and the issuance of ownership interests
and other securities under equity-based compensation plans, including, without limitation, U.S. state corporate laws, U.S. federal and
state securities laws, the Code and the requirements of any stock exchange or quotation system upon which the Common Stock may be listed
or quoted and the laws of any other country or jurisdiction where rights are granted under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Beneficial
Owner</I></B>&rdquo; has the meaning assigned to such term in Rule&nbsp;13d-3 and Rule&nbsp;13d-5 under the Exchange Act, except that
in calculating the beneficial ownership of any particular &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d)(3)&nbsp;of
the Exchange Act), such &ldquo;person&rdquo; shall be deemed to have beneficial ownership of all securities that such &ldquo;person&rdquo;
has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable
only after the passage of time. The terms &ldquo;Beneficially Owns&rdquo; and &ldquo;Beneficially Owned&rdquo; have corresponding meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Board</I></B>&rdquo;
means the </FONT>Board of Directors of the Company, as constituted from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Certificate
of Formation</I></B>&rdquo; means the Company&rsquo;s Amended and Restated Certificate of Formation, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Code</I></B>&rdquo;
means the Internal Revenue Code of 1986, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Committee</I></B>&rdquo;
means a committee of one or more Directors appointed by the Board to administer this Plan in accordance with Section&nbsp;3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the Class&nbsp;A common stock of the Company, par value US$0.001 per share, issued subject to and in accordance
with the provisions of the TBOC and the Certificate of Formation and having the rights provided for in the Certificate of Formation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Company</I></B>&rdquo;
means Caris Life Sciences,&nbsp;Inc., a Texas corporation, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Company
Group</I></B>&rdquo; means the Company and each of its parent corporations and subsidiary corporations, whether now or hereafter existing,
as those terms are defined in Sections 424(e)&nbsp;and (f), respectively, of the Code, or one of the members of the Company Group, as
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Compensation</I></B>&rdquo;
of an Eligible Employee means, unless otherwise determined by the Administrator, the gross base compensation or wages received by such
Eligible Employee as compensation for services to the Company Group, excluding overtime payments, sales commissions, incentive compensation,
bonuses, expense reimbursements, income received in connection with any compensatory equity awards, fringe benefits and other special
payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Effective
Date</I></B>&rdquo; has the meaning set forth in Section&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Eligible
Employee</I></B>&rdquo; </FONT>means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;An
Employee who does not, immediately after any rights under this Plan are granted, own (directly or through attribution) stock possessing
5% or more of the total combined voting power or value of all classes of Shares and other securities of the Company or another member
of the Company Group (as determined under Section&nbsp;423(b)(3)&nbsp;of the Code). For purposes of the foregoing, the rules&nbsp;of Section&nbsp;424(d)&nbsp;of
the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock
that an Employee may purchase under outstanding options shall be treated as stock owned by the Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Provided
that, prior to the commencement of an Offering Period, the Administrator may, in its discretion, determine that Employees who are a highly
compensated employees within the meaning of Section&nbsp;423(b)(4)(D)&nbsp;of the Code may not participate in such Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, an Employee shall not be eligible to participate in an Offering Period if: (i)&nbsp;in the event the Administrator designates
a service requirement, such Employee has not met the service requirement designated by the Administrator pursuant to Section&nbsp;423(b)(4)(A)&nbsp;of
the Code (which service requirement may not be more than two years); (ii)&nbsp;such Employee&rsquo;s customary employment is for 20 hours
per week or less; (iii)&nbsp;such Employee&rsquo;s customary employment is for less than five&nbsp;months in any calendar year; or (iv)&nbsp;such
Employee is a citizen or resident of a non-U.S. jurisdiction and the grant of a right to purchase Shares under this Plan to such Employee
would be prohibited under the laws of such non-U.S. jurisdiction or the grant of a right to purchase Shares under this Plan to such Employee
in compliance with the laws of such non-U.S. jurisdiction would cause this Plan to violate the requirements of Section&nbsp;423 of the
Code, as determined by the Administrator in its sole discretion; <I>provided</I> that any exclusion in clauses (i), (ii), (iii)&nbsp;or
(iv)&nbsp;shall be applied in an identical manner under each Offering Period to all Employees, in accordance with Treas. Reg. Section&nbsp;1.423-2(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Employee</I></B>&rdquo;
means </FONT>any person employed by the Company Group and who is an employee within the meaning of Section&nbsp;3401(c)&nbsp;of the Code.
Mere service as a Director or payment of a director&rsquo;s fee by the Company Group shall not be sufficient to constitute &ldquo;employment&rdquo;
by the Company Group. For purposes of this Plan, the employment relationship shall be treated as continuing intact while the individual
is on sick leave or other leave of absence approved by the Company Group and meeting the requirements of Treas. Reg. Section&nbsp;1.421-1(h)(2).
Where the period of leave exceeds three months and the individual&rsquo;s right to reemployment is not guaranteed either by statute or
by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Enrollment
Date</I></B>&rdquo; means the first Trading Day of each Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;</FONT><B><I>Fair
Market Value</I></B><I>&rdquo; </I>means, with respect to a Share, the fair market value thereof as of the relevant date of determination,
as determined in accordance with the valuation methodology approved by the Administrator (based on objective criteria) from time to time.
In the absence of any alternative valuation methodology approved by the Administrator, Fair Market Value shall be deemed to be equal to
the closing selling price of a Share on the Nasdaq Stock Exchange (or such established national securities exchange as may be designated
by the Administrator) on the trading day immediately preceding the date as of which such valuation is made, or in the event that the Common
Stock is not listed for trading on the Nasdaq Stock Exchange or such other national securities exchange as may be designated by the Administrator
but is quoted on an automated system, in any such case, on the valuation date (or if there were no sales on the valuation date, the average
of the highest and lowest quoted selling prices as reported on said composite tape or automated system for the most recent day during
which a sale occurred).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Offering</I></B>&rdquo;
means an offer under this Plan of a right to purchase Shares that may be exercised during an Offering Period as further described in Section&nbsp;4.2.
Unless otherwise specified by the Administrator, each Offering to the Eligible Employees shall be deemed a separate Offering, even if
the dates and other terms of the applicable Offering Periods of each such Offering are identical, and the provisions of </FONT>this Plan
will separately apply to each Offering. To the extent permitted by Treas. Reg. Section&nbsp;1.423-2(a)(1), the terms of each separate
Offering need not be identical, provided that the terms and an Offering thereunder together satisfy Treas. Reg. Section&nbsp;1.423-2(a)(2)&nbsp;and
(a)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Offering
Document</I></B>&rdquo; means the document setting forth the terms of an Offering as approved by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Offering
Period</I></B>&rdquo; has the meaning given to such term in Section&nbsp;6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Participant</I></B>&rdquo;
means any Eligible Employee who has executed a subscription agreement and been granted rights to purchase Shares pursuant to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Payday</I></B>&rdquo;
means the regular and recurring established day for payment of Compensation to an Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Person</I></B>&rdquo;
means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association,
trust, joint venture, association or other similar entity, whether or not a legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Plan</I></B>&rdquo;
</FONT>has the meaning set forth in Section&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Purchase
Date</I></B>&rdquo; means the last Trading Day of the applicable Purchase Period or such other date as determined by the Administrator
prior to the commencement of an Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Purchase
Period</I></B>&rdquo; shall refer to one or more periods within an Offering Period, as designated by the Administrator. Unless designated
otherwise by the Administrator prior to the commencement of an Offering Period, the Purchase Period for each Offering Period shall be
the same as the applicable Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Purchase
Price</I></B>&rdquo; means the purchase price designated by the Administrator prior to the commencement of an Offering Period (which purchase
price shall not be less than 85% of the Fair Market Value of a Share on (x)&nbsp;first day of the Offering Period or (y)&nbsp;the Purchase
Date for such Offering Period, whichever is lower); <I>provided</I>, <I>however</I>, that, in the event no purchase price is designated
by the Administrator prior to the commencement of an Offering Period, the purchase price for such Offering Period shall be 85% of the
Fair Market Value of a Share on (x)&nbsp;first day of the Offering Period or (y)&nbsp;the Purchase Date for such Offering Period, whichever
is lower; <I>provided</I>, <I>further</I>, <I>however</I>, that the Purchase Price may be adjusted by the Administrator pursuant to Section&nbsp;10
and shall not be less than the par value of a Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the U.S. Securities Act of 1933, as amended</FONT>, and the rules&nbsp;and regulations promulgated thereunder
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Share</I></B>&rdquo;
means a share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Share
Reserve</I></B>&rdquo; has the meaning set forth in Section&nbsp;4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Shareholder</I></B>&rdquo;
means a shareholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.34&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means any foreign or domestic corporation, limited liability company, partnership or other entity of which 50% or more of the outstanding
voting equity securities or voting power is Beneficially Owned directly or indirectly by the Company. For purposes of determining eligibility
for the grant of Shares under the Plan, the term &ldquo;Subsidiary&rdquo; shall be defined in the manner required by Section&nbsp;424(f)&nbsp;of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B><I>TBOC</I></B>&rdquo;
means the Texas Business Organizations Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which </FONT>national stock exchanges in the United States are open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B><I>Treas.
Reg.</I></B>&rdquo; means U.S. Department of </FONT>the Treasury regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>ADMINISTRATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Administration
by Directors</U>. This Plan shall be administered by the Board unless and until the Board delegates administration to a Committee, as
provided in Section&nbsp;3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Powers
of Administrator</U>. The Administrator shall have the power and authority to determine when and how rights to purchase Shares shall be
granted and the provisions of each Offering (which need not be identical). The Administrator may delegate administrative tasks under this
Plan to the services of an Agent or Employee to assist in the administration of this Plan, including establishing and maintaining an individual
securities account under this Plan for each Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Specific
Powers</U>. In particular, the Administrator shall have the authority: (i)&nbsp;to construe and interpret this Plan and apply its provisions;
(ii)&nbsp;to promulgate, amend and rescind rules&nbsp;and regulations relating to the administration of this Plan; (iii)&nbsp;to authorize
any person to execute, on behalf of the Company, any instrument required to carry out the purposes of this Plan; (iv)&nbsp;to impose a
mandatory holding period pursuant to which Employees may not dispose of or transfer Shares purchased under this Plan for a period of time
determined by the Administrator in its discretion; (v)&nbsp;to exercise such powers and to perform such acts as the Administrator deems
necessary or expedient to promote the best interests of the Company Group and to carry out the intent that this Plan be treated as an
 &ldquo;employee stock purchase plan&rdquo; within the meaning of Section&nbsp;423 of the Code; (vi)&nbsp;to adopt sub-plans applicable
to particular Subsidiaries or locations, which sub-plans may be designed to be outside the scope of Section&nbsp;423 of the Code; (vii)&nbsp;to
correct any defect, omission or inconsistency in this Plan, in a manner and to the extent it shall deem necessary or expedient to make
this Plan fully effective; and (viii)&nbsp;to exercise discretion to make any and all other determinations which it determines to be necessary
or advisable for administration of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Decisions
Final</U>. All decisions made by the Administrator pursuant to the provisions of this Plan shall be final, binding and conclusive on the
Company and the Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>The
Committee</U>. To the extent permitted under Applicable Laws, the Board may delegate administration of this Plan to a Committee or Committees
consisting of one or more Directors, and the term &ldquo;<B><I>Committee</I></B>&rdquo; shall apply to any person or persons to whom such
authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration
of this Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative
powers the Committee is authorized to exercise (and references in this Plan to the Board or the Administrator shall thereafter, to the
extent the delegation is applicable, be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with
the provisions of this Plan, as may be adopted from time to time by the Board. Subject to the limitations prescribed by this Plan and
the Board, the Committee may establish and follow such rules&nbsp;and regulations for the conduct of its business as it may determine
to be advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification</U>.
In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed
by Applicable Laws, the Administrator shall be indemnified by the Company against the reasonable expenses, including attorney&rsquo;s
fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Administrator
may be party by reason of any action taken or failure to act under or in connection with this Plan, and against all amounts paid by the
Administrator in settlement thereof (<I>provided </I>that the settlement has been approved by the Company, which approval shall not be
unreasonably withheld) or paid by the Administrator in satisfaction of a judgment in any such action, suit or proceeding, except in relation
to matters as to which it shall be adjudged in such action, suit or proceeding that such Administrator did not act in good faith; <I>provided</I>,
<I>however</I>, that within 60&nbsp;days after institution of any such action, suit or proceeding, such Administrator shall, in writing,
offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance
on Experts</U>. In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may
rely upon the advice of experts, including employees of and professional advisors to the Company. No director, officer or agent of the
Company Group shall be liable for any such action or determination taken or made or omitted in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>COMMON
STOCK SUBJECT TO THIS PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Number
of Shares</U>. Subject to the provisions of Section&nbsp;10 relating to adjustments upon changes in the Common Stock, the aggregate number
of Shares that may be issued pursuant to rights granted under this Plan shall be an amount equal to 0.85% of the fully diluted shares
of all classes of the Company&rsquo;s common stock after giving effect to the Company&rsquo;s initial public offering (the &ldquo;<B><I>Offering</I></B>&rdquo;)
(assuming the exercise of any outstanding warrants and conversion of all preferred stock and senior convertible notes, and including,
but not limited to, shares subject to outstanding awards under the Amended and Restated 2020 Plan, and the issuance of the Company&rsquo;s
common stock contemplated to be sold in the Offering) (the &ldquo;<B><I>Share&nbsp;Reserve</I></B>&rdquo;). Notwithstanding the foregoing,
the Share Reserve shall automatically increase on January&nbsp;1 of each calendar year during the term of this Plan beginning in 2026,
by a number of Shares equal to 1% of all classes of the Company&rsquo;s common stock outstanding on the last day of the immediately preceding
fiscal year, unless the Administrator should decide to increase the number of Shares available under this Plan by a lesser amount (the
 &ldquo;<B><I>Annual Increase</I></B>&rdquo;). The &ldquo;<B><I>Amended and Restated 2020 Plan</I></B>&rdquo; means the Caris Life Sciences,&nbsp;Inc.
2020 Incentive Plan, as amended and restated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reversion
of Shares to the Share Reserve</U>. If any right granted under this Plan shall for any reason terminate without having been exercised,
the Shares not purchased under such right shall again become available for issuance under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Source
of Shares</U>. The Shares subject to this Plan may be authorized but unissued Common Stock or reacquired Common Stock, however reacquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>ELIGIBILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Eligibility</U>.
Any Eligible Employee employed by the Company Group on a given Enrollment Date for an Offering Period shall be eligible to participate
in this Plan during such Offering Period, subject to the requirements of this Section&nbsp;5 and the limitations imposed by Section&nbsp;423(b)&nbsp;of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Enrollment
in this Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise determined by the Administrator, an Eligible Employee may become a Participant in this Plan for an Offering Period by delivering
a subscription agreement to the Company by such time prior to the Enrollment Date for such Offering Period designated by the Administrator
and in such form as the Company provides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise determined by the Administrator, each subscription agreement shall designate a whole percentage of such Eligible Employee&rsquo;s
Compensation to be withheld by the Company Group member employing such Eligible Employee on each Payday during the Offering Period as
payroll deductions under this Plan. The percentage of Compensation designated by an Eligible Employee may not be less than 1% and may
not be more than the maximum percentage designated by the Administrator (which percentage shall be 15% in the absence of any such designation)
as payroll deductions. The payroll deductions made for each Participant shall be credited to an account for such Participant under this
Plan and shall be deposited with the general funds of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Administrator may designate that a Participant may increase or decrease the percentage of Compensation designated in the Participant&rsquo;s
subscription agreement, subject to the limits of this Section&nbsp;5.2, or may suspend the Participant&rsquo;s payroll deductions, at
any time during an Offering Period (and in the absence of any specific designation by the Administrator, a Participant may not increase
the Participant&rsquo;s payroll deduction elections during an Offering Period); <I>provided</I>, <I>however</I>, that the Administrator
may limit the number of changes a Participant may make to the Participant&rsquo;s payroll deduction elections during each Offering Period
in the applicable Offering Document. Any such change or suspension of payroll deductions shall be effective with the first full payroll
period following the Company&rsquo;s receipt of the new subscription agreement (or such shorter or longer period as may be specified by
the Administrator in the applicable Offering Document). In the event a Participant suspends the Participant&rsquo;s payroll deductions,
such Participant&rsquo;s cumulative payroll deductions prior to the suspension shall remain in the Participant&rsquo;s account and shall
be applied to the purchase of Shares on the next occurring Purchase Date and shall not be paid to such Participant unless the Participant
withdraws from participation in this Plan pursuant to Section&nbsp;8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise determined by the Administrator, a Participant may participate in this Plan only by means of payroll deduction and may not
make contributions by lump-sum payment for any Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payroll
Deductions</U>. Except as otherwise determined by the Administrator, payroll deductions for a Participant shall commence on the first
Payday following the Enrollment Date and shall end on the last Payday in the Offering Period to which the Participant&rsquo;s authorization
is applicable, unless sooner terminated by the Participant as provided in Section&nbsp;8 or suspended by the Participant or the Administrator.
Notwithstanding any other provisions of this Plan to the contrary, in non-U.S. jurisdictions where participation in this Plan through
payroll deductions is prohibited, the Administrator may provide that an Eligible Employee may elect to participate through contributions
to the Participant&rsquo;s account under this Plan in a form acceptable to the Administrator in lieu of or in addition to payroll deductions;
<I>provided</I>, <I>however</I>, that, for any Offering, the Administrator shall take into consideration any limitations under Section&nbsp;423
of the Code when applying an alternative method of contribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effect
of Enrollment</U>. A Participant&rsquo;s completion of a subscription agreement will enroll such Participant in this Plan for each subsequent
Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation
as provided in Section&nbsp;8 or otherwise becomes ineligible to participate in this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitation
on Purchase of Shares</U>. An Eligible Employee may be granted rights under this Plan only if such rights, together with any other rights
granted to such Eligible Employee under &ldquo;employee stock purchase plans&rdquo; of the Company Group, as specified by Section&nbsp;423(b)(8)&nbsp;of
the Code, do not permit such employee&rsquo;s rights to purchase Common Stock to accrue at a rate that exceeds $25,000 of the Fair Market
Value of Common Stock (determined as of the first day of the Offering Period during which such rights are granted) for each calendar year
in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section&nbsp;423(b)(8)&nbsp;of the
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Suspension
of Payroll Deductions</U>. Notwithstanding the foregoing, to the extent necessary to comply with Section&nbsp;423(b)(8)&nbsp;of the Code
and Section&nbsp;5.5 or the other limitations set forth in this Plan, a Participant&rsquo;s payroll deductions may be suspended by the
Administrator at any time during an Offering Period. The balance of the amount credited to the account of each Participant that has not
been applied to the purchase of Shares in such circumstance shall be paid to such Participant in one lump-sum in cash as soon as reasonably
practicable after the Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Non-U.S.
Employees</U>. In order to facilitate participation in this Plan, the Administrator may provide for such special terms applicable to Participants
who are citizens or residents of a non-U.S. jurisdiction, as the Administrator may consider necessary or appropriate to accommodate differences
in local law, tax policy or custom; <I>provided</I>, <I>however</I>, that the Administrator shall take into consideration any limitations
under Section&nbsp;423 of the Code. Such special terms may be set forth in an addendum to this Plan in the form of an appendix or sub-plan.
Without limiting the foregoing, the Administrator is specifically authorized to adopt rules&nbsp;and procedures with respect to Participants
who are non-U.S. nationals or employed in non-U.S. jurisdictions regarding the exclusion of particular Subsidiaries from participation
in this Plan, eligibility to participate, the definition of Compensation, handling of payroll deductions or other contributions by Participants,
payment of interest, conversion of local currency, data privacy and security, payroll tax, withholding procedures, establishment of bank
or trust accounts to hold payroll deductions or contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>OFFERING
PERIODS</B>. The Administrator may from time to time make Offerings under this Plan to Eligible Employees during one or more periods (each,
an &ldquo;<B><I>Offering Period</I></B>&rdquo;) selected by the Administrator. The Administrator may, in its discretion, designate the
length of an Offering Period, provided that no Offering Period shall exceed 27 months in duration. Each Offering Period shall consist
of one or more Purchase Periods, as designated by the Administrator, during which rights granted under this Plan shall be exercised and
purchases of Shares carried out in accordance with this Plan. The provisions of separate Offerings or Offering Periods under this Plan
need not be identical. Unless designated otherwise by the Administrator, the first Offering Period under this Plan shall begin on the
first Trading Day on or following July&nbsp;1, 2026 and shall end on December&nbsp;31, 2026 (the &ldquo;<B><I>Initial Offering</I></B>&rdquo;).
Thereafter, and unless designated otherwise by the Administrator, each Offering Period shall commence on the first Trading Day on or following
January&nbsp;1 and July&nbsp;1 and shall end on June&nbsp;30 and December&nbsp;31, respectively. The Initial Offering and each Offering
Period thereafter shall consist of a single Purchase Period unless designated otherwise by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>GRANT
AND EXERCISE OF RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Grant
of Rights</U>. On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period shall be granted
a right to purchase, and shall have the right to buy, on each Purchase Date during such Offering Period (at the applicable Purchase Price),
subject to the limits in Section&nbsp;5.5, such number of whole Shares as is determined by <I>dividing</I> (a)&nbsp;such Participant&rsquo;s
payroll deductions accumulated prior to such Purchase Date and retained in the Participant&rsquo;s account as of the Purchase Date <I>by</I>
(b)&nbsp;the applicable Purchase Price (rounded down to the nearest whole Share); <I>provided</I>, that, fractional Shares may be issued
upon the exercise of rights granted under the Plan if permitted under the applicable Offering Document. The right shall expire on the
earliest of: (x)&nbsp;the last Purchase Date of the Offering Period, (y)&nbsp;the last day of the Offering Period, and (z)&nbsp;the date
on which the Participant withdraws in accordance with Section&nbsp;8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exercise
of Rights</U>. On each Purchase Date, each Participant&rsquo;s accumulated payroll deductions shall be applied to the purchase of whole
Shares, up to the maximum number of Shares permitted pursuant to the terms of this Plan, at the Purchase Price, but no Participant has
a right to receive a fractional Share. Any cash in lieu of fractional Shares remaining after the purchase of Shares upon exercise of a
purchase right shall be returned to the Participant in one lump sum payment in a subsequent payroll check. Shares issued pursuant to this
Plan may be evidenced in such manner as the Administrator may determine and may be issued in certificated form or issued pursuant to book-entry
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pro
Rata Allocation of Shares</U>. If the Administrator determines that, on a given Purchase Date, the number of Shares with respect to which
rights are to be exercised may exceed (a)&nbsp;the number of Shares that were available for issuance under this Plan on the Enrollment
Date of the applicable Offering Period or (b)&nbsp;the number of Shares available for issuance under this Plan on such Purchase Date,
the Administrator may in its sole discretion provide that the Company shall make a pro rata allocation of the Shares available for purchase
on such Enrollment Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine in its
sole discretion to be equitable among all Participants for whom rights to purchase Shares are to be exercised pursuant to this Section&nbsp;7
on such Purchase Date, and shall either (i)&nbsp;continue all Offering Periods then in effect or (ii)&nbsp;terminate any or all Offering
Periods then in effect in accordance with this Plan. The Company may make pro rata allocation of the Shares available on the Enrollment
Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for
issuance under this Plan by Shareholders subsequent to such Enrollment Date. The balance of the amount credited to the account of each
Participant that has not been applied to the purchase of Shares shall be paid to such Participant in one lump sum in cash as soon as reasonably
practicable after the Purchase Date or such earlier date as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
of Shares</U>. Unless determined otherwise by the Administrator, no Participant may transfer Shares purchased pursuant to this Plan out
of the Participant&rsquo;s account with the Agent during the two-year period from the Enrollment Date of the Offering Period in which
the Shares were purchased other than in the case of a sale of such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>WITHDRAWAL;
CESSATION OF ELIGIBILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withdrawal</U>.
A Participant may withdraw all (but not less than all) of the payroll deductions credited to the Participant&rsquo;s account and not yet
used to exercise the Participant&rsquo;s rights under this Plan at any time by giving written notice to the Company in a form acceptable
to the Company no later than 30 days prior to the end of the Offering Period (or such shorter or longer period as may be designated by
the Administrator). All of the Participant&rsquo;s payroll deductions credited to the Participant&rsquo;s account during an Offering Period
shall be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant&rsquo;s
rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of Shares shall be
made for such Offering Period. If a Participant withdraws from an Offering Period, payroll deductions shall not resume at the beginning
of the next Offering Period unless the Participant timely delivers to the Company a new subscription agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Future
Participation</U>. A Participant&rsquo;s withdrawal from an Offering Period shall not have any effect upon the Participant&rsquo;s eligibility
to participate in any similar plan that may hereafter be adopted by the Company or in subsequent Offering Periods that commence after
the termination of the Offering Period from which the Participant withdraws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cessation
of Eligibility</U>. Upon a Participant&rsquo;s ceasing to be an Eligible Employee for any reason, the Participant shall be deemed to have
elected to withdraw from this Plan pursuant to this Section&nbsp;8 and the payroll deductions credited to such Participant&rsquo;s account
during the Offering Period shall be paid to such Participant or, in the case of such Participant&rsquo;s death, to the Participant&rsquo;s
beneficiary, as soon as reasonably practicable after such cessation of eligibility, and such Participant&rsquo;s rights for the Offering
Period shall be automatically terminated; <I>provided</I>, <I>however</I>, that, unless designated otherwise by the Administrator, a Participant
whose employment with the Company Group terminates for any reason other than the Participant&rsquo;s death less than 30 days prior to
the next Purchase Date in the then-current Offering Period in which the Participant is enrolled shall not be deemed to withdraw from this
Plan until immediately following the Participant&rsquo;s exercise of rights on such Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>CONDITIONS
UPON ISSUANCE OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legal
Compliance</U>. Notwithstanding any other provision of this Plan, no Common Stock may be issued under this Plan unless the issuance and
delivery of such Common Stock will comply with Applicable Laws, including, without limitation, the Securities Act, the Exchange Act, U.S.
state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company&rsquo;s
securities may then be traded, and will be further subject to the approval of counsel for the Company with respect to such compliance.
All certificates for Common Stock delivered under this Plan shall be subject to such transfer orders and other restrictions as the Administrator
may deem advisable under the rules, regulations, and other requirements of the U.S. Securities and Exchange Commission, any exchange upon
which the Common Stock are then listed, and any applicable securities law, and the Administrator may cause a legend or legends to be put
on any such certificates to make appropriate reference to such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inability
to Obtain Authority</U>. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority
is deemed by the Company&rsquo;s counsel to be necessary to the lawful issuance and sale of any Common Stock hereunder, will relieve the
Company of any liability in respect of the failure to issue or sell such Common Stock as to which such requisite authority will not have
been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
to Issuance of Shares</U>. The Company shall not be required to issue or deliver any certificate or certificates for, or make any book
entries evidencing, Shares purchased upon the exercise of rights under this Plan prior to fulfillment of all of the following conditions:
(a)&nbsp;the admission of such Shares to listing on all stock exchanges, if any, on which the Shares are then listed; (b)&nbsp;the completion
of any registration or other qualification of such Shares under any state or federal law or under the rulings or regulations of the Securities
and Exchange Commission or any other governmental regulatory body that the Administrator shall, in its absolute discretion, deem necessary
or advisable; (c)&nbsp;the obtaining of any approval or other clearance from any state or federal governmental agency that the Administrator
shall, in its absolute discretion, determine to be necessary or advisable; (d)&nbsp;the payment to the Company of all amounts that it
is required to withhold under federal, state or local law upon exercise of the rights, if any; and (e)&nbsp;the lapse of such reasonable
period of time following the exercise of the rights as the Administrator may from time to time establish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>ADJUSTMENTS
UPON CHANGES IN COMMON STOCK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
(or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, share split (including
a share split in the form of a share dividend) or reverse share split; any merger, combination, consolidation, or other reorganization;
any split-up, spin-off, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock
or other securities of the Company, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then,
subject to any required action by the Shareholders under Applicable Law, the Administrator shall equitably and proportionately adjust
(i)&nbsp;the Share Reserve, (ii)&nbsp;the class(es) and number of Shares and price per Share subject to outstanding rights; and (iii)&nbsp;the
Purchase Price with respect to any outstanding rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
is intended that, if possible, any adjustments contemplated by the preceding two paragraphs shall be made in a manner that satisfies Applicable
Laws and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
good-faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section&nbsp;10.1,
and the extent and nature of any such adjustment, shall be final, binding and conclusive on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dissolution
or Liquidation</U>. In the event of a dissolution or liquidation of the Company, then this Plan shall terminate and payment shall be made
to Participants in accordance with Section&nbsp;14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Adjustments</U>. In the event of (x)&nbsp;any transaction or event described in Section&nbsp;10.1, (y)&nbsp;any unusual or nonrecurring
transactions or events affecting the Company Group or its the financial statements or (z)&nbsp;changes in Applicable Laws or accounting
principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, shall be authorized to take
any one or more of the following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
provide for either (i)&nbsp;the termination of any outstanding right in exchange for an amount of cash, if any, equal to the amount that
would have been obtained upon the exercise of such right had such right been currently exercisable or (ii)&nbsp;the replacement of such
outstanding right with other rights or property selected by the Administrator in its sole discretion;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
provide that the outstanding rights under this Plan shall be assumed by the successor or survivor corporation, or a parent or Subsidiary
thereof, or shall be substituted by similar rights covering the stock of the successor or survivor corporation, or a parent or Subsidiary
thereof, with appropriate adjustments as to the number and kind of stock and prices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
make adjustments in the number and type of Shares (or other securities or property) subject to outstanding rights under this Plan or in
the terms and conditions of outstanding rights and rights that may be granted in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
provide that Participants&rsquo; accumulated payroll deductions may be used to purchase Shares prior to the next occurring Purchase Date
on such date as the Administrator determines in its sole discretion, following which the Participants&rsquo; rights under the ongoing
Offering Period(s)&nbsp;shall be terminated; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
provide that all outstanding rights shall terminate without being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Adjustment Under Certain Circumstances</U>. Unless determined otherwise by the Administrator, no adjustment or action described in this
Section&nbsp;10 shall be authorized to the extent that such adjustment or action would cause this Plan to fail to satisfy the requirements
of Section&nbsp;423 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>AMENDMENT
OF THIS PLAN.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment
of Plan</U>. The Administrator at any time, and from time to time, may amend, suspend or terminate this Plan in accordance with Applicable
Laws. However, no amendment shall be effective unless approved by the Shareholders to the extent Shareholder approval is necessary to
satisfy any Applicable Laws. Any amendment that under the requirements of Applicable Laws must be approved by the Shareholders shall not
be effective unless and until such Shareholder approval has been obtained in compliance with such law or rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Impairment of Rights</U>. Rights granted before amendment of this Plan shall not be impaired by any amendment of this Plan (and shall
continue to be subject to the terms of this Plan as in effect as of immediately prior to the applicable amendment), unless (a)&nbsp;the
Company requests the consent of the Participant and (b)&nbsp;the Participant consents in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Amendments</U>. Notwithstanding any other provision of this Plan, without Shareholder consent and without regard to whether any Participant
rights may be considered to have been adversely affected and after taking into account Section&nbsp;423 of the Code, the Administrator
shall be entitled to change or terminate the Offering Periods, limit the frequency or number of changes in the amount withheld from Compensation
during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll
withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&rsquo;s processing
of payroll withholding elections, establish reasonable waiting and adjustment periods or accounting and crediting procedures to ensure
that amounts applied toward the purchase of Shares for each Participant properly correspond with amounts withheld from the Participant&rsquo;s
Compensation and establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable
that are consistent with this Plan. In the event the Administrator determines that the ongoing operation of this Plan may result in unfavorable
financial accounting consequences, the Administrator may, in its discretion, to the extent necessary or desirable and without Shareholder
approval, modify or amend this Plan to reduce or eliminate such accounting consequence including, but not limited to: (a)&nbsp;altering
the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price; and (b)&nbsp;shortening
any Offering Period so that the Offering Period ends on a new Purchase Date, including an Offering Period underway at the time of the
Administrator&rsquo;s action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">11.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Amendment Under Certain Circumstances</U>. Unless determined otherwise by the Administrator, no amendment described in this Section&nbsp;11
shall be authorized to the extent that such amendment would cause this Plan to fail to satisfy the requirements of Section&nbsp;423 of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>GENERAL
PROVISIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shareholder
Rights</U>. With respect to Shares subject to a right granted under this Plan, a Participant shall not be deemed to be a Shareholder,
and the Participant shall not have any of the rights or privileges of a Shareholder, until Shares have been issued to the Participant
or the Participant&rsquo;s nominee following exercise of the Participant&rsquo;s rights under this Plan. No adjustments shall be made
for dividends (ordinary or extraordinary, whether in cash securities or other property) or distribution or other rights for which the
record date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator.
Shares acquired under this Plan shall be subject to the Company&rsquo;s Insider Trading Policy to the extent applicable to a Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restriction
upon Assignment</U>. A right granted under this Plan shall not be transferable other than by will or the Applicable Laws of descent and
distribution and is exercisable during the Participant&rsquo;s lifetime only by the Participant. Except in the case of a Participant&rsquo;s
death, a right under this Plan may not be exercised to any extent except by the Participant. The Company shall not recognize and shall
be under no duty to recognize any assignment or alienation of the Participant&rsquo;s interest in this Plan, the Participant&rsquo;s rights
under this Plan or any rights thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interest</U>.
No interest shall accrue on the payroll deductions or contributions of a Participant under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Equal
Rights and Privileges</U>. All Eligible Employees shall have equal rights and privileges under this Plan to the extent necessary so that
this Plan qualifies as an &ldquo;employee stock purchase plan&rdquo; within the meaning of Section&nbsp;423 of the Code. Any provision
of this Plan that is inconsistent with the equal rights and privileges requirement of Section&nbsp;423 of the Code will, without further
act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement
of Section&nbsp;423 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Use
of Funds</U>. All payroll deductions received or held by the Company under this Plan may be used by the Company for any corporate purpose,
and the Company shall not be obligated to segregate such payroll deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
of Disposition of Shares</U>. Each Participant shall give prompt notice to the Company of any disposition or other transfer of any Shares
purchased upon exercise of a right under this Plan if such disposition or transfer is made: (a)&nbsp;within two years from the Enrollment
Date of the Offering Period in which the Shares were purchased or (b)&nbsp;within one year after the Purchase Date on which such Shares
were purchased. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property,
assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Employment or other Service Rights</U>. Nothing in this Plan or any instrument executed or right granted pursuant thereto shall confer
upon any Participant any right to continue to serve the Company Group or shall affect the right of the Company Group to terminate (a)&nbsp;the
employment of an Employee with or without notice and with or without cause, (b)&nbsp;the service of a Consultant pursuant to the terms
of such Consultant&rsquo;s agreement with the Company Group or (c)&nbsp;the service of a Director pursuant to the Certificate of Formation
or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which a Company Group member is incorporated, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Rights</U>. No person shall have any claim to be granted any right pursuant to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withholding
Obligations</U>. At the time a Participant&rsquo;s rights under this Plan are exercised, in whole or in part, or at the time some or all
of the Shares issued under this Plan are disposed of, the Participant must make adequate provision for the Company&rsquo;s federal, state
or other tax withholding obligations, if any, that arise upon the exercise of the right or the disposition of the Shares. At any time,
the Company may, but shall not be obligated to, withhold from the Participant&rsquo;s compensation or Shares received pursuant to this
Plan the amount necessary for the Company to meet applicable withholding obligations, including any withholding required to make available
to the Company any tax deductions or benefits attributable to sale or early disposition of Shares by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Compensation Arrangements</U>. Nothing contained in this Plan shall prevent the Administrator from adopting other or additional compensation
arrangements, subject to Shareholder approval if such approval is required; and such arrangements may be either generally applicable or
applicable only in specific cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery</U>.
Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period
of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days
shall be considered a reasonable period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Recoupment
Provisions</U>. Any rights granted under this Plan shall be subject to any clawback or recoupment policies and procedures that are required
under Applicable Laws or any Company Group policy as enacted, adopted or modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Paperless
Administration</U>. In the event that the Company establishes, for itself or using the services of a third party, an automated system
for the documentation, granting or exercise of rights, such as a system using an internet website or interactive voice response, then
the paperless documentation, granting or exercise of rights by a Participant may be permitted through the use of such an automated system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Unfunded
Status</U>. This Plan is intended to be an &ldquo;unfunded&rdquo; plan for incentive compensation. With respect to any payments not yet
made to a Participant pursuant to a right, nothing contained in this Plan shall give the Participant any rights that are greater than
those of a general creditor of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses</U>.
The expenses of administering this Plan shall be borne by the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been
duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any provision of this Plan is, or becomes, or is deemed to be invalid, illegal or unenforceable in any jurisdiction or as to any Participant,
or would disqualify this Plan under any law deemed applicable by the Administrator, such provision shall be construed or deemed amended
to conform to the Applicable Laws, or if it cannot be construed or deemed amended without, in the determination of the Administrator,
materially altering the intent of this Plan, such provision shall be stricken as to such jurisdiction or Participant and the remainder
of this Plan shall remain in full force and effect; <I>provided</I>, <I>however</I>, that no such construction, deemed amendment or striking
of a provision of this Plan shall cause this Plan to no longer comply with Section&nbsp;423 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation</U>.
The definitions of terms in this Plan shall apply equally to the singular and plural forms of the terms defined. Whenever the context
may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The use of the words &ldquo;and&rdquo;
and &ldquo;or&rdquo; can mean both &ldquo;and&rdquo; and &ldquo;or&rdquo; where such construction would be applicable. The words &ldquo;include,&rdquo;
 &ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation.&rdquo; The
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall.&rdquo; Section&nbsp;headings
are included for convenience of reference only and shall not affect the interpretation of this Plan, and all references to Sections shall
be construed to refer to Sections of this Plan. Unless the context requires otherwise, (a)&nbsp;any definition of or reference to any
document shall be construed as referring to such document as from time to time amended, supplemented or otherwise modified, (b)&nbsp;any
reference to any Person shall be construed to include such Person&rsquo;s successors and assigns, and (c)&nbsp;any reference to any Applicable
Laws shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>EFFECTIVE
DATE OF PLAN</B>. This Plan shall become effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>TERMINATION
OR SUSPENSION OF THIS PLAN</B>. This Plan will continue in effect until terminated by the Directors pursuant to Section&nbsp;11.1. No
rights shall be granted pursuant to this Plan after such date, but rights theretofore granted may extend beyond that date. No rights may
be granted under this Plan while this Plan is suspended or after it is terminated. Upon termination of this Plan, the balance in each
Participant&rsquo;s account shall be refunded as soon as practicable after such termination, without any interest thereon, or then effective
Offering Period may be shortened so that the purchase of Shares occurs prior to the termination of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>CHOICE
OF LAW; WAIVER OF JURY TRIAL</B>. The laws of the State of Texas shall govern all questions concerning the construction, validity and
interpretation of this Plan. <B>BY PARTICIPATING IN THIS PLAN, EACH PARTICIPANT IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS PLAN.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"> </P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>23
<FILENAME>tm2415719d15_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;10.7</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(&ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of February&nbsp;1, 2010 (the &ldquo;<B><I>Effective Date</I></B>&rdquo;), is made between
Caris Life Sciences,&nbsp;Inc., a Delaware Corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and David Spetzler (the &ldquo;<B><I>Employee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RECITALS</U></B></FONT><B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company is engaged in the business of providing diagnostics products and services, including, without limitation, pathology and work flow
solutions, tissue banking and diagnostics and analysis, molecular diagnostics, lab services and other related services and products to
pharmaceutical companies, physicians, health care providers and others throughout the United States (which, together with any other business
in which the Company engages is hereinafter referred to collectively as the &ldquo;<B><I>Business</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company and the Employee desire to enter into this Agreement to govern the employment relationship between them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, in consideration
of the foregoing Recitals (which are hereby incorporated by reference), the agreements hereafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;I.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
EMPLOYMENT AND ACCEPTANCE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Employment
by the Company</B>. The Company hereby agrees to employ the Employee for a <U>three (3)&nbsp;year term</U> (the &ldquo;<B><I>Term</I></B>&rdquo;)
commencing on the Effective Date, and expiring <U>three (3)&nbsp;years</U> from the Effective Date. During the Term, the Employee shall
serve in the capacity of Senior Scientist subject to the direction of the Senior Vice President, Group Head, Research and Molecular Diagnostics
or their designee. Upon expiration of the Term this Agreement will automatically renew for successive one (1)&nbsp;year periods unless
terminated in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Duties
and Responsibilities</B>. During the Term, the Employee shall devote the Employee&rsquo;s best efforts and all of the Employee&rsquo;s
business time and services to the Company, its affiliates and subsidiaries, and shall carry out all Company policies and directives in
a manner which will promote and develop the Company&rsquo;s best interests. The Employee shall have the duties and authority assigned
to the Employee by the Senior Vice President, Group Head, Research and Molecular Diagnostics, and as set forth in the Company&rsquo;s
Bylaws, policies and procedures from time to time in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Company
Representations and Warranties</B>. The Company represents and warrants that (i)&nbsp;it has full authority to enter into this Agreement,
and (ii)&nbsp;that it is not restricted in any manner from employing the Employee under the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Acceptance
of Employment by the Employee</B>. The Employee hereby accepts such employment and represents and warrants that (i)&nbsp;the Employee
has full authority to enter into this Agreement. (ii)&nbsp;the Employee is not restricted in any manner from providing services hereunder
or from engaging in the Business and (iii)&nbsp;the Employee is not aware of any situation creating a conflict of interest between the
Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;II.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
COMPENSATION AND OTHER BENEFITS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Annual
Salary</B>. The Company shall pay the Employee a salary at the rate of $102,000 per year of employment hereunder (the &ldquo;<B><I>Annual
Salary</I></B>&rdquo;). The Annual Salary shall be payable in accordance with the payroll policies of the Company as from time to time
in effect (but no less often than monthly), less such deductions as shall be required to be withheld by applicable law and regulations.
The Senior Vice President, Group Head, Research and Molecular Diagnostics shall review the Employee&rsquo;s performance each year this
Agreement is in effect and decide whether to increase the Employee&rsquo;s Annual Salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Annual
Bonus</B>. In addition to the Annual Salary, the Company may award a bonus to the Employee following the end of each fiscal year during
the Term based on the Company&rsquo;s audited financial performance for the fiscal year as well as the Employee&rsquo;s individual contribution
to the Company. The performance criteria used to calculate the bonus shall be determined by the Chief Financial Officer and communicated
to the Employee in writing within thirty (30) days of December&nbsp;1st preceding each year and will be established with a targeted prorated
bonus of 20% of Annual Salary. Any annual bonus payable will be subject to the approval of the Board and shall be paid in accordance with
the Company&rsquo;s normal payroll policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Stock
Options and Other Equity Incentives</B>. Subject to approval by the Board of Directors, the Company shall grant to Employee stock options
with an exercise price as determined by the Board of Directors. All such options shall be granted pursuant to the terms of the Caris Life
Sciences,&nbsp;Inc.&rsquo;s 2007 Incentive Stock Plan and an option agreement. In addition, the Company may, in its sole discretion, from
time to time grant stock options or other equity based incentives to Employee. Employee shall have the right to exercise any vested options
in accordance with the time periods set forth in the Caris Life Sciences,&nbsp;Inc.&rsquo;s 2007 Incentive Stock Plan and the applicable
option agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Vacation
Policy</B>. The Employee shall be entitled to paid time off in accordance with the Company&rsquo;s PTO Accrual Plan as set forth in the
Company&rsquo;s Employee Benefits Summary, dated March&nbsp;2005, a copy of which has been provided to the Employee, as such PTO Accrual
Plan may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Participation
in Employee Benefit Plans</B>. At the Employee&rsquo;s option, the Company agrees to permit the Employee during the Term, if and to the
extent eligible, to participate in any group life, health care or group disability insurance plan, pension plan, similar benefit plan
or other so-called &ldquo;fringe benefits&rdquo; of the Company (collectively &ldquo;<B><I>Benefits</I></B>&rdquo;) which may be made
generally available to other employees of the Company and on such terms as the Benefits are made generally available to such employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Expenses</B>.
The Company shall pay or reimburse the Employee for all business expenses reasonably and necessarily incurred by the Employee during the
Term in the performance of the Employee&rsquo;s services under this Agreement, in each case in accordance with Company policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;III.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
RESTRICTIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Nondisclosure
of Confidential Information</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Recognition
of Company Rights; Nondisclosure</U>. For so long as Employee is employed by the Company (whether during the term of this Agreement or
after its expiration, the &ldquo;<B><I>Employment</I></B>&rdquo;), Employee will have access to Confidential Information, including Confidential
Information Employee has not accessed prior to the date of this Agreement. Employee recognizes that the Company&rsquo;s business interests
require the fullest practical protection and confidential treatment of the Confidential Information. At all time during the Employment
and thereafter, Employee will hold in strictest confidence and will not disclose, use, provide access to, or publish any Confidential
Information, except as such disclosure, use or publication may be required in connection with Employee&rsquo;s services for the Company.
Employee agrees that all Confidential Information, whether prepared by Employee or otherwise coming into Employee&rsquo;s possession,
shall remain the exclusive property of the Company during Employee&rsquo;s employment with the Company. Employee will obtain the Company&rsquo;s
written approval before publishing or submitting for publication any material (written, oral, or otherwise) that relates to Employee&rsquo;s
work at the Company, any Confidential Information and/or any material that incorporates any Confidential Information. Employee hereby
assigns to the Company any rights Employee may have or acquire in such Confidential Information and recognizes that all Confidential Information
is the sole property of the Company and its assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Confidential
Information</U>. &ldquo;<B><I>Confidential Information</I></B>&rdquo; means all information, not generally known within the relevant trade
group or by the public, including all Work Product (as defined below), intellectual property, business plans, training materials, software
programs, promotional materials, illustrations, designs, plans, data bases, sources of supply, customer lists, supplier lists, trade secrets,
and all other valuable or unique information and techniques acquired, developed or used by the Company relating to its business, operations,
suppliers, information systems, employees and customers, regardless of whether such information is in writing, on computer disk or disk
drive or in any other form. Employee expressly acknowledges and agrees that Confidential Information constitutes trade secrets and/or
confidential and proprietary business information of the Company (or its subsidiary, or its customers or suppliers, as the case may be).
Confidential Information shall not include information which is or becomes generally available to the public other than through disclosure
by Employee or by any other person or entity under a duty or obligation to maintain the confidentiality thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Improper Use of Information of Prior Employers and Others</U>. During the Employment, Employee shall not improperly use or disclose any
confidential information or-trade secrets, if any, of any former employer or any other person to whom Employee has an obligation of confidentiality,
and Employee will not bring onto the premises, or make available to any employees of the Company, any unpublished documents or any property
belonging to any former employer or any other person to whom Employee has an obligation of confidentiality unless consented to in writing
by the former employer or person. In the performance of Employee&rsquo;s duties for the Company, Employee will only use information which
is (i)&nbsp;generally known and used by persons and expertise comparable to that of Employee, (ii)&nbsp;common knowledge in the industry
or otherwise legally in the public domain, or (iii)&nbsp;otherwise provided or developed by the Company. Employee acknowledges that the
Company has expressly informed Employee that the Company does not want any access, privilege, benefit or knowledge of such confidential
or proprietary information of others. Employee represents and warrants that to Employee&rsquo;s knowledge Employee has no obligations,
legal, in contract, or otherwise, inconsistent with the terms of this Agreement or with Employee&rsquo;s undertaking employment with the
Company to perform the duties described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Penalties
for Violation of Non-Disclosure Policy</U>. In addition to the legal and equitable remedies set forth herein by applicable law, Employee
understands that violation of any non-disclosure provision of this Agreement shall be subject to discipline, up to and including discharge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Assignment
of Work Product</B>. Any information or innovations, including, but not limited to, inventions, improvements, methods, technology, programs,
customer lists, reports, distribution records, brochures, instructions, manuals, processes,&nbsp;etc., which are, during the course of
the Employment, conceived, developed, or improved upon by Employee for use by the Company or any of its subsidiaries, alone or in conjunction
with other employees or consultants (collectively, the &ldquo;<B><I>Work Product</I></B>&rdquo;), shall be the exclusive property of the
Company, and during the Employment and at all times thereafter, Employee shall not use, duplicate, reveal or take with Employee any such
Work Product or other materials of the Company, other than in furtherance of the performance of his duties to the Company, whether under
this Agreement or otherwise. To the extent that any of the Work Product is capable of protection by copyright as a &ldquo;work made for
hire&rdquo; pursuant to the United States Copyright Act, Employee acknowledges that such Work Product is created within the scope of his
Employment and, as such, is property of the Company. To the extent that any such Work Product, whether protected by copyright or otherwise,
is not a &ldquo;work made for hire,&rdquo; Employee hereby assigns to the Company all rights in such material. Employee hereby agrees
to execute any documents at any time reasonably required by the Company in connection with the registration of copyright, patent application
or other perfection of the Company&rsquo;s ownership of the Work Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Covenant
Not to Compete</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Business
Relationships and Goodwill</U>. Employee acknowledges and agrees that as an employee and representative of the Company, Employee is responsible
for building and maintaining business relationships and goodwill with current and future physicians, customers, payors, patients and prospects
on a personal level. Employee acknowledges and agrees that such responsibility creates a special relationship of trust and confidence
between the Company, Employee, and those persons or entities. Employee further acknowledges that such responsibility creates a high risk
and opportunity for Employee to misappropriate these relationships and the goodwill existing between the Company and such persons. Employee
acknowledges and agrees that it is fair and reasonable for the Company to take steps to protect itself from the risk of such misappropriation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consideration</U>.
Employee acknowledges and agrees that in exchange for its agreement in <U>Section&nbsp;3.3(c)</U>&nbsp;below, Employee will receive substantial
and valuable consideration from the Company including, but not limited to (i)&nbsp;Confidential Information (defined below), (ii)&nbsp;compensation
and other benefits, and (iii)&nbsp;exposure to the Company&rsquo;s physicians, payors, customers, patients, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Scope
of Noncompetition Obligation</U>. During the Employment, and for a period of two (2)&nbsp;years after the termination of the Employment
for any reason, Employee shall not, directly or indirectly, either acting alone, or as a stockholder, partner, associate, creditor, consultant,
adviser, franchiser, franchisee, director, officer, owner, employee or agent of any other person or entity, or in any other capacity,
engage in or provide managed care services of any kind to a company engaged in the Same Business (as defined below) in the Territory (as
defined below); <I>provided</I>, <I>however</I>, the restriction contained in this <U>Section&nbsp;3.3</U> shall not prohibit Employee
from owning not more than 1% of the outstanding stock of any class of any publicly traded corporation, so long as Employee does not actively
participate in the business of such corporation. For purposes of this section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">the term &ldquo;<B><I>Same Business</I></B>&rdquo; shall mean any company that engages or proposes to
engage in the Business; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the term &ldquo;<B><I>Territory</I></B>&rdquo; shall be defined as the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Prohibition on Working</U>. Employee acknowledges and agrees that this Agreement does not restrict Employee&rsquo;s ability to find employment
within any geographical area after the termination of the Employment; <I>provided</I> that Employee is not employed in violation of the
noncompetition obligations detailed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Nonsolicitation
of Customers</B>. Employee agrees that Employee shall not at any time during the Employment, whether or not initiated by Employee, divert
away or attempt to divert away any business from the Company to another company, business, or individual. Further, Employee shall not,
for a period of two (2)&nbsp;years following the termination of the Employment for any reason, contact, solicit, attempt to solicit or
divert, or attempt to divert business from, either directly or indirectly, any Company Customer. &ldquo;<B><I>Company Customer</I></B>&rdquo;
means any person, company, or business that is or was a customer or prospective customer of Company, including but not limited to physicians,
payors or other customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Nonrecruitment
of Employees</B>. Employee agrees that during the Employment and for a period of two (2)&nbsp;years after termination of the Employment
for any reason, Employee shall not, on Employee&rsquo;s own behalf or on behalf of any other person or entity, hire, solicit, seek to
hire, or offer employment to any person who was employed by the Company on the date of termination of the Employment, or who is a current
employee of the Company. Employee further agrees that Employee will not, in any other manner attempt, directly or indirectly, to influence,
induce, or encourage any person who was employed by the Company on the date of termination of the Employment or who is a current or prospective
employee of the Company to leave the employment of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Non-Interference
with Business Relations</B>. Employee agrees that during the Employment, and for a period of two (2)&nbsp;years after the termination
of the Employment for any reason, Employee shall not, directly or indirectly, (a)&nbsp;solicit, advise, persuade or otherwise induce any
person to participate in or with any entity or person which provides services comparable to those provided by the Company or by facilities
managed or owned by the Company or any of its subsidiaries, (b)&nbsp;do anything, intentionally or recklessly, to discredit or otherwise
injure the reputation or goodwill of the Company or any of its affiliates or subsidiaries, (c)&nbsp;solicit, induce or attempt to solicit
or induce any customer, employee, independent contractor, distributor, manufacturer or other professional or any other business relation
of the Company (or any subsidiary) to cease or reduce the level of business between such business relation and the Company (or any subsidiary),
or (d)&nbsp;in any way interfere with the Company&rsquo;s (or any subsidiary&rsquo;s) relationship with any customer, employee, independent
contractor, distributor, manufacturer or other professional or business relation of the Company or subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Reasonableness
of Restrictions</B>. Employee acknowledges and agrees that, given the nature of the Business, and the Company&rsquo;s proposed Business
plans, the restrictions imposed upon Employee by this ARTICLE&nbsp;III and the purposes for such restrictions are reasonable and are designed
to protect the trade secrets, confidential and proprietary business information and the future success of the Company and its subsidiaries
without unduly restricting Employee. Specifically, Employee acknowledges that the restrictions and covenants contained in this ARTICLE&nbsp;III
will not prohibit Employee from pursuing Employee&rsquo;s career upon termination of Employee&rsquo;s employment relationship with the
Company. If, at the time of enforcement of this Agreement, a court shall hold that any of the duration, scope or geographic restrictions
stated herein are unreasonable under circumstances then existing, the parties agree (and shall stipulate, if necessary, in an appropriate
pleading) that the maximum duration, scope or geographic area reasonable under such circumstances shall be substituted for the stated
duration, scope or geographic area. Employee further agrees not to challenge the enforceability or the enforcement of the restrictive
covenants in this ARTICLE&nbsp;III. Employee specifically recognizes and affirms that the restrictive covenants contained in this ARTICLE&nbsp;III
are material and important terms of this Agreement, and Employee further agrees that should all or any part or application of any provision
of this ARTICLE&nbsp;III be held or found invalid or unenforceable for any reason whatsoever by a court of competent jurisdiction in an
action, or by an arbitrator in an arbitration, the Company shall be entitled to receive from employee all stock options and Company stock
held by Employee obtained as result of the stock options being granted to Employee on the date hereof. If Employee has sold, transferred,
or otherwise disposed of company stock obtained through the exercise of such stock options, the Company shall be entitled to receive from
Employee the difference between the option price paid by Employee and the fair market value of such Company stock on the date of sale,
transfer, or other disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Severability</B>.
Employee agrees that the non-disclosure, non-competition, and non-solicitation covenants set forth herein each constitute separate agreements
independently supported by good and adequate consideration. If a court of competent jurisdiction determines that any restriction in a
clause or provision of this ARTICLE&nbsp;III is void, illegal, or unenforceable, the other clauses and provisions of this ARTICLE&nbsp;III
shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Return
of the Company Property</B>. When Employee&rsquo;s Employment terminates for any reason, Employee will promptly (within twenty-four (24)
hours) deliver to the Company any and all Confidential Information, drawings, notes, memoranda, specifications, devices, formulas and
documents, together with all copies thereof and any other material containing or disclosing any works made for hire, or third party information.
Employee further agrees that any property situated on the Company&rsquo;s premises and owned by the Company including computers, computer
disks and computer hard disk drives and other computer storage media, filing cabinets or other work areas, is subject to inspection by
the Company personnel at anytime with or without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Notification
of New Employer</B>. In the event that the Employment is terminated for any reason, Employee hereby consents to the notification by the
Company to Employee&rsquo;s new employer of Employee&rsquo;s rights and obligations under this ARTICLE&nbsp;III. In addition, in the event
that Employee plans to render services to a company that works in a similar field as the Company, Employee agrees to provide the Company
with as much notice as possible of Employee&rsquo;s intention to join that company or business but in no event will Employee provide less
than two weeks notice of that intention; <I>provided</I>, <I>however</I>, the provision of such notice and the Company&rsquo;s receipt
thereof shall not constitute a waiver of any breach of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Equitable
and Other Relief</B>. Employee understands and agrees that, in the event Employee breaches this ARTICLE&nbsp;III, the Company will suffer
immediate and irreparable harm that cannot be accurately calculated in monetary damages. Consequently, Employee acknowledges and agrees
that the Company shall be entitled to immediate injunctive relief, either by temporary or permanent injunction, to prevent such violation.
Employee acknowledges and agrees that such injunctive relief shall be in addition to any other legal or equitable relief to which the
Company would be entitled. In addition, the Company shall be entitled to recover its attorneys&rsquo; fees and costs from Employee should
the Company be required to file suit to enforce its rights under this ARTICLE&nbsp;III, if the Company prevails in such suit. In the event
that Employee is found to have breached all or any part or application of any provision of this ARTICLE&nbsp;III by a court of competent
jurisdiction in an action, or by an arbitrator in an arbitration, Employee further agrees that the Company shall be entitled to receive
from Employee all stock options and Company stock held by Employee obtained as result of the stock options being granted to Employee on
the Effective Date; <I>provided</I> that the Company agrees to pay Employee an amount equal to the exercise price of any such options.
If Employee has sold, transferred, or otherwise disposed of Company stock obtained through the exercise of such stock options, the Company
shall be entitled to receive from Employee the difference between the option price paid by Employee and the fair market value of the Company
stock on the date of sale, transfer, or other disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;IV.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Upon
Death or Disability</B>. This Agreement shall terminate upon the Employee&rsquo;s death or Disability. For purposes of this Agreement,
 &ldquo;<B><I>Disability</I></B>&rdquo; shall mean physical or mental disability of the Employee resulting in the Employee&rsquo;s inability
to perform substantially all of the essential functions of the Employee&rsquo;s duties and responsibilities with the Company for (i)&nbsp;a
period of twelve (12) consecutive weeks, or (ii)&nbsp;for shorter periods aggregating twelve (12) weeks during any twelve-month period.
If this Agreement terminates as a result of the Employee&rsquo;s death or Disability, the Company&rsquo;s obligation to the Employee or
the Employee&rsquo;s estate shall be limited to the payment of accrued and unpaid Annual Salary earned and any accrued and unpaid Benefits
vested up to the date of termination, and in the event of Disability, any disability benefits to which the Employee is entitled hereunder.
In addition, upon termination due to death or Disability, the Company shall pay the Employee or the Employee&rsquo;s estate any annual
bonus referred to in <U>Section&nbsp;2.2</U> above that would otherwise be due for the fiscal year of termination, prorated to the number
of days in the fiscal year for which the Employee was employed, and payable at the same time as the bonus would have otherwise been due
had the Employee&rsquo;s employment not been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Termination
for Cause or Voluntary Termination</B>. If the Company terminates the Employee at any time for Cause or if the Employee terminates the
Employee&rsquo;s employment at any time other than for Good Reason, the Company&rsquo;s obligation to the Employee shall be limited solely
to the payment of accrued and unpaid Annual Salary and any accrued but unpaid Benefits vested earned up to the date of termination. As
used in this Agreement, the term &ldquo;<B><I>Cause</I></B>&rdquo; shall mean any of the following: (i)&nbsp;the Employee&rsquo;s commission
of an act involving dishonesty, lack of loyalty or breach of fiduciary responsibility involving the Company or any affiliate or successor
thereof, (ii)&nbsp;failure of the Employee to perform the Employee&rsquo;s duties and responsibilities, which has not been corrected by
the Employee within thirty (30) days after the Employee&rsquo;s receipt of a written notice from the Senior Vice President, Group Head,
Research and Molecular Diagnostics specifying such failure in reasonable detail, (iii)&nbsp;any material breach by the Employee of the
terms of this Agreement, which has not been corrected, if correctable, by the Employee within thirty (30) days after the Employee&rsquo;s
receipt of a written notice from the Senior Vice President, Group Head, Research and Molecular Diagnostics specifying such breach in reasonable
detail, (iv)&nbsp;commission of a misdemeanor which causes material injury to the business, reputation or financial condition of the Company,
(v)&nbsp;commission of a felony or (vi)&nbsp;commission of an act which a majority of the Board determines to constitute insubordination.
As used in this Agreement, the term &ldquo;<B><I>Good Reason</I></B>&rdquo; shall mean the voluntary termination of employment by the
Employee with the Company within sixty (60) days after the occurrence of any of the following events, without the Employee&rsquo;s express
written consent: (i)&nbsp;the reduction of the Employee&rsquo;s Annual Salary, or (ii)&nbsp;any material breach by the Company of the
terms of this Agreement which has not been corrected by the Company within thirty (30) days after the Company&rsquo;s receipt of written
notice from the Employee of such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Termination
Without Cause or for Good Reason</B>. If the Company terminates the Employee at any time without Cause or if Employee terminates for good
reason, the Company shall be obligated to (i)&nbsp;pay the Employee any accrued and unpaid Benefits vested up to the date of termination,
(ii)&nbsp;pay the Employee a lump sum equal to one (1)&nbsp;month of the Employee&rsquo;s then current Annual Salary, and (iii)&nbsp;pay
the Employee any annual bonus referred to in <U>Section&nbsp;2.2</U> above that would otherwise be due for the fiscal year of termination,
prorated to the number of days in the fiscal year for which the Employee was employed, and payable at the same time as the bonus would
have otherwise been due had the Employee&rsquo;s employment not been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;V.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
MISCELLANEOUS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Notices</B>.
Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by nationally-recognized
overnight delivery service or sent by certified or registered mail, postage prepaid, return receipt requested, address as set forth below;
receipt shall be deemed to occur on the earlier of the date of actual receipt or receipt by the sender of confirmation that the delivery
was completed or that the addressee has refused to accept such delivery or has changed its address without giving notice of such change
as set forth herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if to the Company, to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caris Diagnostics,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8400 Esters Boulevard, Suite&nbsp;190</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irving, TX 75063</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if to the Employee, to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Spetzler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Either party may change its address for notice
hereunder by notice to the other party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Entire
Agreement</B>. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supercedes
all prior discussions and agreements, written or oral, with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Waivers
and Amendments</B>. This Agreement may be amended, suspended, cancelled, renewed or extended, and the terms and conditions hereof may
be waived, only by a written instrument signed by both parties or, in the case of a waiver, by the party waiving compliance. No delay
on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof. Nor shall any waiver
on the part of any party of any such right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege
hereunder, preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Assignment</B>.
This Agreement shall inure to the benefit of and shall be binding upon the Employee and the Employee&rsquo;s executor, administrator,
heirs, personal representative and assigns, and the Company and its successors and assigns; <I>provided</I>, <I>however</I>, that the
Employee shall not be entitled to assign any of the Employee&rsquo;s rights or delegate any of the Employee&rsquo;s duties under this
Agreement. The Employee agrees that this Agreement may be freely assigned by the Company to any person or entity which succeeds to all
or any significant portion of the Company&rsquo;s assets or Business, whether pursuant to a sale of assets, sale of stock, merger or other
similar transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Severability:
Construction</B>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held by a count of competent jurisdiction to be prohibited by or invalid
under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. Use of the word &ldquo;including&rdquo; shall not be limited by the terms following such word. All references
to singular or plural terms shall mean the other where appropriate. The term &ldquo;<B><I>subsidiary</I></B>&rdquo; shall refer to subsidiaries
of the Company now existing or hereafter formed or acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Choice
of Law</B>. This Agreement shall be governed by, and construed in accordance with the internal laws (as opposed to conflict of laws provisions)
of the State of Arizona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Headings</B>.
The section and subsection headings contained in this Agreement are for reference purposes only and shall not effect in any way the meaning
or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Counterparts</B>.
This Agreement may be executed in separate counterparts, each of which when executed and delivered shall be deemed an original, but all
of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Indemnification</B>.
The Employee shall be entitled to the full benefit of any and all indemnification provisions contained in the Company&rsquo;s Certificate
of Incorporation as amended from time to time, and/or Bylaws, and the Company shall provide indemnification to the Employee to the same
extent as it indemnifies any other officer or director of the Company. Irrespective of the provisions in the Company&rsquo;s Certificate
of Incorporation as amended from time to time, or Bylaws, the Company shall indemnify the Employee to the fullest extent provided under
Section&nbsp;145 of the Delaware General Corporation Law, including but not limited to advancement of expenses to the fullest extent provided
by such statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Dispute
Resolution</B>. Except as provided below, in the event of any dispute, claim or disagreement arising out of or in connection with this
Agreement, including, without limitation, the negotiation, execution, interpretation, performance or non-performance of this Agreement,
the parties shall first submit the dispute, claim or disagreement to non-binding mediation administered by the American Arbitration Association
(the &ldquo;<B><I>AAA</I></B>&rdquo;) in accordance with its Employment Mediation Rules. The place of mediation shall be Phoenix, Arizona.
If the dispute, claim or disagreement is not resolved within 30 days after the initial mediation meeting among the parties and the mediator,
or if the mediation is otherwise terminated, then either party may submit the dispute, claim or disagreement to binding arbitration administered
by the AAA in accordance with the provisions of its Employment Arbitration Rules&nbsp;(the &ldquo;<B><I>Rules</I></B>&rdquo;) and, except
as otherwise provided in this Agreement, such arbitration shall be the sole means of dispute resolution. The place of arbitration shall
be Phoenix, Arizona. The arbitration shall be conducted by a panel of three arbitrators selected in accordance with the Rules, unless
the parties otherwise agree to one arbitrator. Any mediator or arbitrator selected under this <U>Section&nbsp;5.10</U> shall be a practicing
attorney experienced in employment agreements and acquisitions and shall not have been employed or engaged by or affiliated with either
of the parties or their respective affiliates. Each party shall initially bear its own costs and expenses in connection with any mediation
or arbitration hereunder, including, without limitation, its attorneys&rsquo; fees, and an equal share of the mediator&rsquo;s or arbitrator&rsquo;s
and administrative fees of mediation or arbitration. The decision of the arbitrators shall be in writing and shall state the reasons therefore.
Judgment upon an arbitration award may be entered in any court of competent jurisdiction and shall be final, binding and non-appealable.
Notwithstanding anything in this <U>Section&nbsp;5.10</U> to the contrary, each party shall be entitled to seek injunctive or other equitable
relief in any court of competent jurisdiction without first submitting the matter to mediation or arbitration in accordance with the provisions
of this <U>Section&nbsp;5.10</U>, even if a similar or related matter has already been referred to meditation or arbitration in accordance
with the terms of this <U>Section&nbsp;5.10</U>. Venue for any action permitted to be brought in court under this <U>Section&nbsp;5.10</U>
shall be the appropriate state and federal courts located in Maricopa County, Arizona.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Representation</B>.
The Employee has consulted with and relied upon independent legal counsel in determining whether to sign this Agreement, and has not relied
upon the company nor the company&rsquo;s counsel to represent the Employee&rsquo;s interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<B>SIGNATURE PAGE FOLLOWS</B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon execution of this Agreement
and thereafter, Company covenants and agrees that it shall provide Employee with Confidential Information as defined herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Laura I. Johansen</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Laura I. Johansen</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Vice Chairman</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EMPLOYEE:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ David Spetzler</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">David Spetzler</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>24
<FILENAME>tm2415719d15_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;10.8</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FIRST AMENDMENT<BR>
TO<BR>
EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS FIRST AMENDMENT TO EMPLOYMENT
AGREEMENT, dated as of July&nbsp;27, 2015 (the &ldquo;Amendment&rdquo;), to the Employment Agreement, effective February&nbsp;1, 2010
(the &ldquo;Agreement&rdquo;) is entered into by and between Caris Science,&nbsp;Inc (the &ldquo;Company&rdquo;), and David Spetzler (&ldquo;Employee&rdquo;).
Caris and Employee are sometimes referred to individually as a &ldquo;Party&rdquo; or collectively as the &ldquo;Parties&rdquo;. Terms
not otherwise defined herein shall have the meaning described to them in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
the parties hereto desire to amend the certain terms of the Agreement as hereinafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
except as amended by the provisions of this Amendment, the terms and provisions contained in the Agreement shall continue to govern the
rights and obligations of the parties, and all provisions and covenants in the Agreement shall remain in full force and effect as stated
therein. In the event of any conflict between the terms of this Amendment and the Agreement, the terms of the Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B></FONT>, in consideration of the mutual representations, warranties, covenants, and agreements contained in the Agreement
and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Recital A, including the definition of &ldquo;Business&rdquo; is hereby deleted in its entirety and
replaced with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is engaged in the business of providing diagnostic, therapy guidance, therapeutic products and services, including, without limitation,
pathology and work flow solutions, tissue banking, data aggregation and analytics, disease diagnostics and analysis, molecular diagnostics,
lab services, basic and developmental research, biomarker or target discovery, commercial development of related products or services,
marketing, sale and commercialization that is: (i)&nbsp;directly or indirectly based on, connected with, or relating to lipid encapsulated
bodies including intracellular or extracellular microvesicles or exosomes, (ii)&nbsp;directly or indirectly involved or based on use,
interrogation, analysis, assessment or preparation of a human sample comprised of blood, urine, saliva or other bodily fluids or any component
thereof for use in clinical assessment relating to cancer or other disease; (iii)&nbsp;directly or indirectly utilizes one or more libraries
comprises of oligonucleotides or oligonucleotide derivatives to assess one or more molecular components of a biological, chemical or other
system; or (iv)&nbsp;directly or indirectly involves molecular profiling of any human-derived sample or specimen and associated therapeutic
decision support for any clinical or research purpose relating to or connected with cancer (collectively and singularly, hereinafter referred
to as the &ldquo;<B><I>Business</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Section&nbsp;1.1 of the Agreement is amended to reflect that Employee now serves in the position of Chief
Scientific Officer of the Company, subject to the direction of the Chief Executive Officer or his designee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Section&nbsp;2.1 of the Agreement is hereby deleted in its entirety and replaced with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section&nbsp;2.1
Annual Salary</U></B></FONT>. The Company shall pay the Employee a salary at the rate of $320,000.00 per year of employment hereunder
(the &ldquo;<B><I>Annual Salary</I></B>&rdquo;). The Annual Salary shall be payable in accordance with the payroll policies of the Company
as from time to time in effect applicable law and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Section&nbsp;2.2 of the Agreement is hereby deleted in its entirety and replaced with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section&nbsp;2.2
Annual Bonus</U></B></FONT>. In addition to the Annual Salary, the Company may award a bonus to the Employee following the end of each
fiscal year during the Term based on the Company&rsquo;s accomplishment of business objectives and audited financial performance for the
fiscal year as well as the Employee&rsquo;s individual contribution to the Company. The performance criteria used to calculate the bonus
shall be determined by the Company and is established at a targeted level of fifty percent (50%) of Annual Salary. Any annual bonus payable
will be subject to the approval of the Board of Directors of the Company and shall be paid in accordance with the Company&rsquo;s normal
payroll policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">Section&nbsp;2.3 of the Agreement is amended to include the additional provision that long-term incentive
program vehicles such as stock options shall automatically vest, to the extent they are not vested for Employee, upon the Company experiencing
a change in control of ownership as defined in the Caris Life Sciences, LTD 2012 Incentive Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">Section&nbsp;4.3 is hereby deleted in its entirety and replaced with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section&nbsp;4.3
Termination Without Cause or for Good Reason</U></B></FONT>. If the Company terminates the Employee at any time without Cause or if Employee
terminates for Good Reason, the Company shall be obligated to (i)&nbsp;pay the Employee any accrued and unpaid Benefits vested up to the
date of termination, (ii)&nbsp;pay the Employee a lump sum equal to six (6)&nbsp;months of the Employee&rsquo;s then current Annual Salary;
(iii)&nbsp;six (6)&nbsp;months of company-paid COBRA, and (iv)&nbsp;pay the Employee any annual bonus referred to in Section&nbsp;2,2
above that would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the
Employee was employed, and payable at the same time as the bonus would have otherwise been due had the Executive&rsquo;s employment not
been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<B>SIGNATURE PAGE FOLLOWS</B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Amendment on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ David D. Halbert</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chairman&nbsp;&amp; CEO</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EMPLOYEE:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ David Spetzler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">David Spetzler, Ph.D.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>25
<FILENAME>tm2415719d15_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;10.9</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(&ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of May&nbsp;31, 2018 (the &ldquo;<B><I>Effective Date</I></B>&rdquo;), is made between
Caris Science,&nbsp;Inc., a Texas corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and Brian Brille (the &ldquo;<B><I>Executive</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and its affiliates are engaged in the business of providing diagnostics products and services, including, without limitation,
pathology and work flow solutions, tissue banking, data aggregation and analytics, disease diagnostics and analysis, molecular diagnostics,
lab services, basic and development research, biomarker or target discovery, commercial development of related products or services, marketing,
sale and commercialization that is (i)&nbsp;directly or indirectly based on, connected with, or relating to lipid encapsulated bodies
including intracellular or extracellular microvesicles or exosomes, or (ii)&nbsp;directly or indirectly involved or based on use, interrogation,
analysis, assessment or preparation of a human sample comprised of blood, urine, saliva or other bodily fluids or any component thereof
for use in clinical assessment relating to cancer or other disease, (iii)&nbsp;directly or indirectly utilizes one or more libraries comprised
of oligonucleotides or oligonucleotide derivatives to assess one or more molecular components of a biological, chemical or other system,
or (iv)&nbsp;directly or indirectly involves molecular profiling of any human-derived sample or specimen and associated therapeutic decision
support for any clinical or research purpose relating to or connected with cancer (collectively and singularly, along with any other business
in which the Company engages, is hereinafter referred to as the &ldquo;<B><I>Business</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and the Executive desire to enter into this Agreement to govern the employment relationship between them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, in consideration
of the foregoing Recitals (which are hereby incorporated by reference), the agreements hereafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;I.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
EMPLOYMENT AND ACCEPTANCE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Employment
by the Company</B>. The Company hereby agrees to employ the Executive for a <U>three (3)&nbsp;year term</U> (the &ldquo;<B><I>Term</I></B>&rdquo;)
commencing on the Effective Date, and expiring <U>three (3)&nbsp;years</U> from the Effective Date. During the Term, the Executive shall
serve in the capacity of Vice Chairman, subject to the direction of the Chief Executive Officer of the Company or his designee. Upon expiration
of the Term, the Term of this Agreement will automatically renew for successive one (1)&nbsp;year periods unless terminated in accordance
with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Duties
and Responsibilities</B>. During the Term, the Executive shall devote the Executive&rsquo;s best efforts and all of the Executive&rsquo;s
business time and services to the Company, its affiliates and subsidiaries, and shall carry out all Company policies and directives in
a manner which will promote and develop the Company&rsquo;s best interests, <I>provided</I> that Executive shall be permitted to (i)&nbsp;manage
Executive&rsquo;s personal, financial and legal affairs, (ii)&nbsp;participate in trade associations, (iii)&nbsp;serve on the board of
directors of not-for-profit or tax-exempt charitable organizations, and (iv)&nbsp;subject to approval by the Board, not to be unreasonably
withheld or delayed, serve on the board of directors or similar board of for-profit organizations (<I>provided</I> that service on the
boards of directors of up to two for-profit entities shall be deemed approved), in each case, subject to compliance with this Agreement
and <I>provided</I> that such activities do not materially interfere with Executive&rsquo;s performance of Executive&rsquo;s duties and
responsibilities hereunder. The Executive shall have the duties and authority assigned to the Executive by the Chief Executive Officer,
and as set forth in the Company&rsquo;s Bylaws, policies and procedures from time to time in force. Among other things, Executive&rsquo;s
duties and responsibilities will be to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Lead
the Company&rsquo;s Finance, Accounting, and Business Development teams, with responsibility for identifying, analyzing, and creating
strategic plans for the Company; <I>provided</I>, <I>however</I>, that Executive will not have responsibility for preparing or approving
the Company&rsquo;s financial statements, but will have a supervisory role over those responsible for such financial statements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Undertaking
and developing major strategic initiatives and joint ventures; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Assist
the Company with raising capital, mergers and acquisitions, structured deals, debt financing and business development, including resultant
work to enact, define, refine, and execute the Company&rsquo;s strategic priorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Company
Representations and Warranties</B>. The Company represents and warrants that (i)&nbsp;it has full authority to enter into this Agreement,
and (ii)&nbsp;that it is not restricted in any manner from employing the Executive under the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Acceptance
of Employment by the Executive</B>. The Executive hereby accepts such employment and represents and warrants that (i)&nbsp;the Executive
has full authority to enter into this Agreement, (ii)&nbsp;the Executive is not restricted in any manner from providing services hereunder
or from engaging in the Business and (iii)&nbsp;the Executive is not aware of any situation creating a conflict of interest between the
Executive and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive agrees to Company performing appropriate
due diligence related to his potential Employment (as defined below) and to the on-going Employment. Company may perform any and all background
checks it deems necessary and require appropriate certifications prior to employing Executive and at any time during Executive&rsquo;s
Employment. Executive acknowledges Company&rsquo;s right to perform the appropriate background checks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;II.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
COMPENSATION AND OTHER BENEFITS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Annual
Salary</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall pay the Executive a salary at the rate of $500,000.00 per year of Employment hereunder (the &ldquo;<B><I>Annual Salary</I></B>&rdquo;).
The Annual Salary shall be payable in accordance with the payroll policies of the Company as from time to time in effect (typically biweekly),
less such deductions as shall be required to be withheld by applicable law and regulations. The Chief Executive Officer shall review the
Executive&rsquo;s performance and decide whether to increase, but not decrease, the Executive&rsquo;s Annual Salary as the Company considers
pay adjustments for other executives. Within ten days of the Effective Date, the Company shall pay executive a lump sum cash payment equal
to $129,807.69. <B>[Number represents back pay owed to the Executive (50% of Annual Salary from 1/15/2018-3/31/2018 ($52,884.62), and
100% of Annual Salary from 4/1/2018-5/26/2018 ($76,923.08)).]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
accordance with the terms and conditions set out in <U>Exhibit&nbsp;A,</U> the Company shall also pay the Executive additional compensation
described in <U>Exhibit&nbsp;A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Executive
will assist Company in developing the biopharma revenues of Company. In this capacity, Executive will focus on the growth of the biopharma
customer base. Executive will be eligible to receive a &ldquo;<B>Pharma Business Development Bonus</B>&rdquo; which will be based on the
growth of the pharma business revenue. The Pharma Business Development Bonus is a one time bonus that will be paid on or prior to March&nbsp;15,
2019. The Pharma Business Development Bonus will be equal to 5% of the pharma revenue generated above the pharma revenue target for 2018
of $6,300,000. Mergers and acquisitons, joint ventures and other similar strategic alternative transactions shall be excluded from the
calculation of the pharma revenue for purposes of calculation of the Pharma Business Development Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Annual
Bonus</B>. In addition to the Annual Salary and compensation described in <U>Exhibit&nbsp;A</U>, the Company may, in its sole discretion,
award a bonus to the Executive following the end of each fiscal year during the Term based on the Company&rsquo;s audited financial performance
for the fiscal year as well as the Executive&rsquo;s individual contribution to the Company. The bonus will be established at a targeted
eligible payout rate of one hundred percent (100%) of Annual Salary. Any annual bonus payable will be subject to the approval of the Board
and shall be paid in accordance with the Company&rsquo;s normal payroll policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Stock
Options and Other Equity Incentives</B>. Subject to approval by the Board of Directors, Executive may be granted stock options or other
equity incentives at the sole discretion of the Company. All such options shall be granted pursuant to the terms of the Caris Life Sciences,&nbsp;Ltd.
2012 Incentive Stock Plan and an Option Agreement. Executive shall have the right to exercise any vested options in accordance with the
time periods set forth in the Caris Life Sciences,&nbsp;Ltd. 2012 Incentive Stock Plan and the applicable option agreement. Long-term
incentive program vehicles such as stock options shall automatically vest, to the extent they are not vested for Executive, upon the Company
experiencing a Change of Control as defined in the Caris Life Sciences, LTD 2012 Incentive Plan. Notwithstanding the foregoing, the Company
shall grant Executive 10,000,000 options pursuant to the terms of the Share Option Award Agreement attached hereto as <U>Exhibit&nbsp;B</U>
within five days of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Participation
in Employee Benefit Plans</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Executive&rsquo;s option, the Company agrees to permit the Executive during the Term, if and to the extent eligible, to participate
in any group life, health care or group disability insurance plan, pension plan, similar benefit plan or other so-called &ldquo;fringe
benefits&rdquo; of the Company (collectively &ldquo;<B><I>Benefits</I></B>&rdquo;) which may be made generally available to other executive
officers of the Company and on such terms as the Benefits are made generally available to such executive officers. This includes the ability
for Executive to take vacation and personal business time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Benefits
are effective as of February&nbsp;I, 2018. Executive will be required to pay the employee portion of the Benefits premium for the period
of February&nbsp;1, 2018 through May&nbsp;31, 2018, which may be deducted from Executive&rsquo;s first paycheck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Expenses</B>.
The Company shall pay or reimburse the Executive for all business expenses reasonably and necessarily incurred by the Executive during
the Term in the performance of the Executive&rsquo;s services under this Agreement, in each case in accordance with Company policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;III.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
RESTRICTIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Nondisclosure
of Confidential Information</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Recognition
of Company Rights: Nondisclosure</U>. For so long as Executive is employed by the Company (whether during the term of this Agreement or
after its expiration, the &ldquo;<B><I>Employment</I></B>&rdquo;), Executive will have access to Confidential Information, including Confidential
Information Executive has not accessed prior to the date of this Agreement. Executive recognizes that the Company&rsquo;s business interests
require the fullest practical protection and confidential treatment of the Confidential Information, At all time during the Employment
and thereafter, Executive will hold in strictest confidence and will not disclose, use, provide access to, or publish any Confidential
Information, except as such disclosure, use or publication may be required in connection with Executive&rsquo;s services for the Company
or required in connection with any dispute between Executive and the Company. Executive agrees that all Confidential Information, whether
prepared by Executive or otherwise coming into Executive&rsquo;s possession, shall remain the exclusive property of the Company during
Executive&rsquo;s Employment with the Company. Executive will obtain the Company&rsquo;s written approval before publishing or submitting
for publication any material (written, oral, or otherwise) that relates to Executive&rsquo;s work at the Company, any Confidential Information
and/or any material that incorporates any Confidential Information. Executive hereby assigns to the Company any rights Executive may have
or acquire in such Confidential Information and recognizes that all Confidential Information is the sole property of the Company and its
assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Confidential
Information</U>. &ldquo;<B><I>Confidential Information</I></B>&rdquo; means all information, not generally known within the relevant trade
group or by the public, including all Work Product (as defined below), intellectual property, business plans, training materials, software
programs, promotional materials, illustrations, designs, plans, data bases, sources of supply, customer lists, supplier lists, trade secrets,
and all other valuable or unique information and techniques acquired, developed or used by the Company relating to its business, operations,
suppliers, information systems, employees and customers, regardless of whether such information is in writing, on computer disk or disk
drive or in any other form. Executive expressly acknowledges and agrees that Confidential Information constitutes trade secrets and/or
confidential and proprietary business information of the Company (or its subsidiary, or its customers or suppliers, as the case may be).
Confidential Information shall not include information which is or becomes generally available to the public other than through disclosure
by Executive or by any other person or entity under a duty or obligation to maintain the confidentiality thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Improper Use of Information of Prior Employers and Others</U>. During the Employment, Executive shall not improperly use or disclose any
confidential information or trade secrets, if any, of any former employer or any other person to whom Executive has an obligation of confidentiality,
and Executive will not bring onto the premises, or make available to any employees of the Company, any unpublished documents or any property
belonging to any former employer or any other person to whom Executive has an obligation of confidentiality unless consented to in writing
by the former employer or person. In the performance of Executive&rsquo;s duties for the Company, Executive will only use information
which is (i)&nbsp;generally known and used by persons and expertise comparable to that of Executive, (ii)&nbsp;common knowledge in the
industry or otherwise legally in the public domain, or (iii)&nbsp;otherwise provided or developed by the Company. Executive acknowledges
that the Company has expressly informed Executive that the Company does not want any access, privilege, benefit or knowledge of such confidential
or proprietary information of others. Executive represents and warrants that to Executive&rsquo;s knowledge Executive has no obligations,
legal, in contract, or otherwise, inconsistent with the terms of this Agreement or with Executive&rsquo;s undertaking Employment with
the Company to perform the duties described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Penalties
for Violation of Non-Disclosure Policy</U>. In addition to the legal and equitable remedies set forth herein by applicable law, Executive
understands that violation of any non-disclosure provision of this Agreement shall be subject to discipline, up to and including discharge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Assignment
of Work Product</B>. Any information or innovations, including, but not limited to, inventions, improvements, methods, technology, programs,
customer lists, reports, distribution records, brochures, instructions, manuals, processes,&nbsp;etc., which are, during the course of
the Employment, conceived, developed, or improved upon by Executive for use by the Company or any of its subsidiaries, alone or in conjunction
with other employees or consultants (collectively, the &ldquo;<B><I>Work Product</I></B>&rdquo;), shall be the exclusive property of the
Company, and during the Employment and at all times thereafter, Executive shall not use, duplicate, reveal or take with Executive any
such Work Product or other materials of the Company, other than in furtherance of the performance of his duties to the Company, whether
under this Agreement or otherwise. To the extent that any of the Work Product is capable of protection by copyright as a &ldquo;work made
for hire&rdquo; pursuant to the United States Copyright Act, Executive acknowledges that such Work Product is created within the scope
of his Employment and, as such, is property of the Company. To the extent that any such Work Product, whether protected by copyright or
otherwise, is not a &ldquo;work made for hire,&rdquo; Executive hereby assigns to the Company all rights in such material. Executive hereby
agrees to execute any documents at any time reasonably required by the Company in connection with the registration of copyright, patent
application or other perfection of the Company&rsquo;s ownership of the Work Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Covenant
Not to Compete</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Business
Relationships and Goodwill. Executive acknowledges and agrees that as an employee and representative of the Company, Executive is responsible
for building and maintaining business relationships and goodwill with current and future physicians, customers, payors, patients and prospects
on a personal level. Executive acknowledges and agrees that such responsibility creates a special relationship of trust and confidence
between the Company, Executive, and those persons or entities. Executive further acknowledges that such responsibility creates a high
risk and opportunity for Executive to misappropriate these relationships and the goodwill existing between the Company and such persons.
Executive acknowledges and agrees that it is fair and reasonable for the Company to take steps to protect itself from the risk of such
misappropriation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Consideration.
Executive acknowledges and agrees that in exchange for his agreement in <U>Section&nbsp;3.3(c)</U>&nbsp;below, Executive will receive
substantial and valuable consideration from the Company, as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Scope
of Noncompetition Obligation. During the Employment, and for a period of one (1)&nbsp;year after the termination of the Employment for
any reason, Executive shall not, directly or indirectly, either acting alone, or as a stockholder, partner, associate, creditor, consultant,
adviser, franchiser, franchisee, director, officer, owner, employee or agent of any other person or entity, or in any other capacity,
engage in or provide services in purpose or function to those Executive provided to Company to any company engaged in the Same Business
(as defined below) in the Territory (as defined below); <I>provided</I>, <I>however</I>, the restriction contained in this <U>Section&nbsp;3.3</U>
shall not prohibit Executive from owning not more than 1% of the outstanding equity of any class of any entity, so long as Executive does
not actively participate in the business of such corporation. For purposes of this section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">the term &ldquo;<B><I>Same Business</I></B>&rdquo; shall mean any company that engages or proposes to
engage in the Business; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">the term &ldquo;<B><I>Territory</I></B>&rdquo; shall be defined as all geographic area(s)&nbsp;where Executive
performed services, and all geographic areas that Executive managed and/or supervised (either directly or indirectly). If Executive is
in a position where Executive&rsquo;s responsibilities are not geographically limited to an assigned location or territory or where Executive
is provided Confidential Information that is not geographically limited to an assigned location or territory (such as, by way of example
but not limitation, management positions, research and developers, and engineers), then Territory means every state where Company does
business and/or did business during the term of Executive&rsquo;s Employment, and all places where the Company had plans or reasonable
expectations to do business in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Prohibition on Working</U>. Executive acknowledges and agrees that this Agreement does not restrict Executive&rsquo;s ability to find
employment within any geographical area after the termination of the Employment; <I>provided</I> that Executive is not employed in violation
of the noncompetition obligations detailed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Nonsolicitation
of Customers</B>. Executive agrees that Executive shall not at any time during the Employment, whether or not initiated by Executive,
divert away or attempt to divert away any business from the Company to another company, business, or individual. Further, Executive shall
not, for a period of one (1)&nbsp;year following the termination of the Employment for any reason, contact, solicit, attempt to solicit
or divert, or attempt to divert business from, either directly or indirectly, any Company Customer which Executive called upon, came into
contact with, or became aware of, as a result of Executive&rsquo;s Employment with Company during the last twelve (12) months Executive&rsquo;s
Employment with Company. &ldquo;<B><I>Company Customer</I></B>&rdquo; means any person, company, or business that is or was a customer
of Company, including but not limited to physicians, payors or other customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Nonrecruitment
of Employees</B>. Executive agrees that during the Employment and for a period of one (1)&nbsp;year after termination of the Employment
for any reason, Executive shall not, on Executive&rsquo;s own behalf or on behalf of any other person or entity, hire, solicit, seek to
hire, or offer employment to any person who was employed by the Company on the date of termination of the Employment, or who is a current
employee of the Company. Executive further agrees that Executive will not, in any other manner attempt, directly or indirectly, to influence,
induce, or encourage any person who was employed by the Company on the date of termination of the Employment or who is a current employee
of the Company to leave the employment of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Non-Interference
with Business Relations</B>. Executive agrees that during the Employment, and for a period of two (2)&nbsp;years after the termination
of the Employment for any reason, Executive shall not, directly or indirectly, (a)&nbsp;solicit, advise, persuade or otherwise induce
any person to participate in or with any entity or person which provides services comparable to those provided by the Company or by facilities
managed or owned by the Company or any of its subsidiaries, (b)&nbsp;do anything, intentionally or recklessly, to discredit or otherwise
injure the reputation or goodwill of the Company or any of its affiliates or subsidiaries, (c)&nbsp;solicit, induce or attempt to solicit
or induce any customer, employee, independent contractor, distributor, manufacturer or other professional or any other business relation
of the Company (or any subsidiary) to cease or reduce the level of business between such business relation and the Company (or any subsidiary),
or (d)&nbsp;in any way interfere with the Company&rsquo;s (or any subsidiary&rsquo;s) relationship with any customer, employee, independent
contractor, distributor, manufacturer or other professional or business relation of the Company or subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Reasonableness
of Restrictions</B>. Executive acknowledges and agrees that, given the nature of the Business, and the Company&rsquo;s proposed Business
plans, the restrictions imposed upon Executive by this ARTICLE&nbsp;III and the purposes for such restrictions are reasonable and are
designed to protect the trade secrets, confidential and proprietary business information and the future success of the Company and its
subsidiaries without unduly restricting Executive. Specifically, Executive acknowledges that the restrictions and covenants contained
in this ARTICLE&nbsp;III will not prohibit Executive from pursuing Executive&rsquo;s career upon termination of Executive&rsquo;s employment
relationship with the Company. If, at the time of enforcement of this Agreement, a court shall hold that any of the duration, scope or
geographic restrictions stated herein are unreasonable under circumstances then existing, the parties agree (and shall stipulate, if necessary,
in an appropriate pleading) that the maximum duration, scope or geographic area reasonable under such circumstances shall be substituted
for the stated duration, scope or geographic area. Executive further agrees not to challenge the enforceability or the enforcement of
the restrictive covenants in this ARTICLE&nbsp;III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Severability</B>.
Executive agrees that the non-disclosure, non-competition, and non-solicitation covenants set forth in this ARTICLE&nbsp;III each constitute
separate agreements independently supported by good and adequate consideration. If a court of competent jurisdiction determines that any
restriction in a clause or provision of this ARTICLE&nbsp;III is void, illegal, or unenforceable, the other clauses and provisions of
this ARTICLE&nbsp;III shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Return
of the Company Property</B>. When Executive&rsquo;s Employment terminates for any reason, Executive will promptly (within twenty-four
(24) hours) deliver to the Company any and all Confidential Information, drawings, notes, memoranda, specifications, devices, formulas
and documents, together with all copies thereof and any other material containing or disclosing any works made for hire, or third party
information. Executive further agrees that any property situated on the Company&rsquo;s premises and owned by the Company including computers,
computer disks and computer hard disk drives and other computer storage media, filing cabinets or other work areas, is subject to inspection
by the Company personnel at any time with or without notice. Nothing in this Agreement shall prohibit Executive from (i)&nbsp;disclosing
information and documents when required by law, subpoena or court order, (ii)&nbsp;disclosing information and documents to Executive&rsquo;s
attorney, financial or tax adviser for the purpose of securing legal, financial or tax advice, (iii)&nbsp;disclosing Executive&rsquo;s
post-employment restrictions in this Agreement in confidence to any potential new employer of Executive, or (iv)&nbsp;retaining, at any
time, Executive&rsquo;s personal correspondence, Executive&rsquo;s personal contacts and documents related to Executive&rsquo;s own personal
benefits, entitlements and obligations, except where such correspondence, contracts and documents contain Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Notification
of New Employer</B>. In the event that the Employment is terminated for any reason, Executive hereby consents to the notification by the
Company to Executive&rsquo;s new employer of Executive&rsquo;s rights and obligations under this ARTICLE&nbsp;III. In addition, for a
period of two (2)&nbsp;years after termination of the Employment, in the event that Executive plans to render services to a company that
works in a similar field as the Company, Executive agrees to provide the Company with as much notice as possible of Executive&rsquo;s
intention to join that company or business but in no event will Executive provide less than two weeks notice of that intention; <I>provided</I>,
<I>however</I>, the provision of such notice and the Company&rsquo;s receipt thereof shall not constitute a waiver of any breach of any
provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>3.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Equitable
and Other Relief</B>. Executive understands and agrees that, in the event Executive breaches this ARTICLE&nbsp;III, the Company will suffer
immediate and irreparable harm that cannot be accurately calculated in monetary damages. Consequently, Executive acknowledges and agrees
that the Company shall be entitled to immediate injunctive relief, either by temporary or permanent injunction, to prevent such violation.
Executive acknowledges and agrees that such injunctive relief shall be in addition to any other legal or equitable relief to which the
Company would be entitled. In addition, the Company shall be entitled to recover its attorneys&rsquo; fees and costs from Executive should
the Company be required to file suit to enforce its rights under this ARTICLE&nbsp;III, if the Company prevails in such suit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;IV.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Upon
Death or Disability</B>. This Agreement shall terminate upon the Executive&rsquo;s death or Disability. For purposes of this Agreement,
 &ldquo;<B><I>Disability</I></B>&rdquo; shall mean physical or mental disability of the Executive resulting in the Executive&rsquo;s inability
to perform substantially all of the essential functions of the Executive&rsquo;s duties and responsibilities with the Company for (i)&nbsp;a
period of twelve (12) consecutive weeks, or (ii)&nbsp;for shorter periods aggregating twelve (12) weeks during any twelve-month period.
If this Agreement terminates as a result of the Executive&rsquo;s death or Disability, the Company&rsquo;s obligation to the Executive
or the Executive&rsquo;s estate shall be limited to the payment of accrued and unpaid Annual Salary earned and any accrued and unpaid
Benefits vested up to the date of termination, and in the event of Disability, any disability benefits to which the Executive is entitled
hereunder. In addition, upon termination due to death or Disability, the Company shall pay the Executive or the Executive&rsquo;s estate
any annual bonus referred to in <U>Section&nbsp;2.2</U> above that would otherwise be due for the fiscal year of termination, prorated
to the number of days in the fiscal year for which the Executive was employed, and payable at the same time as the bonus would have otherwise
been due had the Executive&rsquo;s Employment not been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Termination
for Cause or Voluntary Termination</B>. If the Company terminates the Executive at any time for Cause or if the Executive terminates the
Executive&rsquo;s Employment at any time other than for Good Reason, the Company&rsquo;s obligation to the Executive shall be limited
solely to the payment of accrued and unpaid Annual Salary and any accrued but unpaid Benefits vested earned up to the date of termination.
As used in this Agreement, the term &ldquo;<B><I>Cause</I></B>&rdquo; shall mean any of the following: (i)&nbsp;the Executive&rsquo;s
commission of an act involving dishonesty, lack of loyalty or breach of fiduciary responsibility involving the Company or any affiliate
or successor thereof which causes material injury to the business, reputation or financial condition of the Company, (ii)&nbsp;continued
and material failure of the Executive to perform the Executive&rsquo;s duties and responsibilities, which has not been corrected by the
Executive within thirty (30) days after the Executive&rsquo;s receipt of a written notice from the Company specifying such failure in
reasonable detail, (iii)&nbsp;any material breach by the Executive of the terms of this Agreement, which has not been corrected, if correctable,
by the Executive within thirty (30) days after the Executive&rsquo;s receipt of a written notice from the Company specifying such breach
in reasonable detail, (iv)&nbsp;commission of a misdemeanor which causes material injury to the business, reputation or financial condition
of the Company, or (v)&nbsp;commission of a felony. As used in this Agreement, the term &ldquo;<B><I>Good Reason</I></B>&rdquo; shall
mean the voluntary termination of Employment by the Executive with the Company within sixty (60) days after the occurrence of any of the
following events, without the Executive&rsquo;s express written consent: (i)&nbsp;the reduction of the Executive&rsquo;s Annual Salary,
(ii)&nbsp;relocation of the Executive&rsquo;s primary work location in New York City (<I>provided</I>, Executive may be required to work
in Irving, Texas no more than 2 days a week) to a new location greater than 50 miles away, or (iii)&nbsp;any material breach by the Company
of the terms of this Agreement which has not been corrected by the Company within thirty (30) days after the Company&rsquo;s receipt of
written notice from the Executive of such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Termination
Without Cause or for Good Reason</B>. If the Company terminates the Executive at any time without Cause or if Executive terminates for
Good Reason, the Company shall be obligated to (i)&nbsp;pay the Executive any accrued and unpaid Benefits vested up to the date of termination,
(ii)&nbsp;pay the Executive a lump sum equal to six (6)&nbsp;months of the Executive&rsquo;s then current Annual Salary, (iii)&nbsp;six
(6)&nbsp;months of company-paid COBRA, and (iv)&nbsp;pay the Executive any annual bonus referred to in <U>Section&nbsp;2.2</U> above that
would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the Executive was
employed, and payable at the same time as the bonus would have otherwise been due had the Executive&rsquo;s Employment not been terminated.
Further, if the Company terminates the Executive at any time without Cause, the options awarded to the Executive under the Share Option
Award Agreement shall immediately vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE&nbsp;V.</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
MISCELLANEOUS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Notices</B>.
Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by nationally-recognized
overnight delivery service or sent by certified or registered mail, postage prepaid, return receipt requested, address as set forth below;
receipt shall be deemed to occur on the earlier of the date of actual receipt or receipt by the sender of confirmation that the delivery
was completed or that the addressee has refused to accept such delivery or has changed its address without giving notice of such change
as set forth herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">if to the Company, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Caris Science,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">750 West John Carpenter Freeway, Suite&nbsp;800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Irving, TX 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: General Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">if to the Executive, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Brian Brille</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Either party may change its address for notice
hereunder by notice to the other party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Entire
Agreement</B>. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes
all prior discussions and agreements, written or oral, with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Waivers
and Amendments</B>. This Agreement may be amended, suspended, cancelled, renewed or extended, and the terms and conditions hereof may
be waived, only by a written instrument signed by both parties or, in the case of a waiver, by the party waiving compliance. No delay
on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof. Nor shall any waiver
on the part of any party of any such right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege
hereunder, preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Assignment</B>.
This Agreement shall inure to the benefit of and shall be binding upon the Executive and the Executive&rsquo;s executor, administrator,
heirs, personal representative and assigns, and the Company and its successors and assigns; <I>provided</I>, <I>however</I>, that the
Executive shall not be entitled to assign any of the Executive&rsquo;s rights or delegate any of the Executive&rsquo;s duties under this
Agreement. The Executive agrees that this Agreement may be freely assigned by the Company to any person or entity which succeeds to all
or any significant portion of the Company&rsquo;s assets or Business, whether pursuant to a sale of assets, sale of stock, merger or other
similar transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Severability:
Construction</B>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held by a court of competent jurisdiction to be prohibited by or invalid
under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. Use of the word &ldquo;including&rdquo; shall not be limited by the terms following such word. All references
to singular or plural terms shall mean the other where appropriate. The term &ldquo;<B><I>subsidiary</I></B>&rdquo; shall refer to subsidiaries
of the Company now existing or hereafter formed or acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Choice
of Law</B>. This Agreement shall be governed by, and construed in accordance with the internal laws (as opposed to conflict of laws provisions)
of the State of Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Headings</B>.
The section and subsection headings contained in this Agreement are for reference purposes only and shall not effect in any way the meaning
or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Counterparts</B>.
This Agreement may be executed in separate counterparts, each of which when executed and delivered shall be deemed an original, but all
of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Indemnification</B>.
The Executive shall be entitled to the full benefit of any and all indemnification provisions contained in the Company&rsquo;s Certificate
of Incorporation as amended from time to time, and/or Bylaws, and the Company shall provide indemnification to the Executive to the same
extent as it indemnifies any other officer or director of the Company. Irrespective of the provisions in the Company&rsquo;s Certificate
of Incorporation as amended from time to time, or Bylaws, the Company shall indemnify the Executive to the fullest extent provided under
applicable law, including but not limited to advancement of expenses to the fullest extent provided by such applicable law(s). As an employee,
Executive is also covered under Company&rsquo;s D&amp;O insurance policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Dispute
Resolution</B>. Except as provided below, this dispute resolution provision applies to any dispute, claim or disagreement arising out
of or in connection to Executive&rsquo;s Employment with Company, and including any dispute arising out of or in connection with this
Agreement, including, without limitation, the negotiation, execution, interpretation, performance or non-performance of this Agreement.
This dispute resolution provision applies to a covered dispute that Employer may have against Company or that Executive may have against
Company or its officers, directors, shareholders, members, owners, employees, managers, agents and attorneys. This provision does not
apply to claims for worker&rsquo;s compensation, state disability insurance and unemployment insurance benefits; however, it does apply
to retaliation claims based upon seeking such benefits. This provision does not apply to claims for employee benefits under any benefit
plan covered by the Executive Retirement Income Security Act of 1974 or funded by insurance. This provision does not apply to any claim
that an applicable federal statute or applicable federal Executive Order expressly states cannot be arbitrated. Nothing in this Agreement
prevents the making of a report to or filing a claim or charge with a government agency, including without limitation the Equal Employment
Opportunity Commission, U.S. Department of Labor, Securities and Exchange Commission, National Labor Relations Board, or Office of Federal
Contract Compliance Programs. Nothing in this Agreement prevents the investigation by a government agency of any report, claim or charge
otherwise covered by this Agreement. This Agreement also does not prevent federal administrative agencies from adjudicating claims and
awarding remedies based on those claims, even if the claims would otherwise be covered by this Agreement. Nothing in this Agreement prevents
or excuses a party from satisfying any conditions precedent and/or exhausting administrative remedies under applicable law before bringing
a claim in arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The parties shall first submit the dispute, claim
or disagreement to non-binding mediation administered by the American Arbitration Association (the &ldquo;<B><I>AAA</I></B>&rdquo;) in
accordance with its Employment Mediation Rules. The place of mediation shall be Dallas, Texas. If the dispute, claim or disagreement is
not resolved within 30 days after the initial mediation meeting among the parties and the mediator, or if the mediation is otherwise terminated,
then either party may submit the dispute, claim or disagreement to binding arbitration administered by the AAA in accordance with the
provisions of its Commercial Arbitration Rules&nbsp;(the &ldquo;<B><I>Rules</I></B>&rdquo;) and, except as otherwise provided in this
Agreement, such arbitration shall be the sole means of dispute resolution. The place of arbitration shall be Dallas, Texas. The arbitration
shall be conducted by one arbitrator selected in accordance with the Rules, unless the parties otherwise agree. Any mediator or arbitrator
selected under this <U>Section&nbsp;5.10</U> shall be a practicing attorney experienced in employment agreements and acquisitions and
shall not have been employed or engaged by or affiliated with either of the parties or their respective affiliates. Each party shall initially
bear its own costs and expenses in connection with any mediation or arbitration hereunder, including, without limitation, its attorneys&rsquo;
fees, and an equal share of the mediator&rsquo;s or arbitrator&rsquo;s and administrative fees of mediation or arbitration. The decision
of the arbitrator shall be in writing and shall state the reasons therefore. Judgment upon an arbitration award may be entered in any
court of competent jurisdiction and shall be final, binding and non-appealable. The arbitrator, and not any federal, state, or local court
or agency, shall have the exclusive authority to resolve any dispute relating to the interpretation, applicability, enforceability, or
formation of this section. However, the preceding sentence shall not apply to the &ldquo;Class&nbsp;Action Waiver&rdquo; described below.
Regardless of anything else in this Agreement and/or the AAA rules&nbsp;or procedures, any dispute relating to the interpretation, applicability,
enforceability or formation of the Class&nbsp;Action Waiver may only be determined by a court and not an arbitrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive and Company agree to bring any claim
or dispute in arbitration on an individual basis only, and not as a class or collective action; Executive and Company waive any right
for a dispute or claim to be brought, heard, or decided as a class or collective action, and the arbitrator has no power or authority
to preside over a class or collective action (&ldquo;<B><I>Class&nbsp;Action Waiver</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything in this <U>Section&nbsp;5.10</U>
to the contrary, each party shall be entitled to seek injunctive or other equitable relief in any court of competent jurisdiction without
first submitting the matter to mediation or arbitration in accordance with the provisions of this <U>Section&nbsp;5.10</U>, even if a
similar or related matter has already been referred to mediation or arbitration in accordance with the terms of this <U>Section&nbsp;5.10</U>.
Venue for any action permitted to be brought in court under this <U>Section&nbsp;5.10</U> shall be the appropriate state and federal courts
located in Dallas County, Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Disclosures</B>.
Nothing in this Agreement prohibits Executive from reporting an event that Executive reasonably and in good faith believes is a violation
of law to the relevant law-enforcement agency (such as the Securities and Exchange Commission, Equal Employment Opportunity Commission,
or Department of Labor), or from cooperating in an investigation conducted by such a government agency. This may include disclosure of
trade secret or confidential information within the limitations permitted by the 2016 Defend Trade Secrets Act (DTSA). Executive is hereby
provided notice that under the DTSA, (1)&nbsp;no individual will be held criminally or civilly liable under Federal or State trade secret
law for the disclosure of a trade secret (as defined in the Economic Espionage Act) that: (A)&nbsp;is made in confidence to a Federal,
State, or local government official, either directly or indirectly, or to an attorney; and made solely for the purpose of reporting or
investigating a suspected violation of law; or, (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal so that it is not made public; and, (2)&nbsp;an individual who pursues a lawsuit for retaliation by
an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the
trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does
not disclose the trade secret, except as permitted by court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><B>5.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Representation</B>.
The Executive has consulted with and relied upon independent legal counsel in determining whether to sign this Agreement, and has not
relied upon the company nor the company&rsquo;s counsel to represent the Executive&rsquo;s interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon execution of this Agreement
and thereafter, Company covenants and agrees that it shall provide Executive with Confidential Information as defined herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-size: 10pt">/s/ David D. Halbert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">David D. Halbert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EMPLOYEE:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Brian Brille</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Brian Brille</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>26
<FILENAME>tm2415719d15_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.10</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Caris Life Sciences,&nbsp;Inc.<BR>
Executive and Director Change in Control Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purpose</U>.
The purpose of the Caris Life Sciences,&nbsp;Inc. Executive and Director Change in Control Plan (the &ldquo;<B>Plan</B>&rdquo;) is to
reduce the potential distraction of key executive management personnel and non-employee directors of Caris Life Sciences,&nbsp;Inc. (together
with its subsidiaries, the &ldquo;<B>Company</B>&rdquo;) in the face of the uncertainty that a potential Change in Control could trigger
by protecting the equity-based awards granted to selected executives and non-employee directors of the Company in the event of a Change
in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
For purposes of this Plan, the following words and phrases have the meanings specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Administrator</B>&rdquo;
has the meaning set forth in Section&nbsp;3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Change
in Control</B>&rdquo; has the meaning set forth in the Caris Life Sciences,&nbsp;Inc. 2020 Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Change
in Control Date</B>&rdquo; means the date on which a Change in Control is consummated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Code</B>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended, and any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth in Section&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Covered
Payments</B>&rdquo; has the meaning set forth in Section&nbsp;6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Eligible
Executives and Directors</B>&rdquo; has the meaning set forth in Section&nbsp;4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Excise
Tax</B>&rdquo; has the meaning set forth in Section&nbsp;6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Participant</B>&rdquo;
has the meaning set forth in Section&nbsp;4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Plan</B>&rdquo;
has the meaning set forth in Section&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><U>Administration</U>. The Plan shall be administered by the Board of Directors of the Company or a committee
of the Board of Directors of the Company that is designated by the Board of Directors of the Company (the &ldquo;<B>Administrator</B>&rdquo;).
Subject to the provisions of the Plan, the Administrator shall have exclusive authority to interpret and administer the Plan, to establish,
amend and rescind appropriate rules&nbsp;and regulations relating to the Plan, to delegate some or all of its authority under the Plan
to the extent permitted by law, and to take all such steps and make all such determinations in connection with the Plan and the benefits
granted pursuant to the Plan as it may deem necessary or advisable. Any decision of the Administrator in the interpretation and administration
of the Plan, as described herein, shall lie within its sole and absolute discretion and shall be final, conclusive and binding on all
parties concerned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Eligibility</U>. Eligibility under the Plan is limited to certain senior executives, officers and non-employee
directors of the Company as determined by the Administrator from time to time (&ldquo;<B>Eligible Executives and Directors</B>&rdquo;).
The Administrator in its sole discretion will select and notify those Eligible Executives and Directors who will participate in the Plan
(&ldquo;<B>Participants</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><U>Effect of Change in Control on Equity Awards</U>. Immediately prior to the consummation of a Change
in Control and subject to the execution of a general release of claims in favor of the Company and in a form acceptable to the Company,
all equity-based compensation awards granted to Participants under the Company&rsquo;s equity incentive compensation plans that are outstanding
awards as of the Change in Control Date shall vested in full to the extent not yet vested, with all restrictions relating to any such
awards lifted immediately the consummation of the Change in Control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><U>Section&nbsp;280G</U>. Notwithstanding any other provision of this Plan or any other plan, arrangement
or agreement to the contrary, if any of the payments or benefits provided or to be provided to a Participant or for Participant&rsquo;s
benefit pursuant to the terms of this Plan or otherwise (&ldquo;<B>Covered Payments</B>&rdquo;) constitute parachute payments within the
meaning of Section&nbsp;280G of the Code and would, but for this Section&nbsp;6, be subject to the excise tax imposed under Section&nbsp;4999
of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect
to such taxes (collectively, the &ldquo;<B>Excise Tax</B>&rdquo;), then the Covered Payments shall be payable either (i)&nbsp;in full
or (ii)&nbsp;reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax, whichever
of the foregoing (i)&nbsp;or (ii)&nbsp;results in Participant&rsquo;s receipt on an after-tax basis of the greatest amount of benefits
after taking into account the applicable federal, state, local and foreign income, employment and excise taxes (including the Excise Tax).
Any such reduction shall be made consistent with the requirements of Section&nbsp;409A of the Code. Any determination required under this
Section&nbsp;6 shall be made in writing in good faith by an independent accounting firm, the fees and expenses of which shall be the responsibility
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><U>Section&nbsp;409A</U>. Notwithstanding anything to the contrary contained in this Plan, the payments
and benefits provided under this Plan are intended to comply with or be exempt from Section&nbsp;409A of the Code, and the provisions
of this Plan shall be interpreted or construed with that intent. The Administrator may modify the payments and benefits under this Plan
at any time solely as necessary to avoid adverse tax consequences under Section&nbsp;409A; <U>provided</U>, <U>however</U>, that this
Section&nbsp;7 shall not create any obligation on the part of the Administrator to make such modifications or take any other action. It
is intended that the terms &ldquo;termination&rdquo; and &ldquo;termination of employment&rdquo; as used herein shall constitute a &ldquo;separation
from service&rdquo; within the meaning of Section&nbsp;409A. Anything in the Plan to the contrary notwithstanding, each payment of compensation
made to a Participant shall be treated as a separate and distinct payment from all other such payments for purposes of Section&nbsp;409A.
Anything in the Plan to the contrary notwithstanding, if a Participant is a &ldquo;specified employee&rdquo; (within the meaning of Treasury
Regulation Section&nbsp;1.409A-1(i)) on the date of Participant&rsquo;s termination of employment, then any payment or benefit that would
be considered &ldquo;nonqualified deferred compensation&rdquo; within the meaning of Section&nbsp;409A that such Participant is entitled
to receive upon termination of employment and that otherwise would be payable during the six-month period immediately following Participant&rsquo;s
termination of employment shall instead be paid or made available on the first day of the seventh month following Participant&rsquo;s
termination of employment (or, if earlier, the date of Participant&rsquo;s death). With regard to any provision herein that provides for
reimbursement of costs and expenses or in-kind benefits, except as permitted by Section&nbsp;409A: (i)&nbsp;the right to reimbursement
or in-kind benefits shall not be subject to liquidation or exchange for another benefit; (ii)&nbsp;the amount of expenses eligible for
reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind
benefits to be provided, in any other taxable year; and (iii)&nbsp;such payments shall be made on or before the last day of Participant&rsquo;s
taxable year following the taxable year in which the expense occurred, or such earlier date as required hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Withholding</U>. The Company shall be entitled to withhold from payments to or on behalf of Participant
taxes and other authorized deductions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. The laws of the State of Texas shall govern all questions concerning the construction,
validity and interpretation of this Plan. Participant hereby irrevocably waives all right to trial by jury in any action, proceeding or
counterclaim arising out of or relating to this Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><U>Amendment and Modification</U>. Prior to a Change in Control, this Plan and its Exhibits may be modified,
amended or terminated at any time by the Administrator without notice to Participants. Following the consummation of a Change in Control,
the Plan including its Exhibits shall not be discontinued, terminated or amended in any manner.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><U>No Employment Rights</U>. Neither this Plan nor the benefits hereunder shall be a term of the employment
of any employee, and the Company shall not be obligated in any way to continue the Plan. The terms of this Plan shall not give any employee
the right to be retained in the employment of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><U>Effective Date</U>. This Plan shall become effective as of the date of its adoption (the &ldquo;<B>Effective
Date</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>27
<FILENAME>tm2415719d15_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT><B>Exhibit&nbsp;10.11</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-right-width: 0in; border-right-color: Black"><B>Non-Employee
Director Compensation Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-right-width: 0in; border-right-color: Black"><B>Effective
as of January&nbsp;1, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-right-width: 0in; border-right-color: Black"><FONT STYLE="background-color: white">Each
</FONT>member of the Board of Directors (the &ldquo;<U>Board</U>&rdquo;) of Caris Life Sciences,&nbsp;Inc. (together with its affiliates,
<FONT STYLE="background-color: white">the &ldquo;<U>Company</U>&rdquo;) who is not either (a)&nbsp;an employee of the Company or (b)&nbsp;an
employee of a professional investor of the Company (each, a &ldquo;<U>Director</U>&rdquo;) shall receive compensation in accordance with
this </FONT>Non-Employee Director Compensation Program (this &ldquo;<U>Program</U>&rdquo;) during such Director&rsquo;s period of service
as a member of the Board<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-left-width: 0in; border-left-color: Black"><B>Cash Compensation:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Annual
Cash Retainer</U>. $50,000 per calendar year. For the avoidance of doubt, the lead independent director retainer and committee retainers
described below shall be payable in addition to the annual cash retainer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Lead
Independent Director Retainer</U>. If any, $30,000 per calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Committee
Member Retainers</U>. $12,500 per calendar year while a Director serves on the Audit&nbsp;Committee of the Board. $9,000 per calendar
year while a Director serves on the Compensation&nbsp;Committee of the Board. $6,000 per calendar year while a Director serves on the
Nominating and Governance Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Committee
Chair Retainers</U>. $25,000 per calendar year while a Director serves as the Chairperson of the Audit Committee. $18,000 per calendar
year while a Director serves as the Chairperson of the Compensation Committee. $12,000 per calendar year while a Director serves as the
Chairperson of the Nominating and Governance Committee. For the avoidance of doubt, the Committee Chair Retainers are payable in lieu
of the Committee Member Retainers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Election
of Shares in Lieu of Cash</U>. A Director may elect to receive any cash retainer, or any specified portion thereof, in shares of the Company&rsquo;s
common stock (&ldquo;<U>Shares</U>&rdquo;), provided such election is made prior to the later of (x)&nbsp;30 days following such Director&rsquo;s
initial election to the Board or (y)&nbsp;January&nbsp;1 of the calendar year with respect to which the annual cash retainer relates.
If a Director elects to receive Shares in lieu of cash, the number of Shares that will be issued to such Director for a relevant quarter
will be calculated based on the price per Share equal to the ten trading day average of the daily volume weighted average price per Share
through and including the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Payment
Timing</U>. All retainers are payable in four quarterly installments in cash, delivered as soon as practicable following the last day
of the applicable quarter, but in no event later than 30 days following the end of the applicable quarter; provided that, any Shares elected
in lieu of cash will be delivered as determined by the Company for administrative convenience, but in all events by March&nbsp;15 of the
calendar year following the calendar year for which the retainer was earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-right-width: 0in; border-right-color: Black"><U>Limitation</U>.
The annual compensation for a Director shall not exceed $1,000,000 for a calendar year, taking together all cash retainers and annual
equity retainers (using grant date fair value) paid or granted to a Director for a calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-right-width: 0in; border-right-color: Black"><U>Proration</U>.
All cash retainers will be pro-rated for any partial year of service, including in the year of a Director&rsquo;s initial election, if
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-left-width: 0in; border-left-color: Black"><B>Equity Compensation:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Annual
Equity Retainer</U>. An annual grant of time-vested restricted stock units (&ldquo;<U>RSUs</U>&rdquo;) pursuant to the Caris Life Sciences,&nbsp;Inc.
2020 Incentive Plan or a successor plan, as applicable (the &ldquo;<U>Incentive Plan</U>&rdquo;) with a grant date fair value of $300,000
and subject to the terms of the Incentive Plan and an Award Agreement thereunder. These RSUs will vest on the first anniversary of the
grant date, provided that if a Director serves through the day immediately prior to the next annual shareholders meeting occurring after
the grant date, such Director&rsquo;s RSUs shall remain outstanding and shall be deemed to vest on the first anniversary of the grant
date, and provided further, that in the case of the&nbsp;2025&nbsp;annual equity retainer RSUs, such RSUs will not be eligible to vest
until&nbsp;the occurrence of the&nbsp;Company&rsquo;s 2026 annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Initial
Equity Grant</U>. Unless otherwise determined by the Board, upon initial election to the Board, a grant of RSUs pursuant to the Incentive
Plan with a grant date fair value of $500,000 and subject to the terms of the Incentive Plan and an Award&nbsp;Agreement thereunder. These
RSUs will vest ratably in three equal annual installments on the first three anniversaries of the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Equity
Granted Prior to the Initial Public Offering</U>. Notwithstanding the foregoing, any RSUs granted to a Director prior to the effectiveness
of the Company&rsquo;s initial public offering (whether resulting from the annual equity retainer or the initial equity grant) shall not
vest prior to the earlier of (x)&nbsp;the effective date of the Company&rsquo;s initial public offering or (y)&nbsp;the consummation of
a &ldquo;change in control&rdquo; (as defined in the Incentive Plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><U>Equity
Compensation Grant Timing and Settlement</U>. Annual equity retainer RSUs, other than those granted to Directors in their initial year
of service and in 2025, will be granted each year on the Company&rsquo;s first regularly scheduled grant date on or immediately following
the Company&rsquo;s annual meeting for such year and will have a service commencement date of the annual meeting. Initial equity grant
RSUs and annual equity retainer RSUs granted to Directors in their initial year of service after 2025 will be granted on the Company&rsquo;s
first regularly scheduled grant date on or immediately following the Director&rsquo;s start date and will have a service commencement
date of the start date. The 2025 annual equity retainer RSUs will be granted on the Company&rsquo;s first regularly scheduled grant date
in 2025 and have a service commencement date of January&nbsp;1, 2025. Shares resulting from the settlement of any RSUs will be delivered
as determined by the Company for administrative convenience, but in all events by March&nbsp;15 of the calendar year following the calendar
year in which the applicable vesting date occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-left-width: 0in; border-left-color: Black"><B>Taxes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors are responsible for all taxes arising
from any payments made pursuant to the terms of this Program and, except where required by law, the Company will not withhold taxes with
respect to such payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>28
<FILENAME>tm2415719d15_ex10-12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit&#8239;10.12</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>INDEMNIFICATION
And Advancement AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Indemnification and Advancement
Agreement (&ldquo;<U>Agreement</U>&rdquo;) is made as of ________ __, 20__ by and between Caris Life Sciences,&nbsp;Inc., a Texas corporation
(the &ldquo;<U>Company</U>&rdquo;), and ______________, [a member of the Board of Directors/an officer/an employee/an agent] of the Company
(&ldquo;<U>Indemnitee</U>&rdquo;). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee
covering indemnification and advancement of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Board of Directors
of the Company (the &ldquo;<U>Board</U>&rdquo;) believes that highly competent persons have become more reluctant to serve publicly-held
corporations as directors, officers, or in other capacities unless they are provided with adequate protection through insurance or adequate
indemnification and advancement of expenses against inordinate risks of claims and actions against them arising out of their service to
and activities on behalf of the corporation, or both;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Board has determined
that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense,
liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such
insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company
believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums
and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises
are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally
would have been brought only against the Company or business enterprise itself. The Company&rsquo;s Amended and Restated Bylaws (the &ldquo;<U>Bylaws</U>&rdquo;)
and Amended and Restated Certificate of Formation (the &ldquo;<U>Certificate of Formation</U>&rdquo;) permit or require the Company to
provide for the indemnification of the officers and directors of the Company. Indemnitee may also be entitled to mandatory indemnification
pursuant to the Texas Business Organizations Code (as amended from time to time, the &ldquo;<U>TBOC</U>&rdquo;). The indemnification provisions
set forth in the Bylaws, the Certificate of Formation, and the TBOC are not exclusive, and thereby contemplate that contracts may be entered
into between the Company and its directors, officers, and other persons with respect to indemnification and advancement of expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the uncertainties
relating to such insurance, to indemnification, and to advancement of expenses may increase the difficulty of attracting and retaining
such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Board has determined
that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its shareholders
and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, it is reasonable,
prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons
to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that
they will not be so indemnified;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, this Agreement is
a supplement to, and in furtherance of, the Bylaws, the Certificate of Formation and any resolutions adopted pursuant thereto, as well
as any rights of Indemnitee under the TBOC and under any directors&rsquo; and officers&rsquo; liability or other insurance policy, and
is not a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS,&nbsp;Indemnitee does
not regard the protection available under the Bylaws, the Certificate of Formation, the TBOC, and available insurance as adequate in the
present circumstances, and may not be willing to serve or continue to serve as [a/an] [officer/director/employee/agent] without adequate
additional protection, and the Company desires Indemnitee to [serve / continue to serve] in such capacity. Indemnitee is willing to [serve
/ continue to serve] and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified
and be advanced expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Services
to the Company.</U> Indemnitee agrees to [serve/continue to serve] as [a/an] [director/officer/employee/agent] of the Company. Indemnitee
may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by
operation of law). This Agreement does not create any obligation on the Company to continue Indemnitee in such position and is not an
employment contract between the Company (or any of its subsidiaries or any Enterprise (as defined below)) and Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions.</U>
As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Agent</U>&rdquo;
means any person who is authorized by the Company or an Enterprise to act for or represent the interests of the Company or an Enterprise,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Beneficial
Owner</U>&rdquo; has the meaning given to such term in Rule&nbsp;13d-3 under the Exchange Act (as defined below); <U>provided</U>, <U>however</U>,
that Beneficial Owner excludes any Person otherwise becoming a Beneficial Owner by reason of the shareholders of the Company approving
a merger of the Company with another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Business
Court</U>&rdquo; means the Business Court in the First Business Court Division of the State of Texas located in Dallas, Texas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
 &ldquo;<U>Change in Control</U>&rdquo; means the occurrence after the date of this Agreement of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Acquisition
of Stock by Third Party. Any Person (as defined below) becomes the Beneficial Owner, directly or indirectly, of securities of the Company
representing fifteen percent (15%) or more of the combined voting power of the Company&rsquo;s then outstanding securities unless the
change in relative beneficial ownership of the Company&rsquo;s securities by any Person results solely from a reduction in the aggregate
number of outstanding shares of securities entitled to vote generally in the election of directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Change
in Board of Directors. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution of this Agreement),
individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person
who has entered into an agreement with the Company to effect a transaction described in Sections 2(d)(i), 2(d)(iii)&nbsp;or 2(d)(iv)&nbsp;of
this Agreement) whose election by the Board or nomination for election by the Company&rsquo;s shareholders was approved by a vote of at
least a majority of the directors then still in office who either were directors at the beginning of the period or whose election or nomination
for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Corporate
Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation
that would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent
(50%) of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation
and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iv.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liquidation.
The approval by the shareholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by
the Company of all or substantially all of the Company&rsquo;s assets; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">v.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other
Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e)&nbsp;of Schedule 14A of
Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not
the Company is then subject to such reporting requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Corporate
Status</U>&rdquo; describes the status of a person who is or was acting as a director, officer, employee, or Agent of the Company or an
Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Disinterested
Director</U>&rdquo; means a director of the Company who is both &ldquo;disinterested&rdquo; and &ldquo;independent&rdquo; as such terms
are defined in Sections 1.003 and 1.004 of the TBOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Enterprise</U>&rdquo;
means any other corporation, partnership, joint venture, trust, other enterprise or non-profit entity, including any employee benefit
plan, for which Indemnitee is or was serving at the request of the Company as a director, officer, employee, or Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Expenses</U>&rdquo;
includes all reasonable attorneys&rsquo; fees and all judgments, penalties, settlements, fines, retainers, court costs, transcript costs,
fees and other costs of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs,
telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the
actual or deemed receipt of any payments under this Agreement, excise taxes and penalties, including excise taxes assessed against Indemnitee
with respect to an employee benefit plan, and all other disbursements, obligations, or expenses of the types customarily incurred in connection
with preparing for or participating in a Proceeding (as defined below). Expenses also include (i)<B>&nbsp;</B>Expenses incurred in connection
with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any
cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii)&nbsp;for purposes of Section&nbsp;14(e)&nbsp;of this Agreement
only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&rsquo;s rights under
this Agreement, by litigation or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Independent
Counsel</U>&rdquo; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently
is, nor in the five years prior to its, his or her selection or appointment has been, retained to represent: (i)&nbsp;the Company or Indemnitee
in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of
other indemnitees under similar indemnification agreements) or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for
indemnification hereunder. Notwithstanding the foregoing, the term &ldquo;Independent Counsel&rdquo; does not include any person who,
under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company
or Indemnitee in an action to determine Indemnitee&rsquo;s rights under this Agreement. The Company agrees to pay the reasonable fees
and expenses of the Independent Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Person</U>&rdquo;
has the meaning as set forth in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange Act; <U>provided</U>, <U>however</U>, that Person excludes
(i)&nbsp;the Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii)&nbsp;any
entity owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Proceeding</U>&rdquo;
includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute
resolution mechanism, investigation, inquiry, administrative hearing, or any other actual, threatened or completed proceeding, whether
brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, regulatory, or investigative
(formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is, or will be involved as a party, potential party,
non-party witness, or otherwise by reason of Indemnitee&rsquo;s Corporate Status or by reason of any action taken by Indemnitee (or a
failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&rsquo;s part while acting pursuant to Indemnitee&rsquo;s
Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification,
reimbursement, or advancement of Expenses can be provided under this Agreement. A Proceeding also includes a situation the Indemnitee
believes in good faith may lead to, or culminate in, the institution of a Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnity
in Third-Party Proceedings.</U> Subject to Section&nbsp;9 and Section&nbsp;12 of this Agreement, to the greatest extent permitted by applicable
law, the Company will indemnify Indemnitee in accordance with the provisions of this Section&nbsp;3 if Indemnitee is, or is threatened
to be made, a respondent or defendant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment
in its favor. Pursuant to this Section&nbsp;3, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law
against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable
in connection with, or in respect of, such Expenses, judgments, fines and amounts paid in settlement) actually incurred by Indemnitee
or on Indemnitee&rsquo;s behalf in connection with such Proceeding or any claim, issue, or matter therein, if Indemnitee acted in good
faith and reasonably believed that Indemnitee&rsquo;s conduct in his or her official capacity was in the Company&rsquo;s best interests
or that Indemnitee&rsquo;s conduct was otherwise not opposed to the Company&rsquo;s best interests, as applicable, and, in the case of
a criminal Proceeding, did not have a reasonable cause to believe that Indemnitee&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnity
in Proceedings by or in the Right of the Company.</U> Subject to Section&nbsp;9 and Section&nbsp;12 of this Agreement, to the greatest
extent permitted by applicable law, the Company will indemnify Indemnitee in accordance with the provisions of this Section&nbsp;4 if
Indemnitee is, or is threatened to be made, a respondent or defendant in any Proceeding by or in the right of the Company to procure a
judgment in its favor. Pursuant to this Section&nbsp;4, the Company will indemnify Indemnitee to the fullest extent permitted by applicable
law against all Expenses actually incurred by Indemnitee or on Indemnitee&rsquo;s behalf in connection with such Proceeding or any claim,
issue or matter therein, if Indemnitee acted in good faith and reasonably believed that Indemnitee&rsquo;s conduct in his or her official
capacity was in the Company&rsquo;s best interests or that Indemnitee&rsquo;s conduct was otherwise not opposed to the Company&rsquo;s
best interests, as applicable. The Company will not indemnify Indemnitee for Expenses under this Section&nbsp;4 related to any claim,
issue, or matter in a Proceeding for which Indemnitee has been finally adjudged by a court to be liable to the Company for (i)&nbsp;willful
or intentional misconduct in the performance of Indemnitee&rsquo;s duty to the Company, (ii)&nbsp;breach of Indemnitee&rsquo;s duty of
loyalty owed to the Company or (iii)&nbsp;an act or omission not committed in good faith that constitutes a breach of a duty owed by Indemnitee
to the Company, and all appeals have been exhausted or foreclosed by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
for Expenses of a Party Who is Wholly or Partly Successful.</U> Notwithstanding any other provisions of this Agreement, to the fullest
extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually incurred by Indemnitee in connection
with any Proceeding to the extent that Indemnitee is wholly successful, on the merits or otherwise, in the defense of the Proceeding.
If Indemnitee is not wholly successful in the defense of such Proceeding but is successful, on the merits or otherwise, as to one or more
but less than all claims, issues, or matters in such Proceeding, the Company will indemnify Indemnitee against all Expenses actually incurred
by Indemnitee or on Indemnitee&rsquo;s behalf in connection with or related to each successfully resolved claim, issue or matter to the
fullest extent permitted by law. For purposes of this Section&nbsp;5 and without limitation, the termination of any claim, issue, or matter
in such a Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue, or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
for Expenses of a Witness.</U> Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law,
the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&rsquo;s behalf
in connection with any Proceeding to which Indemnitee is not a party but to which Indemnitee is a witness, deponent, interviewee, or otherwise
asked to participate or provide information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Partial
Indemnification.</U> If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion
of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof to which Indemnitee
is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Additional
Indemnification.</U> Notwithstanding any limitation in Sections 3, 4, or 5 of this Agreement, for the avoidance of doubt, the Company
will indemnify Indemnitee to the fullest extent permitted by applicable law (including but not limited to, the TBOC) if Indemnitee is
a party to, or threatened to be made a party to, any Proceeding (including a Proceeding by or in the right of the Company to procure a
judgment in its favor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exclusions.</U>
Notwithstanding any other provision in this Agreement, the Company is not obligated under this Agreement to indemnify Indemnitee for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
amount actually paid to or on behalf of Indemnitee under any insurance policy or other indemnity provision, subject to the Company&rsquo;s
compliance with Section&nbsp;15(b)&nbsp;of this Agreement (for the avoidance of doubt, excluding any excess beyond the amount paid under
any insurance policy or other indemnity provision, which shall be subject to indemnification);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning
of Section&nbsp;16(b)&nbsp;of the Exchange Act or similar provisions of state statutory law or common law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reimbursement
of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the
Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements
that arise from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the &ldquo;<U>Sarbanes-Oxley
Act</U>&rdquo;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation
of Section&nbsp;306 of the Sarbanes-Oxley Act);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reimbursement
of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the
compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements
implementing Section&nbsp;10D of the Exchange Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection
with, or in respect of, such Expenses, judgments, fines and amounts paid in settlement) incurred by Indemnitee in a Proceeding in which
Indemnitee has been found liable to the Company or because Indemnitee improperly received a personal benefit (as established by an order,
including a judgment or decree of a court, and all appeals of the order are exhausted or foreclosed by law) for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i.&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;willful or intentional misconduct in the performance of
Indemnitee&rsquo;s duty to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;breach
of Indemnitee&rsquo;s duty of loyalty owed to the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
act or omission not committed in good faith that constitutes a breach of a duty owed by Indemnitee to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Proceeding initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company
or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Proceeding or part of any Proceeding is to enforce Indemnitee&rsquo;s
rights to indemnification or advancement of Expenses under this Agreement, including a Proceeding (or any part of any Proceeding) initiated
pursuant to Section&nbsp;14 of this Agreement or (ii)&nbsp;the Board authorized the Proceeding (or any part of any Proceeding) prior to
its initiation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Proceeding initiated by the Company against Indemnitee involving the enforcement by the Company of any confidentiality, non-competition,
non-solicitation, non-disclosure, non-disparagement or similar restrictive covenant agreements, or the confidentiality, non-competition,
non-solicitation, non-disclosure, non-disparagement or similar restrictive covenant provisions of employment, consulting, severance, equity
award or similar agreements, in each case to which Indemnitee may be a party with the Company or any of its subsidiaries or any other
applicable Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Advances
of Expenses.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Following
receipt of a written affirmation by Indemnitee that Indemnitee had a good faith belief the Indemnitee has met the standard of conduct
necessary for indemnification under the TBOC and this Agreement, the Company will advance, to the extent not prohibited by law, the Expenses
reasonably incurred by Indemnitee in connection with any Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will advance the Expenses within forty (40) days after the receipt by the Company of a statement or statements requesting such
advances from time to time, whether prior to or after final disposition of any Proceeding eligible for advancement of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Advances
will be unsecured and interest free. Indemnitee hereby undertakes to repay any and all amounts so advanced (without interest) to the extent
that it is finally determined that Indemnitee has not met the required standard of conduct or that indemnification is prohibited by Section&nbsp;8.102
of the TBOC. No other form of undertaking is required other than the execution of this Agreement. The Company will make advances without
regard to Indemnitee&rsquo;s ability to repay the Expenses and without regard to Indemnitee&rsquo;s ultimate entitlement to indemnification
under the other provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Procedures
for Notification of Claim for Indemnification or Advancement; Settlements.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnitee
will notify the Secretary of the Company in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification
or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof.
Indemnitee will include in the written notification to the Company a description of the nature of the Proceeding and the facts underlying
the Proceeding and provide such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to
determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding or to
advancement of Expenses. Indemnitee&rsquo;s failure to notify the Company will not relieve the Company from any obligation it may have
to Indemnitee under this Agreement, and any delay in so notifying the Company will not constitute a waiver by Indemnitee of any rights
under this Agreement. The Secretary of the Company will, promptly upon receipt of such a request for indemnification or advancement, advise
the Board in writing that Indemnitee has requested indemnification or advancement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will be entitled to participate in the Proceeding at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall have no obligation to indemnify Indemnitee under this Agreement for amounts paid in settlement of a Proceeding without the
Company&rsquo;s prior written consent. The Company shall not settle any Proceeding in any manner that would impose any fine, Expense,
limitation or other obligation on Indemnitee, or disparage Indemnitee or contain an admission of wrongdoing by Indemnitee, without Indemnitee&rsquo;s
prior written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent to any proposed settlement (it being agreed
that Indemnitee&rsquo;s refusal to consent to a proposed settlement that would in any manner impose any fine, Expense, limitation or other
obligation on Indemnitee, or disparage Indemnitee or contain an admission of wrongdoing by Indemnitee, would not be unreasonable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Procedure
Upon Application for Indemnification.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
a Change in Control has occurred, the determination of Indemnitee&rsquo;s entitlement to indemnification will be made[ by the Board]<SUP>1</SUP>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[by
a majority vote of the Disinterested Directors, even though less than a quorum of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by a committee of one or more Disinterested Directors designated by a majority vote of the
Disinterested Directors, even though less than a quorum of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
there are no such Disinterested Directors or, if such Disinterested Directors so direct, by written opinion provided by Independent Counsel
selected by the Board or a committee thereof, by vote in accordance with subsection(a)(i)&nbsp;or (a)(ii); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> NTD: Applicable for indemnitees other than directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">iv.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
so directed by the Board, by vote of the shareholders of the Company, excluding any directors of the Company who are not Disinterested
Directors.]<SUP>2</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a Change in Control has occurred, the determination of Indemnitee&rsquo;s entitlement to indemnification will be made by written opinion
provided by Independent Counsel selected by Indemnitee (unless Indemnitee requests such selection be made by the Board).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
party selecting Independent Counsel pursuant to subsection (a)(iii)&nbsp;or (b)&nbsp;of this Section&nbsp;12 will provide written notice
of the selection to the other party. The notified party may, within ten (10)&nbsp;days after receiving written notice of the selection
of Independent Counsel, deliver to the selecting party a written objection to such selection; <U>provided</U>, <U>however</U>, that such
objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &ldquo;Independent
Counsel&rdquo; as defined in Section&nbsp;2 of this Agreement, and the objection will set forth with particularity the factual basis of
such assertion. Absent a proper and timely objection, the person so selected will act as Independent Counsel. If such written objection
is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection
is withdrawn or the Business Court (or the Alternative Courts) has determined that such objection is without merit. If, within thirty
(30) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;11(a)&nbsp;of
this Agreement and the final disposition of the Proceeding,&nbsp;Independent Counsel has not been selected or, if selected, any objection
to such selection has not been resolved, either the Company or Indemnitee may petition the Business Court (or the Alternative Courts)
for resolution of any objection made by the Company or Indemnitee to the other&rsquo;s selection of Independent Counsel or for the appointment
as Independent Counsel of a person selected by such court or by such other person as such court designates. Upon the due commencement
of any judicial proceeding or arbitration pursuant to Section&nbsp;14(a)&nbsp;of this Agreement,&nbsp;Independent Counsel will be discharged
and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnitee
will cooperate with the person, persons or entity making the determination with respect to Indemnitee&rsquo;s entitlement to indemnification,
including providing to such person, persons, or entity upon reasonable advance request any documentation or information that is not privileged
or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination.
The Company will advance and pay any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making the indemnification
determination irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification, and the Company hereby indemnifies
and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing of the determination that Indemnitee
is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied and
providing a copy of any written opinion provided to the Board by Independent Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within forty (40) days after
such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> NTD: Applicable for indemnitees that are directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Presumptions
and Effect of Certain Proceedings.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
making a determination with respect to entitlement to indemnification under this Agreement, the person, persons, or entity making such
determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement
if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;11(a)&nbsp;of this Agreement, and the Company
will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. Neither the failure of the Company
(including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this
Agreement that indemnification is proper under the circumstances because Indemnitee has met the applicable standard of conduct, nor an
actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard
of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the determination of the Indemnitee&rsquo;s entitlement to indemnification has not been made pursuant to Section&nbsp;12 of this Agreement
within sixty (60) days after the later of (i)&nbsp;receipt by the Company of Indemnitee&rsquo;s request for indemnification pursuant
to Section&nbsp;11(a)&nbsp;of this Agreement and (ii)&nbsp;the final disposition of the Proceeding for which Indemnitee requested indemnification
(the &ldquo;<U>Determination Period</U>&rdquo;), the requisite determination of entitlement to indemnification will, to the fullest extent
not prohibited by law, be deemed to have been made and Indemnitee will be entitled to such indemnification absent (i)&nbsp;a misstatement
by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement not materially misleading,
in connection with the request for indemnification or (ii)&nbsp;a prohibition of such indemnification under applicable law; <U>provided</U>,
that the Determination Period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons
or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the
obtaining or evaluating of documentation or information relating thereto[; and <U>provided</U>, <U>further</U>, that the Determination
Period will not apply if the determination of entitlement to indemnification is to be made by the shareholders pursuant to Section&nbsp;12(a)(iv)&nbsp;of
this Agreement and if (A)&nbsp;within fifteen (15) days after receipt by the Company of the request for such determination the Board
has resolved to submit such determination to the shareholders for their consideration at an annual meeting thereof to be held within
seventy-five (75) days after such receipt and such determination is made thereat, or (B)&nbsp;a special meeting of shareholders is called
within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within
sixty (60) days after having been so called and such determination is made thereat]<SUP>3</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
termination of any Proceeding or of any claim, issue, or matter therein by judgment, order, settlement, conviction, or upon a plea of
<U>nolo contendere</U> or its equivalent, will not (except as otherwise expressly provided in this Agreement) in and of itself adversely
affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which
Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding,
that Indemnitee had reasonable cause to believe that Indemnitee&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP> NTD: Applicable for indemnitees that are directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of any determination of good faith,&nbsp;Indemnitee will be deemed to have acted in good faith if Indemnitee acted based on (i)&nbsp;the
records or books of account of the Company, its subsidiaries, or an Enterprise, including financial statements, (ii)&nbsp;information
supplied to Indemnitee by the directors or officers of the Company, its subsidiaries, or an Enterprise in the course of their duties,
(iii)&nbsp;the advice of legal counsel for the Company, its subsidiaries, or an Enterprise or (iv)&nbsp;information or records given or
reports made to the Company or an Enterprise by an independent certified public accountant or by an appraiser, financial advisor or other
expert selected with reasonable care by or on behalf of the Company, its subsidiaries, or an Enterprise. Further,&nbsp;Indemnitee will
be deemed to have acted in a manner &ldquo;not opposed to the best interests of the Company,&rdquo; as referred to in this Agreement if
Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries
of an employee benefit plan. The provisions of this Section&nbsp;13(d)&nbsp;are not exclusive and do not limit in any way the other circumstances
in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
knowledge or actions, or failure to act, of any other person affiliated with the Company or an Enterprise (including, but not limited
to, a director, officer, trustee, partner, managing member, Agent or employee) may not be imputed to Indemnitee for purposes of determining
Indemnitee&rsquo;s right to indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies
of Indemnitee.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnitee
may commence litigation against the Company in the Business Court (or, in the event that the Business Court is not then accepting filings
or determines that it lacks jurisdiction, the United States District Court for the Northern District of Texas, or, if that court lacks
jurisdiction, the state district courts of Dallas County, Texas (the &ldquo;<U>Alternative Courts</U>&rdquo;)) to obtain indemnification
or advancement of Expenses provided by this Agreement in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;12 of
this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;the Company does not advance Expenses
pursuant to Section&nbsp;10 of this Agreement, (iii)&nbsp;the determination of entitlement to indemnification is not made pursuant to
Section&nbsp;12 of this Agreement within the Determination Period, (iv)&nbsp;the Company does not indemnify Indemnitee pursuant to Section&nbsp;5
or 6 or the second to last sentence of Section&nbsp;12(d)&nbsp;of this Agreement within thirty (30) days after receipt by the Company
of a written request therefor, (v)&nbsp;the Company does not indemnify Indemnitee pursuant to Section&nbsp;3, 4, 7, or 8 of this Agreement
within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi)&nbsp;in the event
that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes
any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to
be provided to the Indemnitee hereunder. The Company will not oppose Indemnitee&rsquo;s right to seek any such adjudication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee is not entitled to indemnification, any judicial
proceeding commenced pursuant to this Section&nbsp;14 will be conducted in all respects as a <I>de novo</I> trial on the merits, and Indemnitee
may not be prejudiced by reason of that adverse determination. In any judicial proceeding commenced pursuant to this Section&nbsp;14 the
Company will have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be,
and will not introduce evidence of the determination made pursuant to Section&nbsp;12 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a determination is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee is entitled to indemnification, the Company will
be bound by such determination in any judicial proceeding commenced pursuant to this Section&nbsp;14 unless (i)&nbsp;Indemnitee made a
misstatement of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement not materially misleading,
in connection with Indemnitees&rsquo; request for indemnification, or (ii)&nbsp;the Company is prohibited from indemnifying Indemnitee
under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company is, to the fullest extent not prohibited by law, precluded from asserting in any judicial proceeding commenced pursuant to this
Section&nbsp;14 that the procedures and presumptions of this Agreement are not valid, binding, or enforceable and will stipulate in any
such court that the Company is bound by all the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;It
is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other
Expenses associated with the interpretation, enforcement, or defense of Indemnitee&rsquo;s rights under this Agreement, by litigation
or otherwise, because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee
under this Agreement. The Company, to the fullest extent permitted by law, will (within thirty (30) days after receipt by the Company
of a written request therefor) advance to Indemnitee such Expenses which are incurred by Indemnitee in connection with a Proceeding concerning
this Agreement,&nbsp;Indemnitee&rsquo;s other rights to indemnification or advancement of Expenses from the Company, or concerning any
directors&rsquo; and officers&rsquo; liability or other insurance policies maintained by the Company, and will indemnify Indemnitee against
any and all such Expenses unless the court determines that Indemnitee&rsquo;s claims in such action were made in bad faith or frivolous,
or that the Company is prohibited by law from indemnifying Indemnitee for such Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-exclusivity;
Survival of Rights; Insurance; Subrogation.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
indemnification and advancement of Expenses provided by this Agreement are not exclusive of any other rights to which Indemnitee may at
any time be entitled under the TBOC or other applicable law, the Certificate of Formation, the Bylaws, any agreement, a vote of shareholders
or a resolution of the Board, or otherwise. The indemnification and advancement of Expenses provided by this Agreement may not be limited
or restricted by any amendment, alteration or repeal of this Agreement in any way with respect to any action taken or omitted by Indemnitee
in Indemnitee&rsquo;s Corporate Status occurring prior to any amendment, alteration or repeal of this Agreement. To the extent that a
change in Texas law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be
afforded currently under the Bylaws, the Certificate of Formation, or this Agreement, it is the intent of the parties hereto that Indemnitee
enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive
of any other right or remedy, and every other right and remedy is cumulative and in addition to every other right and remedy given hereunder
or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise,
will not prevent the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
or Agents of the Company, the Company will obtain a policy or policies covering Indemnitee to the maximum extent of the coverage available
for any such director, officer, employee or Agent under such policy or policies, including coverage in the event the Company does not
or cannot, for any reason, indemnify or advance Expenses to Indemnitee as required by this Agreement. If, at the time of the receipt of
a notice of a claim pursuant to this Agreement or the commencement of a Proceeding, the Company has directors&rsquo; and officers&rsquo;
liability or other applicable insurance in effect, the Company will give prompt notice of such claim or of the commencement of a Proceeding,
as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company will thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such
claim or Proceeding in accordance with the terms of such policies. Indemnitee agrees to assist the Company&rsquo;s efforts to cause the
insurers to pay such amounts and will comply with the terms of such policies, including selection of approved panel counsel, if required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company&rsquo;s obligation to indemnify or advance Expenses hereunder to Indemnitee for any Proceeding concerning Indemnitee&rsquo;s Corporate
Status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses
from such Enterprise or such Enterprise&rsquo;s insurers. The Company and Indemnitee intend that any such Enterprise (and its insurers)
be the indemnitor of first resort with respect to indemnification and advancement of Expenses for any Proceeding related to or arising
from Indemnitee&rsquo;s Corporate Status with such Enterprise. The Company&rsquo;s obligation to indemnify and advance Expenses to Indemnitee
is secondary to the obligations the Enterprise or its insurers owe to Indemnitee. Indemnitee agrees to take all reasonably necessary and
desirable action to obtain from an Enterprise or its insurers indemnification and advancement of Expenses for any Proceeding related to,
or arising from,&nbsp;Indemnitee&rsquo;s Corporate Status with such Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event of any payment made by the Company under this Agreement, the Company will be subrogated to the extent of such payment to all
of the rights of recovery of Indemnitee from any Enterprise or its insurance carrier. Indemnitee will execute all papers required and
take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring
suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Duration
of Agreement.</U> The indemnification and advancement of Expenses rights provided by or granted pursuant to this Agreement: (i)&nbsp;are
binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor
by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), (ii)&nbsp;continue
as to an Indemnitee who has ceased to be a director, officer, employee or Agent of the Company or of any Enterprise, and (iii)&nbsp;inure
to the benefit of Indemnitee and Indemnitee&rsquo;s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability.</U>
If any provision of this Agreement is held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality
and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will
not in any way be affected or impaired thereby and will remain enforceable to the fullest extent permitted by law; (b)&nbsp;such provision
will be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties
hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of
any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid,
illegal or unenforceable) will be construed so as to give effect to the intent manifested thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Interpretation</U>.
Any ambiguity in the terms of this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification
and advancement of Expenses permitted by law. The Company and Indemnitee intend that this Agreement provide to the fullest extent permitted
by law for indemnification and advancement of Expenses in excess of that expressly provided, without limitation, by the Certificate of
Formation, the Bylaws, vote of the Company&rsquo;s shareholders or a resolution of the Board, or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;19.&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Enforcement.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to [continue to] serve as a director, officer, employee, or Agent of the Company, and the Company acknowledges that
Indemnitee is relying upon this Agreement in [serving / continuing to serve] as director, officer, employee, or Agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior
agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof (including
any agreements regarding the arbitration of disputes regarding the subject matter of this Agreement); <U>provided</U>, <U>however</U>,
that this Agreement is a supplement to and in furtherance of the Certificate of Formation, the Bylaws, any directors&rsquo; and officers&rsquo;
or other insurance maintained by the Company, and applicable law, is not a substitute therefor, and does not diminish or abrogate any
rights of Indemnitee thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Modification
and Waiver.</U> No supplement, modification or amendment of this Agreement is binding unless executed in writing by the parties hereto.
No waiver of any of the provisions of this Agreement will be valid unless executed in writing by the party entitled to enforce the provision
to be waived and any such waiver will not be deemed or constitute a waiver of any other provisions of this Agreement nor will any waiver
constitute a continuing waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
by Indemnitee.</U> Indemnitee agrees to promptly notify the Company in writing upon being served with any summons, citation, subpoena,
complaint, indictment, information or other document relating to any Proceeding or matter that may be subject to indemnification or advancement
of Expenses covered hereunder. The failure of Indemnitee to so notify the Company does not relieve the Company of any obligation that
it may have to the Indemnitee under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices.</U>
All notices, requests, demands and other communications under this Agreement will be in writing and will be deemed to have been duly given
if (a)&nbsp;delivered by hand to the other party, (b)&nbsp;sent by reputable overnight courier to the other party or (c)&nbsp;sent by
electronic mail, with receipt of oral or written confirmation that such communication has been received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
to Indemnitee, at the address indicated on the signature page&nbsp;of this Agreement, or such other address as Indemnitee provides to
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
to the Company to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 73%; text-align: left"><FONT STYLE="font-size: 10pt">Caris Life Sciences,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">750 W. John Carpenter Freeway,
    Suite&nbsp;800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Irving, TX 75039</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">GC@carisls.com</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or to any other address as may have been furnished to Indemnitee by
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Contribution.</U>
To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee
for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether
for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement or for Expenses, in connection with any claim
relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances
of such Proceeding in order to reflect (a)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s)&nbsp;or
transaction(s)&nbsp;giving cause to such Proceeding; or (b)&nbsp;the relative fault of the Company (and its directors, officers, employees
and Agents) and Indemnitee in connection with such event(s)&nbsp;and/or transaction(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;24.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Applicable
Law and Consent to Jurisdiction.</U> This Agreement and the legal relations among the parties are governed by, and shall be construed
and enforced in accordance with, the laws of the State of Texas, without regard to its conflict of laws rules. The Company and Indemnitee
hereby irrevocably and unconditionally (a)&nbsp;agree that any action, claim, or proceeding between the parties arising out of or in connection
with this Agreement may be brought only in the Business Court (or the Alternative Courts in the event the Business Court does not have
jurisdiction over such matter) and not in any other state or federal court in the United States of America or any court in any other country,
(b)&nbsp;consent to submit to the exclusive jurisdiction of the Business Court (and the Alternative Courts if applicable) for purposes
of any action, claim, or proceeding arising out of or in connection with this Agreement, (c)&nbsp;waive any objection to the laying of
venue of any such action, claim, or proceeding in the Business Court (or the Alternative Courts if applicable), and (d)&nbsp;waive, and
agree not to plead or to make, any claim that any such action, claim, or proceeding brought in the Business Court (or the Alternative
Courts if applicable) has been brought in an improper or inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;25.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Identical
Counterparts.</U> This Agreement may be executed in one or more counterparts, each of which will for all purposes be deemed to be an original
but all of which together constitute one and the same Agreement. Counterparts may be delivered via electronic mail (including any electronic
signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act
or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes. Only one such counterpart signed by the party against whom
enforceability is sought needs to be produced to evidence the existence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;26.&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Headings.</U> The headings of this Agreement are inserted for convenience only and do not constitute part of
this Agreement or affect the construction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused this Agreement to be signed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">CARIS LIFE SCIENCES,&nbsp;INC.&#8239;&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">INDEMNITEE</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>29
<FILENAME>tm2415719d15_ex16-1.htm
<DESCRIPTION>EXHIBIT 16.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;16.1</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">September&nbsp;12,
2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">Washington, DC 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">Commissioners:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">We have read the section titled
 &ldquo;Change in Independent Registered Public Accounting Firm&rdquo; in the Form&nbsp;S-1 of Caris Life Sciences,&nbsp;Inc. and are in
agreement with the statements contained in the first two sentences of the first paragraph, and in the second through fourth paragraphs
of that section. We have no basis to agree or disagree with other statements of the registrant contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">/s/ Ernst&nbsp;&amp; Young
LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>30
<FILENAME>tm2415719d15_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-align: right"><B>Exhibit&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the reference to our firm under the caption &quot;Experts&quot;
and to the use of our report dated March&nbsp;18, 2024, in the Registration Statement (Form&nbsp;S-1) and related Prospectus of Caris
Life Sciences,&nbsp;Inc. for the registration of shares of its common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dallas, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;23, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>31
<FILENAME>tm2415719d15_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT><B>Exhibit&nbsp;23.2</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the use in this Registration Statement
on Form&nbsp;S-1 of our report dated April&nbsp;4, 2025, relating to the financial statements of Caris Life Sciences,&nbsp;Inc. We also
consent to the reference to us under the heading &quot;Experts&quot; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Deloitte&nbsp;&amp; Touche LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Jose, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May&nbsp;23, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>32
<FILENAME>tm2415719d15_ex23-4.htm
<DESCRIPTION>EXHIBIT 23.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 4in">May 23, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Caris Life Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">750 W. John Carpenter Freeway, Suite 800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Irving, Texas 75039</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Dear Caris Life Sciences, Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We, Nephron Research LLC of 767 Third Ave, 21<SUP>st</SUP>
Floor, New York, New York, 10017, hereby consent to the filing with the Securities and Exchange Commission of a Registration Statement
on Form S-1, and any amendments thereto (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) of Caris Life Sciences, Inc., and any
related prospectuses of (i) our name and all references thereto, and (ii) the statements set out in the Schedule hereto. We also hereby
consent to the filing of this letter as an exhibit to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further consent to the reference to our firm,
under the caption &ldquo;Market and Industry Data&rdquo; in the Registration Statement, as acting in the capacity of an author of independent
industry publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 0.5in; border-collapse: collapse; width: 90%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
    faithfully,</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Timothy Biggins</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Timothy Biggins</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation:
    COO/CCO</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    and on behalf of Nephron Research LLC</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>SCHEDULE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD>Our estimated total addressable U.S. oncology market, which is based on a market study by Nephron Research LLC that we commissioned,
is comprised of opportunities in the following areas:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Early detection:</I></B> approximately $100 billion.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Therapy selection:</I></B> approximately $8 billion.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>MRD tracking and treatment monitoring:</I></B> approximately $28 billion.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Core biopharma services:</I></B> approximately $4 billion.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Data services for biopharma:</I></B> approximately $10 billion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD>We believe our expansive multi-omic technology platform has application across multiple clinical and biopharma settings that collectively
represent an estimated total addressable U.S. market of approximately $150 billion in oncology, according to a market study by Nephron
Research LLC (&ldquo;Nephron Research&rdquo;) that we commissioned.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD>Based on National Comprehensive Cancer Network (&ldquo;NCCN&rdquo;) guidelines suggesting that breast and lung cancer patients would
benefit from at least two tests during therapy, and assuming that these benefits would apply to other types of solid tumors, Nephron Research
estimates that approximately 520,000 newly-diagnosed advanced stage and recurrent cancer patients in the United States would benefit from
repeat testing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD>Accordingly, based on the newly-diagnosed patient, recurrent patient, and repeat testing patient cohorts described above, Nephron
Research estimates that the total addressable U.S. market for therapy selection is comprised of approximately two million unique patient
profiles annually and, assuming an average reimbursement of approximately $4,000 based on blended Medicare, commercial payer, and Medicaid
coverage rates for various genomic profiling tests, amounts to approximately $8 billion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD>According to the Nephron Research analysis, the number of annual unique patient profiles is expected to increase with clinical and
payer adoption of broad molecular testing in earlier stages for newly- diagnosed cancer patients.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">6.</TD><TD>According to the Nephron Research analysis, these result in a cohort of approximately 5.6 million patients being monitored at various
points in their treatment journey.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">7.</TD><TD>Assuming a range of two to three tests annually for each patient, consistent with MolDX coverage policy for MRD, pricing of $2,500
per reference test and $1,650 per follow-up blood test, in each case based on pricing for other tests available on the market, Nephron
Research estimates that the total addressable U.S. market for MRD tracking tests represents approximately 16 million tests annually and
amounts to approximately $28 billion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">8.</TD><TD>According to the Nephron Research analysis, oncology testing associated with clinical trials includes approximately 250,000 cancer
patients in targeted therapy clinical trials.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">9.</TD><TD>Assuming five tests (one therapy selection test to establish cancer type and determine the therapeutic intervention(s) and four monitoring
tests for follow-up consistent with typical trial designs) for each trial participant and pricing of $5,000 per therapy selection test
and $1,950 per monitoring test, based on existing reimbursement rates for other tests available on the market, Nephron Research estimates
that the addressable U.S. market for oncology testing in clinical trials is approximately $3.2 billion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">10.</TD><TD>Assuming approximately 25 Phase 1b trials progress to Phase 2 each year based on recent historical data from ClinicalTrials.gov, with
each trial having two partners per customary industry practice (a specialty lab and a distributable kit) and an average contract price
of $10 million based on Nephron Research&rsquo;s market analysis, the addressable U.S. market for the development of companion diagnostics
tests is estimated to be approximately $500 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">11.</TD><TD>Assuming a rate of rare mutation of 4.0% within the population of newly-diagnosed cancer patients in the United States with advanced-stage
solid tumor cancers, based on data from the National Institutes of Health, and an average reimbursement per patient of $10,000 based on
Nephron Research&rsquo;s market analysis, the addressable U.S. market for commercial services that include identification of patients
for approved therapies is estimated to be approximately $300 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">12.</TD><TD>According to the Nephron Research analysis, it is estimated that approximately $70 billion of the $262 billion spent in 2023 represented
R&amp;D investments in discovery, pre-trial costs, and real-world evidence, areas where matched genomic data has demonstrated use cases
for biopharma applications.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">13.</TD><TD>Based on Nephron Research&rsquo;s market analysis, approximately 14% of the estimated $70 billion in R&amp;D investments in 2023 was
allocated towards such data and services, resulting in an estimated total addressable U.S. market for this opportunity of approximately
$10 billion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>33
<FILENAME>tm2415719d15_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 107.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Caris Life Sciences, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: top; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: top; text-align: center; width: 8%; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; width: 8%; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security Type</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: top; width: 39%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Security Class Title</B></P></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; width: 7%; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee Calculation<BR>
 Rule</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; width: 9%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registered</B></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; width: 8%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maximum<BR>
 Offering Price</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Per Unit</B></P></TD>
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 0%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; width: 9%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering Price<SUP>(1)(2)</SUP></B></P></TD>
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 0%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; text-align: center; width: 6%; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee Rate</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; width: 0%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 2pt; white-space: nowrap; vertical-align: bottom; width: 6%; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount&nbsp;of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registration<BR>
Fee</B></P></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-right: 2pt; vertical-align: top; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees to be Paid</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class&nbsp;A common stock, $0.001 par value per share</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule 457(o)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2pt; vertical-align: top; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000,000</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00015310</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,310.00 </FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Offering Amounts</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000,000</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,310.00 </FONT></TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Fees Previously Paid</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Fee Offsets</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD></TR>
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Fee Due</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,310.00 </FONT></TD></TR>
<TR>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: top; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: bottom; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; vertical-align: bottom"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2pt; vertical-align: bottom; text-align: center; padding-left: 2pt"><FONT STYLE="font-size: 2pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase to cover over-allotments, if any. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>bc_caris-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_caris-4c.jpg
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M%!04%!04%!04%/_  !$( LP#M ,!$0 "$0$#$0'_Q #5  $  @(# 0$
M        !P@&"0,$!0(! 0$  @,! 0$             !@<!!0@"! ,0   %
M @($!PL'"08$! 4$ P ! @,$$042!A,'-P@ALG.S%'1U,4%QL2(R-+05-B=1
MTB.4-18784)R,R0E)E88@<%2@M-5T6*2DY%#4U2AHL2%.&.#A$:C1+41 0
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M
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MF+A):1I7(Z,3;R6ZDG$;;B4JH1F15IWP&4
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MZXE)-G0JZ'-P(?02"6OS32APSQ=Q)C QC=/S.W:,X7>R2G-'$ND$Y!5/@TT
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M>+SE<)]TS&1Z&L_+6J^RLV^3JXS,Y>M(:FKA%DI/2H41$:74JT3183X2--.
M_P#X!)4/.$[->ZUF.'=7#D3K#)B04/N'B6J/TJ,MDS,^^DE&CP)(8$)9-M&:
MLUSSR5E@U+7>5(5)C8R;96F+B<2MU1_FMU-7A^4Z#(LC9<A9XU*:H<_/N2([
MEWE-,NPWK:MU:FF_U3RZK;;-*D(6I9&7<I48%:LG,90F7YMG/4V9!L3B5:27
M 0EUY+O!A-1*)1X>[4TI4?Y!D7!U$ZN<DY8D73,^3,QIS' N++49I9I03T8D
MJ4M:'#29'57D'12$'Y(Q%E-8P
M                         (5UA[P]LU=9X5E:X6EV=";BLO/RHKB2>;>>
M-2L&C61)46#"KSR[HSP$5:Y]>>KK6%E-=HMECE/7U2FU1+C-:995$PK)2\*D
M..*/$DC3AX$\->\##']URP3[IK*3=&4*]F6J)(5.=X<'[2VIAMLS^51J-1%_
MRG\@S$1??LON93S9+R[F!IU*;;+-B6EJB'5L)57&V:R,O+0>)!F5.$C 2$Q8
MMW)Z.3Z\TY@CN&5>BNQ&U.E^0S;:4BO@4 DRSY3R79M0V>,QY*FSIL"^Q=&O
MVDEI#R#@.K;IA:*A8C6:N$^Y08$3[N6V/+G_ /,]2?&8C-=[[WTL79?_ -0Z
M,0&7:D<RV3*.H"[WW,4<YEF9N+[4N&E*'%/(D]'9P$APR2JN/A(S[@"*M8-H
MU"S+1*O^0<P2H-WX%-9<?C/N-K4I1$:4K6@M&1$9G4W%EP4&1ZVZA-O#6L:1
M!A*6=JDP'EW-HC/1T:-.B69=S$2U$DC^11_*,1$/V[WHB=?;YXAD66WQ8CRH
M64IZ4F<=IV<PXJG 2W4L*25?RDVK_P !B P[=WUOV'($>?ER]Q)3KEVF,+AO
MQ$H<+2+(F32LEK10BX#J5>^$1CN\KMAOG)PO5&AF M%JBM<2^:CK'9IZ<<*X
M6UZ+(3\K;RW4*_\ @8PRI-CN^KW-=QB>9<[:J=:W^Z1&3K;D1PR_(:5F:?[!
MEA-FZ1E'IN8;KG.2BK%J9*%"49<'297"M23^5#983_3&(CI[WGO[9NR$>LOA
M 9UJ6B/7#=QS+!C)-<B2W>&FD$53-:XU$D1?E,P%9]7N9V,FYULN9Y3"Y,:V
MR"=>9;H3BFS2:%8:F18B)52J8R+\Y3S7E[6ME*1<8,=\['/Z1;WV)B$MK6BF
MC<(R0M9442OE'EE0^ZQKSJLSY<[='7AN-I=E0VW5%Y[$EI;1+IP?K&7<1>$>
MF$J;IV4CNF<9V;'VZQ+%'-J.HR__ -N81H*GZ+9.5_2(8B+E##*BV\_M;G]4
MA\T0]089]=__ ,0+;^FW_P#]18P,/W4MJ+G9<KG&1F(ZV])M7D]1B<4P@+([
MN6QS+G_\SUU\8BR]36YK+;U6Y>B7U4,K@Y)FM1"B&X;2E(4A:UJ)6%5#(D=\
MA@1K+WJ-6-WL[\6\6"X2=,@TNVU]B,\PY4NX:E.TI^4T_P!@SP850BV^1F7,
M*+=881I?N<K1P("#->#3+\A&(^$R21\*C[Q5,9%DM[BV28]FR2ZI1NM0^EQ'
MGS+NN*;8-)F?RJ)M1C$!BV[MK>L&0F9V6[W%E.+N\UA<.1%2A:2<<HR:7"6M
M%"+@.I5[X1$=:XI]TN.L_-+MW4HY+-QD1FDJK1,=A9MLDFOYNC))E_XC(R76
M5,U*M9(LEJU=,+>S&IUJ1<[@\AXGDMI96E;;JG:)Q*6I)X6BPEA\%0R3=ILJ
MLQVG6/8$&27+G:6X;:CX");Z9"$F?@,QB(B+*]ZN&KW.T"\/Q%=/L4S]J@N_
M1KJTHT.M&=#PJIB36G 8R)+U\ZZ;%K0A66W6"%)CL05N29+LPD(7I7$DDD)2
MVM9&1%6JC,(#T-WVP2,T9%UI6"'PS9T&(W%29T)3Q)E*;29]ZJB(AB(A>QLV
M-F^-QLXIG,6I"EM3B@DVF8TLB,BHEXL/DJ\Y)T/N]\9$DNV'=Q;8TR<UW]UR
ME>CHAH)SP56TE%?\P"VFJ/*UBRGD:WQ,N27YEIGI*Z1WY> GC3,0EQ.(FR))
M430AY91-O@^[>6NO/<R,P8>5N<?_ -R_^W?_ %01$R:\H%RN6JC,\6TI4N7T
M9#IH055*99>0Z\1$7_Z:5#$&5.]26?;5JZSRU?;U'6_;7H[L)]QI)+<9)XTJ
M)U*3I6AHH??PF?@'IA\:WCU:2LQ>UM6LQQR#/Q.S;><9R.S&>.AGH3<))X55
M/R,-$&7 =#(B#YU-V/+^:M8]I@9MG)9@K<)XFGZJ*9(;,C;C&H^ M(?=Q>=3
M"7E*(!L+'EE3;>\]_;-V0CUE\9@PRS5=_P#B]FWD;QZN0"$]16UO*O6U<TL9
MB-A(\LJ);Q&KV=D_/<Z\ML*/+^8'ES8<E)>0F0Z>-YE1]Y1+,U)+_"9?(=/4
M&&5ZI-Y=&4+%&ROG""_.@0$DU;Y\,T*?0P7FM+0XI)*)/<29**B>"G ,<!,&
M5-X[)N<\VVW*=F@ST.W$W4IERT---H4VTMTBHEQ:CQ8,/A,.#*FV;9\VZYVN
M\W,:W>EO7%[VAWW4$ETTJ0DE<!8"+"DNX5"(989QK@FZG#MUCMNJR/B>:QNW
M*>:7TK4E24DA"U2*&I5:J.A4+O )$W:]F^L;D5>J/#$1"6JC:;E#M>%SZ1D3
M[OC>AY/Y2X<6.,0&*ZE<NR\UZG=95AMZ#<GR3C+BM%W7'8Z3?0@ORJ-!)+P@
M(HU<YRD:NLZV_,Q1CD%"6MN5$4>!2VG4*:<21GW%$2JE^4N$9%N[7KZU?:Q'
MV\E6SIS-QS R_#;T["4(:4XPLSQJ)P_DH6&O",,J7KM3=BS*JSYN8DL-091Q
M[JS%P)DI2VK"O1&X1I,Z<*:\!C+"246'=Q5')\\UW]#AE7HRH:#<+\AF31H_
M^8!(MRRIE3+^[5F.[90ES)EKO[D.6E=Q)I+Z=#.:9P&37DE0TJ[YC P+=;VK
MQ^HR^*0S$7'SEF&V95RO=,P7IDY%KA,FJ5'2E*U.(69(P$E9DD\1JPT,Z#RR
MIOGRU[O]VM,W,&2+]*M%ZPFZSEYZ,^XTXZ9UT:#-%&Z_+I5)+Y!Z8-UZ;=V-
M:D2);U+]GRXLDKJVDSP&PVTI2%*+N<#N B/\M.^$1>4>60
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M)JQR?JYC.L99A&W(D$12ISZM+)=)/"1*6=*$7^%)$G\@PRS
M
M                !C^>,K,9VRG=LK2'NCHN;!M)D8-)HW",EH7AJFN%22.E
M2 8-JVW?\G:NY:+OB<O.8&_U,^6E*4,F94,V6DU))G_B,U*^0R&>(ED8
M               09FO=;R5F2[3+U'N5PMTR>\Y)DH);<AHW7E&M:B)Q.(JF
M9_GC/$=:Q;IN0;;*1)N\Z=>$-F1]%6I$=A5#[B]$6,R\"R#B)T@0(5KA,6ZV
MQVXL"*A+4>,RDD-MH25"2E)<!$0P.P
M
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M)E.H9:37N54LR(!TK%FS+&9TN+R[>(=T)FFF*&^V\I%>YB)!F::]ZH#V
M '5<N=N9G,6MZ8PW<Y*%.1H:W$)?<0WYRD-F>)1)[YD7  Q?-&M7(639Y6J_
MW=+-RP:9R(PR_+=;:I7&XF.VX:"IP^53@ 9/;+E!O-NBW:V/%(MTUI#\5])&
M1+:<+$E1$HB/A(^^0#M*4E*34HR2E)5,SX"(B[Y@.O;[C;[M$;GVN6S.@NUT
M4F,XEYI6$S2>%:#,CH94[H#L@.M<;A"M,"3=+B\4>!#;4_)?57"VTV6)2CH1
M\!$53 ?<25&G16)L)U$B');0]'?;,E(<:<22DJ2HN R,CJ1@.8
M
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MJWN5!MI*,U*3;WJ2(Z3,^$S23BD^ B&1)@P
M
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MD!W]4)>T)N>LTH*L*\9@D(@.EPI=C0$)C)=2??2I25T\ "3A@
M
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M[$9'Y7" [&7[%;<L66#E^SLZ"VV]I+$=ONGA3W5*/@JI1U4H^^9F8#T@
M
M
M
M
M
M
M
M
M
M
M !CF>,[V+5YEV3FC,1R"MD7]842.[+=X$J6?D-)50B2E2E*51*2+A,@&.9FU
MV9*RL5N.:4^6<ZW(OTA,"(Y*5!LRS)/3IB4<+;*3.AGPGP*H1DDZ&>#[FZZL
MC6_,Z\MRWI+;+3Y07LP&PKV*W<%Q>FIAJF5P:8V/I,)<'"1&>(R(#@_<OZY<
MHYD90<!JX-SGID*%'MLB(MJ6Z5T9.5&?2BI_0J82M\UF984(7B(C30#@D(&
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M)7<,&'J
M
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M$2:$@BPT01J$4Q P
M
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M/_E/QMU:_P"\']6D_P"F'T_Z[\']TO\ ,^L-+_-_MG_RGXVZM?\ >#^K2?\
M3#Z?]=^#^Z7^9]8:7^;_ &S_ .5FEHNT"^VV/=[6[IH$I.-AW"I&))&9=Q1$
M9<)=\AIJ]">C/&2>'":':DOI?54_4TI:M./&6;LC_P#V[H_!]0
M
M                                                   ^5^8KP&,P
M8CV*"K/RU>$Q?4')4>U^5&6"H!4!F>J8_B+E_K!\VL:;6LE4LO27;'N='%=%
M<H4XZ28UK"]Q,R=FRN:4-EIF;I8Y>;2:[[?7_3G\,5)ZBZG,94 J 5 2MN]^
M_J^H/\=L17<^4ZH7I]L;W&.";G*M.*M7RBS> V?JZ['\2Q*-LYSIC<@>^/;N
MN6]56HM10A4 J 5 6#W:/1LR?IP_$\*^W9WJ75\JW_\ M[W:]LGS)Z$$6PK-
MO'^]UL[-3S[PLO:N6GQW04AO[.T_T_FF0W43%6Y4 J 5 7*U3;.LO]7/G%BG
M-:SM2VYTEMCVRCAOBS,:9)0!YDC,F78=WC9>EW>$Q?YB3<AVMV2TB8\@JU4V
MRI1+47 ?"E/> =5O.V3'KC-M#.8K6Y=K:AUVXP$38ZI$9N/^M6\V2\3:45\L
MU$6'O@.W#S#8+C'@2[?=(DN+=#4FV/L/MNMR5(2I2B94E1DLTDA1GAK0B/Y
M'I
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M,'E]@
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MAQA"+\IJU.$>$9H<;7S[1M__ +MG_N(_XC/^E/\ PC\'G_J*?XH?&![1M_\
M[MG_ +B/^(?Z4_\ "/P/^HI_BA\8'M&W_P#NV?\ N(_XA_I3_P (_ _ZBG^*
M'Q@>T;?_ .[9_P"XC_B'^E/_  C\#_J*7XH?&#LC\G[@  PAG6_JZ?S!*RPU
M?$*N\0Y:'$Z%\F%NVY&DELM2-'HG76$>4ZTVM2TE6I<!T,\'3@:\=65S@3;A
M#N[BR@.Q8[T-<&:U.6[<*G%)J*XPEYW3$1FV;;9D9$?R'0<&2V;.>6LQ/0V+
M'/1/5.MS=YC+92M39P'UX&G35AHG&HE$E*C)1X5<'DG0P]X
M
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MF
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M,&&7
M                                ^5^8KP&,P[6(]C7ZOSU>$Q?$.QRA
M'M?(RP  #-=4>TC+W63YM8TVM9.I9>DFVO<J.*Z*Z(IYT:QG6+[A9E[-E\TH
M;+3,W2QR\VEUS(5_TYN45'Q=#F@   !+.[MM <[/D<=H17<V4ZH7IYLCW"."
M;G*M:*O7JBG>%V>JZ['\2Q*-M9SIB@N]O;NN6]4\6DH@   !8C=C]&S-^G#\
M3XK_ '9WJ75\JW-@=VO;)\R?A!5JJP;RGOA:^S4<^\+*VMEYL=T%*;\SE/\
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MB<%:U.O<H ^T7*W.-O/-S&%LQW51Y#B7$&EMY!DE3:S(Z)41G0TGPU =H
M
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M22HJ\(/+)P
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M*D*21H77&DR*AUX#J7?J ^@
M                                          ?*_,5X#&8=K$>QKW69
MXU>$Q>\.QRI&'[7Y4P8X%3 X%3 X,VU0G\2<N]9/FUC3ZSDZEEZ1[;]RHXKH
MKJBGW13&-8WN#F;LR7S*AL=,S5+'+S:;6\A7_3FY*-U,7.YKX%3 X%3 X%3
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M\[(]NZYKDJ"+IVK-O#RI+&=(*67G&TG;6C-*%*25=._WB,67M>26/I9N,/\
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M9JE0+;&M<F/='#N+=[C.+945L=M4E4)Q#JT+-*](^A2&3;KC2E2NXDP89T
M
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M/4/U)/%!>44JZ;8'KGV9W_\ 08]9:&\T+.T_M\,46W5[76LE\4JFU1;KG8J
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M)!@
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MI]O^IKTY:DOW>$T/X_\ @AGK-W^A]+6FHSPG^])'A'A+^SFZ']0>0O\ !/\
M^PC_ %!]'TQZO_T_'_P?)]=:=_"?^F'^8_J#R%_@G_\ 81_J!],>K_\ 3\?_
M  /KK3OX3_TP_P Q_4'D+_!/_P"PC_4#Z8]7_P"GX_\ @?76G?PG_IA_F?J=
MX'(:U)02)]5&1%] GO\ _P"X,1VSZN'X?C_X$-\Z?&/#A/\ TP_FE019/@
M
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MHVZ.%?R@%?R@.6,?[2SP_GI\9#Q/W8OTI]Z%J_(H9UF
M                                                   ^5^8KP&,P
M8CV->:_/5X3%ZP<KQ[7R,L   S?4_M*R[UD^;6-/K.3J67I%MOW&CBNBNR*@
M=$,8UC^X&9^S)?,J&QTS-4\4O-IM;R%;].;DHL+F<W    )=W<=H3G9\CCM"
M+;ERG5"].ME9^.";G!;,5BO!$V\5LZ5UZ/XEB3[;S?3%"-Z>W]<MZI M!1@
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M[K$
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M"U?T4.ZP
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MC(>9^[%^E/O0M7_%$.K@
M                           'ROS%> QF#$>QKO7YZO"8O2#EJ/:^1E@
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MK8F'#;(\  #EB^DL_II\9#S/W8OTI]Z%K8"*(=6@
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MM]E8N"#:;M\>8JUJN#)%&JETE3&TN2E.X,*4K:;_ #3,@GD&
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MRU ?/W)RG]Y6\X%:(Q9E:9*.W<211PFTI-"> O)Q)0I2$KIB)!FDCPF9 /?
M
M?*_,5X#&8,1[&NM9^6KPF+S@Y=CVOFHRP5 *@,XU.G\3,N=9/FEC3ZSDZEEZ
M0[<]QHXKHKP"HG0;%M9.S[-'9<OF5#8Z;FJ>*7FT^M9&M@FY*(5%R.<RH!4
MJ E_=M/XB.=G2..T(ON7*=4+TXV9GXX)N<%N162[$2;QVSA77HWB6)-MO-],
M4)WE[?URWJA5%GJ1*@%0"H"R6ZQZ+FCE(7%?$"W5WJ?5<M78G=K6R?,L,(.L
M]5;>>/\ C.U=EH]8>%C[7R\V*Z"G-\9N3!\TR$*B7*^*@%0"H"\&IW9GESJQ
M\ZL5%K.<J6W.@]N>W4<-\6<#3I"I-KG/XG9BY9OF&Q;FBY*G9?%S[N7W*K;#
MPP8'4;I&RH!4 J V'Q?16.33Q2%%S]Z+J.GW86.8>7M0',_O+>>O2>>4+M]+
MY,F&')S)Z[,5,<W.+RA]+X@  9%D#WZRSVK"]80/@U#+5,$W*+:Z1G:/ZDGB
M@OB*8=)L UV[+LP<FQZTT-WH>=I_;X8HQNCVVK9+XI5*Q;;GX   !.N[#[RW
MOJ*.>2(;NGR9,5RQ]BYBI@O6>%=KA5\WHSI%RQRDWQ,"<[5[U7IO5=OSNT;9
M_E5PJ)\J?@5 X%0.!4#@MSNZ;.D]>D>) J_<F;Z8+RV9[?US7)9$83=5;>6]
M^8'9;7K#XLK:^6FQQY2J4WSGI/TX>*9#-1+5?E0"H!4!=S5-LXRYU1/&4*>U
MC.5+71>W?;J.%F8U*0*2ZV-HV8^MJXJ1<.CY.GA<Y[B]QK8F&C;H\  #EB^D
ML\HGQD/$_=B_2GWH6M@XHIU2XWU*0PZI)T4E"C(_RD0]2PXQ@\3QX2QC_@I]
M^,.LC_?G?^TQ_IBWO]B]%^7#XQ_FYS^JM4_.C\)?\I^,.LC_ 'YW_M,?Z8?[
M%Z+\N'QC_,^JM4_.C\)?\I^,.LC_ 'YW_M,?Z8?[%Z+\N'QC_,^JM4_.C\)?
M\I^,.LC_ 'YW_M,?Z8?[%Z+\N'QC_,^JM4_.C\)?\K*-76L[/5ZSM9K7<[PY
M(@27C0^R;;*24G HZ52@C[I?*-9JFD>DI>EGGDDA":$/V?MC_-O=!W#J'J/7
MTJ=2K&:6:/[8<)?X1_P6=%9+R $=Z\\WWS(VK"]9@RV;:+ZDXD*#(>P:)AVX
M2V8A/+-RB"T>EQEC\FI%BX*@S!"-PS1FV.Y'U6V]5[D9YA9C0W=[0>8%N2KS
M%>M*I]6+RIIA,1+;:$O.1T-MIKY">!?"9<>6+[K5>L.3\ZN7NX7B.S[/@Z1<
ME$5"YT>;+B7"V2XE3.4^\X;$=J023\PW:HPGB"7-2^L1.9HY6":B8[=3@IOS
M5VEN-O(GQIDI]E;S:6S/0()YI:6F%<*6L'?Q$1B*6@8  !Y][OMERU;'[UF"
MX1[7:8I8I$V8ZEEE!&="JI9D53/@(N^? 0#$[GKJU4V3H'MC-EO@'<XC=Q@%
M)=T1NQ'E*2ATB41'A4:%$5?D!G@]>/K"R1*F76WQ[]#<F6..<V[-$Z58\9*"
M<4ZKO84I46,R\VI8J5(&&01I+,R,S+C+QQY"$NLKH98D+(E).AT/A(P'*
M#PLSYSRIDR.Q*S5>(MI:E.:&(4EPD+>=X/(:1PJ695X221T >0]K=U91\QGE
M%_--O:S*F0F$=L6\27^DK,DI:H?YQF?< =ZVZQ,CWB$NXVN_PY<)N8U;%.M.
MDHNF2%)2TT1%PFIPUI-%/.(ZEP<(#)@
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M- L#D63F:9DRPRLY,)C9J>@QUWAA!$DD2E-D:R-*3,DG7SDD="/@+@!AD
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M@O'9GM_7-<EH1A-E4]YCWZM_937K#XLK;&6FQQY2J6WQG9/TX>*9# EB
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M #J?]<O\S[VY5_WVW_6V/GA_T7J/RYOZ8_R/]T]'^=3_ *Y?YGWMRK_OMO\
MK;'SP_Z+U'Y<W],?Y'^Z>C_.I_UR_P S[VY5_P!]M_UMCYX?]%ZC\N;^F/\
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M;H\F3%<L;8V8J8+UH!7:WU>MZ;T7*_*3>*P)QM7O5.F]6&^^[1MG^56X3Y5
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M$1F>.@#M,W2V24Q%1YK#J;@@W8!MNH44ALDDHU-4,\:2(R.J:\ #M@
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MB#[L?X'WY?XFF9_]1/\ U$'W8_P/OR_Q-,S_ .HG_J(/NQ_@S]^7^+['EZ
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MJ53I#7?/_&0_&M"'^G-9%]/I8Q_UI,4.:]XHIU:
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M-SC*^RV[9;7L#:+;&E1[85Q3'))J)TG9$<U3#<4C!A6ANN)("9P8
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MOW1W,JFV4/QH<1QIB8[-1/N,1<@Y-V,G4IT"I276DZ%/FZ/AX"2!%+(,
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M]=6S,A''-R@F$1=-U1-Y0_B*WV='X[HLW;>4ZHW*5WGGX8)><4/5$G0@J 5
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M(-O>X4L5T5YA4:_D9;P.RN\<I$]::&_T#.R=7ABBFZ_;:ELOB@I;46HHO@5
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M3Q0;"!3KH)'6O?9-F3DX_K3(W6BYRG]OABCNX_;ZMD/%!1:HM91A4 J 5 6
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MI5^(NW@MFLSK,7G"$CV[G(61Y(9O'VZ;%+S5!J+441P*@<"H' J!P?=?H?\
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M9.G9?%1NX<_5MAR@CT;A'P   &RR)Z(QR:.*0I*;MBZ/D[L+',/+VURYK/\
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MSA"1[=SD+(\D-WA[=-BEYJ?5%IJ)*@%0"H#DK]#_ )O[AC][U^YL/%%.I@
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M%)S]L714G=A8YAY>VN#-A_Q3?.T)?/+%R^F\J3##DY\]9Y\^*;F\>H^A\A4
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M @VY^VGU7+)V;W:MLOS+,"%K"5 WLO?JS]DH]9?%A;:\B;%=!5>[\S)@^:9
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MSPS_ &MCE$<8AYG[(O4G>A:V8BE'1;AF>B/\FOBF/4O;!XG[L;&M&HNUSD5
M*@%0&?:DS^*F6.M'S2QJ-7RE2R]O=!S]*VZ*^PJ=>:+-XG9+>N4A^MM#?:#G
M).KPQ1C<_M\]LOB@I!46BI4J 5 *@+%;I?VUF7JL;G%B&[G\NG;%8.S/-JV0
MYQ6H$"6@KKO9_8N6NM2>;0)EMCS*ED%>[S\JE;'E!5>HGJL"H!4 J N5NO[-
M7.TY/$:%;;CS73"];^T<E'''E!- C*9*:[T&TIOLR-QW19.W,KU1N4_N[.PP
M0YQ0O429#BH!4 J V ZJ-FN5>S(W$(5%J>:J8HKZT;)4L$.3,1K6W:_-:!_$
M?-?:LSGE"W]-RM/#+R4#J^=K8YN;$JC8-45 *@._9#_?5NZTQSB1^5;RYK(O
MW]/YLML.;9"*5=&.A>_L:X]5?YM0_6CYDML'X>H\J:R/)KAJ+K<XE0"H!4!(
MNH@_BQEOE)'JKPTNM9.I]GB@D6W/<*5L?#%>@52O-$^\9LOF]9B\Z0D6WLY"
MR/)$=V>WS8I>:F-1:"DRH!4 J Y*_0?Y_P"X>?WO7[FR(4>Z8    ?+GZM7@
M/Q#,&(]C6,Y^L5X3\8NN#G>/:^1E@  $@:D-JV5^M'S2QJ=7RE2R]O-"SU*V
MZ*_HJA=S$=:>S7-O9,WF%#8:=F:>*7FU>K9.K@FY-> MU1(   ";-UG::YV9
M)YQH1K<65ZH7I?M3.],;ET16ZVT,;T.R]7:$7Q+$CV]FNF*);JR75"]2D64J
M(   !:7="]$S;RD#BR!!MS]M/JN61L[NU>GYEF!"UA*?[V?OU9^R4>LOBPMM
M>1-BN@JS=^9DP?-,@(2M"    %_=2&RG*_53YU8JC5\W4MN7=H61I67Q2 -2
MWB@^O;:SF?EVO5VA:NCY.G9?%26OY^K;#E!'=1N&B*@%0"H#9M#]$8Y-'%(4
MI-VQ=#R=V%CF'E[:W,VG_%5\[0E\^L7)Z;RI,,.3G_UGGSXIN;QZCZ7R%0"H
M#)]6Y_$/*?;$#UEL?#Z_+5,,W)L=,S=+'+XH-B@J!?2-]?NR/,O)QO6V1N=%
MSDGV^&*/[AR%2R'B@H946HI0J 5 *@+"[I7O5?\ L]'/I$1W-Y4F*Y.]G^?4
MPWK;" +05HWO/1,I<I/XL<33;';4Z;U>;R[M*V;Y56ZB<JW*@%0"H"ZFZ_LO
M3VA*\2!6VX<UTP6]M7)=4UR9Q&TM4[WKMH5M['9]9D"Q-MY:;%'E!5&[LW+@
MAXID$B4H4    O\ ZF-EF5NI)XRA4VK9NI:O+0\C2PL[&K;I0'7/M2S3UU7%
M2+9TG*4[%&ZYGJN)@E1M6E*@%0'-#/\ :V.41QB'F;LB]2=Z%K9F*3=%.&9Z
M(_R:^*8]2=L'B?NQL:T*B['.94 J 5 9]J2/XJ98ZT?-+&IU?*5++V]T'/TK
M;HK[BIUY(LWBMDEZY2'ZVT-]H.<EZO#%&-S^WSVR^*"CHM!2P   "QFZ5]M9
MEZK&YQ8AVY^Y3MBL'9GFU;(<UJ1 EGJZ;VOV+EKK4GFT"9;8[]2R"OMY^52M
MCR@JM43U6!4 J 5 7+W7MFCG:<GFVA6VX\UTPO6_M+)=<;DTB,IBIIO0[2V^
MS(W..BR=N97JC<J#=N=Z(7H6J),AQ4 J 5 ; ]4^S3*O9D;FR%1:GFJF**^=
M&R5+!!F(UK;M?6M _B/FOM69SRA;^G96GAEY*"U?.U<<W-B51L&J*@%0'?L9
M_OJW=:8YQ(_*MY<UD7[^G\V6V'-LC%*NBW0O?V+<>JO\VH?K1\R6V#\/4>5-
M9'DUOBZW.0   "1M0^UG+?*2/57AI=:R=3[/%!(MN>X4K8^&*](JE>2)]X[9
M=-ZU%YTA(MOYR%D>2([L]OFMEYJ7U%GJ5*@%0"H#DK]!_G_N&/WL_N;)!1[I
M<   !\N?JU> _$,P8CV-8KA_2*\)^,75!SQ'M?-1E@J 5 2!J//XKY7ZT?-+
M&IU?*5++V[T+/4K;HK_"J5W,1UJ;-<V]DS>84-AIV9IXI>;5ZMDZN";DUWU%
MN***@%0"H";=UG::YV9)YQH1K<65ZH7I?M3.=,;ET17"VD+[T.R]7:$7Q+$C
MV]FNF*);JR75"]2FHLE494 J 5 6FW0?1,V\I XL@0?<_;3ZKEC[.[M7I^99
M@0M82G^]I[]6?LE'K+XL';7D38KH*LW?F9,'S3(!J)6A)4 J 5 7^U'[*,K]
M5/G5BJ=7S=2VY=NA9&E9?%( U+>*#:]MK69^7:]7:%JZ/DZ=E\5)Z_GZEL.4
M$=C;M"    V;P_1(_)HXI"E9NV+H>3NP<P\O;6WFT_XJOG:$OGUBY/3>5)AA
MR4!ZSSY\4W-XU1]+Y"H!4!E&K;:'E/MB!ZR@?#Z_+5,,W)L=,S=+'+XH-BHJ
M!?*-M?NR+,O)QO6V1N=%SDGV^&*/[AR%2R'B@H946HI4J 5 *@+#;I/O5?\
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MYKI@MW:N2ZHW)G$<2U3G>OVAVWL=GUF0+$VWEIL4>4%4[NS<N"'BF00)2A8
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MG.D)#M_-PLCR1/=>0FMEYJ65%GJ6*@%0"H#DK]!_G_N'G][U^YLI%(NDP
M'RY^K5X#\0S!B/8UA.?K%>$_&+J@YZCVOD98  !(.H[:QE?K1\TL:G5\I4LO
M;O0\]2MNBV "J5V,0UJ;-,V]DS>84-AIV9IXI>;5ZKDZN";DUVBW%&    )M
MW5]ISG9DGG&A&MQ97JA>EVU<YTQN74%<+90MO1[+E=H1?$L2/;V:Z8HGNG)=
M4+U)Q9*I    %I]S_P!$S=RD#BR!!]S]M/JN6-L_NU>GYEFA"U@J>[VWOW9N
MR4>LOBP=M>1-BN@J[=V9DP?-%  E:$@   -@&H[9/E?JI\ZL53J^;J6W+LT/
M(TK+XI!&I;M037N?Q;S/R[7J[0M31\I)9?%2NO9ZI;#E!'51N&AX%0.!4#@5
M X-G4/T2/R:.*0I6;MBZ%D[L',/+VUL9M/\ BN^]H2^?6+C]-Y4F&')0/K//
MGQ3<WCU'TOE*@%0&4:MC^(>4^V('K+8^'U^6J89N38Z9FZ6.7Q0;%Q4*]T;:
M_MD.9N3C>MLC<Z+G)/MY1:#<&0J?9XH*$U%IJ6*@%0"H"P^Z/[UY@[/1SZ1$
M=R^5)BN3G:'GU,-ZW @*SU9M[[T3*/*3^+'$TVQVU.F]7N\>[2ZOE59$X5P
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M\_\ <,?O>OW-F(I)T:    ^7/U:O ?B&8,1[&K]S]8KPGXQ=,'/D>U\C+
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MC<6:Z87K9VKD^J-R;1&DN4KWI]IS?9D;G'18^W<KU1N5-NK.=,+T)5$E1$J
M5 *@-AVJ39CE/LR-S9"I-2S53%%>6D9.EA@S,:YM6N[6H?Q*S;VM-Y]0MS3L
MM3PR\E%ZK#_YE7'-S8C4;!J^!4#@5 X._8C_ 'W;>M,<XD?E6[DUD7[T(?\
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M"EYNV+H"3NP<X\O;6EFX_P"*[[VC+Y]8N+TWE288<E#>K\^?%-S>-4?2^4J
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MU$YTA(- S<+(\D6W1D9K9>:D-19BGBH!4 J Y*_0?Y_[AC][U^YLY%*.B
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M?:!GZ?V^&*_0JU<R']YK9//ZU$YTA(- S<+(\D7W/D9K9>:CM19:H2H!4 J
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MTX  .>%Z9'Y5'&(>9NR+W)WH-HXIA?;@F>AR.37Q3'J7M@\3]V+5S47.H0J
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M9GLM_=S%$>:M<Z--6REATE+3'=2X:2,U4(S)-!^'J-P25*4TGW(_^:$8=O\
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M$:B:!YI:U5:4M1G5)D7#B$FTW6)/2TON1EC']O%$=6T*?UE;_4A/"7]D(=C
M/Z/,P_S/"^KN_.&T^I:?X(_%I_I.I^9#X1/Z/,P_S/"^KN_.#ZEI_@C\3Z3J
M?F0^$3^CS,/\SPOJ[OS@^I:?X(_$^DZGYD/A$_H\S#_,\+ZN[\X/J6G^"/Q/
MI.I^9#X16<R58'LJY2LN7)#R9#UKB-1%OH(TI6;2<-2(^$JB'>JK0K59IX0X
M?>CQ3OT="-"C)3C'C]V$(/>'S/K5?SANL7[,V:[WF)K,41AJZS9$QME3#IJ0
ME]Q2R29DJAF1'0S$R]-K\E*E+)]R/_EA"';_  0/U>V:E:M/4A/"'WIHQ[(_
MOB\7^CS,/\SPOJ[OSA]'U+3_  1^+Y?I.I^9#X1/Z/,P_P SPOJ[OS@^I:?X
M(_$^DZGYD/A$_H\S#_,\+ZN[\X/J6G^"/Q/I.I^9#X1=BW[HN884^+,/,L-1
M1WFWC3T=WAT:B53SOR#S/N.G-+&'W(_M_P 7Z4]JU)9H1_U(?LC_  BMD(.L
M)UKC%5-M\N&A1(7(9<92LRJ1&X@TD9E^2H]R3?=FA'^$7YU)?O2QA_&"IW]'
MF8?YFA?5W?G";_4M/\$?BKWZ3J?F0^$3^CS,/\S0OJ[OS@^I:?X(_$^DZGYD
M/A$_H\S#_,T+ZN[\X/J6G^"/Q/I.I^9#X1/Z/,P_S-"^KN_.#ZEI_@C\3Z3J
M?F0^$65ZMMVF]9%SM:<URK]%EL6Y;JEQVV7$+7I67&N S.A4-=1\7KM<D]11
MFIPEC#[W^/\ BV&G;=G]-ZB6K&>$82\?W?X1@L>(DFS!];.19>L;)DC*\.8W
M!>>>8>Z0\A2TD3*\1E1)D?"-CIWJX>FK0J1AQ_9%JM4]%'U="-.$>'&,/^"O
MO]'F8?YFA?5W?G"4_4M/\$?BAWTG4_,A\(G]'F8?YFA?5W?G!]2T_P $?B?2
M=3\R'PB?T>9A_F:%]7=^<'U+3_!'XGTG4_,A\(G]'F8?YFA?5W?G!]2T_P $
M?B?2=3\R'PB^OZ/\Q8,'WFA4K7T=WY/T@^I*?X(_%GZ4J_F0^$5N!!5B@
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M@'R3B#-1$HJH\\JEP5*O#\G  ^@    'RMQMO#I%DG$9)3B,BJH^X15[X#Z
M     'X9D1&9F1$7=,^X _0 !^*6E!56HDE6E3.G"8 E25U-)DHB.AT.O"7>
M ?H   /PU$5*F15.A5[Y@/T      ?)N-I6EM2R)Q=<"3,B,Z<)T+O@/H
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M%@MNN75U;KA!@%>SE-VC)\=V(IGI,.);T,(9NBH2F6'R-^,LC;-*"<7A4IS
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M]-@,
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M"(UJ))&9)*ITJ9\!%_: ^4R&%NN1T.H4^T23=:)1&M!+X4XB[I5[U0'(
M  /AYYF.VIY]Q+32?.<6HDI+PF?  ^R,C*I<)'W#       !\N.-M)QNK2A%
M2+$HR(JJ.A%4_E,P'T       #XTS6E)C2)TYIQDU4L> CIBIW:5[X#[
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M 0P<5;2KBX\23<<6K"E*T$I*4M$9F:JJ5W* RS.Q-.LV2V,OH-M]N(PAUM7
MI*TMI(R/\I&##T     '3NKS$>VRWY49R9';:6IV(RT<AQU)%PH2V5<1J[E
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M7&O;.>G+@A+C[KDF(S":7$2Y'1:]$29*DR3X6EI6IQ1D1EB/ 5%$? 92"#
M     ,9L=G:^\%VS N B$M1G;X)$TEIQ;#:L;KRL/=TKO<K^:A)]\P&3
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M(JGI%DE*3/O(K^< R8
M
M
M
M
M
M
M
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ME&(B/$8#\7FR]M.S&+,PR[H2NEP?<N$AQWZ."ZTE+31(26$EDX=.$R;IW%5
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M(&''&SE>'[HVXJ+%38'KDFT-X7%JEFMR,E]+QG0D$FIF@T<)T\K%^:#),O\
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MI-)G72)_P\ ,O?NSTMC.&74-2W41)3<YN1"(TZ!PT-I6E:BPXL23+@\JE*\
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)2G#W:@/? ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>bc_carispoanet-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_carispoanet-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@VAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@.2XQ+6,P,#(@-SDN9C,U-&5F8S<P+" R,#(S+S$Q+S Y+3$R.C U
M.C4S(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7 N9&ED.C@Q8C=B-#4V+3!F.#,M-#<Y,"TY.3)C
M+38V8S,X,65F864R,2(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#I$,#4U
M-C@U0S(R-T0Q,48P.#4S-T%$-$8Q1D8X,S4P."(@>&UP34TZ26YS=&%N8V5)
M1#TB>&UP+FEI9#I$,#4U-C@U0C(R-T0Q,48P.#4S-T%$-$8Q1D8X,S4P."(@
M>&UP.D-R96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B R-BXU("A-86-I
M;G1O<V@I(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z8S$S-S<V8C0M-C4R8RTT,C,P+6$T9C8M,C5D,F)A-3ED9C V
M(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.C@Q8C=B-#4V+3!F.#,M-#<Y
M,"TY.3)C+38V8S,X,65F864R,2(O/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( LD#M@,!$0 "$0$#$0'_Q #<  $  00# 0
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M'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP
M\Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(
M]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5
MX#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'Z
MP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q
M<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&
MK5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#
M'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP
M\Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(
M]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5
MX#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'Z
MP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q
M<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&
MK5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#
M'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP
M\Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(
M]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5
MX#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'Z
MP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q
M<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&
MK5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#
M'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP \Q<(]&K5X#'ZP
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M_
M
M                                    !8,A^=\4\JN_1<\ P7ZD8UY*
M@^+H 7\
M
M                                          %@R'YWQ3RJ[]%SP#!?
MJ1C7DJ#XN@!?P
M
M                                                6#(?G?%/*KOT
M7/ ,%^I&->2H/BZ %_
M
M                                                     !8,A^=\
M4\JN_1<\ P7ZD8UY*@^+H 7\
M
M                                                           %
M@R'YWQ3RJ[]%SP#!?J1C7DJ#XN@!?P
M
M
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M=M"-6RHA*\@
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M",R4&XQ
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MP@$\=T^-8GC.$6QC#W$RK9,:1+5<J$3DMUU):G7.:1_<Z#]Q33S!Q2S8
M
M            !HV5RAI3,N3?&,2>?W4P+T6-SLN[L:2\B5QZ8JI"86@U*C)>
M4EO7QFHZU)/,!-%Z3OF=O&>EAN'V9BXV^%<%6N\WR?<H]N0E^.I)2FX499+?
MEK8)5%Z4I1J+3JYH%&V 0          "P9#\[XIY5=^BYX!@OU(QKR5!\70
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M
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MUOR'H4=QQ:SX5*4I!F9]$P%W@P85LB-0+=';B06$Z&(S"$MM(3SDI21$1>H
MH;MB^-7YUM^^6>%<WF4FAER9&:D*0E1U,DFXE5",P%5;+5:[+$3 L\)BWPDF
MI28T5I#+1*4=3,DH(BJ9\("FNV,8U?W&WKY9X5S>92:&7)D9J0I"5'4R2;B5
M&1&8#LM&/V&P(=;L5LB6QM\R4\B&PW'):DE0C43:4U,BYX!>+!8\@CE$OMMB
MW.,6U+4QE#Z2,^:1+(Z<', 6&'NKW;0'BD1<4M:'DG5*SB-+-)\\M23IZP#+
M6VVV6TM,H2VT@B2A"")*4D7 1$6PB 8O<=V>[V[357&Y8Q;),Y9ZG'W(K1J6
MH^:OJ>J/\(!D4>#"B0V[=%C-,V]ILF6HK:$H92T1:202"*A)ILI0!9HN!8-"
MD,RX>-6J/+CK2ZP^U"CH<;<0=4J2I*",C(]I&0"NN^.8]?S9.^VF'<SCZN(.
M;':D<7KIJT\8E5*T*M.< YVFQ66PLKC6.W1;;'=7QCC4-EN.A2Z$6HR;))&=
M"I4!6NM-O-K9>0EQIPC2MM9$I*DGL,C(]AD8#%%;K=VRI?=RL3M)R:ZM7<;-
M-5:UTZ=-:] !E3##$9E$>,VAEALB2VTVDD(2DN B(J$1 +-/PG#;K+=N%SQZ
MVS9SU#>DR(;#KJS21)+4M:#,Z$1%M 7:'"AVZ*U!@1VXL)A)(8CL(2VTA!<"
M4I21$1>H L\S!<*N,IZ=<,<MDJ;(5K?D/PF''7%4I52E(,S/9S0%R>L]ID6S
MY$D0([MFXM+'R>MI"HW%(II1Q9EITE0J%38 M"-WF MK0ZWB]I0ZVI*VW$08
MZ5)6DZI41DBI&1E4C(!D@
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M^L>1/@/F.K>7;X0MY&!F9$60P:GL+XY(?+]8\B? GYAJWEV^%E(^!]X
ML&0_.^*>57?HN> 8+]2,:\E0?%T +^
M
M                                             "#=\3_?5R[Z?[8H
M6K@Q_KMR0IS'Q?\ 9=EGE4&D=U'1ZTTA0]::0H>M-(4/6FD*'K32%#UII"AZ
MTTA0]:[8R?TAG\-/3(<;HX)<K<7AA.X5,N@     6#(?G?%/*KOT7/ ,%^I&
M->2H/BZ %_
M
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MC7DJ#XN@!?P
M
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M) .,2 ^ZT\\$OI*(^ P'T
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M)!F::MJ--2KMVT"B%Q0K40XI<@2
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MPZ)!"T3'C34ZCLAQE5V3;:(1_P#Q)Z0X2YJ\0
M                             ,9M[M%R$\Z2_P!L4.SN."_QU5+UAPER
M=XA(                                                   ")V^T
MO]1[I^!%\7;%A;&[+;]_+*L=NW4UR[[N2&OJ#,L'I% -(H!I% -(H!I% -(H
M!I% -(H!I)@[JOL]L/>Y]L4*VVGVF_*M79/9,/)G9B,:RH  /,?)B_S)>._I
M/;E"XL#V=N2.11.L^UN\Z>5:J#O?.4 * % "@!0 H 4 =\,OTR/V1'PB'&[B
MERLYT/484POP     6#(?G?%/*KOT7/ ,%^I&->2H/BZ %_   !UO'U(F$+!
M<%4)0[+7"5SL?S/!["CI#KGC=D+@(
M                     &(P5'W1*+]Y?[88[>XX=UDD4ZD0ZY<H50A(
M                                               "*&^LO]1KI^!%
M\7;%B[&[+;]_+*JMOW4UV_H]6&OJ#,T:_I% H:10*&D4"AI% H:10*&D4"AI
M% H:10*&DF!NK^SZP][GVQ0K3:G:K\JW=C=CP\F=F QC,   \R,F+_,EX[^D
M]N4+CP/9VY(Y%$:S[6[SIY5KH.Y\Y0 H 4 * % "@!0!W0R_3(_9$?"(<;N*
M7*SG0]113"_0    !8,A^=\4\JN_1<\ P7ZD8UY*@^+H 7\   '4][GV1,(8
M_<>!0[;7"5UL?S/!["CI#JGC=D+@( !KVW;Z,'N6\.7NQ:=DM91$6ZR9/L&W
M&<=8;2ZI#;M:*5H5J(N;0^<)'RT[[-W]UQ^_90J<Y;[)CDURV7*3/:-G]):,
MDFEM):C74SHG253,!C]HY2^[J],7:5#C7E,.S6]Z[R93UN=:97$CJ0E2FEJ,
MB49FM.E/"84&RL4R:V9ECEMRFS<9\EW5E,F+QZ.*=XM7!J29G0]@@:I/E5[K
MD/.I=:O+<-A]45^XG;'E1&W4+-!DIQ&JFTN:6T30;BM%WME_M<2]666W.M4Y
MM+\26PK6VXVLJD9&7_\ "$"M 8I=\Y9M.;6+"56>Y27KZS(?1=H\<W+?'[F*
MNE]VO4J5S-G.YX#*P   62^9AC6-S[/:[Y<6H=QO\CN.S1EZC<DOEI(TH))'
MP:DU,]A5V@+V IKA,1;H$JX.(4XB(RX^I"/=*)I)J,BKS3H Q#=CO.M&\_"T
M9Q!BO6JV*<?;6W/4VE:"C'1:U&A2DDG96NK@ 8M!Y2^[.[9%%QVRG<[HY,E-
MP(]QAV]YV I]Y1)3\=0BTF9^ZI2FW@$T&X1      ,.W@;T<,W90F)>5SC9=
MEF:84%AM4B7(--"5Q;2",S(JE4SH71 ?-W>\RP;S8$VX6"-<(K,!XHSZ+G$7
M"<XQ2"7U*5\)4,MI ,R 4ETNEOLEME7>[240[9!:7(ERG3TMM--EJ4M1\PB(
M@'18+_:,HLT/(+!*3-L\]'&PY:"4E+C=3+41+(CILYI +D
M #$(/ZS*[Y?[88[NXZ^ZR6)P$.N7.%4.*0
M                         $4M]7VC73\"-XNV+&V+'_);]_+*HMXKJ:]?
MT>K#7]!FJ-<TB@4-(H%#2*!0TB@4-(H%#2*!0TB@4-(H%#22]W6?9]8>]S[8
MH5EM3M5^5<VQ.Q8>3/+,!C&:  !YDY-]9+QW])[<H7'@>SMR1R*'UGVMWG3R
MK4.Y\X         [X?ZY'[(CX1#C=Q2YV<Z'J(*87Z     +!D/SOBGE5WZ+
MG@&"_4C&O)4'Q= "_@   ZGO<^R)A#'[CP*';:X2NMC^9X/84=(=4\;LA<!
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M&D0E+G$9K-QQ2QSX\=^)'DP(KK4669JD-(6RDR0X:MIJ(MAF?"(%Y
M    !B$']9E=\O\ ;#'=W'7W62Q. AURYPJAQ2
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MLRN^7^V&.[N.ONLEB<!#KESA5#BD
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M)A#'[CP*';:X2NMC^9X/84=(=4\;LA<!
M      /BE)26I1DDN>>PMH#XEQM:EH0M*EMF1.)(R,TF95*I<S8 Y      "
MBO"[JU:9[EB99D7M$=U5M8E+4W'7*)!\4EU:2,TH-5-1D5: (H%B&7Q+'EL'
M-HLUB8C(X=XA.KBRLGCWFYG9OCF%QX[;5(RWUZD&DT(;51O8;=3E"46(*GKQ
M.Q*NMM19[F=OB',M+:B6B(_Q*=;"5$9U)M54$=3X!"5Z     8A!_697?+_;
M#'=W'7W62Q. AURYPJAQ2
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MX"                                  :,Y0V+[R,E9MCF+PFKG9+4_
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M"_4C&O)4'Q= "_@   ZGO<^R)A#'[CP*';:X2NMC^9X/84=(=4\;LA<!
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MO65O$Y"$@#$(/ZS*[Y?[88[NXZ^ZR6)P$.N7.%4.*0
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MX_9$?"(<;N*7.SG0]/12ST$     +!D/SOBGE5WZ+G@&"_4C&O)4'Q= "_@
M  ZGO<^R)A#'[CP*';:X2NMC^9X/84=(=4\;LA<!
M   #JE/*CQGI"&5R%M(4M,=G3QCAI(S)"-1I3J5P%51%T0&M'=^>,0L,O&8W
M2#.BHLLQ=L?MC269DA^6AI+^B*N,ZXR\7%JUJ4ARB"2O5328D;'M\UJY0(MQ
M8(R8ELMR&B5L42'4DLJ\.VAB!4@   TORDSIB5J\HI[0Z-QW5[1?YN>%<;^]
MCP__ /)^FY&/6+)4G0U@4-8%#6!1)CDU'7&;QW^7:4"N-ZO;V>;GE=6X4?\
M+B>?^F&[!IBR0!Y[NJ^-7^$?3%[Q/ \H6QP0X:A-7*AJ"I0U!4H$K:0511Z$
M-?BT?@ETA1$\;U;'$YB$@#$(/ZS*[Y?[88[NXZ^ZR6)P$.N7.%4.*0
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M+6?:W^=/*M=!W/F* % "@!0 H 4 * .^&7Z7'[(CX1#C=Q2YV<Z'IX*6>@P
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MZICB<Q"0!B$']9E=\O\ ;#'=W'7W62Q. AURYPJAQ2
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MT3:_%H_!+I"BYXWJ2.)S$) &(0?UF5WR_P!L,=W<=?=9+$X"'7+G"J'%(
M                              BWO[+_ #ZKO./TUC?=A]F^^5=;?G_J
MZ,-84&=:[I% -(H!I% -(H!I% -(H!I% -(H!I);;F/LVLO\3XTZ*\VOVJ_[
MN2%F[%['9]_6EGHQ#-/BC,DF9%4R*M.> M42Y277E(4WK(R,R2@J&5/5,!"#
ME)*->^&^U2::-PBV]YM"S=A]CM^_K2J/>+MU_1ZL-3T&<:Z4 * % "@!0 H
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M0QQ.8A( Q"#^LRN^7^V&.[N.ONLEB<!#KESA5#BD
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MRD!YMY*7^8[OW[)[:H7+@>SMR1R//^L^VO\ .GE6N@[WSE "@!0 H 4 * %
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M+?X)=(4A/&]*QQ.8A( Q"#^LRN^7^V&.[N.ONLEB<!#KESA5#BD
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MC'$YB$@#$(/ZS*[Y?[88[NXZ^ZR6)P$.N7.%4.*0
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MLB/A$.-W%+G9SHRO304H]$@    "P9#\[XIY5=^BYX!@OU(QKR5!\70 OX
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MO1T<3F(2 ,0@_K,KOE_MACN[CK[K)8G 0ZY<X50XI
M              $7=_1TSU7>;'36+(W>C_EZ4J/WSOIM#H6YVL=0V2C2/60:
M@H>L@U!0]9!J"AZR#4%#UD&H*'K(-04/60:@H>L@U!0]9"6FYG;NWLW\3XRZ
M*NVWVR_[NK"_=U9KLS"Z77N9TXVEU"FUE5*BH9#"-J=49:C2IITZO-'I4?/+
MF*]<@'> @GRD?M?O?8X7BC0L[878[?OZTJ>WD[??T>K#4]!G6ME "@!0 H 4
M * % "@#T#W&_9/BW>I]M6*JVOVO$RYEU;#[#AY,\M@C$LV  #S:R3ZQ7?OV
M3VU0N?5_9VY(Y'GO6O;7^=/*M8[WS         #OA_K;'9$?"(<;^*7.SG1E
M>F0I-Z*     %@R'YWQ3RJ[]%SP#!?J1C7DJ#XN@!?P   =3WN?9$PAC]QX%
M#MM<)76Q_,\'L*.D.J>-V0N @ 'G"MWJU;>:?3%YU>7XMX'SC>B%4Z)QO1"I
MHG&]$*FB^H=ZM.WFETPJB;>!Z/"C'J  13Y5JM.3V#O!SMQBP-V/97^=F57O
MI'^[#\V>5H#6-Q5Y0U@4-8%#6!1*[DIG7%;[Y13VA KW>?VUGFYUM;F1_P U
M_GYH;]&H-] 'FA)5^DO]D7\(Q=MO$\X71PNK6.2*&L"AK HY(7U:/PBZ8A$Q
MP/3(4B](@#0/*R.F%67RHGQ=T;9NU[>[S<\-(WO[+9Y_Z;D1-0L%5-#4!0U
M4-0%$M>26=<3OWE%/:$#0-YO;6>;G6IN?V:_S\T)"#46\@#S)EJ_2Y'97/A&
M+KMXH>=[XX9=6H<G"AJ H:@*&K:7JD!1Z<,_B6_P4](4G/&]%1Q.8A( Q"#^
MLRN^7^V&.[N.ONLEB<!#KESA5#BD
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M4)C\2W^"GI"E9XWH*.)V"$@#$(/ZS*[Y?[88[NXZ^ZR6)P$.N7.%4.*0
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M!0 H 4 * % "@!0!/KDY?8WCG\9XZ^*PVWVR_P"[JPM[=_L.'TNM+:8PK8
M 08Y1WVNWOL<+Q1H6?L+L=O2ZTJ:WE[??DMZL-54&>:T4 * % "@!0 H 4 *
M )^;D/LIQ?O4^VK%4;7[7B9<R[MA=APLF>6P!B6<4SOZ0\4?A:;HM[HGPI3_
M $@*D!YP9&7^8;MW[)[:H71J_LK<D<CSOK7MK_.GE6R@[WS% "@!0 H 4 *
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M;-NEQE2V)9FN039H6TA1$@EZR<2:#(C*H4%SB[UK5+N6-,HM=P18<O0QYOY
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M1G%LS&X9.S.8M41$&%:56MMMF,VII*)"HJDO?$K?4GJEZ5*)'Q9=36H;($
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M24)HAO9I(D'U(#:(@    8A!_697?+_;#'=W'7W62Q. AURYPJAQ2
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MZT1HR:4+3;?C''W2(R0X^ZXC46D]*EF9'0^>0[.XX]UDL4J$0ZI<X50A(
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M;2TVEM'N4E0AB6<<P !YQY']8;MW[([:H73J_LK<D<CSIK7MK_.GE6P=[Y@
M       !W1/UMCLB/A$.-_%+G9SHRO2=QM+J%-K*J5%0R%(O2+JC.*-*FG3J
M\T>E1\\N8KUR =X   +!D/SOBGE5WZ+G@&"_4C&O)4'Q= "[+_1Y!.?V3QDE
M?07]R?K\ "I  '!PJIH")6N6R:B,<XE$K%)@FHSV#MB7"B@5;3KP#E5QH^?)
MA\X-(HZ6K:;JS?IU/N6OP>:?KF(JFCN^3#YPG210^3#YP:10^3#YP:10^3#Y
MP:10^3#YP:10^3#YP:10^3#YP:11U2+.IYHVT[#J1E7@V")E-'7#M*FB<:47
MQA&1F7,H9;#(1$DPJ?DP^<.6DBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\
MF'S@TBA\F'S@TBCIE6PU,&BG5+,DH(N:HSX!$W)B'&+97&$JUT,U'P%P%0(D
MF%1\F'SA.DBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA
M\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S@TBA\F'S
M@TBA\F'S@TBA\F'S@TB@5L.O %2BJ8MYI,M@B931>X<<TTV#KF7.%Y83I+UA
MURY.X0D  &N&=^N[67%RB;;[F[<(V'2685\7!B291H>DN*9031--J-TM:5$:
MF]1;*UIM!-%1@^^; ]XEZF8_C,F6N[P8R9LJ-,@2X)I86LD)5^DM-UJ9E0N:
M!1GX(        :/Y1QT@X_V63\%L;ENS%;L3)&=6._=^CAX.6[,C_K(;UHJE
M]=!K(-$]=!K(-$]=!J+@Y@:)ZZ'PE)25$["+@(M@:)&-$!&E)421$7.+8%",
M6(XGW60:)ZZ#60:)ZZ#60:)ZZ$@.3B=8&0'_ /-&^"X-%WFBEV'DG,MK<2[2
MP\;+;G;P&FK.  !"3E2E_JDKR=%Z:Q9&[_9>E*IMZ.V=&,[2M!L;5"@!0 H
M4 * % "@!0!/'DZI4>Z''7%Z:D4Q+9)YB>['JUZ)F53%7;:C_LO^[JPN3=Z:
MZAA]+K2VH,*V   $'>47]K=Z['#\4:%H;![';TNM*E]YOJ%^2WJPU6,\U@
M        $\]Q_P 9NMQEY1)(RBJ0@D\PB=61\T]IF53%3;7C_LQ,N9>>PI_X
M,+)GEL,8IG   ><N1E_F&[=^2.VJ%TZO[*W)'(\YZU[:_P Z>5;*#O?,4 *
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MINM/X\2/LC.JG_Z';/J<&[^Z[DAH'0-^4M4T 5- %30!4T 5- %30!4T 5-
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M"YP!0N< 4+G %"YP!0N< 4+G %"YP!0N< 4+G %"YP!0N< 4+G %"YP!0N<
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M@*&# DL:S6X;6JFQ-#K3F[2,!6<0]^TK]A'M '$/?M*_81[0!Q#W[2OV$>T
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MO>& =UE^1>]X8#@Y.)#:E\2[U)&>U!D7KF Z[?/<EJ6AQ!$:2J1IX*<X!7@
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M        R(RH>TC 4BD(AN)>;2265T0\DMA%7W*O9V& JP
M                 ?#,B(S,Z$6TS 4\=/&J5*67N]C1'S&RX/9X0%2
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M0@UN?CG#U.= ^87K%L =P  L&0_.^*>57?HN> X82XEK!<<<6=$IM,$S\&0
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M>^P.P863/+.)#7'-FDCHLC)3:N<HN QB&>=1.-3&C:-1(?IM17JD+2?#ZQD
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MKYF^!%?\HDMO7!4U^.3J4(83H02-)430J[3"1M 0./&-Z^*UEQE*Z*EJISZ
M.0#CK1K-O47&$6HTUVT/FT 8!O3WN8_NLMS+UP0J;>)FKN"ULJ)*UDCA6M1U
MT((SIJH9F? 1[:!I5CE%[Y+NW\J6/!D/V:IF3C<2=)2::_E6U)2=.@D31"0^
M W^ZY1B%JR"]P4VVY3VC==A(-1D@M:B1[LB454D2J'P5H(2R(UH)24&HB6JN
ME)GM.G#0@!;K;>DG%I0:CHG49%4^A4!R   !K7>?OJQS=:_%@W6'+FW&:T;\
M=F,E!-Z"4:.J6M14VES",2,>Y0F\?*L!L-AN6+2&XC]PD+;D<:TV_5!-$LB+
M61D5#YP0-@;M[[.R+!<>O=X=0Y=+E#0^^I*4MDM:BJ9DE-"+UA RL    !P=
M<2RVIQ?N4E7_ /H!PC-J0DW'/QSIZG.ASB]8M@#N       !U2&C=;Z@Z.H/
M4V?.47M\ #ZRZ3S:7"*E>%)\)&6PR]8!V    U_OJ^SFZ?AQO&&QF]B]KM^_
MDEK>\DTU"_H]:$4A8]%.Z8%#3 H::JMK-O?G,M7:8N!;3J;\IIDY+I4+J4(;
M(RJI9]21GL+FCKQ)OBV9LC2N[U:?Q^QV84X=U\1B7:%G=F(TIR1'?GO]QEC^
M!QD;TT[O6)3ZX?&))<PR0<@F^YCD+,B).FI4H74C&VZ]/P7Q,Q%>]W.=3*S-
MVS;8VI\%%UVCY7!I4T=*>Y3[.)9LKM5JLTYB%;6+O%>T*7+8OS+4=XJF6@VB
M9V&D]M3]0?5JF)?B6S==-DQW-"9F/MK5\.OX6'@7Q99&);-.&,6+8G[-'1X)
MCO\ W+$/LH^#3 H:8%#3;RY.7ZQD7X$3IO#4-X^+#Z698&Y\UNQ>C^IOL:8L
M8  $9>5^I2K?BJ4I,T)?F:U\PE*0UI+UZ&-QW9G\>)DC.T+>^NAA9;LR*M!O
M2MR@!0 H 4 * % "@!0!*WD?_-F5]GA_ >&C;S<[#R3F6/NAS,7+;G27&FM^
M  !"WE/%_J>KR?%Z:Q96[W9>E*H-Z^V]&W.TU0;&U H 4 * % "@!0 H 4 3
MIY/?V18]_&>./"K=N=LO^[JPNO=OZ?A]+K2V<,(V,  $)>4-]K%Y['#\5:%I
M;!['9TNM*D=Z/J-^2WJPU=09YJY0 H 4 * % "@!0 H G?N6^RW&>]3[:L5-
MMCM>)ES+XW?[!A9,\L[,R(C,SH1;3,QB&>6F% <X],O51JIJ17W1D=:5]4!6
MO&4=]#_ ATR;<+H_<G_0(E,//;(#2J_W523JDYD@R/GEQJA=FK^RMR1R/-NM
M^WO\Z[E6Z@[WRE "@!0 H 4 * % ';$+]*8[(CX1#A?S9<[.=&5Z-2'3:;Z@
MJNK/2VGGJ/VN$4@],/K+1,MDV1U,MJE'PFH]IGZX#L   !8,A^=\4\JN_1<\
M!QP-"483CFBO56R&LS/:9FIA!F9GS]H#(0     !$7>K"CY!REK79)1:H[Z8
M4-PN<EUM2O\ AKJ)0UK$R*;%W:W/=:@U'=YN1,&43;4T);-"TE_^9IH2,YQ2
MVQ,8Y44*RV\M,2"Z<)'1I:S0H_754Q QC*<[MF\3/[I(WAW>Y0\1CK>;M4&V
M(2Z:";62&DZ'%$@C--5N+H9F>S@I21>-U68W1S'-X^$%<'YN/MX]<[A:ER-1
M+:5%3I(TEJ5Q9.)7J4DE4)1;.;4,;Q7#[[FN[7*KL]?WFK3BOZ:U:%ZW&GGG
M$$IQ1]41)/0T6DZ'MYP#LQS'\HWA;M,ANT[(Y1VG!$+^3[5(UO-.DEM,I^CA
MK*AH0HM-4J/F;$@,AMF276]<FO)[;<Y"Y2+1=(34-QU1K6AEYQM?%U/;1*B4
M9<ZM. !;\7W47?+-S]SS0[^XU&L)RY$"RJ)2H^F,@G7U:M9$E:RK2B>853YP
M7_#-\F5V7<CD312W'KI;YL6W6>>\9N.,-3T.*,B-53/BTLKXNON347,(B$#5
M[MPQ]%B8O\;(+PK>9Q_&OJ45(Y(UG[F1QG&ZR*B]1^I3FB1FN]?,KUD.+;L\
MLE/J3=7X,Q$AU)Z>,>@2^)XQ1%0JJ-&H]G- ;[W(;M\JQR?.SG++PW<KCDT-
MIUYLM:W&UN*XXB4M5".A*I1)4+@+8(2TCR@%MRM_#4:_*I96_DQE1J,R24)1
M(6[0^855N"80W7OOS;>+N[C09V#6Z-YIQ8I%<)*V$K9CJ-U+32")*T:4T-)$
M1)H(2U-G^>Y#GNX2!DE\6VBYHR?N1*HB5,)XI$-U1$9:CYI@AV;MK7E4"QQ]
M_=\O+<R%CUHFE:K,\;BW.YHL5V*RDCK1*=1:C(BK3:?5&"6/X!@]WW[><^2Y
M)DKY7.W$E,,W#)PERW4*<2FAF1(;21)ZE!?=;. 2AV;N<FON=[N<TW?SICTU
M5LMI7VQ.N+4;[*X;B5*82HSJ?&%U*$GP;?6"@BY?*F[@8N-092GKK-RDXC+:
M%J-Q;/<B)*2+;S5K*@"ER'.)5RW,X1C+;[JKBQ=[A&=(EGK,VET9(S(ZG7N@
MDIK_ $ /F_/=ZWN^O5GBHFKE=W6YEU;:ZJ2TXTE+3A)69F:B4M*EUH7" R_?
M5@1;N=V6/6,KF[=BDW>1/[H?1Q:D<;$;1Q9)U+V%HKP\T0,0S#!;Y8-W6';Q
M7\B>EN7 FXL6'U:#A-<6M;*65ZSV$EL]5$IH?!7A$B8FZ._7#)MV^.7JZN&]
M<9$4DR'E>Z<6RM31K5T5:-1]$<4LT   !9G'9:KBEMPCXLG"TH/W-"/8?L;0
M2O((         %F<=EMW%:&2,DFLC-!>Y.I%M/U2!*YRI"8K)NJ+5381%S3,
M$.B/<V'D&;GQ:R.AI/;_ $ .[NV+^4+V#]H!@&^F5'5NYNII76BXM:$?-DMC
M.;#BNN61YW5EJV]-VCL[$NGBB;>M"+ LJBE=,"AI@4--\/A2?,):5'ZB5$9A
M1QF_BRQRLQRF\8]E.\*XWM5PEVVQ34M\5.88-4E"VV4(H;9*2K29D=:'P#%:
MK@8NKZI;9HQ=?;7@F>#C[[/Z]K>KZWM&_%]9=AX=T12ZVV=*L6Q'%QTXW5E]
M_MMRMMAL-KDR;DQ8D2"7>9Z.+D2%2%$K0E)J4I+:"*A$H^D.>IZM?9?B8E\1
M;.)3\-O%%,\N&T]>PL7#PL'#NNQ(PM+\=\4NNTNY%>&+8^W[.\Q09*C"Z8%#
M3 H:;>7)R_6,B_ B=-X:=O+Q8?2S+&W*NK=C9+?U-]C2EF@#J?=XELU$55GU
M+:>>H^ @$:^5PWQ=HQ-)G51/S-2N>HT-&9^N8W+=GG8F2,[0=\)_!A9;LR*U
M!O2MR@!0 H 4 * % "@!0!*SD@_-F5=GA_ =&B[S<[#R3F6/N?S,7+;G26&F
MM_  !"_E.E_J<KR?%Z:Q96[W9>E*G][.W=&W.TU0;(U H 4 * % "@!0 H 4
M 3HY/GV1X]_%^./"K-N=LO\ NZL+KW;^GX?2ZTMFC"-D  !";E"_:O>>QP_%
M6A:6P>QV=+K2I#>GZC?DMZL-7#/M6  !E-DW;YSD=N1=K'8Y$ZW.&I*)#6C2
M:FSTJ(JJ(]AC'XVT=7P;M"^^(EE]6V/K>L8<8F'AS=;/=X'"U;O<UODJX0K3
M99$J5:GCC7%M!)(V7B-1&A1FHBK5)\ G%U_ PHMFZ^(BZ*Q]L..!LK6L>ZZW
M#LF9LFEWV3WOX,?EQ)$&4_!EMFS+C.+9?:5[I#C:C2I)]$C*@^VRZ+K8NCBE
MCL2R[#NFVZ*3$TG+#I')U@  G=N6^R[&N]3[:L5+MCMF)ES+YW?^GX63/+,Y
M'QRTQ4^Y/JGC_J%S/_$8Q#/JG@V$ Z9$=,@D$9Z30HED?J")BJ8FCSROS:6[
M[=&TGJ2F7(21GL,R)U0NS5_96Y(Y'FS7/;W^==RK?0=[Y2@!0 H 4 * % "@
M#OAI-4R.E/NC<01<S::B'"_FSD<\/ANC*]%&RXYXY![6T%I9]?W2OZ!1[TTJ
M!*    %@R'YWQ3RJ[]%SP#!?J1C7DJ#XN@!?P     !'^[[I\TN/*!8WA$PQ
MYL,28KA.&\GC>+CQ4-F?%\/NR,2A21^3W>$;[59PZY#\T2N2[NADEK[IXTR-
MY*>+T:=CY_?>Y]@*CE+W09N>_P"3O#CL1U8WW<S(-TWTI=XHHZ6E_%\-2.H"
MRY/N%W@XSFDW*]USL.5#N"W5]PRR84MDGU:UM&B4E32T:O<G741>I4U1E&-8
M3O<F8KFEOS.-;&YMWM3D&RM1&XD=;;KJ%I6E2HK22TK,T5U+/W()6W=UN=S?
M&]VF>8O=&(Z;K?V.+MJ4/I6A2N)6CJE%L3M40(<<!W,9K8=UF>8C=V6"NE^:
M7\ELHD)4T;RHRFJK46PB4>E*J\P@2L>/;C]X47=%DV(R(T7Y9NT^%)B)3)2;
M9MQU$;AJ49%0RIP&050M:=R6_P LF+'BEEN#*[!>"-R[6QN0TV33JCTJ2:W"
MJ:5)2DU<4KJN RYX;'L/)SBQ=T]PPBZ34^<-U>1<'K@R1J:8E,%1E"2,DFI"
M2U)49D1GJ52FRBJ6!6C=?RA\4C%C]G9M$FULJ5W/*=;M\@D:U&9FE4EKC:5.
MM%$"%^WM[FMXF;6W#D08T%=QM-N4Q>#:=;C,G,<-"G%-I)*$T6HE*/2DBJ8"
M1%DBO0;+;H4@B*1&BL,NDDZD2VVTI50^;M(0EJ[?9N/8WH(C7:V2D6_)X39L
M(=>(S8D,5-26W#35232HS-*B(^$R,CV4D:BE[K.4K*QY6#RIK<O%U$VV;+DN
M.XWQ;*TK0DEK+CB2DTI,BZ (7NX[B\Y:W-P<!8[CE9#\O'=W$-OFEE$4XRV3
MJMQ*:J)1EL(N:"6V=W6[M5KW11-WV6QT&X[#E0;FTTLG"-J2XZ74K(J5T+(Z
MEP& TE%W);[]WLN\6[ 9D679;RCN=^3K8:<4R1*)*E(D%5MQ)+5M;,_5X 0V
MEN,W)_RSA3I]\=9F9%=$)9>0R1J88C)V\4DU$6HU&=5G2FPB+FF9+6^$<G/+
M<>WF0+A+;C^9-KN+LR*:7DK6;;)*..?%4KJ.C9*YQ!5#HL')OS*%O/A72:B,
M>%V^[/W!JKR5J4TWQCD?XJE:K631+YQ5YP5&<\H#=#?]YB;1?<6-I=RM[;D6
M3 ?631K;4HE%H6KJ24E6HC)5*D?#LVH2Q?)]U.^?--W-GL^1*9FY+ N;[Q*?
MDLD:(!QFVVTFMLM*CUDNNTSYY@A?\[W1YGD&YO#L*MS#"K[9G&5SFUOI2V1-
ML.MGI6>P]JR ;1W48Y=,2W>V/';TA#=S@-.(D(:63B"-3RUE11;#V*(0EF0
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M !YWY"7]_P!U[\D=M4+KU?V5N2.1YLUOVU_G7<JVT'>^4H 4 * % "@!0 H
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M.DD-,6"  "&?*:^TU7>$;IK%E[N]DZ4J<WM[=T;<[3=!LC3R@!0 H 4 * %
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MH:Y@  1NY7/S9BW9YGP&AN>['.Q,D9U>[Y<S"RW9D6*#>U:% "@!0 H 4 *
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MLL8-LP  (5\H+[5;SV.'XJT+3V!V*SI=:5&[U?4<3);U8:QH,^U0H 4 * %
M"@!0 H 4 3@W.I)[=KC#9*)33<8UN:3J6KC%F23]3F]$5'MCMF)E7]N]]/PL
MF>6PAB6?  !YZ9#\_P!U[\D=M4+MU?V5N2.1YHUOV]_G7<JVCO?*
M .Z)^M,=D1\(APOYLNS#YT97HN*.>G75(:-QOJ-CJ#U-G_6+^@^ !]9=)YM+
MA%2O"D^$C+89'Z@#L  %@R'YWQ3RJ[]%SP#!=F$XT1\/R5!\70 OX
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M  6#(?G?%/*KOT7/ =6!N$6(6%@U&O3;(2FEJ*AK:4PC29EMVEP& R0
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M [NQ/R[!R9Y9X,0V   'GSD'S]=._)';5"[M7]E;DCD>9=;]O?YUW*MP[WR
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MN@9 .\        !1N,(FO'QJ?B&>I2?!J6?#MYQ *M"$H22$%1*2H1%S@'T
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M9;TNK+6MY>P7Y;>M"#%!:"F:E *E *E *E *E *E *E *E *I,<D,J2\M['
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M H 4 * % "@!0 H FUN$^RFP_P 7XV\*JV[VV_[NK"]MU_IN'TNO<V0,$V<
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M-TUBSMW.R=*5*;X=OZ-N=J$;*TP          $V-POV4V'^+\;>%4[=[;?\
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MP%0  +!D/SOBGE5WZ+G@+9@L)US&L?E)<-3/<$527%5):R)E.TRZ(#,@
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M *E *E *E *E *E *I(\DLJ2\K['!^%(&D[T<6'TLRR-RN=C9+?U).C15F@
M CSRJOF[&>SR_@-#=MUN?B9+<ZM=^/9X.6[,C+0;ZJHH 4 * % "@!0 H 4
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M0*FD"II J:0*FD"JYXVG_,5H[]C=M2.C6/9W9)Y'TZK/^ZSSHY7I.*9>@P
M8%OK^RS)N]2[:@9;8_:\/+F8';_8,7)GA S2+:454T@5-(%32!4T@5-(%32!
M4T@5-(%6TN3N5-[-E[',\4=& V]V._H]:&T;KS_["S)=U93>%7+K  !K#E!?
M95>>R0_&FAG]@=MLZ75EJN]7T[$RV]:$*Z"TU&U* 5* 5* 5* 5* 5* 5* 5
M* 52,Y*14E95V.#\)\:1O3S</I9EE[C\[&R6?J27&B+1  !'WE3?-V-=FE_
M:&[;K<_$R6YU9[]>SP<MV9&F@W]4Y0 H 4 * % "@!0 H DMR6?F[)>S1/@.
MC0-Z>?AY+LRV-Q?9XV6W.D$-)68  "(O*,^T97>,;IK%H;M]DZ4J.WS^H="W
M.U+0;,TDH 4 * % "@!0 H 4 3/W%?9;8OXKQMX5/M[MM_1ZL+]W4^F872Z]
MS8HP+:@  0ZW\E_J?=^QQ/%FQ:^[_8K.EUI4%O=]3Q,EO5AK:@V!J)0 H 4
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MH  (C\HLJ[Q5=XQ^FL6ANWV3I2HW?/ZAT+<[4U!LS2*E *E *E *E *E *E
M*E *E *IF[B_LML7\5XV\*GV]VV_H]6%_P"ZGTS"Z77N;$&!;4  "'>_DO\
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M]22@T-:@  (_\J/YOQOLTKX#0W?=7GXF2W.K'?OV>#ENS(V#?U3
M  DGR7/F_).S1?@.C0-ZN?AY+LRV=Q/9XV6W.D -(6<  ")/*)+_ %$5WC'Z
M:Q:&[?9.E*C-]/J'0MSM34&SM'J4 J4 J4 J4 J4 J4 J4 J4 JF7N,^RZQ?
MQ7C;PJ;;W;;^CU8>@-U/IF%TNO<V(,"VL  $.]_'VGW?L<3Q9L6ON_V*SI=:
M5 [W?4\3);U8:W&PM0          !-;=#]FV.]['VQ8I_;/;,3+F>BMV_IN#
MYN>6;##MC  ! :_?/MS[[?[8H7CJ_LK<D<CRWKGM[_.NY5O'>^0
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M!4H8%2A@5=L4C[I9[(GID.-_-ESPY_%&5Z!BB'JP     6#(?G?%/*KOT7/
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M%2@%2@%2@%2@%2@%4A.2T5)64=CA?"?&C;U<W"Z69:&X?.QLEGZDD!H2UP
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M>4 * % "@!0 H 4 * )H;I/LXQ[O<^V+%/;:[9B9<ST=NS]-P?-SRS089L@
M (&7XO[\N??;_;%"\]7]E;YL<CROKGM[_.NY5OH.]\A0 H 4 * % "@!0!VQ
M2_26?PT],AQOYLN>'SHRI_"AWK      6#(?G?%/*KOT7/ ,%^I&->2H/BZ
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MII"A4TA0J:0H5-(4*IA;D?LQLG\5XTZ*DV_VZ_H]6'H;=+Z7A=+KW-@C -M
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MSQO5<<3D(2 .*_<*]0Q,<:)XGGVM'5J]4Q>\<3RE,\+CH$HJ: *F@"IH J:
M*F@"IH J: *KA84?W[;.^V.V)'SZQ[*[S9Y'UZG/^^SSK>5/@4<]2   PK>Y
MMW;Y#WN7;$#,;%[9AY<S6]Y?IN-YN>$+M(N%YRJ:0*FD"II J:0*FD"II J:
M0*FD"K8VXE--YMI['*\6<&O[P]BOZ/6AN&Z$_P#L\/)=U93 %3/0(  -<[]-
MN[.[?AQ?&6QL.[W;;.EU9:?OA]+Q,MO6A$'2+9H\^5-(4*FD*%32%"II"A4T
MA0J:0H5-(4*FD*%6_>3(5).2_@0^F\-$WLYN%TOTK6_^?\['R6?J2'&@+=
M!H?E,;8&.]FE?!;&\[I\_$R6YU5__0/9X.6[DM1UH+"4_4H!4H!4H!4H!4H!
M4H!4H!4H!5(KDS[(&1=FB_!<%>[V<_#R79EP?_/_ &>-EMY+F^!HRU   12Y
M01?Z@J[RC]-8M/=KL?2E0N^_U'H6YVJZ= ;0T0IT "G0 *=  IT "G0 *=
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M15I4JC2]Y]8PL6,/0NBZFEQ3$]Y9NXNJ8^!=C>MLNLK%E-*V8KSN^WJ-&6H
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MB,JD=15FW,2W$UR^ZV8F.#ACS87SNM@WX6S<*R^V;;HTN"8I//N[C.!A&T@
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MQ3RJ[]%SP'S!2+S)QLR(BK:X)G39M..@!D    /AH2HR-22,RX#,JT ?0
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M0ZR9)X3UI,T[*;=H#Y;KI;;O&*;:9C$^&HS2F1%=0^T:D[#(E(,RJ0"K
M       !P>>9CM+?D.):8:2:W'7#)*$I253,S/81$0"G@W2V7.(5PMLUB9 .
MM)4=U#K)Z>'JT&:=G-V@.$2]6>?!7=(-PC2K:WJUS&'FW&$\7[JKB5&DM/-V
M[ '9;[E;KM%3-M4MF=#69DB1&<0\T9I.AT4@S(Z .<2;#GL]T09#4IC4I'&L
M+2XC4@Z**J3,JD>PP'>           "BN%XM-I)D[K/C02D+XJ.<IY#/&.']
MRC69:CZ! .5PNELM+!2;K-8@QE+2TEZ4ZAE!N+]RDE+,BJ=-A .-PO%IM),G
M=9\:"4A?%1SE/(9XQP_N4:S+4?0( N%XM-I)D[K/C02D+XJ.<IY#/&.']RC6
M9:CZ! *T            !13KQ:+6Y':N<^-"=EKXN*B2\AE3J_O4$LRU'MX"
M ?;A=K7:4M+NDZ/!0^X3+"I+J&26ZK@0DUF55'S"+: ^3KQ:+6Y':N<^-"=E
MKXN*B2\AE3J_O4$LRU'MX" ?)UZLUL>8CW*XQH<B4K1&:D/-M+=4>RB$K41J
M/H$ K@            %$F\6A=Q79T3XRKNVCC%P">0<E*/OC:KJ(MO#0!].[
M6M-Q39U3HY79;?')@&Z@I)M%]V3==6G9PTH ^)O%H7<5V=$^,J[MHXQ< GD'
M)2C[XVJZB+;PT =LB?!B/1X\J2TP_+4:(K3KB4+=66TTH)1D:C+G$ J
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M,.ALV[%#L=HGW"V04)9AQKJM3C:-+39$AM3C!:E:2+5PF"&]P0
M#'<ZMN&W3%I[.\!J*[B+)(EW),]6B*28JTO)4X9F1&25((Z'L/@V@(DWNT%!
MW<;P\QL-N7B>Z;/KYCL2!:VM4'BK&V^B-,N'$I-),-SC42=.E)FW[HJ&0.3/
MV\6W<V3?!O Q&9;;=!W2^;%IO636PTHCVJ/<XDM1L+6VC2A!J:;):BH6NE5$
M=00N&YS=Y9,E:WAWI%E59-TN>O0TX_B[9NV\G8<)LVW)Q-,J;4PB8JAI0G09
MH+JBH9 2O7)4C1XFZU^+$:2S&9OUZ;991L2A")KB4I*M=A$1$!+=X(
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MGB.\')[;D,.?"RR/#L-G>M<U#,:P14/&:D)4TDG9<MXTO+2WJ4E"4I^Y!*=
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M&-6G<INLL>4'F5JQF+&R'C')#<A)NJ::>>]VXS'4LV6EJYJFVTF":L]!
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MVD":L[O6,6'(I%JE7J$B7(LDM-RM2UJ67$2VTJ0EPB2HB,R)1^ZJ0(7<
M      6#(?G?%/*KOT7/ ,%^I&->2H/BZ %_
M
M
M           !8,A^=\4\JN_1<\ P7ZD8UY*@^+H 7\
M
M
M                 %@R'YWQ3RJ[]%SP#!?J1C7DJ#XN@!?P
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M"JH@&0@ #'\OS.PX-;HUUR%Y;,.7,C6UE3;:G3.3,7Q;1&2",R(SX3Y@#(
M  4-YO-KQVTS;[>Y2(5IM[*Y,V6[4D-M-E52CI4]A<PMH#IQS(['EMEB9%C<
MUNXV2>DUQ)K-=#B4J-"J5(C*BDFDR,MAD HXN9V&9F,_!&'EGD5MALW*6P;:
MB;3&DK-"#)PRTF=2X !_,[#'S.)@3KRRR2; <NT=@FUFV<1EPFE*-RFDCU'[
MFM0&0 ,?N&9V&V999\)EO+3D%]8E2K<R3:U(6U"(E.FI9%I30E%2O" R
M                                             !8,A^=\4\JN_1<\
M P7ZD8UY*@^+H 7\
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MFE;%ID:'"+^HMQ*@3#1Z+O*WAL8EO(R*.^U(PB\89AK;LE>E2;K'ED_>7]/
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M^[LV[+O FYWW18KM,E.7">FXJCNR6$&:VS+:TE[29\29]1IV$0"6H.(
M                                          "P9#\[XIY5=^BYX!@O
MU(QKR5!\70 OX
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M8\<MEL?96\ZR["A1XZT.222EY25-H29&X24DLR]T1%7@ 7X
M                                   !8,A^=\4\JN_1<\ P7ZD8UY*@
M^+H 7\
M
M                                         %@R'YWQ3RJ[]%SP#!?J
M1C7DJ#XN@!?P
M
M                                               6#(?G?%/*KOT7
M/ ,%^I&->2H/BZ %_
M
M                                                    !8,A^=\4
M\JN_1<\ P7ZD8UY*@^+( 7\
M
M                                                          %@
MR'YWQ/RJ[]%3P$&;9\VPN]VO@$#DJA
M
M
1     "EE_CH'?"NT.B1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>bc_casevolume-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_casevolume-4c.jpg
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M%!04%!04%!04%/_  !$( LD#M@,!$0 "$0$#$0'_Q #A  $  04! 0$
M        !0,$!@<( @D! 0$  @,! 0$             !@<!! 4( P(0  $#
M P(# 0<*#A $ P<"!P$" P0 $042!B$3!S%!46$B%'4(<8$R(].T%396-Y&Q
MT4)2DK)SLR1T-947H<%B@M(S0U/#-%24Q+46&'*BDR9C)57AXH-DA&4G\,*C
M1*2%=CA%$0 " 0(!!P@$"P<$ P$! 0   0(1 P0A,1)R- 4&05%QL<$B,C-A
M@9$3H=%"4H*2LL)3%!;A8J+B)!47\",E-=)S!_%C0__:  P# 0 "$0,1 #\
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * QG='Y\V5
MYY>_R;)4 Z<_-[M/S-CO>K= 9-0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M8SNC\^;*\\O?Y-DJ =.?F]VGYFQWO5N@,FH!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@,9W1^?-E>>7O\FR5 .G/S>[3\S8[WJW0&34 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M"CW5LR6T_16T!6: SC#YW"[AAIR&"R$?)0E< _%=0\B_>)038^ U@$A0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H#\4I*$J6M02A()4HFP ':2: P;+=9NEN%
M?5&G[IA!]!TK0PI4HI/>/(2Y8T!^8OK1TLS#R(\'=,+G.'2A+ZE1;D]P<]*.
M- 9W0"@% * 4 H!0"@% * 4!J;J-U]VYTUW"G;F5QDZ7*5';E!V+R>7I=*D@
M>.M)N-/>K- 9AT^WSC^HFVF=SXR,]%B/.NLI9DZ>8"RK22="E#CZM8!E- *
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M$E-E('[D"L UQZ.7SQ[<_P#K/>3]98(_KK\[>ZORM/X)%$#II_\ _P!6A_\
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M,MTT0-U^C]\Q#G_]S^FNL,'(FQ_CIMSSI"]\(K(/I=7Y,B@% * 4 H!0"@%
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M/%3D>= =-W8LR.HH>97P'%*AVV%Q8V%Z R&@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$?!"1D,H1",91=:U2CV2
M3R$>./\ A_B_WM 2% * 4 H!0&+Q-X?"6^)^S\=#Y\?#16G\QE"YI0Q)D\68
MR4:25+4@%Q1U )'A- 87E^N^W<;NSR%EQ<S:$%E]O-YF)#E2FXT]"T:&^:T"
M@ITE164I5W.-9!MAA]J2PU)85J9>0EQM5B+I6+@V-CV&L P2/U9P3W4Z3TN5
M'?:RS#86W,5H\G=<\G1)+:;'5<-J)XCZTT!D>\-TX_9>V\AN?*!2X>/;"U--
MVYCBUJ"$(3<@74I02* QR)U6QTWIFGJ9$Q,Z1!4%6Q;"$NS+HDF,>"56L"-1
M-^">- ,KU&?@[SV3MEG&GR;=S$B0MV25-2(W(8YP2INQ\;CI4">!H"WP_5!^
M<K?ZY6)6MG94IR.VU!)?D2D-I6JX00D!1T]EZR#--NYE.X<'C\XB*_"1D&$2
M$Q):.6^V%B]EIXV-8!)T H!0"@,!C=36\EG<KMK$XQ;^9@,NNQFW5.,-2%Z-
M<=&M3/M?-"'-2EBR"D>RU"@,@V9NJ%O3;<+<4%"F$2DJ2_%=X.L2&E%MUE8(
M!U(6DI[./;W: GJ 4 H!0"@% * 4 H!0"@% * 4 H#PZXEEM3B_8I%__ &4!
M2CL6'.>2#(6=2C:Y3?L /@'"@+B@% * _" 001<'M!H"VTB*^"D!+#Q"5 <
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M4J;!K(-H5@"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M\  *P#671U*LL=V[[(_%MT9EYS&+_G,=! BL.6/$:M"S;O5D&SJP!0"@% *
M4 H!0"@% * 4 H!0%*0Z6F[H%W5'2VGOJ/9]6@/UEH,MA -SVJ4>TJ/$GUZ
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M63Y.5^V$(]D0* RK"YG'[@Q<;,XI:W,?+3K86ZT['60"4G4T\E#B2".Q20:
MOZ 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MI0"@% * MGO:'1)'\6JR'_4^M5ZU 7- 6S/M#QC'@VNZV?\ ]R?6[: N: 4
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M=GPDY/E;HQAR[F0C:FFF0Y%>D3%.*6IM"FW6GE%I:=((\7B%3H)(*4@*5J4
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M2.4IL@H*>YI(X6K6DFG1YS=A*,DG%U7H*E?D_8H!0"@% * 4 H!0"@% * 4
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M"=&^N,/?V/PV+W$CR'>V39GR$(9BR6<9)&.EN,.IAR'04/*:0&U.A"S:_P!
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M%".VIUKPN4Q>U69JG,ON7<41$];>W\?.=BL0W9"HZ9;W.1JCL:DVUO$=BB.
MH*%4>D%TR,:?,5/DHC1&$S(BU0WP,E&7)3#0[ \3\82J0M+(*.ZH'V)U4%#8
M6)R:<SB8V5:CR8293?,3&GLKBR6K]QUIP!25#O&A@ML8S+2_S%7#!!N3V*OV
M6%#),4,"@% * 4 H!0%*0T76_$-G4'4V?W0_:/90'ZRZ'FTN 6OVI/:".!!]
M2@*E * 4 H!0"@*,AU3: EOB\X=+8\)[OJ#MH#VRTEEM+:>(2.T]I/=)]6@/
M= * 4 H!0&,[H_/FRO/+W^39*@'3GYO=I^9L=[U;H#)J 4 H!0"@.,M_8S).
M[WW$XU"?6VK(RBE0:601S5<0;<15R[MO06%MIR7@CR^@\T[[P]V6/OM1E3WD
M^1_.9COP1E?[!(_Z*_J5T??V_G+VHXOY6]\R7L9V+TU;<:V%M]MU"D.)AMA2
M%@I4".^#5/;V:>+N-?.9Z1X>BX[NLIJCT$:UG>C>UE9>=&2W3(<PN2E;AR>+
MQS4-AI<.?NAAZ/(<6_<K>2VA]>AOQ >&K585RB05+?<7H^/-X7,QL/EWLAB6
MD9#-X3:2V66FU;EE8UV&EY4M1UAI2G%N!K@E+B[E6D!-!4];:Z 9%]C:V>WC
MN.1(W1A$;>##8C1VT1HF!4J1Y"2V2'"MYP\Q^]R$IL!W0J?LKT9X$C(1)1W,
M^MIF6N<N/(B,2%)<.:<S0,5:SJC%2W.4\IOBZA*;VM8A4F$] H"<#C,$,])T
M8W%[GPZ9'):UK1NUT.N.$=@+! T#Z[NT%2-R/HWQYCR9+&YGDNICX:(6)<&-
M-AN(PD"1 "GHSOB.*4F0IU&NX:< 4 :"I>9KT?8N1VWM?;\'<#L/_3V%<VQ(
MD/0V)B9>,D!@N6;=-F) 7';<:?;-T*'8H<*"I=2>B,E&S=H;9PNZ',;D]F3W
M,EC\VJ#'E./..HD-J+[+IT+<6)*E..=JEW7P)H*A70]>2SRMU[AW5+R>X94!
M>W\C):89B,/X!Z*IIV$&6CI052%&6'1=07XH&GA05(G$>CC&QD_$Y%_-1<I(
MBP86+RJLEAHLHR&,2%MPW(RG%E41Y+)2VXMLJUZ$JTA5!4E&.@F.8P<?"'-R
M%MQ]E3]@AXLHU&/D5-*,FU_9HY0 1V>&@J0$WT7L?.R&6F/;GDK;R43)0D%R
M*PN4A.6AM1' N3<+<;:#0,=HV2V/%'?H*F5[RZ)8W>.4FY=[+/PYS^"@X.$\
MRTV7(;^,G*R#$UI9-PXEPCQ186%!4C(O0)C%2=Q*Q&0QGD>:\L7&1DL!!R$E
MA62D)D26W9*U(7(CJ/,2&5VLE0&HZ105+'#^C3BL'-Q\J-FO+ W#B0LH[E(#
M$^:XN"%I9?A2G5<R$XA*PE'+U:0A%N*;D*GG:/HUQ-KY7&9AS<CDN7C)N,FI
MY4&/$2\,/%G14!WEDE;KJ9JE/OK)6M0OW; *DGB^A#F+CX3!M[I?7L_:^>C[
MBVUB#$9#L4L.2'%1ER=14ZVKRA022D*2 .)H*E^>BL=G9^+V_C<_*@9_ 9:;
MG\%N1III3\>9/D27G$K:7=#C2DREM+;5P6GO&@J1&<Z"Y/=.6QN<W/O%>1RL
M5,$2Y!Q<5!*\9D#/9,.ZE&'JN&W^6270E-SV@A4CI'HSQI,N1G'<]'<W$[D7
M<@VE[#QG<&E$F.([R#BE++1<=TI==>2M*E.)"N^"%3-=M]*48#?CN]DY%E*!
MCDXF-BL;CV<8R6$):"?*5,J//Y7*LQ=*>4E12+BU ;'H8% * 4 H#\)"0238
M#B2>]0&+S76WI3CC0LA1^B>_Z]9,%"@ !)L.V@,BQ<149DJ<%G7.)'> [!6#
M)?4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'0/)_A'*\J6M][G-<^.J^EA
M7(;LE-^XI-E\.Z: D: 4 H!0"@.(MPXK*+S^56B%(*53)!20TNQ!=5X*NW"W
MK:LP[R\*Y?0>7<?AKKQ-QJ$O'+D?.R-^",K_ &"1_P!%?U*V??V_G+VHT?RM
M[YDO8SM7:"5)VE@4K24J&.B!25 I4"&$<"#Q!JEL=M%S7EUL].[J36#LU_#A
M]E&'XOHUA,7L;=>S67P7]VIS#<W-",TB6$9M3RB"4\5AKG'1J5W.Y6D=2I"Y
M_H#&S3<<M;@>CR8F$PF!;+L9J1'>1@):I:%265*2'FGBO2ZP2$D4%2MM?H-!
MVTXTZC-NOK;@Y['J"(K$9HC<<MN6XI+;5D(#2F[(0E.FW>M05*'^WV!\'_!_
MP_*Y?^A?U=WY+?\ 5]>KROMOKMXNB^FU!4\Q_1^CL;XA;P5N!;S<#)Q\RQ&=
M@QUR@ZQ!$'D>6D\T1M(UML)LA"B?9&Q 5)/*=$<9D<QF]PHR;D?.9/.XO<L&
M<EAM3D&1BFV6>6@W!6AYMM2%@D<%GUPJ0^ ]'J'M:/EL?@YV+&,E1Y,7$IG;
M?A39<9J8^'7&I$I:@N6SHU-<MS3=!%U$I!H*EA']&3&P$89V+FF9L_'PE8N>
M<[BHV9B/P_*G)3;;$>0JT;DEY;;6A:@&[)(5:]!42_1BQ\W,97)O;D>*,@UG
MV&AY$QY4EO<D1<1:7I5^8^F.%#R=*K!"4A/AH*F7N=*<A S^%W+M7<[N(R<'
M%0]OY=+L1J:QD($!96W="E(Y3H*E^V(4>"K:: M=I]#L=M-WI^Y'S,B2-@(S
MC44.M-@RDY]>M7,*?8\JUDZ>WNT%3&LSZ,[.6R&I6Z'!@XV4?S6-QCN/C/+2
M[-EIG28LJ1=*Y4-UX:RPX+WTW6=(H*F7;KZ7[BS&^7-\;8WBYMF7+Q#.!GMM
M8]B:XJ.Q(=D!;+CZK-N7>(N4*'@H#'G_ $:MKPYF(D;:=B1HL''Q\1/AYG%1
M,ZW+8BNK>#UY 06I"U.N<QQ-TJU>PX"@J2,_T?-J9/.;YRLV;+,3>\-V$YCF
ME!MJ J8&3,>C]HYDAR,PZLJ3[)'&X-J"I:0/1\QIB8V-GIL&6J!-=DOKQF'B
MX;RR,_CG\<IF0(RCJ5ID+7S>%CV "@J8GOCT>]R?Z#GP\?G).ZMQ0<;C=N;2
M8<;C0/(L3'RD.2X5*U!#KX;CI)=7IU<L#3<FX5,U9Z&+E;AB;QW)N>1EMV1\
MSC\NN>F*U%:5&Q$>5'CPT,H40A)\K<6XNY*E=P#L"I2>]'_%O8/'X*5EY$J!
M!&Y$/MEM"%R&]TK6XZG6#=LME?BD=O=% ><#T'A0T8)]S)Q"]@LS#S465C\-
M#Q<E]N!'D1TL2UQS9U1\H*E.63QOI2+T%2_QG15>%SV"W!BMR/LRL/E<[DGV
MW(K3K<J+N60W)DQE7-T%*FDZ'4F_?%!4N-R])<CO/=4')[JW0Y/VEBL@G+8O
M;B(,>.XS(;:+:4&<V0\IKQE%2+ JO92BGA0&,XST:L9CL$_ML96,K'MN0#B9
MS.'AQLLRQC9S4U#<F8T4JDZN2ALE2$]@4054%3-,KTEPN5ZH8SJ@Y*=;FX^.
MEIS&)"3%D2F$2&HTIT'M=81*>0@]Y7<M0&.[:Z%2]F_ @VUNQZ.U$QD7 [@C
MR(3,AG*8^$^ZZT+:D*8="7W6N8E2O%/L;B]!4L\'Z/+&V\)E-OXK)8IR%(CB
M!C7Y^W($J6W"\H2\IB8]J09B2E ;\8([ HW4+T%386Q]H(V-L_#;$8R4O+-X
MQ@M.9&>OF2%ME:ED$]Q(*M#:?K4 )[E 9:    + =@H8% * 4 H!0"@% * M
MC^+R+]C+YL? YW/MA0%S0"@% * 4 H"V8]O=5*/L!=#'_#W5>N?V* N: 4 H
M!0"@% 8SNC\^;*\\O?Y-DJ =.?F]VGYFQWO5N@,FH!0"@% * 4 H!0"@% *
MAG(DE^>MUI7B)7;FW]C;M '@H9)+DR/[2?M$_4H8')D?VD_:)^I0#DR/[2?M
M$_4H"C*BRG6%H2^5$_6D)2#X+B@/&*:<8#K3ILL$'E]X$=OKT!(4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% 0>5G\PF,R?:Q_&*'=/>]2LF".99<D.):;%U*^@
M!WS0$X,-$TI"M6H#QE VN:P9+AB!%CG4VBZQV*5Q- 7- * 4 H!0"@% * 4
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MO*6%WTLJ\G;TI1?N%-E&W=- 2= * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4!3>:#S:FR;$\4J':".(/K4!YCO%U%E\'DG2XG]T/VCVT!6
MH!0"@% 6RCY0^&QQ99LIP]PK^M'K=M 7- 8BZLN.K6KM4HD^N:R8/- * F\&
MLEEU![$J!'KC_P!E 2M8,B@% * 4 H"(GMS?+ N.%6( 24=G#O\ _MH9+\>7
M6XEJ_P"^H8'X[WVO^:@'X[WVO^:@/#OE_*7H+>JQMIU7]:] 6^*1*2MU;X4
M0!==]1(/AH"3H!0"@% * 4 H#&=T?GS97GE[_)LE0#IS\WNT_,V.]ZMT!DU
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MV% >Z 4 H"@_%:?\8I = \1SN@CLH#U'=+K=U"SB24N)[RAVT!5H!0"@% *
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M 4 H!0"@% 1F.\C^$\QY.ZXN3SF?*VU^P;7Y.WI".'84:2?#0$G0"@% * 4
MH!0"@% * ME?C$@-_P BP0I?A7W!ZW;0%S0"@% * 4 H#\6E*TE"A=*A8CP&
M@*,9:@%1W#=QKA<_7)/L3]6@*] * 4 H!0"@% * 4 H!0"@!( N> % 0&2R)
M?)89/M ]D?LC]2LF"R88<D.!IH74?H =\T!DL2*W$:#:.*CQ6KNDU@R5Z 4
MH!0"@% 6T@EY:8J>Q7C/'O('<_?'A0%R!;@.R@% * 4 H!0"@% * 4!;206E
M)EI'L.#H[[9[?H=M 7(((!!N#Q!H!0"@% * QG='Y\V5YY>_R;)4 Z<_-[M/
MS-CO>K= 9(M:6T*<6;)2+D^ 4!2C(593S@LZZ;D?8I'L4^L* KT H!0"@% ?
MA (((N#P(- 6\8EI2HBCQ;XM$]UL]GT.R@+F@+9S\7?#W\D[9#O@5V)5^T:
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M4HE2E$DDDT!)4!%[B\F.%F>5Q%SHV@<R(U?6X-0X"W'PT!*4 H!0"@% * 4
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M?/U*P9+F@% * 4 H!0'AUQ+3:G%^Q2+F@*<9M24EQS^.=.I?@[R?6% 5Z 4
MH!0"@% * 4 H!0#MX'LH"VCW96J*KL3XS)[Z#W/WIH"YH!0"@% 8SNC\^;*\
M\O?Y-DJ _.G1 Z>;3)-@,-CB2?R5N@)SF(F.I;;4%,-V6X1V$W\5/[%Z NZ
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M GZ XUD%BA"EK2V@74HV2/":&#)(,)$-O[)Y7LU?M#P5@R7= * 4 H!0"@%
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ML*E*4+CO@F@$&'Y$VO6L**C<D<  * \>4LSG4QVS=L>,Y?AJ">P#U3VT!?T
MH!0"@% * 4!3?:#S9038]J5=T*'$'UJ H19[3Y#1-G[<1W"1VV- 4<G/\G3R
M&C[>H<2/K0?VZ @ "H@ 74> '=)-9,&18Z (J-:Q=]8\8]X=X5@R7U * 4 H
M"(W7\5\W^02OP*ZV\'Y]O6CUG/WELEW4G]EG"VHU>)Y:H-1H*#4:"ANGT;3?
M=&6_(/Z9NH9Q5Y$-;L997 .UW-3[R.EZK8NLC=P!HX:6'X2LBUH&J$B^IT:A
MP%OHT!)4 H!0"@% * 4 H!0"@% * 4 H!0"@% 6D7RWRN=Y0AM,7F(\C4CV:
MD<I.HK\.O4!X* NZ 4!2D.EINZ1=Q1TMI[ZCV4!^L-!EL(O=7:I7=*CQ)H"I
M0"@% * \K0EQ"D+%TJ%B/ : I1EJLIAPW=:X$_9)/L5>N* 26U*2'6Q[<T=2
M/#WT^N* JMN)=;2X@W2H7% >J 4 H!0"@*,EQ24AMO\ CG3I1X.^KUA0'MIM
M+3:6T>Q2+"@/= * 4 H!0"@*4ATM-W2+NJ(2VGOJ/90'ZRT&6P@&Y[5*/:5'
MB3Z] 5* 4!$9/(Z;QHY\;L<6.YX!63!#H0I:@A U*4; #OT!/Q<6VTPI+O%Y
MP<5CZWNBWJ&L&2ZCNJ<04N<'FSH<'A'=]0CC0%:@(_.Y=C 83)9V4T](C8R*
M]->8BMEZ0M$=LN*2T@6U+(39*>Z: U6>O",?TH;ZD9G"I=G2><K'83#3F,GY
M4TPA3ZW$/M>*E+3*%N/ZP.7H4#QTW&:&5,=17G][Q]F# R4^6X)S<$#(J>8#
M3_)6PVN.E&K6E0,A *UZ1?L[]# V7U!G[HG[GP.2V^YA]S;75&$R")34QAP3
MX_E# 1(;"4Z]/\8A0\2Z3<I4"0/WIOU$._T9Q"\:B#(P,T8^0]$F-9. ZZ64
M/%+,IH)2I;>L(>1I\1?"YH9,TD.EINZ1=Q1TMI[ZCV4,$?E&HC.-0B8RN4UY
M1&*DMWUETR&]*S8C@E=E'P"@)6@% * 4 H!0"@% * 4 H!0"@+9/XO(*/Y%\
ME2? YW1Z_;0%S0"@% 8SNC\^;*\\O?Y-DJ =.?F]VGYFQWO5N@,AD-%UOQ#9
MU!U-G]T/VCV4!^LNAYM+@%K]J3V@C@0?4H"I0"@% * 4 H"V_K$COLQSZQ<_
M]T?LT!<T H!0"@% * 4!^* 4DI/$$6(\!H".:AMP)"'02IM=T7/UI5V=G?[*
M DJ 4 H!0"@% * \.N):;4XOV*1Q\/@H"'6TWC4ID$WE*!Y;7<3?O]^U 1:E
M*6HK6;J4;DGOUDP36*Q_+ DO#VP_Q:3W!W_5H9)6L 4 H!0"@(C=?Q6S?F^5
M^!76W@_/AK1ZSG[RV2[J3^RSA2]7@>6Q>@%Z W5Z-GQIR_F_^F;J&<5>1#6[
M&65P#M=S4^\CIBJW+J([.DC$RBF<,:=(M./8UXPX\2/4H"1H!0"@% * 4 H!
M0"@% * 4 H!0"@% * C,=Y%\)YCR8N>5<YGRSF>PU^3MZ>7X-&F_AO0$G0"@
M+9K\8?+Y_BV[H9\)[%*_:% 7- * 4 H!0"@+>2"V4RD"ZF^#@'=;/;]#MH"N
M"% *2;I(N".\: MT_B\@M_R3Q*D>!?='K]M 7- * 4 H 3;B>R@+:."\M4I7
M8KQ61WD#N_OC0%S0"@% * 4 H!0%LU^,/&0>+:+H9\/V2OVJ N: 4!%Y/(\H
M&.P?;3P6L?6^ >&L@A "I02D7438 =I)H8,@QV/$5/,<%Y"AQ_<CO"L&2_H"
MV?\ :'$RA[#@AX?N>XKUC^Q0%S0%O/BJFP9,-$EV&N0TMI,N,4I?:*TD!;96
ME:0I-[C4DB_<H#48]''9N2VQD<5NYUS-;ERSF0E3-S(0F!(3+RC+<=UYAF/I
M9;NVRU=&DI44W4%7-#-3,8W3?%8_*XC+XN7)AR<'@7]LXU*2AU#<>0N.L.GF
MI65.(,=&G4=/;<&A@B]G=*IFS('P=!WAE)#:\BO+27WVH/E,I]]#H>\J=3'"
MGN8MQ"RI9U#EH2"$#30R2&S=AL;&DY[<$S+2LWG]P+C.92?(;8CI4(;9982W
M'BMM-(LE1U*"=2CVFP  &40Y"9SZG2-/*%D(/'V7:K]JA@J9+RGR8>22&XSW
M-9NZ[;3HYJ=:>/=4FZ4^$T!=T H!0"@% * 4 H!0"@% * 4!3?:#S9038]J5
M=T*'$&@+.+DT/N)84FRR+:AV%0[: D* 4!C.Z/SYLKSR]_DV2H!TY^;W:?F;
M'>]6Z R:@+8_B\C5V,OFQ\#G</[X4!<T H!0"@% 49#JFT!+?%YPZ6QX3W?4
M';0'MEI++:6T\0GNGM)[I/JT![H!0"@% * 4 H!0'EQM+J%-K%TJ%C0%*,XH
MI4TZ;O-'2L]\=Q7KB@*] * 4 H!0"@+"9);0O4OBTP;Z?LW;7 ];M- 0+SSD
MAQ3KANI7T .\*R8)'%8_F$27A[6/8)/=/?\ 4H"<K!D4 H!0"@% 0^[/BMG/
M-\O\"NMO!^?#6CUG/WELEW4G]EG"=ZN\\NB] +T!NKT:C_W3E_-_],W4-XJ\
MB&MV,LG@+:[FI]Y'355N721V>_-$JT'X2\4?B/\ .^,.'[= 2- * 4 H!0"@
M% * 4 H!0"@% * 4 H!0%I%\N\KG>4\OR7F(\BT>ST<I.K7X=>JW@H"[H"/D
MY!OF&(@E*U$(4[W$W-C0%\A"6T)0@62D6 \ H#U0"@% * 4 H!0$:F:S#>5$
M5<MI5XBA]:%<;'U* N,B2F(M24W4DA22.T$'M]:@+>#-EO(45-%VQX+&E/K<
M;4!=\Z1_9E?;(^K0#G2/[,K[9'U: <Z1_9E?;(^K0$9.F2^:6"@H0H %O@2H
M'PCO]G"ADD'IT>*I+;EPH@>*D7TBA@KAUH@$+38]G$4!^\QO[-/T10#F-_9I
M^B* _%/-)25*6D "YX]Z@*4::Q**DM$ZD\2"+<._0%Q0%@_.:6LPVE$.+5RR
MON"_;;P]R@+Y"4H2$)%DI%@/ * _: C<ED1'!89/MY]D?L1]6@('BH]]1]<D
MFLF"?QN.$<!YX7?/8/L1]6L&21H!0'XH!0*5"Z2+$'O&@+%F:TPYY&ZHE2%:
M$+[1;N ^$=E 6^Z,T=N;>R6=2SY08#"GPP5: O3W-5C;Z%;>#P_O[T;=::3I
M4YV\L7^4PT[U-+05:9JFE/\ <N]\G$_WL^XU-?TFOQ?X?VE9?Y"E^!_'_*/]
MR[WR<3_>S[C3])K\7^']H_R%+\#^/^4?[EWODXG^]GW&GZ37XO\ #^T?Y"E^
M!_'_ "F>=->I?ZR%92.]BTP404LDV>+VOG%?[A%K:*X&]]T+ J+TM+2KR4S4
M]+YR6\.\1/>KN)V]#0T?E5K6OH7,9RRRW!?"$#VI_@%'M"QW+^$5'B8E/-^3
M>0I\JCKDM>41K--7U:_*&]"N%N"564? * D: 4 H!0"@% * 4 H!0"@% * I
M2'2TWX@NZLZ6T]]1^IVT!2CP&&%AT"[H'%1[_=(% 75 * QG='Y\V5YY>_R;
M)4 Z<_-[M/S-CO>K= 9-0'AUM+S:FU=BAV]T'N'UJ MX\UM:A'<4/*4DI4.X
M2GN@^&@+N@% * IO/-,(YCJM*>R_AH"C&4)+BI=[H%T,CO#NGU30%U0"@% *
M 4 H!0"@% * MI +2DRT_6#2Z!W6S]3MH"Y!! (-P>PT H!0"@% 4)DE,2.I
MT]O8@=]1[* QIUY;Q!4> O8'P\23X2:R8+G'03*7K6+,(/C'OGO"@,B "0 !
M8#@ .]6#)^T H!0"@% * A]V?%;.>;Y?X%=;>#\^&M'K.?O+9;NI/[+.$;U=
MQY>%Z 7H#=?HT_&G+^;_ .F;J'<5>1#6[&63P%M5S4^\CINJW+H([/%(Q$HK
MG'&ITB\Y/:UXPXCL]2@)&@% * 4 H!0"@% * 4 H!0"@(?G9!4]26R2D+*=/
M\F$^&W@H9)&\W[%K[97U*&!>;]BU]LKZE +S?L6OME?4H"$:7:7F3"0I,T/L
MB>H<PW5Y.V4%O4+:=&FY3W;T!*XQQ]Q@E\DD*(!/;P[] ?DF V5F4VF[R2%Z
M/K5$=H]>@+QMQ+J$N(-TJ%P: ]4 H!0"@% * $@"YX 4!'HALRW#,<2;*-VT
M]@*1P!/JT!(4   %@+"@% * 4!^6!-R.([* CW(;<^0MTW2VBR+CZXCM^AV4
M!=B)%  Y*.'[D4 \DB_S#?VH^I0#R2+_ ##?VH^I0'XJ'%4DIY*!<6N$@'Z-
M 6S$5N!(!!*D/#0E9[4J[;>O0$A0$<_ ;:=,U *M*N8MON6[21].@)!*@I(4
MDW21<$=XT!8Y'("*GE-F\A0^U'?- 8\25$DFZCQ)[I)K)@G,9CN2!(?'MI]@
MD_6_^VADE*P!0"@!( N> ':: C6H+4ETS5W2E:M2$=\#L)]7MH""ZHNMHV#N
M!*U64N$[I'=)X5U=TO\ K+6LC@<0JN[K^HSBZYJYJGFF@N:5%!<TJ*&^_1FN
M9&Y3W-$/Z;]03BSPVOI?=+7_ /GR[U_HA]XWT7XLS7&0Y=?:"+\".P@^ U7Y
M;Q1E.2G80#$A$24AYE+KCEM-@ZC6D7^S3=*?5H"1H!0"@% * 4 H!0"@% *
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MMZR8)G&8[3:3('C=K:#W/": EJP9% * 4!;2"75IBI[%>,\>\@=S]]V4!<@
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MZ"@O04-_>C$;R=S?>X?TWZ@O%?AM?2^Z6KP!XK_1#[QT,XVEU"FUBZ5"Q%0
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MC<M82[.:Q%Z&FFJ:$<DFE3.\SKE5='Y-3"&]J0L3MO,YS<>HR&Y*\3A(S2]
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M8O\ .#Z!^I0#RZ+_ #@^@?J4!:-343I*&2DH;22L \=13V7]3MH"3H!0"@%
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M\(H"0=<2RVIQ?L4B_J^#UZ \1FU(05N?QSAU.> ]P>L.% 5J 4 H!0"@% *
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MG719YTZE#O#N)]84 DK4 EEHV>=.E)^Q'=5ZPH"HVTVTD(;2   /#P[] >Z
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M<GP"H$6N1&1;;7!Y\N&J;S9$4B,F^I(3(;+:N'\V;.'U* F* 4 H!0"@% *
M4 H!0"@+')MR7&D"/<@'QTIX$]Z@/>-"A$0%GQ@2+=T<3P/AH"[H!0"@% 8S
MNC\^;*\\O?Y-DJ =.?F]VGYFQWO5N@,FH!0"@% * 4 H!0"@% * 4!1DMJ6@
M+;_CFCJ;\)[H]<<* ]M.)>;2XCV*A?\ ]E >Z 4 H 2 +G@!0'+_ %AV B!D
MY.Y=O,$XA]1<FLH'!ETFZEI [&U'C^Y/@M:R=P;X5V*L77WEX7SKFZ>LI/B[
MAMV)O%6%_MRRS2^2^?5?P/T&I+FIF5D* =O;0"Y[] * O\+A<GN#),8G$1U2
M9TA6EMM/[*E'L"0.))X"M?$8B%B#G-TBC<PF$NXJZK5J.E*7^O9Z3K[IWL2%
ML/!)Q[2@]DI!#N1E@?QCH%@E-^.A'8D>J>TFJBWIO&6-NZ3R17A7,OC?*>B]
MP[EANS#Z"RSEEG+G?Q+D]O*91):4M 4W_'-G4V?".YZA'"N02(]M.)>;2XGL
M4.SN@]T>M0$9NE2D;8S2T**5I@2BE22000RJQ!'$&MO!JM^&M'K.?O%M86ZU
M\R7V6<1_#F:_]2E?]=S^%5T_E[7S5[$>9?SE_P"?+ZS'P[FO_4I7_7<_A4_+
MVOFKV(?G+_SY?68^'<U_ZE*_Z[G\*GY>U\U>Q#\Y?^?+ZS-Q^CKD)\S<^51+
MEO2$)@72EUQ:P#SF^-E$U#^*+<(V(:*2[W-Z&6+P+?N7,5<TI.7<Y6W\I'1]
M5V7*06]&RYM#/)"BA8Q\LH<3VI4&%V(MWJV\'Y]O6CUG/WE5X2ZDZ/0G]EG
M]ZNL\TB] +T!O'T8?C9F/-W].W4/XH\B&MV,L3@;:KFI]Y'4E5R7$1.YU0$8
M&<O*..-8]+=Y#C'!Q*0H<4VH"]7^,2 U_),V4YX5_6CUNTT!<$@ DFP'$DT!
M0C N*5*4.+G!L'N-CL^CVT!<4 H!0"@% 49+:EH"V_XYLZF_">Z/7'"@/;3B
M7FTN(]BH7_\ 90'N@% * B#"F^7EU*M*2HJYMQ['O6H9+_E2?[1_R"A@<J3_
M &C_ )!0#E2?[1_R"@(=N,IR5F$1FUHD%]I4EU2 A,@^3MA)0JYN$I 3W.(H
M"4QK#T=@H>X$JN$]MA0%Y0"@% * 4 H!0"@% * 4 H!0"@% * T!Z1FV5Z\;
MNV.@E&GR":0.RQ*V5'U;K23ZE3[A;%KO6'K+J?9\)47'V[G6WBHK]R77'M7L
M-!U/BHS)_P#34!,1&4>D2&\<8R)#B"TDR$EV08[9TZPDI6$J<'C=@T]T*/,_
M-S<M!):5:9\F2.D^3DS?#SH[7]OBK?O92:AH:7A[V66BLE:4=')9>31YI/VC
M9R"^Q#=R"6I)RDC$R5+0 TE4<)(4A16-17>P2H)XVX\>'Y>.R.2C5:"FN?+S
MY,E/6?2.Z:S4'-)^\E;>3(G&F5.N6O(FHY:9<N2/RN!7CE1G]$CR!]EN2Z7&
MM+S"7'5M:7!>UR6R47(U @\+VK8LXE3JLFDG3/D>1/)[<O,:6)P3M:+[VC)*
M3K'+%.3CE^KDRK25'DJ2K6SHJWF$.2GFA.<AQ8J%-IUMR9S9<2E[QO8H&@DI
MXD+!L""FM5XZ23HD]%2;RYU%TR=.7V>LZ,-U1;2<FM-PC')FE<54I9<R5*M9
MU).B:<2.9VZ)N,CSH;BPZXZXTZVZCQ>7':YSSR"@J)0T."O%OV6N3I&Q+%:%
MQQDN19O2Z)=+Y/\ 3>C# ^\LJY%YVUE7)&.E*62KI%9\G,U6NC&TW#B4X/,R
M\6AU;S<=0#;SC986M"DA25%LDE-P>R]?7"WO?6E.E*^FOPGQQV%_+7Y6JZ6C
MRTT:Y*YLM#)ND>V5[FWOCVE(U08"A/F*[FA@@I2?^)>E-N]>N;OO%K#X63Y9
M=U>OXD=SA?=SQF/@J=V'?E]'-[71'854^>CQ0"@% * 4 H!0&"]5W&X^Q-RA
M5]+^/=NE/<6+)2>/?OQKI[JVNWK(XF_4GN^]7YC.([U<1YU%Z 7H#H/T7'&V
MY&Z%.+"!RX7LB!W7Z@_%3R6OI?=+0X$7>O=$/O'0(FM3GT1DW2W<J5?Z_3Q
M_;J!%JE7*ATQ!R928:^<Q[<NUBGG(U(X]U8N@>K0%[0"@% * 4 H!0"@% *
M4 H"V/XO(U=C+YL? YW#^^% 7- * 4 H#&=T?GS97GE[_)LE0#IS\WNT_,V.
M]ZMT!DU * 4 H!0"@% * 4 H!0"@% 0R'):<BIMN_++AU)'L;'M/T.-#),T,
M"@% 0N5R&J\5D^*.#JAW?!]6LF"*0P92N0$:^9XI2>((/;?P5E.AAJN1FO\
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M7UGQGB;DU%-^!4C1)47J2YW6N=MMY6S\D2,KN/*\UXN3LM-6AL6&IQQ=@A(
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MQ+*X7<'B^JJ@):@% * 4!:OI#"DRFQ9*>#P [4'N^J.V@+H$$7'$&@% * 4
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M@/QAKDMA).I9.IQ7?4>TT!YDN*2E+31L\Z=*#WAW5>L* JMMI:0EM LE(L*
M]4 H!0"@*,AI3B 6^#R#J;/A'<]0]E 6.+<9=F9-UN&8ZU.M<R023SU!A OX
M-%N6?4H"4H!0"@% * 4 H!0"@% * 4 H!0#LXGLH"!R61YY+#)]I'LE?9'ZE
M9,%BRRY(<#30NH_0 [YH#)(D1N(UH1Q4>*U]TFL&2XH!0"@% * 4 H!0"@%
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ML-J=<-D)[: QF7*7+=+B^">Q">X!63!7QL RE\QP>T(/']T>]0&1    "P'
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M^L%G0.ZV>WZ';0%R"" 0;@\0: 4 H!0"@+9'XQ(+O\DS=+?A7V*/K=E 7)(
MN> ':: MHX+JE2U?7C2T#W&Q]7MH"YH!0"@% * 4!%Q%%C)3P90?9>>19@6O
M&7R6_$-N/C_QG'[*@)2@% * 4 H!0"@% * 4 H!0"@% 0>3R/,)CL'VL<%K'
MUW@'@K)@CFFG'G$MMC4M78* R2%#1#;TCBXKV:^__P"RL&2YH!0"@% * 4 H
M!0"@% * Q'JE\WFX_P A=^E75W3M=O61P>(/^NO:C.([BKD/-XN* 7% = >C
M#_6=S?>X7TWZ@O%?AM?2["T^ ?%?Z(?>.BJ@!;9AO5GYMMS_ ) []*NINK:[
M>LCB;]V"]JLX/O5O'GT7H!>@.@_196Y\(;B:'%LHAJ*>Y=*G;'UKFH/Q5FM=
M,NPL[@;/>Z(?>.GZ@I9Y89@),,:X9G#GQ_:$]H//19S_ .&?;/6H"_H!0"@%
M * 4!#-R)2,@IE ]K+ANW:XL3Q/[=#)?2<@Q&<#2[E1XFW<!H8*XD,$ AU%C
M^Z% .>Q_.H^V% .>Q_.H^V% ?BI,="2HNIL!<V()X4!2BSF9:E);!"D\;*[H
M[] 75 * MF_Q=\L_R3MUM>!7:I/[8H"YH#&=T?GS97GE[_)LE0'YT[2E?3O:
MB5"Z587'@CP&*W0$_&44:HSANMKV)/UR#V']HT!<4 H!0"@% * 4 H!0%L][
M>ZF,/8"RW_4[B?7- )!+RTQ$]BAJ>([B!W/7[* N"4H25$A*$BY/8 !0&.9"
M<J6Y9/!A'L!W_":R8/$*&N8[I'!M/%:N\/JT!DK;:&D);;%D)%@*P9/5 * 4
M!;-_B[Y9_DG;K:\"NU2?VQ0%P>P\+^"@(>"_.#_)""I";W;5XH3Z]C0R27,E
M_P PG_J?^[0P8'N#?>>V]O\ QN EPHB]N9#"Y7*I6VXM4X/8<Q2L&^E 0I,B
MR18DD7N.R@,*P'5GJ!F\5)#D2"C+R]NXC>6(&/A2LDIN!F7'FS$7&0^VM]YK
ME#VQM:4JU>P&GB,DQ.ZORXW2+ [\>;@-YO<#$=F!%;EI\A7E92#9I3Z^#;:"
ME:G=1U(2A0XJ%B,&6])MV/;YZ=;>W7)\G$S*1$ORTPU%;"7R2'$I*BHC2H$$
M*-P>V@,ME+=1'<6R+N >*.V@,:S#CSNUMQK>\97P=)&H]O\ $.<*VL'Y\-:/
M6C0WCLMW4E]EG#5ZNT\R"] +T!N_T9/C7F/-_P#3MU#N*?(AK=C+&X%VJYJ?
M>1U#5<ER$+O#XI9_S=,_ +K:P?GPUH]9H[PV:[J2^RSY]7JZ3S<+T O0&]?1
M;^-N9\W?T[=1#B?R(:W8RP>"=IN:GWD=5579;Q%;D$0X.8)\=R5$T#FQV+\Q
M8U#@FQ'=H"5H!0'E=RA6D JL; ]EZ B('PBEPHL="18I=N$CO6H9)*\W[%KZ
M*OJ4,"\W[%KZ*OJ4 O-^Q:^BKZE 6605D0E&D63QN6;DW\/"@+V&E:(K27!I
M6$\10%!<IF8X(C2KA1/-5V72GM ]6@+X  6'90"@% * 4 H!0$9'9:=F99'D
M2HRENM:I?]H4&46<3_P>P_>T!<1IS3J@PM0\H%TJM[$E/>/AH"[H!0"@% *
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M@% * 4 H!0'E:$N(4A8NE0L1X#0%*,M5E,.&[K7 G[))]BKUZ KT H!0"@%
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M5JLEALV==X _8I'LE>L* J)2AEL)'BMH'T * I1@7"J4L64YP;![C8[/H]M
M7% * 4 H!0"@+9_VEQ,H>Q]@\/W/</K']B@+F@% * QG='Y\V5YY>_R;)4!:
M; F-1=C[8#GB-/XB \A";D(*XR"1QXVOV4,F8)(4 I)NDBX([QH8/V@% * 4
M H!0"@% * L,E/$9'*;/MZA]J._0&/<5'NDGUR363!/8F(EE*EN#\9!TJ2>U
M([?V:P9)*@% * 4 H"F^Z&6RNUSV)3W2H\ * _([1:;LHW<42IQ7?4>V@*M
M* A]V?%7.>;Y?X%=;>#\^&M'K.?O+9;NI/[+.$-57<>7Z#504&J@H;L]&DWW
M5E_-_P#3-U#N*O(AK=C+(X#VJYJ?>1TW5;ET$-N_XIY[S=+_  "ZV\'Y\-:/
M6:&\=ENZDOLLX!O5U'FD7H!>@-Y>C!\;,QYN_IVZA_%'D0UNQEA\#;5<U/O(
MZEJNBXB%WC\4<_YMF?@%UM83SX:T>LT=X;-<U)?99\];U=!YQ%Z 7H#?'HL_
M&[->;?Z=NHAQ/Y$-;L98'!6TW-3[R.K*KPMPL,US_@N3Y-,1 ?TC1,=MH;-Q
MQ-^'@H"_H!0"@% * A,_N_;6UV^9G<DS#41J2RI6IY0_<MINH^L*W<-@;^(=
M+<7+J]N8Y>.WKA<$JWKBCZ.7V+*:[R'I$[/C+*(,.;- _E A#*#ZFM6K_EJ1
M6N%\3)=Z48^UD-O\>8*#I",Y^I+K=?@+)KTD<"I5G\+,0COH<:6;>H2GZ=?:
M7"E[DG'X35C_ /0,/7O6IKUI_$9;@^LVP,XM+(R!Q\A9 2W/1R!<_N[E'_-7
M)Q&X<995='27[N7X,_P$BP?%N[L2Z:>@^::I\/A^$SUMQ#J$N-*"VU@*0M)!
M20>P@CMK@M-.C);&2DJK*BC)!;*92!=3?!8'=;/;]#MK!DKI(4 I)NDBX([Q
MH#]H!0"@% 4WW0RV5VNKL0GOJ/ "@+'&)Y<K(H,SRASFH4ZQ_,+4R@E/J*%E
M>O0$E0"@% * 4 H!0"@% * CLED1'!99-WSVG[$?5K((#BH]]1]<DFA@GL;C
MA' ?>'MY]B/L1]6L&22H!0"@% * 4 H!0"@,1ZI?-WN3\A=^E75W3M=O61P>
M(/\ K[VHSB&_AJXSSA07\-!07\-!0W[Z,)OD-Q_>8OW3M0?BOP6^F786CP%Y
ME[HCVG1]5^6X8?U5^;G<OY"[]*NING:[>LCA;^_Z^]J,X9O5PGG<7H!>@.A?
M19-Y6Z/O<+[I^H/Q5X;?TNPL_@3Q7NB'WCI&H$6L87U<^;/='Y []*NGNK:[
M>LCB[\V&[JLX'O5NE!B] +T!TAZ)A_&MU_>X/W3]0GBC-;^EV%D<$^*]T1^\
M=.5!2SC'=R&8CEK8B*E@NQM+38^N2^DA9^]GQ_6H":29VD72U>W'BKM^A0'[
M>;]BU]%7U* 7F_8M?15]2@/#AGAM12EO58VL57OX+B@+3&>5*?<7("B-.G4L
M&][WL+T!Z7/;EOIB %+:EV4K[(#N>N: DZ 4 H!0"@% * _" H%*A<'@0>\:
M C8^00V\(2@5)2HMH<\%[ $?L4!)T H#&=T?GS97GE[_ ";)4!8;$@"7LG:Z
M5G1Y/A\>TXH6-UIC-W [G#OT,F9H0EM"4)]BD!(]04,'J@% * 4 H!0"@% 6
MLZ8B&UJ/%U7!"?#W_4H#&UK6XM3BSJ6HW)-9,$OBL?IM*>'C'BTD]SP_4H9+
MY_VAQ,H>PX(>'[GN*]8_L5@%S0"@% * 4!;)_&)!7_(L$I1X7.Z?6[* N: 4
M H"'W;\5<YYOE_@%UMX/SX:T>LY^\MENZDOLLX-U5=IYAH-5!0:J"ANWT9S?
M=67\W_T[=0[BGR(:W8RQ^!-JN:GWD=.U7!<Y"[O^*>>\W2_P"ZV\'Y\-:/6:
M&\-ENZDOLLX O5U'FL7H!>@-X>C$7?\ 5F8Y6G\VF^J_;SV[=E0_BCR(:W8R
MPN!]JN:GWD=1?CO>:^BKZE5T7"8YOXSQLK<6G2/_ "R=Q;)U7\F<MVUMX+:+
M>O'[2.;O2OY*]3/[N?V6<1P-N,Y#:N0S[$M:LACYD2(K&AFX6F;K#:P[K]EJ
M;4-.CUZMJYB'"]&VUDDFZUYJ<GKSU*(M8-7,/.ZI982BM&F?2S.M?0\E"7W%
ML:)M:?#B9*1+D1^:]#R$R RP^WY<P$:H[ #X)4DJTGFZ%6\8(M6MA\;*]%N*
M2=$TFVNZ^5Y.JO-4W<5NR.&G&,FY*KC)Q49+25*QCWLZK3O:+Y=$_6^GR%;T
MS&U1D#)9PS+\IQ<5K7+D",VE:F&6"JQ?!5I6C7XNE9NK3QP\?_3QNZ---I97
MD5>5OYO,Z9:KG,PW2GBYV-/25M-NB[SHLL8QKXN1JN2DL],NVN@6 5MCJ9N/
M"J>+X9Q;+K;JD%I9;DEA] 6V2K0L)< 6FYLJXN:CN_;_ +_"6YTI63].:JS\
MV3(2WAC"O#8^[;;K2"Y*9]&6;D>7*N1G2E08LXC-P!HX:6'X2LBUH&J$W?4Z
M-0X"WT: DZ 4 H 2 "2; <230&@^I77-;3KN#V0Z+H);DY@ *!(X%+ -Q_\
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M!<Q"[O\ BEGO-TS\ NMO!^?#6CUFAO#9;NI+[+/G]>KI/-@O0"] ;T]%T_\
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M&Y!UC))KUDEY.Q_-(^U%?(^X\G8_FD?:B@'D['\TC[44!Y7$CN(*"VD!7"X
M!^C0'B+":B!7+)*E=JE=X4!0@E)GY,":9!#K6J,>R,>0CQ!_Q?QG[Z@)"@%
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MFN2E6N5//DR-9S<G4]S(-],<9C83YW'AWU,B=NIUU"RG2Z-!*4W/C*.C7<V
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MK-A[T5K#6K-A-.,O>3;^5->%4J^[%>GO/+HHSB5U;VLW,R>[L5C)K6]\M!3
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M6G/$K$6)7(Y5&,='2>BI*E:KO-9\[63FR;=NZ<IM_J=LW:N*4(V"<:;0[#;
M2VI#[BXZ4D < V$ HMV5S<%@[=_ WKT\LZO+T)2^&N4[>\]Z7<)O;#86UW;6
MC'NK-23<$NB*CD+#,IQF+W/O[ 1LC&PN9W+#B2L;(=6(R"YH6EY!<X!*EJ\;
MOG63QM7WL.=RQA[CB[D+4I*2S\U'3T+J-7%*UA\9C+,;D;,\1"$H-O15>\I*
MN:LGEYWI<M"RR+N,G3=N9!2VLY.V?"8A+?:<#C>0S\D-HBQ4.J*>9H6E3RU
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M8)1BJ)<B*E?D_8H!0"@% * 4!91#)\LG\Z,AE@.-^3OHMJ>3RD:E+\*570/
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MWK1ZT<[>>R7=2?V6<!7JZ#S=07H*"]!0WIZ+QONW,^;OZ=NHAQ1Y$-;L987
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MXE\F&MV,G7!VT3U.U'7%5\6H16Y?(1@IOPDXZU!T#G.,?QH&H>QMX: E: 4
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MNTSU.U'6M5Z6L0>]?B=N'S9-][KK:PGGPUH]9I8[9[FI+J9\XJN0\_B@% =
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M%76U5NJ.X1_XC'O5JK;W'L5OU_:9Y_XH7_)7>F/V8F :J[9&*#504)W9*O\
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MF;?P^R)&:"MB86;BULXHQ4EU_%86,VEJ%(=4LA87):0^XO0+I'+M8WH#9E#
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M)32J^@]9;>\#,RH,F7CYA>QC3#$&?\(E62TM.NO+6[)+!YCA+B4MJT#EH0
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MO@RE%8/"/$7%"JBN63S)5I7X4ESMI<I+M[+C.+W/!&5T9C;0F/.LN1RF,XQ
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M!VMR+^NM:Q] :J<O$4 H!0"@,9W1^?-E>>7O\FR5 .G/S>[3\S8[WJW0&34
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M3K.H.6&8;U9C"9TVW/%4HH#L!U)4.)%Q74W4JXNVOWD<3?MSW> O2YHLX/\
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MWM1G&-B03;@.TU<QYG%C0"@-[^C4JTS<:+=K<0W]13OU:@G%B[MKIEV%L?\
MSU]^^O1#[QT)5?%PD;G?)/($^6O.,,>41;.-7"N9Y0WH3P[BE62KP&@)*@%
M<$=7X*\EU@W7'0X&RF0%ZB+]C;8M^S5L;FCI86"]':4;Q)>5G%W)-5[W88F=
MIR@ 3)2 H722@\1>UQQ[XKM>Z])%O[C'YK/S_2LC^U(^T/U:>Y?.8_N4?FOV
MDWT]@+QG5+9S#C@<+F4A+! M;\82*Y>\XZ.&N:LNHD6XKRO8JVTJ4G'K/H35
M0E]"@/GSU*QZ\IU6W@PVX&RWD9*R2+W]M(MW*MS=4=+#6]5%$;_OJSBKC:K6
M;(#_ $E)%KRD\>SQ#]6NM[E\Y&_[G'YOPC_24G^U(^T/U:>Y?./[G'YK]ID_
M2: O&=7MI1UN!Q2I:%Z@+=H6+?L5QM\1T<+<7[I*.';RO8NW)*G>._JJ8O,4
M H!0"@,9W1^?-E>>7O\ )LE0#IS\WNT_,V.]ZMT!DU * 4 H#%^I*5KZ>;L0
MA)4M6'GA*1Q))C.6 K>P&TV]:/6<[>;2PEUOYDOLLX&VI"FL37N>RM@+0A*%
M.C0G5J[YX5<EI-5JCSIO&Y"Y&*BT\O.;FWHAR8UCL<O,0<I)Q,5]]_-F6TZN
M4XXM"U,-D$K*&BK2REP J\=2;)X#E8!J+E-0E!3DDH:+6CG[SY*OY5,W=3RG
M1WO%W(PMNY"X[4)-W-.+<ZM/065RI&M(*5*]]K)D49U)EB?A<,TN8B7EV(,B
M/+90^WD70K6I2%KEMW"^85*TM:CR@/W5?O=]MQ=VD6HMU61QY,R@\U/G?*]1
M\]YWE/\ +N4U*<8TEWE<:[U=)W%6NE5TA5Z"7[Q*^B-$F1MTY]4EA;23CD %
M:2+GG)J.\2Q:M0K\[L+!X0NPG?N:+3[O:=<U 2SC'.H/Q"W3YHR'O9RMO!^?
M#6CUFEC]FN:DNIGSVV@H&=)L;^U#[JKFLYV>=MZ+_;CTFZMR/0MQ2<%*>R$=
M8B82.O*J#C;3I4R^X%LH!"4EX(4G2CNBN=A(RL1N)1?>N/1SM94J-_NUY38W
MC.&+E9DYQ[MF.GE2>23K%<FG3,CQU:F8B=#5(@24DH5-:A08TA,B&WBTI1Y,
MXA"3:.I8U!3-@?%NH)/LOENR%R$9*2^2FVU23GETE7Y27SO3D;Y-C?-ZS>O0
ME"7RY*,5)2@K:<="22\MO*G#/W:M1?BJ^A\H'=>X+&__ )<C\.FN!Q)Y4-;L
M)]PHO]^YJ]IV!4#+(,=W\E2]B;H0@%2U8F>$I':28SE@*V\%Y]O6CUFCO!I8
M:XW\R7V6?/W:T.9'FOJD,+92IL!*G!I!.KOFKGM1:;J><=Y783@M%IY>0W1O
M)#LQG&XUW-0\K*QL>3)D9E4QETON+Y:S&:L2O0W[%I+EM2BLILG@.5@&H.4U
M"4%-Q2CHM4S]Y\E7\JF9:-<IT-[1=R,+;NQNNW&4G<TXO2S/0C3O4C\A2RRD
MYN/=R*PZE/.KQ>/QCF29STR*Q)+V79D-2E.NR A191H)<#+7L6^9[)164V38
M#][N@O\ <DH.VI4I'1:S5R\VE+EIR:-<IC>UQJ5F$KBO.%:W-*,JUT7HJG>4
M(?)T\[<W'NY%>^B-#F1MXYM4F.XRDXNP*TV!/E#7"H_Q+%JQ"OSNQD^X1NPG
MB)Z+3[O:CKZJ_+/(C=7Q7S?Y!*_ KK;P?GV]:/6<[>>R7=2?V6</,\KG-\_5
MR-0YNBVK1?C:_"]JN^5:9,YY9C2JKF-C;]&'SFE[%Y".RF*N8N!!3+2N(,4R
MALL%MLD<E]SBGD:=2BFZ@#Q5'=V^\LY)Q;KHZ3T>]INNE5_*BL^EFRY*\DSW
MT[.*:E:G%*.GHQTUH>[2CH45>Y.6;W=-)M5:B_% [YR;.65M^2B2W)DIP\9J
M:IO2"E]#CUT+"0 %!.GUK5O[NLNU[Q4:7O'3HHCE[ZQ,;[LR4E)^YBI4^<G+
M(_32AGGHX?&C+?D'],W7!XJ\B&MV,E? &UW-3[R.E*K8NTB-U?%?-_D$K\"N
MMO!^?;UH]9SMY[)=U)_99PZV$*<0E:M""H!2[:M()XFP[;5>#S'EE)-Y39?4
M%['YU#*(.0C!4-W(R4)7,:?0Y%2ACEJ9(/M(=TGE0NUOCWZC6[(SLMZ47WE!
M>%JC[U:_.I\JY\HFV_)V\510G'N.[++<4DX]RCCE[FE3N6<\<N:IC6],HWED
M;=?$A$F2WB&69BFPD%#J)#]D*"0 "$%'<[+5TL!9=IW%2BTVUT:,<OMJ<7>^
M)5]6):2DU:2EZ&I3R/H5/50S_P!'#XT9;\@_IFZX'%7D0UNQDNX VNYJ?>1T
MI5;%VD1NKXKYO\@E?@5UMX/S[>M'K.=O/9+NI/[+.'6UAMQ"U(#B4J"BVJ^E
M0!O8V(-CX#5X-51Y83H^<V1O:;C=P0XR8TIEO)M+G95UF1,:?3$C+2URH,=U
MH:% %*BTTGV/@)(J.;OMSL2=4]'NPR1:TGEK.2>5?O2><FN^+MK%VXJ,DIKW
MEQJ5Q2T(O1I:A)=UK(]""\/H;9!;VS;LUK$81605E?@M@N2IZW"]S)LS2XZ$
MN%2KH; 0T/"DGNUO;OPZ@YW-'0TWDC2E(QR+)SO++UI<ARM[XMW%:LN?O?=1
MRRKI5G.CE1U=5'NQZ8M\IG7HX?&C+?D'],W7"XJ\B&MV,E? &UW-3[R.E*K8
MNTCLZ%'$R@F",DK2+03:SOC#AQ^C0$C0"@.%O246!UBR(_\ #@?@&ZLS<.R1
MZ7UE0\3+^LGJK[));>R88P.Z,4Z^AIJ=#8++2](+DEJ=&*;*(O=*"X;7[+FN
M]BK.E>M32RQD_4G"7;0KO!XC1P^(MMI*<(Y,F64;MNGLCI?"9.W_ *>C[*DX
M9V<PV[';G>7OPYMG).2:D 14\@)/E#"D)1H7[%-UJ\4^RYC]]+%*XHO*XT3C
MX8./>R_)DG6JSO(LJS2"*PL,#*TY13BKFDXW,LKBEW%H4_W(-*.C+-'OONOQ
M:/;6!OS'#_YR%]VBNCC/#/H?4?'<ZR6];[Q](*I<]$"@.!NO"P.MF?3<7\IA
M^]6*M/<FR6_7]IE,<1K^KO='W49;MZ<RYL[<.!?EL,+EOX]<)I\I;NX7]+B]
M1%[)2!JXV KI8JVUB;=Q1;HIUIS4R+VYB(X"]%X&_8E**<I6]%.BRZ65U]"S
M\R+WREEG8\[!SY;$=$-UTP',=-2X9TDR$)4F1%2HZV]*"MMY038)3;5< _#0
M;Q4;D4WI)5TH^!:+\,N1U=''+G>8^WO(QP$[$Y*.C)Z+A-/WDM)>.">6-%6,
MVHTT8TTJI/4VVU@=4\"FXO\ #6.X?_':KZ;P\JYJRZCH[D7?LZT?M'T8JG2_
MA0"@% * C,>(OPGE^1'<:?+S7E+R[Z'E>3MZ5(OW FR3;NB@).@% * 4!AG5
MQMQWICNQII)6XO&20E([22V>%='=JKBK>LCE;WDHX.ZWFT6<G=%W'<6\Y'FO
M-8U#[+S<B0_(7!D--%Q"U+C/MA6ET!-P""%IU(L=5JL_'VF["[KDU*J6CI)Y
M_%'ECU.CY"B\#B(?G9/3C&,H4<M-P:7=RPDLTU3)5-258T>E0S=V?M9S9DC&
M-Y &(VB:JX=<8R$G)*EWBN.QP>6XVID-ZE**M'C6(4 %:JMWUB5-QRO1Y$XQ
MAH]Y*6=/2KFI7)R9MB=_"/ .VI]U*YRM7)W/>=QRAX91T-&K=='O4::[UG$R
M6W,;LW<6V49!0R#K7XRIIEMUB;*8G-EA3#Y6E?*2VDV2I ]DM?&P37VG:O7,
M3;O:/=3R96G&+@ZU6:K?+7D2YV:MK$8:U@K^'T^\UEI%.-R4;L=%QG5/145F
M:^5*66BB2/HD0Y<;-[Q7(94TAQ$8MJ4."AS7CPJ.\3Q:C"O/+L+ X,NPF[BB
MZTC#M.J*@I99B'56.9?3?=,8*T%W&R4!5KVN@UTMV*N*MK]Y''WU/0P-Z7-"
M74<A=-DKVYE82"_&U:G4>42E+CMHYZ5)U)=0%J:<3>[;MO$591X U;&+LUL.
M.5\N15S.N9^)<\>59#S[A<;7&QN*D:Y.\VDJJE=)*L7\V?R94D\B9L21FMK'
M:^9Q,;+\\27Y0CR9+1$E9=DLK;4ZT$%+FI*%*,@D+;3=(3V)/(CA\1[^$W"E
M%&J3R9(M.CKDS^#-+.WRKNW,9A%@[MJ-S2TI2HY1>DZSBTY1I255%OWE5.*R
M*-:1<7G96UCLUC%PY:#*A);2RU&4Z"_/2\X)+SR5("%-J;4DLN'Q[63;V03M
M8>&(_,N<EDE7/3)&BT4LM:U\2S9WS5T,9=P?Y&-J$EI0I11TN]<TGIRE54<7
M%K0EXJ4C\Y1R#T5,.O&Y?=;ZG@X)#<902$VM[8\>_P"&H_Q3#1C;Z9=A.>!\
M4KTKJI31C'M.G*@1:9B?4]AN3T[W-'=ORW,=(2JQL;%![M=/=:KB[:_>1Q=^
M3<,!>DLZA+J.5MA*Q6(P6<PTB:,?CGV2ZIYI:QD%K"5I0TV-)2\TM:TAUE2D
M]Q8(T$U:&,L2T[<H1TFGR^'DJWRQ:2[LDG\WE*&P.-4X7HWIZ"E'/')-T32B
MJ9)Q;:TX2:Y))K0;,HP>Z,8IG'<[)-0LQ'Q<6*9[C2@EMN)DGG76#H0;J7'Y
M?<.L#03=1!TL1@[E94BY0<Y.E<^E;24LKY)5Z/%R'2P.\[6C#2FH7(VXQTFG
MD4+LI..196[>CR/2\#=9-%;!9G:D&)GT^7QXT7)O2'V(Z65\R-'?8>;;04<O
M3(4DN)!84KEH("TJ[2G\8FQB)RM]UMP23=?$TXMO/W<WB\3S-9J_7 XS!VX7
M^^HQN.34=%UA%QDDJ:-+C3DEH-Z$::499VI3T7<5$Q^4W.]'"@M]J,7-2BH7
MUNGA?L[:Y?%4%&-NG/+L)'P'B9W9W5+D4>TZ3J %LF)]3?B!N+\B<^E75W1M
MEO61'^(O^MOZC.7]H9"$SBL[C\C-3CX4AC6MYA2D3UJ2A:$--@)TO-+6M(=9
M4I/<6"-!-6ACK4G<MRA'2:?+X>2K?S6DN[))_-Y2AMUWX1M7K=R>A&4:U5=-
MM52BN2<6VM.$FN22:T&R?V]N['(=Q!G2VV3'Q4>-/GINQ)CB'DG' TT$M+#I
M6P4)4BWCCM6+*OH8K!3:GHINLVTLZ>E;2J\JI25:/DY%F.QN_>MM.WIR2T;4
M8REX91T+S>C'NO2K;T:JG>6>2I(\8;<6W<<QF%/>3H@2ER9S4*,I84\9K#C;
M,!YM3-E(9-E:@L);)N"HD6S?PMZ;A2NDM&-73)HM-S3TL\LU*5EZ%4_.$WAA
M;4;M=%1DY248U6EIQDHVI+0RJ&>J>C%O(Y-JF5>C5_7]P_>8OW3E<KBSP6^F
M782#_P"?>9>Z(]<CH:J]+C,3ZF_$#<7Y$Y]*NKNC;+>LB/\ $7_6W]1G,.!G
M0?\ 1>;QDZ8W#;*^>TF.XI$R2_I ::=;*2EZ.%)U>R!:5=7UP!L_$VY_F;<X
MQTN3+X8KE:>>,O5WE1<F2B<'=M/ W;=R2CETEHMJ<I?)C)4I.W7+GK!UERI/
M('=Q1<?E\%(?W"C(-8N*^Y-R$53XDS5A0?$)14V"&2X$M("^ &M? $)'/6%E
M.W<2MZ.FU2+I2/)IY_%3*Z>A<[.M+'PM7[,I7E/W<9.4HZ>E-UTO=MZ/@TJ1
MCI9*:4LE8Q4=LW.8"%FW<QN>4E4W+I>=>E-,AU+"7Q(2\A;92D(<<5H*5-A0
M2A5N%SIV<?A[T[2A962%,C=*TT:.O*EEK6F5>W2W1C</:Q#NXF597*MR4=+1
MTO>*2:IDE)Z+3BFE%TR5=,U]&O\ K^X;?S,;[IRN)Q9X+?3+L)5_\]\R]T1Z
MY'0U5Z7&8AU3^;W</Y*K[I-=?<^V6]8CG$G_ %M[5.9<!/A#9F:QDV:W";*P
M^A,=:D39+VD);9=;TZ7F+@D>,"TJZOKK*LS$VY?F83C'2Y,OABN5IYXR]7>6
M3DJJ,P=VV\!>MRFH9:JC:G*5.[&2I2=OES]QUERT>5.YO -[MQF9Q^2C,18Z
MWEJCM2)+$1.*0IKR9K0&U$/>S+K"04JTB_%1ORXX>\\/*W*+;=,M(N6GETGG
M\.;1EG5?02">,P\<=;O0N148Z3HI34?=+1]W&E&]/.YP58RT5DK)U@MKR86*
MGY+(M;@B>2/(>6WC'VW6$3"I3S+:)+2&E-H0$GFJ;"E"Q2A/$W1O8R$KD(Q=
MN553O)IZ.9MQ;=6_DIY.5O)D?'W;<A8N3FKT-%J7<E&45/Q12G%1<5&G?<:O
M(XQ65UCFWHU?U_</WF+]TY7$XL\%OIEV$K_^?>9>Z(]<CH:J]+C+3(^5^3#R
M)EM]_FLW0[P3R^:GF*[G%*;J3X10%W0"@.'^IN-DL]8-U9!93Y.\]I18^-?0
MWVBW@JW=QQ:PMM^CM//G%F(A+&7(+.I=AEJ<_ 9F;7R<G+F.N+%5Y=#QSCBH
MXBQFT%IA"-*>2[)6VI#R+E.H\SL57S>&FXW8*%:O(Y)5JVZRK\I03K%YZ=W.
MCXK&PA/#7976G&/>C!RT=&*6C#1R:$KCBXS66.E_N>%EEMW-X%O(9+*;D?'E
M^>9E+7(BLI=$824R4NME"T@(<<5R]"D:@E!M<7-OMBL/=<(PM+);<<C=-*FC
M1UY4LM4Z5?0JZ^!Q>']Y<N8E]Z]&>6,:Z.G[Q25'X92>CHM5I%T=*NF'[.QD
MJ5U1V?-:*.0QDH?,U$A7"0E7 6[U?7>T&\-<?[DNH^O#>(A#%6H//*Y'K1WA
M5-GHP4!PCO;'S(_5?>,QY 3'>GR>4K4"3=V_8.(X5<6YXM8:V_W4>=^)[\)8
MJY%/*IRJ;-;SN&7-A39.0A_#"\6(\5D.O#&0PE;"1R5H0'(SBF4OW0 =*S<'
MQ@!S7A[JC**C+0TZO(M.7BSY:32EHY>59*9*G0CC++NQN2N0]X[5$M*7NX>#
MPM+2M2<%/(JTEEKWJ*TVY/VAB86=83EDB+/<?,0.M*5);B<N0PT74AO0^M14
M@J840@<%WO?3]<5;Q-V5MZ&6*5:/(Y5BW3+6*S][/GC3GUMW7\%A[=Z/O.[-
MRT:QK)1I.,=+NTFW6+]VZ162=<^C@G3K'S'NK^TYK: 8K4A <7J ((UGL[>[
M6SOJ+>%N/]T_/"M^$<5;@WE<^P[GJH3T&* 4 H!0&,[H_/FRO/+W^39*@'3G
MYO=I^9L=[U;H#)J 4 H!0$?G<9\-87(X<N\@9",]%YP3KT<Y!1JTW%[7O:];
M&'O>YNQN4KHM/V,U,;A_S%B=JM-.,HUYJJE32G^VAKY2J_N0]WJ:_JQ_A?Q?
MRE8?X]7X_P#!_./]M#7RE5_<A[O3]6/\+^+^4?X]7X_\'\X_VT-?*57]R'N]
M/U8_POXOY1_CU?C_ ,'\YFG3CI0CI]D9D].6.0\K9#'+,<,:;+"KWYB[]E<7
M>N^OST(QT-'1=<]>Q$FW!PRMUW93]YIZ2IX:<M?G,V/4<)H6.9QPR^'R&)+G
M*$^,]%+NG7H#[91JTDB]KWM7VL7?=7(SI71:?L9K8JQ[^S.W6FG%QKS55*FD
M$^C)&0;HW'I)[2((']/4V_5G_P#+^+^4J]__ #ZN?$/ZG\YZ_P!M#7RE5_<A
M[O6?U8_POXOY3'^/5^/_  ?S@^C0R18[E40>T>1#W>L?JQ_A?Q?RC_'J_'_@
M_G,RZ;=)&.G>1F9!K)^7&6P&"WY,&--EA5[AQ=^RN+O7?/YV$8Z&CHNN>O8B
M3[AX:_MER4_>NYI*E-&G+7YS-DU'29EEF,?\+8B?BN9R?+HST7G :BCG-E&J
MUQ>U[VO7VL7?=7(SI71:?L9JXNQ[^S.U6FG&4:\U50TC_MH:^4JO[D/=ZF_Z
ML?X7\7\I5_\ CU?C_P '\X_VT-?*57]R'N]/U8_POXOY1_CU?C_P?SC_ &T-
M?*57]R'N]/U8_P +^+^4?X]7X_\ !_.9CTYZ2HZ?Y:5E$Y<Y#RF.8Q9,<,@7
M6E>J_,7?V-K6KC;UWU^>MJ&AHT=<]>Q$EW!PPMUW97/>:>E&GAIRU^<S951L
MFI:96#\)XN;C>9RO+([L?F@:M'-04:K7%[7O:OM9N>[N1GGT6G[#7Q-GWUJ=
MNM-.+C7I5#1_^VAKY2J_N0]WJ;_JQ_A?Q?RE6_X]7X_\'\X_VT-?*57]R'N]
M/U8_POXOY1_CU?C_ ,'\X_VT-?*57]R'N]/U8_POXOY1_CU?C_P?SF9=.>DR
M.G^4EY).6.0\JC^3\HQPSI\=*]5^8N_L;6KC;UWU^>MJ&AHT=<]>Q$EW!PPM
MUW97/>:>E'1IHTY4_G,V34;)J6F5@_">+FXWF<KRR.['YH&K1S4%&JUQ>U[V
MK[6;GN[D9Y]%I^PU\39]]:G;K33BXUZ50T?_ +:&OE*K^Y#W>IO^K'^%_%_*
M5;_CU?C_ ,'\X_VT-?*57]R'N]/U8_POXOY1_CU?C_P?SC_;0U\I5?W(>[T_
M5C_"_B_E'^/5^/\ P?SF9=.>DR.G^4EY).6.0\JC^3\HQPSI\=*]5^8N_L;6
MKC;UWU^>MJ&AHT=<]>Q$EW!PPMUW97/>:>E'1IHTY4_G,V34;)J6F5@_">+F
MXWF<KRR.['YH&K1S4%&JUQ>U[VK[6;GN[D9Y]%I^PU\39]]:G;K33BXUZ50T
M?_MH:^4JO[D/=ZF_ZL?X7\7\I5O^/5^/_!_./]M#7RE5_<A[O3]6/\+^+^4?
MX]7X_P#!_./]M#7RE5_<A[O3]6/\+^+^4?X]7X_\'\YF73GI,CI_E)>23ECD
M/*H_D_*,<,Z?'2O5?F+O[&UJXV]=]?GK:AH:-'7/7L1)=P<,+==V5SWFGI1T
M::-.5/YS-DU&R:EIDXCT^ _$CR5PWG4V1):]F@W!N.(H"[H!0&I=]=$&-[;D
MD;A7F?(U2$-(Y'DH>T\I 1[+FIO>U^RI7N[?_P"4LJU[O2I7+I4S^H@&^.$?
M[AB97_?.&DEDT:YE3YR,>_VT-?*57]R'N]=+]6/\+^+^4XG^/5^/_!_./]M#
M7RE5_<A[O3]6/\+^+^4?X]7X_P#!_.5H7HW1XDZ-..X2XJ.ZV]I,( GEJ"K7
MYQMV5\KG%+G%Q]UG5/%_*?>QP%[N<9>_?=:?@YOIF]:@Y:8H#3F\N@<3=^YY
M^Y7,P(KDU3:RSY&ETI+;:&QXY=3?V-^RI=@>(?RUF-KW>EH\NEZ:\Q7F]>#W
MC<3._P"_<-.G=T:TR)?.7-S$/_MH:^4JO[D/=ZW_ -6/\+^+^4Y'^/5^/_!_
M./\ ;0U\I5?W(>[T_5C_  OXOY1_CU?C_P '\Y<XCT<8>*S,#,?#H><@R696
M@P4I*RPXE8&KG&U]/;6O?XG][;E#W5-)->+G6J;F$X'=B["Y^8;T)*5-#/1U
MIXS>50HLX4 H!0"@+*)Y3Y;D.=)0\SS&_)V$6UL)Y2+I7;C=2KK%^X: O: 4
M H!0$9N+#IW!@LAA%/&.F>PN.7@G64!P6OIN+V]6MG"W_<78W*5T74T<?A/S
M6'G9KHZ<6J\U33?^VJ'\HW/[HGW6IE^K)?A+ZW["MO\ 'L/QW]3^8?[:H?RC
M<_NB?=:?JR7X2^M^P?X]A^._J?S#_;5#^4;G]T3[K3]62_"7UOV#_'L/QW]3
M^8S?ISTO9Z>OY!]K)JG^7H;04J9#.CE%1OP6J]]5</>N^'CE%..CHUY:Y_42
MC<'#D=U2G)7-/32Y*4I7TOG-@5P"7D9N+#IW!@LAA%/&.F>PN.7@G64!P6OI
MN+V]6MG"W_<78W*5T74T<?A/S6'G9KHZ<6J\U33?^VJ'\HW/[HGW6IE^K)?A
M+ZW["MO\>P_'?U/YA_MJA_*-S^Z)]UI^K)?A+ZW[!_CV'X[^I_,/]M4/Y1N?
MW1/NM/U9+\)?6_8/\>P_'?U/YC-^G/2]GIZ_D'VLFJ?Y>AM!2ID,Z.45&_!:
MKWU5P]Z[X>.44XZ.C7EKG]1*-P<.1W5*<E<T]-+DI2E?2^<V!7 )>1FXL.G<
M&"R&$4\8Z9["XY>"=90'!:^FXO;U:V<+?]Q=C<I71=31Q^$_-8>=FNCIQ:KS
M5--_[:H?RC<_NB?=:F7ZLE^$OK?L*V_Q[#\=_4_F'^VJ'\HW/[HGW6GZLE^$
MOK?L'^/8?COZG\P_VU0_E&Y_=$^ZT_5DOPE];]@_Q[#\=_4_F,WZ<]+V>GK^
M0?:R:I_EZ&T%*F0SHY14;\%JO?57#WKOAXY13CHZ->6N?U$HW!PY'=4IR5S3
MTTN2E*5]+YS8%< EY%;EPJ=QX'(8-3QCIGLJ8+X3K*-7=TW%_HUM83$>XO1N
M4KHNM#0WA@_S>'G9KHZ:I7/0T[_MJA_*-S^Z)]UJ8_JR7X2^M^PK?_'L/QW]
M3^8?[:H?RC<_NB?=:?JR7X2^M^P?X]A^._J?S#_;5#^4;G]T3[K3]62_"7UO
MV#_'L/QW]3^8S?ISTO9Z>OY!]K)JG^7H;04J9#.CE%1OP6J]]5</>N^'CE%.
M.CHUY:Y_42C<'#D=U2G)7-/32Y*4I7TOG-@5P"7D5N7"IW'@<A@U/&.F>RI@
MOA.LHU=W3<7^C6UA,1[B]&Y2NBZT-#>&#_-X>=FNCIJE<]#3O^VJ'\HW/[HG
MW6IC^K)?A+ZW["M_\>P_'?U/YA_MJA_*-S^Z)]UI^K)?A+ZW[!_CV'X[^I_,
M/]M4/Y1N?W1/NM/U9+\)?6_8/\>P_'?U/YC..G'3!CIZ]D'FLDK(*GI:00ID
M,Z T5'N+5>^JN'O7>[QRBG'1T:\M<_J)3N#AR.ZI3:GIZ=.2E*5]+YS/ZX!+
MB)W-@T;EP&0P3CQCIGM%DOA.LHOQOIN+]G?K;PF(>'O1N)5T76AS]XX-8S#3
MLMZ.FJ5YC3W^VJ'\HW/[HGW6IA^K)?A+ZW["N/\ 'L/QW]3^8?[:H?RC<_NB
M?=:?JR7X2^M^P?X]A^._J?S#_;5#^4;G]T3[K3]62_"7UOV#_'L/QW]3^8SC
MIQTP8Z>O9!YK)*R"IZ6D$*9#.@-%1[BU7OJKA[UWN\<HIQT=&O+7/ZB4[@X<
MCNJ4VIZ>G3DI2E?2^<S^N 2XC<Z88@)\N=<:8\HBV6UP5S/*&^6/4*](5X*
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M<>5>UFTJ(*C?APKZPM3FFXIM+/D/C.];@TI22;S5><\*W%@$2)L5>5AIDXU
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M0^ 6RE7UVJXTV[:^4;%R4]!)Z7,?:>(MPA[QR2CS].8MU;RVFES%,G-0^9G
M%8@!]!\J!L 6B#XP)(2.^2!VU^_RUVDGHONY\F;I/Q^;LUBM-=_PY<_0>4;V
MV@XK)I1FX15A0I65'/0/)TH)2I3ESP 4"DGO\.VCPMU:/=?>S9,YA8RP]+OK
MN>++F)'%9?&9R"WD\1*;F0'2H-R&3J0HH44JL? 017RN6Y6Y:,E1GVM7878Z
M4'5%[7S/J* 4 H"-Q_D_PEEN5%6R]SFO*'UWTOJ\G;LI%^XE-D&W=% 25 *
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M^?DZ3&F=F;I@;K?R0V^B:QC9NXLJ7P_'2,NUFD@1H7MB@4Z;A+G.3H3RDVU
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M.KJ^7F6;(6.4Z.,97:NV]J/S&DHQ$).,G95MEQ$UZ( V%M,E+H2A+N@Z@Z'
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MDM&.71:Y>?.LW)S/*8[C^E&>PK,AO";E3%?AP)&'VO)5#YBX4.;+3*>4[[:
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MHCM<.8\Z\^RVA)4!Q- 8 UUTS*>DB^IIP>/R3C$YIB=C\?D_ZI%D.(2!(YK
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M>UPQO/*;QD2>?(F08F+A1PWH$:+%6Z\L:M1UJ=<=*B;"P2D>$C!D- 8QN':
MSF>P^>9R#T"1C8^0@/\ D_BK>AY-I"5I2X"%-K0XRRZA8O8IM;C< 8W%Z)[<
M_P!(9S:F:R.1S+VYI#,K/9V4^!D92XBFO)]2TI"4AMMAIH:4"X%SQ)-#-3*?
M]&8G_5&2W@7'SGLCCVL.F05I_%8;2UN%,;Q?$UK7S%DWU*2G[$4,&.1NCF#:
M1D#,S.9R,[,OQW,[D),M(?GQ(C#L=N"_R6FT>3!#SET-H2HJ.HJO0S4L8'0W
M"8J/&B0<M.>92_A1,5/+<EQW%[:<4] @(T(:2AM#I2I3A2IQ0N%*-[@*FTZ&
M#&,_L_X:W!C,^QD'L>_#A9#%RO)QI=>AY-#9(0Z"%-.-NLM.(6+VL1;C< 8M
M"Z*PHNW)N$5NG.F?F)#LG<.>;D,HGY+G,B+H?*F5H"4L)0VGE(01IU ZB21F
MI7C]$]K1,]'S4:=DD18V,8V^U@EOM/XP8>.REGR+E/-+7RG-"5NCF76KBH]R
M@J,?T,V!A<ED<CM^*[AD9>1%?RD#'J0Q#DQX<5R*(;C0008RTN%;C7UR[*O0
M5+;&]#<%A68L;&Y7(.,-SL3)EG(.B6ZYC]O%3F.Q[:K(#;#+I2X#I4M5CJ42
MK4 J;2H8,8S^S_AK<&,S[&0>Q[\.%D,7*\G&EUZ'DT-DA#H(4TXVZRTXA8O:
MQ%N-P!BD;HCCVMMS<"]NC.KEYEYY_<F:1(91-R@?9$71(*F5I"4L(0TGE)01
M:]]1)H9J7;/17:\7<#.=BSLDU&8QC. :P7/;=QB<.PREGR-+;K2UAI>A*W '
M+K4+D]E!4HX?H=M7#0G(#.2S#[#_ )-'E>43=1>Q4&,]%CXMPA";PT(D+.CV
M95XREE7&@J4<=T.PN'1"9@9>>ZTQ(PQE*G*;D..X[;2ENXZ"DH0TE#;3JDN%
M92IQ=K*4;W 5-IT,&,9_9_PUN#&9]C(/8]^'"R&+E>3C2Z]#R:&R0AT$*:<;
M=9:<0L7M8BW&X Q2-T1Q[6VYN!>W1G5R\R\\_N3-(D,HFY0/LB+HD%3*TA*6
M$(:3RDH(M>^HDT,U)%/1/IHSF]N[AB8)B+E-LJ2O'O,I2E3A;BB&WY0H@J=+
M;:4:"I5P4I-^%!4NVNE^ CL3HD>5/:A97.2-QY:*E\%F8]-;+3\5]"D$+B+!
M\9D]I XT,$(ST(V7B<H_D-KLIP;&2R>*RF8A1FT!AY&"&N+':0 D--\Y+;R[
M W*>Y?@,U-HT,&,9_9_PUN#&9]C(/8]^'"R&+E>3C2Z]#R:&R0AT$*:<;=9:
M<0L7M8BW&X PH] ,#)P;6*RFXLY+GJRB,[D\QY2TF3D)\=*$1ERDJ96TM+"&
MFPVWH"+H"B"KC0S4FFNCNV4[@C;@?FY&4Y'GL9Q4%]]"HKN:C0Q 1/<"6TKY
MQ9 2I*5AHGCHO05)+'=.L5APZ,3D,E"3(S\G=,Q+,G2)$N;K+K#OB^-&)7JY
M7?2GCPH8(2-T8P4!"$P9L@OR\U"S^XITE+3DG).8L\R,RLMI:;;;0ZEM=FV@
M/%/"ZBJAFILNA@4 H"VR,"+E<?*QDY'-A367(TEOLU-/)*%CUP30&NXG1R*M
MS:"\_G9^4C;09BICXO7R<=(F8OA"F+8!44O-#BK2O2M5B19(%#)/2>FVW)>/
MWIC73(\FWX73G+. *!>AMP5<DZ?$]J;3VWX_0H8*V1V#ALC/PF44_+CS]OP)
MV+QC\=[EJ0SDFF6G%DZ3=Q(804*[AXT!CXZ+[?:S,3<+>0R,G*0A&DH;GR/*
M8DC,0(1@Q\G*:TI+DE+1 4I*T)58**=0"@,U,LV9MB+LO:N)VO$=+[6,CI95
M)4-*GG>*G72D$@%Q94L@=EZ&"ON? 1-U;;RVVIRE(AY>&_!><1;6A,ALME2;
M_7)O<>&@,69Z8B3NO#[NW%GI^7DX=AI4?%.+#>,1E41_)ESVF!<H6IM3@Y>M
M2 5E5M7&ADH3>B^UI3,GR69DL9DI&:F;D:R\&2EN;&G9-DQY(86IM82VXTHH
M*"DVO<64 0%1C^C&W,/N+'[APV3RL XK&LX/'8UF2VJ&SC6$)1R$)<:6M(64
M)<<4'-2U@$GN4!25T4V_\*0LR<IE9,N(J!+?CS)1>BS\KB&>3#R$U 2E3C[8
M2@J*%H2LH05))2*"IENRMKQ]E[6QFV8[ZI28#6EV6X-*WWW%%QYTIN=)<<4I
M>F_"]J&">H!0"@% 8SNC\^;*\\O?Y-DJ =.?F]VGYFQWO5N@,FH!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 6$(.>7Y/7,$A!=;Y<86O&')1
M=!_XCX_KT!?T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4! -[
MVVH\7 WE65*:R?P"XD:KIR=]/DY%O97];PUM/"W5\E^'2^CSFFL99?REXM#Z
M7,4H^_MIRY>4@Q9Y>D85,A63#;$A:6O(U:7DZPV4J4@FQ0@E7@K+P=U*+:R2
MI3*N7,8CCK,I2BI5<*UR/)3/R%7;6]-L[O$@[=F^6IBD!]09>:2E2B1:[J$
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M)4 Z<_-[M/S-CO>K= 9-0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M2D#Q$>Q3P[@[@H#\<BQ75EQUAM;A06RI2$DEL]J;D=G@H"JE*4I"4@!*19(
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * QG='Y\V5YY>_R;)4
M Z<_-[M/S-CO>K= 9-0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 8SNC\^;*
M\\O?Y-DJ =."#T]VD0;CX&QW'_Z5N@,FH!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@,9W01\.;*X]N9>M^ALE0'SNQ_]0B_>D?2H?LN: 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
; * 4 H!0"@% * 4 H"VD_P ?#^^J_!+H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>bc_novelcircul-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_novelcircul-4c.jpg
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M%!04%!04%!04%/_  !$( ;\#M@,!$0 "$0$#$0'_Q #<  $  04! 0$
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M^CX[D<.YR)TF(B<A<!EAQH-...-@$NOM'FU;/#3Q4!T3&K_#RG'K7DMN0XW
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M+B5QY24:Z%73=2DJ2->*DZCU: ^2/32_ZH6G_@<?^]RJD'UMLW_TGPG_ ()
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M86HG0?;5I"$_ZY30'0<KR_'<(L;N29-,$*S,*;0Y)#;CVBGE!"/):2M1U)\
MH"+-;[;4O8N]F*<B:3C[$E4 R'&9#;BY26TNEIMI;8<6KD6E7D(- >.%;][7
M9]<TV6P7K2[N$AB'+:<BN/: G[67$A*CH->4'F]2@.DN.(:0IUU00T@%2UJ(
M"4I U))/8!0');]Z3.S5@F+@O9")TALE+AM[#LII)!T^ZH3TU?ZJC0&#FV9;
M,;L;2W6XW>].HPQJ2U'D7)J/(1(BS@I"F]$%E2B?+3KY"DZ*H#7^CE;]H,;L
M>1N;=WY^^K:++^07&4P]'4AM"72RE+:VF_) #I\GF.NNI[!0$UQW??:C*G)[
M=FR-ISNR(NXSUOLR(C;45I:&U.*7(;;3H%.)&FNO&@-+!])[9:?=A:6\AZ2E
MJZ;<R1&?9B*5KI]U6@!(_G+T'JT!UY*DK2E:%!2% %*@=00>P@T!R[*_2)VD
MP^YKLUTOP>N3*N22S!9=EAE0X$+6VDH!'A2%<P\(H#WN'I ;0VRUVR\R\E:[
MNO =,%UIB2\5&.4AQ*T-M*4VI)6GR7 DT!/;-=[?D%I@WRTO><6NXL-RH;_*
MI'.R\D+0KE6$J&H/81K0&=0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MD\>.BV@/YM2#$]$B\S(6[#5C;<4+??H,N+-9!(2KHM*?0K3LYDE! /@"CXZ
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MU/+J#KQX0#Y2V]N^ WS.)^3[X3I<V*Z%RE--H=<5+F.+'!Q3.BDMI&IY4Z>
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M^D^$_P#!(']W14 @/I/[2W#<G$XMSQYGKY-CRG'H\5/OY,5X#K-([-5@H2M
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M:=-: KZ7NVZ;/%Q7)L=A=/&;;"387&V=5(C-M+4[&U))/*KJ+3S$]H&IU4*
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MO7X@?Y?I4!-8&!X=:\<E8C;;+%B8W-2XB9;F$=-MT/I"'"OET*BI( *B==*
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M%AM=B95SLVN)'A-KTTU3&:2V#IZO+4 V- * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% <^R/8[:?+)CUQO>+1'9\A16_)8ZD1QQ:N)4L
MQUM\RB>TGB: ]<7V6VMPV8W<,>QB)'N#)"F9;O/*>;4/JD+D*<*3ZJ=* GE
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% 0-6R^UR[\<G5C44WY4OO(SM7><RRYUNKISZ:\_E=E 3R@% * 4 H!0
M"@% * 4 H!0"@% ><B/'EQW8DMI#\5]"FGF'4A;:VUC125)5J""#H0: YC</
M1QV4N3YD/XE&;<)YB(SLF*W\AAU"0/4 H"5XGMU@^#)<&)V*):W'1R.OLHU?
M6D?4J=65+(]0JH"3T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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ME* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M:V#5% * 4 H!0$OC?B[7Q$^T*Y<MK.M'8CUJI84 H!0"@% * 4 H!0"@% *
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M5.A[#7OVG=@XJ3C7I6WR'-X_HW[;&29=Z=N]_D.+ZC[EQG*)<5P&JNBELG@
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M-*BAY0[S9[C)E0K?<(TN9!5TYL=AYMUUA>I'*ZE"B4'@>"@*51+31G4(% *
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M5WD=W)WCR3#[O>I]DOL&\1+"^TF9C<6S376VV%*0'$RKLAPL,OZ*44I*=-=
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M%E)(!/'MH#TY4_!'L5 /*2 &P0 #KX*D&)J: ]XO%:M>/#P^O0&ME'_?+?\
MTX^N% 3NH)% * 4 H!0&A@_K7=O[/&_VJD&^J * 4 H!0$2MX\TN]YMRM!]O
M$QH>-$E()(]90-98["C-K5B!0"@(MDVW&#Y@_P">Y!9FGKF!HFY,*7$FC0
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MM<)BW6YA$:#%0EJ/':'*A"$C0 "OE]RY*<G*3JV?:[5J-J"A!4BMB,FJ&04
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MVUEC'8C-K$9Q0"@% 0Q7OCZ]=8X[*4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MAP85O9#$%AN.R/J&TA(^CIVU4DR* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4!$+[^L3'] /;74D&9'^XI^C0'I4 \97W(?&J08E >\3WZ
MOB_Z: ULK\<M_P#3CZX4!.Z@D4 H!0"@% :&#^M=V_L\;_:J0;ZH H!0"@%
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M;&[WNWIQO#\TE<UV6K2UW1T@><%1^XNG@.I\!7U79[[3F\ISKDRMKBV5Z/\
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M6^*KLCL'LX?#5VJ/T*RI4*-FYJQ H!0"@% * \9,9B9'<BRD!QAT<JT*["*
MQ\?G2(,LXY<7"ZI*2Y;)2^UUA/:A1^&CZ8K%)4+IDFJI(H!0"@% * 4 H#\L
MU_=%^N?;K[0CX&]I05)4VJ,;R-:0I%FGJ2H I4(KQ!!["#R5AX]OVEWHV?!W
MW_1+N9KE(4VM2%I*5I)2I*AH01P((/8169.IJM-8,"I*EU"I45(+A0@J*$&3
M$@S9[I8@1G93X!46F&U.KY1P)T0"=.-5E.,563H7MVIW'2*;?46)9>4\(Z6U
M&05=,,A)*RO73EY>W77AI4U5*]!3*ZY:8F8FS7A4]JU)M\DW1[0,P>BYYPLG
MLY6^7F.NG@%4XL,N:JIOK@9/#W<^3*\SZ*.O<8KC;C+BVG4*;=;44.-K!2I*
MDG0@@\00:R)IXHP2BXNCVE!5BI=0J5J2#T9:<?=;9907'G5!#;:1JI2E'0 #
MQDFJMI*K)2;=%BS-N]GNE@N+MIO41R#<F.4O17ARN)ZB0M.H]5)!JEJ["[%2
M@ZIF2_8G9FX3662VKSF%64URHJ074*EPJ2"M""X4(*BA!<*D@]&7G8[S;[#B
MFGVE!;3J"4K2M)U"DD<00>PU#2:H]A*DXNJP:/L'9+>-K-8B,<R%U+>614?:
MW3HE,UI XK3_ /N >_2.WWPX:A/S;G/*'II<2VO\;_[?PW=W;]B_CO/UK(\*
MZ_\ *O\ N6_MWKRKIIV6O,'M!0"@(8KWQ]>NL<=E* 5) J"10"@% * 4 H!0
M"@% * 4 H!0"@% * 4 J2!4$B@% * 4 UU[*D@5!(H!0"@% *$"A(J2!4 4)
M% * 4 H!0"@% * E\;\7:^(GVA7+EM9UH[$>M5+"@% * Y_G/^()_H$_7&N!
M_(/]E/\ T_W(ZG*_]S'R_48=M'^Y-^NKVZ\7I/VEY3T5_P!=F5I6V8#!NP_W
M5/QQX?4-<_7?M^4VM-Z_D-+IZ_LFN(=$V-G'V]WM]X/#ZM=/E_KR[#3U7JKM
M++/_ (FQ_3-_75Z/^+?N7>Q?6SD<[]6'E^PZY7O3S H!0"@% * T,']:[M_9
MXW^U4@WU0!0"@% * B^1+[SND*P@ZQFQY]<!X%(0=&D'U"KB?6J\459L*R%1
M0"@% 5"%DA(2>97$#QB@-1D5[-AL\ZYQX3EWF0F3)%HB+0);S:2.8H2HZGE'
ME<!QTX:FL]FUQ)J+>5/I>PU]1>X4'))R:Z%M^GT1RW+\NSB)BTS</!,EAWW$
M;TA+=JMLN/TKA#E2U".TB&MD'J.(=(U9>2>P@UV=-I[,KJLW8.,X[6GZ+2Q>
M:NQ-=*.!K-5?C9=^S-3A+8J>DF\%EIM:ET-=!URTLW2/:8#%\D)EWMN,TFYR
MD)2VEV4$#JJ"4 ) *M>P5P[CBYMP5(UP75T'HK*FH14W65%5[WTF/?8KKT,2
MHG"X0%"5$5_/;XE/K*&H(K$U4RDCM\UJY08\]C[E(;2XD>+F&NA]4=E83(9-
M * 4 H!0"@% ?EFO[HOUS[=?:$? WM+%>]/K5)"VGV!N/#W<E2L><P7(VK3:
M.XX0>C.W%B&I4GRRI?(YQ.J2D<WJ5X/12TB4^+#,\[_I;P/IW,(:V4H.Q-1C
MD72ECC^!QC']O+?-QP;@Y\_>),:[SI#$&%8(R9DZ4MI2NO)6XY]K2@. CCQ4
M>RO07M;*-S@V5%.*57)T2W*FW8>4TW+HW+7B+[G+.W102<GO==FTW+6Q4%>7
M+QH762IJ[6%5_P 3?5'#+TA03KYM(:7Q2M/AT\'B/ 87S>7"SY5Z,\L\=G6G
MN-A<AB[SMYGZ4,\'2G^F2?3O^S81J/M<7MH7]R53"FXM/E;=JT20NW(>3%6^
M/JM0\HCQ:"MQ\PIJU8IA3;^:E:=QSH\JKH7J*XUV?EKEK^KS&^.R,=S([1CC
M-T>0\BP(R3+9"F0[YBTI():9:;\MQS7@$]IU!\8K6^+-6Y3RKU\D,=O6WT(V
MWR./%A;S-/AY[F%:=22Q;ZC R/;:Q+PRX9IAJKRS'L;K#-WM^11417U-R2$(
M?84WY*D\Q *.)'A\&N6QK[G&5J[E>:M'!UV=#K]9@U7*[? =ZUGCD:S*XJ/'
M8U3#;T>7MR<_VRPW ;7U)>0R)%^N4&+-L-K0RDG1PIZJY*@-$H]^EO0ZZI\-
M5T6OO:F>$$HQ;4G7NI]I;F7*]-I(5=QN<E%QC3OS=6VG9TF9Z/-R>L%RS/)V
M %+L^-RI"4GL)0ZTZ!Q\?3-4YW!7(V[;_JN+ZG]Y;^.3=J=V\OZ+<OK3^PDT
MO&K?:M[KMG*4![&8-J<S^+U#H'BZT5M '70$RB2D:^"M*-^4]%&SLFY<)]6_
M_M.A/2PM\QE?6,(Q=Y=>&'ESXKL,_*&;GD>^.W\IBY/6:Z7JP19?>$1*%.LN
M+9DJ4$I7JG16A2H$::$UCT[C:T-Y.*DHS:H^G&)GU6:]S.PU)PE*VG5=&$]Y
M"+/MQ;[U^F>8Y7.NMPMMDNKT.0S:&6Y%VDO*=)7(<#AY4)XA2CQU\KLTX].[
MKY6^%:MJ,7**?I.D5AL.-:Y7&Z[UZZY2C";7H).;==N."7X[*8Z["=O,>S.[
MY')@S;BYB6/1Q,#3$=M=ZEH5P"&V0HH!U2K56I\'#CPS:O77+$()J.>;IM]!
M=KVFKH>66M5<N2BY<*VJTHL\NI+9Y>S#'#QLF!V+-<U=LN(S)\;'(<1<^YR[
MK'1Y[%9C_=4]%A1ZB@2E*0-"2>SA5[NMN:>QGNJ+FW1*+P==F+V&.QRZUJM4
M[=ER4(K-)R2S*FW!;>A=IGY!MO87,/N67X>N\LMV)QANZP,@B)C.N-R5<B'X
MZF_)(YNU!X@<2>SFQ6.87.-&U=RO/7*X.NSH=?K^BS:OE5KP\KUG.N&UF5R-
M-N"<:8;=J\NZNV7MQ@N&7*P6/+L@G1LZG&),4B+&;=MT%3C@*&I)*DK))'+S
M(/#MTTTUP>/OZB,YVH)VU58OTI=:Z.\V_A>ETERW;O3DKTJ/!++'JET]W:U0
MU7I#?]8,A^+!_N3%;/(_]E#_ %?W,YO\D_\ 87?]/]D3F-=P\V5%2"ZA4N%2
M05H07"A!44(+A4D%10@R(<R5;Y;$Z"\N/,C+2ZP^THI6AQ!U2I)'$$&J3@II
MQDJIE[=R5N2E%T:Q3/LS9S=Z)N#;Q;+JI$?+8B-9#0T2F2A/#K-#Q_#2.P]G
M#L^9<WY3+22S1QMOS=3^P^T\@Y['70R3PNQV_FZU]J.JUYX]8* ABO?'UZZQ
MQV4-20?..V.*9'N#A\[)EYWD=OR?O&XQ8LEN>MV&A,62M#05$<"FE)  YAH"
M?&*UH1<E6KJ;=R2C*E%0D.WF]LRXVG#[=E4(O9-?;E<K#)EQ.1,82K1J5NE)
M*2 XG0Z)';KV"K0N52KM*3M4;IL1*)F\F.6NY9M"NL:3&CX0F#Y[*"4N"2NY
MHU9;80A14I:E:( (&JC5N(E7J**VVE3I/?%MS57K)/T1R''I^+Y"]$-SM\:>
MJ.\B5#2L(4I#D9UU(<02.=I6BAKZ]2IU=&J"4**J=41M&YN7C>FX86NQ2',;
MBPXZ]4F,DM(=>*57!Q:G 2SH"D(3Y>H.J>RJYWGI3 MD62M<?I@7*](&S):3
M?U8_=$[<+E>9)S4I9$'G+G1#O3ZG6Z'/Y/5Z>FM.*MM,-XX+V55=Q,=P=PK9
MMW9X%[N,61.ASI\:VI3!2'70J7S<JPC4%?%.G*G4G7A5Y2RJI2$')T(4-_%J
MD7*RIP:_',+:!)>L ;8+@MZDA0E*>#I:"3[WD"ROFX 'B13B=%'4R<+IJJ&W
M?WMQ]^PXS=,=M\V^W7+VW';%8XB6TREIC_=U.J<6EMI+1X+4I>FO9K4\145.
MDKPG5UPH83^_V.0,9N]^N]LG6V=CD^);<BLLE+?G4-4UQ*&W24+4A;9!YTJ0
MH\P'"HXBI4E6FW3>93F\:U-6^+!Q*[2,FO3DE=GQ]88C27($3EUF/*?<0AAI
M7, D.J"BHZ:5.?JQ(X?6J(D.-Y_%RO&;E?+1;I2KK:7),.?C[O2;FM7&&G5<
M4ZKZ?,21RJY^4A0.M64JJI64*.C.78;OS?&MO9^8YM8I2VXL\0V)3'FS;;ZY
M$XQ0RV@.<P4QP#BE\"0=":Q1NO+5HS2LK-1,Z?>]PX-CS.!ACL)YV9/MLNZM
MR4% :2W"]\@ZD'F/@X5E<J.AA4*JI XOI*6)Z'8KU)QF]QL9O^D>%>#&2XVJ
MXJYN6*AM"BXLJ4@H2L)Y2KLX D8^*MM'0R<!XJJJC>VC>^PO1,I=RFVSL6G8
MBTU*NL"XH0IWS62GF9<;+*EI7SD<O*D^^X597%C7"A5VGA3&I?CV\;5RO=IL
MF0XS=<77D:%N8Y(N:6"U+Z:.H6U=!UPLN\OE=-S0_1X44ZNC5*B5NB;3K0K@
M&\L#<%]1@62?!M+"'DS;Q-#;4-J8R\&A%2OG^V.%)#AY-4@'3774!&YFZ!.T
MX])M<TW+M^*OVFU6Z!)R/)+\IT6BT6PME;J(XU==6XXM+;;:![Y2E?Z=)E.G
M65C!OJ2.685N*Q:\VW<S#)TW&VVNWILJ7+/,U<D1I"V5-=!II"UH*G7.7D+1
MY5Z@ZUBC*CDV9I0K&*1.&]YO-3=X>28M<K#>[=:)&11+=*7%=,V!$'VSI.L.
MN(#J3ISMK(4G4'LUTR<3>C'P]SKC0C5[W6M676G'KOYKDECL,G(;-%M%TA.-
M04W%Z7U-4K#A*EQ$*3RN^2.?@4ZBJ.=4MNTNK;3:P;H2AS>ZPQL1RK*)L"5'
M>Q&XNV>?:E<ADN2D.(;;#6AT4'2XGD/AJ_$5&]Q3A.J6\LNV\Z;?(N+<+%;I
M=8N.M-.Y=,AF-T[:IQD/K:'4>09#C2#S.)8"N7QZ\*.YU; K?7MV'M<MY;<J
M\PK#B-EN&639,!F\RE6P,H:C6Z4 6G%KD.-)*UI/,AH'F4*<3&B52.&Z5;H:
MGT<;I(NN#7>XR'9+W4R"[*:$PKZR&@\.1"DN$E'*.'+X*K9>'E+WU22[#"B^
MDM8GK=;,@E8Q>HV*SGE07KV6$.LLS@I:0P$-+6XYJI'+S-I*>8Z#4ZZ.,MM,
M!P'6E54D^-;MHOTR_6:7C-UM62V2(+DFQR4L&5*AN ]-3)0Z6^92AR<JEC17
MA[=+*=:JF)25NE'54/"W;O2I%VF8S=,3GVO+$0'KI:K0Y(@OJG-,$!3;;C#Z
MT(=U(\API[:*>-*8DNWA6N!&-N][[J[ML<MSVUR5N![S:%-A-L\MTER);C#4
M6%'2X5\Z2E+1ZF@U!5S::FJ0N>C5EYVEFI$D$C>Z/:;=D2\FQN?9<AQVWIO+
MUD><C/.2+>XYT@\R\PZMM0"O)6.8%)X5?B4K5;"BM5I1U3-9/W(MN33L)N1C
MY%98,_($1+%TEH@MW-M<4N!Z2RO52HIU.B>"CVU5SK3;M+*%*['@;RX;ON6*
M_P *W9+BMRL]CN=P3:+??'W8;C:Y+BU-M*6PR^MY#3BD^2XI&G$:Z59W*/%%
M5;JL'4U^T4N5(SC==N1(=>:CWUMN.VXXI:6T&,E7*@*)"1J>P5$-LNTFYZL>
MPTUIW9Q_#;-DE\?.0W>&,T?L4E$]QJ:\Q(=TU$-#>A\V3IHVUQ7Q[*JII)O'
M:6=MR:6&PD$'>^&Z<FAWC&[G9+[CEK<OW=,[H!Z3;FP?MC:FW%H!U'*H%7 G
MM[=+<3;5;"G"V4=4S&A;_6R0Y8I\O&KQ;\/R)UB);<FDM-)BF5*'VM*T!PNH
M;4KR4NJ0$GM'D^53B[,,&2[+QQ55T&Y8W>M;UASN_=VR4,X%,FP9[)+?.^NW
MH#BE-:*(T4#Y/-I4Y\&]Q7ANJ6\B<G>/+).X.*VVRX[*DXY?+*BZB*DQ0\Z)
M(97U0XMT<J(X<Y7$\"3[WF%5XCS*B,G#65MO%,F.,[HJR_(7[?8L=G2,9CRY
M-N=R<N14Q1*A@]0=$N]?DYAR)7T^)/BXU=3J\%@8Y6\JQ>.XZ#5S&* 4 H"7
MQOQ=KXB?:%<N6UG6CL1ZU4L* 4 H#G^<_P"(I_H$_7&N!_(/]E/_ $_W(ZG*
M_P#<Q\OU&';?Q)OUU>W7B])^TO*>BO\ KLRJVS 8-V_%4_''M&N?KOV_*;.F
M]?R&FKB'1-C9_N[OQ![==/E_K2[#4U7JKM/.T?XFQ_3-_75Z/^+?N7>Q?6SD
M<[]6'E^PZY7O3S H!0"@% * T,']:[M_9XW^U4@WU0!0"@% * B5L/G5SO-Q
M)UYY1BMGQ(BI".'KG4UECL*,VM6( !) '$G@!0&OM%\LU_$I5DG,S_,9"X<T
M,*U4S):/*IM:2 4D$>$<?!66Y:G;IF5*JJ[#%;O0N5RNM'1]3.62]Y<<PC</
M-;=EM[7)M([M?L4..DS.BX&2B6PGIZI00L!2DJ4/9KM1Y9<OZ>W*W&C]+,WA
M7'T6>>ES:WIM5=C=GZ/HY4L:8>DL-GE.27#?*Q3<*SK%7^]7YE^N\ZX6&<2D
M"/&><;=CH6HN\Z.52#S(0"-#7<ARJ<;UJXLJ4(I26]XUZ#SDN=0E9O6Y9VYS
MDX/<L,JVUZ-AGGTAHTW/[#EMDQR7.O$>SNV2= 2M*5R5N*0Z@M])#AT2X%'W
MNNAK%\&<;$K<YI1S9D]W1]1L/GL9:B%VW;;ED<6M_2J4KTG2MM=O;Y)ODC.L
MR@(L,9^8;M:,(CN+7$C7!;725/>;42D/E/O4@>23KHDZ"N1K=9!05JT\[IE<
M^EKV4]QW=!H9RN.]=CDJ\T;?0I4IF?1F^F!V6N >D% 8N(*Z46=;>.D"8ZVV
M#\VYHZGZXUBEM+HD55)/*5*BP8SLR:\W&B,(+C\AY0;;;0D:J4I2B  !VDT!
MHHF?8/.@-76+D=M<MKRU-LRO.V4M+6V>502I2@"030&V<NMK9AHN+TZ.W;W-
M.26MU"65<W9HLGE.OKT!ZR9D2&EM<N0W'0ZM+32G5I0%.+]ZE)41JH^ 4!;+
MN$" &S/E,Q0ZKIM%]Q+?.L_4IYB-3Z@H#)H#\LU_=%^N?;K[0CX&]I:1J"!X
MJD@Z5O1EU@S2^V.?C[RWXT&R1+?(4ZTIHB0PMTJ2 KM "AQKD<KTT[$)*:Q<
MV_(Z'<YUK+>HNQE;=4H16[%-DIP?<NTOX!;\$NN6W/!+A99#SL"]VUMV1'?C
MR%J=4U(:84E94%*/+X.SU:TM7H9K4.]&W&ZI)5BZ)IK#!O W]%S&V]*K$KDK
M,H-M256G5UQ2QZ32G/$V#=''<D9R^X9C;;.XV'KK-9=8<Z#RE(DMM-.K4KE+
M:B1KIJ3IIPK9\'Q-+.#MJVY=":V]%6EO-1Z_A:RW<5UW8QIBTU@\)43>XDB=
MQ]NVMP!;64.C:@V%[''#TW.KTY#BIBW0WIS!77/+KIV<:U?!:EZ?,_WL^?N]
M&GZ3=^(:1:K*E_@X;M].Q^DVEMKFP\YB67>B)$W<RC+;AYT,=R5MZV&1#T:F
MQH8Y41GVAX'$);3J->&I/$BKW>5MZ2%N-,T*2QV-]*?4ZF*SSJ,==<NRKDN5
MCAM2V1EVI)&OS[((;N//Q+9NQ>,N\[4A*K+*BRH[/1"N8]9QYSE44D CE3Q(
MK-H[,E<3EIXVZ?U)Q?=1&OK]1!VFHZF=VK]5QDL.MM_8:_>7+K%F5\LDZP/+
M?C0;+$M\A3C:FB)#"W2H *[0 H<:S\KTURQ;DIK%S;\CH:W/-9:U-V$K;JE"
M*W8IL\=OLHLF.XWG<.Y/+;N5\M0M]K;0VI86M:E%84H#1/@[:G6Z>=V[:<5A
M"565Y;J[5FS?C-TE.-(^<WMXW2M5PV;@8BVVLYGR,VFY3%(X*L\)Y;["$N:^
M ]-/+\:M:URZ<=8[G_UXR2_,U1_:;=[FUN7+XVE^[A%NG]$6W''N\YNV]S,/
M.>[9Y*[*=$3';(U;KVL,.%3<AJ.XC1(TU6.=?:G6M=Z"]P+]M+UYMQQZ*K[C
M9AS/3^)TUUO]NVHSP>U1??BS3X=?L?A9)><H8S^7B4UZZ/OHC-V]Z8S-@*<Z
MC?.$*Y>8\RAR.IT'CK8U5FY*U&V[*N+*OZDJ/Z=*-;1ZFS&_.\K[M-S;ID<L
MT:U6SRX-'J]D^(9#N3?\OM>32=O4NK:5:I,>$Y(#XY.60IY$90*2XI(7RD*"
MN8\W&H6GO6]-"U*"O;:UDE3=2N[9]1#U6GNZRY>A=>G55EI%NOM547TM5ZZX
MXD@=WJQJ+N@<ABHDO6>99$V&^7B,TF'-D/\ -SF>VTG3E6"$A/-Q"1P[ *U5
MRF[+2Y'3,IYXQ>*2]FN[:;CYW8CKN*JN,K>24DLK;]NF_8L=B1&LXOT%S'WX
M]LW7O&5&2IL=RRXLMEKI!85H\X\YRJ*= ?)3Q(K=T=F2N)RT\;=/ZDX^9)'-
MU]^#M-1U4[M?Z6I[.MR=/,;K),KVJSBY6K<.^7*?!R2(U&3=L;C12X9C\4@I
M+4@J#;:">!))/+]2#6MI]-J]/&5B$4X.N6;>Q/>MK-W5:W0ZJ<-3.4HSBEF@
MHUS-;I;%Y>CH3(3N]DMIS#<.[Y%8W%/6N8(H8<6A3:CT8S32M4JT(\I)KJ\K
MT\[&FC;GM5?K;.!SK4V]3K)W+;K&66GDC%?6B$5U#BE14@NH5+A4D%:$%PH0
M5%""X5)!44(*T(,RV7.?9KA'NEKD+BW"(L.QY#9T4A8__6A!X$<#5+EN-R+C
M)53,MF].S-3@\LH[&?:NTFZL#<:T]*1R1LGA('>$(< L=G6:!.I03VCZD\#X
M"?EO->5RT<ZK&#V/['U_6?;^1<[AS"W1X7(^LOM75]7=7H]<,]*0Q7OCZ]=8
MX[*5)!\_87B^^V'X[,PZR6VQQ$R)LV4UD,J<\\6DS7U.<PBH8\I: K@"O0GM
MK7BII4P-J<K<G5U,FX[*W[%[!@:\$>CW3(<*G2+A)1<UJCHN+EQ21*65I"^1
M1*M4:ZZ#P\.)VVDJ=!"NIMYMC,"3LMG64IW#=RA^VQ+CEJ[+<+<J(IUV*Q*M
M',0PZE24J4C0)2IP:%6I4$C0"HX;=:])*NQ5*=!)-LMO9=DR,7:[8'9,>D18
MSC35TMMQD37G'G"D*"&W64!#:D\VNJRKLJ\(T>RA2<ZJE6S,O>$9:C=E>66A
MF).QG(+2U8KZA]Y<>3%::>6LNLZ(4%ZI7H$\.-'%YJ] 4EDH]J=2'':O=-W!
M4;(NFUIP=#B6%Y8EY9G*M:7^N&A#+7*'^ 1S]3DT]7C5<DJ9>@OQ(YL^-=QT
M/='"+KD]DQBUX\&AW-?K5<G@^X4:1+>LJ7RD)5JK3305><6TJ&.W-)MO<5A8
M;?&-V,DS!8:[FN=EB6Z(0X>KYQ'<<4KF3IP&B^W6IRO,WU$9ED2ZSGF,;2;A
M8;8<"O=J;M\K,<1CW.!<;,](6B)+AW&4MX=*0&B4.)U2K53>G:/!QQQA))/I
M1EE<C)M/8RV_;/;@9)8<PO%R,!&:YC<;/(<MK+RS#B0+*ZDM-=938*W"G4K5
MR $]E0[;:>]B-V*:70B2[M[5W+*<GL^:6FW6^_+M\1VVS\>NKST1M^.XX'4.
M,OLA7(ZA>OOT%)2?'5YPJZ[2ENY1-;"6[88JG%K ^RK'(&,S)LER1(M]LD.3
M&B2 E*UNN(;*ED#RM$Z5:"HME"ER57MJ<J&SNX4C;C)=M'N[F&6;@J[8O>$O
M.+\X=,XS0B2UT]6QIH@D$\?'IQQ<.65Q,_%CF4C>LX7NID.>6C.,LC6F"W&L
MURM2[= ?==6T[) Y%J<6@!74/@3[P#M435LLFZO<4S14:*NTQVMJ<Q;VQVQQ
M,"+WMBE[MUQN_P!N5TQ&ANO+66E<GE*T6G0$#UZC(\J6XGB+-)[T9>:[.WK-
M;_N!UY#,.SY19[9"MTL**W$3+:^9"2MO0>1SA.NAXBIE;S-]9$+BBEU,]X>(
M[FYCDF)7#<"-:[3;<-=5, MLAR6[<9_1+2'$A;389:3J5<IYE'L]43EDVJ]!
M&:,4\O29^VFUB;=MNG"]P[="N8,^9-<B*TE1R'I2WVSY:1J0%>*D(4C1B=RL
MJQ,?*=L[O8;YBV5[40+<TO&F9D!6-ODPXCT2X*ZBRTMM"@VX'-5^]T5K] G!
MIIQZ!&:::ETD7D[+9UE(W#=RB1;8EQRQ=DN%M7%4Z]%9E6?F(8=2I*%J; Y4
M*7P*M2H)' 53AMUKTEU=BJ4Z"^W;3WMRTY)'."6+'+S+L<^VP+I!N<B6MV5,
M;Z82$.L)Z;*@3S$J4H<.!J<CH\$@[BJL6\3=9!MEE5RVYVTQB.F-WIBUQL<N
M[A3I#0:MC92]TE<GE'73E! UJ7!N*6XK&:4I/>>60[.WNY[LLWV&_'1M_<I%
MOO.1P5$]9RZ65+B8W(G30H62T7/'R\:2MMRKT"-Q*%.DTF0[*7B-E^1W>)BU
MFS.SY)*5<&A<YLBW2H4AY 2ZA?3;=0ZR2.9( "N)!JKMXMTK4LKJHE5JAO&=
MOL\P;,7,BV[M]G>M5[M<"V7.S2Y#T=J ];T%MI;"T-+*V0E2M4<H4:ME<75%
M7.,HTE4DVS>%9%@^+7.T9*Y'?N<J[W">'XA5TG&Y;@6E82H:HU.IY-3IXZM;
MBXK$K=DI.J(-"VCS1C9?&\'=3$&06N^,7.6E#ZBP([=R7+/*LH!)Y%#ARCC5
M,CR)=9DXD<[ET4-SF^V>:W[+\MO>/SFK8+SBC5BMMP#JTO-S&Y9>4"$)U2A:
M"4\Z3J.T"K2@VVUN*0FE%)]#--@&TF2V3.L;RA['+)C=JMUMFV^;#M<A<B4X
M^Z$<K[SJVD=0K*3IJ2I/A4K7A6,&FG2A:=Q.+56S7Q=E,\E;:N[<W-%L1^C=
MU3=L6GJ>><8N!$E]Y34UI*$J;0I#O(2@D\=1V<8X;RT+<6.;-O/9>T%[G8EE
MT"'@]DQ>_P!TM2K7!EQ+D]-<>ZKJ5N)6IQA ;:/(E0'$ZTX;H\$B.(DUBVB;
M91@60W9W;!<1+!_12<Q)NW.X4Z(;BEE1;\GRB%'@.%9)1;IU&.,TLW6<M;V)
MW!<:C-7"V627?H.01KM/S1Z0Z]=KK&1,ZW* IK[1R(Y0I'.4GE  ^JK#PY=6
MW:9^+'KV;#L6W>&WK&LHSZ[70,B)D=U1.MO265J+*6$MGG&@Y3J.SC6>,6FW
MO-><DTEN1SM[9S-UV6Y04IA^<2MPD98S]O5IW8E:5:D\G!SA[SZ=8N&Z>6IF
MXL:^2AL]U<0O#-^S7/W@S^C7[O[A9N;J'SCSHK6][SET".7ZKF[?!4W(NK?4
M5MR5%'IJ:/'<4W)W"V^P+%[BW:HN#16K1<WKVP^ZY,E0XB&WF6$QBVE+;AT2
M%KZBD^$?!J%&4HI=!9RC&3?29MYVOW28.X^,XZ+2]C.>R)=R[TF.NIDQG)K(
M0ZQT4H(45%(2A7. D>5Q][4N$L4MC(4X^BW6J-NG;_/++>=MLDL\:#,E8_9&
M\>OT%^0ML-H<2P''F7 V>?E+:N! UX?0G+)--="*YXM23Z74U<S#\ILN=2=S
M/T?@XU$LR9\V\R;)-D27[^REI?097"2RA 65:*4H\RN;LXU#BT\U*?:64DUE
MK6OF.OX&]D\G#[/+S,-HR>3&0_<F66^DAIU[R^ER\RM"V"$'CQ(K+&M,=I@G
M2KIL)%5BHH!0$OC?B[7Q$^T*Y<MK.M'8CUJI84 H!0'/\Y_Q%/\ 0)^N-<#^
M0?[*?^G^Y'4Y7_N8^7ZC#MOXDWZZO;KQ>D_:7E/17_79E5MF P;M^*I^./:-
M<_7?M^4V=-Z_D--7$.B;&S_=W?B#VZZ?+_6EV&IJO57:>=H_Q-C^F;^NKT?\
M6_<N]B^MG(YWZL/+]AURO>GF#3R;Z_'D.,)M$U]+9T#K2$E"O5!*APH#Q_2.
M1_D=P^]H^SJ2!^D<C_([A][1]G0#](Y'^1W#[VC[.@'Z1R/\CN'WM'V= :Z/
M<IK-YFW)5FG%F2TRVA(;3S M<VNOE>KPH#8_I'(_R.X?>T?9T _2.1_D=P^]
MH^SH!^D<C_([A][1]G0#](Y'^1W#[VC[.@'Z1R/\CN'WM'V= :O&%<]M6X4E
M"W),A:TJ]\%%U6H/JUE6PHS=5((_?<XQ/&+I M&17)%LE7-*EPWI*5(BJ*5<
MO*I_3IH4>.@616U:TMV[%R@LRCMW]QJ7M99LR4;DLN;979W[$<[R3%8N;[CR
MV,-GO8^[%A(1G616IWD,M$Q/-'A)0/(6\4#J*?\ J$D:ZG05U+-]V-.G<2G5
M^A&713;+LZCCW].M1J6K3<&E_DE'IKLC_P!5,<W0J&\M>P>T=K82TG'$374^
M^D3GWGW%'QD<Z4CZ"16O<YOJIOUZ=B1LVN2:.WLA7M;?X&V9VEVO8(*,0M9T
M[.=CG[?C$U@?,=2__LEWFPN6:1?_ %1[B26NRV.QI*+':H=K01H1!CM1]1V\
M2VD&M6Y=G<]>3EVNIN6K%NTJ0BHKJ21G5B,PH!0&)CO"\7T#LZD<_1+7&L<M
MI9&GW5W ?V_L,*1;8*;ED-[N$:RV."XOIM+FRR>0NK'$( 22?&=!PUU%"QR+
MT@?WL1ME;P,OG6);;LN$F4FT,RVBJ.IU!Z:2\XKB'0CB>U&OAH#39= AV#=7
M"H>8X?&R@Q\:E^<V#%[6F3#YO.7NFMB)(7V(3IS$G77LH".FRPKALA<932TQ
M<0R/-8J[9867>L[:XCD@,K97K]S=T.I;'8-#KY52#;9'>[FBP6/:S)E*?R7
MLVLC+4I[0+F65Q3J(4H<>)Y%);7IKIY/,=2:@&?Z1ESQ7+,YEXAD-W8MT?%\
M;F3K=UWBSU,@G<BH[1T[0&T(5_K4!U ;L@^CT=T0X#<!9^*O +KKYIIZWG/T
MJ ^$5_=%^N?;K[0CX&]I05)4WUUPS*K%:8%]O%J?AV>Z!"H$UP#I.AU'51RD
M$^^1Y0U\%:UO56KDW",DY1VHV[NBO6K<;DHM1EL>^N(@X;E%RL$O*8%J??QZ
M I29EP0!TFRV$J4#J=> 4-=!2>JM0N*VY)2>Q"WHKURT[L8MPCM9I16T:)<-
M3H!Q)[ *%2];;C+BFG4*;=02E;:P4J2H=H(/$&B=<43)-.C J2IZ%EY"$.+;
M6EMW7I+4DA*]#H>4GMT/#A4)H.+23>QFVR3%L@Q"X)M62P%VZX+91)0PX4J)
M:=UY5 H*AV@CMX$$'C6#3ZBW?CFMO,JT-C5:2[IIY+L<KI7R&H%;)J%U"I=0
M@J*D%U"I6I(*BH!=4E2M""HJ074*EPJ2"M""X4(*BA!<*D@J*$%:$%U20=L]
M'_;>]WN^Q\S5(?MECMCNK4ADEMR6ZG@II!^;^I=/A'DCCJ4^5Y]S&W:MNS12
ME+S=?;N[^WW'\7Y1=O7EJ*N$(/:MLGN[/:[NSZZKYN?8B&*]\?7KK''92@%
M* 4 H!0"@% >,>7$F!Q41]M]+2RTX6E!82XGM2="="/"* ]J 4 H!0"@% *
M$@: G0G@/5/;0"@% * 4 H!0"@/&3+BPT)<EOML-K4&TJ=4$ K5V)!)'$^ 4
M ?EQ(I:3)?;94^L-,AQ825N*[$IU/$GQ"@/8D)!43H!Q)-  01J.(- >+\N)
M%+29+[;*GUAID.*""MQ78E.I&I/B% >U * 4 H!0%.9/-RZCFTUT\.E "I*>
M*B!J=!KXS0'E,AQ+A%>@SF&Y,*0A34B.\D.-N-K&BDJ2H$$$'0@T"="D.+#@
M1FK? 9;C1(J$M,QF4I;;;;2-$I2E.@2 !H *!XGO0"@%"!0D4 H!0$OC?B[7
MQ$^T*Y<MK.M'8CUJI84 H!0'/\Y_Q%/] GZXUP/Y!_LI_P"G^Y'4Y7_N8^7Z
MC#MOXDWZZO;KQ>D_:7E/17_79E5MF P;M^*I^./:-<_7?M^4V=-Z_D--7$.B
M;&S_ '=WX@]NNGR_UI=AJ:KU5VGG:/\ $V/Z9OZZO1_Q;]R[V+ZV<CG?JP\O
MV'7*]Z>8**6E YEJ"4^,G04!8X^PRIM+KJ&U/*Y&0M025KT)Y4Z]IT!.@H#T
MH!0"@% * 4 H!0"@(A90&'[M /OH\YU0!^ _]M3]=66.PHS;U8@P+RBQOVR3
M'R-N+(M"D*7(B3>DMM:4))]X[PUX<#66UG4DX53ZC%=4'%J=''K.1^BY*A2M
MO[RY%91&<7?I+KD=O7E;0XRR6TIU)/*E/DC7Q5W.?1:OQJZ^@OK9YO\ C<XR
MT\VE3TWAY(G:Z\\>I% * 4 H!0&)B8ZJ[O/UU1(FJ0V?&AA*4:^SK6*6TNC%
MW%V_M6Y&/=Q7-]Z&\P^U.MMQB*Y9$28QKTWFR>&HYB"/$? ="*DD/O>SV49=
M@UVPS-<\>O1N#T1R+/[MC13&1$<YRD(94.H7-!S*4KP<* E,S;YJ7N5:=QC<
M%H=M=L=M(MP;!0X'EJ7U"YS:@CF[.6@(E(V$BNPLAMC%^>8MU]R-C*FXXCH4
M(TAMSJ.MI/..9+FB1KPY=!P- ;7<?9>R;AY)C65NRUVV\X](:<4\TV'/.HS+
MR7TL.:J3H L$I5X.97 ^ #98IME;L=ON5Y'<) O-TRJ?YZZ[)80/-X[8*6(R
M.*M4MI/+S<-?%0&BM>QULM^%7O;]VYN2<9NUY:N[$53*4^;1VYC$M41/E$*0
MKH\O-H-.8G2@/@I?W1?KGVZ^T(^!O:6*]ZKUC4D+:?6>>H&08-=MOG/*E8YB
MMDR6T-CZCS)"VY7#^C('^M7A](^'?C>7]=R<'Y?5\Y]&U\8W-/+3NG^.U"<?
M]-5+S8>4\8*3:<!O^V$=0Y;/@ZKQ=V] %=Z7!1E+"_&4-\@'J&K2]._"^_ZK
MN5?]*P\[*P_QZ6YIU_19S2_ZI>DUY%0XYDV'V2U;1X3F,-#@OE]?G-SW%.%3
M93&=<0CE0>">"1V5Z"QJ9SU=RT_5@HT\J/*W]';CH;5Y+TIRDGY)-'1;5B>&
MX/NQMJVU E2$WNV0)S>DG3I720[P>5S#RFP$G5L:?Z#R;FIO:C2WJM++*2V?
MTI;.WK.Y9TEC2ZVPE%O/"+V_U-[?P([G3>*7S>6;;+9BUTN$L7*X-W>!&F<S
MUPE J*%,GD5T6PH%2^W1'BTK<TCNV]&I2N12RQHZ>JNO'%_:<_7*Q=U^6-N4
MGFGF6;UGCLVT5<>J.ZAM-P=KK';,&.;-XX]BT^VW%J'<\?[U;NJ'HSA2"I+R
M.<MN:G3E5V<?)[*PZ+F$YW^%G5Q2C52RY:/LZ4;',.56X:;C\-VG&5''/FJN
MW&C^E#/WUN&'KPW!V6+/*;G2;%&78'U2M6X<;5DEMU'+]M44#EYN''C6/E$+
MW'NMR5%-YL-KQV;L3)SZYI_"V4HNK@LF/JK#![\,"M_VBM%WWF<Q;S^8SCEN
ML[5WNLR2^J5+$9H!)2VXZ%:<5(2-00D:G3P4L\SG#1<2BS2EE22HJDZKE%N[
MS#A9I**AF;;JZ+=6O4:*V8SMIN7:,C8PFTS<=R+'H3ERA><2S,;N$9@^5U4J
M Z;A\D:(.@*AQ(UK:G?U.DG!W9*<9O*\*96]V]&A;TVCUUNXK$';N6TY+TLV
M9+?78^QT5=K+G\:VNQ/"<)S#)+9<+M+R*.[UK;'D]!E196.H\5Z<P*0I(2VG
M0*UXGA41U&JOWKMNW*,5!K&E=O1^):>ET.FL6;MV,I.XG@G184J_/@C.D[08
MBSO':\2[P>:Q2\P$7> VXM*)*PXE?)%#BAH"I2#H2->7A[[C5(\TO/1RN95G
MB\KW=OT^HO+DNG7,(V<SX<XYUOZ?1KY.[#;B0C<VUP;-<HMO8PR9ADUM+GG,
M>7,7/:D)U2$.,N*0D$ A7,4J4D^II74Y?<E<BY.ZKJZEEIVG#YK:C:DHJR[+
MZ:R<D]FQM=NRJ(/74.&5J2"HJ 75)4K0@J*D%U"I<*D@K0@N%""HH07"I(*B
MA!6A!U+9[:.9N'<?/[@%Q\3AK ER!Y*GUC0]%H^/X:OJ1ZI%<#FW-8Z2&6.-
MQ[.KK9ZGD/(I:^>:>%J.U[^I?:^@^SH,&';(;%OM["(T&,A+4=AH<J$(2-
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MDUCLVTV;**E3RRG/,1R_ ;#;+A GL9OC<-JV6^2PMHVYV.VI *G0H\_-TT<
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MI.@':30&JM;1R&ZHNA'_ ++;E$0M>Q^2.!='\U'8GU:QR99(EU4+"@% * 4
MH!0"@/RS7]T7ZY]NOM"/@;VE!4E2X4(%207"A!=0J5%2"X4(*BA!=0J!4@NH
M5+J$%14@NH5*U)!45 +JDJ5H05%2"ZA4N%205H07"A!44(+A4D$XVQVUNVX]
M[$.+K'M$8I5<[B1JEIL]B4Z\"XK3R4_1/ 5RN9<QAH[=7C)[%O\ P.YR?E%S
MF%W*L(+UI;OQ?0?;^/8_:<6M$:QV2.F-;XJ>5M [2?"I1^J4H\5$]M?*K]^=
M^;G-U;/N.ETMO36U;MJD8_3O-G6 VA0"@(8KWQ]>NL<=E* 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MKUYX]8* 4 H"&*]\?7KK''92@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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ME* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H"7QOQ=KXB?:%<N6UG6CL1ZU4L* 4 H#G^<_XB
MG^@3]<:X'\@_V4_]/]R.IRO_ ',?+]1AVW\2;]=7MUXO2?M+RGHK_KLRJVS
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M%I0<:*TA7*L=BDZ]A&O;0%KD2*\VEIYAMQI*@M*%H2I(6#J% $::@\=: ]J
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M)3B6NIUE,)7Y)=#>FM1Q5MIAO)X+V55=QM[YNW'BY),QC'<>N>3R;4RS(O\
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MO,T+2KB^BI-[WN1D=EML.X?H)=) 7$\]N:1)M[0AI"E ME3LE(<=T3S<C>O
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ME%NG25SQDEFVHV.V.V=RQ[:-[;K*'4*DRDW./)D15:@M7!UXA:=0-"4N:Z>
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M464$?4-?^HX?42FM9LVT2J+&:AQF8C">5EA"6VT^)*!H*PF0]: 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MAX9;QW CY\_)_EIXCJ'AEO'<"/GS\G^6GB.H>&6\=P(^?/R?Y:>(ZAX9;QW
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M:3X?YQXUC;J72)!5210"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H#Y^]*;]2+E\2'_ 'M-:>L_:9ZK^*_^RM]DO[6<#P3]5H7QGOZQ5>>EM/H?
M,?WY>3ZB1U4YY$=Q_P!7F_[2CZU56CM.MRK][R'**S'JR=[7_P"(W#^SCZ\5
MCGM.#S?U(]ITKT7/UDOGQH?]:Y73T'K/L/(?S;]JSVR^J)]M5V#Y<* 4 H!0
M"@-#!_6N[?V>-_M5(-]4 4 H!0"@% * 4!K+ACUGNBNI,BI+_@?1JVZ/]=!!
MH#7G%'&R/,KQ-90.QM:D/)'K<Z=?IU;,R*%/T:N:N"[[(Y?YC323[.AIF9%"
M]&'6Q:@NX.R;BH>"4\2CY".5/TJBK)H;R/&CQ&DL16D,LI]ZVVD)2/H"H)/6
M@% * 4 H!0"@% * 4!\?GTO\M"B/T>MW Z>_?^RKWGRW:]N7F/F[_E=[V(^<
M?Q@99^SUN^6_]E4_+=KVY>8CYLO>Q'SE?XO\L_9ZW?+?^RI\MVO;EYA\V7O8
MCYQ_%_EG[/6[Y;_V5/ENU[<O,1\V7O8CYR[^+W+/V>MWRW_LJ?+5KVY>8CYM
MO>Q'SE?XO,L_9^W?+?\ LJ?+5KVY>8?-M_V(^<#TO,K_ &?MWRW_ +*GRU:]
MN7F(^;;_ +$?.5_B[RO]G[=\M_[*I^6K7MR\P^;K_L1\Y7^+K*_V?M_RW_LJ
M?+5KVY>8CYNO^[CYRO\ %SE?[/V_Y;_V5/EJU[<O,1\WW_=Q\X_BYRO]G[?\
MM_[*GRU:]N7F'S??]W'SE?XM\J_9^W_+?^RI\M6O;EYB/F^_[N/G*_Q;Y5_D
M%O\ EO\ V5/EJU[<O,/G"_[N/G*_Q;95_D%O^6_]E4_+-KVY>8CYPO\ NX^<
MK_%KE7^06_Y;_P!E3Y9M>W+S#YPO^[CYRO\ %IE7^06_Y;WV5/EFU[<O,1\X
MW_=Q\X_BSRG_ ""W_+>^RI\LVO;EYB/G&_[N/G*_Q993_D%O^6]]E3Y9M>W+
MS#YQO^[CYRO\664_Y!;_ );WV53\LV?;EYB/G*_[N/G*_P 6.4_Y#;_EO?94
M^6;/MR\P^<K_ +N/G*_Q893_ )#;_EO?94^6;/MR\Q'SE?\ =Q\Y7^*_*?\
M(;?\M[[*GRQ9]N7F(^<[_NX^<?Q7Y1_D,#Y;WV5/EBS[<O,/G._[N/G*_P 5
MN4?Y# ^6]]E3Y8L^W+S$?.=_W<?.5_BMRC_(8'RWOLJGY8L^W+S#YTO^[CYS
MLFTV[EMW*@NLNH1!R2(.:7;PK5*FB= ZT3Q4GL"O"D]O @GS/-.53T<JKTH/
M8_L9['DG/(<P@T_1N1VQZMZZOJ[CI-<0]** 4 H!0&B-]?!(Z2/9-;OAUO-'
MQ#W%._G_ )I'TZ>'6\>(>X=_/_-(^G3PZWCQ#W#OY_YI'TZ>'6\>(>X=_/\
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M!\!!\!% 68]<9+,A>/W1PN3&$]2'*5P,B..&I_GI[%>S6)JA=,D=5)% * 4
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MFTY9>A;3F>9YKG]AQZ?G>+R[5DV"7)E+EE<0DQ;A"<E:-1^4$*1("75 *;4
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M$:$1V1R,Z_&42H>H:[>AMT@Y>T?+OY?K5?UBMQV6E3RO%_8O(?3E= \4* 4
MH!0"@% * 4 H!0"@(K<$FVY.A\\(MX:#2CX!*CCR=?C(X#UJO%E6;*LA4BV4
M[:X?GDIE_)X;TM]EDQHX1*D,-H225!1;96@*()UU5K6[I]=>TZ_QNGD7VG/U
M7+K&J_=6;RM?4S@WHO7=['\LRC;FZ_:I;O,ZRVK742[:M33R /&I"M?]2O2\
M^MJY:A>CL^R6SZ=9Y+^-W7:O7-//;]L<'].H^HJ\:>]% * 4 H#"NL]-MM[\
MP\5H3HT@<2IQ7!*0/#J30&SQ^W*M5GBPG.+Z4<[Y\;KA*U_^(FL!D-E0"@%
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MX%(5P4-/$=:Y&5/8?1+O+[-WTHX5Z5L/')<PE9$TS%,=,6(TKJ%M*BM2EZ:
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M^39_6=SV1P[!,2;=1;K_ &O(,RDH4J4_!E,R%-QTJ'D-(2HJ".*>=6G$Z:^
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B]/IIZ6G2T')RZ<O+IPTT\%4+%U * 4 H!0"@% * 4!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>bc_publications-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_publications-4c.jpg
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M%!04%!04%!04%/_  !$(!&8%WP,!$0 "$0$#$0'_Q #G  $  @(# 0$
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M%3Z&-H_T&P7Y-MO:P5/H8VC_ $&P7Y-MO:P5/H8VC_0;!?DVV]K!4^AC:/\
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M%3Z&-H_T&P7Y-MO:P5/H8VC_ $&P7Y-MO:P5/H8VC_0;!?DVV]K!4^AC:/\
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M8?$UD!( 8
M
M
M                                             TO<WWEQ'ZQZ=^.+
M4,PP]"_/G<WX7L/B:R D ,
M
M
M                                                          :7
MN;[RXC]8]._'%J&88>A?GSN;\+V'Q-9 2 &
M
M
M
M           -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@) #
M
M
M
M                        &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@
M!@
M
M
M                                     #2]S?>7$?K'IWXXM0S##T+\
M^=S?A>P^)K("0 P
M
M
M                                                  !I>YOO+B/U
MCT[\<6H9AAZ%^?.YOPO8?$UD!( 8
M
M
M
M    TO<WWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
M
M
M
M                 :7N;[RXC]8]._'%J&88>A?GSN;\+V'Q-9 2 &
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MMDBE8J.:YCTJCD5.E%13#+L
M
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MJ(G=,L/T6V_T_<Z4T3@=.WLB27F.LXH;ES5YF]:C:O1J]UJ*JHGF'Y9;(
M      BG>K>.7:>#$I;XEN3N<OXQU;I)NICB\6ZNO,B,<KJ]9T53H,BN.>[4
M.Z.722.QGM,-"_@B64".D1O_ %YUE6OFMH9HPN?IBXGN]-8:ZNI%FN9[&UEF
ME=3F?(^%KG.6E.*JM3\LH0[5.A<_J;"X;/X.VEODPCKAM[:0-621(;E(UZUK
M$XJC5BHZG&BUZ$4S#"I^ TKJ+4^4BPV"QT]YD)7HSJHV+1BJM%61R\&-3NN<
MJ(AD?H]I;$2:?TSAL%++U\N,L;:R?,G0]UO$V-7)7OJT_++U@
M
M
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M0=):S*Z5R-;1)'2M5:KT>"8H+;&&0
M
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M)AD
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MK8!^0           :7N;[RXC]8]._'%J&88>A?GSN;\+V'Q-9 2 &
M  !^96JL7-A-39G#SM5LMA>W%LY%_P#E2N;7T:5/TP]_:+5<&B]Q<%G[Q_)C
MXIU@O7KT-@N6.A>]?,8C^?T /T48]DC&R1N1\;T1S'M6J*B\45%3I13\LN0
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M',]G:8D>SVQ__P#3?_ZC_P#I1 JR9'Z9Z0^:>!^#K3V!A^65<NV/_P#Z;_\
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MLUI<QLF@F8M6OCD:CFN1>\J+4_++N
M
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M,8.34D&-L)-5S0P3);SXE%L5=%:L5$<V;D=&G,_A7B#P+JA^0
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M^66[
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M1TCL)N7JN\BB7#3XBP<J==?Y-CK5C&5XJC'HCWKWD:WZ@J,G4/9\W)QF<O\
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ML1&L8U*-1J<$1$3H1##+D
M
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M'H7Y\[F_"]A\360$@!@
M
M
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M*@*@*@*@*@*@*IL[."?^MYOO^*Q^R$9W_P"SLYTH[O\ M+^98LAJ:
M &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M
M
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M^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M
M
M                              ^*B*BHJ51>"HH'7;VMM9Q]3:0QP0U5
MW5Q-1C:KTK1J(@'3)B\9->QY*6R@DR,2<L5VZ)CIF)WFO5.9/04#+5$5*+T
M=-O:VMG'U5I#'!%57<D348VJ]*T:B)4#&;@\*R^7*,QMJW)JJJMZD$:3JJ]*
M]9R\W^D#/         5=[0'S\9Y!!Z^0G6X^S_:GS(!O[M/V8\Z*SO(^
M      $V=G#W[S?DL7LA&=_^SLYTI[O>TOYEBB&IL        :7N;[RXC]8]
M._'%J&88>A?GSN;\+V'Q-9 2 &
M
M
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MIT(KVHJHGU2'7Q2Z83.R[:MB>5WGX?L   *N]H!/\]L\@@]?(3K<?9_M3YD
MW]VG[,>=%E#OH\4 4 4 4 4 4 4 4 4 FOLX^_>;\EB]D(QO_P!G9SI5W=]I
M?S+%$-38        TO<WWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
M   !\1S75Y51:<%IQ ^@                             .$TT-O#)<7$
MC8H(FK)++(J-8UC4JKG*O!$1.*JH&%BL]@\\R23!Y.TR<<*HV9]G/'<-8KDJ
MB.6-SJ*J=\#T                  !\1S7*J(J*J=-% ^@
M
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MGJRXR>0LM$8J9MPW&Q7,T5N[E6EK;JQCT8M4;UDW"BT6OID,L+4F&0
M%=MZ[.]VPUKA=Y]-L<D%Q,W'ZGLXUHRX:YO!7)T5>QJMJO!'M8[I,L+ 8^_M
M,K86N3L)$FL;V&.YMI6]#XIFH]CD\]%,,LD
M
M                     !JNY?S!U#Y%)]8W]W]HLYW/WCV:_F4T+)5@
M       "].)]ZK'R>+UB%5Y?3GGE;6+T(YH9AYO4   *O=H#Y]L\@@]?(3O<
M?9_M3YE>[_[3]F/.BP[R.@         !-?9Q]^\WY+%[(1C?_L[.=+.[GM+^
M:.E8DAJ<        &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M   5HPJKK3M692[G3K+32MM(RV:O%K5MXVV_LL[WIYIEA9<PRJMOE++N-O1I
M?;*T<KK.Q6-+Y&KQ:^ZI/<.X>HMV-5/1,PPX]IG%7.D-:Z3W)PT:1NC6.%_*
ME&)<8]Z2Q([_ *[%5E.\P0+/XG)VN:Q=EF+%W/99""*ZMW]^.9B/:OU%,,HG
MWIWO;MW+;Z;T[:MR>LKYJ/9"Y'/BMV2+RL5[6*CGO>OI(T7S5[B.R-,M&=KA
MT*9]9[5>9O6IA)VV37JWI1G(C$Y5\Q94=W^(8>===HO6.3U3I3 V,#,+D)KN
M+&ZHQ5Q;\RQW2W:0NY'R>$B*Q?2]+5JG'I%!8776M</M_IN[U+FW+XM;T9#
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M>8@D2\8
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MAK_J,RPL,89
M                                                         -5W
M+^8.H?(Y/K&_N_M%G.YV\NS7\RFA92KP           7IQ/O58^3Q>L0JK+Z
M<\\K<Q>A'-#,/-Z@  !5[?\ ^?;/((/7R$[W'V?[4^97G>#M/V8\Z+#OHX
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M<RLY'Y:[N;]$7@O)5(&KZ*153S#,B9#
M
M                  :IN7\P=0^1R'0W?VBSG<[>79LG54U+)5:
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M=*I'"U&-JO=6B<5,,LT
M
M     !JFY?S!U#Y'(=#=_:+.=SMY=FR=538LE5@           +T8GWJL?)X
MO6(55E].>>5OXO0MYH9AYO4   *O[_\ S[9Y!!Z^0GFX^S_:GS*Z[P]I^S'G
M18=]'           FKLY>_>;\EB]D(OW@]G9SI;W;]I?S1TK$D,3L
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M,;)Y$6G!\B(CG>E3I7N(!F@
M
M          &J[E_,'4/D<GUCH;N[39SN;O/LN3JJ:EE*K           !>C$
M^]5CY/%ZQ"J<OISSRN'#Z%O-#,/-Z@  !5_?_P"?;/((/7R$\W'V?[4^97/>
M'M7V8\Z+3OHV          $U=G+W[S?DL?LA%^\'L[.=+^[7M+^:.E8@AB=@
M       &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M
M
M                                     &J[E_,'4/D<GUCH;N[39SN;
MO/LN3JJ:EE*K           !>C$^]5CY/%ZQ"J<OISSRN'#Z%O-#,/-Z@  !
M5_?_ .?;/((/7R$\W%V?[4^97'>+M7V8\Z+20(V          $U=G+W[S?DL
M7LA%^\'L[.=+^[7M+^:.E8@A:>        &E[F^\N(_6/3OQQ:AF&'H7Y\[F
M_"]A\360$@!@
M
M
M    &J[E_,+4'D<GUCH;N[39SN;O/LN3JRIL66JH           %Y\3[U6/D
M\7K$*HR^G//*XL/H6\T,P\WJ   %8-_OGVSR"#U\A/-Q=G^U/F5OWB[5]F/.
MBP[Z-          !-79S]^LWY+%[(1?O![.SG3#NS[2_FCI6((8GH
M!I>YOO+B/UCT[\<6H9AAZ%^?.YOPO8?$UD!( 8
M
M
M                              !JNY?S"U!Y')]8Z&[NTV<[F[S[+DZJ
MFU"RU4% % % % % % % % % % +SXGWJL?)XO6(51E].>>5R8?0MYH9AYO4
M  *P;_?/IGD$'KY">[B[/]J?,K?O%VK[,>=%IWT9          ":NSG[]9KR
M6/V0B_>#V=G.F'=GVE_-'2L.0M/@       #2]S?>7$?K'IWXXM0S##T+\^=
MS?A>P^)K("0 P
M
M
M     #5=ROF%J#R.3ZQT-W=ILYW,WIV7)U5-BS%4            O/B?>NQ\
MGB]8A4^7TYYY7+A]"WFAF'F]0   K!O]\^F>00>OD)[N+L_VI\RMN\<_[7V8
M\Z+3OHS4!4!4!4!4!4!4!4!4!5-/9S]^LUY+'[(1?O![.SG3#NQ[6_FCI6((
M6GX       !I>YOO+B/UCT[\<6H9AAZ%^?.YOPO8?$UD!( 8
M
M
M                                        !JNY7S"U!Y')]8Z&[NTV
M<[F;T[+DZLJ;EEJF           !>;$^]=CY/%ZQ"J,OISSRN?#Z%O-#,/-Z
M@  !6#?[Y],\@@]?(3W<79_M3YE:=X^U?9CSHM) C(          35V<_?K-
M>2Q>R$6[P>SLYTQ[K^UOYHZ5AR%K         -+W-]Y<1^L>G?CBU#,,/0OS
MYW-^%[#XFL@) #
M
M
M       -5W*^86H/(Y/K'0W=VFSG<S>G9<G5E3BA9BI2@"@"@"@"@"@"@"@"
M@"@%Y<3[UV/D\7K$*GR^G//*Z,/H6\T,P\WJ   %8=_?GTSR"#U\A/=Q=G^U
M/F5IWD[5]F/.BT[Z,          !-/9T]^LUY+'[(1?O![.SG3+NO[6_FCI6
M'(6L         TO<WWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
M
M
M                                           U7<KYA:@\CD.AN[M-
MG.YF].RY.K*G!9BI            7EQ/O78^3Q>L0JC+Z<\\KIP^A;S0S#R>
MH   5AW]^?3/((/7R$^W%V;[4^96?>3M7V8\Z+20(P          $T]G/WZS
M7DL?LA%N\/L[.=,NZ_M;^:.E8<A2P0       #2]S?>7$?K'IWXXM0S##T+\
M^=S?A>P^)K("0 P
M
M
M       #5=ROF%J#R.3ZQT-W=ILYW+WKV3)U94X+-5$           "\N)]Z
M['R>+UB%39?3GGE=>'V=O-#,/-[   !6'?WY],\A@]?(3[<79OM3YE9=Y>U_
M9CSHM) BX          33V=/?K->2Q^R$6[P^SLYTS[K>UOYHZ5AR%+"
M    -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@) #
M
M
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M7Y\[F_"]A\360$@!@
M
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MN7O7LF3JRIR6:J            %Y,3[UV/D\7K$*GR^G//*[</L[>:&8>3V
M  "L._OSZ9Y#!Z^0G^X>S?:GS*P[S=K^S'G1<2!%@          FCLZ>_6:\
MEC]D(MWA]G9SIIW5]KDYHZ5AR$K$        -+W-]Y<1^L>G?CBU#,,/0OSY
MW-^%[#XFL@) #
M
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M'G1:2!%0          FGLZ>_6:\EC]D(KWA]G9SIKW4]KDZL=*PQ"EB@
M   &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M
M
M                                 &J[EN:S0.H7N5$:VRE557O(E3H[
MM[3CZT.5O>::/+/);*G19JGJ@*@*@*@*@*@*@*@*@*@*KQXKWKL?)XO6(5-E
M].>>5X8?9V\T,P\GL   %8M_/GTSR&#U\A/MP]F^U/F5;WG[7]F/.BXD**@
M        !-'9U]^LUY+'[(17O#[.SG3;NI[7)U8Z5AB%+&        -+W-]Y
M<1^L>G?CBU#,,/0OSYW-^%[#XFL@) #
M
M
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M,PP]"_/G<WX7L/B:R D ,
M
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MO)"B@          3/V=??K->2Q^R$5[Q>SLYTX[I^UR=6.E88A*QP
M#2]S?>7$?K'IWXXM0S##T+\^=S?A>P^)K("0 P
M
M
M             4QW&^?FHO+Y_7J67H.SV=6%7[P[3DZTM7-YH          !
M9_L]_,:X^$9O8H2"[][1'5CIE/=P=GGK3T0E<X"1.J:XA@IUST;7H1>D#H@5
M+NX6ZZ88JLA\U?MG >%N3\P]0>1R?6.AN[M-G.Y6]^QY.K*G19ZF:@*@*@*@
M*@*@*@*@*@*E$7@O0&%UK)%ML?CKM%JU+>&.?S6JQ*.]!2I<OIW<\KVP>SMY
MHZ'IPW,$ZJD3T<J=*)TGD]G:  ZIKF""G7/1JKT(O3_H K-OT]K]<QJU45%Q
M]NY%3C5%?*B+_H+ W#V;[4^957>B?]RGU+>F48$A1,          )H[.OOUF
MO)8_9"*=XO9V<_F3GNE[7)U8Z5A2$K(        -+W-]Y<1^L>G?CBU#,,/0
MOSYW-^%[#XFL@) #
M
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M.E88A"R0       #2]S?>7$?K'IWXXM0S##T+\^=S?A>P^)K("0 P
M
M
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MX7L/B:R D ,
M
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MJX;:IQBCH^?S?4M_U@9@%8]_/GRSR&#U\A8&X.S?:GS*G[U=L^S'G1<2)$@
M         FCLZ^_6:\EC]D(IWB]G9S^9.NZ/M<G5CI6%(0LL        TO<W
MWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
M
M
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MPO8?$UD!( 8
M
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M?@\KN:/>6FU<?VKXF>3BGR2V@TG2
M
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M5JL=LW764B/''QN3BWYHLM\669*W732."[XF^G+=L
M
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MMQ=>'Z"E3KV
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MYCU]]UEMLV[,5X:),.*D8
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M,TS/#2(X/'P>1KQO.:  +Q8KWKLO)XO6(5!E].>>7T'@]G;S1T,L\GNP[?\
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M\I=. E0
M                                             !@YK%6^=PV1PEXJ
MI:9*VFLIU;Z;J[B-T;J>;1P%3M'7N\6S.W^5V5EVWR&J+R)U_;Z9U#BT:_%3
MPWZO>C[ER_U:-=(YU'JBJG@KRTYE/TP[383<3:C3VU.N-.8QFHM7Z)DOI-2X
M"WE1))K?+/<YS+=[O!5T+)'QK2M7+S-140%6UX_#ZZWLWPTEN+EM(7^B=&Z'
M@E='[M-;#D+V\EYJ,;$GA(Q'*U:KPY47C5R(AAY.X]IJ_<#4>7P^WNRD.&U/
M<SW&.N=R<];6]LC(.987W5NYT?,YSV5Y)6JYZ-7P45>@RL3MCH+'[8Z#PFA\
M;)U\.*@Y);E6\JS7$CEEFEI5:<\CG.1*K1.%> ?EMH       %-=Q?GUJ'R^
M?UZEG;O[/9U85!O/M63K2U@WW-          "S?9^^8]Q\(S>Q0D#W]VB.K'
M3*R>[?99ZT]$)6(\E !AS_VJX;:IQBCH^?S?4M]'I \+<GYAZ@\CD^L='=O:
M<?6<??78LO5E3LM-1=0%7&57-C>YOID:JIYZ(9CC?C)=2V9CD3;J_.X;2>B=
M!V[,';YR-]DEQ;>/.<MDQR1,=([D;P=*Y7K17>EX]\B.CT^34:G/.W-GSJ33
MTN.:>]P+%WEK<.BT6FMC%&6-FL;7H\%L3,\FU->#DX7@:VL\!IB^T5N+I['L
MM+/*-9D),(YW)$V>!K)&JU:+RHO/1:)1:(M.)NZ&_+GMS:;)=6;?F[7AI/ Y
M&],>GTE^FUV&R+;<GSO5UI%8MK$^+CX:<'%P/5P#](;P7N7L+[3[,+JIT,F0
MBS%E,Y[7/JC*R\R(G2Y*HY%14[QK:B-1NVVRZW)MXZ[.S,=#?TE^DWU??9?B
M]7EIM1?;-?%PS2/)-8EHVDM=0::Q&4PEYA;7-6>7DCDO89YG1-5MO1&M1$:Z
MJ<R<R*IV-7H)SY+;XOFR;(X*1RHWN[?%NEQ7XKL5N6,DUNK=3BX.2>#@K5[.
MO]/Z:9IO3NNM*VK\78YUSH9\2]RO:R1&N5'1U5:(BL<BTX*E%HAJ[OU&:<V3
M!EG:G'_%\?E=#?&DTUNGPZO3VS9;EFDV>]/#')Q37P3QH^.VC-0%0%5XL5[U
MV7D\7K$*@R^G//+Z%T_L[>:.AEGD]W1=PK-%6/A-&O/$O^TGV0.5O,EQ$V1.
M"KP<WO.3I0#M K'OY\^F>0P>OD+#[O\ 9OM3YE/=[I_W8ZD=,HN)&AM0%0%0
M%0%0%0%0%0%0%4T=G7WZS7DL?LA$^\GL[.>>A8'<R?[V3JQTK"D%6F
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MIOVEZ4^$[;V1"R=Y=FR=65.[G[;BZ\/T%*G7L
M
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MOE1W3]VM)@R6Y+=JMLUCA^1+1P4I
M
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M4L-O]JNE?TP6RT;WG2=U?0 S -6W)^8>H/(Y#I;L[5CZSC;[[#EZLJ=EIJ'
M          !>'%>]=CY/%ZQ"G\OIW<\OHK3^RMYHZ&8>3W .N>%L\3HG]#DZ
M>\O<4#KM)G21K'+_ %\2\DB>;W%]$"M>_GSY9Y#!Z^0L3N_V;[4^93??#MT=
M2WIE%U21H74J"I4%2H*E05*@J5!4J"I4%2H*IH[.OOUFO)8_9")=Y/9V<\]"
MP^Y7MLG5CI6%(*M4        TO<WWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D
M,              -&UOM-I3<+(VN1U*MW*ZSB6"WMX9UBA:CG*YSN5$KS.X(
MJUZ$0Z>DWEETULVXZ</B<77[GP:V^+LM9V8I$5I#/T7MUI'0$5U'IBQ6U=>J
MQ;J5\DDTC^KKRIS2.6B)5>"=\\M5KLVIF/636G$]]#NS3Z.)C%;3:X^&O2VH
MT73 ,:\E<UC88OZ^9>5GF)W5]! .Z&)L$38F>E:E/^D#F       !B7C71JV
M\C2KX?3HGVT:]*>AT@93'->U'M6K7)5%\Q0/H
M
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M7#CP69+;]JZ[CCD_XXG.TFNU&759,5^/9LLXKN7A^&O'P<3?SE.Z
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M7)&BHJ]_H3@JG+TFBC59YMM^;9%9K/@M^-V]?O&[0Z:VZ^-K)-(B(\-WQ?\
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M20HK8G7",3K%8BU5&JZM/,(UDV=J=GBKP<R9XHOBR-OTJ16G%7PLL\WJ
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M]6.E88@BV@       #2]S?>7$?K'IWXXM0S##T+\^=S?A>P^)K("0 P
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MN_WNB'3[O=@Q\T_>EI5S_P#=59_!:_X60Z5OZ5/6\\.-=^NQU/\ QERU'_\
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M\"KS<DC55CVHO"J(YJHBTXH1O5Z><&6[',UV93#0:J-5@LRQ%-J/^7OFJW@
M                                                 !Y4EFS(7,LC
M5Y(V49SHE>9R=/U.@#/MK:.UCZN/SU5>E5 [@   !7SM(I_;]/+W4ANJ>BZ*
MOUB8=W_1OYX\Z$]Y/3Q\T^9!Q*41          "3-A_V@0^2W'K4.'OKLT\\
M._N'M4<TK4$"6*   %-]Q/GUJ'RZ?UZEH;O[-9U84OO7M>7K2UDWW+
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MQV12VV*0SSR>X
M  !C7DKF,;%%_7S+RL\SOKZ" =T,38(FQ,]*U*?](',     *^]I#_?]/_>;
MGUT9,.[_ *-_/'G0GO)Z6/FGS(-)4AX          29L/^T"'R6X]:AP]]]F
MGGA(-P]JCFE:@@*Q@   ION)\^M0^73^O4M#=_9L?5A2N]9_V\O6EK1T'+J
MJ J J J J J J J JLSV?_F1<?",WL4) =_]HCJQTRM'NOV2>O/1"5".I:
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MHZ9[&HUSU1*(KE1./#OGZFZ9X)?F+8B9F(XW:?E^@
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MKN)/]_+U8Z5AR!+>        -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@)
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MIN7E[ZH,FYK]B;\5UN2(^CQL8N\6+UD8\UEV&9XMJ.#W? E&[59I&63."/\
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M+YZ&<F.['=-MT4F'YQ9;,MD7V36V>*66>;U
M                          &)=JLSV63%IS^%,J=R-/L@92(C41K4HU$H
MB)WD ^@      K]VC_\ ?M/_ 'FY]=&3'N_Z-_/'G0;O-Z6/FGS(.)4AP
M       27L1^T"'R6X]:AP]]]FGGA(=P=JCFE:<@"R0   ION)\^M0^73^O4
MM+=W9L?5A26]NV9>M+6CH.4          %F=@/F1<?",WL4) -_]HCJQTRM3
MNKV2>O/1:E0CB7  #5MR?F'J#R.3ZQTMU]JQ]:'#W]V#-U94Y+9?/(
M     +QXKWKL?)XO6(4SF].[GE]-:;V5O5CH9AY-@   *P;_ 'S[9Y!!Z^0L
MCN[V7[4^91O?:?\ Z$=2WIE%E22H)4J"I4%2H*E05*@J5!4J"I4%2H*IJ[.?
MOUF_)8O9"(=YO9V<\]"S.X<_W\O5CI6(("N$        TO<WWEQ'ZQZ=^.+4
M,PP]"_/G<WX7L/B:R D , '3<SI;Q*^E7>E8WON7H0!:P+!$B.6LKEYI'=]R
M]('<     $47FJM\+ZXNI,!HNPL\?!*^.%,K=UN)VQJK>9J1OC1J.IPYN'FK
MTG=MT^AMB-O+=,S]&."$8OU>\[YF<>&VVV)_BNX9^&'J;8;G+KOW3Q.6QSL-
MJO!R=5D\:YW,WBJMYV*J(M.9JHY.YPXK4\-X;O\ P^S=;=M67\4MG=6]?Q>U
M9?;L9,<_.M:HS?3,S:DU'H^PTY[J:EL+^2QPMG:2.:V:.%\K9)[B21.6-C$:
MRO'BKJ<.DWYW19&*S+=?LV3%;IGP<7!'+X7+C?\ DG-DP6X]O);=LVQ'AI6L
MW3/%$<'E8\N\.M-+:CQN*W3TS!B;/)2HRQRMC(LL;*JC5YO#D1R(KF\_A-5$
MXTZ#%VZ\.;%-^FOFZ;>.)]T>\_=F^M3@SVX]7CBR+YX+HFL>?W^)(^X>XF'V
MYT_[N91CKB:9Z06-A$J))/,J*O*BK5&M1$JYW<\U51%Y6@T5^KR;-O!'AGD=
MO>>\<>AQ;=_#/%$<LM&M=?[W16;=1Y30ELNGN5)I;&WG5,HRWZ5<D;GKS.1.
M/)U:.\Q#J7:+0S=ZNW+.URS'S:^[PU<2S>.\XM];?@C8XZ1/SZ<U?@I5K_9I
MOK;)ZBW%R=FKEM+V]M[F!7IROZN:6[>WF3C1:+Q-K?UDV8\-L\<1,?!:T>ZV
M2,F;47V\5UT3'OS<F?5$:PX'.HU42*YL+JE>#4EZER>A6I&=/-,MG6CI3351
M7#?'U9Z$=]F+]F#%[BW]U3SO .WW@[5]F$:[J]B^U=YFOZS=:7?:4TBS3_*[
M+VT*>[;X*<&-;*JI*J?;=2M%K]JK4[QMZ6MN[,FWZ,S\WX.+WVCKMF[?.'U?
MI1'SJ>_Q_9\S<,QNCJ#*ZHO='[8X6+-7^*\',96\E6*PMI:JG5U;17.JBM6C
MD6J+1%HJIS\6[\=F*,NHNV(N]&(]*75S[VRY,]V#261?-GI73-+8\1IS='4%
MMJ^WT)N1A8L-FL@Q7XF^LY%ELKI41? 17*JM5:+2KNG@J)5*L^[\<X9S8+MJ
MVWCB>.#3;VRVZB-/JK(LNN]&8FMMST-<[FSX'.V6B]*8I<_K:_9UK;)'I%!;
MP\?Z2>3N<$5:<.'%52J5\=)N^,F.<N2[8QQX?#/,V-X;UG#EMP8;?69;O!Q1
M$<LS[NAX%QNGKK1.1L&[I:?M+/3V2E2V9F\5,Z6*WE=Q1)6O5R]"*J]'!%5O
M-2AM6[NP:BV?P]\S=;P[-T<?,T;M[:K27V_B\=MMETTVK9X(GQ^[FJ]S<G='
MZ/<UIBVN(8'87-23I?WLKWHZ"*WZI5<Q&(O,JI)P3NJ:V@W?^)LR3%=JVE(Y
M:U;F]-[?@LF*)B-F^M9Y(BGQN6WFM=<ZQR=S>9?3'N'H^6WZ[$7,[JW4KE>W
MDYVJ[@CF*KO2(G>53&MTF#!;$6W[=]?G<GNKXV=VZ[5:F^;K\7J\4Q6V9XY]
MT>)(QR$@0%MY_P#<;K_R-WLEJ2K7?IN'G_J0;=OZQJ.KY[61VG<A@Y](6FGE
M6.ZU5=7T'N391T?<HY:M<Y&IQ1'(O)YJJG>X?C<%E]N:<G%9$36? ]^]%^._
M!;BX\EUT;,>'W>!MV<UM#M?HS#S9^.7):GNX;>SM\= J+<75XV-J.:BHB\$<
MO%R(O2E$551#FZ?1SJ\UVQ\VVLS,^"(=?6;PMT&"S;B;KYB+8MCCNN:_D]P=
MYM-8_P"4VH=&V#M.Q(DM];65TY]];0=+GO\ "<U>5.GE;P[M$XIO8]%HLMWJ
M[,L[7@K'!,N7EWEO'!9ZW+AMV(XXB[YT0R]=[R/T_IS36L\#:19+2.<E2&\N
M9'/9/ CN-$:RJ<R(V5JHJ\'MH>.EW7ZW)?AOG9R6QP<D^[@]YLZW?7J<6/46
M6[>*^>&?#'NX??A*,#;"*V9=Q*SJ$C21+CA18^7FYN;O4XU.)LS6GA23:BFU
M7@1#AMX\QJ'1.L]9^XMLF"PKG0XN.5[U6[1%\-)45*(B,>RM.ZJH2'+NNS%G
MQ8MJ=J[C\7-[Z(X-]Y,VFS9]B-BS@M^MS^]1M^E=?6$^V-GK[.10XG'MMI)Y
MX(*K%$R*1T3&1I1%57<K4:WOK1#GZC1W1JIPV5NFKK:3>-LZ*-1DB++:5X/!
M2:<#5++</=_5-@NH](:.LV:<D17V,>3N59>W43>A[&M<QK>;N<W#O*J<3?OT
M6CPW>KRY)VO#LQP0Y>/>6\-19ZW#AMV/!M3\ZZ&=9[PSYK;S.ZIPV+2+4^FJ
MIF<#>.<BPNB=_2^$U$=3D:]6U:G%JHO0>5VZXQZBS'?=\S)Z-T>'D\SVLWU.
M729,UEO]S%Z5D^#E^"OD;GH'53-;:/Q6IVQMA??Q*Z:%BJYK)HWNCD:BKQHC
MFKTG.UFF_#YKL?([&[M9&JT]F7BVH^'BEI6VF\\>X&K<YIU;..VMK-LD^(N6
MO<KKFVBG6)7JBI2JHK%\'S>\=+7[J_#8;;ZUF?2\4TJX^Z]^1K-1?BI2+>&V
M>6(FGQ,_7>O+C!:TTMHO$XR"_P AJ*1?&Y)E5KK>V1[6]8WEXK1J2N_[!KZ7
M0VY<&3+=-(LXO'/NIY6WK=YW8=3BP66[4Y./Q1R]/D8N=W0SDVIY]";=X5N=
MU!CFHN6O[J3J;"UJB41[DHKGK7BE4X\$KQIZ:?=]D88S:B[8MGBB/2EXZK>N
M2<\X-+9ZR^WTIF:6V_+[N6G7AMT=38G5ECH[<_"08B[R_@X?*V,JRV4\M43J
M_"5RHJJJ-]-6JI5**BGIEW?BOPSET]TW1;Z43QP\L&]L^//;@U=D63?Z-UL_
M-F>1G[E;K)HR_L-,8'&OSNM,K1;/&1JK6L8Y5:CY%1%7BJ+1$[B*JJU.GRT&
M[O7VSDONV,=O'+WWIO?\+?;BQV^LRW\5OQ^[R-,UCKG<_%:1S4&XNE;>VPV4
ML+JR;D\1-UZ6L]S"Z.))V+))X*O<C5<BHGGKP.AI=)I;\ULX,DS=;=$TNX*Q
M$\-'(UNOUN/3WQJ<41;?;=&U9-=F9BD5BL^'PMD[-_[)\7]_O/\ $/-3?O:[
MN:.AT.['8+>>[IEZ>^UPEMM-J62M.:&&)/\ \6XB9_K/#<]M=79SST2V>\%V
MSH,G-'PW0BS;EZZ"W+TS;R*L>+UWIO'R/5>#$OVV[5_E*YBI_P#B'<UT?B=-
M?/APY+OY:^[R(SNR?P>MQ1_#J,5G\U/D_P#TDC?S4TNG]O;NRLE5<MGWMQ%E
M&SB]?&*];1$X_P!6CF^>Y#C[FT\9=1$SZ-GSI][B^%(>\6JG#I)MM]+)\R/?
MX_@:%MOA6:.WUETS'1&V^F;>W>Y$HCY6QVSY'^;S/1RG4UV7U^@]9RY)G[SA
M[LP?A=Z3BCP8HCWZ6U^&J2]4ZCW2CSL^'T7I2VN+&WCC>N:R=RD=O(Z1J.Y6
M1M5KEY5JU>/U.%>-I\&EG'%V7),3/\-L<*1:O5:Z,LV8,43$?Q73P3S0\G26
MZFH'ZS;M]N)A(\+J*YB6?&W%K(LEK<M1'.HVJNI5&.HO.O%%:M%/?4[NQ^I]
M?@NV[8XZ\<-71[WRSJ?PVILBR^8K;,<4^[G\7&XZXWG70^O8=+7N.\:L)\>V
M[@=;<\EY-=2NDCB@CC1%15>]B)Z)G2;J_$:?UD74F+J</%$>&6-?OS\)JHPW
M6UB;:Q3TIGAB+8CQR\//;L[N:1ABU#JC0UO;Z4>]B3)!<];=0-D<B-ZQ[7.1
M%6J)X4:)7A5%4V<.[='GG8QY9F_FX)]W.T]1OC>&FB,F7!$8_%-9CG_X2!J;
M<&#';:W&X> C9?VZ6T-W:13*L:.;-(QBH_EJJ*WF6J=]*'*T^BF[4Q@OX)K,
M2[NJWE%FBG4X_G12)BOCF'JZ%U%/JW2.(U)<P,MI\E D[X(U5S&JKE2B*O'N
M'AK,$8<UV.)KLRV=WZF=3I[,LQ2;HJUC';E7][N_E=MGV,++''VJ73+Y'N65
MRK%!)16]'3*J>@;M^@MMT=N>LUNFE/?GXG-Q;TOOWA?I=F*6Q6OAXHGSO)S&
MZ>K\QJW)Z/VPP-OE+C!KR9?)Y"58[9DM:=6U&N8M4<CF^FJJHM$HE38Q;NPV
M8;<NHOFV+_1B.-JYM[ZC+J+L&DQQ?./TKKIX*\G@;GHO-ZMOL5>7.O<1!@+V
MRF>S^CG;+!)"QB/69%JY&MXJG%R]!S=5BPVWQ&&Z;XF.3AYG8T.?47X[IU%D
M8YMGEX)CEYD>MWCUGK/)7EKM+I=F4Q5B_JI<WDI%@MWO3U#5=%YZ)SJZBHJM
M:=?\KPX+8G4Y-FZ?X;>&?.X/YWJ=5?,:/%MVV_Q7<$>;IKXH;#9:RW'Q^E-4
M9K6FG+3&W^"M5NK%()^L@N^2-\CT\%TBM1O*U/3=WS#3OTNFNRX[,5\W1?-)
MX.&&_9KM99@RY,^.+9QQ6*3P7<$SXVL8O>O6>KH,7%H73$>5O5CBEU!<J]Z6
M=HZ5Z_T+7.6/F>C$YE\+SD4WLFZL.";IS9-F/X>6?'X>"KFXM^ZG4Q;&GQ1?
M-(VY_AMKX/!PT;-C=P9KO>?+Z 7%VT<=E9MF]U6U\9D3JH)48[AT(LJ]WN&E
MDT46Z*W-M3PSQ>#CGXG1Q;RF[>-^FV8^;;7:\/%$^=XF3WSNL3K34.CGX7Q_
M(6+HK?!6=FY[KF^N)D:Y&N\%6L:UJJY[NY3NFSCW1%^"S+M4B?2F>*V&GEW_
M '8]3DP;&U=;2+(CCNF>CQL+,[K[MZ)2+,ZXT7:LTN][63RX^?K9H.=:)SN2
M21M:KPJUK57AS<3TQ;MTFH^;ARSM^../X(>.??&\-)2_488]7]6>&/AGS<[N
MWIU5G,SMP^^TIC(<IHK,8])[_+NF;');-61BMI$YR.5:\%2BT7@I^=U:>S'J
M:9+IMR6W<%M./WW[W[J\N71[6&V+\5]M9NKQ</(Z]D\[N4_":8Q<VE[>/17B
MZL3-I=1K*L36O5K^IZQ75<]$2G*9WMATVWDNC)/K*^C3SOSN+4:WU6*R<4>J
MIZ6U%:</@KRLQ=UM>:NS>4L-K-.VE_B,-,MM<Y;)S+''+*U514B:U\?33P>*
M\.*TJB'X_+M/@LMNU%\Q==%:6QTO7\WU6IRW6Z3'%UMDTFZZ>.?%PQ[N1)&C
MLEJ3*X2.ZU9B6X7-)))'+91RI.WEC=RH]')5*.Z42J^><;58\5E],=VU;R\2
M0Z++FR8JYK-BZL\%:O?-5O
M          <)96PQNE?Z5J54#ILXG-:Z>7^OF7F?YB=QOH(!D@       5^[
M1_\ OVG_ +S<^NC)CW?]&_GCSH+WF]+'S3YD'$J0T          ),V(_:!#Y
M+<>M0X>^^S3SPD/=_M<<TK3$ 66   %.-P_GSJ'RZ?UZEI;N[-CZL*0WOVS+
MUI:R=!R@          LSL!\R+CX1F]BA(!O_ +1'5CIE:O=7LD]>>BU*A'$O
M  &J[E?,/4'D<AT]U]JQ]:'"W]^GYNI*G1;#YW           !>/$^]=CY/%
MZQ"F<WIW<\OIW3>RMZL=#,/)L   !5_?[Y]L\@@]?(63W<[+]J?,HKOO^H1U
M+>FY%I)D#          ":^SDU5S.<<G0VVB1?,YI%I]92'=YY_MV<\]"S^X-
ML^NRS]6.E8<@*X@       #2]S?>7$?K'IWXXM0S##T+\^=S?A>P^)K("0 P
M 8;/[5=++TP6ZJV/O*_NKZ &8     &/?WUMC+&YR5Z_JK.SBDN+B1>*-BB:
MKW+Z"(?NRR;[HMCCG@>>3);CMFZ[BMBL^\A?3^K=W-UXI\SI&6PTGI)LKX+.
MYNXO'+V=6+17<KD<SAW>"(B\*NZ21YM-H]',69:Y+_#3@B$0TVLWAO&)OPS;
MAQUI$S&U=/F]WA>'M%9YC&[[:TL<]DDRN5CQZ+=W[8FV[9GJ^U<CNK;P;1'4
MX&SO.^R_08ILMV;=K@CCIZ33W-9DLWIFMR7;=VSPS2E?1\#-V;CC7>;="56(
MLK;J5K7T\)&NNY%5$7O*K4KYQY[TG_2P<WFAZ[DB/S'53XY^]+)[5C&_('%S
M(E)F9>)&2?;-YK>XK3ZB'GW=[1='U?/#U[W<&ELGP[<=%SR]U6LNMT=J+?(H
MU,+(Z)[85_J^O?-#5%1>E%Y8V\3UW9$VZ743;Q_)/RO/?,Q?K-)%_%7SQ\BQ
M1$TY5][.;8F:LW,9;HUL#<C$D364Y48D]Y1$IW*=!+-^5]3@K]'S6H)W9B(S
MZFG%M1TWIJU:C7:6S:.Z/$+KS_ZEY&M/%<MO6CI3/4W;.&^?JST*V;*[8Y#5
MFB&Y&RUIE\):NNIX)L=8RNCA56<J<U&O1*N3IX$QWKO"W#GV9Q6WS2.&>-7N
MY=T7ZC31?&:^R)F>"V>#I3CHS:[3.W=M>76 ADN\]<QOZ[*7KTENI57PN7F1
M&HUJN1%5&HE>[6A&]5O#+JIB+YI;'@CB3#0[IPZ*V9QQ,WS'I3PS*$-B;;=.
M]TUD[O1>1PMO%+DI5R"92.9]XZXZJ-55RQL7P*+X->[S$EWQ=I;<ML9;;Y^;
MP;-*4X4,[OVZZ[#==@NLCYTUVHG:K2/@^5N><VSW@U;F].934N7P5-/WK+RW
M?9,N(Y43K(WO1*Q<?ZM*)5.)SL.OT>&R^W';?\^*<-/'X_&[&HW5O#4Y<=^6
M_'_;NK%-JO''B\35\''KZ_WNU_)I&[QEKFHW=7*[+,DD5;)KV,8D75M<J)1L
M?-Z!NYIT]NAP^MBZ;?J\OC^%S=/&KOWGJ)PS9%WUZ^CXJ>]\#:=8;?[X:XP4
MVG\[E]..L)GQR+U,=RR1'Q.YFJURQ+3O+YAHZ76Z'3Y(OLMOK[WQNEK=W;SU
M>*<>2_%2?%=X/>:]O?B'V]UM#@<NYEW)%(VQOW-KR2N:ZQBD5.;C1W'I-O=.
M6L:B^W@\,?\ ZHT-_89B[28[^'^&?'Z$2GK5EEJ:_P ,^VTCDXL3F5>Q67D\
M+;AB1HM7-Y'(Y.*>81;37XK;ZY;=JWDK1-]9CS7XZ8;HLNY9BK3\+IS>FVR]
ME<9O6=A>XB*5KKVTCL(XWRPIZ9J.1C5153NU.CESZ*;)BS%,7>"=IRL&FWE;
MDMG)FMNMKPQLQPQY$466AL)K[?S7&+SKKAMM;Q+<QK:RK"_G1;=G%41:I1R\
M#NWZR_3;OQ764K/!P^^B^/=^+6;USV9*TB*\$T^BY:BTK9;!ZUP>L<*JY#2V
M0N4Q^4;D&QSSVSW>&KHI58BM7D1SFJG'P5:JJ>>#4SO/#?BOX+[8K%.")YX;
M&HTENY<]F?'\['?.S=M<,QXXGFKY'K;OKJ"ZWPT19X.:TANVV:RXJ7(HY]HV
MZ<^?F5R-15K1C.6B>FY3SW9ZNW0Y9OB:5X:<=.!^]]>NNWG@MQS$3L_-VO1K
M\[XH]^C;+_!=H"_L;JQO,QIAUI=0R03M6&YHL<C5:Y%K'3H4T+,V[[;HNBW)
M6/''QNK?I][7VS;=?BI,4XKO#[S!Q6T66AV2R>W^7N(;W(*MQ=8I]NKEC:])
M$N(6ISHU4YI&KS4[CE,W;RLNUUNHMB8C@B:^2?@Z"W<]]N[;M+=,77<-*<M=
MJ/A:M#N7,O9M5$<Y<\CODFUJ(O.LCDHE.[7Q;_O(=&=!'YE]7VGN^TXMN])_
M)OK^R]WV/A;EGM*,T5V=\AIWE1+FWQ:OO53CS74STDF6O=1'N5$\Q$.?AU/X
MC>,7^";N#F\#KZC1_A=T78O#%G#SSPS\*-=7S7479=THRWKU,UY&RZI]S22Z
M>E?,YVM.QI8B=Z9*\G!_^4=UMUT;DQ4XINX?+=YZ)-QN,W];CK-N/S&EVV"0
M1):M9!<HU(48G(B4CI3EI2AQLF3=^U.U;DK7AX8^-(\6+>NQ&S?BI2*<%W%Y
M'+;W:_56%U)JK-ZRN\==P:I@6.\ML<DK6.D>Y>95;(QJ(BM<[NKQ4QK=X8LF
M+'9BBZ/5SP5HSNW=.?%FRY,\VS&6.&+:^>$>Z1U/=Z!VJW'TQ</7W5TS>RV-
MF[H6N25;>-S?.<Q\J'6U.GC4ZO#DCBR16?L\/Q0X.BU=VCT.IQ3Z6*Z;8^UP
M1YY9]WIR7:F]VDU#R=4V)J83/K2B(_(\TKN;O\KI9EX^I0\K<\:RW46?:M^S
MP>:/*][]+.[KM)EY/F7_ &N'SW>1LFD(5U?OWJS5,J<]CI6!F%L%7[6X<BLD
MIYRI/7_K&GJ9]1H,>/PY)VIYO=3R.AHK?Q.]<N:>+%&Q'/X?_+RH_P!G(=SK
MOY4Y+2.0Q%I-)DWKFFY..66Y65U7(ZK$])57=*]-3I;VG2V>KC+%T_-^;L\5
M'*W#^,R1E]5=9;.W.UM1,S7XOE;IJK;3>;6[\2N?S& Y,5=,O;:6U9<QR-<B
MI6CEB6J42M.'&AHZ;7Z+3[6Q;?\ .BG#3XW0UFZMXZJ;/67X_F36*;5>ATZ2
MZNZ[3NK9,G_OEM84QS7_ &J(RU8BLKW5C<O1W%4_6IX-UX]GBF[A_P#UYWXT
M=+M]Y9OXXM^;_P#GS)6W-9"_;K5;9T:L?N3>K1_1S-@>K5\]%1*>:<+03/XG
M'3Z5O2D^]8B='EK]"[H:CV;_ -D^+^_WG^(>=#?O:[N:.ARN['8+>>[IEU]I
M.?J=J;^.O^\7-I']29)/_8,[AMKJX\43T/SWHNIH+HY9MZ:M9WDP%S;[8:.U
M=C$Y<KHY,?,R1$XMB?'$Q5X=Z1L2^=4W=UYHG59,5WHY=KS^:KG;[TUUNBPY
MK/2P[,^]P>>C(NKV+=3>/24=LG/I[3>+BU#.U5JGC-XUDL35[E458%]!Q^+;
M)T>CR5]*^[8]Z."?.]+\D;PWCBB/0Q61D]^[AC_Q^%SN?[+VI;/N>.X=?1Y8
M9/:C%O#NJ?%=YX^-F[YN_(^M9YI^)Z5[N)KC6FL<KHW;"&SM;3!/ZK+ZAR*.
ME:V5'*Q611MJGIFN:VJ+S<JKP0\;-#@T^&W+J)F9O]&V/.V,F\M3JM1?@TD6
MQ&/TK[N7Q1[N)HNH<3K+$;T[?.UAJ"/.WL\R+!)#:QVC88TD5',1&(G,BJO2
MO$Z>#+AOT6;U5FQ$1RUJXNIPZC'O+3^OR>LF9\%NS3AXGN:OCCD[46D&R-1[
M4QZ.1')5.9C+US5\]%1%0UM---UY.M_2W=;$3OO#7Z/]:4-W&,DVRU4V1J.:
MF-G<B+Q\)K>9%]!4J<3=LTU6/K0DF^8B=%EZLHCL'/?V2Y:JKE2WF1.[P3*.
M^LAW[_U?WX^XBN/AW!/-/_\ D2ILPJ+M;I=46J>)HG#OH]R*</>O:LG.DVX^
MPXNJCK *B]JC4M%K_P"F,Z/)K,Z^;]*LZWGN<#3_ *[DZG_C8]#4&W6X.C=6
MY;7>U-S;W+,RY;C+:?O*(DLJN5[E8JJU%JY7.3PV.;S*B*J*>6#7:?/AMPZF
M)C9]&Z/=\;WU.[-7I=1?J-',3M\-UD^'W<\2P,QNI+K_ &:UJK+)^*U/B8F6
MF8QZJJ\C)I4C>YJJB+RJU)&JUR5;147OKZXMW1IM;BX=JR[AMGWO^'CGWO.L
MW=F^;L9+(I='/-)^"K?=CH+"#:O3?N<C>JDMW23.;]M<.E?UJJO=5'U3T*'*
MWO-TZN_:Y?@\#M[@MLC0X]GD^&O#\+U=TOV;ZL^";SV%QX;O[3CZT=+:WMV/
M+U+NAJ?9NMH(-J,9+$Q&27-Q>2SN3I>])WQHJ_\ 98U/0-_?MTSJ[J^"(Z'+
M[L6Q&@MF/#-U?+3S-9P/_P!U&I?@QG^&LS=S?I5G6\]SFZ?]=R=3_P ;'3HR
M"WE[3VL9)F-=+!8ODMU=TM>K;1BJWS>5SD\Y3]:J9C=>.GAG^I^=#;$[[S3/
M@MX/_P )CU]#8SZ'U)%DD:MBN,NUFY^A$;"YU?/14JGFD=T4W1GLV>/:CI2W
M>-MLZ7)%W%L7="!-+.N7=E;-I/7JFK<I:UZ.J\98JT\SG5Y*=13\UMIXNA!]
M)-WY%?7QT_FCSU3'LS^RW2_D3?7.(]O7M63G2W<?8<751U=Z#W,VHRV5SVV#
MX,SIF_E=>76G+AJK,Q:U5(TJU7<J*J-5CT<J416NH=>W6:7666V:BMM\<$71
M[O=RPX%^[];N[)?DTE+\=TUFR>/WODFOBE)FV6XEAN5IQ,U:P.L[N"1;;(63
MUYEBG:U'>"ZB<S51R*BT\SI0XV\-#=I,FQ,UB>&)\21;JWE9KL/K(BDQ-)CD
MEN9SG7                                    /BN:E*JB5Z*@?0
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MMJJ>JJ"4CA@      !7[M'?[]I_[S<^NC)CW>]&_GCSH)WG]+'S3YD'DK0P
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ME>*JJKPZ$TMY:[\5DVHBEL12(='<^[/P.&;9G:NNFMT^-OIRW;
M                          -9O72.NI>MKS(Y41%[B=R@9>I92WZVS*1M
M>WCRN>Y454J&&1UE_P#<8_Y:_8 =9?\ W&/^6OV '67_ -QC_EK]@!UE_P#<
M8_Y:_8 =9?\ W&/^6OV *^[C[R[ 0Y?4&G=P)+&3*XI5MLCC[K'/N7S*L;5I
M&[JG(]514;Z;@J=R@913M+LIK/<?83,:8L;^?1FF\UJF3,8VSR$,EP^;#QQ-
M2.)\:R,HQ96L?7[98^;BBHH*L3=#1&[6,W?VEP.9U]97.8G==0::R%MAK>U@
MQB1MC;R^+1T9(UR<K6HOI:!E,6I]T=A=/Y;(Z8W3O,==:CQ,45OFH[K%NN5N
MI'6['IR<L,C7(Y')X*.\'H6E PPNQI@<KC=.:PS3;"YQ&B<_FI+W2.*O.9)6
M62<R))1U>#F+%'S?;=77HHH)68#       "O_:._W[3_ -ZN?71DR[O>C?SQ
MYT"[T>GCYI\R#N)*T+.(#B X@.(#B X@.(#B X@29L3\_P"'R6X]:APM]]FG
MGA(^[O:XYI6E*_6<   %.-Q/GSJ'RZ?UZEI[N[-CZL*,WO/^YEZTM9.@Y-0%
M0%0%0%0%0%0%0%0%5F=@/F1<?",WL4)7_>#M,=6.F5L=T^QSUYZ+4J$<3$
M:KN5\PM0>1R?6.GNOM6/K0X/>#]/S=25-RVGSB           "\V)]Z['R>+
MUB%+YO3NYY?4FF]E9U8Z&8>38   "KO: ^?C/((/7R%E]V^R_:GS*$[]?J,=
M2WIN162= *@*@*@*@*@*@*@*@*@*IL[.'OWF_)8O9"&]Z/96<\]"T?\ KZ?]
MC+U8Z4_0?V:=UHO]4^KX/_:;Z!7ZZ68       !I>YOO+B/UCT[\<6H9AAZ%
M^?.YOPO8?$UD!O4UU;P*C99$:Y>A.E?] 8=-HBSR/O7=#O A3O,1>GT5 S
M            84RI9W"7/1!-1DWF.3H<!D0W$-PBK"]'4Z>_]10.T#XYK7M5
MCDJUR45/,4#!ANH[3FM;E]%C6D;EJM6+T='> SFN:]J.8J.:O%%3H ^@
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MG9NI*FY;CYM           !>;$^]=CY/%ZQ"E<WM+N>7U1IO8V=6.AF'DV0
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M>*6..1[T5K'JG*B^9TJ&'I@8;_[5=)%TP6ZHZ3O*_N)Z &8
M##B_LMRL"\(9JOB[R.[K0,P
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MJ)7I#+V@P
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M_P#7O:,W5CI6)*_76ZYX6SQ.B?T.3I[R]Q0.NTF=(Q8Y?Z^)>21/K+Z(&0
M   &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!ATW,'7Q*Q%H]/"C=WG)T
M* M9^OB1SDI(U>61O><G2!W           #&O)7M:V&+^OF7E9YB=UWH(!W0
MQ-AC;$STK4H@',             &-<V-O=.1\B*CTX<S5HJIYH'79(EN^2R5
M**U>>-WJF._UIT 9H             ,*\:ES)'9HE?\ XDCO4M3O>:H'9;6-
MO:JKHT57KPYG+5: 9(
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MHRYEZIS.K<OI>-47ZP&>    -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@)
M# !AR_V6Y2X3^IFHR;S'?:N_U 9@         !\54:BN<M$3BJ^8@&+:(LTC
M[UZ>G\&%%[D:=WT0,L               !C7D3E:V>)/Z>%>9J=].ZGHH!W1
M2MFC;*Q:M<E4 Y@          #A-*V")TK_2M2O_ $ =-G$YC'32_P!?,O,_
MS.\GH(!D@
M           QKR5S6M@B_KYEY6^8G==Z" =T4388VQ,X-:E$ Y@   #2MV_V
M=9[[S'[-&=/=?:K.?S2Y6]NR7\WGA3\L96(          <F4YF]ZJ"2)7R9Z
M5OG(5/*XH?3#(  @#M&_[]@/O5SZZ,F?=WT;^>/.KSO9Z>/FN\R$"6(,
M      $E;%?/^'R6X]:APM^=FGGA)N[7;(ZLK2%>K6 .,DC8HW2/6C6I50,>
MSC=1US*E)IO"IZEO<0"H6XGSYU#Y=/Z]2UMV]FQ]6% [ZG_>R]>[I:R=%QZ@
M*@*@*@*@*@*@*@*@*K(;%0.?H2Y?$O\ 3LR4TD?GI#"E/10KWO#VF.K'3*X.
MYW8KNO/W;4LP3-GB;*WH<G%.\O=0C2;.P !JNY?S!U#Y'(=3=7:\?6A'N\?Z
M;GZDJ:EO/F(           %Z,3[U6/D\7K$*3S>TNYY?6NE]C9U8Z&8>+9
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M^+O(_NM S           !AO_ +5=)'TP6ZHY_>63N)Z &8
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MW-NV54H[BCD3HJ@89 &J[E_,'4/D<AU-U=KQ]:$>[Q_IN?J2IJ6\^8@
M      7HQ/O58^3Q>L0I/-[2[GE]:Z7V-G5CH9AXMD   *P;_?/MGD$'KY"S
M.[?9?M3YE ]_/U&.I;TW(M).KT          )I[.?OUFO)8_9"&]Z/96<\]"
MU/\ KSM&;JQTK$%?+L<7O;&USWK1K4JJ^8@&-9L<]77<B4DF](B_:QIT)Z/2
M!E@ .+I(VJC7/:UR]"*J(H'( !I>YOO+B/UCT[\<6H9AAZ%^?.YOPO8?$UD!
M( 8  &)=M6)S+V-*NCX2(GVT:]/U.D#)8]CT16.1R*E4IWE Y       ZYIH
MX&.>]4\%*T[J@=5G$YK'32_U\R\S_,3N-]! ,D                  =-S!
MU\2L1:/3PHW=YR="@+6?KXD<J4D:O+(WO.3I [@        '1=3K!%5J5E<O
M)&WON7H Y6T"6\21UJ[I>[ON7I4#M
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M=<KQABJR#S5^V=_J S
M          #KGF;!$Z5W&G0G?7N(!BPX^%6I+<L1]PY5>_II5>-*=' #.
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M(5+*Z8<C#(  @#M&?[]@/O5SZZ,FG=ST;^>/.KCO?Z>+FN\R$27($
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MK;2^QLZL=#,/%L@  !6'?WY],\@@]?(69W;[+]J?,H#OY^I1U+>FY%I)U>@
M        !-/9T]^LUY+'[(0WO1[*SGGH6K_UYVC-U8Z5@KB9MO$Z5W&GI4[Z
MKT(5\NQQM(711UDXS2+SRKYJ]ST .\ !USS-@B=*[[5."=]>X@'3;6K49UEP
MUK[AZ\[W*B+15[B><!E  -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@) #
M  =3+:WC>LC(VM>O=1 .T      '5XM;]9UO5-ZSIYJ=T#M
M       !TW:QI;2K*E8^5:IW0/(@RT\:L;(B/C2B+ZJG?J&7J^/6?W9OU0P>
M/6?W9OU0'CUG]V;]4!X]9_=F_5 >/6?W9OU0'CUG]V;]4#R9\M/+SL8B,B<B
MHGJJ+YH9>S;+&MO$L24CY4Y4##M
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MCN/*WN)]0#PMR41- Z@1.")9243T#J;J[7CZT(]WC_3<_4E3@M]\P
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MSD151O*Y*KYZH!YC<M=I)SN5%97BRB(E/,[H9>\U4<B.3H5*IZ(8?0
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MA&;V*$KKO%VF.K'3*Z^Y789Z]W1:E4C*=L.;^U7*6Z?U,5'S>:OVK?\ 6!F
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MS$##Z           /CFM>U6.2K7)14\Q0/)FQ3(46:-5D1BH[JE[K4Z4JGF
M>K&]DD;9&+5CDJ@'(
M  QKR5S8TBCXS3+R,3S^E?00#Y!C[6!6N:RLC43PEJO'OTZ ,H      &'/C
MK:5'N8SDF7BCDK3F[].@#MM9UGB17)25J\LC>\Y.D#O
M   !AV_]IG=>._JVU9 GF=UWH@9@           Z+J!9HO 6DS%YXG=YR?9
MYPR++$UZIRN5/";WE[IBH[#(QKR)SV-FB_KX5YF>;WT]% .Z&5L\396>E<E?
M^@#F  TO=K]G>=^]1^S1G4W5VJSG\TN-OKL>3F\\*AEDJDJ J J J J J J
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MM97+S2.[[EZ0.X#5=ROF%J#R.0ZFZNUX^M"/=X_TW/U)4Y+??+X
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M[[1FZL=*PI7R[@#$O'.>K;.-:/F].J?:QITKZ/0!E,8UC48Q*-:E$3S$ ^@
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M_P"N^T9NK'2L(5\NYQD>V-CI'K1K4JJ^<!CV;'.YKJ5*2S<43U+.X@&4
M &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360&Z2_VJY2W3^IAH^;S7?:M_P!8
M89@                  PW_ -ENDDZ(+A>5_>23N+Z(&8
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MG1/]*Y*?]('39RN>QT4O]?"O*_S>\OHH!D@
M              !AR_VJY2!.,,-'R]Y7?:M S             *E>"] &';*
MMO,ZS=Z3B^!?]E>EOH 9@       '!LT3I'1-D:Z5G%[$5%<B+WT[@',
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MS*YC^]3I^K4#KQN0FFFZB9>?F15:ZB(J*G'N >L!C>/VG6=5UJ<U:=VE?/Z
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M)YP4B  &F;L_L\SOWJ/V:,ZNZ>U6<_FEP]^]AR<T=,*BEFJ7J J J J J J
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MU>G^;,]\(W?L[RTM)[&SJQT*>UL_W\G6NZ7C4-IIU* J4!4H"I0%2@*E 5*
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M;144-HJ*&T5%#:*BAM%10VDF;$._S_"B<*VMPB^=1.!'>\$?ZD\\)MW,N_\
MHQU;EI2M5Z   !3/<5/\]ZA\OG]>I<&Z^RX^K#Y>[P_J.?KW=+6:'3<$H H
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MBJ"AM%4%#:*H*&T504-HJ@H;15!0VDF;$+_S A\EN/6H1SO#V2>>$W[ES_\
M1CJW+3E9KZ   "FFXOSZU#Y?/Z]2X-U]EQ]6'R]WA_4<_7NZ6LT.FX!0!0!0
M!0!0!0!0!0!0"S?9^^8]Q\(S>Q0E:]Y>U1U8Z97YW!_3KO\ )=]VU*Q%EB,:
M\B<YC9HOZ^%>9GFIW4]% .Z&5L\396>E<E?^@#6MQ_F+G_(Y#J;J[7CZT(YW
ME_3,_4E4"A;[Y;* * * * * * * * * * 7<Q7O79?>(O6(4EF]I=SR^O=)[
M&SJV]#+/%M   !23M7)_S1C^"[7V28L7N]V7[4^95G>CMGV8\Z#J$D1,H H
MH H H H H H H!8SLBHUN?U1,Q'+=,L;=8Z>E5B3*KVJG?6C:$/[RU]79SST
M)UW2F/69(\4+>QR-EC;(Q:M<E4(,L5S        TO<WWEQ'ZQZ=^.+4,PP]"
M_/G<WX7L/B:R D ,                      '3<P=?$K$6CT\*-W><G0H"
MUGZ^)'.2DC5Y9&]YR=('<           ,-O]JNU?TP6ZT;YLG=7T ,P
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MK;T,L\6T   %)>U;^U"/X+MO9)BQN[W9?M3YE5]Z.V?9CSH.)(B8
M  61['_SDU)Y##[,1#O+[.SGGH3CNE[7)U8Z5KHO[+<K;K_4S5?#YCOMF_ZR
M"+(9@       &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M             >)>7C[>\E\6\&M$DKQ17)W0R]&PNUNX5<]*/:O*ZG0OFAAE
M         ,>[E=&Q(XOZ^5>2/S.^OH =D$+8(FQ,Z&IT]]>ZH'8
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MO3IKWZ!EZ?7P_=&_RD#!U\/W1O\ *0!U\/W1O\I '7P_=&_RD =?#]T;_*0
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M2>0P^S$1[R^SLYYZ$Y[H^UR=6.E;@@:RF')_9;I)NB"=4;)WD?W%]$#,
M  !I>YOO+B/UCT[\<6H9AAZ%^?.YOPO8?$UD!( 8
M  ,>\E<QB11?U\R\D?F=]?0 [(8FP1-B9Z5J4\_OJ!V         -9NIYI9G
MK(Y:HJIR]Q$Z*4#+W;![Y+2)STHM*=[@BT0,,D             'BYF1_7QL
MZ&M;5J^:O!?K!EVX>:5_61/57,:B*BKQHJ]P,/5 XO56L<YJ5<B*J)WU UE;
MF=TG6K([K*UK4,O;CN;QT;'+:JY51%KSM2O#IHO0&'/QB\_NB_A&@/&+S^Z+
M^$: \8O/[HOX1H#QB\_NB_A&@/&+S^Z+^$:!XEU<7$D[W2*K7-541E?2T[G
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MA%14146J+Q14 QIK"UG<KWL\-?MD547SP/EE([D=;R?UT'@.\UOVJ^B@&4
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M^G7?Y+ONVI3(LL8  :/O)^RW5?P=-]8Z>Z^U8^M#D;X['EZLOSRH6PI(H H
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ME 5* JE/L_L:NN9W*E53'34\Q>MBX_Z2/;_[/'6CHE*N[,_[<]2>F%G"!+,
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M@   I;VID_YFQ_!EM[)*6/W=[+]J?,J7O7VS[,>="="2H@4 4 4 4 4 4 4
M4 4 L7V1OG'J/R*'V4B'>;V=G//0GG<_VV3JQTK9D"6:  ,:\B<YC9HOZ^%>
M9GFIW4]% .Z&5L\396>E<E?^@#F   :7N;[RXC]8]._'%J&88.D)4AUON'(C
MDZF3,V44K.ZQZ8:PHZG>=W^_7O 2$&                    ,.3^U720)Q
MA@H^7O*[[5H&6YS6-5[EHUJ55?,0#%M&K*YUY(E'2\(T7[6-.CZO2!E@
M    ,:\B<]C98OZ^%>=GF]]/10#MAE;/$V5GI7)7SO, [ ,:\B<]C98OZ^%>
M>/S>^GHH!VPRMGB;*STKDKYWF =@        #$NW.E>RRC6BR>%*J=R-.GZO
M0!E-:C6HUJ4:B41/,0#Z 541%55HB<54##M46XE=>N3P5\"!%[C$[OH@9@
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M!:P=1$C%6LB^%([ON7I4#IN56XF;9M])Z>=4]2G0GH@9B(B)1."(
M   ,-G]ENECZ(+A>9G>23NIZ(&8  PV?V6Z6/H@N%YF=Y).ZGH@9@
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M*SKQAAJR+O*[[9P&1/,V")TKNAJ<$[Z]Q .NTA='&KY>,\J\\B^:O0GH 9
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MIU]5^L0[O/[.SGGH3_N;/]W)U8Z5K,<C8XGV].66)RI(G?KT.]%"!+.9@
M U>Y?(ZXD=)PDYEKYE R]>UGOW6\:]2CTIP>YU%5 P[NMO\ ^[M_E_\ 0!J&
MY#[AV"QBRQHQ[=0Z=6)J.KS+[L6O!5[@9=.A?GSN;\+V'Q-9 ;^J(Y%14JB\
M%0,,6U58)'V3UX-\*%5[K%[GH 98               #&O)'(UMO$O\ 33+R
MM7O-[J^@@':QD=O$V-*-8U*)7@!C_P"]W2(G&WMUJJ]QTG_0!F
M    PYO[+<-N4X0R49/YB_:N_P!0&6US7>E5%ITT6H'7/!'<QK%(G@KW4Z47
MOH!C6V,AMI.MYE>Y/2UX(@&<     '&1C9&.C>E6N2BH!@QXB".5'JYSFHM4
M8M/]('H  ,6[L8KNBN56O;P1R=[O*!TV4+;.>2V7BLB(^.3U2)TIZ 'H
M      &A;S_LVS7_ );_ !41U]T=JL]_HEQ=]]CO][[T*DEB*PJ J J J J
MJ J J J JR+#_?K7[]'ZY#\7^C/,],<_.CG7K*G7*  ,+W+L^LZSE7IKR5\'
MZ@$!]HA/\P8CR-WLKB<]W?97];S*P[WS3/CZOG0V2JB#;0*&TR\59V^0R=K8
M7=['C;6X?R39"=%=% U&J[F<B*G>HG'I4\LM\V63=%NU,>"/"]L%D9,EMEUT
M8XNX[IXK>#C\S?K/;G26I;3(LT-JF7)YS&1+.ZSN[?J(YV-X5C7E:J(J\$7C
MQI7I.+?O'/@NM]?BBVRZ:5B:TYTEQ;GTFJMOC29YOR616ET4B>;@CRQ5JVFL
M=HJ^L9K_ %7J&;$O9+U,./MK99YWLY4<LJNHY$;6K?2\%0Z6IR:BRZ+<..+^
M#CF:1S.)H;-%DQS?J<TXN&D6VVUNZW%/!X.+@F)9FN]%0Z/;C,C89)N6TYFH
MG38^^Y49)1C6N5KFITU:Y%141.]0\=!K9U.U;=;L7V328;.]MW1HMB^V_P!9
MBR16V[P\5>'EK'#$\'(]"/;[$87&6N5W$U F 6_8DMEB;>+QB^=&M/">VCN7
MIZ.7AT*M3QG>&3+?-FFQ^LV>.Z9I:VORG%@Q1DUN;U.UQ61%;O?X_@C@Y6CW
M#8&W-PRT>Z6R;*]MK+(G)(^%'+R.>WN.5M%5#KVUI%>.G#S^%';IB+IBWAMK
M.S/AFWP3/)-'6?JC&T"AM)4V ^>]Q\'3>RPD<[P=FCK1T2F'=.?]R>I/3:LR
M5^M@   *4:O7_-F>^$;OV=Y<.BC^QCZMO0^:=Z7?[F;_ "7_ 'I>-4VZ.;M%
M10VBHH;144-HJ*&T5%#:*BAM%10VBHH;144-I:+87YA-\LG^LTK;O#VK[,+Q
M[F37=_V[O,DXCB;@ #2]V?V=YW[U'[-&=G<O;,?/YI17O7^EYN:/O0J)0MI\
MT% % % % % % % % % /K$\-OGH8EF.->QGI&^<A1TOK^.)R,,@ " ^T2E;[
M ?>KGUT9/NZWH9.>WSJ5_P"QO:8.:_IM0G0FJHZE 5* J4!4H"I0%2@*E 5*
M J4!5)&QJ?Y]A\EN/6H1OO%V2>>$^[B?JD=6Y: K!]$   !^=6[R?\T-6_"E
MU[(I;.[>RX^K"D][3_N9>M+2N4Z+E5.4%3E!4Y05.4%3E!4Y05.4%3E!4Y05
M75[)R4VRN_A>Y]@MRN^\7:8ZL=,K3[K=DGKST6IU(REP  TC>']E^JO@^;ZQ
MT]U]JQ]:''WUV++U9?GW0MI1A0!0!0!0!0!0!0!0!0!0#]+,'[R8WR6#V-I2
M^;T[N>7T)I_9V\T=#//)[@  !3/M1?M+C^#+;V24LCN[V7[4^94/>WML=2.F
M4*T),AQ0!0!0!0!0!0!0!0!0"P_9+^<6HO(H?92']YO9V<\]"?\ <WVV3JQT
MK272+!(R]8G!O@S(G=8O=] @*T&4BHY$<BU1>**G> ^@  '3):V\K^>2-KG]
M]4 [D2G!.@ !I>YOO+B/UCT[\<6H9AAZ%^?.YOPO8?$UD!( 88UY$YS&S1?U
M\*\S/-3NIZ* =T,K9XFRL]*Y*_\ 0!S             !\<Y&M5SEHU$JJ^8
M@&+:-=*]][(E%D\&)%[D:='U>D#SLPZ3QA&NKU:-16)W/-#+OPJR<DJ+_5(J
M<OG]T,/5             !@9=9$M/ ]*KD1].]__ - \S&ND2[C2.M%X/3N<
MO=J&6Q!@          -"W/TIN!JZUQF-T1K!='6J3/7.7D-LVXO);?E3D; Y
MRIR+S)Q6J<%Z>%%"&]!YW<G;7M"VVS&I=6SZXTWGL4_*V5[?-3QRR=&V9R=8
MZKEXK YJHKE14<QR<O% R[-R-N=],9IS4VX;]X)X,MA([S*X_%6MG%;XQMG:
M-=*V%U5XO=&STSF*G-P7F],!Y>=W^U_F]GMK8]/=3C=RMT;M<2S(<C71VS;:
MX2UGN6,6K6J]71O2J*C6N6G%$!1Z5KF]PMC]YM':(U-J^\UKHK7S)+:&XRK&
MI=VF2B5&UC<VJ\BN?$G*KJ<KUX5:BJ%GPP       T/>;]F^9_\ +?XJ(Z^Z
M.U6>_P!$N'OSL=_O?>A4HL55M0%0%0%0%0%0%0%0%0%618?[]:_?H_7(?C)Z
M,\STQS\Z.=>DJ9=0   5V[1'S@Q'D;O97$Z[N>ROZWF5=WQG^_CZOG0V2I Z
M@*E*T;17*Y4:UJ)57*JT1$1.*JJ]" K7@2KBV0[0Z=O<SF)&-U]G[9;7%XA7
M)SVEL_BLL]/2K6CE3OHC4X\U(WEF=XY8LLC^SCFMUWTIY(]WC33!L[ET]V7+
M,?B,MM++/HQRW=,\U(1WIS+8'"7;Y<[AHL_:OB1L=K/,L"-?S<RR\R(M55.%
M#NZG#ERVTQWSCFO'$5]Y$M%J]/IKJY<<9HI%(F:?:]]*6M+6SS]SMYK'KWP:
M6R-U:V<.&FC9&VS8KVN5(^1$16NZNCE7N(E%H1S17788U&&E<EL73M?2Y_*F
MV],=FHOT>IK3%==9;%DQ'S:\/!XIIP^*E.!Z&LM:VV/W373USIC'WUM=R6=G
M>W%Y&LUY<1W*-:U87.54:QG-P8C>*U[JGAHM#-^B]9&2ZV8VIB(X+8IR^.>5
ML;RWM&+><8+L-EUMTV6W3=%;KHN^CXHKQ4XZHUW(P-AIC6^4PV+\''Q]5-!#
M55ZI)XT>L=555HU5\'S*$@W;GNSZ:V^[TN&)\=/"B6^M+9I=;?BQ^CP3$<E8
MXOB\35CHN/4!5*FP'SWN/@Z;V6$CG>#LT=:.B4R[I3_N3U)Z;5F2OEM@  !2
M75Z_YMSWPC=^SO+CT4?Z^/JV]#Y?WK=_N9O\E_WI>-S&Y1S=HYA0VCF%#:.8
M4-HYA0VCF%#:.84-HYA0VCF%#:.84-I:383CH%OEEQ]9A6G>+M?V87QW)FN[
MOMW>9)Y&TZ  &F;L_L\SOWJ/V:,[.Y>V8^?S2BO>S]*S<T?>A42A;3YGJ4!4
MH"I0%2@*E 5* J4!4H"I0%7)B>&WST,2S$\*]3/2-\Y"CI?8$<3D89  $"=H
MFGCV!JM/Z*Y]=&3[NMZ&3GM\ZE?^Q_:8.:_IM0G5.^GU2:JB*IWT^J JG?3Z
MH"J=]/J@*IWT^J JG?3ZH"J=]/J@*IWT^J JG?3ZH"J=]/J@21L:J?+V'BG^
MZW'K4(WWB[)//"?=Q/U2.K<L^5@^B0   _.S=U/^9^K?A2Y]D4MG=O9<?5A2
M.]NV9>M+2Z'1<HH H H H H H H H H!=/LH?LSN_A>Y]@MRN^\7:8ZL=,K5
M[J]DGKST6IT(REP  TG>#]F&JO@^7ZQT]U]JQ]:''WUV++U9?G[0MM110!0!
M0!0!0!0!0!0!0!0#]*<'[RXWR6#V-I2V;T[N>7T-I_9V\T=#//)[@  !33M0
M_M+C^#+;V24LGNYV7[4^94'>WMOV(\Z%22H<          %A^R9\XM1>10^R
MD/[S>RLYYZ$_[F^VR=6.E:U41R*UR51>"IYBD!6BQ;15A>^R>M>3PH57NQKW
M/0 RP      :7N;[RXC]8]._'%J&88>A?GSN;\+V'Q-9 2 &'QSD8U7NZ&HJ
MKYR >!'DY89'NB:B0O<KNK7N5[RAEZS<A9N:B]:B52M%Z4##[X_9_=F@/'[/
M[LT!X_9_=F@/'[/[LT!X_9_=F@/'[/[LT!X_9_=F@/'[/[LT!X_9_=F@/'[/
M[LT#X_(VC6N<DJ.5$54:G2OF >3+DYI_ E1$@<J<S6\%Y47HJ&7OMY>5.7TM
M$IYP8<9(HY4Y96(]$Z$5*@8K$2SN>J3A;S\8^\UZ=*>B!F@
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MDQ)W$QELB?A)2R>[G9?M3YE/][I_W8ZD=,H8H2=#*E 5* J4!4H"I0%2@*E
M5* J4!587LG)34.H?(H?92'=Y_96<\]"P.YGMLG5CI6K( M, PX_[+=+#T03
MJKH^\C^ZGH@9@     :7N;[RXC]8]._'%J&88.DYDM]:[AW"N_H'9FSBF91?
M!>W"V"HY.XJ*B^?_ * -\@N8+E%6%_-3I3H5/04,.X
M  &'/_9;AMTG"*2C)_,7[5W^H#,           &&O]KNZ=,%LM5[SI?^@#,
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M[1/S@P_D;O97$][M>ROZWF5#WXG_ &,?5\Z&B6J[V@&T V@&T V@&T V@&T
MV@&TE7L_K_GBX2O'W.F6GF=;"1KO%V:.M'1*<]RIKKKH_P#X=WWK5FBNET@
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M+UG>I3[(%6.T]^TF/X-MO7REE=W.R_:GS*<[W=MCJ1TRABA)D-* * * * *
M* * * * 6$[)_P X=0^10^RD.[S^RLYYZ%@]R_;9.K'2M40!:8!C7S6+;/<]
M>7D\)KDZ4<G10#$M\PCWMCF9RUHG.B]WS@/4    &E[F^\N(_6/3OQQ:AF'C
M8-CY-6Z_E8J]6S,VD2QTX<_N/8.YD[ZJCD1?. W/$03),LRM5L:-5*KPJJ@>
MT&                    .,C&RL=&]*M<E%3SP,>S>Y$=:RK66'@B^J9W%
MR@        '1=S.BCI'QFD7DB3_:7N^@!RMX6V\38DXT],[OJO2H':
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MGHM3@1A,0 !I6[O[,M4^02_6.GNKM>/K0XN^^PY>K*@E"W%#% % % % % %
M% % % % /TAPGO+CO)8/8VE*YO:7<\OHS3^RMYHZ&>>3W "HBI1>*+TH!Q:Q
MC$HQJ-3O(E *=]IW]I,?P;;>OE+*[N=E^U/F4YWO[='4MZ90S0DR&% % % %
M % % % % % +!]E'YPZA\BA]E(=WG]E9SST+"[E^VR=6.E:D@"U #&OTC=:2
MI(O*VE:^:B\/]('F6^)G<]CIJ,CX.7CQ\X,O<#    :7N;[RXC]8]._'%J&8
M8FB6I<:UW#NJUACS%HR%M?MO<:PYG4\WO_8##?P
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M6H9AB:$54UKN1"G]7#E;".-O>;[CV2_755 W\,
M'"9_5Q/?2O*U74[]$ UR.\N(E18Y%1J=#*^#TUI0,O;;?U:B^+S<41>#*I]<
M,/OCW_TT_P#(_P"D!X]_]-/_ "/^D!X]_P#33_R/^D!X]_\ 33_R/^D!X]_]
M-/\ R/\ I \:XO;F9[U5[FL6J<B<$1.BBAE[=B_K+2)W+R\*43H\%:?Z@PR
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M)_S+U7\)W/LBEN;L[+CZL*'WQVW+UYZ6G4.DY%2@*E 5* J4!4H"I0%2@*E
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M<GVO+]L&5M=N-6)KO0>G-8=6D,F9Q]O>30MJK8YI&)UK&UXT:_F1 _+9P
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M"@"@"@"@"@"@"@$J]G[Y\7'P=-[+"1;O+V6.M'1*Q>X/ZC=_CN^]:LV5JOP
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MH]E9SST+$[D^VR]6.E9J\>Y4;:Q+26;A7U+.ZI7ZUV1&QL3&QL2C6I1$ Y
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MO"@"@"@"@"@"@"@"@"@$P=F=/^:-OY%=>M0CG>'LD\\);W5[='5N74*S7&
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M:25&NZ]W#P$145.^:6KMSS9_:NBWCK/AI3P.ENZ_2^M_V+9OKLQ;;'%,S/\
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M[.3KW=,M<Y?,-QHU.7S 5.7S 5.7S 5.7S 5.7S 5.7S 5.7S 5.7S 5.7S
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M^L>G?CBU#,,/0OSYW-^%[#XFL@) #          PW?VJZ1G3!;K5W>=)W$]
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M\.'_ /B;-/K(@$G17EP^)CEMGN541>9%1$7S4##GXW<?W1_U4 >-W']T?]5
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MBF*/U%]2@9VB@-I+W9X^=>2^#G>SQ$9[P>PMZWFE,>ZLUU-_4\\+($%66
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M9V&>O/1:F8BR<  #3MU_V<:F\AE^L=3=7:\?6AP]_=@S=65%J%P/G@H H H
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MU2>I3Z@H;1U2>I3Z@H;3,Q42>ZEEX*?[Q%Z]#\9(^;/,],5WSXYX?J 4ROL
M  *D]K9*ZJP'P>_V=Q/^[/LK^MYE7]\/;X^KYU>N4ER"5.4%3E!4Y05.4%3E
M!4Y05.4%3E!4Y053AV5DIN3=?!-Q[/;D8[Q]FCK1T2F/=*?]R>I/3:N65RMH
M   /SOUVG^>-2_"M]_B9"Y-%V?'U;>A\][QG_:R]>[[TM?Y3;:%3E!4Y05.4
M%3E!4Y05.4%3E!4Y05.4%5S>S*E-LF^7W/UF%:=XNU_9A<?=+L/VKO,F,C:8
M  #0-[OV6:D^\1>SQG8W-VS'S^:4>[Q?I^7FC[T*,4+:4-4H"I0%5@M$2[:Z
M5T>YN'UK;8S7.7@8F1S<MG-<2VD4C>9\%LQ.5&JU?!5_-55\+U*-AFMMU>?/
M\_%-V*R>"W:B*^.?B^6MC;LNT.FTOS,\69LD?.OFV9V8G^&V."G/X9X>2(CQ
MFE- 1ZUL<;>ZU;?:8FA6ZR.:CMI87I*CGU@1'+(O.Y$1>=>'A="KT]F=3J9T
M\W6XMF^M(MK$^_X/(C<:+1QJ[;+L^UCF*S?LS'#P_-\/#P<?C2)KANW6JK6S
MPN-W$L\)I#$,1,5@+?'7#XVO1OA2RR<Z+)(Y5=X2IW5^V<Y7<;1?BL$S?=@F
M_)=Z5TW1Y(Y(]W@BDBWC9H=3;;CLU-N/%C]&R++IYYF:_.NGAX?/-TSJ>G,U
MIG5>VK=N=2Y9F!R6*OEO\'D;B-[[9[).=7Q2*Q%5O&1Z]S[7O*B]'48<V#5_
MB,=NW%UM+H\//'DCX7+T>IT^JT,:3-?ZJZR[:LNIP>&L3Y9Y/![^)N5J;3SM
M.::V]TE=NR6)TZR66[RBL=$RXO)U5SEC8]*HUJN>M?\ :X=%5]-W:;+ZW)J,
ML;-V2E(Y(CE^!X;WUN#U&+28+MNS%69NXJW3QTKX./R\'$C.AWD6J4!5RC3P
MV^>GUS$\3,3POTBC](WSD^L4?/&^F(XG(PR  *R=JM*Y'3/WB[]?$3WNMZ&3
MGM\ZJ^_'M,/-=YE>:$V5M4H"I0%2@*E 5* J4!4H"I0%2@*I:[.*4W,M_([K
MUJ$;[Q=DGGA,>Z/ZA'5N7'*P78   %#]T4_YBZG^$;CUZEP[K[)CZL/GC??;
M\W7NZ6I4.FXQ0!0!0!0!0!0!0!0!0"W'9F_9[<_"EQ[# 5IWE[5'5CIE<_<O
ML,]>>BU,I%DY  &G;K?LXU+Y#+]8ZFZ>UX^M#A[^_3\W4E1BA<+YW* * * *
M * * * * * * ?H5AO>?'^30^QH4AF]I=SR^G--[*WJQT,X\6P   %2.TC^T
M./X.M_7REF]VNR?:GS*2[Z=OCJ6],HAH2E!B@"@"@"@"@"@"@"@"@$\]E[W^
MSWD<7LI"^]/LK.>>A9/<7V^7JQTK.%>K=        -+W-]Y<1^L>G?CBU#,,
M/0OSYW-^%[#XFL@) #       #$O&.8K;R-*OA].GJHUZ4]#I R6/:]K7L6K
M7)5%\Q0.NY@2XB5E:.],QW><G0H"UG6>)%<E)6KRR-[SDZ0.X !'>VNSV VU
MR>I<]9WMYE]1:KN_'<ME,DZ)TRKS.>D;.JCC1K$<]SJ4[W<1*&:N>Z6SNEMU
M[;'KF9;O&YS#2K<87/XJ;Q;(6DBT5>KDHY**K6JJ*G2E4HO$%7F;<[%8#06H
M;S6E_E\GJS7%]$EK)G\[.EQ/';I1.KA1$1&(J-1%7BM."*B*J JE0,     P
MW?VJ[1O3!;+5W>63N)Z &8  KAVAOG7C?@YOL\I/N[GL+NMYH5-WRNIJK.I_
MY7(A)11!-L%#;!0VTF7;F_P_8=G,G/[L*O+5*TZV?N$?LC_ZM_4\T)?-W_\
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ME!4Y05.4%3E!4Y05.4%4L]G)*;EV_D=SZU"-]XNR3SPF7=#]0CJW+BE8+N
M "B.Z*?\Q=3_  C<>O4N+=?9,?5A\[[\[?FZ]W2U*ATW%* * * * * * * *
M * 6W[,_[/;GX4G]A@*S[S=JCJQTRNCN7V&>O/1:F0BR=  #3]U?V<ZE\AE^
ML=3=/:\?6APM_P#Z?FZDJ-4+B?.Q0!0!0!0!0!0!0!0!0!0#]",-[T8_R:'V
M-"C\WM+N>7T]IO96=6.AFGBV    J3VD/VAQ_!UOZ^4L[NUV3[4^92/?3M\=
M2WIE$-"4(,4 4 4 4 4 4 4 4 4 GGLO^_V>\CB]E(7WI]E9SST+)[B^WR]6
M.E9LKU;P       !I>YOO+B/UCT[\<6H9AAZ%^?.YOPO8?$UD!( 8
M ,.W_LT[K1?ZMU7P+YG=;Z &8!B2HMM<I<-3^BEHR9$[B]QWV0,L
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M/V^7JQTK,%>+@        -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@) #
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M &,?4\Z".4F2N:G*"IR@J<H*G*"IR@J<H*G*"IR@J<H*ID[-"4W!N?@N?V:
MBO>;LL=:.B4Z[E3_ +T]2[IM6U*T74   %"-;)_G+47PG>_XAY=6A[/CZMO1
M#YJWG/\ MY?\E_WI>%0W'-J4!4H"I0%2@*E 5* J4!4H"I0%5NNSGPVY;Y=<
M_685AWD[7]F%X]S/T_[=WF2T1A-@ !HN\O';+4/WF/V>,[6Y.VX^>>B4:[S?
MIN;FC[T*5<I;KYZJ<H*G*"IR@J<H*G*"IR@J<H*G*"IR@JY,;X;?/0Q+,3PO
MT+9Z1OG(45+ZHCB<C#(  K?VGTKD--_>;KU\18'=7T,G/;YU1]_?:8>:[S("
MH3=5Y0!0!0!0!0!0!0!0!0"5.SVG_,>#R2Y]:A&N\?8YYX3;N9^HQU;EN2K5
M[   !1[<Q/\ F#J7X0N/7J7+NKLF/JP^;M^_J&;KW=+5*'3<,H H H H H H
M H H H!:WLW_ #!N?A.?V&$K+O/VJ.I'3*\.X_8+O\EW1:E\BB>@ #4=TOV>
M:D\AE^L=7=/:\?6AP>\'Z=FZDJ1T0N1\WE$ 40!1 %$ 40!1 %$ 40!1 %$
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MFGBV0   JGVB?G_'\'P>OE+0[L]D^U/F45WW_4(ZEO3<B6A*D#* * * * *
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M%6+Z   "DFY2?Y_U)\(7'KU+FW5V3'U8?-6_OU#/U[NEJM#IN$4 4 4 4 4
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M6I;(FL   :EN?^S[47D4OUCJ[H[9CZT.!WA_3LW4E2NA<SYJ* * * * * *
M* * * * 7UQ'O38>3P^L0HK/[2[GE]5Z7V-G5CH9AXMD   *K=H9*Z^9Y!!Z
M^0M'NQV3[4^91'?G]0CJ6]-R***2I :E%!4HH*E%!4HH*E%!4HH*E%!4HH*E
M%!5.'9J2F<SGDD7LA">]?LL?6GH6?W ]OEZL=*R!72Y@       #2]S?>7$?
MK'IWXXM0S#$T+\^=S?A>P7ZN%L5 W\,       ,.X_M,[;1/ZIE'S_\ LM]$
M#5MU-*9+6>C[C!8E8DO)9H9&]>Y6,Y8W\R\41WUCL;HU>/3:B,E]:4GB1SO#
MN_+K='.+%3:F8X^#BE O\.&N_5V'X=_M9./W+H_K>3Y57_LK>/+9_-/])_#A
MKOU=A^'?[6/W+H_K>3Y3]E;QY;/YI_I/X<-=^KL/P[_:Q^Y='];R?*?LK>/+
M9_-/]+*QO9_W!Q>1M,G;.QKKBSFCN(4DE<]BOB<CV\S5CXI5.*'EE[PZ+)9-
ML[=+HIQ<OOO;!W/WGBR6Y+?5UMF)CYT^":\B19L5OK<R)+<?)Z:5$Y4?)%S.
MY:UI56*M#@VY=U6Q2/6Q[N=+KL._[IK/J)]W,UC#[7[M8'460U3C7X>/,9%)
MDDE6KF1K</1[EB8L=&K5*)YG Z.;>N[\V&W%=M[-M/?IR\+B:;<.^-/J+]19
M.*+[]KFC:FLTC9:R_LZ:^E>Z226Q?(]5<][KAZN5RK5555CXJIT8[R:.(I$7
M>3Y7'GN7O*9K,V5ZT_$X_P .&N_5V'X=_M9G]RZ/ZWD^5C]E;QY;/YI_I/X<
M-=^KL/P[_:Q^Y='];R?*?LK>/+9_-/\ 2?PX:[]78?AW^UC]RZ/ZWD^4_96\
M>6S^:?Z6;A^SWK>PR^/OIGV*PVMS#-)RSO5>6.1'+1.K[R'CG[Q:2_'=;&U6
M8F.+Q<[9TO<[>&/-9?,V4MNB?2GP3S+1%:KJ   "%]X=J]2Z[U!99/#.M4MK
M>S;;/\8D<QW.DLCUHB,=PHY"8[DWO@TF&ZS)6LW5X(\4>-7'>CN]J]XZBW)A
MV:193AFG#69Y)Y4=_P .FO/5X_\ #O\ :SO_ +FTGUO)\J(_LC>/+9_-/])_
M#IKSU>/_  [_ &L?N;2?6\GRG[(WCRV?S3_2?PZ:\]7C_P ._P!K'[FTGUO)
M\I^R-X\MG\T_TG\.FO/5X_\ #O\ :Q^YM)];R?*?LC>/+9_-/])_#IKSU>/_
M  [_ &L?N;2?6\GRG[(WCRV?S3_2?PZ:\]7C_P ._P!K'[FTGUO)\I^R-X\M
MG\T_TG\.FO/5X_\ #O\ :Q^YM)];R?*?LC>/+9_-/])_#IKSU>/_  [_ &L?
MN;2?6\GRG[(WCRV?S3_2?PZ:\]7C_P ._P!K'[FTGUO)\I^R-X\MG\T_TG\.
MFO/5X_\ #O\ :Q^YM)];R?*?LC>/+9_-/]*1-GMJ]2Z$U!>Y/,NM5MKBS=;,
M\7D<]W.LL;TJBL;PHU3@;[WO@U>&VS'6L75X8\4^-+NZ_=[5[NU%V3-LTFRG
M!->&L3R1R)H(<L<   *OY/L_ZYO,E>7<3[%(YYY965G>B\KWJY*_T?FEF8N\
MFDMLMMG:X(CP?*I#4=R]X9,MUT3929F?2GPSU6+_  [Z\]78?AW^UGK^YM)]
M;R?*U_V/O'EL_FG^D_AWUYZNP_#O]K'[FTGUO)\I^Q]X\MG\T_TG\.^O/5V'
MX=_M8_<VD^MY/E/V/O'EL_FG^D_AWUYZNP_#O]K'[FTGUO)\I^Q]X\MG\T_T
MG\.^O/5V'X=_M8_<VD^MY/E/V/O'EL_FG^D_AWUYZNP_#O\ :Q^YM)];R?*?
ML?>/+9_-/])_#OKSU=A^'?[6/W-I/K>3Y3]C[QY;/YI_I/X=]>>KL/P[_:Q^
MYM)];R?*?L?>/+9_-/\ 2?P[Z\]78?AW^UC]S:3ZWD^4_8^\>6S^:?Z3^'?7
MGJ[#\._VL?N;2?6\GRG['WCRV?S3_2GK;#3&1TAH^TP656-;V"29[UA<KV4D
MD<]**J)W%[Q!=[ZNS4ZF<EE:3$<?,M7N]N_+H=%;ARTVHF[BX8X9JW Y"1
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MI^QMX\MG\T_TG\/6O/5V'X=_M8_<^D^MY/E/V-O'EL_FG^D_AZUYZNP_#O\
M:Q^Y])];R?*?L;>/+9_-/])_#UKSU=A^'?[6/W/I/K>3Y3]C;QY;/YI_I/X>
MM>>KL/P[_:Q^Y])];R?*?L;>/+9_-/\ 2?P]:\]78?AW^UC]SZ3ZWD^4_8V\
M>6S^:?Z3^'K7GJ[#\._VL?N?2?6\GRG[&WCRV?S3_2)V>]>HJ+SX_@OW=_M9
MC]SZ3ZWD^5F.X^\>6S^:?Z5IFI1J(O2B4*OE>\<3Z89  $3;Q[<:AUW=8F;"
M.MVLLHYF3>,2+&M9',5*4:ZOI26;BWKAT=M\9*_.F.*.=7W>O<&IWE?CG#L_
M,BZM9IQT\4HQ_AZU[]TL/P[_ &LDW[GTGUO)\J#_ +&WCRV?S3_2?P]:]^Z6
M'X=_M8_<^D^MY/E/V-O'EL_FG^D_AZU[]TL/P[_:Q^Y])];R?*?L;>/+9_-/
M])_#UKW[I8?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'K7OW2P_#O]K'[GTGUO)\I
M^QMX\MG\T_TG\/6O?NEA^'?[6/W/I/K>3Y3]C;QY;/YI_I/X>M>_=+#\._VL
M?N?2?6\GRG[&WCRV?S3_ $G\/6O?NEA^'?[6/W/I/K>3Y3]C;QY;/YI_I/X>
MM>_=+#\._P!K'[GTGUO)\I^QMX\MG\T_TG\/6O?NEA^'?[6/W/I/K>3Y3]C;
MQY;/YI_I;IM;M)JK1VK(LUEG6JV;()HG=1*Y[^:1$1."L:<7?&^]/JM/..S:
MK6../E2;NWW8UF@UD9LNSL[,QP37C]Y.9!UI@  !7/5^R&L\YJC+YBS?9):7
MUU+/"DDSFOY'N54JB1K12Q=#WATV'!9CNVJVVQ'%\JF=Z=S]=J=7DRV;&S?=
M,Q6Z>*?>>)_#UKWU=A^'?[6;O[GTGUO)\KF?L;>/+9_-/])_#UKWU=A^'?[6
M/W/I/K>3Y3]C;QY;/YI_I/X>M>^KL/P[_:Q^Y])];R?*?L;>/+9_-/\ 2?P]
M:]]78?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'K7OJ[#\._VL?N?2?6\GRG[&WCR
MV?S3_2?P]:]]78?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'K7OJ[#\._VL?N?2?6
M\GRG[&WCRV?S3_2?P]:]]78?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'K7OJ[#\.
M_P!K'[GTGUO)\I^QMX\MG\T_TG\/6O?5V'X=_M8_<^D^MY/E/V-O'EL_FG^E
M->TND,MHK3$V(S*PK=/O)+AJP/5[.1\<;4JJM;QJU2%;ZUV/5YXOQUILQ'#S
MRL[NQNO-N_2SBS4VIOF>":\%(^)OAPDK  'A:TQ%WGM*9;#6'(EY>VSX8>L7
ME9S.Z*JB+0WM!GMPZBS)=Q6S5RM[:6_4Z/)BLIM7VS$55U_AZU[ZNP_#O]K+
M$_<^D^MY/E4W^QMX\MG\T_TG\/6O?5V'X=_M8_<^D^MY/E/V-O'EL_FG^D_A
MZU[ZNP_#O]K'[GTGUO)\I^QMX\MG\T_TG\/6O?5V'X=_M8_<^D^MY/E/V-O'
MEL_FG^D_AZU[ZNP_#O\ :Q^Y])];R?*?L;>/+9_-/])_#UKWU=A^'?[6/W/I
M/K>3Y3]C;QY;/YI_I/X>M>^KL/P[_:Q^Y])];R?*?L;>/+9_-/\ 2?P]:]]7
M8?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'K7OJ[#\._VL?N?2?6\GRG[&WCRV?S3
M_2?P]:]]78?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'O7OJ[#\._VL?N?2?6\GRG
M[&WCRV?S3_2L_80OMK&UMY*=9#%'&^G%.9C41:?4*QR71=?,QX97G@LFS';;
M/'$1#(/-[   !".Z^U&J-::I;F,.ZU2T2UB@_IY7,?SL<]5X(QW#PB;;EWS@
MTF#U=]:UF>".;QJO[S=V=7O#5^MQ;.SLQ'#-.*OB:/\ P]Z]]78?AW^UG<_<
M^D^MY/E1;]C;QY;/YI_I/X>]>^KL/P[_ &L?N?2?6\GRG[&WCRV?S3_2?P]Z
M]]78?AW^UC]SZ3ZWD^4_8V\>6S^:?Z3^'O7OJ[#\._VL?N?2?6\GRG[&WCRV
M?S3_ $G\/>O?5V'X=_M8_<^D^MY/E/V-O'EL_FG^D_A[U[ZNP_#O]K'[GTGU
MO)\I^QMX\MG\T_TG\/>O?5V'X=_M8_<^D^MY/E/V-O'EL_FG^D_A[U[ZNP_#
MO]K'[GTGUO)\I^QMX\MG\T_TG\/>O?5V'X=_M8_<^D^MY/E/V-O'EL_FG^D_
MA[U[ZNP_#O\ :Q^Y])];R?*?L;>/+9_-/]*2-GMM=1Z%R>2N\TZV6*[@9%%X
MO(Z1>9K^9:HK6]PC>_-[8=99;;CK6V?#":]U>[^JW;ER79MFEUL1%)KX>:$O
M$16(        :7N;[RXC]8]._'%J&8>'H?*);ZOW#BY$D8W+V:-D]*[J_<FS
M1$7OT5'+Z-.X@$F,GB>QKVO3E<E4X]\,.761^K;]5 '61^K;]5 '61^K;]5
M'61^K;]5 '61^K3ZJ >=<Y=L4JQQ,Y^7@YRK1*^8!D8[D=;]:B\TDBJZ5R]/
M-WO0 RP
M
M
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MR20HO13HJGF@HLECI[FYQ]I<WMOXI>30QR7%HKD>L4KVHKH^9."\JK2H89(
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M.\&B5T;?ZH8YVF[^"]CR%K/,VBK;R.C2C9$JC>#E\)6^"B.1043N&
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MG0*C+F1.E%?3P/5<[E3P>15,N79JN\4SLDY>29S.HM;?/^ZE:4149*]>?_\
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M:U+A-7;7:6SVG,=[D86>Q9#:8JO.EJEHJVSH6N6BN:QT:M:Y4JY./=#\RWD
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M6LIWXU]2#P+9!@        TO<WWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
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M9^QEO<WJ_)-Y+_4F9G\:OI&*J*K4=1J-151*T3F6B55:(&:I1#
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M^?.YOPO8?$UD!( 8
M
M
M                                                    TO<WWEQ'
MZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
M
M
M
M     :7N;[RXC]8]._'%J&88>A?GSN;\+V'Q-9 2 &
M
M
M
M                  -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#XFL@) #
M                                         >?GKB:TP63N[=_5SP6D
M\L3THJM>R-SD7CWE0]]/;%V6V)XIF.EJZR^ZS!?=;-)BVZGD4Z^F[<?_ (_+
M^#A]K+6_)M%_ZX\L_&H/]Q;T_P#=/DM^(^F[<?\ X_+^#A]K'Y-HO_7'EGXS
M]Q;T_P#=/DM^(^F[<?\ X_+^#A]K'Y-HO_7'EGXS]Q;T_P#=/DM^(^F[<?\
MX_+^#A]K'Y-HO_7'EGXS]Q;T_P#=/DM^)<?#3RW.'Q]S,[GFFMH9)'KPJY\:
M*J\.^JE49[8MR71'%$ROW373=ALF>.;8Z&<>+9
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M'NCO[7ZS>$8\V6;[=FZ:4CS0GP@"[
M
M        #2]S?>7$?K'IWXXM0S##T+\^=S?A>P^)K("0 P
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M.*=93AQZ S1O5O<07=O%=6TC9;:=C9896+5KV/3F:Y%[J*BU##L
M                                     &E[F^\N(_6/3OQQ:AF&'H7Y
M\[F_"]A\360$@!@
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MQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
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M&.D5O<I3@"J2-M=M=-[4Z;72VE?&/<M;B6\_MDO7R=;,C4=X5&\/!3A0,.K
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M/2:KL9,EF]4OB6VCS.=NUOKF*%W!61KRL:VJ>#7EYJ<*T5:BJ50P
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M;XZPA9;6-I$RWM;>)J,CCAB:C&,:U."-:B(B(&'>
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MU=R1-1J57A5:(1N^Z;KIF?"E5ED66Q;'@BC(/R_8
M                                   #5]9Z#PVNH+2WS,EQ&RS>^2+Q
M9[6*JO1$7FYF/[QO:36Y--,S93AY7/UN@QZJ(B^O!R-0_A\T/_><C^'B]I.E
M^>ZCDM\D_&Y?[>TWUO+'Q'\/FA_[SD?P\7M(_/=1R6^2?C/V]IOK>6/B/X?-
M#_WG(_AXO:1^>ZCDM\D_&?M[3?6\L?$]O2NTFF='Y=F:Q4UX^[9&^)&W$L;X
M^61*+P;&U?\ 2:NIWIEU%FQ=$4\7_+;TNZ<.FR;=E:^/_AOAR79
M
M                              -+W-]Y<1^L>G?CBU#,,/0OSYW-^%[#
MXFL@) #
M
M
M                                           &E[F^\N(_6/3OQQ:A
MF&'H7Y\[F_"]A\360$@!@                           !Q9(R1O-&Y'M
MXI5JHJ53@O0!R
M
M
M                   &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
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MQDB<\CH8(TBF=$U?%VHYC)(VUY74\) )$
M
M
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M$*VT;U5RJG+$KY.6C:)Z9>^!G
M
M
M                &E[F^\N(_6/3OQQ:AF&'H7Y\[F_"]A\360$@!@
M
M
M
M                             #2]S?>7$?K'IWXXM0S##T+\^=S?A>P^
M)K("0 P
M
M
M                                          !I>YOO+B/UCT[\<6H9
MAAZ%^?.YOPO8?$UD!( 8
M
M
M                                                        TO<W
MWEQ'ZQZ=^.+4,PP]"_/G<WX7L/B:R D ,
M
M
M
M         :7N;[RXC]8]._'%J&8:EA=09S#[A;D08O2>1U!#)E+![[K'W&-A
M9&[W'LDY'-OKNV=S<*U:U6\>FH&T_+?5_P"[7._CF _.@8/EOJ_]VN=_',!^
M= 'RWU?^[7._CF _.@#Y;ZO_ ':YW\<P'YT ?+?5_P"[7._CF _.@#Y;ZO\
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MYW\<P'YT ?+?5_[M<[^.8#\Z /EOJ_\ =KG?QS ?G0!\M]7_ +M<[^.8#\Z
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M= 'RWU?^[7._CF _.@#Y;ZO_ ':YW\<P'YT ?+?5_P"[7._CF _.@#Y;ZO\
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MYW\<P'YT ?+?5_[M<[^.8#\Z /EOJ_\ =KG?QS ?G0!\M]7_ +M<[^.8#\Z
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M= 'RWU?^[7._CF _.@#Y;ZO_ ':YW\<P'YT ?+?5_P"[7._CF _.@#Y;ZO\
MW:YW\<P'YT ?+?5_[M<[^.8#\Z /EOJ_]VN=_',!^= 'RWU?^[7._CF _.@#
MY;ZO_=KG?QS ?G0!\M]7_NUSOXY@/SH ^6^K_P!VN=_',!^= 'RWU?\ NUSO
MXY@/SH ^6^K_ -VN=_',!^= 'RWU?^[7._CF _.@#Y;ZO_=KG?QS ?G0!\M]
M7_NUSOXY@/SH ^6^K_W:YW\<P'YT ?+?5_[M<[^.8#\Z /EOJ_\ =KG?QS ?
MG0!\M]7_ +M<[^.8#\Z /EOJ_P#=KG?QS ?G0!\M]7_NUSOXY@/SH ^6^K_W
M:YW\<P'YT ?+?5_[M<[^.8#\Z /EOJ_]VN=_',!^= 'RWU?^[7._CF _.@#Y
M;ZO_ ':YW\<P'YT ?+?5_P"[7._CF _.@#Y;ZO\ W:YW\<P'YT ?+?5_[M<[
M^.8#\Z /EOJ_]VN=_',!^= 'RWU?^[7._CF _.@#Y;ZO_=KG?QS ?G0!\M]7
M_NUSOXY@/SH ^6^K_P!VN=_',!^= 'RWU?\ NUSOXY@/SH ^6^K_ -VN=_',
M!^= 'RWU?^[7._CF _.@#Y;ZO_=KG?QS ?G0!\M]7_NUSOXY@/SH ^6^K_W:
MYW\<P'YT U/<'5^J+G$XQD^WV9M&MSN"E9)-=X1S7/BREL]L:)%D9%YI%3D;
,5$:CE3F<UM50R__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>fc_abcdaiassure-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_abcdaiassure-4c.jpg
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M%!04%!04%!04%/_  !$( U\%(P,!$0 "$0$#$0'_Q #H  $   <! 0
M         0(#! 4&!P@) 0$  @,! 0$              0(#! 4&!P@0  $#
M P(# @<'# \%! <##0$  @,1! 42!B$Q!T$346%Q(C(4"(&1<I+2%1>Q0E*R
M(S/3-%15%E:AP=%B@J)3D[-TE+0U-C=#<Z,D&(-$=2?APF,E1=57\/'#9-2U
M.";6XH1E1F:F"1$!  $#  4'"04&!0,$ @(#  $1 @,A,1($!4%1<:'1$Q1A
M@9&Q(C)24P;PP3,T%>%"<I*R%F*"TB,U\:+"0],D5.)CLP=S@Q?_V@ , P$
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M+%-444RRAHK511*6>!*HHCH2I1$,4531,(TJ41[I*E$A@/--HV4HC';535%
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M[GIMS%YJKUZ4-4H<F]ID4Z.Y3^NV']*5U>$_F8Z)<;C7Y2[IM];PPO<OFSZ
M]"</B/HFVE=?-UH;F6RURSFWB,CG][(-3G%M2?&OGW$<EWB+XK.OG\D/J7#,
M=D;M92(U<WE;GF-D;.W!;OM<WM['7T,@(/>VL6L5[6O:T.:?&UU5IV;QELFM
MMTQYV[EW;%DBE]L3YGB;K_THL^E^Y[3YD=([;6;B?<8^.9VN2"2%P;-!KYN:
MW4US''CI=0U(J?;<,WV=XQSM>];K[7SWB_#XW7)&S[MVKR<\?;]L\WV[G+W;
M.?Q>X<<\LO<7=174)!I4Q/!+3XG"K2/ 5TLN.,EDVSJF*.3@S78KXOMUVS5]
M,W"*4"6'C#*ULD=/L7@.'[!7S.)F'UUKF^=VXO8&ULANO+C7;V3 (+8'2^XN
M9/-BA:?WSN9[&U/8MG=\-V?)%EO+U1SM7>MXMW?'.2[DZYY(?/7=6Z<UO//7
MFY-P7!N,G>.JXCA'&P<&11M^M8P<&C]M?0L&&W#9%ML:(?+MYWB_/?-]\Z99
M_IITKW+U0RDEGA@RUQEII.3R]P#ZO;M=R'#B^1U/-C;S[:#BM?>]]LW>VMVF
M9U0VMQX?DWJZENB(US]O4]6[7]G?I=MJ&,W>-=N'(M [R\RKG.87=NBWC+8V
MCX6H^->5S<3SY)T3LQY.W_H]K@X1NV*-,;4^7LU>MN0V)L)C!$W:F&$8% WY
MOMN7Q%J^)S?'=Z9;?@MW^79_+#7<YT/Z49^-S+C;<%C,X<+K%N?92M/A 83'
M[[%GQ[_O%FJZO3I_:P9>&;MDBDV1'1H_8VW:NWK#:.W<9MC%E[L?BH>X@?+3
MO'U>Y[GOT@#4YSB30+4S9)R7S?.N6[@PVX;(LMU0X][6W^0<#_XP?[L]=?@O
MXUW\/WN%]0_@6_Q?=+QZ[@T^1>O>$A]!MB;&V/!LW;=RS;&)-U<8JQFN+B2R
M@EEDDEMV.>YSY&N)))J5X#>=YRSEOC;NIM3RSSOIVY[I@C#9.Q;6;;=-(KJ9
M>^V%L+(,[N]VIAYF4I^(P,('B=&QI'N%8;=YS6ZK[O3+8NW/!=KQV_RPY=O7
MV8-C9V"6?:+W[:R]"8XR]]QCGN\#V/+I(P?LF.-/L2NGN_%\MD^W[<>B>QQ]
MZX'AR17'[$^F.W[:GDO<^V,WL[-W6WMPVKK3*6AH]A\YCV.XMDC<.#F.'%K@
MO68<UF6V+K9K$O$[QN]^"^;+XI,-@Z6]2,ETTW+'E8"^?"W.F'-XP'S+BVKS
M Y"6.NJ-W8>'(D+7WS=;<]E.6-4\WVY6SN&^W;MDVOW9UQSQ]M795[R@DM;^
MUM[^PF;<V%Y$RXM+AGHR0S-#V.'E:0O#S6)F)T3#Z1%+HB8TQ.F%6)]U;:A;
M2.CU\"&^'LX*)BV=:T5C4ENL7>PM]8N(R!(:EQ-34_9>53;EMG1"MV.Z-,K<
M6$S^+8G.\8:2K[<*;$I'6CXS1[2T^,44[<2C9HB(/$FTG95&PD*M4T1N+.TO
MK&YQ>2MH[W$WT;H+VRF%8Y8GBA!\'B(Y'BJUF)B8FDQJE:;8F)MF*Q.N'()O
M92Z<S7AOK+(97U$'6[%=[%P%:EHF,>O3[E?&NK'&<T128BO/I<2[@.[S.U$W
M4YM'8Z'9X;'8/'6V&Q%JRRQEC&(K6UCKI8RI/:22227.<XU)-2M6<DWS-UTU
MF70MQ6X[8MMBD0M+IG@6:V6&^&+F8%L1+7NA92 $D>XLL,,KR];IV]BV@4#I
MIGD>3@L5GXMW1#+?^%;TRQ2V&LF8:%1*89"$\EAEGM7\1\U899X5% (")01"
M0BBD04H1H2A0(HH$%*%WC\%E<P7NQ\&N-GI2O.B.O@#CS/D6+)GLQ^]++CPW
MY/=ACY+"^?(^*.W>]\;BQU!YNIIH>*SQ?;2M6&<=TS2(/F*\'G7#HK=I_E7@
M?L!._MY*R=Q=RTA*ZQQ,'XQ?&4]K+9M?V2FW?.J/2B<=D:[O0E-SAH*=Q8.G
M(Y/G>0#[@4[.2==U.A&UCC5;7I'9RZ#=-K%%;-[.[:*^^4[FWEF9._NY(B%E
M/>WMQ^,3O>/L2X@?L466VRV-4,-U]UVN5OIKQ5ZJ40"E"M&T$UHJ2O#(0CA0
MK#+/:K::4*JNFH% @0@CS""2E.!4@@<Q1!"E."E":E150E*%*%:,FJK*T,C'
M1H#G>\M>6S"9QJ0>Q($R@$$K@I@2J14B]./X;?M@JR1K;1O;\8LO@/\ JA:&
MYZI;V]ZX:N M]HB @("!1$T7>,<UN3LG.(#1/&23P &H+'D]R>ADQ^]'2R]O
M!.-U%QB>&BYD>7%I#=)U&M:4HM:ZZ.YU\C/;$][JY6')!ED(X@O=0^5Q6SR,
M$ZPH+^RQ5Q>,[UI$<1Y./;[BQ7Y8MT,MF*;M*%YBI[)G>&CX^1<!R\J698NT
M%^*;=*R[5E8D5 D<?V%9"D_DK0K+:_\ Y$N=_K;W^A#,_P")3?P/M IP^Y"V
M7WE@LK$(" @((4'@0. \2"*"%$10HA1*[@5(-1"9 00(!-.U!'2YO!S2T^!P
MH42ASYH@H.=!7D@4""724$"*=E5(G9WH] 'R'DHFB8JRT->Z9JYTXK7G6V;=
M2=52B.:"SFDC;*X$A9(B:,4S%4L<D;Y6,#@-1 U'LJIF)H1.E&[(LYG0=X):
M<0X>/L2WVHJ73LS1;FZH>55?94VDING$UHIV4;24W3RFS!M)?6)?"%.S"-J4
MAFE/$NY>!32$5E2>]]?2/OJT0K,JENZ"KQ<ZRW2=)::><HNB>1-M.53: K*H
MT'@1*-*J!%0D0"%(E1 @(""([4$*"M:<?"I!0""5S2X@J4)'#20I1**)$!$(
M$>!!*@%$*D,CHI!(VO#@:>!1,5A:)HR4C3*UMS 2V9@X.;P/CY+!$TT2S3%=
M,+, ZB7<^VOA65158T$\0JRE=L:*K'+)"[B9R6*99(>(?:9W/^D/5.]L(7ZK
M+;L,>)AIZ/>LK).:>'O'N;_!7MN$8=C=XGENT]G4^><<S]YO,Q&JS1V]<]3)
M>RCMMV8ZG_/3V5M=NV<UV7.%6^L7 ]7B;Y:/>X?!6+C6;8P;/+=-/O9OI_!M
M[QM\ED5\^K[^I4]K';+L/U*CST;*6FX[..X+P*-]:M0()1Y=+8W'X2C@F;;P
M;/+;/5K3]08-C>-ODOCKC1/W>EHO1?=;=F]3=O9F9^BP?<"QOR?1]6O1W+R?
M$W4'^XM_B&'O<%UO+2L=,:7.X7O'<[S;=R5I/1.C]KZ&R1Z7.:>;20?<7SR)
M?4)A3TJR'(_:<%.CN4_KEA_3+J\(_,QT2XO&_P I=TQZWA5>[?-7T1Z#BO1[
M9W]1_P#QI%\ZXC^9OZ?NA]7X;^6LZ'11&7&@%2N=5TJ/%?M7;\Q&Z-T8K;>%
MN&7D&VX[AMY=1$.C]<NG,UQ-<*AW=MC;JI]<2.87M>"[M=CQS?=HVZ>B/^KY
M_P#4&]69<EMELUV*UZ9IH\U''MC;4OM\;NQ&UL>PNER%PQDKP*B*W:=4TKO$
MQ@<Y=G><\8<<WSR.#NF[7;QEC''+/HCEGS:WTO>Q@-(P!&T!K .%&M%!^POF
M</KCR'[7N['W.?PNQ[>3_E,9!\Y7S 31UU=U;&'#PLB;4?#*]?P/!2R[).N9
MIYH_;ZGA_J+>)F^W%&J(K/3/9'K><;2TN<A=V]A91F6\NY66]O$.;I97!C0/
M*2O2771;$S.J'D[+9NNB(TS+Z,[)V;C^GVU,=M+'!I;9,U7MPT4-Q>O [^9W
M:=3A1M>30!V+YUGSSGR3?/+J\D<D/JNZ[M;N^*,<<FORSRS]N1F7N6*&>5#4
MKT51!4"HWBH3#A/M:FNP<#_XP?[L]=O@OXUW\/WO._4'X%O\7W2\?.]$^0KU
M[PD:WTCV6:;'VM_X-CO[K&OG.\?BW_Q7>M]7W3\#'_#;ZF9)';R6%L,A>"Q%
MJTQ%O>"G=AOI'PU6&S:KI9;MFC@WM,;(M]Q["=NB"(?/>V")A*!Y[\?,\,FC
M)[0QSFRMKR\ZG-=_A.\3CS;$ZK_7]M'H>;XWNL9<&W'O6>KE]&OT\[Q:O9OG
MSVO[,&X'YWIE\UW#]=SMV\DLF5XGU6<=_$./@+I&CQ!>*XOCV,]8_>BOGC1V
M/H? \TY-VI/[DT\VOM=&WMN5^Q=J93>,>/=DW8>-L_J3'B(O#I&QZB\AU&MU
M:G4!-%SL&+OKXQUIM<KJ[SF[C'.2FUL\CR+NGVGNK.Y'R,M,C%@+%_*VQ<36
M/ [*S2ZY*^'2YH\2]9@X/N^/7&U/E^U'A\_'=YR3HG9CR?:9<[NM];VO7F2\
MW+E)I":U?>SG_P!==.-WQ1JMCT0Y4[WFG7?=_-+)X;JQU*P$C9,;NG(!K:?<
M;B9UU"0.PQSZVD>XL63<L%^NV/5ZF7%Q'>,<Z+Y]-?76'I7HYU[M=^WD6UMU
M00X[=<H/J-S -%G?.:*F/22>ZF(XM:#I?R%#0'S>_<.G!&W9IMZX[8>NX;Q:
M-XG8OBE_5/9/5/D=O[GQ+BU>@HU3JY?93;72G<>Y<-<OLLQ9Q0.LKJ.A=&77
M,3'$:@1Q:XCDMC<HMR;Q;9=%8FM?1+4XA==BW:Z^V:3%*>F'CKZ>^L-:_I;=
M@CP-A_!KV/Z9NWP0\'^L;W\<]78]5=&LOD][],\7F<_?NN]QSS7;);N8-#I6
M13%K 0T <!P"\OOMD8,\VVQ[.A[/AV2[>-WMNOFMVG3YV8OH)('NBF:62#ZT
M]H\(*FRZ)C0O?;,:)8>X'O+9M:ES'R#G19H899'+C3A\*P=K9''W:+#B_$O9
MLWX=C"E;34!P*"^@=P"PW,]K(1.6&6:%956$$0BT!"$PE)XT[5*J9L,LII$P
MN/[T559F(6BV97$>*OW_ .ST-/USSI5)RVPO&*Z50XVWAXW-ZQGA:WSC[BCO
M)G5">[B-<IH'X"&XC,\<MU '?=N/, <J<.9471EF-%(E,3BB=-9;-MW<L^4S
M4=A#;LM,='#(8[=G9II2M*#M6AO&[19CVIFLU;N#>)OOV8BD4:3E<A?R75TP
MW#@P32!K6G10!Y\"ZN+';%L:.1R\N2Z9G3RL*]SGDF1Q>3VN)/U5M1H:LZ5-
MPX*RLP'L1"!\(0$$*(&H5([1Q]Q*"O  ZE#Y%6Y>UD&#DL,L\*C^8586E%$"
M"""4\U(@@(':@B*:?$4$ VO!HXI47#0(:$^EX%36O&A4;*YQJ2HHM$KF,Z@%
MCEDA554B""!1!%GFEIYEI!]XU21D,OF)LP^)\T38C$' :"3753G7R+#BQ1CK
M26;+EG)KACF\.:S2Q0F1*!1$B($"J)JBB5UZ[?.B[EUU,8:4,9D<6T\%*K'L
M6UK2%]JZE*RD90"BF4)CP'A4);G9F,VL190MTBA"YE]:RZ5NJ$MZYC;28R>C
MI*6>]!?JEIX_:73<T*"F2K(7F-QUK?QW;[BY]7= VK!PX\":\?(L63)-DQ2*
MU9,>.+JUFC-:O'_\!KR6K_K;'^A-F6DY*;^#]H%&'W86R^\L-)69B-)0-)00
M0$!!EL.+/2\S:#,'<&R<M%.:U\VUR,^*G*QUT(A<RB$UBU>:?$LUM::6*ZE=
M"DK*B!2I I4G@/=059[9]MH#RTEX)\PZJ4-""1VJMMU5IMHH\.7U!5650()/
M#@I0G@>(+B*5XUACP2WL(\"BZ*Q,)B:35>96_COC'W;"TLJ-9I4U[."Q8K)M
M9,E\7+"JS,**" J30!$JH@<34\!X%7:3LJ@B8*5')5JM1.7,;R*A*>"[C:[N
MW'S?"HNLE:V^%T-+J$&H6-D0=(QO:*^ *:(JQEQ 7.,@XD\2L]MS!="VIX0K
MJ%!Q-.)[4$**4" @@@(%!X$$"T'L%%-44*40*((J$HH" @A1!"BE"" @B$$>
M"A*4\^')2@0$"@/,*1*YM40E4@@(($>!$ ""<-H5"5S:S&)Q!]!W-8[HJR6S
M1<3P 4D9Q!YJEMR]UJ1C:$*95A=1CBL<LD)<OF;;;>#R6XKVGJN)M9KV0$TJ
M(&%P;Y7$!ONJ+,<Y+HLC]Z:&3)&*R;YU6Q,^A\TKZ^N<I?763O7F2\O9I+FX
M>>;I9G%[C[Y7TJRV+8B(U0^29+YONFZ=<R]J^R5M8X?IU=;CF86W6Y+QTC''
MMM+*L,?\?O2O$\;S;>>+.2V.N?V4?0?I_=]C=YOY;YZHT>NJM[5^U?GSIHS/
M0LU7FVKMER7<SZI=4@F 'PC&\^)JKP7-L9]GDOCKC3VK<?W?O-WVHUV3U3H]
M=)\SPX>7 T/85[I\Y?2#I?NG]-NGFW=R/?KN[FT9#?.)J?6[7[A-7P5<S5[J
M^;[WA[G-=9R5T=$Z7UC<<_?X++^68T],:);70K5;KD'M/"G1W*?URP_IEU^$
M?F8Z)<3C?Y2[ICUO":]V^:.D[>Z^=5]JX6SV]@LZVUQ&/C[JTMS9VDI8RI=3
M5)$YQXGM*YN7AF[Y+INNMK,^6>UUL?%MZQVQ;;?2(\EOWVK/<76OJKNJWDL\
MSNB[?9RC3+;VW=V<;VGL<+9L=1XBK8N';OCFMMD5]/K5R\5WK)%+KYIYH]5&
MG8JRM\AD+>QN;Z#%V\SPR2_NQ(8(0?KGB%DCZ>1JW;[IMMF8BOD:&.V+[HB9
MI7EG]E7O7H=TNV1L; C,[:R$.XLGE(PR\W'$YCV/9P<880TN[M@-"YI.HGTN
M0 \#Q'?,N:_9OC9B/W?OGG?2^&;AAW>S:LG;F[][[HYOM75#JI;X%RG9?/#K
MYD),GUBW;/*:F&\%HWQ-M8F1 ?Q5]$X9;L[M9'D]>E\NXQ=M;W?/E]441Z!8
MV/*=8MIV\H!9#=/O*'CYUG#).WWBP)Q.Z;=VOF.;UZ$<(MB[>\<3S^J)G[GO
MB7M/OKP</I<K-Y66&.5%U:\%90:42K1JDK0X7[6O^0<#_P",'^[/7;X+^-=_
M#][SOU!^!;_%]TO'SO1/D*]>\)&M](-EG_\ 8?:W_@^/_NL:^=;Q^+?_ !7>
MM]6W3\#'_#;ZF8)XK$V$!X$&-W9:Q7NS]QV=P-4,^)OXWCQ&VD/U0KX;J9;9
MCXH];%O%D78K[9Y;;O4^;3.+&GQ!?1WR:=;U3[&TCW1;VMB?N0^;90/WY-PW
MZB\KQZ/PY_B^Y[/Z;F?]R/X?_)Z5R^)MLUB,CA;QNJTR5K/93C]Y<1F,GW*U
M7FK+YLNBZ-<3$O6Y,<9+)MG5=$QZ7%-G>RCL3"PQ2[LGGW+DAQDC#W6=B#X&
MLC(D=3PN?Q\"[6?C.:_W/9CTSV.#N_ ,%D5R5OGT1V];H3.C72J.#U=NS<7W
M=*5="7/^.7%W[*Y_C]X^.73_ $[=OEV^AY\]H7H5@-GX9N]]EQ/L\:R>.WRN
M*+W2Q1]_4,FA<\ES6ZO-<PN/,47H.%\1ORW=WDTSR2\QQCA5F*SO<>B*Z8Z>
M5YSM[FXL[B&\LY70W=L]LUO,PZ7LEC(<US2.1!%5Z2Z(F*2\G9=-LQ,:X?2/
M9V>&[]H8+=% ),M90W,[6\ V=S=,H'B$@<OF^?'W62ZSX9ZN1]8W?+WV*V_X
MHB?/R]; ]?W-=T,W4!S;!;@^47<*S<-C_P"79Y_5+7XM^3O\W]4/GJOH;Y8]
MJ^S_ %^B#"D<"+B^H1S_ !AR\=Q'\S=T1ZGT'A/Y6WIN];I+[VVO6>J9,<3P
MCN1P(/C7/BR;=-OH=2;XNBEWI8'+8VXL'5>-=N[T)AR/E\"W,62+NEIY<<V=
M#!3"G'LH5MPT[F1S@TV&'8#4"$GWZ+!A]Z_I9\_NV=#".%#Y5MPTP-H#5*BX
MA/$*DLEK(Q.%/!XU@EGA=M8Z2G=M+N'8"L=:,M*ZES%C+Z7B(2&_9.X*DY+8
MY62,5T\BNW$N9QN)XXV^#F53O:ZH7C%37*'<XF(G7,^8C@0T<*^5-J^>2ALV
M1RU0%[90G_E[,$CZYYJ5.Q=.N4=Y;&J$C\K>NJ(W-B;X&M"F,5O*B<MTZM"T
MDFFD=]TD<^O.I-/>62(B&*;IGE2  <@K*I"*<T&P;(!_2%AIP[B7_P!5:>^_
MA>=M[G^+YFMY"&1U[=4!^_2T^.5O8YC9CHAHY+9VIZ961M91V++M0Q[,I#;R
MCFU3M0KLRIECAS:K55HD=P-$0A3A5$"D9QMY<XS;-E<6$IMI[B]N!/*P-#WM
MB8S2"2":"O+DM38B_+,716(MAM[<V88FV:3-TJF?@BBW#D&1,$<?>-(8T4:"
MZ-KC0=E2:J,%TSBMJMGMB,MU/MH6[ KRK"HH62HJB@()2*J1*@F;VA +0>?+
MP(*T\TM[)&X@N>R)D3G'C71455(B+8\Z\S-T^9&K+<<.,B:SW5 O+G5(XE7H
MI5-&]1,)B5W%)3A58YAEB5R' \:K&R,O98&:[B$TK^Z8[BUM*N(6M?GBV:0V
M;,$W164M_@YK.(S1N[V-OI4X$>XIQYXNFB+\,VQ5B:FJV&NG4)*(401 *CF@
MB@@0:\%(BH"B)HBB4[>2K*856<BHE9$J!>V>3N;-I9'1T78UW8L5^.+F6S)-
MJ%WDKF]&B0AL?V#>2FS'%J+LDW+3M61C3,8Z5[(F^D]P:VO*I-%$S32F(KH4
MYXNY>T:@]KVA[7 $5:ZO8?(K6S56Z*+9XKP5X4EM^H>/_ J^XN;_ *W0_P!"
M;,?XC-_!^U"8?=A.7WEBLK$(""%!X$"@\"!0()=)4AI*"!%$! 0599&OBMV-
MK6)KFN\%2XGA[ZK$:96F=$+G&W5K;/D-R*:@ UU*T\*IDMF[4MCNB-:UG>R2
MXEDC;I8YY+1XNQ9+8I$*3-94U*!!$1.<?*E2BJV!H(JJ[2VRJZ6@5'!5JLD,
MS6@\:T4T151?*YW+@K1"DW*=2>:L@TCP<40O(B1&WBL4ZV6-2VE>6RDCPK)$
M:%)G2KQR!X\:I,+Q*E/ ?3;S[0K6W*W0MZ&M.U74321NB>Z-XH]O @&H]\*(
MFJ9BB6@4H"VHJ.5$$JE @(""""*"9HJHE(11!*I0(" @E(4H001""90E*X5Y
M<%*$NAWA4U10;R014)$"BD2$44H001#2H$]*J$HT0344)7UI*".Z?Q'97DL-
MT<K+;*=T6@_O>PJ*U3,45H@JRM#C7M3;H^9.FT6!A?IN]RW;('-' ^J6=)Y3
MY"[NFGRKK\'P[>?:Y+(ZY^TN%QW/W>[[$:[YZHT^NCQ2:D$#@?"O:OGKV-M7
MVH>D>UMM8C;=KCLX8,59PV;7-M;8!YB8 Y_XSS<ZKCY5XW-P?>,F2Z^9M]J:
M\O8]U@X_NV+';9%M_LQ$?N_ZE;/^U-TAW%@\G@+W'9WU/*6LUE.3:VIHR=A8
M7 >M<Q6H\:C%P;><=\71-M;9KKG_ $K9>/[KDLFR;;Z713]WE_S/&8%.%:TX
M5\*]F\&]:>Q[NGO\9N+9$[ZR6DC,Q8LYGNYJ0S@> -<V,_PEY+CN&EUN2.7V
M9]<?>]O].;Q6V[%/)[4>J?1H]+TW1>9>O<>]I\?^3F3_ *Y8_P!,NOPC\S'1
M+A\;_*7=,>MX17O'S1ZMZ9^S-L'>6PL#NG*Y#+0Y#*6W?W$=M-;MA#M;F^8'
MP.(%&]KBO)[WQ?-BRW66Q;2.GM>VW3@6#-AMONNNK=')L_Z68S?L:[8D@)V]
MN2_L[@M)C%_'#=1D]@=W0A< ?%58<?'\E?:MB>C1ZZL^3Z;Q4]B^8GRTGU4>
M:>H?37=/3',MQ&Y8&ALX<^PR$!+[6ZC8:.,;B :MJ-3' .;4<*$%>FW7>\>\
M6[5GGCEAY'?=QR;K?LWQT3R3]OMR+GI?U1W#TMS\64Q4KYL1,]HS&'+B(+J$
M'CPY-E:*]W(!4'PM)!IOFY6;Q92=?)/,R;AO^3=<D3;/L\L<D_;DGDZ*Q/T4
MPV5L=P8RPS6)E$V.R4$=W9R\M44K0]M1V$ T(["OG62R<=TVW:XFCZECR6Y+
M8NMU716'SRZX6S[3J[O&*0$%V1DF /V,S6R ^Z'+Z)PV:[M9T/F'%K:;W?T_
MM7OL^7T6/ZR;4FF-&37$MJ"?LKJWDA;^RX*G%+:[M?T>J:K<'F(WNR9Y_7$Q
M][WI*.:\)#Z5*SD:LL,<J)"LJBUJ"LP4HJ2O#AGM;BFP<#_XP?[L]=K@GXUW
M\/WO._4/X%O\7W2\>.]$^0KV#P<:WTAV6W_]A]K?^#X[^ZQKYUO'XM_\5WK?
M5MT_ Q_PV^IER%A;  :A2,+OO(QXC86Z<I*0&VV)O2VO"KY(71L'NN> LN[V
M[6:R/\4,&]W[&"^[FMGU/G"T4:!X OHKY1.MZU]C:Q<S%;QRC@=$]Q8VD;NR
ML+)9'?;M7DN/7>U9;TSZGM_IO',6Y+N?9CT5[7IP 4)/  5)/  #M*\P]>X5
MO_VI=E;5N)L7MBW=NC*0ES))X9!#CF/'#A-1QEH?Y-ND_9+N[MP?+EBM_L1U
M_L>=WOCN'#-+/;GJ]/+]M+BN7]J_JM?R.=CG8[#1\F-M;03. [*NN3+4^Y[B
M[6/@N[VZZW=,]E'GLGU!O-U=FEO1';5I>Y>M/4_>&)NL%N/<$E[B+S1ZS:=Q
M;Q,?W3VR,^]QM(HYH/ K>P\/P8KHNLMI,=/:YV?B>\YK)LOOK$^2/NAH2WW,
M?0#V>"Z3HIM1SS4AMZT$_8MO9@ O <4T;U?YOZ8?3>"S7<[*_P"+^J4W7^HZ
M,;N /FF"VJ/_ .<A4<-_,V>?U2OQ?\I?YOZH?/U?0'R][6]G\?\ D_A?ZQ??
MWAR\;Q'\S=T1ZGT+A/Y2WIN];=;L<Z\5@L;EZC;962RK;SM]8LG<'1'FT>*J
MM=BB[3&B5+<LVZ)TPV"PVIC&R"\E896/\Z.%_H,!\7;[JTLF]7TI#=Q[K96L
MK_(8+&Y&$0S0BC11CF^:YOD(6''GOLFL2S9,%E\4F'.[S;N1M[V6UBA?.UA\
MR6E 0>2[=F\6S;69HX=^[WQ=,1%56/:V0+=<\D=LWMUFI59WFWDTK1NM_+-%
M9N,P=J:761[U_:R'E^Q55G)DNU6KQBQVZ[ES%>X6W-+:T=(1R=)R/CXK'-F2
M=<LD7XXU0K_/,U*00QPCP@5*KW,<LK]]/)%%"2]NY/2E/'P$A6BRV.16;[I6
MY\XU=Q/A/%74%(("" :7&@16%5ELYY[56;EHM73+(4J1[ZQS>RQ8RN%G9B;X
M7CHC( QS-+: ^=3P^1:^:.\MHSXIBRZJRF@;)-++IH)'N> >8U$E98NI%&.;
M:S53]4:1R4[:-E3-DPCDK;<J[$+>3&L<.2O&12<2QGQE.(%5EMR,%V)CYK5\
M?)I([5GBZK!=9,+<UKQ%**RB]L\I=6L'JK6PS6P?WS(KB)DS62$4+FZAP)IQ
M6*_%;=-=,3Y)HRV99MBFB8\L55'7$]W/)=73S+<3.UR2'F2?(HBV+8I&J%MJ
M;IK.N5=O)573JJR"E41(B$$$I([%(-[4%1D;I' -%1VGL59FB8BJL][(1W</
MI<B56(KK7F::EL:ZZGC59&-&G@4"721Q4BJQZK,+1*\@D;WC-9\W4*^2JQ70
MS6RZ,VFENGE3AY%Q)=J$LVGN7ZZ:=)K7R*8UDZFAT;V<NQ==R (0BB4$0(@"
M)@HA01"*+""<&IX*!48565DQ4)1KXN*#)6^'GN+6*\AI*)'Z3;MX/T@^<:E8
M+LL1,Q+/;BF8K"ADGV;[L^HQ.AB:-+F.^S'/M*OCB[9]J:J9)MKH69) U T(
M-01S!"R,:E-*^1Q?(XN>>;CX K1%%9FJDK*MOX^'_P"!+F_ZW0_T)LQ_B,W\
M'[4)A]V$Y?>6*RL0@(" @(""*+% H$*!2)=)4H0(HB$/&@K26EQ$ ^2,M:ZA
M!/:%6+HE:;9@;!7BXI-Q%JJ(FMHJU6HBZ1C1R 2()E1=-PH**U%:J1<XUJ>'
M;16HJNLA;6ENR!ULXN>^A>T\P*<Z%8\=TS,U7OMB*467U>U96)% 074?H!8Y
MULL+>3TRKPI*4$M.IO-2A=1R"1OC[5CF*,D352F@-"X#RJT7*S:H/<Y[BYWI
M&E?<%%:%92J4)QR4 6BG)!3+2%-4(*00$ <T%5HHJI*! +13D@IN%*!60@@(
M""%$  H*T-I=7 >Z",O;&//([%6;XC6M%LSJ41^R.!\H5E44%-_ @#@K0K*:
MBA*" @4!4B  ""8"J@14)10 B5>/E4<U25H9*%PFCTN](+!.B6:-*+6Z742J
M7B_VIMS_ #WU*^9('ZK/;=K'94!JWUJ;[O.?*"YK#\%>QX-AV,&URWS7S:H^
MWE> X_GV]XV.2R*>?7/9YG)MN[;SF[<O#@MN63\AE[@/=#:QEH<6Q-+W&KR
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MN':%U.';Y&[WS%WNW=4\_:XO%=PG>K(FWW[>N.;L\[Q9=6MS8W,ME?026MY
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MS:-#+&+G6-]%!%=%MN:LH*@&H![0LUDS,:6.^(B="! YTXH+8M:2:BO%743
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M4@LB32MW/]Q@'\X]JB="8TR^;W1;HUENM>>R6+LLBS&18ZV];NKZ>-TX+Y)
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M>:O<7$<J\5:BE6L=1[/*97I_NK&8:$W68OL1?6MA "UIDN)K=\<;=4A#15Q
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M5%G85)SJE2A(3Q4JB"(*)5%"4[>2A*HUI*K,K*C645:IHG[NHH>2BJU%O-;
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M?*3P.'X?6G]<WWYD^B.Q ['VB.>+9\>3Y2>!P_#ZT?KF_?,GT1V(C8^T#_\
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M?]S8I/4RRUV<0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!2GN(
M[9@?*2&$AM1QI5!.Q[)&A['!S3R(XA!,@(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @Q^9_$Q\,?4*#"V]U/:NU1.H.UIXM/E"E#-VF5@N*,D^Y2^ ^B?(
M5"5^@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @("#'YG\3'PQ]0H-?4H$%[:9
M.>VHUQ[R+[$\QY"@S=M>073:Q.\[M8>#@H2N$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$&/S/XF/ACZA0:^I0(""+7.:0YI+7#D1P*#*VF9<VC+H:F_R@Y^Z
M.U!EXY8YFA\3@YI[0H2G0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&/S/XF/ACZ
MA0:^I0(" @(*D%Q-;OUPN+3VCL/E"#-6F7BFHR?[G)X?K3^XH2R7/B$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$&/S/XF/ACZA0:^I0(" @(" @N[7(7%KP!UQ?8
M.Y>YX$&;M;^WNA1ATR=L;N?N>%0E=(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M\J<4 @CF.7- H3R!X<2@ $\A5 H13Q\D @@T(H? 4! 0$&0M,M-!1DWW6/\
MC#W>U!FX+F&Y;JA<'>$=H\H4)54! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$%*XMH+N%T%PP21/YM*#GUW8V\6:DL6 BW:\@"O&FFO-2JO(\+
M:RDANH4\+BB4_P P6_C^.?W$#Y@M_'\<_N('S!;^/XQ_<04?FJS\#_C*0^:K
M/P/^,@-Q-HYP: ^I-!YR@3R86UBH':C7E1Q_<06=I8V\N:CL7@FW<\ BO&FF
MO-$.@V]M!:0M@MV".)GHM"A950$! 0$! 0$! 0$!!C\S^)CX8^H4&OJ4" @Y
M/UQ[FT?L#<6;MGWFPMO[A%]NR)D;IXXH3 66US-&T$NBAD)+N!I5$L9U#ZDX
M#<MYM&RP6]([7IW?9.:UWSNK!78@?:N]5,EA:RW;6U@CN) X%X(]&E0@T0[T
MRO=[3M<WO?*8_IW<[LSN'L=W&X=;7.0VY;V<;H))KDMJ]HE+XVW) .GS@134
M@N;3?VY]G;=BZF',9+<'3?;FX<QM^WGN7.F=D\'<VU,==REU.^,-Z.Y;/2KF
MNIV()KJ^R^"-KMKJUO[-;9=CMHQ9W%Y"*\=:RY'<-T^2:Z:Z4#_F'VKG,@BM
M.-6CT35!C<GGNH>;Q.ZLYF-S9G!9[;6R,%N5N-L9_5(1F'QR%SYX2WE(&ATL
M- TN<:BK10+O<NZNH>S';DM,!N'*9BXR.S\)NJYN+Z3UB:QGO[]MO?7-HUD3
MA#&R%Q(8R,MC](#S4'2>B-_F+UVY>\S]AG-K,?:.P\-GG9-SW%C.]C^_9+>2
MP0/T2T$C&.!+34<.2$NLH@0$!!-'(^)P?&XM<.1'!!E[3,@T9="A_E!R]T(,
MLUS7M#F$.:>1'$*$HH" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MVUW!=-K$[CVL/!P]Q0E70$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!
MH-__ )EF^&?M%*&6M.;_ "!!<J 0$&.4@@FC^^,\H05KSFSW4&)L/\RP_#'V
MB#?E"1 0$! 0$! 0$! 0$&/S/XF/ACZA0:^I0("#G&;DRG5+==_TNV[=2X_:
M6'#&]0MP6Q+)I'S#4W#VDH]%[F^==/;Q8TZ>9H27:<-A<5MW%6F#P=G%88BP
MC;!:6=NT,CCC;R  ]\GM/$J!?(" @(+>_L+'*V5QC<G;17F/NXW0W5K.QLD4
ML3Q1S7L<""".8*#A-K:W?1/=5CLZ\F?-TCW'-ZMM*_N'E\F$RDA+FXR5[JDV
MT_'U9SC5CO,/#BI'3B"TEKA1P-"#S!"($! 0$! 0$!!%KG,<',):X<B.!096
MTS)%&70J/Y0<_="#,1R,E:'QN#F'D0H2F0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0:#?_YEF^&?M%*&6M.;_($%RH! 08Y2"":/[XSRA!6O.;/=08FP
M_P RP_#'VB#?E"1 0$! 0$! 0$! 0$&/S/XF/ACZA0:^I0(-6ZC[MGV/LG*[
MCL(O6<W&V.SP5H!J,V5OI!;VC-/"OW1X<1X&E!/C=O;@Z.])+?&[.Q0W/NV#
M3<934\A][D;R0/O+IQ-'/)>YQ K730<FK;W3'CR9(MR7;-O.U-\RY<>*;L5N
MW=S-.^E;VA__ *8,_P"-^$7=_3]P^=ZGG_U'B/R.L^E;VA__ *8,_P"-^$3]
M/W#YWJ/U'B/R.MMN'WUU>N\9;W.0V*VWO9-7?0=Z6::.('!Q)XA5\!N%?Q^I
MI9>+<7MNI;ND71S[=$^2WQU;ML==7%GL9LUY%'J@A[XNUOJ!2@(/*I4> W#Y
M_48N+<7NFEVZ1;'\=6G_ $K^T/\ _3!G_&_"*_Z?N'SO4W?U'B/R.L^E;VA_
M_I@S_C?A$_3]P^=ZC]1XC\CK;M88W.=8NF>9V_U0V\-O7.2,MI' UVM[ P,?
M!=QAQ):^.7SF5/-E>17%WW#AQ9*8KMN*:W<W'-FRXZYK-BZNKR<[%]*=RY3<
MFSXV;B<#O#;UU<;=W. :UR6,<(W2\APF862UIQU+1;[=4! 0$! 0$! 0$%6"
MYFMG:H7%OA'8?*$&:M,M#/1DWW*3P_6GW>Q0ED4! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0:#?_YEF^&?M%*&6M.;_($%RH! 08Y2"":/[XSRA!6O.;/=
M08FP_P RP_#'VB#?E"1 0$! 0$! 0$! 0$&/S/XF/ACZA0:^I0(.>;WB;G.J
M'2?:4K==FW(9'=%V.RN%M0VUJ/%/.'#R(EV'/;@PFV,;)F-P7T6.QD):V2YG
M=I8'/.EH\))/8%DQ8;\MVS9%98<N:S%;M7S%L>5J'TX])?UML?C.^2M[]*WK
MY<M#]6W3YEOI/IQZ2_K;8_&=\E/TK>OER?JVZ?,M]++6G4W8%];1WEIN&RDM
MI:]W()  =)H>=#S"?I>]?+N]#!?Q[A]DTNS61/ENA&XZE;"M+>6[N-P63+>%
MNN5_>@AK:TJ:5\*C]+WKY=WH+./</OFEN>R9_BAB/IQZ2_K;8_&=\E6_2MZ^
M7+/^K;I\RWTGTX])?UML?C.^2H_2MZ^7)^K;I\RWTMJVYNG;V[K!V3VUD8<G
M8,D= ^>W=J:V5@!+3R(-' T/A6GFP9,-VS?$VRWL&\8\UNUCNBZ/(Y/BXOF+
MKUO[",.FUW'A\1NF*$<&BX@?+C)W >%P8PN]]86=OZ($! 0$! 0$! 0$!!=V
MF1GM:-KKB^P=^T>Q!G+6^M[H?<W4?VL/ _\ I4)7* @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @("#0;_P#S+-\,_:*4,M:<W^0(+E0" @QRD$$T?WQGE""M><V>
MZ@Q-A_F6'X8^T0;\H2(" @(" @(" @(" @Q^9_$Q\,?4*#7U*!!H=WYGM"[%
M=(?N<FV,Y'"#_*-N[9SJ?P42ZQN#;N#W5BY<+N&QBR&+F+726TP);J8:M(((
M((/:"LN'-?BNVK)I+#FPV9K=B^-J):9] G2#]5+7X\WX1;_ZMO?QSU=CG?H^
MY_+@^@3I!^JEK\>;\(GZMO?QSU=A^C[G\N&7L^E?3S'VL=E:;>M8[:*O=QT<
MZFHU/%SB>:?JV]_,EKW_ $]PZ^:W8;)GRPFN>E_3^\MI;2XV_:OMYVZ)6:7-
MU-K6E6D'L4?JN]_,DL^GN'636W#9$]##?0)T@_52U^/-^$4_JV]_'/5V-C]'
MW/Y<'T"=(/U4M?CS?A$_5M[^.>KL/T?<_EPV[;6U-N[.QQQ.V,=%C<>Z1TSX
M80:.E> "YQ<22: "I/(+1S[QDS7;5\[4M_!NV/!;LX[8MCR.69L:_:8M3&*F
M'8=P;@CL$N7B$5?*6/HL+8;XB! 0$! 0$! 0$! 0$ $M((-".1"#*6F8D91E
MR-;/LQZ0\OA09F*:*=@?$X.:>T*$IT! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!
MH-__ )EF^&?M%*&6M.;_ "!!<J 0$&.4@@FC^^,\H05KSFSW4&)L/\RP_#'V
MB#?E"1 0$! 0$! 0$! 0$&/S/XF/ACZA0:^I0(.<]291M_=_3#?[JBUQ.<EP
M>3DY-99[CMS;->_P-;.R(D]B)=V4 @(-&SFT=XY'+7-[C=VS8ZPE+3#9,B#F
MQZ6@'CJXU(JNYN^_;MCQQ;?ABZZ.6NMY'?N$\0S9[K\6]W8[)I2V+8FFCG\N
MM3Q.SMZ6.3M+R^WA/?64$@?/9OB#6RL /FDAW!6S[_NM^.;;<$6S,:)KJ5W3
MA'$,6:V_)O=V2V)TVS;$5;ZN"]@("#ANUYQN/K#U+W;&X28_%-QVS;"0=LEB
MUU[>C^!-.UGE"D="1 @(-;WQCL]D<!._;NX[G;%]81SWKKRS@M[E\S(('N[E
MS;EKVAI(#JM%>"#D^R.I>Y<#MW962W5=YKJ!N+J38R7.%PUG;X^V;:7%D ^5
MC7-[HEKVOJ7R5#&L)/-$MW?U@Q5KO3]!LMB+BPRDT=])CI/7+"Z,[\;"ZXDC
ME@MYGRVQ?&PNB[]HU>(HA8;>Z[X+.2XIUYMW,8/&9[%WN9P62O602QWL6+A[
M^[CCC@>Z36QE2W4!KIPX$(FBK9];,?>;8Q>YF[:R3G;CNH;':6)MKBQO+O*2
M7$9EJ#!,YEOW303.+@M,?:B%>]ZL3VF=LMG7.S<Q!NK(8LYB>TBELIQC[/OY
M+>2:>5LFBD6@2^;75J:T NJ$&$VYUG[W%;<Q.,P.?WIN+);>;N5DP-C!<S6?
MK4MN]UQY[8V2-,?UH(?5K6U=5!+8]<I<UOC;UGA,1+<=/,SMZ;/W&8>88Y8&
MP3B*>>35+5L5H0^.:,-+W/\ 1J$2R=GURQ,[;6[O]M9?%8C,V-]E-J9.\]6[
MK+PXZ!UR]C&LD<ZWDDB:7Q"<#4$0M+7K[:WPMV6>Q=PRWF2Q;<_@;7_E Z_Q
M@%9IP[O=,0B'8_C)4:1YP05LO[0&T;"PQ^1QMA=9>*\PK=SW3&3V=@^TQ;RY
MH+O7)HQ+/6.2D$.IQ#:]K:ATS&9*QS6+L<UBYA<8O)V\-[8W !;WEO<,$D;J
M'B*M/$=B"^AGE@?KB<6N\7;Y4&:M,Q')1ER.[?\ 9_6G]Q$LF""*@U!Y$* 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$!!H-_\ YEF^&?M%*&6M.;_($%RH! 08Y2""
M:/[XSRA!6O.;/=08FP_S+#\,?:(-^4)$! 0$! 0$! 0$! 08_,_B8^&/J%!K
MZE @P>\MJV&^=IYC:&3=W=KF+9UN+BE3!."'P3M\<4K6/'D07'1O>][N_:SK
M'<8[C?FV9CA=VV1X.;?VPT]\!05CN&TFC<!I-2!R*A+-;_O=Q6.%MY=NLEU/
MOK6+*7%K$+FZM\<^2D\T$1!UO:*?6NH"7!I(HI@<\R75#J'BLA#BX=NF6"YG
MN+;%W-W;W1N;CU2*:2)A9&U@?)<LA;-WC&MCA#],@U I1"-SOOJIG=J1Y_;>
M(8S(V62OK>?'VK1=Q7]OC;*X;,(IS4-$MTT"VD',M#3P<4$YZ@]7HV6ME;;0
M?/=06DDE]>75M<QLDFB#G,:SN_-U2L#?1X->=/91*"U;OWK+99#,RNVI+D&'
M2RVL^XFA@@[EK8W7,4I'W2)[@7]Q4S=H.D*1TK8F8W7G,=>7F[,7%B+EEW+!
M:6D7>DFWBH!(YTH;JUFKFD-'FT[5"5GU4W['T\VA<YB"'UW<%V]F.VWBF\9+
MW+7=66\#6U!-7><^G)C7%0->Z>[1=L79V-VY<3^N9:,27><OR=1N<K>O,]W*
M3VUD<6M_>@*4-F0$!!1O+<7EE=V1<6"[MYK8R 5+1/&Z,N [::JH-#P?2BSP
M5QTUN(<M--]&MM?6EHQT+&B^;D(>Y+I2'$QE@XC36J%6 PO0.UPN2Q=VS<LT
M]AA;K+WF/M'6%NR=YSD,T4INKL.[V=[.^.A[NP!M/ &9Q_2*'%Q]/?4<]/%<
M].K'(V&-G]6B?ZP[)6_<":1CG$-,7IAG$.Y'@@P=IT!BLYKG.6^YY;+>S\G!
MF[#+8S'V]EC[6[MX'V[BW&M<Z)WK#'GUAQ<"\T\"#:\?T^O8]V?IMF]P/RF>
MEVY+M:[[NSBL[>1DURZX%PUC'NTN:': SD0*UJ@YU8])MY8#?N$Q6T<]>87$
M8/8QP<>\?48+J.>=V2DE=;/AD?I;(&2=XPM/ M',$A$MKM>AV&Q,FUF8'+7%
MIC<!B+K;>3LIX8KD97%9"0SW3)''289)9'.<9(QPKPY<2%*UZ('U+'8C,[MO
M<MA=N8^^Q>T+22TMX'6#<A;.L^^GDC/_ #+X87:(M08.%3Q09G$]++/$7NV;
MV/*S2NVQM>39\#'0M:)H96M:;AQU'2\:!Y@J/&@UAOL^V=A:X+YDSD,64Q&+
MBP=S=97#667@NK6VEDEAD$%R:0S1F1S0YCR"*50=@L[=MG9VUFP,#+:*.$=W
M&V&/[FT-JV-E&L!I4,;P;R""L@(+FUO[BU-&'5'VL=R_]"#.6N1M[JC0=$OV
M#N?N>%0E=H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M$! 0$#EQ'-!D;3+RPT9/66/P_7#]U!FH+B&X9KA<'#M':/*%"55 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M([]I=#B&NWSM7=>5<[7_ ,2L?A?M%?1.!_D<?1/KEY/B7YF_[<D.FKM.>("
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M8H]-N^]X<\5Q7VWQ_AF)]2^6!M" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M5,/L;>.+L=M7VTK#(6.]=R; S$&X<A*Z<2S9H11FU%U),[S)P=382\@MX4H
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M_A^^7@^(_3N7!6[%[=O_ '1V^;T/I_!OK/=]ZICWC_:OY_W)\_[OG]+K0(<
MYIJ#Q!'(A>2?0XFJ* @(" @(" @(" @(""G//!:P2W5U*R&VA8Z2::1P8QC&
M"KG.<:   5)*F(F9I&M6ZZ+8K.B(<JNO:3Z06MQ);G-OF,9TF2&TN7QD_O7"
M.A'C"[=O!-[F*[/7#@7?4.Y6S3;KYI[%'_J;Z0?G:?\ L5S\A6_0M[^&/3"O
M]Q[E\4_RR?\ 4WT@_.T_]BN?D)^A;W\,>F#^X]R^*?Y9/^IOI!^=I_[%<_(3
M]"WOX8],']Q[E\4_RR?]3?2#\[3_ -BN?D)^A;W\,>F#^X]R^*?Y9/\ J;Z0
M?G:?^Q7/R$_0M[^&/3!_<>Y?%/\ +)_U-](/SM/_ &*Y^0GZ%O?PQZ8/[CW+
MXI_ED_ZF^D'YVG_L5S\A/T+>_ACTP?W'N7Q3_+)_U-](/SM/_8KGY"?H6]_#
M'I@_N/<OBG^63_J;Z0?G:?\ L5S\A/T+>_ACTP?W'N7Q3_+)_P!3?2#\[3_V
M*Y^0GZ%O?PQZ8/[CW+XI_ED_ZF^D'YVG_L5S\A/T+>_ACTP?W'N7Q3_+)_U-
M](/SM/\ V*Y^0GZ%O?PQZ8/[CW+XI_ED_P"IOI!^=I_[%<_(3]"WOX8],']Q
M[E\4_P LG_4WT@_.T_\ 8KGY"?H6]_#'I@_N/<OBG^63_J;Z0?G:?^Q7/R$_
M0M[^&/3!_<>Y?%/\LG_4WT@_.T_]BN?D)^A;W\,>F#^X]R^*?Y9/^IOI!^=I
M_P"Q7/R$_0M[^&/3!_<>Y?%/\LG_ %-](/SM/_8KGY"?H6]_#'I@_N/<OBG^
M63_J;Z0?G:?^Q7/R$_0M[^&/3!_<>Y?%/\LG_4WT@_.T_P#8KGY"?H6]_#'I
M@_N/<OBG^63_ *F^D'YVG_L5S\A/T+>_ACTP?W'N7Q3_ "R?]3?2#\[3_P!B
MN?D)^A;W\,>F#^X]R^*?Y9/^IOI!^=I_[%<_(3]"WOX8],']Q[E\4_RR?]3?
M2#\[3_V*Y^0GZ%O?PQZ8/[CW+XI_ED_ZF^D'YVG_ +%<_(3]"WOX8],']Q[E
M\4_RR?\ 4WT@_.T_]BN?D)^A;W\,>F#^X]R^*?Y9/^IOI!^=I_[%<_(3]"WO
MX8],']Q[E\4_RR?]3?2#\[3_ -BN?D)^A;W\,>F#^X]R^*?Y9/\ J;Z0?G:?
M^Q7/R$_0M[^&/3!_<>Y?%/\ +)_U-](/SM/_ &*Y^0GZ%O?PQZ8/[CW+XI_E
MD_ZF^D'YVG_L5S\A/T+>_ACTP?W'N7Q3_+)_U-](/SM/_8KGY"?H6]_#'I@_
MN/<OBG^63_J;Z0?G:?\ L5S\A/T+>_ACTP?W'N7Q3_+)_P!3?2#\[3_V*Y^0
MGZ%O?PQZ8/[CW+XI_EEN6R^IFR>H#9AM7*LO)[<:I[5S7PSL83348Y6M<6U^
MN%0N?O6XYMV_$MI7T.EN?$=WWJO=75F.35/HEMJT71$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$',MT?XE??"_:"XO'/R.3HCUPZ'#?S-GVY)6N'].?R-^J5\ZX?
MKN\SUN]:H95==HB"*#5UY1VQ0*MK^-0_#;]59L'XEO2QY/=GH7V9]*'R._:7
M0XAKM\[5W7E7.U_\2L?A?M%?1.!_D<?1/KEY/B7YF_[<D.FKM.>(" @(" @(
M" @(" @Q^9_$Q\,?4*#7U*! 01+G%VHDEPI0]O#D@F,LIH-9H.(%>%4$6]]*
M=#-3R132VI\T=E!V!!99#.8K&\,KF+.R-:EMW>00.J/")'@U""G99["9,D8W
M-6%ZYQJ6VU[;S.)\C)"24&2D=<L([TO:ZNL:J@U/;Q^J@IZWBE''@=0X]OA0
M1$D@^N//4/A'M\J"5 0$! 08S<>W\3NW;^3VOG8N^P^8MWVEXP4U!K^(>RO)
M['!KV'L< @Q?1_>N2>ZYZ6;ZG!ZC;5B8)+AU0W+XH^;;9*#5Z0>VC9A4ELE:
MTJ H2ZN@XAE?9_DEP?J&.SQ-[9LOQB^_@#(G')/<Y_K6ESC)HJ.Z+6M[MPU
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MI321M<ZD>IX:7:'/&EQ8#PJ*FG#LJIB>66.^*Q$1&G[D_JK7F)D$K9'/C#Y
M 6Z'U-6&HXD"G$<%:V:5JPSII$34>S0TP/&IS'>8[4=(!Y@#EQ/:HIIJ3DI&
MRI^KN+7590Z@ X^:!V&JFJ(KS+=\;F%S:BH)%>?$> J)B&>RZ8T+C&Y*]Q<G
M?P./=C[Y$?0>!X?W5-MTVSH4S[O;O-E,D:M4\L=L>3T4=@Z<]3,A@+UN6P$U
M/1%_CI3]SD9X'@?Q7CB/?"KO>YX=^Q[-\:>?EMG[>EPMUWK>^"[Q%]D^S/\
M+?'V\\/8^S=YX?>^);D\5)21M&W=H\CO8)"/1</ ?K7<C[X7RG?]PR[GDV+_
M #3R2^\\)XO@XCA[S%.G]ZWEMGR_=/*V)<YV1 0$! 0$! 0$!!QOVH/])+_^
MMV?]*%W^ _FXZ)]3S7U)^2NZ;?6\*+Z2^3B @(" @(" @(" @(" @(" @("
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M_P#Z+@-P5M%J;;SY.2+2V5Q)M+4O-:'2-4CJ_P %/:F=>MAK==KB+::_M/\
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M! 0$! 0<;]J#_22__K=G_2A=_@/YN.B?4\U]2?DKNFWUO"B^DODX@(" @("
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MW>&W9MK6G2Y+F_\ ]9BT[NM3L.X]8IRH,O%W5?=UT6NWF^(@0$! 0$! 0$!
M0$! 0$! 0$&@Y=S&=?>F9DY2X;<D</'_ &C3:/=_%1+MR@:'U=CS4FSICAYW
M0:)H'7(B:]T[V=ZT-;'HY4<6N=^]%%,(ENE@V]996[,C(R6_;&T7,L(+8W2
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MF_2#KAU%W&P!]E@;#$[1M9QQ#IF]YDKIH^ Z9C7>-:KHN@(@0$'G[>O5O>F
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MK^UOZQ+_ '>5<GB_Y2_H^^';X'^=Q],^J7T'7RU]B$! 0$! 0$! 0$! 0$!
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MV[3Y=#>WK@>];O9MW6UMC7333[VD8/ YG<N2BP^ L9LCDYZF.VMVZW4'-Q[
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MI0J:H8MW1/.9.#.P;FSL65FS5A98ZXOY63.GD;;7HNWO>USRQE&_<XVQ!K>
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MW[2Z'$-=OG:NZ\JYVO\ XE8_"_:*^B<#_(X^B?7+R?$OS-_VY(=-7:<\0$!
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MA2E2>*]#P_>-ZRW3WUFQ')]JO+\4W7<\-EO<9)ONKIY='FBCEJ[3SH@(.D=
MO]7]K?UB7^[RKD\7_*7]'WP[? _SN/IGU2^@Z^6OL0@(" @(" @(" @(" @(
M" @(" @(" @YENC_ !*^^%^T%Q>.?D<G1'KAT.&_F;/MR2M</Z<_D;]4KYUP
M_7=YGK=ZU0RJZ[1$$4&KKRCMB@5;7\:A^&WZJS8/Q+>ECR>[/0OLSZ4/D=^T
MNAQ#7;YVKNO*N=K_ .)6/POVBOHG _R./HGUR\GQ+\S?]N2'35VG/$! 0$!
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M*%W^ _FXZ)]3S7U)^2NZ;?6\*+Z2^3B @(" @(" @(" @(" @(" @(" @("
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MY\X06E/5K"!KN#FOGK</H>7!WF?Q5,UY6&;-'O5_[>KE27&6R\K6QR7+VQO
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M'W_BN+==$^U=S1]_,[W#>"YM\]J/9L^*?NCE^VEZVV5T$Z;;*9%+#BVY7*L
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M5;0RR- GG%'4X%P%$%.]W-+;Q82";=^;@Z6.WQ<X["[C%S<-N[C .QQ,[/6
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M5IS<Z-MKM71JP,^*Q]N!7U_($-'A#Y6Q_M+TFXSL;K-W\4ODOU+'?<6BS_\
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MX/ZO^KY!N]-\^H(F-,=[7S6:?_%[K7R9]^$! 0$! 0<;]J#_ $DO_P"MV?\
M2A=_@/YN.B?4\U]2?DKNFWUO"B^DODX@(" @(,OM7;E_N[<>,VSC!_SN3N&6
M['D5$;3Q?(X#ZUC07GQ!8-XSVX<=U]VJV&UNF[W;QEMQVZ[I^WHUOI'MK;N,
MVG@<?MS#1=SC<="V"!O"IIQ<]U*5<]Q+G'M))7R7/FNS9)ONUR^V;O@LP8XQ
MV12+?MU\K*K SB#SI[2W^+;<_J]U]O&O/\6UVO%_47XF+HN_\7#UY]Y=Z>]G
M+_(5U_XI=?:1+U?#/PIZ?NA[CZ>_*S_'=ZW75U7I!!HG5WI];]1]DWV$T-^=
MH6FZPTYH#'>1 E@J>37\8W>)U>8"Z7#M\G=LT7<FJ>C]FMR^*;C&]X+K/WM=
MO3^W5+YVO9)$]T4K#'+&XLDC<*.:YIH00>T%?5HFKXQ,3$TE*BH@[C[,?3N+
M=V\I-QY.$283;6B9K'CS9;^2I@:1VB/29#XPVO KSG'=][G#L6^]?ZN7L]+U
MGTYN'?9^\NCV<?\ 5R>C7Z.=[>7SI]1$! 0$! 0$'E?VLNG<;6VG4G&0Z9"Y
MEAG0T>D"--O.:=HIW3B?WG@7M/I[?9TX+NFW[X^_TO!_4_#XI&\6QIU7?=/W
M>AY87M'SX0$! 0$'2.@7^K^UOZQ+_=Y5R>+_ )2_H^^';X'^=Q],^J7T'7RU
M]B$! 0$! 0$! 0$! 0$! 0$! 0$! 0$',MT?XE??"_:"XO'/R.3HCUPZ'#?S
M-GVY)6N'].?R-^J5\ZX?KN\SUN]:H95==HB"*#5UY1VQ0*MK^-0_#;]59L'X
MEO2QY/=GH7V9]*'R._:70XAKM\[5W7E7.U_\2L?A?M%?1.!_D<?1/KEY/B7Y
MF_[<D.FKM.>(" @(" @(" @(" @Q^9_$Q\,?4*#7U*! 0 "XAK02XF@ XDDH
M-#S746YGSL^R^FV'.[]Y6WFY%XD,&$Q9\%]>M#AW@YB"+4\T[$%:+HGN+=($
M_5??&1RK7U+MN[>>[!81FH4+"+<^L3 ?923=O)$L[CO9]Z)XQ@9;[$P\M/K[
MRV;?2$^%S[GO7$^,E0(W_L_]$\C&8Y]AX:(.^NM+2.S>/&'VXC<#XP4&"EZ'
MYC;#>_Z3[VR>"+*%N!S4CL]A) WDPQ71,T=>6J.:H\"D6F,ZBW^*R]KM'JOB
M6;1W/>.$.,R4<IGV]E93PT6ET\ QRG^0N*.\!*#H!!:2UP(<.!!X$%$" @("
M @(-0WMLF;<5QC]R[;R P/4/!!PPF=TE\3X7'4^RO8Q]]M9#S'-A\YJ"_P!E
M]9+#*Y1NS-]69V?U%91GS3>O M;^@KWV-N31ES&[F TZV\B.%5"6;W)TPV[N
M?*9#-9#O/G2\M;2S@N/,>+86,\EPQT;)&N82YTE) ]K@YOFGS209J-9B]GS:
M4#P^&]O&:"98HP+<Q"Y.@F=[#$0]Y<P<^&BC*:0$JBB9GL^[.;)"Z6YNYV6X
MD,4<QA>WO)X#!*YU8JO!&ET;'$MB<*L#:E*E&V;/V9B>GEAD6VU_*ZQN91>3
MFZ=''#$8XFQO>-+6 %^C7*]WI.J42Y_FNJ.9ZD3W&U>B\NG'-/<YGJ1)'KQE
MFTU#X\?7A=W7#AH^YLYDGL#8]J;5PFR<#;[<V_$]EC"Y\TT\[N]NKJZF-9;F
MYD/%\TAXN<?(. 1#-(" @(" @ $F@XD\  @T3<'4=T6=FV3L+$/WCOVWT^O6
M$$@@QV,;(:!^1O""V,\">Y960TY!!4@Z-;NW6T3]5M\7MS$_SCMK:SGX3#QU
M%"QSXSZS./WTDC?(B6<QWL]]$L8P-@V+B9R.)DOK<7\CCX7/NC*YQ\9*@5+_
M * ]%,C&Z*XV%A&-<*$VUE%:N]QT C</<*# R]";W;8-QTHWGEMLO;0MPN1F
M?G,&\--=#K>\<Z1@/HZHY00I%C9]1LIMW+6NUNK^*BVOF;V46V)W!:R.FVYE
M)J5TQ3O\ZVE=0TBN*5["@Z(YKF.+'@M<W@6G@040@@(" @YAUNQGK.W;3),;
MJ?87 #W?8Q3C23\8,7K_ *7S[&\763^_;UQ^RKYQ]>;IWFYV98C3CN]%MVB>
MN+7AGJ%;_-^Y[APA88KQD=RTFIJ::'$T/A:O0<1MV,TZ-$Z5?I//WVX1;,Z<
M<S;YO>CURU>.1Y<60P-<\ DAK"\@#F>W@%S8FNJ'K9B(USZ91]=N0TM$FEII
MZ(#?M:)M&S"1PEJ"YCB]PU<0:T/(^.J:1/29[?.8\D<B0> \')6K,HI1!H>X
MEM.([#P2(J5HJ-?(&E@Y#C0]A':%:LPBD2JCO)IF.B>Z6XE/+CWFOR_MI6J:
M1"I-+''&+2'SFAU9Y!_M'CL^"WL]]36%)KK40))G48RI'-K!R]Y15%!D<CFF
M1@JUG,\.':I5F8A.(;B6,W#6%T0)U.%.%.)X>ZD5DFD324Y@ M!<.)&HD- !
M-?*>0_;4Z8BJNB9HA)<"4-9W3(V,;1K6"E3VN)-224JG9E&SMI;R;N8J-H"^
M25YI'&QO-SCV ?\ H36B:1%97,U^V.-UEC"Z.V=YLL_HS3GEYQ^M9X&<O#4J
M:\Q-O+=IGU="%KD',A]4NV"YL&U+87G2YA[>Y> 2T^+T?"%$2BZS37E^VM.[
M'"[)FQ3_ %B+F^"E+B,=M8ZG4!X65]Q3$5U*[5/>BGEY/V>=CQSTCB1[BC6F
M=&F5ZTLNI'')7#V3.C'<S/&MI<S@ _MI04!"MJUHGDV8T*48=&T7+Z4J"QCP
M:O -"6G]Z1X4MFFE6Z(U1+(V^3@ I- &\"&EO%K23SIS]RJWK,]L:XHY67=;
MKM,73/DG4KY6^LIHF16-1K$8E)  +FM\YQ/[YW'R*<F6+HB(FK4W?=[K+YNO
MB(G5T\\KO!9"\A#;6,,$=PSN7:@T:HR[SNP\>?%9;:717F<W/AOB[7YFS;8W
M5D=NN#\?)*V.$O:^$R5A[S6=)T$4/ \?"LMV*W);2[2YN6VZ)BZW1L_;SNB9
M7<F*PFW[G([KMXV7^7MY8&6%JXN]>UM+=3XS4-:PT\^O,<%S,T5I9;-8B?1T
M2R;ANUT99R3&SR5KHGIC5'WO.,EQ(R)T%:Q.<U[VT%:M! X\^U8[[J2]MBMB
M=.M97,YE:WB V,:6-  X5KV<^:U+KJNA9$PM+6VDR-_:8V,?=+N:.!O\-P!_
M86.RV;[XMYY1O.>-WPWY9_<MF?1&CK>^?9RPK9MT7>1:REOBK/NXZ<FR3D,:
M/B->NE]3YHLW:W''[T]5OVA\U^A=WG+OM^:?W+>NZ>S:>G5\T?<! 0$! 0$'
M&_:@_P!)+_\ K=G_ $H7?X#^;CHGU/-?4GY*[IM];PHOI+Y.(" @("#T5[(F
MVV7^[<UN>9@<W#VC+:V)^MGOG&KAXQ'$YO\ "7E/J//LXK<<?O3ZO^KVWTKN
M\79;\D_NQ3T_].MZ_N;JULH'7-Y/';VS*:YIG-C8VIH*N<0!4E>!FZ(BLOHM
MUT6Q6="P_2?;7YYL?[5#\I8N_P ?Q1Z88^^Q_%'I/TGVU^>;'^U0_*3O\?Q1
MZ8.^Q_%'I< ]HK(X_(Y3;S\?=PW;(X+ILCK>1DH:2Z.@.@FE?&N%Q2^VZ8I,
M2\=]07Q=?CI-=%WW.,+A/-/2'L_9G$8[8]S!D,A;6DYR=R\13S1Q/+2V.AH\
M@T-.:]/P[)9;CF)F(T\_DA[7@&2VW=J3,1[5WK=6_2?;7YYL?[5#\I=/O\?Q
M1Z8>A[['\4>E#]*-LCB<S8T_K4/RD[['\4>D[_'\4>EE&/9(QLD;@^-X#F/:
M:M+3Q!!',%9HFK,\ >T%MMFVNJ^<A@9HM,DYF4@'];;JDIXN]$B^H<'S][NM
MM==NCT?LH^0\>W?N=\NIJN]KTZ^NKF*[#@"#WQ[.6W&;>Z48=Y9IN\OWF4N3
M3B3<&D?_  FQKYEQK/WF]7<UOL^C]M7U_@.[QAW.WGN]KTZNJCH^0SN#Q,C(
MLID[2QED;K8RYGCA<YM:5 >X$BJX%^6RS1=,1YWIL6[9<L5LMNNZ(F5I^F6T
M/U@QO]L@^6L?B,7Q6^F&;P&\_+O_ )9[#],MH?K!C?[9!\M/$8OBM],'@-Y^
M7?\ RSV'Z9;0_6#&_P!L@^6GB,7Q6^F#P&\_+O\ Y9[#],MH?K!C?[9!\M/$
M8OBM],'@-Y^7?_+/8?IEM#]8,;_;(/EIXC%\5OI@\!O/R[_Y9[#],MH?K!C?
M[9!\M/$8OBM],'@-Y^7?_+/8KV>Y=N9&X;:8_+V5W=OJ6007,4LCM(J:-:XD
MT JK6YL=TTBZ)GI8\FZ9\<;5UEUL<\VS"SWUMR+=VSLWMN5H?\XV<L,5>R;3
MJB=_!>&N]Q=#=,TX<UM_-/5R]3E;Y@C/ANQS^]'7R=;YH4<TEKQ1[>#@>PC@
M5]>?#I$0(" @(.D= O\ 5_:W]8E_N\JY/%_RE_1]\.WP/\[CZ9]4OH.OEK[$
M(" @(" @(" @(" @(" @(" @(" @(.9;H_Q*^^%^T%Q>.?D<G1'KAT.&_F;/
MMR2M</Z<_D;]4KYUP_7=YGK=ZU0RJZ[1$$4&KKRCMB@5;7\:A^&WZJS8/Q+>
MECR>[/0OLSZ4/D=^TNAQ#7;YVKNO*N=K_P")6/POVBOHG _R./HGUR\GQ+\S
M?]N2'35VG/$! 0$! 0$! 0$! 08_,_B8^&/J%!KZE @(.<[KO]P[YW++TFV'
M?28LV\;)=^[KM_OV+L[@5996A/ 7MPVOG_[)G'TD2ZUM':&W-BX&UVSM:PCQ
M^'LVTCACXN<X^E)(\U<][CQ<]Q))4#.("#F>:ZY[/Q^5=@L);9'=67C>Z*2W
MP%L;QK)6-+G,,A<QA< "2&N<1VKL8>$YK[=NZ8LM_P 4T</>.-8,5\61M9+I
MFE+(KII6GEFD3J8>+V@[><,,.P]TR"01.C+;*,ZA<ZNZ(I-Q#]+M/AH:+:NX
M'?&O)CY>7FU\G)RN?9]2X;Z;./)-=G]WXJ[/+JNI-.>FA2/4';75I@V)G^GF
M=NL)F&L]9=D+&/U6**0N[N=[Q*2P!S3HD;Q!%6\0L.\<)NP63==DLT<E=-8Y
M-6MM;GQW'O62++++],1-=G12=4Z]4TFD\M)6&WKO.].-UVO2O>-Y+D\-DF//
M3_=5T=4L[815V*O7]MS&WC#(?OK.'I"@XCT3I"($! 0$! 08G<NU]M[RQ3L'
MNO%6^8Q3B7-M[IFKNWGAKB>*/C=^^8X%!J%OL+?VU2UO3GJ)=V^,83HP.ZX!
MG;-C>QD=R'173&CL&MU$2O(=R>T?;?<[G![-R@'#O[;)7UAJ [3'/!(6U\&H
MH)79;VD,F[N2W9NVX'>E<=YD,Q.WX+&MMX_?<@LCTC_2*1ESU7W1DM^2,<)&
MXF;3B\"U[7:@?4+0@24/+OGN0=$@@M[2VALK.&.VLK9@CMK6!C8H8F#DUC&
M-:/$ B%1 0$! 0$!!H&Z\UN#<NY?HGZ?W1L,\Z".[W;N5@#OF3&3^@R*O WE
MR >Z'UC//\8)=0V;LO;FPL%!M[;%FVTL(:ND<?/FGF=Q?-/(?.DD>>+GNX^X
MH&?0$! 08[.X'#;GQ-W@MP6,.1P]]&8KJSN&A\;V'Q'D1S!'$'B.*#C.*ERO
M2C<V-Z<;FO)<CLW-O-OL#<=T[7/#.T%PQ%[(?2=I'_*RN](#1Q(X2.C\1P/
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M=]LRRW;G[./[W;Y*\B93E1D[P%]@W:[:Q63SVQZGP[?8IO&2.:Z[UL,MAIB
M@("#I'0+_5_:W]8E_N\JY/%_RE_1]\.WP/\ .X^F?5+Z#KY:^Q" @(" @("
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MW3:V4,=O".W1$T-%?'P7R7-ENRWS?=KNFOI?=]VP6X,5N.SW;(B(\R[6)L"
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M?.N9<[AO!-RRQ=M8XFE.?M=]Z&Y._P SMK;>3RD[KF_N!*9IWT#G%LLK16@
MX  +N[I=,XHF?+ZWS;CN#'@W[)CQQLVQ,4C_ "P[NMIQ! 0$! 0$! 0$! 0$
M&/S/XF/ACZA0:^I0(-$/_P"L7M3O*:!L_+=S7^4^<K;53QZ42Z%OG8UMONPA
MQMYF,KB;:-SC*,/<BU[]KVZ2R;4QX>WMH0MW<]\NW:[:MMMNG_%%:=#G;_N%
MF^8^[ONNMMY=F:5\DZ)K#23[/6$=(9)MX;KGU%[I&39*-[7]ZT-D#P;?B'M:
M&O\ "."Z%_&;[K9MG'CI,4]V>WDY'+Q_3^*S)&2,F3:B:^]&O17]WEI$3SPT
MB^Z6V&#O[VRWMG]T6F+GE>^QS&,NR_&OBD8(],\7<RNBDTM#7ZJM<!PX<$P<
M9RXK;;8MLG9BE9C3HU<JN\_3V[Y[[[KKKXVYF9B)C9TQ$3HF)UQ&GR:-3&3[
MPRVQ<E*1GH]X;?C[W(6N<%;>X@OY6L@C=DAYK90UOF1'6T5]*G +>LWG!O%F
MS%LQ?-+=F(K6V--+9_=K.FZ7.S[AO&[Y-N+XV*S=MW33VYI;%U\:[]FW19;%
M(F:5IH=>Z8Y!EQ!?;AW%<QMW-FO5[J?66LC98OK'9-C/(-?1Q;6CG$UIQ"XF
M\[EDQSHBNO5II,:X\NSRSJ=_<N*8<]M:TT1/M:)FV[1;=3DVZ>S$Z?)#H@O;
M-U--Q$=6G31[37O*Z*<?KJ&GA6CW=W-+J1ELGECT\^KTIHKFVG-()F2G2'T8
MX.\QU0'<#R-#Q2ZRZW7%%K<EMVJ8E55%W%<GI_ZE+CNZZCL.+UFGHT&9?W5?
M=UJ1O2($! 0$! 0$! 0$! 0$! 0$!!H.6T_3YTT[ST1AMQ]SX.]K::OXJ)=N
M4#'9&\G#VXZPI\X3-U![A5D4=:&1WAY4:./G4KPJ4%2U@M,7 V-TC1(_SI9I
M" ^60\7.))_8Y <!P43*8MF=2>6?&S-T3RP2,[6O<QPX&O(^,)M1SK=W=S2M
MAA;:.C\?-+9\ 0V%]8C332K'ZFTHT#@!PKX5-5$*YVUI5L.0C XD'U>;@.=#
M5AY?O>)[ $%6#+123-MIX)K6X>[0QDK#I<X:O1>VK3P83SY>5!?H.+;D_P#U
MD<%HIJ.R\IWM.>CYPMM-?%J4C>40(" @E<UKVECP'-<*$'B""IB:(F(F*2\F
M=7.GD5G=7^WYFEN+OVF?&3@$F,:JLH23YT3A0\:D<3Z2^M;AO-O$=TI=[VJ[
MIY_/KZGY]XCNN7@/$HOQ^Y7:LUTFV==D]'NSYKN5Y'O[.XQ][<8Z_;W-_;/,
M<H^L<1R=X@1Q!Y47FLEEUETVW:X?9MVWG'O&*W+CFMM\5CLZ8U2MG:XZ!XI7
MEX#Y#VJE6<$E$J*C9#X*A6B2BI%(]AUQN+7\N':I@5A<1O:[OHP".;HSH=[W
M(J:ITL[MS$X+(7<S<WE'XS'B"1T%S)$0'7 ;5C">(H3S(6?'9;-:SH:&]Y<M
MEMO=V[5TSU,='81T>6R^MN97A;N8UE/#K>03[C52+8Z6SM3T=*&F9@!BQ\8!
M^S/?.]VK@ E)Y(36WEN3M.2-/-AMP>;G-A8T>6M2IB;NCT(F+->OTI!<2MHZ
MXN;4M/-O=LF=[S6_MI6>68(B.2)^W2J?..)AXOQC+RH(:]Q?:MKX0V)QK3QE
M5FZWF^Y&Q?/[U.M?X\665T0B[-HVOXO.T-MP?$Z,?;-]U;&/9OG[FEO-U^.V
M9B*S37]ON2;EQ+L7.]KY&7$>KS+R(ZX9>VK7\CXTSVQ;I4W#-=DMC:UL"YS1
M'$ZI+B"'5I04-!2G'WUI\D.I33*I$XM<(W/TQR$"3P4!KQ5HUJ732)F-;,9.
MUL;"[C9B[WUJ/NV/,S0YA;(6@D4/'S3P6UEMMLF-F7)W/-ERVSWMM-/VUMEV
M_<2W)%;J2V$H/?/:Y_'2-7$,()U&E/+5=S#DV[(F-;S'$,?=W71?%8UQS-HV
ME@,=DLV^PO[A]DR]N'1V[XV][5^L-8T < '5=YW8J7W39;,TJT\U\9(MV=7J
MY-7WM6WSG9,QN?*W4;RVS$Y@M8P?-;!;_<HFCQ!K5S;,DVVO0V;E92*QJUM<
MCN8HF%SZ.)< 6"K9 T \0ZE #R/:L7>3&ET/#Q?;2B>YR<LE'0/<(])JQNK[
MG6H+ XFI%.U3=O%]T*8N'XL<ZF+DN 1SXUX#PK5VG3BQ9RSE8;KF:VU933#B
M2>"Q3++;&EZ&Z.=/[^.&TL88-6X\])'JC/.-A]!CCV!C27O/9Q\"]=NF.W<]
MWG+DT:*ST<D?;E?&..;[?Q??[<&#3;;.S9Y9_>NZ/_&'T+VQM^SVM@;' V/&
M"SC##)2ADD/%[SXW.)<OE>^;S=O.6[)=KNG_ *1YGV_AVXV;EN]F"S59'IGE
MGSSI9=:CHB @(" @("#C?M0?Z27_ /6[/^E"[_ ?S<=$^IYKZD_)7=-OK>%%
M])?)Q 0$! 05K2[N;"Z@OK*5T%[:R,GMIV&CF2Q.#F.!\((JJW6Q=$Q.J5[+
MYLNBZW1,:7T2Z4]1+#J7M"TSL!8S)Q@09>S:>,%VP><*?8/]-A^Q/A!7RKB&
MY7;KEFR=7)//'VUOL_#=^MWO#%\:^6.:?MJ;NN<Z8@\Z>TM_BVW/ZO=?;QKS
M_%M=KQ?U%^)BZ+O_ !</7GWEWI[V<O\ (5U_XI=?:1+U?#/PIZ?NA[CZ>_*S
M_'=ZW75U7I!!Q/VD>I\6R]IOVWC)@-S[AB?#&&GS[>R=5DLQ\!<*QQ^.I'HK
MT7!-PG/EV[H]BSKGDC[Y_:\QQ_B4;MAG';/MWQZ(Y9^Z/V/#@X"@Y+Z,^4B
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M^>" @(" @(.D= O]7]K?UB7^[RKD\7_*7]'WP[? _P [CZ9]4OH.OEK[$("
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M! 0$! 0$!!QOVH/])+_^MV?]*%W^ _FXZ)]3S7U)^2NZ;?6\*+Z2^3B @("
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M$MNZI??<7\&?[9BI8Y'!]5_F^]Z;]GK_ "9M7X,W]/,O0[G^#'G];Y)]2_\
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M[=C=O9R&3-1U$N$O&OL,HPMI6MK<MCD-*CT0Y!MA!:2TBA' @\""@(" @("
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M>%%])?)Q 0$! 0$! 0$!!#2/ $35%$" @(" @(" @(""% >81( !R""*($!
M0$! 0$! 0=(Z!?ZO[6_K$O\ =Y5R>+_E+^C[X=O@?YW'TSZI?0=?+7V(0$!
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MCD<'U7^;[WIOV>O\F;5^#-_3S+T.Y_@QY_6^2?4O_)9>F/Z8>@EMO.B @("
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MO3?L]?Y,VK\&;^GF7H=S_!CS^M\D^I?^2R],?TP]!+;>=$! 0$! 0$! 0$!
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M%L=,ZE#*0[YZ;--[D9KC?&PXA6ZO1$W]),;'7[Z]D+6LOX6CB_2QD[1Q'>+
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M][TW[/7^3-J_!F_IYEZ'<_P8\_K?)/J7_DLO3'],/02VWG1 0$! 0$! 0$!
M0$&/S/XF/ACZA0:^I0 $D "I/ !!J6UL<SJ#OJ[W5??=MI[)NY\5M>T=QAN,
MU$!'?Y)PI1QA=JM+8FNG3*X<7 @EUN2-DL;HI&A\;P6O:>(+2*$%(FB)BKRK
M?[9L</W^TLYC\%)FMI12=WDMQ6M_>RW^W#+_ ,C+;,L'L<XPZWPSM#':=+>/
M->SLSS?3)9-^SDY+)MC9O_>B=KGUP\1=N\61W5\63=BC7?;==-V.OLS&S35I
MB8I*ITOVO8;MZAXZ_P 3CL$W;VUCZ_?9?!660L=>1(?'#9.]?D+BYE1._2R@
MH 34IO\ GNP[O,73?M7Z(BZZV='+=[/H5X=@C/O-MUMMFQCTS=;9=;[6FEOM
M37_%J\DO5"\6]TXXS&MZ<]0&[=M08]D;X=<WN%MQ]ZQ^X(6=_=6T0I1D5[$U
M]PQ@-!,R2@&NBD;FB! 0$! 0$! 0$&O;NV-M7?=K!;;GQXN9;-P?C\A"]]MD
M+-X((=;W41;)'Q'('2>T(->@PW6S:+1'M'>EENS%LH(L;O6W>R]:WE09&Q +
MS^^FB)_:)7S>I'6VT^Y7W2JUO7C_ +QC-R69B/\ !N(8G#]E!)+OOKYDV.9B
M^GN%P3N3;C.9]MRT>,PV,#G$>1Z#'W?3O>&\ZMZK;WN,EBW\)=K;9C?A,3(T
MCBR>8/?=3-)^M,C0@WO$XG%8#&V^%P5C!C,1:BEO8V<;8865YD-;S)[7&I/:
M40O$!!6M[6>Z=IB;4#FX\&CRE!F[3%06]'R?=9?"?1'D"A*_0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$'GWVA?\F;J^##_ $\*U-\_!GS>MZ+Z:_Y+%TS_ $R\
MQ=+OOV4_W</VSEYZ]]<XOJL\[HJH\\('8?(?J(//;O2/E*SP^@0@I2RFV_\
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MESCR XE!EK3#<GW9_P"S'[9099C&1M#&-#6CD!P"A*9 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(" @(,A:8J:>CY?N47C](^0(,U;VL%LW3"VGA=S)\I4)5D! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$!!Y]]H7_)FZO@P_P!/"M3?/P9\WK>B^FO^2Q=,_P!,
MO,72[[]E/]W#]LY>>O?7.+ZK/.Z*J//"!V'R'ZB#SV[TCY2L\/H$(*4LIMO_
M #!C/ZS%]L%6[4U=[_!NZ);=U2^^XOX,_P!LQ4L<C@^J_P WWO3?L]?Y,VK\
M&;^GF7H=S_!CS^M\D^I?^2R],?TP]!+;>=$! 0$! 0$! 0$! 08_,_B8^&/J
M%!KZE "0:@T(Y%!J.VLC'T\WW=;<OR(-G[YO),AMRZ=PAML_,WO+W'.-:-]9
M+3=6U::G&5H\[2"2Z)NG,WF!Q$F2LK%^1ECDC:ZVB#GRECW@.+&,:YSW '@T
M<_"H&F-ZD[N-G?RR['O+>^LXS+%:2/>X3%K6ZFL>R$AQ#M?(<6:3S-!-$(?2
M7NDAY?LZZMGLG9;RP2]\Y\0TDF5SF0ECHWN'=QECB:^<0 E"KH>+OADL=:Y!
MK'1>LQ,E,3PYKF%PJ6D.#34'AQ 4)<WP5PWJ;U!;N^U=WNQ-EFYL=O7+:F+(
M9N8&WO+N,UHZ*VCUVL3P*.>^:AH 2&D93%XX[IW!MBWAAR@W#D)=P[/)R5UC
M;2>_<V.#+6LEQ9N:3)'H$S(^/ \UZRVZ^,=E]U;=BV+;_9B9BW79,1=R3JJ\
M=$8KLE]EE+HR73?92^;8F[1;DB9MY8I6C1;W$VV[+JPV7M^VQ<^0STP@EO,+
MN7+9=]E:1.:^YGFAG>(M C!8-?I$\ 2NA;DG#$Y;YNI9&J['9;6>2(F-.MS\
MF.,\QBQ[,S?-*VY;[]F.69B=&KG>DWLR.T\GBH8LD^_PF2N18-QUTV/O;<NC
M<]CH)(VM):T,HYKZ^;QKPX^;M[O><=_LQ;?9&UM16DZ8UQ/+IUP[M_?;GGQ_
M[DY,>6[9V;MFMNB9B;)B(F8BFF+JZ--=&G4-PXQG3?>MMGL<!!L?>U\RRW#9
MMJ(;+/W5&6N18WDQMTX"VNJ4#GNC?Z6HGD/2-P(()!%".!'C1 @(" @(" @(
M+BVLI[H_<VT9VO/!H09NTQL%M1Q'>2_9N[/(.Q0E>H" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M !>FB(MB(CD?GB^^;[ING7,U;JI5$! 0$! 0$! 0$! 08_,_B8^&/J%!KZE
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M3^R@@@!I<0UH)<>0'$H,K:8=[Z/NCH;_ "8](^7P(,Q%%'"T,B:&M'8%"4Z
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M" @(" @("#'YG\3'PQ]0H-?4H$! 0$! 018Q\C@QC2YQY <2@RUIAN3[L_\
M9C]L_N(,NQC(VAD;0UHY < H2F0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 08_,_B8^&/
MJ%!KZE @(" @(+^TQ4]Q1\GW*+PGTCY @S=O:P6K=,+:$\W'BX^4J$JR @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(,?F?Q,?#'U"@U]2@0$!!7MK.>Z=2)OF]KSP:$
M&<M,9!;4<[[I+]D>0\@4)7J @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @Q^9_$Q\
M,?4*#7U*!!-'%),\,B:7//8$&8M,,UM'W1U._DQR]TH,JUK6-#6@-:.  X!0
ME% 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&/S/XF/ACZA0:_SX#FI0R-IB)9J
M/G^YQ^#ZX_N(,U!;PV[=$+0T=I[3Y2H2JH" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(""UR%L^ZA;%&0#J!)/8!5!"UQ]O:^<!KE^S=S]SP(+M 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&B;BWGNK$YBYQ^-VM<9*
MRAT=U>QMF+7ZXVN--$;AP)+>?8NGAW7%?9$W7Q;/-H<[-O.2R^8MLF8Y]+%_
M2+OC]2+OXEQ^!6;P6#YL=7:P^,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y
M<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3Q
MF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ
M[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?
M-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>
M"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/
MP*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_
M$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J
M1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=
M\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#
MZ1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+G
MK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S
M?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:
M>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL
M=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6
M#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!
M3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXE
MQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+
MOXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC
M]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2
M+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?
M8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y
M<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3Q
MF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ
M[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?
M-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>
M"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/
MP*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_
M$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J
M1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=
M\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#
MZ1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+G
MK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S
M?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:
M>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL
M=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6
M#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!
M3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXE
MQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+
MOXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC
M]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2
M+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?
M8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y
M<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3Q
MF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ
M[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?
M-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>
M"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/
MP*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_
M$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J
M1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=
M\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#
MZ1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+G
MK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S
M?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:
M>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL
M=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6
M#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!
M3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXE
MQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+
MOXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC
M]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2
M+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?
M8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y
M<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3Q
MF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ
M[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?
M-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>
M"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/
MP*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_
M$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J
M1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=
M\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#
MZ1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+G
MK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S
M?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL=7:
M>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6#YL
M=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!3P6
M#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXEQ^!
M3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+OXE
MQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC]2+
MOXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2+OC
M]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?8?2
M+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y<]?
M8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[#Z1=\?J1=_$N/P*>"P?-CJ[3QF;Y
M<]?8?2+OC]2+OXEQ^!3P6#YL=7:>,S?+GK[&T?I%G/S)+_@OSIR?^/?D?H>G
8_&\2TNYL^+][9\WQ-SOK_A_=KY_A?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>fc_centraldogma-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_centraldogma-4c.jpg
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M%!04%!04%!04%/_  !$( 5@#[@,!$0 "$0$#$0'_Q #8  $  @,  P$
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M5U"'BE#\Y:?>I2PI"+^Y";C]T:NB*JF<C\@SW2]+VG*N+)O_ -M?2D'Z$I6
M/L%4;!IW*/+ SF-Q6(VF>Y(G2F8K#4MTS6RM]8; *)'>+7-!^@B00D!1N0.I
M\+FN*O- H% H% H%!7N]\U:'QW._"L_)?7EBTE\08K"W7/+7<)/<KM;%['\N
M@@N-N>\9R;MK^MXG#OPXK$-V;\Y*=1YBO+<;;"?*0% 7\R]_,]E706_4"@4"
M@4"@4'#_ *J /]ZJ_IQ\6_\ RZY0C[>E']:#O]E2?ZQFDCMJN*J*]3.\[7I.
M'P+FK9)>-<G2'VY2VT-K4I+:$E(NXE5K$GPJP.87>9>4W5=R]MR0/[Q\H'["
M;"JCPUS)RFROO1MN2*A[%OE8_85<4&\:KZI>1<*\VC/&/L$ $!Q#[:8\CM_>
MNLI2+_2M"J:#JWCWDC6N2L0<IK[Q#K/:F= >LF1'<5>P6D$@@V/:H=#]8('%
M6WT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@H'U-<I9/3\9"U379"HF8S*
M%O2YC9*768:3V -D=4J<5<=PZ@)-NI!%@<;M-2ITE+3*'),Q]5DH0%...+4?
M8!<DDU4=?^E#"97"X796LQCY./EN2X]FI;+C"BE+2K$!Q*2?&I(Z'J*X6Y*Y
M;Y%Q_(&S0,7LTZ-CHN1DL1F&G;(0VTX4!*0!X"U<D:NGFCE5*@H;9D"000"[
M<=/>".M!W_KV79V# 8O.Q[>3DHK$M%O !]L+M]E[5Q5S-ZE.5=IP&YP]=U7,
M2,8W"AI=G?++[.]^0HJ 5[^U 21_"JPBF/\ ?/RI_P"+,C_3?_55'97 ^?RF
MR\7X;+9J6Y.R;BI2'Y3Q!<7Y<EQ*;D>-D@"I*K(J!0*!0?G;S. .5=LL+?\
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MD.K0C4"M"5$)7^(CJ >A_P"S'QIH-UVWGV;JNI:MN"M6,K';*P72!-\OY9X
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MZ3=VF1-BFZ+)=4O&9%E<R"VHW#<I@ K[1[ MNY5_ 'TU)%6<T?K5VS^T'?\
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M/K)JC]+M6P,?5];Q6NQ;%G&16HH4!;O4V@!2S]*E74?KKBJ7H% H% H% H%
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M6'PA<7(F-'N:>F.620@CHI+:18*'B5*]EC5A%6\<ZO(W+=\)KS""M$J4V91
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M=A^@%56!QC51VUZ7-,.O:$O8)3?9D-D=$A-Q90AL70P#_")6X/H4*DJO*H%
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M(7,F.V5(DN@6[G% #P_)2.@]@\:BMJH% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!X4I*!=:@D
M7 N387)L!]IH(79-LP>I,PG\X^IAO(2FX,8I;6Y=]T$I!" ;"P/6@]=EV"9@
M?PWY3#RLO\_,;B/?)B_R[;E[O.=#\(^P?2*!LF8S6(7BTX?"N9A,V8W&FJ;=
M2U\LPO[SRK@W ^SZZ!L>P3,$[BFXF&E989&6B(\N(+B,VOQ><\?A'V#Z10>V
M=VS!ZW*Q4/+OJ9D9J2F%CTI;6YWOK( !*00D74!<T$T5I24I4H!2C9()ZD@7
MZ?90>:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*#'C3X,Q;[<.2U(<BK+4E#3B5J:<'BA823VJ^@T$=@=JP6S.9)K#
M2?F',3)7"G H6CL?1X@=X%Q](Z4'IKFV8G:59).*+M\5+<@2O.:4U^>:\>WN
M\10>^O[7@MH^?_!)/S'X9)7!F70MOM?;\0.\"X^D=*"1B3X,]+BH,IJ4EEQ3
M+RF'$N!#J/O(5VDV4/:#UH,B@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@QYD^#CFTO9"2U$96M+:7'W$M)*U]$I!4
M0+GV"@CMCVK!ZG&BR\])^5CS)+<*.OL6YW/NW*1\ -A9)))Z4'IL^V8C46(4
MC+ET-SY;4!CR&E/'SGK]MPGP'2@]]BVK!:JW"=SDGY9&0DH@Q3V+<[GW;E(/
M8#8=.I/2@D94^#!+(G2FHQD.)8C^<XEOS'5_=0CN([E'V =:#(H% H% H% H
M% H% H% H% H% H% H% H/E*E1H49Z9,=0Q$CH4Z^^XH(0AM [E*4H]  !<F
M@A,SD\OD-6<RF@+AY')/H0YC7'UWBN)4L!1[D$>">ZW7Q\:#QL.J8_<\)&Q>
MSMJ(0XS*=1%=6T!(:'7M4+$IN2.OU^-!/.--.A(=0E80H+1W *LI/@1?VCWT
M'O0*!0>BVFG"@N(2LMGN05 'M5:UQ?P/6@ALSJ6&SV6PV;R"'%3L"ZM_'E#B
MD)"W  >Y*397W1_]EZ#Q,=VQ.T8UJ"Q$5J*F'3E'W%*$M+X!\L-I'0B_;^WX
M6%PSV\QBGLH]A&IK*\Q';2^_!2M)?0TLV"E(O< W'[(]]!G4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$%"V&7+VC):\YAY
M<>) 9:>:S#B0(D@N@70V?:4WM]A\.EP87"Y?&Y?-3Y^;>R4+).H<@0'4)0B$
MA (*$*!-P;^X>'ON:#)Q.N8/!2,A+Q,)N))RKQE9!QN]WGC<E2KD^TDV'3J:
M"0:CL,%PL-(:+JRX[V)">]:O%2K>)-O$T'N !>PM?J;>^@]&8[$?O\AI#7FK
M+CG8D)[G%>*E6\2?::"/PFMX36VI+&#A(@M3'URY*6[V6^Y;N5\1-O#P'04&
M#KN+S.LX.4UE\M)V6<AQ^4V\MM#;RD$=R&4I!M?ITZ^)]@M096KYN1L6#BY>
M5C).'?D!15CYJ>U]OM64BXL.B@.X=/ T$Q0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!016R9=_ X.;F(V.?RK\1 6C'Q!W/N
MW4 0D6/@#W'IX"@P,[C\SM6LL-8K(R=7R4H1Y*G@VE<AD=%K96GN'7\E5E>/
MT4&=G-:PFS06<?L,-O(Q6'42$(>!MYS8("_A(]BCT\.M!)/1X\D)3(:0ZE"D
MN(#B0H)6DW2H7O8CV&@]R ?$7MU%_>*#T>CQY 0)#2'0VL.-AQ(5VK3X*%_
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M]8VF%M3$Y^%&E1DP);L%U,QHLJ4XS:ZD DW2;_7[Q03M H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H([+9W#8%$=W,S6H+<MY$6.I]00%O.
M7[4"_M-J#$P^IXO!YC,YR$I\S<ZXV]-#KJG&PIH$#RTG[H^(_P#V4$Y0*!0*
M!0*!0*!0*!0* 1<6]]!J>)A:GQEC(V'^?5%C9":I,7Y]\NN.RI!OV)4KZO\
MCZF@VR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@U3,1-
M3Y*QF2UM4_YEF%)0UD407NQUF0RKN[%$7]H(/_&.@;2VA+;:6TW[4 )%R2;
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MNNNL:VMPYS]/K:)GEKE^FW1&I"U.(&??92">H;[I7P@_1>LEAC3N.73^"/\
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M4H% H% H('+;%)QF>PV&:Q$N:SE2ZEW(QT]T>+Y20073[.[[/M\*">H% H%
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MW3&.VL\*\8XSX1Z/M59ROPAR0T_EN0Y\:&Y'F%[*Y:-!>*S"*UE:T6=[2X$
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M'^)0._G'^9U7^DR/\2@=_./\SJO])D?XE [^<?YG5?Z3(_Q*!W\X_P SJO\
M29'^)0._G'^9U7^DR/\ $H'?SC_,ZK_29'^)0._G'^9U7^DR/\2@=_./\SJO
M])D?XE [^<?YG5?Z3(_Q*!W\X_S.J_TF1_B4#OYQ_F=5_I,C_$H'?SC_ #.J
M_P!)D?XE [^<?YG5?Z3(_P 2@=_./\SJO])D?XE!A9E?-/X1D/FF=7^6^6>\
M[RW,AW]GEJ[NVZ +V\+T'(&NKV1&3:_154P98D>5^'>9YYZ^SRNMJJ.K^,E\
MZ*$?],4POPCIWJG],EV?O1'^&_\ E>M15O5 H% H(K9,K,PF$EY6!C'LQ+C)
M2IK&Q>CSI4H)(3T/@#W'H>@\*#-@2'9<&-+>CKB//M-NN17;>8TI:0HH5;I=
M)-C:@R*#PLE*%*2.Y0!(3[R/92$E^<.S\C[QL6>D9/,Y24)"9(>1 4M7RS"V
M7.]"$L*^"S:AX*3[.O6OK6#98,=(K6L<N?C/M]+XKN>X;C+DFU[3KKR\(T]'
M+@[C')$# <98G?-UO#7*A1'I$=I!+KDJ2TE7EM-DCJHW(!/0>)Z$U\X_H;9-
MS;#BXZ3/U1YOJG_R%<6TKGS<-:Q]<QX-?QV_Z=RRN3QSMNOY##S<C'^98Q6:
M9,9<EA'QAQA:3?N3;O%K'I<7L:]5]GFV>F?'>MHB>=9UTGTO)CWV#?:[?+2U
M)M&O3:--8\X:4SJO'?I]Y+Q66F/%. S&/E,QYDT_,2(,YE0)4D-H!\MUM?E@
M]A(/ML:R$[C<=QVUJQ^JLQPCA%H_.)XL7&VVW:MW6TS[MZSQGC-;1ZO"8X<G
M0&#SV&V7&LYC S6LAC'[^5)85W))2;$'V@@^(/45J^7#?%;IO&DMPPYZ9J1>
MDQ:)\81FSZ!IFYN,/;1A8V3?B]&'GD?G$IO?M[TD**;]>TFU=V#>9L&L8[37
M5T;C8X-Q,3DK%IADY5ES7]1R#>K0FVI&.@2#B8##82V'6FE*:0E"0!8J %JX
MXY^)ECXD\YC6?;Q<\L3BPV^%'&M9Z8]G!^<3N>V')Y5R;*F29^3G+[9 <6MU
M4@K5_)K3>Z@H].S[*^L1AQTKI$1$1]CXK.?+>^LS-IG[7Z78Q*D8V&A<=$1:
M6&@J*T EMHA NA('0!/@*^0W_5/'7B^X8XTK'#3AR\G/6S;YRQR!J^UYC1XF
M/A:)%1,@I6^M?XM*8CI*9#S%CV)/;>P(N/9<UM.#:;7;Y<=<LS.2=)_NQ,\H
MEI^YWF]W6')?#%8Q1U1X]<Q'.8^GUKHXZG87):)KTS7F%1<*Y 8$.,LW6TA"
M CL4?RE)((*O:>M:_O:7KGO%YUMK.K9MA>E]O2<<:5Z8TCR;/7C>XH%!!9+.
MY"#L.(PT?"R9D'(AXRLLU;R(A:3=(<Z'[QZ#J/HO03M H% H% H% H% H(S8
M?QW\%F_HS\O^/>7_ )C\YW>1YEQ][MZ^%[?309.,_$/PZ'^+^5^*^2W\]\O?
MR?F.T>9Y?=U[>Z_;?V4&50*!0*!04CNO&.U:XG8,IQ&ZF/$V1E36=U\? 4K7
MT7)QY*DI0]VE0["0GKTZA(&Q;7?XLO17<\9I/NV_"WH:MO.W9L/7;:\(R1[U
M?_=3RGZ>2(S7,&GZQH<?1],6_KVR@,X:)#S3#D%[')>^!<N2I2>SX!W+*DJ5
M=?6QZUZ,7;<V7/.7+I>O&TS6=>K^['TY/-F[K@P[>,.'7'?A6(M'3-=?WI]7
M/UL_)<E\><:<9LZ]H.>Q^0R[+2,?C V^VO\ SJ03WRW[%02D**GED]+_  ^V
MNJFQW&ZW,WS4F*\YX>$?NQ]SNR=QVVSVD8\%ZVM'"./C/[T_?+ C<N\7\5\=
MJPFL9MK.[)'86M/EH><^;R;_ %<?=<*0.TK/<;KOVCM'LKMMVW<[O<=62O16
M9]'"L>$?3FZ:]UVFRVO1COUWB/3QM/C,^OT\E [YM>C9C3L+A<,U,E;9%E/Y
M#-9^4VVTF7(R [Y)-E*6KXTMA!4!\*?>:V?:;?/3-:UM(I,1%:QX1'+\6H;W
M<[?)@I2D3.2)F;6GQFWZO3STT;/$]1?+#.K0XF&A,M8_#QV(4C,?*N2%$MA+
M:%..+*FTJ5TZ%/4UX[=EVLY9FTSK:9G373]KWU[_ +R,,12(TI$1U::_7X);
M))]4:L-,V7/9>1A,1#95)?>D2(L&R$CN"0VS9?<3\*4]MRKI713_ .,ZXI2L
M6M,Z<IG[WHR?_+]$Y+VFE8C7C,5^R$IC=2]18UM&X9'>QB<:(9R+B,A+?4XT
MP$>9^<;\E:0>WKV^(\#UZ5T7W';_ (GPJXNJ==.$1^;T8]KW/X7Q;9NF-.KC
M,\O3P;'I^V>HV!K$3;LMCX&Q:\_',U;$AQJ#D$11=8<[@&T#N0.\7"OA->7<
M[?M]LLXZS-+:Z><:O;M-UW2N*,MJUR4F->.E;:>?A^*V>/>4=:Y&A^9BU.1,
MHAI#\G$S$^7)0VL"SB1X.-&_1Q'3WV/2L'O-ADVT^]QCSCE^R?0V'8=RQ;NO
MN\+?PSS]?ICTMVK',H@7/TN_2UGRA#_0OY,^>5=_SOSG<;=OY/;:W[?T4$]0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01,[5]=R>48S61QD>7E(S?DQY+[8
M=4VCN*K)"K@&Y/6UZ"6  %AT \!0*!0*!0*"#:SF2<VI_7U860WBVHJ9*,Z2
M/EG'2H L@6OW"_O]GA:QH)R@4"@JK?\ @W"[AE#M&(R4S7MS38M96*ZXM)4D
M?#W-E8L/\FI/VUFMGW6^&OP[5B]/*?I]^K7]]V7'N+_%I:<>3^*)^GV:*;W;
M*\M_B.&X0WJ;$FL9^=#MF8AM(?@%_L[7+=MAW#N^) 5=/BH5L&UQ[3IMNL43
M'1$^[/*)T:UO,N]ZJ;/-,3%[5]Z.<UU^GAX.M(T9B'&9B16TLQ8Z$M,-(%DH
M;0 E*0/8 !:M'M:;3K/.7T.M8K$1'*'UKBY% H% H% H% H%!BY*4]!QTN;'
MBKFR([+CK4-FP<>6A)4&TWZ74184&/K^2EYC#0\G.QSN)ER6^]W'2""ZR;D=
MJK >Z_@/I H)*@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'SD,,RF'8LA/>P^
MA3;J#X*0L=I'3W@T&#AM>P>NQ1#P6/CX^,/%$=M+=_I40+J/TF@DJ!0*!0*"
M/SF0E8K$3<C"@N9.7&:4ZS 8(#KRDCHA)(/4_4?J-![X>;(R6*AY"7#<Q\J2
MRAUZ"\07&5K2"4*(MU'A09M H.?]ZP?$\+FO7'LZSBF53X\U[+MR'$(;,P%E
M45R0V5! 4NZ[%8^/K>];1M,NZMLKQ2;<)C3U<==/IP:?O<.SKO\ '-XK'5%N
MK7SX=.OKX^MOW+NDY3=M;@#7'F6\]@\A'S.*;D=8SST4* ;7[+*"NGT_0;UC
M.W;JN#)/7^FT36?/BS'=-I?<8J_#F.JEHM77E.G@T?\ 0;DGE#:\5GM]C?H3
MC]=:D)@_@LU*LD[*DV"UI?1WA#?P^!]G2Q[B1D?ZO;[3%:F&?BS?37JCW=(]
M#%SL]UO<U;YH^#&.)TZ;>]K/I\OIXJC]07%NZ8G/1,HB1E=JPBXR([.2E_YW
M(84A2R67"TA-A=7<E12+]Q]MZSO9]_AOCFNE<=M>4<(GTM;[[VW/CR1;6V2N
MFFL\9CT3HM[TM:CLVL:GE).P1W8+.5DMOP(,@%#@0VWVJ=*#U3YET@7ZD)OX
M6K ]_P!SCRY:Q2=>F.,_A[&Q_+6URX<-IR1,=4\(G[_;^"^*UIMKT>>9CLN2
M)#B6F&DEQUUPA*$(2+E2B>@ '4DU8B9G2$F8B-9Y.==0VKA[-<YY.=COD [(
MBQ6,+)5%\E#V32ZZ7UM*4D#S% H 7T*_R;^W:]SM]WCV58MKPF>KC^[PTU]'
MW-+VNYV.3N%K5Z>,1TSIIK;6==/3RX^+HVM3;JYQY*XQR&EXO(S->VJ;B^/<
MWDXPV/ M(04L1\B^AB0XRZHW2D]X!1:Q'0DBMLV.^KGM$7I%LE:STV\YK&L:
MPTSN/;[;>EIIDFN*]HZZ^46G2=)_!?V!PV.U[#0,'B&_*QF/8;CQ47[CY;:0
M 2?:3XD^TUK&7+;)>;VYS+;<.*N*D4KRK&D)"NIW% H(*5G<BQM,' -X62_C
M)4=;[V=04_+,.([K-+'CW'M'^$/'K8)V@4"@4"@4"@4"@4'H]YQ9<$<I#_:?
M**[E 7;IW6ZVOXT$/J:-H;P<=&XNQGL^"Y\PN""&"GO/9;N">O;:_2@FZ!0*
M!0*!01.=U?7-GC_*[#BHN39'1*93*'2GV_"5"Z?L-=^+/DQ3K2TU]3SYMMBS
M1IDK%O7"NI_IJXAG.%U&'=B%7BF-*?2G[ I:@*RM.^;NO[VOKB&%O\O;*TZ]
M.GJF6/'],'$;!!<Q\J1;V.S'@#]?EE%<[=^W<^,1[(<*_+>RC]V9_P 4I?(<
M%\;_ *.Y7$X;78<2;-B/1X\U22\\TZX@A"TN.E:@4JL>AKHIW;<?$K:UYF(F
M.']CTY.R[7X5JTI$3,3&O.8^MSOZ=84S/;0-$STD-8+!2W-B7A7$V4_DHO9&
M2%'VI;)"U(]I3X'V;5WJT8\7QJ1[UXZ.KRK/'[6F=@I;+F^!>?=I/7T^=HX?
M9S7WM7_Q)Y B:"S^<U/6%,Y;;5#JV_+/Q0X)]A'3S7$FX(%NA%:SM_\ 2[><
MT_KR>[3T1^];\(;=N?\ 6;F,$?Y>/2U_3/[M?QE[;^I?(&WX_BF&HG"1 UF-
MV=0;#Y5"@J-")'Y3ZP%J'0]@"A[:FS_TV&=Q/ZI]VGK\;>S[UWT_U6>NUC],
M>]D]7[M?\7W/;DIY[;<SB^'L,LLLY!"9^U/L_#\OA6%@>2"G[JI"P&TV\$^(
M[338Q&&EMS;PX4]-I\?9S.XS.>]=I3AU<;^BD>'^+DL>/A<1$?CRHL".S*BQ
MA C/H:0EQN(D@AE*@+AL%(/;>W2L1;+>T3$S.DSK[?/ULW7#2LQ,1&L1I'J\
MO4SJZW:@L0C;4YW-*S3L->O*4U^!(CA0D)2$GS/.N+>-K=3]E!.T"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@@LMFLQ!SV&Q<+".S\;D%.B?D
MT.)2W##:04E22#?N^L?1<T$[0*!0*#C#>=D+WJB@RY1_S7&97&P6P?R6V_+"
MO^6M2J^@[3!IVR8CG:MI^]\RWNXU[O$SRK:L?<[/KY\^FE H% H% H% H% H
M(7:\OE,'A'\EAL0[G)[2D!O',+#:UA:PE1N0K[H-^@H)=E:W&6W'$%IQ:0I3
M1()22+E)(Z=*#WH% H% H% H% H% H% H% H% H% H% H% H% H% H% H/"B
M0DD#N(%P/?\ 100FIYG+9W#IR&:PSN"G%UQLP'UAQ80A5DKN G[P^C]J@G*!
M0?G3R=K6VP>0LW&S<.2]DID]]UAWRUK^90ZX2VMH@'N24D6"?#[O2UJ^K[#/
MBMMZS28TB(]GK?%^X[?-7<WB\3K-I]OEHZBX^Y6US1>/H6!Y"ER<3M.OQ@W+
MQF08<;ENMEQ08^721^=3V=J1VGI;XK"M,WG;\FXW$WPQ%J7GA,3P].ODWW8=
MSQ;;;13/,UO2.,3''T:>?#]K>-'Y<U3>\A(PV/3,QV;CM^><;E&#%D+8)MYB
M$W4%)ZCVWK';KMV7;UBTZ36?&LZPRVT[GBW-YI&M;1QTM&DZ>:3VSDC1]'=8
M8VK-,8Z1)'<RPOO<=*+V[BAM*E!-_P HBU=.WV6;/$SCK,Q#NW/<,&VF(R6B
MLS]/!/8O*8W-X^/E<1*:FXV4GS(\IA06VM/AT(]Q%C[CTKS9,=L=IK:-)AZ\
M>6N2L6I.L3XLNNMV-9Y#U^;M>CY[7<:\&)^1AN,1UJ)2DN$7"5$>"56[5'W&
MO9LLU<.:M[<JR\._P6S[>^.LZ3:'"N/XPW;#;%C/TDQDO7L>C(Q8\C-2FEHB
MQU+> "_.2"BU_!05:]NM?2;[_#?';HM%YZ9]V.<\/)\HQ]MW&/+7XE9I'5$=
M4\HX^;]$*^5/LJA>:UX_)<@ZGJ^\Y!W&<;3(LA]]0=,:-)R+2CV-/O#[J4CL
M(OX7^F];-VN+5P9,F*.K+$QZ9BOHAJG=II?<X\>>W3AF)GGI$V\IE]>"WXT3
M;MUUS4<B]E>-L<8J\5(=<+[3,MU!+S+#JOO(!O\ L ^WN5Q[M$SBQWR1%<LZ
MZ^'#PF8^GY7LTQ7/EQXK3;#73I\8B9YQ$^,?3TS>M:VVHH%!!8[-9>7LF6P\
MK"NQ,5 0RJ%F%K"FI9<3=02FPMVGIXGZ;4$[0*!0*!0*!0*!0*!006.B;4UL
M>5E9+(1W]:>2T,1!;:[7V5I3^<*UV%[GZ3]GM"=H% H% H% H% H%!Q[S!$R
M?#/,L3D? QTK@Y<NS&VEW2RJ2M!:E-+[>OQ%?F_WW3PK?>VVKOMG."\\:\/9
MX3^#YOW:E^W[Z-Q2.%M9]&O*T?C[5W81S'<0\5O['DY RN7FI.6R,MM7>K)9
M;(V4E+:DCX@I2DH04C[H[K>-:YEBV]W44K'36/=B/X:U^FK:<,UV&SG):>JT
M^],_Q6MY?='HXOIJ\=KBOC_+;INSH5L4_OS>RO\ 3N5+>_DXK=R0 BZ66TW[
M>[PZ&IGM.[SUQ8OTQ[M?5Y_C*[:L;+;6S9OUV]Z_KGE7V<H9_%&MY+'XR;MN
MS(MN6VNC(Y4$&\=JUHT07ZA++=A8]021UM75W#/6UHQX_P!&/A'I\[>V7=VS
M;VI2<N3_ #,L]5O1Y5]D+!K%LP^,M,E<1]$)Q+4Q3:Q'=6GO0ETI/:I2>EP#
MXB@C]9C[!$P<2/M,QF?G4!7S<N,CRFEDK)39-D^"; _"*"6H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H%!#[1/S>+P4N=KN-&7S#01\OCRX&0Y
M=:0KXC^Y22JWMM:@DHKC[L5EV4UY$E;:5/,=P7Y:R 5)[AT-CTO0?:@4%1;7
MQ)NFSY^?DH_(N3PF'E+"H^)A%XH:2$A)LKYA%NX@JL$V%["L[M^XX<6.*SAK
M:T>,Z?DUW==KSYLEK1GM2L_NQK^;D#DS S=)Y#RN(=GOY"9 ?:=1DI1)?=*V
MT/)<4257/Q>^M[V.:N?;UMI$1,<HY>3YOW'!;;;FU)M-IK,<9YSXOT$U/.L[
M/K.(V&.06\G$9DV'Y*G$ J3]:572:^7[C%.+):D_NS,/L.USQFQ5R1^]$2F*
M\[TE H% H% H% H%!!9')[#&V3$XV#AQ*P,M#QR65\Y*#&4A-T#RSU5W&P^W
MZ*"=H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H(*'D]B>VG(
MXN5APQKD=AIR#F/.2HOO+ [T>4.J;7/^#^^%!.T"@6'C[1X4%8\SZ9F]FQV#
MS.LQF)V>U?),Y:/C9/:EN6AHW4SW*M:Y"3U(!M[[5F.V;JF*UJY)F*Y*S76/
M#TL'W?:9,U:7QQ$VQVBVGGIX-/9U3D+E'>H6WYR!*X\A8.&[%A.QY#+^3>??
M-U#N*"GR@%*'Q(^KQ/;[YW&WVF"<=)C--IUG6-*Z?FQL;;<[W/7+>LX(I&D:
M3$VF9]G+V??PB),*3Q;R+G<SO6%R6]8_.1(S>)V!$-J<\V64]KD9QH!+:._P
MN .@!]JK=];1N]O6N*U<4UF=:ZS'M\_IZG1-;;'<WOFK;-%XCIMI$SPYQ/*(
MU_+TI'B_!<SZQK4J9@<7B(>'R4Z5E(NKY94IN;$9>4.QIMQL%*;I3T0M/3Q-
MB2*ZM_EV>7)$7M:;5B*]5=-)]+M[=AWV'%-J5I%;6FT4MKK&OA&GXPTEB?F,
MSQYD>8Y?(LV!NT5Y]UG#M24MP8ZFGBA$(Q#<DN)L4^RQ%P>IK(S2F/<1MHPQ
M..8CWM.,\/U:^AC*6OEVUMW.>U<D3/NZ^[&D\*]/I\/7QB74>JY.9FM8PN8R
M#'RT[(08TJ3'M;RW7FDK4FQZBQ-:9N,<4RVK$ZQ$S'VM[VV2V3%2]HTFU8F?
M;#5.<ISN.XGVB0S#1.48H9+#J/,0$ONH:4YV^]L*+@/L*;U[>U4BVZI$SIQ^
M[\^3']YO--GDF(UX??.FOLYN0N*N3=]Q>]8-IC+S<C'G3(T*5CI+[DAMYEY:
M6BD)<4H!0!^%0\/JZ5O?<-C@O@MK6(F(F=8C1\X[9W'<TW%(BUK1:8B8F9G7
MP=WYK X78X*L;GL?'R4!1"C'E-I=1W#P4 H&Q'O%?-<66^*W529K/H?6<V''
MEKTWK%H]+VQ&%Q& @HQF#@L8['M]41HK:6FP3XFR0.I]IJ9,M\ENJ\S,^E<6
M&F*O32(K'H9U=;M*#T>4XAIQ;2/,=2DE#=^WN4!T%SX7/MH(C4\CG<K@V)VR
M8H8;+.%P/0 X'NU*5D)/<G]T #:@FJ!0*!0*!0*!0*!0*"!VC#YO,L06\)FE
MX1R-,:D2G&VTNE^.W?N9/<1;NOX_LB@GJ!0*!0*!0*!0*!0:?R;H&.Y(U*7K
MDTAJ2?S^-F$7,>6@'L7]1N4K'M23[:]^QWEMKEB\<O&/.&-[CL:[S#..>?A/
ME*@^)3F<AN>$XOY(=1%7H!?F8C%O=W=.E@_F%=Q/:M,9LJ6SV_D^](-;/W'H
MKAMN,''XVD3/E'C_ -4\VH]KZ[YZ;;<</@:S6/XI\/7TQQJM/,__ !,Y)8UA
M'YS3=(<:R&=/BW*S"@3&BD^"DLC\XX.HO\*AX5A<7^EVTY/W\O"OHKXS[>4?
M6S^;_6;J,?\ X\/&WIO^[7V<Y^J5LU@VPE! [!A\WE)F&D8G-.8J/ EB1D(Z
M&TN"8P+7:421V@VM]M_$"@GJ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!006OO;8[,S"=DC1&(3<HIPBXBU*6Y$ZV4Z%$V5X>[K?IX7"=H%
M!ZN.-M(+CJ@AM/WE*( 'UDU8C5)G3FXI]5+.#?WF%FL-D8LUR;##,]F,\V\M
MIZ*HI!<"">WN0I(%_P!R:^A?+\WC!-;1,:3PUCS?,/F:,<[B+TM$ZQQTGQCZ
M?8M/TF[B,KJ,[4)+EY>">+T5)/4PY9*K#^"YWW_A"L-\P[;HRQDCE>/MC]C/
M?*^[Z\,XIYTGAZI_:Z%K56Y% H% H% H% H%!!:N]MCT>:=NC1(TE,MU,!,)
M:EI5#%O+4ON)^(]?=]0H)V@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@@MK>VQC'L*TZ-$E9(R6DOHGK4VV(I)\Q0*2/B\/LOXGI03M H% H
M% H*6V?GUV$O/_HAJ<_8L=KWFL9'-M?!!:E- W'1*E+0@_?4+6'7PL3L.#M'
M5T?$R12;\J^.GTY-9W/?)KU_"QVO7'SM^[K^4>/HX\N+SQ[PYQOEL+AMURD1
MG8MAR*3E9>7=+GDORI:R\LF/W!NR%$H"2W[.HO4WG<MQ2]L59Z*U]V(\HCAS
MY_:;#M.UOCKFM$9+V]Z;>$S/'ERX>I=%:^V9J>\;YH^FPE-;ED([#<QIP(@/
M#S5R&^TA2?* 42E7W>H[?97NVNTS9K:XHGAX^7M8_>;W;[>NF6T<8Y<]?8T#
M@3CK3(NKXC>V\=$>V?(I>EJFLJ+J(WS#BREEE)4I+9;00VJP[KW!-9/N^]S3
MEMBUGHKPT\]/&?/7FP_9.WX*X:Y^F.NVLZ^6OA'EI'!==:\V@H% H(+9'ML9
M5B_T6C1)"%S&TY;YQ2D%$(_?4WVD74/M^HT$[0*!0*!0*!0*!0*!0*!0:MC,
M5@] 8R<V;F'4Q<K.5*<>RLE/EMO2" &VU+[0!?P'C0;30*!0*!0*!0*!0*#3
M-]XTP.^HBR92G<=L.-4'<3GH1\N9&<0>Y-E?E)"NO:?LL>M9#:;[)M]8CWJV
MYUGE+&;[MV/=:3/NWK^FT<X1G%6J;;H\>=KV<$";CU//3V]@C+=3-FRI3G<X
MJ4TX%?G+?E!9%@D5W=PW&+/,7IK$Z:=,\HB/*?+V.CMFUS;:)QWZ9C69ZHUU
MM,_Q1Y^U8U8EFF'*RV+A2XD"9,9CS9ZE)A1W7$H<>4@74&TD@JL/&U!':OJT
M756)S$69+F)GRW9SBIKOG*0MZUTH-A9(M]=!.T"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@@MHQ^RY!F C6<JWBGF9C3TY;C*7P[%3?O:
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M% H% H% H% H% H% H% H% H% H% H%!";9K,7;L*[A)DJ5#8=6VX7X3GDO
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MP[+<<QGR[7E>3#/W&U]!=0^WZS03E H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H%!\I$>/+8=BRVD/QGDEMYEU(6VM"A8I4E5P01X@T$
M#G).:P+&'B:G@FIT1<IJ+*9;<1%;B0O K2GH+)'L'[%!L= H% H% H% H% H
M(':,GL>,:@*US#C,.OS&F)J%/)8\F*N_>[=7C;I02IQV/,\94Q&?Q,-^0)OE
MI\\,W[NSS+=W;?K:]J#)H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H,8X['JGIRBHC)R:&RPF86T^>&B;E <MW=M^MKVH(O6\GL617
ME!L&(&*1&F.,8Y0>2]\Q%3]UT]OW;T$[0*!0*!0*!0*!0*#7L++SF9<SD'9<
M&W"QK,ER+ *W$2$389!'>M%C8*'BE7OM[*";BQ8T&.U$A,HCQ&4A#+#20AM"
M1X!*4@  ?10?:@4"@4"@4"@4"@4"@4"@4"@4'QEQ(T^*]"FLHD0Y*%,OL. *
M0MM8[5)4#T((-C00>:QN7QFJN8SCYJ%!R,=*$8YF0DIBH0%@K%D ]>WNMT\?
M&@]M@VO&Z9A8V4VE[RPXXS%=7&:<=29#HZ]J0"H)N%'K[/IH)Y2T(L5J">XA
M*;FUU'P O[30>U H%!ZJ6A)2%*"2H]J03:Y\;#]B@A<QMN$P67P^$R+JT9#.
MN.,XY"6UK2I3025=RD@A/WDCK_QT'B:C;3M.-7!<AC4 PZ,HVX%_.%^Q\ORR
M/AM?M_Y7T4&<UA<0SEG\ZU"91F9+26'YR4 /K:1:R5+\2.@_8'NH,^@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$%)U3'2MJA
M;@X])&3@QEPVF4/%,4MN%1)6UX%7Q'K]7N%@0LWEI.T9+!OX1^-B8;+3L;-K
M6DL25N %2$IM<%-_>? WMTN$I'R./F/R8L24R_)AJ");+3B5K96H7 <2"2DD
M>^@R:!0*!0*#!;RT29CWY^'<;RB60X$)BNH6%NM W;"@>T*N.WJ>E!!QVG]_
MTI4;9,=*P#F5;6U*@AWMDLA*R 0L)%NX)"K%/@;$4$_C,>SB<;$Q<92UQX3+
M<=I;RBXX4-)"05*/B;#J:#+H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H,>=#:R$*3 ?4M+,II;#BFE%MP)=24DI4.J38]"/"@U
MTPU\>Z.8FMP)6=<Q+1$."MWOE/E;MR"LI]G>38)\!8#P%!,C,1HV(CY;-J;P
MZ'6VE/MS'4(#+KP'YI2R0GN"CV_2:"1!!%QU!H% H% H,:5D<?"=C,3)3,=Z
M8OR8C;KB4*=<M?M0%$%1M[!01>2S>5A['B</%PCTS&9!+RIF70L!F(6TW2%I
ML;]WAXCZ+T!O5,<WMCNXI>DG)O1! 4R728H:2H*N&[=%7'OM]%Z"=H% H% H
M% H% H% H% H% H% H% H%!ZK;0X.UQ(6FX-E $72;@]?<:"%V74L+MK4%C-
MM+=;Q\IN?&#;BFB'VKA))21<6)H/&R8&?G#C#!S4G#_(RVY;XBV_SEM'BRYU
M'PJ^T>\&@\;+B,]E58LX3-*PZ8<QN1.2EI+OS,='WF3<BUZ#SL6!GYI[%.P<
MU)Q*<=+1*D-Q;=LIM/BRYU'PG[1]!Z6#VSVIX79)>)FY5I;DC"24S8!0XML)
M>2005!) 4+I'0_\ '03*FVU*2M205HN4*(!*218V/LZ4'M0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"+QNN8/#S\CD
M\9";C3\NXE[(OHOW/.(O8JN2/RB>GM)-!C:_A,KB967?R.;?RS60E*D0V'T)
M0F&T;V918FX%_H\/#QN'C6T[<ES*_I4J&IHS'#B/D@L$0OR [W?E?50>=;D;
M6^K)_I1$BQ$MS'$8KY1967(8^XMRY-E'[/J%!XUE.W)&2_2Q4-1,QPXOY$+%
MH73L#G=^50>=8P>4P<>:SELV_G')4MV2R[)0E!99<MVLI )N$V^@>X"@R<#K
MF#U>$K'8"$W A+=6^IEJ_:77+=RNI/L 'U"U!*4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$9G=>PNS0#B\]#;G0"M+I
M8=O;O;-TFZ2#TH,3:<%D\YCH\+#9I_ /,2&GE28J$K4MINX+1"B $JN/V/ B
MXH/.TIVU4>%^B"H:)0F-&>9X64&%U\P([/RO#[+^V@;1(VN/'A'4H<69(7+:
M1.3,66THAF_F+001\0Z>_P"HT'C9T[<IO'?HDJ&EP3&CDOG@L@PNOF!OL_*\
M*#SLF$RN97BU8S-OX<09C<J4EA 7\TRCQ97<BP5]H^@T&3E=<P>;EXZ=EH+<
MJ7B'OF<:ZY?N9>Z'N38CVI2>OM /LH)2@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@\*4E NHA(]Y-J#PAQMS^36E=O'M(/]RK,:)$Q+VJ*4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@]5N-M_RBTHOX=Q _NU8C5)F(>4J2H!22%)/@1U%17F@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4 D 7/0>^@]$
MO-+/:AQ*E>X$$U=)2)B7O44H% H% H% H%!\C*C)D)AJ>;$M:2XA@J <* ;%
M03>Y'TURZ9TUTX./5&NFO%]:XN10*!0*!0*!0*!0*!0*!0*!0*!0*#AOD'"O
M[GZA<AJ+V0=C1LAD6XR7>KH:2MA!/:@J ^RXKZ/L\L8.WQDB-9BNOVOE6^PS
MN.YVQ3:8BUM/5P6%/])61QL=4K4=P=;RK8[FD/M*C)4H>'YUEPJ3]?8:Q=/F
M*MITR8^'U_9+,W^5[4C7%E][U:?;$L/BKF;<]0W0<9\I..R$JD)@MRY:N^3%
MDKL&^YWKYC3EQ92B>A"@KMKGW#MF'-A^/M^'#72.4QZO"8=7;.[Y\&?^GW/'
MCIK/.)\./C$_MY)?U@O/,8G55,NK;)DRP2A13?\ -M>-C71\MQ$WR:^4?B]/
MS7,Q3'IYS^#&],W(4_'9"5Q3MBG&IB%+D882">]*K=[L>Y/M'YU']][Q7/ON
MSK:L;C'R_>_"?PGV.OY=W]J6G:Y>?.NOVQ^,>U.>KIYYC2,(IEQ3:CE0"4**
M3;Y9[W5YOER(G-;7^'\8>OYJF8V]-/XOPE9W#RE+XNU-:U%2U8V.2I1N2>WW
MFL/W+_<Y/YI9WM/^TQ_RPI_U6;#*D/:MH&+>4B9D)'SKZ4**3\2OEXX/;U(*
ME.=/WHK/?+^&(B^:W*(T_&?P:W\SYYF<>"L\;3K^$?B@O37E\AJG)>R\<9N0
MIQY[S6D=RBI)F8QQ25=G=[%ME:K^T)%>GOF.N;;4SUC^RW[7E^7LML&ZR;>\
M^?UU_9JZSK1WT(H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H%!\Y'\@[_ 5_<JQS<;<G W$/'3?+FTY+#Y;+28K<.*N8'DCSUK4
M'D-V/F*_?WO7T[N6]_H\46K6)UG3R\'R/M6PC?YK4M:8TC7S\6T\A\?;AZ?)
M&,V74]GD.XN0_P"0D]62AX)*PVZUW*;=0I*5>(]G4>%>+9;S#W&+8\E(UB/I
MI/.'OW^QS]JFN3%DGIF=/;Z8Y2NC>]K<W'TW3MJ"?EI&0Q\=UY#9("'DRFT.
M!)O?M[TJM]%:_M-O\'N,8^<1,_=+9][N?ZCM<Y>4VK'UZQJY\X1Y&R?'&UP9
M6<==&H[&GR);CJBIL!#A;3(22?%I=PO]Z3T\*VGNNRKN<4Q3]=.7Y>W[VG=F
M[A?:9HF^OP\G"?S]D_8ZZY;61Q=MCC2K'\*DJ0M)_P#X9(((K1.W1_J<?\T/
MHO=)_P!)DT_AE5WI$>>>TS.J><4XH92P*U%1M\NU[ZS7S'$1FKI_#^,L#\JS
M,X+Z_P 7X0W?U ;4=4XNS#S+A;G9,)Q<0@V5W2KAP@CJ"&@X16.[/M_C;FL3
MRK[T^S]NC*]]W/P-I:8YV]V/;^S5RIHD[-<9;[I&?R\E?X;F669BKK44_(3U
MN15=P)M=('F6^JMUW=*;K!EI6.-9T]L<?V/G^RODV>YQ7O/"\1/^&VL?M=]5
M\Q?72@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
MY)]8$F0UGM;:;><0TN&^5-I6H))#HZD VO6\_+=8G'?UP^=_-=IC)CB)\)^]
MF_\ RH*. 8R^M;0^WGG(R)+#;S0::4XM 7V>8VON1<G[WQ?577__ $/_ ')K
M>D=.NCM__F/^W%\>2>K37Z>22]-/*>QY;)Y'0=OE.3'X+"Y,&7*5W/MB.M+;
MK+BR25 =P4DJZBQZVM;I[YL,=*QFQQIK.DQ'+CREW_+O<\N2]L&6=9B-8F>?
M#G#HN/EL5+;=>B3H[[+ [GW&G4+2VFQ-U%)( L#XUJEL=JSI,3Q;I7+2T3,3
M$Z>E[8_)XW+1_F\5,8G1>Y3?GQG4/-]Z>BD]R"1<>T5+X[4G2T3$^DQY*Y(U
MK,3'HXL.9M.L8^3\E/S4"+,O;Y=^4RT[?W=JE UV5V^6T:Q69CU2Z[[G%2=+
M7K$^N$HEQM38>2M):([@X""DIM>]_"U=.G@[]8TU<Z<C<Y[+AN4\5INORL>G
M77W\>F1.2$O.*1)<2'07%++:0 ?W-QXWK:]EVG'?:VRWB>K2W#U<O2TON'>L
MN/>5PXYKT3->//GSX\G0D3(X_(!9@2V90;(#A8<2X$D^ /:3:M6M2U><3#<J
M9*W_ $S$OADL]@\,4#,9.)CRYU;$M]MCN%[=/,4+URIAO?\ 369]4:N&3/CQ
M_KM%?7,0RXTJ-,81)AO(D1G!=MYI0<0H>\*22#7"U9K.DQI+LK:+1K$ZPH?*
M\0.3.<H^^?I?&:91+CRCC2Y;(!;*$@1DI[K%M838^![%$6/B=EQ]RBNRG#\.
M>4QKX>OU_BU++VJ;=PC/\6.<3I^]P_=]4_<O)S*8QJ6F [-81.7;LC*=0'3W
M>%D$W-_9TK6XQVF-=)T;7.2D3TS,:^3'E[%K^/EI@3\M#BSEV[(K\AIIY5_"
MR%*!-_JKG7#DM&L5F8]3A?<8J6Z;6B)\M82==+O*!0*!0*!0*!0*!0*!0*!0
M*!0<93/_ #9I_MEG_5TU] K_ ,5_AG[WS.__ #/^./N=FU\_?3'%_JT8CQ.2
M,9,BV;F/8MEU]2.BN]M]Y"%GZ;) ^ROH/R[,SM[1/+JG[H?,OFB(KNJS'.:Q
M]\MO]7"W7=;TQR0.U];DA3J?<LLM$C]FO!\NQ$9,FGH^^61^:9F<6+7GQ^Z&
MN<X:=D\+!T_F#7U+9E*AXU&3D-?>:FLL-F._[>B@D-F_2Z4C\JO7VK<UO;)M
MK\M;:>K7C'XO%WG:7QUQ;O'STKKZ)B(TG\/J\TASCNT;D7A+5=IC!*'EY5+&
M2CI/\C,1&>#B/;TZ=R;]>TBNKM6UG;;V^.?X>'IC6'=WG>1N]ACRQ_%I/HG2
M?IZE^<.?JLU+^S(_^+6L=S_W63^:6W=I_P!GB_EASK&R,#D/U./9;(RV&<!K
M\A2VG)#J&V_+Q5FVNPK(![Y%G+>XFMKM2VV[;TUB>J\?^KG]G!IE<E=WW:;6
MF.FD^/\ =Y?_ %<6)R_.@Z/SKBM_P4MB5!EKC9"08CJ'0%M$,26SV$V*VQ<^
M_OKL[;2V?8VPWB8F-8X_7'V_<Z^ZWKMNX5STF)B=)X?5:/;'WNRF7FI#+<AA
M8<8=2EQMQ)NE2%"X(/N(K0)B8G27TN)B8UA[U%*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#YR/Y!W^ K^Y5CFXVY2X#X9Y%7Q
MMM&3R[>&>S9E1%Q/EXZRVI%WD.=Y(0YT^"WA[:^G]SV7]5BK7JBNDZ_8^1=H
MW_\ 1YK7Z9OK&G#U^UM.T[_G?47L^(TIL0M7Q;;Y6RU-?*E+?/P7*BE/<YVD
MAMI*1<DB_N\6WV=.V8K9>.2=/"/#\O.7OW.^R=VRUP\,==?&?'\_*%\<K:]!
MU/T_9;6\=W&'C($:.VM=N]?9(:NM5NEU&ZC])K6NWYK9M_6]N=IF?LEMO<\%
M<';;8Z\JUB/MA2.%X^>WOTY-SX#9=SNM9"=*A(2+J<C*"%2&@/:2!WI'B2D#
MVUL67>1M^XZ3^F\5B?7X2U;#L)W/:^JOZL=K3'J\8_'V-CT#DA>W<#[CJ63=
M[\[KN'DAE2S\3V/#1#:OI+5O+5]'9[37DWFR^#OL>2OZ;VCV6_;S^M[=CW#X
M_;LN*T^]CI/MKI^'+ZFP^D#_ &*SO]J?_EVJ\OS)_G5_E_&7L^5/\B_\WX0U
MGU49ES/[?K''D)Y""CM?D*6L(;3(G.!EKS%*( [$I*KGV+KV=@Q?#PWS3']D
M<?IZGA^9<TY<^/;Q/]MN$?5^+V]3&!UE6FZQ-UR?#D*UP)Q19COM+<,-;:4H
M44I420A38']_4['FR_&O%XF.OWN7C])^Q?F+!B^!CG',3\/W>$QR^D?:O?B+
M:?TQXZP&;6YYDQ49,::?;\S%_,N$_P (I[OMK6NX[?X&XO3PUUCU3Q;9VK<_
MU&UI?QTTGUQPENU8YE"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4'(GK#_VBUG_0G_ZT5O7RU_EW]<?<^=?-G^;C]4_>V*1ZLM8Q
MVLQX6 P\Z1G&8J&&A,2TU&2ZAL("E%#BU* (O8)%_>*\L?+V6V29O:(KKX<_
MN>RWS1BIBB*5M-M-..FGWH_TX<<Y^.YG>1=EC+C(G0I$;'M2$]CCYD$..O%!
M (3\/:FX^+N/LKM[WO<<].&DZZ3$SZ-.4.GY?[?DB;[C)&FL3$:^.O.52<1Z
MWM'($G(<>8.<G&X;(^5D,_+[2HEB$5);20"GO'>]T;N+JZG[M9SN.?%MXC->
M.JU>%8],_P!G-KO:MOFW4VP4GIK;2;3Z*\OOY+3Y1F3N!>/\=QEJV6==G9IZ
M3-EY0($=]J(>Q)0CM4>TK5T[P;V!]]8785KW#/.?)7A6(B(Y\6?[E>W;-M7;
M8K3K>9F;<IT_:EM,]*VNY348N1VG(S1LF4CIE%4=:$MQE/I[TI*5H45J%_CN
MKJ;VMXUT;GY@R4RS7'$=-9T]?T\'HVGRSBOABV6T]=HUX>&OW^EJW#FQ;!H7
M)$_AK/S%R<'->DXL)N2AF1VJ\IY@*OVI='0I_? GJ*]O<L./<;>-S2-+1$6]
MGE/J>#M.XR[7=3M,DZUF9KZI\)CUM%W[C+#ZGROCM!A3)+V,ENX]IV2]Y9?2
M)JTI64]J4IZ _#TK);3?7S;6<TQ&L=7JX,5ONW4P;RN")GIF:\?'BZ*DZYA_
M35QWL^<UV5(GSIQ81%$[RU 2B5--&S:$72GS"M0/B$VK5*Y[]TW%*7B(B->7
MEXMSMMZ=GVV2^.9M-M--?/E'WZJKXST;CO>,7(W+EK<&G<]E'G?+AOY)F,^V
MA"BGS'0M7?W*4#V)Z)";>-^F:WV[W&"T8MOC]VOCTS/U-?[=LMMN:3FW66.J
MT\NJ(GV_3D^O&F93Q=S:-'P&<3F]&S+R([2VWD/M%4EL*97=LE =0LAM93]X
M7Z>%IOL7]7LOBWKTY*^C3ES]GBY]NS?T6_\ @TOUXKSISUY\O1K$\)8NQ 'U
M9L@CI^,XX_;Y#!KGA_XK_#;[Y=6X_P"9C^>OW0^?J%DY.!SK"EX)09S26(!@
MNV2;22I26U?$"+@V\:O9JUML9B_Z=;:^I._6O7N$33]6E=/6V#?/3&QAM'R>
MU#/R\CMF/CKR&27([51Y'EI[WNVX\P$ *(4I2K^T"_3R[3OLWSUQ]$5I,Z1Y
MQY>A[-[\N1CV]LO7-KUCJG7E/GZ6Y^E+;\IG]/R6#RCZY)P+[2(;SA*EIC24
M**6[GJ0A2%=ON!MX 5C_ )@VU<>:+UC3KCCZX9/Y8W=\N"U+3KT3P]4^"_JU
MAMY0*!0*!0*!0*!0*!0*!0*!0<59J?!Q?JH<R&2DM0X$?+LK?DOK#;3:1'1U
M4I5@!]=?0\5+7[7I6-9FOXOF&:]:=WZK3I$7CC/J=*9SF_BS PUS']FAS"D7
M1&QSJ9KRS[$A+)58G]\0/IK4,7:MUDG2*3'KX?>W?-WG9XJZSDB?Y>,_8YGP
M4+-^HGF([%(AJ8UB(ZRN7W=6V($8@MQ^_P "X[8W ]JE*MVBMPRVIVW:=$3[
M\\O3,^/JAHV"F3NV^^),:4B8U]%8\/7/YRW_ -8O_=&J?Z3+_JVJQ?RU^O)Z
MH_%F/FS]&/US^"[<9@L;LW&F-U_+M>=C<CAXL>0CV]JHZ+*2>ME)-E)/L(O6
MNY,ML6YM>O.+3][:,>&F;:UQWC6+4B/L<+;A!SW'KF?XORP+L,3F)S#ANE!4
MRAQ+4AL=19UIVRNOL /5-?2=M?'N>C<5YZ3'[/9,/E.[IDVDWVUN75$_5KI,
M>N)^FCK7";.--].6/V3N"'X6":^5)_\ 674AID?:XI-:-EP?'[A-/._V>/V/
MH>'<_P!/VNN3RIP]?*/M41P5P9B>4,/E<]L<N;%BL24Q81AJ;27'$H\QXK+K
M;E[=Z+6^FME[MW6^TO6E(B9TUG7[&I=E[+3>TM?),Q$3I&GV\XGT)+FGT]8+
MCW3AM&MS9TM4>4TU/;F*:6A+#UT!8\MM!!#G8GK^ZKJ[7WF^YS?#O$1K'#3S
M^OR=_>.PX]K@^)CFTZ3QUTY3[/->OI[VG]*>+<.MU??-Q(5BI76Y!BV#=_K:
M+9K6N\[?X.ZMY6][Z_VZML[%N?C[2NO.ONS[.7V:+1K#,\4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'SD?R#O\!7]RK'-QMRE
MQ[Z1_P!8.?\ [+<_UIFM]^8O]O3^;\)?-_E;_<W_ )?_ '0DO5OJ[&,RN W3
M&M"-)F>9%FOL_ HOL=KC*R4V^.Q6.[Q^$>ZNGY=SS:M\5N,1QCV\W?\ -.VB
MEZ9JQI,\)]<<ED\@[!^E7ILE["5!3N0Q<-Y\CP#_ )S(='3W+"A6(V>'X/<8
MIY6G[IT9O?Y_C]JG)_%6OUZQK]KU]*OZJD_VC*_N(J_,'^Z_PPGRS_L_\4_@
MI;F359O#N_2<[@6B-7VF-,8^73\+03,:4W*C*MT !6'&Q;PM;[M;#VS<5WN"
M*7_7CF/LY3^$_M:QW;;6[?N9O2/<R1:/KC2U?QC]BS/2"0G2<\I1LD92Y)Z
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M1V6ZI%[I%^EA[JRV?NF?-B^'?28X>''@PNV[/M]OF^+36+<?'AQ6-6)9HH%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!H>_\ $.G\
MDRX<W94R5/P6U,L?+O>4.Q:NXW%C<WK)[/N6;:Q,8]./H8G?=JP;RT3DUUCR
MENT2,U"B,0V+^3';0RWW&Y[6TA(N?;T%8ZUIM,S/BRE*Q6(B/![O-)?:<97?
ML<24*MT-E"QJ1.DZK,:QHT/0N'-,XWR,K*:TB4F5+9^6>^8?+J?+[POH+#K=
M(ZUD]WW/-NJQ6^FD3KR8C8]IP;2TVQZZS&G&6Z9/%X[-8^1BLM&;F8Z4@MR(
MSR0MM:3["#^R/=6.QY+4M%JSI,,IDQUR5FMHUB?!3<OTJ<629AE-?B41DJ[O
MDV)22S:_@"ZVM=O[^M@K\P;J(T]V?3I^UK5OEG9S;6.J/1KP^V-?M6?J.DZQ
MHN-_"M7Q[<&,HA3RDW6ZZL"W<XXHE2C]9Z>RU8;<[K+N+=62=99W:[/#MJ=.
M.O3'W^M$<A<4:=R8U'&R1G!,B IC3XJ_*D(0KJ47(4E2;];*2;>SQ-=^S[AF
MVLST3PGPGD\^_P"UX-Y$?$CC'*8YO;CKB[6N,8,V!KRY3K<]Q#LE<UQ+JBIM
M)2+=B$) L?=4WN_R;JT3?3AY&P[;BV=9KCU][GJU79?33Q=L<YW(IBR<1(>4
M5O)QCJ66E*/4D-N(<0F_N0 *]V#OFYQ5Z=8MZ_I#P;CY=VF:W5I-9G^&?PXI
M31."M#X]RJ<YA&Y;V6;0MIN5+D%92EP65\#:6T&X]Z:Z-WW;/N:]%]-/1#OV
M79=OM+]=-9MYS/\ 8R)?"^E3=Y3R&^B5^D29#,P*2^0SYL=*4H^"WA9 N+UQ
MKW/-7!\&-.G33EYN=^T8+;CX\Z]>L3SX<#:>%]*W#:&=NS*)1S# 8#99?+;?
M^;*[D?#8^WQZTV_<\V'%..NG3.OAYFY[1@W&:,M]>J-/'R;KFL3$SV'GX/(!
M1@Y*.[$DAM7:ORGT%"NT^PV/C6.Q9)QWB\<ZSK]3*9L5<M+4MRM$Q/M:SQ_Q
M=JW&B,@WK"9"4Y(M*D_,O%[JP%A/;T%OOF]>S>;_ "[K3XFGN^7I>'8]MP[/
MJ^'K[VFNL^3=*Q[)E H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M/S&&F5N!E#BW4)273X(!)L5?1XT'NY.A-2FH3LEI$U\%3$=2TAU:4^)2@FY
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M&TNY?%,-,/OSH[3,FQC.+=0E+G=X=A)LJ]_909+CK37:'5I05J"$=Q [E'P
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M 41Y,J,&42"\V([EBATJ'8H*\+*O8W]E!ZHFPG93L%N0TN:R IZ,E:2ZA*O
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MDWO;NHJJ<CF<UFO2CH7S^1?5+QN[)@P)R7%&0PTTT^IOL<)O=LK/E_N0 !T
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MF1*ESI3;4J(X"OM6D K0IOMO='<>O<2/%V3Q6 .+]) \!@<7_J;5'%MU H%
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M8V_\$Z)R'F(NR9$3L3M$1KY9O.826N!-4QX>6M:+A0L2+E-[=+VH:O2-Z?\
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M/P/5\BK,8I'S2_,3*6M3A*UV^)-U'I0U8VQ>FOCW:L_-S6<EYJ3#R4KY_(8
MY1\8E^1W!7<I@=0+CP2L6]E#5(\@\ \>\CY/$YK*M3,;F,*P(4*=AI)@NB(D
MDI8)0#\">Y7;VV([CUH:OANWIXX]W?8GMLD'(X78I;0CY*?@YKD!<QD )[)
M2"E0*4A)-@2 +GH*&J9C\+<:1N/E\7MX%G]#'1=Z$5++BWB0KSU/=WF>;< A
MSNN+ #H+4-6N:UZ:^/\ 5X68QL2;FI>-S.+D8)Z'.R+C[#,"7V]Z&$=H"#\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>fc_clinicalmole-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_clinicalmole-4c.jpg
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M%!04%!04%!04%/_  !$( LD#MP,!$0 "$0$#$0'_Q #B  $   <! 0
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H# ;Q_NB-]*X;_-(M -B_
MJ1MKZ*@_HZ* S] * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!@-X_W1&^E<-_
MFD6@&Q?U(VU]%0?T=% 9^@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * P&\?[
MHC?2N&_S2+0#8OZD;:^BH/Z.B@,_0"@% * H39L/&PW\AD'T1H,9"G9$AU00
MVVV@74I2CP  H#SEN[UN,1!E.P]G8964;;44C(S'#'97;K0T$E9!ZBHI/L5-
M"#7<5ZW.Z7YS$:3MB%*#[B6T,QGG6'%%9TA(4OO!<D^"E 7?.WG=S%V5S"G;
M?P$]F/C&68SC;*XS+JDJ=92M7;6DD\2: VK?G-K>^WN3&T]V8P-KS><0P)^4
M4RE3;)<:+EPW;0%+(L+BW3PZ* V7U?.86Z.8>U9L[=#2528,KQ9G(-MAE,A)
M0%&Z4V3J03Q*0!Q'"C).N5 % <TYZ;XW!R_V(O.;;82Y/<E,Q52'$=XB,VZ%
MDNE/0>*4H&KA=0]JI!KOJZ<S=W<Q<9F1NI"'U8QQA,?)MM!D.EY*RMM00 C4
MC2D]D="A?V3!VVH H!0"@.#>L=S.WARZ<VX-JRVXJ<B)AE!QAM_462SHMW@-
MK:U=%2@;#ZOF^-R;_P!F3,SN>2B3/:R+L5M;;2&0&D,LK (0 #Q6KC1@ZQ4
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MX'KK$WI&[*Y:U#@W%)5CQ.M6G]VPR]R2LPM7]+&ZE.4I99)[4XT3CCCLK1/
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M=Y?C*<TU%+!);6Y.N&RB3\E>"ARZR^)B<]MZSI60C,P7VI?<2EOMI965RF%
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M"'IER\'!QOKE<F>@B@% * 4 H# ;Q_NB-]*X;_-(M -B_J1MKZ*@_HZ* S]
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MYGX3#9W<$B;BY E%^*X&]"^[BNK3>R >"@#TU)![&J"10"@% * 4 H!0"@%
M2K0AU"FG4A;:P4K0H I*2+$$'I!J4Z$-5P9AQL_:*0 ,!C@!P $-BW_HJ_\
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MTI*RO42I238='L*$'IWD?G,ON3EA@\SG9:YV5D>,]_)= "U=W*=0F^D <$I
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MX^RAXEJO>S]I^D?67S%]+<Q_B$GXRGP.G]W'V4/$M5[V?M/TCZR^8OI;F/\
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M:6JDM4K-%1QS<NTT<-#"6AE?J\T9Y>2E$_Q*NR]D8W>FV-RJ@.R5;ZPK*<A
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MM'*]',YJ>6BQPHGQ5X27?6PXVT,#LS( RD9+<,-R3DHLM(1W+K;B$A*$Z4J
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MLYLM/WZ5\Q@*RS!% >QO5'_4+,?2[GZ,Q7G_ ,Q_WX_E_%GI_P I?II_G_\
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MK1<18WYKK>IE;4)9\L:.5*5?'0Y;6[.;% >QO5'_ %"S'TNY^C,5Y_\ ,?\
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MESN^BRPM&H#A>]N'"H).)2,;ZT^9C',SLC.QK;G:;9>GQL2I1Z;!KO&=/M+
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MJB,AXPQ_*#[]6B^/&&/Y0??H!XPQ_*#[] 3EQ"4ZU* 2>@^W0$GC#'\H/OT
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M^_0#QAC^4'WZ JT!*M:&Q=9"1T7- 2>,,?R@^_0#QAC^4'WZ >,,?R@^_0&
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MVOHJ#^CHH#/T H!0"@/-7KA?W#MC_BY/\TBI1!J_)7_0CFA_L)7Z": TCU;
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M4VF(XU+?7';;0X5=IPK;5V;>U0DV#HX'@1TB@% 7$+_>$^T?VJ RE0#%S?\
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MFDC&E36*QDN;D]J[AV6Y&3)C8XP8^4DAV')D>+,AAYW0") CH2"OB.LT)+O
M<F-T0-ZXO)9R.]*A1I.'R</+X^? 8,!6,Q[45<1U+L94I;25-N)"([X;=0LZ
MD@WN(/0Q-R3:U^H=%"2% 9&1_N:?:34 QU2"=I00XA2NA)!/W* \RPN0.\S
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M@MYK9C4.$UYM[8D[>E8^3(G0UY./%A.K5D(LR0E@.RE:%EMA+2T,=UV2DGI
MDP_('*LNX3$9+;&'^0,+,W:N4Z'F5-9)&9;/R8\J.$ W9N&=#M^["0H= L!;
M*Y [V9P0Q^):@P)4K:>&@Y_NY*4#*9O%9+QI]N0HMN!8>8NWW[B5C\!0*.%
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M?#H24== =+Q3K3['?L.)=8=2AQIU!U(6A:=25)(Z00;BH!:.>_5[9_;J02T
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M=#A>1C8L:$EX@)*Q&:2T%$#HU:;VJ 0<]^KVS^W4@EH!0"@% * 4 H#(H_W
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M_P"*5_"_<%0"[H!0"@% 8#>/]T1OI7#?YI%H!L7]2-M?14']'10&?H!0"@%
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M@JO[%2#VZPV66&F5.*=4VA*"ZLW6HI%M2B.L]=4DE2@% * 4 H!0$KO\6O\
M@G]J@,+4@4 H!0"@% * 4!D9'^YI]I-0#'5(% * 4 H!0"@*C'\<W_"'[= 7
M>0]ZCVS4 L*D"@% * 4 H!0%Q"_WA/M']J@,I4 Q<W_>%>T/VJD%O0"@% *
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M:- 8VI!J6[][/[:R^W-MX?#G.[HW.Y)^3X"Y"83"8N.;2[*><?4ARVE*TA"
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MP<:TJJ'$/LQ1O3K<'Y\>[70^./W4.@YGP!^^N=)'[,<;TZW!^?%/''[J'0/
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MW6_$M/*HTXC;Z#0_"IK/*=>UP&BSO5MCSITF:=[YYHR77'BVAX!">\45:0/
M+VK90WTXQ2[J&!JY[B<I-]]<QY2A]F.-Z=;@_/BJO''[J'04> /WUSI'V8XW
MIUN#\^*>./W4.@> /WUSI'V8XWIUN#\^*>./W4.@> /WUSI'V8XWIUN#\^*>
M./W4.@> /WUSI'V8XWIUN#\^*>./W4.@> /WUSI'V8XWIUN#\^*>./W4.@>
M/WUSI'V8XWIUN#\^*>./W4.@> /WUSI.CP.7Z('+QSE^,S->0MA^/\L.+!FC
MQAQ:]05X4ZK)]@5J9ZS-J.^RK:NKP8&YAHLNF[G/)X-9OWL3G'V8XWIUN#\^
M*VWCC]U#H--X _?7.D?9CC>G6X/SXIXX_=0Z!X _?7.D?9CC>G6X/SXIXX_=
M0Z!X _?7.D?9CC>G6X/SXIXX_=0Z!X _?7.D?9CC>G6X/SXIXX_=0Z!X _?7
M.D?9CC>G6X/SXIXX_=0Z!X _?7.D?9CC>G6X/SXIXX_=0Z!X _?7.D?9CC>G
M6X/SXIXX_=0Z!X _?7.D[NTCNFD-7*M"0G4>DV%KFN;;JSJ4J(U;F%L=&_\
M!M81>5EX=+<E$KQJ H(=5W:%HT$_BG7?[@K,T>J^'GFRJ6%,3!UVD^)MY,SA
MC6L3F/V8XWIUN#\^*W'CC]U#H-)X _?7.D?9CC>G6X/SXIXX_=0Z!X _?7.D
M?9CC>G6X/SXIXX_=0Z!X _?7.DE'JQQPHZM][@L;:!WPX>&_'C3QQ^ZAT$^
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M"5:T-I*UJ"4CI)X"@*+4Z*\O0VX"KJ!N+^U>@+B@(*%Q[/50!)N/9ZZ C0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0& WC_=$;Z5PW^:1: ;
M%_4C;7T5!_1T4!GZ 4 H!0$%*2A)4M02D=*B; 4(;H02M"TA:%!2#Q"@;@CV
MZ4"=2"'6G;]VM*])LK20;'V;5+3033V$5+0DI2I0"E&R038D^Q2@J%N-M)UN
M*"$#I4H@#[YHE4-I;2*5)4 I)!2>((X@U!(U)MJN+>'JH 2$@J4;)'$D]%J
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M! D 7- 2]Z/!0$] * 4 H!0"@,!O'^Z(WTKAO\TBT V+^I&VOHJ#^CHH#/T
MH!0"@.2>L<E*^7*4+9,A"LG 2J.DV+@+MBB]Q[[HK>[D_4<75E]QS7S%^DV5
MZT?O,)MC:6:P&&YC916(7M7:N2QC@Q.VUR1)6VZU%<#KY"%+2WK/X*57/7T"
MLG4:F%R=F.;O)QEC*E.%47*8FETERU;U$LG=6Y1ZL*U_==7R5-(Y-P4L;SV$
M6\7YJN/X>5*<EHD*D#<0T:0%(02ALM]ITA?:_P#NULMYSK9N];O*22I2G=^F
MNS[,U.YX4U%CJ]U6#=:U[WT4VX^@S.,P.W.8".9NXN8;Z_.#"9"9%AER0XT<
M5#B(U1ULI2I(3=0/$CM%/LF^/<O7--W$+*ZLHIO#UF]M?M@95JQ:U?Q%S4/K
MPE)+'U(K93[8T+?(OSMX\MN3GG>@S',EN&)&FI?))D1N\>907#P)UM!))Z[W
MZZJ@HV-3J>[PRP;7(\'YF47)2U&DTG?8YKB3KPJK6/.C;=E0X>UN=^7VALQ:
MD[0^1T3<GC$.K=C0\D7@ $:BK0I22"4W_"/4D6P=5)WM%&[=]?-1/A<:&RT4
M(V-XSLV?[>2LHUPC*OF.?N.I'JLY.'W@\=&55&[C5=WO_E-"^[T].K3VM/@X
MUM$O_P#4B^#+7^$TK?\ _C27#GIY<^PW_F"U'W-S8VQL'=LAQC93V+7.3"#R
MH[4_(I6I :<4@I*M"4A03?\ ]5:O1MVM).];5;F:E=N6/&;K>"5_6V]/==+6
M6M*TS2XGS?;:;%N[E;R^1R[R.(8Q"!C,2S-R4!A#[]FIG<+)6"'+GC^"HE/L
M5B:;>&H^(4G+&65/!;*\QFZO=>E6EE!1ZL%*2Q>#ISFK\ON7^/')%Q_:KJ<#
MN7=&*:\=S"GG;*=05:2HJ4H-@ZE)); MJOU"LW6ZR7QM+G7A;EA&B^S\IK]W
MZ"/AU;3R3NP595?V7D+SDFQA]O9K,[.>VN-N;SB1(KV3<8EKG1IK"20AY*E+
M5H42NY3T\?8L+>]7.["-U3SP;=,*-/B+NY8V[-R=EV^[N)+-26927'R&(Y^S
MI>5W#BL!A<<<[+P6.FYW*X21_N3L1U(C(<* M"G7657<0A''P5?W/!0MRG)Y
M%.48J2VUV^1/88V_IRN78VX1SN$93E%^JULKRM;4C=^3.XV,SM]>)Q;C^3P&
MWT1H$+<LDJ2K(N]R%O%+*TA3:6BH( 4I7M\*UV]+#A<S2I&4ZMQ7[N.&/#7:
M;;<VH5RUDC64+=(J;_>PQPX*;#F._-NG<?.O.Q_,Q.]0SBX2_$UY,XD,7X=X
M%W&J_1IK<Z._W6BB^\[KK/'+FJ:#7Z?OMX37<]]2,<,^2G*7G-[;Z,SS2VUB
M&]OL9]IO!.E.)E3EX]H!IU0"N^2024^#KJWNV]DTLY9W#K[5'-P<1<WOI^\U
MEN&17/Z;ZKEEX>,S_-69%P'*S;FSQ$7CD9U_'XI_'XY:YSL>(C2[*0RH76]I
M2CNP>E5_9K%W?%W-5.[7-D4I5>%7P5XN,S=ZS5K1V[-,N=QC2/6HMLJ<?%RF
M,Y88[;&^.7^>V%GX;TW&[4RLDX^--+\62F*OO'8BW$A2%I59;@TJ\%7M?.[I
M]1"]!I.Y%5I1JO[WX&/NRW9U6EG8N)N-J;HG5.F+C7AXRWY1;1P47D7D=T0(
M13N3,8;+1YLL..J4\EI<A+:0@J*18)2.RD57O+4S>N5MOJ1E&BZ"C=.DMQW;
M*[%=><)IO''UBSF/M2>6/))F.\EU]>>P]FT*U+/<]XES@./8/!7@JY%-:G4M
M]B?X%J<D]'HTGCWD/-6O08KG#%0_S%WK)<VUYPB'M^.\)'C/BYQIL1XV #J7
MH/:*4<>'@O5[=DJ:>TL^2LWP5S?Z3'WO&NJO/N^\I;7#3)_JY:&5YE8LY';W
M*'%DHW>)/9!DR'(3<]*HK:@I3Q(6BXX@J[7AXU9T-S+<U$O[=.)5RXO@,C>5
MK/:TL?[M>-Y<W57#M-JS.P<K/Y00MK8"#$VY*3-#\K;J<@Z_%E-!YQ2XAEZM
M?Y8$+X'@1IX#C6#:UD(ZMW)MS5/6RT:P];+R;#8WM!.>A5JW%6WFJX9FT\7U
M<VW';YC.<DYF 5A<OA\/MY6UYV)R+C&:Q'C"IC2)NA 4IMXJ4%)(2!8=%ONG
M&WK&YGC*4^\4H]5TIAS&7N6=KNY0A;[IQE24:UZW(SIU:8Z 4 H#$8)*0YE]
M.,.-OD'25'_\K/=M_P!)Z![[WO\ X: R] ><-N82-L/F1CGM\8I&:RN?RDCS
M?WS&FN.N*=>24!IZ-KL $JTW TIZKVN.NOW7J-,U:EE4(K-;:\Z9PNFLK2ZN
M+OQSRN2>2ZI/:^!Q^R15W;RMV&_SNV[B7<0%8_/1<ED,LSW\@!^4G6X%DARZ
M>T;V00/8JG3;POK13EFQ@XI8+!=!5J]UZ9[QMP<<+BG*6+Q?28+GKD6)^[G\
M3",Q"=BX=J3B_$679"&<HXZT\DO*0"$($=L=I?7QZJRMT0<;*DZ?U94=6E6-
M&L/*S$WY<4[[A&O]""<:)NDJIX\2RKA-PYE[J3NC'<M6'9SF,V5O%]*\[*8<
M+/9+3:T1EN@C2E:E+2KC^#[%:_0:?NI7G3-<M+JK\:&SWEJN_AITWEM7GUFL
M.!=6O*7NQ6]M[=W;O'9>%V@-N/L8_P 95.1/5-3,B(4M#"]"BKNRH+*K:M7A
MJWJW<NVK=V=S/65*9:4?#SEW0JU9OW;,+7=M1K7-FS+@YC3?5PVR W@MS*VK
M$2I2)J?.GY3<,M7:=;L85RD='=]'O>U[>PWY?]:WWCX.IEPX/WO.:OY<TV$+
MO=K][KYW7A7J^;SG0>?4^4SB]LX=<MS';>SF;BP,_.966E)AKN5(+@]ZE5B2
M?WO@O6JW/!.4Y4S2A!N*Y3=;^N-0MPKEA.:C-\AA\3A\5L+GAB=L[%U1<+E\
M4_(S^';=6ZPTID*[B19:E:5J*4IOX/X59%R[/4:&5R]C*,EEEP\J,:U9AI-X
MQM6,(S@W*-:I4V/[?B:=RLVTG*;ZS.9<V2G,)A;JFVW2K*&,J"6G L)$2_Y7
M03K]G5;JK8;POY+$8][EK;74RUS?]W :O=>FSZF<W9SY;LNOGIEQ[/#3\3I7
MK*?Z1Y?_ &\(?VENM/N/]7'F?W&^^9/T,N>/^Y&O/X;#[$YP;)QG+]/B!S3,
MKSEPD9U:XQC-M!3;RVU*5I5?5I5UZ?;OEJ[/4:.[*]CE:RR>VM=A@RLV]+K[
M,=/U<Z>>*V4I@Z?;8:MMG:Z<SS2W7DU[5B9M,'=*S\K2<FY">AA#^NZ&$JL[
MI]^+CB>%9M_49-+;CWCC6WL4:UPX^ U^FTO>:R[+NE/+=]9S<7''BX>,S^_<
MR>5F_P#=N7;<[B+N_;KDB!QX'-0B&$) \-EA9MX:Q=':^+T]N.UVYT?Y'B9N
MOO? ZJ[/8KMNJ_/'#]IB^9&S_-GE'RYVHJ(F5*.9@IFPG72PA^5+;>6\TMT$
M%*5+64:[]D>U5[0ZGO=7>N5HLLJ/;1*E'0QMXZ/N-#I[5*O/&JK2K=:JO/A4
MRVY\ -N>K_NZ$G;\?;*E/(>,"'/7DD*N_&'>%U9N";:='@'LU8T][O=?;>=W
M,-KCEX)<!DZFQW.[+L<BMX[%+-PQQK^!N?,'/97!\E)F3VX\1EH^,B)2\RJ[
MC*'>Z;<<!%R"E"E*"NKIZJU^BLQN:U1GL<G^)M=X7YVMWN5M]91CY-B;Z#F6
M=VUM[82N6.YN73S@W)FY\2-*<;D./'*Q920J0MY*E*![1XD :=7L)MMK5^YJ
M._MWUU(Q;6'JM;*?;@YS2W=/:TOP]S3OKSE%/&N>+QE7[85Y%3%[VVW*W3S<
MYBXS'[7<W#F5Q<<G&3$RDPTXQ]45O3(*U+3>QXZ1>^FW75_27U9TEF3GDC65
M52N;%X&-K-.[^LU,8V^\EU,KK3*\L<?QY:4,OSEPNXE1^7^!?GKD;EP>'R.3
M>F-DJ4],Q<9AV]SQ.HM*L2+FK.Z[MNMZ:5(3E&-.23:_$N[YLW:6+;E6<(2E
M7C<4G^!2P6;=W3SKVKS&:4ZC$9Z3/Q6*9<X 1L?C4A9 (Z%/NN?>JJ]:5G17
M+'[T%&3YY2]"138ON_O"WJ5ZLW*,>:,/YFRC#VNG/<V]YRU[5B[@3"S4<^.R
MLFYCUPP>U=#:" YT:K'P6JJ6H[O26UWCA6#P4:U]!1#2][KKK[I7,LUBYN.7
MR<)EM_JR^*YRY7>N%4XY)VIBL?D)F/;X^-8U;JVIB.)M=+:N\!/1IOTVJQH\
MD]'&U/9<E))\4ML?/@9.OSV]?*]#;:A&37'&M)>;'R&8Y9;>VOO_ )99IC,Q
MCDL*YGLG/B)6XZT20HEI=VU(5[U71T5CZ^]=TVIBXO++)%/\3*W9I[.KT<U-
M9H]Y.2V^385O5DVK@(FQ(.[X\/1N+(IE1ILWO'%%QIJ4L)3H*B@6"$]";\*I
MW]J+DK[MM]6-&EY"OY:TMJ.F5Y+KRJF\=F;H-OW=ISW,39NU1I7&QAD;HR39
MN"!$3XM#/W7GBK_P5@:;^GI[ESAE2"\N,O,O.;+5_P!756K7!&MQ^3"/\3\Q
MB/6 S&0QNU\1#CS7<9B<QEXF.SN4844+8@.ZBX0L>]!MQ/@X==9&YK49W9-K
M-*,6XKC9C;_O2A9BDW&,YJ,I+@CPE+<6U=N<KN7FZ,_RS@IAYA6-'],9>=D+
M+23_ !UW%K%T)4IS4!U5-C47-7J(0ONL<VRE/)^!3J-+:T.EN7-,J2R[:M^7
M;P;3G^6P&W]E[9Y=[UV/*<.],M.@-NRDR7'7,J)B=4E#R%*4%#78'AV;VZ;5
MM;=ZY?NWK5U?TXJ7!ZM-E#2W;%K36;%ZP_ZLY1QKZ^;UJ^7H+OFC)=QO.5.]
M4/K;C;-B8=Z>A U7AS)CC$C@.O0]5O=\5+1]U3&ZYTYU&J^XN[TDX:_OJX65
M"OY92:?F97Y,F<>;&1S626KQG=^!7N)MI9OI8D9$I83;JLRE%4[TR_"*,=EN
M>3HCCYRO<V;XV4Y;;MO/Y'/#S4-!VS.S.*A9/&P7EA7-?OH>,=.HI1+1EUPG
MS>_"T=Y2]7M5M+\(3E&37Z?%\V3,OXD:;33N6XRC%_JJJ//WF5_PNIG9C:8?
MJQ;AQK2RI&-S3D1"KW.EO)-VX^T:QHO-O.$NU&O\+,N:R[GN17[LZ?QHV_'[
M8&VN5G,$C:T3:ZI6(<5>%DW,IXQHC/=I6LJ[O3JX6/'5[%8$]1WNJL_U'<I+
MACEIBNDV=O3=SHK_ /35JL.">:N#Z#5^3<%,??>R^[Q?FFX[MY4MU3<@R4[A
M2MO2'%)22AHI-WM*NU^Q6;O.=;%SK=YUZ;*=WZ>(U^YX4U-GJ]U_3KMKWN&W
MB7'QFP[&VMM;FIF]XY7F0#E-Q8_+28#.)D2'6D0(+) ;#;;:T6"B""KK*?#>
M^)J]1=T<+<;'5BXIUHNLS-T.ELZ^Y=GJ>M.,W'*V^K%;*)?; VB2E+?K&XQM
M'!M.U7 E-S8 2U 5A1QW=+_V?@;"2IO6*_Q?_(Y-F-YPT<T7N9*532K&[C:P
MR70RZ<<,(VR8CZN_ [O6I:BL()Z[UO;6E?PJL8=:&;;UL]:K#:<W>UD5K'J>
MMU;BAL>7)3*\=FW&AUG=CB4<_-A*6L);^3<G<E5D_P 4O[E:+3+_ .A=_-$Z
M75NF\['Y9_<1YJK2O?G*I;:]2%9=^Q2;@CNT>"F[E_0O_E0WJZZG3?G?W(U#
MF5L79F^.9+6U\'!;:S[BD9/>FX>_=O%AI"4H90A3A;#SPTV['9%C8@FV?H=7
M>T^F[R;ZOJPC3:^/CHC6;RT.GU6K[J$>OZUR=7@N+;2KYC,<\I&%3'V=RX6)
M2<'->+\QG&-.2Y @8Y@I;2$-W6H%:D\?WMZQ]TJ=;E_#,EAFP59/[=)D[\E;
MI:TV.63J\J;>6*P\_P!QCMOQ,'S(Y!!6YXAF93:,2?%;[Q;S2V)<!A:6E*"5
M()5W?=DA=^/55V]*>EU_]-T5QQ?!BF\?/4LZ>%O6[L_JJLK2DN'!Q6'FIM+3
M$[3V_@_5NRN>Q4/Q?+9O")=RDD..K+RVU*TDA:BE-M1]Z!5RYJ+ES>,82=8P
MGAR%JUI+5K=,KD%24X=9XXESGRG,*Y-[*SK[C&RLQCFW,BA+BF43)$>$V68[
MBTD'25$#3?M%7AM:BSU/B;L%6Y&6'(G)U9<U']3X2S-TM3CCP9FHJB?VX3+[
M!C1]K\U]X[)VLXKS,8QK4YR '%.LPLBX4@MME15IUI4I13?_ --6-9)W=+;N
MW/[F:E>.)DZ"*L:V[8M?VU%.G!&7$N?[;#A+4W)[=Y.KQ<M;CVW][M(F8ITD
MGQ;*XS(I;D,\!P#K+:5@D](]NNF<8W=9F7K6L'RQE'!^1G(*<[.@RO&%Y5CR
M3C/%>5(]QM_Q:/:'[5>;,];6PFJ"10"@% * 4 H!0%KD$MJBK[Q.H_@#KU'@
M+??H"DQB8[2DK62M0L;'WMZ OZ 4! BXL: )/4>D=- 1H!0"@% * 4 H!0"@
M% * 4!A\M*=2X(Z"4IM=1' F]"2RBRW8[J2%$H)&I)-P10&RT(% 2.>]H"E4
M KHX)%ZD$: 4 H!0"@,!O'^Z(WTKAO\ -(M -B_J1MKZ*@_HZ* S] * 4 H#
M%Y[;N%W/!3C<]$3-@I=;D)965)'>LG4A5T%)X&KUF_.U+-!T9CW]/;OQRW%5
M5KT%[,AQLA#D0)K8>ARFEL2&E7LMIU)2I)M8\0;5;C)Q::VHNS@IQ<98IX&%
M9V+M..<$IC&(0K;06G!J"W-49+J0E82=5U!0''7>LEZNZ\U9>OZW*8L=#862
MD?[?J\E2PW!RKY?;IRR<YGL#'F95.G5()<;+FD6'>I;4E+E@ /R@-7+.\-19
MADA-I?;9Q>0LZC=>EOSSW()R^VWC\I?;EV+M/=^-BX?<&,;E8V$M+D2.E3D=
M+2D(*$Z.X4@@!)L!T5;L:N[9DY0E1O;P_>7=3H;&H@H7(UBMBV4Z*%;;&SML
M;,AK@;8QC.-C.D*>#0)6XI(L"M:BI:K=6I1JF_J;M]UN2<F5Z;1V=-'+:BHH
MQ2N5/+M6XO.M6WXQSQ=\8,GMZ>_U:N][K5W>O5VM>B]^-[U?\1U'=]WG>79Y
M.*NTQO"M+WO>Y%GK6O+QTV5Y:&4W1LW:^](:(&Z,8SDHS2BID.@I6VI0L2AQ
M!2M-^O2H58T^JNV'6W)Q9D:K1V=3'+=BI(8;9FV=O[?<VKB,>F-@'DNH=A:W
M%I4F0"' 5+4I1U _C4NZJ[<N=Y)UEQ\PLZ.S:M=U"-(.N'/M(KV=MIS; V:O
M'-JVR&DQQCE%91W2%!0&HJU<"+WU7I\3=[WO:]?C)>CLNSW.7J4I0H;3V%M#
M8S+[&U<4UCDR2DR%H*W'7-%](4XZI:R!<V&JPJK4ZR]J&G<EFH4:306-*FK4
M5&OVVLDW3R]V;O5V-(W-B6YTF("F._J<9=2@FY05LJ0HI/XI-NGAQJ=/K;UA
M-6Y43^W"1JMWZ?4M.[',USK[B[VYM#;FTD2F=MP$8Z/,<#S\=E2PR7 -.I+9
M44HX#CH O5%_4W+U'-YJ%S3Z2UIZJW'*GT=!78V[A8V=E;F8B)1G9K*(LJ8"
MK4MEHW2D@G3P]@50[\W!6V^JG6A7'3VXW'=2ZTE1OD,3NGEMLC>LIF=NC$-Y
M&7';[EEU:W4%+>HJT_DUIZR:R-/KK]A-6Y94^8QM5NW3ZF2E=AF:PX?P+B-L
M/:41>"<CXQ"%;:0ZW@^VXH1DO@)<T@J()('2JYJB6KNRS5EZ_K<M"N.AL1R4
MC_;KEVX5+N/M? Q,QD\]&A);RV80VUDY*5+N^AE.A 4G5IX)X7 O5N6HN2A&
M#?5CLY"['2VHW)7$NM/UGQT*N!V_A]LXEC!8*(F'B8VON(J"I24]XM3BN*RH
MFZE$\347KT[LW.;K)E5C3V[$%"VJ17 8##<JN7FW\V=Q8?;\:)F"5*1(1K(;
M4L$$M-J44-W!(["165=WAJ+D,DIMQ^VWC\IA6=U:6S<[R$$I?;8MB\AEG]H[
M;DY')99_'MN9#+Q/DW)/**CWT2VGNE)OIM8VX"]6%J;BC&*>$75<CXS)EI+4
MIRFXXS65\JXC&9/E?L/,8;&[?R>&;D8C#A2<;&4X\ R%V! 4%A1Z.LFKUO7W
MX3E.,J2EMV8F/<W9IKEN-N4*QAL6.'G*;O*GE\]MI&SW,(TK;C<@S&X7>/ )
MD$%)<2L.:P;*(]]UU*WCJ%=[W-UJ4KAL(>ZM*[/<N'4K6F.WCVU,WMS:^W]H
MXU.(VWCVL=CDJ+G<M ]I:@ 5+4HE2E$ "ZB36-?U%R]+--YF9>FTMK3PR6XJ
M*,O5@R10"@,1@R2YEKY/Y2M/= 3P_HHT-_T?@3[WWW_BH#+T!IN#Y4<N]MYD
M[@PN CQ<O=2D2;N.%M2P02VEQ:DH)!([ %;"[O'4789)S;B:NQNK2V;G>0@E
M+CQ\W%Y#.R=MX29G86Y9,-+F<QS3C$*82K4VV\"%I !TFX)Z16-&_.,';3ZL
MMJ,R6FMRN*ZUUHX)\Y3B;4V] D9B5%@-HD;@4%9EPE2S)(2I "]1/ !2A86'
M&IEJ+DE%-X0]7D*8:6U!S:CC<];E+4;"V?YLHV:O$,.;9:N6L<[J=0@J67+I
M*R5 ZE$@A5Q5?QE[O>]S//QEOX"QW/<Y5DXBUVORRV+LQ4I>VL,W!<F-EB2X
M''75K:4;E&IU:R!<= JO4:^_?IWDJTYOP+>EW9IM-7NX9:X/;^):X+E#RXVU
MEH^<P>!:AY6+J,>2EU]105H+:K!;BD\4J(Z*N7MY:F[!PG.J?,6[&Z-)9FIP
M@E)<-7Z3:<QA<5N#'/XC-PVIV-D@)>C/I"D*L;@^P01<$<0:PK5V=N2E!T:-
MA>LPO0<)I2B^!F(VIR^V;L</>:V(9QZY  ?>25NO+2#<)+CJEKTC\75:K^HU
MM[44[R5:?;@,;2[OT^EKW45&O3TLR&#VW@]MIFHPD-,-.0E.3Y@05*[R2];6
MX=1-B;#HX5:NWYW:9W7*J+F+]C36[-<BIF=7SL;BVWA-V8E[![AB)FXM\H4[
M'4I: 2VH+2=3:DJ%B+\#2Q?G9GG@Z-#4::WJ(.%Q9HO@,=M7EYLO9*G7-KX=
MF ^^-#T@%;KZD7OI+KJEKTWXVU6J[J-;>O\ ]R3?W="+&EW?I]-7NH*+?3TO
M$QDOD[RUG9ES<$K -.9AZ09KDKO7P52"OO"LI#@3?5QZ+5>CO/4QAD4^K2G!
MLZ#'GN?22N=XX+,W6M7MZ3.[AV=MG=;D![<.-:GN8MWQB IW5^2<)221I(N#
MI3<&X-JQK.INV4U"5,VTS-1H[-]Q=R*EE=5R#=&S]M[T@M8W<^/1D83+HD--
M.*6@)="5("@6U)/0HCIII]3<L2S6WE8U6CM:F*C=CF2=3&PN6&P\=MZ?M2'A
MFVMOY-Q+TZ#WCRDNN)T$$J4LJ%M">@]57IZ^_*XKCEUH['@6(;LTT+4K2AU)
M;5CZ>0GVWRUV-M'QWS>PS,-.1;#$Y!4X\AUH7["DNK6+=HW%N-1?UU^]3/*N
M79]D3IMVZ;3U[N"6;![77I*6W^5?+W:V57F\#@(T3**OID#6X6PKI[H.*4&[
M_P#PP*F]O#47HY)S;7VV\?E*=/NO2V)Y[<$I?;9Q>0S<7;>$@YO([CB0T-9S
M*H:;GS05%;J(Z=+8-R0  +< +]=8TKTY04&^K'8N<RX:>W"Y*XEUI4J^.FPA
M,VW@\EEHN<GPD/Y:"R]&C2%E1*&I(TNI";Z2%#@;BIA?G&#@G1-IOR;")Z:W
M.:G)5E%-)\CVEE%V%L^$G"(B8EIA.W%/.80-E:1&5*-W2FRN.LFYU7JY+67I
M9JR]>F;EIL+4=!8CDI%+NZY>2NWI,3E.3O+7,Y9_.9/;[4C*R7>_?DEU])4[
M<'40EP)ZO!5^WO/4VX*$9T2YO08UW<^DN3<Y03DW6M7Z394[<PB<S*W (2#F
M)L=,*7).I1<C(-PV4DE-K^Q6)W\\BA7JIU7.9_PUOO'<IUI*C?)Q%+;^U-O;
M5Q:\+M^ B#BW%K=7&;*U)*W>"CVU$\;>&IO:BY>EFFZLIT^EM6(9+<<L>(K;
M?V]AMK8IG"8"(F%BXY6IF,@J4E)<45JXK*CQ42>FJ;UZ=Z6>;JV5:?3V[$%"
MVLL5P$(^ QL;/3=R(0I66GL,1'75J*@EB,5J0A"3P2-2U*5;I-)7I.VH?NIM
M^5B.GA&X[G[TDEY%_P!2XRF*QN;@/XO+Q&IN.DIT/QGT!QM8Z>(/@/$'J/&J
M;=R5N2E%T:*[MJ%V+C-*2? S [7Y;;(V89IVUAVX7RBD-S1K=>#B!>R2'EK
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MS/GXS.AH[,)J:CUHQRKDCQ"+L[;,)K-,Q<>AIG<3CKV:;"EZ9#DA)2XI0*K
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M0-1N>CJ% 1TIZ;4!&@% * 4 H!0& WC_ '1&^E<-_FD6@&Q?U(VU]%0?T=%
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M^V'_ -G_ /4?^6I],_Y/X?\ D/J__%_%_P 1]L/_ +/_ .H_\M3Z9_R?P_\
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M * 4 H!0"@% * 4 H!0"@% * 4!*>R=0Z.N@(]HGP#]N@! /2+T!&PM;JH"
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MVI8,8C9V5:DPH49@KBY'/M[?VT[DG1"E/1682(ZG%K>392TEQS6E:.]4@(!
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M% * 4 H!0"@% * 4 H!>@% >@O5&_7K-?1*_TEBN5^9/[$?S?@SM/E+]3/\
M)^*/8E< >GF*PG?]YE>^QR,>/'G.Z4BW]*1H;M(5;K5Q3Q_%H#*T H!0"@%
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M&6Z5#^21V4?=ZS0$[2&&'5--]E2QKT#WH [-Q0%>@% 0!!)'6* @OC8=9Z*
M *' $6H $\;DW- 34!!-^)/7T"@(T H"VGLK?BK;1Q7P('AL;VH#6RE0.D@A
M71;KO0DS<*-,8CI*%A*E7465CAQ]D<10@FD2UH1HD-*:N>*QVD??'10DII4E
M8U((4GP@WH"[B$V4GJ%C0@N: 4 H!0"@% * 4 H!0"@,!O'^Z(WTKAO\TBT
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MI7?^BK[MN\=-_P %/OO_ !4!F* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MFN,18X4IP(;3:PU+)4?NFLS0W)7+$)2=6T:S>EB%G4SA!4BGAP_>:O6::P4
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M2%*[+:R4 WX@7X=%=?"5:KA7V1P5VVU25,)?9]#P+*KA9% * 4 H!0"@% *
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ML2N /3S#;?,8N9CQ?(N9 C(N]\ER_P#1G.[;O'3?\%(LKA^-0&9H!0"@% *
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M_%'L2N /3S&8?QS7D_&X#4$>.N>+J9M>0SH19]=OPE&X-^/"@,G0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0$";<![XT  M[)/2: C0$"FYO<B@!%^NU  +
M>S[= 1H!0"@/"WK+_P"KF5_V$/\ 1T5Z7N+])'G?WGD/S)^NES1^XY7#R,_'
M%\X^4[%,EI4:06%J;+C#A!4VHI()2JPN.NMW*$94S*M,3GK=V=NN5M55'3BX
MBV  X#HJLMFPX/-;QVM =R^"E2L?BI[IAOR&O]V>?82'-"@H%"EH2L*%Q=.K
MA6)>M6;TLLTFUCRXFPTU_4:>+N6VXQEU:\#:QYL*@[[WD68L<YV9W4/28P[P
MW04-K:2;])*4.+0DJ)LDZ1PI\)9JWE6/_7[U4>(ZBD5G?5V=#7W-KFP*,7>&
MZ(4(X^)EI#4/Q?Q)+25#L1B7%%I"B-2$GO7+A)%]1!X&JI:6U)U<56M?+AZ$
M40UU^$<JDZ4IY,>C:RZPNY=\[6Q'?X/(S<;@Y[[C:%LJ*6%RF4)[PHO<)<2A
M:;J195B.-6[MBQ>G2:4I)>;T%VQJM3I[=82<8R;Z4EYZ-8[3%?+N8\>A9/QY
MXY#')9;@R2JZV410 TE!/0$ <!5_N897&F$JUY:[3%^(N9HRJZQI3DIL-G&Z
M.:J,@F6B?E!D<K$;GLEL$J<A1 XIM]I"4V2AH)=(6@#2-75>L+X?2N-*1I%T
M\KI@^?#S&S>LUT9YJRS35?\ M5<4N3'9R\IJ,S(SLD6#.DKDF,RB-'+BM6AA
MN^A"? D7-A6PC",:T5*NIJ)W9SIF=<JHN1+@-F?SW,N'A\5.DR<K&P32FQAY
MKB'&XY4PVMMONG2D!90VI:$=HV3P'"L*-G32G))1<GZRPKCQKG\YLI:C60MP
M;<E"-,KHTMC2H^'"JYBSQNY][X8Q6\5D9\,OQ4PH*&BM)7%[Y3B$,BW$!U2E
M(*>(438WJY.Q8G7,DZ.KYZ</D+5K5:JU11E)9E1<U7L\M:>8JP,AS!Q&X\A+
MQZLI&W0XEUW+!+;OC*VW"''%26U))4DDA9[Q-KV-4SAIYVTI97#@V4\G["NU
M/5V[TG',KF+E@ZXXNJ\^/.%;XWZJ E2LQ/\ DWQC6AP$AKQA+PE!(6!;LN@.
MI1>R5<0!1:2QF]55IYJ4^[ /7ZIPQD\N;SUS>9XT)$;DWSMB3W"IL[&2TJ=E
M):?2IMQ+DPH6MY*74W2I9;0K6./ $&I[BQ>5:*2V='!Y]A'Q6JT\J-RB\7C_
M *J8X\RQ,*O*9%R <8Y*<7CE2#-5&4HELR5)T%T@]*RGA>LE6XJ6:F-*>3B,
M)W[CAD;>6M:<O&9E&XM\9?!JP;>1G2\#AVD2G(B5J4W'CL.)2A:[<=#:W$Z
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M=?\ +7KSYD<)\W?V[?._N/)==T>;EQ!?;C2VW74H4UQ0X7&DOA*'$E"E!M1
M4I(.I-R.U:J)JJ^R+EJ665?PKMY'YN4]%^K+OQO;><E\N,RXIF'EUIFX)R0
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M^%65=C:[Y.>:DDHRPXZ2I1\7 <Y?;2R\XTAU#R&UJ0EYO5H6$FVI.H)-CU7
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MU7;5R48IRC',Z\D=K\AIMAT]=;$TXH!0"@% * 4 (!Z10"@% * 4 H!0"@%
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MWO'0]>S<GNVM2&[@=@#21[9H#.T H!0"@% * 4!*L72: HU *R!9/'IJ034
MH!0"@% * E/OQ[ - 34 H!0"@% * 4 H!0"@% >%O67_ -7,K_L(?Z.BO2]Q
M?I(\[^\\A^9/UTN:/W'(JWQS0H"NU/G,1W8;$MYF*^;O1VW5H;6;%-U)! /
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M,3M>2,B# B/3Y;Y#;*,C*?=BF,V4)43=UI2$DCJ)40!>L>WO2.1RN*F+HO\
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M<'[H%""DMY9?:>6PZGNPH$!(5?5;P'V* G<FQE)*7"IO^$A0L?O4!.U.BK2
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MCS^V-Z2XORV/\.GAVJ]W/V7Z!XQH??6_;CZ1Y_;&])<7Y;'^'3P[5>[G[+]
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MI!Y@[#3T[GQ7W)L<_M+J?#M5[J?LOT#QG0^_M^W'TDWGWLF]SN+&IL.E4ME
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MZ+^SX*ZGY7I\6_R/[T<)\\U^ C3WBK[,OQ/+=>GGB0H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4!ZD]6;]3<I])K_1V:\U^:?U,?R?BSVCY%_1
MS_\ 8_\ ;$[57'GH8H!0"@,!O'^Z(WTKAO\ -(M -B_J1MKZ*@_HZ* S] *
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MP3CEJWGE3#%<Z[6%'PEUMSEOEMQ;A7C&6I3.$9FNP)&6=BE!:4UJ)ULJ6++
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M?D7]'/\ ]C_VQ.UUR!Z$* 4 H# ;Q_NB-]*X;_-(M -B_J1MKZ*@_HZ* S]
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M%R%$GJ'>LC]VN3^:'_\ 47YU]S.]^2%77R_]<OOB>HP^]) 3%NAD<%/D=/\
M '[M>8GMQY'Y[MMM\R\DAM)!#,74I5[J/BZ.-ST\.%>K_+OZ*//+_<SP+YNI
MXG<IQ1_V1_ P7+S>IV%FWLZW#\=D&([&CM*7W: XZ4D*60"2D:>@6OX16?O+
M0_&6E;KE54V:[<N]?#KSNJ.9Y6DJTQ=,7Z/.6>[-[;EWK,$S<$U3X;*O%XR1
MHCLA72&VQP'0 2;J-N)-7='H+.ECEMQIQOA?._LC&WCO34ZZ>>]*M-BX%S+\
M=KPJV76$W!A%8!>U=T1Y*L8)9R,.;CRV)++ZVPTXDH=[*T+2E/#4D@IZ:MZC
M37>][ZTUFRY6I5HU6JV;&L>,OZ366.X>GU"EDS9U*%,RE3*UUL&FJ<331G<7
MOG:V$P,_%8S'2VY$F'D\<7B(VJ0W."@R](=T=Y=L$)+2#HX:KWN#A7=!?NW8
MSE)44H2_>PR[5%5ICVGCP&ST^]M+8L3MPA).4;D*]7K*=<KDZ9NKLRKJX5,<
MYOF,N5EWS%=4UD,!%P,=M2P>Z5'1%25_P;L*4 .L^W60M!)1@JKJW)3?+7-_
M,C \46:X\K:G9C:2KLHK:KS=5OR\!#=.YMM;@R>'DJAR7A'4?EW)NAF/-GMJ
M="@%(9_)!:&P4=[[Y9-U=%-)I;UF$U5*OJ1Q<8X<N-&\:;%P%S>.OTVINVY9
M9.G]R3RQG-5XH]6JCAFVR_>V&3RO-,YX9=K(Q%14R<E%RN&DX\-1Y,1V*X4
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MR263+3&M4Z^@UVKT5NUIK-Z,G)W<U:JE''+LQ==NWD*T';V"RNV<A/Q\B?\
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M1%(#;SB0A:@XVESM)!(!&JU9NAU#U%F-QJC?IH:[>FC6DU,[*>91ICLVI/\
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M45)I23=:TRX/;TUE1+;A;Y'8V73+:;Q\)3:'Y,#'(BORH[LA,S(QD/M!6C0
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M"@,!O'^Z(WTKAO\ -(M -B_J1MKZ*@_HZ* S] * 4 H#@WK/?W/M_P#XE_\
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M*"B$I4> -KUZMN2+6AM\K_\ F_P/ _F:2\5O/"E%_P#S2Z:X+B=#F-=(<@*
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M&OWDZ:2Z_P#1/_:SP77MY\R"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MRHY<.@FS)N N]A<W(V+O])]WBGZO[B6:N;UNI*F/[W9,:6JL4OQ[W"259?\
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M"@,!O'^Z(WTKAO\ -(M -B_J1MKZ*@_HZ* S] * 4 H#@WK/?W/M_P#XE_\
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M<R-6,FP(4^>RE6 Q6+@MI6I#;<R$I@O*3I7V04I< 5:YU'PU>ANOKJ4HQ?\
M4G)_EEFIP<QB7=^-VG"$YK^C:@L:+-!PS;'Q*6/#5KA-@^M/;STN9(8<5"F)
MFL96+/E0U2>]>1 8C*2M#$AHA:5H64E16E04;VZ\'PF\HI-9EE<6E*E%GE+A
MB\*-<35#;KY@T\IRDFXO.KD92AFQ[N,&J1G'&JE3;%U=:<.O1N8&/:Q[&-<=
MEF -L3<0[#M=CY2DNON(7HUZ=(*T64!<6'#A6?/=TW-R25>]C.O#E2BJ5Z<#
M46M\PC;5MN67X>=NG!WC<G6E:4Q6.U888&/RN[<=*W#M;<:GY633CFL=\I8R
M6."',>AEMU*%*6M*@]W17>PXGM"K]K1SC:NVJ*.9SRR7^JK5=GJUI]QB7]X0
ME?L7W*5S(K>:,N!P45*F+JIY:^7$R;6ZL$U,SS*MPY%\;BC(2C<#L=7CL$ID
MB0IA24O=I#@&EPM* O:P(N*QI:2ZXP?=Q7=OU*]675I79M7!4SX;PL*=U=]-
M]]%?U7'KPZV9PPEBG^]E=*[$T73',[#C(Y63*;ERV6%0\EMY<C0IQ69Q\/Q-
M,B2D*(_+$AUVRB;H'35N6ZKF2"65-YHSIV)2S4CS>JN=ER&_K2N7)24I)9)V
M\U*]["&12FJ_O>O*CVQ6TM96_L8_LUJ#$[J-ED8OY&F1'XJWS(2J07G'FW^^
M#:2LGO25,ZPX."C>XN0W=-:ARE5QSYTU*E,*)-4KAL]:E. M7=\6I:)1A2,^
M[[MQ<6\U95<E+-E5?6QCFS+;PF21S&VY+WKF-U9&1,4L3(C^$<>:7(T0HRU*
M<82TF0VA"R2DME>I([7 *-ZQWNR]'30LQ4?5DI8TZSV.N5MKCI1[. RUOO3S
MUMS43<O6BX55>K%NL4L\4F\'%NJ6.";-AVCGXN4G0\U#&0Q.!P^1SDF3*0RE
M..>8FZWD+DNI<2&W$)6AO04KU#3HZZP-;II6XN$LLYSC;25>LG'"D53%/%UP
MX:FVW9KH7KD;L<]NW;G>;=.HU*LDYNJI**:C2DJ]7+PTTK+;ZQ<W9S>/@*1&
MG'&0\/,@.Q%N%:8BDJ+C;X>[L J'>\6=85<?OJW%G=]R.HS2Q6>4T\W'P-4K
MR>M2G0<]J-[6KFB4(44N[A;<7&M<M'52S9=O6]7-6O.<UKHCCA0"@% *  $D
M =)Z* ^@<-84M[3?22A8OT]M ->#-49]5)U2.5^LC^H$?Z28_FGJZKY8_5O\
MC^]'!_._Z!?^R/W2/*%>GGB(H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4!ZD]6;]3<I])K_1V:\U^:?U,?R?BSVCY%_1S_ /8_]L3M5<>>AB@%
M * P&\?[HC?2N&_S2+0%OLF4$[-VXG3V1BX0''C81T4!LR5!:0I/0: $@=)M
M0$I>:'2L?<X_M4!+WZ3[U*E>T* X1ZSBE*P^WKH('C,CB?\ 9IKMOE3^Y<YD
M>9?/G]FS^:7W(X%MK R-S9J+A8KK;#DC6I;[Q(;;:9;4ZXM5N-DH0HV'37=:
MK4*Q;=QJM.#C;=%YSR_0Z.6KOQM1:6:N+V))-M^1)F2@;;PN:W)'P^&R[RL6
M6W7YV5F1!'[AF,AQUYP-(>=*DAM&I-U)))M85CW-5<M67.<%FP2BI5JW1)5H
MN%\IDV=%:OZE6K=QY*-N<HY:**;D\JE+#*JK%-[*(R,/ER^]N7/[>D/R5'!L
MF2DP(9FR932GFFVE-,!U'OTO)<]_P36//>:5FW<27]1TZTLJBZ-NKH]C5-AE
MPW-)ZJ[8DY?TDY=6&>4EFBHTCF7K*2EMP6TM<AL8X\;BOE&'OD"?$QRG6P2R
MZ9A=&LKOV.[[KM"QXWX\.-VWO#/W?5:[R,I<JRTZ:UP+=[=/=N\L\7W,X1KP
M/-FQKP9<N.WS%OO7:B=HSVL>'93ZE!1,F1%$:.\D$:7(KB7G0\TJ]PKL^UX+
MFAUGQ,,U$N12JUR25%1\F)8WGN_X.YDZSY7'+%\L'FEFB^/#FKLKRMC/Q]D1
M]X"8%O.*;6_BPV0MF&^Z\PS(*R;$+<84FP'@/75N.\%+4NS3#@E7;))-QIR*
M1>GNF4=$M3FJ\*PIZL6Y1C*O+*+6SB95R^Q48M&"'CZR<TJ,$Y)Y@-89"9*0
M24S ZLJ[HFSH+22FQ^[39WAWCGU?4KU4ZSP_TT6W@Q=2=3NGN>[ZS_J9>NXT
MM=;_ "9GZO[W45*-\5:^0Y>IA[@R&!1+E(5CL=-R2GYD(1@]XBAQ?Y$!YP*:
M<".P[J_\/"J+>\LUJ-RBZTHQPE6F:FWJK%5Q7G+M[<V347+.:7].$YUE#+FR
M5?5ZSK&5,)>; EPO+PY>3C6!.<MD,-(SFB/&,A^T9UYON&F^\3WBU=UV>TGB
M;5-_>7=QD\OJS4,718I.K=,%B1I=S=_.,<SZUJ5W".9X2E'*E55;RX8K;0N8
M?+/QG-9S%";*?&%C1Y1;@P#)G.>-%L=V8Q>;T.-]Y^53K.G2KP5;GO7+;A.B
M6=M=:5(JE<<U'5.F&&-478;DS7;L,TI=THND;>:;S9<,F94<<W65<*/B-;@8
M;$2I#L:9E3C5M.K03+8*?R:%H3=02M1"])6='A3;5QO6PN7[D8IQAFPX']L-
MF/+L-19T]J<W&=SNZ/\ >B]B:VT;I*E>KR4KB80BQ(!N ;7K--<B%"3JO*'/
MQ=K8O<^=D.MI++F(:4PM2=;L=Z;:0E"3Q5^3"KV^[7,;ZTTM1<M6TGCWGD:C
MU?.=O\MZV.CLW[S:P=K#A<7/KT7#U:FSRWMLM8R7L1S(,2-F[<R6";<?[Y-W
MVY+[SLUT%"@393H;5H]Z$WK70C><UJ,K5V[&[A39114%YJJNVIMYSTZMST>=
M2L6)V%7-ZRE*3N/"G'1TV)&3PC&%Q>ZL!+R;.&Q.;1F)B<9\F.1T-.8(PGM+
MKQ944FZ](;6Z0XJL:_*Y<L7%%SG#)'-FK_<S+!5Y-J6",[2QLVM7:<U:MW.]
MGER.-'9[N5)/*Z;:97*DGB:UC\7LSZNFIB<>G)-*QSZLK(:\01+CY+O%$++C
MS[<@%L)&AIM!0M/3J)K8W;NI^,<<V7K+*NO1QXJ)../#)NJ?$:?3Z;1>'*2A
MG626=KN\T9UVUE*,^K3JQ2RRB\<U3(*Q&WD;MPL9F%@E<N'D.,8G)7C+?DR7
M(#FGQM:E%[5WM_?I 2K2.FU8ZO7OAYMRN=^L91ZU$LZ]7]WU>+:JF4]/I_B[
M2C"U\*ZJ,^K64G;EZ[KFKGXU@Z<))BL9C-M[=3$?<Q[&<5M7<C&5<CR([JUR
M"\WW3;BVEJ"EI2; <3T@=%57KL[]ZJS.'?67&J>RCJU7@*-/8M:72Y6X*Y\/
MJ5.DHMMYEEBVGBTL*>@O/-K:4;%8R)D/DJ:_!GX)<;*,H@QVI<22\VV^-#2R
MZXV!?O%R/?&Y%@#5GXK42N2<<\5*-VL>N\K2;6W!/B4=AD_ :2W9A&?=S<)V
M*32MI3C*24L$\TE3UG/:ZM8&CJCX7</-V/ATQ<;BMMXZ>[&/<:68SL*"^ZZ5
MNK4LA2W$#3KOX . %;I2N6=WN=93G**>.+4I)+!<"3X#FG"SJ=[*UEMV[4)N
M.&$7"$I2ZV.+E%4KS&[O[BV]N;);3W1&RRI,C%[G<COIFH:BOHAY%WOVSI[Q
M9++1&A*B?#P%JTT=->L0NVG"BE:KA5K-%4? NL]IT5S7Z?57-/?5QR<-0X]:
MD7EN2S+#,^K'8GQ5P5#AV?6AS/91;:@M"IDA25I(4E0+JB"".!!\-=GIE2U%
M/LK[CSK6R4M1<:=4Y2^\ZUZLWZX97Z-5_/LUR_S3^GA^?\&=Q\B_J[G_ *__
M )1/4=>:GLYA=OF(7,SXKCW(!^47?&%.7_I+O=MW?3<GLJ%DC^#0$=V_JIG?
MH^7_ #"ZR]'_ 'X?FC]Y@;Q_2W?R2_VL\%5[>?,8H!0"@% * 4 H!0"@% *
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M * 4 H!0'J/U:E!O96241V3E'+D<2/Z.QTB_[E>:?-/ZF/Y/QD>T_(OZ*?\
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MR?BSVCY%_1S_ /8_]L3I652M,Q95[U0!0?8M;]NN//1"A#;4[*:2GI"@21U
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M6/B*?5.J[,.A_P P^AM#V[G3'^4D3ZN&P5&PR.4O[+K _P#D5'U3JNS#H?\
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MY4S.<K\_FMS[BW/@\/N;(Y;9D;'H;:RV4::9RD7*R> [M*FFU% 2%+'>-VU
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MCM^_ L[NU.IU5R,9UBK*:G_JG6G%Q*N'&=N"5.\7#V>I _=KFSJRL  +#@*
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M!>@(D@"Y-AX30%/O@>#8*S['1]^@&EY?OE! \">)^_0$R6FTF]KJ\)XF@)Z
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MJ9BYH],M/9C:3JHHP>[.6T?<.<C;KQ&7F;=W3'8,,Y*!H5WT51U=V\VXDI6
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M.$SR)[W*>":KB72/'M)QOH8^U=R<^<)GD3WN4\$U7$ND>/:3C?0RF[ZUO)P
M."?-4M'$!,)VY\(X@"G@FJXETDK?NDXWT,J?:NY.?.$SR)[W*>":KB721X]I
M.-]#'VKN3GSA,\B>]RG@FJXETCQ[2<;Z&/M7<G/G"9Y$][E/!-5Q+I'CVDXW
MT,?:NY.?.$SR)[W*>":KB72/'M)QOH9(/6LY-NC4O(30 ;!LPGOO\!:G@FJX
METDO?ND7[SZ&3_:NY.?.$SR)[W*>":KB721X]I.-]#+K'>M#R=R4YB G+NQE
M2%AM+\J,ZRPDGHUK(LD7_"/ =?"J9[FU44WEKS,KAOS22DEFI7C1V%MQMUM+
MK2@MI8"D+204J21<$$=(-:9JANTZDU02* 4 H!0"@,!O'^Z(WTKAO\TBT V+
M^I&VOHJ#^CHH#/T!02TM$I;B>+3J1KX]"T\!]\4!7) %SP Z30&/6T<@OO1V
M&6^#*K E1OTD'\'AT4!.XMQ32X\Z+W[+B2AP( <0M*A8@I/41TBI3H0TFJ,\
MB<\O5I5#$C>'+*$ZN"-3V3V\E!"V1TER*#Q4CPM"Y3^#P[(['=F^<U+=YX\$
MO3Z3BMZ;DI6Y96'#'T>CH/+?1P-=:<:* 4 H!0"@% * ='$]% 2]XW^,/OBH
M)RLB5)! ) )Z!4BC!(3[X@>W0A*H*@!<D >$T%"/3Q'10"@% * 4 H!0"@!
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M5-CJ )46P>TXP+6"SQ2>R;]-=?NW72OIQDL8\/!_UY#C-Z:"&GI*#PEP</\
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MS#8[(LJW_!B1X*'6V4!F2VA:9"G=+RK)62E8*;\;\*JM[OO)65)K^FW7;Y.
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M3,JT=?*7;=V=NN5TJJ>0R?GUO/S;5L_Y>G':ZK XI3RE1PE*@H)"239&H:M
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MNDT=R%Z5ZXTY25*1V>?F,'6ZZU.S&S:348NO6VUQXL.%G)ZVYI!0"@% * 4
MH"K&BR9LAJ'#97(EOJ#;##*2XXM:C8)2E()))Z *I<DE5["8Q<G18L]@<E/5
M98QQC;IYFLHD3N#L/;ILMEH](5*(N%J_^&.R/PM70..WCOIRK"SL[7H])V^[
M=QJ-+E_%\$?3Z#U,A"6TI0A(2A("4I2+  <  !7)G8$: 4 H!0& WC_=$;Z5
MPW^:1: LMJ3O%-C;92D:G5XJ#8'H \7;XFA)?IRTA7Y-92D*L.\ XI!Z3:@,
MTRTAEL-MCLCKZR?":$$] * UO?&YLCM;!N3\/@INXLLLEN'CH""HJ<*2075]
M"&Q;BKC[ -9.FLQNSI*2@N-F+JK\K4*QBYO@2/#V^]G>L%S&SKF?W-MG)OR#
M=$:.A@ICQVKW#;*+G2D??/2237=Z;4:+3PRPFO2>?:K3Z[4SSSA+HP7,:O\
M4?S<]#LG^9/NUE>):;MHQ/#-5[N70/J/YN>AV3_,GW:>):;MH>&:KW<N@?4?
MS<]#LG^9/NT\2TW;0\,U7NY= ^H_FYZ'9/\ ,GW:>):;MH>&:KW<N@?4?S<]
M#LG^9/NT\2TW;0\,U7NY= ^H_FYZ'9/\R?=IXEINVAX9JO=RZ!]1_-ST.R?Y
MD^[3Q+3=M#PS5>[ET#ZC^;GH=D_S)]VGB6F[:'AFJ]W+H'U'\W/0[)_F3[M/
M$M-VT/#-5[N70/J/YN>AV3_,GW:>):;MH>&:KW<N@?4?S<]#LG^9/NT\2TW;
M0\,U7NY= ^H_FYZ'9/\ ,GW:>):;MH>&:KW<N@?4?S<]#LG^9/NT\2TW;0\,
MU7NY= ^H_FYZ'9/\R?=IXEINVAX9JO=RZ"!Y(\VPI*3L[)W5T'N#;A?IX^Q3
MQ+3=N/2/"]5[N1'ZC^;G'_\ 0_)< 3Q9MT"_6:>):;MH>%ZKW<B5')+FVL$C
M9N4%C:RF"#3Q'3=N/22]UZI?^-DWU'\W/0[)_F3[M/$M-VT1X9JO=RZ!]1_-
MST.R?YD^[3Q+3=M#PS5>[ET#ZC^;GH=D_P R?=IXEINVAX9JO=RZ!]1_-ST.
MR?YD^[3Q+3=M#PS5>[ET&0PGJ]<W,UDX^-.W).-;>59V=/3W,=E Z5*/$FWX
MJ05'J%6[F]=-"-<R?(B[:W1J9RHX./*SUURUY,X7EAC^ZQ454S.OHTY#.OM@
M2';]*&AQ[IK]XDW/X1-<GJM>]1*LG1<"^VUG8:3=ZT\:157PRX?V+[,WCY/F
M_P @O[U8G>1XS-[J7$/D^;_(+^]4=Y'C'=2XB"H,M"5+6RL(2"I1"2LV N;)
M2"2?8 N:GO(\8[N7$>8N<;_._F X[M_;^S\OC=DH59319*9$\I/!<@@\$=:6
M0;#I5<]'1Z%Z6SUISBY_=S>DYG>'Q=YY(0DH??S^@XW]1_-ST.R7YD^[6X\2
MTW;1H_#-5[N70#R0YN $^9V3-N-@P2?VZ>(Z;MH>&:KW<B">2/-Q20KS.R8O
M<6+)OP\(O<4\2TW;1+W7JO=LC]1_-ST.R?YD^[3Q'3=M$>&:KW<BFODKS;0H
MI.S,J2.L1U$??%/$=-VX])5X5JNPR*.2G-M9MYFY1/\ "CE/[=/$=-VX])#W
M7JNPR?ZC^;GH=DOS)]VGB.F[:(\,U7NY= ^H_FYZ'9/\R?=IXEINVAX9JO=R
MZ!]1_-ST.R?YD^[3Q+3=M#PS5>[ET#ZC^;GH=D_S)]VGB.F[:'AFJ]W(@GDC
MS<5J_P#T.R8TFQNP1][C3Q+3=N/22]UZKW;(_4?S<]#LG^9/NT\2TW;1'AFJ
M]W+H'U'\W/0[)_F3[M/$M-VT/#-5[N70/J/YN>AV3_,GW:>):;MH>&:KW<N@
M?4?S<]#LG^9/NT\2TW;0\,U7NY= ^H_FYZ'9/\R?=IXEINVAX9JO=RZ!]1_-
MST.R?YD^[3Q+3=M#PS5>[ET#ZC^;GH=D_P R?=IXEINVAX9JO=RZ!]1_-ST.
MR?YD^[3Q+3=M#PS5>[ET#ZC^;GH=D_S)]VGB6F[:'AFJ]W+H'U'\W/0[)_F3
M[M/$M-VT/#-5[N70/J/YN>AV3_,GW:>(Z;MH>&:KW<CO7*'U7U8GQ?<W,6&)
MN3X.P]O$!R,P>D*E$$AQ?_PQV!^%JZ!HM;OA3ZEIT7:]'I.BT.Y7#KW55]G@
M7/Q\QZ),"<>EA7   6L !P  Z@*T'>1XSH.[GQ$/D^;_ ""_O4[R/&.ZEQ#Y
M/F_R"_O4[R/&.ZEQ'.>:NX.8N#@_)7+O:\[)Y^2BZ\LF.5Q825=!0%<''O!^
M"GKN> V&DA8FZW9I1XJXO]AK]9._"-+4&Y/AI@OVGDJ9R;YSY"6_/R&ULO*G
M25J=DR7VU..N.+-RI:E$DDFNKCO#2Q5%.*1Q\MW:N3JX2;*'U'\W/0[)_F3[
MM3XEINVBGPS5>[ET#ZC^;GH=D_S)]VGB6F[:'AFJ]W+H'U'\W/0[)_F3[M/$
MM-VT/#-5[N70/J/YN>AV3_,GW:>):;MH>&:KW<N@?4?S<]#LG^9/NT\2TW;0
M\,U7NY= ^H_FYZ'9/\R?=IXEINVAX9JO=RZ!]1_-ST.R?YD^[3Q+3=M#PS5>
M[ET#ZC^;GH=D_P R?=IXEINVAX9JO=RZ!]1_-ST.R?YD^[3Q+3=M#PS5>[ET
M#ZC^;GH=D_S)]VGB6F[:'AFJ]W+H'U'\W/0[)?F3[M/$=-VT/#-5[N70/J/Y
MN>AV3_,GW:>):;MH>&:KW<N@?4?S<]#LG^9/NT\2TW;0\,U7NY= ^H_FYZ'9
M/\R?=IXEINVAX9JO=RZ!]1_-ST.R?YD^[3Q+3=M#PS5>[ET#ZC^;GH=D_P R
M?=IXEINVAX9JO=RZ!]1_-ST.R?YD^[3Q+3=M#PS5>[ET#ZC^;GH=D_S)]VGB
M6F[:'AFJ]W+H'U'\W/0[)_F3[M/$M-VT/#-5[N70/J/YN>AV3_,GW:>):;MH
M>&:KW<N@?4?S<]#LG^9/NT\2TW;0\,U7NY=!M_+_ -63?VYLG_\ I3"D;<P$
M<CQE]Y"?&WNONX[1/2?QU=E/LGA6'J=\6;<>HU*3Z/*9VEW)?N.LTXQ73Y#U
M]MK9>-VCAV<%MG%B!BF>/=H&I;CG07'EGBXL]:E?<L.%<G<U/>2S2E5_;8=A
M;TW=QRQC1&5^3YO\@O[U6^\CQESNI<1*J'*0I*5-*!6;)N.DT[R/&.ZGQ%CG
M'IV$Q4C)IQ,W*/,I_(8Z V7)#[A]Z@=21^,M7 #PGA5R#C.5,R7*RB<91C7*
MWR+:>/>8FV?6!YEYCY3SNU,DW#8NG&XIEI0BQ6SU(23Q6?PW%=I7M6 ZS2W]
M'IXTC-5X7PLX[5V-;J)UE"5.!<"^W'PFG*Y(\VT)*CL[)D#ILP2?VZS/$=-V
MT8/A>J]W(F^H_FYZ'Y+\R?=IXEINVAX9JO=R(?4?S<]#LG^9/NT\2TW;0\,U
M7NY= ^H_FYZ'9/\ ,GW:>):;MH>&:KW<N@?4?S<]#LG^9/NT\2TW;0\,U7NY
M= ^H_FYZ'9/\R?=IXEINVAX9JO=RZ!]1_-ST.R?YD^[3Q+3=M#PS5>[ET#ZC
M^;GH=D_S)]VGB6F[:'AFJ]W+H'U'\W/0[)_F3[M/$M-VT/#-5[N70/J/YN>A
MV3_,GW:>):;MH>&:KW<N@?4?S<]#LE^9/NT\1TW;0\,U7NY= ^H_FYZ'9/\
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MN+D\,-H\ZMS_ #U/\J>^%4]Q;[*Z"UW]SM/I9!6Z-S*24JS4\I(L1XT]T?\
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MXW[:G'8S+A]T&^J_L&K!DEZVL.("AU](H034 H!0"@,!O'^Z(WTKAO\ -(M
M-B_J1MKZ*@_HZ* S] * 4 H!0'A?UK.5_FINM.]<2SHP.Y'%*DA [#.2L5.#
MV \ 71^^U]0%=YN36][;[N7K0^[]FSH//=_:'NKO>Q]6?^[]NWI//==&<R*
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#TCZKW,OQ26KEGF7K1)RU2-N
MNK/!N61J=C7/0'0-2!^.+?A5SF]]+5=['@];FX_)]W,=/N;6?^&7#ZO/Q>7[
M^<]3US)U(H!0'+.?G+KS^V4Y)Q[.O<VWPY-QND=MYBUY$?V=21K0/QDV_"K9
M[NU/<W<?5E@_P?X?]#5[RTO?VL/6CBOQ7X_]3PT#<7%=L<&* 4 H!0"@% *
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M H![- 0(!H#<U\RLPG 2,!C<9B,0F=%1C\IDL;!;CSYD1O3^3=>!-@LH27-
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MQ!@,IC0(C2(\2,V+(:9:2$H0GV !7"MMNKQ;._225$J)%2H)% 8S<FX<9M+
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MRE%5NT@B]8-R]=G%QE*F2Y#'J\--M,,/^IL;>GM6GFC#-GMSPZV-.*M7UO\
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M7(.-$J\*J7K/R_8MS4JN5.!T/0%<\=** 4 H!0"@% 8#>/\ =$;Z5PW^:1:
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M4$E1CE*&RE*NU<DD<* RT_<&8Q^.8;G2V83ZLD[CW<H[%<6DLMLN.H<2RE7
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MD-M%8=L.GP$$4(*T7/Y2-K<D/M!F*ZD/P[&2XJ&MX!4LNI6HA*05=FW9T\:
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M1I+,9E(0TT@!*4I'0 !0%6@% 48\6/$2M,9I+27'%O.! MJ<<45*4?"23Q-
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4!@-X_W1&^E<-_FD6@&Q?U(VU]%0?T=% 9^@% *
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M\((%)>R&VEPVL9*,2&W%=AY!6A#CTI#@80=14FP44M<5)MQZJ 0]A08B9/\
M3'W'7VW6 Z=&L-N-=PDDD$J6E ';4>T: J0MIJ+N:?R3Q*\J$,I[JW8;0A*5
MN)&D!*GECO%I%QT4!5>V7C%)85'6N--BK>>CS&TM]X'GW0]K5=-E6/"RN!!-
MZ J93;!S>/:@Y6<MXA+K4EQ#:&P\V\+%)1Q L0DCVN/ F@+1K92&5MO,3!%>
M;0-1B,-L(<?#R7N]=0+A?:3P"NBYX\: RN%PJ\,'T)EJ=C/.+=3&T);::6XH
MD]V$^]3;I3T:KJZZ NW<;$>67%)(4>)TFP)H"X::;90&VDZ4#JH">@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@+:9#1+;"5'2M/%*O!0%BSAB%@O. H'X*>
MN@,N  +#H% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * P&\?[HC?2N&_S2+0#8OZD;:^BH/Z,B@,_0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% 8#>/]T1OI7#?YK%H#PSC/[MA?\ #M?^@4*BZJ *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
G!0"@% * 4 H!0"@% * 4 H!0"@% * 4!:Y#_ '9/^WC?SZ*D'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>fc_companion-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_companion-4c.jpg
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M%!04%!04%/_  !$( C4#M@,!$0 "$0$#$0'_Q #1  $  04! 0$
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0'U.Q?)^6@.5R]8O*M=0XY30"@,UZ4_P <8_XDC]0=47_09?I_
M31T97+.J<7?>>_J>7[OB^<Z]&^W_ )7VF>0?=?SOLQ\9IFOHCY$4 H#]']I_
MPM@_W?$_4A7C^I_EE^I^$_06C_@A^F/@-9?>>_I@7[PB^8Z[7V_\U[+/G/NO
MY+VH^,XMKT8\@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%3?KCY4\]&2MI^F;
M?J#Y$\U>,,_1:V$>=\F/QOR5E$AD&K#$4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 3L7R?EH#E@O6+RK74..4T H#->E/\<8_XDC]0=47_09?I_31T97+
M.J<7?>>_J>7[OB^<Z]&^W_E?:9Y!]U_.^S'QFF:^B/D10"@/T?VG_"V#_=\3
M]2%>/ZG^67ZGX3]!:/\ @A^F/@-9?>>_I@7[PB^8Z[7V_P#->RSYS[K^2]J/
MC.+:]&/(!0"@% * 4 H!0"@% * 4 H!0"@% * 4!4WZX^5//1DK:?IFWZ@^1
M/-7C#/T6MA'G?)C\;\E91(9!JPQ% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H#'=\;SQ.P=MR=R9@7'6FR%B+$9MSI,IVZ-LA?A=;*JKX!15K:TNFE
MJ+BA'IX+B:>LU<--;=R?<7%\"P[=R_6?(Y" _G=M87%[>EFBR8PRWG,I&9)%
M*Y<=!%V)H1.VMJ];T<8M0G*4ER+*S4L7-;*2<X0C![JO,O$9*SO+9\C-EMN/
MN#'N[@%5!<:$ELG]:=H(*+Q-/"*<:TWIKJAG<'EXT-U:NRY]6IQS<*JI1D=[
M[+Q#C[65W%CX3T5X8LII^0#9MON#J$"%5NBJ/'R5,-+>G3+!NN.P7-98MUS3
MBJ8.K)+6YMLOYE-N,9J"[N!6T>3&!(;*2H*.M%0$7C<5UV[=/'LK!V+BAG<7
MEXTP,EJ;3GU:DLW"JK_5,2%,W_L/'HJS]S8R,HR3@D+LIL224S9'&U%5NBA=
M-?@2Z7JV.CORV0D\*[-Q5+7:>.VY%8TVK:MO1O).;W=M/;34=[<.<@XQN6B'
M$62^ *\"V]-M+JI#Q3TDX5A:T]VZVH1<J;<"R[JK-JF>:C795[3V>W%MV.U!
MD/YB$W&RFI<9(*0VC,E !7"5H[Z21!2_;6*L7&VE%UCMPV<YEU]NB>94ELQV
M\Q:)^],9.VGF<_LK,8C(OXYH^7)D213'M2$]5))BJ:!7P*JHB^.U7PTTHW8P
MNQDJ\F-.0HGJH2M2G:E%Y=]?-3Y20N[\/A]MXG.;RR^,QCF0CM.&^W(3N;KY
M@)'W4B52-OC<52_"L?AISN2C;C)T?#%<_*2M5"%J,[LHK,EC7S6Z?V\43SW)
MMQJ% R;F7ACC<JX+&,F\\.1)=.^D&SOI4ETKPOX*J5BXY..5UCM5,46O46E%
M2<E26"=<&^0^87<NV]R#(/;N8AY88A\N4L)\'^62]FK2O8MEL78O@I=L7+5,
M\7&O%"SJ+5ZO5R4J<'4P7<.^.H!=2'.GNR(&%<=8Q;>7>EYHI*(H$: 0CR%X
M*BD-N'9>NE9TMCX?KKKEZ67S:>,Y.IUFI^)ZBPH5RYJSKLK3<48GJAGI![FV
MON#$PMO]0L!CW,G'&5(4\-)81$TO\[@HMHI#J12[/"EB1)N:""R7(2<[<W3!
M><GPIQ_K@+?:5R3N6IQ5N["+DJOS&O6KP[O?3IDC&_=OXO!86;O7/X;&Y;)Q
M6GS%B4*Q72-.)QU)5(FK]A^K[M:CTER4Y*U&347PQ[O*;T=9;A;B[LX*4E7;
M@^;D+YD<_@<1BDSN4RD2)A"0";R+KP)'-'$N&@[JA:DXIIO>M:%F<Y9(Q;EP
MWFU._;A#/*24>-<"&WO;9CL61-9W#CW8<-AN7+D-R -MF.^NEMPR%51$)>"5
M8]+>32<'5NBP*UJ[+3:G&B57CL3/:#NK:^3RCV#QF;@S<S''6_ CR&W7A%.*
MKI%5O:_&W9X:QEI[L8YI1:CQH90U-J<\D9)R6ZN)YRMY[.@YAO;TW<&.C9YQ
M4$<<[);!_67J@HJO B\ KQ6ICIKTH9U!N/&AC+5V(SR.<5+A55*\WNW:NV7X
M\;<>;@XF3*_^.S,?!DS2]M6E5N@W2VI>%1:T]VZFX1<DN")O:JS9:5R:C7BZ
M&.0.K6TY^_LEL )#(3H @VQ-<D-\F7.-418K0)Z2F"K8_#=%2U;<^SKL;$;U
M,'NIL7%FG;[3LSU$K":K'EVO@OZVDO:F[W).S1W/O7)X.+I>>!_(8N6AXM $
MU%M$=,E36J<%%"7C[MTK#4::E[J[49OD:\XSTVJ_\%<O2ASQ?F]-?&7_  NX
M-O[BQY9?!Y2-D<2V1@]-C.(XT!-BAF)+X"$50E1?!6K=LW+<LLHM/@S<M7[=
MV.:$E)+@:R;ZSS@VICMP'B$R.:W=D9$78^W8EV77(;+G*!V4X:E9;IK,A2WI
M#:R75.P^S(]:X9J1MQ3G)\=N!PUVM+J8SRYI79-6XK!T6%95\*XK=B75S<_5
MG!87.Y_>&$P3./QF+DSXHX^2^X[WEE$4&7D)5NB\=1CXJI5C2W)QA;E.LI).
MJ6SBC8>HU=J$YW8PI&+:RM[MS\J+"'4OJUC]IP^H6:VSA<EM"1';GR&</(D-
M9&/#=1%YA _J$E%%N2#?W;)Q39>ATLKKLQG*,TZ><E1ON&E'7ZV%E7YPA*VT
MGYM5)1?&M=G(;,P>[]K[C1M,-E8[\AR&UDUAJ:!);AOB)"ZXV7$1])$5>Q%K
MCW=-=M>E%TK2NZIW;.KM7:99*K6:F^G&G=+ _P!0XZ;JVQ'QLN%E-D[H65CF
M<E%53-C+Q4Y@)S472;;HW#2@W0D[:VEHWU4W).-R%'1[XODXK::;UO\ [6\K
M4K=RJJMTERUV/92FW>2-Y[TG;8W/L; Q8C,B-NN<_"F//*:.,@R@*A-:51+K
MK7UJPTVFC=M7)MM.VDUWRS5:N5J]:@DFKC:YJ4\I<7-^[%9..V[N;& <MTXT
M82E-BIO-%H,$152RB7HK?PU4M)?=?,EAR%[UEA4K..+IM6TG9O<NV]L)'<W/
MEXF(;DN<MCOKPLJXJ*E]*$MU1+\5[$\-5VK%R[7)%RIP++VHM6:=9)1KQ=#5
M>%ZG[OR>#S^18DX+O$#=:X2&[E74APRQ_:B XV7Z1XD]3CQ2ZI?LKM7=!:A.
M,6IXV\SRXNOB1P;/:-ZY"<DX5C=<%F=%E\;_ -S9V?W?M':[[4;<6=A8E]_B
MPQ-?!ITAO;5IO=!O^<O"N-9TUVZJPBY<R.Y>U5FRZ3FHOE9Y2=[[+A99O 3-
MQ8YC-N*(CCW)+8O:S1%$215]$B14TB5E6]91TMZ4<ZA)QXT,9:RQ&>1SBI<*
MJI9&^K&TUZBN].WI#;4MEH+SS?;1MR<;HM)!;#M5ZY=E_!V5LOL^[\/UU,.%
M-WK<QJ_4[/Q/455:;:[ZTR\Y+VGNN5,VS.S^\9^$C-PIDADYN*EHYCVX[1(@
M(ZZX7!U%6Q#Y."*MJKU&G2N*%I2=4L)+&O-P+--J9.TYW7!4;QB_-IRM[_ZY
M"Z0=X;2RF)DY_&YV#*PL%%6=/9?$FF$3C^E7M#A[253/378R4)1:D]BIMYC8
MAJK,XN<9IQ6UUV<Y]A;MVGDLI]1X[.P)>9Y:/I 8D ;ZMJ.O4@HO'T5U6[;<
M:B6GNQCFE%J/&@CJK,IY(SBY<*XC[7;37._9A,Y!7<EU'ZJ1\%DZD2ZCH1?6
M1..GMM4_#W<F?*\O&F ^*L]9U>=9^%<2\UKFR* 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@"=B^3\M <L%ZQ>5:ZAQRF@% 9KTI_CC'_ !)'Z@ZH
MO^@R_3^FCHRN6=4XN^\]_4\OW?%\YUZ-]O\ ROM,\@^Z_G?9CXS3-?1'R(H!
M0'Z/[3_A;!_N^)^I"O']3_++]3\)^@M'_!#],? :R^\]_3 OWA%\QUVOM_YK
MV6?.?=?R7M1\9Q;7HQY * 4 H!0"@% * 4 H!0"@% * 4 H!0"@*F_7'RIYZ
M,E;3],V_4'R)YJ\89^BUL(\[Y,?C?DK*)#(-6&(H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% :PZ[X#-9K:&/R. BED,CMO*Q\RN."Y$^RPA(:"*75
M22Z+9.-KVKL=DWH0NN,W13BXUX'#[9L7+EF,H+,[<E*G&@3K/LK>F,DX/:F6
M=C;YS,27&Q6,?C2&7V,@;!J N.:%;%1+AJUVO4_3+UB2G<C6W%IMU6,:])6^
MU[.H@[=J5+LE)133PE3>Z4P-*&YM"=TFP.Q-NXHV^LK$]@5B!$<9RD>>W(4G
MGW7E!%0-*IQ4^'#LT\/H$KT=5*[.7_C3CYK5,%3^N^?-MV):.-FU%J_791J2
M=<6WNPV8X8;,N&9CM[!9G>'7F5E\:Q.E0<>"Q'GVD,FG%A.F1-7OI)3;$D(>
M/!++6AUTX6M*HMI.6/2MO2=&5BW<O:QRBI.,53D\U[.A%C@87$8S9G0C-8^
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M;$+-<F&9N7=>VG#F+H.D$(0  $UU&@@(H2^-;)Q_#5)>?&Q!D2%AL&1+UD:
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M%+O96GN**<?15%B]A%GM_5VG)J2\]U>"VEHW+OW=^\9+$G<^4=R7=CYK$=U
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M4+<74?JAF!<:VMTPFQC[&9FXYL;',)_B)MHGW5\FE%H"Z;)V+N>'N"1OC?\
MGURVZ9$=84;'P4./A\?%(T,FV6E6[ADHCJ==]+APLE ;#J0* 4 H!0"@% *
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M515K(@]Z 4 H!0"@% * 4 H!0"@(\Z;&QL*3D9A\N'#:<D2'/9::%3)?P(E
M:/=#J'UUB8.<6'A;4Z?I/A9W'SY3QR<X\S$=1YDFV0$6V%=1/SC)4 JC:3L)
MTS#]2>F&X-V[LVOB\=NW;N?EKFLC%<?.#F6.2P#9,M&HN-O"@M_HA72J=GAH
M#:FV-Q8W=VW<7N?#FKF+RT9N7%(DTEH=%"L2> D[%3QU)!=J 4 H!0"@% *
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M12=9)8\IWNQ>S[>MO.$VTE%O#DH8[C]M[BRR1%QN(F2^_JX,)6&''$>)GY1
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M@.G^\=I,R,IL?#PMR8IYW#[@@E C*K.1@KRW;*H743X. OLDE$29K_+#IO\
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MYG,WFG!*7*98/T@BL@VC#&KM3QU"#.BZR(% $[%\GY: Y8+UB\JUU#CE- *
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M.PY.T7LSF<UF7=P;LW$\T]ELHZT$9O3&#ELLL,@JHVTVBEI2ZK=55: S6@%
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M0_3'P&LOO/?TP+]X1?,==K[?^:]EGSGW7\E[4?&<6UZ,>0"@% * 4 [.*]E
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M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%J 4 H!0"@% * 4 H!0"@%
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M6GQ77P4!-+#X\F9#"MKRY3XRWO2*ZO 0$A7OPXMCPH".FW,8A2!LZL.5S.?
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M0DET6@$';N)Q[P2(S1=X!QY_FFX9D3LE!1TR4E6ZEI3R>"@+K0"@"=B^3\M
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M)K+30DT++^IAO0I*I*3:J^BZK(J66A![Y/(YS%N1,>;Z2I>05TT?CQ%/D-L
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M !F7FI#0JJKH*4WK<%+]B:D4K?XJ$E[H!0"@% * 4 H!0"@% * 4 H!0"@%
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M1YWR8_&_)642&0:L,10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M.M*FG_VT:<!4]+QJO"EIVJO.I4W4IY";ROY5U;C7?F3[U&C[D0W.6-CCB7H
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MJFOO/UBT\[?LT:.2XW;PWO>HLNUCUBEW*>-$ZA7W3JG%<<R;\#0RX;H*-'3
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MNAT6GD@WU\+MJYS/5[?3[:-VL^R63N5\% E?ZK%QS\SR]%:]\10W0F(>&<]
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M7TQ\$S]']I_PM@_W?$_4A7C^I_EE^I^$_0.C_@A^F/@+Q6N;8H!0"@% * 4
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M 4 H!0"@% * 4 H!0"@% * 4 H"ZM?)A\5/-5++$42OD#_!YZF.TAEMJTP%
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M_"?H'1_P0_3'P&LOO/?TP+]X1?,==K[?^:]EGSGW7\E[4?&<6UZ,>0"@% *
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M'8T"0B5Z6X)&+::46RJ@$MULE :'ZT;EW)C=Y9&)-SV=VWB(^';D;+^S\4I
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MW!=A"TE%9K6Q\8O^U][H+@G6XXC>:CX/:.(Q$;<$:1'RHQD<YCKDD=/,U^!
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MOJ7:;;\[,GO3Y"^?W#=>I5^,4O-47':I(A9WJ:4[;DC:>VL#!VM@9[HR,HS
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MGZ!T?\$/TQ\!K+[SW],"_>$7S'7:^W_FO99\Y]U_)>U'QG%M>C'D H!0"@%
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M13WZE&+-D-[FVV]9&<S!<NMDT262X^+@52"Y@8."AMDA@27$A6Z*GN*E 54
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M\[Y,?C?DK*)#(-6&(H!0"@% * 4 H!0"@% * 4 H#7_7&!(R72/=\6(*F_\
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MFZ/M],F"?7.39^1F,J.2AHZH8A'B-#0HT5;\KEI^C&Q<1];C625"&S9U20*
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M1S4:7*:MW2.W<4%)2;=,..RCJB^2=FR7Y2OME#Q&/D3GL7""3*)W7+C*#;@
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M4JK&N&]4XKP%,;M9N%'A3'<Z\'R;SYF<QB=O0QR&<F-PH)NMQ@?<52$GWCT
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MRY41Q20'!NA672J+VHG8M9V[DK<E*+HT5W+<;D7&2JF2VD1AIMEC]&RT(@V
MJMA$$THB>1$M6#Q=66+# JU$@Z4)=*]J7X4 4R6]R5=7;Q[?+0#6?!-2V3@G
M'P5% ?4<-%U(2HJ):]_!4T!B^+Z>;'PN9/<6+PC+.:-72261O/<M9"KS5:!T
MS!I3U+JY8I>ZUN7-;>N0R2EYO<W<:;>Z:-O06+=SK(Q\[CB]NVE<%7?0R-MI
MIEH&&&P:8:% ::;%   %+((B*(B(B>!*U&VW5FZDDJ(KJ"10"@)<'UC\B5A(
MR1-JLR+7(^6/RU<MA@SR(1,2 Q0@)%$P)$42%4LJ*B\%14[4J2#XT ,-"PP*
M-, * #3:( " I8104LB(B=B)4MU=60E1417K.Z+J6Z)9%OV)4$C45D2ZV3BG
MN4 UFJJNI;JEE6_:E -9:=.I=/LWX4 U$B615M>]O=\= -9\5U+<O6X]OEH!
MK-?SE[;]OA\= %,U144E5%XJE^%Z :SX>DO#LX]E* M^7PN)S\9F%FX@3HD>
M0U,8:<4D0)$==3;B:51;BM66[LK;K%T;5.X57+4+B2DJI.O=1<%,U+6I+J\?
MAJLM&LK*FI;%Q+CV^6@&L^'I+P2R<?!0#426L2^CZO'L\E %(E+4JKJ\=^-
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M1A0#$?25L8XMDX=B7UCU6'P(E"#T=PI.0L3$Y]EQCL=TCT_*=W!15+7X7[:
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MRW&X%3VWLF@3H,2<VUC<HNJ7J:4GVR,!;=Y2ZM/IH-TU)Z*JJ\>R@)'V=_\
MKI>/20@A)FA, D#@  \VXC=K\>#>F]"",F'S$3*OY6$D8'ICC3,@&!(&R81U
M"-]X2*QNBVB@*IX^-TLB 9-0D4 H!0"@% * NK7R8?%3S52RQ%$KY _P>>IC
MM(9;:M,!0"@% * 4 H"U[CQKV7PLN!&,0E.")QR<OHYK1BX"%;CI4A1%MX*
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M@MS,E*1U\H<*4$;ZE>&";R-M("?(&*IRC%S42HHIX%XIV >Y15A,SWG8/_\
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M 4!=6ODP^*GFJEEB*)7R!_@\]3':0RVU:8"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% $[%\GY: Y8+UB\JUU#CE- * S7I3_'&/\ B2/U
M!U1?]!E^G]-'1E<LZIQ=]Y[^IY?N^+YSKT;[?^5]IGD'W7\[[,?&:9KZ(^1%
M * _1_:?\+8/]WQ/U(5X_J?Y9?J?A/T%H_X(?ICX#67WGOZ8%^\(OF.NU]O_
M #7LL^<^Z_DO:CXSBVO1CR 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5-^N/E
M3ST9*VGZ9M^H/D3S5XPS]%K81YWR8_&_)642&0:L,10"@% * 4 H!0"@% *
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M%^+X*9B:'))>L7E6NP<0IH!0&:]*?XXQ_P 21^H.J+_H,OT_IHZ,KEG5% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@.0"]8O*M=LX930"@,UZ4_QQC_B2/U!U1?\
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M_N&S"QK[L+:RQCEHEL7FHS_<>V4QN"@2<)LW"RL>[@V)DW)RG0;E@^;*DX0
MKPJJHB(0V!;K7$TVISW)*=V:>=I);*5PW'V.MT/568NUIK4H]4I2DZ)UICA6
MO+L-;=/8$+*[UP&-R+0RX$J2C<AEWB+@*!+8D\J7KO=H7)6]/.471I'Q?8=J
M%[6VH36:,GBGOP9F>^]OQH>U966FX+'8O*M97NF)=PB\R.<456Z3$!QQL55$
MX75"5>%DXUR=!J)2O*$9RE%QK+/MK_QP3/I>V-%"WI9796H0FKF6'5[,M?\
M^2C:QZ=U-I4N'V>L,.J/U?'3;/U>K3FW45>4NX47DI'T7U<M;\V_B2].NOYO
MA<SSYO3_ /U[:\^XCX;1Y/J.2/59/X]W7>CEIPW]\UMB\JUB9CF0DXR'E05L
MT[C-$UC(1+="00(5]&UA2_97>NVG<CE4G'E6T^/TVJ5FX[DH1N*C\V7HKE2Y
M-BY#/.I+F#QN4C;=Q>V\;";DQ\?+*<P#@R1*0J$X"*IJ.E?5[.RN-V:KDX.Y
M*Y)T<E1[,-A]7V[*Q:O1L0LVXJ2MO,EYV+Q7,]G,29FW<"WUZ;VP&/9';RR&
MFUQR(O)TE#0U2U_"7I>6L8:BX^S.MS//3;O](QGI+"[?ZA175U7F[OXZ[.?$
MKZ<[9VOF&]TLYV(V9/9!O#XA\KWBO2>\"VK=EX>D@>]6':.IO6W:<'_;FERT
MI6O?-GL7L_37OB%=BL;G5P_XUS4R\-QYX/:&(C]-\U)S$0'MV.Q)V0A.G?F1
MH^.>"+<?%J<YBWK*_K)RU<%!TMUC%\KDLW@H8:3LNU;[-NN[%.]EN27&*@\N
M'=JRV*WA-E;4P&4D86)GMP;E!V6OUFAG%C0VBT"#8 0W,KW4E[*V*W-3?G%3
M<(6Z+S=K?%\AH.-CL_26KDK4;UV_67GXQC%;DL,7QXEVC[4VT_OO8\N%#MMG
M=C*RW,,^JN RX($CC:*JW4-5E&]:TM7>6FO*3\^TZ9EOX/G-^'9NF>OTTX1_
M\M0G+(\4GEQ7-7'G/'?.$CPMKOS\YMR)MG</UDL?!M0$)KOD(?E"=:UN(B"-
MEU\./X\M#?<KRC"X[D,M99O[9;J/#H,>V=)"WI93NV8V;N>EO)AGCOS*KW;_
M .G9NF3^*D[BQVV\M@H&58RDM .7,$R?:;5M?1;TD@HEQOQ3PUM]IQG&U*Y"
M<HN*V+8^<YGV_.U*_&Q<M0N*<O2DJM*FQ=!\/<.VPWC'7)[9QL?;T&2_#R$6
M*VXB.L*ZK?.)"-5YC2)J2WN^.BT]WX=Y;DG.233>YTV<S,YZ[3+6I7+%M6X2
ME&22VJM,W/'RDG>FW<3L+!RL4Z+&1W'EY1OXV:JHX<7"LE^A=&RV0WU_%?Q7
MK#1:B>KN*:K&$%1KC-[5S1,NU='9[-L2MND[MR58O:X6D_-?/+R\*F>Y+:&'
M+(R<9-VG#Q^RF,.,TMT-@<=]F4K*'<7E/2XNOAHTUQ;6KN9%*-URNN=,FU-5
MX;N<^KU'9EAW)6Y6(0L*WFZU+*U+]5<>;I,>VAMY9?3S%9?&;7Q6=S$B=*9F
MNY5P651EOU-*FZU=47A9+\*WM9J,NJE"5R<(J*IEQQZ&<GLS1Y^SK=RW8MWI
MRE)2ST6&-,6US&KLC?ZRFW8;BDDAU"B,+=EE4-45MM;E<![!XKPKZ&WZ$<:X
M+%[7RL^%U'\L\%'SG@MD<=BY%N(U6%)MOI+U:D[8>9V[G2<D[>=+1',4)QV*
M9+PTBEU(%5>()Q3M'Q+\WVMV2KZ=R&$]_+_KR])]Q]N_<4M*U9NUE;>S>X\W
M%<G1P>^UW[MA%MWB1]!F_L:^-^ O<%[T?*>F_5]-QE[D_P!H^WNV/G$CZ#-_
M8T^ O<%[T?*/J^FXR]R?[1]O=L?.)'T&;^QI\!>X+WH^4?5]-QE[D_VC[>[8
M^<2/H,W]C3X"]P7O1\H^KZ;C+W)_M'V]VQ\XD?09O[&GP%[@O>CY1]7TW&7N
M3_:/M[MCYQ(^@S?V-/@+W!>]'RCZOIN,O<G^T?;W;'SB1]!F_L:? 7N"]Z/E
M'U?3<9>Y/]H^WNV/G$CZ#-_8T^ O<%[T?*/J^FXR]R?[1]O=L?.)'T&;^QI\
M!>X+WH^4?5]-QE[D_P!H^WNV/G$CZ#-_8T^ O<%[T?*/J^FXR]R?[1]O=L?.
M)'T&;^QI\!>X+WH^4?5]-QE[D_VC[>[8^<2/H,W]C3X"]P7O1\H^KZ;C+W)_
MM'V]VQ\XD?09O[&GP%[@O>CY1]7TW&7N3_:/M[MCYQ(^@S?V-/@+W!>]'RCZ
MOIN,O<G^T?;W;'SB1]!F_L:? 7N"]Z/E'U?3<9>Y/]H^WNV/G$CZ#-_8T^ O
M<%[T?*/J^FXR]R?[1]O=L?.)'T&;^QI\!>X+WH^4?5]-QE[D_P!H^WNV/G$C
MZ#-_8T^ O<%[T?*/J^FXR]R?[1]O=L?.)'T&;^QI\!>X+WH^4?5]-QE[D_VC
M[>[8^<2/H,W]C3X"]P7O1\H^KZ;C+W)_M/J;\VRM[/R/134O_0S>RZ)_D^[3
MX"]P7O1\I/U;3<7[D_VG,A>L7E6MPI*: 4!FO2G^.,?\21^H.J+_ *#+]/Z:
M.C*Y9U10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * Y +UB\JUVSAE- * S7I3_ !QC_B2/U!U1?]!E^G]-'1E<LZHH!0"@% *
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M;;L\-:.K[6OZF.65$N3?SG6[-^W-+H;G60K*6YRHZ<V",\KCGTHH!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@.0"]8O*M=LX930"@,UZ4_QQC_B2/U!U
M1?\ 09?I_31T97+.J* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MX_XT]ZF5"H[X_P"-/>IE0J.^/^-/>IE0J.^/^-/>IE0J.^/^-/>IE0J.^/\
MC3WJ94*COC_C3WJ94*COC_C3WJ94*A);W'BGO4RH5.42]8O*M=8XQ30"@,UZ
M4_QQC_B2/U!U1?\ 09?I_31T97+.J<K=?_X_+_LH_G.O1.P/E?:9XM]X?/\
MLQ\9JVOH3XP4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@*@]<?*E0R
M5M.]P]0?(E>.,_32V$>=\F/QOR5E$AD&K#$4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H"7!]8_(E82,D3:K,BUR/EC\M7+88,\ZD@4 H!0
M"@% * 4 H!0"@% * H-UIL@%QP0)U=+8DJ(I%:]DOVK9* KH!0"@% * 4 H!
M0"@% * 4 H"ZM?)A\5/-5++$42OD#_!YZF.TAEMJTP% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * )V+Y/RT!RP7K%Y5KJ''*: 4!FO2G^.
M,?\ $D?J#JB_Z#+]/Z:.C*Y9U3E;K_\ Q^7_ &4?SG7HG8'ROM,\6^\/G_9C
MXS5M?0GQ@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5!ZX^5*ADK:
M=[AZ@^1*\<9^FEL(\[Y,?C?DK*)#(-6&(H!0"@% * 4 H!0"@% * PK>'4+[
M,9)O#X_!3=P9,89Y:?'@*R"QL:T>@G55]QM#)214;:"Y%9?%0&.R^ML'*.M,
M].L>&Y]&//.9%]Z0N,8:Q[:BGZ,WVEYCAZN"(F@;>D8W2\5!K?JIU!ZRYPML
MYWIMC,SBMKY%@)./)F*Q)D3)#MC;[RV/-Y31 J:0<4-7%55+5#;)5"9UCZQ]
M7=@Q<&VN(@X5Z2T;\S(^GDXKSC CJ814%I&E]*ZW4E5/57@JT;H$CH';T^7E
M<#B\I/C=SG38C$F3$O?E.NMB9!?_  JMJR(+E0"@% * 4 H!0"@% * EP?6/
MR)6$C)$VJS(M<CY8_+5RV&#/.I(% * 4 H!0"@% * 4 H!0"@-,=>96"SC&,
MZ>Q<3]H>HF3<61M^(R^<5S&:44"R3K[2H3+;2+V_GKZ*7J&2B=TCW?F/KC/=
M*MW99G.[JVF+)CFV+(LR$^*65X4OI?:)=#J7XW%>U:(&V:D@4 H!0"@% * 4
M H!0"@% 75KY,/BIYJI98BB5\@?X//4QVD,MM6F H!0"@% * 4 H!0"@*'76
MF&C??<%IEM%)QPU01$4XJJJO!$2@(.,SV"S?,^ILI$R/)X.]S?;?T+V>ERR6
MU >&Y-U[:V?CURVZ<K%Q&.14'GS'1:$B541$'4MR7CV)0&L9;F\NI^^]SX'$
M[HE;1VIM XT)?JH&5R$V?)CC))PW'A<061!P$$1'TEO4 F;*ZA/[?3<FVNI^
M<BE*VKDHF+9W(]HBA-;R3(O1><(^@#UETN6LG"_AH#;/:ET[%[%J0?: 4 H!
M0"@% * 4 H!0"@"=B^3\M <L%ZQ>5:ZAQRF@% 9KTI_CC'_$D?J#JB_Z#+]/
MZ:.C*Y9U3E;K_P#Q^7_91_.=>B=@?*^TSQ;[P^?]F/C-6U]"?&"@% * 4 H!
M0"@% * 4 H!8E5$$5,U5$$!2ZD2\$1/=5:#'=B;*R&T]@;'[IC=^2<G.W)):
M;?F1<1RP8@MNWLA$?$RX?\.R_!MZO5:JLK"C&"=$Y;9'V5[L[L_L_+#6.<[L
MDFU#T85\/?V;"U;KZ=S,1DL4UMHW<_BMP,+*PCS+=WW!;%#< A'M(!5"X>#R
M+6QI.T8W(2=VEN5MTEP-'M'L2=B[;5AN["\JPXNBJUT8F/O[8W)%Q29V5AYC
M.&+CWYQDA:1.Q"7PHB^-4M6['5693R*:<N%3E2[.U4+76RMR4.-/Z="^9?IG
MN;$[2@;K)AYQ)@N.28:1S183#:*J./$O8A(ETX(EJU+/:=FY?E:JL-CKZ3X(
MZ6J[ U-G21U%&W+%QR^@EOD_]B'NK"0HV>A8K;.-RC928K!#!R+2]\<D'JU*
MV W505$2R]E[VX5;I;\I6G.[*.#>,7A3EY2CM+1PAJ(VM/"XLT5YLEYSECL7
M#O5K3 MV8VWN';W*^O<7)QPO\&3D-J &O;9"XI?W+WJ^SJ;5ZO5R4J<#3U6@
MU&EIUT)0KLKLZ20&RMY.%*%O;\\BA")2A1@K@A#K3RW'C9+U6];IU3SX^=LQ
M+5V3K7F_\9^9MP[O=[A'P^V]P[AYBX'%R<B+*HCQQVU( 5>*(1<$1?<[:LO:
MFU9_DDHUXE6ET&HU5>I@YTVTV?[\ADO3C:$/-[UD;<W7!> 8T20Z]#<4X[P/
M-:5&]K%V%Y%K0[1U<K6G5RU)8M8[50Z_8?9D-1K96-3!^;%O*ZQ::IPY'S&"
M JD-U[;K^):[#/F(NJ/0/7'RI6+,UM.]P]0?(E>.,_32V$>=\F/QOR5E$AD&
MK#$4 H!0"@% * 4 H!0"@->=7>JD;I5A(61+'ED\ADY/<X,1'$8!21LG2(W%
M$K((BO8*JM0W0(Q3/R]C]5ND[W5'*1)N*=AXO(";T-YQN8TVWJ%^.1,D OLJ
M;:+H/T"M=;<:;423<#%Q'41QC9W5#9N.:SN!QL/(1&XKPS(*PYR$SI;)L6U
M=3"B3!7 A05N2=@@SB5U!V)A]R1-CR<U$B;C?%L(F)U:3L:+RPX)I%20?0%5
M15\"5-07_(M*] DMC&;F&K3FB*\B*VX>E; 6I%2Q=BT!SK]V[=O4[(9[([3W
M-'>';^&B:"CRXZL.8V2+FEJ,!D(D8:-0AJU>B"*A>/%5)9TI61 H!0"@% *
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M6B1<SD;K Q[[[;<A^RV_1MD2$7%/ E2#1GWC>G'4S>&4Q67V8XY)QN-B._\
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M-QV=PS7I.W(RQF69#&$2P1D=< 1,R=05?_275-:)4(,V/4@4 H!0"@% * 4
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M^M14&R,1,F9#%PYV0@.8N;(9!V1CGC;=<CF:75LC:4@51[+BMJD$V@% * 4
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MR +SSCHM_)BX9&@_%0E6WX*E12V)$2N3E12DW395MA'GT:%A'G$8 M8-(9(
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M]MH"M-DB<LS<;5/<J*T)+ANGJ5]WC>3 Q-UK'S<=OBT4G%3']/A] ^[W3_\
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MJ2NWE@WAA&4L*[$VU'FP)<)O)\ED<_.1,CE,Q$6;!<=%48B0P.3Q%"T-H2\
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M5#,EM.]P]0?(E>.,_32V$>=\F/QOR5E$AD&K#$4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H"7!]8_(E82,D3:K,BUR/EC\M7+88,\ZD@4
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M1>L (*J/;JXT!.DY%S-;BQ,9AUQK%M..(^ $H\]\HA&0E9>(-B8W_P 9?X:
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M H!0"@% * 4 H"ZM?)A\5/-5++$42OD#_!YZF.TAEMJTP% * 4 H!0"@% *
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."@% * ^IV+Y/RT!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>fc_discovery-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_discovery-4c.jpg
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M%!04%!04%!04%/_  !$(!&8%W0,!$0 "$0$#$0'_Q #L  $  04! 0$
M        !P$#! 4&" () 0$  @,! 0$              04#! 8"!P@0  $$
M 0(# @4*$ D+ @($#P$  @,$!1$&(1(',1-!42(4"&%Q,E+2%196%S>!D:'1
M0I(CD[.45765U5<8L;+3=+0UM39V8G*"HC-3<^,D-%3!U$,XX6.#PT0E)O#"
MHV2DQ$5EA?&$)Q$  @$#  0("P4%!P0" @$%  $"$0,$(3$2!4%187&1L1,&
M@:'!T2(R4G)3%!7PLC,T%N%"8H*B\9+2XB-S-<)CDR1#@[,E-J,'1%0F_]H
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MW_:6(0#H3\S.Q/S)1_ M0,D) $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M $ 0! 1[?^?/;_\ A/-_VEB$ Z$_,SL3\R4?P+4#)"0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M,[$_,E'\"U R0D 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M CV_\^>W_P#">;_M+$(!T)^9G8GYDH_@6H&2$@" ( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M]1U"JR]" ( @" ("/;_SY[?_ ,)YO^TL0@'0GYF=B?F2C^!:@9(2 ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MG5K..'8KDYLJ$(*A""J$! $ 0! >T^F_]PMN?S"#^(%\7WK^;N^\S].=W_\
MCK'N1ZCJ%5EZ$ 0! $ 0$>W_ )\]O_X3S?\ :6(0#H3\S.Q/S)1_ M0,D) $
M 0! $ 0! <SU"W2W9>RLWN?0&7'UG/K-=[%UA^D<+3ZAD<T% ?F]:M6+UJ>[
M<E=/;LR/FGFD/,]\DCBYSG$]I).I7H@DWH;TI^4_<LK,@Y\6VL4UDV3DC/*^
M0O)$<#7> OY7$GP-!\.B ]SX+;F"VQ19C-OXZ#'48P (:[ P'3PN(XN/C<XD
ME>23/GKP6H75[43)H'C1\4C0]CAXB#J"@,,04]OX>2/$T&QU*,,CZ^.IL9$#
MR O[N-HT:"X]GJE >2=R>EMO"]*^/;&+J8FIJ>22QS6[&G@.I+&#UN0^NIH0
M<3/Z1/6&>0R?"1T>OV$=6FUH_P#U*F@.BVWZ5/4;%6(_?X5<]2U'>LEB;5GY
M?\B2 -:#_G1N2@/6.P=_8#J-@(\]@9#R:]U;J2Z":O, "6/ )'8=01P(7DDC
M3TANJF[^F<VW_@T:XAR;;?G'G,/>^57,/+R^4-.$A4H$8;+])7J/F]X8##9)
MU#WOR&1JU+7)6Y'=U/,V-^CN?AP/:E"#.ZI^D_G??BUA>G;XJF,J/="[,/C9
M/-8>PZ%T0>',;'K[$EI+NWAV)0&^Z;=5]]7^D.]MVY3)#(9K"R#WOEGAB#6#
MNV$@MB:P$<3VH"-OWJ>JGML=^*GW:F@/0/H_=1]R=2<%E\CN4P&Q3MMKP>;1
M=TWD,0>=1J=>)4,DO]7^N6%Z8-9C*\(RFZ9V=Y'0#N2.&-W!KYW $C7[%@XG
MU!H4!YHRWI+=6\E.9*^5AQD1.HKTZL/(/4UF;*__ %E-""F,]);JYCY Z;+0
MY&,'4Q6ZD'*?4UA;$[_62@/9'3G<>3W=LG#[ES%6*G?R4)G?7@+C&&%[@PMY
M^/E,#7:>#7M7DDZA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0'YI]0/[_;I_.^0_I,B^O8?X$/=CU'P_/_ #%SWY=;.=6V
M:(0&[V?_ 'NV_P#G*G^'8M?)_"G[KZC<P?S%OWH]9[XW+E,+G]SV>D>XJP?2
MSV%?=KR$AI>63.BEC;KK]T8 V5A X:$^!?,;%N=NTLF#TPE3Q=7 SZ[D7(7;
MKQ;BT3A6OAHUS\*/&F.VCD]B]:L'M?*C6Q1SN/$<X&C9H'68W12M[>#VD'U#
MJ.T+Z!/)CD8<KD>&$O!H>@^8PQ)XN?"W+@G#PK:6D[[TO/[^83\T-_I,RK.[
M?X$O>\B+?O7^8A[OE9HMG^C;O+<>'CW#F;E3;6(E8)8G7RXSF)WL7NC&@8#K
MPYW@^HMG)WY9M3V(ISER&MB=W+]Z&W-JW%\>OH_:8^_/1YWELG$/W%6GKY_
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MF*BH/0F$QD.$PV.PU?3N,=6AJ1:<!R01B,?4"@DSD 0! $ 0! $ 0! $ 0!
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M/556)<<MU33_ '=I>7RE[F6HPWU;:_>HWSZ5Y#G/2N<X=1Z&A('O-!P!(_\
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MF6_IK%AWK_Q=K^3[IFW!_P WD<]W_P#(:'*$CTDF:$C7,U=="1]A'XENVO\
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M\>UQ8Z]*]E>OS-[0U\KF\Q'AY-=$!SVXL!D=KYN[M_+-:S)8^0PV6QN$C \
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MU:UGCO5EV;\[;MR4J)ZG4^.A75_#[,K7MH;P83MC(O=-%9##,V"21H9*R6,
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M>+TUX//H+^/Z@=*ZO3#<VT-M9".E2ITK^/Q@O2%MJ_)-5<XS\KFM/W220M'
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M7!371\33TQ>KFHJ[7;.UNCG3/+C=]W>U?-R5.9V,J0.BF>Q[VEH<65W2.>\
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MY_(2M+:=J^R.N3P#G01#G(]3RVC7U%#!Z,4$A $ 0! $ 0! $ 0! $ 0! $
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MR5+U=Q9/6G88Y&.'@<UP!!4PG&<5*+JF>+EN=N3C-.+7 ]#+(60QE4("D%5
M"$%0@"D@J$!4(050@J$!5" $!5209N)Q=[-Y*KB,9%W^0NR-@K0\S6<TCSH!
MS/(:/HE8[MV-J#G)T2UF:Q8G>N*W!5E)T2_M-ANG9^XME7XL9N6F*5V>$68H
MA+%-K$YSF!VL3G@<6GAKJL&+EVLF.U;=4G3A769\W OX<^SO1V9-5I5/1I7
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MAT\#=!H"51;]N-2MXT-$:+S+HH=)W:M)PN95S3)MZ?ZF_#7Q$2_O#=3?A/\
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M%CXEV-NTFG2KTUUZNKQG6^B;N3S+=.7VO,_2'+56VJ[2?_CTW:$ >JR1Q/\
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M_!7O=N_=8]&9CW;)W%RM)YKCFMT':?-F\!]-1WD?_L6^;RGON8O_ %+OO?\
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MD,.ZD_TY<]R[_P!1YN7T8^+GI'%@GT;)-!_^"VOZ=(OG5[_FO#'[B/L>)_\
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M?OPG].L^_'[DCSBOHQ\5" ( @" ]I]-_[A;<_F$'\0+XOO7\W=]YGZ<[O_\
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MR=Z]TFFO;IS$Z:Z+Q&$8ZDD9;EV=SUFWSNI6>]>M-;':LRSL9Q8V61SP#V<
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M" ( @/:?3?\ N%MS^80?Q OB^]?S=WWF?ISN_P#\=8]R/4=0JLO0@" ( @"
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M ( @" ( @/S3Z@?W^W3^=\A_29%]>P_P(>['J/A^?^8N>_+K9SJVS1" ^D(
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MF$'\0+XOO7\W=]YGZ<[O_P#'6/<CU'4*K+T( @" ( @(]O\ SY[?_P )YO\
MM+$(!T)^9G8GYDH_@6H&2$@" ( @" ( @-#OC^Y>X_S7=_H[T!^:*]$'IOT.
M_P"M-V?S>E_'F4,'K!S6O:YCVAS' AS2-00>T$*"3Q;Z3'2_';-S-/<^WH&U
M<+FW/98IQCEB@N,',>0#@ULC3S!H["UW@T E$$#*0>^^B^Z;6X^CV-R4TI=D
MJ%6>C+*>+N>ES,C<2>TE@83KX5!)Y+^7SJ]\:;'WJO\ R2D@F[T:>H^]M[;D
MS5/=&8ER-6M1;+!%(R)@;(9FMYAW;&GL*A@D7K+UGQW2RC!7@@;D-SWVE]*B
MYQ;&R('E,TQ''EUU#0.+B#Q&A($GDG.]=.JF?G?-/N.S2C<?)KXYWF<;!XAW
M7*X_Z3B5)!KJ75SJ?0?WE?=N4+@==)K4EAOVLQ>/J(#V/T"W9NS>NQ!GMVSQ
MV+4EN6&I/'$V%SX(0UO,\,T:3S\X\EH[%#)-GU1ZM;=Z78QD^2UN9BT#[WXF
M)P;++IP+WN.O)&#P+B/6!4 \F;G](_JCN*=YK9,82D2>2KC6",@>#65W-(3I
M_E >HO5"#DF]4NI39>^&[LQSZZ\;U@CZ1?H@/6GHT;EWANS:63RVZ\G)DF,O
M>:T'3M9SM;%$U\AYFM!<"9![+7L4,DY;JQZ3[,)?L;>Z?1PW;5<F.UFIONE=
ML@.A; P$!^G9SN/+KV!PXI0@\_Y+K)U2RLKI;6Z\BQSCJ6U9C49]!L'=@?24
M@R,+UOZJ8.9DU;<]RRUIU,-Y_GL;AXB)^<_2(* ]/]&O2!Q_4.9FW<_#'C-V
M<A,(C)\VM\@U=W7,26O &I82>'$'M BA)S?I*;MZC;$R^(RFV,Y/2P63A?"^
MNQD3V,MUW:DZO8XCG8]N@U^Q*(@@OY?.KWQIL?>J_P#)*0>V^FNY'[OV'M_<
M4KQ):NTXS;>- #9B^Y3'0<!]T8Y>23S=UWZT;XP74:_@=J9J2AC<;#!!)%$R
M)S73NC$KW$O8XZ^6&_04H@XO;/5[K1NC<.,V[2W18\YR=F*JQW<USRB1P!>?
MN78T:N/J!2#V5O+>6"Z=[;DSVX;#O-:X;%$T:.L69R/)C8. +W:$^ #B3H 5
MY)/'V\_27ZB;DM2MPMH;>Q',>YKTPTV.7P=Y.X<Q=_F<H]1>J$'$1=5>I<$W
MG#-W9?O-=?+NSO;]%KG%OU$!,O2WTH<Q7R%?#=1GLN8N=S8FYIC&QSUR> =*
MU@#7L'V1#0X=OE=BB@/1_43*7,;T^W%F<-:[B[5QMBU3MQ\K^5T<1>US=00>
MS@H)/$?R^=7OC38^]5_Y)>B"4LMZ1^>PW3+;=2C:;<W[E()YLCDIFL=YM$VS
M+'&>[ ##(]K01J- WB0=0HH#A.FN]^I.\.H&-Q$V\LI#/D/.612&P]\+)A5E
M=&3"[6,MYPW4<BD&ML]<^LM.S-4M;ELQ6:[W131.AKAS)&$M<TCNNT$:("3>
M@'6;>FX.H4.W]W9E^0HY*M/'5CE9$P-LQ 3-<"QC3Q:Q[=/54,$^=7]SVMG]
M.,]GJ$WF^1@@;%2F !<V>Q(V%C@' @D%_-V>!02>,?E\ZO?&FQ]ZK_R2]$'H
MWT:=Q[\WECLUN+=V8FR%!DK*..BD9$QHD8WO)G^0QI/!S /HJ&23PH 0! $
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M_P!PMN?S"#^(%\7WK^;N^\S].=W_ /CK'N1ZCJ%5EZ$ 0! $ 0$>W_GSV_\
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M6">SN[C*[9[P\/G5G[K*#X^5SN7U@O))VB ( @" ( @" ( @" ( @" ( @"
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M@*05" JI(*J" @ 0'T%)!5""H0%0A!5" $!520$ 0'T%)!500%(/H=B$,JA
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MO9N'\W,_#M4,$E=>>A4W4%[-T;7=''NF"(0V*LI$<=R)GL/+/!LC== 7<"-
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M\HL@C=]% 8'1K:OPQZD8'$R,YZ4<XN7@1JWS>I]U<'>H\M#/]) ?HBO)(0!
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M!H=W?S5[[<)!_5 :]2=Y#_\ K61_I,BZ; _+6_<CU(XO>'YJ[_N3^\SU'N[
MW^I?HY;?CVHSSV[7IXZRRJPCFD=2C[B>)I) +VGGX>$MT[5Q>/>CB[QF[FA-
MR\>E,^A9-B69NN"M:7LQT<VAKP:>@TOHP].MU;5R>7W#N:C)B8KE=M&E3MCN
M[,KFO$KW]V?*#6AH'$<=?46QO[-M7HQA;>U1U;6HUN[6[KV.Y3N+9VE1)ZSX
MZ3;FH8GK_P!0\#>E;"_.7K(I.?P#[%6P]W=@^-S7N(\?+XU.\;$IX%F:_<2K
MS-(C=63&&\K]M_OR=.=-Z/&R/NHO0/J&S?F3& Q$F3Q&5N2VJ%V)[!&QEEY?
MR3%[AR%A=RDNX'34*UPM\8_81VY;,HJC7-Q<Y2;PW!E/)DX1VHR;:?.^'F);
MZRX<[?\ 1TJ8(SLM28UF,J2V(CK&^2![&/+3XN8'146[+O:;Q<Z4VMIG2[WL
M]CNM6ZUV5!=#1Y&P\U.OE\?8R+.\QT5J"2W'IKS0LD:7C3PZM!7>W5)P:CKI
MH/F..XJY%STQJJ\W">J_2;V3N?>=3;VX]JP29K%4XIA)6I?=GAMGD>R>-K-2
M]K@W0EOJ>!</N'*M6'.%Q[+?'HU<!]&[RX5[)C"Y:6VHUU:==-*X]74;KI?1
MW+U(Z?V=F]8=N6O,:AB;2R=X.K6;#8SJS5KN6421Z:=Z/9M.AU/-S:^\)VL7
M(5W&FJO6EI2\E'Q<'5M;LMWLS%=G,@Z*E&ZIORU7'PK7736+O2JS67DW1B]L
MR4'4-N8NMWF,?H!%:DE#0][.7AI& (PWM;Q/8X*[[NVH*U*Y6LI/3R?VZ_[#
MG>]5ZX[T;=*0BM'+Q]&KC6G@9&'2KYS-H?G>G^&:KO>/Y:Y[LNHYS=7YNU[\
M>M'H#TH.G>ZMQWL/N;;V/FRE>K7?2N5JC#+8C/>&1KQ&W5SFGF(/*.&GJKE.
M[^;:M1E;FU&KJJZCM^]&[KU]QN6XN5%1I:7T&5Z.NR\GT[P.XMZ;VB=A:]F*
M,LAMCNY8ZM4/?)+(SM;S%VC6GRO)[.(7C?F5'*N0M6O2:XN-\![[N84\.U<O
M7EL)TU\2JZOIU/3H+_H^[M=NC;6]<1BK4>/W3/D+V5HF5K7]VW)-'=2EAUYQ
M'*/+X>(>$+QOG&[&Y:E);4%&,7_+K7A1DW#F?,6KT8/9FY2DN3:U/EH]?@.(
MR&^?2IQEZ3'V:%V2>)Q9WE;$0V87Z'35DD4+FN!]0JSMXFZIQVDX^&;76RFO
M9V^K<G%J3IQ0372HF#L[<6_,]U\VO#U#+FY[&=[7\W?#'7?'')5EF:"V( <0
M\.U\2RY5BQ;W?<=CU9<M>%(QX63E7=Z6UD>M&JU)?NM\'.8/I1_.C_\ VVK_
M !I%E[O?E?YGY#7[U_G%[J\IHMAY+K#L6A#N39]&])M[*%SM&5G7*,YB>8CS
ML:'<CN9I;S>2XZ=NBVLVWAY$G"ZUM1Y:-</VUFENZ[O#%BKEF,G"?)M1=-&F
MFKQ,G+JY%'N_H3'O#>>'9A=X5HX9:L+P6S13OLB+NV\VC^65AY^[=KRZZGBW
M5<SNUNQG]E:EMP?1JKXGP\/A.PWO%9.[>VOPV+BI3C7I4Y_26FCU<.HN]2<;
M8ZQ]%<-F-HM\^R%-U>\^C$=9'/CB=#8@ X?=&%Y.GAY>&NH7G N+!S91NZ$Z
MJOAJGS,][TM2WENZ$[.EJDJ>"C7.J^+1K.!]'+IINJ'?,6Z\QC;.+QF'BG#'
M7(G0.FL6(W0AC&R .(:U[G.<!H" %:[]WA:=CLX24G*FK31)U*+NWNJ^LE7K
MD7!0KK5*MJG#SG2;>W-0W3Z4EF]BY6SX^K2GH0SL(+9#6A#9'-(U!;SEP:1V
MCBM._CRL[J2EH;:?2_,6>-EQR-\R<=*C%QKQT6GQU(K](CYX=P_YM'^@P*^W
M'^3A_-]YG)=X_P#D+O\ +]R)+NX^'HF5=/\ PJ']-B7/6/\ EWSR^ZSK\O\
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M[(3(!IWDGLI)"/&]Y<\^NO))O$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! ?FGU
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MKD_+K'VVK:KHYW72];UZM1S06^504D%0@*A""J$%0@*H0 @*J2"H0!" @/I
M54GD( @/I" %(*J""H0!205" JA!5" I!4("JD@JH(" ! ?04D%4(*A 5"$%
M4( 0%5) 0! ?04D%5! 4@^AV(0RJ$ *054$%0I!4(054D%4(" ^QV*2"H0@J
M$(*H0$ 0! $![3Z;_P!PMN?S"#^(%\7WK^;N^\S].=W_ /CK'N1ZCJ%5EZ$
M0! $ 0$>W_GSV_\ X3S?]I8A .A/S,[$_,E'\"U R0D 0! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0'DGTM;&X\?
MN#%,BR=MFV\I3<#CFS/;6-BN\B0]V"&G5KX^U2B#S2I!ZW]&KHW:PI;U"W16
M,.1FC+<'2E&CX8I1HZP\'B'/:>5@\#22>T:0P>E5!(0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $!^:?4#^_VZ?SOD/Z3(OKV'^!#W8]1\/S_ ,Q<]^76SG5MFB$!
M](0 @*H0$ "D'T$(*H05" *2 @/I00 I!5" @*J2"H4 JI(" ! ?00@JA "
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MA/-%9OAIBC>.QT<+1R@CP%_,1X"$J"7E " ( @" ( @" ( @" ( @" ( @"
M( @" \#[UZ1]3+^\]Q7J>U[\U.UD[L]>9D1+7QR6'N:X'Q$'5?3<7>.-&S!.
M:JHKJ/D69NK+E?G)6Y-.4N#E-'\C/53XI9'[R5M?4\7XD>DU/I&9\.70/D9Z
MJ?%+(_>2GU/%^)'I'TC,^'+H*_(SU4^*>1^\E/J>+\2)'TC,^%+H*CHSU4^*
M>1^\E/J>+\2(^D9GPI=!7Y&>JGQ3R/WD_73ZGB_$B1]'S/A2Z!\C/53XIY'[
MR?KI]3Q?B1'T?,^%+H'R,]5/BGD?O)^NGU/%^)'I'T?,^%+H*CHUU3^*>1^\
ME3]4Q?B1Z2/H^9\*705^1KJG\4\C]Y*?5,7XD1]'S/A2Z"HZ-=4_BGD?O)3Z
MIB_$CTD?1\SX4N@?(WU3^*>1^\E/JF+\2/2/H^9\*70/D;ZI_%/(_>2GU3%^
M)'I'T?,^%+H*_(WU2^*F1^\E/JF+\2/21]'S/A2Z .C?5+XJ9'[R4^J8OQ(C
MZ/F_"ET%?D;ZI?%3(?>2I^J8OQ(])'T?-^%+H'R-]4OBID/O)3ZIB_$CTCZ/
MF_"ET%?D<ZH_%3(?>2GU3%^)'I(^C9OPI=!7Y'.J/Q4R'WDJ/JF+\2/2/HV;
M\*705^1SJC\5,A]Y*GZIB_$CTCZ-F_"ET#Y'.J/Q4R'WDI]4Q?B1Z1]&S?A2
MZ!\CG5'XJ9#[R4^J8OQ(])'T;-^%+H*CH[U1^*F0^\E/JF+\2/2/HV;\*705
M^1WJA\5,A]Y*?5,7XD>DCZ-F_"ET%1T=ZH?%7(?>2GU3%^)$?1LWX4N@?(]U
M0^*N0^\E/JF+\2)'T;-^%+H'R/=4/BKD/O)4_5,7XD>D?1LWX4N@K\CW5#XJ
MY#[R4^J8OQ(])'T7-^%+H'R/=4/BKD/O)3ZIB_$CTCZ+F_"ET%?D>ZG_ !5R
M'WDI]4Q?B1Z1]%S?A2Z!\CW4_P"*N0^\E/JF+\2/2/HN;\*70?7R/]3_ (JY
M#[T5/U3%^)'I(^BYOPI= ^1_J?\ %7(?>BGU3%^)'I'T7-^%+H'R/]3_ (JY
M#[R5'U3%^)'I(^BYOPI=!4='^I_Q5R'WHI]4Q?B1Z1]%S?A2Z"OR0=3OBMD/
MO14_5,7XD>DCZ+G?"ET#Y(.IWQ6R'WHI]4Q?B1Z1]%SOA2Z"OR0=3OBMD/O1
M3ZIB_$CTD?1,[X4N@?)!U.^*V0^]%/JF+\2/2/HF=\*70!T@ZG?%;(?>BI^J
M8GQ(](^B9WPI=!7Y(>IWQ6R'WHI]5Q/B1Z2/HF=\*705^2'J;\5LA]Z*CZIB
M?$CTCZ)G?"ET#Y(>IOQ6R'WHJ?JN)\2/2/HF=\*705^2'J;\5LA]Z*?5<3XD
M>DCZ)G?"ET%1TBZF_%:_]Z*?5<3XD>DCZ)G?"ET%?DBZF_%>_P#>BGU3$^)'
MI'T3.^%+H'R1=3?BO?\ O13ZKB?$CTCZ)G?"ET#Y(NIGQ7O_ 'HI]5Q/B1Z2
M/HF=\*705'2/J9\5[_WHI]5Q/B1Z1]#SOA2Z"OR1]3/BO?\ O14_5<3XD>DC
MZ'G?"ET =(^IGQ7O_>BGU7$^)'I'T/.^%+H*_)'U,^*]_P"]%/JN)\2/2/H>
M=\*705'2/J7\5[_WHI]5Q/B1Z2/H>=\*70/DDZE_%>_]Z*?5<3XD>D?0\[X4
MN@?))U+^*]_[T5/U7$^)'I'T/.^%+H*_))U+^*]_[T5'U7$^)'I(^AYWPI=
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M /B[=^]E/J^'\2/2/T[O+X$^@?)EO_XNW?O93ZOA_$CTC].[R^!/H'R9;_\
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MB?F2C^!:@9(2 ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @(]O_/GM_P#PGF_[2Q" ="?F9V)^9*/X%J!DA( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" CV_\ /GM__">;_M+$(!T)^9G8GYDH_@6H&2$@" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ("/;_ ,^>
MW_\ ">;_ +2Q" ="?F9V)^9*/X%J!DA( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" CV_\^>W_P#">;_M+$(!
MT)^9G8GYDH_@6H&2$@" ( @" ( @-/N+=>W=I5([VY,C%C:DL@ACFG)#72.#
MG!HT!XZ-)6Q8Q[EY[,%M,ULC*M8\=JY)15::3FOEKZ4_&JC]L[W*W/I65\-E
M?]:POBQ'RU]*?C51^V=[E/I65\-CZUA?%B/EKZ4_&JC]L[W*?2LKX;'UK"^+
M$?+7TI^-5'[9WN4^E97PV/K6%\6(^6OI3\:J/VSO<I]*ROAL?6L+XL1\M?2G
MXU4?MG>Y3Z5E?#8^M87Q8CY:^E/QJH_;.]RGTK*^&Q]:POBQ'RU]*?C51^V=
M[E/I65\-CZUA?%B/EKZ4_&JC]L[W*?2LKX;'UK"^+$?+7TI^-5'[9WN4^E97
MPV/K6%\6(^6OI3\:J/VSO<I]*ROAL?6L+XL1\M?2GXU4?MG>Y3Z5E?#8^M87
MQ8CY:^E/QJH_;.]RGTK*^&Q]:POBQ'RU]*?C51^V=[E/I65\-CZUA?%B/EKZ
M4_&JC]L[W*?2LKX;'UK"^+$?+7TI^-5'[9WN4^E97PV/K6%\6(^6OI3\:J/V
MSO<I]*ROAL?6L+XL1\M?2GXU4?MG>Y3Z5E?#8^M87Q8CY:^E/QJH_;.]RGTK
M*^&Q]:POBQ'RU]*?C51^V=[E/I65\-CZUA?%B/EKZ4_&JC]L[W*?2LKX;'UK
M"^+$?+7TI^-5'[9WN4^E97PV/K6%\6(^6OI3\:J/VSO<I]*ROAL?6L+XL1\M
M?2GXU4?MG>Y3Z5E?#8^M87Q8CY:^E/QJH_;.]RGTK*^&Q]:POBQ'RU]*?C51
M^V=[E/I65\-CZUA?%B/EKZ4_&JC]L[W*?2LKX;'UK"^+$?+7TI^-5'[9WN4^
ME97PV/K6%\6(^6OI3\:J/VSO<I]*ROAL?6L+XL1\M?2GXU4?MG>Y3Z5E?#8^
MM87Q8CY:^E/QJH_;.]RGTK*^&Q]:POBQ'RU]*?C51^V=[E/I65\-CZUA?%B/
MEKZ4_&JC]L[W*?2LKX;'UK"^+$?+7TI^-5'[9WN4^E97PV/K6%\6(^6OI3\:
MJ/VSO<I]*ROAL?6L+XL1\M?2GXU4?MG>Y3Z5E?#8^M87Q8CY:^E/QJH_;.]R
MGTK*^&Q]:POBQ'RU]*?C51^V=[E/I65\-CZUA?%B/EKZ4_&JC]L[W*?2LKX;
M'UK"^+$?+7TI^-5'[9WN4^E97PV/K6%\6(^6OI3\:J/VSO<I]*ROAL?6L+XL
M1\M?2GXU4?MG>Y3Z5E?#8^M87Q8CY:^E/QJH_;.]RGTK*^&Q]:POBQ'RU]*?
MC51^V=[E/I65\-CZUA?%B/EKZ4_&JC]L[W*?2LKX;'UK"^+$?+7TI^-5'[9W
MN4^E97PV/K6%\6(^6OI3\:J/VSO<I]*ROAL?6L+XL1\M?2GXU4?MG>Y3Z5E?
M#8^M87Q8CY:^E/QJH_;.]RGTK*^&Q]:POBQ'RU]*?C51^V=[E/I65\-CZUA?
M%B/EKZ4_&JC]L[W*?2LKX;'UK"^+$?+7TI^-5'[9WN4^E97PV/K6%\6(^6OI
M3\:J/VSO<I]*ROAL?6L+XL1\M?2GXU4?MG>Y3Z5E?#8^M87Q8CY;.E/QJH_;
M.]RGTK*^&Q]:POBQ.QHY7'Y*E7R-&PR>E;C9/6G9[%\4C0YKAZA!U5=.#A)Q
MEH:+:W<C.*E%U3549'G$/MPO!['G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP
M@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$
M/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@
M'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/
MMP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'
MG$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/MP@'G$/M
MP@'G$/MP@'G$/MP@'G$/MP@/HR,:T.<=&GL/KH#Y\XA]N$ \XA]N$ \XA]N$
M \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA
M]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$
M\XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]
MN$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \
MXA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N
M$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ \XA]N$ $\1( >-3V("X@" (
M @" ( @" ( @" ( @" ( @(]O_/GM_\ PGF_[2Q" ="?F9V)^9*/X%J!DA(
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M 0! $ 0! $ 0! $ 0! $ 0! 5!T((\" VH.H!'8>*$E4 0! $ 0! $ 0! $
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M $ 0! $ 0! $ 0! $ 0! $ 0! $!ESN::T;002.74 \>Q"3$0@( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MMJE*TX:,I[>^[$\IXRKM)M5X*K6B2%2E\$ 0! $ 0! $ 0! $ 0! $ 0! $
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M,E $ 0! $ 0! $ 0! $ 0! $ 0$>W_GSV_\ X3S?]I8A .A/S,[$_,E'\"U
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M@;708+MF5JFUPI/6GH?,8*RF$( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M1V*UQ,N.3;VXII<I29^!/#N=G-INE='V1S2W"O" 'L*!'Z$=-OF\VI^:*/\
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M=&,/:=.Q<)O'#AC348RVZJI]+W7G7,NVY3@[;3I1_P!B.Z546X0! $ 0! $
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M]5(_>9ZW#@X!P.K3Q!'$$%?/SZ@% " ( @" ( @" N0.Y9F'U=/I\$!LT)"
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MXMYF.':TZ:@^$+-%U29KSCLR:JG3BU%I>CR$ 0! $ 0! $ 0! $ 0! $ 0!
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M 0! $ 0! $ 0! $ 0! $!'M_Y\]O_P"$\W_:6(0#H3\S.Q/S)1_ M0,D) $
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MCSQ<XZ?0[!P6+)RKF1/:N.K,N)AVL6&Q:5%]M9O%JFX$ 0! $ 0! $ 0! $
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MIOE.Y566X0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&RK.YH6^IP^DA)=0! $
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M?[#X_94'M*;:T.E.&2U5\>DUZS&L$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M=M[%=FKI773@KRTUF,O9C" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M,:X0 ]A0(_0CIM\WFU/S11_H[%\DS_S-SWI=9]QW9^4M>Y'[J.G6B6(0! $
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MT>PNH[N?F)>[Y4<;WL_*Q]]?=D>.U]!/EQN=J6,K6W#0=@Y*\65E>ZM6DNB
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M/S11_H[%\DS_ ,S<]Z76?<=V?E+7N1^ZCIUHEB$ 0! $ 0! $ 0! $ 0! $
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M7N?JT:N\0 /U-$ <V1@Y7MT':-1KQ]1 4#W \P.A\8 " %[CIQT#>( X >L
M@/IQD#1S#0/X]@'-ZIT[?HH"@D>/#QTTUT&NGBU\7J(#BLIT\KYW?N-WMG,K
M9NTL$P/P.VBUC*%6_P I:^X[3RI)"#Y =P9VJ0=F>/$]J@'T'N!U&@=IIS
M.T]<#5 ?/,>)[2>TGC_"@*AS@-!V ZC7CH?&-?"@--NC$97/8YE3$9^WMO(1
MS1SLR5&.":1PCUUCD9.US',=KY0TUX=JD&CV9T[K[4R^7W1D<Q=W)O#.,B@R
M&:R BB(K5R3'!## UL<<8)UT XH#LU " ( @" ( @*H#:M/,T.\8U0DJ@" (
M @" ( @" ( @" ( @(]O_/GM_P#PGF_[2Q" ="?F9V)^9*/X%J!DA( @" (
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M,Y&Z;EN6W:;E3EI-:>"7[RX-F7!PE_9O7^_CW28SJ#7DLQTCR7<O7J/K7J9
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M $ 0! $ 0! $ 0! 1[?^?/;_ /A/-_VEB$ Z$_,SL3\R4?P+4#)"0! $ 0!
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M4"/T(Z;?-YM3\T4?Z.Q?),_\S<]Z76?<=V?E+7N1^ZCIUHEB$ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0$,]8,/B<]U2Z0XK-TH,CC+%G*MGIVHVRPR 0-<
MYC@0=" >*D&OSFW,3TLZP=.[.P8!AZ&\[-S$[AV_4)90GBBA,S;(@UY6O8>!
M<T!"3GMO]69-G]+MN6L!@L-MFEFL]E<=8R4PM.P>+$$LA[ZP YTA?.X -!D:
MW7Q! 2%?ZB[S?DML;'VY5PN4WUF\=+F<CF62SNV_6Q\4AB$T09K+*9#IRMY@
M.WBA!6YO?J1)NC']-,)4P<^^68UV8W+F)O.FX>I6=*8H&PPZ]\]\O#4%P#>*
M Y]_73<E*G'8S.&I4[&!W/#M;?T$3Y9V0QW-!7N4I/)T8XN;J) =-4!F[GZX
M7MO9#?4\6.K6MN;5LX_ XU\CI(9;6?OAKI&RR^4UE>!KN:0AO, @-14Z_P"4
M!W%BWW-N;@RU' 7-PX?)8%]@T!)CR.]J6HY'%X(#FN:]KO*;KP!0DV5CJQU&
MQ6W-O[_W!@\72V3FLCCJTM>-\LV0KXS),#1:D<"&-<92-&<0UA&O'5"#MMJ[
MSRNY]][UPD5:NS:>U):V-@N /\ZGR<D8EG:3KR<D;7 <!KJ@.V4 ( @" ( @
M" ( @" ( @" ( @" ( @" ( @,J:-C:['M: XZ:GUPA)BH0$ 0! $ 0! $ 0
M! 1KN_ION*;>D74GISFZ^%W<^JS&YBIDH76<;DJ<9YHQ*&.#V/9V!S? I),'
M,[ ZF;G;AMQ9C-82CO\ VOD77MNR8^O9.--6>$16*ML/?SN$G%P>SV/B0@U^
M7Z.;LW72WUE=T9G'G>N[L,W;N/AHQS,Q6/HL<)-.:3FED<]_%SN7P#@A)N=W
M[-=$SIKN')YBEC<1TR=YYG;5HO9')%'3%9SHW:: :\?+T0@CG96Q,MU$Z8Y'
M)8&XW#Y%^][>Z]IW;T+W0S1PRAC'2,X.[J4!W*[1 =9<Z39_-Y7=&Y^J&=Q\
M^/S^V)\'EXL7#- RBR.43M?!WA<7M8UG.YSSS%W #1 1W#FLIN7<'2G:E?>F
M)WT<-F*ER!FWZKVO9CJ+"?.\E(9'B-S6-Y P-;JXZG4H2=/DO1\WC8Q6>V[5
MR^"=0RF<.X&9NQ5G.:L$V6SBO9F&H:U@;H'-UU #> U0@[?*]-=PS]3\KO#'
M7Z#]K;KQ<&$W7C+D<HN-KP1R,YJ<D9Y>9W./9C0<>'8A)I-F=&LUM*?&8RSC
M]F9G!XR9@&>LXI[-P35(G:LYW-\@V!HW[L7=HUT0@S&=+=VY7J3A=^;BFV_0
MFP=B><Y';]>Q!D\I!('LBKW'2.Y>[:UPY_9<Q'#1 2\H 0! $ 0! <#)\]E?
M_"TW]H1*P7Y5^^ONLTG^97N/[R.^5>;H0! $ 0! 1SOKIQFLONC&=0MAYJ+
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MRIIV?6I1^KRZZ<M#7[!ZE= ^G&7DS6VZNZ66IX'59X['FLD3V.<UWE,$[=7
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MX;,2=]N2QS9#<%@.Y^?(V]'R^5X>3@S7U$!VR@! $ 0! $ 0! $ 0! $ 0!
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M:A%/T4J5?M:V^3EKH/-6UNK>:VGC=U8O'T:LU;=AE-M]CO#)$)F2,/)R.:.
MD\(787]VPO2MR;=;>KQ>8X+'WS<L1NQ45_JUX]%:^<P.FO4;*],,W8SF'J5[
MEBS4=1?';Y^01NDCD)'=N:==8PLV=A1R[:A)M).NCP^<U=V[QEA77<BDVTUI
MY6GY#=;)ZU[CV9!EL::-+,;?S,TMJUB+["^!LTYU?R<3Y+AH"UW,.'CU6ME;
MJMWW&57&4=":UF]A;\NV-J,HJ<)MMQ>K3K\'(ZF9D.ONZ<CMW,[4?B\76V]E
M8?-JU"G :T5&(@ZB!L;@"2X\Y+]>/J<%CAN>U&Y&YM2<HNM6Z[7.9)]X+TK4
M[6S%0DJ))4V5R?;S&+T_ZW;AV#@K&UQCJ.:V_8>Z84L@QS@Q[]"X M.A:2-2
MUS3Q[-%[S-U6\B:N5<9+A1CW?OR[BVW:<5.'$_MJ+6RNM.Y]C9S-97%5JDF/
MSUA]J]A9&%M1LCW.<.Y#2#'RAQ: .!;H"#H-/65NNUD0C&3=8*BEP^'C/&%O
MN[C79SBELS=7'@\'%YO ;MGI'[PALWA5Q>,JX2W5?3CPE:)\%2(RG5\P[MP+
MI7#@2>'B"UOH=II5E)R3KM/7S<QNKO+?4G2,5%JFS31S\YRF)ZH9G#].LITU
MKTZLF(RLKYIK<G>><M+S&2&Z.#?_ (8[6K>N;OA/(C?;=8\'!P^<K;.]KEO%
MECI*DN'AX.7D-3LS>^X]@9EN<VU:%>WR&*:-[>\AFB)!+)&'M&HU'A'@*V,K
M$MY,-B:T&I@Y]W$N;=M^9D@9'T@+-^.S*W8^VH<M;8^.QD_,R^8F0$.<"2':
M\?LG%54-S*-%VMS97!M%Y<[P;56K-O;>N6S]GXS4[2ZQ/VQM^EMRYM'!9VMC
MG2/I6<A6Y[+72R.E)<\\P)!=P( X+/D[L[6XYJY.#EKH]!K8F^>QM*W.U"XH
MZ55:==3G=^]0=Q=1LPS,;ADC#H(^XITZS.[KUXM>;E8TDDZDZESB2?6  V\/
M"MXL-F'A;ULKL_>%W,N;=QZM26I<WVKXCE5O%<$ /84"/T(Z;?-YM3\T4?Z.
MQ?),_P#,W/>EUGW'=GY2U[D?NHZ=:)8A $ 0! $ 0! $ 0! $ 0! $ 0! $
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M! $ 0! $ 0! $ 0! $!]NED>T,<=6CL&GB0'P@" ( @" ( @" ( @" ( @"
M( @" YJSO_:M7<M7:4E]KLU:<8Q#'Y;8Y WF:R1PX-<[[%IX_45A'=]^5EWM
MGT%]M!5SWIC1R%CN2[27!Q<-'Q-\!TJKRT" ( @" ( @" (#@9/GLK_X6F_M
M")6"_*OWU]UFD_S*]Q_>1WRKS=" ( @" ( @" ( @" ( @" ( @" ( @" (
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M:M:YQ:#ZP7BUC6K7J14>9&6_F7KWXDY2YVV:9;!J! $ 0#L[4 !UXCL0! $
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M=6]BQM4\@Y_8_<PYO%[E )24 ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M3;33KZ"6I:=-:Z=6KQER.CMJ2_B*[LQ-%0LPQNS-U],N-.=Q=WC(XFR$S-:
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MI/U.'G_9^Z4^X=\._+Y>3=R4%IN+U7R>#4I?O4;YY87,G8A $ 0! $ 0! $
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ME2M7KEHTNJ_>Y.#0D3PSF+&EXT?H.8<.WZ"Z%:M)1O654D! $ 0! $ 0! $
M0! $ 0! 9E)W![?6*$F6@" ( @" ( @" ( @" ("/;_SY[?_ ,)YO^TL0@'0
MGYF=B?F2C^!:@9(2 ( @" ( @" \^^EQ_<7$_G:'^CV%U'=S\Q+W?*CC>]GY
M6/OK[LCQVOH)\N" ( @/N-_=R,DY0_D<UW(X:M/*=="/$5#543%T=3U-TCWW
MC>H4^XX\ILC;E9N'QKK]?S:@S5\C21ROY^;R>'@7$[RQ)8RALW9O:E33(^D[
MHSH9CGM6K:V571$Y38^_<_U!W54@V_T_VL_(8ZK:L.K"%M-CXY1'$7<SBX$M
M+APT/ GUUNY>)#&M-SNW*2:X:\I78&?<R[Z4+-JL5)ZJ<2(WVMTRW=OKWRR.
M*K5:6*HSNCNY"W,VI1AF<[7NF.<3KIS#@-=!IKVC6XR,^UC[,9-MO4DJOG*#
M%W7?RW*44HQ3TMND4^+[>8^:W2K>=W>%C8]&K#;S=2-MBR^&>-]6.N]C7B5T
MVO*&Z/;ZO'3353+>-F-E76Z1?)IKQ4/,=T9$LAV(I.2UZ=%-&FOA+N6Z3[JQ
M&;PF!=+C[MS<,KH,7)2N1SPODC+0X.<-"S0N'%PX^#L7FWO*U.$IZ4H:ZJA[
MO;FOV[D+=8MW-5'H-9+L+<<.]1T^?%#\)3.VJ(A*TP]Z]@D [SL["LRS+;L=
MM^[2IK/=UU9/R^C;KQZ-53(K=,]Y7=XVMAT: M;BHD^>1Q2-,$+&AI<]\IT:
M&#G:-3X3IVKS+/LQLJ\W2+U?V'M;KORR'CI5FM?%S^,R-V=*MV[/Q46=O-JW
M\%))W#LEB[++D$<Q^PD+.+3KPU(TUX:KQC[QM7Y["JI<4E1F3,W1?QH=HZ2C
MQQ=4N<XE613! $ 0! $ 0! $ 0! $ 0! $ 0! $!)W13JCC^EF9R>2R./GR$
M>0K,K-;7>QCF%DG.2>?MU]=4N]=WRRX1C%I49T>Y-Z0P9R<TWM+@.EQ/5SI/
MLBW+F-A[ F;N$M>VM=R=MT@A[P$'E!=*1P.AY>4D<-5IW-VY>0MF]=]'B2U]
M1OVM[8&*]NQ9>WP.3U<VOQ4YS6=.>N,NUMU[EW=N>G-F,CN-C&RFN]D(86.)
MT >#Y(;RM:/  LV;NGM;4+=M[*@8=W;][&]<NW4Y.Y34:KIAU<GV%3R6W,OC
M&9[9>8YC>Q4C@QS7R-Y'/C<01Y30 YI''0:$+/G[M60U.,MB<=3-/=6]WB1E
M;G';MRUKQ=7!S:CI!UKVEL["Y'&=(MJ28+(Y8<MK,7K!L3QMT('=@ND)+>8\
MFKPT'CRE:?TJ[?FI9-S;4>!*B+![[L8UN4<2WL.6N3=6NOKT<3.=VUU2I8+I
M+N'IO+CII[>;GFG9D&R,$<?>LA: YI',=.ZX^NMO(W?*YEPOIZ(K5T^<T</>
MD+.%<QW%UFVZ\&J*\AJ.F74S+],LU+DJ$#+V.NQB#*8R8\L<\0)(T=H>5[=3
MRNT/:1IQ6QGX$,N&RW1K4^(U=U[TG@S<DMI2UKC.LO[YZ#S&>]5Z;V1D9VOT
MKF^^*HR1X(YFM8\@ :ZZ!F@\ 6A#$SE1.\J>[I^WA+6YG[L=9*P]KWFEU^0[
M[HQFO@YZ.^[\RZE!DHZN1M&6A;!,$\3X*C'QO \#FN(59O2UVF\+<:N-8K2M
M:TR+7<=U6MVWIM*24GH>IK9AH.5I]<=D;+Q5YO2S97O)N')LY)\A<G-IL/;I
MR<[GN<&DZM;Y+=>)![%NRW3?OS7S%S:C'@2I4T8[\QL:$OE;6S.7"W6G7T:$
M<MTSZOVMCU<I@,YCV[AVAFR]^2QLS^63O96\DDC'N#@>< <[7=N@T(*W<_=B
MON,X/8G'4RMW9OEXRE"Y';MSUKK?1Q^(Z(=:]I;.PN1QG2+:DF"R.6'+:S%Z
MP;$\;="!W8+I"2WF/)J\-!X\I6I]*NWYJ63<VU'@2HC>>^[&-;E'$M[#EKDW
M5KKZ]'$SE]H[FZ1U=OP8O>^S;.3RM>260Y6G;=$^9LCN8,D:'Q\ /)[7>IIJ
MMW)Q\MW'*U<44^!K^TT,/+P(VE&_:;DJZ8NE?&O*;[,]=69C?>T]P-PQI;6V
M?S-QF'BE#IBUS!&2Z0M !T8P!NG #M/:M:UNAPL7(;59W-;^WA-R[OZ-S*MW
M-BD+5:+AT_V+0:F]U>D'61W5?$8\QM+XR<98D!+HA4;5E87L&@+@"6G0Z'3@
M5GANW_T_EY/P^&J-.YO>F>\J$>+0_=V69._NJ.ULQN'&[TV'@9MO;QKW//[^
M2EE#VSR!H :8VN+""?9GE',-=>U8\/=]V%MVKTU.#5$N+PF?/WK8N78WK$'"
MXG5NNOP5IS\9T-_K1TNW/D*NZMY=/WVMX56QA\E:SI4G?#[ R-<1J&Z< ]C^
M' D@+5ANO*M1=NU=I!\:TK[> WI[ZPKTE=O6:W%Q/0^?]J?$:/Y=LEDNJ^*Z
MC[@I&2CB(YX*6&J/Y1'#-#)&-'O'E.+I.9[B..F@T  &S](C#%E8@],J5;YU
MYC1^NRGFPR+B]&%:17*FNG3I9PF_-R0;PWCF-SUJ[ZL&3G[]E>1P>]GD-;H2
MW0'B%9X=AV+,;;==E%/O'*63D2NI44CT-Z/]W+=/^FFY]U;NKFMM&)[;^(BL
M LFFLAG(XQ->. E<(F,=X7+E-\1ADY,+=MUGJ?(OV:6SM]PRN8>'<NWE2'K1
MXV_V^BERGF/*Y2YF\I=S.1?WE_(3R6K+_'),XO=IZFIX+L[=M6X*,=25#Y]?
MO2NW'.6N3J8:R&$( >PH$?H1TV^;S:GYHH_T=B^29_YFY[TNL^X[L_*6O<C]
MU'3K1+$( @" ( @" (#6YO-U\%7@GG@GLOLSQU*]>I'WLKY9=>4 $M'@.I)6
M>S9=QM)I45=)ANW5;575U=-!@?"FU\6<W^*Q?RRS?*KVX=/[#%\P_8ET?M'P
MIM?%G-_BL7\LGRJ]N'3^P?,/V)='[1\*;7Q9S?XK%_+)\JO;AT_L'S#]B71^
MT?"FU\6<W^*Q?RR?*KVX=/[!\P_8ET?M'PIM?%G-_BL7\LGRJ]N'3^P?,/V)
M='[1\*;7Q9S?XK%_+)\JO;AT_L'S#]B71^T?"FU\6<W^*Q?RR?*KVX=/[!\P
M_8ET?M'PIM?%G-_BL7\LGRJ]N'3^P?,/V)='[1\*;7Q9S?XK%_+)\JO;AT_L
M'S#]B71^T^J>ZX;.5K8:UC,CC;=R.:6J;L#8XY!7Y.<!S7OX@/!T*B>*XP<U
M*,DJ:GQB.2G-0:DFT]:XJ><WZTS;*/>UC'/>=&-!<X^(#B5*50<S5WDZ[6AN
M5-N9J6K88V6"458P'QO',UPUE!T(.JWI8>RVG.%5R_L-*.5M)-0E1\G[2]\*
M;7Q9S?XK%_++S\JO;AT_L/7S#]B71^T?"FU\6<W^*Q?RR?*KVX=/[!\P_8ET
M?M'PIM?%G-_BL7\LGRJ]N'3^P?,/V)='[2HW7; (&VLV >T>;1\?_P!<GRJ]
MN'3^P?,/V)='[2GPIM?%G-_BL7\LGRJ]N'3^P?,/V)='[1\*;7Q9S?XK%_+)
M\JO;AT_L'S#]B71^T?"FU\6<W^*Q?RR?*KVX=/[!\P_8ET?M'PIM?%G-_BL7
M\LGRJ]N'3^P?,/V)='[2U:WN_'U);5W 9JO1A:7SRNK,Y&,\+B&RDZ#M.@7J
M.&Y.BG%OG_8>99>RJN,DN;]ITRT#=" T%O=4<&3M8JKBLCD;%(1&R^E V2-A
MG;SM',Y[-3IQX+<ABN45)RC%/C9JRR$I.*C)M<2/@[JLCB=LYL#PDUHOY93\
MJO;AT_L(^8?L2Z/VCX5S_%O-?BT7\LH^77Q(=/[">WE[$NC]H&Z[!.@VWFM?
MYM%_+)\NOB0Z?V#MW[$NC]H^%<_Q;S7XM%_+)\NOB0Z?V#MY>Q/H_:!NNP>S
M;6:)]2M$?_OE*QD_WX=/["/F'[$NC]I7X4VOBSF_Q6+^63Y5>W#I_8/F'[$N
MC]H^%-KXLYO\5B_ED^57MPZ?V#YA^Q+H_:/A3:^+.;_%8OY9/E5[<.G]@^8?
ML2Z/VCX4VOBSF_Q6+^63Y5>W#I_8/F'[$NC]IL,)FJV=J26J\,U<PSRU9Z]I
MG=31S0.Y7-<W4CUB"L-ZR[;HZ/171RF6U=5Q555I:T\AL5@,P0! $ 0! $ 0
M%U\[GQB,@<K=-".W@@+2 ( @" ( @" ( @" ( @" ( @" M6:M:[7DJ7(63U
MIFEDL,K0]CFGM!!U!"]QDXNJ=&CS.$9IQDJI\!%T?1^AMW/6L_@[+Q@I*\QN
M[<D:)H+#@PF.(\^H=%KQY7 D$#0J_N[ZG=L;$UZ:]6>IKEYSEK'=RU8RG=MR
M:MR7I6]<7R:>#D?@T&AMX[$7=CG=ERW+8W#;G[HO>XF/O^<@PEO8&AHU_P#S
MT7.G6D@8O=NUMR8_W@EG%>>:'S9]>9G<@DLY2(]>'#P#M0@UNQ\I/MW)3[%S
M;M)8GEV,F/L9&/U=R@_Y7LF^KJ/ @+74/JM!MJ;X/;<B&4W;.1&R!@,D==S^
MSG#>+GGP1CUSH.T0<A@^G%G(73N3J+8=E<W-H[S![^:*,>!LA;P.G^[9HP>J
MA-"16AK&,BC:UD48Y8XV -8UH\#6C0 >LH)" ( @.8F^=*E_A:?^TVK<7Y5_
M[B^Z:;_,KW']Y'3K3-P( @!T+7,< Z-XY7L< YKFGM#@=01ZA0$>9_IJ^"XW
M<6P+!P^>@)>VK&_DAD/A$9/!A/M':L/J(0;? =6,OE\3<P60HR4M]0%M2#2/
MEBFL//*#H_@QX[2TG3PM\2D&O\K:TS[^5;YWO:9W/#5D/?1Q-ET'?2\@T=*X
M \C ?$A)TVS-BOM/&X=T--B:Q]WAJ6 XO:\N+N>7F/$GP-[-$()'AKP5XVQ5
MXF11-UY6,:&M&O$Z (07$!K-QWFXS;^4R+G<@JU)YN;LT+(W.'\"V,:WVEV,
M>-I>,ULJZK5F<W^[%OH1 O3UEV)FQML5G-94W!#D\CN*+D8?.:Y<Z.)KRX$\
M&Q^3H?"NNWQ9M9$,AW%M*.S"/)Q]9P/=^[?QI8D+3V7/M+D^73Z->'@)MVKL
MW#;/ALPXD2GSIX?*^9YD<0P:-;X!H-3X-?&OF^#NZUB)JW7TN,^LYV\;N6T[
ME/1XCH%9%:$ 0! $ 0! $ 0! $ 0! $ 0&14=I+I[8$?^J ST)" ( @" ( @
M" ( @" ("/;_ ,^>W_\ ">;_ +2Q" ="?F9V)^9*/X%J!DA( @" ( @" (#S
M[Z7']Q<3^=H?Z/874=W/S$O=\J.-[V?E8^^ONR/':^@GRX( @" ("=_1E_[K
M?/YB?_&<N8W]JM>^=MW7_P#F]TL>BA\YDWYIL?A85Z[P_EE[RZF8>ZOYR7N/
MKB8^Q-XUX-OY#8.]-JW,[L++Y262O=Q\<PGAN=XT.Y',T$A:0UP:'!P\/,#H
MIR\9NXKUJ:C<C'4Z4:\A[P<O_3E8O6Y3M2EH<4ZI^#7U\]:&YEKS] .H^<Q&
M&QTV[-HY#&Q#*U.5QL0T[3G-:V22)I#7 AP&K0'M=X#Q&!26\<>,I2[.<9:.
M=<GVH;&S+=65.$(N[;E%;2XD^-I<_.9+]B;0VKO#I;OO:OG>,P>Y,I"WWERG
M">L_F'+R\VKN0EVAYB[P'F(/#PLN[>LW[-RDI0B_2CJ9D>#8L9%B_;K&-R2]
M&6M?;EKST,V[LW=#_2D9D68JP<:+T.3-[NW"L*C*[0Z0RD<O!PY--=>;AVK'
M')M?3-G:5:4IPUKQ&6>'>^L;>R]FJ=>"FSQG4X:/'6]R=<L=YA+E<O/)"7XN
MI-YM;M4A"X.CA?VC4DAVG;J!X0M*ZY1MXTJ[*5=+54GREC:5N5W+CL[4G2L:
MZ7&FI?;B(JM[YVMAM@[IVEM_866Q-+--C9;GO69)H(+,;AW;R)(_)<"!XB2
MKJ&)=G?A<G=C)QU45&UTG/W<VS:QKEJ%B<5+7M-M)\#T_;40HNE.*" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" Z?&]0-TXC:61V/0MLCVWE9'2W
M:QAC<]SY QKB)'-+AJ(V]A6E<P[4[JNR7I1U?;PEC9WA>M6)68OT9NKT+D\Q
MS"W2N" ( @" ( @" ( >* [3?'53>G4**I5W'>YL?2#>YHP QP&5C>7OGC4E
M\A&OE./#4\NFJKL3=]G&;<%I?#Y.8ML_>M_,25QZ(\"U<_/]E2K.+5B5(0!
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MP(#@0.>R+"MM.+VHRU/[:FN%%O9N.:TJC6M?;6N)^4Z-:IG" ( @" XO<_\
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M71%KP.9@!T/'L*]69SA-.%-K@KRZ")QC)4EJX388C-8C,4*61IRQ/@R,7?U
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M[-X/,[UE!)W* ( @" (#F)OG2I?X6G_M-JW%^5?^XONFF_S*]Q_>1TZTS<"
M( @.=W/N7WHTHTQS9-X#BYPU;$UW8=/LG'P! <QN3;U7<&-9%D;4S-]2S,EC
MBB/,]KCH&,>QN@8UK!KKKS,*D&RZ<YC$Y7=EG%;L@G;O2C)I2FO2:F9M=@:/
M)&C>\:!S>'F!Y@A!-B$! $!IMV8)VY]N9' -LFF<A"8?.0SO.0.(U\G5NNO9
MVK;Q+_87HW*5V76AI9V-\S8G:KL[:I76<KMWIQ9P>ZL9FGW(Y\=B,)%AJD(8
MYLO>L(+Y3Q( <2X_15ED[R5VQ*%*2G<<WYNHJ<3<[L9,+FU6-NTK:7-^]X=)
M(:HCHP@" ( @" ( @" ( @" ( @" (#[B=RR,=ZH0&T0D( @" ( @" ( @"
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M_P# 8MC*_&G[SZS!B_A0YEU$?9_I1-D]R2Y#'6Q1Q%L.L6HNZYWQV>(+86\
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MZK^.0_73Z]B<;Z&/TSF<2Z1^[AU7_)U7\<A^NGU[$XWT,?IG,XETC]W#JO\
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M=9*XW%/ICYC'3)XX=#\X\XZF_P#D8'\7N?RZ5QN*?3'S"F3QPZ'YQYQU-_\
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M<W)P]BM58L%*J+R[O[)N6':E1UUMJK?DT<>OE.8ZLO\ A+U#VMLT'6K7TMW
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M0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D)^D_^[_3_F'Z]?P/Z_\
M(/WE9/BT/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_P"[_3_F
M'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D)^D_
M^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5D^+0
M_'?^0GZ3_P"[_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(
M/WE9/BT/QW_D)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_ )"?I/\ [O\ 3_F'
MZ]?P/Z_\@_>5D^+0_'?^0GZ3_P"[_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O
M]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_
M )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_P"[_3_F'Z]?P/Z_\@_>
M5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D)^D_^[_3_F'Z]?P/
MZ_\ (/WE9/BT/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_P"[
M_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D
M)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5
MD^+0_'?^0GZ3_P"[_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z
M_P#(/WE9/BT/QW_D)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_ )"?I/\ [O\
M3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_P"[_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ
M3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT
M/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_P"[_3_F'Z]?P/Z_
M\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/QW_D)^D_^[_3_F'Z
M]?P/Z_\ (/WE9/BT/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3
M_P"[_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]?P/Z_P#(/WE9/BT/
MQW_D)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_ )"?I/\ [O\ 3_F'Z]?P/Z_\
M@_>5D^+0_'?^0GZ3_P"[_3_F'Z]?P/Z_\@_>5D^+0_'?^0GZ3_[O]/\ F'Z]
M?P/Z_P#(/WE9/BT/QW_D)^D_^[_3_F'Z]?P/Z_\ (/WE9/BT/QW_ )"?I/\
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MD#GNZ4[+=(]TCSAZA<][B]Q/)VESB23ZI0'9J $ 0! $ 0! $ 0! $ 0! $
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M ( @" ( @" ( @" ( @" VL;N9C7>,!"3Z0! $ 0! $ 0! $ 0$>W_GSV_\
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MZ?:_B_\ )/\ Q'P_I#L6,:R.R31ZN:R8_P#XE1]0N_P_W8^8GZ?:_B_\D_\
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M\:;7C,193 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M/E\YD:67I=S3@#B#W3H^Y>'\K6<SN#^8<?H>) =RA 0! $ 0! $ 0! $ 0!
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MA77#\1Q3<J1Y>+7PT)E95S\%2ELP4I:-6K:>BOHU>AOPFK6R:80! $ 0! $
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M%\5WE^:N^_+K9^E-S?D;'^W#[J.A5>6P0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M&T0D( @" ( @" ( @" CV_\ /GM__">;_M+$(!T)^9G8GYDH_@6H&2$@" (
M@" ( @(2])C^Z.-_.,7X"==?W6_,R]Q]<3Y]WZ_)0_W%]V9Y>7TL^*A 9^*C
MI"RRUEZUF?"QO#+9IN;%("]KN0"1['M:21KH1Q *P7G+9I!I2X*^:J9L6%;V
MD[BDX5T[-$]-::6FN#BTI,S]G[5R.]-PT]OX[423G6:<@N9! SB^1W9P:.P:
M\3H/"L&;EPQ;+N2X/&^(V]V;NN9V1&S#][6^)<+?VTNBX3VUMK;F+VIAJN"P
M\7=4ZK>74Z%\CS[*1Y &KG'B3]+@OCN5DSR+CN3>E_:BY#]%8.%:P[,;-M>C
M%>%\KY6;9:IO! 8N2_JZW_P9/XA7N'K+G/,M3.#Z# CI!M/7_P ,_5E>K+>W
MYN?/Y"KW1^3M\QC]:_\ L-F>IN_"?AG+WNOUKG^W/J,>]O5M?[L.LDY4Y=!
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MXIX:2.K&?^IN/F;W<?J#1OE./M0A%#LD(" ( @" ( @" ( @" ( @" ( @"
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M6/A(-RT![$'CR-U[7GZG:I()TQV-I8FG%0Q\38:T0T:QOU23X2?"2AY,I $
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MU<11AQ''P(#.]1 5 T0@( @" ( @" ( @" (#85':P@>U)'_ *H27T 0! $
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MOSE @" ]K;#_ +D;<_-E/\ Q?%=Y?FKOORZV?I3<WY&Q_MP^ZCH57EL$ 0!
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MSL[;$.V<6V%VC\C/I)=F'A?IP:/\EO8/I^%2>6="A 0! $ 0! $ 0! $ 0!
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M%9%::7>U5TN.H. \EED\W^DS0?P(#$P]+V/! =O1@$40.G$H#+'$^L@*H0$
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M],B!=6<,$ 0'M;8?]R-N?FRG^ 8OBN\OS5WWY=;/TIN;\C8_VX?=1T*KRV"
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MJA(0! $ 0! $ 0! 1[?^?/;_ /A/-_VEB$ Z$_,SL3\R4?P+4#)"0! $ 0!
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M.-NENFTEHKJ\1^9;,K<KJ=_:<6_2V:;7@KH, Z:\.SP+.:H0! $ 0! $ 0!
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MCR$ 0! $ 0! <%)\]E?_  M-_:$2L%^5?OK[K-)_F5[CZT=ZJ\W0@" ( @"
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M#>WAD6LRU8=/2BMK1PZ:TZ#D,;=6)D;NR,F*DG"<MC3^[Z+5=>G3I,;I)L3
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M4AHU<M:LD?=I875.[:Z*,@N#GD^2#V(":FM:UH:T - T '  !#R50! $ 0!
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M)&73G+A :^Y6#9._8.#N#_7\:$GU7C[$!FCAP0! $ 'A0@J@" ( @" ( @"
M( @" ( @" RZ3N+V^L4!F(2$ 0! $ 0! $!'M_Y\]O\ ^$\W_:6(0#H3\S.Q
M/S)1_ M0,D) $ 0! $ 0! 0EZ3']T<;^<8OP$ZZ_NM^9E[CZXGS[OU^2A_N+
M[LSR\OI9\5" JUSF.#F$M<.(<#H0?74-5!L[52I;ACGP-2Z^&I4B?F99@V5D
M=@N+7O:8V@,B)+0WGXZ^%:\)RBZ7'&K;V::-'AUOCH;MRW"24K,9M1BMMO32
M7#J6B.JE=).G17K)"R&OLW=MCNS'RQ8G)2G1O*.#897'LT[&./K'P:\5OW<C
MJ[]E>]'RKRGTKNOWFCLK%R'2FB$G]U^1^#G]#+@SZH$ 0$6=&[$-:WOW;UAX
MBS-/=&2N3TW\)!6O.;+7F#>TLD:=6N5SO--JU->J[<57E6M> H]UNCO0?K*Y
M)TY):4^9E-VSQ9'K=TYQ]%XGN8:MF\AE(F<37JVJK*\4DGB#Y#RM7K&6SA7F
M]"DX)<K3J_$8LM;>\,=1T["N.7(FDD^G02HJ0Z$(#XEEB@B?/.]L4,32^21Y
M#6M:T:DDG@ !VE2DVZ+6>9244VW1(\L=9^KPW6]^V-N2$;<B>#;LC4&Y(PZC
M3_ZII&H]L>/@"^E[CW-\O_JW5Z;U+V?VGQ?O1WC69_Z]E_Z2>E^TU_TKQO3Q
M$7NJP8VM:@RM:[5S_P#T\N-!TAC;&_5[G2M>WG/,TL,9:1XUTNV[DDX.+AIV
MN'HX..IQ79QM1DKBG&YZ.SP+C>TFJZJ;-#5]O$]JV33" ( @" ( @" ( @"
M( @" ( @" ( @" VNVMOWMU9REM_&NC9=O/+(GS$MC'*TO)<0''0!I[ M7*R
M8X]IW):H\1O8.%<S+\;-NFU+575Q\I+6PNDG53;6[J%\-;B\?!.QUZVVU$Z*
M6LQP,C#&QSG.YFZ@!S!Q\([5RV\=\8-_'E'UI-:%LNJ? Z_M.XW1W=WIBYD9
MTV(IK:EM*CC72J)MNJU571K.XVQE\1F^OV=M89[)H(L-YO/:B(<R6:*6NUS@
MX=O+PCU_R5395FY:W5!3T-SJEQ)J7]OA.DP<FS?W]=E:HTK5&UPM.&G_ *?
M<]L1U+=.V]_=-!994SMS(6[=(2NY6R\SFZ ::D\KX1WF@UY7>%;^\%+'O6,J
ME81C%/D^R>CE15;JV,NQEX-=FY*<I1KHKJ\.AQ]+1J?"9O1'IYGME;INVMS&
MO3N6:4E>GCQ-'-/+&)HGOF C<[1C2UK>/A=X%AW]O*UE6(JU624DVZ-):'HT
M\)L=U=RW\'*E._2,G%QC&J;:K%N6AO0J)>'@X=9TR!.T>K.@UUCM@>K]PLK9
MWI^8Q.>/7$T=T+_TMX<T_NS-+Z,_]^,E^:9?Z376YWI_*Q]]?=D5_<;\_/\
MVY?>@=/TYQLD6TMX9S9U:O;ZC,R%B&(SACI88^\;HU@>0!JTR.:>QSAH=>71
M5N\[J=^S;OMJQLIZ.'1_9S+G+S<UAK%R+N*HRRMN2TZTJ\%>-5:X'+0Z[-#:
MN&]CT?W<-]VA8SSHY)15YHG35Z[F,+1(V$<K=='. \7TAJ_^M]0L_+JD*K3I
MHWIU5Z#?IF_2,CYN5;E&Z:*QC1:]G0N%\QSVWL)?WIZ/S,%MUK+67J77F2J7
MM8[5M@R\NKR #R/#AJ5OY-^.+O;M+NB+CK\%.M%3AXT\[<'8V?2G&6JJ]JO#
MR.I]=+\5/E^FV]^FX<RONF"W/WE65PX/Y(XP"1J-.\@<QQ&NGT0HWM>5O,L9
M6NVTM/2^J51W?QW>W=E86J\I/0^9+7[T6G35T&UZ1[*R^R\1NNMN$PULSDJ8
MDAQ3)8YK#:\#9F=ZX1N< U[G\K>/@*UM\YUO*N6G;JXQEZU&E5TT:>*AO=VM
MUW<&W?C>I&Y.-=BJ<ME;2VG1O0VZ+F9S.SP?W==V]O\ WKS] "HK'-_Y>S[O
M^,HMUK_]!D^_Y+8]'O/PPP[BVM%;AI9W)QMEPTT[0YCIV,>P@@GRN4EKN3PC
MF\2=Y,=MV[S3E"+]*G%H_;IYC+W,S%%7L=24;DU6%>.CZ::'3ATF\L97TD:D
ML[78VJ65VN>ZPR.IW98P$DM<9 3J!V::^HM*-G<\DO2>G@]+S%E/)[Q0;_TX
MZ.%;'^+]O(<QT[DZT8VDW<6UZ+<I@LY8EL35970]R^;O#'(\LYV.C)+2-6Z#
MAQ[ K+>2W;.7979;$[:2KIK2E5P.I2[D>^;4.WL1[2W=;;3V:.5:-TJFGHX*
M+Q&+Z0.*V]C-R8Y^*@AI9>U5[[,T:P:(HY"1R.\D <SO*YO& ':<=3E[N7KU
MRS+;;E%.D6]?]B_88.^./CVLF#MI1G*-9Q6I/@?.]->9.FG3$2ZHX0( @/:V
MP_[D;<_-E/\  ,7Q7>7YJ[[\NMGZ4W-^1L?[</NHZ%5Y;! $ 0! $ 0! $ 0
M! $ 0! $ 0! $ 0! $ 0! <1U/PWG^"&2B;K9QCN].G:87<)!]#@[Z"$HAI0
M>C3[N_NGG/YG+_ %O8'YFW[R*_>/Y6[[DNHQ=A?W,PW_  7?A'++O3\U<Y_(
M8]T_E+?,=$JPM"7.E6&\VQ<V:E;]VONY82?!!$2!I_G.U/TE)Y9("$! $ 0!
M $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 9EC_M8_\ 1_@0DPT(" ( @" ( @"
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MKQ\2_*2R+KM2_<=*JO+S<ZYR3\)GNGG2B#)YG';B?N[>-V UJSFQO9&UFH<
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M" ( @" ( @" ( @" ( @" ( @" ( @" X&3Y[*_^%IO[0B5@ORK]]?=9I/\
M,KW']Y'?*O-T( @" ( @" ( @" ( @" $:]J IQ'JA"0@" #M]1""J ( @"
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M >UMA_W(VY^;*?X!B^*[R_-7??EUL_2FYOR-C_;A]U'0JO+8( @" ( @" (
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M;)IA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M*;X.#EH6,ZW>N3MQKM0UEKE[KO8UFW>G39NJL:/FU])SZWRJ" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#VML
M/^Y&W/S93_ ,7Q7>7YJ[[\NMGZ4W-^1L?[</NHZ%5Y;! $ 0! $ 0! $ 0!
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MS#W,[T'O8ZC>KXZ>3*EPM7)S5A :Z(D&0:Z:]@"X?.O1M;TC*47);&I*KX>
M^H;KQIY&XYPC*,&[FN3V5^[PECJ'%DMJ])<9M7,RR9^U<M-LQ9MFLU&JUO,6
MPQ6'<7/(#N74>Q+O  %[W:X9&?*]!=FHJFSJE+E<>+RT,6^HW,/=4,>ZW>E.
M55/7"'\,9:VZ5IR.7 J&9U0VO=WENK8FW:#A%-;Q3>>=X);%%&.=[R!VZ-'
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M9"TDC[+31 2A5EEGJP3SP.JSRQLDEJO(<^%[F@NC<6Z@EI/*2."@%U $ 0!
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MN$E':HZ<9=7L\! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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ML" D-0 @" X&3Y[*_P#A:;^T(E8+\J_?7W6:3_,KW']Y'?*O-T( @" ("/\
M"[&R%?J5U W-EXJMC;6ZZM"K5K%W>2/;7B,<[9HRT -=KIVG4*08N\.BFTLW
MM&QM[:5.IL_)-MU\MC<CC*S(A'D:/^P?*QG+SMTU81VZ'@@,9F-ZS;HIV]G=
M0*&WHMMY&G8H97/XFY8\]D[V%S&2PU7Q\K7<_*YP<_335 <SL/HYE=N9O!^_
M>Q]I6/>>>*27=U2S99>F-9NL=AE1T9#9R\-+M9.7M(\2 LX7HOO3'8W:%2Q)
M1,V#WO=W1D"V=Q!Q]I\CFB,\GE2>4-6\/70';=6MI;PW'F]D;BV5%1GO[3R-
MK(OKY.=]:*3OX.Y8WF8QY\))0&GWGMCJ[U(VK7Q6Y*.#QN3H9_$Y2H,?=FEB
M?4I2]Y/SNEC!#^SD:!Q\:$FTWCTYN;IZC7]P7IH8-FW]I7-N79C)I:CEL2%Y
MD$9&G*UOE:\W@0@AK/Y#<UC ]-.G]W<>V]RPU\YB680;?F?9OY*K1<'"Q,P#
MD@CBC'EZ%W,?"/#))T.[>AN_LQ+OVK!3V_D;.Y+[LECMW9&:5V6CK=XU\>/C
M:8W"!K WDYV.Y>4GR3JH!O<JS*=.=[;HS> W9MBA7S]"E;W3CL_8=%9QL]:L
M86W(8X]73,>UGDQGEYCX4(./V=THRF\ND.PL[4J4,A?Q4N4LQX+<#98J62QV
M2G<X<[H_*B?JULL3N4CQC1 =/D>C.<R&R)\/A]K;?VEEK&=Q&2D@QER::.6E
MBY1(3-+)$W[HTN>&-:--/"@.JZT;*W%OX1XS&;9P>8HF!XI9G)W9Z&2Q=Z0E
MO?0F"-SBQHT> U[27#CP0$@[<QU[#[=Q.(R=]^5R5"G!6N9.0:/LS1,#72D?
MY1'AXJ ;) $ 0! $ 0! $ 0! $ 0! ?37<K@[Q$% ;5"0@" ( @" ("/;_SY
M[?\ \)YO^TL0@'0GYF=B?F2C^!:@9(2 ( @" ( @" A+TF/[HXW\XQ?@)UU_
M=;\S+W'UQ/GW?K\E#_<7W9GEY?2SXJ$ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M>UMA_P!R-N?FRG^ 8OBN\OS5WWY=;/TIN;\C8_VX?=1T*KRV" ( @" ( @"
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M$??AE-V.;/S.T\V?*V8MY=>7V30==-5E[26QL<%:^$Q]G':VN&E/ ;%8C($
M0! $ 0! $ 0! $ 0 @.!:X!S2-"TC4$'M!![4!JL9M?:V$LR7L+@L=C+TVHF
MM4ZD,$K@>T%[&@\5(-JH!JLEM;:V9M1W\S@<=DK\.@AM7*D,\S WL >]I/#P
M*0;4     -  : -  .   [ % " ( @" ( @" ( @" ( @" ( @" (#:0NYHF
M'U/X$)/M $ 0! $ 0$>W_GSV_P#X3S?]I8A .A/S,[$_,E'\"U R0D 0! $
M0! $!"7I,?W1QOYQB_ 3KK^ZWYF7N/KB?/N_7Y*'^XONS/+R^EGQ4( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MR/:&..K1V#3Q(#X0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! 95
M)WE.;XQK]) 9J$A $ 0! $!'M_Y\]O\ ^$\W_:6(0#H3\S.Q/S)1_ M0,D)
M$ 0! $ 0! 8-W_:-_P W_P!4(,9 $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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MVN<6 DG3QKC,B*C=DEJJSZ'BR<K,&]+<5U&<M<V0@" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M" @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M/\"'NQZC8K6-L( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" NOG<^,1D#E;IH1V\$!:0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M'Q-!=_ @#@YA#9&N8X]@>"T_5T1:0]&O040! $!5K7/<UC!S/>0UK1VESCH
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MGA<W0^#0Z'356=S=E^W95YKT?'I*FUO;&N9#L1EZ:\FM> [=59;! $ 0! $
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M37AKJK/Z9?[#MJ>CKY:<94_5<?YCY>OI\VBO%4[=59;! $ 0! $ 0! $ 0!
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M,JMX[SM8,5*XG23IH_M1N,#N?'9_;-7=E<25\7:KFV!.T"1D3=2>8,+AJ /
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MYFMT]CKV$]HXK6GF6Y[5N+J]EOQ5-RW@7K;C=DJ)3BN7UJ=!LNIT4MC=E:O
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M( (250! $ 0! $ 0$>W_ )\]O_X3S?\ :6(0#H3\S.Q/S)1_ M0,D) $ 0!
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M;2U^4U,;?L_F%8R+?9REJT\>KIU:.$FQ<R=:1QU>ZEW>FF/Q=VECXL@Z_/)
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M*;\*-PM8V@@" ( @" ( @" ( @" ( @" NO@<R-LA((=IH/7XH"T@" ( @"
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M:'MU'@.AXK3G!PDXO6G0WX34XJ2U-5,A>#V$ 0! $ 0! $ 0! $ 0! $ 0!
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M)6CC++5)P=J\1O:\-/*'.=H.UG#0'1:T]VV<?+C&:VK=S57@?VZS:M;VR,O
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MC.GTD),I $ 0! $ 0! $!'M_Y\]O_P"$\W_:6(0#H3\S.Q/S)1_ M0,D) $
M0! $ 0! 1[U9_J>K_.8_XKU=[G_&?N^8YS?_ . O>74R)%U9PY=K6)*EF&U"
M&F:%X?&)&A[.8=G,T\"/77F<5*+3U,]PFX24EK1EB2S@\Y'8GY/.J-ED\O=.
M:^/7F$C@TMX::'P>LL5%>M46J2H9JRL7E)TK&5735QL]%Q2,FC9-&>:.1H>Q
MP["UPU!7 M-.C/J*::JCZ4$D/[7Q6&R_4/JMM?<=2"Y%>GQESWOML:]LU5]-
MK!*UKNT->W3F;[%VG85>W[DX8]BY!M44E5<==10X\(3R+]N:K5Q='PK9U]/0
M93>D.9VV2>F>],AMZF-2S"WFMS&-:-=>2-E@\\8]4/)7CZC"[^/;4W[2]&7B
MUGKZ9.U^7NR@O9?IQYE72ND^Q/Z0F-'+)3VOG8VZ 20RW*,[O5<) ]@/K%13
M EJ=R/0T2GO&+=5;DN3:3\J.DVAE^H>0MSP[RVU4PM1D0=!9JY 7#)+S %I8
M(V\HTXZZK4R+=B*79S<GRQH;N/<R)-]K!17)*OD-#2V+F]U[PDW;U';$ZAB+
M#V[2VU$_OJL(8=!=L'0"2=XXL!&D8_RNS9EE0LVNSLZY+TY</NKB76:L<2=Z
M]VE_5%^A'@]Y\;XN+GU8743=1S6;R'2Z+8C]YP^8PW\C$;L%)C8YI'-86F4M
M/,"W@YC@X'L63"Q]B"ON[V>FBT-F+.R-N;QU:[70F_24>OR'%[QW8S*=(NH.
MRW;6=M*SM&IC87XOOX;,;8KLC98N5T/D^Q;J>WM\>JL,;'V,JU=V^T5QRTT:
MU+3K*S*RU<Q+UG8[-VE'15/UM*U'5]<*M6/IA3DC@B9([(8;5S&-:>-J+Q!:
M6ZY-Y+T\$NHL]ZI?++WH?>1,:H2]-?G,@S$X>]D7G05H7O:?\H#R1]$Z+/CV
M^TN1CQLULF\K5J4W^ZCS]B6W19\ZJ=TZS3C?;?YP6<A#!Y7DOX//E<&]J[J\
MX[-)5I+1H^V@^:8ZGM;4:5BG+3JY>?F,374EWC)/B[>*RF H@" ( @" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @*.]B?6*E$/4
M3M@/ZCQO\VA_B!<#E?C3]Y]9]0P_P(>['J-BM8VP@" (#A=U]']@;RNNR67Q
MG)DY/]K<J2/KR2:#0%_(>5QX=KAJK7&WID8\=F,M'$])39>YL3*EM7(>EQK1
MTTUEC&]$>F>,H6L?%@V3LNQF&>>R^2:?D)!\B1SM6'4:ZLY2O5S>^5.2DYZN
M+5^WPGBUN/"MP<5;5):ZU;Z>#P&WVCTZVML62R_;,$U1EL-%F%UB::)Y9[%W
M)(YP#AV<P\"U\K/NY-.T:=.1&UA[NL8E5:3BGRM];+^[]B;9WU7JU=S576H*
M<CI:[6RR0\KWMY2=8W-UX>-><7,NXS;MNC9[S,"SEQ4;JVDG76UU&->Z:[/R
M6U:6R[=)[]O8][9*M832M<US.;0\X<''V;NTKW#/O0NNZGZ4M>A'BYNW'N6%
M8E'T(ZE5]>LV&#VA@=N;?.V,17=#AG"9I@=(^0Z6->?RW$NX\Q\*PWLJY=N=
MI)^EYC/CXEJQ:[*"I'3HT\)K=H=,MF[$M6+NV:+ZMBS$()G.GEFUC:[F TD<
MX#BL^5O"_DI*XZI<B-?#W7CXC;M1V7+7I;ZV:[<_1?I[NW)NS&3QKH\C*>:S
M-4E?7[YWCD:PZ$^-VFI\:S8^]LFQ#8C+1RZ:&OE[DQ,F>W.'I<E54K=Z+]-[
MS,?')AA%'BV=W29!-+"&@O[PEW*\%[B[B7.U*B&]LF.UZ7K:]"/4]S8D]E.'
MJ>K1M=3T^$R]U=*MD;TRC,SN*@^UD(XF0-D;/-$.[C<YS1RL<!VN*\8V\K^/
M#8MNBUZD>\O=&+E34[L=J25-;74^4ZJ_CZ>3Q]C%WXA/0MQ/KV(7=CXI&EKF
MGUP5H0G*$E*.AIU+*Y;C.+C)535&<OM+I;LG8]^7)[<QYK7IHO-WS232S'NB
MX.('>.=IJ0-=%O96\;^1%1N2JM>I(KL/=.-B2<K4:-JFMOK9E[PV!M;?;*<>
MYZCK;*)D=6#99(>4RAH=_LW-UUY1VK'BYMW&;=MTKR&7-W?8RTE=CM*.K2UU
M&8-I;>.VX]H3466-O10MK-I3ZRM[IGL1JXEVHTU#M=0>*Q_,W.U[5.DJUJ9O
ME+78JRXU@E2CTZ$<K@NAW3?;V3;EJ>+=-:B/-7;;F?8BB=XVL>2-1X"[5;][
M?&3=ALN6CDT%9C[BP[$]N$-*XVW3I-QM'IKM#8MFU<VU3?5GN,;%8<^>68.:
MQQ<.$CG:<2M;*WA>R4E<=:<B-K#W9CXC;M1V=K7I;ZV:;.]#>G&X<M)FKN,?
M%;L/,MIM6>2"*:1QU<Y[&'34^$MTU]=;-G?&3:AL*6A:JJM#4R-PX=^;G*&E
MZZ-JO09[^D>P'9C'9V/%"#(8D5VT#!++%'&*AUC\AK@TZ'M)''PK"MYY&Q*&
MU52K75PZS8ENG%=R-S8]*%-FC:I35HK0^=X=(]C;XOMRF;HO&2#0R2W5E=!)
M(QO!HDY>#M!P!(U]53B[SR,>.S!Z.)Z2,S=&+ERVKD?2X]1B3]#NF4\-"$X;
MNV8YI;7,4TT;B2[G+I'->"]VOA=K])9%OC*3;VO6Y$8Y;CPVHK8]35I:\NGP
MFQW9TLV3O?(Q97<E!]J]#"VM'(V>:+2)KG/ TC<T=KBL.-O*_CQV;;HJUU(R
MYFZ<7+FIW8[32IK:T>!GUNSI=LO>T]6SN.B^U-3A\VKN;/+%RQ$ZZ:1N;KQ\
M)48V\;^.FK;I5UU(]9FZ\?+:=V.ULZM+74S"SO1KI[N2\W)9?&OFMMAAK![;
M,\8[JNP,8-&/ X =JRV=[9-F.S&5%6NI<)AR=RXF3+:N1JZ4UR6KF9K#Z/?2
MD@@X>70\/^[L_P HL_US+]KQ+S&K^F\#V/ZI><Z_/[&VKNC$U\)G<;'<HU&!
ME3G+A+"&M# 62-(>TZ :\>/A5=8S+UF;G"5&]?+X"WR<&SD0V+D5)+Q<SUG&
M5?1VZ75IQ._'V+(:>80SVI71\/&&EI(^BK*6_<MJFTEX$5$.[>!%UV*^%^<[
MG<NT=N[OQ@Q&X:#+M)I#H@[5KXG@:!T;VD.:X#P@JKQ\J[8GM0=&7.3B6LF&
MQ=CM+[:CEL/T/Z<86O>KU\6Z8Y"!]6Q/9FDEE$$GLFQN)')K[9NCO56]=WQD
MW&FY>JZZ%PE=8W'AV5)1AZRH]+U>3P'2;1V3MW8U*?'[:K.JU+,OG$L;Y9)M
M9.4,UUD<XC@T+3RLN[DR4KCJUH-[#P;.)!PM+93==;>GPFYNTX,A3L4+3>>K
M:B?!.P$M)CE:6N&HXC4%:T).,E):T;DXJ47%ZF<UL_IKL_8D]FSMFD^K-<8R
M*PYTTLW,R,DM&DCG:<3X%NY6\+V2DKCK3D1786[,?$;=J.SM:]+?6SZWATYV
MEOM]23<]-UM]$2-K%LTL/*)>4N_V;FZZ\H[5&+GWL:O9NE>1$YN[<?,IVT=K
M9U:6M?,^0S[FTL%>VN-FV:Y=M\5XJ8K"1[7=Q!R\C><'FX<HXZK%'*N1N]JG
MZ5:^%F>6):E9[%KT*4IR(L;1V-MK8M6S2VU5=5KVY!-.UTLDW,\-Y0=9'.(X
M!>\K,NY+3N.K1CP\"SB1<;2V4W76WUG+YOH-TSSEU]^7%OISRN+Y11F?7C<X
MG4GNP2T:_P"2 MVSOK*MQV5*JY54K[^X,*]+:E"C?$VO%J-YMGIGLW:%#(8_
M!T70PY2/N<@]\TLDDL?*YH!<YQTT#G:<NG:M;(WA?OR4INNSJT&YB;LQ\6,H
MVXT4M>EZ2NT.F>SMB6;-O;-)]6>W&V&=SYI9M6,=S :2.=IQ496\+V2DKCK3
MD0P]V8^(V[4=G:UZ6^MGQO/I?LS?LD-G<%$OO0-[N.[7D=!/W>I/(7-]DW4Z
M@.!T\"G$WC?QDU!Z'P<!&;NO&RVG=C5KAU,U+^A/3"3&5L2[#?\ 3UGOD$C9
MI6SO?* '&21K@YW!HT!.@\ 6PM\Y2FY;6E\BIT&J]PX3MJ&QH3KK=>FM2'O2
MBKP4+^U:5?R(*V/FAA:3J0R-[&MXGB> 71]W9.4;C>MM')][HI.REJ2?D))Q
MG0[IMN#%X;.7<8]EJS1JRVF5IY((9I'0M<YSF,( +B>/+IJJ6YOC*M3E!2T)
MNE56FDZ2.X<*]&,Y0TM*M&U71R$@WY\1L+:EFW3H&/#82LZ5M"BQO,(HAJX,
M:2T$^$DGU2JB$9Y-Y)OTIO6R[N2MXMER4?1@JT7$CRW''D_2#ZFLN-H^8X2%
ML4=U\8U[FA"XNTDE  =-)S%K?%ZS=5W3<-UXM*UD]7++FXE]M9\U49[ZSE/9
MV81U^ZN-^T_MJ/7T,,5>&.O P1P1-;'%&T:-:QHT  \0 7SMMMU9]4225$?:
M@D( @" ( @" ( @" ( @" ( @" ( @" (#5[CV[B=UX:S@<Y";&,M\G?1->Z
M,GNWB1NCF$$:.:"MBQ?G9FIP=&C6R<:WD6W;N*L7_:1\WT=>EK7\YH67#7V!
MMS<OU' _55O]=R_:70BB_36![#_O2\YVVV]D;3V@Q[=MXFOCWR#EEFC;S3/
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MH274 0! $ 0! $ 0$>W_ )\]O_X3S?\ :6(0#H3\S.Q/S)1_ M0,D) $ 0!
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M@N>>QK07$_0'%!R%.():00X=H(T(]<% $ 0%'>Q/K%2B'J)VP']1XW^;0_Q
MN!ROQI^\^L^H8?X$/=CU&Q6L;80! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!@W\)ALJYC\ICJMY\8+8W68(Y
MBUKN) +VG0%987IP]637,S%.U"?K13YT9D<<<,;(86-CBC:&1QL :UK6C0
M<  %C;;=69$J:$?%JM7NUIJ=N-LU6Q&Z&>)_%KXY 6N:1XB#HIC)Q::UHB45
M)-/4S&Q&%Q& I,QN$HPX^A'[&O68V-FO9J0!Q)\)/%>[MV=V6U-N3Y3Q:LPM
M1V8)17$C.6(RA $ 0! 7'0O8P/<!RG33CXT!;0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0&OKX#!5;?OA5Q=2"_JYWG45>)DVLFO,>=K0[5
MVO'CQ6:5ZY);+DVN*IA5FVI;2BJ\=#8+"9@@" ( @" ( @" ( @" ( @" (
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M $ 0! $ 0! $ 0! $ 0! $!F6/\ M8_]'^!"3#0@( @" ( @" ( @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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M/T[G=L=K%/(XM;&?*];B.'%5]C>%NY1:F^ WKV#.W5ZTC:JR*\( @" ( @"
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M-_FT/\0+@<K\:?O/K/J&'^!#W8]1L5K&V$ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0&!?Q-:[&=&B.P&\L<P'%O'7L!"TLC#A=7%
M+@9N6,J=M\:XC7X'*Q=^_!6)8VWZ[>=D#I!YPZ/F(YC&3S:#Q]BU-WWWIM2U
MQZ>@V\W&>RKT4]F7#3T:\^HWZN"H" ( @" ( @" ( @" ( @" ( @" ( @"
MLV[,=.M-:F<UD<+'/<Y[@QH#1KQ<[0#URO%R:A%R>I'NW!SDHKA.4Z>[MRV[
MJ-N[DL<VE#'*&5)8RXQRL(.NA=VEI&A(X*GW3GW,N$I3CLI/1R_V%QO; M8D
MXQA+:;6GD_M.Q5V4@0! $ 0! $ 0! $ 0! $ 0! $ 0! $!FTFZ,<[QG3Z2$
MF4@" ( @" ( @" ("/;_ ,^>W_\ ">;_ +2Q" ="?F9V)^9*/X%J!DA( @"
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M%) 4 ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
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MQ'BHO'6I])Q]P8UN%+BVY<+J_%0E#IMO:;=^.L,R#&,RM!S66#'P9(R0$L>
M=="=""/&NPW+O-YEM[7K1U^'A.2WQNU8EQ;'JRU<G(=LN@*$( @" ( @" (
M@" ( @" ( @,RQ_VL?\ H_P(28:$! $ 0! $ 0! $ 0! $ 0! $ 0! 1)NW<
M^X\7NF2M<=R8;F9W=4M'<RU3R\SN;37FUUX@^25CN6XSBXR54S)";@U*.M'<
M''Y*H'V</.)*\H;W,0(<.1W$$<Q+3ZZII8M^RV[3T<7]N@M8Y-FZDKJT\?\
M81;N>23![REGPCA7NQ]R\M@',T696#O(PT=H<=-6^JKJ%=E;6NFDJI4JZ:B7
M<%GH,K&*L[XHLY!&QV0H,>'NA>X<0?6/;XNPKV>#<(0$!HMQ;SVSM2+O,[D8
MJTA&K*^O/._AKY,;=7'7QZ:(",[?73(Y:=U38FVK&1DUT;8LAW+][BUT_P!*
M0(#"?+UUSHUL9&M@X'<0R/NF/;]H)7_3<A)9=L#?5SCD]]V7N\4;K#@/H%[
MH!\#I;G(_*AWI>;(>TGOM->WP3>-"2Z-I]4\?H[%[W?/R^QBL/FT.GC[P2-4
MD%]F\>MFW-797%5\[4;[*2!K7.#1X=:Y!^G&@-_@>O.U<A**F>@GP-T'1WG
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M/*Z9SQ7YNWB">>3UWGZ"@4.\ACBK0BM5C9!6;P;#"T1QC3_): $)/I $ 0!
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M ( @" ( @" ( @" ( @" ( @" ("[ WFF8/5U^EQ0&R0D( @" ( @" ( @"
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M_P =ZS;H_!?/YC7W[^87NKK9Q*N#GP@" ( @" ( @" ( @" ( @" ( @" (
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M2XN[-P]7:=.:IGK9-8( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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MK1P  "'D^D 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&33;K(7>(?PH#.0D(
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MZC3BLV%C.Q;V6ZZ:F'>.7')NJ<4UHII- MTK0@" ( @" ( @" ( @" ( @"
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MJ?(;E;YHA $ 0! $ 0! $ 0! $ 0! 5T/B* H@" ( @" ( @" ( @" ( @"
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M%C@?)8?"/I>H)J=[##%7B9! QL<,;0V.-@ :UHX  !"#[0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $!G4FZ,<[QG^!"3)0! $ 0! $ 0! $ 0$>W_GSV_\
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M0&8@" ( @" ( @" H][(V/EE>(XHVE\DCCHUK1VDGQ! :2O&_<,\>1M,+<'
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M$%$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0%0-2 .TH#:@:  =@X(250! $
M0! $ 0! $ 0$>W_GSV__ (3S?]I8A .A/S,[$_,E'\"U R0D 0! $ 0! $!K
M<G7@L.:RQ$R5@&H;(T.&O'CH5ZC)QU.AXE",M#53 ]Z\;_X<'WIGUED[:?M/
MI,?86_970A[UXW_PX/O3/K)VT_:?2.PM^RNA#WKQO_AP?>F?63MI^T^D=A;]
ME="'O7C?_#@^],^LG;3]I](["W[*Z$/>O&_^'!]Z9]9.VG[3Z1V%OV5T(>]>
M-_\ #@^],^LG;3]I](["W[*Z$/>O&_\ AP?>F?63MI^T^D=A;]E="'O7C?\
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M-_\ #@^],^LG;3]I](["W[*Z$/>O&_\ AP?>F?63MI^T^D=A;]E="'O7C?\
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M/Q'S%3O/\)<Y&"Z(YP( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M]C7@CZ(X_P "@&V0! $ 0! $!P6/\CT@*_+_ /$QWE?1JD_^BDADY(0$ 0!
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MVKDJI:(\/%5\GVY\'>+*DK:M*+HWIEP<R)P7T(X ( @" ( @" ( @" ( @"
M( @" ^B]Y'*7$M'8#V(#Y0! $ 0! $ 0! $ 0! $ 0! $ 0! 8^0@-K'VZHX
MF>&2(#_/86_^J @SHK)_^2]VH?95;S@X>+GC;[DJ&2B1D)" ( @" J#H=?$@
M.4R-<UKDL>GD.//&?&UW%2#&0! 40'28: PT@]PT?.[GT_R>QJ@&P0! $ 0!
M $!P6W@;G7RW(SBVE0<UY'@(AC9Q^BY203DA 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $!4#4@>,Z(#; :#0=@0D( @" ( @" ( @" ( @(]O\ SY[?_P )YO\
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MN2[-M:ZFNHND9>K.B_VG>- T\()T(^DM#';5V+CKJ;M])VY5U4.[7:G)! $
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MKZZ X7HX#F-];TW0.,+G^;1'_B2EW#_1B:I()M0@( @" ( @" ( @" ( @"
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MEQ'!=CN3=DL.VW/UI>*AR.^MY1R[B4/5CXZ\)W*Z(Y\( @" ( @" ( @" (
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MD;0UH^@ A!>0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&=3;I&7>,_P(29* (
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M4,=>SP$!1WL3ZRDADRX3^IL?_-XOX@7'9'XDN=G98_X<>9&>L!G" ( @" (
M@" ( @" ( @" ( @" ( @,6'*XNS<N8ZM>KS9#'!IR-1DK3-6#QS-,S==6 C
MB.;P("SB,_@=PPSV-OY2IEJ]:9U:Q-1F98CCG8 3&YT9(#@#KH@-@@" ( @"
M ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @"
M ( @" ( @" ( @" $AH+G'1HXDGL " YG?FS:6^-OS8BSRQVF_=:%HC4PSM&
M@/JM/L7CPA 1=T_W->KVG]/]UM-?<>-/<4W2'4SQL'"+F^R<!QC=]FSU0AZ.
MHN3S9JS+A\?(8Z,)Y<M?9V_S>(^V/V9\ 4 V\,,-:&.M6C$5>%H9%$W@UK1X
M$!]H @" ( @" ( @" P\EC8,G$QLKG0V8#SU+<7"6&3QM/B\;?"@,6KF'5Y'
MT-P/CIWH6.E\[)Y*UB%@U=*PGL('%S4!PE2M:ZS[M9#&)(=@X1^LKSJTSN/_
M .G*!I_D1^J5)!Z#AABKPQUX&-C@B:(XHV#1K6-&@  [  A!]H @" ( @" (
M @" ( @" ( @" ( @" ("K1S.#?&=$!MAP&B$A $ 0! $ 0! $ 0! $ 0$>W
M_GSV_P#X3S?]I8A .A/S,[$_,E'\"U R0D 0! $ 0! $!PG4[^JZW_'9_%>K
M7=GXCYBIWG^$N<C!=$<X96-CL2WH&U*S;D[29&U7CF9(& N(<-1J-!QXK'<:
M475T7&9+2;DJ*KXC,VS V]N3'1EH+'V!*Y@'D\K-9- /$-%BR9;-J7,9<6.W
M>CSU\I.BY$[ X3K1D3BNE.[K0.CG8V:L#ZML>;C\(K+=D-O*MK^*O1I*O>LU
M'$N-^RUTZ/*1GF]N9GH[#MC(=/<A#C)-SV*.!RV&R+'28D7IZY O#1S3%(TQ
M^4&_[3APX<;BU>AFN:O+:V%*2:]:E?5Y5I\!2W[$\#LW8:CVCC"47ZM:>MKT
M/1IX_ ?&8W?M[*V,UTNZWYC'ULWB9*UG![GQHDK.;-*SO&2-(YQ!/"=-=7 .
M:>S375;QKD%&_BQ;C*JE%Z?[4R;N5;G*6-ERBI1HXRCH\/#LR7CJ:#/]2+UZ
M+;&VLY(-R9[;&>QV?BS>WFC(09/#4G2MEL\M<N[J5C21+&[3RNS@5M6<)1VY
MQ]"-R$H[,_1V9.FC3K7$S1R,UW.SMR>W*W<A/:AZ2E!5TZ-37"N,E23K3!N,
MBCTHPUG>&2>UIDN<KJ.*J%[>8><V9VM\L Z]VQI<>(X%4JW8[6G(DK:XM<GS
M)=9?_55>T8T7=?'ZL5JUM\^HXK>&$ZF8G<FT-Q7-UPR]1LU?.&H8ZE3;[T4\
M=.QTELADA[V41\C'E[W!QX#P*PQKN-.W<@H/LXK:;;])R6KD5=16Y-K*A<MS
M=Q.[*6S1+T5%KTM>ETI6O@.LZ-RS;9RFYNG>YG$[U%^?<$]\^3'EJV0< +D+
M> ;H6B.2-O!I'KZ:6\Z78PO0]2BC3V6OW7Y&;NZEV$KEB?XFTYM^WM?O)<'$
MTM%?"2;G<[B=LX>YGLY:93Q-",S6K$AX-:.   XESB0UK1Q<2 .)5/:M2NS4
M(*K9=WKT+,'.;I%$'=-LCG<IUNN[CR&/&"H;JV\_(5,0W5D[ZU6W%!7L76^Q
M,[VEQ&FI:P\JZ/-A"&$H)[3A.E>5IMJ/(<Q@SN3SW<DMA7+=5'AHI))RX*]-
M%H/02Y<ZT^7L;(QT;QJQX+7#Q@\"I3H0U4@.O')4RK8(J[+4T-AT,=65O,R1
MP<6-:1J-=?778R:E"K=*K6<9%.-RB56G2G&8TT4D$TL$S#'-&]S)(SVM<TZ%
MOT"LB::JC')--IZSX4D! $ 0! $ 0! $ 0! $ 0! $!0]A0@D/<.1O8[9N D
MHVI*KWMB:]\3N4EO=$Z$_05)CVXSR)J2KKZR]R+DH8\'%TU=0M3VLITYFO9Y
MO-<A?K2GD:&2.T>UK'>#B[4CU0IC%0RU&WJ>LB<I3Q'*YK6KR&!\GEILS.^R
M$46/,39'W'MY0'/.@8&EPU/AUU6;ZA&FB+KQ&'Z=*NF2I36:S'[6=9HNRV2O
M18S$\[HXK$PYG2D.+=6MU' Z<.*SW,JDMB,7*74:]O%VH[<I*,>/C+.<VY/A
MH(+\5B.]BK7""Y".',1J X:GMTX:%>[&2KC<6MF2X#S?QG:2DGM1?";*/8[X
M*45K-Y2#%2V/]A7F&KM3X'$N;H?'IV+ \ZLFH1<J&=8-(ISDH5-MNJE-C=@X
MRC8+72P30L<Z,ZL.@?H6GQ'M6KBS4\F4EPI^0V<N#ABQB^!HU&\:.;AFQD&1
MOG*33,+:C&1\A!):--![)SM1Q6UASMM2<8[--9K9MNXG%2EM5U:#[^ S:D<?
MOWF:V.LS#6.N[1Q^B2YOTQP4?/;3]"#DD3\CLKTYJ+? ;?8N$Q[)LA,^U6NR
MQ\T+&<@<8Q&]S>]'-KHU_@6MG7I-15&OMJ\!M8%B*<G52>K]OA-3A<+9J[AB
MJX'.0OL.KR2NMQ,$C  X QN:20=>U;%Z\I6JW(.E=7E-:Q8<;M+<U6FOR&*W
M;%K(ULSDVWA/=QT\[;4)8>>1T9YB_77AS#B."R?,J#A&E%)*AB^5E-3EM5<6
MZ\IB;=VY+N'SI[;#:M:HQKY9WM+QY6ITX$> $K+D9"LTT5;,>-C.]731(N8O
M;+KU!^8O78L;A0XLBM3#5TO$@%K=1PX>->;N3LRV(IREQ<1-K&VX[<I*,>-\
M)\YK;4V)JP9*O:CR&(LGEBMP\-''L#AJ>W3Q^HILY*N-Q:V9+@(OXSMQ4D]J
M+X31Z./DL&KW:!H\;CP ^FMLU"7J=J'"7<)M!VACEIR=_KH=9- 0/](B1<S.
M+NQG>Y?MY#IX35J4+/\ #]O*1I+0=B]QC'.__!KL;&'QL[QI8?M2%?*>W:VN
M./D*!V^SO;/%)=9O^IG]?U_YHW\(]:>[?PGSF[O/\5<QQJM"J" H[V)]920R
M9<)_4V/_ )O%_$"X[(_$ESL[+'_#CS(SU@,X0! $ 0! $ 0! $ 0! $ 0! $
M!5 1'2ZH[CRW5G([!@?@\)4Q-V.L,=F389E\I4=&U[[=(@MCY>)#&Z.UTXD*
M0<=D_2:DKC(;AI2X!NV\;=?6;MFU/,W<EVE!,(9+41;]R8XZ.DCB+3S,'%P*
M4!S_ %#LY".QZ0-_#2QQ0S4</+?F/.V8XZ>H2_N"W324APTY_)TUU4@E79&[
M-I=/]LX#;&Z[V&P6;N5JLM2AB*UB*&2M8#8JKG^0[69VG+(XGV7J* 2P06D@
M]HX%0"B ( @" ( @" C[=^^-R0;SQG3C8E"G9W-<I29?(9'+.D%"C08[NVDQ
MP^7)(]W8W4#3PJ0:;??4#>NRJ>)@O9;:5+<%FK+/9J3LR%B2Y/"\Z-IUH=9&
MQ%@'-*_7E<=.Q :YO6K=&7QO32UMK TG9'?\=^&:C>G>(ZERB TN[Z,:F%K@
M]SM&ESFZ <4!\CKCG=OX+>K-Z86M-O+:&1I8BO6Q,CV4LE/EP!3+#+JZ($Z\
M^NN@]5"3;[CW[U#Z<[2M;EZ@5,#/;LR5:6%QV*DLPLBOVW$.;;GFY@886^6^
M1C==&G@A!S-+KYE"W<^-=<V[N#+XS 6MQ8C*8%U@X\OI.TEJVHI"7M<WF:YK
MFO\ *;XCP0'68#JP^K@JVY^J3L?M7$YZ.*QM6M$9[%F2N(0^9]HL8]K7$N:Y
MC6]C3H23J@),K68+E:"[5>):EF-D]>4:@/BE:'-< =#Q!UXJ 7$ 0! $ 0!
M$ 0! $ 0! $ 0! 9$L+&0LD;KS.TUX^,(#'0! $ 0! $ 0! $ 0! $ 0! $
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MN!SM3SZGR91J.?F.FG8@.SP>=Q^X:#+^/?S,/DR1NX/C>.UKAX"$(-D@" (
M@" ( @" ( @" ( @" ( @" ( @+U9O-,WU./TD!L4)" ( @" ( @" ( @" (
M @(]O_/GM_\ PGF_[2Q" ="?F9V)^9*/X%J!DA( @" ( @" (#A.IW]5UO\
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MC;N=V;T^D%V;=&!SMJM8Q?G,W&+WKCCEE<UQ>.9Q:6LT\"$D\*" @" ( @"
M( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (#&NWZU%@=8?REVO=MXZ
MN(&N@T6O?R(6E63,]FQ.ZZ11&VX+_5C)[LP0VK!!%LR32/-/E[OG:><]Z7%^
MDG",CN^Z^RUU5/VV3D4V%LQU/[:^@[+"L;HLXEWYEMWUIMTKQ>CJT>MZVUP:
MC?[BP&5AV]8]YG.ES&H!D8XME,!=Y;6$GV7+P\:W\;"C:])Z9<9RN1ERN:%H
MCQ&BV3T_G=.W-;FB=SL(=6I3'G>7-['RZD]GV+?HE6)HDH(0$ 0! $ 0&%>P
M^(R@TR="M<&FG_40LEX?Z8* YVQTKZ>67%\NWJH<>TQAT?\ $<U 8XZ0=-P2
M1@(M3XY9R/I&1 ;&ETZV+CG<]3;])KAV%\+93_\ K.9 =%7K5ZD8AJPL@A'9
M'$T,:/H- " N( @" (#E]Y;.K;FK=]#RP9B!I\WL'L<.WNY-.UI^HA)%?_XA
M=&[#;UQUB/)8Z)]2K=KDF6)CB7,#F<P#N0N)8[B"%4YNZ[&6ZS7I4I7[<1:X
M6\[^*MF#]&M6OMQFMREW&;%]ZL=N:\ZWTYR+GS8V[#&#9[TQASWL#/+9RN=R
MN;V:'LU5%CQR-W7U;;VK#KQ<73K\1U]G=_UZW*=B/^O"E=-%2NA5>AU1/^%Q
MN.Q.-@IXIG+2:WFC.I<7<_E%Q)XDG75=DG551\\DFG1ZT9ZD\A $ 0! $ 0!
M $ 0! $ 0! $ 0! ;.%O+$P>I_#Q0DN( @" ( @" ( @" ( @" ("/;_ ,^>
MW_\ ">;_ +2Q" ="?F9V)^9*/X%J!DA( @" ( @" (#A.IW]5UO^.S^*]6N[
M/Q'S%3O/\)<Y&"Z(YP(#+D?-:I,DFL1\M$-K5ZQT;*8WDNU: /* /:2=5C24
M9:%ZVFID;<HU;7HZ$N$[OIKG6EDNW[#O+:73TM?"T\7L'K'RAZY5/O*Q_P#(
MN9ESNR_KMOG7E)$5(7@0! <3O/ICAMY9&MFG9')X/.UH'4O?3"6O,[,E-[N9
MT$CN5X<SF\H<.!5CC9T[$7&D9Q;K22JJ\969>[X9$E/:E"25-J#HZ<7-PFYP
M.SMM;;PE7;V*QT+,73C,,<<C1(YP=J7%[G EQ<22XGM)6O=R;EV;G)Z6;5G&
MMV;:MP24413@LK4Z*RR;,WW3<-D,GD=M7=G<&Q RM.\R"G<<QKG1R1N<0U[O
M)<WQ *ZNVWG?ZMI^G3TH5II7[T>0H[-U;O\ ]*\O].OH3UZ&_5EKHU70]7-0
MZ3*]8ND>/@:ZA?JYS)3<*6*PT0O7)Y#V,8R)I )_RRT+4M[NRI/2G%<+EH2-
MR[O3$@M$E-O4H^DWT>4YWIYT:?8#-Q[T%JA#+DY,WC-A0VG/Q&/>]W/%WD78
M^9I)>="& G3E\"VLS>=/0M4?H[+N4]*7'IXOM4TL'=3_ !+M5Z6TK:EZ$>%:
M.->!<A.*YTZ8("*.HF<&0R3,57=K6H$F8CL=8(T(_P! </7)71[OL;$-MZY=
M1S>\;^W/86J/7^PY>1\U>FRHRQ%+6M\EJ6*/1SF2,U:&O)&K7 > '16"2E*M
M-*T%<VXQI54>G^TQ%D,80! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M!U+@!P<2.&A7EIMJC_:2FDG5?L,N.;([>R39:\S8KT&AYXGB6-S7@.Y26\'
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M" ( @*.]B?64D,F7"?U-C_YO%_$"X[(_$ESL[+'_  X\R,]8#.$ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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M 0! ;2%O+$P>I_"A)]H @" ( @" ( @" ( @" ( @(]O_/GM_P#PGF_[2Q"
M="?F9V)^9*/X%J!DA( @" ( @" (#A.IW]5UO^.S^*]6N[/Q'S%3O/\ "7.1
M@NB.<" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @
M" ( @" ( @" ( @" ( @" ( @" ( @" ("CO8GUE)#)EPG]38_\ F\7\0+CL
MC\27.SLL?\./,C/6 SA $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0&98_[6/\ T?X$),-"
M @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M @" ( @" ( @" ( @" ( @" ( @/I@YG-;XR @-JA(0! $ 0! $ 0! $ 0!
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M4V/_ )O%_$"X[(_$ESL[+'_#CS(SU@,X0! $ 0! $ 0! $ 0! $ 0! $ 0!
M$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $!D2S
M,?"V,:\S=-=>S@-$!CH @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
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M'>Q/K*2&3+A/ZFQ_\WB_B!<=D?B2YV=EC_AQYD9ZP&<( @" ( @" ( @" (
M@" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" ( @" (
M@" ( @" S+'_ &L?^C_ A)AH0$ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0!
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MG]I]4(!YM/[3ZH0#S:?VGU0@*MK3<PU;PUX\1V(#8(2$ 0! $ 0! $ 0! $
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MH3\S.Q/S)1_ M0,D) $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0$>W_GSV_\ X3S?]I8A .A/S,[$_,E'\"U
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M_P"?/;_^$\W_ &EB$ Z$_,SL3\R4?P+4#)"0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $ 0! $
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M_2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5YO\ 2. _62 ?#S?G[*\W^D<!^LD
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MS?Z1P'ZR0#X>;\_97F_TC@/UD@'P\WY^RO-_I' ?K) /AYOS]E>;_2. _62
M?#S?G[*\W^D<!^LD ^'F_/V5YO\ 2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5Y
MO](X#]9(!\/-^?LKS?Z1P'ZR0#X>;\_97F_TC@/UD@'P\WY^RO-_I' ?K) /
MAYOS]E>;_2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5YO\ 2. _62 ?#S?G[*\W
M^D<!^LD ^'F_/V5YO](X#]9(!\/-^?LKS?Z1P'ZR0#X>;\_97F_TC@/UD@'P
M\WY^RO-_I' ?K) /AYOS]E>;_2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5YO\
M2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5YO](X#]9(!\/-^?LKS?Z1P'ZR0#X>
M;\_97F_TC@/UD@'P\WY^RO-_I' ?K) /AYOS]E>;_2. _62 ?#S?G[*\W^D<
M!^LD ^'F_/V5YO\ 2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5YO](X#]9(!\/-
M^?LKS?Z1P'ZR0#X>;\_97F_TC@/UD@'P\WY^RO-_I' ?K) /AYOS]E>;_2.
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M_2. _62 ?#S?G[*\W^D<!^LD ^'F_/V5YO\ 2. _62 ?#S?G[*\W^D<!^LD
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37^[#6%C6N#I XEXY6D!Q D__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>fc_keydevelop-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_keydevelop-4c.jpg
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M%!04%!04%!04%/_  !$( 3L#NP,!$0 "$0$#$0'_Q #7  $  04! 0$
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M@6QL"\+K@KZ"%K4J+]5* N8+J9T_W-)"%@]QP9<US@W%%X0>-?0+9Z2+]A*
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ML=>^D4B7Y)O=$<7572AN-R&FK_\ BFV(?LZJF@);F]V[;VYB S^:R+47#.J
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M;IT I1-JO@%^*X""=N[PN$B_L5#!SCJ%O.3U/ZA.3<ID$A81R4D. X[J)B'
MYFA#4!NJ^'XP]/$E_8J09O4O:_2C#8R!+Z=[J<S,W6C&1AR!)"5%%5YP+R6D
M045-*BM^U/9H#H.T]WSMQ>K7O3!9-Q9#NWDCLQ7374217GFS:!57BN@@-!]
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MEQU'V"(IVU (GZHWT@9;\4.?A+%2P9_4_8_1C"[XS>3W;NF6DK(22E_F_@V
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M)T'E-AWFHJD)+9H6T;[--R7O[[ 9/JO?2S#_ +G+_FZ,$0ZQ?2ENW\9R/X]
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M-W54 E(2$Q15NB$*V[K76H!&=J>K5T\VP;\ESS65G.LNL-OS3;5&4>!6R)H
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M+5K;<O[U+6J ;'8'3G ].,+)P. <DNPI4@Y3A2W!<<1QP ;5$4 !$2P)W4!
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M^G5Y-)?[_NT<SF=VF];^KM9.LZB67'-G]+VLN[R&G//K<O6JO1R^CR5W^6G
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M)J+M6UNU;\5IE6X58&/'!;@RV*\.* *+X>*=B=U^%,JW"K"QXZVNRVNE1(?
M/ @]ZJ<.T>[T4RK<*L]%ED20Q; 31%%"04140ENJ7MV*O&F5"K*ZR((3U:_T
M.]^,L-^4X]6'=WWZ]F?PLK>\_N/XK?QQ)P[\H?VR_NU7+ LWB4U) H!0"@%
M* 4 H!0"@% * 4 H"$]2.W9/Z68O^(_5AHO^SY<OJ*W78VOFQ\TB;57ED* 4
M H!0"@% * 4 H!0"@% * 4!"]V?Z[Z<?W_*?DMZK#3_<7N2/QHK=5]_8]J7_
M )R)J'$A1>RZ57,LT?)>_),.7EIN6S,61\]"^_CL7)FR"  %7C\,:.G9KMQ4
MNU*\OI;LH7I-S;=9>CLISEJ[6:*J<$WM/SOS5EVX.4D1YT=HCC$R2-^(1U)>
MR<;V5*]'UTI4:>QHX\B5:XHXU,S$O</2Q)DN8])GX;**DA]QUPW#8EIX4);B
MJH*KPK96L.1FO"0VVTRNR-YX=@3=%Z)'R#:FVB"117$74'OKI8OVZR@O1:,6
M]J91TJBSLWD<YMN)%_K.<Q,EAH7#0 U J'<EX61+\5M7/._"Q"4Y[(T$U6G$
MSI.SNC;.WG2=S&>YDI^+)B9*-$\38MO@G!HBXZQM>ZI9:H/SMQJX1Q5%7Z^(
MQDTS;-='=K [#=QTA[&XEFPR02RN2E 1Y9*I+P4EXFJ?L57KO:[%--)R\WTX
M Y%__I7%@;DQ&Y]MH+;&-N_,CO.*KKA@A(JM+V+X2[/8KN[O[W:N*-WA>Q\Y
M-:JA\^,P8V0R+']7-9$R<WS24A=14<D#JN"HJI[XK]G9QKTV4SS'V.DF>>58
M>:FH$%OXLX*HJ(26M?APOZ*LC3B<5V7D/GOUJMKSU-$;_.Z"#!+QU!'<!M$N
MBK;WJVJMN;6V;XGZK+VK69H% * @V7^E_:?XCS'\['JPM]DN>W#ZRNN=KM^Q
M/SQ)S5>6)I-R[2P>[(K<?+L*KT=5.%-9)69<9Q4MK9>"Q 7U."]Z+0&GB;3W
M=CY#3<3><E_#MBK?E9\1B5)5.60HJRDT$I(2Z[D*WM:A)%>FO1[([:R$3=6Z
M\IYC>L:.6.F3<2Z\S%RD9'#=!Z>T[=7)&MPR(]5JA(ELZ[4F(H!0"@% * 4
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M*7!R0+#DLR7@%QIH@=MXC A(--]2+PH0;!C-XYY=)NI'<60[#:;D_$FZZR9
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MS8J7U* W5 :S#;@PVX&/,X:6,MCEM/:P0D3ER YC9>)$]\/&@-G0"@% * 4
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M$HSK(QE7FGI+0+;2FK78-Q)502=#V#LW=^+W;(S6Y)DQQ[1*%Z0"QO)3FWW
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M&2W7'Y<)A]YV.<)UQUL#(XKJW-DE)%N!+VBO!: P(6S]JXYCRT'"PF&-+@*
M1VTN+P"TXA+:ZZP$0*_:*(B\$H#R=L_:N2CG%G8:&_'<Y*&!L!94BBH,]U_
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M33 9?#%+3*QO+FQCL+B5).*//XV(HO.@JHBJ&IS0)6XZ:D,Z!0@4 H!0"@%
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MNF@J36A H!0"@% 07;'TI]1/[KM[^8D58W^RV>6YYT55CME[V;7\Q.JKBU%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@,CN_DOKUKYS9S'DOY1/M?KK4PP$\2
MQ69K% 0KJ]]%^[/Q>?\ &&K#N[M-OVBM[T[)=]EDU3WH?:!_%2J\LV*$"@%
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M0"@% * 4 H""A]-TC]$(_P"5'JL?_B7S7\"*I=OE\J/QR)U5<6HH!0"@% *
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M^PBK5EW;%RO[%7T9_"RK[TDHZ>K=/2A\:?F)\[\H?U56JQ8%J\2FI(% * 4
MH!0"@% * 4 H!0"@% 0+JC-APUV/YM\&->[,9HYA(-](O7_82Z77V:LM!%RZ
MVB_ZY?457>$XQZJK_P"V/UD]5%1;+VIVU6EJ* 4 H!0"@% * 4 H!0"@% *
M4!!-Y3(D;?\ TT:D2&V779^31H#)!4M6-<;2R+VW,A'ZJHE66FBW8O-+@C\1
M5ZN26HL)O[4O@:\[2)W5:6@H!0"@% * 4 H!0"@% * 4 H!0$!S,J*'6;:$4
MWVQE.83+\MA21'"U.,DEA[>* :I]JOHJRM1?X2XZ;,\/K*R[.*UEM-[<D_Y>
M9^)D^JM+,4 H!0"@% * 4 H!0"@% * 4 H" -RHJ]=9,5'@62FT&$5E"1314
MR3AJBI]J2%]1;U9N+_!)_P#]7\**E-?F#7_\H_'(G]5A;"@% * 4 H!0"@%
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M\)64HSC'[OJ]J61I>FY;JNNW[552INF]S8=G=<GEY_#MS6GL ,W/N2(QN9?
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ML:>M_P#:-G_>^4_I:^>_X6Z[XX<Q]-IK]]KW9_U#3UO_ +1L_P"]\I_2U/\
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MT<@M>I&%$[Z>SC6_O;J_P[ZRN6J]6E<>,X^X^M_%+JLN:C]:M,.(^MM/6_\
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M'^Y/TN'!I)K-+P;7A!<GE([_ $<CXG(91J!(@<AO$8C'9%J6UD5.2Z\^<N&
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M7U;^CZI;YE?^_I/W=<WYUJ^DO=1U?D.BZ#]Z7.=188:BQV8K Z&&&P9:"][
MV*"*77T(E4[;;JR\2HJ(N5!(H")[TZ:[-Z@G"<W7!.8>/%P(A-ONL:1>5%)%
MY:I>ZBG;7;IM;>T]>K=*X[*G!J]!8U5.M5<N&UK'D(M^K?T?_P E?^_I/W==
MGYUJ^DO=1P_D.BZ#]Z7./U;^C_\ DK_W])^[I^=:OI+W4/R'1=!^]+G'ZM_1
M[_)'_OZ3]W3\ZU?27NH?D.BZ#]Z7./U<.C]T7YE?X<?^.D_=T_.M7TE[J'Y#
MHN@_>ESG5$1!$1%+"*((IZ$%+)5,7I[0"@(?O+I?LGJ!*B3=U0')<F$V3$<V
MY#K%FR+6J*C9(B\:[M-KKVG35MTKQ5.#5=WV-4T[L:TPVM>8C7ZM_1__ "1_
M[^D_=UU_G6KZ2]U'#^0Z+H/WI<Y\Z=:.D+VRMZ08&UXCK^#W$H!@V;JZ:2E4
M6SC*1<55"5"%5^Q).VRUZKNSO%7[+=Q^E#UN3?\ 3<>-[W[J>GOI6UZ,_5Y<
M,OC\Z.]X+U9NFL/#08N>@NY#--LC\X3 E/M Y(5+GI$"1$%%72/#L3CQKS5W
MOO42FW!I1X%18'K;/^OZ6,$IQ<I4VO,\39-^KITA:=!T,*_K;(3&\V2J7%;I
MPU^Q6E]\ZMKUE[J-R[BT2=<C]Z1U154E4E[5XK5.7AY0"@(9O'I3L7?V0CY7
M=./<ESXS"1&76Y#K"(RADX@JC9(B^(RXUWZ;7W]/%QMNB;KA4K=5W;I]3)2N
MQJTJ8M;/!RLCOZM_1_\ R5_[^D_=UU?G6KZ2]U')^0Z+H/WI<X_5OZ/_ .2O
M_?TG[NGYUJ^DO=0_(=%T'[TN<?JW]'O\D?\ OZ3]W3\ZU?27NH?D.BZ#]Z7.
M7HGJ]=)8,MB;&PSPR(S@/,DLV02(;9(0JJ*?'BE8R[XU4DTY*CXD9P[DT<)*
M2@ZK]YG4%52527M7BM5!='E * @^[>D/3_?.53-[EQKDG)HR$?G-R7F$5MN^
ME%$"1+I=>-6&G[QOV(Y8.BY$RMU7=FFU,\]R-72F+7F-%^KAT>O?YD?7_GI/
MW==/YUJ^DO=1R?D.BZ#]Z7.?-?4/H[E=O=36-E8!DGXF>=%S;SAW).0Z2H0N
M%Q^05"UJOV*:E[:];H^\HW-,[LW1P];Z<?!XCQ6O[IG:U:M6U53]7Z<7#Q;3
MZ-A^K3TFCQ(\>5C9$R4TV(/S%EOMJ\X*6)S0)Z1U+QLG!*\I+OO5-MII+=1;
M#V<>X-&HI.+;WYGM-CC>@'2G$Y&)E8.'>"=!>;DQC*9(-!=9)#!5%2LME3L6
MM4^]]5.+BY*C5,$;;?<FCA)2C!U3JO2? =,55)55>U>*U4ET>4 H"";JZ-].
M]Z9ES/[BQCDG*O VTZ\W)>90A9'2'A D3@B6JQL=Y:BQ#)"5%R(J]3W7IM1/
M/<C67*T:7]6_H_\ Y(_]_2?NZZ/SK5])>ZCF_(=%T'[TN<?JW]'O\D?^_I/W
M=/SK5])>ZA^0Z+H/WI<X_5OZ/?Y(_P#?TG[NGYUJ^DO=0_(=%T'[TN<SL-T'
MZ7;?RT+.8K$O-9+'O!)B.E+?<$76UN*J)$J+9>Y:UW>]=3<BX2DJ/8]B-MGN
M;26IJ<84<=J])G1ZJBX% * @&YNBO3?=^;D[BS^+=D9>9H\R\$I]H25H$;%=
M $B)X11.%6=CO/468*$)4BN)%3J.Z=+?F[DXUD\=KY#4_JW]'O\ )7_OV3]W
M6[\ZU?27NHT?D.BZ#]Z7.?,N1Z,9V/U9'IE&U$,EY'8>0(;C\UE<_,EV)X 1
M4)/WZ::]=#O.#TO7O@Q7[V[Z<&T\1<[GN+6?AUPX/]W?].'8?3(^K=T?$1'Y
MGD'I1$UE-D(I62UUL2)=?8KR/YUJ^DO=1[?\AT70?O2YS9X#H;TRVQF8>?PV
M)=9RD ^;%=.6^Z(G91NHD2HO!>^M5[O34W8.$I;'Q(WV.Z-+9FIPC22PVLZ'
M566PH!0'/-P=#NF>Z,S+W!FL2Z]E9YHY*="6^T)&@H-](DB)P3NJTL]Z:FU!
M0C+8N)%3?[HTM^;G.-9/':S6_JW]'_\ )7_OZ3]W6W\ZU?27NHT?D.BZ#]Z7
M./U;^CW^2/\ W])^[I^=:OI+W4/R'1=!^]+G'ZN'1_\ R5_[^D_=T_.M7TE[
MJ'Y#HN@_>ESFUVUT4Z;;1S<7<6!Q;L?+PM:QGCE/NB*N K9+H,E1?"2]M:;_
M 'GJ+T'"<JQ?$C?I^Z=+8FKD(TDL-KY#H%5A;"@% <YS70CI?N'+S<[E<0Z[
MD\@Z4B6Z$M]L2=/B1((E9+KZ*M;7>NIMP4(R5%Q(J+W<^DNS<YQK)X^DS6N>
MK9T@<;-L,3(9,Q41>&;((@4DLA(A$J*J=O%+5M7?6K7VEXD:'W#HFO5?O,^:
MMM=&LUDNJ[G3C)B3;6,>)W+302P_-S:H2/!VVYPD"-^R27[%KUM_O.$=+UT?
MM8+CW>#AY#Q6G[HG+6=1+"+VO]W?X=E.5'TQ^KAT>O=,(^G_ #TG[NO(_G6K
MZ2]U'MOR'1=!^]+G-SM;HUT[V7F6MP;=QCL;+, XVT\Y*>>01>'0?A,E3BBV
MKGO]Y:B_#).55R(Z=-W7IM///;C27*V3RJXM!0'J*J*BIVIQ2@.:93H#TJS.
M3F9>?AWCGSWW)4HQF2 $GGB4S5!0K)=55;)5M;[WU4(J*DJ)4P137.Y='<DY
M2@ZR=7Z3Q?A,3]6_H]_DC_W])^[K/\ZU?27NHU_D.BZ#]Z7.>?JW]'O\D?\
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M,CN_DOKUKYS9S'DOY1/M?KK4PP$\2Q69K% * 4 H!0"@% * 4!!.M'T89_\
MY+\.CU9=V=IAX?A95=[=DG_#\42>N_*']LO[M5BP+9XE-20* 4 H!0"@% *
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M#<_X@Q'\_)JPGV2'MS\R*^':[GL0\\B<57E@* 4 H!0"@% * 4 H!0"@% *
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M3SD='%(T--3?OK NE;(5KT%"[M;?LS<^[',:&-D8[#+AHV6B^?:%J0[YJ0Z
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M'\T2NUGWECYG\DB72@><C/-QSY4@P(6G%2Z":HJ"5O86N L3AD38^\)K>*W
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M$=2:>:JH/@H#<0\'N'.],-X0=P([GG),25\RX[(PI S&GU@J.B\X!)PB=55
MD2PWTBJHE"#%GXW=V-7)L0F,K$PI'C,?C8N)%([$)ER&C\J6#,0.:Z7F!Y1)
M?@I<;!J6I!3BAZL/_-N<R3V59R(2,1&DX[EL)$2-)QS:3W38%%U$V^I%[_PF
M-A\-[P"G:Y[X*?AX>Z'-Q?,L=7!;R<5MX2R&0!UKXV6T3?/C1S!5TLF*-HNO
MQ*FB@-5+=W_@X&&R&;F90)^5;Q+&4FBS&*<,B;E423#C6;X693PMC>P^)+G0
MD]>Q_4AJ>WG8"Y]V6.-R\'!&^B*X449S+C2RV3%&TDJQSBCD^B:E%M#\5T4#
M8/QNH\QJ9%Q$W<3.!CM961A)4D0;R;K[$6,<<)'.;UJ"R5>1D7!13&Z%X--Q
M!9RK/5F+?',S,J6'D.Q9,O)&VZ]+9>DP#)P&O)-D[R0DB.H !=*KI]XO #MN
M%'(#A\>.6?&5E$C,I-D@TL<77T!.8:-+Q#45UT+V=E209U * AF_/\9Z??I(
M/X!*KOTGJ7?8_FB5VL^\L?,_DD2]]PFF''1'60 1"%T'4HI>UUX)?TK7 6)Q
M^+UAF2LA'B^79CY.0#<1^#)?%N%!G.2'!,)+O+UZVQ;TZ@)6W"(4#WVJH)H>
MPNN92(S.6F8N-!P8.QHL^24WG$V[-9==!P4%I$)H>5XE]\2%<4X64*&.?6K,
M@CLY<=#2#C&<O\Z13>-N0Z[C#@Z285172*MS$,A<&Z66]K4%#993K6,";EF8
MV)&9#PR33D2&90F;@Q'XL4- ("IXG)2*:J5FQ!>U:"A5D.I.?5@X<O'IMV<Y
M#FR<?)?)'EE2,;S'5!MM$+0!M-:[/:24"\/B%:D4.J,N*\RVZHJ"N"):"[4U
M)>R_4H05T H!0"@% * 4 H"%;E^DGI]]IG?P1JK"QV>[_!YV5M_M-GDN>9$J
MRK#LK%S8S*:GGH[K;8JMD4C!41+_ %5JO+(XIF&-\9#IYM_;F)VSDH66Q>.&
M(4LC!I^/DXT(0C&QRI8 H*Z)7><4A"R>!=5T@R+N:QO4Z4F3Q4&+D@DI)R\U
MK)M2P:8)J?C2&*#)*XA:@D%9!THC9#J[++0@RINU]P8S,/17X&5R?3P)XOKC
M(DPW)!$]!91'+D\+ILC)%PC;U^_)'+*B+0&PV=M'<.!W#B\BC,F/'EO9]<\!
MR>:RK3TSG8^[2F0HJ"I:>6ETN6KMH"(2MC;SS./<QL_&9%R=9M=SOR9RK&R,
MX,K%>CO0]+R:1:9!XO"+>D%1NRDB:1)*=\[/W7D-X?G#MN*HRHL2%@HLLGA"
M^/R3C[>0<NI:E*.BLOBB\2(+)=:$(RNFNRLCM/.&P4%8N$A8UW%X]Q2;*[36
M7FO,)85OQ8=;+L[_ $T#(L. ZD87;$'$P<=/.1*VX]BVF8<IIL(F426KHN.J
MK@B%VBX.C?WNGM5+@9V4V'NV?+FR2+)JLU=R$\@9)QL55'D<PND1=1!Y=R5G
M3;1]E0&'*P/4J0LPVX^3;WBX$MQ_-#+$(+F-=QQ@Q%9;1W0#XR%#3\6FAP2<
MUZ2\0DE&[MM2X& VZNVXN6+>&';='"Y&(XW*5N2^ JZU/*8Y8V'S1.:2WMIN
M)"J#0@B4C;/55U[<#OFIC6X'4?.0,8%\A-B/26B%J/(.6FDFF$,&!1IDD74A
M'XM5"2YC-I;WB9S$YQEJ;-VZRTT,_'O#\WSR97(N&W':U27C%J)J1_E..ESF
M_!?@@J!WNI,2#.?35$_1*5^4V*L5V-_,7P,JY=NC\J7QQ)S5<6AP[?+.^,?E
M-U/[7Q^2:ESI@3L;DH DX+K\/%Q6VF3:#@8..(0J3RBTF@D7C:H)*]P9/JDJ
M9;%XAG+CD&)&==CS&X[1,>6=8U8U&7#30:BI)H&RJA(J'[(&;)C;QQFXCQ&1
MF;A?V.S.(HF1A(DB>;SL:,Z#;QM KBQ$<*0.H1X'8270B4!?Z?8/=FWLAC!/
MSPXW(KN$\GCY.CR<5Q,D3T(FQ%+MJX#IKP5=:<5XHE R*R<-O[<L!O&Y,MPF
M9N8][<[;_*CLMY%G+1R3YM(15"9%I'C+3J#0+9+X[I0DG+L%K&]0<K,W)@I&
M9BY%F WM_*!$7(MQFXXJ+K!:1)6%YJJ^IJB"6KWUPLDD$4@GU0RT]V,J9O$8
MN?D,8Y*$K&[#;)^8DUEJ0^/B;Y81]1MAH'5=M5[:@&TV*&]X6X, SEH\\L>]
M#?;F0D:6'$QY@Y(-'W% $9?5^[8Z$)' *Q645): TR8CJ*SG<MO9N*6,3=89
M+&N2HL=V5EH##*7Q3[\74H&+2,N)I;37>1QH24NRNJGE>= CYI9CF)?!B$2N
M+Y1Z,3I#(YK[8A(*6@BC;3VE]E51%&UU00;;)2NI>=RN2FX!,M Q[2Y&5@X\
MEEN*V_(8QT/R;;XNIK%DY*O^$M*DJ+JL- 2CI4.Z/FR<[N.?(EMNNME#8G1I
M4:3'7E#SA,Y0@3B*Y<DTII'B(JJ5(9/Z$"@(/C/I@W/^(,1_/R:L)]DA[<_,
MBOAVNY[$//(R^I>-GY79TV'CXAY%>9%=EXMHT;<FPF9+;DF,!$HI=UH3!$54
M0KZ5X+5>6*.89+%XK=K_ %"B;=P+L2"6W&XKF!D07,>Y,RK2O.L/MQW ;0N6
MBBTCO81>'B@)4$DIWQ RF2V;NC&QHV4GS #$D$!QD%87DDPZXD)4$5<6PJKB
M$2^/@E20BQN+/;QRFZ,'(VUCLQ!@M/1!=5YAT(\EE^0;4M'V31!:1EM$/6XN
MHM0\M/"2T!J8TSJ=F?F: 0YO'M-1,'"STHV6F#*8DMP<B;9$BW3EBFIT$TZ2
M106_9 /6V-\/>:Q&Y/GR1%:A3XNWD;!'&9I@_,93YT-H.)DR,=6U/0!"JE[]
M2L!L=L8WJ#MW;67Q>,*9)F-[:QC^$'*<HQ:S*QWVWV&EL(H(\ME>47A$E[;$
MM :W%8/<F;W/MV2X[N,]KXO*C*C/YG2Q,%TL5*21S@4!4F.8K30J0^_-Q \"
MHM =PJ2!0"@% * 4 H""[2^D?J9_>L+^2PJQU'9[/)/XRKTO:=1[4/@1N]\M
MRWME[A8@12G3GL=+:CPP1")UQQDA$$1>"W5;57%H<8:V/OO"NXM<1"=?E[$\
M[MW9CTA0<;.'(QDAP)A:EL*(OE8G'[)M;^%:@RJ;O%0M[9?)0\9&G[FB[,D2
MD\S/R2-QLL)?-T@G14U;0@91[D:2TI\;J$%Y="#6-8SJ%,F8+,Y-C),Y6/*Q
M3QDR",-.2CP,ADRFC'&YLI+5MMZ]T;0EM8>*"2]!:ZF3B@PVI6X8\.8_B?SA
ME2VVFY#,PW'ER 154+#&T"*$3:* W'E+?4M 7\+C^I36.8F*62A2L8&'*)BF
MVV&8C[DC*20G\]ML$UIY8FR.RII2QCXKT(-ATZRNYRWN&)STW*G*=PTF=F(6
M1\NL09XSFFA.%RN*,6YB-672H6^SU4!V&I(% * 4!D=W\E]>M?.;.8\E_*)]
MK]=:F& GB6*S-8H!0"@% * 4 H!0"@()UH^C#/\ _)?AT>K+NSM,/#\+*KO;
MLD_X?BB3UWY0_ME_=JL6!;/$YKF.JPX_+[LQ$;' X.WL3)R$*<<@4;F3H#*/
MRHG+1%(.4+K"J7&^LK)X%H*&9C>HR2,AEX<Z(@CC')Z"$7FOR7&8+L=K6+0M
MV5%5_P 2Z_#;LM=4D&5&ZI[)F'"2'/.0S.&&X$EJ.^4=L,FX;,57G4#0WS70
M)H=:IXTLMJ"AZ74[:B1%G Y*=BFZK$%QN(^7G2!#(UB)HN\((V9$87&R7O94
MN%#5R>H6XE>;DX';![@V[-5DL7EH#RJVZQ);;=!\M3=M%C)%457B/L\ H7-R
M]196'R9X^)&@HRD\,4,[*3?(QDD>0<R#JFXC;ED0$; >%U(E[DXA0U\?JIG,
MM@I.ZL%MKFX3$16I.99E2>1-5PF1DO,Q0Y9":LM$)ZG"!'-2(-NVH%#+>ZIH
M[G,SAL7CP?:@8SYQQD]R0(A-DLM-R9,5&T'6!-LOL%J7@JFJ6\"U(H3S&SV,
MKCHF4BW\K-9;DLZDL7+>!#&Z=RV6A!E4 H#!RN%P^=CC$S>/C9&*!HX+$MD'
MVT,>PD%Q%2_&@+L;'8^&\_(B1&6)$GEI)=:;$#<1D=#>M11%+2*:1OV)V4!D
MT!".I_\ A>WOTGP?X8-6.@]>?RY_"5G>/W</F6_C1.7/E"^JO[M5JP+1XG/X
M'4N,<[<GSSY;&P-OOK$<B&XX>64E>1AATHR-)\7*4D6.K9%JN*>^N@R*%YWJ
MWL9ED7W)SO)%%\\819#B05%Y8VF9H;+DDKJ*VB':ZI?WO&@H;.9O_:>/8&1,
MR"-,DLX!)6W.)XMY(\@41!NI"XJ B=I*OAO0@UCO5S8S(@KDQY'/&LII(D@C
MB"R\,=TI*"VJ-"#A")*=NU"][QH30R)/4/$(^C,#4\R&1:Q3TUX'F8A/$X3;
M@,/<HA=<;(5%1'PW144DLM 6X_579DJ)YR-)D.(X,0X3"0Y*2);>1U^6<C-$
MVAN@YRW+$*6325[(E!0ROSW@Y''82?MFV1#/32A0R<1R.@^7YJR",3!#3EHP
MX*II]]:@(8[UDQLIB.]-P',9'!%N$>8Z!\O+1W= 8\44%^.NA*+B=EKVJ!0R
MIO4K=N*=W$WDL!"T;=:@G+<C37W[?.2V!PA2(A(TPB*;Y)=4!%41+LH*$IV_
MNQW*9*/C)*1'EEXP,K$GXQ]94-X$=5IU <41NB:FR%>_5['&2"54 H!0"@(9
MOS_&>GWZ2#^ 2J[])ZEWV/YHE=K/O+'S/Y)$R(1,5$D0A)+$*\45%[EK@+$T
MF0VIAYF++$QFDQD8M*(L!MEHD$3YFE$)LATJ7%4T]O'MH"]B-K8+#8R-AL=
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M'1CPAOQ1'DC/$ETU>]]-0*&S?W9U1A2-P1RAXO)S,%CH4[YO@1Y7/>=G\\5
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M["1*._;@UGMK+1TE%XQ?-Y4RSMRE7++;LJI=+]OG6!-:X3>* 4 H!0"@% *
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M&6W%F)+@LOK'QS7*:A,L,-@'+?%5:=3@FA7%741)8*DIW1LMG=KS#.6R#Y8
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MJIJ[46J._8C&*G;>:#V<:>Z7U;SKMW&WEFJ3I6G ^-?7N);7&;Q0"@% * 4
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M;-G;XJ++YJ^4V;>T]L8G&S]M@80\%FI//A8G4+;<:62HZ7DT54T_&BCXMCP
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M1*F_IW:HZJ49826#_:N%'9;NJ=5@UBGBOV/@9(JYC:/J<* 4 H!0"@% * 4
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MO@95R[='Y4OCB3FJXM"RS,B22,([[;QM_*"V8DH_51%6U 5N/,M!S'7!!O\
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M-6$^R0]N?F17P[7<]B'GD3BJ\L#0R9>U\UD<?&=R,:1*@R?-182/-EKE-"2
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M\9,&U.$I*GHR3IA6J?@K2J\1'LWM?,S,'M+#Q,.!Y&3!W.ODYC9-("9 T>9
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M1>I(-GS'/WR\?96E$*LIJ2!0"@% * 4 H"CDLZR<Y8\PDTD=DNH^A5]% >Z
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M;0V(V2R61$X>B@#3++ (VPV+3:7L (@CQXKP2@/6VQ: 6PX"*62H2);J55)
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H#([OY+Z]:^<V<PE_*)]K]=:F& GB8]9FL4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
3% * 4 H!0&1W?R7UZU\YLYC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>fc_miprofile-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_miprofile-4c.jpg
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M%!04%!04%!04%/_  !$(!80$)@,!$0 "$0$#$0'_Q #A  $  @(# 0$
M        ! 4#!@$"!P@) 0$!  ,! 0$!             0(#! 4&!P@0  $#
M P(# P4(# H(!0$ $P(! P0 $042!B$3!S$B%$%1D3(587'14B.3519"DM(S
M4[,T5'24-0CP@:&QP7*R8],88H)SHR1U%S?A0^.T-E;"1,0EHD65M29V@V2$
M9:5&)W<X$0$  0," @4(!P8& P "  <  1$" Q($(3%!46$3!7&!D=$B,E(4
MH;'!X9(5%O!"8G(S!O&"LM(C-*+"4W,D%^+R0V.#P__:  P# 0 "$0,1 #\
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MC,S83P2(D@!=8?:)#;-LTN)"27145%NBI45FH% H% H% H% H% H% H% H%
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ME-UW)YF:3KQOY#(R%53,U-]]PNU555U$JU0@9')X6<$[&2GH&1CE=M]@R9=
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M"\X5_C$TJHJ-E[(S>_LL>$V]X<LD+1/@Q(>!A7!!40D#7;42(NJR>2Z^2@]
M_P L'5O\PB?KC7PTJ'^6#JW^81/UQKX:5'T=G,%,VS^[M.P&104GX_;SC$H0
M)"%'1976B*G:B+PO45\'54?9O[I&0B/; R>-;<19L3*..OLW[PMOLM(V5O,2
MMFB>\M21U_>TST*)L;'[?5P5R62G \#-^\C$8#4SMYM1 /\ '2!\:51]>Y_
M2T_=,B1$!4?8@1,BH6X\LY0R%5?> ]50?(54?;W[J^5C3>EXP&S19&,G2&7V
M[]Y$=5'A54\RH?!?<6I*M+_?#RD;D;6PHDBR]<J8X%^(MV!L%5/])=5OZM(1
M\J]O!*H^^]Z0'<5T GXQ]%%^'MQN.Z*]J&U' "3TI45\"54?;/[J'_;!_P#Y
MK)_%,U)5[G4'SK^]]?ZG8!?)[37C_P#P[E6$?'M4?I;L>9&R&S-OS8;@NQWL
M=$(#%45/O(HJ</*B\%3SUBJ_H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M$L,I]I=0,!?UDNB*XO8@\.U4I(^KNL?_ &LW;_RU_P#LUBK\ZZR1]L_NH?\
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M&M+CS 154;^ZE!/H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H%!U=<%ILW3X  J1>\*76@JF<X<AEM]K%
MS2:=%# M+27$DNBV5WS4&3VN_P#14W[5G_%H'M=_Z*F_:L_XM ]KO_14W[5G
M_%H'M=_Z*F_:L_XM ]KO_14W[5G_ !:![7?^BIOVK/\ BT#VN_\ 14W[5G_%
MH'M=_P"BIOVK/^+0/:[_ -%3?M6?\6@>UW_HJ;]JS_BT#VN_]%3?M6?\6@>U
MW_HJ;]JS_BT#VN_]%3?M6?\ %H'M=_Z*F_:L_P"+0/:[_P!%3?M6?\6@>UW_
M **F_:L_XM ]KO\ T5-^U9_Q:![7?^BIOVK/^+0/:[_T5-^U9_Q:![7?^BIO
MVK/^+0/:[_T5-^U9_P 6@>UW_HJ;]JS_ (M ]KO_ $5-^U9_Q:![7?\ HJ;]
MJS_BT#VN_P#14W[5G_%H'M=_Z*F_:L_XM ]KO_14W[5G_%H'M=_Z*F_:L_XM
M ]KO_14W[5G_ !:![7?^BIOVK/\ BT#VN_\ 14W[5G_%H'M=_P"BIOVK/^+0
M/:[_ -%3?M6?\6@>UW_HJ;]JS_BT#VN_]%3?M6?\6@>UW_HJ;]JS_BT#VN_]
M%3?M6?\ %H'M=_Z*F_:L_P"+0/:[_P!%3?M6?\6@>UW_ **F_:L_XM ]KO\
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M]E\*[@Y2278Z1G5)4<!O2J.!K$5T][3Q3UA6H-UH% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!!R3FF))3^Y=_
MD!:!A?V/C_T9G\6-!.H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M"@4"@4"@4"@4"@4"@4"@TKJ!TZ;WY[.=3/9/ S,6KJQW\4_R-7/0$+6EKK9
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M_P 7I^X_5N\ZK/1/^X_S0=3_ (N,_5C_ ,6GZ?VO\7I^X_5N\ZK/1/\ N/\
M-!U/^+C/U8_\6GZ?VO\ %Z?N/U;O.JST3_N/\T'4_P"+C/U8_P#%I^G]K_%Z
M?N/U;O.JST3_ +C_ #0=3_BXS]6/_%I^G]K_ !>G[C]6[SJL]$_[C_-!U/\
MBXS]6/\ Q:?I_:_Q>G[C]6[SJL]$_P"X_P T'4_XN,_5C_Q:?I_:_P 7I^X_
M5N\ZK/1/^X_S0=3_ (N,_5C_ ,6GZ?VO\7I^X_5N\ZK/1/\ N/\ -!U/^+C/
MU8_\6GZ?VO\ %Z?N/U;O.JST3_N/\T'4_P"+C/U8_P#%I^G]K_%Z?N/U;O.J
MST3_ +C_ #0=3_BXS]6/_%I^G]K_ !>G[C]6[SJL]$_[C_-!U/\ BXS]6/\
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M=/*O3Y)AU;KPF<>*<V.^W)9'"9CG'EB4Z!TR"5A<)EIVZ<3B'MQ XYB84]9
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M3-VXW:F&S4+*KE7&68V3C<U(R&^6E$-# 311^R336'S>G#=DOMFW3T32K?\
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M_1F?Q8U!.H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H%!@=AQ7I#$MUH2DQ=?AW%[0YB6*WOHE91=,1,=$I2
M*U9ZQ4H% H% H% H%!2[F_(8WZ;$_'C03!_)C][^E*(G44H% H%!B:DQWG'F
MF70<=CD@/@!(1-FHH:"2)Q15$D*R^1:!'E1I8$Y%>;?; S:,VB0Q1QLE$Q51
M5;**HJ*GD6@U',;W';\+<6X)\G&/[?QT-F7B C2D27(,F7'5!S5W$YJBB,:%
M74EUH(\[?#+^9VB>'R<4\'D'IHYDVG&GVP2/CSDB)NHJHVH$@DO%.';PH-KQ
M6=PF=;<=PN1C9%MDM#I17@>0"7BB%H5;*ONT&>5D($%%6;*9C(+9O*KS@MHC
M36E#/O*G='4.I>Q+I08,3GL)GFC?PF1C9%II=+IQ7@>0"7L0M"K95]V@PKNG
M;0Y/V*N8A)F%+0D!9#7/UK]CHU:M7^C:]!43.H>WH&\4VA-F1H[J02G.2WI3
M+8 XCP-"PHDJ*ADAZT]R@N)^YMN8N:UCLEEH<.>_;E19$AMITM2V2PD2+Q7@
MGGH)$_,XC%@XYDY\>&#((ZZLAT&M+9%I0EU*ED4N"+Y^%!59C>VW\9M2=NYF
M=&FXR(P\\T;,AK0^ZR!$C(.74=9*.E$[;T&*)NA,X.$E;>FXQ^%+=0<HV<I'
M'P0HY/(VPC5T)U%1%(2MW+K06+6Z=M/Y/V*QF(3F7N0^!"0T3^H/6'0A7NEN
M*=J4%;M[,9&?NO=^,E.H<+%2834!M $5 'X+3QHI(ERN9*O&@KHF\1A;LW?$
MW%DX\/!8LL8WCBDJVP(G*C$ZX/,*RFI*ET15X4&WQ,ECLA"#)09;,G'."IA+
M9<%QDA&Z*J&*J-DLM^-!&Q6Y-O9QQYK"Y6)D'8_W\(K[;Q BK9%) );(OGH,
M3N[-KL2HT)[-00ES4%8C!26D-U'/44$U775]C;M\E!,R>6Q>%C>-R\UB!$U(
M'/DN"R"FMU044U1%5;=E!JN]=]X_$;4:RV%RL#GY5^/!Q,YUX'(NN3(!@WKH
M2(8L(1.$B+]C9;4&7;N3P\5R69;Y:SK0,(_("1(@*C"-K9QZ\8&U %U(BH7=
M&@E;(WSA]\8>-DH#S(2W@)U[&C(;??9%'";130%NE]-^R@M<MN' X%&US>3B
MX[G7Y/BGFV5/3:^G6J7M?C02$R6.*.Q+28PL25;PSZ.!RW;BIIH*]BN**7#R
M4%3G,\T6S,ON';TUF0C$"9(@S6"!]E78[1JA(J7$D0Q]Z@PPMWX:#@,+,W+E
MX<*;/A1Y!+*>:CJX;C0D9")*G"Z^3@E!?N38341<@[):" @<U91&(LHVJ7UZ
MU73IMQO>@TS=>^X"[8EY#:&9ARYT:7C67"C.-2M#<N>PP>H44K:@,D15]]*#
M="EQ E!!)]M)KH$ZW'4DYI-@J(1(-[J**2(J^ZE!'RF:Q&#8&5F9\?'QR+0#
MLIT&1(UXZ44U2Z^XE!K>]=^8[ ;(F;IQ,Z%)(@1K%/$^!1G9+AHV/>$N\@*N
MHA%;V%>R@S077(6ULIE(>Y#W"Z,=YYO($L5QH'V6BU<M(P"*#J2^A=5NR@Q[
M7WOAY&"VX&=S4)O<N3Q\%]Z,X\RR\Y(E1P<6S5T5%-2N(HGO4&Q93-8C!QTE
M9F?'Q\8BT"[*=!D2->.E%-4NON)0=FLMBGXL><S.CN0I2VBR0= FG55%6P$B
MV+@*]GFH,&+W'M_.&\UALI$R#L>W/"*^V\07X(I(!+9%MP6@ZR=S;<AY)O#R
M\O#8RSI"#4%V0V#Y$Y;2B I(5ROW4MQ\E!IF=W=$G;SD;6^M<;;V,Q<)J1/>
M:?BA+>ER7' %E"D(8@C0M:S1!U*ICV)VA99'?F$VOB]O++S$?,)EIC6/')+(
MC-(8DI"Y)7EV!1;4;'H1$1?-0;?$F1,A&;F0)#<J(\FIJ0P8N-FE[7$A547^
M*@ST"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%3F/R25_L7?[!51(PO['
MQ_Z,S^+&H)U!T>!PVB!ISE.*EA<LA:5\]EX+00?!93Z37YAN@>"RGTFOS#=
M\%E/I-?F&Z!X+*?2:_,-T#P64^DU^8;H'@LI])K\PW0/!93Z37YAN@>"RGTF
MOS#= \%E/I-?F&Z!X+*?2:_,-T#P64^DU^8;H'@LI])K\PW0/!93Z37YAN@>
M"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-T#P64^DU^8;H'@LI])K\PW0/!93Z37
MYAN@>"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-T#P64^DU^8;H'@LI])K\PW0/!
M93Z37YAN@>"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-T#P64^DU^8;H'@LI])K\
MPW0/!93Z37YAN@>"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-T#P64^DU^8;H'@L
MI])K\PW0/!93Z37YAN@>"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-T#P64^DU^8
M;H'@LI])K\PW0/!93Z37YAN@>"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-T#P64
M^DU^8;H'@LI])K\PW0/!93Z37YAN@>"RGTFOS#= \%E/I-?F&Z!X+*?2:_,-
MT#P64^DU^8;H.[,7(@Z)NY!76T7O-\D!U)YKIQ2@G4"@I=S?D,;]-B?CQH)@
M_DQ^]_2E$3J*4"@4"@\RW+DG-C[KSF6B-"1;BPW/B-=JO9G%FD=L$'RJX$ED
M?>;]RJ*%R+D-BXS/;#AO(<W.Q()X9_O#JR.3(<=.<0E6ZDCFF6J>36M!@RV*
M@8N)U?Q41@4A8_;F.CQ&R1"T-Q\9)!NUT[11."T&Q[DP^,FY[IKCY4-HX3DB
M6^]&T"C9N,XQPQUBB(BHA(BV7S4%KE([$'JGMF3#;%E_)8S*QIY@B#SFHI1'
M&4.W;RR,M*^34J>6H(F\\=C,IU*V%%RH@\R+&9?9BNV5MUYH(BCJ!>!Z.)HG
MD5-7DH*KJL;F RT#.;;3P^YG\5G&GECBB./1(L GP(["NKD/HTK=^Q2LGK51
ML;>V=CETV3&.-QRVD>-\0Y-5![S:L\Q9BN]O,_\ -YM]6KO7O4&I;&5_+;MV
MK.SK(O925L=J1,<> 5<<>*2Q\H=T]8NU?-5&/8N.W7F]IRI9XW!SAW!(G'FR
MR12?$O.^(=9-I\4:)$Y2#R1!%L(BB)02=L[:>A=0\!B]RFUE,K@]I  2M*D'
M-";RT<3F7)20$1$(N/:OEH.-T1(L6=U5B1V0"+(VPSDGF$1.6LTF9[1/(/8A
MD#3:$2<5TI06LV.PQD.EO*:!I/$.N'H% 2Z8:1=5LB<;5!K.]\ME\UT]7=.+
MQ..Q6V4DP\GBW7E+VF2E-:)F6V+8BVT;FK4B*1$J%8NU4JC>]I__ #KJ!^F8
MW_\ -K%05NW<=CI75K?$^2RV]D(;6("*1HA*TV[&<U$"+V*:II4O,-J#3]ZQ
MTB;HS&V\ C(X;-9#;I9N"X1-P4FS')2&VX+2*HI*%B,+J"G?NFKUUO1NZ;9W
MA,W#M_,3&,+CQPKKB&]CRD$^Y"=8-HXR"38#H4E ^/8H(J)4%)L3;>">Z&A%
M>@M.M9+&27IRF*$;KI(X6LB5+J0K;0OV-DTVLE45FVG]S9W/X24V,"=DH&TL
M-*AKF77M2'D1<\5)9%L#13,FP;<-4U(B(G82W#-G=K9;$,R\CFF\<W'S&X]N
MR&<=CQ,V&I*3&FY+J\X1[SR(WKTCQTW6ZJM!MN1A0VNJ.W&VHS0-N8;,(X(M
MB*$G/@<"LG%/?J#CHW'CM].L$\VT .FTZA."*"2IXARUU1.-61UV)'C9#/[T
MS&2:%W<#>7=QBFZ-W&<='9:6,T"%ZK9B7.X<"(U5;U!H&9Q< L[*VM&9%=H-
M[TPRMP@XQPD2(1/S(X)Q1 4]!FVG"[A);BJ54>N;V;;9V+N-ID!;:#$SA  1
M!%$2,?!$3LJ*U3!YF;D8^/P.V,9"DY7&X7'>U<IDE4&60EL(;4<1; G'%)!4
MR2XB*6XJJVJC5]IQV9KNS-KYKD'AF<CN@F\<TBE <F8N:HQ60%RZDVTV3SC0
M%V:$7[#@&\]6F 9V3,DQ(K3D[Q>)%M%LUK4<I&4 )Q$54#4O'S5!TZ="!3\Z
MYG4OU$;?1O/$:W%(ZJ11?!^:&H75I.W5KU_*:J#MAV(^2ZH[HDY0$>G8>-CF
M,*#J71B'*:-QUUI%X(KKJ$!FG%>6@^2@T3J/#A0)^]<?B66QQTC'X;)96,VB
M*TUDW,ER1=T>J#CS(]^R(I( JOG6CV+.LMQ]MY8(S0@*0Y*BV H@JJM%Y$\]
M0:CL?;&TY'2/#X^;#C.8?(X>,_E#<051TW8P$ZZXXO'4B\=5[C9+6LE!IFPG
M]WYW*1,BC4"=E,=MW#C"=S+CZ.I'FMNF<EK0!IJD* \T_6N%NRJ)&>V?D8*0
M8^X&X"8K.[OQDH<3CN8L9LB9,7[\T1X/&"&8H*(JJ5_66@W+=L2-C]V['R$"
M.#4Y),V BM(C?,C%C9+R,%:R*"N--DB+P14O4&H;1P.YMQ=-6(P0\!.A;CB%
M)R,N2[**4_+EHI.NO$C2KS@<5>PNXHH@V04M1L.T\24??&2@YKDY#)QMO8)N
M=,)L5YTH#F"ZZFI+]\DOQXT&L-QHQ87""K+:B/4.8 CH&R N0F7%$M9$X=B4
M'N#;3;((TR MMCP$ 1!%/>1*@[4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4%3F/R25_L7?[!51(PO['Q_P"C,_BQJ"=01Y\KP,&5-TZ_#,N/:+VU<L5*
MU_)>U966ZKHCK2Z:15K&*W9D$*+]8(\=EB=CURK#\,G'5!L.7K!QM1U73FCI
M(;ZN*62NO)M[>.B9X33C^W8Y[<L\-73%4K(;ZP$")"G<TWXTV8D!%::=4VW;
M*I(X&C6*C;U5&_&L;-K?=,QTQ%65V>V(B>N:)B[C@QV9LG(.M1X\64D0";<5
MXS(@ Q%0$$)'%U_>T0EMQ][7W-TS$1TQ7]NSM9=Y$5KUNKN[MN,Q8LQR>'*F
MJ8Q103)UPV?O@BT(J:D/V0Z;IY:L;?),S%.1.6R(B:\T>1O;!,S<-%;=*0WG
M!<*'(9 W&[-V]91%;75;<>SRVK*-M?,73\/-C.:VL1\38ZY6\H% H% H% H%
M H% H(V1F)CL?+R!-D\,1EQ]6FTN9HT"EI%/.MK)6=ENJZ(ZV-TTB94V-W$:
M84]Q9Z3CXV&, ?9E1GB<:!MQ;6<,D055%5$N/E\U;[\/MZ+(F;O(U6Y/9U73
M%$J+NK;\R-+ELS@1B B%,5U"9)H22XD0N()6)/56UE\E878+XF(F.?)E&6V8
MF:\AO=. =@OY%)HC%BFC<A7!-LP,K*(JV8H=RNFE-/>\E)P7Q,13C*][;2M7
M5O<L!YU@V3!(#C,E]Q]]3CN@D100[,N-H2BFOO$JI;AVWJSANB)ZZQV\^U.\
MB?)ZD3_J!L_EJZF4 @0$=32#I*3))?F@B JDU9.+@W!//6?RF7X?VZO+V,?F
M,?7^WJ[4Z?N? 8Q6$F3FP\2WSFE#4ZG)6R<U5;0D%OCZY6'W:UV8+[JTCDSN
MRVV\Y=)>[MMP9JX^5D6FY8*VCH=XD;Y]N6KA"BB"%?NJ:HBU;=ODNBL1P2<M
MD3299<WF"Q"8[2RCWCIS$%;EIT(_?O\ 8M[6[*QQ8]=>R)E;[]-.V:,;>[-N
MNY'V4WD&RG(\4501"44D!?4TIVT(YP]35J]RK.WR1;JIPY^;K\B1ELF:5XJC
M$;XAS&I^4G2F6<4W+<A0FA9D)((FW"!+ZQ17"/2I:6P[J=OEK?DVLQ,6Q'&E
M9XQ3]O*UV9XF)F>5:=*V+=NW B1)JY!M8\YQ68FE#(W'16Q @"*EJ'[(=-TX
MW[*T_+Y*S%.7-L[VRD37FQ.[VVJQ)>B.Y-I'V'#8=2Q**/M>LRA(*BKO]VBZ
MU\B58VV68K3]NOR=J3GLB:5_;ULZ;HP98X,J$I7(1N$RA-M.N&CH*J$!-B"F
M)#I6Z$/"L>XOU::<67>6TKT,);OPOM;&XEMU7G,K'*5$>:!QQH@$@$>\(J*:
MM?E7A;CY*R^7OTS=\,T8]];JB.MT;WAB&<7"R&4D,L'-$S;:C&<Q%%M50B%6
MVT(A'[(M"(E6=O=-TQ;'+KX'>VQ$3/3YV:;N_;6/%DI.1:_XAGQ;"-:GE./V
M<U$:0ET)Y2[$K&W;Y+N4<N'G6[-9'.5PTZT^T#[!BZPZ*&VX"H0D!)=%14X*
MBIV+6B8F)I+9$U=ZBE H%!39?+RX\V+A\0PW(RTL''[OFH,,1V=*$XXHHI+<
MB$1$4XJO:B(JUOQXXF)NNFD1],M5]\Q,1'-$C[I2%[18W4+.,D8P6779 FI1
M76)*J#;C:DB$ES$FU%4NA>>Z5G.#52<?M:O3P8QEI75PHQ9_?6$P^,E26Y0+
M-;B>+89=!T1^4%591U4'Y/6J637I6LL6UOONB*<*T]=.M,F>VVV9KT+)_<V%
MB3&L=,E@U/<1O4U8E0">X ADB*(*2^JAJE_)6J,%\QJB.#9.2V)I,\74]U[>
M;=G,G/#F8VR3K(2HV9*@H"JB64U54L"=Y;IPXTC!DF(FG/DG>V\>/)S]:MOI
MC4RRS1\$KOAD72?,Y][<KE:>9K\NC3>W&UJ=Q?JTTX_MT\CO;:5JP[6W$&Y&
M,C*:Y:QHL]Z''<;U=X&4'B2%94*ZJA);A:LL^'NIB.F8B4Q9-<3,==%%B-_2
M)#L9_)M1&\9+;EOD4=XG'X;<+61')%1]54&VI.PK)9;UT9-I$1,6UK%//7J:
MK<]>=*<?-3K;@&3Q[LIJ$W( Y3S"RVFA6ZE'0A'F);[&Y(EZX9LNB*TX5IYW
M3JBM$NL&10*!0*!0*!04NYOR&-^FQ/QXT$P?R8_>_I2B)U%*!0*!05F6V_B,
MX_C9.4C(^_B)0S\>:J0JW( "!"[JI?@:\%X7LOD2@XR&WL/E,IBLS/C(]DL(
M;SF,>4B3E');Y3BZ45$6X_&1;=J<:#H6V,&<G,RW8B..[@9;C9='"(@?99;-
MH0456R)I,D6W;00L7LC#8OV8J.2YKF&==>Q3LV2Y(<CH^QX=6Q(ENH(VNE$.
M_G[:"UDX;'R\K!S3[2ED<:W(9ANZB1 "7HYJ:46RWY8]J<*#4]X[8^L>\]JK
M*ANO8J)'RA.S62)HHLD_"\@P= A,'%TGI45\]!>8/9^)P4M[)@<F?F'VDC.9
M/(OG*D^'$M:-"1\ #4MU$$1%7BMUH*M.EVU$18FF5]7U/F_5SQ3WLG7KYGY-
MJTZ-7>Y7WO\ T:"WS&U<;F9\+*FY(AY2 A-LS(+QQW2CN$!FPXH\#;(@%5$D
M[4X6H(,SI_AI&0DY*#*R&(>G.<_(MXN8[$9DNZ4%7'&P72AJB=XP027RK06S
M&WL5'RS><;:-<HU!'%C(-QPR6*!\Q!+42W75Q4E[R^>@.[=P[\[(9%^,CLG*
MQ&\=/UJI [%95U1;4%73;Y8[\.-Z"OQ6Q\+BF\:V!RI:89\Y&)*9)<?*-KCE
M%Y8$2W5M&R44$K^?MH*W_I5M$HYX]UN4[A-6N-ACEOK!BN:M:$PTA(@*A+<?
M('V-J#9X>&Q\#(9+*16E";EC:=GN:B76;#0L@ME542P"B<*"GR>P\#DLC)S8
M+)@9Z4@"[E8$AR/)T-@@(&H5LH63U%%4OQ[>-!G9V3MEK"3=ON04E8[)D3F3
M249ONRGC1+NNNFJF3G=&Q:KC9--K)8.N'VA%PTQ)@93*S.6BBQ'G3WI#+8DE
MN $O>X=BN:E]V@G8[;V)Q.";VW!85O#LLE&;84R)4:-%14U$JEY5XWH*Z7L3
M;\F#BX;(/P7,)'&'B9T)]QB7'CB M\M'1+40J(#J$]2+9%5+I09&]FXKV<&-
MG/3,DVW+8R"/3I3K[WB8A@XT6I22R"0"ND40?<XK063V'Q[^7BYUUI5R<)A^
M+&>U$B"S*)LG!THMENK0<53R4$+ ;4QFVG97LER0W"DF3@8XWB<B1R<,G#Y#
M971M",E)43AYK)01\QLC#Y;)+F0=EXS+N #,F=C)+D-U]EM540>T+I-!NNE2
M34/D5*#(SLK;,>#CL<Q!1N)BY@Y.((FYJ\:.I><X:DI.&JF2DKBKJ7MH+?(0
M8N4@2L9-#F0YK+D:0VBJ.IIX5 DNEE2Z+Y*#7I73[ /OQY$8YF.=9BLX]Y<?
M+>B^(AQD5&FG]!(IH"$6DO72ZV*@[_\ 3[:28(-MMX]&L2S)6=$::<<;.-*4
MU<1UAP"0VB0B)44"3M5.Q5H.&MB8E8,B!DI>1RS$DX[I^T)KSZH4-X9#6A+B
M@V,45;)<NQ;I06TC XN1FH>X394<Q":=C-2FR("*._93:<051##4(FB&BZ22
MZ6XT$+/;/Q&X)4?(O%(A9F*!,Q\KCWCBRQ9<5%)M3!>\"JE]!H27XIQXT&$=
MA[83"S,$<4W8F2="3DG77G7),E]L@-''7B)7")% ?LK(B63APH+^5&9FQ7X<
MA%)B0V33HHJBJ@XBBJ72RIP6@U$>EVU 9& RDQG H" [@6YCXXUU!1$^490K
M*BZ4U#?27V2+=;A:9O9V&SCT::?/@92$V3$3)8YXXDEM@[*36IM40FULBZ#1
M1OQ1+T'+>S\3X2%%F.2L@L":&4CR)LEU]Y);2*(DI$78B+ZGJ^Y06$_#8_)2
M\=-F-*Y)Q3Y2H)ZB'0Z;1LJMD5$7N.$EEH*)[I[ABE/2($O(XEF4Z<B7"QLU
MZ+&=>=6YFK8%8")>)*WINO%>/&@O(^$QT7*R<TRTJ9*7'8B2'E,BU,Q5<)M+
M*JIP5TN/:M^-!6R=C[=DXA["JP;45Z:YE1<:=<!]J>X^LGGM.(NH#1Q5(;+;
MR6MPH+J!$2!#8AH\[)Y ('/DFKKQV^R,E[56@D4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4%3F/R25_L7?[!51(PO['Q_P"C,_BQJ"=01,I'=EXV9%8M
MSGV'6F]7!-1@HI?^-:SLF(NB9ZV-T5B8:NSM)W#;6&-@&0C;A6-%9E/@XJ.N
M"SH1UMM]Q#4-0H2-K:PJM[5V3N(OR5OXVUG]J?6YXQ:;*6\Z0@,[9SS$)R2$
M0$E)FV,PW!*6;SALML-LD)ONW^454(EXZ?(BULG/9,TKPTS;6G;7EU,(QW1%
M?XJ\TG);6RSCK\^/<W6\LYD68S,DXINL/0QC*B.BG=,5U*E^"]B]O#"S/;2(
MGX:<J]-65V*[GVU^BB1C-M/1\CA\DW#\(C!Y!^>#\A93ZO3!;%#YBWNI:.-E
MX5C?FB;;K:U]VG"G)E;CI,33K^ETC[?S,"5AI@--O^#G9,Y+(N("HQDG3,7$
M54LNA%34/HJSFLNBZ.N+?_%(QW1,3VS]+=*X'44"@4"@4"@4"@4"@4&-\G09
M<-AM'7Q$E;:4M"$:)P%2LMKKY;58I7BDO,-PX3(1\-GLHWC8^)9F) %,/S$=
M8=F!,;(GW$:'2%[H%Q15*VHO)7KX<MLWVVUFZE>/93DX,EDQ;=-(BM.';7FN
M<KMO-[C/(9"1';QTHH\6+#BJ^IJXL66,M2-UI$T(2B@#INJ<2]RM&/-9CI$3
M6*S,\.N*-M^.Z^L\N7T35U';F25H,K&QJM9F--8EFQD)JS%E-QVG&D#F]Y 4
M4>)6UMZUK^X[ZVNF9]F8F.$4I7_#B=W/.(XUZ9YIV4Q69SNF4[$"&X6-R<$H
M[CJ.*CDOE(TJD"6LNA=7F]VM=F2S'PK7VK9]%:L[K+KN/9,>EDA[>G1\A E$
M+2-QL&N++2O%'U-HK)P]3N5+LULVS'7=7ZR,<Q,3_#11KM#+Q6XZ''=GLOXN
M%C)L:+/.$@%$ P+LL)MFCB_Z2>;CPZ/F+9KQI[4S%;:\VGN;H[>$1SIR6<C:
M<M(>ZHD-IEMK+1F(^/!25;(S$%BQJJ*MD5.';PK5&XBMDS^[,U]-6R<4TNB.
MGU+?<&*EY)O$#&TWA9&++?UK;Y)G5JMP6Z\>%:,62+=5>F)AMR6S=2G1*K';
M60&$;&EI'"W![6X+P\/XQ'[]GKZ4[/Y:W=];6O\ !I\]*-?=S2G\5?I8DP&;
M@^S,G'::F3,;,R3I0B<T<R/D73)"!PD5$<%%%;+P5%)+U>]LNK;/"+HMX^1.
M[NBDQQI,_2XQNU\JWF<?FI81VS*=/R$R.V2DC*RXX,-@)6345@^4+AQ5;5;\
M]LV3;%>5L1YIK_@6XIU1=/7,NWU6R'*9#0S=O<;F9+C_ /:Y..&B^KZ]B3X:
MG?VUZ?<T^<[J?_*K#)P.Y8[TER&G-@RLL]-E0X\A8CKK#C#8-W=1+B@F*J8H
MJ*2>7R+E;EQS$5YQ;2M*]/4DV7Q/#E5WVYM[-X$-M ZRT]X.+*@Y 67ETM>(
M=!X7!5Q+N"G+TK>Q<47SU,V:S)K[9B8\W#S&/'=9I[(F)8,/M_<6V_9LZ/$8
MR,AN 6.E14>1DFR1\WP<!PA5%%=6DT[>Q4O663-CRUB9F.-?HHEF.ZRDQQX4
M3-K[3FX'(Q'WR9<:9QA173:11M(=EE)(014NC8Z[#[W96O/N(R6S$5]ZOFI3
MTL\6*;9CR?;5>;8Q\C$[>QF,EZ?$Q([;+NA=0Z@&RV7APKGSWQ?DFZ.4RVX[
M9MMB)Z%M6EL*!0*#7\QC\FSF(FX\,RW*DLL.0IL)P^4KL=PA<$FS6XH8&/82
M6(57BBVKIQWVS9-EW#C6)[6F^V=470JY6W\UF#DY6>RPQ-D.XUN/!U\Q&8<"
M6,D];EK$X9:BLB62PI?M6MUN6RREL5I&KCVS%&N<=UW&>ST1-73-83<1!N/&
MXR)&E1MQ(1!-D.Z/#F<<(Y"Z&E5,40+AI\]EMVU<>7'[%UTS$V='7QJE]E_M
M1$1[7JHQS=K3'<O/25#=R&(RTEF4ZC<\X[;>AMIL@=9140T'E(0J/;V+5MSQ
M%L4FDVQ3W:]?3YR<4ZIK%8F>MQ-V=DWL?-1I024F>/-QVFGB85YO@B KH)<#
M5+V7CQ1+\*6[BV+HZM&E+L,S$_S59&\#E(ZP,W"QY^T8DM^1*Q\N;SW9 OQT
MC<Q'RU(AB(CI'LTW2_&I.6V:VS/"8CC$<N->2]W,4NB.->OS+C:>,R6.9RCN
M4;99D9'(/SP98)30&WA!!$B5$N::>\J<+UHW%]MTQIZ(B&W%;,5KTS5JV!VI
M-QSF.<G8R'C QBRRRN71UM2F1G>;\D8B*:FUU"X2O+W=/9?C79EW$75I,W:J
M4CJGA^W!SV8IB8K$12M9Z_V[5GTZQSK4![)O'SV#M!PKY(J$6(B$:1B5"1%1
M30E+W4TK6G>7Q-VF/+/\T\VS;V\*^:/)')NU<#J*!0*!0*!0*"EW-^0QOTV)
M^/&@F#^3'[W]*41.HI0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*"IS'Y)*_V+O]@JHD87]CX_]&9_%C4$Z@P39D?'PY$^66B+%:-]\T1246VA
M4B6PHJK9$[$H*+#[_P!G9YEB3C,NPY'E,0I45UQ59!UK)H91M"NH-R/EGW/6
M14LJ(M!9-;AP$B9[.8RL-W(<PF?"!(:)[F@*D0:$+5J1$552U[4&:'EL7D-'
M@)T>5S0)UOD.@[J; ^61#I5;BA)I5?/PH)E H% H% H% H% H% H% H(F4R4
M/#8R;F,BYRL?CV'9<MVREH98!7#*R75;"*KPH-7A=4=G3\<],24;$F.0MOXB
M4VK&2$C!IT?^&.QJBMOM.(HHJ:22K1%PQO':,J44&-GL<]-%7!*.W+8)U%8'
M6XFE#OW!347F3MJ*[M;LVN^4,&,W </(IJ@ ,IE2D)KY=VD0KEWTT]W[+AVT
M%1E.I.V\5EL5BG?$2!S(&["R45I7\>K;*KSC.2*\L!:%-;BDO='C5H+:9N[:
MF.,6LAG<?%<(B 0?ELMJI B*26(TXHBI>H.5W9M83%LLW 0RB>TA%93-U@VO
MXCUOO5N/,]7W:"MR'4+;<#+-887'9DH\<6;<.&WSV6L:B'HD&XBZ=#BMD(*-
M[K[Z51(Q._-G9L"/&YJ(ZH37,48*Z(&D]D4(X]B5+N"BI<4O4%E'SF)EF Q)
M;;[3D?QK<AHD-@H^K3K1P5452Z>>@RMY3&N@CC<QD@7@A(X-KZ5.W;\42+WD
M6@Y3)8\C%H93*N&?* $,5(G-.O2B7XKIX\/)05Y;JP@0"R)R$!H!(R;+@Z@
MYRU)05;Z45.WS<:M!9-3X+Q-@S);,WA4VA$Q52$5LJI9>-EJ#"QE\?(62*/(
MVL1TH[W-5 [XVNJ7[4X]M ]LXA6VGDGQ^2\?+9<YH:3/@FD5O95XIZ4\]!.H
M% H% H% H% H% H% H."$3%0-$("14(52Z*B]J*E!S0*!0*!0*!0*!04NYOR
M&-^FQ/QXT$P?R8_>_I2B)U%*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!05.8_))7^Q=_L%5$C"_L?'_HS/XL:@G4$#-P6<IA<CC)#RQX\V*_&
M=D"J(K8/-D!&BEP[J+?C0>/KT*VKGX,T<!NAY</D),-Z:Q$\+)B<V!&Y"HVB
M(J-DIKXCNKW'5(D3O5:HL7/W>]IO<TBEO@Y()5?DL-L-254IT^::H\(:A(EG
MFVI7OI%/=NJ+S:.Q\3TOA#,E96.,&/'-F7+D1V(JFZ\\&ETGE52&Z" *V)(!
M%WM.JE1NA9K# _(BGD8HR8B"LIE7FT<:1Q405,=5QU*J(E^V]14F3*C0VN?+
M>;CL(0@KCI( :G"0 2Y*B7(B04\ZK:@RT"@4"@4"@4"@4"@4"@KMP8R-FL#E
M,/->*/#R$.1$D2 41-MI]HFR,5)%1%%"NBJEJ#SJ'TEZ=9W'19&WI8'C&<:.
M%9D8TX[C9"Q-9E..<P1*[IN1Q%Q;\4_BJU1RO0S:D5I'VLA,@OQ@8(,@R3#+
M[?@TR.D^8C7!?_OBZI+_ *(^[=45!] \,&TLGC]M9%'I^:A^%CY20HHW'21/
M+(K+C+&%"1QMQQ7640]*D(ZE[5I4;KF>EFW,SC<5AW#?C8S$8R=A6&(Z@"%%
MR41(;FI5%>\@)<53[+MO16JM]+]AP,RJ9[<8S-RZF<M+"64)IPAB3XD[F\E
M30VIQ6@542UK\;\:51U7]WC:4C&'ABR4MW"&T8G&M'(EE\AR'S>;RM6E&3)O
MD?>K\=-Z5&T;VZ88[?4N$YD9KL6# 8?88CQ&F6W460RY'*S^A7$;4'.^S?0>
MD;IPXJJJ"Z&;;/(1)SDER0$.:_-:B2FFG6=$LXKSS:BB!=>=$;=;<7O!Q%.%
MK*HVE-E@<-B'(R#C@A"]GR3%EACF@A:T) :  !=7D =/N4J48W-@P)#RRI,M
M]9;AJ\\XUH:0GU<$B<TH*V56T5E?[LB3RWI4HEX[9V,QDQB8QZT1QYR-W!0A
M&0AW BXJJ(KA:>S^.E1%>V'!>BG!66\D0C60(Z6R(9*W1#U$*W%$7[VO=I4H
M[L;,;AS7\I%DI[3E&CSLAYH7$%]+CS&ANB!W"(=/9QOVWNJ499FSHLMY]Q)3
MK82W5=E@@@6M-2&@HI"NE$5/)VTJ40<AL9MQT%Q[JMH]X5J61Z%%(\-6E1!#
M0O>7E=J*G'WDI4HW*HI0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"EW-^0QOT
MV)^/&@F#^3'[W]*41.HI01Y\^%BX3^1R,@(L"*!.R)#I(#8 *7525>RL[++K
M[HMMBLRUY,EN.V;KII$<Y4VUM];2WLW(=VOE6LBD0D&2+:$!AJOI50<$2LME
MLMK+73N=GFV\Q&2V;:N7:;_!NHF<5T74YMAKC=S5F\W.3J%/PCSXCAH^$BY
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MT=0E:8 STZ515+3I3SWH(TGJ3LF,RS)++ [%>8;E^)CMNR&6HSM]#KQM 8M
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M&'L:4<N5S.79IN/+!!T67G\;I>E2CH[T4WQ)@2(\G=1%-ODWX\CQ,M!7(/M
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M"J6WO#'.O+':CRBD$I^'9Y5C?%HB R;123@*@M]5EI0J!NS")$7*M YX!PQ
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M,S(> 2/EB2JJB:@!&(N(*DB+:@UO#=1)F9<W5!GP<IC(\*1)9B9)(.@8<=F
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MG'!H;>>]0;70*!0*!0*!0*!0*"IS'Y)*_P!B[_8*J)&%_8^/_1F?Q8U!.H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ME*(G44H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MC-!X,5")I 4Y0DFE4#AW45$MPK*;[IKQY\TTQZ$./MG;\7Q/A\<PV,Q-,EM
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MIIN3"0H<4F'5)TD13YQGW>YQ2Q)6JS?XXFZ:3QG[&[)X;DNMMBMO"*?2@_\
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MFOF-"5D[Y$2#Y45*<3@]8A2AG0V)@-N-!(;%T6W@5MP4-+HA"O$5\Z+58L]
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M++.P(L(6<CB[]XWA Q)-.CO*I*"B>I+(G9\8KT:H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!4YC\DE
M?[%W^P542,+^Q\?^C,_BQJ"=0<%ZJ^\M6$EK]=+E*@4"@4"@+V511[[:R[VW
M9[>"?>CY10;Y!Q01QU;$*D"7(;(27%2%=0HNI.*5CT,NEH&4W)U?QT/)2!P;
M+,:" DP+?_WPD*(1R-.*.-<U"<30ZJ(A!VB)7IQ6D/5V#)QAMPTL1B)$GF54
MOY:K!DH*_=/M/ZNY+V+J]K^ >\!R].OQ'++EZ=?=OJM:_"HRGH>4O?\ 5EE]
MN7ADR#^WV^6V$')>%')FP]+BHZ\9#PYC(B^38*O?:)47OZ:<5X+6"'4^7MG<
MD++-OQ\N\4F=AY;$AE'F@D-J]&BM:6]*JRXG)-'/L;+J+MIQ3@S/97JA%"5B
M\7BA=6 O+C9">B/+);%'3 K@\WJ(Q!H#6PZ3->'"G$X.CN>ZOMK)8;P<1Q]M
MIY(KR@J,.JBJ@NE_Q&H%0M(HS]F-SUC;33B4AZ8VCB-@CI(3J"B&2)I12MQ5
M$NMO358L6666.)D+ 15G(P\L9$LJ\W2NCUN';;MHRZ(>4XG<'5.%C(+)89Z8
M*8_G9&?+;4I09'F CC8L\QKF +:FZ.G3J(4;0N\A).*TAM.V\OO[(9)6=PXI
MG&XYV*2@XS<W&I( PJ*I$9"2&KKEAT]U6[*I=M5C-%%BY/4X)V&3*JZN/3$N
MN9MYP&&M$AL7115Y8\7C/E&/+5!$$*XW)%IQ7@RQ=W[N:F;<Q\/&GE(#F'Q\
M_*R>29.KX@'D=+G:P!#16P(6]!*>I?5M0HB8%>I,F'B%E%/:RX3IKV620C+<
M8XS J33*ZVR5.<7+ 29X".M>U$H31WVG.ZMKG,4QNN$J8\O&C-(%84;\YY0=
M)QI$1! >4TRWI0C$M9+J%4J14FCU2JQ*#Y@ZN^S_ /K2OM;3[)Y>,\=S+Z.1
MR>]JMQMYZ^8WE.^X]?\ M?%^):/G_;IHTV:J\J>US:_-39)!-\"L,37)0E;O
M>XP.4UXE&;IQ'7S+\O\ BX5SSII/WN>^-KQTS9[]M.7N4MU:>SWO=[6:6O3X
M_'.8E(S:O0Y3D*-*4K1YA351MI"<X$HL)=HOBJGV58SIF9F.KMZ_5^U6V[Y*
MDZ=/*::NB[5PCCV>[_#2BJR<C:^F6N+C,ZXV/B)"0V[ _D-3)/\ 82J?#F(2
MN6\J)Y*PF;:QY(Z^QSYKL$1=W=L5BV-/#WKNGR],37M6NVG<:]UAV^>'988Q
M*9B*,,(HD#*MH/K(A*JW4E6ZK6[',3EBG7'^J&6'1\_C[N(BS7[.GE31/'TU
M?0?4#=>X=MS,1'P< )JY)Y6$ P-Q7'U<:$&K@0\H5$W#5XD(1T\4XWKZZ7W\
M0TZ7D.M>1TYJ-#3&R0A/,LX@6T=8"2:OKSG$)T%<,.6V(CJT+JNB\5M.*\%H
MYFNJA,RFF<1JCJ1)&>5$:EKJ=(Q<6YD CI1 Y:CJ2_K<*<4X,^$W+U!;VW,C
MY'#O/;@@M1RCR3C*/.:7EMR")M'K..MKS2$!<#G(**FC55*0Q+N#JO(?%/8(
M1WFT:L2)JB_\0T.KF(KJ&:MDJDJ J(GJZE5%IQ.#&YNOK&RXVRNUHCZ&R3JR
M0(P#G(RI(PH<PR2Q)ZZEI*^GN]M3B4AD=R75J)D9C+<5F<HON!'>6.K4,8ZM
MLN HBCZFX2DC@74DTWXHO;3B<&7;65ZD.;KT9?&N-82=8G&GA$@B@(ODI-OB
M:=[7R0Y9-JI(NK4FE;WB31Z91B4"@4"@4"@4$+<:Y <'/+$(JY5(+JP4'2I>
M(Y9<NVKA?5;MX493T/.BWAU1%GFP-J%)C1L:Q+09?R,V7)32#S(BAHVVYJ55
M1#6VE+HJ]E.)2%CBLGU&G;ECQ<SC @8F#-)M^1&*[<EE8+RH:ZU7Y-7>6HZ>
M\)=TDX7IQ.#9MJ)G!QKS>X'7'IK<V<#3SH--F<5)3GAU4640?O6BW"]NWC>B
M2NZ(4%AB_P#S?]7^FM=[;C6-:FXH*7<WY#&_38GX\:"8/Y,?O?TI1$ZBE H%
M H% H% H% H%!H<_HOTORF6>SD_;<9_)R73D2'2)W2XZX2F1&VAH"J2K=;C0
M;PPPS&9;C1FQ9CLB+;++8H   )81$4LB(B)9$2@R4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4%3F/R25_L7?[!51(PO['Q_Z,S^+&H)U!P7JK[RU826OUTN4J!0*!0*
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M1L5CY64F*21(3+DA]6P)T^6T*D6D 12);)V(EZ#)$E,SHC$V/J5B2V#S6L2
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M]B[_ &"JB1A?V/C_ -&9_%C4$Z@ZGZA>\M6$E0(J6KI<I=*!=*!=*!=*!=*
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M,AF4RXCK;VIUID>X8 8CI[4XT%-N3;'43>.W)&V<K,Q4!IT!Y\^'XAPY1LN
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MN.X*DKS<J$[%01MP[7+K?R5!28S;^_<#BF]J8N= <PL44BXW-2.:N0CPD[H
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M/8?Q"@3OC0<%64!N^M2*]ATV75?U;+>@AX3>&V-QR'HN$RC$V2P/,<9;+O\
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M/EE-24U5#)"(N)>55H&/V;M_&%CG(\=QQ[$J\N,>DR'Y3C"201MP0-YPUTJ
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MG@O<>6:") BD?>]7MH4;5M7=N,WA"?FXQM]H([J,NM2F^4XBFT#X%:Z]TVW
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M% H% H% H% H% H% H*G,?DDK_8N_P!@JHD87]CX_P#1F?Q8U!.H%! K:TE
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MI,CP]OSFW9[-CC$X<V(JM ZG R!$N>E50;I?C15E,T_]7<.BV4DV]DK>=/\
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M&VQ(C$40SMK)$2Y6X)=?+:@PPX$'',^&Q\9J)'NI<IAL6@U%VKI!$2ZT&9
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M8/Y,?O?TI1$ZBE H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ME*(G44H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M?Q8U!.H%!J.ZF,T^Q$'"&X#J/W>5HD%5'05D*Y#PU6NO&W;I7LK:TJ L?O\
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MQLB+0H(C2JND=.L5"QKZ*#UT$- %#+4:(B$2):Z^5;>2H.U H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M92)X_'/0=6CQ,=QG7;5;F(0WMPO:]2&4M=':LHWW)+N1<;?=1L55A3$ ;$1
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M3VG@_P"]3[5::C3VG@_[U/M5IJ-/:>#_ +U/M5IJ-/:>#_O4^U6FHT]IX/\
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M=5M6FR\$*W>3L7RT%Y0*#J^TW(9)AX4-ET"!P"XH0E=%1??2@KGMNX.0IJ_
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M H% H% H% H% H% H% H% H% H% H% H% H%!4YC\DE?[%W^P542,+^Q\?\
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MSU];;EU2W"UJHMLC,?Q4[#[2Q$=,_N=6)$UN?F'11(L4#%LWG70;4E)2=%L
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MO^+0-&X/P\/YEW_%H&C<'X>'\R[_ (M T;@_#P_F7?\ %H&C</D?A7_V+O\
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MV#:*!0*!0*!0*!0*!0*!0*!0*!0*"MF?M?&>](_L#065 H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M'N\"1$1%3CP5$1.*4U0:99&-OMQGSD,11;>-54B%4XW]R]J:H-,I7@I7X/\
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MM\:9[)K]-(7=:FXH% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MH*?,=0I^$R\N"]BQE,-&VC",N6-6G&B)%(E111TG!1ODEI5$77J5*4*NY]3
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"MF?M?&>](_L#065 H% H% H%
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M9()-J/JD*+VU!0XWICD#R^)R>\]V3=UM;==63@H4IB+%:;E<LF1DR/#@//?
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M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K9G[7QGO2/[
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MIN#<F#8^L<US.(\R3Q162PK;B,H"%I]9/55%MV)6,,Y3-HY#9,R5TIS\LO\
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M03!_)C][^E*(G44H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MF<5\ENQ:J-0#K'DWGH$)IO%BLB9,A+ED.6]"?6"W',N0#;2NH2$\31HXB()
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M6L+D>LV!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*([N>NO\
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MIY]N4R;$?\H=%P5!NP(YWU1;#W20N/D6]!G$A,4,%0@)+B2<45%\J4'- H%
MH% H% H% H% H% H% H%$3D[$K4WH.;_ &+D?T5_\65!G@_D,;_9-_V4H)%
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M;T7>OJE^@^&^+8=[;[/"_IMZ?-UPWZO+>P44H% H% H% H% H% H% H% H%
MH% H% H% H% H%$=W/77^+^:I#*6C]1MNIGXV#1O&-Y%V-FL8^]K;;<5N*U*
M WBNY]B@I<D2JCS![9?4%T\UEHN*&,YO.+-9F0X[O(E W$>%W'QY+BGRP0H@
M.PT)OU%=2_#C15CE,)G]TS8T##X!<+MV/D,;*BE*Q,9DHIC'FM/"XP3B@^VV
MBM6*W=4^[>W BKQ^Q\O#P;GM'%3X,^$&)7&^$C,Y0?'PF)K+NN.X6ER.O-72
M*Z="&.E044)"K',;8WE-?R#>&Q9Q<[N#%(.XF#;;"!&ECCP;MC\A?F"A* QE
M:34/$C[EE4@O86T(&Z\U)(-MR-M;6<Q#>.G1W6VH9R);<EMYA$9;4Q)(XB8\
MQ>Z7,TC=$6B)^]<7D\4NW8NV&R63"@Y2)@S=L;3>5*&B0R=4[BBJ(.BA'PNM
MO+0:XA=06E;D8QO//8=K(0B@XO**@SI?R/+E _(:)"89$E%T"-5 C0T5.6HT
M'"X3J4K)\A_)PEB\DHK$,HS#)D_N&5XE2;$;$JP2;+CV#WD[_&BN[D7JD&2B
M8XID^-AV)<UB#D>64U^XY+5'.4+1CK;6-84)VXVU:N]9:"+,VSOIP<#EYQ9>
M;EB^LH26E? VF'98FD '&1LVK&EL1&XEQ5-?K+03APW4081R>9D%>)[P"8M2
M8\&..7;HHJHRB:?RY.WMU</4X4%?C<9NO#Y5QU^)DHS<C(0IF85P62PCF(;P
MT5F>KK8:KN*;9@@H.K6(Z?D[T'H?3&;(+;,/"S(\EJ;AXT5E]Q]M6VUYS O-
MM@1<2)ILP%SAP+AVWHDMTH% H% H% H% H% H% H% H% HB<G8E:F]"S2(N&
MR**MD6,]Q7L3Y,J"DA[NA,8]M9C)QSC(VW, N*Q]:(@([P2Q&G$4%%3W:M$2
MX^[<9)%%:;D:C51; FE$C)O[X@W7M;3B7N=EZ4*LN/W1BLDA&P1@T+2R$==!
M6P)H>TA5?62W'AY.VE%0,=O:'D(I2TCN VTV1O BH;@D%NX@IVJJ$*I[]*)5
ME3>$-76&DBOES1=,C$441&.NEU46_'02Z2_DO2@R!N[&K$*8ZU(8$.4I@XWW
MQ%X5)"L*K<405523A2@Q%OG!@($YSP4T4Q!62UJ(CK(D'M5$X(JIPNOOTH5=
MW-Z81J0,1Q7AE6^595HE)I;V03MV+=4]*+V+>E"JVQLY,C%24C1L*IN-JRY;
MF"K1D"H2(JHB]WSU%2Z!0*!0*!0*"FS&X Q$IB,4<GN:!.FH*B*("0BJHBI9
M?6\JIZ>%41AWMA"6/IYZC+6T4D:)4<02TFHVX]Q>!?R7I1*IKV=8C<_Q+1BK
M,A8XBW9Q306T=4^%K(@JJK?CPJ*CP-P.SUQBA#46LF#CPJKB:VV0]4R&W%"[
MO8OV547M0*"EW-^0QOTV)^/&@F#^3'[W]*41.HI0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0?(/[U_P#\]Q/_ "AO_P!S(K] _MS_ *]W\WV0_*?[O_[5G\D?ZKGB
MN%PV1W#EH>$Q#"R<G/=%F,RBHFHR\ZKP1$2ZDJ]B<:^CS9;<5DWW32(?([;;
MW[C)&.R*W7-PR>Q=F89N9"G[^BEN2&+G,@1($F1%5]I%NPDI%05)533?3IOV
MK7G8]YGR4FW#.B>F;HB:=>E[>7PO:XJVW[B-<=$6W3%>K4SL=.=MQ=K8'<^Z
M-VKAAW&#QX^,WC7IR"D9SEGS#;<&UE5.P5K&=_ENRWX\>/5HI7VHCGYF?Y1@
MLPV9<N;1WE:1HF[EY)5.X^G&=P<S%LP%#/P,\T3^"R&+$W0F "7,0!4UHX%^
M\%KI6_!O\>2VZ;O8FSWHNZ/N<N\\'RX;[8L_Y(OBMLV]/7PZX:V.*R9194X8
M3_@H)HS-D\LD:9=);(#A*EA)5^Q7C7;WME8BL5GEVO+^6RZ9NTS2WA,TY3U2
MV+8NRXF[DS4G(99,-C,#"]HS9/AREFK2%I5!;$@553WZX]YNYP:8MMU3?-(X
MT>EX;X;;NXONNOT1CBLS35P\E83<OT[CQF-OY; YUK,[;W%-]F1LAX=R*\S)
M0A$A=8<55X7OW26]O>K5BW\S-]M]FFZR-5*UK'9+IS>#VVQCOQY-=F2[3JI,
M4G^667=^P]H;2/*8XM\-3=RXLE;/#AC93:F\BI<$>55;2R+>][5CM=[FS:;N
MZI;=TZH^KFN]\+VVVU6SGK?;^[HNY]5>3*O37"XK%8J9O/=K.W\CG(8Y+%P/
M R)J+&<NH$\\U804K>JB$J>6U3\POOONC%CF^+)I,ZHCCV0R_)L6/'9=GS1C
MG)&J(TS=P[9Z% SL]UW8$G?OBQ%F/E!Q"X]076I&TCO,UWLB<;6M77.ZB-Q&
M&G.W57ST>=9X?JV=VYU>[=ITT[(FM?.[ELMP-H87=JS!5O,Y)S%#$Y:ZFB:_
M\Q2O947S6K'YO_FNQ4]VW55NCPNNWQYM7]2[32G+M1]\;6<V3NK([6=E#.=Q
MQ-B4D 5L3YC0.<!555+:K=M;-IN/F,5N2E-7K<GB&S^4W%V&NK33CRYQ$_:W
M&#TMV;D,!.W,QU!9]D8LF&\FZN)F79=E61L=-]1W7A<4KSK_ !'-;DC'.'VK
MJT]NWC1[=G@VUOPSFC<>Q;2L]W=PKYZJW&=.L1*QN4W1D-T-P=C8^<F+C9I(
M3[[TN00(XFB,BB0#94NKA)6W)O[[;K<<8ZY)C5IU1%(\K1A\(Q7V799RTQ6W
M:8NTW36?Y>;3\W"QV.RDB'B<D&8QS2CR,DVT<<'A(4)51MSO#9545OYJ]'#?
M=?9$W6Z9ZN='B;K%9CR3;9=KMC]ZE*^9N,3IUA(N#Q.9WENQK;I9]HI&'BI"
MD3E-D2TZWC:L+:+YDU+QKSKM_DG)=;BQZ]'O>U$>BO-[EG@^*W%9?GR]WWD5
MMC3-W#MIR1MK;#Q.=P.:W-E]R-X/"X62S$=D'$>EJXLFZ-D@-*A)=?):L]QO
M;\>2W';9KNNBO.(Y>5KVGA6+-BORW9=%EDTKIFZO;PXHC&R6\]NJ/MC8N5;W
M$,AOFIDE9<@,-H(J3JN(]Q$6T3B7EO9.-;)WDX\4Y,UNBG16)\G+K:(\,C-G
MC%M[^\K'O4FV(\M>K[DG,[3V/C8,E86^V,GFXO;!CX^2D=TD)!(69)+I*UU6
MZBB*B<%K#%N<]]T5Q3;;/3JBOGAMS[#:8[;J;B+KK>B+)I/DNK25\QTMV5)P
M,K<[/41DL%"?;ARI7LB8B@^\EP'0JZENGE1+5RSXCGC)&.</M3%8C7;R=MO@
MNUNPSFC<>Q;-)GN[N?DK5K,S9#;&S)V]X>5"9BXN97"QQ1DVC?#E\P9":EN*
M$GV"I>NVW>3.:,,VTF;=7/EV?>\V_P ,B-M=N+;]5L7Z8X4K'Q=GD6[O33#8
M-J$SOO=K&W<YD& DLXH8;TYQAIWU%EFVHHU=.-N\J5SQXA?DF9PXYOMMFE:Q
M%?Y>MVSX-BPQ;&XS1CONBNG3-U/+/0XA](LN>_F]AY6>Q!)Z,YD(^7!%D1'H
M;;9.B\VJ*-Q)!7WK4N\3L^7[ZV)GC33RF)ZDQ^ WSN_E[[HMX:HNYQ,=?0PQ
M^E>5+>64V;.EMQ7\=!D9-F<(*ZQ*C,-\ULVE14N+HKP6_#BG:E97>)6=S;EB
M*ZIBVG5/;Y&&/P.^=S?@NNIIMFZ)I6+H[/*T%%NB+Y^->L^<E(A39F-EL3\?
M(<BSHQH['DLDK;K9CV$))Q1:POLMOMFVZ*Q+;BS7XKHNLFDP^I>E'[PL/.<C
M;V_'&X6:)4;C9BR-Q9*KP1'O(TXOG]0O<KX?Q'P6['6_#QM^'ICR=<?2_3O!
M_P"XK,],>>=-_P 71=Y>J?H>^*BHMEX*E?+OLW% H% H% H% H% H% H% H%
M H% H% H% H% H% HCNYZZ_Q?S5(92TS?F?W-M\,6]@6H#S<^=%QC@SE>$A<
MFO"T!BK5T5!O=47M\]5&JR.L,J([O&,Y"B//;;@/3(!,R+^)=QRHS/1UM$(V
M@:?,1"]U(>-%HDX+J1N#<AMXC#PX$C*NR9;;>61QY,8<7'@QSW1 A%Y3!U\8
MZMK;O7+5IHCK/ZB[GB9C<6'9B0)$[;T('_! DOFS'_ C,<1MQ 5ML552 $,E
M);4&'<?65<;%G9'$0&)>/9* W!>DR1C)(-Z(64FV4N"<B$@F*<5)PM-%HV^%
MN7,S]S,1(F+YNT94()3&;%5L1N C@\%2VE46UNV_'LHBE3JY@8+:.YLQ8&2_
M*.(+'>)O'197@TD/H:BO><0ETMH2Z?(MBH4=9'5K&ADFB:C/AM]OVHS)EO,.
M"\_*QDAB*@0P3BZA/.DU>W>*VFZ<:%':=U8A,S6<='Q4T7S:RGC79+7+& _B
MF&GU"0 JI*A@\!B36JXJEKWH491ZJ8A6#;5F0DH&E;6:L9U,>LY,:F3Y(FO?
M6[*ZO5\FF^OA0HC8KJ@4QZ7!E1"9?<F,8[$9)&75QQR)F.CS& ><]85,W5'@
M/#NBMB6U"C<ML9L=Q[?QN<%OE+.8!UQF]]#BI8POPOI)%2]!;4"@4"@4"@4"
M@4"@4"@4"@4"@4"@41.3L2M3>@YM;8;(JG;X5_\ %E08\?BL8,2(8Q&D(6DT
MKH3AS$12]*T$E<; 5D&%C-JRVJ$ ***B*BHJ*GN\$H XW'@MQC-7L0I<46PG
M?4B7[$6ZW2@R+%BJ9N*PVIN\72T#<K(B=Y;<>"(G\5!&9PV-8FOY &!\5(!&
MS->*(")ZHIV(B^6W;Y:#,WCX+2$C<9L4+B2("6X7]SW5H.B8G&II5(K=PMI7
M2BJB(ED3WK>2@R' @N%K.,V1JJJJJ"752#0M^'&XHB<?)0=HT2+#;Y41D&&D
M^P;%!3AP\E!FH% H% H% H,3T:/(0A?:!Q#'06H46XJM[<?)>@ALX'%1Y#LI
MN,*/.JVJK;@*->J@)V"B?Z/;Y:"4]#B2!4'V&W!4Q<5"%%13&UBX^5+4'<&&
M&U0FVQ A'0*B*(J#>]DMY+T&2@4%+N;\AC?IL3\>-!,'\F/WOZ4HB=12@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@^0?WK_\ Y[B?^4-_^YD5^@?VY_U[OYOLA^4_
MW?\ ]JS^2/\ 5<\UZ7[OC[%WUB=S3&2?A1B<;E@"7<1F0V31$"72Y"A:K>7L
MKV/$=M.XP78XYSR\SPO!M[;M-U;DN]WE/G6>;V#MT?'9?";[PDK#IS9$..^Z
M^UDC[3%DF%:7OK?3?5:_;:M&'>Y.%M^*^+N4\M/EK5W;GPO#=-V2S/CFWC,5
MF=772C8LE"Q&\>FNP<9&W1A<7-P34X<I'RDI6'6UD/H06 0,BX"MT3W*X\=]
M^#<Y;IQWW1?IIIBO*'HY\6/=[/!9&7';-D3JU74GC3H1,UG,-)#8W3_:&X C
MP]LNO29&\)"'$9&9(<YIN,H7?0&^.CXZJB>[6>+#?'>Y\ME9R4C1''A'7Y?H
M:\NXQ3W&VP9(B,4S,Y)X16M>'T^7@G]5=V[?WGMXG=M9-N&WCLD^>3PQB$8\
ML^X@ F6 0$4,CMQ N(I=>'EU>';;)@R?\EM=5L4NYZ/X&[QG=X=U@F<5T6Z;
MIU6\(F_E_P D=:@Z4;DQ^VL?O=^6]$"7*PRLXV-/;%]F3(1S4C7*-%$[I]BM
M=?B6"[+=BB(FD7<9CHCKKT//\#W5F#%GFZ;:S9PB[]Z>JG3Y%MG=UX?<V*Z=
MYMR9&QV3Q,](F8P,9$CPX[02!<&6U&!-+:&(_*$G;P\U<^';7XK\UE)NBZVL
M73QF>'NUZ>QVY]YBSV;;)JBR;+XBZR.$1%?>IT<.:^ZIYV7G0W(] WGM>9MV
M42O1<6PVW[6<:!1(6Q<2,A*XJC^%X^>N7P_#&.;-6+)%T=/[O^KEYG?XMN+L
MMN33FQ39/*WAJ\G+FP[&RL7%8>#%WAO+;^;Z=)'(Y6W)8.2<E')QM55F,V32
M. 8DMKBYI\U9;O'-]\SBQWV9:^]'"V>V>-/H:_#\T8L=L9LV/)AT\;)XW1PY
M1%*_3YFL;9G[?SVP<]T]<R<? 3'LN&:PK^4-0C.MB'*5AQX4) -!1%NJ65:[
M=Q9DQ[BS/IF^-.F[3SZZT>9M,F#-M<NVU1CF;]=NKE3A%)GK<[FR6!P^U-H;
M#Q^6CYF;C,D[E<QD(6HH31/&@BTVX2#KL-R(D2U,&/)DRY,TVS;%UNFV)Y^6
MC9N,V'#AP;:V^+YMOU771[L<>M8=6L)@]R;IW#O7$[SP+T.0(OQ\>DAU9KG(
M8$% 01I1U$H=WOUK\-S9,6*S%=BOK'"M.'&?*>-;3%GS9-Q9FQTI6(U>U-+8
MX<NS@H-MYC%1>DF^,-)F-,Y;(2\8Y!A&MG7@8=NXH)Y=*<5KJSXKYWF*^(]F
M(NK/5P<6US8[?#,V.;HBZZZVD=,\82^F,O-8Z%+DX;>F%P;;SNC(X+/*2L2&
M0%%1U6R:< [W4>ZJ%PK7XA;9?=$78K[^'"ZWG'9SAN\&OR8[)FS-996>-E_*
M8Z^7U>E0]3IFU)^\Y\K9C3;6$-&T_P"' FHQR4!.<;#9<1;(O52NKP^W+;AB
M,OO?33HKVO-\:R;>_<S."/9[.4STS$=3T+IYE?9>'QS&X=Y[?G=/B3FY3:V4
M$Y,R.AH2FU':)E20[E=% ]-^-O/Y&]QZ[YFS%?&7HOMX1/;,U?3>&YN[QVQD
MS8[L-/:LNXW1V1%/VZG7ISN+%0-M;UQV!S>,V[+R&4CO8,-PZ76_ M$2V(3;
M>120+#?2O&F^P7W9<5U]MU\1;.K1U^F#PS<X[,&:W%?9CF;_ &-<_N^>O1]*
M+B]X1=L]1)4S=N8QV:QN=Q#N)R.4VXTB-1FI'=%1 6FN^*@FO2/JK?BO"MF3
M:SEVT1CMNMFR[5$7]-//+3CW]N#>S=FOMOMOLTS=CY17S<^#3\WL+%XG'R<E
M!WK@LM%:1%AQHSSR3Y"7043D$WW"MQ5%.U>CAWM]]T6SBOMGIK$4CSU>+N/"
MK++;K[<^.Z(Y1$^U/^7H]*7BLOBV>C>XL&[+:#,2LQ"DQX*K\J;+0(A&*>9*
MUY<5\[VR^GLQ;,5;MOGQQX7DQS=&J;XF(Z:<$B+GL8QT2/"A+97/CN9K(-XX
ME^55AN.B<Q1^+JX5A?ANG?:J3I[NE>VK;AW5EGAFF+HUQDKIZ?1U+O?43;75
M3.)OC&[LQ>&+(1V$S.+S+CC$F(^PVC1<H1 T>!4%%'2O_AS;2[+L\?<W8[KJ
M3.F;>,37KZG7XABP>(Y8SV9K+-41JMOFDQ3JZUSCNH&TY'5'!*Q.%G:6VL _
M@HV6FHK7B2&,8<Q1*ZHADJ(*+QKFR;+-&UNK'MWWQ=2.CB]##XGM[M[9$74Q
MXL>B+KN%>#!TSW_MV7M]86\9HP=P[<QD^!@I[RV&5CYC"@D0RM?4T:"K?^CP
M3RUGO]EDMR5Q16V^ZV;HZKHGWO/TM7@_B>&_%IS71;?CMNMMF>%;9CW?-PIV
M>=X2**@HB\%1$NE?4OSZ>;F@]/Z7]%,_U#,<A*U8K:@K\ID7 [[Z(O$(P%ZR
M_P"FO=3W5X5X?B'BV/;>S'M7]75Y?5S?4>$^ Y=W[=WL8^OIG^7U\O*^RL)A
MX6W\1#PF-YG@(#0LL<YPGG=(^4C-555_@G"OSW+DNR7S?=SE^LXL=N.R++>4
M>=/K4VE H% H% H% H% H% H% H% H% H% H% H% H%$=W/77^+^:I#*5/F,
M7B<X<.#D"U/0Y+&4CL@YH<YD-U# U1%NHH=K^3R54:;)V/TM#$Q(STB/'B@$
MR&,Y)HM/2$R *LD77]2*ZIZD<74JKJL5!93-G[/RV07,1I[D;+39:2HTZ!+1
MMU)*Q&VC1JRJ*H[':;5P-*H2")6NB+0<LX/;.$R[VX"W"^P\ZXS'R+;\\$C2
M)4:,+(\X#X<U6T%21+7X+:@CX?8'3C#2X6&B-QWI>,&<Y'QDE\9)C[3=%Y]T
MFG%)56R" $2=UONI8:"\VW]6,)@V\/A<BR[BL(VD<B*4,A8[8*J"#AJ2JFE$
MTIJ7@B6\E!2,["VW&E1<Q[1-IY)+OLV2R;32%&G2/%>#NJ$+H*\I$'#5QLB^
M<)$C8&S)P#A7$(G(3<QP(X221]E,O+26;J6+4*\YI":/[%1[M!Q_TOVV2-&Z
MY->EB<PY4QR29/RO:3 QGQ?7L(5;;;$41$TZ!TVM0JD_].ML^"\!RGO#^)\9
M;G'?G)C_ &7>]^SD<+?&[W;0JKW.G&V(DYEV--D19ANA*@0W9).QEGPX8169
M*1C6QFTTT!6]6Z:E35QH+?:> A[<&3C(>3=FML!%9"$XX)#$!F.((B /JDZJ
M$\9+ZREYD2@NER6/24D%9;*32+EC'5P>:IZ%=TZ;WOH13M\7CV4&9N0P\;K;
M3HFXP6AX!)%(#5$)$)$[%LJ+Q\BT&2@4"@4"@4"@4"@4"@4"@4"@4"B)R=B5
MJ;T'-_L7(_HK_P"+*@SP?R&-_LF_[*4$B@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@I=S?D,;]-B?CQH)@_DQ^]_2E$3J*4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M'R!^]>J?7W$IY?9#7_N9%?H']N?]>[^;[(?E/]W_ /:L_DC_ %7/!Z^H?$%
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M@W#8)F.WRB+F P31FCJ]WO=V^HJ(M-VX.;@XNUH.V 1&,:4R/CD?17FV\@[
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MY3((YCL;-RY8EV9<VVXN)@L<M&6E14Y(2'F-)F-KZK7]6@CIC<%D7%7V:,+
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MY:"KQ@8UN?EPAND[-*2#N10[KH>-AI!%%5$2W+$%LE!:4$27CH\V3"E/J6N
MZ3[ H5@5PVC9N2>6PN%;W:"70*!0*!0<+=45$6R^>@K\/AHN%8=:8-U]^0XK
M\N7)/F/O.DB)J,K(G!$011$1!%$1$1*"QH% H% H% H% H% H% H% H% H%
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MC/WIO^JG\U!WH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MQ4]%*E#0'Q4]%*E#0'Q4]%*E#0'Q4]%*E'.D52VE+)V):HM'&@/BIZ*M4H:
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M% H% H%! SG[%R7Z*_\ BRH)C/WIO^JG\U!WH% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M5$)7E&0G<OP02+BG"E!!9ZDYZ:P])A8=H&'Y;4#'.RG%: 'W)R0M#^G45_\
MS>Z/"VGM5%I0JLMS9/)8C<6(FSY1K@=+#,B+ >!MT)KSJ@CCC!(IOLN*H@B
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M253!S0"IJLM[HMJ4&ZQG3?CLO.-DR;@"9,GZP*2(JBONIV5%1<Y^Q<E^BO\
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MOKK 4$@5_4;>A$1$5$\E;<UD7=Y=/5;,>2:?8TX,DV1BMMX5NOB[MF(NF?\
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MRH)C/WIO^JG\U!WH% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MBZN9QLO!?XZ#:JBE H%! SG[%R7Z*_\ BRH)C/WIO^JG\U!WH% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MNH2>&#5I16@5>]Q)22@]%J*4"@4"@4"@4"@4"@@9S]BY+]%?_%E03&?O3?\
M53^:@[T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K9G[7QGO2/[ T%E0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#A1$K:D1;+=+\>*4'- H% H% H%
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M']@:"RH(4N8Y'<0 $511OQOYZV6VUAKNNF)8/:;_ ,0/Y?AK+1##O)/:;_Q
M_E^&FB#O)/:;_P 0/Y?AIH@[R3VF_P#$#^7X::(.\D]IO_$#^7X::(.\D]IO
M_$#^7X::(.\D]IO_ ! _E^&FB#O)/:;_ ,0/Y?AIH@[R3VF_\0/Y?AIH@[R3
MVF_\0/Y?AIH@[R3VF_\ $#^7X::(.\D]IO\ Q _E^&FB#O)/:;_Q _E^&FB#
MO)/:;_Q _E^&FB#O)/:;_P 0/Y?AIH@[R3VF_P#$#^7X::(.\D]IO_$#^7X:
M:(.\D]IO_$#^7X::(.\D]IO_ ! _E^&FB#O)/:;_ ,0/Y?AIH@[R3VF_\0/Y
M?AIH@[R3VF_\0/Y?AIH@[R3VF_\ $#^7X::(.\D]IO\ Q _E^&FB#O)/:;_Q
M _E^&FB#O)/:;_Q _E^&FB#O)/:;_P 0/Y?AIH@[R3VF_P#$#^7X::(.\D]I
MO_$#^7X::(.\D]IO_$#^7X::(.\D]IO_ ! _E^&FB#O)/:;_ ,0/Y?AIH@[R
M3VF_\0/Y?AIH@[R3VF_\0/Y?AIH@[R3VF_\ $#^7X::(.\D]IO\ Q _E^&FB
M#O)/:;_Q _E^&FB#O)/:;_Q _E^&FB#O)=VI[IJ=Q'N@1):_:G\=2;(6+Y=/
M:;_Q _E^&KHA.\D]IO\ Q _E^&FB#O)/:;_Q _E^&FB#O)/:;_Q _E^&FB#O
M)/:;_P 0/Y?AIH@[R3VF_P#$#^7X::(.\D]IO_$#^7X::(.\D]IO_$#^7X::
M(.\D]IO_ ! _E^&FB#O)/:;_ ,0/Y?AIH@[R3VF_\0/Y?AIH@[R3VF_\0/Y?
MAIH@[R3VF_\ $#^7X::(.\D]IO\ Q _E^&FB#O)/:;_Q _E^&FB#O)/:;_Q
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MEXC#L \F;PQ/JS'E..J*8^2KW I*-:7CY=D%%1%3BEZ4>ET0H% H% H% H%
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MF7T4"R^9?1034[$K4W(.<_8N2_17_P 65!,9^]-_U4_FH.] H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H*V9^U\9[TC^P-!94"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@@9S]BY+]%?\ Q94$QG[TW_53^:@[T"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@K9G[7QGO2/[(T%E0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*"!G/V+DOT5_\65!,9^]-_U4_FH.] H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M8E H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M'I;_ !946:P$J$^W)BNIJ;?9(7&R3SB0JJ+7FW6S;-)BDNZ)KR9JQ4H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!P7JK[RT%-A#584?
M^HE5%U44H% H% H% H% H% H% H% H% H% H% H% H% H% H% 7L6@I,EZ\?
M](9_&)51=U%*!0*"DW9NW;^R,%)W'N68$+%Q4[QEQ,S7U6VQ3B9EY!2NC;[>
M_/?%ED5F6K-FLQ6S=?-(A\O9#?W7/]X&2]#Z8P7ML[$U*T64<<\,3B)W2YDI
M$4E7CQ:CHMO*JU]?9M-EX?%<\Z\G5S^C[9?,W;G=[WA@C19US^WU+7;_ .Y=
MB.[*WGN>7.F&JF^WC@!@5)?[U]'3+W]*5IR_W+?RQ61$=OW496?V_9/')?-T
MUZ/VEMX_NB=(4%!4,F2VMJ6:M_Y 1*X?U#NOX?0[H\%VOPM:W!^Y;M&4!'MK
M<$_'2+*H!-%J:UJ\G$49-$_UEKKP_P!RY8]^V)\G#UN/+_;V&:Z+IM^F/L:R
MS(_>'_=U)'LF*[PZ>QUN^H.')::91>*B9)SH]M7V2$W?SUUS;L/$>%O_ !Y)
M\WW3];5JWNQXW?\ )CCTQ^WH?2G3GJ5MCJ?@ SNVWU+2J!.@NV&3%>5+Z'!1
M5[?L23NEY%[:^4WFRR;6_1?'DGHE]%MMU9N+-=G^#;ZX744"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%7G/O43]*;_F*@EQ/5_BH)- H
M% H% H%!#F4&+!?LIC_7_&%06- H% 541%55LB<55:#YLZB?O%YO)YQS870W
M'+G]P(JA(S+3?B&&B%;%R17N$@^5UQ>7YM7;7U>S\'LML[W=3HMZN7I]4<7S
MVZ\3OF_NMO;KNZ^B&KX[]U3?V]Y29WJSN\TGNIJ*.V19"0'DTJXXHM!9$[&Q
M)*[+_'L&"-&WQ\/1'K<D>#9<TZMQDK/5#?(?[GW2>.T(2'LM+=1.\XY+$+K[
MS;0HE>;=_<6ZF>&F/-][NL\#VML<8F?*CY3]SCIC+9(<;.RN/D?8FC[<@/XP
M<:NO\1)6>/\ N/<VS[46SYOO89/ =M=RK;Y&B/\ 0/K;TBD'FNE.XURL-M5-
MS'MKX=UP1XV.*Z1LN^;@6KS)7HQXML]Y&G<6:9Z^?T\X<7Y;NMK.K!?JCJ_;
MAY_0]2Z0?O#0=[3DV=O.)]7.H+*JT<)X2:9DN!VHVCG>!SSM'Q^*J^3Q_$?!
M[L$=YCG7CZ^K[NUZFQ\3MS3W>2-&3J]7J>X5\\]HH% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H."]5?>H*3!?D<?^HE5%Y44H% H% H%
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M[HOSTZ+;9CT2C])L?E5W!N3!XA).QG7]H,$QC)<US)<Z=,U(WF6S4S $#@)
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M0YE!BP7[*8_U_P 85!8T"@4"@4"@4"@4"@4"@4"@PJPA2ADKVB"@/\:WH,U
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MJ.OG;=;Y:=*)NGIVT&[-T>S7XF V=AY+(!-R;SO);6:TCS$<-(O/.N**DM@
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M>R\,V^2=IJB9[WO-?&>.F9IY/,B9#I[@\;)WB0D4O%L89O.[4E(XJ:XLF0V
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MY(?-7'W2)QUPEN1&2W557SJJU@\^ZZ;IF9FLRQT8E H% H% H% H% H% H%
MH% H/LG]VG_MH'Z?)_\ L*]/;>YYW[3_ &E_T(_FN>OEZJ^]74^O4F"_(X_]
M1*J+RHI0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0* O8M!29+UX_Z
M0S^,2JB[J*U#?G3/:?4AJ"SNJ.[(#'$X<5&7C9LKR"A7T*E_52N_:;[+MIF<
M<TJ\_>>'X=W$1EBNGMHTK_*_TB^CI7ZX]]U7H?GV[ZX]$/-_3NR^&?Q3ZS_*
M_P!(OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO](OHZ5^N/?=4_/MWUQZ(/T[L
MOAG\4^L_RO\ 2+Z.E?KCWW5/S[=]<>B#].[+X9_%/K/\K_2+Z.E?KCWW5/S[
M=]<>B#].[+X9_%/K/\K_ $B^CI7ZX]]U3\^W?7'H@_3NR^&?Q3ZS_*_TB^CI
M7ZX]]U3\^W?7'H@_3NR^&?Q3ZS_*_P!(OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^
ML_RO](OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO\ 2+Z.E?KCWW5/S[=]<>B#
M].[+X9_%/K/\K_2+Z.E?KCWW5/S[=]<>B#].[+X9_%/K/\K_ $B^CI7ZX]]U
M3\^W?7'H@_3NR^&?Q3ZS_*_TB^CI7ZX]]U3\^W?7'H@_3NR^&?Q3ZS_*_P!(
MOHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO](OHZ5^N/?=4_/MWUQZ(/T[LOAG\
M4^L_RO\ 2+Z.E?KCWW5/S[=]<>B#].[+X9_%/K/\K_2+Z.E?KCWW5/S[=]<>
MB#].[+X9_%/K/\K_ $B^CI7ZX]]U3\^W?7'H@_3NR^&?Q3ZS_*_TB^CI7ZX]
M]U3\^W?7'H@_3NR^&?Q3ZS_*_P!(OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO
M](OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO\ 2+Z.E?KCWW5/S[=]<>B#].[+
MX9_%/K/\K_2+Z.E?KCWW5/S[=]<>B#].[+X9_%/K/\K_ $B^CI7ZX]]U3\^W
M?7'H@_3NR^&?Q3ZS_*_TB^CI7ZX]]U3\^W?7'H@_3NR^&?Q3ZS_*_P!(OHZ5
M^N/?=4_/MWUQZ(/T[LOAG\4^L_RO](OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_
MRO\ 2+Z.E?KCWW5/S[=]<>B#].[+X9_%/K/\K_2+Z.E?KCWW5/S[=]<>B#].
M[+X9_%/K/\K_ $B^CI7ZX]]U3\^W?7'H@_3NR^&?Q3ZS_*_TB^CI7ZX]]U3\
M^W?7'H@_3NR^&?Q3ZS_*_P!(OHZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO](OH
MZ5^N/?=4_/MWUQZ(/T[LOAG\4^L_RO\ 2+Z.E?KCWW5/S[=]<>B#].[+X9_%
M/K;1L;H]L?IUDI.6VO%>8F2F/"O$Z^X\BM:Q.R(:JB+<4XUQ;KQ+-N;8MR3%
M(FO)W;/PO;[6Z;L<4F8ISF4C??2O9W4AR"[NJ,[(/'(X,56GC9LCVE2OH5+^
MJE8[3?YMM7NYI7L9;SP[!NZ=[%=/+C,<VG_Y7^D7T=*_7'ONJ[_S[=]<>B'G
M_IW9?#/XI]9_E?Z1?1TK]<>^ZI^?;OKCT0?IW9?#/XI]9_E?Z1?1TK]<>^ZI
M^?;OKCT0?IW9?#/XI]9_E?Z1?1TK]<>^ZI^?;OKCT0?IW9?#/XI]9_E?Z1?1
MTK]<>^ZI^?;OKCT0?IW9?#/XI];E/W8.D2*A)CI5T5%3_C'O(M_C4_/MWUQZ
M(3].[+X9_%/K>QUX#Z-5YS[U$_2F_P"8J"7$]7^*@DT"@4"@4"@4$.908L%^
MRF/]?\85!ERN,B9K&3,1/%3@SV7(TD!)156G14"1%3BG!>U*DQ6*-.;#;FQW
M8[N-MT3$^27FO^73I9]'2/UM_P"ZKG^7L?-_I7P_X)_%=ZS_ "Z=+/HZ1^MO
M_=4^7L/TKX?\$_BN]9_ETZ6?1TC];?\ NJ?+V'Z5\/\ @G\5WK/\NG2SZ.D?
MK;_W5/E[#]*^'_!/XKO6?Y=.EGT=(_6W_NJ?+V'Z5\/^"?Q7>L_RZ=+/HZ1^
MMO\ W5/E[#]*^'_!/XKO6?Y=.EGT=(_6W_NJ?+V'Z5\/^"?Q7>L_RZ=+/HZ1
M^MO_ '5/E[#]*^'_  3^*[UG^73I9]'2/UM_[JGR]A^E?#_@G\5WK/\ +ITL
M^CI'ZV_]U3Y>P_2OA_P3^*[UG^73I9]'2/UM_P"ZI\O8?I7P_P""?Q7>L_RZ
M=+/HZ1^MO_=4^7L/TKX?\$_BN]9_ETZ6?1TC];?^ZI\O8?I7P_X)_%=ZS_+I
MTL^CI'ZV_P#=4^7L/TKX?\$_BN]9_ETZ6?1TC];?^ZI\O8?I7P_X)_%=ZS_+
MITL^CI'ZV_\ =4^7L/TKX?\ !/XKO6?Y=.EGT=(_6W_NJ?+V'Z5\/^"?Q7>L
M_P NG2SZ.D?K;_W5/E[#]*^'_!/XKO6?Y=.EGT=(_6W_ +JGR]A^E?#_ ()_
M%=ZS_+ITL^CI'ZV_]U3Y>P_2OA_P3^*[UG^73I9]'2/UM_[JGR]A^E?#_@G\
M5WK/\NG2SZ.D?K;_ -U3Y>P_2OA_P3^*[UG^73I9]'2/UM_[JGR]A^E?#_@G
M\5WK/\NG2SZ.D?K;_P!U3Y>P_2OA_P $_BN]9_ETZ6?1TC];?^ZI\O8?I7P_
MX)_%=ZS_ "Z=+/HZ1^MO_=4^7L/TKX?\$_BN]9_ETZ6?1TC];?\ NJ?+V'Z5
M\/\ @G\5WK/\NG2SZ.D?K;_W5/E[#]*^'_!/XKO6?Y=.EGT=(_6W_NJ?+V'Z
M5\/^"?Q7>L_RZ=+/HZ1^MO\ W5/E[#]*^'_!/XKO6?Y=.EGT=(_6W_NJ?+V'
MZ5\/^"?Q7>L_RZ=+/HZ1^MO_ '5/E[#]*^'_  3^*[UG^73I9]'2/UM_[JGR
M]A^E?#_@G\5WK/\ +ITL^CI'ZV_]U3Y>P_2OA_P3^*[UG^73I9]'2/UM_P"Z
MI\O8?I7P_P""?Q7>L_RZ=+/HZ1^MO_=4^7L/TKX?\$_BN]9_ETZ6?1TC];?^
MZI\O8?I7P_X)_%=ZS_+ITL^CI'ZV_P#=4^7L/TKX?\$_BN]9_ETZ6?1TC];?
M^ZI\O8?I7P_X)_%=ZS_+ITL^CI'ZV_\ =4^7L/TKX?\ !/XKO6?Y=.EGT=(_
M6W_NJ?+V'Z5\/^"?Q7>L_P NG2SZ.D?K;_W5/E[#]*^'_!/XKO6WK:>T<)LK
M$^Q=OLFSC^:;^AQPG5UN6NNHE5?)6ZRR+8I#W=ELL6TQ]WBBEM:\Z_6NR]5?
M>K-VJ3!?D<?^HE5%Y44H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M 7L6@I,EZ\?](9_&)51=U%*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!05><^]1/TIO\ F*@EQ/5_BH)- H% H% H
M%!#F4&+!?LIC_7_&%06- H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H."]5?>H*3!?D<?^HE5%Y44H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% 7L6@I,EZ\?](9_&)51=U%:%U>ZAETVV
M>YFHD9)N9EOMX_$1#NH'+?NHJ:#Q41$2)43M]6Z7O7I^';/YK+IF:6Q%9\CR
M?%-]\IAUQ%;IFEL=OF_:>72I=J[+ZQ-9+&Y[=>_T>N:.93;L> PD7EJBJK(/
M(J+P6R:D"_NUOW&YVDVS9CQ>2[5-?+3[VC;;7>Q?%^3-6.FV+8IY*_<F/=>.
MGD;.^PI4B9&_XLL=[3?A/MX_Q8$H*WSR%$NA(HWMI\M[<:PCPG<39JB(GA6E
M8K3R-L^,;:+],S//36DTKRI5,W?UGV%L;)2\/N&:ZQDXD=J4L8&3<)T'RT +
M5DL1>54\B<:U[;PS/GMBZR.$S1GNO%=OMKIMR74F(J@X3=+$7J!OIO*;N63C
M<1&CRG\*]$\.SBVD:0R/Q'8Y=%NMOX^RMF7!,X,6G'2;IF*UKJ\S'%N(C/EU
M9*Q;$3II31PZ^E;;)ZJ[5W_-D0=OC-U,->)%Z5$>C,O,*: AM&:(A(JKP\ON
M5HW6PR[>V)OIU<)JW;7Q#%N)I97E7C$QP:[U/W[NN/NK!],.GB,-;MSC1RY.
M4EAS&8,)O5\H@*BB1+H/UD5.")95)+=>QVF*<5V?-71;PI'3/[3'[0X?$-[E
MC-9ML%(OOBLW3^[''CU=$\_)3BN-E;.ZA;>RYR]S;\<W-BW6"$L>[ 9BZ9"D
M*B8N 1+9$U)IX=M:-UN=ODLICQ:)KSU3/!T[3:[G%?7+F[R*<M,1Q],O$\/N
M7JWE=F;LZF1]^%&7;61EQQPTJ''*(^S%1L].NR6(D<T"B#>]N-UNGT.3!M;,
MV/!.*NNV.,3-8K7U/F\6XWF3%ESQEIW=TQIFV*3$4GGYZ?;Q;#N7JMNO<4_8
M&WL=EV-BQMVXD,K/SK[(O(CQH2)'95Y4%+J%TN2*NL>/D+EP>'XL=N6^ZV<O
M=W:8MK],T_;A+JW'B6;+=AQVW1A[VV+INF*\9K[,5X='9SCR3Z?%RDWIELUR
M;U$W"[N)QJ3H8R+$)1?<!Y4%EI&8Z'<KW[U_+VUXUV.W=9J8;-'#E7TS67NV
M7W;7#7/?KFO/3U\HI#G;O5+:V]\=FTP4Q^!DL2P9S(\V*34N,*@2B\K#GKBE
MKV3WE[4IFV&7!=;KB)BZ>%)X3V57!O\ %GB[1,Q-O.L<8\S0 RVY<GTMVKF<
M#O?(Y24_EF<?*S$6$W'.1'F348<4V7FG%%6!U:"X>=;UZ?=X[=S?;?CMMC36
MDS6DQ;7G$QS>7&3+?M;+K,MUTZJ:HMB*Q-U)X3$^[#4L_OCK1C9FXH./DRG\
M?%G29$*><45="!A)/A'6DTLV)9"FV=[>>W!>'?AVNRNBR;HB)F(K%>FZ*]?1
MQ>9GW?B-LWZ>-L733AQTV32G+G=PG_'A]45\6^Y*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*"KSGWJ)^E-_P Q4$N)ZO\ %02:!0*!0*!0*"',
MH,6"_93'^O\ C"H+&@\&C[BZD=8=S9^'LG/-[1V/MZ2N.]IA&"7,FRF[ZE%#
M5$$$M?@0\%'MNMOI9P[?98[9RV]YDOBM*TB(?*QGW6^RWQAN[K'9.G535-T^
MKSQT<^--VD[L#I7MO%1-_9:7N3.R3>;:E0L>1/R.62G]Z811'0!"BJ1<>WC7
MG1M_F\ETX;8LMBG.[EYY>K\Q\ICMC-=.2Z:\8MY^:.J$J)U=V/.V5-W]&F.%
M@<:7*R"<DTDL.ZQ#EFS;4A7,:PN\.S6YHQ3'M7<NJ?.SM\2P789S1/LV\^'&
M/,TS>W5[;.>VKDI&T]XO;?#%9"#&E9]G'G-:,I"&?*;%435?0NHD[+6["KT-
MKX=DQY;8R8XOU1/LZJ<OV_:CS=WXIBR8;IQY=&F8K=IU1QKZ?VZVW[MZO;-V
M3DF<)EGI,O+DRDE^-CXKDMQEA>".O(VBH JO\?N=E<&W\.S9[==L1%M:<9IQ
MZH>CN/$<."_1=,S=2M(B9X=<KS>&4D0]C9[-8MU69<?$S)D)Y1[P.!&-QLM)
MIVHJ(ME2M&VQQ=GLLNY3=$3Z6[>Y+K-ODOMFDQ9=,>6G!Y!TE'J/NK';;W=E
M>IHN1IAI(E;<*%%YCC;;A"3*N"0DFI![4#A7N>(?+XKK\=N'C'[U9ZN;PO#8
MW6:VS+=GK$_NZ;>OE7[F2'F.H?6;<NXQVGN9=H;,VW)7'1'XT<),B=+;OJ,U
M-1L'"]D7U5%+*MUJ78MOLL=G>6=Y??%9XTI!;EW.^RW]U?W6/'.GE6;I]/[1
M*%%ZJ;V'I]U%PN=D@SU"V*G*]K1@%!D-F>EMY 4=-^ZOV*)91X7O6R[88>_Q
M761_QY>CJ[&%GB.?Y?-9?/\ RX>GKZI_:.I[%TYR<[-;"VWELH\LC(S<=&D2
MGU1!4W7&A(B5!1$2ZKY$KP=[CMLSWVVQ2(NE[^PR79-OCONFLW6VS/H>$],)
MG5+J%B#SLCJDF(5O(.P_9KD&(Z9BRHK="4FU[VJR)IKZ7?V[7;7Z(P:N%:ZI
M?+^&W[S=8]<[C3QI33:W2+O3=!]6>I. +($N'P>%;EXJ(H-Z69"QVC4T73=>
M\2K8E5*\Z[:XOE<-]/:ONI/;QEZ>/=Y9WF?',^S9;$VQPX>S$O,XF]^J>&Z7
M8OK$[O=9SDB9R']M3XL=&) I))E0:,$$]5AU+I1%M?CPX^O=M=M?N;MMW=.'
MO1,\.%7B6[W=X]I;NYRUXS6R8CCQIS\U?\&];WWON[.=2X'3C';B;Z?P7<8U
MD5R$AAMZ3*D/6LPWS5$4T\1LBHJJ)<5X)7G;7:XL>WG-=9WTZJ4B>$1U_MUP
M]7>;O-DW4;>R^,,:=59B)F9ZN/[<);'N?;'5*-LV(]'Z@E&S&#BSG\K.;QS!
M>T$%5<910541M0 =%T1;WNM<F#/M9S3$XJVW3;2-4^SU^6KKS[?=QABF:EUD
M75G1'M=,>2D<&O\ 1B;O[+;;@]4-W[X<F;<6/->FX-8#2:1C$XWKYS2(9:>7
MKL(<>RNKQ.W!9DG!CQ4NK;2[5UTZ)]'-R>$9-QDQ1N,N6MM+JVZ8Z)F.<>2O
M)NNUNM6Q]VYQK;L!R7$RDH"=@-9"([$24V"*2JRKB)JX)J\BVKSL_AF;#9KF
MDQ'.DUIY7J8/%,&;)&.)F+IY5B8KY&LMYG+Y*#U8#$[VF3\G@WWGH,9B +#F
M,<C \8Q05P#1\35OEJJ#Q0;I8BKM[JRV[!JQQ$74K[7O5IQ[.=?\'GQFR76;
MC1EFZZRM*64TTU>SR]KE3MI7G+27]W]8,<_AH^-G3LFF6P^,C2#EQ6T6/F-Q
M-O. ]<&11!C*%K%P3L*]>C&VVET73=$6Z;KIX3SMLIPY_O/-G=;ZW1$3-VNR
MR)K$<+[Z\>7*VGK>X]+LME<YT_P&4SA.'EY$5/&N/!RG"= B B(-(VOIOV5\
MWO\ ';CSWVV>[$\'U'A^6_)M[+K_ 'ICCY6W5PN\H% H% H% H% H% H% H%
M H% H% H% H%!P7JK[U!28+\CC_U$JHO*BE H% H% H% H% H% H% H% H%
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M_P#]*SRW?ZI>NUX;Z H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M-G,["PF2E0X)9EX,WF6CY\QN*#++,QY 3F/7X<$ !1+)[B4&>+U)CY9[;\?
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MG? B)"T(2W7A=$U)2@BN]4&L6W,=W+B7,8C$&1DXH-R8TPWF8:@CP$C1_)N
MC@$J*JC957782LH)<K?61@0,8<["(WF<W+2'B80SF#CO7:5]#659 %%$2TC9
M2(DL*+>]*#O.WIEV<HWM_'[:D3L^F.9RLN.DAAJ.RV\XXURED&NDG-;:H*(E
ME[55$H(V%ZE#F2PTY<)+A;9W"YX?$96238.%()LG %Z-?F-(>@Q EOQ1+HFI
M*4'$3J=%E3(+B8XPVWDY0P,?EUD,J;CSI\MHBC(O,%IT^Z!]O$5441;TH5=,
M;U,<R#&/RZ[?EQ]K9"6N-'*NN-(;<E9)1 (V$521DW101<O]DBZ=/&E!(V%N
M7<^?F[B8SN-"+$QV3DQ(<AM]MSN-<O2T0@B+=$+5J7SVI(P+O8,2>10&,EF)
M<C<182)$7P_<D%#%\1:(4;08Z(*DI.JI"JDMU2R4$+<'4/<,?"Y$<=A%C;HQ
M4_'1<A">D,JT,;(2&Q!UMY4TF+@JH)P10*]T[O%06D_?LZ+)7&P\&LW,1&&I
M.8B)-C,I&60A*#0&ZHHZZ2"JHB6&UKDETI0= ZBO95]8^TL#)S1) A9?G<UF
M(P47("X30BXZME=7EJFCL3RDE!G3J .3;QP[3Q3^9F9""&55HS"&$>(XJ@'.
M<<NB.$8D MBB^J5[(EZ4&O[9WW)9Q)ZH,J5G,IF<TD7&SG0C''8A32!Q'G7"
M(0!K4(#HU:KCIX+= NX_48,C&B,8G$OR]R2'Y,5[$(ZT(QG(&CQ!.R$4FT;'
MF-Z3&ZGK&R<5LH&Q,ODLMDMX/3XLF%(C9%EA,9+-"Y)!CXQ$C1"JBK1D6L3'
M@M^Q%O15=@>H.>'#S9^Y<,02ERTG$XB-$?9?<E2/&.L-QT1-(AH$.^X9:=*$
M?!*41LN"W3(GY5_;^:Q9X?.LL#-:CJZ$EE^(1JVKC3K=D50/NF)"BC<5XH2+
M16K,[OS&%RN]G1Q$S+8K$Y 7YDE'@ 6(R0(KIA&!Q?E2!-3A .E+K9%U+:B+
M;*]16H\EYC!8XLRW"CLR\@\$AF*@-R YK8-(^HJZZ3?RFG@EE&Y76E!2AOZ-
MC<IN+<J),RF#?C[<+'1(J*ZXJ997&VU::)42YJX&KL]WLH-IP^[)TG-IM_<&
M&=PN2D1RF8]2>:E,2&FE$71%QNUG&U,=0*G8MQ4N-BMHJ!05><^]1/TIO^8J
M"7$]7^*@DT"@4"@4"@4$.908L%^RF/\ 7_&%06-!Y_@<?-WWC4W1DLSD84?)
M*ZN,QV-D+#:C1$-0:(E;[SCI(/,,C)112TH-DXU%>SN3.83<V\V(>,G9Z%BE
MQ[CQ$^ (VRD!LC1E'53F/+I(R =**JI<KE074SJ&VXZRSMG'+FS*)'R+]Y+$
M% 8FBIL"/B"34Z8BI('!$3UB&Z4H,:=1CR;\>-M/!R<V<C&1\V#J.LQ6$BRB
M=  5QQ53G:FB3E^DD2E P?4E,R6%FEA)<';6XBY6'RDDFP<)XFB= 'HU^8UK
M0'$%5OQ3O(.I*4' =2"5F/G',)):V5+?".QGC<;1=+SB,M/G&5>8+!FJ:3[=
M*H2B@\44&IY'>N[IFS]TS<KCW8:8K-MQ(;N/?!V08-92.VD<0;TJI*"Z5)2L
M5^/"@W,NH36+<R;&Z\8[AI&/A^TVQ1QN6,B)K1KY,F[)S4<405M?*0V547@H
M(I]34Q[.2<W#AW,>[!Q\G,,,L28\XI$6%IYXCR26SH:PN'%%OW27C902YV\=
MPP<*UG'-KN RHNOR6'IT9EYJ.V7R=T-=*NF'>Y>JPKW5*]!T>Z@NR\@QBMKX
M21F9<G&1LXT\K@1(J0YBN"WK=<O9Q5#@&E5\O!$I02-O=0(&?GMXTH<C'23B
M/25&7H'0]!D+%F1R42).8P?+4K*HD)B0JJ4HHYOZ$QL%_J$_!E!BF8[DX(J"
MA2G(H&J 8 B\5=!$< >WO(G;01I6_,FPXUC@V^2[@)DIDG'.S8S(L15<-ME3
M?)5!7'="Z6QO:RW)+751'6)U)9S<O&0]LXT\B[.AADI O2&8AL1BD%&-$$U)
M7'&S;-'!#@-D[W>&Z@QN]1YKBYJ1BMLS9^,V[+D0LO*%QEHU*(@FX45HRN_8
M"OVCWD4$N7"E!*?WW(EO/#M+"/[ABPVF7YDIIUN,W:2T+[;;'.MS75:,34>Z
MB:A12NO ,"=2$R<F)"VEAY&;D3<6UFVG%<"''&,\X;2 XX[=1=U J:-*^6]K
M4H.H=2V\B6&C;>Q+T[)9B,_-2')=:@DTU$=1A\%)S4ANMN+I4 OV7542UU!S
MF.I36-D9$XV,*;A<(9-YK(#)CM$R30"X]RF7"0W>2)7<M;RH.HD5*4%UNC=T
M3;,#'3UBOY),I-C8Z$S!03<-Z;=&E[Q".B_K$JV$>\O!*BJ*?U-]@1,L6Z<'
M*Q^1Q<5O(C"8-N9XJ(XZ+"E',-*$8.$@FV2"O$;70D6K1&>5OS*,.MXUK;ZN
M;@!A)>1QYSHK01F7#<!@5>)=!NNHVJH \$^R)."JH.S'4+VUX--H8A[-*_#9
MR4DE=:B!'8DJ8M@1.*J*\2MFF@>":;J2(J74&M[)W<VWB,1E,U,R4=CP.X,E
M+9E(VK8,1,D@KX@50W>:T)H#:-GIMJ3CW:"SW+O3>D/:.9SL';!P"CP3EX]R
M;*81U%[4YS''02"NI0U+\6Z+06S^\,PV]%P\;;QR=TNQRG2\<,IH6(T9'%:
MG)*CI4G"14 !%56Q7L@WH("]4&I!8B#BL)+EY[*OS89XPR:96'(Q9 DH9#JD
M0"@(5Q(=6ONZ;ZDI07&X,N&/W)MZ(3\L%E!D'$CL*RD5U(S"&J2-8J?=O=OE
MDG'UKI155BNI#^1;PF0D;?E8_!;D0 PTV2XTCA2'F5?9;>815)I'4$D N/&V
MI!U)1$' =1,V&VCRVY\1RIK^1D8W$L1Y+#BRGTER&@:OW ;1L&N^X2V5!4O<
MI02BZI,QVSC3<._[=;GPL:6,B/,RM19/6D9T'4(05LE;)#4M*AI*Z62ZJ"8'
M4 HD?*CG\-)@9C%E$1,:R;<LI7M)PFHOAG!41)7'!)M4+3I5%OW>]15*]O+(
MP-YB_NG'R<'!Q^WLAD9#:/#+B/ $B(EQ)JR*\%U'0HW[R:56]$6C/4IF*X^&
MYL:>&$84C)1522Q-)UF%I5X"&.1*+PH8+H[R%?NDJHM*"OD;EW#,WELN'DL+
M,P<:;(G."JOMOM.@WCWR1J2C)6!Q%43$%U#P6Q72@MLCN3<T;J+C]NQ,8#^
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M-B=[6LI 2=M^%!)>=".RX^ZMFVA(S5./=%+K0:X_O[:C&/#(NSDY90HF61E
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M88]Y6D;DQ2N1\VRFXIIJTDBAI3309I1Y^5A]^[F^L4]F;MW(SRPL=D@"*TU
M9:>1EUK39X3+4A\RZH)6'3:]08_#.Q=P=3=R0\A.9GQ\3&E,@D@B8!US'OF*
M\M4TKRULH7[*" U W!*R>[-QX+)SEW+#QF!R;$1'B6-*=;CN.N1S91-*B\@$
MW[BG=+51OVTLX_N_/9'<4"69;38C1H.-CHH\MV2X"2I#Q):^H$<;8MJ[I":=
MM0>;97"K%V5U/DQ<C,60YFG([?B7EDLMDKD)4=1H["IBO9?R)9>%4;3NK(YG
MI^_E7\9DI>2:=P$[(A&R+B2$:FPGX[8O"1(F@%&2JN!P!$!%1!XU!/VG"WO!
MW!&*2SD/8#T=X<HYE\C&G$3XJ),.L"PG<(KF)@.ENUK#=*"%EL>[#WGO7.Q,
MCD&YD3;T:0RTDDEC(XHY% 3E*EK"J:P1>PKKY:"U;S4]8?30EGDKV7<:\=WA
MU2A7$R'RU);BFL1-=/FH-*AKNE[:>T<^>Z\E[5W!DVL;DS16^3X*8ZX"@RSI
MT-N ("@/(FN]U6]ZHLYF5SF&RN3V5'S4E(,C+XF''RLLT?FQ(^59=<=;!YQ%
MNI$SRV2<0E$G/+84J##OC(;AV>.>PN W!)+GX8,G#>FGXR3CY0S68NL3<15)
MMT7%5 <NFH"MP54H-UW3(F;-V))/'9!PIC"LQPRV3+Q)M+,E R4AU2LA<I'5
M.RIIL-K::*U3>D*;MS3A(^<R,V!G\3EF9S$R2KSX'!AJ^$IERR$VM_DW!3N+
MK'@BIQ(LVILO9O1AK+8V0])FQ\3'D-/SC*3RB=:;366KM;:U:]/99*=([3HF
M0V?EL$$;<4[(AF5E0I\3(O"^;G+AORDEL\!Y2MDVB$C::-)^K=!H-?BYK<VW
ML!LW,/Y>5FLCEL=-S&4;>LC<A]G#\\&FVQ3Y-M#%%00[5XJJJM!-E)EL5"V-
MGV=U3)<K/93'-9(7'0.'-:G-FZ8,-*-FA2VL.59= V+5Q6@YQTO/;AE[8QLC
M-RXT.8YN4\CX91:?D# R(-1PYHHA-H E:X6)4X7[:#:^GTN>[#S&,GRW)ZX7
M+2L;%F2%0I!QVQ;<;YI(B:B%'-&JUR1$5>-Z2/-]O,Y+!])X.]H.X)3F1@&3
M[,,7!]FNM>.-KP2QT1174)<K7]]YG>O]C5&P0\SN%^6ST[7(O)GX.;+QV151
M*2> 9M/:=)11$170-J&I:>):_*E0;#N!Z;E]YX[: SY&,QA8]_*R'(9\F1*)
ME]ID61=MJ  UZW.78EN*71+W"".-EY+<TC:#N=R<7%X3'QY+*-RE"=,=G.R!
M5YR0GRA RC: (IPU>M>R4%)B)>X=Q97"8&9GY8X^,YN"+,EQ%!A[)#B9<9F.
MX3K:(H$*&0NJUIU$B]B<*".R>XL;MZ7N=_<F0G9'!YY<7&:=,!C/8]G)I!1N
M0T(Z7'":/OO<#4T0DM:U!-AQLSGV]\925NV=!=PN6FQ\1X9QMJ- :BL,O"C[
M>E4>34I&2/7306E$3MH*G<6[LU)P0;NQ'M(,MC(>,E996Y3<;#1GY#34@V58
M=6[RD#R:Q1%5$4;$A519;DF;@8_ZC9UK.2VDP:-Q<+":408C\Z%%><<)++S#
M4S+0IW0$[$XU!,RD?-Y.9OV:FXI\(<"8+A(T0Q::8,,<Q*4G$TKSD)Q5N#EQ
MTW2W&]!EV]+R._Y\IR?EI6,;Q\+%N1X.+=\-=W(1 EG(<6RJ:*1<IL2[B:"N
MBJJV#M@,]FI'1%W<+F369G1P\^2&7TA\H^R+RMO((=RUQ0D0>%!"]DYMK.;4
MQ1;JRKL/<$&3(S>IT1<=>A RZ!,&(HL9")TD,6;(0V3A:ZABQ64S>2G8[9$K
M-R&HK>3S,5W)":!D9<?$$T3#'.1$L:H]=PP1#(6U[+DM!'R$F='S[.UY$YW)
MP</N?#.0I<HD<DMC-CO.E'=<1$UJVJ:Q4N]H,46]KK1UVS.Z@[B'%;KC,35<
MF31>E7R,7V6,!7^4ZPD1+D*M-(MEMS>:/>7M2@V#;#,_/;;9WW(S<Y[*2V9$
MUN''>4(#5Q<$(R1Q327*X"2G<U,;JODJ#K[>R?U6Z9R_:!^*S$K%MSGM0ZI2
M/0'77!+AQU*.M=/FH->PLCQNV,1M_&EE7<ZJY>6,;#RP@(#"Y%YI'GWG%0>!
M<&Q[UUO<51%M1-VEE]P;QS>UGLCEGX\-=N,9>;"AD#3<F>DKEZG#!.+=D+4
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M"@4"@4"@4!>Q:"DR7KQ_TAG\8E5%W45!R^9Q>!@GDLO)")";405P[K<W"00
M1%%(B(E1!$4557LH--S'42-$RNVC:<<BX:?+F0L@U+AR&I1O,PU?9;::< 7%
M)5LJ: +4E_,M6B-@:WKMZ1B2S,=]UZ,$A8+C+49\Y02Q6RL''%M71-%\A"GG
M[%O45B>Z@;0CXB-G'<D(X^8\<2,O+=5XY3>K4PC*!S.<B@2<K1KNEK5:#,N\
M]OAEF<*\^ZQ.D.)'85^.^TP<@F^:C*/&"-JYIXZ-5_)VT'![UVZ.1=Q;;[LB
M3'=\-).+&D2&69&G5RG'6FR;$[?8J5T[%XT%1MOJ?@,YM<=T3$=Q<=75CJS(
M9?0R=)XV6P:16A)TST^JV)*B\*418'U#V@SBBS,G(^&B!)]GN \T\W(":HZT
MCJP0<WFJGJAHN7#3>Z4HK&WO2'$3)2,O)9\.U.:A8Z-$9DN35)^(U)%EUG0I
M*^J&1:6Q6P6O94*P86^HN*=W=#VJU'E%X['CD69GAI*#\HZC8@0JRFC@MR(U
M33V+9:41SCM]XYO!8B9F9D>3E,H#AL,89J3*1]&B5#)AK0KR@*6U$0V1??2@
ML WKMYV=%QK#[SLN6#+J-MQI!<H)-^2LA4;^1UV72CNE:45,S>X<1MYIAS*/
MJV<ISD0X[8&\^^\J*6AIIH2,ULBJND>"<5X5!IVZNHT+V;AEVW/,"S&4+%O3
M6H+\MZ(L=MQU\281M5!Y.6@(#H\-6K2J)5HBXW#O*-LY-OP\D,F>]EI"0SE,
MQG3)-+#CI.D$=HDNJMHFA+=MTX"M%5T/J3BH62W'"W%.1I,9DA8;)MAT@C0W
M8T=QLY3C8D+:$;A=YU1X>XEZ41>YK>^V=OR5B928H/-M))DHTR](2/')51'G
MR9 T:;547O.63M\B+:*L,KGL-@\86:RTYF)B!Y>J:X2(RB/$@ NKLL2DB(ON
MT%=C]\[9R13&X\HPD0(Z3I$:1'?CO^$*^E\&G6Q,VUTK8@%>/#MH*G.=4<!B
MMMY;/Q0D2WL.302L:4>1'E"4A4Y:FV;6L0(5U":AI7SU:(L&MW13RKBNS(L;
M!-XKVFX,H'XTYM!?-LG7!>$!%E$'[+O7]RBC/4/:#L6=,=R/@X^-8&;,*<R]
M#4(CBJ@R-+X JM*J+WT33YZ4&-SJ+MI864DQ777Y&+AED2AE'D-//1DN@NLB
M;:$XV1)IUMH2)Y:4$7%[X>S$3"[C98\'M21CY,W-R9C;C)176VX[K0H3J-W"
MQNW- 5"T\%HC8L1N#'9R*[,@<_DLK8TD1GXQVTH2*@/ !$A"J*BHG\M15%MW
MJ/@L]$=EN(]CT')'B61E,/M<U[Q+D9E!5QL+DXK=U%/4O8JM!<Y;=>W<#XQ<
MQD6H0X^,W.FF\JB#49YPF0<(K605,"3M\E05*]3=FH1->,>6:-B3'I#E+-)D
MD4D>".C7-)FPJO-$5#R7OPJT$Z3O;;,:!C<B,U)3&8'F8H(;;DMZ2&G6I--,
MB9D(BMR738?+:]087^H6SH^,@Y<\H!0\FX;&/Y8.N.OR&KZV0: %<5T=)7;T
MZDLO#@M!:9?.P,)':D3D?5'BT--1X[TITBTJ2IRV0,N"(JKPH(+V]ML,XS'Y
M89Z2(F6X8L8H.2'I)(*DHM--"3A**(NI-/=^RM0=&-][7F8US*P)AS8K4CP+
M@Q8[[[XRT%#5DF0;5Q#1%[PD*:?+:K08DW?"G2MOO8B?#<P^6\9S.:CXRG/"
M-*2BR"#82;(2YHNV5+6MJX4';%]0-HYJ9$AXS(H^600EQ[Z-.C&DJV.LQ9?(
M$;<(1[RB)*MK^9;*"#F.INW\?@<SG(*/Y%K#LF]\C'D<E]6R5M49>1H@,4--
M)$&I![5X4H+/);OQ^/VG*W:C3SD2,R3HL.-.1G3-%T"&EX1(=1*@W(?=[*"A
MR&]-P;1,BWC$ANQGX,J;#/%D[J23"%#**:/>LKB%\DXFFZBMQ'A1$[&;AW/$
MS^/P>[8L)LLS&>?Q[N/-TD:D1=).QG>:G>70:$#@VU:2N*<+AN-12@4"@4%7
MG/O43]*;_F*@EQ/5_BH)- H% H% H%!#F4&+!?LIC_7_ !A4%BJV2Z^2@\LV
M]U ]L9E)L_-/P,<_E9&*Q^(+%/ML.HTX<9H7)3K5T=<,=?KBB>I:_&JC:UZA
M[05)BM9!7D@O#$?5EEYR\LS)M(P:07F/:A6[07).U41*45'7J)B?K)B]OA'E
ME[4A.3FI/A)2("@\TR+9BK/<55-5)35-%N]VI2B)F\,S/PZ8)8! /C\Q#@2=
M8Z[QWU)#1.*67AP6BHD7?F)B8R"_GLA%+(Y)Z:S 8QH2'O$K#D&VH,MJ"N&8
M"@HXB#ZUU3N\:"?]=]KKAFL\$]',=(>6(QH;=)\Y2$H*P+"#S>:A"2$WHU)9
M;HEEJ"?A<YB]P0O'XE_G,"X;#J$)-N-/-+I-MQMQ!,#%>T2%%H-2VGN'<60V
M]&WGN#)P&<,49^;,@QX;B&VTVAKP=60:KI0;K\GQ]RJCLSDNI&0PH[H@,8\.
M<VDN)MAX'.>Y&)$,6SEHYI"00\.#2@)<%NG>H++:^[_K/D7TC-(&)+&8W*0C
M)%1__P"^"R-0.)=410Y*)9.Q;T5$#)[KRVY\_C,=D(&/Q^&>B,- ]$<DO.\^
M,W(,B))#:)Q/2-A\E$=F,ONK<TS)%MUV'C,-C)+D!J3-CN2G9DJ*NEY4$'64
M!D3NW>Y$2BJ\$M<*\=^YMB SD\ECVH[>'R9XC>;(*3GAT(0Y<V,:Z=3'RC3I
M:QU(T:JO$%N&P;8ST[<<G*9!MIH-L-/>$PKZ75V6K"J+\B]]/)5SN,V]9!4[
MZ2&HJTP^8AYR&L^ IK'%^1&7F"H%S(CQL.<%\FL"LOE3C0:IG<]N+V_E\=BL
MEC,5&P^/BSD+),FX#[DHI"*CAB\VK;8HPG$1)>\J^1$JHD;-WCD-P3'XF7AM
MX]YS'8[,P&$(E<\+/97F":%;O-/MN!>R=U1NB+14/Z_3&>G.8Z@28X+';&;*
MPK#33QDY#:,@B&Z(ZB^504<)1X()>Y1$C&;QQ^'QD,,_F)&4RLULY8 &->:D
MHPTJ X?A&6E<!H2O8G!]RY+01-Q;XD"/CMM3(\G%/[:R^:AR!%'@-^'R.0:$
MBI<4YA:A\ON6H+5S?V!Q4.&F9E%[1."S/FMQH[TA663&ZO.HP!\MM51;*=NQ
M?,M*"U#=.WG0GN-9!IQK%QFITYP%4@"*^V3K;J$B*A 0 1(0*J<*BNC6[MM/
M1,3.;R;*P\ZR4K%/JJH#\<&/$DXBJB:11M-2J5K>_01\7OK:V8<=;B3M"M1U
MG:I+3L0#AIVR&R? $-I/*8JJ)Y>U*"C7J-CLGNC:^&P4N[.6.4X^U(CO,'(A
MLQ''0>CJ\(:@1Q N87[?=JHSYC>XX+?K>"R#W_WM?Q'C(L-AAR1,>E#)5LN6
M#*&9"(6U6&R72Z\:"[Q&\-MYYR,SB<@$EV8P[+C@(F*DU&=1A[@0I8FW"0'
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MG7.DR@!:;#/(N2O^$<(T$SY1ZM*J*ZDT+QH(NZ(&X-W.[DFQMORF8$K&XF%
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M I3B!*>#%/9(&VL@YCT0>4LH6N[S$76-[(1"@D2(2K03\%^1Q_ZB4%Y44H%
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- H% H% H% H% H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>fc_miprofile02-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_miprofile02-4c.jpg
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M%!04%!04%!04%/_  !$( ^($)P,!$0 "$0$#$0'_Q #/  $  @,! 0$!
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M/_\ EDU)'Z@J*\54%%(EL*<55>"4$,,QB7'$9"?&)U5LC8O I7\UD6]!-H%
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MC'S([ILN6MK;)1*R^2Z6H#S[\@^9(<)UQ>DS)2+\ZT%WLS#X+/;AB8O<6:#
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M;LSL&0BH_&R$MIQ"Z=0/&B_[*#O/Z<<C'Q_B[@^TD@A*&3% EX(CCK!Z$_\
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M4<%=C*A.D**@I856Y>:BJO +G=C^.FZ2G[=R4S$[P>B#C\O"85Z*TG"Y/&G
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M"@F9;<^WL&U'?R^18B,2A,XSCAV%P6@YA:%2Z+U>*6Z?)05H>(FS3CR)'>:
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M.E1$?C/3R?>:^4?:./R@B7B7MX21%%<-F$5%XHJ*_CZ#@,['?VE)QNP7B_\
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M\='9N7R_)TV\M!I\+UQRRM]+BN7V+\32O[G@WSNRQ>=;R?WFK5;]*]!] H%
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MG8N6UZ[9#^>@W06N1#9:]4$H)% H% H% H% H% H% H% H% H% H% H% H%
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M^4Q3T#,DXU$GE'ERV6"4F&04E!YMXA)MUU%L5R2Z51W.$_\ N?N__P .PO\
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M6_LS2PC;T$ZJ+=?*M!S6=8D9#PIW_'GY*?)'"YC(QX1N2WB<Y#)-B#;AZKN
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M V4ED3@<['.XU%)+W158=.U_TNMY*6-^'\+-I[0?=R6'DRL7&;="6X /@#(
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MVAMOF#<F;:M:<>BW'YN-!XSF<3(>8CL363?E 3L9M#34X +92%.E4H)U H%
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MF9S+[*R'WXYO<_'RGA;>!L"3EZ;&O2NL4X>6@MW9!)O;',OXJ*N\',!,=;R
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M(I&=^"II64NML>#F*VEF'LQBI:(^],66XZ[%9=DDTZZ_)=CD\YJ5 5^03@*
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MDM?EZ4X63ILE+*7&&Q*XMIY7I"RYD@A-^0H"WJY8"V"((\$1!%/RW6HJRH%
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M9*BLJ!01I49Z0HJU+=C(-[HT@+JOY]8E01^[I?WI)^JS_AU0[NE_>DGZK/\
MAT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'
M0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (=
M[NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#N
MZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I
M?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_
M>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z
M2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)
M^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZ
MK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL
M_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_
M (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\
MAT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'
M0.[I?WI)^JS_ (= [NE_>DGZK/\ AT#NZ7]Z2?JL_P"'0.[I?WI)^JS_ (=
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M9X22FIVW,C/8 FV)><S$AIMP5;<$'ISICJ!411545%LM!WM H% H% H% H%
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MY>A4LA'UU%>"EQM2>XY9N\IG=U]OA^"8]KPX[:PB-O2HJO'3XZK"# @XN*W
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MXN255$,M1)U!MUE2@MNU1E:YZ/!R=*N<S4FG0/25[VLGE6@A1)^0DY65'*&
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M1,93-5X3CYQ/F^0_CW?G_J;(^^3V:\K]]R^;P?W_ '?_ -N7RP_[3\>[\_\
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MWG#S9SRQ..%=)\<O/\=7Z1KXM]\^>[SQ+&Z-WX_;,DE&-*V_FP?(>*BDHX;
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M@4"@B3LIC<6+9Y&6S%%TM#2O&(:R1+J@W5+K;CPH-3F<PS4AR*[/8"0R!.O
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M4 E1!34A*2\.I?A5HM>)O'(/,!)[3#@+)E]B*-) E<QXIS+.2?M!NIZ$$1L
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MSX+TIV"U):.8RB$]'$Q5P!7H4A1;I02*!0*!0*!0*!0*!04VZOY&_P#M(_\
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MN2RWC'PFXW(HK9269;4A9+;G6!0*QK91(+*/!:#I\>Q*C0V6)LHITH!L[+,
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M*47'09'TNL1HW^CP2Z7\ME%I)[TA-2D@.Q7PGJO"+IU.J" )D8H-]0]:PJ/
ME1?-2BT>3O&0,7(S(\*[$:-#E0T<(=3X3'3!%LA=7@/!"M2A/C;L@R)O=Q,N
MM31(Q<;)$5$1E"YIHJ*MP!1TJJ?I*B>6E"!*WHL9QE]R*H8YZ*DQI>!ON-DO
M5TB)612'BB$OSTHM):W:+V03&A%+MQ*K0Q%44)'6E)7;G?1I$$14MQ6]*&+>
M\HCLUUIL4['$:DO2WD77<& ;< FU'@2$)+^5*46V!O*"AR&9,9^/(B@+CH+H
M)-#BLZ50A)46_.'^W\JBU=^/FA<AJ<>\1[FLN2$X(4MHF@Y8"JJ5M3GI$EN'
MYU%MS&]2<DFUV,S4R,8\=$Y;UFT154^8HH*<"^?AYZ46W#OG&.MD^RR\407
M:*4H*+3:DHH2N%:P(.KI6E%I4K<K<!]\IK!L0HT L@\I)=X=+BAITBJIT)?I
MHJ,]OG&10)9<>0R\-EY1!92"^E7!NJ*K:'8%*W2J4I+9L[AFS(V7>B1;.X]
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MYDJ*RH% H(#&$Q4;E]GB@TK1JZTH7321)9;<>"+;T>B@][FQ/V:)"9$6D,0
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MEY09=<>BDZ\X\U&AJ;R":]8@,5"R)H6B/H.7R4L,A)1J>ZQDV"C]TXT!^QE
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MH!8VH7K*-GRUZOFTV^<,X^X<[%:SIS8ZOR<2R'-(DY49#;BD\KPK;43;BH/
M-1"MTMPH-;F\,L+3[K01I<5AH7.WL :,N*ZZVW<-9H*"RADKESXV_1XV",.Y
M-Q1Y:2WVFB6>;++#*N(D5I!:%Q1$U=1M2>4^!HI6M;K6H),C=N>CPRF.Q& ;
M)&[+I-.3SY#S0D:N&V-@%E%*Y)<C3H3I#;C]QY7(;@Q\20K44+2.UX]I#<<1
M&V0(72<2XJV2DNBWR65>-@B_CF>;$Q\!CM1XI$34N0TZ+3R*($+&D"-1=34M
M^*KP]'I1 W,[LW#,[1V>$PQRWG01'KN.-(PV\:MN-M&I:BY8V(M'I="\+AF6
M3SN0Q4]!D"W*3(QV6P8;,'6HCW)-6[H2+K5#)$<X4&_%;ERF0G08HA'<CR%U
MR)#0N_8(+1&4<M2_WHJ@HI+;A^C>@C1<GN&-/D-$0R')$I^Q/\T8[;#;LD0$
M4XZ5TL@FJ^GCJMYPW83<>7R3KY&+;S:QF#".T*-.-F1.@\ZADX0N-H0(@Z%6
M_2G301X&X<^+(+R>T SI60CP.*^]J<:906K(*#Z:EQOQX='% VQMV9A_;\S,
MN1XS/(<;0;N 2BV=E=%01SBXW?2(D8J:^1*#4FZ\W+F:([;,*&$YF.:OCJ>%
MIUP@07&T<U"KB()"1"-E73QZ:#"#N/<3D9L_L9#Z10E2GB;<1HB;95PVVP'T
M24D4"N2V7R>2@F0MV9"1(G-N1FU<8@.SP@B+HR6C;<)L67+HJ$I(E[BE_D5+
M*H>8S+93)YEIUV2V[B(<9]Y780.HS)<^SMI34M^6A$*BM[KQZ>"!42M[967!
M>".;40]:)'FJTY=]#-JS;0 3EG!%SK<2Z.*)UM(6DO>4UA6U[((*DL89LD)*
M3IM&+<A )5&R"IBK:HA:K+PLBJ@9L[ES"'%8R*Q(:RE9-)BMN\D!=!2Y*H9)
M=Q5&R$I(GR7LBA5O;WS3^+ENJU'QQJ#_ "GW;N*T\TVJI'(&C(D=5;**K:_&
MP*O2%S-W)D(,AF,#0&X,=AU(KJ'VB6KHKK5I1LB<O3<KHOY.%P]GYW<$;&P)
M3#$=R4Y"6;,$@>T*>ID4;;1%N/\ >JMRNO5Z.FP5LO=FY ?DXUF*R$N.Q)M*
M(=(NFRCJ<YEHG-9("MCJ;%"O?TD\H9.[UG-2'&6T8D1V6X[CTD04%N1@+O+!
M7.OJU:FDN*EQTZ[4&#F[LTVTS$ V7\F^4UM5%@Q1O03R,%I4[DH<L>8*#T*B
MJHW2X3\7N&9(G1X4B2P O:7!D&)Z92JV%PC<40;*JDMU)>/SV"!*RVX&9+T)
MR8K+$J3D"ASW&]#3#4;6/)>)!ZMK(;;GF7RJ/$/8F6.0VI2,C)B2&(VO$Q"=
M0NU$+9:C5S3_ )BYIPMY$1;<:"7&S,;)R8"RLP4>,L>.Y'5AQ&QDRE54>$SL
MMU%=*<O_ 'K_ #!ED=VR8>5GPA)A6HCB,JP &Y) 3CBZDD^L(\L3)!)."6XJ
M2=%!5AO/.K&/)&P+_P!C&D,8V.*B::QDBX9&NI";4FQ)+='K+06#.X]QR66W
M!9BHT8MAS6T5Y7%D&\ .@K9F H/+%2#473:Z<*#&%N3*S,=.9=<:<G-X8)S$
MB*"V)XF5UDO6)0+F<!;4>A+W7BB >W7EL<_$@2VFI$WFB#_+;-L767&@(2;4
MB5=0$5B%$+@EUTT$(-W9Z*[(<D(Q)>4(SBXT&WA-M'H@.FZ"JBKRFROJX*O3
MQ0K#03V]RY=]%(19?BQU%>U11<$95WD 5"^I$"U]?$KKT+;C01I&\<["@N/S
M68K#K3+<GGFV^D=TG6VS2,-E4D<36O6X\$3J]-@G[AW3/PT^3$;9:<;1IDXY
M#8U!''$!QU^Y@@"%^JA60O6X*E!H<W-N-N.<DXL1L5;) !2)1%P(P2%<)[4C
M:@NI11+VZ.OTT$<MSY3GJZCBMX\VC=%MUHP>4@>BW-%LND !PU(+$MOTO+09
M0]T9R>@.PUC.\\2-IU <*.C(<\Q4FQ)51TD;&Z<SJZD\O2%CC-S39N:B0'VV
M66Y;3KBQ=+B2&^2#1H:DO5435Q;<$\G2M[!S4+.3%Q+3D_)/:3;?>,VIB";D
MQM148Y.FT",+IU*C?E\ZVH)SLC<<EF1+C]K4IL\6HT<92,%R19-U 34R2-65
M!0BZVOHX7H+4\UGE#'MQ.0XCD6([)D/M.(1.2GA8*P@J(.BZFJ?);@G&@B2M
MX9%(+\< 98SB@[R!4'"32U'=,GN7TZ-;5D2_R7O08.;LR;V12#$?CI&9=A]H
MF*R6A1<<1IT+<Q;(:JA-FMN'D5.-!XQN[,D/*:9:63I1OLKXNJ^TMVT%]U11
M+@>M;(@IY./I6"S@;CEKEV\7E$::U@XV!M"7VC[3Y,ZB1256Q)$'EW14)57K
M<.(=/5"@M('_ "Z?.O\ MK1GU;,>B36#(H*;=7\C?_:1_P#4-U8$QGT'/F*@
MFU H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MY0_F#JI0:'MN860 A(C<W2 M(1N.D>@5)4124M2^F275>@E3H6@%MO!G?7"
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M4"@4%I _Y=/G7_;6C/JV8]$FL&104VZOY&_^TC_ZANK F,^@Y\Q4$VH% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MT"@<$Z>% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M0M0#!<F/-O<LDOU$:4K*B^CQH+YC8&_-V;"VZUMW&[2@0H79)N*SD%]X)XO
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M43CSE4$_V]%!LF1MZ1XCJLG*D29 JX*BXW]C)%UQ6Q$4T_9J/+0D5;6XKY:
MD'<$<WC-)YQU<?[6XTX!R[.R"=%(Q%_]-$4.'D1%1*#8<+>8L.OR)DA'W&G&
MW19Y;@@(L-JV3;8H*JXKFI"5"\]N%J"3+QV??G0<M'1V/)8@L@Y'%X" WE?
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MF4S$1TZZQ7SZ&7<<<1$S/7II-_+JRD[QVS%@PLD>1;<B9%%* 4=#D$^*)=5
M&1,U04])4'AY:8]MRSE.-:X]?"OFD]SQQC&5Z9=*UOY- [PQH'D'I+K8XZ)V
M3E.,\U^07;&D<%'&!:U@JW32G6NG'A67[;+2(ZS?NT]MG[C'69Z17MG7V4A3
M?$G;429@([;QR6-P*\D:4RVZ8!R!55UH(*J+J30HK917IK9CV/),9STV5][3
MGWW'CEA'7?=:3X+=C=FW9.67!L3P/)(1MHV@GH)QI+F N*.@C%/2 24DXW3@
MM:)[?DC#?,:.B.XXYRVQ.JF?\0<0_F\-AL)+9EO3YKD60BBXEVF6'G#-@U1
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MRU-%U%RD55NLL+I>R\Q/+T^6FAJ#E(HII&6"#TV0T1/]M-#5ZF6CIT3!3_\
M:)Y?RTJ#5&FO8G)0WL?/=:D0I <MYDG%1"%.A+B2*EO)9:SQRG&;C28898QE
M%3TEAC.X\)!;Q>'[/!QS5^7&8)!!%-5(E7BJJ1*JJ1$JJJ]-7DSGDRW93<IQ
M\>/'CMQBH]B1V^#\0W]=/IK"V9V^#\2W]=/II8=O@_$M_73Z:6';X/Q+?UT^
MFEAV^#\2W]=/II8=O@_$M_73Z:6';X/Q+?UT^FEC),E$%+#*!$Z;(:)Q3\M-
M!ZN5C*MUF!?A_P#43R<4\M31=7O>L?A_G!X<4^T3Z:5!JQ7)Q%32LL--D2VM
M+63H\M-$%R<1555E JEP)=:<4_/5T'CT^#):-B1(;=8= FW6S-%$FS2Q"O'H
M5.FD:3<$Q<5+7$E8R!$8Q\%YJ/!BM@S&C-F@MMM-(@@(I?@@HB(E7++=,S.L
MRQQQC'&,<8J(Z0W+E(RK=98*OGYB>3\M8Z,]42=W'E.R)D^SRQ@2 F0A>)"%
MJ2TBH#HI>VH=2Z;]'36S#DG"]LU<5/N\FK/BQSK=%[9N+\)CI*3WA"7BLEN_
M_&GTUA;8\[?!^);^NGTTL.WP?B6_KI]-+&0Y*&/HRFT^8T3H_+30>]Z14Z)8
M<>'IIY>/GJ:#5*EXZ=&?AS7FI$22V3,EAPT('&G$42 DOQ14546LL9VS$QI,
M)EC&43CE%Q/4CRL9$BLPHKS3,..V#$>.!(@ TVB" "E^""B(B4RRW3,SUE,<
M8QB,8BHAN[UCWU=L&]K7YB7M^>L:AGJ\[UC7OVP+^?F)Y/RTT-3O2-:W; M>
M_P#>)T]-^FFAJQ7(PUM>2VMDLES3H_/5T1YV^#\2W]=/II8=O@_$M_73Z:6'
M;X/Q+?UT^FEAV^#\2W]=/II8=O@_$M_73Z:6';X/Q+?UT^FEBZQCK;T5#:-#
M#42:A6Z<%^2M.?5LQZ)E8,B@IMU?R-_]I'_U#=6!,9]!SYBH)M0*!0*!0<7N
MO.[FC[HP6UMN=F;+-19[S\Z4V3J1$AE'^U0!,-:V=41"Z=9455LBHH5<C=V1
MR&8R.$B;CQF#CX)6H<K(S :<D2YZL@ZYH8-YM&V@1P;KQ4BNB60;K1JQGB-D
MY4?$39 Q#B-9M[;6Y7H>IUE))IIBR8YZELTXX32$AW4>;:]QNH=/.SDYS>,3
M;,!MHX34!_)9QQT")1;,N3%:!46R$X:.DNI%ZK:^>H./Q^_9*;4V1#A]V8?+
M;C@]K<?>06,=!BL "NFVRK@:BU. #32$G3=5L*U1O3>FX6'LSM^#DL;N',-X
MB1F,#.BB-G'(I"+D:0RTZ5E4C;T&*IJ0EX7'B$W=?B)(@;;P><V['"4[E64R
MYL/(JVQ$9D94LD452SB-D@!_ODE07&3W2;>XL'B\<XP>/E1)>7RLHKER\=&;
M$6R"R_\ U'70LO'JB5!QJ>(&=G8 ]YP\YA(H<DIT+:KYMDZ[#1%< 'I*/HK;
M[@<>JWI K"J%Q6J.A_%>6W7D(.*V:XU"BO8V-FLCEY37/)EB?J6*RTRABBNN
M(!D2DND!3H522T%=M\<ZUXMSX^X'6),EG;T=(TV,!,B^P4UU=1M$I:#$KH2(
M2HO!4MT)1;[\_F^Q/_\ (1__ (=-J#GMS3,AD]L>*D2#V3&KC2DM./-QM1R6
M.Z&GW$=5#"[A<Q11SR(B<%M5$T]P9O9^S\,LR?"GY7,'#@88GVDQ\2.KC"N$
M<@N::D#;;9FNE14K(*65;U!NQN[IT#<V)PD_/XW<4+.*\RS(@HVQ(C2V62?0
M2;!YU":,&SL72)(B+>_"C?LW-;QW.<_)27(D/$P)N2QL6.+)&Y+.)(<9%XSY
MGV8"HH.@152LJW2Z(D$-_=>7VYN'#X_*[AQF:3+31QLS&1FAC2XCSP&K;C8H
M\X1 A#H-'$O9=5^%JHB;:@[E_P"JF\C[X8Y#8X<Y378N+K!!(4&Q+G]11&Z*
M=EOTV2@['9V=F9^%DI$T6Q.)ELECVD:141684MQAM5NJ]91%-7RU!QR>(6YG
M=E[:S<2-%>S><S98=630PCH"R93 FJHJD.A&A,EXWLJ(G&J+'+[GS&(G8O9S
M^:Q[6=D1GLAD\],:&-':C"[RP%F.3MB<,BTBBNV00(ENMD6"9M#=C\[/9':F
M0R,+,2H<=G(0\ICE$1>BOF;2BZV)N(#K9AQTE8A(51$6Z4%WN5<H$8'8.8BX
M.*WJ*9-ELH\J)P04'6XV \;W4KT'%?\ 47)M;)W?DQ?@Y+,;3<-H)T*YPI@<
MEJ0TX@B9:2('-!@AJ@FB\;5189?+[WVO'B[FS,F%(Q)RHT?*X9E@@.*Q->!A
M#9D:R5PVB,5-"!$--6G3PJ"=+RVX<]N3([>VW(9Q<+!BPF3RC["RG')<EOG
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M,^@Y\Q4$VH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M^K:$-G!4#$V[C<5XHM!4^$V:W5F-OMNY^(BL\Z?HR9S$D/.&W/>!&E;1H+"
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M+<0Z6@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@YK=O\
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MH];HZ.-!IG;XV?C6XCTW.0F6)S8OQ75?!0-@ELCJ$BJB-JOZ:]7Y:"VEY&!
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MXVTX0BBCP15(DOYJ"K3+2W(:R,?F9#^1D8Z:YEF4TFL-]ME5$A:(;-$V[U!
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M BK]J:$:7 /)QJTCJ:BE H% H% H% H% H% H% H% H% H% H% H% H% H%
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M5E0*!0*!0*!0*!01'(;IF1I,>!"6Z /+LGR)<%6@Q["]\<_^[]B@=A>^.?\
MW?L4#L+WQS_[OV*!V%[XY_\ =^Q0.PO?'/\ [OV*!V%[XY_]W[% ["]\<_\
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M_P"[]B@=A>^.?_=^Q0266R:;T$Z3JW5=9VU<?^%$2@V4"@IMU?R-_P#:1_\
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M-;M_D>1_8'51T8>@/S)45E0*#E?$3_RN?_?L7T?^(QZ[>R_]OPR_Z9<?>?\
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M>GCQ93C,9Y;K]E.$A9$\A"V_M_*R0:_"ZRI>XI)*6D.XB6/&(^C4CAZ'[>5
MKT\L-N6>>,?^RHQ_X]9^73XO.PSG+'##*?R7.4_[FD?.?5\&ASQ W1CX>;C-
MF4V6Q'@3L5/R<%<>)C-FI$-%9 ]1-HEC$K"7&R^>LH[/BRG&>D3.43$9;NF-
M]?-A/><N,91&LQ&,Q.45^;*NGLZ^"U+*OXK);FBR9S<?+MAB(P99B&KTN9(>
M!TD$8Z$HD:V40$4L*75;UH_3C/'"8B\?5-7I$:>/XNB>2<,LXF:GTQ=:S.OA
M^"'B=Y[MS;F(P;;H0)TB=EL=.G28J)(T8UL3;=2/K4 <+4-Q55&UUMT)6SD[
M7BX]V?6(C&8B)T]7A?DT\?=<W)MQ_+,Y9Q,S&OIZ37G.GVT8%D]TYS*;>B)F
M>Q2\?G,EBI;S$8";E]CB/$+I 9=55&UP2XZN*="5=G%QXYSMN)PQRC7I<QH3
MGR\F6$;JVYY1.GYJQR^WO63LN?FW=S;<W7(6(^Y'E'C\649 9[.P?V,N-*15
M5TA3EFXG FS7H1+*NJ,<>.,,^.+UBYOQ\<9CP\:\X;=\\DY\?)I-345X>&49
M>/A?]L_"^RVO.D9/;6&R4M;RID&-(?6UKN.LB9</G6O/Y\(PY,L8Z1,_B[^#
M.<^/'*>LQ$_<MJT-Y0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!04VZ
MOY&_^TC_ .H;JP)C/H.?,5!-J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<UNW^1Y']@=5'1AZ _
M,E165 H(F1QL++15A9!KG1E<:>4+J/7CN"\VMQ5%X& K6>&<X3<=?YZ,,\(S
MBIZ?RU0G-K8)V!,Q9Q;P9\I9\MK6?7DDZ+ZG>]TZXHMDX5MCN,XRC*]8BH]U
M4USP83C.-:3-_&[_ !:$V?B&\B_D(Y28Z2S-V9"9D.MPWGG1TFX;"%H4B3TE
MMQ7BO'C5_<YSC&,U-=)K6/BQCM\(RG*+B^L7I\FF3L/;DD8H"T]&"+%;QRC%
MD/,(]":'2+#V@DY@(B_I<>GCQ6L\>[Y(OI-S>L1-3YQY,9[3CFM*J*TF8T\I
M\WKVQL 00QA#(QAP(X08[V/DO17.QM>@P1 2:@']'5Q'R*G&I'=\FMUE<WK$
M3KYG[3CB(V^G;%14UIY>Y/7;F'4<H)1]29IL6<FJF:J\ ,\A$557AU.%T_VU
MK_7S].OY>GSMM_1P]6GYNOMTK\$&7L;;DTR5Z.:-.Q&X$B.#S@-/,L<6>8*%
MQ-I>+9^D/GK9CW?)CTGQOY]?GXPUY=KQY=8\*_E\O"7D38NW(A&]R'9$MV1%
MF2)<E]UY]V1 _N'#,B554$X6Z/DIEW?)EI=14Q41%5/5,>TX\=:UF8F[UN.B
MX?Q<&3D(F4>:U3H O-Q7;JF@9""CB61;+?0/36B.3*,9QCI/\'1.&,Y1E/6/
MXH4C:V"E3G,B_%US'I$68XYK-+OP$5&"LBVZJ+T="^6MD=QG&.V)TJ8^$]6N
M>#"9N8UN)^71CD-I8')G.>E1E61D%CF_(!PP=1R%=6'&R$D4#;5542"RTP[C
MDPJ(G2+^_K\TS[?#.[CK7W=/DC1-B[;AD;J1W'Y;TB+-DRY#SKK[TF#_ '#C
MAD2JJCT>:WDK/+N^3+QTJ8JM(B>K#'M./&YK69B9GQF8Z3*<.VL*$&/C1C(D
M*++3(,-:CZLE)"RD.][_ -XJE;H_)6O]?/=.5ZS%?"J_!M_0PV[:TB;^-W^+
MCY.Q7I^X67.ZV(.+B91O,))2:\^V;K+BNH;4)1%MIYPM*.'Q1.LJ7);UWX]W
M&/'/JF9G';TB/GEUF(\'!EVF_./3$1&6[K,ZQKICTB;ZS_%UN-VSC<9D7\JT
M4B1/>$FA>ER'9"M,F2&K37,)= *2(MD\R>9*X<^?+/&,=(CV17QEW8<&..4Y
M:W[9OY+=UMMYLV710VG!4# DNA"265%3Y4K1$U-MTQ:BP.UHN%2*Z;BRYT&,
M>-B3#N+B0%<1P&B1%TJH:1'7:ZVKIYNXGDOPB9N8]OFY^+@C"O&8BHGV>35D
MMB[<RT]Z?.8=,I)LO28POO!&<D15!67C: D%7 Y8HA*G0B7JX=WR88Q$3TOP
MBZGK%^3'/M.//*9F.M3UFKCI-><4WKM'!K-DS5:<59<EB>]'YI\CMD4A,'Q;
MO9#N ZE3TK)>L?W.>V(\HF/;4^#/]OA<S768GXQXMN1VM@<JLXLA$1XLD$=N
M62D8DJ0R(V%%1)% @(U(2"RHOEJ8=QR854_ENOCU^9R=OQYWNB]U?=K'RGHJ
MI>RL9'PV0CQ(*Y>?-5EV0YD);R2'SC$BM7E=<P)M/[I1]%?-=5K=CW64YQ,S
MMB/*(J+ZZ>WQ:LNUQC"8B-TS769N:Z:]8KP\E?M_8$=6\T]N&&"%G"B*[%[2
M]*?%8 KRW7)9*)D]J74A!IT6'3YZV\W>3Z8PG\E^$1U\-OE^+5Q=GCZISC\]
M>,S^7I.[K?X:4Z*-M7&LM16Y#LK('"E).C/3I+LAP'Q FQ5"(NA!,NKT<:Y,
MNXRF9JHN*TBM'5'!C%7<U-ZS>K<6V\,<\LH4:\XI3<\G=1\9+,=8H':]N#1*
M-NC\M3]?/;MO2J^%W^++]'#=NK6[^-5^#1B-J8O!R2>QAR68UBY6.[2Z4)KF
M+J+EL*2@-U55LB62_"U9<G<9<D5E5^=:_-CQ]OCQSZ;KRO3Y(V1V)MS*2Y<J
M8RZ3.0_F< 'W0A2R04!"?8$D UTBB75.-DO>LL.[Y,(B(GITFM8]TL,^TX\I
MF9C\W6/"??'24R9MC%3L,Q@Y'.6'%)ER*X+[HR&SC&AM$+J%KN*HEEO6&//E
MCG.<5<^S37KHV9\&.6$83=17C-Z=-4<-EX54#MBRL@XT,@&GITEZ0X#<QI&G
M@$B*Z"0IT?E2LI[K/PJ.G2(CIK#']MAXW/7K,SUZO']B[7D!H<@HB=ECP;@X
MX!<F$2''74)(NMHDNVYZ0\;+QJQW?+'CXS/SZ_/QCHQR[3BGK'A$?+6/EX3U
MAM:VU"BQ6$59.3DP'RG0G)TIQYQ)'*)I/M#5;)I)1M:W&]KUC//E,STQB8J:
MCP9QP8Q$=9J;BY\>C7M+;[N%8GS)XL=]YJ4>0RBQ45&4>,1;$ 4D15$  1U*
MB:EN5DO67<\T<DQ$7MQBHMAVW#^G$S-;LYW95Y]/NB(]_5;1<9"A2ILR,UHD
M9!P7IAW5=;C;8M"ME6R6$!3A7/EGEE$1/2.GXNC'#'&9F.L]?P4\38VW8639
MRK##O:(KSLF T3[I1XKLD2%\F&E+0',UEKX>5>BNC+N^3+';,]8J=-9KI<^Q
MSX]IQQE&5:Q,S'LF>M1[;EMQFSL#B3BG$9/_ "#TB1CQ<=<,8RRPT. TBE80
M5.@.A+\*QY.YSSNYZQ%^VO-EAVV&%5'29KV7Y,)FR=O2Q-49<C2BENY$)L5Y
MQF2W*?!&W#;<$M0ZQ320IU53R5<>ZY,?&XJJGI4)EVO'EX5-W<=;5F9V=$BX
MF'$P&(&0[$DN2@=2<[!FB\^A<UX92"9D9J2\S6O63YDK=Q=S,YS.>57%=+C3
MI%?@U<G;8XXQ&&/2;ZS$W/6;\Y\?-KP?AUCXN$&%D1Y.0[=)RC3^/>=;<BR)
M:KJ1E]51Q>JNDR+T^*JGDJ\O>Y3G>/2HQUK6(\XZ?R8\798QA676YRTO29\I
MZ^_S=)!V_CH,F/-#FOY"-&.$$R2\X\\K#K@NDA$:KJ52%%NO^RN3/FRRB8\)
MFZAUX\..,Q/C$5:(WLK;#39,ICP-@XTF";3BDX!1ISW:'@42545"<ZW^RMD]
MURS-WXQ/QB*AK_:\55MTJ8^&4W/S2L+@(N"!UN+(EOMGI0 F2792- ' 0;YI
M%I1/S^>L.7FGDZQ'PB(;.+BCCZ3/QF9_%@NU=OJ]F9!00)W<( WF%)25) -M
M<D45%6R=1;=6WYZO[CDK&+_)^7V>+']OQWE-?G_-[=*_!7,^'NV&P?%YA^8[
M*;88DR9<E]]YQJ(]SV 4S-5LV?HV_+>ML]YRS53$5?2(CK%3\VN.SXHO2YFN
MLS,Z3<?*4K)[-P.6=E29+)A-EN1WCF,.N-/@]#$@9<;,2300H9)<>E%XWK#C
M[GDPB(B=(O3W]6?)VV&<S,QK-:^.G0QFRMMXA^/)@PU"1&?E2VG2=<</M$]$
M20X2F2ZB<M=;TY.ZY,XF)G28B/A'3Y)Q]KQX3$XQTF9^.77YO7MG8)T%1MIR
M,\L\\L,F.\XT\,QU-+AB:%=$,54"'T5%52U2.YSCVZ;=?)9[;"?"M=WQ0\CL
M:%,">3,R2W,GMN15DONN2NSQ9)"LAN,#I*+7,0=-T3AP\R)6S#N\L:N(J-?*
MYCI?G3#/M<<KUFYT\ZB>M>5NFCQV8D=J+&!&X[ "TTV/0( FD43Y$1*XYF9F
MY=<1$14-E12@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@IMU?R-_\
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M2(]_@MF=H\B+*BLNML-2'<>\VRT"HVTF/Y-P&ZW5"Y7"_1>M$]S<Q,ZUN_\
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M6G'GJ(BNF[_Y-L\-S,WUV_<KXNQW(_8;S4+L;T1Y?L[:NRORGE3TN&KM-O\
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M3$]:N*G&)CR5^"\'(,=UG,[BFE,W*4J1+R!M"V_%?"1*24+)I(:N7+-+HZ(
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M95 LB6#2V-D6_P ]<')RSG&,3_3&V/=U_B]/CX<>.<IC^N=T^^HC^"PK4WE
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MP.$P(2&\)CX^/;EO%)DC%:%I''C](R042ZK06- H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H%!S6[?Y'D?V!U4=&'H#\R5%94"@H\SU<MBC7@)
M!+;1?)J)L31/RH"UT\7Y,O@T<GYH^+!QMMYMQAYL'6'14'6G!0VS DLHD)(J
M*B^9:L36L$Q$Q4H&-PNW-M1I)8C'0,)"5%?G.1FFHC6AI%)3=,4%-(I=;DMD
MK;GR\G+,;IG.?"]?DT<?#Q<&,[,<<(ZS41'S<EL#<.!W&]N: VBN=OR,G+QH
M<YA6^V8J2C3;<IIMY/M&2)M4O;APU(ETKN[S@Y.*,)\L8QN)Z91>DUTEY_8]
MUQ<TYXQXS.41,5NQG3=%]<=/P\X=='P&WX;P28>&Q\>2VMVWV8C#;@KYQ(01
M47YJX<N;DRBIRF8]\O2QX>/&;C&(GW0VY4T;Q4XUZ.08_E--"?VDE8\<7E'O
M9YSZ9=)';5EAII5NK8"*K_PI:N.9N71$5"KD8><\^XZ&25L#)2%M&0+2B^2Z
M\5K*,YA-K5W'D/O4O<-U=\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?>I>X
M;IODVG<>0^]2]PW3?)M.X\A]ZE[ANF^3:=QY#[U+W#=-\FT[CR'WJ7N&Z;Y-
MIW'D/O4O<-TWR;3N/(?>I>X;IODVG<>0^]2]PW3?)M.X\A]ZE[ANF^3:=QY#
M[U+W#=-\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?>I>X;IODVG<>0^]2]P
MW3?)M.X\A]ZE[ANF^3:=QY#[U+W#=-\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;
M3N/(?>I>X;IODVG<>0^]2]PW3?)M.X\A]ZE[ANF^3:=QY#[U+W#=-\FT[CR'
MWJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?>I>X;IODVG<>0^]2]PW3?)M.X\A]ZE[A
MNF^3:=QY#[U+W#=-\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?>I>X;IODV
MG<>0^]2]PW3?)M.X\A]ZE[ANF^3:=QY#[U+W#=-\FT[CR'WJ7N&Z;Y-IW'D/
MO4O<-TWR;3N/(?>I>X;IODVG<>0^]2]PW3?)M.X\A]ZE[ANF^3:=QY#[U+W#
M=-\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?>I>X;IODVG<>0^]2]PW3?)M
M.X\A]ZE[ANF^3:=QY#[U+W#=-\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?
M>I>X;IODVG<>0^]2]PW3?)M.X\A]ZE[ANF^3:=QY#[U+W#=-\FT[CR'WJ7N&
MZ;Y-IW'D/O4O<-TWR;3N/(?>I>X;IODVG<>0^]2]PW3?)M.X\A]ZE[ANF^3:
M=QY#[U+W#=-\FT[CR'WJ7N&Z;Y-IW'D/O4O<-TWR;3N/(?>I>X;IODVK2!&=
MB1T9>?60:*J\Q10."KT63APK"9M8BDFHI04VZOY&_P#M(_\ J&ZL"8SZ#GS%
M03:@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4'-;M_D>1_8'51T8>@/S)45E0*"NS<)Z;"_RENW1C
M&3$U<!5UI;H*_(27%?GK;Q91CEKTG26ODQF8TZPKHTEF9'"4Q=&W+]4N!@8K
M8@)/(0KP)*W98SC-2UXY1,7#E?$;;.3W/@V6,9IEE!D!->V^^?*BY46N*1W3
M3H5%36UJNVIHB&BCT=W9<^/%G>6EQ6Z.N/MC^/C71YOU+ML^;BK&(RVS$[)T
MC.OZ9G[XOTW^;1P6.;E>(&5@#MY)&./"2AE9+<$AHX\K&/@MG(#0%;5)<1.6
M^"ZF@#B6I5&O2SKML9WU.Z*C'K&4?W3_ )8ZXSUF>E:O+QR_>Y8_IWCLFYRF
M*G"?'"/\T],H_+$=;T?;25%)51+(JW1$\E?.OJ$56^\<DSC02[,8@E9$O(FG
MK,M+\I%8R3U43SUG>W&<O/2/XRP_-E7EU_@Z:N-TE!\_/<.<B9-QE]XW8,G,
M&Q!(&DN QVU)R(2HENN@J;9]-[C?T;U$J'NS,Y!&H\/L#LF23*A)!73CLB^P
M\\K;B)Q5P.2B*FH;H2+U>BE#=B=VY+*YEB$$)MJ*3++DA#,4=3GQQ?UAJ-"(
M44N79&O.NI+6I0BO9:2UE);S.5=<R3612*U@QY;@NQ1$"-!:0=0KI4C1S5TI
MYEM0>8_=N>R(8Z6K46/$DRP A54-QQDXKKRLB@.EI=$@$44K:O52E! WKE9S
M$9QQJ)""<Z*,2I!HK32<M7":=$'57F<-*:B"_'JI:RJ+82]X9V$[)C"W&DR"
MR,F-#Z&@;98;!P&W2<=!-;FKJE?HXZ5I1:9'W%D9FZH$ G8[$8BF@]C@(BEB
ML8!1"=_1TJJW&UN"C95OP#LJBE H%!"FSW8;C3;<"3+1SI..C2B'%$ZVMP%_
M,BT$V@4"@4"@4"@4"@4"@T3)!Q6">".[*(51$98TJXMUMPUD"</GH/8KY28X
M/FPY&(TNK#VE'!LMN.@B3\RT&Z@4"@4"@4"@4"@4"@4$(\@Z,\820))-K;_.
MBC7(2Z7XJKB'PZ/0H)M H% H% H% H% H%!#R$YV" $U!D3E-511BHVJC9+W
M7F&'3\E!+ E(!)145)$7272E_(MKT'M H% H% H% H% H% H% H%!3;J_D;_
M .TC_P"H;JP)C/H.?,5!-J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<UNW^1Y']@=5'1AZ _,E1
M65 H%!2S\.^,AS(8@@;DNV65$=ND>0J<$);<0<1.@T^946NC#EBMN73S\8_P
M:,N.;O'_ &J\LFTQU<DR]CW$X+SVR-I5_P!UUI"%?[*V[)G\LQ/V\F&^NNCT
MLUBEM>8V2EQ06Q,R)5\M@%555\]/TLO(_4Q\V;:97(+H@,'"87TI\P$$T3_]
M$PMU5?,3ED^1:D[<>LW[(_C/\E]672*]L_R7F/Q\;&QDC1D73=3<<-=3CCA<
M2,R7B1$O2M<V><Y3<MV.,8Q4)58,T)S)(VX3?99)Z5MJ!I5%?F7RT&'>8?!2
MNF_]RO308!/8:14:@2 0B4U06+7(NE>'E6J"SHZNB^N/D<X!T YV?K(*]*(O
M2B4!)[ N$\D"0CQ)8G$8ZRHGD5>F@Q27$'5IQKZ:CYI6CVNYTZU_WOEH/%D0
MB%P"Q;R@Z7,=%8R6,[WU$GE6Z=*T'KDN(ZA([C7S0U$C0H]]1!Z*K?I5+<*#
M-,@R+A.C DHZ:(AFC"H1(/1=>E;4&7>J?!RO<K4#O5/@Y7N5H'>J?!RO<K0.
M]4^#E>Y6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]
M4^#E>Y6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4
M^#E>Y6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4^
M#E>Y6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4^#
ME>Y6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4^#E
M>Y6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4^#E>
MY6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4^#E>Y
M6@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H'>J?!RO<K0.]4^#E>Y6
M@=ZI\'*]RM [U3X.5[E:!WJGP<KW*T#O5/@Y7N5H)<=_M#:.(V;=U5-+HZ"X
M?(M!MH%!3;J_D;_[2/\ ZANK F,^@Y\Q4$VH% H% H*69N 8FZ,5MI8ZF63B
M39B2=:(C:028'2HVXZN?TWX6H/-S;B';C.-=*,LGO')0\6B":!H6:ZC7,6Z+
M=!O>WEH*Y=U96;F<_@L)BVI$[!.0@,Y4I8[3K<UA7E)%%IQ44+(-E3CTWH*_
M'[OWKDLGF,3'VY!&5A'66)1'DS0#*0P$@5"T15L@FB+=$XT$EK=6YLEELUC\
M'A(K[&%E!!>?E3R8)QXHS,DE$!C.6%$>0452XVH+'*[H/ XR"YDX2O;AR+B1
MH6%@&C[C\I14U!LS1I- @*F;AH(@**JT&N)/WX<B.<["XYJ"\8"^VUD'7)+
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M5E,N.,O"XR) ! 8$BBJ"1)PZ47C66'/GC%1.C'+AQRUGJS+;^)<9>9?85Y)
M,-R3=,S-U(JZFE,E*ZJ*\;]*^6I^MG$W$]+^_JOZ6/C'E]R/D=I8'*..NRXQ
M:Y',24K;KK2O \ -FVYH)-0$+87%>'5K+#N,\.D]/N^UL<^##/K'4D[3PDE7
MB-IP%>-I]%:>=;5M]@.6#K6DDT'HL*D-M2)9;TQ[C./]GA/@3P83]O)7.;!Q
M#F1:?17&H#4(X/9FG7FS-'G^>[S'!-"-'%]-"O=>-;H[S/;7C=^'E4?)JGM<
M-U^%5X^,W/S6*;3P(SPR 15!QLP>%@7#&-SF10 =Y*%R]8BB"A:;_F2M/[C/
M;5_S]U]6W]##==?R^3)G:^(BRH\N$#L1R.VVSHCONMMN-LHJ-BZ E9S2BJB:
MK\.%)Y\YB8G7X?AY+'#C$Q,:#.UL,PI&+;I22(R66X^\<A"<;5JZ.$:DFD%T
MCQZODI/<9S[O*HKS(X<8'-LX]<,[AHZN,-NGS^TB:G([2AHZCRF>I2/6*%<J
M1SY;]TZ_A7D3PX[=L?:?-Y^%L5VQR<B.MO2%US&F7G6H[[BCI4W&0) )53I6
MW'RT_<957ETTUCXI^CC=_;Y,LAMO'SL>S ;18O962C0WF^)L-.-\DT#5=+JW
MU;K>W34PY\L<IGK<W/M\?Q7/AQRQKI73V+2.PS%8:BQP1MA@!;:!.@0!-*)Q
M\R)6F9F9N6V(B(J&RHI0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!04VZOY&_^TC_ZANK
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M)B)@2$!(BB2+=%1>A46@]H% H% H% H% H% H% H% H% H% H% H% H% H%
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M51A1QNHDMF6TZP$IBO >D2521?(2JO34W9><_-=F/E#R1C<9+DMS9D"-)FM
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M17]4]?9'E_-WX>N;\(^]TE<CI*#A7-M9AS+Y',S0"1&R[<B#-@,V;?&&V/\
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<UNW^1Y']@=5'1AZ _,E165
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M)8[1R_\ ,J"NW6ZMHJ#;R=*JM!MH%!3;J_D;_P"TC_ZANK F,^@Y\Q4$VH%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H%!S6[?Y'D?V!U4=&'H#\R5%94"@='30%5$2Z\$H/$(55114
M4DZ4\J7H/:##FM*0@ACK-%(!NEU%.E43RIQH,E(45!5415Z$7I6@]H% NB=/
MEZ*!0*!0*!=+V\M H/%)$LBJB*O!+^5:#V@4"Z7MY?-0>*2)9%5$5>"7\JT'
MM H% H%!XA"0ZA)%'SHO#A0>T&LWV&TU..@ W4;D2(ETZ4XT&8D)"A"J$*\4
M5.**E![0*#Q"$KZ51;+9;>1:#V@4"@\54%%(E1!3I5>"4'M H%!BA@1$"$BF
M-M0HO%+]%T^6@RH% 541+KT4'B*BHBHMT7BBI0>W3H\_10*!0>$0CQ)4%%\Z
MVH/>GBE H%TO;R^:@='30%5$2ZK9//0>(0JJHBHJCTIYJ#U51$NO!$Z5H/$5
M%1%1;HO%%2@]H/$(2OI5%LMELM[+0>T'BD(VU*B76R7\JT!"0DN*HJ>=./10
M>T!%1>*+=*#Q"$KZ51;+9;>=*#U5MQ7HH% NE[>7S4#Y/+08@XVX".-F)MKT
M$*HJ+^5* #C;FK02%I726E46Q)THMO+094"@4"@4%-NK^1O_ +2/_J&ZL"8S
MZ#GS%03:@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4'-;M_D>1_8'51T8>@/S)45E0*"DW)MR-GX[
M9$ELA$1PH#I&X( XZ"@JD(*B$EEZ%1:HJ?P]N<&W(ZY4I#+L9&P5QT]3<LFU
M1QXKC]H"E:S2\$HB)^%=V)*E26\P3!R6@;,FW%(E?: AYRJ8*B JK_=#P'I1
M;TL;Y.V]U 4M<?EE1Q\F@CO//.FK3#)D8BHJBH2EK762\53A09'M'*#)@N1,
MBL468T.')%EPP4F8VOF('!=.K4EEZ:6(LC:FZI3D9XLN*R(ZO:97,/\ N75Z
M@"&A40@1!NYTDO&EC*7B-V#.[)#R#[C.MPV)*OD -QT;(09<N)<PU<42(O2T
M\$7RT%E/Q&YY,X7(V3*-"5&U>!HKFKB!I7EZQ5! 5ZZB5U/H5;<*"&[MS<IR
M&Y8Y!6Y"- T^I2'#%PFR<U* J-F^8A\%%+A\M!(9P6YVDD.GF%0WQD-B!.$8
MLMFR@QT%5'B;9\2<M<O[*")(PF\0GQP9R;SL<CD:G>:@-MHK=F#(--S4%X*%
M['TK0;2VYN5ZZS,J:M K) T#[C>MYI]IPW%)!ZJ.(!:6^(A>W%*"=W5N9(D0
M&\@/.;%T)7,(U5P453974B)8[V%Q4LEKVH*MO;N]FXP*N9!V?8@-TR/JA]EH
M4;"B71077?TK_F#8>V-S"33PY=QZ0VRZ-U?<%$D/.:M5M-E#2(#IMPXZ;+03
M,A@,SD9@N.S":!IQ'V'6'G&]"I%-G0@(GZP]:G?B/56@AI@][FW+<>RX=H>9
MT,-MF8-MO&(HXX/5O:XW!"OINM!D_M[=+R,O+DR'(- ;;\AMXQ!Y'":)5%K2
MHMJJ-D"=.F]TH,7=N;JNO+RIF3Q+>2KR@\T(J2MHB"WI(;J.L>%[+;II8VQM
MO;B&= E3,@LD(CA/B+SI*@%R'6M&D %#12-#0BZPI=/-0>Q,-NT(\YN7E4YD
MEI\([J.%]B3I(K6CJ]()JN1:E]&W0M!X6WMS$^3*9AQ(7:!474=/FC"0T56+
M:>+A)QYVK5^C\M!M7![D!R%+7(\^7$;-LPUDTV8\]MQ!*PKJ4@!04R2Z*M_*
MM!':VWNP&B<7.GV]>LA*9FRBJ073EJ*);0A"G^\NKIH)47#;C:9GD_D2,GR8
M6''YQER6&U0G&N:HHJD?63FVOQ3S4%5 VEN:+!2 N970*O:&Q<7DJ!BZH-E<
M-9*!D*D=^NG2E+$YW ;P)Q%#.D("*MMZ;)U6R703EP741AU'+6LO6&@D1=N2
MEPO=LT67'$G). G2*382F=I(2(Q15)!ZFKRT$&+M?<,(68C&8=''LL@'(9<1
M'!>TKK-#< NHO 1;M8>E*6),7";I5B8,S+EVA\6Q8)H[-MB)BJHEQ4D-!$D4
M[]92\EDH/&\+NMHT<[U-YU#4C%QQ!9(!,31 $0N*DB:5U*2"E[)018FU]S1'
MRG=O$ISSA..Z7G49L4CF(ACI35]G]G=-*\$XVI8DSL)N^5/ER&,ND:&2DL:.
MV1?,E[BMKCPZ;(762@VS,#N-T63AYEUMYMB.R7-.Z%I-PGU) !!4S$@ 3MU;
M7^<,(NW\^VWD=63)N3-.*XT?.-U6&V26[::DX]5+*=DU^6U!7GMW=DA7($K(
M&ZRY&;!R0\]=HG%-Q'A1H034C@Z535_=^2]!)3![T+M',RHBKJJL;E.&*1UX
M*:6(5UB=E$=7]WTI>@S#;FZ1:-P,ZZDU>8K)NFKC8*1-\O4V@B): 0TZ.*JB
MT&AW:NYWXS@NYEXW#..J-$^8HC3-R<%";$;*1H*H?3;AT<*6-[^V\\+V0=QF
M1Y)9!]Y\'D=/['6* EQ450^":42]@7K)02IF)S[KVJ--(XH@T("D@VB46QLX
M"D(EUC+K<WI_1M05DS;V\F<?(>8S+LG)J*J@BXH 1$X=T 5'2'V:@(^94U=-
M!O<V[NMTG%[X,([I(@1D<UJTUH5-*F8+K5"6Y*J=9.'D2@T+M3=C+00X6<-F
M$VPRTP FNILP 4<53("(A*RH*?H>2EB46"W2LDW(^4%66N:<(GC)Q4--7)%4
M0>(65$=NJD7&RVX4&Q,5N*%&R+C^2?F$1 ;#8$EU:%Q#)L-(H0DHW;U77S]-
M! A;?WHY!!9N:=9DD!%;FI8!)IP6VR5 NI-F0D1_I^7HH-DK:.X'R:!,MSHH
M*Z9!),W2U:BY*HJC^B*C?SJE^-+&;&W-V,]A3OUPF %%FB!7(W>8JH0*8*B
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M-(J+_=$BC97%]+FWO^C\M!JRN.W<QAHD6'.>D9<B<$I(%I1'C=$FW7%T:>6
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M@[V'*,!.<!(CQM\]&[. (-!J<,2TII4R$105]8E3HH,>P;Z VU[8+HGJ-SK
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M!?M )=5_1H(\L=\8^\AUWM )$ 4-E *2<YQ-2@(H&CEH:6ZP^CY:"RC,;U"
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MJL9J@'TKU^ BB<;EP#I<(Y-<Q<5,CK7(-M $IQP!;4WA!-9((\$12OT5%6%
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MB0JC82,ED& *B\5T!Q^3HH.BH% H% H% H% H% H% H% H% H% H% H% H%
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M*!0*!0*!0*!0<UNW^1Y']@=5'1AZ _,E165 H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H%!3;J_D;_P"TC_ZANK F,^@Y\Q4$VH%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MNO!50:#LJBE H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H*;=7\C?_ &D?_4-U8$QGT'/F*@FU H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H.:W;_(\C^P.
MJCHP] ?F2HK*@4$*;D68KS,7E.29+R$8,,BA$@-JES74HHB(JBG%>E>%!!<W
M+B1B-SC%Q676I,@41I5/3#32YP3]+]$4\M48N9K!,8R(?)5<?+9[0+ ,W0(_
M54S<"W5$5--7E1?)1$=S/81MU^...==>C@XU)::C@:@S&T*J+9;**(X*H(W7
MY+T&P\]A YLE(CA\AKM/.%A%O%?NI/BOJ+I75Y5\U!LE9_#"#\>0PXZB/$R[
M'5A2U<IL'B<TJEE 0,2U?^V@BINK:[1-.@"(3XCV=P6A17(XW07 7@I EETH
MG'S)2A;0W,9E$?)J.*K%DDPYS6D%4>C=5"2Z<;)Z)>;HJ*\RD[%XT\=V]M%*
M3*"'")&]>A]T24>-NJBZ;7^:@@?B7:[\"5+?<;&#'-]IY7FETEV$U U%++J0
M52XV\G%*J,&,YM"5.<A-*PKLQ"YI$V(@Z<=WDJ)*2)J(36R73R\*"Q9R&WW'
M.:R_%5Y5;:U(H(:J1:&Q\_%> >?R5%1G,OAH;PE&CJ\@,-F[)B-"8-1G"70I
M$-NIP4K#?@E[54(6X=MY!EN:R^RBMD38:]*. 2F396Z;(J@5U3S45LC[@P J
ML:-(9".T@Z7&U%&%4C<!1!1X*HJV6JW!/+029&6QK,.3D>:#[,2.LIU6;.GR
M-)&BH@WOJ05T^>H*HMSX!Z5&AL,',EN,QYT9MIE"5 ?$U:)%*R(2"!+TW1/G
MJHD%F<.QCV\FS&(@G/*TK0,H#ROW)#%P3TV(5!4+4ODH(;>Y]L3&FY,9OM3K
M,H6V&0:17D?=ZJ&(E:UT+B7YZ"1,SFWDPQ9?(,_Y&,\,9UIYE"<9=-T6%$@5
M%M922]N&GCT4&UK,[<DO2&2)H3@/GC25X!%$-&P,P!23T+&(JO1?A16J/N+;
M1RGF8YM(N. 0*0(@C8":"2 "]/&X\!3S41,')XCMT=IG2<QY58 @%-0BH$]8
ME6RH*H*_)>HJM+<>WIRL.SXYM-N-F<9Z8T(-FPO]Z2$2JFE$1%-%XVLMJJ)Y
M3]MN"ZIN12$A;%U%05U"7]VBI;K)YD\E%:(V;VH_'$V9,;L\EQUY-:("$XT9
M(9JAHG%"!>*^;A1%LUV*;':?:1MZ,YI?:-$1155ZPFG#I\J+45$=G03R!LK%
M-]V(FE^4C8J#*.!K45(E1>(V54%%Z4O01BRNUVE; 7(ND&ND4;TM,.B1)JZ-
M(GH5+>5?)51[.W-AL0;L601-)%QSF55!;71V2.J"6FWZ273J]-%:F-U8>7+:
MAJVZ+LO[)A7&K(XGZ2=*JB)T+J1/RTI&_O/;S,LL.X3#$EAP!".8B%S4 42!
M/,FL1U>?A16YE[ FV_DF5C\ILG"?E6%!0E%$-=2IY41+JG34%,_N+:)1XO,9
M$H;[[D!HT9'EAH=Y17MZ+9.6#Y5X6JHN#SF'5T6C>$FB:;>22ME8T/DHMHI]
M%R45M\U17O><%)LA&V#)6$Y<N< #RP41UZ"*^I51%Z!1;7H-+F>V^3P"4AET
MQ1'N8FDD;511055Z4(D+JVXU4"E8*&Y(1(S;98_DO.$+0B@]IN(D*\.-DXT&
M4#<F+R$09;3R(ALK*%JZ$ZK%M2%I&ZW4;%IZ4NE%8ANC%%"8G*XH#)#FQVE4
M%<,%5$0D025++?RK\G32A(//X5HT;<GL@X1JT(D:(JFEKI;Y+IQZ*@R7.8A"
M(5FM(HN*R5R1$0QZ4OT</*M!HE[CQ<1B,_S"?28JC$;C@3KCNGTE 4XJB4&E
MS=>+!6K(\XDH46"H-W[07!%!OCZ0WZR%:WY%JTC!W>&&9;1YTG19<!IR.YRB
M5'1?,6TT(EUX$:(5T2WS)2A/7,1NTO1P;=<;C+IDR@%%9;-!UJ*K>ZJB*E]*
M+:]16DMR85'$;&8V?50S,"11!"%"'5QO<D5-*=-!IR>[,+B7)K,UTQ<@0AR3
MZ"!%>.9DVFFWI%J&VGIXIYZ#V-NK%RL@.,!'1DN$8LZ@ZIHT1@1(J*O50@5.
MM:_DJT-[6XL0Y+<@K)%J6VZ3')=701$%KJ*+TCQLB^5:@W][0"Q[V3:=1Z&P
M)F;C:*5T;2ZZ?/\ );IH(,'=.+R#K#3/-'M# 2@)T.6*-N-\WK76XJB<"1>A
M>%6D;0W-@C0"[<R+3I +#I&* [S1$A4%OQ%=8HB^55J*CQMY;<DLQ7DFBVDM
M'%;%Q%%45H=9H?2@V3SKQ\E6A8/9G%QR0'Y;;;A-=I1LEL?)N@H6GILJJB)\
MO"H/$S>(5+C-9(=:-:D-%'6J7M=.'1T^;RT'C>=PSK)/M3V#9 U:4Q,536**
M2BENE;(O10:OQ%B%R$+&-R1=EST,F!;5"32V',527R<*"UH% H% H% H% H*
M?<V9<P>,28R+:N&\S'$GU)&@5XT#46A")42_0*4%='WO%(FX<R%(:S)M-NI!
M;$7",G%5-(*I#941-2HYH5!XK5I+;\9O7#96?'QL9'TE2&]:"XVH\LT#F*VX
ME[B:#TW2WDO>E#<UN,4A29<R.0.,37,>U'9)'3=<1S0"#?0ERO?CP3S^6BH,
M3>33\K)O26BA87%L-$\])% /M#A$A-JNNR*"CI453I7@MJ4EK7;F:3<&'CY5
M&A8)Y7!-@'@D(!-N$VH\QOJJJ:>-JBK6@4%-NK^1O_M(_P#J&ZL"8SZ#GS%0
M3:@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4'-;M_D>1_8'51T8>@/S)45E0*"!.QG:I+,YB0Y$FL
M";0NMH)(3;BBI 0FBHJ7%%3RI05GX/@FTS&E2'I$2.9DTP6A!4'31TFSTBFH
M5(47C5M*;"VGCTC!#CN.L1@1]KE@HV6/*-''&>*+85)$M;BB<+TL:AVBR+[\
MH)S[4F6C@RC91MO4#NE"TH(6 NHES'K+Y5Z++'B[09T.,MSGA8<?;?5K2T0\
MMA+-L+<.+0):P+YN-[K=8E3-M1);CKR//,O/.&;I@0W47F08<!+HMD(6Q^5%
MXI14)[8N&==<?1%;-PT54 &T$&Q2PBV.FP*-U47!ZZ*JJB\:6E+=O#00BSX9
MBKT7)&\Y+:<6Z%VA-)CPM852HJ)+VKB)6'BX$ .+BX+*1XC,<M'*;!E66]*K
M=45L5N"^141:"$_L7%O.ZT?D-MIS"%H3'2+CK2M*0W%;<"551.E>*U;2DIW:
M>/DI(&4Z\\,D2;<34(]1Q]))HFD47B=_R+:EB&YL#"O1@C.&Z*-LNQ@<94&3
MY;@B(*2@*:C:0?LS7B*W6EE+)_;L5QQ58><BL.M-QI4=G2@.LLWT"MT54X*H
MJHJEQX>:BJT-AXP'([JOO.N0D<;A<Y&S%MAXE-QI1T(A(5[7+BB(GY5I386Q
M\/JA&VIH>/!68Z&@.!RB(R(2 ALJ+S%3\U+*9XW:ZQ(LR,[(46L@L@I+3*(B
M"L@DTBV1)<1;%%$!M;K*OFI8,;,QT)YN3CWGHTEHW3:.XN((O$1:$$Q5-(H2
MB"?HI2RF\-L0UCM0Y3ARHC$D9;#;NDEY@HNI7%5.NIF1&2KY5\R4M6,G:<%\
MVGFWGF9$>2Y,8<%15!==(27JD*HH]7@E+1ZWMB/R78LF0Y(B./#)5LT'43MR
M4U<)$ZVM5Z+(B(B(E!#'8.#%&A^T=$&!B/)(47N:PB(A(>I/2-4U$?I7I93(
M=DPD=[2LR44T":*.^1 O*6,*"U8="(MD3CJOJNOY%E),3:L.-EES1R'WYRDI
M(KA#IXHY=+(-U3[4K<>"61."4L:#V5CGV&8TN1(?:B@K41%4!Y3:H2*B6%+J
MJ+UB7BMDI938&TH;$IR;$>-B6KYRF7T%LG&S>4U='40JI >LETET+T4L8O;-
M@R&78KTE\H<@=$EE5#[0!=-YM%+3=-!N$O#IX(MZ6+.5@\7/7&E.CC(<Q+PR
ML>;E]33X-DTCB6MQT&2?EJ*T2L$DAZ4XU-D1FYR)VMII11"(01M"$E%2%;(*
M+I7C:J(+6R<4S%<C"1GS2YA\T6S!2T.M\6U'3ILZ75^;S4M*;I&T,5+6&4HY
M#Q0P9: C=U$;;".)I<54N2'S/M/6TCYJ6KP-I08T06(#IL2FW^U!-)!<=5U$
M(4UW1-2(A+9%I:,YFT\5/ES9<E72/(- Q)%#1!5ML@*R<+I?EI?C2U;.X$/'
M+BI$UYZ$@ VR*BV)-\HT)M4(02ZCI3IZ?+01!V=&$'2[?*68[);FI*56]0NM
MF3J(@Z-.A3,E4;>6EHUN[&QCN/7&K(D(P3A.N%J%2-"2VE;C:P](<.JO12RD
M]_;XN'+[/,?BQYQ<V3':TZ5=LB:D51U)?2FH;V+\JT5 '8F(#'CC@<>Y8HXB
M$2@7%T! EMILBH@(HV]%>*4M*2Y&V(\@W-<N0K#[4=F2VI"1.=D74V2F0J6J
M_I<>-+&6.VQ!Q<IV7$5>8Z/I."#C@N* -D8FHZDU( W'HHJ*&S88)(1)3HI.
MLN0%L6VP>4"U"J"(6!46]]%M5U5;KQI:,X^S,5':<9!30#;=8110 +DO*"J)
M$@W+3H32I="4LIX.SH*.1C-TGQAH3,=M\&W!&,9"?*5%'BB$ JA+UOEI93+\
M'XTHD:,;KZ.0WG)$60V?+-HW;ZA;TI8 X\!1+)Y*6,0VA&9=)V/+>:4>4L5$
M1M>0K/1H516Z*JF1H5]1$JKY++&D]AX=X7&I3CS[*B#<=")!-AMO3U&S!!+2
MJI<D6]U55I92PD;?%QR6L>8_%CSBYDF.UI05=TH.I%4=27TIJ1%L7Y5HJ .Q
M,0&/''@X[RQ1Q$(M"\70$"6VFR*B"BC;T5Z*6E),C:&+EO-R))ONO-Z.N;FI
M2Y;!L)J54ZWI:UO^F(EY*6KT=K0HT5IG'.%%DLO+)&6@@;A.%K0E.Z6+JN$B
M7Z*6CU_:>*D]NYRND.0,7)(Z[(JB2DB)9+HEUI:MQX$96/7%Y*6[,A$C8D!B
MV"D+1ZT$E 4NBV02\Z4$>-L_$Q'GG6%>$7D=%&M:<ML'A42$$MP3K$J)YUI:
M*^=LALC%<8\K"NA'CS'G"U$L:*K6D!'3:ZHWQ6Z=*TLI8'M* J)RW'$^R&.0
M.:'6R:%HFD$@,514L5Z6,7]GXY^.RP;SYG':CM,O.&CI7B.*ZV1:T74J$O&_
M2E+*:2V/BEEA,%>6;97!@&VTC:5%!-%9TZ54D%$4NG@GFI93)[8^(>;!M7'T
M1J.,9I-:*(\MU'0<MIXF*IINOZ/"EE,X^T8L20Q)AR78_9S-]MEH6Q9[0\"-
MNN:-/Z2?H]"*JK2RG15%*!0*!0*!0*!0:9$2/+1M)#:.(RX#S=_T7&UN))\J
M+04V0VEC):2G8[8L3Y*Z^T%K<$#(A(B$-8H)$H)<ALJU;1(PVV\;@VV0@HX*
MM,A')>8>EQ&T1!(P1="DB);5IO45(?PN,D17X;D=.1(=62X@J0%SU)#YB$*H
MHDA(BHHK090\1C8#9MQ8P #@B#B+<M:!>VI2555>*\5XK0;84&'CHXQ(+ 1X
MPJ1"TVB"**9*9+9/.JJM!(H%!3;J_D;_ .TC_P"H;JP)C/H.?,5!-J!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0<UNW^1Y']@=5'1AZ _,E165 H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H%!3;J_D;_ .TC_P"H;JP)C/H.?,5!-J!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0<UNU%7!Y&R*OV!K9$NO!/,E5$@=X;7011<K'Z$_2I2O?Q
MCM?[UC_7I0?C':_WK'^O2@_&.U_O6/\ 7I0?C':_WK'^O2@_&.U_O6/]>E!^
M,=K_ 'K'^O2@_&.U_O6/]>E!^,=K_>L?Z]*#\8[7^]8_UZ4'XQVO]ZQ_KTH/
MQCM?[UC_ %Z4'XQVO]ZQ_KTH/QCM?[UC_7I0?C':_P!ZQ_KTH/QCM?[UC_7I
M0?C':_WK'^O2@_&.U_O6/]>E!^,=K_>L?Z]*#\8[7^]8_P!>E!^,=K_>L?Z]
M*#\8[7^]8_UZ4'XQVO\ >L?Z]*#\8[7^]8_UZ4'XQVO]ZQ_KTH/QCM?[UC_7
MI0?C':_WK'^O2@_&.U_O6/\ 7I0?C':_WK'^O2@_&.U_O6/]>E!^,=K_ 'K'
M^O2@_&.U_O6/]>E!^,=K_>L?Z]*#\8[7^]8_UZ4'XQVO]ZQ_KTH/QCM?[UC_
M %Z4'XQVO]ZQ_KTH/QCM?[UC_7I0?C':_P!ZQ_KTH/QCM?[UC_7I0?C':_WK
M'^O2@_&.U_O6/]>E!^,=K_>L?Z]*#\8[7^]8_P!>E!^,=K_>L?Z]*#\8[7^]
M8_UZ4'XQVO\ >L?Z]*#\8[7^]8_UZ4'XQVO]ZQ_KTH/QCM?[UC_7I0?C':_W
MK'^O2@_&.U_O6/\ 7I0?C':_WK'^O2@_&.U_O6/]>E!^,=K_ 'K'^O2@_&.U
M_O6/]>E!^,=K_>L?Z]*#\8[7^]8_UZ4'XQVO]ZQ_KTH/QCM?[UC_ %Z4'XQV
MO]ZQ_KTH/QCM?[UC_7I0?C':_P!ZQ_KTH/QCM?[UC_7I0?C':_WK'^O2@_&.
MU_O6/]>E!^,=K_>L?Z]*#\8[7^]8_P!>E!^,=K_>L?Z]*#\8[7^]8_UZ4'XQ
MVO\ >L?Z]*#\8[7^]8_UZ4'XQVO]ZQ_KTH/QCM?[UC_7I0?C':_WK'^O2@_&
M.U_O6/\ 7I0?C':_WK'^O2@_&.U_O6/]>E"MSVY<#D,8<.%/:?E.NQT;:;74
M1*CX+P1$\R4I'0L>@Y\RT5-J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05TUM51;=-44#T5U2OQH
MC5V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY
M:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1WY:!V1SY:"5$C.B2=-!?- J,&G
MG%4_LJ*FT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@P-I#Z:#0L,5H/.Q#0.Q#0.Q#0.Q#0.Q#0.
MQ#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.
MQ#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.
MQ#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.
MQ#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.
MQ#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#0.Q#09#$$5H-Z B"J>
M?A094"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4%%C\[/R$A\QQPM8=A]^.L]R0**21B)LC1M!7J
MZQ5.)?+06+66Q3\8YK,Z.Y#;)0.0#H$V))Q5%)%LB\:#R1DFVPB.L(,AB6:6
M=!UL1%G03BNHI$FL41/T+KQOT4%3@]TKEW&!>C#$!V%&FJ1.H6DIIN"RU;2-
MR40U?EZ*"ZD9''PP-R7+98;:(0=)UP002)+BA*2I953HH(K>X<,[D9F*&:UV
MZ VT]+:4Q30#UU%5NOF2Z^:Z>>@VN9K#M-,ONY",#$GC'=)YL1<2]K@JK8NG
MR4$,MS8YQ_(PL>8S<GBS::E0P<;;)#?TV2[A"/!"2_'IX=/"@M4DQE1HD>!1
M?_N%0DLYU5+J\>/!+\/)0:XN1@3FC?A2F9++:J+CC+@N")"EU15%51%1*#!K
M+8IXG@9G1W#CCKD"#H$K8+^D=EZJ?*M!N<EQ655'GVVU$>82&8C8+VU+=>B_
M"]!'7-X849(LC&09"BD=5>;1'%/T=''C?R6Z:#8YDL>U+" [+9"<ZEVXQ."C
MI)QZ 5;KT+Y*#T<CCS<D-!+9)V(FJ4"."I-)TW-+]7H\M!J[ZPRL-RDR$;LS
MQ\IE[G-Z#<O;2)7LI?(E!NF3X..:1_(26HK*KI1Q\Q;%27C:Y*B7X4&$G*XR
M$ N3)K$=LT0A)UT 11+H5%)4X+01QS EGCPN@4$(S<CGJ:<7'C<06T&W%=+1
M'T]%!8-NM.Z^48GRR4'-*HNDTZ16W0O'HH.=8WG">A9^8K#C:X!QX'&B4;O@
MT*J#C:HMM+BH0C?RHM!=!DX*R&X#DAEO)N A]A5T%>3JZEZJ+=;)01\;N##Y
M<9IX^6V\&.><C3#0DL#C7I76_0G'C\BT%?A=V0LECPS$N3#B8R::IBU*0*FX
MV*VN=["A+P+2*K:]EXT%X<V&W);AG(:&6[=6HY&*.$@I==(WNMD2]!@[D\<S
M)2$]+9"8HJ:1R<%'5%$555 O>UD7R4%;B-Q=XQ(\V7'&%'?B,S%=-]I1#M"E
MH;5+H2+I1"NHHG&R<46@F%EXSC#$C'&W/:??"/K8>:TI<K&NI21%T(BJHCUN
M'!*#<WD\<Z^]%:F,G)CHI2&1<!3;1%LJD*+=+?+05TS<V.:98<Q[S.0-^9'@
M(+#HD@G(-$524=5M(:CMY42@MR?8%7$)P!5H4-U%)$406]B+S)P7C\E!J'(X
M\Y(P@ELE,,.:$='!5Q6U_20;W4?EH/8N0@3N9V*4S)Y):'>2X+F@NFQ:56R_
M/02*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#%PU;;,T%3414D ?2)42]DOY5H/GJ
M[5DPMIX[3%>D2C=CR=P0.:;BNLF]VB2T+1&K:KK7B(IUD11\MJ#*1@'L_F$E
M/XE8V%F3(*N1W0$"-K$@^^+S[=^&MXFVQ%4OI!-7#A06.\,?D9L@%@0W'4AX
MV?V4FU%![7+$([8I=4LH@KA?-05SF$?@RDFECY#L"+E(B"VT*.NK$Q\'E,."
M"+=1YY*OG3IH-,F#FSBGE4QLAK<[^6?GXV.H \RC8B,0&Y9(2@(N,)=50KA?
MJK=+*&Z=@Y67>S4&9BB)K)9J$,LB$4:<Q<=MDT5"1>L*JRHF/3<K6H-$O$Y&
M6YE,:YAW'9V2R+;4C(F()&9PC;S>@6BOQ3E);E"GIJ1+\H3(V(GR9:@_#=:5
MS<CLZ6\0"(+&B@I1R0D7K"7+9_\ BO?HH*HML9]S!/B['=!<67=F/C!RS>/&
MC+0I+S2$NC4^R*-@)?H#;]-:HM)T6-B=G[ARL5F862R;/9G%?:%B09:$BL"T
MR" (HFO[--**OEJ"%-V\4G'HUA,,["PV*QO=<>.38M2I#3SS"O(+:JBJ@-,K
MIUV4S+Y+K1ORF+R&Z<A-*9AG!Q$Q[%P![1I$W,?'<*9(,PU7$2.S6E>*^;C4
M$7L#68D[KCP\,X>0S,KNKO!UI$B-08;81U(35;?9JCI"(<5<^3BE$E,1D'XS
MN#/&/)F7LJDR9G'!'E\F/*1YI\'555(^2(- "<17I1!15H(LK&YIZ'*8A1)0
M;=3*,R^6Y':[:K+JNNR&^4=^:T#ZMF.M-2IJ3K(*7@G+B#B2<7,PD6:YEI$H
MY,UR<P')<9EFV$GG\!%HA;9 F^6B+U4&RH1)06>6"1%W*[DY.)>RS!00CXE&
M!%P6WE<-7P-#)$!7$5K[1>KI%45>'$*.!M*9 QF4*3C1DY6)A6L1C#ZKB&I@
MZ\X#6M;(VCCR-\43J@E!KR.,EX"&>298-V?"R.,BX:*1"ARAC1AB((*JKP+G
M/$OETHJU1V. CKB(#^-2.^Y(A_:R99B*#-DR!YSKC:WNMS)474B67AT5!RCF
MU<FUC]NBU&)XI8L0MR,*2(HLF^DTG%ZUEY;B.-K:_!Q:HV0<7D9#$+$2<23>
M8;RJ9/+9=P!1E>3(5_F-.WN:NB@M *>B"J)60;+!9X6-D6=D3 *"XSG7QG$]
M'4! RE/NNEP5%L0W/JE?B-! >QDK%3,I&+"EE>TP(\#"&( <<6@:4'&72*R-
M"KBJ9JOI"J>DHVH++9^VBQ4N;-G-J<\&86+8EN(BFY&@1@'4*JJJ@FZ;J_+Y
M:"MAL9-K;>8QKN*?7=<AN8<F7H3EOOO$0 ;;ZK94TFF@?T133PM08?A1962"
M/*QYEC.](JKS-*MK#P\-.SJ27XB4CBB?V4&$O![A>E378,-([KDS*3XA=0 1
M]J",&&2^9355<1;>2ZT&V1';>PF)@1L'-9P\*0PF8A*PB2'64;,M-KKSAYZ-
MJ]95U)?TDO09XO%963G69\S%)!C.Y)Z:0=2X1XD(8L-#T*J:BUD=DOI7AY*!
MN"/F4?W/&@XQ^7,S;<6+$?32D<8BMHRX1.*J65M7'3T>DO"W3P#1F<7FG'=P
MQMM1I#425$1'N:TVT2265:81(;A*BDCD<#2R]020;*FHJHN=M1HL*4DAN'D"
ME9 $C'(D1VXK3#$$=33?*! 1L+ND@6%55;\;6J#K*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*"KSW_ ";/]Q_S<3_FO[O_ )AOH_W_ %/]ZU!:
M4"@J]N_RL?\ E_[^5_RG]U_S+G_YO7_W[T%I0*!0*!0<OD?_ #WA?^6_Y.7_
M ,Q_?=(?\M_O^O\ [EZ#J*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
J*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>lc_colorectal-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_colorectal-4c.jpg
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M%!04%!04%!04%/_  !$( A$#N@,!$0 "$0$#$0'_Q #+  $  @,! 0$!
M        !@<$!0@# 0() 0$!  (# 0$              0($ P4&!P@0   %
M @,"" H'!@('!@,)   ! @,$!081$@<A$S'2%)065@@805&1(I+3U%475V$R
MDW2T%3=Q@=%"(U2Q,U)B<[,D=39RLD/D)36A@R93PS1$9$6%M3@1 0 ! @0"
M!@8(!0,% 0     ! @,1D5($%!42DA-3!18A46%QL=$Q08&A,M(S!N$B<K(U
M8J(T\,%"(W-#_]H # ,!  (1 Q$ /P#OX
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M=-:1(B2F5$MMUEU)+0M*BV&2B,C(P8LD
M
M                                        !PUV0T1:WKWJ37;B)+MW
MM<K=C[[SG&S?G*1*4C-P&GS&\2X$JPX#!E+M.X:PU;U JM?D(-QBE0Y$YUM/
MUE(C-*=,B^DR2#%P_I-:.H?:FC73?USZ@56C/0Y1PZ' IKJVHC$@VR>+^DE1
M$EI!+;3YOGJVF:L>$R^AMM'-6;MOC0S5VSKTEN5.J6M19G)JH\HW'W(\B-)0
M;;KA[5FA37FK5YQDK;P 2P-%-1JAI9V0+HNVCI2JM-UU^)35.)):&Y$MN(T3
MBDGB1[LC-9$>PS(B/8!/TM8SIIJ+.T+=[0KNI==*]B9<K+49,MTHY1&GS0;>
M8ED9*-!&LL/,_DR^$!)+WU>NJ^>Q[$O-Z<_ NN/5F*;/J$%Q<1;RV'%)WA&T
M:<-X@TFLB\W-C@1%L ^M)='Z=J!0+1D]I2_KN=K3";6DN0;5+>FPW&CMH<8/
M.;F4EJ)CS\&L<RS4:C/$$<X'J?$NZBUF\KWU,N>!JHI;S]OTVE)<;I3.[+,T
MUYBTY$K5YN+9IR%M/.>(,EWUOM-7K#[+- NEA[+?M7G.V\[6#0G%)1,ZERDI
M,C2;JFTH3P89U&HN# $P]*=:+]GJYZ9-MG4Z[-1*S5:ZZVFI5"E*?=<B.<J9
M,TM+6MTU+R&M)F9E@9IX, 29<\0M(9]2[5-:TW;O2K1YC:'7SNAM2BJ*\T)N
M0:%*)PCPP7N_K?5+@\ ,OJ7QVE:A8M*GVM;MU7U=C,YJ"EA-J6BHCFSU&HD-
MR7<ZB;)2E)4DB7B:OY> P8PA/90U!NN)K'7M,94RM/VBY&D28%.NC$JI#<CJ
M;4WG2HSW9J0M1+0GS3/!6 ++W[+7_P#IW5W_ +=6_P#[A($_0OGM32N2:!7L
MYC@:XK#)?_.ELMX>10)#DW3:=#TBU T>ON8LH5MW/:TABK/'YJ5.-'))18GA
M_,F,K]H*@-UTZ>C2FV]3:PC_ -9O2[ZI5W)*C/.;+)-H3P[<-Z3YX_L!5W]N
MN0]TGTOE0FN42,)CL=DSPWB]]$4E../A/8"0C>H%=N_6?66R=.]>*>WIY3&7
M,\*(TVN0N4N:M""03^=2?ZZFB90M/FH5CCB8"6]IQ)-]J#2!+994H.DDDB\!
M%5UX 0N#MB1:&_H+<#U82V<F,[#<I"UX;Q,TY+:"W?AQ-M3A'A_+F!(979&7
M4G.S_:9U(U&HBF)BFOZW)DS7B;_<1?5^C "5W @
M
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M+A/:#%G
M                (C:.J%A7Y4:G2;2K354J-&5EJ;#:'4&R9K4WM-Q"2/SD
M*+S3,!+@
M
M                                             !Q;V+_U1U<^\(_&
MR@92[2!B
M
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M'QMTJZSQ?([Q Y9N=$G--KK@^-NE76>+Y'>('+-SHDYIM=<'QMTJZSQ?([Q
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M-4]*GHQ,S@W]GN[=^F.C5TIB(Q2X:3>         %)Z<$?>)UN/P$S:A8_\
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MW'4.:/<0.(M:HS@X>[IG*3HG=/N.H<T>X@<1:U1G!P]W3.4G1.Z?<=0YH]Q
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M/'X1M;G<=M5$X881$9-3;;?L:9C''&9G-(AJML
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M="
M
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MHQG^7_RICT815G]RP1N/.
M
M                                      #BWL7_ *HZN?>$?C90,I=I
M Q             $'NW2#3V^*B56N*CI?J1))M<IIUV.M:4E@6<V5HS8%L(U
M;<-G -6[M;5R<:H]+OMCX]O=E1V=JO"GU3$3EC$X- 79NT@(\?R-P_HY;+]:
M.'E]CU??+L/-WB?>1U:?DXCN*&S3[@JL",@VX\69(8:;,S4:4-.J2DC,]IX$
M0\O<C"J8]K[KM+DW+-%4_3533.<.[M"/TDM?[NY_OW!ZS9?HTO@/[F_R5[WQ
M_;"Q1N/-
M
M                         #BWL7_JCJY]X1^-E REVD#$
M   !_-:]/^L;A_YG-_$+'B;WXZO?+]/>'?\ %M?T4_VP[DT(_22U_N[G^_<'
MJME^C2^#?N;_ "5[WQ_;"Q1N/-
M
M                                           #BWL7_JCJY]X1^-E
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MQ/$C\ X+EWHU4TX?B=IM=A-^Q=NQ5AV,4SAZ^E."2CG=6
M
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MFT>LVUR;EJ*I^E\!\<V=&TWMRU1^&F?1]L1.'V8ID-ET@
M
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M?,0[@[/_ .D%L_[.1^+>'J=C^C3_ -?6^$?NG_)W??3_ &TK+&\\N
M
M                                               "M+KURM"SJ_+M
MRJ0*X]/A;O>NP:1,EQCWS274Y'6D&E6!++' ]AXEPD"X-*?:9L B,_RNY=FW
M_P!AG^K P>_: O>?0-!Z_==MO/0JA.B1&:>^I*V)#)55]E@UX&1*;<0AY1EP
M*2HO&!"!ZGZ9V;HG;EL:@6! _*;AMRL4MB;465KW]1@3'TQI3,LS4>])[/F,
MU%B1EYN #IH$<DW'/L&A:P:@_'2@JNJGK:C2J574Q5UJ#1J2ZT9-Q'V&B<5!
M=4M*E)7D(W,<V)%M,R>5#UIJFAVD=GRET*3=U,NB759-OQF)Y/N4RCMNH5$B
MNR$(DDXM*'<,,WF8&C^7 A@C?87J!U:^M3:J;)QSG<GE&PH\QM[Z3)7D,\"Q
MPQPX )=O@Q                             '\V[]_P"NKG_YM/\ Q+@\
M5?\ U*O?/Q?ISPO_ (=G_P"=']L.V>S_ /I!;/\ LY'XMX>GV/Z-/_7UOA?[
MI_R=WWT_VTK+&\\N
M
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M\V[]_P"NKG_YM/\ Q+@\5?\ U*O?/Q?ISPO_ (=G_P"=']L.V>S_ /I!;/\
MLY'XMX>GV/Z-/_7UOA?[I_R=WWT_VTK+&\\N
M
M                              "!:STRB5;3>LQ+BBU:52".*^\BW6R>
MJJ%1Y;+J'8Z3)6)MK2EQ>P_,)6P%A5SUM6/K=6*U7-,]3WZ0FYXC,"^J% 0P
M<J8Q&;4P1N,2DI?BN[L]RIPD8&DL,.'$.@*-2(%OT>GT&E-;BETN,S!A,XFK
M)'C-I:;3B>)G@E)%M!&<     XM[%_ZHZN?>$?C90,I=I Q
M                '\V[]_ZZN?\ YM/_ !+@\5?_ %*O?/Q?ISPO_AV?_G1_
M;#MGL_\ Z06S_LY'XMX>GV/Z-/\ U];X7^Z?\G=]]/\ ;2LL;SRX
M
M                                              -+=MP.6M;\VNLT
MJ=7'HI()JE4IK?S'UNN);2EM!FDMAJS*,S\U)&?@ 4'<&E&H>MTYJKW50J+I
MI'0XV]'J,$OS"\2)I6)$<UDVFF247@(UF6)D"NC:=#.GT^) .0[*.*RVP<J2
MK>/N[I))SN*P+,M6&*C\)@C)     <6]B_\ 5'5S[PC\;*!E+M(&(
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M&HD.I0HR+':9$.:UN+=R<*9Q==O?!]YLZ8JO6YIB?K]$QG&*5C8=0
M                                                   "L-2X)T"D
MW7>%7O>MT*@2(L%D_P L:*0=*W,A!+D1VTLNK/>8Y7CR*P1F/P8D5$+:T^>O
M.G%5K3UYN2L4]6!<HA2J>\E*C_E626,4J_U58& O6GQ7(4"+">DN3'H[+;+D
MQ_+OGE-I))N+RDDLRC+,K B+$$9(    #BWL7_JCJY]X1^-E REVD#$
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M[]_B_P"*AUGB7Z/VP]O^R_\ (Q_34Y=T8_52U/O[?^!CH=I^M3[WU?\ </\
MCKW],OZ%#V+\X@
M            K;7ZFSZMH_=4"DHJ;E5<C-J@-T-M;U05);?;6TE"&U)4:#6D
MB=RGCN\P+",P^T3.."PNIZ2:@,U+=(.8S'H1O,H?REG2VXIY!K22L<JC26)>
M @,%SP)7+X,:=N'8W*6FWN324;M]O>))61Q&)Y5IQP46.PP1D     .+>Q?^
MJ.KGWA'XV4#*7:0,0
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MZHZN?>$?C90,I=I Q
M                                          %+]J/]*W?O\7_%0ZSQ
M+]'[8>W_ &7_ )&/Z:G+NC'ZJ6I]_;_P,=#M/UJ?>^K_ +A_QU[^F7]"A[%^
M<0
M0^[9]*KS[^FD*Z'J!><^&FHL+IIH_,68;4A)*>1O$+02%*0;1FHO">&T!S_=
M-.TX9N;X87]KW<LB7,-$:H4)R0VPPXE\B,H\F2S$W;9.)/!2%N)Q2?T@R=34
MVG0:/3HE)IC"8U-@,MQ8<9'U&V&$$AM"<? E)$1 Q90    #BWL7_JCJY]X1
M^-E REVD#$
M                                   4OVH_TK=^_P 7_%0ZSQ+]'[8>
MW_9?^1C^FIR[HQ^JEJ??V_\  QT.T_6I][ZO^X?\=>_IE_0H>Q?G$
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MM3=6GF5I=9<?;6VX@R4A253)1D:3+89&7 8,I=J Q
M
M      %+]J/]*W?O\7_%0ZSQ+]'[8>W_ &7_ )&/Z:G+NC'ZJ6I]_;_P,=#M
M/UJ?>^K_ +A_QU[^F7]"A[%^<0
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M1H*F(K)N&1K-MF5)0G,9$18X%MV 2[<!B
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M$L-O_A&>WQCL-GN8NQA$?AB'D?W'X)7L+D7*JHJ[6JJ8PCZ/K_[K7'8/(@
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MDH0DB)*4D6!$1%P$0#B_L7_JCJY]X1^-E REVD#$
M
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MSM/\ Y;>]F9YS\.]=75.Z_JK_;PN=I_@'+;WLS/.?AWKJZIW7]5?[>%SM/\
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M>A+:+!M3#B"4V:2+# C298 Q90    #BWL7_ *HZN?>$?C90,I=I Q
M
M
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MEIALH9)1EB>TR1B#%N     '%O8O_5'5S[PC\;*!E+M(&(
M
M
M             "N->[9D7AI#=-MPZ9)J\Z=':3#@05M-/KDMR&G&5$IXTHRM
MK2EQQ)GYR$F1;3(%A&8&KNKR8,8JGHO5SJ)-(Y8<:H4\F3>))9S;)3N;+FQR
MX[< %R4^0_+@19<J,N%)?9;=>ANFE3C*UI)2FU&@S29I,\IFD\/$",D    !
MQ;V+_P!4=7/O"/QLH&4NT@8@
M
M                                                   *2IMPTBB=
MH>^BKE7C4Z,N@T/DZ9LE$="E;R5FR$ZI)'X,< 5^.S]J?1ZAI)09EXWA#D7$
MMRHE+>J4]@I2B149*6L^=9'L;)&79]7 "5VM.M/M(?86EUEU)+;<09*2I*BQ
M(R,MAD9<!@C]@    .+>Q?\ JCJY]X1^-E REVD#$
M
M
M        !#[DTITVO"I'6;IM:FU>JFVEDYDR,AYW=MXY4YE$9X%B8"N[2T\T
M)NZN7;0H^FM)C.VG4$4R0\Y$8-+ZULI>SH))8D6"\-H*NZ'$BT^)'@0641X4
M5M#$:.V1);;::224(21;"))$1$0(]@    '%O8O_ %1U<^\(_&R@92[2!B
M
M
M                          TMVW70['MRH75<<CDM&IK9.2'22:U&:E$A
M"$)+:I:UJ2A"2X5&1 *@LS4.V:5 U3OB#9]?I54ILABLW11JEN45!Q*X:'"<
M;9-XT-X,)SF@UX[/'L!5VTJIPZU2X-9ISF]I]1CM2XCO!G9?03B%?O2HC!&8
M     XM[%_ZHZN?>$?C90,I=I Q
M
M                                                       0O5>S
M)U^6//M^DRFX=:)R+/I4B0DUL)FTZ2W+9)U)8F;:EM$A>!'@1XX& HE4/7VM
MU;46FM:=HH<K41$*#+K<RJQ7Z?3H[-/_ "]]]!,GO7U&6*FDI21EB68MAD97
M1M(@TFPK-@4QV4EBA6S3&8RYLE1(2B)3HZ4&XXH]A$2$9E&"(?;6O>G%U5J#
M0Z?*FQGJOG_(9=0I\N##J6[+$^2/OMH0YLVD6)&?@Q!<%F@C471=%!LR@SKG
MN><W3J'3F][+ENXY4D9DE)$1$9J4I1DE*4D:E*,B(L3 >MOUZF710Z=<=%=-
M^D56.U,@O*0ILUL/I):%&E9$HL2/@,L0''_8O_5'5S[PC\;*!E+M(&(
M
M
M                      "KNT053^$==53%2D);<@N5-=.-:9::8W.87-4T
M;9DK$F"<-6'\N(+"D;NE6GJY*U$U%.K2RT_TYH+,6Q:K#DR8,9-=-AV0Y(CY
M5M&M]M9LL$2MBL2+ ]@*FVO%6N"3V2WJG6,S-=J-*H)UPT_TS2[,D0RE%@7
M1FM23+Q&"1]+==IN.S3],J1)I[26I=%N&@R**EM)%NGVIB&V]WA]7!"E)+#P
M 0N\$<>WOJ_IS?=7N63?5?8IU-M=NI0;-L^4T\XN15FF76/S.8@FU-YB49IB
M(49Y"Q6>"C!E@]Z)>VK59T9TXC=G!42M3*+3VZ;>33J8Z3C2F8L8VFL9RF2,
MRQ<S;O']H"-]A=527?>IJZPDD5=7)SJ"$Y2(I)R9.](LGF[%8\&P"7;X,0
M
M
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MVD#$
M
M                               !#]4[>MJY[$JU+N^I.4>WTI9FRZLR
MZW'=B\@?;E(=2XXE:4FE;2>%)[-@"A[CZ!:D,WOJ+8^I53MVTY$6+"U,9BTA
MV04V*B.;;;S:9#)/-&<=>53K2%%NRQPP(S!72EMP*32K=I%+H&'Y%"A1HU+R
MJSIY(RTE#."CX2R$G:"-H     XM[%_ZHZN?>$?C90,I=I Q
M
M
M                5YKA:E7O/36K46A1FY]42["GL4N0HD,S?RZ8S+5%6I6P
MB>)HT%FV8F6.P%A0KM_5BN5;5JD4.PKE<N+4*/!IM)ITZF+B,Q#.E% ><FON
M'NFVFEFH\<QDK L#P/$BNHK-H+EK6?;]L.O\I=HM-ATU<G;_ %%0V$,FO;M\
M[+B#%NP    '%O8O_5'5S[PC\;*!E+M(&(
M
M
M "M-?;@K-L:6U:JT*>JDS"?I\9RKMDE2H<:7/88??(E$9>8TM6WP</@!85A?
M-QW/>%T7R[9U\RZ);.E-OLU!N135LNQYU:=8>E_\6XI*TO-(:92EQOQGX#Q(
MPOVRJW)N:S;=N2:P4696*9"J$B,6.#3LN.AY2"QV^::L 1O0    '%O8O_5'
M5S[PC\;*!E+M(&(
M
M                                          ""757+M_\ J:DQK Z2
M4J/!C'3VW)T1IFKKEKW<F,:)!96TM(/,HW<266)$0*J6.B\(=K3+)A=FMN+:
MM07O9U+8N"D,LON9DJQ<R&1J/%">$^ B+@V .BJ4;BJ9"4]#*G/&PT;E/)2%
ME'5D+%HE-^:>0_-Q3LV; 1E@    .+>Q?^J.KGWA'XV4#*7:0,0
M
M
M                  %,W_4KQOC49G2*T*V]:])A4M-;NVX8*4JG[N2\IF-#
MBK5CNEKR+<4YA]7##PDHJ-W58EZZ(T*7J+9%]7#<L6A)Y=7[9NJ:FIQYM/:\
MZ3N7%-H4PZE&9PEIQQ-.&&&PPZ!IT^-5:?$JD)6>'-9;DQUF6&+3R"6D\/I(
MP1D@    .+>Q?^J.KGWA'XV4#*7:0,0
M
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MMI2RD1ZX:36W&DI5YAHD$DR94C;G+!18;0%B@@
M
M                         #BWL7_JCJY]X1^-E REU_<>'1ZK8\'(I/\
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M"/H
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M+?/*1)2DL%8[ 5;P(
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M=6A%_P#>@)9$EQ9\5B=!?;E0I+:7HTEA:7&G&G")25H6DS)25$>)&1X& ]@
M    !\4I*$FM9DE"2,U*,\"(BX3,P$28U6TODSDTN->M!>J2S)*(C=4AJ>-1
M\!$@G3,S^@!+@    $>I5]6C6G:\S3JLPZJUWUQ+@4K,TB&\T1J63BW"2G!)
M)/%1'ALX0&ZAS(=1BLSZ?(;EP9*"=CR6%I=:<;46*5(6DS)1&7 9& ]P
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MX#(P'T
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M6?DJV*6FDOFTSC^QDVT_N E;@(
M
M       .+>Q?^J.KGWA'XV4#*78]4BN3J9-A-*)+LEAUE"E8Y24X@TD9X>#:
M,[=71JB?5+BN4]*F8]<.3B[*%\X;:O22/_MR?4#VG/[.FK[OF\/Y>OZJ?O\
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MLK9@=HG3"H6%&U%E29D"TYE071S?EPGU&V^@E&9NI92[E;,B_P SZNW \%;
M3!5]Q7)9VINLNG4W1)*:A<5%J'*;LN6F,+8B,T(TX.QI3^1"7#=+$FTF9X'B
M18&H!NH=PTG0W6Z^G;Z?_*K.U!*'5Z#7G4+Y&4Z(TIN5%<<21DEPS4;B25_*
M7C,B ;/1;>7AJ-J'K<3+D6TJXF%2K6D2FU1U2H%-:P>EDEPDJ)IQ9$ILS(MF
M./ !+9]F-E3]@U:ZB2I$:\+DK5PQ$K2:%<GERC;;/ ]I9DM9B^@P)70"
M
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MK?U&F&$DA"$XXG@22(@&8
M
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MG%M(L V]%IB*)2(-'1)D340&&HR9<YPWY3J64$@EO.F1&M9D6*E'M,]H#.
M
M
M                           <6]B_]4=7/O"/QLH&4NT@8M'2[0MVC7%7
MKKIL/<U^YN2?G<O>.+W_ .7M&Q'\Q2C0G(@S+S$ECX<3 ?@[+MI5S3+P.%_]
M13Z>FCRYF\=\^"A9N$UDS9"\XS/,2<WT@,6)IS9L*Q5::QZ82;*5%=@'3%.O
M++D\@U&M.\4LW,3-9F2L^8CX# >5*TRLVB7-%O"G05MW!#H[5N,2E2'W,*:P
MI*D-FE:U$I1&E/GJ(U'XP$N
M
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M7'=@I;)"'C<./NEL;TT$V1)<RJV;=I 2ZG!
M
M                                                           '
M%O8O_5'5S[PC\;*!E+M(&+F.WM1K?T\UWUG?NEB;'I$Z30B*M1H4B=&;>9II
M8,/<E;=6A2R7F:Q3E5@HL2/ C*VMDZ=R=2:5JC6*VBJVM0M1:HR_2&&E*@5
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M=+Z?+F731:]!J<RXSILJG(I-.BJ-<A+S\IEDS-U/FICD9YSX> L0Z6!
M
M
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M-B:[(DWF[ >DQ'$H2W'.G1SCIW9EM/.1XGF 3$
M
M
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M[F^JWSCF^C-]K Q.YOJM\XYOHS?:P,3N;ZK?..;Z,WVL#$[F^JWSCF^C-]K
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MTJ!3F+@>Q_,945EA$Q>\42CWRT$2SS*(C/,>TP&Y
M >#4V&^\Y'8D-.OL_P":TA:5+1_VB(\2_> QJW H51ISD>XXL2722-*WFJ@V
MV['Q2>*34ETC3L/@,P&1 C08<*/%IC+3%.:;2F*S&2E#*6B+S20E!$DDX<&&
MP!^BF1#DG")]LYB4YU1R6G>DD_":<<< 'L                   #X1D? >
M.&P\/& TZ:3:A7"JJ)@T[I7D\^:33'YAN\N3:YAO,N7S>'@V -LZ\TPVIY]Q
M+3*"Q6XLR2E)>,S/80 R\S(:2_'<2ZRLL4.-J)25%XR,L2,!^P
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M"Q6XXHDI27C,SV$ -.M/MI>86EUE99D.(,E)41^$C+88#]@
M   /RM:&TFMQ1(0G:I2CP(B^DS ?H!BJ>IT_E%.4XQ),DFW+B&:'/,66!I<1
MMV&1X8*(!BP:9;EJ0%LTR'"HE,S[UQN,TU#8WBB).8R02$YC(B+$!LTJ2M*5
MH42D*(C2HCQ(R/@,C >29<5<A<-#[:I;:26XP2TFXE)\!FG'$B,![
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MEIJ$"+/0DTHE,MOI2?"1.))1%_\ $&+)
M 1'5&RBU%T]N*RM\F.[6(:V([Z\30W(3@XRI6&)Y2<2DU8> !3UP0-6M6;9H
MVE=RV0Y;T1,FGJO"Y'YL5Z"Y&ICJ'E\B0RM3BU/J:+(2DEDQP5XP5T>"
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M49=UD29*/$_$ Z5IT!BET^)3(I&46$RW&8(^$FV4$A/_ ,"!&2
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MBP:4VG*:MIEAB Z789;C,MQV4Y&6DI;;27 24E@1>0@1Z
M
M
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M1F7"$IT\O*%J%9%"O2 C=QZS$;DJ8QS;I[ZKK6.S'=N)4C'Z 1)@
M
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MT^^K;AW)36)4-J21I>@U!A<67'?;/*XRZVX1&2D*(RQ+%)\*3,MH,4@
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M#1&FU"1(9_<;:TJ+]H$K?!
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M):%8'@>"DF9'M(!]>?9CMF](<2TRG#,XXHDI+$\"Q,\"VF> #T
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M                      !YI?84\N.EU!R&R)2VB41K2E7 9IX2(\-@#T
M                    %;Z[?IO4?]M%_P!^@=9XG^A/V?%Z7]M?\ZGW5?!R
M0/'/KX     O;LT?^XW#_L8W_?<'?^#_ (JOL>"_=_X+7OJ_[+<U&MAZZK9D
M06;@JUNFRER0J70GVXLEPD-++=J<6TZ9(/'$\F56)%@HAZ5\X0KLQOQXG9[L
MV3(6W'BLP7W7GEF3;:$)DO*4M2CP(B(L349@LJAU[GUO5+3*OZBJ4_3M-J'(
MIR;+@GBTY6'WJE'C.520@R(RCY'%HB-JVJ(S=418I(%AV #$
M         :*[++M2^J:W2+PI,>LTQEY,IJ++1G0E]"5(2LB\9)6HOV&8"@X6
ME^G=2UYIM)L.VX-'I6G"6ZQ<M4A-Y''JM*0?(8)+Q^JA&,AW#$C\U)X&"NF0
M0                     <G7E;M"B:V:A7#J#I36[XH%0:HGY)4J;3"J#+"
M8L+)*,LSK1GBHT$>[)1^8?[RKXTC<TWDV3#GZ5QH\2TYKCCZ(\9M3&21CD=2
MXVKSDN)-.51'XO%@ G((                    K+M#4>JU_1>[Z/0X3U1J
MLN&EN+"BH4Z\XO?MG@E"2,S/ L06%8V(WH'&N^@4F?I7-L.\'7$.V]+K]+*(
MU(FQB)PBCOMO/(-U)EF)*S(\</"9 .FP0                     5)>U9J
M^HEQ/:3V5*<A4R-E/4&YXYY5PXKA9BIT19;.62$_77_X#1YMJS21%8/9/:0S
MH3;C32-VRB15DM(QQP0FJRTD6/APPX0)72"                    (1J/?
MKEGQ85*H4,JO?MP.+B6Q0\3(GGD%BX^\9;41F$GG><\!;,<5$ JS1JU9EIZY
MWW"JU3?K=P2J'1IU=J\E1'RB?)=D*<-I!$1-,IP)MEHMB$)(@6710(
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MM5>=K-UU'$C.35YY[R0K$B(C2@\&D&1%BE)'@"RGP(
M   *KK]ZZU4>LU*GTK3%JXJ63A_DM7BUN)#0MI1%E*2S)(G$*2?UC1F(_ 7C
M*V&BUAU:P+/>AW"^P]<M:J,VO5HH>)16YE1<WBVF<VW(@B2GZ3Q,"5B @
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MYT=-3D4]#C<-W?R(ZVT/&DUI(X[C9F2LI<("LK+[.MLVIK+5;KAV\B+;,2%
M5;+Y3I#JVZ@C>E),T+>4H_-4G_,Q3XO""XK_  0
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M8D!@MJ#.AU.%&J5/?1)@3&D2(LEHR4VXRZDEH6DRX24DR,C!&0
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M-=LGHC);KS\J*J14XL^:\Q&AK5,)#<3,E+)-F6=:EXF>4LOA =/ @
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MC.3B2;/%67;@"NAP0                  'Q2DH2:UF24)(S4HSP(B+A,S
M4-(F+U\O^WW: C'2?3^K%6';A/ZE7KT(E-L-03_F8CJ6HW'MJ5GYJ?\ 2,JW
M;OBW;,H;S%DU&)2[@4I!LS*A'5+CI01^>1MH6@\3+@/'9X@1679X4W$9O:WZ
MFPHK^IE>=7>52WW*&:A.EMH=3*9/(WNVE(P)#&0MT18;3V@LKJ!
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M)PU1E2IBR<<>Q:CMN9C5B?U\-I[ 7%9P(
M
M
:                               #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>lc_oursolutions-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_oursolutions-4c.jpg
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M%!04%!04%!04%/_  !$( ;8#M@,!$0 "$0$#$0'_Q #?  $  04! 0$
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M5^9FX2Y]D>695L981(<"% PE*)BCQHKZG9H':M&[91=1THBF1,[E?3S51(4
M$Y]!2EU&M<=)0"_0 48KU H% H% H% H% H% H% H% H% H% H,"7FX;'V1I
M*>D6T7'D$"F=O5DVZ(&-T )U!*%Q[@7H+<)D>/9*W.[QV69R[5,VA19@X2=$
M*80OI,9(Q@ ;=P:"QE&(XUFD8$/E48C*Q@*D<%;. $2E63OI.%A 0,%QL(4&
MNDV7VM3BB0A,8:!&)N_**2(<RY'8D!,5"'UZBB8A0*8 -8P<!N%%Q3L;A&(P
MRD:I$PK1B:'!X6*!ND5(K4LDH"KH$BEL! 5.4#&  HC4,YVUCY>-:X]S(Z%V
MM!ZI/9HS.D *O5$')'Y2"J<P)I(G6**KDXAJ$ T@)0$PT5TM%9)PDFX;J%50
M5*!TE2"!B&(8+@8HAP$!#H&B*Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*#4LC0VX@RRTCEAHJ.3R=$D?,.)-5% CY!%,Z9$5!6, ' I%3AI[Q
MAH+:S/;&=B#SQS1#V 2C7$(>2(LB=D2+<:"KMA5(;E@D;00#%OW H)9GB6,,
MC.U6,6W1&19MXYX9,@!SF30ATT$C=\A"*&*4.\-!A.-N,$=,C1SF 9JL3QC>
M!,@=.Y!BV1Q40;6_HTS")BAWZ"55QV#7EEYU9@B>8<L@BEWIBW5.Q YE 0$?
MF:CF-;OC0:Z^VAVRDNP=OQ=@X+&,@BF9%$M1"L"E$I4#%O8Y" (Z"G = \2V
M&@DA8X/@H/\ )%@CX CPC1M(RCA1-J10C,G(:D454,4.H4V@EQ[MJ"#8?@WE
M#-]A<4[@9AK++JRK^%:.FSH5USKE<J.#))J&,(\W2IK[AK#14FKME@2N4%S0
MT"V+DY5"KC()@9,QEB!I*J<I# 0Z@!P YRB;X:(QVNT>VK-.82;XTR D\0R,
ML!B"ISD3GYADKG$1*F)^L)"6+?C:]!C+X=M)N)RLV6C(N>2505:^5;%506;H
MB=$Y%1 ="@)F Y0Y@#H&^FPT5EN]O-L\N+#2[N#C9A&.:E;PSO01=+L0E#0F
M @(E41MQ*4VHO=#C1%,CM'MG+*-%)+%V#D6+$L4V*HD D!BD30F@8GR3D3 ?
MJP. Z.DMAH-@C,;@89\^DHJ/1:2$F#<L@Y2+91<&27)0 X]WEIAH+\%!*4"@
M4"@4"@4"@I44313.LL<J:291.HH<0*4I2A<1$1X  !0:PVW-VW>+(-VF8P;A
MPZ.5%LDE)M#G55.(%*0A2JB)C"(@  %!-P\S$Y#&H3$&\2D(MSJ%N[;G!1(^
M@PD-I,' ;&*(#\(4% 0,,$Z.3@R2](#- C1DM(<\69516!'5\S6(FMWZ#T(.
M(+.'R4&:03RC0L<>0T_7"S34,L5'5\T#G,:W?&@A(?;/ <?GE\GA<>9,IUP*
M@G>(I@!BBMQ5%(OR4A4'BH*8%U_G7H,J/P7#XE.$2C85JU3QL7!H(J28%!F+
MPIR+BE;Y/,*<P&[]Z#"-MAMV5EV(V.L08DC#0?+%( *$4*H+BV_J^8&NW?XT
M%+9?!<Q=/97%WT-,9&R8+1/;$54I $$'0@?DKD14ORCG3*)B"(:M/30<]P[;
M%EM[DC3-\O4QV (T34AX=A -U6;4SF861*)U57*ACF,84R)((%ZB=S:;B:BN
MNAC./]LEI 8UN9Y/(I-II0Z93]K0;D.FFFL!K@<I2J'+80Z!&B(*+VGVWA8N
M3A8S&F3>,F4^1*-P3U N@%P*D8QA$W++<="8#I+^: 4&T*NXZ.%HT7<(M3.#
M V8HJ'*F*IRE$P)I@80$Q@*41TEXV"@RJ!0*!0*!0*!0*"'=M<9@WC[,9 &L
M>[.V2;2$RX,1 .RH',9,BBIQ H%*90UKCTC08F/NL&R"1>97B[N.E9)5)*/?
M2D>NDY.*2!CJ)HG.D8UM(J&, #WZ#'A-M,!QN;<9'!8\R833G7K=HI@42<X;
MJ<HOR4N8/%3E@76/$UZ#,C\'Q&)2AT8V&:M4L?5<+PI$DP*#15Z"@+F2 .@5
M 54U=_4-!C-]N,$:LB1S: 9I,21KB"(@5, ($6].!UVUOZ-0P7,%!(#B\"#B
M)>I1[<KZ 05:0:XDN+1%PF1,Y$^(6*8J9"B'>"@Y9AVR3R+S2-RV9;X]%)P2
MSUTQ98NQ5:@Z=OT#-C*N#N%%!3(1,YQ*W1ZNL^H3"(!1<76A@889T,G%DEZ0
M%:#&A):0YX,S*@L*.KYFL -;OT1KL=@>V. .'^4L8B,@%%"'[9)& C=)))4P
M"<I3'$"(D.80$Q2:2F-T\:":9HXOA4 T9-3-(3&V94V[,ACD;MDP4-I3(4QQ
M .L8UBA?B(T%Q/&X%)U,/4X]$KO( 3":6 O6=@BB#<@*C^=I3#0'P4&#)8#A
MLQC;3$).%:N,;8$138,#DZC<&Q="0HF 0,F8A>J4Q# 8 [M!#J;:;5/D8W&%
M8:/<CC0]K8L3GYCAJ#HQC&,:YQ4$BQ@-J!01*I;B VHJ1';7 Q3@$R0+1,F+
MK"YQ[DDY0LE#'UFY(D$HE*8P )B?)&P7#@%$9:.$8BW8QD8A#-4X^%>FE8IL
M5, 3;/CF5.*Z8=PXF75&_P#K#088XEM[E$3)E+&QTM"Y$X[9)'3!-P@Z=(@5
M'FB<HB',)RBE Q1N42]P0H*XG;K"8-I'L8R&01;13PTE'@83JF1>J)F2,L!U
M#&-K$AA+<1Z*"[)X#ADRSF6$I"-733(54W,TDH2X.5T"D(FH<>G60$R:3!80
MTA:@G&3-M',V\>S)RFC1(B#=.XFTII% I0N81$; '=&@OT"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@Y'OVBDNVV[273*JF;.\? Q#@!BB'-4Z0'A18:WNF^C]O=
MS(3*L09()SB&/9-*Y8P:%*EVN)C&/.;'=%3"_!X"::2@A?K' +V$*#7).<W>
ME\!R!:25E_1V5PZ4?RDN[;P[1%F^(T*X1"-%FJJH=NN054A!8#*$#2<J@&O0
M9K#(\YBXO;K (F0FWI7N+AD+Z3BFL4K*BDF5J@BU1[=RFY4DA6U*'$BBHAH#
MNF-03F/Y-NMET_"[>Y%(CA<ZTQ\\[/.&B#-61>F-(+,6_*(KVI!$NA(B[C2!
M[&4*F @'&@UN63R"'R_V@)4V0+R 0N(L')H]ZV9+,W"IHJ1,F"J1D1#00R8F
MT%L4^L0/J"U!L$!D6<9NZFH>(R='#FF%P4&LF9!FT42=/)..!Z+AP5=,2ILT
MP#E%30T".D_7#2 4&-CN<[C;J3\+%QD]Z&M)3!8W*7'9F+=VN22>.W"%TNUE
M4#D& A3:37$Q;6$HB(T'4-GLPD,^VQQC,)9,B4G*LB*O"HA9,5BB*9S%#C8#
M"74 =R]J)+=Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#D6YB"#C=
M[9E)PF15,7\]<BA0,4;0JXAP'O" #17.-VEF.&Y3N*IA;9JBW+@AY+)HX&B#
MB,\J@_3+'J.6YR&2%91$7' Y>L0 $0'A0;]*YCE6-;C+DR1>1;XVZ Y<,9,F
MK12(DN3&F<&:N'&@SE)Z91-4R9;D3,0@ 74(C0:SA&X.Y[EM!YMD1I F%RL0
MZF,JD7[2,1B(I S(SULO&]E64=*$3$ 1,1P!S* .L= @):! 9UNLZF97&X15
MZ_>RN(KY'BQ\M;1S%R,@BX20+H2CQ#0W5!<IBINBE.4P6$;:K!:<[GY9R,<Q
M"'=Y$YGY26?L\A.]812.11X1\>F]%HBD8$6)C+%4*LFMUPY(F$NH0ZH=3VZ]
M*L@Q1RSW.B!%R@_<(,PDTFAEWD>F8#M7#E%L91 BP@.DY2<-1=0 %[ '%X)V
M^Q3;D\IAB<?$Y+([B/8!.2.Q15!-M(3ZK82F* %,)"E,%BE,' H %@H)C<?<
M'+L+1DW..S\Q/N\&3C$\A4581:,&==<Z1ER/%C%27,LJDJ4X$8\$M1+AQM0;
MOB,KEV?99D\EZ0JPD#BD^I!-L<:-FIQ<D8%2.LJ\6<)J*?VCF#RRH\O0GI-<
MPC0<HV RR:>026*@Y"'A<>B)B1:QBS=-0T\9S(O"'<%.H!@!JT/9,2$L<YS7
M/8FD#"4U@N0Y_F*^&X?#Y$GBT<[V]CLC76C8UB)ROU7 H!R4U$A132M;4F"=
MK!8NFXC096";DYYNLYQ&!3F"XNY<8PIDDQ(,&Z#A9ZY3D%(TJ:)'::A")%,E
MSEK%$W7(0!* WH.C[(Y/.YAMTQG<D>(OY=1Y*-EGC5,J""A64DY:IF3(41 "
MZ$BVXC^4:$NAT0H% H% H% H/#D*H4Q#E Q# )3%,%P$!X" @-!QC&<;QQ/?
MS-4$X9@1)K!X\LV*5J@4$E17?B)R6)U3#8.(<> =X**YUM)+YCA^W^TLTWG.
MTXYD4T;'7&,G;(%02;O5WIB+E< 7GBN0Z5S7/H,!K:0M<0V7;3/MVLS<XMEI
M&4BX@,@<K#-,E4(I*%91AP6!$[1=-87IED3D3*H"Q1YES]4EBV#!P_/LSF=O
M\1FLBRZ27R[/CF4AH'&XZ,!R#:/(J"P)'>DY1> IJN%EAT@-B$ M^(7<?W$W
M)RQ;;3&U9LL*_GSY:QR-\FU:'<J&QMR1!(Z)1YR)%S  B?1K3N)A H@!;!DL
M=S\RQYZBZR:;1D,2Q;+'F&97*@W13*NW=LT%V#]<Y *1 [9=0K9P"8 0==[!
M;@&XX_&Y%NULO((Y<^6C76<MWR[/DD3(K'QDB8XLD;$ FO2@*8J:QU&$3%$>
M[0:3*[BY-MU#3F(.<?B(W<:/:0H1LE!(D&-=1DI)%BD7!4%.1RCH'.:S953E
MZK6/H$:##R9QGKR(\FY:G*>0"91ARD#(Y C&MY$RZTNF1V@<L8H9(R9-)%$S
MB0@]<2CJT@-!*P.<[L9-D"4[$,Y1:)])G$2YBQ:Q9(1*#9OE(]<YECK@^[6F
M"8N!-P*)OJP3TV,(;/M@_P RW'A@W!>92O',I1:2098TS:,P;LD$%EF:0*J+
MI*+'<D,F"IS"<I-?4T:>D.8[1NI:*V[V4!>0\K$F\A=E 9%LV<*-44VLF<2-
ME!3UE,<Z>H5-0GXB4#:1TT&R0>X.>JXO@FZKO(VSICFDU'QKG$2H-P9(-9=T
M+8B;5<I <&<MKZU!44,4VDX:2@ 6#&BLYW,3@\:W!?9.1ZPD,P'%W./=@;)-
MCQZTPM%E4YQ"@KV@F@JA3%.!! -(D$;F$/I"B% H% H% H.1^TZ0#[(9,42%
M5$3QNE(_R#F"3:Z2FN V 1X"-J+#FN0Y+/X5E.X><*Q++'<XCX.&CHZ!9J%=
M,7C66E ;)RJRHE;<U1%03I 0Y":"E$!/I/<H;:C*;ZDC<E9QS.7=)IH1[B(D
MIM"%0E@4%T)))!NDT5%LH;L]E6HKE* *7*?4%J"RVSG),GF-O,8Q?+GC1E.(
MY(ED#^3CV:4X1U"+-B]F,B*0(I.4!4.F<>4)1* FTFX&H,*)W'SZ:G(W:TTX
MDA)CDD[!/,U0;H"NX9P+)N] J2!B"W([4[3RU.H)"<I0P%OP *W&=;D!(-L&
M:Y(B:1:YL&*KY0#%!07,>XA5)3K)?H@=H#9(XD*4FL $26$Q1"^;*-V@B,JQ
MV-?NI^3P_)D&,E+Q[1B2;7QYPP3>#V=NJ!6IW:9U2IWT !B (E)KM08;K<O+
M\LD&,-@<I,/XM'&VDPC.1#")4?/7KY=PW(=VC('13(BB9J8JJ2"93"H)@$Q+
M!<-DW44E<BV,CH[-V 1TUDKG'(R>CD3%,"2SZ49IN2)F*8X< $^FQC6[_=H.
M-9[)2>4;9/,!D'!UW6U$=+.LD53*)-;^%<]BA!.(V'Z]N"CS_6TA177I_*,Z
MF5]RYF$RA+&V>W8BE'Q1VK=9-T9O')2*CB0.L4Z@(+ KRT^09/24HGN8:(UP
MF?[EYHEFTU$3XXPTQO'(3)X^)!DV<'[3(Q1WRC5R==,3"D!D])@* *7'@8MK
M"&J;H9=+9;@FX<D!DHDSK",3GA.R01*YU2*K@ZK8[D2<TZ0\  !-U?S;:C7*
MZ\JYSB5SM7;)EF*\6$#!MI=S-BS8J2<DY?N7"28\M1$4 ;H<BRG+2*8QC &H
M.Z1JN![C[@[D9)AD:6<;Q+%W!R$O.&CVJ3@KU2$G C1,W46 PIINR]>]C:2#
MU>M8P!&[?95G62L-M\:AYEMC#7(&.4/)52,C&91+Y,E2I(]E3,F*21K*#J,*
M9@-<PB&L0, 3..9WGN7FQ#"%\A)%2SQQDZ,UDS1JW*Y>%Q9\5D0C5%<JR*:B
MX*%66^K-I*4=(!?@&];,9+D>21>4ER:03DWL)DTI!MWB2)&Q#MH\Q$R#H3X7
M'B)N(\;]R@Z51"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$'E6'XWFT<E%9.Q!^
MQ0<)/6Y>8JB=)RA<4U4U$3$.0Y;C8Q3 -!C8SM_AN'E>>CT0BU6D;>4'1Q.X
M<N  ! "K+KF44.4+C8ICB 7&W3084#M3M_C"KI2#A2-4WC=5FLTYJZK0&S@P
M&42(V54,BF0PAQ*F0H4%D^SVW!X..QPT(7R7#JG7B !PZ*NS.J&DP-W *@LD
M40ZN@B@%M8+6 *"Y);3;?2\;$Q4A"E4;013IQ"I5W"3IN14+*%(Y35*MI.'R
MP%2QN[>@ON]L<$>NC/',.F=PK%&Q]<P*K%!:+.F9(4%BE4 %0 AC%*90#&+<
M;"%!8F]I-N<B,Q/,8^W<&CFA(UL(&52NP3$!*V5Y9R\U$!#@DKJ+T\.(T$\W
MQF :S89$VCTD9H&"<05TF&D2L$5#*IH%*'5 A3F$0  H+F/X_#8K#-,?QYF1
MA#,""FT9I7T)D$PF$ U"(](B/3025 H% H% H% H% H% H% H% H% H% H%
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MHB!E!3U#W1O04QFV6"0PH^3(5)N1M)'G&B13JBDA(JIJ)G513,<2IW*J>Y"
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M/[MK^'0P26/>T)MU-2Z&.RAW^)Y$Z&S2+RABM$++#P"Q#+!RA$1$  O,U#W
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MCC:_#_QT,&TX+O-M]N$\6B(&2,CD;4!,Z@))%5A))   (B*"Y2F,  (7,34
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MU86F XJ^ ID"J(% KF0<I@)B*JF5U)I7X$ H\+V&AR/HLI2E*!2@ % +  <
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M*/*3E\I3543Y1^68;M4@1YW+N'7, " AI$!R/J-FR9QS5%C'MTFC%N4$V[9
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MP,'*Y?@LA)QZKJ1C'SQ2+=IJG(1JH9DH8YE"E 0.!@(!  PA8;#\ ANM H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H-&BL>AV6ZV0Y VC%D9>2
MBV)7TJ*J@MURI'43(F"0ET 8@$"Y@->P]'?#>:!0*!0*!0*!0*!0:_E J@K
M\J3+&@,J@"A3',3M1.6K=L&GY0F^5I-PZM!L% H% H% H% H% H% H% H%!
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M !T^!P 2*<;T)=)HA0*!0*!006:94PP?$YG+Y1-59A"M%7JZ+<NM4Y4BWTD
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M_@O7J?\ ^=_O?%?_ .G_ /Y_>XG[2FY@YKF)H.,6UX[CQE&R D&Y%G5]*ZW
M.( )>60;CP 1#Y5>8\XO^'LQEX_'7A57T1RT4_\ U3_MU/LG_P ?^3>*S%7F
M-R/@M;U%GIJY+ES[/P4_[W$J\:^]% H% H% H% H% H% H% H% H% H% H%
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M"@4"@4"@4"@4"@4"@4'!O9UWNA-VI#,&D/B88R>/<I/I Y7)7/:W3X5$S*&
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M1$;M%@*FVN$'8*MDO+;YPYEI%HR,(H)KN3"9-HW,J("*:"0)MTQ,(7 E^%[
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MV7]08;Q!O#H8GX&[+^H,-X@WAT,3\#=E_4&&\0;PZ&)^!NR_J##>(-X=#$_
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M[4/_ $#"_P#=$%_C"T'0G?\ >U_ZP_\ O#519H/+AWPH%P[X4"X=\*!<.^%
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M)/JD,H*2B:A!30>B(IV$NLO"@^G("6-.PK*7.P=Q9WB153QTBF"+M P]*:I
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M*!0*!0069E8GQ*8+***HQPH%[2JW*518I.<G82%.( (WMTCT51L+C5VA76
M?6;4 =%[C>U06Z!0*!0*!0*!0*!0*!0*!00^/E9E//\ 8SJ'$9MX9X"I2E C
MH4T.81/2(W( :=)AX]-!,4"@4"@4"@4"@4"@4"@4"@AY8&8S6-"X.H5T5T[%
MB0A2B0Z@LE0."@B-R@!-0ET_G<.B@F*!0*!0*!0*!0*!0*!0*!06G6CLCKF"
M()\A7F"7B($Y9M0@ ]VW108.. V+C<*5D<ZC$(]H#514 *J9$$":#'*41 #"
M6VH &UZ"3H% H% H% H% H% H%!X(@ 7'HH- G]Q016490*95SIB)%'JEQ1
MP<! @!83V'NW /RUZ;)^335$579PB?Z>?[=7O>)\P_4D453;R\15,:)JG\./
M1Q8?9'2@?9R?NY3<;=B0?'!1XY<0RBR@% @"8T>6X@4. 5TV>M4V[]5-.B(E
MZ3RN_7>RENY7.-55.,\SZ.K1=F4&@[@;.X7N0[:2LVF[93S%,6[6:B72K!\5
MN8VH4142$-2>KK 4X#8;VM<;E2V![>XMMM"F@L4:&;M5ECNWBZRAW#ERZ5MK
M6654$3'.:P<1'\E$;10*!0*!0*#B?M0_] PO_=$%_C"T'0G?][7_ *P_^\-5
M%"/Z9+_;+_GH-MJ*^4=Z?:,W!V_W'E<4@4(T\6R3:G1,Z0545NNW(J:YBJE#
MY1AMPKVGEGDUC,9>FY7-6,X\D]/L>3\S\VO9>]-%$4X81RQ/:T'WO]V?^&AO
MNRWV]=G].Y775MCL=9]09G53LGYCWO\ =G_AH;[LM]O3Z=RNNK;'8?4&9U4[
M)^9],[ [AS^YN"JY'D9&Z<@20<- *S(9-/EHE3$O QCC>YA[M>0\VR=&5O[E
M&.&$3I>M\MS568LQ75ACT-RSK+F6!XA,YC(H*N64,V.[6;H:>:<I/S2ZA +C
M?NC73NR06/;E.'V1)XEEN-O,4G7;1:1C =K-7;1VV;&(5?E+ME#E!1+F$$Z9
MP =)@$+A0;0M-G)--(E!@NY:KIN#NI9(4A:-%&^@026NH!P.<#]4"D'HXVH,
M_MK(3*E!REJ1("JQ=9;D3, B!C<> " =(T [UFFU[<=PD5EI!3M)CE!+0/0;
M6(VL/?O05]H0 A5>:3EG#40^H-)BVU7 >Z%N-!XFY;+)"NDL11  N*I3 8@
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M)V$I+AJ&]@Z:HV!QJ%PJ)P #ZS:@#B #?C4%N@4"@4"@4"@4"@4"@4"@4$/
M%:E//=E6.L)IIX9T"A-'+<BFAK3)Q'40H:;&[MQX51,5 H% H% H% H% H%
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MY>K=N4X>[:]GE<[9S-.]:JBJ/XY83U:;<*!0*!0*!06G0%%HY XB5,4%0.8
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MVA+47K(%,%AU!W!KZ'Y/9JJRE,QKGWOD_P"H:XISU6.JGW-%_$7&?G.?$_\
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M7K<.[5$M4"@4"@4"@4"@4"@4"@X5[1FZ8XO#^AT&OIR&83'M2R8V.U9&N43
M(=!U.)"]X+CPX5Z?R/R[OJ^]KCX:>N?Y//\ G&?[BWN4_BJZHUOCP     X
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MR@-4;;*;J;<0C_R9+91',WX.18G;K."%.FY "CH4N/4^67B>P<0XU!=R+<K
M<266;Y+D3&,<MRI*+-W"Q2JE(XU\LXDXFTCH..JU@ !O07YW/L*QF):3L[/,
MF<1(:?)[LZQ3$<ZRZR\C0)A4N7K=2_5X]%!2\W"P6/AV>0O,BCT8*024<,9$
MSE/LZZ2)!4.9,][&TE"_"@UR-WQV^D<QG<-"410=P3-"04=*J%*BLBJ@JY5%
M/NV023 ZHFM8#!5&YADL *D.B$DWYN0%,>$)S N\*1$7!A1^=9(.9P_-XU!$
M1NY^W<Q,M<=BLGC7DV^1%RT8H.4U%54PN(Z0 >)@ !$2_*MQM:@U29WRQW$.
MPDS%W'('E,@?034\>\!RD@W8:]:[HQB$T'3$I4UD@N)#G*%QJC:FF;,4U<G<
MSC^*904 = >V$>@8Z3==LFN!WI3E("!C:P$A=0ZB" ]VH*T=R\!7QUSEB60L
MAQYF?DNWQE0*5%:X ":A36,50=1=)!+J&X6#B%!-PLU%9%%MIN#=IOXEX3F-
M7:(ZDU"W$+@/P" @-!GT$#.?WE+^K_TU41M H% H% H% H%!#98 &QB5 7WD
ML!1+>1'6((?6DZWU77X_)ZO?JB=7_3J]71US=3YO'HX=ZH+= H% H% H% H%
M H% H% H(J$  --6>=LO+NA$.O\ V8>6C_9NO_1]/5ZO6X=V@E:!0*!0*!0*
M!0*!0>4'Q3[0FY0YKE(P48MKQN!4,DD)1N1=Z'555N' 2E^03^40^57TGR/(
M=Q:WZH^.OJCFCM>!\[SO>W.[I_#3[W'Z]$\V4%0?H%PMT\NYN'#K#T]WC\%:
MMW_R4:<-,Z-?PS_Q;UG_ ,-S1CHITZOB_CD4UM-$H% H% H% H% N(" @-C!
MQ 0[@A0;.R= \;E5Z% ZJH=XP?'TUG$O.7[/=5X<W-['5]EMPQPV>\ER2NG'
M98Y2+B;Y*#D>J1;X '@4_P %A_-KSOG?EWB;6_3'QT=<:NS^;U'Z;\V\-=[J
MN?@KZIU_=/\ )]< -^(5\S?77M!:<_W5QUN7]2K]9QZG4'K<./5Z>%!B0( $
M!$ #GMH Q; #X-5G'U)?K>OUNO\ *ZW'CQH)"@4"@4"@4"@\,8I"B8PV* 7$
M1Z+54F<'SQNEN$F1P9VW,"B@@9"&0'B72 V.Y,'>$0ZO?L'PU]&\J\O[JWNS
MRSIJ[/L?'_.O,_$WIJC\%.BC[ZOMYNC#7+@*JJJZIUUCBHLJ83J*&&YC&,-Q
M$?RUZ>(P>5F<9Q4U4*!0*#Z*]CK_ )SN%^6&_P "%?)?-_\ +N>U]V\F_P *
MU_I?5U=2[<H--W8,^)MODQXQQ)M)(C%0[1Q!)\Z3(L6PDY"8"43#<  2@8!$
MM["'30?/&->T;F*>+0\1G&S.3SLU%HI)+R)H]94KA9N4" Y$JR B50]M1NFQ
MA&PT98/J/&)E7(L<BIY=@O%+235%V>->%$CEN98@'%)4H@ @<M[&"U&*6H%
MH% H.)^U#_T#"_\ =$%_C"T'0G?][7_K#_[PU44(_IDO]LO^>@VVHJ%RW&(_
M,L<D<:E-0-)!(4^:3@HDJ @9)9,>X=,X%.7X0KFL7JK5<5QRQ_'6X+]F+M$T
M3R3_ !C[8Y8<'SAGFVZ.W\;BR3('F?X?D#9OE#<%$T-16Z2FAX3FF)=-PF<B
MI;?.$ #JUWV6JM9:]->.%%=$[OV\WV<CH<S3=S-JFB(QKMUQO?9_5]L83_P=
M"/;<?<D$P^LPW;Y<#'[J;O)3%N4.Z @R3-?N65/_ *M=?_CV/[[O51_[O=#L
M=&8O_P!EJ=M?_MCKGH=0KJW:%!R6(QZ<0GMZ7*T>L5"=6;'ASB7@Z D&@W-R
M^/&RA1)^6J.=I0^98M$;?.<0A9M+=)KC&/PL@W.T(KCCMHWT\UI(+'OV<[?4
MJ?F)F*<+V^L^30;$PAI]#<2<Q["X^898;D*LTXRY.;9D)&(OW2)BD>QKH3 H
M<7"PE$R0:RZ!,:R8A80A<61RY^TV9Q9SA4S'*[?O&[?))!ZDFFT(9I$N6)3H
M' X\]-0Y@."B8"4H6 >(VH,3;W!'\>ABV!9LWS#RGC4N20(JU;,U,>4>-G*K
MA-\5\1#F:%]8F5*HKS;G,0P#TT'5]VRXK(M6D'E^%2^5,%=3EHZAV1G9VCI(
M0 HD514(LW5&_44)8.FY@H.;(%W@80F(P&6-\@5BU8IZ5XY@RM7TTL].\,#)
MG(.E"G(B4C,4^:L'5.KJU'L'6#(V:PC)XK(MNW.10J[=*$P!S%.5G28"#>1-
M(MK(W$1L<42GZ/S/@H,7&<#R",VQVCC4L;79RD-F@/Y)J1(B:K1D=U(ZUE *
M;@F*:B=["/5, 6[P0+#M,Q@&Z>WL3A+V5F,LRC)VS*52;I#&'76?J)ING+G5
M]2+40 UE U?5AHO<*">G\$S$\YF8DC73XCO*\%>M7P$"SIO%(,2.W!>/0F*1
M]?>H+LW@4^\VMWP8$QY4\]/Y!).H9,4B"N\2 K46JR0W$1*4Q3"F/"P@(A09
MF3IR>)+;N)2^(NIQOF:"LA'SR9$#L^QI1!&_9'ZJIR\@C8Z2ABB<!*)3W+UK
MA031,/E<R]F7&,=AU2DGBX]CSR-,Y 2IG>QB;1XD14!X@50Z($-?H :@QLVF
M,DW>Q4^V[+"YN"=SIV[;(W\N@FW8QS$BQ%'8IK@<Q7*AB%,FB"%[B8#&$H -
M4:LVEE$'F]T"A@\CD[W(9QTP:N639)9HX5-%-$B-':QC%Y!$A/K%17J:3B);
MF 0H*L6<.=N-R7+"9QZ1RJ2B<&QB'?2,,V"07(X1!T10HD,8JHD<F)?7\GJ!
MKMP&@N83BN4[8.L0RJ?Q=X_C$8J88!#0Q"R+F!6E98\DB0J)! 3$% Q6QSH@
M;0) #Y WH*\=V\R,\]ADM+8Z=M#/<UG<J&%6*FJ$.Q>1BI&I7!2&.0BAEP!<
M2D$0(HI;I"@V";QJ>6W!W3B2Q3D6VX.,LV,%,)HBI'IN&3-^@JFY6+^B-J7)
MI P=8.B@BL9]*LAR/9E-7#IB';X0D]:Y&\DD4T$$G(P:C,I41UB99,RE[+%+
MH^3W3< PH/ <A:[.[51P8ZLUR**R^+E)5ORBE<MD@E%3N5U1*(VNB8=9KC<I
MK=%!0IC&5PC!";6QV0>(Q&ZLQD;EFS0!=XI$.Q>I)N44;@90HBX(:Q>MIXVX
M4%6:8'F<K+YK-1T:^[&GE^.9*1NU!$KR0CHZ)026*T*ZNB=9%4.84BH:3'3T
M]-AH+SC%L?DXF9RA\RS]S-N9"(62DEHU%.5;O8@JQFCQNU303UE2!0R2HG2.
M!@$"V$ N!'8MLG>8/L)C'6=M^SY*ISA<$,D1NJ9(%C@@HLBF=0B2JB6@ZJ93
M"!3B(?!45MU! SG]Y2_J_P#351&T"@4"@4"@4"@4$-E@@7&)418^5 !$MXX=
M8 O]:3J_5=?A\KJ]ZJ)U?].KUM?7-U_G<>GAWZ@MT"@4"@4"@4"@4"@4"@4"
M@BH00$TU9GV.TNZ 1Z_]I'EH_P!IZ_\ 2='5ZO5X=V@E:!0*!0*!0*!0*!0<
M>]H/<H<)Q;R-%+:,EG2G0;F*/60;6LJMWP&PZ"#\X;A\FO0>2Y#Q%W>JCX*.
MN>:.UTWFV=\/:T?BJY'Q0  4 *'0' *^EOFSV@4%0?H%QOT<NY>''K#T]WA\
M%:MW_P E&C'3.G5\,_\ !O6?_#<TX:*=&OXOXY%-;31*!0*!0*!0*!0*#+C7
M?97(:QLBK8JGP=X?Y*L-7-6>\HT<L<C9!#I ?Y:S>??5&P^X/I)"CC,HKJFX
M@@ D<XW.NS"Q2GX])B<"&_\ 9'NU\W\]\O[BYWE,?#7U3_/EVOKWZ<\U\59[
MNN?CHZZ=?W3]FMV"O,/7+3G^ZN.KS/J5?J^/7Z@]7AQZW1PH,2!$!@(@0;=B
M 6+808AJLW^I+]5U^MU/D];CPXT$A0*!0*!0*!0<TW<SEIC40=CKNX<ELHF0
MUCF(-P!,+<0$_0(]PMQ[U>F\CR$W:^\F-%/)[?Y>]XO]2^9Q:M]Q3/Q5Q\71
M3VU<GLQE\F24D[EGJK]Z?4NJ/0' I"A\DA0[A2AT5]&HIBF,(?*JZYJG2Q:S
M8% H% H/HKV.O^<[A?EAO\"%?)?-_P#+N>U]V\F_PK7^E]75U+MR@^>EMS66
M*>TSDT5F.6)Q&)ACC([!C)O2MV(/#JD$3)D5,!.8)=5Q#C:B\R.V+W\Q==AF
M8[@9_'=H3RJ23@_*+U!(PQ!2H]G%$#"74D(Z])@^&A,/HV.D6$NP;2D6Y2>1
MKQ(B[1V@<%$E4E U%.0Q;@)1 ;@(41DT"@4"@4'$_:A_Z!A?^Z(+_&%H.A._
M[VO_ %A_]X:J*$?TR7^V7_/0;;44H.6;E068Q<RVSG;1N1?)'J'D&69J<$5&
MZXCV5V<.(:F:IM0B(<4S&"]J[7*7+55,V[WX8^*/OC_='6ZK-VKM-47+.&],
M;LX\F'-/^V>K%NN&8JRPO&F&.,3F6*T((N':G%5RY4$3K+J"(B(G44,8X\>[
M6CF+TW:YKGGZM4-ZQ9BU1%$<W7KG[4]7 YR@4"@4"@4"@4"@4$9!X[#8V@Z;
M0C4&B+UXYDG1"F.;6[>J"JLH.L36$YQ$;!P[P4$G0*#2\CVIP?+)-65GV*[M
M5R"17K7MSU-DY*@%DP7:)K%05 O>.F-^[>@W(A")D*FF4")D "D(4+% H<
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MT$3&%$HHELF(GZPB0.K<W'OT$C0*!0*!084M+1T''.)65<$:L&I!4664&P
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MLF;%[0X/IECH&;G7$QU#&-J(<VHIA$!,.KIH,I[MOB,BRRJ/=LC':YH;7D1
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M#K#?C1BV.@4"@4"@XG[4/_0,+_W1!?XPM!T)W_>U_P"L/_O#519H% H% H%
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MF-WB@CWOJ0,4!_VA"NTL>4YJ[R43$=.CWM"]YAE[7XJX]_N<FR3VM$0UHXC
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MZ:M\<[(8Q^HO[.M6E[6V1%-]?C+-0G>3<J$'_P 1#5)_3-OFKG83^HYX.O\
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M0*!0*!0*!01F1>4/(,AY)531D^6'955S)D2*?F%N)S*W( :;_*H)9;1S5.6
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M!<>CB'QT#EFZW1U>GB'QT#EGX='6Z.(?'0.6?CT=7IXA\= Y9^KT=;HXA\=
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M)QG3T3V+&2O3,QA&,?W4]JV6!E#(-7()I<EX8J;<1<MP,)CW$NHHJ:B='2<
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M DAVH$P6$O;&NCEB;2 \SFZ+W#Y.J_P5/$488XSA[)[&7@KV]NX1CACRQVK
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M5TU5017.U6.%DW"=A,0W<&PW ?R5E3.$X\J51C#CD[D&=X^_.P?2)P.'634
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MLJ!$7 Q*W( NL3W);3:]_E=ZN'O[?)BY>YKU(&X&*!@&X#Q :V'"I,( %QZ
MXC09DI$OH@[9-^0I#.T".T-)@/=%2^D1MT#PZ*PHKBO'#F95433RH\>FN1@E
M([&,AF&YG<9&K.6I1$.<4"E*82](%$PAJM\%<5=ZBB<)ERTVJJHQB$4*2H <
MPIFTIFT*&TCI*>]M(CT -PZ*Y<7&MC6:*1HBD:HIHCRBJ!Z*HI&@I&LD4#TU
M4*"F@I'HJBD:"D:HIHBFJ*:"D:H\&@I&J*1JHI&JBD:#P:"D:HIJH\'IH*:*
MIJHI&B*V[9P\<H,V:1EW;E0J+=$G$QU%! I2A^41I,Q$8SR$1,SA#H+[!\'Q
M(R3+.,B<C/'3*HO&Q"(*@W X7+K.)37X?DOWK5UU.9O7=-NF-W75SMR;-NWH
MKJTZH:-,MXE"66:X\Z6DHP-/97"B0D64N4!,&@ OU1'3T5OVYJFG&N,):M<1
M%6%.F$<8IR&%-0ADU"_*(<HD,%^^!@ :Y&+P$ECF,0B2ASE#48A2&,8I>^(
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MM!+$6->UDU"B)##Q[AJSLYBU>C&BJ*L''=LW+4Q%=,TX\G3]S&R''IO%)A>
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M*ZS9=-RV4,BX1.51%9,PD.0Y!N4Q3!80$!"X"%)B)C"6,3,3C#]&MEI3/I?
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MJHI&LF,J:(\&@IJCP:(IH*1JL5(UDBFB*:HE5<EF%<51PHRB88XB]-* W*F
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MNUS:[J9^#5]N/+JZ$[&[S[@1*48#1PP.\AT09L)1S'H+R!690L#<7!@U<OX
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MDWF5_P#=5O!J]_;XHVG=U:I>>BV3^97_ -U6\&KW]OBC:=W5JE2.+9/YE?\
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MA!@Y:SLF$5I.99,QT5$EN-QU%,00'@("%!1O&AF$DQVSQV0-&*&F\@1:Y(S
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MVGY-C6&@H3S7+8"7S:?F'[A/#IYV>#60<*'$,?FCPK1RT.F>X\M!=1<S93@
M%6!,;]8U!'9IG>0I8O@#&.E91":QK$6.;R MDW3@9%^DDB1JQ>'0*<=#DI'H
MJ<VQ3"4HCT#8KL4)+I.=TFKZ%=F7QW,L7)- EJ,=/FL5T$T5R )A G-0=E*;
M3\KEE[H41H4'NCN5'+Y2A)^39AZ]SA3#L31$56Z3=P9N1?Z\X%OV=)$AU+%
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M$C/)</!0V3\N5<K)N'#>89*/!:@*11(FH4$C%YIA$@#;@/&P7T=YLCFG[A.
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M:1ZH%#2  7A00T?M'AT<R;1:97R\1'O&,A$QKI^Z<-F*T4J"S8&Q%%!T$(8
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M< -0Q39=E]MRQYXKR-JCCQ3> Y!EUQ L>R<G>-R%'F:BG264%0BI1UE&UC<
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MW;EFBXC$]0IMUR(*$ Y$Q,8Q+]%Q[@B%!DOML,+DH^?BWK RK/)E&:TT3GK
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MRD7(('=++Z"%3 0-8PW*'8\9;-6ZTZ+9Y*.Q6E%E5RRX.0(BJ9-(!29=H33
26H  "04=2>H36,(WL1/T'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>lc_plasmabuffy-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_plasmabuffy-4c.jpg
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M%!04%!04%!04%/_  !$( E\#M@,!$0 "$0$#$0'_Q #D  $  @(# 0$
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M[?AH#;= ?%*"05*("0+DGH !0&"VSO3:N\FY;NU<JQEF(+H8E/15%;:7"G4
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M([3;6@NI66EH+;;1TE;:FE(6GH>H-NT"T<F'EB-FYTIGDS;^QMKA2/8S,Q#
M?> 0G5XRY23;S]0\PGIW4!P]W/F'/<B#/[;W8[&F9[;KB0G+0=(8F,+4MO6
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M VA'RS!S^,D,!V1)2&TE8;66U%-T>://3UZU(+P.3^0N6=SYZ+L3=>+V-LS
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M3Z':#U[S(-F;-WWS)B^?,?Q;OK<43+0EQGI$H0XC#+:[PW'VP%AEM8*5 7J
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MI&JI!G(-_P#UJY$V-O9P%[&W_P!-:J =>]@?_61LTV-A!;Z__D9E =G.P/\
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M=MJ YI2E/HI OVV%J ZG(<1YU+[T=MQY'H.+0E2D_$2+B@.U24JZ* 4/A%Z
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M/A_1_P!)7RTJ![/A_1_TE?+2H'L^']'_ $E?+2H'L^']'_25\M*@>SX?T?\
M25\M*@>SX?T?])7RTJ#HB0HSB7"M%]+BTCSE=@/3L-*D'?[/A_1_TE?+2I(]
MGP_H_P"DKY:5 ]GP_H_Z2OEI4#V?#^C_ *2OEI4#V?#^C_I*^6E0/9\/Z/\
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M"@% * 4 H"+!_1N_6N?E5()50!0"@% * 4 H"+ _1N?6N?E5()50!0"@% *
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MVG_F*!]QVB(9<Z@D4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MH0>OX2JK=R*=*E"MR:K0SV2WEM?$*Q:<CE&(XS16,6XI1+;_ (;?C**5@%(
M1YUR0+54Y)%*BV4/([SQ.ZL]L/+[8WVB!@Y\V:RC&HCJ6G,F+9MQM*U)!2$*
M[STZW'=5MR3:HRXHM)U18LQR]QS@,V=O93/L,Y="T,O1TAQSPG';!"'%-I4E
M"E%0L%$54[D4Z5*5;DU6AW<J9?)8'CO<68P\@Q<G#AN.Q9"4I44+'80%@@_9
M%)ND6+:3DC2^5S7)6RMA8?D].^7,LY/$-UW;F2C1O#>];*?S+"F4(<U>=8=]
MNM66Y**E4OI1E)QH;Y8WC@5YJ'M>1+3'W3,AC((Q*PKQ@QV*43IT^:00>M7\
MRK3F8V5TKR(F5Y'V9AWLW$G99IJ;MZ,B9EF%)<NPP[8(4HA)%E%0M:]'-+S$
MJ#=.L\\[7Y-9CX_-;UW%O64YR$^U/;Q&TUNJ$!L.'_AK,)04$BP*25=AZ]>M
M8T9X-MXF5*&*26!;N%MT[*QC$.9FM[S,GO?</@P\A"R$AYUA&07YX9;04>&A
MP!5CI5UJNW**YXLMW(R?+!&Y\EO#;6(SF,VUD<@VQG<QK.,@D+4X\&Q=13I2
M0 !VDVJ^Y).A846U4I_+7(.7VM['VQM".U+WMN5XQL8A\_F64IMK><%Q<)N+
M#L[2>@M5%R;6"XLKMP3Q?!$/#<=\I1<C R^6Y+E2W$/MNY+%HA1DPG&0;N--
M]-:;]@54*$NDESC]DS^X.8>-MKY1>&S>X8\?),V]982%NEG5V>*6DJ"/]ZU5
M.Y%.C92K<FJI&7RN^]H83 Q]SY/,1F<#++:(D\*\1IU3P)0EOPPHJ*K&P3>I
M<DE4A1;=#&XKEGCW-8W)Y7'YUA<3"M%_*ZPXV[':%SK<:6D+">G;IJ%.+YDN
MW)84*WQ7S- WW(D8G+.Q8.XUR9)QN+8+JUNXYC3H?*E"WG7)[OBJFW<S%=RW
ME\AM1YU+#+CR[E#:2M0';9(OTJZ63$[3W-C]X[=Q^Y\4AUO'Y-H/QT2$AMX)
M)(\Y(*@#T\M1%U5291HZ&O\ GG<>XMO87 )VYDG,7)R>8C8]^2TAM:PU("DF
MP<2H=#97V*M79-)4+MJ*;=3"RLAR#QAO3:.*RNZ%;LVYNJ9[-<;G1V69C#R@
M-+B%L)2"D7%[C_L-0W*,E5U3)I&<714:.SBC=2<8YR=E=UYAP8C$YY]/K$YY
M:VHS L E&HG2FYZ)%+;I6O2+D:Y:=!?]L\I["W?DE8?;^::DY1*"Z(:DN,.K
M:3:ZT)>2@J3U[4WJY&<7P+<K<EBSIS?+W'.W<T=OY?/L,99"T-O, ..^$MVV
MA+BFTJ2@JN+!1%'<BG1L*W)JJ1)SG)VP]MR,C$SF;8A2\4AAV<P[K"T)EW#-
MAI\\KMT"+FI<TN)"A)\$8^3S3QA#PL//O[CC)QT]:VHA&M3JW&O32&@DN I_
M"NGI]D53WD:5J3W<JTH9B=R#LS&[<B[NFYF.WMR:4)B9#45-NJ=OH2@)!45&
MQ\T"]5.22KR(4&W3F<=I\A[-WPJ2WMC*M3I,.QE1K+:?:"K@%3;J4K -NVUJ
M1FI<!*#CQ*1S?G=SXZ=LC"[;S#N%.X<J<=+E1VVG7 VXWT(#J5"Z2;U;N-JE
M"Y:2=:\C%LYC?O'7).U]I9C<BMVX'=/CM)]:899G1G&$:_$NP$@H[NJ?+WBH
MK*,DFZU)I&46TJ4+WG^7^.-L95S"YO/QXV18T^M-V6XF/XGH^,MM*DMW[M9%
M7'<BG1LMJW)JJ1E-R[]VAM''1LKN#+,1(4T@05W+A?)3J'A);"E+Z=;I!J92
M2XD1@WP(2.4]@.82#N,9MD8;)2QCH<HH= 7,*BCPM.C4%7!'45&>-*DY)5I0
MR^6W7M[!Y+%8C*ST1<EFW%,8J.L**GW$ %24Z00+ CMM53DDZ%*BVJHTQ@-]
MN;7W-S#F,YDG'(&,GQF<5&EO.K81(>96&6&TC5H#C@"?-%JL*5')LON%5%(N
MG'?,6W]U;87D<YD(<#.XV+ZYN*$A2T-04*6L)U+<Z6TI_&JY"XFBB=MIX%@V
MGR9LC?$N3!VOED3Y<1L//-);=;4&5*TI<'B(3=)/0$55&:EP*)0<>);*J*"U
M8QQM./C@K2#H'0D5KKOO,V-KW42_%:_'3]L5:+I&@N-I:6%+2#XB^TC\:I8*
MMR"M"E;4TJ!__.*!V&_<[0AEUJ"10"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0&"W?M]S<F$<Q\:0(>0;=8F8^6I/B):E1'4O-
MJ*;BZ24Z5#\4FI1#,5M[;NYL=+G9[(R8"\_FY,966;8;>]4;A0VBTEN.5*"R
MX;ZBM?2Y(T]!0&(VUQQD,?NIO<697C%+@*DKBR,9$]4DS'9:?#+LO\!)2BXT
MM"RE**CUJ:D)';OS;V CY+;><CXJ&UFW]PX]+V21':3+6%%0(4\$ZS<"W;V5
M")9L%#3;9)0A*2>W2 /N5!)SH#ID2XL1*%RWVV$N+#;:G5I0%+5V)&HBY/<*
MAM+B51BY<%4[JDI% 4S<?*VP]I908;<&47#R*BA#;7JDMT+6XDJ2A"VV5)4H
M@$Z4DFE 6C%Y.'F<=&RN/6IR#+;2\PM:%M**%=02AQ*5)^)0!H"70"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@.*T(<24+2%(/:D]0: ZO4HGT*/M"IJ!Z
ME$^A1]H4J!ZE$^A1]H4J!ZE$^A1]H4J!ZE$^A1]H4J"/$BQEI=*VDFSJP+CL
M /04()'J43Z%'VA2I(]2B?0H^T*5 ]2B?0H^T*5!T3(D5$1]264!00H@@=AM
M5</>11/W656MF:PT?S^F3A,IL?D+P').*VWDM632WU\-IXMD+(_W"F_E(\M8
M]W!I]!D6L4UTFT<=O?:&5A1Y\#.0GHTHH2PH2&TE2W"$I191!"B3;21>]7E)
M/F67%KD:*RV[L]OC&[]F*RV+VOM#$.RX#V*=B-OSYKK"2G4\MU8""X;(1I05
M ]AN*QW)R3Y(R5%1:YLK[L)C+['X(Q63;+D&;D'(LJ.HGSF-6DMDCNTC2?@Z
M51Q42KA*1L3DF%#Q_*'$\.!';BQ&YDS0PPA+3:=2&R;)2 !<U=FJ2B6H.L9%
M;W$K*<,9/-;PP<[&;CV5F<IZQE\0^4JR#<EUVRPTXDJUE"K@)(Z=XZ$U2^QB
ML45+MX.J9M3F)X/<2;F?2DI#F.6L)4+*%P#8CRU=N>ZRU;]Y&B,[MK9NU>,<
M'R-A\TO'<@1H\.7 0J5ZVER6X$%:$QG2M*>A4?-2--K5CN*44^9D*3<FFL"Z
M^V"QSELK-;D4C'/Y3:J?%#Q#2$RW"I2V[J/0@]+'XJN5[:;Z"W3L-+I.S:N0
MQF<YLY'EX]YJ=CSB(['BHLXTIQ@)0L ]0H)4"GR7%(M.;$DU"/E,%L:-'7[L
MV>DK90J0E&4TO*2"L6<5;SB+].ZJ8_\ &RJ7_(C(Y;:;F=]V[ 9'%- 9_!0(
M>;@+;2 XIZ&V%*Z]Y4C5]FU5.-;:(4J7&9+C2:GDOE/(\BW\3%8/%1,7C>E@
M)DIOQI12/(G44_$JD'FEF(FLL<I\YJ=7M/D?8?),YM2]N8];N/R+R$E?@&1<
M)6;=EPI1'ETV[2*FYA)2%O&+B;<:W=MK(1&GL9FH+ZIH"(.F0T?$=<'F)2-5
MR2?P>VKV9<F6,KYHTMP+(VA'V7NAO=2XK>=3D9QW2)^D/%)/7Q-?4I]+[-ZL
M6J4=3(NUS*A4=D;QS.UN-<%B\*U%0K=&YI<7;<_+H4J'!A@@B002";+*M(!'
MX1JB,FH^5E<HIR?4BR;79EM>\(F-D\W'W#D7<&\C*RXD=N*R3J0H,+;;4I)*
M195U$FQ%ZJC_ ,G&I1+_ (^%#.>[9(QGL3/1%N,#+MY[)%+*M(D):*TCH#YV
MGI;R5-FE&1?K5%\WCA^0YLIV3MO<T/%89,;2Y"D8T2W"X-14KQ?&18$$"VGI
M:KLE+DRU%QYHI'"N(W^YM#:61B;DBL[1\%#GL56/"Y'J]U#P_6?&'G7ZZM%6
M[:E18X%RZXU>&)R]Y1"G,'M5I"RTX[GX;:'DVU-J<"TI<3?IJ03J'PBE[@O*
M+'%^0SVWN'&(.XHN[=U[BR.[<YC@1BW,B6D,QM0(*D-,H2G5U[?^VUJU;QJW
M4H=RJHE0U-A]Z+V)M[E;-M06LC)<W3ZG'CR1>.'9"@A*W?\ 83VFK$994WUE
M]QS.*ZB5F$9MKE+C)[<6Y8&>SKLE:EHQ<9$5$6.XWIL%(6M3C;EU)3K/<;=I
MJ77-&KJ0J9945"5N@Y3AK*9_>^!FXS<6S<QDA)S>&D%*I[<E;FE89<25:BA7
M0)(Z=XZ$U+[%6L41'MT3JF9_"0L=FO>/W%*G1$/^KX"%(B)?0"6EO!M"E!)[
M%:3IJI8W'Y"EU5M>4C<1;;V^_NOE=I[&QW&F<HJ$RA;:5!N*L.++2;CHDD]@
M_P"P5%M*LB;DG2)2]D;UR>UN*]MX7#-P_:F>W),QV/GY4%R' "7"LO+%P24E
M5TBX[S5$94BO*7)1K)^0L>UD3HWO%16LAG6,]E581].2FPF&XC85J2I+*VVE
M*!*0 H%1*K$7JJ/_ "<:E$O^/A0SOO!Q?7\UQM \9R-ZWG"QZS'5H?:\1L#6
MVKK9:>U)JJ\N!39YF*QF&7QQSEC(&0FN9Y.Z,;(;QF9S)+\Z*^P"HLH=Z#2L
M#J$I%[CR&\)99]-26\T.BA4^,H>[LQM_<>&QN8V["=E3YR-S0,Y%==R2I#BU
M!Q;JPZ@%/T=T^;5$*M-51<N-)IT9:G>*LMC-O;%=PVZ\8=[[.BR48XRCXL&7
M">7<>8I6H:4Z4!P CXNAJO(Z+'%%OO%5U6#*[O3?#N]^*\!N2?!9QKF)W<Q$
MROJIU1BY&6I2WFS:Y2J_P^=WFJ)2S13ZRN,<LFNHN/)F>PN7Y4XJBXJ>Q-?C
MSW)#Z8ZTNA#3Z$I;42DD#44JT_%5R;3E$MP3495,?MQI+VX.>D+0'.I4E)&K
MSDPW2" >\'LJE<9%3X1._96WMM;Y]W6!MJ3E8^/>DQ$-2I@<0%MOIE*4T'@5
M))"E #2H^=?IW5,4I0H1)N-RIF>+MW;CA;TD<8;M:Q\[)8_&HDPL[B4V0N*A
M8;2AY/X!Z].SXNH-50DZY64SBJ9D;JJ\6"SXV+&<@L+6TE2B@7)'4UKKOO,V
M-KW42O4HGT*/M"K=2Z1H46,XTLK:2HAQ8!([@>E""L;^8995M0M-I03N+'WL
M+=SM 7>H)% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H"F\A>CM?_ #%COREU*(9<J@D4!Y=]Y_C/D;>6X\/D]M1'LQA&
MHOJR8+"TI,:47%*4X4J4GHM)3Y_=IZVZ5J]7:G*2:54=]X:W+2Z:U.-QJ,JU
MKTKH\WTGH#86+S6$V7@L1N*3ZWFX4)EF<_JUW=0D C4?2T^CJ[[7K/M1<8)/
MB<=KKMNY?G.VJ1;="Q5=,(UQRHAU>4X\+3:UA.Z8JG"VE2@E'JTBY5I!L/A/
M2I0*-G-VN8_<&X]JO3Y@W'*W?A7\=CD>.IWV2[ZD%NHT@@1O-=#A!T@Z@>IZ
MR006]HL9O<^+E9=S*R%YC=&XL9E=4J6AMW$,HE+9B*2E02F,%H;6FUKD>E8V
M(%93,@MX=F/R!/R;#$+ .IX^"GIC;CF6C3)C2B@HLIR8V$Q4LA942@W -U4!
MM3C+&9?(;NR6:W@J8[N'&XK!LMM2''$QF),F!>8IMI)#7B+7T<4 >P=E0P;@
MJ"10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * BP?1>^N7]VI8)50!0
M"@(\_P#Y*1]6K[E5V_>11/W64\=E;0UAUR(\>6PY&E-(?C.I*'67$A:%)/0A
M23<$&H)*(UPAQ,QD499K:6/1D&W ^V\&R-+J5:@H)OI!!%^RK?=QZ"YWLNDR
M$GBOCN9GW=T2MMP7L\]J+LQ;04I2EH*%**3YNH@^EIO\-3DC6M",\J4J26^/
M-EM1<)";PT=,7;;I?P;5C:*Z3J*F^O0WJ<BZ",[Z>)/R>UMO9G*8S-Y3'LRL
MKAE+7BY;@NXPIP **#W7L+U+2;J0I-*A7V^'N,6<W^\;>UX(S/CJE^M%NY]8
M4=1<TDZ=1/6^F]4]W&M:%7>2I2I:LMB,;G<;)P^7C(F8R8@M2HKHNAQM7:DC
MR56U4H3IP*KB.'>+\%/1E,5M7'Q\@V=2)'@A:TJO>X*]5C?OJA6XKD5NY)\S
M+;JV)M#>[+#&Z\1'RC<8E3'CI.I&H65922" ;=1>QJ914N)$9./ ^XO8VT<)
M*5,Q&'C0I"X;>,4IA'A@PV?0:L+#2/BHHI!R;XL^0MB;0QVVW]GPL1'8VS)#
MB7\8A-F%I?-U@B_X5^M,JI3D,SK7F5_?)W%M'9\+;_&&VT3GWBG%PV$K2W&@
M,J;4 \X%]"VBUNWMM5,JI4BBJ-&ZR9/XNV*UQWLV#MT.!^<F[^1DI! =E.]5
MD _@CHE/^R!4PCE5")RS.I:YL&'DHKL'(1VY4)].AZ.\@.-K2>Y25 @BJRA.
MA2L;PKQ7B,HQFL;M6#'RD9P/QY*$'4VZDW"D@D@$'KT%4*W%<BMW)/"I)S_$
MO&^Z,F<SG]M0IV458+DN-V6O3U&O20%_[UZ.$6ZM!7))43,KF]E;4W'AF]O9
MK$1I>%9T%B$IL);;\,63X81;18=!IMTJIQ35&4J33JB+A..-B[;E0IN!P,3'
MR\>RY%B/1V]"D,O*U.)N.W4>I*KFH4$N")<Y/BSE!X\V5C=RO;P@86/&W(_X
MGC9!L%*U>-;62 =-U6ZFW6B@DZAS;5*X%D<0AU"FW!J0L%*DGL(/0U44D/#8
M;%[?QD;#86*B%BX:/#BQ6A9#:+DV ^S1*F"#;>+(V?VMM[=+<1K<&/:R#<&0
MB9#2\+AN0U?2XGX1>H<4^)*DUP,O;I;NJHI*TWQ]LIJ%F,<C"11!S[JI.98*
M+HDO+-U+6#?SK];U1E705YWTD+%<3<<8,PE8G;<.(YCY)GQ'&T'Q$22G1XFL
MDJ)MT\XFH4(KD2[DGS.I/#O&*<X=QC:\'VR7U2S*+=[R%*U%S23HU$F]]-Z=
MW&M:#O)4I4L+&V,!&W!*W4Q :;W#-81$E9 #\ZXPW8I03Y!I%545:\RG,Z4Y
M'S%;6V_@Y64FXF U$E9I[UG*.M@A3[W7SU]>IZFBBD')OB8A?%W'Z]NG::]O
MQ#MTOF7[/T'PP^KJ7$V-TJ/E!J,D:4H3GE6M<3NPG&^Q=MRH4W X&)CY>.9<
MC0WH[>A2&GU:G!<=NH]257-%!+@@YR?%F1S.U]O[AD8Z7FH#4V3B'Q+QKCH)
M+#XM9:.O;TJ7%/B0I-<!EMK;>SL[&9/+X]J7D,,Z9&+DN#\XPZ;74@BUKZ11
MQ3XA2:X&#W#Q+QMNK(JR^X-M0IV26 ER2MO2XL#\<H*=7^]>J7"+XHJ5R2X,
M9CB7C?/Q<="R^VX<F+B61%QK904AA@=/#04%)"?@[*.$7R"N27,RIV5M,[;_
M '0]CQ1MG1X7LL-)#&D'5Z([[];]M^O;5654IR*<SK7F8W%<5<=X1,).)V[$
MB>SY?M&(IM!"T2RG1XNHDJ*M/3SB:I4(KD5.<GS,QCMJ;=Q.0RF5QV.9CY#-
MK2YE9"$^=(4@$ KOVV!-5**12Y-E?9X=XRCQ,I 9VS#1"S7A>TXX2KPWO5UE
MQNZ;V&A1NG3:U4]W'H*N\ETF5VKL#9NR$OIVIAHV+,H@R%L)\]S3V:EJ)40/
M)>IC%1X$2FY<2QU44%LQ7_TZ/_,%:Z[[S-C:]U$RK1=(L#]$OZQ?Y52P5;D/
MMVG_ )B@?<=HB&7.H)% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H"F\A>CM?_,6._*74HAERJ"10"@% * AY++8K#1_7
M,Q.CX^)J"/'ENH8;UJ[$ZG"D7/<* D-EAW3):T+UI\QY-E70>O10[J [* XK
M;;<*2M 44'4@J -E#O%^PT!T'(X\2!%,MD2E.%E+'B)\0NA'BE 3>^K1Y]OQ
M>O90$F@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"-#['_KE_=H"3
M0"@% =,MM3L9YI NM:%)2#TZD55!T:93)5317?8N1_$3\\5G=] P>YD/8N1_
M$3\\4[Z!/<R'L7(_B)^>*=] =S(X(Q,YP**$).E12?.':.VG?0'<R.?L7(_B
M)^>*=] =S(>Q<C^(GYXIWT!W,A[%R/XB?GBG?0'<R'L7(_B)^>*=] =S(>Q<
MC^(GYXIWT!W,A[%R/XB?GBG?0'<R'L7(_B)^>*=] =S(X-XF<YJ*$).E12?.
M':.VG?1'<R.?L7(_B)^>*=] =S(>Q<C^(GYXIWT!W,A[%R/XB?GBG?0'<R'L
M7(_B)^>*=] =S(>Q<C^(GYXIWT!W,A[%R/XB?GBG?0'<R'L7(_B)^>*=] =S
M(X(Q,YS5H0DZ5%)\X=H[:=]$=S(Y^Q<C^(GYXIWT!W,A[%R/XB?GBG?0'<R'
ML7(_B)^>*=] =S(>Q<C^(GYXIWT!W,A[%R/XB?GBG?0'<R'L7(_B)^>*=] =
MS(>Q<C^(GYXIWT!W,C@C$SG-6A"3I44GSAVCMIWT1W,CG[%R/XB?GBG?0'<R
M'L7(_B)^>*=] =S(>Q<C^(GYXIWT!W,A[%R/XB?GBG?0'<R'L7(_B)^>*=]
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M?W: DT H!0"@% * 4!%A>B]]<Y]VI!*J * 4 H!0"@% 18/HO_7.?=J6"54
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M ^*P6$6M3B\;%4M1*E*+#9)46O ))T]OA?F_YOF]E ?58;#K2$JQ\921',$
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M)% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MZB[&:21Z6KGS!(T/L?\ KG/NU()-0!0"@% <5H0XDH<2%(/:E0N.G7L- <J
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MW5N+&V2NVL]:-\$94-.Y1S5-XJDNI44B,XH ]"--C_+6F,4^>MO?LKG]'Y:
M>MO?LKG]'Y: >MO?LKG]'Y: >MO?LKG]'Y: >MO?LKG]'Y: >MO?LKG]'Y:
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M]VHWMF<7X^:CNC4 XM,=Y4<_FEO- Z5J186\MNMZSK>MNV[?=Q>!=5V2CE7
MV+6"6A0"@% * 4 H"+C_ - KZQ?Y1H"50"@% * 4 H!0$6!^A7]8O\HU+!5N
M0^W:?^8H'W':(AESJ"10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4!KKFG;60W+M&.C&8IG/2L9DH64&#FR&XL&8B*[J6W)6Z%)T $
MK%TGSDIZ5(*ML1YK(9_&RH?$^ Q$8N.$9['3</)<C^&"E:D"*CQ%$*(0K1V:
MNM ;NJ * 4!3>0O1VO\ YBQWY2ZE$,N502* 4 H!0"@% * 4 H!0"@% * 4
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MIH!XLCZ#^FF@'BR/H/Z:: JW(>_H_'6UI&Z<GCWY<:.ZRR6(RD:R7UA -U$
M $];UE:;3N_<R)T+EN#G*B,%Q9S/C>55Y5O%8B7!<Q(9+OK*FBE8D:K6+:C8
MC1V&KVKT4M/2K3J5W;+MTJ;$;DNN:M#!.E10KSD]H[:UY8.7BR/H/Z:: %V3
M8Z8_7NNL6H#AXL[]G3_6?>J0/%G?LZ?ZS[U /%G?LZ?ZS[U /%G?LZ?ZS[U
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MQ<)Q9=<;8205K/34I1)4HV\IJY=O3NNLW5DRFY.K9DH?8_\ 7+^[5DI)- *
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M"@([\Z%%=9CR9+3+\DZ8[3BTH6XH=R 2"H]>ZJE%O%(FA\A]C_USGW:@@DU
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M;C3^";]!5-^=UNEQNJZ2)N3=)&?DS8D2-(FRGT,Q(B%N2GEJ 0VAM.I163T
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M9=S,Y_(.!U:/!;AQ5N,Q&FK6*$-:B+'\(JN5=];6SIK=J.6*]IE0MQBJ(K3
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MLAMC-8W(*4[C\JEM2BU(4"AUEULE*DDI(5;JD]M2#T@>T_'4 4 H!0"@% *
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M.NI3H*B191U%:EF_96T;RT27Z$>7MTHD0DLO.-N.H:6MID O.)25(0%&P*U
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M7*6$G](4@W4 :NW=3;M249NC?RQ*Y7(Q=&7C:ONU\@YV+[4SR4;9Q*!XKHE
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M>E ?%)0M)0XA#C9();<2E:+CL.E0(Z4!\*&U%*EM-K4C]&I:$J*/YI()'V*
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M*-U&QJ08;;FS-_,[U@[GW#(V7*DH26)4_'X9;.87&""$M-2EOK4E(-NG46J
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M$HR5E-KOL,M5SIQR/E+STIB7_A)9:\^@S>$X/9DX-#V=FR(6?>NHLLAM;4<
MV"5#KK)'4G57.[I_=*Y;UCCI+4+NGC]9N2<\.,<.RD\,4ZT+L-)6.+HR^X3&
MP^,]LOM14R\G#BK>G/K9;09*K@$@I20" !V]PKS3==5<\4[A&5QV[$YJ-J*E
M)Y%B\4\O%UX85=*,R8Q5F.&)YEG2D3Y\N>VTEAN4^X^AE'HH2ZLJ"1;R7K[
MTEAV+,+;>9PC&-7SHJ5\YII.KJ3ML2,3$W'BY6>;\7#,R$+F(*=8T"_4I_"
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MNQ,7'1&;==]->GM4;=!<DFW=7.WKKNS<WQ9@3EF;9@MU[+D9"6<EB=)?>/\
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MK5II-\>C&A5*]"+XE<W!MK=&V&(L'.L+8@!:S%2V^W*BMON?I&PMA;C:'2$
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M[A]J..;A3J\YL9R=WW.*YGK78N3VKE]IXR?LI++>V76O^!9CMAA#8"B%(+8
MTJ2JX4/+7+WX3C<:G[QKIIJ3S<2Q58*!0"@% 1H?8_\ 7.?=J6"34 4 H"H[
M\Y+VAQO$C2]TS%,&8LHB1F6U//NE%BHI0@$V2"+D]*RM/I;E]T@N!<A;E/@9
MS 9[$;GP\3/8*4F;B9R/$C247 4FY!Z$ @@@@@BX-6;EN5N3C)4:*91:=&9*
MK92* C0^Q_ZYS[M2"34 4 H!0"@% * BX_\ 0*^L7^4: E4 H!0"@% * 4!%
M@?H5_6+_ "C4L%6Y#[=I_P"8H'W':(AESJ"2JS/^;?\ K%_=-20=- ?4*T*"
MB-0!ZI/81Y* U;L+BS/;#S64BQMQMS>.,JN8^_M]R-IEEV8@MC\_U " ;'3Z
M0 Z7H# 8S@?=&+PV1V/'WTIOCB87G&L2W$M+*G.J6W'B>C6H)+H;].W=<U(,
MNKAF:O#<:XI6<8\3CY_UB0\(SFF</%#EFTZ[M]EO.O4 L>9V"_EN4MO\D)R+
M;,?!Q'HB\6II2G7B]XGG)="@E('B=A30'7%XZ+/)^<Y!E36I..SF+&(=PI:6
M%A&E"%J4[JTE*@D] GOH"H1N%][8#%S]G;-WXG&\?Y);I7"E0O'R,9J1T<;8
M?"@ %#S2>E^_OJ093,\(XZ1@MC[=VW/3C,=LS(>TEKDM*?>FJ5I+FHH*0E:U
M F_8.SNH#:[J_$<6Y:VM15;R7-Z@'&@% * 4 H!0"@% * 4!F,(TV4N.E(+@
M( 4>X6[J S%02* 4 H!0"@% 43>.P,WO/+-J>WEE,+M1#"6GL'A2U#=D/:E%
M2W)FE3P!20D):*.R]Z F[2XSV'L6[FW,,Q%G.G\[D7BJ3.=41;SY+Y6ZKIY5
MT!QY-BR9.UE.,1W)C4.; G3(+*?$<?BQ);3SJ$I'I$)3JMWVM4HAF'VCEHTG
M<6Y=V1D/'![ADXZ%AI"H[Z!(?C1E(6O0I 4EO5YGB+2$^;VU+",)M#%[V@<F
M,S]PX=DRY^,E^U<NS*4ZV=4II3247: 2&PE+;;-_1U*O>]'P(7$E[VP.Z6-U
M8'-2MU.2MMO;@@!C;9A1T-M*.H)/K*?SITD%77M[*(,V=ZO*_:C\Q-4E1T1V
M9"G9 3(*2%@*.E)N;#K4@[_5Y7[4?F)J >>.<>'LXQDT\K<=N.-[E@J$G(Q8
MJ0EUQ3?7UAE*?27;](C\,?#<*V^CU4:=U<]U_+Y=!ZQX2\1V7:_Z[74E:GA%
MRX*OU9=7V7]5^:EMX:YHA<F04XZ?+3C]XQT?\3!TI")"4]KL>_:/QD=J?A'6
ML?5Z1V77C$T'B?PK=VJXYPK.Q)X2YQ^[+Z'P?EP-M>KROVH_,36 <,/5Y7[4
M?F)H!ZO*_:C\Q- /5Y7[4?F)H#H99D&1( D$*!3J5I3U\VI(._U>3^UJ^:FA
M(]6D_M:OFI^2@'JTG]K5\U/R4 ]6D_M:OFI^2@-:\R<J*XFQ,"4F.O*Y3*O+
M9A1UJ#+"0RD*<6XI(*N@( 2.V]9^BT?Q$FJT2+]FUWC.K:G-&W\[QTOD/,R5
M8.+%==AS8CA0Z?6V0"6V#8%S6%)*!:_E[+TOZ.5N[W:[5>!G:3:]1JKZL68Y
MI/YNE]"-*16-X^\_O5#\L/8WCC#N'MZ)0@_@I(Z+D. ><1T0G[&K8/)HX88S
M?R]'S_-[))Z3PGHG&+5S57%\O)"/+G)^K<JO=XXVE[AC;A:C2(4C&K:2W$AO
M%F*XJ*E(;4M %[V U:5#5W]]:R6LG.S*S.DH233S*N#XH\4N:Z_<G*<Y5E)U
M;YU-EPL(QC4K3 4(Z7%:G/#0D:C\-_)6DT>WZ;1Q<;$%!/C0QKEZ=QUFZG>X
MEQA/B/3O#1V:G @)Z_";5ESN1@JR:2Z\"VHMX(YAF40")=P>H(0FUJK33(.B
M=BO:45R'->\6.X+*3H2#TZ@@CL(-8FLTEK5VI6KL<T9%RW<E;DI1=&B-B=N1
M\(VXC'NJ1XI!<6M(6I5NSJ>X5A;7L^FVZ#C9C3-Q;=6_\"[?U-R\ZR? \R>\
M3LGDC<?(D%S ^-E82X[+.,9B2$M&')3?Q"XG6GPRHV6'/)W]*ZW0;UM]F7P]
MR["-Y_5;6:711<_(9FFC2VY-8=-#<V_,SN38G#LG*SDMYO.P,;'8GH?;#L=Q
M]P(9===':I U%2O+WU:T]N-W4))Y4V8%N*E<IP1JKBC>63W9MJ1-W;!@R(YD
MAO&R\:TB%(0E@:5@H;'AZ4WL@6Z];]U>6^-[VU:#52TL=.W.[%2NR32:4FZ.
M+HZRJJO@NEG1V+%UTE&;27)XE7Y PF[SNIO<RIL-O:.UW!,Q4EA:A)=4I22A
MHQ[%Q;[J]+)"?,Z^2M[X+N;!:MW=+IINY=O*MSO%QBETM*&6%6W2M'Q*=0[K
M2<E3E@9CC;'[F:&2RNYL1"QF2R$KUJ&B-'9:E-J<!2L%:07$CJ E)77'^.?$
M>GUDK.FVZ]*5N%5/(Y*$GAD2:HI4QP6%3*TVGR5E+UELY!V)C.3L=A\5/RJL
M;NW&.+:8R"V ^RMMT@>KOK"@HV(!2J]DF_E-=#X5\86]'&&DU,G*Z^RWR3KV
M4Y?:Y/YS NZ>492N078?+Z3[%VI$XZ:@\?1W');L.(<D[E'DZ#(7*>4E:4)!
M(2ALI%DWZ:OAK2?W(MQN3LZI047-R@Y+J58I]/.C\Q?VVZ[F:K\W0:[WGCLO
MFN18<'9LUS"95G#H<SN2"R&E-J>6&K(2"2JU@?O5LMHW7;=+X7M2UUKOX=[*
M,+?O=M2E]K".%7T)<"?AO_<SG%)2E3M42=.M\68=C=T_B%$C:VXXOMAUY3F2
MQV1C.A!?]8/G^*';JN%CXZJN[!8\8N&OT=QZ=12LW+<X5RY,5DRNB[,NM<.L
MOJX[/9:KS+%N/"S]Y;/QN>RLEMMR"TG-'$,@^H2 D!TM.K)\0W0- (-@HUSW
MA_=M-L>]7-+9M2N1G<5AW)R7>K&E8Q24<N9U?/+CR*[L)7+=6Z85-3O;GSF7
MY!D9TR7]N2]PSDF4N.DQE-1Y+@2!I(ZV38:B#YW6O?=UTFEO;?-3M0U2M1E*
M,94DG**?H-993A1)T/0>X,BSM# 2LA'@NS$P@D"*SU?>45!-U*L23^$I1O7R
M3L^CN[WKK=F5Q0E=J\SKE@DLU(QJJ+E&.&!O)R5N->@U!MJ/#Y@WIE,IN+4S
M$B1FO QL=PI/AA1;2@N6OYO52[6N37N>]7[O@[9[&GT;4YSN23N35<6G.3RJ
MG'A%<ETF!!=]-MDS>G#V$PNW\EF\1/?;]227_4Y)0IHLW +86 %:NOFDU@>&
MO[CZO6ZZSI-3:A^]>7/"M<U&\SB\*88XX%5W3*,6TSEM?<6_M[;==VO$AMM,
M-1?5W-P*6J.LMVTM)3J24J5TTJ4CK;KT-5[SL_A_8MP6OOSFY2FYQL*DUG>,
MI42S4QK23RU?D13&=VY'*J%)>R>X-N9C)8W<[LES+-,)CLR"XF0]%?9<1(CO
M,+<OYFI/G:;%2217I^WV]NU^B4]+"#L7DZI1RJ2=8R4ET\G7@S#N*:DJO&)$
MW3OO<NZXS+><D-KCQ+NH98;#+9<M8K4!VFWVJL[%X3V[9YREI8-2G@W*3DZ+
MA%5X+Y^97<O2GQ/5>W^#,1EN"X^UVGRO)95M.>B39:"@Q\G)90I!TH-TH2G\
MVH=;BY[:BYKY1U6?DNS1<TC2N^U<KYBH<.^[AEXN<FY'DW&P7L4RT6(F.4ZF
M8'9!6#XIT$!*4A-K$W-^RLK6[G&44K+=>G@7;VH379/0.[MB8[>6TYFS<@\I
MC%26D--"*A#18+)2IHM@"P""D>;:UNE:.S?E:N*:XHPH3<95/&.\,;G?=\WY
MZE@)2)<SU5MZ)E<A 97XP>"DN-LI7K 'X"]!U&NNLRCK+59*BKP3-I!J]'$W
M?N3W<L+OW!X+/8%IC9F=DQFY.5@LQB8RG)2$..)+>I)0IM14$V[NA%::SN4[
M,I1D\ZKATX&+'4.+:?:1>)\G$>[]Q7&3XLC(0,*A$9AH)0EZ5*DN%751!" I
M:R?]E/EK"C&6LOODY>I%E)W9^4C<1\N1N8(>3BO0CC,ECM F05Z),=UA_4$*
M0HI'3S2%)4*JUFB>F:=:IB[9=MFT&XCS+:6F7PVT@!*&T-(2E*1T  '0 5KF
MZE@Y>!+_ &H_U::@$>(U(4'=$@ILZL'S$FYOV]:D@D>!+_:C_5IJ"36O+'"6
M-Y51CWY>5=QN7QNM#,YII#H4P[8J;6VHI!ZIND@BW7MK8Z/72T]:*J9?M7G;
M+1L78L/C_;$':^%E.*BQ I3C[J4EQYYU16XXKN%R>P=@K&U%^5Z;G+F6YS<W
M5EB\"7^U'^K36.4#P)?[4?ZM- / E_M1_JTT!6.0]W_P\VAD=VR]<U$%* W$
M;2E!<=>6EIM)58Z4ZE#4>X5DZ:P[UQ06%2NW#/*A1.$.99?*;F5QD^"C$YC'
M!$I1BDO1G67U%-_SGG)6E0ZB]CW5F:[0_#T:=4R]>LY*49N+P)?[4?ZM-:HQ
MAX$O]J/]6F@'@2_VH_U:: U9S)PD.5&\;+:RYQ^9Q8<;:=6SXK+C+Q25)4E*
MDD$%-PH?%6ST.N>GJFJIF19O=WUEMX_V&QQ[M2!M7&3EOM1-:WI+B$A3KSRR
MM:]-R$@D]$CLK%U-]WKCF^9:N3<Y5+-X$O\ :C_5IK&*!X$O]J/]6F@.B,P^
MH.VD*39U8-DIZF_;4@[_ %:1^U+^:GY* >K2/VI?S4_)0#U:1^U+^:GY* >K
M2/VI?S4_)0#U:1^U+^:GY* >K2/VI?S4_)0#U:1^U+^:GY* CPV'EM$ID*0-
M:Q8!)[%'KU% 2/5I'[4OYJ?DH!ZM(_:E_-3\E 0,SD(N QK^6RV1,>!'&IUU
M20>TV   )))-@!1$&/VKNG$;RB.R\'DG' PH(D,N-AMULGJ-22.PCJ#4M4"=
M3/\ JTC]J7\U/R5!(]6D?M2_FI^2@'JTC]J7\U/R4!'B,/*;44R%)&M8L GM
M"CU[* K&_6G&U;4UO*<ON+'VN +='?)0@O%02569_P V_P#6+^Z:D@Z: 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4!F\'^A=_G#[E 96H)% * 4 H!0"@-
M3\P;JY/V\_"8V;C4M[<?96K*[F;AN9F3!6E5K(Q[+K2UC3YVNZ@#^#4@H/""
M,#OK?6Y<[G-XS=Y9K;.19;VZ[-D*@I0RY!96XZ,6UX*$E+KKK6I31M:U[B]
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MG4M+J74V<"F5(&HK/Q6KJKVCMZ>UWEMM2CSZ?\393M*W'-%XH]+; XTVGQK
MD0-KQEM^N+#LR5(<+TAY200G4L]R0;)  %<]J-5<ONLWP,&Y<E-XEOK%+8H"
M+!]%_P"N<^[4L$JH H!0"@% * A9?$8S/8R5ALS%;FXN:V6I45X:D+0>X_=!
M[C5<)RA)2BZ-$IM.J*]L/C_:&PHLR-M3&I@B2\?672M;SKOADA(4MPE5D@V2
M.ZKU_4W+S3FZT*IW)3XLMU8Q0* 4 H!0"@% 1H?8_P#7.?=J02:@"@% * 4
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MZQ?Y1H"50"@% * 4 H!0$6!^A7]8O\HU+!5N0^W:?^8H'W':(AESJ"10"@%
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MK@-CTZW3W =]>3>(?$]^]J.ZTLI1C###C*5:>CDES,[1Z",89KB3;]2-=3^
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MC5&0U0DU20* 4!%@^B_]<Y]VI8)50!0"@% * 4 H"-#['_KG/NU+!)J * 4
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M,N'VDN:6"^[S6)Y;XYU.Z:&W;G"3C!MUFN3Y*O*N/EZ<#EP;Q9NZ+GL9O3(
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M/*:U&R>/;VJOQTU^*C<=<5[KDJU5.*PZV5ZCQGN=J/>+NY1Z,K]ID9ON@85
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M!0"@% * 4 H"-#['_KG/NU()-0!0"@% * 4 H"+C_P! KZQ?Y1H"50"@% *
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M.U*!T->/[WX6U^HW-WK<EDFTU+-C"E,*<</JT]1=T>X68:=0:Q6%*<3?H%@
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M?*5NS6,HXT:I5=*^52YJM!<M)2EBF67D*,]&=Q3#;*O9++!9:<)U(2ZBP"5
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MJ6"34 4 H!0"@% * C0^Q_ZYS[M2"34 4 H!0"@% * BX_\ 0*^L7^4: E4
MH!0"@% * 4!%@?H5_6+_ "C4L%6Y#[=I_P"8H'W':(AESJ"2.J?$0HH4ZD*2
M2".O0B@./M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M
M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M
M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M&%],G^6@'M
M&%],G^6@'M&%],G^6@'M&%],G^6@.QJ5'?)2TX%*':!VT!W4 H!0"@% * 4
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M"P)[*U=O77X696+;RPFZRIA*5."<N.7JX%Z5J#DIO%KAT+S&>A;;SN8#+S*
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M::=CI$-+<8J+:4M.%>HW425*^Q4:S7N])./9IZ3J;M]SX84)G)7+V,XODX[
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MDZML[2*HDCFE"47TI";DDV%KD]IJDJ/M 8MW)0\3$DS)SGALI?6+V))43T
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M*UE_33LOM<.D\TWOPWJ]JE^\6:#X37NOV/J?FJ7^L4Y<BP?1?^N<^[4L$JH
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MV%V9*<GD4*/@GP?V:8UHN!U[HW,W-S;T[ N/1F%V)<Z-N%SL4I)3U -KCO\
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MQN12%X^8Q+0H:DJ8=0Z"D&UQI)Z7J9VIP]Y->5%-N["XJQDI>1U)=6RZ* 4
MH!0$:'V/_7+^[0'')Y.#AL=*RV3?3&Q\)I;\E]9LE#;8U$G[%2DVZ(OV+$[]
MR-NVLTI.B76SR7BX>;]Y_D5W)Y3Q87'6"5I;922/S9-TM)/9XSUM3BAZ*?\
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MT\_\6_%92VM8)U6N!T3?KI%A5J%J$75*AF7];?O14;DW)1X59E<?^@5]8O\
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M,;IV=/S623-AR$);<0EMU#I5YFF_5-@;_%5'B/PI=W#5J_;E%52B\W*G->S
MR=%N$;-O))/S&=GY7#[0PB)><GHBXZ&AME4I\VU$ ) L+DJ-NP7->D;?HIY(
M6+=9N,4NMT7%G/:S5V[2E=NM0C7YSOPN<Q&XL>UE<),;G8]ZX0^R;INDV(/>
M".\'K61>L3LR<)K*T4:?4V]1!3MR4HOFB8^PS)97'DMI>8<!2XTXD+0I)[00
M;@BK49.+JL&7I14E1JJ(6+CP,<PJ)$99AQP^M++#*$,HN3V)2D 7JN4I3=6V
MWUXE,(0MK+%**Z%@>6M\<0<C9'>V8FN-(D1)TAU^/E9$IIIE3*R2VV=:]0(%
MFPC3W?B]:[^QXAV_2Z6'>35NB2H\,?FZ_P!)Y!N'AC<M3K;DHQSJ3;4JKARZ
M\/=X>K$P''6!R6+Y=Q&WU9.' S<"2AV6TB6TX2A UNL)+:E!;BDW26P;^7LJ
MG7>(-OO6)6XSSRDJ)4?'DZTIAQ,_:?!F]:>_;U,[4K=J+3<ZQI3FL'7'W>'J
M/:M>?'J@H!0'3*EQH,=R7,>1'BM#4X\ZH(0D=G52B *HG-0BY/@BJ$')T2JV
M5G";YBYG))@ICEIM\%41\+"PL 7ZVZ"X'2Q-</M/BZUKM7\/D<*URM\Z8XKZ
MN!M-1MLK5O-6M.)8X?8_]<O[M=V:D\Y>\UNS)9K)87A_;)+F1RSK+N2;1?SO
M$7:.TH@&R;_G5^0!)K<;?;44[LN$3U[P+M]NQ;N;E?PC;34?,NT_]J\K-X[!
MV9C=@;5@;8Q@NB*B\A^WG/25]7'5?SE=GD%AW5K+UUW)N3YGG&[[G<W'53OW
M/K/!=$>2\WSXF+Y3Y1PO%6 :S.58=F2)3PC08#!"5NN6*E74KHE*0+E7Q5A7
MKRMJI&V;9<UUW)!THJMOD<N+N3<+RGMY6=Q++L1V.\8TZ"^07&70 H><GHI*
MDD%*JFS>5Q51&Y[;<T-W)-UJJIKF7>KYJA0"@(L+T7OKG/NU()50!0"@% *
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M]W=4CJ?"VY/0[C;N5[,GEEY)8>IT?F,![KVZE[@XU;Q<E97+V_(7!NJUS'4
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MLUVU9W#3WKB_X[D9)UI3ZK\V63JF>1MO;FS4W9L79T=;36.:E/.!(4EE:UN
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M\V_?5Y[%/3VE?C-.<*2I3#IP?/Z3'TOB&WN>L_Z]VWEOOND\<U9=G&-,./\
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M'C(]<B?3(^<*4!T19,=(>U.I%W5J%R.H)Z&@)'K<7Z9'SA44 ];B_3(^<*4
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M/5M:0\2% 18'Z%?UB_RC4L%6Y#[=I_YB@?<=HB&7.H)% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"F\A>CM?_,6._*7
M4HAERJ"3P!S/.;:W;E)V"=!1)ENN3WD$*2B4M:M:$$WNDGKJ\O967+==WM;9
M:5]*S/-)=EK-W:?[JOV:KTTQI6AC^%/#NQ[AO&IG*/?J,8N*DGW;N-OO:<I9
M<,.69TX(IT/<,/U-"I[I,U.KQ$)0;KL>ENZY%=#MGBVU'2TU+<KL>KWNC'A7
MI-7XE_M1JKNYUVZ$8::XUQG_ ,;^M@^UE^RE5\N!@'I2'\EZZX@EM3J5J0;*
M5H38%/7IU KSJ_J^]U4K[36:>:E<5C6E3Z(VW;IZ';+>CMS[=JUDC.F59DJ*
M=.*QQXU)WM=#,]4G%H5';7Z;"R"A7;<63V W[.[NMW=KI=_LW;K5.[3X5=<'
MR;]O'F;73;?#<]LCH=ZE'47(_P#JQBX/,O=G%\87%]J-$WR2=#&R$H4ZI<=O
MPV2;I:OJ*?LV%ZYO<MHN69.=M5AU?5^FGI-K+:-1I;:4IN]18SHE)]<E'"O2
MTJ=2.D=.SI;LMTKGC!XF0P84<M%T^D"LBW\Q5;K8U_[ZV^AU]";^2Y\#B_&[
M_P#\)J5AVHQCC]Z<8\N''"7"/O/!$)*P7%+D(\0KU:TDZ?.5?KT\AZVK3J2;
MJ\:U.OG;:BHVWEI2G/!<O.L*^<R6'GP\6OUAXK=6YYCK;:;%" KJ;J("B1V"
MNBV7=+>W2=W*[DY++2N516&-:.K?FHO*>>>-/#.K\16EI8SC8M0:GF:<Y3E1
MK+E3CEC'FW5R=*4RX[PX.V;OG*[Z0[)A/R>-)S3CN1,U!.-E0UH*HP2A1TET
M**%#3YR#<W[;X.EW6[JM5+40F\RDU+'W:?5\W1T&)N>V[5I=HCH<D&X**4:*
MN9-9I/RNKKS9G-S^\1E^-^0Y6T<'@(4+9&!E&&]BT-%N0^D=7'D+! 2I5]2/
M-L>^]ZJU.XW9WG*;S>4O[5X3TKT,<G9E)55*95YOGZS3^\<AQENG(9O<^*=R
MF#R<Y]R2WA7V&I3"WGEZE+2\A:="222I"AYO<2*T.JN7>\B[44XMO-65'%=*
MPQ\F!V6BMZNQ"-J>6:BJ9DZ8+J^DV'[J\_8K6]F\=-QTEW>,EF2,;E''$JBA
M ;U.-I9 \Q10E?GDJN+CIW[/1-*>*QY&C\4V]1+3N2DN[5,T>?IYX\BT3N2>
M".-=V9'([5P\W+[CA/.,-)0O1C6G%$I>\!QPFVGJFX0K_9Z=:["6\:S70[F*
MSKF^"\\OT8G![%_;%W+ROVH*&;'%MY:]7!5\N"P-7;JS7)'+DI[)8+#963@_
M$]7$>&AZ0TIUQ15=U2$Z2HV%[^:FPK3;7L^GV6,KMV3OZFYC*5,?\L5CEBCW
MS2Z?;=A@N^G!WJ55:)_Z4^"Z^+/8'$FQ87'NQL?"5!;AYIV.W(SJT'Q'%RRB
MZPI?>$DE*0.@[JOWM3*:=RYAA7R(\/W[=[NYZN4Y2K&M(+DH\J+YS%CG+CS%
MS'X^:R\: VXM:VG"Z'U&UA92&0LI/2N.VWQ)\9=<>YG;ARG)8/RKBJ\N)#V'
M4N-8)R?DI\YSWASQL3:VT(>\(DDYR'DGE1L<S (UNNM]7 HKTZ @>EJ%^HZ=
M:Z2>JA&.98U*-)LFHOWW9:R.*JZ_+&IYMY!]Y7>N8W+!S.RIDC#;<C(;,:"Z
MVBSSZ0DOID>D' %>:.OH]18DUK;FJG*54Z([K;_#FGMVI0O)3F^+Z%RIT%K@
M>^/D%;@!R>VV6]JK4$E##JU3VDVL5E2K-KL>ND)3\=7EKI5Q6!KKGA"/==FX
M\_7[K^E&$1[W^^6\GD7U8G'O8QY*TXV(0XA4=0Z-K6L*)<'XZ?-OW%-4+6SK
MR,I^$M.X16:2DN+Z?9U?2;9X#YWF<C#)XG=R(L/,XY")#,EB[++T=Q6@W"U*
MLM"BD=#U!^"LK3ZG/52.<WW8XZ/+*U5QEACBTR3RUR?L?B6#E(NV&H47D/*L
M%YA,2*V3K4H)#LE2$@?C*2%DW(ZBU3?NPM54:9F6]JVS4:^47<S.U%\WZH_H
M/,>P]X<C;CY*Q67.Y7O:*'VWI\Z?+3'B(@MJ3XP<"U);\/3<: .I/07K60G)
MS3KB=]K]'I;.DE'NU2F"2J\W*G.O6;VW[[T!V5OA_;F*PK64P\-Q"I\TOZ7'
MO'2ER\<I!39*5"Q5?4?)6PNZS+*B54<=MWACXG3]Y*>64JT5.%,,?E@5#<_O
MA;CDS&_W/PD:%CFEA2U9(JD/O)':DI:4A+8/P%1^&K,]=)OLJAM=-X1M*+[Z
M;;^[@EZ>)=D>^#LW]WDS7,/-.Y I*',0DI#9Z J<3(-TZ.X73J^#OJ]\<LO#
M$U3\):CO<JDLGVOT=/J.]OEC@+F:-$A;YBMP\A$;<EI8RNID,^$-3B6Y312%
M72G5IU#5Y+T[ZS=]]?+RE#VK<MN;E9=4\.SC7H[+^2+OAN:^$(..BX[#[EQ\
M+&QF_!BQ0ER.AMMOS0 E2$V^#R]M7XZFTE1,U5[9]PE)RG;DV^+XF+WS[P^P
M,5L[*93:V=AY;/(1X..@(6H.+?6H(U:=(.E )7?L-K U1<U<,K<7B7]%L&IN
M7XQNP<8\WU?+ \/8+<><VWG8^Y<--<CYR,Z7TRP;J6M1NH.7]-*[D+2KHH=M
M::,G%U7$]9OZ:W>MNW-)Q:I3V'I2/[Y3K6*QJ)&U_6<VD@9=:9 8C%()!+ T
MN*NH=;*]'X:V*USHL,3A9>#ZSE2Y2/U<*OS\#/9SWN-HPL*M[:V/E3\\\Z"(
MDU'JS+:5C4M2G$E>K2?-L+7/P5<GKE3LK'K,'3^$[\KE+LE&/2L3SURKOZ)R
M5N-C=,>&,=,>A,L9*(#JM(9*D%078:DJ24V/;;H>RMYM.KCJ8ST]Q>\L/I]I
MZWX5TWP^GGH[CS1JW%]3XKRIX^LI2G<<%Q282B&2CUMKQCHD(2;JZVU-J7V'
M3T'=7*ZG3RT]UVY<O7T,QKVGNV9RA)X\G3T>5'MV)[SW$T';^(>6^^S(>C)U
MXB,RN0[$+8"?"6JR4].Q)OU OTK8K66U%?,>0R\-ZV5V2HFD_>;I7K,]NSG;
M:6W^.HG(F+"\S!R3R8F.C-'P5JDJ"BI#I4"6] 0K5YI[.G;>KD]3%0S+$P]+
MLE^]JGIY=AQ57SPZND\K["E<387,IY,RN6E17L9,<E8S90:+\I<I"2ZU_P 4
MD!)9"C8*4E)N+*^'56LB>9OAR_2>@ZZ&MN6_AHQ3S*CN5HJ<'V>GTEYE^^5N
M-<?3 VO"9E^*HZWY#KS?@6\U.E ;.L'M5JM\%9#UTN21JH>#[=>U<;5.22Q]
M9B^%N9-^3>1$2MX;DU[3EA_VNK)NH:@,E2%*;#.JR6U:]*4H1VCX*MV+\L_:
M>#Z2_O.SZ:&EI9M_O%3+E59/IKTX<RY8CGC@+9&=RLG;.V)#,J0_X3N4@16D
MH?9*[K4WK=!2@$:@D!.KR5D+468.L8FJN;%N>IMQ5VXFE]5MX=%<.)Y6S#Z)
M>9R,Q$ER:F1)>=1->24NO)6X5!:P22%*!N1>M4ST6Q'+;BJ4HEAT=1LO8?/N
MY^.]ERMI[?@PTR')(D1LFXW=: N_B^(BX#BS9 0I78.G7I;)MZB4(T1H==L-
MG5ZA7;DG2E&OFIT+C4M[/O?;U+,:-DL%C93 2&\DI!?:=D((LO04KLVHCX#8
M_:J[\;/FD:V7A*Q5N,Y)\N&'M,=LO$\0\?;RQF]IV_&YV)C+7,Q.)B1W79Z%
M*0HH1+4V%(06]6DV/GJ\@O5%M6XR4F\/7YR]K+NNU=B5E6:2>$I-I1_TUXU]
M1N.7[W7'+>)<G0861D9)+P:;Q;K2&'%-FY\7Q-:T!%AY=5^EN^LYZZ-,$ZG,
M0\*:MSRR<4J>]Q\W2:+R^9]W+([F1F58O</JF6(D92*R\RS%@OOJNYH1I+CF
MD];)7IMV7[!@2=INM'[#KK5G=86<F:W6.$71MR2X=2]%>DOO+_)VX.)IV!V7
MQ88^)VA#A(DQWVT-S!)6XM16E2W-=K=JOPR57/=5^]>=MJ,'1&FVC;;6OC.]
MJJRN-TZ*>C_ U!OOE_>'(V-@P-RJCI8@/.R0F(WX(<<=  4L74+I%TI^,UU>
MBD]-I7J+O%K!?,O/\QZ?L.R:?:+4]1&N::5*]')?ZGB_,77W==Z[#XX7F-T[
MKSRF)\X)QS.%8CO.N>$%)=,A2DI*2+^:GK<=?@KDK%]*<KDWB_IYG!^(]+JM
M<XPMPK]9R;7'H-SS/>IV2]D\AA-O1I4Z6B.^,/.4T?5)<]"%%ID)!#H2M0"0
MK3U\G?63+6QQ27D.5AX8U"A&=QJ*JLRYJ/-]&!YTS?O!<A[GVOG-J[E>9FQ<
MR&DI=2TF*Y%\)U+BDH\()U)4$Z"E=ZU\M1.46FZU.WL;!I;-Z%VW5.'GKAU_
M05/9G(F\>/7);FT,D<<J?X8ECPVWDK\$DH\UU*@+:CW=AJW"Y*'NNALM9MUC
M5T[V.;+PXKCY#?&;]Y;;#^/VED<GM/'[GW<S';>RTEQ*4)ANA:@IME3C2R'%
M:?$Z'2BX[3V9DM5%I-Q39QUGPY>4KL8W)6[=>ROM>7%8<NLPGO&<Q[;Y QF"
MPFWHC4A/A,Y21E'-*GXRWT&\1!'HJ'_MOA %4ZJ^KE$OEU&7X>VB[I9SG<;6
M+CEY.GUO8<.+O>?E[%VTUMC-X1.3B0$H:Q3D)2(BTM==:7O-*5'K<* N>NJY
MZTLZMPC2E?45;GX96INN[">5R]ZN/H/1IWU RW%>0Y3VY'0N4C&S)F/5*;27
M65M)7J;61J-D+2;@&QM6RE<4K>=<:'"0T,K>L6EN/#.DZ<Z\_0>;>+/>/W?A
M\GF)N]\F[F\08+TMN&[H2Z9B5(#2&%!(T!1592;$!/6W2M9:U4HMN3JCO-T\
M.V;D(*Q')+,E7JYU->\L<GS.5L[$STS&MXQZ)#$)+#3JGDJ <6YJNH)MZ=JL
M7KKN2JS=[5MD=!;<%+-5UX4Y(]#Q.1L# ]V*6-FY*0[E,+CX^+EG]%*BRYJ@
M@GSK62"I?AJ1?H.G4=,Y74K%(O%?2<3+;[DMW7?12C.3DNAI?+$\BP%0QD8B
M\HE3V/\ 6&U3T!12M;&L%T:A<@E-^O;6K1Z5<4LC4.-,/+R/>>]^-^,^6]L1
M\_$=CI>9QC@P><9=+3;<=M)T>*+C4TVH><%CS>HZ&]=/IYPA.-V/U?F/*-HW
MC6;5JEQIG[<>FO&G6U]!XNP&T,UN9V?B-LN^MYM LO%,.I2)L9M5UEI6I*7=
M"@%Z.]/G#T:O;UI.\<=1;Q4DJ_0SVO?KEJTH:J2_=RI65/=?*O1585Z<.9+V
M!A]B.;DCIY S*L;CH#BWY\+U9;R9!BJ*C'\9M9 +FFU[? #>N6MY7+M<#F-?
M>U*M/X>&9RP3KPKSIU&&>9VSE]W.L1'U;?VC+FJ2Q(DA<I<2"I9LI:4><LA/
MX([^E^^J<'+H1E)WK>GJUWEQ+EA5FX=]>\MN92%;4X]?1CMLXY+4.%F0@JR$
MEF,A* Y=P!* O3>P1JMWUE3U,J98X)>DYK0^&[7_ "ZA9IRQ<?JJOST\IL:!
MR1(S? +L;DW<"-O;AW B7C</DGVG$.RF4:4I>6VP@J""26W'$HM;KVGKD*]F
MLTFZ-\/EZC17-N5O<JZ:'>0A24DN3Z*OGS2-*<7;[3P5O3(/Y)IO-QI,1$60
MC$3&GHX"EI=#@6D*0M24CHFXMJZD5B6;O=2KQ.JW/0_]IIXJ/8:=>U%I]%.H
M][8K)1,SC(68@**X.08:EQED6*FGT!Q!MW7!%;Z,E))KF>07;<K<W"7&+:?F
M,!AN2]A[ASTG;&%ST6;G8NOQ8;2CJ/A&R]"B E>GOT$VJW&_"4LJ>)F7MNU%
MJVKDX-1?/Y</.0LORSL7'+R,"+FH<_<$&'(G(Q+#Z5.O&.TIWPT*%TZR$^C?
M5\%42U$%6CJZ%VUM>HGEDX.,)-+,UPJZ5\AX EN97D;=N3RC#,2-D\N[(R3D
M<O(BQPI5W%)0N0L#4>X*5YQK0MYFWTGLD%#1V(Q;;C%*/"K]1BLI&RN-D'!Y
M=+C#V.6M'J;IN&EN$%938D>=8'4#8U#36!DV96YKO(4>;GT_X&U. =L,;KW*
M]*W=':G<?8&(ZK)NY-W3$BJ6-3(05*3I)4+D#IIO>LC3P4I=KW5Q.=W[4NQ:
M2M/+=F\,O%])[>VQG-L9[%-2-HS8DW#L?F&O4%(4RUX8L&]*.B+#L38=*WEN
M49+L\#RC4V;UJ=+J:D\<>)J7_P!5/';6[I6W);4J/BXSCK!SZDA4=3K-P?S:
M;N:"1I2JW4VZ 5B?&PS4Y=)T?Y8U3L*XJ-OZO/'U$+<WO0[(D[)S$W:4EX;E
M ]4@0I;19=#CX(#X *@4( *NWM ![:V6WTU4Z*M%Q-MLWA#4WM;"%Y?NEVI-
M<*+ZOE?#U\B9[L6P'MM;1>W5EFU)S>YBE\>)?6B$BY:O<GJX5%P^4%-^RMAN
M%]3GE7")?\=[Q'5:M:>V_P!W8PPX9OK>CW?,S>E:P\V% 18'Z%?UB_RC4L%6
MY#[=I_YB@?<=HB&7.H)% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% 5S>^<FX# F1BDMKR\N1&Q^.#X):$B:^AE*EA-B4HU%9'
M?:U2B&0MH9G,*R>X-L[@E-Y"9@%15C*MLB-X[,UDNC6TE2DI4@I4GS38BW2]
MZ,(K^U]X;JF9';60R[T=S#;R,OU7'-,Z%P/5FUO,V>U$N^(V@^)J2+*MIZ5+
M1"9&WMO_ &O/W5@-D1I+RMQQ-P0%/QU19*&@$!2S9]38:/FGN71(-FPLQN*!
MA</D<R^%N1\;%>F/(0DZU(CMEQ03>PN0GI5N3RQ;Z$7[-MW+D8+C)I>G _,?
M*349+*3<DVUX#4M]U]J.#J#3;BRI+8)[0D&U<]?O3O7'<FZREQ9[KM^BMZ+3
M6]/:2C"W%))8+Y,BU9,X4 H#FEPCMZC^6MUHMWO:;L^]'H?T,V>EW&[8P]Z/
M0_H9S_-N?']HUNV]OUW']W-^;]#-I71:OCV)>C]#./AJ!!0JR@;@]001V6(K
M!O\ AZ]'&W)27H?L,6[LUQ>XU-?+S'Q27"2I5U*/4F]R2>^M-<V_4V_>MR]%
M?F-9/1WH<8/T!2G"E#:[E"+A"2.S4;G[9K"=MQ>*:\QBY:/@6;;_ "1R!M9A
MV+M[<,Z%&>0EM3*%ZT!" 0D("PH(L#T*;53:CW;;@LKEQHN/E-?J-NTVH:=R
MVI-=1BG\]G)DEV9D)3D^8^RN*[(G 27%-.=HUN@FX_!5>Z>ZLN&FOW'V82?F
M9G6]!5*-N#23KV4U\QC@TKOL/Y:V=G8]5<XI176_H1N+6U:B?%9?*9#$9;)[
M>G-Y7#37H&1:"@W+866W %"R@".O4="*VT=LTFD[5^=7T</4L695W:='&%-2
MU-?9?#T<2&])6\XMU9U..**UK/>I1N3:L;4[[2.33QR+I]B]I3=W51CDL1RQ
M7RP1D(VZMS0L3[!A9>7%P_K!FF&P\MI!D*2$%9T$$G2D#R5S,[LYU<FW7$YF
M[IK5VYWLXJ4Z4J\701=U[I@R'94/.9!F2^A3;[J)3NIQ"TE*DKNKS@03VU0F
MT4RTEF22<(T74C#A*4]@M4&4<]:] :*U>$DE26[G2%*L"0.RYL+FA%%6IQN;
M6OT[AW4)% * $7%CV'M% #<DJ))4>TDW)^R: ^$ ]"+CX: ^]>G6]N@OW#R4
M H!0 @'M%Z 6% +#M[Z 4 H!0 $@W':*N6KDK<U.+HT5PG*$E*/%':0'$W';
MW?)7:W[4-TTZN0PN1Y?[?8_TG3W;<=?94X83CR^CV'57$2BXMIJC1RS33H^*
M.U4F2MAN*MYQ45HJ4TPI:BVA2_2*4WL">\BJ2A12=:8G50J% "24Z"247OI[
MK^6WEH!0"@% * 6% * 4!V-!6G3<^$3JT7-BKLO:NAVC;>_EWES_ (X^O]'3
MZ#<;=H>^EWD_<CZ_T=)\<5<V'8.^J-WW'XF>6'N1X=;Z?84[CK>_G2/N1];Z
M?8<*T)J3ZA:VUI<;44.((4A:24J!'4$$=010AJN#!))))N3U)/4DFA)\H!0"
MUJ 4!F!NO<Z8\.(C,S$1,>TN/"CH>6AIIEV^M"4)(396HZKCKWU-68OP=FK>
M15DZO#BS#V'06[.RH,H4!S#SR65QTN+3'<4E;K(40A:D7"5*3V$IN;7[+T(R
MJM:8G"A)V(?D-@I;><0DH4T4I6H MK-U(L#Z)/:.RA2XI\4=T"=*@/HDPI#D
M64U?P7V%J:<3<$'2I)!'0UU>S:Z+7PUW&,O=]GL-_M]^W.+T]Y*4)<*\/)[.
MLCJ1H[/1/8:U&XZ">DN4>,7[K^CRF!K-)+3SH_=?!_+F?-2M.B_FDZK=.T"W
M;6K,&A\Z'IWB@,GF=Q9[<2HB\]DG\DN"PF)#7)67%-L(-P@$];=:ER;XF/9T
MUJS7NXJ.9U=.D@1G&6)#+SS*9##3B5N1EE24.I2H$H44D$!0Z&QO4%Z:;32=
M&^9LF5S_ ,I.S'GX.8&-QZV3$CX>(TA,&/'\/PTH:0H*(*!Z*BK5\-7WJ)]-
M#11V#1J*4HYG6KDWVF^.)K5AYZ(M+T5Y<=U 4E+K2BA8"P4J&I)!\X$@^458
M-]**DJ-5/L:0]!D,S(CA8DQUI>8>0=*D.(-TJ!\H(H1**DG%JJ9UK(62I9!*
MR5&]NI/6]"I(R&+PV<W!)3$PN/E924-+8:BM.2% >BD'2#8>2]2DVZ(L7;]J
MRJSDHKKP,[G)6Z]I8B3QEEH/LC5):R.88(/K$IPMA4<.K!(+;:572A/FZKD]
M>RN6:*RO PK$;&HFM3"6?!QCT+IIUOIZ#9'NJ[SFX#?KVW&VB_A\\PXY.4D*
M48ZH#+CJ';)OT/5!Z==0^*LK1S:G3I-'XITD+FF5QNDH/#KS-*GTFN-V;CVC
MGLWF\G@=M*Q[>1=6N$')BW&V"M9+COA! &I5[I3JTHOW]*M6[4K]S+;6,N".
MAV_0ZE1MVG/.UQ[/'S]"YOBRZ\#\3JW[GD93,-J3L_%.)7-4I)(E/)LI,=-O
M+T+GD3T[2*[E0AH+'=0]]\7]/L-CXDWJWLFD[FTZW[B]'3/Z(]?D9[K1,AMH
M2VW=*$@)2E*%  #H  !6G/G9MMU9R]?C?C*^8KY*@@>OQOQE?,5\E 1XDQAM
MI0457*UGT5'H3\ J05C?LAIY6U V2;;BQ][I([0[Y1\%"&7BH)% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 8C<V 8W-A9&'?
M><BJ<+;L>6S;Q6)$=Q+K3J-0(NE:$FW?V5*(9B<)L_)8EQ_(/9UR5G<C+8DY
MB?ZLRVF3'C-EI$9+0N&T!/X23JO<WZTJ*$/;W' P64@R7<P_.Q.%]9_=[&.-
M(0(GKEPO4ZGSG=*24(U6TI/?VTJ*'?R,B6(.$F184F<F!FH,N4S":+[P8:4K
M4H(3U(%Q>U$&<7]]P9++D>1MG/.QWDJ;=:7B7U(6A8LI*@18@@V(J'&I*DTZ
MKB:3:XUX"S&1R;<':>XG),)_PIT.*S.M%=6@.!M20KS?-4% >0UB/16_DSI8
M>)M=%4SIT^ZB1_!KA7_R5NK^HG__ (U4_!6RO\T:_P"TOU4/X-<*_P#DK=7]
M1/\ _P :GP5L?FC7_:7ZJ'\&N%?_ "5NK^HG_P#XU/@K8_-&O^TOU4/X-<*_
M^2MU?U$__P#&I\%;'YHU_P!I?JH?P:X4_P#)6ZOZB?\ _C4^"MD?FC7?:7ZJ
M.2>'>&$VT[-W6!Y/ G$?RDUEV8SM>Y.2\^'H,BUXPW.W[MRGF1"RO"?%,Y/_
M (?@-X8MSI8LPGG4_9#Z%G^6MM#<;RXM/Y=1N=/_ '"W.W[^2YY8T_\ %HIR
M.$-D3YT['8O)[E5.QJFT3HIP:WG8ZGD>(V' E2+:DG4/@J]_VD^:1MH?W,O_
M %K$7Y)-?0SM;]WG#@_G9.YW!_[O;ZT=/]][_LI_V<N445O^YESZNG2_U?\
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ML.U7%/"BB3_#?.BZ BP8G@"WX0_/^E3X.UT>ME/YCU_\3\,?8<E<5\)J(/\
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M#X:2?1'93B.!G=N;AQ^Z</'SF+#H@R=?A>L-J9</AK*#=*K'M2:@DRM * 4
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MH9=9O9B2E*2I24*42VI-U=E027/.;.V=^_O+,3V' $:'LN$\Q'$=L--N/(R
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH#@RRS';2S';2TRF^EMM(2D7-S8#IVT!TOX['RFI+$F(R\Q,&F6VXVA:'A;3
M9P$$*Z=/.H",SM[ 1DI1'Q4-I"6%0TI;CM) C+.I30 2/,)%RGLO0'*%@<'C
M89Q^/QD6) 4OQ#%88;:9*[@ZBA*0+W ZVH"68T92W'%,H+CR0VZHI!*T"]DJ
M-NHZGH: BR,'A9;T21*QL5^1 _Y%UQAM:V.S]$2DE'9^#0$B)"AX]GU:!':B
MQ]2E^$PA+:-;BBM2M*0!=2B23WF@.?@,>-ZSX2/6-/A^-I&O1>^G5VVOW4!!
M=V_@9$J1-?Q<-V9,:,:7(7':4Z\PH6+;BBFZD$?@GI0$I,""EIUA,5H,O)"'
MFPVD)6E*0@!0M8@) 3U[NE =#F$PSTQC(O8Z,YD(J"U&EK9;4\TV18I0LIU)
M%NX&@.V)C,; 0VW!AL1FVF_!:0RVAL(:OJT)"0+)N;V'2@/HQ\ )80(K(1%5
MKC)\--FE=1= MYIZGLH#M<89=4VMUM*UM*UM*4D$H58BZ2>PV-NE 'F&)+?A
M2&D/-7"M#B0I-TD*!L;]A%Q0$;)8;$9E#3>7Q\;(-LK\1E$MEM\(6/PDAP&Q
M^$4!]R&*Q>6CIB92%'G14J2M+$EI#S84CT2$K!%QW4!6=K\:[?VY@\AM^0A.
M9QN1RDW,NLY%IIU"79\A4@H2C3ITME5D=+VH"T*QF.7%=@KAL*A/@I?C%M!:
M<!%B%(M8W MU% <8V(Q4*(UCX<&/'@,*"V(K32$-(4#J!2A( !!ZW H#O$:.
M'7'PT@/.I"'7-(U+2F]@HVN0+GMH##3-L,MX*7AMJ.M[7=E'4)F-BQPIM:B-
M:TMJ06RH@6NI)\M =^UMM8K9VWL=MC"-EK%XQE,>.E9U+(3VJ6K\)2C=2CWD
MT!EZ 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MKIJ2>Q2% 7LI"@4J'<16JN6W;DXOBCS#7Z&[HK\K%U4E!T?M74UBC+5;,$4
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MQ:7']J/GCBSU36C/&A0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M +X<G?\ Q3G_ ,PJMOJ_^&WY/8>J>)O_ *30^3_:C=M:D\J% * 4 H!0"@%
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M9-CSFFE>&ZN(\V^E"_Q5%M2K'XZ X-Y?#/3?9C.4A.9/]B1*97(^+PPLJO\
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M6B]B0*D'5L_9VVHO(7+_ !JG'MN[#3C&<FW@WKKCHD-V<;(!-_,/HGMZ#R5
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M00@!(NI94I1L.U1)-:1NKJ>-W+DKDW*7&3J^7'J6!W5!;% * 4 H!0$+*_\
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MZ8XIJ5&<ZH<;+J24*'>#;J* O^X<?!Q'O+[!=PT1F"]/Q4Y,D1FTLH=* ZA
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M/?6R]FLX]N8SNV8[#=G+<4VN,&C;6A !"R?(2*@&"F<E[PS.;SF+XNVG'W'
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M H!0"@% * 4 H!0"@% * 4 H!0"@.B7+BP(SLR:\B/%925O/.J"$(2GM))L
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M92ZX!V!PH4G7\:NM 63'X^!B8$;%8N,W"QD)M+$.&P-+3+2/10@=P% 2: 4
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H * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>lc_significant-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lc_significant-4c.jpg
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M%!04%!04%!04%/_  !$( F@#M@,!$0 "$0$#$0'_Q #?  $  @(# 0$
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M$^WL\BYCO7$NS+1U^)#,E$I2GGW2?ENJ26NW56U*=>NF[T::P3KS=_V-RO\
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M3$ZSLF<1()Q70U1J^4VA!F?I/N]X_P!D!&:=,^P\I5^U")2FZW*6WIQ)U/\
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MIZZ%J9Z$ S?(W'&-\H8ZO',E;7V"63\64PHD2([Z2,B<;49*+70S29*(R,C
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MN/(]I9+J<D>C2)<EQ;'M#:H;K;J";,F23H9MEKN28"Z
M
M
M       >2TJJV[KY%5<1&9]9*3VY,22A+K3B===%)41D?4M0%=H\NW"J)7M9
M8A$-W77:IR0IK_V9NFC_ .J L># @UD1FOK8S4.#'22&(L="6FFT%X)2A!$1
M%^ @'H
M
M
M
M
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M12?@;^0'<NC[..D\2<2[:[HZC[W^2OTBD_ W\@.Y='V<=)XDXEVUW1U'WO\
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M+LAY6FY:U)(S,]-"'R[B..W'J<EML4B+IH^Y\'S7Y='BOOFMUUL3,I&->VP
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M_P#32O\ ,:'N?I3]>3S6_F^7_7O]O#Y[OR:WCZ"^2
M     ,]C.%Y-F*I2,;@'.5#2E4DB<:;VDYKM_=%)UUVGX#!U6NPZ:GS;MW>Y
M.7\FST'"]3K=[Y%F_N\NV(Y?/,,=44]E>V<>GJ8ZI-E*4:&(Z3))J41&H^JC
M(BT(C,S,QD9L]F&R;[YI;'.Q--ILFIR1CQ1O77<D.R\HK7&K1^FNX_LME'V&
M\P:D.;>X@G$^LV:DGJE1'T,<=/J,>>R+\<UMG_PY:K2Y=-EG%EC=OMY8V3RQ
M7FK')+'#(8H S.-XM>9;,?@4,8I4J-'7+>0;B&]&6S2DSU6I)&>JDEH7NC$U
M6KQ::V+LDTB9I][/T/#\^LOFS#;O71$W<L1LCS^>&+*-)..<PF5^R$LFC?VG
MVR<,M23NTTUT+709._;7=KM\C#W+MW>I.[6E>:OD\[J')P &9IL5O<@@6UG5
M1B?A4C)2;%PUH1VVC)1ZD2C(U=$*/1/N?@&)GUF+#?99?-)OFEO^/OAL-+P_
M/J<>3)CMK;BC>NVQLC;Y?-/)Y&&&6UX                           #Z
M3X*_!_QD)*P_0P?!GZJ8K)O^[=Q^\9/^A4,G2_WK/ZH_%A:__C9/Z+OPEH,/
MN+\P@              V3S-LKC'+O"'5$IVEQVKO*MLR_<SA)4F1I^%&B?\
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M(]4*,B\#-)EJ7NCV6CU'[C#;DI3>A\WXEH_VFIOPUKN3,?=S=###,:\
M        ;Q\9?V>XU_N^/_F$/C'%?^7D_JE^D.!?]?A_HM_!*QK&[
M      % ^:#_ .7XW_TTK_,:'N?I3]>3S6_F^7_7O]O#Y[OR:WCZ"^2
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M^[=Q^\9/^A4,G2_WK/ZH_%A:_P#XV3^B[\):##[B_,(             ?A\
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M6QLB(I,S/VS1MM+&'#H=7?9ANPV763%;YFMUTUB+8CR1,^>:[9V-?![Q\I
M                      ?2?!7X/^,A)6'Z&#X,_53%9-_W;N/WC)_T*ADZ
M7^]9_5'XL+7_ /&R?T7?A+08?<7YA
M                                     ;Q\9?V>XU_N^/\ YA#XQQ7_
M )>3^J7Z0X%_U^'^BW\$K&L;L             4#YH/_ )?C?_32O\QH>Y^E
M/UY/-;^;Y?\ 7O\ ;P^>[\FMX^@OD@
M        /1 L)]7*;G5DIV'-:U[4F.XIIU.XC2>BD&1EJ1Z#KR8[<EN[?$71
M/-.UVXLM^*Z+[+IMNCDF)I,??#W7&4Y)D"4(O+:78--GN;;DO+<0E6FFI),]
M"/3TZ#IPZ3#A_MV1;YH9.IU^HU.S+DNOC[;IF/0Q(RF"
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M^W\-O4>$>&=G/O7=:R1YYZX            ][T@&I'X
M
M
M                    *,\WDB3$X)O9$-]R-(3,IR2\PM33A$JTC),B4@R,
MM2/0P%Y)+1)%[@#D!P9Z$9^X ^=_3P\?0(.4JW>CIIJ%=M!]"C@ST$J/DG-2
M,]/#Q(!]$>I;O>UT%'SW"]SK[@@=PNN@HX[G73;\ D#Z2K=X> 0"EDD]-.H#
MDCU+44?/<+W/3H(/HST+44?/<+3P$*N242C,O<%!2MOHU <D>I:@.0
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MK='W1=,0F25$HM1ALYR
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MF&Y#*TN,.I2XTX@]4J0LM4J(_<,C'1,3$TEW1-8K#M!0
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M%I/P-*BT,OV2 5I6^7?A2HLXMU6877QK6&\F5'F()SNI>0K<E6XU]=#ZD1]
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M>>^RVEYUMA>]26UJ4A*C+W#4E1?L!?@R8]M]LP8]1CR32RZ)F&<'4[@
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MU&/+7<FM$@W)]TAU.\U+W1*AJ7ND*.0'&Y/ND!0U+QU+0"CG4C\#
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M74CZC<V7Q?%8Y)?.-5I<NFR3BRVS;=;RQ++#FQ@
M                                                 #\# 4Q2_P"*
M/*_Z(5?\-? 7.         ^%I/H:=?'4R(Q!$,$Q:RQAS*%V#K;I7=Y+MXI,
MF?J,R2024KU_&+;UTZ#HP8IQ[U>>9GTMOQ+6V:F,46Q,?+QVV3YXKMZ4OT_R
MOA&2TYI_E?" \5SJ5/8&6NOLSVG7_P"[4.&3],^9WZ?^[;YX_%J%Y3[.NK<P
MMSL)344I$!$>/WEDCN/+D)-+:-QEN4>G1)=1Y[ATQ&2:^3\X?9OKK%?DTUF[
M$W4NF9IMI$6\K<KN(,]-?P^]H/1OB;H9LZ^1+D0&)+;DZ(2%2HR5$;C:72,T
M&M/B1*(NFOB)%T3-'9..Z+8NF)I/)/--.5ZM2%=8               #X6@E
M::EKIX> ),-7?,)B3D_DW%7X-*Y(C3TLHN9$5A:R<3[2E)D\ILM"]3IJ?H'K
MN#ZB+-/DB;J3')Z'B^-Z:;]3BF+*Q=2+IB.;>C9/V4=>.\68\]EO*<>=C*CK
M*MM9XT2VWB;29-K,NP>I;NI%Z3%SZ^_Y6"8OVS/K?Q--P[%^XSUQ[+?T[/LY
MG3A/%M#-:XH.WQI9JLF+9>3=UMY&Y;#9G&-\M2V]?B^ :KB%\3GBV_DFW=_.
MAI.&8YC3S=CYKM[T;*J8K+.?@6:1[95>:9M1,6_&KYB7&2/1:]NO37;LT,C(
M>@OLMU&#=B[]4<L>;K>=LONTVHB[=_3=-(G9MK/_ .*W$^;;*C5_W;KE=3_Y
MU\M=/$B,R\1I/#V+VYZ&[\39:T^7'IGF^Y:59S1.M.,7>1&:EIMTK(J]N IU
M1I[9NH;W&LB^-ZWN:#39.&19J?DS=S5JWV/BDY-)\^+>6:4^^C#M<_W2ZL[%
M5'%2XF53Q#1WG--+<G#6>II+XG;T+W1WSPFR+MV+IY+IY/9=5O%;]V+ILBM;
M(Y?:ZEJU.2OV.7Y-C:XZ4-42(*FY"3,UN^VM&X>XO MIEH6@TV3#N8;+Z_JF
M[H;G'FW\U^.GZ8MV^=*2,M"(_'08M671"J+,I-M19/:NPVVG:";906FDJ,TN
MIKBU2I1GX&KTC-RZ>++[+:_KBV?2P,6HF^R^ZGZ)NCT,?8\AS(/&U/G*(+*Y
M-F5:I<,UJ)M'UBXVVK17B>TE]/=';;I(NU%V*OZ=[;YG1=K9C3698B/6W-E?
M:F(_-82#2D]/ B+0AK(EMJ<SL(R/P')'(              HCSB?V"7_ ._:
M;^=HH)*]B\ 5R   #J?:)]M32B)3:R-*TJZD:5%H9'^'4-G.L3,36.51\CRI
M<;OR'7D/V+#;BS6AAM]&Q!*/7:G<@ST+T:F-9/#L4SS_ ./N>ZM^MN(1$1.Y
M/V[O+TH9R'Y><'Q*LK)=?*GJ?FVU?7.=YU"DDS,?)MS0B07K;3Z#%U&AQV1$
MQ7;,0W7"OJO6:G)?;?%M+<=]_)SVQ6.?RJLL< HHO%EAFK+SYV\3(7*9!;TF
MS[,WX&:2+7?IZ=1KIPV_)F_GWJ=%7K<'%<]_$;=-,1N78M_D_F\[93RQI+[I
M*U7@?M<SJ7OO&0WO#_[/WOF/UIMXG=/V6_@N<;%XL
M                                                    _ P%,4G^
M*+*OZ(5?\-? 7.              (=G6=XEBT!V%D5JS72I\9_V-M[75S1)I
M/3:1^!F1#'S9;+(I=-*PV_#>':G57Q=ALF^+9BM.9H3A-Q"H;^KL[ EJC0[&
M#-=)M)+4345TUK-)'IUT/H/)X[XMOB?)+]"\3P7Y\-]ENR;K;K>7GNBD-LR\
MT_%Q:D3=J9'U_P"JH^='H.\L7V_X^]\<GZ*XA'L>]_!$:3S"<?5_(&4Y.^B?
M]77,:M8B;(Z>[NAH<2YN3W.G51:=1CV:W';DNNVTFC<ZCZ4UU^BPX8W=['-\
MSM]JE.9,/[U?&&G1NU/W_94?.C)[RQ?;_C[VE\%<0CV/>_@MG&,FJ<MHH614
MKJGJR>DUL+6G:LM%&DTJ2?@9&1D8V&.^,EN]'(\EK-+DTN6<62*76\K,CFQ
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MO%&^NR1$:-:4H;/V?<@BT3ZNNFGB0UM^+A\X[:S;N[:;?2V%F7B47W4B[?\
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MP7*3A*/I^#Q&RH\4[!
M                            #\# 4Q2_XHLJ_HA5_P -? 7.
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MV;:U&6BC,O%)#HUVFLQ61-L<[=_2G'-7KM3=9FNWK8MKR1Y87'Y=O[(L>_\
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M2_?OFZD16:[.1[!R=8
M                           'X& IBD_Q197_ $0J_P"&O@+G
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MKI^V-D4ANP/3/AP
M                         !^!@*8I/\465?T0J_X:^ N<
M       % ^;5EYS *UYMM2VF+-M3ZR+4D)4VXDC5[FI]!JN)1,XX\[Z#]#7V
MQK;HF=LV33TPJ_B?S"2\3K*+"7:5I^K:?..Y.;>44C22Z:MQ(,MNJ37X:^ P
M=/KIQQ%E-CU?'?I2W5Y,FIMR3%\Q6E(IZL>7[FYJ-VTMQZJTZF/1OB;D
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M(FVR8F9\GZHV+Q&Q>(
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MFZ>I[4D1#S6NB(S;/L?;_I:^Z_A-\W3,S7)R_P!+=<>F?#C4@   -2
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MVOG+DC(_ P'(
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M7F%RW'<7]K^KG,6K)3ASY;TYTW53'D]''U*42="^+KH"-D0
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M9&.V)B8K#!R678YW;HF)CFG8](K@
M                      #$Y*UD+]'/9Q61'AY MA95TN:A3T9M\_BJ<;09
M*4DO21&"PHBXE>8S'"9+(^4./ZE3Y&;/M\-V)W"3IN-'>?3J1:]= 2DK*XCM
M<JM*>8YEF58_ELU$DTLS<7+2*TWL29-N_E'/7UZ^/@"K",$=)1(Z'%O(:2E]
MPB)QTDD2UDGP)2M-3T]\!SV4D>XD$2C/51ET/4O29^D5'PF%%;<<=:80VZ\>
MKJVTI0I9_P#E&1$9_LCBKT>!:>\**9I/\465?T0J_P"&O@+G
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MOSUNF7GGF5KXCT^<NVCPHR#=D2'8*$MH0GQ4HS1T(AQNS:J(K-?1_!V8^%<
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MBOI*]QZ?\)> #[$
M    !PHM4F7ND USYKFT>#Y&K+:SF"5A.83FVF_LPXCZ_@329:-+>E.V2GDJ
M41%JZUH"I]P=F?(><XFNVY'Q@\;M6I"F8A[7&"G1221IE%&>U=8)>O[FX>I
MBSP     _ P%,4G^*+*OZ(5?\-? 7.
M            (1S%_9;EO^[)'^:,?4_VKO,W? O^PP_UV_BIOR=?_*,I_?,7
M_1K&MX9_-]WYO;?7_P#=Q>:[\8;-C=/EP     X4HD^)@."5JK3WM0'T
M  */Y28S>TA3(M[1X/816[R&>%1LGE/(C2$=MS<IY"TFGVLE:=EM&I&6[W &
M7PR7Y@DWD"'F-'B4#$4I6F0JFE35RFR2@^V3+;J$HTUT(_<(!;):Z=?$
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M+O=EEF'DO)W(42TZ$9+3U(R46I&0[&+R;':
M                      #$Y,YD35%8.8HS$D9$EA9UC%BM;<-<C\4GEMD:
MB1[NTM052-I&Y01R#.ML&QKCR9EA5]>5W-F2Y'UVR\<<B4VKM-J6AC74F#/3
M>CJ8$K4X_E<E2:^0KDV#40;8GC**W0O/R&#CDDNJSD)2HEZZ]"Z )@"    !
M^!@*8I/\465?T0J_X:^ N<
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M!K/4R0A]9)27O$70AO=#,SABKY7]666V\3R;L4B:?A"TQFO*
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M6[^R&D_RY/\ IUCNT/\ 9AJ_J[_L\G^7_P!86P,]Y$
M                            '"M=IZ>.A@*'L7N7\-Y2RNWQ/ W<OP_(
MV*Y\G5W42!V9\1CLN$RT]NT;46F_=U-1:ET Y%G8+?9=?P'Y.8XDK$)[;QMQ
MX*I\>S-UHDD?<[D<B)/4]-I]0$K     #\# 4Q2?XHLJ_HA5_P -? 7.
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M @  .-2 <GX *8I/\465?T0J_P"&O@+G
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M9M.MFLC-)FE7H5H>AD,O#GLRQ6V6@XEPG4Z"^+<]M)NY.=+B/4=[4@
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MMI<JND-2V4N%,?/8:VE*22M.NFH"^@
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M;BHM?';BLJ<.:_JLT-)21JTZ:Z +X
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M .#+7TZ &GOB4')^!BBF*3_%%E7]$*O^&O@+G
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M-2?,/%XWL\]CP&)665F4N/T;&47&)&VF!&-V07U2NS*1^34ZE9[F-OKI3U\
M%S\,0L,H8F28ABJ9RK&AN'VLFF7"S>L)UC(0A\YCKQF?<)Y*DFE73H6FA +0
M     #\# 4Q2?XHLK_HA5_PU\!<X
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M<41&I6H"R      _ P%,4G^*+*_Z(5?\-? 7.
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M0@2T5     _ P%,4G^*+*OZ(5?\ #7P%S@
M                                 X,21K]FOENO<KM,P=KN1[&AQW.'
MVI5S0,0(DALW&F6F?5></>6I-),Q27OXEQO+["7%RA'+]EEV+07I5?(J955$
MAMO/1%*C+)3B")PMBTZZEXZ"%%Y%KIU\11R     HCSA_P!@E_\ OVF_G6*
MO8@'(
M                 "/9QC#6:8E=XF^^N*Q=PGX#DIHB4MHI"#1O2E6A&:==
M=#!6O.1</Y3@[E/EU[SG;Q9$!#.-U<LJ>$O8W8NMM(9-"===ZTM^L?AH O;C
MW&,IQ:NDP\JR^3F4QU\W69\R*Q#6RWH2>T2(_0R(R,]3Z@53$$    #\# 4Q
M2?XHLJ_HA5_PU\!<X
M                 "&<CY\U@%7"DM5K]W>7$QJIH:2*I#;DN?()1H0;CGJ-
MH(D*4MQ71*2U!59<0<B4U308E51L;D4C.77]] DQW)R; H5K'>??<2;I(3W4
M/+0LD&DB)/O@B_R/4M?#W@'(    "B/.)_8)?_OVF_G6* O8@'(
M
M   #@_ P&N_-?)5-+N6\%>Q27?U%+<8^>26[4YNN:KIL^2A<!*$J2M<E6OY1
MQ"-"2GQ/J MK#\W9RBZRNC.$Y!GXK9?5LE#BDN)>;<90^S(0:2+0G$K^*?5.
M@"7@    !^!@*8I/\465?T0J_P"&O@+G
M                                 5SS#C4+)*NC;+(48OE$&WC2\1M7
M4H=1];I):6V%,K,NZAU"EI4V1D9EU] "C^&\;8A<GL85G7(U)=Y5ALFRNJS#
MZ",[&05A:J6Y)?D//='5LI>42([9ZMD>JO ();:IT)):> #A*MWAH9>\(.2/
M44-2UTUZ^X Y 41YQ/[!+_\ ?M-_.T4$E>R>I:@KD
M                                                     !PKJD^F
MO0^@#5_FOCN7/M<HR?#<[I:%+*Z:XSVKOFCD18S]/^5@R24R9+:-Q""2ILR_
M*I\.H+187E[8Q^7BT[+ZG*V\VM\JGN3\AR%EE45M4UM"62CMQED2V&V$)2A#
M;A;M/6/Q!%O&9%U,]" -Q::Z]/= <@/DU=#/4M"Z>(&USZ %,TG^*+*_Z(5?
M\-? 7.
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M&M]A,;&LHA3E65;'*SL:=Z+5[HUHPHU'*4>TD*V'L/\ &U+W0&XY> #D
M
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M&5%O83E;*-29CRMR6G#U-!D?QO= ;(
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M+TU7JZ\:EF6[XNI]"""9JJSSA:IX#R DF9$<RE(RU/\ .T45%[%X=0'(
M
M        #Y7H2%&?AH>H#4'F7CF?=YUDN=9-B\O):/'+K%YL5DFERTN8RS'=
M*S9A,:Z+4EU?<?0DM5: 4JL;RPU5565F7NXC02*#CBPNUR\29GQUQ);S"F&R
MD+-MW1SLD\2B8[G79T 7+DM! RK'[3&K5'<J[B'(KYJ"\39E-FVO34CZZ'T
M4)!X8Y5MX&'<=9U;TS_&F#SH<UJ= 3(3;6K5/K[ Q(;<_)-$G1!O&A1[MO0(
M59=O@]OGD7-<2Y*5#L>/[ER.BD@0#>C2T1&TI<<3)=29'O[R4J2:#\ 172O*
MY3QN5L8S6NL+ Z"EARFY4>5;V#\Q<M;B%L&A:EG^2+:?<;W;5>DC$5L0:2UW
M?C$6FI=!44W2F9^:+*B,]23A]61:]="]M?,!<P
M                                      "J.=<BNZ:KQFHIK?[.%E5[
M$H)N2$E"G(,>4EQ1FSW-4)==4@FD+61DDU:^.@+"KN-LWRR/]UV/R<FF75C-
MR/)ZVQ:GN(?ESJJN5(0E]\R+7\@:$:*+0M>@#:=):)($-"\-"T <@   HCSB
M?V"7_P"_:;^=HH)*]B\ 5R
M                                   X5\57X# :G<L9CF[_ "+<1ZS*
MYE! PJXQ.+"QVN4VP5DQ>O(]HD3%J(UN-GJ;24H,DEIUZF"K?XFR>RR+)N2H
MSMBJWH:;(%0J:<>AH1K&:7(BH6DB)28[IFCWO#4$6F XT+W '.A>X XT+W"
M<GX& IBD_P 465?T0J_X:^ N<
M                         S(O$!7?+%O4,LXYB5Y2,7];FMLS0RH<LR["
M&7&W'ENF1D>JD$WZA%H>O@9 JE.)9^(89R/IAO'=718+DEM8XE4Y+&DNR+5V
M;4DIQQ3C;VXDQ75MN)23:]=R=5^@"6UR3U21@CD    !1'G$_L$O_P!^TW\[
M1025[)ZD"N0
M                       '"_BJ_ 8#6/F:QXVRAS.%9E@<3([/C]VHJZ%Q
MY]3$B=/OB2MMC>T:5I;0M:?$U?C&GJ"K$X)MU%3VN"3<<K\6NL(EIK)U72+-
MZK-,AI,EEZ.M:4K/>A?K]PMV[74Q":+9%0    /P,!3%)_BBRK^B%7_#7P%S
M@
MX,!1W*UFWEE'<U%WQMDURS06\--0]4J1&F/O;%K38P'4/(4E#/Q%*/\ ;%T$
M6C!\>+JYMW@V--<0Y5BM3B)RW:.=8]HJ^.](94EQR0:7EK<6O<K12M3WJ,Q1
ML:GXI CD    !1'G$_L$O_W[3?SM%!)7LGPZ> *Y
M                                                     8?*+>51
M4<^VAUDFY?AQUOMU4 DJER5)+HTT2S21J/T:F"PUZSANE/D>!FS_  SEM[>L
MLUUDN77K05>Y,99,X_M+!R$H<D0]ZFR,T^J>OCT 69PXMB<639">(W.(VM[:
M*FV3&0F@Y,ASM(0E;6Q:R2RA)$A"?0"56B     'X& IBD_Q195_1"K_ (:^
M N<
M  '!@* N*C)^9^2,KQ=&7VN*<?X3[' 6QCCJ8<VRM)K'M+ZGY*DK4EME"D(2
MVDO6,S/4!V451E'#7)6+8JK+K3+<!S1,V&W&R-U$N=66$%CVEM;,E*4*6TZ@
ME-J;670]#(_$%7VGP]P$<@    *(\XG]@E_^_:;^=8H"]B <@
M
M (]G&2-8AB-]E#K1/_4M?)L$L'T[BH[1K2C7T;C(BU 4IC_!V7YO15N:9ORG
MEL7,+:,W8JCT$UNNK*]4ILG$L1XQ-+(TMDHD&:S,UZ:GX@43GA+(LELZ_(,6
MS68BTRK"K9^CDW"6R85/BI0AV+*<;3JE+CC2RWDGIN+7T@2M,     /P,!3%
M)_BCRO\ HA5_PU\!<X
M                  "B\@\O5M99=?Y7C7)N28D61R&YL^LJ#83&[[3"(^\M
MZ#/4TMEJ(KMQ?R_VM1F%'EN1\EY'ERJ!QY^!77"F%1TNR&5,*7ZB$GJ25'Z1
M25W$6A: CD    !1'G#_ +!+_P#?M-_.L4$E>R>I:@KD
M                                                        !@<S
MQB+F>+7.*377&(EU#?@//LZ=QM$A!H-2=>FI:ZD IB/Y<,VBQV8L?G+-&H["
M$M,MI7&)*4((DI(B[?H(A%JL+BGBW[LH]T4C(K'*+6^F%86%M;]LY"W$-)92
MG5LDEH24%Z!188(    'X& IBD_Q1Y7_ $0J_P"&O@+G
M                                                      %$></^
MP2__ '[3?SK% 7L7@ Y
M                                          _ P%,4G^*+*_Z(5?\
M#7P%S@
M          ,#>9CBN+''^TUW!IBF*-$3ZQE,Q>ZHM-203JDZZ:]= J,R3R7&
MNZ@R-)D1D9&6AD?@9&73P 1V?R'@=7:)H[/)ZJ'=*4395\B=';D[S\$FVI9*
M(S]!&!"3$ HGSB?V"7_[]IOYUB@+V(!R
M                                                  ,!!S/$[.ZD
M8[6WL"9?1-?:JN/+9=EM;#T5O:2HU%M/XW3IZ05EY<N- CNS)CR&(C*36\^Z
MI+;;:$EJ:E*49$1$7B9F"486CSK#,H=D1\9R&NN9$4MTEFOELR5H3KIN4EM2
MC(M>FO@ D/H_8 4S2_XH\K_HA5_PU\!<X
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M8-ISV1M!+,W#));=?5W=? 0;?EX .0
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M+IU 4UQ7;YA=^8?+)F<8PC$[E.*UC;=:W/:M"6R4Q_1TWF4I2DS/5.S37IJ
MV+
M       5;EG#KEQE4W-,3RBSPW(+F(W6Y"_6I8>;G18^XFC-N0E1-OMI4:6W
MV_620%'NK.*8&.4V'XYB-I94%#B$@I"841\C*R29*-;4Y2R,W$K6HW%^'K&
MC4W@:T<SV[Y&J,_MZO(;QI$1:BCP)B8D)LR4F+$.2RLVFMQ;E$D_6/JK4!;-
M-"E5U?%AS9CEC+8:0V_8/I0AV0M):&XI+9$DC/Q,DD1 *8\XG]@E_P#OVF_G
M:*!*]B\ '(
M                          #RV$&+9PY%?.93(A2VG(\F.OXCC3R30M"O
M>41Z *>I/+S"K7\>A6>36UYA&'26Y^)8E.-CV>))8U)A3SZ$$[)2QN/L)=/U
M.GB F,W K2;'S&,>67+1981)BN-NMDJF23/:45?JD]F[XQFK7UNH*C7'O"]S
MQNQ3T]1G%F]B=.2DHH%PZUIEY*C4I7>=:92ZI2EJ-:E[MRC\3!%O>@!3-)_B
MBRK^B%7_  U\!<X
M                         HCSB?V"7_[]IOYUB@+V(!R
M
M         !^!@*8I/\465?T0J_X:^ N<
M                                          41YQ/[!+_]^TW\ZQ0%
M[$ Y
M                           _ P%,4G^*+*OZ(5?\-? 7.
M                                                           *
M(\X?]@E_^_:;^=8H)*]B\ 5R
M                                              !^!@*8I/\ %%E7
M]$*O^&O@+G
M                    %$><3^P2_P#W[3?SM% E>Q> #D
M
M        #\# 4Q2?XHLJ_HA5_P -? 7.
M                                          *(\XG]@E_^_:;^=HH)
M*]D]"T!7(
M                               'X& IBD_Q195_1"K_ (:^ N<
M
M     41YQ/[!+_\ ?M-_.L4!>Q .0
M                                                   /P,!3%)_B
MBRK^B%7_  U\!<X
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MX U]X U]X U]X U]X U]X U]X U]X U]X U]X U]X U]X U]X!R"@
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M/SX"VL.@9168[#A9G;M7N2-I5[=:1XR833RC49I-+*342=$Z%X@,\
M          XT/<9Z]#] #D  0+FYNV>X?SMFCW?6[E!9IADW\<W#BKZ)]_3P
M 41GDFLE^6GA=FC6AR=)L<+:Q\HYEO\ ;FNWO[9)_&0E+N_3PZZ@+4\R,AVP
MX(Y+A4CJ7[*-42$RF(ZR6ZVV9$MU*TI,S3N:)9Z'XD A?*<BLET7E\;QUQI4
MN1D] _1=G0]8+4):GU((NO;2R9;].FFFH"[<\J\UMZ!R)@%]'QS(5.-J;LY<
M--@TEI)ZN)[*E)(S47377H I>OX>\P];F4_.#Y+HY=]8U[%4Z\]0=M!1HSBW
M4D2&WR+7<L]3 27[+>9O]8>._P A+_C "$4-_P"9&^Y+S'C=&:X^Q(P^/627
M)QTJU%(*V:6Z1$CO^KV]NGCU 3?[+>9O]8>.?R$O^, 'V6\S?ZP\<_D)?\8
M/LMYF_UAXY_(2_XP ?9;S-_K#QS^0E_Q@ ^RWF;_ %AXY_(2_P", 'V6\S?Z
MP\<_D)?\8 /LMYF_UAXY_(2_XP Y+%O,T9Z'R'CNGITHEZ_P@!"N*[SS(\IX
M:SF,7-<>KFGI4V'[(JE6Z:3@27(QJW=\OC=O=IZ-0@33[+>9O]8>._R$O^,
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M]EO,W^L/'/Y"7_& #[+>9O\ 6'CG\A+_ (P ATFY\R4;E.!Q<>:X\<F=2/Y
M5E]2KT2F/)1'[7;[_74U;MVOH 3'[+>9O]8>._R$O^, 'V6\S?ZP\<_D)?\
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MBU/T"H]*%H<22VU$I"B(TJ2>I&1EJ1D9"CZ
M?*DDLM#\#Z&7CX@*[H>".*\8R-.5T6/-1+=EQYZ'HX\Y&B/2M>\Y%CK6IIE2
M]3U-M!>]H DE7@^,TUG?W%; 0S8Y0ZV_?NF:G"EN,M=E.]"S4DB)'JZ)(B,!
M',3X+XNP>[+(<8H40[9M#C,)U;KTA$-E]6YUN(V\M:&$K]/:273IX= %B@ #
M@Q)$;K:K#8^4W-G6>Q%F4]N.F]=96A4UQF*1I8)])*-1)02M$ZD0*DHJ
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MEN09EJ7I(!PFVK%V*ZA,Z.JU;03JX!.H.0EL_P 8V]=Q%U\= 'M(R/P/4
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M?J:;OQM1%YVP/"616F6<1X3DETM3MK8TL)^:\KXSKYM));A^^LRW?LBHGP
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M=3$57[N)4U;Y3*;F.&T;?*;!P,K/+B4KZT=L9=BWWB=?,]RT+0XIHVE>IM]
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M1;=4),E&DU:Z=2 9GH Y
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M4IT-UMQ:'$Z%U\2"$F&S!&DNFOI,!]
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M42# L@Y%NGIB,ZQ&/CC#:$K@R8MHU9H=-1F2VE$A*32I&G4_BGZ 3D3H
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M^'0A!YJCR]8!4JRMQ]$ZZ>S>$U6Y0];S5RG)K3)+(G%*T2:7-%_&1H1:%H1
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MSU,$3WC_ #6GY%Q&JS2A[A55LP3K3;Z=CS2TJ4VZTXGT+;6E2%>^704JDP
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MT)):F1=0&N7EFSW%);G*-7274"RR"?F5_9U%6U(1WI<;:VIMUM/B;:].BRZ
M*-3,Q=/$\3+TY2J1RM]H43ON97I]2_72K#14(J,B)2-J=7">UV[O7]((_0UE
M2ULMK=1VW5)(UMZZ[5&74M?3H8*^P     !5W/N6XSC?%^5Q,AM8E6_;4UG%
MJT2WDM*E2/9%_DVB5U4KUBZ%[H#'\(9]A4CAC&IL>_KWH6/45:U?2$2$&B X
MB*C<F0>OY,RT/4E"*AGENS_"K/+N4ZNLOX$NSN,SL)]7$9D(4[)A^SLGWV4D
M?KMZ)/UD].@J-E     '!EJ :$6NA%U\0&M/F^S#%J_$Z"AL+B'%O/M+06/U
M>\\A$CV)F:7<?V&>O;3H>JO 2JO5RYE./'E7#O,<*Q8L>.J:XL8-K=Q%E(AQ
MRM8IQFI"UHU(FTNHV+7X)U%*/=@-O!S[S%Y?FV+.(GX?38U"QA=Y'43D.59J
MEKF.(8<3ZKA-(425J29D1F"+_         :Q<SO5=ASQBM-FN0.8!C<6AE3:
M;+H+R:V=,LG'NV] ^LED:6FT-$3IM'\<_P!@!F_*M-:>Q[+*JJ--AB-7D4UC
M'<K-LVW[MES1QV3(6?\ UAU*S-"I'_.:%IX 4;!$                   #
M@]/2 @&?99Q/@R(TWD";5P7)ZC1$*:PA^2^I!>ML;2A;JR27B9)T+T@KWLYI
MQ]&P(LT;M:^/QX<<WTV1DEB#[,I1H/U3(BZJU3MVZF?334"'7QQEW'&6U#SW
M&T^OE5,1TVY3%:VF,3#ZR)6CC&Q"D&HNI&I):^@!-00      %9S<]X+1<2:
MN??8W]=JD^SRHKSD,Y'M6[;L61^L:]W31774"J7W,+%8L1^RR)B B%#:-Z3+
MG-LDTRPT6IJ4MQ.B4I+W3T()(>C'GJ"94Q9^,.17:.4CO1'X';]F<0L]=Z#:
M]4R,_20@RHH     .%*))&HST(O$P& +-L35EIX(5Q%5F!1?K Z5+A'**+J1
M=Q2"\"ZEX@J-9CRUQ/@=XBNRW)(-9?O-)4<=25.R41U*U3W>RA:FVS/J7<T2
M?B")_&?:DM(D,+2XPZE+C3B3U2I"R(TF1^X9& [@     !P9Z%J P]=D^-7,
MFTA5=O#FRZ5WV:Y8COMNKB/$6O;?2DS-M6A>"@&(H,@XSRR]E2L7LZ6ZR."V
M2)<JO=BRYC+2O5(E.M&I9)]'B%1+R+0B(O N@#D      0G-N7..N.9<:#FM
M_'J9DUM3\6,XEUUU;2#VJ62&4+/:1]-3 9BMS'%KC&TY?674.3BZV%RBN&WD
M^QDPV1FM:G3/:DDZ'NW&6GI!4>PGE;B_D2WD1<*OXEO;Q6"=D%'0M#IQM^TE
M$IQ"=[>X^AI,R 3\$                                 '6\TVZTMMU
M*5MK2:5H61*2:3]!D?30!55'R9P)=94C%Z*ZH9&4]Y;45IAII*ER&?C(8?[9
M-N+3I\5M9F"U9C)\YXDK\BK,2RZYISRA]YHZJIGFT]*2^^9=LT(4E2D*7TVG
MTU] 5(6 DO=/4_?!'(      Q61S:*MIY=ADTB+%H8K:G9\B>:"BH:3U,W#<
M]73\((A6!Y_PYG4V0W@%G5SK:"V2G6X;)1I:(ZST):4K;0LVS/IN21I]\%J^
M&^1N%5\B*QINZI3Y&-WV3:2&O:S?V]8_M.S0W=/^:[F_T: ++06B"(O @'T
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M7N+41%[X*E]9]7.0(KE4IE=:MM*H:HFSV<V%%J@VNWZIH,C(RV] 1[?
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M7&W$V.XCD+J';B&A]Z6TTON,Q5RWW)'LS2M3U0SW.T7HZ=.@(LT
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MJ&I)Z;2/H QW'6!U'&N&4^%4REO0:9@HS4E\D$^Z2=?6<-"4D:NOCH E(
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M2)792A/J^!:$ SX
M
M
M
M
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M#*HZDI4<BLD(DM)4:DJ]0U((E$773P,O$!%+CAFEGWDK(ZBVL:&UD6#-VW[
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M,D[7#941H4M#C3NXCU(@5,EYA3HS!6#J[WUXFK.]/\F?8]C)_P!F_=/#?O\
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M7$Z))3;:%+ZH2E24J-)GH"LN7-=#;PW6:J-95TBTKIT[$;2QA&Q#M"AQUO\
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M+G,1F[&RB5=6B_L;2#$4] 8JGH3DYF0I[4D[74-J2VDM5*5TTTU,A1XW.?\
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M;!N)*RVLQYW(G8)*J)B#G%'G1V'UF>IEHXV3NPDFM)DA1F!1=8(
M   @]EQXQ<YY/R:U6S+H++&CQB93N-F9N)<E+><4I>[38I"]FW37WP5 J+@S
M*,09K[2@R1F=EE%:6LJLDW#3KS,NKMV6(ZHTU3:R<-Y"8S*B?1^,CJDR4H"K
M,8WP[:4^6T69S[EF7;,S;ZWR-+;"FFGYE\Q%CH1%2:U&VU';BH;+>:E+(MQG
MJ9@/ICA^R9J,<K2MF=U'FDG,77.TO1V/)D37_9TEN]51>UD6[P]4^G4!B[;A
M._D7+]O&LJV?%D9/-R)ZAMXSSU8ZU.A18:%/-MN%W'XWLZE,[B-'KGT(R)1"
MKLPC@-K'TT,+)I,+(::IH)U!+@/1"[,E<NU:LFW>TM2T)2@FB3LZZ'X'T J]
ME]Q=E,3)I<_CQ>/UN/6=!'QJ3764)UYN*S'D2WC6Q'94AI:5%+/5MS1)F7N&
M8#'GP)-AUT^'4WK:9#,'$6,>D2HYN]N7A:UNM+E)2M/<0^HTDHD&6TM=/0!5
MY[?@O)<F?N[_ "*WJWLDL;&GO(41,)U=2W)J(;T)<9]"W>XZPZV\LMY*2M)G
MN(O5)(%61B<<749K%J/ZEJ*I!7[>0Y#,QYM3$,FJEO=%;44A7==>=>[1;M-$
MH2KW"U"0Y9@V4RLZA9WAMI"A3UU3N/6C-G'<DM%#<?3)1(8)M;?Y9I9*]19[
M%DKKIIJ B</A&^A1^/*EB;5(CX2Q!;5DC;$EJ]UA/=Q]EA:'B;]GE(233C;N
MY))4H]JCVZ"K/XIQ3.QRXQBS<L676Z \J-UEMM2>Z63V:)[9)U4>G9)&Q6NN
MH""O8LYPL]C]RWD3;5ZZS:U<\UTUC:1I<&;;/6C1,IA&:FY3*I*DH2M6CVJB
M]&I!(\+XTMK7RVL<:WZG*BXMJF6Q(6Z@E.QW)[KKZ#=;(R+<7<3W&R,M#U3J
M D-=@>3/Y'-RS()\%-I8XNSCDF-7-O%&1)9E2GR>;-U1JV&E]);5==2/J @3
M?EXL*E%:J WCU^M5-3TUW'R2'(>:)VEB%#*1$-EPC)+K>A.,.),M4D9*+51&
M*K'SCC6+F[N*5,[V=.#T4E<VQI";6CVIQB,MB$A"FUH[;;*W#=,NNII2"(39
M\"3JU5BG )\.NK%7])EE12S&WEQ6;*J2:)1+6A1K-$DD,J,RZDI*O=!:O:CA
MK)9$B;F,G(8M?R7(MX]]"D5\-2ZB*Y&@G6JCFP\YW'42&%*3(<[B%J/::=NQ
M) 5>O)L,Y6R^DJSMIV/,9'0WL"]JTQ69OL+A02<)3;YK<-SUS61D:"]73T@/
M+D'$N;9M#N+/*<EBQLLE5BJ>D:J6'VJV!&?D,R):3-;W?<5+)A#+SB5MF36J
M4$1ZF88JMX#N6+!RT<G5%:<B^QF_754\)R/!81CJ5)=8:(UZF;NI*)Q1%UUU
M+P JG.2X7E/V[C9_A-E!C6+]:BAN85LPZ_'7":D*DM/LFPMM:7FE..%M4>Q:
M5==II(P%<1_+I<TT&B=AR:/(K>OK#I;)K(83QPWFD3I,UF0S[.YO:=(Y2TN(
M/<A9&7Q=O452B[X:LI\/*X]19Q:<KZEH*>#%B,O,Q8R:%U]Q<?:RZVLHLA+W
M84AM9*2V9]0&"C\"9#&386\*?35>0JNJ7):>OKH3C%-'ETT-4-<=;9+WJ:=0
MI6KB=J]Q[M.F@%6;A\/Y(NR9N[J[AOV:\QC9G,*-%<99)#%2=:<1LE.*/U>A
MI<5XD74M3 JR>.87?81Q[E&*S)$>TJVRMY%"J*VZB8MFQ<DRU-R$F:DFXE;V
MQ)M^)%X:@(GQYQ_G]YB/'9Y990XU'C-/&E4]:U#>8GJGOU"H313^ZLR3[*W(
M<3M;(C6OUE;=-H"0-<6910T^ 2<3MX19?@]-]GG/K%EQ==80WF8[;J5DVHG6
ME$N,VZVI!GX&E1&1] Q\3A[,J"PI\IQZ^KG<MB.7\^Z*=$>*#/FY(]%<<2E+
M;IK8:9*,DF]#6H]I;O%0%6.E\!Y$X<*7];55E.EKN)61L6D!QZN^L[UU#BI\
M2-W3+NQT(*.REY2B[?XR5&K459*EXJY&POV9[#,AJBDGC=%B\PK*$\X@CHV7
MFRFM&VZ1FLC>4:65>JK\970!TO>7]R/2R,?J;A#<'ZHQ:GB./LJ4X7V9M'+%
MUUS:HB,WS<,B)/Q3]X"KU)X>R2LDL75+;07+N#F-OEL-J:P][(J+=M/1UQW.
MTLEDXVV\:DN%ZNXNJ=# =''>)1+7EK+.1(,:0QBC#[K5"U+9-A#ES+;99MYL
M9#B4K[:RBLM$X9:+7W33T/509K+^,;^[O<SEU5E#9J<YQH\>LD2FG5R8TB.S
M,;CO,*0LD*09RS[J%IU]7U5=0'1EG#]ADD149%JTRH\)L<+W*:4HN_8*B&4G
MHKXJ?9CU3X]?$!Y\ZX<GW>21<MID4ME8'5QZ:QKLDC//Q%(B...M2&%L+2MM
MPC=6E:3)25I,OBFG4Q5Z7.*KAS/<9R&$=-0TV,LLLLNTL=^/8R8C48V55KNJ
MS9.'W%=Q!&DU()*23H>J@'GK.$GF<4X\Q2TLVY43#VY\>T-MM;?MC-A6RZY1
M-^L9MF12MVIZ^ %757<39R\S0U.2Y% ?I,,ARHF-'!B.,R)3S]>[6,OS^XXM
M)&RPZOU&-"6M6XS(B)(#SUW#>9XO!]@Q&^KF47..5>.9,]/B//+0_40E0FYL
M(D.H+52%=67?5]5)[OC$8JGO'6,Y+B%/&QNVL8D^DJ*ZJK:0H["V9"2@PT,2
M%OK4M1+[CB=Z-J4[4]#U!$R                          %4V7#16^.YG
M3R[(F;&^OG\FQ^UCMFEZKG&PRW'<+56JE(4T>_::=[:E(Z$9@M6,A<39WBS2
M?L1?5<23;T5519([.AO/);D5$4XB)T%*'4EKL5IV'?5]5)[OC$8?<;@QVMH,
MYQJOMTG79+B]7BE2M]HU/1D55>_!)U\TF1+-?>)>B4I\# JD7W<3_M=]I/K)
MOL_9+[*^S]M6_P!H[_>]HW;M-NG3;IK[X"LKKRVY)94;>.IO*R1%5C-5CB)M
MC"<DR*QVI9)MQ=:GN)0VF4HM[BE>ND_2K0B(56?7\3X^[8Y-,RR! R!FYNU7
ME<U,BH>]DWP8D0TEW25ZQG%W&I.GH]P!$$<.9H_+M*.=;U2<&L<L5F7>9CR#
MNDN%.1/1'0XIPFFC)3:4&\DC5LU(D]0*O>UQ1EU++I+W'+BO^OJBRR62IF=&
M=5">@Y5/*:XC\DM+B7&30WM,CT5H9'H1ZD$<1Y=K6K@4DJ+,I\BR&MCV-?8-
MW\-TJ^4Q86CMHVZTF.YO8>:6ZI/3>E25&730C JGF)X=85N:LSEUT6IH<>Q]
MJCK8]>VAB&]+FO(ES7(S1*4IME!M,H1OZF9J]S4PC=]PUED]S)Z.JO($;#,G
MO(N4R4R(KSMDW-8?B.NQTK2ZEOLK.(E25[=Z=33H9=2%7-YPSD&07F;V;DRJ
MI6,FIK6C0W4LR$'.^L4=N/*M$..&VMZ*DM$K:22E;E:J).B0*O=:<.65A0\E
MTZ;=E"\\BPHT9PVEZ13AUC%>HUEN];<;6\M-.AZ *[Y9J+>(6><=X=/5*E9Z
M\S/7CZ:B:[+*?,**R^IF>9E%3%6AKN/..&?9T5IJ9D1!=?)&(7>3LX[/QJ7$
MBWN,V[5S"18MN.0W]L=^*MISLJ2M.J)"E)4G7UB+4M 1'D<26;=#:U"+9DWK
M#-D9HRZ;*MJ&46C%B4=2=W56C6S=X:GKH"L;B_"3N+96T^W QRRQABPDVL.?
M,AOG?1UR7W)24)<[BFE*:<<T;>,B42.FFI:@52&[X@I<QSFQRK.6F+FM*OBU
M=!6GWFRBMH6Z[+6X:7"):GUK07AT2@BZ@(O5\29_AZ\6D8I<55A)QNJL\;;.
M\:DJ0=5,G,R(FA1U),W&&F&V5$9Z*(@'IHN&\FX^C5$[C^_BKR")7G57+%O&
M7]66#)RWYK9H;C.)5&..Y)>2P2-Y):42#(]","KVV&&<JJRZIS^MG8\>2-4K
M]#:Q9#,U,'8]-3*2XQL6;AFDD)29+/KU/IX$&+M.$<BDHA6RKN%>9(]<N7N3
MQKB&I--9.+BIAQVSCLK-:6X3:$>S(6MPMQ&I>JCW$*LIQOP[/P2?C<N1;,3D
MT-9>5CA,QCC)=5=6S=DA:$$M26TMI1V]G7WCT 8G)^&,QL*S,L/QZ_KX>%YE
M/=NY"I<1Y^RBS93K3TAAM274MJ9=6V:B4I.]&]1%NT29"KT,\).UN<3+B-"Q
M^XQVUN%W\E=U#><MHC\AQ+SS<=Q"^TXDG$]QDW$$;9GIZQ)("KKF\*WYQ*-I
MBRKK)NKOKRZF5-Q'>>K):;R6[(;<=:;<3O?BDX?:WD:#-2OBGHHA5Y\7X2S+
M!6L:?QC(:]=O6T\O&K9Z="<5'7#DSU3FI$=IMU.UUI2C+M+4;:B/34M" JZ&
MO+M-.@^S[]\T3/V$/!N^W'5N]H]I-],K0W--G@1MZZ_^4!5G>6:W,I_%M7"D
ME'/,"NJ%3C]3'>D1&76K:.HGTLN&;BFVTD2UDI7@1]=.H#IL.)<NRB;/R/*[
M>N1DLIVBCQD5L=],./64-JFU-!&ZX:UNON%ZRCT)/JD6O4S#TY-QAF<FQRYC
M$[V#!QKD!*?M"U/BN/S(3IQ$0'G8*FW$)4;K+:"VO=$++<6I'M 8^9P]F<#[
M5TN(WU="Q+,6XD"4S,B//S*^%$JH]4:HSB7DI==6VS_SI$E)[3Z]2,5>%[@&
MU+)FI42PK#H(5S1W%9(EQ''[B-#HE1B15LO&X2&X^C!J2M!;C4H]Q'J:@*LA
M%XAS7ZO9PJQOJY_CQ5XYD4MMN(ZBS5K;*MTP4K-TV^T;VTU/:;]-4DGT@/F5
MP=;26FDG=1R=0UFS:U=A9D:LSD=]H]-_@QX+_;>C0"KT0\$?X\<D7US,AV.%
MN8I6T&61%Q)+TM?U(P^TA45#)KWH?]H42VE(-70MI]0'M\OV#3L/PDI5VT^U
M?W2T/.MSMOMK%=$:3$K8KYIZ;V8C39++T.&OQ/4S$O'7\0Y%$>KH+MM"51T>
M8O9A5K0RZ4MQB;[>X_&?U6:-Z7)A$AQ'0TIZIU,!D6N*)[>4)R [-HVTYB]E
MW9[:MW8>HRJ"CZ[OC$9=S=X:=- &'J>$GJ+-'K)B%CUKC4FW?OBD6<-Y5W$?
MDOG*4VRZA?:63;Q[V7%I)2"Z>L:2,"KQ(X/R:;]I9$ZQJJA=],IYAU5&Q(16
M'(J+1NP=G+;><4:94A*.RKMZ)Z$I1K/J!5G<JX>GW^29#E,.W:B6DM['K''E
M.,*>;BS\;5)47M""<1W&GBD&A24FDR+4R/70"KS.\2Y;>SU9/E%W"^TTJXQV
M?(C0([B:]BNQB4Y*;C,FXHW5..J>=6MUP_%1$2=$]0\D?AK,8L6FQ"/?5[?'
MV-Y%%R.J1[*\JU<9CV"I_L3[AN]O:A2S)+J$[E$E.I%ZQF*K9QQG(H].PUE<
DJ+-O24Z<B3 97'C*2;JS:)+;BW%%HV:$JU4>JB,P1E0 !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>lg_carislifesciences-pn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_carislifesciences-pn.jpg
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M @   @ " #A"24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4
M9,     !_]L A  $ P,# P,$ P,$!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)
M" H*# P,# P*# P-#0P,$1$1$1$4%!04%!04%!04 00%!0@'" \*"@\4#@X.
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!3_P  1" %U <0# 1$  A$! Q$!_\0 P0 !  (" P$!
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M]'<V=5RMW=7&//L^J0HI8YHVRPO;)$\=3'L(<UP/(@C@5UDQAO=G$X[G-11
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M2<S8VS3C'&-OY;/EM6RU_9%6$\)V?A*"ZAVX@(" @(" @(" @(" @(" @("
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M@\"M%N6JK=4TU1A,-ZMW:;E,54SC$N^N-R" @(" @(" @(" @(" @(" @("
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MAFM?OW-EOR1VRV[*Z!8M[;GGGLA.^,Q6,PMG'C\/906%A%PCMK6-D,3?8U@
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M]M;V<$=K:0L@M86AD,,30R-C&\ UK6@  >@+4YJF9QG>VR*8B,(W/JHH@("
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MN[7MRU'KJFKHV=[I+ON.[/HIBGIV]R.\MYC=Y,NXF34TMI&>4=E%!; >QT;
M[\+EVEO1\I1_#'IQEU=S6,W7_/#HPAJ-[N)K_).+K_5.6N">8DOKAP_!UT7V
MTY.Q3NHICJA\56<OU;ZZIZY8J3.YN8UFR5U(>=7SR.-3[7+FBU1')'8X9NUS
MRSVOR/.9N(]462NF'TMGD:>'+DY)M43R1V$7:XY9[65LMPM>XYP=8:HRUL6\
MO"OKAH_ 'T7#5E+%6^BF>J'-3F[].ZNJ.N6VXKS$[R8AS3%JB>Y8.<=['#=
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M44T4Q33&$0[*P9B @(" @("#3==[J:&VYMO&U1E(X+IS>J#'0_;7DH_)B;Q
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MYI.OZAC/Z*)_[=W>J@MR:8N)Y=/+NW&MM-P->6M<FX-GPF&F;_9QS;<3M/\
M2=K&'W.9[U.G1]8U?Q8V;4[/Y3QYHYOKT;]YT?2/#A>NQM_C'#GGG^G3NM.M
M/;@(" @(" @(-)W*W2TMM=ACD\_/UWDP<,?BX2#<W,C>QH/)HKWGG@/;0'L,
MED;F:K\-$;.6>2'7YW/6\K1XJYV\D<LJ#[G;NZMW3R7Q6<G\'%0N)L,/ 2+:
M &M#3Y[Z'C([CZ*#@O1\EI]K*TX4QMY9Y9^.#SC.ZA=S56-4[.2.2/CBT)=B
MZT0$!!LVG=O-<ZMZ3IS3U]D(G<KB*!_@?+*X!@^5R^6]G+-GUU1'7]GUV<G>
MO>BB9ZONE/!^4?=;)]#\D,?A8R*N%U<^+(!]6V;**_G+I[ON#+4^G&KHCOP=
MQ:]OYFKU84],]V+?L7Y*6T#LUJ\U[8K.R_\ ?DE_]Q=;7[E_K;[9_#LJ/;7]
MKG9'Y;19>37;F$ WN7S%T[M#9+:%OX/ <?QKXZO<>8G=33';WOLI]N9>-]54
M]G<RL?E'VC93J;DY*<^J[ K[>F,+AGW!FO\ Q['-'M_*_P#EVOV3RC[1OKTL
MR4=>73=@T]G5&4CW!FO_ !["?;^5_P#+M8J]\FVW$U399;,6KO0Z6WE;^ P-
M/XUS4^X\Q&^FF>WO<-7MS+SNJJCL[FKY3R4Q$%V%U>X.[(KRR!!_/CE'\A?7
M1[EG^5OLG\/CK]M1_&YVQ^6A9ORB[J8WJ?C'8_,QCBUMM<&&4^UMPV-H/YZ[
M*U[@RU7JQIZNYUUWV_F:?3A5U]Z+=1[;Z]TD'.U%IV_L(6\[B2!SK?A_VK Y
MG\9=Q9SMB]Z*XGKV]CI[V2OV?71,=6SM:LOK?&(" @W7;C=/5NU^5&0T[=$V
M<K@;_%S$NM+EHX=]M>#@/=>VCA[*A?!G,C:S5.%<;>2>6'89//7<K5C1.SEC
MDE?C:W=S2VZV)-YA9#;Y6W:/O'#S.'Q$#CVBE.N,GW7M^6AX+SC/:?<RE6%6
MV)W3R2]'R.H6\W3C3LF-\<L?'%ORZUV0@(" @(" @K5YB?+U'J>.ZUWH>V#=
M2Q@RY7%Q-X7S1Q=+&T?TX[1_2?7][:]'U?\ 5A:NSY>2>'X^G0U36-(_;$W;
M4>;ECC^?KTJ5.:YKBUP(<#0@\""%OK05GO*?NX<1D1MGGIZ8S(R%^ E>>$-X
M\U=!4\FS<V_]IZWK4M>T_P =/[Z(VQZNCCU?3H;=H.H>"K]%<[)]/3PZ_KTK
MF+1&]B @(" @(" @(" @T#>3<BVVPT/>Y^K7Y>;^J8:W=Q$EY*#TDCM;& 9'
M>H4YD+LM.R<YJ]%')OGH=;J.<C*V9KY=T=+S:O+RZR%W<7]],ZXO;J1\]S/(
M>I\DLKBY[G$\R222O5::8IB(C=#RJJJ:IF9WRM-Y9MA6W@M-RM9VU;4$3:>Q
MDS>$A'%MU(T_-[8@>?O\NFNGZUJN&-FW.W^4_;O[&X:)I6.%ZY&S^,??N[5O
MEI#=Q 0$! 0$!!&F\6\>#VFPGC3]-[J6\:?NK$AU"\CAXLM.+8FGF>;CP':1
MVNG:=7FZ\(V4QOGXY74ZCJ-&4HQG;5.Z/CD>?.J]69[6V<N=1:DNW7F3N3WG
MNX,8P>['&T<&L;7@T?NKTRQEZ+%$441A$/-+^8KOUS77.,RPJYWSB#,Z;TEJ
M;6%\,;IC%7&4O#3J9;QES6 ]KW\&L'K>0%P7LQ;LT^*NJ*8<]G+W+U7AHIFJ
M5B]$^3;,78CN]>YAF.B-"['8VD]Q['3/'AM/U6O"U?,^XZ(V6J<>>=W9O^C:
M,M[<KG;=JPYHW]N[ZK!:3V+VMT:(WXO3UO<7K./QV0'QD_5](&6K6GZC6K6L
MQJF9O>JJ8CA&QLV7TO+6?31$SQG:D1K0T!K0 T"@ X  +JW:/U 0$! 0$! 0
M" 0014'@04$?:LV0VOUF'OR^GK>*\?\ ^>L1\'<5])=#TAQ^N'+L\OJ>9L^F
MN<.$[8^;K,QIF6O>JB,>,;)^2OVMO)KD;<2W>@<TV]C%2W&Y0"*:GH;/&.AQ
M^LQGM6RY;W'3.R[3ASQW?\M:S/MRJ-MJK'FGO_X5SU1HS56B[W[OU3B;G%W)
MKT>.RD<E.9CD%6/'K8XK:+&9M7HQMU15#5[^6NV9PN4S3+!+Z'S"#+:;U+G-
M(YFVS^G;R2QRMH[JAGC/9VM<TU#FN'!S7"A'-<-ZS1>HFBN,8ES6;U=FN*Z)
MPF%_]E-[</NQBC#*&6&KK)@.1Q@/=<WEX\'4:NC)YCFP\#V.=YMJ6F5Y2K'?
M1.Z?M//]7I6FZG1FZ>%<;X^\<WT2LNF=R(" @(" @(*H>9G807#;O<K1EM2=
MH=/J+&0M]\#BZ[C:/G#G,!S]_GU5W+1=5PPLW)_ZS]N[L:9K6E8XWK<?]H^_
M?VJC0S2V\L=Q;R.BGB<'Q2L):]KVFH<TCB"#R*W68B8PEI43,3C#T<V,W.BW
M/T/;9*X>W]HL?2SS<(H#X[1W90T4HV5O?'"G5U-'NKR[5,E.5O33'IG;3W=3
MU+2\[&:LQ5/JC95W]:3%U+MA 0$! 0$! 0$!!Y[>8_<L[@Z]FM;";Q--Z?+[
M'&AIJR20.^WG'IZW-Z6GM8UI7IFC9+_/8QGU5[9^T?'*\RUG._Z+^$>FC9'W
MGXY&4\N.R;MQ,S^TNHH#^Q>*D'5&X4%]=-HX0C_LV\#*?8WM);PZQJ?^>CP4
M3YZOE''N<VC:9_HK\=<>2GYSP[U\V,9&QL<;0R-@#6,:*  <  !R 7G,SB]'
MB,') 0$! 0$!!H>[.Z.'VJTO)FK^EQD[CJAQ&-#J/N+BE>/:(V5#I'=@X>\6
M@]CD,C7FKGAC=RSPCXW.NU#/492WXIW\D<9^-[SIU5JG-ZSSMWJ/4-TZZREZ
M_JD>>#6M'!K&-^:QHX-:%ZA8L46:(HHC"(>77[]=ZN:ZYQF6&7.X&2P6G\WJ
M?)PX;3]A-D<G.?LK:W87O('-Q[ T=KCP':N*[>HM4^*N<(<MJS7=J\-$8RM7
MMGY0;>'P<KN;=>/+P>,#8O(C'JGG;0N];8J?7*T[.^X9GRV(_P#E/VCO[&Y9
M+V]$>:_/_P 8^\]W:L[A,#A--V$>+P&/M\;CXO<M[6-L3*TI4AH%2>TGB5J5
MV[7<J\5<S,\[;;5JBW3X:(B(YF17$Y1 0$! 0$! 0$! 0$!!T<OA<1G["7%Y
MRQ@R..F%);6ZC;+&?71P/$=AYA<ENY5;J\5,S$\SCN6Z;E/AJB)CG5GW+\H6
M.O&S97;2Y^!NN+S@[UY?;O[:0S&KF'T"3J'Y30MLR7N&J/+>C&/[1OZX:GG?
M;U,^:Q.$_P!9W=4JGZATUG])Y.7#:DQ\V-R47%UO<-Z26GDYIY.:>QS205N5
MF]1=I\5$Q5#3+UFNU5X:XFF6*7,X63T_J#+Z6S-GG\#=/LLM8R"6WN(^8/(@
M@\"UP):YIX$<"N*]:HNT317&,2Y;-VNU7%=$X3#T2V<W:Q.[&FQD( RUS]D&
MQYG& U\*5PX/97B8I*$L/M:>(7F&HZ?5E+F$[:9W3\<KU#3M0IS=O&-E4;X^
M.1(RZMV@@(" @("!SX'D@HQYE=D1H?).UIIBWZ=(Y.6EU;1#NV%W(:]( Y12
M'W.QI[O#NU]#T74_WT_KKGST_..^/SQ>>:UIGZ*OV41Y*OE/=/XX--V"W+=M
MKKVUNKR7HTYE>FPS+2>XV)[NY.?7$X]1//IZ@.:^[5LE_IL3$>JG;'=UOATG
M._YK\3/IJV3W]3T9!! (-0>((7ESU$0$! 0$! 0$!!$OF*W#.W^W5X;*;PL_
MFZXW&%IH]GB-^VF%""/#CK1PY/+5W6CY/_1?C'TT[9^T.EUC.?Y[$X>JK9'W
ME2':[;O*;G:NM--8ZL5L?MLG>TJVVM&$=<A])X]+!VN([.*] SV<IRMJ:YZH
MXR\_R.3JS5V*(ZYX0])=.Z?Q.E<'8Z=P=N+;%8Z)L%M"/HCB7./:YQ)<YQXE
MQ)*\KO7JKM<UU3C,O5+-FFU1%%,81#)KA<P@(" @("#%ZCU#B=*8._U'G)Q;
M8K'1&>YE/$T' -:.USB0UK>UQ 7-9LU7:XHIC&9<-Z]3:HFNJ<(AYM[H;C9C
M<_5=UJ+*$QVU3%C+"M66UJTGH8/2X^\]WSG5[* >J9')T96U%%._EGC+RO/9
MRO-79KJW<D<(:8ON? F#:'R^ZIW/DCR=SU8?2+7=_)S,)?. >\VV8:=1[.L]
MP>LCI72:AJUO*^6/-7PX=+O-/TBYFO-/EHX\>A>'0NW6D=N<6,7I;'MMFNI\
M1=O^TNIW#YTLI%7>H>Z.P!>?9K.7<S5XKDX_2'H.5R=K+4^&W&'UEM2^-]@@
M(" @(" @(" @(" @(" @(-:UIH+2FX.*=B-58Z.]@ /@3>[<0/<*=<4@[S3^
M(]H(7U9;-W<O5XK<X??I?)F<I:S%/AN1C]NA2'>#RZZFVU=-F,7UYK1P[QOV
M-^WM6D\!<L;R'&GB-[I[>GDO0-.UBWF?+5Y:^''H[GG^HZ/<RWFI\U''AT]Z
M%UWSH6U;=Z]S6V^J;34^$=62$^'=VKB1'<VSR/$A?SX.I4&G=< [F%\><RE&
M9MS15_Q/%]F3S=>6N173_P QP>DVD=58?6VG;#4^"F\;&Y",2,K0/8X<'QO
MK1[' M</2%Y7F+%=BY-%>^'JN7OT7[<5T;I9M?.^@0$! 0$!!T<SA\;J#%7F
M$S%NR[Q=_$Z"ZMY/=?&\4/K!',$<0>(XKDMW*K=454SA,..Y;IN4S35&,2\W
M]W=LLCM9J^XP-R738N:MQA[]PX3VKC05( '6P]UX]/'D0O4]/SM.:M17&_EC
MA+RS4,E5E;LT3NY)XQ\;UQ/+'N&=;[>18R^F\3.Z:++"[+C5[[:A^&E/M8TQ
MDGB2PGM6CZWD_P!%_P 4>FO;U\OQSMXT3.?OL>&?51LZN3XYDU+H'?B @("
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M?LY'.];Z"3V.6LZEEO\ /F*J(W;XZ)^,&S:;F?\ 1EZ:YW[IZ8^,6_+K79"
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M7LD>RC7#\L=J[_/7?U9>WEXX>*KIG;$?',Z#(VOVYBYF)X^&GHC9,_'.FQ=
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M;.Q\%[+S-ZB[3OIV3STSW3M[6YKX'WB @(" @(" @(" @(" @(" @(" @("
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MPYXG;BE)=.[@0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!QDD9$QTLK@R-
M@+GO<0&M:!4DD\@$$2:P\P^B=./DM,1UY_(,J"+5P9:AP[#.00?S&N"N"8HI
MN]_=U-47#K32UBRU)X,BQ]JZ]N #Z3()!^!@5P,7 8;S*:@[SY,O$U_,/NF8
M\<?2WQ(OW$V =J-_I*.?=71->KO98$@_\8\41T[G1/F%PY,C79EP''JM,B9R
M?S8IW'\2#"R[E;QZ8N!!D,MD[.X:?YK(Q]3C3\FY8:H-BQ?F8U_9D-R$%AD6
M?.,D3H9#[#$]K?XJ8+BW/ ^9\Y&_L\=?Z:Z'W4T<'C6]UU4,K@VH8Z(5Y\NM
M3 Q6'440$! 0$!!63<3>#)8C>&T^!NY!I_3\C+.^M(W'PI_$I\47-' N:#T-
MKR<RH5P19B*6.>)DT+@^*1H?&]IJ'-<*@@^@A17- 0$! 0$&I:IQ^XEU>,DT
MCF,?86(B ?!>6KIGNEJ:NZP[E2G#I00WKC<3?+;F6#[^9C+BQN'%MO?V\!?
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M[;>'<2W.7=<NLH[.?!20X5]\T])M6W9:'U#A3J\3CV!5&Q?YMS?<WPOW5_\
MZ'\?]R?L]X@Z/CZ5\3Q/_A^G[3K]'"OSD$H**Q6H]1XC2F(N,YG+@6UA;"KG
M'BYSC[K&-^<YW8$%/]P-V-5;FY%N)L&RVV%EE$=CAK:KI)G.-&^+T\9'D\F^
MZ.P5XG)BE';GRX6-O!#EM?$W-ZZCVX:)](8^T"9[#5[O2UIZ?6Y3%<$\X[%X
MS#VK;+$V<-C:,X-@MXVQ,%.')H 45VT! 0=:_P =C\I;/L\G:PWEI)P?!<1M
MEC/M:X$((/W$\N6'R5O+DM"@8[*-!><8]Q-K-05Z6%Q)C<>SCT>IO-7%,$!:
M"QTPW&T]C+V)T-Q%EK:.X@D:6O8^*=O6UP/$$%I!51?98LA 0$! 08C5.>M]
M+Z<R>H+FABQ]O).&GAUO [C/SG$-^5!Y]W=U/?74][=/,EU<R/FGD/-TDCBY
MQ/M)6;%<S8357[2[?6=O._KO\*XXZ>IXF., PN]GAEK?:TK&5A)ZBB @(" @
M((M\PMHRYVNR4CFAS[6>UFC)^:[QFQDC\UY"L)*F"R1Z':< ;I[$AH :+*W
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M#%,WE\VOAPV,AUQFH0[,Y!G5C(WC^SVKQPD%>3Y1QKV,]KE)6$[**(" @("
M@KWK_3%OC-^=&YNV9X<6;N(I)PT4!N;1P:YWYS3'7UU*J+"**(" @(""!/,]
MJCX+ 8W2D#Z39.7XJ[:.?P]L>Z"/0Z0@CZBL)*OFH-&973F&T_F[ZGPNH;=]
MU:AH-6!CJ!KB>%2US'CU.51('EPU5]R:W=@YW]-EGHO  )H!=0U?$?E'6P>M
MP22%OEBR$! 0$! 01UOM'XFU>?XTZ6V[OP742L)*D:R1Z'Z=_P /XG_H[?\
MY35@R9) 01]O1I.+5F@<E$(^K(8UCLA8.'O"2W:7.:/KLZFT]-/0K"*/K)%Q
M?+GJ";,[?,L;AY?-AKF2S:3Q/@D-EC_!UEH]06,K"7%%$! 0$&OZ[C;+HC4C
M'>Z<7>UI_P!.]!Y_+-BNEY??]*\/^DN_UJ18RL)/440$!!%GF&R,MAMC?Q1.
M+3?3V]JXCGT&3Q'#Y1'16$E7O8-MN[=3!^/3@+HQ \O$%K+164A==8LA 0=/
M+6#,KB[[%RGICO;>6V>ZE:-F86$T[>:#'Z.P#M+:7Q6GGSBY?CH&P.G#>@/(
MXDAM30<?2@RE]8V63M)K#(V\=U97#3'/;S-#XWM/8YIJ"@T@;-:&'V)@O'8P
M'J&)=?W9L00:_P UXE*5^;R5Q&Y_=6,^[?N;X.#[I\+X?X'PV^!X-*='ATZ>
MFG9101#YD-:/P6EH=,V4G1?YXN;.6GBVRBIX@X<NMQ:SUMZE825<MN-,?MAK
M7#X&0$VL\PDO*</ZM"#)**]E6M+1ZRJB^K&,C8V.-H9&P!K&-%  .   Y +%
MDY(" @(" @(-.U9HZZU%JC2&<AFBCMM.W-Q<7+).KQ'B6-H8(Z CWF"M:</P
M(-Q0$! 0$!!2W<&_GW-W?DQ]B\O@EO(L/8.;Q#88G^&YX_)+B^3V%9,4\[ZZ
M.@R6V+V8^$-?IL175HP<VV\#?#D;7T",]7YH4A95 Q]]<XN_M<E9/\.\LY8[
MBWD'S9(G![3\A"R1Z":;SEMJ7 8W/6G\QD+>.X#0:])>WO,/K:ZK3[%@R91
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MGD\$]K/);7,;H;F%SHYH9&ECV/8:.:YIH0010@K)&RZ&U_J'0&4&0PD_V$A
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MQEYEKUW19V,$ES.[T,B:7N_$$%#((\CN#K=C'DG(Z@R%9".(8;F2KC]5@/X
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M001R(51:K9_?6TSL,&F]97#;;/, BM,C(0V*[[ UYY-E]O!WMX'&87%.JBB
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M)D+R0GJNI*]1B8X\7%Q]]WS1ZR%91<V*..&-D,+&QQ1M#(XV -:UK10  <
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33QZ?TE>?92G3W:**W) 0$'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>lg_datacliniclogo-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_datacliniclogo-4c.jpg
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M%!04%!04%!04%/_  !$(!!L#M@,!$0 "$0$#$0'_Q #F  $  @(# 0$
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M)2#^*\VE_P!!*,%-\V_]J^U_^O%_XHT!]5_;!_V20/\ UN9_Z5:C*:\^\?\
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MC1\FWFE)%0A541?P]"2]TJD-DP/N@VR-%%F;K^$G212RRCC&V1+\R%LT&_\
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M]E0$-$\'^)H3B.LZK#(A6Z(^CD@?Z1=,T7^J@+S#A0\?&;AP([46(TG%J.P
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MOF"_,2>4U%?Q2@+I0'C+B1I\5^#-:%^');-F0PXG(#:<%1(21?5%1;+0%/\
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@.HF!WXDBV];*B_Z% =J 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4!P1(*76@-8;;YQ\;:KGV=5S69%S/NN T]C(2]\V$=4
MD$GE%?:J<?R(O/T]M"GE*W#;EDE#UC09CC"QW3CY'(RXT"%R%$[*%U(_>2]1
M1.2)UZ4!:,?M6-QC,>+L&18#)O--//$V2K%$W?9P;,^O'FBH//W?%?6H5HMB
M*BI?^Y5,3F@% * 4 H!0"@% * 4 H!0"@% * 4 H!0''(?2Z7H#F@% * 4 H
M!0"@% * 4 H!0"@% 5K:]SQVK#%9<!V=EL@1!C</"#O3))BEUX#T00']]PU0
M1^*UMMVW+JYG%N=Y"Q1.KE+Z8K%O[%SD\%Q*7F/(>XXA^,WFG-8UEZ<O^(P,
MK.??D&/S<-@!;!$7HI=1O\:WPLQEEJEU(\R_O[UFGF.U:KDI2;[W1)>]=)-Q
M=]R>-F1\5OF)7!29IBS"RL=X9>)>?+\K7>XB31E^Z+PI?X+6#M)JL77XG5'>
MRA)0OQT-X:DZP;Y5HJ-_Q)=%2^BMT_'XI^-<QZQS0"@% * 4 H!0"@% * 4
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M<*/D8LIH@^DF KC!N)U#D***]"1%NA(J?!: JK.L17(NNQIZQXS^&C!$<QD
MC<C-D(HB "&JE9$2WN6]0$1Y#A3Y4.?E\)/"$UK&+F25>6.$@FY(MD2)&,^C
M+O!"$G N2)9$]:%1^?GBO[=_(7G+.PLP41(^H.3.[G]AGE=2;!U'S8;;15-Q
MTA5/5+>Y+JE4B/U6BQH\2.U%B,A'C,@+;+#8H   "@B(B-D1$1$1$2@/:@%
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M#V%;Q\+%C@<A.P[4?%HZD-4BO+9P$>(S3FI<BY&JW^-9)4P-,YN;<I.K9K[
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MU1?TYR?**Q9N]1W7Z:PYI5EA&*YRE@BM^,F9^L/9'QMF912YN*%O(8V:=_\
M&(4WJY:__DG^8K^U*Z_4G&]IW$%13\+7*2_]R^9YWH\9[;5M+CU.%)1D_P 4
M9?\ ME6O6B-WIC4G_). '= A%B2PTQ&TR/%&5?1]I1X\NG*W+^BMVT=U;2;M
M5U:X_3G2C.;U".WEO[:W&EQ=N?U4I75'GQ,?6@T\/)D&+XU)D\4<"6NTM8XE
M+'"EQ2*JVN'>4N2=.O&L[WG/:-[BNK4M%?JZ>FB1AMOTRWT8[2FG1+S%'Z>&
MG+PZFZ]-#MEO'VCM>3\#B0U^"F.DXK(/R(R,HC9NMN-<25/FG);?MI:WE_\
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MR_)N&P08.6UB\SA)[;L:8X:LH$1Y$!X0(!54.R H?BEJGI^[5B3<EJC)9>W
M;BSK7(VMC(D;&P(^.AAVH<-H(\=M/W6F10!3^A$KSU+5BW5G12F!F5D!0"@%
M >4A.33B7M<"2_\ 0M5$9\#_ ,^:R4R+FL7G-FUW*(N)<R,:+C,1D(SDK 1S
MB,N-E*=0Q11)55%Z?-/EY[WUE.E?<?76?VGZE=@IQMIQDJKQ+)E/SV8P8Y;7
M5UAF>YA=;B0(C)Y3L!-DE%F.S'C(6"5L>1.KQ1%_"O/O[JW.["2>$<S[;T?T
M+>;;8;FQ<C2=WZ%58X4SX%MS.V:9EG,G#;V3;H>KY4<DW(P88O".<6<S.3(2
M&PDF]W$3NIT)4Y6^-=[]0LOC[CXU?LWU1?\ QK_<CZK\$9IC8]-RFR0&'&HV
M4SF5EQ8S_%'A!7[")\5(4+V_!52NV$U..I9,^7W.VGM[LK5Q4E!T?6:WA>&M
M_P O"F8K)X3&X&=*W-_;V-K9FI)R$*([."7V(_::;+OD(]HE(T;LJ^O1*S.<
MG_(WAK*^3/)V0F9W&-MZ9-U9=>BY=B9QG0\@DI9K4QME$2_;-1%!4^JIU11Z
M5 9F9T'REMVL:EFLT6-A^8/'^42? FM.D6*RX@VL9_N<0$V!ELDMTX7;/TN-
M4$YD]6VKR)L6HY':L0W@,#J$Y,^./^K;FR9F7;8-B.*$T(@VRQW7#4E52,N*
M<12]0'ME?&60E^9\;Y#BR&V]?_2QCYW&>A2LACW3+'/JENJLC)?]U_DE4#PQ
MXPG>,86>QDN4$J&>1D!K(BI$L7 =TY$2*2DB+=MR0_?X65* A$\69;=<+M6'
MW*$FOSG=A>V+3\]CI(29D&4O'Z>4VJ""@XVH>\+\3 E&]KU"U+WXLU_/ZMH6
M&P.T.1WM@AMNID7X5TCN/N/N.$;:*@V0N7+C9+7M5(7"A!0$/F&GVCC9)AM7
M"AF2FT'4B;-+%9/FB=:V1?#F<UZ+5)K'3\#6>(/';1YIV7,Y.0#K.EPL?!U^
M.Z7$&7,FR3\F0@%_NBI9OE\DM7I7JV]K"*_^1MR_X71+JXG+;G&Y><G2D/I[
M5B7)_?M2#+.:_EY3<-Q]I"C'.3M19;)HJ&C;CE@+BOM(56N1;.[*'F13DN-,
MUUK,O^2V\;OERDHMY:L%)=#>#-2:KM\?5\?NOC+6C3*Y2)F'X&G8R.2R%9B9
M!D'1YDBD@,,&X?N)>GI7M2VOG3MWY^%:4[CRQ7#K?(\F_O?(A.S;6J;=+<5C
M@Z8X?ABWB\$;NU'!#KFMXK @2/)CHS4=QVUD(P'WDE_@I7KP=S>\Z[.YEJ;9
M[FRVWZ:Q"U6NB*CW(HNFYS'^/,A-T/:'AQL=)<B7KN3D*C<27%ENJ[VT=5>*
M.MD2B0DOXI7J;NU+=15^VJX)2BLXM*F7)\SP]AN(;*<MM>>GQ.4)/",E)UI7
M+4FZ4SXHLN?\C:MB7&(L>8F6S$PQ:A8G%D,J6Z2^J\054$43W*1JB=*X;.RO
M7*NFF*SE+!+O/4W'J>WLM1U:IR=%&.,GV<.MT16<YCWO(^]+AHT^7C\-IS8/
MORX) #RYB6/L 3,3'^"U=2LG12M7?M[BVFWUM*4KV2?Y%Q[6>3NK3W^[\M2E
M"%C%N.?F2R2;37ACRYF+LVKR]">@>06\[E<TN$=%K*-Y%T'U_292H$CAP;!;
M@O%W^BL]ON([E/;N$8Z_ITJGC6*X]AAN]I+9..Z5R=SRWXM5)>"6$LDLL)=A
MF[3A<+M?D/&8?*-!,QD[79]K6)>)2&%!QHNO$D]1(:U;:]<L[64H/3*-R/P9
MT;VQ:W.^C;FM4969_P#-#VJ2/CS('AY<CQ_G199V/&#W8TAIH& R6/5>+<D4
M%$13%$X.I\"2_P :T;ZWYE-Q"NB6&..B7Y>IYHZO3;SMM[:Y3S(8KAKAPE\G
MTG?-DB>8=:2_7]&R?3_ZHS65K_PKG\\/F8WO_P!C:_\ KN?&!QY!5$SFB"OJ
MN?"W^2O5-A_;O?\ U_\ 4AZI_=V__P!O_1(V$'5%_:M>6>Z=J 4!";9L,?5L
M%*SLD"=",@"VP"HA.//N"RT"*OIR,Q2_P]:L+;N245[4Q,9S4(U9ABQO(K$D
M.2L<:&XVF0A"PZ(@R7^$[+W=N1C\.867\*R;MT>#[_D1*701_P#/)O8F3L6+
MQ3V1UR+WE6:RZ".NMQE(77&&2ZF**)<?<BE;HGI67D-246Z2=/?S,?-33DE@
MC-@;C"R>?@X?&M?4Q,AB/UV+DT)$:)A7 ;$>"IRNO-"JRLR47)\'I[1&XFTE
MQ51%VM99[.TL(VRUMQ67/X@JDA4CC)10_LW0D3W?&L9;=K3_ !_;0L;J=?X?
M]3'QF^8R5E<'A9+1Q<GG\7^L0FS5#!6DXJ3*&G17!$N7[$7Y59;>48REPC+2
MR1O1;4>+53NYO&+-O:SALN27-31?K1&S:.F,?ZA1;(ODB<;^G+I3R)>'^/+O
MH%=B]7\.?=4C6_)#+NLYK8/TN0A86,Q->C*X"@ZU*9&0*-/)[5(1+WC;HO[4
MK/\ 2RU*%5XFU\B><J-\B<V;<L?JN.@3LHVX@3)$>*2-V/LH^J(3I_\ TMJ]
MS)/1*PM6G<;BLTJ_=ULMRXH)-\T6)M;HOX+9?Z*TIFX[U2"@% * 4 H"O;OM
ML#1M7R.TY(#=B8YM"5AI+NNN.$C;;87LG(S(13Y4!TQ$C=5CQ)&=BP ?>5/J
MX4,W%6.)]41'36SBAZ'84O\ NU,2X&'HVW3-J>VIN9':CA@<[*PD=6E(E<:C
M T2.'R]"7N=43I5(8.7W?*Q=CT? Q(\= VLLB,F0[S)6/T^/WQX"BI?E:RWJ
M%*_D_+N7QNG^0,NN+8<S.BRUA=P2<_3YBEVR10+\PD N<70NO$D]>M 3V3WS
M(1/(&$T\0B1X.4PTC+NSI!%R!UAQL$;%.0HJ*AW6_6@1>(3CKL8''G&W3+KS
M92P*B]4MU+_1JAF10@H!0"@% %2Z6H"%PVHZSKTN?/PF+CP9V5/O9*0R""Y(
M<N1<G"]56Y$O]-9SN2FDI-M+(UPMQ@VTDF\QD-1UK*Y>#L&1QC$G-XSICL@X
M"*^PBK>P%ZIU6D9RC%Q3P990C*2DUBB#3P]XN$YSB:GC.63_ ./?XN%G$Y<[
M6M84Y(B^VU;OU5ZB6N6'2:?TMG'PK'H)C-:5JFR08V,SV(BY''PB XD:2T+C
M;1-CP%014Z6'I6J%V<'6,FFS9.U":2DDTC)S.M8'8<8YAL[CV,CBG;<H<EL7
M&O;^6R*G14^"I6,)R@ZQ=&93A&:TR540N-\6^/,1BYN%QFMP8V*R0\,A&;9&
MSX)94%Q5N1(BI=$5:VSW%V<E)R=5ET&"LP2:25'F2,W2M4R6*@X.?B8\G#8T
MFG($%P$)E@V$LVH#\%%%LE:U<DFVFZLS=N+232HCQFZ!IN1V&-ML["QG]FA\
M?ILH8)]0"M_D7DGJHW]JKZ5E&]<C!P4GI? CM0<M5%4S(>JZ[C\W,V2%CF&,
M_D!1N=D0!$?>!.-A,O543B/]58NY)Q46W1<"JW%2<DL6<2]4UV?G(FS2\:P[
ML,$%9A9,@19#+9<KB!^J(O,OZZJN247&KH^!';BY*32JLF0>2\4^,Y^7+9<E
MJ^-?RZFCSTUU@+D8]>X:+857I=2)*V+=7HPT*32ZS6]O:;U.*KGV\S"DX_Q+
MY3>&),CXW8Y6+]S0."AFV%^*J"V'DW=/W;A4MW;EGZ&XU,KEJW<^I*5#-;T7
MQI/7-81O!X]U'W(SF=@BP" ;K8(<=701$&Z"MQJ*_=33U/PY8D>WMM-.*I+,
MS\YX^TG9I$"9L&$B9&3B[) >?;0C90514$52WM14O9>E(7KD$U&32>9E*U"3
M3:55D<P,%IN,G93"XZ%&C3\R)9#,16P02E"^I-$\[\"Y*I"M82N2E2K>&709
M0MQC6BSS)/!X##:UCF<1@8;6/Q<;EV(<<4!H.9*161/FJJM24G)UDZLL8J*H
ME1$E6)D* 4 H!>@*9Y0@;)E]0R&%U4 +*Y,0AJXXXC2-1W2L\Y=;75 NB(GS
MK?8E&,DY9(\WU*U>N[>4+--4L.I/-]QK7,>#,GA<;C<AIV=R&1SFOOL2,/C<
MC( 8(=LQ5P6D44[?)+_'\*ZX[JK:FE1YX8GA7O07;C&5B<W.VTXJ4O"J9X=)
M-!JVZQL]OJLP8[F'W&";K,DI(B\S-2(K(1R!?5.1*BGZ6ZUJ\R+4?X7\SM6T
MOQN7Z):;T<'7%2TZ5%_:=,EH&QO>)]2U.-$93,XJ7CGYS"/ #:)%-2=(3]"7
MK?\ &BO1\R4N#J)^GW/T5JRDM4'"O_"\2%VG1_) 2-^P^NXR%D<)NCB2AR+T
MI([D=>"(3:MKZET]J^GQK9;NVZ1;;3B<>ZV.[3OPMQC*-[&KE2F%*4X]!/XO
M2]BBY[-Y)YAH8T[5HF%CN(\"E]<RSVS!41;H*%^]Z5KE=BTE_%4[K6QNQNSD
MZ4=J,*_Q*I@XW0-GC83Q9CW8S0R-5E_4YIM'@5&P5"1"!4Z'U7]VJ[T:S?YD
M:K?IUV-O;0PK:=9=S+U!US_Y\-AS.4B,/XZ>SCFX!.@#I<HS;HN]"15%+D/[
M:TN?@26>)ZD-L_U%RY))QDH4PY:J_%%9S^BY.3/R\W&QFP9#+8[+8N(R_P#0
ME(&-"6.\V+C5E9-5,E$E^*=>BUMC=5$GR:?'B<%[83<Y2BEA.,XJNFM(:7BL
MGG\#JUK^RC#R^4P^*>Q>:?2'&8";DUF9%^&P\KKX"XX3K+"J)DC"W*Q7);=+
M'..";JL>&"?SZ0K%VDYPAID]*59UE**=7S47BU'/FR.E:1M&0_F:8WCW(Q9>
M#CH\)F?.27+5R),5YSN&I&(IQ6XB*V_IK)78K2N39JGLKTW<DE37&"595EX9
M-OBUQX%NRF*SQ9_92C10D8G8<2,1F4CP@3,J,T^V@&V754-71L0^G6]:%*.E
M<TST9V;OG3HO#."72FM7NQ5.T]_T'(H&AMJT'+!H*Y#JG\/C!)A>/S]ZVZ?"
MFM>+I^TS\B7]+^#/_;0O ^B?LKG/1.: 4 H!0'4_RKUM^- :)\E^"1R\^1L>
MH"TW.EDKLW%N+P9==)?<ZV7H)E^\/HJ]:^I].]:\J*MWJN*REQ70^@^']8_;
MTKLG=VS2D\XOZ6^:ID^?,TS)T':8;I,RM<G-G;H*1S=0E^*(0<A5/Z:^ICOM
MO-55R/?[,^(GL=[!M2M26&6FM>:PJN^A;-6\3>0,ZBPY+3V%P3K01Y#T[H21
M0/NHVRPBJ70DY)>R7KS-WZGL[7BC2<ZUPYY5;/8V'I/J5_PS_IVZ4\7+@HQ3
M>73W<#Z0TW5<1IF(:P.%:5N(TBF;A+=QYT[<W#7XDO\ \*OB=SN9[BX[D\W[
MD?I6SVEO:VU;MK!=[Z6:OW[6-A>V#==CP^,?E2C@P<>$<!_^2&/D,N-RFFKV
M17&24'@^1);]ZM]F["D8MTQ;ZFLN_(MV$JN45C1=O^AC8W(^1\?E4D95V<<2
M+.:',XZ+$DO-A%!\@ F24."@K2C<8ZFI?F*RI4FK332IEAW?&IFG--=>)U@.
M[\Y#;R>SS-B8QSC[3$V-#:X2V8RQS<%P ; C4B?X"X27XC[?15JS\I?32M/?
M7["1UYNN9C0D\C01)R6WDH>1ENG+C##93L/Y55CB7UW%%%&>RERY*(70[=42
MMDW9JE@TE[L<NDQCYE&^)@8K8]TS#;DK$2YTG/D@28V-DJDD'(Z?4"YD(X.-
MB#;1*K;;0(JJA6ZV7K9V[471TIS[L'T])%.;556OMB3.;RFW,-X]K4#V62TT
M?U#$K)LO$XZXKS N1S;%D5)!%7"Y22$$2_'DJ)6BW"W5Z]/9\?\ 0V3E)8*O
MMP)3,X?/L^-M1C8J!)3+XN>DD&0;YO,*TQ+X&HJBVLI#Z_%4I"<?-E5X-?82
M2DH*F?\ J8,M=[P\^.V$S-SX,>3%-B(8NDY+61'8-X5EM-D(J#BN6;?%&K<O
M<*HE%Y<EP6>/?3 M9+GP(R#@<W'P;>.E!G&\=C)$=Z48 Y]4+K6>)UU&S$%,
MP&.2.H(7&WN2MTKD-552KP_]'VFI0EIICG_U5^!GY=W:\S"CX_+-9T6L3(;?
MRC\=AQHB-G,MD!-F *KJC%7G_#1?:E_A6*=J-7&E7E_M^TR:FTDZ^S++XSD[
MN]F\I_-3\E4)LE>B/L/BPU)202#V771%OBK7'V,\AM[E6_2N;<.W3PTZ.XW6
MM3S-JUS&X4 H!0'4A0D5%Z72W2@/@N!'\?'FW=7R[>MZO,PN0Q>&R?U[,1V6
M\_,"04V0XLQSIVS;#\GM1"NOJE:M$>2[CK6ZO+!3E3^9E-S#&$S&3TR? Q,/
M%PMEQ^+D3X..0QAN&YDI$5PP12541T&D7VK^SYUYFZA'SX8>U3]"] OW)>D[
MQN3;7&KY>XN^<=\;0&\]F '4H,G$+L)-:H\Q"Y*>!R;<%B.Z;CZ2.4EI3=+\
MI7Z@EDKU7;AR7<?GBWE]KZY?[F?5?A'$0<5H,9S%QD@XG)RIN3QL $46V(DR
M01L@%^JBH<21?QK)&B<G)U;JV;&JF H!0"@% * 4 H!0"@.%1%M?X=4H#46^
M:]L&M;B/DS4,.FP,RHH8[:==;XI)D,,ER8E1N70GFKJ*BOYAZ)\T]+;WH7+?
MD7):,:PEPKQ3Z.DXKUFDU<2U84:^9'Y3RWC]HA%AL#X_S>P9D_;'QF6Q?TD-
MIQ>B$^](N#8BJ]53K6R&SG:EJE=C!<XRQ_X:9F%RY;NQTN&NO"4?C4M/B;QT
MSH&NJQ)",6PY60[D<W)AMBTRLF25U:9Z(J,M(B "?A>R7KEWVZ>XNUQTJB5<
M\.+Z39L]I#;V],4EU<.A=!L010;V^-<9V&'.Q&-RD<HF3BM3(IK<F)#8.A=>
MGY214K*$I0=8MI]#H:[EN-R.F:4ETXF)A]4UK7T-,%BHN.[B6<**RVT1)\E(
M1NJ?TULNW[EWZY.76ZFJQM;-C^W",/Y4D2,>'%B*X49D&E>)7'E 4%3,O4B5
M$2ZK;U6M56\V="BEDCL]'9D-FT^".,NBH.-FB$)"265%1;HJ*E18.H:35'D>
M+>,A-.-O-L@CK0=IHT$4(&O[ JB70>GHE6KI2I-,:UIBO:AW*#$.0U+<9 Y3
M"$C+Q"*N A_F025+I?XVHFTJ(.*;J\SLY$C./C)-H%D@*@#RB*N")>J(5KHB
MVZI2KI2N!:*M>)T<@17B;)YL7"9)#9(T0E T2W(;IT7KZI1-K(CBGFC(1+):
MH9'- * @=PUN-MVO3=?EO.1VI@#VY3-NXR\T8NLNC?HJ@8"5E]?2MMJZ[4U-
M<#7<MJY'2R/QSGD-I(D/+-XIWM&/UN39<>!7F1]5".H>QPOQ<44ZVJ3=O&E>
MCVY".O"M"(PFK;)KF ?TW%/1#PPI(;Q&3=(DDQ8\DR- =:05%PF^:H!"0HMD
MY(G6MMR_&Y-7)5KA7DVO;L,(6G".A9? 0M.R>O9K%3M;^E<QF*P/Z"W&F..-
MNJH.MN"XI !):P>Y/GZ4>X4X-2K64M71R"M:6M.25#V>UO8XDS9"QAPW(VT"
M#CIOD8+#E?3#&<5$02[H$((0I<51?7I5\^+4:_@]^-0K33;7XOLH867\>3I;
M(#CY[,6=B8F-8UG)&"N.1Y6,5R[C@=$(7!<4"%%ZBJW^%6WNE%UDJZG+4N:?
MV&$[%5@\4O"^3/5-$G1$V>-CGV$@Y[#LXUDG%+NA+8:?:5URR+R$^ZA+;K=%
MK%[E>"J^F5>S S5E^+'!KWD4GC3+K@LQ CRHL.3E,'%PY1&B<6$<J,/ ICB<
M45"(?8G$;\4]UUK='=Q4U)K*3ETT? URL-Q:KP2Z,"R9W2TVN87Z^[;#IC#Q
M[$>*Z;;B.R^DAPE2R*BB(("=?1;US0O>7C'/5J[LC=*WKK7*E">U2+EX&OP(
M&?D-2\O%:%B3+8Y<'E;3BCGNZH1(B*7]]?X5A.492;C@FS*$7&*4L6B:K S%
M * 4!'3\YB<8\,>=-:8D$"NBR1(KG;1;*?%.O%/B5K4!W>S6(CP RLB?'9Q;
MG;X3G'0&.7>5!;5'%7BO)21!Z]56U!0B-\UG&;GJ\[5,H\3#.5%&VGFE1'FW
MFB1UMQM%]2 P0[?A0(CX><RL!Z'AMES.('*M(A3BBJ:/.M_NFK)=&>YZJJJJ
M>O&I4M",BX3*:+D\_D<9D\:FN;-D%RJ-Y)7 ?9R4D !P6B:NCH'VT,1Z$G5.
MJ=: 3-4BY_.:9GX>2C2L5IY9(,H)]3=<FQ>TJ>U;-D"KS(3]$6@(!/&V1RWC
M3:]&P&<@RM4SCI/:A+12>2)&D.H\XP9@I(ZV+B%VC$E6R]?2@)/(X:+,\D83
M9&<IC'1QF,D:\[CI1*I'->=;*PDB$/).'%0_-0&P'<G%PV/;?SDB+ 'FC(<3
MXM*2WX ')!525$Z"B7^54'#FR8)C'GEI&089QC2B+TQYP6FFE-4$>X1JB!=2
M1$Y4J2A('(8:5L7#0#>+@T)+92*RK9$^/1+T!ZT H!0"@% * 4 H!0"@% *
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M1C,C"RTLY[FEY2?JN*DNI9PXD Q0'7/@KI HMD2?NC^*T%3:]4@H!0"@% *
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MHFO;[+Y"9HH>BJJ@*W_"FN5-/#,.*K7B2U8F0H!0"@/"3"AS./U;#;_"ZAW
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MLG1/Z*&1V:CL,*JLMBWRZEQ2UU7U5?FOXU0>M * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H# RV:Q>#C+-R\MJ%$14'OO
M$@!R+HB77XK\$HDVZ($$ODK1T5$_F""BKZ(KOK_<K;Y4^3,=2)?#['A<^PY(
MPL]B>TR?;>*.:.<#LA6*W5%LMZU24HNC5#,AR\G^/&S)M[;,.VX!JT8'.8%0
M-%X\30C3B5^G$K+6:M7'^%F#E'F3#&R8*3E7\&SDHKF:C#W)&,%X%EMAT]Y,
MWYH/N3W<;=:P2E2M,#+ 938\)A7XL7*Y*+!DSC[<%F2\#3D@TLBBT!*BF2<D
MZ#?UJ)2=:*M!@LR/V/?=0U$F@V7-0\6Z^B$RS)<072!55.?!+D@714YJG'\:
MSC;G+)5#:7$RI&WZO#QT?,2\S!9P\NWTN2<D-#$=Y7MP>4N"WMT]U8QC)NB6
M(=$JGC"W?4\ACY>5A9N"_CH"7GR&Y $$>][*]U]B63]ZU5PFG1K,)H]3V_60
MQ ; 68A#@G%06\HK[:1"4EXH@O<N"W5.*67JO2IIG6B56*JE29:=%X$<!;BO
M5%^:5$P=ZH% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * ZF2C:WQH"E9[RGK.#RGZ"RLG-[$/5
MS#86.<^4V/S<0/8W^QPT6NF&WG)5^E<W@<%W?6[<M&,I<HJK[>"[:$>]YAQV
M/07M@UO8<'CKIW,C-QI%&;1?BX4<W2%/Q4:S_2MX1E%OE4UOU",<9PG%<W'[
M*]Y=\5EX&;AL9+%2F9N-DCS8EQC1UHQ5/@0JJ?MKEE%Q=&J,]"%R,TI1::)"
ML3,4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#@B0>JU&P<(8JMDI4':J!0"@%
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MG=<+T>3P$LC6WC_[@<[K?V]8/>\KA'-AC8@W,-EY@S6XSXDRZ+48N#C9JXI
M8(2HM^E^O6NF]M(O<.*=*XHBEAB?0&0V?8?Y4A;'K&O_ *U,FL,2UQ9S6H)
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M>SNP9*9E$%CN@V])DRD$5(WGB0455+D1$M=5CZ7UGP_[DBH;M16"48TZB?\
MMNTG/:QXEP&B^0->;BY/6'R>BO+(C3XSKI277FWF"9(N!-\^/NLJ+^VN@^9,
M'QAJV[>"EV+3(FOO[/H\O(R<QJF1QKL<)31S2Y'!FMR#:XH))<7PY"J+UMZ5
M"YD5@='\FZ?B\Z]!QO?VKR7G#S.YYG&S(P,X* ^:"K$57S GWVF+BABB)S52
M1>B7%)#QWINZ>)O)NR8K4]>)_P %[$ZQD(9I.C"6+R3C8#)-EEQSF4=RUR3\
MU_2_QI"1\G>-=JC^4M=\X^-68V1V;%QG,1GM:E/I$3)XUU5_P+Y(H@^W=5'N
M>U;)\NHA8SVWR9FLQB&<3J$W!X&,IS-AG9-V$4EU&6B4($1@'3Y$\YQ17U(1
M 47YU"FN?$7CG;-6\.[7K.QZ<T>V2)67?Q3:/P)"R$RIN*V*/H:B"M*7OYJG
MX7]*%,71M W]O0O&'BO;=6DQL!KJJ]M.0B9.,"J[&1PH?8*.^CI!W'!<<4.J
M<42J0]M?T?RCXUWOR27C?!B6H;.TQDL'*R609?5,Y%93O=Q'GB>[4E$4.X5R
M$K*O2H#E[QWF9GE /+6NZ4]JSXX&? V3"I)B,NYK*3@1MIL4:<5I1955,I)J
MG/I9+I0''B72M]T/0]+UYWQO$:WS#/+&E;0[+QYM1XDI\_J9')ESO/*C!\4;
MMU*WRH#Z:JF(H!0"@% * ZD2#Z__  6J,'"G:W3ULB_A>I4M!S5/W5M\Z.0H
M0FS:UC-LQ9XO) ? 7&Y$65'<5F3&E,KR;?8='J#K:]1)/V+=%5*SC)Q=3&4:
MJA3(NF^1L9CI6N0,S@YN'FG(.7+GXQY)CBSB(WB=!A\&7#)3)26P\ODE;7.#
M=6GWFI0DE1/W$]H^A0=* G"DN97-OLLQ7\F^@@J1HH\68[#0>QEAM%7BV'QZ
MDI+UK7<NMM<C9""767'FG]"^GXUA4R..XET2WN7X?LI4'=%NEZH% * 4 H!0
M"@% * 4 H"H^0-3D[/C8SN(D#"V?#R!R."FN(I-A*;115MU$ZJTZ!$VXGR6_
MPKHL75!^)5B\&<6[V[NQ6ETG%UB^GIZ&L&:35V-.FGC2#]$V)I?\<U3*/(U(
M:)?C%<=) DL*O^#,%OQ]4KKG;E%5^J/YE\^3/E)V=4M,?#+C;D\5_+7ZH\F=
MY,)S&LK)R[L?$0@_/*GOM1VA3\+ER)?P 56M:BY.B3;Z##]/.*K*D%SDTE]Y
M8M$UES;LEC,NC+T;1\1(3)0CE-E'>S&3;%19?[)HA-Q8]U5GE8C)>2UE<EY*
M<<YM4_E7VOB>MLMHKCC)?VXO5RURX.CQ48\.+>)O,$5$ZV_HKSCZ4[4 H!0"
M@% * 4 H"O;Y_P!1MF_Z)G_\F<JK,CR/B7P!HL[R)D<KKBY=_$ZR46.]L 0U
M0),MH#7M,":HO$>5R+^CHM=$W0Y;:K5'MYCT6-X*WC#S=&G26$..F1ADX2*\
MRXRXHD"F*#S OD2?-%I%ZEB6:4'5&Q_.WFC8I3.!T?475QN0S<"%*S$E@E%X
M2R0BK49L_4$7ER,DZJBHG3K?"$$9W)/)%R3[4= 36OH%.46VJUR_F19+O>25
MQORX7X]OE^[:_']Z_6L?,9EY:[2M?;=Y5V-_.RO%>Y2"FRH0O)BICZJ;Z'#)
M1>CF2W4A1$4@)>J(EOE:W(K!HEN3Q3+D_P""/%L#(Y;:/(TH<Y+RDM^0S)S<
MM66(S+A*HLMW<%%XHMN2K^Q$K'4WD9:$G5F@M'R432/N B8KQYE/J-0R&5:Q
MXHT[W8S\.5:XK\#5M5]I^MQK;)5CCF:8NDL,BQYG8,C]PGF9G1')ST/Q]"D2
M$2)&-01YF"B]QTU3HINDG$+HJ B_.]8I*$:F3>N5.!=O,?@#2<)H>0V71,<N
M#SN$CD^2Q''523&1+/-NH1+>X*2\OZ%J1DVZ,LH)*J*M]GT*'*D;C&D, [%=
M9@\VB%.)(A.*ET_;65UY&-E9GUQW42W3U]*YZX5.D[ 7-+VM5!VH!0"@% 4+
MS5_V3;I_T1+_ /1K6ZQ_<CUHZ=K_ '8]9^<&HZY(V_9\3J\1X(TK+R6XC+[J
M*K8&XMD4D&ZV_97TER>B+ER/L;MQ6X.1GX32I.<=VIIB:RU_*D"3DY*FA*C[
M<1X&"%OBBV4E-%3ETK"5U1473ZC5/<J*B^;H6-OQ/ Q\;&CN>Y8W5\WEV&Y<
M+$2F9,EQN.^EVCEN, 01T-.OO6Z(O6W6M3W$FWIBY)9O[.9H>\;;T1;2,C#^
M!-SR\S;<3SC1\]J8L$>.,B)9RRP<<9&*8IQ)7!;NW?\ -=/QM);N"47PE[A+
M?02B^$BOXGQKGL[@,-F<2H296=S3FO0L990>^I::!U3(BL(A8^JJO3JJUME?
MC%M/@JFU[N*DT\DJD^GAR)/ERL!K6Z8G.[K#%TCP$9N2WWS815=:BRG&T:><
M%!7HBI?X5I_4M+5*+C'G]II_7-4<HTB^)YX?Q SD\/K60E[=C,5E-N[HX+$S
M&I?-UUJ047@;K;1M@JN)Q3DOQK*>ZTM^%M1S8GO7&36G!=7VD$_C-MTW"RY@
MY9_%.1\S(P<[&1GW63&7#;$W#+MJ@$B<N"=;_P!%;$X3DE2N%>\W:[=R235<
M*U)N%$VYYZ+]=O$R'!?P:[&[*[\U[M1T<)KM< *Y.<D^'MZ^M:VX).D4\:<#
MGE<MI54>-.! YK9,M"=:#"[QDLRT8JKC@G-B\#O9!XNG<KI\4K9&$7G!+N.B
MU"$DVXI$EM0;_JDO'Q)FT39"SVA)76)LE09DH7!^,:J2?Q6#]KB)Z+6%MVYI
MTBL.@PM.U--Z<NA9<SK+E[!B-IRNM9[>I\)O%O/1BR#3DV2#CK)\;"V)H:(7
MJBK2.F45)06/4-,7!2C!/N)G+XO8\;LCNIQ?(<R;F(J2UFHA9!AEL8<4Y2J)
MN%[^:!Q3IZ^O2M<91<=6C#L-4)1<=3AAAP16L3D]RRV+R.53:YL=G'.0VG1>
MF2>J3G%;0KH2H@AQN5_Z*W2C!-+2L>@W3\J+2TK'J-Q?;3DLVOFM[#SM@?S4
M.+!G"+JR7GXSJAV[&*.$O]'2N'>1B[2:5,3A]0A%64TJ.I]P#T%$KQUD?.'-
M4"@% ?+/WUJB^-, OP'.-7_R9^O8]+^N75\S5<R/I7"R&',+CG0<$VSBL&!B
MMQ(2;%45%3U1?A7D2S-AIC[I_)N+TWQWD=88D=W;MK87&XO&,+RD*U(7MNNJ
M*75!0541_M$MD^-NS967.ZI?AB261J'=/'V3\;?9D[A,T!-9N5.BY/(QU3_
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M=;>O2O2W]V4+BIE3#!&J$:KI/H71?$/C[Q[E)N:U. Y%R>2:[,R2_+DRW'0
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M^"W)<E.OC)!&Q5+*R;HB0H@]4Z(O6LE>N:M2CDJ?(QT*E*])><1IHXO<<YN
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MF2V0"KR*V?,G151M8?AZ4"9A[]I>TYW9=:S.$B,!"PT2/];%66+9N$Q-CO\
MTS3OY@)!;)4=]%1%!>A+0)E_\@XO*[+I6:P>NY(<9FIT8FHDKFH\2NBJ*D/4
M4,44%).J(5ZI$5#:-;RN:\<[#A,+KS&$R^02(D:&$UE4,F"94C4Q]@\4!13X
ME;KZU"GKF=3RV;UG 8IAH\1E\?-.9&RK$B.CV.D +Q-/JVV@M/ 9DB.L"G%0
M)4^%4AA9W1\QDO%./P18Z$>YQ3C$3<>1VXS1+.;?E*RXYU0# 2LB];+QJ%KB
M9&_:ADYVR:9+UN T]A,$UD&YT<7V&DXR@9%H$%[DBBB@JJJ=1_=ZT83/#9M0
MV2?Y8QFWP66G,!!7'I( 90L/ODW]4!F!)[D1I'Q(VB]KR=.BB-!7 W!5,10"
M@% %5$]: X0A7JBT6(>!7M[78$TS/KJ:7V?].E_HZ);E]7V2[7'ETY<K<;]+
MUG;IJ6K*N)A<KI=,SYV\59#3(?D?3(FG06I>1R&,D-;5.EN9;]?AY%J.3L@I
M[;R_3_Q'10/<E^2KP]MJ[;ZEHDWDGAE3L.6TXJ22SX\^TPM++%CY]SQ9DL6F
M37:IXP?KRR_ZRK:MHC/TR-?XGVKWX]SX7_"LI_VE3*G10L'XW7.OM0S-P_D=
M=DW_ /SQ+D$W/ON?R$+*S45<7V!^A_24C>Q7^_R[OQ[GYNEZQMU48Z*:>/SK
MT"=*RU9\#+\E8C><[K/B+&Y;%AG-O6%.D9?$9!V2PQ)EQL3W5;?<B$!(^I)8
M/<@]WUZ4MN$93:R^\KU.,*]O<<RE>3PGXQ3,9/)9;QZLIM=\G-A*:FI"5'N#
M#XBJO)&8?XL/=>7 $ZT33NRHDG^$B34(U=5Q/72LG ?\>>9,7JV.B1]>QT.8
M>&R.$/(.1Y928#Q?PUF$JHXUQ 31BP\EZ5C.+UPU/'IH526B6G*G S?)$G.[
M!HNB^,,%$RDJ=FL7%R.>/%$#,UG'P8[?'^+(( $G)1-(MSY6$NG6K945.4W3
M/"N7N)>U2C&,:]GWX&TO$FU9/;-'QDW/,NQ-F@H>+V&*^*B89*"O:?O=$1>:
MHCB*-TL7K7+>BHRPR>1T6Y-Q5<R]\A^=::FP(0JMD6J#F@% * 4!Q=+VOUH#
MFZ4!Q=*E0<U0<+9>GSH"+S>LZ[LL=(FPXN+E(Z?D"8R#W%5_L\T517I\*V6[
MDH.L70TW;-NZJ3BI+I52$Q7BKQOA)0S<;K&/9E@MVWB8%TP5/B"N<N*_ZFML
M]U=DJ.3.>WL-O;>J-N*:Z$6Y!!%Y(GN7XURY'<=JH%*@72@.+I\Z YH!0"@%
M * KV^?]1MF_Z)G_ /)G*JS(\CY<^S;_ *P;+_T=%_\ 2E6Z]D<]GB>7WD?]
M:-=O_P UO_\ IEJVLA>X%3\JP)6M;WINV3FU_2LAC<#.8=LJBJ06&&W@_P!4
M* A6^2I5CE03PDGU'W7^HP5@IDTD-_IW9^J^JY)VNQP[G<Y>G'CUO7-0Z3X4
M\;Y2<?D?</*&(C*]#U^+F<TB<54%.4CC<<%X_P!I3YJG]D5KHEDD<L?J;)WP
M;JS'FS=<OL/DN>YG3Q;;4@<=)<)0?<?(D1>"+T9;XV0 1$NJ7Z=%DWI6!E!:
MG5D=-CXV%]TD.%B&68^.B[%"89CQ1%MEOAP$A$01$2RW1;?&LOPF/XS,\413
M\;_<<6 V%4BF;TV"TZYT%SZQ%<C$*K\'?:@K\UK&3K$L?#.A],^<M@AZYXJV
M25+,1<EQ#Q\5LELKLB6BM" W]5ZJ7[$6M4%5FZ;HF?.?VQY1_ XGR!E8J(4B
M)#ADURZISY."BK^"*MUKD]4W,MOMY7(JKBL#I]*VZW&XC;DZ*31:6MOV>+-_
M50RL@IB+S+N.$31V]1(%]O%?E:OQ>UZONXW/,\R3?7AW'Z_/TK:RAY?EQIU8
MKM/IG#RUGXN'-4.V4AEMTFUZJ*N"A*G]%Z_:[%SS+<9TIJ2?>C\>NP\N<H5K
MI;7<9U;C6* 4 H"A>:O^R;=/^B)?_HUK;9_N1ZT=.U_NQZS\]O%>6QV!\CZM
MFLO(&+BX&1CR)<DT)1;: KD2H**O1/DE?17XMVVER/K-U%RM-+.A?\?Y>F9B
M#Y$Q&T92&..R&'FLX-&8$:*;\PI39M"CD9@#7D"$MG"LOQZUQO:Z7!Q3P:XU
M.&6U<5!Q6-57'K/+;6=*\MY6/O#FZ8_69,F'#8V#$Y1J3]1'>B,!',HB,-."
M\!""$*<A6_1;5E!SLK1I<J9-=_8+;N68N&EM/++WF?G/*V"FXW>I6O37,?.:
M/58^G*\A),=;UXG 61<4XB?5#5"7T6W7K6,=O).*:_-7M)#;33BI<=5>VA8'
M/,6@XIC2-PPXVR_\PRL]M>NLB5XKL^$D.43'-$%1)1)YM$/U*W3X8?IYO5%Y
M423ZG7[C1^ENMRB^"HOD5#5L9XZ\>[7&\A?SS#SF(Q#ISL/AH+,H,O+=&_99
M>!UH6V;*J=PU-4LBV]:W3E<N1T:&F\WP^\Z+DKMV/EZ:/CE3L+)JWE[7L7B=
M PLR9%;:.-F&LWD1A@_.PDZ?,==C2H[KC9$/;YH2BVJIQOTY(E:9[:3<GRI3
MIH:KNVG*4Y)<L.>&1KD=Q?US3Y>*QF7C3LX>Q29,E\F F)(CI& !DBLIH^CA
M\EOT+YUT^6IS3:PTG8K.JXFUAI)R-N<.?FHF07,0HN6<TY<84R2R+<5O)=PO
MX1MBR3:7#_Z7QZ_.L)6VHTHZ:O<:)69*-*?B(6+.A,;CCM@W/,8S,Q,0P<YN
M-B@!L)+T15./$5&H[0H3KJCR(A7V7^2)6;CX'&":KS^\WM-P<8)JOSX]?(Z3
M-IU7/:QD,<L61C<I#G#GX+TR:L]9$A\Q:FL"O9;X*X/!ZZ^JM6^*5=$XR3SP
MI]A%8E"2:=4\.728'DB' F[#G=FQV<QV0B9">Z_'CQG7"DJV^:D)*!M!:R?F
MZ]*SL-J*C1Y&S;S>E0:=:$U(VG#AYDR>TQ9S:XLOK7(DX@4VB,\>XVU[#%;W
M<5!L0V^?2M:@W946O:IKC:?D*-.*^*(O^>)F8T?8\1G)4?ZMYW&N0&&HD>,;
MBL.N=Q;QV@N@B7H2UGY2C.+2YU,_(TSBTN9>OM%_[7P_Z+F__8ZT;_\ M]IH
M]5_M=I]^CZ5X2/ECF@% <+Z+^RC!H'S)XTT3=\R;7D3;,ZD2.#4^%A(9LMPH
MP//MP1<$4CFI$3KB#<B54Y+\*Z[&XG;7@2J8N/,ZR=(UOQ?!A:BOD_;,3!E,
M/%CH:R6'R%B*38&$=Q8A*WQ[H\11?]2G2CO2N-RTQ=,\/O%"P:WXA\8:)N,"
M>ZW*S6^YCZAZ)G,^^YDIRE%$2<43)$ %%"2Q(*+\EK&=^Y.+645P6!4DBQ;@
MFE>08V1\3[$9N.902C2HK2&+H*TT$L'!/BJ)Q10,37VJ7MZ]4K5;=R#4T5T>
M!K?5/%K$3-2O'.:\B;'L^+PT-L7=>=_Q7'A%>#BTS)>:][@*'Y6T<%.EOPKI
MNWG36HI-\3%+@<:%X[U#QUDI?C+5]XV2+FW&W%1@C9*&V^\VW(-QII6%;1U&
MN*W)51$7^U4O7YW$KDHJGMT\RQC3"I,>+M&U/QIN6=U;6,_F)TZ0 9+.0<BC
M3L?ZA^RB_P!X&FR1PA7T$K+\>J5JW%V=R,9227# L50PL3X+UIG?-@V[ ;CG
MX&\LR@+-NP5B1X[A20"0+9QQC(VX!"HJJ?VNOYJV/<2<%%I./#_4QH1K/AO"
M;)FLOY+\8[/G]%R4Y]]K.,PXZ@U+DL'_ !B&,]QZJXA7]1YWXHE9N_*,5":4
MJ9!*N*-C>),;K8X^?E<)G<AM$^6;;>5V#+&3C[KK3:$C((H@#8M=Q45L 3B2
MJA7)%KFO5;HTH]"]L3)&R:U 4 H!0"@.IWMT]?QK&614:&\5SM*AZ.UB-[2&
MSO;62=9V2+E! LD]EW9Q$T[8D5QWFI-&RX%QXVLJ(*V[MRI.=8?2UA3*E#5;
M=(XYD2YL\^-Y*P_EQY '3<SDGM,#()*$Q/&FJMQ3[*BG;1)K+CA&I?E/T1*V
M*"=MV_Q):J=/'W$=5*O88&28DX#&^0=TU(%RFNY'(9W&[Q@(]GDXIR;:R,5O
MT1QGDB/BG1UOW?F&]9IJ6F#P:2<7\G\C&C57P+'JYX7"^0IB;RD6/'E:[A!T
MN9/0!AC#CQU2<RPX[_#!SO*AF'0B%17T2M,]3MK1P;U=? R5%+'L([=9>K.[
MEI3NLR\'C,:_KN=^@D92.*XX6#<9X?PR5M$ B0U'X*E[(M9VXR4)*6>I$;\2
MIE0BO($0<_M,C':O#Q^7=E>.VV_HT9_B.PEF^Y8(+QXOBTJN1A+X\:SL2I!-
MNGC^6%?F8S56\,T?0>E9G"9S5\3/UN8N0PI16@BRG"4GE%L$&SU[*CJ6LXA(
MBH5[UYUQ2C-J69T)8%@K$"@% * 4 H"-RN PV<:"/F<?%R,=LNX#,QD'P$T2
MR$@FBHBV6UZC2>9G"Y.VZP;B^AT^!$+XU\>DMSU/#$OHJKCXU_\ Q*FF/)=Q
MT?K=Q_W)_P"Z7V@?&WCT%NWJF'%?15_3XW^TIICR7<'O=P__ ))_[I?:23.L
M8"/C',+&QD2/AWE)7H## -1S4E1550!$2ZJB54DC1.Y.;K)MOI,+_-_I7_,,
M+_S(TH85'^;_ $K_ )AA?^9&E!4K.]X'7-3UN=L6/U/'3V\6P]-FLNV8_P 7
MC-&Z2 J =S)101Z6Z]:4*F5^!-U0]@@:KD]+Q[67GPV<FT;+K/96')<,&U'N
MH!D8\%5P4'HG5+I4*8 [GXN<QV/G-::A/S(F7F2(!-, _#+ @I2&'TY*B.DH
MKVQ^*=5LE7 F)E:QLGC;:<SB<)$TT&'\JDOB^X#!L L*/&E*B&V2H=PE-I[?
MRGR%?RT&)*:4YHF\Q)\K'ZE$C)"[P*+JL.$CS#SK"@X+:J3:J32D-TZBMZ!U
M14(&^>/YF*AY8=,A.-E@)VQY*,QU=CC <;;5D5<; 34NY?ER2W%?PH7$M29+
MQBU'UU^=K<1E-FR/Z3C2:1B0WWB$E R,%MP(D1OIU0U1%2F!,3$>R^EMX<<T
MWH+;L9<N[@'!18PD$MN8D)OU7J+CB^J?E%+K0=IU:VG0(6PAA#TYJ)GXV;Q^
M$5I%84VY,^-]6#PJ*]0;1+$J=;^E,!B;MJF(H!0"@-9[IN&X'ND'QYH;6.:S
MCV+=ST_)9A'W(K4)M\8P TTPHDXX;A=5Y(@#\U5*WPA'1KEE6F!HG*6K3'.E
M2,\F>4LUXUU?!E+8QLC=<D9E(B*\;&/5B TLB>XT3R@7M;2S0DO(C(4LM+5I
M7&^2^?464]"7-G7R%YBDZN[I.5PD <OJ6Q1Y65RT@$-9;.(BLLOK)C@*V)0!
M[N&"HJJ(K:U90V^O4FZ-?$D[J236*9'_ .>+-S]?^JP$7'R\UF-M?U+7)!N.
M)CC::4B:F2#!5(T[0*7$%]RV0:R>W5<:T4:LP\ZJJN+H9N[;MY'\?:/#R.:+
M"RMCF9J)B@D1HT]R"D.82B+Q1@4GR=&RW;:4K_"]86[<)S=,J&4Y2A''.OM@
M0VV^7]EU;4]0S3TC$-R<Y+FLS\K*QV6;@QFHK#KW<&&J#,%50.)*0VZ\OR]:
MV6["DVE7#I7QR,+EYQ2;IU\OF7[4]UFY'Q='\@[/BRQLE<<]E,ACVE)Q59CB
M9H;2&O*SH CH"75$)$7K6BY!*YH3-L)-PU-&'XWS/DS9V<?L^Q-X2-JF=A!/
MA08"RCR$8) BY'%QXU5IV[9)W%01L7Y;I2ZK<7IC6J="VW.2JZ49 >%O)>T^
M1G7GLRF/C0D:D&S!@X_)L.LJS*)@;RY*+%=14&]F25;K^"UGN+,89>WS,+-Q
MR_T^97].\_YG86=;@9?%1<?LF:S4:,[%17%8D82:DE&YL52)24A./V7455XE
MZ^J5NGM4JXU27<^3-<-Q5I<6_<6]O9_)I>6RT5T<!_+PPASBOBW-^N7&G***
M+5U<[??11NI<>/X5H<(>5KQKD;5*7F:<*9F#I?DS:]G\D9G6)*XYC!XK*9'%
MBP&/R9RW&H(HH.+-1%AB1*ON B0O@B75*SG:C"*>-6D\U\"1G*4FN'5\R,U/
MS3MF<\KRM%6#CY./CY3*P'V(S,QN=%@XQ>#<UY]Q5CF!GQ;(&_<A$E93L1C;
MU="]YKA>;GIPS?N-]BO)+UQG8<T H!0&L]BWF-JGDYF+G<D[%UY_!J\$86G'
MP*9]6H\^+(&2+P2UUZ5IE.DC)*J(IG?OY@VG:EUW+//86#K!28X*VXP+4X3=
MNX(O !<K(/7TJ:ZMTY&5*(YB['M.>Q^C:GC,D<+*9O#CELYG5 '9(QFFP$D9
M$DX]UQP[<E3VIUM5JW1<R$IIN2QS6Q/8K&>0%V2(;#E\3.-J1.;DM*G(P>;%
MM>"(B\@(5M64<Z5(R!TOR_@F]#CM;'FWW-H%J6,ATXLEP^XCSO;][;*@MAX^
MBUA&XM/25Q,K6=CS\M/$R2LB\[^M1LBYEE)1_P 9)F+W 5RR?NEU2UJJD_#T
MD9L+=-B;U36,IGW$Y%#8(F&TZJY(.P,MHG]\9"-9S=%4BS*GXPR6SPIV3TS=
MIIS\_%:C96-+>1!)R)-!.X \41%1AY";O^RL85R960/B[>]@^J;Q6Y25DQ<_
M)GEK&4-4NKD1]QMR$ZJ(B(:('-J_YAZ>M8PD^/$LD1T/.;/G-4\9L'GIT27L
M$Z6QD\A&)L9+@-=]12Y 0].")^6L:MI8YEXLMT67L>E;AA=<RF9>S^O;']0S
M$?F@ SHDN*WW;*XT(HXVX-TZC<5K95II<S',ID+9<E(RKK&W;IDM/W8IQMQL
M;)BMCA.QW5%EMOF'!T3"W\0G4*Z_UX:N;HS+L-^!U%+^M;T:SM5 H!0"@,'-
M8QO-8?(89YPFFLC&>B..A;D(OMDVI)?I=$+I0&N/%'@W#^)Y^0GXS+2LB>08
M;CN!*%L4$6B4D5.")U6]93EJ,(QTG7RMX)P_E?)0,ED\M*QYP(QQ0;C V0D+
MA\U)>:*MZJFT24%(LV<\9ZOL^H0M,V*/]?CH,=F/&?7^'(;..VC8NMF/4#LG
M6W3X+TK%-IU,VDU1FM/^[3(3'KK8^1,^FEJMOT'D';[7*_;YW_+^'&WX5GKZ
M#7Y?2Z&TM1\=:EI&OEK.!QX!C'A))B/?Q7)*N#Q)7R+\ZJBV^5NB(E8-MNIG
M&*2HC5W_ '4M.BYL\M@L]F<(P2DHQ8$@6R; _P S8/<5- ^2+>L_,9AY2KA@
M3<;[;O'N,S&NYW"#*Q^3U^2U+[R/*\LTFCYK]3W+\B5?WQXTULOEQS+!Y%\7
M:'Y)*-"V5M&\TT!E FQ7$8R -B2<N"]5($)4NBBJ(J_"]8J361DXIYFIO(/A
M76=3TS+[3MNS9G9?TB"Z&$AY.5R8:DNBK3/$$ZDJ&0JB7^%9*3>1@XI9U9@_
M:)K+SV"VG-9!CGC,H;..81Q+@\D<35_I\D4T&_SO\JFXC&:<)*J>:&WE*#UQ
M='P9M]CPOK#,\91/R78@%R&"X:*WT6_$B1$)1_"]?'V_VOM(7-=9-?EX'UUS
M]R[J5O3X4_S4Q^PV,V"- +8]!%$1$3HEDKZQ*B/ECM5 H!0"@(S8,% V;#3L
M!EA5S%Y)DXTQH24%)IQ+$B$*HJ73XI1-IU1E&3BTUFC5'_=3\*_\RR/\NE?\
M)77^KN\_@>A_D;_/W'/_ '4_"O\ S+(_RZ5_PE/U=WG\!_DK_/W#_NI^%?\
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M:_C(V&PT5N%BX0(U$BLCQ!L$^"?M6ZJJ]57JM8&U&?0"@% * 4 H!0"@% *
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MR\KW47ZEHT+B'"]^MQZ$EAX]*QH95.,CA<NYE)$V(7\"1,B$^R1V18\= 57
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 LE * 4 H!:@%DH!9* 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% <73YT!S0"@% * 4 H!0"@% <73YI0"Z?.@
M'(?FE <T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@<P^=4E1W ^="G:@% * 4 H!0"@% * 4 H!0"@% * 4!U(Q'\RV^- <=UO\
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M962Z\JH2&)+P<(>GX5HN)-5/9],N2A>E:=:.*:SX9YUYKB?3J*B^E<Y]*<T
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M(@MR]43K04/7&[=K&8-6\5F(<PT<['!A]MPNZE_99%O?VET_!?E0$S5(* 4
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M7=>C0T-VJJ2]YOL>H5E2>1]C?SQJ?QSD#\/\8#_3KY73+DSV=<>8_GC4T_\
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MBP##JVO>YL);XK6MJJ9VV;T(7[<U)9M/&/XNI)Y]!]V@ED5/E7$?<G:@% *
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M2R=$Z5YJ.MGH:*HJB>OPK(AIP?%$C->2<QN6U"!X5EYMS%1$/GWNRV*";J?
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M6T:FNFVET;;$3101;+8"K&&"53U/5K$I77*";3@X-\*UJE7BZ_(OQZOA-?\
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M"^;1.*G'N+=.G50/M?6X3N,U[$XR0B#(A0XT9T!+D@FRT($B+\;*E R4H04
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M9Q@9;Q;I>*P.&:V?<7LWWMHU]N1GH RA:PLPV6I[[Y(HR>X)V^E46B-!3XU
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M+GV.9= < UY-7Z%?C\D7X?\ </H\=U"556,OJIPY21]7Z3ZA*S)23I*+[_\
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MML5[B*B!VA$53K:]U6M_GR_.NYFORX\O>>;7C* TY'>#7LSWXSC3S#GZO$Y
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M4 0 3T%*M0. ?V4^=0#@'5+=%]: < _LI0'"--IZ"GRH#LB(B63TH#F@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MBY/)&FT^[7PV272;.]+_ /$7:RTL\?\ S6U_-[F>L7[J_$TXR;@NY.4X"*9
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M9J7-1$;E:M.^\F=VMB+TTQHC.PYJ/]1XUP-M(MT1?G7G'4<T H!0"@% * 4
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M=HV*VQS5/(.*8=PN0E/3])S;ZFPC9S"5V3C2?;(" A<4G&1(K&)=/<EJ]_\
M47I6_,LR\224X]64J=*P?4?/?I[,+OEW8K2VY0;Z<7&O.N*^XV]KNGZKJ, \
M7KF+8QT)PE-]MH>KI*EE)PBN1K;I<U6O'O;B=Z6J<G)_#[#VK.WMV5IA%17M
MWFMMTTCPOI@IFI&JQ9><E/<L/@H_<,IT\OR U#0NVO6W(NWQ%.JUZ6WW6ZO^
M!3>GC+DOYL_>>;N=MM+"UN"<JX1YRZ%E[B[>-=;G:UKG:S*B>QY.0]E<X;?^
M"^NF%S,&[=.#:<6AMTL-<>[OQNW/#]$4HQZE\^+ZSMV=AVK?B^J3<I=;^2R7
M0BX5QG8* 4 H!0"@/FG[@-CS&J^1L%E\(_V90XI0<;7JT\W]2:J#@^BBO]:>
MJ5S[C;V[\'"XJQ?M5<4^H\^_=G:N*4,Z&L_/V2R>Z:KIV[0H1#K;7U4><YZK
M%R+AB*MG9$]BH'L.UE_;6[]N[-;.%RTYZW*6I5I73TI455T+%9XU,=[>=Y0G
M2B2:?0_L-M^&\1A\[]MD;&;!,_3\,X4ER9,0A#M@Q-5Z_(T5$Z@B5Z&ZFXWV
MU[8&W;I>0JG=W.^$MCW/*9AG)2H&1VC%OZY,F*P['@2@D\01T'' X]VR((GZ
M*EKUS*[)12Y.HC=M2DVGGAUEFV/6\=I^A96'N>VY*;IQ8U,.L<V8PN,MD@M-
MDUV&A(G$1+>ZZ>JK5\[Q:DE6ILFHP@]3=*'I'\<8?)XQ[8LKLF0S;,S7Y&)@
MS748:2-BY[2*Z;8,- A.$(CU._I\ZOG/"B2QKVE\M/%NN'N.FHZII6=Q,C/:
M#EY$''Y/$K@,DL, 95XHP=L)#C:@BA*;%2XG;JA>GI6+NR>:K1U+!0DM47FC
M'UW2?$L3%X;R%J7# P<*+_++ G8*1& #BOMR.YZH2I>]N7-$5.M66XG)-2Q3
M)!0HI+"A5<-D?&.=SC3&5W',964Y"FX77I>981A&V\F/;=X2D8;5]PAL@*ZJ
M_LO5\YI8)+)]QIA.W)K%XX*IGYA_QAJ&63!L9G)8C/8O"CK61=QT4S^HB*P@
ML&[VVU#O-7YMN)94553JG2L7=;Q?.OMUF3G;A+35UH=L7BO"6MX? ^0]=9>P
M;&#FC #)QXS@291*RK1L2&S%2,'$7D1(B>Y+I5GN)RJI.M20C9A%22TTP-AZ
M]Y<T;9<HSAL=DC#)/W^GCRV'8JNV]4;5T115_"]ZT\#=&]&4J)EZ147T6]#>
M<T H!0"@% * 4!Y?31^ZCRMBKR(HBZJ>]!7U1"]42I0'H@H*63THE0'-4'"H
MBI9?2@*ON'C_ %7>3Q);+ 28N%E).QZ\S#@\/SX*G(5LEQ7Y5OM7[EJNATU*
MC,)04LRT)>R7]?C6A&9S0"@% * 4 H!0"@% 4>7YA\:0-W:\;S=BC1]X?,&F
M<*ZC@OF;P<VT15#BO(>J>ZA:&%#\H^,-^SV4\<8+9X\[9XPOLY#'PT)QYE(Q
MH#RJ1MDW["]JJMTOTJ9.H*SL7@G/9C-Q<MCMX+',8PB<Q,4\1!D*R3K?;<5P
M_P"&CW+K;N O'X?.N^WN(1@XN%:YXLYY6FW6M#+VKP!B=O@8>+E<W*65CI#3
M\J0VTPRD@$1$? 08%KM]VW15(^'R6L;.ZE:;:2Q]EW&<K:DD=MU\(R]H@GB<
M=M3F+P\EOA/C.8Z'*<=5"0A4'A%@VK6_<7K4L;A6Y:G&K73[5).W7!.AKE?L
MT87_ /;9_P#9]#__ '5>E_EG^1>W8<[VJ?$NFAS]+A;\_P".9V]!L'DW!C]4
M_C&<>QC4;B]L.(JC3"@1")H1<7N77JE>1<N*3\*HNMLZXQIGB;BR^6Q^ Q,O
M-9=Y(V,Q[)R9D@D(A;9:'D9J@HJV%$NO2M)D1>D[UJGD7!CLNF9-O+X,W7&&
MYK(N""N,K8TLX(+T7\* L5 * TK]TB+_ )L&5+_BPYS#K*^7:^L"]_PO:N[9
M?W.QF$LB^^1LCD<1IF8RF)DNP\E&9Y1I4>$N4=;)7!2XQ!5%=6R^E_Q^%<=J
M*<E7[#-O ^-]<W_R)%\B[GDV-ARC>4GMXH,G*#37)#[Z,M$#2.Q$<O%01)4%
M55>[Z_"O<N68>7%:>?XO:ISIXL^H_N&5M/!>Z*[^5<85N2W]ZD''K\^5J\K:
M5\V-.9O9=M-1U-1P*2+]],=#1V_KR^G"]_Z:U7?KEUL1R1JB5$\08+.F[D<]
M,DYK'9B6^WDWB>E!C\QFF4C.,H^VRK+9DA#P;-?8:(O1:VIWI*B6#7>D8TBB
MR8/PGK&NIB_T7)9B">,BICT5F:0%)A ^4AMB0H@G,6S</@0\31"5.5JPENI7
M$ZT=>CL+H2/=KP[KC+\20F1R92(;V5ELF4@5)7<\*C+4K-I=%O[/[*U?U$FJ
M="_].0T+@>4#PEIL!MB.T].<@ D!)D)V1RC3CQ%DB'*'@G<)O@">U10N \D6
MU'N9MUXX\,JYT&A4H=9OC74<#K$.'DLS/C8#7,D6RA,E2Q'M21=.0JN.*VEV
MT-PRX_,O7TK'S9N3<5C)4]NDKBJ493->\?\ A_94?T_"YC,=]S$"V4)UQ^.^
MN&^N^J9(/J(XJH(^7L/J2HMEO6^5Z]&DFEG[Z&.F+-DYOQQ SN73-.9K+PIQ
M8],-)2#)1EN1%0R<LZ"MFBFJF7O&Q67I:N:%YQ6FBSKEQ,G'B0<'Q/HWZW-D
M8;)S8F=Q\AAV\*4*NXXD@C%;9;%0) ;.,@(H&A<A02]>M9O<7&L<4_?C]I%"
M*>!V9\#Z/%DQW\<Y/A#%/'O,L1Y)(T,G$D1L/J)"5W+N&IW6Q<E54OUK+]5<
M>=./#F1VT26%\0:]@9F"G0IV1)W77<B_C@>?%QOEF#4Y/<3@G)"55MZ6J2OR
MDFGQI[LBJ"3J8LSPGK<YC)M/9/+"YE,NSL9R6Y0B^QE(P\ >CFC7\-4%!%;?
M 42JMQ/#+!:>P:49 >'M<"!E\.L[)'@<R$D9.'*6OT39S?<\ZRV@IP,C574Z
MJ(FJJ(I6/GSJI857'JR&B-&N!UF^&-9R?U?ZG.RDQ,A CX[)=V6MY7T1J[&D
M.J(BJOLF7)LTLB=/:M57YJE.#;7;F30C.C^,X#.8P>?D9K+S\M@$E##?FRA>
M0TG"(.HZ/;%%11 41!XHEK^MZP=QZ7%))2^1=.*?(CHWA?7(LMJ:.2RIO,NY
M62'<DB2=[.BH2S7^&G547V?V5K:]Q-\N'_IR,5;14&?"VQXG969.N9N1CXF/
M;QT+#9))*.FUC\> @3,J*XP2/&0JX D#@)Q)+]4ZYO<J2HUG6O6%"F1O445$
M_P!!/E7$E0VG:J0J_D7_ *A;9_T-/_Y,Y3B<^X_M3ZG\#\UM%BQY6S8H9<),
MI';>;>/$7(3G]M45(@* DO-Y?8/3X]>G6M\LC\RV,%*\JJJ7#GT=I]",QGBQ
M\F!'$\HS*89/<(H17W,GH^/A2B,(T,Y!\QX(1HVVGN'@3H\@M6C,^NBJ*B5<
M%J_-;2KAGW+AB\4:K\MZ^3"8?:,4VT[I&01_':WFA$&961CX\U%'Y306_B=5
M#NJ(DZ@\S%"6ML6>#ZI8^F:IHR3XNG/[>)].?9XG_P"ZN3_TS*3^IIFL)9GT
MGH/_ (_:R1FS_"#7E?,Z3+UV6[Y(W"$;.88.'+=;R&).[9.$9$K*QTLH\NG&
MRVM6!]$7Z=XB\=9+8<=MDW LN;'B6FX^,R"&\#L9ED% 0:X.(@"@JJ61.OQJ
MBI#/?;OX6?QK>(=T^$6/9G%EF6N3_LG&*";HDCG)%-!'FB+8K)R1;4!4,UJ7
MVSZQ(U@'M>A<=MV-"UX\:W(<CEGDN/>16#X-*"AQ0NB#ULGK4*7(_#OAK,%L
M^&<P$*6>8DL2]KA]UXU?E(JR&3DCW/S>[F-_P_"A*D[A/&.BZUL+^V83#-Q-
MBDQVX4G(";QNN1FA &VRYF2*(H H/3I:JB-LQME\?>,_+,7&Y//8N'G6HJJ]
MB<HR9MOM754)6948P<$55.J"=EH4\7_"GBR5J4C1I>L0W]7EO#*DPG$<,W9(
M+='C?(U>)Q/1#5SE;I>U!4C2^W3PF;,V,NF0$CY)F-&R#8]T1?:A*A,HXB.>
MY144+DO4E1%556@)QOQ-XZ;S#V?3 1SR\G'_ *+)DO*X]W<;VT:^F<%PR$F^
M*(G$D_NT%3 PO@KQ'KVNY?4L1J&.CZYGO_DQ 5M71D\5N/,G"(K O4$0O8O4
M;+05/%K[?_#C&$QFN1]1AM8;#RRR6.C KP]N:5OXZD+B&3B(B()F2JB=$LE!
M4V0(H(H*>B)9*$.: +Z+0&E/*>KL[QM</4'Q12?US+/PW"_W.8,B+VC_ *"2
MR_A6ZTZ1KTKYGV'H^[>SVTKZX7;:?3'3/4BO:9Y%R^R^.(.BLO=CR$Y+75Y*
M>K\>.T/\::2?_2V!(>7_ )2U64%&5>&9W^H>F6]OO9;AXV-/FKE)O*/;+A^4
MPM%RF'\=;EYCR2,=O"ZW$CN!%9Z$K4,#0 %5O[BLB7^:WK/0[BBEFV<_K]Z4
M_3MM<FZMZV^MF/(\F^8V_$37GIO)X\L>1_6.Z4L).P.,*0L9!29S[RN^AJ7I
MU].E="LVO-\K&O/IZCX#5.E>DD\KY7W_ #ODSQ]K>E2\?C];W3!EFA67'*0^
MUR8<,D->0\U;4;MB/%"+H2VK%;>"MRE)5<68^9*36G)_>=M/\@^39F8\J>/\
MYFHDC/:;'27B-C:@ V*@0*=G(J&@*JBB6]WM55_-5N;>VE":6$LT6-R3JN**
M_P"']ZW#7O!^0\Q[3L)9O%M#D9+F#<B@+[DYR4K8*LWFI(*FJ)Q1NPBO3TK+
M<682O*W%4>&/8+<I*-6ZD]K7D#S3,S>J27,3D<IB,VXVFQQ7L,&-@XYB4@DC
MT27WC<<%GDO^%OS%+^U5K7.S949+!-98Y]G291G/#["L^(L5N,CSUY7;@[''
MA/QI\1S+N?IH/),:YFJ "$\G9]MQY7+Y_"M^X<%8A55PYFJ"EYCQ]JLL<3S+
ML&#WWR\FTK'>UW1834J##@,HRZ\1JG:[CQ<C(U0A;55]J>J):M3VJE"%,Y&Q
M7'J9@9+R=Y@POB?&>=7\C!F8V2;4J?IJ01;CM8Z4\K+:-S$-7E<'V$I%TN7I
M9.N2L6Y7';54^=2.Y+3JKFS/V/R;Y0S'E+6M.\?S<9 Q&T:TN?Q:Y&,;IB3S
M)D*OD*JJD"C<$"P_VN58QL6U;<I5\+H/,DY471\SK+\H>2CV8_' /2'<WK..
MC/;5GM=Q(94WLG+'D#33#QM@TR(+<C5.1$ED04J*Q;TZWDWA5T#N.M%PY&U_
M$>P;OL&G,2_(6&+"[*T\]'>;,.SWVFU3MR.UR/M]Q%ZARZ$BVZ6KEOQC&5(.
MJ-T&VL2^5I,Q0"@% * K)>0])#+/X-S-QF\I&5P9##A*';5I.1\B)$%+(GSJ
M5+1D)GMS\5YO%E#SF5@9##9!KF4=P5D-.-@X+=["*V43(4OT5%M6<+DK<E*+
MHT:[EF-V+C-:D^#*.V'BZ$<G'X3R9F<)"CJHN0&LBZL=I.:!Q:*6TXJ6)4&P
M&M=SW\I8RA"3YZ?C2E3ACZ?&*I&4XK^9_.M">UESPQK648R4//L3]FRA$PWF
MLI+*;.=XN=I0[SJKVQY^RP\45>E:;V[N78Z6TH_EBJ+W?,VV=C;M2UI-R_-)
MZGWOX(OD?<-7?:GO,91@@QC0/Y!;JG8:<15$C14NB*B*M<F1VT9/"2$*$*W$
MDNB_@M4AS0"@% * 4!\I_=&JIN>&X^OZ4MOE?Z@[5*59Y6\^I=1LV)I^)'QX
MFEO")8R1BRCR5.UB<=:)PG5NB+<7%YC\K)7PEO?R_P FKL'^)1Y5C6E.''''
M ^@6WC';:.@U%KB(GVTZ@$TB+ +L #G%;O;Z%)CJ%SM^ZI(*K7Z/O/[LCY]?
MV(URJLN53ZAE?RT&-B?6_0#A@-GZ!7^S]*AWLRK2E[;_ -CC_17(>FZ&I/+&
MT8M[>\#K>7BR\CKN%1<MFH<".4LG)+HJ$5IP$Z<415-;^MZ''?FO,2>2Q^P]
M/$.Q-2-,V;351]LM>"4F,":VK$DL7)$S84VRZHHW45_HI6I-O):'#\N75P*M
MH:3/&VKZUY%@H;NHYJ*$?<H07)674<-MJ<"?AT%Q/]/H-5JMN,9K)Y_:8K_'
M_,WX_P#U!;ZF6P7SA=>"QUF/*"G;]Q5];T)_\4*_3JQ[\/O/HR>NN)%A'D5A
M)"%UI<84GM(RCW^XJPI=.7]CA_10]-T-18_^>$\L^05TK]-0[X[Z[]61]1_P
M"\.WV?\ 77O3$Y%J\R6BG#.IG^6CV)K0<&]G6XSVR!G<<;K,%3",XX+IJV *
M[U3DED55^-&+^I05<ZHC,I/V/R)Y"U_3]CQ#&J/81X-@YN24DS)+;*J*-Q'
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MCQ#F<=E]7?D9YEW%Z:HL8<VXI-Y&1CP!QMN++=1[MJ+0FB(H-IS444J$J3F
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M9BA<=?&)'3BVCKYJXX2)ULI$JDOXK5!+T(* 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!48,1W)0FGECD\*/(HH0?$5<_)R^7+X7JT93+H04 H!0"@% * 4
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MA24D31?5\T;$W+-*K:(WR*]O6N*_;C%)KBWEB=,)-MIF[JY3:* 4 H!0"@%
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MPJ2VO;'AMIQC>8P$YG)8IY21F9&+FT:@2B2(OX*EJ2A.#TS5&8-4)6H8B@%
M+I0"@% * 4!&9S-P=?Q[^3R+G:AL(BD5KDI$MA$4^)$O1$JA)MT69\H[-]S&
MR/YV0WKK:N0!519;:*R(@JOHH@2G_?'Z7_+TZKQSW%'2*/TW8?LG794]S-PD
M_P *IX>AUX_ Q,5]S&WQ\I$++MFS#YHKJ.JK@J'QY"K:+Q7XJ/5/5+^BXQW+
MKXE@;]S^QX>5)V+CE-9)TIWK(^K]3VK&[AB6\OBS0F31$<"Z$H&J(7%5%51>
MBHJ$G14ZUVGY?<M3M3<)IQE%T:>:-;[1Y%\IX;></IT+ 88EV=W*I@'9,R0A
M]C#LB_SD(VTJ"KR%8!%?;^]0QH9TCSUK>)BYG]>QN2C9#67\?C]B88C=YMB=
ME$%&0;-#3N 1$G$Q2UE1?C4)0DP\PX!S9YVIAC,NN3QDJ'!R3B0N4>.[D01Q
MA3-#7VD*\N2(MDZK5%,#RVS?]D:WV#XST;'0Y6QO8MS/SYV5=<:@Q8(/)&;'
MBR).&XZXMD1+(*)=;U 1.H>?<1L+>#Q^1P\Z'MF7E97%N8N,"2FFLA@57ZQO
MO7!%1!L8K;JA)\:HH2&+\[Z;EV-7E18V2&+M[\N-AWW8G %7'<EDFZJG_#!L
M0,E)?@*U!0R]4\TZ9N&6QV*QJ3F$SC4B1KDV;$<C1,JS#7^,<-POSH**AV)!
M7BMT2U U0KFP>8=@C>3<EX[P4/$!.Q;4%YB+FYI0)>82?[B3&W'MEV4N)\E5
M5/I:A:$[B?->N9C8TU:-B<V&43Z8GE>QSC;3+,XS".\ZJE<&W%;+B2I^VU"4
M.\3S;I>3Q>7RF$2=EPPF3/#SH\"(;SZ/ !.]X0NEV% 2(7;\51.E!0CF?N!U
M&1C\-DV<5G2A[#(CQ,(?Z<0_5N3&C?8[5S1%0P;.R_#BM[510D-W\GR,%XFR
M7D_!8TG?T^.<S],R@G$=)MEWM&)(/)1);7%>J+Z^BU 8V5\D[!@LKK;&1@Q'
M,9DL)-SF5.*KSDEM<<TVZZW';5$0^2.CPY*B]%_"A:'OBO..E9^'B<C@!G93
M'YK&R\O"DQHRJ"-8ZWU+3G(A4'FU41)M4O<D^=!0[X+S7JFQ3-7A0(F3 MRB
M29^OO/Q>TR^S"%3=3D1]"0;+Q7K946@H8">?M2,,(3.+S;I[%&F3<0T$"YO1
M\<O\<T17$L@I[NOJ*HJ4J*'K/\]Z5BL@] RD?*1&XC6,DSYSL$TBQ6<X2!#-
M\D52#F:]M4XW0D5%JDH2</RWKN3V#):]B(>3R+F)EOXN;/BPR<A!DHC'U#D7
MN\D5'$'HG(4%2LB%4%"!#[B-+=P^'SS&.S;V*SKC+&-D-X\E%Q^3(<BLM7YV
M0W'&C01_"ZV2J*&7,\\Z=CG9$?)0LM!DQ\5^NHQ*A*RX[$1X8Q"T)FBFZ+IH
M"M)[K_A04-@)EKX5<S]#+Z1_J?T[M?X[^3GVNUR_PGPXW]>E"$C0'!+857\*
M ^<_./D_>M.VMC$Z_D8T3'.Q@?1!:;?D(Y=4(7>:%Q14L0].J5];Z+Z;M]S:
M<KB;DGSHNP^%_<'JVZVEY0M2BHM<JNO)]F)K3*^:-RVC"?RWGHL#,QWW1)5<
MCF#SAB2*V HR067DGJ/7K:O6_P #MX2UQ<HTZ5AS/+V_[NWUJCAI<L<=+J^2
MITE<V/+RY9,XV0^+C4"ZNHTB#'%]?S R(]!::3V"B>J\B^->6]+E6"HLEU<W
MS;/VOT'T^[8L^9N&YW[V,NCE!<DN@CL@OT>/8QR^V5*49LT/WA#BOT[:_*R*
MKBHO]H:]OTJSG<[%\_;H/S#]_P#JRO[B.T@_#:QE3\[_ /;EVFW?M=_ZXYHK
M=?TI.O\ ^L#7#^Y?[4/YOD>/^T?[\_Y5_P QL7'.93Q_Y"W65F=3RF?;VR='
MFXK8<3&;FVAM1&F$@R/>),I'-LB#E[20[^MZ^"9^EFH,EXN\MAA,Q,RF%8R;
M_DB"\YL6*QP%S9G?JC6082?W75 U&,;T/^$@H*"B?C0J)J7XYW_![TS,G8)[
M:=+TA[&_IC *#K^3PK9Y XXH+A(CDK%K)&P';NH(J/NH0LL^3G<EY?Q>^Q<!
MM>,P4O!1L4XD?%QR>.0QDWG#;F-O\R:;4#$T,;%9?7I0'EX!\?;GIV<P$K;(
M3QMIJ98V*^XVRRN*=;R'>=@$C*_Q$=0@>!QRY>U43U6B*R \>X3RIA_)8Y.7
M@IL3]9RTQS:I;D87<?BPE23?=:QBJY9Z/D.U'5YY$4V3"ZK8N*"$KY*U+<LA
MY4R[N'Q.3E1LF>JR8  RTN!E%AI3KS_ZC(+^(TC*$AAVR0E*W0O2J$0FK8O;
M,3C_ !B60TO.OQ_&\G+O9[&E#!5>+**^W&E0A5SC(<CD2$J#[T$U(?1: E=?
MPNS:KY)F>7YND9$]4S;F2''ZY!8;DY/%/RTB)]>41#]CDU(YH\C:\@NG/\Q5
M 86HZ_LND;%DIV6\>3\KC-FP\YO':S"9CR8,/Z[,RYC6,DND2,L@+;HD?3MC
MS)$3VVJ@WWXJUG*Z=X[UK6<W(23E<7 9CRG!)3$3%%7M"2^H-(J-BOQ$4H0N
M- * X541%5?1.M ?-.&\(97.:YFYL@7-7\BXW;,QG]+SBJ*N--2WA<:1U 4N
M4=^UG&R]/6WP7NEN$I+C&B3-2C5=)$:3XW\KZY@--W,<)'>WO4\EGRR.KR'V
MXX386==Y.%%?12;;,5]S?+HJ=%]++G<O6Y.4:^&26/41*5$R[SH_D;RWL&IL
M9C43TO4M8S,;9)DO)2H\F?+E8ZZLQV&8ZKQ!2)>;AKU'T^2Z4X6JT>IM4Y9E
MQGFJ4-9P_MSV>?XJS<E!R>(\B?J>0FQL4N1>;@S8I2%<2.;33O;%'VU4>267
ME:ZVO73+=Q5Q<8T7#(QT-JO$V%Y-TW,;-X"Q>KZ?J;N)GLOXLAU=";0H8Q7A
M-X.XI\20;*O/E<[W]5KFLW(QO-MUSQ,Y*L27\Z:%D/(F6\=Q(^/D2\'"S9/Y
M]V,]]*XQ#)A04^X)@:+=?W%Y5AM[R@I<Z&4XU*U/\'LZIY3T38-&Q,Z?B(89
MD<^Y.GNS61^HA*S&;M*<-1%PR(34$7HO7TK:MSJMR4L\*8=)J=MJ:?6:[E>)
M=B<@OX_6?$V9U/=2_P")Y3&[/V\'$DJM_J&_XQ+P0O?VD"]O;>_6NI7XUJYU
MC_+B8T>5"X;!XW\A3<EY4<."YDY&?TW&X6!DP5L6Y^4CL"V^HH1(HHIW6Y(B
M5IC?@E#A253;1XGOF('ES?\ QK"\0EH+FMPWHF.QF6V7)Y"(ZTS&@JTKCC3#
M*DXX9=KVC\+U(NW;N.XI5S=*&"U-*-*%=RWC?8PW[>,KD?'F?S\'+9;ZK$3<
M1G1Q+*Q@9!M%)L7@4B51OR)+VK;&]%PBM25%^6I))IX)]Y].:3E\SF\$W.SV
M ?UJ?W#:7%RWVI+J W81-39]ON3K7FSC&+I%U1O3;18JP** 4!\Z>3-'B>1/
M+N9U60@I)D:4CN-D%_N$UK(79<1>MDO[2_O56O7V]YV;"FOS]^!31& @2=UT
M'.>+<JRH;QI+DG*ZVPXEG28;)4R,!+JGI;N *)>O7N25J[&ZOHGA+Y2(E@7W
M0=QSGFO6-8\.NJ\D>$?>W+)IT[F$@J*QV4._YWBXMGT_=O\ %:XK]B.VG*]S
MPBOXG]A4\"0^SA!3-;T(#Q 5C" IZ(*./HB?T)4]7^F':3F73.^%<OF,7/>Q
M.8@MY1W/Y&9(>Y$L=S#SI+<AV*\HBJ]QMQD#3X"2+\ZXH;V,6JITTKO2I7JQ
M,C&E^"=BRC4V.SD,8,4@SCD/-@KA3<E^O75L)JB-E!F_J)%>P\42LH[V*HZ/
M\.'!:>76&3V>\1J&4Q#F"##1&6=;F:V\RZ*M.MR)@6:DL<052)#0D7E[K$5N
MJK6F&[HGJJ_$I=W (B9/@S-PVD<P>0Q>-SK&/P3>$?1#; <QA@<"0^8B%R1U
MMP_<ES7]ZMBWL7@TVJRKU/[ >4K[=<DF.RV)@92.F*9CM#JL=Q7$6.^^]'D9
M)7505L,@V+#QO9"ZI\*JWZJI-8_BZ<U'NJ%A@=9/@;9BQT$<<6/B94)4V4KK
MDE^2$5)KS3MNVXRK3X6;]X=MOWV451.E6.[C5UQ6'N7N]Y#,S7@_8)$C+'C_
M -,2&_L2;%%:;4XKTAER.K)Q7R1EP11LE[C?M,;JO1%K&&[C15K].GWUJBU/
M%/MYG_H6>@$[CRR.0P$'"8J0ZK[_ -(XP;AR$1QP5/MES017\UDMT3I62WRU
M1='12;(S9.CZ(YI^>VO(-#%8Q6<>@O084,5;1GZ6&$=U2%!$44S%2]OK\>M<
M-V[KC%/.-?>ZANI*8;_K9LW[('_H3KG*RS53$4 H!0"@.C@B0*))<2Z$B]45
M%]46L99%1\)XW0,7NGD_R#E/TQQS&X_-$S@2C68C?5!(5":X"EB]HIT2UO6O
MMY[F5G;VXUQ<<:\J'.HZI-DIY#\%>:X4T9&&%G.8AQT7HD: 8-OPWSXBBJCG
M$ELJ(I$)*/QZ5IVWJ6U:I.L7\49.,D\#[&UA,T.O8L=C[2Y\8K0Y-6%4FEDH
M"(XHJJ)>Y7KY.>ER>CZ:X&TE:P H!0"@% * 4 H#J8H8J*^B^M :[FXWQ_BM
M]E;F\U(/<&H0Q)\E@9$@&(2V4>Z#:$ 71+HMN5NM8Z56J.M[NYY/DM^"M<N/
M66J%M6O923+@P)S;TF TU*DB%UXL/M]QMP5M8A4?B-[>B]:RQ.3,UKK^B>&L
M%L4[.:QC7_U;,1S;F%!24^PW'REBLH#R!KFBH2)T44^25@K:3P1ZEWU3<7;<
M;<Y54:-8+ATEAT4/'FC8IC6M31V/A#E.A%D&C[L5R6Z5B$)+B*)*JC9/=:Z6
M2K&*BJ(YMUN;FYGYEQU?<>,?7?&^%V(O*6-;<8S.Q#V5>B&^J3E<1%LD4;H1
MKPY70.BIR6BBE*IE/>W9V59DZQCET=N97-L\;^%-OER-CR$-W'9U'QC2W\<4
MB!D3E/#R%LV&T12,Q2]^WU2ZWZ+6,K47P.FQZKN;,=*E6/*6)#0_!?A&5+^G
MR;>6DOMMN/\ T>;F2VA[3%NXXG/@BH"$E[*O2L59CUG1_G=RL(Z8]45\S>&L
M,XEC P&< "-X-MAL,: H0BD801&^*'[D3C:W+K6U'B3G*<G*3JWF2]4P% *
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M)V3QRILT8XDEE]P&8S;W?:5L.@NAS"X\[JMOA\::NA$)8=<B *M@])%LD5"
M3%!5%]45$&UE^--70B'/\NQE+DLB4I(2FA*XBKS5+*5^/JJ=+_*FKJ!GP,>U
M $A;-P^2W5750BZ(B)U1$Z(B5C6H,R@% 4S.'NKTUXL1&5(I,NQ&0)P002(P
M_P 85;]5X\NVGP^-5$9U:<\@LQV8S<6.O:;X]]USF1V5!'DG._*R<B7XJM7
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% $2U * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!AS,I
MQZ<ITAJ,"JB"3S@-H2KULBDJ76C:69G"$IND4V^A5.8V2AS&^[#>"0TJJB.,
MF+@+9;+8A54Z+18X\"2BXNC5'TX'JD@%ZVM?TH8G*O@GSH!]0%T3KU2Z_@E
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MTC684O Y#<]I>U5=MRN09>C1Q^B:E/,NFX3O'W"+?1$3W+9$ZUE.PM3HZ*M
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MV2MJ/HJ.(*HO3UH6A /?=7X6<TO-;OAM@'*8_"DC#\=J/*!]9;P.'':4"9Y
MCRMD(ND/!/WE2I4$WX-\X:SYSU--AP8+$R491;S.(+N.%"><4E;;5XFFA<Y
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MHNOGU&N<G517$BMIW*3X?Q#<23D2V<D"1/5<K*X90HC*(O:;&+&/G;W?Q74
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MDMW%4[?V;4=]UKTU)0RLK]O.KYL)K62R$PV)F!QFN((*V!-#AG4?CR0+BO\
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MA)^[0$MDO..J8S/3<(8//GCCD1'Y#"L.&4V'&*4ZP#'=1[\H*(N*"-J?MO\
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M*]E[&W*XHXQ3U>*JDG189>]'F?JYJWJ^IX84<6L:<?<;^B/OR(C#TB.45]T
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M-<AZ ]'%1NV?KT2U91:4LN#S1&JDONK&RZ5N'D[/:KE\Q-SN(US#2&/J'$E
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'"HBI9: "*"EDJ('-4"@% * 4
MH!0"@% * 4 H!0"@'K0'@U"BQU<*.T#).EW'2;% 4S7]XE1.J_BM1JI:GFSB
M\=';5IB*RVT1<U;!L!%3O?DJ"*)>Z>M45/9([0FK@BB.JB(3B(G)41;HBKZJ
MG6HU4AXLXO'1A4(T5ED%/NJC38 G<_M>U$]WX^M4'=N##9><DLL-MR7K=YX
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M 4 H!0"@% * 4!U4E141$O>@"%=;?W/C0':@% * 4 H!0"@% * 4 H!0"@%
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M=%ESQ.'];%3TRI'K>=<L#<'="]K]?E7GU.\[IU2]4"@% * 4 H!0"@% * 4
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M&<%FD;SY)/Y'U1K'GK3MIQ&1V-(N4PVK8V-]6_G<O!*+!(>2!Q:=0S[AJJ]
M%+K\.M>'<VLX-*J;?!9GI1NI]AIS</*OC/;W<?EMG:W7 :?F#-G%;$R^<;&2
M#8)0-5CB;B<$^*\%O;TZ+7H6[%V":CIE)<.)RS<9/'4NFIY2LWL*:HWXPR\;
M QHV$4<OF,DPZVK08%$;EC(8)&5:[ZC(5!(!ZDG(;J551BI^8M7BP7\W)]!K
M3DUHHL/ASRS)G4?)_CS0L8QLK$'>GM+G.?3Q-DRZG,QA*I*"$+:O>P5(51%[
M:>G2M5VQ<N>&L-7)8,V0G&#;:E3FW@?4+)BXRVX"W Q0A7\%2Z5Y5*'<=Z 4
M H#5?W#J:>,Y9M<D?&9!5@@$#<1Q9((*@+GL4DO[>71%LOPKTO38*=]1>5)?
M \GU6Z[=C4L]4?\ F1H3%Z'L XO)3Y[,F%B7C <UAL8VYD'VI49TG+YT)'"5
M+[B>Y78Q(*=5%+6KV83A&254Y<']-4\/ U@FN4CQ;VNY%O2U'\2IJHTVZ3B\
M6GSB6OQGY&D8O<,)J<'(#,Q^9<[8XAN0N2A,MD!EWXD@_P"/'0%!4.+*1"Z^
MVL/4-O"5N4FO%'C2DNJ:6#_FC@3TO<S5R,8OP2X5U1R?T2?B5*8PED;3V?R;
ML\7<ET?1]9;V'+PH364RR2)S>.$([QJ  SW!)7#6UU7\H^BK=:\*U8BX:YRT
MJM%A4^FN7I*>F,=3I5XT.WDGS!'\<R]:B38"R',T^/ZEP._Z? $FVW93G%%Y
M"!NB/P1>O6L=OMW=4FGEET]!;^X5JE>/W8]AZ[IY$VO"[G!TO4-8;V+)RL8[
MF'4=G!CT!AE\6%02< Q554D^7K5LV8R@YREI5:95)>O2C)1A'4VJYT.R^7<8
MYXG3RK%B.E$=CJ47%N6%]R:KRQ1C72Z*JO\ L0D3JG6BVTO-\M]_12OP+^IB
M[7F++YUI\3"F^8NQXCC>4(^-1QQQ8K$G%&YP5F4],&$^T1V5?X3BE^[UM\*R
M6V;O>77VI4QGN5&TKF>2]]"R;%N[F!V_3]62*,A-ID3HY2D/CV/H8JR+\41>
M2E^7U2U:86M4)2K]-/B;;EY1G&/YF_A4C-Y\AYS"[' TG3, FP;7.AN91QM^
M2,*'%@LN(TKKKI(2KR-> B(^M;+5F+BYS>F-:=IA=O.,E&*U2?33 \YOD_)X
M?QSD=TV'6Y.)S6/,HB:^^8F<B:3@LL@PZ"*CC;IF/ T'Y].E8QLZKJA&2:?$
MRE=TV]4E1\B(S_G)C$>)\/Y2BXHIC62>BQG\8AJ+K+KKA,R&T6R\C:,#%$LE
MU3X5MAM)2O.W7(U2W<595SVZN_ EY?E>'^N:] Q#09+$[#AY^=C9)MSBB-06
MP,10;+U/E9;JBBOPK6MO+2V\'%I=YL=]:DEDTWW%9Q7W#0<SXJD>186-3]1@
M2(L/)8$W>+C+DR0VRV7/C=0('$< N/N]/@M;Y;*2O*VWFGCU*ISQWL96O,7-
M>]T7Q);/>4=P+8\U@O'^H#L;.L*T&=F/S0@(K[S2/I'BB0FKAH"]56R7Z5KA
M8AI4IRTZLL/B;9WY:FH1U:<\2.7[BM>_5M'8**;& W2$<H<H\7'Z)[O?3@V\
M*(J(*N_PR/E9%M\*R_17-,^<'E]A/UD&X\IJI=M7W=[8]JW#7%AHP&JRHL3O
M\E)7_JHZ/J7&R<;7M;K7/<M:8QE7ZC="[JE*/Y7\BYUI-XH!0&OO.?\ V1;?
M_P!'N?Z*5Z7IG_E6_P"8\WU/_P 6Y_*S\Z53V7015;=+BGK_ '*_54?ESRR7
M<;4R#>4PD#396LFY+QC\2/D,1!!$!W]3;]LHXYBBHX^+G1QLT55!;65/3\OL
M?IMU<WD-RDKBG*W<D\5Y3QMJ:X6W!UC+#Q5=:GVDW<LV[$K.,7%2BOXOQ-4_
M$GA)8U1L[P6YCWO/^T2,8WV6)&,)]UA1$5:DO+'.0W8;HG%WET1:W:;L/1;,
M;KJXO2G6NJ,=2@^V-,3?M7!^IW'!*C5<LF].KW]G:7O-N9'QIE-AGYO'L[%X
M=VV?];DY;:H<K&R9G!EQ7A_W6/R$;*BW#\/C+2CNH046X7K:HN4J8JG3\3LN
M)[:4W-*5FXZM\8UP=>CX$U@($+(>;/(#$MD)$<(.OR!$T0A5UA'3;/Y*HDET
MK3=;CLK5&_JF;K23WEVOY8?]1[8P4+[@-D5?CJ^/1;I?UE.?.ES_ ,"'\\O@
M90_\R?\ )'XLBMFBNX3S+HT;6<8P[]-@\J#$%7?I6A;4VE6Q\3M:_I:MEEZ]
MG=UM_7$PNK3NK>E+Z9?])F[#CWLAXGG1MHQK>,RVRSH\?.16$0??*R+<;FBH
MME+M"-C_ 'O6M-B6G<IVY:E!/2^J-?B97HN6W:FJ.;H^V5/@1^L[=F&=6>\9
MN2%7R)B<E_*H.JG\0HBHKC61XW1>"0T5R_\ ;'KZUMW&W@[OG4_IR6OMR</]
MQJL;B2M^2WXXRT=F:E_MQZS)\)2\;J_B:9)D.$F,PL_-*;KRHKA,Q93JW)?B
M2HB?M6KZHI7-TDLY*'?1$]-<;6U;;PBYXOBE)E;\>Y#)Z_Y-@2<SC\AC2\A8
M]Q<H>1;%EMS.13*2':XF:61AQ613I^5.E=&ZBKFV:BU+RI84_(\'_P"K$T[:
M3M[A2DG'S5C7\RRRZ/@3FWZIE\UY'S.Q:A(2%O6OXW&/8AQPN,62T\<E'H<D
M?WFWD%++ZB5EKGL;B,+$87%6W*4J\UE22.C<;=SON=MZ9QBJ<FG7PLS=3V['
M;SO^&R;4<H.7B83*0<WB7T1)<":W*B=QIQ%ZHE^H%Z$G6L-QMY6+$HMUBY1:
M?"2H\3*S?5Z_&6349)KBG6.!N-$LB)\J\='KG-4"@% 5#R;LV0T_3IVPXP&W
M)L56D;!]%5M>XX(+=$5%]%^="FL=,VM[RQCPSDQYI<AC".+DL6!=D(KI<@+U
M52!'F^V\P\2\4=;45J%J8>Y>'L+L$R1E,+)/&YN2I/RV":4H[SQ=3=)@?>V1
M^IDTA@J]>E>EM]]*VJ/%'PWK/[4M;V3N6Y:)O_:W\FR B;IY'\28&/@RQ4-W
M#,NN?3Y-.4ADR=/FHJZV2(A77HAH*_A77Y=G<RU)X\CYQ;[U+T.RK,K2T)ND
ML6G5US6''C0V1X<\G9[?Y>78S#$9AN TT;7TR$BJKI$BWN2_V:Y-WMHV:4XG
MTO[;]>O>I2N*XDM"6737[##\H9G)P=LA1LY.RF(\?K#5PYV&!5(YO)4477!$
ME%!2W2U7;P3A6*3G7CR'K6YN6]S%793M[?175;6<NEI-K ]]<W1=8UJ5E96>
M'=,0N38A8J0R7^.LMR>B!)YB/5.G_P '1).UKDDHZ'3$V[/U#]-MY3E=_4P\
MQ1BU34E+)2RQ]NA6O9=Z>QF:D:O#QKTS+_I;N4CFR38"H@2MV3N*B<D7W5SP
MLZHZF\*T/6W7J7EWG8C!RGY;FJ4YTICQ-7?YRM_71]:R(PY2R94^.T_FE*+V
MYH&Z8JR#?J"E;C=11/:O6O0_3VM<E7@\,<.D^07K>_\ T=F:A+5*<4Y^"DTW
M]*7!O+)+/$V)-\G/Q93V.QFORLC/@1VY6;CMO1V_HNZ'/M*1G9QQ$Z\6[UQ+
M;IXN22X9XGU%WUAQDX0M2G**3FDX^"N-,71OHC4\I/F3&D_BX^%Q<O,O9J 6
M0QK<44YF0&K:LDBK[%11+D2]$M1;65&VTJ.C-<_7[3E"-J,KCN1<HZ>ATH^7
M&O(B_)6XR]?S^B9"3)D8[&2'7#S$-I5-5%!!>V8 B\^*E;I6>WM*<9TQ=,#G
M]9]0EM;VVE*3A&4GJ6?#)I=)'%Y+A;'Y0UUO7<I(;P#426YE8[K;D=LE;;-U
M"(7!2]D2]T^5;'MW"S)R6.%#B7K4-SZE:C8F_+TR<U1K@W^)+KJ6.'Y@C/%C
MY<G"RH6L960D3'9UTVB;<,R40(V1+N-@:I9")*TO;9I--K@>I#UZ,G&4K<XV
M[CI&YA1\JJNI)\VCTSGE>1@4G3Y6M3DUS'2DAR,JZ3<93/D@*;+#JH;@(J_F
M'UJ0VVNB4E5JM"[KUS]/KG*U/RX2TN3HNBJ3QE&O%=G$INR;GL^-R?D=[%/2
M'V(4;'.X\D(%;A#):YDZ(.)946_5$1>M=-NQ"2MUXU[:,\7=^I[FU=WGEMM0
MC;<<O#JCC)5X=YE#N^U-[CJY/8Z>X4S".N%@6W&E^HD"2\7S5"1L4)/==5]M
M8^3#1*C6>?MB=/\ DMPMS9K"?BMR_IK3C)?B>.E)KIZ#9&C;M'W:!*DMQ'($
MS'R'(60@OJBFT^UZIR3HJ?LKCO6G;=*UKB?0^F^HQWMMR2<7"3C*+X21:JT'
MJB@,/+8Z)F,7-Q$]ONP<@P[$E-WMR9?!6S2_XB2TJUB@?,OC"<6D9%KP!Y%F
MS(&QX0'F=!R3<MR#"S^)4R..(F*J"2&[]H@];(EKVKOE*JUQHT\\*T-,H5SJ
M1WDS)YS=LD[X$TI))[;FFQ;VN>&7?R,/!X<C'Z@I5P $=<"X TJWZ_-4K8IJ
M*UNE.&%*FJ$'7[ZF\?(+<[1O#&>8TD7 FZ]@'F<)V_<ZVD2+VVR&WJ0"/)/Q
M2O.MTE<5>+.N66!\)?;GX>\0^9M7S^/V?.OM>67W7EQ;!24:5&^VA-R!%P5^
MHY.*7>&ZDB)Z)ZUZVXNSMR5%X33!)YYFTMK\'[]I?VF;9JN^Y>-FSPCT;.Z[
M%AJZ]] ##@I(:[CHBJAP,R%!2PW+YUSQO1E>3BLS-Q=")RWD<%^P?'1>[RG2
M7V]3<6_4>Q*)ZW[/IVD3]BUFK7_Y'O,:^' R/LOW-S2=2\KX/+HL5_6V$V((
M;UAX*$9P7;I\U5MI/Z4IO(:G%KC@+>"Q-6^/9>9T[[9O)7D7&DL7+;AFH>NM
MY!M5"0W'6[LI )+*G/NJ"K_I5NN)2NQCR51BHMEMU3[6=&S_ -LCWEB1,G!N
M)8N=F6>)A]&"P3=LRK7"Y(0M64N=[K?X5A+<R5[3PJ-*H9ND^7-PB?9=M!MS
MWOU;$Y$=>QN24U5]B!.5DN(FO6X";@"7JB*EO1*3M+SURS(I/28WCW[2M;WS
M[=P\A07I\GR+E(LR;BHP.-I%5V*^XTW'5LAN:N(VMS4T]Q?AUES=.-W3P"CX
M3Z8^U#%^2,!XL;UKR;CY6/RN'FNQ\8,PP<-<:0@;0\A(KH!$8IR7HED]*XMT
MXN=8FV*P+/+Q?ZEH.O\ %Z TL!\)HMYC_P"1[W'NM=I[\%[G(>B^X4K4_J,B
M"E>/8[V4G3,CLD%(THH<C+X\"".#$+'$T4-6K'R#MHA<#<7C[DM5C<IDB-5,
M1KQQ,3%Y#"O9W#3)LG'?XYDWD59S)BV:(;:(2]MAT21QPU^*DJ(J*E%-*CIQ
M+0F8>CM)M6.S\S)8Y)\%(D@\5'?16TC1([[??NH@:G=T3$K"VJ<N2+T6I7 &
MTX^5QTAMMUB4R\R[Q5IUMP" N:V'B2*J+=45$MZJE:T#-JD% * 4 H#"RF,@
MYB&[CLG%9FXZ0*A)BR0%UIP5^!"2*BU8RE%IQ=&B2BI*C541>)TK5]?8?CX;
M$Q8C4H.U)000E=:M;MDIW50Z_EO;\*RG=G+-O PA;C')(P&="U/$MQBU_!XZ
M!D,4+Y85](P6BO2AXN&/&RV+IRLO5.E92W%R5=4FU*E<<Z&"V]N-*158Y895
M.-8\?8G ZP]KDQ!S+>1>?FYJ1.; _KIDL^X\ZXW912ZV013\J(G[:SO[B=RY
MK7AI1*CR2Y$LV(VX:?JKG7B^9F1M'U.%C96$CX6(.(GIPG1":$VWQ1+(CO.Z
MG;]WE>WPK4[]S4I:G598Y&:LPTN.E4>?2>C.D:JQAY&O-X:'^AR[_5P#:%QI
MY5MU<0T7DO1+*75+)5=ZYJ4E)ZD/*AI<:*C->^2?&Q2M?U_5]*U>"[@X&:B9
M7)8X39A1W(T55YM*A)[R=0K77^FO0VFZTSG.Y)U<6D\\6<FXVU81A;BJ*2;7
M"A?6M*U9[!C@W,'$'"FHO'BR:!6.ZB>IBB6-4^:WKS_.FI:E)ZN=3K\J#CII
MAR.%T/3R?A2#P<-9.. 6<>\K:=QAL+V!HO44ZKT2IY]S%5='GCF5V8.C:6&1
ME8[5]?PL@Y.)QL>#)=3BXZP" 1CZ^ZWKU^=<L;<8/!)&4+<8NL4=8.J:WCI?
MUV.Q4:-.)"0I+;8@X2'^;D2=2O\ C2-J"=4J,BM0BZI(0M.UK&I+3'X>%&2?
MR2:C3 "CHEZB2(G45^(^E56HQR69C&S"-:16.>!X)H>GMM@R."@BRVVK+8HP
MVEFU7DH^E[*OJE1V8?E1%8MI445W'==0U91B,EAXBA 4U@ K0\65<_-P1?RH
MOR2IY47PR,O)@J>%89#^2]5&*YCUPT1(+SB/NQ4;'MFX**B&0^BKU]5J^3!*
ME%0GDVZ::*AE2=9PD]B-$G8Z-*AQ$M$9?;%T6D5+>U#1;=*KM1DDFDT92MQD
MJ-)T-$>6L!"Q/D76G\/CV8&*A8O(3<J[':%EAMIL#17'%%$2_7B-^JKTKE5E
M?J+:C''5#+HE4^;WUF2W=IP5(J,]7!9%0\.86)F]FT61/AMY' RM96.*NMH]
M'^JA*X#K9<D5$,%7T]:[?5K7_P#L+FI8-U[-*^:->WLZ]Y&36J+MTYJL6Z_'
MXGU'A]6U["O'*P^*BX]YP>!N1FA:,@O>RJ*)=+UA"W&/TI(^GA:A#Z4EU(G*
MW&P4 H#YB\^;7K47RGK.D^2FQ?\ &6;Q1E+%QM$^DR1/N-M3 >%$<!0L@%Q*
MR"JJJ+7I[.W)VG.'UI^V!S7FJI2R/GWSQX1P_C((&?UC88^9U7+.*$9HWFCF
M,JJ*:*BMK9UNR?X042R^J=4OZ^SW<KM5*-&NX\[<;=0:<7F1N_3\_,F^*LAM
M2FF0+!P/\8D70W(K>1D(RX:EZKVT%5)?5+*M9VE%1N*/-_!%E75&OMF?2GW;
M9W#;!X;27@YS.1B,;%&CNR(IHZTCS33R&'(;HJC?K:O'].A*-ZDE3 [MQ).&
M#]J#[7-BQ>J> )^=S$MF%#B9#(O*Z^2 -VVVU04153D2JED%.J_"KZA%ROJ*
M7#YDVSTVJGSWE-^F[AYA\>^0]M^FQJRW,9(ENM\FXC3$6>XTI^]25!06[EU]
M;UZD;*A9G".-*_ X)7&[B<O;$M^M['A=@^\IO8,7-;?PTK(OA%FJ2"T[QQY,
MHH$2HBH1C8/[72WK6J<''9T:QI\S8I*5]-<_DT:MPNEYG?-MWG#:_)5O*QVL
MCD&L>A**Y 8LL5.**(MR)453$?BHUV2NQMPBVL,%U&EP<KCIR^PNVR>4,MY(
M^WR/K,MQ?US2YT1<FR"(*R<0+9L,/J*6_P "XH-NI;XB2^M<MO;QM7W+A)8=
M#]LCHE<<[:YKWEIUW7M2\C>%L*&X>54QN!UMLW'=>*-!;=A/L(861;@\[R$E
M[?YN7+YUIN7)VK[TV\7QQQ+&"G%-SRX8?ZDB] UG"X'+N9J/D3TR3X_P[939
M+;;.7%F9E4B,.$US($[8B!\.74!1/C6*<YM)4U:Y=6$3)I1DWC]*_P"8I&R8
M3RIX#PGT4F5%VSP]L!(':4R>Q,L741X4XHJ.1W#$.0FT:7M="6U=%N=K<RKC
M&:[S!QG;HLXL^\M2S3>Q:OALZU%<@MY*%'EA">ZN,B\T)H!*MKV1?7X^M?-3
M6F372>G%U29,UB9"@% 5[==:7;,!(PP/#'>/BY'?<;%]L76U0AYM'T,"_*8K
MZBJ_&NC;WO*N*5*^[W\^72<F[V_GVG"M'W]ZXIY/H(7Q[B\SA<<_B\M&>B.Q
M3%MIGZGZR$@(-O\ $GG/XR,_)I^Y-^B*J5LWER$Y)Q=4^BC_ .+AJZ5F<_I]
MJY;@XS5&GSK'_@;QT]#^G)8&L(VA9+(^:&-FQN+DQ<= G$_D,@41G#8LFVQ<
MXBVR"D]/?(C_ .,.<1'X(M=7ZG3M]#=:K#B^'<C4MJGN/,4:<WDN/#B^;)+S
M/A<WLLSZ+$:!)R&?9C@FL;U GLPG(,LUO=TD('1;:+W**\D/K9$5;UHVLHQ5
M7/#C&E:G3N5*4DE"KX2Y=9'Y7Q1OV^[#LDK-9U<)"7#QM5CO'#8F?J,1&D>E
MOHAE=E#DK<52Q=$]+)6<=S;M1BHJN.KJ?!=QC+;SN.56UAIZ^9"9CQ5O_D9-
M:78FY&"R^.U.1C'Y[<G^&F6C2Q%L)*M'S-F2R"D:)\"^:6K;'=6[6I1Q6JO9
M3ATHU2V]R[IU5C2+[\/<RR975-YV_ >/-5B85O0X6)EGD,RK"1YT:$_B!M"%
MII2LZV^\2N(A7Z)<E5?73"[;A*<F];:HNW/N-ERW<N*$4M"3J\N&7>R%S'C+
MR$SI/D30' 78&,KE,=F\1DD!F&DLYDIIW)-=H#XM=M6R*R=%Y=*VPW-KS(3^
MEI--=2=#3/;7';G;?B3DG7H;3DO;F6I_PU@M9\EZ#L&A:^$*!#?R19^4TX9<
M6781-L<D><)>KB_NI^VM,=W*5N<9NM4J=YT3VL8W(2@J4;KW/YDGO<';->\E
MXWR/K^!=V> >%>U_)8V&\TS,90Y0RFWVT>5!-%5.!)?IZUC:E"=MVY/3CJKP
MRH97HRC<5R*U8.-%WD'L>&\K^3'-1B3H ::Q$R3^>DRFE9R)1/H$1,8TZ!D@
M./$9DX:#[!1$^/2LK4K-G4UXZJG*M?J,;T+M[2OIQKU4R]Y .>-?(N)QV0U)
M&RS<&+N&'VC&Y=!9C(\T^ZC^01&!/BVC+HJ7!.B\O:GPK>MS;;4OI>EQIRY'
M/^GN).#\2U1DGSQJR2+Q3LFO>5"E80%D>._TS-NXR,A *8^?EQ17HH"JHO:<
M<'N-HB<1Y$G[=:W4)6J2^JL5UT-JVTHW:KZ:2]^96<]X5W1SQEJ;N#CFQM@P
ML;B-OP?)M!EPH<H9#1$O+CW8Q@BB5[\%5+]+5OANX*[*N*Q:?93N-$MK)VH4
MK54375BO>7N2F_\ C_<MRF8'4'MLQ>V2&<CC)4.2Q'^GEA&&.;4D7B%1"X(2
M&-^GX^G(O+O0C66G3@^^N!U/S+4Y.,7+4ZKHP2Q(/6?#.6CR]4UW:H03M>;U
M#)8;8)+1"K0RY\P97;!2]W(56X."G11O6Z>\BU*47CJ378C5#:-:(R6"@T^V
MA9/".F;IJ.6WA-R=*<[-FPPQN7-14IT2%%[#;I(*JJ'P$$/EUY7]?6M&[O0G
M&"CA0W[6S.VYN6-7\,#=">E<)W"@% :^\Y_]D6W_ /1[G^BE>EZ9_P"5;_F/
M-]3_ /%N?RL^#=3PF-R2NY#//R(^"C>TAAM&[(E2+(0QV^(F(+Q7D3A"J"GS
M6OM?5]]>L4M[=1E=E^9I1A'C-XIODHIXODL3X/T_;PN)SN.2MK\J;<G^5<.F
MKRX%]3:EQ>JYJ!@XK.NL064D8B3'27(EC)== '1*3,;%&W'6U7_ H!?%.E?$
M?XE7M]:G>E+<.XZ7%+1&.E1;CX+;K*,9<)ZECF?2_K?+V]R-M*THJL::I/I6
MJ2I%R7+'B3?VDDA>3,DH+?\ ]D.V)?55[S75?FOS6OKOW"J;6-</%]IY7H$E
M+=2:Q6GORSZ3?+NLZ8KCVHN['-?UJ3DK.ZX7$X@S7'4D?1_4@US%M3]W9[GX
M7^%?)J_=_N*"4U'ZN-,M5,J])]4[%O&VYMQ<OIX5SI7.E>'9E@9T6'IVNY_/
M^1).T/&KCX8G8>^3:P6GF%06620&T5OM*XB<N5NO5:PE*]=MQLZ.F/YL<WGQ
M,U&U:N2O.?1*M*='50[ACM5PF^9';9>QS%V$H\>).AN\/IRBO$1160 &KDJE
MR4.V2DMEO\:.[<G95M06E.JZ^)DK=N-YW')ZFDGU<,"/S+&D9K;HVTGMN1@Y
MZ S(CPV(P<!CQU,6I DV<<E_.HH2GZ+;X5MMN]"TX*VG%O&O'BN)A-6I7%/6
MTTO=QX'#>MZ?M$R;B6MRR<W-.RFI4I2<;%[N81VP-MH3 AP8>7D8@GYE]U1W
MKME*6B,52F6'B[>*,/+LWFXZW)UKVP?5^&1,9"+HV%W"7LTN;V=Q7%,XV;-
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M;!LDQO&X."*'-G2.C30DJ BDJ7]5)$_IKF2;=$9'Q[OOVW>+/+V#R'E7[?\
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M,8F.ZC7)6[DJ\R^/PK+4J+H#S/+)^&@FY&!,')HRQ&BX^%)CHPB]QN**M25
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"U * 4 H!:@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@*+NOE+7=#S&%Q.<=42S3I!W!_+&9&P]YW
M^\4U0?ZU^%=NWV=R]&4HY1]J'E[SU*SM9PA/\?N657T5+LT?,>5T)%ZBH]45
M%ZI7$>F>E"B@% * 4 H!0'D[*CL&V#[H-DZO%I#)!YE:]ANO5;)Z4+0/R8\8
M%<D.@TVGJ;A(*?UJM!0Y;>:=!'&S$VUZH8DBHJ?.Z4%"-F['@X#+<F9E(<:,
MZ:M-O/R&F@(P_,(D1(BDENJ)0QD].9C-[GJCK@,-9[&N/ND@,M#,CJ1D71$%
M$<NJK\$2I4QUQYDED<I Q4-9V3EL08HVY/RG09:%5^9&J)5,FZ+$RFG!= 3$
MD(21"%4]%14O>A3O0"Z4 H!0"@% * 4 H!0"@% * 4 NE * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
MZ4 NE * 72@% * 72@% * 4 H!0"@% * 4! [1NNJ:6Q'D[5EH^)8EFK<=R2
M7!#,4Y*B=%]$K?9L7+KI"+D^@U7;T+:K-T16?\^_A_\ ]\L;_P">_P#A5T_X
M[<_]N7<<O^0VW_<CWC_/OX?_ /?+&?\ GO\ X5/\=NO^W+N+_D-M_P!R/>/\
M^_A__P!\L9_Y[_X5/\=NO^W+N'^0VW_<CWC_ #[^'_\ WRQG_GO_ (5/\=NO
M^W+N'^0VW_<CWF7B_,GC#-9"-B<3M$"9DIAHU%BLN<G''"]!%+>JUKGL=Q!:
MI0:2,[>\LW'IC--F3-\I:#C<L>"G9MEG,-N=DH1"ZKO<14141$!;VNEU3I6$
M-K>E'6HNAG+<6XRTN2J6SNHJ\;+>N34CIH%=M^Z7K;TIJ1#A7K+;@7SI4'=#
M15M\?E53J5G*^BV]:I"MX;-3IFW;#A)"!])C(^->C**6/E,%]7.2_'JVEJW2
MMI6XRYU]U#3&;<W'E3WU,W8]JP&HXQW,[+/:QN+841<E/K8>1K811$NI$OP0
M45:QM6YW9:8*K,[DXP6J3HCRP.Y:SM&&_F'7\DSD,*G/G,:+V K:7-#0K*"B
MG54)$6U+EJ=N6F2:?(D+D9QU1=4,-N>K[#AGMAP>48GX2.KB/SF"Y- K \G$
M)?AQ3JOX4N6IVY:91:8A<C*.I/ Q(?D;2,@UB7X6;C/LYYYR-AS;/DDE]G\[
M8?WP_%%K.6WNQ<DXM:<^@D;L))-/,\,CY3\?8G8V=1R6P1(VQO$(! ,UYH;G
MY!(D11$BNEA(D5:L=K>E;\Q1;CS)*_;C+0Y*IQL/E3Q[J>1+$;)L,/&9, %T
MHL@U%Q -+BMD1>BU;6UO756$6T)W[<'24DF,YY4\>ZT[%9S^P1,>[.8"9$%\
M^/=CNJJ X-D7VJJ+UI:VMZ[71%NF#,;FYM6Z*4DJEF@9&#E(;&0QKX2X,H!=
MCR620VW&R2Z$)(ME1:YY)Q='@S>FFJHRJA10"@% * 4 H!0'!$@I=?2@-+SO
MN6\8QM\:TM<@KC)*3,C/"J+CF)8JB"RI_%%7HKB>P5^/JJ=\=C=<-=.SB>3+
MU2PKOEM]O!&V9^2A0X#V2EO"S!BM')??54419;%24KI\+)7 DY2TK-GJ3DH1
M<FZ)8]A\!>0MQE[]M>0V:5=&)"]F$PO^Y0VELT/PZK^8OQ6OT7:;=6+:@L^/
M2S\5]3WDMU>E=>3P71%/#_0^B_MI\@938L7-U/*H<E,"TT4+(EU+Z9Q5 &7%
M7U4+>Q?[/3X5\UZOM(VI*<<->:Z3[G]M>HROPE:EXO+I27&G!/J^!] IZ)^R
MOGS[,YH!0"@% * 4!H_[K)TS%^(I>1Q\AR).CRXQ,2635MP%4[+8D^:=%J2R
M/-]1FX;=M.CP^)\JYK%>7<IH>#SW\PYG/.YY#)K P(<M28CLFH&4MX$!!7DB
M=L;+S3K>U8.K1X]R&X=F+URDY?AH_>SSR;7EO6?&0;4[M67A@,I,;.P$Z+)C
MS&'%$B%P'7$)#8XI_A+IU]OK1Y$E'<6[&M3EU-?/D?8GC'5L)M&A:-FM@BAD
MIV-BE(C%*07A[TMH1<<(314(U1.BK\UK)'T-F"G;MR>.%>]&G, &'Q6B[--=
MP4">CWDU['7=:1MYAMV8P(''<!.0$T5E#X6NE3@>5:<8PDZ)_P!7YHMGG';)
MV5P'EG1LC#BE#U_$X[(P9@(2ND4Y].AB=Q0AX="&JV;][<U0NP:RBG[=Q:MP
M\F[#I;<Z9)QT1O"8V1BHD)EUQ5FY.+.5IIZ2SP54:1LG.(=T;$HEU]*J=#HO
M7Y6TW3!.*ZZT1X[+Y/W['3?(L7#XC$N1O'S46>;\Q]^\J(_$*40(((G%W@*V
M5?:B_.E3"[N;D7<I%4MI///C\#C(>8,]/BY"?I.'#(+B&H;A8YYF4\_->EQF
MY;D9AR./;;-L'$%%<1>1_A12JC.6XDZN"KI]_5U&XL9*6=!BS59<C+)9;>6,
M^/!YI7!0E!P?@8WL2?.K4[US,RA10"@% * 4 H#A?2A&?,7W+>;=\\8;5AL5
MJ<B,U"FXXI3XR8XODKJ/D%T552R63TJ/,\#U7?W-M**A3$W-XAV3*[?XXUO9
M<V8.97)Q>_+-L$;!3YD/M%.B=$J(];:W7<M1D\VC2?W)>;O('C3=\=A-4D16
ML?*QH2W0D1A?+ND^XW=")?2PITHV>/ZGOKMB:4*8HB]O^YC8\%XMTV1"=BO>
M1=AC%D)[JL"K$>(#S@(:LWMR<XV#K\%7Y5:F%_U25NS!JCG)5?0C67_>S\T(
MB+]5 $23D!+ %$)+V54ZV7KZU.T\O_,[GHYY'NU]TWG=\$<86,\TOHXWC%,%
MM\E2Z+4KTFQ>J[MXI)KJ9)ZY]VGE"#L<!K;HT67B'76VYL5(BPY"-.D@J;97
MOR2]TN*HM6ILM>L7U<2N)4ZJ=Q]%[CL6]9WR;&\5:/F6-72-A?YBS&P.Q&\C
M),')*Q68\=AY4;1.2*3AE?X(EJK/LD0JYORWL>[GXGQ^UPL)E-9P\7)[)M#.
M+:D/3Y,]UP&&X\20XK;;2 "DZ5R7ET&R4!1,YY^\H80,'$>"#,R&O[#G,1NY
M1&+MY/'Z\U&D.OQA)55@U8?5PQ15XD*_#I0M#WV;[@MW/+^2,AJ\F(FGX;7Y
M4W49!1Q>5Z7C9L>%(E<[V=:)QQP6Q3HO&@H8L_S/Y:QV F2"R3YX4\[@<;BM
MPD:VY#EO,Y,7EG-M8TR7OJQVPX$")?DJ=:%P/,/.'E#(874G&<NXWC]@S6:A
MX_9(.O%.FY/$XV*#K$D<6CBDVJNJXV=EZ"/*R4&!=\?YGV#7=SPF!V,<ML6*
MFZF.8=6%K[K&3*>>1<8[K\-OD<<$:% XKTOU^-"4J4*%YS\GY^+I:)FI&,+-
MX#(YB<]B-;7/23D1LLY#:%8P&*M C2)R7^VEOC0N!<?\]>X:_P"4LMA-C>8>
M\>QH^'Q*9=Z,D*1!SF7QR2F'I0=5!F0X)M$)=&C44543U$H5IKS)Y.EX70]@
MV#/?REJ.6P[,S);<Q@DRD!W,.3'6CB3%0O\ %&NV#? Q1+D2JI=*"A:XWF#<
MX.W'.S4R+_(4;>\EI.1!& ;<CLNQ&7,;()Z_04>4@<)>BH2505G*>9?)DY-3
MR$/*NXG$;M*V&=BV\?@5S<]G#8TF@@(4<20B5U.;QN>B(0U!0^E--D3Y>L8J
M3E)3LV<]&:<?E2(GZ:\X1C?DY%555DNO4+]*I&3M""@% :<\X><7_#LO6H,;
M5Y&TSMI>D1X42&^C#R.QD:L CVG5,C5WHB?*MUFQYC>-*$<J&O#^ZS?FS;;<
M\%[(#CJJ+0$ZXBFHBI*@HL3K9$5>E;_TT?SKV[25>=,NLR\%]UF=F[KK.F[%
MXNRVKO;1,&##FY*1VT12Z$8@<8.X@72Z(OQK&6V2BVI5H$\:'TRV2D"*OK9+
M_MM7&G4R*_N&<F8*+BW88@1SLMC\<[W$541J9(%HU2RI[D1>E9QC6O4*E@%;
MI6"K3$':J!0"@% * 4 H!0"@% * 4 H#PDMNN-&C+B-.JB\'5%#05_U*VO6J
MXI.+47I?!F2="F:%L&9V4ISD]QD&H3B-(TRUQYJ5_<I*JJEK>E?*?M_U'<;U
MSE<:I"BHE3.N-:GJ;_;0L:5%9DGDI>3C;# @-2FF8,MM]YU2:0S 8R"2HA*2
M)[K_ !3I7?NK]^WNX6U-*$U*3\.*T4XUXU[#GMVX2M2E3&+2[R%QFR9K;\I*
M;P)-P,+#7B4YUOONN*J^U!%504O95_!*\O:^J;GU&]*-AJW;AG)K4W\L3KN[
M6WMX)W*RE+A6B)R+^NPLO%C39(3\?+!U$?%E&7&G01"1"X*HJ))?X>M>O;_5
MV;\83DKD)J6.G2XM<Z8'%+RIP;BM,E3C4UQ_G-VPWW66&8[I 1^T&")>(*J*
MJHA?!$ZK7Y__ /R??N;45%T_AJ?0?XRPHIMO$N6D[\WL3SD&<RD;(B'<!6U5
M6G!3\UD7JBI\J^N]"_<"WTO*G%1N)<,F>3OO3_(6I.L?@5O9/).8@YV=#Q8L
M%$C.=H",%(E,4L?6Z?O7KY[U+]S[BWN9PM:=,73*N7WGH;;TRW*VG.M7CWGM
MG]_SF-+&RX0L'C,C&;DAS!5)"3VO!>Z>BI6_U']P[JR[<X:?+N04LN/XEW_$
MPV_I]J>J+KJBVL^XSMTWO(8>7 B81&G!DQQD.(Z/-5[JV;1%14M=*[/6_7KN
MWN0C8H]45+%5SR-.QV$+D9.YP=.[,PI>[;+#V5G7W4C+=V,R^2-JB\G4!31%
MY?!25*X;GKN]M[V.W;C35"+\//3J][-T=C9E8=S')O/ED>F5W[8)N==PFJ1F
MS[!FV)&B&;I-="5.2HB(EEM\:V[S]P[J[N78VD5X6US;IUX&-KT^U&UYEUYE
MPU+(9O)8OOYZ,D2:+QMHV@J!$(63DHKZ=:^J]'W&YO6=6XCIE5K*GNZSR]W;
MMPN4MNJ+'7NG$* 4 H!0'RS][:?_ #L:K_Z_(_\ 0I7T_P"WE_6EU'@>MU=A
M)<T?*V%U;$R<FWBMFS7Z ^\TTXU_BCDU><A1[;9BVHJ"J)(2W]$_&OIGO7.#
MG:CKBG2M:99M<\3YJUL4Y*$Y:6UU_P"G:77)>%,?"RV8Q;&UQS#6")-LR,J$
M_&AX\$L(6*YD^XZ:\&FVQN2_A7)'U23C%N'U_2JXO[*<6>A+TI1K6>6;IET]
M;*E-UC3QQ,^?A]P9E3X*<QQ<Z"] >D-\D&[!7= BZWX$0K:NY;FZII3MT3XI
MUIUY'*MC&46XSJ^F-/MZS"WK47=&V)W7GY3<UUJ/$DD^V"MC:9&;DHG%55?:
MCEJW;/<K<6]=*8OXT.7=[*=F>E>+L-A>/]/=T[S)XR9>E-RUS3>,SC9-BHHV
MWD!4Q;6_JHVZJGK7F;G<*_M;V%-.J/<>GM=L[&XMXUU)/O/ICS(W)#>,:] =
MA%*/7<QCH\*5D6\>X])G*T+38EW <%302XD*C=4X\DKY38./E23K]47E7Z?<
M?2;KZUCPDJ5IF5'#^-=ZD;+#:F8F8.EO9G&3W([IA":"(UCW8\D3C-2'%#^+
MPN*$2G^8NMZZY[RPK;Q6M1DN>.K#&BK\CEM6+CEBO#5/W8X5PQ(C;?'NXZMH
M\+,-Q)4.1#B;$QGW@F&9K'?E F+;Z.$I(@= X?D]5K=8W5J[><:UJ[>G#DGK
M[S3=LW;=O5R5RO'C6'<3\O2-R+8)DK&ZQ-B:%)R,(V\,\\DM^.^Q#<;>F!%*
M2+;H&9"%G'+?[IQKECN+.A)S6O2\<JUE@JTX+EU5.AVIZOI>BN5>C.E?;D;9
M\1-9/5?'&OX;=B7'9J,;L!1GR&W#=<-]PF1!SFJ&I J<41;]+6Z5YF[E&Y?E
M*WC%XX([MJI0M14\&L,75FQO@M<9UE+U[_M&W'_U/"_^++KJG_9AUR^1SQ_N
MRZH_,H_GQ6 SGBUW(*(X<-LBK*)VR-"?'^&IJO1$1;^M=OIWT7J9Z']YHW=-
M4*_F14]FVW1\'XY\N2M 8D19DK*NXN:^I<V967GJC+A1>)%T03)?;:NFU9NS
MOV5=:^E/JBLJFB5R$;=S0GG3#'%YT^/O(KP_DXN&'R9H;.,G86%^BM9C'8_+
M,K$DH28](TP^T7[I.BA"2>J5T;Z#F[-UM2>K2VG5?56*[CGVDTO,BHN*I55P
M;\-'@_B4#QZ$G![)X?UUR[N-R,QG9\:_=%0%F,+%E,K^QV.AI^VN[<M3MWI\
M4G%]F7N9A94K<X0:JG1UY>U"[#-T"%$\NAY&BN30+<P7Z.*2#DG.3@_2JU[A
M-13JJ<5_+>N+3=;L>4Z?T^.737@;W**5SS$WXL.=.CCS,[<?KB^X#.CCLK@,
M2[_+T%7'=I:!Y@AYC[00R&SGQ7\*U;?3^BC52:UOZ#*_J\_!Q7A_%V&3Y/9S
MTOS#":U;])D3ST.0KWZBV3T(XW?=Y*R+?3DO3MW]MO7I6.SE!;5^9JIYJRSX
M9_,QW$92O^'371C7*F.1L[[??TTO$&H+B^Z,5(IHJ/DAN=[O.=[JB(G'N<N*
M? ;5YGJ:E^JGJSK[J8>X[]FUY*IT_>;2K@.L4 H!0"@% * C<UFL9K^.DYG,
M3&H.*AMJ[*E/D@-@"?&_Q5?1$3JJ]$K)1<G1*K,)S45J;HCX>\V?<QE][%_6
MM,-[%:@JJ$B4MVYL\5Z>ZW^#:7^PGN+]Y?A7TNT]/4/%/%^Y'Q?J'J[N>"WA
M'WL^?D5>/%?\%\1]!M7K-)]9\]&4NPWVUNNX8WPUB])S60-UO-.)-B-N75Z-
M@VRXM 17Y*+SB<P%?1L?D25S;;;0E?E<2PCA_P 7'N.OU+?W(;2-AR^O%OE"
MN'?\.LHJ6X6/I?\ -;X=?A7N<<#X_P##XL/]3Z6^WS+8;2M927F5)IS9Y3IM
M2$'D#;,!49'G:ZH)&I]?PKYOU+;W-S-Z/_CX<<<3[KT'=V=E:BKKH[S='P6G
M#V9]+QI$>2PV_'=!UAP44' )"$D_!4KY1Q:='F?H,9*2JG5'LBHOI4,A0"@%
M * 4!HG[MB$/#DPS;1UL9L(C:)503$7D)154ZV5$M21YGJ3IMVVJXQ_YD:UU
MC?-[V_/>&ML"7,C8G/9/+Q\]"QSCP8UM8[Y!&C.M@O%!!E$X=SJ7KZU#1;W%
MRZ[4L4GJJNK*I3,OO^\8#Q'L>3V.1*RW\Q[)E, U$SCKSB/8ER&Z)*R+B\A%
MEU1,"#IR2WI6-<#3?W%RU:DY8J4Y+_A:X'U7X;)V/X>ULV/>^UBVU#VJ?(Q;
M2WM'JMU^"5DCU]MA8A_*O@:OTW2H.Z:=M>O:]M/UC_\ ,Q[&.23$R8P0LXV^
M#QQ7&WRLZ($"(0BO)+U*'!:LQG"<8R_%6NG)Y]IE+H;WE$M\D1=J$LCL$2)K
M^?0\/(BQX<G&N<R%CO.(1*E[**KZ+=5]*9F;L>=KI+&2TO#D<[KXXRL1G.P,
MCM;;47R%E\:D4@Q;LI]K)L]LV8[C@FJC"18Z6O;A?U];R@O;=XIR^MJF#X<^
MC N4OQ=GY_\ G%.3FXG?\@08T%X@BN(,18T58:F**ZO/D!$5EM9:RH;Y[9R4
MZOZURRPH86$\5;IJ>2.5J>VQH$;*18,?88K\#ZD5DX^.$49<3DX/;<<; >8G
MR'EUZU*-$CMYPE6,E1TU8<EPQP-N8V*&/AL0T>-]&00.^^?<=-4]2,E]27U6
MLCN2HJ$;_->,7;%TY.]^L)!_5%7LG]/]+W>S_AK<.?+]R][=:AAYBUZ.-*DX
MA@J70D5%2Z+?X+5-AS=+VOU6@.: 4 H!0'"^BT!\/?>Q_P!>]:3_ / Y?\J<
MJ<3X_P#<'U0ZC</@_P K>.</XGU7%Y/:<=!R4*(K,N)*D"RZVXCA*J$)=?C4
M1ZVQWEF-B"<TJ+F?/_W6[9KFV^0L9.UK*1\K#C8EIE^1$-'6T=^H=/AR3I>Q
M(O2JT>#ZQ?A<N)Q:=%PZS19.N/FVDIPR 4%M%O<A:'IQ&_3HGHGI1GA)MM*3
M_P!"^>4-VUK<'-:BZKB7L-AM=Q:8MIB48..&J.DXKBJW9+ER7E\UJ4/1WNZM
MWM*@M*BJ8F9I_P#G'_0(ZZ[OL7 8A3<[.,?SX8TP7E[E5A314Y+UO\:&RPK^
MA:;BC'@G*A$YZ1F,)N&+SNZ9&)NDA@F93PM9+]1!Z/&.Z,N/M$JCZ=$O1FJY
MKA>C*XU<ZF?6_E69AMWS^HL:E@LQDO)[^'7-P<C@LH&OR8&"EV$DD3C$P4'7
M%0095LKDBJG'XT_182U*O,KN_P '1M%T[Q_F<YC=FUC;50L3W,3F#_7HF*[A
M/Y!V9,%71D1V2+OE?TY)QX^E#(F)S7B/2_)NC>)W,%):A! FO8O84DJ]%=F;
M.+L1UN<1(1NO3$:/@Z9]35!1/D!58K/CS(ZUA]/T_1<ID<UD\?F=,@ZZWDVX
MHMX+"Y3G*F29;@J+7.0(\245(B+C0N1<?(7D2?,DZ9K>>T!Y-GB*.WAC96P8
M_&A$D8:6L9E"E/?PWT-2YH@K=17JGK0B-?;MD].UW+SV5UO-XK'ZE+8V?*97
M![)&AOXR3M\<%DM8]D4$GFKJMP8+B1*JC^:A3<6='!>)LOKF3Q,7-;IY)S\(
MM8UR#*FJ[+F1&WBR+SDJ1(3BV#/+D;Q_E'B-J&*-2;%B(^HL:/C4U'8-7V]P
M,SA,9'@[?%Q@_IS#@Y)XSR"B@. XX_<!-!*XVM4,BS-9SQ\FW#XTW?79@/>6
M<#C!S^1E9)O+11D,B[CX#!R&AXDZZC7() %8G>/QJDH4G-A@BU?6&L5IVR9#
M0X\P=%_1V]H:A0ILJ%DWF8\>;&,+N(X:*9.)QZ%Q)>E"EGRN3QV4D;KXAE^.
MB<'8Y<+*[I'E[-CX91\AFFVG.,0G4%7.T+0*G9_>2R>M <9S:-5VK<];P,S"
M9K6\5K6=E^/M:V7 9UB++&4J#'XE$;1)",&C HI]4%/6@/I_7L.. P\3$!+E
M3PB@@),R+Y2ICO55Y//%U,NOJM4P)2@% * ^2_O>C3H\7Q[L> RIP]PQ^8<C
M:_"8;Y/NR9:-*CH'?V]I6P_=6ZFE=VSSE584Q,9$7Y2\@;1I>W:-B6YTG-2?
M',2+,VO)$2N$_+F\&9'=(;>T@/@/^^6KYS=WOZJTKZ<?;W'W_H?IT+FSGK>-
MZL8_\./Q^!@[+C,[F?O TJ-F]H??U)XAVO2$E6=8X.M(X[$:LH\.9-+Q5;]$
M%+=4KZ2$XO;MQ6/$^!E"49M/A@?:;7Y?6Z]+JG[*\]&3*;Y*_P"(Z]_^4>%_
MY8%;K?'J9BR?S^PX?5,%/V//RVX&%QC1R9LMU;"VT'55LEU55]!%.I+9$ZUI
M2;=$4HFJ^7,IL^5QK7\@[%C-<RZ$N/V"<RP#/$6U<$Y#(N$ZP#B)_#(QZW3T
MK=.VHKZE5<")]!L=G(P'U?!J4RXY%7C*$'!)6BM>SB(OM6R?O5I729'9N?!>
M<-EF2TX\V(FXV!B1"+B7%51%NB$GI\ZI#@<A *6< 93*SFT0G(J."KPB75%4
M+\D1;_*G2#AO)8YWO]J6RY]*7"5Q< NT:?NG9?:OX+0')3H?!YP9+7".JI(/
MF-F^(\BYK?VV3JM_A1@U1C?.J[#(8FZII.PYS2GI20PVN*PR,5S^(K2OLLN.
M"\Y'%47DZ@)Z+TZ5N=FBQDD^1CJQI1FV"GP1E!!*2T,YP%=",K@HZ3:=%- O
M=1Z>MJTF1PF0@DZVP$IDGW>?::1P5,^W^?BE[KQ^-O2C!@XS9L-E9^5QD.4#
MDS#/I%GM\A]CJM ];HO6PN#R^2]*M&LP9K.3QLE@)4>8P]&<+MMO-N@;9'>W
M%"1515OTM4H#V8D,2FT>C.@\RJJB.-DABJBMEZI=.BI:@/2@.#OQ*WK9;5&#
M6/B9YMEW.PW"092/B:M+T+B*D*K;\%K\^_:,E%WK;^JJ_P"H^@]75=$N%/L)
MS8!+(;'&@Q5YR0QL_N(B_D^H$6V[K\.2ITKUO48N]O(VX8R5J[V:J)''MI*%
MER>6J/N*[XDEMM-Y+#OW:R#;J/*T70E%!X$EOF*IU_;7C?M"[&*NV7A*J?=@
MSM]7BVXS61L5Z6S'D18I$J2):D# (EU5 %3)5_!$3UK[NY?C&<8/.=:=BQ9X
M*@W%M<#1FIYN)K^QNY*8)DP(R&[-)<E(U6WK7XQZ3OK>RW;N7$VJ26!]IN[$
MKUG1'/ [ZG+)C.S=B!M&HN/9DRG 3\@JZA"VW?\ $B2R5GZ3><-S/<I45M3E
M_NPC'O:,-Y"MN-MYR<5W9D)&EMC&R+;[)2'Y@#P?1>C;B.(9$O1;W]/6O)M7
M4H34HMRDE1\L:OO.J<?%&CHD3D8$RVCRXWYI6!D)*:^*K&D^UQ$_876O8M?_
M )/ILH_BL2U+^6>#[GBSEG_2W*?":I_Q(]M,C/[+M< IG\1K',@;G2Z=N(B"
MVBW^:VK9Z):EO=[#7]-I+NCE\C#>R5BS)+.;?OS/3/H7^<M;?F^MBV_:G"LO
M4/\ ]P__ +8?])CM_P#PO^%F/LD7679V4G8G)DQ):?<5(+C:JCCB'959=!;6
M5;JB+Z5K]3L[.5V[.U<<91D_"UGC^&2X=9LV\KVB,9QJFLU\TR]>*I^1G8B4
M$YTWF([XMQ77%4BXJ-R'DO541;5]G^T]Q>NV)*XW)1>%>K(\?U6W"%Q:4E58
MFPZ^W/$% * 4 H#Y;^]@N&M:F:(A*.0?7BOHMF4]:^G_ &^JW9?RGA>LRI93
MZ3Y^WC$)-SK'E#"K]5I^9E,3'WFK&6/DJ0J]&E"/5M0)%X*J<2&UJT_M[?\
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M[A<E;<#D*]"]PDB].OSJ'E^H>GQW45C1HTE_W(,ZO5=OB*J__<;G_"53Q/\
M^/R_[GN^\Y_[D&>_]\(G^1N?\)0?_P >?Y_=]YL3QG]INI:PWD"WQ(VVRY)-
MI#4VG&68[3:+=$'GU(E7JOR2I0]+:^D6[:>OQM]%#!\E?:1B-FRL25HLB%J>
M.9C*S*AC'<=[SRFI=R_<3]U4&E#'=>D1N/\ IM0PQPS]Y2/^X_G?_>^)_D;G
M_"53S_\ ^//_ +GN^\RL=]D$U)K'ZMMK)XQ#193<:(0O&VBW41(G%1%7TO\
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M)QGNXZ3H-&C0J/?<Z$-U7VULVMNS&XW&57B2Y<N.*K'V[S['\7HG^;C3K?\
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M9O5)RYLSBJ*A+5B44 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M/"W>VN7]Y=5M5:;?8;#*1X_\6Y?$XI>4');<Y%P^.%4>D=\L<T+##9$O)!0
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M?=H((,;)MO3V1>@/CPX,S6V2<3CQXO G(5Y(MQ"1#R9N>M;AF-VV#8)+_C/
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MROW)VFI?B5Q::<$OQ>ZIN5HU<;!Q14%(4)0+U2Z7LO[*[CY([T H!0"@% *
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M!3I54HHUO;;IQT:EIK6FN.?/,Q,=L7@O#2H<S#XDH,K'=Y<>\Q@LDV;"R?\
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M)#>.;=DLE,%E\T;=:3FK'>&Z$5KT!9= \H^.DAZ1J&*DR87\R8@I^JQ\HO\
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MM D[3 V]_'..9+$JRYB8I27_ --B/Q6NPRZS"Y]@#;;3B)"WT_;UH*E*\/\
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M'X=>M26ZNMIZ&J9?3]H5N*XKWF/JWCYK47X:XV=LKV,@(K<'#S<JDF"VWQX
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M2TF''Q[9(:1VK+T%21%5512*R76N);FY<P<=*[,6;G"*R9?U5$]5M5,3F@%
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M)4JZ5-TK%N4_*AJUITKAI=/JPS2Y'D/F?'/@XU#Q4V9DX@27\G"BN1GTCL1
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M"@% * 4!4O*&L3MU\=;3J.,FICLCG,7+Q\682J@-NR&B 5-1NJ JK8[=>-Z
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M+^A.GKR[>QY;<I8R9]/ZYZ\]["&WLIPV]I)1B\W19RZLDNW,VM76?)B@% *
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MJ:4#GBE-*%3A0%?5*M$#GBB>E* *(JEE3I2B!S5 H!0"@% * 4 H!0"@% *
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MW0FSLG(#$D^/K0M2OIX/U%J/%2'+RT+,QI,B<NR1Y[HYA^1-;!J03\@N7-'
M; 5%1LB /&UJ4)4EM1\5ZGI&0_4L W);?%B3%:23)=D@VS-DI,>$.ZJJG-^[
MJW7\Q%\Z4%2'=\$:5]&SCH+V4Q<(8GZ9-9QT]Z.D^!W7'48EVOW!%7G4%>A(
M)D-[5*%J9<SPSJ$F<LAHIT/%NNQI$S78<MQC#RGX0@#+CT4>BJ@M-(2"J(?
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M30M+2-](F!A)'^M3+"VC 6'(I_\ ;(]+B[\W$]R_.@+%0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M2\0P818:MHCZFVZV[W>:>T@7U%05"142O.O[>=ETD;5)2R+S7.44 H!0"@%
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M.2_]*]0%X\,X_P"R%WQ?K3GDQ[%CO91B7-"^_D =1[O'QY(RO!%X<?2H"/\
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M:_.M<[<9+$[MIOKNVE6#^[I7)FJ_\S.9)<1A7HN+7 X,CEQ9S$9V/.%]'.X
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MD5',?3_P+05.1)"2XK=*%.: 4!HG9?(^>ULW?%NAXX<MY6DN3W\9$?,&8L>
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M5))4\3K_ *<@HKN,C7/&D/58+>,Q6=RXX&'S3%8UV0+C<-'$)$$"(.9BW?\
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M1XSS<>;(C  &+)?1R9$=%$R=)7!_@BI^T>*E:@,'1?*N:VS%9LWXD)G+P,7
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MZU=1%N&X2DH_2Z<<>E='(CX_EK'$1G(T,FVCEME'CH[D%D)BNZ2O.NHBJ@N
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@"]$
M5: U%OOW&Z%XYV5[5=@CY(\DRTT\1Q8X.LJ+X\AL1. JK;UZ5WV-A=O0U1I3
MK^XYKNYA;=)$9A/NET799JXS7L)L&3R*-.2%BQH+1N=IE+F5E?3HE9S].NP5
M9.*77]QC'=0DZ*M2^XGRQXZS&,B91C9L6RS,:!\&9,V.R^"&E^+C9'<2'T)%
M]%KCE8N1;3B\.AFY78-5310,W]UWB_!Y65BW6\G,2*Z;*3H4=M^&^K:V(F7>
M\B&*+TY)79#TV_-55._'X&F>ZMQ=&1X_>+XH)P&DB9KN.$@B/T;=U4ELG3OU
ML_Q5_/#O^XU_KK66)]!)Z5Y)WB@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'F\IH"]O\ /UM^VW2@
M-<Z#O6S[FYM+#V.APG-=R$C#-J+[KHOS8R(JDJJ"*+2H2?,JQ3J>MO-I;L*V
MU)O7%2RRB^'65K >6]PVLUA83$8X,Y'QJ9>1C94QT5>;<<=;;8C*@7(U[2J;
MBIP'D*?.L5<U99G9>],LV?%.<M#EI345AE5R[\%FZ,L<7?=AV3+2=>U+&,CD
M<0Q%<V&5DW7!C194MON)"%&D4W'13JXJ*@AZ=56U52;RS.26RM6;:N79.DFU
M%1S:6&IUR7)9L\,KY"WJ!IF?S;.J-KM&NRTC/X%Z6HC-;404'(LCAQ_C*XG;
M0Q^:%UK).IR;BS"VUHEKC)5Y4Z'THZIY:D9[0L?O.CPF):/36,;E<7DG7(TF
M!)<?&*^P\(@2B]'=/W@2)=.J>J53D2Q-I"Z"J0<D5P+(8CU5%5+^GJE" C%$
M5>2)Q]57HB?MH"*U_.N9O&A/EXR5A73==:2#D1!N0G:=)L2L!&EG$'F'6ZBM
M R7$D)+IU2@.: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!
MU1P%+BBW+Y4!VH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@'KTH#3OW.PX9>&-EE'':*4V$;M/D JX'^--)[25+IT6W2O1
M]-;_ %$?;@<>\_LR/S^BS9^/?^IQTIZ'*XDWWX[A-'VW$XD/(%1;$BV5*^Q<
M5)4:JCYY2:=4Z$YFF]2SOU>6PD=K7YQR8</&Z@"NR^ZVXUP=D)+=Z)_$%/87
M]KI6F#N0I&3U+&LL%V4-LE&>*P?Y>?\ Q$OY P<K3X.&T;86YS.X857W9<9V
M4U)Q;4.<J/-?1BVJ\")557?F5:]O<\QRN1IIET8X<_D97K>B*B\UW=AM_P"S
M"+%D;-MA2&&WB:AQ":)P!-057#OQ5454O^%>;ZRZ0CULZO3?JGV?,^T?2OF3
MW!0"@% * 4 H#A21* "0FEQ5"3JETZ]4Z+0'- * 4!PJHB77TH#A' 5+HO3Y
MT)4Y0A+T6]"G- * 4 H!0"@% * 4 H#@EXBI?)%7K0%5QWD;3<OD Q6,S425
MDR)6_HFS57D(?5%"UT_UUJE5S.^[Z?N;</,E;DH\^'>6.5,C08CDZ6Z#$5D5
M<=><7B BGJJJOHB5:G%&$I.D55LQ\1F\5G8YRL1-8GQP-6S>C."Z"&B(JIR%
M52_6HFGD;+MBY:=+D7%\FJ,D*II% * 4 H!0"@% * 4 H!0"@% >;I<11?C?
MHE* TMJ4C+>.-AWJ!D<!E)[6<S3^=PDS&Q2E,2&Y;8IV2,5LTX!#8NYQ3XWM
M6I53=5Q/HMRH;NU:<9QCH@H24G1JG'I["I9S18[NO-8#:M8R*['@\<!ZQLF!
M%QV04^0CCSD;O,E9$:><XCW40%2Y(J5BX84IB=UG>/S==NY'1*7CA*E*+!.C
MYKD2>BQ]Y\39?(R=NQ4W88&U,PLA-RF'9^M>B9=I@6Y+<AIM4)1(KJ+H]%_I
M6R,7%O"M33O)V-]"*M2C!VVTE)TK&OAH7/><[F<MXWR\MK7<@#TAV,&+Q;32
MR,D\"/MF3AQVN7;Z(2\5*Z(G6U[5N/G;EN-N5%)2YM9=CXE<W[QYL>.V4-U\
M9- D';I,%K>,.Z*BVCC3H'&S#;?P?841&0-OXC?JG(;U304C.:MM$S3L5&AX
M?+L[C#Q6:C;]*3OD].=D1G !L3;7_&3?F$T]&)LEX"E^@]*A28@^-=<>V?QU
M&D:WD?T>3AY;^U(\$Q(GZJX,4FBFW/BCW=9<7W?%$^"I0$4Y@-C/".-X[$Y(
MS8S.R.0,+FL?*?@3XDV2TY';<=1P7XSQA[HLH5L%B$K)05/J2'S^E9[@J!]L
M.8*7<42MU13_ 'K+\?C5,3WH!0"@% * H>^[_+T^3%9CP6Y0R0<-5<,@LK:H
MGP1?6]?*^M^MR]/E!**EJ3XGT/I'I*WJE66G2UPYG39/)D; XZ ;;3<C,3F6
MWTA(:HC8&*$JF275/7V].M3U']P0VMF#IJN32>FN557'Y%V/HL]S<FJZ80;6
MJF>/ @7O,62:@0YGZ4RJRE>10[I6'LD@^O'XWKQKO[LG"U"?EKQ:N+X4Z#U(
M?MN,KDH:WX=/#GVDIJOD38-IR"1XV'9"$U8I<M724 '^RGMZFOP&O0]*]=W.
M_N4C:2BOJE5X>[/DCB]1]'L;.%97&Y/*-,_?D:VVK[B]ST_R1G=2F:S&R^(Q
MDE8L5,.LA[)N([AWLLRX;1H+? !:X/JA>V]QO7VA\N1FK_=3L6>T#?\ >9&!
M@,IIQXP&((//*K@3C91YUTU3H "XI=!2UNJU 868^\/)XW(;2D;6&,CK>+?^
MCPFPPY!OQ)#[F3<AQN\H"J"U(::<-IX%(.8\5Z*BU08T_P"[O=8FL/Y$=/B)
MEX>/:V22IO/?1?H,\V(T-UL[(ING)=-DPZ(/;)?V"'D]]X&W-#L]]=Q0L:_*
MBM.9!R6;8C&.1V7WPCFHN2[(BF@12(A_*5U]0,YK[J-_=9RF?C:SAYFMXC&%
MGWHS<J4SD'\>.3>Q?%M7&NV+O)I';'TXK;\U"EA\A_</N?CS*8C"Y;#X1K*L
MX6+GL]&D3GVBGE+E_2K PG\,N_(;MR)3];C[41;T(<X[S_Y!RWB2+Y(8U['0
MI>0V2/@X<+(++:9*#,EC!;?0Q$E,D=*Y**<;(2)U2A2EPOO.V,,4]ELGJ<=Z
M&./G3'7X#CIA#?CST@1ADH5R[+SEA)T4]BD-QM0'GE/O6V"'C\:":@S#S4TI
M3B%+==*$[!">W!CRHY@@\T4E>!YM50@,/D5"$KD?NWV#&9*;"G8G$1VL?G&L
M?D' E',5C%NMKV7Q2.1?4.2#2W!BY1_]U#XT!/>'/N4V/R9N.MZW/P^/@1LU
MB9>8?<8<=-P%8?=9!D.1654[?(R7UOZ#0'TK0"@% <*JHET]: INX^3-9TR#
M+=G3&'\K&'^'B6G1^J<<5$40XI=1O>]R3TKBW.]M6$W)X\N)Z&UV%[<22BG1
M\>!\_8O[F-EQ^WE(V)AN3JTM408# BVY#$CLC@N(BDYQ&_-"_-\+5XFV]5G*
M3E/)O+D?5;CT&WY:5MTDN/YO9GTU@MKP&S1EF:]DHN3CB@J9Q71<4.:*HH:(
MMQ541?S(E?20N1FJQ=3XJY9G:=)Q:9-5L-0H!0"@% * 4 H!0"@% * 4 H#$
MRDX<9CY>1,5-J&R[(,!_,0M IJB?BMJRBM32YF,G1-\C54O[@<+%\:8CR:F'
MF/8[,S/T^-CFU;64CW-T.MRXJEVEM9?BE>DO3IN]*RVDXJK?=]IYS]0AY2N)
M-INE%T5K\".Q?W&.979"U1GQ_L0YIDV4G1B9;YQ6WR$1=>1"51#W(MU^%;+G
MINBWYGF0T\,<S7#U'5<T>7*O4>LO[C(+>6RK.,U7*Y?6L%.3%YC8((@Z#+]^
M)*C JKA BHONZ7_JK%>FRTIRG&,I*J3Y=9L6_4I/3%R471O[BZ9;R_XXP6<9
MUO+['#B9I_M\(KBFG'NVX(X5N+:K=.AJE<4-K>G#7&+:.N>XM1EI<DF9;WDK
M2X[.?DOYA@&-6<%G83XN+](XXO$1.P];JEO;>L%M[KTTC]?T])F[T%7'Z<S7
M\G[C]:7;\SJ6.1E]86*<GXK(JXXK<N<+/>2+VT;11]O7ER^%>C'TRYY<9O"L
MJ/H7,\Y^I6_,<$U@N]F5H/W$:/L>OXQ_8\S QFU2HSLN;B6E=,6A:4R5$)47
MW=L.?"_+\*U[GTZ[;G)1BW%<3=:WUJ4562K[?(NT7R5I,Z1@XD/-1WI&RMF_
M@FQ0[RFF[H1!<4M;BOYK>E<4K%V*;<?IS.M7H.F.>1$S/./BR!CV<M+V>(WC
MY#ST5AQ!=,C=C*B.\0$%)1"Z7.W'\:W1V5^4M*BZFF>\LP5922,K,^8/'&OP
M<?DLML<1J%EFEDXUQKN2%>83U<061,N*+T553HO3U2L(;2]-M1BZK,RGNK4$
MG*2H\BJY'[BM+B;O@-5BRXTW%YN/WBS;+I$TPX[?Z=M0$%4E=6P]"]JK[O1:
MZH>G7I697*4<7E\>XYI^H6HW8PJO%[(MD/R[XZR&S+I\/8HCVQ(9,I#12L3S
M?YFQ=5.V1I_9$E6N26UOJWYCB]/,ZH[FT[FA26HP4\[>)B5P1VJ&1L@ZZZ H
MZI $=>+BDB!=+*O3Y_"]9?HMS1>!XD_5V:M:EAF26M>5_'NX99W!ZUL,3)95
MIM7BC,J=U;&W(A4D1"M=+\56U8W=K?M+5.+2+:W-JZZ0DFRY(MTO7.=!S0"@
M% :C^YO_ +$=H_U$;_E35>CZ=_Y$?;@SCWG]F1^>\1D9$R/'-SM-O.@VX\@$
MYVP(D0CXC=2XI<K)\J^QDZ*I\]%5:1O*%.QFCX#R+I&FX!OR3A7HP.GN3$>X
M0T>C\31ZPN(J,K<P4#2RHJK^'CRC*[.W<G+RW7Z>>)Z<=,(SC%:D4G?X+.JX
M7$ZDF0PVS/ST:V ]G@\W<DWW6NS]$ZZ1E_#2W(17K^ UU;9NY)SHXT\.GAUG
M-N/"E%M2>=3;GV5?]9=O_P#4H?\ Z4ZX/6?HCULZ/3/KGV?,^S*^:/;% * 4
M H!0'D\\VPV;KQ"VTVBD;AKQ$11+JJJOHB4#-.R-@SOE387L!K,ES'Z-!) R
M^4956WI">G!L_44+]VWPZK7L*U#:V]<U6Y+)<NM'BN[/=7-$'2W'ZGQ?4S;T
M"'&Q\)B##;[46."-- EUL(]$ZKU7]JUY#;;JSV8I)41DU"B@% =3]*!F@R=<
MD,[%+DY>8$R/,GA#CLRW -18%#%&VT7A856Y<OW?R]:_+I3<HWI2N2U*4]*U
M/\/+Y]&6)^AJ&F5B,81TN,*MQ7XG3'Y=.9MG07GY.HX>1(=)U]R,*N.&JD1+
M=>JJO5:^[](DY;2VVZMQ/CO5(*&[N12HE(LM>L>:* 4 H!0"@% * 4 H#@OR
MK^RHP:CU, _SZ>1EXI=86'NO1%LK/7K^-:8_W'[<CZK>M_XC;?S7?B4--Y;S
M>!RF%G9F5CO+[LU['+!E/G%C,=YTA'BV7\)8P,=5N*DOKZJBU@IJ2Q^H]G_&
M.S>A<4%/:**GJBJR>'/-2<L,Z%Q\$3F,".P>,CE-RBUJ7WL?)9(3%['SKN@J
M*%T51)50NOQ2L[6%8\CR_P!QQ=[RMY33YT:2Z)QP?NI0C/,F1#7O)?C9V9F\
MEC-=S+V3#/,1),I&7QA1@<C(K,?DO1PNO >M_=TZUZNWAKMSHDVJ4/C9-IHC
M_+WD#!9I=19U'8\E$RD[8\5C)@PEGX\7,=+>4'Q)2;;!56Z67\WRK+;691U:
MDG1-\,R2:=*#?)D37_-NOX'*;'E\;J$[ RI<J(QD)R-G+8=[31694B1>*=?@
MMKKU]5F#E9;23E7H*\S8GBX\9*AYK-Z_GLEF-<E2U:B#EGGGUCG"3LO]HY!*
M?;,TY=43]E<>X<JI-).G SC1(I>O;_LK7E''97,R#_S<^1FY$+4XQ\A2)*Q*
MKV3+DB(BSF^;HV_-[4^%=-RS'RFE]4,^W[,C",L>LSMT:FCYVT#$,Y7(Q\-G
MHN7DY3&L37VHSSF/9 V%5L21$LJ]43U^-8V4G8DZ8JE.TLOJ+KMVH2<MD',T
M>=RD*!$QKC+&.QTQZ$'U(J3GU!JT2<BM8$14Z5IA.BTT6>9''B:]\,Z[EMP\
M>Z9N&5VC-OSYC+YYEE[(R28EMFKS*#V^:(!"O A(;*G&NG=24+DH**Z,"*-<
M:D3X/\D8")JLX]QV/(S-@/(9"*Z<S]0G*W&CR#;9$"%LP&PI^ZM_G6>ZL-S\
M*5*+D6+5";\&Y!=@VWR')#-9+*8?$Y1J)@0FRI3C;,5Q@7"%&I"HJ>[I<AOT
MK7N8:8PP2;6)8O,WK7$9"@% * X)+_\ PZ@-/^/Y65\LXW*[E.S.0QN+D9"=
MC\!C,5(^D2-$Q[Y14==4453?<-LC7FJB**B(E#+(FX&U%H>*;P6^Y<\_L\1F
M3/ERX,12D'B6GR0)C[# V;$ 40.WJ2+QOUH2AVR'F[QMC?JE+)G(C8YJ%*RD
MN+%?>C1(>3;1V-)>=$.*,F*HJ&*K:_7XU2'9SS1X_B..L3Y4F!,;FQ<:$21"
MDB^X_D4(HB@ MDJ@^@%VS]%M9;+0M#P=\Z>.V& ^JDS&<J<I_&I@S@2ER7UT
M9E)!1U8%LE0R;5#;OT-%]JKUL%"J^2_,>#R.AYMK2LZ_C-D^@DSL/.!E!5Q<
M8H%,;:5T5139%5%U+7'KQNJ5"I%UA^6M*6)D%E27XDG%?2!)B38[K$AU<BO"
M(3(."BNI()%1M1OU1;VH2AX#YM\?OFS#A294[-2$FHWA8D*1(G*YBS$)37
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M5TZJ2WH*G. \9XW 3(4YB6Z\_CE082*#+(HR+#D<0/M *F7%Q5(RZDMJ(-F
MUX=P<<A&/+>&,K8#(;)MDS<<::)D7.Z0*8>TO<(K8E1*"IFY3QE R+:@,YYI
M2C18;@F#,AHVH;3C0<FW05.5G%)"2RB75*"IRWXPP;+>/ )$LRQT\<F#CSG<
M-TD:;:5IU5'WMEV6S)%ZJ0I5H2IZ87QKAL+*D/-FK\-UN0PS"<;:$0:FFKCP
MDX((XY=55!YE[1Z4!B_YL$<@)BI>PY)_&Q8KL+$,H8-%%:>1!52-L45XA$4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@.G=%4NG7X5CJP*.Z/
M_@I4'>LB"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MFD(6U,4<*_$+I=;>MD_"@,:'DF9;9.$VY%L\<<1DCVB,FR5+@BKU$K7%?BE
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MD2Z7Z=*X-CZQMMZVK,M3CG@U\3IW&RO6*>8J5)!K(QWGWXS)BX]&5!? 212
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MZMG<1AM;L5*DG)4YM'S6]V<KOJ%B;AJA&,JO@FU@9TG1W6/+34C#X<<?KSN
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M)%7TX*MT2WR5:4(3V*RC&7AA.C X#+G5ON@H*0JB$)#ZHHDBHJ*E 9M * 4
MH!0&'E)J8Z"].5AZ4D<"=^FC KK[G 57BV"6Y$MK(E1E1\OZIXSS.]^ F_'N
MX:;)Q6:,)C939I-QYT:<4QV5&E-\57D@*X"W0NON&OC=\]S:WGF6=G&ZU_\
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M[B,$Y69[B3;JGN'@NZ*QY)'IV]W"K2FH+HMK[RDXS7]HB?<Z]M+>B2F]:75
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M<;JN.#&8QM1:1>;KQKR<<<5.I$O_ ,%J^PVNUAMX*$>_F>I;MQA'3'([SO\
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MBH+"N.%5SKGU8KH-J>/- EXDV,QFVQ:DL(J8W' 0D$9#'@;KBA[2>,4X]%5
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MC<Q)?045*QV%K5>MMPNUAFYOPQ_EP]QEZA=T;>ZE<LZ9O",(^*6.;Y&[FD5
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M66L)04LT9*361DZSIVNZ;B@P>K8UC$XAM3,8L4>(JXXMR,E6ZD2_$B55J*-
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
@ * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>pc_platform-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pc_platform-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@VAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@.2XQ+6,P,#(@-SDN9C,U-&5F8S<P+" R,#(S+S$Q+S Y+3$R.C U
M.C4S(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7 N9&ED.F1B,#8Q-C0P+3-B9C,M-#0S92UB,V1B
M+3)B868V9F$U8C$R,"(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#I#-T(X
M.45"1C%!,4(Q,48P04,V,D%".$5%,S8P.#,P1"(@>&UP34TZ26YS=&%N8V5)
M1#TB>&UP+FEI9#I#-T(X.45"13%!,4(Q,48P04,V,D%".$5%,S8P.#,P1"(@
M>&UP.D-R96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B R."XS("A-86-I
M;G1O<V@I(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z83AE9F,U8S M864U-RTT9F9D+3AE.3<M,# W-V(Y-V0S-F1A
M(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.F(U,C8X960R+31F-F,M-#=E
M-2TY9C S+6$V-#DS.#<T,&(X."(O/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( L<#M ,!$0 "$0$#$0'_Q #<  $  04! 0$
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M',_]PG^C?\TH22;IS_+W:?[&QWZ*W0@DU * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4!S/_<)_HW_ #2A))NG/\O=I_L;'?HK=""34 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0',_P#<)_HW_-*$DFZ<_P O=I_L;'?HK=""34 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0',_\ <)_HW_-*$DFZ<_R]VG^QL=^BMT()-0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MPXB@)CUUZ^[@E9^=M'9DYS&8?&N+BS)\911(DR&R4N!+@XH;204C0>]:][$
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M_P#/)_\ "JI(.C?.$ZS;FE[KR&S-OSG<9@L4KU:4J*LM/29  +FM:;*"$DZ
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0',_\ <)_HW_-*$DFZ<_R]VG^QL=^BMT()
M-0"@% * 4 H#XQZZ=,]_[AZI9W+X7;LV=C)'JO@2F6]3:]$1E"K'S*214H@^
MA.@F$R^W>EV(Q.<ANP,DPY++L5].EQ(<DN+3<><$&C).;?.BV3NW=N1VVYMK
M#R<HW%9E)D*C(UA"EK:*0?=L:(@V?S7-H;GVE W*UN7%2,6N4]$5'$E&CQ A
M+H5I]RXO[M&#C_5KI;U$S74C<F4Q>VITK'RIBEQY#36I"T:4BZ3?E4@^@\/T
MS1NSH;A]B[H8=QT]N(@I*TCQHLMI2BA>DGSV4+\4DCA4$GS+ENBG6'8N5+^+
MQTR0MDGU?*X):W"I-^8\$AU/+DI(J2#);P/SD=R>'$=;W,ZV2G2F:])C-7!X
M$E]:$\/*: ^YX2I2X49<UL-35-(,EI)"@ETI!6D$<#8WXU22:W=6UL-O/ S-
MN9YCQ\=,3I7I.EQ"P;I<0KC923Q!^C<<* ^-MZ_-EZ@[=E.KP# W%B-1++T4
MI1)2GL#C*R#?_P!65"JJD$-9Z==7$ X]C;>=;:/I,B-)0UQ\O )H#M,7HKO;
M<G0V+M[(0#CMU8/)2)F(AR7$#QXKZ0I:"0HAM2E*44Z[<4\;!5Z@')MM[3ZW
M[6S#T?;.'SF,R;Z? ?6PPZTVI%[]YPCP[7%PK5[AJ05YWH;U9@Y-UJ1@I63D
M.!#[TV->2VMQY(<6"Y\)25**5GZZ_,<: [9U&V9N[,= =E;>Q^%EOYV ]#]<
MQZ$7>:#,9]M2E)[!<CZ-0#4?-GV!O7:N^Y^0W'@Y>-@NXIYA$B0WH0752&%!
M(/E(23[U&#KW7_!9C<?3'(XG!0G<ADG7HJFXS"=3A2A]*E$#S 41)PCH!TWW
MYMOJ=C,KG=O38&-;9E)<E/MZ6TE;"TIN2>TFU&06M]87K_A]^[AS^!AYB-#R
M$QUY@XIQ<EE<<'2T5(8*@2$)3Z:;T!$V.D_6KJ-G?7LUC)PF22E,C*9H*C)0
MA("03XH"B$CDE"#[E2#[3V'M&+L7:6+VK#<+S>/:*7'R-)=><47'5VXVU+4H
M@7-APJDDYK\YO:^X=U[-Q4';>-?R<MG)H>=9C)UJ2V([R=1'DNH"I0(+\V38
M6\]J;SRLW<>#EXR&]BULM/R6]"%.F0RH)!OS(!/O49!]3U!)"^K>,R&8Z;;D
MQ>*C.3,C*B*;CQF1J<6HJ3P [: ^4^DO2WJ)A>I&V\IE-M3HN/BS$KD2'6M*
M$(TJ%U&_*JB#>=?.B.[$[NR&[ML8Y[+X?++]9?9B)+LB/(4!X@4VFZE)405A
M20;7L>5S"!%,3L+KON[;:MOKC91K:V+9<D,0<CXD9I:F4E:&FFW %.*)X-BV
MD'M%2#<]%NF?4';W4_;V8S&VYT3&QW7O'DN-%*$!R.ZV"H]@NH4!U/YR?2+/
M;W..W3M9CUW*8]E4.9 !"77(^LN(4WJ(!*"I=TWN;\.50@<'V'T]ZIX_=N)+
M>WLS"B(GQ%SUF._'9+33R5*UJ(2D@"_,U(.E?.3Z>[VW3U C9+;N"EY* C&,
M,JD1V]: XEYY13?R@*%0@=*^;/MG<&U=BY#'[CQS^,FN95U]MB2G0M32H["0
MH#R721[U&2<^ZX?-US61S<S>.PF4RTY!9?R.'"DMNID*XK=9*B H+/>4F^H*
MO:X-@J0<D.W>N<C$(V.K%;A5@T+U)Q:H\D1@0HJ'$ITZ=7> OIOQYU(.V="?
MF]Y/;F68WGOE"&9\3OXK$I4EPMNJ%O%>4FZ=20>XD$V/$V(M45!%?G!].-][
MEZES<I@=OS)^.7&BH1)8;UMJ4AH!0!OV'A1 [?\ -[P.9VWTTAXK/07<?D6Y
M,I:XTA.A82MPE)MYQ1DG$/G!].-][EZES<I@=OS)^.7&BH1)8;UMJ4AH!0!O
MV'A1$'7>D^V\_ANADC 93'/Q<V8^42F ZG2\5/%TM@ _77%J$GS3M'I'U,A;
MKP4R5M;(-18^0B//NJ:(2AMM]"E*)\@ O4D'T#\Z#:>Y=V8+ 1MM8N1E'X\M
MUQ]$9&LH26@ 3[IJ$2:'YKVR-W;2S&X7MRX:5C&9,:.AA<E&@+4AQ1('N T9
M!]+U!(H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4!S/_<)_HW_ #2A))NG/\O=I_L;'?HK=""34 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0',_P#<)_HW_-*$DFZ<_P O=I_L;'?HK=""34 H!0"@% *
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M'48<N//B,3HBP[%DMH>8<')3;B0I)'N@U (;THWS-ZA;4&X9\-J"_P"M/Q?
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MLO#8I].WT177Y63D/-%Q,ME#HTI;2>141[WGJ0;C9/4?(YC<D[8V[\-[!WC
M8$U++;HD1940J"?%9< '(D=T_P!(4! .AT H"TJ3'0O0IU(7]:2+T!=H",;>
MS>Z<CN'<..S.!]F87'.MHPV2\9+GKK:@=2M(Y6L#YKVYB@)/0$8QV;W3)WKE
M\)-P'JNUH<=IW'9[QDJ]9>6$E:/#YBQ4H>;3Q](4!)Z 4 H!0'+>LW5;(=,&
ML*YCL8WE%Y-<DO-.+4VI+,1"'%J3I!^"H\ZD'2<?.BY2!%R<%P.PIK+<F,Z.
M2FGDA:%#W014 Y=LOK&_N_J9E]F-8YMK!PV93N.R@6HKDF&^B.H@>CI*BNQ'
MDJ0=:J * M25J:CO.(]-"%*3?R@$B@.1;+ZB[[SO1QK>D3%-[@W8M]UM$!FT
M9"D(DEHFPYZ4B]ASJ0=<B./O16'I3/JTEQM"WH^H.>&M205(U#@K2>%QSJ 7
M'"M+:E-IUK )2B]M1 X"YY7H".;%S6Y\]@A/W;@_D_EO&=;]0\4/7:0>XNXY
M7Y>]?D10$EH!0"@*7'$--J==4$-H!4M:C8!(%R2?-0''L9U'ZG[Y9=SO3S;6
M/^2277&H,S,R7&I$U+*BA2VVVP- U CO^2I!U/!2<M+Q$.3G82<=F'6@J9!;
M=#Z&G>U(<3P5[U0#84!SK?.\<W@=_P"P-NXY;2<;N)^:UDDK;"UE,=#2D:%7
M[OI&@.BT H".X'>F)W'G=P;?QZ'Q,VVZRQD''4!#9<?"U -FY*K!!N2!YJ M
M87-[IG;ISV*RN!]0V_ \'V3E_&2OUO6FZ^X.5OI<CQH"3T H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H#F?^X3_ $;_ )I0DDW3G^7NT_V-COT5NA!)J 4
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M.[I"K6M>U =5J * 4 H!0"@% * 4 H!0"@% * 4!S/\ W"?Z-_S2A))NG/\
M+W:?[&QWZ*W0@DU * 4 H!0'--Q;9SLWK1LW<\6&7,#C(,]F=,UH ;<?:<2@
M%)4%&Y(Y"@)-U#QD[-;#W)B,8R9&1G8V5'BL I25NNM*2E-U$ 7)[30')\ML
M3><;:?2S)1<0,K.V4E"\MME;K:5.J4VVG4A2B6RMHH.GB>)X7J09N4QW4?>?
M4+8V[)NVO8^W,'*?'JKLEEV<E,EH:Y#P0=*4$I0E"$E2^!)YB@)'M7;&>Q_6
M/?>YID,M8/+1\<WCIA6@AU3#"$. )"BH6(([P% (>V,\WUXR&[EPR-N/;>3
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M1TCB[/W9#5$E.HG,3HA6A:@U+>=^$V5)XH7Y:D&@VL_U-Z8XE.R)FT7-V8:
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MX@4!H-J(ZF]),>[LIK:SF\,!%==5M[*PI3$=?@O++@:D(=XI(4HW5R%["X%
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MB=0-D$26($M22R\E9L]'6M!(&L!/>"K=EQ>XD&VB;SZAYG,P\=(Z:3L<ZZM
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M,NE("BI)3J^$D4!K-K3>K?3;!HV0]LX[J;QH4S@\U!F,QV7F-1+:7TNG4V4
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M2V.'90&UV)L#%[$B34Q9$C(Y;*O>M9?+S5!<F4_QL5$  )3<Z4]ESVF@)82
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M"@% * 4 H!0"@.9_[A/]&_YI0DDW3G^7NT_V-COT5NA!)J 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H"AX%3:@.=J U]"2]%22Y<<@.- 9M"!0"@% *
M4 H!0"@% * 4!2M:4"Y]X=IH"WX1=[SO;Z*1V?5H"CU1-_2-O)0&0E(2 E(L
M!0'M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"T^P'T
M6OI6DW;6.:5>6@*8[ZG+M.C3(;]-/81]</,: OT H!0"@% * 4 H!0"@% *
M4 H"AQU+0NKF>0H"TF4DFQ20#V\Z H0?6Y'B\X[!(;\BG.T^]V4!ET H!0"@
M% * 4 H!0%J0LH;NGF3:] 8-"3*BK)!0>-N(H09- * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@.9_[A/\ 1O\ FE"23=.?Y>[3_8V._16Z$$FH!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% 6U,-*-R./FX4!2I'A=]H<!Z2?** NI4%
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M)R&O_D3T=S)<LOD\V#7%8?T(R/G>8NXOM61;M_OB/R59W_U>?_Y%[/Q-=_\
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M * 4!S/_ '"?Z-_S2A))NG/\O=I_L;'?HK=""34 H!0"@% * 4 H!0"@% *
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M@CB""*-5)3:=4=KZ?]0DYE+>&S3@1EDC3'D'@) '8?(O^FN7UV@Z?GA]OP_
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M7;TMIW+CHE[^2YGPAU*ZEYWJ5G%9+)J+&.9*DXW&(42U':/T-2U6[Z[<?,
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M_<TJOZC3J^FW./FVXT3I7@\$19YN/$Z+[UB,*M&C[NCLLI4LJLA"5I2+D\>
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M3':!)N?9;/$\>U5<KK__ )-S_,=CV_\ ^+:_RHEU8)G"@% * 4 H!0"@% *
M4 H#4;@W)C=M10_.47)+H)BPFR/%=([?[*!VJ/O5DV-/.\Z1V;V86KUEO31K
M+:]BWO\ #F<=SNX,GN*4).1<'AH)]7B-W#+(/UH[3Y5'B:Z2S8A:5(^W>SA]
M5J[FHEFF_!;EZ<35U?,04 H!0"@% * 4 H!0"@% * 4 H!0'7NG73WP UN#/
M-??^"X,-8]#M#BP?A?6I[.?/ESNOU]:VX/#>_D=GVGM66EVZL=R^;^1/-T;H
MPNSL))S^?D"-CXPXGFMQ9]%MM/PEJ/(?\.-:G3::YJ+BA!5;.CU6JMZ:V[EQ
MT2]*+F?"/5#J=F>IF=.0FDQ\3'*D8O&!5VV&SS)[%.*MWU>]R %>J]N[=#1V
M\JQD]KX_@>,]U[I<UUW-+"*^V/#\>)!ZVAIA0"@% * 4 H!0"@% * 4 H"IM
MQQEQ#S*U-O-J"VW$$I4E23<%)'$$'MJ&DU1E49.+JL&?1O2OYPFLL[>ZB/\
M>-FXFX2![B4RP/H>,/\ G[55QG<NQ4K.PO&/_E^GLX'?=J_D2E2WJ7CNG_YO
M_-[=[/HE*DJ2E:%!2%@*0M)!2I*A<$$<"".VN..Y/: 4 H!0"@% * 4 H!0"
M@% ?-6^7L8CKON1&3WD]LF.O!1VSE8W%;BE-,?>"!QLH=^R;'N\*ZO2J7[&&
M6VKCSO!^,L3D-7E_W">:X[2Z>U>$</GZB);<R&2=C])FXN.:BN0LOEV<&^$E
MI&0<3ZNIM]25FY4ITZ%*O8VMV5GWH13OU=:QCF_P_=A[,37::Y)_MZ1IEE-1
M?ZOMH_;AZC#1+PBMEP]P1<G/5\X%>>\-U/BR#/42X1X9:)MHMI^#?5W>7"J\
ML^LX-+]ODY4]/EB6W*'05U2E^ZSTWU\*>SU^7D9N3DX>="ZAY+JG/D1>KN/E
M(3@8X>>:+"DJ[B8B$'247X=MD64.=ZMP4XRM1TZ3LR7FV8^//YX%<W"<;T]3
M)J_!^7:J?Y>7PC1\S.$V'E-V$?. F3(3T7;<5[;[96^R3)6TA0<'A=[QU'4H
MW'%RX5R JAQ<+7_LTG6;S;..SP^1=4XW+S_?-K+;3CM6Y.N&.:M?7AN1,.A)
MZD'IWC?D6<&<8,C,$_VQZUZQXNMN_A^!W;:+>EQO6!W7]OUY=7/6BIEI3?Q-
MCVC]U^VAT<F6KKFK7=LH<[RR\2K(=7V)N\WMNNJRDE4;"-@K;RJT//D-.)1Q
M/$!%[V&JZN%;6&:FGI;4_*JR_3@L322R_P#NJW'!YG2/ZO-+#TV5J\#:;MS\
M#.8S:>#W)M_&[>R#6VC(;FY-R>U$;8U.AE,*+&6F[JPD+2IS5Q.FW#C9T]J5
MN4Y0G*:<]BRUKA7,WN7*AE:N]&[&W"Y",&K=:R<J4QIEC'>]N->&XQY$M_/=
M+-DS\SGX,A6&3DW%[9SDQ^,C)Q8SUDE+C2DE;C8^]H05@\!I[09BE;U-Q1BU
MFR^:*3RMKX;WAXD3;NZ.U*<T\N;R2;69)[J4QW+'Z%6X\TUG9>RHTW'1L/T_
M?P1<PN(S\R?'QB)"7'$.J,B/=U:P4CPBL^@4WY\5FWTU<:;E<S>9Q4<U,-SP
M\>=1?NJ]*U%Q4;3AY8S<E&J;_,L7LPKNIQQRI:E-8_IG@^I&?1E.EZWLAZQE
M<=(D.Q'BVXI++3SI2A9\(@)Y72@G35$<97IV(Y;M(X-*OJW8^][2[--1L0U$
M\UJLJM-M/'!-\G[%L)I\W7V-\KNI"=NO.2,"),,8UYXK4XJ-XDCPR2YWB"GD
M5<;<ZP.\Y^E9SX2HZ^-$9W8NGUK_ $VW&L:>%9>GQ-'MW;&ZMX[VZNX/;^XV
M<#B)>4,;/7C"2^^RZ[)2$-FXT\ M*AJ%[UD7K]JS9T\IPSM1\N-*81,33Z>[
M?OZF$)Y$W26%:K-/#XU,O>&P\,.IO3?IFS+F1]OJP;\*2J.]X4AYA*Y#K@41
MP'BJ1W[#MJWIM7/]M>OM+-FKR_*O<9.JT</W5BPF\N6CQQ:\SQ_S4Q-1N&-M
M'Y;[VPO52;(B1<%BT1]@LN//-MICLM:6%L:2 MT@(/&X4HJN.'"_9E=Z-N5A
M)N<O[FSUUY;?# Q[\++OW8:EM*$?[>+V4P:XO9XNO TV0P\G<.)Z,3-[(?>R
M6;FKQ#SC[CB'W\.W*:\#5<W!L\O2X.\4Z3<\*R+=U6I:A6J4BLWA+*Z_!8<:
MF#>M=:&EE=JW-Y?&&>-/=)T>]4>.!DNXS'8#;W7["8P%K&8U_&Q8K:W%.%#:
M)RTI!4LDGWS5'4E<GI92VM2?_2779A9AJX05(IP2_P"=DEQKENI/3Y/B$)/3
ME!"=5@?[C)-[7\U8MS_X]W_]S_[HF9IL-38__P >/_;(YU$QC&'Z3;6ZD0IT
MMK=+&X_9\>5ZRLM,Q4!QSPT-WLD:AJ/ENJ_.MH[CN:J=EI9'"NS:\$:A6E9T
M=N_%O.ITK78J-X+W^MDRWU*VZ]U$ZCJZFSID/,8Z)_\ 0#3:WVD)!;5X18#/
M#4H^'S[INLJY7&!I(W%8L]!)QD_[FSUUKZ^>PV>NG:_<7WJ&U*,?[>WU4IZN
M6VNPZUT#*E=(-M%1)5IEW)-^4QZM+W?_ .7/U?\ :C==C_\ A0_XO^YG3H?^
M*:^RK3SV&^A]R-]6(9HH!0"@% * YG_N$_T;_FE"23=.?Y>[3_8V._16Z$$F
MH!0'BE!(*CR'.@,14IPGNV H27F'_%NE7!0^G0@T\S_%._95EPV&%/[F8ZT(
M<0IMQ(6VL%*T+ 4E23P((/ @]H-5%!CG'8U440%08RL>GBF&6&C'!O>X:*=
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MD\#7G-RW*W)PFJ26U'J5J["[!3@\T9;'Z>];C+JV710"@% * 4 H!0"@% *
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M4VEZ-(:.I#C:Q<*2?/7G$HN+<9*C1ZG&2DE*+JGL9>JDJ% * 4 H!0"@% *
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M42]F=[9J%L*'N[!2,7FK/,(R,P)?88*'92(ZTLL:E+2XDKTE+K@TE/$=E&\
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M[(1HDQ&18\!;L6?I;9D,G4KNA;C:N/--P0#2HIN)H18D>2JBD4 H!0"@% *
M4!I=S[CC[9QWK2P'9S]T08I^&L<U*_L)[?H5E:;3N]*FY;7Z;S UNLCIK>;;
M)_:O3<CB,F3)FR7ILQTORY"BX\ZKFI1_H'D'974QBHI)8)' SG*<G*3JWM+5
M24$HZ?X3$Y_<2(67</@MMJ?:B#_WE2.:"1R '>([:P==>G:M5AMX\#;=JTUN
M_?RW'A2M/U<OGS-ON':&0VK);W;LZ0I_%LK4XE;=UNQ2"0M*QS6UP*5 \1R5
MY:QK&JC?72NJDOC]&9FK[?/2R5_3NL5[8\:\8\>&\V\MC%]5<)[4Q_APMWX]
ML"0R5 )6GGI)[6U? 7\$\#VUCQE/17,LL;<O3V\49MR-ONEG/"D;T%CZ<'N>
M[VG*>()!%B"01P/$<#Q'"M^<@>@*(40DE* "L@$A()L"HCD">'&A)-,9LJ'G
MMFNY?!R').XHKA,N$JP 2D7+24^4CO(5\+E[FLN:R5J_DFJ0>Q_/ZF\L]NC?
MTKN6FW<B\5_X?FGO(6TZXVMN1'<4T^TH.-.IX*0M!N"/(016S:3P9HXR:::=
M&MAV9U;G5'9T9<?)#&2XKH3EV]1\ A(^^:T@BZ2/OB+FWEKFDEHK[K',FO+Q
M]-S.VDWW/2K+/(T_/PYUY;U[SGFZ&]FPVHV,VPIV7+BJ5Z[E%'[T]<6TCE>Q
M]$H 2.7&MQIG?DW*Y1)[%P.<UJTL$H6:R<=LMS].6!&ZS35B@+T6)*G/IC0F
M%R)"_1::25J/O"]4RFHJK=$7(6Y3=(IM\B=X;I)GIVEW*.-XU@\2@_?7K?8I
M-A[ZO>K57NZ6XX1\WP-_I^Q7IXS:@O:_3UD]Q72_:N-TK?87/?'PY*KIO]@F
MR?HWK47>Y7I['E\#H;'9=-;VK,^?T)=&B1(389AL-QVAR;:0E"?H) K72DY.
MK=3<PMQ@J122Y%ZJ2L4 H!0"@% * 4 H"&[DZ6]/-TA9S6 B+D+!O*91ZM(N
M>TN,Z%'WR:V-CN6IL?9-TX;5[&:K4]ITFH^^VJ\5@_:CC>ZOFF07@N1LO-+C
MK-RF%DAXC?N!YH!21[J%5TNF_D\EA=C7G'Z/ZG*:O^(Q>-B=.4OJOHS@^[^E
MN^MCJ4K/XAUN$DV&08'CQ3Y/OC=PF_D78^:NKTO<M/J?LDJ\-C]AQ>L[5J=+
M_J0=.*Q7M^I#ZV)JA0'J- 6DN ENXUA)"5%-^(!((!MYJ,E4KB?0\;K]LO9.
M'Q.WNGVUR<(XWKW"B:LMR7%.)T+2EU!.MP\_$5W;62$CX/&R[)?U$Y7+]SS?
MEIL]G#E[SOH_R#3:6$+>GM^5_?7;[=[Y\,%RVW5KY-['Z(P,'M&*]C86\YC6
M0]0E**GVV7$(DN)425'N%++=BH\.TU8[9U=1KW.ZU)VDXU6RNSZLR>[]'2]M
MC"S%Q5YIT>U8)X^%(H@O2'IGM'<.V,_OW?4F0,!@U*;,.&2'5%MM+JUKT@J(
MLM(2$VXWN;5M>Z=PO6KL+-E+-/>_8:;LO:]/>LSU%]O+#<N2J_B874#IIMB-
MM=GJ-TVRYR6SG7A&F1)BDIF1)"K618A!58D H(U 65WDG4+NA[A==UV-1'+<
MI5-;&O3U;L'@8_<>UV59_<Z6>:W6C3VQ?N^NQXIU7,,?,./GQIX89E&,ZA[U
M:4@.QW?#4%:'4&VI!Y$>2MY<AGBXU:JMVWU'.VIY)J5$Z.M'BGX\N)WN%\X[
M<NX-QXW Q]MQ'-JSDHQ3VV&0%KD)D@-*"7%!(3S[J-(3IX*^NKDY]AM6K<IN
M;SKS9^%,=GH_@=O;_DMV_=C;5I.W+RN&VM<-KHO5LW/B9OS@9V$V!M3$]']H
M(,:$\M63R:-16KP"ZI;2%J-RK4Y=7$W ;3V5:['">IO2U5W%KRKV8^[XLN_R
M*[;TEB.CLX)^9^%</''';595Q(ITWZ Y/>.!D;DW!.&W\4^V$81Q\ *D/N$)
M;6H+M9I2B$I^$N_=X6OL.X=[C8N*W!9Y+[N2W^OX&M[9_'9:FT[EQY(M>7F]
MS\/CNY\PW+MO,;1S<O;^>CF-DH:M+B>:%)/%*T*^$A0XI-;S3ZB%^VIP=4SF
M]7I+FFN.W<5&C4UD&(=EZ&]6_DA,3M;<3_\ ]*SG/[N^L\($E9],'L:6?P@[
M#WA\*_-=Y[7UX]2VO.O^I?5;O8==V'N_[>72NO\ MRV?X7]'O]O&OUH1;_\
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M<6-0X@I3S"B*B@JC(=Z>RGMDY7;J\@U[8SF1&8R$Q+2DQDR5S&I3B&FM14$
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MH#*T)U:M(U>6W&@/: 4!S/\ W"?Z-_S2A))NG/\ +W:?[&QWZ*W0@DU * 4
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MRU_IO:OT_A\#J>WZ_J_V[GW_ /=^/%'U!C<*QC&3&QS,;'1KW\"$PAI OQ[
M/Z*YLW1D+@LZKNJ6\?\ N*)'T!:H!6AIIH6;;2GW * @W5KIQ#ZE;6=QQ2E&
M=AA<C"RU<T2+<6U'GX;M@E?O*YI%;;M?<):2\I?E>$ER^J_#>:7N_;(ZVPXT
M\Z^U\^'@]_MW'P;D($S%3Y.,R#*H\^&ZN/)85Z2'6E%*DFWD(KUJW.,XJ475
M-51XI<MRMS<)*CBZ,NX?+Y# 96'F\2\8^2@.HD1GAV+0;\1V@\E#M'"J;MJ-
MV#A)535"NQ?G9N*Y!T<74Z7U,W_M[,;CV_U#V,Z_BMYKCH>SC;;>EIF:V-(*
M5J'?41=*^Z4J1IOQ*A6D[?H;ENU.Q>2E;KY>:^7Q3]1T7=.XVKEVWJ;#<;M/
M-P37/?P>YKUG.F\R_(SGMO,D9*2\Z79;LQ/K)6M? K4E2D!93?4$J5I)%CPX
M5N792MY(>5;J8&@6HD[O4GYFWC7'W55?#9ZB1=3,:Q&S;>4CS6IB,JTF0IU+
MJ%/.KT)U2%M(::\)+Q)* 4W58JY$5A]ON-V\K367#\*U=:;_ &&R[O94;JFF
MI*>.U5>"\U$E3-NXXLA5;,T8H!0"@-KMC<$S:NX<;N. ?[UC7T/I1>P6D&RT
M$^1:24GW:Q]38C?M2MRV21EZ34RT]Z-R.V+K^'KV'W["G1,G"BY. OQ(,YEN
M3%<^N:>2%I/T#7DDX2A)QEM3H_4>V0G&<5*.R2JO!E^J2H4 H!0"@% * 4 H
M!0"@,+*^V3#4,"8J<EJ3H,]+BF-%^]<-%*KVY<: YG%ZC[M3M_";IS3>+C8G
M*Y=G%J1%1)<=0WZR]'</>)N5%L>&$IO<VXU15ES*JT)HSO[;$C''(LR'E 2U
M8TP?5GQ/]>0CQ"QZJ4>+K"._;3Z'>]'C552C*PWO_:3TC&PV9RW)V6UF!$1'
M?+R_ >##VI&BZ/!6=+VNVCX5J50RLH=ZB;1BM9%_(3'<<UBF/7)AG19$50AE
M?A^LH2ZVDK:U<"M%[=O92J&5AGJ)M%YY<=4QV.^EZ*P&Y4:1'4H3W/!C.I#B
M$W9=<[B71W=5@2+TJB<K,V;N>"Q"W$_CFW<I.VVTM4R!&2K6N0F.)*6$*(TJ
M6I"D\$WMJ%^-*D4-/MG>#TO;B]V[@RF&<P*VFG&9&'+[H;<6;*965%16L%2$
M)2E"5E7#0#PJ$R6L:(2=]-/Y+;\3# Z9N55C,S'FL.QY4<>HO2T MN!"D%00
ME25$6*3PI493.C;^VG*\=:9_@QF8ST],R2T['C/1(UO&>8>=2E#K;>H:E()X
M$'D0:FJ(RLU66ZIX7&QL7,:Q^2DQLGD&L<A2H$MA24NM*=#R$+9U."R>ZE(N
MJ_F-1F)469C>_<3&;EJR<IMV0,G(QF/A8UF3)E.JCH#A06?#UJ<0DDNE *$^
M6IJ,I<7U&V>(\&0Q.<EG)MR'<?'B1I$B0\(:PW(2&D(*PMI2K.(4 I)YBE4,
MK-]BLKCLYC8N7Q$E$O&36P]%DMWTK0KD>-B#V$'B#P-24M4-C'07'T("BC4;
M:D\"/<JB>PKM_<C?-MH:0&VQI0G@!6*9H6M+:%.+-D)%R: \0&S=U L7 "56
ML2+<+T!70"@% <S_ -PG^C?\TH22;IS_ "]VG^QL=^BMT()-0"@% * 4   Y
M"@% * 4 H!0"@% 6'UI;6A7PAS'F- >HDH6=)&DGE>@+U * 4 H!0"@% * 4
M!X2!S-J ]Y\J LR39KEQN+>:@,*A)DQ%DW0>0XBA!E4 H"AYU##:G7#9*1<T
M!\R[ES#F?ST[*N$E#KA0P#\%EONH ][C[]=QIK/2M1COW^)Y9KM1U[\I[JX>
M"V?7UFJK),(4 H!0"@% 9>,RF1PLQ,_%25Q92;74@]U0'P5I/!0\QJW<MQN1
MRR547K-Z=F6>#ROTV\2S(D/RY#TN2LNR9"U.O.*XE2UFY-5QBHI);$43FYR<
MI8MXLR<-BI6;R<;%PQ=^2L)!/)*>:E'S) )-6[MU6X.3V(NZ>Q*]<4([6?2^
M(Q<3"XV/C(2=,>,@(3Y5'FI1\ZC<FN(NW'<DY/:SU&Q8C9MJ$=B,VK1?% 8N
M2F1<=!D3Y[Z(N/BMJ?ER'3I0VRVDJ4HGL  XU5&+DTEBV1*2BJO8? '6[JY,
MZH[AT0U+C;0QJR,3 -TZUBZ3)=3^,4"0D? 2;<[D^D=L[?'2PQ^^6U_)>F)Q
MNMU;OR_PK8OF<NK;FO% >I:=D+1'CB\A]26FA>W?<(2GB?.:52Q8HW@CZ?ZG
M;UP'3+$;3V$UM_%;L:AP MQN<L/,,.,V:UI"-0UK5XBB3V>[7+Z/3SU$IW<T
MH5>[>;>_.-K+%I2PX[#%ZHOX[?FT>F_4>$IAB4Q/AMS8@=27&6I3R0I!!.K2
MVZU:Y')5ZKT=;%V[:=:4>[A^#(NPZD(3YK?[C?;MQ\'*_.)Q6>><1(PVU,"Y
MGI[C2DNMI$-Q\MA2DD@761PK&L3<="X['.65>NA=E!/45_2JD#^;CECD^HF[
MMU91]MM^7CWY;CCRTHNN5*#E@5$7( M85L>ZPRV802V.GL1B:/S3E+D2+H_O
M?!1>E4C+9A]D9?8K^3?Q3+SB4NGUII:FO#0HZEW+JD=VL;7:>;U"C'9<4:^H
MR-/<73S?HKZ(B[,@9+YJF7]9D-JR2,LY)<:+B?%4HS&E*5HOJ^&3RK*IE[BJ
M+#+\F6+E9Z5\3H/5CIQ*ZEQ=K.8C/8J#[*A>&^F:^+J4\AHC3X9/+2;WK7Z+
M5K3N>:,GF>Y&1J+#NTHTJ(Y"]N[=_1B6]L&,G;^81#4)AGJA(F!2IB0YI#B[
M&R>5NRMNK%K5KJO/&N%*TV&([UVP\BRNF.PZ+LW$S.H/S?LG@X<J#$S>7RDN
M1I?<3'80KUU#RNZG44)(!TC36NOS5C6*33:C%? OPB[MBF%6W\2SM*+M?YO&
M*R^>SVX(69WQD6 Q Q&,<#U@V=:$<.\ 5V4XXL) 2+"YJ;\KFODHQBXP3Q;]
M/8(*.F3;=9/<:>5.\;YJWWR4@SI624Y(92XD.*\7(*6JZ =6DGCRJ_&-.X;,
M%'Y%N3?[:N^OS*-LO1D?-8W1&\9I+YER-#!6@.$>/'Y(O?L\E+J?^X0?)?!E
M4?\ XS]9,NC>4P>\=@;<5N&:TQD.GF2+J5O+2E989966E6402/#7;AVMBL/7
MPE:O2RK"ZO3TYE[2RSP7^%^GB:7I'U*QFYL]O^-E7X43+[L?$S"C*@&$\VRV
MMEN,[J(NE*-'<OQ3>W'A5[7:25J%MQJU#!TVKF46+ZN-K!-[.?I\"WU+F]2=
MO=/<SC\QAMHXK Y)3,62UA%E,EPNN)L\TT% &V@7*A<"ITD;%R]%QE<<ECYM
MGM)O.Y"#;RT9B?.0>C/Y[IXIE]IX-LI"BTXAP(/CL7OI)M5?:4U"[X_)EO5_
M?;-?\ZE]B1OK#+CO-OH&+4"II:7 #ZRLV)23QJYV5-695X_(HU_WKP9PVMX:
M\4!<CR)$20S,AO+C3(SB7HTEE10ZTZV=25H4.(4D\014-)JCQ3)3HZK<?>?0
M7JZGJ;@/4LD^EO>>)0E.3:LE(D->BB4VD6X*]%P)]!7F4B_G/=>W_M;E8_9+
M9RY>GU.PT.KZ\:/[EM^IUQ9= [R KR%)L?IUI39%&H<E72?[0M4 O-A/,$*/
MFJ0?,7SH^FZ4%KJ-B&;:BB-GD('"YLAF0?I-*_Y?/7<_QSN'_P#3R?./S7S]
MIYW_ "KMG_\ 4P7*?R?R?J/F*NY/.A0"@% * 4 H!0"@/K;YM^Z?;6R7MOOK
MU3=O/>&B_$F'**G&N)^M6'$^86KSWO\ ING?4ULFO>MONH>H?QO5]73.V]MM
M_P#2]GOK[CL=<X=2* 4 H!0"@% * 4 H!0 <"#0@Y]"V#EHVU]K8)<J,96"S
M8R\IQ)7X:V!*D/Z&[B^O2ZD<>%[U33 N.6+,3/\ 3C+9'.3=P,.19#ARR<E$
M@//2(R'8Z\8U =:<>8&IMR[>MM:0H6X$<>!H*6%#/PFQIV*RK&4A(B88>R\C
M$=CQ7'9I;R&1EM2/'#CZ4ES\'=PJM=7FHD0Y5.>[FZ?;FP^UL[F\HJ,]/^3Z
ML5(=CNR\C)F3ERXZ_6W/&"3I7X9464>C>UR+6I:="XI*OK)9N[#37F,UN7J
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MI]Z3% 0^I*'"TE*5VX%12I;BQWE$US7;K$=2Y7KOF==_M_H;74W':2A' XO
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MH)5GQV*FWTX%$=&LS4G@N&\YGO>-LF)DV&-D>U6XR6C[2B9U"6Y4>3J-D
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MG*"M3:7BRT>S0Q][%O=TWKMM';R68KE\3S#N5[JZB<N=/9@1^LLUPH!0"@%
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MVY')&!BRG;MVG&+SN1O]T]0-BS>H72O*P]P1'L9@VWTY>4@N>'%*F$)3XET
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MJ4;DGF2:[T\F;J>4(% * 4 H!0"@ !)L.)/(4!]-[6Q(PFWX&-MI<::!>_\
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M+ERWQ2E[,/F?5U<">EE)XJ ]^@*J 4 H!0"@+"_2-0#U%]0M0%ZI H!0"@%
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M0#6\>38'NG^J@%GSS4E/N"_]- /"4?2<4?<X4![X#?,BY\Y)H"H-H3R2![U
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MO%SWPI1ROY3>@*J 4 H!0"@% * I+C8YJ'T: H\=OX-U>X#0#Q5GT6U>_84
MN^>Q*?=)- >:'5\"Y9/F% 4^J@^DM1'NT!<#+2>2![_'^F@*P .0M[E >T H
M!0"@% * 4 H!0"@% * 4 H#FES_^0=K\/D;R_P#YI0DDO3G^7NT_V-COT5NA
M!)J 4 H!0"@,:4DV2L<AP- :XM+:47(_;Q6SR2KSCR&A)L83B%M$I-E7[R#P
M4D^0BA!DT H!0"@/";6'EH#WE0%-RH7O9- >)N0+*X^0T!4#?S$<Q0 D#WZ
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MV[TZ5FJNFPWY'@'4G\$?2'D/EK!-H7N?$4!X4@\>1\HH#RZASXCRB@/00>5
M>T H!0'A('.@/ ">*O>% 54 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#F
M?^X3_1O^:4))-TY_E[M/]C8[]%;H02:@% * $@"YY"@+38*U%T\N2!YO+[]
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M \M >J)*;MV)[+\J H\&Z3J42L\=7D/FH#UM9)T+X.#Z8\HH"HDWTIY]I\E
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M()2+DD^04;H2E5T1Y=:";%;3@N#I*FU@CF#:Q'G%"/=[AXCQX*?=4.U*G7%
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MY(1CP21F507!0"@*'$:K*3P6GT3_ ,* -KUCR*'!0\AH"N@% * \(OQ',<J
M W]WM% >T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#F?^X3_1O^:4))-T
MY_E[M/\ 8V._16Z$$FH!0"@% * 4 H#%9[\R0OL0$-@^]J/]- 95 6WW"VW<
M<SP% 8)4HFY))\M"3(96XZ-&JP',]MJ R$-H1Z(X]I[:$%5 * 4 H!0"@+<A
MT,,K=/P1P'E/8/HT!3%:++"4*XK])9\JE<30%Z@% "0.= 4ZK^B+^?LH"E25
M*%^WR4!0$*)M:U0"B0ZTUI\182X/0MQ4?^4<ZD%"'Y4GNM(# 'I*<XJ]Y/\
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M"=?]NU_/5NW8MV_MBD7+E^Y<^Z3^'P+F2WKO+,*:7E<_.EK8>:ELJ<>-T2F
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M09#GLIEY<IF#J^\ID.I2A;H3]<4I2DGR"KN59LU,=E>1;S.F6N' R7\]G),
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MSD<3J45*]<AC4A(O^,!+?_-6Q[;JOV^HC-[-C\&8>LL=:S*._=XGYX<N!KU
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M0"@% * 4 H!0'U=\S;>2 [G>G\U(>U#VQBFUD#O#2U)0G5VD>&NP\BJY'O\
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M$MBZC[@H"VF4VHV-T^<T!47;G2T-2NT]@H#22[^LNW-SJK*AL1A3^YD*ZC;
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M8T;4?*GP;)I6 ; 4 H!0"@% * 4 H!0"@% <VZ^;3.[^E.=B,M^)D,6E.9@
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MTZ[J_#XHUG\==T(P;74)[:3">F;T[U!+XE$Y71J*/&T?@[7!&FW/A?X57?\
M:K6?H]1]6E=GE\./IZBU_N]U6NOTO[6:FWS>/#\>6)<SO6O>$3);PBX#;$'(
MXS:#C;LK(NRG&PJ"Y8)5X=P2XJ^H:38 '@>%1:[9:<;;G-Q=S=3>57NZW8SN
M*%M25K%O-N\/>;+;?63.Y3=NVL5FMLM8G;N\F''=ORTRO6)7<!L7@FR;*(M8
M)20% W/&K5_ML(6IRC/-*W]RI1>HNZ?NER=VW&=O+&ZGE=:OU^F\B.P>J$7
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M6O/%KVNINV-YX+%2L$Z]FL>G)8>9N54=YG(O9E34:;AE-PU.RI.K679 '=0
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MU.:[.LUD>"QHZ<5[_%T\2"[!W3#V9!W+FH\I*LLQ)P[F&CN MO3&XV1,AXA
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MV4&DCBF.V?K$_"(])7'D$V\X[GW!ZJ>'V1V?4[#1:16(X_<]OT.K5IS8B@%
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MW=VAJ$HS\L_<_#Z'*:S02LO-'&/P.+UOC5"@% * 4 H!0"@% * 4 H!0"@%
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MYI>.Y?/V'JG\,[=EA+526,O+'P_,_;AZF=KKC3T<4 H!0"@% * 4 H!0"@%
M* 4 H!0$*ZO8C*9_IGN+#86*Y.RLMIE,:(R 7'"B0VM6D$B]DI)K8=NN1MZB
M$I.B5<?4S6]SM3NZ:<(+-)TP_P")',I^*ZI=0=DX+I@-I/;7PL1F"QF\[E'D
M$K;@H2G[TR E1N1KL+D\!P%S6VC<TVGO2O\ 4SR;EEC'GS--*SJ[^GAINGTX
MI14I2?Z>"]_NP-5U#V9U0S$K<V &(R^5P++49K9R(,Q#.(9@Q2 /&8)'C/Z$
MI&D][5J/*U7]'J=-!0GFC&6.>J\U7P>Y5]5*%G7:35W7.&64H^7)EEY4D]ZW
MNGKK7D2)C;6]-N;YZ?[LC[;>R\*/MJ%@<JPTI"78<E+1:<+P-^"-05?ML1?A
M6+*_9NV;MMSRMSE)<U6N!EVM-?LWK-S)F2MQA+_"TJ.I"-P[*ZQ;B(.XL)F,
MKGH6;3(7D!,0K$B%>R1"AC2.)[Q<3Z*0+\ZV%G5:2W]DHQBX[*>:O^*7R-;?
MTFNNM=2$I24ZUS>6G^&//C]232\-U!P6Y.J4F!L-W/X_>3ST+'RRMI)0ESQ-
M+NA5U*9(<U$\!J2FY'9B1NZ>=NPG=R.W1M>S#Q,V=G4V[NH<;.=7<$\.>[;3
M&N[8L3"D; ZJ8'%[<V=ZMDLQM5K$OMOP<%-;@MIRLMQUU:)CW-32"X!Q.@@<
M.V]<=9I;DIW*QC/,L9*OE5/M7'WEMZ'56H0M)2G!1>$9*/F;;I)\,?#WF+'V
M%NF#T]VQ#>VON!O>V(.2<Q>4PSK3+T%YYXJ::?0HW+3A[^I)! O;F15;U=J6
MHF\\.G++52W\6N92M#>CI8+)/JPS97%[&]BER?%&=G-D=6AF-N;VS;64R655
MB!CLY\F)C$;)QWD+<*!=2'$*2M"D%S0FQ7JY<+T6M5I<D[4,J6:L<ZK%[/#?
M6G*A-W1ZR5R%VYF;RTETY)26+I7U4K3"M>5>M]*=MM;5V3%QC4&?C X_(E+Q
MV7=:?ELJ=4!92F$(1902%@!/"_&M'K[[O7G)M2P2K'8_:=!V_3JQ84$I1Q>$
MJ-KV8$[A_P"*:^RK73V&SA]R-]6(9HH!0%*D)6+*%Q0&.XZXS][OJ/8KMM0D
MMID.I-R;CM!H#G^L?_D!XOP/D;S_ /YI0$HZ<_R]VG^QL=^BMT()-0%)2.8X
M'S4!95WKA?>!X$'B"/<J 8Z$/1"3'!=C\RQ\)/V!/]% 9;3Z'D!;7>3V^4'R
M$>6I!IIG^*=^RK+AL,*?W,T>>VW@]SQ6H6>A(G1F'1)80LJ26WDI4D+2I!2H
M&RE#@>1J6JE*;1:C;1VO$QAPT;$1F\6IYN4Y&#8LN0RM+B'5D]Y:TJ0DA2B3
MP%*(591E]F;4S\X9+-8>-.G!DQ5.OHU:V#?N+')8!42G6#I)N+4H@FT1O='3
M4;HR[CKWLR-BY*8[<J2W"4<L8\92%^"'RX6^\4:4NEO6A)(3QXU#52I2H2W/
M;;P.YVF6<] :G)C.>-&4Y<+:7;22A:2E2;C@JQXC@:J:J4)M&%,V)LZ=CV,5
M(PD40(KKDB*RT@L^"Z^2IQ3:FBE2-9/>"2 >VHHB<S-@,!A1(Q<KU!DRL*VX
MSB7R@%R,V\@-N);4>(U)2$GRU-"*F+\C]L#._*9.,91G;ZU3$:D*4O3HUK2D
MA*E:>[J4DFU11$U>PQIG3[9$^/CXLO Q'8V+;]7@M%%DMQ^!\&P(U-DCBVJZ
M?-2B&9FO?Z9;=R6X\IGL[$CY)B<B"B)#<:LE@04+04D@V6A>L'PU#3PY&HH3
MF=*&_D[:V_,1DFY6-8=;S'A#*)4@6D!A(0WX@[="4@"IH4U95.V[@<FJ<O(X
MV/*5DF&XD\O-A?C,,J4IM"[\PA2U*3Y";TH*LQ\9M#;6'1$3CL<VUZB\Y)AK
M45NK:>?;\%Q:5.*4JZD'0>/*E"6VSR3L[:\Q"6Y&*86$3CET$)*%)GK.I3X4
MD@A:K][CQY'A2B%6:W.=/L/N7<ZL[GFVYT(XUO&I@.((*5HD*?+@<2H&R@H)
M4CMMQO2E62I-+ V&7V3M'.IAHRV%BR40$>##06PA+;' >" C2"T;"[9[G#E2
MB(3:-C['Q(R,;+"$P,G#87#B2PVD.-1G2A2VD'L02VG@/)4D5->_LS:DC!L[
M:=Q$;V%&5XD6$E&A#+FHKUM%-E(5=2N\D@\3Y:BB)JZU,B#MK XPL*@X]IER
M/%5CV7 "I:8BUAQ36I1)*2H:C<\Z4%6(NV=OPFELP\8PRRN&UBW$(18&"P%A
MM@_V$^(JP\YI059$=U=,F]PN-PXJ,5!PXA(Q@?\ 4%.9)B(E.@M,N%P-VT\&
MBML^$25)N:AQJ5*5"89;;V$SF/:Q66A-R\?'6TZPRY?[VY'MX:TJ!"DJ3;F#
M4T*$V@=NX(L*C''L>KJFC**;T]TSPZ'P_P#9^(-=_+2@JS'B[0VS!S;NXX6,
M9CYEXK4[):U(U+<%EK* =&I7PE:;GMI1$U>PW=20* 4!\J_.VZ>%+L'J=C&K
MI>\/&[@"1R<2+17S]DD>$H_V4>6NG[-J=MI^,?FOGZSE^]Z79>CX2^3^7J7$
M^6ZZ<Y0W.UMV[CV3F&L_M;(.XW*M H#S5BE;9()0XA0*5H) NE0(JQ>L0O1R
MS549%C43LSS0=&=UP&^/G*=>D+V_A9HA817WK*9:,RF!&0A0LI*Y"05DD'BV
MR;GM%JT5W3Z+1^:2J]RV^[ZG26=3KM;Y8^6.][/?]#<9C%=!.@>#R&W\HRG?
MO46?$<A36;I"8_C#2H C4F)SX$:GO<!JS;GJ]9-27]N"=5S^OP+MR&CT4'&7
M]R;5'Z?E^)\M+;6TLM.H4VXGFA8*5"_*X-C74IU.0::>)V[YIJ\4CK)!]HZ?
M65P9B<65=DK0";><M>**TG>LW[9TXJOA_6AONQ9?W..VCIX_TJ0/JUF-S9WJ
M)N%[>"W%9:-.?C>K.DE$=EIPI;::2> 0$V(MZ7I<;WK.T5NW"S')LH8/<+MR
M5^6=NM7Z>GB;+*=6\AG.E,'IGFX"<B_BYGK.,STAU1D1HR0-+"4VNJP*T74L
MC00+=T&K<-"H:AW8NE5BN/,KGW!STRLR56G@^'IC],#G((/*MD:HOQ)<J!*8
MG0GEQYD9Q+T>0THH<;<;(4E25"Q!!%P142BI*CV%49.+JMJ/O7HA\X*+U!V\
M]C,R -_XJ*XZN(TFQR2&$%7B,('-PV[[:>WBGN\$\#W/MKT\LT?L?NY?0]#[
M7W-:F.67WKW\_J0W%]%>HN=EG(3F&L8I]PO+>F.#7J4K43X;>M5[]B@*TM3>
M4/I7%-Y6+C(D7./M3<LTD)=FM-> TXH7&L(NK22.8!MY+#A5)4;-"=*;$E1\
MIH M"'$*;<2%MK!2I*A<$'@00: ^;.K/S6<?F2_GNG'AX[*J[[N#60B&Z>9+
M*O\ I*/UOH?8UU6@[Y*%(7L5^K?Z^/Q\31:OMBEYK>#X;OP/DG,X3,;=R#N)
MST%['9)@D.QI""A8L2+CL4DVX*3<&NSMW87(YH.J.<E"4'22HS JX4"@% *
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M3?4#V=NW$MS&0#X+Y%GF21S;=1923[AL>VLO3ZJ[8E6#H6+UB%U4DJGS!O\
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MNE(!\PH#FO\ N$_T;_FE"23=.?Y>[3_8V._16Z$$FY<30%([QU'EV"@*J 4
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MWBA.8R\;L%O!3(TK 9F;CTB/"B9.. P\U-1CFDLM.+#K9\-PMI"%K;TW2!Y
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M4H)',D >_6Y.<;H=LZQ3#L7"8GI3@FTL8I<1N=EI.D%R6\ITBZB;D=]K6?\
ME2+)3:N-[+#]W=GK+F,JN,5^E4^CI[7M9Z-_);G^WV(=NLJD,JE-[Y/-]8U]
MB5$J'%V(LF47!%9<?+2%/.AM)7I;1Z2U:0;)'::Z^4XQVNE3SV%N4ZY4W15=
M-R6_P+55E H"8]-=E.[WW&U#<"DX>):1E7A?@R#P;!X66X>ZGWSV5J.ZZ]:2
MRY+[I81\>/@OPWG0=B[4]?J5%_9'&;Y</&6Q>M[CZV0AMI"&F4):9;2EMII
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MC3E$!$:4I;8##JR;)0X03<6YBZJ&5FTC[JPLC-';X6^SDR'3'3)C/QVI/JY
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M\/3(C* MPXBE"<VSP-?A>GVYHN\<5N7,2HDI>-D9)<C(>/)=ES&IJ%H8^]+
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MI7U?N6/ [W^,=A6I?[B\JVXORI[)M?&*W\7AN:/HTDJ)4HW)XDUY\>O-U/*
M4 H!0"@% * 4 H!0"@(?U$<W$UBX*\(F:O'B6GV^,,$*RP@%M8!BA8-R'?#+
M@1W]%]'>J&51H:!&_<'AFL?/AY/)YO!M86=,0\XMM2Y+S$V/&#+B%M-N>LAU
MT,I"BD)XA8OQ$5)RMF3E.J&2V\J?&W!M=R//A8]C*(9BS&I"'DRIB8:6D+*6
M[.)4L%6H!/D)!N%:!1KL9LAOJ<RO.0LIB6,;E\,U%E:)$]"8+D2<M2&W%22V
M-!2IM:5I*.8&G5<4J10C['4[.9O([8;P&,8+$O*9#%9MA<D%)<@QU. L/>'<
MHT_?@K0"JV@@$W$5)RI5J22/O^/(QN'R2<<X$9C-O8!#9<3=M3+LEKQR;<0?
M5[Z>?>\U34C*:.-U=$C&8G(.XAO'>WU.JPZ<C/;CM*CQD NOON!"O#3J4E#:
M %*7<&R>-F8G(7=P[Q=SG2QS<V"=?Q4B3)BPU+;4CQV%'(MQ) ;<LI)!&L(<
M L4D*%&\ E25&6\ME)G3#,0'9^:FY?:4Z-/7-CY HD3([\!@R4NL.A*%*2M*
M2VIM=QJ*2".-SP"69'K/5Z*'5-3,>S=KU%Z4["G-S66(<^2(JG'%H0 '&'%H
M\5OZTZDJ4 :9AD,O)=4H4+(/8UJ(T%^OR,;"ESI:8<1U4!EMR4ZMQ2%:$MN.
M!@ !2E+OP %Z9B%$T4?J:'\R[N9#,QS$' L):P32TK*\JO+.0 EOB$**W-*$
MNWTE%E<JC,59=W,WN0ZDSL'ZY#SFW'&LY&$!V/ B2FY"),?)2TPDK:=4EOOM
MNJLXA:1V$$@U-2%&NP3NI&1Q+TC&Y7;3B,^W(QK4>!&EMNMOQ\P^J,R\AY:6
MP-#B%)=2I(M:XN"*5"C7>6CU-RD?UQ>0VPMB/ALC'Q6X'T3&W4LKF*9#3L8:
M 7T6?;4O5X93Q "B*5&7F5(ZL8QS-HQS<=I4%[(O8=IY,M"IGK+!6@N+B)25
M)CJ<;4@.:K\E%(2;TS#(6H74[)Y")BY'R;5!3N/&R9VWEO2VW"N1&8]8\&0E
M*;-A2+J0H%0[O>TFPI4921=/\QFL_LW#9G/L-L9.;$8?665A:'@ZTE?BV &C
M63?P^.GE<U*>!3)49+(?^*:^RJ)["J'W(WU8AFB@% * 4 H#F?\ N$_T;_FE
M"23=.?Y>[3_8V._16Z$$FH!0&(^3(<]4;-D#C(4.P'DGW30&4D!("4BR0+ #
ML H#V@-#,_Q3OV59<-AA3^YG/NI$"1,?VH^B-/?A0LJMZ>YB0X93+2H4AM*Q
MX)\0 K4E)T^7R49$=YS^)M#+NLKBY+'9>-MU4'+,0'TM^LY1#+^1A/L&6BZ_
M%<<4AQ:TKU*6T/OG>)JFA7F/,:VVO<RF]X[07D C;RF&\9CX*0@M'(24M/*@
MZR&')*!JMJ/AF]U)O3?B'LP>\LQMC;K0EC&[K,_UU4/&MP<E#@MY9V-ZN$@-
M(EE96RZRY<K7;2OTM2N("G$G,MQL7-OY#Y$9?!2=M2WNH:WEN3LV(X<$V\YM
MQ3K4R_%#C6G2U<: -&D::4PYD5QK7 N/;'RZ&T/87#C'YWY59M^+D4L-I4S$
MD1YR8[ZE)X^"5K;T^Z#:E!FX\"I_"8U[9^,B0]KY/#;AQ8:=?2O$C(MR)C+3
MB%-S!JM,;6I2R'-?I%+@4E7&II@17':=)V5GG,UCBS)@#'3\2&(.2CLJ2N(W
M-$9MQYF.I)[R&2OPR;#O CLJI,HDJ&@V1@-QL["P>-,Z1MZ;',OUV.6&77%)
M<DN*2#X@5IX'4"GRU"6!5)JIB;=?SV#V<C8;F'FP]QP(B\5C\E%94[CG%!"D
M1Y:9"+A""-*UA8"D&XL;7);*!T;J0N%LS,'%MN,P\BUEXS..BSL8<8U":>+>
M2B..+<?0I0DN->&MU+@4;I*C?O530KS8DBR6"S(V!#B.8V<7V-V.3Y,>&")J
M87MIY_QF]"@K\&0M)2;VJ:8%-<?49T3;L//[RP[\[#Y"9MZ'B\FPXYN!#KA]
M9D2(JDI6)!)7=&OP]0( O:U*8D5HB$(PF0QFT,@[O3;TW(.':HAXF0Z$N''&
M$W)\9MU:W 6%&[;GC7[R;#5=%JBF&)77'![S+;QFZ\C-V](C8IZ-+Q\K$)A9
M*-";"%X_U%*%RY,PD.+XK4A<<6TA(U)([U,2*HQ).&GH;VC@,3A)&$WXB)F(
MLO(OJ2VJ5D/9K@==$@+)?#CA*TO'@C4/1)TTIL)KMX&6G8S^0$%3$#(B$YD,
M(UE<0YC$8AE,6/*6XMQ?@K(=4A-T.K2L@MFUU TH1F-_!<3L3=>3E0L-(?V[
M,=6V7'H*(TUF;*DLQX\6%()3ZQ'=*BI+=K,H0.]:R1.PC:B8[DQ\^1N_9,R-
M&6[$@2YRYSZ "AE+D!UM!6;\ I9"1YZJ>U%">#.6Y7#[RRN3FY#V!)@Y)V)N
M2'.8A1&H\?2]%<1$'K*3KE+>6EMP+4=(6>23PJAU+J:^!EY/:T?;D'+'*[;=
MFXIW;:&L,ZRA"VX$IMAYR=XZEK26775J0XJ0>*[<5734T(3KOWF)AMJY?(''
M^U/7FO6D865B<I$QC<PMQ68\;2VF6HE<;2M#@=0I(!2I1[VLU"0;*F-JY2-"
MQ456 >@PL=D,RUEV&<4U/:6_)DE<*2&"0)#(8*FT.("E-W"=(XZ5!4M.[/F0
M\'N7$Y7;^4W0_D,&F-M"8]'2'F&PPZ!#5=0$1:'57U$C4@I[Q*;!0G-BMQ.)
MNW,SD,KT_2A4W'M0,3-9R4^&&TN,.+8BI2TLN)6$E92JW=O=/,553845P9'L
M[TUEM2MP1]LXY[5%P4&/@ICCQ"W'URI3D]+;ZU7$I]M90I\V5W_2M>H<2I2V
M5,7<.V%9<9#([>VC)@[=8BXKUC#NQ$,.2Y43(LOJ6S$)XN,Q0ZVI?-S7H!4!
M4-!.FUE]G:F5D[F?7,1.QZUY5G(86;%Q;;GAP4A!89$LG5'0AM)8=86E-@56
M!U7J:"N!AXK8,Z3M;/\ M?;SIRPV?C(F(;>3=U&0CQY9*(_>[KR'"WWTV5?3
MQJ*8$N6*\3MN+]:]EP?7=7KOJ[/K/B>GXOAIUZO/>]ZN%DRZ Y%UQZ)Q>J&-
M]JX9+<;?>/:TPW5$(;G,IX^K/*Y!7XI9Y'NGNGAM=!KWIY4E]C]W/ZFKU^@6
MIC5?>MG/E]#X4F0Y>/EOP)[#D6=%<4S)C/)+;K3K9TJ0M)L001Q%=O&2DJK8
M<%*+BZ/:6:J*388&%CLEG,;C\O-3C<3*E,LSL@L$I8CK6 XX; \DWJU=DXP;
MBJNFPO6(QE<2DZ)O:?;O5UOI#B9& R'43*M2]H8&"@;2V/COOJI)4A*0^X$+
M!<0$)0EH*4EL &ZCJ(KB=%^XFI*TJ3D_--_#Z[SOM:M-#*[K62*\L%Z>%-WM
M.0O]6>IO7?<,3IKT[93M+;#Z2VN/ [JF<>V-+CDAY 3I;"3;PV](42$=Z];=
M:*QHX.[=\\N?'EZ<S3_O[^MFK5KR1Y</3Z&ZWU\WGI]GG)&W^CV:87O_ &O'
M99S6 D/W]<(0+NA:[)2\?^IH/AA1"5!LU9TW=+T*2OQ\DW@^'X>_Q+NI[39G
M6-B7]R"Q7'\?##P/EV=!EXV;(QN187&R$-U;$J,Z-+C3S2BE:%#L4DBQKJ(R
M4DFMC.1E%PDXO:L#'M]/G510>T H!0"@% * 4!>BS)<!],F#(<C24>@\RM3:
MQ[BDD$53**DJ/$JC)Q=4Z'0L%U\ZO[>"$P=US'FD< U.*)R;>3^\I</T#6ON
M=MTT]L%ZL/@;&UW356]DWZ\?B= Q7SR.IL.R<E Q621VJ4RZPX??;="?N*P)
M]BL/8Y(V,/Y!J%M47Z>)+(/SW)*;#);,0ORKCSRC[E;"O_%6)+^/K=/W?B9D
M?Y&]]OW_ (&Y:^>SMTC[]M.:@^1$EI8O[Z$U9?\ 'Y_K7L+Z_D</T/VF;COG
MC8?+SH^+Q.S<G,R4MQ+,6*T\TI;CJS9*0 ">)JB78I13<II)%</Y!&;48VY-
ML^CL9(FRL=%DY.(,?D'6TKDP?%2_X+BA<H\1("5:>5QPKG)I*32=5Q.F@VXI
MM4? C/43J%BNGV',V79_)2+IQV/"K+=6!S/D0GX2O>YD5L^V=MN:VYECA%;7
MP_$T?>N\VNVV<TL9O[8\7]%O9\VY+KSU)R 4EO(M06U<TQ&&TGWE.!:A]M7H
M5K^/:.&V+EXM_*AY%?\ Y=W&YLFH?Y8KYU9"<MN?<6=459G*RYU^.F0\MQ ]
MQ)-A[PK<6=+9L_9!1\$<[J-?J-1_JW)3\6V:JLHPA0"@% * 4 H!0%:GGEH0
MTMQ2FV[^&A2B4IOSL#RJE12=27)M);D2O8O3G<6_IO@XMKP<:TH"9DW@0PT.
M9 ^O7;DA/OV'&M9W#N=G1QK-UD]D=[^BYF\[3V34=QG2VJ13\TGL7U?)>NBQ
M.@[2W?M/I5OF3@\5DAF=GY%#+4[*!M(=CR4W25)<0!XK0/$Z> "N[<I[VAUF
MBO\ <-*KDXY+L:TCN:\-S]'MPZKMW<M)VC6NU;GU;,\JE.BK&7BONBMN&YX5
M:\V^W?AMM=),1)FX'#+W!D=UN.QHLZ8/6HD=B0-09"A<K*P>X/2<L25=VQPM
M%?O=QN*-R?3C9HVE@VUOY4W[EPQ-IW+3Z;LUIRLVW>EJ&TI2\T8I_EYUW+;+
M%MX4.73\%O\ Z5Q,;F#/7AW\RE9,.-(*)*0WR#[0X&X5<>EIY'2KA726]1I.
MX2E#+G4-[6'J?]*[JHXF[I-?VB,+N;I.[7RJ7FP_5'UU6VF^DL"(97,Y;.RS
M.S,U^?,(T^-)<4ZH)O?2"HFP%^ '"MM9L6[,<L(J*Y&BU&INZB>>[)SEQ;KZ
M+D857C'.C=+>F3^\Y8RF42IG;$5=GEBZ527$\?";/D^O4.0Y<:Y[N_=EI8Y(
M8W'[N;^2.P_CW8):Z?4N868O_F?Z5\WN\3Z@::9CLM1X[:68S"$M,,M@)0AM
M LE*0.  '(5YHVVVVZMGM,8J,5&*HDJ)+8EP174%0H!0"@% * 4 H!0"@% *
M UN9QV1R#+2<9F'\/(:7J+T=MAX.)((*5H?0L$<;BUC>H"(G*Z78-.,D,GUS
M*.+@Y&,\RIYMIZ6_DY+<QU\NV0$/EYI);4G2E'9;A492O,S20.GV7W+D\G,W
M0[DX^/D8Z'C6',D]#7D7%19HF%>B&"PV@%"4=JG.)-K)J*5)S4V$MW#L''[@
MG2LJJ;(B9)_V<MAUKPUH8?Q#KKS#@0XE25]YY6M*P0>%K$7JIJI2I4,5KIM$
MBK8EP\Q.;R[&6>SHR3G@NN*>ELB/(:4@MA!;6W=( 2"CAI/"HH,QXSTT@,3X
MSZ<M/]EX_*KSV-P^IH1F9CQ=4Z"0C6MM2GEJ2A2NX3P[+*#,76^G4"'B<# Q
M61EP<CMIMQG%Y9/A./>%(%G6WFUH+;B%@)N"GFD$6(I09C9YS;!W!M=>V\CD
MY"WE^ M652AE+Y>C/(?0O0E ;]) [NBUJEK A.CJ8!Z?P,@N9(W3/E;AES83
MV+*Y1;8:8B2K>,F.U'2A+:G-*=3G%?='&PI0G-P,N-M60K$Y#!YS-RLYC9T<
MPTHEM1D.-M*24:BMEI!6Y8COJ[1>UZ4(J8#?3N#$Q."A8S)S8N5VZAU,'-J4
MV_*=,L?WHR4N(+;OCJ[[ETCOV(M:HH3F*\CT]QV:<>D9O(3)DR1CF,6[*06H
MS@,649C4E'@H2$.H=LI-AIX#A4T"E0TFY>G.1FXV2\WDI>9W+/DXEJ1D7ELQ
M'&<?CYR)!$<-(0VV4]YTV3=:N=^ $-$J1N/X>1I$E>0RV7FY++N3($Q4UWP6
M[-XEY3T>.AMMM*$MZE*4NPU**B2>5E",QDSMB8N?%S\1R5)0G<4V-DI:T% 4
MT[$]7T!NZ3W3ZNF][\S4T(4BO'[17BITE>.S$IG!2WI,I[!J0PXP'IBE+=\-
MU3?BH0I:BYH"[!7*PX4H*EN+L+$18^UXH?D.,[5CO1886I-WFY$8Q5>,0D<=
M)N--N-*#-MYFRVM@3MC!Q< F<]D(L!(8A.R4MI=1%;&EIHEM*0K0D!.HC4>V
MB5 W5F_A_P"*:^RJ)["J'W(WU8AFB@% * 4 H#F?^X3_ $;_ )I0DDW3G^7N
MT_V-COT5NA!)J L27BTD(;&I]SNMI\_:3YA0%3#(8;T ZE'O+6>:E'F30%V@
M% :&9_BG?LJRX;#"G]S,"9D(&-:$C(S&83!(0'9#J64%1Y#4L@7JHH+D:3'E
ML-RH;Z)$5T:FGV5AQM0!M=*DD@\: M#'04Y)>8$= RCC"8CDRWWTQVUJ6ELG
MZT*4HV\] 9-R.5 +GD/H4!9CS(LSQ3$D-OAAQ4=_PEA>AYO@IM5N2D]H/*@+
MCKS<=OQGW4LLIX%QQ00D7-A<D@"Y-J )0A%PA(2"2HA( NI1N2;=IH"J@*2\
MVA:&5.)2XX"6VRH!2@BU[#F;7XVH"JY\O*@,89*!ZRY$$QGUQI2$.L>(GQ$J
M>25-I*;W!4E)*1V@4!>>>;9;+LAQ+;0(!6XH)2"HV%R;#B384!H\]M[:&3F1
M)VY(D9Z25HBQ3+40EU>HK0UH*@EPW!*4J!J&D2F]Q(+GRU)!'X.W-H;:G>T(
M<.- R$Y9BM/K4?$6MTEPLM%Q1MJ*2HH1:]N7"HHD35LWK3S;[:7F'$NLK%T.
M(4%)4D^0BX(J2#U24KTZTA6@ZD:@#I4.T7Y'ST!CNY+'L+D-O3&6EQ&TORT+
M<2DM,KU:5N7(TI.E5B>' T!B(W/MQQ:&V\U!6XX4AM")32E*+B@A(2 HDW40
M!YZBI-&6LQM/;FX)3,S-XUJ=(82&T%[44E 5K"5HN$K3?C98(I0)M&YY"PX#
MR#EPJ2!<^7ERH!<^6@*&WFG?$#3J7"TLMO!"@HH< !*5 <C8@V/EH"N@%SSO
MQH!<^7GSH!<^6@% * 4!QOKET+B=38JL_M]+<3?\9 2E:B&VLDT@62R^H\ Z
M!P:=/V*N%BG;=O[@].\LL8?#\.*]AJ>X=N6I6:.$_C^//U,^'9\";BYLC&Y*
M,Y#R$1Q3,J*^DMNM.H-E)4D\00:[:,E)53JF<+.$H2<9*C1CU44!2E*[RB5*
M "1<W.E(L +]@[*@FM3['V.TST9Z#.;[Z=0V=Y[NRQ;7ELC&2I^/%2FZE(<0
M@H=#4=/!2196M6I5D\N.U#>JU?3NO)%;%Q_KZ8G<Z:/[31]2TL\GM:W?.B^.
M."V<:ZD[^Z?;@]D=1=@L3MJ]4WI*W,W&A*T14JTDKDH=38EQQ2@!H'>&K6D'
MBK<Z337H5M7*3MTPKM\/3E3EI-9J[,\MVU6%VN/#Q].=2?L=%NE^TNG6(=ZU
M9)_#;ZW=*+D6<A:R]"4M.I*'4'4E2$ZDJD*6G@M>G4/2K >OOW;S_;K-""]O
MIN-@NWZ>U97[ATG-[>'I^9\]IP_J9TWSO2W<BL!FU-OM.MB3C<DQ^ E15$@.
M)OQ201923R/E!!.\TFKAJ(9H^M<&<_K-%/37,LO4^*]/3>0ZLPP!0"@% * 4
M H!0"@% * OPX<O(RV($!AR5.E.)9C1V4E;CCBS9*4I3<DDG@!5,I**J\$BJ
M,7)I)5;/OKH!T$B=,H*<_N%IN3OJ4A25NA0<;A,KYM,GEJ(]-?O Z;WX'N?<
MGJ)98X07O/1.U]L6FCFEC-^[P.C;_P!_8;8&'.1R)#TYW4G'P$D!Q]P?1LA-
MQJ5V><D V.W=NN:RYEC@EM?#\>")[QWBSVZSGGC)_;'?)_3B_F?&FY=RY?=N
M8?S>:?\ &F/FP X-MMCT6VT_!2F__$W))KUS2Z6WIK:MVU1+W\V?/^NUU[67
MG=NNLG[$N"Y>FTU%91@"@% * 4 H!0"@% * Z4_T-WRQM?Y1F.A;X =5B&E>
M)+$<BX<LFX)_L ZK>?A7.Q[_ *5W^E7#]6ZO#\=AV$OXGKHZ7KTQVY-LLO'#
MX;?7@;K#=?\ *8R=A(S6+C8_:T!M+&0QD)M(\8J%G'4%0&D@]]* >=PI1O<8
M=_\ CL+D9MR<KDG52ENX+Y-^Q&PTW\QNVIVDK<868*DH1ICQ:KLXI5\6]JQN
MLVP(>+=8WSM0)>VEF[.J\#BVP\\-0('8VY>Z>Q*KIX=T5<['W&5Q/3WL+D..
M]+YKW[>):_D_9H66M7I\;-W'#9%O_P ,MW!X8>5%O8G6W([1VW)P,^&G+>K@
M+P*GCW8[M_1<[2VGTTZ;*'HW (*:NX=AAJ;RN1>2OWTW^'/<_;XV^T_RJ[H]
M-*S*/4I_IU_*^?&*VJF.ZM'6/.L]G\ON;*/9C-RE2I[Y[RU< E(Y)0D<$I'8
M!6_T^FMZ>"A;5$CE-9K+VKNN[=EFD_2BX(UM9)AG1.F73"7O22G)9$+C;887
M9Y\=U<A:>;37_I+Y)]VN?[MW:.ECDAC<?NYOY(Z_L'\?GKI=2YY;*W_JY+YO
M=XGT_$B18$5F#!91&A1D!N/';&E"$)Y #_\ 2]>:SG*<G*3JWM9[1;MQMQ4(
M++&."2W%ZJ"X* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!I=Q[C8V\Q%'
MJSV0RF2?$/%XR+I\>1(*%.$764I0A"$J6XXHV2D$^05#9*536)W=F8TW#P,W
M@!CY&8F/1&DIF(D@(8A.RRYJ2A(XEOP])MSU7M2I-#/9W?@48V#/S.0AXAZ:
MTRZ(LF9'44F0.X M"RA8)!"5()2;<#2I%&9)SL5F9EF9ZFH4+$ML.NSWI+ ;
M*7TJ)*DZ]303IYN !7P;TJ*%H[PVBF/$EJS^/3%R"RW!>5*:"'UI5I(;)5WB
M%=TV[>%*H49BHW/.E3MSXW&XKUN=MYV,RPSZPEKUM4J.W(]):;-Z0NW&][4J
M*;#6;<W]*RZY3^8PZ,!B(<B3 >R,S(1E(]<AK*%MA*;7!TJ(5?D+VJ$R7&AN
M4;NPS<:;D,I+BXW%Q9"8S,Y^7'++X6RAY*TE*SHN%\$+LJPU6L0:FI%&6U;N
M@HW(<(M3*<:,/[<.9+Z0QX7C>%:_HZ;=_7JM:E13 W,#(0,K#:R&+E-38#X)
M9E1UI=:6 ;'2I)(-B+5)!L(?^*:^RJF>PKA]R-]6(9HH!0"@% * YG_N$_T;
M_FE"23=.?Y>[3_8V._16Z$&1(RLA;A\%6AL'NV N?.;T),K&2/6'G%/=Z1I&
ME79H'8![M"#:4 H!0&AF?XIW[*LN&PPI_<R [\5C$9S8R\L8Z8:<M(U*F>&&
M@?9DJW%SNW\G;Y*/<1'8R$9+/-X3+YE_89;C;7R4['8^?/C.,QX3>1\&2N0J
M,XZE4="G$B.RMS24^(0/PE4UX%:55B;*+N?<3DB%C-Q;C;P,9,.;.AY1ER)*
M,Y3,DMLMN/>'X*ULMV+S3205DW%@#4U(HMR+&-WSG%XT;@SN;?;QF.VQB<O,
MCP8T<.OS<IZPTITEU)"$ H2I*39*3Q4=((HF'%>\HQ^],T^M&#G9],+'G-^H
M2-P>-$D/,QU8Q$YN.9"6TL>(XZ5(#GA\ -'%=C2HRK::1O=KV"P&=3C,VX<J
M,GN/*,9%M<./%D)QRT)U/>*VL.$**4^$P 5BZNZ+5%2:5?L,F9EY1D;TR[^3
MO(EPMN2T8J4EA^*EN8MH+6AEU!)2V20D]BCQN0+.(6[UDCC[NRZ\E"E)SH>R
M\K<#^&D[/T,D-04/NM7TI3XP<;:0))?4K0H<+:2FJJE-/@4;8W;G&/DAEMP9
MX3,=N+&9"9E?';98C1Q ;0\EYHMI24!*2I+FI1"N?"U0GL):6-#/ZE9%S'93
M#9F XA$Z%@]R3(+ZDA02MJ(RXE5E<Q< D5,B(KY&JRNZMS;?=<@/9\NMS\=B
M)[N5E,,?_#C.G")*?0E*4I\)*"%)2YJ"%=XDIO4-T)23-8Q,#6\\DQ"RZ,NF
M3F\'!3E7&XS[R0O&RRG2L(\/Q4&R@XE(/'2>VF\G=[3)=W?N'-8*:J:^PD;>
M1CL3N)EUAIUI>>=R3#;RB'$%-FVDI=2!P'C)/-(I44291+S;^:G;7F93/)7D
ME[O,9W;!# ]43$5+;:1I2GQDK2E 6IQ:B%WX"Q33ZD4I7P,B'U/?&,VK*F9D
M.O+Q68G;F:BH97+#F-90;^%;N+;6;:" +\^ -,PR[3$@[DR68R^/Q62F>NL8
MS<N)7#><>CRGDB9CY+JFUO14-M+(4"1I3P!M<U%2:? KV[NF?.3M/'8S/)A2
MDP(N0SF/:]GQX@85K\&,RR6@H/3%)L-*K(0%*X$HO*8:VX&-"W]OA>#=W"9\
M=#3T1+F4\5^+*]ENO2&&2\W$9;2ZA$5*W/&0^HV*05<0J\58RJM"6;0;@S-\
M;MAJRJ=RP_9>(;7(?2PZ2A:YA+;BFD);<YZO1X7L:J6TI>Q$3<P^*CX;<+V,
MC1,?/3OF+$CS6HS6ME)FP@ D6%P/K>54_4JKBO V>:W7N?#SI.V1DW),9K,F
M$K,N.Q(4IMAW&-S6F%/.-%E*U.+4E*RW=21I'>XU-2$EM+K&[MRQ'')>Y<R6
M<?AL",O.:Q*(TI4I:Y,IAMSQ=&C\&A"EA&E&L<PD$%446XUK&_=PI\7&.9Y,
M5AC/XO'KRKJXDUUN)D82GW&EO--H8*M8LA>CNW%RJU*DY5[C-=WYF]NB5E?:
MGRAVICY\C"-3%-H*I,B3&9>A$N,)"5*1**H*EHLE16FXU)-*T(RIDJVK'R4'
M=$R)D7DRLDYA,4_GI* E*5Y,+D-%>E "1J0FW >BE-2MI2]A-ZJ*10"@% *
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MAU)YDAM*$J3\'@1VUK)Z%2U,;S>Q;#<6NX9-+*RE1M[?K[*>!*_FK;'EY[J
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M4+:S?3C9V<D1\AM0NN,1)K9;3)?U*"G' I(7;6I:;HMHU<4G@*L1U.HT5_\
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M<M*-O0<MYKUVND[A:U"\K\W#></K.VWM,ZR58\4<^K8FK% * 4 H!0"@% *
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M]VG^QL=^BMT()-0"@% * 4 H!0"@+3@[UZ@%*05&U 7=/G/T:D#2!Q*C;W:
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M7EN7J/4^W]KTVACELQ4>+WOQ?HB05@FT% * 4 H!0"@% * 4 H!0"@% * 4
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M>K]K[M;UD*;)K;'YKE\#P7OG8+W;KE?NM/[9?*7!_'=O2@5;PY@4 H!0"@%
M* E&V^G.]-UE*L-B'G(RO_>W1X,>WE\1S2#_ ,MS6MU7<]-I_OFJ\-K]B-UH
M>RZS6?Z5MM<7A'VOY'9=K?-ICME$G=^3+QX%4''W2B_D4\L7/_*@>[7(ZO\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H#F?\ N$_T;_FE"23=.?Y>[3_8V._16Z$$FH!0"@% * \)MP'$GD*  6]T
M\S0'M 8<K),1E^&05N#F$]GNF@*$S#. 9C7;)XNK/-*?-YS0&8TTAE ;;%D)
MY"@*Z 4 H!0"@% * 4!X4@\Z 6%K=E -(M:W"@/$GL/,4!50"@% * Q4_?9J
MU_ 83H3]FOB?I4!E4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4!KLG@,%FDZ,SBXF11:VF6PV^+>2SB55<A=G#[6UX%N=J$_N2?BB$Y+H'T=R
MI496T(+97S,4+A\_)ZNINU9L.Y:F.R;^/Q,"?:]++;!>K#X$3F_-*Z.2B2Q#
MG0K\A'F.*M[GC!RLN/>]2MZ?J,278M*]B:]9HI7S+^G+BB8N9S+ ^M4Y&<'Z
M.DU?7?[V^,??]3'E_'K&Z4O=]#7K^91M,G[WN?(I':%,L*X^\!5S_P"P7/T+
MWEK_ .NV_P!;]Q3_ /A/M;MW3D/_ -@S4_\ V"Y^A#_Z[;_6_<=ZV#M*;LG
M-;>DYV5GH\4Z8,B>E'CM,!("6BM !6E)!TE7$#N\@*T.IOJ]/,HJ-=M#H-+8
M=F&1R<J;*_ WN3QD#,X^1B\I'1*Q\I!;?8<%TJ2?Z"#Q!'$'B*M6KL[4U.#I
M);"Y?L6[]MV[BS1E@T0F%T1Z90K%.$2^L?"D//N_2*]/TJW%SOVMG^>G@DOD
M<[:_BO;;?_I5\7)_,DN/V9M'%6]G8.!&4.2VXS07P_M:;_3K7W-=J+GW3D_6
MS;V>V:2S]EJ$?^%&[    %@.0%81LCP]TZNSM% 54 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@.9_[A/]&_YI0DDW3G^7NT_P!C8[]%;H02:@% * \)L":
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M H!0"@% * 4 H!0"@% * YG_ +A/]&_YI0DDW3G^7NT_V-COT5NA!)J 4 H
M>/"@+1;/9RJ 5I3I%NWMJ054 H"T['8?MXJ HCD3S^C0%3;3;*=+20A/D% 5
MT H!0"@% * 4 H!0"@% * 4!2G@=/T/<H"J@*'5%#2UIXJ2DD#S@4!%E*4M1
M4HW4>))\M"3;85Q9#K1XH38CS$WH0;:@% * 4 H!0"@% 69,E,9*5+!(4;<*
MJC&I1*64QO:K/UBOI?UU7TV6^LA[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U
M6?K%?2_KITV.LA[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.L
MA[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^NG3
M8ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^NG38ZR'M5GZQ7TOZ
MZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?
M2_KITV.LA[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.LA[59^
ML5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^NG38ZR'M
M5GZQ7TOZZ=-CK(>U6?K%?2_KITF.LBV<BS?@A5O>ITF.LN!ZC)LI^ J_O4Z3
M'617[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^
MNG38ZR'M5GZQ7TOZZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^NG38ZR'M5GZQ7
MTOZZ=-CK(>U6?K%?2_KITV.LA[59^L5]+^NG38ZR'M5GZQ7TOZZ=-CK(>U6?
MK%?2_KITV.LCU.4:4H)"%7) [.VG39*NHSJM%X4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * YG_N$_T;_FE"23=.
M?Y>[3_8V._16Z$$FH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * \4
M.T<QRH #<7% >T!K7<,TM94VLMI/$IM<>]RH#,C1FXK?AM]O%2CS)H"]0"@%
M * 4 H!0"@-?E?P3?V7_  J]:VEB]L-55\QA0"@% * 4 H!0"@% * 4  )(
M%R>  H"M33J!=:"D<KD=M0FF2TT45)!Z 3R__2_"@H>4!Z$**2H))2GTCV"H
MJ*'E2"AUYA@MA]YMDO*T,)=<2V7%_6H"B"H^9-2DWL1#PVE=02* 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H"MK\*C[(?TU#V$K:2*L,SQ0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#F?\
MN$_T;_FE"23=.?Y>[3_8V._16Z$$FH!0"@% * 4 H!0"@% * 4 H!0"@% *
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M-GE * 4 H!0"@% * 4 H!0%;7X5'V0_IJ'L)6TD589GB@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0',_]PG^C?\
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MA!)J 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * IT)YVH"J@%
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M\TH22;IS_+W:?[&QWZ*W0@DU * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M7!1J'$<: WE * 4 H!0"@% * 4 H!0"@-?E?P3?V7_"KUK:6+VPU57S&% *
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MF@% * K:_"H^R']-0]A*VDBK#,\4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M 4!S/_<)_HW_ #2A))NG/\O=I_L;'?HK=""34 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0',_P#<)_HW_-*$DFZ<_P O=I_L;'?HK=""34 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0',_\ <)_HW_-*$E?3_>V'C[#VNPY%RY<:Q$!"BWA,
MLZBZ8S8.E;<525#AP4DD'LH"1_+O"?FF9^(<Q^IT('R[PGYIF?B',?J= /EW
MA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0
M#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q
M^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?
MB',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^
M:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+
MO"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.
M@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0Y
MC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,
M_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3
M\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^
M7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J
M= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXA
MS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF
M9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[P
MGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!
M\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_
M4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q
M#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-
M,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EW
MA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0
M#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q
M^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?
MB',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^
M:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+
MO"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.
M@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0Y
MC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,
M_$.8_4Z ?+O"?FF9^(<Q^IT ^7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3
M\TS/Q#F/U.@'R[PGYIF?B',?J= /EWA/S3,_$.8_4Z ?+O"?FF9^(<Q^IT ^
M7>$_-,S\0YC]3H!\N\)^:9GXAS'ZG0#Y=X3\TS/Q#F/U.@'R[PGYIF?B',?J
M= /EWA/S3,_$.8_4Z YU\L<3_'CU[U;*^!\DO T^Q\GXVOVEJOX/JWBZ;?#T
):;\+WX4)/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>pc_strategic-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pc_strategic-4c.jpg
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M%!04%!04%!04%/_  !$(!&8%W0,!$0 "$0$#$0'_Q #?  $  04! 0$
M        !P,$!08( @$) 0$  @,! 0$              08$!0<# @@0  $#
M P$$! 4+$ 8%"@4!"0$  @,1! 4&(3$2!T%1$PAA@2(R%'&10E*2TI05%A<W
MH=%B<B,S4[,D=96UU59V5['!X8*B5+)#DW2TPF-S@Z,T-54V&,/39"4X\>+4
M)O#$1*1%)Q$!  $" P4#"P,"! 4#!0$!  $" Q$$!2$Q05$287$&\(&1H;'!
MT>$B,A-"4A1B<O&2(S."HL)#%;+24^(D-!8'\I/_V@ , P$  A$#$0 _ .A>
M3G)SE3FN5.C<KEM&XB\R5YB+.:[NY[2*2665\32Y[W.!)<XFI)1+=_F)Y,_N
M)A/@,/O41B?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?
M,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8
M?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W
M$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\
MQ/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A
M]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<
M3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS
M$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'
MWJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q
M,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,
M3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?
M>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$
MPGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q
M/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]
MZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3
M"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$
M\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'W
MJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,
M)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3
MR9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>
MH8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$P
MGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/
M)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]Z
MAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"
M? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\
MF?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ
M&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)
M\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R
M9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H
M8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PG
MP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)
MG]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZA
MB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"?
M 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F
M?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&
M)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\
M!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9
M_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8
MGS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP
M&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G
M]Q,)\!A]ZAB?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB
M?,3R9_<3"? 8?>H8GS$\F?W$PGP&'WJ&)\Q/)G]Q,)\!A]ZAB?,3R9_<3"?
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M! 0$! 01[?\ TYZ?_A/-_K+$('(GZ&="?F2Q_$M0E(2 @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((]O_IST_\
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M @(" @(" @(" @(""/;_ .G/3_\ ">;_ %EB$#D3]#.A/S)8_B6H2D) 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MT^J"5. ON4_.FVYK9+,6MEB'XZTQ<4,C99IA))*9W/&UK6@-IP>V*"5% ("
M@(" @(/CG-8TO>:-:"7$[@ @B#.]YCE3AB]EO?W&7F;[#'V[G"O5QS=DP^)Q
M4X"[Y4\Z[7FKE\M8V.(DQUIC(8IFS3S-DDD,KW-H6-: VE/;%!*J@$! 0$!
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M2'9_='^CG)_GF?\ X:V42E/J@$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MCG>-2,KD< [%]WG$Y:5@$N;U*^X8XBCC!!:S0,'J!S)#XT$4(/TLT==Q'0^
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M0=E<\<C:9?D9G,M82=K8WUI97-M*/9137,#V'Q@J$N"5*'9_='^CG)_GF?\
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M%&"7%O,G4]MK+76=U+9L='97]R7VS9!1_8L:(V%PZ"6M!(Z%*&0Y,_2II/\
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MD$5CD"UL5Q&P@.%9/(K4B@)J>A0E"VKNZ?IC+F3(:)RC\2^4<<=G/^5V9KM
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MRAQEK)=WMP]SI&P6L#2]SG/>: 4!H*[3L&U!@D'<'=7GCEY5LC80709&ZCD
M-:./ _;XG!1*7'&K]NK,\1N^,;O\>]2A)W=<(^=BV\-C=T]P$D=RKY2XV[WA
M'R^PPKM&'C)'JW5PIA#GYFQ[2=U0I':'>KREU:\N+/&6T4CX\C>Q>E2L:XQL
MAMVE]'N H*OX*5ZE$#C6SO[['R=M87,MK-N[2"1T3J>JT@J1\O+Z]R$QN;^Y
MENK@BAEG>Z5]!T<3B2@E/DOR:S>O\[99/(6C[;1MK*V:\O)FEC;AL9XNQAK3
MC+Z4<X;&BNVM 0[R7RE3N)3!;RSB-TIB8YXBC%7O+17A:.DG<$'YEZB;ESG+
M^?.VLUGE;JXEN+J"YC?%())GE[JM> =Y7TABT  D@ 5)W!!-?*+N^ZAUI?VV
M5U/:38K2,;A)(9P8KB[:#7LXF&C@UW3(:"GFU*8CMV""&VACMK>-L5O"UL<4
M3 &M:Q@HUH V  #8OE+\_.<?+7*<O-6WL3[9_P GKZ>2?#WH:>R=#(2\1<6X
M/CKPN&_97<0OI".D'5_=>(^;?6FW=-(3ZGHBB1R@I'2/<^(^4NI!T^@P_CE$
MCK:YMX;NWFM+A@DMYV.BEC.YS'@M<#ZH*A+\[.9O+C-<MM1W.)R$,CL8][G8
MK(EI[*XMR:M/$!3C V/;T'P4)^D-0MKJYLYFW%G-);W#:\,L3C&\5V&CFD%!
MDYM.ZA.!.L+FTF&#FNA9MR,NQLMU(U\E&EQJ[8QQ<X;.LU08=!^F^F)V76FL
M-<QD&.:QMI&ENT$/A:13UU\I<*<[>6N4T!K"^E-L_P"3>3GDN<3>-!,7!*XO
M,).X/CKPT.T@<72OI",T'7/= #'Z:U,QP#@;V$.:=M083O"B1''.CD#F](Y.
M[S^E+.2_TA</=,(;=IDFL>(U,;V"I,8]@\;AL=UF<1!J#[Q.IPU-.KH02_W9
M<C-8<V,>R.-[X+ZWN;2X<QI<&M='VC2ZFX<<;14I(ZSYK<M<?S/TN_"W#Q;9
M*W=Z1B[ZE>RG (HZFTL>#PO'CW@+Y2X2U=R_U?H>]DL]28J:U#'$,NPTOM91
M6@='*T<)!]6O6 OI#%8; YK45ZS'X+'SY&]D(:V&VC=([;TGA&P=9.Q!=:NT
MOD=&9^ZTWEG1NR=DV$W0@=QL8^:)DW!Q=):'AKJ;*U0;%R4C,O-;2;179?L=
MLV^8"[^I!T%WO_\ TGIX=/QB_P#$.40.0%(_0SDFUDG*72K' .8ZQ#7-.T$<
M3@05\I<Q\Z.06;T?D[K/:5LY+_2$[W3".!IDFL>(U,;VBI,8]B_JV.V[3]8H
M0>@(/T"Y Y,97E)IJ7BJ^WADLWCJ]&F?$T>Y:U1*4E*!PKWGB#S;R !J1:V8
M/@^XA?4(0Z@(+W%XC*YNZ;8X>QGR%X\@-@M8GS2&NSS6 E!U/R*[O60P&3MM
M::[B;%?VI$N*P]6R.BEILFF+26AS=[&"M#M-"**,1-?,O1D>O]%973#GMBN+
MJ,/LIG>:RZA<)(B: D-+APNI[$E0E^>&;P>6TYD[C#9RTDL<G:N+)K>8<+@1
MTCH+3O#AL(VA?2&/0;=J#ESJ/2^E,1JK.PFRBS4TD5G92M+9^RC8UPE>#YH?
M7R0=M!7<0@P6GY!#GL7,:4CO+=YJ:"C96G:4'5?>]R=W'IK 8>&*0VES>27=
MU,UCNR:;>/@C:YU* N,KB!X%$#DVRR61QKS)CKR>TD.]]O(^(GQL(4BE<W5U
M>S.N;R>2XN'^?+,YTCS39M<XDE!-O(+DUF]3ZBQVJ\U:26FE,;*R[CDG:6&\
MFB/%&R,.VEG$ 7NIPT'#O.Q(VCOB?^*:3_W>\_TX5$#F52.^-;D?^WZ^-=AT
M[#0^K;L4)<#J4.NNY\1\F]2CI].A_$E1(I]\,CXDTN.GTJZV?]6Q(')*D?HG
MRH@@N^4^EK6YC;-;3XBWBFB> YCV/BX7-<#O!!H5\I<G\W^0VH-!Y"YRF"M9
M<EHV1QEAN(6F66T837LYP*D!NX2;B-]#L7UBA#B#Z7.(H22!N""<^ZCD;BSY
MDS6;&/?;9''SP2N:USF,?&YLS'.(%&[(W-%>M)%+O49.ZON9OHDL<D=IC;*"
MVMW/8YK)"^L[W,)%';9 TD>UHD"'[3-YJPB,%CD;JV@.^.&>2-AKX&N 06;&
M2SRAC&NEFD=1K6@N<YSCN &TDE!USW:>3^6TQ+/KG5-LZSR%S ;?%8^4<,T<
M,A#GRR-.UKG !K6G:!6HVA1(YFU_E+O-:WS^7O(I()[R_GF$,S'1R,C=(>S:
M6N (X6<(VJ1BWYW-R6IL9,E=/L2*&V=/(8B.K@+J?40><3A\KGK^+&86SFO\
MA.>&*VMV&1YJ:5HW<!TD[ @[QY&<LI>6>D3:9(M?J#)R"[R? 0YL9#>&.%KA
ML(8*U/MBZFRBA*3E Y7[XUUY>D+,'<+^9P]7T=H_H*F$.9L7'VV3LHOPD\3=
M]/.>!O4C]-LICX,OC+W%70K;7T$MK,-]8YF%COJ%?*7YHW^GLSC[ZYL)[*?M
M[262"6D3R..)Q::;.L+Z0Z6[HVDY[>34.J[VW?$^D6,M#(TM-">VFW@=42B1
MO/>F9Q<JI75IP9"T=ZNUP_K2$N'5*'??=VN!<<GM-FM3&VZB/33@NY@/J*)2
M@?GCW?\ +8')W6J=%6;[[3ETYT]SC[9I=-9/<:NX8V[70UVM+1Y&X[ "6*'/
MH+HW5%6O:?4((4CW/<7%U*9KF5\TSO.DD<7N--FTFI02CRHY':EYBWT%Y=P2
MXS2+7M==9*5I8Z6/>66P</+<[=QTX6]-3Y)#NW'8ZRQ&/M<5C86V^/LHF6]M
M SS611M#6M%>H!?*7$W/;DMD]#YJ[U#@[1\^C+Z1TS'PMXA8OD)+H9 /-8#]
M[<=E*-.W?](0L@VG0>@-0\Q,Y%A,# 75(-W>O!]'MHNE\C@-G@&]QV!!K$C.
MSD?&=[7%O5N-$'6O<]D!P.IX=G$R\MWG;MH^)PW?W5$CUWA.1.1U'>R:YT7;
M^D95[6C+XIE ^?LQPB:('>_A #F>RI4>56J!R7<VUS9SR6MY"^WNHCPRPRM,
M<C'#H<UP!!]52*8<X"@) .\(,II>_N,5J3#Y2T8^2YL;VWN8F1 N>YT,K7@-
M VDFFY!W3W@GM=R;U,\'R716I!.S?>04WKY2X!7TAV?W1R/FYR?@S,]?@ULH
ME*?5 (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((]O_IST_\
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M @(" @(" @(" @(" @CV_P#IST__  GF_P!98A Y$_0SH3\R6/XEJ$I"0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M! 0$! 0$! 0$! 0$!!'M_P#3GI_^$\W^LL0@<B?H9T)^9+'\2U"4A(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@CV_^G/3_P#">;_66(0.1/T,Z$_,EC^):A*0D! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 01[?_ $YZ?_A/-_K+
M$('(GZ&="?F2Q_$M0E(2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @((]O\ Z<]/_P )YO\ 66(0.1/T,Z$_,EC^
M):A*0D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MVHPHIBF.Q5;^9NWIZKE4U3VRQB]F.(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(-MTIS/UYHIS!I[-W%O:L(_(I'=O:D#H[*7B:*];0"L#,Z?8S'W
MTQ,\]T^ELLKJ>9RW^W7,1RWQZ)3QI#O<-/9VNN,-P[@[(8LU'55T$KO&>&3U
M JOF?#7&S5YJOC\EPRGBSA?H\]/PGXI\TIS!T9K:$2Z9S%O>R4XGVH=V=RP?
M90OX7CU>&BJV9R5[+S_J4S'L]*XY74,OF8QMUQ5V<?1O;,L)GB @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(""/;_Z<]/\ \)YO]98A Y$_0SH3\R6/XEJ$
MI"0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%KD<GCL/9RY#+7<-C8PCBEN;
MF1L4;1X7.("^Z+=5<]-,3,]CSN7:+=/57,4Q'&4$ZW[U6E</VEGHZU?GKYM6
MB[DXK>R:1T@D=H_Q-:.IRM&4\.W:]MV>B.6^?A"H9WQ19M[+,=<\]U/QGRVN
M<=9\X.8&N^.+-Y9[,<__ /UMG^3VM.HL::O_ .L<Y6_*Z9E\OMHIV\YVSY=R
MCYS5\SFME=6SE&R/GY\6C+9M0(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @J6]Q/:S,N;65\%Q$>*.6)Q8]KATAS:$%153$QA.Y--4TSC$
MX2F/1/>7U_I@QVV:D;J/%MH#'>N+;H-^QN "XG_I ]5[-Z#E[VVCZ)[-WH^&
M"T9+Q)F;&RO_ %*>W?Z?CBZ1T-S[Y?:X[.UCO?BC,/H/B_(EL+G./1')7@?7
MH'%Q>!4[-Z-F,OMPZJ><>6*\Y'7<KF=F/15RJV>B=TI/6E6 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MSO8C26VN(W12M/A:\ A;.BNFN,:9QCL:>Y;KMSTU1-,]NQ07V\Q 0$! 0$!
M0$! 0$! 02KRYY]ZVT));V,UR<OIQCFM?C[PE[HXZ[>QD\YE!N&UO@6CSVC6
M,Q$S$=-7./?"Q:=KN8RLQ3,]='*?=/#V.\(Y&31LFB<'Q2-#V.&XM<*@A<OF
M,)P=?B8F,8>E"1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 08M^:
MC$G"V,NC!IQ5H3Z@09%DC'L:]K@6N%0? 4'KB;UA XF]80.)O6$#B;UA XF]
M808^YRS(93$QG:<)HYU:"O@WH+RWG9<1-EC\T]!W@CH054! 0$! 0$! 0$!
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MNU)MP#$=H%:$>#:B5]C&L9:-#34U/'780[I"(7B @(" @(" @(" @(" @("
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M$! 0$%.:)L\3HG[G"E>H]!04[.5TC#'+]_A/!)X>H^-!<(" @(" @(" @("
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MHV>R *H6=T^YEJMNVGA+H>1U&WFJ=FRKC'EOA)*UK9B @(" @(" @(" @("
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M4(.T$%!^4^L<*[3FK,[@'-X/BR_NK0#[&&5S&GQ@+JEBY^2W35SB)<CS%O\
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M! 0$! 0$! 0$! 01[?\ TYZ?_A/-_K+$('(GZ&="?F2Q_$M0E(2 @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M7K.&%N]/=5\?CZ77[7->UKV.#F. +7 U!!V@@A5!<WU 0$! 0$! 0$! 0$!
M0$! 0$! 04;BYAMFATSJ5W#>2@MH9&WUSVH/W"#S&G>7NZ2/ @OT! 0$! 0$
M! 0$! 06M\PM8+EE!+!Y0KL!;TCQH$&0MKAXC8XAYW!PI5!=(""C<74%J 97
M4+MP&TE!]@N(KEG'$ZH&PC<0@JH" @(""G-/%;L[25W"W<.LGP(/%O>0751$
MZKAO:=AH@KH" @(" @(" @(" @CV_P#IST__  GF_P!98A Y$_0SH3\R6/XE
MJ$I"0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M:(/F'B>V25[O)H TL.PU.VM$2RZ($! 0$! 0$! 0$!!:9)ADLY #3AHXUV5
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M$+K)WDK3]B^=Y'U%V/)T=%BBGE3'L<)SUS\F8N5<ZJO:P"RF&(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#J'N?YBC]3Z?>
M=XMK^!OJ%\4A^K&J3XFM?97WQ[X][H'A&]MN6^Z?=/N=3*D.A.?>^%A!D>5L
M&5:TF7#9*"9SAT17#7V[@?5<]BL&A7.G,=/[H^:N:_;ZLOU?MF/@X.5[<_$!
M 0$!!//('O!WW+BZATSJ>62ZT+</HT[7RX][S4R1C:3&2:OC'VS=M0[0ZGID
M7XZZ-E?M^:P:7JLY>>BO;1_Z?EV.\[*]L\E9P9#'SQW5C=1MFM[B%P?')&\<
M37-<VH((.PJB54S3.$[)AT&FJ*HB8G&)5U\OH0$! 0$! 0$&$RUQ,)^Q#BV-
MH! &RM>E$O>.N[KLW,[-TX:10U (KT5*"]]*N?\ *.]TU$'I5S_E'>Z:@>E7
M/^4=[IJ!Z5<_Y1WNFH'I5S_E'>Z:@L<E=W/"QAC= UU2=H)=3PA$F(GF=,Z%
MSBZ/A+MNVA"#,HA9W0-O*V]:/)'D3@=+#T^)!> @@$&H.T% 0$! 0$! 0$!
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MR9Z:>4>6,K]D=#RN5VQ3U5<ZMOHX0DQ:9OA 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 06V0QV/RUI)892UAO;&8<,MM<1MEB</"UX(*^Z*ZJ)ZJ9F)['G<M
MTW*>FJ(F)X2AS-=USEKELHW(6IO<3;.J9["RE;V+CUM[9DCF>$ TZJ*PVO$.
M9HIZ9PJGG/RP5B]X8REROJCJICE$[/7C@SF'[O7*;#T<,"V^E'^LOII;BO\
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M!JK^T[1W:5[2IXJ[ZHEG81DNR94Q>://#N+Q^%$*E,EUP>L_ZZ!3)=<'K/\
MKH%,EUP>L_ZZ!3)=<'K/^N@4R77!ZS_KH,'>=MZ3)V_WRO1NIT4\")9K%]IZ
M&SM*[SP5]KT(A>(+>][3T67LJ\?#LIOIT_40:[!VG;,[*O:<0X:=:);4B! 0
M$! 0$! 0$! 0$&L7?:>DR]K7CXC6O5T?41+.X[M!9Q]K6NVE=_#78B%T@("
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MK8_5%7?9*A9W6+^9V8]-/*/?S=)T_0\OE,)B.JO]T^Z.'M[4GK2M^(" @("
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M);H/W07!H_J;)T'QH+Q 0$! 0$! 0$! 069_*KOAWP6QJ[J=)T#Q(+Q 0$!
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M.:!YS:#A<2M5D,QF;F8JBO#"-\?MY1W\VYU++96UEJ9HWSNG]W.9[.7?R<W
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M=2JPR]7;A[6[T2CJS='9C/J='JDNH! (H14'>$! 0$! 0$! 0$! 0$! 0$!
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M'.ZJ9IG"=\/"E\B @Z:[H_-3XCSDG+C,STQ.:>9L.]YV19"FV,$[A,T;/LP
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MQ/N=%2NXKFVVR38Y[SN<=I="2?)>=K?-=T.=>=,U2+_T7-E?M^:@ZKI,V/\
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M9 ]!L_P+?606UYBXY6@VP;&]N\;@0@8_'OMGF64@O(HUHVTJ@R* @(" @("
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MU[7->*M<"' ]108:'*^C@0\/:Q,)#9*T<6]&Q$LQ&]LC&R,-6N%0? 40]("
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MK[*=_;V?%T2QC(V-CC:&1L :QC10 #8  -P"IDSBZ;$1$80]*$B @(" @("
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M7^\N;:CEOP7YIC=.V.Z?+!U#3,U_(L15.^-D]\?'>DA:ULQ 0$! 0$! 0$!
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MI49?A 0$! 0$! 0$! 0$! 0$! 0$! 06<GY5="'?! 0Z7J+^@>)!>(" @("
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MGJ]4/'->(<Q=CIMQ%N.>^KX1ZT=])))+B2YSB22234DD[22>E;E68@1(@("
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MD5+U[+]-<7(_5LGOCY>Q>?#V8ZK=5J?T[8[I^?M=/JL+4(" @(" @(" @("
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M/E-.T;]RW^0U&;L]%S[N$\^_M4_5]%C+TS=L_9^JG]O;'9SC@C1;Q5Q 0$!
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M=5,QU<O?[O7S19/'FM?ZJO[O!X5TV3RUU+=G%8B"26.-T[R]S8V#B+6 GI-
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M;3/?Y2XGS-I:X_,9&PL;D7EC:74]O;7;=TT44CF,D%/;  JZVZIJIB9C"<%
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M)=-Y/)!W#)# X0G=]UD\AG^)P65E;7Y+M-/:P<_?_#EZZ^4>O='K<L*_.1"
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M,;]RKN-Q*"!ZO"VI]6BTFK7^BW%$;ZO8M'A[*?DO3<G=1[9\O8G=5)T,0$!
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MJFC\5-'75CC&.Z/AZDR7/*;)<QKR<<_]2VTNHWV_::;TWI^X$4EA"TF2Y=%
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M-TQBO5\/L06]W"Z6,.CV3QGCB/A'1XT%2WF;/$V5NRN\=1&\(*B @(" @("
M@(""S=^57?#O@MC5W49.@>)!>(" @(" @(" @(" @(" @(" @(" @(/C@' M
M<*M(H0>HH+6T<87OLGFI9Y41/3&?K(+M 0$! 01[?_3GI_\ A/-_K+$('(GZ
M&="?F2Q_$M0E(2#Q+&V6-T;Q5KA0H*%G([A=;RFLT/DD^V;T'UD%T@(" @("
M @(" @M[N9T<89%MGE/!&/"=Y\2"I!"V")L3=S1M/6>DH*B @(" @(" @("
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MI\O+<T>=IF]>IM1NWSY>6]T/8V-IC+*VQUA"VWL;.)EO;0,%&1Q1-#&- Z@
M JS55-4S,[Y;NFF*8PC<N%\I$! 0$! 0</\ >JUV=1ZY9I>SEXL5IIABD#3Y
M+[Z8!TQV;^ <,>W<0[K5_P!"ROX[/7.^OV</BJFJ7^NYTQNI]J4N[?R/9IRS
MM]?:LMO_ .(KIG'B;*5NVS@>-DC@=TSP=WL&_9$@:C6-3_),VK<_3&^>?R]K
M8:=DNB/R5[^'8Z.57;L0$!!XFE;!$Z5_FM%?[$%M;VC7M[:Z8'SR'C/$*\/4
M-O4$%X@Q6I-28726&NL_J"[998NT;Q2S/VDD[ UK14N<X[&M&TKVLV:[M<44
M1C,O.Y<IMT]54X0XCYM=XG4VOY9\3@GRX321):+:-W#=7+>N>1IW'\&T\/7Q
M;U?LAI%O+Q%57U5^J.[XJIFM0KN[*=E*%EO6K$! 0$&1P6?S6F<E#F,!?38[
M)P?>[FW<6.H=[3T.:>EKMAZ5Y7;5%VGIKC&'I1<JHG&F<)=E<E.\99:YD@TK
MK(16&JI ([2Z;Y%M?.I3A .QDI]KYKO8[:-5'U+1YL8UV]M'KCY+/DM0B[]-
M>RKVISM28)7V3]S?+@)Z6'H\2K;<+Q 0$! 0$&/SF$Q6I,1=X+-VS+S%7T9B
MN;>3<YIV@@C:"" YKAM!%1M7I:NU6ZHJIG"8?%=$5TS35MB7Y\<W^563Y6:D
M=CY2ZXP5YQ2X;(N'WV(':Q]-G:1U >/4=N*Z5I^>IS5O'=5&^/+@IF;RLV*\
M.$[G9W(K79U]RYQN1NI>US%@/B[*N)JYUQ;@ 2'K,C"QY\)*HVJ97^/?F(W3
MMCS_  6C(W_RVHF=\;)22M4SA!9C\JNZ_P"HMC0=3I?[$%X@(" @A#O,<NSJ
MS1GRFQ<9^46F Z[B?'LDDL]CIF5&VK*"5O5PD#SEO]%S?XKO15]M>SS\/@U6
MI9?\EOJC?3[$C<M]4MUKH7!:FX@9KZU8;KAW"YC^YS >I(URU><L?AO54<I]
M7#U,W+W?R6Z:N<-I6(R! 0$%I>.=(6V<9H^7SR/8QC>?'N073&M8T,:*-:*
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MZW>X=]9 ^,;7K=[AWUD#XQM>MWN'?60/C&UZW>X=]9!BKC*7+Y'")W!%M#0
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MT>M/\,K9XFRLW.%:=(/2/$JZV[V@(" @("#5.8N@L1S(TM=Z:RPX#(.UL;L
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ML</'UKVIN8431PG"?.\YH^J*F57B]! 06<_Y5<-M1MBCH^?P^U:@O$! 0$!
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MI'GBEFF=MDEE=[)[SM)\0H  O?,7Z[U<UU;Y\L'G:M4VZ8II9Q8[U$! 0$!
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M2:':L#/W:[=BJJB<)AL=-LT7<Q317&,3\)=S6O=OY)V@ CTC;/(Z9IKF<_\
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M"#Q-$V>)T3_-<*?VH*-G*Y['12_?X3PO\/4?&$%R@(" @(" @(" @(" @("
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M9N/"0:M=U%!CH++T*ZA?.0YKB6L<-@#^BOJH,P@(" @(" @ACO4VGI/)7-R
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M$! 0$! 0$! 0$!!0NY1%"0&\;Y/(8P]+G;$%O!BK>(L>^KY&T)J?)XO407Z
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M5@Y__8J[FUTG_P#+M][II45U80$! 0$! 06?_=+NFZ"Y.SJ;+_:@O$! 0$!
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MR1Y<!/2P]'B07B @(" @(" @(" @L_\ O=WUP6Q\1E_L07B @L<A8.N^%\9
MD;LH=Q""G98ML577(:]QV!N\#UT%WZ%:?@6>L$#T*T_ L]8('H5I^!9ZP0/0
MK3\"SU@@>A6GX%GK! ]"M/P+/6"!Z%:?@6>L$#T*T_ L]8('H5I^!9ZP0/0K
M3\"SU@@>A6GX%GK!!9WN*$I#[8-80*%FX'P[$%;'V)M YSW R/H-FX (+U 0
M6;ORN[#=\%L:NZC)T#Q(+Q 0$! 0$!!'M_\ 3GI_^$\W^LL0@^\B:?,SH,-
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M+[_">)OA'2WQA!6BE;-&V5AJUPJ$'M!2N+FVLX77%W,R"W8*OEE<&,:/"YQ
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MUM*(O/+32F_PH-<B$AE:V.O:5'#UU1+:D0(" @(" @((]O\ Z<]/_P )YO\
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M-SK2^(\EK,?"T^%QN''_ $0JGXAJV41W^Y</#E.VY/\ ;[W7ZJ"YB @(*5S
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MI9@YD3H>S$3@VGE/?6O$I0WW3'=3O]3Z<Q.HH]3PV[,K:0WK;<VTCC&)V!_
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M^9W.S06-;H_%XN>2&![VVUI>XZ:6>!SR7%K  UWG$GA<"I0Z!YQQ9_4?(IT
MQ]Q=:GOK;%SSXR"$BY[8S0/F'9;V\!XBYO110E@.ZGIW4.G\+J-F?Q5UBGW%
MU;N@;>1&(O#8W@EM=]*A)&U\[>3%MS0Q\-]CY66>K,<PLL[B2O930DEW82D
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M#</ <?C;.U<W=1T,#&'ZH7*\Q7UW:JN<S[76\M1T6J:>41'J9U>#($! 0$!
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M9*/<TDM%!3?5:#5\Y;ILU6XGZIX+%HV2N5WJ;DQ]%/'X.\U0W01 0$! 0$!
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M>F[<FN>+KN4R\9>U3;CA'KXLFO!EK2URN,OKBZM+*\@N+NR?V5Y!%(U\D+Z
M\,C026FAZ5Z56ZJ8B9B8B=SRHO45S--,Q,T[]N[O7:\WJ(+#*X3$YN#T;+6D
M=U%['M&^4VO2UPH6GU"O:U>KMSC3.#'OY:U?IPN4Q5"+=1<ER..XTS=5Z?0K
MH_49(!]1P\:WV7U?A<CSQ\%1S?ASC9GS3\?CZ4797$9/"7'HN6M9+2:M&B44
M#OM7;G#[4K?VKM%R,:9Q5&_E[EBKIN1-,]JQ7J\!!-?)/+]KC\AA)'>7;2"Y
MA!W\$HX7 > .:#_>57UBUA537SV+WX;S&-%5J>$XQY_+UI55?7 0$! 0$!!:
MWC',+;N(5DA\X>VC.\?UH+ACVR,:]AJUPJ#X"@](" @(""-;?GIH&YU?\AXI
MKHY[TY^,X#;N[/TF.0QD<=?-XAO4X"2E (,!K'6>GM!X5^>U+=>BV#7MB9PM
M+Y))7U+61L;M<X@$^H"3L"#%Z+U]IGF;:.R.F;ET]C92]G>12L,4K)Z!S6O8
M[HH>('<4&YH""S'Y7=\6^"V-!U.E_L07B @(" @((UU'STT#I74\VD<M-=-S
M,#X8I&16[I(^*X8R1E' [=CPIP$E*!XFB;/$Z)_FN%#]=!1LY7.8Z&7[_">%
M_A'0?&$%R@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(.,^:.?^4>
MN<O?1NXK6*7T2U(VM[*V^Y@CP.(+_&NR:/EOP92BF=\QC/?.WY/S3XCSW\O4
M+E<?;$],=U.SU[_.U!;A7'2_(+6OQMAI-)WTE<AB6\=F7':^S<:4_P"K<:?:
MEHZ%S3Q+I_XKL7J8^FO?_=\_;B[AX(U?\]B<K7/U6OM[:/\ Z9V=TPF14YTE
M&?/7EK'S.T#>XJWC!S]C6^PDAH#Z3$TUBKLV2MJS?2I#O8K9Z=F_X]Z*I^V=
MD]WR:O4\G_)LS3'W1MCO^;\VI(WQ/=%*TLD82U[' AS7 T((.XA=(B<7,9C!
MY1 @(" @(" @W#0?*[6_,F\]%TKC'W$#'!MQD)?N5G#7;]TE=LK3;PMJX] 6
M'F<Y:R\8USYN+-RN2NYB<*(\_!V)RP[JFC='=EE-6EFIL^VCFLF93'PN&WR(
M37M"/;2U'V(5/SFLW;NRCZ*?7Z?@NF2T2U9^JY]=7J]'Q3ZQC(V-CC:&1L :
MUK10 #8  %H%B>D! 0$! 0$! 0$! 0$%F?RN[X=\%L:GJ=+_ &(+Q 0$! 0$
M! 0$! 06UY$YS&S1??X3Q,\(Z1XP@K0RMGB;*SS7"O\ 8@]H" @(" @(" @(
M" @I7$(N(G1DT.]KNIPW%!YM)C-%Y>R9AX)6]3A]=!70$!!'M_\ 3GI_^$\W
M^LL0@M>2SI&<G= WU2XQX.PCE&\F(0- ]S38B4E@AP#FFH.T'P%$/J @(" @
M(" @(" @(" @(" @LY_RJX;:C;%'1\_A]JU!=DAH))H!M)\""UM09Y'WKQL=
MY,(/0P=/C07: @(" @(" @I7, N(C'6CM['=3AN*#S:S&:*KQ25AX)6]3AO0
M5T%*Y@%Q$Z.M';V.ZG#<4'FUG,T57BDK#P2MZG!!70$! 0$! 0$%K>/<\MM(
MC22;SC[6,;S_ %(+AC&QL:Q@HUHH!X @@/G%CO1-5B\:*,O[>.0G[..L9'K-
M:KAI-SJLX?MGYN<>(;/1F>K]T1ZMB/5N%;$! 027R=T[Z?F)<]<,K:XT<,%=
MSKB04_PMJ?5(6CU;,=-$41OJ]BU>'LI^2[-V=U&[OGX1[DZJIN@L!K75%IHO
M2V4U+>4<RPA+XHB:=I,[R8H_[SRUJR<K8F_=IHCC/^+!SV;IRMBJ[5^F/3/"
M//+\^X]2YZ'.3:DMLA/;YR>9]S+?02.BE,LKN-YJTC82=HW+J$V+<T=$Q$T[
ML'"8S5V+LW8JF*YG'&-^U.&A^]+F\=V=EKBS&5M!1IR-J&Q7;1LVN9LCD\7!
MZJKN:T&BK;:GIGE.[X^U<\AXMNT84YB.N/W1LJ]&Z?4Z+TCS#T?KF#M=-Y2*
MYF XI;-Q[.ZC^VB?1U/"!3PJJ9G)WK$_73AV\/2O^2U++YN,;543/+CZ&T+#
M;(06F2QECEK.2RR%O'<V\@(,<K0]NT4K0K[HKJHG&F9B7G<M47*>FN(JCE*+
MLQR>L;UDDVG9S973#1]C<$R0\0]J_:YH.\5XO$M[E]7JC9<C'MA5,WX<HG&;
M$]/],[O3O]J,<WIG.:>E[++64D )HR:G%$[[5[:M/KJP6<Q;NQC1.*GYG)7L
MO.%RF8]GI93EUFOB35EC.]W#;7+O1+CH'!-0 GP!W"[Q+'S]G\EF8XQM]#+T
MC,_@S-,SNGZ9\_SP=+*CNJ" @(" @(""SM_R:=UH?O;JO@/@Z6^)!>(" @("
M#A;"_P#Y-'^*KK_BI%](=TKY2((XYT\N(^9FE(L.R]] R-M<LN;"<L[5AEX7
M1ECV!S:M+7'<=A""WY+<HQRHQ%]!<Y$9/+91\3[R:.,PP-; '!C6-<YQ]FXD
MD]/@4B3U M[N9T<89%MGE/!&/"=Y\2"I!"V")L3=S1M/6>DH*B @(" @(.%N
M=_T_Y#_>\7_PULOJ$.Z5\I$%I= P2,O6"O!Y,P'2P]/B070(< X&H.T'P(/J
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(-9Y@ZB&EM'Y7,-=PW+(3%
M:=?I$WW.,CU">(^ +9Z9E?Y.9HHX8[>Z-LM'KN?_ (62N7>,1A3_ '3LCXN*
MMZ[2_,8B&8TMJ*\TKG['/6.V6TD#GQUH)(CY+V'P.:2/JK#SF5IS-FJW5NJC
MT3PELM-S]>2S%%^C?3/ICC'GAVOBLG9YK&VN6Q\G:V5Y$V:!_3PO%:$=!&XC
MH*XK>LU6JYHJWTS@_3V6S%&8M4W;<XTUQC'G7B\62X0[U_+'Y):Q;K+%P\&!
MU,]TDX8*,AR0'%*WP=J/NHZW<?0%>]%SGY;?XY^ZCV?+=Z'/]<R?XKOY*?MK
M]OSW^ESVK K@@(" @(,QIK2FH]8Y)F(TQC)\ID'_ .JMV<0:/;/<:-8W[)Y
M7C=O46J>JN<(>]FQ<O5=-$3,NM.6/<_Q=@(<MS,N1D;P4>,)9O<VU8=AI-**
M.D/6UG"WPN"J>;URJKZ;,81SG>M^3T"FGZKTXSRC=YY=.8W&8[#6,.,Q-I#8
MXZV:&6]K;,;%$QHZ&M:  JS7757.-4XRM5%%-$=-,81"[7P^Q 0$! 0$! 0$
M! 0$!!C)\O$.-D()=N:\^;7K07MM$R&!C&'B%*EWMB=I/C05D! 0$! 0$! 0
M$! 08R2Z9CKB2.G'%)Y88W>UQW^N@OK>XCN8^TB.S<0=X*"J@(" @(" @("
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M^-HKX:%$*GI%Y_E#_M&H'I%Y_E#_ +1J!Z1>?Y0_[1J#AK$RRM[S+BV,N_\
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MX!7[*W?RVJ:NSV;'(<_E_P &8KH[9F.Z=L,*LI@B#ICE_IWY-Z:M;65G#?7
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MO4<%,/F4V6..N,3W;I+&Z:6W#-*W+Y&'>TS6;Y.$^$<5$2A?N@_^M,[^:_\
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M.6C+4S]5W?\ VQ\9]DN9UTMPX0$! 03#R#UK\3YM^EKZ2F.R[@ZU+CL9>@4
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M!=<$! 0$! 0$! 0$! 0$%M>1.>QLT7W^$\3/#UCQA!6AE;/$V5GFN%?[$'M
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M^9T^QF/OIV\XWMOD=7S64_VZOI_;.V/1\,'4O*?GQC.8UX,#?61Q>HQ$Z9C
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M6B@&P ;@$&.ET[I^:[-_-BK.2^+A(;I]O$Z;C;2CN,MK44WU09) 0$! 0$!
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M6KKXX81WSLAO=!R'\W/6[4[L<:O[8VSZ=WG=J+B[]." @(" @(" @(" @("
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M0.)WV1*ZCD<M&7LTT<>/?Q<(U3.SF\S5=X3.SNC=Y<VIK.:L0$! 0$! 0$!
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M3'->T/::M<*@^ H/J @(" @(" @(+-_Y5="+?!;D.DZB_H'B07B @(" @("
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MW'X>=?/!>F_R<[^6J/IL_5_Q?I^/F=5KE;OH@(" @(" @(" @(" @(" @("
M@(" @(" @(+:]M!=Q<%>%[35KD%A:V1L[N,W!!XP1&YN[CZC7P(,P@(" @("
M @(" @(""G.8Q#(9?O?">+U*(,/!B)) R1[@R-VWA]E3^A$LVUH:T-&P 4 \
M 1#Z@(""/;_Z<]/_ ,)YO]98A!1Y'1LEY4:&<RIMK;!V#8R?92&W9Q.'@KYJ
M)20B! 0$! 0$! 0$! 0$! 0$! 0$!!;W<+I8PZ/9/&>.(^$='C05()FW$396
M[*[QU$;P@J(" @(" @(+.'\JN3<'[S%5D/A/LG?U(+Q 0$! 0$! 0$! 0$!
M0$! 019S_P!:NT?R_NHK1Q;E,V3C;1S:U8V1I,SZ]%(P0.GB(*W.D97\U^,=
MU.V?=ZU9\1Y[^-E)B/NK^F/?/H<-+H[C @(" @(" @(" @(" @(" @GCN[\V
M1I?)-T7GY^'3V2E_(;B0^3:7;]E"3NCD._H:[;LJXJM:SI_Y:?RT1]5._MCX
MPNWAK6/X]?X+D_15.R?VS\)]OG=@*B.KB @(" @(" @(" @(" @("#7;NYE%
MW,8W&/RJ$-)%>'8"42R%ID)7P-+X9)'#87L;4&B(5_37_P"5F]R/KH'IK_\
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M/X61IBJ/KN?75Y]T>:/7BWU:%;1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M'BD=UN.]!70$! 0$$>W_ -.>G_X3S?ZRQ"!R)^AG0GYDL?Q+4)2$@(" @("
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M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(/,C&RL=&\5:X4(]5!;V;W
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M'PATV*<KIMGA13'IF?;,M%Y>]XBPUSK>;2]SC?B['7S2,%-([BFDDC:7/9.
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MF9ZI^FGGS[OBNVJ:[8R4=,?57^V.'?R[M_M4--3XKO#<J>#4UJV"^[5]M/-
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M@[>(LK1X\ICNIPW% M9^WB#G"DK3PR-ZG#>@K(" @(" @(" @(" @(" @("
M@(" @(" @(" @P>L=+8[6FF\AIK)BEM?1EC90*NBE'E1R-\+' .\.Y9.6S%5
MBY%=.^&%G<I1FK-5JO=5'HGA/F?GKJ#!9'3&;OL!EH^RR&/E=#,WH)&YS2:5
M:X$.:>D%=1LW:;M$5T[I<'S.7KR]VJW7&%5,X,:O9CB @(""XL+^^Q=Y#D<;
M<R6=_;.X[>Z@<8Y8W4I5KF[1L*^*Z*:XFFJ,8EZVKM=JJ*Z)FF8XPS6C-(9O
MF!J6WT_B 7WEVYTMU=RU<R&$&LD\IWFE?5<X@;RL?-9FC+6YKJW1Y8,[(9*Y
MGK\44[YVS/*.,NW([;2W)?ES)&UW9XC$6[WO?(:2W5R_K(WR2O-!3=7H 7.Y
MJNYW,=M4^B/D[)339TW*8;J:(],_&9<EVG/[FS:8\X]F?,C""&SSP0S7#0[H
M$KF$DCK=4J[U:/E:JNKI]<X.74>),]31T]>/;,1C[%OH'EUJ[G!J">Z=/*;0
MR\>9U#=\4O"XT):TN/W24C<RM!TT"^LWG;62MQ$1MX4QY;GQIVF9C5+LUU3.
M&/U53Y;W1FKN[KI2]T'%I_2\#+//XWBGL,G-MEN)W <;;EX XFR4ZO(-.$4'
M":KE]9NTW^NY.-,[XY=W=ZU^SGARQ7E?Q6HPJIVQ5.^9_JGM]7",-CCF_L+W
M%WUQC,E ^UR%I(Z&ZMI11\<C#0M*OM%=-=,54SC$N1WK-=JN:*XPJA;K[>0@
M(" @(+[#YC*8#)6^7PUU)99*U=QP7$1HYI_H((V$'81L*\[ENFY3--48Q+VL
MWZ[-<5T3TU1NEVAR@YVXKF';1XG*F.PU?$W[I:UX8KH-&V2"O3TNCWCHJ-JY
M_J6EU9:>JG;1[._XNO:+KUO.T]%?TW8X?N[8^"6EHUI$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>)IHK>)\\\C8H(FE\DKR&
ML:UHJ22=@ '2IIIFJ<(VS+YJJBF)JJG"(XN;>:O.67.]MIW2LKHL+MCN[]M6
MR7(W%K.EL?7TN]3?TC1M!BSA=O1C7PC]OS]G>XGXF\63F<<OEIPM[JJN-79'
M*GV]V^&5<W-! 0$%[B,1D<[DK?$XJ!USD+I_!#"S>3O))W!H&USCL VE>%^_
M19HFNN<*89.6RUS,7:;5J)JKJG"(CR\\SNB-L[&SZ]Y:9[0,EO)?%MWC;D-;
M'D( >R$W#5T3@=K2-O#7SF[1[(#6:;JUK.Q/3]-4?IG?AS\MT^;'>:WX?S&E
MU4]?U45;JHW8\:9Y3R_=&V/U1&[\JN<\N)['3FKYG2XO9'99-]726_0&2G>Z
M/J=O;]KYNDUG0(NXW;$85<:>?;';[>_?:O#/BV;&&7S4XT?IKG?3V5<Z>4[Z
M?[?MDO5FA;VX>_5?+F_^*-22CMY6P. L\@#Y7W5NV,O-:M>YI!)\K?Q"M9+4
M::8_#FJ>NW&S;]U'=QP[/1RFZZIHE=4SFM/K_%>G;.'V7/[H^V9VS,3,3$SO
MW]4:5AN?N2Q-X_#Z^P[HKNW=V<\]JWLY6.'MX9#0]=6O'@"W5_PU1=IZ\M7L
MG=$[O-,?#SJUE/&]VQ7-K/6L*J=DS3LF.^F?;$QV0V'7_,;E[F= 9 LNXLH;
MQO86M@TF.Z;<G:QY8X![!&1Q<9;P[*;:T.OTS2LY:SE.R:.G;,\,.,8[IQW8
M;VWUSQ!IF8TZO"N+G7&%-.ZKJX3A.V(IG;C,8<-N.$\NKJ#A(@()AT5RHQUW
M!8RY?/3XG55_:NRF,M;1OEVUJP^3<3/&X.J"!Q,/16M:4_4-:KIFJ*+<5VZ:
MNBJ9_5/[8CY3\>CZ/X9MW*:9NWIM7ZZ?R413^FF-U=4\IV3&VF>W''#9-2YS
M)Z?QLVG>;V$^4.* ?\4:@M0&&64-)C8]PH8GD @N%';-SQ5RUN4R]N_7%W(W
M/Q5?JHGA''OCLW=M.YNM1SM[*VIR^JV?ST;?QW:=F,[Z8G]L\,=^S=7&-3GH
M[]BZ$X\(" @ESD3H;X]SAU-D(N+%8=X-N'#R9;VG$T>I&"'GP\/A51\1ZC^&
MU^&F?JKW]E/SW>ET3P7HW\G,?R*X^BU.SMKX?Y=_?@Z?7,7=1 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$&#O<=<FX>^)O&R0EP(.ZO0:HE>6N
M-:R$"9SNT.TAKB /61"MZ!#[:3W;D#T"'VTGNW('H$/MI/=N0/0(?;2>[<@>
M@0^VD]VY!87V,E#P^W!D:10@FK@?&B5UC+22V8]TNQ\E/)WT _\ U1"_0$!
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MN!;312Q??Z$&NXLZCXT%3'Y W1='(T-D J"-Q""_0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$!!J/,C0>/YB:6NL!><,=U]^QUV14P73 >!_P!J:\+QTM)Z
M:+.R6;JRUV*XW<8YPU6J:?1G;$VZM^^F>4^6_L<!YC$9# Y2[PV6@=;9&QE=
M!<PNWM>PTV'<0=X(V$;0NG6[E-RF*J9QB7#;UFNS7-%<854SA*Q7H\1 0$!
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M'4=U<6]47/:1=R_U4_53SY=[JNE^(;&;PIJ^BYRG=/=/NW]Z65I%H$! 0$!
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MU5U;(QV?"(\N+;^9?)3,\M=/X?-7MTV_=>/?!D^P81!:SD!T36N.UP<.(<1
MVCPK R.J49JY53$88;NWFVVJZ!7DK-%R9ZL?NPW1/#_%OW=0U<VVR.8T3<NH
MV]:,GCZ_A8@(YV^J6\#O[I6L\09?&FF['#9/N;SPAG,)KL3Q^J/9/N]#"]Z/
M2 PVLK35%LREIJ"$B< ;!=V@:QQV>V86'U05D:#F>NU-N=]'LEA^+<E^._3>
MC=7&WOCY8>MI(YR:ZBT39:$LK[T3%VC)('W40/I<UN\DMA=(:\+& \(X*'AV
M5HMC_P",LS>F[,8S/HQYM/\ ^>S,9:FQ3.$1&&/&8Y=F'8L](\K-9ZVPN3SN
MGK'M['%BE''@?<R#:Z*W!%'O:WRB*]0WFB^\QJ%FQ7317.VKU=[QR6C9G-VJ
MKE$;*?7W-->U\;W1R-+)&$M>QP+7-<TT((.T$'H6PB<=S354S3.$[)?%+Y$!
M 0$! 0$$S\N>\5JG2/98W47'GL RC&B5WY9"T;!V<KO. ]J_U 6JOYW1;5[Z
MJ/HJ]4^9;],\37\MA3=_U*/^:.Z?=/IAU3HWF%I+7MGZ5IO(,GD8*SV;_N=U
M#]O$=H%?9"K3T%4O,Y.[EYPKCS\'3,CJ67SE.-JK'LXQWQY0VA8;9" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(""-M;<Y],:4[2SL7#+YEM1Z/;N'
M8QN_YR45 I[5M3UT5DT_0+^9PJJ^BCG.^>Z%)UCQ=E,CC11_JW.4;H[ZO=&,
M]SG/5VO=2ZUN3-F;H^BM=Q06$-66T7J,J:G[)U3X5T7(Z;8RE.%N-O&9WRXQ
MJFMYK4:\;M7T\*8V4QYO?.,M96S:,0$! 0;1H70F7UYE3C\<6PVT'"^^O)".
M&&-Q-#PU!<XT(:T=.\@;5J]1U&WDK?57MF=T<Y]S?:-HM_4[W1;PB(^ZJ?TQ
MW;YGE$<=^$;74N#QNC>6]IC]/V\\5G<9*40PNG</2;RXIO<>G?0;F@D-&\!<
MNS%W,Y^JJ[,35%$8[-U,>7GXN\Y.QD=(HHL4S%$W)PC'[JZO+S1,Q$;XAJ'/
M'E_DM38^'/XB26XO,7&X28SB+F/A)XG/A9^$'LA[-HZV@';^'M3HR]<VJXB(
MKG[NWE/9[)[U;\9:%=SEN+]J9JJMQMHYT\9IC]W/]T=L1$\PKISAC;-!Z_S&
M@\H+NQ/;8Z8@7^/<:1S,'2#MX7CV+AXZC8M3J6F6\[;Z:ME4;JN7R[%@T77+
M^F7>JC;3/W4\*H]T\I]L;'4C7:1YK:4Z+W$7>P@^1/;W#!XRR5E?&#TM=MY?
M,9G3<Q^VJ/1,>^)\L)AW>)R6N9/]]%7FJIJC_P!-4>N)XTSMY#U)C++#9V^Q
M>.OV9.RM93'#?1"C) /J&GFDC82-A(77,I=JNVJ:ZZ>B9C=R?G?/Y>W8S%=N
MW7%RFF<(JC=/ENY<MC%K*8 @()QY28C(/T=<9324UK::DER;;;)Y2YC;-):8
MQD0D=V;'U!).VGLMWL012-;OT1F8HOQ-5OHQIIB<.JO'#;/EAY]O4?"^4NU9
M*JYE9IHO3<Z:ZZHQFBU%,3/3$[-L_P";=^F)C&<S;6+5MKD.8%M;Q8G#6LD5
MECIIH3#<YB1[O+F --C0*L);4M!J?)H,G2*YRM5.5F9KKF)JJPG&+?*/CV]^
M,X7B*BG/T5Y^BF+=NF:::)F,*K\SOJX;HVQLVQ$\L(B%6YSL0$!!F=+::R.K
MLY:X/&-K/<.K)*1Y$43=KY'^!H]<[!M*PLYFZ,K:FY7NCUSR;/3=/NY[,4V;
M>^KCRCC,]WR=FZ;T_CM+86UP>+9P6MJSAXCY\CSM<]YZ7..T_67&LWFJ\S=F
MY7OGRP?I?3\C:R5BFS;CZ:8],\9GMEE5BL\0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!'M_\ 3GI_^$\W^LL0
M@I<C[6*?E!H>YN0)9Y<)8/<3M )MV>3XD2D<  4&P#<$0(" @(""G+;P3T[5
M@>1N)WH+>W_)IW69^]NJ^ ^#I;XD%X@LYOR6Y%R-D,M&3> ^Q=_4@O$! 0$!
M 0$! 0$!!XEE;#&Z5YHUHJ4%&SB>&NGE^_S'B=X!T-\007* @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(..>\'RD.D<F[5V @IIG)2?E,$8\FSNG[:4
M&Z.0[6=#3Y.SR:WW1]1_-3^.N?KI]<?&')?$FC?QJ_S6X_TZIV_TS\)X>CD@
MU6-3! 0$! 0>HY)89&302.BGB<V2*5A+7L>PU:YI&X@BH43$3&$OJFJ:9B8V
M3#M'EOS#TSSKTE<:3U7'$[/&#L<MC7T8+A@W7-O2AW@.\G;&_P#ND\^SN3N9
M&[%RW]N.R>79/EMAV'3-2LZI8FU=B.K#ZJ>?]4>6-,^:9<O.[UB.7^KSJJ',
MW&0$#)8\;:2QLC,0F:6.,DC3]T/"2!1C>M,YK%>8M?CFF(Y^7#UFF^';>3OS
M=BJ:N4<N^>/HAHG>RU'C)S@=*P2MEREK))?WC&D$PQO9P1M=3<7U+J=0KTA;
M+P]9JCJN3NG9#3>+\U1TT68^['JGL_Q1#RLY997F;GQ86_%;X2T+7Y?) ;(H
MSN8RNPROIY(Z-YV!;W4,_3E:,9VU3NCRX*GH^D5YZYANHC[I]T=KL[*YO1'*
M'2EE'>/9BL!:&.RLK>-KI'N+C[%HJYYWO>[:=[CM5 MVKV<NSA]54[9=<NWL
MOI]B.J>BBG9'EOGG/'BCWFMR4PG,NQ&LM$S01:AGB$[)8G-]#R3"*MXW-V!Y
M'FR>)W6W::?JE>5J_'=B>GUT^7+T-'J^AVL_3^:S,17,;^%7ES]/##D+(8^^
MQ-]<8S)VTEGD+5YBN;:9I9(QXZ"#_P#R5>Z*Z:Z8JIG&)<GO6:[-<T5QA5'!
M;+[>(@(" @(" @N<?D;_ !-Y%D,9=2V=] [BAN;=[HY&.ZPYI!"^*Z*:XPJC
M&'I;NUVZHJHF:9CC"?=!]Z/,8[LL?KJU^-+,4;\9VH;'=M&P5>S8R3Q<)]55
MG-Z#15MM3TSRG=\EYT_Q9<HPIS$=<?NC[O1NGU.D=*ZYTIK6T]+TUDX;T  R
MP \$\?V\3J/;ZI%.I5+,96[8G"NG#V>ET'*9^QFJ<;545>V.^-[85BL\0$!
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M!6_)Y:JW13-V8KN1&$U8;>['?\=[FVHYRB]=K_!$V[-575%O'9$X88X;L?\
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M]B=[?$@O$! 0$! 0$!!9Q?E5R9SMAAJR'J+O9._J07B @(" @(" @(" @("
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MH.8DD63O^TQ&DO.-^YOW:Y -.&V:[>-E.T/DCHXCL7AJ&JV\O]-/U5\N7?\
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M8IIBF-T.%7KDW*YKG?5./I="]V#EOZ??2<Q,M#6SLG/ML&QXJ'W%.&6>AZ&
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M;:J)CHJIY],;ZN_M2=F]56&7TRS55Q:_'G+[)AL6=Q!HZ\Q=Z/),D+R6[*N
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M @(" @(" @(""/;_ .G/3_\ ">;_ %EB$#D3]#.A/S)8_B6H2D) 0$! 0$!
M0$%"\E$<#AP\;G^0QGMG.V406T&)@B+'O)>]M"0?-XO609! 0$! 0$! 0$!
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MN:+JD_C_ .W5U4]M,\.WZ9Z9GO=.8[):8YFZ5>6!MYBK^/LKRU>:20R;"6/
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M+D=T\)[FL+,:X0$! 0$! 0;=IOF=K?2>)OL'ALK)'B;^&2!UK)]T;#VPHZ2
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M 0$%K>2.HVVB/W:;R0?:MZ2@KQQMBC;&P4:T4"#V@(" @(" @(" @(" @("
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MFL.'W-H&@ETD5!VL0 WD@<3=E>)H'2HT'4/XU_IJGZ*]D]D\)\N$OKQ;H_\
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M=M25T/2LO=L9:FW=PQIY<G&O$&<L9O.UWK&/35AOC#;AA.'9.&.W:U1;97Q
M0$&0@P>6N<9<9J&SE=A[1[([F^X#V,;Y"&@%W75PW=8ZUCU9BW3<BW-4=56Z
M.++HREZNS5>IIF;=$X35PB9X8^>/3'-(;M X716H<1#JN&?4N(SEE7&_%7D=
MI?/<UH8T]HTN: YI#JBO$-F\*O1J5W-V:YLS%JJW5]77PIY[MGRE<9T6QIV9
MM1FHG,6[U'T?CV8US,1A'U1,Q&,;=F/5&S?#QH3ECZ=K>^P&K[:6W9B;8WTV
M.CD:^68.+.!@DB-""'[7,._9LZ)U+5^C*TW;$Q/7/3%6&R-^,X3W<7SHGAW\
MNH56,W3-/XZ>N:,8QG=A&-/?MF.[8V_!3:?YBZ(R. TEB!@LUIZ=N4Q%L)?2
M"^8$N:XR2<))?Y4;@\D-JW;0 #49FF]D,U3=OU_DHNQTU3AAL[HY;]F_:L.2
MJR^JZ?78RMK\-RQ5^2W'5U8SPG&K#&9VT_5C$?3.Z,(N<IK[1VJL9'<RZDGT
MF9174>)L[4B^NI@T,#1<M830!O"#MJV@<!N7G9TW,Y:N8BU%[#_;JFKZ:8_M
M]??NQ>^9US)9ZU%4WZLKC_O44T?77.Z/KB.&&''&G"*HC<B#)ZM;:7^4CT,V
MXP&G\C'';RVC9G.DECAV!SW$DM+JDN#7=)%2":VZSDNJBB<QA<KIQG'#=CR\
MNUSO,:IT7+D9.*K%JY$1-/5,S,4[IF=\3/&(GC,8S&_5EM6A$! 0$%]A\-E,
M_D(L7A[5]W?3'R(HQ4T&\DG8&CI)V!>%^_;L437<GIIAEY3*7<U<BW:IFJJ>
M$>6[M=.<MN3N,T@(LOF>"_U(!Q-=2L%L3T1@[W#VY\5.GF6K:[7FL:+?TV_7
M5W]G8[GX?\*6LAA=NX5WO^6GN[?ZO1@E%5=>Q 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!'M
M_P#3GI_^$\W^LL0@^\BFEO)G0=>G!V#AZCH&D?4*$I!0$! 0$! 06=R3<2ML
MV^;Y\Y'M1N'C07@  H-@&X(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @((9YK<@,)K?M\UI[L\3JEP+WD#
MAM;IW_.M:/)<?PC1]L"M_I^KUV,*:_JH]<=WP5'5_#MK-XW+?T7/55W]O;Z7
M(>H],YW264EPVH;*2QOXCM9(/)>WH<QPJU[3T.:2%>K-^B]3U43C#E69RMW+
M5S1<IZ9CRV<V)7NQ1 0$! 0$! 0?*"M:;>M#%NO*S7-IR[U9'J6[Q?QJ(X)+
M>.,2]B^(S4#I&$@@NX06T=T$K7:AE)S-KHBKIVMUH^H4Y*_^2JGJV8=W;Y<V
M\<].<F+YCX["8O3HN(<= Y]YDH;EG9O])IP1,(!+2&@O-03O6NTK3:LM5557
MACNCN;OQ!K=O.6Z*+6.&^K'GP]Z)M.8*ZU/G\9IVR_[SD[F.V8[VHD=1SSX&
MMJX^HMW?NQ:MU5SNIA5LEEJLQ>IMT[ZI=VZZS=ERQY:WMY8 0LQ5DRRQ,6S[
M\6B"W&[;0D$^ %<WRMJK-9B(G]4XS[9=KSU^G(Y2JJG9%%.%/LI< %SG$ND<
M7R.)<]YVDN.TD^$E=.B,'":JIJG&7Q2@0$! 0$! 05K2TN;ZZALK*%]Q=W#V
MQ001-+Y'R/-&M:T;223L7S55%,8SLB'U11575%-,8S.YVMR4Y-VO+W'MR^88
MR?6%Y']W>*.;:1NV]C&>O\(\;]PV;3SW5-2G,U=-/V1Z^WX.PZ%HE.2HZZ]M
MVK_E[(]\I<6C6I99?+8_!8ZXRV5G;;6%JPOFE=T#< !O))V #:2O:Q8KO5Q1
M1&-4L7-9JUEK55V[/333&V?+U.1.8O,/(Z]RIF?Q6^&MB1C[&OFMW<;Z;#([
MIZMP\/7-*TNC)6\-]<_=/NCL?G;7]=NZG>QGZ;=/VT^^?ZI]6YIBW2LB @("
M @(.S-0!^(Y8Y".$NBDM,))%&YA+7-<RU+ 01N(7&LMA=SU,SMZKD?\ J?I?
M/1.7TJN*=G19F(PX848.-'/<]Q>]Q<]QJYQ-22>DDKLD1@_-,SCM=!:)Y[87
M%Z2M;+4PN9\Q8_DS!;L$CIH& =F\N>YC00/)=5U3PUZ5S_4/#EVYF)JLX115
MMV\)XQQ[_4Z_H_C2Q9R=-&9ZJKE'T_3&,U4\)G'".R=N.S'BA+4][B,CGKZ_
MP-J^QQ5S(98+23AK'Q@%P 9L#>*O"!N&Q7;*6[ENS33<GJJB-L\W+]0NV+N8
MKKL4]%NJ<8IV;.>[9ACCA'"-B^O]?ZSR5E!C;K-7/H%O$RWC@B?V+#'&T- ?
MV?#Q[!O?4KPMZ9EK=4UTT1U3..._T8[O,RKVMYZ[;IMU7:NFF.G")PV=N&'5
MWU8RUM;)I1 0$'MD,TK9'QQN>R%O'*YH)#&EP;5Q&X5<!4])7S-41ACQ?44S
M.,Q&[?V</;,1YV0P6GLSJ:_;C,%9OO;US2\QLH U@H"Y[G$-:VI JX@+PS.:
MM9>CKN5=,,O)9&_G+GXK-,UU<H]LSNB.V4S<M\1F-/W60Y8:ZLGVN.U/;RR8
M\ES)(S/&RD@C?'QMXN"CO.\DL;L\H*FZK?MWZ:<YEJL:K,QU=W#&)PG#'TXS
MR=*\/9:_E:Z].SM$T49FF9IW3]41MPFG&,>G;O\ IZ:?W0KXS'9'4VA\QR^O
M'.;K31%QVN)E:7-D>V$N,)C)+30MXHVG< 6%>=Z[1E\U1FJ?]G,1]7GWX^V?
M^*'ME\O=SNGW<C7C_(R=6-&^)GIQZ<-V^,::9W1$T5*V6UD^73NG^;^(? W.
MV(.)SUC(\1BYC<1QQ4K6K7TE8!4AKN(^;1?%C(1%ZYD:\>BKZZ)_;RGT?3/;
M&'%ZYG5^K*V=5M33^6C_ $[E..'5'&G?S^NF-\15U3N7VE,Y?Y>[AU9B,!9Z
M1TC/*^]S^:EFB<^[$/&PQ#R6%K>T+JGAVD5J#L=X9W+T6J9LUW*K]V(Z:*,)
M^G'CQX>7&,O2\[=S%R,U:LT97+U3-5VY-5,]>&,8;HPCJQQV;<,<8W50-K'(
M8_+:JS.3Q32W'W=Y--!6H+FO>3Q4-".(^53HK17O(VJ[67HHK^ZFF(GR[')M
M5OV[^<NW+7V55U3'GG?MY[\.&YA%G-6(" @(-UT'RRU!KJ=LELPVF%:ZD^3E
M:>S%-[8QLXW> ;!TD+2:EJ]G)QA/U5\*8]_*%HT7P[F=2JQICIM\:YW>;G/E
M,PZCTAHC :)L!98:"DKP/2;R2CIYG#I>[JZFC8%R_/:A>S=?5<G9PCA#N^E:
M/E].M]%J-O&J?NJ[Y]VYL:US=" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @CV_^G/3_ /">
M;_66(08KDMD76O*;14=L ;?XFL"QK]X;V#-FRB)2;#?VTD;7ND:QQWL<14%$
M/?IEI^&9[H('IEI^&9[H('IEI^&9[H('IEI^&9[H('IEI^&9[H(+&[RQCDX+
M8->!O>=H/J405L7(V6*24_?G/)E)^I3P407Z @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @U[5^B=-ZZQ
MAQ6I+)MS"*F"8>3/"\CSHI!M:?J'I!"RLMFKF7JZJ)P][ SN0LYNCHNTXQZX
M[I<A\S>0FI]"&;)XP.S.F6DN]+A;]W@9O^[QC< /9M\GKX=RO61U>WF/IJ^F
MOU3W?!RK5?#M_*8UT?7;Y\8[X]^[N1(MXJP@(" @(" @(" @S.E=4YC1F=MM
M18)\<>3M0]L3IHVRLX96ECP6NZVDBHH5CYC+T7Z)HKW2SLEG;F4NQ<MX8QS;
MQS-YVYCF;@L7AKZPCQWH<[[F]-M(YT-Q)P\$1#'BK. %^PN=O\"UN1TNC*UU
M51..,;.SFW6JZ_7GK5-N:>G"<9PX\O?S1<MTJX@(" @(" @]1QR32,AA8Z26
M1P9'&P%SG.<:  #:22HF<-LIB)F<(=C\BN2L>B[:/5.IH6OU9<L_)X'4<+&)
MXV@?\ZX>>[H'DCV5:%JVJ?GG\='V1_S?)UKP_H496G\UV/\ 4G='[8^//T<T
MWJNKDM[Z^L\99SY#(3-M[*V89)YI#1K6-WDKTMVZKE44TQC,[GC>O46:)KKG
MIIIC&9ER9S0YEW>N\CZ/:ET&G+1Q]#MCL,CMW;2#VQ]B/8CPU)ZQH^DTY.C&
M=MRK?/+LCRVOSYXC\0UZG=Z:?ILT_;'/^J>WERCSH_5@4\0$! 0$! W;4&PY
MG76L,^V2/+9JZN()122W$AC@<.HQ1\+/\*U]C3LM8VT44Q,<<-OIG:W&;UG.
MYK&+MVJJ)WQCA3_EC"GU->6P:<0$! 05[BQO;2."6ZMI8(KEO:6[Y6.8V1@-
M.)A<!Q"O2%YTW*:IF(F)PW]CVKLUT1$U4S$51C&,;XYQS; [0F7;HENNVR02
MXITX@?#&XNGC\MT?%(*4:.(- %:^4#N6OC4;?\K^-A,588]D\=GF]C;SHU^,
MA&=B8FWU881/U1MF,9Y;<...V%]IKE5K'4LW"RS.-M>R9,+S)-DMX7-D/"P-
M/ 2XN(V4'](7CF]9RV7C;5USCAA3A,[-_'@RM/\ #6>SD[*/QQACU7,::=N[
M#9,SCV1[DK<L\)8Z7O<QRQUA'VV4S%+B&#A:ZQN;2.,D.CDHV0NJU]0X;.'9
MMJJKJ^8KS--&;L3A31LQ_535CQC=R]/<OWAW)V\E<NZ=FXQKN_5$;.BJF(_3
M.RK'9._=T[-N*PY?PXK-Y/7NC\C:-P>1OY(P<?BY.QK%9.<V6&%SP0 3YWMF
MO- !N]]3JN6;>7OT3^2FF)^JJ,=M6Z9]W*8CBP]#HLYJ]G,I<I_#57,?3;G#
M91,]5-..S^[]T53LB(V4M;OU7B],V$TEA9:5PVG+J"YP./NKKTW)7%Q"^@X7
MASAP@.+BWP=2^]/C+W+]4155>KNQ,5U13TT1$^_M][SUK^99RM$S11EK67KI
MJM4U5]=RJJ)V<XPC''#AAQC=JVJ>:K;C5\.L-&02XO)OLO1,A).(WMF<12O
M*@\&RA<37A;Y(IMVF3T;IRTV,Q,5T]6-.&.SS]OOG:T6I>)>O.QF\I$VJYHZ
M:IGIVSW;=VS"9F<>FGZ8PVQO=W5Q?74]Y=/[2YN)'S3/H&\4DA+G&C0 *D]
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M%\OL0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$!!'M_].>G_ .$\W^LL0@QW)C&"YY1Z&F@?
MP1OPEA5CMI:>P:" 1O1*2X;.WBC;'P-=P[W. ))1"IZ/;_@F>Y"!Z/;_ ()G
MN0@>CV_X)GN0@>CV_P""9[D('H]O^"9[D(+"[Q0FD[2!PCKYS:;/5%$%W9VC
M;2+@!XG$U<[PH+A 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M?F2Q_$M0E(2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MP !51?XC!]1(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M_P!98A Y$_0SH3\R6/XEJ$I"0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MZ&="?F2Q_$M0E(2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MMG#<^.",/\;J<1]=:N[GLQ=^^NJ?/+?9?2\I8_V[5%/=3&/IWLRL)LQ 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M9T)^9+'\2U"4A(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @CV_^G/3_P#">;_66(0.1/T,Z$_,EC^):A*0D! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 01[?_ $YZ?_A/-_K+$('(GZ&="?F2Q_$M0E(2 @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((]O\ Z<]/_P )
MYO\ 66(0.1/T,Z$_,EC^):A*0D! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MFO/Y5YO](X#]I('R\UY_*O-_I' ?M) ^7FO/Y5YO](X#]I('R\UY_*O-_I'
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MFO/Y5YO](X#]I('R\UY_*O-_I' ?M) ^7FO/Y5YO](X#]I('R\UY_*O-_I'
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MFO/Y5YO](X#]I('R\UY_*O-_I' ?M) ^7FO/Y5YO](X#]I('R\UY_*O-_I'
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8C'.E:X7_ &8:PL:UP=('$O'"T@.()?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>pc_unique-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pc_unique-4c.jpg
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M%!04%!04%!04%/_  !$(!&H%X@,!$0 "$0$#$0'_Q #B  $  04! 0$
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MXD->>X]U]PBPDM$1OH'XQ^:WNKBOU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$:=X7XD->>X]U]PBPD
MM$1OH'XQ^:WNKBOU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$:=X7XD->>X]U]PBPDM$1OH'XQ^:WNK
MBOU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$$:=X7XD->>X]U]PBPDM$1OH'XQ^:WNKBOU+9HJ2$00$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$$:=X7XD->>X]U]PBPDM$1OH'XQ^:WNKBOU+9HJ2$00$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$:=X7XD->>
MX]U]PBPDM$1OH'XQ^:WNKBOU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$:=X7XD->>X]U]PBPDM$1OH
M'XQ^:WNKBOU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%KDLGC\/
M8SY/*W45GCK5O:7%S.X1QL:-E2X[-^Q!H&-Y^<ILKDFXJUU'$VYD=V<;YX9[
M>%SB: "66-K!7PD)022@(" @(" @(" @(" @(" @(" @(*0N;8O[,3,+]W#Q
M"M?%5!50$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$'F21D3'2RN#(V N>]Q :UH%223N 01;GN\5RIP-RZS=
MF'9&XC)$@QT3[A@(_P#F;(S]BXJT%QHWGQR^USFX-/86XNFY6Y$AMX;BW=&'
M]DQTCO.!<T4:TG:4H),4! 04Y)X8:=K(V.N[B<&U]E![:YKP',<'-.X@U"#Z
M@(" @(" @(" @(" @(" @(" @(" @(" @P>JM7Z<T3C69?5%\W'XZ29MLR=S
M)) 97M<X-I$UYVAKCN0:?_S!\GOWGC_-KO\ \%!O&GM18;5>(M\]I^Z%[B;K
MC["Y:U[ [LWF-WFR-:X4<TC:$&40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$:=X7XD->>X]U]PBPDM$1OH'XQ^:WNK
MBOU+9HJ2$00$! 0$! 0$!!RGWK]<9*SSN#TQA[^>S=:V\E]>&UE?$7/N'=G&
MUQ81Z+8W'[)6$<\>^_5G_OV1_.Y_OU1MO+'F-G\%K_3^1R>8O)\:V[9#>QSW
M,LD787/X%Y<USB#PA_$/"$'Z#+BH@(.=>]IE,GB\'IJ3&7MQ92/N[AKW6TKX
M2X"-M > BJL(Y6]]^K/_ '[(_G<_WZH[\Y.W$]URPTM<74KY[B2QC=)-*XO>
MXDG:7.))7%6[H/S<SVJ]4Q9S)QQYS(-C9=W#6M%W.  )7;/37)$I=V;/Y[)<
MSXK?(Y2\N[?U&Z=V,]Q+*RH#:'A<XA21VBHH@(" @Y][W#<L="XHVG'[5-R(
M]L>"M*F)_8\=/H:UW[.+AZ:*PCC54?HURF&5;RUTN,WQC)#'P]H)J]IP4_!\
M5=M>#AK7;UKBK<D! 0$! 0$! 0$! 0$! 0$'F22.&-\TSVQQ1M+Y)'D-:UK1
M4DD[  $',/,[O4>JW$^%Y<11S&,F.3/7#>.,N&\V\1V.'U;]AZ&TVJT1SIG=
M>:TU-*Z7/9Z]ON+?').\1"O0V-I#&CQ-5&OAS@>($\77TH)$Y2Y[6TNN,!@\
M'G;ZTBOKV&&>*.=YB[#B#I28W$L-&!QVM0?H.N*B @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(.2^]+S.R$F6^#
MC$7#H<;;1QS9LQFAFFE D9"XCZ!C2UQ'2X[?1"L(YG5$T]V[#Y2UYL8:ZN[*
M>WMS;WCF2RPO8QW%;/ X7$ =*2.XUQ5@=9:OPVA=/7>I,[*8[*U;YL;*&665
MVQD48)%7..[JWF@!*#BC7G>#Y@:SN98[.^DP.$)(AL,>\Q/X.CM9VT>\]>T-
M^I7*B(MN+FYNI#-=3/GE=M=)*XO<?&7$E!<X_-9C$R";%9"YL96FK7VTTD+@
M1X6$(.W^[AF=6ZBT [,ZLR4N2=->2QXZ2<-,@MX0UAJ\ .?63CVNJ=BDJV[7
M'-'17+OL&:HOW6]S=,=);6L44DTLC6FA(X&D#;],0H(=SO>^P$ ?'IO3UU>O
M&QDU]*RU97KX8^V)'E"M$='6LIN+6&=P#72QM>6C<"X T4550$! 0$! 0$!
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MK9U1$)"722.:*EL<;07O/UH*"'K_ +VW+ZVF,5EC<I>QC_;".&)I\0?+Q>R
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MO\*#'(.LNZ3K6\O;/+:&OI3+%CVMO\6'&I9#(_@FC%=S0]S' =;G*2+[O/\
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MGH/\+$D#4M&:?;JK5F%TX^4P1Y2\AM9)F[7,9(\!S@#LJ!6GA0?H%A>5_+[
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M,5:R$>D][FSS 'ZD-B^V4D>^^-^/T?\ 6Y#Y=LD#EU4?IAHS_@_3WN;9_P!
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MIL<*GTDA',ZHVK07+_4?,/-PX? VSG1ES?7+YS3ZO;1$^<^1V[8-S:U=N"#
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MU^!PB24"C6,!VB-@)#:]9/31<5:YWBN6V0U_I&"YP<7;Y[!R/N+>V'ISP2-
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M0>L9H#0V&E$^*TWC+.=I!;-#9P,D!'4X,K\E!L: @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @((T[POQ(:\]Q[K[A%A):(C?0/QC
M\UO=7%?J6S14D(@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @C_G=
MALKJ#E=G\/A+22^RETVV%O:PT+W\%W"]U*D;FM)\B#C'X$N:_P"ZE]]JW[Y<
MD=5=VO2^H=)Z%OL;J3'2XV^?E)IXX)P YT3H(&APH3LJTCR*2J9% 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0:?S2T_G=5:"S6G=.20
MQ97(1-A8ZY<YD9C+VF1M6AU"Y@<T;*;=J#B#,<E>:>#D>R[TO>S-8?QME'ZZ
MPCK!MR_8N2,)'H#7<TG91:8RSY:TX!87)-?]V@WG2?=PYFZDN&"]QWM#CR1V
MEWDB&. Z>&%I,A/C:!X0E1V!RWY;X'EE@1AL,#-<3.$N0R$H FN9@*5-/1:W
M<Q@V-\)))XJW% 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 011S_T-JW7^C[;"Z4[!\D-VV[N[>:3L7RMCC>UC6.(
MX?2=4\1&[>K X]R?*/F;B'EE[I3)>::%\%N^Y9]O 'M^2JBQM>7>O[V01VNE
M\M*X[-EC<4\I+*!!)>B>[!KW4%S%-J5C=.XBH,KIG-ENWMKM#(F$T)ZY"*=1
M2H[$TMI?#:-P=IIW 6_J^-LV\+&D\3WN.USWN^B<X[2?F+BK,(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""
M-.\+\2&O/<>Z^X1826B(WT#\8_-;W5Q7ZELT5)"((" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""-.\+\2&O/<>Z^
MX1826B(WT#\8_-;W5Q7ZELT5)"((" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(""-.\+\2&O/<>Z^X1826B(WT#\8_
M-;W5Q7ZELT5)"((" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(""-.\+\2&O/<>Z^X1826B(WT#\8_-;W5Q7ZELT5)"
M((" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M=?<(L)+1$;Z!^,?FM[JXK]2V:*DA$$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MX2YK)0YU!6@H16GC*!9-+6RDM+6OE>YH(IYIZ:(+E 06>5_()O$/N@@]X_\
M(H/K @LQ_GI_F_F(,J@(""C#=13R/CCJ>  \1% 0:C9U[D%9 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$$:=X7XD->>X]U]PBPDM$1OH'XQ^:WNKBO
MU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M4'80=U$%D<39U):US*[PUQ 05[>TM[4$0LX2?2=O)\I05T! 0$! 0$! 0$!
M0$! 08K)6K6Q.N'N,DKI&AI=N:TNW (,J@(" @(" @(" @(" @(" @(""-.\
M+\2&O/<>Z^X1826B(WT#\8_-;W5Q7ZELT5)"((" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""VFNRR86\41FF
M+>,M!#0&UIM)0?;>Z[9[X7QF*:.A<PD'8>D$(+A 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0*@;T! 0$! 0$!!2EB,CXG T$;^,^'81\U!50$!
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M@?C'YK>ZN*_4MFBI(1! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M]PBPDM$1OH'XQ^:WNKBOU+9HJ2$00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M^0M^N=\M!D$!!@\MYV1MFG:WS=GC?M16<1&#R^R_MG#8[S=OB<BLXB" @("
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M'NON$6$EHB-] _&/S6]U<5^I;-%20B" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @I02NE#BYO#0TZ?8V]2"J@(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(.#N]5992UYNS7V3C>_&7=K:/QI-0QT$3
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M\8_-;W5Q7ZELT5)"((" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M @(" @(" @C3O"_$AKSW'NON$6$EHB-] _&/S6]U<5^I;-%20B" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M^>[SG&IIT)43ASTY&V_->UMLCC;F/'ZKQS'16T\P)@G@)XNRE+07-X7$N8X
MTJ=AKL"&\7R[[V>GK:/!8?)2QXJ ". MR%K)$Q@W!G:N,C6CH ;LZD$LS: Y
MF9/D/E=$:DO(LKK>])[*XEN7R QNNHY@V2:1HVM:' 4%-P""R[MO*C6'+'WQ
MC545O&,GZIZJ;>835[#MN/BH!3TVT0:1S8Y!<Q=7\U<AJ["V]H_$7$UI)"Z6
MY$;RV"&)CJM+21M84$I<\N1UKS8L[6^L+EF/U5CF.BM;F4$P30./%V,W""X
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MZY&<N<QROT9-IS-W5M=W<E_->-ELS(Z,1RQQ, )D8PUJP]""3$! 0$! 0$!
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ML?\ .#[DH,E%^*9]:/E(/: @(" @(" @I,E>Z=\3FAH: YIK4D$D>3<@JH"
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MNK0?.09) 0$!!0?9VLCS(^)I<=YZZ=8Z4%= 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$%"[F,,5(]LTAX(A]4?G(/MO;L@C:P %XWO.\D[S5!60$!
M0$!!Y<QC_2:'>,506MJ3;RNLW'S1Y\!/2P]'D07B @(" @(" @(" @(" @("
M @(" @(" @(" @C3O"_$AKSW'NON$6$EHB-] _&/S6]U<5^I;-%20B" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @UW5FN])Z'M/6]39.*R#
M@3# 27W$M/Y.)E7NV[*@4'25Z]-I,NHFF.VOH\KPZO7X-+;Q9;HM],]T;W.F
MM>]5EKPR6>A,>W'0;0W)W[6S7!'6R$5C;]F7^);=I/MVVW;FFO9&[R[_ $-!
MU_W=?=6W3V\/ZUV_Q1N\M>Y ^=U'GM3W9O\ 4.2N,E=[:27,A>&@]#&GS6CP
M- 6T8<&/#%++8MCL:3J=7FU%W%DNFZ>WU=3%KO>00$! 0$! 0$! 0$! 0$!
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M'=MZ;9WQX=<5AN*Q[*B @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M/G_U6^5!>(" @(" @(" @(" @LY_ZK<-NALBDHR?P?2N\FY!>(" @(" @("
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MN+FD&IZ?$@RZ"-.\+\2&O/<>Z^X1826B(WT#\8_-;W5Q7ZELT5)"((" @("
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M7$ER"V*859( 2.OH0,C>PWL(MK2LLKG#8UI%*>,!!E8FED3&'>UH!\@0>T!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0"0
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MP-R"X068_K5WQ;X+8T'4Z3K\B"\0$'B:5L,3I7^BT5*"C9Q.:QTTOX^8\3_
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MK]/BF;]EUVVG5'0^>?<O,K-7GBW'-;;(I7KGIIV;O\*(A6?:F(" @(" @("
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M @(" @(" @(" @("#Q$Y[XVN>.%YWC_\T'M 0$! 0$! 0$! 0$! 0$! 0$!
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M$! 0$! 0$! 0$! 0$! 0$! 0>'/X7,;0GC)%>@4%4'M 0$! 0$! 0$! 0$!
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MSCB-0-A!V$'PH*R @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M8@66]O&37@C82:#K)))Z2MHTFCQZ:SALCVRTG7\QS:W)QY9[HC='<UI>QC1
M0$! 0$! 0$! 0$!!V'W7=8',Z/N=+74G%>Z?E_  G:;.Y+GLW[3PO#V^ <(7
MS[[@TOT\T9(W7^F/"'UK[4UOU=-.*9VXY_=G=YZ]T43LM8;F(" @(" @(" @
M(" @(" @(""SG_JMPVZ'XJ2C)_!]*[YB"\0$! 0$! 0$! 0?"0T%SC0#:3X
M@M;0&:1]Z\4X_-A!Z(QT^5!=H" @(" @(" @IS&01N,7IC<*505$! 0$!!9C
M^JW?#N@N35O4V3I'E04'?YVW^:^>@]YK\A=]<WY:"]A_%1_6CY2#V@Q^:_(7
M?7-^6@O(/Q$?UC?E(,?C?RZ_^O\ FN091 06;_ZU="+?! 0Z3J+^@>1!>("
M@(/A:UU.(5H017K"#Z@(" @(""-.\+\2&O/<>Z^X1826B(WT#\8_-;W5Q7ZE
MLT5)"((" @(" @(" @(" @(" @("#7[RUE?>3")IDV\1X=M.+;0HJ_M,<YD(
M$LLC'DU+&/H!["(K^HC^7G_WA0/41_+S_P"\*##7MC=RVLES<S2QQMIV=N'D
MG:0*N**R=K9 VL)[>;;&WZ,]01%;U$?R\_\ O"@Q]_CIP\/BXYFD4/$>)P/S
MD57P\+HQ,YYH^H:6=(IU^RB,F@(" @(" 2 *G8!O*#$W6;BB?P6[>UIZ3ZT;
MY.M!DH)#+#'*10O:'$=515!40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M;MLI-N^NR>WQHW/(3D:PECKHAS26N!R8!!&P@^<LQ_6-=U?NL#_;W+?"Y\^
M;D9_:S^DQ]\G]8UW5^Z?V]RWPO\ Q5(>0/)&>:.&"=TTSW ,B9DN)SCOH '5
M*D\YUT16?_%8^W>6S-(C][\4AZ[TUI'56%BT]JNX;;XTRLGBB%P+5SG0 @4-
M14#BW>)8G29\V&_CQQ6>ZK.:[2X-1C^GE^'?OIN1P>0_(L DW= -I/MH/OEE
M_P"L:[J_=8+^WN6^%_XMXT+RET-H*\FR^F;:3UN[A$/K,TSIZ0DA]&$[ '$
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M 0$! 0$! 0$! 0$! 0>7L;(QT;Q5KA0CQH+>S>YO%:RFLL.P'Z9G04%T@("
M@(" @(""TNB9Y&V3#L=YTQ'0P='E070 : T"@&P =2#Z@(" @(" @(" @("
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M;W,+K20UDA]$_31G<?F(+I 0$! 0$&*SWY(S^<'RB@O[3\D@_FV_*""L@("
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MTUDWS=$Q'E\/&VSEOW#AUN2,<6W6W3'93P\2#N]''&SF9&YC&M=)C+9TCF@
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M03!@+PV5V^,["'=(07* @(" @(" @(" @\M8UE>$ <1XG4Z2>E!Z0$! 0$!
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M 0$! 0$'F21L4;I'FC6BI06UJ P.N;@ALT^VCC2C>@;4%TUS7"K2".L;4'U
M0$! 0$! 08?(174MO-/</X(F?BH6].VE7%!D[7\FA_FV_*""J@H7OY'/_-O^
M44%/&_D,'UOS4%#%>G>?SSOEE!6E_JURVX&R&6C)NH'Z%WS$%CB]F2N_&[[M
M%9EWHGQ%$8C ?BIOKA\I%9A$$! 0$'CLH^/M>$<>[B01OWA?B0UY[CW7W"+"
M2T1&^@?C'YK>ZN*_4MFBI(1!!XDD;%&Z1YHUHJ4%"SC=1US*/PTWG$?2MZ @
MND! 0$! 0$!!:78,+V7K!7@\V8#IC/SD%T"' .::M(J".HH/J @LX/ZK<.M3
M^*?5\'^LWR(+Q 0$! 0$! 0$!!\)#0230#:2@M;4&>1]Z\;'>;"#T,'3Y4%V
M@HW<K8H'%PXN+S6L^F+M@""PML)!%()I7%[R*N9LX:FA/A(V(,J@(" @(/CG
M-8TO>0UHVDG8 @QC\;:W+73VS]CJEH'H\2"]M)6RP-X6\!9YCF?2N;L(05T!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!;9%YCQ]W(-[(9'#HW-)7.R*W1WN
M-\TME^9^_;UK[*_.@@(" @(" "#L&T^!%9&TP.=OP#8XN\N0[T3#;RR UZN%
MI73=GQV[[HCQO3CTF;)%;;+KH[(F67@Y;\P[FAATIEW-.YWJ-P&]>\L 71.N
MT\;\EO\ JAZ+>5ZN9I&*_P#T7>Q=#E+S.(!&D\G0]=NX'V"NO^IZ7_LM\KT1
MR36_]5WD'<I>9K07'2>3H.JW<3[ VI_4M+_V6^5)Y+K8_P#JN\BSGY<\P;:I
MGTIEV-&]QL;@M]D,(79&NT\[LEO^J'1/+-7&_%?_ *+O8P]WA<S85-]C;NV
MWF:"6,#[9H7HMS67;KHGQO-DTV7'%;K9M[XF%C4;B=J[7GH(@@(" @(" @("
M @(" @(" @(" @("!4=:+1<6UC?7IX;.UFN7=4,;Y#_H@KA=?;;OFCLQXK\G
MPQ-W=M9FWT'KF[%;73&6F!Z8[&X</D,7GG68(WWV_P"J'KCEVJG=BO\ ]%WL
M7\?*CF9(*MTEE /JK5[-_P!< NJ>9::/_LM\KT6\FUMW_P!5WD>_@DYG?NGD
MO]PY3^IZ7_LM\KE_1-;_ -5WD4)N6',B#;)I++T%:EME,\;/K6E<XYAII_\
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M"R_EA\GYR"C<Y2".(F!PDE.P#;0>$H+>RR<TD[8IZ$/V @4(**RZ((" @("
M@(" @(" @(+./^M71EWP0$MCZB_I/D07B#XYK7;' $>$50?0 !0"@ZD! 0$%
M.X_)Y?K'?*04<=^0P?6A!=(""E-<P6X!FD# =U=Y\B"@,I8.-!.*^$$?+""[
M!#@"#4':"-R#Z@(,1/+?7\TEM;#LK=CBR27KH:';\P(+:UMVVN99 TEP97:>
MDEE45L"($5V'<@L[8^KS.LW>@:O@/U)WM\B"\0$%O=V[YQ&Z-P;+$\/9Q"K2
M1T%!3;;W$EQ'<7+F#L0[@;'7>X4-24%X@(""-.\+\2&O/<>Z^X1826B(WT#\
M8_-;W5Q7ZELT5)"(LX_ZU=&8[8("6Q]1?TGR(+Q 0$! 0$! 0$! 0$%FS^JW
M1CW07!+F=0DZ1Y4%X@;MJ"@X17D#V;>%VS:*$'>#\U!\M)G2,,<OX^(\$GAZ
MCY4%P@(" @(" @LY/ZU="'?! 0Z3J+^@>1!>(/A(:"XF@&TGP(+6U!GD?>O&
MQWFP@]#!T^5!=H" @(" @(" @(+2[:87LO6"O!YLP'3&?G(+II#@'--6D5!'
M44'U 0$!!\J"2*[1O"#Z@(" @(" @(,/=?YW;?6C_609A 0$! 0$! 0$!!9/
MS&*CR<6$?>P-S$\;IXK#M&^L.BCH'/#*\7"*C;1<^"ZG%38X3DMXN&NWJZ48
M7FM1AHY,'I'%V^&L+:1\8[.-C?.:XM<6QL 8*TWFI63^C.2>+)=-TRQL7VXH
MX,=L61'5'J:A>7MYD9>WR%Q)=3?32N+J>(;AY%Z;;8MW.BZ9NWJ*J" @(" @
M(" @(" @(" @("#X@NK#)9#%2]MC;J2U?T]FZC3XVG8?*%QNMB[?%7*VZ;=T
MMG=K'&9^R]J-=X:WR^/=L,G9M>0?IN!VX^%A!71;BOQ7<6*Z;9=E]V/-;P9;
M8NCN:!J7NXZ;U%!+E.5V8;#+Z3L/>O<^,?4MD(,L?4!(';?H@LYIN?9,<\.>
MVO;'LW>2C5-;]JXLD3=IKJ3\L[O+OCQU[X0!J;26I-'7YQNIL;-CKK;V?:BL
M<H&]T4C:L>/"TE;9I]3BSV\6.Z)AH.KT6;2W\.6V;9]/=.Z?$PJ]+Q" @(*]
ME97N2NXK#'6TMY?3NX(+:W8Z65[CT-8T$DKC??;9%;II$.S'CNR71;;$W3/1
M&V4ZZ+[LF9O8F97F!?-P&+%'.LHG,DO7-ZG/-8XJCZ]W06A:OJ_N"RWW<,<<
M]?1[9\W>W?E_VGER>]J)X(ZHVW>R//VQ"9\%9Z"T!";?1&%B]:IPR9*8%TK^
MNLKZR.!ZA1O4M7SY\^IFN6[9U='D?0='R[3Z2*8K8CMZ?+O4K_-93)DB[N7&
M,_[%GF1^P-_E77;9;;N9!8  ;!L"YH(" @(" @(" @(" @(" @("#ZUSF.$C
M'%D@W/:2'#RA!GK'5V3MF]A>!M_:.!;)'-3C+3O'%3;L^F!73.*)VQLD;389
M;2F!QF*@:ZTP-GDI',QMDXQVL;IY"Z5S(VCA;Q./$Z@WKHOC)DNF9K=,;YWN
M&/'9CMX;(BV.J-D=;8EYW:(*%W,Z*.D>V:0\$0^J/3Y$'JWA;;Q-B&TCTCUD
M[R@JH" @(" @(" @("#'W\+;N:*W;LE +G/Z&L\(\)0>[/',M27N=VDA%*TH
M $%YP,^E'L(' SZ4>P@<#/I1["!P,^E'L(' SZ4>P@HW-I%<Q&-PX>D.&\%!
MCXK(6%S%+*[C8XEH=2G"X[JH,N@(" @(" @(" @(" @MKR5S6MAB_'S'A9X!
MTGR!!6AB;#&V)GHM% @]H" @(" @(   H-@0$!!A^%L^<>V4!S8V#A:=HW _
M-07]W!"ZUE#HV[&.(V#80.A!0PKG.L0":\+G >+?\U!D$!   W(,(/\ B#_X
M_DT5FT006]W"Z2,/BV3Q'CC/A'1Y4%2"9L\396[G#:.H](05$! 0$! 01IWA
M?B0UY[CW7W"+"2T1&^@?C'YK>ZN*_4MFBMGR4TKKM[7$AK#1K>@#K\J#)8A[
MW6M'#S6.(8?!O^641?H" @("#X2&@DF@&\E!\8]DC ^,AS';B-Q0>D! 0$!!
MB\T][8XF#T'$DGPC=\M!;XB67UCL@28RTEPZ!3I16<1'ED;(V\+!0;Z(->R$
MDCKR7BV%IH.C8-R*R%C<WCK<4@,P!(#R\-) \:(N>WO?[)_WC4#M[W^R?]XU
M [>]_LG_ 'C4#M[W^R?]XU [>]_LG_>-08K)3W+Y0R5IB:!41\50:]-0BKK"
MO>62L/H @@^$[_E(C*H+2[)FD99,/I^=,1T1CH\J"Z #0&M% -@ Z@@^H" @
M(" @(" @(/A (((J#L(06EJ3!(ZR<=C?/@)Z6'H\B"\0$! 0>1&T2.D'I. !
M\E?GH/2 @(" @(" @Q%TUQS5NX \(:*FFSZ)!ET! 0$! 0$!!@=6:TTQH;&.
MR^J,C%C[/:(Q(:RRO KP11BKGN\#0N[%AORW4LBLO-J-3CP6\62Z+8\-W6Y0
MYD=Z[4&;[7&: @=@\8:M.3F#7W\@J=K&[61 CZYWA"V72\HMMVY-L]70T;7_
M ')?=[N".&/FG?\ AX;FK]W#-7+N=F+NLE<RW-WE(KR">YN'NEED>Z!T@XGN
M)))+.E>GF>./R\TC=3TO%R#473K8FZ9F;HF-O=7U)XU-#ZOJ/*Q 4 N9' >!
M_G#Y:P^*:V1W-VRQ2^6+78ZQ 0$! 0$! 0$! 0$! 0$! 0$! 0>X)Y[69MS:
MRO@N&;62QN+7CRA)B)BDK$S&V&V1ZOQ^<Q[L#KW&Q9?$R['2.C#G C8'.9UC
MH<RC@O-&*['=QXIFV7;?=9FMX,UL76RC#7'=OCN;9^H.5=Z,E8.JYV'F>#*V
MFTB&5Q'%]9)1WU16Q:/GU)X-1%)^;VQ[&E\Q^UJQ-^EFL?+/JGU3Y9<_7EG>
M8^ZFL<A;R6E[;N+)[:=CHI8WC>'-< 0?&MMLOMNBMLUB6@Y,=UETVW1,3'1.
MR5#<N3K2_P N>[[JG63(LMG"[3^FB.T]8N&_UJ:/?6*)U.%I'T;Z#I <M?UW
M.L6#W;/?N\T=\^KT-NY9]M9]32_)_P =G;\4]T>N>_:Z$P./T/RXM'8_0^-9
M)>N'!<96;\)+)3Z:4@.=M^A;1O4M.U&?-JIKEG9U='D\)?3=%R[!H[:8K:=<
M],]\^$+2^R%[DI>UOIG3.^A:=C&_6M&P+KMMBW<R*V7)! 0$! 0$! 0$! 0$
M! 0$! 0$! 0?';&D^!!&G?!G;!IK06&J#Q/N+F2,[QV,$; ?9D*]/+8K=?)*
M+.6_>(Y@<O'0V4MP=0Z:C(:[%Y"1QDCC%-D%P>)[-@V!W$WP+W9]%CR[=T]:
M5=A\M>=NA>9\38<-=FTSS6\4^#O:17;:"KBP5(D:*'SF$[-]%K^?29,._=UN
M42WUD3WW3YY10,\R%O@.]WE7C5<H" @(" @(" @("#Q-*V&)TK_1:*E!1LXG
M-8Z:7\?,>)_@'0/($%R@(" @(" @\31,GB=$_P!%PI_VH*-G*Y['12_CX3PO
M\/4?*$%R@(" @(" @(" @(/A(:"YQH!M)\ 06MH#-(^]>*<?FP@]$8Z?*@NT
M! 0$! 0$! 0$!!B(O\]F^L_U6H,E=?DTWUCOE%!98/\ (OLW?*"#)(" @P@_
MX@_^/Y-%9M$$!!C+AOJ]TP$.-I<.)<&UV2TV;MNWY:"_@XQ#'VE>TX6\5=]:
M;:H*B @(/,C2^-S >$N! =U5&]!YAC=&SA<16I-!6@KT"J"..\+\2&O/<>Z^
MX1826B(WT#\8_-;W5Q7ZELT5(4UK;SD.EC#G#<=Q^0B*-H3!(^R=N;Y\)ZV$
M[O(4%X@(" @(! (H14=2"G!$88FQDU(KM'A)*"H@(" @(+*<"[N!;;X8O/F\
M+CZ+4%Q#;PVX(A8&UWTW^R4%5 049;2WG<'2QASAT[C\A!5:UK&AK &M&P ;
MD'U 0$! 04IK>&X $S ZFZN_V0@]1Q1PLX(FAK1T!!87V3=;R]C$T.<VG$7;
MMNVFQ![QDC9VRS'\>YWX0^#H \""_0$! 0$! 0$! 0$!!89.1L+(IALG8^L9
M^6#X"$'BRRCKB40RM#7.KPEM:;-M#5!DD! 0$! 0$! 0$! 0$! 0$! 0$'PD
M-!)- -I)W40<\\V.]#A=,NGP6@Q%FL\PNCFR+CQ6%N[=YI:?PSAU-/"/ICN6
M<TG*[LGO7^['G_!JO,N?X\%;,7OW>:/;X;7(>H]39_5V4ES.I,A-DLE+OFF=
M4-;]*QHHUC1T-: %M.+#9BBEL4A\]U.JRZB[BR73,L2NYY6W\J\JW"\R=*9)
M[N&*+)VS97=4<T@B?\AQ7DUEG%ANCL93E67Z>JQS^M$>78["YB6_8:IN'THV
MXBBE'A/#P'Y+5JVFFN-]-U$4O:LO2\X@(" @(" @(" @(" @(" @(" @(" @
MN\9E<CA[GUK&7#K>7Z,#:QXZGM.PA<;K(NBDN5MTVS6&PY7 Z,YT6YQVH+ V
M&J88R;?*V;?/: -GGT/$RO\ LY?L37:N.#4YM%-;)K;U3X>>'5J]!I^86\.2
M*7=%T;_\.R6/T;R1T?RPB9G=2?\ [Q:@#SZHY\5+6)P-6%D;N(!_3QO)H?1I
MT^C6<XS:KW;/<M\\^/P[7DY9]N8-)/'?_P E_;&R.Z.OM\E&?R^?R&9<1._L
M[7Z&VC)#/LOICXUC+,<6MJ8M=B" @(" @(" @(" @(" @(" @(" @("#W#&9
MIXH1OD>U@'US@$F:0(+[XF29<<P<+B8G59C<2'2,^EDN9GG[F-J]_++:8YGK
MDESNLLXO44DL$T=Q!(^&YA<'PSQ.+)&/&YS7-(((ZP@Z5Y3]Z_*X8P8/F:'Y
M3%"C(\_$WBO812@]88/QK1TO;Y_20Y8?4\NB[;CV3U=#E$NO<-F\1J+&6^9P
M5[#D,7=M$EO=6[Q)&YI\(W$=(.T'85@+[)MFDQ27)?K@" @(" @(" @(+.3^
MM70BWP0$.DZB_H'D07B @(" @(" @(+2Z!@D;>L&QOFS =+#T^1!= AP!!J#
MM!0?4! 0$! 0$! 0$%I=$SR,LF'8[SIB.A@Z/*@N@ T  4 V (/J @(/+)(Y
M1Q1N#V@TJTU%0@](" @LY,@QLKH(HGSR,]/LQ4#QE!]AOXY)A;R1OAF(JUL@
MI7Q%!=H"#&7-M=0WWKUJP2\0H^,FAW40?9KC(3QNA99EA>"TN<\4 .SP(+FP
MM3:6S87&K]KG$;JE!<H" @LO:\>O^O=IM_DZ?4\.^J"]0$!!2N(6W$3HG;*^
MB>HC<4'FTF=+'239-&>"4>$=/E05T! 0$!!&G>%^)#7GN/=?<(L)+1$;Z!^,
M?FM[JXK]2V:*DA$6UY$YS&S1?CX3Q,\(Z1Y0@K0RMGB;*ST7"O\ V(/: @("
M @(" @(""C<S^KQ%]*O/FL;UN.X(%K!V$0:XUD<>*1W6X[T%9 0$! 0$! 0$
M! J*TZ>I 08Z]QAN9>VB<&N-.(.W;-E=B#UC(VP-EA/X]KOPGA'T)'@07Z @
M(" @(" @(" @(+')QMF9'"-L[W?@Q\LGP404[+%FWE$TKPYS?1#=VWIVH,D@
M(" @(" @(" @(" @(" @("#$:EU/@M'X>XSVH[V.PQ=L//FD.TN.YC&BI<YW
M0UHJ5VXL5V2[AMBLNG/GLPV3??-(AQ1S@[Q&H.8+[C!X R8?1I)880>&[NVC
M96=S3YK3_)--/IBY;;HN6VX:77;;O0^<<TY[?J*V8_=L\\_AV(4W;!N69:L(
M"#W'-);R,N(3PRPN;)&X;PYAX@?9"DQ6*2YV73;=$QOAWQK>YCS6+TSJF"AA
MREDQX+=HI*QDS=OV16E:>.&;K)Z)?7\UT7VVWQNNC\6F+UO,(" @(" @(" @
M(" @(" @(" @(" @(,]IK2>0U+-Q15@QS'4FO'"HJ-[6#Z)WR NG+FC'WN['
MBF_N3'A\)CL%:"TQT0C9OD>=LDCOIGNZ2L3?DF^:RREED6Q2%[-#%<1.AG8)
M(GBCV.%01XEPB:.;0=0:1EL>.\Q@,MF/.?!O?&.DCZ9H]D+V8\U=DHU;?N7H
M00$! 0$! 0$! 0$! 0$! 0$! 0$! 09;3-OZSG;)G1&\RGQ1@GY:Z\LTME7'
M?>!S0SO./55PWT+.XCQK!T?U*)L3O](.6=T=G#AM\OE<91HO8@@(-TY<<T]7
M\K<F;[35SQ6,S@<AA[@EUG<CK+?H']4C-O74;%Y\^GLS12[RJ[OY6\X-)\UL
M:ZXPLIM<S;,:[)86X(%S;D[.(4V/CKL;(W9UT.Q:QJ-+?AG;NZW*)2 O(H@(
M" @(" @HW4Y@B+FBLKCPQMZW'<@6T'81!E:O/G/=UN.\H*R @(" @(" @(/A
M <"UPJTBA!ZB@M;0F%[[)YKP>="3TQGH\B"[0$! 0$! 0$!!;37]K 7,>^LC
M1Z(!.WJ0+.-S6&>3;-.>-_@'0/($%R@("#Q+$R9ACDJ6'> :5\&Q!:XT!K)V
MM #1/( !L  *"]0$!!C,3^.O?YT_+*!D/\PL/KC\L(,F@(" @(""VO+L6K64
M89)9'<,;!LJ3X4%&2ZOX&&66V:8V[7\+]H'L(+R*1LT;96>@\!P\J#V@(" @
ML[C^K3MNQ^+=1DX\'0[R(*D5[:S/[..0%_0-HKXJH+A 04);RUA=P2RM:[I;
M7:@]Q7$,X)AD:\#?0[D$<=X7XD->>X]U]PBPDM$1OH'XQ^:WNKBOU+9HJ2$0
M06;/ZK=&+=!<$NCZA)TCRH+Q 0$! 0$! 0$!!9Q_UJZ,N^" EL?47])\B"\0
M$! 0$! 0$! 0$% 0$7!FJ*;=E-NT 4/@V(*Z @M+L&%[+U@KP>;,!TQGYR"Z
M!#@'--6D5!\!0?4! 0$! 0$! 0$'PD-!)- -I*"UM09Y'WKQL=YL(/0P=/E0
M7: @(" @(" @(" @(" @(" @(-,YD<S=-<L<([*YZ;CNI0YN.QD1'K%U*/H6
M#H:/HGG8WQT!]6FTU^>ZEOEZG@UNNQ:6SBOGNCIEP7S%YF:HYFY@Y/4%QPVL
M3G>U^+B)%M:L=T,;TN(])[MI\5 -UTVDLP6TMW];Y9K^99=7?6Z=G1'1#35[
M&+$! 0$':7+7(^^CN^XF6O'=:>E=9S'>0+:0M _W4C%J.HM^GJYCYO#TOJ7+
M<OU=#9/3;L\GX+5<W>(" @(" @(" @(" @(" @(" @("#X@W#1^B)LZ6Y#)!
MT.'!JQOHON*=74SK=T]'6O+FSQ9LC>]6'!Q[9W)>M[>"T@CMK:-L4$0#8XV"
MC6@=  6*F9F:RR4139"HHH@(-0U)I)L_'?XI@;<>E-;#8V3K+>IW@Z5Z<>6F
MR4:(002""' T(.P@CH(7L00$! 0$! 0$! 0$! 0$! 0$! 0$!!L>EIH,9%E]
M0WFRTQ=H^65W4UC3(\_:L71EVTMCIE7YUW^0FRU_>9:Y<77&0GENY7'>73O,
MA^Z6UQ%(IU."W5! 0$%]A\SEM/92VS>"O)<?E[-W';7D#N%[3T@]#FD;'-=L
M(WKC=;%T4F*P.X^1W>%Q?,B*+3NHS%C-=1-V1 \-O?M:-LEN3N>/HXCM&]M1
MNUK5Z*<7O6[;?0YQ*<EC%$! 0$! 06</]:N3<G;#%5D/A/T3OF(+Q 0$! 0$
M! 0$! 06UY$]S6SQ?CX3Q,\(Z6^4(*T4K9HVRL]%PJ$'M 0$! 0$! 0:AD'S
M6MPZ 1.DN75<!0\-"?2JBLCAGWL=P+6[DXG-CXBP&K1Q4(I3J!09Y$$! 0>(
MXHXN+LQ3C<7N\+G;R@]H" @Q-A-%;7-Y'</$;W2<3>,TJ*GI*!<RQW.1LVV[
MA)V9+GEIJ -G2/$@RR @(" @(,;D_P IL/YWYK4%S?\ Y%/]8?E(/F._(8/K
M4%T@(/$Q>(R8_2V;MII7;\A B+S&TR;'TVH+;*5-F\ T)+0!U[=R##VEO.^Y
M8&M(+7 N)%*4**V1$$&+P[&/BFE>T.D=*X%Q%3N!^:@<+8\TT1@-#XJN V [
M_G(-([POQ(:\]Q[K[A%A):(C?0/QC\UO=7%?J6S14D(@@I7, N(C'6CM['=3
MAN*#S:SF>*KA25IX9&]3AO05T! 0$! 0$!!;7DKVM;#%^/F/"SP#I=Y @K11
M-AC;$ST6B@0>T! 0$! 0$! 0$! 0$!!\(!!!%0=A""TM28)'V3SL;Y\)/2P]
M'D07B @(" @(" @(""TNR9GLLF&G'YTQ'1&.CRH+H - :T4:!0 =00?4! 0$
M! 0$! 0$! 0$! 0$!!'?-OFY@^56$]:NZ7F?NPX8K$M=1\KAL+WG;PQ-^B=Y
M!M7NTFDNU%U(W=,L7S'F./1X^*[;=.Z.O\' NK-69[6^<N-1:DNW7>2N#2NZ
M.*,'S8HF[FL;78!XS4DE;MAPVXK>&V-CY1JM5DU.2;[YK,^%(81=[R" @("
M@Z>[I&9CO8=6Z"NG#@O(&9"U83L!IZO,:>6(^1:YSBRDVY(Z-GKCUM[^V,U;
M<F&>^/1/J;6Z-\+W0RBDL3C&\'Z9AH?DA>>M6>I1\0$! 0$! 0$! 0$! 0$!
M 0$! 0?$&[Z*T2<L69;+L+<6#Q06[MAG(Z3]1]UXEX\^?AV6[WKPX.+;.Y+3
M6M8T,8 UC0 UH%  -P 6+9)]0$! 0$&KZFTNW(!U_8-#;]HK)&-C90/];PKT
M8LM-D[D1\06DM<"US31S3L((W@A>U'Q 0$! 0$! 0$! 0$! 0$! 0$! 08KG
M+FO>ER'RSV.,=]J.1F.MW-V&ETZCO)V+'JZ:WCU$?JD[G#>[8%LCB(" @("#
MW%++!-'<6\CX;F%[98)XG%DD<C#5KV.;0AP.T$(.TN[]WB6:N]6T3KJ=L6K
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M" @(" @(/A(:"YQH *D^ (+6T!F>^]>*<?FP@]$8Z?*@NT! 0$! 0$! 0$!
M0$! 0$%M>1.>QLL7X^$\4?AZQY0@K0RMGB;*ST7"OB\"#V@(" @(" @(/$LK
M88W2O]%HJ4%&SB>UKIY?Q\QXG^ =#?($%R@(" @(" @(" @(" @(" @(-!YL
M<U,+RLT\<G?4N<Q=<4>(Q8=1]Q*!M)Z6QLJ"]W1NWD!>W2:2[47TC=TRQG,>
M88]'CXKMLSNCK_#KE^?FI]3YO66<NM1:ANG7>4NW5>\[&,8/1CC;N:QHV-:%
MO&'#;BMBVV-CY-JM5DU&2;[YK,L.NYY1 0$! 0$$@<D]5#1_,_3V5E?V=E-<
M"POB31H@O1V)<[P,<YK_ +%>#7XOJ8;HZ=_D9GDVI^AJK)Z)FD^/9^/B=6:]
MQOM=J6Y<T4AO0+J/QOV/_P!(?)6MZ>[BLCL?2,]M+^]K:]#SB @(" @(" @(
M" @(" @(" @(-QT1HXYR49/(L(Q$3OP<9V>L/:=WU@._KW=:\N?/P;(WO5@P
M\6V=R7VM:QH8P!K6BC6C8 !T!8EDWU 0$! 0$!!JFJM,^NM=DL>S^NM%9HA_
MM6CI'U0^2O3BRTV3N1H"]B" @(" @(" @(" @(" @(" @(*D$#[J>*VBVR3/
M;&WQN-$F:140QWP=2QR9O3FA+-X-OAK5U]=M:=HFN/P437#=41L<X?7+V\LL
M]VZ^>DES2LPXB @(" @(/H+FN:]CBQ["',>PEKFN::AS2-H(.T$(.U>[WSUA
MUW!#H77$K3JZU9_Z??2'A]L88V[:G9^':/3'T8\[K6N:[1\'OV?#Z/P<HE.U
MYB27!UH &TH6$]/7M6(<U7%0B'MFOV3AP#V]0&[V41DD'B6,2QOC=N>"T^5!
M@9<;<0U?)3L6D<3V[=E=]-Z*S\8:&-##5@ #3X*;$1Z0$! 0$! 0$! 0$!!@
M[JRDN+R7U;S@*%]30!QZ$5DK"U-I#P.-7N/$ZF[Q(BZ0$! 0$! 0$&!DC>_,
MS21?CH6\;/#YK:M\H16;AE9/$V5GHN%?^Q$>T! 0$! 0$! 0$! 0$! 0$! 0
M$! 06]W,Z-@CB_'RG@C'RSY$%2"%L$38F;FC?UGI*"H@(,%?7USZR]D;RQD9
MX0&[-W245ZA]6N6=K<6TCYJD.DB#J'Q\)&U!=0/M;:O86DS2=YX"2?*2B- Y
M_7 GY):]:(Y(Z8:Z-9&\(]!%A*"(C?0/QC\UO=7%?J6S14D(@@(+>^>UEI*Y
MS>(4I3Q[$&&M\E<Q/9Q.+XA0%IZO BLOZ_#]+)]HY$/7X?I9/M'('K\/TLGV
MCD#U^'Z63[1R!Z_#]+)]HY!\.0A )X9-@KZ!08:;(7,Q<'O_  ;M\8V"G5UH
MK887!\,;VCA:YH(;U C<B/: @(" @(" @(" @(" @(" @LV?U6Z,>Z"X/$SJ
M$G2/*@O$! 0$! 0$!!9R?UJZ$.^" ATG47] \B"\0$! 0$! 0$! 0$! 0$!
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M @(" @("#1M7Z=$1?F+%OX,FMW$T;B?]H/\ 6]E>O#DZ)1IR]2" @(" @("
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M[JXK]2V:*DA$$!!Y>QLC'1O%6.%"$%E%B;>*425<X--6M-*5\/6@OT! 0$!
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MV>?<RN'F]L_Q+:=L;?Q=(:<U1I[5V,CS&F<E!E,;)L$]L\/ <-[7#>UPZ6N
M*U;-@R8;N&^)MEG,>2V^*VS6&672[!!:9+'P92SELK@>9(-CNEKAN</""N5M
MTVS41/>6D]A=2V=R*30NX7=1'0X> C:LE$Q,5A%!5! 0$! 0$! 0$! 0$! 0
M933V,.5RL,#A6WC_  MQ]8T[O*=BZ\EW#:KD_O(Z^&N>95Y!9R]I@].AV*L>
M$U8^5CJW,HH2#Q2#@!&]K LUH</T\45WW;7&41+WH(" @(" @(" @()(Y*<U
M+KE5J^/(RO>_3&1++?4%HVI!A!\RX:WI?"23X6\3>E>35:>,UE.F-RQ+]#72
MPW]G;Y3'2MGC<QMQ:S1D.9+%(T.!:1O#FFH6HS$Q-)<UW%*V:-LK-K7"H4'M
M 06<?]5NC"=D$Y+H^H/Z1Y4%X@(" @(" @(""QR;!<,BM6DB5[PYI'0&[R4%
MY'&V)C8V"C6B@0>D%K>2.HVWB/X:;S0?I6])05XXVQ1MC8*-:*!![0$! 0$!
M 04+N%TL=8]DT9XXCX1T>5!ZMYFW$396[*^D.HC>$%";^JW#;D;(9:,G\!^A
M=\Q!>(" @(" @(""UNXI))+9S&U$<@<_P"A072 @(" @(" @(++*P]M:$AP:
MZ(B0<6P&G1Y:H+2 Y*2*1\EH&SW \YYD%&M(H!3?L161LK<VMM' 35S:U(W5
M)JB*Z#S)(V)CI'FC6BI*"WLXW$.N9126;;3Z5G0$%T@I7$[;:%\[Q5K!6@Z:
M[ @MW7=Q#P/N( V)[@TEK^(M+MU10(-![POQ(:\]Q[K[A%A):(C?0/QC\UO=
M7%?J6S14D(CX]H>US#N<"#XB@U]F-FEE>R,@QL=PF3<-B*RS<;9AH!CJ0*$D
MG;\E$??:ZR_DA[)^>@>UUE_)#V3\] ]KK+^2'LGYZ![767\D/9/ST#VNLOY(
M>R?GH'M=9?R0]D_/0/:ZR_DA[)^>@>UUE_)#V3\] ]KK+^2'LGYZ![767\D/
M9/ST'B7'V+8WES!& #Y]3L\.TH,.+0EIF#P^V:X-?(W;0;-M-_2BMD:&AK0W
MT0!3Q(CZ@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((V
MYW<S8N66BY\A;.:=19 FTPD+J'\.X>=*0?H8F^<>L\+>E>_0Z7Z^2G1&]B.:
MZ^-)AF[]*=EO?^'X/SREFFN)9+BXD=-<3.=)--(2Y[WO-7.<3M))-25O<1$1
M2'R*ZZ;IK.V9>%7$0$! 0$! 0$! 0$'4_=>UC;Y[!Y;E'FI=S)+W!N<=HC>>
M*:-OACD(E:/JG= 6M<UPS9?&:WQ^'F;]]N:N,F.[3W=&VWNZ?/M\<]39KNUN
M+&ZFLKIO#<V[S%*/JF](\!WA=$3$Q6&<F)B:2I*H(" @(" @(" @(" @(-SY
M>:=]M,B<M=,K86#AV8(V27&\>1F_QT7DU.7ABD;Y>K3X^*:SNA+RQ3)B#6==
MZ]TWRZP,NH-37/8VS3V=O;L\ZXN)B*MBA94<3C3Q#>2 O7I=+DU%_!9'X=[H
MSY[,-O%=+BO5.N>:O>)S[\%@K&=V&8\/AP-F[AM8(ZT;)>SGA:YWA?1H^A:M
M[P:73<NLXKYCB^:=\_LPUC+GSZN_AMCW>KVRE30_<\L(HH[OF'EWW,Y )Q6*
M)@@9L&Q\[AQOZ0>%K%B-5]PW3-,-M.V[V/=@Y1;$?\DU[(V1[?0G?3O*OESI
M2,,P.F<?:N:01,8&S3U'3VLO&_\ TEKN;79\OQWS/C9C'I\>/X;8AMP :  *
M ;  O$]#Z@PN;T?I34D;XL_A+')-D!:\W5O'*ZAZG.:2/(5WXM1EQ_!=,=TN
MN_';?%+HB4,:R[I.@,TR6XTG-<:9R)VLCC<;JQ+J;C#*>(5/TCQ3J6=T_/\
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MJ @(" @(/CB0TEK>)PW-W5*"G;RF>%DI'"7;Q6M*&B"J@(" @(" @(" @("
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MG-L;DN<>&VGVD_2R#?[*"YBFBG;Q1/#V]-$%1 0$'PM:2'$5+?1/55!]0$!
M0" 10[B@M[>(Q/G\T-8YX+ * 4#&C</$@N$%.6>& !TKPP'=7I06]F1</?>D
MUXO,C'TK!\TH+Q 0?'.#07.-&@5).X (+.S(N9'WM0X'S(0#6C!T^5!>H""F
M((6RF8, E=O?3:4%1 0$$:=X7XD->>X]U]PBPDM$1MHV)LW,+F5&UOX-N7QT
MD\FWSG>TMB&LZJ#?Y?$@DE 0$! 0$! 0$! 0$! 0$! 0$%G)_5;H3#9!/1LO
M4']!\J"\0$! 0$! 0$! 0$'F.-D3 Q@HT;@@](" @(" @(" @(" @(" @("
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M @(" @(" @(" @(" @\2Q-FC=$_:UPH4%&SE<YKH)?Q\)X7>$=#O*$%R@("
M@(" @(" @(" @M,E/)!;%T6QSB&\74#TH,39WEQ'.WSG2!QHYE:U\5>E%9?U
MN7^RR_(^>B'K<O\ 99?D?/0/6Y?[++\CYZ!ZW+_99?D?/0/6Y?[++\CYZ"G-
M>S,B>YMO(T@&CG 4'A.U!AX[VY9*)!(YSJ[022#X*(K9AM%400$! 0$! 0$!
M!9Y;)VV%Q5]F+UW#9X^WEN[AW5' PO<?8"Y66S==%L;Y<,E\66S==NB*OS!S
M>7N]09G(YZ^/%>9.YEO)SO\ /G>7D>(5H%]%QV19;%L=$/B>HS3ER77SONF9
M6"['0(" @(" @(" @(" @(" @(" @F;D7SLEY=7KM/:B+KK0>1>1<Q$&1UG)
M)L,K&[:L=_M6#ZX;:AV(U^A^M'%;LOCSMFY/S>=-/T\FW'/[O;W=<>.-N_HC
M5.F(L:R+-861MWIJ]:V6WN(G"1D;9!5OG"H+' ^8[R+!X<O%[MVRZ&]9<<1'
M%;MMEK*]#H$! 0$! 07N'L#E,M98X;KB9K7TZ& U<?M05QONX;9ESLMXKHAT
M&UK6-#&BC6B@ W !8%FGU 00ESKOYM2ZLT;R<BE?#C-2SNO-2&)Q8^7&6M7&
M .&YLI8X/\ HK")FL[.TQ]I#8V$#+:RMF-BM[>%H9''&P4:UK10  ="BO&2L
M+?*XZ[QEXQLEK>0R6\\;P'-<R5I8X$'>*%!3PF-;A<-CL.Q_:LQ]K#:-D(X2
MX01MC#J5-*\*#1.;LGMQ;X'ES$7<>LL@VUOQ&>%[<39M]9O7 ]%6,$0/6]6!
MK7=\R-QB':KY59-];[2.2E]1#B:NQUT\OC+:] )_T@DHFY14%6O_ %67O_[-
MM^[C5Z$.\SB!?8[1ESC6GWUC4-G:X<Q^;,XSU<\-(VT;V;9#U<-4@3JHJ">\
MXUKL9HD. /\ ^\EH-O46N5A)3LHKGW4NJX>5W> N-0:KC>S2VK,3:V%IE:%S
M+5]D\EP=0'S>)W$\#<'!VX%5$Z^KXS*/LLJT1W1A:Z2QNF.XV\%PSA<YA::$
M.:5%4\5@<-A!,,18PV?K#@^;L6AO$1NKX!T#<.A!D4!!'6MK/U?+-N6BC+J,
M./5QL\T_(HO=@NK;1&M+O00$! 0$!!?8K%768NA;6PHT;9IB/-C;UGP]07"^
M^+8K*HLY_<[K73-C<<KN7=S3(T=#J',PNJ8.(4?!&\;YG;I'#\6-@\[T?7H]
M+-\_4O\ %"3+DH - :T4 V +.N+Z@(" @(" @(" @(" @(" @(" 0""#M!V$
M(/T'[M6K':KY2X@7$ADO\*7X>Z<XU)]4H(CY8G1K5-?CX,L]NUSA+B\"B @(
M" @(" @(" @L[D&WF;>-] T9./J3N=Y$%X#7:-R @(" @(" @(""G/,V")TK
M]S1NZST!!3M(71L,DOX^4\<A^4/(@N$! 04YV&2"2-OI/8YH\9%$&->Z63'B
MR$$HGX6Q[6T;5M-O%NIL095HHT#J%$'U 0$! 0$! 0$'QSFL:7.-&C:2@^,>
MU[>)N[=U;1L0>D'B65L,;I7^BT5*"C9Q/:UTTOX^8\3_  #H;Y @N4! 0$!!
M9VOY9>CIXF&GV*!C/R6O6]^W[(H- [POQ(:\]Q[K[A%A):(C?0/QC\UO=7%?
MJ6S14D(BROIKL.9;V;*R2 DR'<T(,8;5UKDK422&25Y#WN/75%; B" @(" @
M(" @(" @(" @(+2[!A>R]8*\'FS =,9^<@N@0X!S35I%0? 4'U 0$! 0$! 0
M$! 0$%I>DR!MFS:^;TCOX6#>?G(/4%A;6[^.-OG]!)K3Q(+E ) !)- -I)0:
M9D^;G+'#W#K3(ZLQD5RP\+XFW+)'-/4X1EU#XT%<\R]#R:?R6IL?FK7)XO$P
M.N;\X^5ES+'&P5-8V'B!\=$&,Y?\X]%<S+V\L-+2W,EQ8Q-GN!<0.A:&/=PB
MA)-35!OY (((J#L(*#'S8Z*,&>V;^&80]K2:@TVTH@O8963Q-E9Z+A7_ +$%
M.(R=O,Q[N)HX2P4H!6NSY""N@(,'K#5N'T/IZ[U/GG2,Q5EV8G="PRO';2-B
M;1HW^<X(,/R]YIZ3YG0W\^E9)Y(\:Z)ET;B%T-#,'%O#6M?0-4&Z(" @((<[
MSNI#@.4^0M8G\-UG)H<9%0^=P2$RR[.HQQN:?&LKRO%QYX_5VL!S[4?2TEW7
M=[OM\U7!*W9\H$! 0$! 0$! 0$! 0$! 0$! 0$!!-O)#GM/H%S=*ZK#K_0=T
MXM(<#*^Q,A\YS&[>*(DU?']DW;4.PVNY?]7W[-E_I;3RCG4Z?_CR[<?_ (_A
MV>3MZ"U#IBWM[2+46FYFY#2]XT30S0N$HC8_:"'"O%&>AW1TK"XLLS/#=LNA
MN]^.*<=DUMGP\C5UZ'0^H" @("#=N6%AZQG)[YP\RSAHT_\ S)C3[D%>/5W4
MMIUO7I;:W5ZDMK%LD("#G?F]>#1W/3E[K:__  >#GBDQEU=.]"-SG/8XGJHV
M<//@!ZE81T1OVC<HH@ @BHVA!%>F'>^[G'J?4Q\_&:0MH],8LD&GKDW#=7[V
MG=4?@HO(51JG,5YY<\\M*<PFGLL)J>/VASCZD-$@H(WNIU L=]@41/ZBN=LI
MC\MDN\[>6^%R[\)>MT_')ZY'!%=<3 Y@=&YDP+:&H-1MV*HJY+,9G0/./"W/
M-2];F].W]NZSTIJ%T3+2#'7DM!,)(H_,$D@HPRDU#*4H.-!T(HJ"N\W_ );H
MC_\ :2T^Y>K"2G516!U?H[3VNL)-@-26@NK&7SF.!X9890/-EB>-K'MKL(\1
MV;$$(\L(]4<H.9K.4.7NW9/26:MYKW3ET_88C#5S@&[>"M'-D8/-XJ.;0.(5
M1T8HH@(-8US:=MBF70%7VL@<3U,?YI^8O1@FEU$E'B]J" @(" @R.'PUWFKC
ML;<<$+/QUP1YK!\UQZ N%]\6PJ+.=_/NSTG:W'+OEA<_^L-)BS6H(B'>K'<Z
M.%X]*<[G/W1]'G>CZ]+HYOGCR;NB/#H29<D 4\-222=I).TDD[R5G7$0$! 0
M$! 0$! 0$! 0$! 0$! 0$'3O<SU)ZMJ#4FD97 1Y"VBR=L'';VML[L9 T>%L
MC2?K5AN:8ZVVW=6QRAV,M><A 0$!!B,]JG3>EH8;C4F6M,3!<.,<$E[,R!KW
M@5(:7D5(""E@-9:3U2^>/36;L<M);!KKAEE<1SNC:^H:7!A- :%!DLCDL?B+
M&?)Y2YBL\?;-[2XNIWB.*-@Z7.=0 (,;@-9:3U2^>+36;LLM);!KKAME<1SF
M-KR0TNX":5H:(+W-9K$Z=QEQFLY=QV.*M0UUQ=3'AC8'.#&U/A<X >%!A_A&
MT(,':ZEDU#8PX"^D?!9Y">9L$,LL9<US6.DX:D%CO8076!UII'5,LT&F\Y8Y
M:>W:'SQV5Q'.YC'&@+@QQ(%4%_F,KB<+CI\EG+R"PQ<( N+JZD;%"P/<&#B<
MX@"I( \*# ::Y@Z)SUY[2X34>.RE^T.,$-I=13R/C8 XT:QQ-6@^=U>1!=9O
M7^A]-WOM;J#46.QE_P #9?5KNYBAEX'5H[A>X&AH@V"*6.>)DT+Q)#(T/C>T
MU:YKA4$$=!"#V@(" @(" @LS_6KKAWP6QJ[J=)T#R(+Q 06[[ZTC>8WS-#QL
M(KN/A05P0X!S35IV@C<0@^H" @(" @(,?&YWK0'$[M>V>'MVT[,---FZFY!D
M$! 0$'E[ ]I8[<X4* Q@C;PBIWFIVDD[4'BYF,$$DH%2T;!X=R# >O3OD:Z=
MQD8'!Q8=QHBMD1! 0$! 049;2VG=QRQ-<[=4[Z(*K&-8T,8 UHV #8 @C7O"
M_$AKSW'NON$6$EHB-] _&/S6]U<5^I;-%20B"#$WW^;6?D^64&60$! 0$! 0
M$! 0$! 0$%K)DK&)Q:^8<0W@5=\H%!ZAO[2=W!%*"X[F[03[-$%<@$$$5!V$
M(+6U)@D?9/.QOGPD]+#T>1!=H" @(" @(" @("#R][8V.>\T:T5)\ 06]FQS
M^*[E%))O1'TK!N""Z0$'%_>/YN:@U+JR?ECI2:6/$6<S;"]BM21+?W[B&NB<
M6[2QCCV8CZ75)KYM+ V72G<VL7XR*?6F=N&925@=):8P1-CA<1Z)DE;)QD=)
M#0.KK2HV*ZY*XCE'RLYE28[(2Y)V6QCPV2XC:R2**"-_F<331U2^I-!T(-![
MF'_$NJ/[C!_3%)'1FN><7+WEY,+/4N6;'DW /&.MV.N+D-=M!<R,'@!&T<9%
M>A08G2/>$Y6ZRR$>)Q^6=:9*=P9;V^0B=;=HX[FM>:L+CN#>*IZ$&=UOS"TO
MRNM[?(ZKN)+7%Y*X]6M7Q0R3TN3&^0M(C#B 6L<:E!E-&ZTP&O<(W4&FIWW&
M+?(^%LDD;X7<<1HX<+P#TH-6T_SXY;:GU+!I'#Y":7.7$DL,4+[6:-I? U[W
MCC<T-% QW2@SNN>9.C>75G'=ZKR3;1T]?5;5C72W,W#2O!&P%Q KM<?-'24$
M&<VN>/+OF+RHU-AL!D'QYCAM9(K&]B-O+*UEW"YQC)JUQ !<6AU:;:*BCW+?
M\IU?_>++[B9)'4J@(" @Y%[Y&>,N7TSIACAPVUO/D9V@_17#Q#'7Q"-_LK:.
M2X]EUWB:']TYMMF.)ZYGT1ZW,"V-HH@(" @(" @(" @(" @(" @(" @(""6N
M3?/#+\L;KVKR#'Y315TX^M8VH+X"_P!*6WXM@/TT9\UW@.U8K6Z"W/'%&RYL
M?*><W:2>"_WL<^;N]CIJYPF&U1AXM8\O+EF1PMT"]]K#Z3#O<&M-"US?HHG"
MHZ.I:_;DNLNX,FR?#PJWV(LRV1DQ36V?#PAJ7S-A'A"];H?5 0$!!+7*^S['
M!3WA%'W<[C7ZB(!@^358O5W5NIU,EI;:6UZV[KQO6("#6->Z$P7,73EQIO/,
M=ZO(1);W$=!-!.VO#)&2"*BM"#L()!V%!&VFX^>/+&!N N\5#S!TM:-[/'7]
MI=1V>5CA!HR.2.Y(:\-&[SZC=6BJ,OE=?<U,IC[BRTGRXOK+,3QNCM[[-7EE
M;VEO(13M'"*65[PW> UNU!MTOMYI/1]CC,%BY,[F[6S9;0L;+%#$ZXCC#>.6
M29[:-<[:>$$^!%8;DKIS,Z5T1#B-1V3K34CKBYO<S,9(YXKB\O)7322QO8YU
M6FH X@"*421ZYV:'N-?\O<CA,=!V^;C='=XEO&V+^M0N%//>0&@M+FDUZ4@9
M'EU?:SDP%GCM=89^/SUE R*XNV3P7-O<F,!@D:Z-[G!SAYSFN;OKM01_#@=>
M0\]+KF.[3<K]+S8[VJ8T7-IZX.$-/:]D90.$N;2G'6FVB(DW6^C,-S"TO=Z9
MSL1]5O&!T<E 9;>=HJR5F\!S#[.T;BHK1>6S>;>B;3WI:QQ U%A\?^"Q.H\?
M=0F=UNW8QDT%P^-_FC8""338:[U46//O2FMM<LT]8:3PINFXF^9E+JXGN8+:
M)W WS8V!S^(NVFI( '6D"8,9>7%]:-N+JQFQ\Y)#K6X,;GM(\,3WM(\JBHXM
M,YS TAJ'4%ED=(WF=TW>Y"2]PF4Q$]M+*V*=K"Z*:&>6(MX7AW"02**HJ833
M.I=4<PK?F/JZP;A+3"V<UAIO!]JRXNJW9!GNKI\=8VN+0&1QL<[A%2378BI/
M4! 06>6M1>8R[MB*]I$X ?5 5'R5RLFDQ(B$;0*[^E9-Q$! 0$&8PV ER377
MEU(+3$0@OFNWD-!:P5=PEU!0 ;7'8%U7Y.'9&]4#\Z>\9#+:S:#Y43&VQ#>*
M')ZBA):^?H=':.W\)^BFWNW-V><<EI=%MX\F_J]J3+F4 -% * +,.+Z@(" @
M(" @(" @(" @(" @(" @(""0^1.?.G.;NE;[B#8KF[]K9RXT;V=^TPU/B<YI
M7DU=G'ANCLKY%A^D"U!S$! 0$'&7>CRTNK^:NGN7]G)5EBV"V<T;:7F5D979
M_-]BK PG(J\GY9\_+C2-]*>PN9[O3\[SL#WL>3 \#ZM\; WP.0=2\]?BBU=_
M<'?=-4$!]RW_ #?5W]VLOZ2961NO>\U%+:Z.Q&D+,EU[J"^#GQ-VN?!9T/#3
MPROBIXD@:9WF,)'H_E=R[TA%3^H%T<A&YTL%NP2/^R?(YWE2!HG=[R=SH3G#
MA;.^/9VVH;5EH\FH#H\C"RXMC0]<@C""8.^'JA]OI_!:)LW$W67N3>7,;-KC
M#:C@C:1U/D?4>%B0(6Y$V5UI?O!8S%2T?>VCLGCIVL%"Z2&WE+VT/TO9.]A!
MD.]D_CYKAX]&3%6<D9ZV%TK:^RUP\B0.W]._\/XG^YV_]$U09) 0$! 0$%"[
MF,,5&;9I#P1#ZH_.0>K>$6\38QM(VN=UN.\H*J @Q^- -BZHK5TE?#M.]!5Q
MGY!!XC\LH+M 0$! 0$! 0$! 0$! 0?'M:]I8\5:X4(/4@Q<V,CMQZQ%5_9D/
M,;J$%HWH,FQ[9&-D8:M<*@^ H/,\S+>)TTE>%O0!4DDT"#'-O+UU[ R1HBAF
MK2,[74 Z>I!E4! 0$!!&G>%^)#7GN/=?<(L)+1$;Z!^,?FM[JXK]2V:*DA$$
M&)OO\VL_)]T4&60$! 0$! 0$%"6X[.0,X21YI<ZHV<;N$>/:@KH" @(+:_>Z
M.SF>PT<&FA\>Q!:X>WA-FV0QM+WEU7$ G8:(*.;ABBCBFB:&2A].)HH=U>CQ
M(,O&XOC8X[W-!/E""A>1.>QLL7X^$\<?AZQY0@K0RMGB;*ST7"OB\"#V@("
M@( (.[:@(" @(+.X_K,[;0?BF4?/_JM\J"\0$!!^>.BY8[;O#6,F:(:]NI96
MSF392X=<O:TFO5(0N0_0Y<1HO.?XJ-8^Y5S]P4'+W=5RQP+]?YP,$AQF#=>A
MAW.]6XY*>7A5D:WR*TI;<W>:EQ/K1[\C"R&?,9)LCB#=2]HQ@:XM((;Q2AQ
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MJ'<)IM%1OHHK0M/X/(0ZWN=0V6-FP5GD(9AJ2RDECDM;N^8]C;>Y@9&YP$G
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M+%C=KG7-I-"!3K+V +E;FQW;KHGQN-^CSV16ZRZ([8F&(!!W&J[GD$! 0$!
M0$&_\NN<6M^6<S68.\]8PQ=Q3X6[K):.J?.+!6L;C],PCPU7@U.AQY]\;>MF
M=!S?/I-ELUM^6?#8Z9TQS.Y5<V^"&:7WK:QEV&VN'-:V60_22;(YO+PO\"U[
M+IL^F_6M\/(WO2\RTVLV1/!?U3X;?2V"+1&;Q.?QHN(?6; W47%=P5<P-:X.
M\]IVM\NSPKJG/;=9--]'OC!=;='55,*Q+)B @(" @(" @(" @(" @(" @("
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M;W5Q7ZELT5)"((" @(*<T+9V=F\N#*^<&FE1U'P(*&,_(8OLONB@NT! 0$!
M0$! 0$'QS&N])H/C%4 -:W8T #P;$'U!2N9Q;Q.D(J[<QO6X[@@\VL)AB\\U
ME>>.5W6XH*Z @(" @M[.T%FQ[ XOXW%]2*;Z(+A 08.YRMP97MA(9&"6C94G
MHJBLECG,=9QE@X0!0CP@[3Y41=(" @^<+>+CIYU*5Z:(/J @(" @H75Y9V,7
M;WMQ';05#>TF>V-G$=PJX@5*"OOVA 08K*7!M[B)T.R8--7=!:>BB"KC;Z2Z
M+HY0.-HJ'#94(,@@^$AH).X;2@P;LQ<F3B8&B.NQA%=GA**R+,G9N8USI.%Q
M%2T@[#U;D1:WMWCF65SV3VM<\%SR :DD[SL0:US*R3(.4^JKJ!]2S#74?%U.
MDMRSI^N7JTD5S6=\/!S&9MTV28^2[T/SA&P +Z"^,2(" @(" @(" @(" @(/
MK6N<X,:"Y[B&M:!4DG8  -Y*DS18B9FD.B^5W=7S&H88,WK^:7"XJ2CXL3$
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M_A)%@.6_Q+N[UN4N.EGW$0$! 0$! 0$! 0$$N=V/X[M._P SD/\ !RKP:_\
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M @(" @C3O"_$AKSW'NON$6$EHB-] _&/S6]U<5^I;-%20B" @(" @(" @("
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M5+OHCO/2?*NU'U0$'EWHGQ%48OO9?\$\N/\ ZO\ A8ERY=\=[T=$.5EFT$!
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M&P@JB:N\YJ*35.@N6F>>P-?D(9[FXX?1;+/;VTG" =NVKO84@3GW;/B5TO\
M6WG^.N$D2LH" @(*;)0]\D?"08R 2>FHKL05$! 0$! 0?'-#FEKA5I%"/ 4%
MG:2B&9V.D=62,<<5>F*NS;X-R"]0$! 01IWA?B0UY[CW7W"+"2T1&_+_ ,[F
M%S1F;^*FR>+=&[=4##6C3\D%%20B*;)FR/<P @MZ^D D;/*$%1 0$! 0$%A>
M75R939V4=9J OE/HM!06=@R2'*R122&1[6$N<:[20#T^-!FT! 0$! 0$! )
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MS6UV"MV]E/$ :(+GG7B<MRSYX2ZG9;EUM/D(M08F1]>RF(D;-)'7ZF0.81O
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MYY77; :\$]Q&^>1E1OX72%M? @F7NL?$YB_[U>_T[DD<S\BO^H+$_P!]R/\
MAKA48[*7V-R//>^N.;+IO:=N9N(LNWSR600O>R*/S/.[)M&-\S;P>CM05^?6
M;Y893.XVTY765O;XO'VSF7EW:6YMHYYI'U'I-:Y_ !3B<.G8@VOGU;,'*#DR
M]OFF+&,: !O;'8V\;1Y ?D*#HGNV?$KI?ZV\_P =<)(E90$! 0? UH<7 4<Z
ME3UT0?4! 0$! 0$%G>P.<Z.[B_'6_$6M^F:ZE1[ 07,4C9HVRL-6N%0@]H"
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M>PU'G11.;3RK!?E-3.WAEML\QT=NSCM;$<GRYYLX&\P,61LM08B]8&WEG!<
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M!1\9+' [P6FA^4OI$/AMT3$TG>\JN(@(" @(*]G9W61O+?'V,3KB^NY66]M
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M @(" @(" @(" @(""XL(#<W]I; 5,T\3 /KG@*732)(1QWP,@V[YGX^R:?\
M+L1$QX^JGFED^51>KEEM,4SUR]$N?UE4$! 0!Z3?KF_+"#L7O>_%YI'W09_A
M)%@.6_Q+N[UN4N.EGW$0$! 0$! 0$'1')KN[X+5FDOA!YB923&Z;G$C[&WAF
MCM1V$3BPSSSO!X&ES3PMV;-I.U8G5:VZR_@LBLK$-Y'*#NHT'_[TVWC]OH_O
MUYOS.K^7]U:0?!!W4?WHMOT]']^GYK5_+^Z4AGM&:/[M6@]26FJM/ZJLF9>R
M;*R!T^:BEC GC,3ZL+Z'S7%=67+J<EO#=;L[C8^\P^3/+WGE=Y+5>D-41/U:
MV**%\]I=17MC6%A$3)XHRYS ZE.)IKTT=N3#JLFGB+;K?=\Y2KB6\M+K'WES
MC[Z(P7UG+);W,+M[)87%CVGQ$%;'$Q,5AQ4500$! 0$! 0=\=U/&NL.3>-G<
M*>V5W>WC?"UTQB']&M7YC=7-/9$.<)K6-40$! 0$! 0$! 0$%*ZMK>]MIK.[
MB;-:W#'0SPO'$Q\<@+7-<#O!!H4& P'+[1&E;UV1TY@+'%WSXS ^XM86Q2&)
MQ#BTD"M"6@^1!LB#XYP:"YQ :-I)V!!2@NK>Y+A \/+?2I795!60>9.(,<6>
MG0\/CIL0:J2\OXG5XZ[2=]45M,)>88S)^,X1Q>.FU$>T'P.:26@@D;QTA!]0
M$! 0?'NX6N=2O"":>)!AS;7F0!GO"8H&@N9"W8?*BO>!_)I/K_F!$99 0$&O
MY4R&\=Q^B .#JX:?/15_AS(;=P?7@#O,K\FB(]7.5B@E,087ENQQ!H 4%W!.
MRXB$L?HGKW@H*B @(+.X_P PL_%+\H(#/\SF_FF?+*!=Y&*T<(RTOD(J0-E!
MXT%6UNX[N,O94$;'-.\(*Z @(*-U!V\1:#21OG1NZG#<@6L_;Q!Y%'CS9&]3
MAO""JYS6-+G&C1O* UP<T.::M.T%!&O>%^)#7GN/=?<(L)+1$;Z!^,?FM[JX
MK]2V:*WR3^JW0G&R">C)>H/Z'(B\0$!!2N+B*UB,LIHT;-FTD]008PW]\ZYM
MZM[&WF> UA +BVHJ37;THK,(@@(/(CC#S(&@/.]U!7V4'I 0$! 0$!!9R?UJ
MZ$ VP04?+U%_0U!=N<UC2]QHUHJ3X @M;1KI7/O)!1TNR,'Z&,;O9WH+M 0$
M%KD\A:XC&WF5O7<%G8P2W5P_Z6*%A>X^0!!PG/WG^=$HFOX+Z*''&8L818P.
MCC+ZN;'QF,U(:.DUV*T':>@=31ZRT7@]3L(XLE9Q33AOHMGIPS-'UL@<WR*#
M8T! 08G5$DD.F<S-"]T<T=C=/CD82US7-A<001M!!0<=]V'4VK<]S-FM\MJ#
M(W]O%B+J6&UO+J>YB,[9[?A/!(]S0>$O\X"NX;E9':T$S9XFRMW.WCJ/2%!$
MG>(^$_WHVGP9>M^L>M?^J^UE?7O5^ \/9\/G\/%Z79^=NZ*H&F-1ZIT9R5]]
MW-@3NS6$@N+V=H:U]\ZWB<YT;9!5K3(6=9&RG%MJ@\<G^?EES<RN8L+;!SX>
M#%L@?'-<S1ROF[<R#:R,$-IP?3G?N03#QL^F'LH'&SZ8>R@<;/IA[*!QL^F'
MLH,)J[56.T9IK)ZIR;9)<?BX3<7$=N&NE+00/-#G-'3TD(-#Y2<\+#FS=Y]E
MCB9<;8X-EJ_M9YFR22F[,U 6-: VG9=#G>1!O\N4]9_ %IBB>0'/K4\-=NRB
M*S#6M8T-:*-:* #J"($@ D[AM*#!3Y:^=YT+6Q,)(8UX)-!TE%4K7)70O6R7
MO \.HQG *<(.\H-C1! 0$! 0?F7S#Q1P>O=38FE&VF3NV1_S9F<YA\K2%]"T
MM_%BMGLA\9YCCG'J<EL_-/IV-:7I8\0$! 0$$T]US3<>>YJ6]]<1B2WP-K-D
M:.]'MC2&+R@R<8^M6'YMEX,-/FFC9_MS!]35<4[K(KX]WK2+WPM93L]I-!6L
MA9!,TY;)-:?3#7&*W::= (D<0>D-/0O!R;#$UR3W1ZV7^Y]5,1;AB=_O3ZO7
MYG**V=H)0% 0$! 0$! 0$! 0$!!4@GGM9XKJUD=#=0/;+!,PEKV2,(<US2-Q
M!%0I,1,4ESLOFVZ+HWP_0S%W4'.3DLV6Z8UTNH<3)#.T4HV^8UT;G-'1PS,X
MF^(+1+XG3:C9^C/F_P 'U['=&MT>W].WS[I\DOSP+7,)8\4>TEK@=A!&PA;W
M#X_,4E\500$'N*9]M+'<1FDD+VR,/4YA#A\I28K%'.RZ;;HF-\.[^94K<E#I
MS4,?XG(V0<TC=1X9,/D/6CZ>.&;K>J7VJ;N*(NZX:$O4XB @(" @(" @(" @
M(" @(" @("#/:(M3=ZMQ,8%>";MCXH6E_P Q=6::62Y6[W./>(RK<QSFU1,P
MU9:206#1U&U@8QW^EQ++:*WAPVNZ48+VH(" @#TF_7-^6$'8O>]^+S2/N@S_
M  DBP'+?XEW=ZW*7'2S[B(" @(" @("#KK4)/_)ACFU\U]E9->.@M]>;L/@6
M!L_G9\.ARZ&A\JN0W+_7>BK/4F?U6_$9.YEGCDLFRVC UL,KF--):NV@5VKU
M:C5Y,=_#;;6/&D0W7_E6Y3?O])_O[#YR\_\ 4,OR>DH?\JO*;]_9/]_8?.3^
MH9?D]*T:]W-FB'7^JX(S^";C0W9]%V5WPM)IX#\E=O-/X=O?ZB$,\TOC.UG[
MM7_].Y9#3_PK>Z$:FN]! 0$! 0$'Q[N!CG'<T$^P@_2SDWAS@>5>D<8[TV8R
MWE?]?<,[9U?#5ZT_57<66Z>USAO"\JB @^.<UC2]Y#6M%7..P #I*#E+F5WL
M;V/*RZ?Y86<5RUDG8#,W#'3]O)7A_JT+2 03L:YU>+H;TJT&N-UOWO(8O;E]
MEDWVG#QF%V)MCYF_\4(!(/8J@ZST3=YV_P!(82_U,UK,_=V<-QD(V,,09+*P
M/+> DEI;6CAUJ#/(" @(" @U+FC=7-ERVU;>6<TEO=P8B^E@N(7&.2.1EN\M
M<US2""#N(0<Y]TC5&IL]JW/09S-7V3@BQS7Q17MU-<,:\SL'$!(YP!ITA61U
M-+:7=_,X7+NRLV.(9&W>X ["?&H(4Y[-YJ-T[9LY6"]JV_>,V,7^6^K")W9<
M/#^$X>/TNS\[=]#Q)"L=KC)\Q\/W9!?:KO+FPUM&^V$MS#*8;QL3KUHC$CXB
M"'F,@/VU^FVU519]U_/:PSVA]:S')W&3ST+PW$/R4\EPUEP;9YC!,KG4:7\/
M$DBMR L>>$FJ<X[F.+\:??;N'_JS0'#(=HS@=:F@);PA_%PG@W=.\-ARG>4Q
M>.YA1\M(,#=W&9CREMAKR[FDC@@;)<NC':1@=HY[0V5KA4-J@G108RUC<V6V
M' 6R,[7MC0CTMU3TU09- 0$! 0>)?Q3_ *T_*08S _DTGU_S @RR @^.(:"Y
MQHT"I)Z@@LX(FW9==3L#FOV0L<*T8.G;UH+P - :T  ;@-@08"YQ\MQ>2.MO
M/:QY+C6@JX&HVG;1%9&WQ<+(@)QQ2[W$.<!XMA"(J^UUG](?MG?/0/:ZS^D/
MVSOGH'M=9_2'[9WST'B3$V$H DB)X35IXW@@^ @H/D>(Q\5>"(@N](\;R33K
M)*"UO<4_C#[5M6D;6$[0?&2BJ^)A[%LP<:3!P:]G53=[-41>7$IAB=(&%_#M
M(! V=)J4%5 0$&!N[R6*[F]7/9@D!U*&I;T[45>6^1CF@I<!W'N<6M)!IT[-
MR(KMOK9K0UO'0?4.^<@CKG]<QW')/7K(^*HPMT3Q-+10,\*+"4$1&^@?C'YK
M>ZN*_4MFBI%EC;-&Z)XJUPH411LY'EKH)?QT)X7'K'0[RA!<H"#R]C'TXVAP
M:>(5V[1TH,;DORZP^O\ FM091 0$! 0$! 0$!!1NI^PB+@*R./#&WK<=R!;0
M=A$&$U>?.D=UN.\H*-R3<3-LV^AL?.?J1N;Y4%1U[9Q'@=,QI&RE1L]A!4BG
MAF%8I&O W\)!05$!!#/>@U3[W.5-]9Q/X+S/31XR&F_LWUDF-.HQL<P_7*P.
M?\/RNN+WNNYG48:_VQ=EVZ@M&[2/5;'ALY#0[OP?;G9T;4$E=SG5\M[IC*Z*
MN).)^$NW7%HUSJN%K?\ %-L'4)1(/*DC3>=O,_66B>>=QZAFL@<%CY,;=NPC
M+N2*TD:V"&1\18T\(;(0>/9TE!M'*.YYR7&KI>:?,I][;Z(=CKR\>Z><1VD4
M/9B5ACL^TXFL#15I[/;OJ=Z#0<ES7YQ\\=7OT]H.XN<5CW\;[:PL9?53%:L(
M!ENKAA#ND<7G<-31HJ=H2AH#EIS>T6-2W6NM0R9+ .P5ZV"V9D)[R(W;V"A=
M'.UM"UH?M Z4'.')V77_ +ZY<?RU8T:DR=E-9FZ>&CU:V<YCY90]WFL(X ./
M:=M!YQ"HV"]U5SJY'ZX;!G\Q>3WWX.[FM+N[DO;*]MWDBM'DBAX7-X@ YI!W
M%!.?>8UUF['0>D-0Z1RUYB1EYFW''9S/@>^":V[5K7F,BH'$%!'F9BYDZZ[N
M^*S\6<N;FRL'Y=^J3=W;^.ZM.T:V.-X=Q=J  X $[.C>@C7E)HSF?K&XS,?+
M/+OQ$UI'![:R17CK*1[)C((:$,=Q4+'_ %OE5$[<_>:^HM/7F-Y8Z*(AU7<V
M]L,MD8!VEPRXN0T1PV_&2 ]WI%SFG8YM-M5!HNM.7G/7E+A;?7MQK.YN^&6(
M9***\GN!"^5PX1*R<&.1A=YCJ#>=G6@F6VYZXH<D&\S+VPA.H!(<6['Q\;8'
MY8;@VKBX1EOX;AXB0WS:D[4H('TY9<_.?-]?Y3%YN>SQ<,H;(Z.YDQN,AD(!
M$438>)[B!0FO&1LJ=HJ&T:ZY7<Y<#RCGBSV?DO8+*[OKK.MDR$DS9,8Z&WBA
M@'&T&1A>)7ECMH)'B01CRET7S3U>,T.6&8?B)K1MN<D8[PV9E[7M>RW-=Q4X
M'^*OA0;?W@M5\P=+<RYL1C=2Y''V46-L3ZO9W+F0F<M?VC@.L^;4TVH.FN=&
M7RV'Y)YC+XF^GL<K#:V+HKZWD='.US[F!KB'MH1Q!Q!\:"(.06LM7ZAY?\S[
MO-YZ_O[RQQ_%87%Q<22R6[S:W;N*)SR2TU:T[.D!!#FDN9'.+,6]_H[3F5RF
M7U#G9(!:W+I>WN+6"W$CIA!QCA89 1QR'T6MKL.U!)M[K+7G(SE'88K4C97\
MT,MD;YF/.2G;D.PL^/M#=/>V20/#&EK61E_I.%=Q15E!R^[PN:T:>:,FL;QM
MVZW.4ML;Z]<QW+[4-[3B:R/AB87-\YL8V4V;#L1$O=VOF_E.8^&O\-J603:C
MPG9N-X &&YM9:AKW!M!QL<WA<0!6K>FJ"=5!2N7OCA<YGI"FVE:"HJ:> (%L
M][XR7FM'.#74I5H) *"J@X([SV%]J.;N2N&MX8LM;6M_'U$F/L'D>-T1*W7E
M5_%@B.J9CP\KY;]Q8N#5S/S1$^KU(=66:V(" @("#I7N;O8-4ZFC+@)'6$#F
MLZ2&S$$^2H6N\Z^"WO;O]JS[V3NCUM<[V,<S.;''("&28NT="3N+0Z5II]D"
MO1RC^!XY>+[F_FH_9CTR@U9IJH@(" @(" @(" @(" @(.^.[!#<1<G<.Z>H9
M+/>20 BGX,W+QL\H*TCFDQ^8GQ>A]8Y#$QHK*]O_ )2X5S3HWYG)/BH8G7=P
M6$;N$RNI1;GB^".Y\PU4Q.:^GS3Z5BNQYA 0-Z#M7 WWODY!Z/R_%VEQC6LL
MICO+?5W/M2#]HPK3<UO!J;XZ]OK?7>6Y8R:/'=U13R;/4U]<WN$! 0$! 0$!
M 0$! 0$! 0$! 0$&\\JK9C\_<Y"8AL-C:N<7G<#(0-IZ/-#EY=3/NTZY=F/>
MX;U+EY-0:ES6>E-9,G?W5V3UB:5SA\BBV6RWAMB.J'-BUS! 0$ >DWZYORP@
M[%[WOQ>:1]T&?X218#EO\2[N];E+CI9]Q$! 0$! 0$!!USJ'_HQQG]SLO\<U
M8*S^=GPZ'+H:-RIM^[!)HNT?S1%H=8&6?UKMG9 /[(2'LJ^KD,]"FY>G43JN
M/_C^'Q)%&Z^J=Q[Z6P^VR_SUYJZ[M_=78^^J=Q[Z6P^VR_STKKNW]TV-;[G'
M!\(.J>R_$^UGX+^;];'#\BB[N:?P[>_U)"&>:7QG:S]VK[^G<LAI_P"%;W0-
M37>@@(" @(""[Q6-FS.5Q^&MVE\^1NH+.-@VDF>1L?S5QNNX8F>H?JE:VT-E
M:P6=NWA@MXVQ1-ZF1@- ]@+2)FLU=BLH" @BWO%9^YT]RAU!<6;S'<WC(L>U
M[30AEW*V.3V8R\((0[G.D<9?Y+/:PO8637V+[&TQO& [LG7 >Z605W.X6M:#
MU%W6K([!4$5<Z--\UM2QX:SY:YP86V+IVYJ4R^K480PQ/[5C72BE'BD?7M0<
MT:YQG-+E,VVS]OS-&7G=.(9X+/*33SQR$.<#);S.<'L\T@D@[=X5$W0\T,QK
M;NWYK6,<[\;J:RMY;:ZNK)YA<VZMGL/:1EM"WC8YKB!NXB @@WEWK;GUS!M[
MO0VE,S=3W4TGKM]FKNZD[:WMVM$8C$[RXQL+MM(QQD^#B06\FM.=/(?6L=CJ
M3)75Z/,N)["\NI+RSO;5Y(+HWR%Q:20X<;0'!PVCH0=0<RH.8.OM'Z>O^469
M]K&Y5T5S=3N>VW)L;J#M&/,H:Y[2PT!;'YVWP(.<==Z<YJ<L+0:D'-!N3O(9
M6LNK2URT[[MKGF@)AE=^$:#L=L\E*T"7]-\R[_F;W==9Y#,AOM]C<;DK'(21
MM#&S%MH7LE#1L;Q-=1P&SB!H *!!S?R7^$F]S62T_P L7MMLOE;4,O<DX]F;
M6TBD:YSA)MX*N+6U#2[Z7:J,WG,_STY#ZLB9E\S<75S*!=QQ7%W+?8Z_C#J.
M#NU-=I'"XT;(W>*;"H)!YZ\SLS/R_P!!ZTT3E;W"QZBNGS2^ISR6[RQ]F]YB
MD+"WBX)&]/2$54S.9R^H.Z"[*9R^GR.2FO&B6[NI'32N#,IPM!<\DF@  1#N
MPW$]IRMYCW5K*Z"Z@CDEAFC/"]DC+*1S7-(W$$5"2,#R UCS'UGF]58*;4N1
MO;Z;3.0&(%W>2N9%?N="R"4.<7<#FEWI@5""(,GA]9VO,L8"]R!?KPY2*U&2
MDN7N_P#4'/;V<CKBA<*.H>.E0J)VUMI[GEH?E2_4><U7DO;['Y8^M/L\G/-&
M[%W44<;'.=YIJR=NSP/4$A]W+F;<YOE?E[S4]_-?9'2\MQ+>W5U(Z:=]H8S<
ML<][R2:4D8*]#4$5]WS4_,?F)S1;)E-2Y27 X]LV4O[,W<WJSJGABAX"[AX>
M-[3PT]%I0=GJ @("#Q+^*?\ 6GY2#&8'\FD^O^8$&606[;VT<_LVS,+SL J-
MZ#Q=$SR,LF'8[SYR.A@Z/*@N@   !0#8 @HW<QAB\S;,\\$3?JC\Y!ZMX1;Q
M-C&TC:YW6X[R@JH" @(" @(+.Y'J\K;QOH>A.!]*=Q\B"Z<ULK"QVUCQ0^$%
M!Z0$!!8W.,AN).UXBQQ]*FXH+J"".WC$48\T=>\GK*"H@C3O"_$AKSW'NON$
M6$EHB-] _&/S6]U<5^I;-%2%-=0P.#'DF1PJ&-!<ZG70(BTDGC<\7EN27P^;
M<1D$.X#U@]6]!D&N#FAS35I%0? 4'U 08O) ^O6'U_S6H,H@(" @(" @(" @
MLXOZU<F<_B8:LBZB[Z)WS$%KD[Z>*40PG@  )<-Y)04(+EYLKQW^VH"9.D\6
MSY'0BKS&6EL;.)[HFN>\$N<X G>>M$4)HV6N7M_5VB,2"CVMV U)&Y!F$!!Q
M5WQM6>NZOQ6EH7%\.$M#<3QLVDW5\0>&G21&R,CZY6!7L>[5ST?AH;)FJ[2#
M&2P<'M:,C?B%L4HJ8S&(."A#J.;2F]*C4.[=F9]&\Z;7&9#\ W*-GP=]$=XN
M&NXH:^*5G!]FDAWF@'<[LJUPJTQX\$'<1ZM$K [*YIXJ]S'++5&*Q;"Z]GQ=
MPVWAC&U[FQEW9M Z74X0/"N(Y%[K&N=.:-UID+?4ES'809BT;;6U_.0R)DT<
M@>&/>=C&O%?.)I4!61V%G=2:>RNG\]8XO+6=[>MQ=W.ZWMKB*:01")S>,M8X
MD-J0*J#D+NA_&I<>Y%U_30*R,AWT26ZVPQ::$8:H(WU]8G2!\Y^74QY-<J;;
MBI"!:-:VFYK,4\!H.^FP;/ $&YZ#8^3NAYUK!Q$6^3<0.ILQ)/D 0:IW0]3:
M>P&8U/!G,I;8U]Y;6KK4WDK(&/$#Y>,!TA:*CC::5K3Q)(T[O#XR:QYWY63)
M3OM;/(R65W!?M:7EMJ^&.,R,:""[@+'M !WM0;O!W;\;F<<V^@YMV-WBIVB1
MLKHPZ,MWCB#KS81U':"@M^9_*R70G(>QAQ69BU)B3J'VVFR-HP,@$5U:"U81
MPR2@M#XP.(.WOH@W?NI\Q=(6>BYM(9/(VV,S5I=S7+67<C(&W$,X:0]CGD!S
MFD%KFUJ  =R2).YPY3&9WDYK*;"7MOD88;.2.66TE9.QLD98][2YA(#FM-2%
M! /= U-I[ Y+5=MF\I;8V6\ALGVOKDS(&R"!TX?PND+02.T;LW^PK(UKO90R
M1<VI)7MI'<8ZTDA=T.8.-E1Y6D) F7G/S.T+F.0\UMC<U;7.0S=M91V5A%*U
M]R'QS0RR"2-I+F< 8[BX@-NS>0@T'NT?%OS9]SQ_A+Q!B>YWV9YF9/B +VX6
M<M)W@>LVP-/921G>^C9S-SFD\H[SK.6VN;.-U*AL['ME+:]!>W:!T\!ZD@8#
M1')'&ZWTY9YC'<TX+<RPL];QLL1;+:R\(XX7M==--&G8'<(#AM&Q!-/(3DU8
M<N\UE\YC]6VNI(YH/:Z:.RC:UL,H>R8A[FS2^=0#S=F]!/*@(" @Y4[Y. )9
MIC5,;=C73XRX=39YP$T6W[&1;)R7)MNL\?AYFD?=.&MMF3JF8]<>B7**V=H
M@(" @()7[N>K(M*<U,6ZZD[.PS#7XFX>30 W):82?!VK&#RK%\SP_4P33?&W
MP\38>0:F,.JBNZ_W?+N\]$X=[?0-QE\%C]=XZ(R3X/BMLFUHJ[U*9P+9/%&_
M?X'D[@L/RC41;?-D_I;N]L_W)HIRXHRV[[-_=/L<<+;'S<0$! 0$! 0$! 0$
M! 07^$PN2U'F+' X>$W&4R,S+>UB'2]YI4]36CSG'H JNO)DBRV;IW0[\&&[
M-DBRV*S=+] -17..Y-<F9HH)!3!XQME9.]%TU[(WLF. ZWRNXW4W;2M'QQ.I
MU'[4U\3ZUFOMT.D_8MI';.Z/++\\!6FW:>DK?'QX0$! 0=8]VF_]O^5>K]'N
M<#/CIS=V[?HN"YC#V@#^<A=[*U?FEO!FMOZ_#UOH_P!M9N/3W6=-L^:?QB7L
M&H!ZQ5=#9'U 0$! 0$! 0$! 0$! 0$! 0$!!LT^2]Z/);6^JCLGGMY;2UZ#Q
MO:+9A'V<M?(NF+>//;:[K-SAEC>!C6#;P@#V%LBOJ @(" /2;]<WY80=B][W
MXO-(^Z#/\)(L!RW^)=W>MREQTL^XB @(" @(" @ZYU#_ -&.,_N=E_CFK!6?
MSL^'0Y=#D99UQ"0-A-"@(.D.YG_QWJ/W(9_B6K$<T_AQWN4(;YI?&=K/W:OO
MZ=RR&G_A6]T(U-=Z" @(" @()3[N>G_?#SBT\Q[2;?%NERLQ K3U1A[.OCD<
MQ>+6W\.&[MV+#OZ+)2RY VG !%5P#MM2&@[?D+4G-DD! 0:#SJTA=:XY9Y[
M8]ADR;H6W-C&/2?/:O;,U@KTOX2P>-!R5W<>;&/Y8ZBR.)U1QV^!S(C9<7'
MYQM;JW+@QSV@%W"0]S7T%1LZBJ.QW<T.6[;(9%VK<1ZF6\0D]>MZD4K3AX^*
MO@I50<M=ZCF7FLCJ.TTCB+]\&E!8V]Z[U=[F,O77C3(U[W-IQQAA;PMW5J>J
ME@8GFQR>Y=\NN7>-RN/U _+:MR,L'8%LT1MYH7-<Z62*)C>(1C91SGGHZT&R
M\L_^E#7G][O/Z&T08KNB:JP& U+GL=FK^*PGREM!ZBZY>V*.1UN]Y<SC<0.*
MCP6CIH4D6O>TU?I_4NL,3C\%=PW[L1:21WMU;N$D8EFDXNR#VU!+ VIH=G%3
M?5('SG/JS5VDM&Z$Y7PW,^.MFZ?M+W,,C+HI)99R]O8/<*'ABX""W<2=NX(*
M6M.3W+K1W)VVU>W4+\EJ[)Q6<F.CCFB%M(^=['3-CB:TO(9&7U<Y^\;:;D&=
MY&_$!S7_ +M>?J]R# ]U#5FG],ZYR4&?OHL>W*6/J]G/<.$<)F9*Q_ 7NH&E
MP!X:[#2F\A)&5[WFMM-:@R^ Q&%O8+^7#174N0NK9[98F&Y,7#'QL)!<!$7.
M'14) UOFEA[_  ?(3E+89*%\%X+J::6&04<PW-K/,UIZB&NW(K<G?]&3?[[_
M /\ 5*(N>[1\4W,S^8F_P,J2-:[GOQFY'W&N/\1;I(UO75Q;8OO)W-_E'^KV
M%IJ:TN;N5U1P6S9XGR.V;1^#KM0=M2LT[S TOEM/Q7]OE,1?036+[JSECN&<
M,C*5#XR6\;.('P&B@X'Q.H<KRS;K_1%ZQ[+K*VLF%N&L-&MN+>Y:TN-:5:8S
M,T'ZH="Y#J#NCZ/]I-!76J+F/AO-1W!=$XBA]3LRZ*/?UO,I\(HI(Z#4! 0$
M @$$':#O"#Q'#%""V)@8T[2&BFU!2OMEG/\ S;OE(+.],<6#+W !K8F$>/8@
MNK&)[8NVF_*)J/D\&S8/(@ND%G;_ -9G==G\4RK(/]9WE07B @(/+WMC;Q/-
M&CI*#T""*C:#N* @("#XYK7M+7"K7"A'@*"UM'&)S[.0U=%MC)^BC.[V-R"[
M0$! 0$!!&G>%^)#7GN/=?<(L)+1$;Z!^,?FM[JXK]2V:*WMG^:R_S+?EHCS'
M0Y.Y#O1,;*UW(+>WR4%N70'B= UQ[-_4T]!'@166!#@' U!V@^!$?4! 0$!!
MCKK(O[0VMDPRW V.-/-:@IXF:ZDFN([EY>8Z#;N!J0:(,J@("#Q++'#&Z65P
M;&W:YQW!!BGYJ"Y:^*V):20PR.V<(=TTW[D5E8HV11MC9Z#10(BC=6,-W1SZ
MM>-@<W?3J08^>)MI;7=K3TFB2-YWN:"*@^)%7V,_((/K3\LHBTO?\WM/$/EE
M!ED!!S]K#NR8C4>LKC7V4U!?3W$F1BR4U@V&'LW1P2-<R N()[-K6-94>=0;
MU:B=+;(6CH(RZ9K'!H#FN-""!MWJ" <UW:<)J#F+=ZUQ&ILAC+J6\&5;#!#;
M/@BNPX2<32Y@?MD''M._P)49OF'W:\+S#UA=ZPO,]=V5S="!IMH8HGL9ZO$R
M(4+MNWAKM5J)O H .K8H('U[W5=$:ORD^:Q%W/IV_NGNDN8K=C)[1TCC4N$3
MBPM).\->&^!6H]\NN[7CN7EWD\BS45U?7&2QMSBI VW9"QL5UPU=P\4A):6@
MC:E1>\J.[UA>6.HG:HQV;N\A)+:R6@@N(HXP&2N8XDEG2"SJ4#G-R$Q?-O-6
M.2O,Y>8NY@M18QPVD<+VEC9'R.>XRM=T/I04W;T%SK;N_836VDM-:5NLO=6L
M>FC%V%U&R-SI1%;.MJ.:=@J'<6Q!M>@N6N*T/H@Z$,[\MBG^LMG-TQK>TCNR
M>-CFMV4(<0@AG(=S+3<^1DGQVI;RTQKW%S;.2WCGD8":\(EXV5 Z*LJK42[S
M#Y0:1YEXFUQ^H8Y1>V#."RRMNX,NH]@!%2"US214M<".JAVJ"&!W+<3V_$[5
M]P;6OXL63!)3Z_MB/]!6HGG3G+[!8#0EOR]F#\M@(8)+:5M_PO=+',]TC@[A
M:T4!=YM!LV=(JH(2S_<VTO=W4MQI_45WB;9Y+FVMQ V^;'X&N[2%Q Z.(D^%
M6HDCE;REQ'+W2N1T?+>39O%Y]TMS=,NVQMC+)H60/C#8PT@.8!6I*@C2^[F6
MFYL@^:PU->6N-<XN;:26\<\C6DUX1+QL!IX6*U$H\U.2NFN:MC9,R<TMCF,<
MTQV>4@#7/$;J<3)&.H'M)%0*@@[CM-8-!TWW0]&XF&^.9RMQF+ZXMIK>SE=$
MV"&VDF8Y@G$0<_CD97B9Q.X:]&ZEJ-NY?<A\7R^P6J,#99JZN[?5%L+6:26.
M)KH*131<;*5J:3?1;-B"TY7=W;!<L-076?M,Q=9)]U9OL'VT\<<; U\C)..K
M-M1P4\J@D'5.@-*:SP5QIW4-@VZQMP6OIQ.;)'+&:LDC>#5KFG<1XC4$A!SQ
M>=S+#^VI98ZNNX+"4E\<5S:0W#PT?0-?&^#:.LM*M1-?*;E/B^4V*O<9C,C=
M9'U^9MQ.^YX&M:]C>#\&Q@%*C?4E02"@(" @B[O#::.I^4^=AB87W>-8W*VP
M J>*S/&_V8NT"R/+LOT\]O;L\K#\YP?6TE\=,17R;?0_/=;T^0B @(" @^@E
MI#FDM<#5K@:$$;B"HL3,36'=G(GG%C>9NGVZ8U&^-VK[.#L+ZVG +<A;AO"9
MFM=L<7#\:SKV^B5IFOT=V"_BM^&=W9X=#ZIRCF=NKQ\%WQQ&WM[?:B7FWW7<
MQB[RXSG+: Y#"RDR/P8=_6K8G:6P\1_"QCH;7C&[SMZR>CYK;,<.79/6P/,_
MMZZ+IOP;8^7V>'E<ZW^/R&*N'6F4M)[&[8:/@N8GPR C9M:\ K/6WVW16)JT
MW)AOQS2^)MGMV+7B'6N;KH<0ZT*'$.M"AQ#K0H<0ZT*'$.M"AQ#K0H<0ZT*'
M$.M"AQ#K0H<0ZT*-ITIRYUQK:X9!IK"75XQY -V8S%:,!Z7S248/9KU+RYM5
MBQ1[TQZV0TW+M1J)C@MFD]/1Y=SLSDSR.P_*BSES^<GAO=621.]:R!\VVLX*
M5>R$OI0;//D=0D=0K74];KKM1/#&RWJZWT;E7*;-';Q7;;YWSU=WM<\]XGG'
M%S&S$. T]*7:0P\A<R;:!>7="TS4/T# 2V/QEW2*9WENB^C;Q7?%/FAJ//N:
M1J;XQV3[EOGE"*S+5A 0$!!./=4U(,-S.&(F<!;:@LY;2CMW;P_AX_*0Q[1X
MUA>;8N+#Q?++:OMO4<&IFR=U\>>-OM2KG\<<3G,ACJ4;!.\1UZ8W'B8?8(6'
MLNXK8E]"F*2QRYH(" @(" @(" @(" @(" @("#X30$[Z=""U[SN3&G.5NDM#
M1NX;K*3B\O&@T=V=JWM'!PZC+*W[5706\66Z_J>BE(HY+6=00$! 0"0VCCN:
M0X^(&I0?H5K_ $+I#G/I' V=UJ$6EC:NCOK>YLI('&3B@,=#QU%*.6JX<M^"
M^9X7/>C3_E$Y>?OG>_;6GWJ]G]2R?+Z4H?\ *)R\_?.]^VM/O4_J63Y?24/^
M43EY^^=[]M:?>I_4LGR^DH?\HG+S]\[W[:T^]3^I9/E])0_Y1.7G[YWOVUI]
MZG]2R?+Z2BY/<TT8UH>[5&3##N<6VP!KX>!<?ZI?\L%'QO<VT4\\+-4Y)SNH
M"V)^X3^J7_+!0=W-M%,/"_5.2:X;P1; _<)_5+_E@H^?\G&B/WKR/L6WWB?U
M._Y8*,YSHTM::)[M-SI2PN9+RSQ3+*WAN9N'M'M%XPU=P #IZ%UZ7).34\4]
M-?03N<Z\C>2UWS;R]Q+>S26.D<6YC<E=Q4$TTKQQ"WA+@0'<.U[Z'A%.DA9;
M5ZJ,-NS;=*1"<;_(=T31%Z[2-WC["ZN(7>KW]R+:;(]E(-CNUN*//$/HN FG
M@6-B-9DCBK/H78U/FYW>]+2Z2=S,Y/3B?#,A]<N<5!(;FWEM&CSY;5Y+G-=&
M 2Z,G<#N(H>_3:V_C^GEW]?M)A8]S(@ZZU&0:@XB,@_^9:N7-/X<=Y"'.:7Q
MG:S]VK[^G<LAI_X5O="-37>@@(" @("#K#N8:9=74^LYF$-<8</9R?0N#/P\
M]/$3$L'S3)\-GC<H=.'_ #YOUO\ J%8%S9=$$! 01#S%[N6@.85]+FGMFPV>
MG/%<7M@6ADS^ETL3P6EQZ7-X7'I)5$<P]RW#-FXI]6W+[?Z1EG&Q_P!L97#_
M $4J-^UQW<-)ZTP>#QK[^ZM,KI^RBQEIF"&32RVL#:,9.RC&OX=I!;PTJ4&J
MX[N=Z.M\3>VN0S5Y>9:Y#&VV0;&R%EMPR![BR'B<'%P!8>-YH#L%4J,IG^6=
MGRJY ZWT[8Y&;(VT\<UZ)+AC&.8Z1L,9: SH_!U0<_<@^4^!YL-U-C<O//9W
MEA%:2V%];D$QND?('AT;MCPX-'41T%!/^@NZCH_268@S>:R$VHKFT>);6VFA
M9;VHD::M<^,.D+RT[@7</6"E1NW-CDQIKFS:VIRDLMAF+ .;9Y.W#7/$;R"Z
M.1CMCV5%0*@@[CM-8(WP_<[T?9V5[%ELU=Y'(7$1BM+EL;;>.W<2#V@B#G\;
M@!0<3^'P5I2U&ZZ.Y#XS1VBM3Z)M<U<W%GJ>-\4UQ)%&'P]I$87%@&PU:>E!
MJ=MW0]$1X*]Q5QD[N>_GECGM,KP1,FM^!KFEE!4/8^M7-/4*$)4?-'=T71F!
MRD>2U%DIM1L@=QQ6$L++>U<0:CMF!TAD'U/$&GI!&Q*B0>;G*'&\V[+%V61R
M4^.CQ<LD\9MV,?QNE:&;0_J V'PE08\\C,4>4PY3>VUS[7";M_;'LX^VKZSZ
MS3A]&E=BHJ<ON2.+Y?:8U%IBRRUS=P:BC?'-<2QQM?#QPNAJP"H)HZNU08_E
M5W?,/RKU%/J+'YFZR$T]I)9.@GCC8P-DDCDXJMVU'9JBCS5[N&F>9F9.I(\A
M-A<Y*QD=Y-#&V>&?LP&L<^-SF'C#0&U#]P&Q!=Z0TAI?N[Z'O'Y;4+3CO7W7
MTV1OFMMF!T\44/8L:TNK7LN)HVDN<5!REJN:/GSSH?[S,>^TAS4\4#9)6^>8
M;=@9)>2M!HT<#>/AWTI7SBJ._,)B+'3^'L,'C6=GC\;;Q6ELSI$<+ QM3TF@
MVE074\[8&M)!<Y[@QC6[RX^-!\AN!*]\98Z.6.G$QU-SMQ!!(*"L@(" @\31
M":)\3C0/:6DCPH,2^TNKUPL7S,-G;T$CFM/$YPW#::;$5F    -PV!$6UX]S
MN&TB-))O2/TK!O*"X8QL;&L8*-:* > (/2 @(/$D8D;PDD4-01L((0>FM#6A
MHW 4'D0?4! 0$%K>1NHVYB'X:'S@/IF](07$<C98VR,-6N%0@]("#X2 "2:
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M_<\TC826^<UQ<1MER$<PQ5BYP!,+!&V69S>HOXV-KU CI*UCG.::VV=&]O\
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M\,<#G[S'!M+</[:U/7#+YS?8VM\BP>*_BMB7T6Z*2PR[$$! 0$! 0$! 0$!
M0$! 0?6,DE>V*)I?-(X,C8-Y>XT \I*"P[T>H8]+:)T[RKL)*75_PY#+\)H3
M!;NJT'H(DG)/V"Y<OLX[[LD]T/12D4<G+.((" @(" @(" @(,WI[66KM(F<Z
M5SEYA_6N'UEMG*6-E+*AI>TU:2*FAI5==^*R_P"*(D9[X:.;O[[97_>L^\75
M^5P_+"GPT<W?WVRO^]9]XGY7#\L!\-'-W]]LK_O6?>)^5P_+ ?#1S=_?;*_[
MUGWB?E</RP+3)<U>9N9L9\9E=792[QURTQW-L^?A9(QVPM=P!I(/2*KE;I\5
MLUBV*CI7E#EM"\V.23.4&=R0QF9LHO4Y(&R,AN'-CF[:WN+<2 AXW!S17:"#
M2H*P^IMR8<_U8BL+&Y;?\F6G/WWO/S:V^>K_ %2[Y"CR>Y?IEQJ[6MV3UFUM
M?GJ_U2[Y2C[_ ,F6G/WWO/S:V^>I_5+OD*-QT5R_Y<]VVTS&J\OJAUS/=P-A
M=+=F&-QBB=QB*""/:][G'HKT;EY\N;)JIBV+3<XIU)FGZDU'F-12Q]B_+WMQ
M?&'Z07$CGAOD!HMCLMX;8MZH<6+7,$! 0$!!V#W.M#&TQ&7YA7L=)LH_VMQ9
M((/JELZLSQT$/E\VOU"P',\U9BR.C;+E#J)81R$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!!2GMXKEG9RMJ-XZ"#X$'BVLX+6IB'G'87'::(+A 0$! 08?4+&OM
M8V/%6E^T>0HJ\M,?;0<,K&DOX10N-:;.A$4\M#+-"TQ@NX#5S1OI3>@Q^-8Y
MMVU[SV;6 N<7>;4$4Z45FQ<VSC1LS">H.'ST150$'QSFM!<X@-&\G8$'EDT,
MI(CD:\C?PD'Y2#V@(/,A>&.,8!>!YH.ZOD0?020"=A(VA!]0$!!3G8Z2&1C3
M1SFD ^$A!K4<$TK@V-A<3N(&SV45L[ 6L:TFI  )ZZ(CT@(""-.\+\2&O/<>
MZ^X1826B(VT9$RYY@<RXPT&WCR^/=*ZGIR^TEB.&O4T='ST5(T4,4(+8F!@.
M^B(]H" @(" @(" @(" @(" @(" @(+.X_JT[;L?BWT9/XNAWD04G]I*;R0RO
M88"1&UIHT48';1TH+VW>Z2"*1WI/8UQ\9%4%1 0$! 06MZ96L;)'(6-:Y@+0
M-KN)P&T]6U!Y/]:N^'?!;&IZG2?]B"\0$! 0$%+L:7';BFUG >L[:A!50$!
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MH':S_P O+_O'_/0.UG_EY?\ >/\ GH':S_R\O^\?\]!Y<Y[Z=I(]X!J ][G
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M'$[+:T!J*_\ S'GSY#U[-P"SNGP1ALX8\;L:0O2@@(" @(" @(" @(" @("
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M0@L[4FWE=9./FCSX">EAZ/(@O$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MW=#G$-\7E40$! 0$! 0$! 06K,A:RW'JT;N*3;M \W8*[T%T@(" @(" @("
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MZ!W$/'0CYJ#T@(" @M)\C:P.<PNXI&U\T"NWJJ@]6<19&97D&:;SWN'AW#Q
M(+E 06>2:&X^8-  IN'C""M:?DL'\VS[D(*R @(,9<V<L_;37;ZQ1AQAA;L%
M #0GPH*F'_R^/QN^Z*"_0$!!CB^/&SO#C2WG)D &TM?T[.HH+V&>*X9QQ.XF
M[CU@H*B @(+2]M[BZ+(HY.RMS7M2/2/4 @L!;Q6N7MHH11H82>DDT=M*#-("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @U_6>B]/:]P,^G=26OK%A-Y
MS'M/#-#*WT98GT/"]M=A\AJ"0N[#FOQ7<5L[7FU.FQZBR;+XK$N!.:G*?4/*
MO->I9(&ZPMRX^U>88TMBG8-O"X;>"4#TF5\(J%NVDUENHMK&R>F'ROF?*\FC
MOV[;)W3X=+05[V&$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 02IR:YTY7E
M;D76ERU^0T=?/KD<96KHW.H#/!Q; ^GI-W/&P[:$8S6Z&W/%8V71TM@Y3S>[
M27<-VVR>CJ[8=*9O3N)S>)CUOH&=F1TY>-,SXK?;V?TQ8W> #7CC(JP]'5K=
MM]UEW!DV3#Z59?9ELB_'-;9:6""*C:#N*]"OJ @(-CTGI"\U-.9G$VV&@/\
M6KT[!YNTLCKL+J;SN:NG+EBSO<K;:HOYY<^;*:QEY9<K9?5].0AUOF,U;FAN
MNA\%N\;3&?\ :R[Y/1;YM2[V:31S$_4R;^B'=V0YM #0 !0#8 -P"S"" @("
M @(" @(" @(" @(" @(" @(" @(" @(,GI[3N;U9FK73VG+)]_F;UW#!;Q[
M /2>]QV,8T;7/=L"X7WVV6\5TT@=]<E^2&$Y3XPW$KF9+6-ZP#)9?AH&@T/8
M6X=M;$T_9/.UW0!JVJU=V:>JWJ<XA)K[&"2Y]:E'&\ -:T[A3;\U>%6/NO\
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M!]M)'2VT;WGB<0:NZZ&E4%= 0$! 0$'@2M,IBV\0%:]'_P ;4'M 0$! 0$!
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M" @(" @Q]N]K,C>AY#2[LRT'94!O0@^VK@_(W;F'B;2,<0VBM$%^@(" @("
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M?)AI<+P%PV\'9M \54%3'7;KRW$CQ1[26NINJ/\ \T%V@(" @(" @(" @("
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MJ"Z0$! 065Y^567U[ON4!_\ FD/\T[Y807J @(" @(" @(" @(" @(" @("
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M&Y6]O;VD38+6)D$#!1D430Q@'@#: +RS,SO>^(B-RJHH@(" @(" @(" @("
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MH" @M+VPBO>$N)9(ST7MWH*'M?? <(OW\/UNWY:"M9XZ*T<Z7B,DSM[W(+Q
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M-] _&/S6]U<5^I;-%20B" @(" @(" @LS_6KNF^"V.WJ=+_V(+Q 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>9&=I&^
M.M.(%M1T5%$%FZS@L[*=L3?.,;N)Y]([$'C"_D(^N<@R* @(" @(" @(" @(
M" @ISQ=O"^(GAXQ2N]!40$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 06\E
M]:0R"*24"0_0[3O\2"X0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!XE,HC/8 &7<WB]$>$T06U
MBZ8NN&32&5T;^$.(IT [ $%X@(""E;V\=M'V4=>&I.TU-2@JH" @I7':=BXP
MDB0"HH 2:=&U!50$! 0$! 0$! 0$!!&G>%^)#7GN/=?<(L)+1$;Z!^,?FM[J
MXK]2V:*DA$$! 0$! 0?'.:P<3B&CK.P(*%U.8H@(]LTAX8AX3T^1![MX6V\3
M8F[:>D>LG>4%5 0$!!9R9.TC>8P7/>WT@QI=1!Z@R%M</[)CB)?I' M/R4%T
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(""C>?D
MD_\ -N^4@M,+^0CZYR#(H" @(" @(" @^.<U@JXAHZR:!!Y;+&\T8]KCX""@
M]H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(+&^-Z]S+>T'"'@F27Z
M4>-!BKRR9926K0XOD>ZLCSTFHZ$5L:((" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @MK:%\<MPY
MXH)'\3-O10!!<H" @(" @(" @(" @(" @(" @(""-.\+\2&O/<>Z^X1826B(
MWT#\8_-;W5Q7ZELT5)"((" @(" @ISQ=JT#BX2T\0-*C8@M;-@E?ZQOBC'96
M]>H;"[RH+Y 0$!!YD)#'$;P#3V$&.P8'J;G4VEYJ?($'G(^;D+%PV.+J$^"H
M^>@RJ @(" @(" @(" @(" @(" @(" @(*<TO8QE].(U #=U2X@#Y:#Y#*90\
M.;PO8[@<*U%: [#Y4%5 0$! 0$! 0$%&YN([6%TTFYNX#>2=P06<=YDYVB2&
MU:(W;6\3MI'LA!Z@R,GK M;R'L97>@0:@H,@@(" @(" @ISQF6&2)IHY[2T$
M[JD404<?:OM+<0O<'.J35N[;XT%T@(" @(" @("#$F-MYEY8[@<<4+!P,.ZN
MSYZ#YE+2WM[<7%NSLI6.'"YFS>@RD3B^-CSO<T$^4(/: @(" @(" @(""D97
M"X;"6>8YI(?7I%-E/*@JH" @(" @(" @(" @(" @(" @("##9K\HM/&?EA!F
M4! 0$! 0$! 0$!!XE<]D9=&SM'CT65I4^,H*-E--*)1/P\<<A9YE:; #T^-!
M<H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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ML3XC.7T_"2N>VG40!\Q!<(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @("#P]SVNC#15KC1QZ0*$H/: @(" @(" @L\G/)!9O?$
M>%Y(:'=52@HW=L;:V?/%/+VL8!!<\N!V](.Q!D(W%\;'G>YH)\H0>D! 0$%.
M&43-+@TMHXM+7;Z@TZ$%1 0$! 0$! 01IWA?B0UY[CW7W"+"2T1%^@;VVCU]
MS.[=Y;<NRV.9+LJT\&'M ' C=7T?)7I14H @BHV@[BB" @(" @MI[^VMW\$C
M_/Z0!6GC0>;)ID#KM^V2;:.GA8-P07: @(" @(+#VL[-[G6L[X&O-2QNUM?
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M;/2;7PA!FT!!RSWJ_P#B[0O_ -7^GA5A'0.I.8.B=(2-@U)G;3'W+QQ-MY9
M9N$]/9MJZGAHHJ\T]JS36K+9]WIO*VV3@C($IMI&O<PG<'M])I/U005LWJ+
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M-"X/BD:'L>TU:YKA4$'J(0:WJ/F'HC24PMM1YZSQ]TX<0MI) 9^$[03&WB<
M>@T07NGM6Z9U9;ON=-Y:VR<,9 E]6E:]S"=P>T><VO1Q!!"7>]_X(P?NJ/\
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M.G:^K2MD<RN[C:#Q-K]4$'G46K]+Z2A9<:ERUKC(Y=D0N9&L>^F_@9Z3J=-
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M5]O=2-C/ R1K-@:WZ%$='22,B89)#PL;M)*BOD<T<O%P':TT<"""#OV@H/:
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M$'4RBB#EG-[.]]CJ[/Q&_P!S7*HFGG7CKG*\JM4VEHTNG]2,X:W:2VV>V9P
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M_P",F21*5U$Z>W?$P@.<!2NZH-5!\@CD;)++( TR%M&@UH&BF]!70$! 0$!
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M,P5=&\$/8\ TKPO:UU.FBBH'T/RU[P>@+B+3^&S...DFW;9I"]S9&]D7@R<
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MQVJ"%-.<M^\MI6U]ZN$U+8V^GF$LAN7O9,(HW$DF+M8'2MW^B-@.[K51D?\
MESS&,U7I'4F)RD%]=XR[CR&ILCD9)A=7EP+ALKW,:&R"G".%H+QMWDI4;AWA
M.7N<YCZ0LL/@KBUMKFWOA<R/O7/9'P=A+'0<#7&M7A14@:.QT^(TG@\3<N8^
MYL+"VM9G1DEA?#$UCBTD TJ-B#FSO+V-MD^;&B<;>M<ZSO(;:VN&L/"XQ37S
MF.H>@T.PJPC:QH/O":)B."T)J:TR>F(ZLQOMD(S=VT5?-83+$X>:* 4<6]36
M[D&1Y;\B<EBM4'F#S(RPSVK^+M;=C"Y\$,I;PB1SWAI<YHV,:&AK.BM!154D
M<P= X/F-IV;3V;:YK2X2VEW'3M;>X:"&R,KL.PD.!W@^500WA]!=X[0-K[W]
M*9[&Y33\=6V3KNG% T]396$M^L#WM'0JC-Z$Y#Y*'5#>8'-',#4.JHWMFMX&
M5=;12LIP/+G-9Q%GT#6L:UIZ]E%5;?S1P',[+^U5[RVST.(NL>Z5]S:W%1'=
M=H&AH=5DC"&@.HUS.FM5!&F9Y?=X;F-;-T]K3-8W%Z;>]CKT6@#GS!C@X59&
MT%]".(-<]K:[>@*HFS#:'T]AM&0:#CM_6-/QVKK.:&;:9F2U[5SR*><]SG.)
M;3:=E%%04SDWS8Y:9NX=RAU)#)A+QW;.Q.0(#@-WG!['Q/(V#C;P.HK4;!A\
M1WE,CJ#&^^/4&,QV(M9XKJ[MK9K#)<11/JZ,]G%6C@.$CC&]!/"@((=YN\HL
MKS(U9I3),DLSI[$/IEK2YDECFF@?,Q\C8^S8[>QI JYNU4:Z_ESSVT'VF)Y9
MZEM[[2?$XV%GDA&ZXM6.)(8#-&]M!7Z%U#OX0B+KE_R'S;-5LY@\U<LW.:DB
M<V:TM6.=)%',ST'O>YK0>S^@8QH:T[=J55+.N-'XW7FE\AI?*DLMKU@#)V"K
MXI6$/CD;7I:X TZ1LZ5! &GN5G>+T&V73VD-16+=/R/<Z*65S7QQ\>]S8YX)
M'1D[W-945Z]ZJ+K/=VK4-V<-EK;-PY35PO'7VH\ME))F]M3LNRCA#6R>8SA<
M/.H37H%&A42USAT5E.8&A;S3&&F@@O[B6WD9)=N>R("&5KS4L8\[AL\U15QH
M'2.2TMRWQ^C\A+#)D[2UFMY)8"YT!?*^1P(+FM=2CA7S4&I\A.56H>5UEF[;
M/W-G</R4MO) ;)\CP!"UX=Q=I''],*45D6?.[DSF==9/%ZOT??1V.J<4UL;1
M,YT39&Q2&6)[)&AQ;(QQ-*BAKO%-H;-RNM.;UN;]_-&^L[J-S(68V.U$8D:Y
MO'VCGF*)@/$"WI.[<%!(R""N<?)?4FI]4V',#061CLM3638FR13.,0<^W<3'
M+&\-<.( \+FO'"0!X:T;QRSM.:,5ED/A2N[.[N)71BPCM&QC@C#7"0/[.-C3
MQ&G7TJ"-<MR'UCH_4UQJODMFXL8VZJ9\-=U$0:3Q&-I+9&/97T6O:"WH<K5%
M#(\J.=G,Z6"TYF:BM,=IN%[9'X_&@.<]S>G@:UK2>ISWNX>AJ">=-:<Q&DL'
M9Z>P4 M\98L[.&/>XDDN<YQZ7.<2YQZ25%95! _-_D9FM2ZFAY@: R+,;JJ(
M1FXBD<Z$22P -CECE:#PO#0&D.'"0!M&VM%IC^67.C7)MK'FWJ6-FE(7L?=8
MBQ[-LUX(R"&2NMXXV\)(%27.\ !V@C9N27*O.<LKK4XR<UE)89>>&7'QV;Y7
MNCCA,WFO[1C:>;(VE"?&BK/X(]2?#S\*/K5E[05_)N.7UNGJ/JWH]GP>GM]/
M<@FE00ORRY1ZDT7S+U3K+*75E+B\WZYZK%;OE=.WUF[;<-XP^-K11HH:..U4
M-9<H]2:AYR:?YAV5U91X;%>I^L03/E%R[U65[W\#6QEIJ';*O"#>.9/+K#<S
M-.28'+.,$K'">POXP'26\[00' &G$T@T<VNT=1H1!#."Y?\ >7T9"-.:=U%C
MYL#%YEI/<N;*V&/HX1- ^1H'T@XFCH51''._0,^BKG2]UF<G+G-6YR:YN<WE
MI2>%[HG0-CCB:?18P.(\/@%&BCLO/83'ZEPE]@,K&9,=D8'VUPT&CN"04JT[
M:.&]IZ"N*N;\-R>Y\<MKZ[LN7>H+23 W<A>#.6!O0 ]\$T4@:^@%3&36GD51
M=ZI[MVJ]2X+U_*:@AS',>ZNHY+S)7LDL=I#91QR#U>!K(W'TW-=7@:-E !TJ
MB?7Z>M,GI5NF,_#'=VDUDRROXA7LWTC#'<)V$;15IWC?O45 ]MR:YP\M+ZY/
M*C4L%Q@+EYD.-R)#7 G8.)CV/C+@-AD86$TW*HV33^![QU_G<9>:JU#C;'!V
M=S%/>6-JQIDN(F.!?&>SB&QS:C;)3IHBLUSVY:YWF=IW'8C W%K;W-G>B[E=
M>OD8PL$3XZ QQR&M7#H02!IK&SX;3F'Q%TYC[G'V5M:3/CJ6&2")L;BVH!H2
M-E0H.:.]=88[+:HTGC<2#/K2\8ZT=:Q4+G6\TH;;AW43(Z0-\JL(Z+T/I:VT
M7I+$Z8M:.9CK=L<DC1023'SI9/LWESO*HK8$$5\]N6N<YG:<QV(P-Q:V]S:7
MHNY'7KY&,+!%)'0&..0UJX="HW_3.-GPVF\/A[IS'W6/L;:TF?'4L,D$+8W%
MM0#0D;*A019SKY1ZDYCY[3>4PEU96\&'X_66WCY6/=Q2QO' (XW@[&G>0J,_
MSFY40\U-/V]G#<MLLWCI'38ZZD!=%^$ ;)'(!MX7T;M&T$#?M!#0\1I'O,S8
M^+2^0U+C\;B(F"W?F(Z3WW8-\VD;FQM<74W.<6N^JJB,ARXY%9+EUS-NM1X^
M[@GTI)9NM(&32O?D"Z1D3G/>.R:S;(QQV.W%%7G,GE'J36/-#2^M<9=646*P
MOJ?K4-P^5L[O5KMT[^ ,C<TU:Z@JX;4$TJ"%](\H]28'G/G>8EY=63\+D_6^
MP@B?*;D>LO8YO$UT8:*!NVCRJ)H4$+\C^4>I.6N5U'?9VZLKB++]CZN+-\KW
M-[-\KCQB2-E-CQN)5%3FKR-.L,S!K71^3]H-;V_ 3= N;%.Z(<+'.='YS'M
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M8QOFL;X:<-1/:BB @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M,\LL.>+):BO(Y9HQ_)M>(H6N^I=(XN^P2!K7>=PUII?#<N;.P;PVF'$]I":
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MN (%S<-9#&ZAW\+GAQ'@0:'R'GY38# >^?5^=Q<^N,O++<74F1FCDN+=G:.
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M)?Z@VY+V.)MG/CN(V4<VI'FO Z14[@DHZ$^ KE)^ZMI]M+]^E59S':0TUHW
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M+VY]KO:3A_JWJW;]KPS"7TNU9P[J;BJ)34$6:<Y-^T'-/+<R_;GUCVT]9_\
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M5.1N@<YRXT;-@,_);R7LE]-=M=:/=)'V<D<30"7L8:U8>A426H" @(" @("
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MQC\UO=7%?J6S14D(@@(" @(" @(/+&"-C6-]%HH*^!!Z0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0"0!4F@Z
MT'CMH:T[1M?&$'M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M]8<:HBUQ<DD%[-8EQ=$WBX*]!:?FA%9E$$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%EE87S63VQBKA1U!O-#M06]AD[1EK'
M%*_LY(QPD$'H\2"WR=S'?F*VM*R/XJD@$#JZ45FV-X&-9]* /8"(](" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @("#$Y#_ #2R\8^Z099 0$!
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M1Q]7G4\7$:?(072 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(""E<3B!@(8Z1[CPL8T;2?F(*5C<RW+)3*T,?'(8R&[?1H@ND!
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M1H/._G!RLSO*+6>'P^L<3?92\Q5Q#:6=O=Q232RO;1K&,:222=P"+#H!$$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
)0$! 0$! 0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>pc_unlocking-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pc_unlocking-4c.jpg
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M%!04%!04%!04%/_  !$( LD#MP,!$0 "$0$#$0'_Q #@  $  04! 0$
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M3(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @C.^_P B5/GG _IBF@=.?W>[
M3^9L=^*QH),@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("",[[_(E3YYP/Z8
MIH'3G]WNT_F;'?BL:"3(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @C.^_R
M)4^><#^F*:!TY_=[M/YFQWXK&@DR @(" @(" @(" @(" @(" @(" @("!V<3
MV(" @(" @(" @(" @(" @(""SOY?%8H1G*7J](2ZB(V960AQ;IKR\Y&NFJ"X
MKV(+4,=FK*R>O*T/BFB<'L<T]A:YNH(05$! 0$! 0$! 0$! 0$! U&NG>.U
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MX<ULC0=!V\#HJ4I>@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M5E;X\;20V:N7#Q(GCO:\</ICB I'Z/7LQBL73&1RMV"A1/+_ 'BW*R"/5PU
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MMEM-@$0$+"\ZEDKSQ X<%.@VZH! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$!!&=]_D2I\\X'],4T#IS^[W:?S-COQ6-!)D! 0$!!QQN7W8NI.
M7W)F,K5DQHJWKUFS#SV7AWAS3.>W4"(Z'0\5.J&@KU.;'7K./L<IGJ2R02EA
MU;SQ.+3H>\:A2-P8_P!U_J5DL?5R5:3&>SW(8[$(=9>'<DK ]NH\(\="FHV]
M[R.9FVSTDPNTGO R&4-6I8:P\##0C;)*0>!(\01CX"H@<G.V]D&[:CW46CY*
MDO/QC7?7>T1PLG(^#E>%(ZU]TO<WRCLO);:E?K/A+?B0MU[*UT%X '^D;(?C
M42)E[P]GV;H]N0Z^E(VK$/\ XEN$'Z6J0EP1'6GEAFGC870P<IF<.QH>>4:_
M"5*';'NK[@^5NFGR5(_6?"7)JP:>)\&;2PP_!J]X'P*)2Y>ZJYF?>O4S<N3J
M:S0MGF9 1V>R8]GAAX\@Y(^=2A(/=GF\+J_AV??H;D?_ ):1W_LI([P5*7,_
M7O873_<N[VY"YO:EMS<8@ABOT;H\1KXP#X<@T<TM=RG33B"-.SOF$-F]+H=A
M[$Z;-=AL_#D-NT))9<AG'.#8G6'.'B$@:AH&K6AO'AIQ)XHE(L+U)V'N.[\F
MX/<%*]>Y'R^!#*'.\.,:N=\ ':H&)L];^E%2^<;/NFG[4UQ8XL\22$.!T.LS
M&.C_ *R"<U;=6]6BN49X[-2=H?#8A>V2-[#V.:YI((/E""L@X=Z_=8,EO3<-
MS;6(LNAVAC)75VQQ.T;<FB.CY9-/6;S#[F.S3TNTJJ$/.P/=LW?OC Q;BEN5
M\/0MM\3'MLM?)-,SCH\L;IRL=]:2=2..FFA+40#=FU-T]+]T_)>2<ZEF*G)9
MIW:DC@U["3R30R#E.FH([B""#Q0=E=!NJ4O43:$KLS(W_$6$+8,I( &B6-S2
M8I]!P'.&N#M/KFD\ 0%$I2>CU8Z;9.[7QV/W/0L7K<C(*T#)07R2R'E:UH\I
M)T"@4\]U?Z:[8R#\5FMQU:^1B=R35V>).Z-_V,G@M?R$=X=H@DN$SV%W)CX\
MK@+\.1QTA+6V*SQ(SF':TZ=CAW@\0@O+-JM2KR6KDT=>K$.:6>9PCC8T=[G.
M( 'PH(!;Z[=)*4YKS;JJND!Y=86S3LU_EQ1N;\>J:"88#<>#W3CFY;;UZ+(8
MY[G,;8@.K>=G:TZZ$$:]A01S.=8>F6W+3Z67W+4CMQGEEAA+[+V.\CA V3E/
MF*#([9ZA[)WDYT>V<Y5R$[1S.KL?R3AOE\*0-?IY^5!K[WH_W3VO^=J?]\J8
M'/GNQ?O<QW_*W/\ 8N4RAW#D,CC\34ER&4M0TJ,(YIK-B1L43!Y7.>0 J4H%
M)UYZ11V/9G;IK&373F;'.Z/_ %C8RS^LIT$XQ.9Q.>HQY+"7H,A0E]2S5D;+
M&2.T:M)&H[QVJ!<V;5:E7DMW)F5ZL+2^:>9PCC8T=I<YQ  ^%!!8NMW2B:^,
M;'NJE[2YW('$O;#J3I_;.:(_CYT&2RO5#I[@[\V+R^XZ5/(U^7QJTLH#V\[0
M]NH\[7 H/F1ZH]/<1+##D]QTJLMB"*W V63EYZ\[>:.1O#BUPX@H,KM[=FVM
MV036=M92ODX*[Q'.^L\/#'D<P!^$(,7E>J'3W!Y"?$Y?<=&GDJI#;%:64->Q
MQ < 1\!"#.83.X?<F/CRV"N1W\;*YS8[4)YHW&-Q:[0]^A&B#(H" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @((SOO\B5/GG _IBF@=.?W>[3^9L=^*QH),@("
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MYV-QG.ULGF?.\-<!Y0U@/VP34=,5,=3QV.BQ>-@95HUHA!6KQ-#8XXVMY6M
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M @("",[[_(E3YYP/Z8IH'3G]WNT_F;'?BL:"3(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @C.^_P B5/GG _IBF@=.?W>[3^9L=^*QH),@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @("",[[_(E3YYP/Z8IH'3G]WNT_F;'?BL:"3(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @C.^_R)4^><#^F*:!TY_=[M/YFQWXK
M&@DR @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @("#GKJ?U!WYF^JM+I'TYR&,VYF,.RGN&Q?SMB:"/*Z./+C
MX8X6ETD3]1XW*>;0. TY>)+8.XG];K&"P,&UH=N4]R6(W'<MR^^W/3JR-8T@
M5(XPU\H<XN&LCAR@#@=> :XQ_O![MQ?3;J/F=U8&M<WMTWN_)=V+$.E=CK<D
MCFQLG:7ZO8QA<7S-[0T:^CKHT:,CTZZI[_N=1L=L;=5O ;FI9O"G/0Y;:PF$
M=#1V@CG\220&)_9$_P!%Q/<@U'BNN762/8,74]V]L-F,B_*''0]-?DV%EVXT
M6O9^6N^O(;!>6ZR >'P:"=3WDZ)[O_KSO+876J+'WX8STKI4,98W-&8V&S0&
M6D=7;9,@](MBF,8>!J-#H!J041HV'MO?>?RO7?=VQY;,,NUL5AL=D,=''&WG
M$MO3G<91Q<#KP[D&UD0(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M""QLY.*M/X+FEVFG.1W:_P *"M[=4^_-^B@>W5/OS?HH'MU3[\WZ*#X_(5&-
M+O%:[0:\H.I/P(/-.^RX7-#2QS>.AX\$%V@(" @(" @(" @(" @(" @C.^_R
M)4^><#^F*:!TY_=[M/YFQWXK&@DR @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#FGWE;VV;EB+;V\>E^0S
MUC(.@Q6R]T4):T3GY>\USHJ[9_$9+#H]NNC@YKM"2W3M)A\S^Y>MO2WHQM+9
MV/P65W/U,MTWP9+/4*K\K%C(FR>L\MU$UAD;VLC#G<KG,+BX@:.#!U</N.QT
M!W/L_I3M;=6#W#'-#9SEO<]1F-RV=]N>3?D@D,LH=*YC.4ZG@W1HU<42J]+M
MIMAZO[=SO2C8V?Z?[*JXZQ6WU%GX9:,-Y_A:5(HX9Y'NDECD/,Z5O#S]O,&I
M]O;'R4G3C_">)Z4[BJ=<6Y26QB]Y>P28J&G_ 'P2,E=D7OCX-CU:&]GD\J#?
M];IUE=P]:]S4][XV:_MS,;"IX7)Y@0NCIV;GC,\812:<HDU!D:!Q;IKPX(AA
M/=VV5U$VAU7W70WK1G?0P^%I8'#;A,#HZV0IT9G>S/$GJN>("QK@"2WET/$(
M2ZB1 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(+!M6&[(;4K=6D
M@1#LU:WO/P_P(+[0>1!]T'D0-!Y$'E\;'M+'M!:X:$(+2*".C. P?<9O1U/$
MAX[!KY"@O4! 0$! 0$! 0$! 0$! 0$$9WW^1*GSS@?TQ30.G/[O=I_,V._%8
MT$F0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 04IJU>QX?M$3)?">)8O$:'<DC>QS=1P<->!""J@(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(+:R3*YM1IXR<92.Z,
M=OT>Q!<    #0#@ $'U 0$!!XEC;-&Z-W8X=H[0>X_$@\5Y7/86R?VT9Y9!Y
MQW_ 1Q05D! 0$! 0$! 0$! 0$! 01G??Y$J?/.!_3%- Z<_N]VG\S8[\5C02
M9 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$'F1[8F.D>=&M&I/P(*59C@'32#264\SAY!W-^((*Z @(" @(+:?[C(VT
M/4X,F'VO<[XC])!<H" @(" @(" @(" @(" @C.^_R)4^><#^F*:!TY_=[M/Y
MFQWXK&@DR @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @("#X2&C4G0>4H*$E^E%Z\[ ?)S GZ 573(MGYS',[)"_^2T_Q
MZ*>B1;OW'5'J1/=\.@_C*J^7(H.W*?K*_P!%_P#V*?EBD[<=H^K%&/AYC_&%
M/RX%,[@OGLY!\#?JE3\N!X.=R)^O:/YH4]$#Y\N9+[Z/Z+?J)T0/GRUDOOW]
M5OU$Z('WY<R7WT?T6_43H@?1G<B/KVG^:$^7 ]C<%\=HC/PM/\14?+@56[CL
M_70L/P:C^,J/EP*K=R_9U_C#_JA1\L5V;BJ'UXY&_!H?XU'RY%PS-XY_^=+3
M]LTC^)4]$BYCNU)?[.=CCY.8:_05/3(K]O$=B@$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$&*COB[9C@<WEAYN8#M+BWB-?,@RJ @(" @("#X0' M<-6G@0?
M(4&,J9 -F;3+2Z,.+&//K::\-0@RB"QO9'V1[8PSG<1S'4Z#3L05&7ZSFAVK
MAJ-=.1Q_@"#U[=6^R=_0?]1 ]NK?9._H/^H@^&_6 )U=PX^H_P"H@HT\E[5,
M8C'R\"6G77L\J"_0$! 0$! 01G??Y$J?/.!_3%- Z<_N]VG\S8[\5C029 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%&:Y
M5K_VTS6'R$\?H=JF(F1CYMP4F<(P^4^8<H^G]15QCD6,NX[#M1#$U@\KB7'^
M)5QC@64N7R$O;.6CR,T;_ JXI M7R22'61[GGRN)/\*JT'A 0$! 0$! 0$!
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MSOO\B5/GG _IBF@=.?W>[3^9L=^*QH),@(" @(" @(" @(" @(" @(" @("
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M>V#[S-_JR@>V#[S-_JR@\RW@R-SQ#+JT:^DP@?&4%#'V77)WR2M]-C0&:>J
M3Q^,H,D@Q$MYT]H5',T@\0-<!ZQT/?YM4&70$! 0$! 0$&(]N=5MOKL9K#S^
MJ>T%W;IYM>*)9=$" @("",[[_(E3YYP/Z8IH'3G]WNT_F;'?BL:"3(" @("
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M8=_P'M05D! 0$%*Q+X,?,T<TCB&QM\KCV(/L$0AC#-=7=KW>5QXDH*B @("
M@((SOO\ (E3YYP/Z8IH'3G]WNT_F;'?BL:"3(" @(" @(" @(*<\O@QEP',\
M^BQOE<>P(/D$7@QAI/,\^D]WE<>TH*J @(""VF^X2BR.$;M&3?!]:[XNQ!<H
M" @Y9WS@MV=#\UO?JO@H,/O/IUGK;;V[<'D^6/)UGE[6/;!.0YCV-+O1C?KR
MC0!A/I(E]W9E=P[LZZX/-]$V5F[ZK[.;/E_\3-(Q3<1?D;8JQ,9%K.VSSR:N
M<PANA )TY@0U;;DTZ [6PV$B=3WEA^J%>AFO;>26LW<(\:21T8K:--<.>P-;
M'W#3B>));&HR;DQ?7;<5;JS['D-]979=INV<C@N:+&PXN%TTDL,E>5OBMD<]
MKW"221PT]$=O AKK9C9^E_3?:W4"#2ML/J'MZWMC>0C8XQULJSVJ/'WW-;Q]
M/^Q>[L U)])S42ZC]V[]Q>Q?FR/_ +SD1+::($!!\)#023H!VDH+"QD.UD']
M,_Q*]7'WK%LG<L'.+B7..I/:2KRP^(" @(" @QE7!XJ@,A8FAKR^USSW+=FQ
M%$-&3N#G,>]PXL;I]<5?MEO;2-9X1$1IKV?:QZ8*4ZITCC,S,S$=O?Y&,CW;
MM"Y9LG&,=F)XV^!=M8RA)<:&Z?V<D[&:. 'U@<?@5Z=KFK$=7P]T6MIZ=/M8
ME=]M[VGH^.8X3-:S;T3:(]FJYPN4V=N*+P,(ZC:%1KXG4!"V.:NUW"1AKR,:
MY@/8\<NGE5&;'FQ3K?6->W7GW<>WR+FVS[;<1ICFL]/#3328[XFL\8\L:+[%
M8FKAVW(J8:R"W;DNB&-C8V1&5K&EC6MX:#DUU\ZM9,DWTUYQ&C(Q8:X]8KRF
M=?-JOU:7Q!>9*/VS%%XXO8!(/A;V_2U5B.%F96=8157U0@(()N+<.]G;WBV=
ML]N*9)\B29M\N6CL2"61MIM9L(= ]OAM.NI?RN(^Q*A"/X+KEC\C5KW[M*4?
M*?R1#C\97;&Q\-K*032O9+;L31PN9K"X1O\ 0UX-',7!-1EHNMFS+&2R6+J"
M>>;'LNNCE+ZT,-EV+E;#::QTLS/#Y'N]%T_(V0 EA=HFH8OK7LW+R8YM:.Y%
M#>I7,G/8LLBACJU\;++#9YR^0&5['PO!96$A#=''T7 IJ,KL3J5MSJ&+PP3;
M$4V/96FGAM-CYC!>:Y\$@=$^1OI!IYF%W.PC1S0D3JE,%((""/;B=>O93#;;
MJ7)L?6R0N6<E;J.\*V:]%D9$$,FA,?BOD'.]OI!HT&FJNTTB)M/'33VB*6ZN
MVZ;\C9QVW<SD,!B99(,OEJV7LM+9:PUL>!7DL>)8$.OW1S=.(<&\VBO1-ITU
MF(F>4:?3347>X-KXM\6&Q^W)[$-C<4CV5\P_(WYF5ZL=?VE\\49F ?(YF@B#
M_1!.KNS14TR3QFWX>S2/,,5DLGN/:N^\)B7;@95V@P5J[(<G.'LEI^%)XLEF
M>0:FP]T3N5[B.)&A 5<5K>DSI\7D^SR#:K7,D8V2)[9(GCF9)&X/8YI["'-)
M!'P+#'U 0$$!W;U*CV;NCY.RE1T^!;B(\@YU.,RWWW;.3@QT$4;2YK2UQG&O
M?JHF4*.*ZR[>REQ]!^)RN.LLBR#A[?'7@B=;PQ NU!+XY8)8M0>=SA$X=CSH
M4U%LSKIM&>@^]0Q^4ONJPW[>5J5(H7RTJN*>([$TCC,&/87$>'X3GEXX@: I
MJ*<G6C&4)+T=BA>S$S;5QM"KB:@;*VICZ-2],9G3SAKG-99!YVD!WJ@<PXM1
MDZ/5_:^3R%&KCJF0LXW(WH,13SK(8Q0=D+-;VL0GFD$H+8R.9WA\O-Z.NH*:
MB?*4B @E,X]@Q#8!P>YH8?Y3N+OXU8K\5EK+;2K K*8 @("!W$]@:"YQ/  #
MM))[ @I^/6_XB'_6L^JI#QZ__$0_ZUGU4#QZ_P#Q$/\ K6?50>F212.#(Y8W
MO/8QDC'..G'@ =2@]* 0$'N*62%XDB<6/'>$F-4Q,QR9>')QVX_ LD13<#'*
M/5YAV'S+&MCTY,NF:)YLI!+XL8<1H\>B]OD<.U660JH" @(.8NI&UMX=+-V[
MWZQ[..*W+M[-5H[&\]N9?ECMPUL?7Y7^S63S :L/]DX<== UQ#42M.IW4>AO
M6SL/"W]O9W]DU[%T=W9J+&XR>][<9&MEHXQ_@ L;&QP\6?M#N5K1IVH-/U,]
M'E?<WK8JE#8BR6+W'7,L]FN^*H^2WDYY6>#)V2AHT\3D]4\$3VMSXG_%V+]Y
MG;K.L$F/R>Y<O@[E;9=K;W/!2J"!LLUH6()P9BY[ X,>9"WN U]4AJCI$).F
M&P=E=9JC9&;4S)R.UNI#(_2 @EOSLH9 M TUA>X1O>>/+HT>N43+H[W21I[O
M6S ?L,A^DK2(ENI$" @(" @Q61LRU++70CE+V>F3Q#M#P^@@NV6IG,:XUGZD
M G0MTX_"4'KVB7_AI/HL_P I ]HE_P"&D^BS_*0?'69@TGV:3@->UOU4%E0M
M2V[8,PUY&N+=!H&D_P#X:(,L@(" @(" @C.^_P B5/GG _IBF@=.?W>[3^9L
M=^*QH),@(" @(" @(" @MF?WBP9?\U#JV/SO['.^+L07* @(" @^.:U[2QPU
M:X:$>8H*%9SF\U:0ZOBTY2?KF'U3_$4%P@(-.Y_W:>F6?W[2WS/C8VD36KN=
MQ+O%EIY2Y8 \*:>-TOAAT3B]_"/TR[TNQ$ZI)O;HUL3?N2JYS,5;%3<%*'V6
M#,8JW/CK@K$DF%TE=[.9G$\':Z:G335!99/H)TQR6Q\?T\&*?1VQC+C,G3BI
M6)H)VW6->T3.G#C(]Y$CM7/<3V>0:#5<;1Z)=.]E/R=K#X^67+YBNZEDLQ?M
M3W;\M9X ,?C3O<YK3H.#-.P:]@0U7\/2G9$/3G]E+L>9MD^SNJ>PS2OD?X;Y
M#-KXA/.'-D/.UVNK2!IV(AG-J[8Q&R]NX[:V B=!AL7$*].)[W2N;&"3H7O)
M)XGO09A 04I[$< U>?2/8T=I55:S*FUHABI[,DY](Z,[FCL616L0QK7F5%5*
M! 0$! 0$!!"LN!=S-NCN;ARM?)L_'.XXZY+'&7-?(3Z,MH2<!!+P:-"T.XD;
M+%\-(MC_ ,\_BCCV=U=/Q1Z6ESZ7S37-_P#U5_!:8CG/9-]?PSRB-:Q/.,>V
M6.CB\/ S(9'%8!V)9/CI</&YSK&6D),XF+&/)E#O5B?HUQ+M>SA=TFU[3I6U
MNKCU=E>S3CR\O9P6=8I2D1:]*=&M>B.=Y^]KPGXNZL\)F9UU[*MROB'9(Y#>
M 9CKOR32M96Y7)ALU\N7ED)A?%J\3NCYAX;->?0 AP44M?IZ<7Q1U6B(GE->
MW77\.O;V*LM,75UY]*ST5FTQPF+\HZ9CCU3&L:1KKRXPE>W)<U-B(9,_&8\@
M7/#2]K8YY*X/W*2>-GHQS/;QDC;P:?H+ SQ2+ST<O9KVQ$]L=TMGM)RSBCYO
MWO;,=DVB.$6F.<1PB655AEB#(XYX>R2%W$=NGF/ JSDCM7\4]B+6H37L2P'Z
MQQ ^#N^DKL3K"^HJ0017<G3W ;JRD>8R,V0KW6TWXN8XZ]-1$]&5_B/AE\$M
M):7<=00?.F@M+_2C9-^I;Q_LMBGC;\=.K?HTK,E>O/3QT+J\%9[&G3PA&XCE
M'PZZJ-$/DG2?9[XK].)MVMB[\S;GR97N2QU*]YD[+(M5HP?N4OBL$FHX:Z\.
M)30>6=)-DM^3HYJ]JW0QD]F[7QUNW-8J.N773.EL2QO)YY'&Q+Q<?KO@309W
M;&UL?M*B<;B[%V:B.1M>&]9?;%>*-O*R*$R<6L:.&FI^%2EFT! 00_>&9CV[
ME\=GY8O'9C<7F)_!YA'SN_NK&-+CZH+G#F=W#BK^.O5$U[YC[1B(,9>BQN2Q
M?[1<-4KYM]BQ?95CJN=3EO#6>.@^6SPC)+M#,TN':--=!5-HUB>B>'GXZ=_#
MZA]Q.5]LSVV\%)8IVW[6O3T&WL:0ZM8JSX>0UY WG>&R-8SEDCYBWF' Z%+5
MTK:>/Q1V_P 0;:VG\LW<PS>=J?-Y+%R1X^2&[QY'.YYQ+'*W02U[#)&O8Q[=
M8_29Q !4WR=,1T\(GC]/+ SFPZ>+IT<LW 1-BVZ_*3_)9CU,,D;(XHY)(B?6
M8Z5KP'#@X@Z*WEF9F->>G$2I600$$<S^Q-L[GO-R69K236VPP5@]DSXQX56[
M%D(QHT@:B>%CM>\#3L*:#&93I+L3,U[-7(T)98;<V4LS-]HE;]VSCFOMN&CN
M&KF-<S[ C@HT$9W7T2K9#'28[:TL=*?(LR$&7S60LWYL@YF6\/V@@Q2L;.UQ
M9S^#/Z'. 1H-04PA+*_3#9U>P;8K3/M/;:;),Z=X+SD*D%*PXM!Y07Q5HQP'
MHD:CM301J#HZRIN_$9''25\;M7"6Z^3AI5Y+DEFU:J4?88S-'+(:[7<NGB3,
M9SO#6@]Y+0;54I$%WC(FS78FO(#&GG=J=!HWBJ;3I RF;L-DECB8X.:P<Q(.
MHU=_V*,4<-6'GGCHQ:O,<0$!!#^H->"_#MC%W&";'9#<>/K7ZK]?#G@,=AYC
MD ]9A<QI+3P.@5=9TUGR2IM$3I$]\(W6V+0S62SK<9B-LX_'XO)28V"&?"^U
M2N;%#%)SND$[!J3)V<JN]<Q$<9]:U\N-9X1ZE:7IG6@="R>/:4;[,G@UVOP&
MADEY2_D;_>>)Y6DZ>91\SS^L^7'D]2VK;!H6\ID<-!%M5V0Q3:S[L?\ A[U6
MW6.?$1_>N\-*GYDZ:\?6?+C73AZF+S.VL31V[O\ CL8?#QYO;$-.?%YC$T3C
MYF/LPML!PTD>6O8[L<'=G:IB\S->,Z232(K;A&L>1NV0ZO)/:>)^$K&7WE 0
M$!!7KW+%8ZQ/(;J"6]QT5NU(MYUVF6:^9GZ]N:TSQ(6QD=XYSJ#YQRK&FLQS
M9M;1:."MS7/O<?\ 3/\ DJE4<US[W'_3/^2@ISOO"%Y9&SF X%KBX_$"T(-0
MYWW?=B;XWA5W?F\:QTK;!L9R!YF,65+(#%#'/&)6QZ1NY9->0D\@;ZI*);EB
M@A@@96KQMAKQ,$<448#&L8T:!K0W0  =FB(:YGZ$=.9^G$'2HTK#=G5IS;KU
MFVIO&9,9G3\PF+B_UWN.FJ)U7&RNBG3[865FW!AJ4]G<=B$UI,SD[=C(7! ?
M\VR2P]_(/+R :]Z&J^PG2G8^ V#-TRHXXOV98CLPS4+$LDQ<RXYSY!XCW%^O
M,\EI!U:>SL1#*[*V;@>G^V*&T-L0OKX/&B05(9)'S/;XTKYGZO>2XZO>XH,^
M@(" 2 -3P [2@HPVJ]AQ;"\.<WM'$?PH*R#XYK7:<P!TXC4:H/J @("#X&M;
MJ6@ GB=!IJ@I"W7=,8!(#*.'+YQW:]B"L@(" @("",[[_(E3YYP/Z8IH'3G]
MWNT_F;'?BL:"3(" @(" @(" @H67N#6Q1'2:4\K3Y!WN^((*L<;8F-C8-&M&
M@"#T@(" @(""WLM<WELQC62+74#ZYA]8?QA!7:YKVA[3JUPU!\Q0?4! 0$!
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M-@X\/D973_)\TU;'3/\ #\1V-B=I5+_# ;S<G;P'G5&2T6MK';]?:,TK8("
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MMD)<&^0..JBO.OI^M7?[MO-'U-M/];XA_ K*MY1(@(" @]PSRUWB2)Q:X?\
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MVM/\*#XYCF>L-$'E 0$$I>/D_#-B[)'-#3_*?Q/\:L5^*RUEMI5@5E, 0$!
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M4'T]=4T&(J='MWT(;KGX>O>-VS@,AF(6Y1\9RT%'&QUKN/ED=H=1;9[6'O\
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M[&CM/:3WGXT'M 0$! 0$! 0$%M8!B<VVWZP<LH\L9[_B[4%R""-1Q!["@("
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M$PE?Y:.>U%$:[#)#ZY+>W4]G#M3',1S8^:LSR8-S7-/*X$$=H/ K)8;X@("
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MUU GL5MGY%U6>2M-*^I6,\#C'*V*S;AADY'CBTECG-YAQ&JKIS46Y(]ENC&
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M*=GP-+FN=_(7&[37#N)QSYO<]EV^:,V*N2/Q1$N'5T*Z("#=ONY9K+X>;?\
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M+&RUTXK^.W8R%:Y!:X1N],#5S#P(5A=7" @(" @(""RGL13RMI,>/2.DI[.
M[6@^4H+T  :#L0?"0T%SCHT#4D^0(*%8&0NM/&CI.$8/=&.SZ/:@N$! 01G?
M?Y$J?/.!_3%-!3Z<,'^!=LS\O)SXF@(V:\W)$VLSE&ITU\J"5(" @(" @("
M@(""VE_N\PL#A&_1DWF^Q=\78@N4!!:Y"V*=<O']H[T8QY_+\2KI765%K:0B
MQ)<2YQU)XDGRK-8KX@(" @R='+R0:16-7P]@=VN;]4*S?'KR7:WTYJ[[%.U(
M1']R<>+7NT#'?#Y%:B\QPE5:D3QA1^,'SCBK\3JQYC00$! 0$! 0$%2&%\SP
MQ@^$]P"B9T36NJSW1NG&[,Q_,_2;(S ^S5@='/</KG>1@_\ U*]M=K?<W[JQ
MSEB>(>(8]ECUGC:>4?3L:!S&8R&=OR9')2F6Q)\36M'8UH[FCR+M<.&F*O36
M.#S#<[G)N+S>\ZS/TX+%7F*N<=C;^7N1X[%P&S>EU+(FD-X-[7$D@ #O5O)D
MKCKU7G2%[#AR9KQ3''5:>S[?-#8&/P6"P=/.&"2MNJ;'-\'<>+FB\*>*,#[I
M[*\Z<!Q/'MT]8%:3)GRY;4UUQ1;C2VO">[J^GH=-AVNWP4S=,UW,TX9:3&DQ
M&G'H_;S_ #0L=_'$Y/";<W!AY9I:Q;+C>:R"V;EA])@?KVEO*X<W>KWA_P S
M'DR8[Q$3PMPY<5CQB<.;#ASXIF8XTX\^'?Y8TGBA-FU:O3NM7IY+5EP =-,\
MR/('8-7:\/,MO6M:QI6-(\CG;WMDMU7F;3WSQ4E4H>F,?*]L<;2^1Y#6,:-7
M$G@  .U1,Z<951$S.D-F;4Z36KG)>W*75:QXMHL.DSA]N?K!YNWX%S^[\6K7
MX<7&>_L=?X?^GK7TOG^&/R]OI[OK\S9,M&##05ZF'KMJUFAP#81H2?/WGX2N
M8R9+9+=5IUEW6'#3#7II$5AEZ[Y#68^P-).75ZMKRTAR\4DA8]IC9]:[M^B
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M&MUOUF :^FQHTD:/LHQKY6@<5U.T\4ID^&_PV]DO/O$?T_EP:WQ?'7_5'O\
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M^[N<&+.]=@U2[#>E+E,-$-35':Z6!HXF+O<SZSM'H>KU7A_B77I3)/'LGO\
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M?'L9(QT<K0^)X+'L<-0YKAH01Y"%(U_LZW)LJ]#TTSA<V!ID_P '9-^IBN4
M3(VJY_8+%=OH<ITYF .'>MGN:QGB<]/\\=T]_FM[):K:S_3S&WMR_P#KGOK^
M7^*L</+''O3?*?DN_P#\M/\ [-RUU/O1YX;.W*?-*.]+?W:[1^::G^S"R]__
M /IR?Q2P/#?_ ,F+^"OU)#D\MB\)3=D,S=AQ]!CF1OM67B*)KI7!C0YSM -2
M=.*Q<>.V2>FL3,]T,W)DICKU7F*QWSPA2R.X<'A<7+G<ED*\&*KQF9]DRL+2
MUHYO1T)YB>QH;Q)[%-,-\ENBL3,RC)EICK-[3$5CM8#I90N8[86)BOPOK6K/
MM%]U60<KH6WK$EED9;]:6MD&K>XK*W]XMGMI.L1I&O?I$0Q/#Z37;UUC29UM
MI/9U3-M/1JEZP&P<\>\[:C-W:- ?VK&WK)\O*1&S^%=I^EZ3UWMYGG7ZXR1&
MWQU[9EHKF7?O'=#F0T.9#0YD-#F0T.9#1.-D]6-V;)>R&I8]MQ /I8RT2^(#
M_P ,^M&?Y/#R@K3;_P (V^[XVCIM^:.?I[W3>%?J+=["8BMNJGY;<O1W>CAY
M'2VQ>K6U=\M;6KR^P9K3TL99(#R?_"=P$@^#TO* O._$/!\^TXS'57\T?;W/
M8?"?U'M?$/AK/1D_+;[)[?K\B>+2.G$! 0$! 0$!!Q_[P_0/Y%-K?VRJW_V=
MQ,V9Q4+>%4GBZ>)H_P UWO:/4[1Z'J]5X;XAU:8[SQ[)[_)YWGOCG@OR]<V*
M/A_%'=Y8\G?W>;ES,NA<6(" @(,G@=OYK=&4@PNWZ,N0RE@Z15H&ZNT':XG@
M&M'>YQ '>K>3)7'7JM.D+V'!?->*4CJF7Z&]+,!N/:&Q\5M[>F3AOY6'[C 6
M]D<7+K'7#W'64QAIT=H.'#L;J>%W>2F7+-L<:1].+UWP[!EP8*TRVBTQ]-/+
MHD>4LV&/\%OH1.&H<.UWE5K%6)XLV]IY,4LA9$! 0$! 01/J?SGI[N&-CO#=
M+!#").5K^436H8R0UW D!W!9FS_[]//]DK.:-<=OIVL&=O\ 6';[GU,9GH<U
M1A<6Q>TOB?.6M.@YO;HRYOP"=WF5Z,NUR<;5FL^3_P#C[E/1EK.D3K]/+[SV
MGK@\"/V*E$>(,S78XD^0Z.E</I*=-IWS_J]Q_.\GL0_=HW=9CR-7<>[J[LO@
M&4<I/MRJ0]Q8^W V,RQQQ0P<OIM=J?%(U'#B"LS!\J)B:4G2VL=4^:>7&9^I
M8R=4ZQ-N,:3IZ6_;(TLS =@>[^$KGZ\H;">:DI0(+BE.()P7?V;O0D![.4JB
M]=855G26:K$QN=5<=3'QB/EC/9]#L6$RER@@'6;J6WI-L*[O#V Y&Q'+!4JU
MG/\ !A\:T\1M=-)H[DC;KJXZ>;OU1,,)TGDZQ8_;-O\ QQ/A=ULCJR7<%E<+
M=EEEO33/EF%>22:-D8:W5L4<C>'+IKWH,;TBZK;[W7O7?^U>H>+QN#EVA'C9
MFU\?*^P8FY"&2=S)IR\LD+&M;J6,:-=>U!"?^H?J6W:\/6R7"8IO1.;*>P"E
MK8^7FXXVC4%XOYO!U\0:>%R^;7Z]#1D-U;_ZE9#J]O'9^ WQA=G[?VQCJ.2K
M29:E#/'8-J!CWMDFDE86M!))>W70=R# Y_K[U>M='^GN\-N8BM4WKN?*RXZ;
M'30.=!<;"R8L= V5S7M$_A#D'-KQT!["AHFN3ZY6,_#T>S.RY868+?V5-#,U
MIXQ-+$UL?W:#FU'*^-X<PN X]HX=HT;SK$QEU5YU='Q83WQGL^AV(A<("",[
M[_(E3YYP/Z8IH/G3=S7=/=J%AU P^/;KYVUHP4$G06]^>>K1LV:U9URS#%))
M#4C<UKYGL:2V-KGD-!<1R@DZ(.0-NT*^Z^N.'O\ 2G8V4Z>;EV[=@GZHBU)#
M4H&A<896US6BE>V5\XYC&YL;?LB/KFE3:W47!9N][QG1_-T\;:L8;&09UN1R
M,4,CZU8STG,C$TC06LYW<&\Q&I[$0@]^7=_23</5O!5]G9G<4?4*Q+EMHY##
MU76ZKKF0A=%+#;>T_<!'(\.U=]8''R:A:XK8FZ>A>8Z7[UMX2]N#'8K;$VU]
MU5\%";]NG//.^\V1L+#K)'XLSHW.;V!NO>T$E%]Y[#WQENC/4K=]S;.0AR^_
M-TU,O2VRVN^;)0XJM.T1&>",.<V0M+B]O<.)[> 3'ISMX6.M>$W'TBV3F=A]
M/Z]&U#O0Y6K)BZF2<8W>R1PU)7$O?'([F\1H'?Y/2#%[5Z4[PN="Z66QV.M8
MGJILC<&3W!M:&Y"^">4>TF22J6/#28[48TTX![@W4\NJ#:_NKXC,8/HMAL?G
M<58PF1;9R,C\9;ADKRQ-EO3/8"R4!P'*1RZCB$1+<Z(8O-V?#@;7:?2EXN_D
MCZI5[%76=5K)/#1'UE,<0$! ^F#P(/$$'N(*"/#9>#J.]HV^V7 9,<&WZ#W.
M<6=OARQ3.?'+$/K8W-T;];HLK^JO;A?XX[I^R8XQ/E8?])CCC3X+=\?5.O"8
M\G9V*[,*S"T\A?PT!R.Z9H'\N0R,GC6;,X:?#;)*_0-C#O\ -L#6:<-.]4_-
M^9,1:=*:\HY1'F[_ "\U48?EQ:U(ZKS'.><]W'N\D<$>CV]#,R";,[9RF7R\
M;29<G:R40F=(\:2%HCLM9&T]@:QH ;P67.:8UZ;UK7NBO[.+&C!&D=5+6M';
M-HU]DZ1Z'FQA;=**6YM3;F0Q.>'+)%8^4(I89G1]D5J.6P]LD3AZ!X:M'%O$
M)7+%ITR7K:O\,\/+'#A*+X;1&N.MJV_BCCY+:S.L=GU)[KS .Y>0N )8#J&D
MC4MU[]#PU6L;00$! 0>XHG32"-O#7M)[ !Q)/P!1,Z1JF(UE#^LO49G3;:AK
MXR0-W5F6NAQS>'/7A T?8</*-?1^W/>&E9WA.QG=Y>JWW*\_+Y/IV-+X]XI&
MQP=-)_F7X1Y.^WN\KF;IQU?W5TYNEU.8WL-,\ON8FP\F)Y=ZSV.XEDGVP[?K
M@5VV^\,Q;JO'A;LF/IQAYMX9XSGV5OAGJK/.L_3A/TEU)B\GL/KAC'7L5-[-
MEJS&B9KFM;=@<0#I(WZ^/CH".';H05Q4QN?#KZ6XUGU3YNZ7HFFS\9Q=5.&2
M/^*/)/?'L[IU:[W'M;+[8M>!D8ON+B1!:9J8I /(?+Y0>*Z/;;K'GKK6?1VN
M*WNPR[2VEXX=D]DL*LMKA 0;8Z9["#Q#N7-1:LX/QU9X[?)*X'N^P'Q^1<UX
MGO\ 37%2?//V>]V_@?A&NF?+'\,?;[O6VM8B=(P.C_MHSSQGSCN^ C@N8=T]
MQ2-FC;(WL<.P]H/>#\"#V@(" @(*<T0FC=&3IKV.':".PCX$&)S.Z,/MG$R9
M7<-IE."'T'\W%SY!V-C:.+B[34 +)VVVR;B_1CC6?IS86]WN'9XYR9K=-?K\
MT=LN9>H?73.[J,N,P)?B, [5K@TZ6IV]GW1[?5!^P9\9*]'\-\ Q;?2V3X[^
MR/-[Y>->-?JS/O-<>'7'C_U6\\]GFCTS+4VJZ=PNAJAH:H:&J&AJAH:H:&J&
MAJAHW-[M>>93W1F]M2N#6Y:M'>J@]\U,ED@'PL?K\2XC]3[?6M<D=G#UO5OT
M1N_AO@GSPZ97"/3Q!!.J%:Y=BVE4H778Z[+N&N*]]D<<[H7^S6-'B.4%CN&H
M](=ZV6PM%9R3,=4=$\._C'<UF_I-HQQ6>F>OA/"=/AMW\%U7V]N^@RW8RV\[
M.:I"I9:['RT*59KG.B<&N\2!C7CE/'SJBV;#;2*XXI.L<>JT_6N8\&:DS-LM
MKQI/":UCZHA:;)R\6!Z.8'.6*\]B#&X."S/7KM#IW1PQ OY&N(!( )[5<W6.
M<F\O2)B.J\QQY<UG99/E;''>8F>G'$\.?"$R8['9K&Q3!L-_%9"%DT?.ULL,
MT$S0YIT<"'-(*U\]5+:<IB?5+91-;UB8TM6T>B8EJSJ'L+8FW\53R6 P-*AN
MJ7+XR/!NK1!KGV_:XWEC6>KR^&UY<--.4%;K9[S/DM-;WF:=-NK6>S3WM%O=
MCML=8M3'6M^NG3I$:Z]43]6NOD;??Z[M/*5HH=!/-\0<B]>,\S-]2[56%P?6
MP-6+'-([/'?K--] N#?B7I7Z<V_R]OU3^.=7C?ZUW?S-S7%'X(]K7.JZAY]H
M:H:&J&AJAH:H:&J&AJAH^LD?&]LD;BR1A#FN:="".(((28UX2F)F)UAN[IW[
MP.1Q)BQ6]"_(8P:,CR31S6HAV?=/OK1Y?6_E=BX[Q+].TR:WP?#;\O9/F[OJ
M\ST?P7]8Y,.F/=:WI^;\4>?\WU^=TEB\KCLU1AR6)M1W*$XYHIX7!S2/XB.\
M'B%Y]EQ7Q6FMXTF'KN#<8\](OCM%JSVPO%:7Q 0$! 0$'Q[&R-<Q[0YC@6N:
MX:@@\"""A,:N)O>'Z&G9%I^\=JP'_"-N3^]U6#44)Y#P '="\G1GV)]'O:NO
M\-W_ ,V.B_WH]O[7FGCGA']//S<<?!/./RS[O\.YH!;QR@@(-D]+>BVZ^J%M
MLM.,T-N1OY;>:G:?"'+ZS(F\#(_S#@/KB%K]WOJ8(X\;=S<^'>$YMY/#A3MM
M[N^72>6W'TF]V';YQ.*A%_=MB-KC5:YKLA:=H>62S+II%%KV#3^2T\5IL&UW
M/B5^J>%._LCS=\NWF^U\*Q]-8UO/_%/GGLCZ1#DS>76/?F]=SUMT9#)/K6L=
M.VQAZM4EE>D]C@YIB8==3PXN=J7=_#@NZVWAN#!CG'$:Q:..O.7'[CQ'-FR1
M>9TF)X:<H=U=*NH>/ZN;'KYJ+DAS,&E?+5&G^QN, U(!U/AR#TF>8Z=K2O.=
M_L[;//-?PSRGOCWP]"V.[KN\,6[>WSLXYKF.+7#1S3H1YPK+(?$! 0$! 01+
MJASGIWN)D9:V22"&)CW-Y@QTMJ%@?IJ.+2[F&AU!'!9FS_[]//\ 9*SGC7';
MS,(T=;, YU62*IN*&'T&V'>!*]P;PXGQ*DQ/#B7AQ\Y[5?\ _$R<>-/7^V%,
M_-KY?IZ!NYNK[W%C=HUFD< [P9@/B+[C6GZ*?)VW^Y/L_P"E'7D_+]/6A^[Z
M^]KL63R.<L8FA>H"A8R>+@%0WYZHM1")LS(#)(Z'4CT9I^4</1/!9FWG#68B
ML6F)UTGCI$Z3RUX:^:%G)%YB9F8B8T^MOVSPLS#[=W\)7/5Y0V$\U)5($!!F
M:\CIZK)6<;-8Z:?9-[Q\8^FL/)72632=89"-[96-D8=6N&H/PJVK1/J5<%3:
M5L2[2GWM1L.97OX"JR&622M(?3>(YR&OY-->7MU\G:@T9[L6*-K=NX-[]/L5
MD-M=#,Q3\+%X7*6&RF;,16>2:Q7A$DW@QLY)(W OXD\. Y6$RDW3_:N7=UMZ
MY6,ICK=3![@CP\%#(2POC@L-;2DBE,$C@&OY"[1W*3H>U!J)V"ZB7>BM;W6Y
M-GY:/=$>3;2L;D-8_((Q,>2]N%YMO7E(TT;X?K'3[+T42R>^=N[7I==][7-^
M]-\YO+;MS$8NKM\XS%6;X=/!68R01S1E@:[AR\P?P([0@J8S9/5*MLOHK3W1
MC<A:NXK?-:\*K@^[8Q>#82(&6Y6!W*(V][CHQI#>&F@"XW1TNW?M#KOM.';&
M)FN=+LMN>/=CI*M=\K,5DGQF"ZQ[V B.&75DC>;1O#E;ZI0=966.T;/&-98N
M('V33ZS?C12JL>V1C7L.K7#4'S%!Z01G??Y$J?/.!_3%-!0Z>R/9LG:LTAU;
M;Q&/<]W_ (QJQG7^<B4M1 @HQU*L,\UJ*"..S9Y?:)FL:V23PQHWG<!J[E'
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MKF.NLJ+SI".+,8H@(""([KZ>X;>6>V]F,XV.W3P'MCAB;,$=BM8?<C8P.>)
M=#'R:MT\JB8U3$H;FN@T&<S.;RES<=I\.5K96E7@?#&]]6#,U8ZSXF2%VOA0
MB/6&,-:&ZG77M5/2F+)/'TLV[-G\[GLPWY4?FGUI&P3-Y6U_9Z3:+@TL(+O$
M:W4\W9KP4Z(U83]DVY/D"':IWS:DV_CI*AP\#Z<0E;7I2 LK7)8WQ^U1&,"-
MP(9S: NYCKJT3JMZ/0C'4-O3;>9FK#HIJ&'QIF,,0(9@\E/D6.Y1Z.LAG,9
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M_P#:C]XE_H_]J![4?O$O]'_M0/:C]XE_H_\ :@>U'[Q+_1_[4#VH_>)?Z/\
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M @(" @("".YJ;Q+8C'JQ-T^,\2LK%'!CY)XL:KRT("##;L);@I2.!%FCH?\
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MWU;1:(F.4O.;TFEIK/.%)2H=Z^ZOO ;LZ7_X?MR<^0VW*:#M3J[V6362N[X
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M$! 0$! 0$! 0$&M,\?D+K#M_*/T;2W/C+&#E>>P6JC_:X 3Y7!SVCX%N,/\
M,V=Z]N.T6]$\)^QH\W\K?4MV9:S7_-7XH]FJ>K6-JB.3W'OFID+-;';)&1H1
M/Y:][Y7JU_&9H#S>$]I<WX"LZF##-8FV7IGNZ)G3TL*^;-%IBN+JCOZXC7T+
M7_%G4;__ %Z/SY2_R57_ $^W_P![_191_4;C_9_UU/\ %G48<1T]&OSY2_R4
M_I]O_O?Z+']1N/\ 9_UU5,KE=PY78F[9-PX+Y"FBQEYM>+VV*_XK#4>2[FB
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MPN;'A=R8ZY,[0-@CLQ>,2>S[F7!WTEC9-GFQ_>I,>A>IN,=^5HE)UB,@0$!
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MCK2OUK6'>2&4Z>D>Z-_'R<RYC?>#Y-O\5?BK[8\_O;K:^(4R\)^&S=*T3:"
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MNSN0>X,+AZQB=6QU:%T#W30F.&-A9(]O(Y[=&C1Q:.4D=W!!?("#XYK7-+7
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M34,N"Q_^;,=-_P"PM7XK?IVN2?)IZ^#=^!X^O?8H_>U]7'['?R\K>XB @("
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M 0$!!Y>]L;7/>=&M&I/F""E68XAUB0:22\=#]:T>J/JH*Z"+9(ZWIS]MI]
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M4-KXQV1NN#I'OC@J50X-DL6)GB..*,'M<2X=@X#CV*!A>J>X+&W]E7WX\_\
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M- ;Z^O+QU4P,ATT@RM;8&VX,T'C)QX^!L[9=1(WT!RM?KQY@W0.UXZJ!*D!
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MP*WE^ZKIS9]8;)$! 0$! 01G??Y$J?/.!_3%-!BNFURTS9FUZ_*9&#$TAX?
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MX=M]K,SBKTZ\^,S]<I:L%L1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MYYP/Z8IH'3G]WNT_F;'?BL:"3(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@C.^_P B5/GG _IBF@=.?W>[3^9L=^*QH),@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @("",[[_(E3YYP/Z8IH'3G]WNT_F;'?BL:"3(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @C.^_R)4^><#^F*:!TY_=[M/YFQWXK&@DR @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @((SOO\B5/GG _IBF@=.?W>[3^9L=^*QH),
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @("",[[_ ")4^><#^F*:!TY_=[M/
MYFQWXK&@DR @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((SOO\B5/GG _IBF
M@=.?W>[3^9L=^*QH),@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("",[[_(E
M3YYP/Z8IH'3G]WNT_F;'?BL:"3(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @C.^_R)4^><#^F*:!TX(/3W:1!U'R-CN/\ ^2QH),@(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @("",[\(&$J:G_ /G6!_3--!^=V/\ ]PJ_Z)G\"*UR@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
E@(" @(" @(" @(" @(" @(" @(" @(""VO?V+/\ 30?[5J#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>pg_bynumbers-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg_bynumbers-4c.jpg
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M%!04%!04%!04%/_  !$(!=T$9@,!$0 "$0$#$0'_Q #N  $  04! 0$
M         @0%!@<( 0,) 0$  04! 0               0($!08' P@0   %
M P(!! H*# H&!@D"!P ! @,$$04&$@<A,1,4"$%182*STY1U5AAQT3+2=*05
M51<W@4)2DB-3D[25M18VD6)RLC-S5-35)J&Q@J,D)\&B0S0E9>'"8X-DQ#5&
M*,.$178X1/#QI1$  0," 04*"@D#!0 ! P('  $1 @,$$B$Q05$%87&1L=$B
M$U,&%H&AP3)2<J(4-!7PX4)B@I*RPC/2(R3QXG,E-8-#L\,'DV-T13871";_
MV@ , P$  A$#$0 _ .A=G-G-J;UM3AMUNV&VB9<IEHAO2Y;\1IQUUU;234M:
ME$9FI1G4S,"3-_H)V9]!+)Y"S[T"''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!
MQ]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?
M>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\
MA9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"
M63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S
M/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T
M$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z
M<?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%G
MWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/
M(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@
MED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03L
MSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]
M!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@
M''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9
M]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63
MR%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H
M)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[
M,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?
M03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH
M!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6
M?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED
M\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ
M"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.
MS/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''
MT$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z
M <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%
MGWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9
M/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^
M@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03
MLSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q
M]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>
M@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A
M9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"6
M3R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/
MH)9/(6?>@''T$[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$
M[,^@ED\A9]Z <?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@''T$[,^@ED\A9]Z <
M?03LSZ"63R%GWH!Q]!.S/H)9/(6?>@',(S/9S:F%F6W$&)AMH8B7*[SF9[+<
M1I*'VF[)/>2APB*BDDXVA9$?VR2,"3-]B?J9P3S)!\"D"%-A
M
M
M
M                                       #7N>?OYM7Y[N/Z@N0 ;$_
M4S@GF2#X%(!380
M
M
M
M     U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
M
M
M
M                              ->YY^_FU?GNX_J"Y !L3]3.">9(/@4
M@%-A
M
M
M                                                       #7N>?
MOYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
M
M
M
M                     U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
M
M
M
M                                              ->YY^_FU?GNX_J
M"Y !L3]3.">9(/@4@%-A
M
M
M
M           #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
M
M
M
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M8 'TAY#8+B^46WW6'+DF1J)EB0TZNA<IZ4*,Z$ +D
M  +5DM\9QG'KID,EI;\>UQ7ICK+="6M+"#69)KPJ= !H?UO\3]'KC]^Q[X2Q
M!GNUN]EGW3N,^WVRV2H*[>RB0MR2IM1*):]%"T&?$"3: @
M
M                                                           !
MKW//W\VK\]W']07( -B?J9P3S)!\"D IL(            !BVYGU<Y=3A_X-
M<.)<#_[LX /S<%1    7O&\PRC$):9N-761;GB/4HF5F3:Z=A;9U0LNXI)@#
MMK8[=]O="S/L7%M$;*+62"GM-\&WFUU)+S9'R$9D9*3]J?<,A!)M<0
M    #2F?=97%<(O4W'$6N;<KQ 7S<@D\VQ')>DE4)Q1J4?+^+$L# ;!UG\KR
MW-;!8(5IA6RUW*XQHLDU&Y*D<RZZE*B2LS;21T/ET Q!U2().*>ME]9L3S1&
M\/(%2$&B0!^F^,_NW9_@,;P*12274              'Y_\ 6#^N')_ZV-^:
M,BH@UF .ENJAN#T.XS-O+B[2-/U3;/J/DDH3^&:+^6A.LBY.]/LJ$*#K802?
MFYN81%N-EU/GFX?G+@J(,^ZKA$>[$:O8@RZ?>$"@[E%)(
M    !A^Z_P!667^:)O@% #\XQ40=(]3[]Y,D^ L^&$*#KL02
M
M
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M_P!F#$F]!
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M25>3C;R(4DGYZBH@K$S+G*B1[(AYYV&A]3L: DU*1TA\DH4I*"Y5J)*4]O@
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M2;S1J1WVC335V0!W0*20
M
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MA:CX)2JM>0E5H0AB3>8@
M
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M[JC3J^R*23+
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MC6-V.+C./VS'H1FJ+;(S41M:N"E$R@DZC[JC*IBDDN@
M
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M>KPG!TW*XL\U?<A-$R2E146W'(CZ.T?:,DJ-9ERD:J'R"%)-Q"    %-<;=
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MJY5'W5&9B 78
M
M &O<\_?S:OSW<?U!<@ V)^IG!/,D'P*0"FP@                      &H
MNLK8/ES:FY/H1KD6=YBXM=LB0KFG/X&W%']@2@.$!)!T9L3U?[A=9\7,,XAJ
MBV.,I+]OM<A.EV6LN^0MQ!\4M%RT5[OM:>6'!V ()
M
M
M
M   U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
MHKQ:H5]M,ZRW%!N6^XQW8DI!&:3-I]!H41&7$CH? P!A^*[,;;8<ZW*L]B95
M/;.J)LLU2GDJ+[9)NFHD'_((@!GH
M
M
M                                                    ->YY^_FU
M?GNX_J"Y !L3]3.">9(/@4@%-A
M
M
M
M                 #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
M
M
M
M                                           U[GG[^;5^>[C^H+D
M&Q/U,X)YD@^!2 4V$
M
M
M
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M       %HFY3CUNO<+')UP98OER2:X,%9GSKJ2U5-)4_BG_  +N
M
M
M                      ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%-A
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MTTI.H@DM=EWYVQOMT8M$:[+CRY9DF&<R.]%;>-9T22%N()/$^!:C*HE@;)$
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MZ$JA.I09D1\*TH +T
M
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ME!39$E+JXZTDA:B+E719D:NR1$!)T2(!@N\WU5Y9YN>_U #Y[)?51BGP%/\
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M]D027X
M
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M(;9KRZFC;_A:/MB2#JD02
M
M                                         :]SS]_-J_/=Q_4%R #8
MGZF<$\R0? I *;"                                 :MO=MWZAWJ?(
MQ>\6*X624\IR'$NS+S3L5M5*-DIA/?$7;4K['8$@AAFUU_:S ]QMQKPU><L;
M8.+;H\-LVX,)I1&2N;U$DS.BE%[DO=*,ZF=2 SS&\5L>)Q9,2Q1NCMS9+LZ8
MI2UNN.RGS(UN+6X:C,SH0@%Y
M        !B.=VW<"<S!?V_O$2V38KCBY4>X,F['E(4DB2E2DI4I&DZGWI?9
M&O;MM]O+N*PBQ[A7ZU6O%5.(7.B6!MY3\E+:M1)4I\N!5(CY3*O$TG02#-LW
ML&9)Q.!C>UTJ+9G&U-05OOZO^'MR&E(JR9$HR6FB"+A7M&1\1 *O;C;ZU[<8
MZBR6]Q4J4ZLY-RN+I4=DR5D6I9\3H14HE->!=LZF8&7@
M
M
M    #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
M
M
M
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M!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK
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MB;Z\9R3M*O\ FRWH\1IW2-@-9<:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2
M<:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#
MC2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <Z+ZH14RS(?-R/#I&I=I?XH>MY#=N
MR2_WI^KY3KX:$=+   #D#?4Z;FW;^1%_-FQUGL]\%#\7ZE/GWM@G_:5-Z/Z4
M-<ZAL!I[#4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4
M8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@#
M#4 8:@##4 8:@#&]NK,=;MD'P=C^>H:3VK_CI[ZG4>P/\U;U8\:G1XYX=A
M #A++%?YIOGG"7X98[=9_P $/5CQ'R[M)/\ +J^O/]2EGU"[,>PU &&H PU
M&&H PU &&H PU &&H PU &&H PU &&H PU &&H PU &&H PU &&H PU &&H
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MKK2I5-"TG[!U(Z*]M<6-1'YJZ%06UY;;0IKA:::45/)Q+R''V]FV:=M,L*)
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MDC"L-0!CJ3JS'7#KKYS7^;LCF_:CXB/J>53L_87X.?\ R?MB;K&H'1
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M(:0?9-!+7K/DJ9%V#&6V!L^=)ZLT;$C(FYG<P?:G:E.LU""OA5Y+NYF\:O\
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M8?0II]I1H=:61I6E:3H:5$?$C(^4AMZ214=,QSV4%BJHJ,J$*D)*6.KX)_\
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M:G'_ &)?YX^,/M[XVI^']*&P=E/_ #*7X_UR-%9$?_Y&,E_Y];OYS W"V_\
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M=:UG*$;=$YKNL4;.S;_UF&[,VU]3C4G=K)5DJ84E)U1G=<ZL[[F;4QB]MO\
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M,0U#)F$8ZS@G_P#C4H__ "5_^<L<UG_ZWXT.TTO_  ?_ (E\IR9J'2CBS#4
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MF1<61&RLJ>4N&*;YYYB5L;L\5Z//@,)T16Y[:G5,H+D2E:%H5I+L$HSH7 N
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M)T            #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
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MWX           #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
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M ,-0!CK'JM'7"KMYT7^;LCG7:?XB/J^53KW8KX2?K_MB;T&I&^@
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M ,-0!AJ ,-0!CK;JJG7"+OYU7^;,#G?:;XB/J^53K78SX6?K_MB;W&IF]@
M         :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"             <:]8
MDJ[G3?@T7P1#J/9[X--]>,XAVN_]"7JQXC56D;$:>XT@'&D XT@'&D XT@'*
MZSWB[8_<&KI9)CL&X,UYN0PHTJH?*1]@R/LD? QXUJ,*T<,T22%S;W56WFDZ
M<EC)-*%UR'/,NRJ,W"O=R4]!;5SB8C+;46.;A_;J;CH;2I7'W2B,Q;V]A0H+
MBA%EUY57A5R[N]K75U%(U9NB:&2*<$41%7=4M<N\72=;+?9Y<E3MLM7/?)T8
MR+2STE9..Z3(J]\HJG4Q<0H0C.4T3G29UUMF+2I=5)TXTY*\8/A35B5UX5*Z
M/F.41)]KND>Y.-S[+'Z%:WR)!J8CZ5IT)JFAE1:BXUY1XRLZ,HRBL<DU>6ZO
MT0N(;2N(5(5$FN*G'#%<F1,N3QJ>X]F638JB0S8YYQXTNG28KC;4F.X:>)*4
MT^A:#45."M-0N+*C799Q=4S+E1>%&4FTVG<6J*E*3)+.C(J<$D5"_P"9Y8UD
MN%XBS)N*Y^2PWKJ]=S=YPW$')>;4R9K41).J$\"0=$D5. LK.T6C<552.&"I
M##X$5_'K+_:6T$NK6@DI+*I'I,;O]J2-E7)F31FS%(]NMN(^44G+^_JAJ0XT
MZE+275J:(R0;RTH)3VFITYTU#U395JC\Q,N_XM7@8\UV_?*D7JKS=Y\FM6>7
MXG+3CV7Y+BRI!V*>J,U+*DJ.I#;\=VG(:V7DK;49=@S34A<W%G2KMCB[9ES*
MGA3*65GM&XM7Z*2Q1<Z9%1=^*NGB*:_9!><FFIN%[D=)E-MI8;-+;;*$-(,S
M)"4-)0E)$:CX$0KH6].A'#!&3/KXSSN[VK=3QU5Q*S9D3)O(R'VQW*LCQ.2N
M5CMQ=@.ND27DMF2FG"36A.-K)2%TJ?NDF*;BTI7"-4BDOIKSE5GM"O:265&2
MQ5<^[OHN1?"7"X[C9M=)4"9*NRT2+6X;\ XS3,1+3JBHI1)80VFIEP.I<2X#
MPI[.MX))$CDEG=U?A<NJVVKRK*,I35X*\61(MX(HB$;ON%F=]:DQ[E=5N1)C
M?,RHC3;4>.M)N)=,S:90A&LU)(S7IU'2E:":.S[>DJ+&.5,RY57,V=<O@S%-
MQM>[KHJ3FJI)&5,B)G?,C([Z6?0[$IFXV:S[2JR2KJI5O<:1'>)#3+;SK+9:
M4MN/H;2ZM-"II4LR,1#9UO&>-(Y7?.K/N([)X$*JFV;N=+HI37"S9D=430LF
MQ+X5(6//\PQV!\EVJXZ;:E?.MQ)##$QEM9U,U-HDMN$@SJ==-!57V?0K2Q2C
MSM:*J+XE1RFUVO=6\,%.?-U*D9)X,2*W@%MW S"U3+C/B7$E2KLXE^XJD,1Y
M277D&9I6:'VUI)1:CH:2*@5-GT*D8Q6.2&1&54;@5!1VO=4ISG&>6HKR=(R=
M<OI(J:5+)=+E<;W/?NEVDN3+C)5K?DO*-2U&14+CVB(J$7(1<"%U2I0I12,$
M9$T%A7KSK36=15E*6=5/I=+Q=;UT/Y4DJD_)\5J!"U$1<W%8KS;94(N":GR\
M1%*C"F^%&Q*LEWUSJ55[JI6PXU?!%(IN13,AY!N]SMD:?#@2%,1KFT4:>VDB
M,G6B42R2=2.G$NP%2C":Q62.L5=-P4KJI2C*,%9)HTMU"IQ_)\@Q:0[)L,Y<
M-;Z.:D((DN,NM\>]<:<)2%EQ/@I)BBXM:5=$2HCMXMY4RH>MI?U[62K2EA?/
MI1=]%=%\*'MYRK(L@N#%TN\]R3,BZ2B&9)0VP2#(TI:;024((C+D2DB$4;2E
M2BL819%S[N^N=2;C:%>XFDZDU58YMS>1,B>!#UO*LB:O[N4MSW$W]\W%.SB)
M.M1O(-M?#3IXI,RY 6TI+22EAYB:-X)M"NE?ITDO2*_.WT9=S,4CMWN;UICV
M)V0I5IB.N2(\4R+2AUXB):B.E>-.V/1*,$FLT3G*C.>,KJI*DE)5YD5543=4
MR%6Z&>K@';7;PIUDV%1>>=9CN2N861I-'25MF]0R,R]V+)-EVR2Q)#*[YU9_
M5=O$9)=NWJPP+4=&PYHXF]9L7C*''<XRO%([\.PW%4:')42W8RVVI#/.%2BT
MH?0M*5\"[Y)$?#E'K<6-&NJ+4BZIIRIQ-D+>SVK<VB+&E/"BYT9%1];*BY=U
M,I0W;(;[?FXS=ZGO3RA\[T=4A7.+3TAPW7#-9]\9J4=>^,Q[4K>G255A%(NS
MMN9$+>O>UJZ12I)9879\N=77+G7PELTBX+1QI .-(!QI .-(!QI .;YZK14R
M:^? $>&2-.[4?PP];R'0^Q'Q%3U?*=3#GIUP   .(.L2?_-J]?U</\T:'4=@
M_!P_%^I3BG:?_P!">]']*&K=0SQK##4 8:@##4 8:@##4 8K[5?+K9')+MIE
M*BN3([L*2I%#-<9\J.(.I'P41#RJT85&Q([*Z;Z%Q1KU*+X%;$BQ7>7.A48]
ME608I)<EX_.7"=>1S4A!$EQIYL_M'6G"4A:>/(I)CSKVU.NC31V\6\N=#UM;
MVM;265*6%\^I=]%R+X1D.59!E<EN7D$Y<UQA!-1T&26V66R^T::;)*$)X<B4
MD%"VI4$:",_CWUSJ+J]K7,DE5EB;-J3>1,B> N4C<C-I1VA;UX=.18CK:Y24
M-(DM43HH;R4$XLM/>T<4HJ<!XQV?;IB:.2>=,K<&9/ 7$MK7<L#S5Z?FKD=/
M"SKX54C>=Q<SO[,J+=+LMR%-;)J3#:;:CQEI2ZEZO,LH0@EFM)&:R3J/LG03
M1L*%)46,<J:<JKF;.N7-HS%-QM.ZKHJ3FJHJ,J9$3/BS(R.Z9V?=+1=;[=;W
MT+Y5E*E?)T5JWPM9)+FHK%>;;+21<$U/EXBXI484WPHV)77?726E:XJ5L.-7
MPQ2*;D4S(>0+W=+7%N$.!)4Q%NC)1K@VDB,G6242R2=2.G$NP)J4835%DCK%
M704KBI2C*,%9)HR[J%?CF:Y/B92$6&X*C1Y9$4J*M#<B,[3D-;+Z5MF9=@S3
M4>-Q:4J[8XNJ9ES+PIE+BTVA<6KI2DR+G3(J<"NA5IW(S--\5D:;G_XLN-T%
M2^8C\R<2M>9-CF^:T5XZ=%!Y_+Z'1]'AYKOG7/K=W?PGM\VNNEZ7'SFPYH^;
MJ9F;P%#=\RR:^76->[E<G7+G!YLH#S>E@HQ,GJ03*&20EO2?$M!%Q'K2M*5*
M"PC'(N?2^^^?PEO7OJ]>HE2<E64<VAFS,S-X"ZJW3SE=X5?G+FA=T<BE!><5
M$B*0[')9NDEUHV>;6>L]6I:357LCP^6VZ0P8>:[YY9\V17="Z7;%VM7I<?.P
MX?-CF=\J,RY=*HY8K]D5ZR>X*NE^F+FS32EM*UZ4I0VCW*&T()*4(*O!*$D0
MNJ%"G1CA@C)].$L;FZJW,\=26)?IF3,B;B'WQS+\EQ&2Y+QNY/6]UXB2^ELR
M4TZ2:T)QM9*0NE3]TDQ1<6M*NC5(I+Z:RNTO:]K)94I+%5S[N^F92IR'/<KR
MI,5N]W#GF82S=B-,LLQ&VW#Y5I3'0V6KAR\HHH65&B^".?/E5>-5/:ZVG<W+
M)4D^'-D1/THA57'=#/;K;'+1/O;KL-]!,RE$AI$A]I)4)#TA""=<33A1:S'G
M3V=;PGCC#*F;.R;R9D\"'I5VQ=U*:TY5%6*HRYG5-V38E\*J6!R\W-VTL6)R
M2I5HC/.2F(O#2AYU))6HCI7B22[(O$I02:S;G*C/N%@M>HM-*2KS45VW5$^\
MW.Z1X,6?)4_'MC'18#:J$33&HUZ"H1=E1\H0I0@JK%&62NN^*MQ4JI%)*Z01
MDW$,^P//U,7?,+_D]W<;O5QQJ9 MTZBDO*G$EE,9*5,I[U1$V6E7"E.)C$7M
MD\*4*<>;&I%53[N7%GWS.;/VDL:M:K5FN.=*4473BYJ1S9LV<QF^[B9EDMO3
M:KU=5OV\E\\Y'0VS'2Z]P_"/<RA'.KX>Z<U'V1?4+"A1EBA%E\*\#YO 8^YV
MI=7$,%2;QU,B/OLB/X7+7*R*]32MG2)SJCLS26+4I)Z%1VVUFM)(4FAD9*.I
M'RCWC0IQQ,GGY]TM9W56>!Y+_;1H[C:B^7;=#.;Y;7[5=+KS\64A+4M71XR'
MWD(,C)+CZ&DNK*J2]TOL"UI;.MZ<DE&+*F;*K)O([>(OJ^V+NM!83FZ+GR11
M5WU1'7A+<C-,F1C+F'=/->-K5J*"ZVTZ39FX3I\TM:#6V1K+49-J(C/EY3'L
MMI2Z7I<//UY=[+H7PEJE]72AT&+^WJR:WR+G3+ER*A<[9NIGMH@1[;"O!]%A
MIT0N?8CR78Z>0DLNOMK<;(J<"2HJ=@>%39MO4DLECE7/E5'WT164NZ.V;RE!
M(1GDCF=(JV\JHJIX"V8YFN3XF_)?L%P5%.:G3-:4AM]AXBJ9<XT\E:%&53H9
MIJ53H/>XM*5=$2<7;-H5/"F4M+2^KVJJM*6'%GS*B[Z*Z+]-9"]9ADV1,G'O
MES>GL](7,)+YDK2^XA+9FGAWI:4I222[TB+@1":-K2I*\(HF1O +B^KUT:I-
M9(^++K^FC,F@LNH718L-0!AJ ,-0!AJ ,-0!CHKJF'6]9+\%C>$6--[3_P =
M/?4Z%V,_EJ[R<:G4XT(Z@   'YU9F?\ G#(?.4SPZQV6T_@AZL>(^>K]/\FI
MZ\N-2QZA=%DPU &&H PU &&H PU &&H PU &&H PU &&H PU &*B#"G7.6U
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MAJRHSQK(J %0 J %0 J %0 J %0 J %0 J %0 J %0 J %0 J %0 J %0 J
M%0 J %0 J %0 J %0 J %0 J %0 J %0 J %0!T7U2C_ /&LE^"QO"+&F]I_
M,I[ZG0.QO\M7>3C4ZJ&AG3P   _.;-#_ ,XY#YSF_G"QV2T_@AZL>(^?;[XB
MIZ\N-2QU%T60J %0 J %0 J %0 J %0 J %0 J -H6"0]BFSMSRJS+./?[Y>
M4V!<]O@\Q :C=(6AM9<4*<5P53E20P5>*5[V-.>6,(8VUR=LNMC9K6:VVSI5
MJ>2<ZG1XM*1PXLFIUS[ABUGP3([[:)-\M?1'HL9F1)DM'.C)EI8BD:G5G'4X
M3M"(J^YX_9(7]6]ITYI"3NJHGFJSKFRLQB:.SJM6DM2.%4BBJO.BZ)'.N%W\
M1F=LV]BVG'[+<[IA]]RZ;?HOR@KY)-UF+!B.J-+)$MIA[G'U)2;AI5I))&DN
MZ,94OY5*DHQJ0I)!6YS/)=.=49-'"9ZCLN-*E"4Z,ZRU$Q<UT2*+FRI%7EIT
M-DWS[(VKQVVY#F5LR&5.9M-CM+-[M\E#:43#8>4VLFW&54+G=*E,G721+X\@
MI7:=2=.E*"1Q3EA74^73JT[Q6FQ:-.M6C466&$,<5R.V1<VO[.C+E+%<+'AU
M_P $N>78G"F6B=CLF*Q=($N4F:V]'G&:&G4.<VT9+UI,E)TTH+J%>O2N(TJJ
MI))HK*B-E3.F=<C%A4MK:O:RK48K"5)8XD5<2*DLB*[)E<RI.UUMLDF!CEXP
M_(KW-EMQE77)+<EU$6$[*2E9ICMH8=0\3)*(EJ6X55$K@0L5VE.HBU(5*<$1
MVBK/)M>5&?1DS&4CL>G16-*I1J356Q3B[15?13"J2PZ55<[YBTP]NL9LMOS.
M9F;\I:\/NS$(FX.E"IK3O.)2VDEU)'.'H6:S,]*:\#,>\[^K4E22DB?W8JN7
M[.;A;-NJ6U/95"C"M*NLO[,T3(W.3+P/D7/D3=+1B4/&[T_.3%P2]Y$I<EQ2
M&;?,7HA0EF7-),VXRS6X53(U.*2DZ%P+B+BZG5IHCUH0R:4\Y=/VLB;Q96,*
M-59-0G4>6:,EYD=&:.5<^563(FZ9UAV.6/ ]W+_C,J-+N',6R4_;)1O%%<:B
MO6];[C;R"0K4X:%DWJ(TZ5%JT\:%B[NXJ7-G"HBI%Y(Z,^7$V3<='WC.;/M:
M5GM"I25%DT5PJ[,F!\J:596?)E1VU8CC&(V/)6+OET'';O*Q^VKC1(6-P'E3
M)DF8\@U*UR&X]4-(2G4I7-?;$1&,A<752DL:2SBDI.JR5&1$WL65?"8JTLJ5
M?'72E-815$2$5Q*LO62+HB,Z\W2B(I6W7:E=U<Q>78[1<<9_:*XKL\RT7A*U
MKB/H(G">:<<0TMQE355<4U)2%%4^QYT]IX$J).4:F".))1TIJ7.ROQH>M;8R
MU5IRIPE2Z26!8R?FKG=%5(XHX<NXJ*CJ7G;E>V"=TK-9K%#N3,J!-6B#D#LI
M#Z)KK*5$9.Q>:23:'**T*0LS+O:EQ.EK?^]>Z2G-8LJ98LV'>5\JIIR%]LM;
M%+Z%.E&3Q56GB?%OQ;(BY65%U;K:7NA_^*3OA#WA%#9J7F)O&F7'\DM]2EJ/
M0\!4 *@!4 *@!4 *@!4 *@!4 *@!4 ==]5#]Q[QYV7^;,#GO:7XB/J^53JW8
M[X6?K_MB;Z&IF\@           :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
M             <=]84J[F3?@T7P9#J79WX--]>,X7VO7_L9>K'B-6:1L9ISC
M2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:
M0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2
M <:0#F]NJ\5,EOGP%'ADC3NU'\,/6\AT;L-\14]3RG4(YV=?   #AKK&'_S<
MO?\ 5P_S1H=0V%\''\7ZE.,]IOCY[T?TH:KJ,Z:RPJ 85 ,*@&%0#"H!A4 P
MJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 8
M5 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 QT;U1SK>\F^"QO"+&G=IO,I[ZF
M_P#8[^2KO)QG5@T,Z:   'YQ9J?^<LA\YS?SA8[):?PP]6/$< OD_P BIZ\N
M-2QU%R63"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&,XPS+['%L=SPC,X[\
MC%+JZW,9D0])RH%P:2:$R&DK,DJ)2>]<2?*GD[N+N[:I*I&M25$G')ES2CJ7
MR&<L+RE&G*A715IR5T5,\99L2>#(NX7VQN;:84B\7.'EK]]E7"TSK9&M[5J>
MBK)<YDVR4ZXZYH223/CIU"UJ^]7"QBM-()&49/B1<ROH3D+VBEE:PJ+&LM19
MPE%L"Q\Y&SJK<9-&76K++!8H\[,I>'WVPP6[2Z@FI;MOEQHQF3#B.AF:D.I0
M>E>I%%4(ZD*5M9T:DU2DE6,UQ:,2*N?SM&HKC>PN*4$E6E1E3CA9I+%43S5Y
MN5%;(KY]#%LM&362S_MY#D7J1=TW>T';[5<GV74N2'><;7125J6I!<#(M2N3
M^ >]6WJ5.B5(I'#)U1\V<\*%W2I=/%:BSQPPQDJ+E7)OMX2W8[D=IMVW>;8[
M+=4BZWIRU+MK:4&I*^AOK6[J47!-$JX5Y1[UZ$YW-*:9H8W\*(Q96MQ3IVE>
MG)>=4Z/#^&2JIE]YRZRYW*;R61GL[$[K(981>;0IB:]'.0RVEM;L0XBC3I<T
MZM#FFBC/CVL;2MIVR=&E%*D45<,GB[/FEBU:TX#,U;VG=KTJW$J,E1,46DJ.
MB,JQPZ%U+I?*8M'R:TL8'EV/.SGI=TN=TA28#[K:]4AB*IPE.+,S5I49&1Z5
M*,_9%^MO-;BG-$1$C&2+N.QC8W=-+2M262RE*4516SHBKEW"[L7[$[UMQ8\:
MFY'(QMRQNRW+K;&(KSY70Y#G.(>0;2DH4ZE)$V72%$1=@R(6\J-:G<SJ)!)X
MV971,+:-;:>:7$+BWJV4*4JBT\&+%%(JN-U=-+.B9.<W@0N"]P\1<W=_:DG9
M+>+3;6FV//*;URH_.VTHAFI%2UFA?NC3RE4RKV?)+&LEGT>3&DL6XO/Q>,N/
MF=#YATV7HY1PKDRIS,/A9<_B<M]@R#&;) OFWJ\HE-627)C7"T9?;&)#*6Y;
M36AQ+\8S0\II25:#IQ)2=1$9<GK7H5:DH5^C3$B*DH25,SZ%RH^G>4\+:ZHT
MHSMNE5(*J2C4BDD96RO'))M&^CLNBD3D[.&Y/CN0V[+7LS<MTDY$MA;<MAE#
M942:$+F'J-3B%+*O-EIX<M1Z>[K7I3A*FE+$C)F7].K)IRGFMXEM7IU(UEKX
M5=722-^;6CZ,FZ7W')^T.)9S S:)?YDZ 4OGXEC3!<:?A$^:B,Y+RCT*2R2N
M!,ZC6=.0A:UX7E>@M%8(BMEEBR2WDW=UF+RUJ;.MKF->,Y*CY(86POZ2YE2/
MW7534D]YM^?+?:.K3KSJVS/@9I4LS+A[!C8*:-%$74:I65)354S*I3U%9Y,*
M@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 8Z]ZIQUP:\>=E_FS Y[VE^(CZOE
M4ZKV/^%GZ_[8F_!JANX           &O<\_?S:OSW<?U!<@ V)^IG!/,D'P*
M0"FP@            ''W6#*NY<SX-%\&0ZGV=^#3?7C.$]L%_P"QEZL>(U;I
M,;&::XTF <:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, XTF <
M:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&D
MP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, YO7JPE3);W\!1X9(TWM3_  P]
M;R'1^POQ%3U/*=/#G9V$   .%^L<?_-V]_U<+\T:'3]A?!Q_%QJ<;[2_'S_#
M^E#551G36F%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ
M85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85
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M;C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2
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M8JD+DLQ4@ J0 5( *D %2 "I !4@ J0 5( *D %2 "I !4@ J0 5( *D %2
M"I !4@ J0 5( *D %2 "I !4@ J0 5( *D %2 "I !4@ J0 5( *D %2 "I
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MA4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4
MPJ 8Z3ZH!UOF3_!(WA%C3^TWF0WU-[[(_P E3>3C.LQHAT@   /S7S<_\YY'
MYTF_G"QV&T_AAZL>(X/>I_D5/6EQJ6&HNBT85 ,*@&%0#"H!A4 PJ 85 ,*@
M&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0
M#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 8[%ZHYUP2\^=U_FS Y]VD_GCZOE4Z?V
M2^&GZ_D0Z!&JFZ            :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
M             <D[^%7<>9\'C>#(=6[.?!IORXS@7;-?^REZL>(UCI&R,:4X
MT@P<:08.-(,'&D&#C2#!QI!@XT@P<:08.-(,'&D&#C2#!QI!@XT@P<:08.-(
M,'&D&#C2#!QI!@XT@P<:08.-(,'&D&#C2#!QI!@XT@P<:08.-(,'&D&#C2#!
MQI!@XT@P<:08.-(,'&D&#C2#!QI!@YN[JTE3([U\"3X5(TOM5_##UO(=+[ K
M_DU?4\ITL.<G9P   X.ZRATWAOG]7"_-&ATW8?P<?#QJ<A[1_'3_  _I0U-J
M,9TUUAJ, PU& 8:C ,-1@&&HP##48!AJ, PU& 8:C ,-1@&&HP##48!AJ, P
MU& 8:C ,-1@&&HP##48!AJ, PU& 8:C ,-1@&&HP##48!AJ, PU& 8:C ,-1
M@&&HP##48!AJ, PU& 8:C ,-1@&&HP##48!CI7J?'6^91\$C>$6-/[2^9#?4
MWKLE_)4WDXSK4:*=&   #\T\W,_VTR/SI-_.%CL%I_##U8\1PJ]3_(J>M+C+
M#J,71:,-1@&&HP##48!AJ, PU& 8:C ,-1@&&HP##48!AJ, PU& 8:C ,-1@
M&&HP##48!AJ, PU& 8:C ,-1@&&HP##48!AJ, PU& 8:C ,-1@&&HP##48!A
MJ, PU& 8:C ,-1@&&HP##48!AJ, PU& 8:C ,=D=40ZX'>?.Z_S9@<_[2?SQ
M]7RJ=-[)_#3]?R(=!#53<P           ->YY^_FU?GNX_J"Y !L3]3.">9(
M/@4@%-A             .>=V]L\UR?-)-VLELZ3 <980A[GV&ZJ0@B46EQQ)
M\#[@Z#L3:UK;VJ0J2:3KH7R(<?[3]G[^\OI5:-/%%4CEQ13,FZJ&#?0EN7\R
M?&8OC1G/G]CZ?LRY#5NZ.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J'
M]0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.
MU>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]
MF7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A
M\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD
M^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^
MA+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J
M]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(
M.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L
M?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q
M?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<
MOYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J'
M]0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.
MU>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]
MF7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A
M\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD
M^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^
MA+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J
M]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(
M.Z.U>J]J']0^A+<OYD^,Q?&A\_L?3]F7(.Z.U>J]J']0^A+<OYD^,Q?&A\_L
M?3]F7(.Z.U>J]J']1M'9' ,KQ"]7.7D$#HD>1%2TTOGF7:K)PE4HVM1EP[8U
MCM!M*WNJ48TI8E1=2IHW4-Z[(;%O+&O4E7AA2463+%<K[BJ;N&DG3P   Y(W
MPV8W*R_<J[7_ !ZR],M,E$5+$CI,5K4;49MM7>NNI45%),N)#>ME;4MJ-M&$
MY,J/H76NX<ZVSL>ZN+J52G!XJVE-2:U->>KEO)Z.?'(7CQE?G=GZ?BER&&[O
MWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7
M(.[]]Z'M1Y2E/8#=])F1XTNI<.$F(?\ ^L(^>676>*7(.[U_U?M1_J*EKJ[;
MMN-DL[*ALS^T7*CZB]FBS(4+MVS]/Q*5IV<OE^QXX\I/U<MVOFAKRICWP?/K
M/TO$I/=N^]#QIRCU<MVOFAKRICWP?/K/TO$H[MWWH>-.4>KENU\T->5,>^#Y
M]9^EXE'=N^]#QIRCU<MVOFAKRICWP?/K/TO$H[MWWH>-.4>KENU\T->5,>^#
MY]9^EXE'=N^]#QIRE*YU?]W6UJ06.J61'36F3%TG[%72,5)MRS]/Q+R%"]G;
M_J_''E/HUU>-XGDZDXV9%W9<(O\ 6\)^=V?I^*7(1W>ONK]J/*?3U<MY/1SX
MY"\>)^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R
M>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1Z
MN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4
M>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW
M5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.
M[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?B
MER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9
M^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP
M^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR
M%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GH
MY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KE
MO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E
M'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?
MM1Y3>/5LVRS? ;K?I.66SH#$V.PW&5S[#VI;:U&HJ,N+,J$?9&M[<OZ-Q""4
MY.RKH7RFU=GMFW%K.:U8X71&RHO$IT2-4-T   #AO*NK_NW<LGO=QAX_SD.7
M/E2([G2X:=3;KREI.BGB,JD?9(=(M]L6D:48K/*B)HEJWCE-SL*]G6G)(9%D
MJYXZ]\M/JY;R>CGQR%X\>_SNS]/Q2Y"W[OWW5^U'E'JY;R>CGQR%X\/G=GZ?
MBER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW
M9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7C
MP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQ
MR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\G
MHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>K
MEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'
ME'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U
M?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N
M_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI
M<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?
MI^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/
MG=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A
M>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.
M?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;
MR>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1
MZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[
M4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OW
MW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(
M.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E.E^KE@^48'B-SMF5P>@
M3I%Q5)9:YUI[4T;#2"55E:R+BD^!F-/VW=TKBK&5-71(MIUKK-Y[/V5:UHRC
M53"JR?.BZ$U&XQ@#90           ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@
M%-A
M                               /#,DD9F="+B9@"SMVTI9JD(5S3*U&
M:$TJ>GM_9 DNK3#33:6T)+2DJ%7E @GH1]R7\  :$?<E_  &A'W)?P !H1]R
M7\  :$?<E_  +?+M2)#ANMKYM2O=%2I>SV !]+:E+32X]-+S:CYPNW7D/V#(
M 5H
M
M         U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
M
M           I)9F\M$)!TU]\\9=ALO; %41$DB2DJ)(J$1=H@!Z
M  *241L.(FH+@GO7B+LH/L_8 %41DHB,CJ1\2, >@
M
M                                             U[GG[^;5^>[C^H+
MD &Q/U,X)YD@^!2 4V$
M                                             (.NI9;4ZOW*2J8
M^,-I24J?=_IWCU*[A=A/V" %2             \,B41I454F5#+N& *6(9LK
M7"6=='?,F?9;/V@!5@
M
M                      U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
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MFK4:&Z>[I2@U_:=@EI42&+$Z/F8V?9.TEOJ:S6.%E;.^A-XV*,29H
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MT_7\B'08U4W(           #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
M          #A7K/_ %MS_@D/P1#I.P?A$WUXSD_:3XU=Z/$:=(; :P>B2"9
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M&GZ_D0Z!&JFZ            :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
M           <*]9_ZVY_P2'X(ATG8/PB;Z\9R?M)\:N]'B-.D-@-8/1)!,@*
M3T"#?V!=5^\979H&07>^Q[=;KBRW*BLQ6SEOFTZDE)UF:FT),R/D(U4[(U>\
M[00HS6$8K)8JV7)RFYV'9B=>G&I.:122(J,CJR\#+PF<N]4+'S8-+&3342:'
M1Q;#*T5['>$:3_ZPQB=I:CY8(V^9>79&BJ9*DGWDXLG&:3W.V;R?;!QJ1/6W
M<+%)7S4:Z1R-*><H9DVZA530LR(S+B9'V#Y1LNS]J4KO(F22:#4-J;%K6+*O
M.@N:2>5-!AEDLMUR*ZQ;)9(JYMUFKYN-&;]THZ5,S,Z$24D1J4HSHDN)\!DZ
MM6%*"SFK(AA:-"=::0@F*4LR?3Z)G4Z,Q_JD/.14/91D7,2U$1JB6]DG$H,^
MP;KIE4_80-0K]I416IPR:U7R?6;[;]D,CU:F75%/*O(3OW5)6W%6[C.1&[,2
M1FB+<&20A9]KG6C/3]X8BCVFRM4ADW%\GUBX['HSTJF75)/*F;@.=;S9KICU
MUE62]15P[I"6;4F.Y2J54J1D95(TF1DI*B.BBXEP&Y4JL*L$G!713GM>A.C-
M833#*.=/I_HN=,A1CU+<] @F0D@D0DI4N-B@M7.]VVVR%*2Q,E,1G5(IK)#S
MB4&::D95H? >-::PIRDF=$52XMJ25:T(+FE)$X5.O(_5EVS921.%<)!D7NG9
M1$9_DT(+_0.=2[17:^BG@^LZW#LE8Q1EQ2WY<B(?1SJU;8K0:4LSFU'R+3*5
M4OOB,O\ 0*4[0W::4X"J79.P5,TD_$:MW*ZN<K&+9)O^)S7+E;8:%/2X,DD]
M*;:055+0M!)2LDEQ,M*3IR5&P;.[0)6FE.JF%5S*F;ZC4]K]E%MZ:U:$EE&*
M.J+G;2KID7@3PF)[%XQCN69ZS;<E)+T1N,])CPEJ-*9+[6FC9T,C,B2:G-)<
MNGCPJ,EMJYJT+994\[HCZDU^3PF&[-V="YO$A6S(BJB>DJ:-W(ZMN9<CFS^L
M1@.%6+&(=\LT&/:;L4MN,AJ*DFD2&EH4:B-M-$U3I)6JG</E(8'L_?W%6LL)
MJLHL^71X3:.UFR[6C;QJ4XI3EB;(C.C+H3)NOX-)D^P./8_<=M8,FX6F%*DJ
MD2B4\_&:<<,B=,BJI23,Z%P%AMVXJPNU2,I(C)I7497LO:4)V$92A%5>658I
MK-0;F0($;?7Y/CQ&&H!3+4GHB&D)9-*VV#41H(M)DJIUX<1L^S:DEV;B55?#
M/*^7/(T;:U*";96"13#CIHS(V6,'R'2&;8OC,?#,CD,66 T^U:YKC;J(K*5)
M6F.LR41DBI&1C1[&ZK+<4T6<FQ1TKK0Z=M:RMXV5:24XHJ4Y_93T5W#GWJ[X
MCBV4WRZN9$RW-?M[#3D*W/\ %M?.*4EQTT?;:*)30ZEW_)6@W/M#=UJ%./1K
MA22JZIXD\/D.<]D;"VNJTUK(DE@B88KF5\ZMI;(FKG:V+CUBL,Q3&7[-.L$9
MJW3)YOIDP8Y:6U(:)!I<)!<$4-6DZ%Q^P8\NSMY7KI.-15DD695XMT]^V&SK
M:V6G*DB063O%,V1LNI/+X#1Q#<#G9,A)2>D!!,A)2I(@*21"2":0*5)%RB2%
M)$!2?0A)2I)/*)*5-T=7:,W)OMZ0LN^Z"1)5VJNI]H:7VK_AAZWD.E__ *?_
M !57U/W(;W7;GF5$I^B6-1$IQ)UH1GRCG!VLR$N3AR 0 !QKNU]8N0?""\&@
M=CV+\%3WO*I\V=IO_3K>MY$,)/LC,&ND#$%2$# J('RB"HB?*(*D(F!)$Q!4
MA Q!4A$P)(F()(F!49#AF#Y!GET5:K TA3C:><DOO+)MEELSTZEGQ,^/82DS
M[@L+V^I6D,=1=[6IEMF[+KW]3!23-G5<B)O_ %.IN^V=5B&3257K(G5OG36W
M#82A!=LB4XI1G[.DAJ%7M3)^93R;J\AT*AV'@B?W:JJOW4;C?B0M^2=5R8Q%
M<D8M>BER4$9I@S6R:-=.-$NH49$9]C4@B[9D/:W[3Q56JP9-:<GUEO>=B91B
MJT*F)?1DC>U]7A.?IT*7;9C]OGLKCS8KBF9##A46AQ!T-)EW#&YPG&<4E%71
M3G56E*E-831I15E0W1B?5FR>[L(F9+.:L;+A$I,5">E2J']T25)0BI?QE'VR
M&JW?:2C35J:+/=S)R^(WJP['7%5,5:24TU>=+C9-S*NZAE[W54L2F=,?(IC<
MBA_A'&&G$5['>$:3_P"L,6G:BH^6"-OJ9R78FAAYM22+O(OBR<9I/<;:K)-M
MY+7RF29=IDJ-$2Z1R/FE+(JZ%D?%"Z%72?+QH9T.FT[/VI2O$YN229T7Z94-
M'VML2OL^28^=!<TDS;RZE^B.RF&P8$VZ38]NMS"Y4^4M+4>.T6I:UJ.A$1#)
MU*D:<5E)61##T:4ZLTA!'DN9#H7'.JJ\]$;D97?#C2UD1JA0&TN$W7C0WG#H
M9]NB*=HS&EW':9$DU*#IK7D^LZ-:=C%6+UZC+JCH\*\GA4HLPZK=SMT%V=B-
MU^5'6DFM5ME-DR\LBXT;<29I4K^*HD^R/2U[20G+#5CAW4S>'Z*>5]V.G"*R
MH3Q-]E<B^!<W@R;YSVZVXRXMEY"FWFU&AQM9&E25).AD9'Q(R/E&XHJ*CH<_
ME%8JRY%0^1B01,02A$021,"HB8$D3$%1$Q!)$P)(@5$3$$H1,"HB!)$Q!4A$
M021,"HZMZG'_ '3,/ZVW_P V0-([2YZ?XO(="[)>;5_#^XZ@&FF^   !^;6;
M%_G/(O.<W\X6.Q6G\,/5CQ'!;U?\BIZTN-2Q:1<EFXT@'&D XT@'&D XT@'&
MD XT@'&D XT@'&D XT@'&D YL39_:TMT[U<+6Y<56MB!%*2J0ADGS4M3B4)1
MI-:*5(U'6O8&(VGM#W."2;$JJV=C/;'V7[_4E'%A2*/F?D-Q>I[#]+W?($>/
M&O=YEZOVOJ-I[H1ZWV?]Q37+JD0[?;ID_P#:QU9Q6'7R1T%):N;0:J5Y\^6@
M]*?:1921.CSKZ7U'G4[)1C%5Z7,GH_[CF)"%.&E*$FI:S(DH253,SY"(BY1N
MBJQSY$559#;V#=7'/LNYJ7<VBQVS+H9R)R3Z2I!]EN.1DK\H:"[HU^[VY;T<
MD>?+<S</(YM%CV;NKAEG_;CNY_R\K&2Y]U9XN$X?=LI;R5V:JVM)=3%5#2T2
M]3B44-1/*I[KM"SL]O+7K1IX&Q;OU%_?]F8VU"57I'PIFP_6<^:1MAHSC2 <
M:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <[#ZI
M)4P2\^=U_FS Y]VD_GCZOE4ZCV2^&GZ_[4-_C53=0           ->YY^_FU
M?GNX_J"Y !L3]3.">9(/@4@%-A             .%>L_];<_X)#\$0Z3L'X1
M-]>,Y/VD^-7>CQ&G2&P&L'HD@F0%)(@(-H6G?O<#'\0MN'V"0Q;XMM2XVF>3
M1/2G$..*<))F[J0DDDK26E%:=D86IL:WJ5I59HJK+1HS;AL-+;]U2H1HTU1,
M.EG7.^ETW,QG.R&\.YU[SVW8_<)SE^M4XU].;>;0:X[:4&KGB<0E)I))TX*.
MA\G+08W:VS+6G06<4P*F;=W#+[$VQ>5KF-.:XXJ[Y,VZ_P!$T9S>>_RX"-I,
MD^4#3H4TTF.2N4Y!OM\UI[NJA^P-:V,DO>X8=W@97-MV\L$L:F/,R<+HWC-*
M]4:) <R+(YKI).Y1X;#<:ONB:><4;ID7LH01F-D[2RDE.")F55^KRFI=D(16
MI4DOG(B-O*N7B0RWK37S-+1!LB+)(DP<<?4\5QEPU*;-4@M/--NK10TITZC2
M5:*.O+I(6'9VC0G*6-$62,SZM+&2[55[FE"'1JL8*[JFO(SKP[_@+AU7LCRN
M_P"-7=N_R'YUM@R6FK7.E*4XLS4@U/-$M1F:B;[PRKR:J#R[0T*-.K' B(JI
ME1/$OAR\![=EKJO6HS2HJRC%4PJN7?3P9.$UGUJ^@?2!;NC:>F_);?3=%*UY
MYWF]5/MM/;[%.X,WV;Q>[R?-BR<"&M]K\'O46SX$?A5OIO&C!M1HYTGB.U."
M738IW-)UK-W)$VRZRDS.D2$EST1<@FE<VEPD=[S:>&FA]D:9=;2N(;02BDN9
MB@C,FG"^A])T"SV1:U-DRN)1_N)"HKO+/%9-D=M":#F]/(-T.>J3(24J7K$?
MWKL7G&)X= M;K^&?JKQ%[8?$T_7CQH=[9VM3>#Y,XE1H4BU3E)6DS2:3*,X=
M2,N2@Y-8H]Q3]>/&AW3:BJEG65,B]'/]*G!^*7#*8M[A'B,B4F^N.(3%1$4H
MUK77@DTEP4D_MB5WM.7@.LW,*,J:]*B86RN<(LIUX5D]W54FJY,.GE\.37D/
MT#ES&(%I>GWE3;4>-'4]/4?%I*$(U.<O*DB(QQZ,%E-(PSJN3R'T'.HD*:RG
MD1$==6Z<,[8X;)SK*TVFW7)5FDM-.38\Q*5+6@V5)TDG0I!D??<M1UC:5XEK
M1QRCC159M_A.$;%V=*]N.CC/HU1,3Y\S;W"9OO!M=DF+62+DF19:_D;AR406
M6Y1.J6@G4+<JE;CKE"_!\E!B]D;3I5ZBTZ=)*>1\C;B:$369CM!L:O:THU:M
M=:O.PIB?(Z*N=92]$W-U=?JN@?")?AE#5^T'QDMY.(WGLI_YT-^7ZE-+[I__
M -0'_P"]M'@HXVO9G_F?AGQR-!VO_P"XOKTOTP.G<\_<;)O-,_\ -G!H-A\3
M3]>/ZD.J;9^ K_\ '/\ 2IR5M!@-TS>YS7;/?%V&=:FVW6Y3*5FZ?/&I/>J0
MXV::$7;'2=KW\+6$4G#&DM&]X%..]G]DU+ZI):=1:4J;94=\KIG148K-X=OK
MSAC]LN%\R%W(9EUYY'/OI<YQ"8Q-T(U...&9'SG)V!1L?:%.Y2484TII%LVZ
M^I$U%7:/956RE"56JM99XLJNZ8<.E57TC'<'VZR?/Y2V;%'245@R*5/?,VX[
M1GQ(C41&:E?Q4D9_8%]?;2HVD7J+E7,B9U,7LS8USM"34DR)GDN2*?3<13<4
M?JLES)'*R@RD&15)J%5"5=GBI\C,OX!K$NU67)3R>M_M-VCV#5LM?+ZG^_+X
MC!LZV,RG#(;MVCN(O%F8(U/R(Z5(>:07*MQHS5WI=DTJ53LT(9BPV]0N9)!4
MP277F7>4UW:W96YLH+4BJ5()G5,BINK'5O*NZ8E@N++S7)X6--RBAKFDZ925
M(YTD\RRMWW)*36NBG*,K?7?NM"55L6%LF^J(8#9=@M]=0H)+#C?*SYHK+-DU
M&Q,FZO>061-O1:)Q7F7/DE%YE#"F$M)-"EFZM9K61(3IXU_TC!VO:.E5Q8XX
M$BCYW?<3)G-JO^QE>@D.BGTBSEA;"S9%7$JNN3(9#$ZK\A49"IV2H:F&7X1M
MB(;K25=HEJ=;-1=W20L9]JXHO-INF[)O(O&9"GV!FL465=$72B0=.'%'B0UA
MGNW%^V]FM,7/1(@2M70Y[%>;<T\J5$?%*R(RJD_L&8V79VTZ5[%5AD5,Z+],
MQIFV=AU]FS1*C2C+S9)F7D7<X%4Q$N498UY21 4GT(24J23RB2E3=W5M_>&\
M_ D^%2-+[5_PP];R'2^P'Q-7U/W'2"T)<0IM952HJ&7<,<X.U%/#6I.J(Z=7
M&>"3^Z0?(8 J@!QKNU]8N0?""\&@=CV+\%3WO*I\V=IO_3K>MY$,)/LC,&ND
M#$%2$# J('RB"HB?*(*D(F!)$Q!4A Q!4A$P)(F()(F!493MWF\G;_)V<A89
M.4REIUB5#)SFN>:<3P2:]*Z462%\GVHQNT;%+NBM-5;*BHN=OHF0S.R-IRV?
M<)6BF+(J*CLZ+NLNEE\!?[OO[N9<YAR(]S1;6"5J;B1&6N;3[)N)6I7^TJ@L
M*6P+.$66.)=:JOD8R]?M7M"I)XSP)J1$;QHJ^,Z$V2W N>?8P^_>TI.[6Y_H
MS\AM)(0\DT$M*])4(E<3)1)X=GLT&E;:L(6E9$AYLD=M1TKLUM6I?VRK4\^"
MLJZ\F??UL:3ZS=LBP\\B36$DAVXV]MV41<JG&G%M$H_90E*?]D;5V:J+*V6*
M_9DK>)>,T7ME1C"]C),\H(J[Z*J/P(B> HO6&S.'BMJQVSI9B2X$=,:1=EI)
M]YPFJI;T)61H31!))1J)1F?'@/3N_0E6E4FZI)7PYDW?'O'BG:RZA;PI4VBL
M4999U5LV?)FSN[KER%PVRWSSI67VJT7^=\K6JZRFH3B'6VTNMKD+)"7&UMI2
M?>J,JI.I4K3CQ'AM+8ENE"4Z:89115X"[V/VENUN84ZLL<9R2.9'1\CHS:=_
M(;^W@M<2[;:Y(Q+))I8A.3&E*Y4NQ2YY!D?8.J:?9H-.V356G=TU32K<.0Z'
MMVC&K8U4EHBLO#'*G$:5ZK.*QY5PN^82FR6Y ),&W&HB,DN/)-3RRKR*)&E)
M&784H;1VFNEC&-)/M95\&;Q\1I/8RQC*<[B2>;S8[ZYUWV9-Y5,EZQ>YU]Q1
M=MQC&I:H$V8T<V=,:ISQ,:S;;0A1D>G4I*C49<>!%6AF+#8&S:==)5*B8D3(
MB;NDRO:G;%6U6%&C+#)4Q*NYF1.%]W(9!U?]P[IG6,S(U^>Z3>K,\AIV49$E
M3K#R34TI>DB+46E:3.G&A&?&HL]NV$+:JBP1HS3-NIG,AV9VI.\H*E17G!<^
MM%S>5/!K-)=9;%V+%GJ+M#;)N-?HY2G4I(B3TIM7-NF1%]T6A9]M1F-H[/7*
MU;?"N>"MX-'(:7VLLTHW:3BC)41_Q:?(N^JFES&S&G'15OVMP9_85>;.VPU9
M*5LD2BF=(?(N>;<6E*N;)S1P(BX::#2ZFTKA-H="DN9B1&9.1SHU+8]HNR^G
M6']S!)7Q2SH^AV\1SB-R.>$3 DB8$D3$%1$Q!)$P)(@5$3$$H1,"HB!)$Q!4
MA$021,"HZMZG'_=,P_K;?_-D#2.TN>G^+R'0NR7FU?P_N.H!IIO@   ?F[FJ
M?\Y9%YSF_G"QV*T_AAZL>(X'?+_D5/6EQJ6+2+HLG&D XT@'&D XT@'&D XT
M@'&D XT@'&D XT@'&D XT@'.HNJ%;R)O++HI/%2H45M7\DG5K+_K)&D=IIY:
M<=]>(Z/V/IJU6?JIQOY".[V\&Z.-9Y=;/BQFW88*6$H6< GTFM3"''#YQ2#K
M12C+E[ ;,V9:U:$95/.5_M;I5MC;%[0N90I)S(MEPOH15RFM9/6+W7F1GXC]
MSC&R^VMEU)0V"/2M)I/[7M&,U'85I%45(KDW5-=GVFO915,294U(:YL-R<L5
M\M=Z8_IK;+8EM^RPXE9?ZAEZU/I*<H+]I%3A,!;UNBJQJ>BJ+P*YULUUE+=?
M\WL>*8C;5/P;A.9BRKK.JU5MPZ*YEI/?5[2EF7\D:$NP94Z$JE565$563RKR
M<)U"/:6G6N84:,722HBR7R)R\!FF^_':3*/@S?AVQC=C_%PW_(IEMN? U-[R
MH<"Z1U4XBXT@'.DNKWM1@>=8?/NN46LYMP8N3D9MTI$ADB92PRLDZ6G$%P-:
MCJ-.VWM&XMJR1IR9%B^9-:ZT.@=G=E6MW;RG5CB5)-GDF1HZE36<Y26THDO(
M05$(<6E)=HB49$-OCE0T*613Y:144.-(!QI .-(!QI .-(!QI .-(!QI .-(
M!QI .-(!QI .-(!SL'JEE3!;QYV7^;,#GW:7^>/J^53J?9'X:?K_ +8F_AJA
MNP           &O<\_?S:OSW<?U!<@ V)^IG!/,D'P*0"FP@
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MB)B"2)@21 J(F()0B8%1$"2)B"I"(@DB8%1U;U./^Z9A_6V_^;(&D=I<]/\
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MX6?K_MB;\&J&[@           :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
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M5UO^F1$P8D7.=$I;:M4V7T"R7'@DC,N?+IS'.XW Y\1,"2)@21,05$3$$D3
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MI_B\AT+LEYM7\/[CJ ::;X   'YV9FG_ #AD'G*9X=8[-:?P0]6/$?/%^O\
MDU/7EQJ632+HLG&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D X
MT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&
MD XT@'&D XT@'&D XT@'.M^JH5,(N_G5?YLP.=]IOB(^KY5.L]C?A9^O^V)O
M<:F;V   'RDOE':-RE5<B$]M1\A #YQXJ&VR-U)+?,]2UF1&>H^7B *D
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MQ891]9&4JN[;W>>'%&>1WA+$G"6F@N2T<4 .* '% #B@!Q0 XH <4 .* '%
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MPHE$5#4O6TDZ%RF= EM&4K2%2#8YJD431B567@91#9$(7]2C45>CI)*:JF?
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M7_SC,\.L=HL_X(>K'B/G#:"_Y-3UY?J4LM!=EBXH <4 .* '% #B@!Q0 XH
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M8#6#T203("DD0$$B$D$B I/2$D$R I)$)(/2 @F0DI) 4GH$$R$D$B$E*DB
M@D0%)(A)!(@(/2$E),@()$!22(202("DD0D@D0%)(A)!,A)2>D!!,A)2I(@*
M21"2":0*5)%RB2%)$!2?0A)2I)/*)*5-W=6W]X;S\"3X5(TOM7_##UO(=+[
M?$U?4_<=)#G!VH@\ZEEM3J_<I*I@#XPVEI2IYW^G>/4ON%V$_8( <?;M?6+D
M'P@O!H'8]B_!4][RJ?-G:;_TZWK>1#"3[(S!KI Q!4A P*B!\H@J(GRB"I")
M@21,05(0,05(1,"2)B"2)@5$3$$D3 J(J$$H1,"HAVQ!41,"2)B"HB8$GAB"
M2!G0N(%1$P)(F!41,02A$021,RY.R!41,"2)B"HB8@DB8$D0*B)B"4(F!41
MDB8@J0B()(F!4=6]3C_NF8?UMO\ YL@:1VEST_Q>0Z%V2\VK^']QU ---\
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M1"0=-??/&78;+L?9 %41$DB2DJ$7 B[A #T       !KW//W\VK\]W']07(
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M0N%LZOD;.Y]K[@5YQU#13I5N=EKD%#>@1)\>3*CR55+FWFFUF:#(TF1GR$?
MS$4+Z%9V23,[K%414W%*[G9E2@V*4%DJX5C&<5E%=4D1<F9M3Z2ED8E>XF5%
MA;[*$W\Y3< F2<2:#?>-*4%K(]-#U%Q'K&ZIRH],B\UG\"%O4L:L+CW=4Y^)
M(Y]*Y$R^$N%MVZRRZR;G$@0TO/6:85ON='6R0PZ9N$:U*,Z$VGFEZG*Z2'E4
MVA1IQBLER31TR9\WCRID/:CLFYJSG&$76G+#+*F3SLN]S5RYB5LP"]7-<YQ$
MB!%M5ODJ@.WJ9,:CVY<DJF3;+ZS(G#-):BT5[WB=",@JW].#9)+*2/A2*K)M
M:IH\.DBALNI562I*$81EAQRDB05=49?:=$?)HRZ4*=W"LG:R-K$BMZW;[(-/
M1H[)I<2ZAQ.M+B'$F:#;-/?:]6DBJ9F5#'HE[16DM7%S4S[FYK?</">S;B-=
M*&%5FN9$RN^E%S-I?,FG,IL?",#F62/FDRY';KG":QBY(*1!DQYZ(TW2E2$+
MYLU&VY1*M)F78.A\HPE[?QJK12.**]+#(J+%X^5#9MG;+G0C<2G@G%*%3+&4
M989:$5LJ+D7R*:=(;2:*I(@*21"2"9"2D](""9"2E21 4DB$D$T@4J2+E$D*
M2("D^A"2E22>424J;NZMO[PWGX$GPJ1I?:O^&'K>0Z7V ^)J^I^XZ2'.#M11
MN?\ %2B:Y6&#)3G:-?8+[  K !QKNU]8N0?""\&@=CV+\%3WO*I\V=IO_3K>
MMY$,)/LC,&ND#$%2$# J('RB"HB?*(*D(F!)$Q!4A Q!4A$P)(F()/M!E%!G
M1IIL-2BC.H>.-)2:V'="B5H<21D9I52BBJ7 >=2&**Q=4=,Z9TWCVI3P323)
M)E167,K:%W%TFVH64VF5@=WRIS"L<*X6^?%ALM)AN$R;<A*U*-2>>,S46GA1
M1#6*EK.-S&ETU1I15?.1\G@-[I7U.=C.X6WHXH2C%.8K,OXO*8>>+WK-%NY2
MF+:,9L\I7-1C>?;M<!;K*$H4B.E]Q2E'PJHRJ6JO$N09/WJG;-2>=229\BRE
MEULGT0P?N-6]5:[4Z,)9G5(0=$1&BZOOZ'?*6.5AV3Q<B1BCUL=_:!U24-0D
M46:]9:B4A23-*D4XZR5IIQKP%W&\HRI=*DDP:_IQ%C+9US"NE!8+TBZ/],C;
MKL5]UVYR*UVZ1=$K@W&+!I\IE;)K$UR&:CTD3Z&E&:>)&52J7#E'A2VC2G)(
M\Z*R\W%%8XMYR[K;'KTH+-%C-(^=@E&2P]9$7E3)G+OE%F=N..;:P+-"2[=+
ME"D(2VPA*7'G52U)3J41%6A=E1\!:6U9(5;B4UYL53/HYID;VV6I;VD:<>=.
M,LR957%],YBN28E.QE+)S)UNEJ=4IM;=NG,3%M.(]TAU+2C-)E_!W1D+>ZC6
M=DDGK15'WG,1=V,K9L4H25=$9QDJ;Z)_H7>V6RW.[4Y#=G(K:[G'NT!AB6:?
MPJ&G$+-24J[!'3B+2K4DE[""+S5C+)P&2H4*:[-JU%BF))Q1%TZ2.WEMMUQA
M9JN?%;DK@X[*E0U.IU&T^AUI*7$=I1$HZ&)VA4E"5+"K/41%W493SV32A42O
MB1%PT9JCZ%18Y2NN^V"86W]CRF/<()3IB)TBX)=N,8DJ:8)"FFXR*D:W"+43
MB$FI1*H0\*6TEE<SI+&3)A1.:NEW5=2:ES,75?8Z0LZ=9)Q>6)9/..5F9(ZU
MSNF57R%_Q*V(_;^T-7#'X-L:>Q=V4U&8,I+4A*H3JT2EDX:]+B^R1\2I]D[.
MZJ+[O+#.4FJ-J;G)S=XRFSZ2+=T\5*,46BZ)G17@O.ROE7A,$9L\R=A5F)JS
MP8Z)]W<B,Y&[()I]QSFT_@726O2AI.K5K,J<.QQU91:L8UY<Z2M!\#>-,F?Z
M;V#2A*=K#F11)5&Z1V7,F177(FE\V3\WW?VHRANVW&ZMR+5*AVIA4J>J)<XD
MA3;1$9D9I;<,ZJH9)+[8^!<12FTZ2RC%4DBR5D>,D\AZ+L6LD)324))!'7#.
M*LG@7@UE/:]KLJNT&+,:.%%?N+9/6FVS9K$6?-;49DE4=AQ1*42C(]!G35V*
MB:FTJ4)*F54CYRI%5C'?5!0V/7JP27-1998QE)$E+U477HUZ"U6#"L@R.7-B
M0V$1D6PC5=I<]Q,.+#(E&C\.ZZ:20>HC(D^Z.A\.!CVKW=.E%%57Q>:B957>
M1"VM=GUJ\I11&P><LN:D?65<V]GX%,XOV*2<;V47\H,Q'9#V4-+AW6&MF4T_
M%5!<2?-26C5J1K;41IKP47$JC%T;E*U]S7;H\J*Z,N),Z+N*9NZLUM]FIB95
M6MDE%45%3 N94T.G":C,; :L1,05$3$$D3 DB!41,02A$P*B($D3$%2$1!)$
MP*CJWJ<?]TS#^MM_\V0-([2YZ?XO(="[)>;5_#^XZ@&FF^   !P!EY?YLOWG
M&7X=8[59_P $/5CQ'S5M!?\ *J^O+]2EEH+LL7% #B@!Q0 XH <4 .* '% #
MB@!Q0 YGEBL]AL&)IS?)H7RK(GR7(>/V5:U-,.''(C=DOJ;,E*;0HR22$F55
M<O ZEA:]6K6K]!27"D4><M.7-%-U=9LEK0H6]K[S7CC6:K&G!V1<.><FRJB+
MD;7GR*Y;;WFK5[MSEO5C%CMZU&DV9ENBKC2&B2HE&1*)TR54BTGSA*X'VQ<4
M+%:4\723EN2DZ+XN)BTNMJ)7IX.AI0W8Q6*IX<7&Y]+3MMDEWAQ9C:H415P(
MCM,.?,8B2IM5:"Z.TZHE*JK@DSH1]@4U=I4J<E3G+A\Y4BJI'?5"JAL:XJP2
M3QCC\Q)2C&4]'-15TKFS/H*.T8)E-\*X_)\!2EVAY$>YMNJ2PJ.ISG.+O.FD
MD)3S2M:E&1)[(]:U]1I8<4O/1XZ7S9FSY\FLM[?9ES7QX(_QJB2=HX7?/B9F
MPJ[YM)YD>%WK&&(DV;T>3:YVLHER@2&Y<5Q;?!:"<;,R)1=HQ-M>TZZK&+I*
M.=)(J+P*3>;-JVL8SEAE"6:45245;.CII+G%VLRR4PPK3#8N,MM+T*S29L=B
MY/M+*I*1'6LE<2(Z$JAGVA;SVI0BJ^<L4SR2*K%/"7<-A74D3S4G++&"SBDY
M)K2*J_"RY,Q:[-@^37Y%Q5;8)K.TN-LW)#JT,*CFYSG?.<Z:22E/-*UJ50DT
MXBXK7M&EAQ2\_-I?-F;?R:RRM]FW%=)X(_QJF)V3"[Y\3,V%7?-I+J[M7E33
MC*ZP5VA]LWDWY,U@[4E*5DV>J5J)!*)9DG3[HSY",6R;5HJB^=B3[&%<>OS<
M^8OI;"N$5%>&!?\ ZF./1YV\_,[Y&SOF)6K#[[8<\M5BN5EC76;)-+L6 ^\G
MH4QEU"M#B7D*H:#H:B.O*5#+E(*MW2JVTJD9K%$SJB<Z*IH;63;[/K6]]"E.
MFE22Y4BJIADBNRN[-I\#-H+1:<2O62S;@5NBLQHL%1KN$EYY+$&&E2S2DEOO
M*H15X)(U&HZ=GB+FM=TZ$8XE55EF1GE+P(6%M85KF<D@B12'G*JM&&73*2\&
M557=92BOMB>L$Q,)Z7#G&MLG42+=);F,&DS---;9G154^Y.A_P (]:%=*L<2
M)*/K(J+XSPN[9;>>!91GNPDDDX4XLYL*Z7:#A^+8>=OQRS3'KK;URY\BXPRE
MO..$^I'NU*JDJ%]K082E1E<UJN*I-,,F1(R9,QM->XIV5M0P4:<EG#%)9QQ*
MJNNE5+3>+58<FPV1FU@@)L]SM$AF-D%J84M<-2)529D,<X:E-U61H4WJ,NU2
MG&YHU:M"X2A4ECC-%6$ESY,\5UY,K_1+"XH4;JU6ZHQZ.5-42I!/-YWFSB^5
M,N3#EW&;+;WMM<A;M\B<T_;I;T-E4J;;8<^-)FL1T%53BVFUJ[U)'QTF9D/>
M.TJ2S2*I)$5615BJ15=3J6T]C5XTUFBPDL464HQG%91BF=51%S(7>W;9MW';
ME&4MSX;5W>N28Z"DW",Q'3$Z.I9I5K,M+YK(CT*573QH+:IM)87?189+%(OD
MC)5=_P!.[K+RCL:-2PZ?'%)K-LLX)'#A56W)JN5E5VT%DL>WE[R"&Q*@2K:F
M1+KT"W/W",U.D:5&BC;*EZJFI)D6JE1=5]H4Z,E2229,ZI%5BF^I86FR:MS!
M)0E!Y>;%9Q24LK9(OK14RL8P_'>C/.1I+:F9#*U-O-.$:5H6@Z*2HCXD9&5#
M(9&,DDCIE13$2BL56,D94T'SH*BEQ0 XH <4 .* '% #B@!Q0 XH <4 .=5=
M6 J89=O.B_S=D<X[4?$1]7RJ=B[$?"3]?]L3;5WD/-Z&FS-*5$9J,N!GW*C4
M3H)\[.ZLWW$*[[4FIJ/B?>\"X_9 DO($        !KW//W\VK\]W']07( -B
M?J9P3S)!\"D IL(      4;'_#/JB'_1+JMC_P!9/V !6     X5ZS_UMS_@
MD/P1#I.P?A$WUXSD_:3XU=Z/$:=(; :P>B2"9 4DB @D0D@D0%)Z0D@F0%)(
MA)!Z0$$R$E)("DD15,B+E,Z?P@0=&7EI%]W7S_;0EDVWD=MB1;>:^"2N5HAL
MO1C4KL)[QPC]D:;27H[.C<=7)57U9R5%XT.B7"=+M"XM>MC'#Z\(Q6.70F17
M+;#NL.[Y?N%:[>M2[):,-GV.SU,E48M*62)1&786XA;G^T+B5*4*-&4O.G6C
M*6_)^)%;P%G&M&=Q<QCYE.WG".]##QJBKX3XSW+-(P+"KBUA'[5VN/;E07Y3
M,N:UT2>A]:GVG&8AZ4&LUDX2EE59'VB(3!)I<58K5Z.2R?-'+%LBHLL[9MP5
M%I2M:,DH=-%(X55)33#)%7$BQCD1W=\\GW#XE"8S:=?\EO\ C#S,C#[5;F(V
M&,KDHE2FS/FVW7EK(WS;::TJ<,BU&G2>HNSZ8UMXPIPJ(U64EZ3(R:51/LNJ
MYMU\AX='&[G4JU*2HM"$$2DF+%+0BJOG-&.5=+,KZ_OD'R]"P3!9UKQU-AO+
M=^D2+/;(K<AYPUZ6ELJ-N2MYPU+4FI)5[HJ&14,4V_1RN*T93QQP(DE5DUOE
M1DR>(JN^FA9T)1I='-*JK"*))5T-DEB5U71IR+F4MN20+;>+$[N-+L3^*WZ-
M=H[-QC*YPH5P<D&IUUR,AXB6AQ!I-2T5-)%V1<6\Y4ZB6Z32I%8JRZ8MD3$V
M14U+G+6\IPJT5NYTUHU(SCB3[,U5U7"BY4EK3,VG5D=UQ+(I76#CW6-;W7;0
M[=8-T;N:4GT-4,C:<YPG_<'R:2[[BKO2XF0LZ5U2CLQ8K),6"46TOE1FS_5E
M+ZYL*\]LI.,56&.$L7V<*85?%F^O)G+9-<D,XYO,39K;)R^PVW2*J3-)SI-4
MG_HJ+B"(M6T?T)?IB6-191I[0;)_<A_]R9]H;MJE;4XLZC$2RQ%I?N+-U)I^
M4PY"D2'R<0IQ$4R-276]!$M14+3IJ*9I.-[43I>BQ)'#DBN)$1LF+4KY-T]:
M2TY[.HKT'3X%J))EDBQ59.CX=:-ES9&*['+Y)O>2R;,JR'C5U7B$RR8O">6\
M;JG'#-YC2Y*,E%J2;B4*K]D>=Q0C2HI/'TD>FC.:Y-Y<D? YZVMS*M<RI]&M
M&2V\J=.*K)WSQ99>%E\9:]K\<R&SP,]F7:W2;?"_9FYPZ2VU,&N3I2LDI0YI
M-1H2E1J-)'I[-*E6XVG<4JDJ"0DDEZ6"Y,N3Z<)8[&L[BC"YE4A*,>@J)SD;
M+O+GS+O:6='U(0V<TE21 4DB$D$R$E)Z0$$R$E*DB I)$)()I I4D7*)(4D0
M%)]"$E*DD\HDI4W=U;?WAO/P)/A4C2^U?\,/6\ATOL!\35]3]QT5(E(:0HFU
M$M\^]0V1D9ZCY. YP=J)1F.8:)!G59]\M7;4?*8 ^P XUW:^L7(/A!>#0.Q[
M%^"I[WE4^;.TW_IUO6\B&$GV1F#72!B"I"!@5$#Y1!41/E$%2$3 DB8@J0@8
M@J0B8$D3$$D3 J,^M)']#F3'3A\L6_C_ .[<&#K?'T_4EY#:K;_R:W_)#B4K
M<ZM5QR'',%NN-PGYUD9L[5K<;B(6]S-T8<7TA*T((]"W#4E15+O^Q4>-C5A1
MJUH5%2,EFLLN1XJG-WV\1[[3H5+FA;3HQ64$II#FHJM.*KB=-"JZ>MX#-;<I
M,2]67$)KR$YP6%S+/&<4X251KE*-3D6.IRO>.(:JCE^V(BY1B:G.ISK13^UT
MT9+NQ3SE;2BKQ&P4EP586\E_O^[2@B^C.3K"+_96,>/)G,(VULUYQN9D-\R&
M$_;;!!M$^)="FMJCI?7(;YMN*7.$G4M:S29)[@RNTJU.M&G"FJ2FLXK%LK,O
MG9-"(8/8UM5MY5:M:*QIQIS26)&Q.C)#*V55;(5,Z;D%KMNT]QQB.Y)OL6#,
M=B1VFE/J<T27#6GFT%J41HU:J?:CRIPI3G<QJJT5E%\K:$T[Y<U:M>E3LYT4
M59I&;(B._.5\F]GW"T9QC]E>Q.!G4"T/8O-FSW+?(L+REJ9>T-<ZJ5%YTDK)
MLE=XI/%)*.A4IQN+*O42LM"4DJ(D<6+2F5L,FR/I++:=I26WC<Q@M%926*P7
M,N1\47RMH5,R+D1FRL*A2,DVXR_%[2@Y%_;DP;M&M[9:GY+#!K;>)I)<5&C4
M2C(N)UX<1%[-*-U2JRR1:4570BKF??*]FPE<6%>A!'FBQFB:9(F163<)8E:K
MGBF(9ID=^B.V^)<+8=CMK<I"F')4J6\@SYI*R2:B;2V:EF0BZJPKUZ5.FJ26
M,L:ME9$1<^^^0FQMZEK;UZU5%BDH='%%R+)9*F9_11'4I\@@3)VS^%2X,9V3
M%M\J](GO,H4XAA3CC*TDX:2/35*345>P*J$XQO:J25EDD&W<BYB+FE.ILZWE
M%%5(+5Q-H=8KEU9#8$)*CW*Q?@=3P1NG=_\ #G2_UC#U/A:G_.OZT-BMT7WR
MA_\ RT?T*8$BU7"];08O:;5'5*N$W))C,9A'*M:X[9$53X$7;,^!%Q,93I8T
M[VI*2LB4T?A4PW03K;-I0@CRE5DR?A/OG5EO&,V(\ QVSSG+/ 5TO*[ZB&^E
MJX3V"/51PT%_PT;B3=:),ZK_ (QT6=6%:IT]24<4LD(NG-BNYZ4M.G1N%6T+
M>K;TO=Z4)88Y:D\,FE)-UO,AHT?:W5RO/IMI/*(=_MFW+F0P)S$!_'[['E7%
M*74-,-I;0EN*HT-K:4G0;=".I5,N(Q]E"?1+"5? J++%%4CK72N547.YF+^K
M36NE6%LM1))%8324T=&1LD<B*F;#GR9LI89DFY9WM[FB;9;%,Y7^U"+U?;/%
M2LWR@K94U3FS[]?-OU4LJ=Z??'0748PMKFEBD\.CPQDN9W?P/'-KS&/G.I>6
ME9(1:ITV.<417PJBIFTM+*NKSE8MURLUWLFP"&+Q'<ANR<I:E1XCY:'B8<@.
M(2XIL^^02S0K3J(JD5>0R,>U.K"IM!X*[4V?=Q(6]:A4H[*1*B+%5K.RYVZ-
M4=O!Y<QJ,QL!JY$Q!41,021,"2(%1$Q!*$3 J(@21,05(1$$D3 J.K>IQ_W3
M,/ZVW_S9 TCM+GI_B\AT+LEYM7\/[CJ ::;X   ' F7%_FR_><9?AUCM=G_!
M#U8\1\T;17_*J^O+]2EEH+LL'% #B@!Q0 XH <4 .* '% #B@!Q0 YLZ- ?S
MW;.U6:R4D9'A\B8I5H13I$B!/63IO-)Y5FA9:32FI_PIKKLII:7DISR0K)'G
M:$E'(RZG3Z9S;H4EVALZ%.EEJVZSYFF4)J^**:67(R>5'J;';<A+"\KB9)CR
M(L*V6K_@)<JU-QGT2"D-\"D*:2XI>E2N51F/.O5I>\4EI5'64\J)-51F7[+L
M>UI;U_=:Z5Z*12%/FRE22*I+$GVL**^?7RWS,7K0Y-M-VB8&K(;9+@02M-VC
MS)Y)TLLI;YC1&/0VMI:%)-LN->)\3%I9QJ)&4)5^CDDI8HK&&E7?G95145W,
MEM"=&4X3A:K6A*$,$XSJ-D1L+1R16*HJ+%,J9URJ6QZ[S;[B>[5VF0?DR;*E
M6;ID!)*3S3B)*T+2HED2B/4GOJ]D7$:,:5>U@DL2(E1EU\U"QE<RN+:_J2C@
M55HO'4J35%SZ7S[I;K,Y&8VBBOW%'.VUC,XSDALRJ2FDPJN%3NI(>]:*K?JD
M?.6@K?FR%M;3A'9<5FCQ2ZB^ZG1Y?$?3,\1S*[;I295K8?F'=IJ)UGN[!*7&
M.*X:5,.I?21I)#2-)&JO>Z1397=O3LD2:HF"+2BN=]*-NJ5[2V?>UMHRE319
M=)+%":>;A7S5Q)D:*-ET,7[([A;[I;=YKA9%)5;WI=D23K)D:'#3(6AQ9*3P
M-*UD:JERU%G;4ITYVD9^<U3BR<"&2O:]*M3VA.EEBLJ.5,R\Y77PKE?28<\I
MT]DHK9J4;19.]WM3TUZ @RX<G95_I&51$^8K_P 2?K4P*R5=CI__ #"__;0S
M+'"6O(=G'%U4YT-Y&L^)Z$/OZ2KVDER#$W.2E=INIQ1-BLG6OL]5SX9>)9<1
M8.@3KYM?<[;8&UR9UNR)Z;>+?'(UR%1G&=#3YH(M1H2HC29%6GNA>XXTKV,J
MBLDJ:)%5S.^5-_\ T,5T52OLV<**+*4*RRG%,JX5BR2;.SY-.LUK,MMPMJVV
M[A$>B+>03K29#:FC6V9FDEI)9%5-4F52[0V"%2$\L516U&I5:-2DJ).*Q54?
M*BIDUY38N8V.]77%]O\ Y+MLJ:7R2M%8S#CW?G)6>GO$GQH?(,#95Z=.M7QR
M2//TJB:$-LVG:UJUM:]'"4O[>B*K]I=1]6[6YA^#2<6O;Z+?D.;3H"7H3YD2
MX5NB.&M+\@N5!J6KW"J'I+N&0I6JES<I5IIBA1C+*GVI+D9->33K$:'N5DM&
MJJ0J74H/%?L0BKXI:LJYE;)O*AF6)XVQ8=Q)%BM.'N-0K2Q-9DY).5)<DNDJ
M,XE#B*+1'+G3.B4);4>@S/L'3%7=RM6T2I.KEFL52",R<Y,F;%DUOG,_8624
M-H='3MU2--)HM26)57FJTDRI#G:$2*JR[Y@$&%*N.R<N/;X[DM^-DS<F0TPA
M3JFV3@*03BR21T3J[VI]D9JI.,-HHLE9%I,CZ\>8UFE3G5V.J019*E=U9'9.
MC7*K:-TOUIQ6+8)N&-VG&%Y!/NS4&[2;[)7)*,P;JR4IMI,9;:$\P156MY2N
M/*DB%G6NEJQK8ZG1I!912*875M*XD5>=H1&WS(VU@E"5MT=%:LJB0J+-<;1?
M/%,"Q1,&=5DLMU&,!W%099_E!&5/_%9ITY.5]9C-[.^%I>I'B0U;:SI>UWZR
MI^M3&:#(&,<4 .* '% #B@!Q0 XH <4 .* '% #G5'5C*F&77SFO\W9'..U'
MQ$?5\JG9.P_PD_7_ &Q-T/QV9*=#R=1%Q+L&7V1J!T(I6VD0)))25([]$D9\
M:++D*O= %>         #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
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MRG6S2YP?;/0X7=+L_9 %0        U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2
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M5]>7ZE+-I/M"[,>XTGV@#C2?: .-)]H XTGV@#C2?: .-)]H XTGV@#C2?:
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MHS.JE=LP(+'<%N+ENDY7O5&22/L)[ $G&/64<=<W7G<Z9G2'!TF9=@V",_\
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M@#C20!QI( XTD <:2 .-) '&D@#C20!QI( XTD <:2 .-) '&D@#C20!QI(
MYT_U:TE^QUU(RJ1W)=2__;LCFW:GXB/J>53M78/X.I_R?MB;<BF<=U4)7N2[
M]@S[*#Y2^P-/.C%8 /%I2M)H454J*AEW# %+#4ILU0W#JMKW!G]LV?(?V.0
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M8!QI, XTF <:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, XTF
M<:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#G3G5N*F(73SDKP#(YKVJ^(
MAZGE4[=V"^#J?\G[8FW9C2EH)QK^G9/6WW>V7V1IQT<^C+J7VDNHY%%6G:/L
MD /H *68A1$F4T576>-/ND=D@!4-K2ZA+B#JE15(P!(    &O<\_?S:OSW<?
MU!<@ V)^IG!/,D'P*0"FP@    .3B8 HXW_$O*F*]P54,%_%+E5]D 5@ HY'
M_$OIB%_1(HM__P!5/V0!6 #!,HV;VYS*[N7W([-TRZNH0VX_TF2U5+9:4EI:
M=2G@7<&2H;3N*$,$),F\G(8FYV3:W$\=2+RWU\BEG]7+9ST<^.3?'BX^=WGI
M^*/(6O=^QZOVI<H]7/9ST<^.3?'A\[O/3\4>0=WK'J_:ERGOJZ;.^CGQR;X\
M3\[O/3\4>0=WK#J_:ERCU==GO1WXY-\>'SN\]/Q1Y".[UAU?M2Y3WU==GO1W
MXY-\>'SN\]/Q1Y!W=L.K]J7*/5VV?]'?CDWQX?.[ST_%'D'=VPZOVI<I%SJZ
M[0J0HD8]1=.]/IDWE_+!\[O/3\4>0CN[8=7[4N4C&ZO^S\AO7^SFE9&:5HZ9
M,JE1<I?TP?.[ST_%'D"]G+#J_:ERGV]7G:#T>^.3/'!\\O/3\4>0CNY8=7[4
MN4>KUM#Z/?')OCP^>7GI^*/(.[FS^K]J7*>^KWM%Z/?')GC@^>7GI^*/(.[>
MS^K]J7*/5\VB]'OC<SQP?/+ST_%'D([M[/ZOVI<I[ZOFT?H]\;F>.$_/+ST_
M%'D'=K9_5^U+E'J^[1^C_P ;F>.#YY>>GXH\@[M;/ZOVI<I[ZOVTGH_\;F>.
M#YY>^GXH\A'=K9_5^U+^H>K_ +2^C_QN9XX/GE[Z?BCR#NSL[J_:E_4>_0!M
M+Z/_ !N9XX/GE[Z?BCR#NSL[J_:E_4>_0#M-\P?&YGC@^>WOI^*/(1W9V=U?
MM2_J'T [3?,'QN9XX/GM[Z?BCR#NQL[J_:E_4/H"VG^8/C<SQP?/;WT_%'D'
M=C9W5^U+^H]^@/:CY@^-R_'!\]O?3\4>0CNOL[J_:E_4>_0)M1\P?&Y?CA/S
MV]]/Q1Y!W7V;U?M3_J'T"[4_,/QN7XX/GM[Z?BCR$=U]F]7[4OZCWZ!MJOF'
MXW+\<'SV]]/Q1Y!W6V;U?M3_ *A] ^U7S#\;E^.#Y]>^G[,>0=UMF]5[4_ZC
MWZ"-J_F'XU+\<'SZ]]/V8\A'=;9O5>U/^H?01M7\P_&I?C@^?7OI^S'D'=79
MO5>U/^H]^@G:SYB^-2_'!\^O?3]F/(.ZNS.J]J?]13GLAM>Y)YANQ40UWSJR
ME2^4^1/]*'SZ^]/V8\@[J[,ZKVI_U%3]!>UOS%\:E^.$_/KWT_9CR$=U-F=5
M[4_ZA]!FUWS'\:E^.#Y]>^G[,>0CNILSJO:G_4>_0;M?\Q_&I?C0^?7OI^S'
MD'=/9G5>U/\ J'T';7E__ _C4KQH?/[WT_9CR#NGLSJO:G_4>_0?MA\Q_&I7
MC0^?WWI^S'D([I;+ZKVI_P!1[]"&V/S'\:E>-#Y_?>G[,>0=TME]5[4_ZA]"
M.V7S)\:E>-$_/[[T_9CR$=T=E]5[4_ZCWZ$]LR__ ()\9E>-#Y_?>G[,>0=T
M=E]5[4_ZB]XW@.)XC)>EX];^B2)".:=7SKSM4$9*I1Q:B+B78%E=[2N+J*1J
MRQ(FXB<2&2V?L2SL9+*A#"LD9<LER>%5,E&-,V   &&7;:G [Y<9%VNEJY^?
M*5K?=Y^0C4JA%6B'"(N!=@AF:.V;NC!(0FT4S9(\AK5UV:V?<U95:E-Y2SKB
MEY%*+Z$MLOF3XU*\:/;Y_?>G[,>0M^Z.R^J]J?\ 44S>R^VB7U1G;)4Z:VEG
M*E=\GLE_2]@1\_ONL]F/(3W1V5U7M3_J*CZ$-L?F/XU*\:'S^^]/V8\@[I;+
MZKVI_P!1Y]!^V'S'\:E>-#Y_?>G[,>0=T]E]5[4_ZCSZ#MK_ )C^-2_&A\_O
M?3]F/(3W3V9U7M3_ *A]!NU_S'\:E^.#Y]>^G[,>0=T]F=5[4_ZCSZ#-KOF+
MXU+\<'SZ]]/V8\@[J;,ZKVI_U#Z"]K?F+XU+\<'SZ]]/V8\A/=39G5>U/^H\
M^@K:WYB^-2_'!\^O?3]F/(.ZNS.J]J?]0^@G:SYB^-2_'"/GU[Z?LQY">ZNS
M.J]J?]1Y]!&U?S#\:E^.#Y]>^G[,>0=U=F]5[4_ZCSZ!]J_F'XU+\<'SZ]]/
MV8\@[K;-ZKVI_P!0^@;:KYA^-R_'!\]O?3]F/(3W6V;U7M3_ *CSZ!MJ3_\
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MVDN=DOL@"L   8\FXO,J44>B6-1J2@RK0C[ $ET;ND12$J6O0LR[Y-#.A_P
M02^4X/XW_JJ]H /E.#^-_P"JKV@!@><28[N:[926UU:CWN=SIT/@2[#<DD?)
MVP)/KL3]3.">9(/@4@0IL(    %),4IPTPVSHMWBX9?:MERG]GD %4E*4))"
M2HE)4(NX0 ^<AXH[2G#XF7!*>VH^0@!&(R;+7?\ %Y9ZW5?QC]H ?<
M        %&[_ ,+))\N#+]$.]Q7VJ@!6
M   #XR7^8:-=*K/O4)[:CY" "*P;#1)4=75'J<5VU'R@#[
M         *>6RIQLG&OZ=H];?=[9?9 'T8>2^TEU'(HN3M'V2 'T
M                                                     %&[_P 5
M)*.7%EFBWNZK[5/_ $@"L              !\WF4OM*:7[E14KVC[!@#YPW5
M+0;;O].R>ASN]H_L@"H                        !9[G-?;?YEI1H2DB,
MS+E,S[H$GUL[IN)>)157J)2E]D]7;_@ @N8                   *"[.<W
M&(B*IJ45#[1EQJ7= %';YT@Y"6G%FM"SH9'Q,C[9 27L""VN69I;IK2X:$&=
M312O\!@"X-MH:0EM!42DJ$ )   -?9X9_MWM8GL'>[@9_8Q^Y #S8GZF<$\R
M0? I *;"   1<<2TA3BSHE)5,P!3PVU&2I3I4=>XT^Y1V" %4 *-/_%2M7*Q
M&.B>T;G9/[  K                !!UM+S:FEE5*BH8 ^,-Q9I4P[_3,GI4
M?;+L']D@!4@                             HT?\5*-WE88,TM]HU]D_
ML "L                          %&G_A96GD8DG5/:2YV2^R *P
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M5^P(5%0J147,>K6EM"G%G1*2J9]PA!)3PT*5JENE1Q[BDON4%R$ *H
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M!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK ,-8!AK
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M!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ
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M_BR]?R(=$#5S;P           ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%-A
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MB_::9V,SUOP?O/CUNRK/Q3^IF_SF15V8\VIOQ\I';+SJ7XOVF_-L_JZQ/S1
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M;/\ \E@_SF1S6A_ZR^O+RG:+K_P$_P"*'[3DO4.E'%V&H PU &&H PU &&H
MPU &.E.JJ=8N4_UD+^:^-#[5>=3_ !>0ZIV%\VMOP_<=$#1SIH 'E2K2O'M
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M2\E"E)H1T(R);:TGQ(E<>!UX#GMA?3LJN)MQ4^FDZQM39M/:%# JMIC),O\
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M%0#'2/587(*+E7,MDOOX/*JG8?&A]J?.I?B_:=2[#>;6_!^XZ%YV?^(1]_\
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M2)@5(1$$D3 J.R>J%^X5Z\\+_-F!S_M)_/'U?*ITWLK\-/U_(AT(-6-Q
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MAJ ,-0!AJ ,-5 ##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4
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M#^\B<?=/'"37GOE#Y.C$GF:?]IS?.:?LC3*7_G4<7F=(F/5AQRS[CL=%K/\
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M$1!)$P*CLGJA?N%>O/"_S9@<_P"TG\\?5\JG3>ROPT_7\B'0@U8W$
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MT/ B8%2$1!)$P*CLGJA?N%>O/"_S9@<_[2?SQ]7RJ=-[*_#3]?R(="#5C<0
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M0:L;B           !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
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M90GB?$SY(ZT1,A:)*A=V5Q66E&%2GT;+!T1I31/-55RY,^I<VE=8T&PFHN*
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M1,"I"(@DB8%1V3U0OW"O1_\ G#GYK''/^T?\\?5\JG3>ROPTO7\B'0@U8W$
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M86;P.Z\!C-1?&,85 ,*@&%0#"H!A4 PJ 8ZEZH1UB9;_ %D#^;(&C]I\]/\
M%Y#H_8[S:OX?W'3 TLZ$   '#.5_O1>_A\KPRQW&R_@AZL>(^6-I?%U?7G^I
M2R&+HLB!B"4(F(*B!\H%1$^405$3$$D3 J(&(*D(F!)$Q!41,"2)B"HS',76
M+Y8,:R:*MLGF(;=BNL9*OPK<FW)-++AI.AFEUC09*(J:DJ*M1B;-%I5:E)7R
MRQQ7<EG3P2?A0V#:"QKV]&M%N;%*<DTHL/-7\4&S9'14<^]UW!9G[;6W"T1%
MHNL9Q")UR,TT>A1G'W8[/;HA3Y\.YW112V>L+N59^:N9-4E9%7PL>M;:T:EA
M"W1%QHO.EKC%9+&/@67B(/;@M+VP9P5$0TW-#^AVX43I7;B>7+2S7W5>?5J[
M5"!-GK[XM=^:V;[S87_*2NUD^7):I'G/YVN#K-M_&KGTM63X+)PFWXIED:[\
M[;IDF:T_:UQDI5TDDIHKGR/D)/:%%6VN8W$JM)8<Y$3G/HWCVH7UG*TC0KI4
MYDED\,.GUBT\YM>5Z-/,7T\;7%).LW(G3VIG.5UD1))M;>@J:3H=>R/=KSH\
M\,;_ 'L+<;N6C[/Z;-5Z/#]W'B?/J9M!=T9+@<2"SA]F:N+6,W.?$EY/=;AS
M9S'H\0S,F&68^I*$E51D>HU&9]H6JVUS*2U9K''&*I",79%72JKG+^-Y9PBE
M"FDTISE%:DI-B5(_91(YDTN[ON&&Y5?G\HR*YW^06A=PD+>0T9UYMJM&VR[B
M$$E!=PAD[6@E"E&FGV4_U7PKE,->W4KFO.JOVE?>30G@3(9)E6X3.08-CV+-
MPS9GVXFRNLTR3204)M3$0B,N/>-K41U%A;6"TKB=55=)>:FI\LN%4,K>[5C7
MM*5!(M*'G+KPIAAP151?=Q6KOMO9,*1%6BYP%H3<+BHRH_%B*?5%:*G&C?2%
M<#[)5$4;!:=U.L_-EF34JMB7PX2;C:J5;*G09<4?.EKC'%ACO)BTEGV]RB)A
MV51[].8<DQF6)3*FF#22S.3'<9(RU<.!KJ8N;^VE<45A%6553Q*BEKLJ\C:W
M$:LD543%FW8JGE+9C:\61-6G+V9SEL<:-*%VM;2)#3VI)DO2\1I65"41I,RY
M>4>MPE;#_:6+_>=O$>%HMOC7ITEA;[+.BY->369-.R''6<>D8)M[%GK+(945
M5TN-W6PV\^J.H^89;::,VVT$M6HU*69GV>')80H55J)6KK'F(K)%\CYU=<JY
M-PR\[F@E);>UC+^ZL<2S9U;S41$R(CJ[OXB@W+G07+S!L-L=;DP,8MT:R(F,
M&9MR'X^IR2ZDSY4F^XX23+@:2(QZ[/A)(+.61:DEDVI\R<"(6^UJD%JQIP5%
M2E&,'32J9U_,J^#*848R)B")B2HB8@DB()(GR 5$0)(F(*B)@21$$D3 J0B(
M)(F!4===4E;J<0NQ-F=#O!$HNQ0XR*_Z!S[M)\1'U?*IT_LK\+/U_P!J'28U
M<V\           #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380
M #D+K E7<J9\&B^#(=4[._!IOKQG!^V*_P#92]6/$:OTC8S2W&D XT@'&D X
MT@'&D XT@'&D Y4HGSVX+ML;DN)MS[B7GHA+,FEN-D9)4I/(9E7@/-:4%DDU
M1,2:=)[)7J)!::27"JNJ/D=-PIM(]#Q<:0#C2 <:0#C2 <:0#C2 <:0#C2 <
M:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <K;5=KK8Y:9]
MFFO0)J2TD_&<4TO29D9I,TF52.G$CX#RK4*=6.&<4DFZ7-O=5;>>.E)82UHK
M?1-P^][R/(,D=0_?KE(N+C52:Z0XI:4:J5T)/@FM"K0AYT+6E01J<4CO'I=7
MU>ZEBK3E-4S.N;>U9M!:](N2R<:0#C2 <WEU9"IDE[^ H\,D:;VI_AAZWD.D
M]A/B:OJ>4Z;'.CL8   ?G]OB9?2QE/PHO!('5MD?"4][RG%-N?'5=_R(:^J0
MRIA!4@ J0 5( *D %2 "I !4@ J0 5( *D %2 "I !4@ J0 5( *D %2 "I
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M5"(OV"O1T+5\L+X]G_NK Y_VC_GCZOE4Z;V57_&EZ_D0Z%&K&X@
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MU?GNX_J"Y #Y['O$G:K"&R4:F7[' <8,RII/HZ-2.[I[?9Y0)-C 0
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M6C3Q15(Y<44S)NJA@JME-R4I-2[,24D53,Y,;QHS:]H+'T_9ER&KIV0VJO\
M]+VH?U%.C:#<-Q9(395&I7 OP\8O];H=X+#K/%+D'=#:W4^U#^HJ?H2W+^9/
MC,7QHGY_8^G[,N0CNCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/
MH2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7J
MO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER
M#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/[
M'T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,
M7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W
M+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A
M_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NC
MM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_
M9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH
M?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9
M/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/
MH2W+^9/C,7QH?/['T_9ER#NCM7JO:A_4/H2W+^9/C,7QH?/['T_9ER#NCM7J
MO:A_4?-[9K<:.1&Y9O=<"(I,8S_T.B.\%CUGLRY">Z&UM%'VH?U'K6S&XSZ-
M;=FKQH9')C$9?8-T.\%CUGLRY!W0VJF>E[4/ZB?T);E_,GQF+XT3\_L?3]F7
M(1W1VKU7M0_J'T);E_,GQF+XT/G]CZ?LRY!W1VKU7M0_J'T);E_,GQF+XT/G
M]CZ?LRY!W1VKU7M0_J'T);E_,GQF+XT/G]CZ?LRY!W1VKU7M0_J'T);E_,GQ
MF+XT/G]CZ?LRY!W1VKU7M0_J'T);E_,GQF+XT/G]CZ?LRY!W1VKU7M0_J'T)
M;E_,GQF+XT/G]CZ?LRY!W1VKU7M0_J'T);E_,GQF+XT/G]CZ?LRY!W1VKU7M
M0_J'T);E_,GQF+XT/G]CZ?LRY!W1VKU7M0_J-H[(X!E>(7JYR\@@=$CR(J6F
ME\\R[59.$JE&UJ,N';&L=H-I6]U2C&E+$J+J5-&ZAO79#8MY8UZDJ\,*2BR9
M8KE?<53=PTDZ>   '&^[&Q^Z&2[B9!?;+8^DVN;()R*_TJ(WK03:$UTN.I47
M$NR0W_9VU;:E;PA*3*B:EY#FFU-BW=:ZG.$'BJY,L>4PWU<MY/1SXY"\>,A\
M[L_3\4N0QG=^^ZOVH\H]7+>3T<^.0O'A\[L_3\4N0=W[[J_:CRCU<MY/1SXY
M"\>'SNS]/Q2Y!W?ONK]J/*/5RWD]'/CD+QX?.[/T_%+D'=^^ZOVH\I$^KKO(
M2DI/&_==GID*GV3Y\0NV[-/M^*7($[/7W5^U'E)>KEO)Z.?'(7CQ/SNS]/Q2
MY!W?OO0]J/*/5RWD]'/CD+QX?.[/T_%+D'=^^ZOVH\H]7+>3T<^.0O'A\[L_
M3\4N0=W[[J_:CRCU<MY/1SXY"\>'SNS]/Q2Y!W?ONK]J/*/5RWD]'/CD+QX?
M.[/T_%+D'=^^ZOVH\H]7+>3T<^.0O'A\[L_3\4N0=W[[J_:CRCU<MY/1SXY"
M\>'SNS]/Q2Y!W?ONK]J/*/5RWD]'/CD+QX?.[/T_%+D'=^^ZOVH\H]7+>3T<
M^.0O'A\[L_3\4N0=W[[J_:CRCU<MY?1SX[!\>'SNS]/Q2Y!W>OO0]J/*11U=
M=XUD9IQS@1T(^F0BK[%7Q'SNS]/Q2Y!W>ONK]J/*2]7+>3T<^.0O'B?G=GZ?
MBER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW
M9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7C
MP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQ
MR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\G
MHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>K
MEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'
ME'JY;R>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U
M?M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;R>CGQR%X\/G=GZ?BER#N
M_?=7[4>4BKJZ[QHI7&^!F15Z9"X5X=A\0NV[/T_%+D'=Z^ZOVH\I+U<MY/1S
MXY!\>)^=V?I^*7(.[]]Z'M1Y1ZN6\GHY\<A>/#YW9^GXI<@[OWW5^U'E'JY;
MR>CGQR%X\/G=GZ?BER#N_?=7[4>4>KEO)Z.?'(7CP^=V?I^*7(.[]]U?M1Y3
MH+JU;>9C@$?)&\MMWR>J>N&J(7/,O:R9)XE_T*UTIK3RC5MN7M&Y6'1J[.^1
M=S6;CV=L*]JE3I8X<6%LJ+F?4;X&LFV@  !RA?=HMPKE?KM-A6?G(K\R0XR[
MTB,DE(6ZI1&1*<(^)'VAU2UV[91HPBL\J11,TM6\<"ONRFTZEQ4E&EDE*2IS
MH9E5?O%M^A+<WYD^-1?&BX^?V/I^S+D+7NCM3JO:A_41/9'<[YD^-1?&B/G]
MCZ?LRY">Z6U.J]J']1X>R&YWS'\:B^-#Y_8^G[,N0GNEM3JO:A_40/8_<_YC
M^-1?&A\_LO3]F7(5=T]J=5[4/ZB)[';H5_\ H?QJ)XT1\_LO3]F7(3W3VGU7
MM0_J/#V-W0^8_C43QP?/K+T_9ER$]T]I]5[4/ZCP]C-T?F+XU$\<(^?67I^S
M+D)[J;3ZKVH?U$#V+W2^8OC43QP?/K+T_9ER%7=3:?5>U#^H\/8K=+YB^-1/
M'!\^LO3]F7(3W5VGU7M0_J(_03NG\Q?&HGCA'SZR]/V9<A/=7:?5>U#^H\/8
MC=3YA^-1/'!\^LO3]F7(3W5VEU7M0_J(_0/NI\P_&HGCA'SZR]/V9<A/=;:7
M5>U#^H\^@;=7YA^-Q/'!\]LO3]F7(3W6VEU7M0_J(GL+NM\P_&XGCA'SVR]/
MQ2Y"KNMM+J_:C_4>'L+NM\P_&XGC@^>V7I^*7(.Z^TNK]J/]1'Z!-U_F#XW$
M\<'SVR]/Q2Y"KNOM+J_:C_41/8/=?Y@^-P_'"/GMEZ?BER$]V-H]7[4?ZCP]
M@MV/F#XW#\<'SVR]/Q2Y">[&T>K]J/\ 41/8'=GY@^-P_'!\]LO3\4N0GNQM
M'J_:C_4>'L!NS\P?&X?CA'SVR]/Q2Y">[.T>K]J/]1$]@-VO1_XW#\<'SRR]
M/Q2Y">[.T>K]J/\ 4>>K_NUZ/_&X?C@^>67I^*7(3W9VCU?M1_J(GU?MV_1_
MXW#\<'SRR]/Q2Y">[6T.K]J/*>'U?=W/1_XW#\<(^>6?I^*7(3W:VAU?M1Y2
M/J^;N>CWQN'XX/GEGZ?BER$]V]H=7[4>4AZOV[AK-'[/=\1$?_>X?(?_ +X1
M\\LO3\4N0J[M;0ZOVH_U#U>MWO1[XY#\<'SRS]/Q2Y">[>T.K]J/*>'U>=WO
M1[XY"\>'SRS]/Q2Y">[FT.K]J/*1]7G=_P!'OCD/QPCYY9^GXI<A/=R_ZOVH
M\IX?5XW?]'?CD+QX?.[/T_%+D)[N7_5^U'E(^KOO!Z._'(7CP^=V?I^*7(3W
M=O\ J_:CRGA]7;>#T=^.0O'B/G=GZ?BER$]W;_J_:CRD3ZNN\/H[\<A>/#YW
M9^GXI<A/=V_ZOVH\IYZNF\7H[\<A>/#YW9^GXI<A/=Z_ZOVH\I\W.KMO"A-3
MQSLT(BF0C,S/_P!^(^=V?I^*7(5)V>O^K]J/*>^KGO'Z.?'(7CP^=V?I^*7(
M.[]]U?M1Y2)]7+>3T<^.0O'A\[L_3\4N0GN_?=7[4>4Z7ZN.#Y1@>(W.V95!
MZ!.D7)4EEKG6GM31L-()565K(N*3X&8T_;=W2N*L94U=$BVG6NLWKL_95K6C
M*-5,*K)]"Z$U&XQ@#90           ->YY^_FU?GNX_J"Y !L3]3.">9(/@4
M@%,V5_PLHG.1B0>E?:2YV#^R *P            !33V%R(JFV_=\#(NW3L "
MR,QWFWFUO(4VVE:=2S(R(N($F2 0
M      %FN["U2&U([\U)H2"XJ[WCR=KB!)]K3%>9UNND:"41$E)\#]F@$%S
M                            !\WFD/M*:7[E14]CN@#Y0W5+0IIW^G9/
M2YW>T?V2 %2             I9BU+TQ&CHX][H_N4%RG_P!  J$(2VA*$%1*
M2H1=P@!(                          ?&5S?1W>>*K>D]1=G[  M+%W>1
MH0ZDEME0C/CJIVZU DNO3(GXY'WQ 0.F1/QR/OB #ID3\<C[X@ Z9$_'(^^(
M .F1/QR/OB #ID3\<C[X@!:G[N\LUI:226SJ1&==5.WR@27:)S?1FN9*C>DJ
M$?+W:@0?8                                         4LQ"DZ9;15
M=9XF7W2#Y2 %0A:7$)<0=4J*I'W# $@          !1L_P#%23DGQ9:JAGNG
M]LK_ * !6                  ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%,
M^>:2^TII?N5%3V.Z *5B>TA/,REDF0@S0HSK0Z=FO= %<1D95+B1\A@
M       (N-I=0IM952HJ&0 IX;BB)49TZO,\*_=)^U, 50
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M\6C[T@ YAC\6C[T@!;%V6KAFAPB:,^0RJ9$ +HTVEIM+2/<I*A "8
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M?#^ "3)6%J<9;6HJ*4DC,NZ9 0?0
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M@CTTIVZ=D"2[P'ER8J5N\5<4F?;H!!&-6.\J&KW!]^P?\4^5/V !6
M                          /F^\EAI3JN1)<"[9]@@!\XC*FVS6[Q?=/6
MX?=/D+[  J                    6^Z3'(R4(:X*76JNT1=K^$ 4T&YNZS
M1(,W$F52,BJHC^P!)7]/9^Y<^\4! Z>S]RY]XH .GL_<N?>* #I[/W+GWB@
MZ>S]RY]XH ?"5<TH9,V4J)P^!&I)D1?P@"EA7&0<A#;JM:'#TT.E2,^R0$EZ
M,B,C(RJ1\#(P(*=NWQ&G.=0WWQ<2J9F1'W" %2         "E.W0U.<Z;95Y
M3*IZ:^P *H
M
M            !KW//W\VK\]W']07( -B?J9P3S)!\"D IFS'_%2%2CXM-U0Q
MW?NE?]  K !\WGDL-*=7[E)5IVS[! "B9M;*R)V0D^=49J4@N"2KQI3N "XD
M1$1$14(N0@         4C]NC2%FXHC2L^4TG2H ]@JTMG&61$ZP>DR+@1EV%
M?9 $I;*G&R6UP?:/6V?=+L?9 'T8>2^TEU/(HN)=H^R0 ^@
M                  HS_P"*EZ>5B,=3[2G?_0 *P
M  4$UM,MYN(7*GOW%]E*>2GV0!]8D!F(9J09J6?#4KM=P 50       #YO,M
MR&S:<*J3_A(^X +=T)NWNMR2,UM$>E9J^UU<"5P[0 NH
M
M
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MW# %/#6I&J(Z=7&?<G]TV?(?_0 *H
M
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MQ"7$'5*BJ1]PP!(
M
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MCM);(ZJY5J[:CY3 'U                %&Q_PSZHA_T2ZK8_\ 63]@ 5@
M
M
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ME2$&:DFL])$9:M( R# ,>F8MA5DQNXK:=F6V(B-(6P:E-*4CETFI*3,O9(A
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M4@!]0
M
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M)K[)E3N 27"'+3+:UD6E1'12>Z!!4
M
M                                        #7N>?OYM7Y[N/Z@N0 I-
MEX)3=FL"6:]+J;'!22CXD:2930OL 29Y 83#?<87Q=41*0OL*3V2^P8$%Q
M                 !27'0J,;9EJ6X9);27+J['\  IXUI)EU+KJ]>DZI214
M*O= %S %M1*8@ON1EJ_ UU(IQTUY4F +BE25I)23JD^)&7: 'H
M       "C?N<9DU()6IQ)'P(N&KM5 'UB,FTU51ZG7#UN*[9F /N    #YOJ
M6AAQ;956E)FGV2( 8R3SQ.<Z2SYRM=5>($E_)^=0JQ2K_6$7_0!![S\[^RE^
M4+V@ Y^=_92_*%[0 <_._LI?E"]H .?G?V4ORA>T '/SO[*7Y0O: %A>>>6\
MIQQ1DX1GV>3N$!)D$4U/PT&]Q-::*[I'P_TD!!:G[2ZT2G$J);2>-"]U3L]S
MD DO3)MFRWS7]'I+1[%. $$P                   6>3".9+=..9$2:$XI
M7)K[14[@$E?"B%$:T5U+4=5*[H$%2
M
M                                        ->YY^_FU?GNX_J"Y !L3
M]3.">9(/@4@%,ZF-*6@G6OZ=D];?=[9?9 'T9=2^TEU'N5%6G:/LD /H
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M /FMIUL>$?3!M=Z76ORIOVP^6W/5RX!\UM.MCPCZ8-KO2ZU^5-^V'RVYZN7
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M#AAK!PPU@X8:P<,;LZM9UR*\_ D^%2-+[5_PP];R'3>P"?Y-7U/W'2@YP=H
M  #\]M]"_P";>5?"R\$@=4V3\)3WO*<:VW\;4W_(:\H,J85Q0 XH <4 .* '
M% #C2 <4 .* '% #B@!Q0 XH <4 .* '% #B@!Q0 XH <4 .* '% #B@!Q0
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M<@ V)^IG!/,D'P*0"FP@!\I+)2&E-UHKE0KM*+D, 1BO&\UWY4=0>AU/:40
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M!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ ,-0!AJ
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M*G)))N&.N;.M;2PU8K!6=E1LA21H\F8^W%ALKD2G3TM,,I-QQ:C["4IJ9G[
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M_P U7SSA+\.L=ML_X(>K'B/F+:*?Y57UY?J4L^H79CV&H PU &&H PU &&H
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M 8:@##4 8:@##4 8:@##4 8ZAZM!UPZZ^<U_F[(YMVI^(CZGE4[3V$^#J?\
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MK>0Z1V$^(J>IY3H^:XF(\W+(^*N\<1V5)Y:_8'.CL1](LYF69I15*RXFE7:
M%4 . -\4G]+&4?"D^"0.K;(^$I[WE.)[=^.J[_D0U]098PCB@!Q0 XH <4 .
M* '% #B@!Q0 XH <4 .9)M_;;/=\WL%IR!"W+/<)K,22AM9M*/GU<VGOBXD6
MHTUIV.T+*]G.%"<H><B*O 9#9L*=2YA"HCQE)$X<G&=T6>9MMA-RA8'850;=
M=IQJ)FTPR)3ZC:;4X:GC02E%1*3/4Z?'L#F-6%S<16M-Y132N;P?4=CI3M+:
M<:$,,92^RF?,^7P)G4Q3K,E7::X_"8?ADB^V#\6F\O$8[M+\#+?CQH</&5"J
M.FG'3NG8C;&#@F)1;C*82K*;PRB3<)*R(W&FW2):(Z#I5*4%367977L::<PV
MQ?RN*RQ1>9'(G+]-!V386S(VE!)*G/FCKN?=\&G=\!:&.LUAS^;)Q9$1[Y(7
M(Z$WD'.(YE3QJT$KFZ5)HU<"7JY.-*"X78%9*'2/SF?#]-.X6T>TUO*XZ)$Y
MKMCT/R;I<M_]M8&:8=,O$:.E.3V-E<N')0G\(ZPT1K=CJH55$I-307872G*J
MOCL:_E0K)%5YDU9=_0O+N'MM_9L;FW6:)SX(Z:U1,\=W<W?"<[=7W;:)N!EK
MDF\-\]CMC0B3+8,JI?><,R995_%/2I:NV2:=D;=MJ^6VHM'SIY$W-:FC=G=F
MQNZZK/+"GE5-:Z$X^!CJ'='=6Q;36J";\-4V=,,VK=:XYI9+FV"+4I2C(R0A
M)&DB[T^)\"Y::3L_9U2]FK*R)G7?.A[5VM3V?!'1UEF1,F;=T)]&SE?@^9XW
MNYB#EP:B$J$^:X5TM4Q*7-#A$1J;67%*DFE1*2?9(^P=2+RN[6K95L*KESHJ
M'O8WM':%#$B9%R2BO$<8;P8$G;O.9MCBZCM#Z4S;4:SJKHSQF1(,S,S/0M*D
M5/EI7LCHNR[SWJ@DU\[,N_\ 3*<GVU8)9W*P3S5RQWE^MT\!@=!E3"N;.C;'
M9)*V[/<E%P@IM!1')W15&]TGFVE*2:>#>G4>GAWPPDMKTDN.@9<3MH;C-CCL
M*M*U]Y24<++)LKY/ :QH,V:XXH <4 .* '% #B@!Q0 XH <4 .* '% #B@!Q
M0 YU-U0"I$R[^L@?S9 T?M/GI_B\AT;L?YM7\/[CIH:6=!   #@C+E?YKOOG
M"7X=8[99_P $/5CQ'S)M%/\ *J^O+]2EFU"[+!AJ ,-0!AJ ,-0!AJ ,-0!A
MJ ,-0!AJ ,-0!C;^P.5XWC=YNYY$J-$2N)S\:YR"+6V;!GK:;.AJJXE==*>*
MM-.(U7M#:5J].'1NN5EBF[I7>\3F]=D+^VM*U1:S1>+I)=&'/%-+R?,F?"AL
M:9UF,.8F<S%ML^5$2=%2B2VW4NVE"EU,OY6D8"'9BX6+K**+JRFWU.W%G&;1
MA.2:\B<"/QL;1M-TL&<XZW/B$B?8[DVI*VGD5(RJ:5MN(5V2,C(R&N5:56TK
M85YLXZN-#<;>O0O[=)Q:=.::4X45#D;*;-$VXW2**>M=IML^+/8T%J<Z(:T/
MDDM1\5)*J*F?$R'4;2O*]LG^U**Q\.5/K.%W]K'9FTVRK"$XR37A=)-E7.F;
M*N54T&[_ %EL!_L5U_(,?W@:?W8NO2APK_2=#[]67H5>"']9>,7WPQ7+[Y%Q
M^T0;F<V4:M*W664M(2A)J4I9I>49$1%VA:7>PJ]M26I.463=7D,AL_M7;7M>
M-&G"IBEK2+(VMIJ7G=>^0K!M_?9$T_\ O<5VWQVR,B4M^8A322*M*TU&L_XI
M&+39%"56[@D?LJDEWHY?JWS(=HKJ%#9]59?;BL$WY(WBSKN(IHKJ_;?Q,EN<
MG)KRP3]KM*DMQ6%D1MNS%%JJHCY2;30])\IJ+M4&Z=HMHRH02E!6E//N1^OR
M*<W['[&A<U95ZJ/"GD1-"R_VIQIJ-R;E;N6C;EV)!=B.7*ZRT\]T5M9-$VP2
MM.M:S)7NC(R21)XT.M.SJ6S-CU+U%DBX8ID?/E^F<W_;G:*ELQ8P6*SG+*SL
MR:U7+NMDT+F+Y;)V-;H8>B4J.4NR71M2'HKY$2T+29I4DZ'WJT*+@I)]I1'R
M&+.K"M87#.TX:4^F9?J4R-&I;;5M'5,5.HF5%^F147,J;Z'&^;8T]AV4W+'7
ME&XF&[^ =/E6PX1+:4=.%30HM7=J.L6-TES0C432GCT^,X%M2P6RNIT5^RN3
M=1<J>+/NF/ZA?&+8V'=]H,BLV%(SJ3-A+M2X\64EAM;IR-$PVR05#:)-2YPM
M7?#!4=LT:MS[NB2Q.J:&YK[NYJ-EK]G+FE9)=R6&!8QDSRQ--FR86TY<IKS4
M,Z:TPU &&H PU &&H PU &&H PU &&H PU &&H PU &&H QU+U93KAMU\YK_
M #=D<W[4?$1]3RJ=G["_!S_Y/VQ-UC4#H8           &O<\_?S:OSW<?U!
M<@ V)^IG!/,D'P*0"FP@  'BB)232?(94/[( L2K1*)S2FAHKP76G#V.4"2Y
M(MD-*$I4C4HBH:JJ*I]OE @E\FPOQ7_65[8 ?)L+\5_UE>V 'R;"_%?]97M@
M#D3K -ML[E34MEI+HT4Z5,_^R(NR.I=G?@TWY<9PKMA_Z,O5CQ&L*C9#36%0
M#"H!A4 PJ 85 ,*@&%0#"H!CJ?JR0N:PZZ3S(R5*N*FR,RI5#++=#+[*U$.;
M]J)O<1CJCQJIV;L/3:TG+7/BC'E4RO(ME\&RBZ2[U=6)*KE-4E3S[<A:>*4D
M@J)XI(B))%R#&VVV[FA!(05,,=PS=[V:LKNI*K4BN*6=<2[V\:>W%ZODG';<
M_?,4ENW&!%2;LJ#()/24-)*JEH6@DI61%Q,M)'3DJ-JV=VB2M-*=9$BJYE3-
M]1H>V.QTK:FM6WDLXQ1UBOG-K149%WF3PFCM0W YTPJ 8ZLZL\(V,'G35)-*
MI=Q<T*/[9MIII)&7^UJ(<U[3U'N8QU1\J_4=I[$4EC92DJ>=-?"B1CY7,DR#
M93!<EN<R\7)B3\I35\X\^W(6GOJ$G@DZI(B(NT+"WVW<T()"*IACN&6O.S-E
M=5)5)HN*6=<2_P"AIS<C8"3C%ND7_%Y;EQM<1!NRXD@D]*::255+2I!)2LDE
MQ5WJ3(NV-JV;VA2O-*=5,,ES*F9=S<-"VUV0E:TUK4)+.$4>22\Y$UNF1=W(
MC;I@6U4)5RW&QJ.DC4:9S<DR(J\(M7S^Q1'$9K:U3!:5%^ZJ<.3RFM; H=+M
M"C'[Z2_+SO(=CY9B-ES2VHM-^;<=@H>3()#3BFC-Q"5)*IH,C,J*/@.56EY4
MM9XZ>16;6=YVALZC>TTIUD58HKYU3+X-\UC?>K5B4QA9V&;*MDVGX/G5%)CU
M[2DJ(E_9)?V!L5OVFKQ7^XB23@7D\1I]WV)M)I_:E*G+\T>7QG.][P^[XSE"
M<7OK1,2S>:0EQ'?-.-.K)*76U<-23_A+D.AD9#>J%[3KT>EIJZ-]$4Y;<[,K
M6UST%5,,G1'T*BYI)K3_ $5E=#N*\2/DNQ3Y4>C?0HCSK1%R)YEHU%_!0<>H
MQZ2K%%^TJ>-3Z*N)]%1E)/LQ5>!#\^]52J?*?$=O/F)COK#93L[$,?FOGJ?D
MVV&\ZKMK<80HS_A,<5O8)"XJ13,DI<9]*[,J2J6E*<L\H05=]8H<,Y)%:@9'
M=X+)$3,6;)9;(N0DMNJ27^@AV&VFLZ,)+G6*+XCYVOJ24[BI".:,I)P*IDVS
MBO\ F;CGPA?@5C'[:^#J;WE0S'9I/^RI;Z_I4SSK0'3)+'\!<\,8PO9;^&?K
M>0V3MU_/2]5>,T5J&YG-F%0#"H!A4 PJ 85 ,*@&%0#"H!A4 QN_JR/FC*[N
MW2J7(!5^P\BG^L:;VI_AAZWD4Z/V%^)J>I^Y#I6Z1'9"4+:+4I%:I[9'VASL
M[ 4T&VNZS6_J;214(B.BC/[ $E?T!K\8[]^8$'!N]Z2^E;**5_[TGE.I_P!"
MV.K;'1K2GO>4XEMZ3WU7?\B&OZ#+F"<4 .* '% #B@!Q0 XH <4 .* '% #B
M@!R3:G&EI=:4:'4&2D+29I4E23J1D9<2,C$*B+D4E)*BNF<V9L IQW>/'GG5
M&XZXN8MQQ9FI2E*AOF9F9\3,QA=M(B64T3<_4AL79Z2RVC35<_._3(Z1ZRW'
M:>X_"8?ADC3=@?%QWEXCH':;X"6_'C0XTQJ BYY'9[:Z1&U,G18ZR/D-+KR4
MG_H,=&N)X*4I)H15\1R:S@E2O""YI21.%3]"\UF.V[#,BN$<]+\2V37VC+@9
M+:CK4G_20Y':02=>$5TRBGC.YW]5:5M4FF>,)+P(I^;]#)-2Y2*I>R0[$<#T
MGZ4V"4JZ8[:YLG\(J;"CO.ZB]T;S25*J7=J.-5HX*DD30J\9]!4)XZ49+I1%
MX4-1]6*SL6O%\C-!?AOEV5%4KL\W$0VE!'[&I0S_ &@JK.K#U$7A535^S%%*
M=&HFJHJ<"(:DZU,MV1N/%BJ,^:B6MA+::\*N.NK4=.V=2+[ V#LY!$ME77)>
M)#5NULU6[1-"03CD95U0YBR=RRW&=6S*%(0GM*+GD*,O9+3_  "P[3PR4Y>M
MY#)]CIK_ '8Z.:OZB'6\@MIE8G<DI_#.HFQG%4^U;-E:2_A6H3V8EDJ1]7R\
MA3VQBRTE];Q8>53F>@W4YX=A6C_^E5?F67X5P<[J?^K^-.)#K-'_ ,5?^.7E
M./*#HAR8]H <4 .* '% #B@!Q0 XH <4 .* '% #B@!Q0 YU)U0RI$RW^L@?
MS9 T;M/GI_B\ATCL;YM7?C^XZ8&EG0@   X$RX_\V7WSC+\.L=KL_P""'JQX
MCYGVBG^55]>7ZE+-4798,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,=
MK[.XM.Q+ X%ON:3;N,A3DR2PKE:4^=4H.O(9)).HNPJHY'MFZC<74I1\U,B;
MK?7XCZ#[.6$[.QA"IDDKR5-3Z.!GW7.9MZ+]%O\ N->),)9.1(RD0FW$\BCC
M()"SKV2UDJA]DAT'8E!:-I!)9UR\.;Q'(NTUU&XVA46.5(M%/PHR^T_@,!J,
MV:RQU'U<<**V6-_,IK=)UWJS!U%Q1";5Q5_[Q::^PE)ERCG/:2^Z2HE&.:&5
M?6^I.-3L?8S9?0T5N9)SJF2/JI_4OB1%,&ZQF9_*^1LXI#<K LI:Y6D^]7-=
M21GR'0^;09)[AFHAF.S=ET=%:LL\\WJIRKY#7NV>TNFN$MXKS:>?UEY$\:J;
M;ZO\)N)MC;GT$1+G/2I#IEV5$\IDC/\ V6R&L]H:BRO))Z*13Q/Y3=>R%*,-
MFP5/M+)5W\2QXHH: WVF+E;H7I*E&:(Y1F&B/[5*8[:C(O\ :4HQNVP8)&RA
MNNOC4YGVKFL]I5'7(F%$_*GE<V[U8I;CF)W>&KBVQ<.<1W.=901E_P!0:OVH
MBB5X2UQXE4WGL--?=*D=4^.*<A@G69BH9S>WRD$1')MK?.4Y34V\ZFI_8-)#
M,]F)O;235+R(:UVWIM>QEK@G"DI?4:6-7 ;::"QU=GQ__CK&/_RNS?SXPYK8
M?^LOKU/W'9-I?_V[#_CH_L.4M0Z4<:85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"
MH!A4 PJ 8ZGZL9UPVZ^<U_F[(YQVH^(CZOE4[+V&^$GZ_P"V)NT:@="
M       U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$             XZZPQT
MW-F_!HO@B'4NSWP:;Z\9PSM>G_8R]6/$:KU#8S3F&H PU &&H PU &&H PU
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M;O&HG00           ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%-A
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MJ5*"B\VU=4;J:17FHK,J:LF_ESGKLWLW97%C2E.+R6+XD5EYV7>R.V5-!?\
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M 8:@##4 8:@##4 8:@#'FH@)8]U 0PU &&H PU &&H PU &&H PU &&H PU
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M#"H!A4 QUIU5_P!R;OYU7^;L#G?:;XB/J^53KG8SX6?K_MB;U&I&^
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MYPR#SE,\.L=FM/X(>K'B/GB_3_)J>O+C4L>H718L-0!AJ ,-0!AJ ,-0!AJ
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M):B,VJ$G09UXIH5-/(*L*:BA)R33G1O!J/CJ%1YL-0!AJ ,-0!AJ ,-0!AJ
M,-0!AJ ,-0!AJ ,-0!CKGJI'7![OYU7^;,#GG:;XB/J^53K'8[X6?K_MB;Y&
MIF]            :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
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MEE%",ZJ,U*[ \*E>$)1BN>>;P(Y=4K:I4ISJ13FTT3%X52*>-2W4(>Y:N-)
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M@T#K^QO@Z>]Y3YV[2?\ I5O6\B&$T&8-<%  H %  H %  H %  H %  H %
M H %  H %  H %  H %  H %  H %  H %  H %  H %  H %  H %  H %
M H .C.J^5(V3_P!9"_U/C0>U?G4OQ?M.L]@?-K[\/W'0(T8ZF   'YM9L?\
MG/(O.<W\X6.Q6G\,/5CQ'!;U/\BIZTN-2Q5%R6;"H!A4 PJ 85 ,*@&%0#"H
M!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4
M PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#'8?5).N"7GSNO\ -F!S[M)_/'U?
M*IU'LE\-/U_VH;_&JFZ@           :]SS]_-J_/=Q_4%R #8GZF<$\R0?
MI *;"             <-=9PZ;LS_ ()#\$0Z7L#X1-]>,Y'VF^-EO1XC3U1L
M!K#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#
M"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#'17
M5#.N5Y!YN1X=(U'M+_%#UO(;OV2_GGZOE.O!H1TP   .+-W4UW(R'X27@T#L
M.Q?@Z>]Y3YS[2K_V5;UO(AA.D9@UQQI .-(!QI .-(!QI .-(!QI .-(!QI
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M0#"H!CL7JCG7 [SYW7^;,#GW:3^>/J^53I_9+X:?K^1#H$:J;H
M !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(            !POUGCINU/\
M@D/P1#I6P?A$WUXSDO:7XV6]'B-.U&P&LL*@&%0#"H!A4 PJ 85 ,*@&%0#"
MH!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A
M4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,=&=4$ZY9D/FY'ATC4NTG\4/6\ANW9/\
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M#O50]"7BY1W!N^LA[7(/5MR?YV@?[[Q8=ZJ'H2\7*.X-WUD/:Y!ZMN3_ #M
M_P!]XL.]5#T)>+E'<&[ZR'M<@]6W)_G:!_OO%AWJH>A+Q<H[@W?60]KD'JVY
M/\[0/]]XL.]5#T)>+E'<&[ZR'M<@]6W)_G:!_OO%AWJH>A+Q<H[@W?60]KD'
MJVY/\[0/]]XL.]5#T)>+E'<&[ZR'M<@]6W)_G:!_OO%AWJH>A+Q<H[@W?60]
MKD'JVY/\[0/]]XL.]5#T)>+E'<&[ZR'M<@]6W)_G:!_OO%AWJH>A+Q<H[@W?
M60]KD-G;2[<W/;YJ[-W*7'E?*"F%-='U][S).$>K6E/+K*@UG;6U*=\L%@BI
MA?/NMR&\=F-@UMEI42I*,L>%L+Z'U[YL@:X;H   ')F0]5+,;Q?[K=F;W;&V
M9\R1*;0OI&I*7W5+(CHV95(CXC>*/:&C"G&*QED1$T<ISNOV8KU*DII./.55
MTZ5WBV^J#FOS[:_C'BA[=Y*/HR\7*>/=2OZ<?'R#U0<U^?;7\8\4'>2CZ,O%
MRCNI7]./CY!ZH.:_/MK^,>*#O)1]&7BY1W4K^G'Q\@]4'-?GVU_&/%!WDH^C
M+Q<H[J5_3CX^0>J#FOS[:_C'B@[R4?1EXN4=U*_IQ\?(/5!S7Y]M?QCQ0=Y*
M/HR\7*.ZE?TX^/D'J@YK\^VOXQXH.\E'T9>+E'=2OZ<?'R#U0<U^?;7\8\4'
M>2CZ,O%RCNI7]./CY!ZH.:_/MK^,>*#O)1]&7BY1W4K^G'Q\@]4'-?GVU_&/
M%!WDH^C+Q<H[J5_3CX^0>J#FOS[:_C'B@[R4?1EXN4=U*_IQ\?(/5!S7Y]M?
MQCQ0=Y*/HR\7*.ZE?TX^/D'J@YK\^VOXQXH.\E'T9>+E'=2OZ<?'R#U0<U^?
M;7\8\4'>2CZ,O%RCNI7]./CY!ZH.:_/MK^,>*#O)1]&7BY1W4K^G'Q\@]4'-
M?GVU_&/%!WDH^C+Q<H[J5_3CX^0>J#FOS[:_C'B@[R4?1EXN4=U*_IQ\?(/5
M!S7Y]M?QCQ0=Y*/HR\7*.ZE?TX^/D'J@YK\^VOXQXH.\E'T9>+E'=2OZ<?'R
M#U0<U^?;7\8\4'>2CZ,O%RCNI7]./CY!ZH.:_/MK^,>*#O)1]&7BY1W4K^G'
MQ\@]4'-?GVU_&/%!WDH^C+Q<H[J5_3CX^0>J#FOS[:_C'B@[R4?1EXN4=U*_
MIQ\?(/5!S7Y]M?QCQ0=Y*/HR\7*.ZE?TX^/D'J@YK\^VOXQXH.\E'T9>+E'=
M2OZ<?'R#U0<U^?;7\8\4'>2CZ,O%RCNI7]./CY!ZH.:_/MK^,>*#O)1]&7BY
M1W4K^G'Q\@]4'-?GVU_&/%!WDH^C+Q<H[J5_3CX^0>J#FOS[:_C'B@[R4?1E
MXN4=U*_IQ\?(/5!S7Y]M?QCQ0=Y*/HR\7*.ZE?TX^/D'J@YK\^VOXQXH.\E'
MT9>+E'=2OZ<?'R#U0<U^?;7\8\4'>2CZ,O%RCNI7]./CY!ZH.:_/MK^,>*#O
M)1]&7BY1W4K^G'Q\@]4'-?GVU_&/%!WDH^C+Q<H[J5_3CX^0>J#FOS[:_C'B
M@[R4?1EXN4=U*_IQ\?(/5!S7Y]M?QCQ0=Y*/HR\7*.ZE?TX^/D'J@YK\^VOX
MQXH.\E'T9>+E'=2OZ<?'R&]]C]M+KM=C<^RW>9'F/RYRIB'(NO02%,MMT/G$
MI.M4#6MJWT;NHDHHJ,C9=]3;=C;.G94I0FJ*JR?)O(;.&&,Z           !
MKW//W\VK\]W']07( -B?J9P3S)!\"D IL(
M
M
M
M                         :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
M
M
M
M                                                  &O<\_?S:OS
MW<?U!<@ V)^IG!/,D'P*0"FP@
M
M
M
M               !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
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MDI^,#N_:_>X1WGO/N\ ]:G=7[JW>2GXP.[]K][A'>>\^[P#UJ=U?NK=Y*?C
M[OVOWN$=Y[S[O /6IW5^ZMWDI^,#N_:_>X1WGO/N\ ]:G=7[JW>2GXP.[]K]
M[A'>>\^[P#UJ=U?NK=Y*?C [OVOWN$=Y[S[O /6IW5^ZMWDI^,#N_:_>X1WG
MO/N\ ]:G=7[JW>2GXP.[]K][A'>>\^[P#UJ=U?NK=Y*?C [OVOWN$=Y[S[O
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MR,&;$           !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
M   !R=OS]8DOX/&\&0ZOV;^"CORXSY^[:?\ IR]6/$:P/E&R&EH0,0I4A P*
MB)\H@J0@H05(1,"2)B"4(*$%2$3 J/# D@8@J(F()(F!41,02A$P*B)B"2)@
M5$# DB8@J/# DB8@D@8%1X8$D#$%1$02>&!40,"2)B"HB8@D\,"2 %1X8@E"
M!@5$1!)$P*B(@DB8%1T9U/\ ][<A\W(\.D:EVD_BAZWD-V[*?S3]7RG8(T,Z
M0   'Y[[Z%_S:RKX67@D#JFR?A*>]Y3C.V_C:F_Y$->T&6,*XH <4 .* '%
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M #B@!Q0 YV/U1"I@=Y\[K_-F!S_M)_/'U?*ITWLI\-/U_(AT&-5-S
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M#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2 <:0#C2
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M(= C53=            ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%-A
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MXILEF?94I))-1]NHYUM>VC0NI1CFSIX4.P;!NYW-E"<\LLJ+X%;BS[ISW?\
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M3BC6E)*,N"25W3(6VPKBO7N%64I+%$5<ZL7?:6UMK:T3!3C&2R1'1$1<RO\
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MV)OP:H;N           !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
M      !R=OS]8DOX/&\&0ZOV;^"CORXSY^[:?^G+U8\1K ^4;(:6A Q"E2$#
M J(GRB"I""A!4A$P)(F()0@H05(1,"H\,"2!B"HB8@DB8%1$Q!*$3 J+C9\>
MR*_*=58+7,N2XQH-XX+#CYM&NN@U&V1Z:Z3I[ MZUQ2I?R22+ZU1.,N[>VK5
MGZ*$IMGPQ63<"&W,3VKWERE34/(+G<K-C52*04V8Z:S;+E2W'UF=:?=D2?\
M4-9N]IV%!UIQC.>Y%/U-Q&[V&Q=J7*I&M.=.GIQ27-J2+\;(=$76Y8SM3A//
M*246RV=A+,2,G^D=<I1#:?NG'%<I^RI7"IC2Z5.K?7#9Y37*NK=WD^I#HU>M
M0V9:OFA!&1->I-]5T[ZKI4YMV)SI9;KS)=\=)+V6$\TM=22V4QUTGFRX]@S)
M3:"[:B(;OMNR_P -$@G\3<#,O*N\<T[-[37YA*55?YGWL2JZ9_RHFZB&X>L#
M@-US;%8S]B9.5=[.^J0B(DRUO,.)TNI01TJLJ)41=FAD7&A#6=A7T+:LJ35H
MS3/J70;IVFV;4O+=%IH\H*[:T7/Y%\&LTWL5MIECN?0;Y=+5*MEILREOO/3&
MEQS6[H4A#:"<(C4>I554X$1<>4ALNVMHT4MUA&22E/4K^$T[LWLFX][C4G"4
M(PR\Y%30R(C_ $\1NKK$7^+9]LKC"=613+PMJ%$;[*CYQ+CATY:)0A7'MT[8
MU?8-!:EU%=$75>)/&;KVGN4HV,D?+-HIPNOB1?$<2F.HG%2!B"HB()/# J(&
M!)$Q!41,02>&!) "H\,02A P*B(@DB8%1$021,"HZ,ZG_P"]N0^;D>'2-2[2
M?Q0];R&[=E/YI^KY3L$:&=(   #@C>TO^:F3_"B\$@=8V1\)3WO*<-V]\?5W
M_(A@%!EC!.* '% #B@!Q0 XH <4 .* '% #B@!Q0 XH <4 .7.SXYD&0K=18
M+5+NCD<DJ>3"8<D*;)1F235S9'2M. \*M>G2\^21?6J)QEQ1MZM9^CA*;9\,
M5EQ(;?Q':K?')S:M]VN5TL.-U(I"YTQXC)OLDB-SFI1TY-1)3W1KMUM*PH\Z
M,8SGN(GZF-QLMD[4KLDYSIP^])?TOR'3#CF*[2X,DC,H>/61C2VDS(W75\3H
M7)J==69GW5'7@-)1*M[7URFOT\"'0U6ALZV]&%-.'ZU7QG).W&XCC6]#&9WM
M9--7N6\S/,U=XTW.JALM1\B&E<W_ +*1T&_L$6Q6E#["(W@\JY3ENS-J+\R2
MM45DJ*J+N)+-X$R>!#J#>K"IF=X#-M-L03EWC.-SK>THR22WF*D:*GP(U(4M
M*>Z95X#1MDW:6UPDI>:N1?#]9TC;EA*\M90BCR3G1WTY4=#1_5ZVLRB+FZ<H
MR&U2;5 LS;Q,%-:4RMZ4\@V2)"5D1FE*5*4:BX5H-HVYM*DM#HZ<DDLFS963
M.:9V:V17C<]-5BL$@[.C.JHVG0RKE,]ZTF3L6W"8V,(<_P".ODE"EM%_98AD
MZM1_^\YLB[?'M#$]G+99UUJ:()XU^IS-]K;M*=LE+347Q1R\;?1#F*-N!GL.
M.S$B93=H\2.A+3##4Z0AMMM!$E*4I)9$1$14(B&\RL;>2JJTXJJ_=3D.:0VC
M=01(QJS1$S(DY,GC.D.J[DF19#&R@[_=YEU..Y"Z.<U]R0;>M+VK2;AF95TE
M7V!I?:*WITEIX(I%\69&U'0^R5U6K)5Z2<IMA;$JKZ6LTGG.X.?0\VR6)$RF
M[,16+I-:88:G2$-MMHD+2E*4DLB(B(J$1#9[.QMY4(*M.*JL8_935O&F[0VC
M=1NJJ)5FB).7VY>DNZ85>,BR'(5,KO\ =IEU7')1,*FON2#;)=-1)YQ1TK0J
MT&2I6].D^"*1?4B)Q&'K756LW23E-O2DJ\9;*#W+=Q0 XH <4 .* '% #B@!
MQ0 XH <4 .* '% #B@!SJ'JC%2)EG]9 _FR!HW:?/3_%Y#I78SS:N_']QTJ-
M*.B@  !^<V:%_G'(?.<W\X6.R6G\$/5CQ'S[??$5/7EQJ6*@NBR<4 .* '%
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M-X            U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
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M XT@'&D XT@'.N>JD5,'N_G5?YLP.>=IOB(^KY5.L=COA9^O^V)OD:F;T
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MI .-(!QI .-(!QI .-(!QI .-(!QI .-(!QI .-(!QI .-(!SISJEE2)E?\
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MA:#%P6IX8$D3$$EWQK%;QEL]<"T-H_ -*DS)<AQ+$6-';]VZ\ZNA(0GM_P
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M19\:MO9#)VEDM>G4FBMT<<6_E8L%!>&,% #B@!Q0 * '%  H %  H % #B@
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M]1*)>K\)S9)T4[VG9'AT%=:'3]++I,.)OL9GPX?$^?3N%RES;1NO=>AAT6/
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MC'I%>2HZ^'*W@S&.VG*DMQ)*2)&"*R-N9'\.<Q07IC2)@5$1!)$P*CHSJ?\
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MWA\9>LALV/,KP_#;+9HK-XS.UV1=PO3Y+=7&7*-M&J,C41(4HTJ4ZKCJ)5.
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M3 .-)@'&DP#G6/59*F$W;SHO\W9'.NT_Q$?5\JG7NQ?PD_7_ &Q-Z#4C?0
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M3HTD5*=+$V)><N-75VR)N(G#E,1H,F89Q0 XH <4 .* '% #B@!Q0 XH <4
M.* '% #G5_5<*F%7;SHO\W9'.>T_Q$?5\JG8.Q/PD_7_ &Q-Y#4C?@
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MSLDX?_W)>"0.N;'^#I[WE/G_ +1+_P!A5];R(8+I[@S!KSC3W #C3W #C3W
M#C3W #C3W #C3W #C3W #E9;KG<[.^J5:I;T&2MM;*WHZU-+-MPJ*35)D=#'
ME4I0J(TT22;I[T;BI1EBIR6*LV16*/3W!ZG@XT]P XT]P XT]P XT]BG$ XT
M]BG$ XT]P XT]P XT]P XT]P XT]P XT]P XT]P XT]P XT]P XT]P XT]P
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MP XT]P YU;U7BIA=V\Z+_-V1SGM/\1'U?*IV+L1\)/U_VQ-X#43?P
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M LCS3[AI*41&PF2^A)H86X1D9(.ID1EJI4>4]HKEE"FLJ<7>3IHSX4^TB:^
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M<TJ5.;4Y](C9V6/@9?\ 0M!CW+4@!4>&()0@8%1$021,"HB()(F!4=&=3_\
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MSHV^2%9*DD5I(D9(V\JHRI]&8QN@R!B'% #B@!Q0 XH <4 .* '% #B@!Q0
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M]L3=XU$Z"           !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
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M21)27:(56]O"A32G#-$\[R\J75:56IYTE^B;R)D0MVD7!:.-(!QI .-(!QI
M.-(!QI .-(!SJ3JS%3#;KYS7^;LCF_:CXB/J>53L_87X.?\ R?MB;K&H'0P
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MAZL>(^8=HK_E5?7E^I2SZ1=E@XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D
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M!QI .-(!QI .-(!QI .-(!QI .-(!QI .-(!QI .-(!QI .-(!QI .-(!QI
M.-(!QI .=$=6,J1LF_K(?^I\<_[6>=2_%^TZYV \VOOP_<;^&BG50   X1RQ
M/^:;YYPE^&6.WV?\$/5CQ'R]M)?\JKZ\_P!2EGTB[,>XT@'&D XT@'&D XT@
M'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D XT@'&D
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M8!QI, XTF <:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, XTF
M<Z%ZLW"/DI=G7#X?8?'/^UGG4OQ?M.O?_I\O-K[\/W&^QHAU<   .%LK37*+
MV?\ \?*\,L=PL_X(>K'B/EK:2_Y=7UY_J4M&DQ=F/<:3 .-)@'&DP#C28!QI
M, XTF <:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, XTF <:3
M.-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C28!QI, XTF <:3 .-)@'&DP#C
M28!QI, XTF <Z;ZMQ4Q"Z%_YDKP#(YKVJ^(AZGE4[;V"^#J?\G[8FY1IQT@
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M?U!<@ V)^IG!/,D'P*0"FP@
M
M
M
M             !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
M
M
M
M                                       :]SS]_-J_/=Q_4%R #8GZ
MF<$\R0? I *;"
M
M
M
M    &O<\_?S:OSW<?U!<@ V)^IG!/,D'P*0"FP@
M
M
M
M                             !KW//W\VK\]W']07( -B?J9P3S)!\"D
M IL(
M
M
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MI,R,J<#$L#(L2W$PK.2<_96\,7!UE.MV.G4T^A!G34;3J4+(J\*Z:" 9.
M\)234:2,C45#-->)5Y !Z      /%*2@M2S)*2Y3,Z$ /0    8=F&Z&&8-)
M8@7V<HKI)3SC%NBM.29*F^/?FAI*C2GO3XJI6ATY !=<4S#',WM2;SC$]$^
M:C;6I)*2MMPB(S0XA9$I*B(R.AEW>0 7P :^R;>W;3$+K(L=]O7,7:*:2D16
MXTEXT&M)+*JFVU)]RHCY0!<<2W3P'.'SB8S>V9<XDFOH:DN,2#2GE,FWDH4H
MB[)I(P!F          ,;SO,[?@&,2\INC#TF%#4TEQF,23=,WW$M%36I)<#5
MQX@"\6FXLWBU0;O'2I#$^.U*:0Y0EI0^@G")5#,JD1\0!6
M
M
M    ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%-A             -$]:PJX)9
M"/B7R[%X?_MY E ;3R[&\3O&.7")DL*,=F1'=6^ZXA!<PVA!F;B%4J@T$6HE
M%R4$ T/M;N;(V\V'C9#>8;]TALW=VW6]I*R;44=:=9&2ED?>I63B:"2#I7I!
M=$Z7I.G-\[H[--.J@@DU#(W#C;F['9ED<6 Y;VD0;E$YAU:7%&;4;5JJDBX'
MK$@Q7:[<^XVS;BP8_AF+3,NNMNC*.Z*C+*-$C*=><<2TIY:5$IW29*-"4_9
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M1F5:5$@O.=;N6/;[([39<@94S N<>1*7==7>,E&2I6GFTI4I2EF1)21=E1"
M8I<=^K]9FF[W>MN;O PUQ2:W9U:.?0APZ)6Y'T416O(IPO9$L0?7?N\VW(=B
M+A>[.^F5;)W0'XSZ:D2D*EM<I'0R,N0R/B1\#!"3*$YM8L!VML%_O[BDQTVV
M RPPT6M]]]<=&EII)F55'0SY>!$9GP$ QJ5O9DUB:;O.8;=W&S8BXM"574I#
M4EUE+ADDE/QDH2ILJG]LKN<3X"0;>AS(MQAQY\%U,B%*;0_&?;.J'&G$DI*D
MGV2,CJ0@'W
M
M                        !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
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MI31IYU:D$DUI2?>H-*>)%R""3+
M
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MX!#"2]SWQ\>S]S0SJ<&ZK25U3;8J;VIA=V)LBF+B$M,=3A<IH2LS41'RT,^
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MVB3*)!-DZZE)$M>@C,DZCJ=.P(!4@
M
M                                           U[GG[^;5^>[C^H+D
M&Q/U,X)YD@^!2 4V$
M   /D46*4DYA,ME,4@FE2"27.&V1U))JI6E>- !]0
M                  &'Y%MW:<ER['LQF29#5PQPUJB,-&@F7-9U/G"4DU?>
MJ( 9@
M
M                            U[GG[^;5^>[C^H+D &Q/U,X)YD@^!2 4
MV$
M
M
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MG/X2["T,@           !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
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M5?/.$OPRQV^S_@AZL>(^7]I)_E5?7G^I2SZA=F/8:@##4 8:@##4 8:@##4
M8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@#
M#4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8:@##4 8Z?ZM1UP^Z><E^
M9'->U/Q$?4\JG:NP?P=3_D_;$W0-/.C            :]SS]_-J_/=Q_4%R
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M<)?AUCMMG_!#U8\1\Q;13_*J^O+]2EGU"[,>PU &&H PU &&H PU &&H PU
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M&N7.VXT;GH%@JY8H[ZVY3<K+LQ.YL5NDJ(F22X6]%].ZVHU?J&QFFL-0!AJ
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M_P"3]L3=8U Z&           !KW//W\VK\]W']07( -B?J9P3S)!\"D IL(
M           !Q[UA#IN7-^#1?!D.I]G?@TWUXSA7;#_T9>K'B-6ZAL9IK#4
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M:M#JNP/@H?B_4IPCM8G_ &53>C^E#6>H; :FPU &&H PU &&H PU &&H PU
M&&H PU &&H PU &-^[-[(.W-<?+,TC:+65';=:72HJ0?*EUY)\C?W*#XKY3[
MWW6E[9VXD$6E07G:9:MQ-W=T;^;H_9SLNM54KW,>9]F"_:W9?=W/M:>;YVR-
MW-WH&!PW+3:5HDY:^BC3)44B*E1<'72Y*T.J$'R\I\.7 ;(V1*[ECGDIIX]Q
M/*IMNW^T$+""TZ:HM5='H[J^1/(<@.39+TM4]]U;LQ;IONON*-3BW35J-2E'
MQ,S/B9CJ"01(X43)F.'2E*4EDJKB7*^E];ZS] T.Q[_8TO1U$<6Z1"6TLN)<
MW);JD^'<4.**BT:C+GBO$I],1E&O118KS9QR;RH?GU)8?AR'HDE!MR8ZU-/-
MJX*2MLS2HC[I&0[7&221%3,I\SSIRA)8R1E164[YPRWNVC$+#;9*>;D0[?%9
M?0?VKB&4DO\ ZU1QF]J)4KSDF99+QGT?LVC*C:4H2SQA%%WT1'-5[ 9&Q>KM
MG9(5_P!ZN9W1DCY5-REND9D7<TI_A&Q;?MUIPHOHCAX&-0[)WD:]2Y;-*>-/
MQ*O(AB/6CMKK5^L-XTGS,B(Y$U=@EQW3<I]DG1D^R]5%I3AJ5^%/J,'VXMVK
MTZOI1P_E5_W$^JW;G'+U?[OI_!,168A+_C/N&Y0OL-<?L".U-5$IPAK55X$^
MLJ[#4'JU:FJ*1X5?]ID76,R!FTSL+0HC<.+.5<WFD*HO1&4U0BKP+551$?<%
MCV=MUJ1K;L</"YENU]VE&=OD?#/&OX</'EX#SUI,>^89OY1KVP[KU?3CXR._
M%OU<O$;-QS/8>1X0YF[$-UF(VU*?.(M23=,HAK)1$9<*JT<!@+BPE1N>@545
M71'WS;+3:D+BS6Z2*HC25M/-?D-8EUI,>I_]!F_E6AG^Z]7TX^,U/OQ;]7+Q
M&B]QLLC9MF$_)(D=R*Q+2PE+#RB4M/,LH:.IIX<334;CLZU6UH1I*KJC^-54
MYQMB]C>W<Z\45$DV1=R*)Y#%=0R1B&&H PU &&H PU &&H PU &&H PU &&H
M PU &-_]5HZWC(O@T?PBQI7:G^.GOJ=)[#?RU?5CQJ=-#GYUH   /S_R]7^;
M+]YQE^'6.U6?\$/5CQ'S5M!/\JKZ\OU*6;4+LL6&H PU &&H PU &&H PU &
M&H PU &&H QV%U=3KMI&^%ROYXY=VB^,7>0[EV0_\Z/K2XS0.^ATW5R#V8OY
MHR-UV%\%3\/ZE.:=J4_[.K^']$3!X-KNMT-16R!(FF@R)?1FEO4,^2N@CI49
M>I6A3\Z21WU8U^C;5:O\<92;4BKQ$KE9[Q9E-(O%ODV];R36RF6RM@UI(Z&:
M2<(JEW2$4Z].IYDDDVI7)K6M6BJ)4A*#^DBIQF8[/85^W&:18DEO79H%)MSJ
M7>J:;,M+1_UBJ),N73J/L#%[8OO=;=53SI9(\O@XV,YV=V7[]=QC).9#G2WD
MT>%<F\^HZ=W?S3]B,)F38[FB[3?^!ME#HI+SR3JX7:YM)*61]LB+LCGNQ[+W
MJX2*^;'++>31X<QUWM#M+W*SE*/GRYL=]=/@1UWV32<1ZAUP^?F.W-E[BW<M
MLL?=09&IAA45Q)<J51W%-T/V221_9'(]M4UA>5$UJ_"CGT#V<K)5V?274F'\
MJJGD.5MVK>[:MR,DCND9&[-<EIKV42Z/I,OL+'1MDU4J6E-4]%N#)Y#C>W[=
M:-_6BNF2R_-SO*=)]7NWNP=M(3SI&GI\B3*01\N@U\T1_9YNI#0NT-1)WBHG
MV41/+Y3J_9*BM/9\57[2R7QMY"PVG(HZ^LI=H9*)27;;\F-&79=9;:DK+V2T
M++[ O:MNJ;(BOWL7"JQ\J&-H7<5[03BOH8$X(S7B4J^LO;W96!Q9S2#44"X-
M+?,OM6G6W&JG_MJ07V1Y=F:B1N5BOVHKY%XG/;MI1E.RC)$\V:*N\J*G&J&E
M-B(#MPW/LZD(-34,I$I]1?:I0RM*3/\ VU)+[(VW;U1(6<]UD\?(:#V5HK/:
M--43)'$J_E7RJAT#U@K@U!VPN3#AD3EP>BQ6:]E9/)>/_JM*&D]GZ:RO(JGV
M45?$WE.E=KJD8[.G%?M+%$W\22XHJ8'C_62L-FL-JM#MDF.NV^''B+=2XU12
MF&DMFHJ]@Z#,W'9NK5JRFDTYTE73I4UVQ[84*%O3I+3DJPC&.C0B(;2VVW-@
M;DL7%^# >@IMRVD+)]2%:^>)1E33VM(UW:6S)62Q24DEB?-N&X['VU3VDDEA
M%8X&SMI?D,*NW64L-INLZU.V28XY!D.Q5N)<:)*E,K-!F1&?(=!E:79NK4A&
M:33G(BZ=)@KCME0HU94UIR>*JFC0K&GMWMS8&Y$JU2($%Z$FWMO-K2^M"M1N
MJ09&6GDII&T['V9*RC))*DL39MPT7M%MJGM*4%A%8X$7/NMR&MM0SYJ;#4 8
M:@##4 8:@##4 8:@##4 8:@#'575@.N&7;SHO\W9'..U'Q$?5\JG8NQ'PD_7
M_;$W>-1.@@           :]SS]_-J_/=Q_4%R #8GZF<$\R0? I *;"
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MDY-/;5&=YA1**&TX6E:EJ3R.&DS)":U(^^/D*N2V+LF=:HE6:-".7+]KZM?
M8?M)MZG;T94:<GJR1LGV47.^I6S:4S[_ #MMGG+NW^61KYH4] 4E4:Y1T4UK
MBN&1JTUX:DFE*T\2J94KQ&[[3LDNZ"T\RYTW_ID.8[%VDNS[E*K.F:2:XK]$
M71F9SK^?!P?=O&D-J=:NUF=4EYEYA9I=9=(CH9<BFUD1F1I47<,AS*G4N-GU
MGRPENZ>5#MM6E9[5MT16J07*C9T7C1=Q=Y2,*'@VT6,J:2ZU:K.VI3SKKZS6
M\^Z9%4^-5.+,B(B2DNX1!.=SM"L^64MS,B>1"*=.SV3;LZ4X)ERYU7C5=Q/
M<@[E9R]G^62KZ:5,P4I3&ML==-3<5LS-.JGVRC-2U<3H:J5H0Z=LVR2TH)3T
MYUW_ *9#B>V=I+?W,JK-'-%-44^BKIRJSL8CJ[HR9A6.M=K/J ?/_P"#NW\Y
M\<UVI_Z:;\/(=GV(G_2+ZM3CD<DDK@7$=*.,,>ZNZ 8:NZ 8:NZ 8:NZ 8:N
MZ 8:NZ 8:NZ 8:NZ 8:NZ 8:NZ 8:NZ 8:NZ 8Z!ZK!UO&1?!H_A%C2NU/\
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MY)]U;I%[&HS%$*<(>:B)O'I4K5*GGR66^KE-J'J>+#4 8$M1<AF7L'000PU
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M&H PU &&H QUEU63KA-W\ZK_ #=D<Z[3_$1]7RJ==[%_"3]?]L3>@U(WT
M        #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X%(!380            #B[K'
M'3=&;\%B>"(=/[/_  :;Z\9Q7M7_ .A+>CQ&IM0V(U)AJ ,-0!AJ ,-0!AJ
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ME:5IBH)15+@=#'AL62+;.F992_4I=]I8JEXRYTC#]*&MM0SAK##4 8:@##4
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M95D\=$U7*LET0T:&RFJEJ(NK^M-2U?MF?>]FGR:-@_\ ZE_\/[S4$_\ &_\
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MBVI4*^&FF'FQ647Q8)-ECBTMK,-J,F89A4 PJ 85 ,*@&%0#"H!A4 PJ 85
M,*@&%0#'6_54.N$7?SJO\V8'.^TWQ$?5\JG6>QOPL_7_ &Q-[C4S>P
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MHSJ9GVS,P"Y3S5W0(8DAUQO5S:U(U%I5I,RJ1]@Z<I"%1%)1T(ZA(8:@##4
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M+'4719,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ
M85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85
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MPU X8:@<,=?=4TZX->/.R_S9@<][2_SQ]7RJ=5[(?"S]?]L3?@U0W<
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MA4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4
MPJ 85 ,=A]4DZX)>?.Z_S9@<][2?SQ]7RJ=1[)?#3]?]J&_QJINH
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M=-<85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ 85 ,*@&%0#"H!A4 PJ
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MOY$.@1JIN@           &O<\_?S:OSW<?U!<@ V)^IG!/,D'P*0"FP@
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MG6)P#U/+[Z4Q/)G??AWEAZ"\([IU.L3@'J>7WTIB>3.^_#O+#T%X1W3J=8G
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MLJ2P66)U?Q(;)&(,V           !KW//W\VK\]W']07( -B?J9P3S)!\"D
MIL(
M
M
M                                                      :]SS]_
M-J_/=Q_4%R #8GZF<$\R0? I *;"
M
M
M
M                   &O<\_?S:OSW<?U!<@ V)^IG!/,D'P*0"FP@
M
M
M
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M9H+W/%.KD %?DN2P\7A1YLUA^2F5*8@,LQ$$Z\I^4OFVR))FGE49$9UX<I\
M!9SS^/;^GM9-;)5FG0HR9R(QZ)?28ZW283S"HYJ);G.*0VIO@HE+3V%$8 ^<
MS-'66)\"]0)F.W%5OESK<]6-*4XW%;JX;1I4MOGVJDKFG.!]M1:J 19SQQ>J
MWVFT7"^3H$*%.G.)*.P:F9C2EI,C4M*%/*T*_!(I[)$9 #YQ<WN=RR^W0;5;
M^E8M<;.W=6YO.-MN$3KJ"UFA2B71*54-&FM0!>\6R9W*(WRFS;7(UFD(2];)
MSCK+G2&EUH9H;6I39]G2OB7(=#J1 1N>3OVBZQXTZTOHL\E]F$W=R<94CI$D
MTH;(VB7SA(-:B;UTX*[&GO@!;D[BPEO74FK;+7$M4T[1T@B;(Y5TYQ"$QHZ%
M+)2ZZR,W%:4%QJ?!5 +M8<C7=94NUW"WNVJ]0T-/NPW5MO$J.^:R;=;<:4:5
M),VU)/D,E%Q+D,P/A,RIVV7J-;[G:GXULG2$P85U-QE;;DE:34A)M(6;B4JH
M:4J,O=4J1$=0!+&LI5DYNRX=N=;L57$0[FXXU^&6PZIEPC9)1N(HI*J:BY"X
MT/@ /E<LN?CW"9;K/99=Z<M:4*NJXQM-DT;J.<2TWSRT<ZZ:*+T)Y"4FIEJ(
M 8ZS?'\LSNVE$9D2,41:X]UA/L2RBMF[)=71UYE*D.+T\WS?-KX$>JJ0!5WC
M(;K:]S+;&5*_RL]"9A3HII+2BX7%Y[H;Q*(M7$XRV3*M*K2 (M9/<96YR;>Q
M*_RVS&EVWH:20KGKHPF/*<=U^Z+FFW":TUIJ-7: %S_;CH:[BU?[3(M3T&!(
MN[:5N,R">AQ*<Z9&RM1)6DU)J@_NBH9\: ?&/GK\YN(W L,MV[7%E4Z%;G%L
MM+*W]Z2)$A9K-+.LU42V=5UJ6G@J@%&K);\QETZ(Q9YLZ0JT6Z6=I0ZPAF*I
M3\M#FIY;A-<XO2DB2E1ZB3V"*H RRUW:-DEB8NUH>6TS/8-<=U:*.-*41EWR
M%?;(5P4D^R5 !BN'7R5<,DNEN@7I>06.#&:*9+DH:;=CW12C,VD\TAJJ%M]^
M9:#)/"BN-" NN&2[P\K((=ZGE<G[==%QF9!,(C$3*HL=\D$A!GP2;JB(U*-1
MERF +W=8<R=%*/"GN6UPUI-R2RAMQWFR/ODIYU*DI-1<-6DZ # FK[D1R'<5
MB75,B0Y>SM<2^.-MF^F&Q"*;)JA*2;6\T9&P2]--1D:DF:55 NEN_:*3<+WB
M<B\NH5;EPY42[I:8.6N!,)RK2R-'-ZTK9<23FCW-.&KB8%K>OF11[3?8#$Z3
M.*WWB+;(]\BQD2)2(KIL+DFMIIM25KCI6XV:R;Y:5+42@!EV*38-PMBY-OO+
MU[8YYQM4B23:76G&S)*V5(0TR:#29<4K1JX@"^
M
M
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MEMTF3=7&H2I]]N2)-XCI==)J+":BDP@F5<V?.O%S3>LU$@E5/D)*2,#+0
M
M
M                                            &O<\_?S:OSW<?U!<
M@ V)^IG!/,D'P*0"FP@                   14A"Z:TDK29*34JT,N0R[H
M D
M
M
M                               #7N>?OYM7Y[N/Z@N0 ;$_4S@GF2#X
M%(!380
M
M
M                                                         U[G
MG[^;5^>[C^H+D &Q/U,X)YD@^!2 4V$
M
M
M
M                      ->YY^_FU?GNX_J"Y !L3]3.">9(/@4@%-A
M
M
M
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M_$_TW<O\( #I^^?H_B?Z;N7^$ !T_?/T?Q/]-W+_  @ .G[Y^C^)_INY?X0
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M_$_TW<O\( #I^^?H_B?Z;N7^$ !T_?/T?Q/]-W+_  @ .G[Y^C^)_INY?X0
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M_$_TW<O\( #I^^?H_B?Z;N7^$ !T_?/T?Q/]-W+_  @ .G[Y^C^)_INY?X0
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5I5L0;:2;-:B4E*S-1)30B,U$)/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>pg_carislifesciences-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg_carislifesciences-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@VAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@.2XQ+6,P,#(@-SDN9C,U-&5F8S<P+" R,#(S+S$Q+S Y+3$R.C U
M.C4S(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7 N9&ED.F1B,#8Q-C0P+3-B9C,M-#0S92UB,V1B
M+3)B868V9F$U8C$R,"(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HP,40T
M-S=#0S$W1C0Q,48P03,P-3DU.30U.#,X0C-#02(@>&UP34TZ26YS=&%N8V5)
M1#TB>&UP+FEI9#HP,40T-S=#0C$W1C0Q,48P03,P-3DU.30U.#,X0C-#02(@
M>&UP.D-R96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B R."XS("A-86-I
M;G1O<V@I(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z,F$P,C0U-6(M8V-C.2TT,V0S+3DU,#DM9C5B8V8P868P83@W
M(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.C)A,#(T-35B+6-C8SDM-#-D
M,RTY-3 Y+68U8F-F,&%F,&$X-R(O/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$(!G($^P,!$0 "$0$#$0'_Q #C   !! ,! 0
M         P0%!@$"!P@) 0$  P$! 0$!             0(#! 4&!P@0  $#
M P,!!00%! H*#0@$#P$" P0 $04A$@8Q05$B$P=A<3(4@9%"(PBAL5(5P=%B
M<I*R,R06%X+20U-SD[/3-%3AHF-$=+34)355=3<8\,*#HV2413;QA&65)G8X
M">+#I+565QG$I2=&$0 " @$# @0#!0<# P(& 04  1$" R$2!#%!46$3!7$B
M,H&1H=$4\+'!0E(5!N$C,_%B<H)#DJ*R4R0T%L+28T0E_]H # ,!  (1 Q$
M/P#W]0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0'+/4GU)S_#\['QF*C0WHSL1$E:Y*75+"U..((!
M0X@6L@=E>WP>#CSXW:S<S&GV'E<OEWQ72JET*BGUQYB>L'&_XM__ #U=W]IP
M^-OP_(X_[EE\%^(JGUMY>>L+&_XM_P#SU1_:L7C;\/R+?W')X+\3<>M7+C_O
M+'?XM_\ SU1_:L7C;\/R+?W#)X(W'K/RXC6%CO\ %O\ ^>J/[7B\;?A^1']P
MR>"_$4'K'RT]86/_ ,6__GJC^UXO%_A^1/Z_)X(W'K!ROMAX_P#Q;W^=J/[9
MB\7^'Y#]?D\%^(I_6]RK_4X'\![_ #M/[9B\7^'Y$_K\G@C(]7.4D:Q('^+>
M_P [4?VS%XO\/R'Z_)X(4'JSRG_5('\![_.U']MQ>+_#\BWZ[)X(TD^K/+4L
MJ,>+CO. \.]MXIOW'[X=:I;V[&NC?X$KG7\$4#,?B6Y]B-_G8G%)2TX@E:FY
M WH"@EUH R!M= NMO=HL IT4-?,R8:U<:G93/:W@)8#\2WJ-.E+9R^)Q$5 E
MLP@$M2$E"G6C+<*RJ419E@ N'])0JF'#NM;=HE'XZ_@+<AKH7[&^LG)\A',[
MY."U">4/DBIMX+6UT#BOO=-YU2+?#7ITX&.VLN#F?,NNR'O]:W)O]5@_P'O\
M[6O]NQ>+_#\C/]=?P0?UK<F_U6#_  'O\[3^W8O%_A^0_77\$']:W)O]5@_P
M'O\ .T_MV+Q?X?D/UU_!!_6KR?\ U6#_  'O\[3^W8O%_A^0_79/!!_6KR?_
M %6#_ >_SM/[=B\7^ _79/!&O]:_)_\ 5(/\![_.U']NQ>+_  _(?KLG@C!]
M6.3C_>L#^ ]_G:M_;<7B_P /R(_7W\$8_K:Y..L6!_ >_P [3^VXO%_A^0_7
MY/!"9]7.4C_>D#^ ]_G:M_;,7B_P_(K^OR>"-/ZW^4_ZIC_X#W^=J?[7B\7^
M'Y$?W#)X(U_KAY5_JF/_ ,6__G:?VO%XO\/R']PR>"-3ZQ\K'^\\?_BW_P#.
MT_M>+Q?X?D/[AD\$:?US<L_U/'?XM_\ SU6_M6+QM^'Y%?[CD\%^(F?6GEP_
MWECO\6__ )ZG]JP^-OP_(K_<LO@OQ-3ZV<N'^\L=_BW_ //5/]JP^-OP_(G^
MY9/!?B:'UOY</]Y8W_%O_P">J?[3A\;?A^17^YY?!?B)_P!>/,?]1QO^+?\
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MH?6+F8T^2QM^W[M__/5(-5>LG,TZF%C?\6__ )ZH3D0:_P!<_,^R#CO\6_\
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M4(,@4!Z Q?\ T;#_ , U_$%8,V0[J % % % % % % % % % % % % % % %
M% % <5]7D%7)HI_]A;'_ *YZOI/;'_M/X_P1X?/^M?#\RBI;U_/7HG&+I:%5
MDF#8^4VXVRXM*'7KEE"C8KVBYVWZV&M5=H)VBJ'&%*\L+!<NM! U.]L!2DGN
M-C>J[D3#,L2H<E*%,NI6EQOSD$=J-VR_\+2J[D6V,>I:%3)&T5#?T57<6VFW
ME7ZT$&X:/95="89OY8MK4%BO<OALR<,XU);=<B'^64P1\PV-;+;"@4K[E-J!
M"@;5EFU1:FC/,7,V9$3ET7*O.MN-IB-R&\C=12&H3B4LO^,E>@VI*"5*NG;<
MBOG<^Y6_;[ST*:H?XS/G+L(B2$K9QK4=[Y+>+N$K475271^F\J_B^PGH":X\
MN1WHZKHEH$H.R^F>683CWR\%,LMH;2KS+N.*6"=SCA[-H.H [[_#7H>U<A0T
M]'^_Q9RY:R0OJ1FE'(-0UH_G6/=+K11]DH!(4H#34@I-M;W'0BNCF9GT-,=$
M<_PO((Z5I=R/F)><3\E.>>6$H4TH%#2@%&ZO+4@HT\("+:7KS:9I3\]'^1KM
M+'$,->38?RLF)&D.6LQ*"T/+5'\"BTNX L4_$KZJU5%51*E_819PM#K'%?DW
MHQ>C/1WR02I<=?FFQ/VEZ_GKW^/"J>?=,L#NUIL.'X;I!/[X@#\]=;M!2!ED
M92HJ2ED;GAY-DG_=7DM_F)-97RNO3J65"G\JY&F&D;'= ^6QL%SN+B6M1W!.
M\UY_)Y2JI\SHQXRJ8SE,C+\H8AQE_,,-!QY?E&[:2A"0T020% *45'L!3K7)
M3E7=]J4FML5563K$8^:PVL*2O352"5)T[B>OO[:^CJY2/,:U-U) JS9$")0.
MVKR4@2*.ZK$">RK$0(J22:24@26@7N-:O+*P)E 'TU,B!!3=R;=*O**0(*0*
MM)6!)38^BDB!%38OH=*O)6!)0[*ELJ)%'=4ZB$)E .O;5B($5(%S:ID@24W]
M56DB$(ENK%!-3?45,B!!2/JJ2HDM&E2#K_X<4@<NR=O^KE_Y=FO!][_X:_\
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M4D:\7]3?5/D$AMIE[B$YMX#R3#ERTKU[=CS:;U$L.#IW%,[F,[*>@YAIAB;
M?4Q(1&)4WO0-2E2M;:U>KEE;="U+BD+)2O;TTL#V>VKVZE:] #!_3O\ 0*J6
M,F,L_;_VO^S0&"PL#XQ_!_V: U\A?Z2?J_V: T+#U]'$@>U-_P!FH C%$@AQ
MW<D[E%(.TZI1H.V@%_YQ^F@_V)_;J0%Y'Z3?\%7[= >A,7?]60K]?(:O;]X*
MP9L.Z@!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0')/5%)/((Q_]C1_E7:]_
MV_\ XW\?X(\CF?6O@4U+5_=7H''"%0WW=E1)$% Y9P]M]:\UF9&1SIBW<CXC
MS?(A#71)2@&]N]/BMT(KR\_'K?5ZQV.VEO Y/G./9;#1G<G*@?J?'O2A-$6*
MCR%*8L+I45JVM^5V^8M2W#U(UOX]L.2NL0OX'96R9$I83D&93S;;J(192_*F
M[%(9#965^6P7-GF;[IWJVA*C\-K JR6UIK[_  1KL?7M^\D./\@S> RV*<?2
MJ?"X^REJ8A%T*^06^I]U%S<W0'%GQZ@?O:WQWM6R?9+^.IC>AVO@69=:9S>/
M<=+_ .H\V"F18!*\;D5%#;EA^BL$*[B#7?BR-.RGH_WG/:O[BZ\9EIDP'FW#
M9R#(>BKOH2@*W-J([BA:0/=77CMH9VJ2>1!:A/K!L4H4KKM^'7XNSWU>UF0J
MHY/A/5-UN0YB\FKSIT4N1W73HI[R I:'0E.@\QJVG>E5<*Y>UP_$V>)'5L?,
MAY:(B9"<#D=TJV+0JX*02+@UVUON4KH8NL'GSU5Q[C#\MI<>\J&VJ5'E):6V
M5165!9202;A)5N19/A5=-RDBWB\I?-KU.O$<0D(CQ80+2B@2RE9!3XUN.*^$
M'KM;3U[U5YM93\F:-'8>+9!YGBL-M%G6BG>MJ(0T_%2RX$ID I ^\W62FRMP
M.H/8KKK;:M._AV?B9-25F8N2')[D&6TIR$2['2IIM#CN\'S"VT$E( *R3IWZ
M:6K%ZM+XE^B,\=B!<891Z05P&0V64S'FX0!2G;L<<6>J;>7X$DZ#II5JUGO_
M  (MHB1>3$7E&&VX<5^2KS;MM-(6DO%U!"DW4XH7N;J4JYKEMFW7=4DFOS*J
M67WC26$R%-.-E:W5@R)*&VUL&0JZ1;:?" /@T[SVUZ/&2J]?/_4K=F<WEW6Y
M\AIJ0&XLR*Y*4I9VAI^.W'2C<>Q)#B-:Z;7=[-()'+(<R9G.2OY-MQ*V$N25
M1C\2EJ=VBZ&_B42&R $ZD&O.IAW-M]S?1(O6"X;^M)"V9096B, LM1FGGY(4
MK4^>R^&%@GKX%$>R]=3P.^G;R4S\:LQM>#L.#P,;%1]L8J2E1*O)VEI*2H>(
M;;]O776O<X^&N-0CAO=LEBB]=<LR@2V6JVI6!/9KTJTD0)*1>FI FI(/LM5I
M$"11?MJ\E!)2!4R($2CNUI+*P)*1[*O)2!(H/OJ\E8$BCOH!!;9^BKE8$%-V
M.E6DI FI%3(@04W5I*P)[;=:"!,IH0)J;%7DB!(HO21 BIH7O5BD"2FQ>ID0
M=7_#ZG;RS)?]GJ_R[5>)[U_Q5^/\&>M[2O\ <?P_BCT97R)].% % 5_F2MF&
MN?[ZC]FH8@Y\'P.VJ$P9#Z3VBK(09\Y/>*20'G)[]:E,09\Q/::F08*TVH#7
M>*$FI4#0AFBEIZ?E[![ZO6KL]"KLDM346=25(4"D=G97H4XT=3EMFGH-YTG-
M-L)9X^F.W/5H9<M*G$-I]C:=5'V7%=BI1=>AAJWK)$)].9^8<$[EV5FYUQ)W
MAJ8X8N.0K]Q&:(38?NE&M/U-:Z427[R':WDOA^;%)V<XWQUKY:.$S)#?A3&C
M (801WVTK7'AODU[>9QWRJI6,CRS*Y)LH4?EHP'\BUH+>WOKNIQJU.-\AO0K
M:^:IQ4AD,GS)"5I!2+E(23K6U^&LE6GT@BG,V6TZG66W4O(2\@^%Q*5C^R%Z
M^#M7:X[H^MJYU\3)-M*J7-#4HJS2A!@FU6!I0!0!0!TJ&0S6UZ Q0&P% +(%
M[5) X;'AK1!"@%&2;;34 R031@PI&VJHAB2DZ:4"$E(OK4$LU"":$&X0.ZI2
M!MM/=5DB ((Z:T)1H0:!FA%JA@TH#2JLE%BX/_\ ,L3]Z[_DU5+).N54!0!0
M%=YY_P#*.5_P0_CIJ:]2&>>D@_1V7K8K!D"QT'6DB!1(UO22(-@!4@R0%"QZ
M4)DVCOR(:]["KH/QMJU2H>T?LT#4D3SQOY_@W*I&+^ZR#>/D20RH;C]PCS#8
M"^X$((M]%'T(6@KZ:K1D^'8_(*(<GRO,?RJ[;=V0?5YSQ &@!WI*1V)L*A=
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MJ'ZKF-_&P^A1/[Q:3^:J6+(0_5[LU+T-YYZ,R9$G<_&6&GMI4%-^/:;"Q-5
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M'E=$CX/=7Q>>L6\SZK&YJ'G#OKF1J'FI/;4HJPWBI(-2H&I  @]M %" J"
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M!%Z=&CV\]1:OT\P;:@'HC$J"\7!4DW2J.T0?84"L6;#RH 4 4 4 4 4 4 4
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M#<2J 4#Z;4!D/)/;009#B3VT$&=XH59LE0OUH0.&^S6M40.T=]&2A5/90"M
M;A((O4@-M :D7J&#5*.X5 % V ->VI0,AN_94D&BD%(H2)%)TJ :*3W4 @[I
M0,;+%A[ZK9$"1ZU4DL/!O_F:)^]=_P FJC).O54D* * @.:C=Q;)I[VA_'35
MJ]2&>=8;N97E9D&9CDH@,A*HV1;7X'4K%]A0L7W#[122*U*CDXQ3)+D!7D*)
MNIDB["CW[?LGVI^J@D&W/$&9#98D'1*%&Z5V[4*Z'\_LJ0*ELCL]] :$$&H)
M,4!LDD=*F"K-5V"5N+-SU)/:?;0(BGN?2,.?)?N]"3T2D^-O][?K[J2(DK>=
M]>H7'&_G'U-2H'Z#A*5_O01J%4=D@JEBX+ZQ\&]1X^[&/+AS4':]#D@;DJM^
MD#T/9I42F(9:IV,W;7V%;7!_)N)U^@]A%&@F-XLM2E?+RAY<D=$]B[=J3^Q4
M$CTCI:I(,6/=0%[Q=F>,1S^DDJ^M9K5+0QMU*:TO[PJ_=$W]YK,T+OQ3D28)
M$.2HJAN&R;F^Q1_8JEJR65H.BI4E:0I%E)(N"-00:Q@U-OHIH ^BF@,7!Z?D
MIH!ID8360B.170#O!VD]BNPU*M#(@X_E6'(DAV.YHXTHI(_-70FFC%HBU$U)
M!J3>@,4 4!H\-S2@/B%E)]Z=:@&$JW:]AL?KH2;4 ;@D$D@ =2385*(9&R^1
MX.#<R9S22.J4G<?R55V2+*K8R8YQQU]5F)!6.E[4W#:RQ87(19N4@>2OXEJM
M?][5D]2KT1W# '_FM@=+ Z?36%^IK7H25@>VJE@M[3]= %O:: U<4&D*<4?"
MD$F_<!>G<2<2S$L3LG*F*U*UFQ[A70E!DV1*S8Z4($R0*D%*SDSYN8K9JTWX
M4Z]M9MDP>K\#_P!!XS_@C'^3361J2% % % % % % % % % % % % % % % %
M % % <V]04;LVQ_P5'^4<KV>$_D?Q/,Y7U?85A" !;MKMDY8%TMCOZU267@=
M(;(%^VLRXJEJ]Z25@52@CK4%X-TH!-4DM @_BXLEQIUQ W,J\Q L-OF 6"EC
M[13]G=H*S:+R5KE3;$$L(:8.=Y3/+HQ+&1=4J,QM2/,?6!9+;+0()5MW7T!O
M7/DLEHM6RU9.69C@67@R9^<P$P.YE,AM4R/+"8,+)RW[R"B.RD!$9" DN_>J
MU%BK:3<Y6J^W4TJX.E^EW*8><Q+F)<649;#^!^(ZDMOM,N>-"74+\25H*E-D
M'L (TK;%>="EU#DN4K%8^<");"7T.H4R\D_W1ARV]M1ZE"K:BMVDS.3S7 8R
M?I_S;)<$93)>Q:Y25L%BV]6-<;4M%D[D)W>62%.*/A*>Z]>56SQ9-D=3:)4E
M#]3H3+&5?^62M1DNO*87(3M>2V"%;%IZ ^( D#7W5Y^6R]1I:EVM"M1 B#B(
M*_F 7O(>W1VRI*VG'%W;"U@63N&X@)/3KUK=62C7Q('$**M+41ATAIYY8DR$
MH%E>8ZH#8/W6PI'O-94MK),&O)\VZJ7(Q<$EAL+#DY94%)#B1NV$@ GRQM2=
M>MZUS-3!0TPV!RN;?,J6E89=.UFR?,)2=4JV@C0FVN@[3I6";;BI9'>>#^D>
M10EB=+4G'H0M+[:0E+TA:DF_C<58&O0P\/(WN;V_ QO==#LT6"^TDB4_\QK<
M LM,I%^P!L?EO7LJOBY,)'/EA( 3T'9UK8I ;3W5)$"1;UI+(@T+=NM6D0)[
M:F2HFI)!TU%)9(DI'=6DF<"93?2DD$'R#(N8=AC((;+K9>2Q(0.Q#E[*^@C6
MN'D9GBO5OHW!T8Z;DXZCB&Z)4=M_^^)2NP[-R0K]FO0I?<I.5UAFY1W5J4$R
MFDLB#12;=E3(@14$(4@N'P*4$G^R-JAVA22J2X.0\JY)*FY?RL42MS%..P?*
M5X2Z](4$@$'L !U_)K7@VRVM;>NO1?:>C7&E6"]\=B3(N."<@^F3,=)<=6WJ
MVD] A![0.^O;X]76BGJ>=F:;T)130TKKDYX$RCOJ8($U-BK 14GOZ58I W4D
M5,%1)2 3[:L0)J14R3 @4V[:O)2#IOH4+<GR'_ 5?Y9JO%]X_P")?'^#/4]K
M_P"1_#^)WVOE3Z0* * Y=Z_2A$X 7B;?SV./K"ZK;H2CRT,^D?;K#7P+R;C/
MI_3_ "U>LB3=.?3U"ZGJ)-OU^"/CJLB389[LW]?;5X8DV&> TWU DS^O1^F*
MD2'Z]'Z5-1)@Y\((5<$C4"I3::8E-03+O$,1FXS.08*64/(!&Q(&G=IW5]AQ
M.=D=4CP<_%K)O_07"EF.Y*DJWP_"5-@#<DGHJN_]1?MW.'TJ(M&!PV!@+3\A
M%"EB_P!XOQ*(/M-<V2]WU9I55+8[)5'9'F:)(\*1[.RU<B4LZ6X1!.Y)Y]12
MTV4WU"CUTZUTJD'-;).A.82 ^\ I=[?I=EJY<V1(ZL5'$EB=A-N1E1G=4.)*
M%^XBU>1D;LH/0IH<*FS'\9D)..DDI>C.*;4#[#H?I%>6]-#O1LUF1TW7I+$#
ME&82="JQI+ L,NG0;JLF1 NC+)_2]E6*M#EO)I[5 4DB!9.21^G4"!=.0!^U
M4H@4$X6U5UJ9 J)J;=:$0+M2P>VA9#UF4._ZJE"!\U(&FM6(@<HD)T]M2B!9
M+B21:I(%DD6ZU)!L"#VT!HHCLJ&292JB JGLJ2HH!>I)-"!VU! FI":$B"Q8
M6[Z$C9[I0@9N=M5MT)$5FQJD L'!#_\ A/$_>N_Y)50T2=@J"0H H"-S\)W)
M8>7!8 +KR-J0HV%[@]?HJ4X9#.=?U?YG^](_Q@K3>BL&IX#G!_<$'W+34[T(
M$G?3_-/-EMV(A39ZI*TD4W(0,7^ <CC()8BEUL"X;4L*4![%#4^XTW(F"N28
M$QHJ"XX!3HI)78@^T%-6((]Q+S>JF@$CKXQ^U1(-D9)S;,2_FMW]RTUO3$V8
M6R01DGG>#:;*)+B&$]JEN) ^NNROM^2^E3DOSZ8];=#GO)^08B8VLPY;16H$
MI"74+[.S;667V[D44NC^PMA]QX^1PKK4\P\P?RDK-.%:BY"0?NR/@W'J2".R
MO)R-U</0]>E=RE:D[Z5OO8_EC.JFU24[=R3:ZDZBQJM;:EG1H]W<,FOR82&9
M"O,38#7KK74CEL3&5Q"7A8IU!W)4-"".T&C1"9%-NN1G!'F+5J;-O7\*CW'N
M5^>JEA\$W&KB_K_V*$%Y19KB\6U[AM%OIN:V70Q?4HS84.BU?4/VJS9JATR\
MZ@C[PGV$"B(9.P^396*VF,);B6AHUTL/940)'J>4Y?LEJ/U5,(2;_P!*,M_K
MBOJ%(0DR.4Y;_6U?52$),+Y;ETCPRC]*14[41+*YF,A*FO&8^X%O?;5M )2/
MVJ0)(\^8JRMX(.H( %0#7QC[0^K_ &:$AXN\?50&"5CM'U?[- 8!<&NY)]X/
M[= ),>8D*;W)\!VVL>G4=OMH#9QQQM!7=!MV6/[= <OYOELFXE:$N:"]DHW6
M_/6;9=(\O<^S'*4RVT1'R$%?B3OT-CT(K"UDCHI1LN/I^OD,T,%Y:4%5K@;K
M?[-*WDFV%H]+\ ASF\SBTO+20%F^I&FTUTTZG-D4([,]S'*8=_\ 5L=ME3#2
M4E)6"576+FY!JUJ)LI6S@W;]0,P3XFX_T!7[=5]-%E84'/LK<W88/T*_;IL1
M.X4_K R:?][L*^E7[=1L0W#7(\_R+T-YE4=EL+04E:5*W 'NN34JB(=BC%Y_
M8+-@DZD[[&YU[JN4&RWY8Z1@?_2@?^;4$C>0N>ZRXTW'2VXL62LNA0%^^P%0
M"N*XWE=3O:)/4[CUJNTM*/5N$06\-CFU?$B*RDVZ7#:161H/J * * * * *
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M]PZ2I_ \_-8Z:6P  D:#H*]J3B@3+8%7DI BI'[?T4D0);4GIJ#VU,E8$BV
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M&O9KB32JNW[:BW0NF!]'L/B@T])7YTMLW2E;#1CHN2;(9NI-M;77N)]]=F/
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MI;6[>AP"Y2M!LI) ]E2B"ZL@G6Z_K-6*CA*+]5*_A&I *8!L0I25C5*KWL:
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M;>1_)N#J#;\HHT"+:>6%F/)NW(3TL!M6!VI/[%02T+;.Y9^H5)!C:?[Y^04
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MU-BE2%- @@]Q%<%^IUU1A+Q'4:?152P.23L("=562.G;0(<XMY/ZSA#9_=D
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M6VB3MV(4E>)@*0;H5'9*3TT*!:N1]3H0\J"0H H H H H H H H H H H H
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M_P#!@J_XA>,#_<<E_P#N]^A*/J?0D* * B>3_P#0,[_!C^,*M7J0^AR8C[Q
M]BB?=I6YB;C3I02;#6A9 H:4#&,YXLL.J'5*%* ]J4DU#*C=EX%EM:]"4I)[
M-;"]JI+DAJ2J9Z>PO*.A75(0GZ-MZND0V<A]:'2OCJ/(0M.[>%NI&MK"R;=W
M;7M^W*+->1Y_(6M7YGE6;%4E?W25%7Z125&O3O370[DS:(UD&" G<>])20/S
MU-59$6AG0N#9T<=9R&<GX\Y!J*E),35._4#10O8B]]=*TR.VQR>?EV>M2LZG
MH3AW(WN1\>QV<>:4RN8EQ:6E;5*2A+BD)!*0D=$]U>'DT9UU4:%ZQT@FUKGW
M5Q6-DB;*=P!^UW5@RYJ 0M /6QO4 62*-DH=,T!(,D7'T4!.MJLE ]A-59!7
MLTL?/N =R=/HJ5T*,;LMI2Z'F%*CR?[ZT=I/[X=%#]\*0"D^L7K,_P"F>.Q#
M[K+TJ3DV)2RY&1'VA4<"Q*'PH=O1)%9MFJU<LYO&_%1Q&?!ANY3B^0D30P@+
M="HOQ*U40FQV@D]!4IAHL_$_Q*<>RN11@<#Q^1!?EA;J'9[K3<9):3N(/DIW
M*4H"R0.VK;BCTU9UC ^H,'D"W<2MA43+A)4E"3YS#B4BY4AP!)! UV+2#[34
MI."*M/5="4"A;KKVU,%I-"2: U/OJ0,DI*X* !=2DC0=:)AE#Y%C<BH+6AFP
M_=J"?V:Z*62U,FFS@7J+A\S(BNI:2PDW^TXKI]"37H8N8JZ0<MN/\R?@< R4
MV1$>7'EL.,E&GF%*BV;=H5;I6[Y56=-=2.#B7COW%5^FE36VXEHL7$F)<C-L
M,Q$."2=4;+@_6DZ5>8.;DI[/M/7OIIQOEF/=DS<HT\F%\L$6>>6H;UE)3X5J
M(O85Y>2R9:E6CHKR\RK)K;BPVGHH:;=2M;LI!(5X>C3R$C4$:"N.R1T)LB\B
MUR)U]3S;TB&D@#R8\R4&Q;N"G%'7WU1(M.A=L:Y)/'<5\V^MYUAFQ+JRXOS%
MN*NI2E7).VP%ZH_ LG))I4?-)[P*L2A=*B#4 72I7?0&5+4'F4W-E;[W/<F@
M2%AN[%&_OJ"0Z]23[S2 =5A?Z''_ ,$C^**P9L+U "@"@"@"@"@"@"@"@"@"
M@"@"@"@"@"@"@"@/&WXOO5"?P7FV*@0<6E]R3B&GQ.DJ4(Z;29*2@)38J4 F
MYUM8BN[CJ4<N9N2H8'GJF^(1^3\Y;8P!DDJCLA2UEQHV+92A7CW*&NWL%;1+
MT*3"&S'KEPDJ07AD&(2U;43GX2Q'-^W<"=*))N$]? M+6L:'2HCD*?%:GPRA
MZ)(0'69+6K:VU"X4%#2UJJU'4M*';.Q:$J:>.Q0NE2%!:"/8=:HR!RD.#[2%
M#VW2?R:5$L:&ZWO*25OV:;1JIQ2@E"0=-5$@"HW0M2Z4E;S'J=PO#094@Y2/
M-EQPM"(3)W.*?^%(5<62G=\2C6/KUC0T6&TZG )7+7\HU)Y% GR#R1:UHF3X
MZ$,L;9"@'&R=;%5@D7/9?2N"+;]7U.Y6KMT70>8GD+C4%;<DRIX:>0(D%#A=
MWIZ@!M:CKK=:W/#46QV;TZ%UDK&O4M R#>9P\_&%&+A,R9>U3"%E<H_= '8$
M%* VDW&JK6Z"NFKA:F#4LYUR^=%EYYUF#+7/;0E##T]:2UYQ:2$@(;^PT@ )
M0CV7[:^[]JX7H8_4M]3_ ''Q7NG,];(L5?I77_4@%/%2PJ]P@!*+DGPIZ5]#
MCK"^)\OGM-I\.@Y0\T;!21KU[JVU,$ZM]!Y!D.Q7D*CON1P/$HM**-!KV$5A
MFQ8[I[JIF^&^7&_ELTBZ8/UB]1>.Z8SD,CRT]&I'WR+=UE=E>?D]GX]^T/R/
M0I[QGIW3^*.DX3\6O+X10WGL;$R38^)QG[MP_EM7F9?8/Z+?>>C3WZJ^M?=J
M='POXK>!SPA&9B2L4XO[92'6QV=FM>5D]IY%)TD]7'[K@OWCXG1<'ZF\"Y&D
M*Q7(H;BC]AQ8:7<_N55Y]L&2GU(]"N:ENC+,E7FI"F5)<2=0I!"P1[Q>LFRZ
MU-2I?:*OH^Y&J,F]20:W-25DT4>ZC*R:'6KD&I%2#!%Z@&"GNH!-2.^DL0)%
M![15Y96!NXWK<Z@=/94P0></6G#NS.8E3BXZTA#<M^0^2VXU'#10AILC4WVJ
M^ %1O;MKY7GO;R7/1I:'U7 4\9>*;.(H^2PL1O(39"G(3SK2Y2&E+ 0'1N9C
MN)=*=Z/#K8':=*H_F>U=3:-M=TZ'0_3+,?TF]086<Q7GPXCDUMF>]'*&VWDA
M!"(I2RD>"Z0LI4+6&M=/#=J9E6>IS<VJO@M:.AZI:L0#V@=!7UA\F+6-5!C;
M?LJ9 ;/9208* :2#7942!/9J:O)$&A%^R]1(@T*.[K5A(F4]XJTE8+1P(6RD
MG3_>Y_CIK@YOT+XG;Q?J?P.A5Y!Z04 4!YR_&VHI]$E$:?\ .T+\SM99?I+T
MZGSICR#U)K@M4ZJV)9B01:Y]M<UJ&R9)1WM=%>VL'4O)=.-\G>@D-+7=!T%<
MF3%X&M;P7Z-R9EU((4 #6*KXHUWBCN?;VFS@J^TAW*WD\_<E*575[*TK0H[E
M>5-4M943<^W6M=I7</8P?D6V)-CT-5=2RL/OD'R/%UM63J:21LIAQH&XZ=:I
MM)5B F.;2=:E5)=B)<?%R;ZULJE&QHX_NNDG2UJU52FX]<8#*_UB>@F-S"E[
MLSQ-WY>7;KY*+-+)]XV+JWNF+]1PU;^;'^YGI>P9_P!/SGC_ )<R_%?ZE2B.
MA#H 4I?Y!7Y[DI*/U;'8DD#:]:UMVNM>?9:'6]4/VT@J"2H"^H %9)2<K<(I
M')X QV76Z@;4/J$EN_0$Z+ ^FOI>#FWXTO#0\'E8E5[O$;P)!QV62^SHG<B0
MT?=J17>JJU75]SS;)ULH.<^HV+:PO+Y[4<6@S2F?#L/#Y<D;B![E7%?3>VY7
MEX]6^JT?V'QWN>%8N1:.CU*OYAT_/7I0>7)GS!T%($F=^GYZ0),>9W_12"LF
M YKUUI DQON3<^^C0DU\T>ZIAB38.#M-0),^8 >NE4:$F2XGH3]53 DP5 ]:
MJ6D-J3;7W5:2&S"TCLJ2($RV#K:I(@34V".X5!#0W4QW=M:[M#.!!QBK*Q#0
MW6R0=14R1 W7'O<BK25@;.1JLF1 T<CA.FM63*#=3)!OWU:2#N_X,D[?Q$<8
M_P #DO\ ]WOU(/J?0D* * B>3_\ 0,[_  8_C"K5ZD/H<F)^]&F@2?RG_8KH
M,10:T)1D:5!)A9TM1$,ALV5KBNMH(2I:2D*[KZ?LU6Q*(R3D&VAL!^'0=O2I
M52K9 S<E%7<.MI< [5)!/U]:U53,X[ZU94-X*/'A-AEI]PAYT7-NP@ ]+BO<
M]OQZM^".3+K9(\]*L22EM:4#[9T->N^IJ;-(2+J"3;O4:(AEZC-.P_2+D62:
M3L^;G08>Z]B6W%+4I-^X[*YN3>-J\9.:M4\KL_Y>AWKTLPW_ . /&MR+%4)+
MFG^Z+6K]FO"RV^9G9752=1QV*;;3N*=!7)9FJ0Z<9MT%8EQJI-G?;M-2&*)H
MPAPWV5 'K*CN35@2BG2G9V6!_+5+$2-WV8LNZGV_O#]M.BM.\]M1)$#7Y H/
MW#F[KX5Z'Z^E3)$'E?\ &9.7$B\0B%M:WEQ)R#ML0DK6D>+4?DJC-*'EQK,(
M:C(;2YM+2$A>MOA%1)>#KOX9Y;63]9>/,R$A]EM$N0@. .)WM1U%*Q>XN.RH
MZE;5E:GO$8S#B8C+?*I:S/EK2EYL;=R"-J@K;H3;OK5+N<=,%:VFNAN.ZKG2
M;5 -'#X3;K4@;QK?+,_O!4 C,NF*\E0=3?LZU>").;Y[#X5S>I:+'WUHD5;*
M=)XMQAZ(LR6-Z%;KW2#^<5HI12W0\Y\EP<-'-,W%AH#<)F3M90D !*=B3I:O
M=XV+>BKLJUDMGIO@PYR5A+=R0/J%Q7?DP[<=F<'(R[K5KXL]JH4SC^/MQ7U@
M2I1:"&U DJ0E'LZ:]]?(Y=+'HTZ:#O'Y#U"Q/SN67C,++X#%A"0RL!U.86TV
M5%ZQ4@M**2%* )^'3XC6%NI>L06%W$,SM6'FV4.M^>F0ZVIQ'E[=]]B5)/37
MK6M(G74SNVEH0>*CS%8Y"YZ0TEYQR0B*!;RFEJ^Z:58GQ;0'%7Z;K=E8NNKD
MM2V@^87NU[:JS9#M)'6@%D=*@&%JM(8O_NG\6A*'(/;WT 7H#JT+_0X_^"1_
M%%8,V0O4 * * * * * * * * * * * * * * * * * \5_BR].,_S3U=Q&2Q
MST>+$@8&&&WYB"^TN0)\Q91Y8T-AM4K=H=!79ALU6([G/DK+D\_<\2<KZF''
M<]R2L1@8[2&H<P-%3192VDW;2 0DNKW;SKMZ5UU:=='J<]T]VJT,I?85RC'\
M8]/LM/Y3@9>QK+X[( O8]QK>-R2DA("$I%]]D[3;::C:H^:"=SW?+,$QZH8N
M#B\WCN'\*DY!.5G^4P<(W*7^KX["QL9:2CJDJU403HFY/6F.:J6]";O<]JZB
MO#GN4Y.8KT\]-LC^K,'B259KDA!6Y(DD[77&KWVH*D[&D)M=*=RJB^BF-2M7
M-H[%E;S?+^!>I?'^'O\ )GN61LP6Q/BRVTAZ.EXD)(*22E5AY@UZ=15:K=66
MB]GMLDB8]7><3V$.\=XQ(;#K =:S;[C0?;2I: &F]BOB1<^-0[;6.E>=FO.B
MZ'?BK'S/J>;-GS>47)R+:D,*95'<4TA38<2@B^WJ2D6[=>IKB5H['6ZRBUR,
MS#Q_%G^+XS'+CQ'UMO&8D#<I219&T#2Q!/7J3K6>UNVYFK:V;485PUO'\2;Y
M,[)4S/3(1';BLK4I_P"\3\2U!1\24_9'A^JK+D3:$9O!"ECG'9EW+<DF.M07
M/Z+Q3#QK"V'4,O+#B @ **5!*]P4XI9'A'OKIPY-K3:W:R99:2FNB@[#+_#3
M)2U?'9]I4I2!YR'VCL"R/$$+3J0#T5MUK[2OO3A;Z?<SX^WM-==MNOB5')>@
MGJ)CKEJ$QD&Q\)C/)W$?O5[37J4]ZX]NK=3R\OLN9=(L4O)<5Y)AE;,IB9D0
MCJ76%A(_L@"*]3'R\63Z;)_:>/EX.7'UJ_N(P/A (&JK 6/?VUM$LRW[5T,J
M.EQ:_P"^O6BLS*^->7WR:E]=NX^S3I5BCLV*N'H"22 !<?7656]3HM2KB1-M
M00O<G0]XT/UBK6HK+5294NZ/1LM&#YORSCZ?.Q&=EQK* 0CS5*0.T^%1-Z\_
M+[?@R6^G[CU,7N&:BG=/Q.D87\3_ *DXK:G))B99H"UY"-B[>]%>=D]CQV^F
MQW4]ZR4^NGW,Z/A/Q:<?DA*.08.1#4 "X[%6'4]U]IL>VO,R^S9Z=(9Z.+WC
M!?JX^)T;!>M?IGR"R8F>:CNJZ-2P6%:]A*M*\R_&S8_JJ>E3/COT:+I&F0YR
M/-@R6I39U"F7$N#_ &I-8&HI<WZ5,A:F+U8@*D&C[\>*R9$I8:C@I275?""L
MV3?WU1V@LE)EM;,A 7'<0\@]"VH*_-4RF084WV="#K>IDB!NI%KWUK22L'(O
M6S&8].+Q^:,-J1ES);Q<13C:GE.*<W.L)V @*2VX-_B[Z\'W>BVJW>?P/>]G
MR-WM7M'XGCKE*<_+CG!YZ*RN)C5!<6&DMM.L@K62 H'[RXON2K6U@HW KDQY
M*]NYVWI9N7V+CQ#,RH&/P>9XW,Q^'7C<@PW\BME:TN)NXM;[VU1*M@4$('Q*
MZ$V2*G'D].^Z)8R4]7'MF$^I[%XDYG9/'L=(Y0PF/R%U@+R##0VH2XI2BD =
MET;21V&OJL=FZIL^3O5*[2Z(G0F_2K29P&WWTEEMH;14;AM1C8*M(VHU*>ZI
M*P:E/LJ9(--E1($]E7DB#0I]E5)@LW!DA.3D'_<#_'37)S'\B^)U\5?,_@7V
MO)/1"@"@/-_XX#;T/6?_ +7@_F=K+)T+5ZGS>8=![:XV=%239=N!7/8V3).,
MZD6]M86-%J2D>0!:LF65239G+3T40![:K"+#K]8.$?$;5,(-C=V6;ZJ^DUHJ
MHS;'V&9^=>WK/W*=??5;:$5+BTZRR E   Z5@;HV7+ &A%4:-1C)<0Z""!TJ
M404//)5'<*AHB];5J9.T%<7*U/Y:VV%7<14_<U=5(W'H+\)_*T,\KR? ISB1
MBN3QE7;<MM+C:%)<";]%%"KCVBN[C5K;=CMTNFCFSY+TVY:/7'9/["=RD*5@
M\K,P\CPR<>^N.L=MVU6O](UK\UY&%X[VK;JG!^V\7-7+CK>O2R37VCQMUE3*
M75J\0UN3:O&O5S"/56N@Y3EL>TD7>0%=FNM56"_@9O!=]$17)9$#+,L-LN_S
MIA>X+()'EKT4*[^%NPV;:T9QY^%>]8Z$ ]CEMM-K\PJ7&4$J(3:Z55Z]>0GV
M/,MPH6MBF>I:2\U!?4K=(A MV-@KY=PW3IUT57TOM-I5EXGR/^0<95K6Z[:'
M//,TOUKWCXT/,%KT$F/-M4 QYHJ4B)-?,T)H#!=[/R5,$-F/,TJ F'F'W5$!
M,R7.[I4*I,F0Z>O;4M"3/G5&TF3</6IM1,FP>OH.^J-"10."A)FZ3^:I74@U
M*$W%JEL&BF@:)P0T-UL=3:X/0U96DI W6Q5TR(&ZVKW)%7*0-7& =?SU*9#0
MV<CZ7M]%3)$';OP<M[?Q"\9/^XY+_P#=[]73*0?46K * * B>3_] SO\'_YP
MJU>I#Z')$GQJN>@2/I-S708B@-J$HVN.^H+&%]E$595>1SFVTE%[ZI%K]=12
M)(DIF3SL=C<2XA/O-ZWKC9D[%0G\JCA2MLE('LKKIC9D[',/5#*?/8N&KS%J
M"'[A*>AW#0_1:O7XM=J9A,Y%]IRE(4XL%>]5_P!U8#Z*[%J;O1"JQM18$VZ7
MJ[T15=3IW*W\'%] 8&.@9*+*RTC+M2)L-A]"Y#24MN!.]L'<+=NG;7A\K+.?
MR2,L=6J-OJV>G_3[%IB\,XTQ:P;Q<,V[BMI*_P!FO)M:6SN5="X;4I39/2LV
M6&SO;4$D>L_>D=#M_)>H#-TU+"%T]14$CQ@^--25'<AW:I*1V"J,(1#]^AO5
M62;!X%0 ^FB9$'DS\933\S*\799=9;*(4E=WW/+!N\!8&QUTJ'J7KH>9HW#^
M<QW(TK&XY<I4@I=C.Q0W*!(!TVJO8^PIUJL&B9T3\*RW7?7#'E_<F0B+D5.I
M4-BDN%E6ZZ;"QOU%J(/H?0M)46T$:@(4"?:36Z.?N:I43K5B3:]0!)\@-K4>
MQ*CI[J$H8I>"(+!O:[2""/:D&K54E6RM9C()0E0W:UO5&90)DA<Z04@^ 'Q&
M]:I%6;2H["\40L#8FX)]AJW<HSS'/6%9[+.J!2XJ0YX5BRK V!([-!7TW%BJ
M,K)NJ+AZ;\BC\=RDC(RF%/-,M;RIM <*+:!922FX!(TO6^:;8VD<&11DH_B=
MQ=]7?3'CF#Q,K)Y#)HFS@IZ2_,B+D)=>193NQ32SY:4J58;DVMW5\/G<7A]3
MV\:^70:H]8/3'(1L[*XKF,LKEF9A*8CPREY41]U+:D!DQW5!I#;B;)\'BW^(
M:]<+-:FB6J4'I7C^2<7B<5D(*X[3LF!$=2W)4A2FPZRA6U0N-=;59*5J5C70
MK\Z5L"D*)"E..+5[5%1N:A:*"&)8]>]L*_/1ET2":$L5!L;B@-'EVDQ+_:4X
M/_5D_L5 '86;"@1G>:$P=9@_Z%&_P2/XHK!FHO4 * * * * * * * * * *
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M@>;+:20DLF0YL2KON DF_;7YYM4/R/T&CT7F=74W8]E<QU&-AH#'D)5\212
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MKB=M#H1-P<7+DD)9:4M1[$@FN*^1+N:U+;CO3GDLY(4U"<2DZW7X1^6N9Y?
MVE$N/2[.LI"GT!'LO?\ -5'=EDF-'N$3(Z@7$WMW51Y&B^T;/8HQAM4"FL]\
MB!@ZV6^G9WUJF59;,*_YD8(OW#Z:YVX9>O0=R62H7MKWU:MR6AGY9-:*Q6!!
M[S&]>J>_NK2K(Z%-YKD?+C)9!\2M+#VUZ/%K+./-8H/GGK>O3@Y9-DRC^E3:
M2F+(D=EQ[;TV#<>H?3N5-]2_P[\AP<B=\YE^!OM3\/$#83(C16TD. . W<0X
MVHD BZ2CNK=4FFO\O8UP9;8\D5E;T]9_;4XE/R&8C .QIKX+>J0E9U!UK.W&
MQO6$>FN9F7\S*WR;(Y=QMJ8U->4V_M!.XE9#OP@?V7AJ7Q\:Z5,<O/S]KM$2
MG#Y=R$N9,4M#2KI0T^H^8L#[0%^P]]=2XKK7="1QO/DLM;-_:(XUP[ELC1:A
MYK?^$:K-(I2VNI9&'0UEE+:\+.693*:/=(:T6/KJ+5-I)C/+'S34Y!!;R#29
M%NU+@.QQ)_LA?Z:Q53"VC(L/ ZC45.TK(%T&H=1)J7>VH2)DQYHMJ=:-"34N
M#MJ($AYH[Z0)#=4$!O/OJ29,^8>ZH$F?,_)402;>91H&?,Z7J(!N%F^OUU$
MV"]>O;4$B@6;]=.T4!L'--* 40\;>SH:JUW(%$O=;Z@U%JMDHW*DD:&HK6"1
M): 1<?DK22!!;?6U"#M/X1T%/KWQSV,Y#\L%^KTZE+=#Z6UT&84 4!#\I_\
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MU6DAO4]T\,EN3>.X*8^HJ?D1&77"3KO7J;V]M3)#/-^967U27DD63,DI4HD
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ME\K;[$69\;D>/+A/G.H=V-)*5(=2$$>)"K;MHUZ_174Z*QSJ[J0RN(3UR5B
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MI*@1<)&B;]E;6I5]D<].3EIHK-+]O$X=ZN_A6B/15YOTM83%G) +V!4X2P\
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MEQP^%*?CVCM.FOT&A,$9("WD?=NI4;Z!!T-^I.[Q:>VHD$=*"(R/-<)"6]5
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M>RHZAZ'HK&@#'0PD[DAANQ[QL%8LT0ZJ"0H H H H H H H H H H H H H
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M.1]2JUS^DG]L5:2L$:^(2[G[LGLU"3^Q5BL$;)3#4-B[%M?W;NQPI5L<!0L
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M&RDKD.)^R-0V@=-3UKNNDU!PT>UR5WD^4R47E0C89*V(N03'3'AQP&]BE'8
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MTAKS5)&S7<KR[IM;KN%7MJBBT9.)$UB."U(7,B)62A2M0V!_8C<#[:S5C2$
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M_P!7X#]:,Z2-V((!/5,EI5AW]!6BY'_:RKPK^H;NBNLYH&"P?-'<I)!^@WJ
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M/KH2[::$=(R..CQ0_DF68[D@I2N(4!Q]:_LBZ;G6K1KH5G34GX.1CNQTXU&
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MFVTV%X]]USU^(WMI4J"&9E8[&ML!B3'CQW;!8L2[NMK=*NQ5ZM+92$M0_7;
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M&ECY124+ZJ?!3M UN!<55JK+)M"[,!!"74S%-)T3Y2D*6+#3L&E1%2SW#O\
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M,?TJ>_U9/\(_M4VDF/Z5N_ZNG^$?VJ;2)+*RLNM-N$6*TA5O>+U0DWH H H
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M:6J2&-WI,=K1;F]7Z".GY*E(J[0,G,H[T:2EI/9I<_M5,)=2F]OH0^4S,*"
MYE9:&5'X4NK 4K]ZCXC] JZKX&-K^(EC7Y.;*E8^#+5&W!#;KC*FPZLB]FTJ
M\1 '4D 5:U77J16ZMT+BQ&=@X4Q)31;D>?XVSJH7%^SII63.BI8_3_?^MI/Z
M'RYL#JJ^]'=6-S='1:S+!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M%7]1D>9PC,H_28 _VZ:I?H6KU/*[^/2H[E)\0^%0\*OK%<IT,9.1W6[Z>:@:
MW^%=OS'\E0!HAM+JBL$!8)"6SHH#O(/?4HAF%-*ZD7M4D& V47M\0Z&K)E6@
MCEZ*]\S#>5%D_P!]:-B?WR?A4/>*M)3:63&\T>B/!65;6AW:4+R,( *4@Z%+
MS)N%I(ZI(4G]S4HB&-<SZ?<,YE"7(@I9B+>NEZ5 ;#T%V_\ K4!7PFYZL$6_
MO=-T]2YR#->FW,_3_P O*8%[_F5IPI8>;6Y*Q85>^U#R/OX:_P!PO3]Q4RT1
M!=N%?B.R>+>CX?G$=S>Z?+95(4A#JK:?<R$_<O\ N5M7[*T5BK/1/'>7\?Y3
M'\[#S$ONI'WT8@HD-G]VV?$/HTJR<E7H3P!L#V'I5DQ IN%20;@T!N%=] ;W
M- 9H!45)!L"1T-2&* F@1N#W4!O>_P!%2!0.6]M00T*!7MH0;;CWU,@40JQ%
M2B#*S=1M4A&I5?J: T)J&#12N^JR6-2J_2I1!H57[:ADB:B#0&AJ )4),$7J
M0:G2D$, ;WO4!!1$A5B#2A)H2:@DU42+6H0S6A".B1?]%8_P:/XHK(N+4 4
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M#!-Z$&* Z)$_T5C_  :/XHK$T%J * * * * * * * * * * * * * * * *
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MU ,4!BQH#% =%B?Z*Q_@T?Q16)H+4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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M4^*H?.1L7.1VAR.XVKZ"TZD?DKGO[!QWT=E]O^AM7W7,NL,N.(_&6NX1GN*
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M>6ZI-U)&VP*>MO>*P:.RO0F_3EI3.0D)6XI:_(5<K-S\::SMT+HZ1698* *
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M ]X-1 3)N#B\7BVPSCH;,5H?9:0$#\E2#JD3_1&/\&C^**Q9H+4 4 4 4 4
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MZ$H*MI"02=+"N=G8NA8N$-J1FI@_N89-CVZK15+EJE^K(N% % % % % % %
M% % % % % % % % 4CU"]5^&^FD/SN03-V0<251<5'LY+=[K(N-J?W:R$_37
M?Q.!EY+BBT\>QR<CE8\*^9Z^'<\>^I/XC.<<\4[ Q[IX_P =7=(@PUD/.H_W
M9\;5*OVI3M3W@U]OP_9\.#5_/;Q?\$?-<CW#)ET7RHX]7MGF!0  2;#4GH*
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M$QL#O*HY< 'OKT\7N/&R?3=?;I^\XK\/-3K5_O*,XVXRXIIU"FW4$I6A0*5
MCJ"#TKT$Y.0UH0% =(]._7#GGIRXTQCYIGX)&B\-.*G8X3_N1ON:/=L-N\&O
M+Y?MF'D:M1;Q7[:G=Q^;DP]'*\&>Q/3/UTX7ZEI3$B/'&<BM=S#S%)#BCVEE
M>B71^]\7>D5\1S?;,W&U?S5\5_'P/IN-S<>;1:/P.G5Y)WA0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0$%S(.*XQD@TK:YY0VJ!M8[D]HI$B8.$R6Y3@M*!6H?"X
M=3;WUF\)K7(,UB6S;RUW[@K\VM9.C78TW+Q,HR-KAY)0KN-__IK,L/69V-+.
MV3O;(N?F6R%IMW+0JV@[TFH!%Y;BQSA:3%DK7CTA:Y$> X6G7A8;0ZT==#K8
M)/OH0RAY;T_?05_J]Y+VVX\AX>4Z/9<:7]]JKJ2<SSO&)<-Y7S,=R,Z= 5)L
MD^X]#]=73*M$&(<]AU"FW#N38H6DE*P>\$:BKHJ7+&<JSL=+;,Q8F(0+*3(T
M7;V+&OUU#2)3+-&GIR,<R4QW&47M]X+HU[0H=1]%9E@6U?QWW+(L%?L"W04D
MACO%<9R.=5>,T$QDG:N8Y=+25#L"AJI0_135I(+WBN/XOCR/.9VO2TCQSY &
M\'MV=B1[M>\U3<(*5R7D, Y!:@D2'0+!Q78>\#LJ'+)T,\3SSZ<HTX5FQ)MK
MT%1M*MEQS3J9?+^#N+ 4%,9PGZHM=-/I*M'6HUO(;*M?#788B]AW5 &LW'P\
MBPJ+D&$2(RNK;@O8]X/4$=XI DCD1LYA+?JUS]:XQ M^KY:[24)'0,R""2!V
M)<N/;4.43HR2QF<@91:H["EMY% W.XZ0GRI2 .IV$^(?ND$BI3DAJ"2J2#8*
M[ZD&US4@V![J$"@5W4)-PJ_2K%0*KU5DB.X]]028J40S52NZK%37<>^A)B]
M!- 8H  N0D:J/0#J: 8Y/,XC$ ?K.>S$6?[FM8\TW[FTW6?H34 C#R61+5LP
MF'F3$GI*DV@1_>DNW6H>Y%"-/$T,?EDY5YV39Q<<]8V-9WNV[_/D;E _O4BF
MH,Q^)81MXRI;"LE-/63D7%2UD]_WA*1]"12$3+)E*-J0A("4#HD: >X4 $$=
M: Q0AA84".DQ/]$8_P &C^**Q9J+4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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M1#>WOM)$5EPMN+2I0N0@;21WU"<EHA$MF,_C\+D9>+C85L^01Y;@D2$]4@]
MJK-1W*)RN@WP$_(SH>;FJ?6F6AO^:JW%SR; D!.^^@[C>KUZ%;=41T#DW-'6
MPI&1\T: %V*R0;_ND[*JF2VD.9?J,[@%ACD>1QS4EVR(T="5"0I:B FZ I1U
M]UJO#91W78GI_*\CCYB(9QR)*5,M.;P_Y*][@U!!21U]M5;AEDI4DP,T$1S(
M?:92$C<XAJ6R\I/9V6J-Q:!HUS?#*)2XS.:'Z3D912/I055;<BK3)!OE/'W&
MB]\Z&VDD)4MQMU "CT!)1UJ=R$,BN2SH.0&*<@R$2&TR"%*;.X!6FA[C1,AH
MG8*TB4XDD)!'B)-AH38"^EZE@D2@]=IL?902:*2.WI4$FNU/=0&JO"A:A]E)
M5]0O4D=CFS'J)DW<YE\1&CMM,XY,4!]1*E+7);+A%N@VBU=>'%6REG'FR6JQ
M"7+E9!XOS'"XLZVZ)!/<*[:U55"."UG;5F&T7Z"Q[: JGJO*Q<'AA5F(+F1@
MN2V$*B,OF*5+&Y22IP)4=H(U ZUV\*MGD^5PX?F<_(==D-:'(\7EVY#+LSCW
M%N,8AMA7EJF9-:I4@>'=N"92U;O[%'6O6MBAQ>]G\-$<CNU]-4AMB.<>I?)<
MSB^/P,V[!$^4U'^7QC;4%K8I8W:,(38!()ZU;)QL&.KLU,+N37)DLZJ=9U^!
MZ\\M"24L_P DD[4?O1H*^33<'KPA4)%AI4R3 JEL=W9599:!4)%NE1),";IV
M(6O]!*E?P0354Q!S[C:/,R$4VT)6OZP37(SM1T@,C7W?L54V)+BP 6L]I0K^
M,*ROT+UZEGK$U"@"@"@"@"@"@"@"@"@"@"@"@&\Z=#QD-_(Y&0W%@Q4*>D27
ME!#;;:!=2E*.@ %6K5V:24MD6LJJ7T/%/KA^(>=SA<CB_$''(7$ 2W(DB[;\
M\#0[NA0R>Q'57VOT1]Y[9[0L$7R:W_\ I_U/E>;[@\ORTTK^_P#T.!U]&>.7
MCT^])N:>I4KR^/P2G'(5MD9:3=J&UW^.QW*'Z* I7LK@Y?/P\9?.]?#N=?'X
MN3,_E6GCV/6OI[^&7@G#PS.SB/Z29Q%E>;+0!$;6+'[N/J#8]KA5]%?%\OWK
M-FTK\E?+K]_Y'T?']MQX];?,_P /N.UH0AI"6VTA#: $H0D62$C0  = *\)N
M3U3:H 4 4 4 4 4 4 4 4 4 4 4 4 4!RKU!_#[Z?<]#LLQ/U-G5W(R>.2EL
MJ6>UUKX'/:;!7[JO8XGNV?!I.ZO@_P"!Y_(X&++K$/Q1Y']2?0KG'IL5S)<<
M9/CP/AS$)*E-I'9YR/B:/[[P]RC7V?#]TP\G1/;;P?\ #Q/F^3P<F'5ZKQ.9
M5ZQP'6/1SURSGI?,3 D[\EP]]=Y6-)\;)4=78Y4;)5VE/PJ[;'Q#QO<?;*<I
M2M+^/YGH\3FVP.'K7P_(]V\<Y)A>6X:+G^/RT3<7+3N:>;[#VI4DZI4DZ*2K
M4&OSW-AOBNZ74-'UV/)7)7=5RB5K$T"@"@"@"@"@"@"@"@"@"@"@"@(7EVG&
M\A;^]C^,*E XV@VZ]:L!5)UUZ5* L/::-"6;A M;J/;4HJPVW 2=4CL(!3]1
MJ8GJ0M!E-P>,R0M+CI4OIO N?H)L1_"JCPUL662R*QD?3I?B7AY91;7R7;J'
M["OR&N:W':Z,V68I^1PW(<4?,GP5.-IU\QB[B$^TVUO[Q7.Z-=37>F1\1X37
M0@.>2V%!+KS@-D7-M;51EI+U"5@./-*>B*2N4M/WLU5MZQVA-M /8/K-4W$0
M4WE7.%26S$A>% -RH=33J#GTJ;(D$J6LJOV5I!0CG"2J_7WU=%3+0)4+4()K
M&+VO(([.M0R3H$!\_P!(^#$'01\UH?:8U6IT)L=\C?Z.U^]_9KN1@+BK(@V!
MJ09H#8'OH#) /6H9 PGX:#D'$2'$*9GM?R,Z.KRI"/<L=GL.E1!,B"9V:Q(_
MYT9.4@)&D^(BTE(']]8%@O\ ?-V/:15=43HR5A3H>18$K'OHDL=%+;-]I[E@
MV*3[% 59$#L*[JD@V!TTH#"[FI F3WGI1D,3D28T-'F2W6XS9%PMY26P?=N(
MO]%01U(H\G@O$HQ4>3E%= N,T4,$]WG.[4CZC4ID[30KY5,.IBX=@]P,V3])
M5M;'T)-3J(0G_1J%((7EWY&7<&H$UPEH'V-(VH ^BH@22K$=B(T&8C2([(Z-
MM)"$CZ$@"I(%"">M"3-"#7MH J40PH08J0% 8)O4 Q0@P3:@.DQ/]$8_P:/X
MHK%FR%J@D* * * * * * * * * * * * * * * * * I?+Q?)-?X!/\ '76]
M.AC?J5TBU7*C:2+)-2!M4$@05$)!U)L/IH#PC^(#UQS/(.793B\5Z3 XGA'W
M,<F A9C_ #4IE12XZ^4$%5U#P).B4^VN2[=GY'31*J.=\4B<O>\C-X/YF 4K
M\R!DTN&.&BR-5I>)2-X/>/?6#:3@Z:U=E)[R]#.6<RY'Q94;U"^75RN L(,F
M,MI1EQUH2XEQ2&E* 6@*"7+=I%]:Z\5]R.3-C=&=62H&W?6QB+H-@#0#3.)2
M[C'6E+"$K"DJ6;V2%"Q)MKIUJ651S[+8:-C?!%R;62"PDJ<CA:4IM>P5NZFL
MR_<C?EGE#0J'T_MT@F2<_5SSW&IC-R5&5%*3:]@$+TJT:%9U'/$H;\5_([B+
M#'R0GP@:E-*HBS&$&--=6TVRSYKBR$H2D6NI707Z7-06DD7<1*B9;'G,8WRI
M'GMK:4X$E8*5#4:DBH)?07Y<B_),A9LJ\:=18?9%'U(KT$X.0<Q&%GR&&RIY
MYYEE#=[7WA5[D7-M*TQZF=^IR/FW).<RYST?'988J"V4LLQXK:05+5I;=8J_
M+772M:]486;8UX=P^$QF<8]/><RF7?EMJ=EOFY*@K=TUTT[:G):5T*56LG>>
M6(<&=:+;K:;-,A:%@DD>\$5YUF=M>@0$H5#S*MZ2OY=)W Z"[R>VH3+-=!K$
M2PMQ ?7M1?QK191 [P+BYJ4RK1:S^H&,(\$.R'HOFH\U1(;4';>&W7P]]3K
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MJY(SY>>=:+4*$3K%:<'B6NW1Q8TM]D>TUXG/YBR?)1_+^\]#C86OFMU.RI2
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MLIO>VI _)0ED-R<A.+0R1HY+*B/WJ3^W1 8\2:'SDM=K!#&W^$H5+9"194M
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M7RL9/1F8T!YB0-?"JX6C]RH=M?G?.XCXV5T?3M\#Z_BYUFQJW?O\2ZUP'4%
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M^*\>9MY>.9.W4%P>8?\ ;7J8$DJS$BL#:Q';: [$I %2!:UK6%K=U 9L3[:
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M7Q/,Q^GFO7M^>I[6"S>-/N9_HGC<%(E9KC.)QS.=<2L#;&9B!TN:J2M]EOS
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M[21JGJ+$UT<KCUQT3G5LYN%RK9KM-:)'I2O,/7"@"@"@"@"@"@"@"@$(<./
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M:YMVFM9T*P."I3>XH44J;L7$CL!T\0[O?6"LZEK55AHN)!=85'<9'E+!2L)
M6A25=0I"M#7/>CNY/.R<)+Z614+TSXQ)E./+08S6T!+,>0IAD_NO+!L#[K5%
M$YZE*4R*5;H3D3TSX;"'@BLA*CN4I4AQ5R>_QT]/Q9?TF^I*L<2XE%39,>*
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M3LNA.]/J9+$S&+3+87=E1LF0R;H/L(/3W&LFT]&:U7=#UI47,)6V0&LBV+E
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M9 MT'=5?JT703MZ]1C,GN2-\N8Z&HZ2+K5TUZ #M)[A6RBJT,G-G(K%DIO\
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MI1ZGJ&L#4* * * * * * * * :9/*8W#0G<CEI;4* R-SLB0M+;:1[2HCZ*
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M',8N/F\9)Q4I2T1Y2=BU-*V. 7!\)[.E2G#DAJ5!0U>D4)@@P<_EHO=9_?\
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MV^*K(@]0>F?#F."\+Q> ;0$RT-A_(K'5<QX!3I)[;'P)_<@5#)+;4 * * *
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ML<G6LA0)\Z*RK3VVKS=R\#OAE(Q7"<SG43)K>2906YDAE?F-J!6M*[J5X38
MDW [*[,?*MBK"1RWXU<C;97/4'A.<PN!DK>DL+>DH6Q%6WO4$.*M9120FX'7
MK4YN4\M'5J",7&6*\S)Q_F'*L_A83/$HK\5V;\H9CL\-*2YY\-05YI2%*(*B
MJZ4J!O7E6JW,'H;DF/F/75SBV7_H:]A1E)@5%B-E^0(X,EQIL:6;NE-UGP]E
MZNL2C4K;(WT'_P#7#R3C[G)I'*L T[C84R+&9^6ELL)BAQM3J&@M227PH*N%
MJ%QV]:G8NQ6MCJ;O,4YSA\;^:/Q6LE#:?90I:%A(<2%@**0+BUKVI5ZQ!%UI
M,EMPPVXB.GN:3_%%=RZ&+%FU"]J@#D&I($UD$VJ -W;$=-:D,:*3<Z5 !2VV
M6R\ZL-M)^)2M!0ACAE3*V!)*'Q'.H<\E5B.^W6WMJ2!8,QY#"WX3J9#;?Q[;
M@IOW@@&@&Z4I[=!406E&\B&ZT$^9JEP!2;="GLJT^!5&C;0*@$CK4$PD.SBG
M5(W>42D]+"]63@I"8D8KK'A(*1[>E0W)9*#4CNJ"39+!4+I3>I( HV:'KW5!
M)@(W&UJ!"@: &@L*@D"D VM4,D+"H 6% 7^+_HS/[Q/YA7*^ITH5J"0H H H
M H H H H H H H H H H H H H H#RW^(U3I]1,6RV+ XEA15WD295@?8.M6
M1!3X;GEH2VC0)%U"UMWM(K0@D!,V)^+3VZBU0 ,Y&PF_C)TZ]* P<@RI(;)L
M-"#V>XT!YC_%'/CIS.#9A37OUF]#6'& ;-,,)=)"T:W"G"5 CV7TK>G(=*.J
MZM]2KK+%OPSY!EB'R1EE#CF:2[&\^2Z=P7'5N+:4$C<"%;MXO8BU9N[LE5_]
M2R7<]!-JRRDA2GFVU#7:4W*;52"9(3 \;X%B>2.Y3'XW'L<CD@E<F.QL<W.'
MQ%-SM25'J4@421#+V\I0:43X>WI8:Z$GOJ8(DA'7WPLD 62"+@#5(U-ZJ6DH
MV=Q2L@\5![8FQ*FDW ([;BH*G<.)I2UQ_%-I6%H1$:2E0U!VIMUJ4!SG#]VG
M72PM6B*L\H\S7N];>#=XD8>_TOKJCZDH]IHT*O>:DJ*)(% ;._"D]E0PR'Y0
MX$<8R15TV('UNHJC(74L"U>-7OJ2!(K-0#8+]E2!3<>^I(#<: K7.<'E^2\:
MDXO!Y)6,GJ6E8=2HMAU";W94M.J4J[QW=U3V(^!Y)S/,_4+T)R"DO9"9"<?4
ME7ZIRC?SD"7XM2@7"3<#XF5I75%:"RE]4=A]-?Q3>GW.WD8C,O#C/(   W+)
M_5S_ $!4U)6$[!<_"^$V_2-7E,G:T=T&FTGX5)"D'J%)/0@C0@]XJ\%3!2#[
M*J#"5K95N:44&_V214%;45NHXC9)3#I<=3YB5GQ]_OJBK#\3FMQX<U)IF1CY
MH&QP!9^PYIK6DIF+JN^AER $FZ!8]?#I1T*.L%=S?$,)FTG]90T*D_8DH&UY
M/<0I.OUU1U,;4768?D<XS/IIR#&I6]@WDY.,-1%>(1) ]A-@KW7HK6774O7-
MFIUBZ^YE&?F(CR%0LBR[ GI-E1I"2A5_8" 3]%ZLLB[G7CY>.^C^5F2V'!N:
MLM(^(I-[5J=:<]-1)3=J%C&PF@,$5 &LCQ)4GM U% 4+(!1R[0]HJ"46,I(<
M( [!0ELU<3N:5[C4%).L?A.TYOFA_P#9:_\ C+-4MT+TZGKNLS8* * * * *
M * 9Y?((Q.)GY1P7;@QWI*P>T,H*S^:@/G_PEISD7J+@D3E>:YD<O&7+6K4J
M\R0E;A/OUJY!]#*H2% % % % % % % % 4/UCY7_ $/]/,QDVE[)TAOY& 0;
M*^8E70%)]J$[G/[&I0*E^&3C/ZF]/U9IY&V5GI"Y )T/R[!++0/TA:A[%49!
MSS\5O%OE<QB.81T6:GM&!,4!IY\?QMD^U2%$>Y%2@R__ (9.6_KS@[G'Y"]T
M[C[WE)!-R8D@EQH_0KS$>X"H9)VVH 4 4 4!\\,?_P!X<7_MIO\ XT*N0?0^
MJ$A0'EK\6633*R_&>/L?>2F&9$I;:1N7_.EH;;%AVDM*TJR(9VWTBX:O@W \
M9A9*=N26DR\B.Z3(\2DZ?H#:W_8U#)+Q4 * * XC^*;_ +MXO_:T?_(OU*(*
M'^$G_IKDO_!8W^474L(]554D* * \M_B9],Y+<W^L3#LER(\E#6<;0+EMQ "
M&WR!]E2;(5W$ _:JR(.>>DOK+E_3:7\F^E>0XK(7NE8^_C:4>KK!)L%=Z?A5
MVV-B):![1XWR;"<MQ+.;X_,1,Q[XT6C12%#JA:3JE0OJE54)):@"@"@"@"@"
M@"@"@"@&.9RL3!XR3E9RE)B14[W5(25J N!HD=>M2E+@BSA24Q/K)P6]ESGD
MW[3&<'[%;>@_$Q69>90?53FO'N3IP?ZEEF0(CSBY5VUHVI5LM\0%^AZ5IBHZ
MS)6[DZ*GU.]/E;;9]E-@!9:7!I]**R5;>!:4*(]1>!J<W?TBC$=B;J _*FCK
M;P$U\2C\7Y/@&/4OD.5?R3#6+F(4(LI:MK;BB6_A)]QJ]E\D!?5/8ZBUS#BS
M@NC-PE7Z7?;&GTD5S[&C9-%(]6<SBLAQV&W GQY+@G-*4EAU#A"0E=R0DDV%
M^M:X_E>IGDU4(O;&5QBTMA$Z.0$)!L\V>B?WU5:9"9'<JE1E\5S7EOH)^2>M
M9Q*OL'N-1W18\\LN)0VR%$7++-[G]P*^NXBG%6/VU/E^6XS6DQ+=0J#(L1<(
MZ ]?$*WR5:J_@SGI9;E\4>AN A2N'XBR2;,:W'[I5?%V<,^O2D2]0T+3PO+7
M.I0W8#3^ZHJ*O4LT<46I8*S^Z5^<U]C6J:1\I>SW/XLF?3M6[GT!/^X.FWT*
MKS/<]*UCS/0]MEVM/D=[ 5Y@(Z7\7MKY\]Q=2M>GYOC,B>O_ #G,_CBKY.J^
M!6G0@/6A)5@(R4[K>8LD(MN("+Z7(%_?45+69XA]1\BR.?SUN-."#)A?).H2
MI*GDL.L);O?0%:3XOR5IA76#'*]4*,3\7,?RF0A<H@XUS*,,Q)C.5Q\E3@++
M:4%Z.XVV]Y=RFZ5 A8Z5LTX4HS?69'3$'B<O$NQ,CR'%S<K"2Y(3/:G2&0^^
M0/)$QMZ-=U(L$74=$UC?=NTT-:JL:ZE@].\^,?G)&-;&(<AY^0G9'Q.6^91$
MVLD?=L/I\Q2;B^BM/=46<P-L(]7855\/').I;'U;1704%$FRA4 <!7MH0:K/
M4T!#0@\Q(R7GK?<;4_YK0><\Q*$J \+5_A1I\/8: =D@@+3\*NE^M20QO'83
ME>01,>[XHD=/S#K9Z*(!-C]55MT"-IRY<B4MY;AW$^&QL$CI8=U:HR:8ICW7
MXXE()\,@(!/;X3<T9-10[UR(L=NWF2'T(!/3:GQJ/U"H0>I/260[!4 +.Q'"
M@D==BO$/SUDGJ:OH0X5L<386(MK6M44LR2AJ3\CD)+FY;C);#:BHW2%7O:U&
MOFJB*OY6S?'RC+=1!DGS$/@I94KXD+ N->XVJEUMU+4<Z$>\A+;JT'[)*2/:
M*L!6-,E"=$B-N!+#ZT)7=*2H WO8D>REEH16&Q;*(2B8XR-4MFP-@"?JJM7-
M46?5B#2EKD,0HR$N3)'0N$[$) N20-38"]2W""4L6DY'Y1MT@1Y2FDGS$A*F
MCX=;IU-3ML5=D:S/*'D.-BWG-(=*+[@DK2%6O]-5F32!"H8"B!?HO^C,_O$_
MF%<CZG2A6H)"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@/,/XAV4_P!8$&0H
MV(P["4@=;_,R?VZO4JSG;3A )OJ .O4FK 5'GO*V!))-@1[+]_90#SY:0H E
MLD=E^T#]FI@&BV'$CX1<Z6'46]HT]](!Y<_$!C\W.YM#6W!>>;:QZ&4+:0MQ
M-RXI1^$'OK-AEG_#OA,SB7>1&=&+4-\1'6%O)\IPK1N"B!J=MC]=2F2CLO),
MLQ"Q[Z&UEM918+TUOJ#?MZ5:2"H<36EW)AU1*BE6XDZW7WW[_P E02=(=GN)
M04MDJ*1>P/7V>R]6D@@7YC]UJLHI[QVGMI!!6<D_*"5J*RE%KH(/4GW]PJH+
MCZ3<T^8FR.(3%:A"YN*<)&U2$FSK0/:1\8]EZ('2N0+ CIL>P&ID0>4>7J)]
M;N#@]?F,-]?G+JDR3![6;6%*4.T$UH4%DZD=QH0;NGPI'8*AAD5GVT/8":TZ
M-S:TH"ATO]Z@]GNJC(74EUGQ*OUN:$"6[VT!L%DZ=: V"^^D@P7#V4D&JC/+
M"W,;Y2Y*%:QY!*6W4]J0M-RA7Z*K6[ZLBU2$RL'C'.<?)XQR7%MR@I),K!Y-
M \U _3;(.H_1<9/U5>9$0>5?4[\'^5PSSG(O2*6Y,8:W.' 2G )C:;:ICO'P
MNC]PYUZ:UFZEDSG/ _7;U#])YRL#-\V-'BJ(E8'),NKB)/VBJ,2'8YU_E(RM
MI[4&I3@.LGKGT^_$#P3G7RT5^2G YJ20VQ$FNH7#D._HQ9J;-N'_ '-S8YV;
M:LFF4=6CJ:PI*RVX"E8U*5"QUJ8!BU]*@DUVV-QHKO[:AE&D^H[BY:=$T!WH
M!_DU]H]EZ)M=#G>#PT)F-FH,GPO),=TZ'[2;_G%:>IVLC"U&NJ'*XK;[?F)4
ME:1]I&MJ;$^AG$D+F..8W,QC"RT)J?%(/W4E <L#VI)U2?:FU4AF%J3U.9YC
MT7BA1=XSDG\4L7\N+(O+B #H 20Z@>Y9K&$NFG[BM5:O1P4;)X#G'&_'E<.J
M?!1<*GXR\MFPZE24@.H_LD&K*[Z]5Y'57E6752,(>6QDY)++Z=R39:3U23^E
MVI_L@*TKD3.JG(I;N.BWN&X6*/TDFX/U5H;IMC.2GPDCNH)*%D&_^=V?WU5)
M18D ETFW90LP*/ KN(/YJ&<G5?PIH".<9K_LM?\ QAFL[&M#UO69L% % % %
M % % 5GU%2M?I_RI+=RLXB> !U_T9= >'O2M]N/ZD<5=>("/UI%22>@*W0D?
ME-79!]!ZH2% % % % % % % % >7?Q,YN3R'E?'O3G%'S'D*;==;!T5,G*#3
M*2.]*=?<NK(@])X3$QL#AL?A(0M$QT=J*SV$I90$ GVFUS522G^M/%OZ6^G.
M9@-(WSHC?ZP@@"ZO.BW79/M6C>C^RJ4#RU^'[EO]%O4:"T^O9CLT/U9)OT"G
MB"RKZ' D7[ 34L@]R54D* * * ^<YG-XSF9R3R5+9AY3YAQ"+;E):D;R!?2Y
M JY![&QOXA_2C(-A2\RN"X1<LRXSZ5#WE"%H^I55@D;\@_$9Z98>&M['SUYF
M;M):AQ&G$[E=FYQU*$I'?J3[#2 5CTHX/D>=<C7ZU<Y#:WIC@>P&.00MMI+?
M@;<(UL&PFS:3KN&\ZVHR#T#4$A0!0!0'$?Q3?]V\7_M:/_D7ZE$%#_"3_P!-
M<E_X+&_RBZEA'JJJDA0!0";[#,IER-);2]'>2IMYEQ(6A:%BRDJ2;@@@V(-
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M6"0$I'<D: "JD@10!0DOT7_1F?WB?S"N-]3I705J"0H H H H H H H H H
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MB!8BK[BNT40HWU&E%8C:.4DV'2K;B'44&O9:IW%=IN*B28%!;MJ9(%$@?74
M4L.ZI0/-7K9BLC/]0W4QL;D)R#"AAOY)K>W<)-[JM7)E3=C:CT*K'X#RZ4XG
MRN/Y1A0;* IQ+:;J"@= HVK)4L6=D/$^FWJ8ZKS4@,,I\!\]]A('L(234^D_
M *PYC^DG*I+H5DLG"96.P++BA[_+0=/IJU<3#L6C!>E4O#349+]:0WI,8I,1
M_8\A3+UE W2-NY*@>I^JM%BAZ,SW3V.Q*Y#)_4S$3RW6980A D,K+:-S=KK3
MU4!IT)KJ5M##;J12.3\RAK06I1DL*) 3.CI<2JW8'4[55,LB"7A^H;P &5PR
M@3T=@NA:3;K9#ME'^%4[B-I.0^8\8F';\_\ *NZ#RIB%,+N??=/^VJRLB(9/
M-;'T>;'<2^U^FTH.)^M-Q6A1B:@H=E"#0W'94$FA[:D@U)'U41#,$CLZU#(0
M@8L93Z9"T NHN4J.MB18D#H#;MHB1)Z*\M+B672T'A9=@"1I:Z3I8T@&3&69
M33QL6VFU-BY\7BMKT]E"4AH8BOUBY*7&6XM:F$M+"B$I\O<"N][:!5[6HR4*
M%C?D)CC9 =*&5)4!K=O<#V=EQ4=PY@C927Y6(S5DEMUQS:ZE!ZHV(W[;=+B]
M0^X78FG<;C)D)AM#3:8=FU1U- (VH38I"2.@TM0F(&&4<:3DF@\\^PTZT\I9
MC[M5!*1<@ ]+^&]0QH.,H](BQX8C/>0RMQ DR2@.J2R$];'2Y-KGLJ41:21C
M)D(:"92T./Z[G&QM0H7\) ]U599"UQ4$F=Q[Z Z3$_T5C_!H_BBN-]3J706J
M"0H H H H H H H H H H H H H H H H H#SOZ];7.7P62D6..94M9M\ ?D
M7 W#K[JO4AG,F]RBI((\12+/)(3J?M FQ\-ZDF!TRZ%,+"D$LK40W>Y* CM5
MH>G0 4 Z4N2TCRG4D-O$!( O<K -[6N".E"!G(*OE5*?0EY3A4$I04I40%:J
M)Z:=EZ@DK$SS2%H"E.N>9XG5VT;^RH%1%SI8G\E6(&16P'//6D*=MY2FP-B_
M,T(%M/#K\*@-:$0;><MY:&TJ$E+Q2H@[F]I^$>98$GI:U02-V7FBXA#(+K[2
MBVIIM-KK4;%-]563WWM0@LL%YQ2@BSC+XLAUA?PJ)T)4;V[-#]=)!(>8LA2%
M(2AL%)2$G<;'31(M>_=4@:91E+Y>2AJS+BB"7_ 56U*5 =/HZU4%>3AGU^:L
MMJNA03?9;:I6MD]=P ^JH))%&"\NZELWC)0;%:K@*"MH)(U2#VT)&T6&N%*B
MR&'?.?B+$A"%MAL'RU;B%:@@>_4]E"&=NB9*+E(D?(PG/,BRD>:TL=QT((["
M""*N4@<(.HOT- #Q\(O501&??0S@ICCBMJ$ANY/9]Z@55DH>O*LI6O::N4&:
MU$&]024::2<ED2$B^YWQ?V)J0>)V%O0), QI1C2M[C\1]22I*9#Z5$)('5)*
M;$U4LRRRN9X5L0\A)B/#D3?BEQ(_@8\P>'>'2>WN U&A%"NUGHW\*G(WN08;
ME<AZ.W&#>0C(;:;4I6GD*-U*5;7W"K(F#T0A>G6K%3<*[ZD&=PH#-Z T?(\A
MT?I((5[=*6Z!$>_BU-*2]CC<)O>.HZZBWA-9.I=,29F;B6W1M6-%(5H?=8U"
M9$"R$.->*&04'4QU'P_V)[*LF0+-.MO*LBZ7DZEM6BQ^V*M)!0O4;T;X+ZGQ
MBGD..2WDT@B/EXMFI;=]=%CJ-.BKBH>I*E'C'U2_#5S_ -/5/9" V>1<93=2
M9T-%Y#21<W=9&NGZ2;U5J"Z<G'\-G,WQS)-9GCN0D8S+1U7;EQ'%-.)(["1U
M]H-02>IO37\9DQ@,XOU4@F2R+)_I#C4 /I&NK\<62OVENQJRL4:\#U=QKEG'
M.98M.9XKE8^7QJOB=BK"E(/Z+B/B0?8H58C4E]X(N#4@U4=-* 3N.M 9!%Q4
M%H%T54%D].O_ )DRA_\ 9FQ^5-0PCIU5+A0!0!0!0!0!0!0!0!0!0!0!0!0!
M0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!
M0!0!0!0!0!0!0'/O7&9'Q_I/RB9*CIEQVHH+D=9(2L%U L=I![>^N[@*<]?B
M<7.GT+0IT/G9ELOP+-,)8G<49<:2I*T),F2FRD@@6*7-.M?:WX^.ZBS;/C<>
M7/B^A*I&_(^EQL#Q?81:Y;G24GVVNHWJBX6+LV:OG<A:M)FYPWI,YX?U9D8Y
M/4LSU*M]"VC4/@U\8+KW/)_2G\$;_P!%/2M\*2W-S,17?YD=\:_OD(_/4?HO
M"QHO='WI_ 2<].>*2T_\T\Q4RNUTIR,*R?X3#BO=?;6&3C7JIDZ<7N&/):(^
MYE Y#CLCQ?)G&9!;;BU-I?CR(RPZP\PY\*T*%NX@@Z@Z&N-V=7#.^KK=348-
MY&Q!6; =#?I4^H1:AT[T)<W^I^!5^E(2!<WZWK+*YQW^!GB49J?'^#/;82?I
MO7RZ/IH%1?MJQ H+BI3(:%DA7T5,HK LD*^BK)D0*V/94R0Q0(4:E,J*(3J-
M+7J0.&T*4;;"KV@7'Y*LBK.?<U3(1G%E3J@SY#7W=RC80-3< ZFL[=2]>A7$
MSRA20W(<4%"ZM3;N.U.I(OW&J-ETA5$_)M$J#ZG$ ';?>5A)Z];6M[:B6&D2
M<*2'$I=2H[ +K5LL1<ZBRNWVU**C]+C1:4XAU%V4WVZK*0>T;0.WL-715F0I
MXMH6%*#*[+<*0DWMVA*M23VBK25$[^6=CN]O=<H2ZZ$(Z:**4@#IW'2DB!J'
M$/-)2ZEL-[M5BYW;3T"@;ZTDF#1Q-T+*2VGPW#)25FP.ERH6"C[-*;FBKJAK
M'=7%4EQD*95WPUJ;<*B+BR4FQ]M761>!1T9.0.:95@@*R*U(%D[,HT"+]@#F
MA_+6E<B9G:C18(G-W71:3 0^D&RG8#H58^U*KVM^^K10S-N"2C\IP$FP5)5$
M6?L2FU-Z]VX73^6@DDV5,24[X[J'T==S2DN#_:DT:8E&2A0J&PD:VJ))VF0*
M262,T)6@5 ,BW;4$F"E%K!(%^NG6_?4R1 R7AXZDJ;0MUN*M04N*A9#2C<*Z
M=ER.RH)U-I$>29HFLJ;*DH4V&U@CX^IN/:*!(S(+R&V4J:,ELH*)2&P LJM8
M*3>P&NM2BE@Q+,F/!0S*3Y:TE10UNW;$%1*4W]@JK+H?5 "@.EQ/]$8_P:/X
MHKC?4ZET%J@D* * * * * * * * * * * * * * * * * \\>NP0>90MZ26T
MXUGSB%6&PR'P+=M[U>I#.7*E1EH0A2%,J2I*DA6TK(039*K]"1T[Z$CYMRR$
M>004!&J5#9N 5H-/:>MNNE)!EM!4RZ%O%+: ;E 4%>,W%E$ZV .@^FI RGRI
MCUXS2D+;"5):"MP>*0;F^T)L /A'T4*E<G/J92EUUPNH(MM>2GS%) M\-]3<
MC<?94DD.@O/2$J3M4Z&SL?VV/FI)-AWV&MNVH!A?S"U/)39#8\)*#L4YL-U*
MW:6-_A"J 60&FU):42ML-A:7+*\M823J1TW?I:ZF@)^"Q(84%-L*#:T#R]Z@
M1XN@4I-R+F]@: FVW/O!\JQ?>2VI9-@E8%BLD_9!_+42(%T.+?O&4M2UHMO3
M(.U>U/0E1%KDGN-0(-"IN,@N:LRUC:G?]XG;T*0H&VOLM00-7<FS%652%EOR
MP38;=+)(/ATNE5^\T).>9OE&07'=CP465JKSFO$I2+W*3>UN_6H()ST7YJ^C
M(RN)9%Y3B)BER\4ZXJY+J$W>;U_2398Z:@U=%3O32]R4FI(-GCX!>J@@.6 +
MXSD$G6Z6OR/-U#)74E'E>)7O-21 Q6K7O%""C3%).1R W*/B>%NSX#4@\02"
MIQO&DJNL37$@J-O"C<0F_9;LJI<1S"DKE[DFZ5)2;VVGKK<=_?4L@]4_@X/_
M .#G+#V?K*+;_P!W54H@]/MJN*$,5!JQ!FI!N#WU!:!.01Y#G[TT$"H/0U62
M1O*A1YH^\&QT#PO)^+Z>^HB2",<$K'J ?&YH_ \GX3^U6;31;1CD%B4E._17
MV5@V4D^PU*L1!MYC['\J"ZU_?4CQ#]\.WWBKD"H"'&K@A;2QK;4&_6I*G$?5
M#\,G!O4$O9+',CC_ "5RY$Z( EIQ>G\LUHE5[=>OMHTBR;/&7J-Z-\]],)*D
M\@@*>Q6ZS68B@N15CLW$:H/[ZJ,L5;C/*N1\,R;>8XKE9&)R39!#T992%@=B
MT_"L:]%"A)ZG]._QGMN):QOJ?C"AWX3GL6CP_OGHY_*4'Z*ON*-'I?C7..(\
MSB)E\4SD3*MJ%RAEQ(=3^^:598/T59:D$P5J2;*24D]+BU"3*7#>H Y\]#39
M==4$-C52ED) 'O-($EC]+I<:=G,G)B+#C)82D+'0E*D@VJC+(ZI52P4 4 4
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M <*DMRHSB76E%"BE6U:"0;$$:&@%94J+!CNS)K[<:(RDK>?>6EMM"!U4I2B
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MLDJT'Z.O=22' U_6W(7]JY[V0<N=B76G-H;7NN+W*4JN/AW#MJ8$F(^"2\"
MCRE!2E/+64^,WW$%)5J>W:E5S2"&S=G&0(S*VY#"-C:_OEQV77@VYU&]*S]W
MWW'YJO!5L>KP,,MB8E]EMA( ):*B5%1N!9(L#?I=)MVFD$23V'AKCM&3"+TH
M+LDI4HAP;>B%6L1[[U=2B&2#+S2W&FYK*FI*3=#BGTD;1HHDHW$D=/':ID@4
M?4AU&V*Z%-LB[L>QNJ^M]>NG10H!B\$K2%1FUM-K\3JEAUY1'?8* (OVVJ&2
M#K[[;:/)2XZA*C=3 #*%=MP5[;J(_2JI*-'9SB+K;<+;:0 \'R;CVZ#8;WTM
M228&[,UMUQ"S(2E)T*6FP5I*3I90UT'8;TDAH<(GOHN&)#AW%3;K,E*5(41V
MDG;LOU%NM3N*P;J><:0TZ_'"&_B0"E-DJ U/C))%))&RLLF0K8N;N%[+04:F
MVMMJ00?8JU)@0;.$I:=D*0IY2E!+3DO:SJ1T!43<#I[:;@ZF%+"P$.+8\Q1-
MFE(4X24Z>';X3K[JF2(-2A+*'$2Q)90YX/+>2EM!*KZ -@GL^T:ADZC%Q$>*
M@[7D-+!\S[Q/F )T&[[R^MNXU $)$*,Z%O&._=S5Q[PK"E [K-A0 VD=W3I1
MDH1^11#*%,RA%?)\#,2WGJ!%R/-T2GKKJ:+0EZC^+G>98MD*,YYQI)N&Y2$R
MSL-K7<4$GO\ A-:KD7KW,G@I;JB8B>H[*G4HR.-;).JI,=X-K O86:<\=_IK
MHKS/ZD<UN&OY66S&^HF*)"&,T[#5<)1'F:I))L" H+!%_;6RS8[&;PY*]BVP
MN52Y""I'RV00GJN,H)5_M"I(K95J^C,-]D]42#?)L<JPE-/Q5=I4CS$?2I%S
M_M:H\;-/40_C3\?,/\TF-O'IM"@"/H-C575HLK+L."VM/4=>E59=&NXU!, 5
M$&@@-WMJ 9"AVU)#.GP_]$C_ .#1_%%<3ZG2N@O4$A0!0!0!0!0!0!0!0!0!
M0!0!0!0!0!0!0!0'FS\0;JT<VQP"3L;QC3JEH4 H6D/IU!L% 7Z'OJR(9RQ#
MKJY(3("765K44VNVKQ#0#[05T5:I!(F1Y3+PL4,*47'5A5_,6B]U6UO;IJ.N
MM22)*/GQQ,2EQM]I:EW2I24I638 GJ2/L]@O;M%0".=2O:E:U;FWDE8E$*2+
M)N DZVOH>X"I*C%]Q:GD/;7'V2EM8?;!43L4 2L@Z^*Q'A]E0R2-G-%2EL[$
MB[:W/ 2$K*G!<ZD$+3V]FT40&;2 RL-+1Y=R%**5J*VR5&Q*2+WL-W36I Z0
MMAEEQ24!T-N%* L7:M?=O4+WW*!^STH"0AS#N2MA/F(?NXG>XM>S:;(L- !V
M^T5 'CF3W,!I"@A:7=[@"@-VXZG;8E.X#04 Q5/9"/-4-I*CX;C8I2U:!(MV
M@7UTT[Z@$<XAI:EE:0&.H%BIQ&TV58?LD5 $'@C532$AQ12IK[2=R=/<K<!X
M@=* 8O!APK6K>K=XGE"Z1M).T$'N[ZD$+DH?\V7(40H%.GA%EE.O7K<7TOUH
M"[>AW)U8W-2N)2B1C<H3)Q;JMJ!\ZVF[C83V>:@;K?I)TJ2IW]Y=T)(.E""'
MS82YAI;:A=)"+CW.(J"4.WG "ONUH"/>='?:I)(#D7)<!QJ&[*Y%E(V*96VH
M(5*<"%+*DE("$'Q*N3]E-"3P@Z3Y,5)&J7Y!([K@U! AFU[I:=;D-('U"@/4
M_P"#G7C'*SV?K../_P!G-3)#/3C9TTJP%P>^HD&X/?TJ2(-J"!.6?YH]^\-"
M17<;#W"J@Q0 #;I0&P5WT FZPS)U<T='PO)^(>_OJ&DP*L(>V^2Z I2?Y-Q/
M10]W?4D"$F-'EQW(DUE$F([HXRZ I)]OL/M% 0IA9;"B^+*\MB4BYQSROYXR
MD?WAU7Q@?H+^B@D>X_)P<JTMZ Z5EKPOLK'EO-*[G&SXDT&HTSW'<%R>"YB^
M0XYC)P'@0MF0@+%CW7&A]M3)!YVYG^#CB^2<<F<'RKN"?-U)@R@942_8$DD+
M2/<340B9.-YC\*?K!C'%MQL?#RC/V7XDD(W#VI6 ?RU,,MN0RQOX6/63)R$-
M+P[$)!-E/R)"2 .^R0;VJL,B3TAZ3?A9Q?!RSD^79V3D9[1\UO&Q75LPT+[?
MNPKQ&_?2!)ZA],T,,YW(,Q4%N.B.-B%'<?B1VT9*.I54L% % % % % % % <
M7_$:0,/Q$DV Y%$))[O+=J4#M%0 H#C6(_\ REN0?_B\U_E(U3V!V6H!PSU
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M6)Z'MTTZTDF!%Z.\HDJ=ELS&@/*<=6ELCML6+>)6O1)N2:22.%9&> 8KSJ7
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M_P#<4"I)/5GX,U7XKRG_ +59_P"+"I15GJ)!N!0@734B3=))J23<:4 E,/\
M-'K?H&H; ON%0 N* +B@"XH N* +B@,T 4 4 5,@34!K21 @JP!OUH2(+5;4
M?300(E?::@%N]+%;L]D_\"?XS=0R4=9JI(4 4 4 4 4 4 4 4 4 4 4 4 4
M4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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M4A<L(4E3$>-YFWYN005)2/B"=ME D@75V=A- -Y,-J&RIR0KS5(*27W=S@<
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M+$D :7/;4DGJC\&[EN*\GMVY5H__ +.*DAGJ=A6Y([Z%1T-*DDV!M4@W'2A
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M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
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M5RC",3&GF6"7%02?)='5QE)U(_>GQ)[TU)3HSD>5!$],< J=2@)2E(N3J;6
MJ"TGKC\'\*1%XMR,24;%.9-I823J 6 -:L@STVV+6H5'*"0?90"Z5=HJ23>I
M A-TAO?O?V156(%R=:D!N%02&X4!F@"@"@,T 7- %S0&* 25VT*C5Q7MJP&3
MBNV]02(A0-JJ6+OZ1D'.Y.W]Z7_';J&#L%02% % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
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M%\#8M6P !MYYL@%1M=*4CW@B]1 D6=\A#L<S([OFHL#+9"0"5?"E-AH3IN4
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MERZ^CIOG<L/W#G^4;H0=EJ"0H H H H H H H H H H H H H H H H H H
MH H H H H H H H H H H H H H H H H H H H H H H H H H H H H H
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M#I46F?$ GRR5+618I\PV3X05'2]6:DJ+S5Q)<+YN7YLE]*DL?-H<5YL5QEP
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M_L4W(0$GT^Y"['<:2&-R@ /O.X@]U1),"IX%GR2;,_XS_8J)$&/Z \@[F?\
M&?[%)(AA_0#/]S/^,_V*23!C^@'(.YG_ !G^Q22-IG^@.?[F?\9_L4DF _H#
MR'_<?\9_L5,HB _H#R'N9_QG^Q3<(8?T!Y!_N/\ C/\ 8J)1:#/] N0?[C_C
M/]BID0:G@'(.YG_&?[%)$&BO3[D)Z!C_ !G^Q421 W7Z<<D5T#'^,_V*F4(&
MR_3'DZN@C_XW_P#1J)$&B?2_E (.V/\ XW_]&H+%D].^%9SC.6R$O)AD,24K
M#7E+WFZEH(N+#L2:$'1Z@D* * * * * * * * * * * * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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M+,?S%BWW274%6IMT%^E%B;*7OMZC1'J-'7TQ[G^,3^U5_0\S/UO(73SQI?2
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M[WC)R<GC8>22@MIF,-2$MD@E(=0%V)'6UZZ4Y1QM0X'520% % % % % % %
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MOP(J/RV8Y*=B_(H2AOHXI9UTO4P4W,TG<MG-((1":5W@K4*KT)5I(MC.9/)
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M1ZZ(]>C^5-GU+X@%#B>!"M%#'1+CV^0BO6KT1XUNK)FK%0H H H H H H H
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M0;ZFI*LR1W5)4 GO%2D0S;RR*M"*FWDT@&?*O0&/*M4- PI/<*J0:%-Z QM
MJ :V-0P!3[:(!L';5H)%&F''G$,LI*W7"$H0.I)[!1^ 74:YG%Y:3DF.(H8=
MCRYJ/.G/$6#<2]MJ5:C<X=*Y\U+9+^BN_5FF*ZHGD>L=B(RD=/.LXUZ?X6S?
M!N.+0KD#Z#9J3,:U3&"AU0WU7WJK2R66RPUTI3K]A1-XUO>M[O0D?4'CV4YB
M]QWC\60(_$&TB3*#! 4^M!"4)'99('@[ ?$>@K&]'EO6J^EEL=_2W3UDA.6Y
M:3!<8],.!I2WF74)3,DLZ(@10-+*[%$?#W#Q]2*VY6358,9;%55^>W4M_&.
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M,?\ *(KGY'TFV'J=/KA.L* * * * * * * * * * * * * * * Y3^(_C/\
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M+&WX05FRT_0K\]8Y#LQVE%5">\5D;"J10JS?;[*E%&QS"=^7DQWR+AIUM?\
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M!CLM#ES&D)9<CLO)4X'$^(IMVD#72]$TQW@E960<B/1&VXCLE$EPM..M %#
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M&->R^)R^8YOR/,NX:4W-AM9*2B2A*VG$N$#S$$I"B@!6V@.\T 4 4 4 4 4
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M,I9T!1N\13[>E5MT-:J6>_.,DGC>')%B8,:X[ON4UU+H>5;J2M20% % % %
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M!*DJ%Q=-?"YZ9%DNLB:M)]EBS4KBKL:VQ]QS/DZ'<IE',KPZ:8B')"I##&2
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M0% *LV!HV+"US^DJE^2DH1S>X>^UQT]/!\SZ.WA\".DICXI"GYSA:9?65-,
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MR#F"5$1+9GPYTH-(EQU)01'6I0;&O46O7!R[875;.LG5@KD5OFZ'LJO+.T*
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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MO*G$@!2./*3IV[YL<_\ FT[!'TIJI(4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
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M%<G1A<M"RBU@-0GPJ0U:^]!\*@+]X)K[3EW63%:K>D,\OCK9=6KU/3?])L=
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M/_G595^1OS7\2D_-'D?2"LC0* * * * * * * * * * * X'Z\^NG)/2CDV
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M+/DXV:,E$1\S#>7'=V*#ET[VRDV-NEZ [1")5#CJ425%I!).I)*10"] % %
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M.8Z(M((L;*801IV5[%>B/"O]3)FK%0H H H H H H H H H H H H H H H
MH H#PG^-+C$3DGJIB684U$;E(X]'$.)+6$19C8F33Y25$>!Z]]NIW7L0-#7H
M\6]J5F)K)R9JULX;U/+O&&LTY)8F<?0^,@AWR6E- I4B0KP[-VX64;VM?7LK
MV;JE\;GZ3B5<B<I?:>I>"8_D_'>,KB\@<CISQ?D+*XRT/AM;P"BA>RZ/,23=
M5M*\55QTM\CT.]97D6NK1=7>9-1I+&%@83,SY241W)JL9 M$;7+:%W'I"E)2
M=N[<XD#PU=5FKLX+6W)I1]11^,<:RF,C.\.SS8:BY0Y")C\@U=Z*ZS,WAMQ"
MM!H5[BD^+2NS!FKDXDIZU?[M4>7FXV3#S8:^6R*'(XU/@<DF<.4AZ7/QS+"W
M945M3K;@?T&U*4E77]("O97N=K55MJU\RE.'5.U5:-O_ %*9R-G*\DA?J-F6
M_%9@AQF.HE/\W2IS>M!/PD*7U3]5>KDXSRXG5MT=HF#R<?(ICR*\*RU1W[TD
MXKP&/Z=,\5Q&4.2E-7DY%+X#$UN<Z=SBPU>X1<V24$@CK7Y/[CP\_&RMY*_+
MVMVCM/F?I7 Y&'/B2H]>Z[R0&9X_EL)\UY_+<@QQQL+?&.2L!*R@&P6NVX#L
MT^NN?%=7M50M6M?M.B^-UK;5]#E2W1"X7A,!!7',!R3*R$UE@K4Z9"E;6S(6
MH6T23Y:+GJH]M?J/!]OQ\;DY+5JU*4/R[Q]I\)FYWZCBT3<K65TU\R*D/3&6
MP8=D/!.YQY:=R;?HV_9KW6FUHSR**DK>F_/S?4K:)L^6]YC[S*VT[D[8[80"
MN^T^T$?GK@IDO9ZN4>SZ..B^50QE.G_*YC'H0%(;=#C7B)-U%-];_O37BX^3
MEQ\K99RM8^WH="QIXX'J)+ZB$-IWO*MY;8ZJOI8>VO<6>R1B\-&9Y"WE</C'
MUY*-\KYJ"VEM:D^<-^FJ!<I_LK5X_O&;+;CO2*D\1XGEBKEG,,1R7-\7S$3*
MX>6N%DX:PXS*;-E)"S90MVI(ZI-?#.J:AGNUNZVE'H?UIY7ZBY3@+2,G-"\=
M)2A<[Y2,B(5MZ;@\I&IOT[ :X<+6X]/DWO:FKT/.N,ELMOPU>:ME+3B0ZXV2
MA:4$V4I)&N@-=\-GE*).XYS,,X=EEMGEF2FR76@N+\PPTM+S:?#9 ;V*%K;2
M5$5E?VKD4R[+47CH]/O/1I[ABOCFMG\&BDN\LYB^IM"G%16'5* =CE29!"4W
M2+J*@"0*];#[)5-;Y:?5''?W"[T6A%1>1S'77GD,N/-,A*W9+ZU/.)WJVC<I
M7>3;WU[/$RX\#V8ZJJZGGY9R:W9*P>1R9L+.1MJ1#DQT)=2 =RV6W4K2->A*
MQV5R>\9EEI6UNJ>AKQEME+N=P]"\Z]GN.2N'NS48UW 2TF(IQIM461'E?>MI
M<#GA4LJW"]Q?0U\EF4.3Z3A9)IM?8O7.W\5Z?X:?R29,3%7#AO-PL1'=8=>?
MD/ H3=4="3M*BGPJT%57S64'1GNJ4;LYTT/*#6]/$83L9I#KZ$I#J5]0NQ"E
M)MUU%?1^TY&KWJEU/E^1515G4^#R/.]%9,(*<;F*D3BX4JVJ"CM*1[B*\OW*
M?U>O@CU..YX[1SOC'')V=P\-#+#GR[B$I,U3H8C!2196Y:]#:^NVY[M:^U7(
MQ8L*=YB.Q\]%G?1HZ+P3//R/5#,2\,&'<4]BX3#K;NXQW),!I*&U6%G!9*3M
M4/$!7PF=-6<IKYFSW^':U>G@67G&;Y#G.3<.Q\MF+$Q;^39E9-N %J\Q$3Q-
MJ>>>^\6 H:7M6%W"M\#HRWM=+PDXSZ@3%\:SLV.N.I#[JW)32G1=L,K5="@>
MT$'2U?=_K*XL%(U;K)\O>C=FNFITOT\_#UD.;XR#R_*9L8I$Q(4PVPV'I 8/
M4J*O "KLL#:_LKY+-GMDNW;63V,/$^71P5_U?],\CZ/-H=BMB7Q[)N>6UE&B
MO>V^A-T!W<2I+AM\5R%=*K75F>7$Z? G^%<UY%SWTTSPE25)Y%QZSS,HJ*EN
MJ9:#R%*!&E_*VJ2-.MJW]RY=\WI*VNU0</M?M^+BO+;%IZC3^XZ%QSE'&,WC
M,;R/*3G,7)S$9$MJ*M#LA*'W$$+5%6A"K*!NFRSI:N&-3Z>N562G["7PR1F>
M+\GD8UA;$9,"5"Q*73YDA3#"%.+4HZZJ63M2.EJYEE?JJ'#[&.7YJ/0\@XO(
M<;F.I;B1')#H%REW<YM-[:VZ$^VO53Y.9PF[>1P.^*O@COW&,9S7*<-QHX[E
M8T.&W)=9<@SHS<E(\L@HV+7;2QU2KM&AKGY'$>&^VZBT=#IX_(>2B='*.U<,
MXYFI\C'/\[R?ZY_5JT.LL-M(BQRM!NG<VW\>WJ-QM7,TEHNYUJ7]3/.W/.#9
MK@O(G(6>2A2)RW)<24TL*0XPZZH(6KM0=+;55^K^U<['R<*M7MH_BCX3W/CW
MID=?YHF#.:XUC\+P_CW)%Y^%)R&8==W84*49C# 4IL+\.E@4&^[M(VW%ZK3E
MN_)M1U^6O=^/D96XW^TK?S="*R4UK$%;<E]I3K92C[A8=;W+ *;*3<&X/UUZ
M"Y&.-WB<*XV1.&1L/(QS+4%J)=:0@E!'PE>MK#K5JY4WM[FUL#K4LL91D-6U
M07!M3<6-STO6B<-'FYZ32R?@SE.2R_!7<_,=R/$D2TB8[\T\F?):6\4K(64A
M)VI*K=UAW5^8\FRMELX[O]Y]G@35*SUA'K#\#<SA;WJ9GF>&P'<7&_43CC\2
M0M;SA<,R,"KS"I22 + 6V^ZL[7KZ>U=9_@62>^7X'O6N8V"@"@"@"@"@"@"@
M"@"@"@"@/-?J7AV>;?B(C<-?V^1+X7.BJ6K7RW)1DA*P.]*MBA0%G_"YRN1F
M_3@<:RET9[A\ES#3&5G[Q+39)9N.P)3=H?X.@.VT!R?\1G-'.&>EN5,-1&9S
MEL+C4(^,N3 4N%-M;I:"RDC[5J Y9Q/BR/3OUX],.+A"6WAP]QB;M.BYI,R1
M(5[;K!M[* ]5T!7^5<XXCPB(F;RS,QL4PY<-"0L!QPCKY;8NM=OW*30%$@?B
M:]$LA*$1OE"&5DV2Y)BRV&C_ .D<92D?V1% =4A3862BM3\=):EP9"0MB3'6
MEUIQ!Z*2M!((]H- <O\ Q+?]R'+?\%%_XZQ0%H]*/^Z_A?\ V'C?^*-T!8<Q
MFL1Q_'NY7.SF,=C6!=V5*<2RTGN&Y1 N>P=M <P/XG?1%,WY+^DX*MVWSA$F
M%F_[_P FUO;TH#IV&S>(Y#CF<M@IS&1QD@79E17$NMJ[QN23J.T=10#^@*?R
M_P!5/3W@:PSROD$7'RR-PADJ>D[3J#Y+(6X >P[: JV+_$OZ*960(S/*&X[B
MC9)F1Y,5O7_='6DH'TJH#HT_D6"QF#<Y+-R##> ::$A>2"PN/Y*K66%IN"DW
M%B* 6Q.6QN>QL;,8>2B9C)B [%E-&Z'$'H10#V@(2'R_C.0Y#.XG"R;+W(\8
MV'I^-23YS3:MEE*%NGWB?KH#CWXP?^Y]?_:</\SE =T@_P"A1O\ !(_BB@*9
MRSUF],.$2%P^1\DBQY[?\I"9WRI"3W*;CI<4D_O@* 9\4]>?2?F<]O%8+DC*
MLF\H(8B2FWH;CBST2CYA" I1[$I)- ='H"&;Y;QM[DKW#VLDRKDT=@2WL8"?
M.2P=MED6M;QI[>V@*P?6WTO/*HW"F.0LRN12WQ$:C14.OMA\G;L4\VA38-]+
M;]#UH#H% % % % % % % % % % % <\]=%+3Z2\J4VA+C@B#:VY\"CYJ-#;L
M-89_H9O@_P"1'SR<5@5+0[D\'*Q<FY_G<3[YFZ?WNU7Y*\:#W)'<->R>!$G&
M9C5M*6DK'B2L>^Q%OT31,F":@O.(CLM)93(86DK4E92-1^B#V_31Z@3=?P<M
M:H2GDQI>A,1^VM_W*^H/[DFK)E'!9,%,R>#4E_$2'(KH%BJ$X6K^]'0_2DUA
MGX^/,HNDPU/5'0.,>L.6CON-9]'SPW7#[03&E(%K>))'EN 6_<FOFN5_CV.W
MS8+;7X/\SG>&>A9<KG^/\IYAQ!I)1(B;)RGX\MH)0A;C02E*@NZ"5$>$ FO.
MIP>1Q.-FW*&]L1Y,I$)C/E/H1Q[--!S&NK@2E+2?EU)\R(HI\7B97<I5^B4G
MZ*SXOOV;'9+)\R7A]0QY751$G LWZ&<LXAR5KE40Y!3K,A4IQY+QDPWTE)*F
M'$6!0E716X6MI7VW#][PYTJT>O@]&OS*O'2[W3J*\0Y#R21G'L5S#C\7!PI#
M'S$/)P7E.QDK-T!EU6Y1&ZYV@6V]E>Q>V-5ZZDX_4=HC0LC.5A.Y!]^!EHK>
M0QZ ',ACYB'Y8:O;:Z"G8^V"/"T^G?;P[KVK2DUU:T(;5G">I=H')8Z<4VYF
MUQUI0ZE#LB,TZ(Z0H;D+<;4"N/NO<]6_;:MEE[E:VOBR;L;=;+P-LG$3^IY;
MD5276'FG5K7X' MLI-MB@"%#7LKK]:MTU;K!]33W3#RZ>GR5JEH_,JO).+^J
M'$F<1R;BLI_-8 0FT1<"Z\6L>TSY1=6 EEO>RI*AX%!6TWM7A\;W/';);%,V
MHX\WYGREJJVJ4/\  Z9Z9>M4B?!:C8YWR6GU*C/8?*->7)8=! NEC<5;#>VX
M#RU#6X->X[*R.-UAZC_(I69BWEL-QTO$K0TQ_(B_79J;"_9V5SNC1M6R$VW$
M(L7+)3<"ZC87.@HE LRY8+FN6X_%5#CA#T<JW(;>"CL)Z[;$6![JDRV22W]:
MN9'6#&/M^\'_ )U-T#TRMY_-N\BG)R#T9$=_8&UAJY"]O0G=V@:52VII70B5
M TJBTHE<#R%WB\AW+-M><A+1;>:-]0HBUMNI-Q5UH9W@G7O6]V,O8_@)@/84
MQWB/KM4R9JHVS'/G>70VHB8ABLH=\U6[<%$H2; A0'?4IB((1NYM>KILACDV
M;:\QU80@$ K5H!<V'Y:TLTE)5/4C4I4YF( <@R7769#;P4IP?JUEYE*RIU^U
M[F*GQE)ZND(MI7!>;-/_ *?:;=A/'NX]H\<6(<R5,D37Y.$QTD77*4MP>;G)
MFX#:0"KRPOX01MU.FF-I1$M]O-^+,;:]=%W\O)#G$P,;E8F9QS65>#"7P[S'
MEB;($YSQ)<A,.)^!#:-K9+71-T)ZDU:E5::_>_'R1#=DT_+1>"*7ZF^K&!XE
M$8B8^/Y;>U+''.-QVTJDR_)02AQ;!(LPFU["X1\2KJTKJLZX]>A%,;?374H$
MG"\I]6D\.X]R]MO&/O2)3CD7&29+<:2A"4/%<GYC<M>U).Q'PJUKQO<.?Z%%
M>R^7\6>E7B^G56LM;=/@=ZQF'XOP?'+Q6$CAV;]XGYA+:/.!>)4O<M*4BP[4
M]!7A<;!R>;DKDR+;C3Z>7\3GM>2MYSFK*TNS5/LNMW+?SCI5\BE:" 4@H\3]
MB=0U9 [55]-@PXN-39C4*>O=_$K56L]2J<BYI$P>/B3<UEV,:I^<643<A(;0
MDA(^\2DL A@ ';]UNV$VN3739V>I9.J<'(\AZC9.=FLQA^(\8=4'OYA"Y4PX
MXF,V\AJR9"&KW>0"K>@J[[G6L7>B<KJ:TI>^C6C$.'<'Y%#8?<R7*\A+>D-^
M2] F@B.I0U5L1N)"2;C451X\F>NZ(@]SA>T9[;K5K\E5K9_P.A8K'OQ<?&QV
M]&QAL!#8'A(5KM0@: "N[C\:NR;:R?5^V>S\?93->;[ET_E7Q\1PTB.AU;D=
MD+2E"4.!I.XV2.A/1(^FM[\BE*PNQZV?W;!QZ*KM+4_+7L1ZICKK@9VIC-LW
M#6T!UT@]PZ#\M>5;F7<QHF?+7]_S?-Z:V;G+\1AG&ELXM^2YN2"4!2WE[G5%
M2@-$_P"P*XK6?B>!?););=:SL_,B9.<PN,DK8<4Y,R!.]49*5.N D:>!&@O^
MZ-5E]BC8E)RW*YL9;D/&)@0DCPOSE6!/L::[?>:B5W9"3\"'D0H@;2YRKD3S
MBW0%?JZ&E2=U_P!PT+_PE5.K[#1=3#;N&BM+_5>(7"AI0=\N2$I>62- E.I^
MLUG;3N77P/I%P[7B. (Z?JV'_D$5[5>B/!O]3)NK% H H H H H H H H H
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MHI5*#YV^6UWJ^IWOT&A.9/C6380\'1'R#8$9Q)(076K[@1?112;W[17POO\
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M:EMZ%LF['8@,QT.%J6AQLO/AGYQ8<\T!*&V1J%BXLI6@)%8\B\+:B*)SJ5Z
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M)<M^]6&G#[$&@.EX_P!0<1+]-F?4IU03B3BOUL^A)U3L:\QQH?NDJ!;_ 'U
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MIC(P)$^)%<<5Y+B@IY(NE>\!1ND@A1%^ZLWH74'9,!-$_$P) LM3K#2"4^$
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M=M3GJ9!"0D)V@=^NE8FI[!__ #=3F_U9Y+_^+KO_ !Z)1A'THJI(4 4 4 4
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M*QHH'8&4$=2I9%TIO0'3OQ+?]R'+?\%%_P".L4!8?32*Q.]).)09*=\:3QZ
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MW.>4R8;L%K.8L3<<S(04.*@!^.W'<(_=-I0=-#V:5(+A^,'_ +GU_P#:</\
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MY.30+QIS0VAU"=-;:'3J*_3L=?5KLM]2Z6\3Y+)?T_G[>!9)#KT2)MBI!+8
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M*3M&[Q$6!OX:\S!P./ABUF[W6DL\I4R6UZ:E-F<Y4W'V8]GY..WM'FJ"8^@
MO]Y(%K7.T*"!7I6S6[(Z+TWV=KVFS.=<FY[@5(PO(,CG\<F/Y\I"73*^8"[
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M\!!O(Y):WH\MA<924$G>I*[^SI>FA$"S64RT-#+4*&[.047(;+=T^S:L&]-
M:/YR:4!4O!2+&Y5]PRHBW?8BI6G1CIU3'L+/8]];<>;B1$0L&\B1&6VA( OJ
M6U]M6B5&A7<EV9JYD^,8]]!*%.I?3N!9^82$WT%SM58T=/&"5?\ 9CJ8[C(C
MK+TAUV/'<^$(=0_K[+ V^FH[R7W"[XBS(*,DW*6O%LKU?=2TH)(-NU0/73I3
M<RKA]31<K&NOQWF\G'#C=[$?=J%QV%"Q5'5/JE]Q$(=N.3I$]EQ&3,EXI\N.
MX7WEK1M%]J2=RD]>@-46*B4)*"'CK:KJU*?8GF,SR**X6QD XO:4GSGT.K!'
M5.UU (]UZR?%QV<P<%_:^+9RZ?<X'T?E&<$F/,<C!YPL_+%&U-MOF>822E=[
MW%4?!J]%I]IQW]FQ.FU.RUD:S>79)K*Q\C^I52F!%?B.H95L6A2G4N>9M4FQ
M ">S6BX4+;/>3E7L4**W[ST[?F6B!R7TPR6(@P^7\:6J1%C(95(2T%%TA"4+
M5=)0=1^E>O"R^W<['=VQ7T;GK_U/>].W5:E;R/IK^'W-)DRD*..RJXZI#;A2
MIH>>FZO)ND"U[) \>G6]==.5[GB:32LI@R=)?S5T*^UZ33T!L\8YI(0AU";Q
M93B9K7A0/ I+V^P%MHL17N/W%Q\U)/%?N&QO=2U(^U?C!*X_TY]6WVFW\=-P
MF3>0\N%\D2N$\MQ-SNNVL@>S2U96]WX^.SK966G4]*F3UJJRMU\AH[F_4;!Q
MD1\SQV7\BVZ"IZ(MJ>T%-.V5:Q;<'C&E=].1AY"2K:9\46QY:VNJKYK=DFOV
M^XVSGJ)@>5-1H/((Z?/^:86ZSDF%-/)0A0\P(4ZE)1=.A(75:\>M7NQZ?!_C
M!HJ4]57M.Y=ND^3^!/0$HC2%RO3[/H;QRTK4O Y%Q4J&C=H&F7KJ=2DITVK*
MZWQNU7%WN?CXE*5;K+>JMI\/$V6R(BE,OP$\>=><"CCWR'<,ZXH@J=B2D!2(
MZS]I*P&U7\2=+UKN5JP7JKI-3I9-?%?MX%Z]+ XUR]XJ:4WY<20 HH0G6Z1?
M<V@)/LVJ(/94>W->LZST3_;J>7R,;K26GY=8^R6R0]8WB_E,6+(7MB*&TI"E
M$ET]+I/YZT]U>V]8\/V[HSX^*:SY_MW11N.9%F'GH"F$)$B(\7FW9+;;4=*D
M)*TEWHX$@CH 5'HFO-P8K*ZO*_$]FV!KBJS[Z?M_U(N3F.09K*IY"&E93D$A
M3J1R+*@QX+2-I&R&Q;>EM([4IW$_:KLMD]1MV9DL2K5I+L-W4\0P^08S7/,L
MGD649;#L=B64(A,NKTLU'O;P@)U7N/;6SFZ:M/Q(RTJ\=J3JVMMYCY5U&>'Y
MOELA$C8;AV&G9Z?'26W'\?&4M"2I9-_.7L;Z=@O5,G)KCHO4O6GF=.?/?*UN
MU54E7M_U&!>]3<ZY'@P,4Q":?4B-'?RDD/ZK(;2 S'"4ZFP\2["M,K6/&\C5
MG6NO^IO_ &_DJCR;=M>LD\]Z/<VA8^9D>0>H"(#D=MT)QN(;88*G0+J0"$DW
M)TW$DCLKP,?O+R7K7'C<-]6<F/'ZEE66Y?XE2'H_QQ][S<T])S#ZK**\B^[*
M3TOT6=NMAV=E?5O!:8=SZVOL7%HXR95W[HF\/Q#@$3DN$P^5;8B8%U,MQ]00
M&[+2TG;9022 HI2%;1K7@^\*^'%.!MV^)Y_N>'CX758&K::]]3I>2QWHWC,7
M-$$QWLJ\VI<0E;KQ2\YH1J;))%?(47N.2Z=]%]AXB>2Q.CU"]+,*%?J>.E)0
M0$F)%2@[CU!-D_EKD?M7,R.';[V_$J\5N\G._4CES'+LMB7\+&?83";4TOSV
MBX"%**S9*0=#7T?L_$R<&K^;YI_;J>EPL^3C65Z.&5I,C(K4]O7((;^!;<8(
M4--0%*Z"OH?U>;^H]2WO/+:CU(DU*\@N$HM,/76G:XLA""4CO)UJ;\W+:NV=
M"<OO/*R8_3=OEZ&(_P"L/E/NXZF6PFP*Y*4$@=EK@FLOU67:JJVB,7[GRG55
MWM*JA0(Q8[TB.H+8Q[1-QOD/;G![1N6K\U86N[=6<%KWMU=F-(3$J*^\TT_"
M:03_ "J-JP2>T'834*T*$S/7S&N:CI;;WJGM2E*(NAI"P0"=?B2D57[9);?<
M;7PZ'2)$AR]]Q"E-((O^^-2OM(T[FSDKCJ4D^>HFW;(:'YA4[9Z(37Q-6HC"
M"9!A.K:4-R5*<44D=AN *F+> FOB-7,WQQ%P3%!3\04\HD6Z]M1%O F:^)](
M^(K0YQ/!+;MY:L=$4G;J+%A!%J]^GTH^=O\ 4_B3-7*!0!0!0!0!0!0!0!0!
M0!0!0!0!0!0!0!0!0'BC\7^7GX_U,Q3,92 VK!1U'<PRZK<9DP:%Q"CV=+U]
M/[5'I/\ \OX(\+W"?477IV^TX K/9"4P['G^1*BNH4DL.1F18GH0I"$D&O5:
M7@>=3=_4<Y??6Q+>CZ?=K*;D:]=/R5R[M3MV*!5$MQ) .V_=VFU6W$;#KGIE
MZ 3/6-F%G.2K<POI_C)#C\B</ _/3M 4S%N+ 7%EO:A/1.Y6E>/S\M;NM5V/
M0XN)TW-]X/6"!B,;BXW&.)P48?B,!(;AXZ.D(24C[2OM&Y%SN)4HZJ->=6D'
MHNRD3<"18 V/8*T,F5/GN;A\?XIDLC.79M* VRD:J6\LV0A([S71AH\EU6JU
M*6T4GF&1,?S\L39P"%(!2TTGL!-]3V_FK[/B<"F!2];>)\[R<]K=.@K R.7P
MN0&1PTQ4:78H6.K;K9ZMNH/A4DC0A0KHY7#P\FCQY:[D_P!M"G$Y>7!96QN'
M^\Z_Q/D?"N7>7%Y'#;B<FT1\JLE,=TGHIER^E_T%&_<37Y9[E_CN;B-WQ_/B
M_%>3/T+@^]X.3;T[_+D\'W^!&^ND2'!PF(A1D".')CEXZ1M2A#30  '70JKL
M_P 2Q[N3>WA7]_\ T,O\AR>GAKYV.(AD;"NURFQ^E/45^JP? *\6@E<!)3C.
M00Y9(%_ DWM=M2@;'W'I7S'^0\/U^.[5^O'\WV=SV_9<[PYEN^BWR_D5OU.A
M*Q7J%FDMJ\,I;4YHCM3(:2H>^UB*\/V:Z?&4'M\^FW-;S(C&<AB/3(R)P!C)
M=0J4SH5K90H%:4A5M5 ;:^@?)=EM/(]%)RCH_.>9(Y'D&YL%29RW&5I#CI4A
M+*'W%N!HHL-RFT*#=CX46\-^M1@QN-$OS.2E-M7N?4JA;*VR'$ ;DD&UR->S
M6O=5-RU1R.]5;1R6;U!S>$E^G,'"8"[43$XX-R"Z IQ$IQ8#@4;?:)*O<17Y
M@^+>G.LK^,SXKL?99N13)QZ*IR/B45]_DF&;VI::,A)2DIN2D J)VZ]/;7M9
MI6-OHH/*:D]4YUMS,^EC+"%;U,2XC;BE>([$OH!N/=7PN&:9]/$^HS/U.)KX
M?N.)&5!7,D1FWO+2VZXAM;HLA:4**001>UQWU^TX.96]4[:-H_.,O$O7Z=41
M'*6\@,6X,>DKDI4D[4:E2 ==O?I7+[OCODXS5-?R-/;[UKEA]2$PD+))\Z5E
M$>7OL7#<K78:V"0/HKY7B^U-_-DT1[F7E?RKJ61,V(("G%LM,PO@ ?5=Q5C;
MPMIN2>ROK/4JJ:52KY]?N/%6"^^79[O+_4Z!Z7R&,3$Y7EDHO%8CM-M/W*DM
MJV;=G<D%2^O8=*_,O=KUR9]*[5T@^P]LW4Q-VU9P=G+);Y"UEW EUE+ZG%)<
M"5(*2I7B.\%.FZ]R*]V])P1_VG!2\99\SU5Z*YI7*\J[$F2D92#"C%3)D"[A
M2L[0%H5N#B1V.'V"OE[3C>FC7@?08[>HM=?B5C\2./XYQW)X!6!Q4>%,?DK6
M^J.E25+0EM1(" =MS[J^A]MY.9Y*JUG9(\CFXJ5T2B3FC&0064.? %:W44Z'
MM%Z^^Q\E1)\SEXTLD&<EOT+ZE)_10L"NE9*6Z,YK86E$"QR#J25-64HIVJ"A
MU]IUUJUNFAC6B3UZ$%D(BIV4Q#0!D2G9"DMIL!N*FS86]]>+[AEIB=+Y'T9Z
M_&K*:HH'&9P.8P>Z#D<9(A%UU*4)=0H)4XXL)\! L;GN-<3YF&^.VRRCXG5;
M!>K3LNQ[IP;2FL;#:4+!,=H6]H0!7S#M.ILDR3 JII$"Z#86(O4,E.!:4C&9
M;%O<?Y1!1EN.RAM=AO#<4'6RVU=4J3>Z2D@CLHK6JTZN&A*[G"?6CTM5PGTY
M<1P&'\YQ$RA)R#["=\MD!)"52B!N<2"HCS?L]"$UT<-M\AY+O6RA%>9;=@K2
MJAJVOF>5%*"DE23J>A%>[)X36HIA&?/R[:3]E"UG;W 6_9J:?43D^DL#JD@D
MB_7X>TW]M=<'&8VJ&B[&_P!.M+(&H2"+'XCJ;Z5*@'I;\$]OZQL[:VF$<'_[
M7'KQ_=?^-?'^#/1X'UOX'N>OF3VPH H H H H H H H H H H H H H H H
MH H H H H H H H H H H H H H H H H H H H H H H H H H H H H H
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M#Y?R=KDJF5LQC':8:<L5+"U*4NW7;H.E>GQ>*\*<N6?4^T\"W%5G9J;1^!C
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M=9&];25 ^8PZDA+B+=%)(5WZU.U7J[4:LN_C\&CBP<G'EF'KT?Q.A+YM^O\
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M KZWWG.ZXUB[O5_!'!Q:)V=SK?X?^21'.$Y2!)QR9<O%/%*7%)+P2)*0I3Q
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MWB@. >H7X=F,4IWG?HH\[Q?FV/0M]N!"61%EA(NII+9N$*4!8)_DU?"I.NX
M6KT\]6WN>>C60YOY:6.08F)-;R;+8LA,Z$P7=R0>B5I*%@'I?;K:] 07X1,9
M'B>D;>32-TS+Y"7)EO'5:E-K# N3J;!N_P!)H#O- % >>.;?_E;^G7_8DK_)
MY"@&7XM'\A(=]...P(8R3F2S9=;Q:UAMN4^P6FVFE*40$A?GJ1<G2] 6+^G_
M .)+_P#E1#_^^8O^=H _I_\ B2__ )40_P#[YB_YV@&?X?>%^H7'.6\^Y!S+
M!IP,3E$EJ?'AMR6)2$O*>D.+2GR7%D!/F]56H!CAFFW/QC<B4M(4IKCK:VR>
MJ5%$1-Q]"B* ]&4!Q[\4C;;GH=R4K2%%M4%:">Q7SS N/H)H!;+9:7B/PUG*
MQ5D36N(,>4[?Q)<<@(0%@]X*KT ?AFQ$7$^B_&_ED@.3DOSI*[6*W7GUZGW)
M2E/N% =;H H#QGZ&\G]6&$\QY%PCA#')D9S-ONY'*/SV8;@>1]Z&BAU:20GS
MBJ]OM5(.M?T^_$E__*B'_P#?,7_.U *#ZN8O\0GJUQR+QZ;Z;Q\9\I-;GLS&
M<K#=<"VVW&]H!>%KAS\E2#U3#$@0XXE_Z4&T>?T/WFT;NGMJ +T!YXPP,_\
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M%H5=*AV$4!,T 4!YVP?_ .6)R7_\7&_XL*I!Z)J <@_%#_W'<H_^H_\ 'X]
M36*X\GEOH7C>,J4$'+<6BPT.'HA;T!"4*_L5$&@*#^%/F:)'$I/IGF;Q.7<0
MD2([T!ZR7C&4\I6X#M\MQ2FUV^'P_I"@/0= % >:/0:<WZ=^J'//2#-*^6>F
M3U9?CI<\*9#*P20DGJHL^6JP_17^C0'I>@"@"@"@/.OI@3._$YZJ9'K\O%C1
M+]U@PBW_ *F@.]9W#PN0X7(X'(HWP,G&>AR4]OEOH*%6]MCI0'C;&<YS'#_0
MSF/I(^HKYCCLTKBV.80?&MC)N+*]B>I!V2-I'Z::D'K+T[XC'X)PC!\3C[?^
M;(J&WUIZ+DJ\;ZQ^_<4I7TU .._BW_FN$X1E^GR7(XYW=UVUK_\ U= 6K\37
M$I?+O2++-8]LO3L2MK+,LI%U*3%N';>T-+<(';:U 6?TBYU ]0^ 8;D,-Y+D
MKR$1LHT#XF9S* EY"AU%SXDWZI(/;0%XH H#S1P.:WZ8?B/YGP_,*$7&\\4C
M+8-]?A:=DK6XZ&TDZ E3C[8[U("1U% >EZ * U<!*% =2"!]5 >=?P9D)].,
MXPHV>;STCS&^U-XL8:_4: ]&4 4!YD]7,%CN'>O/I?RGBC:(.<Y%D50\U'C
M(#[!=9:6ZM"=+J0^L+4>M@>HO0'IN@"@"@"@"@.<>O:&7/1_EB)$CY5@Q$AR
M0+^!/G-W/AN?JK#/]#-\'UH^>0Q_$(C+,Q4?(YA,A2DL/I:+;+BD?%M<>))M
M[$UXSK9GNK8O,:($;]83Q&9#* TV/*T)2#]DD 7JME!%7U%YCRVDH2/- (2?
M,C$I=!MV%)! -5T+,0C894V0AJ-C7//=7O2XM9=D*4G70:GV]:TI\SA%'\JF
MV@UY%R:#QA#"<O/?80_N0U%B)"5G9U+BAXNO;6E,5LDQ&A2^2E(W=QI.Y3BI
M>&DR>(*^>R<9+:+RVPAMM]T@D(*B0O:.WOK2_'6.]59Z/K!2G(=ZMU6J);@+
M'JCRK)G S,,PW\JPO(?,I;3'<?!L$+#B[?=)&FFGTUR<[F\7#A3W*)V^+GS,
M<-[IMWZ%\X]^$1J3D&,[R;**8>6^Y,=AQ5J/FJ20M.]QT!*4A1T*0:^7Y'^6
MJM73%6=.K_;4PO6NY674Z^UPCTH]-'XCN2:A-3_EE^5)D$O35E;HW>6G:I=B
M!8[$"OGUS.=STU1MIOMI7[66:M9G,.9<U:RO/9>?XVAT-IC,P&6Y+2E.6"0%
M$-I5< D>'<??7UOMW M@XRQ9.LRS3/Q*Y\7IWZ20.7R\YU;Z>1Y)26W!O#%T
MO/;NX--V;1TZ'=7K8^/2G1$XN'APVFE$GX]_O(UV4[$4TMUHP"TC>)#R1)F$
M%/A"6P0$;NS=M[ZZ(.MMOJ1.2ST#%Q79\QU+38#;3\YXE]96ZJYW)4D[+VM]
MV/9NK2F-WF$4M=44MZ$4&>3960ZU!::B8H_>(R;B@^94=?@*"WX=BM2I"U:U
MZ6#AMJ6OO['N<'V'F<SYDO2Q-3OMW7D3^)XOB,0SYS*C(R92WY^3D'S9+A0K
M<GS%:;E)T V_35\V3&J.E?FE0_ [<V7V[A<>V/!5Y<EZ[;7LNB?](ZY)S%$7
MS'Y3JI$DDMALW<)6;)VI2B]R.U*-!]HFO-P8%6J55_H?%4QXN-CA16J77_\
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M[UZ+A6EIF4]BR<[;3^O$2@#:9':=-Q;Q)%CKV]FM<N._RDP/>!R'&_UBUJ$
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MM 5X@-P*3JE0N;@41CCWXLL A./A<DX_GX;?A9FY!M:).T=-^UI-S[2I1]M
M6#BG#/7=_DN.SW/^<PTXR M3B\!AHUF) 4DHV.N*0R2-;^(+L>ENM =CH H#
MEWIUZ7Y3A_/^>\SR4^/+:Y9*2]"882L+990XZL)<*M"=JT#P]U =1H#BV8]
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M+X;A?XA\KFL9D>:<ZQ^-Q,&2U*>Q.#C%0D):4%%IQ:T-*VK VJ\2A;LH#MU
M>=WO2#U5]/.7YOD/HOE\;^HN0NF3-P&9#@;:?4HJNWL2;A)4K:0I)VG:=U@:
M Z+#X]ZG9OT[R>"Y=R"+C.:9 NHCYC!-K\N*RLI*0D+\I14 %)*@0;'0W%Z
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M^!VK%9U97.2^M/+,\ZW'Q!_5\914DJC?'M4-0N2Z-+6^PE->OQ?\?X^)3?\
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MQT.Y]OD(KWZ?2CYV_P!3^)-58H% % % % % % % % % % % % % % % % %
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M;J /T'.MN\&N)W:TLCNK5/5/0^F?#=.(<?\ ^S8?^017N4^E'SU_J?Q)NK%
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MU\&'%^4LS6D.J0/(4@A2)"0VA32CM4TM"P#XKV6"-#XNA-7S8E>L/QT^/D_
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M;35M:=OL-J7=#T7Q1D1^+8-@&X:Q\1 /2^UE Z5^[XK;J)^*1YUNK)>M2H4
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M1H /::\31'N2V0["9#;^0:>>+J4J0$Z@H! UVV[*LX)K/<>N+B*W,3&GWF[
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M#,/R^"CRFLFQO<8ON\I]"BV\W?2^QQ*D@VUZT!QQ[_\ +$8__%P_Q54!Z)H
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MCT/2] +_ (15*5Z-1 HDA,^:$@]@W@V'TF@(Q[_\L1C_ /%P_P 55 >B: *
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M2CT"NGQ$=!7BY<SS7FQ\)[G[CEYV=Y<OP2\*KHO,J>=Y1B(J<BX^](8Q<R0
MV'OOUNE W!2TBQ/3PA6@ZJ%ZBN-VM"/'R75:ZDWQ#$'%38/,E923+>R4%3V+
MQ#R=K:#+4I*#:^VR4IN???I6&:SS3BB$GK;X:GS.7'_<';$M,:O%GY*'^(ZR
MF6#<93K$\C+2&W!/E**4(#;R]MP56400%;=MA;76];*BK6*GT5:UHE2JVU71
M+3[(\61.*P\QB6]-R<EF=%<0VJ)&0P@%D!1(.ZY*B18#7\@KMM\E81]%DX]O
M;J[;.E\F:GTQ+QU?\WQCH-IPEYO*Q\:VB:U"?VH<DPI+;:V0JUDI3JJZR-O[
M-9XZM5/#KB>16</93J]-/C\2?R2IG)N4)AN)EK>;4JT@0FIT=2V !Y3BWO"$
MKVE&@U -<^/%Z>-4HE\)CXLXFDX71#' QG\AF813&<:@XT?\V,J2I+94XM0;
M2RM+EE)3<[@46U%J[*Z54:^9M96JMS6C6C.^QVVL= A8I"]R(:"A9-@5.J)4
MLDCVFPK==(70\X<-R47!4-O8I)_;JR \C2 M&@'>GO%NRK259*P'$E0ND7[3
MU^BU7KJ5+EB%!-B 0#755&#+$E1<04W\-M*O)0C9BE %*=3TUJK)(62I 5?H
MK[797-8V1%N NN$-G[L&Q2.VJ@P]'4\R_%7N#,EM;*NFF])%['32H:E-%IT/
M/?)L#)@9R;'+#K>$RZHYR\EMEM;+<A*_**G7%N%2E[@'$ -[!7$WL4=SMQVB
M^G=:?'N13D/(Y+ SN/J;RS>4Q[@D8]"GX\>7*E1] G<U?:AY)%MR15;6V.?Y
M6=N6UJJT36KCOJUYQYZC[&JD9W#2<4^RW!R!:<:ARI+D?)F$ZKP W1N!4V0;
MZ:B]<V5]+2VE^T'!EQ//C34MI[DOATK]I!F),XWR+&)Y"ZSE)3##I<<0CY1+
MK-BE.P-DV-QH1IWBLZ95D^>JT_<:<3DUY&/?WZ->#[U_@7"9@9/,N+KP.*R0
MPW(C+BY7%2P0X'F_+#+D<*3?Q%*TK3W@:]#7G<GD6X^:N9K=C5=K_P"WNGY]
MSOY>;+FK27_QK:O_ !ZP<UP^?B?,/8H99Z9D8[C;>29;;VR"_%<\HNH"B %C
MLV$;AX>ZO4M2->SZ?F98\B:4.67-K(J8S[$J.0O)-;W)*V;%J0@Z>8A.A"B/
MY1&AO^ZKGR8ZVKM?A!')XU>3C>.ZTM^'F1G*^&\3AXZ=ZBX#&J=R4:0K(3&4
M$E2O, #I;/39XM^@[_HPP<C)7(L.1Z1'Y'R.'/GX7)KARQ:K7ROI]L]_""JX
M?EJ<[C947]7NPE12VXV)(45)2Z;DM$@60OM3]-=V3'L23<GV&'-ZDLN\ -.8
MY,V(50<@TRLKCR2GRI3*%64XPHV2L?WQE7B'47K&#HD<X665QDRL,I8=8)>=
MQB%E#S9^T]#6=>GQ-GZE#I3)564,K?'3+5TNI3_#X>!>,)RZ',B,M91]#C*U
MG=-6@(CK=6JX2^G^X.^WX%=AKP\_"M2;5Z?N/AO<_8<B^;$M]/Z>I ^J\4,R
M84I(&Q]*D)6D#Q!*D$74.MKFK>W9-+)R>G_CMFJY*/LTU]O^IP#)^IG*8LES
M".0VEY& M:$.H:'WD8&Z-P3U('VJ^R>+'>BG[SU%DR8[-=2Y8;)_KO ,S4I<
MC"0-\J)<AKSD:;MO?7E76VVU:I'K8WNHK>),8=V9 +B\5D1&R9228<H?S:4W
M;X#N\*C[#8]U0JR6EKH;SYF/R 0IO&.8S+=9#*#NBG3XFRKQ(_>FEI1,2?37
MA@(X?Q\*-U#&P[GV^0BO<I]*/G+_ %/XDW5R@4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4!RGU,%\]'_ .!H_P J[6U.@*8=*V(;@358 6.O[=00)N&POWU
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ME*)]P% <<_")_P!S<7_M";_'% 1KW_Y8C'_XN'^*J@/1- % % % % % % %
M% % % % % % <T_$$S(D>C7+F(C:G9+D1*6FT"ZE*+S8L*PY#2QMLO3)7&]U
MG"1\^^*>D$*?,)Y.VF2D_>O1&_Y%)'0+6+75[!7S7(YSQTFC^!\MS_\ (_6N
M\7&6G>_Y>'Q&G,<9$Q'(9L3'QT1826HX:8:&U"0 16O%R.^--N6?2?XZ[6XF
MZVKW6\^XECU29BD0XK!F24#PMJ 2PTD?:<)T-NOBLFNQY+;%2=#[2W.SWPK
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M=*3[%:6 L?X<^&<DX%P*3QWE$ 8^:WE)3L=L.MOA<9Q+90L*;6L"Y"A8F^E
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M+:$Z74M0U/8-:[%=:*W3L>CGR['6.MG"\^Y*9*9Y.-#:&WIF25;YB#$; *6
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MGK\.V.UZTR?\=FDY_EU^K[$4?!\FBQ7WL3'PDO'+QSVQ:TH(0IJ,YL(1N&I
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M$@WW#O\ HH27;TQ-\S*_X*K_ "B*I?H#JE9 * * * * * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
M* * * * * * * * YK^(%,E7HWRY$1"G)*X:4--HON4I3S8MI[ZQS?0S?!]:
M/G 6H6 )3,",KR4#<(8-XD.XT+I'Q*_<CIVUXR3/;Z$%$,M3,IR:I*I2EH\P
MH ";WN;6J^A3IJR0E12_YC3:2M;J=G:  H=]35.ST1V<3BY.1?9C4V_!+S9&
M0_3/ QS"GR"I"HJ@Z^A1\#EB+!5SH!7OTPM5W6Z'W''_ ,3XN"E,^5N*-.T]
M'KW+HHNR%(CL,E]YVQC0^A< UW.=-K8ZV/4=;"N#D\UW;K7H<GOG^06SMX,#
MC'T;_J^'A7]_<(OS<AZ1"QCZ'<BZA1RN96H)8982/$E*NB&4CJK[70::'SDC
MX68T('(J:CS6FL('E,L[")<E("I"NOG>6H62A75"5=EKU:2>KU\"HHE<XRN7
M984WY.+DRE+5+4D**FVC=Q3B[ZWKTL>&L:G9PO;.5R,F.*_[=K3NCM7K/D=#
M?E,-+2U=;49FV[R_B (\*4?[HOHG]$:];5CR,RM\M>A]%_D'NZSM\?#IBHX<
M?S/\D0&4<F,3UMJ9;"V%%+D5%G$-;$A7E*[-POXAW]:XTCY#JY[L7XE.Y%"D
M9&?R/#HBPW821!;=2%><[(7N!-R>J1XA5<RI;;M<ZZGR_(I_<'7'6WRUM-HT
MZ>8US><C05N/9-]3+4A@*6^+EU2'_#N"1XDA8\*?W'L-;8J2H1] G6E8Z)=#
M./Q/'H,!KE..>D&=D(*G7BZHK"6BZ" $GIJ@:=+5#M=MT:A59YW&63+FO>RB
MM;?)]W7]XS:?QG(,BX^,T^R8!;DSH[5T1]B5? M>VZB3W=YKKJMM?W'KX?3R
M5M?<ZWK#JEW9)2&Y66RC276,?(P^BIK3IWR4,I!V@(-PC<1[ZI7Y:SW"=MKR
M36R;VZOYCN7",8F%A$2W2$R,A]ZK=X3Y"!9L?LUMCTJ>=:9:\&6W=$0W<D%1
M.A&EO=]-7T*0)MN"X0V0"K12NS7N'LJ T;->!7Q;SUW'MJR*CU"06[;_ &VT
M_P#+6I@ACZ,RXA8*5W2 +]4@&U7JRC198#BV@+W.G4]*Z),FB8;<%@5$ CKK
MH*LF5:-9+E[;=4TLPB,EA*D^-6E^EM*S;+H8ON!22D-DG[+ENI^FH+0)M-J\
MH*=VC]#6Q -0 \ME5V9"B%_$+BP5[B.V@.?>J&'D.11(QJX[>4>:6W#=EMA]
M#;R!HLI4%7NC<G2N7.E'Q_@:5K*:.+2%8+(<78EY7/+EM\>94\E7&U%H.)?*
M4J;4FY-D'XDJ-[>RN2+RH24^/9&V1WR8JWKI#U^'\Q$R&HO+<BWYGGR^-B&F
M$\X\A;+J2\L["L$72#MMN/VO?5=<=I^'W'H8;4NTK:U;^_7I/8VXWG>.8B6>
M.P(4B"W%FI9G^<E?E>6A1;W)<5NT&_=;KM-:9J2Y[/H6RO%ZMEC36.7MW>'^
MA->HD/E>'D-' 1FI,QF5Y4]MTC8MM2#L=O< I5H2H=M;52O\MNM3W[9>1[CQ
M:8Z+?EQ-SXND*/C!"8>3E&\ICW)#;4=Z2D)5&5XF272=S1(T 4K2YK@=4Y/
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M)^4<3QD>4UD>)OIC9%R0AM+*UK6X@%HI<42+MGXDIH"Z$@=3;LH H H H H
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M4OV.1\W61EI(_>_Q14F+ZGGWU #;62\^VT%.Y9]U8WZEZ%3XK+VY%]"B0Y(
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M#CQGGU27F6D-N27+!;BD) *U6[5$7- +T 4 4 4 4 4 4 4 4 4 4 4 4 4
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M1U+MV7M0#_TO]8>09#E4GTN]4\8WA?4&*@NPW&/]$R#"4E14U<J\6T%?A)!
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M!F]""]^E/_3DS_@A_P HBJ7Z$G7*R 4 4 4 4 4 4 4 4!R#\4/_ ''<H_\
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ME;V[J%;057/LKTDZ8*;H^!^S8/T_L_"KDNOFA:/JV^PW:6_D)32(;6_)2B1
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M-&P1\@@I*B;CX;]AJK+(9.*WBQZJ )2/$"!VW/2JD@IH-E!W!3:SV]!;W]M
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M#C3B2E25 ]00;&@/-4# >J7X=,K.9XCB'N<>E$YY4EK&QU%62@+7U"4@*4;
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MOA'"<_EV),AIJ;D78XC1H\=:PEQW<"Y?8FYLK9?I>@.X4 4 4 4 4 4 4 4
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MT K0R2&*"[*7NV;020%=Z+T)'@:8CM^:M-T"]TC73OJ2&S,:0A2%%T#:D^%
M%BI/8*%9':BM:"XSM2A-MMNH^D]E2B!1B0MLV2L@$7W=IUUOWU8$FQ-V(25D
M!)U.X'J3I5D18EH<AMU-M_WE^WKK[*T3,VB99?+6PK6D;+E5A>Y/95DRK'@F
M!5@=$#0D6L">X5)4U"[JW^*]K$DBWLJ&R4,Y+R M)2? >MSVBHDGH-E/-!O<
M3H1M![#VVTJK+P-G'E.()"K[!<)/?[?942(,JDH8: )LX-0#8#WTD0*M/E20
M\KXE)%P19))&E[=E2A!EU*"ZH@ : W'NUM4D-%!]3($<0XN=2PV)T5P(<>0
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M1I8T!Z/H H#  %R!:_6@,T 4 4 4 4 4!@@&Q(U'2@,T 4!@@'0B_OH#- %
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MDP,I3NY1)3ML#MVFX-^VH)B1NDEQK:H';<;2--3W^^H984;"W+H \3@(5I8
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MD=L)Q]U.Q7SKX2?A]A%>HK31-]R;^Q\E4]5+Y(W)^);&42W<6PXZYO=2@>8
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MHDII2TH"DE-P5*M<J\?9K0@>(CM%L%RQ+EMBBGZ"?;]- /CC(P9W(6$A&XV
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MKH*$F2?;0%_](U$YZ8/_ &-7^5;JE^@.Q5D H H H H H H H H H H H H
MH H H H H H H H H H H H#AF1_##QIG*/9G@O(LUPR=(67'DXR4HL%2B2?
M"HA?4G3S+>R@-'/PY9'-)$7FWJ7R3/XD_P KCO/^69='<L%3H([]+^V@.M<3
MX?QO@^&:P'%L>WCL8T2KRF[E2UD %;BU$J6LV%U*)- 3E % % % % % % %
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MAHW)]6N%A0X=QX+MO&,A!5NE_ET7KUJ]$>%?JR<JQ4* * * * * * * * *
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MF";E/PC60;4@#MK\-7K:@KMQ)Q-U [A)A7TMT^_]_6K 4_\ #3ZT.[@OB;B
M"0G^<PK%(Z"P?.OM-1! ]:_#?ZOM.-N#B;JT!)W-JDPTJW6*>H?M[:$,6_\
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M3!8^<V6IL3'Q&)+1(44.M,(2M-P2#8@C2O070\RSELF:DJ% % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
M% % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
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MBB_\LJ=K$FP__. >B1)'ZNY%<?\ L47_ )93:Q)L/Q^>B9Z8[D7_ +E%[?\
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M"YL@+R[)[HZ?XZZ]'C?3]IYO*^K["&:;L+BNJ#FZ#EM&FM4DT1R+U(:4ODR
M.QA/YS7E<E3<]GC.*05A+"K6L![>^N:$=,BB8P'Q4VC<*!EL :@]U3"(D4'D
M#J1]=21J9$J*C30_30 ,G';U%OKH08.<9%]1?LUJ))$'.2- ?&-.\BID"!Y0
MA1VH7<^RD@0<Y*XE).H [0*B4"/=YPRV3=8"AU!-C42"D<VFF?"7-/10(OUK
MMQ=#AR]3SGF"527";:$W]U9L(C1V*M8CO[Z@L;*.A()W=] (.G3Q*T[J :+
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M(_1M4$F-MNRK2"P-?R2/WH_-7&^ITHWJ"0H H H H H H H H H H H H H
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MLJVIK=9#GMA(Q,!;:K6T%:;S#TX-_EUGLO4[BNTEL;CBLBZ:I:YI6A9F<99
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M, 9[?^!3_&57H\;Z?M/.Y/U?80UK5U'*;)%[56QHBG9Q]3>96$C[*=:_(?\
M(W_^:_@CZ_@UG"B18=0I@%6IKPMTHV:U(2>XOS"6T6'?6%M3>J-\?(>)VVM[
M:MCJ[.$5N2[X/E>+K7;7AWMV,U9$0[.9A76LB_Y:[\'"6/6S+O48*YK&"O*0
MKQ?6:]#U531%'B([)YYQYO<C0GM-<N3/9]"],:13G<@XMU2G"I1/U5PMVL]3
MJ2)F#-4ZUM T]O6M*XG!A9:@XAS> T@FYUM6].->W8LK)%@Q49]6VZ2GWU[.
M#BM+4YLMT<=]6W=N3DP3HXH>!9Z:BOJ^!1+$>%RG_N(Y)%B0(VYKD#"7FCT>
M2+  ]MQW5HV14H/.8& AR4*PCF]+A)(2+>$5%60T5!5DGII^Q[*O!4;NJ U(
MTO[S0#-9UM<:=?V*@&S>NH'3O_.* 5TL!;IV'MH!N\1M!U [JD$>]UO;LL/9
M4@122!;46/4=:L@;_:W%5K]+]/=0'3_2/#<;R\EU>8<_DE_>M"V[9;2P-:U@
MIY'9Y66]...1U2\<RV^^@ *23XTJ2?#X4WZU;>2J)$C!YURKE$-;<& C%XU=
MPIY8V'81U 'UU75EUH9:2K$X"4ZCS9LQ ($A=U)NKJ1<Z"J/1%TV>6N0ER1F
M93KEU+6HE2CWDUC7H4?4C4M: Z@'V:U(-@Q?3H3T%J$"H8]EP3H*$FPBVL.E
MJ$"HB7( ]]J%A01#<W3IVV[Z@"B884-!<$[;]M1),"J85M0+$"^O93<3M'+<
M4!0T%ORU$DP2\*,G=<"W:*J62+3 :M8CL%5;+P3[-PD6ZVM1E6>A_P (9_\
MP]S(_P#L==O_ 'IBIJ]2+'LFM#,* * \U_CF3N]#%CM_6\$_D=H2CYC--ELD
M=IUJ$0V96A3GAO<WK0H2,1E21KW:4(9)M_#:I(,J7M5<>^I ^8>2M!0H]1VU
M5H#&9%W V%_;566(E:"P% ]*HR45O)+WO>\Z?15D2,:D@* R$W'4>Z@"Q';0
M +F@ WH2 %]* Q<ZCZZ V"K#7LH!Q&4HJNDV-NRB YAK+,UEY/8H!7?K4IZD
M/H=XXD\7$)3?JF]=_IM(YY)',- )N;#7I6#1H1.."/GXP'7SF_KWBJ!]#T[.
M\*TI/4(3^055D2((U%Q5D5-7FUN:@7KES859'H<7DNC,-PU%DN :WKXSW#_9
MRQXGVG"Y/J5&R7RVO:JXUKGT9ZBM)(M. B]]*PL6@RL]U8M%Q%1MUK."\B2R
M*LBEALZH6]E7*214G;N-K6K6I#(UZP"JU1FR)? -ZV*2,E1=X(M<U5N"(,LX
MZZNE0[$;2<AXX;0+51V--HY=@A(M:J[@T0\N(+D6UK16*.I 9"&-I)&M;5L9
M.I77(?C.E;*QCM.T?ADB%OU>P;EK6:FZ^^([79PK3F7V_N.'W&O_ ./;[/WG
MO:OICY * * KO.[_ -$<K87/E#3^S34,'G-YQ9LTA)25?$KL JK+I#EAM"$[
M4$'O-2!6@"U :.N):25*N3V "Y- <_SS^7Y7(<P^.68,)"5&9+.BP@=0D=]9
M6L^B+05)O@&1X^Q^L.&R,ACYJ4%P(<?6^9"0;^8MI=TB_8!59@JT6'B_,O4=
MR0U$RV!&0C$#?-;4&' .\I.AJ5<07^'R;&2'$QI)7!FJT$>6/+4K][V'Z*T5
MTQ!,H4MVX;%FQH5'K]%7('*&TH2 ![^^@% .VA H$@V!H"\<;5;$-I/8M5A]
M-=F)_*<F1?,5;+-%>4EE1^[\PV36%NIM7H(H9L+)\/NTTJL$RQ9#:AUU'>*0
M)' ;[15DBLF0@G5(O[31HO(*;"=7% #LOH*HT%)LE (N#<'M%02!187H!-0
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MZ_'O\E__ 'G\$?9>WK_91OBY+SP^'P]!W5Y.##DN_E1KDA#Y<,/N#2]C7O\
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M^1C[RCHM@QV)K$\L?>4$38KD95[$.I-OH-?9<7WS'=?-HSQLW$CHRXQ7&9*
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M8OV:G6K21 &UO;VU4D05VVJR0%X[MQ:JM :YIRS1-49*92'B"XI0UO58+"=
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M2" *LBK&#J$WN!6R9FT-2@WMTJ0;);/9J*B21TANP'?56R5J+)0+:U$EH-@
M*@E(VJ"34JL;5)!E*KZU#Z 4!O5"P7%3 ,;A2!(;A4P#&ZD U*A4D2:[QWU,
M%=QC=4D&%=: Q0&A/=TJ03;7\FC]Z/S5ROJ="Z&]02% % % % % % % % %
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M6%;<7(=:KHCU+<ZEG-J)MF\3UK]&)BRVUP20MP"ZD1VU*('?9)I?V7W&O_\
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MKHCI42.&6Q;K7V55!X38X-AV58J!'=0#G#I/ZT:/L5_%-8Y?I-*=2UUQ'2%
M% 1N?1OP\M'>BWY14HAG.Q"[]?9:K;64W$I$P4PMKEI:(:0A1NHVN+:V%74)
ME7+0S5@Y4?'HFNM_<%(6% @D!70D=G6K:201/)L[C>,<1GYW-H4O%0PV9:4"
MZ]CCB6[@:$V*@:VI1W>U=2E[*JEBA;9CLMOPGG4,N(2ZTM#A*%(6-R2+]X-8
MN:Z/L73D:_TER+)V,N*?_<N(!_+5=Q.U%BQDO-9!H*$-N_;XBD_1>M-2KA#Y
M],QI-Y,!PH[T!+H_)425@8*DX0KVO!#3G:'$EL_E H2/&4XU8^Z:;6.Q3:A^
MQ4D#V._$8/P*0GOM<59V(B23&1BJ:VMO)W'0 G::R@T>AYQ_$%D!@\TG+1CY
MS[T%,5*-%H20I2B+>VXO7C<ZDY4_+^)]/[3><%E_2Y_ X=D\&PSQW'3)Q0YE
MG_+4XA*4C8E0-KV'Q&U_8*SKD:LZHTSXDTG!>,0A#>,991X4A /UZUY=KZRS
MU<>.$C2;$=1&6^P/O02K;;K73B<F.70BL+R]F)+!GMKC[24BZ2H7'M%>E7"V
MI1Y]N2EI8>9+.QLU*$6'9V.H[I2[:!*?A00?TCK[JSRULNO4TI=/IT+' CE$
M8REFR +"W:3TJE.IM9Z#"?C<G,=8$#)JC)N5G8FZ;VL*[%=56J.5X[6Z,M6#
MG9#&_K3CS/EY*3&D1-C[8/F.$J\:=H[B;7K['C<6JQ5NWME,^!]QY]EG=*I6
MU7^IZ6C-%B)%:6G:XAAM*QULJVHO7@3JV>H^FHHKX:DA&E"&:*.MNRKHJS6@
M-DJ&@[:AH)BR5]!:J-&J8J.E028('TU)$&I%20%@.E % 8)L/;0"9-]34E3!
M( O0&NX5(,%5]*$F* * V2>R@!1[* UH#55 3[/\DW^]'YJY6;HWJ"0H H H
M H H H H H H H H H H H H H H"N<@-IC=O[V/XRJ[L'T_:>=R5\WV$5>N
M@YT@*M-:AET5'EJ77'&"WTN;WKY;WCBK,ZSV/5XEMJ9#,Q9"AV5X*]LJ=OJC
MYB%(5U4*T7MU"/5'S<)5KDU=>WT*^JQRB*;6)K5<"G@1ZK-Q$OT)J_Z*G@1Z
MC,_*:=2:NN)1=AZC,_*HMJ#>K+C578C>8,1ON-2^/7P&\T,-NK>A3P(W,T,-
ML:D5*PU78;F:JC-I0LI%CM58^VQM6JI5=AN9XDYED53#,8D'^>LR'4.H'719
MM7LQ%$<+^HY+-OO-^WK[JQ-D1CY3XNS4@>[WU=,$9*)2#<6%NZK$$0[<'O%_
MIJ"38 "RM->MC0@=-:C0 GL[:D@7N-ENZP ZFK(@9R-Y%QIUO_Y>VK BU@]>
MS7W_ %5!(D 4G<3<VO\ _14%@1N-E:D7Z=EJLBHLW8 7-[:=EZD$BV?"!X2.
MW36J,%@P.T24W/;IV5-5J'T/7GH(67)S# 4"XU9Q:.T C2O?Q/Y#Y[E+YT=)
MAN^8SR*:KME% /OTK==#S[=61N-C.A9*@4@GPGV5HUH9*VI?L<X3&.MEMV%N
MV_6N2U89Z6.Z:D?H4"MP#X0M+B!W!P:_EJAJV*!(3X.MMP_VUZDB1)+UW71U
M2DIU]MC4P4G45#NX$#6U07DRDWO[* 2>.E712Q'/J OKT%:51SV9%IE*9GLB
M]VW00H>ZME5M',\FVR8Q@R$2URR/Y>-)6DCO0>AKMVZ(\2U];+Q97N9+DS>0
MX: UXFF2'75'H$D_GK;!5:LXN;DML2\TCK/I"^'>1Y!";;41"/\ UJ*\?WA?
M[2?_ '?P9[W^-Y)Y%J^%/XH[-7RA^AA0!0'FW\<=_P"H]5NOZW@_F=JU>I#/
MFTE!MI6AF(24D:]E ,TKUL>EZE 6)%KT8,MD;JJ!ZDZ:U(([(J 1[]*$HKJS
M=U5JJ6-2.P_^1J!("][FQ[-:$,VZ:@6J085<:Z=.G90E&FEO;4$F* U[ZJ09
M&M ;(0M2@EM.]Q1"4('4J4; ?234-P2>TO2?T^D\?XOC.*1FPG.YC;/S3W:V
MT3?:?=T K\J]W]RK;+;/9_)CTKYL^DXN#9C5/YKZOX>!8>6XOD/'N1RQ(SQC
MIS#"8N,AHN@(*?#9  \2M0;5P>W<CC\O!6U:;E1RV;Y%:EG+B5")=/%^1\<P
M6)E9F0G(.1+M3)%O$IMSH3[!>U<E?<./R<UZ8_E;Z?%%]EJ5JWKM/'/JMQ;^
MB7/,I"91MQ\X_/03;0H=U4![C7Z][+R_U'%K9]5H_L/FN7BV96ET[%5Q+ODY
M)E?2Y*;UZ]CEJ>DHBP>,X"1?4-CZ@Z:)Z%#HF0FI$DGL50J3F/<#C"2.T5=$
M&T@601[Z YUQ'8<])6HWLXM/UFOC??HAGN^WN#N4)425'2A12; #;<7TK\@S
M[Z6<'TE5*&>6QT>/'<>:>VN[?"@G6YK7C<B][)-!U*;QKBX7FA/D&[E[D^ZO
M=YO,C%M1ACQK=+.GWL D= +5\=!V&BE59(&BE5: -W5UM5$"14*T@"*[[AK6
MB(!:]=**H&SCEP;"MJU(+/Q;CSDE:9+R" >E?4^R^UOD9%:WTKH>=R^2L==#
MJF,@IC-BV@Z6K]?X^%8Z0CX_)D=G)*^ZNE(P-*D&1<]M /\ $#_G!H^Q7\4U
MEE^DOCZEFKA.H* * 99=KSL;(:!L5)M?Z15JJ61;H5!.)> &QXV[CK6^TPD<
MN3,NQ%6UYP+6Q0N4@D7%NM-JZC<5?/3.63\;@V\<ZE$!F4V<NG1*G8B 1M'?
MK;2K45==WV%;;M-I6O52%)RWI5R3%PV529LQA#,=E NI3BGT!-A77PX]:K?[
M:&>=[:2B[X/B"\=QC"X_)J+\Z%!C1WU7O=QML!5K>W2L,MJY,EFNC;&-.E4O
M(DH>#Q!T4D;NMNZL75(T5FRP0XD>,D!KH.E5;<%TIU%WK^7IT]E15^)-O(K^
M10EPD.(2L=R@%?GK8R1$IQ6/7<F.E-_T+H_-:H@F1VU@F%)^[D2&3V!+FX?4
MH&CJ%9F7,!*1=?SH?VC[M+Z /$=;DH[A5(9;<<4]6^'Y)SC63SDWRD(A.)4\
MI#FY"VY;B&[*21?0D6L:\SEX6HN^Q[/M_)5=V/\ J2./9/%MM-&.E2R5.%4<
M+6'"$I7MVIMKM'07KPJ9);9]1FQ0D3:5KC-M-FQ58"PZ#2LVI+UT1,Q7DN(\
MMQ *3;2NFJ@ROJ!P&*=WR7$! 2"IQ0TT2+UVX\CJCARX58A8V-C,%;S12'I"
M@XM1 &T >$?V(JM\KMU-*X57H3+\/(3^+.2\$GS&HJT_,+-S<J)'9TO:UZZ.
M.IEOL8\BT0EU[$MZ.*R60Y(<=F8!(?C+82ZT4K;;!(6LK2=1X19)[Z]!4INT
MU/.RYKK'KI#.\\>X;Q_B\C)3<1'VS<B\IUY]SQ+2%G=Y:+_"D'7VUZ>3/?)6
MM;/2JZ'R^/#2M[7JOFL]66]W0I]B$_FKCJM#KL)E5Q:KE#0U))HKK4E68H &
MAO4D"J3<BJ,NA<&J&A@]:D@Q4D&N\4!@J]E"K-2;U(-%*[C4@UN:$A0!0&+U
M)# &] 9J"0J2K,$T81HHGH*J6+"S_)-_O1^:N9G0C>H 4 4 4 4 4 4 4 4
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M^4?^(^VM_0>@O<<_B93^)SUF (^98([?N"/V:H_\0]M_H++W+/XF3^)_UB(
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MH U/7I4%@%0$85TJMBZ+ U_)(_>C\U<YJ;T 4 4 4 4 4 4 4 4 4 4 4 4
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M(=%*-=.FK/(3<U7>/E7CXMCEMEQYP16]5#52NP)'4U1W24FU:.UMJU?<D $
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M^FM,K^8RPI;3O/X<GV,]#R<A3ZI<EY#;KSKA)<4O8 22JY-SVU>CEZ&=EH=
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M4L@@)'[\DUWXZ5:^>WV(J^%==$I\RCS_ %'R/(I")><EJG202E)=(V(3^BA
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MU#8@5;1KKV]E5; Y2 !I0DU6NPHB)%\2;Y%JW2ROXIJF3Z67Q]2S5Q'4% %
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MUXF5_3]D_N5:U^3>X>SY^':+KY?ZNQ]=Q^7CS+1Z^!#D^VO&@[36]"#&X5,
MU)J2#0JJR VE(\QO::VQVAD-%>BXD*S495C\>E?0\'D[,E7YG-GINHT>HN*I
MVX]I(_1'YJ_7,-IJF?$Y5#+$!<7UK?J8BZ&NA(TJL@52D :4D@2<(&G;4H,0
M4J_2I($B;=:E: =X0@Y)GW+_ (IK++])KCZEMKB.D* * I_JGB\EFN!9C%XA
ML.Y"0EE+*%+#:3:0VI5U*L -H-ZM5PY(?0\>9[\*;_*N5S.3<BY4SC?/:3'1
M#Q<=4Y\)2225..%I"3W6O75D:LY,:)Q!;\/^&CTDBI=&1<S&63)9;8ELNOHB
ML.!KX;ML)N/;XJS=59RR^IT3BOIIZ5<1:;9X]Q&#'#2@M"WD&2YO_2)?*]?H
MJRK5$0V=$9G(<2$"R1T"$>$ #I8#2KIE(-Y#;K@):<%NQ*KC7WBC(&8;"W%,
MRQ:_4$!2%'VBK5<$-20'(,!#4R9,5L)2G5SR]+'I<#LJ]7!#15\1/<CY96(E
M*W"0V5QG#]H)ZW]HZUK9:21*+3CU7)(-G$**%I/8>E9M%DRLYU"W<#*C'4%8
M4F_8I))3;Z:M4J]-1'C4\SL4DK/W[!+3OO'0_2*NT4[DZT_L\MP)*TA5EH'4
MH/7ZC6-DS9,G4L(4A*TI4$'H3IU[ZH)-E^6TA25N(0D==ZTBWUFI((3/<5XS
MRZ)\CF"E[R0IS'O(=+:T+4+J2E:3;:NWUZUQ\CCURU2?5=SNXW*O@LW7N4"3
MZ-\-AM_-3(4N6S'(>+,QY3L<%O4%: D;@#KKI7E/@TJYAGJ_W+)?243_ !J&
MTZ[&=;3I+NXE8%DI3?P^X5W8,:C1'+FRN'+$O63@K?,,#\C*:2IWR%H9"AXD
MR4ZHZ] K;MM[:TY%):L<W%O"=3QYP^!D>$YI,A#9<P3SA3/CJ!*6E$6*U)_0
MM_* >_J*\;E\?<MRZGM<7,JO:^C/5_I9ZC+Y7C7 VOR,KB-L'*0]UW4!L[6E
MJ_220!XAUT/;73PN7:RV7^I='Y'-S.*JMVJM'U7F=-B921-W-7NH%*FG" H-
MN6L5:]--":]FC39XV2B2%B_B<A&D8/)I:GPWDD.QI2$2&E$_I)<"DG6MG5=S
M!SV.7X;T+XWQCU1PW-^!0V,5"3'FQL_C/.6&O-?2/)=CI<*K7-PXC=IH16+K
M#DTF5#.NNLOLK#3C:@X>@ O<=XMUJQF:*2ZD[5-K"NT;3>I RR+9=B.-.H5Y
M>A(*3;0W%%U$%&?S4;"Y8,I0VXSM\M_S'T(42?%?8KI7955:U<,I96[(9->I
M42;ED8Q,%^%YRBD/>:TI*0 2GPI.[6U:6PK;I9-^!3=:NK6GB6.&K-QY@==:
M5)2ZI*@^U98*5=JR#:PKQZMIG<X:+Q!D(=0%)5=75?L/=6]7)A;0D@J^O4&D
ME3-^V@(7D2C^JI1_<?LU\?\ Y5;_ / R_!?O/9]L4Y:G-7'MC6^Q4>@2.I/8
M*_!^-@]3)M/L&])%<;CLL]N=>:LZYJ&TJ!VCVF_6O8R>R\N[2Q8K/S@YOU.-
M+6R)4<?S+G1BP]JDC]FNG%_B7N>3_P!J/BU^9A;W'CU_F%1Q3+*3J6DG]$KU
M_(*]"O\ @_N+4Q7_ .(Q_NW'\7]P@OBV73_<VU>YQ(_/6%O\/]QIUJOO-:^Y
MX+=&_N&CO',TDD"/N_>K0?V:Y[?XWSZ?R3\&C>O-PON-4\?ROSC*I$%Q4?7S
M;65H1;4 U[OL/M?(P<JM\N.RK7]YS\OD4OB=:V4B^&XGA.-,N,X3$F"RMQ3[
MH0V;J6HW)43<U^E^XKC\JU<N9;K8^FG0^;P5R8_EJ]&1[^-@2''5RF X5J)(
M4+7]XK\ Y?,N\U[5?=GV^&:T2\AJG 81!44PFKD@].WV5S_K<_>S+NS8_ V@
M) T&@]U<EM62>B<5_P!%PO\ @[7\05_2_!__ %\?_A7]R/@,WUV^+'==ID%
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MVBJ@-@[J@&-HH(#8.^] 3?#V$HRC[H "BP0;?OTU2#6K+M0N% % >>_QF?\
M<RK_ +5A?F<KVO9__P!C[&8YOI/GJDV%?<G""+><@]MZ\GW3_@L;8?J0O(/F
M"UJ_.CUR.\QIJ0GS@-I&EZ^K]BO6NZ3BY*EH6<3"DBQL;U];;T[GGK=4;KX]
MCY U0FQK&W!Q7[(OZK1$SN&1BE2F;I)Z;=-?HKS<_L^-]#2F4N?H-QG)N<PG
MIAAAQQN.@E,I(4@IWD$#<"+ZUAP.,N/:[MT@X?<G>U:[(F>_@>K^28>4K.0\
M;)X_#&%=9;#GR3384I=M5$!-P:WQ9*[6U;YO,X;[]R37R^17.3>GWI2<XWAI
MG%HT<SE)4B;("PLJM8W( T'LK!\9Y$[Z-FWK5QM*']YS+D/X:?3V1GW\;@^4
M+B3W'@EN, DPF@OX4H4H%1U[ZXG[:W7=#2.A<]3ME-H@LS^$O)XE]R CF6.=
MR3>IB>4M7@MH=S=Q7(N"W64;_JGNAI"GIE^%7D^5Y6I?.D?(<0QCR5%]D@N9
M(H(*4L)6+I;/VUK'30:U3%PWNE]$9Y^8HVUZO\#VP8[.,B)L$I:90@,LMFR4
MM((3H-.@KV-TL\;;"*ARSU!Q/'V7')3XLTZEMQ*2"0IT]"!KVC6MZXN[,K7@
MHK'JG ;R+PGH=A1'-[T-V0DH4LNE.]M*3K<@&U:^F0[+Q'RO5/#+::#TA")*
MT)4ZE1V[5+!)3K;4=#40EU-%KT(N3ZIXG<&42F@\]9#"EN!*5+[!?]FBR50=
M&QE%Y<Z_-0EP*\P.!*6%_%NMXF%=AW#5I7;TKKJDT<#F2\P)/G,M38JR'&[;
M'4GXVU#K;O'=6=DBU2"YMEWY[V(EA*X4;'ID,RD)%DJ,Q)8+B#<W1:QN:G#A
MJZV3Z]C/-FM2]77IW_@2+4]J!Q29,= #R6D*4MHGQK*P'"Z#I\84I*1[Z\[W
M"SKB\>QZ7MM5?D*-._V'7_25Y,CAD;(6UGNO/7ZW2E6Q)_VM?.8U"/JLCEEZ
M21WUHS,W2X0;=E1!,&KCF]UML$:FZA?6P]E59*'+\H-H3Y9'F.D):2>U1]GL
MJ D0./QT>!F\L]JJ;/0R^X\>JPFZ#;NL;5G2BK=OQ-K7=L:7AH2Z$]YZ5NT8
MF5*%K V- (J=MIU]U$2""3J:D@W)(T%59)D7'4WJ"),^6#KT-6F"'J+-)2DC
MOJ"!T@:7[ZH$)NJ[NSK5D&-5KU/6K(AB9JR*B:CI;MJ21NZY;3\]5;+(C);^
MT$DUE:QK6IMQ):E\FBD]-KI_]6JN:QN=1J@"@"@&.8M^K)-^FW]D5>G4K;H4
M5UTG1(-NGOKI,B(EL ?>@;3TJK1HF-$3U-*VI)-M":$P/6\DNUPKZ*F2NT=(
MS)2 '->ZW6CL-A*P<HPZ?$2DD=M2F4M6!ZJ8U_<E;E=@&M2R@BM]\FVP[>\5
M$LF$;)=V]5W5U))O]5)0,^<H]#TH#0O*[S4HAD9F^4X+C$!W*\BR+..QS !>
MD2%[4)!(2+^\FPJTB&RCPOQ%^DV26I$#D,-20HH"G7/)"BGJ4E82"*B46VM#
M/DN>X_R7)1\C@<I#R*51D^<B(^V^IHH44C>$$[0;Z;JVH]#.Q$9:>]BL>GD,
M5H/OXE0D.,="M@^%U(/9X3?Z*NY9-3H$?*0>1X2!E<6[YL!X>:WV*U%BE0[T
MG0UFT6B"(R,;8L.)T"]?I[11,L:,,>8TXU]AQ/\ MDZBH;(-(\)O<%J.J/R^
MRHMT+IP4'G6)SF7R[;>*$5$1#9$B1)*EK2HFVU+2.\=I->?GK.B.W#>#E#N!
MFX#/XZ4Z^)+,L!+I2V&]I0I3=K"]]$]37S66KI>MCW<5U:MJG:L' #ST E-X
M\)&^X%QYB[V)^@U]%B4PSR;M(DVTLQ5/O(T;N=I':/96R42S)B&*D(^9E3I6
MCRTI".TJ3?X1W 5'F39%B@S$M1W99UF2%>6T>@0TCK;WG05JF8M$AQ]Y]M3K
M"!8JNOVE1( ^H5%5X&=QIZE9;+8O!PL=B$*>GY>=&@.N(^)F.\NSKH';M'Y*
MM92TO%J?@9UT5GX)P:P4-0(28D1)2SM^]>=N7G%=I4H?L_57N96W9R?.X:*M
M5'Q8PGNL%I<=3K$9]RWDN.#9JDW 2X/ "?W0'OJ-SK#+NJLFAMB^92\1G6H4
MC<$RC9QEPDIWA)-T*/>1:Q[ZY.<]M:7\X?\  [?;5OO?'Y*R_BCJ[$]EUM#J
M%60Y:P/837(M3L?466JXT-4:%2L\U05\>EH W%2>GN%?'_Y#CW\=+_O1[WME
MHS(XNK&2#QQ?E,@NV!W]%$;K_D%?G'*JJ9]>A]LLDDO&.S%M-=J"$_D&E3_C
MN/=[K1OS9Y?N3C%?X$W$(V ?4*_>4Y/@F/DWJ2IL#:D$FU"#.XT ;[A0)VBQ
MU]P-0^A->I%X8927):1N6(ZMVXKMHM*;C0ZZFLJ2=&7;V)!EZ6&PE]!\P:%0
MZ'VBIDQ%0X3VFIED'=<;_P!'1/\  M_Q!7*^IL.J@!0!0!0!0!0!0!0!0!0!
M0!0!0!0!0!0!0!0%3Y1_I[?^!3_&56M>AC?J0FE6,X-#UH($U=:D@Q0&IZT!
MBA!@V^FK(@T)UL>E711G-?47U"5AO-P.#7?)$;9<J^C 4/A3^[L;^RN[C<;U
M/FM])CES;-%]7[CA;[RBLK65.+4;J6KXE*.I))UUKVGH><NI8N!\$R?/<GY#
M'\WQC95\W,5=* E.I 5^<UC?)7&MUNGAW8>ZSVTZ]YZ+S9V!65XYZ>158K@S
M37SYNF3FI!%RH:'RMVHMV=IJ]./;/KETKVJOX^)YF3E+&XP_-?O=_P / YYD
M,Y,R4M;SCQD/.$_SEY1U4>T ]*]BF.M%"4(\>]K6>YN0QG'\]R%U8BH"FVT[
MI$Z4KRXC"1IO6XK2WL&I[*C)FQXE-G]BZLK3'DRN**7W;^E?'\NI*XY7#H3_
M )&#QDGGV8VD*>2DL89A?MMJX+CJLBN:UL]];-8:_P#S/\C2.-1[4GR+6[+_
M (_MCM\=2?=R/-LD@QLGFFL;"""W^IL&E++;0MVNM6W'WFN58<%/F5=[\;:_
M@SM>?DY%M;].OA32/M0OC\' AD+::^^ZJ>6=[BCWE2KF]9VS7:U-*8:5<KJ3
M+:" %!5U#IO\6GTUS[OV1U.J?9"[4.!,)9R;DD1R05",H)N?<:VKENOI2GS.
M6^"EOJ;2\H$58[TEANK;E,3G)"?$X% 7)5KV?L5NK\^RFKJ>7?%[/1M7WSW-
M)N)]/4X[(Y#CF.?C99$5?DR'+A-E*2DZ=+ZUE;)RY2RV34]COXF#VY6W<?&U
M:)U&SLJ%D\U R)84K%P,<8_DJLE2G5H\LC32UR365<-DF_YMTGJY^12-CUJZ
MBD5*&[(:;2AM.B$I%@!W"U6RW=NK./CXJX]*I02*1VUR-G:JZ@ZA+C:FG$A:
M"-4J 4#?V&E,KI:4R<F"F2L64E+FX!F#)^=PJ9<-Y.JCBW%LN ]A(1I;Z*][
M#R/7JZY$G_Y=#X[D\2W#NK8-R7A3K^ WD>HN9;C)AYQ,3E6+;\+\?/QDHDI2
M5:[7;)-QWU=>V8Y;QNV.W_:]/N*?WO,ZI9JURT__ ,E8?W^/V%;EP/2WDTAU
MK$3G^"9]8NJ-+!?QCQ3TLZ!N0#U%P:GU.5A4W2RU\5I;[NYU4Q<+.VJ-X;?T
MO6GWZQ)7,G@^4<&4RG-1$C'.!2HF0CK$B#*:.MVW$>#<>SH:[,7)IG7R.?%/
M1K[SSLW"OQG_ +M=J[1JK?=I]\$QQWG&5PKZ'L1*=@*"M6[E;.X]4J23UL;F
MJYL%,JBZDC!GRX;;L+C\_!KQ\3H+V5X/ZF0Q YS 8BY)9*&<S$ "-W0*) !2
M:\7)Q,F'7&]U?!]?L/H\'N6/)IF2I9_S+Z?M\#D_/_23,<$>$QB^2XZ[XF<B
MT-_EI/3S-NEC^E5,6=73[1V/5R8X:TZ_=]Y5<//R6%G,Y7"3'(4]HW1(9-B1
MW*'0@]QJV3;>L64HBBO2TU<,]%>GGJO$Y06\/FPB#R'HVI.C$FPZIO\ "L_H
M?57@<CCO'JM4>WASK)Y,Z=7$SL"H!D5!9!562&G=0&#TH#455@QM'UT ;14$
MD_Q,6G/?X(_QDU#+T+?4&@4 4!Y\_&9_W-*_[5A_F<KVO9__ -C[&8YOI/GD
MDU]PCA9LB_FH(ZWMI7D^Z_\ Z]C;!]:+:QP7/2X7S[;8# 3NZ&]J^$KQ[-2>
MD\BF"@YQKY=_R7C9Q%TGW]:];VMPVC#,^A%"2&^BJ^A60YAVUE@W:ZORUO7D
MP5=4QP<R%IL#<] *U_5R0J':OPU?(_TJRCN4?:CDQV0@O+2V"%."Y\1&@KSN
M9F5:2WU8>/U&DO,]:Y&#CI?(6TPW6WW&PV%%EP+([KV)KR:9'!2U%U,9C )D
M<@B-R6VW]JA9+Z;[1[.ZKX\VU.)2*6Q2UT9 Y'@N'=Y0M;F(8V>:E2"VHI5?
MOO753F658W,Y;<6K>[:A>-Z;XF5R1WD$EMU"([FUB.'/NWE)&I6.Q*>X=36G
MZR_IJL]3GM@IO;6A:9B&V"M+7B?59*B.H*] %_1656WU,K)+1'-N=<P;Q<%]
M#:B,F\EUG'LW!4IQ2-J21?1(MN)[J[\6(X[W:.0JE(9R_P"N,P43N1N0TJ7*
M(VH04D-I*6NFX)%@LC<:[GB2.6MV]"I?(9;GN3EQV7!&A1C>9DG!N2W?^YH_
M2>[>Y/4UCD>[Y>GF;X_DFVC\C2;P7)G;CG IUA"V8K,J0DNAQU^X0EP_%[/,
M&H]M:^FG7;X(KZL/=X_O([+^BF9AIM%0%FVYR(Y;>TKM"5IN#KT4-#7+;B5L
MIJS:O,?2R'.+Q_)\.U\GF$W#( B/K-R$]C3NM]I^PK[)Z&M<=+5T9EDLGJBV
MM^ILC#0[+LXXXD!3)4%*\P=H*1U/;?W]]5R9:UU9I3$[:#" .;YO(M9AP)@M
M!+B$2YP*WEQGP=S9:MXM3="]+5YMO<G1Z([Z^V5NM7!;V7.7P>,38ICMYIAI
M-T/,)'F[476KYAE1!6"!LNV;ZU;)R\/)KMM\K9GAX>7C7WU>Y+[STSZ<QQ"X
M'QN.W'5%9,!IP,+45J;+UW-I40";;NVO!C;H?1MSJ6UM>W0T"%%O(2FZCK[*
MF1 GC!YQ<F %2"=J#?L';:J+J2]#1F:F3F)30MY<)M"?;YCVI^I(J%J_@2]%
M\1OFY*<?DL1/)LR\M<)X]EGDW03[E"J7<-,TQK=5H?J>6DV KH,%T-+DZGK2
M"P $G2JP!?NJQ!L-I-S56A)HMP)-1!#8BJ4F_6KP1([9>W6-0T0/D*&VLP-G
M56O<U-42V-UJ%Q6D%37<*E(@26L >VH;+)$?(61J36=F72(F2HKN+UDU)JG!
M)\0;"<_&5]K:Y?\ Q:JI9:%DY9TZL2X4 4!'YL@8J23TVC\XJU>I%NA2DH0M
M/6]=1@(2(I(N #4DD!+94E1"@!^2J,TJ1JE.-J\5[5!HC"9-KDW [Z%D91DG
M&%>8%$I&A%)#K):XLA*&6W' 4NN@$H/5(/37L)JQS-#\/&R0GMZWZCV4944"
MD@ J-( F[+"0=N@';5D((V7EFVDJUW*[O:>ZH=H)VR>(_P 1'JD[S;D']"L*
MZ7<#B'29SJ?$W)GIN#<CJAGHGO5<U;:X++0XZZBT4J2VVXII!2DFQ /0V)[N
MM&DRC;&F%=GMY5C]4OKAO)*7'GF5%%T-*"[+M8%-TWLJLZ*;)%K.$?0GC!8Y
M3AX\[(/,QYV5C!Z7CF62AI"7DBX )[M3[ZY\7.]3(Z56YR=F7A^EC5[/:H'_
M  /BR>&X^3C79R\@QYBGBI +;3;=R$I2E6I41;<>E>XL$J6?.Y.<]T5Z(L,A
MB-D8)?QJE28]R"HI(4E:>SV^^N>^*U'J=>'/6ZT(1A]2$VZ;%6UZ@]HJC.J1
M20Z64O.)3X0E3@ Z70DFWTU5II!.=#G<5M$9_'\F,]3)R45M_+"0LK9D^<I6
MU*&@"I+C6FQ21:UP:Y(2K+[G35N8&/+X"/U(Q+;3YKD9:%A*05*VN/B]K:]%
M5X_*PNU(1Z>#-MM++WCX.33># B/O-EM 6M+2P-UKD7MV=*]7&H4>1R7M5OJ
M2D'A_(9)+DN$MIDZ-M.;6].\W-:I&;RU7<UG<'RD1M3X<CM(3U2IS<H ^P T
M=2OKU*[R/+/<9B,/JA.S8*1Y;JXQ!<0H=I0JUP?8:SLVBR:L:\']4N-YS/Q\
M3&DJ1/>0M+462VIEPE W$"XL56&@OK2EY<$9*162\Y1UIZ:'GC=;(*6Q:UK]
M3]5>EBKW/(S/<MHRD. M%93<6T'3IW"M]QAM*S-$=\D$J8W:*[4'WI.AK2EX
M<F=Z;E!"2$-L+9@25;8ZG4E@ZJ2V004E!ZVOV7TZ=*CD463#9,MQKO%GJUTZ
M'2(\'D&0Q;\/ .-+R"4MA2GU>4R$[Q<[M;K('A KR:150SVLL6<ERQK62:A-
MMY9H(F@?>;#O23["*T;39S(1RD7YB(XT38*MK7A>ZXM^'X,]'B7VV.6<@QB$
M(>:2ZIE+:DJ!2.I[1;N-?EWN"BRT1]=@Y&B(N2PY "$.+WI>4EQK2UDJ T/T
MBI_Q:,GN*T^E6DR]SO.!M$G%?2 #V5^UH^)9(-NWUJY L%"_MJ2#=)[2*$29
MM?45!$FFU158#Z*N@/<8H_-%:K_=MN+O[DFJ-%C"YZ4Q$1FF$I*CN??-U*6!
MT _1K%="T#,*).HZUJD5.\XW_HZ'_@&_X@KB?4W0ZJ"0H H H H H H H H
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M3 DAJ0EU%T*2+C4]E54@O'%4H=C<K<<&XLX<;">Q3DAM-Z^:]\O;_:7C?_\
MI9[GM54UF?A3_P#J1:_3R5D\'A\_R+"Y.5"R+(:9:4TZL '>/$03J1TKY_)R
M+KD5QIPG+/I.+Q:+B9,L)OZ=5^)U;AOJWZDX4(R^=D-<C;>6EQMF5N^9Z= M
M)  MU%:OWEX[VQK7QG^!O_\ QRN3%7)?Y96FW_\ J+E@?7?/S<S%DYSC2'%R
M7U*98@K4E:$(238^:%!7T5Z./WFEU95KT2[GE9/\9O1)N_5O2"S8OU]XIE6$
MB7&RG'YK[BT_*2X#[BR0K:/+>;3Y:MWT$5]76-)/S[+Q\JLU'VE9Y5ZQ1"MW
M"89YK'.-.%MQ<@DR X=%$#7Q>TFK^O2KT^9_@57"O:OS:+\3@1RLS(\RF9F1
M,<F1&5*;@E1\'E'JNQM\=OJKU.->UFK6^P\SE454ZU70L#&&R_,\^]C,0E:&
MRED39:+E3#8%[)/3>HD@ ^^N_*]J/-QUD[]Q[@>+XYCDHFLH2B.FS4<&Z1VE
M2CU4LGXE=]>;;([:(]"M%52R-8@Y7D^397B6$PL+"D[Y$]U-MQ3X3\L+'<NW
MPK/A3KVUT7LJ4U>K1QU3O?1:22O*'\5$9?>D!+.A^\2K8M*NNX&Q[?KJF*8-
MLE4GH<:F9+)\H<4G#(1(BL+\E[(3&]C6W[0;6V;KO^A:M[9$NA.'!:_5=QEC
M>*8O#S?/:;\^:ZN[LET GK>R4]$@5P7JH;/<QXU6$BY+3J23<D#\U?,V?S'I
M56A9N-P'\A$>@1$[I,M09:'9N785HGH5[G>E9*%CF&XR5A7D-MLV3V^6@)/Y
MJH729AO,LNBX-CV"QUJ)+)",C*M/)+2"4OGPI21KKI>H;+06!MQC'00M1#2&
M4%3BU&R0E N5$]G?4N$I*1+@J>'=>:AOYF45"1EY*Y20H6(8/A9%N[:+_35,
M::3GN;Y(;278?<R2J3Q-<A!^\C^5)01WMK%_R&HS+Y)*\=QD@DL9,&0Q\:8"
M"7&TE5NFX#6MJ6FJ92ZVV:'(N385,E1="=HZZU)!A2[:]E1($UO6'MJ2LC"1
M+ O8]*) :-ON.KL!H>VKH$W#2JP)UJK('Q60!5( V>=ZU9(AB*72HU(@V4K2
MXH!F^]87K-LO5$:^Z3VUFV:)#4IN231!DUQ-%L]'/>'+?XM54NM":]3I%<YL
M% % 0G+WC'XWD'QU0V#_ +85->HB3F..Y8QX4/%/M-=*92U&NA88F6QTL )=
M2E9Z)) _/6DHSVM!-B1WTDI<0%']T+'ZJAH*2%=QBRH@J;V^U:?VZHT;*PS<
MQ-_[NPFWZ3@_8HD3O&OZNAQW4NOR67$-^)3*%*)5;LO85#+*S8_9RFY>XD*'
MV3I<=G<*HK%74>LR!:X7?WU=,HZBQ>!!\5AVU8H-GY2647W[QUUH3!PCU^]5
M/Z&\:7#QSZ&N2YG?%QJ$JLM"+'S71[0GPI]IHGJ2UH>.V'&L?%*PO=(4D_>'
MX]ZM0=";F^IO70[PCGVMLBE+LD[CVDGVGM_+7))ND6CBV-EO.1,;#8+V<SSH
M:8:L/#'!LHDGI?I]=196VQ7ZK:(M5TW;KOY::L]N8=,7B\!IMQX9#((8;;>>
M!*472D ^6.Z^ESJ:]KVWV6O&^:?F??LCYGW;_(;<OY$HQKMW?F(Y_E$XOLX1
MM[:Y*2E<IU6FQ"S9( '4V[*]F*5U2/&IZEG#9><7EFL9CVVF'$IB0TGS5W.B
M4VUO^D2.E>5DKN;;/<QVVI)$VTQ@^3>7*0X6)KB-RTI(0EP=1<6^*N"]6NG0
M]7'DT@=C 0 X$K96M:=2E:C^6UJHS7<,#@^#XMN.T[#Q[ A)V1?F%(*FD[]^
MGF*)^+6LW5=RV]MBO],^)Q#Y;4QA2Q?PQ65.?44(M^6HFI#K9FCOJ)&OMCP,
MA)TT4OR8K=N_<^Z-/HJ&Y[#814SU18:20X]A<<OM7D<H';'VIC-G^-4*?""=
MA7\AZEX5]IP3N?<>AM*T*(;9D+/N4^Y?_:U5R^Y95CL5K)<O]*'X_DY?U(2\
MRZ-JT,26HZ".ME!E!-4=?%FB;78YOFVOPZ>8C)PN;,LY*(M,AAYYYZ1M<:.X
M$:#H1W5B\2[,V65]T=WP\U_)1H\[(/)D/R6D/+>0CRDN^8D*W!'V000;5[:3
M54CQ+6^9DN^MLLD)3TZWJL$S)5LFAMQ( -KJZ]!^6U:)25;@@VT!.:9^;=;;
MQB%A3DA]5F&@D7+BU:@) U5[*B\JC+X[+>F=VXA-X6<+&AX_/XO+J5=UQ^/(
M9=2M1Z$64=$C05Y'S=3U;ZLM 9C.I'RZT*0>@0H*'=I8G2IW,RV]Q!W'**;[
M"/9:K[D^I1IHB,AA6719^*V[V'S&TF_Y*PR\/CYOKI5_87KGR4Z6:*_.X=@I
MG^DP G:=%-+6W;W6)KGX_M'#X^3U,6-5MXHZ+<W->NVUI1'+X-B+?S9^2Q_9
M)<3_ +8"O629R[Q%?#74C[C(H-NQULI/UI)J($B*^-9EH6;\EX=Z%V/^V H0
M(G$9L+"%0UZZ7!%K^^]))@3=BS8MS(86A"?B6=0/JJ6Q!%Y!EF>RAIQ]3/E/
M-OA;9VJW,JW $]Q[:)HF&BV,*Q:< [+#03DW$F[@4;%*U6.E4NG!"ZD IQ-M
M=!WUG4T:,A8-B#H:U11Z'>\;_P!'0_\  -_Q!7"^INAU4$A0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0%2Y2;3VO\"G^,JM*]#&_4@MQJYF!-Z"#%"#!(%6!
MF@,%/=0"9%^M6(.:>M#CC> @M)(#;LDE8_>)N"?KKT. IR_8<?+?^W]J."O*
M*@;Z7/=7ML\ZIT_TTB,Q<&J8&P),U9*W+>(MH.U*;]U6VN$>/R\LY&O O!*%
M=3M':#5-3#1Z":VV7T[5H2M(T&\ _GK2MFC"]$RL\AX>YF6X>.@R_P!6P4/K
M?FK NK8L>,H]M@ !77CO76S4N-#D=LE76E=*S+_T(+)9F/'@N\9XQYF+PB"4
M/R4W$F01\;CKANKQ'I:M\?';:M?5F63F5VNN/1=V-^/X/&?-%V;D76B$!3+2
MO"AQ)Z*LFZK_ +ZM\EK):+XLXULLVK6VZ2E_'36/B76*MQEP-N)VCL5M*01V
M$ UQ9J)J4;<+-:EMME^!88IND6Z#I7D7/JL;T)!KQ"L6S>HKMU%4DV@E<5DY
M6,>#\5>U7PJ0=4J'<:C)C62L,G'DMBONK]Q;$<BQ.7:1&R[1:"5I<L?$T5HU
M%_9?LKS'Q<F-S5R>O3F8\JBZ@2YS(@SL,TAEU#KOFI6T$$*( !N?95_;U:F7
M5:08^Z[<F%1JY3.=-L+3U[*];)9'C8L;2'24Z:]:YV=2,.I.VLUU-GT&&.QD
MF?RC$ML(OM?W+6/LI2"37=7(L>&[?@>;EPVRY\:79R6[-9/^C:Y#*6$RV7@3
M*QSFJ7D*ZE /;7-@P^O#Z-=++M\3;F<G])*A63^JC_F^!QWF?"H&0Q#G+.!+
MD/8QK<J5$BZY" L_$G;HK9?[8.E>_P ?EWI?TL\)OO\ RV/E\W"P9,7ZCBS:
ME?Y5]='X1U*.WRYC,PT87U,QZ<WA+I;A95M0&2C&VBTKT*PGJ?;77;C;7.%P
M^Z_E9GCY3:7K:U[66ME]I7<]QKD7I]/QF<P&5$O"!25X7,%&YMEOJIMV^[:I
M7P*2?"H=U5QJN=--:]Z_Q.J^?T77IY6[;?#XEN;>Q^6C1\_B8GR+.2\Q+L.^
MYIB6T?OVD)U'EW.]LWZ&W944WPZW<NO[NS.7)Z=;)T6VE^B\+=T+-(+2@IM0
M" -$@$ >P U#<&U:[M#IO&'&>2\?R'$LH@/-K:6]'WZ;+)LM*#[4]/;7C<VF
MVRR+KT?VGN^VY'KA;_[EY'GR7">Q60EXJ5_+0GEQR;:JV'0V]HL:\]V/H=LJ
M1QBLA)Q&1BY:&2W)A.)=;MT(2=0?8H7!K*^J9>JAI^!ZVQL]C*0(N1C*!8E-
M(>;'4[5I"K?1>U>7TT.MZCNH+(U/6H)"@,54![OIH _/0&/ST!/<3_TY[VM?
M^<FJ,UJ6ZA<* * \^_C)%_1I?_:D/\SE>Y[+_P#L?8S#-])\]DITM7W2J<$F
M$%*)+2E?"E0)]P.M>'[RXPLZ,&MCK:>785O&!&\>;Y>T"_LKY)9ZJL'2\3;D
MYICD(FSI#_5*W%$=NE=7MCEMDY8@M6.QT=0\0![Z]3*5QLE/U%CGOB0FYTUK
MEW/H=,)D%F^+00C<TD!79:NG%=F.3&B'QN/$# \L=(L78L9A/]E)2?V*\'_(
M:+_8:_K?_P!+/4]JTIF_\5_]2);B303P7.$_$[(92/X0KXR[GFU\JL^MXR__
M .?=?]R+C 8+>,QP':G<;^P5\_GO.6_Q/N^/3_\ 'Q_ R_.FP_U>]$=4Q);4
MYY;S1&Y(*;'O!N*UXV1X[VM7P.;G85DQJK)21ZA\W,'$;\L],3!?<?CMNA(
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MI&RD7M<5!(FIH=M63(9HI(2*DB"/ENA*34-EDBOR7-RK"LS0U:%]: PZL 4
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MF-7%04.O-J*TI) 60>U"NJ5I.H[ZE(J[$EC>:Y27B5L^5(D3HR$>:A+:]JG
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M$70UEX;<I@^PO,$*]Q"*NN19=H*6QKXG(^7_ (>>0\<;<FSN+-9''-@J<R>
M<4YM2.JEMILX@>]%=-.5/1_>9/%7P.7KXAQY_6'-E11V!P)>3<>^QKIKGMW1
MB\*&3G!<G?\ F$Z),MKY3N]A1'M)W"KKD+NBKP/LR,D\9Y!%!5)Q#RD#H[&*
M7D:?O=?R5LLU'W*>E==B%=\@*V/I4PZ" 4.I*"?X5KU=:E(9]I_3^W] N+6Z
M?JC'V_\ =FZ$%CH H H H H H H H H H H H H H H H H H"E\M_Z39_P"
M?XZZLNAE;J01Z5)4UJ0 ZT!L1K4$,#I4E1&2YY;#BP;62?S5>FK1%G";.<JD
M..R%N.KN2HC6OJ:55:I(^-R9+.[;9(QEI-AI6=C6FI(,L:A:="*PLD]&=596
MJ"?#8R4-V'+:3(8<!2I"Q<?EKE>':Y1UUY,J&<(Y!Z")8S0Y#Q-Y4*0#][&2
M;(6GN(KT\+75Z,\[DVW)I:EWP?&\JPA D$I4/C2?97=;-6#PUQ;.T]BX18*F
MD@+Z]M<=[R>ECP[1WL2@>RL9.A)(&[K5855FJ'[<:XN=*Q;@V2D60TE.E4DN
MJBJ0$]E066@$ZU!:3!5I2!)B](*A0!0DS4$A>QH2AO(%TD7L#UJ"Y:<)E_,Q
MZ&7W2"E-M-2;5%\4_,1CS;9JR#S61:+Z3Y7FJ;OL\SK8UZG'Q..L'A<SD5W=
M)CQ*Z<;+FK6(L91"]5)2#:_OKN>:M5#9Y->->]IK7J/F.&/1VS,SDEK'0$CQ
M%Y0'A[;$UQY?<*+Z=6>IQ_:<K^K1?B+\9R'$75/)XLP)XC$I?R3J;M;T]?+O
M\5N^N6V7)F4V<+L>BN+BXNE5-N\B4R2N3*4XHW)/T5JXB$<Z;=I8U<"@=PZG
M2LTS9UT#&<;P^2R[>4GL)>E11]R5 6!'VK=]<7,<GI>W_*FB[W&@&@'2O+9Z
MP4)"A 5 ,*ZU4DUH#-_952QBA)H;=E5!/<2_TY[_  )_C)HBU2X5)<* * \Y
M_C9R"<;Z)KDJ9#X&6A)V$V&H=UK?!>U;37J5M$:GS9<Y<\K5J"VD=-2378\N
M9]S.*^ BKEN4MM0TT@=G6J3E?<:"*N2YAS^Z(2/8G_9K2MLK_F8;CL(+SF5.
MJY)2DGLTJ[5OYK/[RF[P1CYV<[8F6K7O-;5X];=Y&YB E[W"VN2K=V^*JK'B
MF)+*62W'^-9CE&71BL&A$F>AEZ=L=<#:2S$'F.>)7;M&E8\K"DTJEDX(Y"6S
M+:F,(6EA]7GO-H27"PC=XBK:";#MO7!\"TFT.(XQ/VH =3)7N96!;>%$D$7Z
M7I!,C;&(6Q(6V\DH6DE1"M#VU$- TPY6&UE1U(*C8]A!HB7T%>/J2EMRX%E'
M<;GM">RI70AFG%R7)CA4?#9"]IZ7W$W_ "56O46'G%)[T2>^]"?<CSG"H%YE
M:D+\I:B+!22+ A2@H=HI4ACCAN2<P_(W,HB-&FMMK7NQ\UOS(KP2LD)=2"+I
M%^SMI7J'T,8)R"GEKS>2\U.*=4IF6N.D+?0WO;*BT%:%82%;;T7U$]AQ%R1Q
M/.GGL))=80L2(D*6+-/EEUI24%9'PJ*;;K=#TJ++4FO0F^13<_B.60>(<IEC
M+083B8\^$F2F1&?#UE$)DHNHA0*?$%:5-Y0IYF_)N:KFV5)P[.,ES'D)6_C7
M7X;*DI1Y7G.L**DO+";;5W3TT%R31Z:EIG0FE9_#\?#S<?D*9\G$,,1FI,^'
M)8:6XA1+CK2DE:G%N7 2'0$I [S6CS6:2[%'CJOB='P_*>4JPF*F<CP+SS^2
M+SI=QC8=4F(/]&6W$0HNN*>&HVV%M36/J$^CW(Z!SS YMQ[RUN01$>:CNHEI
M\LE^1?RVT=I4JW2U:JQDZ:Z%K"FO/7#\ULRVE%#K 6DN(4GJ" 2=*LG/0I9-
M.&94@@V(UJQ1C5Y) -6)+)AV$&&F_;7B\A_[A[W&48Q:5AVY*=OYZM5E[(JV
M4XBT0HE/UB]7=H,]DE*?YI.]-Y*$8=T/-NO)\[&+40VM9/5%K[%_ND_36N+)
M:3')2J/:OI9GVN58-C)>6XR^4I\^.Z!O0HCJ2-"#WBO2JY/-R:.#J4=M*4"]
M69@+I2+:55R2+ME(&MK]]5 >8GLTH)%$K3:U1!*9HZNR;:U*0;(F8HA!J[(1
M3LLXHDBHDU1$PTK6YKKK4)DLG4,> &U25&[B=JO8*JR3"W-J--*@%0Y%-V(4
M+]*RNS2J(7T?DE[U:Q([-DO_ (L[7.7/6M2 H H"J^I+*Y'!\TRVG<M;  3W
M^-)J&2NIY3.*D-FRHZA;J #6>UFLBS<!Q)&BA[P:M!61XVRI%DV(]E:):%15
M3:3U0DCM!%$A)D0H3@W+80HD6)*:#H)JQ&+5UBH^JIVD;A)SCV&<&L8?6:;"
MV\0/$L&H&\:U^NM-A7>R.F^G.#EI)92MAT_;^(?4:.HW'*?4KA<#AF#>S<AM
MB6\XM,> PGPN.R5_"+=PZJJBKJ6G0X:[Q5]$-3\AR\IX[WE=JW5=GL Z#V5M
ML9D[#+CW'AFN0P>/-)5(<F/HCHCM':[)=4;):0?LA1^)78F]6HEN@B3O/J9S
MYKBF(/I'P:4V[Y*&V.5YZ( A$M]O_><>VHBL'PI3_=%76JNZU]OQ_=_J5>IR
M)G%^6CYJ0;-%=E+*BEQ8 O?74"L52=66F4,I[;LY]*8ZRW#18I(%R"/T2>M^
M\USY+KL*U$?+C0AY4<#<;E:OB42>]1K!LT@U2N0VYYS2O+6-?]FKUR-%'1,M
M7'^7>6\(\I5G;=I)"O=7IX.1.C/.Y&#NCJ6(Y$EXI2%!*C;=KTMV>X5W+4X.
MG4NF.S >V#=X>P^^M$C-LL\68ETK6@DN6)3_ &5FD?D)-76IFQ\9:5MKOHE2
MVDI'[AM5A^:M(*2;PYQ1/6S\2'DR$W/46<4?V:613'8L6.?8E)96TOQ)(ND]
M?AVG\U43+V4DRRT'&BAT7:4%-K[]O2CT93=*DYA.Y'DN)Y%S%Y1Q3*V[K9D*
MT0\TH^%:">HMU Z'K6K2LB];P2^)]4I3+B?(G$*[0VH@$'OM63PU>C-ZY62^
M8Y'BN614L9!IAG+I(^4R2$I;<"NQ+I3;<DGOZ=:KB_V;35Z>!.9+-5*R4KHP
M@Y8YS&NX_D#/GY/$I4TVXNXE-^7\(W]5()\*D'V$6KYOWJE_;[+E\?Z&_GKV
M/7]MO7F)\?+]?\K*9FH>0S>)9R^*0\9N/=;R3$I_8"I NEYL*2 "E;:B A6M
MP*^KP9:Y:5O7I;5?:?+9L=L5K8[=5H_L'ZVDY6!Y]PHJ187\-PH7N2>A K6]
M8(QW//OK9/4.&XW%[RJ6].98BM@@7\@J41<V'UFO&Y]EL2\SW/;U-V_!'-N"
M\:DY)]<R:T IM:FHJ'K%"5H%UNJ2+E>WHD#2^M?)\S(U\M7'B?4<:DK<U\#V
M5Z-\A@\2X^K(M7)1>$QH+EUQ0+JU:6*B.U79I7QW+RY<5]U-/,]FF.N1;7]P
M\Y'S3E&?XM/5QYE4B9@GY$C)QXZ2$F$M!27BV-/"D_9'MK/!3D9>1NM:UUMG
M75+_ *EG?'CKI\KF#CN"]3IO!&L6K"3WYV347G9\!+A0Q&9=((2TX-VY9'C7
MN&WH+7O7;EXE<ME:LTLOYD561UJ]WS3V.ZX+\2'IWEV4F:](ASKIWM2F4MC]
MT4N-GRR1^]3>M+9>1B7S4W>=7_T.9*ENC+[%YEPCDL+RS.BRX3X"'X[Z4+"A
M\0"DK\*K'6J?W?!72VZD_P#:RZXU^JAP2C/ZI6PU%@O1TQ61MCM-K0EMM'4!
M(3H![!6J]TXUO_=7V]2'@R+^424(D.\E4YIA"/C<+GEA.O7=<6JSY_&_KJWY
M%5AOX'F#UWPW$^02I.<X*T%9V"TJ3F783>UB4A'Q$MI 'F :[TC7MO6^+E_,
MEV9-L&D]S@3*\BM@2D1ENQQ;[YL;TW/2]M1?VUZ7J4>DG*Z6\!S%S+D=>T*6
MTH=0;@_4:L\:9"M!+(R\>:E3<]EJ4D]/.;2K\XK/9MZ%Y36J/J/PT('$./AM
M(0V,;#"$IT 3Y"+ 5ZU>B/,MU)NK%0H H H H H H H H H H H H H H H
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M'NF-+ )LE?0UCG^:IT<;Y;%G;LJUCIWUYK9ZIN;@V[.TU4DR* P3V54DP*@
M:@L8H2:$]W2@,&J@L'$A::]_@C_&34(M4M]6+A0!0'FG\='RY]#MLIWR659F
M""X!>QVNVK7%9*VI6W0^7#Y?#A7'5N2+V"AV=YKI;LM49Z=Q>)*C/1WD/H<^
M=20&BGX+=MZFN9O1HEUUE#%[YAJZFG#:]MI%Q6+;KT)F>H\?>;G--I+7D )
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M@)60AY)O*8M:F<F2N- =;T6A*A9YP'O(\(-4HW5RNI9]"QQ\:X);:@@NNI4
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MN&F?1W@HMPCC0[L5!'_[,BOH:]$>';JR?JQ4* * * * * * * * * * * *
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M4L)'A3L)^(ZWKFS7SNVZTUK5]M9^)C? K-;+:D/P_AL7DLV9A9TLPI:$*6-
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M"*5"T.&E?06(.OTUIL17>_(^TO %%?!.+K-@58B 3;IK&;J""Q4 4 4 4 4
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M&YD7(RN7F$F5D93U_P!-]RWU @59)(K+&1:2L[G!YBN]9*C^6]2#*6TBX0@
MCL&E2"T<5X+E>6+4J,\U&81HMQSQ&P[@*LDR).A#THXYA82I>1<<R,E(-@H[
M6[_O15MI22W^E[L>+"D"*TAA-[ (2!IW7JRT(;);D7'N,9@ID9#$QW9"%I6)
M#: R[=*@KXF[7Z=M2NJ(EG<^6\[XO$QT!IG)-P9KS+23&MO:+!; Z@;2$@5]
M/2Z6MFM=3YNU+.56KT9IZ!Y-'(LKEA%@J9PD9T)B2%I""^H_&HI[*\O/F61P
MCU^/A=*S;J>ET-H0E*4I  '=7(=$CE" H;B!561J-9Z$A)L*)EDCGV3&Z2I(
MZ7UJ34S%:L*DABSJ%+&Q/6A4=0H(391&M615LEDI"$T((G(R"? G7NJ)+I$<
MQ%+BPI0UO4%FR>CM);0+Z>RI,VS63-;90?$+TD)%)SN=2V%>+OZ5FV:U1SG)
M9<R7#95]=;5G)H-VG%+%Z@#68HA)UK.Q9%=F/A*KWK,DU8F!6A.HJC).C^AJ
MPOU0P_?LE_\ %G*K7J&>P*U*A0!0$;R#_H:7^\_9%6KU*VZ'.0FNDQ%-M6@@
MWL*D@U(M0D1<ZU4D1)O50:FH9(U<%C4@24FXTH#A7K?Q49+'/E*+E0*DFUS?
M_P"FN;+U.JFJ/(3$R1BYH>"2),19;?;[5)!UI1PY*-3H7IB>%AG,PC<* \Y*
M>U/;]5=CAZHRB"[XJ='G,)*2%(6++'>#6E+E&F53FO%0J[C#6^*ZFQ3U!'MJ
MN3&H+TMJ<7RV*=Q;VVQ5&4? L]0?T3[NRO/U-Q@D7]U"$.647L.^H+"'(4^3
M#85U45J_-I4HAG?N'>G\CBN&ARL8$O3);*'I4T)'FJ4M-]HOT0F]@!5DWW,Y
M+C#RPV&/F8@=1\*GFP$NV_=)/A5]-75PTF1.<]$^(<G;&3Q95C)+X)1-A)VH
M4H?WQD^$D=MJVGN4U.0<J](.=<42N1\F,UC$ DRX"2I:4@:E;)\0^BNBN>.I
MGZ:>A18CJY4I&.B;Q,?6&DL&Z%%9-K*!JSS4MV+;6F=#Q?'LIP]J5E^4M"+/
M93Y&-8=*5*!=^V GL/8:\_->J4I'3CI9O7H3'ICPH\QY'CL;%++#TM\,?/2U
M[6EO.$G>LZ_0*\5WM9ZL]1426B/2'-\IB/3^0YP;C+:/,9;;&2GVW+\\H'F)
M"NZ^HKR^2V[NM>B[G;B2VION7GTQ5D<+C\0Q%/S&7Y4IQQ)W@J0RTFY.O7:-
M;5\G@HO<>>\3G;CT._.ZXL.Y_$X7ZZ<;2QRZ6U*R+DV6""\\Z27$[A<(5?I;
MNK[C'P<?&7IT4)'EODVRQ9DOZ'3N)XER?B,FMN*O),J0S/<Z)> N H]EZPS;
M5=;NAIC;M5QU/9OIIR5GD?#\=(86E3\1'R<D)/1;'A!]RDV(KUN'R:Y:::VK
MH_V\#R>;A>/)Y6U1<4E0UO<UZ4)GGRQ4:@$]:K"1(RR,Z+CHZGY.X-$D%2$E
M=KCMMTJRJV]"4CDC,&/EN1.Y_CN18FQ[GSXJ%#SFR="+>_OKXOE>PY%RWGQP
MT^M3Z[%[C58%BOH^S\2T*84]'6DDA\I5L4=%!8&G3N-;Y..GCLJ_+:'!S*\6
M4]"A9)><G821QYN<Y@'I+A?&2QB$(?0\=2O<4DG=]O=>]?,<;W/W3&DG995_
MW=8^)Z67A<6UI2<D5CIN;A<9SD?U6>@9U^&$?T?R46(IE^:BQ!;DA *4NJ.T
M)4- =37W_MGOGJJ+)U:ZIGSG)]LAS5S^!S#F/IIC(61<QLEF5B9#[C;K$]G9
M.BJ:DI"@TXW<64F^W<DU]-DX?ZA>KA:\ZO\ @>?3D6Q?)E3^)QK+P<IB)T["
M/I^9@,.%IQ#Z"IA78#L5<IO[#6-^/R,%59J5;[32N3%E;2>I2FO3/A6<R24S
MLN>'I>5L\TL&5$*R>FA!17-ZE+*5U*WPVJ=7Q?X*X&2B(F1>>F;%6 4KB14*
M20>XE53'?L<^XG8?X'..IUF\HR#H&IV-M-B])9=$DC\%GIFP+2LWD5VU.Z0V
MBX]H HO@0S9?X1O1./94G(R5) U\V>$Z_15X\BC9[GXW#BX[CN(Q\$WA1(49
MB,;[KM--)2C7MT UKG9J2=0 H H H H H H H H H H H H H H H H H"F\
MK>0G*M-$V46$GZ"M8_8J)*61$#7I5I*&:J H O0F3(T-Z@DVJ"#((-06"@,5
M)4* 2=3O!]E 4KD^-#[*R!=0N;UKBOML99<>ZIS0E4604*TUKZ/%D5D?.9L6
MUDW"DW(K8Y634=X$#OJO4DD&W- 315#M X#H.@J8*;A9*JF"LR;A0&IJ8)=D
MC?S4]]ZF#-V O #2D#<8+]]+U,%=PF5FYH1)L%GW'OJ(+)BB5'MJC1K6QA2[
MGV=*JT:JPV=]U9P;IC!S11(^JD"3#;Q&A-JR:1LF.4O@Z51F@QF2=J3;VT2(
MDH'(\D$[T@ZG\]7[%EU,<%Q:ILWYEU-P#>]>9R<O9'I<?'XG<L>P$-I%N@ K
MSCN)5L=#4@5H  H!)Z0Q'&]Q0%NMZ2(*GGN;,0VUIC7*NQ0Z5:J=W"#^52<3
MYIS.?-\RRE6L;Z]E?6^V<%-IV/F_<>8TMJ//F;R#LR4M3BMP[;=":^S<(\O@
MXG6LOOU((ZUD^I[%>AC;IIUJ()W'IG\$R-OJ/G3_ /8CG_&X]?.>_*,-?_+^
M#.WAVF[^![HKXH]4* * X5^+5EY_TE4VR@N+_640[4]UG-:ALLCP6N*XQ?YE
MQB/;4EY]ILCZU51LT1$2IG%X[ZWI6>@>8;7:0Z5E-OW@-1/D-!NYS7A;)L<J
M[(7?5,:*XH?0I6VHA^!$HC9'J5QUEPIAPITE ^VLML75[KJ-JG:R'9#%?JHV
M $L8,$GXE/R56O[D)'YZG8R-XR?]4<ZH_P TA0(Z?\&MX_3O54["'=D;)Y_R
MZ0YN&0$<6M:.TVT!^0U.Q$;V1TCD?(95A(R\I2+W*0\4"_\ 86J55(C<Q@ZX
M[(!^8><?_P (XI?YR:F")$DMH'V0#WV%2&:.IZV%^R@%(9V/M@Z)*AN/LJ!W
M+/,3BA(;DIE;BC:2@?EJFI=K5#3,9.+/D!QO5M*0 >^U*U@6<LB5K!^'2KE#
M2Y[Z 62VHZ@@5 -9!\I(V];=:D@TBJ6M2BI5["I#.U^CJ=L-[3O/Y:U10N7,
M'?+Q+A![#5B",]-5$8YQ76Y_9H07"0X?KH)(+(7* "=R47#:3J!?L [*AMO0
M)+L>P/03BZ,'Q.*XXBTAY/G.']TYKK6N/H3E?8Z^@7-JN8#E(LFU0R1E/U2?
M=4(LBBRV#\RLG47JR-!Q'8.T6%6*-CIJ*+WH5;'J$!/4]*D@1D/)2D@=E061
M%K;2M6X]34%ART&VD@W%_;4E6(2LFAE)"3<CMI(52F9KD@;2JRQ>L[,UJH.<
MY?-.2E*VF_NK.30BXR%N*N=2:@$TVR4H[JD@B,J]L2;:5FRR*?-E'<;FLBT#
M1J4I*@>RLV2CK/H ZISU1PY)T\N7_P 5<J*]2&>SJU*A0!0$=GO^AY?[S]D5
M>G4K;H<[ [:ZH,#=/6I!M0@35?6A(@LZ7^BJDB50#!H!N]UJ"1$]* K?+<4G
M)8QT6NL BWL-9WU1KC<,\,^J7'7,!G59!IO^;.DI?3V;NPUS(U96<'FOU4_\
MNXK^92-4'J$*4?S&NC';L9M%RQF2<QL@.-_Z(X;D?HD]M;+J4?0Z/%E1\C##
M3A!;<%C;4A1'6NBMC)J"@<NX=M"G6V_,97?>.H4.\>VL<U'V-:6T.3Y##OP'
M-R05Q2=%'JGV&N%J#8T;*6AN/U5 (O,K+[;(5T\P)^A561!ZXX'.$WC.-7OV
MJ:1Y)[=4:5:2K+9E\?Q^'"3+Y+(1$"_@*/Y55^RPZU9*02O%IW$\O&&+X_*
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M0G>2FYN0-.ZL,MH1U8JRSL?"<,(L)!(LM0%]*\2]MS/8I6$="CM;1ITJI8=
M#6@$WI##"2I2N@N: K66Y<Q&W(8.]0Z=U5D)%#S'*7WTK6X[M;'7L J$B[9S
M'/\ J'C(R'$I7Y[HN+).E_?7L<'C.]D>=R\RI1MG)\]RZ7E=R;EIDWL@: CL
M/?7Z'Q\"Q5A'R%)Y%M]M%V\RIN+WG3Z:WLY/8HH4&J4:U$%Y%4-@G2K08NVI
MZ6_!:C;ZAYT__8KG_&X]?.?Y!_P5_P#+^#.[V]_[C^![AKX8]T* * \P_CV4
MM'H(X6UJ03F( )0HI-K.Z7%J ^61:022I.Y1ZE7B/Y:F$1+,A( L  GN H&9
MW6H#51N: U-"#(Z4),7H TH !M4@V*AV4!K<=E %Z@ ".@%0)-MQ/;4@P#4$
M"B"%&I2)%DJMI>D$"4A5QWVH2$2R=Y)"=+ZD"I1!W#T?%\:XL&_7\];56AG)
M8^<.;<0Y[B/=5X U].$VQ15?0FJM MSQ2!XE >\U @:XZ.SDLYCL8%A2I$A"
M2$ZG:#<U62]:ZGO3C,),+$L,H "4I2 .F@%=*Z'/=S9DXC0WH0*!15ITJ"!&
M6V2BW7OH2F5J1$"G[D:7JQ9L50T$BU3)5LW "!>]JA@:2)81< BU"R1%OS4B
MXOUH6@9KR*4=%"U1),$?,SR&@?&/=>U1)9(IF8Y0I14A"SV]M5;+I%-EY!^4
MHW)-ZH2)-0W'2%'J:B 3<. $V)!L*F"!W(2&FS[*ED%*S<D#=KTK%LND4J6^
M5+-927-&U:U1@[#^'A85ZHX<?[G+_P"*N5%>I#/:E:E0H H".SW_ $1+_>?L
MBKTZE;=#G@Z5U&!FYJ09OI[: T6=* 05J+55DB1-0#%02).B_2@$#T- (N(#
MC:D'H18U5J2R<'GGUAX:U+;D)+8V. V(%[$URW4,Z$Y/(<^$[CI;V*E@@H)#
M:CVCLM4HAHE\!F%((QDT[EC1I1/Q#NKHI:3-HO\ ALJN M#:E$Q%'2^I2>XU
MJGJ9OH7^+)C3XOD/6+:OA7W5U5UZF2T*/R;B2F?,?8;"T*N2#JE23^S6&3$F
M]#>MSDN:Q#T0J>CI)9^VWVH_V*X76&;,K61O\D% ^+>+'N-JJ5/0OICGRGA<
MEU!NZR4OI!_= '\XHV6J=,SD/BOJCCH#SV45B,Q$3\"_@)5J00="+]#6R*M$
MAPOTS;PF01E7LTC(?+JWMMQ@$V(Z;C<Z55SWZ$)*9*]ZP^HBN&9!K%8.2(F1
M?*,FZML[E^8DD);V]!N.OMKU_:\>.KMEOV6B.;F-W2JNG<\S<AF<EY1E)O-.
M2-'YR:^I)2$A"6UJZA*1T)^T:\7F<WU\L-].B\$=W'XWI8Y2T+)Z><7R>8S;
M:\:A ?Q;1R2O-^ A@A03W7)&EZ\O+D21WXZ2>S_1+AZ/4I6;]4>3,(B.Y<I@
M8U<8 -H^73M6M2==5&L:U>5S;1?Q-,F38HJ1W-?1?G/%D2)&(1^M,4MPO>;%
M3=X#VH^GLKBY'M[G<U*\3?#S:V43#)CCGI?F>4^EDG*+>6UR!Q+KF-B/(VBS
M)L$N Z@JL;5RU]FJ\;R](UT\#HM[G&2N-=SET;UERN'],9W#FVHLN6XXMIWS
ME:M J\12#V@C3N-9<?)>JMB:G'=2O(Z<V&K:RJT6J57#YWF6:4RUC@Z4O'8@
M11YBMP&NB3>O+S<?CXM;1IXG=BOEOJNA=<1PSGCT']8NR4*\MRWR.0#L9])2
M;A:'%(V_EKRLW.XU'"3U7U54K\#=8<BT;3\F6U'KAE^%9:'B>:1%)0ZV%Q\H
MRI+A*4G:=Q02%6KU.-NY>/=6WJ;/LO7X/\SSN32F*VUK;/W?<=DXUZ]\9R+K
M4560:>0X 6WB=H(/9N[".Y7UUVU]YY?$:62OJX_ZNEU\5T9Y]_;:9-:-)_@=
M.@\CQ4]"7&I";*("=Q "K]"#T/UU]%PO?>%RE\EX;_EMH_N9X^7@YL;U7W%$
M]667%Q67VHOS9"TE;*;;MATNDFN;_(.);-AI:CBU6>G[/F5,EE;H)X*6V]CV
M"FZ5!/PG0BW8:\[A96\:5_J74]'DT^=QT*]RT.HR;$B/=1=:'F :^)!M?ZC3
M+B5KRNZ&*\4^ TCJ1((^8^[<&FX=#7)?!:NB-%D3(WD?ZOA8Z0NX4%).Y!L;
MBU=&)QHRC3>IYCQ?'^#S^:J>Y:Y(9P4AP>0U'5M;4]?X%]P-?6^W^[Y*KT7=
M[>Q\_P [V^K_ -Q)2>ELNU(A\+R68BL(QO'L5CG8^)A((O9Q.W>JW:1TKW*)
M3!XSZ2>0'I(V@G4$?EK6U9T9G5M0T1<J3O00%Z7T!/0^PUPY>,^J/0Q9T^I#
M(S(*S$F^$]$O=WOK/'R+5<6+7QIZU&,]U;-R3="OA<Z@UZ*NK')91U/KUP(W
MX-Q@]^)@'_\ 9FZ\VW5FJ+#520H H H H H H H H H H H H H H H H H#
ME7J8!^O8Y_\ 9$?Y5VN;+U)121I6('<:>\PKXB15TX(@GH>62Y8$ZUIO*NI+
MH>0X!90-ZV5I*P*4)"J@#;LJ2#*=.NE"3)5W5  JM0&A-ZDJ-WTE0(I!)3>1
MXX/-JL!<5?':#*]9.434*A2%#I8ZU[V#+N/#Y&*"0QLNY&OMKTJ:GC97!9H;
MFY*2>M=40>=OD?\ G!(M?6LTTC3:[=!)8>=&U.MZK;/6IM3@WR&[&.>)N[K[
M!7/;FH[J>S^*)9K&J*19-NZN5\L[5[:EV';.+-]3KW5G;E&M?;T2'R"0GI6/
MZ@ZEPT:_(*[*K^I++AH3?C.!)%NE4]<T_2C#Y1Q)UK1<I&+X)AQ!0F]K5T4Y
M".7)PV,52%=+WO\ DKM5TSRKXK5$WE@ FKQ)G,#)4K:3<UG:AO6[&$V<FQ%]
M0*PAG55IE(S>5\)1>Y-9V<'11#GA6&7.F"2XDE-[UY')R=CUN/2%)WG&1$L-
M(3:PM7"=A**>;91=9M:DHF"$R?)XT0%*575V &J;B8*+EN4R92BE*MJ3<6%6
MZD,YERSFCV.<\J.VI]\FUA\(/MI 3(N*UR#D4-2GDJ;0K79\-ZTJM2&5?*<1
MC8U"WIJP#J=JC:UZ^M]K6JT/F_<FG5ST.;Y-YE<E:6?Y-)VI/N[J^P;.#AX_
ME^89I22:@] 6;0HGOJ\&.YCE#6ESU[JL8GI3\&B=OJ!F]/\ X,YK_P#6H]?,
M_P"0?\%?_+^#/2]M?^X_@>V:^&/H H H#R_^/G_N#7V?\\P/S.T!\M0KO.O?
M4D&%'70T!B@,'2A!K?2] % % &M 8UJ9 :T :T HRQ(D**([2W5]R034-@D$
M<>S2T[_DUH0!<J7X15=R)AD:ZE33BFU_&DV/OJQ!+\>X])Y&\J-$=#;WV=PO
M>J6OM+UJ[.$6P>CW+$]!H>T))ZUEZ]33T;#R/Z*<H=-W%%*?WH3^>H?(198+
M,L&._#_-?(5+?"DZ$W6!^8BL+<N"ZXK[D\KT[X#Q=A0S<QK<1JD:F]7Q5SY7
M\JT+^GCIU9KQO(\,Q[KF/X_(OYI\(O;J:]*G'SI1!SM8V]"5SG&\I.94%'S(
MZQ<6!.AKE_4PX?4FV$A(D:?A&3&924-]IK599,]D";TF>X3N=5;NJ'8;2]>A
MF(7E?42,ZZ2I,-!=UZ7)L*MC<LEJ%)] (R0TPVCN2*[5T.!BVZ^@ZFI@@51X
M1J=:@DU=<W)ZU"!$/V"R=*N!JZ\A"3KK4"",DSP ;&A=(@Y>0ZZU$ETB"EY1
M0N :K)9(@9>6>[#I426(*9.?=N+G7MJ"2+,=V0O6YJ(#9(Q<2+ $?MU,$223
M<$(L+=*F")%K):'76H!"Y6<E+:@%51LE(YUF)A6I0O6+-$5QQ=U:5D2"7/;4
M [%^')>[U4P_^"E_\5=I7J0SV[6A4* * C<^;8>6?W _C"KTZE;=#GFX=E=<
M&!FXJ 8)%2#4GOH2(K-ZJP)$U4&I430DU[+4 @H6.M :E-Z@%7YAA49."L)3
M=P#3Z*SO64:TM!X^]5>#K7OE,-E,IDD@]IMV5SR;]3BI*W"&W/NY3)M?H015
MTS&"T\?SPDGY.4?YRD6-^B@.T5O6TD-%YQ.9=QZDMJ.^*HBQ.NWWULG#,W4Z
M!$DQ\A#"'OO&5Z;CV5TJ\F3*CR?AZ7;O1SKU"A\-NY599,7=&];]CD'+N-N-
M1P([7ER4N K;M9*@ >E<&V&:LO/H6M$A$G"RA8K;6VI"NHV*T_(:I&NI*Z'6
M7>%26=8@\UFWA':!W5I$(JT:L.Y'B+;N9=<7%9B)4XZHD[%)'5)'37I5ZK<T
MB/I6YGG'.<A5S?E>1Y#G%K2U**WD%LD% ;'W21W:BNSEY-F+:BF&CM:61\7)
MY*4Y:2^IR.RKSUH4?"5VM<U\]DQU^J-6>E2UGIV+IPSE>1QL3,B,0EO+M?+.
MW%B$CM2>RN?)C221OCNW+/27H1ZOO\ Q*,-.!D81YPN%GM0I7Q$>^O,OFRTO
MNQ_=V9T^G2ZBWWGK/C7/.,\IC)=P4U =(NJ(Z>_LL:[N/[KBO\K_ -NW@^AP
M9N%>JE?,OQ'N>>D0\-*D,-I:2&U!*4'372XMTZU'O6?)C]ORV24[>J_>.%2M
MN15:_:?,/U(0$<OSB4H\M*I;JD( T%U5Q^U-OC8Y<_*COY2C+;XE9@9#(09"
M'X,MZ+(;.Y#C+BD*21V@@BO2R8J735DFO,YZ9+5>C:.J\:_$'ZI\7CIB1<ZY
M-B#0,STIEI .I W@FQ]]>-D]GX[?RK9\-#K7)GZEN?CW^\B^=^IL_P!19<'(
M9?'PX<Z$TIA3T%LLAX*5NNXBY&X=XKHX7 7&W0YW%<N?>DO K$;*R8BTK8=4
MDC6Z3:N^^.M^J,*V:Z'7_3W.^JTG"3N0\2D?,X[%/M1YD +"W2I[X5!D]4]-
M17QWNG%X"R*F50VI5NGXGL\;)FO737R+ZKUYY+B'U8[F&"=8E,V2X %)(_L5
M5YRX&1J<.=M>;DZO4I7ZJ1YHFH'KEQ>04'SE17%'Q-.IL#]5<N3C<^O2+'12
M^!KK!+J]4^+2[/":VX0+!))'7NO3!FYV-_-4FV+%9?4B-D^HN#-UB6T@=PUM
M78^7R[OZ2M<&&O6Q1<_RQK,.)C1IR/*6;;MW4'LKT>/7*];HQRVHE%65+E_#
M5O\ 'W0S<24_>-J0=24Z@_77=AO&1-,Y<U/DAE7P/KERS#X.3P[DNZ=BWD>1
M9P74E([*^IIRKI?+V/ ?'JW+1$S%-/1$ST(4F&Y_=4:A/=NJ^#W>;;;J&4S>
MVZ;JLKTHJ4DJ94'4'M3^R*]_'GI=:,\N^*U>J(28$R$E*K!?0*]OMJN7$K(F
MF3;HB*9R;T%9BS4^9$4>W6P[Q7#5VHX-G%M3[+\"*3P;C!1\!Q,#;[OEF[49
M0L-0 H H H H H H H H H H H H H H H H H#F_J#B,I/S##T*&](:3%0@
MK:0I8"@XX;7 ZV-<^1-LDJ/]&L__ -62O\4O]JLMK\ 8/&N0 Z8N5_B5_M5;
M:_ &Z>/<B2;IQDH'_!+_ &JKM?@3)(1,?R5H@*QDFW;=I=OS5=*R[$$Y'B99
M5@Y D)[[M*_:K525@=_JW('_ 'HZ/[!7[56@K!C]69'_ %5W^ ?VJF"( XW(
MG_>KO\!7[50(,_JS(_ZJ[_ 5^U2"8#]69'_57?X"OVJ0(,?JS(_ZJ[_ 5^U0
MB#16+R1%OE7?X!_:H((J?@,HZ#M@O*OW-J/[%1!,'-N3< Y(^I2XF'EN$Z^!
ME:OS"N[!EVLXL^)V70A<7P3F3*P'<%/2D=\=S]E-?08.3CC6R/FN7Q,K?RU?
MW%P@\1Y):SF)E(M;JRL?G%:9.7C72R.?![?E?6K7V$@CB&>4;*QL@ ]26E?M
M5YN7EI]&>]@X$=42L3B662+*A/)[[MJ'[%>5DS.Q[6+#6I(M<8G-BWRCWTH)
M_8K#<S:$/$X&<$@?*.W'[@_M4;8A&WZDGI/AB._P#1-D-(5_5,X@#Y1W^ ?V
MJ:C0Q^IIX_WJ[_ -5DF#56'GG3Y1W^ K]JC1,B?Z@F$W5#=_@']JJPRTC"9Q
MK)+OY<-XCLLVK]JM%DLBCI5D4KB>8OICW_\ %J_:KOQ\EKJ<&7BID;-XMR(#
M[O%REC]RTL_L5Z6/E5[L\?-P[]D0$GBO+5$E.$G6[@PY^U72\^-_S+[S@KQL
MJ?T/[B%R'%N;AM11Q[)+)[$172?XM9O/C_J1O7CY?Z7]Q4!P'U%R$\!WC.3:
M9*OC7$> M]*:X,^>O8]3#Q[=T=EXIPS,8J(VEW%2DN@:W96/V*\2\MR>M50B
MROMYUE%FL3,41^BPX?V*IJ:05K)1^:R20UA9P2>Z.Y^U159!79'%^:/JW'"3
MK?\ !W/[6K;0Q#^A?+E* .#G:]3\NY^U4P0:GTPRWF?-/8.8XYUO\LXI0^I-
M5U$$7GX?-<1"4UAN&9=\I%@6<?(=43[ E!K?#6;:Z(SO,'#,YP_UQY))6M?!
ML^Q&7<$+Q\D*4/;=&@K[/AY\.-1N7WGDY.*[/=92R)3Z,^K/;PG-W]L"1_:5
MZZYW'_KK]Z,O1O\ TL61Z-^J^G_X%9K_ -PD?VE7_7<?^NOWHKZ.3P8Y;]'?
M546OPS,^W^8/_P!I5USN-_77[T86P9>U7]PZ;](/5(:GAN8![/YB_P#VE5?.
MX_\ ]ROWHKZ&7^E_<=Z_"MPCF/&.;Y:7R+ 3\5$=Q2VFY$V.XPVITR6%! 4L
M"YL";>RO!][Y.++AJJ65GN[/R9Z/ Q7I=[DUH>M:^./;"@"@/.GXU^+<EYAZ
M**P_%,1,S>5.6A._)8]A<E[RT!S<O8V"=HN+FU ?.3_P_P#KEV^G/(__ +KE
M_P";J2 /X?\ UQ[/3GD?_P!U2_\ -T #\/WKG:_]7/(__NN7_FZ@&#^'_P!<
MO_Y<\D_^ZI?^;H#0_A^]=#T]..2?_=<K_-T!D?A[]=2;?U<\B]YQDH?^90&#
M^'SUU!M_5SR/Z,9*/_F4!C_P_>NO_P#+CDG_ -URO\W0"K'X>?7-Y6U?IYR%
MM/>K%RA^7RZ"##GX>/71I93_ %><B<'84XR41^1NI!A/X?O7(FRO3?D>W_LN
M5_FZF07#B'I'ZT82<V97IGR!451\2_U5+*D^_P"[Z5%TFB]+0RW\XX/ZM2X0
MAX'TPY %N)\:DXJ58'OOY=<],>LLVR9=-#D)_#]Z[.N$J].>1%:CXE'&2@+G
MWHKH.8E\9^'K\0V-=3.Q_",TP\C4),)\7]XV56T,LI[%VQV'_$[!3Y4CT\Y"
MX46 *<9*(T]OEFJ/CT9HLUT-<IQ[\3>14?\ \ >2,H[-N*ED_D;JU<..I%LM
MWW&$3@GXF@YM'"N2I0KJI>*E#\Z*Z,>/$[?,M"N^W9D7EO2#U\FOE3_I_P D
MD7U*SC)9O[/Y/2O1MRJT^6BT,FFR5Q'I+ZLXYM*V_3'D8ECXEG$RQK[_ "Z]
M;C^XX*+IJ5V1T.@XR)ZW08/RKWIAR)]8^%2L7+_S=?/^X8,/(R;ZN#LIG=5$
M$!G>,>O^42KY;TUST<'_ .S))/U>76>/C8<=>LLI?-9E:9]//Q$-.'S/3KD+
MJ?\ LN5_FZK\AG+._P#X9> ^ID/D.1R?+.)9/"MD-ML_.PWH^X#4D;TBKQ5=
M&2W\I[+3#F!(!CN7 _1-:;Z^)R.K!,6;?6.Y_!--R\2-K,J8F?ZNX?[ U.ZO
MB-K\!L\QD3\$1T^Y"J;J^).UD5(B9E5RF"^?<VK]JCO7Q+*K(I_'<@7>V.D_
M0TO]JHWKQ)@CG\+R)=[8N5_B5_M5&Y>):"*D<;Y.N]L3+/N97^U4;EXDD4_Q
M#E2[_P#,\TW_ -P<_:JLHF1@YP?EB_\ X)-_Q#G[5)7B#0<!Y4KKA9@_] O^
MUJ97B!XSP'D:+?\ ,TO_ !"_VJF5XD:CH<+Y(@:8>9]#"_VJ;EXB&-7N)\L%
MPC"3CW6CN'_S:AV1,$1*XKS8W"./Y%7M$5W^UJFY$P5K)\(]07@0WQG)J]T-
M[^UJC99%1F>F?J4ZLD<3RQ'_  )_^UK)EADKTL]2K_\ RCE__<7_ .TJD PG
MTJ]2[_\ RCE__<G_ .TI .L>@G ^9X+U&Q>1S. GP83;<H.29,9UIM)5'<2+
MJ6D#4D 5*09Z^JQ4* * C.1-O.X66W';4Z\I("&T J43N'0"K5<,A]"BMXG*
ME *H3X5V@MJ'[%=>Y>)C#-_U1E/]3>_@*_:J-R\1##]493_4WO\ %J_:IN7B
M(9H<1E?]2>_Q:OVJ;D(8FK#9;_4G_P#%J_:JNY"&)JPN7_U%_P#Q:OVJC<B8
M9K^I,Q_J+_\ BU?M4W(0P_4F8_U%_P#Q:OVJ;D(8FO!Y@W_F#_\ BU?M4W(0
MS3]19G_J^1_BU?M5&Y"&:+X]F%(4E6/?((M_)*_:J'9$PSD_/?2KDD\K>@X6
M4_NZI;86HF_L KGO7P.BEO$\O\W_  [^J3<Y60PO#,Q()/C0S"?5<>P!%168
M)M#U*I_43ZV%29#? .0MOHU!_5LD$G_%U9,S9:,1Z5^LZVPB9Z?Y]MT6!*L;
M*L?;JBNBMU!2"XXCTX]78!2G^A>;\A6BDF!(N+>]%:*Z1#+O%]/?4)QO8]Q/
M+>6L64E<)X'\J:WIF4F3QOJ0N<]"^:SV5*3Q?)+!!*4B(\%I5[/#4Y/3MW1=
M2BK\1]&?5/C/)&I"N&YA47S"2^B"^1M4+&]DZ5Y]JJ>IO5G=V>$<UVW3Q[()
M[;&,Z#_%J-$#GOKGZ=>J<_B\7 <>XOE<A(GK\^>8L-YQ+32.B"I*2-Q[J[^+
M2J3LVD^VIA>S>D'GR/Z#^M)A_+_U?<@;6I1WJ.-D]!T^Q7G\N^Z^G1'5@2K2
M.Y)L^@WJY#Q3P' \\[+)!VC&R22/9X*\VZL[=-#MHZ5H]=2Y<@] N<XH8D<7
MXAGI#,J(AZ<VN!)469.FY));%B?T>RL57(YE&BM1=&*0O2_U?90E/]"<XD(T
M ./D#_S*P>"W@2\U?$L6)X7ZS8M]$F'Q'.QWT&Z7$0I(-_X-<N7@/)HZEZ<E
M5<IG2',_^(23C8\"3QG,N-LKNL''O@N(Z;5>"N5^W9/2MBFVRRB#;]73>K0I
M1R#U#])O5+.Y1S,1.$YDN25;W6VX+YLH]>B.VNCVWC9,&-8VG"\C/E9J7MN3
M12T^B/K#V\$SO_W=(_M*]K8_ X=Z\19'HIZPC_\ X;.@_P#9\G^TJ-C\"=Z\
M11/HKZP)'_R-G/\ [OD?VE-C\"=Z\3']2_J^>O!L[_\ =\G^TJ-EO E77B2&
M)]-O7W NK5A.+<E@><4>?\O"E-I<\M6Y&\!%E6(OK7-GX5,Z7J45HZ2NAOBY
M+QOY;0=E9ROKAE6TL<X]-)N?CJ2$NDXU]E[W@[" ?=:OD\O^+Q??@M;';\#U
ML/NE*K;9*!PKT8C\L86[BN,YWC63M<P,ICY*HI/<AX(.WZ36'H^Y\=Q;'ZM?
M&O7[C;U^+DZ62^.A3YOH+SZ*XM@<;R)6D>%;+#CS:OWJD V]QKU,3SW4^G;[
M:M,POZ*TWU^]%5/I#ZL-N*3_ $-S:@"1<09!!'\&O:KQ[1])YCS57<?Q?2/U
M.((<X9F4'O\ D7QK_ K;T'X%?6KXG6>(<"YED,'^I\_QS*1I3/A9D.1'D:?O
MBFU?+\KB\G!GW8Z.U7Y'LX>3BR8]M[)/XE3Y+Z!<K^:+B^,3,@W>X<8C+43[
MP!7H[,UE-:VJWY,PWX5UM5_:9P_HOR=++D!/%\K&8DILM+D-\(2?[)-JX,O&
MY4SM;CR.NG(P;8W+[RK9[\+OJ1 WR<#C)<BWB#)86"?9TM7L<?)G4;J67V'E
MY%B?2R.>9/T0]:U$F/P3,)>1<+2,=(6%'O"@FQKZ?!R;O2R/%RXJ]4T0$KT2
M]<WVMKOI]GO#>^W%R?R6;KKR.K74Y:2NI]9^"QI,/A/&H<QE<>7'Q4%J0PZ-
MKC;C<="5(4#T((L17(:$_0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0!0
M!0!0!0!0!0!0!0!0$?E\YC,$RT]DG_*\]P,1FD)4Z\\ZH$A#3;84M:K FR1T
MUZ4 SC<KQ<B5!A%N5'EY%QYF,S*C/1UE<9H/+N'$IL-IN%=#TZT!.4 QR^6A
M8. O)9!2D14+:;4I"2L[GW4LHT&OQ+% /J 1ERF(,5^;*7Y<:,VMYY=BK:VV
MDJ4;)!)L!V4!F-(9EQV9<=6^.^A+K2[$70L!238@$7![: 5H")5R")^O4\?9
M:?D3$H#LIUEO<Q&2L*+?G+) !7M.T"Y[["U 2U % % % % % % % ,,7F(.8
M$PP5*4(,IZ#(W)*+/QR L"_47/6@$,IR*%BIL3'.-O2)LS<L-1T;RTPV4I6^
MZ20$-I*D@DGMT!UH"28?9DLMR8[B78[R4N-.H(4A:%BZ5)(T((-P: KIYY@A
MD/U3Y60_66PNB-^KIF\LASRBY_)6V;C;=TH"8Q&6A9N C)8]2EQ5K=;2I22@
M[F'5,KT.OQ(- /J * * 1;E1G7WHK3R%R8X07V4J!6V' 2G<D:C< ;7H!:@"
M@"@"@$?FHWS7R7G(^<\OSOE]P\SRMVW?MZ[;Z7H!:@(G+<DQ6'?8ARG''<C)
M2I<>#%:<DR5H1;<L-M)4H)%]5&P]M /H,UK(16YC*'6VW0;(?:6PZD@D$*;<
M"5)-QVB@-,EDH6(A.9#(.^3$:*0XYM4NQ<4$)T0"=2H#I0&\^=$QD&3DI[H9
MA1&EOR'2"0AMI)4HV )-@.R@&65Y%CL.S#<E!];F0<\F%&88=??=7Y:GB VV
MDJ%D(4HW&EJ :P>9<?R3^/C09*G7LDJ4TPCRUH4AV!;SVW4K 4VM%]4K - 3
M] % % -?UE"_61Q'F_\ .(8$LL[5?R)7Y>[=;;\0M:]Z =4!'Y?.XG MQ7LO
M*3$:FRF8$92P2%RI2MC3>@-BHZ7.G?0#Q]YJ,PY(>5M992IQQ5B;)0+DV%ST
M% :Q)3$Z(Q.BK\R+);0\PNQ3N;<2%)-E $7![10"U % % -962@0FY3DE]*!
M"8^;E)'B6VQ99WE";JL?+7;36QM0"S#S4EAN0RK<R\A+C:K$72L7!L;$:&@%
M* * 2DOMQ8[LIXD,L(4XX0+G:@%1T'L% )XZ?'RN/B9.&2J)-9;DL*4"E1;>
M0%I)!U!L>E (XS,0<N9R82E*./E.0).Y)39]D)*@+]190U% ;3\K#QKT!B4I
M27,E(^3BA*2H%XM./6-N@VM*U- /: ;2\A$@KBMRG/+7->$:,-JE;GE(4L)\
M(-O"A1N=* 1PN8@Y_&1\OC5*7"E!2FE+24*(2HH-TJU&H- -,+RK"9_R!CGU
M+<DL+EM-K;6A19;>+"E&XL/&+6O>@)J@"@"@"@"@$GY,>*E"I+R&4N+0TV7%
M!(4XX=J$B_52B; =M )Q<A$FNRV8SF]V"[\O*3M4G8[L2YMN0 ?"M)N-* <T
M BY*C,O,QG7D(D22H1VE* 6X4#<K:#J;#4VH!![*PX^4B8=Q2A-G-/OQTA)*
M2W%+8<NKH+%U%N^@-968@P\GC\0^I0FY,/JB)"24D1DI6Y=0T%@H6OUH!_0!
M0#"5F(,/*8_$/J4)N3#ZHB0DE)$9*5.74-!8*%K]: ?T 4 4 4 P_7$']=?J
M#<K]9?*_/;-IV>1YGE7W=+[NR@'] ,L9E(>7C+E0E*4RV^_%45)*3YL5U3#@
ML>P*0;'MH![0#7&Y*%EX361Q[OG0WP2TYM4BX2HI.BP"-0>HH!U0!0!0!0!0
M!0!0!0#")F(,[)9'%1U*,S%EE,Q)20D&0WYB+*.A\/=0".+ST7,29C$)F08\
M-Q3!G+;*(SKK:BAQ+2B;KV+24J-K7&A- 2M 1^7SF,P3+3V2?\KSW Q&:0E3
MKSSJ@2$--MA2UJL";)'37I0&V+RK&686\PS(8\M9;6W+CNQG 0 ?A=2DD6/4
M:4 Z?>:C,.2'E;664J<<58FR4"Y-A<]!0&L24Q.B,3HJ_,BR6T/,+L4[FW$A
M2390!%P>T4 USF<Q/&\8]F<W)3#QD<H#TA84H)+JTMHT2"=5* Z4!(4 4 4
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M :\=Y$F9SG!2\4ZB/C^1-9)Q^"J>]-E.HCA*FW7V5%3;"D*\.U)W)W;#T(2
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M?HH!AF9D3%,HD<-SS\QR9@\I*RKPEKF70Q#*V9JMRB&G ]M2DI"0K<1;PC:
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ME-]QLH)4KQ ;<AY<B1#Q*L)G-[RN,9F<XJ,]O\;,2.6WEV-MR5*)3NUO?VT
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M,S(Q.'9:8Q^!1'G-B',RTIIA[(Q926W U-9"E/I0@[VA<:*OMNBR )7&$.Y
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MCML(:1Y;:6D)0$HO?:D) L+]E :Q\=CXBPY%B,L+'F64TVA!'G*"W-4@?$H
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MI[#:@-H^/Q\1Y^1$BLL2)*MTEUIM"%N*N3=:D@%1N2=: S,@0<BR(^0BM2V
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MK::6N?KH!!>)QZ\FUF%L).08;<::=_12]LWFWZ1#:!NZV%NE /: * * * *
M* * * * * * * * * * * * * I7J9D([>&C<???>8'(I Q[[D4.JDHA;%.2
MEMAA*U@^4DH"@/"I8H"*Q/,<[,P/&H6*^6=S<R=(PF0DS4O)2RK'L/K4^6CY
M:R7$L)6E!VW\P:@4!ESD65@8?(S,*(S,E.9R./CX]Y$B8[-FF0I+26R7T>7O
M(4I8U0A-U:)2: =)Y'S69#RTW'HQI5Q[^;3&%I?M.G1V$.RDM+*D^0T"O8TI
M:7"2+J%NH#9WG'))L+.Y_#QX3>$P3$><EB5YBI,MAV U/<1N0H)94E#NU"K+
MNKJ * >YOFTC&YR(S$D,2H2Y,&++QZ(LE4AE.16EM+CDE!4RVI)6E0;6D73V
MZB@%.4C,KYQQAO"^0A]<'+I>E2@IQ##6Z$2I+2%(+BB;  K2.IH"M9'E4YK-
MX[*9N*W^L>+#/MSVXBB&G_EH3$A"FMY)3YC;B/"HG:JXN;7H">R?*^4\2:CY
M#E$>'*@2X\E:FL>'&W8TR/&7)2SN<4H.H6EI:?,VHLJWAVGP@8RW+.4<09CY
M'E$>%*@S&7R6H'F-N1IK3"GT,;G%+#J%AM2?-VHVJL2G:?" @\CDR>>\./(E
MPG-[&46GY%+K?DO%EF[7WBE>8FUR'/"=/AUH!23DTXCE/,9GSC$%PQ\*VW(D
MMK?1O<,A("6FU)4M9O9*4FY- 0(Y%F^39SBSD5MEO,0<IF<8[(?:?88V,1"?
MF/EG"'02"C[I2^I^*U 73!9WD,S)2L).8AN3,1+#.5E,K=:0N(_&+\=YEM25
M^,J*4.-J<\-BH*(L* J_)9/(G9/J5&?G-/8&-@@MB!Y:TN(+T25\+A<*05%/
MC.PWTZ6H"1E<PSO$HI>Y$Q$DQ3AWLG%:@!U*VWH:H[2HZBLK\Q*S(1M<"0>O
M@Z4!)<6Y'F\CEW<9DFA(C?*B4G(L09D!EIX+"%QU"6/&2%;D+21<!5TC2X$4
M>?9B1E'U0(A>QT;*'%F B#-=D/--OB,](3*0/(3L4%*"""-B3=0)T 4A\PY.
MMC&9N6S!.'GY9>&5$9\POI29;L1J2EU2MINI"5*:V:))\5Q:@(R%R3F^,PZB
MM^%E,ED>32<-"6\V\RU';,R2A2U_>J*TMI;'EMI*=!MW=H F)W-9>.Y+!Q@E
M1LE$D3F<3,9C1)"51WWF2O>N3O6R%;QJR;$)(UOU ;8?FO)I43 Y[(L0D8C-
MSUXTPF X9#-UO(:>\U2MJKEL;V]@L#HHVU <'E^?B<6<Y_DD148)40S8V'9;
M<7++;P!BA3X64[U[D[TADA-]+VU >\6Y'F\CEW<9DFA(C?*B4G(L09D!EIX+
M"%QU"6/&2%;D+21<!5TC2X$!@,GEV<OE\#A$,HF9/.Y:2[-E!3C4>-$1%2M0
M;2I!6M2WFTI3N ZD]+$!"?D^39/E7'(:F8;/(<5D\ECY$@%Q4,M+QJ)*)"6[
MA9NVZV/**]%$^.PN0%<CE>2SL[A,6I$,\DPV<<BN21YJ8:XTG$27T2/+N5[@
M@E)9W_&/CVF] 2D;FF9@Y]OC^=;BK\F<C'S)\=+K:5">P7H+H0HKV;EMN,.)
M*CXR@@V-@ ]',IK7"Y7+WH25AUQ7ZGAI):4ZP_(#$,NJ5?:7=R%J('A2KH;4
M!7^<9CF.,P>7PV0D0?FLEAI\K'Y&(T\UY+L-"5/LJ;+BB;MN$M.A:;$:IZ7
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M2L=C,GG/OL?CT19617Y/E[TH"&'$K6J^KBTI"4 VZ^(@.<+R[D'+T158%N)
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M0D;?L^'2@(#^K['%T3CDL@<Z)"97ZZ\QKYNZ&51PBWE>5L\M2D[?*[=WQ:T
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M;@ '2@%'^#8R>N<O,2YF4$R,]!0F4ZD"/&DK2XXEGRD-E)*FVSO5=0V)L=*
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M2DZB[06DW6/L@D7H#9[FD=EMD?JG*/3EL&4_CV8OF28[ 4I 6ZD+(!64*\M
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MB5&XN!3L3SG,S<2O.OS),&7DVLNN'BYL-!;3^KFW%->0MM7A" D>:7M_F*T
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MFXH!]A.:1\@UBHS:9&5G38S,N1*B13'9:9D.+:;==;==4IM*U-KLD*6JR2:
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M0$9%Y?ALB9:,2X<D_!FC'3&(I0IQIS>A"UJ"E)\"-]U*'<;7.E 2WST+YO\
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M@3$K7#E,R$-+\MQ33B5A*Q]E1238Z]* V9E19#:G8[[;K2%*0M;:DJ2E2-%
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M!=F>IIIQ"E$I"5V6I-R1I91H!U)FPX00J9(:CI=6&FB\M+84XKHE.XBY/8*
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M+20W=!3<7-^@ZT VR'(\=!2$LK$V5\W'@*BQEH6ZAZ2X$#>+^$)!*U;OLI-
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ML,OBE23"3.CF8%;#'#J"Z%_H[;WO[* 49GP9#C[4>4TZ[%.V4AMQ*E-*UT6
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ME*5%!VJ4.G6@*VIM$>*,>K'"!Q7*S\A*Q#DO%KR)9;5Y*$1F8RDGR?FEE]Y
M<2!L\.VYT ;XO&/,C%.9;&.C,3>%B#'>?BDR3D&$+*VE+"24.A!^%2O8+T U
M7@W%[H?)I3N+8GXC%Q,4M[%?K#8VF&E#C;+EE*9>;?WK4@A)N4J%^P"QY3BC
M;N)]0I+^.7,S-T'&SG&U+E..1,7%#3K"@+A0=257:MX[]M 3G&HT&'SSE =@
MICY*;\I-C2/EMA=8^5:;=4EX(L?O00I.Z]];4!7\SC6$.\T@Q<9MS4K*8N>Q
MY,0A;T(KQX6XEU* %I\QMS>-UP4DD=M )RX6-.4Y-@T+<?P.0;G/YG*-07&L
MAC'UNH<\LOAK^=-.+*BAO:HA";>)OH 8O).PI7'N09."EG!8U[*0!E<?!=CL
M/-RFXZF92HH25M)<4A;:C8IWBX.U2: CGH<Q;L7)Y%F1B\"K)Y]YQ<S&F:EM
M^5+0J*\\PNY0EQH+#;FW3=8V*J N2,#B$>F3^(E9.2O"O-.NB>S&4RXTTZ^7
MD);C);)#;=P@-%!'EBQ\- 59[(2)N'@XS)8R+%Q3IG(B9=G"*E-S%)4A+268
M2P?)7(2I:CYEPK8=MP;@!UAN-G(LM/Y[$N29C?"L;$!FM*6I,K^<EYNRK@/7
M"-]O$--: 93<"O$<>XX]C\<N&^OBV3CYF0AM2'2HX]I:1*</B*_-25;G#NW7
MUN30&L"-@YV%XZQQ;#28^3QV(>&84(KL=QN,]BEH^6D+4!YKCCRF5)3=9)05
MW[2 Q<P;CA5$Y-+=Q;.0Q&+B8I;V*_6&UM,-*'&V7+*4R\V_O6I!"3<I4+]@
M'3\]!DA[AK2?.F&%E$&1)4G<O:C'RVRZX4BPNHBYZ7- 4[CO&QB^/>GTN)BE
MQLRU/2,@^&5"4EF0Q)#P?61OV*)3<+-K[>Y- /.2O<=B^J+<ODL-4F&CCVQI
MY<=<R.TM<ZQ2IM"5V6O0(44:@*%^P@1F$XS.<R$1;>+>C/1,%E3QX3D$B"J3
MD2Y";)5O"'6V?+ 'Q(2+=] 0\+"Q_P"CLQY61>:SF*X]D&LABQC/U<^I;L,H
M<3)D 6<(<'F!6\[E>,$C6@)>$K%"-@IG"N/R#EL'BY#F4C&*Y&4MDP"$09"E
MI'FNNOEI0%UFZ%*OVD"'?Q;V5C<A:A,N3\1DX>&"S!QCN*BN.M90AYMM%@M1
M;;-EE7B"+ GN E>=HD.SI.*Q>/3!EXE[&G"1H6+4[)D1VWF'%/HE)3L9::*G
M$$(LI(2HGX@* =Q\7'BN<AQS6,\K*?TIQ^0<2S%*5.8]V=$<2Z%H0 M'@6I5
MB=I!O0#-,-E>);P(QCW]9[>53)7D#%7YB7/GO,5-,K9M,<LZ?'JC[K;?P4!*
M#C3#6$.3CXE2,X.5KF-R0TKYL-.9LI*PH^(-F.HBWP^6>Z@)OEV&D9'D^*DP
M(C:L@WB<PW$R#C*5B/+48ACGS"D["% J3[C[: K.&CXM]7$(F Q#\+DF(=0>
M0/.1'&7&&!&6F4W*>4D!XOK(V^)>]5G!HG=0$[@,,G">D"8D+'KCSU8-;C\8
M(5\RY+5$.[>#XU.*5IKKV4!&XW 9=K-0N,/Q7?Z/23$Y#-D!!$=+T5A#+D19
M-P5.24-2-O<%T Z]/XV23E,<]-B/L!OC,&(XMYM2 'F)+Z5()4/B  -NXT!O
MQWB2\G*SZ\T_,3C#R"3,9Q"@AJ*]Y9;4VXH[ XX@J2%[=^PD="-* A_U"Q Q
M\?+9'$NO8U?)<E.Y*VEA;K[S)D2Q%>=0+K<8:6IMS8 0$V4!9- )'#0LMGF<
MCBL*I7$W\YCW8R'8I2PIU$*2F5*;8<0"VVJ[+97M2%+25:WN0"=A^0.1IK.)
MBR&<BXSS%,-U*%)*5R<@RIK:H[0%.("O*)(!ZWM0$QP7$89_*2)D28'DI@F#
M+Q Q/ZJ;2A:TJ2E])0 I;>U2 D_"%*[Z OPQ&)3(,M,&.)9()?#2/,)2M3@.
MZU]%+4KWDGMH#E?J([D,AEIL2-$+&4Q\C'.8I,;&KD3);27F'%R!,V[6FVBI
MQ!VG<D)43\0% ;3N-J_H]S'(MXMS^D"N0KEX^6&5*E@-OQO+<85;<$A*3;9I
M:_>: RZY-R'.L;,:B_+3H.=?9F18V,6VMN$69+*)$F<1XDOI#:P$G;XDI.J;
MT!'P\7FX.&X[CXS3L=[F..3Q[)H+82[%7&\QY,A:564-L8R&[_I>4* >Y2"Q
MCLMR'$\<C#(M3X,]$YA4%Q,K'*3 *&@Q)* %LN%"&DLZD$C8=H( "L%+&#S^
M*?9;$N5*APTY^%+AJ0[CV&H'EJE,S5) ;;2E*4N,E1!45;=JRH* L&0981QG
MB>:XKCG96%PSL:>QC$)69!Q[D5QB[;;EU*<;0\'$H4=QVV^*U ;<@YIC<A@Y
M(PK)R(2MA$_YB#(=:BQG'0EQ]QA;:"YY0\9;'BTN; $T!5,)Q].2,.-,A.3L
M(.5KF-%V#\C&<CG"JLZ(Z0$ADODV*A9:]3J: 2R<$P&IV4=9/ZZ8S>9<P^*F
M0')L7(HD*:/E[4H)0M90@,O C;XM%)W"@+]R9,Z0KBDMN$X9#&1^9?BHLLMD
M8V9X%+'A WE+>XZ7(H#F8CSLRQFY,2"X7Y_%<O'G0(.+7C6V,@YY!1"\T[5N
MOI)<"=W350V[K4!*96!&RJ&F?3K&/X_(PL3/B9)2([D!P(<80EN(XMP(W/E8
MN@[E>6057%_$ GG(V*R\9P\$P\B&F)@LO%RH9ANP5!#L/8S#6E2$%Q\/;5)2
M-Q1M5J-WB VYS!1'Q2^*8_%H@L,X12\.(^*.0E2Y:T.E;#"P-K2VU(0M15XU
M*6%7%B: UR.*D+D\O99QS@Y!EL=C)49;+/ER9<9IM"9Z&I 2G[Q:0IL@K"KD
M>PT!KRB)B<]&R;O"L0^UC_U%-@Y8QH3L)+SCJV1&CI;*&U*>:(<5=*;MIN+C
M=0$SR? JQF<:X_@(XBXKF["<;.;BH2A,8PKN//VN GS(I<9N!\8;[Z FN>0<
M6RGB\N;CVWL5B\HCY@_*_,ICQG(DA@'8E"R$;U-)T%AH3TO0%2A87S>1OQ,U
MD%P<\K-KG1@<4''766Y/FQRQ-LO[HLI2RK4;4[D$"@'6-&*1Q3)X25C7&O4/
MY')?.ER*XN4]+6V[O=;DA!"T.WNT4N?"0C0C: $<IQM6,Q?'D8+%+BN+XUDX
M,_Y5E27%?S!HM-/%(W%7F)\&_P 6Z]NIH#&4XVK&XOC[>$Q*XZW>-9.%D1&8
M(6N\!HM-/D"ZE%Q/AW^+=?O- /N/#!XJ>ZURW&.#(2T8U.&DRH;DELQ40V$)
M8:4$.!M;3X=+B#M-U;^AT C,HE]N*]A<C!\B%-FY^0W->Q9RCKCSN0=#<9AI
M0VI4\V?,"E:+%@GM( D>-\7;R:7W>38E4F2KBN$B*,]HK5YP:E^>@;K@. E.
M^WBZ7/2@&F);<QV4XI-0VO(<DG0,0QF<9D(;SCS+:60A<IF4M-F5M;E*=0I5
ME:C1PZ@+^J&)GY#(Y81H4B2T_P <,7<PA:MREY%DJ;"D:[BBYL-;:T!9H6(;
MQ?J*I>,@B'BY&%M)5':\J,N0U*'E[MH"2X$*5;MVGNH"H9F+ #'+\1F<1)F\
MSR<N0[@GD1UNO/(6A(@KC2DIVM)CV3N\:?+4E2CUNH#'('9$# \VXO(ARI?(
MLJ^F7#9B175HEH>C16UNMK"=@2E:%[P5 IMTU3<"Y\-P[47,<LRCT+RI\O+N
M;)3B"''(PC1@D(4H7\NZ3HGP[KGK>@(WC'%')KN4D9B3-^2;Y!.G1L2O:S&4
MIN25M.&R XXC<$NH"EE.[6QH"&QW&Q&XYQ_(-8I;6>3R4R9$D-*3+#3^3?#J
MUJMN\M32S<'P[#W6H!G$B1U8J!@DXM\>IT;*-R9$]<9PN(=$WS'IJY>T)5'6
MUN%O,\2%!JU_" ,\2PF[*8YK)Y%V/RK'2I,R9"5C W)></G!P+G!*@XRZ%7"
MM_B3M&BA8 2G'>,,8O%>G,B+BC%R+:"UDW@TI+X;>QCY<3(4?$0IT(OYGVPG
MMM0$$G#9 XWC[B,3*5C,=B<6WS6$&UI7D&&TA3,=""+K7%)\UY(U4W=G7=M
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MN[9<D WMK0%G@8E&+]1'U8R"(>*DX9'S!CM>5&<DM2E!&[: DN)0I5NW;[*
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M .B<9E/N8QK'SUN.9C&-1XF4><;<2E<L1VUN*0M:4AP$J^-%Q>XZ@T!,T 4
M4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 S>Q<1_)Q,NXD
MF;":?8CJ!( ;E%LN CMN6D4 \H H H H H H H H H H H H!O/A1\E!E8Z6
M"J+,:<COI!L2VZDH4 1TT- ;0XK,&)'@QP4QXS:&6@3<A#:0E.ON% +4 4 4
M P&'@C-'/[#^LE11!*]QV^0EPN@;>E]QZT _H!MD8,?*8^7C)B2J)-9<C/I!
MVDMO)*% $=-#0"L=AN+':C,BS3*$MM@FY"4"PU]PH!2@"@"@"@"@"@"@"@"@
M"@"@"@"@"@"@"@"@"@"@(Q."@C.+Y"X7'<@6!%8#BRIIAHG<OR4=$EPA/F'J
MK:GNH"3H#1YEJ0RY'?0EUAU)0ZVL!25(4+%)!T((ZT!E"$-H2VVD(;0 E*4B
MP &@  H#:@"@"@"@"@"@"@"@"@"@(UK!PFLY(Y"HN.Y%]E$5!=65-LLI.Y26
M4=$;U *<M\1 OT% 25 % % % % % % % % % % % % % % % % % % % )L1
MV(K08C-(99!)#;:0E(*B5*-AVDDD^V@%* * * * * * * * * * * * T>99
MD,N1Y#:76'4EMUI8"D*0H6*5 Z$$=10&R4I0D(0 E*19*1H !V"@,T WGPH^
M2@RL=+!5%F-.1WT@V);=24* (Z:&@-H<5F#$CP8X*8\9M#+0)N0AM(2G7W"@
M%J * * * A,[QEK/.,K=R61@I;2IMQK'RE1D.H5U#@2-?>+'VT!*PX<7'Q&(
M$)I+$.,VEF.R@60AML!*4@=P H!:@"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@"
M@"@"@$PPP'U20VD25I2VM[:-Y0@DI25=; J) ]M *4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
C 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>pg_casevaluegrowth-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg_casevaluegrowth-4c.jpg
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M%!04%!04%!04%/_  !$(!+ #A ,!$0 "$0$#$0'_Q #A  $  04! 0$
M        !@,$!0<( @D! 0$  @,! 0$              0<$!08#" (0   %
M @,# @L/#PH%! $$ P ! @,$$042!@<A,1-!"%%A(C+3%+1U5A<W<8%"DK(C
M<[-T%97%-H9(D:&QP=%28M(SPR14E,06X7*"DS0E-28G&.)#4V15HF.$A43Q
MPH-&HV4X$0$  0("!08)"@4$ @,! 0$  0(#$00A,1(%!D%1<;%R-&&!D<$B
M,K(3,Z'14H*2PE,4%37PX4)S%F(C0R32!_&B)6/B%__:  P# 0 "$0,1 #\
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MM?MCWQP<7A8<&/#U.*E: GD;4TI\F&3.\EN[E;!$I>
M
M
M         #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
M
M
M        -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
M
M
M       U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M
M
M     #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
M
M
M    -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
M
M
M   U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M
M
M #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
M
M
M-0_2>^9/QH">1+]*?)ADSO);NY6P1*7@         "F\^S';-Z0XEII/7..*
M)*2\TSV +)N_V%Y9-M72(XXK82$R&E&?G$H!D=^T@
M      !#\W:I9$R)-8MV:KL5OF26NV&6C8D/8FL1HQ59;61;4GO,!;98UBTY
MSC=F[%ER]%-NKJ5N-Q^UY+54MEB4>)UI"=A=,!.0
M !1>E18].V'VVJ[N(M*:_5,![;=:>3C96EQ'WR#)1?5(![
M     !$,WZH9%R'+CP<UW4K?*E-F^PV;#[V)LE&FM66UD6TN4!:9:UDTXSA=
MV;#EV]%,NKZ5K:C]KR6L1-)-:NJ=:2G81&>\!.@
M                                   &H?I/?,GXT!/(E^E/DPR9WDMW
M<K8(E+P        '.6M7.-7EB?)RCD7AO7J.9M7"[.$3C49TM[;2#JE;B?1&
MKJ4GLH9UI."'*M\S/F+,TE4S,%TE7*0HZXI+JG"+I)29T27225!(QAH6226:
M3)"NM49;#IT# =@<T>'<CRO>[O,E/NPGI;<.%&=<6IIOM=O&XIM!G0L1NI(S
M+[T1(Z*$)            6MR@1[K;I=KED:HDUER,^23H9MO(-"J&6[88#YJ
MWZ-=\OWNXV*;(=*5;9+T1[JU$1J86:#,MNXZ5(?I#JWFDYF<N.5;SEV2Z;DB
MURTR6L9F:N!,1N*O(2VEG_2$2-Z9CO+&7<OW2_2:<"V17I:R/E)ELUT\^E!"
M7S2DW:YRY#TI^6ZI]]:G758U;5K,U*/?RF8_2';O-GRV[9=-8]TF8CG7YY<Y
M9N&9J)A/K3);>0TIQE_.$2EN,0   X[YWWRTL7>O]X=$PA&N;!Y6X'N29[48
MF1W2/RD                  $0U&U&L&FEA5>;VHW'G3-NWV]HRXTEXBKA3
M7<DMZUGL271,R(PXQSMKYJ-G-]U)7-RS6I1F3=NMJE,))'06XFCBS,M]54Z1
M#]8(:T>??DN&](=6\ZHZJ<<4:U&?3,ZF K0KE<;8Z3]MF/PWT[4NQW%M++S#
M09& ^B^F3-W9T_R[[_2WIUX=A-2)<F2HW'C7(+BX5*/:9H)1(V] ?E*5@
M            Y;S1SN9427)@9>RTVE<=Q;7;%P?-9&I!FFO":)/*7_4$X(;>
MT1SK>\_Y'1F._FSV^[+D-88Z#:;2VVHB21$9J/9T3,$M"\[_ .5F7N]R_;U!
M"$1YLOE>M7N>9W.L3([N'Y2
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MJ=MT]E)-IE<,C4MM:"V$X22-9&GJ3(CV$9=5& Z"$)
M                                   &H?I/?,GXT!/(E^E/DPR9WDMW
M<K8(E+P       :5YTQ.'I2\:*X2GQ#<I][51;?/H)@<.B4/IWE]^/*L-KDQ
M3)45Z''<84GK3;6TDTF5.2AC\I9$!Y<<;9;6\\M+;3:36XXLR2E*4E4S,SV$
M1$ Y NFH&@>1)DF-D_)[>;+@3KBG+G<#2J+C4HSHT;J'*I3N+ TDJ;C/>)0U
MGG_4BW9YC,M,Y0M-ADL.$M$VVMFT\IO"9&VO#A2I)U(]J:E39RB1'\CSY%KS
MGE^XQ5&E^/<8CB#+EH\FI>89;# =!\\.#<3?RM<L*E6E")4?&5<*)*S;70^@
M:TIV='"?0$0- 9%S+;\I9DBWNZ62-F"$R2DN6V:1&VK$5,2<25I)2?0XDJ+I
M"1U-D#,V@&?\P6R9;[+'R]G2(^F1!C*;3#4X^FM,"F#)IWI)5U72V"!&^=]F
M:2E>7\H,K-,5:'+I+07HU8C99KTDT<^KT@@:.TNO&1[!FIN\9]@OW.TQ&E+C
M08[3;Z7)54D@W4.K0DT)+$JE>NILI42)?K5G[2[/D2WRLG663:K_ !G31(=7
M&CQFGHJDGL5P'%XEI42<-2W&>T!9<W.]OV;5FS-MJ,F+F3UOE)(Z8D.MFM)>
M<XA!^<$CO8?E+1G.HRO[\Z>-WUE&*5E^4A\U$53[6DT9=(OZ1MJ/I)$P..LM
M7I[+F8K5?V*\6V2V):2+EX+A+,O/(J"4-Z<[3,S=TS'8+'$=XD2%!.<9IZTU
MSE=3_P"AI)E_.$0,5S5\K>_6H;E]>1BB9?C*?)1E4NV9)&RT7I3<4732)D>>
M=1F.3==2/>,W#[2L45IIIJO4D]*0E]Q?FJ)3:3_FD$#$\W?(%JS[GE;5^:*1
M9[3&5->BJ,R2\YC2VVA=*'AJHU'T<-#V&$C8_.=TLRQ8;#;\WY9MS%K=1)3!
MGQHB"99<;=0I2%X$T22DFC#4BVXMNX1 YZR5F"5E7-EFS#$6:';?+:=50Z8F
ML6%Q!]):#4D^D8D;KYWNW.EA,MWO7^\.B($:YL'E;@>Y)GM1B9#G/^5N?[DA
M^U$$"2\T'Y:7WO7^\-")%]SP_P#',K^Y)/MB @:\YN7ECRY_\SN)\3(D7.R\
MIL3O1&]OD! CV@6GEFU&SH[;LP&M5JM\-<YZ,THVU/FEQMI*#6FAI35S$9I.
MNR@2+GG":;V33K-<)C+B5LVBYQ>V&XKBU.\)U"S0M*5+,U&DRPJ+$9G4S"!@
MM%\D6W4#/\&P7A:TVOANRI2&CPK<0PFI()7)B,RJ?0K3: EG.-TOR]IU=[-(
MRNTN-:[NR\2HBW%O$V]%-&(TJ<-2J*)Q.PS/:00,?S:)CD75ZSM(,R1,9F,.
MD7*DHSCI$?\ 2;(PD.<CF:3F#5&Y0U+,X-D2W;XC==A&E)+=53=4W%**O0(N
M@$!HMG;2_(Q3[CG6SR;M?'EDW!4B.Q)98CDGJC(GG446M1T,\)["*A[3 1W5
MF_9%S-FGWZR';G[7 DLI.=$>::83VV2E$I;:&EK225)PUW=54^4!N3F?7N04
MW,N7%+,XJVF+@TV9[$N(4;3AD7X1*17^:0B1U<(2^8^92=+,5W)_\L4V23E=
M^+BJK]<?I#JGF?O1U97S''29=MMSVG'2Y>&XR1(^NA8B1:\[Z%+F1LHE$C.R
M%(<N&+A-J<H1E'WX2.E0@<G.-.,N*:>0IMU!X5H61I41ER&1[2$CK3FM()S3
M/-J#.A+EO),RZ<-!")')(D;WT>YNQZB6 LTWNZ+MUI?<6U"8C(2MYTFE8%K-
M2SPI3B(TD6$S.G)RL1EM=[2G2_3W+>F%JG/2X$R9+N4EYTDH6I#1I-MM6#89
M8G35YJ2,1 TKD'+:<X9SLF6G%FVQ<9;;,AQ/7)9KB<--:[<!'3IB1UOJ[HGD
M0M-[I(R_98ULNECBKFQ)49&!U28R3<<0ZKKG,2"475F9UH8A+B9*E)42DF9*
M(ZD9;#(R$H=4:Q-2<^: 94SW((W+I;4QW)KM-IID%VL^K^DZEM0@:9T+NAVG
M5G*TC%A)Z7VFKIE,;4P1?560D7VOEU=S)J_?&XQ&[VL\U:XS:=IFJ.A+:DET
MS=QA _>;W>56'5RQDZ>%N<IZW/%6FV0VI*"_K"0$C#:RW3WXU2S7,)6)*9[L
M5*OP8=(Y?6; =+Z+:49;O&CEKAYNMY3F;I,7?> I;K6%:DG'955I2#,N$52*
MM.J$#CN[LM1KM/CL)P,LR'FVT5,Z)0LR(JGT"(2.HM M(]/,Y:>,7K,EE3.N
M:Y<EI4@WY#9FAM1$DJ-N)+9Y@B1&^=TTVQF?+;+186F[8I"$]!*7E$1;0@:M
MTAR7!S_GZUY:N;JVK<]Q7I1M'1Q3<=M3F!)G6F(TX:\A"1LKG&:/Y5T_@6B^
MY3:<B1I;RH4J&XZM].,D<1"T&X:E%4DJQ=53=2@B!JG2^<[;M1\J2F3,EINL
M-!TV50Z\EM9>>E1D)'T@'Y2
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M "]RMWWM_=+8D?2D?E(
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M?H^D WESE=-]0,\W*T3\M0$W&T6R*M"F6WD)D$^\Y5P^&X::D:4-TPF9](1
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M+G[)FC.J%NSCEZX3<LRV8<6YPWY#RN'A0TT^A2E'1>XB*HE#N\?E(
M                                              U#])[YD_&@)Y$O
MTI\F&3.\EN[E;!$I>
M
M                                            #4/TGOF3\: GD2_2
MGR89,[R6[N5L$2EX
M
M                                           -0_2>^9/QH">1+]*?
M)ADSO);NY6P1*7@
M
M                                          U#])[YD_&@)Y$OTI\F
M&3.\EN[E;!$I>         @DG4N.K4=C3>S6YRYSVV.V[U-0XEMF T9$98R-
M)FI1DI'4E3KD[=] B%SYT.F]JN4RUR6+H<F"^[&>-$=HT&ME9H4:3-XJE4MF
MP3@+7_=AIA^KW;]F9[.& S.4^<5D+.688.6;2S<4W&X*4AA3[#:&B-"%.'B-
M+JC+8D^0,!5T6U:N.J7O_P"^%L8MWO.Y';;X#JW>(;_%Q5Q)*E.&5/- ;6$
M                   "&ZIYTDZ?9)GYKB1437X:V$ICNJ-"%<=Y#1U-)&>S
M%4!>:>YG?SGDRT9HE1T1'[DR;RX[:C6A%%J30C,B,]B0$F 1O,V<8.5)=K3=
M65MVB>XZS*O!J0F-"<0T;K9/U/$7%PFA!D5,5"/>50P-]U+GV33Z-J K+,M;
M"B0_/M3CK;<R+$=,R2\I)$LCV85&C8:25U5,*J!,K'>K;F.SPK[:'B?MMP93
M(C.ELJA95H9<BB/8HN0]@#(
M
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M$1%4SIL$#7?-RFRK)*SCI=/=4XK+%Q6J I>\XSJUH5AZ"<2"<\UP3(WR(
M
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MF.24M85]55.#90ZUV"$K@!S[DXSA<Z?.\1K\C)M:'7"_#-$)=?JJ/ZHD=!"
M
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MA)PW"+SRY D;N$#G[2.F8=<]2\W,]7#BF5J:>]"HR<2WU)\NR+7SQ*'0(A(
M
M                                        U#])[YD_&@)Y$OTI\F&3
M.\EN[E;!$I>         T)D2%,TCU7O&2W8[O\$YM7[X9?E(;4MEB54R-A1I
M(R3L,V]OWK?WPE#?8A*(0--,IVS.<O/T2.ZG,DY*TR'S>6ILR<)*54;,\);$
MD EX"(Y'TURIIY[X?PQ'=8]]%-KE\5Y;V(V<>&F,SIUZ@&7S/EJTYOL4O+E\
M;4[:YQ(3(;;6IM1DVXEQ-%)H9=4D@#+&6K3E"Q1,N6-M35K@DM,=MQ:G%$3C
MBG%54JIGU2C 0G..@FG&=;@Y=Y\!R#=7E&N1+MSG:ZG5'M-2TF2D&H^56&I\
MIB<1<Y*T1T\R',*YV>W*?NR/R<^<LY#S?)5%2)"#_"2DCZ8@;"<;;>;6TZ@G
M&G"-*T*(E)4E14,C(]AD9 -/7#FQ:4S[BNX)B2XB%J-:H4:2:(U3VF1$I*E)
M+I)41%R"<1)YNC>GTR-8896OM6+EIU<BU-177&B0ZXIM:U+,E569FT@S-9F8
M@5<]Z2Y(U&=9E9EA+<GQF^"Q,8>6RZEK$:L.P\)E51GU23 87*G-]TSRE<FK
MO#M[LVX1U$N,[/=-\FEI.I*2@B2C$1[C-)TY!.(E>=L@96U"MB+7F>$4EII1
MN1GT*-M]E9E0S;6G:5>4MQ\I;! B64^;WIKE"YM7B+#?N$^.HEQ7+BZ3Z65D
M=24E"4H14N0U).F\MHG$2K)>GN6<@-SVLM,NL-W)TI$I+KRWB-Q)&1&6,SIO
M$"CE/33*>2KK=+U8([K,^\*-4Y;CRW4J,UJ<V)49D75*/< SU^L=OS+9IMAN
MJ%.6ZX-*8DH0HT*-"MY$I.T@%GE#*%CR-9&\OY>:6S;&EK=0AQQ3JL3JL2NJ
M49GO 0[.>@>G.=[DY>+C"=A71\\4F5;W> ;ROOEI-*T&H^56&I\IB<1<6;0[
M3FQ6"Y9>@VY? O#1,7&8MU2ICK1*)>#B[#2FJ2,THH1\I ,RK33)SN3&<@28
M*I&6(Y4:C.O.FM)DM3A'Q"42ZDI1F6T0(-&YKVE$>6F2N+-D-I5B[5=E*X1T
MY#P$E=/Z0G$;<MUN@6B#'MEKC-Q+?%034>,RDD-H0G<1$0@1753.3V2<G3;E
M 8=E7R01Q+/&8:6\M4MU)DE1D@CZE!56==]*;S(!CM$\@NZ?Y&BV^X%_?UP6
M=PO"C/$HI#Q%1LSVUX:22D]M,53+> V*
M                  *+\EB,G$\LD] MYGYA ,<Y?$D=&6C,NBHZ?6(2A3*^
M/5VM),ND9D N6+S'</"Z1M'T3VI^J0)9%*DJ(E),C2>XRVD('Z
M                                       U#])[YD_&@)Y$OTI\F&3.
M\EN[E;!$I>
M                                        +.X3DPVZ)VO+ZQ/0Z9@(
MZXXMU9N.*-2SWF8E#R   "[A3W(BR+KF3ZY'VRZ8"1MK0ZA+B#JA15(Q"7H
M                                              &H?I/?,GXT!/(E
M^E/DPR9WDMW<K8(E+P
M                                               S(B,SV$6TP$5E
M/G)?6Z>XSZDN@DMPE"B      ,Q9)!]7&4>SKT?;(!F!"0
M                                :A^D]\R?C0$\B7Z4^3#)G>2W=RM@
MB4O
M                                6\Y1HB/*+?@,OJ[ $7$H      !=
M6U1IFM&7*9D?GD8"3"$@
M      U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M
M      H3$&Y%>06\T'3S2*H"+"4       N[6@US6N@FJC\X@$E$)
M                                       !J'Z3WS)^- 3R)?I3Y,,F
M=Y+=W*V")2\
M                                       !^*4E"36LR))%4S/=0!$W
MN&;JS:KPJG@KT!*'@      9NS1C0VJ2LJ&YL1_-+E\\!E1"0
M                                   :A^D]\R?C0$\B7Z4^3#)G>2W=
MRM@B4O
M                                  ,R(JGL(MY@(_<KAVRK@M'ZPD]I
M_?']P2ACP     !D8%L6^9.OD:62VDD]AJ_D 9XB(B(B*A%L(B$)?H
M                                         -0_2>^9/QH">1+]*?)A
MDSO);NY6P1*7@       U;JIJV_IQ<;?":MK<Y,UE;QK6Z;1I-"\-"(DJ'2;
MIW/3G:*JIJFG9G#4XOB#B&YNVY133;BO:C'7AR]" ?[HIG@\S^TJ[&-Y_BMO
M\2?)_-R_^=WOP8^U/S'^Z*9X/,_M*NQA_BMO\2?)_,_SN]^#'VI^9),A:]2<
MYYLM^6UV9J*B;Q:OI?4M2>$RMW8DT%6N"F\:_>&X*,M8JNQ7,[.&C#GF(YVV
MW1Q;=SN:HL3:BF*L=.UCJIF>;P-VCCUC
M                                             #"72X8S.,P?4%L<
M47+TBZ0E#%  "[@0E3'-NQE/7J^T73 95RSQ%[4XFS_!.I?7J(2IE8V*[7%F
M7G$)%TQ;HC!XDMXE%Z)6TQ N@
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MYT6Z0(MS@K-R%-9;DQG#2I!J:>22T'A61**I&6Q1$8(7
M                                    ,3=+A@(XS!]6>QQ1<G2+IB4,
M*  *\.(N6Z3:=B2VK5T" 29EEMAM+3940D0E[
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M&>NT%%22S+<:2IU!$9F9449]29G3=4P?EG0
M                        !CKE<.UD\%H_7U%M/[TON@, 9F9U/:9[S$H
M%6/'<DNDTV6T]Y\A%T3 26-&;BM$TWYJE<IGT1"58
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MYX;C<VZLU8S=%==$Q3&.G1]&?"[$' K*
M                                         %G<)R8C=$[7U=8GH=,P
M$<4I2U&M9U4HZF9]$2A^ /332WG$MMEB6K81 )+"AHAM82VN*VK7T3^X(2N0
M                                                        &H?I
M/?,GXT!/(E^E/DPR9WDMW<K8(E+P
M                                                 !;3)B(;6-6U
M9[$(Z)_< 1MUU;SBG7#JM6TS$H> 'ZE*EJ)"2JI1T(BWF8"16^"F(C$K:^HN
MJ/H%T"$)7H
M        U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>       "$:C:C,Z>LV]YZ
MWKGE/6Z@B0Z36#A$D^5*JUQ#=[JW5.>FJ(JV=G#DQUN6W_O^G=5-$S1->W,\
MN&&&'@GG0#_<K!\'7?VI/8AO_P#$Z_Q(^S_-R7__ $*W^!/V_P#_ "?[E8/@
MZ[^U)[$'^)U_B1]G^9__ -"M_@3]O_\ RR>7M?HE_OEOLB+$XPJ>^W')XY*5
M$CB'3%3AE6GFC&S7#55BU5<]Y$[,8ZOYLW(<;T9K,468LS&W5%..UJQ\3<8X
MY9(
M         *,F0W%:-UP]FXBY3/H$ C4B0Y)=-UP]I[BY"+H$)0I &_86\!G[
M9;^UT\9XO7U%L+[TC^V(2R(
M                      -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
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M$(Z!"4+<  9JUV_!24^75;VTGR=,P&6$)
M                                 :A^D]\R?C0$\B7Z4^3#)G>2W=RM
M@B4O       !HKG*_P!@R][-*]2V.ZX3]>YT4^=5/_L'X=GIJZJ7/(L)3@ E
M&F_R]RY[O8]60U>]>Z7>S+?</_N-CMT];M,4N^FVOM=?(QG_ +P7+N98)AQ'
M!1IQ:,BZ>7W1^?*E<XQM<3AVN$I^X)4ZY5$A#[+Y+9:01'Z##]2JB)3K.MMO
MUYS%SHK;E=MUZ^/1,O+X$:JG%L-<-R:V@BVJJT3B<)%51;.4!>9LO^F^>K%H
MOE?1IME[4"WW6UR8[4!@TR;7#B-_IARU)21I)+F!2\1]5A-53WF'O3S-VC65
M-3]<EZGE!9E2[Y-3%>N44Y)/PVWGN.PRHT+(U&:DFIHNJ7U.PZ; @U@RZMS)
MNAMLS);E?P[>L_2G[3:K@G$1V:2]&)#:T+K5#BL:J'L42J[24 VUF)YG(O.=
MS;=LLVEE;T;3F7<CL\9LD-SI,=9&AM2&RVFHFT%L*M"V;0&K"SDK-N8=#[Y+
MSO$O-[=S-:U.Y8M%JCV^'8V),AM*HQO-()PU'AP$AQ9XB)1EL*IAMK0G+N7Y
M.<]?,RR+?'>O\+,UUCP[BXVE;\=KB25F3*C(S;JH^J-%#/97<0$M0NY<R^GF
M),WQ-KBE>EW4WUW FD]L&Z5T5&Q&Y3%7@EP]_6@<K<V<K+9<J\X/1)S+-J8M
MYE:+TV<:WMH8-]J);7%,L421$=3,TIK]\"&A<[:AR\]9 L]\NV;8<:^IS$W)
M8TYM%I8BILZ692VS>>E8..DSJ2JJ<(E*614,ZT)=5<ZR]7RSZ=0DPURHV5+A
M=HD'/$^ DURH]@?Q%)-%",TDO8@U=/#Z($0YCNF9[)I^G,.E^D&9HDC3/.\J
MW2%YN9-]M_+2GY"$.HE2D-$;B%H;-*,;A*2FO+B-1+H#GA1XT/FYOQ(;AO1&
M'[6U'>6LW5+;0XE*5&LS,U&9%7%7:"(8O2^\<TK*]UE7+)^8C<NGO3**X-39
M%RDL'!:;)^3B1*3PSV-[J5/<1;: :6M=&G(>5=2<FYHSA;)%OTLS,Y>$Z1,S
MGU.LV5Z;)(R)Q!E1M4E'Y-6)77$K;M4DF4@LAP+7GO7W(-L;9MFIM].2O(<0
MH_!D.)5;I3A]J.I01-FILZD>).^O1 0[(D:TYLR]I[DZX:IVNPW6QW6 NWY4
M/+:HUWB7EE[#PC?2XE2E+</JG3*BE&2E;=A!LS1_+N7YF=^<+F25;X[]]@WJ
MX,0Y[J$N/1VS[:4HFE*(S0:E%U1IH9T+H -:Q<M9<+F%RKX=JB>_2IG;!W'@
MH[9-\KVF*2^)3%7A>M;^MV <J;YNU+GRLXO9*ON:8N0\OPLJVY[WV7:6+K=,
MPE+B(6MEE4I"R-)*=6A*$)-2EDJE:GA"!9 =<5E+FS-O+,S:S;=6TI5O213V
MSP]+:H!NKG?0&[JYI1:GGGHS4[-\.,N1$<X,EM+QD@UM.$1X%I(ZI5R'M!$(
M@O*USTPU<SMIY9)LF[WK/V3)TC)V8;N[VU>D7)AITBAIF+PG@/AK7NY&S/=4
M$H%D:);,U94R-D6XZI6S+=WL]UA' RJYEI3%WAWMN1A2CCDXA:EK<5U3IE0S
M/JJ&1D03BY9JLVFVK\N1IAF.%FTLVYM)C-.GTJ$IVYQKEQUIDR(L@TDHB:62
ML%>H3LH:BV@(;1^U7#5;(FH&H=NR5+OEXN#USC7K+WO@_<8$K9'E1Y9K2>'#
M53#:-K9]4G:>P)G<\YS,MW^PZ73L\1,JY6LV3X3C6=I%F9G3\P,+;2268R)2
M7B2WA51+9)4LU)5O,]@:PR] AW?2W1.P7=M4JU/ZA2+?)AOU3BC/26DN-*27
M6DHEJQ)_",!NO48\JZ:\X[*^9<_VUN+I6W87+?EI]$3':K;=E/J<69LM(-*%
MJ(U'B)'HTGZ$S2%/.T[(VH>O6AEPL:8EYR9-1?#CD3/Z*X]#)U2CX3B4[4OH
MQ5-.U15V@)#I/#A6CG4ZQ6NTL-PK<<&T2%0XZ2;9XRX[*U+P)H534ZM1]-1]
M$$<C$3+\US?^<1F[-.=X\AK3W4-B(Y$S*TRY(8BS(J20;+_#2HTU,U[B,Z8#
MI3%A#*ZO<XO+4W(Z9NF-R@7<D7JW6R\WR7#>E0K*W-XCC<Q;3K9$LTFUU!E4
MB5^%0C&#6&2I>6+IK)J0F_YX7FG*=PT^F)S)FJ/":MS:V4NL,ON,-0V\"^$@
MS22TH4>+$GJJ DRW><SRK#G/173R]PL^V.-D^2[8,SVF"<:=%1Q*%;7U(*BU
MO-DI*2J:C49'7>1!;Z>HLV<_%99W=5K5$N>6;A;W[5E1K+:H5S8FQ2+CPW'D
M.DHR6:5)=<5U+BNJ54P&<RWFJUY U3MUGTHS'!SUEC.>:'GKME1Z"KWVM,F0
MX:)$MN2:"7@9).]VG4IV;U. .T ?D          'XM:6TFM9X4I*IF?0 1N?
M.5,<H6QE/6)^V8E"T  &5M=OXAE)?+ULMK:3Y3Z)](!FQ"0
M     8^3&N#EXM\IB43=M8:DIF1.5UQSA\)1;/085^F 9
M                          !J'Z3WS)^- 3R)?I3Y,,F=Y+=W*V")2\
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M%%ZY+)M"73+IKI4_J@/R+'M92'ID-AA,MW8^^VA*7%ER8E$1&?G@+P
M    #,B*I["+>8"/W*><E7":/UA)^F/H^8)0QX  R%M@')5Q72]82?ICZ'F
M) 1$14+81;B$)                    8>;&@N9CM$IZ7PI[#$U$6'4O7D.
M<'B*IOZC"GTP#,                                         -0_2>
M^9/QH">1+]*?)ADSO);NY6P1*7@
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M6Y*%'>%L3#MZRK@)I/!XY'0Z;:MTJ0#+@
M             -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
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MK9!.%Q5269:RG4KP.#PJIKA.G$Q]$NMY0&4
M                :A^D]\R?C0$\B7Z4^3#)G>2W=RM@B4O
M                                         'E:TMI4M9T2DJF?2(!0
MBH4K%)<*CCVTB/T*"ZTON@+D        !:I_1I)M_P#)?,U(Z!.<I>?O 70
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M>W&;2JT+:DG/<.F)+J>%P"+:1[:N5H1^< R(
M                #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
M                                          M7OTA\HQ;6D46_T_O4
M^?O 70          I2&2?:-%:*WH5RDHMQ@/R,\;S=5%1Q)FEQ/046\!6
M!97"<F(C"G:^HNI+H%T3 1U2E+4:E'52CJ9GO,Q*'X ]M-+><2TV55JW$ DD
M.&B&U@3M6>U:^B?W!"5R                         QTF+<'+Q;Y;$HF[
M<PU)1+B;:NN.\+A*_H85^F 9$
M     !J'Z3WS)^- 3R)?I3Y,,F=Y+=W*V")2\
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MAB8B+#J7KR'.#Q%4W]1A3Z8!F
M      &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
M                  &-NS*GS90WU3M541TJ5,_.H 0K<ZVV?%=6VI1UPMJH
M7G[P%SVF?ZP]Z?\ D .TS_6'O3_R ':9_K#WI_Y #M,_UA[T_P#( QLVVR.*
MIQNKJ#*IJ,ZJV%R]$$LK$(DQFB2K&6$J*!"L P4VWR">=>(L31F:S57:1'M/
M9T@2S31$32"2K$1)*BNB5-X(>P           8^ZM&\VTA!U<-=$HZ.S;]0
MMD-V,2U/;#70B36N[H@+B3,8BH,W%%C+<V1]4?G (Y(D.273=</:>XN0BZ!"
M4*0 15V%O 9^VV_M9/&=+U]1;"^]+H>:(2R(#PAYIPS2VM*E%O(C(S(![
M      <U<Y#Y46GW!^><%D\*_ K[7FA2?'_>[?8^]+2]1V:M"H!4 J 5 *@)
M!D7Y:Y<[YP_;T#7[Q[K=[%75+;[F[_8_N4>U#MT4F^H    &(FN6E.8K2W)2
MH[PMB8=O65<!-)X/'K0Z;:MTJ0#+@
M         -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
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M/TGOF3\: GD2_2GR89,[R6[N5L$2EX
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ME'M0[A%)OIX   !CI3EU3>;>U&;2JT+:DG/=.F)+J>%P"+JB/;5RNP_. 9$
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MS"NG\%8>%A]<_P 4WTZ'3!*7Z4^3#)G>2W=RM@B4O
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M    8B;%A.9BM,IV7PIS#$Q$:'4O7D.<'B*IOZC"GTP#+@
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M@I5]-@   ,7+FH:OUL@G"XJY+,M:9U*\ F>%5-<)TXF/HEUO* R@
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MJF\V]J,VE5H6U).>Z=,274\+@$75$>VKE=A[N0!D0
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MKZ;    8Z3%N#EXM\MB23=M8:DHF1=M77'.'PE;O085_5 9$
M          ?AJ2DR(S(C/<1GO ?H      _"4DS-)&1J+>5=H#P^X;3+CA%4
MT)-1%YA ,-$F/OS&B>/B%4\*=Q$9EOV= $LZ"     !J'Z3WS)^- 3R)?I3Y
M,,F=Y+=W*V")2\   %JS^CO*BG^375;'_P"Y/G;P%T
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MMIGN(!(+; *,GBNEZ^HO2ET/-$)9   6KGZ-()XOR+U$.] E>A5]HP%T
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M@]Y +Q*DK22TG5*BJ1](P'Z     U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M  "C)9-UOJ#HZ@\;:OPB^Z _&)33Y)(E$3IEU39GU1&6\J *X
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M28[)6X      )#D+Y<9;[Z0O;T# WCW6YV*NJ6VW/WZS_<H]J'= I5],@
M,1-7:2S%:424J.\*8F' 46+ 31<'CXJ'2IU;I4@&7
M  4WW4L-*<5MIN(MYF>XO/ >8S2FFZN;7G#QN'^$?)YA;@%8      4I#)/M
M&BM%;T*Y246XP'Y&>-YNJBHXD\+B>@HMX"L M6/T=Y44]C:JK8\ST2?. 70
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M?= >F'2?:2X6RN])[R,MY *@   -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
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M9))X2/>6)9GBZ-$] :/BG,U57J;6/HTQCXY_EYW4\!9&BG+UYB8].JK9B?\
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MBFSM6*:_HU=<?RA97 .8V,W<M<E=&/CIGYIETN*U7>
M   .8.<U\J[/WO\ S[@L;A;X%?:\T*:X[[U;['WI:1'8JX      !(<@_+G+
M7?2%W0@8&\.[7.Q5U-MN?OUG^Y1[4.[!2[Z6    8B:NTEF*THDI4=X4Q,.
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MVS(15]9XS3R%7<5.D O@               6J?TF2:_^3'/"GH&YRGYVX!=
M   UEKTDU:>2#+<B5&,_,QT^V.FX;G_N1T2X;C:,=VU=JGK<HBUGS^
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MT=;-S4FPDGD<>4=.@F.X?VAH]^SADKG1'M0ZKA2G'>EGIGV:G80I]]'@
M#$7.,Y(DH)GJUX.J1NH1'OV]&H"XBP'&F22MYQ*MYI0HB25?. 5NU#_6'O3%
M]P [4/\ 6'O3%]P [4/]8>],7W #M0_UA[TQ?< 8F5;I#;BUGU3-:F[6IT,]
MYEO!+/(H24D1U*A;>B"'Z     Y?YS?RKL_>_P#/N"QN%O@5]KS0IKCKO5OL
M?>EI"H[%714 J 5 *@%0$BR"?^><M=](7="!@;P[M<[%75+:[H[]9_N4>U#N
MT4N^E0   &.DNW5-YM[49I*K0XU).>Z9%B0ZGA<$BZHCVU<KL/=R ,B  +)U
MM$Y\T+*K#&PS+E</DKTB 7333;*";:3A07(0#&7"*N5*(F#JM*"XE=A%MV;>
MF N(]M;;:)+BE&O>HTJ4DO.(C 5>T6.BOTZON@':+'17Z=7W0#M%CHK].K[H
M!VBQT5^G5]T!BY-K<:4MPCK'(\1GO42:[=G+0$LXC#A3A.J:%0^B0(?H
M"U?_ $=Y,HOR:Z(?_P#VJ\[< N@        %JG])DFO>S'.B>@;G*?G +H
M     &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P   >'6DO-J:7UJBI_* IQ75
M+0;;OY=H\+G3Z!^>0"N          +5?Z3()K_DLT4YT#7Z%/G;P%T
M         "A*=4A!-M?EW3PM]+HGYQ *C3266TM(ZU)4_E >P   0?6"%V_I
MS?&R*JFFVY">EP'4.']8C&\W'<V,[;GGF8\L3#EN*K/O=V7HYHB?LU1+CP7
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MO2T@.Q5R      "19!^7.6N^D+NA P-X=VN=BKJEMMT=]L_W*/:AW<*7?2@
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M::)>%Q:4I/$9)+K@2[ E-J4E+S15>9/$@NB7*GSR!^55IQ+K:7$'5*BJ0#V
M  #E[G.?*NS][_S[@L;A;X%?:\T*;XZ[U;['WI:/J.Q5T5 *@%0"H!4!(L@'
M_GK+/?2%W0@8&\.[7.Q5U2VNZ.^V?[E'M0[O%+OI0   !B)L6&YF*TRW9G"F
ML,3$1H52]>0[P>(JF_UO"GTP#+@+5C](>5*/\FFJ&/,]$KSP%T M?[3)_P#9
MCGYQN_\ " N@        %"4TI:"<:_+M'C;Z?1+SR 5&74O-I=1UJBKYG2 >
MP    &$GPI3DI2T(-:5TPF7)LW&"5^U%D(:0DY*B-)$1D1),BZ6T@0]]KO\
MZTOTJ/N ':[_ .M+]*C[@!VN_P#K2_2H^X '&D&1EVTO:7WJ?N ,5&M\M,I!
MJ2:"0HC-?)0CY/-!+/ @       !J'Z3WS)^- 3R)?I3Y,,F=Y+=W*V")2\
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MT                       #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
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MFE(,\)[TJ^]46TC 6T:YLO&AI9T>/89^A-72/I@+X
M   :A^D]\R?C0$\B7Z4^3#)G>2W=RM@B4O      'AUEMY.!U)*3OH8 VTVR
MC TDDIZ! /8    "B[%CO*);K9*47*8"E/D+BQ\;1%B,R26S80"T@W)]9J0\
MA3M-I&VFIEYNX$KSMW_MW_2?R@@[=_[=_P!)_* =N_\ ;O\ I/Y0#MW_ +=_
MTG\H!V[_ -N_Z3^4 [=_[=_TG\H!V[_V[_I/Y0#MW_MW_2?R@';O_;/^D_E
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MEHH=2W&1@+X           &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
M         6LT\:$Q4D1N/'3;MHDMZO. 568[,=.%E))KO/E.G1,!5
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MR\H#(  "VE)-LTRVRJIK8LB]$V>\O.W@+A*DK22DG5*BJ1](P'Z
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M3RFH]A$ \QF3:;ZLZNK/&XKHJ/[@"L M6?TA]4D_R2*H8Z?WRO/W +H
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M(3\)\CH;<AM32JETE$0Z2U>MW8QHJBJ/!.+B;^6NV*MFY3-$^&)CK68]F,
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MRV7^%;IHZ*8AEY+W!:JDJN*,DMIZ*CW#&9S]CLDPT2*U5O6KHJ/:9@*H
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M1UJ2W]'I^> ]*4E"36HZ)253/I$ MXJ5+Q2G"HMWK2/T+9;B^V N0
M  !Y<;2ZVIM952HJ& HQ7%&E3#IU>9/"H^B7(KSR 7         #4/TGOF3\
M: GD2_2GR89,[R6[N5L$2EX            "U/\ 29--[,<ZGT#=_P"$!=
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MF37>S'.A= W?^$!C[NM]+R2J9,TZFFPC/E\\$LA;L?:;6,J'3J?YO("%T
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M,@               "Q?@-$9R&$4?2>,D^A,RVTITP%VTZEYM+J.M452 >P
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MH]J'>PIE]'    ,1-BQ',Q6F6[,X4QAB8B/"J7KR'>#C53?ZWA3Z8!EP
M            %JG]&DFW_P E\S4CH$YREY^\!=          "C)=4TV1-[7G
M#P-E^$?+YA;P'IEI+#26T[:;S/>9GO/SP%0        !J'Z3WS)^- 3R)1I>
MZI.GV3GE]9+LMN-9\A/=JM[>EB 38$         "VE*4O#%;.BW>N,O0MEO/
M[1 +A*4H22$E1*2H1=(@'Z                     _%*))&I1T215,SW$1
M ([<9W;;A)3L90?4]$SZ(E"R  &2MEOXYD^\7K)=:D_1&7V@&>$)
M  !X6TVZ1$X@ED6[$50'LB(BH14(MQ$  *,EI3K=6]CR#QMG^$7)Y^X!Z8=2
M^TEQ.RN\CWD9;R 5         'AYU++:G5[DE6G1/D+SP%.*TI"#6[^7=/&Y
MTCY"\X@%<!QCK4?^I^8/9&.YFA;NXNY6_'[4OGKBG]SN]-/LTH#4;MRY4 J
M5 *@%0&T.;^?^I,/W-)]K,<WQ'W.>F.MVG!O[E3V:NIUX*K7R  "U8_1W513
MZPZK8/I<J?. <Q<Z+Y6V;O=^?<%B\+_ K[7FA3_&_>K?8^]+1=1V"O2H!4 J
M 5 *@)'I]\O,L=]8/="!@;P[M<[%75+:;I[[9_N4>U#O@4R^C@   &(FJM)9
MBM*9)+]^#8F' ,L6 FBX/'Q4.E?R=*@,N                 I2&2?:-%:*
MWH5T%%N,!^1GC>;JHJ.I/"XGH*+> K         +5C](>5*/\FFJ&/,Y5>>
MN@         !J'Z3WS)^- 3R)7I>TE_2O)S2MRK';MO*1]JMT/S@$LBNJ<0:
M7-CS9X'"Z9<OG[P0K@       Q]V<>;83PC-*3.BU%OZ0"E9E+7QE+/$982)
M1G4Z;=GF ,J                      ,#<[AQS-AD_62/JE%Z(R^T)0QH
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M[!?;$H8@  74&$N8Y3<TGKU?:+I@)(VVAI"6VRPH25"(A"7H
M      4WFDO-*:5N46_E(^0_. >(KJG$&ES8^V>!PNF7+Y^\!7      %&2\
M;3?4;7EG@;3^$?W 'IADF&DMD=3+:I7*:CVF8"H  .,-:O*?F#V1CN9H6YN/
MN5OQ^U+Y[XI_<[O33[-* U&[<N5 *@%0"H!4!M#F_>4F'[FE>UF.<XB[G/3'
M6[3@[]RI[-74Z]%5KX  !3?:)]E;1G0EE2H#D[G*PUQ<WVDUJ)1*MB4E2OH9
M#Q_;%B\+]WKC_7YH4[QO3_W**O\ ^<1Y*J_G:7'7N       !)-/OEYECOK!
M[H0,#>'=KG8JZFTW3WVS_<H]J'?(II]&@   ,=)>NB;S;V8[1*M+C4E4]XR+
M$AU'"X)$>(NNJOD/=R ,B                  *4HTE'=-2<222=4]'8 Q$
M.YR"<0VX1NHIA)*2JK87)T02R7;O_;O^D_E!!V[_ -N_Z3^4 [=_[=_TG\H!
MV[_V[_I/Y0%O,N+C;1<)I;:S.F)Q-"\[I@/RU/KD+>6[U3O4]7TNA3D 9,
M         &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E(;JWQ6$(2?KAK(D)^^,]@
M#Q;(3L8UK>H1J*A)(Z^> O5OLH42%N)2L]R3,B,!4      %-+S#IJ:2M*U;
ME)(R/8 HQC-E:HBCZSJFC/E;/D\[< N@                 !B[I<.$1QV3
M]=/KU%Z$NAYHD8,$ "M%BN2W2;1NWJ5R$0"3,,-QVDM-E1)?5,^B8A*H
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MRCVH=\BFGT:    Q\F-<7+Q E,22;MC#4E,R-MJZXYP^$HMGH,*^7E 9
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MPVF6[,X4QAB8B/"J7KR7>#C52M?6\*?3 ,N
M                U#])[YD_&@)Y$FTS4I6F&2HK9T<>LENQ']ZWVJW4_M$
MFZ4I0DD)*B4E0BZ1 A2DO&RW5)5=4>%M/14>X!^QV28:)%:JWK5RFH]Y@*H
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M:).KVI]JM=@N=KAW>1!<M\=ZWG%:@1[='=;)F41'1A9D9$V@^NH8)EUF#\@
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MYE1Y222I=FMQ(0G:E#:8K>%)5KR A+P%JS^DOG(/\DW5#/3/T2OM +H
M   !:O?HSY2"V-.40]TC]"K[0"K(9X[1HK11=4A7046XP",]QFB4HJ.)/"XG
MH*+>0"J           "A+E-Q&C<7M4>Q">4S 1EYYQ]Q3KAU4KZW2(2AX "(
MU&24E4SV$1=$!F(T'AFEA6UYPL3ZB]"W]Z73,Q"68(B(J%L(MQ
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MF"H!4 J 5 *@-I<WP_\ 4N'[FE>UF.<XB[G/3'6[+@_]QI[-74[!%6+V
M<J\Z3Y76;O=^?<%B<,? K[7FA4/&W>;?8^]+1(Z]7X      ))I[\O<K]]H/
M="!@[P[M<[%74V>Z>^V?[E'M0[\%-/HL   !BI<UIJ_6N"J'Q7I+,M;<ZA'P
M"9X.)-:&9<3&7*76@,J
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M$7FWL1V25:7&I*ISQD6)#B.%P2(\1==5?(>[D 9$
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M/:AW\*;?1(   #'28MQ<O-OEL22;MC#4E$R-4ZNN.\+A*I2G485\O* R(
M                                     #4/TGOF3\: GD9O3^(_(TYR
M8^RG$@[%;$X=QD:8C9<O( G-N3AAM%BQ;#\ZI[O.!"Z           !:W%.*
M&Z6+#L*G3,CW>> LK;!D,O\ &=+ DB,J5VG7S %]*(VU)EH*IM['"+E;/?\
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M3,BPW,P6J6[+X4UAB8B/"J1<9#O!XBJ;SX>%/I@&6
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MFZK*CJ#PN)Z"BW@*P       . KC_B$OV9SU1B];7J1T/E2_\2KIGK6P]7B
M     #?W-B_M.9OYD/[+XX3BSU;7UONK5X ]:_T4?>=$#@%N    .*=;C_U2
MS#[)'[E:%M;C[E;\?M2H#B?]RN]-/LTM?U&[<R5 *@%0"H!4!M/F]'_J9"]S
M2O:S'.<1=SGICK=CPA^XT]FKJ=ABK5Z    .4^=-\KK+WM_/N"P^&/@5]KS0
MJ/C7O-OL?>EH>HZ]7Y4 J 5 *@%0$ET\/_/V5^^T'NA P=X=VN=BKJ;3=7?+
M/]RCVH=_BFWT0    P\U5J+,=H3))9W=3$TX"DUP$T7!X^*ATK^3I4!F
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M,:J/]RGP:_)\RT=T\993-X47?]JOP^K/15\^#9Y&1D1D=2/:1ENH.7=V_0
M           !J'Z3WS)^- 3R)?I3Y,,F=Y+=W*V")2\!:O\ Z.\F46QM5$/^
M9Z%7G;@%T         M6/TAY4H_R::H8\ST2O/ 70       ,7=+APR.,P?K
MA]>HO0ET/-$C!@@ 5XD5R6Z3:-A;UJY"(!)666X[:6FBHE/U3/HF(2J
M "U=_27RCEM:;HM[IGZ%/VP%T          +5K]&?..?Y)VJV>D?HD_; 7"T
M)<0I"RJE14,ND8"A%6HB5&<.KC.PC/T2#ZTP%R      /G_<3_O"7[,YZHQ>
MEKU(Z(?*]_XE73*UJ/5XE0"H!4 J 5 = <V'^TYF]CA?9?'"\5^K:^MYEI\
M^M?Z*/O.BAP"VP   '$^M_E2S#[)'[E:%M;C[E;\?M2H'B?]RN]-/LTM?#=N
M:      !M3F\^4V%[FE>UF.<XA[G/3'6[#A#]QI[-74[%%6KS    <I<Z?Y7
M67O;^?<%A\,? K[7FA4G&O>;?8^]+7&0=/9>?9AQF;I!MC:7$,$J8Z1/.NN$
M:DH993U:SHDSY"H1[1N\_GZ<K3C--571&CQSR.:W5NJK/5[,5TT<FF=,XXZJ
M=<ZO!TL&QEVZ3LQ'EBU,G.NJI*X;#;14XBVU&DSZJE$]2:C-6PBVF,N<Q13:
M][5.S3ABP8R=RJ_[FB-JK:V='+_'AU1K97-.4+=E:,33F9(%SS AXFI=JMY.
MO$PG"HU*5(-*6S-*B)*DEMJ?2&/E<W5?G'W=5-&&BJK",?%K\;+SV[Z,K3A-
MVFNYCIIIQF(U_P!6&&/),)#;])8E[)VVV#.%KNN;6F#DE98Y.X'22G&:&I*B
M)M:Z<A;CWF15,85S>M5O"JY:JIMXX;4X:.FG7$-E;W%3>B:+5^BY=B,=B,<)
M\%-<Z)G^)PUM<1X[\J0U$C-J=DO+2TTRDJJ4XL\*4D71,SH-Y55%,3,ZH<Q1
M1-=44TZ9G4V8YHR[QY-@B9C@R\_0XZI4C++2'L6%*"6;:)!EPUNDD^L+[&T:
M&-\1A%R;=46IG#;T>79UX>%U4\/3C-JF[35?IC&;<1/DBK5-7@\VE$]//E]E
M?OM![H0-CO#NUSL5=33;J[Y9[='M0^@(IQ]#@   ,=)>NB+S;V([)*M+C4E4
MYXR+$AQ'"X)$>(NNJOD/=R ,B          (;G[4>R9#A8I1]M7=Y)G$MK:B
M):N3$L]N!%>4]_)4;G=NZKN=JT:*8UU?QKES6^]_V-V6_2]*Y/JT1KZ9YH\/
MD<LYNSQF'.LTY5YDF;"5&<>$W5,=DC^\14]OX1U,^B+1R.[K.4IV;<:>6>65
M"[TWSF=XW-J]5HY*8]6.B//K1P;)I0          ;&T_U>ON3%MP9AJN>7BH
MDX;BO7&4]%E1[OYA]3YF\<YO/<=K-Q-5/H5\_/T_/K=IN/BK,;OF**_]RU]&
M==/9GS:NC6ZAR_F&T9GMC5WLLE,F&[LJ6Q:%EO0M.]*BY2/[ K#,Y6YE[DT7
M(PF/XT+VR.?LYRU%VS5M4S\G@GFEE!BL\           !J'Z3WS)^- 3R)?I
M3Y,,F=Y+=W*V")2\!^*2E:30HJI45#+I& LFI;4:L62Y1;9X4J/E3R&8"^
M    %B[+:DTBQG*K</"I1<B>4R 7J4I0DD)*B4E0BZ1 /T      8^Y3RC(X
M31U?47I2Z("/F9F9F9U,]IF8E  J,,.2'4M-E51_4(NB8"318S<5HFV]^]2N
M4S$)5@     !2D/$PT:Z55N0GE-1[B ?D9DV6Z*.KBCQ.*Z*CW@*P
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M:WGG#JHS/ZQ$6XB+81;A;-FS1:HBBB,*8?/68S%S,7)N7*IJJJUS*T'LQP
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MIP#M(OUA[TX#\7!Q(4GCO;2,MJZEMZ) +&);)+<E"W*)0@ZU(ZUIT 2S((
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MT>U#Z!"G'T,    Q,R+$<S!:I;LSA3&&)B(\*I%QDN\'&JF\^'A3Z8!E@
M    8;-.9(&4K%+OMQ/UF,GJ&B.BG75;$-IZ:C^IOW$,S)Y2O,W8MT:Y^2.=
MK=Y;PMY'+U7KFJGDYYY(CI_FXQS%?[EF>\2KW=7.)+DJQ&1=:A!=:A!<B4EL
M(7-E<M1E[<6Z(T1_&+YGS^>NYR_5>NSC55\G-$>"&+&4P
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MB)2V%FI)8B+<HC2I)]&E>469NO/QG+$7,,)U3'A4;O[=,[MS4V<=J,-JF?\
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MAHY/LZNC!M\<@L8         :A^D]\R?C0$\B7Z4^3#)G>2W=RM@B4O
M          !2D2&XS1NN'L+<7*9] @$9DR7)3INN'TDIY"+H"4*0  SULM_
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M5 *@%0"H!4!)=.S_ ,_Y6[[0>Z$#!WAW:YV*NIL]U=\L]NCVH?004X^A0
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M:)\FOQ.T!3#Z9         &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
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M3A^>I)BE=YV/<YJY1R1/R3IA]/[CS7YG(VKDZYIC'IC1/RPD@UK=
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ME73*V'H\0      ="<UO^U9G]CA>J?'#<5>K;^MYEH\!^M>Z*/O.CQP2UP
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M      '0G-:_M6:/8X7JGQP_%7JVOK>9:' ?K7NBC[SI <"M<   !Q#KD?\
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MYLJ 5 *@%0"H#:_-U/\ U/A>YI7M1CG>(>YSTQUNOX2_<*>S5U.RQ5Z[@
M')W.K^5]E[V_GW!87#/P*^UYH5-QGWFWV//+0E1US@BH!4 J 5 *@)-IT?\
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MFE-R;SF&4F3=K@WM;3;F,3D9%,1[T$<I9%0]J$[1KZ<W%R)SER)BBU&%-/\
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M       !C[S_ &/^F7VP$?$H      !D;*9]MGTT'7ZI ,^(2
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MD_&@)Y$OTI\F&3.\EN[E;!$I>       "TN31NPW"+>DL1?T=OV $:$H
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M$-C#G79@          U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M               .+\]WZ_:LZMYQLSV3[OGS)F0UM0F,IV^>FTVY;Z",WY,Q
MW$2GGL:5$PPA)FI)<FW$?INK)<?(&N&C5HM^5U7++>3T.)CR+1;I"H4EDX:C
M)V"ZXG$HVU&?58554DR.I&"&!YF#:&M%D-M)PMHN]R2E.TZ$3I$15/I 2N>=
M!E>^9NMV3+=!RK+S=885[3=<P6J"ZAA;L:*PM!-FM2T&6,W3+J3KO A6YMTG
M2%R/F6+IQE>3DW,4.0Q&S9E^XF^<QEUKBDP:N,Z[U.UTDX:;:U+<!+>H(
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MHJZG: K!=8   #DOG7'_ )PLG>W\^X+"X9^!7VO-"J>,N\T=CSRT%4=<X,J
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MS+N            &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
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M-AFH-L @     1/4[R>9F[W2/4&-GNOO=OM0TF_>X7NQ5U.&!<;YR
M =<\W/R<I]W2/L(%8<2=[^K"\>#/V_Z]7F;:',.W    ?.FY?XC,]G<]68N^
MWZD=#YFO?$JZ96H]'B      #HKFI_VK-/L<'U3XXCBG5;^MYEF\#>M>Z*/O
M.EAP:T@   '#6NWE7S'[)'[E9%K[D[G;\?M2HKB3]QN],>S#78W3G
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MH72%>9W>%[-U;5R>B.2%R[KW/EMWT;-FG3RU3ZT],^;4D0US<@
M  #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
M             (GJ?Y/,S=[I'J#&SW7WNWVH:3?G<+W8JZG"U1<;YT*@%0"H
M!4 J 5 ==\W/R<I]W2?L(%8<2=[^K"\.#/V_Z]7F;:',.V    ?.BY'_ 'C,
M]G<]68N^WZD=#YGO?$JZ96M1Z/$J 5 *@%0"H#HOFI_VK-/L<'U3XXCBG5;^
MMYEF<#>M>Z*/O.EAP:T@   '#6NQ_P"J^8_9(_<K(M?<G<[?C]J5%<2?N-WI
MCV8:ZJ-TYTJ 5 *@%0"H#;/-Q\J,+W++]J,<[Q!W.>F.MUO"G?Z>BKJ=HBL%
MU    .2N=?\ +"R=[/WAP6%PS\"OM>:%4\9=YH['GEH&HZUPA4 J 5 *@%0$
MGTY/_4'*O?>!W2@8.?[M<[%74V6Z^]VNW3[4/H8*>7^    QTF-<G+S;Y4>0
M2+6PU)3-C5.KCCG"X*BV>@PKY>4!D0             R(R,C*I'O(!"\P:49
M%S&I;LNUHC2U[3DPC[7<J?*9(ZE1_P Y)C=9;?6;L:*:\8YJM/\ -S.>X9W?
MF]-5N*:N>GT9^31/CAKJZ<VR,HS59;ZMLN1J6R3G_K;4GU Z&SQ75_R6_)/F
MGYW&YG_U]3.FS>F/!53C\L8=2,RN;MG5H_T:7;Y">0R==0?U%-?;&SHXHRLZ
MXJCQ1\[1W. \_3ZM5NKQS'W5L7-^S_7_ /!+I]L'^(/7_)LG_J\G\WA_@V\?
M]'VOY,C"YN6:W:'.N<&,GE)LW7E%YV!!?7&-<XJR\>K35/DCSRS+/ .<J]>Y
M13T8SYH2VT<W*P1U)7>KK)G&6U33"4QFS/H'7B*IYAD-3?XJO5:+=$4].GYG
M0Y7@'+4:;URJOP1Z,>>6RLOY(RIE<B]Y+6Q&>(J'(,N(^?FN+Q*^N.;S.\,Q
MF/B5S,<W)Y(T.WR.Y\GDO@VXIGGUU>6=*0#7MN                U#])[Y
MD_&@)Y$OTI\F&3.\EN[E;!$I>                       "-9WSK;,AV=N
M]79E]^,X^B*2(R4J7C6E2B,\:DE2B#Y1L,AD:\Y<V*)B)PQTM/O7>MK=UF+M
MR)F)G9T>''GF.9K[_<KDG_Q]S_JV.S#??XOF?I4>6?F<K_G.2^A<\E/_ )'^
MY7)/_C[G_5L=F#_%\S]*CRS\Q_G.2^A<\E/_ )'^Y7)/_C[G_5L=F#_%\S]*
MCRS\Q_G.2^A<\E/_ )'^Y7)/_C[G_5L=F#_%\S]*CRS\Q_G.2^A<\E/_ )'^
MY7)/_C[G_5L=F#_%\S]*CRS\Q_G.2^A<\E/_ )'^Y7)/_C[G_5L=F#_%\S]*
MCRS\Q_G.2^A<\E/_ )'^Y7)/_C[G_5L=F#_%\S]*CRS\Q_G.2^A<\E/_ )-L
MV>YL7JTP;Q%2M$:X1VI3*'"(EDAY!+22B(S*M#V[1R]ZU-JY51.NF9CR.ZRU
M^F_:INTZJXBJ,?#&*]'BR   1/4_R>9F[W2/4&-GNOO=OM0TN_.X7NQ5U.%:
MBXGSH5 *@%0"H!4 J Z[YN7DY3[ND_80*PXD[W]6%W\&_M_UZO,VV.9=L
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MCDSA2X[$Q#$*I%QTN\'&JE:GP\*?3 ,L
M             U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
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M*/O.F!PBT0   '#&N_E8S'[)'[E9%K;D[G;\?M2HSB3]PN],>S#70W3G
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M,M;4ZA'P":X.)%:5+B8BY?0@,J
M       U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
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M3R_0   &.E/W1%YM\>.P2[4ZU)5.?,MK;B.%P2(\1==5?(>[D 9$
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MR<O-OE1Y!(M;+4E,V-7:XXYPN"HBIZ'"OEY0&1
M !J;6S7O+NBL:!V_!?O-VGDMXK;"4E+C4-HR0N0ZI520C&I+::]<H]FXP3$+
M_.6IN:LN2;<WE_3R[YKASX;<Q<VW.1T-LK<,RX*B<54U$1$HSW;2Z8"CI%K"
MO565F:&YEF;EU_*\I%NFIFN-.DJ8?$)UDC:V8FL!8R_"(!&<W<XB]9'D2;EF
M73.^0L@PIO:$K,ZW(_4EQN"EXHI&:S:6JF!1J+%4J;3(@,&\H\AF7':E1EDY
M'?0EUEQ.Y2%EB29>:1@A4          &H?I/?,GXT!/(E^E/DPR9WDMW<K8(
ME+P         !'LU9[R=D=$-S-U[B6=-P<-B#VVX39O.)I4D%O.E2J?)4NB
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M_3T5=3M85BN8   !R-SLOEC9.]G[PX+!X9^!7VO-"K.,.\4=CSRY_'6N%
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MKMZP$XME@@          &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
M'XI*5I4A:24A1&2DF52,CV&1D8#6VJ.B^7-2LN,Y?3P;&;4V-/[<B1&%N*[6
M,SX9D9)V*KM!*EG?37/5]NC<O)>H\W)=J*,B([9XEOBRXV%!J,UM<0T&TL\5
M#4GH%T &*+F^V^U:52=-<GYENE@F3I:;E<<T-.&NXRIAK2IUQY25-F>,D$FB
M5)V$5:[<0Q2K4K35G4K3:;IU/NK\9N<W$;=NN!#T@SAO-/XU)/"DU+-KJMV\
M!,+9"3;;;#MR5FXF(PU')Q14-1-()%3(NC0$+H      :;YR_D]C=]&/:7QU
M/#7>I[,]<.%XT[C';IZJG)(LM2P       #O?3[Y!Y8[U0>YT"FMX=YN=NKK
ME]'[I[E9_MT>S"1C ;0  $1U3\G.:.]LCU!C9;K[U;[4--OON-[L5=3@L7 ^
M>P       '8_-P\F;'NR5ZHA6/$7>YZ(79PCW".U4VV.;=B    ^;US/^\IG
ML[OJS%V6_4CH?-U[UZNF5I4>CR*@%0"H!4 J Z0YIA_I6:_8X/JGQQ/%&JW]
M;S+(X)]:]T4_>=.#A5G    .$]>O*UF3V2/W(R+6W+W.CQ^U*D.(OW"[TQ[,
M-<5&Y<Z5 *@%0"H!4!MSFV>52#[EE^U&.>X@[I/3'6ZOA7O]/15U.UQ6*Y@
M  '(W.S^6-D[V?O#@L'AGX-?:\T*LXP[Q1V//+G\=:X4      $GTW\H65.^
M\#NE P<_W:YV:NILMV=[M=NGVH?1(4^OL   !BIDQAJ_VN$N%Q7Y#,M;4ZA'
MP":X.)%:5+B8BY?0@,J
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M<T7FWQX[!+M3K4E4Y\RVMN(X7!(CQ%UV)?(>[D 9$
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M&,;-;FR=%FNJ+<8Q3//S=+-R/$N\KF8MTU79F*JZ8G13JF8\#K45.^@@
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M=KMT>U#NL4@^HP       &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
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M:HG'">:=6'\8X8PA@V;2.S.;9Y,8_NR5ZHA6/$/>YZ(73PEW".U4VZ.<=>
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ME+P       <R<Z4_[XR[[FD>V(%@<+?#N=,*FXY^+:[-77#0%1VJM2H!4 J
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M[SI\<*LP   !P=KYY7,R^R1^Y&1:NY>YT>/VI4EQ#^X7.F/9AKBHW+GRH!4
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M*@%0"H!4 J S&4C_ ,U6+OA$]O0,7.? K[-74V&[N]6NW3[4.]123Z<
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MI]J'T7%0KW    8Z3&N3EYM\J/()%K9:DIFQZ[7''.%P3+9Z'"OEY0&1
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M@,"I&!@5( J0!4!]!=._D!E;O3![G0*<WAWFYVZNM]";J[G9[%'LPDHP6S
M!#]5_)KFKO;)]08V6[.]6^U#4;Y[E=[$]3Y_U%O*#*@%0"H!4 J 5 =H\VGR
M7Q_=LKU1"LN(>]ST0N7A3N,=JIM\<XZX   !\T[I_B<WV=WU9BZK?JQT/G6[
MZ]73*U'H\P      =*\T;^UYL]C@>JD#BN)]5OZWF6)P9ZUWHI^\ZA'#+*
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M\?\ :M=NGVH?0$4J^E        &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
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M5     <P<YHZ9JL_>_\ /N"Q^%O@5]KS0IGCOO5OL?>EI&H[!7.!4# J!@5
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M6.(*@%0"H!4 J E&FI_ZB93[\0.Z6QA9_N]SLU=38[M[W:[=/M0^C0J%>H
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MXDJ 5 *@%0"H"4::G_J)E/OQ;^Z6QA9_N]SLU=38;M[W:[=/7#Z-BH5Z@
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MQKHJHF::HPF.1ELG'_FZP=\H?MZ!CYOX%?9JZF7N^/\ LV^W3[4/H2*7?1P
M      #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX       .6>=B=+SEKW+)]L
M0.]X8^'<Z85=QI\6UT3UPYWJ.S5Y@VSIGI79\SVP[IFN7)AIN*)7\.1HAI2Y
M(][T&N0\LUMK(FD'A;*FTU&?0'/;QWG79KV;41.SAMS/)M:HUZ^7H=;N?<EO
M,T;=ZJ:=K'8BG#&=GUIG&)T1HCI1'*RM-VH+DC.?OO(N!OX&H=KX#328^$JN
M*<=J9JJ9T01%NW[1L,S^:FK"SL1&&NK'7S:&IR<9&*<;_O)JQU4;.&'/,RN-
M3<FPLDWZ+%M4MR99KI!8NMM=?227RCR<1)2Z1$18B-![B(?G=V;JS%N9JC"J
MFJ:9PU8QS/WO?=]&4O131,U4UTQ73CKPG'7X=#)6'*65X>0TZ@9K3<+C%D7
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MKO9E\_!;:B@       ':_-E\EL?W;*]40K/B#O<]$+AX5[C':J;B'.NL
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MIC:U1CCAY(A <G'_ )OL'?*'[>@;C-_ K[-74T&0[S;[=/M0^A@IA]%@
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MONEKL4^S"3C!;(  $(UA\F&:N][WV!L]U]ZM]J&GWUW*[V9?/P6THL
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MYXO9AK0;AH       ;AYLOE8@>Y9?M1CG]_]TGICK=1PSWZGHJZG<0K1;P
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MRKSM3_OK+7N63[8@=YPQZESIA6'&7Q;71/7#G2H[)7Y4 J 5 *@%0&7RF?\
MFFQ]\(GMR!CYGX5?9GJ9>3^/1VJ>M]'A3+Z$    :/YU/DVB]]H_M#XZ?ASO
M,]F>N'&\6]SCMQU5.-18RI0       'T3TW\GN5.\\#N9L5!G^\W.U5UK[W9
MW2UV*?9A)Q@MB  "$:Q>2_-7>][[ V>Z^]6^U#3[Y[E=[,OGS46RHXJ 5 *@
M%0"H!4!VUS8_)9']VRO5$*UX@[W/1"WN%NXQVJFXQSKJP   'S)NG^)S?9W?
M5F+HM^K'0^?;OKSTRM!Z/(      '37,_P#[7F[V.!ZJ0.+XGU6_K>98/!_K
M7?J_>=3CAUC    .!N<!Y7\S>R1NY&1:6YNYT>/VI4SO_O\ <\7LPUH-RT
M     -P\V3RL0/<DOVHQS^_^Z3TQUNHX9[]3T5=3N,5HMT   !Q]SNOEI8N]
M?[PZ._X;^#5VO-"LN+>\4=GSRYY'6.)      !*=-/*+E+OQ;^Z6Q@Y_N]SL
MU=38[M[U:[=/7#Z/"HEY    ,=*D7-%YM\:.P2[4\U)5.D&6UMQOA<$B/$77
M8E\A[N0!D0    '*/.H.F;[+WM_/N"P^&/@5]KS0J3C7O-OL?>EH;$.N<!@W
M]I_<94W+V8I5MS1*SCG*YV=YJ3E.<I]MMLG*)<=QOJ6F0IM.PDHH9D9ERCCL
M_1%-VB*K<6K=-<85QAXHT>KCX5B;KN55V+LT7JLQ=JMS'NJMK",=<^E,Q7,>
M#PQRL9IKE;,&7<OP\Z6RTRYU_P P2$0;,_&CJ?3;[?Q"1*EN&25$A3B:MMUP
MT3B56@R-XYJW>N39JJB**(QJQG#:J_II\6N?#A#%W/DKN7M4YBFBJJY=JV:,
M*9G8IQPJKGFQC1&K1C..",ZYP9\/4V^/S(SK#$QU+L1QU!I2\V3:$XFS,J**
MI&52&?N2Y35E*(B8F8C3X-+5\2VJZ<_<FJ)B*IC#1KT1JYTL0^_?=/\ );>2
M<T0LOJL)N^_D25.][W&YJG"-,E1;W2.BC30E'U5$D9U(M=,1:S-WWUN;FWAL
MS%.UH^CX&XBN;V3L?EKU-KW6.W%5>QZ6/K3SQS:]>$<L([S@&8;&IUQ*+A)Y
MQB([-)"<*>V%LI-1X>0U)PJ/S1F[AJJG*4X\\X=&+6<4T41GZMG7,4[73A\V
M$L/H\?\ J;EGW8GU*AD[V[I<Z&#N'O\ :[3O 5&OT   !S/SMC^27_V'[L.X
MX7_Y/J_>5KQK_P /U_NN9ZCN%;%0"H!4 J 5 9S)A_YPR_WRA^WH&)F_@5]F
MKJ9N0[S;[=/7#Z*"FGT,        U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M      #E3G;G_?66?<LGVQ [SACU+G3"LN,OB6NB>N'.51V2ORH!4 J 5 *@
M,QE,_P#--C[X1/;D#&S/PJ^S/4R\G\>CM4];Z0"FGT$    T?SJO)K%[[1_:
M) Z?ASO,]F>N''<6=SCMQU5.,ZBQE3%0"H!4 J 5 *@/HIIMY/,I]YX'<R!4
M&?[S<[576OG=G=+78I]F$H&"V(  (1K%Y+LU][WOL#9[K[U;[4-/OGN5WLR^
M>]1;*CRH!4 J 5 *@%0';?-B\E<?W;+]40K7B#O<]$+=X7[E':J;D'.NK
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M&IJ;]ZN]7-=<[554XS*6:.G_ *G98]V)]2H:[>W=+G0VVX8_[]KM.\A4B^P
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MYZ(6[POW*.U4W(.==4    ^8UU_Q.;[.[ZLQ<]OU8Z'S_=]>>F5H/1Y
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M\6^W3UP^C0IM]!        -0_2>^9/QH">1+]*?)ADSO);NY6P1*7@
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MX3 Q 8&(# Q 8&(# Q 8)UHT?^J.5_=J?4J&JWMW2YT-WN*/^]:[3OD5*O8
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MQ54E0"H!4 J 5 *@/HUIKY.\I]YX'<S8J'/]XN=JKK7KNWNEKL4^S"4#";$
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M]V]TM=BGJA*1A-B  "#:R>2W-G>Y[[ V6Z^]6^U#4;X[G=[,OGE46PI,J 5
M*@%0"H!4!W!S7O)3']W2_5$*VW_WJ>B%M<,=RCM5-S#GG4@   /F'=3_ +TF
M^SN^K,7/;]6.A0-WUYZ96E1^WF5 *@%0"H!4!T[S//[9F_V.!ZJ0.,XFU6_K
M>9WW"'K7?J_>=5#B%B    . ><$?^L.9_9(W<C(M+<W<Z/'URIS?_?KGB]F&
MM*C<-"5 *@%0"H!4!N+FQ'_JU ]R3/:C'/[^[I/3'6Z?AKOM/15U.YQ6JV@
M  '-?./^5%I]P?GG!9/"OP*^UYH4EQ_WNWV/O2TP.S5F      #/Y%^6N7.^
M</V] U^\>ZW>Q5U2W&YN_P!C^Y1[4.W!2;ZA    8^2_<T7BWQX["5VIUJ2J
M=(/KFW$</@D6TNNJNNP]W( R     #D;G9G3.5C[V?O#@L'AKX-?:\T*LXP[
MQ1V//+GZHZQPV!4# J!@5 P*@8%0,$[T8/\ U2RM[M3ZE0U>]NZ7.ANMQ]^M
M=IW^*F7D    Y@YWYT_A#_[']V';<,?\GU?O*[XQ_P"+Z_W7+^(=LKO Q 8&
M(# Q 8&(# Q 8,[DE7^<LN]\X7="!BYOX-?9JZF9D8_[%OM4]</I$*=7X
M     U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>       #DWG??XWECW))]L0.
M[X9]2OIA6W%_Q+?1/6YMJ.P<&_,1=$$X&(NB!@8BZ(&!B+H@8/W$1[C P9G*
M)_YKL7?&)[>@8^9^%7V9ZF5E/CT=JGK?2L4XOH   !HOG7^3.)WWC>T2!TW#
MO>9[,]<.0XJ[I';CJJ<6U%B*K?F(NB0)P,1=$@,#$71(# Q%T2 P,1'N,@1@
M_:@/H[IIY.LI=Y[?W,V*BS_>+G:JZUY[M[K:[%/5"4C";   $&UE\EF;.]SW
MV!LMU]ZM]J&HWQW.[V9?/&HMA2C\Q$!@8BZ(&!B+H@8&(NB!@8BZ(&#]J [A
MYKWDIC^[I?JB%;;_ .]3T0MGACN4=JIN8<\ZD   !\P;J?\ >DWW0[ZLQ<UO
MU8Z%!7?7GIE9XB+>8]'G@8BZ) G Q%T2 P,1=$@,#$71(#!^U!&#I[F=G^F9
MO]CM_JI XSB;5;^MYG?<(^M=^K]YU6.(6&    X@URRTB=JKF*6<E39N.1SP
M$DC(J162WUZ0MG<EK')6YQY_:E0W$N\)M[QNT[..$Q[-+7O\'M_KB_2%]T;K
MW'A<U^JS]&/*?P>W^N+](7W0]QX3]5GZ,>4_@]O]<7Z0ONA[CPGZK/T8\I_!
M[?ZXOTA?=#W'A/U6?HQY3^#V_P!<7Z0ONA[CPGZK/T8\I_![?ZXOTA?=#W'A
M/U6?HQY6UN;KEU%NU/A2DR%.&F-*+":2(MK1ER&.=XAM;.3F<>6.MV'"6>F[
MO"FG9P]&KJ=EBKEW    .:^<?\J+3[@_/."R>%?@5]KS0I+C_O=OL?>EI@=F
MK,      &?R+\M<N=\X?MZ!K]X]UN]BKJEN-S=_L?W*/:AVX*3?4(   #'2H
M]S7>;?)CODBU,M24SHYGM<<<X7!,MA];A7REO 9$    !R'SM3IG*Q][/WAT
M6!PU\&OM>:%7<7]XH[/GES[4AUCA\#$GH@8&)/1 P,2>B!@8D]$# Q$>X#!/
M-%C_ -4\K>[4^I4-7O7NESH;K<G?K7:?0(5.N\   !R]SP3I_!__ -C^[#MN
M&/\ D^K]Y7G&'_%];[KEZI#ME>8&(NB(,#$71 P,1=$# Q%T0,#$0&#.Y),O
MXSR[WSA=T(&-F_@U]FKJ9F1[Q;[5/7#Z2BG5]        -0_2>^9/QH">1+]
M*?)ADSO);NY6P1*7@       Y,YW_P#CF5_<DGVQ [KAKU*^F%;\7?$M]$];
MG6VDE=QBH61*0IU)*2>TC+ID.SIUPKW,3,6ZICF3GWO@?JK7]6G[@S=F.9R_
MO[GTI\KV[:HK*L#T)MM="/"MHDG0RJ6PR'YB*9U8)F[=B<)F?++R5N@F="B-
M&9[B)M/W!^MF.9^??W/I3Y7IVTQ6%FT_!;;<3O0MHDJ*O1(R'YB*9C&,'[JN
MW:9PF:HGQHYFB/'CHBFPTAK$I>+ DDUH1;Z#QO1$8-KNZNJJ:L9F=2URB?\
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MM>$<D>&6I1UBO !OCFT_VG,G\R']EX<'Q9ZMKZWW5L_^O?6O]%'WG08K]<
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M3,X\^,3#4HZU7S/Y%^6N7.^</V] U^\>ZW>Q5U2W&YN_V/[E'M0[<%)OJ$
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MS%?9(;F]KAJMV>K5TL[HH?\ JME7W<GU*AI-Z]TN=#K]RQ_W;7:?0D50NL
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M_P NB-4>!CQD,-G\B_+7+G?.'[>@:_>/=;O8JZI;C<W?[']RCVH=N"DWU"
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MF-FKI9S1-+GC6RI5"B+MY.TTF1=:KI#1[U[K<Z'8;EF/SMO3_4^A8JE=(
M#EGGCF1?P=7_ /V/[J.UX9_Y/J_>5_Q=_P 7UONN9+6HO?.%[,C[([>CUH5Q
MF8_VJNB6QAL'&I??<U6J\67*%I5&?PV%MUJX54A'%2ZXA1DTHL5.I2>U1><-
M/ELG<M7;U>,?[DQ-/@PB=;I,[O.SF,OEK6S5_LQ,5:M.,QZLZ>2.6'E<G3F3
MFB<\Y"N</*3C9%!CQ%M*EM.DE%35QU+(TF9+V8Z[2VC]11G:;%,1515=QTS.
M.S,:>;#P<CSJN;MKS==4TW*,O,>C%.&W$^CKVIF,,=KEY87&9LU6%W+D7)N4
M8<EBQ,2E7&1*N*D*ER)2D&V1F374)2E)TV;]FZAU\\ID[T7IOWZHFN:=F(I]
M6(U\NF=+UWCO'+3EJ<IE::HMQ5[R:J\-NJK#9_IT1$1H\.CQZDSB9$U#K]^O
MU(V-_D8VZM=71"RR.HOXTRYWT@]T(&LS?P:^S5U.JR4?]BWVJ>M]+A3Z\P
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MH'T:        U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
M
M
M          #4/TGOF3\: GD2_2GR89,[R6[N5L$2EX
M
M
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MD'NH?0'MF-WS;M^\HJBNF)PG#DECY;><7+ONJZ*K=<QC$5<L-A#5MP
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MOWDQA3S8<L^&6VQHW1       U#])[YD_&@)Y$OTI\F&3.\EN[E;!$I>
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M+<)%OMI+4Z4=M2U%C<ZXZK4H]M.B,2_F+EZK:KG&69E\M;R]&Q;C9AEQX,D
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MGL0D               !J'Z3WS)^- 3R)?I3Y,,F=Y+=W*V")2\
M
M
M                  &H?I/?,GXT!/(E^E/DPR9WDMW<K8(E+P
M
M
M                 :A^D]\R?C0$\B7Z4^3#)G>2W=RM@B4O
M     >5K0VG$XHDI*E5*.A;3H6\!Z              'X2TFHT$HC6FAJ37:
M5=U2 ?H
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M"2ZVA)*;50CV&1J(856;<Z2)3:HZ;:S"FWZ9EV,A:7G'6FXO'-,I1DI)+4?
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M\!Y2IS;RX[*9#<K&:7,*W_7623Q$%3HU,+>;?,W3)5O)4)7OI GO*LSDB.Y
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M\G%=>LKD5+,N(2F^,W*8)VKC2E+P*(ZE0E&5*'RT(A*
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M7(,2S+?GSTMJN4B:BXDF*M\FFG&8QPVZK<6;CRN&:L2GC.IGUI84T"9@
M                                             #4/TGOF3\: GD2_
M2GR89,[R6[N5L$2EX
M
M                                            -0_2>^9/QH">1+]*
M?)ADSO);NY6P1*7@
M
M                                           U#])[YD_&@)Y$OTI\
MF&3.\EN[E;!$I>
M
M                                         #4/TGOF3\: GD5=,]3=
M.86G.4H<S-MGCRX]G@-/L.SX[;C;B(R$J0M*ED9*294,C(!*O&MIAX9V3X1B
M]D!&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM
M,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&
M!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",
M7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.R?",7L@&!XUM,/#.
MR?",7L@&!XUM,/#.R?",7L@&#5?C#R#_ +C/?C^*+5[T_P ']J]O]N,]K]L>
0^./A<7%@QX>JPUK0$\C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>pg_revenuegrowth-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg_revenuegrowth-4c.jpg
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M%!04%!04%!04%/_  !$(!48#]0,!$0 "$0$#$0'_Q #I  $  04! 0$
M        !@,$!0<( @D! 0$  @(# 0               0<$!@(#!0@0   %
M P(!! </$ <& P8#"0 ! @,$$04&$@<A,4$3"%%A(C(4M#=Q@;%"([/3=)05
M=18V=A>1T5)RDK(S4W,D5%65U597H<%BDS0U)X*BTL,F&.%#I,+B@\34./"C
MA"5E\6-$1;5F*!$!  $" @4&"0D'!0$  @ '  $" Q$$(3$2!09!47&Q<C1A
M@9'!T2(R$S/PH5*"LL)3%!;A0I*B(Q4U8M)#) ?Q<V/BLU07="4V_]H # ,!
M  (1 Q$ /P#I7:?:;:^Y[88;<;CAMFESY5EM[TJ4_ CNNNNN1T*4M:UH,U*4
M9U,S,$IC]#&T?\#6+]FQO8P1B?0QM'_ UB_9L;V,#$^AC:/^!K%^S8WL8&)]
M#&T?\#6+]FQO8P,3Z&-H_P"!K%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_X&L7
M[-C>Q@8GT,;1_P #6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/
MH8VC_@:Q?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/\ @:Q?LV-[&!B?0QM'_ UB
M_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\  UB_9L;V,#$^AC:/^!K%^S8WL8&)
M]#&T?\#6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_ (&L
M7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_@:Q?LV-[&!B?0QM'_  -8OV;&]C Q
M/H8VC_@:Q?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6+
M]FQO8P,3Z&-H_P"!K%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_X&L7[-C>Q@8G
MT,;1_P #6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_@:Q
M?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/\ @:Q?LV-[&!B?0QM'_ UB_9L;V,#$
M^AC:/^!K%^S8WL8&)]#&T?\  UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6
M+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_ (&L7[-C>Q@8
MGT,;1_P-8OV;&]C Q/H8VC_@:Q?LV-[&!B?0QM'_  -8OV;&]C Q/H8VC_@:
MQ?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6+]FQO8P,3
MZ&-H_P"!K%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P #
M6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_@:Q?LV-[&!B
M?0QM'_ UB_9L;V,#$^AC:/\ @:Q?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/^!K
M%^S8WL8&)]#&T?\  UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6+]FQO8P,
M3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_ (&L7[-C>Q@8GT,;1_P-
M8OV;&]C Q/H8VC_@:Q?LV-[&!B?0QM'_  -8OV;&]C Q/H8VC_@:Q?LV-[&!
MB?0QM'_ UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_P"!
MK%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P #6+]FQO8P
M,3Z&-H_X&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_@:Q?LV-[&!B?0QM'_ U
MB_9L;V,#$^AC:/\ @:Q?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/^!K%^S8WL8&
M)]#&T?\  UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_X&
ML7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_ (&L7[-C>Q@8GT,;1_P-8OV;&]C
MQ/H8VC_@:Q?LV-[&!B?0QM'_  -8OV;&]C Q/H8VC_@:Q?LV-[&!B?0QM'_
MUB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\#6+]FQO8P,3Z&-H_P"!K%^S8WL8
M&)]#&T?\#6+]FQO8P,3Z&-H_X&L7[-C>Q@8GT,;1_P #6+]FQO8P,3Z&-H_X
M&L7[-C>Q@8GT,;1_P-8OV;&]C Q/H8VC_@:Q?LV-[&!B?0QM'_ UB_9L;V,#
M$^AC:/\ @:Q?LV-[&!B?0QM'_ UB_9L;V,#$^AC:/^!K%^S8WL8&)]#&T?\
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M\!6WQ9L$2G
M
M                                                         @]P
M\L6.?-F_>/V< V8\D>#? 5M\6; E.
M
M
M               !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M
M
M                                  "#W#RQ8Y\V;]X_9P#9CR1X-\!6
MWQ9L"4X
M
M                                                     $'N'EBQ
MSYLW[Q^S@&S'DCP;X"MOBS8$IP
M
M
M            (/</+%CGS9OWC]G -F/)'@WP%;?%FP)3@
M
M
M                               0>X>6+'/FS?O'[. ;,>2/!O@*V^+-
M@2G
M
M                                                  @]P\L6.?-F
M_>/V< V8\D>#? 5M\6; E.
M
M
M        !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M
M
M                           "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M
M                    Y.)@*'AL/](:^[3]<!4;=:=(S:6E9%P,TF2N/G /
M8
M                       @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
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M,CS*SXK<TP[JQ<GTM//+9\'?;:21K<<2;.E-4H2I5#1QIS",!UL(2
M          (SDFXF#X@LV<DOT.!)))+.*XX2I&DRJ1]$C4NA\W<@(OC&_&"Y
MEE<7$L;5+F2I27EE,-CH8Z4L-FX=>D-*^)%P[@3@-AW7_*YOM=W[PQ ^7PY(
M=?\ 5 ^2>0_"*/6$B)'1HA(
M                                            @]P\L6.?-F_>/V<
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MS'LSM2+SC4]N?;UGI-;=24A9$1FAQ"B)2%%7D41"!F@
M
M  0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G         "(;J^3/+_ ('G>L+
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M^<@&T.KAF,S&=R8%M)P_>O(#][YC%3TFXHC-A=.34ERA5^Q4KLA([O'%(
M
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M32ZLN51-OKTU\S480-0;:&9;B8H9'0_?>#Q+VP@2/I&.*0
M
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M4.O^J!\DLA^$4>L)$2(9UO\ Y68]\'+]?4$#3FVGE$Q3X7@^,($CZ1CBD
M
M               $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP         P.;
MV:7D6'7ZPP%(3-N<"3$CJ=,TMDX^TI"349$9D53X\ '(_P#VF[F_I=H]TO\
M_P!..6*'2NR^$WC;_!8^-WQ;#EP:D/O*5%6IQK2ZO4FAJ2@Z^<.*6"W[VEN6
MZ%JM)V)V.S>K6^YI5+4IMM49])=(6I"%G4E(09<.R)@:'+JG;G),C*9:",N)
M&4E^M?<XG%#KMJSJO>*,V3,XS$UZ5#;8O,<C-QAQ[01.&DS))TU%J2K@9<#X
M&.*7-.9=4>Y(DNRL%NK3T-1FI%ON1J;=01^E2\A*DK[6I*?-$XH00^K)NZ2S
M25LC&5::RF,4\WBHC_H$XB58CU5\_9NL*YW6YP;2F&^U(2;2ERGR4TLED9)2
ME*.;\8(Q'80A+1V_NRMWW-E6>[8V[%9NL)MR+,.8M;:7(YF2VZ&A"^*%&OA3
MTPF!IK_M-W-_2[1[I?\ _IQ.*'6>!8LSA6'6?%V32H[='2V^XCO5R%56\LJT
M.BG%*40XI9Z5%C3HST.8RB1$D(4T^PZDEMK;66E25)/@9&1T,C <Q9WU2RD2
MG9^W]R;C,N&:_>FXFO0W7C1M])+53L$M/^T)Q0ULYU8]W$+-*;;&<27(M,Q@
MDG]THC_H$XC,6;JG;B374^^TRWVJ/Z91NKDN^<AM.D_/60C$=(;IX/>\SVTD
M8?;)++EX<3#+PJ4:F6EJC.MK6H]).&6K29TXB$N;/^TW<W]+M'NE_P#^G'+%
M#J[;G'I^*8/8\<N:FUS[=&2Q(4PHU-&HC,^Y-1),RX]@<4N>-QNK=G^69Q?,
MCMLFV(@7&2I^.E]]Y#A(,B+NB2RHB/AV1.*$EV+V,S+;?,9%_O[\!R$[ >AI
M3$><<<Z1QUI95);2"I1!\X2-G;K;76G=+'TVR8YX)<XBE/6NXI3K-EQ144E2
M:EJ0LB+45>8CYA"7*\[JN;K192V8T:'.8(Z)DLRD(0HNS1[0HON1RQ0V'MYU
M5G8)NW3.Y$>3*Z%U,*T,&IQA+RT&E*WW#).K09ZB0@J5IQ/D$8B%?]INYOZ7
M:/=+_P#].)Q'5.V.-W+$,#LF-7A32[C;F5-/JCJ-31F;JU%I-24F? RYAQ2U
MQNEU;+'FTY_(,<E)LE_D&;DILT:X<AP^5:DIH:%GRJ4FM>4TU,S$XC1LSJN[
ML1G3;8B0IB".A.L2T)2?;H]T:OZ!.*%:W=5?=.8XE,M$"WMGWSC\K70O,82X
M9AB.K=J\*F[?87!Q6=/3<78BWEI>;0;:$I><-S0DE&9F1&H^/] XI3, ,B,J
M'Q(P&B=P.J_B64R7KKC<@\=NCQFMQEMLG8*UGQKT54FW7^PK3_9$XC3=RZJ>
MYL1U283ENN#7I%M2%-&9=M+J$4/SS$XH6C/5<W8=625Q83*?LURT&G_<)1_T
M!B)?8NI_>G5H7DF11HS7*MJWM+D+/M$MWHB+S=)B,1NW=K;ZZYEMRG#L?=9*
M8TN)T;DQ:FT&W&H1F9H0KB9%]B"7.7_:;N;^EVCW2_\ _3B<4.ML%LDS&\,L
M./W!3:IUL@QXDA3)FILW&6R2K29DDS*I=@<4L^9$HC2HJI/@9'Q(R,!SAN/U
M5K?>9;UWP*6U:9#QFMVTR25X'K/B9M+02E-E_8TJ+L:2X"<4-2N=6+=Q#AH3
M;HKB2.G2IF,DD^WW2B/^@3B)OA?5(N;LEN5G=T:CPDF2E6^W&;KSA%Z53JTI
M2CMZ25YPC$=2V>SVRP6R+9K-%1"M<-!-1HS142A)<>>IF9F=3,^)GQ/B(2QV
M<8VC+\0O6-+-*57*(XPRM?>H>,JM+.A'P2LDJ <D?]INYOZ7:/=+_P#]..6*
M'0.Q&V%RVQQJ?!O;D=V[W"8;[JXBE+;)E#:4-IU+0@S,CUGR<XB4M6[H=6S,
M<JSN\9'CLBW-VNY.)D);DO.MNI=4VDG:DEI9<5DI7+SABA4VIZMN68IG5KR3
M)Y%O=MML4M]+45UUUQ3Y(-+7!;2"HE1DNM>8,1U&(2UMO!M#;=U;3';5(\ O
MMN-:K=/TZTT<(M33J>!FA1D1U+BD^)<Y&',,SJO;LQI"V6(<.8TDZ)D,RVTH
M479(G="OJI'+%#=>PFT.7[?1<F/(RC-.7EAEF*TR]TJDJ:)ZIK,DZ2+U0N0S
M$):E_P"TW<W]+M'NE_\ ^G$XH;[V$VTR';*Q76VY"[%=?FRTR&3AN+<22";)
M'=&M".-2[ B4H]OWLQENYM]M5RQYZ$U'A1%1WBF.N-J-9N&O@2&UU*AA U_A
M_5CW$L.66.]S)5J5$MT^-+D);D/*6;;#J5J))&P1&="X<0Q0Z\$)
M
M          !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M
M
M                             "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"
M4X
M
M                                                $'N'EBQSYLW[
MQ^S@&S'DCP;X"MOBS8$IP
M
M
M       (/</+%CGS9OWC]G -F/)'@WP%;?%FP)3@          8:^Y;C6,N0
MV;_<V(#UP6;4%IY5%O+(TD9(253.AJ27GD S("%O;D6QG<AC;14.0=TD1#G)
MF%H\')!)4K2?=:J]QV $T  'AYYF.@W7W$M-EP-:U$E/'MF \L2(\E)KC.H>
M01Z34VHED1]BI5 50%-Y]F.CI)#B6FZD6MQ1)34^3B8 S(CR4&Y'=0\@CH:F
MU$LJES5*H#T;C:5I;4HB6NNA)F1&=.6A<] &!R_-L8P2WLW7*IW@$%]XHS3O
M1.O5=4E2R31I"SY$*.M %Y%R*SS<?1E,:3KL3D7P]$K0LJQB1TFO0:25WI5I
MIJ QV'9_B6?,2I.)W#P]F$M+<E71/,Z5+(S25'D(,ZD7, D?2(U]%J+I"+4:
M*EJTF=*T[ #T          !G3B?( L&KY9'V8DABY176)ZS9@NH?;4A]U.JJ
M&C)5%J+2JI)KR& M(V78S+O\C%H]T87D41.N1;-5'TITI572=*E123X<P#-
M
M
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M1\323J25I.G.D^Y/MB!DP
M
M                    0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G
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M2,!K_JN75RX[5,17%:CM<V5#17E)!FF01?\ YHF1N@0
M
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M@-*=4=EQO;VZ/*[QV[NZ/]F.P1_TB9&_A
M
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M#CCF-;5V./(2:)<]"[D^D^!_G:M;=2[/1Z*B9&S!
M
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M*R-X(0AM"6VTDE"2)*4I*A$1<"(B(0/T
M                           'XI24)-2S)*2XF9\A ,1*O/$T12_^(K^H
MA*&,<E273JXZH^U6A?4(!3U*+B2CKYH"NS/ELGW#IF7V*NZ+^D!EX=V:?,FW
MBZ-T^0_2F?\ 4(2R(
M            (/</+%CGS9OWC]G -F/)'@WP%;?%FP)3@
M
M                           1ZY3SDN&VV?J"3X?VC+G$H6       S5I
MGFY^:O'59%ZFH^<BY@&6$)
M               $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP
M
M                             L;J^;,4R2=%N'H+S#Y?Z $=$H
M!^H6IM:7$'123(R/MD EC+A/-(=3R+(C^J(2]@
M                              (/</+%CGS9OWC]G -F/)'@WP%;?%FP
M)3@
M                                           !A;XH];*.8B,_JT^L
M)0Q(        "16E1JA((_2FHOZ:B$KX
M                        !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M
M                                      ,-?$'J97S44GT#$H8@
M    !([2@TPD5],9J_I$)7H
M               "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M
M                             8V\J9\&)"S]5J1MD7+V_. 8$2@
M 'IIM3SB6D<5+.A )8VVEIM+:>]01)+SA"7H
M                            !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*
M<
M                                         M9LUN&W4^Z=5WB.SVS[
M0"..NN/N&ZZ>I:N4Q*'@      "*O N4!GK7 ..73O%ZLHNY3]B7UQ"62
M                                                   $'N'EBQSY
MLW[Q^S@&S'DCP;X"MOBS8$IP
M
M  +:;-;AMU/BX?>([/\ X (V\\X^X;KIU68E#P  +B)">F&?1T)*>5:N2O8
M>G+=,;/BT:B[*>Z] !2*+),Z$RNOVI_6 7#5JF.GQ1T:>RLZ?T<H#+1+:Q%H
ML_5'?LSYO,(0E>@
M          @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.         '-&_^;9-C
MN;1H-GO$N!%5;F75,QWEM(-:G7B-5$F15,DD+!X>REB[EIFNBFJ=J=<1/)"H
M^+\]FK.<BFU<KHIV(T4U3$8XU<S5?TJ9W_$MQ]U._P#$-D_MV4_"H_AAI?\
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MRLVW5QW$.I0M)5-*C09T,J\A@+H           "I?4Y0
M                         !;39C<-O4KBX?>([/\ X (V\\X^X;KIU68E
M#P  +F%"<F.4+N6D]^O^HNV DC33;+9-MEI0GD(0E[
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M2]@
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MTSU:K!F.8[@66XYU:I-OB[16(\>MR):%I2[<7GWVB=1K21*T1R-L]-::4'V
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M$;>><?<-UTZJ/^CM$)0\  "YA0G)CE"X-EWZ^Q_X@)(TTVPV33940GD$)>P
M
M  0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G         #D3K/8?EU_P!PXDVQ
M6&X7.&FU,-*D0XKTALG$O/F:34VE15(C(Z#>]PYFU;R\Q7733.U.N8CDA7/$
MF4O7<S%5%%54;,:HF>66EOHSW'_A&\_L^3[&-A_/9?\ $I_BAJ_]MS7X5?\
M#/H/HSW'_A&\_L^3[&'Y[+_B4_Q0?VW-?A5_PSZ#Z,]Q_P"$;S^SY/L8?GLO
M^)3_ !0?VW-?A5_PSZ'T(PMA^+AV/1I32V)+-LA-O,N$:5H6B.@E)4D^)&1E
M0R%69J8F]7,:MJ>M<>3IFFQ1$Z)BFGJ9P8S+
M  !^+)1I423TJ,C)*J5H?9H YUOFP6[^86]>(YGO"_<<$?<)4R*Q:(T6?(92
MO632Y"%&?*7*>HCYT\P)Q;\LEFMV.V:WV"T,E'M5KC-0H3!&9Z&(Z";0FI\3
MH1%Q,$+\                                            !;3)C<-O
M4KBX?>(YS/ZP"-O/.2'#==.JC^H1=@A*'@  7,*$Y,<H7!LN_7V/_$!)&66V
M&R::*B"$)>P
M               $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP
M
M                   "WF3&XC>M?%9]XCG,P$;??<D.&ZZ=5']0B[!"4*8
M N8<-R8YI3P;+OU]C_Q 2-EEMALFFBH@O_Q4Q"50
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M\6II]E1+;65:5)1<#XD,&Y;JMU335&$QR2]6S>HO4171,54SJF-,+@=;N
M
M          %O,EMQ&]:^*S[Q'.9@(V^^Y(<-UTZJ/ZA%V"$H4P !<PX;DQS2
MG@V7?K['_B D;++;#9--%1)?_BIB$J@
M                                      (/</+%CGS9OWC]G -F/)'@
MWP%;?%FP)3@        !S[UEOP^-_:3/19%@<)ZKOU?O*@_]"]JQT5_=:&&^
M*E  !V/M+Y.;!^05ZZL4[OOOMSI\T/I/A?\ QEGL^>4T'BMF0;<+>';G:LX2
M<[O:;4Y<2<5";Z"3)6XEDTDLR*.TX94U%R@/&';T;9[@PI\W#<@9NWO:PJ5,
MBH2XS+0R@N*N@?2VY3FU::5YP3@O=M-R,>W6Q9K+\83)1:GGG8Z$S&TLO:V%
M:552E2RI7DX@A+P       ?BE)0DUJ.B4D9F?8(@&F&^MGU?7)B8*<S:)U1Z
M2<5#GI9KVW51R01=LU4!.#<,*=#N<./<;=(;EP)3:7HTIA:7&G6G"U)6A:3,
ME),CJ1D"%<       &+R2_0<6QZZY+<R<.W6>(_/EDRG6Z;,9M3B]":E55$G
M0J@+'!<SL^X>)VS,K"EY-HNJ%N14RD$T\26W%-'J22E$7=(/G 2(!K.X]8/9
MZTY4>&S\H8:O:)"8+_J;ZHC,M1F1,NRDMFPA=4F1DIPJ&7&@)P;,!#565=9'
M97"KY*QO),H1$O<)PF9<1,2:^;2S22J*4RPM/(9<X)P2_#-P\)W#A.7#"KY%
MO,9DR3(\&7ZHT:N*2<;425HK3AJ2500DP    "$X!NEC.Y$K(X>/(E)=Q>>N
MU7+PII+23D-FI)FV9+5J35!\3IY@";          "V8N-OE2)$.+*9?EQ#24
MMAMQ*W&374TDXE)F::T.FH!BLOS7%,!LR\@S&ZL6BTH43?A$@SJMQ53)#:$D
M:UJ,B,]*$F=",!'-O-[MLMU)<J!@U\*XSX3?3R8JH\F,XEG42-='VFZE51%P
M[()P;!!   (MGVXF(;8V1O(LUN'O=:79+<)M[HW'C4^\2E)226DJ5WJ%*/AR
M$8"3M.(>;0\THE-.)):%%R&E15(P'H          6\N6W$;UKXJ/O$<YF C;
M[[DEPW73JH^0N8B[!"4*8  N(<-R8YI3P;+OU\Q%]<!)&66X[9--%1)?5,^R
M8A*H
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M@)(RRW';)IHJ)+ZIGV3$)5
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M)*V!W2Q]K:?)K&Q9KWD&!VYZV3\<N;R_ #6\MY12&7-%-9$Z1F9D1DI"#*M
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MKYB(!)&&&X[9--%1)?5,^R8A*H
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M1&2%56I7#5QY#&C[PS,9B_5<B,(JE:FZ,E5D\I;L53$S1&&,=,L\,!ZP
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MLS)1L3'**/HF28=<U]SP+ND)3QX<0&2
M                 $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP
M                                                     #'7-DI!
MLM(_#F9Z2YM-.)F \Q+2ALC.41+4?(DJT+T %S[W0OQ)?5/ZX![W0OQ)?5/Z
MX![W0OQ)?5/ZX![W0OQ)?5/ZX![W0OQ1?5/ZX#&/6MQ@S<4HE1TF1J-/?::\
M3IV@2SB=.DM/%-"H9=@$/T       %"5*;B-](YR^E3SF8"-R)#DEPW73X\Q
M<Q%V"$H4@ !7B1');FA'!)=^OF(@$D88;C-DTT5$ERGSF?9,0E5
M0C=;=+'-H\2D97D*NF0TIM$:VLN-(ERE..H;43"'5HUF@E](NA\$D9@)'8,D
MQ_*K>F[8S=8EXMBE&@I<!]N2SK30S3J;-1$HJ\2Y0&.NNX.$V/(X&(7:^PXF
M3W30=OM3KI%)>Z59H1I1R]TI)DFO*9 +S)LMQC#+<=VRN[Q+/;B/24B:\AE*
ME'Z5.HR-2NTFI@*S.16%^Q-9.W<HWQ=>CIFMW1;J413C+22DNFXLR223(ZU,
MP$7QO>G:G+[S\7\:RVW7&\GJZ.&T]1;N@JGT6HB)RA<>X,^'$$X)V9D15/@1
M<I@AKIK?O9E^](QYG-[2NZK<Z!#:9"3:4Z9Z223WX(S,^!=WR@G!L4$
M#&721<V)=J;@,]+'?E&W<5Z=71Q^@=42JU*G=I05>/* R8
M                                @]P\L6.?-F_>/V< V8\D>#? 5M\6
M; E.
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M95X\*TH<H=B8^W&9L-J9A3#N$-N''1'GFHG#D-):227=15)6LNZKSU!Q9$
M  !C;HJ[)EVHK:DCBJE&5S,R2=(W0.F1EJ.OX3H^]X@,D
M                               (/</+%CGS9OWC]G -F/)'@WP%;?%F
MP)3@
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MY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M                              *;[R6&E.JXDGD+LGS$ \165-MFISB^
MX>MP^V?-YP"N           "T1^:RC;Y&)!FI'8)SG+SP%V  *,F2W%;-QP_
MM4\YF C4F2Y*=-QP^TE/,1=@A*%(  5HL5R6YT;?)Z97,1 )+'CMQFB::+@7
M*?.9]DQ"54                              8VZ1;E(EVIR"_P!#'CRC
M=N"-1IZ5CH'4$BA$=>[4A5#[ #)
M             "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M                                               6G^*E4Y6(Q^<;
MO_N@+L            !2D,D^T;=:*Y4*["BY# ?D9XWFJJ*CJ3TN)["BY0"3
M);BM&XX?:2GG,^P C<F2Y*<-QP_M4\Q%V"$H40 !6BQ7);I-M\"Y5*/D(@$E
MCQVXS9--%PYSYS/LF(2J@             #'G?;(7 [E%K^7;_XAD?E[OT:O
M)+$_.V/Q*?XH/?VQ_K.)_?M_\0?EKOT:O)*/SN7_ !*?XH/?VQ_K.)_?M_\
M$'Y:[]&KR2?G<O\ B4_Q0>_MC_6<3^_;_P"(/RUWZ-7DD_.Y?\2G^*#W]L?Z
MSB?W[?\ Q!^6N_1J\DGYW+_B4_Q0>_MC_6<3^_;_ .(/RUWZ-7DD_.Y?\2G^
M*#W]L?ZSB?W[?_$'Y:[]&KR2?G<O^)3_ !0>_MC_ %G$_OV_^(/RUWZ-7DD_
M.Y?\2G^*%S&FPYJ5+AR&I"4G12FEI<(C[!Z3,=5=NJCVHF.EWV[U%S315%71
M.*N.#M    8RZ0)DR7:GXTCH&H4HY$INJBZ5HV'6]'<G0^Z6E7'AP 9,
M                                          0>X>6+'/FS?O'[. ;,
M>2/!O@*V^+-@2G
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M!4 J 5 *@%0'1W5MI[Q7L^?PMOC_ /#%<\5_%M]F>M='_G_=[O:CJ;N&DK0
M   8NZVTY\NT2"D=![WRSDFW^.JPZUHY2^SU<_( R@
M                            @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
M                                              !:2"\*?3%Y6D46
M_P#^RGSP%=IAE@C)I!((^6@"H      +5^"P]J4222\?$G"YE<Q@*D9XWFJJ
M*CJ3TN)["BY0%8!2>CL/TZ9!*IR&?* HQO4'%0U=Z7=L'V4&?$O.,!=@
M        *,F2W%:-UP_M4\YGV" 1F2^N2\IYSE/@1%R$1<PE"F  /3:2<<2@
MU$@CY5'R$0#/QI%NBM$VVZ5.<Z'4S[)\!"57WQA?CB^H?U@#WQA?CB^H?U@#
MWQA?CB^H?U@%K+NQ(,DQ:+X54LZT\SF 74"6<MHU*+2M)T41<GF@+H
M  !Y7WBO,,3")U.!Y!ET[OVZO1%\TZH?)M<>M/2I5(<G# J0&!4@,"I 8%2
MP*D!@5(#!TCU:SK8KW[;;]:%<\5_%M]F>M<_ '=[O:CJ;N&DK/    8N[6Z/
M.F6B0](Z!<"6<EAON?55FPZUHX]I9JX=@!E
M                     !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
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M"15)=*\<=U&CNN)]PI2N''@ RH
M            @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
M                             %H7YU*U<K$<Z)[!N<Y^< NP
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MP   #%7=FUNS+.NXO&U):F&NVI(Z=))\'=2:3X'7U,UG3M ,J
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M6QVC],G^L!=@       \K[Q7F&)A$ZG ,C\.[]NKT1>].J'RA7[4]*F.3B
M      Z3ZM'^0WSVXWZT*ZXJ^+1V9ZUR\ ]WN]J.IO$:4LT   !BKL5I.99_
M?$S*24L_>RFJAR?!W:UT\/P>OON'G@,J
M             P]X>?2ZAM)FEK34J<*G4$O=OD35,F1-],E)T)2E:3\SB1U!
M"[Z:;^BE_>%]8 Z:;^BE_>%]8!#K@I[Z5\==Z$BD_%Z^I)K67%'AUG,U5IPH
M8)>]F/)'@WP%;?%FP1*<
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ME"@  *L>.[*<)MHN/.9\A%V3 9JWQFTJ-U!5;15#2N=1^F7Y_(0A+(@
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M5)454F1EV2X@/T    !Y7WBO,,3")U/G_(_Q#OVZO1%[TZH?*5?M3TJ8Y.
M      #I3JS_ .0WSVXWZT*ZXJ^+1V9ZUR\!=WN]J.IO(:4LP   !BKO+MT:
M99VIS'3/RIALP%T2?1/^#NKU\3*G<)6GAV0&5
M                !;2UJ,DQFCHZ]P,_L4%WQ@*Z$);0EM!42DJ$7:(!Z
M!![AY8L<^;-^\?LX#QM(I]&U>$)BM(6P5AMFA1KXG^:-\3X<H)3'I)_XA'W?
M_@"&,NCLHUH2\71HI4DI.I&?F\ 2O;0MU<=72&9H)5$&?]((9
M                             %H_^;/IE%P:<HA_M?8J\[D 78
MU%N9O3#QE3MDQHVYM^35#\@^Z8BJY*'3OW"^QY"Y^P-NW3N"K,87+OJT<D<M
M7HCY1SJ[XAXNHR<S9R^%=WEG]VGTU>#5'+S.;+G=;C>IKMQNLER7.>.KCSJM
M2C[7:(N8BX$+(LV:+5,441%,1S*3S.9NYBY-R[5-54\LK0=S&
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M5VN$:%,L[#\8GW)TLX\=P]/J+A1W7=95X]Z@T\./$!E0
M                     !^*4E"36HZ)253/M$ MHB5+-4MPJ+=[PC]*V7(7
MG\H"Z     0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G #RM"'"TK22B["BJ7]
M("V;_-9)L\C#]5-]A*^=/G\I +L
M      'E:$N(4A952HJ&7:,!0B+4G5%=.KK/ C^R0?>F N0   :+WBW<7 6_
MB6+/Z9A5;NEQ;/BUS&RTHO3_ &:B[WD+NJTWG<6Y(KB+]Z-'[M//X9\'-'+T
M:ZJXKXIFU,Y7+3ZVJNJ.3_33X>>>35KU<\&=>)\HL-3@"
M7-ON$VU36;A;GE1YD=6MIU'*1\GF&1EP,CX&7 QTWK-%ZB:*XQIED9;,W,O<
MINVJIIKIG&)CY>6-4QHG0Z2P'.HF8P#)9)8O,8B\,BER&1\"<;KRH,_/2? ^
M8SJ;>VZJ\E<YZ*M4^:?#U^6(^A>'>(+>]+6GU;M'M4_>I\$^6F=$\DS-8\=R
M2Z331<3Y3YB+LF/#;6DD6*W$;Z-OE],KG,Q"5<!;2VU$29#)>JLGJH7IDGWQ
M *[;B74)<0=4J*I& ]             +0_SJ53E8CGQ["G?_ '0%V1$7 @
M   !Y7WBO,,3")U/GY(_Q#OVZO1%[4ZH?*E?M3TJ8Y.        #I;JR_P"0
M7SVXWZT*ZXJ^+1V9ZUQ\!=WN]J.IO,:6LP   !B[K<C@2[1'*/T_OA+.,;GX
MFC#KNOD/[#3S<H#*                                      "TD?G#
MR8A?@TT6^?:YD^> NP     !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<  "E
M(9)]HT5HLNZ0KL*+D,!^1GNG:)2BHXD]+B>PHN4!6
M                    !:RTJ0:9;956UWY%Z9L^4O.Y0%RE25I):3JE15(^
MT8#] :OWDW&/#[45HM+NG(KB@^C6D^,>.=4F[]L9D:4=NI\W'9]P[J_-7-NN
M/Z=/SSS>G]K1.+-__D+/NK4_U;D?PT_2Z>2GQSR.55*-1FI1F:C.IF?$S,Q:
MB@IG%^"4                 "_LMYGX_<F+K;7.CE,*J1'Q2I)\J%%PJDRX
M&,7-9:C,6YMUQHGY8PS\AGKN2O4WK4X54^2?!/@EV5A-\M628]%O-J.K<@J/
MI53I&WD\%MJISI/D[7'G%-9W*5Y6[-NOD^>.=]+;LWC:S^7IO6]56N.:>6)^
M7A2(83U   6C7YM(..?X%VJV>T?ID_U@+L           %"4\IINC?%YP]#1
M?VCY_. >V&4L-):3QIRGSF9\I@*@      \K[Q7F&)A$ZGS[D'^<._;J]$7M
M3JA\JUQZT]*E4<G# J!@5 P*@8%0,"H&!4#!TQU93K8+Y[<;]:%=<5?%H[,]
M:X^ ^[W>U'4WF-+66    QETGS(<NU,1H_3M391QY3E%'T31,.N:^Y*A=TA*
M>/#B R8                                    "SD7*/'6;9U6X7*2>
M0C[!F J0D:62<,R4X]ZHM1<YGS>< N      !![AY8L<^;-^\?LX!LQY(\&^
M K;XLV!*<    M'?S:04@OP+M$/=I7I5?U +L
M                 !:1_P V>5$/\&JJV#[7.GS@%.]WB%8+3,O-P5HAPFE/
M.F7*>DN"2KSJ.B2[8[\O8JOW*;=.NJ<&)G,U1E;-5ZY[-$8S\N>=4.*,DR"=
ME%[F7VXJK)EN&O01U2V@N"$)[24D22%U93+49>U3;HU4_+'QOF'>&>N9W,57
MKFNJ?)')'BC0Q0RWGLYBV)7S,KE[UV)@G7TIZ1Y:U$VVVW4DFM1GS5/D(C/L
M$,'.9VUE:-NY.$=;U-V[LO[PN^ZLQC.N>2(C5C/EZ>:&X;9U;/4T+O-^HZ9=
MVS$8JDC[3CBB,_[LAI][BS3_ $[>CPSYH]*R,M_Y].$3>O:>6*:>7M3/W8?E
MWZMJDLK<L5\UOD7<,3&=*5'VW&S.GW!B;'%>G"Y;T<],^:?2C-?^?S$3-F]I
MYJJ?O1_M:2O-EN>/W%^TWB,J+<(YT=:70^4JD9&1F1D9<2,CH-UL9BW?HBNW
M.-,JOS64NY6Y-J[3LUTZX^6CR)#@VV^19XZXJVI1'MK"B1(N$BI-)5P/0FA&
M:UT.M"Y.%3*I#S]X[ULY*(V]-4ZJ8U_LCY0]C<VX,SO.J?=Q%-%.NJ=71'/.
M&G#HQF,8;8C]6RV):I*O[[C_ -DTPAM%?M5+6?\ 2-4JXLKQ]6W&'3^R%A6_
M_/K44^O>JF?!3$>>>M$,RV'OV.0GKI:):;Q!82;C[:6S9DH07$U$C4LE$1<M
M%5[0]?(<1V;]445QL3.K3C'ET8?+2US>W!69REN;EJJ+M-.F=&%41T8SCY<?
M UK9;-<<AND:S6EDWY\M6AILN!<",S,S/D))$9F?8&R9B_18MS<KG"FEI&4R
MES-7J;-J,:JIT?+P1IEO.V]6V-X*D[O?%^&J*JT1&BZ)"J<A*<.JB[>E/F#1
MKO%=6UZEO1X9T_-J^=:N6_\ /Z=C^M=G:_TQHCQSKZ<(Z$"W#VBO&"LIN;3Y
M7.QJ42%RT(Z-;*U=Z3J*JH1\A*(Z5X'0S*OO[KWW;SD[$QL5\W/T3YOVM1W]
MPM?W93%R)]Y;^E$8;,_ZHTZ^2=6.B<)F,=?QHS\R2S#BMJ>E2%I:8:055+<6
M9)2DB[)F=![]=<44S55.$1I:C;MU7*HHIC&JJ<(CGF=39FX&V%EP''(4J9='
MI&1S="&X:$HZ#6DB4^JID2M":Z2/EJ9=L:UNS>]W.WJJ::(BW3R\O@\<^EO&
M_.'+&[,K157<F;U>'JQALX_O3S[,:HY=,:&KAM#0P  ;/V2S=6,Y*FSS'*6:
M\J2RLE'W+<GD:<[53/0KS2,^]&K\0;O_ #%C;ICU[>GICECSQ^UO?!^^)R>:
M]U7/].[HZ*OW9\T_L=6"JU_   HR6>G:-*3HXD]3:NPHN0!^QWB?:)=**[U:
M>PHN4@%4          6D?\X>5+/\&FJ&"[7.KSP%V       #ROO%>88F$3J
M?/F1_B'?MU>B+UIU0^5J_:GI4QR<        '3'5D_R"^^W&_6A7?%7Q:.S/
M6N+@/X%WM1U-Z#2UE@   ,9=)5QCR[2W!8Z:/)E&U/7I-71,= ZO74C*G=I0
MFI]D!DP                        %M-F)AMDK3J6HZ)3R *$2Z-OZDO:6
ME%Q(S.A']4!=>%Q?Q[?W1?7 /"XOX]O[HOK@'A<7\>W]T7UP#PN+^/;^Z+ZX
M!X7%_'M_=%]<!CSO1=+0FZLUY:]U3L@,J1DHB47$CXD8#"S+9(-YQUHM:%&:
M^7B5>)E0$LG!2A,1HD*U)TUKVSXG_2"%P      (/</+%CGS9OWC]G -F/)'
M@WP%;?%FP)3@   'EQM+J%-K*J5%0R 4(CBJ*CNG5YGN3/[)/I3^H N0
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M,IN81T6D]"D_9(/F\[E >XD]F69I15*RXZ5=CL@+H
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M0"^         >5]XKS#$PB=3Y\2/\0[]NKT1>E.J'RO7[4]*F.3@
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M(N"S-)D7;X& L(,V2<I"%+4M*SHI*CKR\Y>8"6>!
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M3@   #DXGR +2-^<.JF*[SO&"_LERJ\\P%V L4M-SW5/.IU1T50R7)6A\5<
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MDI)*2HDBH1=H@%O+6HR3&:.CKW"OV*/3& KH0EM"6T%1*2H1>8 ]
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M/SAY,0OP946^?:YD^> NP            %I_A9788DGYQ._^\ NP
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M1GJU=FO+43LQAAR..,XX\K\;<<:63C2U(<+D6DS(R\\A,Q$QA)$S$XP\B7$
M     &Z.KI8CE9!<<@<3ZC;F"894?)TTD^4O,0E5?MAI?%.9V;--J-=4X^*/
MV]2S> LEMYFN_.JBG".FK]D3Y728K==@                       #ROO%
M>88F$3J?/"0?YP[]NKT1>=.J'R[7[4J=1R<"H!4 J 5 *@%0'3O5>^3]^]N-
M^M"O.*?BT=F>M;W OP+O:CJ;X&F+(    8J[L6MZ99UW!XVI+,PW+<@E:>DD
M>#NI--*'7U,UJIV@&5  %*0R3[1HK17*A7847(8"WCW)AS2VXK2^?<J+TNKD
MX'R<0%Z                 HR6>G:-*3HXD]3:NPHN0P'[&>Z=HEF5%EW*T
M]A1<I *H           +1[\YD%&+BTW1;_;/TJ?ZP%V       "#W#RQ8Y\V
M;]X_9P#9CR1X-\!6WQ9L"4X 4GXS$@B)Y&JG(?(9>>0#TVTVR@FVDDE!<Q ,
M',@24/..$DUMF9KU%V#X\02S,1)(C-))6HB27=%R&"%8            !^&5
M2,N2O. CC<"0ZJC:=39F9$[R),B.E02D:4Z4DFM:$15\P$/T
M    !:,?G+RI9_@TU0QYGIE>> NP    '/\ UB\6,G+?E\9'<J+P&>9<QE53
M*C\WNDF?VHW_ (6SFBJQ/:CS_+I5#Q[NW31FJ8_T5==,]<>1H0;ZJ0 7EJ=M
MC%P9>O$9V9;D&I3T5ATF%N42>E/2&E>DC535W-:5IQ'3>IKFB8MS%-7/,8X>
M+0R<M5:IN1-VF:J(UQ$[,SS1CA.$8Z]&.&K2F:HF*Y1BU]NEJLWO!<["EB01
MM27I,>0R^Z31H7TYJ-*RK5)I/NN2@\:*\QE\Q;HKK]Y3<QCV8B8F(QQT:XY^
M9LLVLGG,I>NVK7N*[.S/MU54U155LX3M:ICDPG3JP'H>*X=;[(U?K,=[NMXB
MMW.6HY3L=$:)(-71(9)HTU<-):U&X1D1T(B"FYF,U7<FW7[NFBJ:8]6)QJC7
M,X\F.B,$56LGD+5J+]KWU=VF+D^O53%-%6.S%.SAZV&F=K&(U1BQN08[8\9S
M)5MN#\I_&%)1*8D1B;\*<BR&NE:(M=$:JF2%*,NR>GF&3ELU=S&6VZ8IBYJF
M)QV8JB<)\/AP\6/*P\]D,OD\[[NY-55G15$TX;4TU4XTZ]&/),],X<CUN%:+
M-:KA:%6**J'#N-IA7$XZW5/J2Y)2I1D:U4KS<A$7:(1NR_=N45^\G:FFNJG'
M##5X'+?N6L6:[4V:=BFY:HKPQFK35CRS^SHAF[M PC#KVUAU[LR[B\REE%YO
M1276GFW9+:%FJ,VCU/2T2ZD3B%&OD,85BYFLU:F_;KV8G'9HV8F)B)GVIU^M
MAR3&#TLW9R&[[\96]:FN:8CWES;JB8FJ(G&BF/5PIQT;5,[2&Y787,8R.Y6%
MQ?2^ OJ;0Z94-;9]TA1ES&:3(S(>QDLS&8LTW(T;4?\ WYVN;SR4Y/-7+$SC
ML3ACSQR3XX5['=,8ML1SWVL)WFX+<[E3TMV/';9(BH24,$E1K,]534NE*<!P
MS%F_<J]2Y[NG#DIB9F?'HP\7C=N3S.4M43[VS[VJ9Y:YIIB.BG"<=>F:L-6A
M)YF"6V\95C$'']<&W91%;GG%>7TKD-!&LWB)2B(UI2EM1MJ5WP\NC>-=K+W:
MKOK56:IIQC1M:L.C7IYGN7=S6K^<R]%CU*<Q3%>S,XS1&G:Z8B*9V9G6\PH6
M%Y>]<L?L-I<MD^/&?DV2X')<>=EJAH-9MR&UGT9&ZA*E5;TZ#^R(3<N9K*Q3
M=N5Q73,Q%=.S$13M<M,QI]6=&G''P.%JSD<]-=BQ;FW73355;JVIF:]B,=FJ
MF?5B:XB9QIV=F>>&!LUYP^W0F6KGC)WB:I1JER'IST=.C4=$LH8).GN:54LU
M\>T,^_8S-RJ9HN[$<D13$^7'S8/+RF;R5JB(N9?WM7+,W*J?%3%.&&CEG:T^
M!ZS;&X]ER;WLLA.OQ)K4:3;XZRUR4IF-I6EI24EWY&K21<I\!&[\W5=L;=S"
M)IFJ*IY/5G7T.6^-WTY?-^[LXS37%-5,:ZO7B)BF8Y^3#H9[)\.L5AP;IVB6
M_E$&ZM6^[RR<)3"7G(SCSD=I*%&DR:,DH4H^.LE<U!@Y3/7;V:PG1;JHFJF,
M-.&U$15/:TS$<V'*]3>.ZLOE<AM1C-ZB[%%=6/JXS1-4T4X3AZNB)F=.U%7)
M@UR-B::  #L3:?%E8IA<&)(1HN,RLV<1E11.O$5$GVTH)*3[9&*>WUG/S.:J
MJCV:?5CHCTR^D>&-V_D<C135&%=7K5=,\GBC"$W'B-H      !CKG-=C:$,\
M%*J9J,J\"[ #Q"N:EI4F02E*32BD),^!]F@"Z\/:^P<^X4 >'M?8.?<* /#V
MOL'/N% 'A[7V#GW"@'XNX-)2I1(<X$9\4&1<.V QK=VE=,1K,E-F?%!$1<#[
M'."6=!      \K[Q7F&)A$ZGSOD?XAW[=7HB\J=4/EVOVI4QR<0       '3
MO5>^3]^]N-^M"O>*?BT=F>M;O OP+O:CJ;Y&F+(    8J[-VI<RSJN+AHDHF
M&JVI(U$2Y/@[I&DZ%0_4S6?'@ RH  \N%J0I)G2I&5>Q4@$>9@2'E)T)]2,_
MPG(5"/E!*1EP*@(1]^X2_"%FE9H)*C(D%R%0^<$LHW-<4VA1QG#,R(S-)%0Z
M]CB"'KPMS]%=^H7UP#PMS]%=^H7UP#PMS]%=^H7UP#PMS]%=^H7UP%I/GOI;
M2EMM;)J,ZJ415X<Q4J _;3*?>4MIU1K)):B4?*7: 90      6CGYM))[D9?
MHESL$OTI^?R +L          4I#Q,-&Y2JN1">RH^0@'Y%9-EJBCJZH]3BNR
MH^4!6       !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<     +1C\V?5%/\
M&NJV/,],GS@%V             MI:U*TQ6SHX]P,R]*@N^/^H!70A+:$H05$
MI*A%VB >@                %K+4I>F(V=''N^,O2MERG_4 N4)2A)(25$I
M*A%VB ?H    #&9%8H62V2=8K@58TUHVS415-"N5"RKSI41*+MD,K*YFK+W:
M;E.NF?E'C8.?R5&<L5V:]5<8='-/BG2XGOMEG8]=YEEN2-$R$X;3A<QTXI4F
MOI5$9*3VC%U9?,47[=-RC55#Y@SN4N92]59N1A51.'[>B=<,>,AALA8['=,C
MN;%HL\=4F=(.B$%P(B+E4HSX$DBXF9C'S&8MV+<UW)PB&;D\G=S=V+5JG:JJ
M^6,^!.<IL]WQZP.8K9+1<%6QI92LBOJHC[;4M]FI)2E1H(O!V3,])J[Y7==B
MOAY._;OWHO7*Z=J=%%&U$S3$_>JY<-4:&U;SRE[*Y><M9M7-B)VKMS8JB*ZH
MY-7PZ.3'7/K*>8V:Z9,SBEXL$-ZX19=IB6Y2H[9K)$Z&1LNM*)/>TH2BU4(R
MXEP'+(W[>7F];NU13,5U5:9_=JTQ/A=6\\G>S=&6N6**KE-5JBC1&JNC&FJG
MP<^G")C3&AC=T'XYY.FV1G4OMV6%#M2GT'J2MR(RE+G'M+U)\X9.Z*9]QMS&
M'O*JJ\.U.CYF%Q%53&:BU3.,6:*+>//-%,1/SXQXE;<XC)_%:ERXU:Z?W:AP
MW1JO?_EN=;LXAUY;_P#QK75*18[*O&42(-UON-Q*P6VCE9E<6Y"&41(Y$72.
MI-:67W23P1J29J[FI4*H\[-46\O351;NU>M,X6J=G':GDC1M4TXZ^;2]G=]=
M[.5T7;UBGU(C:OUQ7$;%/[U6G8KKPU8Q,SHQT1BC-XS.S73([U>)V/Q[LB?+
M4[%=DNRF'$1T]PVDR8>0GO4I,^'+4>G8R%VW8HMTW)HV:=.$4SIY=<<[P\WO
M6Q?S5V[<LTW8KJQIQFNF8IU1'JUQ&K#QX^+WB.$/Y&J5DDN!(1BL1PU.1X#;
MK[[ZS.J8L9/=*,^))-:CHDN)G4<<]O"+&%JFJ/>51KJF(B/]57)XN7DASW3N
M:K-[68KHJ]S1.F*(F9JGZ%$:9\&,SZL:9EGK+>+JSNG9[QEMN?L5OD$NWP(S
M[3C#4:*IA<5IMOI4I+0V:TZC*A5,S.E1@YBQ;G(5V[%47*H]:J8F)F:MJ*IF
M<.6<-'D>KE,S=IWO:O9JBJS1.-%,3$Q%-.Q-%,4XX:*<8QY-<Z,5I@^/WG$,
MFN5[OL1R%$QN)-5)=?0I#3CKC*V&FVUJ(DJ-Q3A:*'W1<@[=X9FUFK%-NW5%
M4W:J<,-<1C$S,QX,-/,Q]SY&_D,W7?OTS13EZ:YG&-$S-,T4TQ,Z)FJ:O5YU
MEAF$2W(2<RNUIE7&RLKI MD5E;SMPD)K1'<)5H82:?57%%S:4D9GP[L_O"F*
MO<45Q37/M53,1%$>>KFCQSA#%W3NBY51^;N6ZKEJF?5HIB9FY5S:,=FB)CUZ
MI[-,3,Z*T#(G+1F-PR/<&!<&+]+:4Y 4VT3+D9QTC;2\AN30C)M!:6JU(J=D
MB,N%S*Q=RU-K*U4S13.G3C%6&G"9IYY]IWV,_-C/5YC/T7(NU1,TX1A-,SHB
MJ*:_HQHIQQB,.>&7EGA"MIYRX1W=415Z(V%2/!C=.X>!+-&LT\.BIWU.ZJ,2
MC\U_<*8JV,?=Z<-K#9VXU?ZN;D>A>_M\[FJFCWNS[[1M;&/O/=SACA^YAK_>
M:D&VJ\ &QMFL)5EF4-S);>JRV@TR99J+N7'".K37;J9:E?V2/LC7-_;P_+6)
MIIGUZ]$='+/RY6Z<)[GG/9N*ZH_IVO6J\,_NT^>?!#K45,^A0       %C(:
M1.D$P9>ILE5Q9<NI7(DC_I,!0L%RL5VA*F8]-8N$(G7&'),9Q+R.F84:'$&I
M)F6I"B-)ES& RH     9$94/B1\I ,<];FF?SB.DS<;,EDV9U(R+E(@%^VXE
MU"7$'5*BJ0#T     \K[Q7F&)A$ZGSND?XAW[=7HB\J=4/EZOVI4QR<
M   '3W5=^3]^]N-^M"O>*?BT=GSK>X&^!=[4=3?(TQ8X   #%795I3,LY7%!
MJDJEF5L,M5$R>@=,S/3P_!Z^^X>> RH  M9:C=4F&V=%.<7#+F;+E^KR +E*
M22DDI*B2*A%VB >77$LMJ=6=$I*I@+1F"TZ7A$I%7G#UFGC0B/D*@"^Y.!
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M[("Z      &,?NS9ZFF:DH^Y)T^]*O"O9 9!EI#+2&V^]25"/L]OSP'L
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M9L"4X      %-YI+[2FE<BBY>P?,8#Q%=4X@T._AVCT.%VRY#\\!7
M!3?>2PTIP^-.]3SF9\A /$5E33=7.+SAZW3_ +1\WG *X
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MM"5&LB[DE)415[9F0#'QYSLB6R4CNT$KN4D5")1\"/S@2SH(
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MD(=#*>P       4W9#+-"=<)!GR$9\0%&*1NK5,67%SN6B/F;+Z_* N@
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MGIG37;CQU?[6<M_5K>-1*NM_2E/.B-'-1G_M+65/N1A7>+(_<M^6?V/4L?\
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MI4>>/4HOL4\R?.(!<@               M&OS:0<<_P+M5L]I7ID_P!8"[
M%*0ST[1HK19=TA7847(8#PS)2I@W73)"FZI=(^92>4!A)\]<M>E/<L)/N4]G
MMF)0L@ !Z;;6ZLFVRU+5P(B 2*!!1#14^Z>5WROZB$)7@
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MQ/>]X^1?8GR'YQ@+LCKQ+D           !1DO="T:DE5Q1Z6T]E1\@#]CL]
MT2*U7WRU=E1\I@*H"T>_.9!1B_!-T6]VS]*G^L!=@        +221L.IF)[T
MNX?(OL#Y#\XP%V1D95+B1\A@            (/</+%CGS9OWC]G -F/)'@WP
M%;?%FP)3@                !:._G,DF"_ LT6[VU>E3_6 NP
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M0!DP   ?BDDI)I454F5#+M& MHBC:4J&X=5-\6S/G;/D^IR +H
M6C7YS(.0?X%JJ&>V?IE?U +L!2D/$PT;E*JY$)[*CY" ?D9DV6J*.KJCU.*[
M*CY0%8        !^*22DFE15294,NT8"VB*-I2H:SJ;?%HSYVSY/J<@"Z
M        !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<                I27
MN@:-9%J6?<MI[*CY" ?D9GH&B29U<,]3BNRH^4P%8                  6
MB_S:23O_ )+YDESL$OF/S^0!<K6EM)K69)0DJF9@(]<+@J6K0BJ6$GP+L]LQ
M*%D  /2$+<63;9&I:CH1$ D4" B(C4JBGU%W2NQVB$)7@
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MTMQ5$QVCH\]W)']BGTQ@*[;:6D);05$I*A$ ] +1'YU*-SE8CF:4=@W.<_.
M78           +:6VHTI?:*KS)ZDE]DGG3YY *[;B76TN(.J5%4@'H
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M45'4GI<3V%%R@*P#DGK!^49_VI&^],6GPWW..U*A^-/\C/9I:L&RM(
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M,22/D^J R@"WENJ0A+37X=X]*.UV5><0"JRTEEM+2.]25/\ Q >P
M    %HU^;238/\"]5;7:5Z9/]8"[          $'N'EBQSYLW[Q^S@&S'DCP
M;X"MOBS8$IP              +>6XHDI8:/U9X]*3[!<ZO.(!5:;2RVEI!42
MDJ$ ]@                 #\6M*$FM9DE*2J9F CMPN"I:M"*I82? NSVS$
MH60  _4(6XLD((U+4="(@$B@6]$1&I=%/J+NCYB+L$(2]1OS=U4-7>=^P?\
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MH.JXGI\>OK!IHVF<TMQ7V1=%P33M&0KWBCXU'9GK6UP3W>YVHZG0HT]8(
M#%7:WQILRSOOR28<@RSD1VST^K.''=:T%7CWJS5PX\ &5
M  ?BDI4DTJ(C2? R/B0"R=9;A*3*81I0GN7DESH/G\X!?$9&1&1U(^)&
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MM1U-_C3EA@   ,5=XENDS+.[.?Z%^+,-Z BJ2Z5_P=U&CB1U[A2U<.P RH
M                _#(E$:3*I'P,NT MHIFRM4-9UT=TT9\[9_6Y %T
M      "E(>Z!HUD55GW*$]E1\A /R,ST#1)4=7%&:G%=E1\H"L
M(/</+%CGS9OWC]G 4=H7R+;3"7-)(9EV*VJ))<$I=\$;U$7:/F!*? @
M     'AYU++2G5]ZDJ_^ "E$:4A!NN_AWCUN=KL%YQ +@
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M$:UGJ5H9-!H34^)T(!?67'[#C4,K=CMKB6B 1U*+ 8;BM5I2NAI*2KYP#)
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M *K3B7FTNH.J5%4@'L          6C?YU)-WE98,TM]@U\Y^=R +L
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MWTZH?-5?M2I#DX        .J.JG\G<@]NM>M"O\ B?XM'1YUK\%? N=J.IT
M-.6$    Q5V.TE,L_OB1G).6?O9350I/@[M:Z>'X/7WW#SP&5
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M+B?,DNP0A*^   !:SS)3/04U./'I0GM\M?. >(ML9C.=+J-:R[VO B 7H
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MHJ^S+L854OD   !A+QTO3G6NCHE='YNDZ^>(3#YY*[Y7FF+RA\RQJ?@E(
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M        ?BDI6DTJ*J5%0R[1@+:(I3:E0W#JIKBV9^F;/D^IR +H
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MO+MT:99VIS'3/RIALP%T2?1/^#NKU\3*G<)6GAV0&5
M   >'4=(VMNM-:337S2H P;=JE&\25EI01\7",J4[0)97P)/X][^\,$'@2?Q
M[W]X8!X$G\>]_>& >!)_'O?WA@'@2?Q[W]X8"QG6UXUDM@U.E2AZU541^?S
ME>6Z*N*P:7._4>HR+FY@0O             $'N'EBQSYLW[Q^S@&S'DCP;X"
MMOBS8$IA+<T-:$D2G7>X0D^0S/L]H@'B/;H\=25D1J<27?'V>S0!ZF2TQ&R6
M9:E*.B4\@"C$N;<@U)=HTHN)&9\#+SP%UX3'_&H^Z+ZX!X3'_&H^Z+ZX!X3'
M_&H^Z+ZX!X3'_&H^Z+ZX!X3'_'(^Z+ZX#'G>DD[0FZLUIJKQIV: +N4DU(1*
M9XN-=TG^T@^4O/(!<-N)=0EQ!U2HJD8#T          /Q2B21J4=$EQ,SY*
M,!<;B<DS::.C!?54?UA*&/  'ZE*EJ)*2,U&="(N4S 2"WV],5/2.4.09<3Y
MDEV"$)7X    "UEJ-U28:#H;G%TRYFRY?J\@"Y2DDI)*2HDBH1=H@'Z
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M<L$   !BKM<(T*99V'XQ/N3I9QX[AZ?47"CNNZRKQ[U!IX<>(#*@
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M\    !Y<<2TVIQ9T2DJF H1&U:5/NE1YX]1E]BGTJ?.(!<@
M"RN;:764-?\ FJ61-$79YZ]J@"A$M)-J-<DTN<*)25:>;QH O/ 8?XE/U #P
M&'^)3]0 \!A_B4_4 / 8?XE/U &E^LHPRSB-J)IM*3.Y%4RY?P#HW#A:/^Q7
MV?/"N^.Y_P"G;C_]GW:G,8LA2P         ^@D#_  ,7\BW]Z0HNY[4]+ZHL
M^Q3T0N!UNT   !Q_UB3_ -27_:<;[TQ:/#G<XZ94=QC_ )">S2U14;(TLJ 5
M *@%0"H!4!L[J_G_ *H6O\E+\76->X@[E5TT]<-NX2_R5'15]F79(JM>X
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M:0<8_P "[5;/:/TR?ZP%62ST[1I2='$GJ;5V%%R /V.]T[1+I1?>K3V%%RD
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M@%0"H!4 J V=U?S_ -4+7^1E^+K&O<0=RJZ:>N&W<)?Y*CHJ^S+LH56O8
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MDZ.I/4VKL*+D ?L=XGVB72BN1:>PHN4@%%?YK))WD9?,DN=@E\Q^?R +L
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MW6XHQ$ZZ57S^HDOKB$L@       "T;_.9)O<K+%4M=@U^F/SN0!=@
M      #RXM+2%.+.B4E4S 4(B%&2I+I4=>XT^Q3Z4@%R       #2/6<.F(V
MCX2+UAT;APOWBOL^>%=\<]TM]O[LN6ZBQU-X%0,"H&!4# J!@5 P*@8%0,'T
M*M_^ B_D6_O2%&7/:GI?4=GV*>B%P.MV@   ./.L7Y2G_:<;[TQ:'#O=(Z94
MAQA_D)[-+4]1LC3"H!4 J 5 *@%0&S^K\?\ JC:_R,OQ=8U_B#N5733UPVWA
M+_(T=%7V9=F"JUZ@   /*^\5YAB81.I\UY/"2Z9<I.*]$793JA\WUZY36X[M
MYK=<1^*5PNDJ0A4A3S\];ZS?=CJ:)OP9P_3-U(U=T9U,^(\RWNNQ1>][33$:
M-6&B)QUQX7MW=]YFYEO<553.G7C.,QAALSSQRZ5OCNZ^X&)VM%FL-Y5&MC1J
M4S'6Q'?)M2S-2C0;S:S34U&? ^<<[^[,M?KVZZ<9Z9CJEUY7?6<RUN+=NO"F
M.3"F>N)1BYW2XWJ>_=+M*<FW&2K6_)>4:W%G2A5,^8B*A%S%P&=;MTVZ8IIC
M"(>7>O5WJYKKF:JIUS*X=R&\OV%C&'91JL,:0J8Q#TH)*7UD:5+U$6HZD9\#
M.@X1E[<7)N1'K3&&/@=M6;NU68LS5ZE,XQ'AZV5N^XV;WRT,6"Y7I]RRQFFX
M[<%LD,,FTRDDH2LFDHUT(B[^HQ[60R]NN:Z:8VIG''7KZ=7B95[>N:NVHM55
MSL1$1AHC1&K5ACXV/1E>0MXTYAZ)RRQQZ04QR#1.DWBIQU4U4X$>G5IKQI4=
MTY6U-WWN'KX88^!CQG;T6)L;4^[F<</#U^+5RZU-&1WMO'W<51+46/O22G.P
MM*-)R222"7JIJY$EPK0<IR]N;GO</6B,,? XQF[L69LQ/J3.UAX=72Z8ZI_R
M<R#VZUZT-'XG^+1T>=9/!GP;G:CJ=!C3U@    ,9='+LB7:DVY!*C+E&FYF9
M$>F-T#ID95,J>J$CD 9,           'AUUIAI;SZTMLMI-;CBS)*4I253,S
M/@1$0F(F9PC6XU513$S,X1#0FX>_2B4[:,'41$54/7A::UYC)A*OOU%YA<XW
MW=?#>JO,?P_[O1_\5)OWC:<9M9/QW/\ ;'GGQ1RM#RI4F=(<ES'ER)3RC6Z\
MZHUK6H^=2E5,S&]T44T1%-,81"J+EVNY5-5<S55.N9TRI#FZ@          9
MK&\LO^)32G6*8N,Y4NE:[YETB]*X@^"B_I+F&%F\E9S-.S<IQZXZ)>GN_>>8
MR-S;LU33/+')/3'*Z9V[W>LV:DBW323;<BI3P52O4GZ<ILJ/E/\ L'Q\WE%9
M[TW'=RGK4^M;Y^6.GT]2\=P\4V-XX6Z_Z=WZ/)5V9\VOI;(&N-U
M     !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*6_XJ5V6(Q^<;O\ [H"[
M         >'6DO-J:7WJBH8"E$=4I*FG?P[)Z5]OL*\\@'F41LK3,1Z3N7B+
MG;/G\X!<D9&1&1U(^)&0#],R(C,SH1<I@,!<KB<@S89.C)=\K[(_K"4,<  !
M$:C)*2J9\"(N6H#/VZW%&+IGBJ^?(7V)?7$)9$       %O+<424LM'ZL\>E
M)]@N=7G$ JM-I9;2T@J)25" >P             !:/?G,@HQ?@FJ+>[!GZ5/
M]8"[         :0ZSGR0M'PD7K#HW#A?X]?9\\*\XY[I;[?W9<MBQE-@
M    #Z%V_P#P$7\BW]Z0HVY[4]+ZBL^Q3T0N!UNT   !QWUC/*7(]IQOO3%H
M<.]TCIE2/%_^0GLTM3#9&F        -H=7WRI6O\C+\76->X@[G5TT]<-MX3
M_P C1T5?9EV:*L7H    \K[Q7F&)A$ZGS5D_XE[[=7HF+MIU0^<*_:E3')P
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M2[Y7V7_@)0QH  $1J,DI*IGP(BY:@,_;K<48B>>*KY\A<R2^N(2R(
M/PS))&I1T(N)F?8(!;12-Y:IBRIK[EHCYFR^OR@+H   %M)GQXJB0X9FL^.E
M)5H7; 5FG6WFR<;.J#Y# >P    'AUQ#*%..'1">)F H1[A'DKZ-LS)?*1**
ME:=@!9W>0^VI#:%&A!E4S+A4Z\E0'NS.+6VZ2N)$HCU'RF9EQJ?G ,F
M    T?UG?DA:/A(O6'1N'"_>*^SYX5YQSW2WV_NRY:J+&4X5 *@%0"H!4 J
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MDTGRUT5[FH"]   !2D/$PTIPRJ?(E/.:CY" ?D5DV6^[.KJSUNJ[*C^L K
M      HR6>G:-)'1Q)ZFU=A1<A@/V,]T[1+,J++N7$]A1<I $EGIVC16BR[I
M"NPHN0P'Y&>Z=HE**CB3TN)["BY0%8       &CNL_\ )"T?"1>L.C;^%_CU
M]GSPKWCCNMOM_=ERQ46,ITJ 5 *@%0"H!4 J ^A]O_P$7\BW]Z0HZY[4]+Z?
ML^Q3T0N1UNT   !QSUCC_P!3)'M.+]Z8L_AWND=,J2XO_P A/9I:EJ-D:<5
M*@%0"H!4 J VAU>S_P!4[5^1E^+K&O\ $'<ZNFGKAMG"G^1HZ*OLR[0%6+R
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MUM]O[LN5Q8JG@        !]$;?\ X"+^1;^](4?<]J>E]/6?8IZ(7(ZW:
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M@                6\MU2$$VU^'=/0WVNR?G$ JLM)8:2TCO4E3S>R8#V
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M.BK[,NTA5J\    'E?>*\P_0$PB=3YH2?\2]]NKT3%UTZH?.E?M2I#DX
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MU:N[H9EWM2JHB($NS;=)0XPVPIXWY+2$I==4G0:U)(B-="J15/C0'%>@
M-&]:+Y'6@^;WS3XNZ-NX8^/7V?/"ON-^ZV^W]V7*@L93X         ^BEO\
M\!%_(M_>D*/N>U/2^G+7L4]$+D=;M    <;=9 _]39'M.+]Z8L[AWND=,J4X
MN[_/9I:CJ-D:>5 *@%0"H!4 J VEU>3_ -5+5^1E^+K&O[_[G5TT]<-KX4_R
M-'15]F7:8JU>    #ROO%>8?H"81.I\SY)_G+WVZO1,773JA\Z5ZY4JB7$J
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MQB6TDR/61'52CX4/LF8##B4        ,Q8B/U<^;N2]$!F!"0
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MSP&5       !QAN>9JW R$S.I^&.%YQ4(A<VZ.YV^R^9^(YQWE?[<HF/6:\
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M3Z#?>/4O2DTT*O8(5YOZQ;LYK9HB*8PC4N'A3-7<QD8KNU375M5:9;'&OMN
M   :*ZTOR.L_PF7B[HV[ACX]?9\\- XV[K1V_NRY2J+$5"5 *@%0"H!4 J 5
M ?1FW?Y?$_(M_>D*1N>U/2^F+7L4]$+D=;M    <9]9+RG2/:<7[TQ9W#W=(
MZ94MQ;W^>S2U%4;&U J 5 *@%0"H!4!M/J[^56U?D9?BZQX&_P#N=733UMJX
M5_R%'15]F7:PJU=P   #ROO%>8?H"81.I\S)/^)>^W5Z)BZZ=4/G>O7*D)<
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M7:[XO-(2ACP   7D6VR))DHRZ-KG6KL=HN<!GX\=J,V3;14+G/G,^R8A*J
M                /+C:76U-K*J5%0P%"(XO2IATZO,GI,_LD\RO/(!<@
MP^6_)6^_!\OUA8R\G\>CM4]; WCW6[V*OLRX*J+L?,14 J 5 *@%0"H!4!UO
MU>?)RU[<D^BD5=Q)WR>S"]>#/\=':J;6&LMW    :*ZTWR.L_P )EXNZ-NX8
M^/7V?/#0.->ZT=O[LN4:BQ%1%0"H!4 J 5 *@%0'T:MW^7Q/R+?WI"D;GM3T
MOI>U[%/1"Y'6[0   '&763\ITCVG%^],6;P]W2.F5+\6]_GLTM15&R-0*@%0
M"H!4 J 5 ;3ZN_E5M7Y&7XNL:_O_ +G5TT]<-JX5_P A1T5?9EVN*N7:
M\K[Q7F'Z F$3J?,N2?YR]]NKT3%U4ZH?.]>N5*HY.)4 J 5 *@%0"H#K+JD?
M)K(O;S7K(T'B;XM'1YUG\'_!N=J.IT2-0;X    Q5WN$2%,L[$F,3[LZ8<>*
MX9)]1=*.ZYK+5Q[U"D]SQX]@!E0       :,ZR%D-VW6?(6T_P"&=7#D&7V+
MQ:T&?:(T*^J-YX5S&%==J>6-J/%KZU5<?Y/:M6K\?NS-,^/3'5/E<[BPU-@
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M#>P   &-N<V?%E6IJ''Z=F7*-F:YI4KH628=7KJG@7=I2FJN'$!D@
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MX!LQY(\&^ K;XLV!*<
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MPLVWF7"-*T+2=#(R/D,A:]%=-=,54SC$OGZ[:KM5S17$TU4SA,3R*(YNH
M            !(\+PR[YO>$6NV(TM)HN9,41FVPT9\5*[)GZ5/.?GF7G9_/V
M\G;VZ_%'+,_+6]K=&Z+V\;\6[<:/WJN2F.?T1RNP\;QVV8K9XUDM+71Q(Z>*
MCXK<6??.+/G4H^7ZA<!3^;S5S,W)N5SIGYO!#Z/W?D+62L4V;484T^69Y9GP
MS\M#*C$>@            @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
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M7(7 53G,[=S5R:[DZ?FCP0^@-V[LL9"S%JS&$<L\LSSS\NAFQA/4
M     $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP
M     #B'=\Z;EY'[:_Y:1;^Y^YV^A\\\1?Y&]VO-"$5'KM?*@%0"H!4 J 5
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MU!O0   #&71JZN2[2JW.$B,U*-=R29D6J-T#I$7$CKZH:#X4 9,
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MJ5QP=H              (/</+%CGS9OWC]G -F/)'@WP%;?%FP)3@
M                    '#^\!_ZEY'[:_P"6D6]N?N=OH?/?$7^1O=KS0A%1
MZ[7L"H&!4# J!@5 P*@8%0,&Z>K*=<ZN'P6[Z^P-3XG[M3VHZI;_ ,$=]K[$
M_:I=7"MES    ,+F'R2OWP=,]86,K)_'H[5/6P=X=VN]BK[,OGX+J?-@
M     ["ZN/DU:]NR?12*PXC[W/9A=W!_^/CM5-MC6FY@   -"]:SY&6;X4+Q
M=T;;PS\>KL^>&A\9=VH[?W9<E5%AJG*@%0"H!4 J 5 *@/I-;O\ +XGY%O[P
MA25SVIZ7T?:]B.B%R.#M    <5]9CRHR/:47[TQ9G#W=(Z94YQ7WZ>S2T_4;
M&U(J 5 *@%0"H!4!M;JY'_JQ:?R,SQ9P>!O_ +G5TQUMHX7[_1T5?9EV\*O7
M0    \K[Q7F'Z F$3J?,25_B7OMU>B8NFG5#Y\JURI"7$       !UMU1/DU
MD7MYKUD:'Q+\6CH\ZS.$/@W.U'4Z,&H-Z    8VYQ+C)E6IV#(Z%B+*-Z>C4
MI/2L= ZC10B.O=J0JA]@!D@               1G)-O\1RLE*O-L:<E*+_&-
M>HR"_P#B(H9T["JD/3RF\\SEOAU3AS:X\CP]X;CR6>^+;B:OI1HJ\L>=JF]]
M6Y!FIS'+R:2XZ8\]%?,]5:IZV-JR_%<ZKM'CI]$^EH&<_P#/XUY>[XJX^]'^
MU!+CL?N);S,V[<W.;+T\5]M7U$K-"O\ ='NVN(<E7KJFGIB?-C#5,QP=O.UJ
MHBN/]-4>?"?F1^3M]G,2O38[<*%RFB,XX7U4$9#T*-YY6K5<I_BAX]S<6\*-
M=BY_#,]2V+#<O49)*P7(S/@1>!O_ / .S\_EOQ*/XH]+HC=.=G_AN?P5>AD(
MNV6?S#(F<>FIKR=,V;!?_FZ1CU[WR=.NY3XIQZF9;X=WC<U6*_'&'7@E-KZO
M^=35).?X+;6SXJZ9[I5EYB6261G_ +0\N]Q-E*/9VJ^B,.O![V6X'WA<]O9M
MQX9QG^7'K;#L'5WQJ":';]-?NKI4,V6_S9@S[!Z34L_NR&O9GBB_7HMTQ1\\
M^CYFY9'@/*V]-^NJY/-'JT^GYX;4M%CL]@BE#LL%F#&YT,()&HRYU&7%1]LQ
MJU_,7+U6U<JFJ?"WW*Y.QE:-BS1%$>"/EBR QV8                 (/</
M+%CGS9OWC]G -F/)'@WP%;?%FP)3@                           '#N\
M)_ZF9)[:_P"6D6]N?N=OH?/G$7^0O=KS0@]1ZS7RH!4 J 5 *@%0&ZNK&?\
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M   &,NENE3I=I?CR.A;@2CD2$=UZJV;#K6C@9%WRTJX\. #)@
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MCH?>^6<G13\+5AUK1RE^,U<_( R@
M              @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
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M   &*NUOC39EG??DDPY!EG(CMGI]6<..ZUH*O'O5FKAQX ,J
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M(=NF0[6Y=>,A>4RB+<8-YF.O+C)4O6E1QWFVU)-1H,B7Q(Z&1'R@2WZ"
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M79JU.3+.JXNFW);F&NVI(S+7)\'=(TG0CKZF:SX]@!E0
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MY5V)^U2ZW%<+@    83,ODA?_@V9ZPL964^/1VJ>M@Y_NUSL5=4OGB+G?.H
M        [*ZM?DR:]NRO12*RXB[W/9A='"7<([53;XUMN    #0/6Q^15E^%
M"\7>&V<-?'J[/GAHW&'=J.WYI<BU%A*K "H!4 J 5 *@%0'TNMO^71/R+?WA
M"E+GM3TOHFU[$=$+H<'8    XFZS?E3D>THOWIBR^'^Z1TRJ#BGOT]FEIP;$
MU,       !MCJW>5NT?D9GBS@\#?W<ZNF.ML_#/?Z.BK[,NY!6*Y    'E?>
M*\P_0$PB=3Y>RC_.7ORBO1,7/3JA0-6N5*HY.)4 J 5 *@%0"H#KKJ@?)G(_
M;[7K(T/B7XM'1YUD\)?!N=J.IT>-1;P    Q5V.TE,L_OB1G).6?O9350I/@
M[M:Z>'X/7WW#SP&5                          &NML=IX^VMVS2ZL75R
MXGF5W=O3C3C*62C*>6XLVTF2E:R+I.^.G)R EK29U7LI=SRZ[B0=UKG"R2Z*
M=1X4F RZZS%<55+#:ENGI0A)$@M!)X$!BF=SV,++-L9.W>XF43LHF+E'/A9&
M\VVQ,B/H*C*FTI-1=QW1'4^Z2I1<.88K'"M@[C:\V@;@;C9K,SS(K''7#QY4
MJ,W"8AMK(TFLVVUN=(Z:5&72*/C6IU423(8LUCNU%_QJ[[AWN)G%QDS,S4XY
M:42T%(9L[JTN=&MIMQ:DN=$IPM*:(+0A*3KR@,#B_5V2UEENSO<_+[AN#E%F
M,EV;PYM$2WPW:ZND;BMJ6DED9$I)ZJ5(CI4DF0Q;O!           (/</+%C
MGS9OWC]G -F/)'@WP%;?%FP)3@          646SVF#.G72% CQKE=#;5<IC
M+2$/25,(Z-LWEI(E+-">Y3J,Z%P(!>@               X1WF/_ %0R;VU_
MRT"V]T=TM]"A=_\ ?[O:\T()4>L\$J 5 *@%0"H!4!O#JM_+VX_!3OC# U7B
M;NU/:CJEO/!G?*NQ/VJ77(KA;X   #"9E\D,@^#9GK"QE93X]':IZV#G^[7.
MQ5U2^=U1<SYW*@%0"H!4 J 5 *@.S>K5Y,6O;TKT4BL^(N]SV87-PEW".U4V
M^-;;@    T#ULOD59?A0O%WAMG#7QZNSYX:-QAW:CM^:7(E182K"H!4 J 5
M*@%0"H#Z7VW_ "Z)^1;^\(4I<]J>E]$6O8CHA=#@[    '$O6<\J<CVE%^],
M67P_W2.F50<4]^GLTM.#86J        -L]6[RMVC\C,\6<'@[^[G5TQUMGX9
M[_1T5?9EW(*Q7&    \K[Q7F'Z F$3J?+N5_B7ORBO1,7/3JA056N5(2X@
M     .O.I_\ )C(_;[7K(T3B7XM'1YUD\)_!N=J.IT>-1;N    Q5W>M;4RS
MHN+)NR79AHMJB*O1R?!W5&H^)4]3)95[8#*@
M                     "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M                     !P?O.?^J.3>V_\ EH%M;H[I;Z%#;_[_ '>UYH02
MH]9X.!4# J!@5 P*@8%0,"H&#>/5:.N?7'X*=\88&J\2]VI[4=4MYX-[Y5V)
M^U2ZZ%<K>    83,ODAD'P;,]86,K*?'H[5/6PL_W:YV*NJ7SLJ+F?.Y4 J
M5 *@%0"H!4!V=U:?)BU[>E>BD5GQ#WN>S"YN$^XQVJFX!K;;P   &@.MG\BK
M+\*%XN\-LX:^/5V?/#1^+^[4=OS2Y#J+!585 *@%0"H!4 J 5 ?3&V_Y=$_(
MM_>$*5N>U/2^A[7L1T0NAP=@   #B3K.^521[2B?>F+*X?[I'3*H>*.^SV:6
MG*C8FJ%0"H!4 J 5 *@-L]6WRMVC\C,\6<'@[^[G5TQUMFX9[_1T5?9EW**Q
M7&    \K[Q7F'Z F$3J?+N5_B7ORBO1,7/3JA056N5(2X@       .O.I_\
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M==-=,54ZIC&/&JCBY@       (/</+%CGS9OWC]G -F/)'@WP%;?%FP)3@
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MHMW    8N[7%B#,L[#L8GUSY9QF7.'J*R8==U\2/F0:>'9 90
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M]QCM5-PC7&W    .?^MK\B;+\*EXN\-LX:^/5V?/#2.+^[4=OS2Y!J+ 5:5
M*@%0"H!4 J 5 ?32V_Y=#_(-_>$*6N>U/2^A;7L1T0NAP=@   #B+K/>521[
M2B?>F+*X?[I'3*HN*.^SV:6FQL350       &VNK9Y7+1^1F>+.#P=_=SJZ8
MZVS<-=^HZ*OLR[G%8KA    >7/P:O,/T!,(E\N97^)>_**]$Q<U.J%"5:Y41
MR<0       '7O4^^3&2>WVO61H?$GQ:.CSK'X3^%<[4=3I$:DW<   !C+K<G
M(,NTQT1^G3<)9QEN<?4DDPZ[KX$?.C3QIR@,F
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M)\R'+M3$:/T[4V4<>4Y11]$T3#KFON2H7=(2GCPX@,F
M      #76^GDPO/VT3QIH>_P_P!]H^M]F6H\7?XNY]7[=+CJI"VGS^5( J0!
M4@"I %2 *D 5(!WOC?R=M'M*-ZTD4?FOC5]J>M]0Y'N]OL4]4,F,9F@
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MUWZCHJ^S+ND5DN    !Y<_!J\P_0$PB7RWE?XE[\HKT3%S4ZH4+5KE2$N(
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MZYHJ-X5G@5 P*@8%0,"H&!4# J!@S.(G_P!66+X1B>OH&-FO@U]F>IF9&/\
ML6^W3UP^B0IA]%     #@/>P_P#57*/;?_+0+8W1W2WT*.W[WZ[T^9 JCUGB
M%0"H!4 J 5 *@-[=5(_]0;E\$O>,,#5>).[T]J.J6Z\(=[J[$]=+L,5VM<
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M=[?9IZH908S,        0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G
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M76U@   .>NMV=,'LGPJ7BSPVOAOX]79\\-+XL[O1V_-+CNHW]66!4# J!@5
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MK7?SR57O[:)XVR/>W#WVCZWV9:KQ7_C;GU?MTN+:BUE$8%0,"H&!4# J!@5
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MM9);6:#JDUD@DZS(^/=5'59R&7LU;5%$1+OS.],UF*-BY7,T\WRUMH]4P_\
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MZH4+5KE2$N(       #K[J>_)C)/;[7K(T3B3XM'1YUC\*?"N=J.ITB-2;L
M   Q=VMS$Z99WW9),+@2SDLM\/5EFPZUHXF7,LU<.P R@      YGRC?[-K-
MDEWM$6/;SBP)DB,R;C+JEFAEQ2$ZC)TB,Z%QX"P\IP[EKMFBN9JQJIB=<<L=
M"GL_QAG;&9N6Z8HPHJJB-$ZHG#Z3%?\ <CGWZ-;/[A[V897Z8RO/7Y8]#!_6
M^?\ HV_X9_W'_<CGWZ-;/[A[V8/TQE>>ORQZ#];Y_P"C;_AG_<?]R.??HUL_
MN'O9@_3&5YZ_+'H/UOG_ *-O^&?]Q_W(Y]^C6S^X>]F#],97GK\L>@_6^?\
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MHJZI=XBM%M    /+GX-7F'Z F$2^6\K_ !+WY17HF+FIU0H6K7*D)<0
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MMB,=F)JGHC7+'ZBI6O#LCM=&#].I<#(R/L'P!#\K4JER<E>:H)*UX%Q/F(@
MSIP/@?8, (ZG0BJ?*9%QX ,WAIE\;\?^$H?KZ!CYKX-?9GJ9>3^/;[5/6^DX
MIQ?8     ^>V^7E9RKVY_P M M7=/=+?0IC?7?;G3YFO:CU7C%0"H!4 J 5
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M;Z,R?P+?9IZF6&.RP       $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP
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MV:NI\TA<"B@        !W%U6O)2S[?E^BD5OQ!WJ>B%K\,]SCM2W2-=;2
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MVIZ5\V_9CH70X.P   !PQUI?*Q)]HQ/O3%D;@[K'3*J>)>^3V8:7&P-8
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M/1VJ>M],!3Z]     !\\M\_*UE?MS_EH%J;I[I;Z%-[Z[[<Z?,UZ/4>,
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M2ICDX        .CNK;_D5[]MM^M"N>*_BV^S/6NG_P _[O=[4=3=HTE:
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M2W6->;0    YXZW_ ,AK'\+%XL\-JX;^/5V?/#3>*^[T=KS2XW&_*T
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MM1U-VC25H    ,9=+C*@R[2Q'C],W/E''D+[KU)LF'7=? C+OD)3QX<0&3
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M3=HTE:    #&W.7<8TJU-08_3,2I1LSUZ5*Z)CH'5ZZD94[M*$U/L@,D
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M$IP         Y9ZY/X/#?-N/H11NG#/_ "?5^\T'BW_B^M]URL-T:
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M3TKYM^S'0NAP=@   #ACK2^5B3[1B?>F+(W!W6.F54\2]\GLPTN-@:P
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M=3YG"WU&@        #N3JL>2AGV_+]%(KC?_ 'J>B%J\-=SCM2W6->;0
MYXZW_P AK'\+%XL\-JX;^/5V?/#3>*^[T=KS2XW&_*T         'U%MG^6P
M_P @U]X0IJY[4]*^;?LQT+H<'8    X8ZTOE8D^T8GWIBR-P=UCIE5/$O?)[
M,-+C8&L        -N]6;RP6?\A-\5<'A;][I5TQUMCX=[[3T5=4N\A6BV@
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MR5 *@%0"H!4 J 5 ?2;%/DO9/:$7UE IO,_%J[4];Z RGP*.S3U,N,=E
M    (/</+%CGS9OWC]G -F/)'@WP%;?%FP)3@        !RSUR?P>&^;<?0B
MC=.&?^3ZOWF@\6_\7UONN5ANC0        &<POY8X]\)PO&$#'S7P:^S/4R\
MG\>CM4];Z9BGUY     #YY;Y^5K*_;G_ "T"U-T]TM]"F]]=]N=/F:]'J/&
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M?=<K#=&@        ,YA?RQQ[X3A>,(&/FO@U]F>IEY/X]':IZWTS%/KR
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MK[,NP15*_0   'E?>*\PQ,(G4X*?_#N_;J]$7S3JA\E5^U/2ICDX
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M>JNQ/7#M$5\LX   !@<X^162?!<[Q=8R<K\:CM1UL3.? N=FKJ?,X6^HT
M      =R=5CR4,^WY?HI%<;_ .]3T0M7AKN<=J6ZQKS:    '/'6_P#D-8_A
M8O%GAM7#?QZNSYX:;Q7W>CM>:7&XWY6@         ^HML_RV'^0:^\(4U<]J
M>E?-OV8Z%T.#L    <I;^>4)_P!JQ_O3%J\-=SCM2H#C?_)3V:6L1L[10
M    &QMC/*1;?R4KUA8USB+N5733UPW3@S_*6^BK[,NM14SZ%    >5]XKS#
M$PB=3@I_\.[]NKT1?-.J'R57[4]*F.3@        Z.ZMO^17OVVWZT*YXK^+
M;[,]:Z?_ #_N]WM1U-VC25H    ,9=+=*G2[2_'D="W E'(D([KU5LV'6M'
MR+OEI5QX< &3      'SFW+/_43*_A>=XPL6]D.[V^S3U**WGWN[VZNM%JC.
M>=@5 P*@8%0,"H&!4# J!@ZOZH7&SY1[9B^MN#1.)O;M]$K)X0^'<Z8\[I,:
M<WT   !JKK'^1Z__ &T+QUD>YN/OE'UOLRUWB/N%?U?M0X/J+/4[@5 P*@8%
M0,"H&!4# J!@5 P?2W$_DM8_@^)ZR@4YF?BU=J>M?64^#1V:>IF!CLH
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M-)GV=)T'0]>)QB)?2[$_DK8_@^)ZR@4YF?BU=J>M?.4^#1V8ZF8&.R@
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MM3UKWROP:.S'4S QV2        @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
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M(T8Z)JB,)KPC",:M/1CA#*EO7N45*7E)4*A?FD3@78_ C%_L&1^A_-5Z6?\
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M/@[I&1T*A^IFL^/ !E0     !Q)G7RUR+X2E^O*%V;N[K;[%/4^7M]=_O_\
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MG0B'1F-_9*NU53%>F:9CV:N;H9>3X2WG;OVZZK<84U4S/K4ZHGI=4"K%^
M  #FO/\ :7/+[F5XN]LMJ'8$I_6PX<AA!J3H25=*ED9<G.0LG=F^\I9RU%%=
M6%41IT3Z%);\X7WAF<]=NVZ(FFJ='K4\WAE'/H.W*_52/=4;V0>C^H<C]/\
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M-&$\[2?T';E?JI'NJ-[(-U_4.1^G_+5Z%7_HW>GX<?QT>D^@[<K]5(]U1O9
M_4.1^G_+5Z#]&[T_#C^.CTGT';E?JI'NJ-[('ZAR/T_Y:O0?HW>GX<?QT>D^
M@[<K]5(]U1O9 _4.1^G_ "U>@_1N]/PX_CH])]!VY7ZJ1[JC>R!^H<C]/^6K
MT'Z-WI^''\='I/H.W*_52/=4;V0/U#D?I_RU>@_1N]/PX_CH])]!VY7ZJ1[J
MC>R!^H<C]/\ EJ]!^C=Z?AQ_'1Z3Z#]ROU4CW5&]D#]0Y'Z?\M7H/T;O3\./
MXZ/2ZPAM&Q#CL*+2IIM"#*M:&E)%RBJ+E6-4SX7T%:IV:*8YHA7'!V@   -
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M%"^'0R@       $'N'EBQSYLW[Q^S@&S'DCP;X"MOBS8$IP
M
M                                             ,5=WK6U,LZ+BR;L
MEV8:+:HBKT<GP=U1J/B5/4R65>V RH
M                @]P\L6.?-F_>/V< V8\D>#? 5M\6; E.
M
M                                              !BKO-@19EG9F1^
MF?ES#9A+HD^B>*.ZO7W7$NX2I/#CQ 94
M                  0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G
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M(RX<<G.Y.S%FF_9F=FJ<,)UQ+%R&?OU9BK+WXC;IC&)IU3'REMH>&V$
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MTIY(Z(UM\#66V@      Q=VN+$&99V'8Q/KGRSC,N</45DPZ[KXD?,@T\.R
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ME(M*2J=#,\S>=R=BFU;IF+5'+,3ZT\[ W1:C;JO7*Z:KUSDB8G9CF;F&OMF
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MD7JRV4Z*(,^QW"?J$.$W[DVXMS/JQ..#G&6MQ<F[%,;<QA,^!EAT,@
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M<5+Q&9-OH(R2LJ&7$JCKM7[EK&:)PQC!W7LO;O1$5Q%6$XQTLJ.AD
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M0C%9@       "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M
M                                           &,NDBYL2[4W 9Z6._
M*-NXKTZNCC] ZHE5J5.[2@J\>4!DP
M              !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M
M                                             #&W15V3+M16U)'%
M5*,KF9DDZ1N@=,C+4=?PG1][Q 9(
M              0>X>6+'/FS?O'[. ;,>2/!O@*V^+-@2G
M
M
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MMOD5O3&F[6YT^W;7[D:7$RXTRX-]) <+NM)-K,E(=2M-44K7F P;<!
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M#):&)5JG(Z6%()+BEF2U(X.))1D1T[- &RP0        @]P\L6.?-F_>/V<
MV8\D>#? 5M\6; E.         &ANN&H_H0N*%\(#EQM:;@=3(BC^&-F=:?VB
M2"82S>;:.P[N6&VV>5=';%?+;)*;C=WB*(GF)+::]RC4DUIH1*,DJ2HM)&2B
MH!#7NU&X.Z6.;N2-B=T9T3)I"+;[Z6K)(220_P!$FE$2D)))$9I(^^22B53B
MLEDH!0ZPDV3N?GV)=72RNJ*)<'6[[G+S)F1M6J(K6AI1E6AK-)J(CY%]%S*
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M(<"OV6[RXQE-U2RUA&$Q),BUM$YK?E7F<1-&M;9%1+;+:2-)F==?:,P&T@0
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M@5^W$RC![<M++6 V*Y%D-]<4YZO(E0B,HD9#1%Q0:E&IPU'2G)Q(!M$$
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M&+/3<!OV1;XV[/;XEAK$\/MCT;&&$N=(^]<KD6F5)6FA$A*6_4B2=3,R)7:
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M6WQ9L"4X
M
M                                                      $'N'EB
MQSYLW[Q^S@&S'DCP;X"MOBS8$IP
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ML\,9E@
M                  "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M
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M
M           !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
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M6.B)%8B-_@V&TM(^U0DDEZ UNJK&9EME-.S$1S*PXN0
M                                                      "#W#RQ
M8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M                                              !3?88E,.Q9+:7H
MSR%-O-+(E(6A944E1'P,C(Z&0F)F)QC6XU4Q5&$ZI6=DL=JQRV,6:R1BB6N+
MJ*/&0:E)02U&LR+49G2IGSCLNW:KM4U5SC,NNS9HLT111&%,<C(#J=P
M ,7,QRR3[S R";"0_>+6EQ%NE+U&I@GRTN:"KI(U%P,Z5'=3?KIHFB)]6K7X
M717E[=5=-R8QJIU3S8LH.EW@
M                                    "#W#RQ8Y\V;]X_9P#9CR1X-\
M!6WQ9L"4X
M
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M1<3,^2@#\0M#B$N-J);:R)2%I.I&1\2,C+E(P'H
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MO\B).9AP(<^'<(S*X[SGA;TEM:76S6M*='0EI-!]U7F!"7@
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MD0,ID(7E-TGRG'9'1H;;0MQ.JIJ=6AI+:-)I2CON;29*;W"U0;G:95CE-?\
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M@2V0"
M  !![AY8L<^;-^\?LX!LQY(\&^ K;XLV!*<
M
M
M                     "#W#RQ8Y\V;]X_9P#9CR1X-\!6WQ9L"4X
M
M
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1DE!H)*M3A*JM.E)EJ-)+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>ph_cancercate-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ph_cancercate-4c.jpg
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M%!04%!04%!04%/_  !$( 28$9@,!$0 "$0$#$0'_Q "U  $  @,! 0$
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M)7G, Q*\Y@&)7G, Q*\Y@&)7G, Q*\Y@&)7G, Q*\Y@&)7G, Q*\Y@&)7G,
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M4_\ \-I3_P# 5_O(9-#[Z_W;/<?9I_XO-#6Q@
M                                    +^+I5V5&M[QW*''D75)K@0WE
M.)<<H>&F(DFDC,]A;1FJUXB9^$_V]K53[:9B)ZHB:NR%(^R[&D.Q9"#;DLK4
MVZV?:2T'11?X#1$Q,8PS3$Q.$]K77R^2M*^2OFJ*AW_LIM /(9T.A'0SILKY
MJ@+&=:E0;7:[HMY*T7-+RDM$1D;9,JPG4^PZCE37U533DZUZ?3335C]RN^PR
M,C[:&6V@ZN16M/M[#\]/, $==I;2[*^2O[0"O8?D/L/R'3S
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M8 ]+J?\ ^&TI_P#@*_WD,FA]]?[MGN/LT_\ %YH:V,
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M^*>IDW9,TF32I'Z?$J*2#BI3T?2XD;34G;BQ5KMJ&CTX?_I\?WQ7W'7U8?\
MU?#L[,'9JQ:VH5W8<@SG[8LFSM\A28WPZ,1&64N.ILL1$=229=I^4<]",9IG
M&,?GVXS^[I[F<*:HPG#Y=G3&6#YP/J/D
M                                /4V/_LO5?\\#_P!89-3\M'U;=+\.
MI_U\WEU>L?[1J8F!0           !DJD9*(S)1=BB,R,OV&0@SC7BQXU9F_B
M/%M^VM0P,98(U$5"49$14*AGV>;]@ =3+"9F:=T^SN %&I9$E:E*26PB49J(
MB^RO8 R:UG0U+49IV),U&9D7V5/8&!C+'[=I^<P!*E)(R0I24J]8DJ-)'^TB
M/: 541$1*422/$1$9D1*\Y%YP E**I$HR)7K$1F1'^TO* 542<LE*)NM<!&>
M&OGIV +J'J%JVMI7;K3&C71+1LE<B6ZIPL:<*EDVI6 EJ+M40X5:75VU3ADT
MT:\4?;3$3G_SYJ1-4$9(4I.(J*H9EB+[:=H[LT?!DJD6$C,D[I'L[@%A)NZW
MK5&L[##<6&THG9!MU-<B014S'#/S%V)\@YQIX535,XSY.M6KC1%,1A'G*N'5
MR            #[ 'I=3_P#PVE/_ ,!7^\ADT/OK_=L]Q]FG_B\T-;&
M                                                       S4SH1
MF9D781G4B_8(%3I2IT\U=G< $I1)P$I1(,ZF@C,DU\].P J=*5.G;2NRO[
ME*(B(E*(DF9I(E&1$9]ID5=@#![2PF9FGR$>TB_80"1K<,R-2U&:=B3-1F9?
MLJ>P,#&6*GMVG0^TJGM_;YP"JB3@)2LOMP5/#7]G8 8E821B5EEV(J>$OV%V
M ,"@
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MHN)L*6\;1$;?3N$HJ%7;4]@Y5>[F:HJP[':CV44T54]7W8>#T(P/HL
M       ,@,     ,@,                          #>__ $H_\G^8JM B
M
M
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M *D 5( J0!4@"I %2 *D 5( J0!4@"I %2 ;WS+*C_R?YBJT5(1"I %2 *D
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M/<1P@&:>XCA ,T]Q'" 9I[B.$ S3W$<(!FGN(X0#-/<1P@&:>XCA ,T]Q'"
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M5\Y&()
M
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MV/OL$:&G\DD.(=)"C4:#4AQ.).(Z*K0Q%78@
M
M                                      ":?57^S_,@$
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M:W%K69J6M1G52E&9F ZQ
M
M                       $T^JO]G^9 ,Y1[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@$W&S-+98D["IM,!#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>3Q$ 91[R>(@#*/>
M3Q$ 91[R>(@$DMG1?B3M+>+SD K:$ 4( H0!0@"A %" *$ 4( H0!0@"A %"
M *$ 4( H0!0@"A %" *$ 4( H0!0@"A %" *$ 4( H0!0@"A %" *$ 4( H0
M!0@"A %" *$ WOD65'_D_P Q5:*$(A0@"A %" *$ 4( H0!0@"A %" *$ 4(
M H0!0@"A %" *$ 4( H0!0@"A %" *$ 4( H0!0@"A %" *$ 4( H0!0@"A
M%" *$ 4( H0!0@"A %" *$ 4( H0!0@"A %" *$ 4( H0!0@"A %" *$ 4(
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MJ#/U?L 2$
M
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M)F52[1@;E;IU%WLQM:<E6:,S;&TJ5$NMF23,!6'R2(RCQLNJ+RD;B5'_ !$
MQ;+9(+5>KI,V*9VNYM6MIA;I$;4A+45UM]-/*18L*OV@/(W'0QM-W21;;?+=
MM]O=AQ8L!UU;\N;#8=;.9DFXJN64?%&C-XMJ<SRN"CUNB(+T&V7#%#<ML"7<
MY<NTVUY.4Y'A/8,"3:_\(E+);A-[,)*["[!)'I!
M
M                                          &QOU'?Y2_W) 0 8
M       &0&  !6W.Q0;NXT]*<ELO,H4VER%+?AFIM9D:D+R5I)1&9>4J^8R%
M'5;[?!M4&/;+9'1$M\5!-1HS140A!;:%_B=3,]IGM,!T"       ,@,
M                -[_]*/\ R?YBJT"(
M
M                                              #8WZCO\I?[D@.G
M!%Y1\0!@B\H^(4,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7
ME'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\
M0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8
M(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+R
MCX@#!%Y1\0!@B\H^( P1>4?$ V.(CFAK$V9D2?"5>PA!KP1>4?$*&"+RCX@#
M!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>
M4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q
M &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@
MB\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*
M/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@
M#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1
M>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'
MQ &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!
M@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O
M*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX
M@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P
M1>4?$ 8(O*/B ,$7E'Q &"+RCX@#!%Y1\0!@B\H^( P1>4?$ 8(O*/B 22B-
MA71LZ4V^+R5(00   E)-2T)41K;IF((R-2:]F(BVE7[0   9(C,Z$53\Q ,
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M\QD9"UT543A5&$I37%48Q.,.@>'H 9-)D1&9&1'V?: R:5%0C(R,^S8 QV;
M&
M
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M*AAUM?J1<6&KJ;AP[PY$LTR[M.08\R*TU)@()2HSJI!4-#F(LMS$E1X552&
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MAQJ4J6EQ4>:IHGS(R>?6ZQ#S=B3<-2\1Y9F*/K&G+O'N\!PF8B[>];7UVV7
M<,E&P_%))&@EIV*3A-*D*+M29""W$
M
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M=A%VF M!
M
M           $T^JO]G^9 ,8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?
M< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]Q@&!>Z?< 8%[I
M]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I
M]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I
M]P!@7NGW &!>Z?< 8%[I]P!@7NGW -CB%FAKPGL3MV ->!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7NGW &!>Z?< 8%[I]P!@7
MNGW ))0O"OPGV>;[2 <G4/\ -5W@,=0_S5=X!U#_ #5=X!U#_-5W@'4/\U7>
M =0_S5=X!U#_ #5=X!U#_-5W@'4/\U7> =0_S5=X!U#_ #5=X!U#_-5W@'4/
M\U7> =0_S5=X!U#_ #5=X!U#_-5W@'4/\U7> =0_S5=X!U#_ #5=X!U#_-5W
M@'4/\U7> =0_S5=X!U#_ #5=X!U#_-5W@'4/\U7> =0_S5=X!U#_ #5=X!U#
M_-5W@'4/\U7> =0_S5=X!U#_ #5=X!U#_-5W@'4/\U7> =0_S5=X!U#_ #5=
MX!U#_-5W@'4/\U7> W///$VP9.*(U(J9D?:=15:>H?YJN\1#J'^:KO .H?YJ
MN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^
M:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA
M_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .
MH?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P
M#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN
M\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:
MKO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_
MFJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H
M?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#
MJ'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\
M ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:K
MO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\ ZA_F
MJ[P#J'^:KO .H?YJN\ ZA_FJ[P#J'^:KO .H?YJN\!L0^\:'#-Q5221EM_U$
M T ,          "2$FM:4%VJ,B*OV@*6!J6!<=,JU4PTZFWH8E23:62<[!"4
MXE94(Z5,VE8=OF%%A!F,S[?$N37X<>:RS(92X9)429""<0D]OK4/L(!T[#6I
MHE)-U%#<;Q%C02NPU)K5-?)4044K5=L;MAW2 ?Q!I%R9L[C;2B2I,AR8F$L]
MM:I0LZ_ZB+8*+WPJ,R;4EPB4:,2#)1&I)T,ME=I'VD(*^^75NR6*ZWU3?5-6
MIAZ0\PTM)*4IA.(V\6TDJ_F[!1NCS#D29,<XLAA$9##G5OH)$9XGT&L\E>(\
M672CE2+"9EV@.6\7MJSMVMTVCE-W6X1+8RMI:22DYJE)2[7:2DIP]A=H"=XO
M42R1V79*'GWY3J8T&%%1FR9+ZB-1-M(J1'1*34I2C)*4D9J,B 8MEPN<UQUN
MX65ZTDA)+;==D1I*'"/M*K"U&E22VGB*E/* L4&3I)4THG$.%5M:#):5%_I,
MJD?^ @P;C26R=4ZVEE1DE+JEI)"E'V$2C.AF?F(!ICR52)<R)TLAHXBVT$^\
M@DLR,QLG*L*)1FLDUP*J145L%&]!I<2E32B<0HS)*FS):3,CH9$::D9D>P0$
MFE:34A25I2HT*4A1*)*R[4F9&=#+RD8 >$LRJDED[7ZJ+\,J5JO;X=FWQ ,*
M4A"#=6M*6222S=4HB;PGV*Q&=*'YZ@)&1EL/_P"J@,            WO_P!*
M/_)_F*K0(@ KKY<7+5;79S;9.+;[$*,R(_\ $AVT=.*ZHARU:^BF9<^E+T[J
M&P1+P^TEAV3F8FD&:DE@<4C89TW1[]SHQI:DT1..#Q[?5G5TXJF,,5R,S0BI
MUEMUEAQU"'Y&+IVEK2E;A-D1K-"3.JB21^*G9Y1130=5VJ=(OL?!)B(TZ2%W
M"1,84PVIEQI;Q/-5,U*;PMJ\1I*M-FP!RQ=<VE^!<+A*CR[<5OC,3E1I;:4O
MO1)E>F<92A:B4;JDY9(J2DK\*B# >D0:E(0I:#:6I)*4TJF)!F532JE2J78=
M!!D
M
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MHD(9)U2EDVFM$54?AI3PT$D>S$           ;W_ .E'_D_S%5H$0 46L?\
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M2_JX5*6WF?Q8>TQ)'I1
M
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MT))"$I+L2E)4(B+S$ R
M
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M5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_LF =*QS_9, Z5CG^R8!TK'/\
M9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_LF =*QS_9, Z5CG^R8!TK
M'/\ 9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_LF =*QS_9, Z5CG^R
M8!TK'/\ 9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_LF =*QS_9, Z5
MCG^R8!TK'/\ 9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_LF =*QS_9
M, Z5CG^R8!TK'/\ 9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_LF =*
MQS_9, Z5CG^R8!TK'/\ 9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E8Y_L
MF =*QS_9, Z5CG^R8!TK'/\ 9, Z5CG^R8!TK'/]DP#I6.?[)@'2L<_V3 .E
M8Y_LF =*QS_9, Z5CG^R8!TK'/\ 9,!-$9DDK(GJU*AGA[-I&(J((
M       #-#I7R><!@       &?M\@#   S0R[0&                  !M<
M]1K^4!J
M
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M6 W+MLLYL8C4PJ0HC2X;K)X'"=2I*#2X2B/&DTE0_((.T0
M
M                                                !-/JK_9_F0"
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MB;:X]R?N64F?=[@_='X\=1K;8-]*$):)9DG&:4MIQ*PD1J,Z +P0
M
M                                                      !-/JK_
M &?YD @                                                 VN^H
MU_* U
M
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M(W2[@# C=+N ,"-TNX P(W2[@$@
M
M
M                                  <K-R@2)TJV,26W+A!2TN7&2HC<
M:3()1MFHO(2L*J?L 3BS8DY+JHCR7DL.KCNF@ZDEUH\*T']J3V& W&I*3(E&
M1&HZ)J=*GVT+N 9 <5SNT"SQTRKBZ;3*EDVE1(6X9K41F140E1^0!50]=:5N
M"$.0;@E]MU;332T-NX5KD.DRV25&@B.JCIL[.T]@#T0   .2VW*'=X+-RM[F
M;"D%B9=PJ1B34RK11$=-FP!U@   TS)<>!$D3I:\N+%;6^^X9&9);;2:E'0J
MGL(@$H[[<J.U)9,S9>0EQLS(TF:5E4JD=#+8?E ;    8-2242#41*54TIKM
M.G;0!S6^XP[K&ZR YG1C6ZT3A$9$:F'%-+I4BJ1*295\OD =0  Y;C<8=I@R
M+E<'29A14&X\Z9&JB2^Q)&9_L(!U     ,)4E9529**IE4CKM(Z&7^!@-$&?
M"ND5N=;I#<J&[BRY#*B6VK"HTG115(Z&1D YKO>X-E;95*S''Y+F3%BQVU//
MO.$DUF2&T$9G1*34H^PB*I@+!)XB)5#*I5H>PP&0   06ZTV2C6M*<"<:ZF1
M427E/[-@"$27&GQ69L)Y$B')0EZ.^THE(<;66)*DJ+89&1U(P&X!KD2&(D=V
M5)<2U&80IUYU9T2A""Q*49GV$1%4!S6JZ,7B(F=%;>1'6?X1R&EL*6BA&2R2
MLB5A41U*I .T   ')(N<**N&V\Z6.>]TT0DD:\;N!;AD6$CI1+:C,SV; '6
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M,R?FG%:PJ/$3"24LZD5"H1EV@.L
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M=4I*E+4MXZI;+PDBE2,S,Q1&2D[C?)9-+S"N&HH%O6E?\3%DC%,</]F:E?\
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M(ZMU#AM2+B^:_"A"4D@U(CD9D6RE*$(/=
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M X9"=#G!N>8MTH:KI^+@ZNJ;OF[>DPEBS,VM>G_CQ5VX@',@OTW^#7M*5?\
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M",^G,\-,7AKZNT!B2G0IM6E2U**SDB+\.0SU/P@TFY_RV/++I_7IAS#[:?8
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MZY>*O4>'LQ;<(#W@
&    #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>ph_powerofbigdata-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ph_powerofbigdata-4c.jpg
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M%!04%!04%!04%/_  !$( 18#M@,!$0 "$0$#$0'_Q "_  $   <! 0
M         0(#! 4&!PD( 0$! 0$! 0$!             0(#! 4&!Q   0($
M P0""0T. P4%!@<! 0(# !$$!2$2!C%!$P=1(F%QT3(4=947"(%"TB.3LQ55
M5C=7& F1H;'!DK+35'2TU-4VEE(D-6)R,Q8X\$,E92?Q@J)S129C@Z,T1&24
M=A$! 0 " @(" @(" P " P    $1 B$#,1)!!"(346$R!7&!%)$CH<%"_]H
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M^>4:CV44R>=#F%\L;YY1J/90,H'FAS#W:QOGE&H]E$,HCFAS#WZQOGE&H]E
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MA_UJV?M3'OJ8#V]K_FW3XL8][1$JSR\O/3C_ .H[4O[-;_W-N+4^'SH=T!"
M0" 0" 0" 0$8(C%$#!4(@0" 0" 0" 0"*$ B! (! !M@-BT'_6^FO&E'[^B
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MO/3C_P"H[4O[-;_W-N+4^'SH=T!" 0" 0" 0" 0" 10@$0(! (! (! (!%"
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M! (! (!%" V+0?\ 7.G/&E'[^B(/=KUGJ?B@/+;[0OY\*7Q-2_GN0'R9 (!
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M?.7J?Q0GWX07X3_:-?.5I7Q2OW\P1\8& @(":0VQ%C*VJRU5U4[X(G.IK+-
M(SR5M,HZ:Z98VWD9Y-&PZXJ@<466VI-*"L 2-I41LCO^O#S>ZS-K8;KZM(*5
MTB$Y@5SS%($IB<8VT=9LP92TT[UTS:5/J D#L2,<;,.VK.UNJU5UD:L#UOH6
MV*<@L5K#"6ZH!)G)2QWT]F,9;:RYE"II,P>F*B1(G!E<U!I5(1PDY%@ *EC,
M^K!% Y52)/6W[NU* OJ5MBG"7%JG6!:2TT<$9<9DJ[D16>LRRB\>%K"% 3RJ
M<&83(W#_ +&,;^&]576U19V&:.QV)YUYFGSO5CCH'_%7WB!+_ F8,-(;-,CH
MPA%" F )$]V\Q*)UM%(!.T_<]0[\(BI)11+!" 0" 0" R5A_UJV?M3'OJ8#V
M]K_FW3XL8][1$JSR\O/3B_ZCM2_LUO\ W-J+4GA\Z;H(BE()&,@=IZ(L\JJ\
M$'K>LVF1!(3.0F.W#*84LHS$'=$5+ (! (! (! (! (! (! (! (! (! (!%
M" 0&Q:#_ *YTYXTH_?T1![M>L]3\4!Y;?:%_/A2^)J7\]R ^3(! (! (! (!
M (! 3I:4M)4F1D99?7?<AE<+RVVRIN-8Q14LE5%2H-L)D59BJ8V $RPVRA:2
M97EQ9%JKDT[#"V*VA)14J62L*=1(X!:04B&5]<>4E56TM33%YQA2;LZYG6Z%
MY6U-'H3*0.$(ML5$U+AL2V3<5*0_4!:[6E1"5N 2XBD@ 8#88,9X6=>];7'4
M*MS+C+7#2'T.N!:E.#OB#EPG B@RLLNI<;(2I*@I*\,",=LB/O0RUA,JH<XB
MG>(I+G$XJ5#;G)F5 B6(,5G*]>;N-TXMPJ5+?<"R*I]:LSH4HRF4XF0Z!!9%
MW=G54593,TU?X<Q3L@L/91@5#K) .TCLQEKV]?*E>ZZ@?51"W,,I;:ITHJ T
MVIL..YE',YUC,XPB[;2^%A2U511*6NG<*2M'"<G)69*AE,Y[!%8Q5>\VZOMU
M<Y3W)H,5.1+A2E25@H6.K(I)&(A$V8W(5'"4Y;MD/E,I%)*3(Q:1"(I 1W'M
M11[=\C_FET6?_*J<?_#$GA/EXRZ]_KC4_C>O_>5P5KL4(!$" 0" 0" 0"*$
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M#4MH:\)273E<=;K%^UEI"NL<RC/$8)B2M;=7#!.6>N8M;-V*4N4#JE(SI5F
M6-@<2,43'>SC;S86(R**0F:<V 4H!>&^?JQ1D:%L5M)4L.5#;.1/%2IY*EN.
M2PD@@8;(I&,4E))ZI20.\EWO;GTQ$JB(+$>GM?CBE>W7)#YI=%^*J;\TQ)X9
M^7C+KS^M]3>-J_\ >5P5KL @$ @$ @$ @$!,D3.,#./*<M$KR)[!^["+M9\+
MZDI5.(>1Z]""I,9=I)ZJ2.*%(4T2'&1,J!D0I6 ,XWAYY;:O:1BMR%BFJ"GP
MLA%0D*& )P)D=YVQ':]>%Y2.HHF74NKSUK;F5*%#--+9V)7N3,>MC,CI=?9(
MW<4HJZNM<2$/5>9"F>_EQ!MFJ1QC<<+9.&2T/8+1?G:JDKJP6RL6DIH:]Y13
M2I<*2HYU;CE!B6N6]QPK4;U+9:JYNT*RJXTH4NE9= 6R$( 27)G>KO@.@B$-
M9B,&%4M3;*FYUM8LW-#P%-0R/#7Q""M0*<$$#&47&6IO<L_4:IO57I"WZ7K:
MU-58J!QQRFM[S9S-AY044I6)R)RX=$<-=?R>KLE]5)5]8J;,W0TB4-U+M8'*
M>WJ,A3<%.+A693S^N'8C5TF7/2XBNB]7R[74T#+IK4U):;J&6FP0\D("$A(&
M](&'9C-UFKMT?G;PVI%^NNF:E6E;]1M? =N4FJ51H#+:GDH;4DNN*"IJ5,XI
M C.)LQV2^V,-6M]QOUBU,S<6W70R'EE.VH92T\<Q;0!,%>0B-7UQAGUV^&>U
M'8K(UPJZRURZTUF1^Y6UY"N.@9B4);!VI*MVWIPCS3,=]],SRPO,RR,:27;+
M$P\Z:ZH8\/O-(5)+;=4[BE*4I)RY4[C'HZMO;FN/9IZ8CGB\([N#[)^SE^<O
M4_BA/OP@OPJ?:-8<R]*G_P I7[^8K'R^-$K(!(5([ACCMZ(E:KZ+9M%'J+E1
M:KY24Z+E=*A/@-=3TO\ ^[I13SRK4L; L#&.6.7"3\GSS6+;XJVFD*0PVHA"
M5F:D]()[<=8[+6*J=J9<3(Y2#.<0M=/TU?$FSU%.MYIQ27FTH;=F7$YA+VO=
M(D]:<<;J]>G=9&"N%P"GJRH3--:PO$CJ!3BNKU4[!(#&4:FN'FN]WJQI@X:R
MF>!)#SA2E1.9(2D24"!O)$6S";W$9>J4Y:$52JID^%5B,[060H! PF =DIQ)
MRY39IB2NJJ0!UUNX$GL?^R.GATPJ9%<>:R$+1,J"E*$P/4B6<->'>M(4K+SE
MEM]NHP_<:]I#C%0XM/@[1;,R.L025 ;H^7W<5C9T.DK=*:;U3>EZQL;(LMF8
M%4* +(<=N"DF63..])$XX3.^)'+#Y*OMW7?+Q6W9\+XE:^ZZ9J)4$K42A..$
MDB2<(^UK/68=OA<(N-3=*Q@W1]VHX#2*=)4HC*TQ@E,_]T2B;21TZXSVF;-I
M_4%UJ:&]7!VWEYMWX+4TG/\ YA"<X2LG'*H)D)QSNV)F-6<M$4DI6I)&4@D%
M)W2W1W<ES1<(+XCP*FVQF4 ,9;)0O@G%?0&L]/W%KD-9;C6U)?>36BKHZ9H2
M:%JJ4R&?LI4B/D]&+W;/=M?_ *WSRX$IS(2K, 3(CO93VCIC[%?/@V,Q Z<,
M(RU\MYME$*BD0MI +18S8F2I(VS@_6?1^KGJ_;_36+S6HJZR31*:9L )!.X@
M$_?A'Y_[O?>S;#&*4") 2Z>W"/%4A$HHA (@R5A_UJV?M3'OJ8#V]K_FX2?_
M "QCWM$8VN(UKY>?_I$Z3J-3>E%K"K:4EMJVTEM6I2TE25'P-HXRV8"/I_4^
MO=^7R_N_9FFN&G.VY-%5TK;U-_E:HA2&T+'#QP*T]@;X^GMKCA\KKWQS_*SO
MFG[$PI5.*A;9XR5H:0"5ND':.A(WQQNDCT7?+5;W9:NI4EQ<W:-@EMIM2@2D
MC$$I&X=,>7><O5U;8C&-K4XA8=(9ME4HRD2$)6!+$=$_\,<NS$=);6KU%34)
M0:)Q$W6EE:2C!*0,)'L':(\UWR]/7JQK:0IT!32G2DJ/$1@"Z!.?:CE9\O1)
MRZ9I;3%7?G;#:*2C+3#B55)+Q4<JPH**U*3,A.&_"/'W[XCNR_.BZ4K++5BM
M[J*E+:RXI] ,BL(2%2*@)##=MC'U9;<USVVS<.%4\^.@DDDG$COAV1V8]WA'
MT/RHL]J:M=M34M%PZE7P*NM6@A+3 "DELJ7*:YE.*8^3]GLLM_IRK>M5>CHC
M6: W9+C3L5UOIS26Y"$Y#492HG/TR&!,<>C[EEQ3+Y KZ1VBKJBB>(+U,XIE
MW*9IS-DI(23NF,(^[+F97)1!:7TJ0D**>ME) G+&7J]$+S,-ZWF-OU2S776C
MH+S5%)34,A+02G(E'"P*4CU,8\NF_.'K[.O,RTE+:EREO.7U8]3R3RR"6Z1N
MWO/K(-6X0AIOH P)B2\K9ACI2)'1%J1*=L%J*4SB(FR2BP3(;S.);WJ4$S.S
M&(W-<[>J_KK6]0E'&6E2"KAI*,93$\8LY=.[JVZ[S&.R2)[$,//;BI#@8*@9
M[X%((0&Q:#_KG3GC2C]_1 >[7K/4_% >6WVA?SX4OB:E_/<@/DV9&^"@,HA.
M$R%26D^IZD4\-JHM0TC-%6MUS"Z@J::9IFT.%+8+9WA049].7",X=[V<8:V_
ME=>ZH"4GUHV)GN$:<,<I"RI)"4C-FV#IE#*W5,EEY,^H04RS@B4DDX&"<QF+
M/JF^6*F?I:"I##54TIMPEM#DD*P,LP,IB)B-?LVBS8J4-4:Z9#)%7/B-5 ,B
MD#>#M!@PQ[CCKJU..*4M:B2I:NLHD[R3MBBK1TK]8[X/3HF^05#$)P';@*2T
M>V<,)*2"4D$SZPVXB E'5GAUAL/1 3*>=6H*6LK4, 5$DR&[&"HR5PRO=/;
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M>N'/>YK5LO4G'5S?9/V<OSEZG\4)]^$%^%3[1OYR]*^*5^_F#+XS;0IQ65)
M5M .$Y0&1MU]NMG2X+97.TH?!2\VV2!]S9$P88YQ:U*4IPA2UDJ4O:23C%@I
MP5,(&%>E?\&>0Z-HB-1?5#O'J6W0D+XAQ!.,QOB'AM.F: )JF'ZI16B96DK3
M)"0K"6$<]MLO/V;+G72*.EK&Q1I#I6U-XR4""G#">8#$SVQK1G6,5RZTQ4ZK
MUI:[#2TZE.NJ*U-!4E*#:2HD$QGOW]=<O;US+ W@<&[7)I((2BH?:.]<@L@
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M3M+0@OW=IPM)J S4)"@EUIIHR5AV4B/3.W,?/WZ_6UKM91FHJE&C;4XTXM7
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MUZSU/Q0'EM]H7\^%+XFI?SW(#Y,@$ @)BM1,R9GI@J[I:2IK$GP=LN*1,K&
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MYE:WA3S,N.1,($MLHFUXX:UG+8[-2-5"+Q5BI4VBEDIAXC,%*6H9BXG:9)V
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M>WTQGVGR_KW^N[)W],QM)MAKNN[ZW3TZK?2.)36OI+-P2A(,VA@8F'YW_?\
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M77T_&Q?-/H9M;09:J:=("@^YGS-/.I&=!(.$DIQ*4Q,.&WM%U8=87ZSN.U-
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M1/$)J*AL9RE.V9!W88F.>]Q'/LN-:[/7A5CNH;HE)-MHU$O4JP$AYL8I64#
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M9U*?"'G'FFN"Q/$92$-$F>4F1Z<(1*L\AVD2&T=.,:9F,\I0-\"(S&Z$7/\
M"$XJ$0"9P6U""$!L6@_ZXTV?_-*/W]$![M>L]3\4!Y;?:%_/A2^)J7\]R ^3
M(! (!!5W1U'@I+H4>)E4$ 82)WDQ!4H:@LU;#J3Q%I5G*5@8K/23NA5BZJKF
MZ\_4+N"35%W%&9Q8#:QO2)]&&,6,VK-+"BA4UY79D<!29'[_ &(JS6U7K*&G
MI4TBTU;;Q?;XCB$)F6ESEE4!L,L8S%VBWI:=VHJ@PW(E4B21A(;XTQEL%/\
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M6XJ2^6ZGMM:6J>K;KJ924J;JV3U"%)"BF72DF1A+EJQB%;<-D:90@I$" 0"
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M-LJ[HRW=JMRDMJBKPNJ:2"Z!BK,E)[($"*-2]3\=Q,UOTJ%E+"U=52FYDI)
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M^M6O]J8]]3 >WU?\VZ?%C'O:(E6>7EYZ<?\ U':E_9K?^YMQ:GP^=#N@(0"
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M4_%%<GEM]H7\^%+XFI?SW(#Y,@I!" 0" F1*8)W$&"544L2(2,LS,R@N>/"
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MR1*70<1]V4=L5@D-L00G ,("8I 3,GK'8D?C@N4% )P!F=\MD$E2P" 0" 0
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MF]8N5%XJE)8N[[P!2TE(3)* D=8R)![6V.>DNM>SN[-.Z9OELVCZC1U?1?\
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M]7>[:XOF+7(3.?XX]3"M2ONT[R'F%9'4DE*NV)1!24HJ,U8G&9Z23."IPU,
M[SLAD2D98"6*(00@$ @$ @$ BA 549=JA,#$)Z3T01G;5J>HM-JJJ"E8;6Z\
MH*15K/MC0EBE*=X[,=NOMNHHVZKJ+AJ&WUM8X7:ARL8*U*.,@X@"0CGOO[57
MME6_-JWXLI_>T1SK4\O+WTXO^H[4O[-;_P!S;BUF>'SG ("*24J"@9$$$';
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M"DJ/51@)9B90258G;V8(A (! (! (! (! 1@I,C">!VP"9Z8J(0"($4(!$"
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MM%H[_FNN1658;J6A3-("44[2E MA8!P*A'V/I;<)M'S$1[49[9Q]+#E5*($
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M'FBZ27"NG:<2F1PRDSBIP^;SRO\ 0_D)<]:Z>_\ ^W+G_"P$/-?Z('TZUO\
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MT4!RO]$&8ESUKI[I:<N<_P!V@)ARP]$//U>>E?FZ!IVYS_=8'"!Y7^B#,_\
MKI7?VY<_X:'(AYK_ $0/IUKO[<N?\- /-?Z('TZUW]N7/^&@'FO]$#Z=:[^W
M+G_#0#S7^B!].M=_;ES_ (: >:_T0/IUKO[<N?\ #0#S7^B!].M;_;ES_AH!
MYK_1 ^G6M_MRY_PT \U_H@?3K7?VY<_X: >:_P!$#Z=:[^W+G_#0#S7^B!].
MM=_;ES_AH#,:7Y:>B4SJ2SO6_G=75-P;KJ9=+3?\O7) =>2ZDH05&G 2%&0G
+N@UEZH^L]2#+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>tb_micancer-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_micancer-4c.jpg
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M%!04%!04%!04%/_  !$( E\#M@,!$0 "$0$#$0'_Q #%  $  @,! 0$!
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M^C0W_:<TI_PT'9QI,:8P$F(\$B,XEVWFB0P)/6A"JHM!MH% H% H/+=W>?\
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MBRQ5!^7?9&SMJ3,M(Q.[86YMP260!YO'DG+8BB=[VU$I*1:;DMK=%)'JN?\
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MRV1.'N[./;?AD%V)[<0IK?,O]5P0,21%3H)$7Z:#T)_RU\F&>6B>:J/..D(
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M5J0.<\C,%+W+Y4>9^$@"ISI3,?LS2=)NM-NN "?22CI_MH/*?++<D39V_P#
M[BR*$D&#*19:HBD0M."31D@IQ510E*WT51[7^9[S,VENK"X3;^V<BUE#&2N0
MDO1EU-M"+1-@*E:VHN82Z>E+<?14@:_RIXY<6UN_?>2%6\'!A]F-Y4NA\M.T
MOHB>G0 !?]I*2*G=NRO(?=,:3N/9.\X^W91@3Y86<!BRCG%5  )!<#CZ Y@_
M92U!Y[Y-9O,X/S+VXYAG#1R9.8A2F05=+T:0X+;@FG0J(*ZN/0J(OHJCK_S4
M,.M>:AN.#8'\?%<:7UBFL+_Z15*0/5?RY>;&TPVM@?+F0X\UN87I+++/*(FW
M4<==DH2.)<41!)475Z4J2/S%Y@?^O=T_^;Y#_:7*H]<_,A@I@XO8&YD B@.X
M6/CC<2^D'F@1X47T(I"X5O7I7U4@;?R[>=.V]@X[(;7W83D6!)DK.BY!MLGA
M%PVP;,'!;13M9L5%1%?3>I(_4&S/,/:?F W->VI-6<QCS!N0XK3K*(3HJ0V1
MT15>A?145S?Y@_\ <]N?_HXW^ULT'Y9_+5_OAP?_ $<W_9':ZE$'\P?^^'<_
M_21O]D9H/T;@O_R5W?\ ]79__P KU17Y?\F?]ZFT_P#S%G^^JBR\_P##2L-Y
ML;@&0"HW.=&?&->@VI (5T^A"U!^D:0/:]A_F*V-AO*V%BLLX\WN/$0.PAC0
M9<))"L@K;2@Z**"(0H.K6J66_3PO,#\LX'_ZYC/^]L?]8-4>\?F^_P#6F"_\
MK_\ QAVI B;.P,S/_ECW8U !79,'-+D.4/%2;C,Q2=Z/4"D7]E!Y]Y/;\C>7
M.^8>XIS!OXU6W(LT&K*ZC+R)U@151%4202MZ4X51^R,-YY^7>YYS.%VSDCGY
MV6T\Y$A=FD-*1L,&^HD3C8BBV!?37*OPHN07<VZ0R.ZY[@ADYH'ELC;6X#3K
MB<UP1X_4%5TBGJM72.]\Z<;Y2X<\)CO+!])CP-OGF)@/N21/7R^2BD2Z-26<
MU("):Z7H/8_R@)JVQN9$Z5FLI_\ H5J2/RO$>/#9YB1(;4CQ\L''6NA55AU%
M(>/1]6U4?LG?/F7M3S'\G=ZR-KONO#!BLI*%YDV5 GG!41ZW!5ZJWTJM17YQ
M_+Y_OAVQ_P!))_V1ZJBM\Y,!+VYYF[EA2@(4D3GIT8B3@;$PU?!47TV0]*_2
MBI0?HV/YY[''R11LLBVFY&\-X5X/Q[0LQ&.SHNFW\M5Z^KHT_3PJ#\W>4.WY
M>Y?,G;>/BMD8M369DDD3@$>(:/.$J^C@-D^E42J+;\P?^^'<_P#TD;_9&:#]
M&X+_ /)7=_\ U=G_ /RO5%?E_P F?]ZFT_\ S%G^^JC])^<+'DAO+<DC;N[L
MPN WGBFF@')H*@*MO"CPMF2BK9HB&BV)15+\%Z:BORGO'!8W:^X'<;A,['W!
M":07&<I"10!57C9>*HA#;CI)4^FJC]X>2^9R^X/+#;F5SAFYDWHY@Z\YQ-P6
M7C:;<)5XJI  DJKT]-<J[R@4"@\3\Q?RYXWS#W7+W5+S\B$[*!EM(K; . ",
MMBWP)215O:_]M7([Q/+O%.^7+7EM/?=?Q0P6\><D$%MY1:MI<2Z$*$BBA)P6
MH.=\OO(79OEQG2W#AI,^5/5@XP)-<9, %Q14B%&VFUU6&W3T*M7(C^:OD5CO
M-/-0\S,S#V.<AQ4AHTTR#J$*.&YJ52)%_7M02</Y+PL1Y893RR#,/.Q,DX;B
MSU9 7&T<)LE1 1;+Q#TKZ:#G-B?EIQ6Q=V8W=<?/R)CV.)PAC.,  GS6C:XD
MA*J60[TR/=*@I]S;6P&\<2[A-R06Y^.=XJVY=" TZ# QL0$E^!"J+0>#9G\H
M&W9+YN8+<4O'LDMQ8DL!,0?H0A)E;?IO5RB9M#\JN-VSGL;GY.YY,J3C)+4Q
MEN/&",BN,&ABA*1NKI54L7T4R+'S*_+/@=[YN1N/#Y,\'DYI<V<WR4D1G75^
MLX@ZVU$BZ2L2HJ\;7O3*JB'^47:[6&?B3<Y)D9IXFU;R(-"VVR(*JD(LZUOJ
MO95(U^BW&[*.V\K?)&%Y7OY9Z'F7L@.68!AQMUD&T#EJ2H2*)+=>LM%<+#_*
M+A8<R/,'<\HBCN@Z@]F;2ZMDA6^O]%,H]4\U?+*)YIX2'A9F0<QS<24DP76F
MQ=4E%LV]*H2I]N]15'Y4^1V/\J\K/RD/,/9$IT=(Q-.L@T@HAH>I%$E55X6J
MY&/F/^7[9GF'./,D3N'S[MN?-B(*@\J)9%=:+@16_6%17UJM,CSJ+^3R(U(1
MR3N]TV16Z"S!%IS@OH(GS1%_XM,H]C\PO*7:7F7#8:W TX&2B!RXN6C*+<H$
M7CI5511(57CI).'&UKU%>-.?DYBJ^JL[O<&-?@!P!(T3]I) I_R:N4>K>6?D
MUB?++&Y>%C\G*G.YH "4X^@"V/*$Q%6VQ3@O\1;W);\*BO/,=^4C"X_(1)X;
MFE&<5YM\06,VB*K1H5OK^FU7*/T;45!S.*C9W$3L+-)P8>1CNQ)"LEH<Y;P*
M!:2]"V7IH/SMDOR>X5UTBP^Z)45E5ZK<J,W))$_: V?_ ):N466V_P I.S\;
M*;D[ARTK-@VJ%V4 &&P:IZ#TDX:I^R8TR/>X^,QT3'-XB-%::Q;321FX0@*,
MHR@Z=&BUM-N%JBO"-U?E.V=F)CLW;N2D8'G*I%$Y8RXPDJWZ@D0&*?1K7Z*N
M45&._)YB&G1++;IDR647K-Q8H1B5/H(W'K?=ID>_9_:F#W1@'-M[@C)D,6X
M@0O*O,U EA<0TLHFG3J&U17@65_)[A7I!.87<\F'&5546948)1"B^C6#C-[?
MLU<HZ7R\_+3A]B;C@[H//RY^1QZD; -M-QF55P";)#2[I*FDEX(24RK[O_\
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MR6ZY&?D0WLB39%&;8 Q#E- UP)215N@7JY'?P?+N-"\LR\M4GN'%* _C?$%
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'A)2RQOYBMUY%H!-V+M!9
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M?+=XXQ/3Z_I^]8O>7OF%M7+[9WQLQF'/S43 1,!N'!27N4#R1VPN3+RHB<"
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M2OGWYE)XM]>9FTW\LSZQT[_5]/7P=D<O7MBL5K77XS$>D]>D?1ZS7PWZ$H%
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M[>Z_#LOG<9N56H;..8\6@RQU(#V*0;.&2*I==EQ%%Q$]! MNM0<Y+WWNIAF
MKN.;BS)@C,<B*!N.QXDEUQ&><BD.D66P0I;E[ 1(B>NJ.YQ.7#(8./F9(I&;
M<95YZZ]01&^HD);7!;:A+TCQJ"FQV\&(^WHVXMTR&L>SE3)_'1])*817$U,@
MJ#J(W.78SLG!55.A*#=D=QHX[M:1A)3,G&9J>K#C[=G0<C]CDO)H)%LBZVAX
M_I2@W3-\[0Q[XQIN9BLO$1 2$:6;(35M>82<&TU(J7-42@F9G<>#V\TT[F9K
M<47U5&!*Y&YI1%+2 HI$B72ZHG#TT%5-W(XYN#:;&(DLR,+FTFFZ\W9T708C
MHXVK9BMD2_\ IH,XV[X$+;\7,;FR&/9*2XZV#D!TY$=Q0<-!1I5 3,D ;FB!
MU50O0EZ##,;BEM=M<QDB"<0,(_E(O\0SFD\/\HT9TZ585.DM=]5DM0:]N[[P
M&18Q,"7E8R[AF1F"=CBNE"DFR)FV"_54^*KRT)21*"?@\M-D93,X/*(/;<:Z
M#K#S8J /09:$3!V55ZPJ#C1_2%_3:@OJ!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*"GK=F4'Y8WTSY>O>>F\V?,R3)AX9["XT<><9R8P;LA0)# 5AV)Q=-NJ
M5T^BN9[KZ*3L.9S&R/+'$;M@R7,*YO98>'CRX_9I#FW5$A8[0#0BH:A5174B
M*H]/30=/O^*]L[S@/)3)S&U-JOX5B#MS+/8;Q;&,<MPRDQ!!M0&*9DJ&I?KI
M9/12>YZ(#.1'8V$V;@\1N!K^B,Q.R\\M_O853& 9FI)!BQ7A<%A'#4T S%14
M?JHJ4%7@L;MJ7L#<D/<F<E;<A0]\+D,#EI6/5$&<VP+[;DF&C2-BVZER(2$0
M0E3H7A03\]G<QN'RNP^YMQ8AER/M_>D;GYG'XYQAF?B6G+.3QC&*N"VX2HAH
MJ6*U^BGH/5/-?;P>9GDTZUL 0?0QBY7!1VP6,W(2(Z+PMH!H"BAH*HB*B59Z
MP0W;8\^]D9EO'8[)=MP^ZY3C,-_ RX$L)#4MQ4;4;HTH\M#7^9JTVXK:F4P\
M!WQN?+;IP65/,O+CMPX[<K1ALF!B$:6$U'G"(S9,SEJXI$B:T<1P1-51++4E
MT]9V_M_#YCSO\UW,QBVIO*@XYI@Y3/,! >B_Q$;4DMUM*:E'CPJ^KGT>7;<!
MJ#LKR?W%NC%R<EY>;=GYEO*Q1CN/C$D&\8PI#K-E(FV^-NJJ)_;7+IUWF1G,
M3F\ULG?&TY@,>7..?R$:3F&\.[D(D'+.@V(27H2BTI(H7 7^@%6]64AR^[L3
MB'_+O<67PNY!W2&X-T8$\BL#&.XJ,T^!"VZ;07)%5QI0UFWZ4Z=5%?K?$X;$
MX""UB\)!8QV.82S46*V+38^M=(HB77TKZ:Z<IU H% H% H% H% H% H% H,V
M?YH?M)_?4GLL+6L790><X':[6YV\YE,I/G+C<QE)BGC67E8C/QHR]A%#010U
M$P8ZR:[$E!49J(QD_P"HH+2.M1,WF\3MII(R*T346"#3CW+44ZB(BOB*IT=-
M4=%MZ7C]C2,KM7)/!"PD%1R&%DOEI;2#.=42:)PO2U(4A53*^DPNM0<M.PHY
M0]YL[%U3<3-QK?:'N8<@'\FTZIK'CONJ5Q-E-)B)\L2(>A5*J/08>_=H38[3
M[>68;<=1;Q'BY4MLA%2(7&"LX!"B+J0AX5!Q.1V[N3<> W#NGQ,H)9^$9L8D
MX;3QMPF&S6*UK-5(2)%YQ(GU7#6W15'3[J<?S_EC/F1P(7IF*28C0HJDJ*TC
MR@B=*JJ)IJ"--S47"[GB[MD*I;3SV,CQ?%0$C:C/,NN/,$\HHNAIX9"V<7JH
M0HA*ETH-^XWV=\8QS!;3S<!XR-L\JVAD^#L!;ZV%<C&BAS> DJ+?1J3TW0*?
M"2LS@MV;EG;A<QD/"8_&8]R>Y$;D +;+(RE#EH2JEA1%U(B=%K51GA\GB-[Y
M%W)R\I%;ERXC\+;N&!]LY,>-("[K[HB2JC[B"BJ"?RP33]93J"M>RT/->7N-
MV*RJANQQ(6&DXE459$=V&XTDAUP4NHM #9.(XO5(=.E54DJB/_2BYK"[VG,/
M2TR,;-9&3%@\YXH,AR+I,&GHBDC3K;BCI,5'K?IH/0MO9/;F7DG/QC33>:DP
M8$J?I;TOI&D@9QA=/2E[)S-(WX>I+U!P\5CR_+<&ZW=U2H\;)CEU41D3#BER
M4AQM!:$<!%3IZUN-46N]7/+N2&2=F/,CNIIH!CN0"4,SSU#7&[/RK.D5R%0M
M<?7PO4'SP#?;LJ)N&:_C)$YC&,QVV)K;]XKYLIVTAY!Z%-T^&M$14 4$>"E<
M(.%W@]M3R\VK&R;D),]E(3#.%8(SC1N6$=M>9)<=^H+2+J=5/V1125$JB-F<
M=@9NVL)C(N2#.#-W'#+/3HCB7?DR"(WE)657EB26'0B]5NPWH+O'2H>UF,GL
M;=VAW;<2#(E8J9(;ULOX-H+/1GDLJ$<45T$GZ[6DN*Z[02?,E('_ +<S!$!;
MQ5H-P05: (W:F+I9-*@*!^C2GJH&-/RQ@1LFN.F0WHIQU3*AVHI@=E5="\P#
M<<L"J5E6WIXT%1$C02W'(8\KI;,9EW%R1R3T>\C$LS"Y:0G$ 5Y2O)_$4A;5
M%4/K_JU1 ;PFZ<!NC9&+!,9R&%R2BX RS</F-B<AQTS)=3KBJI:BZ26ZT$S<
M9;0D/,S-DNQTWZ[D&NS>'*HOF[V@>U=L!K_FN7KYJO):W1UM-!.\-RVZ]VYK
M+P,F,#'8T/Z?:;.*$H7[:7Y:JCUK(ID+2VX+RZ@F;&RC6'Q4/:&9DJN8QDQW
M 12<#0<H8C/:&7!$;HB%%T&7H1;I>@[B@4"@4"@4"@4"@4"@4"@4"@4"@4''
M;ZB'.F[3C!(D1"/,+_K,0D!X+8^8O!2$TLO0MQXIPH*C?&VX.#V+N%^.4B9D
M9W9BF3I3A2)+O+D @"J^@015T@ H*75;7554)\++1=I;GSN/SYI"Q^9DAE,5
ME'UTQG"..TP\P;J]4' )G4(DJ:A)--[%8*3<&59W<.X\UA%27MS#[=RL!K*-
M+J:E39@B;@,$ET<%H8XH1CU=162ZB5J)*8./MO,;0W"W(ERF)&G$R&9[STY&
M.UQR)MYCFD7)+6 M&0_6 [+T5!!9VIGM[X+-YIC,^&M;J=*7%C.06B<;9CZ6
MX)*X2ZTZK0/I]DB6U43,S)C;NQ&PLW+BJ,B1E8[4QBQ#H56W>TQW$5.LVCS(
MZA+JJH"OH2@]!GXK&Y1&TR,1J4C2JK?.!#MJZ4X^A;<4Z%]-01MQ0G9FVLMC
MH0?QY$&1'C@-DZ[C) *)Z$XK0<2NZU:Q6SXL;),8+$Y+&)(<S3X"X"%&;9_U
M1M7%1L'"0C5>9?@"H@JM]-%3M@B<:P"HX](:3>&5)M]YKDF8''G&CBMH ("&
MI:DL*(M[^F@G;7W'LK#XK=$++JU'DN9C,'D83S5W9Z/3'116FU15D(86;1 0
MNC3:@J<7&RNW\AB SF;_ *:><V_CX<*5*C,O-H4<G2?BE(?N@.#J:U#J_B61
M4OIX!;8O&1,=G]E>'Y)<O$E2LY,[: @+*G(:4S1L6D0!#7JM;TWH*_#MX^/L
MK;&6/.L[<S^/\2+&2)HB4=UMR0?/9=:-04Q)!!>H0FEKBO2BA)+(9#-Y%S+2
MX90,A-V2^ZY')"LVZ;RK:Y(BIQXHA(A6Z41:".>3V[D?*S#[3PPBNX7(L"-C
M<*(JU-C3V>4:.&W9#:Y))S3<*R62^I;\0[:"J2O,7,/LE=J!BX,*2GHY[KS[
MZ#^D6U$O^.E0=90*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!04];LR@^*(JJ*
MJ(JIT*J<4H/MZ#XJ(J65+IZEXT#IZ?\ \[4!41;HJ(M^"W]-!]7CP7BB\+4"
M@^<+WMQM:_IM0+)=5LEUZ?IH/MZ O'I]/30?+(B:41-/1;T6H"=5$0>")T(E
M!]H% H% H% H% H% H% H% H,V?YH?M)_?4GLL+6L790*!0?"$214)$5%2RH
MO%%1>E* (B H((@BG!$3@B)08\II#5U 'F$EB.R:E3U*M!G0*"#B<3"PD$,;
MC@5N"TIJRRI*2-B9*>@;WL"7L(] IP3A03&VVVATM (#TV%$1+_V4&7308(T
MV*ZD 4+UHB7H,M(ZE.R:U2RE;C9/1>@^T$.)BH4&7.G1V],O). [,=554C)I
ML6@3CT((BED_3ZZ"43;9K<P$E]:HBT#EMJ2&H)K%+"5DNB>I%H,J#X0B26)$
M)/4J7H @ )8!04^A+4$/+8J#FX#V,R3:NPG]*/-H2CJ020K*HJBV6UE3TIPH
M)JHBI9>*+08BVV"W $%?6B(E   ;% ;% !.@12R)?Z$H,J#%  2(T%$,K:B1
M.*VZ+K094$-_%P9.1B95]I#G00=;B.*J_P -)&E'%1.BZH")?U?IH)E H% H
M% H% H% H% H% H% H% H% H/A@#@J!BA O2))=%_L6@K(FW,% R)Y6# 9BS
MW&U9<=8'EZ@545441L*K<4XJEZ"TH% H% H(&.P^/Q3+\:$WHC/ON2U855)L
M'7BYAZ!*Z"BG<]*<-2JM!/H*K!X1K"Q7(R.K(4Y<R:+ABB$"SI#D@@&WH%7-
M/TT%F8 X*@X*&"](DET7^Q:#)$1$1$2R)P1$H,2 #MK%"TJA#=+V5.A4H,J#
M'0&M7-*<Q4LI6XV]5Z")C<3"Q(R1A@J%,D.3)3ADIFX^ZJ7(B*Z\$1!%/0*(
MB<$H)M H% H% H% H% H% H% H% H% H% H% H%!3UNS*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*#-G^:'[2?WU)[+"UK%V4'E&(RF E9?/-;
MBW'-9R;6;E1HL0<A*8 60($: 6VC$+<?5Q]-43LUDX[N\,C!S^X,A@(#78XN
M)2.2Q8SKCP*9D3Q-$"DI$()<_1:UZ"VWUN*=B\>[A-ONHFY'X4F2,HQYHPHL
M=LE*6Z/0JZD0&A7ZYK]D3M!49K-RRQ&S3GY&=C\;.B+,S&2@MF3UPB 0"9MM
M.:4(W-2]5+Z:HEY$6)$#:$+&YR9/P^5R:HYD&IBH[)CK#E/(//8T+HU@/U53
MHM4&W+P9VS'H>=Q63EO8;M4:'EL5/?.6WR);PL(\R;VMP'&S<$E37I(;I:]E
M0+#>[9R0P4#M$B/'FY5EB4L1]R,X;2LO'IYC1"2(JB*K9?10:\T66Q^Z=K)'
MR;@XB5(<A.XQ !1- @R7=;CIZG"5";#2B*GIO>@K-R[L-[<;^V(V0?QT3&L-
MR,N]CXSDW(GVA"4 ;$&W4:;$4U&Z0JJJJ"'&ZT$S,S-ON[8Q^9?W?(Q^VA8%
M6\I'D--K)ZEQ,WE B4K"2V&UUO=*"IE9C/EL; /Y";*CNSYP-3,I%8_UI<8A
MO.-O$# .HV;K3;>O2-D([</11-+,M0=L1G-J9IW-2L[/:QV.R,XTEI'>>72X
M1BB-K_!$#-6RLNI-*VOP@LV-OXG%RX?;<_/=R^L7 *5DC$I"H5U%8XD#2BJ\
M-(M(E!OE[N;P^0=B[CA.8S'JYIA9E51Z X*Z43FN"B<@KJJ6=1!X<#6@B[[@
M-R=MY;.Q<A-C2H>,DO0W8,U]AK4VR;@'H:- );VXJBW3Z*"SVWB&L?#:DA*F
MR793+1.+-EORT1=-[BCID@WOQTVH*J5OSEC-R$#"S<CMW&FZU-RT?E6U1UTO
M*PR1HX\+9(0F0#TBJ!J5*#=)WLR>1#$8''OYF>]!8RK"L$VW&*')(Q U><)!
M2^A=*=)>JUU0*^;N%O.%M#(X]'XZ.9B1'E0GOX3PO1H4T7&'A$E&XN!;I4;V
M)%5++06:[SQ,G;&/W RV\ZQEW&(D6&-@DK)E.HPK*W)$$VRU<SK=722^B@U;
M);6+*W/C@>?=B0LJC40)+[LDFVR@Q7%$3>(RTZC(K7]-!#\P)\>'-VRUD<D_
MC,/*FOMS78[[D53TPWC;$C:5"MK%%LB^B@C9')8Z-M,G=LY6?*B2LA%BR<DT
M[(R$B.T;K?/(%=1XALU?H&R*MZ"VV[D=OPL'.SC.XG\GB&-9RYF0>1Q8W9QN
MX))H @5$XD)#?HH*[:^X-PS]PYN1F!-C''CH>1Q6&5M$?CQW')0)S?UE>=1I
M#,/U. =**JA$V)D(,L8\R?N7(2-PM0TF93$325AL%=&[BC'-ELE!LETHHW1.
M%UJB7BH9[AQ#6[-UY63#C9( DP\?'F' BQ(KW68$B9)LC=42%3(R7K+841$2
MH.RQK;#4".W&DG,8 $1N4XYSS<1/UE<XZE^F@X/<N2Q+6^7(6X,W*QF/'$QW
MXK#$Q^&!/')D"X:HP0ZETB"<:#[N7)1(P[<89S>0A;6<CRI4G*1>=(=<%H6T
M9$WU;>)$7F$5RM?3TT%Z]G(&W=KQ)<*6[N I:BUAE5X'GI\B2JDT NBB"J*G
M%3M86Q4EX"M!S+.:W2FP-P/3)Y/[AC9.1 [;$85>4)2P:566Q$RTL@:Z542*
MPZEXU1MDS836Q]UY3;>Y9V2DQH;XJY*?17H<AEHB3JD#9-%Q0NNG19>BH+3!
M923O?*#F<?.5K9V*=<8B"P=CR,QN[;CCUN(L-JJHVVMN8777J(&H.@W-F1V]
MM_)9M6^:4&.X\VRJZ>8X*=0+^C45AO0436RLF_CD>R&X\B&Z7!1T\C%?((S3
M_!=+41?X*LHJ6T. 2D/UB5>-!STW=&0R.+VR]FIDK!QW/$!W#(Q8.&B2L879
ME!#!MY0 G=1HB^A.GA5'5EG,9MS:C&2C3GL^T_I'%'S@D2)[\DEY+39BB"2D
MJV1>@134O!%6H.7@[TS6%VOG)V?EQI6=#.NXF$KEV83;SY-HTWU1UJTSK7C9
M3-!X=8DJC-[-(SM?=I-;BGR]TQ\0]+<"6P6.-A!9=Y;\:,33:@"K^M<^*)<M
M5!<[3D[3D303#9V5DIZ,*9L/SY4H-"Z44M#QJ/2J<;5!VE H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!3UNS*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#-G^:'[2?WU)[+"UK%V4
M'!X![-;;D9Z-)V]/E!,R\N=%D1"B&T;$A14%Z\@"1>"W11H)>ZY&8S&.RVU8
MVWGGCR#3D)J;(-A,=R9 :%>,D<)RP:E7E\O4JI9.G500LOY<MG RS\#)Y/Q>
M=!&.ZC<OEA(<CQN0TA(2*@HMKJE[7(E]*T$O"+E=G[>PV)<Q>2S#@1&T?=!Z
M.^XU(0!1625QQKJHMT$DN*(G%:"G;P&:PL#"Y$\<Y(?#/R\W/Q4 VW5B-3F)
M0\MO630GI-T=>GI)2).%46\UO/[OF0(KN-<P^V8LAB?-<FFTLN4<4T=:8!IH
MG$ .8(&X9DBJB:4'C=()&^)46$6VY4U]N-&;S+*N/O$C;8IV>0G$B5$3C02\
MY!E9'*[7G0@1Z)"G.R9+HD-A9<@R&A)+KUKDX*=7UWH*YQK+;;W-F<I%Q#N6
MQV>2.\APE9&0U+C-)'Y;J/&W=LP$5$T+JKJNB=-!AAES&U</'A3<&_/<EN2Y
MLH<83#C,=^;*<D=G07G&E41YFE#1-/#C:@QVZSE]GX(&W<,_("9-ER_#,<;#
MB8UF2X3K; H9MH0C?CR^ DJV33:@@EM#-Y*+ELTTTUB<_+RL;-XG'O'S&6W8
M+3; I)5FZ:I  2.JWJTH264E'B&O=#62W=C&\>[L]^-N'FQ%&9)6&XQ'1J2V
MZXH21<4E1!$K:0U+]E*#HYS&[<U,D06S;P6!;)6UF#HE3Y062ZMB2$TR"W5-
M1H9?X1Z:#&=M>/CMAY3:VW(ZH)X^:Q#CDXJJ3TEMQ>)N+PU&=^*V2_H2@O\
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M@4"@4&)@#@J!BA O2))=/]"T&5 H% H% H% H% H% H% H% H% H% H% H%
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M3<.KP^$+%.YEQ7^;XM..<B:=/+0V&F='2M_Y5[_30<]"V7FL"SB7]OY-E<E
MQK&'G-S&B6++9C75H[-FA-FV1&HJBJBH2HJ="H%QMC;TW!N9>3D<CXE-S$M)
MSSO+1D0)&&F$; 4(K *-)I155?6JKQH)&!PA85S+F3_.\4R#N01$'3RT=;;#
M1TK>VB]_IH&!PA85S+F3_.\4R#N01$'3RT=;;#1TK>VB]_IH*F+L=&=D-;0<
MGFC\?^)'R;((#C4AN0LEET1)22X&@K9>"V^F@V0MLY*?D@RV\7XF0=C1SAPX
M4:.H1!%XQ)UTQ>)PB,^6"6OI!$X7NJT&U=DX0-Q8[/18,..D!B2SR6XK0D3K
MYL&#B&B(HJ')6W[7^D)N%P:XR9ELE)?25D,M)YSCJ!HT1VA1N.PB77@V*=/I
M(B7TT%)"V_N["2\LN&G8XX63GO9%!F1WR= I""BA=MX45$T\%M07>WW,Z^.1
M?S8BV)SGTQC""@D$%M4;;4[*MR-1)S]!(GHH,MNX8L%CC@D]SU.5,E\Q!T<)
MDIR0@VNOU>9IOZ;4$.)M@XNV<CMY92$4\LD22-%D#Q)YYU.K?CHYMNGC;T4&
MJ9M)R1MK$X=B<L?*81(CN/R*!J$9,,$;0B;U)J QU 8:OJDME1>-!CC]JNR<
MA*S6[5BY/(R66HC49MC_ %./'9(CT@+JFI$9EJ(R^A$1+<0VPMF8C'[G=W%#
MB1&-4-J(TRS&;;)MQMQTR<$Q1%34+NE43U4$S;>#+!076GWTEY&9(>G9"8@Z
M.;(?*ZJ@W*P@*"V"7X"*4%2FR$+8LG9KLS4;R2":FH%M#KL@Y+1Z-7'EF0\-
M7&WHH+;!.YU]W*O9D!98[:;>*81$0DB,@#:&2HJJJN."XXE^@51*#+;^&+",
M362>Y_:Y\R>A(.C2DQ\GD#I6^G5:_IH-.+V^6.QN4@+(1Q<C+G2T<T:="3G3
M<0;76^G5:_IH(;^S^?M+%;>&:K.0PS<(L?E!;0N7+@"* [RE6RB6E4(%+B)*
METZ:#Y VM)EY)[-;O<BY&:<<8<>$RRJ0F&1/F$J"\1J1F2"I$70@HB)TJH?8
MVQ\1#W8.YHD6(P(0>Q-QFHS8*+O-5Q74,42RJ*Z>C^V@L-O80\,Q+*2^DK)9
M&4[.G2D%00W'%00$4525!;;$&AX] T&3F&(]SQ]P\ZPL0'X'9]/%5?>9=UZK
M^CE6M;TT%>_!F93>T.8]'-G%8",Z3#Y+9)$V<B NA/2+30DBJOZQ\/JK0=-0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!04];LR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@S9_FA^TG]]2>RPM:Q=E H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H%!S2Q\K?\ [<UW;_,K=D^=GROSS7=O
M\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O
M\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O
M\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O
M\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O
M\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O
M\R@=GROSS7=O\R@=GROSS7=O\R@=GROSS7=O\R@S;CY;F!IGM7NEKQE]?_25
M)[+"S[/F/GVN[+\6L6AV?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY
M]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'
MS[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F
M/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?
M,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L
M^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'
M9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0
M.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6
M@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7X
MM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LO
MQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9
M?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GN
MR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/
M=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV
M>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^?9[LOQ:!V?,?/
ML]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q\^SW9?BT#L^8^
M?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+0.SYCY]GNR_%H'9\Q
M\^SW9?BT#L^8^?9[LOQ:!V?,?/L]V7XM [/F/GV>[+\6@=GS'S[/=E^+01ZW
M9E!B1" J9D@@/$B);(B?I6@^-.M/ CC)BXVO08*A(O\ :E!C(DQX;#DJ6\$>
M*R*F\^Z2 V CQ52(E1$1/6M!]8D,2F&Y,5T'XSPH;3S1(8&!)="$ANBHOK2@
MV4"@4"@4$:3D,?#>C1YDMF/(F&K<-IYP6S>-$NHMB2HI+;T#02:#6T^P\I(R
MZ#B@MC0"0E%?4MEX4&R@4"@4"@P==:8:-Y\Q;9;%3<<-4$1$4NJJJ\$1*#X3
MS(M<\G!1BR%S5)$#2O0M^BU!B4J*#0OF^V+)?5<4Q05_0M[4&;;C;H"ZT8N-
MEQ$Q5"%?T*E!\)]@'18-T!>/ZC:DB$OZ$O=: R^Q(%38<!T!(@(FR0D0@722
M*J7XHJ65*#90*!0*!09L_P T/VD_OJ3V6%K6+LH/FH=6FZ:K7MZ;4$=_(0(J
M LF4RRCA*VVKC@AJ-%LHI=4NOT4$GHXK0?$5%34BW%>*+Z+4&J-+BS6^=#?;
MD-(JCS&C%P=2=*7%52Z4&Z@4&L)##CSD<'0)]E!5UH213!#OIU(G%+V6UZ X
M^RR38.N"V;Q<MD2)!4STJ6D47I6PJMD]"4&R@4"@4"@P==:8;)Y\Q;9!-1N&
MJ"(HGI55X)09T&MM]ETW6VG!-QDD!X!)%4"44)$)$Z%LJ+Q]"T&R@4"@4"@4
M"@^*J"BD2V%.*JO!$1*"+CLKC,NPLK$S&)T83)M7HS@O ACTCJ!52Z7H)= H
M% H% H% H% H% H% H% H% H%!\U#JT737:^F_&WKM0?#<;;2[AH"65;DJ)P
M%+JO'U4&EB?!E&K<:4T\:)J46W!-;>NR*M ?GP8SS<>3*99D/?RFG'! S_9%
M515_LH,3R6.;,VG)C .-WU@3@(0VZ;HJ\*#:S(CR!0X[H.@M[$V2$BVX+Q15
MZ*#"-/@S"<")):D$RNET6G!-0+U%I5;+^F@W<QO4@ZQU*JHB72ZJ/3_HH/JF
M"$(J2(17TBJ\5MTVH,&GV'T(F' =$5424"0D0DZ46WIH/KCK32@CIB"N%H;0
ME1-1JBKI2_2MDZ*#.@4"@4"@4"@4"@4"@4&L)##CKK+;H&\PJ(\V)(I I)J3
M4B<4NG%+T'WG-<WD<P>?IU\JZ:]%[:K=-K^F@SH% H% H% H% H% H% H% H
M%!3UNS*#P5W%-></G#NC!;K??=V3LAJ(Q$VZVZ;#$J;+!7#?DHVHJX(HFD!5
M;5.\JO<Y(V_Y*,XO:WEEM=IW<F\YY-X[%"\;$-'&&D5U]XRYBMM@")= 'BOH
MIV1SV[=_;ARNV/,7RZWYA8V-W1"V[)RD9W'O%)Q\W'F)-D8*Z &) 7 @(:95
MOVUO[<D/"['\N-@8:+D]S_TU!R^1?R,@HL"% -L6VU+E X9&X7U1%.CC>F1]
MF_F R6-VM-R&1VZ+&[-O[@B;>W'A1?5T$[4MQ=BNB*:^8-N4A(G'ZUJ9,)V9
M\W=W8>3B=L9#%8;$;URC<G(2$RN25C%0,:V[RV>=($%5Q]SH1MM/02WLE,IA
M&C?F"=F;=C-P,*SD?,.5FW-KL8:'-!R Y.:;YRR!EH/_ &56E1S5IU6X6NE,
MKA6>;.Y?.3$[1Q,C*L8S#27\]!BF]A9\E5<!TVT99)39;5 <-2;>X\!2Z7O:
MDY(=;N_?V_-IXG%OY)O:F+R;\=QR>F5RSS#)R@.PL1!2.IN7&Q*9(EO524<'
MG]Z,>8F3\AMV-Q%@N3,]+%^&9(XK+[+!MN"AHB:DU#=%]*6J>R^[J?-V1DMU
M>86S/*!G(2,5@<ZU,RF??A.*S(DQ8 HHQ1<&Q ADO745Z*LD.NQ/ECLCR^2=
MN#8^W8L//!"=: B?=9;>1$0T%YPU-$N0)=Q154IA'(;2\[,ED]X)L[,A@Y\F
M7"DS(4_;.0<R$9I^$*DY&DJXTW8E1%42"Z+9:97"CC>?^^_Z0Q/F--V=$#8S
MC[</+R&YQ+-1QQ]6">CLJW960*R=<T(N/!$LM3)AV>8\QMYY7>67V9Y98*#D
MG=N TN=RN8E.18@2)+?-:C-"RVX9'IXD2V1*N456X?.;.,9S([<P$? ,Y#;T
M9DLX]GLKV!EZ>\TCJPX*:%)Q11>LZ:(*71*95%/SZS&9D;2C;'VV&3D[RPTK
M(8Z-)D(R3$V*[RC!\T11Y+2H>LDZRJB(*<:9,+OSA>>RF,V3LK*"C8;OSL&%
MFV&2NV<6,V<V0Q=4X@XK'+7UBJIZ:2D.6P&WX'G1YB;W?WPKDW;&S<@F!P6V
M$<<9@"K;2$[(>: AYAFJ]75P1*=U[*?SIV?L39LGRSPC&&T;*7-SI.3PT<'I
M:/ [&ZXBRBF9W72N@/[$J20Y[&[F#9V(\T_,#RJ9<Q&QX<&+CL5A)FL.3G5-
M&W)/8W54HX"+B<#$=:IT6HKUO:GD)Y?>$8S*;DAN;CW4Z+$^9N#(2'W);DM=
M+RD!H::!0_JB/"W!;U<)E,V<?@?G)OO:D4>7BLE$Q^YVF47J-RY*N192BG0G
M,5D#+_%=?33U1ZG5"@4"@4&;/\T/VD_OJ3V6%K6+LH/)WLK-R'F!G,+CI+L%
M,D]'Q)9M&[@RWCXG:G(T9Q;HLH^T.$ETT@(D7$D0:HCY%S9> W-DV,EA7)>(
MP6-@XV&PD0ID879KKKSJN.N(38&>IK6X\:7^L1>F@G2?_!=J[>\NLWD68DO*
M-.!DW79*"D?%-%=UH'7"0B72XW$ NGCJ_5H$9F?N'RJP(XYE)T>(<<)^,8,1
M[;!QSRLNL-FI(*ZD;14%203MI5;$M!VFU'=LS(!Y';,1F(R^X3<MIN.D1T)#
M"JV;;[>D5%QM4420DNGZ*@YR7YBS(>U8V5* TYGUER(<[& [=&TQKCBS3$E2
MZZ&63,.'%5%/308;ZW*Q(@9O&) 9RN"CX=J=-)7S:0SF/H,=I":L2(0 XXJH
MM_J^N@^NY@-O;GWME$C%+?%G"LQHC:H)OR)'-99;0BX)J,Q34O0G&@QRI[L_
MJ+9K6X8\$XSF3<<&3CR=3D/#CIG\,Q>XF)(JV<'3Q3B/&J)6]-U1YNS-PN;.
MS,)[*0X+SSAM/J9M-H!7,58+4)\.HO1JZ:@LH^<S>/S&&P^X&HJCEVI(M3(7
M-1M)<>SH-*CMUZ[/,-%5>D%H*I[?.<?>CM8;%L21R>7EXC%.NO* $U!CF3DI
MPA0NHCK3HZ1XD*);BM!(?WED]M.9-C>,9C1$Q[V7ASL>I(T^S&(&WF2!Y54'
M1)QNW6420TZ++00\7O\ EEE\5"R<O"R6LPX4<(^)E]IDQ)"MFZ N<51P%$%
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M!OH5T%%"5$M=$5;VO0<EO<\B_MB!C)AQ8^_I$IDMO-P2-\1G,FBH\(N")<L
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MIBA)I?C.*TX"H2(O A7]/2G"@JWM\8 (N/E1BD3DRJ.ECV8<9YYUT(RHCIH
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M@4"@4"@4"@4"@4"@4"@4"@4"@4&;/\T/VD_OJ3V6%K6+LH% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MQR3$%=!4(45P ^JJ7M0<D]G)H;3WQ,P&=DSMO1$;'#9AQT77FG^*2VVWUN1
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M5<7VMYQ,F&:QD A<>CMY.8LYI&-6@7.2:JV:(J7UJ0WM90^GAMQ<\][AC/\
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M_*L_AC[*!V"#\JS^&/LH'8(/RK/X8^R@=@@_*L_AC[*!V"#\JS^&/LH,FL?
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M:Y,Q58-M7"$^HEU5 M77>4]''Q,KFLQM3:F+3<60?@0O,1S;^$W T^0S'L2
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M^NFH52J/3L'EXV?PT#-0_P#LT]AN0V*JBD/,%%42M^L*]5?IJ"PH% H% H%
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M*N'/\5;A-YDQ#M@XHX2SU55TZ%?1 *.CBCZ4-4U7H(&ZLCE]KP=T[>3+RY#
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M(/P-L8N!-<YXN0F6VP08@GH(">0S=)UM1TJNI41*#HM_9#/.XI<'BI!Q<RS
M/+Y69"4@5IJ&.L6@+I19+P<M/3RT<]509;TS^-=9VHQ*R9XK%YJ3VJ1*;?*(
MI16(IO\ +YH*)(AFK2+9>*7H+(<C@ML[;?SF(??RL:20I"!9;TTY4IPD9:99
M-XW+*9V'AP3I7TT',$_GL-N3;<2=E'I)QG!<W"@.DK#\O.J\TTV@+T-,*TO*
M'T)I]-46>YLQD<AN[!8;$R78\"!DV$RKC)$"2'SC/2$BJJ6N(-!S7$Z%U GK
MJ"MQ>3V]G]PYIC-9>8.3/+/0,=!CS)T=H&8B P(B+) WUC S5?6M49PMT9',
M;FW)MO;T[_Q<IJLDX\7-9Q<"&RTR;HMEP)YQU3T-]'01]5+$'HT"&&/A,0@=
M=?%@$#G2'">>-4Z2,RXD2KQ5:@DT"@4"@4"@IZW9E H% H% H% H% H% H%
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ME#RY V,1XH^V;I6]ZE!Z34"@IZW9E H% H% H% H% H% H% H% H% H% H%
MH% H% H% H%!FS_-#]I/[ZD]EA:UB[*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0567PWBDS#2^?RO"9BS=&G
M5S+QGH^B]TT_SM5^/1006MJ\K;68V]VN_BQY,^T\O^7XFZZY;3JZVCFVZ4O;
MT4&W%[;\-RP9/M7-T8N+B>5HTW[(;A\R^I?K<RVFW"W305K>QE;,3[>JZ=P.
M;BMRO> 0\CZWHU?7_P""@U1]J;IQ7BC&$W TU#RTR5.)943G/0SEN$X79E1P
M15.MP1T21"X]'5H)N*V3"PV3B2X3Q)!AXA,*W%)+F0HZCJNDY=+DOZW5XJMZ
M"NC['RS6#Q..7+--Y7;3@> 91J-Q1AMI6.7):)Q4-'&E4'-!!QL0Z21+!)/:
M&3RAY&=N#)@]DIF.?Q4)N*RK<2&S*1.:8 9D1F:B"D1$G 4%$3C<.DQ,'PO%
M0<9S.;V..U'YMM.OD@@:K76U[7M0<]BMM[@V\2X["9.-_37/)]B-+C&Y)BM.
MN<PV&G = 2"ZER]8W!%MUD1*#2FT]QXX9^.V[G6X.$R#STEL78J/2H)R25QY
M(IZQ!1(R(P1T"T*OZPV% G8G9T3"YB%/@/*$*!B0PK$,AU%H;=1Q'"<5;J2V
MLO#BO&]!K79U]N[CP/;?_4#N0>[1R_Y/B.KAIU=;1J]:7^B@PD[9SD?/.[BP
M65;9>>A1H#V/EL*[%<&*3I"XJ@8&)HKRV5%M;@J+P5 UL['<1N&[+R92<J&8
M#.Y&832"C[H,DP+0 A?PVQ#0 )<K(/&ZJJT$V+M7LV&SV)[7J\;?GR.=R[<K
MQ#5U=.KK:+]-TO\ 105D79F9P\IN1@\LRT3N-A8J:Y)C*\X*8\2$'8]G!05)
M#*X'J&]E]:$'V-L>=BX>U@Q>2 IVV6G(O-E,J;<J/( 0<UB!BHN=020A*U[\
M++P#=,V.4AN<Y'R1Q<F[ETSN-F@VB]F?&.W'T$"E9P" 3$TN-Q-42RV6@V-;
M7RD_(KF-R9!F1,9BO0\;&AL*S&C=J1$>=ZYF9N&@BG$D01NB)Q55#>YM3F;4
MQ6V.UV\,\,_UKE_S/#'67?J:N&OE6Z>%_30:<EMG+9K,P).4FQEQ&)G)DH 1
MXY-S.8 $ -F\3A#H34NM0!%-.JMDO<).XMOS<ED,1FL5*:CY3#&^K(2FE?C.
M!*;Y3B$@D!"2(B*)B7#BG%"6@XS<FV,GB\?"9/+.RLGEMUP<@60;8$5CN$
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M=N.CC2MNMEJ5&TU"2Z2X?5XJH4.Z,&Q#VW V/C9KSV\,A+2;!R2")26Y:O\
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M'B>,^=C_ (H>V@>)XSYV/^*'MH'B>,^=C_BA[:!XGC/G8_XH>V@>)XSYV/\
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M/%L5\]'_ !0]M \6Q7ST?\4/;0/%L5\]'_%#VT#Q;%?/1_Q0]M \6Q7ST?\
M%#VT#Q;%?/1_Q0]M \6Q7ST?\4/;0/%L5\]'_%#VT#Q;%?/1_P 4/;0/%L5\
M]'_%#VT#Q;%?/1_Q0]M \6Q7ST?\4/;0/%L5\]'_ !0]M \6Q7ST?\4/;0/%
ML5\]'_%#VT#Q;%?/1_Q0]M \6Q7ST?\ %#VT#Q;%?/1_Q0]M \6Q7ST?\4/;
M0/%L5\]'_%#VT#Q;%?/1_P 4/;0/%L5\]'_%#VT#Q;%?/1_Q0]M \6Q7ST?\
M4/;0/%L5\]'_ !0]M \6Q7ST?\4/;0/%L5\]'_%#VT#Q;%?/1_Q0]M \6Q7S
MT?\ %#VT#Q;%?/1_Q0]M \6Q7ST?\4/;0/%L5\]'_%#VT#Q;%?/1_P 4/;0/
M%L5\]'_%#VT#Q;%?/1_Q0]M \6Q7ST?\4/;0/%L5\]'_ !0]M \6Q7ST?\4/
M;0/%L5\]'_%#VT#Q;%?/1_Q0]M \6Q7ST?\ %#VT#Q;%?/1_Q0]M \6Q7ST?
M\4/;0/%L5\]'_%#VT#Q;%?/1_P 4/;0/%L5\]'_%#VT#Q;%?/1_Q0]M \6Q7
MST?\4/;0/%L5\]'_ !0]M \6Q7ST?\4/;0/%L5\]'_%#VT#Q;%?/1_Q0]M \
M6Q7ST?\ %#VT#Q;%?/1_Q0]M \6Q7ST?\4/;0/%L5\]'_%#VT#Q;%?/1_P 4
M/;0/%L3>_;H]_7S0]M \6Q7ST?\ %#VT#Q;%?/1_Q0]M \6Q7ST?\4/;0/%L
M5\]'_%#VT#Q;%?/1_P 4/;0/%L5\]'_%#VT#Q;%?/1_Q0]M! Y+/NP^ZGLK=
MF^<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#
M[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL
M^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4
M#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=
M3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW8?=3V4#DL^[#[J>R@<EGW
M8?=3V4&;3+/-#^&'UD_53U_HJ3V(6O(8]V'W4K%H<AGW8_=2@<AGW8_=2@<A
MGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2
M@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8
M_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<A
MGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2
M@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8
M_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<A
MGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2
M@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8
M_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<A
MGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2
M@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8
M_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<A
MGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@<AGW8_=2@JZW9E!YG/\Y<9BO-=
MKROR6.<CA(:8[/GE=%8ZRY0$;3!-Z;BIZ"024K*7#TU,]1?8O?+>3\PMP[!2
M 33F AP9Q9!7$(7DGH=A1O2BCIT=.I;U1U#4J*^ZZRP^VZ\RMGFP,2(%]1(B
MW3^V@^=MA]3_ %EK^*:M-]<>LXG!13CQ5/50;Z#R?&^;^>W/,E/[)V/+SFU(
M4\L8]G%FQHBN.-.(T\XS'=76;;97NJJET3@E3(]1<FPVD-79+0(V2-N*1B.D
MRZ!6Z\%6_!*HS5]E'DC*Z':%'F(SJ37HO;5IZ;7]-!B<N(W("(;[8RG$NVP1
MBCA(GI056ZT'EVX?-C*8?>&]-LL8R.\SM?;']1QGW'3$GGU4D1HT0501ZOUD
MXU,CKMJ[O;R^P,7OC.<G&,RL:WDY]C4F&!5OF'UB1%413TVJCC,1YO[NW7&'
M.;,\N9^3VFZXB1<I+FQ<<[)94D'G,QW;DH?K=94NG14RKU9R7%:>;C.OMA)>
MNK3)&*&=NG2*K=;?151Y-NKSARNW]Q>8.%8Q<=]K9N!8SL5TW3$I#CZ*JMFB
M(J"*:>E*F5PZ7)>89X7RF7S-FX]'W&<.UF'\:R[H%2<:%PFQ<(5X(I<%4?[*
MJ.IPN5#+X''9T@[,W/AL35:,D7E"^T+FE2X(NF]KT$M9446VWE?;1IU41IQ3
M'22ET(*WLMZ#X<R&V*DY(:$4<Y*J1BB(ZOZG%?K?1TT&;[[$5HGY3H,L!]9Q
MPD $OPXJMDH /,N$0-N"9@B*8B2*J(272Z)T73HH/.,[YLOANJ3LC8FVY.[]
MQ8X!/,DR^U#@0%<34V#\EZZ<PDXZ!%5J9'6;>SV3FX1,GNS$?TO-%UQIV%)E
M,R!1 +2)H\VJ J'TCZ?75%VK[ BV9.@@NJ@M$I(B&I<405OQOZ+4!I]A_7R'
M0=5LE;<T$A:33I%;="IZJ#!)D0I"PQ?;66*:B80Q5Q$]:C>]!]"5%=?<BM/M
MG)91%=9$Q5P$7HU"BW2@!*BN$ @^V1.*2-B)BJDK?UD1$7CI]/JH-U!FS_-#
M]I/[ZD]EA:UB[*#F)6XLT_GI^$P&-C2_"VHYS)$N4<9.;*0R%L!!AV]A%"55
M5/K)0)&Y\@>0\!P^,&?G([3;F6+G<J!")X-0@;Z@I$9=(@#2EIL1:44;A]R.
M?SN&PCTW(XR.>562Q#@1(TLB:D.2W6V6[N&R"A8CZW46R)>@UY/<6XL'AYV5
MRN(C$;/(:@Q8<PW2?D27A8 "5R.V@)J,>/6_10;\5N').9Y[;6=@-1,B,5)\
M5^(^LF.\PCG*-+FVT8&!*-T4;*BW1>E$"[DSH4,FAF26HY/ERV$=,04S7]4=
M2I=?H2@W(XV1DV)(K@64Q1454U=%T]%Z#2]/@QHZS)$IIF(*V)]QP0;1;Z;*
M2JB=/"@VB\R8 X#@DV[96C14420DNFE?3=*#7%FPYS9.PI#4EH25LC9,7!0Q
MZ1515>*>J@J=V[D7:N&?R_ATG)"P)N.,Q=":6VP4S,S<(1$4$5]-U7@B+0;,
M]N ,,$1IB,Y/RN2<5G'8]E1$W3$%<)2(U00 !12,UZ/I5410PP&X3R[\['3H
M+F,S6-5M9<)TA=%6GT)6G6G0ZI@>DDOP5"$D5.%!:R9T*&30RY+4<GRY; NF
M(*9K^J.I4NOT)056WL\N4P2YG)"W"0'YC+MSLV Q)3L="4CM:Z-HJWZ%H/F<
MW F/@XZ=C^5,9GSX4)'$.[?+F/BR1B0W151"NE!:O3H49]F-(DM-29"JD=EP
MQ$W%3I0!544O[*"N7=.$'<!;8.4 Y86 DJV1@B*+IJV()<KJ:JE]-NBU!)@Y
M%UW'G.RL;POEF\CC;SS3B"VTX0"XIMDH(ABB':]TO9>-Z"4S+BR(XRX[[;L4
M^(/MF)-EQMP)%5%X\*#XQ-AR77F8TAIYZ,2!(;;,3)LEZ$-$55%>'IH 38;D
MIR$W(:.:RB$['$Q5T!+BBD"+=$7Z:#Y+GP<> N3Y345LRT 3[@MHI+Z$4E2Z
MT&UQYED5-YP6Q$2,B-4%$$4N2K?T)Z:#&/)C3&0DQ'@?CN)=MYHD,"2]N!"J
MHM!2Y'<K+$[#Q<<;$T)^17'3"!U"5BT5]_H"_6NR@V*W307] H% H% H% H%
M H% H% H% H% H%!4;GS1[>PDG*M15FR&U::CQ$/EJZ](=!EL-2H5KF:<;+0
M0G=P93#0I>3W5#C0X$<0Y789#LU]YYPT &@:5AI5(R41!!NI$MK4'V%D]X2S
M8D/8*-#@.FB.,/SE6:VTJ_7(&V3:U(G'0CJ_M4$=O<6X,ED,I'P.+B2(.+E=
MA.5*F&P3CP--N.:0".[9!5S1Q+BJ+01LGO#-QG<](QV'9FXC;BB$YQ9?*D.D
M,<)+R, K2@JM@X/UW!U+=.%!=RLEEI$*%/VY$C38TII'U*7(<B*C9B)-J*"R
M[>Z+QO:U!!VGN+-;AAP,I/QT2!C\E%&5%%N84B1_$$205!6&TX(O65"6@Z17
M6A/ED8HXJ(J"JI>RK9.'Z:".YE<8U$&>[-8""2V&43H(TJW5+(:K;I3UT&YV
M5&8CE+?>;:BB.LGS)!;0?6I*MK?300W,F\LW&M0HO;,=.1TGLBT\RC; M@A
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M,?N3.X:' (#44/#Q)@ UI7@2"^9/.+ZQ.@OHV,P3N_Y^'R\.*C$+&Q2VSC7
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MBXW&;B=A!M?*Y]7)D&$AM8YEQ8A*S',7"7J/21%P@6P*XJ#;K<0N(,+;N/\
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MWLK*;G9/%1)DQH4!M^0PVZ:"BZD2Y(JV1>*)Z%H)TF+%F-HS,8;D,H8.(VZ
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M\I=5S2I*8]9$]%7J)'E!O3)[G\I\1O7=DALIST>3)R$AIM&6T!AUQ+H WM8
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MGP1QUML")M%5%1$*RJJ*B(MEH/CV]]K,P,=DO$!=AY="\+-D''ED& J2MMB
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M/"AE<DY@$T2"16ZI*/IJ"JW9D,@[F<OC,D]EHL-N*VNWX>':)"R#AM&KMWQ
M^N)V#01 (I8BNA70-FTH&09RNV2?BNLBSM%J*\1@2"W(0X]VB*UD-++P^B@H
MFFI$O9^SB!,FPNU'6XVX(T%IQJ?'/L;D4G  P57$;([DC:%=M5(;V1%HRSF&
MP^6VMN+(X*7E=P9!^-&Q[G;1?-"9&4CG+ ":;0[7)2LBV3IH.IWADIK&=@P)
MLF=C-KO1C<6=C&C=>>GHX(A'(VVW2;30JD.D44UX:NK98.=QO:<3MG:^3R,6
M>Q%Q^X<A*G)*;-^8S'DGD ;=?%M"5;J\WK(46VJ_1>J-N;QF5EY?=.2A0'YD
M=F5M[)MQ!#3VYB!9YUIKF:1(T1-0C?ZZ(*VO07$O*L;RSFW P,>236*F%D9^
M3>CNQ0C@$=UE8]WQ E==5U!(!3JCJ4K=6\%3'Q<X?)&9C5@NI/*--M"5HD>4
MSE.FG\.U]2WU=''IJB;N=U,7N4IFU'98[PEN0PF8E([IP,A'0Q!3<,FU;;)M
MI5_C@XBCITEJX#4'HU H% H% H% H% H% H% H% H% H% H%!QV_5=9?VOD!
MQS^38Q^8&3):C-<]QIKL<IOG("(JKH4T6P];[-UX4$,NP[ZW-'?B1G7=O0\;
M/@Y&:\RXPU)\15H.S!S$ C04:(W%1-*+I2][V"+Y>1LE.GNR<RIN.;4:/;$-
M\^(R'&30I$H;W7^( QP5;_6$TJBSS6WH6<WWCERV-&=C6,1,03?:YC(/G)C6
M2ZI9"447^Q*@B;H3';9SVS)B1UB8#'%D&G#CL.&RQSH]FT5&A+3J6]N%!MGS
MCWGD\3'Q<62&WL7*;RV0R\ADX[3BQD(F6(X.B)N*3EC,T'2(C:ZD24%5%V)-
MW7MG)3,IDLEBY^YC>R#N/0VQ;8)S2D03$FE-%:;;9U)J3K(O10=SMG(S,M@,
M=D,C&.)D7F1[;&=!6R;D!U'1TEQMK1=*^E++06U H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H%!3UNS*"!)PN)F9.#FI4-IW+8Q'@@32'^,
MR$D4%T1+I0304U)T+9/503Z!0*!0*!00(V%Q,/)SLU%AM-9;)BR$^:(_QG@C
M(HM"1=*B"$NE.A+KZZ"?0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#-G^:'[2?WU
M)[+"UK%V4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4$;(1G9L)^(Q*<A.O H#+80%=:U<-0<P2'4GHN*T&K#
MXF%@L;'Q..!0B1A40UDKAD1*I$9F2JI&9*I$2\5)55:"=0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#FED96__86N\_Y=;LGS
MM&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#
MM&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#
MM&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#
MM&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#
MM&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#
MM&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET#M&5^1:[S_ET&;<C+<P-,!J]T
MM>2OK_Z.I/986?:,Q\@UWE?A5BT.T9CY!GO*_"H':,Q\@SWE?A4#M&8^09[R
MOPJ!VC,?(,]Y7X5 [1F/D&>\K\*@=HS'R#/>5^%0.T9CY!GO*_"H':,Q\@SW
ME?A4#M&8^09[ROPJ!VC,?(,]Y7X5 [1F/D&>\K\*@=HS'R#/>5^%0.T9CY!G
MO*_"H':,Q\@SWE?A4#M&8^09[ROPJ!VC,?(,]Y7X5 [1F/D&>\K\*@=HS'R#
M/>5^%0.T9CY!GO*_"H':,Q\@SWE?A4#M&8^09[ROPJ!VC,?(,]Y7X5 [1F/D
M&>\K\*@=HS'R#/>5^%0.T9CY!GO*_"H':,Q\@SWE?A4#M&8^09[ROPJ!VC,?
M(,]Y7X5 [1F/D&>\K\*@=HS'R#/>5^%0.T9CY!GO*_"H':,Q\@SWE?A4#M&8
M^09[ROPJ!VC,?(,]Y7X5 [1F/D&>\K\*@=HS'R#/>5^%0.T9CY!GO*_"H':,
MQ\@SWE?A4#M&8^09[ROPJ!VC,?(,]Y7X5 [1F/D&>\K\*@=HS'R#/>5^%0.T
M9CY!GO*_"H':,Q\@SWE?A4#M&8^09[ROPJ!VC,?(,]Y7X5 [1F/D&>\K\*@=
MHS'R#/>5^%0.T9CY!GO*_"H':,Q\@SWE?A4#M&8^09[ROPJ!VC,?(,]Y7X5
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M9+\G;>4V^#/+..N5%@4DM/(I";2L.NIP1.LA65+I51U- H% H% H% H% H%
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MUY(S;H-,1VBCJBJIOF("1JBV >*VNMDXU1;/>8F+'&8Z?%A3),G)S'<4QC!
M1EAD&!=(X[HD:"!#RCU$I:43K7T\:@VO;QF%(>B8K RLI(QXM^,)'<8 ([SC
M:.K' W3 7GA%451#JI=+DE[4$#QZ-GMR[*R>)D.+C)\;*.<M=;5U 61476UM
M8VR0A422XE=*#+#[DFL;7QN1@Q)N;QIQSD/Y7)2(45\! RNK]R;!-*)TBEK)
M06>W]XQ\\N,:6!)@2,I!>RC+,E 0ACLO RFK21<31P3'_#TV7A08Y'?.,QC.
M0??CR7!QV2CXAP&6T<<<D2Q9)OEBBW)%5\!]=_HH(:;[F>(%@#V[,#="M=KC
MXQ7(Z@</5I5]9 FK8HA=0A5=6I4LBCUJ"RB[H/*8(,OAL7)ERB=<C.8PR:CO
ML2&#)MT'E</2.@@5%45*_!1NBWH.;W/NUN1MQC**Q+@2<9GL=%R>/LI21=&4
MRJM"C*DCJ.B8:-*JAB2?30736Y5GSQVUGL3+PSV79>\/<-QLA? !NX".QS+E
MO"*Z]-^A%4272M@W[(R,N;A3BY%]9.3Q$J1BIDE4LKQPW% 75_Q.-Z#+Z56@
MF;LD/Q-JYR5%<)F2QCY;K+P+8P<!DR$A7T*BI=*#@GLOBRSS#&Z,_+@,> XR
M3&;:FR(@F\\Y)1YQ48(=1+I"ZE5$K=F:?PS^U,A@Y[[N#@,R<GDT5TW^TXMO
MD,.&:FJDXK:2><*DOZE!(\T-PSL?'BP,/**++:T9>:\T5B2%$D,ARUM=;/&X
M(?2*%4&N0W$R>[MV-9S-2\?"QK,#L9,Y!R"W'%YDR<<1 ,055)+J1HO104[.
M?*4QLYS=V;E0H<R!E'"DMNO8TIBL2(X17W!845U&R2N:>"=9>'HJBVS$S"<O
M:;$?.R!VQ.GRAE33R#[:N\N*^8@<DW$<THX*6'7Z*"LEY:7%Q.YBVWFY60V]
M&=Q28[)F\LCERG9B-RX[$I;JZV((WJN1:2(AOZ!#N/,"7+@;+SDR"^<:8Q$<
M-E]I=)@2)P45]"U!R.Z7MX#N5Q83TH$!?]1C, 9 Z*B')5FP\M;'K65SB2P=
M%TM5'J :] \RR.637IZ-5N-K^BH,J"GK=F4'E?F)*WYE/%]K,^7$3<V F-<K
M&3Y&1C-LJ;C-B*0RZ.L-!JME;NMNBRU)'&X?RNW[Y<.[ W+BH[6[,CMO!O[?
MSF+!\8SQ-/N]H XCDBP+RR_AZ34;C;^R87*)N7RR\QMS;;\RMQ2\2S'W5O4\
M6QC=N,RFC6/!Q;H**O/JHM*Z2(I%I6R="*M,&4S=/E!NS=FXO,9I60@XS<NV
M<5C<7D7'&S!9\ N8H$ DIH*$B(2J-K=%ZLP1)E\-YP;V8V-&R^T6,.WM7,0)
M.3,9[#Y2>SIRS=CB*H@M -R74NM;H@CTK3J='I/G5MW,;M\J]T[;V_'[7F<E
M#5F'&U@UK-3%;:G%$4X)Z5I*0Y3S!V9O)Z'Y9;CVYCF\GF-C/@_/PAO@P;S;
MD1([HMNEU-0JG"ZV6DD.0S_EYYH;FD^:V:GX!F),WCMN)!Q$%B8R]9]A7!Y#
MCA$"<P1L1GP;XV%5M>IA<NXSFR]SS,SY-RXT%#8VJ3BY\^:VG9T+'BPG!2N?
M711ZEZJ.:W1Y0[MW3(\V&FVFH)9Z;A<EMB6^Z),2'L2&M0>%O48@I)H74/TT
MF%RN9&$\Q?,G=VRLCNG;C>T\3LZ865FNG,9FN3)PM*T#<86%72S<E)3<5%5.
M&F@P\OME;BVWY0Y_;NXMJMYJ?.R>3D%MQR3' )<2;*U)_%52;%5!=2:EO=$3
MA2.Q*9Y*;1W?MF?GW)T25@MCRTC^ ;7R4\<I*BO A<]Q'1)Q&VRNB"VCA='H
MI ]AJH4"@4"@4"@4"@4"@4"@4"@S9_FA^TG]]2>RPM:Q=E!YM*VON*/A9^3Q
M<03W5#S\S-X>,;H #P.N&R@&Y>PB[');I?AP]-43V-KS\#,V@&+8[7$PT3(,
M9!Y3$"-Z2VV>M=:W57G@557T*O&H,9[&5W3F=O20P4C#2</,27+RDLHZ&#*-
MD+D9E67'"<1[5I/H#3Q^L@I0;L)L>!+P$6'NG'BY+C2<BXT"N+U0E37716[1
M(G6!07Z*"?@,/-Q^Z=S3G6>7C9WAZ0#U"6L8\?EGP155-*\.M0983%SXF[=T
MY.0UH@Y%8'8G=0KK1B.H.<$6Z6+AQH.EH% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H.?W'C)60R6V7X[(O,X[)K+E*2C_#;[
M%):0T0NE4-P4ZO'C0<=FMJ;B@8#<&T,'#[;MV0T$W;XHXVV45Q) ..P+&0]3
M@KD=>@456UL@A>CNL9FI60DJP]A9^/!!4DD2TC(VJHJ)I3E/N%=;_9J"+@\9
M,A[AW1.?91N-DI45V(ZBBJN"U"99)51.*6(%'K>J@^9;&3I.[]N9-AK5!@-9
M );NH4T%(!E&TTJMUNHKT4$&+M8)>Y]U2LWCF9.)RC<%N*KXMNHX++!@ZFE;
MJ*(J^G^R@J8F'W9BH.U\F['+)9';BS,=.B<T.T2<>\2-MOM..%I)Q!99<TN$
MBDBDBKJJBVB1\OGMP+GY>//&8Z% ?@XV/*4.U/.S#;-UPQ;,T !1D!!%+4MU
M543A>"OV]D]T8W:>*P,':\I<[!A1H9G.<CQX(/--"V1$Z#KAD"*E_P"&V2JE
M4:F=@/2'\'A,XA3\'B6).1ES.8K/:LW.=+4>ALD,4!#?(>/_ #B)=;5!;8+;
M"[7W1,\&B\O;>6B ])573<)O)12Y:%9PB)>:R0IPZ.4G1>@Z^@\YSA)C,COB
M!++EAGL0>1QYZ>!E%B+%D@B^D@06CT_9+Z%JB*Q_46Y]CXG:985R(Y+BP6LA
ME2<9."W% 6S-QE4-7'",1T@"MC8EZRHB74-3FSHF-RV:3+;7D9QG)37I\+(8
M]Y!4DE+K)E]LY#6@@*XB:)I(+<46Z4'78?"O8[<LF0Q$2+A!P^-@0FQ(=(%$
M=E*K2"BJJ( N!QZ/54%#,VSG7?+&=M\(NK,/2)+C<;F!Q!S)G(%==]/%M4+I
M^CIH)8)G]O[QW'EEPK^2PN6&%V5V";*R$>C,*V:$VZXWU%X6*_!>E+<:"/B]
MLYUF5ALI,C@W+D9V;FLI';< AB-R8+\=MO5PYA"BMB:BGUE54ZO&@DPQSNT,
MCG([&%D9F!E9CF4QLF&XP*H])$>9'D(\;>C28J0N)J%0*RV4>(:<-M;.0,EM
M>7-!IQV.N9EYER.5F6I.6=&0C;:$J$0H1$"+;T76UZ"D9Q&Y6,'MO:F6P4J1
M@(D?M.:"$<5U9,@'B5J&:./M_P )/YKJI=#ZH="FE4=-/<R[><Q&[X^%EO1^
MQR\;D,=J82:PCSK3C3J!S5 TNRHD@N71"1?0J5!5M8+<\QJ=*F8X8LF9N?'9
M8(PO-N*$&,D02(R1;*:(R2D(^G@-^E0Z-<7D/_<!,URO_"O!UAJ_J'_M':D<
MTZ;ZOJ\;VM0<I)V_N*.!A*@ORMOOYW)S,KC8+PA)D19.I8IHJ.-Z@0K*;>M%
M7A=%1%%:-#.U]QQ\-DO#,$S"D.;D@YC'XHI :.R1DBZN8XBD@F7).Z)J1"7A
MJ2@Z-]_*YS+XG(3\:Y@\%@#>R,V3D'&1,Y"1W&! $:<-.6 NF9N$J)P1$OQ5
M((.T\LN.8QYI$<.3O;+3\BRR5FRCPB W0><1;_\ -MM7'IU.(E!=[U=RDG$S
M<!B<4]-F9:(]%:E(33<1E7Q5I2>,C0D04+780)5M9.-!7 QD]M;E<D,XF9E,
M:YB,? :D0UCWYL)V3J0Q=>:5.JX*HJ72@E.8R5G]QQYV1QIM8-W"3(,AB23?
M,1V8^SJ:,6S/I;:7BBJGTT',Q]D[C+9NXXN3:%_<3L),/BD1P"1V'BQ(8AZE
M7J$^2JZ:$O!2X]%4=#"VFS*WAN'-9S$QI$>4./3&R)#;+Y)R62%U!U(1!8E^
MB]02-P#DX>Z<-FXF,D9*%'A9"+)&&3/,!R0Y%-NXO.-714:+H7A0:Y\6;N/)
M[9R#N)=CQ($R4<V/.Y"F %#>: ](.."J*9BB66]!1[BVKEV&-T0<% 5W%Y+P
MS(PH;!M--C+CR![6  1"@J;;3;GH$BO^M>]%MN1_+[IVOG,-$P4Z),D0W!C+
M,6*#;CBV1 0FWW+*O3UD1/IJ#M:!0*"GK=F4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4&;/\T/VD_OJ3V6%K6+LH% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!KD2&(C#LJ4Z#,9
MD2<>><)   %+J1$MD1$3I5:#,#%P!,%U 2(0JG0J+Q2@T09\+)Q6YV/?"3#=
MORGVB0@+2JBME3U*BI02*!0*!018^1@2T<6-);=1IXXKBB2+:0VMB;7_ !(O
M2E!*H% H(\2?"G\_L;X/]F=.-(Y9(6AYOZP%;H)+\4H$V!#R,=R+-9%]AT#:
M,33]1T5 T1>E+BJHMJ#.+&8A1F8<4$;C1VQ99;2]A;;1!%$OZD2@VT$=Z?"C
MRHT%]\&YDS7V5@B1#<Y2(1Z4].E%NM!N<<!ILG7"06P12,EZ$%$NJK08L/LR
M66Y,9P7H[PBXR\V2&!@:7$A)+HJ*BW14H-E H% H% H% H%!BXV#H$VZ*&V:
M*)@2(HJB\%147I2@^Z14D+2FH45$*W%$6UT3_10?:!0*!0*!0*!0*!0*!04]
M;LR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@S9_FA^TG]]2>RP
MM:Q=E H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MQIG)SF,5$5IHWE65*54;14!%LBJGUEX)074N7$Q\5Z;/?;BPHXJX_(>-&V@
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MC$EBK9$1IMQ.CU^FJ)FRUR1;PWFN6!@)^O&ZQB$9LZ>RK:RN")7]?"H.[H%
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M;G;DAKCN7=.5RE=YU[6OJNG3?HH+.@4"@4"@4"@4"@4%/6[,H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H,V?YH?M)_?4GLL+6L790*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0* J
MHB77@B=*T&ME]F0".QW!=;7@A@2$/#Z4H#3[+[?-8<%UKBFL"0ANG3Q3U4'T
M76B<-H3%76[*8(J*0H71=.E+T%5N'.#AMM9/<,40F) BO2FP0[ XK(J6G4E[
M75+7H+1M]IPB:0Q5X$%7&D5%(=272Z=*7H(V/FR)G:NTP7H/9Y+D=GGJVO/;
M;MI>#ED5@._!"L7#BB4$IIYI\$<9<%QM;HA@J$-T6R\4H/@2([@F;;H$#:J+
MA"2*@D/2BJG0J4%/$W/&RN'AYK!QGLE&F.- C;6@'&VW7-!.F+A#802Y$GUK
M)P1:"X<?9:( =<$#=72T)$B*2^H47IH,G'&V@)QTQ  341$J(B(G2JJOHH/H
MD)BA@J$))<23BBHOI2@^W14NB\*#7(=)EAQT&R>< 2(&05$,R%%5!'4J)=;>
ME:"KC[BAG)QV.F@<'+9"&4_L+Z@ILBVK0N-N$!$.L2>$;"JWXVNB4&G;^XTS
M*Y(9#813A9.5C&!UW5Y(MNNB*B<5OT)>U!9Y2<.+QDW)$"NC#8=D*V*HBDC(
M*>E%7AQM08XK(CE,3"RPMJT$R,U*1HE12%'@0]*JG!52]J"AVWN;<6X(V.R:
MX!N+B,BT$@7RG"XZ#3HZA56Q:1%7BETUT$G:F\(.ZQR ,-'%FXV2Y'D17;*6
M@7#!IX53I;=0%45]:$/2*T&G$[T8RF3B8XXA1DG)DDBO&X!(;N)F+%=;TIQN
M26='_#?U4&O<V^8^VY,J*L%V8L*$W/E&V0B()(E!%9;52_6-5<)/H;7UT$T-
MU15WBYL\F2!\803FI:DG+<)3(391.G6(Z3^E%^B@QR.ZX\#=>&VFD<WI65:D
M/N/B0B$<& 4@UHO%5<43$4'[*T&&8WC$PVY,-MUU@W"RNOG2Q(4;BWZK',1>
M*\]Q%;"WZR4&C=&]VMMS(\$81RWGR9;4M:-@CLHB%AM%L2J1JV?HLB)Q7HH+
M_&Y*-D\>SDF+A'=%25'+"0**JA"7%4115%1>-!S>/WJ_D)NWVQQ_)@[B6<Y#
M=-Q>9V6("&RZH:4MSD74@WX"J>GA0=:CS*NJPC@\]!UJU=-:"JVO;IM0#>9;
M( <<$2<72V)$B*1)Z$OTK09W1;HB\4Z:#6[(88!7'W0:!%05(R04U+T)=?2M
M!#R>;Q^(=@,SG.6>1D)#C):]W5;-SCZDTMEQH,XTY]^?,B'"=9BQA9*//,FU
M9D\Y"4D;034DY=D0M8IT\+T$H'FG",&W!,FUTN"*HJB739;="T'-KNJ6.3P&
M/DXMR$69.>#H23#FLC!%2$K-*8JCB(A)UN"+QX\*"RS>9+&821FX3'B+44.>
MXTR::C8;6[JMKQ0B$$(A']94TW2]!81I+$R.S+BN([&D +K+H\1-LT0A)/H5
M%O0;:!04];LR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@S9_FA
M^TG]]2>RPM:Q=E H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M**61$LG"U!):QT!EJ2RS&:!F8;CLH!!$%UQ[@9&B)Q4O2J]-!F$.(W#''@P
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M^Q([L_\ #H'B4?[$CNS_ ,.@>)1_L2.[/_#H'B4?[$CNS_PZ!XE'^Q([L_\
M#H'B4?[$CNS_ ,.@>)1_L2.[/_#H'B4?[$CNS_PZ!XE'^Q([L_\ #H'B4?[$
MCNS_ ,.@>)1_L2.[/_#H'B4?[$CNS_PZ!XE'^Q([L_\ #H'B4?[$CNS_ ,.@
M>)1_L2.[/_#H'B4?[$CNS_PZ#-K)1^:'4D?63_\ 9G_7_P!'4GL0M?$XWV)'
M=9'PZQ:'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<
M;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX=
M\3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?
M#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CN
MLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8
MD=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<
M;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX=
M\3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?
M#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CN
MLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8
MD=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<
M;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX=
M\3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?
M#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CN
MLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8
MD=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<
M;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX=
M\3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?#H'B<;[$CNLCX= \3C?8D=UD?
.#H'B<;[$CNTCX=!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>tb_micancerseek-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_micancerseek-4c.jpg
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M%!04%!04%!04%/_  !$( M<#M@,!$0 "$0$#$0'_Q #/  $  @(# 0$
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M_)>/$U*WF)R:$9,I<C&;!52T(:]>4=1L%VMWD@OZGV1_UG]62/2*BM.?N?\
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M F]+.@]!_O"()+/#I0[#AO.Q>EQ=Z[M_Y5(&L_*WREY+YN5;D5;*A2Q.#;;
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MN+K*$7GR:_<CCN+8"MQ+FT$YU*#=WCLG6%I2&'748Y0=V?0.P2'7IHVG353
MW#A_W%>7&?SV,X[AY;EB]E)QK0F]=XH@,V?3>\A"^COT]5G3"O&7F!F\GR/G
M&;R><E-[9W9HB$]7>&**1P&(6]#1BVUF^95%Y\VL-Y,X+C6$J>75_P 5S\LK
M27[[322D]9HG;^(+[8XR(W9V%@8FT?5!>/V??_E#EW^[4_\ UYE)'G3'?_EB
MI_O,?_.,J/8?[N/^'.,_[Y@_[-94A6JOVLT?%,]RS&;MGON"FK;_ ).^E -?
M[M4E&F82R'$N21'8@[O*X.Z)25Y?\L].5G<"_P#.'1U1[7QG[F?*B]CX;5O)
M34+LC#WF/EK3G*!OIJV^,"C=M7[=RF%>3/./!6^/>9O)J5H"%I[TUZN1=AP7
M#><"9_3T/1_G9V51/X3@/D]E\=#<L>998RR0"4]&WBS&2(W;J.YI7$]'](NZ
M#<'D)Y;<*H\CN\KXER\N1AC(3I3Q>X24Q$[(ZL3%(;N3:"_8/]Z@\J8[_P#+
M%3_>8_\ G&5'Z?K%778GBJUY;,Y,$$(%)*;]C #:N_\ <S(-&83]U?EOE*[C
MG*]W$3/J,D4D/O4+L_R%%J[].W4&5P/.WG;R+RZY-R6"_P"7F/>G7[EVR,PP
M^ZPSSN6K$$/31V;ZQ:-N^3IJ]18N.\2SF0_;?R3(QQ&]2+,19.M$S/Z\-2-H
M;$HMZ1'<^K_^[?Y$&L.(8WBN5R;T^6YJ7 4"#6+(157NBTNK>K( &),+MKZP
MZ_V>E!L.UY;^2]2+O3\UADUTT"'$S2D^OS#(^G]Z"6_<%Y<V.#8#@\$$Y9#&
M4*MC&G?V=V+SE.=H=18B8=[2'M]9_JNI H/!^,^7G(:T@\IYC)QG)@;M'%)0
M*S7DCT;0FE"1MKZZZL3-\SNJ+[Q_R?\ *O-\DQ^ POF5XCEK1N<-:+%RL)M
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M!_\ C&M/5%VDD-]=NYR?:+^A0>=H2R'$N21'8@[O*X.Z)25Y?\L].5G<"_\
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M1F]UC[1+7[:91MGS4\MJOFCQ^M@+>0DQT=:V%UIHHQE<G".2/:[$[=/XFO\
M<HJO>5/D70\K,S=S%3,S9$KM7W0H980B$6[P9-VHD3Z^KHJ.[S)\A.&>8ULL
MO,\N)Y 3,TN0IL+]]M9A;OHR;0G9FT8F<2^?1DR-9P?LYJM-K9Y?(=?7ZD=
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MD5.] [1V:Y%IJ\9Z.VCZ-J),XO\ )T90:-L_LZIE/NI\NDCK:] FHC)(S?\
M*&<&?[JN4;+\J/(_$^5=VYDZF6M9*]=@:M*T@A# P,8GJT8[GW:CT=S[$4\R
M?(3AGF-;++S/+B>0$S-+D*;"_?;686[Z,FT)V9M&)G$OGT9,C6<'[.:K3:V>
M7R'7U^I'0$#T_P"4]@F_T)E%W\Q/V[X[S#S=?-W,_8J35Z4%#8, 2;VK[O7=
MW(>I;NO1,JLW%_*FIQGRWR7ES%DY;%;(Q7(2OE&(R UX'!W8&=V?;KKVJ"A\
M5_:UB>+<DQ7(X>1V;$N+LQ6Q@*O&(F\1,6UWWOHSZ*Y%P\VO)FCYKS8F6YE9
M<:^*&<0:*(9=_O#QN^NXATT[M!E>4WE-3\J:>3IT\G+DAR4L4I%+$,6QXA(=
M&VN6NNY05?GG[9.%\OR,V8Q=B;C^2LD\EEJX#+5.0NKGW)..UW?MV&S?-JKD
M5_B?[4H.-\@QN?FY7+8EQEJ&Y#%#3&#<<!M(S.132='=M'Z)E$KYC_MCP7-,
MW9Y%A<F6#R%XWFO0O"UBO),3ZE(PL<;B1/U+J[._71,JBZO[1.,1X:6I;SEJ
M;-R&!#DAB$(XP'7< P;WUW:]2(W[.FG75E%\\IO)BIY46<I/3S$V2'*!"$D<
ML(Q,+P.;B[.)%K]=T5"^9G[<..>8&8EY%2R$N$S5K1[A!$UBO,0LPL;QN0.Q
M:-U<2T?MTUU=V1\X%^WJMPK$<GQA9^2\?)L>>,FE&L,+0C()CO$7DDW.V_TN
MF1%\5_:UB>+<DQ7(X>1V;$N+LQ6Q@*O&(F\1,6UWWOHSZ)D;/\P?+/BWF5C0
MH<BKEWU?<]*_ [!9KD>F[83L[.SZ-N$F=G^35F4&C)?V=1/;UAY<0T===IT6
M*5F^3<T[,_\ ;I_<KE&X?+7R;XCY8QR38D)+F:G#N[&5M;2F<'=G< 869@!W
M;71NK^EWT9157\R/V[8WS&Y58Y1:SL]&6>**+W:. )!%H08-6)R9^NFJN1=>
M(^7=;B?E\7 (;\EFN\-N#WXHQ"1FNE(3OL9W;U>\Z=5!JW!?M0P^#S>,S4?)
M;,TF-M07!B*M&+&]>09&%WWOIKMT5R)KS)_;AB/,'D5KE#9ZWC\E<:-IHSC"
MU W=1C&.P=8R%M!;5MS]4R*U@_V@\?JVHYL_R&SDJX%J5:M --C9O0YO)*^C
M^G31_G3*/0^+Q>/PN.K8G%5PJ8VG&,-:O&V@@ -HS-_]+OU?TJ*RT! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!Y[Y_^V,N<
M<ORG*FY.U%LE($GNON/?;-D8QZ;_ '@-?JZ_597*-R<(XT_#N)XGC#V??'QD
M#0>];.Z[S1W?79N+3M^TZBK @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M68JDHM)#6@;ZHE7@D::7=]>4S9M.U!M50$! 0$! 0$! 0$! 0$! 0$! 0$!
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MJ6LE/;>Y/'CKEJ#(7L4.SW>:W58-AN[BYLS]W&YBQ:$XM_K;@LR @(" @("
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M.V,T4NA&X,VK1;?XG>_5<.K.@L4S08;F7)"SV<O8$<K/7NXVU$T T[->.G%
M\;2202Z21'$6X')NA"3-ZSH.W'8K%T.2<$'#237L8]?/VX;TX[B<KTD$Y$Y,
M ,.XI"VMM'IT9!A<GQUVWF^;%4H27QA;C5Z>A&&I7(*-F6>>$-VC&3Q@[,.O
M5]!]*"QYOEW'.0<7SM/#7AMW),3>E&M&$G>L(PD+L0.+$):NS;29B^900_"H
M#'EF%E. A<>%8Z/O"C(='[]W<-SMT?IU'M5&%9AFKWLIERHRV<=A^9AD;\,<
M1&?NSXF&#OP!F<I.YDD&5]C._JN[:NR#.O<AQ/(O,?A$F&-[=:N&6[R\,9C"
MQ258W:(3(6U)V]9V;LTZ]=$&SE 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$1E:?(9[44^'RL-.N(/'-5LU/>1
M(G)G:02&6(F=FU;35V=!\XY@1X_3FA.U)>OW)Y+N1O3,PG-9ET8B81]4!81$
M !OJB+-U[4$P@(" @^:,SN3,VK]K^E]$'U!\=F)G$FU%^CL_8[(/J @(" @A
M;_'8KW(,+GN_*(L,-P KB([)/?0 '=W[6V[-6T03.C:[M/6?H[^G1D'U 0$!
M 08>4KW[5*2'%W&H77<7CM%$-@1VDSNSQDXZL3,X]K((C'\<R#YL.0\@R(W[
MU: ZV/KP0-6JUAG<7F,1(Y#(SV"VXCZ-T9FU?4+&@(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M07M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MHVG1FZZA94! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M[&#R1@;/#6B'(]V3&+V!%F-V<69NK]>C:*"50$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MNS_Y3$"]"#%Q/$[\/*\7D<A4BDQM/C<&,(Y'"1QNQSB;BP]?\K?6;H@S;O%
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MW<93R$^1C:"WE<A:R156)I.X&P3;8W(=1<F$6<MO3<[Z:]J"Q(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("#6OFISW.<=M8'
MB/#H(;',^43E#1.UJ]>M!$S/+/(S=7VL_1OF=^NFC]?V_B4V1?9MF8IKCKCQ
MGX.)[GSMFJ::M,1.S9/3/A$><L>#CWFAQFM>Y!F.>^-0UJ%V>?&EC*\$7?C
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MD+9(XCO,+=^=<2"%S].P3(G9O[2=09" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MQ+5FCJ3-7M&!##.0=Z,9NVC$X:CNT?KIKU043 \DR.)X5R?,YBW)E;& N9<
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MQ1S SL$@L8L3.):$VK:L_5G7'F,3AW8G,9<U%$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M><]PW=G=G?\ V8?5)F^9]=?C\;7KT4O_ ./NOF9^Y/EZ5_Q;7)Y>S;R;Z_\
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M5]JD4S-L>=IS/XRDEXO<0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MV_/T?0+@@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M0R-R=_XC>A!QQQXKB=GE'&N=W*MG"3.'(0LWXHXZI1W9FCG HR9XV8+(L?\
M;*S]J"[<HQ.-S&'D@REEZ,-<X[<60 QB.K/6-I(YA,V<6<2;_,VCMJSZL[J"
MB8W%1\VY-'8N927D> Q%.[3GOL 04)YLC&,!PPC"S-(XQL;RRB3LSFPCIZS-
M1T2T"S5[#\0QG);'(\;C[E6Y=<>Y*&M4Q\K2@%NS"/\ &E,XP (W=B+J9L^W
M5!8\Q3R'+,M1RG'LEC;F)P<TP%1LC+* Y: ]CR&41LSE VYA!V]4WW=K#I!
M<(PN0S-/D0YJQ7K^Y<DO7*ENAWD<T%^"5]TG\9R%PT=QVDSLXN[.J,,*%/N<
M?G+\T@\9RN5*O+;F)P*6A,,TSSSD+"PC=MC"Y?5'NAB#HW1!=O+PI7Q%Z,#*
M7$0Y*Y%A)")Y&>@$FD>PW=W(&+<,;Z_59M.FB@MJ @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @^$(F+B;,0OT<7;5G9 =F)G$FU%^CL_8[(/C1@+L3"S$S;6=F;7;\G]B#ZP
MBSD3,S$74G9NKZ=.J#A+!#.+C-&,@NVCL8L3::L^G7YV9 F@ALQ'!8C&:"1M
MIQ2"Q@3?([/JSH.4<<<48Q1"P1 S" "S,(BW1F9F[&9!UUJM6G$T%.".O"SN
M[1Q (#J_:^@LS(.<<4<3.T0"#$3F3"S-J1/J[OIZ7=!][J-Q(-@[#UWCHVA;
MNW5O3J@XE!"<+URC$J[CL>)Q9P<---NWLTT]"#F(B B "P@+,PBS:,S-V,S(
M/J @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(-?^:OFG3\K,?C[]O&S9/Q"8X!B@,8R%HP<R)]S/
MJS,NI[?[?/+M,1/;B'']S]SKPJUM-9MW3Y,GF_F;AN&<)@YL41Y"G>]V;&UH
M283L/<9C!A=]6^IN/^Y8<7@WW[IU>$QG/PP].9[CKX_'C=^Z)QB/7/\ PZIO
MB')8.7<7QG*(87JP9* ;+02$Q/&SZZLY-HSZ:+7Y.B=.VVN>O;.&UQ.1&_37
M9$8BT91/FAS>;R_X1?Y;4JA?DJ%7$*YFX ;3S!%KN%G[&+5>_ XL<G=&N9QG
M/Z0UO<N9/%X\[8CNQC]9PL]&Z-K'T[LNV(K444FQWZ,4HL6UG?37M6E>N+3$
M>3?I?NK$SYPRU@]'P2$VU!V)M7;5GUZMT=#+XT@.;QL3/(S:N&K:LS^G17"9
M?2,0%S,F$6[2=]&90F<#F#$(N3,1:[1=^KZ=NB8,OA2 #BQDPN3Z#J[-J_R,
MK@F7)11 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M?X4#^H,/\2WW3_"@?U!A_B6^Z?X4#^H,/\2WW3_"@?U!A_B6^Z?X4#^H,/\
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MF])$+$9?9';]ID$L@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M1MM];J@W"H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M<=1#75M606]M=.O;Z4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MT35'L1--WCZ:#LW;MSZ]FB"20$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MK]W_ $[*^WN0TU]^C^9!#R6/!?,^]G8Q<:+V<;QN\PCJ 06ZG>UBT;1AVV"
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M^B"20$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M$T#L3312%/JX[A8P9PWMTU;5E1D28O,P5N?\?;&SRR9WWZ_B[P=W[K(UFC%
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M',5BN\Q_((J%?&7 (>XJ15(@KF,VXMP]TP=['M8MSEIVJC9Z@(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M @(" @(" @(" @("#XQ"6NCL^CZ/IZ'0?4! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M9;_!D#NP^RW^#('=A]EO\&0.[#[+?X,@=V'V6_P9 [L/LM_@R!W8?9;_  9
M[L/LM_@R!W8?9;_!D#NP^RW^#('=A]EO\&0.[#[+?X,@=V'V6_P9 [L/LM_@
MR!W8?9;_  9 [L/LM_@R!W8?9;_!D#NP^RW^#('=A]EO\&0.[#[+?X,@=V'V
M6_P9 [L/LM_@R!W8?9;_  9 [L/LM_@R!W8?9;_!D#NP^RW^#('=A]EO\&0.
M[#[+?X,@=V'V6_P9 [L/LM_@R!W8?9;_  9 [L/LM_@R!W8?9;_!D#NP^RW^
M#('=A]EO\&0.[#[+?X,@=V'V6_P9 [L/LM_@R#DS,S:,VC?(@(" @(,:S2CM
M$)'+-'M;1FAE.)G_ +6%VU0='@\/Q-O]3-^) \'A^)M_J9OQ('@\/Q-O]3-^
M) \'A^)M_J9OQ('@\/Q-O]3-^) \'A^)M_J9OQ('@\/Q-O\ 4S?B0/!X?B;?
MZF;\2!X/#\3;_4S?B0/!X?B;?ZF;\2!X/#\3;_4S?B0/!X?B;?ZF;\2!X/#\
M3;_4S?B0/!X?B;?ZF;\2!X/#\3;_ %,WXD#P>'XFW^IF_$@>#P_$V_U,WXD#
MP>'XFW^IF_$@>#P_$V_U,WXD#P>'XFW^IF_$@>#P_$V_U,WXD#P>'XFW^IF_
M$@>#P_$V_P!3-^) \'A^)M_J9OQ('@\/Q-O]3-^) \'A^)M_J9OQ('@\/Q-O
M]3-^) \'A^)M_J9OQ('@\/Q-O]3-^) \'A^)M_J9OQ('@\/Q-O\ 4S?B0/!X
M?B;?ZF;\2!X/#\3;_4S?B0/!X?B;?ZF;\2!X/#\3;_4S?B0/!X?B;?ZF;\2!
MX/#\3;_4S?B0/!X?B;?ZF;\2!X/#\3;_ %,WXD#P>'XFW^IF_$@>#P_$V_U,
MWXD#P>'XFW^IF_$@>#P_$V_U,WXD#P>'XFW^IF_$@>#P_$V_U,WXD#P>'XFW
M^IF_$@>#P_$V_P!3-^) \'A^)M_J9OQ('@\/Q-O]3-^) \'A^)M_J9OQ('@\
M/Q-O]3-^) \'A^)M_J9OQ('@\/Q-O]3-^) \'A^)M_J9OQ('@\/Q-O\ 4S?B
M0/!X?B;?ZF;\2!X/#\3;_4S?B0/!X?B;?ZF;\2!X/#\3;_4S?B0/"(?B;?ZF
M;\2"00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!!U6;5:E7EMW)@KU(!>2:>4F", %M7(B)V9F9NUW01^*Y/Q[.2G!B,I6N
MV(Q[PX891*1@U9MVUGUVZNW731!TP\PXK/?\,AS5,[[R/"-<9XW)Y6?:\;=>
MI,_3:W75!*2WJ4%JO2GLQ1W+>]ZM<S$996B9B/8+OJ6UG9RT[$'>@P\CE<7B
M(1L96[!1@,M@R690A%R=M=&<W9G?1D'&SF</2KPW+F0K5ZEAF>O/--'''(Q-
MN;81$S%JW7H@^T,SB,H1CC,A6NE&S/(U::.9Q9^C.^QWTUT0==W/X+&S>[Y'
M*5*=C:Q]U8L11'M?71]IDSZ/H@[ILKBZ\U:O8NP16+G_ %2(Y0$YM?Y;.^I=
MOH0=Y6( FCKG((V)6(HHG)F,A#3<[-VNS;FU_M9!V(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M\MGE[R4M&+3'SOM)F(7]7L=GZ.S^ED%5OV#XS@^4<!OD_N!8;(7>)SR.[[Z
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MY&_SNN)R=]MVRVRWC:7T'%X]>/JKKKX5C^/S32UVT(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @AN6X23DG&<K@(9AK2Y&M)6"<A<Q
M!Y&TW.+.VNG]J#%YIQ2/EN!EQ@S^YY.,3/&9$1W%7LE$<6_:_P!82 R Q?ZP
M$[(.C%<1FQO(J6;>T!PU,'%A'KL#L[G%*TG>,3N_31M--/[T&?5P4L?*<CR2
MU,$KSU:]#'Q"+B\$$1'++J[N[$\DAZOT;H(L@C\EQ[.PYC*9[B]VI4NY.E7K
M2178#FA>U4F=PF+NY )_X,AQNS/Z ?T:(+'?]^]SF\,:)\AL?W=K+DT._P!&
M_8SEI_8@J;\&L9JIEY.7WVMY;,T9,6Y4A>"O2J2MJ4=83<W=R/0SDD=W-Q%M
M&$6% /CW+LRU#'\GOT9,71LP7)Y:4,D=B[+2E&:#>)NXPCW@!(; Y:Z;6=F=
M!(S!SN.-GK38J>7WBRY#+'8B;W4B_P"C,Q"1^N+?[3U="]&U!V<>P-S$19*]
M=LQW>0Y>;WN[8$.Y@8QC&***,6<B:., $6U=R?J3]701G]'7X<7CY:EV)^4T
M[Q9>>[-&[P6;D\9PSB8L[$,;QR/&&G4!$>W31PF.,X.3!TK V9AGR&0M39"_
M+&+A%W]@M7&,7=W8!9A =7U?35^KH)I 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M&T<2'=!ZQ2[2;5GG,F].UE1<<SR6"C):QDF$R60D:-ABBKTRFKV>\'Z@RO\
MPF[=I=Z0LW]B@J&&X_F."0\2REFK+D1HXR;"YJ*FQ69JT4TD=B!X@%MTD<!
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MKRSX][\3UY"DK$[2P'$7KA(P:2"Q-ZPZNWU706- 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M_L0;@4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!4?-+7_PYY/IV^'6-
M&^5]CZ(.H\9R/DV0PT^<I5\3BL-9;(-!'8>W9L6HXSCB;<(1@$8]XYE]8B=F
M;HVNH57B]7E.?X%8XS2J5J>*OS92I+FIIWE/W:>_9"9XZP@W\3:1,.\]K/U?
M7ZKT8&4]_P F'),IAL/?NV:,U2MQ6U!%!+ S<;D>1M#*42=I;/?QGZO4=.U!
MM/&329J3'<FH9(WP5R@QQX[NX]DA6'"4)G/3>Q".H[==.ORJ"'MPY?!<PNY^
M#&39C%Y>E5JG[J<7O-6:B<SB/=S'&SQ2-/KJ):B3/JVA:L&OZ#9._=:WB:T=
M+EMSDN4R&"%R[^A'5K00TKY62'3>!%J+]UZW>DVU]&)U1=>%GD(^4<@K\H$!
MYA-%4G,JKZT),8!3!7]V8OXC;3[WO6E];>^K/L<5!1?,/,QYC$\BS&8AO5?<
M .CQ['34+8@ ]\ 37)#>+9WDVCC%ZWJ1=G60F5%EY'4N%5Y5DH(Q_IOE%2 K
M.2L,5>2C'!$]>=Y()6&4G[MMT0B.KGT?3HZ#I@SV?Q)<DY)[I"TE(J=G.5K+
M.]AXI0:0:L1B3"'NU8P?5Q+O)B/ZK/J@VNH" @@>/X:Y@[>6KM($F$M6BOXX
M-7[V&2T[R68G;339WKO(#L_^=VTZ-J$\@CKN$H9#*8O,6&-[N(*<Z3B;B+/9
MB>(]PMT+U7Z:]B#!S/$Z>7OAE8[ES&91H'IR7,?,T,DM9W<FCD8A,782=R M
MNX7=]KMJZ"2Q&)Q^"QM;$8J%J]"J&R&)G<M&UU=W(G=R(G=R(B?5W?5^J")H
M\,HU,E!E;-Z_D[5/O?<&OV'F"N\[.)E&V@^LXDX;CW$P]&?1W0<\=PS!XML,
M-:.1QP5.;'4!DD(V]WL=UO8V?Z[OW0]7_P#I01,WE;QVSCBP5FSD)N--_L,&
M=HO<X=KL4; S,Q[8W9GC S(!T;1NC();)<0H7\F69K6K>*RDT806K..F[E[$
M<6[NVF A,#<-Q;"<=S:]'T0?+G%&MUZE=LUEJ[587KE)!;<9)A+34I2<7U/I
MT,=";T.@S#XU@SX\_%7I@V >M[C[DSNPM7V[-K.S[M=/\VNNO775!&4N"XVM
ME,=F[EZ_E,KBADCQ]F_8>1XHYX^ZD%A 0!]S:;B(7)W9M202&&XW3P5F[+0G
MLM6NS267H22[ZT,LYO+*4(.VH;S(C=MVFKOHS((Z_P %I7<Y:Y"&4R=3(VXX
MX#*M9V@$,+=(XQ("V"[ZF3#IN+J_H0=]SA]*]6QH2WKHY+$D94<P,S>_#WO2
M02-Q<3$VT8A,'%]&Z:LSH,K%<;H87%V,90DG K92S6KYR.=N6Q.VAS%(3/J?
M9ITT%F9F9F9F0=4W$L0>+QN+@:6F&(<"QMFL;QV(2 'C=V/KKO$B$]S.Q;GU
M02&)Q5/"X^'&T!)JT.YV>0BDD,Y"<S,S)W<B,B<B=^UW00S<%P;U,QC)GL3X
M7-/*=G%2RN5:([)O)*4#-H4;E([R>J7JD^HZ(.-+@N,KY/'9J[=OY7+8EI!Q
MUJ_8[PH@FB>*06$! 'W"[;B<7)W9M709?](X;^F[W%-LOA&0:X-D>\+O';(2
M22S:'VMJ4I:?(@S+^$H9*3&2VF-SQ%EKE/:;BS3##) V[3ZS;92Z.@@;/ESA
M+ W*@VK]?"9&22:_A*]EXZ,Q3NY3-M9MX#*[D\@1F(EJ^K=703</'\97S39Z
M"-X[HT@Q@"#N,(U8Y'E$1C;U6=G?M^3H@[,IA:.7DQ\MUC<\7;"_4V$X:3QQ
MG&SEIVMMD+HZ#Y)A*$N;#/F)%D(ZDF/;4G[MZ\T@2DSAV.^X&ZH*Z'EE@&K5
M<?+9OSX?'S1V,7C);1/7J'!(,L7=Z,QNT;CM 9#)A'HVB#.R'"<=<R-K+4[M
M[$7KXL.0/&V'@&PX"P"<@.Q#W@BVUI!9CTT;71FT#(EXA@K)Y,KT!7!S%.#'
M9&.R92!+7JM(P,[/_F_BEJ3=7_N0?,3Q=L19CG',92Y%"!1Q5;MIYXF$].W4
M6(W;3U7,B=!&T^$A0NX"E5)@XMQL)9Z58S*6>2_-O 3D<F^K$$DFWKJY'KTV
MMJ%P0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!I3SWY!E<1G."8ZIR6;B^
M*RUJW!E<A"81B,0- XF;R-HVW<_:^G5?0^TZ:7IMM-(V36(Q'YOE_>]]]>S3
M6-DZZVF>Z?R96#Y?QS@G'<SRG(<]M<YQ,,M2"<HRKV2J'*9 .C1./U]S;M7_
M ,O18;>-LY&RNN-4:IZ^L9_-Z:>7JXVJVVVZ=U8Q'E./R36!\Z^)9_DM7C,=
M;)49LF!282]D*A5:F0C$7+=7(WW.+LVHN0CK_;HRU]WM>W7KG9FL]O[HB<S7
MYMK1[QIV[8UXM7N_;,QB+?)!<Y\Z>//C.68/#ULM;>A4MT;7(<?5.3'4[I0F
M "=@"8A=C=FWL.C/Z?2MGB>U[.[7>TUC,Q/;,_5,9]&IS?>-79LI2+3VQ,3:
M(^FLX]?FZN$^9F+XCY3\+L9^2[E<[F(3CH8^H!7<C<E&4M=@D3.^FHMJ1?(R
MRY7!MNY6R*8K6L]9GI6&/#]QIHX>J=F;6O'2(ZVMU6;'><O%+^$SV7D@OT+?
M&8^]S6$NU^XR4 .VK/W1%M=G]#L?]NG1:=_;-M;TKF)B_P"VT3],_BWM?N^F
MVN]\6K.O]U9C%H_!$-^XG@ VJPV8LI5Q5Z(Y,?FIZ$H4K1Q-J<<!=3,V?U/5
M#3=TU[%[_P!EWXG';,QXU[NL?-K_ -_XV8S%HK/A::SVS\(\Y]/#Q3G%O-WB
M_)YLS4EANX&_@87MY*EFX/<IHZC-N>=Q<BT!FT=]=';5NG5:W(]NVZHK/2\7
MG$36<]?1M<;W73NFT3$TFD9F+QB<>K&Q'G3QK+9#'52QN6Q^/S4G<8/-7Z?N
M]"]*3.X!%(YN[/)I_#WB.[T+/9[7LI69S69K^ZL3F8^?R\WGJ]WU7M6.VU8O
MTK::XK;Y?/RSXJMP7STM9SD'*JN<P^1AQF.EG.B08\P:I5IP2S&-TW-]DQM'
MH(O_ )NBW>7[3&O72:6KFV,_5XS,Q'T_!H<+WJ=NS9%ZVBM9G'T^$1$S]7I/
M3\WSE'G/Q/E7"LQ8P^0SF'H5*]2S/R#'UF$H99K$0>[ 92"SRMO;O&$M&'7U
MG[$T>V;=.ZL6BEIF9CMF?A/7Y>AR?=]._1::6O2(B)[HCPS,?3X^/K_-<LWY
MEU^,1U8/Z?Y#G8VI0W)\CCZ#3Q!"8_6EDWQCOT9R(0[%H:N#.W,]]*=<8FV/
MR=/=[C&F(CLV7Z1.8KGI\?#JI?-^80<@Y1Y.YGC.1F?!YG(62)HC.(9@'N1<
M)09VU<"8A<2['U70XO&G7JY%=D1W5K'^/@Y?,Y<;=W%OKM/;>T_CX>+>:^;?
M5B @(-:\HY/E>.<\>\]B23BM#$UILWCV'<,<-FW-&5X-K;M8-@O*W8\6Y]-1
M03EK,2U^?5X);O=X)L!:OS 1"U=BBM0,TSD_V0(NNNFCH.,7F'0>&GDK6-OT
MN.9&6.&GF[$0!7=YR8(3D!C>6*.4G%@.6,6]9M=NJ#'P7,,QD.<<CX]9Q=AL
M;CCIA4G88&:)IH2,SE+OG)Q-V;9M'73M9D&-YD\ARO'[O'[6.G(*E:2WDLM7
M#1WL4*,+/,'7TB,CR-\XH.[S0SMZGQKW+C]WW7,Y897J78G9RAKU8#M3S#T=
MGTCCV#_K&*#"RF;&[G\-!GLI8PW&<ABXK5&:"9Z<-K(RN_>12V@<2%PC<"CC
MW#OW$_K;=&HDL@5["\EX/A*V0M2TISR(7/>).]DL#%5*0.]-VU+:75E!W^:.
M2O8C@F6R6-M'2N5V@(+4;LQ +V(Q-]29V9MKOK\R##Y[S7#5N&YV;"\AIQY>
M*G,5,J]J IAF8?5V-N?4M>SH@O0Z[1U[=&U0?4! 0$! 0$! 0$! 0$! 0$!
M0$$=GL-4Y%AKV#ON8TLA"=><H28)&"1M'VN[/H_]R"09M&9F[&Z((S"X&I@<
M0V&Q\DK5Q.Q($DA,<K':F.<GUTTZ%(^WH@[,'AJ7'L12PF.$AI48AABWON,F
M'M(WT;4B?4B?TNZ# PO$ZF EKMC;EN/'58[446+*02J-[W9]YW;=N[6-W>./
MUO5#IU[4'?G<%/G!B@\6N8ZBS$UJ"@4<)SL6FC%-L*0&;K_LB%^O:@Q+O"\1
M-7Q,6,>3#SX%G'#V*&T"@C,6 X]IB8'&;,V\#%]=&?ZS,Z#J_HH"K9%RS.0'
M-Y3N&LYR*2..X$54]X0PLT;QQQ]3;:,?7>3N^Y]4$KR'!4^2X:W@\@4@4[@L
M$I0ELD9A)C]4G9].K?(@Y9;#U\RU2*V9^ZUK$=LZXNS!,<#[HQDZ=1$]LFGV
MA;7IT01>4X5C,K?LW)IK$4&0]W\5HQ&+06_="UB[QG%R;3H);"'>+,):L@LJ
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @("#27GOB\A:Y#Y?Y6'CESDN)Q-RW/E:5*K[YK$30:"
M0/ZK[M'T8NCZ+Z+VG96->VLWBDVB,3,X]7R_O>NUMNFT:YV5K,]T1&?17N=@
M7,/*WDV&XAY<Y3C=P9L?-[H>+"F=Q_>&U>,*^KF\8CJ73HSK:XD_9Y5+;-U;
MQBW7NSCI\?5I<V/ZCB;*:M%M<YKT[,=W7RQXX6SS P6:N\O\H[=+&V+%;%VY
M2R4T41$%42CKMK*[-H#>J_;\BTN'MI75R(FT1-HZ?'Q\'0YVG9;?QIBLS%9Z
M]/#P\5*P \QX3Q7F'E,7#<IE<MDI<B^*S%6(7QL\%Z+NVEFL$3"+BS:[>I/T
M#HZZ&Z=._;KY'W*UBO;F)_=&/*(_CU<S1]_C:=O%^U:UK=W;:/VS%H\9G^/1
MPP?'.5\1K^5W/9N/WLA6P..M8W-8>O"Y9&JU@IMLP0%H3OI)ZS::Z-\ZNW?J
MW3OTQ>(F]HFL_P"F<8Z9_!-/'W:(X^^:6M%*S6U8CZHSGKC\61E<!RCF5GS)
M\P8./WL=2RF ?"87%VH7CR%TV>,GF>NVI-IW>@Z]K.VGI6.O=JT1ITS>+36_
M=:8GZ8\>F?Q9;=&[D3OWQ2U8M3LK$Q]5O#KC\$OR'C7(9^,>25:#$VI+.&OX
M63+1!"1%4""&)I'F9F]1A=GW;OD6OIWZXV\F9M&+1?'7QS,^#9W\?;.KB1%9
MS2U.[IX8B,Y]'SFW!>1\G\S>9QT:DT%/+<.?'TLF8$%4[C689!A>73;J3 [%
MZ697B\O7JXVO,QFNW,QYXQ/7!S.%MW<O;%8F(MIQ$^6<QTRK7$^+PW[''./\
MJPGF$.3QMBF11V)^_P"/UK%301FCD,MK1#_E8&U$7VMJMOD<B:Q>^NVG%HGR
M^N8GR^;1XO&BTZ]>VF_NK,>,YUQ,>>?18L;2Y+@N2^:G'+/',E/%RQKM[$9>
MM#WM!Q*I,XQG)JVADY" BVKN731NU:M[:]FO1>+UC[>(F)GKXPW==-NK;R-<
MTM/W>Z:VB/I_;/GZ^7S8.3XGR,_VL5>-08:W_4##"YXH8#]Z9VR7>D[Q,V[7
M;Z[].Q>FOD:_[I.R;1V]>N>G[?5X[.+MGVB-<4GOZ?3CK^_/@X\KI\FM<QFQ
M?)L-R7*\5\)J1<5QN#.2O3*WW -+[[)$<; 0R[O6D+U1[6=M%>/;7&GNUVI6
M_=/?-NLXST[<_#T.53;;?-=E=EJ=D=D4S$9QU[L8\_5%<5X=RVIBO)6"S@[T
M<N&RV5DRPE ;/5CEM,8%+JWJ"0^L+OT=>W(Y.JUN3,6CZJUQU\>GDU^-Q-U:
M<6)I;Z+7[NGA]7F]2+XQ]Z(" @J38ZQ+YC7K<]4CQ4V!K57G,-8#D:W8(XG=
M^COM)G<?D=!1Y.#9T,EF.'UXI7PX\:R..X[EY'(H1@NS1/#2F-]78H'%P'MW
M0[?2SJB:Y%F;?,.)'Q.E@[E;D>7C"C=IV:\D=;',3LTTTEAV:(@C%B*)XB)Y
M'V[6Z] E,/'8Q?F+R7WRO.T&<CQ\N-M!%))7-JD$D<HG* N($+MV&[:L[::J
M#-S&-DR7-,-W]0IL5!C<H-F4AW0[[)U8QC)^S4@[SI\C.@JG&^+9N2IEZF:B
MFV8+&3\6P)R__P 36)G,K(CI_P"TC:O%KKVQE\JHG<=EJ5'B^&P7),1>EWXF
MFUB$L=-<@*3NF$H#:..1FD%QZB;,H*[@>/9NO>X8UBC9AQ4%W-RUZTKN<F/Q
MMJ"1JD$QB1;78781;<^WH&OJJB6Y[Q"&#@V:JX"K<MWK8U@:L]BU=,Q"S&3[
M0GDD[&U=]/0H)/S#P4-O@_(*^,Q@3Y&:E,%:*"$2E.0AZ,#,VNNO8@N :[!U
M[=&0?4! 0$! 0$! 0$! 0$! 0$! 0$&!F\O5P&(NYJZ,A5*$)V)AA'O)'&-M
M78!Z:N_H9!TOR+%/QT^4PS>\88*A9!IH6<G* (WE=Q'H^NC?5[=>B"+GYU0&
M[2QU#'WLE>NX\,N$-6.-ME.0F!B-YI(Q8M7^JSNZ#FW/./\ ],7N5D<T=#&=
MX%^M)$06X;$+LQ0%"6CM+J[,P_YM6=G=G9T$_3MU\A3KWZA]Y5M1A/!(W84<
M@L0O_>SH.K*Y7'X3'SY3*3-7HUV9Y979R?4G81$1%G(B(G81$6=R=V9NJ")Q
MG,L?DK,^/>I=HY6"N]P<?=KE#8FKMHSR0MJ[&S$["3,^HN[;F;5M0Q'\P*$4
M]."[B<M2:]8AIP2V:1A'W]@F !=V=]-7?J_H;J_1!8,ME\;@J$N3RUD*M&'3
M?*>O:3L(B+,SN1$[L(B+.[OT9M4$6_,*$>*\6MU+M,#L-3J5+-<HK=B8WT!H
MH7]9]_\ EW:=CN^C,Z#G'R_#28*7/[I1K02/6FK/$7O06VD:'W=XF];O7D=@
M8?2[MIT?5!/-U9 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%2\T"(?+SDI"[B0X^=Q)NCL
M[#T=D%6Y,,W$*_(L,PN_&>54<A-B!'7;4RY5999ZS>A@LLQ3Q-_,:1O\PLJ.
MG%V,K7YG@3P]**_.7#:S''-8>J(C[P&A;FCDUZ]K:(/MZEE*6>QV+NPR9G)Y
M#(GRSD-?%[ "*.E''6HQ"TYQL0-($3ZD^XGB(M&[&"2X9%D+?'LWPBO8M<<R
M.&N$&/E<89K<&-M2>]57T/OHG]5S@[7Z!\J"Q\XPV1R^,IRXD1FR&)OU,K!2
MD/NH[3TY-SPD>CL+DVNPG;1C87?HH*_8O9/-^8W%-V,/&#CZN2MV0LRPE:[J
M6.*!M0@.01C>0FT<CU)QZ-HSN@E8O_TDYR<VN[$<2%X8]']63+VXV>1^CZ/W
M%<V%NGUI2;M%!@\LJY3,\\XWB*<X4Z].I=RWO,H=]I/&<%<2BC)]CR ,QLQ&
MSL+'KIKH@Q)6Y99S1X>P<&7R7%K=+-TK&UJI6Z5Z.W5.*1FUC">/21P)M!+U
M>@]75$-6#*GFHP 81M6<[/(,9NT]6')SUBE-WV[>]>G5AV]'82L2/U_AZH-B
M<3S=O,TK@9 (QR.,O6,;;.%G&*0ZY-I( D[N+&)"6UW?1]6U?M4$^@(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @((_.X:GR'#WL'D'-J60A.O.\1;)-AMH^TM'T=!U\@X_C>3
M86W@,M&\E"Y&\4FU]L@OVB8%_E,79B%_0Z#II<6QE'+5\U \OOE;&AAXV(]8
M_=HS:1M1T;UM6[4&35PM2IF,AG *0[V2"O#,\A;@"*JQ[ C;3U1UD,G^4G=!
M@9GB-3+V[60COWL9D+=,,?);QT_<2-#%/WX..HDS&+N8L6GU3)O2@F+U>6U4
MFK069*<THN(6H6 I(W?_ #"T@F.K?ZPNR".P7&L?@2LSPG-;R5XA*]D[LG?6
MIMFNP2+1F$ 9W8  1$>NC:N^H9&#PM/ 4&Q])Y#!Y9K$LTQ;YI9K$A2R22%H
MVI$1.@B;'"JUD8I2R>0\4J7+%['Y0I0.S6>V[[X W X/!IZO=&)-HS>EF=@S
M<-QNOA1O3169[.5R9-)>REEP.Q(8!L#H(B B#=  186^35WU#H/AV+?"T<-#
M+8@\-E&U3OQR?]*"TSDY3.;L[$<CF?>;A<2W%JW5!(X;#5,'2]RJ.9[Y))YY
MYBWS33S$YR22$S-J1._H9F;L9F9F9!((" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @P_$ZWV+'Z:Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V
M/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8
ML?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>
M)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8
M_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]B
MQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!X
MG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC
M\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+
M'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B
M=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/
MRT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L
M?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH,J.090&06)A+JS&) 7]XDS.R#D@(
M" @Z)[<5<A&097<FU;NX996Z?*X"3,@ZO$ZWV+'Z6Q^6@>)UOL6/TMC\M \3
MK?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^
M6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C
M]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.
MM]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y
M:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/
MTMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$Z
MWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?E
MH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_
M2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K
M?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]+8_+0/$ZWV+'Z6Q^6
M@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M]BQ^EL?EH'B=;[%C]
M+8_+0/$ZWV+'Z6Q^6@>)UOL6/TMC\M \3K?8L?I;'Y:!XG6^Q8_2V/RT#Q.M
3]BQ^EL?EH'B=;[%C]+8_+0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>tb_molecular-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_molecular-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@VAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@.2XQ+6,P,#(@-SDN9C,U-&5F8S<P+" R,#(S+S$Q+S Y+3$R.C U
M.C4S(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7 N9&ED.C$Q,39C83-D+3,X8C M-#5A-RTX.&(U
M+35F.3,R,V0U-3)E9"(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HP-48T
M.$$T1#$W1#DQ,48P.$,U,T%"14)!-48Q-D0R-2(@>&UP34TZ26YS=&%N8V5)
M1#TB>&UP+FEI9#HP-48T.$$T0S$W1#DQ,48P.$,U,T%"14)!-48Q-D0R-2(@
M>&UP.D-R96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B R."XS("A-86-I
M;G1O<V@I(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z.3@X83-A8C0M83(U-"TT-C)B+3DP-&8M-F0R8V-A,34V,S4Y
M(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.F-B-V%C9# X+6%C-#0M-&,Q
M8BUB-SDP+3EF-# P.61B,#,W-"(O/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( E@#M ,!$0 "$0$#$0'_Q #8  $  @,! 0$!
M        !08#! <"" $) 0$  @,! 0$              04" P0&!P@0  $$
M 0,# 00%!P8("@@""P(! P0% !$2!B$3!S%!42(483*3%0AQ@=%"(U06D:%2
MTC,7L6)R)+15=3>"DJ*R0U-SLW0VP<)C-)0E-1B#XT16.,-DA';A\:,G$0$
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MBY+#2PX_8Q[*$JZ*]%<%T4+W%M5=%^A>N!)8&-]]B*P[*E.@S&9 G'GG"0
M 34B(ET1$1$U55P*6_YC\6QU47.6UJJ/KVWQ<_YF[7 VJKREXYNGQBUG)ZYZ
M2:Z-LK(!MPE]PB:BJK^3 M$R7&@1'YTUT6(<5LWI#QKH -MBI$2K[D1-<#FW
M$//GCOFO(4XS429#=@[N2&<IGLM2%!%)4;+<JHNB*J(:#K^7)H.GY 8# 8#
M\F:-@3A?5%%)=/<G7 XQ!_%#XTL9T:OCMV??ENML-;HP(.]TD!-51U>FJY-!
M;/(?E_AOC-R+&Y$Z^Y/F"KK,.&VCKO:0MO<+<0"(ZZHFI==%T],@67BW**3F
M5'%Y#Q^1\S62T78:HH&)"NT@,5ZH0JFBI_Z,"8P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P&!\,?BA_WLS?_  <3_N\RA#?X5^&NPYQP
M.'S"MOVF9LX'CCUCT8MFYETVD$GT<73<H:Z]OIKBHYWX]Y;>>/N:0;& Z;)M
M20CV41%78\QOVNM&*=%Z:Z>XM%3JF!_1:7+BP(SLR<^W&B,BIO2'C%ML!3U4
MB)41$_+F*7/9'GSQ#&D_*N<H8)S7;N::D.MZ_P#:-M$&GTZY-!=J/D-'R6"-
MEQ^P8LH)+IWXS@N"A)ZB6B]%3W+UR!\3?B=_WN67_A8?_<#F4(=Y\5^1N$\&
M\0<3;Y5<L5[[L=\VXQ;W7R#YI[0NTT)GM7V+MTR$NG\4Y]P[G#3CO%K=BQ5E
M$5YH%('@0O12:<031%]ZCID#5Y#Y/X#Q2Q6HY%>QZ^R$!=6.ZAJ2 >NU?A%4
MZZ8$K6<IX_<T*\GK)[<F@0'75G#N1M CJ2.+U1%^%1+7I@5ZN\R>,;:?%JZ[
MDD61/FNA'BL"CB$;KI((BFH(FJJNF!9KWD5%QB"5GR"P8K8(KM[TDT;127T$
M=>I+]"=<"D1_/_B"2_\ +-\G9%S73<ZS):;_ ..XT(_SY-!6?/OEH>+<89B\
M/OVH_*)9QI#8M"#QG7/@XO<!3$@T)4'0DZ^[$#EO@7R\L?E%S9^2N5/*P["%
MN*4]YUUON=X25 !-PBNB>Q$Q*'UW!FQ;*%&L8+HOP9C02(SX?5-IT4,"3Z%1
M47(2BN9<@;XKQ2YY$XJ?_+8CT@$7T)P07MC_ ,(M!P/YSUE):<B;NK!C]JM5
M$*SGF755;[S;1+]*[G=?R:YDAWO\(?)OEKV\XF\>C<^.$^**^G=C%L-$^DA<
M1?\ @Y$CK_XE?]SUY_VD+_2VL0E\\?A7_P!ZH?[/E?\ J9,H?<.8I?SJ\E\X
MN?(_,Y<Z;()8GS!QZF(9;68\??M!$15VHJIHIE[5ZYDAT[_[1.:K!%\+NL6<
M0(2QE5]&T)4UT1U&UU_+MR*CMG O'T#A'AB9QCFJA$9DL3GN1O-'J( ^A"1H
M8HO461#KI[,)<G\2\"\44WD&OL8O/V+V<T\7W+6-1G(Y&\0D@JX1*2+M1=41
M--5_DPA]17=]2\:KW+6_G,UU<TJ(<B0: &Y?04U]27V(G5<A*K4'F3QGR>P2
MJI>0L/V!:HVPX#T=344550%> $)=$]!P,M/Y<\;W]E'IZ?D,:79RR4(T8$<W
M&2(I:)J")Z)@+CRYXWH+*13W'(8T2SB$@28QHXI 2HA:+H"IZ+@>^3^5_'G#
MI(P^17S$2:0B?RHBX^\(FFHJ0,@9"BHNJ;D3I@37'.5<<Y=!^\N-63%E"1=I
MN,%JH%Z[3%="%?H)$P-'DGD3@_$#[/([Z) DZ:_+&XA/Z>NO:#<>GT[<"O0/
M/7B.RDC%C\GC@Z2[160V_&;U7I_:/-@*?G7)H+G<\BH^/U!W]Q.:BTS:-J<T
ME4FM'B0074475"4DTTR!\(\E\R>0;Z[D-2.42TIOFR1L(A_*-+'1SX>C" JI
MM_I:YDA]HP/*OCRSKK*U@7\=^NJ ;<LI H>UD'B404M11?B5-$TS%)0^5?'G
M)[1FEH;^/.M)"&K,9M'$,D;%3+3<*)T$57 V.2^2.#\.G-UO)KIBNG/-)(;8
M=WJ2M$1 A?"*]%423\V!DC^0>&2N-R.7Q[A@^-13[<BQ3?VP/<(:+J.NNIBG
MI[<#6I?*/C[D*3%J.01) U["RYIJ2MBTP*HBN$3B"B"BKU7 V.)^0N'<Y=G-
M<4LQLBK5!)B@VZ AW=VS0G %"1=A=1UP-7D_E/Q]PZ2L+D5_&B3A34H@[WWQ
M1>J;FV1,AU]FY,#8XMY%X1S4C;XQ=Q[!]M-QQQ4FWT'^EVG4 ]/IVZ8%HP/B
MC\67^\V+_LB-_P!\_F4(:GCS\.UEY$X8'*Z^]8B/O./-,P7V#4=S)*/Q.B?3
M54]C:XJ*-Q+E'(_%/-4EQS-B76RBBVT%"_9O RXH/,FB="3HNB^Q>J=<#^A5
MA?TM15_?5M.8@5>T3^:E."RWH::BFI*G54]$]<Q2HX^?O$)R?E$Y0PCFNFY6
M9(M:_P#:*T@?SY-!T"OL8%K#:L*N4U-@/CO8DQS%UHQ]XD*JBY J4OR_XU@V
MKU)+Y'%:M8[ZQ'HQ=S<+XEL4%5!TU0NGK@;-CY.X)5\CC<1F73*<CEO-QFJ]
ML7'C1YY40 -6Q(05=4^NJ8'S/YR\X\@=Y2M?P#E)CQL8S>\J]$:+YE5-'$[N
MQ'-4T3T+3)0Z;X/\L<29X#4U?).3"YR=/G'I@2S>=D:"\\]J9FA:Z-IN^MZ8
M'SGYUY@QS3R/965?,&;3, S%K'6]>WV6VT(MNY$7JX1KZ9([C^'7A_C%B167
ME+?.67/6J\I%E!$MK+ R$$##8K2+^S4T#7?Z]?3(D=KY/Y'X-PQQ&.2WL6!)
M)-R1B)7']J^BJTTA&B+[%VY"4?Q[S#XTY5+;@4O(XSTYU=K,9Y'(KAE_1 7Q
M;4E^@<".\_\ ^Z#E'_8,?Z4UDP/ES\,G^]VL_P##3/\ N"R90N7DW@'B.V\A
M6=C)\@LTSSTHRNJMR.X^ZW(1?VJ-N(J(FY=>BHNU??Z9 ^J./-U;''ZIJD<1
MRD;AQPKG4520HHM"C1:KU74-.N0E4KCS;XKHI)P[#D\7YEM=K@1D=E[23HJ*
ML<'$14]O7 GN,<ZXAS-LW.,7$:R5I-SK31Z/ *^BDV2"8I]*C@6' Y7^(;E5
MKQ/QG.E4SAL3ISS5>DIM50V0?W*9"J>BJ(J*+ZIKJG7)@?+_ (5\8<<\EKR,
MN17+E8M3&"0SVE;1=#W[WW%<1=6V]J;D33ZWUDR4'X=[NVI_*U1!K'2.):&Y
M$GL"J]MUA&S/<J?XBCO1?5-/I7$C[TS%*N>0$1>!<I1>J+43]4__ )9S _GC
MP_CI\NY15<:;D)$.TD!&220JX@;_ &[45-?Y<R0OWECP1=>+:^+<G8LVU/)>
M2*3[;9,.-O$*F*$VI'T)!+14+V=?9@=0_#YS8>3<%Y;PGG$PW**L@FXLQTU5
MQJM?;-M\%/JNUM$W!ZZ:Z>B(F1(C/%/ ?$]/Y!KK&-Y 9O);+^M+6-1G(YN/
MDBH'<-5)%VZZZ#IJOT=,#Z$O/+'CKC=H_2WG((\*TB[?F(SB.*8=P$,==HJG
M421<A)R/ROX[XGV1OK^/&=D-@^TP*&^\K3J(0&K;(F2(2+JBDB8$IQ;FO%.:
MQ3F<7M6+)EI41Y&E5'&U+TWMF@F.OLW#@2TZ="K(CT^QDM1(,<=[\E\Q:: 4
M]I$2HB)^7 H"^?/$22_D_P"*(_=UTW]J1VM?^U[6S\^[%!>FI\*SJ_O"MDM2
MX,AHC8DL&+C1BJ+U$A545/R8'\V.)_\ FJC_ -H1/^_#,D/JG\1'$?'G([ZN
M?O>7L\9Y,S$$%:D,G(!Z$KKB@6T%':J'W-%UZ^GTY$"\^,W_ !WX_P#& 2:K
MD 3>,07C6=>."0 <IYP0+4$15'XB !%->FG5?7"5DI_*/CZ_;FNU7(8C[-:S
M\S/=4E:!EG7;O,G$%$37($97^<?%%G8I51.3QEED2 '=%UEHB7HB(ZZ MKK_
M )630=!R!3^3^5/'O#I*PN17\:).%-3BCO??'7TW-LB9#K_C)@;/%O(G">:J
M8<7NH]@^VF\XXJ3;Z#_25IQ!/3Z=NF!9\!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,#X8_%#_O9F?\ @XG_ '>90A'4'X@.=\7X9'X51##B1(H.
MMLV"-&4P4><-PE0B<4-44UT7M],4$A^'SQO Y[RL;*ULHZ1J5T)CU0I*LR4H
M$A"NU4T[.]11PM57]73XM<2)G\4?/[*VYBYPB.^3=%2BTK[ *J"],=;1U3/3
MUV"8B*+Z+N]^1 _>&?AM<Y5XT7F!VAL7DQEV550! 594&E) %TEZZN;>BC]5
M%3U],5%!\.<[LN!\YK9D=XAJYS[4.WBZ_LW8[IH"DH_TF]V\%]Z:>BKDBP_B
M=_WN67_A8?\ W X@2OC_ /#;:<\X.WRTKL(4J:+BU4(VE= @9,FT[KF]%#<0
MKIM$M$Z]?3(J.8<-Y':^/N9P;E@CCRZR4C<UG73>TA['V3]Z$FHK_+ZY(Z'^
M*8D/RF1"NHE71%1?H7?B!V_P[_\ LW+_ .!N?^]DY"7ROXF_WG<0_P!K0_\
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MU]J9*%R_$QQ>;1>39MLZV7W;? W+AO:?"I-M@TZ&OIN$AU5/<0^_$#H_CO\
M$-Q#CGB9FFLS=#E-1&=B1((M&0R2^)62%Q$4!'110]ZHJ:+HB],B@X%XTXO.
MYESJEI839.=R4V]+-$U1N,R:&ZX2^Q$%%TU]5T3U7)%T_$[_ +W+'_PL/_N1
MQ O7BO\ $;Q;A?CF-QRX@2W+FH%X(C<<15J2CCANAJ9$G;T4]I:BOO37TR*#
M@_'ZJRY_S:)6L-]R?>3MSR G04>-7'3^@0'<2_0F2.H_BMK7X?DB+*(%2)+K
M(_RY_JKV3<;(=?>FB:_E3(@;? _/-%Q;Q!.X--@2';L&ID>O)M ^7<&<IEN<
M)20AV*X6J(*ZIII]"@YCXF_WG<0_VM#_ .^')'TWYDY!X1ON1N\,\B_,P+FL
M::5B\BMJI-I)#N=O<TCA*B(J%M<;4>NJ>W('RES.LXS47S\+B-R5[2"(DS/-
M@XQ;B3X@431%7;_21$1<D?1'D,KRX_"UQNQMU<=G,N0WI+KFI&4?<ZPR9*O5
M5(3;7<OKKD#EO@CR=3^,.1S["]C2)%?/B?+*41 -T'!,3%=ID"*BZ*B_%DC[
MLJK%BWJX5M&$AC3V&I3(N(B&@/@ABA(BJB+HO7KF*7QA^*GDOWQY&"E:/=&H
M8C;"BG5/F)'[=Q?^*38K^3,H0R<)_#'>\RXM6\G2[CP&[)M7FXKC+AF+>\A%
M55"1/B1-WY\5'*^=\/F\#Y58<5L'1?D0"!$D *B#@.MBX)"B]>J%@?3W/>2_
MQ=^%IJ\(]\EUF S++755D1I;;+JK^4@4OSY Y5^%?_>J'^SY7_J9,C[AS%+Y
MY3\6/&X-W:55U2RABPYDB-%G0#;?1UEIQ0 R!Q6MJDB:JB$630<8\[>2^$^1
MIM?*XM2N0YL?N?/6DAMMEZ0A:;046B/<@Z*NXUUR80L_A6BL8OA[RAR!\2;K
M;"M=C0]R*B.'%8?5PTU]43N(.J>W5/9D#G7@W_>UQ7_QG_[L\D9_._&IO&O*
M%\$ELACV<@[.$ZJ?"XS+)7%45_Q34@7Z4P.BV_XCZBV\0N<->K9/\4OP JGG
M/@^3VB*-D\A[MVJBFNS9];VZ9%!SW\/W^^#B_P#VTC_17LF1Y\__ .]_E'_;
M,?Z*UB!](/\ _P"RPG_].M_\U,A+YU_#Q_OAXU_ERO\ 1'LF4*OS^PL+3GO(
M)E\3BS2LI 24+J8"TZK:-CK[ $4$4]R8%U\MS/# T='5^+HZN3@57K&P,7T=
MV;-J-N$_IJ:DNY=B;4TZ8'4_P=?_ $_EW_;0?^:_D2/F[E+,BIYG<LOAI)AV
M<D3 NGQ-/E^C)'UI=>3*?S+XEYNQQJ',8FUM<V_,9D@&FJJKRBV0&6_1&2]B
M>SID)?+_ (JYG'\?\[JN43&#DPHJNMRFFM.YVGVB:)0U5$4AW;D15ZZ:9*$Y
MYT\D5?DWES%M2QW6*V%#"$R4E$%UU1<-PC414D%-3T1-?9K]&!T[AO\ ^R?R
M;_MI'_?,9 Y]^&G_ 'P4O_93?]$=R9'TI^)/CD[D7BZ:M>V3S]3(:LR:!-2)
MIE#!Q43_ !0<4U^A,B$OC3AK/!I$]UCG<BQAP3!/EI56+3B@XB]>Z#B*JBJ?
MT.NOLR4.A-<7_#Q)F1(,/E5])D3'FX[>R*VV(D\: BF3K8(@HJZKI[,#[3X[
M21N-T-9Q^&1'%JXK,-EQS3>0, @(1:(B:KIJNF8I?'?XLO\ >;%_V1&_[Z1F
M4(=-_#SX[X+R+QM!N+SC\*PLUDR@*3):1PB$'5047=JBZ)T],B1] 5];75,4
M855$9@PP^I'C-@RTGY!!$3(2_GAY7XO.XCY O:F:V0 4IV5#<5.CD62:N-&*
M^WHNB_XR*GLS)#N_+OQ#\0NO#SU+$-U>6V4 *Z37JT:"T9"(/.*ZJ;%#3<H;
M54EZ:HG72*#F7X;N+3>0>3JZP:;5:ZBW3IK^GPBNP@:'7TW$:IHGN0E]F3(J
M_F#_ 'H\N_VI)_YZX'WOP3_R1QK_ &5!_P!&#,4ODC\6$1]CR7&DF*HQ*JXY
M-'[%[;CH$GY45,F$+]^'#S!Q]JFH_&$F+*&^5Z2$9\! HQ@9.2=Q$IH0JB:C
MIM7V>_HD<1\\?[W.4_\ B0_[AO)'T9><7G<L_##55U8V3UA'J*^='8!-2<6*
M(&8BB=5)00MJ>U=,@?./A/G5?X]Y]$O;<36I<:=AS3;'>;;;R(J&@IU7:0CJ
MB==-=.N2+)^(OR;0>1;^K#C+AR:FICN!\X;9-(X]()%/:)HA;40!ZDB==?9U
M5 L_%>+3J+\,/,+>>VK)WQLR8H$BH2Q6GV0;-47^DN]1]XZ+[<@5'\,G^]VL
M_P##3/\ N"R9%6\Q?[TN6_[2D?\ .P.G^?\ C$YW@OCGE\=LG(+%-$KIIBFJ
M-$3#;C*KIZ(2J::^_1/;D#]_#IYBXIP&HN*#EC[D-E^0D^')!HWQ(E;1LVU1
MM"5%^ 5'IHO754]J1R+F5R_Y Y]:6]9%<)V[G+\A$1-SQ(9(VR&@Z_&J(.J)
M[<D?T#X10GQ?A]'QYTD)^M@L1GR3JBN@VB&J?1NUTS%+XU_$[ LHOEB?*FB7
MRDV/%=KS5/A5D&1:)$_(X)ZYE"%E'GWB#FWB.KX=S)QZEY%0QACU\QF*<@A>
M:% 1QM6TT(7$1%=;-1U7Z4$L@?/2F0H;0&O:)454ZHA;==%5/SY(^XOPS<?X
MY4^.VK.EF!/L;9SNW$@4VDT^VFB1E%>J=I"]OUMRDGPDF1*71/('_D/E'^R)
M_P#HSF0/@;Q570+?R-QJLLXX2Z^5.::D1G4W 8%ZHJ9DA]ZTWCG@?'GQE4W'
M*^'+%=0D-QF^Z*I_1-44D_,N8I>?)?\ NZY9_L>?_HYX'PUX2_WK\4_\</\
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M]FQTV:_QT?Q$5S)WUP/($@]MNE$-:TQ^6</4G-_U=J*:CL_M-%U]F4]L9/\
M;YG@MX:_-^+?T\R]ONQ?[G;''?Q\/R_AW3TW;TC9_B,\:5=\_1.2)<@8A]J;
M:18ZO0631=J[C0MRHA?#N$%37VYJQ\EU-^.+Z1%=T3.V6[)S_2V9)LK,TWS$
M?#'3N9U\_<"'B#?-R2<E&[8K4"7RZ=U)"-=Y54=_U-OMU]<Q_P!GS^+X6SBX
M>+?U;F7^^:?P/&^+AXN'=UTJQ57XBO&=SRAGB\.7)1Z4ZD>)8N,;(3SI+M$1
M-2W_ !%\**0(FOMR<G)=39BG),1LWQ7:QQ<_TF3-&*)G;-(FFR>G<WN7^;.+
M\.N9=%,KK>?-@"#DXJ^$KS+(.@C@D3AF":;5]4US7IN5Y<]D7Q-L1.ZLMVJY
MQAT]\V3;?=-N_AMK16?(OGZIKO'$;E7!Y'S$^V>6-7&]'4FV76#!7P?%5'82
M 7P^NO14U3KG9HN3WW:B<>6*1;%9V]NZCAU_/++-+&7#-9NFD;-U*5KYCBWX
MB.,EX^9Y'R-9KLV L.#<.M11%#G2FG#U;1"$5#]D77I[.G7(U')LG[B;+*4F
MLQMZH_M--S[%^VC)DK6WAB[9^*8G=Z%SY7Y<XGPZHHKJW26L+D0B=?V&=YZ&
MV#B;Q4DVKH:=.N<&GY=ESWW6VTK9OVK/5<UPZ>RR^^M,F[8C^3^>. \0NKB@
MNW93-E3--NNMBRA(^3PMD#;"[DW$J.(O71$T7KTS;@Y3GS66WV4I=Y=W>TZG
MG>FP9+K+YFMGDWUIN]+]Y!YSX3QYBH5T9LZRNH;-E%J($=)$T8TAM'!)P=Z"
M*Z+Z;]>GNR,/*LV2;MT1;,Q69I%8,_.M/BBVO%=-\1=%L16:3VMZO\R< L>&
M2N=-V2M4D$NU,!T%&2T^NFUI6DU53+5-NW5%]_1<UW\LSVYHQ4^*=W93MJVX
M^;::_!.?B^&-_;7LH\\%\N\>\@63M74UUI#>;CK,!VPB]AEQC<((0&AFBZJ2
M:>_)U?+LFFMXKIMG;39-=J-%S7%JK^&VVZ-E?BBD44?S9Y%Y8WRFE\4^/GDB
M<BND Y=EZ$RVZ1"(BNB[=$ C,D3<@Z;>N6/*]%BG%=J,VVVW=';TW0J^<:_-
M&:S2X)I??OGLZ;Y2/%/"'(^/7M9?S/(=O9/1G4>L8;IN]B2FBZ@NYXOA5=/K
M;M4S5J.:X\EEUD8;;:[IZX]3=I>39<62V^<]]U-\;:3ZULXGY:XIS.!?6-.D
MM(_'$4K#OL]LM$%P_P!FB$N[HV7NSAU'+LN"ZVVZE;]VWIVK#2\TPZBV^ZRM
M,>^L=_V(A//O!%X@WS?;.^Y'+'[G3_-T[J2>UWNH[]-FW];7UZ9O_P!HS^-X
M6SBX>+?U5HY_]\T_@>-\7#Q<.[KI5@=_$1XZ"#:VC)S)5943(]>]+880FW79
M8ND!-:FBJ'[$]25$]FFNN91R74<5MLTB;HF:5[*;_2PGGVEX;KHK-MLQ%8CM
MKN]"1K?.7CRTC\CL(\]P:CC'8^?LW&U2.XLE3%M&-%4S52;44^!-?9JG7-5_
M*M19-D3'Q9*TCKV=K?CYUIKXR71/PXZ5GJV]G7.Y@XGYXX-RV\C\?8&=66$X
M=];]YQ_EVY8]53M$AFB[D1=N[37T3KTS+4<ISX;)OFET1OX9K3O8:7G>GSY(
MQQQ6S.[BBE>Y'6?XE/&E45DQ).<4^LE'"=@A'17C-LB$S#4T'8*AU4B3V9NL
MY'J;^&8I2Z*UJTY/J'2V<43Q5MFE*;6IS7S]1Q_&*\SX:Z3TV:_\A 1]A21B
M6&UQP) [DVJC:JH]51=4]4S/2\GOG4^%EW1%9V[X\GG:]9SS'&D\;#-9F:1L
MW3Y?,YMS'RE_>)X#F&X\^O)*E^N^^9"M)&:)R2\Z@]K8NBIH'7HF6^FT'[;7
M1NX;HNX>O=$;U'J^9?N^73MGCMFWBV4WS.YU3@/D_CM5$X-X\L_FFN065+7/
M1'G&]8SHNQ4(51U2U5542'ZOUNF4FLT&2^<N:VG#;==7MW]CT&AYEBLMPX+J
M\=UEM.S=V]-JV0/)W&[/GDWQW!&4]?5X$[,<%I%BMB(@2ZN;M>BF(_5^MTSB
MOT&2S!&::<,[NU86<QQ7ZB=/;7BMW[-BYY7K,P& P& P&!$V5,S/N*6T<?[;
MM2[(=:9T1>ZK[!LJFJ]4T0MW3 EL!@,!@,!@,!@<R\Y>3'_&7#_O"M '+VQ=
M^3K>XFX&R45(WB'VH")T3^DJ:]-<N.5:&-5FI=\MNV?L4?.>8SH\'%;\UTTC
M[?,H-+X0\C<CK(_(>4^1[:#R.8V,@8T8W%;C=Q-P@NUUM-4U^) 041>B:^N6
M>7FNGQ739CPVS;';U^I3X>3:K-9&3+GNB^=NRNSUQZD;$,HOXG[V,_+D_+1Z
M=1<>%Q5>_9UC"$X.O3>NF[T^MUS==%>66S$16;O\TM-L\/-KXF9I%G^2/6F/
M&'D#@O O&MCR!+FYO:8+=8[K\UA.^V^^T)H( KI(@Z)J1;^I*O3.?7Z//J-3
M%G#;9=P]4[*1YG3RW7:?2Z6[)Q7WV\=-L;:S'?TE:8_XDO%\KD,?C[,N2J2C
M!IFT)C;!5QQ4%!4R)#3XET4MFU/?IUSCNY)J8QS?,1LZJ[>GG=]OU#I+LL8X
MF=O73X>GFHTV9''O_N+D-)?6Z\A^11LJ-0_^6('RHN='-_U=OQ[=G]IUW>S-
MDQD_V^/AMX:_-^+?T\S5%V+_ '.8X[^/A^7\.[I.[>V[G\2'C>IMGJB.4ZX>
MC$H2'ZN,C[ **[5^,C#<B+TU!%3W9KQ<DU%]D732VO\ %-);<WU!I;+YLCBO
MI_#%82'*_.7%>(V\VEF5MQ-DUJ MB[!A=UAA'&Q=13<,P3ZI(O37-6GY5ES6
M1=$VQ%VZL[VW5<ZPX+YLFV^9MWTMV1UN=?B*Y=4<N\.TW(^,S2>KI5NR@N!N
M:,2%B0A-F*Z*BBOJB_E]RY:\ETU^'5W69(VQ;[X4W/\ 569]#;DQS6)OCV7(
MBQDR&_/WCK:3KC8T,-TF )54U"+))41%7J2Z=/>N=%EL3H,WYY]L.;)=,<RP
M?DM]ESM/&_,G"^4<9N^5U[LANLX^)G9!(:0'Q$&U<^$$(M=R(J#UZKTSSV?E
MF;%DMQW4K?N>GT_-L&;%?EMKPV;Z[V]1\DK/*W")L[C[DR!"LFY,*-,<%8T@
M'$%6^ZTH$J_ 2]"1?K"N:\N"[29HB^DS;2:;X[I;<.HLUVGF['6V+JQ$[I[X
M<N_#ASFT<H^64?,[!^39\8DG)D/373>>"/M(7!W&JJJ-FR2_1NRYYWI+8OQW
MXHB(OBFSM^^JA^G];?./)9FNF;L<UV[=G7Z*(WPMS6T^Z^;>7^:V-B_0?-I'
MA04-Z2VRCKJ&:-,:JB(BNM *BB(*:^S-W--+;Q8M-BBV+J;9V1Z9\TM')]9?
MP9=7FNNFVM(C;--O5'GB'1>.>>>%\AY!%XRY'LZ6UG*B0 MXORPR"77:@*AG
MU+3X=VFJ]$Z],J<W*,V/'.2MMT1OX9K1=:?G>#+DC'2ZRZ[=Q12KD?')+0>6
M/,Y6$Z7$KF:JU-Z1#)5D,MBZVI&RBKIO%/J9>Y[9_:Z;AB)GBMW[I[WG=/=$
M:S5<4S$<-^[?&V-WE7_QYSW@G!/$,6\DWT^?2-RGXT>38-:2WGU-2[3+*&?P
MIU5/CT3JJJF5>MTF?4:N;(MB+J1.S=3MF5QH-=I]-HHOF^ZZVLQ6=\SV1#E/
MEGRI0>1N0^/W^.%-BG$G%\W$F-K'<V2'HRM&FPB A+8>BH73\^7?+N7Y--CR
MQ?2:QLF-NZ)J\]S3F>/5Y<,XZQ2[;$[-\VT=XY=YOXMP^YFT<NNMY\NN$#GN
M5\)7661<;1T5)PS!--I(NJ9YG3<JRYK(OB;8B[=6=[UNJYSAT]\V3;?=-N^E
MNR.M6?)?GVLJO'D'DW!I'S$^Z=-FN==84VVBC$'?%X24=AH)_"BZZ^J:IUSL
MT/*+K]1./+%(MW[>W=1P\QYY99IHR89K-^[9NIOKY4KP?SEQ>S\?%R?D,UV.
M]3LQ6;N2^PC2.SGF]5&.#>N_<2%H@IZ=>B9IU?*LMFH\.R*\4SP[>KRNC1<Z
MPWZ;Q,DTX(CBV;[ICJ[4EP_SEPGF5VUQV,$ZLMY(*]!8M(_R_P RVB*6YI4,
MT75$54UTUTZ9IU/*LV"SCFEUL;^&:T[V[2<ZP:C)X<<5MT[N**5[D;R/\0WC
MBHN)O&7'Y<F1&1QF=.AQU>BQS'X2WDA(2[5715 237-V#DVHOLC)2(KNB9VR
MTZCGVEQWSCK,S&^8BL1T\BI?A$=>=XGR!7G"=)+(40B)2_Z /37.[ZCB(RV4
M_A]ZN^E9F<-]?XO<^B<\H]F8# 8# 8# 8# 8# 8# 8# 8# CK^ZA<;I+&_L5
M)(%9'=ER.VFXU!D5)4%%5-2731.OKFW#BNRWQ9;ONFC3GS6X<=V2[=;%7QGY
M7M_"W)8\:V\9QID3GDB4V0Q83#K *I*JJI!]5'-VFWL==<^@<OQZS%,VYYB<
M<1US7I'>^9\SRZ#-$7::)C+,[HB8Z3^5<K=;0//?BE.0*JWZ4=<ELIZ;OG%&
M4CFNG37=ZZ>W*_'P_L<_!\O'=3NV+++Q_P"XZ?Q/FX+>+O\ BJA_&/+*SQ)8
M<ZXESJLE.<GL'%",C4=9#DU$1T4;3WBXI(8%]4D+KG1K]/=K+<63%='!'EI3
M=['/R[56:&[-BS6SQW;ME>+?L\_H4RHZ?AXY(B]%_B.&FGT]A,L,G_(6?DGV
MJO%_QF3^9;[%Y\ZQH;'A?Q<Y&9::-(T;8;8H*HCD$#/14_I%\1>]>N5O*;IG
M69ZSUS^I;<ZMMC0Z>D=4?I3'D#G]D[Y:LN)<LY=9<,X361@<@N5 F,F6:M-D
MG[5H2)>YN-47113;MTW:KG/H]';&DC)CQVY<ET[>+=&_JGL^]TZ[773K;L67
M+=BQVQLX=\[(ZX[?N57Q;%=E^'_+D."VZ^8HT;;)IJ]L;1PE4A3];:*JOY,[
MM?=%NKT\RK^6VS=HM3%NW=W]:3AW]=RO\,-AQ6C[C]]QMIB1;14:)%%E; G=
MXEIH2("*2Z+T1.N:;L-V'F<9+]EM]:?X:-]F>W/RF[%9MNQTFZ/)Q5]BK\Y\
MA\?Y)X0XEQ&K&2Y<4;C!6NK)(RP+33K**3FFU>XIHH:?3KHN=FDT>3%K<F2Z
MG#?6FW?NGU.#6Z_'FT&/%;7BLIQ;-D;)C?Y>I<Y4&!:?B/X/$L([<R&5/#<)
MET4-M2:KWG0547HNTA$DROMONLY=EFV:3Q3^J%G=9;?S3#%T5C@M_3,O'F./
M8\6\W0>02[B3Q:@FP@CUO((D7YP(J-M*VXT+:*GZVJD@]40]=,GEMUN7139%
ML9+HG;;,TKMW].Q'-K;L&OC)-TX[)BD71%:;-U.F]ZH:3QE*JO('([OR%(Y+
M4SHL2+R&2W6O0G6GY4H"BR$0MRN$+C7H(:>NN1FRZF+L5EF*++HF9M^*)V1&
MV/)LE.##I+K,V2_/.2V8B+IX9BDS=\,^7;'8V/#7++ZE\D0/'?&^2+S7@)QS
M/YGY=QI(+8@9#HKB;@VD@BJ;E!=VB:%Z8\ST]E^GG-?9X62O;OZ>EGRC59,>
MJC3X\GC8J=GR_9[-O:E/Q+*B<]\8Z^R8>O\ \3%S3R/_ $,W=[KF_P"HOZC3
M]_OM>>!-,/?BIYH3K8.$U$D&TI(A*!ZQ051U]%T(A_(JXU<S'*\??'^8T,1/
M.,M>R?\ *_?PUBVSY!\FL,"C; 2T1MH$V@@C*DHB(B=$1$Z)CGFW3X9GL]T'
MT]$1J=1$;J_YKGTOGD'N# 8# 8# 8# 8# 8$=?UBW=%9TR.]A;&(_#[VW?L^
M8;)O=MU373=KIK@;<5GY:*S'W;NRV+>[3378B)KI^; S8# 8# 8# B.4\AKN
M*<>L>16Z&5;7LJ](!H4,R'HFT1541555TZKF_3X;LV2++=\N;4Y[<&*[)?NM
MA\;>4;'Q%?.UMEX@CS8O.I$P"^5KV7H[?7<NHMZ?"[OV[.QT]<]_H+-7CB;=
M3,3CB.N8GI'>^:\RR:++-MVDB8RS.Z(F.D]G"O6RT<_$Q0Q[-U&[]RB%J6Z.
MF@S2J7D-4V^X]5Z96_#_ +;?-OR\>SNXX6M+YYK9%T_%P;>_@E5_&O,JCQSQ
M'G/CKE=/+#F$Y9+;49N.KQ2-T96A;+3]4%0CW+\.TE5-<[-=IK]3EQ9L=T<$
M4Z]VVOW.#E^KLTF#-I\ML^)-=E-^RE/-O5F0J)^&N&FO5>7.:?\ P*YV6_\
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MUU?$<=>BQ&6'7^K[C38@3BZJOQ**(J]57US";[IV3,[&RW';;,S$1%2)7P(
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M$;R&OD6U!:U<-Y(\N=#D1F'U4D1MQYH@$M1^)-%77IUP-R(T;$5AAPM[C38
M1=>JB*(J]<#-@,!@,!@,!@,!@<T\K>9:GQ6Y61YE>_9R[,7G19C&(*VTQMU(
MMVO1=W3\BY;\OY9?JXNF)BV+:;_*H^9\VLT4VQ-LW3=7=Y%NX9RF#S7B]9RB
MN FXMDUW1:-44FS$E P54Z*HD*CG#J=/=@RW8[M]JQTFIMU.&W+;NNA.YS.L
MP(/F-Y.XUQFRO*RJ>NY\)KN,5<;7NO$I(.B:(2Z"B[BT%5T1=$SITV*W+DBR
MZZ+8GKERZO-=AQ77VVS?,=4=;E_)_.5UQROX-*D\8*+,Y:1A+@372:>B*VZT
MVG3MZKN1S>FY!7335,N<'*K,MV6(OK&/=,=>]0ZGG63#;AF<=)R[XF=L;8\G
ME=LSSKU"@>8/(DGQCQ,.1Q8 6+ARVHBL.N*T*(Z!ENU$2]-GIEIRW11JLO!,
MTV55'-=?.CP^)$<6V(6Z@LCN:*KN'&T9<L(D>63(KN0%?:%Q11=$UTW::YP9
MK."^ZWLF8]"QP9/$QVW_ ,41/IA07?*LQOS.SXK2L;6(['60MEW2[B:1BD:=
MO;IZCM^M].6D<OB='.HXMM=WGHJ)YG=&NC3<.RE:U\E73\IEZ8# 8# X2]^)
M$W+FXJ*7@]K<?<CSK$YZ(2.;$9<)M340;/1%V+IJN>ECDE++;KLMMO%&RKR<
M_4%;[K+,-U_!.VG]B9;_ !!\5E^/;#GU=#DOC5/L1;"I-0:DM.2#$!774A45
MUU14]=%]%SGGDV6W41ANF/BB9B>K8Z8Y[ANTUV>V)GAF(FWKVK@USN*[XY_O
M%2&XD/[L*V^1W#W=@MJYLW>FNB>N<$Z28U'@UV\7#591K8G2_N*;.'BIYJH:
M@\R<:M?';GDBT Z>F:<=95IXD==(VRV((('UB->@I_Z.N=&;EF2S4>!;\5SF
MP<VQ7Z;]Q=\%JCI^*&(VVU;S.%7,?B#[G;:O2%%;+5=.B;4;5?H1U<L?]AGY
M8R6S?_#TV^I5?_V2V(B^<5\8Y_%TV>MVZBO*ODE1#O:62,NKG-H[&?#5$(5Z
M*BHNBHJ*BH0KU1>BYYW+BNQ7S9=%)AZG#FLS61?9-;;MR0S4W& P& P& P&
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MW7UU?<9;!LC755U)11%7JJ^N9W7W7;)F986X[;9K$1%6SF#,P& P& P& P&
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MN4#)\@W[R_L$8C#[A!37^4U_]&:)U-\K;'R/3V[ZW>>GL1SG*^2.KJ5BZ/T
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M/7WHGR76:._2Y)LN\WE??]#K<>KQ1DLG9*XYQ.\P& P& P& P& P& P& P&
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MVI]3T],TQ$1LCVIR6W1MB*Q3I3NW-F <21/;8" CI ]L>DP2/MFVBJF[MF)
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MB6;*.]I5U)IU%476B_QFS0@+Z4SXWJ,%V')-EV^'Z,T^>W-CB^W=,)_.=T&
MP& P& P& P&!#V=Q(@W5'6-,(XS:NR&WWEW:M(Q'-Y%31%3JH[>N!,8# 8#
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M\9]2\OX9C-;'?T]7H>^^C.<?N,7@7S\5N[ITZWT_GAWT@P& P& P& P& P&
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M<D_ZUK[(<4#^\#DG_6M?9#B@?W@<D_ZUK[(<4#^\#DG_ %K7V0XH']X')/\
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MYM5'^35,LL7Q8J/$<P_\&OB^.VV[[7T3P>S*XX?26)]77X;*NJO7]H(()_\
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M_P#MECI9V2\;]06_^2R?)[W<_#SI'P2&P7_Z*_,CI^0)3FG\V?+.<V<.KO\
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M*KZ@,-/R'@C,MJ;QEM%L45255]FB=<V6Q,S2&G+DMQV3?=-(9W6W6'/EGM-
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M(=L1:)M3(8N[M1TUW)T5L!-/\K/F//-5XNJGLMV/MOT[H_VVBLMZZ5ET[^[
M_P#6:?8K_7RAJ]%0_NP/_6:?8K_7Q4H?W8'_ *S3[%?Z^*E#^[ _]9I]BO\
M7Q4H?W8'_K-/L5_KXJ42='P&)5S$F3'TF&WHK#:AL 2_I*FI:JGLR*BXY"3
M8# 8# 8# 8# 8# ^>/Q1<5(8=/Y)AAJ5,?W==[4ZK73#1 <7Z&7M/S&JYZWZ
M;UGA9IQSNN]O3V/#_5_+/W6EX[8^*SI]WG?&WE>D5HX_)(X:MFB1IRC[%_Z(
MU_YO\F>LYM@I3)'=/N>0^BN9?-I+I_O6?YH]_FES13;5=4<Z^O5/;^;//5?4
M*-B,[#VN?-$;GPKVD#X?C^E5US.V;>MKOB_9PT\K\U)T=&U16Q378G33\J>W
M\N1$LIACW:KZ:?1D#.$YP%W%H>G1%+U1/H)-%S*+Z,9LK%&1)(.FADR9HG1
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M>QWBU$D1U 1-Q+KO5-5ZZY$64ZT39%*0AZVXCTMD[,JVGP8<AR8?;=>%7?\
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MEM]OW/K?TIRC]GI^*[Y[^G3[WT'GE'M3 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MH7JF?5N5\UQZNRD[+NN'PGZ@^G,N@R>+A^3?LZNGJ[G'^3<*?K5.;5"3]?\
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MLA3+>FL)$A6I=<X^Y#9U%.Z3S!-&FBIJNT24OAP); 8# 8# 8# 8# 8# 8'
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MHOH1;B3V%GA]=SG/J=E>&WLA]2Y;R#2Z*/@MK/:Z]E&]"8# 8# 8# 8# 8#
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M -]H@$OA5%Z*NO3 VXC)1XK#!EN-IL (O>HBB*O7 S8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$/9U$B==4=FT^C;-4[(<
M?97=JZC\<V11-%TZ*6[K@3& P& P& P& P& P& P& P& P& P& P& P& P&
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M\-^6NRR;?^ZOV*[-KK<>IQX)B:Y(NF)ZHX:?:E\Y%B8# 8# 8# 8# 8# 8#
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MY"X3%CB@,,0K1IH$]! &F!1/S(F76F_H<W?C_P SR^M_Y32_ES>RQ>LI7IS
M8# 8# 8# 8# 8# 8# TZVJ@U+;[4!KM!)D/2WDW$6KT@U-POB5?55],W9<U^
M68FZ:TB(\T;(<VGTV/!$Q9%(NNFZ>^Z:SZVYFETHOD7':;E=-*X_R"*DVGFH
M(RXA&;8N"!H:"2MD*J*J*;AUT).BZHJI@2+++,9EN/';%F.R(MM--B@@ "F@
MB(IHB(B)HB)@>\!@5JF\?\1H+N3R.LKMEY* VCFO//R7 :=<[IML]]QQ&6R/
MXB!I!%51.G1,"RX# 8# 8# 8# 8# 8# 8# 8# 8# UYT*-90I-=,#N1);1QY
M#>JIN;=%0)-4T5-47V9LQY+L=T76[[9K'F:<V&W-CNQWQ6VZ)B>Z=DO42*Q!
MBL0HP[(T9L&60U5=H-B@BFJ]>B)D7WS?=-T[YFK+%CMQV19;LBV(B.Z&;,&P
MP& P& P& P&!$<:XO0\/J6J/C<((%6T3CB,@I&I./$IN&9N*1F9$JJ1&2JOO
MP-N%5P:]^;)B-]MZQ>23++<2[W4 6]=%5=/A 4Z9NR9K[XMBZ=EL4CNK7WN;
M#IL>*Z^ZV*3?/%=Y9I$>R(8N01["50VD6H<5FV?AR&H#R%VU"0;1"V6Y$7;H
M2HNOLS2Z6W$!T(K 2%W/BV NEKKJ:"B*NOMZX&; 8# 8&E/JH%F<)R:UW#KY
M S(B[B'8^ D"%T5->AET7-V/-?CBZ+9^:*3W=(<V?38\TVS?%>"[BM\DTF*^
MN6[FETF P& P& P& P-*VJH5W72*JQ%PH4D=CJ,O.QG-$5%3:ZP0. J*GJ)(
MN!I\9XI0</@.5O'H:1(S[[DN21&X^\_)>T[CSSSQ&XXX6B:F9*NB(GHB8"7Q
M6@G\BKN638:/WU2R]'K)3AF21PDZ(ZK;:EL0R1-JN;=^W4==%5,"9P(RNX_3
MU-C;6U?%%BQO'6I-J^A$JONL,BP!*A*J)HV C\*)Z8$G@,"'H>+4/&2LG*6&
MD=ZXF.V5F^IFZZ_*>^L9FZ1$NB(@B.NT11!%$3I@3&!@FP85E$=@6,=N7"?'
M8_&? 7&C%?80DBHJ?EP,^ P& P*S3^/^)T5[(Y+7PC6\D XRLR3)DS":9?<[
MKC;"2'7!9 C1"(&D%%T3W)@6; 8# UY4"%.5A9L9J0L5T9,;O )]M\$5!<#<
MBZ$.JZ$G5,#%954"V".W/:[H19#4QA-Q#M?CEO;+X53714],W8LU^*9FV:5B
M8GNG>YM1IL>>+8OBO#=%T=]LUB6[FETF P& P(>SBVSUS1R(+RMUL9V05HTA
M[4< XY@VBCI\6CBBOT>N!,8# 8# 8# 8# 8# 8# 8# @>:\><Y7QBPX^U(&*
MY-$!1\A4T'8X)_514UUVZ>N=_+]5&FSVY9BO#U>:BIYOH)UVDOP1/#-]-N_K
MB?<G2$2%1)$(23147JBHOL7.!;*5'\.^*HA69Q>&T[*W#)1K-&X3(B^RX8N$
M!(@Z;5(1+1/:B+ZIA-4A5^.N!TB1AI^.5T$8<D9T5(\9MI&Y8L?+(\.U$T<[
M7P;_ %5,(:UGXK\;71 =MQ6KF$$U^U3OQ6C19TM05]Y45.IN*V&]5^MM37TP
M)N]XUQ[E%6=)R.KBVM0YM4H,UD'V=0^JJ :*B*/L5.J>S BJGQKX_H8<2!3<
M:KH,.#,&TB-,1FP1N< $V,A-$_M$$B%#]41=,#-RK@'"><?*?QAQ^!>+!4BA
MK/CMOJUW--Z"IHJHA;1W)Z+HFOI@:UKXP\<WLIF;<<5JITN/%&O8=?ALFK<1
MM44&AU'H(*GP(GU?9I@3M;2U%,4TZF"S"*RE'86"L +:ORW1$3><VHFXR0!1
M27KTP-&QX^Y.Y12<A%\0;J6IC1L**JKGS@MBBH6O3;L]V=V+4Q9@R8J?/-NW
MLX:_:JL^AG)J\6>M(Q1?%.WCI[*)W.%:F P& P& P& P& P& P& P*Y0VTZ=
MR+E%?)<0HM9)BM0P0411!V(VZ2*J)JNI$J]<L=3ALLPXKHWWQ=7S73"ET6JR
M9-3J++I^''=;%OGLMNGURI_%?/'%N33FX[L.73P);=D_76M@488KS-+(^5EF
MXK3SA1T%Q?A^8$$)/1?9E<NZ+<WY X7*D,P:Z^KYUG*CN3($*/+8-V2TTA*J
MM?'H2? 75%TT15]$7"&O3^2.(6;5,S(MX$"]NV6'8U([.BN2]\EE'Q;%&G#0
MUVKJBMJJ%ZBJI@1T[R[Q6LY[9^/['OQK"JI3Y#(G&(_*+&:75QL2W;E< /VB
MCM^KUUZ82<1\P<*Y7QGCW)79H40\G-YJIK;=UF-,<=COG'($#N$BKO#3X57Z
MPIZKIA":XASWBO.V[-SB]@$X:>:]63T'H3<B.2@71>NU534"]"3JF!^<0M["
MV/D(SW$<2!<R8,3:*!MCM THBNGJJ*2]5RRUV"S%&/ACYL=MT]\U4G*M5DSS
MGXYKP9;K;?RQ%M/:U^(^1N.\NXC3\S;=6KK+Q[Y6 W8DVPZ4A9!Q@:1-ZBIF
M8: (JJKE:NVU/\@<%JM/O/DU7#U>.*GS$UAK5]I[Y=QOXC3X@=_9FGZI=%P-
MA[F/$HUVG&I%[ 9Y"O:0:IR2T,M5?U5M$:4MRJ2)JB::Z=<"HV7F6FAV,^A@
MU,^TY+&N%X]!J(J,(]-EA!:L''&R==  9::=%7''2%!^G5-2:#GFBA;X5/Y<
M578I,JK)JALN.DVT%BQ;/OM1PCEN<1I=2?;(7!<4" D)%7!1N4WE[AT^MESK
MN2G%Y%=9N4-A#NW6(YMV30-NDT)BX;;B;'0-" U3:NJZ=="$^]S?AL:5/A2>
M05[,JJ[2V;3LID%C?,$@-=W<2;%,E1!0O>GOP-9SR/X_9J(_('N453='+=*-
M&L#FL#'<?!=";$U/12%4^)/U?;I@;1\TX>W<L<<._KQY!*5!CU:RF?FG%5I'
MD06MVY=6U0TZ=1ZX&J?D;@+=?)MCY-6#5PY*0)4Q9;79;EJFO:4]VF_3KI[N
MOLP,O,KE^MX9:WM.^'?8AE)AR!VNMK\.X2374214]/9G?R_#;EU%EEVZZ:2J
M.<:C)I]%ERXYI=;;,PW;N_@<:XY/Y+<.=NNJX;DZ8:::]MAM7"T151-5TT1/
M?G%=%)6MDUB%:X_Y;X5=<0@<QGV#7'H4[YD%B73K4.2R_ <)J2R8$?\ :-$"
M[A37WYBR9_[U_'OW_)XVM_$2PBUC=ZZ:NC\O]WO:[71>UV$FB(7PK]517T5,
M#==\B\ 8@PK-_E%4S7V2:P)+DU@&WT[B,KVU(TW:&J 6GU2Z+I@?I>0^!A6R
M[E>2UBU4"1\C-F#+9)IJ4G_0F2$J(?\ B^N!N-\NXN_.&KC7,&1:.,_--0&9
M+3D@X_;1U'!;$E)04"$D+3314Z]<#FU9^)#A%MQ&MYA#AV!19YV;#T(FVTE1
M'Z>N?LW&WQ[FU%<89W-;27=O'TZZ$T6&Z\L0:V'PYVOI+"XL><-%(IJR)\N#
MW;:A_/.=PGWFVQ46O9OZET3 W Y[7\E\7O\ D'B#Y%#DUDB?7/.M[3$V@/H8
M%JFX#%1).J:I[4SLT6*W+J+++MUUT1/GE6<TSWX-)ER632ZRRZ8[XB9;')^=
M5W".#IS&_%U]EMJ()-1A#NO29AMLM@.\@ =[C@IJ9"(^JJB9HS6Q;?=$;HF7
M7IKYOQ6W3OFV)]3]9Y_3P:VOE\U)KAUA9.G'CU=Q+B"\3@'M^ V7G&S0OA5%
M$E^LFNBYJ;V>=Y$X#62I,&QY/519L,'79<9Z:P#K01]O=4P4T4=NX==4]N!G
M7FW$5G0:MN\@.6EI'295PPDM$[*CF*D!LHA?&)(BJ*CKJB*J>BX$#P[RUQ+E
M5#Q>UE38U+9\LCC*JZ2;):26:&2@* .J*>JCH.B=5Z)UPE.P^<<+L)<R#!Y#
M6R9M<P<N?':F,&Y'CMDH&XZ*&J@($*B2E]5?7"&[1\@H^30!M>/6,>TKC(@&
M5$=%YO>'0AU%5T5/:F!'\*M9US3.S+!Q') SIT="04!.W'E.- F@HGH(HF6/
M,,-F++%MN[AMGTVQ,J;E&IR:C!-^2:SQY(\UM]T1ZH6+*Y<H[D#=D]0VK5*2
MA<.0Y UYH2"J22:)&EW%T30M.JX&W$1X8K R%UD(V".KZ_&@IN]/IP,V P&
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M(I$O7V(B:K@8Z^P@VT&-:5DEN9736@D1);!(XTZRZ*$!@0ZH0DBHJ*F!LX#
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MVA8B1P%IEEM-H  )H@HB>B(F97WW7W3==-9EABQVX[(LLBEML4B(ZH9LP;#
M8# 8$19W+D"YI*L&$<"V=D-..ZJG:1B.;R+HB+KJHZ=53 E\!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"K<,L)L^1R@9
MCY/C#NY$:*A_]&P+#!""?0BDN6FOQ6V1BX8IQ8XF>^MVU0\ISY,MVHB^:\.:
MZV/)'#9L];GO&?Q&TW)JZODLTLEBQDWB4<JL)Q">:9=C2Y3$QO0$[K;PQ#!M
M!1-3W"B_#UJU_1ZIO/,VXXK"Y)'XRU*D<AFQZWB-576K$U^5*D,N2'&II"T
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MT1$T%5AN_%E=?4?!Z&?*1Z%PR;"G*#T=MX)J0(;L-&W -=HH7=W^W14_/A"
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MR0/**-N(0@J_LR+3VZ:I@2>!$0>44%G/9K:V<$Q^3$6QCN1T-Z,Y%%WLJ8R
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M!@,!@>!9: W'0;$77=%=-$1")131-R^W1.F93=,Q3L8Q9$3,Q&V=[WF+(P&
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MER'!<!IX&C3H;PDXW^R3XOB3"%0=_$?P-N2Y";@7K\Q"FL1V&:F09R)=4O\
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M+S8G')/JZ?%NP58K'P!QZX@38=M>VTR3<3F++D%BX4/YN>[#%L(PJX,5.PC
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M)LJZ!+N*6=)D]J9 <?.$QN$>\3K!-FFB]2V@JE\.!+8# 8# 8# 8# 8# 8#
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M3L.V@V:6U;76,BP?8GQQ8(DN8KKALQ&V20VHW81%5Q=J]%PAS"WL^827N?\
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MRUC&N@NIHOU%5-$+TP(*_P#(7&N.G3)*D)(9NK1:1J3&-IQEB4+#T@N^:FB
M(BR6[U5%TZ8'YS3R-Q+@%95W7)IORU1;SX]9%G *N,"],$S;-PQZ UH"JKB_
M"F!MQ.;<<ER;R,4P8J\=FMUEF[+5([0R7F&I ")N*B%J#P:?2NF!@YMSWC_
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M1Y4N;9M(+D2&Q";[A%),2U#>FJ-H@JI$BHF!J<>\F\3Y/R&RXY52M\FN9KY
M224!CRV[5ER0S\J6_5Q4!HE--J:8%A*[I01TCL8HBQVU>57VT0.\2@WN^+IO
M)-HZ^J]$P-:DY-6WTNY@0^XW.H9JUUC'?#MF+O:;? Q35=6W&W0,"]J+[T7
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MN(]]YG,!Y7![!-JK6Q"30G%Z^SVX%%X;X.YCQ6\XO96%557:U-+251R_O>?
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M1*+KCJQVNX([VV1UT'1<)JQ<]\#W'&N(\BNZ:%!:5IOFI.QJIMSYE^LO$_\
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MRZO..VS*IQ61RE_DDB6Z6@R8=GQ]RO$&=NY>['E=5$]J(.TD5?3 @6OP^>0
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MOQG)DHHHI>MHW8=MGN[&UD(FKB@B+NZII@JQKX/\?K&)H8\YN<KL.2-LW8S
ML@D5T983#H24=1Q"1A5:+K\8_6UP56FVX?0WT:FBV[!RVZ";%M*PG'G5<"9
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M[(6U;0T%#;*.8M(HZ?%HXHK]'K@3& P& P& P& P& P& P& P& P& P& P&
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M0KJBHJ+HJ+@>P &P%ML4$!1!$131$1.B(B)@?N P& P& P& P& P& P& P&
MP& P& P& P& P&!B=C1WS9<?:!QR.?<8(Q0E;-14-PJOHNTE35/8JX&"?5P+
M,HA3F4>*#("9$55)-DAL2$3314UT0E]>F;L>:_'7AFG%%)[G-FTV/-P\<5X+
MHNM\ET5I/K;F:728$=R!;,:&T*E15N4AR%KD1!5?FD:+M:(?P_7T^MT]^!MQ
M%>6*PLG_ -X[8=[T^OM3=Z=/7 S8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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@<!HON7 :+[EP&B^Y<!HON7 :+[EP/W1=OHNNONP/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>tb_panels-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_panels-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    1@  _^$#@VAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@.2XQ+6,P,#(@-SDN9C,U-&5F8S<P+" R,#(S+S$Q+S Y+3$R.C U
M.C4S(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2)X;7 N9&ED.F1B,#8Q-C0P+3-B9C,M-#0S92UB,V1B
M+3)B868V9F$U8C$R,"(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HP-48T
M.$$U,3$W1#DQ,48P.$,U,T%"14)!-48Q-D0R-2(@>&UP34TZ26YS=&%N8V5)
M1#TB>&UP+FEI9#HP-48T.$$U,#$W1#DQ,48P.$,U,T%"14)!-48Q-D0R-2(@
M>&UP.D-R96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B R."XS("A-86-I
M;G1O<V@I(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z.&)F,69E-V$M9F,Q92TT-3<P+6%B8SDM,3(Y,C,T,F0V.#5D
M(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.C@Y-C8Q.3DQ+3@Y9C$M-&)C
M9"UA8C-B+6,W-S(P,C@R9#(P8B(O/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_N  Y!
M9&]B90!DP     '_VP"$  0# P,# P0# P0&! ,$!@<%! 0%!P@&!@<&!@@*
M" D)"0D("@H,# P,# H,# T-# P1$1$1$104%!04%!04%!0!! 4%" <(#PH*
M#Q0.#@X4%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%/_  !$( L@#MP,!$0 "$0$#$0'_Q #=  $  @(# 0$
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MZZL-E3M:F]XAGP[Q:ERC7CMW(NH^1?)0?5GT5_\ I6'Z1E?_ )E25:GTM/\
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M);Q(A<$O*BZHO8OE2@L.8QNKF<X^?5/)!??QDW-C1BX(,,AOY2*U'W:BWO\
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M#EWG_P#*Y</AE7_Q8"\Q$_\ 9?T7T5:H]%Z<_1QP_ [BS?);[M]O<94.*])
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M -*>_P"(7NT%QZ53)CO4*P Y(=,%D+J)&2HOXL_(JU)(?7,_^8R=."\IS_\
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M<Z$36=KE H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M6\& +8V+;:%ZQ:)N+ST$BUGS82XV0NV<7LWAQAB1[R4@O#ZMM<EN0<7:J$^
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MT#V@'<7[= ]H!W%^W0/: =Q?MT#V@'<7[= ]H!W%^W0/: =Q?MT#V@'<7[=
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M!&5LM4H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MI]?S4''*<U5-JIM]]KPTU^O015RR&QV:Z6FR76<W$N]]<-BSPC0N9)<:'>:
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M4"@4"@4"@4&Q$_*+];^%*X7[F2S>W*PLQ0*!0*"LYW^9(GZ9L/ZXAT$;TO\
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M4KA?N9+-[<K"S% H% H*SG?YDB?IFP_KB'01O2_\VY#_ *FOWZP=HJ\40H%
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MOBVRH[P%54E 4<T#7U$2BLMNZ?VF MH)^XW:ZG898S[0=TFK*)AP(KL- 0E
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M*XO,3<NX235%[=90JP3.C>#S&6(JL2F( PXELGPH\M]EBX0K>'+CM31 DYR
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MZ:!X6/W$]- \+'[B>F@>%C]Q/30/"Q^XGIH'A8_<3TT#PL?N)Z:!X6/W$]-
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MW"ARWP;?=(UVCM#WW%>"*J<:"BGUTQN[0<O:Q25;QO\ C6_PB7R8W$@S6F3
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M>'F+-,VZ]4\L5W5:_3SIEDELO6+6K)[3?V).,W$Y;$^,L!;*(HXKBFCJ"CY
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M<+]S)9O;E868H% H%!6<[_,D3],V']<0Z"-Z7_FW(?\ 4U^_6#M%7BB% H%
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MLO#3>7%>S2JBV)G^:A(N61K=K8[:[3FJ8E^S0Q1\3)C/SVH8+S^8AI*%'N<
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M#01;X$)D*[B[45%UH)F'U)ZEY1>Y+N,0 */:BLG-M>Z"$>0Q<XD:7(=>>D2
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0;$3\HOUOX4KA?N9+-[<K"S% H%
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MBD*HB\.*>6@J^39K!Q7(\3QF?#D/2\PE/0H+[6Q&F3CMHX1.[E1=%1>&V@M
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M9'A+@;B ;KR\Q1YO;KQ5$1/>T%4LTG)KEG*%><CBX_U2:R?C[3>NHW!^,CZ
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MH]VE5HDY?4J>[=(M@NT!^U7V!D]MM,QJW2VWHSK-RB.2F3)UUA"-M13:ZV@
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M=2;5$3@J(J(FY%I0JD\KP6UYD[%2]2YI6R.;+CUH9?Y<&249\)#2OMH.I;7
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M"X.IJ7,W[E145=:"P.=/;"Q,MERALR'@QMML\:QPY9-6:-*B1SCQS;:VEL)
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M8@KQ<XNJGD;3M^WV4&PB(B(B)HB<$1*#F@K.=_F2)^F;#^N(=!&]+_S;D/\
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MF@>SW.\/IH'L]SO#Z:![/<[P^F@QO1'&0YA*BBBIN5->"+Y?L4&3V>YWQ]-
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MM D/AJBJCA)VZJ**O#CI03% H% H% H% H% H% H% H% H% H% H% H% H%
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M:[17N<[$@LVQ@GT/U2$RW<V&G:GY1?J46C!\XW4^#9\ROMPB6:;%Q.:=J./
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M+1>(T1U#JCB3M]]@@LX3]JN8Z5P<ANC;QN[::I$61[W>:>\5$VJNB:H2Z45
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M6W*\!+NZ7"XW:[@U'Y3#KUPA,06VF$WDH-L-1VQ124B/35>*T*JWD/2.XP,
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M56"^X9E658OC#%XN44K_ &UQB;?(;K)E:9[_ "#;<:=::<;)6VS<YK:;E12
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MV!V_=P-W5Y-N*?[>F.CGCOQMW_2.8]1<-P/'SRQOP\J3>A%V W$V([<7!!$
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M&W8Q19#<YCQ"HYSP+4E9)O82(H\.%!$W3H[)NEC>M+]_:*?<[D_?+S?3@?\
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MV*>?Y?.?LO\ [O[/O'[JR_*T/B\O_,4]BGG^7SG[+_[O[/O'[JR_*T/B\O\
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M<(([2,\Z0A&X"$R*OAM7WY(NJ!P725)AZ=50H% H% H% H% H% H% H% H%
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M [RTUR:(/"!WEIKDT0>$#O+37)H@\('>6FN31!X0.\M-<FB#P@=Y::Y-$'A
M[RTUR:(/"!WEIKDT0>$#O+37)H@\('>6FN31!X0.\M-<FB#P@=Y::Y-$'A [
MRTUR:(/"!WEIKDT0>$#O+37)H@\('>6FN31!X0.\M-<FB#P@=Y::Y-$'A [R
MTUR:(/"!WEIKDT0>$#O+37)H@\('>6FN31!X0.\M-<FB#P@=Y::Y-$'A [RT
MUR:(/"!WEIKDT0>$#O+37)H@\('>6FN31!X0.\M-<FB'4XGJ%RUU<T7:A=FO
MU::Y-$.K+#;S:.(JIKP(5[45."I]BFN3JX9/"!WEIKDT0>$#O+37)H@\('>6
MFN31!X0.\M-<FB&)UD1-MIM55PUU77L0$[5X>BFN3JX9"C- *F1J@BFJK]1*
M:Y-$.C$?F-HX>HJ7$1\J"O9K]72FN3JX9/"!WEIKDT0>$#O+37)H@\('>6FN
M31!X0.\M-<FB'=I@6BW(JKJFG&N,W56+:,M<7-K?S>1YF9"_:=_]Y/30;- H
M%!6<[_,D3],V']<0Z",Z</MQK;=XKRBVHW^]\L^Q#%;G(T^KJB>JNOW*"\T'
M"(B=B:?6H.:!0*#5.< &0**ZBNGD\E!U]H-]Q?10/:#?<7T4#V@WW%]% \>U
MKKL75>U>% ]H-]Q?108I$L'0T$5%P5W-EYB3L^QYZ#*EP#3B"Z^6@>T&^XOH
MH'M!ON+Z*![0;[B^B@>T&^XOHH'M!ON+Z* MP#1= 77R:]FM!C8E@TWH0J3A
M+N<+AQ)>V@R>T&^XOHH'M!ON+Z*![0;[B^B@>T&^XOHH'M!ON+Z*![0;[B^B
M@>T&^XOHH'M!ON+Z*![0;[B^B@Q%+'G@\ JBZ;7$7RCVI]E%H,OM!ON+Z*![
M0;[B^B@>T&^XOHH'M!ON+Z*![0;[B^B@Q.2Q<=;(A7E-^L@\.)^15^M09?:#
M?<7T4#V@WW%]% ]H-]Q?10/:#?<7T4#V@WW%]% ]H-]Q?10/:#?<7T4#V@WW
M%]% ]H-]Q?10/:#?<7T4#V@WW%]% ]H-]Q?10/:#?<7T4#V@WW%]% ]H-]Q?
M108O%B,CF@*H)IHZ/#BJ=BI]7R4&7V@WW%]% ]H-]Q?10/:#?<7T4#V@WW%]
M% ]H-]Q?10<%<$TT!LB-> IPXJO90;##7):VJNXUU)PO.2]JT'3Q@=U:R:&/
M6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:
MSQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6
M>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:S
MQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>
M,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:SQ
M@=U::#6>,#NK30:SQ@=U::#6>,#NK30:VF3D@9!.,$(-$J$3:IKJNFBK]37Z
ME-$G60V_&)W/330:X/&)W/330:X/&)W/330:X=')9J!(T*(XOO5+BB4T2:X8
M8KKC9&Y(5''"T1"3@NB>2FB3K(9'WA>V J:-:ZN)Y21.Q/K:]M-$G60S>,#N
MK30:SQ@=U::#6>,#NK30:SQ@=U::#6>,#NK30:W=I\724414T36N,VT6+JLM
M<7-T>:%YLFRX(2=J=J+Y%3ZU!JQ+@T^2,$OX_L5?O25/*GU^V@W:!05G._S)
M$_3-A_7$.@@L#@^.C7MYLMK?[07H2-=%0B"XO@NW3CPVZ>MY>SAI17H0H@B@
MIV(FB?8HCF@4"@4$/(_+N?QEJC'0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!09HO\ . ^O_!02J]BU
M!&5LM4H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M",K9:JN]0?\ (.5?HF9_)%6'-Z$NM[5_19OR[_$^#*\^^!E H% H/4_H]?\
M5"W_ -7F?W<ZV>&_$AZOX5_7V_5N\3["KO7V-Y7](]%7H]?-$5?QT+@G'_\
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MS%/Q/*2.WL%$5.U%U152@U/FHQU3ESG)UV.^S9D>Y_M 4S2>U.A,%%!UDD!
M%%9,FC;V<L@711HB9B8C;XUUAWU^7-N%ZA6^5:!G3'A,W(LU\)#G,0  5)"
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MPK+CR39+ONQ^V,O9^6L;;)]*WGZ8Z7T9G7T@<9L^+1KABLANY7NZM*4*,O\
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M$979&,8[BKM4G$5$3;ZR4$IBO4MW))MEMK]F\#-N42]/SA20CPQI>/S0@O-
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M4$69\PR-$5-RJNB]J:^2J.M H% H% H% H% H% H% H% H% H% H% H% H%
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M<=45%X+]=*#H$V0(J)JAZ_?*FB^C2J--IKE'S ,D+SHNB\:@S\Y[_>G^%_\
MA0.<]_O3_"__  H'.>_WI_A?_A08GA)_;S'"7;V:KKVT&S'DN1VA9%$(1UT4
MM=>*ZU1D]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H.]T?3[M ]H
M.]T?3[M ]H.]T?3[M ]H.]T?3[M!D9F...B"B*(J^36H-U>R@T_%N=U/3671
M##KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0
M:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N
M3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\
M6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N
M=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=
M3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]
M--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/33
M1!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0
M:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N
M3Q;G=3TTT0:Y/%N=U/331!KD\6YW4]--$&N3Q;G=3TTT0:Y/%N=U/331!KED
M8?)TE$D1$1->%<;K:.5MU9;%<&0H% H%!6<[_,D3],V']<0Z"-Z7_FW(?]37
M[]8.T5>*(4"@4"@AY'Y=S^,M48Z!0*!0*!0*!0<$0@).&J" (I&2\$013557
MZB)01=ORC&+M:Y-[M=ZA3;+"W>,N+#X''9Y8H9<PT70=!75=?)0;-JN]IOL%
MNYV2<Q<K:ZI"U,B.(ZR1 NA(A#PU1>"T&M?\FL&*QHTS(I[=NBS)+4"*ZZAD
MCDN0JHVTFQ"74M.&O"@VKO=;78+?,NUZF,P;;;FU?GR7238RT/WQZ:JB>;AQ
MH,T25&GQ(\^$\,B#+:!^+(;74'&710@,5\J$BZI0:$K)+#!OMMQ>9/!G(;PV
MZ];+>J$KC[<?\H0JB**;?JJE!*4"@4"@T[K=K78K=+N]YF-0K9 :61.DNDB"
MRRGWQHFJHGFX<:#-$EQ9\2/<(+PR(,MH)$60VNH.,NBA 8KY4)%U2@TFLCL+
M^0R<29G >2PXP3Y5M1"YC<5U= <5=-NBK]76@DZ!0*!0<HFJZ)0=1(21" D,
M%["%4(5^LJ<%H.:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#-%_G ?7_@H)
M5>Q:@C*V6J4"@4"@4"@4"@QOR(\1AR5+>;CQ615QZ0\8MM-@/:1$2HB(GG6K
M$3,TC;*3,1%9FD0K0=2NGSMLGWIC)8#UKM6SVC)9>Y@L(Z:-MJ:"BEH1+M%4
M3C6U/!YXNBV;)K=NZ6I'&X)MFZ+[9BW?MW5W+.TXV\T#S)HXRZ(N-."NHD!I
MJ)(OF5%UK5F*;);D35VJ"*GY-8+7>+9C]PG"Q>KUS/9<-1,B?Y7$]"$5%-/^
MTJ5FLPWW677Q'FV[YYF&_/99?;9,^=?NCGHE:PLQ0*!0*!0*"*R+);#B5L*\
MY)-&WVL7 9*28F:(XZN@)HV)+QT\U9L.&_-=ILBLL.;/CPVZ\DZ;>=*IQ1%3
ML5$5%^HJ:I6%F*!01M]R"R8Q;3O&0SFK=:VS!LY3ZJ@(;I;1'U45=57ZE9<6
M*_+=ILBLL67+9BMU7SIA)(J*B*BHHJB*BIQ147BBI6)E*!0*!0*!0<;@W\O<
M/,TW*WJFY!5=-5'MTU\M!S0*!0*!0*!0*!0*!0*!0*!0*!0*#8B?E%^M_"E<
M+]S)9O;E868H% H%!6<[_,D3],V']<0Z"-Z7_FW(?]37[]8.T5>*(4"@4'1U
MQ&6R<+CIV(G:J^1$^O01![]Y<S3F:KNT[-:HZT'D<CZ2'3.+(=C.OS$=9,FS
M1(I>^!51?+YTKK/>./FGY=][*SX/[0OMBZ(MI/\ 4Q_O+]+_ /?S?[*7NU/>
M./FGP>5S_9O:/-;]H_>7Z7_[^;_92]VGO''S3X/*?LWM'FM^T?O+]+_]_-_L
MI>[3WCCYI\'E/V;VCS6_:/WE^E_^_F_V4O=I[QQ\T^#RG[-[1YK?M-NU_2'Z
M<7>YPK3#>EK,GOM18Z%&(15QXT =5UX)JM<K>T,=TQ%)V_+G8<_PEQ^''=DN
MBVEL3,^=R1M>JUV3R"-R-](N-7R4JZ(Q;ICFO\6.:T'Q]@T29;\;L_2Z*FUG
MJU;<;FHXB*2((/N!=E+3LU8:3[=46?IYF5VQBP].+3:KA[-L$_.;Y:;P!"VC
M;D)ITU!LR,?43LXBJ+]6B.F;YC=\J8R!FX7%+G:+)U-LT&Q;>7RFX>TBV ;:
M)O'=Y55?KT5S$>ON/K](2\1LC)V?:')?,@R8\5T9KY,B34IQMP"T1@5Y: (\
MM?ODUH+-&RKJ!D65KB4+-V\5MP89:+[XA8L4B\63*&[R>8*( DJZNHB+H'O4
M&B*[;.H%\R#(NE/4.[QQF7V/CN5/F$<.6W+.W;A%T!3L%W9N73ZNE%6CI1FO
M5W(;QC%YG^-O.)Y$RX=]=?:MK-NBDK:FT[;5CN+(Y8*FPQ>%2T75:B-[)LCS
MNY]4<UPRTYJ.*6:R66'>(9E'CNFKO+W& &\GJ@J^L][Y=---*"LN=7<RRO$L
M5=M=VN,#-95BE7NYP[.Q;F("LQ'2;&=(>GHJHT7+X,L\2U6@W;/U%ZFYY=^G
M-GM-_9L+V68R]=;M);B ZV+T.2HNNLMGHHFX(H*)NT%%7AK05YEV_P"/3>O]
MUCY*3UPLXO<Z')CQ71GOE&0FI#C3@EHD=%V( #L)/?<:HD<RZIY?'LX2,2OU
MQ;N^-8U:[O?(S,>VM65AV0T)(LCGCSGE>U1$9CHB#Y*"W8)<';S]("YWB0(@
M_<L'LTMUL. ";Y(9(/U$5>%00LWJ)U*BR^J^2L7IMW'>G$Z4U%L3L82\2KS"
M(R+KH:$+$?=S51$4B5%U72BM>!FO6.)8[W=Y3]SDV![&9EU8OMR:M0+$NS0"
M;10AA&>Z.YJHB+H*J+IK51L6?J'U!M%VZ=7:YY,UEL+.XD@Y^,QXS#2PUC1"
M?%QDFM3U0AVN*?:6OUD@U<8ZF=0'(?3O/9V5,7=C/;P%JGX2$9@&H;#SA@B1
ME!.<CK*(A.$X7&BN(]QZE9M@?4F\7/,":L-@>OMK9M[$1GGR08=4AYKR(FT
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M@Y/*S"';_!_\T4F<CZNL.2.;M5L3D&;:BWKIHA:Z45@L72/V):3M?MKQ&_$
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MZVO8E"JON]!R<M!6O]H%12MDVU\[PJ=LV\C=N9IS?O=O*TUX^^U\E*%6_GF
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M+.\<.?<2:$8C<QH&W#CJ2GOWB+H_>;5XZ$NE46>B% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H-B)^47ZW\*5POW,EF]N5A9B@4"
M@4%9SO\ ,D3],V']<0Z"-Z7_ )MR'_4U^_6#M%7BB% H% H(>1^7<_C+5&.@
M4"@4"@4"@4$+F<23<,+R:W0F"E3IEHN$:+%!40W7GHS@ V*KHB*1*B)04!.D
MEXR3&(L#,,D=.8UCJ6"W W":9. DP8Y2G7D0R1Z0OAP:U38 BBZ#J2T18<BZ
M;-7^^W#)&[N] N\@K/(MKP,@ZD.98BD$VXJ$J<T'ADFVZVNGJ]BHO%"L=OZ:
MN,Y'#R^[7PY^1-W7VQ/=:C!&C/(W;G;:Q%9;WDK333;I&BJ1F1*NJ\> <6_I
MF5HO%IO=NO1))METOER<;?C";;T?)'T?D1TVF*@3:B*-NZKY=PKK1$=9.DMU
MQR=CLRV90V\UC%N]E6N/<+:D@6D><WRI#>U\$!Z0.C2GHNT$VIP(M0D,(Z70
ML%F!X!V!(M,59"VW?:V0O#0R"(D;<N GN<!M"417EH9#P)5[5#B]]*+;?860
MQI-P-'KU?H^41'3CM/MPYL-IAD )ES4'VB1G\8)Z;A-4X*B+16O>NE3M[Q1<
M6<FV>WM/O./S'K;8VXR-N$(BT_!07]6)3*"NQ]2)>/%/52B.\KI:^]>'9,?(
MG8^/O9#!RYZU+%;<?.XP49W LI23\2ZK &J(WN0M?6V\**S6CIF]8)>.S[3?
MB"78?;;1F_%!T9$7(9B3G!04,=CC+@@C9ZJA"B[DXT1(8+@O[%E>WRG-27[[
M*;FOQ8,5+=;&'&VD:(H\5''$ WE3F/DA>N?'2BK=0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!09HO\X#Z_\ !02J]BU!&5LM4H% H% H% H%
M!1.KEEO-_P 38M]@%U+E[7L[X/L"V;C 1[BPZ;Z"ZJ"2-B*FHKVHFE25AH)T
MIE3+R&37R_G,O_M:W7-YUB*,>-X:T-2&H\1MI3-1'64ZX9J9$I%YM$05%Z3O
M*\Y:O;[O[!O7A<A=Q_PX*ZL@I'C2C^*W:^&65^.5OE[_ +S?LX4H5:Q='Y,C
M%'<$GY LK%8JMNX\#D)LYD)Z+*"5%YKAF3<AME00-ALIO#@:KVTH5=KKTED7
M?$).*NR+)%2>Z9S'85B;8;1%:1MMUEM)&K<EE=7&W]Z[2^]T2A5)6CIJY;<W
MCYB_=N<<*"=L:%J.C$J8R:-""W.0AEXLFN5JTJ@&U2)?+0JO]5"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&Q$_*+];^%*X7[F2
MS>W*PLQ0*!0*"LYW^9(GZ9L/ZXAT$;TO_-N0_P"IK]^L':*O%$*!0*!01CT9
M\G3(054555%X51T\+([B^B@>%D=Q?10/"R.XOHH'A9'<7T4#PLCN+Z*!X61W
M%]% \+([B^B@>%D=Q?10/"R.XOHH'A9'<7T4#PLCN+Z*!X61W%]% \+([B^B
M@>%D=Q?10/"R.XOHH'A9'<7T4#PLCN+Z*!X61W%]% \+([B^B@>%D=Q?10/"
MR.XOHH'A9'<7T4#PLCN+Z*!X61W%]% \+([B^B@>%D=Q?10/"R.XOHH'A9'<
M7T4#PLCN+Z*!X61W%]% \+([B^B@>%D=Q?10/"R.XOHH'A9'<7T4#PLCN+Z*
M!X61W%]% \+([B^B@>%D=Q?10/"R.XOHH'A9'<7T4#PLCN+Z*!X61W%]% \+
M([B^B@>%D=Q?10/"R.XOHH'A9'<7T4#PLCN+Z*!X61W%]% \+([B^B@>%D=Q
M?10/"R.XOHH,L>.\#P$0*@HO%>%!(+V+4&AR'N[]RL^J&OIDY#W=^Y35!IDY
M#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y
M35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!ID
MY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^
MY35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!I
MDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=
M^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!
MIDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W
M=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35
M!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#W=^Y35!IDY#
MW=^Y35!IEFC-. :J0Z)I7"Z8F'.R)B6U6-E*!0*!05G._P R1/TS8?UQ#H(W
MI?\ FW(?]37[]8.T5>*(4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@K.=_F2)^F;#^N(=!&]+_S;D/\ J:_?K!VBKQ1"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%9SO\R1/TS8?UQ#
MH(WI?^;<A_U-?OU@[15XHA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*"LYW^9(GZ9L/ZXAT$;TO_ #;D/^IK]^L':*O%$*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05G._S)$_3-A_7
M$.@C>E_YMR'_ %-?OU@[15XHA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*"LYW^9(GZ9L/ZXAT%1P#,L0L\?(X%WO]NM\X,EOJG%
MERV&'10I[I(J@X8KHJ+JG"BK=\XW3WY66;XQB_"40^<;I[\K+-\8Q?A*!\XW
M3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@
M?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%
M^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-
M\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_
M*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQ
MNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE
M ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&
M+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66
M;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]
M^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'S
MC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A
M*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&
M,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORL
MLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I
M[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/
MG&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_
M"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^
M,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E
M99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW
M3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@
M?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%
M^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-
M\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_
M*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQ
MNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE
M ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&
M+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66
M;XQB_"4#YQNGORLLWQC%^$H'SC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]
M^5EF^,8OPE ^<;I[\K+-\8Q?A*!\XW3WY66;XQB_"4#YQNGORLLWQC%^$H'S
MC=/?E99OC&+\)0/G&Z>_*RS?&,7X2@?.-T]^5EF^,8OPE ^<;I[\K+-\8Q?A
M*!\XW3WY66;XQB_"4%<S;J!@;]FB@QE%I=-+O9'%%N?&-4!N[1#,M$<7@(BI
($OD1-5HK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>tb_technical-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_technical-4c.jpg
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M%!04%!04%!04%/_  !$( ^$$9P,!$0 "$0$#$0'_Q #4  $  @(# 0$
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MP[5%/B2IH/OVF+XN38]TUR$A$#NEND2W&PUVBX\$4C%-55=$)52D",^R=_\
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M$3;-4^ M"%%_R5J2KSK]H"ZPKQU;R*3 ,78[1L15<!445<C1VVG.*? 8D/\
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M>!>-5&R>F\"3'^S9U!GNBHL3'B2/KV$C(LB1)_.NG\U0:(Q[_P!_M7^^1_\
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M]>WL>N@6Z*\3<F5(C.LM-L/M&R2[W4%-$0]=$H-\_:)Z47/J)98%SQT!>O\
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M?Q4H'D=G^I,_BI0/([/]29_%2@>1V?ZDS^*E \CL_P!29_%2@>1V?ZDS^*E
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MZZ3\)<NXW6:,>?;9IBTUIS1;336/C#NL.49C,A].^EN%S6;-+DXQ$O%UOKS
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MP7K&/72:Q/'\73Z-N\NXQWMETUB\QP^&C9]>,]TH% H% H% H% H% H% H%
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M[?.V&2^TVELE]-+?HCKYNC5Z?J6*F^WM,>/76O#)/5RZZZ?QVO1@B("@ B"
MHB"*)HB(G8B)7R;[5]H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M%2@^T"@4"@4'0_!A2C!R5&:?-I=6R< 345^)21=*RB]HZ)86I6W3$2[ZQ9E
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!JVP69C
MJ;<;WDF6*<ZQ0[I,M..V)722 #-J>*([)=:!11UYUX'>+NY #:(HG>4BN_);
M-B6%!B\*W6Z5#C7/*87*9M4MV&V,QQEU!)X1-$-C:WH;'R"71=*#E$ZMMR'L
MGGR+24##<-DW"#?;_)?'C)M^A;(L< (WMR$.JJHZ$NP=Y:Z!+VS)LSE"W<;G
MB@6NQNM.OESK@!W%@&VR<#G1@95M"/0140?+8J\=:(Z9W4F-"Z6,=4%MKIQG
MK;$NJ6Q' 1Y!F(VJ-[U[NH\SBOQ45%VIV7%ZG=29-OB>.GMVNP$Q#Y@L\YP0
MG[0YA\!U7AJO902L/-,B2]OXO><=;AW]RWNW6S(Q.21#F-QW :>:5XF6S;<;
M)UK=JTHJAZBJZ*B$:]QO+\@O'12#>L\BRG!?DVUL;A;KER)LEV1> CHJDPVS
MRQ;50W"BKO#4:*O;_4"^3<HR#$L6QHKC.QM8OCYLR6,&$23(PR6P:-&WC)U4
M544>7M'@I$FY$H.L.JT27CUBN-KM,F3D>127[= QMTVV)+<V 3@30?<52  C
M*RYS'$W(NB;4)2%%#)LV>79_-0P+(L>.UW=RW/W=F<Q(&7;GHT=UAA4:=4&C
MYB&]W@-L5%$1>\A4%8ZQ8+BB6?W@2W(EXF7NQ-290/2&S-N5=HC#PKL<%-#;
M(@)$]"K03+;UMPR^GA/3C&TF7N2P%TNW,DG&@1(Y*;+!OOFCY;W2;,6FFVR5
M4 B7:B:J%8ZB=4LC'IYEQ62WN63.L:?B1[K$<D-$L9J6XV;,EAWEF#S3P+M!
M=HJB[D)!(%2@V/(NV<I"B%#QJ*=R>)Y)++USV1V ;5.6JNC&,C5Q/0+?=]*T
M1K[*<I:S"UX%<"AG;[A$SF';[I;7C!TXLZ%XEIYO>VJB::IN Q^4*HO#72BK
M!UK8E3,7M5OASY%LD3[_ &:(W/AFK;[!/S6P%P53MVDJ%M7@6FB\%H0J.<YE
M<+[T1RZ/<R6VYSCIQ[9D<:*;C*MS D1R1]E443Y$ELA?9+\ ]J]Y"2@VG9\M
M:N^6Y+B@1#9=QL8!.2B(5!_S%HW4VBG%-FS1=>VB((NJD1;?*=CVF3)O'GTS
M&+19V";)Z;-@D>XT)506VD!LW7#->X JJZKHBE0'56;D\SIS>VLCLT:VM!)L
MQ1GHDY9HN;KK&W"2$PPHD&B>A477A06FXYI?7[W<[)AN/I>G+(()=9DJ6EOB
MC*=;%X(C)JT\KCW+(3/@( A#J6JZ(1%P\RL>2Y'@]U;9N,5ZX0;XZ#3L@HK,
M5R 4=B6Q-C(6QQQMQ5 575 (25%XZT5GV7-\ERAF->\=QD7,1F.AX.?.F^#E
MR(9DB>+:C<ES\DJ:FVCC@&8:+HFJ)1%JR"]0L;L5RR"XJJ0;7&>F2-ORE;8!
M35!3TDNFB)Z5H-8](_>+'+U-QG+'I#URR."SF3:R%,N5-EER[I#!254$(SI,
M;&QX(+G915E#.,@OC]Q+"L="ZVBV2'81W*=-2WMRY44R;D!$1&7E,6S%6U</
M8"FA(.J)NH(Y,RLV-W7/[I(C7)R9 FVJ&["204Q)4V;#C)&8@1R)!:)PG@;5
M$VH1ZF2Z:K0067WO*YF2=.(&3XV-I!_(V9469%FC/8%QNWSMT=]>6RH.[2U%
M1$P+14W=FH7+%,WNV82RFVNRMIAZ2YL ;JY-1)?,M[CC!FL1&EVB3K9 B$[O
M1.\HIV41U=2MUU3'L(%U6V<IN*1KF@J0$=KALN3)32$*HJ(\+0L%I]ZXM%=K
MV9725>;ACN$6)NZ)85"/=)TF4EO@,R2;!T8C1 T^3CHMF)'H" &X44M=10B@
M=4,)Q\H^)7F59_+KY>\IL[=Z;:EOEKXQY5D,D;9@)B2JJ+H*"7P45]SW&96,
MY/A,#IF!6^Z,I?+M$MPON)$GRHT:,BQ9*.&J;'V]6T-?[,MIIV<0GKSEL++6
M.EF16-Y]J#<\D%'6#4F'@,+7<Q>C2&T7@;3H*#C9:Z&'Q4$=U9N&17&_;,6)
MXEZ>01RV;'CN*(S)BNJ+$%Q XEOBM3%V?A$VM!.=0[A#8LV.=5K*\A):9,)Y
M9#>NDJR7AUJ/):)-4114'0D#N[#;%:#9=$*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!08\^$S<H$JW2%)(\MER.ZK9*!['14"VD.BHN
MB\%2@TNMTNUZZ-63#7);\?*;Q*3")LUEQ5E,NPG78TV1NUW;T8C.NZZZZJBT
M5W2<@G9ATVP?'R)UB]91<(UGO"-NDU(;"SN&Y=50Q5"35(;K>O\ EI08^"Y+
MD]I@YTY8,6.\0;9E.0/2W3E!#=D%XLW2;A-D!\TA$D35PFQ4]10N"J@7F7U)
MCR@QV/B$ [[=\HA)=K?&)Q(C3-M06R*3*<(35L$5T 04 C(UT0>!*)%(ZGYD
M]>.G/43$[_:ULV46RT>+.(CPRHTF#()0"3&>004PW@0&)@) 2<4T454K8%VS
M"Z^\+^+XG9AO-S@1VY5U?D2D@PXJ2%+DM*XC;QD\X@$2 +>@CHI*FX=2)+$,
MH8RVT+<0C.0)T9]Z!=+:^H&[$G1#5MYDB;4A+0DU$Q70A5"3@M!I/$2Z0RSN
MPY@OB,I+(KPRZ3OF#I[O-'A9'<.H(B#L04%=J)I16SKGU1M=A?R2#?83\2Y6
M$6'H$$-'G;K'FDC,4H2)IO-V1K&Y?:#FF[ND)*'U<ZOTZZECE@QX)>06^)&E
M9$,F:,>%;WI@<QN(KX-.DZ\HH1?DVMJ#M(E3<**1'/\ 6*/&L+5P>L$Y+^-\
M8Q>XXXA->*CW.2B*VB&I(VXT:&VX#J$@JV>_AHJ(5S7J+ES5_##9&'B.5RXW
MF4 6[B+EM*"!BV\X])5@3 F3-L";1DE+>BBJINVADL=4HX8Y=+I=K1)B9!9[
MDEBDX\R82'WKF\K7AVHSG<%P'Q?:,'"V(@DJGMVEH&;:\SO(9%"QK+K&%FF7
M=AV19I,:6D^,\<9$)^.9<IDFW@ D-$VJ!BA;2[JI1%SH% H%!IFWWVX8ITZS
M"P-*Z]>\>NTNQ69''2=DFMW?!RV+N-5)= G-"GQ!\5%8#%XNUHZ,7;#(\MY_
M*[7<',!@3GS49+K\J0$:))W:Z[_#2&I"KKZ%6@RL7E7NPY]U#L.'V%;LD%VS
M;Y$Z8L-@6V[-&;;:1XFWS=>)&]2[F@ZBI%WJ"TCU6A2\>L%QM-IE2\AR60_
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M:<=LF*DZSS<T:7BVO;,]/_!LK'<5M-[^T#DD;*X[%ZEVNRVQS60".,E+&/&
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MM!F2NG>,7%W*RND<Y\;,FX[5ZAR"U94(K'APY:"@D"[4W;D+5"[R*BT&!_\
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M,R(S)>TE5:"6H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H%!&^3CV^-F?3E0/)Q^NS/IRH'DX_79GTY4#R<?KLSZ<J!Y./UV9].5 \
MG'Z[,^G*@>3C]=F?3E0/)Q^NS/IRH'DX_79GTY4#R<?KLSZ<J!Y./UV9].5
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M/N:[6QU[273LK;CPWR:\L3.D:_@TY<^/%ISS%=9TC7M2-:FXH% H% H% H%
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M4_F^G1W([(>F.373,L_OL98J0<EQLK-;=[I(:2E;;!.8B NT=17BBK6W#O\
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M(2KN5*#HNV4YU'L>4V"RY#XB;9\ELUDL.6/LLN;EN#T7F190MB+;BL&[R7S
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M9M43FV><VG-C@T 17"</8VT:[Q[R%QXJ$MC-QM-GS>U6OI=>7;GC-XF3EO\
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MSEOH3BNAS%%#W&GRA6@L(67'XC^$3L4F3;["N>9/7.?<Y:N2C*2EIEQ3<4E
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MBC1O,LLJV.U$U%$91=5X\:">H% H% H% H% H% H% H% H% H% H% H% H%
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M-R/5GOF4#S>+^;D>K/?,H'F\7\W(]6>^90/-XOYN1ZL]\R@>;Q?S<CU9[YE
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MLM$ .N"!N+M;$B1%)?@1%[:Y8B9=DVB'/5$5$5>*]B5%8[UPAL0G[@3PE$C
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M]*?%30U<4?9)TF!<%7P1"-M"131%[%5.U-::3IJ:QKH[*BE H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MPV#^0)LFCWIH0JBZHNX(#I9;9%EL^>7*;EDF/$8OM_;>E3 @A'8<%_4IIJC
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M;I#=DNM]MLJ\9+<HX"X;,>W.M1' A@\A@A/ONIM)Q"Y;:+P4M%0,;.)V18W
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MDV:\_?KQ^3IZ=:#('%MN>.YMXO5'+0W9O \OLY<DY'-YF[T[]NW;\>M!6O\
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M_ J41SH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H%!J[,\BCYG<)G3:S7%F+:P5(^;WSGMAX:.Z.I6^/J2*LI\.Z9)P8;+<O
M?5M%*LM_LF$9):F\4N,D6H 14=9A0;@[;S&&H*T))X5YHE:T113[WA\5$5;I
M?D\.-AW@+M=&/)6KW*QC#KL2-L^91&G%:B<OEH+;A]TVD-H4%SE[T[:*KUJR
M:UVW[.DBS3'0;OUIM4C$I%IW(4M;TRV4!N,C0ZDKC[FPFTT[PF))W5UH)[II
M(@85<<KPZ_2VX<^#X"\"[*<%H'K<MIAPSD 1JB*VV]$>;,OO=$UTU2@K.!3(
MMKRS'<PN)'#LV<)D[=H>DBK0(Y/NX7&"!*>B"4J,!.MHO;MT[=*"TQ!G99U%
MS&Z8G=!MX6V%:;!YP+(36#EQG9<R4R(D2"2MC)9 EU[A*H]J+H$7BMBSMW,L
M]9CYJVW*8GP$EN>4QRYA%;(Q"NG-[N@J@Z?%KZ:#=*:Z)JNJ^E:(4"@4&KNJ
MK-OOU_P_",A?2!C%W?E3'YZ$3#[D^VHT<6''E"HE'<=YCCN]LA<(&B 53<5%
M1V'7&Q]/<DS6S><-OX-;&(MXG7R>\CST&XS7'6W8DJ::J;Y; :<;YQ$XV)("
MJHJVB!(8)D-FQ8,]MF236+6_8[Y<KM-\4Z(*EMN;BSF)7%4U;(7";0OP@(>T
M52@JO1M7,5O5HB9$WY:]EF-,R[8DE4:U?CW*X378J(>FCH,W!DU;^5P-?O2T
M$NAZZ0 S21U2%[?AK68Q;>Y<T72*C(6-VT'+4U[O)":^C"N:[4T)==$H+5F%
MXQF5U&@/W.5'*P8=8;O.RM][:Y$88NGAV667_E"JN@T\?+7BHCV=Y*" Z0QT
ML64L0\LCR8EQN5K5.G#=R<W.1L;:<YA6Q=R:I-9U:<D(I$9-<I-Q<DMH7[)3
M&/U.P1]X%5E^/>X+)Z=T93C4:0":^A5;C/:?ST13<>OT+"K)UFS<8*3I-OR*
MX2)336B./)$@1$; ST7: HNI+HNP=Q:=NI6-*E70^K?3#SW)[==KI,"[O!;+
M5&%IEF.Y;5(C!Y7'7394A!$WJB&J(6FHZ($5;,:3+3<Z(ONJ%MP8KJY+4T1T
MFPE[AQXE7T*VR^;H)Z"8%?@H+9TKN<S.\@>S.ZHOC,?M3&+OM]@MWI#YUY1
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M#0/VEYF47+K+TQP&TY3=L=LV2(<>X+9Y;D4EWOH._0"1")$X)NUTHL(V\/\
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M,A1-Z.#NU41H*_AJJ,;H&2(I*EJN"[4[5TM8\$H*YC^/Y/G>!CDBX7%N67Y
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MY]RNN07&V"0VER]S"F##5P%;,V@T >80$H*Z:$YMU3=HI:A.6K%[198]UBP
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MY9-&T:(32M[=NE!B6OI=88%[MV2SYMROF1VDG?+KG=9:R'6&GV"8<: 1$&T
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M)MX0,?Y"%*#!7*XB9L&#<AWQYVHKTDKN\CDA(&-L[=V_<6O9II03] H% H%
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MQVW$;1=P\"7714731:&C.RWK/TUPFRVG(+]?6TME_%3L;D1MV:4T4$2561C
MXI)H8\>SBE#1G=/^I^#=4;:_=<(NP7*/%-&IC>QQE]APD541QIT0,==%VKIH
MNBZ*NBT1PSSJI@O34(?O==/"R[BI#;K>PT[+F2%#3=RV& ,U1->)::?'08-N
MZW=+KIAEQS^+D3"8O:"Y=TDN@ZT[&=U04:<8,$=0R54$!V:DOR=:+HE,+ZDX
MAGL&=.Q^:7_I1\JZQ)K+L&5$-1WISV9 @8(0]X25-JIV+P6B)/%<GM.9V"%D
MUB)T[/<!)R$\^RY')UH3($<0'4$MA[=P*J=X50DX+03- H% H%!2K-U3Q:\W
MC+[/K)MRX0X#=[GW-GP<)$,3-7&WG%05 4!54BV\-"3451:#KRSJUB.)8S:,
MO=*3=K#?)<>#;I-F86=O*7N4'- 7^S[J\4U5>"(BJJ)15YHBHY;U%L>&7S%[
M!=8\YZ;ELQ;?;7(<8I#+;H[.+YC_ &8]]./'AJOR1)4":M^28_=KG<K-:[G&
MFW6S*V%VAQW0==BD_N5L7A%54"+86B%QX4$I0*!0*!04.U=4[3=>JM]Z3,P9
M+=WL-O9N<B>?+\*XV^C*H(:$I[DYR=H^A:*[<_ZN8!TR6(UF%V2+.GH2PK>P
MR]+ENB'RB%F.!F@IQ[Q(@_'1$MB><XEG&.MY9BUU8N&/N(:K,%5;1M6DU,71
M<02;(4XD)HBHG'LH*_C?6[I?F&5GA>*Y W>+\VVX\X,)I]V,(-?*7Q*-\E?B
MVN+K1=%CS#-,7P&Q/Y)E]S:M5F85 .0]N52,M=H  (1F:Z+H("J_%PHBN85U
MLZ:Y])N$"P7E!N=K:65/@7!EZWR6HR(BJ\K<H&U5M$(54DX)JFNFM%T<\*ZT
M=.^H-W?L6,70W[DVRLMAM^-(BI*B"?*5^,3[8(\VAIMW!K0T6.Q999,EG7N!
M9GBDGC\SRRY/"!(P,T6Q<-D'%[IDVABCB#\DET7C1$'U+ZK8GTHML"YY64KD
MW.2D&$U"CE)=<D**F@H(_"B<*",P?KK@.>7I[&(#DVUY2PRLDK'>H;MOFDR*
M:J0 ZFAZ>E!)5TXZ:<:+HJ4/[772.6R-P)+S'QY74CED#UJD^6@ZJHFTG00M
M%XIPV^FAHO\ 'ZM87*SJ!T\8E.'?;M;1O5I=%M2ARX)BIBXP^BJ)HHB2\/P5
MHCOR3J9B^+Y=C>#7$WW,DRDG$M<6,R3V@LZ;W'5'Y (FJ[E] DOHH+C0*!0*
M!0:89RDL7M'6#J"D47[S"O#L1AMW5 -+?!B,0VS45U1O>XIEI^&2T5<;%@$V
M _;[K>,KO5TOS"H[/-99,V^0Z0*ABD$$Y(-;E50 1W#PU)>U2->/7_,[CA6(
MMP;^_#NEYS:X6:;=$1LWDMHR[H"M@A H;A:9$6E(>Z0B2ZZ<2K(Q;[A?LME]
M/V+_ '2'C&'6^"<UYN4:76XSKDKI@KTU=74::::[&U$C,^):!HH9<YFX8GE/
M3W'8-YN,JW7"X77QR7"0LMU]H;=(?;;-QQ%,A;-!4..O!-56@SW[K=$ZQ,61
M);B64L7D3"@\.4LH9[+:.]FNY )1[>Q:(H.,SK(STAZ<P+C<;TU/D6T'8-EQ
MHW@GST991'-?#HCB-M;T(BY@ BJFY>*(I57RM^[Y-T+S2+>;C>6CQ>^^ A'+
M,8UR>B(Y$<9"?R]XN$"2=$+M+:)%WM:#:<UJYXGF'3K&X=[N,VW7"5>/,5N#
MZ27I MP''FQ<,A15%LT101-*"OV.Q91F&-9+?YN9W>'=8EVOT;'5@O(Q'A-6
MVXR6H_.90=LE?R??YVX5#0$1--5#(MV37WJ5,PW'SN#]BBW#%XV6Y$[:CY$F
M0Y*)MIJ*R]Q-II#YIN$"[U1 %"1%+4);%F;Y8>JESQ.1?YUWQQNPQKE;8UP-
M'GF'7YS[;J&\H[W?D#L)PE(1[O'A0=W4 [_.SS"<7MEZDV:SW=B\G>EA*(R'
MFXK<8FQ;<(2Y1(9_V@]Y!W(FBKJ@0[TN^8?,Z@XLQ>IL^!#QH<BL<J>[XF9!
M>>2:RXTC[FIN A1P=;YFY152354TT#NR?(;_ !?L_P!OR.+<7FL@<MEC><N0
M;>>3DEV(CQ+J*CJ:&6[N^F@D!C73J!F&21I5YG6K%L7DLVJ-;[3(."]*FN1&
MI;[\AYM$=V",AMMIL#$>Z1%NU':&/=(K6-9_@,=Z9*GL6ZS9*9S)SGB)3@ M
MO-5<<T125$X:T&MX^5YE?L3#,H;&;KGL]@;O:V8D)4Q\5<'G,0DC*YRG(Y H
MM&\?Y0N+B$*Z(@7:_=0L@QN5U%NY"1G:K+C[]JL\HA5B-<+F4IE=ZAHNWF<O
MF][L'AI07.QX#(MDJ%=;CE5[NUX857)IO2U;@R7#!1)%A G(;;12W  "BCP[
MRZ<2/O4:X66):X<6[W2YP79DH0@P[";HW.>\ &:QVD8%75':BF:@H[4'4B0=
M:#6=IS_*+59,VLT!;AXZW72T6W%W<I%#G1RR-6&@64H$JNM,.NFXVIEO(?R9
M+PUHK:%@P3R.=&N;N27VZS6@<&2EPG$[&D$ZG$CC"(LAM7B"- ")1&ML1ON3
M9Q9^GN)/WV7$<N-A=R')KO'(6KC*;CNM1VF&GA'\ES''=[I@*%M!!%4WJM%2
MF/V*1CW7DH)727=(!8DZ[!6XN+)E,(5T#F-J^2;W U45#F*1#Q3732@F>JKU
MYC2[!(,KNW@;92ER9W'%<2XM.;6_"N&D=%D+&'\LKWA^_NV*NH(5!5<FS03E
MXAA^-W.^WG&I5H<O<V\8\/C[M.C,N-,1A62*BK8.$1&ZZ";RVH"*.XJ#IB95
MFMEM&1P;6-YCQ)DNS0,0N.81E\3%FWR6L-]M2(R.2W&3;(!7>/>Y:DJ(E!+Y
M=8;]@SN*7&Q9;>9 3<AM%LOL:Z24FMS(LN2@FHH8(C!ZJ.O(0 4=1V\45 MV
M$7.Y3\ASV-.E.2(UNOC<: T>FUAA;9"=5L-$3AO<,N/I6B-72<\R=<6Q:R%(
MN\F9D=YR%NY7"SLA)NP6RT3I(HW''1$!5U99YNBJ :Z=[0D*D+9?<IMPY@%M
MCY.SBC>.S;E%E90"I(AW:,.T6XTATS=,'0+F;3W(V3>J+W]M!]EMY/CO3O'^
MJ3N57.?DPC99=WBNO)Y7+9N#D9B1'2&@\MM-KI$V8(CB'H1$7%%"TM1KIU"R
MS)&I5ZGVO%\9E-6B';[3(. ])F>%:E2)$AYK1U13Q -M-@8CW2)=VY-H91+<
M;!GN#XJQ=9LNU.6F^N2_&NH^])<C.V_DF\XHHI$".F@K\?'6@H%AB97?NDL[
MJ))S&[M91":NTJT*T\(0FAM<N5R&WXR C<A"1L1>5T5(DX"HZ(M!:6;K=^I6
M06NS^82K%8&<>MV171FUO%&ER95W-Q&6?$"F\&6A8<4N6HD9$/>T%44,K"HM
MYAYUF>'WB\R;]CD2WVEVTL7+8Z\TU.6:+[;KFU%>U)O@9][9H):Z:J&=T1DO
MR>EF.H^JDL1IZWM$7%58@278K*Z_Z-H:$J1<,ES%W&\B6WWUZ+=1ZA,V2WS3
M!MU(\%Z=%95KEJ.A (.'H)>GM6@LG@;I@O4#$8,*_P!SNMHR=)T"ZP[Q)6;H
M_#B',9E,$2(K1_DS;< -&R0D7:BBE!'XCCV0YRSDEPR++;Q';BW^^6VQ,6B2
ML%(L2)/=:;)Q1%>>XB@NG-W @;1V=JJ&-8,SRRX7GIQ;KM<-TY+KDMCR,HP"
MS'N+MC9D, ^H:+M0R:%[:.B"2JB<$H+-=W;G=>J;^)>:S(-EE8J<G9"<1EQN
M5Y@+?/;/:JBX@=W7X/101GV>+ EKZ:V*XI=+C-\P@M+X6?)60PQRR--& 44V
M(NO'^1*$JW]LJXW6W]!KUY61MA*DPHMP<;545(CKR;D54]!$@ 7PH6GIH0VW
M@5JQ^RX58+=BS;3>/M0(RV]6$1 -HVA(7-1^4IZ[R+M)5U6B/*%PO%TQ[J=]
MIN^624<&[0++#D0Y;6F]MT([:H2:HJ:T9,E<ZZJWZ[]"L<M&8R+5)S?'G3O<
M\VFY"DXC1.&^@$.BO((JC:KP0M%H)G',LZBX9DO67I7=\KEY$WC6,R+_ (_?
MIB!YA'=.(+B(I:+NT5X53=JFH:HB:JE!#6/JGU-R_%NC73JUY(Y;LFSUJXS;
M]ESK8.RPB09$A>6PBB@(9 T0ZZ:\!XIJJT&Q<\MK?2K!@MV0]6,K5Z[71A($
MAD69]^E?DB H,31E53>1(YOT[JH(Z\="(UMAV>9DY(ZM=-;Y(R*3CS&&3KU:
M!S5EEJ^L*L=&B%PF2+<!\U53<O#;V"NZBJUCG_L7V34^&Z75/Z9S2:_RI06[
M_P"7<\Z?8%UGQ#)KU)N6>8C.9C8U<Y&Q9CT2^*+$1P$040B ?R_R5T4M/@H-
M_P ;S'#NC(EG65/0+S"LY'>LK?0'GHTQYM2-T14%$^4X>UH-J[M!'156B/-V
M-=3,KQ_J1T^.P7O-;WAF8STMD]_-XK+4"8,CEH#]M(=' 0=V_38/!$XJBK15
MUPE[J#]H6^9CD*YU<\.Q/'[P_8[%9K!RF'E*(B$K\IQP"4]R&"J"\-=431$X
MD5N3@F02_M;RK,QGMZBS"QE+@EU:2.LD8_BP_P!2XALY.O>XAKK_ $T7J8UR
MZ\9]B%IZX7,;D=QN%JREJPXJ$P6S8MX27Y2:H.U$5  .ZAZIJ@ZZ\=1HL.;'
MU2^S\&'9Q-S^X9A"NMTB6C+;)=!:..X4P",G(*"**SMY9[11>W375-PT&'9%
MZN=4,PZP6")U'G8]9,1N\CRIN(TVLCFN*]R6B>T$AC-HSQ;'B6O%>'$.-AZQ
MR<L^S_BMYS?,KO8,EFW-^V(>,1FWKS>5BJ0(TPWRRV&J&VIN"B)N3_+1*&B%
MQ[/<RE6KK5TVR"1?I5EMV)RKM9_?%EEF_1Q=B[3;?5DC0A+F:BJEV)V#JJ4'
M1CMAZGV#[-%HZJV'J+.MTRP6_P ;;L<998"T>!9?)%:=!04GG33<:N.*O%=F
MFFBT$C%SMUSKM;NJLN*G-/I,F3R(#:J*;D:.0;0JNJZ:IH*_!052-U:ZFR\6
MA]1[5?\ ,[GU%?>"7[NM61PL0=B$_M*,V@-KP%O7\NAJ2Z:?*[]!ZIZM].QZ
MW=*W\9)]RS3;BW&GPS>%5Y,EO1T0>#@JIQ4#]*=NFJ:411,#ZN=2,2S2P](^
MN%CBQ;I>FC:QS*;2:%!G'%'B)MZ)L)4T3@@Z$H_DT0D6@\^]/8UUZ=X?9_M#
M8Q&)Q,?O]SLV<0F-=\RQ2I *ADFJ(I,F7#X]BKP!:*V'BF*0^J>*_:-LUM-N
M<%YOCUQL;[2[Q<>0%F0R%?\ *5 1?B54H(>1D\CK=T^Z"]+>8KKM]ED>5BB_
ME$A8SJPYS/@YH"3B?Y2)06'(\PR.W]9KM:.J>99#T\L0SV&<"=M33;>.28"*
MN@R75;-"-P43=OX-JJZJB"B4&]^MV1VG&L"D3;KE4O$6GY#$=BY6MH)-P=<,
MMWAXS9">KC@B2(J)W4[W8BT2&B>EO4/-K9U8EX%)FY8_BMWQZ3=K<&>,,LWE
MB3'WJCS1-JJJT6U41"0>/WJ;>)50LE]ZVW[[/;_6P^IL]BY8XXZL*U-LL\F0
MTS*0'%EFJ:NFN]4!"%101%-.*K0;%N>>9[U;SS NG%FO[^&VRZXE#S#)+A:D
M$)SIS&T7P\=QQ"V"*J.BI\*ZZ[42B.GHW9KUC_VK.H-GOU[=R*;%QZ((7>2V
MVS)=CD40F4>1I!$G !4;(T3O[=R\5H3T+'D^;9;%^TM)P^-=Y#.-#ADFYC;0
M4>4DP.:@NIJ*KN31/30:>M=^ZVW;[/*]<SZFSF;G8'#\':&V&O#R&6IJ,FLL
ME3\JXJFNW<*B@B(Z:JJH5L6XYUGG5_J-AW3>RY!(PNSR\4B9=D,VTH(3GG9C
M8%R&'30M@BK@::?Y6NNB410XF09'T;ZL=;[_ '.YEE-]Q_&X/@[E,:!IQ]7R
MB-Q/$"R@(2M(XV+A#IO0=>"K17VT=3.HEK?Q'*[/>\XR>_W&7#7+K)<[(XW8
M'8,Q-SJP=C*(SR]R(V8JN_@7 >ZH9UBG]0;8[]IF9TOCE)S$,A8\(+("Z^+1
M2)*/&RV2*AN"WN41T5?@15T10VS]FW);)?X]Y\#G.0Y)=V1C)=+!EB $^V/]
M_F*(H ]PR73ND0CMTUUHDH)VZ9WUCZWYCA5MR^?AN'8"W%;1NS<MN;,FRAW<
MQQQP2U!%$DVZ*.U!X:DJT&G,<Z@Y9T?QSK=<6IH7+-GLNC60;UX84$ICIRD=
MEK&%-NY1;,Q;TV[U1-%3@I5]P;.,TLO4[$K?9KKF^58Y?'7(66M9;:'8S,9X
MQ3E2HKG*'D@A_*;U5!%%U5=45 J5JO\ UMR#HAD'5D^ID^+(PV?):MEM:990
M9(,/MJXLQQ!1755'=K8$.P4'L[RZ!:IN2=7<3G](>IMRSAZ[Q^HEQMT.\XMR
M 8M;#%W$# (P)JJ<H#5-Y+O(T0E7152@L5D=ZA=>,ZZAC&SJY87C6%W1RP62
M!9$;!QV5%(P.1*(TW."J@B\O5$5%TU';WB->W/KAU9G=)\=E,WL8>;6?/APZ
MY75IL?#SP;8)P3>;0=JBJJ*."*)KMUX:T71L*U7'J-TN^T+BV!WS-IF9X_F]
MOEOR1N33;91YD9MUQ#8%O@V"DVB((\-I+JBJB+1%=Z7Y=DT_J2MEZOYMDN*]
M2I$V6U%Q9YMMC')<8P(66X:\LA(A4D(#4N_HB)N5>)4?T.QC(;3DG6:]L9E=
M3+%[I= DQB1E&KG)2-*$9,GNJO,$]'$V:)N2A*9Z19#G%UZ02>LO4SJ?)M5D
M\KFVN&+4<#2,8R>2$YS77G2E=%0;#8O!11.*T$'BG4++[3U2PJS6F]YO-PO.
MAEPG9&;QV&5</E(K<NV&FI(@*8GH38III\I"X!U='8%WP>]]:LY>RJZSHV"7
M2Y2+A:UY0M7IZ.Q)5')2H*JAJ2;M0TXT)047JSU-<QJW]1;1?LSO/4*0ZU,>
MQQ+(XN)/PW7=#C-(#:Z(+:KH^)*I:<-%7=0;9MD_/^N'5G.+;;\TN.%XA@AQ
M(<&!:!:;E/S9 &2N2E=$]PB39[FR3330>"H2J1\^QPS/CL=3V+K)&9<VLLE-
MS98 C0O2 31QQ 3@*$2*6U.RA*"LZ9=T:R'JU;\DZ?7++K?F,R9=H610A9*
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M(NLJ#@FVA@0.)Z4)"330KM#I!&/#<LQ*XWR9<'<NF.729=7A:1]J:XVPB$V
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M)-DHHVB[51.7\/IH:L[).AD#(L:Z=XV[>GV&^GLFW2XTD60(Y96MH6A0TU1
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MLZ ((Y'>T0E! T!=W#5:"N8[]G6+8K1F3CN6W2=U S:,46Y9H[M"8T.F@HP
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MWP%$;;787%->/>5:)*J76;@%C^T'U#=^T7;DF,W2-$:P)R?">N,,[>@D)M1
M!MW1Y54$10'7?S.*$7$K5]IGW*;T<QWSIBX3.C&,]0I$:^P2%TWPLC8QWV@D
M-AWN4V3CR$FNF]43@6V@N$JZXO?NL\RU?9R:&# R[";O;9!0(SMJMK]P:CR2
M8=9$@:1# P;;5T!1!+TZ[]0D\<ND?%;MA&4XIB4NR7##L7/',BA2H)VPKMDE
MQY,6#:A,P!9#IR]7S<1"00U,E]%!L7I7U/Q["VH>.3[?<)D:^7Y^V77J3RV?
M*[IF$HU60@;2%WDJX/(8>Y6S:"#V"JT19OM%=5\AZ86[&FK#X:WID5Q\!-R>
MY,NR8-K:1!7>XVUHJD6Y5#7AH)</@$*GU ZP]2NG73#$\HC7.PYK=KUD+-O"
M9:@((4VW.MND( 2.$@/$3>U315$?@X4-&1-ZE]:NF>?8?"ZJ>1W#$,XF#:P.
MRMO-';)[RB+8;WE_*-ZFFI$G%$)>[IH04NZ_:?RB\-Y'E>,Y5B=AL^/R)+5H
MQ&\*;MUO#,'O$X9"X*M*\G!@03B7=5?OE+HNC_77-NHEZQ'"^D,.!!O5_P ?
M:RF]W>[[Y,>VQ72Y:M VWM5QP7.[JJ:+N'@G%1)HXYADN;8KGG1S&LSCX]D.
M1WJX71EZ^);?RD8 Y L'$5PU)DU0_P LH]O!$[*#4?3(^L]IO?7'*;'<L<6\
M66Y2W,H?GPY#RR3AI)<((JB2*#2["00-?@HK9%N^T)G]ZPKI?9L:M]MD]5.H
MPS2%V0+C-K@Q8#[H$^30$IKHVVI(*$OR"X+P%2:,CK%?NIG3WIY:IG4%<9S*
M?)RFW1(G.M2G':CNL/F1\ITU1'Q,/R;@]@_&O 0K[$;JU(^UYDT>T7JSLS@L
MH."<J/(>8;L1RV%!H&T-/]90=FXM4!5U[-:+U+' ^T+E=GZ=]6I>9LPQSWIQ
M.. P++)MQGDFDC%O=)M7%54-U")="34-/Y:)HWGT\E91/P>PW#-.2.4S(;4J
MYMQVU9;;=?3F<M 4B5%!"0"X]J+1'GJZ7*39OM8Y[>86WQMNZ>/S(W,3<'-8
M\.8;D14U35.*:T9=2%/KQ]H1.DEJZZ^$Q\<0C.-LW*T;7EF30\4L1R0A(NC*
M*[H  *JJ?+7<G"AHV/D?5W.\PSZW],>CS4"%/6SL9#?[_>@-YN'%EB!M--LM
MJ.YU4=;7CJG>[$T4J(P,KR;,<:ZC]%\6S&+C]_R2\2KF,^^C;ORL=MHF^44$
MG#4F#)LDYJIVKV<*"*MG4SK7U=MF89?@C5B@].K0Y-MMOMES!\Y=U".TJNFK
MS9#R24"16]$VH2[5U1%)0U_TNZPS.F/0'IQC]G>MT&_Y?<;NW'O%\,@MD")%
MF'SI#VQ44E13$6QU1%77X-%+HNEH^T9E3+'4+&W+Y8LMO..8Y(R?'\HLP*,-
MX(^T7&)+".$B. 1HJ(!?)[:)HPYW7?KOCN%8AUFR&'82Z?WAV'%G6*(+RW#D
MR!5%E<TEVB3B@9  JJ B@A(2[E0NCJNS75N3]KN5'L=ZLS=R]WC?MA2XTER*
MW9CEIHT38GKXG@FXQ5!7XNRAU)CK1UNSCIS>[P]#SO$$.W.<RW85X65*GOQT
MT79*>;)>2\2;EV]T>SBFM$B&)+RAK-OM&=!\O986,%[QF5/\,2[E:61$DF0;
MM$UVJJIKIQHK9O6?JAE6.9)B/3/IU'B.9UF;KW)FW)".)"AQAW.O$ *BD6B$
MHI_D+P7@E$A4;9UAZG8GU8E]/^ISEJDV:QXU,R2?=;2PZ#DIB,BN(YL<->62
M() 0=BJFJ+HM#10G?M5YDS86>IAY#B3EN.0"N=,FC,KT-O-[D[O$;]?$HGY1
M1V;$'O:?>T71>I75KK%E?6#)>F73=JS);(<:U76'?+D#J)%M\F,P^[N$%)77
M'2?$6TVIM1%_E0B(/J]U_P G<ZH+AC=@BVOIU=;B/C)S;Q2946&IJW%!L24-
MZ-M&1NDJ;E(4';Q6@PI_V@NML/!\=ZY2;98X_3:?*8AS,=:5]ZY$R9DRY(YQ
M;1'<X!\L$UVHH;D+O471DW>>L#[4/4RZ,M-2"B].WI+;$D.:PXK;<<T%P%TW
M 6FA#Z4H=3#MG7'/K/T_Z)EAMAL34W.I-TM[UE8CK;[<#C4M&(_*1HEY((I\
MQW1"W<=--:&BXXOUCZA8AU(R/IYUE6V36[=87LKAWFR-.-"D2,FYULFW%U71
M!/;KHNH_?;DT)HUV[]JO,FK"UU,7(<2.W$^*GTR;,RO0V\W^3N\1OU\2B?E%
M'9L0.]I][1=&^.N/4RZX1T8G]1L.5AR8(0'X!3&U<:)F<^R&I )"NNQSAQ[:
M)#7&0=<NJ>%8A!R+,&;!;;OGTV&QA-O>==&':(;K>]Z1=']$4D 3;(D;7@JK
MZ.[0T85C^T5D<&^7W#Y^28]FL@L<N5]QW(;"! VW.MT=UY8DIA'"331HC11)
M%VZ?A=T:,>)U;^TC=>DD;K;"CXZSC]OC%*F6,VWSE3XT5PFY,G>A(+7$2(6Q
M+5!375>"*5:IW7#,^H628K@_1YF!;[C?,?9RJ\WF\"4INWQ)"(@L TTH[W1)
M1$E7N]Y/C5":("[?:!ZE8ECW4W&,IC6W_P"3L"CPI\&Y1&W"MTZ!,D,-\TF2
M-%$T!\=40M-2[$VKJ-$/U9O?73*?L]9'F>0N6:RXU=X]NFQ;/&1]RX!;'S#@
M3PJ@HZZ9M&H\40-PKQX45*R>KV>=*NG>!8]>[GCRY-EP1VK!=) OQ;7:[*Q#
M8W/S5(]QNBIHB(*B)+_)M4.>._:>F6"9F-FRN\6;-@L%C+(;-?\ '=8[4K8X
M#*PWPW."#O,<'11UT#BNJT311.N=UZ[Y!]GQS+<X*PKBV1%;YJ6F$T^U.MS3
MSP.Q2%PC(7-Z*(N 6I#NX+P6BP]<O6Z]W7I_&@8W=_(;Z[ B^!NW(;EHPX M
MEJ3+G=,21-I(OH7X:,6OW>KV8],VP#KG86HMD1P& SO'B*5:2)PMH>)BFOB8
MZKPU5!<%27APHK4N3W3!+1]HW*;I]H"&,S%KC:HC> 2I\)VXVSPRM@KP,M@V
M[HZ1[OO-=V[\(=2M7Q)MVG]$+Q:K?%N<CI3C_47_ -4MXHZDQK&53FK',-=P
MB!*)&*KW7"15^&@NKV0=/[GUVPYO[.R#:V<@LMWM%TD6Z&];+>\YX)TXZH)-
MM(3C)H+CA"/!4#5=== YXK(BXDO36]P,2N5CNG3.VW5KJ 96]R&[-G3&ABQ8
M .J&V8]-F$*LH)'MW[N''0-C=/>J=JP-9;&1VNX3Y=TO_@<[S]AMM;4SE,O:
M)0QWNJ]X:)J$0'$'ECL33Y6M$8?VXF\D/I[94A2(@8VY=XS5QBO-F4AV22$L
M=1)%V\H=I\P535>[I0A*.Y_UHF9E!Z(8T_86LVM=N*ZY;DOA7O+8L8W$2,S$
MBJ:$I\LVMV]53O<$1$UH(B=]H+J)CN*=4+!DT6W-]4NG;<22Q-BMN%;9T.:^
MR N\HC0A) <%53<B=Y.":*E#1M?HU?>J66VMW+\^8MMNLE\C0Y>,VB"IG*88
M<;(B.49)M4G4(#$15=O8NBT):TQWK+U"S;JS>L5BW['\39L-Y6V-XE>([RW6
MXP67$1Q]MU3!%<<#4FP;^+7N]XAHB\F^T;D%XR?+8&)Y;BV'VO$9+L"''R/<
MY,O,R+JCNB;P1IC>*@)BBDO;\2%T<G_M)=0\B9Z22,#M5L\9U#9N<:5!N:NI
M'9N-O<2.KG-;+>C(%JZHHBD0=U%W431/8IUCZGV'*NH'3SJ) @W_ "?%+&[D
MMG?L8.,I.9;;$TC\LMR[B5P1'0=>!?*X+0T8_2+JMG743'[OE=RRG&+K;QM$
MV7,Q&'%="?;Y BJM-NHXXJFTJ(HFI)H78*KVT):5R_)\RR[HETBOMK:L>/VF
M;DZ1O)[9"*'&&YM3)2,.(TT2AX=!'5T/E*?>_D*WA<<DSRW]:L!P;((^-S,Q
MN5@NS[N3-6TE=CR!2:3"1G'#5P&M&VD=#7O][LUX$1$?[2N6!T$N>53(<9.K
M-NOBXFML%DT8*Z$^BBB-;]W!A2X(7$P6AHR2RK/)'5_)L'8B8Y%S>)A$:6YD
MY6Y?$'/_ -55\#> ^8L?ON\MOCM7:O'3B&MNDF2];L-^S3)S[%IMGF6&U.2I
M;5LDQ'W[@:).5);CSO- 5044W.'':G;16\+GUGO]_P ]Z4XKT_&-X+,+=[RY
M ]);)XV+0HB8H"H0H)DH.MZJB]_;P[:)HW5>/_:9_P#NSW^8M$?GI@-VQ*^_
M9PD=.(6$3LFZDW%^4%L?B6E7!8>=?U:?6=MT%&Q[>]_DKW=5HR7J_P B#TXZ
MV=*6>IL9R\.V? 6(-W;9BK=C.8"2F^ ")J>TN',T^.@^P.E-SZ@8_P!<;Y9L
M8DXI@N21XTO$+%,C^$>=N%I3GH^W'[6D=(#'@FBHZHIJB4&9F6=S^J_0'I)@
M5N>);]U#G1;/='$XDC-C<%N8Z2?$X+3R_P"30>J,D&3BN!R6<4DVNS.VB$VS
M;95[(F[7%:CH((KY HJ@""<./;I1B\_]-_M$7Z7U;M'3J[9-9,YM&0-OHU=[
M'$D03@S([9N\LD<U!QLD#1%%57CKJFFBET1=IZS?:)S'"<OS+&0QZ+;\&G7
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M-A>BBR]4X#9,I@]-;7:,PN3MSR]V JW:;)42+Q<D2,PU!$11:4^6.B?)&C%
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M_%UTX]F7GZ"-_>:>W-QYJ]\^![IVOEOW1^X_BZZ<>S+S]!&_O-/;FX\U>^?
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M[;=;Z^*)M6VEM/TZ<\?#3]/3/3JUW<<-M-GZ6VG+;BY('*+]<I,>W1$(!CC
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M+>UR6E$P0$-4)"H-N40H% H% H% H% H% H% H% H% H% H% H% H%!#SO\
MF.T?Z";_ .302ZJB(JKP1.*K0:%Z-WN-A=H>8NI$Q8[O81SMAU154%Q=?-A1
M=5UVDK#^U/SJT5U8LU+L[&>7&[PV7+[DV*L97>(<MOG-+)DK<A2,ZVY\IMID
M&8Y O!4%?AH+/#OV77>]8SB5CEQ+';9>+,7J;*9B XZRX+K+0M16B+EB!(9)
MWQ)!1$T3CP"6QJ]9_.B3;21VR=?,>O[=KNMPD([&:E6GELR2?;;90T"5R7Q'
M9KR^8BKJ@JB('9U#9:N^08/BT]KG66YW1Z5<&%_LWO+(;TIEIT>P@5X0<45X
M+L^"@X1XD>U=9W4MPA':O>.E)N;#0H".R+=,;:8>-$TU/ER#;W=JB@HO 4T#
M'P^U6O*+QU!N5_@LSWY%U=Q\PE CS?E<*,R@1T$]41LB<<<,>PB-57T4%4Q6
MRY+>\4Z?WN'"A9 WC#=XA%$NDDV#=Y;RP(QBYR)"$:,M&)*>FN[77MH)9V]1
M+U(P_+&[)(C62P3KK!R&S-1_$O6VZ(TL=#-B*CG,0#%P$<:0M1=$T[JJJ!6<
M4DW1DL9L+5F6X.6([E)MEA5T&&@G<PWRYSI(8"-N8E,11$4+_6'5%-.2I(&[
M\8R&%E=@@9#;A<;BSV^8C+R(+K1HJB;;B(JHA@:$!:*J:I1$M0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00N0?+L_P#B+/\ F.51-5!1
MKB[G.)29=T:=;R?%2,WWH3Y,P;G!:54(N2^2ML/M@FY4!Y6R1/\ O"H*]?\
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MWVX3:B<EQ$0WGG"5QUTD'1$4S(C5$X)K03- H% H% H% H% H% H% H% H%
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MAHHZ%WM:(L- H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M=JKJ>QQU--=""U=0T.RWW#LX:W(W;KBEFNJH2 /EU^4(VIZ]J!*2*Y_(BT%
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MB2Y)":N$2CM4S(=QKMXJJT%LH% H% H% H% H% H% H% H% H% H% H% H%
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M)%E%EYED:9D>)+(44[5X=%<1UD6N>3VJ<$;05'4UX:D*=I)03% H% H% H%
MH% H(7(/EV?_ !%G_,<JB:J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*")LO^U7K_?U_X=B@EJ!01E]OL+'H'CYK<AX2,668\-AV5(==<X"
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MMP?4V_GT#RW(O;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZFW\^@>6Y%[<'U-OY]
M\MR+VX/J;?SZ!Y;D7MP?4V_GT#RW(O;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZF
MW\^@>6Y%[<'U-OY] \MR+VX/J;?SZ!Y;D7MP?4V_GT#RW(O;@^IM_/H'EN1>
MW!]3;^?0/+<B]N#ZFW\^@>6Y%[<'U-OY] \MR+VX/J;?SZ!Y;D7MP?4V_GT#
MRW(O;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZFW\^@>6Y%[<'U-OY] \MR+VX/J;
M?SZ!Y;D7MP?4V_GT$;:H%^*3=N7>1%1F:&OA&^\7AV>/R^'#A51)>6Y%[<'U
M-OY]13RW(O;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZFW\^@>6Y%[<'U-OY] \MR
M+VX/J;?SZ!Y;D7MP?4V_GT#RW(O;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZFW\^
M@>6Y%[<'U-OY] \MR+VX/J;?SZ!Y;D7MP?4V_GT#RW(O;@^IM_/H'EN1>W!]
M3;^?0/+<B]N#ZFW\^@>6Y%[<'U-OY] \MR+VX/J;?SZ!Y;D7MP?4V_GT#RW(
MO;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZFW\^@>6Y%[<'U-OY] \MR+VX/J;?SZ
M!Y;D7MP?4V_GT#RW(O;@^IM_/H'EN1>W!]3;^?0/+<B]N#ZFW\^@>6Y%[<'U
M-OY] \MR+VX/J;?SZ!Y;D7MP?4V_GT$W05S),RM^.RH5J&-)NN07)'#@6:W@
M+DEQIE11QTE,@;::!3%"<=,1U)$UU5$H(Z=G\BPX]><BRK&[C:HEE9&2X '$
MF%(;(E'1CD/EJ:>D2V]J::T$M<\PL=MQ%[-T=*;C[,3S 7HB(X3L=10D5M%4
M==47L54H&9Y=;,%QN=E%W;?>@P1%2CPVT>DND9H @TVJCN)57LUH)B)+C3XK
M$Z&Z+\.2V#T=X%U VW!0A(5]**BZI0=U H% H% H% H% H% H% H% H% H%
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MC.76Z/E*DI& E,6054$0;W*I*("FY>):Z)H'9DV'6;*5AR)ROQ;I;5<*VW:
M^<2;&5X4%Q&W6U1=IHB(8%J!:)JFJ)H&%-Z=V2Y6:):;A*N,F1;Y"S;?>7)C
MJW2/*42#FM2$5"%=I$"BG<4545%154H(F^=.XL'",TB64)%WR?(K5+B/3;D_
MXF7+-8SK;#)..J@"V*N*(@*"";E735252LBR]+;!;SM3S[MPDQ;/R7K39)DQ
MV1;H+[+: V3+1JNJM)JC7,(T#[W1430B8E8+B\^!>+9-A>(A7V8ERN#9N.(J
MRQ%H1=;,20FB#D-D!-D*B2;DT6@ZK=A$>WQ9T5R]WJ<DYKD*[+N+YNLC\+)
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M_;Q>JL4#RN_^WB]58H'E=_\ ;Q>JL4#RN_\ MXO56*!Y7?\ V\7JK% \KO\
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M]58H'E=_]O%ZJQ0/*[_[>+U5B@>5W_V\7JK% \KO_MXO56*!Y7?_ &\7JK%
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M1-5!\$A)-PJBHOI3BE!#9%E%OQIN(,EM^7<+B]X:VVR$WSI<EU!4R0 511!
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MXX)*#H(<>-R3 NT51I6U!?Y%HJ7RCI[AL/+NG\"):FH\25*FQ;DTUW$N$=J
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M>:\UJ;0\MS:9AW@$MW#36@MV-X%D-IR^UWUFW6#'[;%BOP;E&L:O[ID<A16
M,"99#5IP=PFNI(BD*<"6@[>G=FAW.+YPX\\+-LR3(G[($>0XS&<9?F262WM
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M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H(>=_S':/\
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MADMPR1?W[DV[U>)1TVZZZ>F@L- H% H% H% H% H% H% H% H% H% H% H%
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MNHMH1J2H"*NJ *H*?!06"@4"@4"@4"@4"@4"@4"@4"@4"@A<@^79_P#$6?\
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MX+=MLT-F!;VM>7&C-BTVBDNI+H*)Q55U5>U5XK09E H% H% H% H% H% H%
MH% H% H% H% H%!"Y!\NS_XBS_F.51-5 H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H%!$V;_:KU_OR_P##L4$M0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!01*X_%557Q<_C\$V3^LH'N]%^MS_7I/ZR@>[T7Z
MW/\ 7I/ZR@>[T7ZW/]>D_K*![O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\
M7I/ZR@>[T7ZW/]>D_K*![O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\ 7I/Z
MR@>[T7ZW/]>D_K*![O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\ 7I/ZR@>[
MT7ZW/]>D_K*![O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\ 7I/ZR@>[T7ZW
M/]>D_K*![O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\ 7I/ZR@>[T7ZW/]>D
M_K*![O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\ 7I/ZR@>[T7ZW/]>D_K*!
M[O1?K<_UZ3^LH'N]%^MS_7I/ZR@>[T7ZW/\ 7I/ZR@ZRQ>WFZV^;\TGVD(6G
M%FR=PH>FY$7F>G1-:#L]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE
M]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6
MY_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?
MUE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>
MB_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^
MO2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64
M#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+]
M;G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])
M_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=
MZ+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?
MZ])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE!UNXO;WU;5Y^:XK1HZUNFR5VN#J
MB$GY3M35:#L]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z
M])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90
M/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOU
MN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG
M]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]W
MHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_
MKTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE
M ]WHOUN?Z])_64'6WC%O:)PFGYH$\7,=49LE%(]$'<OY3MT1$H.SW>B_6Y_K
MTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE
M]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6
MY_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?
MUE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>
MB_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^
MO2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64
M#W>B_6Y_KTG]90/=Z+];G^O2?UE ]WHOUN?Z])_64#W>B_6Y_KTG]902U H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*
M[A65MYC9%NGA2M\R/+F6ZX6YPP=<CR[?(..Z!$'!>(;A7TBJ+0,6RQG*AO,B
M/%<C6^UW23:(\MTAVRR@J+3SK:)V +_,937M4%6@L5!&G=9 WYFS#;9)Q'8K
MDHKP/+\&VXVX#:,$N_?S"0E)- TT%>-!(H0JJBBHI#VIZ4UH"D@Z:JB:KHFO
MPK01-_R6U8TEL6Z&8>;7"/:87+;)S65+54;0MJ+M'NKJ2\$H)>@UGB?43.,O
MMMLOUOPAMJPW11<:DO7AE'@CD:BKA-"PO%$3=LW_ !:T5LS5/Z>RB/B$*JHH
MJ;D[4]*:T!51%1%715X)\=!]H%!\W#NVZINTUT].E 541-571.SC\=!]H/B$
M):[51=%T73T+\%!]H(+,,F9Q&P2;TY'.;($FH\"W-*@NRYLIP6(\<%75$5QP
MQ'7[WM7@E!47>J<^)E?N?)L2'.;G6RV.RVI7Y!7;G;9<\C!":0MK91>5QXKN
MW<--**MN%Y3$S7%;5E,)HX[-R81TXKNBN,/"J@\R:IPW-."39:>E*(I47J[<
MKZY9VL1QA;H=Z"[3(92)S<$"M]HF-0PD(I-FJI(5U'&Q1. <5HNB;DYMD-IB
MV0[_ (V,*?>KR%G&*S/"2+33D9U])"N"T*+Q:4.7I\>OHHCIQ7J0=]DXRU<K
M9Y6UEUE:O-E-7D>UD"V#DJ&?='OM X#@$B:.#OX)L74J_41\W#HJZIHG:OP:
M4'U%14U3BB]BT'Q"%5445-R=J>E-:#ZJHG:O;P2@^;AW;=4W::Z>G2@*2(J(
MJHBKV)\.E 4A'35435=$U]*T'V@^(J$B**ZHO8J4$;CE_MV4V&W9):",K7=(
M[<N&3H$T:M.CN%5 M%151>Q:"214)$(5147L5.*4$:W?[<[D4G%P(UNT2%'N
M;P["Y:1Y;KS+:H?8I*4=SN]J:?'01N&90]E$:[OR(X12MMYN5G;$#4^8%ND$
MR+BZHFA$@[E3T4%E5=.*]E!\145$5%U1>**E!]541-5X(G:M 145$5%U1>**
ME U1=41>*=M!\14)$(5147L5.*4#5-=->*\43^2@*J"BJ2Z(G%57LH/M!%WS
M(+;CS,1^Y&8MS9L6V,<L"<59,YT66D5![$4B34EX)0<G+I("^L69+;).*]%=
ME'=Q1OP;9MF (P2J>_F&A*0Z!IH*\:"1U37;KWNW3TZ4'U51$5571$XJJT#M
MXI0?%5!12)=$3M5>"4$+F&2Q<.Q>[91,;)^/:HKDI6&U1#=($[K8JO!%,M!1
M5X)K0<<7+,CB.N9F-M;F&0DPS:E?(&P4=2 S>^60KPW"(HOP)03FJ:Z:\4XJ
MGIT6@:IKMU[W;IZ=* JHG%5T3LX_'0?:!0?%5$5$5415[$^&@^JJ(BJJZ(G%
M56@=O%.R@^;DXHG$AXJ*=M!'8_=)-ZLT2Z2[9*LTF2"FY;)_+24RJ$J;7.4;
M@:KIKP)>V@D45"345U3X4H&J:[=>]VZ>G2@^T#5-=->/;I0?$5%[%UTX</A2
M@(0JJBBHI)VIZ4UH"JB:(JZ*O!/C7MH*Y@^3/99CWG4J.$1Q)MQAJT!J8H-O
MG/Q!+543B2-(2IZ%72@LG;Q3LH(RW7^W72YWBTQ"-9EC>9C7!" A!'9$=N4"
M"2\"_)NBJJG\E!%]/,J?S7"K)E,J,$.3=8R23BMFK@@NY4T0E055.'P4%F54
M'M5$U71-?A6@B[YD-MQY+<MR(Q\TG,6N)RP)S63*54;0MOR1X+J2\$H)6@^*
M0HJ"JIN7L3TKI0-4UVZ\>W3TZ4'U51$U7@E U1--?3V4"@4'P2$DW"J**]BI
MQ2@*J"FI*B)\*\*#[0?$)"3<*HJ+V*G%*!JFJIKQ3BJ>GC0%)!TU5$U71-?A
M6@B'[Z<6[RH$FW2FK9$@)<7+XJ-^"54,Q)A-#YG,$1YB]S;M5..O"@K6$W[J
M#E(VS)IT.U0,.N['C(T%#D.79J,^VAQB<-$Y*F:*BN B)LUT0BTXE7Q20=-5
M1-5T37X5HC[0*#YN'=MU3=IKIZ=*#ZJHG%5T2@C;-=)%U8E/2K;)M:QY4B*#
M<SEH3K<<U 7PY9FG+<1-P:Z+IVHE!(HJ*B*BZHO%%2@:IKIKQ3BJ?RT$;%O]
MNEWZXXVR1K=+5'B2Y@J!("-3R?%E1->!*JQW-43L]/;0?+U=I5J6W)&M4NZ^
M/FLPGEA\K_56GD)2DO<TP_)-[>]LW%Q305H)-51.U=/1Q^%:#[015NR&VW2[
M7FR1"-9UA<89N"$!" G*8"2""2\"[ABJZ=G90173C+7\XPJSY3+C!"DW-HW3
MBM&K@!L=-O@1(*K\GX*"TJJ"BJ2Z(G:J]E!]H/BDB*B*J(J]B>E=* I"BH*J
MB$78GI72@^JJ(FJ\$3M6@^;AT0M4VKIHOHX]E!]H/B*B]BZZ<.'PI05KI_E$
MC,\4B9%)C!#>DO3&BCMFK@BD26]&14)41>\C:$O#TT%E0D)-PJBHO8J<4H"J
MB<571.SC\*\* JHB*JKHB<55:#[0?$)"UT5%T71=/A2@^T#LXKV4'Q%14147
M5%XHJ4!"15445-4[4]*:T!2$>)*B)V<?A6@$0BBD2H@IVJO!*#[05F^Y2]:<
MHQ.P,QP>8R.1-8?D*:H3*0X;DE%%$14)24-JZJFE!FY7DD+$<=N&13Q-V/!;
MW#':3<Z^\9(VRRVGI-UPA;#_ "B2@SK:[/<ML5^[LMQ+D;(',CM.<UIIU113
M 7%0=R"O#=HFO;092JB::JB:KHFOI6@^T"@B\;R"VY78H.16@C.V7%I'XI.@
M31JV2JB*H%HJ=GIH),2$DW"J**^E.*4$5C.1VS+;%#R*S$9VR>).1C= FC41
M-055 M%3B*]M!*H0KKHJ+HNBZ>A:".O]S*S6.Z75L!=>@0Y$L&27:AJPV1HB
MJFJHBJFFM!!^^$G_ .+_ '_\('C/(//? [UY?,\'XKE;]-=NO=W:?S4%$O\
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M,Y3%LRSI9&3[L5F;)C?E"0DW&8, IDO%2U6@])6NV0++;X]JM; QK?$!&HS
M:J( /8B:JJT1J#H?9LV+ L1GMY2R-@1@7%M'E;:GR$<+\EXCG(NNG#?LU].E
M%E6'5=L&)=6>ID=7)F86B\WV'8);YDX-L8-QMI4CBXI-MHA&3SA;=%^^[J:4
M$G;,%R:!=,=E6# UQZ[6ZX13N&3'?694J7!-X4G#.T;4Y2NM*X2(:\'=I"HZ
M4%AP_#L<ZBPKME^8QBN]YG7:YQ8ZR3,7+7&MDYZ$Q&B["%8Y +.\S;VF3A$2
MKV:!5L!D32QSHUXBY2)YKD%]8>G//$;DKE,7=!)XD71PEV;N/I35*"W9O>Y=
MAZAR;K#)7'[;@M\N#,12(FS>BRHA@JMBJ:\4VZ]O'1*#7=LQ+-;GBEHO5BPH
M SQ\(EVCY^Y?F')3TIQ =-UTA!2..\A$)1D_)\LMHBFB:!>;?B5CS'JKU$:R
MIA;O;8"V88-JED3D%EQV JN/"PJ[%=+NIO4=404VZ<=0@+9*GR;+9.F[MREL
M8^_F=XQIV>LASQ9VBU)+EL0%DJ7,1719"/O0]ZM"2:[EUH+]?>D.+EC%]MF'
M0&<=O=RAHU%N,!2C$$N*:2(KIJVJ;MCX 1*NJDFJ+JBT$!:,F>ZL7; A!MR)
M$MD5<HRB*/,;1JYL$Y CPC)%15V2AE.$)=OAQU[:"R]1A!V^].F)(BL$LD0W
M%)?^^9M<]QA-/](**GQHE!=2MUO-_P 4<1DI6\7.>K8JYO;$@$MVFNHB1"B^
MA%5*(TC=Y]SQ&/U$Z?V@R9NM\N,5_$7"/39[Y.$P\;:#Q1(TEN9(7X$THJ5O
M6-W"W]0\(QO"KF%@;M>+W.)'==B#<$6+&?MC0-[3-O1=$%=^OHT]-!LJS6NY
M,6]EC)IS-\N3#RO-S4B!%05XH"BVAN()"BJFY"UHBI=26A@RNG:6UH&76,HA
ML16VD0$!AR'+;> 4%. \E3[O9HE%?>N*2RZ:W%N!->MLMV;:&FI\4MC[*NW:
M("FV2=A(BKHM"%%RRQA#SJS].<=Q1N]8E M#]_?QY9Z06I4U^6C'/E$_O65R
MT154354WN(1ZKLT"-R.SY?C'3'J'O@KAMAD.6Q_'+>Q<!G+;Y+DIL9;C! @(
MRTI<MP&D7:A[UT1%TH+5U"PG'\!QYG.<1C'!RVS3X+@SVW#*3<DFSF6'XTPR
M55D)(1TA_*:J)J)#HJ)08\2W1H^1=5L^E =SNV+3'G,<B22-V/"-NQQ7G"8:
M0M$-XBT,D3=IH*:<=0I]JQ/-;MB-IO=DPH4SV2U$N\;/W+\P<IV8Z(O$ZX0M
MJ11G4(A*,GY/EEL$4X:!<\LMT#&<XN&8]1+&-ZQ.7)MYVG*!<5QW'U91IH67
M&"(2:85]">61'UXN*CJ;1W4$!X6[9WDV:3[O@C69QH5VDV*W')NK45J#%A@V
M.QF.:*K3IJ2O$\FAEO'14%!1 S#Q[(9<SI)B6?2)!/FE_:N\4)AO%+B,,*L5
MF6^UR^=^3Y2O+IWS'CP5=0L-LQ3'[7U%R#I_"@@UA-YQ^)=95A$C2&$P9;T<
MS9;0D1KF@+?,%O1%4$+35250K.$].@F?9_L(87$8BWB[0;1,NT8GGHS=U8BD
M+KT1U\%,FAD IMJ8)PW<44=4H-D=+YF+% NEHQZPEBMPMDSEWW'' !LHTQUE
MLT(>41M$VXWM)MQI=I)\!;D0*U'P7$7^O5YN+UI9.<W8[1=0D*I[AFE<+@BN
M_*TU7E!Z/O:"/PGIKBN81,UDY(PY<)<C*+^U#D&Z8N6\!F&*+"4%3D&A(KG,
M#0U-555TT1 K3.093F\#IC99]H<RJ/*Q@L@N]O.<W;F;A,CG%C@<DC%4>!M7
M"<)E.ZIF)$FB(E!L?I;C^1V"[W])%@#%\1F!%>MUC">$]MB<BNC)*.+8"++3
M@<E>6BZ;T(D1-RZAA7_'X&5];4L]]<.586<79ENV,G"2))?&Y."VX^TA(CB-
MIKM$D4=2XZZ)05+-X283$ZGXCBSKL+'G<4'((<-LR5JUW%UZ3')8R:_DVWN4
M+B-(NU#;)11-RT%AFX98H^48ITY176L;ND:Y9%?A-YSGWVXP_",B,M[<ANHG
MB%?=!2T)1!%38*C0=LRR6[ ,_@VG$65A6+*;->'+OC\<B&$V]:PCJS,9:3@R
M2H\K#JMZ(>X%5-PZT$/BG3/%[GT7M&1W22\YES]ACW,<U<?/S*+)2(+K;K+Z
M%^3;9T':V/<41T-"U+4,G$]G5R^1%SUM)L&UXQ8+HS8G-1@/SKZR^Y(ENL=C
MFSE<EI#W"'?T3<NJ!"YLP>(67JQAF.3'FL>C6"%>[9'%TS2SSISDEEQI@E)2
M!LECA(!K7:)*6U$$M*"=ZF=,\*@8]C$#RL)'-RNT%*DR#<<D2'ITUD)+KSBE
MJ;CHIH1%_-I02EW;9PW.K5&QZ(HP;3B%^D0K2T;G*-QF3"<$=NJZJJZHB]O'
MA01UBZ:8GD73*%E=VE.'F%XM;5\?SKGF%QCS9,<9"2&'Q45::954Y;(Z-( H
M*BJ:ZA&X^U_\FY;ATC,Q*5%GX'&NUQM"D0094QV4RJ.NL"2"8IN(@ D5$W<>
MQ*"Y]-8S=ARK/,-MFYK&[3,@R;3!(R,(B7&&+S[3.]546E<$G!;3NBID@Z#H
MB!BR+1;\_P"J606;+6?'6/%8%M*V6)]56$Z]=$D$[,>9^2Z2(UR6M^HAM/1-
MQ:T&M^I=AM=LQGJI@K"+,Q.UVZU7^TVYUQQT+5-FN/LNL-$1*0MDC*/MM:[0
M4RVH@JB('HJQ8_9L9MXVJQ1 A6\3)P6&U)1WN+J2]Y57BM$:<Q.''Z?7U(&8
M8\3V?R N;EFS=E2DA?B 3EDRX:+S&9'*152.Z/+T N22HFB%5*T8YF.5X+!R
M.%A*R,[O$1F\PL\.^QQFC<)#8OM."HMJH1A)1#PHILY2;%1>.H;+MV/6OJ%F
MF6GG++=V#'7X5IMME?W%#BHY 8F/2!95=I././J@NF*D@-B@Z=[4*8D5;)AF
M<6R)<9;\2VY_:8L-R1)<>=8BK)LRC&YI$IJVVCBMBA%KM[JZT&S,]=,,MZ;@
M#I CM\DB8":BAHEIFEH2(J;D3371?Y:#4MHM=]Z@VRZY'=L!/(+C=IUP:BWX
MKVS#E0&H<QZ,PU!$@WQ%81O[WO*YN(M56@L\;'+ADF?XQ8NHZ^-D1\+%^^VP
M'B*!*N34UD%<> =@.H);U%%#;J79V4&!<)DO"(?4?$\8F'9[)&N=AC6IY"4Q
MM#>2$PQ+./S%+8 $9O-#\D'"71$'A0;4L/3/!<:F1KG9K,S'NT43 ;DJFY,<
M1U-IJ\^9$;JEKQ5PBHC36/0O>'&>B5FN4J44"Y/78+F(2'0.4PW!F&K+IB2$
M39*([D5>*)I15ANJ-]+LJRUK"(P0;:6&2\B&S-(O@DNEL<)MMYME%V@K@$@N
MHVB;]@JO'C08.9].L4MW16ZY5$E.CEC5D<N99LW),;E)DG&WFXY(W=YI[<J*
MU_9[2VB*:#H&[BT2QKJ*HGA.(ZJB_P!GV:]M$>=(MKD6/I!@;]I!^Z9-GK]H
M@9'<7)JPYTZ*45Z2L49AJO( D:2. AIH!*@Z&6ZBK=C5DO>*Y4QDC.(1L"PV
M+ F>]?*N;<F-(99;YK#RQF00><T0EJ]P)0(D+=W= @.2U;;U@V78IA?NI;;G
M?(L3SAV8(W"X6^ZM.;@E1!0U,7%VN"C[JN-D(KH*ZI06_%,1QWJ(YD63YG&&
M\75;U<K7#!\S_P#3(ELDG$:9C())R3T;YQN-Z&1&J[M-J(%5QW$[S>.D^.,6
MP?>NWV3(+R[=K'/DHRMZBM7*>R*.OZ;#<;<4'MKOY-P@T-4UU0-M].+CB]QQ
M9CW1A':[7#?DPW;.^VK#\&6R\22([C>XD @<W<!)1TT454=*(I?3O!,0M_4G
M/[E"M++,^W76)X.0*N;F_$VF,;NFI*G>)PU[/OJ*HV.8)84^SDUF2(][YVZR
M2KQ;,AYI).B2(:.R& 8-%[C(*(M\H4V$' D+5=0OV4N6#,KG M)X:UF631[8
MQ+G-R7ACV^WQK@JJ"FX[O1'7":)6T;:)S:*KJ*::A0'+%"R7IWTV][8:3KC!
MR];'K(D.2G B,7*7'Y*OZBKNT&0#F$FXMNJ\=:#T!(:CXCBLD;%"3P]GA/.0
M;>WN5%Y#9&#:=J\532B*+@/3S$;[BU@R_((P9#E-VC0[W*R&8JNR"E2 "0BL
M'JG)9!506FFMHB"(FB\=2J5U+&WWFT9?F&&X>KD^S)+?'/7IJ0'V[A:$VN%"
M54==<;:-E0(>XTXHD/%%55"T3+)"S#K2PU?U.7:(F*0;@-G(S2$Y-.XO\M]U
MI"T,FD%4;0T5$W*O:B*@=&$X19LKG=1)]^)^7,=OEYLT%XGG$*!!DL--NA$[
MVC1&ID1&"(6J_ B4&%;[S>,UL.(]-[HZXN0,7)V'G#[:F)+&Q1T%>-3%1)$F
MN+$7@O%MY:#9/46XV"%CO@\@@NW9F[R6+;"LT=='ILQX]S;(JIMBB=Q3-3-
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>tm2415719d15_ex10-2aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2415719d15_ex10-2aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ? 'D# 2(  A$! Q$!_\0
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C_P Q'0GG.*ZZN?\ "^AW&B&\29D9)9 8R#DD>_O704 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>tm2415719d15_ex10-2asp4img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2415719d15_ex10-2asp4img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G )(# 2(  A$! Q$!_\0
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MU)YD[JY9]H&<,0.!QVK)\!ZYJ.M17K:A<><8RFSY%7&<YZ >E7O!W_(EV?\
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MF:1_NP_^AM7?-_JF^AIB.1^'%P\OAZ6)V)$,Y"^P(!Q^>:I_#;_6:Q_OQ_\
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.D\=L5NT44 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>tm2415719d15_ex10-3bsp2img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2415719d15_ex10-3bsp2img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ #8# 2(  A$! Q$!_\0
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.;))622[)) %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>tm2415719d15_ex10-3bsp2img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2415719d15_ex10-3bsp2img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !# (<# 2(  A$! Q$!_\0
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-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>tm2415719d15_ex10-3bsp4img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2415719d15_ex10-3bsp4img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- .H# 2(  A$! Q$!_\0
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M,CUHW#UH 6BDR/6C(H 6BC-)D>M "T4F:7- !129I: "BC-% !1110 4444
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MD6=,V?V;;>7NV>4NW=UQCO5RL_1MXT6Q\Q@S^0FY@,9.!VJ^*.HT+2'I2T4
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MYXHYZ>ZO]XU"KL[,\9\-ZGHEOXEAUC6M8@GFMH]L%M96,BQQL<\\*,\$]J]
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MHH *,444 %%%% !1110 4444 %%%&: "B@'-% !1110 4444 %%%% !1110
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M6@#H=.UW^T-=U+3EMI$6Q**96& Y89XK:K)M-:TJZUN[TRVN(VOX%#3QJI!
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MSG0%%%% !1110 4444 %%%% !1BBB@ Q1110 4444 (:*6B@ HHHH ,4444
M%&*** $Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?AZU\R^NHUF(^2 -EW/H!7!VDFN^/M0:Y>S:+3 @\F.X)$&>#NQ_RT;KQT%
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MKF)?&MDLHCM[34+HE=W^CVK,/SQ6CI&K7&J2W'F:9=6<43 1O<#!DXY('44
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@H4VC!V@#=Z]JZT=***B4G)W9:BEL%%%%(84444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
